Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM
A1CF	ACF, ACF64, ACF65, APOBEC1CF, ASP	ENSG00000148584	APOBEC1 complementation factor	10	50799409-50885675	Predicted intracellular proteins	Evidence at protein level	HPA037779, HPA044079	Enhanced		Supported	Nucleoplasm		Tissue enriched	Tissue enhanced		liver: 76.0;small intestine: 29.8	duodenum: 23.5	Group enriched	18	CACO-2: 19.3;Hep G2: 41.7
AAAS		ENSG00000094914	Aladin WD repeat nucleoporin	12	53307456-53324864	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA040086	Approved		Approved	Nuclear membrane<br>Centrosome<br>Cytosol	Renal cancer:2.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 46.2	Expressed in all		
AADAC	CES5A1, DAC	ENSG00000114771	Arylacetamide deacetylase	3	151814037-151828488	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002911	Approved				Ovarian cancer:5.58e-6 (favourable), Stomach cancer:2.19e-4 (unfavourable), Pancreatic cancer:5.02e-4 (unfavourable)	Tissue enriched	Group enriched	5	adrenal gland: 150.1;duodenum: 182.4;liver: 386.8;small intestine: 215.8	stomach: 43.5	Cell line enhanced		A549: 7.3;EFO-21: 3.9;HBEC3-KT: 2.7
AADAT	KAT2, KATII, KYAT2	ENSG00000109576	Aminoadipate aminotransferase	4	170060222-170091699	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037502	Enhanced		Approved	Vesicles<br>Plasma membrane	Colorectal cancer:5.59e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 34.7	prostate: 23.4	Mixed		
AAED1	C9orf21	ENSG00000158122	AhpC/TSA antioxidant enzyme domain containing 1	9	96639577-96655303	Predicted intracellular proteins	Evidence at protein level	HPA021294	Approved				Renal cancer:3.26e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 15.9	Mixed		
AAGAB	FLJ11506, p34	ENSG00000103591	Alpha- and gamma-adaptin binding protein	15	67201033-67255195	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039371, HPA040174	Supported		Supported	Nuclear speckles<br>Cytosol	Renal cancer:1.36e-4 (favourable), Thyroid cancer:9.48e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 55.7	Expressed in all		
AAK1	DKFZp686K16132, KIAA1048	ENSG00000115977	AP2 associated kinase 1	2	69457997-69674349	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017931, HPA020289	Enhanced		Supported	Plasma membrane<br>Cytosol	Ovarian cancer:3.19e-4 (unfavourable)	Expressed in all	Tissue enriched	7	parathyroid gland: 389.6	thyroid gland: 59.4	Expressed in all		
AAMDC	C11orf67, CK067, FLJ21035, PTD015	ENSG00000087884	Adipogenesis associated Mth938 domain containing	11	77821109-77918432	Predicted intracellular proteins	Evidence at protein level	HPA037918, HPA037919	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 231.6	Expressed in all		
AAMP		ENSG00000127837	Angio associated migratory cell protein	2	218264123-218270257	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017717, HPA031868	Approved		Supported	Microtubules<br>Cytosol	Liver cancer:4.94e-7 (unfavourable), Endometrial cancer:1.62e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 115.1	Expressed in all		
AAR2	bA234K24.2, C20orf4	ENSG00000131043	AAR2 splicing factor homolog	20	36236459-36270918	Predicted intracellular proteins	Evidence at protein level	CAB034220, HPA048645	Uncertain		Approved	Cytosol	Liver cancer:1.83e-6 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 41.9	Expressed in all		
AARD	C8orf85, LOC441376	ENSG00000205002	Alanine and arginine rich domain containing protein	8	116938199-116944487	Predicted intracellular proteins	Evidence at protein level	HPA068290			Approved	Lipid droplets		Tissue enriched	Tissue enriched	8	testis: 42.4	breast: 5.4	Cell line enhanced		HDLM-2: 20.1;SK-BR-3: 8.9;U-2 OS: 6.0
AARS	AlaRS, CMT2N	ENSG00000090861	Alanyl-tRNA synthetase	16	70252295-70289543	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB034261, HPA040870, HPA044223	Supported		Enhanced	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 178.0	Expressed in all		
AARS2	AARSL, bA444E17.1, KIAA1270	ENSG00000124608	Alanyl-tRNA synthetase 2, mitochondrial	6	44299654-44313326	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035636, HPA061396	Approved		Enhanced	Mitochondria		Expressed in all	Mixed			parathyroid gland: 11.4	Expressed in all		
AARSD1	MGC2744	ENSG00000266967	Alanyl-tRNA synthetase domain containing 1	17	42950526-42964498	Predicted intracellular proteins	Evidence at protein level	HPA021408, HPA022869, HPA023714	Supported		Approved	Nuclear membrane<br>Cytosol	Renal cancer:1.67e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 99.4	Expressed in all		
AASDHPPT	AASD-PPT, ACPS, CGI-80, LYS5	ENSG00000149313	Aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase	11	106075501-106098710	Predicted intracellular proteins	Evidence at protein level	HPA026687	Approved				Renal cancer:4.27e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 81.9	Expressed in all		
AASS	LKRSDH, LORSDH	ENSG00000008311	Aminoadipate-semialdehyde synthase	7	122075647-122144280	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020637, HPA020728, HPA020734	Enhanced		Enhanced	Vesicles<br>Mitochondria	Liver cancer:9.81e-4 (favourable)	Expressed in all	Mixed			ovary: 30.7	Cell line enhanced		AN3-CA: 49.4;NTERA-2: 51.8
AATF	BFR2, CHE-1, CHE1, DED	ENSG00000275700	Apoptosis antagonizing transcription factor	17	36948875-37056871	Predicted intracellular proteins	Evidence at protein level	HPA004940	Uncertain				Renal cancer:4.14e-5 (unfavourable), Liver cancer:6.62e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 19.9	Expressed in all		
AATK-AS1		ENSG00000225180	AATK antisense RNA 1	17	81165507-81183164	Predicted intracellular proteins	No evidence							Not detected	Not detected			adipose tissue,cerebral cortex: 0.1	Not detected		
ABAT	GABAT	ENSG00000183044	4-aminobutyrate aminotransferase	16	8674565-8784575	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041528, HPA041690	Enhanced	Supported	Supported	Mitochondria	Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 164.5;kidney: 135.3;liver: 175.2	thyroid gland: 47.5	Cell line enhanced		Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1
ABC13-47488600E17.1		ENSG00000283199		13	113953705-113973997	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		stomach: 2.6;testis: 5.9	lung: 2.1	Cell line enhanced		hTEC/SVTERT24-B: 1.2
ABCE1	OABP, RLI, RLI1, RNASEL1, RNASELI, RNS4I	ENSG00000164163	ATP binding cassette subfamily E member 1	4	145097932-145129179	Predicted intracellular proteins	Evidence at protein level	CAB012476, HPA036846	Approved		Enhanced	Cytosol	Pancreatic cancer:1.88e-4 (unfavourable), Liver cancer:6.29e-4 (unfavourable), Colorectal cancer:8.69e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.1	Expressed in all		
ABCF1	ABC50, EST123147	ENSG00000204574	ATP binding cassette subfamily F member 1	6	30571376-30597179	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017578	Approved		Enhanced	Cytosol	Liver cancer:9.47e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.3	Expressed in all		
ABCF2	ABC28, EST133090, HUSSY-18, M-ABC1	ENSG00000033050	ATP binding cassette subfamily F member 2	7	151207837-151227230	Predicted intracellular proteins	Evidence at protein level	HPA020091, CAB020682, HPA021815, HPA030388	Enhanced		Supported	Cytosol	Liver cancer:9.52e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.2	Expressed in all		
ABCF3	EST201864	ENSG00000161204	ATP binding cassette subfamily F member 3	3	184186023-184194012	Predicted intracellular proteins	Evidence at protein level	HPA036332	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:4.16e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 76.2	Expressed in all		
ABHD11	PP1226, WBSCR21	ENSG00000106077	Abhydrolase domain containing 11	7	73736094-73738867	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024042, HPA049641	Approved		Supported	Mitochondria	Renal cancer:3.66e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 28.6	Expressed in all		
ABHD12B	BEM46L3, C14orf29	ENSG00000131969	Abhydrolase domain containing 12B	14	50872160-50904970	Predicted intracellular proteins	Evidence at transcript level	HPA002873	Uncertain		Uncertain	Nucleus		Tissue enriched	Tissue enriched	8	skin: 16.3	cerebral cortex: 2.1	Not detected		
ABHD14B	CIB, MGC15429	ENSG00000114779	Abhydrolase domain containing 14B	3	51968510-51983409	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036444, HPA036642	Supported		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:2.93e-5 (favourable), Endometrial cancer:5.42e-5 (favourable), Cervical cancer:6.92e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 90.8	Expressed in all		
ABHD16B	C20orf135, dJ591C20.1	ENSG00000183260	Abhydrolase domain containing 16B	20	63861498-63862988	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level	HPA059272	Uncertain		Approved	Nucleoplasm		Not detected	Mixed			testis: 5.7	Cell line enhanced		PC-3: 17.5
ABHD17A	C19orf27, FAM108A1, MGC5244	ENSG00000129968	Abhydrolase domain containing 17A	19	1876810-1885547	Predicted intracellular proteins	Evidence at protein level	HPA043270, HPA047226	Uncertain		Approved	Vesicles	Pancreatic cancer:1.76e-5 (favourable), Endometrial cancer:1.73e-4 (favourable), Head and neck cancer:6.46e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 31.4	Mixed		
ABHD17B	C9orf77, CGI-67, FAM108B1	ENSG00000107362	Abhydrolase domain containing 17B	9	71862452-71910931	Predicted intracellular proteins	Evidence at protein level	HPA047862	Uncertain				Renal cancer:2.59e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 35.3	Mixed		
ABHD17C	FAM108C1	ENSG00000136379	Abhydrolase domain containing 17C	15	80679684-80755621	Predicted intracellular proteins	Evidence at protein level	HPA048890	Uncertain					Expressed in all	Mixed			colon: 64.0	Mixed		
ABHD18	C4orf29, FLJ21106	ENSG00000164074	Abhydrolase domain containing 18	4	127965306-128039711	Predicted intracellular proteins	Evidence at protein level	HPA050168, HPA051676	Approved		Approved	Nuclear membrane	Colorectal cancer:5.35e-4 (favourable), Urothelial cancer:9.13e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 11.0	Expressed in all		
ABHD4	FLJ12816	ENSG00000100439	Abhydrolase domain containing 4	14	22598237-22613215	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000600	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			testis: 62.8	Mixed		
ABHD5	CGI-58, NCIE2	ENSG00000011198	Abhydrolase domain containing 5	3	43690113-43734371	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB020685, HPA035851, HPA035852	Approved		Approved	Vesicles	Renal cancer:9.17e-5 (favourable), Colorectal cancer:8.89e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 50.6	Expressed in all		
ABHD8	FLJ11743, MGC14280, MGC2512	ENSG00000127220	Abhydrolase domain containing 8	19	17292131-17310236	Predicted intracellular proteins	Evidence at protein level	HPA037658, HPA058209	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:3.04e-5 (favourable), Colorectal cancer:5.25e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 28.5	Cell line enhanced		PC-3: 48.7
ABI1	ABI-1, E3B1, SSH3BP1	ENSG00000136754	Abl interactor 1	10	26746593-26861087	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB008375, HPA029973, HPA068407	Approved		Supported	Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 87.4	Expressed in all		
ABI2	ABI-2, ABI2B, AblBP3, AIP-1, argBPIA, SSH3BP2	ENSG00000138443	Abl interactor 2	2	203328219-203447723	Predicted intracellular proteins	Evidence at protein level	HPA062433, HPA070567	Enhanced		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 98.8	Mixed		
ABI3	NESH, SSH3BP3	ENSG00000108798	ABI family member 3	17	49210227-49223225	Predicted intracellular proteins	Evidence at protein level	HPA017345	Enhanced				Endometrial cancer:7.13e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 62.0	lymph node: 29.9	Cell line enhanced		Daudi: 28.2;HDLM-2: 21.3;HUVEC TERT2: 54.6;TIME: 38.1
ABL1	ABL, c-ABL, JTK7, p150	ENSG00000097007	ABL proto-oncogene 1, non-receptor tyrosine kinase	9	130713946-130887675	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002686, HPA027251, HPA027280, HPA028409	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 83.9	Expressed in all		
ABL2	ABLL, ARG	ENSG00000143322	ABL proto-oncogene 2, non-receptor tyrosine kinase	1	179099327-179229684	Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001866, CAB017106, HPA072754	Uncertain		Supported	Nucleoplasm	Renal cancer:1.78e-7 (unfavourable), Cervical cancer:3.50e-4 (unfavourable), Urothelial cancer:8.40e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 20.3	Expressed in all		
ABLIM1	ABLIM, LIMAB1, limatin	ENSG00000099204	Actin binding LIM protein 1	10	114431113-114685003	Predicted intracellular proteins	Evidence at protein level	HPA038951, HPA038952	Approved		Supported	Cytosol	Renal cancer:2.72e-5 (favourable)	Expressed in all	Expressed in all			ovary: 284.7	Mixed		
ABLIM2	KIAA1808	ENSG00000163995	Actin binding LIM protein family member 2	4	7965310-8158832	Predicted intracellular proteins	Evidence at protein level	HPA035808	Uncertain		Approved	Nucleoplasm<br>Mitochondria		Mixed	Tissue enhanced		skeletal muscle: 37.5;spleen: 28.4	cerebral cortex: 22.1	Group enriched	6	SCLC-21H: 16.3;SiHa: 6.6;U-2197: 19.7
ABLIM3	KIAA0843	ENSG00000173210	Actin binding LIM protein family member 3	5	149141483-149260542	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003245	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Renal cancer:1.28e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 79.4	adipose tissue: 63.7	Cell line enhanced		TIME: 84.5
ABR	MDB	ENSG00000159842	Active BCR-related	17	1003518-1229021	Predicted intracellular proteins	Evidence at protein level	HPA053618, HPA054824	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.21e-4 (favourable), Cervical cancer:4.03e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 12.6	Cell line enhanced		Daudi: 26.9;LHCN-M2: 20.5;TIME: 33.6;U-251 MG: 34.7;U-698: 21.1
ABRA	STARS	ENSG00000174429	Actin binding Rho activating protein	8	106759483-106770245	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	9	heart muscle: 11.0;skeletal muscle: 49.8	esophagus: 3.3	Not detected		
ABRACL	C6orf115, Costars, HSPC280, PRO2013	ENSG00000146386	ABRA C-terminal like	6	139028682-139043302	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030217	Enhanced		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.65e-6 (favourable)	Expressed in all	Mixed			epididymis: 147.3	Mixed		
ABT1		ENSG00000146109	Activator of basal transcription 1	6	26596952-26600744	Predicted intracellular proteins	Evidence at protein level	HPA077039			Approved	Vesicles	Ovarian cancer:1.89e-4 (favourable), Urothelial cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 17.9	Expressed in all		
ABTB1	BPOZ, Btb3, BTBD21, EF1ABP	ENSG00000114626	Ankyrin repeat and BTB domain containing 1	3	127672935-127680920	Predicted intracellular proteins	Evidence at protein level	HPA035022, HPA035023	Uncertain		Supported	Nucleoli<br>Cytosol	Renal cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 50.2	Mixed		
ABTB2	ABTB2A, BTBD22, DKFZP586C1619	ENSG00000166016	Ankyrin repeat and BTB domain containing 2	11	34150988-34358008	Predicted intracellular proteins	Evidence at protein level	HPA020065, HPA030699	Approved		Supported	Nucleus	Renal cancer:3.51e-5 (favourable), Cervical cancer:5.70e-5 (unfavourable)	Expressed in all	Mixed			adrenal gland: 13.0	Mixed		
AC002310.13		ENSG00000260869		16	30534227-30558279	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			adipose tissue,colon,duodenum,small intestine,spleen: 0.5	Cell line enhanced		A549: 1.2
AC002429.5		ENSG00000236197		7	95035731-95214332	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	10	cerebral cortex: 2.7	esophagus: 0.2	Not detected		
AC003002.4		ENSG00000268133		19	57363566-57398584	Predicted intracellular proteins	No evidence							Not detected	Not detected			adipose tissue,appendix: 0.2	Not detected		
AC003002.6		ENSG00000269533		19	57389884-57419994	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			appendix,fallopian tube,testis: 0.2	Cell line enhanced		CACO-2: 1.1;HEL: 1.1;PC-3: 1.6
AC003006.7		ENSG00000269026		19	57682045-57753575	Predicted intracellular proteins	Evidence at transcript level	HPA068553			Approved	Nucleus		Not detected	Not detected			seminal vesicle: 0.2	Cell line enhanced		HL-60: 1.0;U-266/84: 1.4
AC004076.7		ENSG00000268533		19	57394183-57438457	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			skin: 8.9	Cell line enhanced		SCLC-21H: 6.0
AC004076.9		ENSG00000268163		19	57437970-57477536	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 1.0	Not detected		
AC004381.6		ENSG00000005189	Putative RNA exonuclease NEF-sp 	16	20806429-20849668	Predicted intracellular proteins	Evidence at protein level	HPA040755, HPA040868	Enhanced		Approved	Nuclear membrane<br>Nucleoli<br>Endoplasmic reticulum		Expressed in all	Tissue enriched	33	testis: 618.5	parathyroid gland: 18.9	Mixed		
AC004556.1		ENSG00000276345		Unmapped	2585-11802	Predicted intracellular proteins	Evidence at protein level	HPA050406	Uncertain		Supported	Nucleoli fibrillar center<br>Mitochondria			Mixed			breast: 24.8	Cell line enhanced		NB-4: 110.2;PC-3: 145.9;WM-115: 112.0
AC005281.1		ENSG00000226690		7	12483344-12541910	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	6	fallopian tube: 8.1;testis: 1.6	lung: 0.7	Cell line enhanced		HAP1: 1.4
AC006486.9		ENSG00000268643		19	42234583-42255132	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 7.8	endometrium: 5.1	Cell line enhanced		RT4: 21.6
AC007325.1		ENSG00000276017		Unmapped	72411-74814	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	89	testis: 16.5	adipose tissue,gallbladder,smooth muscle,spleen,urinary bladder: 0.1	Not detected		
AC007325.2		ENSG00000277196		Unmapped	138082-161852	Predicted intracellular proteins	Evidence at transcript level	HPA020361	Uncertain						Tissue enhanced		skin: 38.5;small intestine: 37.1	duodenum: 29.0	Cell line enriched	7	RPTEC TERT1: 137.9
AC007325.4		ENSG00000278817		Unmapped	131494-137392	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		cerebral cortex: 27.4;heart muscle: 34.4;skeletal muscle: 40.5	thyroid gland: 14.9	Cell line enhanced		A549: 14.5;T-47d: 10.8
AC007326.13		ENSG00000283809		22	18906238-18947732	Predicted intracellular proteins	Evidence at transcript level								Expressed in all			cerebral cortex: 23.0	Expressed in all		
AC010646.3		ENSG00000269095		19	17235940-17255448	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			epididymis: 1.4	Cell line enhanced		BEWO: 5.8;EFO-21: 1.6
AC010731.4		ENSG00000235118		2	206642418-206649449	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex: 0.6	Not detected		
AC011043.1		ENSG00000276256	Homo sapiens uncharacterized LOC389831 (LOC389831), transcript variant 3, mRNA.	Unmapped	42939-49164	Predicted intracellular proteins	Evidence at transcript level								Mixed			kidney: 69.3	Mixed		
AC011043.2		ENSG00000278198		Unmapped	173872-179372	Predicted intracellular proteins	Evidence at transcript level								Not detected			skin: 0.4	Cell line enhanced		A-431: 2.4
AC011530.4		ENSG00000268434		19	45779437-45785973	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		epididymis: 1.0	appendix: 0.9	Not detected		
AC011841.1		ENSG00000273496		Unmapped	99351-104855	Predicted intracellular proteins	Evidence at transcript level								Not detected			skin: 0.4	Cell line enhanced		A-431: 2.4
AC013269.5		ENSG00000184761		2	130539095-130549883	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AC023491.2		ENSG00000278633		Unmapped	10598-13001	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	545	testis: 67.4	parathyroid gland,small intestine: 0.1	Not detected		
AC025335.1		ENSG00000179859		17	7913324-7916276	Predicted intracellular proteins	Evidence at transcript level						Cervical cancer:8.89e-5 (favourable)	Expressed in all	Tissue enriched	8	skin: 61.7	fallopian tube: 8.0	Cell line enhanced		SiHa: 14.9
AC037459.4		ENSG00000248235		8	22589274-22602084	Predicted intracellular proteins	Evidence at transcript level	HPA024667	Uncertain					Not detected	Tissue enhanced		spleen: 3.6	small intestine: 1.9	Cell line enhanced		U-2197: 3.5
AC068533.7		ENSG00000249319		7	66087761-66152277	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			parathyroid gland: 8.1	Mixed		
AC069368.3		ENSG00000249240		15	64841883-64930920	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		spleen: 8.8	appendix: 6.1	Cell line enhanced		U-266/84: 21.3
AC073610.5		ENSG00000255863		12	48921963-48939663	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AC092835.2		ENSG00000233757		2	95207535-95259774	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			testis: 3.9	Cell line enhanced		SCLC-21H: 6.3
AC104534.3		ENSG00000268083		19	38817471-38840178	Predicted intracellular proteins	Evidence at protein level	HPA002907, HPA051748	Uncertain					Not detected	Not detected			lung: 0.9	Cell line enhanced		NB-4: 19.4
AC113404.1		ENSG00000254893	Ras-related protein Rap-1b-like protein 	5	76170093-76174331	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	8	small intestine: 3.4	adrenal gland: 0.4	Group enriched	8	Daudi: 7.6;Karpas-707: 13.3;RPMI-8226: 11.1
AC131097.4		ENSG00000216921		2	241893985-241902551	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		thyroid gland: 11.5	pancreas: 6.4	Cell line enhanced		REH: 2.2;SCLC-21H: 1.8
AC133551.1		ENSG00000274175		Unmapped	17234-19833	Predicted intracellular proteins	Evidence at transcript level								Group enriched	28	epididymis: 7.4;testis: 4.1	placenta: 0.2	Not detected		
AC136352.1		ENSG00000276760		Unmapped	136160-167571	Predicted intracellular proteins	No evidence	HPA042822	Uncertain						Not detected			all non-specific tissues: 0.0	Not detected		
AC136612.1		ENSG00000275869		Unmapped	933862-936467	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	5	testis: 4.3	epididymis: 0.8	Not detected		
AC136616.2		ENSG00000277761		Unmapped	1167457-1257196	Predicted intracellular proteins	Evidence at transcript level								Mixed			colon: 76.7	Not detected		
AC136616.3		ENSG00000278782		Unmapped	1157687-1240349	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		cervix, uterine: 8.6;tonsil: 6.6	breast,small intestine: 5.4	Not detected		
AC138647.1		ENSG00000226490		8	141514638-141518737	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.8	skin: 0.3	Not detected		
AC141272.1		ENSG00000277836		Unmapped	1270984-1271271	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		tonsil: 114.8	urinary bladder: 94.9	Cell line enhanced		RPMI-8226: 1.3
AC145212.1		ENSG00000274847		Unmapped	53594-115055	Predicted intracellular proteins	Evidence at transcript level	HPA053929	Uncertain		Uncertain	Intermediate filaments			Mixed			adrenal gland: 10.2	Mixed		
AC233755.2		ENSG00000277856		Unmapped	26241-26534	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		tonsil: 197.2	lymph node: 99.3	Cell line enhanced		MOLT-4: 6.1;REH: 2.1;SH-SY5Y: 2.5;TIME: 1.3
AC240274.1		ENSG00000271254		Unmapped	4612-29626	Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles			Expressed in all			testis: 73.9	Expressed in all		
ACAA1		ENSG00000060971	Acetyl-CoA acyltransferase 1	3	38103129-38137242	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006764, HPA007244	Enhanced		Enhanced	Peroxisomes	Renal cancer:6.99e-9 (favourable), Head and neck cancer:1.23e-4 (favourable), Breast cancer:3.00e-4 (favourable), Endometrial cancer:7.53e-4 (favourable)	Expressed in all	Expressed in all			liver: 328.4	Expressed in all		
ACAA2	DSAEC	ENSG00000167315	Acetyl-CoA acyltransferase 2	18	49782167-49813960	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042303	Enhanced		Supported	Mitochondria	Renal cancer:1.36e-10 (favourable), Endometrial cancer:8.53e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 509.5	Mixed		
ACACA	ACAC, ACC, ACC1	ENSG00000278540	Acetyl-CoA carboxylase alpha	17	37084988-37406818	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB013715, HPA036650, HPA063018	Approved		Supported	Nucleoli fibrillar center<br>Actin filaments<br>Cytosol	Liver cancer:1.24e-5 (unfavourable)	Expressed in all	Mixed			breast: 28.8	Expressed in all		
ACAD10	MGC5601	ENSG00000111271	Acyl-CoA dehydrogenase family member 10	12	111686056-111757107	Predicted intracellular proteins	Evidence at protein level	HPA067222	Uncertain				Renal cancer:3.71e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 33.6	Expressed in all		
ACAD11	FLJ12592	ENSG00000240303	Acyl-CoA dehydrogenase family member 11	3	132558138-132660723	Predicted intracellular proteins	Evidence at protein level	HPA048317	Enhanced					Tissue enhanced	Expressed in all			kidney: 35.4	Mixed		
ACAD8		ENSG00000151498	Acyl-CoA dehydrogenase family member 8	11	134253495-134265855	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040689, HPA043903	Enhanced				Renal cancer:6.42e-10 (favourable), Lung cancer:2.38e-4 (favourable), Head and neck cancer:6.19e-4 (favourable), Colorectal cancer:7.62e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 43.2	Expressed in all		
ACAD9	MGC14452, NPD002	ENSG00000177646	Acyl-CoA dehydrogenase family member 9	3	128879596-128916067	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037716, HPA046720	Supported		Enhanced	Mitochondria	Renal cancer:4.32e-8 (favourable), Liver cancer:3.67e-6 (unfavourable), Endometrial cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 52.8	Expressed in all		
ACADL	ACAD4, LCAD	ENSG00000115361	Acyl-CoA dehydrogenase, long chain	2	210187939-210225491	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA011990	Enhanced	Supported			Renal cancer:1.58e-11 (favourable)	Group enriched	Tissue enhanced		thyroid gland: 32.0	prostate: 27.0	Cell line enhanced		HAP1: 1.6;HeLa: 2.5;RPTEC TERT1: 2.5;U-2 OS: 1.9
ACADM	ACAD1, MCAD, MCADH	ENSG00000117054	Acyl-CoA dehydrogenase, C-4 to C-12 straight chain	1	75724347-75787575	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006198, HPA026542	Enhanced		Enhanced	Mitochondria	Renal cancer:3.83e-8 (favourable), Colorectal cancer:7.30e-4 (favourable)	Expressed in all	Expressed in all			kidney: 328.0	Expressed in all		
ACADS	ACAD3, SCAD	ENSG00000122971	Acyl-CoA dehydrogenase, C-2 to C-3 short chain	12	120725735-120740008	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004799, CAB019284, HPA022271	Enhanced		Enhanced	Mitochondria	Renal cancer:3.33e-6 (favourable), Urothelial cancer:6.34e-5 (favourable), Liver cancer:2.43e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Glioma:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 81.2	Cell line enhanced		HMC-1: 30.0
ACADSB	ACAD7, SBCAD	ENSG00000196177	Acyl-CoA dehydrogenase, short/branched chain	10	123008979-123058311	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041458	Enhanced		Supported	Mitochondria	Renal cancer:6.37e-12 (favourable), Pancreatic cancer:3.40e-4 (favourable)	Expressed in all	Expressed in all			liver: 186.7	Expressed in all		
ACADVL	ACAD6, LCACD, VLCAD	ENSG00000072778	Acyl-CoA dehydrogenase, very long chain	17	7217125-7225273	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019006, HPA020595	Enhanced		Supported	Nucleus<br>Nucleoli<br>Mitochondria	Pancreatic cancer:6.87e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 453.7	Expressed in all		
ACAP1	CENTB1, KIAA0050	ENSG00000072818	ArfGAP with coiled-coil, ankyrin repeat and PH domains 1	17	7336529-7351478	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA075570	Approved		Approved	Golgi apparatus	Renal cancer:1.65e-10 (unfavourable), Endometrial cancer:2.97e-5 (favourable), Head and neck cancer:4.17e-5 (favourable), Cervical cancer:3.66e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 94.2	spleen: 69.8	Cell line enhanced		HDLM-2: 59.1;Karpas-707: 44.7;NB-4: 49.0
ACAP2	CENTB2, CNT-B2, KIAA0041	ENSG00000114331	ArfGAP with coiled-coil, ankyrin repeat and PH domains 2	3	195274736-195443078	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034807, HPA034808	Supported		Approved	Endosomes		Expressed in all	Expressed in all			thyroid gland: 34.2	Expressed in all		
ACAP3	CENTB5, KIAA1716	ENSG00000131584	ArfGAP with coiled-coil, ankyrin repeat and PH domains 3	1	1292376-1309609	Predicted intracellular proteins	Evidence at protein level	HPA049317, HPA058381	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			cerebral cortex: 26.5	Expressed in all		
ACAT1	ACAT, THIL	ENSG00000075239	Acetyl-CoA acetyltransferase 1	11	108121516-108147776	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004428, HPA007569	Enhanced		Enhanced	Mitochondria	Renal cancer:0.00e+0 (favourable), Liver cancer:1.43e-5 (favourable)	Expressed in all	Expressed in all			kidney: 534.2	Expressed in all		
ACAT2		ENSG00000120437	Acetyl-CoA acetyltransferase 2	6	159760328-159779055	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB021106, HPA025736, HPA025765, HPA025811	Enhanced		Supported	Nucleus<br>Cytosol	Colorectal cancer:1.12e-4 (favourable), Endometrial cancer:7.25e-4 (unfavourable), Renal cancer:7.38e-4 (unfavourable)	Expressed in all	Mixed			liver: 45.8	Expressed in all		
ACBD3	GCP60, GOCAP1, GOLPH1, PAP7	ENSG00000182827	Acyl-CoA binding domain containing 3	1	226144679-226186730	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015594	Uncertain		Supported	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 48.5	Expressed in all		
ACBD6	MGC2404	ENSG00000230124	Acyl-CoA binding domain containing 6	1	180269653-180502954	Predicted intracellular proteins	Evidence at protein level	HPA028179, HPA028457	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.02e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 42.1	Expressed in all		
ACBD7	bA455B2.2, FLJ38219	ENSG00000176244	Acyl-CoA binding domain containing 7	10	15077523-15088776	Predicted intracellular proteins	Evidence at protein level	HPA043326, HPA062478			Approved	Vesicles<br>Cytosol		Mixed	Tissue enriched	5	cerebral cortex: 40.5	testis: 7.7	Cell line enhanced		MOLT-4: 29.4
ACCS	ACS, PHACS	ENSG00000110455	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	11	44065925-44084222	Predicted intracellular proteins	Evidence at protein level	HPA018873, HPA021654	Approved		Approved	Golgi apparatus	Pancreatic cancer:4.25e-4 (favourable)	Expressed in all	Mixed			spleen: 18.8	Mixed		
ACCSL		ENSG00000205126	1-aminocyclopropane-1-carboxylate synthase homolog (inactive) like	11	44047981-44059977	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			skin,testis: 0.4	Not detected		
ACD	Pip1, Ptop, Tint1, Tpp1	ENSG00000102977	ACD, shelterin complex subunit and telomerase recruitment factor	16	67657512-67660815	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049411, HPA057660	Approved		Enhanced	Nuclear bodies	Liver cancer:2.42e-6 (unfavourable)	Expressed in all	Mixed			testis: 18.4	Expressed in all		
ACIN1	ACINUS, fSAP152, KIAA0670	ENSG00000100813	Apoptotic chromatin condensation inducer 1	14	23058564-23095614	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA000657	Supported		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:4.88e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 77.4	Expressed in all		
ACLY	ACL, ATPCL, CLATP	ENSG00000131473	ATP citrate lyase	17	41866908-41930542	Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007783, HPA022434, HPA022953, HPA022959, HPA028758	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Cervical cancer:1.79e-4 (unfavourable), Liver cancer:3.66e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 100.5	Expressed in all		
ACMSD		ENSG00000153086	Aminocarboxymuconate semialdehyde decarboxylase	2	134838547-134902034	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010533, HPA011179	Enhanced				Renal cancer:2.39e-4 (favourable)	Group enriched	Group enriched	10	kidney: 137.3;liver: 80.2	gallbladder: 10.8	Cell line enriched	16	RPTEC TERT1: 19.7
ACO1	IREB1, IREBP, IRP1	ENSG00000122729	Aconitase 1	9	32384603-32454769	Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019371, HPA024157	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:5.73e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 105.1	Expressed in all		
ACO2	ACONM	ENSG00000100412	Aconitase 2	22	41469125-41528989	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001097	Enhanced	Supported	Supported	Mitochondria	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			heart muscle: 308.9	Expressed in all		
ACOD1	CAD, IRG1	ENSG00000102794	Aconitate decarboxylase 1	13	76948497-76958642	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040143	Uncertain					Not detected	Tissue enriched	5	appendix: 1.9	lung: 0.3	Not detected		
ACOT1	ACH2, CTE-1, LACH2	ENSG00000184227	Acyl-CoA thioesterase 1	14	73537114-73543794	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043705	Approved		Approved	Mitochondria	Renal cancer:5.09e-8 (favourable)	Expressed in all	Mixed			smooth muscle: 29.4	Cell line enhanced		T-47d: 35.8
ACOT11	BFIT, BFIT1, KIAA0707, STARD14, THEA, THEM1	ENSG00000162390	Acyl-CoA thioesterase 11	1	54542257-54639192	Predicted intracellular proteins	Evidence at protein level	HPA041047	Enhanced		Supported	Cytosol	Renal cancer:3.07e-8 (favourable), Colorectal cancer:9.37e-4 (favourable)	Mixed	Mixed			duodenum: 36.4	Cell line enhanced		RT4: 32.0
ACOT12	Cach, STARD15, THEAL	ENSG00000172497	Acyl-CoA thioesterase 12	5	81330005-81394179	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA037723, HPA037724			Approved	Nucleoplasm<br>Cytosol	Liver cancer:5.30e-4 (favourable)	Tissue enriched	Tissue enriched	19	liver: 51.3	kidney: 2.7	Not detected		
ACOT13	HT012, THEM2	ENSG00000112304	Acyl-CoA thioesterase 13	6	24667035-24705065	Predicted intracellular proteins	Evidence at protein level	HPA019881	Approved		Approved	Cell Junctions	Ovarian cancer:2.53e-6 (favourable)	Expressed in all	Expressed in all			kidney: 19.9	Expressed in all		
ACOT2	Mte1, ZAP128	ENSG00000119673	Acyl-CoA thioesterase 2	14	73567620-73575658	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043705, HPA060170	Enhanced		Approved	Mitochondria	Renal cancer:2.28e-6 (favourable)	Expressed in all	Expressed in all			adipose tissue: 96.5	Mixed		
ACOT4	FLJ31235, PTE-Ib, PTE2B	ENSG00000177465	Acyl-CoA thioesterase 4	14	73591706-73596496	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000779	Enhanced				Renal cancer:8.43e-5 (favourable), Pancreatic cancer:1.77e-4 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 8.9	liver: 4.9	Cell line enhanced		CAPAN-2: 9.1;SK-BR-3: 12.3;T-47d: 38.6
ACOT6	C14orf42	ENSG00000205669	Acyl-CoA thioesterase 6	14	73610945-73619888	Predicted intracellular proteins	Evidence at protein level	HPA058258	Uncertain					Not detected	Tissue enhanced		kidney: 3.8	adipose tissue: 1.7	Cell line enriched	7	T-47d: 9.6
ACOT7	ACH1, ACT, BACH, CTE-II, hBACH, LACH1, MGC1126	ENSG00000097021	Acyl-CoA thioesterase 7	1	6264269-6394391	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA025735, HPA025762	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.55e-6 (unfavourable), Liver cancer:2.31e-5 (unfavourable), Lung cancer:1.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 129.2	small intestine: 62.3	Expressed in all		
ACOT8	hACTE-III, hTE, NAP1, PTE-2, PTE1	ENSG00000101473	Acyl-CoA thioesterase 8	20	45841721-45857406	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010261	Approved		Supported	Vesicles<br>Mitochondria	Renal cancer:3.18e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 30.1	Expressed in all		
ACOT9	ACATE2, CGI-16, MT-ACT48	ENSG00000123130	Acyl-CoA thioesterase 9	X	23702253-23766475	Predicted intracellular proteins	Evidence at protein level	HPA035533	Supported		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:3.23e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 46.9	Mixed		
ACOX1	PALMCOX	ENSG00000161533	Acyl-CoA oxidase 1	17	75941507-75979363	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB021094, HPA021192, HPA021195, HPA028759	Approved		Enhanced	Nucleus<br>Vesicles	Renal cancer:5.25e-7 (favourable)	Expressed in all	Expressed in all			liver: 98.4	Expressed in all		
ACOX2	BRCACOX, BRCOX, THCCox	ENSG00000168306	Acyl-CoA oxidase 2	3	58505136-58537319	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038280, HPA064845	Enhanced		Supported	Vesicles<br>Cytosol		Tissue enhanced	Tissue enhanced		liver: 87.9	kidney: 42.5	Cell line enhanced		ASC diff: 10.4;ASC TERT1: 17.4;fHDF/TERT166: 6.6;Hep G2: 7.0;HSkMC: 11.8
ACOX3		ENSG00000087008	Acyl-CoA oxidase 3, pristanoyl	4	8366282-8440723	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035840, HPA035841	Uncertain		Approved	Peroxisomes	Endometrial cancer:2.16e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 22.2	Expressed in all		
ACOXL	FLJ11042	ENSG00000153093	Acyl-CoA oxidase-like	2	110732573-111118222	Predicted intracellular proteins	Evidence at protein level	HPA035392, HPA035393			Supported	Nucleoli<br>Cytosol	Urothelial cancer:6.48e-4 (favourable)	Group enriched	Group enriched	6	epididymis: 9.2;lung: 14.5;parathyroid gland: 6.9;prostate: 5.2;testis: 5.2;urinary bladder: 7.6	thyroid gland: 1.3	Cell line enhanced		A-431: 11.1;RPMI-8226: 15.9;RT4: 23.3;U-266/70: 14.6
ACP1	HAAP, LMW-PTP, LMWPTP	ENSG00000143727	Acid phosphatase 1, soluble	2	264140-278283	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016754	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:6.67e-6 (unfavourable), Melanoma:3.04e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 128.8	Expressed in all		
ACSBG1	BG1, BGM, FLJ30320, hBG1, hsBG, KIAA0631, MGC14352	ENSG00000103740	Acyl-CoA synthetase bubblegum family member 1	15	78167468-78245688	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041642, CAB045955, HPA058869	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 25.6;skin: 13.3	adrenal gland: 8.1	Cell line enhanced		NTERA-2: 3.3
ACSM3	SA, SAH	ENSG00000005187	Acyl-CoA synthetase medium-chain family member 3	16	20610243-20797581	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041013	Uncertain				Renal cancer:9.88e-6 (favourable), Ovarian cancer:1.97e-4 (favourable)	Mixed	Tissue enhanced		liver: 93.2	kidney: 90.8	Group enriched	12	HEL: 85.7;HMC-1: 339.4;K-562: 258.6
ACSM5	FLJ20581	ENSG00000183549	Acyl-CoA synthetase medium-chain family member 5	16	20409534-20441336	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041435	Uncertain					Group enriched	Tissue enriched	5	liver: 142.6	adipose tissue: 26.9	Group enriched	5	ASC diff: 3.6;ASC TERT1: 8.0;HSkMC: 10.0;U-87 MG: 8.4
ACTA1	ACTA, NEM3	ENSG00000143632	Actin, alpha 1, skeletal muscle	1	229431245-229434098	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000045, HPA041264, HPA041271	Enhanced					Group enriched	Tissue enriched	14	skeletal muscle: 45978.0	heart muscle: 3193.1	Cell line enriched	30	BEWO: 452.7
ACTA2	ACTSA	ENSG00000107796	Actin, alpha 2, smooth muscle, aorta	10	88935074-88991339	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000002, CAB003761, CAB013531, HPA041264, HPA041271	Enhanced		Supported	Actin filaments	Renal cancer:1.37e-8 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 11741.0	Cell line enhanced		ASC TERT1: 273.9;fHDF/TERT166: 496.7;HHSteC: 525.6;HSkMC: 250.7
ACTB		ENSG00000075624	Actin beta	7	5527151-5563784	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002621, HPA041264, HPA041271	Supported				Renal cancer:3.78e-5 (unfavourable), Head and neck cancer:4.51e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 7221.8	Expressed in all		
ACTBL2	DKFZp686D0972	ENSG00000169067	Actin, beta like 2	5	57480016-57482809	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271	Uncertain					Not detected	Not detected			cervix, uterine: 0.3	Cell line enhanced		RPTEC TERT1: 1.2;SiHa: 3.0;U-2 OS: 1.8
ACTC1	ACTC, CMD1R	ENSG00000159251	Actin, alpha, cardiac muscle 1	15	34788096-34796139	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037330, HPA041264, HPA041271	Enhanced				Head and neck cancer:3.72e-5 (unfavourable), Urothelial cancer:9.32e-4 (unfavourable)	Group enriched	Tissue enriched	10	heart muscle: 1903.0	seminal vesicle: 191.9	Group enriched	7	fHDF/TERT166: 217.0;LHCN-M2: 930.7;RH-30: 512.0
ACTG1	ACTG, DFNA20, DFNA26	ENSG00000184009	Actin gamma 1	17	81509971-81523847	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271	Approved				Colorectal cancer:2.41e-4 (favourable)	Expressed in all	Expressed in all			ovary: 2397.0	Expressed in all		
ACTG2	ACTA3, ACTL3, ACTSG	ENSG00000163017	Actin, gamma 2, smooth muscle, enteric	2	73892314-73919865	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271	Supported				Renal cancer:3.95e-7 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 8158.9;smooth muscle: 11634.7	prostate: 3438.5	Cell line enhanced		BEWO: 57.4;BJ hTERT+ SV40 Large T+: 177.9;U-251 MG: 176.7
ACTL6A	Actl6, Arp4, BAF53A, INO80K	ENSG00000136518	Actin like 6A	3	179562880-179588408	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012188, HPA018671	Supported		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.89e-5 (unfavourable), Renal cancer:4.80e-5 (unfavourable), Pancreatic cancer:5.44e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 112.6	Expressed in all		
ACTL6B	ACTL6, BAF53B	ENSG00000077080	Actin like 6B	7	100643097-100656461	Predicted intracellular proteins	Evidence at protein level	HPA045126	Uncertain		Approved	Nucleoli		Group enriched	Tissue enriched	19	cerebral cortex: 45.6	adrenal gland: 2.4	Group enriched	92	SCLC-21H: 33.1;SH-SY5Y: 30.4
ACTL7A		ENSG00000187003	Actin like 7A	9	108862266-108863759	Predicted intracellular proteins	Evidence at protein level	HPA021624	Enhanced					Not detected	Tissue enriched	1938	testis: 193.7	all non-specific tissues: 0.0	Not detected		
ACTL7B	Tact1	ENSG00000148156	Actin like 7B	9	108854589-108856967	Predicted intracellular proteins	Evidence at protein level	HPA021803, HPA024664	Enhanced					Not detected	Tissue enriched	589	testis: 58.9	all non-specific tissues: 0.0	Not detected		
ACTL8	CT57	ENSG00000117148	Actin like 8	1	17755313-17827063	Predicted intracellular proteins	Evidence at protein level	HPA027176			Approved	Cytosol	Endometrial cancer:1.62e-6 (unfavourable), Head and neck cancer:7.02e-4 (unfavourable)	Mixed	Tissue enriched	35	testis: 10.0	colon,rectum: 0.2	Cell line enriched	9	U-266/84: 168.8
ACTL9	MGC33407	ENSG00000181786	Actin like 9	19	8697397-8698822	Predicted intracellular proteins	Evidence at protein level	HPA019231, HPA026693	Uncertain					Not detected	Tissue enriched	501	testis: 50.0	all non-specific tissues: 0.0	Not detected		
ACTN1		ENSG00000072110	Actinin alpha 1	14	68874143-68979440	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004303, HPA006035	Approved		Approved	Plasma membrane<br>Focal adhesion sites	Renal cancer:9.08e-10 (unfavourable), Lung cancer:7.63e-5 (unfavourable), Head and neck cancer:2.49e-4 (unfavourable), Urothelial cancer:8.00e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 754.0	Mixed		
ACTN2		ENSG00000077522	Actinin alpha 2	1	236686454-236764631	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA006035, HPA008315	Enhanced					Tissue enhanced	Group enriched	28	heart muscle: 477.5;skeletal muscle: 758.7	esophagus: 22.4	Cell line enhanced		HEK93: 1.8;HSkMC: 5.5;hTEC/SVTERT24-B: 4.9
ACTN3		ENSG00000248746	Actinin alpha 3 (gene/pseudogene)	11	66546395-66563329	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006035	Uncertain					Tissue enhanced	Tissue enriched	124	skeletal muscle: 556.5	testis: 4.4	Cell line enriched	15	HDLM-2: 12.3
ACTN4	FSGS1	ENSG00000130402	Actinin alpha 4	19	38647649-38731583	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001873, HPA006035	Supported		Approved	Nuclear bodies<br>Cytosol	Renal cancer:5.25e-5 (favourable), Pancreatic cancer:5.65e-4 (unfavourable), Lung cancer:8.82e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 118.4	Expressed in all		
ACTR10	ACTR11, Arp10, Arp11, HARP11	ENSG00000131966	Actin-related protein 10 homolog	14	58200080-58235636	Predicted intracellular proteins	Evidence at protein level	HPA071251			Supported	Nucleoli	Renal cancer:8.48e-8 (favourable), Liver cancer:2.71e-5 (unfavourable), Breast cancer:3.24e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 11.7	Expressed in all		
ACTR1A	ARP1, Arp1A	ENSG00000138107	ARP1 actin-related protein 1 homolog A, centractin alpha	10	102461881-102502711	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037193, HPA047443	Approved		Approved	Microtubules		Expressed in all	Expressed in all			cerebral cortex: 114.3	Expressed in all		
ACTR1B	Arp1B, CTRN2	ENSG00000115073	ARP1 actin-related protein 1 homolog B, centractin beta	2	97655963-97664107	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047443			Approved	Microtubules	Urothelial cancer:4.69e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 82.0	Expressed in all		
ACTR2	ARP2	ENSG00000138071	ARP2 actin related protein 2 homolog	2	65227753-65271253	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005083, HPA015050	Approved		Approved	Cytosol	Liver cancer:4.50e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 292.2	Expressed in all		
ACTR3	ARP3	ENSG00000115091	ARP3 actin related protein 3 homolog	2	113889960-113962596	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005085, HPA047016, HPA051683	Approved				Renal cancer:3.81e-5 (unfavourable), Cervical cancer:6.52e-5 (unfavourable), Liver cancer:7.76e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 335.6	Expressed in all		
ACTR3B	ARP11, ARP3beta	ENSG00000133627	ARP3 actin related protein 3 homolog B	7	152759749-152855378	Predicted intracellular proteins	Evidence at protein level	HPA047016, HPA051683	Uncertain				Renal cancer:1.66e-4 (favourable), Stomach cancer:4.53e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 50.9	Mixed		
ACTR3C	ARP11	ENSG00000106526	ARP3 actin-related protein 3 homolog C	7	150243916-150323725	Predicted intracellular proteins	Evidence at transcript level	HPA055957	Uncertain					Mixed	Tissue enriched	6	parathyroid gland: 87.3	adrenal gland: 15.8	Cell line enhanced		CAPAN-2: 27.5;RT4: 21.3;SiHa: 18.9
ACTR5	Arp5, FLJ12785, INO80M	ENSG00000101442	ARP5 actin-related protein 5 homolog	20	38748442-38772520	Predicted intracellular proteins	Evidence at protein level	HPA042676	Approved				Liver cancer:1.84e-5 (unfavourable), Renal cancer:1.37e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.5	Expressed in all		
ACTR6	ARP6, FLJ13433	ENSG00000075089	ARP6 actin-related protein 6 homolog	12	100199122-100241865	Predicted intracellular proteins	Evidence at protein level	HPA038587, HPA038588	Uncertain		Approved	Plasma membrane<br>Cytosol	Liver cancer:7.70e-9 (unfavourable)	Expressed in all	Mixed			testis: 16.2	Expressed in all		
ACTR8	INO80N	ENSG00000113812	ARP8 actin-related protein 8 homolog	3	53867066-53882202	Predicted intracellular proteins	Evidence at protein level	HPA065236			Supported	Nucleus<br>Centrosome	Renal cancer:7.88e-9 (favourable), Liver cancer:5.11e-6 (unfavourable), Colorectal cancer:2.21e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.5	Expressed in all		
ACTRT1	AIP1, ARIP1, Arp-T1, KIAA0705	ENSG00000123165	Actin related protein T1	X	128050962-128052398	Predicted intracellular proteins	Evidence at protein level	HPA003119	Supported					Not detected	Tissue enriched	36	testis: 3.6	all non-specific tissues: 0.0	Not detected		
ACTRT2	Arp-T2, ARPM2, FLJ25424	ENSG00000169717	Actin related protein T2	1	3021483-3022903	Predicted intracellular proteins	Evidence at protein level	HPA006480, HPA025079	Enhanced					Not detected	Tissue enriched	1022	testis: 102.2	all non-specific tissues: 0.0	Not detected		
ACTRT3	ARPM1	ENSG00000184378	Actin related protein T3	3	169766921-169769895	Predicted intracellular proteins	Evidence at protein level	HPA035817, HPA035818	Approved		Approved	Nucleoplasm	Endometrial cancer:4.11e-4 (unfavourable)	Mixed	Tissue enriched	22	testis: 60.6	fallopian tube: 2.7	Cell line enhanced		ASC diff: 10.2
ACY1		ENSG00000243989	Aminoacylase 1	3	51983278-51989202	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003695, HPA036174, HPA036175	Enhanced				Renal cancer:2.93e-4 (favourable), Urothelial cancer:6.77e-4 (favourable)	Expressed in all	Group enriched	5	duodenum: 130.8;kidney: 356.0;liver: 114.9;small intestine: 103.3	parathyroid gland: 35.0	Mixed		
ACY3	ACY-3, HCBP1, MGC9740	ENSG00000132744	Aminoacylase 3	11	67642555-67650659	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039219, HPA048187	Enhanced				Endometrial cancer:4.80e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 80.6;kidney: 53.3;small intestine: 78.6	cervix, uterine: 16.1	Cell line enhanced		CACO-2: 8.4;CAPAN-2: 13.6;Daudi: 41.2
ADA		ENSG00000196839	Adenosine deaminase	20	44619522-44652233	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001399, CAB004307, HPA023884	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.94e-14 (unfavourable), Endometrial cancer:1.23e-7 (unfavourable), Liver cancer:6.77e-5 (unfavourable), Lung cancer:2.20e-4 (unfavourable)	Expressed in all	Tissue enriched	13	duodenum: 487.7	lymph node: 36.5	Cell line enriched	9	MOLT-4: 1479.5
ADAD1	Tenr	ENSG00000164113	Adenosine deaminase domain containing 1	4	122378966-122429802	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	2122	testis: 212.1	all non-specific tissues: 0.0	Not detected		
ADAD2	FLJ00337, TENRL	ENSG00000140955	Adenosine deaminase domain containing 2	16	84191138-84197168	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	43	testis: 32.3	cerebral cortex,skin: 0.7	Cell line enriched	10	SCLC-21H: 3.2
ADAL		ENSG00000168803	Adenosine deaminase like	15	43330674-43354555	Predicted intracellular proteins	Evidence at protein level	HPA046215, HPA048175	Approved		Approved	Microtubules	Renal cancer:7.64e-9 (favourable)	Expressed in all	Mixed			testis: 24.8	Mixed		
ADAP1	CENTA1, GCS1L	ENSG00000105963	ArfGAP with dual PH domains 1	7	897901-955407	Predicted intracellular proteins	Evidence at protein level	HPA007033, HPA012049	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.13e-5 (favourable), Colorectal cancer:5.25e-4 (unfavourable), Head and neck cancer:9.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 80.4	colon: 37.9	Cell line enhanced		A-431: 97.9;CAPAN-2: 69.1;HMC-1: 64.7;THP-1: 87.7
ADAP2	CENTA2	ENSG00000184060	ArfGAP with dual PH domains 2	17	30906344-30959322	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.36e-6 (unfavourable), Liver cancer:3.12e-4 (unfavourable), Head and neck cancer:3.97e-4 (favourable), Colorectal cancer:5.62e-4 (unfavourable)	Expressed in all	Mixed			spleen: 29.3	Cell line enhanced		HAP1: 17.5;HEK93: 9.1;RPMI-8226: 15.4
ADAR	ADAR1, G1P1, IFI4	ENSG00000160710	Adenosine deaminase, RNA specific	1	154582062-154627999	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003890, HPA051519, CAB056157	Enhanced		Enhanced	Nucleus<br>Nucleoli	Renal cancer:7.30e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 121.4	Expressed in all		
ADARB1	ADAR2, ADAR2a, ADAR2a-L1, ADAR2a-L2, ADAR2a-L3, ADAR2b, ADAR2c, ADAR2d, ADAR2g, DRABA2, DRADA2, hRED1, RED1	ENSG00000197381	Adenosine deaminase, RNA specific B1	21	45073853-45226560	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029645			Supported	Nucleoplasm<br>Cytosol	Colorectal cancer:8.16e-5 (unfavourable), Renal cancer:3.56e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 30.2	Cell line enhanced		HHSteC: 55.4
ADARB2	ADAR3, hRED2, RED2	ENSG00000185736	Adenosine deaminase, RNA specific B2 (inactive)	10	1177318-1737476	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	6	cerebral cortex: 13.1	testis: 2.1	Not detected		
ADAT1		ENSG00000065457	Adenosine deaminase, tRNA specific 1	16	75596981-75623300	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040713, HPA040903	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 91.2	Expressed in all		
ADAT2	DEADC1, dJ20N2.1, TAD2	ENSG00000189007	Adenosine deaminase, tRNA specific 2	6	143422832-143450673	Predicted intracellular proteins	Evidence at protein level	HPA035479	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Expressed in all	Mixed			skin: 13.0	Expressed in all		
ADAT3	TAD3	ENSG00000213638	Adenosine deaminase, tRNA specific 3	19	1905378-1913447	Predicted intracellular proteins	Evidence at protein level	HPA058899	Uncertain		Approved	Nucleus	Head and neck cancer:6.13e-4 (favourable), Stomach cancer:6.98e-4 (favourable)	Expressed in all	Tissue enhanced		duodenum: 7.5	small intestine: 5.3	Cell line enhanced		HEK93: 11.3
ADD1		ENSG00000087274	Adducin 1	4	2843857-2930076	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009794, HPA035873, HPA035874	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane	Renal cancer:1.29e-7 (favourable), Pancreatic cancer:3.94e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 201.1	Expressed in all		
ADD2	ADDB	ENSG00000075340	Adducin 2	2	70607618-70768225	Predicted intracellular proteins	Evidence at protein level	CAB009796, HPA034509, HPA034510	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enhanced	Group enriched	10	bone marrow: 40.2;cerebral cortex: 44.7	testis: 4.2	Cell line enhanced		K-562: 41.5;NTERA-2: 86.7;SCLC-21H: 50.4;U-251 MG: 38.9
ADD3	ADDL	ENSG00000148700	Adducin 3	10	109996368-110135565	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009797, HPA035696	Supported		Supported	Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 168.6	Cell line enhanced		ASC diff: 215.0;ASC TERT1: 204.7
ADGB	C6orf103, CAPN16, dJ408K24.1, FLJ23121	ENSG00000118492	Androglobin	6	146598965-146815462	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036340, HPA036341	Enhanced		Uncertain	Nucleoplasm<br>Mitochondria		Not detected	Group enriched	25	fallopian tube: 14.9;testis: 58.5	lung: 1.4	Cell line enriched	25	HDLM-2: 13.3
ADH1A	ADH1	ENSG00000187758	Alcohol dehydrogenase 1A (class I), alpha polypeptide	4	99276367-99291028	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009562, HPA047814, HPA060902	Enhanced		Approved	Plasma membrane<br>Cytosol	Liver cancer:2.38e-4 (favourable)	Tissue enriched	Tissue enriched	135	liver: 1367.7	gallbladder: 10.1	Cell line enhanced		ASC diff: 3.7
ADH1B	ADH2	ENSG00000196616	Alcohol dehydrogenase 1B (class I), beta polypeptide	4	99304964-99352760	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047814, HPA060902	Supported		Approved	Plasma membrane<br>Cytosol	Renal cancer:7.87e-4 (unfavourable)	Tissue enriched	Group enriched	6	adipose tissue: 1624.6;liver: 3000.2	lung: 388.5	Cell line enriched	7	ASC diff: 4511.9
ADH1C	ADH3	ENSG00000248144	Alcohol dehydrogenase 1C (class I), gamma polypeptide	4	99336492-99353027	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047814, HPA060902	Supported		Supported	Plasma membrane<br>Cytosol	Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 508.1;liver: 888.0;stomach: 477.4	colon: 276.3	Cell line enhanced		ASC TERT1: 2.5;HSkMC: 7.7
ADH4	ADH-2	ENSG00000198099	Alcohol dehydrogenase 4 (class II), pi polypeptide	4	99123657-99157792	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020525	Enhanced		Uncertain	Nucleus<br>Cytosol	Liver cancer:7.08e-6 (favourable)	Tissue enriched	Tissue enriched	16	liver: 2628.5	duodenum: 166.3	Cell line enriched	7	Hep G2: 15.2
ADH5	ADH-3, ADHX, FDH, GSNOR	ENSG00000197894	Alcohol dehydrogenase 5 (class III), chi polypeptide	4	99070978-99088801	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044578, HPA061919	Approved				Renal cancer:4.58e-10 (favourable), Endometrial cancer:9.90e-5 (favourable), Melanoma:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 198.2	Expressed in all		
ADH6	ADH-5	ENSG00000172955	Alcohol dehydrogenase 6 (class V)	4	99202638-99219537	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA067946, HPA069081	Enhanced					Tissue enriched	Tissue enriched	7	liver: 359.6	kidney: 53.5	Group enriched	8	Hep G2: 30.3;RPTEC TERT1: 6.8
ADH7	ADH-4	ENSG00000196344	Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	4	99412261-99435737	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039695	Enhanced		Supported	Plasma membrane<br>Cytosol		Group enriched	Tissue enriched	6	esophagus: 215.5	tonsil: 34.5	Cell line enhanced		HaCaT: 1.0
ADHFE1	ADHFe1, FLJ32430	ENSG00000147576	Alcohol dehydrogenase, iron containing 1	8	66430185-66471601	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023062	Enhanced		Approved	Vesicles	Renal cancer:4.55e-5 (favourable), Breast cancer:5.76e-5 (favourable), Liver cancer:9.90e-5 (favourable)	Mixed	Mixed			liver: 14.3	Cell line enhanced		ASC diff: 1.1;RPTEC TERT1: 1.2
ADIRF	AFRO, APM2, C10orf116	ENSG00000148671	Adipogenesis regulatory factor	10	86968192-86983934	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026810	Approved		Supported	Nucleoplasm<br>Cytosol		Not detected	Tissue enhanced		adipose tissue: 265.8	small intestine: 144.5	Cell line enhanced		A-431: 92.8;HaCaT: 235.9;PC-3: 133.9;RT4: 150.3
ADK	AK	ENSG00000156110	Adenosine kinase	10	74151185-74709303	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB032876, HPA038391, HPA038409	Approved		Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:1.93e-4 (unfavourable), Liver cancer:9.91e-4 (favourable)	Expressed in all	Expressed in all			liver: 77.6	Expressed in all		
ADNP	ADNP1, KIAA0784	ENSG00000101126	Activity dependent neuroprotector homeobox	20	50888919-50931240	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006371	Supported		Approved	Nucleoplasm	Liver cancer:1.65e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 81.7	Expressed in all		
ADNP2	KIAA0863, ZNF508	ENSG00000101544	ADNP homeobox 2	18	80109031-80147523	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007126	Uncertain		Approved	Mitochondria<br>Cytosol	Renal cancer:6.39e-5 (favourable), Thyroid cancer:9.90e-4 (unfavourable)	Expressed in all	Mixed			testis: 39.7	Mixed		
ADO	C10orf22, FLJ14547	ENSG00000181915	2-aminoethanethiol dioxygenase	10	62804857-62808483	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039194, HPA040437	Approved				Liver cancer:8.01e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 70.7	Expressed in all		
ADPRH	ARH1	ENSG00000144843	ADP-ribosylarginine hydrolase	3	119579268-119589945	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB001701, HPA036961	Approved		Approved	Nucleus<br>Nuclear membrane	Breast cancer:2.42e-4 (favourable)	Expressed in all	Mixed			lung: 20.1	Cell line enhanced		HDLM-2: 22.2;HMC-1: 16.3;Karpas-707: 18.2;U-266/70: 18.7
ADPRHL1	ARH2	ENSG00000153531	ADP-ribosylhydrolase like 1	13	113399610-113453524	Predicted intracellular proteins	Evidence at protein level	HPA066478	Enhanced		Approved	Nucleoplasm	Liver cancer:2.55e-5 (unfavourable), Head and neck cancer:4.88e-4 (unfavourable)	Mixed	Group enriched	14	heart muscle: 258.3;skeletal muscle: 114.3	fallopian tube: 13.2	Cell line enhanced		SCLC-21H: 24.5;T-47d: 35.4
ADRM1	ARM1, GP110, Rpn13	ENSG00000130706	Adhesion regulating molecule 1	20	62302093-62308862	Predicted intracellular proteins	Evidence at protein level	HPA042266	Supported		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:9.02e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 108.5	Expressed in all		
ADSL		ENSG00000239900	Adenylosuccinate lyase	22	40346500-40390463	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000525, CAB019285	Enhanced		Enhanced	Cytosol	Liver cancer:5.81e-8 (unfavourable), Colorectal cancer:2.38e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 127.3	Expressed in all		
ADSS		ENSG00000035687	Adenylosuccinate synthase	1	244408494-244452134	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024400	Enhanced		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 117.0	Expressed in all		
ADSSL1	FLJ38602	ENSG00000185100	Adenylosuccinate synthase like 1	14	104724186-104747325	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.99e-4 (unfavourable)	Mixed	Tissue enriched	7	skeletal muscle: 428.0	heart muscle: 63.0	Cell line enhanced		EFO-21: 13.7;MCF7: 10.4;SiHa: 23.7
AEBP2	MGC17922	ENSG00000139154	AE binding protein 2	12	19404045-19720801	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020893, HPA022282	Uncertain		Supported	Nucleus	Liver cancer:3.24e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 57.5	Expressed in all		
AEN	FLJ12484, FLJ12562, ISG20L1	ENSG00000181026	Apoptosis enhancing nuclease	15	88621296-88632282	Predicted intracellular proteins	Evidence at protein level	HPA048599			Supported	Nucleus<br>Nuclear membrane<br>Nucleoli	Endometrial cancer:1.72e-4 (favourable)	Expressed in all	Mixed			gallbladder: 19.8	Expressed in all		
AES	GRG5, TLE5	ENSG00000104964	Amino-terminal enhancer of split	19	3052910-3063107	Predicted intracellular proteins	Evidence at protein level	HPA049499			Supported	Nucleoplasm	Endometrial cancer:3.89e-4 (favourable), Renal cancer:7.74e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 331.2	Mixed		
AF011889.5		ENSG00000241489		X	149482543-149533935	Predicted intracellular proteins	Evidence at transcript level							Not detected	Expressed in all			epididymis: 65.7	Mixed		
AF165138.7		ENSG00000243440		21	14591930-14658821	Predicted intracellular proteins	Evidence at transcript level	HPA046639	Uncertain					Not detected	Not detected			appendix: 0.7	Group enriched	7	HEL: 3.4;NTERA-2: 2.3
AFAP1	AFAP, AFAP-110	ENSG00000196526	Actin filament associated protein 1	4	7758714-7939926	Predicted intracellular proteins	Evidence at protein level	HPA015642, CAB024712	Enhanced		Supported	Actin filaments<br>Focal adhesion sites<br>Cytosol	Lung cancer:2.84e-4 (unfavourable), Renal cancer:8.18e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 42.9	Cell line enhanced		TIME: 103.1
AFAP1L1	FLJ36748	ENSG00000157510	Actin filament associated protein 1 like 1	5	149271871-149341802	Predicted intracellular proteins	Evidence at protein level						Colorectal cancer:2.84e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 29.8	Cell line enhanced		BEWO: 57.1;TIME: 37.4;WM-115: 105.1
AFAP1L2	Em:AC005383.4, FLJ14564, KIAA1914, XB130	ENSG00000169129	Actin filament associated protein 1 like 2	10	114294824-114404756	Predicted intracellular proteins	Evidence at protein level	HPA037843	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.55e-5 (unfavourable), Pancreatic cancer:3.76e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 138.0	parathyroid gland: 94.7	Cell line enhanced		A-431: 64.5;CAPAN-2: 68.1;EFO-21: 53.1;HaCaT: 87.3;RPMI-8226: 36.0;RPTEC TERT1: 45.2
AFDN	AF-6, AF6, MLLT4	ENSG00000130396	Afadin, adherens junction formation factor	6	167826922-167972023	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868	Approved		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Breast cancer:7.43e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 110.7	Mixed		
AFF1	AF-4, AF4, MLLT2, PBM1	ENSG00000172493	AF4/FMR2 family member 1	4	86935002-87141054	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA069947			Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			thyroid gland: 91.6	Expressed in all		
AFF2	FMR2, FRAXE	ENSG00000155966	AF4/FMR2 family member 2	X	148500619-149000663	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003139	Approved					Mixed	Tissue enhanced		epididymis: 14.5;placenta: 21.1	bone marrow: 8.3	Cell line enhanced		Daudi: 52.9;HL-60: 25.2;U-698: 74.2;U-937: 18.0
AFF3	LAF4, MLLT2-like	ENSG00000144218	AF4/FMR2 family member 3	2	99545419-100142739	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA044512, HPA053379	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.64e-4 (unfavourable)	Tissue enhanced	Mixed			prostate: 29.7	Cell line enhanced		Daudi: 35.6;U-698: 50.7
AFF4	AF5Q31, MCEF	ENSG00000072364	AF4/FMR2 family member 4	5	132875379-132963634	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023690, HPA029634	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Thyroid cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.2	Expressed in all		
AFMID	DKFZp686F03259, KF	ENSG00000183077	Arylformamidase	17	78187317-78207701	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023861, HPA026536	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			kidney: 87.5	Expressed in all		
AFTPH	FLJ20080, FLJ23793, MGC33965, Nbla10388	ENSG00000119844	Aftiphilin	2	64524305-64593005	Predicted intracellular proteins	Evidence at protein level	HPA034990, HPA034991	Approved		Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Renal cancer:2.37e-5 (favourable), Urothelial cancer:1.83e-4 (favourable), Stomach cancer:8.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 65.7	Expressed in all		
AGAP1	CENTG2, GGAP1, KIAA1099	ENSG00000157985	ArfGAP with GTPase domain, ankyrin repeat and PH domain 1	2	235494089-236131800	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051405	Uncertain				Liver cancer:2.60e-5 (unfavourable), Renal cancer:6.52e-5 (favourable), Ovarian cancer:9.75e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.5	Cell line enhanced		SCLC-21H: 93.8
AGAP2	CENTG1	ENSG00000135439	ArfGAP with GTPase domain, ankyrin repeat and PH domain 2	12	57723761-57742157	Predicted intracellular proteins	Evidence at protein level	HPA023474	Approved		Supported	Nucleus<br>Nucleoli<br>Mitochondria		Tissue enriched	Tissue enriched	7	cerebral cortex: 144.5	lymph node: 19.8	Cell line enhanced		RH-30: 95.5
AGAP3	CENTG3	ENSG00000133612	ArfGAP with GTPase domain, ankyrin repeat and PH domain 3	7	151085831-151144436	Predicted intracellular proteins	Evidence at protein level	HPA012883	Approved				Renal cancer:8.58e-5 (unfavourable), Liver cancer:6.21e-4 (unfavourable), Colorectal cancer:9.52e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 92.5	Mixed		
AGAP4	AGAP8, CTGLF1, CTGLF5, Em:AC012044.1, MRIP2	ENSG00000188234	ArfGAP with GTPase domain, ankyrin repeat and PH domain 4	10	45825594-45853875	Predicted intracellular proteins	Evidence at transcript level	HPA042490	Uncertain					Mixed	Expressed in all			skin: 24.7	Mixed		
AGAP5	CTGLF2, Em:AC073389.1	ENSG00000172650	ArfGAP with GTPase domain, ankyrin repeat and PH domain 5	10	73674285-73698159	Predicted intracellular proteins	Evidence at transcript level	HPA042490	Uncertain					Not detected	Mixed			testis: 11.6	Expressed in all		
AGAP6	bA324H6.1, CTGLF3	ENSG00000204149	ArfGAP with GTPase domain, ankyrin repeat and PH domain 6	10	49982190-50010499	Predicted intracellular proteins	Evidence at transcript level	HPA042490	Uncertain				Renal cancer:9.70e-10 (unfavourable), Urothelial cancer:1.83e-7 (favourable), Pancreatic cancer:2.66e-4 (favourable)	Expressed in all	Expressed in all			skin: 21.8	Expressed in all		
AGAP9	bA301J7.2, CTGLF6, FLJ00312	ENSG00000204172	ArfGAP with GTPase domain, ankyrin repeat and PH domain 9	10	47501854-47523638	Predicted intracellular proteins	Evidence at transcript level	HPA042490	Uncertain				Renal cancer:3.02e-5 (unfavourable), Colorectal cancer:9.98e-5 (unfavourable), Urothelial cancer:7.04e-4 (favourable)	Expressed in all	Expressed in all			skin: 26.3	Mixed		
AGBL1	CCP4, FLJ32310	ENSG00000273540	ATP/GTP binding protein like 1	15	86079973-87029052	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		lung: 1.3;skeletal muscle: 4.4	esophagus: 1.0	Not detected		
AGBL2	CCP2, FLJ23598	ENSG00000165923	ATP/GTP binding protein like 2	11	47659591-47715389	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007718	Uncertain					Mixed	Group enriched	7	fallopian tube: 15.3;testis: 22.6	epididymis: 2.8	Cell line enhanced		CAPAN-2: 4.0
AGBL3	CCP3, MGC32955	ENSG00000146856	ATP/GTP binding protein like 3	7	134986508-135147963	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020397, HPA024150	Uncertain		Uncertain	Nuclear speckles<br>Mitochondria<br>Cytosol	Renal cancer:4.02e-4 (unfavourable)	Mixed	Mixed			epididymis: 9.6	Cell line enhanced		HEK93: 5.1
AGBL4	CCP6, FLJ14442	ENSG00000186094	ATP/GTP binding protein like 4	1	48532855-50023913	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA037994	Approved					Not detected	Tissue enhanced		cerebral cortex: 7.9	fallopian tube: 4.6	Cell line enhanced		NTERA-2: 1.1;SCLC-21H: 1.9
AGBL5	CCP5, FLJ21839	ENSG00000084693	ATP/GTP binding protein like 5	2	27042364-27070622	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030981	Uncertain		Supported	Microtubules<br>Cytokinetic bridge<br>Cytosol	Liver cancer:6.87e-5 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 357.5	parathyroid gland: 50.4	Expressed in all		
AGFG1	HRB, RAB, RIP	ENSG00000173744	ArfGAP with FG repeats 1	2	227472152-227561214	Predicted intracellular proteins	Evidence at protein level	HPA008741	Approved		Supported	Vesicles	Liver cancer:7.31e-6 (unfavourable), Ovarian cancer:3.43e-5 (unfavourable), Lung cancer:1.85e-4 (unfavourable), Renal cancer:6.92e-4 (unfavourable), Cervical cancer:7.13e-4 (unfavourable), Glioma:7.89e-4 (favourable)	Expressed in all	Expressed in all			testis: 169.2	Expressed in all		
AGFG2	HRBL, RABR	ENSG00000106351	ArfGAP with FG repeats 2	7	100539211-100568219	Predicted intracellular proteins	Evidence at protein level	HPA019689	Enhanced				Renal cancer:1.03e-6 (favourable), Pancreatic cancer:9.64e-4 (favourable)	Expressed in all	Tissue enriched	6	salivary gland: 127.1	skin: 22.8	Expressed in all		
AGGF1	FLJ10283, GPATC7, GPATCH7, HSU84971, VG5Q	ENSG00000164252	Angiogenic factor with G-patch and FHA domains 1	5	77029251-77065234	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Colorectal cancer:2.87e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.8	Mixed		
AGMAT	FLJ23384	ENSG00000116771	Agmatinase	1	15572353-15585110	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026443, HPA028321	Enhanced				Renal cancer:5.13e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 158.9	liver: 36.6	Cell line enhanced		CACO-2: 35.2;Hep G2: 70.8
AGO1	EIF2C1, hAGO1	ENSG00000092847	Argonaute 1, RISC catalytic component	1	35869808-35930528	Predicted intracellular proteins	Evidence at protein level						Liver cancer:4.57e-5 (unfavourable), Renal cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 16.0	Expressed in all		
AGO2	CASC7, EIF2C2, hAGO2, LINC00980, Q10	ENSG00000123908	Argonaute 2, RISC catalytic component	8	140520156-140635619	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB019309, HPA058075	Approved		Supported	Nucleoplasm<br>Cell Junctions	Renal cancer:1.82e-5 (unfavourable), Endometrial cancer:1.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.0	Expressed in all		
AGO3	EIF2C3, FLJ12765, hAGO3	ENSG00000126070	Argonaute 3, RISC catalytic component	1	35930718-36072500	Predicted intracellular proteins	Evidence at protein level	HPA048342, HPA075436	Uncertain		Supported	Nucleoplasm<br>Cytoplasmic bodies	Endometrial cancer:5.70e-4 (unfavourable)	Mixed	Mixed			testis: 10.3	Expressed in all		
AGO4	EIF2C4, FLJ20033, hAGO4, KIAA1567	ENSG00000134698	Argonaute 4, RISC catalytic component	1	35808172-35857890	Predicted intracellular proteins	Evidence at protein level	CAB012179, HPA068896	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Head and neck cancer:5.70e-5 (favourable)	Expressed in all	Expressed in all			skin: 24.4	Mixed		
AGXT	AGT, AGT1, AGXT1, PH1, SPAT, SPT	ENSG00000172482	Alanine-glyoxylate aminotransferase	2	240868479-240880502	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035370, HPA035371	Enhanced		Supported	Vesicles	Liver cancer:5.92e-5 (favourable)	Tissue enriched	Tissue enriched	58	liver: 611.6	kidney: 10.4	Cell line enhanced		Hep G2: 5.6;SK-BR-3: 1.1
AGXT2	AGT2	ENSG00000113492	Alanine--glyoxylate aminotransferase 2	5	34998101-35048135	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037382	Enhanced				Renal cancer:7.47e-4 (favourable)	Group enriched	Group enriched	33	kidney: 197.9;liver: 59.3	small intestine: 3.9	Not detected		
AHCTF1	ELYS	ENSG00000153207	AT-hook containing transcription factor 1	1	246839098-246931978	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA031658	Uncertain		Supported	Nuclear membrane	Renal cancer:3.49e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 61.5	Expressed in all		
AHCY	SAHH	ENSG00000101444	Adenosylhomocysteinase	20	34280268-34311802	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041225, HPA044675	Approved		Supported	Cytosol		Expressed in all	Expressed in all			kidney: 159.4	Expressed in all		
AHCYL1	IRBIT, PPP1R78, XPVKONA	ENSG00000168710	Adenosylhomocysteinase like 1	1	109984686-110023741	Predicted intracellular proteins	Evidence at protein level	HPA042589	Approved		Supported	Cytosol	Colorectal cancer:7.00e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 253.8	Expressed in all		
AHDC1	DJ159A19.3, RP1-159A19.1	ENSG00000126705	AT-hook DNA binding motif containing 1	1	27534035-27604431	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028648, HPA028691	Approved		Supported	Nucleus	Endometrial cancer:1.20e-4 (unfavourable), Head and neck cancer:2.68e-4 (favourable), Ovarian cancer:4.92e-4 (unfavourable)	Expressed in all	Mixed			spleen: 16.0	Mixed		
AHI1	FLJ20069, JBTS3, ORF1	ENSG00000135541	Abelson helper integration site 1	6	135283532-135497776	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031698, HPA046684	Approved		Approved	Centrosome	Renal cancer:4.07e-9 (unfavourable), Pancreatic cancer:7.51e-5 (favourable)	Expressed in all	Mixed			testis: 51.3	Mixed		
AHNAK	MGC5395	ENSG00000124942	AHNAK nucleoprotein	11	62433542-62556235	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019010, HPA019070, HPA026643	Uncertain		Supported	Plasma membrane<br>Cytosol	Urothelial cancer:3.47e-6 (unfavourable), Pancreatic cancer:2.42e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 397.0	Mixed		
AHNAK2	C14orf78	ENSG00000185567	AHNAK nucleoprotein 2	14	104937244-104978357	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA000878, HPA002940, HPA004145, HPA020111	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Pancreatic cancer:4.05e-6 (unfavourable), Urothelial cancer:2.23e-5 (unfavourable), Lung cancer:2.79e-5 (unfavourable)	Mixed	Tissue enriched	7	skin: 345.5	smooth muscle: 46.8	Cell line enhanced		hTCEpi: 224.2
AHR	bHLHe76	ENSG00000106546	Aryl hydrocarbon receptor	7	17298622-17346152	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005072, HPA029722, HPA029723	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			lung: 56.4	Mixed		
AHRR	AHH, AHHR, bHLHe77, KIAA1234	ENSG00000063438	Aryl-hydrocarbon receptor repressor	5	304176-438291	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021483			Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	8	testis: 65.2	skin: 7.9	Cell line enhanced		HMC-1: 89.0;NB-4: 80.8;WM-115: 71.5
AHSA1	Aha1, C14orf3, hAha1, p38	ENSG00000100591	Activator of HSP90 ATPase activity 1	14	77457870-77469474	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000903, CAB006244	Supported		Supported	Cytosol	Liver cancer:5.04e-6 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 180.4	Expressed in all		
AHSA2	AHA1, DKFZp564C236, Hch1	ENSG00000173209	Activator of HSP90 ATPase homolog 2	2	61177418-61191203	Predicted intracellular proteins	Evidence at protein level	HPA051137	Approved		Approved	Vesicles<br>Microtubules<br>Cytokinetic bridge	Renal cancer:4.11e-6 (unfavourable), Urothelial cancer:1.85e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.1	Expressed in all		
AHSP	EDRF, ERAF	ENSG00000169877	Alpha hemoglobin stabilizing protein	16	31527864-31528803	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040940	Enhanced					Not detected	Tissue enriched	26	bone marrow: 881.3	placenta: 34.3	Cell line enhanced		hTCEpi: 2.0;K-562: 1.1
AICDA	AID, ARP2, CDA2, HIGM2	ENSG00000111732	Activation induced cytidine deaminase	12	8602166-8612871	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	11	appendix: 4.9;lymph node: 18.7;tonsil: 11.0	spleen: 1.0	Group enriched	5	Daudi: 101.6;U-698: 81.2
AIDA	C1orf80, FLJ12806	ENSG00000186063	Axin interactor, dorsalization associated	1	222668013-222713210	Predicted intracellular proteins	Evidence at protein level	HPA027935	Approved		Approved	Microtubules<br>Cytokinetic bridge<br>Cytosol	Cervical cancer:7.08e-5 (unfavourable), Renal cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 80.4	Expressed in all		
AIF1	AIF-1, Em:AF129756.17, IBA1, IRT-1	ENSG00000204472	Allograft inflammatory factor 1	6	31615184-31617021	Predicted intracellular proteins	Evidence at protein level	HPA049234, HPA062949	Enhanced		Approved	Cytosol	Renal cancer:2.30e-5 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 78.3	appendix: 50.3	Cell line enhanced		HEL: 79.8;HMC-1: 107.9;NB-4: 129.5;THP-1: 46.4
AIF1L	C9orf58, FLJ12783, IBA2	ENSG00000126878	Allograft inflammatory factor 1 like	9	131096476-131123152	Predicted intracellular proteins	Evidence at protein level	HPA020522, HPA056852	Enhanced				Renal cancer:5.54e-6 (favourable)	Expressed in all	Tissue enhanced		kidney: 287.5;spleen: 288.1	thyroid gland: 155.2	Cell line enhanced		AF22: 139.6;NTERA-2: 106.7;RPTEC TERT1: 230.5
AIFM2	AMID, FLJ14497, PRG3	ENSG00000042286	Apoptosis inducing factor, mitochondria associated 2	10	70098223-70132934	Predicted intracellular proteins	Evidence at protein level	HPA028961, HPA042309	Approved		Approved	Cytosol	Endometrial cancer:2.80e-4 (favourable), Urothelial cancer:2.92e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 42.7	thyroid gland: 17.9	Cell line enhanced		Hep G2: 113.7
AIFM3	AIFL, FLJ30473	ENSG00000183773	Apoptosis inducing factor, mitochondria associated 3	22	20965108-20981360	Predicted intracellular proteins	Evidence at protein level	HPA001271			Enhanced	Mitochondria	Urothelial cancer:7.13e-5 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 18.5;colon: 18.7	rectum: 9.0	Cell line enhanced		Hep G2: 5.1;HMC-1: 9.5;T-47d: 5.0;THP-1: 5.1
AIM1	CRYBG1, ST4	ENSG00000112297	Absent in melanoma 1	6	106360808-106571978	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB026378, HPA030948, HPA030949	Approved		Approved	Nucleus<br>Microtubules<br>Cytosol		Expressed in all	Tissue enhanced		placenta: 107.4	esophagus: 71.3	Mixed		
AIM1L	CRYBG2, FLJ38020	ENSG00000176092	Absent in melanoma 1-like	1	26321859-26360052	Predicted intracellular proteins	Evidence at protein level	HPA029629, HPA029631	Uncertain		Approved	Nucleoplasm	Endometrial cancer:5.11e-6 (unfavourable), Pancreatic cancer:3.53e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 51.2;skin: 21.5	placenta: 13.7	Cell line enhanced		BEWO: 33.9;CACO-2: 36.7;CAPAN-2: 27.8
AIM2	PYHIN4	ENSG00000163568	Absent in melanoma 2	1	159062484-159147096	Predicted intracellular proteins	Evidence at protein level	HPA031365, HPA040309	Uncertain		Supported	Nucleoplasm<br>Mitochondria<br>Cytosol		Mixed	Tissue enhanced		lymph node: 52.5;spleen: 30.9;tonsil: 40.1	appendix: 26.0	Cell line enhanced		Daudi: 60.6;HDLM-2: 110.5;Karpas-707: 32.8;U-266/70: 28.9;U-87 MG: 34.1
AIMP1	EMAP-2, EMAPII, p43, SCYE1	ENSG00000164022	Aminoacyl tRNA synthetase complex interacting multifunctional protein 1	4	106315544-106349226	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB017618, HPA018476	Supported		Enhanced	Cytosol	Head and neck cancer:1.54e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 63.2	Expressed in all		
AIMP2	JTV-1, JTV1, p38, PRO0992	ENSG00000106305	Aminoacyl tRNA synthetase complex interacting multifunctional protein 2	7	6009245-6023834	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019098, HPA020057	Supported		Approved	Cytosol	Renal cancer:1.38e-5 (favourable), Urothelial cancer:3.09e-4 (unfavourable), Head and neck cancer:3.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 64.3	Expressed in all		
AIP	ARA9, FKBP16, XAP2	ENSG00000110711	Aryl hydrocarbon receptor interacting protein	11	67483041-67491103	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033674, HPA050217, CAB069477	Approved		Supported	Cytosol	Colorectal cancer:1.93e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 100.6	Expressed in all		
AIPL1	LCA4	ENSG00000129221	Aryl hydrocarbon receptor interacting protein like 1	17	6393693-6435199	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026578	Supported		Uncertain	Nucleoplasm<br>Cytosol		Tissue enriched	Not detected			testis: 0.8	Cell line enhanced		HaCaT: 1.3
AIRE	APECED, APS1, PGA1	ENSG00000160224	Autoimmune regulator	21	44285838-44298648	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038267	Uncertain					Tissue enriched	Not detected			lymph node: 0.3	Not detected		
AJUBA	JUB, MGC15563	ENSG00000129474	Ajuba LIM protein	14	22971174-22982642	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA006171	Approved		Approved	Nucleus<br>Golgi apparatus	Pancreatic cancer:5.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 73.7	placenta: 28.0	Mixed		
AK1		ENSG00000106992	Adenylate kinase 1	9	127866480-127877743	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006456, CAB009893	Enhanced		Supported	Cytosol	Stomach cancer:7.31e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 774.9	Mixed		
AK2		ENSG00000004455	Adenylate kinase 2	1	33007940-33080996	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018479	Approved				Breast cancer:4.37e-4 (favourable), Pancreatic cancer:6.40e-4 (unfavourable), Endometrial cancer:8.65e-4 (unfavourable), Liver cancer:9.32e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 183.3	Expressed in all		
AK3	AK3L1, AK6, AKL3L1	ENSG00000147853	Adenylate kinase 3	9	4709559-4742043	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063324	Enhanced		Supported	Mitochondria	Renal cancer:6.07e-9 (favourable)	Expressed in all	Expressed in all			kidney: 106.2	Expressed in all		
AK5		ENSG00000154027	Adenylate kinase 5	1	77282051-77559969	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019128, HPA057255	Enhanced		Supported	Microtubule organizing center<br>Cytosol	Prostate cancer:3.88e-4 (favourable)	Group enriched	Tissue enriched	9	cerebral cortex: 220.7	breast: 23.6	Cell line enhanced		ASC TERT1: 65.9;BJ: 57.0;fHDF/TERT166: 60.0;LHCN-M2: 159.8;U-2 OS: 61.3
AK6	CINAP	ENSG00000085231	Adenylate kinase 6	5	69350984-69370013	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB005361, HPA034935	Supported		Supported	Nucleoplasm	Liver cancer:9.54e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 26.8	Expressed in all		
AK7	FLJ32864	ENSG00000140057	Adenylate kinase 7	14	96392111-96489427	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003543	Enhanced				Renal cancer:1.14e-4 (favourable), Endometrial cancer:3.18e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 38.8	parathyroid gland: 14.9	Cell line enhanced		BEWO: 16.6;CAPAN-2: 13.2;MCF7: 37.9;REH: 32.2
AK8	C9orf98, FLJ32704	ENSG00000165695	Adenylate kinase 8	9	132725578-132878777	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021443, HPA021445, HPA023894	Enhanced				Renal cancer:1.61e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 16.0;fallopian tube: 30.0;testis: 21.7	thyroid gland: 5.8	Cell line enhanced		MCF7: 1.8;RPTEC TERT1: 2.0;T-47d: 1.6
AK9	AKD1, AKD2, C6orf199, C6orf224, dJ70A9.1, FLJ25791, FLJ42177, MGC26954	ENSG00000155085	Adenylate kinase 9	6	109492856-109691217	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030804, HPA030805, HPA031779, HPA031781, HPA036324, HPA036711	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane		Mixed	Tissue enhanced		testis: 31.2	parathyroid gland: 17.1	Expressed in all		
AKAIN1	C18orf42	ENSG00000231824	A-kinase anchor inhibitor 1	18	5145285-5197503	Predicted intracellular proteins	Evidence at protein level	HPA049365	Uncertain					Not detected	Tissue enriched	11	adrenal gland: 20.1	testis: 1.7	Cell line enhanced		SCLC-21H: 1.1
AKAP11	AKAP220, DKFZp781I12161, FLJ11304, KIAA0629, PPP1R44, PRKA11	ENSG00000023516	A-kinase anchoring protein 11	13	42272153-42323267	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039089	Enhanced		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Cervical cancer:9.26e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 51.6	Expressed in all		
AKAP12	AKAP250, SSeCKS	ENSG00000131016	A-kinase anchoring protein 12	6	151239999-151358557	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006344, CAB026379, HPA056230	Enhanced		Supported	Plasma membrane<br>Cytosol	Lung cancer:6.34e-5 (unfavourable), Endometrial cancer:7.08e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 184.5	Cell line enhanced		REH: 175.6
AKAP13	AKAP-Lbc, ARHGEF13, BRX, c-lbc, HA-3, Ht31, LBC, PROTO-LB	ENSG00000170776	A-kinase anchoring protein 13	15	85380571-85749358	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019773	Approved		Supported	Cytosol		Expressed in all	Expressed in all			endometrium: 74.5	Expressed in all		
AKAP14	AKAP28	ENSG00000186471	A-kinase anchoring protein 14	X	119895837-119920716	Predicted intracellular proteins	Evidence at protein level	HPA060999	Enhanced					Tissue enhanced	Group enriched	14	fallopian tube: 67.8;testis: 73.2	lung: 4.8	Cell line enhanced		SCLC-21H: 2.9
AKAP17A	721P, CCDC133, CXYorf3, DXYS155E, MGC39904, SFRS17A, XE7, XE7Y	ENSG00000197976	A-kinase anchoring protein 17A	X	1591593-1602514	Predicted intracellular proteins	Evidence at protein level	HPA043247, HPA051020	Enhanced		Supported	Nuclear speckles<br>Cytosol	Renal cancer:3.52e-7 (unfavourable), Urothelial cancer:1.11e-5 (favourable), Pancreatic cancer:2.42e-4 (favourable), Endometrial cancer:3.40e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.4	Expressed in all		
AKAP2	AKAP-KL, DKFZp564L0716, KIAA0920, MISP2, PRKA2	ENSG00000241978	A-kinase anchoring protein 2	9	110048598-110172512	Predicted intracellular proteins	Evidence at protein level							Not detected	Expressed in all			placenta: 123.7	Mixed		
AKAP3	AKAP110, CT82, FSP95, SOB1	ENSG00000111254	A-kinase anchoring protein 3	12	4615508-4649047	Predicted intracellular proteins	Evidence at protein level	HPA039765	Enhanced					Tissue enriched	Tissue enriched	46	testis: 179.9	fallopian tube: 3.9	Cell line enhanced		NTERA-2: 4.0
AKAP4	AKAP82, CT99, Fsc1, hAKAP82, HI, p82	ENSG00000147081	A-kinase anchoring protein 4	X	50190768-50201013	Predicted intracellular proteins	Evidence at protein level	HPA005949, HPA020046	Enhanced					Not detected	Tissue enriched	2796	testis: 279.5	all non-specific tissues: 0.0	Not detected		
AKAP5	AKAP75, AKAP79	ENSG00000179841	A-kinase anchoring protein 5	14	64465499-64474503	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004308, HPA053891	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enriched	5	cerebral cortex: 22.5	rectum: 4.2	Cell line enhanced		CACO-2: 9.0
AKAP7	AKAP15, AKAP18	ENSG00000118507	A-kinase anchoring protein 7	6	131135666-131283535	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027172, HPA028327	Approved				Urothelial cancer:2.56e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 72.6	Cell line enhanced		NTERA-2: 27.0
AKAP8	AKAP95, DKFZp586B1222	ENSG00000105127	A-kinase anchoring protein 8	19	15353385-15379798	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004776	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 13.1	Expressed in all		
AKAP8L	HAP95, NAKAP95	ENSG00000011243	A-kinase anchoring protein 8 like	19	15380048-15419141	Predicted intracellular proteins	Evidence at protein level	HPA042485, HPA042546	Enhanced		Supported	Nuclear speckles	Renal cancer:1.08e-7 (unfavourable), Colorectal cancer:3.49e-4 (unfavourable), Pancreatic cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 41.6	Expressed in all		
AKIP1	BCA3, C11orf17	ENSG00000166452	A-kinase interacting protein 1	11	8911139-8920084	Predicted intracellular proteins	Evidence at protein level	HPA061391			Supported	Nucleoplasm	Liver cancer:6.24e-9 (unfavourable), Endometrial cancer:5.15e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 30.5	Expressed in all		
AKIRIN1	C1orf108, FLJ12666	ENSG00000174574	Akirin 1	1	38991223-39006059	Predicted intracellular proteins	Evidence at protein level	HPA051871	Approved		Approved	Nucleoplasm<br>Nuclear membrane	Liver cancer:5.39e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 127.9	Expressed in all		
AKIRIN2	C6orf166, dJ486L4.2, FLJ10342	ENSG00000135334	Akirin 2	6	87675072-87702209	Predicted intracellular proteins	Evidence at protein level	HPA064239			Supported	Nucleoplasm		Expressed in all	Expressed in all			spleen: 58.2	Expressed in all		
AKNA	KIAA1968	ENSG00000106948	AT-hook transcription factor	9	114334156-114394405	Predicted intracellular proteins	Evidence at protein level	HPA052367, HPA063993			Supported	Nucleoplasm<br>Centrosome	Endometrial cancer:2.14e-5 (favourable), Renal cancer:2.55e-5 (unfavourable), Cervical cancer:1.22e-4 (favourable), Head and neck cancer:1.25e-4 (favourable), Urothelial cancer:2.29e-4 (favourable)	Expressed in all	Mixed			spleen: 95.6	Cell line enhanced		HDLM-2: 81.7;MOLT-4: 67.8
AKNAD1	C1orf62, MGC26989	ENSG00000162641	AKNA domain containing 1	1	108815898-108858228	Predicted intracellular proteins	Evidence at transcript level	HPA030270, HPA030271, HPA030272	Uncertain					Tissue enhanced	Tissue enriched	63	testis: 6.4	skin: 0.1	Not detected		
AKR1A1	ALR, DD3	ENSG00000117448	Aldo-keto reductase family 1 member A1	1	45550543-45570049	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB006246, HPA017919, HPA019649, HPA027734	Approved		Supported	Nucleoplasm<br>Cytosol	Cervical cancer:2.66e-6 (favourable), Endometrial cancer:2.92e-4 (favourable)	Expressed in all	Expressed in all			kidney: 380.4	Expressed in all		
AKR1B1	ALDR1, AR	ENSG00000085662	Aldo-keto reductase family 1 member B	7	134442350-134459284	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026425, CAB027391, CAB047353, HPA052751	Enhanced		Supported	Nucleus<br>Cytosol	Stomach cancer:2.44e-5 (unfavourable), Urothelial cancer:7.00e-4 (unfavourable)	Expressed in all	Tissue enriched	6	adrenal gland: 2486.1	seminal vesicle: 449.2	Cell line enhanced		A549: 1469.5;BJ hTERT+: 2394.4
AKR1B10	AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI	ENSG00000198074	Aldo-keto reductase family 1 member B10	7	134527592-134541408	Predicted intracellular proteins	Evidence at protein level	HPA020280, CAB070163, HPA073633	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.80e-9 (unfavourable), Colorectal cancer:1.91e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 635.9;gallbladder: 283.3;small intestine: 387.2;stomach: 414.4	esophagus: 89.8	Group enriched	74	A549: 2731.1;Hep G2: 580.9
AKR1B15		ENSG00000227471	Aldo-keto reductase family 1 member B15	7	134549136-134579875	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020280, HPA073633	Uncertain		Supported	Plasma membrane<br>Cytosol	Liver cancer:1.80e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Head and neck cancer:8.36e-4 (favourable)	Mixed	Tissue enriched	13	breast: 179.9	duodenum: 13.7	Group enriched	8	A549: 14.3;HDLM-2: 11.8;Hep G2: 7.6;NTERA-2: 3.2;SK-BR-3: 3.8;U-87 MG: 6.4
AKR1C2	BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD	ENSG00000151632	Aldo-keto reductase family 1 member C2	10	4987400-5018031	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB047304, HPA068265	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol		Group enriched	Group enriched	5	adipose tissue: 330.4;breast: 105.2;esophagus: 94.9;gallbladder: 151.9;liver: 161.4;stomach: 126.5;urinary bladder: 143.0	duodenum: 29.8	Cell line enhanced		A549: 1864.0;ASC diff: 1674.9;Hep G2: 2661.0;RT4: 940.6
AKR1C3	DDX, HAKRB, HSD17B5, KIAA0119, PGFS	ENSG00000196139	Aldo-keto reductase family 1 member C3	10	5035354-5107686	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010874, HPA068265	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:1.22e-4 (unfavourable), Liver cancer:1.96e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 398.6	Cell line enhanced		A549: 1217.9;AN3-CA: 359.6;ASC diff: 507.5;Hep G2: 391.2;RT4: 424.5
AKR1C4	3-alpha-HSD, C11, CDR, CHDR, DD4, HAKRA, MGC22581	ENSG00000198610	Aldo-keto reductase family 1 member C4	10	5195462-5218949	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044720, HPA068265	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol		Tissue enriched	Tissue enriched	6	liver: 360.3	gallbladder: 64.2	Cell line enriched	8	HDLM-2: 6.1
AKR1D1	SRD5B1	ENSG00000122787	Aldo-keto reductase family 1 member D1	7	138002324-138117986	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057002	Enhanced		Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.91e-5 (favourable)	Tissue enriched	Tissue enriched	31	liver: 229.4	breast: 7.2	Cell line enriched	16	Hep G2: 8.6
AKR1E2	AKR1CL2, AKRDC1, MGC10612	ENSG00000165568	Aldo-keto reductase family 1 member E2	10	4786629-4848062	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037821, HPA037822	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enriched	5	testis: 29.8	thyroid gland: 5.6	Cell line enhanced		U-2197: 19.2
AKR7A2	AFAR	ENSG00000053371	Aldo-keto reductase family 7 member A2	1	19303965-19312146	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032587, CAB032841, HPA064638	Enhanced		Supported	Cytosol	Renal cancer:2.67e-4 (favourable), Urothelial cancer:8.59e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 81.9	Expressed in all		
AKR7A3		ENSG00000162482	Aldo-keto reductase family 7 member A3	1	19282558-19289250	Predicted intracellular proteins	Evidence at protein level	HPA064638			Approved	Cytosol	Renal cancer:8.80e-7 (favourable)	Group enriched	Group enriched	5	duodenum: 170.4;gallbladder: 38.7;kidney: 49.0;liver: 44.8;small intestine: 106.8;stomach: 70.3	colon: 15.9	Cell line enhanced		SK-BR-3: 12.6
AKT1	AKT, PKB, PRKBA, RAC	ENSG00000142208	AKT serine/threonine kinase 1	14	104769349-104795751	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA002891, CAB003765	Enhanced		Supported	Nucleus<br>Microtubules	Renal cancer:2.12e-4 (favourable), Ovarian cancer:4.83e-4 (favourable)	Expressed in all	Expressed in all			prostate: 106.4	Expressed in all		
AKT1S1	Lobe, MGC2865, PRAS40	ENSG00000204673	AKT1 substrate 1	19	49869033-49878459	Predicted intracellular proteins	Evidence at protein level	CAB021903, HPA043590, HPA064427	Uncertain		Supported	Cytosol	Renal cancer:7.34e-6 (unfavourable), Liver cancer:3.70e-4 (unfavourable), Pancreatic cancer:6.60e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 33.9	Expressed in all		
AKT2		ENSG00000105221	AKT serine/threonine kinase 2	19	40230317-40285536	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004204, HPA064521	Uncertain		Supported	Nucleus<br>Vesicles<br>Cytosol	Endometrial cancer:1.05e-6 (unfavourable), Prostate cancer:4.74e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 170.1	Expressed in all		
AKT3	PKBG, PRKBG, RAC-gamma	ENSG00000117020	AKT serine/threonine kinase 3	1	243488233-243851079	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB013090, HPA026441	Approved		Supported	Cytosol	Urothelial cancer:9.27e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 51.6	Mixed		
AKTIP	FLJ13258, FTS	ENSG00000166971	AKT interacting protein	16	53491040-53504411	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041794, HPA046300	Approved				Renal cancer:1.18e-14 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 82.4	Expressed in all		
AL021546.6		ENSG00000111780		12	120438198-120460006	Predicted intracellular proteins	Evidence at protein level	HPA062394	Uncertain		Approved	Mitochondria		Not detected	Not detected			colon: 0.9	Cell line enhanced		CACO-2: 7.5;HEK93: 10.3;U-266/84: 7.5
AL354822.1		ENSG00000278384		Unmapped	51867-54893	Predicted intracellular proteins	Evidence at transcript level								Mixed			skin: 3.4	Mixed		
AL359736.1		ENSG00000281899		13	24321126-24321428	Predicted intracellular proteins	No evidence							Not detected	Not detected			esophagus: 0.4	Not detected		
AL513523.2		ENSG00000279767		1	153772371-153774079	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		lymph node: 1.4;skin: 3.5	cerebral cortex,lung: 0.8	Cell line enhanced		MCF7: 7.6;SK-BR-3: 5.9;THP-1: 5.5
AL592183.1		ENSG00000273748		Unmapped	54224-83311	Predicted intracellular proteins	Evidence at transcript level	HPA049380	Approved						Expressed in all			gallbladder: 147.3	Mixed		
ALAD	ALADH, PBGS	ENSG00000148218	Aminolevulinate dehydratase	9	113386317-113401333	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021023, HPA022124	Enhanced				Colorectal cancer:7.33e-5 (unfavourable), Liver cancer:8.80e-5 (favourable), Renal cancer:1.65e-4 (favourable), Endometrial cancer:5.64e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 147.1	Expressed in all		
ALAS1	ALAS, ALAS3	ENSG00000023330	5'-aminolevulinate synthase 1	3	52198086-52214327	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017498, HPA035860	Enhanced		Enhanced	Nucleoplasm<br>Mitochondria	Renal cancer:6.06e-7 (favourable), Liver cancer:1.82e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 761.4	Expressed in all		
ALDH18A1	GSAS, P5CS, PYCS, SPG9	ENSG00000059573	Aldehyde dehydrogenase 18 family member A1	10	95605929-95656706	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008333, HPA012604	Approved		Enhanced	Mitochondria	Renal cancer:3.60e-9 (unfavourable), Endometrial cancer:4.20e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 89.5	Expressed in all		
ALDH1A1	ALDH1, PUMB1, RALDH1	ENSG00000165092	Aldehyde dehydrogenase 1 family member A1	9	72900662-73080442	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002123, CAB020690	Approved	Approved	Enhanced	Cytosol	Cervical cancer:7.77e-5 (favourable)	Expressed in all	Expressed in all			liver: 760.0	Cell line enhanced		A549: 3635.1;Hep G2: 855.5;RPTEC TERT1: 528.6
ALDH1A2	RALDH2	ENSG00000128918	Aldehyde dehydrogenase 1 family member A2	15	57953424-58497866	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010022	Approved					Mixed	Tissue enhanced		endometrium: 118.1;fallopian tube: 108.9	testis: 96.9	Group enriched	6	AN3-CA: 352.0;HEK93: 116.8;K-562: 305.3;MOLT-4: 330.5
ALDH1A3	ALDH6, RALDH3	ENSG00000184254	Aldehyde dehydrogenase 1 family member A3	15	100877714-100916626	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046271, HPA064749	Enhanced		Enhanced	Nucleus<br>Cytosol		Group enriched	Tissue enhanced		prostate: 217.5	adipose tissue: 74.8	Cell line enhanced		HaCaT: 383.6;HBEC3-KT: 772.3;U-2197: 565.6;U-87 MG: 467.6;WM-115: 498.3
ALDH1B1	ALDH5, ALDHX	ENSG00000137124	Aldehyde dehydrogenase 1 family member B1	9	38392664-38398661	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021037	Approved		Supported	Nucleoplasm<br>Vesicles<br>Mitochondria	Thyroid cancer:1.17e-5 (unfavourable), Renal cancer:2.05e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 178.4	Mixed		
ALDH1L1	10-fTHF, FTHFD	ENSG00000144908	Aldehyde dehydrogenase 1 family member L1	3	126103562-126197994	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036900, HPA050139	Enhanced	Supported	Supported	Cytosol	Renal cancer:2.42e-8 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 121.2;liver: 190.4	adipose tissue: 80.9	Cell line enhanced		Hep G2: 54.9;Karpas-707: 57.9;RT4: 174.8
ALDH1L2	FLJ38508, mtFDH	ENSG00000136010	Aldehyde dehydrogenase 1 family member L2	12	105019784-105084577	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039481, HPA059282	Uncertain		Enhanced	Mitochondria		Mixed	Mixed			cervix, uterine: 8.4	Cell line enhanced		ASC TERT1: 58.5;fHDF/TERT166: 77.9
ALDH2		ENSG00000111275	Aldehyde dehydrogenase 2 family (mitochondrial)	12	111766887-111817529	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051065	Approved				Liver cancer:3.95e-7 (favourable), Renal cancer:5.24e-6 (favourable), Endometrial cancer:2.63e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 441.5	Cell line enhanced		HHSteC: 81.5;SK-BR-3: 150.4
ALDH3A1	ALDH3	ENSG00000108602	Aldehyde dehydrogenase 3 family member A1	17	19737984-19748943	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB045957, HPA051150, HPA063783	Enhanced		Enhanced	Vesicles<br>Plasma membrane<br>Cytosol	Head and neck cancer:7.55e-5 (favourable)	Mixed	Group enriched	7	esophagus: 406.1;skin: 84.3;stomach: 207.2	tonsil: 31.0	Cell line enriched	21	A549: 4306.9
ALDH3B1	ALDH7	ENSG00000006534	Aldehyde dehydrogenase 3 family member B1	11	68008578-68029282	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038525	Uncertain				Colorectal cancer:1.18e-4 (unfavourable), Pancreatic cancer:6.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 64.4;lung: 67.7	bone marrow: 30.7	Cell line enhanced		A549: 137.9;CAPAN-2: 136.9
ALDH4A1	ALDH4, P5CDh	ENSG00000159423	Aldehyde dehydrogenase 4 family member A1	1	18871430-18902781	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004645, HPA006401	Enhanced				Cervical cancer:5.06e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 185.7;liver: 108.1	adipose tissue: 63.8	Expressed in all		
ALDH5A1	SSADH, SSDH	ENSG00000112294	Aldehyde dehydrogenase 5 family member A1	6	24494852-24537207	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029715, HPA029716	Enhanced		Enhanced	Mitochondria	Liver cancer:7.61e-6 (favourable), Renal cancer:3.68e-4 (favourable), Ovarian cancer:6.20e-4 (favourable)	Expressed in all	Expressed in all			liver: 46.8	Cell line enhanced		Daudi: 88.4;U-698: 105.9
ALDH7A1	ATQ1, EPD, PDE	ENSG00000164904	Aldehyde dehydrogenase 7 family member A1	5	126531200-126595418	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023296	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:3.08e-4 (favourable)	Expressed in all	Expressed in all			kidney: 120.6	Mixed		
ALDH8A1	ALDH12	ENSG00000118514	Aldehyde dehydrogenase 8 family member A1	6	134917390-134950122	Predicted intracellular proteins	Evidence at protein level	HPA026292, HPA055414	Enhanced		Supported	Centrosome	Renal cancer:9.87e-4 (favourable)	Group enriched	Group enriched	29	kidney: 74.3;liver: 127.7	cerebral cortex: 3.4	Mixed		
ALDOB		ENSG00000136872	Aldolase, fructose-bisphosphate B	9	101420578-101435823	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002198, CAB020827	Enhanced					Tissue enriched	Group enriched	23	duodenum: 3705.7;kidney: 6574.8;liver: 5092.2;small intestine: 5611.2	gallbladder: 231.1	Cell line enhanced		BEWO: 16.8;NB-4: 10.8;RPMI-8226: 13.6;SH-SY5Y: 17.3
ALDOC		ENSG00000109107	Aldolase, fructose-bisphosphate C	17	28573115-28577264	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003282, CAB020828, HPA067442	Enhanced	Supported	Approved	Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol	Renal cancer:1.29e-7 (unfavourable), Head and neck cancer:9.80e-4 (unfavourable)	Tissue enriched	Tissue enriched	7	cerebral cortex: 766.6	heart muscle: 111.2	Cell line enhanced		RPMI-8226: 165.2;U-266/70: 119.9
ALG13	CDG1S, CXorf45, FLJ23018, GLT28D1, MDS031, TDRD13, YGL047W	ENSG00000101901	ALG13, UDP-N-acetylglucosaminyltransferase subunit	X	111665811-111760649	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002853	Approved				Renal cancer:1.10e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 30.4	Expressed in all		
ALG1L	ALG1L1	ENSG00000189366	ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase like	3	125929275-125937039	Predicted intracellular proteins	Evidence at transcript level	HPA036108	Uncertain				Glioma:1.82e-4 (favourable), Urothelial cancer:6.24e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 13.1;urinary bladder: 14.8	skin: 6.8	Cell line enhanced		CACO-2: 13.2;CAPAN-2: 12.6;HaCaT: 13.5;MCF7: 23.1;T-47d: 18.5
ALG1L2		ENSG00000251287	ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase like 2	3	130081831-130113227	Predicted intracellular proteins	Evidence at protein level	HPA060392	Uncertain		Uncertain	Nucleoli fibrillar center<br>Endoplasmic reticulum	Ovarian cancer:7.75e-4 (favourable)	Mixed	Tissue enhanced		spleen: 1.0	appendix,duodenum,skin: 0.2	Not detected		
ALKBH2	ABH2, MGC90512	ENSG00000189046	AlkB homolog 2, alpha-ketoglutarate dependent dioxygenase	12	109088188-109093631	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB011198, HPA045392, HPA051976	Approved		Enhanced	Nucleus	Renal cancer:1.41e-5 (unfavourable), Breast cancer:6.67e-5 (favourable), Urothelial cancer:8.67e-4 (favourable)	Expressed in all	Expressed in all			skin: 27.0	Expressed in all		
ALKBH3	DEPC-1	ENSG00000166199	AlkB homolog 3, alpha-ketoglutaratedependent dioxygenase	11	43880811-43920266	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA009674, HPA046489	Approved		Enhanced	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			epididymis: 32.4	Mixed		
ALKBH4	FLJ20013	ENSG00000160993	AlkB homolog 4, lysine demethylase	7	102456238-102464876	Predicted intracellular proteins	Evidence at protein level	HPA051422	Approved				Renal cancer:3.09e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 10.0	Expressed in all		
ALKBH6	MGC15677	ENSG00000239382	AlkB homolog 6	19	36009120-36014239	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA073835, HPA074340			Supported	Nucleoplasm<br>Focal adhesion sites		Expressed in all	Mixed			cerebral cortex: 7.5	Expressed in all		
ALKBH7	MGC10974, SPATA11	ENSG00000125652	AlkB homolog 7	19	6372433-6375251	Predicted intracellular proteins	Evidence at protein level	HPA039571, HPA039872	Approved				Renal cancer:7.83e-6 (favourable)	Expressed in all	Expressed in all			testis: 252.4	Expressed in all		
ALKBH8	MGC10235, TRM9, TRMT9	ENSG00000137760	AlkB homolog 8, tRNA methyltransferase	11	107502726-107565746	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038724, HPA038725, HPA061514	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			parathyroid gland: 9.6	Expressed in all		
ALLC	ALC	ENSG00000151360	Allantoicase	2	3658195-3702671	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	21	testis: 23.9	gallbladder: 1.1	Cell line enriched	12	U-266/84: 4.2
ALMS1	KIAA0328	ENSG00000116127	ALMS1, centrosome and basal body associated protein	2	73385758-73610793	Predicted intracellular proteins	Evidence at protein level	HPA043200	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		testis: 32.5	ovary: 9.1	Cell line enhanced		RH-30: 26.7
ALOX12	12S-LOX	ENSG00000108839	Arachidonate 12-lipoxygenase, 12S type	17	6996065-7010736	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA010691, CAB019287	Approved		Supported	Nuclear speckles<br>Cytosol		Mixed	Group enriched	8	esophagus: 50.3;skin: 25.9	gallbladder: 5.0	Group enriched	5	A-431: 22.4;HEL: 36.7
ALOX12B	12R-LOX	ENSG00000179477	Arachidonate 12-lipoxygenase, 12R type	17	8072636-8087703	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024002	Supported		Approved	Cytosol		Group enriched	Group enriched	7	skin: 70.0;tonsil: 17.2	esophagus: 6.2	Cell line enhanced		HEK93: 1.2;hTCEpi: 1.0
ALOX15	15-LOX-1	ENSG00000161905	Arachidonate 15-lipoxygenase	17	4630902-4642294	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004962, CAB004963, HPA013859	Approved					Mixed	Tissue enhanced		fallopian tube: 19.6;lung: 9.8	breast: 4.7	Group enriched	7	HMC-1: 13.6;MCF7: 10.8;T-47d: 3.9
ALOX15B	15-LOX-2	ENSG00000179593	Arachidonate 15-lipoxygenase, type B	17	8039017-8049134	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010562	Enhanced		Supported	Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		breast: 145.0;prostate: 115.3	lung: 26.1	Group enriched	15	HHSteC: 6.5;HSkMC: 11.9;hTCEpi: 25.0
ALOX5	5-LOX	ENSG00000012779	Arachidonate 5-lipoxygenase	10	45374176-45446119	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071285	Enhanced		Supported	Nucleoplasm	Renal cancer:1.80e-5 (unfavourable), Urothelial cancer:7.18e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 41.3	bone marrow: 28.8	Cell line enhanced		BEWO: 10.4;Daudi: 22.8;HMC-1: 20.7;RT4: 14.0;U-266/70: 11.3
ALOXE3	E-LOX, eLOX3	ENSG00000179148	Arachidonate lipoxygenase 3	17	8095900-8119047	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023120, HPA078597	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	16	skin: 36.5	breast: 2.2	Cell line enhanced		A-431: 5.5;HBEC3-KT: 7.2;hTCEpi: 5.2;hTERT-HME1: 10.5;T-47d: 4.1
ALPK2	HAK	ENSG00000198796	Alpha kinase 2	18	58481247-58628957	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027377, HPA027976, HPA028084, HPA029801	Uncertain		Approved	Cytosol	Renal cancer:8.20e-5 (unfavourable)	Tissue enriched	Tissue enhanced		heart muscle: 28.6;skeletal muscle: 14.1	lymph node: 6.9	Cell line enhanced		BJ: 44.5;BJ hTERT+: 25.8;fHDF/TERT166: 37.1;U-138 MG: 25.6
ALPK3	KIAA1330, MAK, Midori	ENSG00000136383	Alpha kinase 3	15	84816680-84873482	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026558	Uncertain		Approved	Nucleus	Renal cancer:3.95e-7 (favourable)	Mixed	Tissue enhanced		heart muscle: 32.8;parathyroid gland: 36.2;skeletal muscle: 47.6	adipose tissue: 12.3	Cell line enhanced		BEWO: 12.8;HUVEC TERT2: 12.1;LHCN-M2: 16.5;NTERA-2: 12.1;RH-30: 34.1
ALS2	ALS2CR6	ENSG00000003393	ALS2, alsin Rho guanine nucleotide exchange factor	2	201700554-201781189	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046588	Approved		Approved	Intermediate filaments<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 16.6	Expressed in all		
ALS2CL	DKFZp686I0110, FLJ36525, RN49018	ENSG00000178038	ALS2 C-terminal like	3	46668997-46693704	Predicted intracellular proteins	Evidence at protein level	CAB046465, HPA048301	Uncertain				Endometrial cancer:8.10e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 38.8	esophagus: 15.8	Cell line enhanced		CAPAN-2: 30.1;HaCaT: 16.9;HBEC3-KT: 25.9;hTCEpi: 18.1;RT4: 15.4
ALS2CR11	FLJ25351	ENSG00000155754	Amyotrophic lateral sclerosis 2 chromosome region candidate 11	2	201487425-201619178	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	78	testis: 74.2	ovary: 0.9	Cell line enhanced		hTEC/SVTERT24-B: 2.0;SCLC-21H: 2.8;U-2197: 7.1
ALS2CR12		ENSG00000155749	Amyotrophic lateral sclerosis 2 chromosome region 12	2	201288271-201357398	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035793			Approved	Plasma membrane<br>Cytosol		Not detected	Group enriched	5	fallopian tube: 15.0;testis: 31.8	lung: 4.2	Cell line enhanced		U-2197: 4.3
ALX1	CART1	ENSG00000180318	ALX homeobox 1	12	85280107-85301784	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001598, HPA018905	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus		Tissue enriched	Tissue enhanced		epididymis: 4.3;kidney: 3.1	ovary: 1.8	Cell line enhanced		HEK93: 19.4;HUVEC TERT2: 13.0;SK-MEL-30: 20.2;THP-1: 11.5;WM-115: 13.3
ALX3	FND	ENSG00000156150	ALX homeobox 3	1	110059994-110070700	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Mixed			skin: 7.7	Mixed		
ALX4	FPP, KIAA1788, PFM, PFM2	ENSG00000052850	ALX homeobox 4	11	44260444-44310166	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001903			Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		breast: 2.2	endometrium,testis: 1.0	Cell line enhanced		AN3-CA: 3.7;BJ: 2.8;HAP1: 4.8;HEK93: 4.4;HEL: 6.0;K-562: 2.8;SiHa: 7.4
ALYREF	ALY, ALY/REF, BEF, REF, THOC4	ENSG00000183684	Aly/REF export factor	17	81887844-81891586	Predicted intracellular proteins	Evidence at protein level	CAB016281, HPA019799, HPA061282	Supported		Enhanced	Nuclear speckles	Liver cancer:1.18e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 88.5	Expressed in all		
AMACR	P504S, RACE	ENSG00000242110	Alpha-methylacyl-CoA racemase	5	33986178-34008108	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB001809, HPA019527, HPA020912	Enhanced		Supported	Vesicles<br>Plasma membrane	Colorectal cancer:7.11e-4 (favourable)	Expressed in all	Expressed in all			kidney: 135.3	Expressed in all		
AMBRA1	DCAF3, FLJ20294, KIAA1736, WDR94	ENSG00000110497	Autophagy and beclin 1 regulator 1	11	46396414-46594125	Predicted intracellular proteins	Evidence at protein level	CAB017825, HPA038535	Approved		Approved	Vesicles<br>Mitochondria	Renal cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.0	Expressed in all		
AMD1	SAMDC	ENSG00000123505	Adenosylmethionine decarboxylase 1	6	110874770-110895713	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029281, HPA029282	Approved		Approved	Nucleoplasm	Liver cancer:1.91e-6 (unfavourable), Breast cancer:3.87e-4 (unfavourable), Renal cancer:4.28e-4 (favourable)	Expressed in all	Expressed in all			prostate: 323.8	Expressed in all		
AMDHD1	MGC35366	ENSG00000139344	Amidohydrolase domain containing 1	12	95943293-95968716	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039720	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Focal adhesion sites		Tissue enriched	Tissue enhanced		testis: 25.8	liver: 22.0	Cell line enhanced		HMC-1: 57.9;Karpas-707: 44.7;SiHa: 44.1;U-266/84: 42.8
AMDHD2	CGI-14	ENSG00000162066	Amidohydrolase domain containing 2	16	2520357-2531422	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041184, HPA041321	Enhanced		Approved	Nucleoli<br>Cytosol	Cervical cancer:5.19e-4 (favourable)	Expressed in all	Mixed			testis: 15.9	Mixed		
AMER1	FAM123B, FLJ39827, RP11-403E24.2, WTX	ENSG00000184675	APC membrane recruitment protein 1	X	64185117-64205744	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065214, HPA065265	Approved		Supported	Nuclear bodies<br>Vesicles<br>Plasma membrane		Expressed in all	Mixed			ovary: 7.7	Mixed		
AMER2	FAM123A, FLJ25477	ENSG00000165566	APC membrane recruitment protein 2	13	25161684-25172288	Predicted intracellular proteins	Evidence at protein level	HPA039458	Enhanced					Tissue enriched	Tissue enriched	53	cerebral cortex: 72.4	fallopian tube,testis: 1.3	Group enriched	5	AF22: 3.6;SCLC-21H: 3.5;U-266/70: 5.2
AMER3	FAM123C, FLJ38377	ENSG00000178171	APC membrane recruitment protein 3	2	130755435-130768134	Predicted intracellular proteins	Evidence at protein level	HPA045593, HPA054230	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Tissue enhanced	Tissue enriched	9	cerebral cortex: 7.0	adrenal gland: 0.8	Cell line enriched	6	SCLC-21H: 12.2
AMMECR1		ENSG00000101935	Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1	X	110194186-110440233	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000590, HPA051762	Uncertain				Ovarian cancer:6.62e-5 (favourable), Thyroid cancer:8.44e-4 (favourable)	Expressed in all	Mixed			placenta: 9.8	Expressed in all		
AMMECR1L	MGC4268	ENSG00000144233	AMMECR1 like	2	127861630-127885922	Predicted intracellular proteins	Evidence at protein level	HPA000590, HPA057234	Uncertain		Approved	Nucleus<br>Cytosol	Endometrial cancer:6.10e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.3	Expressed in all		
AMN1		ENSG00000151743	Antagonist of mitotic exit network 1 homolog	12	31671137-31729174	Predicted intracellular proteins	Evidence at protein level	HPA046157, HPA062290	Uncertain		Approved	Centrosome		Expressed in all	Expressed in all			testis: 99.8	Mixed		
AMOT	KIAA1071	ENSG00000126016	Angiomotin	X	112774503-112840815	Predicted intracellular proteins	Evidence at protein level	HPA067290, HPA067853	Enhanced		Supported	Nucleus<br>Cell Junctions	Renal cancer:4.21e-9 (favourable), Lung cancer:3.94e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 177.9	seminal vesicle: 38.6	Cell line enhanced		AF22: 24.7;HAP1: 28.1
AMOTL1	JEAP	ENSG00000166025	Angiomotin like 1	11	94706431-94876753	Predicted intracellular proteins	Evidence at protein level	HPA001196	Approved		Supported	Cell Junctions<br>Cytosol	Renal cancer:5.03e-6 (favourable)	Expressed in all	Expressed in all			prostate: 52.5	Mixed		
AMOTL2	LCCP	ENSG00000114019	Angiomotin like 2	3	134355874-134375479	Predicted intracellular proteins	Evidence at protein level	HPA063027			Approved	Cell Junctions	Endometrial cancer:1.94e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 76.7	Cell line enhanced		BEWO: 266.7
AMPD2	SPG63	ENSG00000116337	Adenosine monophosphate deaminase 2	1	109616104-109632051	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027137, HPA045760, HPA050590	Approved	Approved	Enhanced	Cytosol	Renal cancer:3.78e-10 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 82.4	Expressed in all		
AMPD3		ENSG00000133805	Adenosine monophosphate deaminase 3	11	10308313-10507579	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038662, HPA047408	Uncertain		Enhanced	Nuclear membrane	Endometrial cancer:2.37e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 54.4	bone marrow: 41.4	Cell line enhanced		BJ hTERT+: 35.8
AMPH		ENSG00000078053	Amphiphysin	7	38383704-38631567	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB008559, HPA019828, HPA019829	Enhanced		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:9.96e-4 (favourable)	Tissue enhanced	Tissue enriched	9	cerebral cortex: 83.7	cervix, uterine: 8.9	Cell line enhanced		ASC diff: 44.1;ASC TERT1: 26.4;BJ hTERT+ SV40 Large T+ RasG12V: 29.1;U-138 MG: 24.3
AMT	GCST, NKH	ENSG00000145020	Aminomethyltransferase	3	49416775-49422753	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005566	Supported		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.90e-8 (favourable)	Expressed in all	Mixed			parathyroid gland: 23.2	Group enriched	12	BEWO: 14.2;Hep G2: 30.0;NTERA-2: 7.6;SH-SY5Y: 11.8
AMZ1	KIAA1950	ENSG00000174945	Archaelysin family metallopeptidase 1	7	2679522-2775500	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020233	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 4.0	endometrium: 1.5	Cell line enhanced		BEWO: 6.7;MCF7: 5.8;T-47d: 26.0
AMZ2		ENSG00000196704	Archaelysin family metallopeptidase 2	17	68247574-68257164	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023299, HPA052406	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:1.32e-5 (unfavourable), Renal cancer:3.14e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 357.6	Expressed in all		
ANAPC10	APC10, DKFZP564L0562, DOC1	ENSG00000164162	Anaphase promoting complex subunit 10	4	144967112-145098541	Predicted intracellular proteins	Evidence at protein level	HPA044547	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Melanoma:8.22e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.7	Expressed in all		
ANAPC11	APC11, Apc11p, HSPC214, MGC882	ENSG00000141552	Anaphase promoting complex subunit 11	17	81890790-81900991	Predicted intracellular proteins	Evidence at protein level	HPA021989, HPA027838	Approved		Enhanced	Nucleoplasm<br>Nucleoli		Expressed in all	Expressed in all			testis: 109.9	Expressed in all		
ANAPC13	APC13, DKFZP566D193, SWM1	ENSG00000129055	Anaphase promoting complex subunit 13	3	134477706-134486716	Predicted intracellular proteins	Evidence at protein level	HPA046114	Uncertain		Approved	Mitochondria<br>Cytosol	Renal cancer:2.66e-7 (favourable), Cervical cancer:1.66e-4 (favourable), Liver cancer:1.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 155.1	Expressed in all		
ANAPC15	APC15, C11orf51, DKFZP564M082, HSPC020	ENSG00000110200	Anaphase promoting complex subunit 15	11	72106378-72112780	Predicted intracellular proteins	Evidence at protein level	HPA036596	Approved		Approved	Nucleoplasm<br>Vesicles	Ovarian cancer:2.55e-4 (favourable), Liver cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 77.6	Expressed in all		
ANAPC16	APC16, bA570G20.3, C10orf104, CENP-27, FLJ33728	ENSG00000166295	Anaphase promoting complex subunit 16	10	72216000-72235860	Predicted intracellular proteins	Evidence at protein level	HPA037815	Approved		Supported	Cytosol		Expressed in all	Expressed in all			thyroid gland: 40.2	Expressed in all		
ANAPC2	APC2, KIAA1406	ENSG00000176248	Anaphase promoting complex subunit 2	9	137174784-137188549	Predicted intracellular proteins	Evidence at protein level	CAB018692, HPA066539	Enhanced		Enhanced	Nucleoplasm	Pancreatic cancer:1.07e-7 (favourable), Endometrial cancer:8.91e-5 (favourable), Stomach cancer:2.87e-4 (favourable), Renal cancer:3.67e-4 (favourable)	Expressed in all	Expressed in all			testis: 27.2	Expressed in all		
ANAPC4	APC4	ENSG00000053900	Anaphase promoting complex subunit 4	4	25377213-25418498	Predicted intracellular proteins	Evidence at protein level	CAB032519, HPA038395, HPA038396	Approved		Approved	Intermediate filaments	Endometrial cancer:5.73e-7 (favourable), Urothelial cancer:1.12e-6 (favourable), Renal cancer:1.17e-5 (unfavourable), Head and neck cancer:1.95e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 55.2	Expressed in all		
ANAPC5	APC5	ENSG00000089053	Anaphase promoting complex subunit 5	12	121308245-121399896	Predicted intracellular proteins	Evidence at protein level	HPA039457, HPA039801	Supported		Approved	Nucleoplasm	Renal cancer:2.01e-9 (unfavourable), Liver cancer:2.31e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 88.7	Expressed in all		
ANAPC7	APC7	ENSG00000196510	Anaphase promoting complex subunit 7	12	110372900-110403730	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009567	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.36e-10 (unfavourable), Liver cancer:1.54e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 48.9	Expressed in all		
ANGEL2	Ccr4d, FLJ12793, KIAA0759L	ENSG00000174606	Angel homolog 2	1	212992182-213015826	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030796	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:8.39e-6 (unfavourable), Urothelial cancer:1.20e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 16.0	Expressed in all		
ANHX		ENSG00000227059	Anomalous homeobox	12	133218312-133236095	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	76	testis: 7.5	all non-specific tissues: 0.0	Not detected		
ANK2	LQT4	ENSG00000145362	Ankyrin 2	4	112818109-113383740	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA008007, CAB015178, HPA035970	Enhanced		Supported	Plasma membrane	Renal cancer:2.41e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 184.4	kidney: 125.1	Cell line enhanced		RH-30: 60.5;SH-SY5Y: 33.1
ANK3		ENSG00000151150	Ankyrin 3	10	60026298-60733490	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013249, CAB015179, HPA038455, HPA055643	Approved		Approved	Plasma membrane	Renal cancer:8.88e-16 (favourable)	Mixed	Expressed in all			parathyroid gland: 283.9	Cell line enhanced		RT4: 40.1
ANKAR	FLJ25415	ENSG00000151687	Ankyrin and armadillo repeat containing	2	189674290-189761193	Predicted intracellular proteins	Evidence at transcript level	HPA036168	Uncertain		Approved	Nucleus<br>Microtubule organizing center		Mixed	Tissue enriched	7	testis: 10.3	parathyroid gland: 1.4	Not detected		
ANKDD1B		ENSG00000189045	Ankyrin repeat and death domain containing 1B	5	75611459-75671846	Predicted intracellular proteins	Evidence at transcript level	HPA059722	Uncertain				Renal cancer:2.30e-7 (favourable)	Mixed	Tissue enhanced		fallopian tube: 3.5	rectum: 2.4	Cell line enhanced		RPMI-8226: 1.5
ANKEF1	ANKRD5, dJ839B4.6, FLJ21669	ENSG00000132623	Ankyrin repeat and EF-hand domain containing 1	20	9986126-10058303	Predicted intracellular proteins	Evidence at protein level	HPA041151	Approved		Approved	Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Thyroid cancer:1.58e-4 (unfavourable), Lung cancer:1.81e-4 (unfavourable), Renal cancer:4.44e-4 (favourable)	Mixed	Tissue enhanced		testis: 33.7	thyroid gland: 11.3	Mixed		
ANKFN1	FLJ38335	ENSG00000153930	Ankyrin repeat and fibronectin type III domain containing 1	17	55882301-56511659	Predicted intracellular proteins	Evidence at protein level	HPA021566, HPA022538	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 14.3;fallopian tube: 8.5	cerebral cortex,testis: 3.2	Cell line enhanced		HeLa: 4.8;MOLT-4: 12.3;T-47d: 4.7;U-2197: 4.5
ANKFY1	ANKHZN, BTBD23, KIAA1255, RANK-5, ZFYVE14	ENSG00000185722	Ankyrin repeat and FYVE domain containing 1	17	4163907-4263977	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024513, HPA024522, HPA065849	Approved		Enhanced	Endosomes		Expressed in all	Expressed in all			parathyroid gland: 37.8	Expressed in all		
ANKHD1	FLJ10042, FLJ11979, FLJ14127, FLJ20288, KIAA1085, MASK, MASK1	ENSG00000131503	Ankyrin repeat and KH domain containing 1	5	140401814-140539856	Predicted intracellular proteins	Evidence at protein level	HPA008718	Approved					Mixed	Expressed in all			parathyroid gland: 74.5	Expressed in all		
ANKHD1-EIF4EBP3	MASK-BP3	ENSG00000254996	ANKHD1-EIF4EBP3 readthrough	5	140401908-140549569	Predicted intracellular proteins	Evidence at transcript level	HPA008718	Approved					Mixed	Expressed in all			parathyroid gland: 40.5	Expressed in all		
ANKIB1	DKFZP434A0225, KIAA1386	ENSG00000001629	Ankyrin repeat and IBR domain containing 1	7	92246234-92401384	Predicted intracellular proteins	Evidence at protein level	HPA019358, HPA021780	Uncertain		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 46.3	Expressed in all		
ANKK1	X-kinase	ENSG00000170209	Ankyrin repeat and kinase domain containing 1	11	113387791-113400418	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012813	Uncertain					Mixed	Tissue enhanced		skin: 4.2	fallopian tube: 1.3	Cell line enhanced		hTCEpi: 1.5
ANKMY1	FLJ20499, ZMYND13	ENSG00000144504	Ankyrin repeat and MYND domain containing 1	2	240479422-240569209	Predicted intracellular proteins	Evidence at protein level	HPA026620	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Cytosol	Urothelial cancer:3.20e-4 (favourable)	Expressed in all	Group enriched	6	fallopian tube: 39.5;testis: 94.2	parathyroid gland: 11.4	Mixed		
ANKMY2	DKFZP564O043, ZMYND20	ENSG00000106524	Ankyrin repeat and MYND domain containing 2	7	16599776-16645817	Predicted intracellular proteins	Evidence at protein level	HPA044900, HPA050447, HPA067100			Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.05e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.5	Expressed in all		
ANKRA2		ENSG00000164331	Ankyrin repeat family A member 2	5	73552335-73565686	Predicted intracellular proteins	Evidence at protein level	HPA065263			Approved	Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			thyroid gland: 26.2	Expressed in all		
ANKRD1	ALRP, C-193, CARP, CVARP, MCARP	ENSG00000148677	Ankyrin repeat domain 1	10	90912096-90921276	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038736	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center	Head and neck cancer:1.95e-4 (unfavourable)	Tissue enhanced	Tissue enriched	108	heart muscle: 3714.2	lung: 34.4	Group enriched	6	CACO-2: 348.0;EFO-21: 1053.3;HUVEC TERT2: 325.0;LHCN-M2: 1166.6;TIME: 1606.3
ANKRD10	FLJ20093	ENSG00000088448	Ankyrin repeat domain 10	13	110878540-110915069	Predicted intracellular proteins	Evidence at protein level	CAB034211, HPA038878, HPA038879	Uncertain		Approved	Microtubules<br>Cytosol	Renal cancer:1.25e-6 (unfavourable), Urothelial cancer:6.41e-6 (favourable)	Expressed in all	Expressed in all			epididymis: 109.5	Expressed in all		
ANKRD11	LZ16, T13	ENSG00000167522	Ankyrin repeat domain 11	16	89267627-89490561	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB019288, HPA041593, HPA049470	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.39e-4 (unfavourable), Prostate cancer:7.67e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 24.4	Expressed in all		
ANKRD12	FLJ20053, GAC-1, KIAA0874	ENSG00000101745	Ankyrin repeat domain 12	18	9136228-9285985	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA040705	Approved		Supported	Nucleoplasm<br>Cytosol	Melanoma:6.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.0	Expressed in all		
ANKRD13A	ANKRD13, NY-REN-25	ENSG00000076513	Ankyrin repeat domain 13A	12	109999186-110039763	Predicted intracellular proteins	Evidence at protein level	HPA039488, HPA043218	Enhanced		Supported	Plasma membrane	Head and neck cancer:7.70e-6 (favourable), Ovarian cancer:6.77e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 113.4	Expressed in all		
ANKRD13B	FLJ25555	ENSG00000198720	Ankyrin repeat domain 13B	17	29589769-29614761	Predicted intracellular proteins	Evidence at protein level	HPA051886, HPA063748	Uncertain		Supported	Vesicles	Renal cancer:5.92e-6 (unfavourable), Pancreatic cancer:7.58e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 25.9	testis: 17.6	Cell line enhanced		SCLC-21H: 75.3;SH-SY5Y: 76.2
ANKRD13C	dJ677H15.3, DKFZP566D1346	ENSG00000118454	Ankyrin repeat domain 13C	1	70260588-70354734	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 19.1	Expressed in all		
ANKRD13D		ENSG00000172932	Ankyrin repeat domain 13D	11	67288547-67302485	Predicted intracellular proteins	Evidence at protein level	HPA039950	Approved		Approved	Nucleus<br>Mitochondria	Renal cancer:5.73e-10 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 69.4	Expressed in all		
ANKRD16	DKFZP434N1511	ENSG00000134461	Ankyrin repeat domain 16	10	5861617-5889906	Predicted intracellular proteins	Evidence at protein level	HPA037920, HPA037921	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:4.31e-7 (unfavourable), Pancreatic cancer:1.98e-4 (favourable)	Expressed in all	Mixed			testis: 9.9	Expressed in all		
ANKRD17	FLJ22206, GTAR, KIAA0697, MASK2, NY-BR-16	ENSG00000132466	Ankyrin repeat domain 17	4	73073376-73258798	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045024, HPA063731	Approved		Supported	Nucleus<br>Nuclear membrane		Expressed in all	Expressed in all			parathyroid gland: 49.7	Expressed in all		
ANKRD18A	FLJ35740, KIAA2015	ENSG00000180071	Ankyrin repeat domain 18A	9	38571358-38620660	Predicted intracellular proteins	Evidence at protein level	HPA046346, HPA046695, HPA049923, HPA051288	Uncertain		Supported	Nucleoli<br>Cytosol		Mixed	Tissue enhanced		bone marrow: 11.3;testis: 10.2	thyroid gland: 3.5	Cell line enhanced		HL-60: 13.8
ANKRD18B	bA255A11.3	ENSG00000230453	Ankyrin repeat domain 18B	9	33524394-33573009	Predicted intracellular proteins	Evidence at protein level	HPA046346, HPA046695, HPA049923, HPA051288	Uncertain		Approved	Nucleoli<br>Cytosol		Mixed	Tissue enhanced		testis: 6.4	skin: 2.8	Cell line enhanced		NB-4: 17.4
ANKRD2	ARPP	ENSG00000165887	Ankyrin repeat domain 2	10	97572499-97583884	Predicted intracellular proteins	Evidence at protein level	HPA040842, HPA040884	Enhanced		Enhanced	Vesicles		Tissue enhanced	Group enriched	14	heart muscle: 35.9;skeletal muscle: 119.4	kidney: 5.6	Cell line enhanced		A-431: 14.1;HaCaT: 11.0;RPTEC TERT1: 10.3
ANKRD20A1	ANKRD20A, DKFZp434A171	ENSG00000260691	Ankyrin repeat domain 20 family member A1	9	67859147-67902094	Predicted intracellular proteins	Evidence at transcript level	HPA043239, HPA047112, HPA047167, HPA047766, HPA051753	Uncertain					Not detected	Tissue enriched	7	testis: 5.2	cerebral cortex,spleen: 0.7	Cell line enhanced		Karpas-707: 3.2;U-266/70: 5.6;U-266/84: 1.9
ANKRD20A2		ENSG00000183148	Ankyrin repeat domain 20 family member A2	9	40223285-40266392	Predicted intracellular proteins	Evidence at transcript level	HPA043239, HPA047112, HPA047167, HPA047766, HPA051753	Uncertain					Not detected	Tissue enriched	6	testis: 4.9	spleen: 0.7	Cell line enhanced		Karpas-707: 9.3;U-266/84: 2.9
ANKRD20A3		ENSG00000276203	Ankyrin repeat domain 20 family member A3	9	66106815-66153135	Predicted intracellular proteins	Evidence at transcript level	HPA043239, HPA047112, HPA047167, HPA047766, HPA051753	Uncertain					Not detected	Not detected			testis: 0.4	Cell line enhanced		HDLM-2: 1.2
ANKRD20A4		ENSG00000172014	Ankyrin repeat domain 20 family member A4	9	64369394-64413142	Predicted intracellular proteins	Evidence at transcript level	HPA043239, HPA047112, HPA047167, HPA047766, HPA051753	Uncertain					Not detected	Mixed			testis: 1.2	Cell line enhanced		HDLM-2: 1.5
ANKRD22	MGC22805	ENSG00000152766	Ankyrin repeat domain 22	10	88822132-88851818	Predicted intracellular proteins	Evidence at protein level	HPA012922	Approved		Approved	Nucleus	Endometrial cancer:8.73e-6 (favourable), Pancreatic cancer:6.15e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 38.6;stomach: 49.2	esophagus: 27.0	Cell line enhanced		A-431: 13.9;CAPAN-2: 43.6;RT4: 27.0;T-47d: 21.2
ANKRD23	DARP, FLJ32449, MARP3	ENSG00000163126	Ankyrin repeat domain 23	2	96824526-96857934	Predicted intracellular proteins	Evidence at protein level	HPA036201	Approved		Supported	Nucleoplasm<br>Actin filaments		Not detected	Tissue enriched	64	skeletal muscle: 495.5	prostate: 7.7	Cell line enriched	8	Karpas-707: 27.1
ANKRD24	KIAA1981	ENSG00000089847	Ankyrin repeat domain 24	19	4183354-4224814	Predicted intracellular proteins	Evidence at protein level	HPA041534, HPA048498	Uncertain		Uncertain	Microtubules<br>Cytosol	Liver cancer:9.13e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 13.5;testis: 7.0	prostate: 3.2	Cell line enhanced		Karpas-707: 3.5;U-266/70: 12.3
ANKRD26	KIAA1074, THC2	ENSG00000107890	Ankyrin repeat domain 26	10	26991914-27100498	Predicted intracellular proteins	Evidence at protein level	HPA040654, HPA041460	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			testis: 10.7	Expressed in all		
ANKRD27	DKFZp434L0718, FLJ00040, VARP	ENSG00000105186	Ankyrin repeat domain 27	19	32597007-32676597	Predicted intracellular proteins	Evidence at protein level	HPA042769	Approved		Enhanced	Cytosol	Liver cancer:1.21e-5 (unfavourable), Endometrial cancer:8.68e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.4	Expressed in all		
ANKRD28	KIAA0379, PITK, PP6-ARS-A, PPP1R65	ENSG00000206560	Ankyrin repeat domain 28	3	15667236-15859771	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.85e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 33.9	Expressed in all		
ANKRD30A	NY-BR-1	ENSG00000148513	Ankyrin repeat domain 30A	10	37125788-37384111	Predicted intracellular proteins	Evidence at protein level	HPA071849						Tissue enriched	Tissue enriched	15	breast: 49.8	testis: 3.3	Group enriched	34	A549: 2.4;U-266/70: 8.1
ANKRD30B	NY-BR-1.1	ENSG00000180777	Ankyrin repeat domain 30B	18	14728272-14852738	Predicted intracellular proteins	Evidence at protein level	HPA060455, HPA071849	Uncertain		Uncertain	Nucleoli		Tissue enhanced	Tissue enriched	11	testis: 14.4	breast: 1.3	Cell line enriched	8	U-2197: 41.6
ANKRD30BL	ANKRD30BP3, NCRNA00164	ENSG00000163046	Ankyrin repeat domain 30B like	2	132147591-132257969	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	31	testis: 3.0	appendix: 0.1	Not detected		
ANKRD31	FLJ40191	ENSG00000145700	Ankyrin repeat domain 31	5	75068275-75236878	Predicted intracellular proteins	Evidence at protein level	HPA057566	Enhanced					Not detected	Tissue enriched	12	testis: 9.9	esophagus: 0.8	Not detected		
ANKRD33	C12orf7, DKFZp686O1689, PANKY	ENSG00000167612	Ankyrin repeat domain 33	12	51887960-51891664	Predicted intracellular proteins	Evidence at transcript level	HPA040013, HPA058753	Uncertain					Not detected	Not detected			placenta: 0.5	Not detected		
ANKRD33B		ENSG00000164236	Ankyrin repeat domain 33B	5	10564330-10657816	Predicted intracellular proteins	Evidence at protein level	HPA056974	Uncertain		Approved	Mitochondria	Renal cancer:4.16e-5 (favourable)	Tissue enhanced	Mixed			cerebral cortex: 12.9	Cell line enhanced		HDLM-2: 44.9;HMC-1: 27.3
ANKRD34A	ANKRD34	ENSG00000272031	Ankyrin repeat domain 34A	1	145959442-145964582	Predicted intracellular proteins	Evidence at protein level	HPA029642, HPA029643	Uncertain		Enhanced	Cytosol		Mixed	Tissue enriched	8	cerebral cortex: 12.7	appendix,parathyroid gland: 1.6	Mixed		
ANKRD34B	DP58	ENSG00000189127	Ankyrin repeat domain 34B	5	80556755-80570488	Predicted intracellular proteins	Evidence at protein level	HPA043327	Uncertain		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		bone marrow: 1.1;lymph node: 1.0;tonsil: 1.1	kidney: 0.7	Cell line enriched	23	RPTEC TERT1: 71.4
ANKRD34C		ENSG00000235711	Ankyrin repeat domain 34C	15	79293285-79298235	Predicted intracellular proteins	Evidence at protein level	HPA045329	Uncertain		Approved	Mitochondria		Not detected	Tissue enhanced		cerebral cortex: 1.9	skin: 0.9	Cell line enriched	29	SCLC-21H: 10.0
ANKRD35	FLJ25124	ENSG00000198483	Ankyrin repeat domain 35	1	145866560-145885866	Predicted intracellular proteins	Evidence at protein level	HPA035453	Enhanced				Cervical cancer:2.90e-4 (favourable), Breast cancer:9.35e-4 (favourable)	Mixed	Group enriched	6	cervix, uterine: 30.8;esophagus: 16.6;skin: 69.8	tonsil: 6.1	Cell line enhanced		ASC TERT1: 6.6;THP-1: 4.5;TIME: 6.9;U-87 MG: 8.1;U-937: 5.9
ANKRD36	UNQ2430	ENSG00000135976	Ankyrin repeat domain 36	2	97113496-97264521	Predicted intracellular proteins	Evidence at protein level	HPA051757, HPA057661			Approved	Nucleus<br>Cytosol		Mixed	Mixed			testis: 13.4	Mixed		
ANKRD36B	FLJ21281, KIAA1641	ENSG00000196912	Ankyrin repeat domain 36B	2	97492663-97589965	Predicted intracellular proteins	Evidence at protein level	HPA051757, HPA057661			Approved	Nucleus<br>Cytosol		Mixed	Mixed			testis: 12.2	Mixed		
ANKRD36C	DKFZp667P0924	ENSG00000174501	Ankyrin repeat domain 36C	2	95836919-95991831	Predicted intracellular proteins	Evidence at protein level	HPA051757, HPA057661			Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		testis: 22.0	bone marrow: 10.7	Cell line enhanced		PC-3: 28.8
ANKRD37	Lrp2bp	ENSG00000186352	Ankyrin repeat domain 37	4	185396021-185400628	Predicted intracellular proteins	Evidence at protein level	HPA036626, HPA058127	Uncertain		Supported	Nucleus<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			esophagus: 31.1	Mixed		
ANKRD39	MGC41816	ENSG00000213337	Ankyrin repeat domain 39	2	96836611-96858095	Predicted intracellular proteins	Evidence at protein level	HPA042678	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:6.78e-9 (unfavourable), Pancreatic cancer:6.12e-5 (favourable), Colorectal cancer:2.26e-4 (unfavourable), Urothelial cancer:5.21e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 17.2	Expressed in all		
ANKRD40	MGC15396	ENSG00000154945	Ankyrin repeat domain 40	17	50693190-50707924	Predicted intracellular proteins	Evidence at protein level	HPA021668, HPA021759	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:7.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 58.1	Expressed in all		
ANKRD42	FLJ37874, PPP1R79, SARP	ENSG00000137494	Ankyrin repeat domain 42	11	83193739-83260694	Predicted intracellular proteins	Evidence at protein level	HPA039917	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		testis: 71.5	fallopian tube: 26.2	Expressed in all		
ANKRD44	PP6-ARS-B	ENSG00000065413	Ankyrin repeat domain 44	2	196967017-197311173	Predicted intracellular proteins	Evidence at protein level	HPA030122, HPA056549	Approved		Approved	Nuclear speckles<br>Mitochondria		Mixed	Mixed			lymph node: 42.7	Cell line enhanced		HDLM-2: 43.2;HMC-1: 30.0
ANKRD45	CT117, FLJ45235	ENSG00000183831	Ankyrin repeat domain 45	1	173609561-173669862	Predicted intracellular proteins	Evidence at protein level	HPA031655, HPA031656, HPA031657	Enhanced					Mixed	Tissue enhanced		fallopian tube: 35.0;parathyroid gland: 22.9;testis: 36.3	cerebral cortex: 7.2	Cell line enhanced		AF22: 9.4;BJ hTERT+ SV40 Large T+ RasG12V: 5.0;SH-SY5Y: 9.1
ANKRD49	FGIF, FLJ20189, GBIF	ENSG00000168876	Ankyrin repeat domain 49	11	94493629-94499583	Predicted intracellular proteins	Evidence at protein level	HPA040273, HPA048137	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Urothelial cancer:6.16e-4 (favourable), Renal cancer:9.96e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.4	Expressed in all		
ANKRD50	KIAA1223	ENSG00000151458	Ankyrin repeat domain 50	4	124664052-124712732	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044008	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.28e-4 (unfavourable)	Expressed in all	Mixed			testis: 27.7	Cell line enhanced		TIME: 120.1
ANKRD52	FLJ34236, PP6-ARS-C	ENSG00000139645	Ankyrin repeat domain 52	12	56237807-56258391	Predicted intracellular proteins	Evidence at protein level	HPA043815	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Liver cancer:3.33e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.0	Expressed in all		
ANKRD53	FLJ12056, FLJ36160	ENSG00000144031	Ankyrin repeat domain 53	2	70978380-70985499	Predicted intracellular proteins	Evidence at protein level	HPA049574	Approved					Mixed	Tissue enhanced		testis: 17.5	adipose tissue: 4.3	Cell line enhanced		HHSteC: 1.3;HSkMC: 1.2
ANKRD55	FLJ11795	ENSG00000164512	Ankyrin repeat domain 55	5	56099678-56233359	Predicted intracellular proteins	Evidence at protein level	HPA051049	Approved					Tissue enriched	Group enriched	6	lymph node: 4.1;testis: 17.3	tonsil: 1.8	Group enriched	6	HEL: 30.8;HMC-1: 15.0;NB-4: 14.3
ANKRD6	KIAA0957	ENSG00000135299	Ankyrin repeat domain 6	6	89433170-89633834	Predicted intracellular proteins	Evidence at protein level	CAB020693, HPA035694, HPA064642	Enhanced		Supported	Vesicles		Mixed	Mixed			cerebral cortex: 23.7	Cell line enhanced		AF22: 15.3;BEWO: 45.7;HAP1: 14.8
ANKRD61		ENSG00000157999	Ankyrin repeat domain 61	7	6031376-6036386	Predicted intracellular proteins	Evidence at transcript level	HPA029511	Uncertain					Mixed	Tissue enhanced		testis: 11.0	bone marrow: 4.0	Cell line enhanced		HeLa: 5.6
ANKRD62	DKFZp779B1634	ENSG00000181626	Ankyrin repeat domain 62	18	12093853-12129749	Predicted intracellular proteins	Evidence at protein level	HPA059835	Enhanced					Not detected	Tissue enriched	11	testis: 4.1	pancreas: 0.3	Not detected		
ANKRD63		ENSG00000230778	Ankyrin repeat domain 63	15	40281444-40282586	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	6	cerebral cortex: 1.0	fallopian tube,kidney,spleen,testis: 0.1	Cell line enhanced		HEK93: 1.8
ANKRD65		ENSG00000235098	Ankyrin repeat domain 65	1	1418420-1421769	Predicted intracellular proteins	Evidence at protein level	HPA065720	Enhanced		Approved	Nucleoplasm	Lung cancer:1.08e-5 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 60.0	seminal vesicle: 31.4	Group enriched	8	Hep G2: 24.2;RT4: 27.5;SCLC-21H: 54.5
ANKRD66		ENSG00000230062	Ankyrin repeat domain 66	6	46746917-46759506	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	13	fallopian tube: 64.0	lung: 4.9	Not detected		
ANKRD7	TSA806	ENSG00000106013	Ankyrin repeat domain 7	7	118214669-118496171	Predicted intracellular proteins	Evidence at protein level	HPA043489			Approved	Nucleus		Tissue enhanced	Tissue enriched	643	testis: 1542.7	epididymis: 2.3	Cell line enhanced		SCLC-21H: 9.0;U-266/70: 7.5
ANKRD9		ENSG00000156381	Ankyrin repeat domain 9	14	102501760-102509799	Predicted intracellular proteins	Evidence at protein level	HPA055985	Uncertain				Renal cancer:1.17e-7 (favourable)	Expressed in all	Expressed in all			duodenum: 50.3	Mixed		
ANKS1A	ANKS1, KIAA0229	ENSG00000064999	Ankyrin repeat and sterile alpha motif domain containing 1A	6	34889265-35091413	Predicted intracellular proteins	Evidence at protein level	HPA036768, HPA036769	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:8.05e-5 (favourable), Head and neck cancer:7.48e-4 (favourable)	Expressed in all	Expressed in all			placenta: 39.2	Expressed in all		
ANKS1B	AIDA-1, ANKS2, cajalin-2, EB-1	ENSG00000185046	Ankyrin repeat and sterile alpha motif domain containing 1B	12	98726457-99984654	Predicted intracellular proteins	Evidence at protein level	HPA044628			Approved	Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	8	cerebral cortex: 111.9	testis: 14.0	Cell line enhanced		AF22: 10.0;SCLC-21H: 13.0
ANKS3	FLJ32345, FLJ32767, KIAA1977	ENSG00000168096	Ankyrin repeat and sterile alpha motif domain containing 3	16	4696510-4734378	Predicted intracellular proteins	Evidence at protein level	HPA041409, HPA041482	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			ovary: 8.1	Expressed in all		
ANKS4B	FLJ38819, HARP	ENSG00000175311	Ankyrin repeat and sterile alpha motif domain containing 4B	16	21233665-21253845	Predicted intracellular proteins	Evidence at protein level	HPA043523	Approved		Approved	Nucleoplasm<br>Cytosol		Group enriched	Tissue enhanced		duodenum: 9.0;rectum: 7.8;small intestine: 12.9	colon: 6.8	Group enriched	10	CACO-2: 1.1;HDLM-2: 3.2;Hep G2: 5.5
ANKS6	ANKRD14, FLJ36928, NPHP16, SAMD6	ENSG00000165138	Ankyrin repeat and sterile alpha motif domain containing 6	9	98731329-98796965	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008355	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.44e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 15.3	Mixed		
ANKUB1	C3orf16	ENSG00000206199	Ankyrin repeat and ubiquitin domain containing 1	3	149761100-149968385	Predicted intracellular proteins	Evidence at transcript level	HPA053749	Uncertain					Not detected	Tissue enriched	5	fallopian tube: 9.0	lung: 1.6	Not detected		
ANKZF1	FLJ10415, ZNF744	ENSG00000163516	Ankyrin repeat and zinc finger domain containing 1	2	219229757-219236669	Predicted intracellular proteins	Evidence at protein level	HPA035208	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:2.01e-6 (unfavourable), Liver cancer:3.09e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 16.8	Expressed in all		
ANLN	ANILLIN, scra, Scraps	ENSG00000011426	Anillin actin binding protein	7	36389806-36453791	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005680, CAB033902, HPA050556, CAB062547, CAB068175	Enhanced		Enhanced	Nucleoplasm<br>Midbody	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.97e-7 (unfavourable), Pancreatic cancer:2.00e-6 (unfavourable), Lung cancer:6.99e-5 (unfavourable), Endometrial cancer:1.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 87.2	bone marrow: 23.1	Expressed in all		
ANP32A	C15orf1, I1PP2A, LANP, MAPM, mapmodulin, PHAPI, PP32	ENSG00000140350	Acidic nuclear phosphoprotein 32 family member A	15	68778535-68820897	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005231, HPA063133, HPA067561	Supported		Enhanced	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			lymph node: 181.3	Expressed in all		
ANP32B	APRIL, PHAPI2, SSP29	ENSG00000136938	Acidic nuclear phosphoprotein 32 family member B	9	97983361-98015943	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063133, HPA067561	Supported		Enhanced	Nucleoplasm<br>Centrosome<br>Cytosol	Liver cancer:1.98e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 264.3	Expressed in all		
ANP32D	PP32R2	ENSG00000139223	Acidic nuclear phosphoprotein 32 family member D	12	48472665-48473624	Predicted intracellular proteins	Evidence at protein level	HPA063133, HPA067561	Uncertain		Enhanced	Nucleoplasm<br>Centrosome<br>Cytosol		Not detected	Not detected			testis,thyroid gland: 0.1	Not detected		
ANP32E	LANP-L, LANPL, MGC5350	ENSG00000143401	Acidic nuclear phosphoprotein 32 family member E	1	150218417-150236156	Predicted intracellular proteins	Evidence at protein level	CAB021114, HPA063133, HPA067561	Supported		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:3.82e-8 (unfavourable), Liver cancer:4.50e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 84.1	Expressed in all		
ANXA1	ANX1, LPC1	ENSG00000135046	Annexin A1	9	73151757-73170393	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA011271, HPA011272, CAB013023, CAB035987, CAB058693	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:6.19e-6 (unfavourable), Thyroid cancer:4.57e-5 (favourable), Endometrial cancer:5.71e-5 (favourable)	Expressed in all	Tissue enriched	6	esophagus: 7548.8	tonsil: 1217.6	Mixed		
ANXA10	ANX14	ENSG00000109511	Annexin A10	4	168092515-168187690	Predicted intracellular proteins	Evidence at protein level	HPA005469	Enhanced		Approved	Nucleus<br>Nucleoli<br>Vesicles	Liver cancer:3.64e-6 (favourable)	Group enriched	Tissue enriched	8	stomach: 459.7	urinary bladder: 60.6	Group enriched	8	PC-3: 118.8;RT4: 140.1
ANXA11	ANX11	ENSG00000122359	Annexin A11	10	80150889-80205572	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004851, HPA027545	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.69e-8 (favourable)	Expressed in all	Expressed in all			esophagus: 203.1	Expressed in all		
ANXA13	ANX13	ENSG00000104537	Annexin A13	8	123680794-123737407	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018535, HPA019569, HPA019650, CAB025135	Enhanced		Supported	Plasma membrane		Group enriched	Group enriched	5	duodenum: 296.6;fallopian tube: 92.7;gallbladder: 227.6;small intestine: 235.6	rectum: 39.2	Group enriched	16	A549: 25.3;HDLM-2: 13.7
ANXA2	ANX2, ANX2L4, CAL1H, LIP2, LPC2D	ENSG00000182718	Annexin A2	15	60347134-60402883	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004311, HPA046964, HPA061798	Enhanced				Renal cancer:2.11e-6 (unfavourable), Pancreatic cancer:8.47e-6 (unfavourable), Liver cancer:2.54e-5 (unfavourable), Urothelial cancer:6.59e-5 (unfavourable), Endometrial cancer:6.88e-5 (favourable), Lung cancer:7.51e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 1488.4	Expressed in all		
ANXA2R	AXIIR, C5orf39	ENSG00000177721	Annexin A2 receptor	5	43039081-43043170	Predicted intracellular proteins	Evidence at protein level	HPA051482	Uncertain		Approved	Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies	Renal cancer:6.36e-8 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 21.9	spleen: 15.4	Cell line enhanced		REH: 21.2;U-937: 66.7
ANXA3	ANX3	ENSG00000138772	Annexin A3	4	78551519-78610451	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013398, HPA013431	Enhanced		Supported	Cytosol	Renal cancer:8.48e-6 (favourable), Pancreatic cancer:1.28e-4 (unfavourable)	Mixed	Expressed in all			bone marrow: 198.3	Cell line enhanced		A-431: 316.4;CACO-2: 302.6;CAPAN-2: 428.5;EFO-21: 275.3;hTERT-HME1: 372.7;RPTEC TERT1: 312.0
ANXA4	ANX4	ENSG00000196975	Annexin A4	2	69644425-69827100	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB005076, HPA007393, CAB017560	Approved		Approved	Cytosol	Ovarian cancer:2.38e-4 (unfavourable), Renal cancer:6.05e-4 (unfavourable), Breast cancer:8.55e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 881.8	Cell line enhanced		EFO-21: 386.6;RPTEC TERT1: 457.3
ANXA5	ANX5, ENX2	ENSG00000164111	Annexin A5	4	121667955-121697113	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB003677, HPA035330	Approved		Approved	Nuclear membrane	Renal cancer:9.29e-7 (unfavourable), Liver cancer:1.64e-5 (unfavourable), Head and neck cancer:3.01e-5 (unfavourable), Urothelial cancer:1.26e-4 (unfavourable), Endometrial cancer:3.64e-4 (favourable), Stomach cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 616.2	Expressed in all		
ANXA6	ANX6	ENSG00000197043	Annexin A6	5	151100712-151157882	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA002462, CAB005077, HPA009650	Enhanced				Renal cancer:1.31e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 431.9	Mixed		
ANXA7	ANX7	ENSG00000138279	Annexin A7	10	73375101-73414076	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004312, HPA064290	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.98e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 473.1	Expressed in all		
ANXA8	ANX8	ENSG00000265190	Annexin A8	10	47460162-47484158	Predicted intracellular proteins	Evidence at protein level	HPA045246, HPA047451			Approved	Nucleoplasm	Pancreatic cancer:2.68e-4 (unfavourable), Head and neck cancer:6.07e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 229.1;skin: 368.9	urinary bladder: 64.2	Cell line enhanced		HaCaT: 409.1;HBEC3-KT: 486.4;hTCEpi: 269.3
ANXA8L1	ANXA8L2, bA145E20.2, bA301J7.3	ENSG00000264230	Annexin A8-like 1	10	46375627-46537864	Predicted intracellular proteins	Evidence at protein level	HPA045246, HPA047451			Approved	Nucleoplasm		Mixed	Group enriched	7	esophagus: 199.3;skin: 460.9	urinary bladder: 44.2	Cell line enhanced		HaCaT: 384.4;HBEC3-KT: 476.5;hTCEpi: 124.5;SiHa: 166.0
ANXA9	ANX31	ENSG00000143412	Annexin A9	1	150982017-150995634	Predicted intracellular proteins	Evidence at protein level	HPA028404, HPA028698	Enhanced		Approved	Nuclear speckles<br>Cytosol	Renal cancer:8.74e-6 (favourable)	Expressed in all	Mixed			thyroid gland: 35.3	Cell line enhanced		CAPAN-2: 31.9;MCF7: 38.4;T-47d: 113.2
AOX1	AO, AOH1	ENSG00000138356	Aldehyde oxidase 1	2	200585868-200677064	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040199, HPA040215	Enhanced				Renal cancer:6.05e-5 (favourable)	Tissue enriched	Group enriched	5	adrenal gland: 368.8;kidney: 97.5;liver: 432.3	ovary: 56.8	Cell line enhanced		ASC diff: 241.4;ASC TERT1: 125.7;hTERT-HME1: 56.6
AP000275.65		ENSG00000265590		21	32578822-32612281	Predicted intracellular proteins	Evidence at transcript level	HPA019055, HPA028849	Approved	Supported				Not detected	Mixed			testis: 26.0	Mixed		
AP000295.9		ENSG00000249624		21	33246774-33283212	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			lung: 1.5	Cell line enhanced		HEL: 3.7;MOLT-4: 3.5;RH-30: 4.4
AP000304.12		ENSG00000249209		21	33584687-33931607	Predicted intracellular proteins	Evidence at protein level	HPA039558	Uncertain					Not detected	Mixed			placenta,testis: 1.2	Cell line enhanced		U-2 OS: 7.1
AP003419.11		ENSG00000256514		11	67351572-67373584	Predicted intracellular proteins	Evidence at transcript level	HPA071529			Uncertain	Nucleus<br>Nucleoli<br>Mitochondria<br>Cytosol		Not detected	Expressed in all			tonsil: 101.3	Mixed		
AP1AR	2C18, C4orf16, gamma-BAR, PRO0971	ENSG00000138660	Adaptor related protein complex 1 associated regulatory protein	4	112231737-112270047	Predicted intracellular proteins	Evidence at protein level	HPA035863, HPA058115	Approved		Supported	Golgi apparatus	Renal cancer:4.05e-7 (favourable), Urothelial cancer:7.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 57.7	Expressed in all		
AP1B1	ADTB1, AP105A, BAM22, CLAPB2	ENSG00000100280	Adaptor related protein complex 1 beta 1 subunit	22	29327680-29423179	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065226, HPA068520	Approved		Supported	Golgi apparatus<br>Vesicles	Renal cancer:7.24e-6 (favourable), Liver cancer:5.55e-5 (unfavourable), Cervical cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 104.2	Expressed in all		
AP1G1	ADTG, CLAPG1	ENSG00000166747	Adaptor related protein complex 1 gamma 1 subunit	16	71729000-71809201	Predicted intracellular proteins	Evidence at protein level	CAB009049, HPA041224	Approved		Enhanced	Vesicles<br>Cytosol	Renal cancer:2.96e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 88.8	Expressed in all		
AP1G2	G2AD	ENSG00000213983	Adaptor related protein complex 1 gamma 2 subunit	14	23559565-23568070	Predicted intracellular proteins	Evidence at protein level	HPA004106	Approved				Renal cancer:1.79e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 59.5	Cell line enhanced		RT4: 119.1
AP1M1	AP47, CLAPM2	ENSG00000072958	Adaptor related protein complex 1 mu 1 subunit	19	16197578-16245907	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045256	Uncertain				Renal cancer:1.75e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 96.5	Expressed in all		
AP1M2	AP1-mu2, HSMU1B, mu2	ENSG00000129354	Adaptor related protein complex 1 mu 2 subunit	19	10572671-10587315	Predicted intracellular proteins	Evidence at protein level	HPA054999			Supported	Vesicles	Renal cancer:3.73e-6 (favourable), Endometrial cancer:2.07e-4 (favourable)	Mixed	Mixed			thyroid gland: 98.3	Cell line enhanced		Hep G2: 212.3;MCF7: 206.6;U-2 OS: 174.7
AP1S1	AP19, CLAPS1, EKV3, SIGMA1A, WUGSC:H_DJ0747G18.2	ENSG00000106367	Adaptor related protein complex 1 sigma 1 subunit	7	101154397-101161596	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA060945	Supported		Supported	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			cerebral cortex: 107.0	Expressed in all		
AP1S2	MRX59, MRXS5, PGS, SIGMA1B	ENSG00000182287	Adaptor related protein complex 1 sigma 2 subunit	X	15825806-15855014	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049894, HPA060945	Enhanced		Supported	Golgi apparatus<br>Vesicles	Ovarian cancer:5.53e-6 (favourable), Breast cancer:9.86e-4 (favourable)	Expressed in all	Tissue enriched	7	epididymis: 920.5	smooth muscle: 126.9	Expressed in all		
AP1S3		ENSG00000152056	Adaptor related protein complex 1 sigma 3 subunit	2	223751686-223838027	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA066782	Approved		Supported	Vesicles	Pancreatic cancer:2.08e-5 (unfavourable), Lung cancer:3.36e-5 (unfavourable)	Mixed	Tissue enhanced		epididymis: 54.2	thyroid gland: 23.6	Cell line enhanced		CACO-2: 130.6
AP2A1	ADTAA, CLAPA1	ENSG00000196961	Adaptor related protein complex 2 alpha 1 subunit	19	49766968-49807113	Predicted intracellular proteins	Evidence at protein level	CAB004306	Approved		Supported	Vesicles	Renal cancer:2.83e-9 (unfavourable), Ovarian cancer:2.91e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 103.9	Expressed in all		
AP2A2	ADTAB, CLAPA2, DKFZP564D1864, HIP9, HYPJ, KIAA0899	ENSG00000183020	Adaptor related protein complex 2 alpha 2 subunit	11	924894-1012245	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017514, HPA043040	Enhanced		Supported	Nucleoplasm<br>Vesicles	Liver cancer:9.27e-5 (unfavourable), Pancreatic cancer:4.57e-4 (favourable)	Expressed in all	Mixed			spleen: 16.0	Mixed		
AP2B1	ADTB2, CLAPB1	ENSG00000006125	Adaptor related protein complex 2 beta 1 subunit	17	35578046-35726409	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB017631, HPA056733, HPA067983	Approved		Supported	Vesicles	Renal cancer:2.62e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 265.4	Expressed in all		
AP2M1	AP50, CLAPM1, mu2	ENSG00000161203	Adaptor related protein complex 2 mu 1 subunit	3	184174689-184184091	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036849, HPA069870	Uncertain		Supported	Plasma membrane	Renal cancer:7.45e-6 (unfavourable), Liver cancer:9.12e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 557.6	Expressed in all		
AP2S1	CLAPS2, FBH3, FBHOk, HHC3	ENSG00000042753	Adaptor related protein complex 2 sigma 1 subunit	19	46838136-46850992	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.48e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 114.5	Expressed in all		
AP3B1	ADTB3A, HPS2	ENSG00000132842	Adaptor related protein complex 3 beta 1 subunit	5	78000525-78294755	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038737, HPA045458	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:7.97e-6 (favourable), Colorectal cancer:1.37e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 65.5	Expressed in all		
AP3B2	NAPTB	ENSG00000103723	Adaptor related protein complex 3 beta 2 subunit	15	82659281-82709914	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039467, HPA039818	Enhanced					Mixed	Group enriched	6	cerebral cortex: 36.2;parathyroid gland: 7.4	adrenal gland: 3.8	Cell line enhanced		RT4: 11.4;SCLC-21H: 26.6;SH-SY5Y: 18.5
AP3D1	ADTD	ENSG00000065000	Adaptor related protein complex 3 delta 1 subunit	19	2100988-2164465	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA074408			Approved	Cytosol	Renal cancer:2.61e-6 (favourable), Liver cancer:9.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 60.7	Expressed in all		
AP3M1		ENSG00000185009	Adaptor related protein complex 3 mu 1 subunit	10	74120255-74151063	Predicted intracellular proteins	Evidence at protein level	HPA045591, HPA048380	Uncertain					Expressed in all	Expressed in all			placenta: 46.0	Expressed in all		
AP3M2	AP47B, CLA20	ENSG00000070718	Adaptor related protein complex 3 mu 2 subunit	8	42152946-42171673	Predicted intracellular proteins	Evidence at protein level	CAB014876, HPA045591, HPA048380	Approved				Urothelial cancer:2.38e-4 (favourable), Endometrial cancer:3.46e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 46.9	Expressed in all		
AP3S1	CLAPS3	ENSG00000177879	Adaptor related protein complex 3 sigma 1 subunit	5	115841481-115914081	Predicted intracellular proteins	Evidence at protein level	HPA049270	Uncertain		Approved	Vesicles	Renal cancer:9.57e-8 (unfavourable), Pancreatic cancer:1.13e-5 (unfavourable), Breast cancer:1.22e-4 (unfavourable), Glioma:5.30e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 90.3	Expressed in all		
AP3S2	sigma3b	ENSG00000157823	Adaptor related protein complex 3 sigma 2 subunit	15	89830599-89894638	Predicted intracellular proteins	Evidence at transcript level	HPA049270	Uncertain		Approved	Vesicles	Renal cancer:5.55e-16 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 77.7	Expressed in all		
AP4B1	BETA-4, SPG47	ENSG00000134262	Adaptor related protein complex 4 beta 1 subunit	1	113894748-113905201	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028162, HPA028652	Approved		Approved	Vesicles	Liver cancer:8.60e-7 (unfavourable), Renal cancer:3.73e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 19.2	Expressed in all		
AP4E1	AP-4-EPSILON, SPG51	ENSG00000081014	Adaptor related protein complex 4 epsilon 1 subunit	15	50908672-51005900	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041749, HPA041891	Approved					Expressed in all	Mixed			parathyroid gland: 12.0	Expressed in all		
AP4M1	MU-4, MU-ARP2, SPG50	ENSG00000221838	Adaptor related protein complex 4 mu 1 subunit	7	100101549-100110345	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA066774	Approved				Liver cancer:7.63e-5 (unfavourable), Renal cancer:8.29e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.8	Expressed in all		
AP4S1	AP47B, CLA20, SPG52	ENSG00000100478	Adaptor related protein complex 4 sigma 1 subunit	14	31025106-31096450	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039963	Approved		Supported	Vesicles	Renal cancer:2.87e-6 (favourable), Lung cancer:7.44e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.1	Expressed in all		
AP5B1	AP-5, DKFZp761E198, PP1030	ENSG00000254470	Adaptor related protein complex 5 beta 1 subunit	11	65775893-65780802	Predicted intracellular proteins	Evidence at protein level	HPA065739, HPA067880	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Renal cancer:2.31e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 25.1	Mixed		
AP5M1	C14orf108, FLJ10813, mu5, MuD, MUDENG	ENSG00000053770	Adaptor related protein complex 5 mu 1 subunit	14	57268909-57298742	Predicted intracellular proteins	Evidence at protein level	HPA055768, HPA057098	Approved				Renal cancer:1.11e-14 (favourable), Colorectal cancer:7.91e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 43.3	Expressed in all		
AP5Z1	KIAA0415, SPG48, zeta	ENSG00000242802	Adaptor related protein complex 5 zeta 1 subunit	7	4775622-4794312	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035693	Supported		Supported	Nucleoplasm<br>Nuclear speckles	Liver cancer:1.35e-5 (unfavourable)	Expressed in all	Mixed			spleen: 15.4	Expressed in all		
APAF1	APAF-1, CED4	ENSG00000120868	Apoptotic peptidase activating factor 1	12	98645141-98735433	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031373, CAB069399	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Colorectal cancer:5.90e-4 (favourable)	Expressed in all	Mixed			bone marrow: 21.7	Expressed in all		
APBA1	D9S411E, MINT1, X11	ENSG00000107282	Amyloid beta precursor protein binding family A member 1	9	69427530-69672306	Predicted intracellular proteins	Evidence at protein level	HPA061287			Supported	Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 18.4	parathyroid gland: 11.8	Cell line enhanced		HAP1: 18.1;SCLC-21H: 7.9;U-138 MG: 7.0
APBA2	D15S1518E, HsT16821, LIN-10, MGC:14091, MINT2, X11L	ENSG00000034053	Amyloid beta precursor protein binding family A member 2	15	28884483-29118315	Predicted intracellular proteins	Evidence at protein level	CAB037065	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 12.2	spleen: 3.3	Cell line enhanced		HEL: 7.6;SH-SY5Y: 21.2;U-937: 11.6
APBA3	mint3, X11L2	ENSG00000011132	Amyloid beta precursor protein binding family A member 3	19	3750819-3761699	Predicted intracellular proteins	Evidence at protein level	HPA045577	Approved		Approved	Vesicles	Pancreatic cancer:1.51e-4 (favourable), Urothelial cancer:1.83e-4 (favourable), Head and neck cancer:4.91e-4 (favourable), Endometrial cancer:5.97e-4 (favourable)	Expressed in all	Mixed			spleen: 6.6	Mixed		
APBB1IP	INAG1, RIAM	ENSG00000077420	Amyloid beta precursor protein binding family B member 1 interacting protein	10	26438203-26567803	Predicted intracellular proteins	Evidence at protein level	HPA017009, HPA063903	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Endometrial cancer:7.48e-4 (favourable)	Expressed in all	Mixed			appendix: 61.2	Cell line enhanced		REH: 169.0;U-698: 134.4
APBB2	FE65L, FE65L1, MGC35575	ENSG00000163697	Amyloid beta precursor protein binding family B member 2	4	40810027-41216714	Predicted intracellular proteins	Evidence at protein level	HPA023542	Approved		Approved	Mitochondria	Endometrial cancer:1.97e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 61.5	Cell line enhanced		TIME: 151.9
APBB3	FE65L2	ENSG00000113108	Amyloid beta precursor protein binding family B member 3	5	140558268-140564781	Predicted intracellular proteins	Evidence at protein level	HPA005571	Uncertain		Supported	Actin filaments<br>Cytosol	Renal cancer:2.06e-6 (unfavourable), Pancreatic cancer:6.79e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 11.5	testis: 6.6	Cell line enhanced		SCLC-21H: 7.1
APC	DP2, DP2.5, DP3, PPP1R46	ENSG00000134982	APC, WNT signaling pathway regulator	5	112707498-112846239	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013349	Supported					Expressed in all	Tissue enhanced		cerebral cortex: 60.1	parathyroid gland: 19.9	Expressed in all		
APC2	APCL	ENSG00000115266	APC2, WNT signaling pathway regulator	19	1446302-1473244	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA078002			Supported	Cytokinetic bridge<br>Midbody<br>Cytosol		Tissue enriched	Tissue enriched	21	cerebral cortex: 70.5	adrenal gland: 3.3	Group enriched	10	AF22: 7.7;SCLC-21H: 11.0;SH-SY5Y: 33.6
APEH	D3F15S2, D3S48E, DNF15S2	ENSG00000164062	Acylaminoacyl-peptide hydrolase	3	49674002-49683963	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029700, HPA029701, HPA029702, HPA029703	Enhanced		Enhanced	Cytosol	Renal cancer:3.32e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 101.6	Expressed in all		
APEX1	APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1	ENSG00000100823	Apurinic/apyrimidinic endodeoxyribonuclease 1	14	20455191-20457772	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000956, HPA002564, CAB004294, CAB047307	Enhanced		Enhanced	Nucleus	Liver cancer:7.82e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 176.5	Expressed in all		
APEX2	APE2, APEXL2, XTH2, ZGRF2	ENSG00000169188	Apurinic/apyrimidinic endodeoxyribonuclease 2	X	55000357-55009057	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048577			Supported	Nucleus<br>Nucleoli fibrillar center<br>Vesicles	Liver cancer:6.13e-7 (unfavourable), Ovarian cancer:5.21e-4 (favourable), Cervical cancer:6.17e-4 (favourable), Urothelial cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			skin: 14.3	Expressed in all		
API5	AAC-11, AAC11, API5L1	ENSG00000166181	Apoptosis inhibitor 5	11	43311963-43344529	Predicted intracellular proteins	Evidence at protein level	HPA026598	Approved		Enhanced	Nuclear speckles	Renal cancer:1.06e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 95.8	Expressed in all		
APIP	APIP2, CGI-29, Mmrp19	ENSG00000149089	APAF1 interacting protein	11	34853094-34916499	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021188, HPA024131	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.99e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 33.2	Expressed in all		
APITD1-CORT		ENSG00000251503	APITD1-CORT readthrough	1	10430102-10452153	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	8	testis: 38.7	bone marrow: 5.0	Mixed		
APOBEC1	APOBEC-1, BEDP, CDAR1, HEPR	ENSG00000111701	Apolipoprotein B mRNA editing enzyme catalytic subunit 1	12	7649400-7665903	Enzymes, Predicted intracellular proteins	Evidence at protein level							Group enriched	Group enriched	21	duodenum: 31.9;small intestine: 31.0	stomach: 1.5	Cell line enriched	17	CAPAN-2: 2.4
APOBEC2	ARCD1, ARP1	ENSG00000124701	Apolipoprotein B mRNA editing enzyme catalytic subunit 2	6	41053304-41064511	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA014252, HPA017957	Enhanced					Tissue enhanced	Group enriched	13	heart muscle: 120.7;skeletal muscle: 403.8	esophagus: 19.5	Cell line enhanced		CACO-2: 3.3
APOBEC3A	ARP3, PHRBN	ENSG00000128383	Apolipoprotein B mRNA editing enzyme catalytic subunit 3A	22	38952741-38992778	Predicted intracellular proteins	Evidence at protein level	HPA043237, HPA056980, HPA066719	Approved		Uncertain	Nucleoplasm		Tissue enhanced	Tissue enhanced		appendix: 29.8;bone marrow: 59.0	spleen: 19.5	Not detected		
APOBEC3B	FLJ21201, PHRBNL	ENSG00000179750	Apolipoprotein B mRNA editing enzyme catalytic subunit 3B	22	38982347-38992804	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA056980, HPA066719			Approved	Nucleoplasm	Cervical cancer:2.58e-5 (favourable), Renal cancer:2.78e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 18.9	rectum: 13.9	Cell line enhanced		A-431: 241.1;Karpas-707: 215.9
APOBEC3C	APOBEC1L, ARDC2, ARDC4, ARP5, bK150C2.3, PBI	ENSG00000244509	Apolipoprotein B mRNA editing enzyme catalytic subunit 3C	22	39014083-39020352	Predicted intracellular proteins	Evidence at protein level	CAB033048, HPA071523	Approved		Approved	Intermediate filaments	Renal cancer:8.91e-10 (unfavourable), Cervical cancer:1.08e-5 (favourable)	Expressed in all	Mixed			fallopian tube: 84.8	Mixed		
APOBEC3D	APOBEC3DE, APOBEC3E, ARP6	ENSG00000243811	Apolipoprotein B mRNA editing enzyme catalytic subunit 3D	22	39021113-39033276	Predicted intracellular proteins	Evidence at protein level	HPA055116	Uncertain				Renal cancer:3.76e-7 (unfavourable), Breast cancer:2.51e-5 (favourable), Cervical cancer:1.31e-4 (favourable), Urothelial cancer:3.01e-4 (favourable), Endometrial cancer:4.47e-4 (favourable)	Expressed in all	Mixed			lymph node: 15.1	Cell line enhanced		Karpas-707: 31.5
APOBEC3F	ARP8, BK150C2.4.MRNA, KA6	ENSG00000128394	Apolipoprotein B mRNA editing enzyme catalytic subunit 3F	22	39040604-39053910	Predicted intracellular proteins	Evidence at protein level	HPA073637			Uncertain	Nucleoplasm<br>Cytosol	Urothelial cancer:8.28e-4 (favourable)	Expressed in all	Mixed			lymph node: 18.5	Mixed		
APOBEC3G	bK150C2.7, CEM15, dJ494G10.1, FLJ12740, MDS019	ENSG00000239713	Apolipoprotein B mRNA editing enzyme catalytic subunit 3G	22	39077005-39087743	Predicted intracellular proteins	Evidence at protein level	HPA001812, HPA073637	Approved		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:8.66e-13 (unfavourable), Endometrial cancer:6.03e-5 (favourable), Cervical cancer:4.70e-4 (favourable), Breast cancer:4.78e-4 (favourable), Urothelial cancer:6.30e-4 (favourable)	Expressed in all	Mixed			lymph node: 46.0	Cell line enhanced		HDLM-2: 29.7;Karpas-707: 30.4
APOBEC3H	ARP10	ENSG00000100298	Apolipoprotein B mRNA editing enzyme catalytic subunit 3H	22	39097224-39104067	Predicted intracellular proteins	Evidence at protein level	HPA021492	Approved				Renal cancer:8.73e-12 (unfavourable), Urothelial cancer:8.43e-7 (favourable), Cervical cancer:1.20e-4 (favourable)	Mixed	Mixed			epididymis: 4.8	Cell line enhanced		HDLM-2: 2.7;Karpas-707: 5.3;U-266/70: 3.7
APOBEC4	C1orf169, FLJ25691, MGC26594, RP1-127C7.4	ENSG00000173627	Apolipoprotein B mRNA editing enzyme catalytic polypeptide like 4	1	183646404-183653316	Predicted intracellular proteins	Evidence at transcript level	HPA015636, HPA015637	Approved				Endometrial cancer:2.65e-4 (favourable)	Tissue enhanced	Group enriched	10	fallopian tube: 19.6;testis: 18.6	lung: 1.9	Not detected		
APOBR	APOB100R, APOB48R	ENSG00000184730	Apolipoprotein B receptor	16	28494649-28498970	Predicted intracellular proteins	Evidence at protein level	HPA041667, HPA042093	Enhanced				Endometrial cancer:3.26e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 30.4	appendix: 27.1	Cell line enhanced		HEL: 37.0;HMC-1: 109.0;NB-4: 22.6;U-937: 24.2
APOL5	APOLV	ENSG00000128313	Apolipoprotein L5	22	35717872-35729483	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level	HPA040968	Uncertain					Tissue enriched	Not detected			skeletal muscle,testis: 0.5	Cell line enriched	12	U-698: 1.2
APOPT1	APOP-1, C14orf153, MGC2562	ENSG00000256053	Apoptogenic 1, mitochondrial	14	103562962-103607523	Predicted intracellular proteins	Evidence at transcript level						Liver cancer:6.34e-5 (unfavourable), Ovarian cancer:4.78e-4 (favourable)	Expressed in all	Expressed in all			testis: 89.8	Expressed in all		
APPBP2	Hs.84084, KIAA0228, PAT1	ENSG00000062725	Amyloid beta precursor protein binding protein 2	17	60443149-60526219	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 44.6	Expressed in all		
APPL1	APPL	ENSG00000157500	Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1	3	57227737-57273468	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011138, HPA073477	Approved		Uncertain	Mitotic spindle<br>Centrosome	Renal cancer:7.26e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.1	Expressed in all		
APPL2	DIP13B, FLJ10659	ENSG00000136044	Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2	12	105173296-105236238	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039688, HPA043925	Approved				Renal cancer:7.65e-4 (favourable)	Expressed in all	Expressed in all			skin: 78.0	Expressed in all		
APRT		ENSG00000198931	Adenine phosphoribosyltransferase	16	88809339-88811944	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026681	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skin: 112.4	Expressed in all		
APTX	AOA, AOA1, AXA1, EAOH, EOAHA, FLJ20157	ENSG00000137074	Aprataxin	9	32972606-33025168	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064930	Supported		Enhanced	Nucleus<br>Nucleoli	Renal cancer:6.01e-5 (favourable)	Expressed in all	Expressed in all			testis: 24.5	Expressed in all		
AR	AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1	ENSG00000169083	Androgen receptor	X	67544032-67730619	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000001, HPA065701, CAB065764	Enhanced		Approved	Mitochondria	Renal cancer:1.03e-8 (favourable), Liver cancer:8.77e-4 (favourable)	Mixed	Mixed			fallopian tube: 42.3	Cell line enhanced		AF22: 15.6;HAP1: 21.1;LHCN-M2: 14.9;RH-30: 28.3
ARAF	ARAF1	ENSG00000078061	A-Raf proto-oncogene, serine/threonine kinase	X	47561100-47571920	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046188, HPA066326	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.45e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 86.3	Expressed in all		
ARAP1	CENTD2	ENSG00000186635	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1	11	72685069-72793599	Predicted intracellular proteins	Evidence at protein level	CAB020703, HPA070383	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.04e-5 (favourable), Thyroid cancer:6.41e-4 (favourable), Liver cancer:6.45e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 91.3	Expressed in all		
ARAP2	CENTD1, PARX	ENSG00000047365	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2	4	35948221-36244509	Predicted intracellular proteins	Evidence at protein level	HPA035925	Approved		Approved	Actin filaments<br>Focal adhesion sites		Expressed in all	Mixed			thyroid gland: 39.1	Mixed		
ARAP3	CENTD3, DRAG1, FLJ21065	ENSG00000120318	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3	5	141653401-141682221	Predicted intracellular proteins	Evidence at protein level	HPA042887	Uncertain				Renal cancer:1.59e-6 (unfavourable)	Expressed in all	Mixed			placenta: 17.2	Cell line enhanced		HUVEC TERT2: 62.0;TIME: 43.4
ARC	Arg3.1, KIAA0278	ENSG00000198576	Activity regulated cytoskeleton associated protein	8	142611044-142614472	Predicted intracellular proteins	Evidence at protein level	HPA056430, CAB079013		Supported	Approved	Vesicles<br>Microtubules		Tissue enriched	Group enriched	7	adipose tissue: 14.2;adrenal gland: 13.4;cerebral cortex: 14.4;gallbladder: 3.3;seminal vesicle: 5.5	placenta: 1.4	Cell line enhanced		HEK93: 9.2;SCLC-21H: 27.7;U-2 OS: 11.9;U-87 MG: 12.5
ARF1		ENSG00000143761	ADP ribosylation factor 1	1	228082660-228099212	Predicted intracellular proteins	Evidence at protein level	CAB007742	Uncertain		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:1.55e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 384.2	Expressed in all		
ARF3		ENSG00000134287	ADP ribosylation factor 3	12	48935723-48957551	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			cerebral cortex: 402.7	Expressed in all		
ARF4	ARF2	ENSG00000168374	ADP ribosylation factor 4	3	57571363-57598220	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:7.29e-7 (unfavourable), Thyroid cancer:9.30e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 325.8	Expressed in all		
ARF5		ENSG00000004059	ADP ribosylation factor 5	7	127588345-127591705	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			skin: 176.2	Expressed in all		
ARF6		ENSG00000165527	ADP ribosylation factor 6	14	49893092-49897054	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002778	Approved				Pancreatic cancer:3.10e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 96.6	Expressed in all		
ARFGAP1	ARF1GAP, bA261N11.3, FLJ10767	ENSG00000101199	ADP ribosylation factor GTPase activating protein 1	20	63272785-63289793	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051019, HPA056273	Approved		Supported	Nuclear membrane<br>Golgi apparatus<br>Vesicles	Renal cancer:3.48e-7 (unfavourable), Pancreatic cancer:4.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.2	Expressed in all		
ARFGAP2	FLJ14576, IRZ, Zfp289, ZNF289	ENSG00000149182	ADP ribosylation factor GTPase activating protein 2	11	47164299-47177125	Predicted intracellular proteins	Evidence at protein level	HPA016649, HPA018152	Enhanced		Supported	Golgi apparatus	Renal cancer:7.65e-7 (favourable)	Expressed in all	Expressed in all			skin: 90.1	Expressed in all		
ARFGAP3	ARFGAP1	ENSG00000242247	ADP ribosylation factor GTPase activating protein 3	22	42796502-42858106	Predicted intracellular proteins	Evidence at protein level	HPA000638	Approved		Supported	Golgi apparatus<br>Cytosol	Endometrial cancer:8.97e-6 (favourable), Thyroid cancer:2.65e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 112.5	Expressed in all		
ARFGEF1	ARFGEP1, BIG1, DKFZP434L057, p200	ENSG00000066777	ADP ribosylation factor guanine nucleotide exchange factor 1	8	67173511-67343677	Predicted intracellular proteins	Evidence at protein level	HPA023399, HPA023822	Supported	Approved	Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:2.48e-4 (favourable), Breast cancer:8.76e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.5	Expressed in all		
ARFGEF2	BIG2	ENSG00000124198	ADP ribosylation factor guanine nucleotide exchange factor 2	20	48921890-49036693	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026078, CAB026382	Supported		Supported	Golgi apparatus	Renal cancer:6.15e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 174.4	Expressed in all		
ARFGEF3	BIG3, C6orf92, dJ171N11.1, KIAA1244, PPP1R33	ENSG00000112379	ARFGEF family member 3	6	138161921-138344663	Predicted intracellular proteins	Evidence at protein level	HPA036350	Uncertain				Breast cancer:8.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 23.7;parathyroid gland: 29.7	prostate: 19.2	Cell line enhanced		RH-30: 13.0;RT4: 15.4;SK-BR-3: 16.6
ARFIP1	HSU52521	ENSG00000164144	ADP ribosylation factor interacting protein 1	4	152779937-152918463	Predicted intracellular proteins	Evidence at protein level	CAB005080, HPA037375, HPA063759	Enhanced		Supported	Nucleus<br>Golgi apparatus<br>Vesicles	Renal cancer:2.83e-10 (favourable), Colorectal cancer:5.75e-5 (favourable)	Expressed in all	Expressed in all			endometrium: 39.4	Expressed in all		
ARFRP1	ARL18, ARP, Arp1	ENSG00000101246	ADP ribosylation factor related protein 1	20	63698642-63708025	Predicted intracellular proteins	Evidence at protein level	HPA047028, HPA050634	Approved		Supported	Golgi apparatus		Expressed in all	Expressed in all			spleen: 27.9	Expressed in all		
ARG1		ENSG00000118520	Arginase 1	6	131573144-131584332	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003595, CAB009434, HPA024006, CAB056159	Enhanced					Tissue enriched	Tissue enhanced		bone marrow: 171.2;liver: 566.2	skin: 78.2	Not detected		
ARG2		ENSG00000081181	Arginase 2	14	67619798-67651720	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000663, CAB009435	Enhanced		Supported	Mitochondria		Expressed in all	Tissue enhanced		parathyroid gland: 94.0;prostate: 161.0;thyroid gland: 157.2	kidney: 63.4	Cell line enhanced		HAP1: 54.8
ARGFX		ENSG00000186103	Arginine-fifty homeobox	3	121570704-121586634	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043049	Uncertain					Tissue enriched	Not detected			testis: 0.6	Not detected		
ARGLU1	FLJ10154	ENSG00000134884	Arginine and glutamate rich 1	13	106541673-106568164	Predicted intracellular proteins	Evidence at protein level	HPA034962, HPA056792	Supported		Enhanced	Nucleoplasm<br>Mitochondria	Pancreatic cancer:3.92e-5 (favourable), Urothelial cancer:7.34e-5 (favourable), Renal cancer:1.09e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 328.3	Expressed in all		
ARHGAP10	FLJ20896, FLJ41791, GRAF2	ENSG00000071205	Rho GTPase activating protein 10	4	147732063-148072780	Predicted intracellular proteins	Evidence at protein level	HPA039589			Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Renal cancer:8.15e-5 (favourable), Lung cancer:2.23e-4 (unfavourable), Stomach cancer:6.26e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 44.1	Mixed		
ARHGAP11A	KIAA0013	ENSG00000198826	Rho GTPase activating protein 11A	15	32615144-32639949	Predicted intracellular proteins	Evidence at protein level	HPA040419, HPA040830	Enhanced		Approved	Nucleoli<br>Cytosol	Pancreatic cancer:2.92e-5 (unfavourable), Liver cancer:2.05e-4 (unfavourable), Lung cancer:8.69e-4 (unfavourable)	Expressed in all	Mixed			lymph node,testis: 15.7	Expressed in all		
ARHGAP11B	B'-T, FAM7B1	ENSG00000187951	Rho GTPase activating protein 11B	15	30624494-30772993	Predicted intracellular proteins	Evidence at protein level	HPA064479	Uncertain		Approved	Vesicles		Mixed	Tissue enhanced		bone marrow: 2.0	lymph node,testis: 1.1	Mixed		
ARHGAP12	FLJ10971, FLJ20737, FLJ21785	ENSG00000165322	Rho GTPase activating protein 12	10	31805404-31928876	Predicted intracellular proteins	Evidence at protein level	HPA000412	Enhanced				Renal cancer:4.64e-5 (favourable), Glioma:1.88e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 45.2	Mixed		
ARHGAP15	BM046	ENSG00000075884	Rho GTPase activating protein 15	2	143091362-143768352	Predicted intracellular proteins	Evidence at protein level	HPA032125	Uncertain		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:6.95e-5 (unfavourable)	Mixed	Tissue enhanced		lymph node: 65.4	spleen: 59.6	Cell line enhanced		HEL: 77.1;HL-60: 97.4;MOLT-4: 65.5;NB-4: 59.8;THP-1: 85.7;U-698: 65.7
ARHGAP17	FLJ10308, FLJ13219, NADRIN, RICH1, WBP15	ENSG00000140750	Rho GTPase activating protein 17	16	24919385-25015666	Predicted intracellular proteins	Evidence at protein level	HPA041703	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:3.59e-4 (favourable), Urothelial cancer:3.76e-4 (unfavourable), Liver cancer:4.95e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 70.5	Mixed		
ARHGAP18	bA307O14.2, MacGAP	ENSG00000146376	Rho GTPase activating protein 18	6	129576132-129710225	Predicted intracellular proteins	Evidence at protein level	HPA031595	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.54e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 48.0	Cell line enhanced		HMC-1: 344.1
ARHGAP19	FLJ00194, MGC14258	ENSG00000213390	Rho GTPase activating protein 19	10	97222173-97292673	Predicted intracellular proteins	Evidence at protein level	HPA035777, HPA043231	Uncertain		Supported	Plasma membrane	Renal cancer:7.47e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 34.2	lymph node: 15.8	Expressed in all		
ARHGAP20	KIAA1391	ENSG00000137727	Rho GTPase activating protein 20	11	110577042-110713189	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038458, HPA038459, HPA076303	Uncertain		Approved	Mitochondria		Mixed	Mixed			testis: 15.4	Cell line enhanced		ASC diff: 16.9;ASC TERT1: 5.7;SiHa: 7.6
ARHGAP21	ARHGAP10, KIAA1424	ENSG00000107863	Rho GTPase activating protein 21	10	24583609-24723668	Predicted intracellular proteins	Evidence at protein level	HPA036610, HPA057861	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Actin filaments		Expressed in all	Expressed in all			cerebral cortex: 88.5	Mixed		
ARHGAP22	RhoGAP2	ENSG00000128805	Rho GTPase activating protein 22	10	48446034-48656265	Predicted intracellular proteins	Evidence at protein level	CAB020696, HPA040391, HPA064439	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.16e-8 (unfavourable)	Mixed	Mixed			cerebral cortex: 8.0	Cell line enhanced		LHCN-M2: 53.6;TIME: 56.1;U-87 MG: 81.1
ARHGAP23	KIAA1501	ENSG00000275832	Rho GTPase activating protein 23	17	38419280-38512392	Predicted intracellular proteins	Evidence at protein level	HPA019818, HPA047291	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:5.38e-5 (unfavourable), Endometrial cancer:6.87e-5 (unfavourable), Pancreatic cancer:3.24e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 41.9	Cell line enhanced		HaCaT: 260.4
ARHGAP24	DKFZP564B1162, FilGAP, FLJ33877	ENSG00000138639	Rho GTPase activating protein 24	4	85475114-86002670	Predicted intracellular proteins	Evidence at protein level	HPA014288	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.67e-11 (favourable)	Expressed in all	Expressed in all			kidney: 106.3	Cell line enhanced		ASC diff: 75.0;HUVEC TERT2: 101.5;TIME: 70.7
ARHGAP25	KIAA0053	ENSG00000163219	Rho GTPase activating protein 25	2	68679601-68826833	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035346, HPA061395	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.93e-4 (unfavourable), Cervical cancer:7.72e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 89.6	lymph node: 81.2	Cell line enhanced		HEL: 59.7;HMC-1: 225.1
ARHGAP27	CAMGAP1, FLJ43547, SH3D20, SH3P20	ENSG00000159314	Rho GTPase activating protein 27	17	45393902-45434421	Predicted intracellular proteins	Evidence at protein level	HPA023919, HPA053053	Approved		Supported	Nucleus<br>Cytosol	Urothelial cancer:3.21e-4 (favourable)	Expressed in all	Mixed			esophagus: 14.0	Cell line enhanced		BEWO: 16.1;RT4: 20.7
ARHGAP28	FLJ10312, KIAA1314	ENSG00000088756	Rho GTPase activating protein 28	18	6729718-6915716	Predicted intracellular proteins	Evidence at protein level	HPA030413, HPA030414, HPA030415	Enhanced		Supported	Cell Junctions		Mixed	Tissue enhanced		testis: 133.0	placenta: 40.9	Cell line enhanced		AF22: 35.5;CACO-2: 31.8
ARHGAP29	PARG1	ENSG00000137962	Rho GTPase activating protein 29	1	94148988-94275068	Predicted intracellular proteins	Evidence at protein level	HPA026534	Approved		Approved	Nucleus<br>Plasma membrane<br>Centrosome<br>Cytosol	Endometrial cancer:6.26e-5 (unfavourable), Pancreatic cancer:9.63e-4 (unfavourable)	Expressed in all	Mixed			spleen: 49.9	Cell line enhanced		A-431: 194.8
ARHGAP30	FLJ00267	ENSG00000186517	Rho GTPase activating protein 30	1	161046946-161069970	Predicted intracellular proteins	Evidence at protein level	HPA036300	Uncertain		Supported	Vesicles	Renal cancer:9.78e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 86.1;spleen: 80.6	appendix: 73.2	Cell line enhanced		Daudi: 82.8;HL-60: 72.0;HMC-1: 106.5;U-266/70: 103.3
ARHGAP31	CDGAP	ENSG00000031081	Rho GTPase activating protein 31	3	119294373-119420714	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036380	Approved				Renal cancer:8.45e-4 (favourable)	Expressed in all	Mixed			lung: 29.1	Cell line enhanced		HUVEC TERT2: 29.2;TIME: 31.7
ARHGAP32	GC-GAP, GRIT, KIAA0712, MGC1892, RICS	ENSG00000134909	Rho GTPase activating protein 32	11	128965060-129279324	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA038382, HPA038389, HPA061505	Approved		Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus	Pancreatic cancer:6.64e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 44.0	Mixed		
ARHGAP33	FLJ39019, SNX26, TCGAP	ENSG00000004777	Rho GTPase activating protein 33	19	35774532-35788822	Predicted intracellular proteins	Evidence at protein level	HPA030117, HPA030118	Supported		Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:3.09e-8 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 25.8	Cell line enhanced		HMC-1: 50.9
ARHGAP35	GRF-1, GRLF1, KIAA1722, P190A, p190ARhoGAP, p190RhoGAP	ENSG00000160007	Rho GTPase activating protein 35	19	46918676-47005077	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB037311, HPA055184, HPA056470	Approved		Supported	Nuclear bodies<br>Aggresome	Renal cancer:5.55e-8 (favourable)	Expressed in all	Expressed in all			testis: 76.2	Expressed in all		
ARHGAP39	CrGAP, KIAA1688, Vilse	ENSG00000147799	Rho GTPase activating protein 39	8	144529179-144605816	Predicted intracellular proteins	Evidence at protein level	HPA044491			Approved	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge<br>Cytosol		Expressed in all	Tissue enhanced		testis: 16.4	cerebral cortex,fallopian tube: 7.3	Mixed		
ARHGAP4	C1, KIAA0131, p115, RhoGAP4, SrGAP4	ENSG00000089820	Rho GTPase activating protein 4	X	153907367-153934999	Predicted intracellular proteins	Evidence at protein level	HPA001012, HPA001083	Enhanced		Approved	Nucleoplasm<br>Focal adhesion sites	Colorectal cancer:1.97e-5 (unfavourable), Cervical cancer:3.94e-5 (favourable), Renal cancer:2.49e-4 (unfavourable), Head and neck cancer:3.31e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 95.1	lymph node: 87.2	Cell line enhanced		MOLT-4: 72.4;RPMI-8226: 121.4
ARHGAP40	C20orf95, dJ1100H13.4	ENSG00000124143	Rho GTPase activating protein 40	20	38601934-38651035	Predicted intracellular proteins	Evidence at protein level	HPA042636, HPA042840	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:2.89e-4 (unfavourable)	Mixed	Group enriched	7	breast: 38.1;epididymis: 43.7;esophagus: 12.6;seminal vesicle: 11.3;skin: 53.8	prostate: 4.4	Cell line enhanced		BEWO: 8.0;HBEC3-KT: 9.7;RPTEC TERT1: 8.8;SK-BR-3: 9.5;T-47d: 14.4
ARHGAP42	FLJ32810, GRAF3	ENSG00000165895	Rho GTPase activating protein 42	11	100687653-100991937	Predicted intracellular proteins	Evidence at protein level	HPA039924	Enhanced		Approved	Nuclear speckles<br>Cytosol	Pancreatic cancer:9.29e-4 (unfavourable)	Expressed in all	Mixed			placenta: 23.7	Cell line enhanced		CAPAN-2: 27.8
ARHGAP44	KIAA0672, RICH-2, RICH2	ENSG00000006740	Rho GTPase activating protein 44	17	12789539-12991643	Predicted intracellular proteins	Evidence at protein level	HPA038814	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 51.6	cerebral cortex: 33.4	Cell line enhanced		HEK93: 9.0
ARHGAP5	GFI2, p190-B, p190BRhoGAP, RhoGAP5	ENSG00000100852	Rho GTPase activating protein 5	14	32076114-32159728	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046993, HPA056507	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:3.97e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 114.7	Mixed		
ARHGAP8	BPGAP1, FLJ20185	ENSG00000241484	Rho GTPase activating protein 8	22	44752558-44862788	Predicted intracellular proteins	Evidence at protein level	HPA069694	Approved		Approved	Nucleus		Mixed	Mixed			epididymis: 14.2	Cell line enhanced		BEWO: 45.6;CACO-2: 25.6;HEK93: 38.0;MCF7: 33.7;SK-BR-3: 30.9
ARHGAP9	10C, MGC1295	ENSG00000123329	Rho GTPase activating protein 9	12	57472255-57488814	Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.90e-9 (unfavourable), Endometrial cancer:6.61e-5 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 78.0	lymph node: 68.3	Cell line enhanced		HEL: 24.8;HMC-1: 103.7;THP-1: 23.7
ARHGDIA	GDIA1, RHOGDI	ENSG00000141522	Rho GDP dissociation inhibitor alpha	17	81867721-81871406	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010005, HPA021407	Approved		Enhanced	Cytosol	Lung cancer:7.63e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 206.6	Expressed in all		
ARHGDIB	GDIA2, GDID4, Ly-GDI, RAP1GN1, RhoGDI2	ENSG00000111348	Rho GDP dissociation inhibitor beta	12	14942017-14961728	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018584, HPA051235	Approved		Supported	Cytosol	Renal cancer:1.08e-4 (unfavourable), Urothelial cancer:3.42e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 955.5	Cell line enhanced		HEL: 1354.5;HL-60: 1418.5;HMC-1: 1684.2;MOLT-4: 1705.9;REH: 1609.3
ARHGDIG	RHOGDI-3	ENSG00000242173	Rho GDP dissociation inhibitor gamma	16	268727-283010	Predicted intracellular proteins	Evidence at protein level	HPA078260			Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 131.1;duodenum: 44.2	small intestine: 17.9	Cell line enhanced		HEK93: 24.6;MCF7: 27.2;SCLC-21H: 14.0;SH-SY5Y: 15.7
ARHGEF1	LBCL2, P115-RHOGEF, SUB1.5	ENSG00000076928	Rho guanine nucleotide exchange factor 1	19	41883161-41930150	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009502, HPA012924, HPA060784	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:3.36e-8 (unfavourable), Breast cancer:5.92e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 144.9	Expressed in all		
ARHGEF10	Gef10, KIAA0294	ENSG00000104728	Rho guanine nucleotide exchange factor 10	8	1823976-1958641	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024649	Approved		Approved	Nucleoplasm		Mixed	Mixed			testis: 15.9	Mixed		
ARHGEF10L	FLJ10521, KIAA1626	ENSG00000074964	Rho guanine nucleotide exchange factor 10 like	1	17539835-17697874	Predicted intracellular proteins	Evidence at protein level	HPA026426, HPA026440, HPA028115	Approved		Approved	Golgi apparatus<br>Vesicles<br>Cytosol	Head and neck cancer:8.13e-5 (favourable), Renal cancer:5.65e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 29.7	Mixed		
ARHGEF11	GTRAP48, KIAA0380, PDZ-RHOGEF	ENSG00000132694	Rho guanine nucleotide exchange factor 11	1	156934840-157045370	Predicted intracellular proteins	Evidence at protein level	HPA011026, HPA012037, HPA014658	Enhanced		Approved	Golgi apparatus<br>Plasma membrane	Pancreatic cancer:1.72e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.3	Mixed		
ARHGEF12	KIAA0382, LARG	ENSG00000196914	Rho guanine nucleotide exchange factor 12	11	120336914-120489936	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018911, CAB025581	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:5.43e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 145.8	Mixed		
ARHGEF15	ARGEF15, FLJ13791, KIAA0915, MGC44868, Vsm-RhoGEF	ENSG00000198844	Rho guanine nucleotide exchange factor 15	17	8310241-8322516	Predicted intracellular proteins	Evidence at protein level	HPA044443, HPA063495			Supported	Plasma membrane		Expressed in all	Tissue enhanced		adipose tissue: 37.2	lung: 30.7	Group enriched	41	HUVEC TERT2: 32.7;TIME: 42.4
ARHGEF16	GEF16, NBR	ENSG00000130762	Rho guanine nucleotide exchange factor 16	1	3454426-3481113	Predicted intracellular proteins	Evidence at protein level	HPA010609	Approved				Renal cancer:1.24e-10 (favourable), Liver cancer:1.82e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 42.1	small intestine: 35.9	Cell line enhanced		CAPAN-2: 48.8;MCF7: 24.6;SK-BR-3: 25.6
ARHGEF17	KIAA0337, p164-RhoGEF, TEM4	ENSG00000110237	Rho guanine nucleotide exchange factor 17	11	73308289-73369091	Predicted intracellular proteins	Evidence at protein level	HPA007991	Uncertain		Approved	Cytosol	Colorectal cancer:8.27e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 37.6	Mixed		
ARHGEF18	KIAA0521, MGC15913, P114-RhoGEF	ENSG00000104880	Rho/Rac guanine nucleotide exchange factor 18	19	7395113-7472477	Predicted intracellular proteins	Evidence at protein level	HPA042689, HPA071867	Approved		Enhanced	Cytosol	Renal cancer:3.11e-5 (favourable), Head and neck cancer:4.21e-4 (favourable)	Expressed in all	Expressed in all			spleen: 30.5	Expressed in all		
ARHGEF19	FLJ33962, WGEF	ENSG00000142632	Rho guanine nucleotide exchange factor 19	1	16197854-16212609	Predicted intracellular proteins	Evidence at protein level	HPA068108			Approved	Nuclear bodies	Renal cancer:8.88e-5 (unfavourable), Lung cancer:6.53e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 20.9	thyroid gland: 11.5	Cell line enhanced		T-47d: 23.8
ARHGEF2	GEF-H1, KIAA0651, LFP40, P40	ENSG00000116584	Rho/Rac guanine nucleotide exchange factor 2	1	155946851-156007070	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043437	Approved				Renal cancer:7.17e-6 (unfavourable), Liver cancer:9.20e-6 (unfavourable)	Expressed in all	Expressed in all			lung: 95.0	Expressed in all		
ARHGEF25	GEFT, p63RhoGEF	ENSG00000240771	Rho guanine nucleotide exchange factor 25	12	57610180-57619379	Predicted intracellular proteins	Evidence at protein level	HPA052016	Uncertain		Approved	Vesicles	Renal cancer:4.20e-7 (unfavourable)	Expressed in all	Mixed			endometrium: 112.2	Cell line enhanced		RH-30: 125.8;SH-SY5Y: 62.5
ARHGEF26	DKFZP434D146, SGEF	ENSG00000114790	Rho guanine nucleotide exchange factor 26	3	154121003-154257827	Predicted intracellular proteins	Evidence at protein level	HPA017722, HPA049195	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:9.74e-4 (favourable)	Expressed in all	Mixed			cerebral cortex,lung: 15.0	Cell line enhanced		U-251 MG: 16.6
ARHGEF28	p190RhoGEF, RGNEF, RIP2	ENSG00000214944	Rho guanine nucleotide exchange factor 28	5	73626158-73941993	Predicted intracellular proteins	Evidence at protein level	HPA037602	Enhanced		Approved	Plasma membrane<br>Microtubules<br>Cytosol	Renal cancer:1.91e-6 (favourable), Cervical cancer:5.31e-4 (favourable), Urothelial cancer:8.98e-4 (favourable)	Mixed	Mixed			kidney: 33.7	Cell line enhanced		hTERT-HME1: 75.2;LHCN-M2: 76.8;TIME: 48.7
ARHGEF3	DKFZP434F2429, GEF3, STA3, XPLN	ENSG00000163947	Rho guanine nucleotide exchange factor 3	3	56727418-57079329	Predicted intracellular proteins	Evidence at protein level	HPA034715, HPA064945	Uncertain		Approved	Cytosol	Renal cancer:1.96e-7 (favourable), Endometrial cancer:2.17e-4 (favourable), Head and neck cancer:2.61e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 64.9	Cell line enhanced		Hep G2: 60.0;RPMI-8226: 63.7
ARHGEF33		ENSG00000214694	Rho guanine nucleotide exchange factor 33	2	38889880-38975449	Predicted intracellular proteins	Evidence at protein level	HPA034661, HPA041051	Enhanced		Supported	Vesicles		Mixed	Tissue enhanced		testis: 10.6	ovary: 4.3	Cell line enhanced		BEWO: 5.4;SiHa: 7.6
ARHGEF35	ARHGEF5L, CTAGE4, FLJ43692	ENSG00000213214	Rho guanine nucleotide exchange factor 35	7	144186083-144195655	Predicted intracellular proteins	Evidence at protein level	HPA044188, HPA045619, HPA045699	Supported				Renal cancer:4.57e-4 (favourable), Liver cancer:5.77e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 44.5	Cell line enhanced		A-431: 47.0;hTCEpi: 30.0;RPTEC TERT1: 41.9;WM-115: 28.8
ARHGEF37	FLJ41603	ENSG00000183111	Rho guanine nucleotide exchange factor 37	5	149551947-149634968	Predicted intracellular proteins	Evidence at protein level	HPA043885, HPA053487	Uncertain		Approved	Cytosol	Renal cancer:6.85e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 68.3	Cell line enhanced		EFO-21: 13.0;HaCaT: 22.9;hTCEpi: 24.4
ARHGEF38	FLJ20184	ENSG00000236699	Rho guanine nucleotide exchange factor 38	4	105552620-105708093	Predicted intracellular proteins	Evidence at protein level	HPA036510, HPA045484	Uncertain		Approved	Nucleoplasm<br>Centrosome		Tissue enhanced	Tissue enhanced		breast: 10.0;prostate: 9.3	epididymis: 6.8	Group enriched	8	RPTEC TERT1: 11.0;SK-BR-3: 6.0;T-47d: 7.9
ARHGEF39	C9orf100, FLJ14642	ENSG00000137135	Rho guanine nucleotide exchange factor 39	9	35658875-35675866	Predicted intracellular proteins	Evidence at protein level	HPA061299	Uncertain				Ovarian cancer:4.48e-4 (favourable)	Mixed	Mixed			lymph node: 2.3	Mixed		
ARHGEF4	ASEF, KIAA1112, STM6	ENSG00000136002	Rho guanine nucleotide exchange factor 4	2	130836916-131047263	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018267	Approved				Testis cancer:7.00e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 61.6;skin: 44.1	esophagus: 14.5	Cell line enhanced		HaCaT: 31.5;hTCEpi: 52.8;SCLC-21H: 52.6
ARHGEF40	FLJ10357, solo	ENSG00000165801	Rho guanine nucleotide exchange factor 40	14	21070270-21090240	Predicted intracellular proteins	Evidence at protein level	HPA030746, HPA030757	Uncertain					Expressed in all	Expressed in all			adrenal gland: 32.5	Mixed		
ARHGEF5	GEF5, P60, TIM, TIM1	ENSG00000050327	Rho guanine nucleotide exchange factor 5	7	144355288-144380632	Predicted intracellular proteins	Evidence at protein level	HPA020980, HPA029504, HPA044188, HPA045619, HPA045699	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:3.28e-7 (favourable)	Mixed	Mixed			thyroid gland: 42.8	Cell line enhanced		A-431: 46.6
ARHGEF6	alpha-PIX, alphaPIX, Cool-2, Cool2, KIAA0006, MRX46	ENSG00000129675	Rac/Cdc42 guanine nucleotide exchange factor 6	X	136665547-136782088	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003578	Approved		Approved	Cytosol		Expressed in all	Mixed			placenta: 63.3	Cell line enhanced		HL-60: 113.2;HMC-1: 452.5;U-937: 117.5
ARHGEF7	BETA-PIX, COOL1, DKFZp686C12170, DKFZp761K1021, KIAA0142, Nbla10314, P50, P50BP, P85, P85COOL1, P85SPR, PAK3, PIXB	ENSG00000102606	Rho guanine nucleotide exchange factor 7	13	111114559-111305737	Predicted intracellular proteins	Evidence at protein level	HPA004744	Approved				Glioma:7.29e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 96.8	Expressed in all		
ARHGEF9	KIAA0424, PEM-2	ENSG00000131089	Cdc42 guanine nucleotide exchange factor 9	X	63634967-63809274	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035419, HPA055291	Approved		Supported	Cytosol	Renal cancer:1.02e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 80.1	Mixed		
ARID1A	B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1	ENSG00000117713	AT-rich interaction domain 1A	1	26693236-26782104	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005456, CAB016334	Supported		Enhanced	Nucleoplasm	Liver cancer:4.18e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 40.4	Expressed in all		
ARID1B	6A3-5, BAF250b, DAN15, ELD/OSA1, KIAA1235, p250R	ENSG00000049618	AT-rich interaction domain 1B	6	156777374-157210779	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016511, HPA075291	Approved		Supported	Nucleoplasm	Breast cancer:1.04e-4 (unfavourable), Ovarian cancer:4.16e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 71.2	Expressed in all		
ARID2	BAF200, DKFZp686G052, FLJ30619, KIAA1557	ENSG00000189079	AT-rich interaction domain 2	12	45729665-45908040	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063044			Supported	Nucleoplasm<br>Plasma membrane	Head and neck cancer:5.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 47.3	Expressed in all		
ARID3A	BRIGHT, DRIL1	ENSG00000116017	AT-rich interaction domain 3A	19	925781-975934	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004793, HPA076330	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Pancreatic cancer:1.95e-5 (favourable), Renal cancer:3.22e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 33.4	testis: 9.7	Cell line enhanced		BEWO: 199.1;K-562: 85.1
ARID3B	BDP, DRIL2	ENSG00000179361	AT-rich interaction domain 3B	15	74541177-74598131	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050320	Enhanced		Supported	Nucleoplasm		Expressed in all	Tissue enhanced		testis: 35.9	placenta: 22.3	Cell line enhanced		NTERA-2: 86.8
ARID3C		ENSG00000205143	AT-rich interaction domain 3C	9	34621379-34628107	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Group enriched	Tissue enriched	8	liver: 5.9	cerebral cortex: 0.7	Cell line enhanced		HDLM-2: 1.8;Karpas-707: 1.8;T-47d: 2.4
ARID4A	RBBP1, RBP-1, RBP1	ENSG00000032219	AT-rich interaction domain 4A	14	58298385-58373887	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048899			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Head and neck cancer:1.91e-4 (favourable), Lung cancer:7.82e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 24.0	Expressed in all		
ARID4B	BCAA, BRCAA1, RBP1L1, SAP180	ENSG00000054267	AT-rich interaction domain 4B	1	235131634-235328219	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027333, HPA053692	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:2.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.0	Expressed in all		
ARID5A	MRF-1, RP11-363D14	ENSG00000196843	AT-rich interaction domain 5A	2	96536743-96552638	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002860, HPA023879	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:4.24e-8 (unfavourable), Breast cancer:2.05e-6 (favourable)	Expressed in all	Expressed in all			appendix: 25.4	Group enriched	6	HDLM-2: 239.9;RPMI-8226: 78.9
ARID5B	FLJ21150, MRF2	ENSG00000150347	AT-rich interaction domain 5B	10	61901300-62096944	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015037	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 62.1	Cell line enhanced		BJ hTERT+: 91.0
ARIH1	ARI, HARI, HHARI, UBCH7BP	ENSG00000166233	Ariadne RBR E3 ubiquitin protein ligase 1	15	72474326-72602985	Predicted intracellular proteins	Evidence at protein level	HPA003295, HPA073245	Approved		Approved	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 65.4	Expressed in all		
ARIH2	TRIAD1	ENSG00000177479	Ariadne RBR E3 ubiquitin protein ligase 2	3	48918821-48986382	Predicted intracellular proteins	Evidence at protein level	HPA067381, HPA069715, HPA070963			Enhanced	Nucleoplasm	Liver cancer:1.70e-4 (unfavourable), Renal cancer:6.60e-4 (favourable), Pancreatic cancer:7.31e-4 (favourable)	Expressed in all	Expressed in all			testis: 49.6	Expressed in all		
ARL1	ARFL1	ENSG00000120805	ADP ribosylation factor like GTPase 1	12	101393120-101407820	Predicted intracellular proteins	Evidence at protein level	HPA062656, HPA073012	Approved		Supported	Golgi apparatus	Endometrial cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 142.0	Expressed in all		
ARL11	ARLTS1, FLJ33930	ENSG00000152213	ADP ribosylation factor like GTPase 11	13	49628299-49633872	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040855, HPA040887	Uncertain					Mixed	Tissue enhanced		lymph node: 7.6	spleen: 6.3	Cell line enhanced		Daudi: 5.3;HMC-1: 8.9;NB-4: 6.7;THP-1: 9.3
ARL13A	ARL13	ENSG00000174225	ADP ribosylation factor like GTPase 13A	X	100969708-100990829	Predicted intracellular proteins	Evidence at transcript level	HPA037377, HPA037378	Uncertain					Not detected	Tissue enriched	11	testis: 7.6	skin: 0.7	Cell line enhanced		CACO-2: 1.8
ARL13B	ARL2L1, DKFZp761H079, JBTS8	ENSG00000169379	ADP ribosylation factor like GTPase 13B	3	93980139-94055668	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048926	Enhanced		Uncertain	Microtubules<br>Cytosol		Expressed in all	Mixed			thyroid gland: 9.3	Mixed		
ARL14	ARF7, FLJ22595	ENSG00000179674	ADP ribosylation factor like GTPase 14	3	160677159-160678452	Predicted intracellular proteins	Evidence at protein level						Lung cancer:2.64e-5 (unfavourable), Pancreatic cancer:6.71e-4 (unfavourable)	Group enriched	Tissue enhanced		gallbladder: 209.1;stomach: 70.2	duodenum: 50.9	Group enriched	5	A-431: 8.4;CAPAN-2: 31.7;HaCaT: 7.9;RT4: 14.0
ARL14EP	ARF7EP, C11orf46, FLJ38968	ENSG00000152219	ADP ribosylation factor like GTPase 14 effector protein	11	30323051-30338227	Predicted intracellular proteins	Evidence at protein level	HPA039634, HPA048127	Approved		Approved	Nucleus<br>Vesicles<br>Focal adhesion sites<br>Cytosol	Breast cancer:2.50e-5 (favourable), Liver cancer:5.26e-4 (unfavourable), Urothelial cancer:7.49e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 53.5	Expressed in all		
ARL14EPL		ENSG00000268223	ADP ribosylation factor like GTPase 14 effector protein like	5	116032324-116060118	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Cell line enriched	12	HDLM-2: 48.6
ARL14EPL		ENSG00000268714	ADP ribosylation factor like GTPase 14 effector protein like	5	116022391-116059130	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.6	Cell line enriched	54	HDLM-2: 119.0
ARL15	ARFRP2, FLJ20051	ENSG00000185305	ADP ribosylation factor like GTPase 15	5	53883945-54310582	Predicted intracellular proteins	Evidence at protein level	HPA044604, HPA063820	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			placenta: 44.8	Mixed		
ARL17A	ARF1P2, ARL17P1	ENSG00000185829	ADP ribosylation factor like GTPase 17A	17	46516702-46579682	Predicted intracellular proteins	Evidence at protein level	HPA046814	Uncertain					Not detected	Expressed in all			endometrium: 14.1	Mixed		
ARL17B	ARL17	ENSG00000228696	ADP ribosylation factor like GTPase 17B	17	46274784-46361797	Predicted intracellular proteins	Evidence at protein level	HPA046814	Uncertain					Not detected	Mixed			ovary: 7.6	Mixed		
ARL2	ARFL2	ENSG00000213465	ADP ribosylation factor like GTPase 2	11	65014113-65022184	Predicted intracellular proteins	Evidence at protein level	HPA044610	Supported		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Focal adhesion sites<br>Cytosol	Endometrial cancer:4.58e-4 (unfavourable), Prostate cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 114.0	Expressed in all		
ARL2BP	BART, BART1, RP66	ENSG00000102931	ADP ribosylation factor like GTPase 2 binding protein	16	57245098-57253635	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043066, HPA048440	Approved				Lung cancer:9.06e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 96.1	Expressed in all		
ARL3	ARFL3	ENSG00000138175	ADP ribosylation factor like GTPase 3	10	102673731-102714407	Predicted intracellular proteins	Evidence at protein level	HPA036292, HPA063596	Approved		Supported	Nucleus<br>Centrosome	Renal cancer:1.71e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 35.8	Expressed in all		
ARL4A	ARL4	ENSG00000122644	ADP ribosylation factor like GTPase 4A	7	12686856-12690934	Predicted intracellular proteins	Evidence at protein level	HPA064513			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		testis: 313.8	skin: 79.3	Cell line enhanced		AN3-CA: 241.9;K-562: 291.3
ARL4C	ARL7, LAK	ENSG00000188042	ADP ribosylation factor like GTPase 4C	2	234493041-234497053	Predicted intracellular proteins	Evidence at protein level	HPA028927	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:3.69e-8 (unfavourable), Endometrial cancer:2.90e-7 (unfavourable), Urothelial cancer:6.99e-5 (unfavourable)	Expressed in all	Mixed			spleen: 72.0	Cell line enhanced		RPTEC TERT1: 234.1;U-2197: 158.1
ARL4D	ARF4L	ENSG00000175906	ADP ribosylation factor like GTPase 4D	17	43398959-43401137	Predicted intracellular proteins	Evidence at protein level	HPA060379	Uncertain		Approved	Golgi apparatus<br>Vesicles	Endometrial cancer:1.16e-5 (favourable), Head and neck cancer:6.66e-4 (unfavourable), Urothelial cancer:9.25e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 62.5	Mixed		
ARL5A	ARL5	ENSG00000162980	ADP ribosylation factor like GTPase 5A	2	151788984-151828492	Predicted intracellular proteins	Evidence at protein level	HPA027002	Approved					Expressed in all	Expressed in all			thyroid gland: 48.9	Expressed in all		
ARL5B	ARL8	ENSG00000165997	ADP ribosylation factor like GTPase 5B	10	18659405-18681639	Predicted intracellular proteins	Evidence at protein level	HPA027002	Approved				Liver cancer:1.15e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 27.9	Expressed in all		
ARL5C	ARL12	ENSG00000141748	ADP ribosylation factor like GTPase 5C	17	39156894-39167484	Predicted intracellular proteins	No evidence	HPA069849	Uncertain					Not detected	Not detected			lymph node: 0.4	Not detected		
ARL6	BBS3, RP55	ENSG00000113966	ADP ribosylation factor like GTPase 6	3	97764521-97801242	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019361	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:2.53e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 19.5	Cell line enhanced		SCLC-21H: 28.0
ARL6IP4	SFRS20, SR-25, SRp25, SRrp37	ENSG00000182196	ADP ribosylation factor like GTPase 6 interacting protein 4	12	122980060-122982913	Predicted intracellular proteins	Evidence at protein level	HPA052098	Approved				Urothelial cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 186.0	Expressed in all		
ARL8A	ARL10B, FLJ45195, Gie2	ENSG00000143862	ADP ribosylation factor like GTPase 8A	1	202133404-202144743	Predicted intracellular proteins	Evidence at protein level	HPA038759, HPA040515, HPA045924	Approved				Colorectal cancer:3.08e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 113.6	Expressed in all		
ARL8B	ARL10C, FLJ10702, Gie1	ENSG00000134108	ADP ribosylation factor like GTPase 8B	3	5122220-5180912	Predicted intracellular proteins	Evidence at protein level	HPA038759, HPA040515, HPA045924	Approved				Liver cancer:3.68e-6 (unfavourable), Renal cancer:4.84e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 118.6	Expressed in all		
ARL9		ENSG00000196503	ADP ribosylation factor like GTPase 9	4	56505209-56524448	Predicted intracellular proteins	Evidence at protein level	HPA072942	Enhanced		Approved	Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		testis: 18.3	smooth muscle: 4.3	Group enriched	5	REH: 14.6;SCLC-21H: 15.6
ARMC1	Arcp, FLJ10511	ENSG00000104442	Armadillo repeat containing 1	8	65602456-65634217	Predicted intracellular proteins	Evidence at protein level	HPA026085	Approved		Supported	Mitochondria	Endometrial cancer:2.87e-4 (unfavourable), Breast cancer:4.81e-4 (unfavourable), Liver cancer:7.73e-4 (unfavourable), Pancreatic cancer:9.15e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 34.7	Expressed in all		
ARMC12	C6orf81, FLJ25390	ENSG00000157343	Armadillo repeat containing 12	6	35737032-35749079	Predicted intracellular proteins	Evidence at protein level	HPA030895			Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	8	testis: 63.2	epididymis: 7.5	Cell line enhanced		HSkMC: 4.9;MOLT-4: 4.0
ARMC2	bA787I22.1, DKFZp434P0714	ENSG00000118690	Armadillo repeat containing 2	6	108848416-108974472	Predicted intracellular proteins	Evidence at protein level	HPA025809, HPA053696	Enhanced		Approved	Nucleus		Mixed	Tissue enhanced		testis: 62.0	fallopian tube: 33.6	Expressed in all		
ARMC3	CT81, FLJ32827	ENSG00000165309	Armadillo repeat containing 3	10	22928024-23038523	Predicted intracellular proteins	Evidence at protein level	HPA037823, HPA037824	Enhanced					Tissue enhanced	Group enriched	12	fallopian tube: 74.2;testis: 61.0	lung: 5.5	Cell line enriched	10	CAPAN-2: 5.3
ARMC4	CILD23, DKFZP434P1735, FLJ10376, FLJ10817	ENSG00000169126	Armadillo repeat containing 4	10	27812164-27999048	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037829	Enhanced					Mixed	Group enriched	11	fallopian tube: 28.9;testis: 40.2	prostate: 3.2	Cell line enhanced		AF22: 6.0;RH-30: 14.9
ARMC6	MGC19595	ENSG00000105676	Armadillo repeat containing 6	19	19033575-19060311	Predicted intracellular proteins	Evidence at protein level	HPA041420, HPA041681	Supported		Enhanced	Cytosol		Expressed in all	Expressed in all			testis: 28.7	Expressed in all		
ARMC7	FLJ22160	ENSG00000125449	Armadillo repeat containing 7	17	75109952-75130265	Predicted intracellular proteins	Evidence at protein level	HPA024229, HPA053076	Uncertain		Supported	Cytosol	Liver cancer:2.24e-5 (unfavourable), Renal cancer:1.27e-4 (favourable), Cervical cancer:2.98e-4 (favourable)	Expressed in all	Expressed in all			lung: 12.6	Expressed in all		
ARMC8	DKFZP434A043, GID5, HSPC056, VID28	ENSG00000114098	Armadillo repeat containing 8	3	138187248-138298389	Predicted intracellular proteins	Evidence at protein level	HPA036996, HPA044869	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:8.90e-5 (unfavourable), Endometrial cancer:2.05e-4 (unfavourable), Prostate cancer:2.15e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 38.2	Expressed in all		
ARMC9	ARM, FLJ12584, KIAA1868, KU-MEL-1	ENSG00000135931	Armadillo repeat containing 9	2	231198546-231374837	Predicted intracellular proteins	Evidence at protein level	HPA019041, HPA026671	Approved		Approved	Nucleoli<br>Cytosol	Urothelial cancer:7.66e-5 (unfavourable)	Mixed	Mixed			smooth muscle: 34.0	Cell line enhanced		BJ hTERT+: 223.1;SK-MEL-30: 176.9
ARMCX4	CXorf35, GASP4, MGC40053	ENSG00000196440	Armadillo repeat containing, X-linked 4	X	101418287-101533459	Predicted intracellular proteins	Evidence at protein level	HPA000429, HPA051930	Uncertain		Approved	Nucleoplasm<br>Vesicles	Pancreatic cancer:8.20e-5 (favourable)	Mixed	Mixed			parathyroid gland: 14.3	Mixed		
ARMCX5	FLJ12969, GASP5	ENSG00000125962	Armadillo repeat containing, X-linked 5	X	102599168-102604159	Predicted intracellular proteins	Evidence at protein level	HPA000996	Approved		Approved	Nuclear speckles<br>Cytosol	Lung cancer:6.58e-5 (favourable)	Expressed in all	Expressed in all			prostate: 33.5	Cell line enhanced		RH-30: 86.0
ARMS2	ARMD8, LOC387715	ENSG00000254636	Age-related maculopathy susceptibility 2	10	122454653-122457352	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA067225	Enhanced					Not detected	Tissue enhanced		placenta: 2.0;testis: 2.9	ovary: 0.9	Not detected		
ARMT1	C6orf211, FLJ12910	ENSG00000146476	Acidic residue methyltransferase 1	6	151452258-151470101	Predicted intracellular proteins	Evidence at protein level	HPA003004, HPA005819	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Cytosol	Colorectal cancer:4.14e-4 (favourable), Cervical cancer:7.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 42.6	Expressed in all		
ARNT	bHLHe2, HIF-1beta	ENSG00000143437	Aryl hydrocarbon receptor nuclear translocator	1	150809705-150876768	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001759, CAB004318	Enhanced		Supported	Nucleus<br>Nuclear bodies		Expressed in all	Expressed in all			ovary: 46.7	Cell line enriched	7	U-698: 274.9
ARNT2	bHLHe1, KIAA0307	ENSG00000172379	Aryl hydrocarbon receptor nuclear translocator 2	15	80404350-80597937	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001056, CAB005081	Enhanced		Supported	Nucleus	Pancreatic cancer:1.46e-6 (favourable), Renal cancer:7.51e-4 (favourable)	Expressed in all	Tissue enriched	8	cerebral cortex: 153.7	testis: 18.8	Mixed		
ARNTL2	bHLHe6, BMAL2, CLIF, MOP9, PASD9	ENSG00000029153	Aryl hydrocarbon receptor nuclear translocator like 2	12	27332854-27425289	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059074, HPA065355	Uncertain		Enhanced	Nucleus<br>Nucleoli	Pancreatic cancer:5.29e-6 (unfavourable), Renal cancer:1.56e-5 (unfavourable)	Mixed	Tissue enhanced		esophagus: 31.2	tonsil: 20.2	Cell line enhanced		U-2197: 148.2
ARPC1A	Arc40, SOP2Hs, SOP2L	ENSG00000241685	Actin related protein 2/3 complex subunit 1A	7	99325910-99366262	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004334	Approved		Approved	Cell Junctions<br>Cytosol	Liver cancer:4.70e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 130.9	Expressed in all		
ARPC1B	ARC41, p40-ARC, p41-ARC	ENSG00000130429	Actin related protein 2/3 complex subunit 1B	7	99374249-99394801	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004832	Approved		Supported	Vesicles<br>Cytosol	Renal cancer:1.62e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 251.5	Expressed in all		
ARPC2	ARC34, p34-Arc	ENSG00000163466	Actin related protein 2/3 complex subunit 2	2	218217094-218254356	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001994, HPA008352	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:1.07e-7 (unfavourable), Liver cancer:3.63e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 537.0	Expressed in all		
ARPC3	ARC21, p21-Arc	ENSG00000111229	Actin related protein 2/3 complex subunit 3	12	110434825-110450422	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006550	Approved		Uncertain	Nucleoplasm	Renal cancer:2.22e-11 (unfavourable), Pancreatic cancer:4.67e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 608.2	Expressed in all		
ARPC4	ARC20, p20-Arc	ENSG00000241553	Actin related protein 2/3 complex subunit 4	3	9792495-9807726	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.29e-4 (unfavourable), Urothelial cancer:2.34e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 164.7	Expressed in all		
ARPC4-TTLL3		ENSG00000250151	ARPC4-TTLL3 readthrough	3	9793082-9835401	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			bone marrow: 4.3	Mixed		
ARPC5	ARC16, dJ127C7.3, p16-Arc	ENSG00000162704	Actin related protein 2/3 complex subunit 5	1	183620846-183635757	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022013, HPA031972	Approved		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.21e-10 (unfavourable), Liver cancer:3.63e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 201.3	Expressed in all		
ARPC5L	ARC16-2, MGC3038	ENSG00000136950	Actin related protein 2/3 complex subunit 5 like	9	124862130-124877733	Predicted intracellular proteins	Evidence at protein level	HPA022013	Approved					Expressed in all	Expressed in all			testis: 75.7	Expressed in all		
ARPIN	C15orf38, MGC61550	ENSG00000242498	Actin-related protein 2/3 complex inhibitor	15	89895006-89912956	Predicted intracellular proteins	Evidence at protein level	HPA040513, HPA047173, HPA052278	Uncertain				Renal cancer:4.19e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 31.0	Mixed		
ARPP19	ARPP-16, ARPP-19, ARPP16, ENSAL	ENSG00000128989	CAMP regulated phosphoprotein 19	15	52547045-52569883	Predicted intracellular proteins	Evidence at protein level	HPA056851	Approved				Renal cancer:1.72e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 510.5	Expressed in all		
ARPP21	ARPP-21, R3HDM3, TARPP	ENSG00000172995	CAMP regulated phosphoprotein 21	3	35638945-35794496	Predicted intracellular proteins	Evidence at protein level	HPA017303	Enhanced		Approved	Nucleoli<br>Cytosol		Tissue enhanced	Tissue enriched	6	cerebral cortex: 127.1	skeletal muscle: 20.2	Group enriched	10	MOLT-4: 54.6;REH: 34.0;RH-30: 19.9
ARR3	ARRX	ENSG00000120500	Arrestin 3	X	70268305-70281840	Predicted intracellular proteins	Evidence at protein level	HPA063129	Supported					Not detected	Tissue enhanced		skin: 2.7	lymph node: 1.1	Cell line enhanced		Karpas-707: 1.5
ARRB1	ARR1	ENSG00000137486	Arrestin beta 1	11	75264182-75351705	Predicted intracellular proteins	Evidence at protein level	CAB003763, HPA049318, HPA070249	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			lung: 80.4	Cell line enhanced		HEL: 151.4;RH-30: 109.6
ARRB2	ARR2, BARR2, DKFZp686L0365	ENSG00000141480	Arrestin beta 2	17	4710489-4721499	Predicted intracellular proteins	Evidence at protein level	HPA065681			Supported	Vesicles	Prostate cancer:2.61e-5 (unfavourable), Cervical cancer:2.93e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 171.5	Expressed in all		
ARRDC1	MGC40555	ENSG00000197070	Arrestin domain containing 1	9	137605654-137615360	Predicted intracellular proteins	Evidence at protein level	HPA022915, HPA044345	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:3.59e-4 (favourable)	Expressed in all	Expressed in all			stomach: 26.2	Cell line enhanced		MCF7: 150.8
ARRDC2	CLONE24945, PP2703	ENSG00000105643	Arrestin domain containing 2	19	18001132-18014102	Predicted intracellular proteins	Evidence at protein level	HPA053788	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:2.92e-4 (favourable), Ovarian cancer:5.84e-4 (unfavourable), Cervical cancer:5.93e-4 (favourable), Thyroid cancer:6.91e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 51.0	Mixed		
ARRDC3	KIAA1376, TLIMP	ENSG00000113369	Arrestin domain containing 3	5	91368724-91383359	Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.25e-8 (unfavourable), Stomach cancer:2.26e-4 (unfavourable), Ovarian cancer:3.30e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 143.0	Expressed in all		
ARRDC4	FLJ36045	ENSG00000140450	Arrestin domain containing 4	15	97960698-97973838	Predicted intracellular proteins	Evidence at protein level	HPA042109	Approved					Expressed in all	Expressed in all			skin: 42.0	Cell line enhanced		BJ: 86.9;hTCEpi: 62.8
ARRDC5		ENSG00000205784	Arrestin domain containing 5	19	4890437-4902867	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	8	testis: 18.2	spleen: 2.3	Cell line enriched	19	REH: 1.9
ARSJ	FLJ23548	ENSG00000180801	Arylsulfatase family member J	4	113900284-113979727	Predicted intracellular proteins	Evidence at protein level	HPA036481, HPA036482	Uncertain		Supported	Nucleoli<br>Actin filaments	Renal cancer:2.97e-6 (favourable), Head and neck cancer:6.08e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 12.7	Mixed		
ARVCF		ENSG00000099889	Armadillo repeat gene deleted in velocardiofacial syndrome	22	19969896-20016808	Predicted intracellular proteins	Evidence at protein level	CAB016162, HPA055264, HPA063675	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Urothelial cancer:5.76e-6 (favourable)	Expressed in all	Mixed			spleen: 8.8	Cell line enhanced		K-562: 18.0;SCLC-21H: 21.2;SH-SY5Y: 14.7;U-2 OS: 16.4
ARX	CT121, EIEE1, ISSX, MRX29, MRX32, MRX33, MRX36, MRX38, MRX43, MRX54, MRX76, MRX87, MRXS1, PRTS	ENSG00000004848	Aristaless related homeobox	X	25003694-25016420	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Endometrial cancer:3.54e-7 (unfavourable)	Mixed	Tissue enriched	7	ovary: 97.7	testis: 14.0	Cell line enhanced		HAP1: 2.0;PC-3: 3.6;U-266/70: 6.3
AS3MT	CYT19	ENSG00000214435	Arsenite methyltransferase	10	102869516-102901899	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017856	Enhanced		Approved	Nucleus<br>Mitochondria		Tissue enhanced	Group enriched	6	adrenal gland: 251.5;parathyroid gland: 119.3	liver: 30.4	Cell line enhanced		REH: 50.0;SH-SY5Y: 29.9;T-47d: 41.6
ASAH2B	ASAH2C, ASAH2L, bA449O16.3, bA98I6.3	ENSG00000204147	N-acylsphingosine amidohydrolase 2B	10	50739318-50816495	Predicted intracellular proteins	Evidence at protein level	HPA061171	Supported		Approved	Focal adhesion sites		Mixed	Mixed			duodenum: 19.6	Mixed		
ASAP1	CENTB4, DDEF1, KIAA1249, PAP, ZG14P	ENSG00000153317	ArfGAP with SH3 domain, ankyrin repeat and PH domain 1	8	130052104-130443660	Predicted intracellular proteins	Evidence at protein level	HPA011136, CAB037292, HPA048565	Approved		Approved	Plasma membrane<br>Centrosome<br>Cytosol	Liver cancer:5.63e-8 (unfavourable), Renal cancer:1.50e-7 (unfavourable), Lung cancer:3.56e-5 (unfavourable), Endometrial cancer:5.81e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 56.0	Expressed in all		
ASAP2	CENTB3, DDEF2, KIAA0400, PAP, SHAG1	ENSG00000151693	ArfGAP with SH3 domain, ankyrin repeat and PH domain 2	2	9206765-9405683	Predicted intracellular proteins	Evidence at protein level	CAB018615	Approved		Supported	Cytosol	Endometrial cancer:1.61e-4 (unfavourable), Pancreatic cancer:4.68e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 73.6	thyroid gland: 32.6	Mixed		
ASAP3	CENTB6, DDEFL1, FLJ20199, UPLC1	ENSG00000088280	ArfGAP with SH3 domain, ankyrin repeat and PH domain 3	1	23428563-23484568	Predicted intracellular proteins	Evidence at protein level	HPA020537, HPA020546	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:5.12e-5 (favourable), Lung cancer:2.80e-4 (favourable), Endometrial cancer:5.56e-4 (unfavourable), Ovarian cancer:8.30e-4 (unfavourable)	Expressed in all	Mixed			skin: 32.5	Cell line enhanced		HSkMC: 27.9
ASB1	ASB-1	ENSG00000065802	Ankyrin repeat and SOCS box containing 1	2	238426742-238452250	Predicted intracellular proteins	Evidence at protein level	HPA003508	Uncertain		Approved	Nucleoplasm	Endometrial cancer:4.89e-5 (unfavourable), Pancreatic cancer:1.56e-4 (favourable), Liver cancer:5.37e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 20.1	Expressed in all		
ASB10	GLC1F	ENSG00000146926	Ankyrin repeat and SOCS box containing 10	7	151175698-151187832	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	8	skeletal muscle: 27.9	heart muscle: 3.3	Not detected		
ASB12	FLJ39577	ENSG00000198881	Ankyrin repeat and SOCS box containing 12	X	64224196-64230631	Predicted intracellular proteins	Evidence at protein level	HPA049542	Uncertain					Mixed	Tissue enriched	14	skeletal muscle: 30.7	fallopian tube: 2.2	Cell line enhanced		AF22: 1.2
ASB13	FLJ13134, MGC19879	ENSG00000196372	Ankyrin repeat and SOCS box containing 13	10	5638867-5666595	Predicted intracellular proteins	Evidence at protein level	HPA048293, HPA061742	Approved		Approved	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			small intestine: 28.0	Mixed		
ASB14	DKFZp313L0121	ENSG00000239388	Ankyrin repeat and SOCS box containing 14	3	57268347-57292682	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		skeletal muscle: 9.9	heart muscle: 2.4	Not detected		
ASB15	FLJ43370	ENSG00000146809	Ankyrin repeat and SOCS box containing 15	7	123567010-123639481	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		heart muscle: 19.2;skeletal muscle: 43.9	kidney: 7.5	Not detected		
ASB16	FLJ30165	ENSG00000161664	Ankyrin repeat and SOCS box containing 16	17	44170447-44179083	Predicted intracellular proteins	Evidence at protein level	HPA066834	Approved		Approved	Focal adhesion sites		Mixed	Tissue enriched	5	skeletal muscle: 23.2	spleen: 4.2	Mixed		
ASB17		ENSG00000154007	Ankyrin repeat and SOCS box containing 17	1	75918873-75932431	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	380	testis: 84.7	kidney: 0.2	Not detected		
ASB2	ASB-2	ENSG00000100628	Ankyrin repeat and SOCS box containing 2	14	93934153-93976791	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.62e-6 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 85.8	smooth muscle: 25.6	Cell line enhanced		Karpas-707: 7.3;RPMI-8226: 6.6;U-266/70: 21.0;U-266/84: 4.6
ASB3	ASB-3	ENSG00000115239	Ankyrin repeat and SOCS box containing 3	2	53532672-53787610	Predicted intracellular proteins	Evidence at protein level	HPA003940	Uncertain					Mixed	Expressed in all			cerebral cortex: 28.0	Expressed in all		
ASB4	ASB-4	ENSG00000005981	Ankyrin repeat and SOCS box containing 4	7	95478444-95540232	Predicted intracellular proteins	Evidence at transcript level	HPA055240	Uncertain					Tissue enhanced	Group enriched	11	adrenal gland: 50.2;skeletal muscle: 11.5	placenta: 2.8	Cell line enhanced		A549: 4.1;Hep G2: 5.2;SCLC-21H: 5.4
ASB6		ENSG00000148331	Ankyrin repeat and SOCS box containing 6	9	129634604-129642169	Predicted intracellular proteins	Evidence at protein level	HPA004341	Approved				Colorectal cancer:1.06e-5 (unfavourable), Liver cancer:2.40e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 22.7	Expressed in all		
ASB7		ENSG00000183475	Ankyrin repeat and SOCS box containing 7	15	100602534-100651705	Predicted intracellular proteins	Evidence at protein level	HPA003300	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Vesicles		Expressed in all	Mixed			testis: 12.5	Expressed in all		
ASB8	FLJ21255, MGC5540	ENSG00000177981	Ankyrin repeat and SOCS box containing 8	12	48147788-48181213	Predicted intracellular proteins	Evidence at protein level	HPA003299	Approved				Renal cancer:6.57e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 98.2	Expressed in all		
ASB9	DKFZP564L0862, FLJ20636, MGC4954	ENSG00000102048	Ankyrin repeat and SOCS box containing 9	X	15235288-15270467	Predicted intracellular proteins	Evidence at protein level	HPA003014, HPA003060, CAB004997	Enhanced				Prostate cancer:4.36e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 48.3	kidney: 16.9	Cell line enhanced		A549: 23.1;PC-3: 48.9
ASCC1	ASC1p50, CGI-18, Em:AC022392.3	ENSG00000138303	Activating signal cointegrator 1 complex subunit 1	10	72096032-72217134	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038038, HPA057567	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.00e-4 (unfavourable), Liver cancer:3.52e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 45.7	Expressed in all		
ASCC2	ASC1p100, DKFZp586O0223, FLJ21588	ENSG00000100325	Activating signal cointegrator 1 complex subunit 2	22	29788608-29838304	Predicted intracellular proteins	Evidence at protein level	HPA001439, HPA052879	Approved		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			testis: 46.0	Expressed in all		
ASCC3	ASC1p200, dJ121G13.4, dJ467N11.1, HELIC1, RNAH	ENSG00000112249	Activating signal cointegrator 1 complex subunit 3	6	100508194-100881372	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031608, HPA031609, HPA031610	Enhanced		Supported	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 26.5	Expressed in all		
ASCL2	ASH2, bHLHa45, HASH2	ENSG00000183734	Achaete-scute family bHLH transcription factor 2	11	2268495-2270952	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Pancreatic cancer:4.73e-4 (favourable), Cervical cancer:5.11e-4 (favourable)	Group enriched	Mixed			placenta: 6.4	Group enriched	6	BEWO: 19.9;NB-4: 4.0;SCLC-21H: 19.8
ASCL3	bHLHa42, HASH3, Sgn1	ENSG00000176009	Achaete-scute family bHLH transcription factor 3	11	8937579-8938211	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA027032	Uncertain					Not detected	Tissue enriched	15	salivary gland: 3.3	spleen,testis: 0.2	Not detected		
ASCL4	bHLHa44, HASH4	ENSG00000187855	Achaete-scute family bHLH transcription factor 4	12	107774385-107776644	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036116	Uncertain					Tissue enhanced	Not detected			parathyroid gland: 0.7	Not detected		
ASCL5	bHLHa47	ENSG00000232237	Achaete-scute family bHLH transcription factor 5	1	201113953-201127184	Predicted intracellular proteins, Transcription factors	No evidence							Mixed	Not detected			endometrium: 0.6	Not detected		
ASF1A	CIA, DKFZP547E2110	ENSG00000111875	Anti-silencing function 1A histone chaperone	6	118894220-118909167	Predicted intracellular proteins	Evidence at protein level	HPA030502, HPA071495			Enhanced	Nucleus	Liver cancer:5.02e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.7	Expressed in all		
ASF1B	FLJ10604	ENSG00000105011	Anti-silencing function 1B histone chaperone	19	14119509-14136956	Predicted intracellular proteins	Evidence at protein level	HPA054036			Supported	Nucleoplasm	Renal cancer:2.22e-16 (unfavourable), Cervical cancer:4.45e-5 (favourable), Pancreatic cancer:1.98e-4 (unfavourable), Liver cancer:2.03e-4 (unfavourable), Stomach cancer:2.49e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 37.2	lymph node: 24.0	Mixed		
ASGR1	CLEC4H1	ENSG00000141505	Asialoglycoprotein receptor 1	17	7173431-7179564	Predicted intracellular proteins	Evidence at protein level	HPA011954, HPA012852	Enhanced		Supported	Vesicles<br>Cell Junctions		Tissue enriched	Tissue enriched	13	liver: 236.1	testis: 17.6	Cell line enriched	25	Hep G2: 331.3
ASH1L	ASH1, ASH1L1, huASH1, KMT2H	ENSG00000116539	ASH1 like histone lysine methyltransferase	1	155335268-155562807	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004806	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.9	Expressed in all		
ASH2L	ASH2, ASH2L1, ASH2L2, Bre2	ENSG00000129691	ASH2 like histone lysine methyltransferase complex subunit	8	38105242-38144076	Predicted intracellular proteins	Evidence at protein level	HPA042289	Approved		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:4.25e-4 (favourable)	Expressed in all	Expressed in all			testis: 74.9	Expressed in all		
ASL		ENSG00000126522	Argininosuccinate lyase	7	66075798-66093558	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003696, HPA016646	Supported		Approved	Cytosol	Cervical cancer:4.05e-6 (unfavourable)	Expressed in all	Expressed in all			liver: 97.5	Expressed in all		
ASMT	ASMTY, HIOMT, HIOMTY	ENSG00000196433	Acetylserotonin O-methyltransferase	X	1615001-1643081	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		epididymis: 2.2	adrenal gland: 0.8	Not detected		
ASMTL		ENSG00000169093	Acetylserotonin O-methyltransferase-like	X	1403139-1453762	Predicted intracellular proteins	Evidence at protein level	HPA003630, HPA021865	Enhanced		Enhanced	Cytosol		Expressed in all	Expressed in all			thyroid gland: 34.4	Expressed in all		
ASNA1	ARSA-I, GET3, TRC40	ENSG00000198356	ArsA arsenite transporter, ATP-binding, homolog 1 (bacterial)	19	12737139-12748323	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045951, HPA048087	Approved		Enhanced	Nucleus<br>Nucleoli	Renal cancer:4.27e-5 (favourable), Urothelial cancer:8.47e-4 (unfavourable), Cervical cancer:9.53e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 93.9	Expressed in all		
ASNS		ENSG00000070669	Asparagine synthetase (glutamine-hydrolyzing)	7	97852118-97872542	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004924, HPA029318, HPA064737	Approved		Enhanced	Cytosol	Renal cancer:6.21e-7 (unfavourable), Liver cancer:9.42e-6 (unfavourable), Head and neck cancer:8.79e-5 (unfavourable), Endometrial cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.0	Expressed in all		
ASNSD1	FLJ20752, NBLA00058, NS3TP1	ENSG00000138381	Asparagine synthetase domain containing 1	2	189661385-189670831	Predicted intracellular proteins	Evidence at protein level	HPA036132, HPA036133, HPA075042	Uncertain		Approved	Cytosol	Glioma:5.68e-4 (favourable), Liver cancer:8.66e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 51.4	Expressed in all		
ASPA	ACY2, ASP	ENSG00000108381	Aspartoacylase	17	3472374-3503419	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022142, HPA022145	Enhanced		Uncertain	Cytosol		Tissue enhanced	Tissue enhanced		kidney: 39.8	cerebral cortex: 24.7	Cell line enhanced		ASC diff: 3.7;HSkMC: 5.5
ASPDH		ENSG00000204653	Aspartate dehydrogenase domain containing	19	50511600-50514690	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042631, HPA042654	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 17.9;kidney: 27.9;liver: 34.6	duodenum: 6.9	Cell line enhanced		HEK93: 12.4;MOLT-4: 13.3;SH-SY5Y: 9.8
ASPG	C14orf76	ENSG00000166183	Asparaginase	14	104085679-104115581	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069761	Enhanced					Tissue enhanced	Tissue enhanced		liver: 29.5	esophagus: 13.9	Not detected		
ASPM	ASP, Calmbp1, FLJ10517, FLJ10549, MCPH5	ENSG00000066279	Abnormal spindle microtubule assembly	1	197084128-197146694	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017816	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.25e-4 (unfavourable), Endometrial cancer:1.97e-4 (unfavourable), Pancreatic cancer:2.40e-4 (unfavourable), Lung cancer:2.41e-4 (unfavourable)	Mixed	Mixed			bone marrow: 9.3	Mixed		
ASPSCR1	ASPL, ASPS, TUG, UBXD9, UBXN9	ENSG00000169696	ASPSCR1, UBX domain containing tether for SLC2A4	17	81976807-82017406	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026749	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Renal cancer:1.26e-4 (unfavourable), Pancreatic cancer:2.67e-4 (favourable), Head and neck cancer:8.55e-4 (favourable)	Expressed in all	Expressed in all			testis: 21.3	Expressed in all		
ASRGL1	ALP, ALP1, FLJ22316	ENSG00000162174	Asparaginase like 1	11	62337448-62393412	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029725, HPA055572, CAB070192	Enhanced		Approved	Nucleoplasm<br>Microtubules	Renal cancer:4.32e-7 (favourable), Endometrial cancer:1.56e-5 (favourable), Colorectal cancer:6.14e-4 (favourable), Liver cancer:9.46e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 181.6	Cell line enhanced		HAP1: 86.4;SCLC-21H: 132.5
ASS1	ASS, CTLN1	ENSG00000130707	Argininosuccinate synthase 1	9	130444929-130501274	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020896, HPA020934	Enhanced		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:8.14e-9 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 1259.9;liver: 1027.3	fallopian tube: 261.5	Cell line enhanced		BJ hTERT+: 709.0;HaCaT: 734.6;RPMI-8226: 956.8;THP-1: 690.3
ASTE1	HT001	ENSG00000034533	Asteroid homolog 1 (Drosophila)	3	131013875-131027649	Predicted intracellular proteins	Evidence at protein level	HPA037010, HPA037011	Enhanced		Approved	Endoplasmic reticulum	Liver cancer:4.03e-5 (unfavourable), Endometrial cancer:2.34e-4 (unfavourable), Cervical cancer:3.09e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 11.7	Expressed in all		
ASXL1	KIAA0978	ENSG00000171456	Additional sex combs like 1, transcriptional regulator	20	32358344-32439319	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064156			Approved	Nucleus<br>Nucleoli	Endometrial cancer:2.86e-4 (unfavourable), Head and neck cancer:9.16e-4 (favourable)	Expressed in all	Expressed in all			testis: 68.5	Expressed in all		
ASXL2	ASXH2, FLJ10898, KIAA1685	ENSG00000143970	Additional sex combs like 2, transcriptional regulator	2	25733753-25878516	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034646, HPA058040			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 26.6	Expressed in all		
ASXL3	KIAA1713	ENSG00000141431	Additional sex combs like 3, transcriptional regulator	18	33578577-33751192	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA039539, HPA040034	Uncertain					Not detected	Tissue enhanced		ovary: 2.9	testis: 2.7	Group enriched	11	AF22: 2.4;HEK93: 1.2;RPMI-8226: 5.8;SCLC-21H: 3.3;SH-SY5Y: 1.5
ATAD2	CT137, DKFZp667N1320, MGC29843, MGC5254, PRO2000	ENSG00000156802	ATPase family, AAA domain containing 2	8	123319850-123416350	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029424, CAB056158	Enhanced		Enhanced	Nucleoplasm	Renal cancer:8.33e-15 (unfavourable), Endometrial cancer:2.04e-4 (unfavourable)	Expressed in all	Mixed			testis: 34.4	Expressed in all		
ATAD2B	KIAA1240	ENSG00000119778	ATPase family, AAA domain containing 2B	2	23748664-23927114	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034555	Uncertain		Supported	Nucleoplasm	Renal cancer:2.35e-5 (unfavourable)	Expressed in all	Mixed			skin: 9.8	Expressed in all		
ATAD3A	FLJ10709	ENSG00000197785	ATPase family, AAA domain containing 3A	1	1512151-1534687	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA058968, HPA064867, HPA065305	Approved		Supported	Mitochondria	Liver cancer:5.90e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 16.1	Expressed in all		
ATAD3B	KIAA1273, TOB3	ENSG00000160072	ATPase family, AAA domain containing 3B	1	1471769-1497848	Predicted intracellular proteins	Evidence at protein level	HPA058968, HPA064867, HPA065305	Approved		Supported	Mitochondria	Renal cancer:5.48e-9 (unfavourable), Liver cancer:1.81e-5 (unfavourable)	Expressed in all	Mixed			appendix: 7.5	Mixed		
ATAD3C	FLJ34599	ENSG00000215915	ATPase family, AAA domain containing 3C	1	1449689-1470158	Predicted intracellular proteins	Evidence at protein level	HPA065305			Approved	Mitochondria	Lung cancer:5.15e-4 (favourable)	Mixed	Mixed			thyroid gland: 3.4	Cell line enhanced		RPMI-8226: 9.0
ATCAY	BNIP-H	ENSG00000167654	ATCAY, caytaxin	19	3879864-3928079	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA017755	Enhanced					Tissue enriched	Tissue enriched	12	cerebral cortex: 108.9	adrenal gland: 8.8	Cell line enhanced		NTERA-2: 7.2;SCLC-21H: 15.5;SH-SY5Y: 9.8
ATE1		ENSG00000107669	Arginyltransferase 1	10	121740421-121928801	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038444, HPA057549	Approved		Supported	Nucleus	Renal cancer:2.67e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.5	Expressed in all		
ATF1	TREB36	ENSG00000123268	Activating transcription factor 1	12	50763710-50821122	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016222, HPA055069, HPA055406	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.53e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 39.6	Expressed in all		
ATF2	CRE-BP1, CREB2, HB16, TREB7	ENSG00000115966	Activating transcription factor 2	2	175072250-175168382	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003769, HPA022134	Supported		Enhanced	Nucleoplasm	Liver cancer:7.08e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 54.0	Expressed in all		
ATF3		ENSG00000162772	Activating transcription factor 3	1	212565334-212620777	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001562	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			smooth muscle: 450.5	Cell line enhanced		BEWO: 126.9
ATF4	CREB-2, TAXREB67, TXREB	ENSG00000128272	Activating transcription factor 4	22	39519695-39522685	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011596	Approved		Supported	Microtubule organizing center<br>Cytosol	Renal cancer:9.77e-5 (unfavourable), Liver cancer:4.07e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 530.2	Expressed in all		
ATF5		ENSG00000169136	Activating transcription factor 5	19	49928702-49933935	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030187	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.39e-7 (unfavourable), Cervical cancer:1.14e-4 (favourable), Endometrial cancer:1.16e-4 (unfavourable)	Tissue enriched	Group enriched	7	liver: 387.6;thyroid gland: 190.2	appendix: 42.4	Expressed in all		
ATF7IP	FLJ10688, p621	ENSG00000171681	Activating transcription factor 7 interacting protein	12	14365632-14502935	Predicted intracellular proteins	Evidence at protein level	HPA016578, HPA023505	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Glioma:7.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 61.7	Expressed in all		
ATF7IP2	FLJ12668	ENSG00000166669	Activating transcription factor 7 interacting protein 2	16	10326434-10483638	Predicted intracellular proteins	Evidence at protein level	HPA041156, HPA041228	Enhanced				Liver cancer:5.68e-5 (favourable), Urothelial cancer:8.57e-5 (favourable), Breast cancer:4.98e-4 (favourable)	Mixed	Tissue enhanced		testis: 35.7	lymph node: 10.3	Mixed		
ATG10	APG10L, DKFZP586I0418, FLJ13954	ENSG00000152348	Autophagy related 10	5	81972025-82276857	Predicted intracellular proteins	Evidence at protein level	HPA044163	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:3.22e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 22.2	Expressed in all		
ATG101	C12orf44, FLJ11773	ENSG00000123395	Autophagy related 101	12	52069246-52077494	Predicted intracellular proteins	Evidence at protein level	HPA039904	Approved				Liver cancer:8.07e-7 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 43.7	Expressed in all		
ATG12	APG12, APG12L	ENSG00000145782	Autophagy related 12	5	115828200-115841858	Predicted intracellular proteins	Evidence at protein level	CAB013272	Uncertain				Renal cancer:1.54e-7 (unfavourable), Liver cancer:1.36e-4 (unfavourable), Thyroid cancer:4.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.1	Expressed in all		
ATG13	KIAA0652	ENSG00000175224	Autophagy related 13	11	46617527-46674818	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039350			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:8.59e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 111.6	Expressed in all		
ATG14	ATG14L, KIAA0831	ENSG00000126775	Autophagy related 14	14	55366392-55411858	Predicted intracellular proteins	Evidence at protein level	CAB037242	Uncertain				Liver cancer:1.63e-4 (unfavourable), Renal cancer:1.95e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 17.1	Expressed in all		
ATG16L1	APG16L, ATG16A, ATG16L, FLJ10035, WDR30	ENSG00000085978	Autophagy related 16 like 1	2	233210051-233295674	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA012577, HPA063900	Enhanced		Approved	Cytosol	Liver cancer:1.48e-5 (unfavourable), Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Mixed			testis: 12.8	Expressed in all		
ATG16L2	ATG16B, FLJ00012, WDR80	ENSG00000168010	Autophagy related 16 like 2	11	72814308-72843674	Predicted intracellular proteins	Evidence at protein level	HPA045444, HPA050312	Approved		Enhanced	Nucleoplasm	Renal cancer:3.39e-4 (unfavourable), Pancreatic cancer:7.06e-4 (favourable)	Expressed in all	Expressed in all			spleen: 99.0	Expressed in all		
ATG2B	C14orf103, FLJ10242	ENSG00000066739	Autophagy related 2B	14	96279202-96363870	Predicted intracellular proteins	Evidence at protein level	HPA000880, HPA001427, HPA019665	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 17.1	Expressed in all		
ATG3	APG3L, DKFZp564M1178, FLJ22125, MGC15201, PC3-96	ENSG00000144848	Autophagy related 3	3	112532509-112562046	Predicted intracellular proteins	Evidence at protein level	CAB037260, HPA040471	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:9.35e-6 (unfavourable), Prostate cancer:1.59e-4 (unfavourable), Cervical cancer:6.82e-4 (favourable)	Expressed in all	Expressed in all			testis: 154.8	Expressed in all		
ATG4A	APG4A, AUTL2	ENSG00000101844	Autophagy related 4A cysteine peptidase	X	108091668-108154671	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036374, HPA064759	Uncertain		Approved	Actin filaments<br>Microtubules	Breast cancer:1.36e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 17.8	Expressed in all		
ATG4B	APG4B, AUTL1, DKFZp586D1822, KIAA0943	ENSG00000168397	Autophagy related 4B cysteine peptidase	2	241637213-241673857	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB037195, HPA069803	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.79e-4 (unfavourable), Colorectal cancer:6.85e-4 (unfavourable), Urothelial cancer:9.64e-4 (favourable)	Expressed in all	Expressed in all			testis: 44.0	Expressed in all		
ATG4C	APG4C, AUTL1, AUTL3, FLJ14867	ENSG00000125703	Autophagy related 4C cysteine peptidase	1	62784135-62865513	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007049	Approved		Approved	Nucleoplasm<br>Cytosol	Colorectal cancer:9.83e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 23.5	Expressed in all		
ATG4D	APG4-D, APG4D, AUTL4	ENSG00000130734	Autophagy related 4D cysteine peptidase	19	10543895-10553418	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA067683	Approved				Renal cancer:2.39e-7 (favourable), Cervical cancer:3.18e-5 (favourable), Stomach cancer:5.03e-4 (favourable), Pancreatic cancer:9.95e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 25.2	Mixed		
ATG7	APG7L, DKFZp434N0735, GSA7	ENSG00000197548	Autophagy related 7	3	11272309-11557665	Predicted intracellular proteins	Evidence at protein level	HPA007639, CAB018771	Supported		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.41e-4 (unfavourable), Renal cancer:9.55e-4 (favourable), Colorectal cancer:9.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 40.7	Expressed in all		
ATIC	AICARFT, IMPCHASE, PURH	ENSG00000138363	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	2	215311817-215349773	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013462, HPA021012	Supported		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 44.8	Expressed in all		
ATN1	B37, D12S755E, DRPLA	ENSG00000111676	Atrophin 1	12	6924463-6942321	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031619	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.20e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 139.5	Expressed in all		
ATOH1	bHLHa14, HATH1, MATH-1, Math1	ENSG00000172238	Atonal bHLH transcription factor 1	4	93828753-93830964	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Colorectal cancer:3.26e-5 (favourable)	Tissue enhanced	Group enriched	9	colon: 17.6;duodenum: 11.1;rectum: 19.7;small intestine: 22.4	appendix: 1.9	Not detected		
ATOH7	bHLHa13, Math5	ENSG00000179774	Atonal bHLH transcription factor 7	10	68230624-68232103	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027008	Uncertain					Not detected	Tissue enriched	7	cerebral cortex: 2.2	endometrium,kidney,small intestine: 0.3	Cell line enriched	14	SCLC-21H: 9.1
ATOH8	bHLHa21, FLJ14708, HATH6	ENSG00000168874	Atonal bHLH transcription factor 8	2	85751344-85788066	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028406			Supported	Nucleoplasm	Pancreatic cancer:8.98e-6 (favourable), Renal cancer:3.80e-5 (favourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 31.6	lung: 17.0	Cell line enhanced		RH-30: 29.0;TIME: 23.5
ATOX1	HAH1	ENSG00000177556	Antioxidant 1 copper chaperone	5	151742316-151772532	Predicted intracellular proteins	Evidence at protein level	HPA055036			Approved	Nucleoplasm<br>Plasma membrane	Pancreatic cancer:9.57e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 151.5	Expressed in all		
ATP23	KUB3, XRCC6BP1	ENSG00000166896	ATP23 metallopeptidase and ATP synthase assembly factor homolog	12	57941541-57957269	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035804, HPA043204	Uncertain		Enhanced	Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.44e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 26.8	rectum: 5.5	Expressed in all		
ATP5A1	ATP5A, ATP5AL2, ATPM, hATP1, OMR, ORM	ENSG00000152234	ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle	18	46080248-46104334	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013067, HPA040622, HPA044202	Enhanced		Supported	Mitochondria	Renal cancer:1.22e-15 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 869.9	Expressed in all		
ATP5B	ATPSB	ENSG00000110955	ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide	12	56638175-56646068	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001520, HPA001528, CAB017527	Enhanced		Enhanced	Mitochondria	Renal cancer:1.43e-9 (favourable), Breast cancer:7.17e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 1254.0	Expressed in all		
ATP5C1	ATP5C, ATP5CL1	ENSG00000165629	ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1	10	7788129-7807815	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA060949	Approved				Renal cancer:9.26e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 463.5	Expressed in all		
ATP5D		ENSG00000099624	ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit	19	1241746-1244826	Predicted intracellular proteins	Evidence at protein level	HPA002865	Uncertain				Renal cancer:3.46e-5 (favourable), Endometrial cancer:1.23e-4 (favourable), Pancreatic cancer:4.60e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 217.6	Expressed in all		
ATP5E		ENSG00000124172	ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit	20	59025467-59032382	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.82e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 132.8	Expressed in all		
ATP5EP2		ENSG00000180389	ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit pseudogene 2	13	27945206-27945590	Predicted intracellular proteins	No evidence						Liver cancer:2.36e-4 (unfavourable)	Expressed in all	Not detected			stomach: 0.2	Not detected		
ATP5H	ATP5JD, ATPQ	ENSG00000167863	ATP synthase, H+ transporting, mitochondrial Fo complex subunit D	17	75038863-75046985	Predicted intracellular proteins	Evidence at protein level	HPA042777, HPA048459	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			heart muscle: 616.6	Expressed in all		
ATP5I		ENSG00000169020	ATP synthase, H+ transporting, mitochondrial Fo complex subunit E	4	672436-674338	Predicted intracellular proteins	Evidence at protein level	HPA035010	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 541.4	Expressed in all		
ATP5J	ATP5, ATP5A, ATPM, CF6	ENSG00000154723	ATP synthase, H+ transporting, mitochondrial Fo complex subunit F6	21	25716503-25735673	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031069	Supported		Supported	Mitochondria	Renal cancer:2.37e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 528.8	Expressed in all		
ATP5J2-PTCD1		ENSG00000248919	ATP5J2-PTCD1 readthrough	7	99419749-99466197	Predicted intracellular proteins	Evidence at protein level	HPA020106, HPA047679	Uncertain		Approved	Mitochondria		Not detected	Mixed			prostate: 6.1	Expressed in all		
ATP5L2	ATP5K2, dJ222E13.5	ENSG00000249222	ATP synthase, H+ transporting, mitochondrial Fo complex subunit G2	22	42639803-42640601	Predicted intracellular proteins	Evidence at protein level	HPA044629	Uncertain		Supported	Mitochondria		Not detected	Mixed			skin: 1.0	Not detected		
ATP5O	ATPO, OSCP	ENSG00000241837	ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit	21	33903453-33915980	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016209, HPA041394	Enhanced		Supported	Mitochondria	Renal cancer:9.34e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 533.0	Expressed in all		
ATP5S	ATPW, HSU79253	ENSG00000125375	ATP synthase, H+ transporting, mitochondrial Fo complex subunit s (factor B)	14	50312326-50335558	Predicted intracellular proteins	Evidence at protein level	HPA046967, HPA062690	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:2.37e-8 (favourable), Lung cancer:5.53e-4 (favourable)	Expressed in all	Mixed			skin: 8.4	Mixed		
ATP5SL	FLJ10241	ENSG00000105341	ATP5S like	19	41431318-41440717	Predicted intracellular proteins	Evidence at protein level	HPA041427	Approved		Approved	Mitochondria	Renal cancer:4.07e-5 (favourable), Liver cancer:1.77e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 50.5	Expressed in all		
ATP6V0D1	ATP6D, ATP6DV, P39, VATX, Vma6, VPATPD	ENSG00000159720	ATPase H+ transporting V0 subunit d1	16	67438014-67481237	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA016938	Uncertain				Renal cancer:1.76e-8 (favourable), Pancreatic cancer:1.20e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 187.1	Expressed in all		
ATP6V0D2	ATP6D2, FLJ38708, VMA6	ENSG00000147614	ATPase H+ transporting V0 subunit d2	8	85987323-86154228	Predicted intracellular proteins	Evidence at protein level	HPA055327, HPA058496	Enhanced		Approved	Vesicles	Renal cancer:2.20e-6 (favourable)	Tissue enriched	Tissue enriched	15	kidney: 59.4	rectum: 3.9	Cell line enhanced		SCLC-21H: 2.3;SK-MEL-30: 2.6;U-87 MG: 4.8
ATP6V1A	ATP6A1, ATP6V1A1, VA68, Vma1, VPP2	ENSG00000114573	ATPase H+ transporting V1 subunit A	3	113747019-113812056	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB006910, HPA035083, HPA035084	Approved		Supported	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:3.82e-12 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 151.4	Expressed in all		
ATP6V1B1	ATP6B1, RTA1B, VATB, Vma2, VPP3	ENSG00000116039	ATPase H+ transporting V1 subunit B1	2	70935882-70965406	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009523, HPA031847	Enhanced		Approved	Nucleus<br>Nuclear membrane		Group enriched	Group enriched	10	breast: 16.1;cervix, uterine: 47.9;fallopian tube: 21.1;kidney: 64.8;placenta: 27.8;salivary gland: 66.5	skin: 4.2	Group enriched	6	BEWO: 20.0;HaCaT: 17.4;SK-BR-3: 34.9
ATP6V1B2	ATP6B2, HO57, VATB, Vma2, VPP3	ENSG00000147416	ATPase H+ transporting V1 subunit B2	8	20197367-20226819	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA008147	Enhanced		Supported	Vesicles	Renal cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 304.2	Expressed in all		
ATP6V1C1	ATP6C, ATP6D, VATC, Vma5	ENSG00000155097	ATPase H+ transporting V1 subunit C1	8	103021063-103073051	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023943, HPA057297	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:8.82e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 123.1	Expressed in all		
ATP6V1C2	ATP6C2, VMA5	ENSG00000143882	ATPase H+ transporting V1 subunit C2	2	10721649-10785110	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034734, HPA067305	Approved		Uncertain	Mitochondria	Renal cancer:1.12e-11 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 83.9;epididymis: 99.0;skin: 123.7	placenta: 55.1	Group enriched	9	BEWO: 71.4;SK-BR-3: 20.0
ATP6V1D	ATP6M, VATD, VMA8	ENSG00000100554	ATPase H+ transporting V1 subunit D	14	67294371-67360265	Predicted intracellular proteins	Evidence at protein level	HPA031515, HPA057316	Enhanced		Approved	Nucleoplasm	Renal cancer:7.60e-13 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 195.5	Expressed in all		
ATP6V1E1	ATP6E, ATP6E2, ATP6V1E, P31, Vma4	ENSG00000131100	ATPase H+ transporting V1 subunit E1	22	17592136-17628818	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009528, CAB018699, HPA029196	Enhanced		Approved	Nucleoplasm	Renal cancer:7.66e-8 (favourable), Liver cancer:1.56e-5 (unfavourable), Prostate cancer:4.18e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 301.3	Expressed in all		
ATP6V1E2	ATP6E1, ATP6EL2, ATP6V1EL2, MGC9341, VMA4	ENSG00000250565	ATPase H+ transporting V1 subunit E2	2	46490750-46542557	Predicted intracellular proteins	Evidence at protein level	HPA052784	Uncertain					Expressed in all	Group enriched	6	epididymis: 7.7;testis: 31.6	cerebral cortex: 3.2	Mixed		
ATP6V1F	ATP6S14, VATF, Vma7	ENSG00000128524	ATPase H+ transporting V1 subunit F	7	128862826-128865844	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009529, HPA048700, HPA062011	Enhanced				Renal cancer:2.49e-5 (favourable), Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 288.0	Expressed in all		
ATP6V1G1	ATP6G, ATP6G1, ATP6GL, ATP6J, DKFZp547P234, Vma10	ENSG00000136888	ATPase H+ transporting V1 subunit G1	9	114587746-114598373	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004615, HPA042898	Supported		Supported	Nucleus<br>Nucleoli	Renal cancer:1.73e-7 (favourable)	Expressed in all	Expressed in all			epididymis: 301.0	Expressed in all		
ATP6V1G2	ATP6G, ATP6G2, Em:AC004181.3, NG38, Vma10	ENSG00000213760	ATPase H+ transporting V1 subunit G2	6	31544462-31548427	Predicted intracellular proteins	Evidence at protein level	CAB004616	Enhanced					Tissue enriched	Tissue enriched	12	cerebral cortex: 16.7	lymph node: 1.4	Cell line enhanced		HDLM-2: 3.0;Karpas-707: 2.5
ATP6V1G3	ATP6G3, Vma10	ENSG00000151418	ATPase H+ transporting V1 subunit G3	1	198523222-198540945	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA028701	Enhanced					Tissue enriched	Tissue enriched	11	kidney: 21.3	epididymis: 2.0	Cell line enhanced		fHDF/TERT166: 1.9
ATP6V1H	CGI-11, SFD, SFDalpha, SFDbeta, VMA13	ENSG00000047249	ATPase H+ transporting V1 subunit H	8	53715557-53843558	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009532, HPA023421	Approved		Approved	Actin filaments<br>Cytosol	Renal cancer:1.46e-7 (favourable), Liver cancer:7.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 126.6	Expressed in all		
ATPAF2	ATP12, Atp12p, LP3663, MGC29736	ENSG00000171953	ATP synthase mitochondrial F1 complex assembly factor 2	17	17977409-18039209	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023329, HPA059422	Supported		Enhanced	Cytosol	Renal cancer:6.00e-5 (favourable), Endometrial cancer:4.95e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.5	Expressed in all		
ATPIF1	ATPI, ATPIP, IP, MGC1167, MGC8898	ENSG00000130770	ATPase inhibitory factor 1	1	28236109-28246906	Predicted intracellular proteins	Evidence at protein level	HPA027999	Supported		Enhanced	Mitochondria	Endometrial cancer:6.38e-8 (favourable), Ovarian cancer:8.20e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 388.7	Expressed in all		
ATRIP	FLJ12343, MGC20625, MGC21482, MGC26740	ENSG00000164053	ATR interacting protein	3	48446710-48465716	Predicted intracellular proteins	Evidence at protein level	CAB033109, HPA047590	Approved		Supported	Nucleus		Not detected	Tissue enhanced		testis: 30.8	thyroid gland: 10.5	Expressed in all		
ATRX	JMS, MRX52, RAD54, XH2, XNP	ENSG00000085224	ATRX, chromatin remodeler	X	77504878-77786269	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001906, CAB009372, HPA064684, CAB068176	Supported		Supported	Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 54.4	Expressed in all		
ATXN1	ATX1, D6S504E, SCA1	ENSG00000124788	Ataxin 1	6	16299112-16761491	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008335, HPA070756	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 17.5	Cell line enhanced		U-266/70: 22.6
ATXN10	E46L, FLJ37990, SCA10	ENSG00000130638	Ataxin 10	22	45671798-45845307	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049531	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 133.9	Expressed in all		
ATXN1L	BOAT1	ENSG00000224470	Ataxin 1 like	16	71845991-71885268	Predicted intracellular proteins	Evidence at protein level	HPA062596, HPA062789			Enhanced	Nucleus	Renal cancer:5.33e-8 (favourable), Urothelial cancer:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.6	Expressed in all		
ATXN2	ATX2, SCA2, TNRC13	ENSG00000204842	Ataxin 2	12	111452214-111599676	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018295, HPA020339, HPA021146	Enhanced		Enhanced	Cytosol	Liver cancer:2.66e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.2	Expressed in all		
ATXN2L	A2D, A2lp	ENSG00000168488	Ataxin 2 like	16	28823035-28837237	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041506, HPA043391, HPA071955	Approved		Enhanced	Cytosol	Renal cancer:7.99e-7 (unfavourable), Liver cancer:9.85e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 187.6	Expressed in all		
ATXN3L	MJDL	ENSG00000123594	Ataxin 3 like	X	13318236-13320399	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024123, HPA027539	Uncertain					Not detected	Tissue enriched	37	testis: 4.9	placenta: 0.1	Not detected		
ATXN7	ADCAII, OPCA3, SCA7	ENSG00000163635	Ataxin 7	3	63864557-64003462	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034989			Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:1.22e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.7	Expressed in all		
ATXN7L1	ATXN7L4, KIAA1218, MGC33190	ENSG00000146776	Ataxin 7 like 1	7	105605067-105876604	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021448	Approved		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 16.4	Mixed		
ATXN7L2	FLJ00381, MGC46534	ENSG00000162650	Ataxin 7 like 2	1	109483479-109492804	Predicted intracellular proteins	Evidence at protein level	HPA029827, HPA054952	Uncertain		Approved	Nucleoli<br>Vesicles<br>Cytosol	Renal cancer:1.19e-8 (unfavourable), Endometrial cancer:7.65e-4 (unfavourable)	Expressed in all	Mixed			testis: 4.4	Mixed		
ATXN7L3	DKFZp761G2113	ENSG00000087152	Ataxin 7 like 3	17	44191805-44200113	Predicted intracellular proteins	Evidence at protein level	HPA064316	Supported		Approved	Nuclear speckles<br>Plasma membrane	Renal cancer:2.87e-4 (unfavourable), Liver cancer:4.03e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 83.8	Expressed in all		
ATXN7L3B	lnc-SCA7	ENSG00000253719	Ataxin 7 like 3B	12	74537827-74545430	Predicted intracellular proteins	Evidence at protein level	HPA056612			Approved	Nucleoplasm	Renal cancer:2.25e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 61.5	Expressed in all		
AUNIP	AIBp, C1orf135, MGC2603	ENSG00000127423	Aurora kinase A and ninein interacting protein	1	25831913-25859458	Predicted intracellular proteins	Evidence at protein level	HPA028730	Uncertain		Enhanced	Centrosome	Endometrial cancer:3.94e-4 (unfavourable)	Mixed	Tissue enriched	7	testis: 29.0	bone marrow: 3.8	Mixed		
AURKA	AIK, ARK1, AurA, BTAK, PPP1R47, STK15, STK6, STK7	ENSG00000087586	Aurora kinase A	20	56369389-56392337	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001454, HPA002636	Approved		Approved	Nucleus<br>Centrosome<br>Cytosol	Renal cancer:1.47e-8 (unfavourable), Endometrial cancer:9.40e-5 (unfavourable), Liver cancer:1.49e-4 (unfavourable), Pancreatic cancer:6.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 53.5	lymph node: 24.0	Expressed in all		
AURKAIP1	AIP, AKIP, FLJ20608	ENSG00000175756	Aurora kinase A interacting protein 1	1	1373730-1375495	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA031821	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			testis: 148.3	Expressed in all		
AURKB	Aik2, AIM-1, ARK2, AurB, IPL1, PPP1R48, STK12, STK5	ENSG00000178999	Aurora kinase B	17	8204733-8210600	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005862, HPA037708	Enhanced		Enhanced	Nucleoplasm<br>Midbody	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.24e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 44.4	tonsil: 33.8	Mixed		
AURKC	ARK3, AurC, STK13	ENSG00000105146	Aurora kinase C	19	57230802-57235548	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034859	Uncertain					Mixed	Tissue enriched	11	testis: 73.7	spleen: 6.9	Cell line enriched	7	NTERA-2: 39.0
AUTS2	FBRSL2, KIAA0442	ENSG00000158321	AUTS2, activator of transcription and developmental regulator	7	69598919-70793068	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000390	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skin: 21.7	Cell line enhanced		NTERA-2: 68.0;SCLC-21H: 136.5
AVEN	PDCD12	ENSG00000169857	Apoptosis and caspase activation inhibitor	15	33866227-34039176	Predicted intracellular proteins	Evidence at protein level	HPA020863	Approved		Approved	Plasma membrane<br>Actin filaments<br>Centrosome	Renal cancer:5.29e-10 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 19.1	Expressed in all		
AVIL	ADVIL, DOC6, FLJ12386, p92	ENSG00000135407	Advillin	12	57797376-57818704	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058864	Approved				Urothelial cancer:2.71e-4 (favourable)	Expressed in all	Mixed			skin: 6.7	Cell line enhanced		RH-30: 8.3
AVPI1	PP5395, VIP32, VIT32	ENSG00000119986	Arginine vasopressin induced 1	10	97677424-97687323	Predicted intracellular proteins	Evidence at protein level	HPA037649	Approved		Approved	Nucleus<br>Plasma membrane		Expressed in all	Mixed			adrenal gland: 42.1	Cell line enhanced		hTCEpi: 154.8;SK-MEL-30: 138.8;U-2197: 116.9
AXDND1	C1orf125, FLJ32940	ENSG00000162779	Axonemal dynein light chain domain containing 1	1	179365720-179554735	Predicted intracellular proteins	Evidence at protein level	HPA071114	Enhanced					Not detected	Tissue enriched	51	testis: 24.5	epididymis,fallopian tube: 0.4	Not detected		
AXIN1	PPP1R49	ENSG00000103126	Axin 1	16	287440-352673	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012987	Approved		Supported	Nucleoli<br>Vesicles	Liver cancer:3.38e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 15.5	Expressed in all		
AZI2	AZ2, FLJ21939, NAP1	ENSG00000163512	5-azacytidine induced 2	3	28315003-28349127	Predicted intracellular proteins	Evidence at protein level	HPA035258	Approved				Liver cancer:1.95e-4 (unfavourable), Urothelial cancer:2.77e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 30.7	Expressed in all		
AZIN1	OAZI, OAZIN, ODC1L	ENSG00000155096	Antizyme inhibitor 1	8	102826357-102893864	Predicted intracellular proteins	Evidence at protein level	HPA027948	Approved		Approved	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 133.4	Expressed in all		
AZIN2	ADC, KIAA1945, ODC-p, ODC1L, ODCp	ENSG00000142920	Antizyme inhibitor 2	1	33081104-33120530	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		testis: 30.1	cerebral cortex: 17.0	Cell line enhanced		SK-MEL-30: 15.1
B3GAT1	CD57, GlcAT-P, HNK-1, LEU7, NK-1	ENSG00000109956	Beta-1,3-glucuronyltransferase 1	11	134378504-134411918	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002500, CAB010893, HPA069468	Enhanced		Supported	Vesicles		Group enriched	Tissue enriched	11	cerebral cortex: 115.4	thyroid gland: 10.3	Cell line enhanced		AF22: 22.9;HMC-1: 22.4;NTERA-2: 22.3;SH-SY5Y: 9.0
B3GNT5	B3GN-T5, beta3Gn-T5	ENSG00000176597	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5	3	183253244-183298504	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017292	Uncertain		Approved	Nucleoli	Renal cancer:1.30e-7 (unfavourable), Pancreatic cancer:7.23e-6 (unfavourable), Liver cancer:5.09e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 49.1	Mixed		
B3GNTL1	B3GNT8	ENSG00000175711	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1	17	82942155-83051810	Predicted intracellular proteins	Evidence at protein level	HPA023585, HPA024547	Supported		Approved	Nucleoli		Mixed	Mixed			bone marrow: 5.0	Mixed		
B4GALT3	beta4Gal-T3	ENSG00000158850	Beta-1,4-galactosyltransferase 3	1	161171310-161177968	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010793	Approved		Supported	Golgi apparatus	Renal cancer:7.12e-7 (unfavourable), Liver cancer:5.87e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 31.1	Expressed in all		
B4GALT7	beta4Gal-T7, XGALT-1	ENSG00000027847	Beta-1,4-galactosyltransferase 7	5	177600100-177610347	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042330	Supported				Glioma:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 27.3	Expressed in all		
B9D2	MGC4093, MKS10	ENSG00000123810	B9 protein domain 2	19	41354421-41364173	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042229, HPA042618	Enhanced				Melanoma:6.39e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 16.8	Expressed in all		
BAALC		ENSG00000164929	Brain and acute leukemia, cytoplasmic	8	103140710-103230305	Predicted intracellular proteins	Evidence at protein level	HPA027132, HPA068307	Approved		Supported	Nucleus<br>Cytosol		Tissue enriched	Tissue enriched	16	cerebral cortex: 247.7	adrenal gland: 15.6	Cell line enhanced		AF22: 50.6;SCLC-21H: 32.7;SH-SY5Y: 21.7;U-87 MG: 73.6
BAAT	BAT	ENSG00000136881	Bile acid-CoA:amino acid N-acyltransferase	9	101360417-101383519	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021251, HPA021330	Supported		Uncertain	Vesicles	Renal cancer:4.24e-7 (unfavourable), Liver cancer:4.97e-4 (favourable)	Tissue enriched	Tissue enriched	16	liver: 340.4	gallbladder: 21.1	Cell line enhanced		A549: 1.8
BABAM1	C19orf62, FLJ20571, HSPC142, MERIT40, NBA1	ENSG00000105393	BRISC and BRCA1 A complex member 1	19	17267350-17281249	Predicted intracellular proteins	Evidence at protein level	HPA054386, HPA068786	Approved		Supported	Nucleus<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 84.2	Expressed in all		
BACH1	BACH-1, BTBD24	ENSG00000156273	BTB domain and CNC homolog 1	21	29194071-29630751	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034949	Approved		Approved	Nucleus<br>Cytosol	Pancreatic cancer:3.11e-5 (unfavourable), Renal cancer:7.14e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 71.9	Expressed in all		
BACH2	BTBD25	ENSG00000112182	BTB domain and CNC homolog 2	6	89926529-90296908	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051384, HPA058384	Enhanced		Supported	Nucleus<br>Cytosol		Mixed	Tissue enhanced		lymph node: 21.2	tonsil: 12.1	Cell line enhanced		Daudi: 101.9;U-698: 57.4
BAD	BBC2, BCL2L8	ENSG00000002330	BCL2 associated agonist of cell death	11	64269830-64284704	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004205, HPA028185, HPA062105	Approved		Enhanced	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 48.9	Expressed in all		
BAG1		ENSG00000107262	BCL2 associated athanogene 1	9	33247820-33264720	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002486, HPA018121	Enhanced		Supported	Nucleoplasm	Renal cancer:2.22e-16 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 174.5	Expressed in all		
BAG2		ENSG00000112208	BCL2 associated athanogene 2	6	57172326-57189833	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018862, HPA019918	Enhanced		Supported	Nucleoplasm	Liver cancer:6.72e-6 (unfavourable), Thyroid cancer:1.26e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 42.0	endometrium: 37.5	Mixed		
BAG3		ENSG00000151929	BCL2 associated athanogene 3	10	119651370-119677819	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018493, HPA020586	Enhanced		Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 98.2	Mixed		
BAG4	SODD	ENSG00000156735	BCL2 associated athanogene 4	8	38176533-38213301	Predicted intracellular proteins	Evidence at protein level	CAB013716, HPA018951	Approved					Expressed in all	Expressed in all			cerebral cortex: 27.1	Expressed in all		
BAG5		ENSG00000166170	BCL2 associated athanogene 5	14	103556544-103562831	Predicted intracellular proteins	Evidence at protein level	HPA016429	Enhanced		Supported	Vesicles	Renal cancer:1.58e-8 (favourable)	Expressed in all	Tissue enriched	6	testis: 241.5	thyroid gland: 38.5	Expressed in all		
BAG6	BAT3, D6S52E, G3	ENSG00000204463	BCL2 associated athanogene 6	6	31639028-31652705	Predicted intracellular proteins	Evidence at protein level	CAB020704, HPA045116, HPA053291	Enhanced		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 135.9	Expressed in all		
BAHCC1	BAHD2, KIAA1447	ENSG00000266074	BAH domain and coiled-coil containing 1	17	81395475-81466332	Predicted intracellular proteins	Evidence at transcript level	HPA023386, HPA076910	Uncertain		Approved	Nucleoli	Pancreatic cancer:7.38e-4 (favourable)	Expressed in all	Mixed			cerebral cortex,gallbladder: 4.8	Cell line enhanced		NB-4: 68.5;REH: 30.1;SCLC-21H: 26.5
BAHD1	KIAA0945	ENSG00000140320	Bromo adjacent homology domain containing 1	15	40439721-40468242	Predicted intracellular proteins	Evidence at protein level	HPA041196			Supported	Nucleoplasm	Renal cancer:1.29e-10 (favourable), Breast cancer:1.55e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 27.3	Expressed in all		
BAIAP2	BAP2, IRSp53	ENSG00000175866	BAI1 associated protein 2	17	81035122-81117432	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023310, HPA027421	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Urothelial cancer:7.58e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 124.7	Mixed		
BAIAP2L1	IRTKS	ENSG00000006453	BAI1 associated protein 2 like 1	7	98291651-98401068	Predicted intracellular proteins	Evidence at protein level	HPA019484, HPA021257, HPA023874, HPA029503	Enhanced		Enhanced	Plasma membrane<br>Cytosol		Mixed	Mixed			stomach: 55.2	Mixed		
BAIAP2L2	FLJ22582, pinkbar	ENSG00000128298	BAI1 associated protein 2 like 2	22	38084889-38110670	Predicted intracellular proteins	Evidence at protein level	HPA003043	Approved					Expressed in all	Tissue enhanced		duodenum: 107.2;small intestine: 97.5	gallbladder: 27.4	Cell line enhanced		RPTEC TERT1: 22.3;SK-MEL-30: 29.5;WM-115: 29.0
BAIAP3	BAP3, KIAA0734	ENSG00000007516	BAI1 associated protein 3	16	1333601-1349441	Predicted intracellular proteins	Evidence at protein level	HPA015627	Uncertain				Renal cancer:1.52e-5 (favourable)	Mixed	Tissue enhanced		adrenal gland: 24.9;cerebral cortex: 25.1;fallopian tube: 42.4	testis: 13.8	Cell line enhanced		CAPAN-2: 17.3
BANF1	BAF	ENSG00000175334	Barrier to autointegration factor 1	11	66002079-66004149	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032896, HPA039242	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 240.0	Expressed in all		
BANF2	BAF-L, BAF2, BAFL, C20orf179, dJ803K15.1	ENSG00000125888	Barrier to autointegration factor 2	20	17693672-17735871	Predicted intracellular proteins	Evidence at protein level	HPA042635	Approved					Not detected	Tissue enriched	29	testis: 125.1	pancreas: 4.3	Cell line enhanced		CACO-2: 1.5
BANK1	BANK, FLJ20706	ENSG00000153064	B-cell scaffold protein with ankyrin repeats 1	4	101411286-102074812	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037002	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Group enriched	5	appendix: 45.9;lymph node: 96.8;spleen: 77.4;thyroid gland: 21.6;tonsil: 87.2	urinary bladder: 12.9	Cell line enhanced		Daudi: 9.7;HEL: 9.5;HL-60: 7.6;U-266/70: 23.8
BANP	BEND1, DKFZp761H172, FLJ10177, FLJ20538, SMAR1, SMARBP1	ENSG00000172530	BTG3 associated nuclear protein	16	87949244-88077318	Predicted intracellular proteins	Evidence at protein level	HPA047164	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			testis: 14.1	Expressed in all		
BAP1	hucep-6, KIAA0272, UCHL2	ENSG00000163930	BRCA1 associated protein 1	3	52401013-52410350	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004322, HPA028814, HPA028815, HPA055560	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.29e-7 (favourable)	Expressed in all	Expressed in all			testis: 118.2	Expressed in all		
BARD1		ENSG00000138376	BRCA1 associated RING domain 1	2	214725646-214809711	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034106, HPA035354, HPA044864	Enhanced		Supported	Nuclear speckles		Expressed in all	Mixed			testis: 11.1	Mixed		
BARHL1		ENSG00000125492	BarH like homeobox 1	9	132582185-132590266	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA004809	Approved					Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	154	SCLC-21H: 19.7
BARHL2		ENSG00000143032	BarH like homeobox 2	1	90711539-90717237	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	37	testis: 3.6	all non-specific tissues: 0.0	Cell line enhanced		HAP1: 1.1;HEK93: 3.4
BARX1		ENSG00000131668	BARX homeobox 1	9	93951622-93955372	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055858			Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:8.16e-6 (unfavourable), Head and neck cancer:1.02e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	stomach: 11.1	testis: 1.5	Group enriched	6	AN3-CA: 27.2;HMC-1: 61.1;NTERA-2: 20.7;THP-1: 19.2
BARX2		ENSG00000043039	BARX homeobox 2	11	129375940-129452279	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB033311, HPA068414	Enhanced		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:3.06e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 103.8;salivary gland: 60.3	fallopian tube: 28.0	Cell line enriched	5	HDLM-2: 158.6
BASP1	CAP-23, CAP23, NAP-22, NAP22	ENSG00000176788	Brain abundant membrane attached signal protein 1	5	17065598-17276843	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045218, HPA050333	Enhanced		Enhanced	Plasma membrane	Renal cancer:5.25e-11 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 419.0;epididymis: 369.1	placenta: 130.6	Cell line enhanced		HeLa: 555.7;SiHa: 845.8
BATF	B-ATF, BATF1, SFA-2	ENSG00000156127	Basic leucine zipper ATF-like transcription factor	14	75522425-75547015	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059588, HPA064962	Approved		Enhanced	Nucleoplasm	Renal cancer:3.74e-9 (unfavourable), Endometrial cancer:5.35e-6 (favourable), Head and neck cancer:7.91e-5 (favourable), Urothelial cancer:4.30e-4 (favourable), Colorectal cancer:8.30e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 31.4	appendix: 26.5	Cell line enhanced		HDLM-2: 321.9;MCF7: 99.6;RT4: 64.2;U-937: 74.7
BATF2	MGC20410	ENSG00000168062	Basic leucine zipper ATF-like transcription factor 2	11	64987943-64997045	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062496	Approved		Approved	Nucleoli	Ovarian cancer:9.39e-5 (favourable), Pancreatic cancer:2.12e-4 (unfavourable)	Expressed in all	Mixed			spleen: 17.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 12.0;BJ hTERT+ SV40 Large T+ RasG12V: 19.1
BATF3	JDP1, JUNDM1, SNFT	ENSG00000123685	Basic leucine zipper ATF-like transcription factor 3	1	212686418-212699985	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Mixed			spleen: 4.6	Cell line enriched	25	HDLM-2: 359.9
BAX	BCL2L4	ENSG00000087088	BCL2 associated X, apoptosis regulator	19	48954815-48961798	Cancer-related genes, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004206, HPA027878	Approved				Liver cancer:1.63e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 80.3	Expressed in all		
BAZ1A	ACF1, hACF1, WALp1, WCRF180	ENSG00000198604	Bromodomain adjacent to zinc finger domain 1A	14	34752731-34875647	Predicted intracellular proteins	Evidence at protein level	HPA002730	Supported		Uncertain	Endoplasmic reticulum	Renal cancer:1.31e-7 (unfavourable), Liver cancer:4.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 55.7	Expressed in all		
BAZ1B	WBSCR10, WBSCR9, WSTF	ENSG00000009954	Bromodomain adjacent to zinc finger domain 1B	7	73440398-73522278	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037081, CAB037158, HPA067010	Supported		Supported	Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 54.8	Expressed in all		
BAZ2A	KIAA0314, TIP5, WALp3	ENSG00000076108	Bromodomain adjacent to zinc finger domain 2A	12	56595596-56636816	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005782, HPA063806			Enhanced	Nuclear speckles	Liver cancer:2.72e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 82.7	Expressed in all		
BAZ2B	WALp4	ENSG00000123636	Bromodomain adjacent to zinc finger domain 2B	2	159318979-159616692	Predicted intracellular proteins	Evidence at protein level	HPA019819, HPA059292	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 55.5	Mixed		
BBC3	JFY1, PUMA	ENSG00000105327	BCL2 binding component 3	19	47220822-47232766	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007752, HPA070403	Approved		Approved	Cytosol	Urothelial cancer:2.62e-5 (favourable), Endometrial cancer:1.31e-4 (favourable)	Expressed in all	Mixed			cerebral cortex,skin: 4.7	Mixed		
BBIP1	bA348N5.3, BBIP10, BBS18, NCRNA00081	ENSG00000214413	BBSome interacting protein 1	10	110898730-110919274	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055206	Uncertain					Expressed in all	Expressed in all			testis: 180.8	Expressed in all		
BBOF1	C14orf45, CCDC176	ENSG00000119636	Basal body orientation factor 1	14	74019353-74082863	Predicted intracellular proteins	Evidence at protein level	HPA003090, HPA003136	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Microtubule organizing center	Endometrial cancer:6.34e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 70.0	fallopian tube: 35.8	Mixed		
BBOX1	BBH, BBOX, G-BBH, gamma-BBH	ENSG00000129151	Gamma-butyrobetaine hydroxylase 1	11	27040725-27127809	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007600, HPA027823	Enhanced	Approved			Renal cancer:1.45e-5 (favourable), Endometrial cancer:6.65e-4 (unfavourable)	Group enriched	Tissue enriched	7	kidney: 473.0	liver: 66.1	Cell line enhanced		hTCEpi: 9.6;RPTEC TERT1: 6.3
BBS1	FLJ23590	ENSG00000174483	Bardet-Biedl syndrome 1	11	66510606-66533627	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA058283	Uncertain		Uncertain	Midbody		Mixed	Expressed in all			parathyroid gland: 65.8	Mixed		
BBS10	C12orf58, FLJ23560	ENSG00000179941	Bardet-Biedl syndrome 10	12	76344474-76348442	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047954, HPA058743	Approved		Uncertain	Nucleoplasm		Expressed in all	Mixed			cerebral cortex: 16.7	Expressed in all		
BBS12	C4orf24, FLJ35630, FLJ41559	ENSG00000181004	Bardet-Biedl syndrome 12	4	122732702-122744943	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061856	Approved				Renal cancer:9.89e-6 (favourable), Endometrial cancer:5.69e-4 (favourable)	Mixed	Mixed			thyroid gland: 16.0	Mixed		
BBS2	BBS	ENSG00000125124	Bardet-Biedl syndrome 2	16	56466836-56520283	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041315	Approved				Renal cancer:2.83e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 91.3	Expressed in all		
BBS4		ENSG00000140463	Bardet-Biedl syndrome 4	15	72686179-72738476	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039418	Approved		Supported	Cytosol	Endometrial cancer:2.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.0	Expressed in all		
BBS5	DKFZp762I194	ENSG00000163093	Bardet-Biedl syndrome 5	2	169479178-169506655	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046125	Uncertain				Pancreatic cancer:1.02e-4 (favourable)	Mixed	Mixed			testis: 12.6	Mixed		
BBS7	BBS2L1, FLJ10715	ENSG00000138686	Bardet-Biedl syndrome 7	4	121824440-121870497	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044592	Approved					Expressed in all	Mixed			cerebral cortex: 25.7	Expressed in all		
BBS9	B1, PTHB1	ENSG00000122507	Bardet-Biedl syndrome 9	7	33129244-33606068	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021289	Uncertain				Renal cancer:1.86e-4 (favourable)	Expressed in all	Mixed			testis: 24.0	Expressed in all		
BBX	HBP2, HSPC339, MDS001	ENSG00000114439	BBX, HMG-box containing	3	107522936-107811324	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006049, HPA050646	Enhanced		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 115.7	Expressed in all		
BCAR3	NSP2, SH2D3B	ENSG00000137936	Breast cancer anti-estrogen resistance 3	1	93561786-93847150	Predicted intracellular proteins	Evidence at protein level	HPA014858	Approved		Approved	Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:3.08e-7 (favourable), Lung cancer:8.92e-7 (unfavourable), Pancreatic cancer:4.38e-4 (unfavourable), Liver cancer:5.42e-4 (unfavourable), Head and neck cancer:8.41e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 32.6	Mixed		
BCAS1	AIBC1, NABC1	ENSG00000064787	Breast carcinoma amplified sequence 1	20	53936777-54070594	Predicted intracellular proteins	Evidence at protein level	CAB033558, HPA051816, HPA054745	Enhanced		Approved	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 108.7;stomach: 155.8	rectum: 80.7	Group enriched	6	RT4: 143.2;SK-BR-3: 277.9
BCAS2	DAM1, Snt309, SPF27	ENSG00000116752	BCAS2, pre-mRNA processing factor	1	114567557-114581639	Predicted intracellular proteins	Evidence at protein level	HPA067881	Enhanced		Supported	Nuclear speckles<br>Centrosome	Liver cancer:8.23e-7 (unfavourable), Prostate cancer:4.27e-4 (unfavourable), Thyroid cancer:5.24e-4 (unfavourable), Renal cancer:6.49e-4 (favourable), Ovarian cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 71.1	Expressed in all		
BCAS3	FLJ20128	ENSG00000141376	BCAS3, microtubule associated cell migration factor	17	60677453-61392838	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052409, HPA057289	Approved		Supported	Nucleoli	Pancreatic cancer:1.23e-5 (favourable), Renal cancer:1.73e-5 (favourable), Cervical cancer:2.04e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.8	Expressed in all		
BCAS4	CNOL, FLJ20495	ENSG00000124243	Breast carcinoma amplified sequence 4	20	50794894-50882676	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038812	Uncertain		Approved	Intermediate filaments<br>Cytosol	Endometrial cancer:4.87e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 25.3	tonsil: 21.0	Cell line enhanced		Daudi: 69.3;U-698: 59.0
BCAT1	BCT1	ENSG00000060982	Branched chain amino acid transaminase 1	12	24810022-24949459	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048592	Uncertain				Renal cancer:1.38e-4 (unfavourable), Head and neck cancer:3.55e-4 (unfavourable), Stomach cancer:4.95e-4 (unfavourable), Urothelial cancer:8.54e-4 (unfavourable)	Expressed in all	Mixed			placenta: 21.4	Cell line enhanced		NTERA-2: 283.1;RH-30: 298.1
BCAT2	BCAM, BCT2	ENSG00000105552	Branched chain amino acid transaminase 2	19	48795062-48811029	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054091	Enhanced				Renal cancer:3.68e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 54.1	Expressed in all		
BCCIP	BCCIPalpha, TOK-1	ENSG00000107949	BRCA2 and CDKN1A interacting protein	10	125823546-125853695	Predicted intracellular proteins	Evidence at protein level	HPA038011			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 89.5	Expressed in all		
BCDIN3D		ENSG00000186666	BCDIN3 domain containing RNA methyltransferase	12	49836039-49843129	Predicted intracellular proteins	Evidence at protein level	HPA039911	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:1.03e-5 (favourable), Urothelial cancer:1.06e-4 (favourable), Lung cancer:3.24e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 7.3	Mixed		
BCKDHA	MSU, OVD1A	ENSG00000248098	Branched chain keto acid dehydrogenase E1, alpha polypeptide	19	41397460-41425005	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036640	Supported				Renal cancer:5.33e-10 (favourable), Thyroid cancer:3.27e-5 (unfavourable), Head and neck cancer:9.37e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 56.0	Expressed in all		
BCKDK		ENSG00000103507	Branched chain ketoacid dehydrogenase kinase	16	31106107-31112791	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017995, HPA056067	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 34.3	Expressed in all		
BCL10	c-E10, CARMEN, CIPER, CLAP, mE10	ENSG00000142867	B-cell CLL/lymphoma 10	1	85266248-85277090	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB001944, HPA017925	Approved		Approved	Nucleoplasm	Liver cancer:7.21e-7 (unfavourable), Colorectal cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 30.5	Expressed in all		
BCL11A	BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856	ENSG00000119866	B-cell CLL/lymphoma 11A	2	60451167-60553567	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB014891, HPA029003	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		skin: 41.0	tonsil: 30.6	Cell line enhanced		Daudi: 24.7;MOLT-4: 28.5;REH: 32.5;U-698: 43.2
BCL11B	CTIP-2, CTIP2, hRIT1-alpha, ZNF856B	ENSG00000127152	B-cell CLL/lymphoma 11B	14	99169287-99271524	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049117	Enhanced	Supported	Approved	Nucleus<br>Nucleoli fibrillar center	Urothelial cancer:7.48e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 12.2;skin: 18.7	tonsil: 7.4	Cell line enriched	6	MOLT-4: 41.1
BCL2A1	ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1, GRS, HBPA1	ENSG00000140379	BCL2 related protein A1	15	79960889-79971446	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.77e-5 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 115.2;bone marrow: 277.0	lymph node: 62.1	Cell line enhanced		HMC-1: 76.7;SK-MEL-30: 329.3;U-138 MG: 43.6
BCL2L11	BIM, BimEL, BimL, BimS, BOD	ENSG00000153094	BCL2 like 11	2	111119378-111168447	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB026332	Approved					Expressed in all	Expressed in all			thyroid gland: 33.2	Cell line enhanced		U-266/70: 73.4
BCL2L12		ENSG00000126453	BCL2 like 12	19	49665142-49673916	Predicted intracellular proteins	Evidence at protein level	HPA020856	Approved		Approved	Cytosol	Renal cancer:8.75e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 24.6	Expressed in all		
BCL2L14	BCL-G, BCLG	ENSG00000121380	BCL2 like 14	12	12049844-12211084	Predicted intracellular proteins	Evidence at protein level	HPA040665	Enhanced		Uncertain	Cytosol		Tissue enhanced	Tissue enhanced		rectum: 16.9;testis: 24.1	small intestine: 14.2	Group enriched	5	CAPAN-2: 1.8;NTERA-2: 1.6;RT4: 1.5
BCL2L15	Bfk, C1orf178, FLJ22588	ENSG00000188761	BCL2 like 15	1	113878168-113887547	Predicted intracellular proteins	Evidence at protein level	HPA029732, HPA029733	Enhanced				Endometrial cancer:5.63e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 47.4;duodenum: 66.5;rectum: 52.2;small intestine: 64.3	stomach: 24.0	Cell line enhanced		CAPAN-2: 22.4;EFO-21: 8.1;RPTEC TERT1: 5.6
BCL2L2-PABPN1		ENSG00000258643	BCL2L2-PABPN1 readthrough	14	23306835-23325369	Cancer-related genes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA000637	Approved	Approved				Mixed	Mixed			seminal vesicle: 29.3	Mixed		
BCL3	BCL4, D19S37	ENSG00000069399	B-cell CLL/lymphoma 3	19	44747705-44760044	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002051, HPA047514	Approved		Supported	Nucleoplasm<br>Vesicles<br>Midbody	Renal cancer:3.13e-14 (unfavourable), Melanoma:3.74e-4 (favourable), Glioma:5.58e-4 (unfavourable), Breast cancer:9.67e-4 (favourable)	Expressed in all	Expressed in all			appendix: 30.1	Cell line enhanced		HDLM-2: 55.4;SiHa: 65.8
BCL6	BCL5, BCL6A, LAZ3, ZBTB27, ZNF51	ENSG00000113916	B-cell CLL/lymphoma 6	3	187721377-187745727	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000307, HPA004899, HPA050645	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.27e-9 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 113.5	Cell line enhanced		Daudi: 112.8;U-698: 150.4
BCL6B	BAZF, ZBTB28, ZNF62	ENSG00000161940	B-cell CLL/lymphoma 6B	17	7023020-7030290	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA059147, HPA075112	Uncertain		Approved	Vesicles	Head and neck cancer:8.56e-5 (favourable), Renal cancer:4.04e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 34.6	Group enriched	14	HEL: 16.2;HMC-1: 46.5;HUVEC TERT2: 79.9;TIME: 30.9
BCL7A	BCL7	ENSG00000110987	BCL tumor suppressor 7A	12	122019422-122062044	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019762	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.54e-6 (favourable), Liver cancer:2.04e-4 (unfavourable), Colorectal cancer:6.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 13.8	Cell line enhanced		Daudi: 37.3;U-698: 41.3
BCL7B		ENSG00000106635	BCL tumor suppressor 7B	7	73536356-73558002	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049943, HPA058069	Approved		Approved	Nucleoplasm	Renal cancer:4.38e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 24.7	Expressed in all		
BCL7C		ENSG00000099385	BCL tumor suppressor 7C	16	30833626-30894960	Predicted intracellular proteins	Evidence at protein level	HPA018676, HPA052654	Uncertain		Approved	Nucleoplasm	Cervical cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			ovary: 29.7	Expressed in all		
BCL9		ENSG00000116128	B-cell CLL/lymphoma 9	1	147541412-147626216	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020274	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:6.74e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 26.5	Cell line enhanced		NTERA-2: 42.4
BCL9L	DLNB11	ENSG00000186174	B-cell CLL/lymphoma 9-like	11	118893875-118925608	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA049370, HPA053421	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			placenta: 35.0	Mixed		
BCLAF1	BTF, KIAA0164	ENSG00000029363	BCL2 associated transcription factor 1	6	136256627-136289851	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006484, HPA006669, HPA027770	Enhanced		Enhanced	Nuclear speckles	Breast cancer:1.64e-4 (unfavourable), Colorectal cancer:3.44e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 88.4	Expressed in all		
BCO1	BCDO, BCDO1, BCMO, BCMO1, FLJ10730	ENSG00000135697	Beta-carotene oxygenase 1	16	81238448-81291142	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043811			Uncertain	Actin filaments<br>Microtubule organizing center		Mixed	Tissue enhanced		duodenum: 8.7;small intestine: 14.8	kidney: 3.3	Cell line enhanced		A549: 9.9;EFO-21: 7.6;HAP1: 3.2;NTERA-2: 4.4;RPTEC TERT1: 6.2
BCO2	B-DIOX-II, BCDO2, FLJ34464	ENSG00000197580	Beta-carotene oxygenase 2	11	112175467-112224699	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039825, HPA040695	Uncertain					Mixed	Tissue enhanced		heart muscle: 21.7;liver: 25.7	adrenal gland: 16.9	Cell line enhanced		CAPAN-2: 5.2;HHSteC: 10.3
BCOR	FLJ20285, KIAA1575	ENSG00000183337	BCL6 corepressor	X	40049815-40177329	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056308, HPA073591			Enhanced	Nucleus	Liver cancer:1.30e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.0	Expressed in all		
BCORL1	CXorf10, FLJ11362	ENSG00000085185	BCL6 corepressor-like 1	X	129981107-130058083	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA031775, HPA031777, HPA068568	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Endometrial cancer:2.20e-5 (unfavourable), Renal cancer:5.00e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 18.3	Cell line enhanced		HAP1: 51.8
BCR	ALL, BCR1, CML, D22S11, D22S662, PHL	ENSG00000186716	BCR, RhoGEF and GTPase activating protein	22	23179704-23318037	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010421, CAB018545, HPA038337	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.15e-10 (favourable)	Expressed in all	Mixed			cerebral cortex: 47.0	Expressed in all		
BDH1	BDH, SDR9C1	ENSG00000161267	3-hydroxybutyrate dehydrogenase 1	3	197509783-197573323	Candidate cardiovascular disease genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030947, HPA058709	Enhanced		Enhanced	Mitochondria	Renal cancer:7.12e-8 (favourable), Liver cancer:9.86e-7 (favourable), Cervical cancer:1.09e-4 (favourable)	Expressed in all	Tissue enriched	6	liver: 170.2	colon: 27.0	Cell line enhanced		U-937: 60.1
BDH2	DHRS6, FLJ13261, PRO20933, SDR15C1, UCPA-OR, UNQ6308	ENSG00000164039	3-hydroxybutyrate dehydrogenase 2	4	103079435-103099883	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036028, HPA036029	Enhanced		Supported	Cytosol	Renal cancer:4.45e-13 (favourable), Lung cancer:1.20e-4 (favourable), Endometrial cancer:5.21e-4 (favourable), Thyroid cancer:7.75e-4 (favourable)	Expressed in all	Expressed in all			kidney: 456.2	Expressed in all		
BDP1	HSA238520, KIAA1241, KIAA1689, TAF3B1, TFC5, TFIIIB150, TFIIIB90, TFNR	ENSG00000145734	B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB	5	71455615-71567820	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Mixed			thyroid gland: 1.6	Cell line enhanced		TIME: 6.5
BECN1	ATG6, VPS30	ENSG00000126581	Beclin 1	17	42810134-42833350	Predicted intracellular proteins	Evidence at protein level	CAB010143, HPA028949	Enhanced					Expressed in all	Expressed in all			rectum: 71.3	Expressed in all		
BECN2	BECN1P1	ENSG00000196289	Beclin 2	1	241957767-241959062	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BEGAIN	KIAA1446	ENSG00000183092	Brain enriched guanylate kinase associated	14	100537147-100587413	Predicted intracellular proteins	Evidence at protein level	HPA002899	Uncertain		Uncertain	Nucleus<br>Golgi apparatus<br>Cytosol		Mixed	Tissue enriched	5	cerebral cortex: 20.0	adrenal gland: 3.8	Group enriched	8	HeLa: 36.4;SH-SY5Y: 137.4
BEND2	CXorf20, MGC33653	ENSG00000177324	BEN domain containing 2	X	18162931-18220883	Predicted intracellular proteins	Evidence at protein level	HPA009420, HPA013142	Enhanced					Not detected	Tissue enriched	30	testis: 9.9	spleen: 0.3	Not detected		
BEND3	KIAA1553	ENSG00000178409	BEN domain containing 3	6	107065182-107115269	Predicted intracellular proteins	Evidence at protein level	HPA017891, HPA062067	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			testis: 2.7	Mixed		
BEND4	CCDC4, FLJ35632, FLJ43965	ENSG00000188848	BEN domain containing 4	4	42110938-42152878	Predicted intracellular proteins	Evidence at protein level	HPA036850	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Group enriched	Tissue enhanced		prostate: 5.3;testis: 17.7	lymph node: 2.5	Cell line enhanced		HAP1: 35.3;HEL: 19.3;MOLT-4: 10.7;U-698: 9.6
BEND5	C1orf165, FLJ11588	ENSG00000162373	BEN domain containing 5	1	48727523-48776969	Predicted intracellular proteins	Evidence at protein level	HPA054347, HPA058007	Uncertain				Urothelial cancer:8.30e-6 (favourable), Breast cancer:2.50e-5 (favourable), Pancreatic cancer:1.29e-4 (favourable), Lung cancer:1.29e-4 (favourable)	Mixed	Mixed			cerebral cortex: 6.0	Cell line enhanced		AF22: 3.2;HDLM-2: 10.2;MOLT-4: 3.6;REH: 5.7;SH-SY5Y: 3.1
BEND6	bA203B9.1, C6orf65, FLJ30162	ENSG00000151917	BEN domain containing 6	6	56955126-57027342	Predicted intracellular proteins	Evidence at protein level	HPA031605, HPA052973	Enhanced		Approved	Nucleus<br>Plasma membrane		Tissue enriched	Tissue enriched	6	cerebral cortex: 39.2	cervix, uterine: 6.6	Mixed		
BEND7	C10orf30, FLJ40283	ENSG00000165626	BEN domain containing 7	10	13438484-13528974	Predicted intracellular proteins	Evidence at protein level	HPA037835	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Vesicles		Mixed	Mixed			thyroid gland: 40.9	Mixed		
BEX1		ENSG00000133169	Brain expressed X-linked 1	X	103062651-103064240	Predicted intracellular proteins	Evidence at protein level	HPA045384	Approved				Renal cancer:8.16e-8 (favourable), Breast cancer:6.43e-4 (favourable), Thyroid cancer:6.88e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 505.2	parathyroid gland: 154.3	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 525.2;HBF TERT88: 582.7;HL-60: 1113.6;SCLC-21H: 490.1
BEX2	DJ79P11.1	ENSG00000133134	Brain expressed X-linked 2	X	103309346-103311046	Predicted intracellular proteins	Evidence at protein level	HPA045384	Uncertain				Renal cancer:3.05e-13 (favourable), Endometrial cancer:8.54e-7 (unfavourable), Lung cancer:1.52e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 226.5	thyroid gland: 156.9	Cell line enhanced		hTCEpi: 64.4;NTERA-2: 86.5;SCLC-21H: 148.6;SH-SY5Y: 61.1
BEX3	Bex, DXS6984E, HGR74, NADE, NGFRAP1	ENSG00000166681	Brain expressed X-linked 3	X	103376340-103378077	Predicted intracellular proteins	Evidence at protein level	HPA018886	Approved		Supported	Cytosol	Endometrial cancer:7.23e-5 (unfavourable), Renal cancer:1.28e-4 (favourable), Stomach cancer:3.48e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 605.0	Mixed		
BEX4	BEXL1, FLJ10097	ENSG00000102409	Brain expressed X-linked 4	X	103215092-103217246	Predicted intracellular proteins	Evidence at transcript level	HPA045105, HPA051935	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:2.54e-14 (favourable), Pancreatic cancer:9.41e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 323.6	Cell line enhanced		HMC-1: 164.0;K-562: 205.1
BEX5	NGFRAP1L1	ENSG00000184515	Brain expressed X-linked 5	X	102153708-102156057	Predicted intracellular proteins	Evidence at protein level	HPA059058	Enhanced				Renal cancer:1.97e-4 (favourable), Lung cancer:3.09e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 96.0	epididymis: 34.8	Cell line enhanced		HAP1: 14.7;Karpas-707: 39.3
BFSP1	CP115, CP94, filensin, LIFL-H	ENSG00000125864	Beaded filament structural protein 1	20	17493905-17569220	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040748, HPA042038	Enhanced		Supported	Plasma membrane<br>Cytosol	Endometrial cancer:1.39e-4 (favourable)	Mixed	Mixed			testis: 6.5	Cell line enhanced		RPTEC TERT1: 14.8
BFSP2	CP47, CP49, LIFL-L, phakinin	ENSG00000170819	Beaded filament structural protein 2	3	133399995-133475222	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038464, HPA062959	Enhanced		Uncertain	Plasma membrane<br>Cytosol		Tissue enriched	Not detected			lymph node: 0.4	Group enriched	7	Daudi: 1.5;U-698: 1.7
BHLHA15	bHLHa15, BHLHB8, MIST1	ENSG00000180535	Basic helix-loop-helix family member a15	7	98211427-98212979	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB034083, HPA047834	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus		Tissue enhanced	Group enriched	7	pancreas: 85.5;salivary gland: 54.0	prostate: 9.3	Group enriched	8	Karpas-707: 27.3;RPMI-8226: 50.7;U-266/70: 63.7
BHLHA9	bHLHa9, BHLHF42	ENSG00000205899	Basic helix-loop-helix family member a9	17	1270559-1271460	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062632	Uncertain					Tissue enhanced	Not detected			cerebral cortex: 0.8	Not detected		
BHLHB9	GASP3, KIAA1701, p60TRP	ENSG00000198908	Basic helix-loop-helix domain containing, class B, 9	X	102720688-102753540	Predicted intracellular proteins	Evidence at protein level	HPA000887			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 18.8	parathyroid gland: 8.4	Mixed		
BHLHE22	Beta3, BHLHB5, bHLHe22, CAGL85, TNRC20	ENSG00000180828	Basic helix-loop-helix family member e22	8	64580367-64583628	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064128, HPA064872, HPA067500	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 12.2	seminal vesicle: 3.3	Cell line enriched	15	THP-1: 52.6
BHLHE23	bA305P22.3, Beta4, BHLHB4, bHLHe23	ENSG00000125533	Basic helix-loop-helix family member e23	20	63005927-63007035	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030575	Uncertain					Tissue enriched	Not detected			testis: 0.1	Cell line enriched	22	MOLT-4: 10.3
BHLHE40	BHLHB2, bHLHe40, Clast5, DEC1, SHARP2, STRA13	ENSG00000134107	Basic helix-loop-helix family member e40	3	4979116-4985323	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028922	Uncertain		Supported	Nuclear bodies	Pancreatic cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 230.0	Cell line enhanced		HDLM-2: 406.6;U-87 MG: 191.8
BHLHE41	BHLHB3, bHLHe41, DEC2, SHARP-1, SHARP1	ENSG00000123095	Basic helix-loop-helix family member e41	12	26120026-26125127	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056035			Approved	Nucleoplasm	Renal cancer:8.73e-5 (unfavourable), Urothelial cancer:1.09e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 94.5	fallopian tube: 70.9	Cell line enhanced		RT4: 97.9;U-266/70: 39.0;U-87 MG: 42.7
BHMG1	HMGDC	ENSG00000237452	Basic helix-loop-helix and HMG-box containing 1	19	45733251-45764534	Predicted intracellular proteins	Evidence at transcript level	HPA049521	Uncertain					Tissue enriched	Tissue enriched	77	testis: 7.6	all non-specific tissues: 0.0	Cell line enhanced		Daudi: 1.0;K-562: 3.0
BHMT	BHMT1	ENSG00000145692	Betaine--homocysteine S-methyltransferase	5	79111779-79132290	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038285, HPA058310	Enhanced		Supported	Cytosol	Liver cancer:7.32e-4 (favourable)	Tissue enhanced	Group enriched	225	kidney: 788.8;liver: 563.6	urinary bladder: 3.0	Cell line enhanced		Hep G2: 2.4;NTERA-2: 1.4;SCLC-21H: 1.1
BHMT2		ENSG00000132840	Betaine--homocysteine S-methyltransferase 2	5	79069717-79089466	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044573	Enhanced					Group enriched	Group enriched	6	kidney: 362.7;liver: 238.5	epididymis: 46.2	Cell line enhanced		Hep G2: 53.5;hTEC/SVTERT24-B: 46.4;U-87 MG: 18.9
BICC1		ENSG00000122870	BicC family RNA binding protein 1	10	58513140-58831437	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045212	Enhanced		Approved	Nucleoplasm		Expressed in all	Tissue enhanced		kidney: 32.0	gallbladder: 19.2	Cell line enhanced		CACO-2: 79.9;RPTEC TERT1: 112.1
BICD1		ENSG00000151746	BICD cargo adaptor 1	12	32106835-32383633	Predicted intracellular proteins	Evidence at protein level	HPA041309	Approved		Approved	Vesicles	Renal cancer:2.33e-7 (unfavourable)	Mixed	Mixed			ovary: 29.0	Mixed		
BICD2	KIAA0699	ENSG00000185963	BICD cargo adaptor 2	9	92711363-92764812	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023013, HPA024452	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.39e-4 (favourable)	Expressed in all	Expressed in all			skin: 69.2	Expressed in all		
BICDL1	BICDR-1, CCDC64, FLJ26450	ENSG00000135127	BICD family like cargo adaptor 1	12	119989869-120094494	Predicted intracellular proteins	Evidence at protein level	HPA061116	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Stomach cancer:1.21e-5 (favourable), Renal cancer:3.93e-5 (favourable), Head and neck cancer:3.15e-4 (favourable), Cervical cancer:6.50e-4 (favourable), Liver cancer:6.84e-4 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 73.9;skin: 58.6	epididymis: 45.6	Cell line enhanced		hTCEpi: 35.3;SCLC-21H: 36.3
BICDL2	CCDC64B	ENSG00000162069	BICD family like cargo adaptor 2	16	3027682-3036926	Predicted intracellular proteins	Evidence at protein level	HPA043251	Uncertain		Approved	Intermediate filaments<br>Actin filaments<br>Cytosol	Urothelial cancer:9.04e-4 (favourable)	Mixed	Tissue enhanced		skin: 28.5	stomach: 17.2	Cell line enhanced		BEWO: 14.7;CAPAN-2: 12.6;HaCaT: 19.6;MCF7: 17.2;T-47d: 13.1
BID		ENSG00000015475	BH3 interacting domain death agonist	22	17734138-17774770	Predicted intracellular proteins	Evidence at protein level	HPA000722, CAB003771	Enhanced		Supported	Cytosol	Renal cancer:3.50e-13 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 54.5	Expressed in all		
BIN1	AMPH2, AMPHL, SH3P9	ENSG00000136717	Bridging integrator 1	2	127048027-127107355	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB001945, HPA003894, HPA005437	Enhanced		Supported	Cytosol		Expressed in all	Group enriched	7	cerebral cortex: 156.4;skeletal muscle: 724.1	adrenal gland: 61.4	Mixed		
BIN2	BRAP-1	ENSG00000110934	Bridging integrator 2	12	51281038-51324668	Predicted intracellular proteins	Evidence at protein level	HPA038666, HPA038667	Enhanced				Cervical cancer:1.33e-4 (favourable), Endometrial cancer:6.34e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 65.8	spleen: 53.1	Cell line enhanced		HEL: 72.6;HMC-1: 116.1;NB-4: 87.3;THP-1: 78.0;U-937: 59.3
BIN3		ENSG00000147439	Bridging integrator 3	8	22620418-22669148	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023769	Approved					Expressed in all	Mixed			bone marrow: 25.5	Expressed in all		
BIRC2	API1, c-IAP1, cIAP1, hiap-2, MIHB, RNF48	ENSG00000110330	Baculoviral IAP repeat containing 2	11	102347211-102378670	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005513, CAB020661	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			testis: 45.8	Mixed		
BIRC3	API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49	ENSG00000023445	Baculoviral IAP repeat containing 3	11	102317450-102339403	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002317	Enhanced	Approved	Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.66e-6 (unfavourable), Pancreatic cancer:3.03e-4 (unfavourable), Breast cancer:3.60e-4 (favourable), Colorectal cancer:9.35e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 138.1	appendix: 117.5	Cell line enhanced		CAPAN-2: 106.1;Daudi: 77.5;HDLM-2: 96.2;hTERT-HME1: 79.1
BIRC5	API4, EPR-1, survivin	ENSG00000089685	Baculoviral IAP repeat containing 5	17	78214186-78225636	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002830, CAB004270	Enhanced		Enhanced	Cytokinetic bridge	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.28e-6 (unfavourable), Lung cancer:4.49e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 26.8	bone marrow: 22.6	Mixed		
BIRC6	BRUCE	ENSG00000115760	Baculoviral IAP repeat containing 6	2	32357028-32618899	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA074409, HPA074738			Supported	Golgi apparatus<br>Vesicles<br>Mitotic spindle		Expressed in all	Mixed			parathyroid gland: 31.4	Expressed in all		
BIRC7	KIAP, ML-IAP, mliap, RNF50	ENSG00000101197	Baculoviral IAP repeat containing 7	20	63235883-63240507	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047850			Supported	Nucleus<br>Microtubule organizing center<br>Cytosol		Tissue enriched	Tissue enhanced		placenta: 9.2	skin: 2.7	Cell line enhanced		REH: 32.5;SK-MEL-30: 145.1;U-937: 33.0
BIRC8	hILP2, ILP-2	ENSG00000163098	Baculoviral IAP repeat containing 8	19	53289601-53291626	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	179	testis: 17.8	all non-specific tissues: 0.0	Not detected		
BIVM	FLJ20159	ENSG00000134897	Basic, immunoglobulin-like variable motif containing	13	102799049-102841535	Predicted intracellular proteins	Evidence at transcript level	HPA050126	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			kidney: 15.1	Mixed		
BIVM-ERCC5		ENSG00000270181	BIVM-ERCC5 readthrough	13	102799110-102876001	Predicted intracellular proteins	Evidence at protein level	HPA045845, HPA050126, HPA050374	Uncertain		Supported	Nucleoplasm		Not detected	Expressed in all			thyroid gland: 22.8	Mixed		
BLACE		ENSG00000204960	B-cell acute lymphoblastic leukemia expressed	7	155356985-155367934	Predicted intracellular proteins	Evidence at transcript level	HPA041918	Uncertain					Tissue enriched	Not detected			bone marrow: 0.3	Cell line enhanced		HL-60: 1.2;NB-4: 1.6;REH: 6.9;U-937: 2.6
BLCAP	BC10	ENSG00000166619	Bladder cancer associated protein	20	37492472-37527931	Predicted intracellular proteins	Evidence at protein level	HPA047390			Approved	Nucleoli	Urothelial cancer:7.28e-5 (favourable), Endometrial cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 224.4	Expressed in all		
BLID	BRCC2	ENSG00000259571	BH3-like motif containing, cell death inducer	11	122115354-122116215	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		hTEC/SVTERT24-B: 1.0;LHCN-M2: 1.2;U-87 MG: 1.7
BLK	MGC10442	ENSG00000136573	BLK proto-oncogene, Src family tyrosine kinase	8	11494001-11564604	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005093, HPA069571	Approved		Approved	Nucleoplasm		Mixed	Group enriched	10	appendix: 22.0;lymph node: 61.2;spleen: 40.6;tonsil: 51.4	urinary bladder: 4.3	Group enriched	6	Daudi: 99.9;REH: 39.4;RPMI-8226: 47.4;U-698: 55.4;U-87 MG: 29.9
BLM	BS, RECQ2, RECQL3	ENSG00000197299	Bloom syndrome RecQ like helicase	15	90717327-90816165	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005689	Approved		Supported	Nucleus<br>Cytosol		Mixed	Mixed			lymph node: 3.8	Mixed		
BLMH	BH	ENSG00000108578	Bleomycin hydrolase	17	30248195-30292056	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039548, HPA064307	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			skin: 139.9	Mixed		
BLNK	BASH, bca, BLNK-s, Ly57, SLP-65, SLP65	ENSG00000095585	B-cell linker	10	96191702-96271587	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009333, CAB016291, HPA038309, HPA038310	Enhanced		Supported	Plasma membrane<br>Cytoplasmic bodies	Urothelial cancer:2.67e-6 (favourable)	Expressed in all	Mixed			spleen: 69.1	Group enriched	5	Daudi: 49.2;REH: 152.1;RPMI-8226: 63.9;U-698: 171.5
BLOC1S1	BLOS1, BORCS1, GCN5L1	ENSG00000135441	Biogenesis of lysosomal organelles complex 1 subunit 1	12	55716037-55720087	Predicted intracellular proteins	Evidence at protein level	HPA021381	Approved				Ovarian cancer:2.19e-4 (favourable), Cervical cancer:2.77e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 214.5	Expressed in all		
BLOC1S2	BLOS2, BORCS2, FLJ30135, MGC10120	ENSG00000196072	Biogenesis of lysosomal organelles complex 1 subunit 2	10	100273280-100286712	Predicted intracellular proteins	Evidence at protein level	HPA048088, HPA055010	Approved					Expressed in all	Expressed in all			cerebral cortex: 101.8	Expressed in all		
BLOC1S3	BLOS3, HPS8	ENSG00000189114	Biogenesis of lysosomal organelles complex 1 subunit 3	19	45178745-45181801	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050111			Approved	Golgi apparatus	Renal cancer:3.89e-9 (unfavourable), Urothelial cancer:6.86e-4 (favourable)	Expressed in all	Mixed			skin: 12.1	Expressed in all		
BLOC1S4	BCAS4L, CNO, FLJ11230	ENSG00000186222	Biogenesis of lysosomal organelles complex 1 subunit 4	4	6716055-6717671	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043840	Approved		Approved	Vesicles<br>Cytosol	Liver cancer:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 12.7	Expressed in all		
BLOC1S5	dJ303A1.3, MU, MUTED	ENSG00000188428	Biogenesis of lysosomal organelles complex 1 subunit 5	6	8013567-8064414	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025613	Uncertain				Liver cancer:8.12e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.0	Expressed in all		
BLOC1S6	HPS9, PA, PLDN	ENSG00000104164	Biogenesis of lysosomal organelles complex 1 subunit 6	15	45587123-45615999	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039928	Approved					Expressed in all	Expressed in all			thyroid gland: 82.7	Expressed in all		
BLVRA	BLVR	ENSG00000106605	Biliverdin reductase A	7	43758680-43807342	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019709, HPA042865, HPA054322	Approved		Supported	Cytosol	Lung cancer:8.65e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 158.1	Mixed		
BLZF1	JEM-1	ENSG00000117475	Basic leucine zipper nuclear factor 1	1	169367970-169396540	Predicted intracellular proteins	Evidence at protein level	HPA025703, HPA027331, HPA067113	Supported		Supported	Nucleus<br>Golgi apparatus	Renal cancer:2.33e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 58.3	Expressed in all		
BMF	FLJ00065	ENSG00000104081	Bcl2 modifying factor	15	40087890-40108892	Predicted intracellular proteins	Evidence at protein level	HPA010120	Approved		Approved	Nucleoplasm	Head and neck cancer:1.83e-4 (favourable), Liver cancer:6.32e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 26.1	Cell line enhanced		HMC-1: 38.8
BMI1	PCGF4, RNF51	ENSG00000168283	BMI1 proto-oncogene, polycomb ring finger	10	22321211-22331484	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB011120, HPA030471, HPA030472	Supported		Approved	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol	Liver cancer:2.60e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 86.3	Expressed in all		
BMP2K	BIKe, DKFZp434K0614	ENSG00000138756	BMP2 inducible kinase	4	78776342-78916372	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026436, HPA026451, HPA026501	Approved		Supported	Nuclear speckles	Colorectal cancer:1.74e-4 (favourable)	Mixed	Mixed			testis: 32.8	Expressed in all		
BMP5		ENSG00000112175	Bone morphogenetic protein 5	6	55753645-55875564	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		placenta: 102.6	prostate: 24.1	Group enriched	9	AF22: 27.4;U-2 OS: 22.4
BMS1	BMS1L, KIAA0187	ENSG00000165733	BMS1, ribosome biogenesis factor	10	42782801-42834937	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036589, HPA043081	Uncertain		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.06e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.3	Expressed in all		
BMX	ETK, PSCTK3	ENSG00000102010	BMX non-receptor tyrosine kinase	X	15464246-15556529	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001048, CAB032495	Enhanced		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	18	epididymis: 125.0	placenta: 6.9	Cell line enriched	125	HUVEC TERT2: 295.8
BNC2	BSN2, FLJ20043	ENSG00000173068	Basonuclin 2	9	16409503-16870843	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018525, HPA059419	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		endometrium: 44.5;ovary: 39.4;smooth muscle: 48.0	fallopian tube: 19.3	Mixed		
BOD1L1	BOD1L, FAM44A, FLJ33215, KIAA1327	ENSG00000038219	Biorientation of chromosomes in cell division 1 like 1	4	13568738-13627723	Predicted intracellular proteins	Evidence at protein level	HPA036943, HPA037362, HPA041290	Approved		Enhanced	Nucleoplasm	Renal cancer:3.48e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.3	Expressed in all		
BOD1L2	BOD1P, FAM44C, MGC33608	ENSG00000228075	Biorientation of chromosomes in cell division 1 like 2	18	57147062-57150300	Predicted intracellular proteins	Evidence at transcript level	HPA036293	Uncertain					Not detected	Tissue enriched	4257	testis: 425.7	all non-specific tissues: 0.0	Not detected		
BOLA2	BOLA2A, My016	ENSG00000183336	BolA family member 2	16	29443056-29454964	Predicted intracellular proteins	Evidence at protein level	HPA045380, HPA046696	Supported		Uncertain	Nucleus		Not detected	Mixed			duodenum: 12.0	Mixed		
BOLA2B		ENSG00000169627	BolA family member 2B	16	30192934-30194306	Predicted intracellular proteins	Evidence at protein level	HPA045380, HPA046696	Supported		Uncertain	Nucleus		Mixed	Expressed in all			lymph node: 32.5	Expressed in all		
BOLA3		ENSG00000163170	BolA family member 3	2	74135398-74147994	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053162	Uncertain				Renal cancer:9.90e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 49.5	Expressed in all		
BOLL	BOULE	ENSG00000152430	Boule homolog, RNA binding protein	2	197726879-197786762	Predicted intracellular proteins	Evidence at protein level	HPA018678, HPA048813	Enhanced					Not detected	Tissue enriched	67	testis: 87.9	skeletal muscle: 1.3	Not detected		
BOP1	KIAA0124	ENSG00000261236	Block of proliferation 1	8	144262102-144291370	Predicted intracellular proteins	Evidence at protein level	HPA047869, HPA066764	Approved		Enhanced	Nucleus<br>Nucleoli	Renal cancer:2.23e-7 (unfavourable), Liver cancer:3.35e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 24.4	Expressed in all		
BORA	C13orf34, FLJ22624	ENSG00000136122	Bora, aurora kinase A activator	13	72727749-72756198	Predicted intracellular proteins	Evidence at protein level	HPA040866	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			lymph node: 10.4	Expressed in all		
BORCS5	LOH12CR1, LOH1CR12	ENSG00000165714	BLOC-1 related complex subunit 5	12	12357079-12469694	Predicted intracellular proteins	Evidence at protein level	HPA039509, HPA043627	Approved		Supported	Cytosol	Liver cancer:3.47e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex,epididymis: 7.4	Expressed in all		
BORCS6	C17orf59, FLJ20014	ENSG00000196544	BLOC-1 related complex subunit 6	17	8188333-8190907	Predicted intracellular proteins	Evidence at protein level	HPA045415, HPA060791	Uncertain		Supported	Centrosome<br>Cytosol	Pancreatic cancer:2.60e-4 (favourable), Endometrial cancer:2.78e-4 (favourable)	Expressed in all	Mixed			spleen: 7.3	Expressed in all		
BORCS7	C10orf32, FLJ40752	ENSG00000166275	BLOC-1 related complex subunit 7	10	102854223-102864961	Predicted intracellular proteins	Evidence at protein level	HPA037648	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:9.08e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 91.5	Expressed in all		
BORCS8	MEF2BNB	ENSG00000254901	BLOC-1 related complex subunit 8	19	19176903-19192591	Predicted intracellular proteins	Evidence at protein level	HPA045700	Approved		Approved	Nucleoplasm<br>Vesicles	Pancreatic cancer:4.05e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 17.3	Expressed in all		
BORCS8-MEF2B	MEF2BNB-MEF2B	ENSG00000064489	BORCS8-MEF2B readthrough	19	19145567-19192158	Predicted intracellular proteins	Evidence at protein level	HPA004734	Uncertain					Not detected	Mixed			fallopian tube: 1.4	Cell line enhanced		PC-3: 7.8;U-266/70: 6.4
BPGM		ENSG00000172331	Bisphosphoglycerate mutase	7	134646808-134679813	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016493, HPA028735	Enhanced		Approved	Nucleoli	Renal cancer:1.54e-8 (favourable), Cervical cancer:7.95e-4 (favourable)	Expressed in all	Expressed in all			placenta: 65.1	Expressed in all		
BPHL	Bph-rp, MCNAA, VACVase	ENSG00000137274	Biphenyl hydrolase like	6	3118374-3153578	Predicted intracellular proteins	Evidence at protein level	HPA036752, HPA036753	Enhanced		Supported	Mitochondria	Renal cancer:5.16e-7 (favourable), Ovarian cancer:5.97e-4 (favourable)	Expressed in all	Expressed in all			kidney: 112.2	Expressed in all		
BPNT1		ENSG00000162813	3'(2'), 5'-bisphosphate nucleotidase 1	1	220057482-220090462	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048461	Approved		Approved	Nuclear speckles	Renal cancer:6.38e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 48.6	Expressed in all		
BPTF	FAC1, FALZ, NURF301	ENSG00000171634	Bromodomain PHD finger transcription factor	17	67825524-67984378	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029069, HPA048289	Approved		Enhanced	Nucleoplasm	Renal cancer:8.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 67.6	Expressed in all		
BPY2	BPY2A, VCY2, VCY2A	ENSG00000183753	Basic charge, Y-linked, 2	Y	22973819-23005465	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	11	testis: 2.1	gallbladder,kidney: 0.1	Not detected		
BPY2B	VCY2B	ENSG00000183795	Basic charge, Y-linked, 2B	Y	24607560-24639207	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	11	testis: 2.1	gallbladder,kidney: 0.1	Not detected		
BPY2C	VCY2C	ENSG00000185894	Basic charge, Y-linked, 2C	Y	25030901-25062548	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	11	testis: 2.1	gallbladder,kidney: 0.1	Not detected		
BRAF	BRAF1	ENSG00000157764	B-Raf proto-oncogene, serine/threonine kinase	7	140719327-140924764	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001328, CAB004552, HPA071048	Approved		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 41.8	Expressed in all		
BRAP	BRAP2, IMP, RNF52	ENSG00000089234	BRCA1 associated protein	12	111642146-111685986	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA040357, HPA058820	Approved		Supported	Nuclear membrane<br>Cytosol	Liver cancer:7.65e-6 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 120.9	bone marrow: 21.3	Expressed in all		
BRAT1	BAAT1, C7orf27, MGC22916	ENSG00000106009	BRCA1 associated ATM activator 1	7	2537877-2555727	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029455, HPA076508	Approved		Supported	Nucleoplasm	Renal cancer:3.90e-4 (unfavourable), Liver cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 14.9	Expressed in all		
BRCA1	BRCC1, FANCS, PPP1R53, RNF53	ENSG00000012048	BRCA1, DNA repair associated	17	43044295-43170245	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB001946, HPA034966, HPA057371	Enhanced					Expressed in all	Mixed			testis: 23.9	Expressed in all		
BRCA2	BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11	ENSG00000139618	BRCA2, DNA repair associated	13	32315474-32400266	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026815	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 5.2	bone marrow: 4.1	Mixed		
BRCC3	BRCC36, C6.1A, CXorf53	ENSG00000185515	BRCA1/BRCA2-containing complex subunit 3	X	155071420-155123074	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048737			Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 21.2	Expressed in all		
BRD1	BRL, BRPF2	ENSG00000100425	Bromodomain containing 1	22	49773283-49827512	Predicted intracellular proteins	Evidence at protein level	HPA000807, HPA001063	Approved		Supported	Nuclear speckles		Expressed in all	Expressed in all			testis: 58.5	Expressed in all		
BRD2	BRD2-IT1, D6S113E, FSRG1, KIAA9001, NAT, RING3	ENSG00000204256	Bromodomain containing 2	6	32968660-32981505	Predicted intracellular proteins	Evidence at protein level	HPA042816	Approved		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			thyroid gland: 101.8	Expressed in all		
BRD3	KIAA0043, ORFX, RING3L	ENSG00000169925	Bromodomain containing 3	9	134030305-134068535	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051830	Approved		Approved	Nuclear bodies	Renal cancer:2.71e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.6	Expressed in all		
BRD4	CAP, HUNK1, HUNKI, MCAP	ENSG00000141867	Bromodomain containing 4	19	15235519-15332545	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015055, HPA061646, CAB068177, CAB068178	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			placenta: 41.9	Expressed in all		
BRD7	BP75, CELTIX1	ENSG00000166164	Bromodomain containing 7	16	50313487-50368934	Predicted intracellular proteins	Evidence at protein level	HPA042389, CAB046458, HPA060171	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.55e-4 (favourable), Melanoma:5.38e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 106.6	Expressed in all		
BRD8	p120, SMAP	ENSG00000112983	Bromodomain containing 8	5	138139766-138178986	Predicted intracellular proteins	Evidence at protein level	HPA001841	Supported		Approved	Nucleoplasm<br>Mitochondria	Liver cancer:1.09e-6 (unfavourable), Renal cancer:7.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 148.4	Expressed in all		
BRD9	FLJ13441	ENSG00000028310	Bromodomain containing 9	5	850291-892824	Predicted intracellular proteins	Evidence at protein level	HPA021465, HPA023197	Uncertain		Approved	Nucleoplasm	Liver cancer:5.88e-7 (unfavourable), Renal cancer:2.37e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 14.7	Expressed in all		
BRDT	BRD6, CT9	ENSG00000137948	Bromodomain testis associated	1	91949371-92014426	Predicted intracellular proteins	Evidence at protein level	CAB012237	Approved					Group enriched	Tissue enriched	124	testis: 235.9	bone marrow: 1.9	Cell line enriched	33	BEWO: 19.0
BRE	BRCC4, BRCC45	ENSG00000158019	Brain and reproductive organ-expressed (TNFRSF1A modulator)	2	27889941-28338901	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA017926	Approved		Supported	Cytosol	Liver cancer:6.33e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 189.5	Expressed in all		
BRF2	BRFU, FLJ11052, TFIIIB50	ENSG00000104221	BRF2, RNA polymerase III transcription initiation factor subunit	8	37843268-37849904	Predicted intracellular proteins	Evidence at protein level	CAB019269, HPA023378	Enhanced		Approved	Nucleoli		Expressed in all	Expressed in all			ovary: 16.1	Expressed in all		
BRIP1	BACH1, FANCJ, OF	ENSG00000136492	BRCA1 interacting protein C-terminal helicase 1	17	61681266-61863521	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005474	Approved		Supported	Nucleus<br>Nuclear membrane	Colorectal cancer:3.45e-5 (favourable), Head and neck cancer:3.62e-4 (favourable)	Mixed	Tissue enhanced		testis: 14.4	bone marrow: 5.0	Cell line enhanced		MCF7: 77.7
BRIX1	BRIX, BXDC2, FLJ11100	ENSG00000113460	BRX1, biogenesis of ribosomes	5	34915376-34925996	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039614	Approved		Enhanced	Nucleoli	Renal cancer:3.07e-9 (unfavourable), Liver cancer:4.11e-8 (unfavourable), Endometrial cancer:1.10e-5 (unfavourable), Breast cancer:2.18e-4 (unfavourable), Ovarian cancer:6.34e-4 (favourable)	Expressed in all	Expressed in all			placenta: 27.6	Expressed in all		
BRK1	C3orf10, HSPC300, MDS027	ENSG00000254999	BRICK1, SCAR/WAVE actin nucleating complex subunit	3	10115592-10127190	Predicted intracellular proteins	Evidence at protein level	HPA060391			Approved	Nuclear speckles<br>Cell Junctions	Liver cancer:5.76e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 225.0	Expressed in all		
BRMS1	DKFZP564A063	ENSG00000174744	Breast cancer metastasis suppressor 1	11	66337333-66345125	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010824, HPA019637	Approved		Approved	Centrosome	Liver cancer:6.74e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 36.3	Expressed in all		
BRMS1L	BRMS1, FLJ39177, MGC11296	ENSG00000100916	Breast cancer metastasis-suppressor 1-like	14	35826318-35932325	Predicted intracellular proteins	Evidence at protein level	HPA046623	Uncertain		Supported	Nucleoplasm	Urothelial cancer:6.87e-6 (unfavourable), Renal cancer:6.55e-5 (favourable), Liver cancer:1.34e-4 (unfavourable), Breast cancer:5.78e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 24.6	Expressed in all		
BROX	C1orf58, FLJ32421	ENSG00000162819	BRO1 domain and CAAX motif containing	1	222712553-222735196	Predicted intracellular proteins	Evidence at protein level	HPA031445	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 46.7	Expressed in all		
BRPF1	BR140	ENSG00000156983	Bromodomain and PHD finger containing 1	3	9731729-9748018	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003359	Enhanced		Approved	Plasma membrane<br>Cytosol	Liver cancer:3.20e-5 (unfavourable), Prostate cancer:5.28e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.3	Expressed in all		
BRPF3	KIAA1286	ENSG00000096070	Bromodomain and PHD finger containing 3	6	36196744-36232790	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022787	Uncertain		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			testis: 38.1	Expressed in all		
BRWD1	C21orf107, DCAF19, FLJ11315, N143, WDR9	ENSG00000185658	Bromodomain and WD repeat domain containing 1	21	39184176-39321559	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030943, HPA030944, HPA030945, CAB034184	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 77.7	Expressed in all		
BRWD3	FLJ38568, MRX93	ENSG00000165288	Bromodomain and WD repeat domain containing 3	X	80670854-80809688	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA012802	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 8.6	Mixed		
BSDC1	FLJ10276, RP4-811H24.7	ENSG00000160058	BSD domain containing 1	1	32365103-32394731	Predicted intracellular proteins	Evidence at protein level	HPA031358, HPA031360	Approved		Enhanced	Golgi apparatus	Head and neck cancer:8.82e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 113.4	Expressed in all		
BSN	ZNF231	ENSG00000164061	Bassoon presynaptic cytomatrix protein	3	49554489-49671545	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034757	Approved					Mixed	Tissue enriched	7	cerebral cortex: 28.2	testis: 4.2	Cell line enhanced		K-562: 1.7;SCLC-21H: 5.1;SH-SY5Y: 2.9
BSPRY	FLJ20150	ENSG00000119411	B-box and SPRY domain containing	9	113349541-113371233	Predicted intracellular proteins	Evidence at protein level	HPA042889	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.56e-14 (favourable)	Mixed	Tissue enriched	5	parathyroid gland: 254.8	thyroid gland: 50.4	Cell line enhanced		A-431: 36.1;CAPAN-2: 22.7;MCF7: 46.9;RPMI-8226: 22.3;SK-BR-3: 22.3;T-47d: 28.3
BSX	BSX1	ENSG00000188909	Brain specific homeobox	11	122977570-122981720	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA015654	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
BTAF1	MOT1, TAF-172, TAF(II)170, TAF172, TAFII170	ENSG00000095564	B-TFIID TATA-box binding protein associated factor 1	10	91923769-92030325	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA070682			Approved	Nucleoplasm<br>Vesicles	Renal cancer:4.04e-5 (unfavourable), Head and neck cancer:5.07e-4 (favourable)	Expressed in all	Expressed in all			skin: 59.8	Expressed in all		
BTBD1		ENSG00000064726	BTB domain containing 1	15	83016422-83067354	Predicted intracellular proteins	Evidence at protein level	HPA067671	Enhanced				Renal cancer:6.21e-7 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 109.7	Expressed in all		
BTBD10	GMRP-1, GMRP1, MGC13007	ENSG00000148925	BTB domain containing 10	11	13388001-13463297	Predicted intracellular proteins	Evidence at protein level	HPA046777	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:1.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 67.8	Expressed in all		
BTBD11	ABTB2B, FLJ33957	ENSG00000151136	BTB domain containing 11	12	107318413-107659642	Predicted intracellular proteins	Evidence at protein level	HPA055898			Approved	Nucleoplasm		Mixed	Tissue enhanced		parathyroid gland: 130.5	thyroid gland: 31.7	Cell line enhanced		A549: 22.8;MOLT-4: 14.0
BTBD16	C10orf87, Em:AC061711.1, FLJ25359	ENSG00000138152	BTB domain containing 16	10	122271306-122338162	Predicted intracellular proteins	Evidence at protein level	HPA040529, HPA057638	Uncertain		Uncertain	Nucleoli<br>Cytosol	Renal cancer:1.50e-4 (unfavourable)	Tissue enriched	Group enriched	7	skin: 9.9;testis: 14.2;urinary bladder: 19.0	liver: 2.1	Cell line enriched	9	RT4: 26.9
BTBD18		ENSG00000233436	BTB domain containing 18	11	57743514-57751781	Predicted intracellular proteins	Evidence at protein level	HPA049325	Uncertain					Not detected	Tissue enriched	8	testis: 4.0	skin: 0.5	Not detected		
BTBD19		ENSG00000222009	BTB domain containing 19	1	44808482-44815585	Predicted intracellular proteins	Evidence at protein level	HPA042633	Uncertain				Renal cancer:4.18e-8 (unfavourable)	Mixed	Mixed			endometrium: 4.5	Cell line enhanced		TIME: 9.7
BTBD2		ENSG00000133243	BTB domain containing 2	19	1985438-2034881	Predicted intracellular proteins	Evidence at protein level						Liver cancer:8.71e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.9	Expressed in all		
BTBD3	dJ742J24.1, KIAA0952	ENSG00000132640	BTB domain containing 3	20	11890723-11926609	Predicted intracellular proteins	Evidence at protein level	HPA041424, HPA042048	Uncertain		Supported	Vesicles	Liver cancer:2.51e-5 (unfavourable), Lung cancer:6.94e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 60.1	Cell line enhanced		AN3-CA: 223.4;HeLa: 128.7
BTBD6	BDPL	ENSG00000184887	BTB domain containing 6	14	105248490-105251093	Predicted intracellular proteins	Evidence at protein level	HPA031355	Approved		Approved	Nucleoplasm	Renal cancer:6.51e-5 (favourable), Breast cancer:1.11e-4 (favourable), Pancreatic cancer:2.25e-4 (favourable)	Expressed in all	Expressed in all			testis: 73.4	Mixed		
BTBD7	FLJ10648, FUP1	ENSG00000011114	BTB domain containing 7	14	93237550-93333092	Predicted intracellular proteins	Evidence at protein level	HPA049926, HPA053406	Uncertain		Approved	Focal adhesion sites	Renal cancer:1.69e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 18.6	Expressed in all		
BTBD8		ENSG00000189195	BTB domain containing 8	1	92080305-92184725	Predicted intracellular proteins	Evidence at transcript level	HPA024216, HPA035311, HPA035312	Uncertain		Approved	Nucleoplasm		Not detected	Mixed			parathyroid gland: 3.7	Cell line enhanced		ASC TERT1: 2.1;BEWO: 2.4
BTBD8		ENSG00000284413	BTB domain containing 8	1	92080305-92147840	Predicted intracellular proteins	Evidence at transcript level	HPA035311, HPA035312	Uncertain		Approved	Nucleoplasm			Not detected			lung: 0.3	Not detected		
BTBD9	dJ322I12.1, KIAA1880	ENSG00000183826	BTB domain containing 9	6	38168451-38640148	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041930	Uncertain		Approved	Nucleoplasm	Renal cancer:4.20e-13 (favourable)	Expressed in all	Mixed			parathyroid gland: 38.3	Expressed in all		
BTF3	BTF3a, BTF3b, NACB	ENSG00000145741	Basic transcription factor 3	5	73498408-73505635	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013007, HPA056420	Approved		Supported	Cytosol		Expressed in all	Expressed in all			ovary: 1442.8	Expressed in all		
BTF3L4	MGC23908	ENSG00000134717	Basic transcription factor 3 like 4	1	52056125-52090716	Predicted intracellular proteins	Evidence at protein level	HPA067026	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:6.73e-8 (unfavourable), Renal cancer:4.43e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 72.6	Expressed in all		
BTG1	APRO2	ENSG00000133639	BTG anti-proliferation factor 1	12	92140278-92145897	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005972			Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.95e-7 (unfavourable), Breast cancer:4.36e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 261.0	Expressed in all		
BTG2	APRO1, MGC126063, MGC126064, PC3, TIS21	ENSG00000159388	BTG anti-proliferation factor 2	1	203305491-203309602	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002355	Uncertain		Approved	Nucleoplasm<br>Vesicles	Breast cancer:8.53e-4 (favourable)	Expressed in all	Expressed in all			ovary: 666.8	Cell line enhanced		HMC-1: 140.5;U-266/70: 189.1
BTG3	ANA, APRO4, tob55	ENSG00000154640	BTG anti-proliferation factor 3	21	17593653-17612947	Predicted intracellular proteins	Evidence at protein level	HPA018400	Approved				Liver cancer:1.16e-4 (unfavourable), Renal cancer:7.37e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 129.1	Mixed		
BTG4	APRO3, PC3B	ENSG00000137707	BTG anti-proliferation factor 4	11	111467526-111512354	Predicted intracellular proteins	Evidence at transcript level	HPA057157			Approved	Endoplasmic reticulum<br>Golgi apparatus		Not detected	Tissue enriched	18	testis: 47.5	fallopian tube: 2.6	Cell line enhanced		CACO-2: 2.8;Karpas-707: 3.2;U-266/70: 2.3
BTK	AGMX1, ATK, IMD1, PSCTK1, XLA	ENSG00000010671	Bruton tyrosine kinase	X	101349447-101390796	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001198, HPA002028, CAB016689	Enhanced		Supported	Vesicles		Expressed in all	Tissue enhanced		lymph node: 65.2;tonsil: 70.8	spleen: 52.7	Cell line enhanced		Daudi: 147.2;HEL: 256.7;HMC-1: 868.2
BTRC	beta-TrCP1, betaTrCP, bTrCP, bTrCP1, FBXW1A, Fwd1	ENSG00000166167	Beta-transducin repeat containing E3 ubiquitin protein ligase	10	101354033-101557321	Predicted intracellular proteins	Evidence at protein level	HPA031156, CAB032986	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 34.0	Expressed in all		
BUB1	BUB1A, BUB1L, hBUB1	ENSG00000169679	BUB1 mitotic checkpoint serine/threonine kinase	2	110637698-110678114	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006123			Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.03e-5 (unfavourable), Pancreatic cancer:2.37e-5 (unfavourable), Endometrial cancer:3.65e-4 (unfavourable), Lung cancer:3.94e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 69.5	lymph node: 24.1	Mixed		
BUB1B	Bub1A, BUBR1, MAD3L, SSK1	ENSG00000156970	BUB1 mitotic checkpoint serine/threonine kinase B	15	40161023-40221136	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008419			Supported	Cytosol	Liver cancer:7.43e-6 (unfavourable), Pancreatic cancer:1.79e-4 (unfavourable), Lung cancer:3.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 40.3	lymph node: 14.9	Mixed		
BUB1B-PAK6		ENSG00000259288	BUB1B-PAK6 readthrough	15	40217428-40276396	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA031124	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions		Not detected	Not detected			cerebral cortex: 0.1	Not detected		
BUB3	BUB3L	ENSG00000154473	BUB3, mitotic checkpoint protein	10	123154277-123170467	Predicted intracellular proteins	Evidence at protein level	HPA003601, CAB037075	Supported		Enhanced	Nucleoplasm	Renal cancer:3.81e-7 (unfavourable), Liver cancer:4.45e-5 (unfavourable), Cervical cancer:2.04e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 112.0	Expressed in all		
BUD13	Cwc26, fSAP71, MGC13125	ENSG00000137656	BUD13 homolog	11	116748170-116772988	Predicted intracellular proteins	Evidence at protein level	HPA038340, HPA038341	Enhanced		Enhanced	Nucleus	Liver cancer:5.07e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 39.5	Expressed in all		
BUD31	Cwc14, EDG-2, EDG2, fSAP17, G10, YCR063W	ENSG00000106245	BUD31 homolog	7	99408641-99419616	Predicted intracellular proteins	Evidence at protein level	HPA028943	Approved		Approved	Nucleus<br>Microtubules<br>Centrosome	Renal cancer:9.66e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 97.5	Expressed in all		
BX004987.1		ENSG00000278704		Unmapped	56140-58376	Predicted intracellular proteins	Evidence at transcript level								Mixed			testis: 3.3	Cell line enhanced		K-562: 22.1;U-2 OS: 18.2
BX072566.1		ENSG00000277630	Uncharacterized protein LOC100288966 	Unmapped	108007-139659	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain						Tissue enriched	74	testis: 7.4	all non-specific tissues: 0.0	Not detected		
BYSL		ENSG00000112578	Bystin like	6	41921188-41933046	Predicted intracellular proteins	Evidence at protein level	HPA031217, HPA031219	Enhanced		Enhanced	Nucleus<br>Nucleoli	Renal cancer:2.15e-8 (unfavourable), Liver cancer:6.43e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 11.7	Expressed in all		
BZW1	BZAP45, KIAA0005	ENSG00000082153	Basic leucine zipper and W2 domains 1	2	200810594-200827338	Predicted intracellular proteins	Evidence at protein level	HPA047288, HPA053272	Uncertain		Approved	Vesicles	Cervical cancer:4.28e-4 (unfavourable), Lung cancer:5.10e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 310.2	Expressed in all		
BZW2	HSPC028, MST017, MSTP017	ENSG00000136261	Basic leucine zipper and W2 domains 2	7	16646131-16706523	Predicted intracellular proteins	Evidence at protein level	HPA022813, HPA026709	Approved		Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Liver cancer:7.86e-8 (unfavourable), Renal cancer:6.01e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 173.5	Expressed in all		
C10orf105	FLJ00245	ENSG00000214688	Chromosome 10 open reading frame 105	10	71711702-71737824	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		cerebral cortex: 2.3;spleen: 3.2	testis: 1.4	Cell line enriched	6	BJ hTERT+: 2.6
C10orf107	bA63A2.1, Em:AC022398.2, MGC44593	ENSG00000183346	Chromosome 10 open reading frame 107	10	61662961-61766766	Predicted intracellular proteins	Evidence at protein level	HPA041398	Enhanced		Uncertain	Nucleoplasm<br>Centrosome<br>Cytosol	Endometrial cancer:1.79e-4 (favourable), Glioma:3.99e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 44.2;testis: 30.5	parathyroid gland: 12.6	Group enriched	6	MOLT-4: 21.5;SH-SY5Y: 6.0
C10orf11	CDA017, OCA7	ENSG00000148655	Chromosome 10 open reading frame 11	10	75431453-76560167	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047446, HPA050419	Approved		Supported	Nucleus<br>Cytosol		Mixed	Mixed			epididymis: 73.4	Cell line enhanced		Hep G2: 31.4;NB-4: 42.2;SK-MEL-30: 71.9;THP-1: 33.2;U-937: 34.6
C10orf113	bA165O3.1	ENSG00000204683	Chromosome 10 open reading frame 113	10	21125763-21146559	Predicted intracellular proteins	Evidence at transcript level	HPA037013	Uncertain					Not detected	Tissue enriched	13	testis: 1.7	gallbladder,salivary gland: 0.1	Not detected		
C10orf120	bA318C4.1	ENSG00000183559	Chromosome 10 open reading frame 120	10	122697709-122699822	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	375	testis: 49.4	epididymis: 0.1	Not detected		
C10orf142		ENSG00000277288	Chromosome 10 open reading frame 142	10	44292569-44294649	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 2.3	spleen: 1.5	Cell line enhanced		RPMI-8226: 1.6;U-2197: 5.2;U-87 MG: 2.0
C10orf53	Em:AC069546.1	ENSG00000178645	Chromosome 10 open reading frame 53	10	49679651-49710261	Predicted intracellular proteins	Evidence at protein level	HPA037951	Enhanced					Not detected	Tissue enriched	60	testis: 43.5	fallopian tube: 0.7	Not detected		
C10orf55	bA417O11.3	ENSG00000222047	Chromosome 10 open reading frame 55	10	73909969-73922777	Predicted intracellular proteins	Evidence at protein level	HPA045739	Uncertain		Approved	Nucleus		Mixed	Not detected			epididymis,kidney: 0.4	Cell line enhanced		A-431: 2.4;CAPAN-2: 2.3;HaCaT: 2.3;RPTEC TERT1: 3.0
C10orf62	bA548K23.1	ENSG00000203942	Chromosome 10 open reading frame 62	10	97589727-97590934	Predicted intracellular proteins	Evidence at protein level	HPA072947	Enhanced					Not detected	Tissue enriched	1082	testis: 244.6	kidney: 0.2	Not detected		
C10orf67	bA215C7.4, C10orf115, LINC01552, MGC46732	ENSG00000179133	Chromosome 10 open reading frame 67	10	23201916-23344845	Predicted intracellular proteins	Evidence at transcript level	HPA038130, HPA038131	Approved		Approved	Nucleoplasm<br>Nucleoli<br>Nuclear speckles		Not detected	Tissue enhanced		fallopian tube: 7.5;testis: 17.4	lung: 4.0	Cell line enhanced		HaCaT: 2.1;SiHa: 4.2
C10orf71	FLJ45913	ENSG00000177354	Chromosome 10 open reading frame 71	10	49299193-49327487	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	34	heart muscle: 28.8;parathyroid gland: 74.8;skeletal muscle: 97.7	prostate: 1.9	Group enriched	17	K-562: 6.2;RH-30: 9.6
C10orf76	FLJ13114	ENSG00000120029	Chromosome 10 open reading frame 76	10	101845599-102056193	Predicted intracellular proteins	Evidence at protein level	HPA050913, HPA053580	Approved		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 26.4	Mixed		
C10orf82	Em:AC016825.4, MGC33547	ENSG00000165863	Chromosome 10 open reading frame 82	10	116663696-116670264	Predicted intracellular proteins	Evidence at transcript level	HPA043022			Approved	Mitochondria		Mixed	Tissue enriched	25	testis: 111.7	ovary: 4.4	Cell line enhanced		Hep G2: 1.7;NTERA-2: 1.3;T-47d: 3.5
C10orf88	Em:AC073585.5, FLJ13490	ENSG00000119965	Chromosome 10 open reading frame 88	10	122930903-122954403	Predicted intracellular proteins	Evidence at protein level	HPA039681, HPA040991	Enhanced				Liver cancer:2.05e-5 (unfavourable)	Expressed in all	Mixed			testis: 14.3	Expressed in all		
C10orf90	bA422P15.2, FATS, FLJ32938	ENSG00000154493	Chromosome 10 open reading frame 90	10	126424997-126670446	Predicted intracellular proteins	Evidence at protein level	HPA038648, HPA057599	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enriched	Group enriched	12	breast: 5.6;cerebral cortex: 15.3;salivary gland: 4.3;testis: 12.1	adipose tissue,skin: 0.7	Group enriched	9	SK-MEL-30: 94.3;U-2197: 33.5;U-266/84: 18.9;U-87 MG: 36.2;WM-115: 29.4
C11orf16		ENSG00000176029	Chromosome 11 open reading frame 16	11	8920076-8933006	Predicted intracellular proteins	Evidence at transcript level						Endometrial cancer:3.32e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 20.6;lung: 4.1	testis: 2.5	Not detected		
C11orf21		ENSG00000110665	Chromosome 11 open reading frame 21	11	2295645-2303049	Predicted intracellular proteins	Evidence at transcript level	HPA037607	Approved					Mixed	Tissue enhanced		bone marrow: 32.4;spleen: 17.6	lymph node: 15.9	Cell line enhanced		HEL: 45.5;HL-60: 15.4;NB-4: 11.2;U-937: 16.8
C11orf40	NOV1	ENSG00000171987	Chromosome 11 open reading frame 40	11	4571423-4577820	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.2	Not detected		
C11orf42	MGC34805	ENSG00000180878	Chromosome 11 open reading frame 42	11	6205566-6211132	Predicted intracellular proteins	Evidence at protein level	HPA063404	Enhanced					Not detected	Tissue enriched	11	testis: 20.3	skin: 1.8	Cell line enhanced		HEK93: 1.2;HeLa: 1.0
C11orf49	FLJ22210, MGC4707	ENSG00000149179	Chromosome 11 open reading frame 49	11	46936689-47164385	Predicted intracellular proteins	Evidence at protein level	HPA040051, HPA040280	Uncertain		Approved	Nuclear speckles	Liver cancer:2.18e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 57.2	Expressed in all		
C11orf52	FLJ25219, MGC14839	ENSG00000149300	Chromosome 11 open reading frame 52	11	111918032-111926872	Predicted intracellular proteins	Evidence at protein level	HPA038387, HPA038388	Uncertain		Enhanced	Cell Junctions		Not detected	Mixed			kidney: 44.9	Cell line enhanced		CAPAN-2: 19.2;RPTEC TERT1: 20.1;T-47d: 70.7
C11orf53	MGC50104	ENSG00000150750	Chromosome 11 open reading frame 53	11	111245805-111286401	Predicted intracellular proteins	Evidence at transcript level	HPA056128	Uncertain					Mixed	Tissue enhanced		testis: 4.7	gallbladder: 2.2	Not detected		
C11orf54	PTD012	ENSG00000182919	Chromosome 11 open reading frame 54	11	93741591-93764749	Predicted intracellular proteins	Evidence at protein level	HPA040088, HPA040511	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.06e-6 (favourable)	Expressed in all	Expressed in all			kidney: 539.3	Expressed in all		
C11orf57	FLJ10726	ENSG00000150776	Chromosome 11 open reading frame 57	11	112074086-112085150	Predicted intracellular proteins	Evidence at protein level	HPA039493, HPA039892	Approved		Supported	Cytosol	Liver cancer:2.70e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 26.7	Expressed in all		
C11orf58	SMAP	ENSG00000110696	Chromosome 11 open reading frame 58	11	16613132-16756881	Predicted intracellular proteins	Evidence at protein level	HPA036591, HPA076406	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum	Liver cancer:5.84e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 217.7	Expressed in all		
C11orf63	FLJ23554	ENSG00000109944	Chromosome 11 open reading frame 63	11	122882528-122959798	Predicted intracellular proteins	Evidence at protein level	HPA039612, HPA040344, HPA077658, HPA077748	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:7.94e-5 (favourable), Thyroid cancer:2.58e-4 (unfavourable), Renal cancer:8.77e-4 (favourable)	Mixed	Tissue enhanced		testis: 63.8	parathyroid gland: 14.8	Mixed		
C11orf65	MGC33948	ENSG00000166323	Chromosome 11 open reading frame 65	11	108308519-108467531	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	26	testis: 94.0	epididymis: 3.6	Mixed		
C11orf68	BLES03, P5326	ENSG00000175573	Chromosome 11 open reading frame 68	11	65916808-65919117	Predicted intracellular proteins	Evidence at protein level	HPA045938	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:5.02e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 49.8	Expressed in all		
C11orf70	MGC13040	ENSG00000137691	Chromosome 11 open reading frame 70	11	102047443-102084560	Predicted intracellular proteins	Evidence at protein level	HPA038585	Enhanced		Approved	Centrosome		Mixed	Tissue enhanced		fallopian tube: 46.5;testis: 54.7	epididymis: 13.1	Mixed		
C11orf71	FLJ20010	ENSG00000180425	Chromosome 11 open reading frame 71	11	114391443-114400511	Predicted intracellular proteins	Evidence at protein level	HPA063943, HPA074787			Supported	Nucleoplasm	Renal cancer:7.01e-9 (favourable), Endometrial cancer:6.94e-4 (favourable)	Expressed in all	Expressed in all			testis: 64.0	Mixed		
C11orf74	FLJ38678, HEPIS, NWC	ENSG00000166352	Chromosome 11 open reading frame 74	11	36594493-36659290	Predicted intracellular proteins	Evidence at protein level	HPA044880	Uncertain		Approved	Aggresome<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 177.5	Mixed		
C11orf84		ENSG00000168005	Chromosome 11 open reading frame 84	11	63813388-63827718	Predicted intracellular proteins	Evidence at protein level	HPA040128, HPA050313	Uncertain		Approved	Nuclear speckles	Liver cancer:1.53e-5 (unfavourable), Renal cancer:5.42e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 42.6	Expressed in all		
C11orf86	FLJ22675	ENSG00000173237	Chromosome 11 open reading frame 86	11	66975277-66977004	Predicted intracellular proteins	Evidence at transcript level	HPA039348	Uncertain				Renal cancer:1.02e-5 (unfavourable), Pancreatic cancer:6.97e-5 (unfavourable), Lung cancer:8.97e-4 (unfavourable)	Mixed	Group enriched	7	duodenum: 68.2;small intestine: 70.9	colon: 10.3	Cell line enriched	5	SiHa: 26.4
C11orf88	FLJ46266	ENSG00000183644	Chromosome 11 open reading frame 88	11	111514785-111537031	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Group enriched	5	fallopian tube: 141.7;testis: 39.5	lung: 17.8	Cell line enhanced		CACO-2: 1.3;Karpas-707: 1.2
C11orf91		ENSG00000205177	Chromosome 11 open reading frame 91	11	33698261-33700801	Predicted intracellular proteins	Evidence at protein level	HPA047064, HPA050487	Uncertain		Supported	Vesicles		Not detected	Tissue enhanced		adipose tissue: 5.8;gallbladder: 7.7;testis: 6.9	esophagus: 3.3	Cell line enhanced		HBEC3-KT: 11.7;hTERT-HME1: 7.8;HUVEC TERT2: 6.8;TIME: 10.3;U-2197: 9.7
C11orf95	MGC3032	ENSG00000188070	Chromosome 11 open reading frame 95	11	63759892-63768775	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045002			Approved	Intermediate filaments		Expressed in all	Expressed in all			endometrium: 24.6	Expressed in all		
C11orf96	AG2	ENSG00000187479	Chromosome 11 open reading frame 96	11	43925342-43944338	Predicted intracellular proteins	Evidence at protein level	HPA038843	Uncertain		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol	Renal cancer:2.34e-5 (unfavourable)	Expressed in all	Mixed			adrenal gland: 163.5	Cell line enriched	12	SH-SY5Y: 199.2
C11orf97	LINC01171	ENSG00000257057	Chromosome 11 open reading frame 97	11	94512432-94532123	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Group enriched	9	fallopian tube: 28.3;testis: 12.6	lung: 2.3	Not detected		
C11orf98	C11orf48	ENSG00000278615	Chromosome 11 open reading frame 98	11	62662816-62665217	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:4.02e-6 (unfavourable), Liver cancer:5.85e-5 (unfavourable), Endometrial cancer:7.62e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 80.3	Expressed in all		
C12orf29	DKFZp434N2030	ENSG00000133641	Chromosome 12 open reading frame 29	12	88033846-88050160	Predicted intracellular proteins	Evidence at protein level	HPA039663	Uncertain		Approved	Vesicles	Renal cancer:3.44e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 17.1	Expressed in all		
C12orf4		ENSG00000047621	Chromosome 12 open reading frame 4	12	4487728-4538508	Predicted intracellular proteins	Evidence at protein level	HPA037871	Uncertain		Approved	Nuclear bodies		Expressed in all	Mixed			testis: 16.9	Expressed in all		
C12orf40	FLJ40126	ENSG00000180116	Chromosome 12 open reading frame 40	12	39626167-39908300	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	77	testis: 15.7	tonsil: 0.2	Cell line enriched	7	K-562: 2.4
C12orf42	FLJ25323	ENSG00000179088	Chromosome 12 open reading frame 42	12	103237591-103496010	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	17	testis: 25.1	spleen: 1.5	Not detected		
C12orf43	FLJ12448	ENSG00000157895	Chromosome 12 open reading frame 43	12	121000486-121016502	Predicted intracellular proteins	Evidence at protein level	HPA046148, HPA061739	Uncertain		Enhanced	Nucleoli<br>Golgi apparatus	Liver cancer:1.29e-6 (unfavourable), Lung cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 20.8	Expressed in all		
C12orf45	MGC40397	ENSG00000151131	Chromosome 12 open reading frame 45	12	104986310-105074197	Predicted intracellular proteins	Evidence at protein level	HPA038722	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:4.58e-10 (unfavourable)	Expressed in all	Expressed in all			appendix: 14.0	Expressed in all		
C12orf50	FLJ35821	ENSG00000165805	Chromosome 12 open reading frame 50	12	87980035-88034037	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	880	testis: 87.9	all non-specific tissues: 0.0	Not detected		
C12orf54	MGC35033	ENSG00000177627	Chromosome 12 open reading frame 54	12	48482503-48496512	Predicted intracellular proteins	Evidence at transcript level							Group enriched	Tissue enriched	66	testis: 86.6	tonsil: 1.3	Cell line enhanced		HaCaT: 1.2;HBEC3-KT: 3.4;hTERT-HME1: 2.1
C12orf56		ENSG00000185306	Chromosome 12 open reading frame 56	12	64264762-64391192	Predicted intracellular proteins	Evidence at protein level	HPA056986	Enhanced					Mixed	Tissue enriched	21	testis: 15.2	skin: 0.7	Group enriched	13	hTEC/SVTERT24-B: 5.6;SCLC-21H: 5.5
C12orf57	C10, GRCC10	ENSG00000111678	Chromosome 12 open reading frame 57	12	6942978-6946003	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046182, HPA059163, HPA066043	Approved		Supported	Nuclear speckles	Renal cancer:2.32e-7 (unfavourable), Pancreatic cancer:8.74e-4 (favourable)	Expressed in all	Expressed in all			ovary: 522.5	Expressed in all		
C12orf60	MGC47869	ENSG00000182993	Chromosome 12 open reading frame 60	12	14803572-14906586	Predicted intracellular proteins	Evidence at protein level	HPA043911			Approved	Nucleus<br>Cytosol		Mixed	Group enriched	6	adrenal gland: 5.9;testis: 23.9	kidney: 2.5	Mixed		
C12orf65	FLJ38663, SPG55	ENSG00000130921	Chromosome 12 open reading frame 65	12	123232916-123257959	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038194, HPA057595	Uncertain		Approved	Nucleus<br>Mitochondria<br>Cytosol	Liver cancer:4.29e-9 (unfavourable), Urothelial cancer:7.82e-5 (favourable)	Expressed in all	Expressed in all			testis: 24.7	Expressed in all		
C12orf66	FLJ32549	ENSG00000174206	Chromosome 12 open reading frame 66	12	64186316-64222296	Predicted intracellular proteins	Evidence at protein level	HPA046743, HPA052855	Uncertain		Enhanced	Microtubules<br>Cytokinetic bridge<br>Mitotic spindle		Expressed in all	Expressed in all			parathyroid gland: 12.3	Expressed in all		
C12orf71	LOC728858	ENSG00000214700	Chromosome 12 open reading frame 71	12	27081058-27082514	Predicted intracellular proteins	Evidence at transcript level	HPA058728	Uncertain					Not detected	Tissue enhanced		testis: 4.8	skin: 1.0	Cell line enhanced		HDLM-2: 1.4
C12orf74		ENSG00000214215	Chromosome 12 open reading frame 74	12	92702843-92708549	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 1.9	cervix, uterine,urinary bladder: 0.8	Not detected		
C12orf75	AGD3, OCC-1, OCC1	ENSG00000235162	Chromosome 12 open reading frame 75	12	105235290-105396097	Predicted intracellular proteins	Evidence at protein level	HPA065311	Uncertain		Approved	Vesicles	Renal cancer:1.69e-5 (favourable), Liver cancer:1.70e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 138.7	prostate: 61.0	Expressed in all		
C14orf105	FLJ10650	ENSG00000100557	Chromosome 14 open reading frame 105	14	57469301-57493867	Predicted intracellular proteins	Evidence at transcript level	HPA029202			Uncertain	Nucleus<br>Cytosol	Renal cancer:1.92e-4 (favourable), Liver cancer:5.61e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 43.7;gallbladder: 27.1;kidney: 63.6	liver: 11.3	Group enriched	6	A549: 10.7;RPTEC TERT1: 26.1
C14orf119	FLJ20671	ENSG00000179933	Chromosome 14 open reading frame 119	14	23094765-23100462	Predicted intracellular proteins	Evidence at protein level	HPA003638	Uncertain		Supported	Mitochondria<br>Cytosol	Thyroid cancer:3.30e-5 (favourable), Liver cancer:5.42e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 70.9	Expressed in all		
C14orf159	FLJ39975	ENSG00000133943	Chromosome 14 open reading frame 159	14	91060333-91225632	Predicted intracellular proteins	Evidence at protein level	HPA041423, HPA052932	Approved		Supported	Cytosol	Renal cancer:3.77e-15 (favourable), Lung cancer:9.48e-5 (favourable), Endometrial cancer:4.28e-4 (favourable), Ovarian cancer:7.28e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 82.6	Expressed in all		
C14orf166	CGI-99, CLE, CLE7, hCLE1, LCRP369, RLLM1	ENSG00000087302	Chromosome 14 open reading frame 166	14	51989475-52010691	Predicted intracellular proteins	Evidence at protein level	HPA039824	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 262.6	Expressed in all		
C14orf177	FLJ25773	ENSG00000176605	Chromosome 14 open reading frame 177	14	98711613-98717761	Predicted intracellular proteins	Evidence at transcript level	HPA018091	Uncertain					Not detected	Tissue enriched	23	testis: 2.2	all non-specific tissues: 0.0	Not detected		
C14orf178	FLJ25976	ENSG00000197734	Chromosome 14 open reading frame 178	14	77760830-77769742	Predicted intracellular proteins	Evidence at transcript level	HPA062581	Uncertain					Not detected	Mixed			skin: 2.1	Mixed		
C14orf28	DRIP-1	ENSG00000179476	Chromosome 14 open reading frame 28	14	44897295-44907257	Predicted intracellular proteins	Evidence at transcript level	HPA059635			Approved	Cytosol		Expressed in all	Mixed			testis: 15.6	Mixed		
C14orf39	SIX6OS1	ENSG00000179008	Chromosome 14 open reading frame 39	14	60396469-60515543	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059518	Uncertain		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enriched	8	testis: 19.7	adrenal gland: 2.4	Cell line enhanced		HEL: 5.6;MOLT-4: 19.1;RH-30: 6.0;U-2 OS: 13.1
C14orf79		ENSG00000140104	Chromosome 14 open reading frame 79	14	104985775-105010482	Predicted intracellular proteins	Evidence at transcript level	HPA042052, HPA061117	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			fallopian tube: 24.1	Mixed		
C15orf38-AP3S2		ENSG00000250021	C15orf38-AP3S2 readthrough	15	89834308-89912882	Predicted intracellular proteins	Evidence at protein level	HPA040513, HPA047173, HPA049270, HPA052278	Uncertain		Approved	Vesicles		Not detected	Expressed in all			cerebral cortex: 19.5	Expressed in all		
C15orf39	DKFZP434H132, FLJ46337	ENSG00000167173	Chromosome 15 open reading frame 39	15	75195643-75212169	Predicted intracellular proteins	Evidence at protein level	HPA039961, HPA041907	Uncertain		Enhanced	Cytosol	Renal cancer:3.05e-4 (unfavourable), Testis cancer:6.02e-4 (unfavourable), Melanoma:7.94e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 123.7	bone marrow: 39.1	Expressed in all		
C15orf40	MGC29937	ENSG00000169609	Chromosome 15 open reading frame 40	15	82988441-83011641	Predicted intracellular proteins	Evidence at protein level	HPA042980	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:4.35e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 23.6	Expressed in all		
C15orf41	FLJ22851, HH114, MGC11326	ENSG00000186073	Chromosome 15 open reading frame 41	15	36579611-36810248	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061023	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		heart muscle: 63.4	smooth muscle: 14.3	Expressed in all		
C15orf48	NMES1	ENSG00000166920	Chromosome 15 open reading frame 48	15	45430529-45448761	Predicted intracellular proteins	Evidence at protein level	HPA012943	Enhanced					Expressed in all	Tissue enhanced		colon: 716.6;rectum: 832.9	small intestine: 330.3	Cell line enhanced		A-431: 52.4;CAPAN-2: 96.3
C15orf52	FLJ43339	ENSG00000188549	Chromosome 15 open reading frame 52	15	40331452-40340967	Predicted intracellular proteins	Evidence at protein level	HPA040484, HPA041834	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			thyroid gland: 50.4	Cell line enhanced		HaCaT: 108.4;WM-115: 137.0
C15orf53	FLJ35695	ENSG00000175779	Chromosome 15 open reading frame 53	15	38696598-38700038	Predicted intracellular proteins	Evidence at transcript level	HPA041914	Uncertain					Not detected	Not detected			lung,urinary bladder: 0.1	Group enriched	12	HEL: 2.5;HMC-1: 1.7
C15orf57	CCDC32, MGC20481	ENSG00000128891	Chromosome 15 open reading frame 57	15	40528683-40565057	Predicted intracellular proteins	Evidence at protein level	HPA041688	Uncertain		Approved	Nuclear speckles<br>Vesicles		Expressed in all	Expressed in all			thyroid gland: 35.2	Expressed in all		
C15orf59	INSYN1, LOC388135, MGC131524	ENSG00000205363	Chromosome 15 open reading frame 59	15	73735431-73752747	Predicted intracellular proteins	Evidence at transcript level	HPA041563	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.38e-9 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 55.9	seminal vesicle: 19.8	Cell line enhanced		ASC diff: 6.2;fHDF/TERT166: 4.8;HEK93: 5.9;U-2 OS: 5.5
C15orf61	LOC145853	ENSG00000189227	Chromosome 15 open reading frame 61	15	67521068-67530143	Predicted intracellular proteins	Evidence at protein level	HPA062820			Approved	Nucleoli<br>Vesicles<br>Cytosol	Renal cancer:5.31e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.0	Mixed		
C15orf62	LOC643338	ENSG00000188277	Chromosome 15 open reading frame 62	15	40770080-40772449	Predicted intracellular proteins	Evidence at protein level	HPA044636	Approved					Mixed	Tissue enhanced		esophagus: 14.9;skin: 12.6	tonsil: 4.6	Cell line enhanced		RPTEC TERT1: 13.6
C15orf65	FLJ27352	ENSG00000261652	Chromosome 15 open reading frame 65	15	55408548-55418764	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA067189	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:3.18e-7 (favourable)	Expressed in all	Mixed			testis: 16.9	Mixed		
C16orf45	FLJ32618	ENSG00000166780	Chromosome 16 open reading frame 45	16	15434295-15625028	Predicted intracellular proteins	Evidence at protein level	HPA041114	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.53e-4 (favourable), Renal cancer:1.75e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 171.9	cervix, uterine: 59.6	Cell line enhanced		fHDF/TERT166: 72.2;U-87 MG: 109.4
C16orf46	FLJ32702	ENSG00000166455	Chromosome 16 open reading frame 46	16	81053497-81077267	Predicted intracellular proteins	Evidence at protein level	HPA041136, HPA041379	Uncertain		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 10.0	thyroid gland: 4.7	Mixed		
C16orf59	FLJ13909	ENSG00000162062	Chromosome 16 open reading frame 59	16	2460080-2464963	Predicted intracellular proteins	Evidence at protein level	HPA051394, HPA055389	Approved		Approved	Nucleoplasm<br>Cell Junctions	Liver cancer:2.43e-5 (unfavourable), Lung cancer:7.58e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 5.5	bone marrow,lymph node: 2.5	Mixed		
C16orf70	C16orf6, FLJ12076, lin-10, LIN10	ENSG00000125149	Chromosome 16 open reading frame 70	16	67109958-67148539	Predicted intracellular proteins	Evidence at protein level	HPA041131, HPA041214	Approved		Approved	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 33.3	Expressed in all		
C16orf71	DKFZp686H2240, FLJ43261	ENSG00000166246	Chromosome 16 open reading frame 71	16	4734272-4749396	Predicted intracellular proteins	Evidence at protein level	HPA049468	Enhanced		Uncertain	Nuclear speckles	Endometrial cancer:7.49e-4 (favourable)	Mixed	Group enriched	17	fallopian tube: 35.8;testis: 113.1	lung: 4.3	Mixed		
C16orf72	FLJ41272, PRO0149	ENSG00000182831	Chromosome 16 open reading frame 72	16	9091648-9121640	Predicted intracellular proteins	Evidence at protein level	HPA041568, HPA067492	Uncertain		Approved	Nucleoplasm<br>Vesicles	Head and neck cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 67.5	Expressed in all		
C16orf74	MGC17624	ENSG00000154102	Chromosome 16 open reading frame 74	16	85690084-85751129	Predicted intracellular proteins	Evidence at protein level	HPA049367	Uncertain		Approved	Plasma membrane<br>Centrosome	Pancreatic cancer:1.54e-5 (unfavourable), Head and neck cancer:1.71e-4 (unfavourable), Melanoma:4.08e-4 (unfavourable)	Mixed	Mixed			urinary bladder: 13.3	Cell line enhanced		HBEC3-KT: 68.8;T-47d: 79.3
C16orf78	MGC33367	ENSG00000166152	Chromosome 16 open reading frame 78	16	49373823-49399431	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	516	testis: 71.0	spleen: 0.1	Not detected		
C16orf82	TNT	ENSG00000234186	Chromosome 16 open reading frame 82	16	27066707-27069165	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	3011	testis: 301.0	all non-specific tissues: 0.0	Not detected		
C16orf86	FLJ41802	ENSG00000159761	Chromosome 16 open reading frame 86	16	67666816-67668758	Predicted intracellular proteins	Evidence at protein level	HPA073475	Enhanced				Renal cancer:2.12e-7 (favourable), Pancreatic cancer:1.47e-4 (favourable)	Expressed in all	Tissue enriched	7	testis: 27.5	parathyroid gland: 3.9	Cell line enhanced		HSkMC: 2.4
C16orf87		ENSG00000155330	Chromosome 16 open reading frame 87	16	46796607-46831411	Predicted intracellular proteins	Evidence at protein level	HPA041179	Uncertain		Approved	Nucleoplasm	Head and neck cancer:7.95e-5 (unfavourable), Pancreatic cancer:6.57e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 56.9	parathyroid gland: 34.3	Expressed in all		
C16orf95		ENSG00000260456	Chromosome 16 open reading frame 95	16	87083562-87317420	Predicted intracellular proteins	Evidence at protein level	HPA040850, HPA067924	Supported		Approved	Endoplasmic reticulum		Mixed	Tissue enriched	24	testis: 80.4	cerebral cortex: 3.2	Mixed		
C16orf96		ENSG00000205832	Chromosome 16 open reading frame 96	16	4556490-4600714	Predicted intracellular proteins	Evidence at protein level	HPA042009, HPA042058	Uncertain					Not detected	Tissue enriched	21	testis: 10.9	cerebral cortex: 0.5	Not detected		
C17orf100	LOC388327	ENSG00000256806	Chromosome 17 open reading frame 100	17	6651718-6693202	Predicted intracellular proteins	Evidence at protein level	HPA046824			Approved	Nucleus<br>Cytokinetic bridge<br>Cytosol		Expressed in all	Mixed			skin: 8.3	Cell line enhanced		SH-SY5Y: 9.8
C17orf105		ENSG00000231256	Chromosome 17 open reading frame 105	17	43780435-43787612	Predicted intracellular proteins	Evidence at transcript level	HPA053028	Approved					Not detected	Tissue enriched	47	testis: 20.2	skin: 0.4	Not detected		
C17orf107		ENSG00000205710	Chromosome 17 open reading frame 107	17	4899418-4902932	Predicted intracellular proteins	Evidence at transcript level	HPA069713	Uncertain		Approved	Nucleus	Breast cancer:5.06e-5 (favourable), Renal cancer:2.68e-4 (favourable), Pancreatic cancer:8.61e-4 (favourable)	Mixed	Mixed			parathyroid gland,salivary gland: 5.7	Cell line enhanced		fHDF/TERT166: 2.2;HMC-1: 3.2;hTCEpi: 2.4
C17orf47	FLJ40121	ENSG00000181013	Chromosome 17 open reading frame 47	17	58541587-58544368	Predicted intracellular proteins	Evidence at protein level	HPA028424	Uncertain					Not detected	Tissue enriched	32	testis: 16.3	spleen: 0.5	Not detected		
C17orf49	BAP18, HEPIS, MGC49942	ENSG00000258315	Chromosome 17 open reading frame 49	17	7014495-7017525	Predicted intracellular proteins	Evidence at protein level	HPA022961, HPA024457	Supported		Uncertain	Nucleoplasm<br>Cytosol		Mixed	Expressed in all			lymph node: 108.5	Expressed in all		
C17orf50		ENSG00000270806	Chromosome 17 open reading frame 50	17	35760897-35765079	Predicted intracellular proteins	Evidence at protein level	HPA043184, HPA063464			Supported	Nucleoplasm		Not detected	Tissue enriched	59	testis: 38.9	fallopian tube: 0.6	Cell line enriched	5	HaCaT: 4.6
C17orf51	FLJ12977, FLJ31874, FLJ33618	ENSG00000212719	Chromosome 17 open reading frame 51	17	21524790-21574458	Predicted intracellular proteins	Evidence at protein level	HPA052106	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Mixed	Tissue enhanced		cerebral cortex: 16.6	testis: 8.2	Mixed		
C17orf53	MGC3130	ENSG00000125319	Chromosome 17 open reading frame 53	17	44141906-44162476	Predicted intracellular proteins	Evidence at protein level	HPA023004, HPA023393, HPA024430	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.46e-4 (unfavourable), Endometrial cancer:8.08e-4 (unfavourable), Lung cancer:9.39e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 12.5	bone marrow: 6.3	Mixed		
C17orf64		ENSG00000141371	Chromosome 17 open reading frame 64	17	60392429-60431421	Predicted intracellular proteins	Evidence at protein level	HPA044415	Enhanced		Approved	Nucleoplasm<br>Vesicles		Not detected	Tissue enriched	233	testis: 185.6	spleen: 0.7	Cell line enhanced		MCF7: 4.4
C17orf97	LIAT1, LOC400566	ENSG00000187624	Chromosome 17 open reading frame 97	17	410327-431062	Predicted intracellular proteins	Evidence at protein level	HPA023583	Approved		Approved	Nucleoli<br>Cytosol		Expressed in all	Tissue enhanced		testis: 28.4	fallopian tube: 10.8	Cell line enhanced		U-2197: 8.4
C17orf98	LOC388381	ENSG00000275489	Chromosome 17 open reading frame 98	17	38835088-38841455	Predicted intracellular proteins	Evidence at transcript level	HPA051696	Uncertain		Approved	Nucleoli<br>Intermediate filaments		Not detected	Tissue enriched	50	testis: 9.5	adipose tissue,skin: 0.1	Cell line enriched	7	hTCEpi: 1.9
C18orf21	HsT3108, PNAS-124, PNAS-131	ENSG00000141428	Chromosome 18 open reading frame 21	18	35972083-35979286	Predicted intracellular proteins	Evidence at protein level	HPA065505, HPA067322	Uncertain		Approved	Nucleoli<br>Plasma membrane	Liver cancer:1.38e-6 (unfavourable), Ovarian cancer:1.81e-6 (favourable)	Expressed in all	Expressed in all			testis: 59.6	Expressed in all		
C18orf25	ARKL1, MGC12909, RNF111L1	ENSG00000152242	Chromosome 18 open reading frame 25	18	46173553-46266991	Predicted intracellular proteins	Evidence at protein level	HPA051314, HPA065021	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 38.8	Expressed in all		
C18orf63	DKFZP781G0119	ENSG00000206043	Chromosome 18 open reading frame 63	18	74315813-74359187	Predicted intracellular proteins	Evidence at protein level	HPA042233			Approved	Mitochondria		Not detected	Tissue enriched	62	testis: 17.8	breast: 0.2	Not detected		
C18orf8	HsT2591, MIC-1, MIC1	ENSG00000141452	Chromosome 18 open reading frame 8	18	23503470-23531807	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA043589	Uncertain		Uncertain	Nucleus	Liver cancer:3.94e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.0	Expressed in all		
C19orf12	DKFZP762D096, MGC10922, MPAN, NBIA4, SPG43	ENSG00000131943	Chromosome 19 open reading frame 12	19	29698886-29715789	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046930	Approved					Expressed in all	Expressed in all			adipose tissue: 122.7	Expressed in all		
C19orf25	FLJ36666	ENSG00000119559	Chromosome 19 open reading frame 25	19	1461143-1479556	Predicted intracellular proteins	Evidence at protein level	HPA050270, HPA067491	Approved		Approved	Intermediate filaments	Renal cancer:9.20e-8 (favourable), Endometrial cancer:1.08e-4 (favourable), Pancreatic cancer:1.21e-4 (favourable), Liver cancer:3.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 21.7	Expressed in all		
C19orf33	H2RSP, IMUP, IMUP-1, IMUP-2	ENSG00000167644	Chromosome 19 open reading frame 33	19	38304161-38305009	Predicted intracellular proteins	Evidence at protein level	HPA054406, HPA059696	Uncertain		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:5.05e-4 (unfavourable), Lung cancer:5.42e-4 (unfavourable)	Mixed	Mixed			esophagus: 177.8	Cell line enhanced		A-431: 535.8;A549: 841.0;CAPAN-2: 498.9;PC-3: 484.7
C19orf35	FLJ45778	ENSG00000188305	Chromosome 19 open reading frame 35	19	2274622-2282176	Predicted intracellular proteins	Evidence at protein level	HPA057806	Uncertain					Mixed	Mixed			appendix: 1.8	Cell line enriched	13	HMC-1: 10.7
C19orf43	fSAP18, MGC2803	ENSG00000123144	Chromosome 19 open reading frame 43	19	12730640-12734775	Predicted intracellular proteins	Evidence at protein level	HPA059965	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			spleen: 125.2	Expressed in all		
C19orf44	FLJ21742	ENSG00000105072	Chromosome 19 open reading frame 44	19	16496311-16521352	Predicted intracellular proteins	Evidence at protein level	HPA041683, HPA049414	Uncertain		Approved	Nucleus<br>Nuclear bodies		Expressed in all	Mixed			testis: 20.2	Mixed		
C19orf45	FLJ35784	ENSG00000198723	Chromosome 19 open reading frame 45	19	7492976-7508450	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	7	testis: 16.7	skin: 2.2	Not detected		
C19orf48	MGC13170	ENSG00000167747	Chromosome 19 open reading frame 48	19	50797704-50804929	Predicted intracellular proteins	Evidence at transcript level	HPA042000	Uncertain		Approved	Plasma membrane	Liver cancer:8.80e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 84.5	Expressed in all		
C19orf53	HSPC023, LYDG10	ENSG00000104979	Chromosome 19 open reading frame 53	19	13774168-13778462	Predicted intracellular proteins	Evidence at protein level	HPA059928, HPA061291	Approved		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			fallopian tube: 116.9	Expressed in all		
C19orf54	FLJ41131	ENSG00000188493	Chromosome 19 open reading frame 54	19	40740856-40751553	Predicted intracellular proteins	Evidence at protein level	HPA059043, HPA059628	Approved					Expressed in all	Expressed in all			parathyroid gland: 12.2	Expressed in all		
C19orf57	MGC11271	ENSG00000132016	Chromosome 19 open reading frame 57	19	13882348-13906452	Predicted intracellular proteins	Evidence at protein level	HPA044012, HPA054615	Enhanced		Approved	Nucleoplasm	Endometrial cancer:3.38e-4 (unfavourable), Head and neck cancer:5.14e-4 (favourable)	Mixed	Tissue enhanced		testis: 20.7	skin: 13.9	Mixed		
C19orf60	FLJ20850, FLJ30108, FLJ34606, FLJ37391	ENSG00000006015	Chromosome 19 open reading frame 60	19	18588685-18592336	Predicted intracellular proteins	Evidence at protein level	HPA043414	Approved		Approved	Vesicles	Urothelial cancer:8.47e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 22.2	Cell line enhanced		PC-3: 78.2
C19orf66	FLJ11286, RyDEN	ENSG00000130813	Chromosome 19 open reading frame 66	19	10086122-10093252	Predicted intracellular proteins	Evidence at protein level	HPA042001	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.96e-11 (unfavourable), Urothelial cancer:1.35e-4 (favourable), Breast cancer:4.04e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 20.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 44.2;BJ hTERT+ SV40 Large T+ RasG12V: 48.5
C19orf67		ENSG00000188032	Chromosome 19 open reading frame 67	19	14081619-14085875	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	11	testis: 5.6	stomach,thyroid gland: 0.4	Not detected		
C19orf68	LOC374920	ENSG00000185453	Chromosome 19 open reading frame 68	19	48170692-48197620	Predicted intracellular proteins	Evidence at protein level	HPA061028	Uncertain		Approved	Nucleus	Liver cancer:2.35e-5 (unfavourable), Renal cancer:2.44e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 7.8	Expressed in all		
C19orf71	LOC100128569	ENSG00000183397	Chromosome 19 open reading frame 71	19	3539154-3544030	Predicted intracellular proteins	Evidence at protein level	HPA048654	Uncertain		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:2.02e-5 (favourable), Pancreatic cancer:2.03e-5 (favourable), Head and neck cancer:2.35e-4 (favourable)	Tissue enriched	Mixed			testis: 29.5	Cell line enhanced		HeLa: 52.4;WM-115: 167.8
C19orf73	FLJ10490	ENSG00000221916	Chromosome 19 open reading frame 73	19	49118397-49119140	Predicted intracellular proteins	Evidence at protein level	HPA062719	Uncertain		Approved	Nucleus<br>Cytosol	Pancreatic cancer:1.58e-4 (favourable)	Expressed in all	Mixed			duodenum: 2.2	Cell line enhanced		HEK93: 7.8
C19orf81		ENSG00000235034	Chromosome 19 open reading frame 81	19	50649445-50659310	Predicted intracellular proteins	Evidence at protein level	HPA060238	Enhanced		Approved	Vesicles<br>Aggresome		Tissue enhanced	Tissue enriched	11	testis: 5.3	cerebral cortex,epididymis,prostate: 0.4	Cell line enhanced		HEK93: 4.0;HMC-1: 1.3
C19orf84		ENSG00000262874	Chromosome 19 open reading frame 84	19	51388289-51390574	Predicted intracellular proteins	Evidence at transcript level	HPA068082	Uncertain					Tissue enhanced	Tissue enriched	54	testis: 24.6	bone marrow: 0.4	Cell line enriched	7	K-562: 6.2
C1D	LRP1, Rrp47, SUN-CoR, SUNCOR	ENSG00000197223	C1D nuclear receptor corepressor	2	68041130-68110948	Predicted intracellular proteins	Evidence at protein level	HPA037413, HPA037588	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			thyroid gland: 51.9	Expressed in all		
C1orf100		ENSG00000173728	Chromosome 1 open reading frame 100	1	244352635-244389663	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	51	testis: 71.1	parathyroid gland: 1.3	Cell line enriched	50	K-562: 4.9
C1orf105		ENSG00000180999	Chromosome 1 open reading frame 105	1	172420688-172468831	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	testis: 46.2	epididymis: 6.6	Cell line enriched	12	BEWO: 26.1
C1orf106	FLJ10901	ENSG00000163362	Chromosome 1 open reading frame 106	1	200891048-200915735	Predicted intracellular proteins	Evidence at transcript level	HPA027499, HPA027511	Uncertain				Endometrial cancer:1.78e-5 (unfavourable)	Expressed in all	Tissue enhanced		small intestine: 69.7	duodenum: 54.3	Cell line enhanced		BEWO: 60.4;HaCaT: 66.8
C1orf109	FLJ20508	ENSG00000116922	Chromosome 1 open reading frame 109	1	37681570-37692249	Predicted intracellular proteins	Evidence at protein level	HPA027110, HPA027127	Supported		Approved	Nucleus<br>Cytosol	Liver cancer:1.76e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 23.2	Expressed in all		
C1orf112	FLJ10706	ENSG00000000460	Chromosome 1 open reading frame 112	1	169662007-169854080	Predicted intracellular proteins	Evidence at protein level	HPA023778, HPA024451	Uncertain		Approved	Mitochondria	Endometrial cancer:9.56e-5 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 25.0	testis: 18.6	Expressed in all		
C1orf115	FLJ14146	ENSG00000162817	Chromosome 1 open reading frame 115	1	220689845-220699157	Predicted intracellular proteins	Evidence at transcript level						Ovarian cancer:5.12e-5 (favourable), Endometrial cancer:6.52e-4 (favourable)	Expressed in all	Mixed			small intestine: 110.8	Cell line enhanced		Hep G2: 35.3;HUVEC TERT2: 34.6;TIME: 63.7
C1orf116	FLJ36507, MGC2742, MGC4309, SARG	ENSG00000182795	Chromosome 1 open reading frame 116	1	207018521-207032756	Predicted intracellular proteins	Evidence at protein level	HPA011888, HPA011889	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.01e-5 (favourable)	Mixed	Tissue enhanced		esophagus: 112.4;lung: 109.2;prostate: 82.0	stomach: 54.9	Group enriched	5	A-431: 50.3;CAPAN-2: 87.3;HaCaT: 108.7;HBEC3-KT: 85.0;hTCEpi: 44.4;hTERT-HME1: 26.3;RPTEC TERT1: 42.8
C1orf122	FLJ45459	ENSG00000197982	Chromosome 1 open reading frame 122	1	37806979-37809454	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:4.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 52.7	Expressed in all		
C1orf123	FLJ20580	ENSG00000162384	Chromosome 1 open reading frame 123	1	53214099-53220617	Predicted intracellular proteins	Evidence at protein level	HPA043835	Uncertain		Approved	Cytosol	Renal cancer:1.53e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 89.3	Expressed in all		
C1orf131	DKFZp547B1713	ENSG00000143633	Chromosome 1 open reading frame 131	1	231223763-231241187	Predicted intracellular proteins	Evidence at protein level	HPA028452, HPA029920	Enhanced		Enhanced	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:2.64e-9 (unfavourable), Urothelial cancer:9.84e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 21.6	Expressed in all		
C1orf141		ENSG00000203963	Chromosome 1 open reading frame 141	1	67092165-67231853	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	13	fallopian tube: 15.5;testis: 28.2	lung: 1.6	Cell line enriched	39	HEL: 13.1
C1orf145	FLJ31994	ENSG00000162913	Chromosome 1 open reading frame 145	1	228203506-228213664	Predicted intracellular proteins	Evidence at transcript level	HPA046612	Uncertain					Mixed	Mixed			thyroid gland: 1.1	Cell line enhanced		HeLa: 1.4;RPTEC TERT1: 1.2
C1orf146		ENSG00000203910	Chromosome 1 open reading frame 146	1	92217940-92245813	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	14	testis: 14.5	skin: 1.0	Not detected		
C1orf158	MGC35194	ENSG00000157330	Chromosome 1 open reading frame 158	1	12746215-12763699	Predicted intracellular proteins	Evidence at transcript level	HPA028396			Uncertain	Cytosol		Group enriched	Group enriched	15	fallopian tube: 42.6;testis: 47.5	lung: 2.9	Not detected		
C1orf167	DKFZp434E1410, RP11-56N19.2	ENSG00000215910	Chromosome 1 open reading frame 167	1	11761787-11789585	Predicted intracellular proteins	Evidence at transcript level	HPA039114	Uncertain					Not detected	Tissue enriched	30	testis: 14.7	lung: 0.4	Cell line enriched	50	U-698: 21.3
C1orf168	FLJ43208, RP4-758N20.2	ENSG00000187889	Chromosome 1 open reading frame 168	1	56718804-56819696	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		fallopian tube: 21.4;liver: 8.6	cervix, uterine: 5.0	Cell line enriched	22	T-47d: 4.8
C1orf174	RP13-531C17.2	ENSG00000198912	Chromosome 1 open reading frame 174	1	3889125-3900293	Predicted intracellular proteins	Evidence at protein level	HPA008270, HPA065778	Approved		Enhanced	Nucleus	Renal cancer:2.73e-6 (unfavourable), Liver cancer:5.84e-4 (unfavourable), Melanoma:7.62e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 17.3	Expressed in all		
C1orf189		ENSG00000163263	Chromosome 1 open reading frame 189	1	154199372-154206333	Predicted intracellular proteins	Evidence at protein level	HPA045779	Uncertain					Tissue enhanced	Group enriched	16	fallopian tube: 127.5;testis: 69.2	cervix, uterine: 6.0	Mixed		
C1orf194		ENSG00000179902	Chromosome 1 open reading frame 194	1	109105951-109113857	Predicted intracellular proteins	Evidence at protein level	HPA031144, HPA049684	Enhanced		Uncertain	Nuclear speckles<br>Cytosol	Endometrial cancer:1.36e-4 (favourable)	Group enriched	Group enriched	31	fallopian tube: 198.1;testis: 199.1	lung: 6.4	Cell line enhanced		AF22: 1.5;SCLC-21H: 2.5
C1orf204	FLJ39187	ENSG00000188004	Chromosome 1 open reading frame 204	1	159834474-159855347	Predicted intracellular proteins	Evidence at transcript level	HPA045602, HPA051028	Approved		Approved	Nucleoplasm		Mixed	Mixed			ovary,parathyroid gland: 8.3	Mixed		
C1orf21	PIG13	ENSG00000116667	Chromosome 1 open reading frame 21	1	184387058-184629020	Predicted intracellular proteins	Evidence at protein level	HPA026831	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.35e-8 (unfavourable)	Expressed in all	Mixed			skin: 30.1	Cell line enhanced		HDLM-2: 32.8
C1orf216	FLJ38984	ENSG00000142686	Chromosome 1 open reading frame 216	1	35713875-35719472	Predicted intracellular proteins	Evidence at protein level	HPA028299, HPA031343	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.68e-10 (unfavourable), Liver cancer:2.15e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 60.6	smooth muscle: 18.6	Expressed in all		
C1orf226	FLJ13137	ENSG00000239887	Chromosome 1 open reading frame 226	1	162366908-162386818	Predicted intracellular proteins	Evidence at protein level	HPA052251	Approved		Approved	Nucleoplasm	Renal cancer:4.44e-5 (favourable), Urothelial cancer:1.13e-4 (favourable), Breast cancer:2.60e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 12.7	Cell line enhanced		HEL: 20.8
C1orf228	MGC33556, NCRNA00082, p40	ENSG00000198520	Chromosome 1 open reading frame 228	1	44674692-44725591	Predicted intracellular proteins	Evidence at protein level	HPA034769	Uncertain		Uncertain	Cytosol	Endometrial cancer:8.64e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 13.5;testis: 21.4	epididymis: 4.7	Cell line enhanced		HL-60: 6.3;MOLT-4: 5.3;NB-4: 5.8;U-937: 9.7
C1orf35	MGC4174, MMTAG2	ENSG00000143793	Chromosome 1 open reading frame 35	1	228100726-228105411	Predicted intracellular proteins	Evidence at protein level	HPA046175	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Renal cancer:1.79e-6 (unfavourable), Ovarian cancer:7.38e-4 (favourable), Colorectal cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 14.3	Expressed in all		
C1orf50	MGC955	ENSG00000164008	Chromosome 1 open reading frame 50	1	42767269-42775747	Predicted intracellular proteins	Evidence at protein level	HPA030236	Uncertain				Melanoma:4.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 21.6	Expressed in all		
C1orf52	FLJ44982, gm117	ENSG00000162642	Chromosome 1 open reading frame 52	1	85249953-85259672	Predicted intracellular proteins	Evidence at protein level	HPA036072, HPA061790	Approved		Enhanced	Nucleus	Renal cancer:1.17e-7 (unfavourable), Liver cancer:5.37e-5 (unfavourable), Prostate cancer:4.93e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 31.8	Expressed in all		
C1orf53		ENSG00000203724	Chromosome 1 open reading frame 53	1	197902647-197907367	Predicted intracellular proteins	Evidence at protein level	HPA065352			Approved	Vesicles<br>Aggresome	Breast cancer:1.63e-4 (favourable), Endometrial cancer:3.78e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 6.2	Mixed		
C1orf61	CROC4	ENSG00000125462	Chromosome 1 open reading frame 61	1	156404250-156430701	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	129	cerebral cortex: 504.3	testis: 3.9	Cell line enriched	9	BEWO: 12.5
C1orf64	ERRF, MGC24047	ENSG00000183888	Chromosome 1 open reading frame 64	1	16004236-16008807	Predicted intracellular proteins	Evidence at transcript level	HPA026676	Uncertain		Approved	Nucleoplasm	Endometrial cancer:1.68e-6 (favourable)	Tissue enhanced	Tissue enhanced		breast: 6.8	cervix, uterine: 3.3	Group enriched	9	Hep G2: 5.3;SK-BR-3: 10.1;T-47d: 4.1
C1orf68	LEP7, XP32	ENSG00000198854	Chromosome 1 open reading frame 68	1	152719522-152720470	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	14	skin: 806.5	breast: 57.5	Cell line enriched	6	HaCaT: 1.6
C1orf74	FLJ25078, URLC4	ENSG00000162757	Chromosome 1 open reading frame 74	1	209779208-209784559	Predicted intracellular proteins	Evidence at protein level	HPA028496	Uncertain		Approved	Plasma membrane<br>Cytosol	Cervical cancer:8.52e-6 (unfavourable)	Expressed in all	Mixed			lymph node: 5.0	Mixed		
C1orf87	CREF, MGC34837	ENSG00000162598	Chromosome 1 open reading frame 87	1	59987269-60073770	Predicted intracellular proteins	Evidence at protein level	HPA031366, HPA031368	Enhanced					Tissue enhanced	Tissue enriched	10	fallopian tube: 47.9	lung: 4.9	Not detected		
C1orf94	MGC15882	ENSG00000142698	Chromosome 1 open reading frame 94	1	34166883-34219131	Predicted intracellular proteins	Evidence at protein level	HPA045805			Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	32	testis: 42.4	cerebral cortex: 1.3	Group enriched	7	NTERA-2: 17.2;U-87 MG: 47.7
C1QBP	gC1Q-R, gC1qR, HABP1, p32, SF2p32	ENSG00000108561	Complement C1q binding protein	17	5432777-5448830	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA026483	Supported		Approved	Plasma membrane<br>Mitochondria		Expressed in all	Expressed in all			rectum: 157.0	Expressed in all		
C1QTNF6	CTRP6, ZACRP6	ENSG00000133466	C1q and tumor necrosis factor related protein 6	22	37180167-37199385	Predicted intracellular proteins	Evidence at protein level	HPA002042	Enhanced		Approved	Nucleus	Renal cancer:0.00e+0 (unfavourable), Lung cancer:9.60e-6 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 52.3;placenta: 41.4	gallbladder: 13.5	Cell line enhanced		MCF7: 83.4;RT4: 39.7
C20orf144	bclt, dJ63M2.6	ENSG00000149609	Chromosome 20 open reading frame 144	20	33662284-33665619	Predicted intracellular proteins	Evidence at protein level	HPA019029	Enhanced					Not detected	Tissue enriched	435	testis: 43.4	all non-specific tissues: 0.0	Not detected		
C20orf173	dJ477O4.4	ENSG00000125975	Chromosome 20 open reading frame 173	20	35523186-35529652	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	137	testis: 34.3	skin: 0.2	Not detected		
C20orf194	DKFZp434N061	ENSG00000088854	Chromosome 20 open reading frame 194	20	3249305-3407625	Predicted intracellular proteins	Evidence at protein level	HPA052103, HPA067418	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Pancreatic cancer:1.68e-4 (favourable), Renal cancer:7.68e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 26.4	Mixed		
C20orf196	FLJ25067	ENSG00000171984	Chromosome 20 open reading frame 196	20	5750393-5863912	Predicted intracellular proteins	Evidence at transcript level	HPA040749	Approved		Approved	Endoplasmic reticulum<br>Golgi apparatus<br>Vesicles	Urothelial cancer:4.05e-5 (favourable)	Expressed in all	Mixed			lymph node: 18.6	Expressed in all		
C20orf202		ENSG00000215595	Chromosome 20 open reading frame 202	20	1203454-1208274	Predicted intracellular proteins	Evidence at transcript level	HPA042786	Uncertain					Mixed	Tissue enhanced		placenta: 4.9	lung: 1.9	Not detected		
C20orf27	FLJ20550	ENSG00000101220	Chromosome 20 open reading frame 27	20	3753508-3768387	Predicted intracellular proteins	Evidence at protein level	HPA047483	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.18e-6 (unfavourable), Liver cancer:1.69e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 56.5	Expressed in all		
C20orf85	bA196N14.1, LLC1	ENSG00000124237	Chromosome 20 open reading frame 85	20	58150904-58161150	Predicted intracellular proteins	Evidence at protein level	HPA058271, HPA065540	Enhanced					Tissue enhanced	Tissue enriched	8	fallopian tube: 729.1	testis: 91.7	Not detected		
C20orf96	dJ1103G7.2	ENSG00000196476	Chromosome 20 open reading frame 96	20	270863-290778	Predicted intracellular proteins	Evidence at transcript level	HPA048649	Uncertain		Approved	Nucleus<br>Golgi apparatus	Pancreatic cancer:4.12e-5 (favourable), Liver cancer:6.12e-5 (unfavourable), Urothelial cancer:1.05e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 53.5	Mixed		
C21orf140		ENSG00000222018	Chromosome 21 open reading frame 140	21	34400317-34401072	Predicted intracellular proteins	Evidence at transcript level	HPA045123	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 2.6;testis: 4.0	esophagus: 1.1	Not detected		
C21orf2	A2, LRRC76, YF5	ENSG00000160226	Chromosome 21 open reading frame 2	21	44328944-44339402	Predicted intracellular proteins	Evidence at protein level	HPA030284, CAB034126, CAB034128	Supported		Approved	Nucleoplasm	Pancreatic cancer:1.32e-4 (favourable), Renal cancer:4.08e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 17.9	Mixed		
C21orf58		ENSG00000160298	Chromosome 21 open reading frame 58	21	46300181-46323875	Predicted intracellular proteins	Evidence at protein level	HPA035110, HPA035111	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:4.20e-4 (favourable), Head and neck cancer:7.00e-4 (favourable), Melanoma:7.48e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 42.4	testis: 9.0	Mixed		
C21orf59	C21orf48, CILD26, FBB18, FLJ20467, Kur	ENSG00000159079	Chromosome 21 open reading frame 59	21	32592079-32612866	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018453, HPA019055, HPA028849, CAB034170	Enhanced	Supported	Approved	Rods & Rings	Renal cancer:1.54e-5 (unfavourable), Endometrial cancer:8.90e-4 (favourable)	Expressed in all	Expressed in all			testis: 77.6	Expressed in all		
C21orf91	C21orf14, C21orf38, CSSG1, EURL, YG81	ENSG00000154642	Chromosome 21 open reading frame 91	21	17788967-17819386	Predicted intracellular proteins	Evidence at protein level	HPA018288, HPA049030	Approved		Approved	Microtubules<br>Cytokinetic bridge		Expressed in all	Mixed			testis: 44.4	Cell line enhanced		Karpas-707: 77.6
C22orf23	EVG1, FLJ32787, LOC84645	ENSG00000128346	Chromosome 22 open reading frame 23	22	37943050-37953669	Predicted intracellular proteins	Evidence at protein level	HPA000650			Approved	Nucleus		Mixed	Tissue enhanced		testis: 145.1	skin: 31.0	Cell line enhanced		U-87 MG: 46.8
C22orf29	BOP, FLJ21125	ENSG00000215012	Chromosome 22 open reading frame 29	22	19846138-19854896	Predicted intracellular proteins	Evidence at protein level	HPA000721, HPA001419	Uncertain				Liver cancer:8.04e-5 (unfavourable)	Expressed in all	Mixed			skin: 15.9	Expressed in all		
C22orf31	bK747E2.1, HS747E2A	ENSG00000100249	Chromosome 22 open reading frame 31	22	29058672-29061844	Predicted intracellular proteins	Evidence at transcript level	HPA000604	Uncertain					Not detected	Tissue enriched	12	testis: 13.9	epididymis: 1.1	Not detected		
C22orf39	MGC74441	ENSG00000242259	Chromosome 22 open reading frame 39	22	19351368-19448232	Predicted intracellular proteins	Evidence at protein level	HPA073701			Approved	Endoplasmic reticulum	Renal cancer:1.44e-4 (favourable), Endometrial cancer:2.16e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.1	Expressed in all		
C22orf42		ENSG00000205856	Chromosome 22 open reading frame 42	22	32149006-32159322	Predicted intracellular proteins	Evidence at protein level	HPA019531	Enhanced					Group enriched	Tissue enriched	8	testis: 10.8	prostate: 1.3	Not detected		
C2CD3	DKFZP586P0123	ENSG00000168014	C2 calcium dependent domain containing 3	11	74012714-74171210	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038552, HPA038553, HPA040433	Approved		Approved	Nucleus<br>Microtubule organizing center		Expressed in all	Mixed			testis: 30.0	Expressed in all		
C2CD4A	FAM148A, NLF1	ENSG00000198535	C2 calcium dependent domain containing 4A	15	62066977-62070917	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:4.15e-4 (unfavourable)	Mixed	Mixed			endometrium: 2.3	Cell line enriched	14	RPTEC TERT1: 22.6
C2CD4B	FAM148B, NLF2	ENSG00000205502	C2 calcium dependent domain containing 4B	15	62163535-62165283	Predicted intracellular proteins	Evidence at transcript level	HPA046880	Uncertain				Cervical cancer:4.22e-4 (favourable)	Mixed	Tissue enhanced		adipose tissue: 15.3	pancreas: 8.1	Cell line enhanced		HUVEC TERT2: 1.6
C2CD4C	FAM148C, KIAA1957, NLF3	ENSG00000183186	C2 calcium dependent domain containing 4C	19	405438-409170	Predicted intracellular proteins	Evidence at protein level	HPA055915	Uncertain		Approved	Vesicles		Tissue enhanced	Group enriched	6	adipose tissue: 2.6;cerebral cortex: 10.6;gallbladder: 4.4	endometrium: 0.9	Cell line enhanced		HDLM-2: 5.9;NTERA-2: 6.2;SCLC-21H: 13.0;U-2 OS: 6.8
C2CD4D	FAM148D	ENSG00000225556	C2 calcium dependent domain containing 4D	1	151837819-151840557	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		skin: 1.9	cerebral cortex: 1.2	Cell line enriched	8	HDLM-2: 17.9
C2CD5	CDP138, KIAA0528	ENSG00000111731	C2 calcium dependent domain containing 5	12	22448583-22544546	Predicted intracellular proteins	Evidence at protein level	HPA046194	Approved		Approved	Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 51.5	Expressed in all		
C2orf15	MGC29762	ENSG00000273045	Chromosome 2 open reading frame 15	2	99141485-99151487	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:1.23e-4 (favourable), Ovarian cancer:4.95e-4 (favourable)	Mixed	Mixed			thyroid gland: 9.9	Cell line enhanced		SCLC-21H: 13.7
C2orf42	FLJ20558	ENSG00000115998	Chromosome 2 open reading frame 42	2	70149880-70248615	Predicted intracellular proteins	Evidence at protein level	HPA031840, HPA031841, HPA031842	Enhanced		Enhanced	Nucleus	Pancreatic cancer:5.94e-5 (favourable)	Expressed in all	Tissue enriched	6	testis: 109.7	fallopian tube: 18.7	Expressed in all		
C2orf49	asw, MGC5509	ENSG00000135974	Chromosome 2 open reading frame 49	2	105337359-105349211	Predicted intracellular proteins	Evidence at protein level	HPA043846, HPA060814	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:5.06e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 24.2	Expressed in all		
C2orf50	FLJ25143	ENSG00000150873	Chromosome 2 open reading frame 50	2	11133053-11146790	Predicted intracellular proteins	Evidence at protein level	HPA062894	Enhanced					Mixed	Tissue enriched	10	fallopian tube: 22.7	cerebral cortex: 2.3	Cell line enhanced		CAPAN-2: 1.0;T-47d: 1.0
C2orf54	FLJ22671	ENSG00000172478	Chromosome 2 open reading frame 54	2	240886048-240896889	Predicted intracellular proteins	Evidence at protein level	HPA052722			Approved	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:2.77e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 112.1;skin: 51.5	tonsil: 25.5	Group enriched	7	CACO-2: 49.6;HaCaT: 39.3;SK-BR-3: 116.4
C2orf61	FLJ40172	ENSG00000239605	Chromosome 2 open reading frame 61	2	47045538-47155287	Predicted intracellular proteins	Evidence at transcript level	HPA047366, HPA052691	Approved		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enhanced		testis: 1.3	gallbladder: 0.3	Cell line enhanced		Karpas-707: 1.4
C2orf61		ENSG00000273269	Chromosome 2 open reading frame 61	2	47065941-47176511	Predicted intracellular proteins	Evidence at transcript level	HPA047366, HPA052691	Approved		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	224	testis: 22.3	all non-specific tissues: 0.0	Not detected		
C2orf68		ENSG00000168887	Chromosome 2 open reading frame 68	2	85606654-85612066	Predicted intracellular proteins	Evidence at protein level	HPA051143	Uncertain		Approved	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Mitochondria	Renal cancer:1.11e-6 (unfavourable), Endometrial cancer:1.12e-6 (unfavourable), Liver cancer:6.76e-6 (unfavourable)	Expressed in all	Expressed in all			endometrium: 26.2	Expressed in all		
C2orf70	LOC339778	ENSG00000173557	Chromosome 2 open reading frame 70	2	26562582-26579532	Predicted intracellular proteins	Evidence at protein level	HPA062453	Enhanced		Approved	Nuclear membrane<br>Vesicles	Pancreatic cancer:6.49e-4 (favourable)	Mixed	Group enriched	6	fallopian tube: 12.0;stomach: 4.9;testis: 17.5	thyroid gland: 1.9	Cell line enhanced		A-431: 3.6;CAPAN-2: 2.7;EFO-21: 1.8;RPTEC TERT1: 2.8
C2orf71	FLJ34931, RP54	ENSG00000179270	Chromosome 2 open reading frame 71	2	29060976-29074261	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051819	Uncertain					Not detected	Not detected			heart muscle,ovary: 0.3	Not detected		
C2orf72	LOC257407	ENSG00000204128	Chromosome 2 open reading frame 72	2	231037490-231049719	Predicted intracellular proteins	Evidence at protein level	HPA044962	Uncertain		Approved	Nucleus<br>Plasma membrane	Renal cancer:4.74e-4 (unfavourable), Pancreatic cancer:5.27e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 2.8;colon: 2.9;liver: 4.7	stomach: 1.3	Cell line enhanced		BEWO: 8.2;CACO-2: 1.7;EFO-21: 2.9
C2orf73	FLJ40298	ENSG00000177994	Chromosome 2 open reading frame 73	2	54330034-54383742	Predicted intracellular proteins	Evidence at transcript level	HPA055221, HPA059596	Uncertain					Not detected	Tissue enriched	7	testis: 83.7	fallopian tube: 12.2	Not detected		
C2orf76	AIM29, LOC130355, MGC104437	ENSG00000186132	Chromosome 2 open reading frame 76	2	119302225-119366828	Predicted intracellular proteins	Evidence at protein level	HPA044977, HPA055362	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:2.16e-8 (unfavourable)	Expressed in all	Expressed in all			epididymis: 53.2	Expressed in all		
C2orf78	COG5373, FLJ43987, hCG1989538	ENSG00000187833	Chromosome 2 open reading frame 78	2	73784189-73817147	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	142	testis: 14.2	all non-specific tissues: 0.0	Not detected		
C2orf80	GONDA1, LOC389073	ENSG00000188674	Chromosome 2 open reading frame 80	2	208165343-208190073	Predicted intracellular proteins	Evidence at transcript level	HPA042639			Approved	Golgi apparatus		Tissue enriched	Tissue enriched	28	cerebral cortex: 37.5	testis: 1.3	Cell line enhanced		NTERA-2: 1.7
C2orf81	hCG40743, LOC388963	ENSG00000284308	Chromosome 2 open reading frame 81	2	74414176-74421591	Predicted intracellular proteins	Evidence at protein level	HPA049564, HPA054835	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center			Tissue enhanced		fallopian tube: 28.5;testis: 23.0	parathyroid gland: 7.9	Cell line enhanced		SCLC-21H: 20.9;SH-SY5Y: 20.5
C2orf88	MGC13057, smAKAP	ENSG00000187699	Chromosome 2 open reading frame 88	2	189879609-190203484	Predicted intracellular proteins	Evidence at protein level	HPA049549	Approved				Endometrial cancer:4.97e-4 (favourable), Renal cancer:7.79e-4 (favourable), Melanoma:9.39e-4 (unfavourable)	Tissue enhanced	Expressed in all			testis: 92.3	Group enriched	6	HEL: 97.1;K-562: 82.2;RT4: 46.8
C2orf91		ENSG00000205086	Chromosome 2 open reading frame 91	2	41935368-41954266	Predicted intracellular proteins	Evidence at transcript level	HPA042517	Uncertain					Tissue enriched	Tissue enhanced		lung: 2.5	adrenal gland: 1.0	Group enriched	6	AN3-CA: 3.8;HDLM-2: 13.8
C3orf14	HT021	ENSG00000114405	Chromosome 3 open reading frame 14	3	62318973-62336213	Predicted intracellular proteins	Evidence at transcript level	HPA048286	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.33e-5 (favourable)	Expressed in all	Mixed			breast: 62.2	Cell line enhanced		MCF7: 415.8
C3orf20	DKFZP434N1817	ENSG00000131379	Chromosome 3 open reading frame 20	3	14675099-14773034	Predicted intracellular proteins	Evidence at protein level	HPA039584	Uncertain					Not detected	Tissue enriched	29	testis: 10.4	lymph node,tonsil: 0.3	Cell line enhanced		Daudi: 2.9;HEL: 7.7;U-698: 4.4
C3orf22	MGC34728	ENSG00000180697	Chromosome 3 open reading frame 22	3	126526999-126558965	Predicted intracellular proteins	Evidence at protein level	HPA059199	Enhanced					Not detected	Tissue enriched	326	testis: 32.6	all non-specific tissues: 0.0	Not detected		
C3orf30	FLJ32859, TSCPA	ENSG00000163424	Chromosome 3 open reading frame 30	3	119146150-119160042	Predicted intracellular proteins	Evidence at protein level	HPA062468	Enhanced					Not detected	Tissue enriched	438	testis: 94.4	kidney: 0.2	Not detected		
C3orf36	FLJ22173	ENSG00000221972	Chromosome 3 open reading frame 36	3	133928145-133929812	Predicted intracellular proteins	Evidence at transcript level	HPA046432	Uncertain					Mixed	Tissue enriched	7	seminal vesicle: 11.8	parathyroid gland: 1.6	Cell line enhanced		EFO-21: 2.2;TIME: 1.5
C3orf38	MGC26717	ENSG00000179021	Chromosome 3 open reading frame 38	3	88149743-88168729	Predicted intracellular proteins	Evidence at protein level	HPA034736, HPA034737	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Ovarian cancer:3.55e-4 (favourable), Prostate cancer:4.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.0	Expressed in all		
C3orf49		ENSG00000163632	Chromosome 3 open reading frame 49	3	63819362-63848636	Predicted intracellular proteins	Evidence at transcript level	HPA053582	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.2;testis: 2.1	skin: 0.5	Not detected		
C3orf62	FLJ43654	ENSG00000188315	Chromosome 3 open reading frame 62	3	49268602-49277909	Predicted intracellular proteins	Evidence at protein level	HPA043328			Approved	Nuclear speckles	Urothelial cancer:1.62e-5 (favourable), Stomach cancer:3.29e-5 (favourable), Breast cancer:3.93e-4 (favourable), Liver cancer:5.20e-4 (unfavourable), Pancreatic cancer:8.15e-4 (favourable), Lung cancer:8.88e-4 (favourable), Head and neck cancer:9.72e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 28.5	ovary: 8.8	Expressed in all		
C3orf67	FLJ42117, FLJ42930	ENSG00000163689	Chromosome 3 open reading frame 67	3	58717365-59050084	Predicted intracellular proteins	Evidence at protein level	HPA069696			Approved	Golgi apparatus		Mixed	Tissue enhanced		esophagus: 13.2;testis: 47.0	fallopian tube: 6.3	Mixed		
C3orf70		ENSG00000187068	Chromosome 3 open reading frame 70	3	185078050-185153014	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA041861	Uncertain		Approved	Cytosol	Renal cancer:6.40e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		smooth muscle: 26.0	cerebral cortex: 19.1	Cell line enhanced		SCLC-21H: 23.4;SK-BR-3: 6.5;WM-115: 10.7
C3orf84		ENSG00000236980	Chromosome 3 open reading frame 84	3	49177632-49191858	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	77	testis: 7.6	all non-specific tissues: 0.0	Not detected		
C4orf17	DKFZP434G072	ENSG00000138813	Chromosome 4 open reading frame 17	4	99511004-99542303	Predicted intracellular proteins	Evidence at protein level	HPA060374, HPA060564	Uncertain					Not detected	Tissue enriched	352	testis: 35.2	all non-specific tissues: 0.0	Not detected		
C4orf19	FLJ11017	ENSG00000154274	Chromosome 4 open reading frame 19	4	37453941-37623495	Predicted intracellular proteins	Evidence at protein level	HPA043458, HPA052894	Enhanced		Supported	Cell Junctions	Renal cancer:1.49e-11 (favourable)	Mixed	Mixed			rectum: 26.9	Group enriched	6	RT4: 70.0;SK-BR-3: 25.9;T-47d: 116.1
C4orf22		ENSG00000197826	Chromosome 4 open reading frame 22	4	80335720-80963756	Predicted intracellular proteins	Evidence at transcript level	HPA043383	Approved		Approved	Plasma membrane<br>Cytosol		Not detected	Group enriched	23	fallopian tube: 30.6;testis: 47.6	lung: 1.7	Cell line enhanced		A-431: 1.1;BJ: 1.4;SCLC-21H: 1.2
C4orf33	FLJ33703	ENSG00000151470	Chromosome 4 open reading frame 33	4	129093317-129116640	Predicted intracellular proteins	Evidence at protein level	HPA061199	Uncertain		Approved	Nuclear bodies<br>Golgi apparatus	Urothelial cancer:2.49e-5 (favourable), Renal cancer:3.04e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 28.2	Mixed		
C4orf36	MGC26744	ENSG00000163633	Chromosome 4 open reading frame 36	4	86876205-86936202	Predicted intracellular proteins	Evidence at protein level	HPA057434	Uncertain		Approved	Focal adhesion sites<br>Cytosol	Renal cancer:7.69e-5 (favourable)	Mixed	Tissue enhanced		testis: 10.6	skin: 5.7	Mixed		
C4orf45	FLJ25371	ENSG00000164123	Chromosome 4 open reading frame 45	4	158893134-159038760	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	50	testis: 20.1	bone marrow: 0.4	Not detected		
C4orf46	LOC201725, RCDG1	ENSG00000205208	Chromosome 4 open reading frame 46	4	158666679-158672255	Predicted intracellular proteins	Evidence at protein level	HPA047287, HPA052670	Uncertain		Approved	Nucleoplasm		Expressed in all	Tissue enhanced		testis: 22.3	bone marrow: 8.4	Expressed in all		
C4orf47	LOC441054	ENSG00000205129	Chromosome 4 open reading frame 47	4	185426249-185449826	Predicted intracellular proteins	Evidence at transcript level	HPA043662	Uncertain		Approved	Vesicles	Renal cancer:4.75e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 21.6;testis: 24.2	thyroid gland: 7.8	Cell line enhanced		U-87 MG: 5.8
C4orf50	FLJ46481	ENSG00000181215	Chromosome 4 open reading frame 50	4	5897373-6018507	Predicted intracellular proteins	Evidence at transcript level	HPA058292	Uncertain					Not detected	Not detected			cerebral cortex: 0.9	Not detected		
C4orf51		ENSG00000237136	Chromosome 4 open reading frame 51	4	145680115-145771032	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	19	testis: 9.2	epididymis: 0.4	Not detected		
C5orf22	FLJ11193	ENSG00000082213	Chromosome 5 open reading frame 22	5	31532266-31555058	Predicted intracellular proteins	Evidence at protein level	HPA043062	Approved		Approved	Nuclear membrane	Liver cancer:6.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 14.5	Expressed in all		
C5orf24	FLJ37562	ENSG00000181904	Chromosome 5 open reading frame 24	5	134845680-134859737	Predicted intracellular proteins	Evidence at protein level	HPA057749, HPA062502	Uncertain		Supported	Nucleus	Renal cancer:5.86e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 49.8	Expressed in all		
C5orf30	FLJ25291	ENSG00000181751	Chromosome 5 open reading frame 30	5	103258702-103278660	Predicted intracellular proteins	Evidence at protein level	HPA043434	Uncertain				Liver cancer:1.78e-5 (unfavourable), Endometrial cancer:2.66e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 31.4	Cell line enhanced		BJ: 149.2;U-138 MG: 113.8
C5orf34	FLJ32363	ENSG00000172244	Chromosome 5 open reading frame 34	5	43486701-43515145	Predicted intracellular proteins	Evidence at protein level	HPA045386	Approved				Endometrial cancer:2.65e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 7.7	prostate: 3.9	Mixed		
C5orf38	CEI, IRX2NB	ENSG00000186493	Chromosome 5 open reading frame 38	5	2752131-2755397	Predicted intracellular proteins	Evidence at protein level	HPA073667			Enhanced	Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		lung: 13.7;salivary gland: 13.0	skin: 8.5	Cell line enhanced		BEWO: 79.2;hTCEpi: 32.4;SiHa: 37.3
C5orf47	LOC133491	ENSG00000185056	Chromosome 5 open reading frame 47	5	173973779-174006140	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	250	testis: 39.4	cerebral cortex,parathyroid gland: 0.1	Not detected		
C5orf49	LOC134121	ENSG00000215217	Chromosome 5 open reading frame 49	5	7830378-7851490	Predicted intracellular proteins	Evidence at protein level	HPA043759	Enhanced					Tissue enhanced	Group enriched	10	fallopian tube: 120.5;testis: 30.9	lung: 7.8	Not detected		
C5orf51	LOC285636	ENSG00000205765	Chromosome 5 open reading frame 51	5	41904188-41921636	Predicted intracellular proteins	Evidence at protein level	HPA043779, HPA063816	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 27.1	Expressed in all		
C5orf52		ENSG00000187658	Chromosome 5 open reading frame 52	5	157671553-157680143	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	21	testis: 38.7	colon: 1.8	Not detected		
C5orf56		ENSG00000197536	Chromosome 5 open reading frame 56	5	132410636-132488702	Predicted intracellular proteins	Evidence at transcript level	HPA043790			Approved	Mitochondria	Renal cancer:3.13e-6 (unfavourable)	Mixed	Mixed			spleen: 25.0	Cell line enhanced		Karpas-707: 38.7;U-266/70: 24.5
C5orf58		ENSG00000234511	Chromosome 5 open reading frame 58	5	170232447-170252575	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	88	testis: 372.5	bone marrow: 4.2	Cell line enriched	9	U-266/84: 53.7
C5orf63	FLJ44606, YDR286C	ENSG00000164241	Chromosome 5 open reading frame 63	5	127042558-127073492	Predicted intracellular proteins	Evidence at transcript level	HPA043240	Approved		Approved	Mitochondria		Mixed	Mixed			cerebral cortex: 36.8	Cell line enhanced		U-87 MG: 49.1
C5orf67		ENSG00000225940	Chromosome 5 open reading frame 67	5	56511567-56606232	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Group enriched	8	epididymis: 19.8;kidney: 9.4	thyroid gland: 1.9	Group enriched	7	CACO-2: 1.7;EFO-21: 5.3;U-266/70: 4.8
C6orf106	dJ391O22.4, FLJ22195	ENSG00000196821	Chromosome 6 open reading frame 106	6	34587288-34696859	Predicted intracellular proteins	Evidence at protein level	HPA034489, HPA034490	Approved		Approved	Nuclear speckles		Expressed in all	Expressed in all			testis: 125.7	Expressed in all		
C6orf118	bA85G2.1, MGC23884	ENSG00000112539	Chromosome 6 open reading frame 118	6	165279664-165309607	Predicted intracellular proteins	Evidence at transcript level	HPA029787, HPA029789	Approved		Uncertain	Mitochondria		Tissue enhanced	Group enriched	6	fallopian tube: 26.2;testis: 12.8	lung: 3.2	Cell line enhanced		AF22: 2.7;SCLC-21H: 1.8
C6orf132	bA7K24.2	ENSG00000188112	Chromosome 6 open reading frame 132	6	42101118-42142619	Predicted intracellular proteins	Evidence at protein level	HPA044588	Enhanced		Approved	Golgi apparatus<br>Cytosol	Pancreatic cancer:4.90e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 80.8	skin: 49.9	Cell line enhanced		A-431: 56.9;CACO-2: 48.3;CAPAN-2: 42.1
C6orf141	MGC46457	ENSG00000197261	Chromosome 6 open reading frame 141	6	49550646-49561907	Predicted intracellular proteins	Evidence at protein level	HPA036199	Uncertain		Approved	Nuclear membrane	Breast cancer:3.92e-6 (favourable), Endometrial cancer:1.15e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 9.3	duodenum: 6.2	Cell line enhanced		HaCaT: 7.6;PC-3: 10.6;T-47d: 6.8
C6orf163		ENSG00000203872	Chromosome 6 open reading frame 163	6	87344849-87365463	Predicted intracellular proteins	Evidence at protein level	HPA044797, HPA052927	Uncertain		Uncertain	Nucleoplasm		Mixed	Tissue enriched	6	testis: 14.0	fallopian tube: 2.4	Mixed		
C6orf201	dJ1013A10.5	ENSG00000185689	Chromosome 6 open reading frame 201	6	4079209-4130951	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	23	testis: 30.1	fallopian tube: 1.3	Not detected		
C6orf203	HSPC230, PRED31	ENSG00000130349	Chromosome 6 open reading frame 203	6	107028213-107051342	Predicted intracellular proteins	Evidence at protein level	HPA049535	Approved				Urothelial cancer:2.11e-5 (favourable), Renal cancer:4.09e-5 (favourable), Pancreatic cancer:3.29e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 47.6	Expressed in all		
C6orf222	DKFZp779B1540	ENSG00000189325	Chromosome 6 open reading frame 222	6	36315757-36336885	Predicted intracellular proteins	Evidence at protein level	HPA038407, HPA058189	Uncertain					Group enriched	Tissue enhanced		duodenum: 24.7;small intestine: 26.4	rectum: 6.2	Not detected		
C6orf223	MGC45491	ENSG00000181577	Chromosome 6 open reading frame 223	6	44000580-44005958	Predicted intracellular proteins	Evidence at transcript level	HPA035765, HPA046117	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:9.38e-5 (unfavourable), Liver cancer:4.59e-4 (unfavourable)	Mixed	Group enriched	10	breast: 22.7;lung: 5.6	duodenum: 1.3	Cell line enhanced		A-431: 21.4;RPTEC TERT1: 25.1;THP-1: 9.6
C6orf226	LOC441150	ENSG00000221821	Chromosome 6 open reading frame 226	6	42890265-42890816	Predicted intracellular proteins	Evidence at protein level	HPA045350	Approved		Approved	Nuclear speckles	Breast cancer:1.93e-5 (favourable), Renal cancer:3.35e-4 (favourable), Pancreatic cancer:5.13e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 13.4	Mixed		
C6orf229		ENSG00000260286	Chromosome 6 open reading frame 229	6	24797321-24798889	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	12	testis: 21.8	lung: 1.7	Not detected		
C6orf48	D6S57, G8	ENSG00000204387	Chromosome 6 open reading frame 48	6	31834608-31839766	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Expressed in all			ovary: 110.8	Expressed in all		
C6orf52		ENSG00000137434	Chromosome 6 open reading frame 52	6	10671418-10694797	Predicted intracellular proteins	Evidence at transcript level	HPA051142	Uncertain		Approved	Nuclear speckles	Endometrial cancer:6.50e-5 (favourable)	Mixed	Tissue enhanced		testis: 18.0	fallopian tube: 10.5	Mixed		
C6orf62	DKFZP564G182, FLJ12619, XTP12	ENSG00000112308	Chromosome 6 open reading frame 62	6	24704861-24720836	Predicted intracellular proteins	Evidence at protein level	HPA030564, HPA030566	Enhanced		Approved	Cytosol	Urothelial cancer:3.62e-6 (favourable), Liver cancer:5.77e-5 (unfavourable), Ovarian cancer:4.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 174.4	Expressed in all		
C7orf25	MGC2821	ENSG00000136197	Chromosome 7 open reading frame 25	7	42908726-42912305	Predicted intracellular proteins	Evidence at protein level	HPA020120, HPA049635	Approved		Supported	Nucleoplasm<br>Cytosol		Not detected	Mixed			testis: 7.9	Expressed in all		
C7orf26	MGC2718	ENSG00000146576	Chromosome 7 open reading frame 26	7	6590017-6608726	Predicted intracellular proteins	Evidence at protein level	HPA042899, HPA052175	Uncertain		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments<br>Cytosol	Pancreatic cancer:6.95e-5 (favourable)	Expressed in all	Expressed in all			spleen: 25.7	Expressed in all		
C7orf31		ENSG00000153790	Chromosome 7 open reading frame 31	7	25134697-25180356	Predicted intracellular proteins	Evidence at protein level	HPA020346			Approved	Nucleoplasm<br>Mitochondria	Glioma:1.52e-4 (unfavourable)	Expressed in all	Tissue enriched	14	testis: 131.4	parathyroid gland: 9.5	Mixed		
C7orf33		ENSG00000170279	Chromosome 7 open reading frame 33	7	148590565-148615860	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Cell line enriched	26	SCLC-21H: 2.6
C7orf43	FLJ10925	ENSG00000146826	Chromosome 7 open reading frame 43	7	100154420-100158715	Predicted intracellular proteins	Evidence at protein level	HPA019359, HPA029463, HPA029464	Approved		Enhanced	Vesicles<br>Plasma membrane<br>Microtubule organizing center	Pancreatic cancer:6.19e-5 (favourable)	Expressed in all	Expressed in all			testis: 33.1	Expressed in all		
C7orf49	FLJ22450, FLJ27285, MGC5242, MRI, MRI-2	ENSG00000122783	Chromosome 7 open reading frame 49	7	135092363-135170795	Predicted intracellular proteins	Evidence at protein level	HPA020060	Approved		Approved	Golgi apparatus	Liver cancer:2.52e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.6	Expressed in all		
C7orf50	MGC11257, YCR016W	ENSG00000146540	Chromosome 7 open reading frame 50	7	996986-1138260	Predicted intracellular proteins	Evidence at protein level	HPA052281	Approved		Approved	Nucleus<br>Nucleoli	Pancreatic cancer:6.20e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 55.8	Expressed in all		
C7orf55-LUC7L2		ENSG00000269955	C7orf55-LUC7L2 readthrough	7	139341360-139422599	Predicted intracellular proteins	Evidence at protein level	HPA045663, HPA051631	Approved		Approved	Nucleus		Not detected	Expressed in all			skeletal muscle: 21.1	Expressed in all		
C7orf61	IMAGE:4839025	ENSG00000185955	Chromosome 7 open reading frame 61	7	100456615-100464271	Predicted intracellular proteins	Evidence at protein level	HPA060395	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enriched	10	testis: 52.9	cerebral cortex: 5.2	Cell line enhanced		HUVEC TERT2: 20.9;TIME: 12.0
C7orf62	MGC26647	ENSG00000164645	Chromosome 7 open reading frame 62	7	88794106-88795721	Predicted intracellular proteins	Evidence at transcript level	HPA023817, HPA024163			Uncertain	Nucleoplasm<br>Mitochondria		Not detected	Tissue enriched	519	testis: 51.9	all non-specific tissues: 0.0	Not detected		
C7orf72		ENSG00000164500	Chromosome 7 open reading frame 72	7	50096036-50159830	Predicted intracellular proteins	Evidence at transcript level	HPA026094	Uncertain					Not detected	Tissue enriched	31	testis: 5.9	lymph node,tonsil: 0.1	Cell line enriched	9	U-698: 7.2
C7orf77		ENSG00000275356	Chromosome 7 open reading frame 77	7	124777292-124790689	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			lung: 0.5	Cell line enriched	8	HDLM-2: 3.8
C8orf22		ENSG00000168333	Chromosome 8 open reading frame 22	8	49054311-49076090	Predicted intracellular proteins	Evidence at transcript level	HPA060329	Uncertain				Renal cancer:2.06e-10 (unfavourable)	Group enriched	Tissue enriched	79	skeletal muscle: 362.1	prostate: 4.5	Cell line enriched	13	HEL: 1.3
C8orf33	FLJ20989	ENSG00000182307	Chromosome 8 open reading frame 33	8	145052378-145056030	Predicted intracellular proteins	Evidence at protein level	HPA024812, HPA026104	Approved		Uncertain	Nucleoplasm<br>Plasma membrane	Breast cancer:2.77e-4 (unfavourable), Liver cancer:8.95e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 26.2	Expressed in all		
C8orf34	vest-1, VEST1	ENSG00000165084	Chromosome 8 open reading frame 34	8	68330722-68819022	Predicted intracellular proteins	Evidence at protein level	HPA044420, HPA053065	Uncertain		Supported	Nucleus<br>Nucleoli<br>Golgi apparatus		Mixed	Tissue enhanced		fallopian tube: 14.7;parathyroid gland: 18.7	cerebral cortex: 6.1	Cell line enhanced		HEK93: 2.4;LHCN-M2: 1.9;RH-30: 2.3
C8orf37	BBS21, CORD16, FLJ30600, RP64	ENSG00000156172	Chromosome 8 open reading frame 37	8	95244919-95269201	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024198	Approved		Approved	Plasma membrane<br>Cell Junctions<br>Cytosol	Endometrial cancer:4.63e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 6.3	Mixed		
C8orf4	hTC-1, TC-1, TC1	ENSG00000176907	Chromosome 8 open reading frame 4	8	40153455-40155308	Predicted intracellular proteins	Evidence at protein level	HPA027188	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			placenta: 233.9	Cell line enhanced		AF22: 130.7;BJ hTERT+: 107.2;EFO-21: 81.1;HeLa: 56.7;RPTEC TERT1: 49.9
C8orf44	FLJ11267	ENSG00000213865	Chromosome 8 open reading frame 44	8	66667615-66685564	Predicted intracellular proteins	Evidence at protein level	HPA043660, HPA054753	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.08e-7 (unfavourable), Urothelial cancer:2.68e-6 (favourable), Pancreatic cancer:4.21e-4 (favourable)	Expressed in all	Mixed			epididymis: 21.2	Expressed in all		
C8orf44-SGK3		ENSG00000270024	C8orf44-SGK3 readthrough	8	66667596-66860472	Predicted intracellular proteins	Evidence at transcript level	HPA006699, HPA027146	Uncertain		Approved	Nucleoplasm<br>Vesicles		Not detected	Not detected			cervix, uterine: 0.9	Cell line enhanced		fHDF/TERT166: 1.3
C8orf46	MGC33510	ENSG00000169085	Chromosome 8 open reading frame 46	8	66460003-66518524	Predicted intracellular proteins	Evidence at protein level	HPA075134			Approved	Nuclear speckles		Tissue enriched	Tissue enriched	14	cerebral cortex: 65.1	seminal vesicle: 4.5	Cell line enhanced		LHCN-M2: 1.8;SK-MEL-30: 1.9;T-47d: 2.8;WM-115: 2.9
C8orf48	FLJ25402	ENSG00000164743	Chromosome 8 open reading frame 48	8	13566843-13568287	Predicted intracellular proteins	Evidence at protein level	HPA025068, HPA026107, HPA027431, HPA027440	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 12.4	thyroid gland: 7.3	Cell line enhanced		U-87 MG: 11.0;WM-115: 8.6
C8orf58	FLJ34715	ENSG00000241852	Chromosome 8 open reading frame 58	8	22599601-22604150	Predicted intracellular proteins	Evidence at transcript level	HPA024667, HPA028286	Uncertain		Approved	Nuclear bodies	Renal cancer:3.58e-6 (unfavourable)	Expressed in all	Mixed			placenta: 23.9	Mixed		
C8orf59		ENSG00000176731	Chromosome 8 open reading frame 59	8	85214076-85220421	Predicted intracellular proteins	Evidence at protein level	HPA044805, HPA071903			Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:0.00e+0 (unfavourable)	Expressed in all	Expressed in all			breast: 119.1	Expressed in all		
C8orf74		ENSG00000171060	Chromosome 8 open reading frame 74	8	10672637-10700593	Predicted intracellular proteins	Evidence at protein level	HPA027986	Uncertain		Uncertain	Nucleoplasm		Not detected	Tissue enriched	42	testis: 12.4	skin: 0.2	Not detected		
C8orf76	FLJ14825	ENSG00000189376	Chromosome 8 open reading frame 76	8	123219957-123241398	Predicted intracellular proteins	Evidence at transcript level	HPA023708	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:5.95e-11 (unfavourable), Endometrial cancer:1.61e-4 (unfavourable), Breast cancer:9.95e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 16.1	Expressed in all		
C8orf82	MGC70857	ENSG00000213563	Chromosome 8 open reading frame 82	8	144525733-144529132	Predicted intracellular proteins	Evidence at protein level	CAB034331	Uncertain		Approved	Nucleus	Renal cancer:1.70e-5 (favourable)	Expressed in all	Expressed in all			prostate: 33.3	Expressed in all		
C8orf86	FLJ43582	ENSG00000196166	Chromosome 8 open reading frame 86	8	38510834-38528662	Predicted intracellular proteins	Evidence at transcript level	HPA025066	Uncertain					Not detected	Tissue enhanced		duodenum: 1.0	small intestine: 0.5	Not detected		
C8orf88		ENSG00000253250	Chromosome 8 open reading frame 88	8	90958637-90985257	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:6.23e-6 (unfavourable), Melanoma:4.90e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 183.0	smooth muscle: 46.1	Mixed		
C8orf89		ENSG00000274443	Chromosome 8 open reading frame 89	8	73241329-73259502	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	8	testis: 13.3	cervix, uterine: 1.5	Not detected		
C9orf116	MGC29761, PIERCE1, RbEST47	ENSG00000160345	Chromosome 9 open reading frame 116	9	135495181-135501734	Predicted intracellular proteins	Evidence at protein level	HPA021439, HPA065287	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:3.53e-5 (favourable)	Expressed in all	Group enriched	6	epididymis: 31.1;fallopian tube: 154.4;testis: 63.3	thyroid gland: 13.6	Cell line enhanced		T-47d: 39.2;U-2197: 39.8
C9orf129	bA165J3.3	ENSG00000204352	Chromosome 9 open reading frame 129	9	93318199-93346414	Predicted intracellular proteins	Evidence at transcript level	HPA071515			Uncertain	Mitochondria		Not detected	Group enriched	7	cerebral cortex: 4.1;testis: 1.7	epididymis: 0.4	Cell line enriched	9	NTERA-2: 2.1
C9orf131	MGC41945	ENSG00000174038	Chromosome 9 open reading frame 131	9	35041095-35045991	Predicted intracellular proteins	Evidence at transcript level	HPA022029			Approved	Mitochondria		Not detected	Tissue enriched	12	testis: 62.1	endometrium: 5.1	Cell line enhanced		RT4: 7.4
C9orf135		ENSG00000204711	Chromosome 9 open reading frame 135	9	69820793-69906232	Predicted intracellular proteins	Evidence at protein level	HPA021261, HPA021325	Uncertain					Tissue enriched	Group enriched	8	fallopian tube: 55.2;testis: 24.3	parathyroid gland: 5.1	Group enriched	9	HAP1: 11.5;NTERA-2: 29.5
C9orf142	PAXX, XLS	ENSG00000148362	Chromosome 9 open reading frame 142	9	136992418-136993984	Predicted intracellular proteins	Evidence at protein level	HPA045268	Uncertain		Supported	Nucleus	Cervical cancer:2.06e-4 (favourable), Pancreatic cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			spleen: 21.9	Expressed in all		
C9orf152	bA470J20.2	ENSG00000188959	Chromosome 9 open reading frame 152	9	110190048-110208189	Predicted intracellular proteins	Evidence at protein level	HPA050769	Approved		Supported	Nucleus	Endometrial cancer:7.22e-5 (favourable)	Mixed	Tissue enhanced		rectum: 44.5	colon: 32.5	Group enriched	6	SK-BR-3: 6.9;T-47d: 16.7
C9orf153	bA507D14.1	ENSG00000187753	Chromosome 9 open reading frame 153	9	86220265-86259657	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	29	testis: 53.7	bone marrow: 1.8	Mixed		
C9orf16	EST00098, FLJ12823, MGC4639	ENSG00000171159	Chromosome 9 open reading frame 16	9	128160260-128163928	Predicted intracellular proteins	Evidence at protein level	HPA020725	Uncertain		Approved	Microtubules	Liver cancer:3.13e-5 (unfavourable), Cervical cancer:7.60e-4 (favourable), Colorectal cancer:9.91e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 151.4	Expressed in all		
C9orf172		ENSG00000232434	Chromosome 9 open reading frame 172	9	136844415-136848801	Predicted intracellular proteins	Evidence at protein level	HPA021200	Uncertain		Approved	Focal adhesion sites<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 7.4	spleen: 3.3	Mixed		
C9orf24	bA573M23.4, CBE1, MGC32921, MGC33614, NYD-SP22, SMRP1	ENSG00000164972	Chromosome 9 open reading frame 24	9	34379019-34397832	Predicted intracellular proteins	Evidence at protein level	HPA053008	Enhanced				Endometrial cancer:3.23e-5 (favourable), Pancreatic cancer:1.75e-4 (favourable)	Tissue enhanced	Group enriched	11	fallopian tube: 173.9;testis: 65.3	lung: 10.9	Not detected		
C9orf3	AOPEP, AP-O, APO, C90RF3, FLJ14675	ENSG00000148120	Chromosome 9 open reading frame 3	9	94726701-95087218	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004633, HPA072729	Approved		Approved	Cell Junctions	Renal cancer:6.33e-5 (favourable)	Expressed in all	Expressed in all			skin: 50.0	Mixed		
C9orf40	FLJ10110	ENSG00000135045	Chromosome 9 open reading frame 40	9	74946581-74952886	Predicted intracellular proteins	Evidence at protein level	HPA042167	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Liver cancer:3.43e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.9	Mixed		
C9orf43	MGC17358	ENSG00000157653	Chromosome 9 open reading frame 43	9	113410054-113429684	Predicted intracellular proteins	Evidence at protein level	HPA021310			Approved	Cytosol		Mixed	Tissue enriched	43	testis: 73.9	parathyroid gland: 1.7	Mixed		
C9orf50	FLJ35803	ENSG00000179058	Chromosome 9 open reading frame 50	9	129612225-129620776	Predicted intracellular proteins	Evidence at protein level	HPA026743	Enhanced					Mixed	Tissue enhanced		testis: 8.1	cerebral cortex: 1.8	Cell line enhanced		MCF7: 1.0
C9orf64	MGC10999	ENSG00000165118	Chromosome 9 open reading frame 64	9	83938311-83956986	Predicted intracellular proteins	Evidence at protein level	HPA054903, HPA066190	Uncertain		Approved	Golgi apparatus	Renal cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.4	Mixed		
C9orf66	FLJ31158	ENSG00000183784	Chromosome 9 open reading frame 66	9	212824-215741	Predicted intracellular proteins	Evidence at transcript level	HPA035652	Uncertain				Renal cancer:1.32e-5 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 17.8	adrenal gland: 4.0	Cell line enhanced		BEWO: 1.5;THP-1: 2.3
C9orf72	DENNL72, MGC23980	ENSG00000147894	Chromosome 9 open reading frame 72	9	27546545-27573866	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023873	Uncertain					Expressed in all	Expressed in all			testis: 32.1	Mixed		
C9orf78	HCA59, HSPC220	ENSG00000136819	Chromosome 9 open reading frame 78	9	129827290-129835863	Predicted intracellular proteins	Evidence at protein level	HPA021216, HPA021232, HPA021242	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.49e-7 (favourable)	Expressed in all	Expressed in all			bone marrow: 71.1	Expressed in all		
C9orf85	MGC61599	ENSG00000155621	Chromosome 9 open reading frame 85	9	71911510-71986054	Predicted intracellular proteins	Evidence at protein level	HPA050767			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 13.9	Mixed		
CA1	Car1	ENSG00000133742	Carbonic anhydrase 1	8	85327608-85379014	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006558, CAB025790	Enhanced					Group enriched	Group enriched	30	bone marrow: 1216.6;colon: 1022.8;rectum: 2316.0	smooth muscle: 49.9	Cell line enriched	1560	HEL: 1145.7
CA13	CAXIII, FLJ37995, MGC59868	ENSG00000185015	Carbonic anhydrase 13	8	85220587-85284073	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024689, CAB025567	Enhanced		Uncertain	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:9.40e-4 (favourable)	Expressed in all	Mixed			small intestine: 16.5	Cell line enhanced		HEL: 14.2
CA2	CA-II, CAII, Car2	ENSG00000104267	Carbonic anhydrase 2	8	85463852-85481493	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001550, CAB010102	Enhanced				Renal cancer:5.57e-6 (favourable)	Expressed in all	Tissue enhanced		colon: 604.8;rectum: 627.5;stomach: 918.8	kidney: 308.3	Group enriched	11	HaCaT: 204.1;HEK93: 884.1;THP-1: 278.7
CA3	CAIII, Car3	ENSG00000164879	Carbonic anhydrase 3	8	85373436-85449040	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004967, HPA021775, HPA026700	Enhanced				Breast cancer:4.24e-6 (favourable)	Group enriched	Tissue enriched	13	skeletal muscle: 1838.7	prostate: 138.3	Group enriched	34	HEL: 44.2;RH-30: 77.2
CA5A	CA5, CAV, CAVA	ENSG00000174990	Carbonic anhydrase 5A	16	87881546-87936529	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		liver: 1.3	bone marrow: 0.8	Cell line enhanced		Hep G2: 1.4
CA5B		ENSG00000169239	Carbonic anhydrase 5B	X	15688830-15788409	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012618	Uncertain		Supported	Mitochondria	Renal cancer:6.66e-6 (favourable)	Expressed in all	Mixed			cervix, uterine: 34.1	Cell line enhanced		hTERT-HME1: 26.3
CA7		ENSG00000168748	Carbonic anhydrase 7	16	66844379-66854153	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047237	Uncertain					Tissue enhanced	Tissue enhanced		colon: 54.6;rectum: 49.8	small intestine: 10.7	Cell line enhanced		REH: 1.0;SCLC-21H: 1.0;THP-1: 1.2
CA8	CALS, CARP	ENSG00000178538	Carbonic anhydrase 8	8	60187347-60281412	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024748, CAB025545, CAB047309	Supported				Pancreatic cancer:5.79e-5 (favourable)	Mixed	Tissue enriched	6	parathyroid gland: 105.5	epididymis: 17.4	Cell line enhanced		HEK93: 15.9;K-562: 29.2;NB-4: 11.8
CAAP1	C9orf82, CAAP, FLJ13657	ENSG00000120159	Caspase activity and apoptosis inhibitor 1	9	26840685-26892804	Predicted intracellular proteins	Evidence at protein level	HPA020404, HPA024029, HPA024100	Uncertain		Approved	Vesicles	Renal cancer:7.94e-9 (favourable), Ovarian cancer:1.27e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 49.6	Mixed		
CAB39	CGI-66, MO25	ENSG00000135932	Calcium binding protein 39	2	230712845-230821075	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037112	Supported		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:9.05e-6 (favourable), Pancreatic cancer:8.33e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 78.9	Expressed in all		
CAB39L	bA103J18.3, FLJ12577, MO2L	ENSG00000102547	Calcium binding protein 39 like	13	49308650-49444126	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003686, HPA045954	Uncertain		Approved	Vesicles	Renal cancer:1.94e-13 (favourable), Ovarian cancer:2.28e-4 (unfavourable), Prostate cancer:7.91e-4 (favourable)	Expressed in all	Expressed in all			prostate: 66.2	Cell line enhanced		CACO-2: 32.9;RT4: 33.1
CABIN1	KIAA0330, PPP3IN	ENSG00000099991	Calcineurin binding protein 1	22	24011192-24178628	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043296	Approved		Approved	Nucleoplasm<br>Aggresome<br>Cytosol	Endometrial cancer:9.57e-5 (favourable), Renal cancer:2.94e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 33.9	Expressed in all		
CABP2		ENSG00000167791	Calcium binding protein 2	11	67518912-67524517	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
CABP4	CSNB2B	ENSG00000175544	Calcium binding protein 4	11	67452406-67460313	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 10.0	epididymis,placenta: 2.4	Cell line enhanced		CAPAN-2: 4.4;HMC-1: 18.9
CABP5	CABP3	ENSG00000105507	Calcium binding protein 5	19	48029953-48044053	Predicted intracellular proteins	Evidence at protein level	HPA043698	Supported					Not detected	Not detected			bone marrow,epididymis,spleen: 0.1	Not detected		
CABS1	C4orf35, CLPH, FLJ32897, NYD-SP26	ENSG00000145309	Calcium binding protein, spermatid associated 1	4	70334966-70337116	Predicted intracellular proteins	Evidence at protein level	HPA044016, HPA055352	Enhanced					Not detected	Tissue enriched	601	testis: 151.7	salivary gland: 0.2	Not detected		
CABYR	CBP86, CT88, FSP-2	ENSG00000154040	Calcium binding tyrosine phosphorylation regulated	18	24138956-24161603	Predicted intracellular proteins	Evidence at protein level	HPA040703, HPA047801	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:4.75e-4 (unfavourable)	Mixed	Tissue enriched	39	testis: 445.1	cerebral cortex: 11.3	Cell line enhanced		SiHa: 25.8
CACNA2D2	KIAA0558	ENSG00000007402	Calcium voltage-gated channel auxiliary subunit alpha2delta 2	3	50362799-50504244	FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034771, HPA071829	Enhanced		Approved	Vesicles	Endometrial cancer:7.62e-5 (unfavourable), Pancreatic cancer:1.21e-4 (favourable)	Tissue enhanced	Tissue enriched	6	lung: 72.9	testis: 12.4	Cell line enriched	8	SH-SY5Y: 201.7
CACNB1	CACNLB1	ENSG00000067191	Calcium voltage-gated channel auxiliary subunit beta 1	17	39173456-39197703	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023343	Approved				Endometrial cancer:3.80e-4 (unfavourable)	Mixed	Group enriched	6	cerebral cortex: 46.7;skeletal muscle: 108.5	skin: 12.3	Mixed		
CACNB2	CACNLB2, MYSB	ENSG00000165995	Calcium voltage-gated channel auxiliary subunit beta 2	10	18140677-18541869	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035325, HPA035326	Uncertain				Renal cancer:3.56e-5 (favourable)	Mixed	Mixed			cerebral cortex: 26.3	Cell line enhanced		HAP1: 8.3;HSkMC: 7.1
CACNB3	CACNLB3	ENSG00000167535	Calcium voltage-gated channel auxiliary subunit beta 3	12	48813794-48828941	FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA059515			Approved	Golgi apparatus<br>Vesicles		Mixed	Mixed			endometrium: 40.0	Cell line enhanced		U-937: 85.2
CACTIN	C19orf29, cactin, fSAPc, NY-REN-24	ENSG00000105298	Cactin, spliceosome C complex subunit	19	3610641-3626815	Predicted intracellular proteins	Evidence at protein level	HPA042504, HPA042548	Approved		Supported	Nucleoplasm<br>Nuclear speckles<br>Cytosol	Endometrial cancer:3.69e-5 (favourable)	Expressed in all	Expressed in all			spleen: 14.4	Expressed in all		
CACUL1	C10orf46, CAC1, FLJ40409, MGC33215	ENSG00000151893	CDK2 associated cullin domain 1	10	118674167-118755249	Predicted intracellular proteins	Evidence at protein level	HPA050611			Approved	Nucleoplasm	Liver cancer:1.34e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.2	Expressed in all		
CACYBP	S100A6BP, SIP	ENSG00000116161	Calcyclin binding protein	1	174999163-175011715	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025753, HPA057038	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.12e-6 (unfavourable), Ovarian cancer:1.39e-5 (favourable), Renal cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 60.7	Expressed in all		
CAD		ENSG00000084774	Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase	2	27217390-27243943	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB007781, HPA057266, HPA069341	Supported		Supported	Nucleoplasm	Liver cancer:1.72e-11 (unfavourable), Renal cancer:1.82e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 22.0	Expressed in all		
CADPS	CAPS, CAPS1, KIAA1121, UNC-31	ENSG00000163618	Calcium dependent secretion activator	3	62398346-62875389	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059328	Enhanced		Approved	Vesicles		Mixed	Group enriched	8	adrenal gland: 21.6;cerebral cortex: 94.1	heart muscle: 7.5	Cell line enhanced		SCLC-21H: 23.2;SK-MEL-30: 7.0;U-698: 8.9;U-87 MG: 20.1
CADPS2	CAPS2	ENSG00000081803	Calcium dependent secretion activator 2	7	122318425-122886759	Predicted intracellular proteins	Evidence at protein level	HPA056398			Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.01e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 45.7	Cell line enhanced		HUVEC TERT2: 36.2;Karpas-707: 40.4
CAGE1	bA69L16.7, CT95, CTAG3	ENSG00000164304	Cancer antigen 1	6	7326656-7389743	Predicted intracellular proteins	Evidence at protein level	HPA029832	Uncertain					Not detected	Tissue enriched	77	testis: 8.3	endometrium: 0.1	Not detected		
CALB1	CALB	ENSG00000104327	Calbindin 1	8	90058608-90095475	Predicted intracellular proteins	Evidence at protein level	CAB002138, HPA023099, HPA056734	Enhanced		Supported	Vesicles	Endometrial cancer:1.60e-4 (unfavourable)	Mixed	Tissue enriched	15	kidney: 336.9	cerebral cortex: 22.5	Cell line enhanced		A-431: 116.6;EFO-21: 179.9;NTERA-2: 72.7
CALB2	CAL2	ENSG00000172137	Calbindin 2	16	71358713-71390438	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000106, HPA007305, HPA007306	Enhanced	Supported	Enhanced	Cytosol	Colorectal cancer:5.78e-5 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 54.6;testis: 24.9	adrenal gland: 12.7	Cell line enhanced		HEL: 57.0;HMC-1: 116.3;U-2 OS: 39.2
CALCOCO1	calphoglin, Cocoa, KIAA1536	ENSG00000012822	Calcium binding and coiled-coil domain 1	12	53708517-53727745	Predicted intracellular proteins	Evidence at protein level	HPA038313, HPA038314	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			skin: 160.7	Expressed in all		
CALCOCO2	MGC17318, NDP52	ENSG00000136436	Calcium binding and coiled-coil domain 2	17	48830988-48866522	Predicted intracellular proteins	Evidence at protein level	HPA022989, HPA023019, HPA023195	Enhanced		Supported	Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 249.4	Expressed in all		
CALD1	CDM, H-CAD, L-CAD	ENSG00000122786	Caldesmon 1	7	134744252-134970728	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000006, HPA008066, HPA017330	Enhanced		Enhanced	Plasma membrane<br>Actin filaments	Renal cancer:1.84e-5 (unfavourable), Melanoma:3.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 1289.8	smooth muscle: 1185.8	Cell line enhanced		fHDF/TERT166: 910.7
CALM1	CALML2, CAMI, DD132, PHKD	ENSG00000198668	Calmodulin 1	14	90396502-90408261	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transporters	Evidence at protein level	CAB018558, HPA044999	Supported		Approved	Vesicles	Urothelial cancer:2.38e-5 (unfavourable), Pancreatic cancer:5.62e-4 (favourable), Renal cancer:6.49e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1325.6	Expressed in all		
CALM2	CAMII, PHKD	ENSG00000143933	Calmodulin 2	2	47160082-47176601	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transporters	Evidence at protein level	CAB007790, HPA044999	Approved				Thyroid cancer:1.94e-5 (favourable), Liver cancer:8.35e-5 (unfavourable), Endometrial cancer:4.84e-4 (unfavourable), Breast cancer:5.05e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1533.3	Expressed in all		
CALM3	PHKD	ENSG00000160014	Calmodulin 3	19	46601074-46610793	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transporters	Evidence at protein level	HPA044999	Approved				Lung cancer:2.07e-4 (unfavourable), Thyroid cancer:9.10e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1313.4	Expressed in all		
CALML3	CLP	ENSG00000178363	Calmodulin like 3	10	5524009-5526771	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010070, HPA044999	Approved					Group enriched	Tissue enhanced		esophagus: 165.7;skin: 42.6	tonsil: 22.4	Group enriched	6	A-431: 12.2;hTCEpi: 3.8;RPMI-8226: 2.6
CALML4	MGC4809, NY-BR-20	ENSG00000129007	Calmodulin like 4	15	68190705-68206110	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA051109	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Mixed	Tissue enhanced		duodenum: 79.8;small intestine: 74.4	colon: 58.5	Mixed		
CALML5	CLSP	ENSG00000178372	Calmodulin like 5	10	5498697-5499555	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA040725	Enhanced		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:2.59e-5 (favourable)	Group enriched	Group enriched	8	salivary gland: 260.7;skin: 650.6	breast: 55.6	Cell line enriched	24	A-431: 355.7
CALML6	CAGLP	ENSG00000169885	Calmodulin like 6	1	1914827-1917296	Predicted intracellular proteins, RAS pathway related proteins	Evidence at transcript level							Not detected	Tissue enriched	9	skeletal muscle: 37.6	esophagus: 4.2	Cell line enhanced		AN3-CA: 1.6
CAMK2N1	CaMKIINalpha	ENSG00000162545	Calcium/calmodulin dependent protein kinase II inhibitor 1	1	20482391-20486220	Predicted intracellular proteins	Evidence at protein level						Head and neck cancer:1.37e-7 (unfavourable), Lung cancer:1.66e-4 (unfavourable), Liver cancer:5.49e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 321.1	small intestine: 95.6	Cell line enhanced		AN3-CA: 195.3;CAPAN-2: 173.9
CAMK2N2	CaM-KIIN	ENSG00000163888	Calcium/calmodulin dependent protein kinase II inhibitor 2	3	184259213-184261463	Predicted intracellular proteins	Evidence at protein level	HPA050835			Supported	Nucleus<br>Centrosome	Cervical cancer:9.77e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 12.2;cerebral cortex: 40.4	pancreas: 5.6	Cell line enhanced		REH: 28.6;SCLC-21H: 37.1;U-138 MG: 32.1
CAMKK1	CAMKKA, DKFZp761M0423, MGC34095	ENSG00000004660	Calcium/calmodulin dependent protein kinase kinase 1	17	3860315-3894891	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009111, HPA028062	Approved		Supported	Cytosol	Pancreatic cancer:2.65e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 51.5	seminal vesicle: 14.7	Cell line enhanced		U-87 MG: 27.3
CAMKMT	C2orf34, CLNMT	ENSG00000143919	Calmodulin-lysine N-methyltransferase	2	44361950-44772592	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA067912			Supported	Nucleus	Glioma:5.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 24.3	Expressed in all		
CAMKV	MGC8407, VACAMKL	ENSG00000164076	CaM kinase like vesicle associated	3	49857988-49870222	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007656, CAB034931	Enhanced		Approved	Nucleoplasm<br>Cytokinetic bridge		Group enriched	Tissue enriched	55	cerebral cortex: 86.2	testis: 1.5	Cell line enhanced		AF22: 6.4;HAP1: 8.9;NTERA-2: 30.7;SCLC-21H: 12.2;SH-SY5Y: 7.1
CAMSAP1	DKFZp434F195, FLJ31228	ENSG00000130559	Calmodulin regulated spectrin associated protein 1	9	135808487-135907228	Predicted intracellular proteins	Evidence at protein level	HPA020527, HPA024161	Approved		Supported	Mitotic spindle<br>Cytosol	Renal cancer:3.09e-5 (favourable)	Expressed in all	Expressed in all			testis: 34.2	Expressed in all		
CAMSAP2	CAMSAP1L1, KIAA1078	ENSG00000118200	Calmodulin regulated spectrin associated protein family member 2	1	200739558-200860704	Predicted intracellular proteins	Evidence at protein level	HPA026304, HPA026511, HPA027302	Enhanced		Supported	Microtubule ends<br>Cytosol	Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 64.5	Cell line enhanced		hTERT-HME1: 124.5
CAMSAP3	KIAA1543, Nezha, PPP1R80	ENSG00000076826	Calmodulin regulated spectrin associated protein family member 3	19	7595902-7618304	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043830, HPA062149	Enhanced		Approved	Nucleoplasm<br>Centrosome	Renal cancer:7.55e-7 (favourable)	Expressed in all	Tissue enhanced		skin: 22.1	duodenum: 15.2	Cell line enhanced		CACO-2: 22.2
CAMTA1	KIAA0833	ENSG00000171735	Calmodulin binding transcription activator 1	1	6785324-7769706	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036342, HPA036343	Approved		Supported	Nucleoli<br>Cytosol	Ovarian cancer:4.10e-4 (favourable), Liver cancer:5.25e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 99.9	Expressed in all		
CAMTA2	KIAA0909	ENSG00000108509	Calmodulin binding transcription activator 2	17	4967992-4987652	Predicted intracellular proteins	Evidence at protein level	HPA051147			Approved	Nucleus<br>Actin filaments<br>Mitochondria	Pancreatic cancer:6.00e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 40.5	Mixed		
CAND1	DKFZp434M1414, KIAA0829, TIP120, TIP120A	ENSG00000111530	Cullin associated and neddylation dissociated 1	12	67269281-67319951	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055748, HPA062833, HPA069053	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:1.15e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.1	Expressed in all		
CAND2	KIAA0667, TIP120B, Tp120b	ENSG00000144712	Cullin associated and neddylation dissociated 2 (putative)	3	12796472-12871916	Predicted intracellular proteins	Evidence at protein level	HPA005777	Approved		Approved	Nuclear bodies<br>Cytosol		Mixed	Tissue enhanced		skeletal muscle: 42.3;testis: 29.3	heart muscle: 16.3	Cell line enhanced		HEK93: 18.6;REH: 11.8
CAP1	CAP	ENSG00000131236	Adenylate cyclase associated protein 1	1	40040233-40072649	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030124	Approved		Supported	Cytosol	Liver cancer:1.44e-6 (unfavourable)	Expressed in all	Expressed in all			appendix: 417.0	Expressed in all		
CAP2		ENSG00000112186	CAP, adenylate cyclase-associated protein, 2 (yeast)	6	17393216-17557792	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA050530, HPA054147	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 125.1;skeletal muscle: 220.8	heart muscle: 70.1	Mixed		
CAPG	AFCP, MCP	ENSG00000042493	Capping actin protein, gelsolin like	2	85394748-85418432	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018843, HPA019080, HPA019092	Enhanced		Enhanced	Nucleus	Liver cancer:3.22e-5 (unfavourable), Renal cancer:2.96e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 238.0	Cell line enhanced		CAPAN-2: 560.8;HMC-1: 788.5;SK-MEL-30: 524.4
CAPN1	CANP, CANPL1, muCANP, muCL	ENSG00000014216	Calpain 1	11	65180566-65212006	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005992	Enhanced		Supported	Cytosol	Renal cancer:7.06e-8 (favourable), Pancreatic cancer:4.30e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 243.9	Expressed in all		
CAPN10		ENSG00000142330	Calpain 10	2	240586716-240617705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004170, HPA056098	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:4.78e-6 (unfavourable), Pancreatic cancer:7.94e-5 (favourable), Head and neck cancer:8.47e-5 (favourable)	Expressed in all	Mixed			skin,spleen: 14.5	Expressed in all		
CAPN11		ENSG00000137225	Calpain 11	6	44158811-44184402	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018070, HPA030955	Enhanced					Not detected	Tissue enriched	33	testis: 54.8	adipose tissue,breast: 1.6	Group enriched	5	NTERA-2: 2.2;TIME: 4.7
CAPN12		ENSG00000182472	Calpain 12	19	38730187-38769904	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053322			Approved	Nucleoplasm<br>Focal adhesion sites	Renal cancer:5.90e-6 (unfavourable)	Mixed	Group enriched	6	cervix, uterine: 7.3;gallbladder: 35.5	lung: 3.8	Cell line enriched	16	HMC-1: 34.3
CAPN13	FLJ23523	ENSG00000162949	Calpain 13	2	30722771-30820542	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029496, HPA029497, HPA030034	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		rectum: 26.8;small intestine: 32.4;stomach: 26.5	duodenum: 20.8	Cell line enhanced		RT4: 7.4;SK-BR-3: 16.4;T-47d: 2.8
CAPN14		ENSG00000214711	Calpain 14	2	31173056-31233858	Enzymes, Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	26	esophagus: 88.2	tonsil: 3.3	Cell line enhanced		U-266/70: 2.1
CAPN15	SOLH	ENSG00000103326	Calpain 15	16	527717-554636	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011960	Uncertain		Approved	Nucleus		Expressed in all	Mixed			small intestine: 17.8	Expressed in all		
CAPN2	CANPL2, CANPml, mCANP	ENSG00000162909	Calpain 2	1	223701593-223776018	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024470	Approved	Approved	Supported	Cytosol	Renal cancer:2.19e-4 (favourable), Pancreatic cancer:2.50e-4 (unfavourable), Urothelial cancer:6.21e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 267.0	Mixed		
CAPN3	CANP3, LGMD2, LGMD2A, nCL-1, p94	ENSG00000092529	Calpain 3	15	42359500-42412318	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040052	Enhanced					Tissue enriched	Tissue enhanced		epididymis: 217.3;skeletal muscle: 336.8	skin: 92.9	Cell line enriched	27	SK-MEL-30: 202.7
CAPN5	ADNIV, HTRA3, nCL-3, VRNI	ENSG00000149260	Calpain 5	11	77066932-77126155	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033237	Uncertain				Endometrial cancer:2.16e-6 (unfavourable)	Expressed in all	Mixed			colon: 61.0	Mixed		
CAPN6	CalpM, CANPX, CAPNX	ENSG00000077274	Calpain 6	X	111245103-111270523	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040383			Uncertain	Cytosol		Tissue enhanced	Tissue enhanced		epididymis: 255.9;placenta: 117.0;seminal vesicle: 100.4	endometrium: 37.2	Group enriched	9	HAP1: 3.4;HDLM-2: 9.9;NTERA-2: 16.1
CAPN7	PalBH	ENSG00000131375	Calpain 7	3	15206152-15252918	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046617	Uncertain				Colorectal cancer:4.85e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.4	Expressed in all		
CAPN8	nCL-2	ENSG00000203697	Calpain 8	1	223538007-223665734	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA073939			Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles		Tissue enhanced	Tissue enriched	8	stomach: 286.5	rectum: 37.3	Cell line enriched	9	RT4: 62.5
CAPN9	GC36, nCL-4	ENSG00000135773	Calpain 9	1	230747384-230802003	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020398, CAB033483	Enhanced					Mixed	Tissue enhanced		rectum: 25.2;stomach: 58.9	colon: 14.4	Cell line enriched	9	SCLC-21H: 17.8
CAPNS1	30K, CANP, CANPS, CAPN4, CDPS	ENSG00000126247	Calpain small subunit 1	19	36139575-36150353	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006872	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			esophagus: 515.2	Expressed in all		
CAPNS2	MGC12536, MGC14804	ENSG00000256812	Calpain small subunit 2	16	55566672-55567687	Predicted intracellular proteins	Evidence at protein level	HPA059749, HPA076768	Enhanced		Approved	Cytosol		Group enriched	Tissue enhanced		esophagus: 59.9;skin: 109.3	urinary bladder: 30.3	Cell line enriched	8	hTCEpi: 158.7
CAPRIN1	caprin-1, GPIAP1, M11S1, RNG105	ENSG00000135387	Cell cycle associated protein 1	11	34051683-34101156	Predicted intracellular proteins	Evidence at protein level	HPA018126, HPA063617	Approved				Liver cancer:8.67e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 248.9	Expressed in all		
CAPRIN2	C1QDC1, caprin-2, EEG1, FLJ11391, FLJ22569, RNG140	ENSG00000110888	Caprin family member 2	12	30709552-30754951	Predicted intracellular proteins	Evidence at protein level	HPA039746	Supported		Supported	Nucleus<br>Centrosome<br>Cytosol	Renal cancer:3.50e-5 (unfavourable), Urothelial cancer:8.36e-4 (favourable)	Expressed in all	Mixed			testis: 32.8	Mixed		
CAPS	CAPS1, MGC126562	ENSG00000105519	Calcyphosine	19	5911707-5915877	Predicted intracellular proteins	Evidence at protein level	HPA043520	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:7.63e-5 (favourable), Head and neck cancer:8.60e-4 (favourable)	Tissue enriched	Tissue enriched	10	fallopian tube: 448.7	lung: 45.1	Cell line enhanced		SK-BR-3: 46.0
CAPS2		ENSG00000180881	Calcyphosine 2	12	75275979-75390928	Predicted intracellular proteins	Evidence at transcript level	HPA040004	Uncertain		Approved	Nucleus<br>Nucleoli<br>Centrosome		Mixed	Tissue enhanced		fallopian tube: 15.9	testis: 6.9	Mixed		
CAPSL	MGC26610	ENSG00000152611	Calcyphosine like	5	35904295-35938779	Predicted intracellular proteins	Evidence at protein level	HPA046811, HPA058495	Enhanced		Approved	Nucleus<br>Microtubules		Group enriched	Tissue enriched	10	fallopian tube: 175.4	testis: 17.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 6.8;BJ hTERT+ SV40 Large T+ RasG12V: 6.0;HBF TERT88: 4.6;REH: 7.2;U-698: 13.2
CAPZA1		ENSG00000116489	Capping actin protein of muscle Z-line alpha subunit 1	1	112619173-112671619	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB045963	Approved				Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.54e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 133.9	Expressed in all		
CAPZA2	CAPPA2, CAPZ	ENSG00000198898	Capping actin protein of muscle Z-line alpha subunit 2	7	116811070-116922049	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007470, HPA007643	Uncertain		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:3.65e-6 (favourable), Liver cancer:9.34e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 41.6	Expressed in all		
CAPZA3	CAPPA3, Gsg3	ENSG00000177938	Capping actin protein of muscle Z-line alpha subunit 3	12	18738101-18739187	Predicted intracellular proteins	Evidence at protein level	HPA038688	Enhanced					Not detected	Tissue enriched	100	testis: 281.4	skin: 2.8	Not detected		
CAPZB		ENSG00000077549	Capping actin protein of muscle Z-line beta subunit	1	19338776-19485539	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031531, HPA056066	Approved		Enhanced	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:1.85e-4 (unfavourable), Renal cancer:3.57e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 490.8	Expressed in all		
CARD10	BIMP1, CARMA3	ENSG00000100065	Caspase recruitment domain family member 10	22	37490362-37519542	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029359, HPA055612	Approved		Approved	Vesicles<br>Intermediate filaments<br>Cytosol	Liver cancer:7.73e-6 (unfavourable), Endometrial cancer:3.47e-4 (favourable)	Expressed in all	Mixed			small intestine: 39.9	Cell line enhanced		U-2197: 76.9
CARD11	BIMP3, CARMA1	ENSG00000198286	Caspase recruitment domain family member 11	7	2906141-3043945	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052984	Approved				Renal cancer:6.68e-8 (unfavourable), Urothelial cancer:1.10e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 54.4;spleen: 40.2	appendix: 28.3	Cell line enhanced		Daudi: 86.5;RT4: 71.8;U-698: 73.9
CARD14	BIMP2, CARMA2, PSORS2	ENSG00000141527	Caspase recruitment domain family member 14	17	80169992-80209331	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 17.8	esophagus: 7.0	Cell line enhanced		MCF7: 6.3;SK-BR-3: 8.0;T-47d: 22.6
CARD16	COP, COP1, PSEUDO-ICE	ENSG00000204397	Caspase recruitment domain family member 16	11	105041326-105101431	Predicted intracellular proteins	Evidence at protein level	HPA053981, HPA062805	Uncertain		Uncertain	Mitochondria	Renal cancer:6.93e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 159.0	Cell line enhanced		AN3-CA: 139.1;HHSteC: 214.1;HUVEC TERT2: 101.4;TIME: 91.2
CARD17	INCA	ENSG00000255221	Caspase recruitment domain family member 17	11	105092469-105101431	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		skin: 3.5	lymph node: 1.9	Cell line enriched	5	AN3-CA: 1.4
CARD18	ICEBERG, pseudo-ICE, UNQ5804	ENSG00000255501	Caspase recruitment domain family member 18	11	105137721-105139726	Predicted intracellular proteins	Evidence at protein level	HPA038582	Approved					Tissue enhanced	Group enriched	7	breast: 10.6;skin: 29.7	esophagus: 3.0	Cell line enhanced		BEWO: 3.0;hTCEpi: 1.9;U-2 OS: 2.9
CARD6	CINCIN1	ENSG00000132357	Caspase recruitment domain family member 6	5	40841184-40860175	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036438	Uncertain		Approved	Focal adhesion sites<br>Cytosol		Expressed in all	Mixed			spleen: 17.0	Cell line enhanced		HUVEC TERT2: 26.1;TIME: 27.4
CARD8	CARDINAL, Dakar, KIAA0955, NDPP, TUCAN	ENSG00000105483	Caspase recruitment domain family member 8	19	48180770-48255946	Predicted intracellular proteins	Evidence at protein level	HPA042071, HPA043513	Supported		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.63e-8 (unfavourable), Urothelial cancer:1.72e-5 (favourable)	Expressed in all	Expressed in all			spleen: 49.1	Expressed in all		
CARD9		ENSG00000187796	Caspase recruitment domain family member 9	9	136361903-136373681	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059502	Enhanced					Mixed	Tissue enhanced		bone marrow: 7.1;spleen: 8.2	appendix: 5.7	Cell line enhanced		HMC-1: 49.3;NB-4: 30.7;THP-1: 30.1
CARF	ALS2CR8, CaRF, FLJ21579, NYD-SP24	ENSG00000138380	Calcium responsive transcription factor	2	202912214-202987063	Predicted intracellular proteins	Evidence at protein level	HPA034557, HPA043191	Approved		Approved	Nucleoli fibrillar center<br>Vesicles<br>Cytosol		Mixed	Mixed			testis: 37.0	Expressed in all		
CARHSP1	CRHSP-24, CSDC1	ENSG00000153048	Calcium regulated heat stable protein 1	16	8852942-8869012	Predicted intracellular proteins	Evidence at protein level	HPA051911	Approved				Urothelial cancer:7.24e-4 (favourable)	Expressed in all	Expressed in all			testis: 260.3	Expressed in all		
CARMIL1	CARMIL, dJ501N12.1, FLJ20048, LRRC16, LRRC16A	ENSG00000079691	Capping protein regulator and myosin 1 linker 1	6	25279078-25620530	Predicted intracellular proteins	Evidence at protein level	HPA029038, HPA029039	Enhanced		Supported	Cytosol		Expressed in all	Mixed			testis: 22.2	Mixed		
CARMIL2	LRRC16C, RLTPR	ENSG00000159753	Capping protein regulator and myosin 1 linker 2	16	67644919-67657569	Predicted intracellular proteins	Evidence at protein level	HPA041402	Approved					Mixed	Tissue enhanced		appendix: 16.2;lymph node: 25.0;spleen: 15.1	tonsil: 10.1	Cell line enhanced		Daudi: 45.8;MOLT-4: 51.3;REH: 96.9;RPMI-8226: 40.2;U-698: 73.2
CARMIL3	BC008134, C14orf121, crml-1, LRRC16B	ENSG00000186648	Capping protein regulator and myosin 1 linker 3	14	24052000-24069728	Predicted intracellular proteins	Evidence at protein level	HPA030596	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 6.7;skin: 6.2	testis: 3.0	Cell line enhanced		Daudi: 7.8;HMC-1: 6.5;Karpas-707: 4.8;SCLC-21H: 12.8;SH-SY5Y: 5.6
CARNMT1	C9orf41, FLJ25795	ENSG00000156017	Carnosine N-methyltransferase 1	9	74981020-75028423	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026756	Uncertain					Expressed in all	Expressed in all			testis: 30.0	Expressed in all		
CARS	CARS1	ENSG00000110619	Cysteinyl-tRNA synthetase	11	3000922-3057613	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737	Enhanced		Enhanced	Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.16e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.2	Mixed		
CARS2	FLJ12118	ENSG00000134905	Cysteinyl-tRNA synthetase 2, mitochondrial (putative)	13	110641412-110713603	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041776	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:2.49e-5 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Endometrial cancer:1.84e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 28.4	Expressed in all		
CASC1	FLJ10921, LAS1, PPP1R54	ENSG00000118307	Cancer susceptibility 1	12	25108420-25195162	Predicted intracellular proteins	Evidence at protein level	HPA039662	Enhanced				Renal cancer:3.13e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 22.5;testis: 41.8	thyroid gland: 7.0	Mixed		
CASC10	bA418C1.3, C10orf114	ENSG00000204682	Cancer susceptibility 10	10	21492658-21497262	Predicted intracellular proteins	Evidence at transcript level	HPA064131	Uncertain		Approved	Nucleoplasm	Glioma:5.81e-4 (unfavourable), Urothelial cancer:5.86e-4 (unfavourable)	Mixed	Mixed			placenta: 4.0	Cell line enhanced		AF22: 11.6;AN3-CA: 15.3;BEWO: 15.2
CASC3	BTZ, MLN51	ENSG00000108349	Cancer susceptibility 3	17	40140318-40172183	Cancer-related genes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA024592, HPA050262	Approved		Approved	Nuclear membrane		Expressed in all	Expressed in all			testis: 95.2	Expressed in all		
CASC4	DKFZp459F1927, H63	ENSG00000166734	Cancer susceptibility 4	15	44288729-44415758	Predicted intracellular proteins	Evidence at protein level	HPA043015, HPA049488	Enhanced		Supported	Golgi apparatus	Renal cancer:1.45e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 141.6	Expressed in all		
CASKIN1	ANKS5A, KIAA1306	ENSG00000167971	CASK interacting protein 1	16	2177180-2196525	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055990, CAB079050	Enhanced	Supported	Approved	Nucleus<br>Cytosol		Mixed	Tissue enriched	33	cerebral cortex: 20.3	testis: 0.6	Cell line enhanced		HDLM-2: 13.8;SCLC-21H: 7.7
CASKIN2	ANKS5B, FLJ21609, KIAA1139	ENSG00000177303	CASK interacting protein 2	17	75500261-75515583	Predicted intracellular proteins	Evidence at protein level	HPA071906, HPA075184	Enhanced		Enhanced	Plasma membrane	Renal cancer:4.83e-8 (favourable), Pancreatic cancer:2.47e-5 (favourable)	Expressed in all	Mixed			lung: 29.0	Mixed		
CASP1	ICE, IL1BC	ENSG00000137752	Caspase 1	11	105025443-105035250	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002685, HPA003056	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.11e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 139.8	Cell line enhanced		BJ hTERT+: 91.3;U-937: 106.2
CASP10	MCH4	ENSG00000003400	Caspase 10	2	201182881-201229406	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003780, HPA017059	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:6.05e-7 (unfavourable), Liver cancer:8.54e-4 (unfavourable)	Expressed in all	Mixed			spleen: 24.1	Cell line enhanced		HUVEC TERT2: 21.4
CASP14	MGC119078, MGC119079, MICE	ENSG00000105141	Caspase 14	19	15049384-15058293	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010059, HPA027062	Enhanced		Approved	Nucleus<br>Mitochondria<br>Cytosol	Pancreatic cancer:5.96e-4 (unfavourable), Lung cancer:7.59e-4 (unfavourable)	Tissue enhanced	Tissue enriched	55	skin: 558.6	breast: 10.1	Cell line enriched	6	hTCEpi: 34.2
CASP2	ICH1, MGC2181, NEDD2, PPP1R57	ENSG00000106144	Caspase 2	7	143288215-143307696	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012175, HPA050678	Approved		Approved	Nucleoplasm	Renal cancer:5.01e-6 (unfavourable), Liver cancer:2.34e-4 (unfavourable), Ovarian cancer:2.89e-4 (favourable), Cervical cancer:7.38e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 24.9	Expressed in all		
CASP3	apopain, CPP32, CPP32B, Yama	ENSG00000164305	Caspase 3	4	184627696-184649509	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000091, HPA002643, CAB008381	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.30e-5 (unfavourable), Endometrial cancer:2.24e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 54.4	Expressed in all		
CASP4	ICE(rel)II, ICH-2, TX	ENSG00000196954	Caspase 4	11	104942866-104969436	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027588, CAB037167	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.27e-11 (unfavourable)	Expressed in all	Expressed in all			placenta: 71.8	Mixed		
CASP5	ICE(rel)III	ENSG00000137757	Caspase 5	11	104994235-105023168	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040937	Uncertain					Group enriched	Group enriched	6	appendix: 20.2;colon: 15.9;duodenum: 10.1;rectum: 14.5;small intestine: 18.9	smooth muscle: 2.7	Cell line enriched	8	HHSteC: 3.1
CASP6	MCH2	ENSG00000138794	Caspase 6	4	109688622-109703583	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB003775, HPA011337, HPA024303	Enhanced		Supported	Nucleus<br>Cytosol	Colorectal cancer:2.64e-5 (favourable), Urothelial cancer:9.93e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 46.1	Expressed in all		
CASP7	CMH-1, ICE-LAP3, MCH3	ENSG00000165806	Caspase 7	10	113679162-113730907	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB025563	Approved				Breast cancer:2.11e-4 (favourable), Renal cancer:5.90e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 74.4	Mixed		
CASP8	Casp-8, FLICE, MACH, MCH5	ENSG00000064012	Caspase 8	2	201233443-201287711	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001302, CAB002047, HPA005688, HPA006191	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.27e-6 (unfavourable), Ovarian cancer:1.25e-4 (favourable), Liver cancer:3.02e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 44.8	Expressed in all		
CASP8AP2	CED-4, FLASH, FLJ11208, KIAA1315, RIP25	ENSG00000118412	Caspase 8 associated protein 2	6	89829894-89874436	Predicted intracellular proteins	Evidence at protein level	HPA053573			Approved	Nucleoli<br>Nuclear bodies	Renal cancer:1.88e-5 (unfavourable)	Expressed in all	Mixed			lymph node: 6.4	Expressed in all		
CASP9	APAF-3, ICE-LAP6, MCH6, PPP1R56	ENSG00000132906	Caspase 9	1	15490832-15526534	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001473, CAB004348, HPA046488	Approved		Approved	Mitochondria	Urothelial cancer:1.67e-5 (favourable), Breast cancer:5.91e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 37.1	Expressed in all		
CASS4	C20orf32, HEFL, HEPL	ENSG00000087589	Cas scaffolding protein family member 4	20	56412112-56460387	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034217	Approved					Mixed	Tissue enhanced		appendix: 17.7;lung: 23.9	spleen: 10.7	Cell line enhanced		HEL: 15.8;HMC-1: 45.4;K-562: 19.8
CAST		ENSG00000153113	Calpastatin	5	96525267-96779595	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009491, HPA036881, HPA036882	Approved		Enhanced	Endoplasmic reticulum<br>Cytosol	Stomach cancer:1.20e-5 (unfavourable), Pancreatic cancer:9.27e-5 (unfavourable), Urothelial cancer:4.98e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 401.9	Mixed		
CASZ1	castor, cst, FLJ20321, SRG, ZNF693	ENSG00000130940	Castor zinc finger 1	1	10636604-10796650	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028222, HPA029927	Approved		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		skin: 26.9	prostate: 15.9	Cell line enhanced		HDLM-2: 12.4;SCLC-21H: 23.3;SK-BR-3: 14.1
CAT		ENSG00000121691	Catalase	11	34438925-34472062	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001515, HPA051282, HPA055838	Enhanced		Supported	Vesicles<br>Cytosol	Renal cancer:1.96e-8 (favourable), Liver cancer:9.67e-4 (favourable)	Expressed in all	Expressed in all			liver: 625.4	Cell line enhanced		HL-60: 310.1
CATIP	C2orf62, MGC50811	ENSG00000158428	Ciliogenesis associated TTC17 interacting protein	2	218356856-218368099	Predicted intracellular proteins	Evidence at protein level	HPA044818	Supported					Mixed	Tissue enhanced		fallopian tube: 31.9	testis: 7.3	Cell line enriched	14	BEWO: 3.7
CBFA2T2	MTGR1, ZMYND3	ENSG00000078699	CBFA2/RUNX1 translocation partner 2	20	33490075-33650036	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA060523, HPA072433	Enhanced		Approved	Nuclear speckles	Pancreatic cancer:6.93e-6 (favourable)	Expressed in all	Expressed in all			prostate: 24.2	Expressed in all		
CBFA2T3	ETO2, MTG16, MTGR2, RUNX1T3, ZMYND4	ENSG00000129993	CBFA2/RUNX1 translocation partner 3	16	88874858-88977204	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059931, HPA062423, HPA065890	Approved		Enhanced	Nucleoplasm	Head and neck cancer:3.95e-4 (favourable)	Mixed	Tissue enhanced		spleen: 18.7	lymph node: 10.4	Cell line enhanced		HEL: 57.7;K-562: 102.3;MOLT-4: 46.5;REH: 103.4;T-47d: 47.0
CBFB	PEBP2B	ENSG00000067955	Core-binding factor beta subunit	16	67029116-67101058	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038852	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:2.89e-8 (unfavourable), Liver cancer:2.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 97.5	Expressed in all		
CBL	c-Cbl, CBL2, RNF55	ENSG00000110395	Cbl proto-oncogene	11	119206276-119313926	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004350, HPA027956	Enhanced		Supported	Cytosol		Expressed in all	Mixed			testis: 33.9	Expressed in all		
CBLB	Cbl-b, RNF56	ENSG00000114423	Cbl proto-oncogene B	3	105655461-105869552	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018327, HPA019880	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			lymph node: 28.0	Cell line enhanced		U-138 MG: 63.4
CBLC	CBL-3, CBL-SL, RNF57	ENSG00000142273	Cbl proto-oncogene C	19	44777869-44800634	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB008087, HPA035266	Approved		Approved	Nucleoplasm	Renal cancer:3.11e-6 (favourable)	Mixed	Tissue enhanced		duodenum: 52.5;skin: 41.9;small intestine: 44.0	colon: 21.4	Cell line enhanced		A-431: 38.2;BEWO: 28.0;CACO-2: 23.9;CAPAN-2: 51.1;HaCaT: 37.6;HBEC3-KT: 25.9;RT4: 29.6;SK-BR-3: 24.0
CBLL1	FLJ23109, HAKAI, RNF188	ENSG00000105879	Cbl proto-oncogene like 1	7	107743697-107761667	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021773, HPA026699	Enhanced		Supported	Nuclear speckles		Expressed in all	Expressed in all			testis: 36.2	Expressed in all		
CBR1	CBR, SDR21C1	ENSG00000159228	Carbonyl reductase 1	21	36069941-36073166	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018433	Approved		Approved	Nucleus<br>Cytosol	Breast cancer:2.18e-4 (favourable), Renal cancer:4.75e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 544.9	Mixed		
CBR3	SDR21C2	ENSG00000159231	Carbonyl reductase 3	21	36134912-36146566	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018434	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.95e-6 (unfavourable)	Expressed in all	Mixed			skin: 20.7	Mixed		
CBR4	FLJ14431, SDR45C1	ENSG00000145439	Carbonyl reductase 4	4	168863770-169010275	Predicted intracellular proteins	Evidence at protein level	HPA037499	Supported				Renal cancer:3.64e-14 (favourable)	Expressed in all	Expressed in all			kidney: 28.7	Expressed in all		
CBS	HIP4	ENSG00000160200	Cystathionine-beta-synthase	21	43053191-43076943	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001223	Supported		Approved	Nucleoli<br>Vesicles		Mixed	Tissue enhanced		liver: 56.6;ovary: 31.1	cerebral cortex: 19.8	Cell line enhanced		HAP1: 171.2;HHSteC: 181.6
CBSL		ENSG00000274276	Cystathionine-beta-synthase like	21	6444869-6468040	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001223	Supported		Approved	Nucleoli<br>Vesicles		Mixed	Tissue enhanced		cerebral cortex: 45.9;liver: 27.3	thyroid gland: 22.2	Cell line enhanced		AN3-CA: 123.4;NTERA-2: 245.4;SH-SY5Y: 82.5
CBWD1		ENSG00000172785	COBW domain containing 1	9	121038-179147	Predicted intracellular proteins	Evidence at transcript level	HPA042759, HPA042813	Approved		Approved	Plasma membrane		Mixed	Expressed in all			adrenal gland: 44.8	Mixed		
CBWD2		ENSG00000136682	COBW domain containing 2	2	113437691-113496189	Predicted intracellular proteins	Evidence at transcript level	HPA042759, HPA042813	Approved		Approved	Plasma membrane	Endometrial cancer:3.22e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 18.9	Expressed in all		
CBWD3	bA561O23.1	ENSG00000196873	COBW domain containing 3	9	68232003-68300015	Predicted intracellular proteins	Evidence at transcript level	HPA042759, HPA042813	Uncertain		Approved	Plasma membrane		Not detected	Expressed in all			appendix: 25.1	Expressed in all		
CBWD5		ENSG00000147996	COBW domain containing 5	9	65668805-65734041	Predicted intracellular proteins	Evidence at transcript level	HPA042759, HPA042813	Approved		Approved	Plasma membrane		Mixed	Expressed in all			breast: 22.0	Expressed in all		
CBWD7		ENSG00000215126	COBW domain containing 7	9	41131306-41199261	Predicted intracellular proteins	Evidence at transcript level	HPA042759, HPA042813	Approved		Approved	Plasma membrane		Not detected	Tissue enhanced		adrenal gland: 4.9	breast,seminal vesicle: 2.7	Cell line enhanced		PC-3: 25.0
CBX1	CBX, HP1-BETA, HP1Hs-beta, M31, MOD1	ENSG00000108468	Chromobox 1	17	48070052-48101521	Predicted intracellular proteins	Evidence at protein level	CAB012265	Supported		Supported	Nucleus<br>Nuclear bodies	Liver cancer:2.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 125.3	Expressed in all		
CBX2	CDCA6, MGC10561	ENSG00000173894	Chromobox 2	17	79778132-79787983	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023083	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		testis: 14.3	placenta: 3.2	Cell line enhanced		REH: 87.4;SK-BR-3: 100.2
CBX3	HP1Hs-gamma	ENSG00000122565	Chromobox 3	7	26201162-26213356	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001973, HPA004902	Enhanced		Supported	Nucleus<br>Nuclear bodies	Liver cancer:2.20e-8 (unfavourable), Renal cancer:4.56e-7 (unfavourable), Pancreatic cancer:4.00e-4 (unfavourable), Breast cancer:7.92e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 201.3	Expressed in all		
CBX4	hPC2, NBP16, PC2	ENSG00000141582	Chromobox 4	17	79833156-79839429	Predicted intracellular proteins	Evidence at protein level	HPA008228, HPA012021	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:8.72e-8 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 85.1	cerebral cortex: 25.6	Expressed in all		
CBX5	HP1, HP1-ALPHA, HP1Hs-alpha	ENSG00000094916	Chromobox 5	12	54230940-54280133	Predicted intracellular proteins	Evidence at protein level	HPA016699, CAB017548	Enhanced		Enhanced	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 58.2	Expressed in all		
CBX6		ENSG00000183741	Chromobox 6	22	38861450-38872314	Predicted intracellular proteins	Evidence at protein level	HPA048653	Uncertain		Approved	Nucleus<br>Mitochondria	Pancreatic cancer:2.46e-6 (favourable), Liver cancer:8.30e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 105.8	Expressed in all		
CBX7		ENSG00000100307	Chromobox 7	22	39120167-39152674	Predicted intracellular proteins	Evidence at protein level	CAB011574, HPA048677, HPA056480	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.45e-5 (favourable), Pancreatic cancer:1.04e-4 (favourable), Cervical cancer:3.63e-4 (favourable), Colorectal cancer:3.73e-4 (unfavourable), Breast cancer:6.18e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 81.6	Cell line enhanced		HDLM-2: 34.6
CBX8	HPC3, PC3, RC1	ENSG00000141570	Chromobox 8	17	79792132-79801683	Predicted intracellular proteins	Evidence at protein level	HPA031462	Enhanced		Enhanced	Nucleoplasm	Renal cancer:5.39e-7 (unfavourable), Liver cancer:3.94e-6 (unfavourable), Pancreatic cancer:3.84e-5 (favourable)	Expressed in all	Mixed			epididymis: 13.2	Mixed		
CBY1	C22orf2, Cby, Chibby, PGEA1, PIGEA-14, PIGEA14	ENSG00000100211	Chibby family member 1, beta catenin antagonist	22	38656636-38673854	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:5.22e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 95.7	Expressed in all		
CBY3		ENSG00000204659	Chibby family member 3	5	179678583-179680974	Predicted intracellular proteins	Evidence at transcript level	HPA069037	Uncertain					Mixed	Tissue enriched	5	testis: 2.1	cerebral cortex,skin: 0.4	Cell line enhanced		HDLM-2: 1.6
CC2D1A	FLJ20241, MRT3	ENSG00000132024	Coiled-coil and C2 domain containing 1A	19	13906201-13930879	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005436, CAB015220	Supported		Supported	Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Head and neck cancer:7.02e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 35.6	Expressed in all		
CC2D1B	KIAA1836	ENSG00000154222	Coiled-coil and C2 domain containing 1B	1	52345723-52366193	Predicted intracellular proteins	Evidence at protein level	HPA027500, HPA031426	Uncertain		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.45e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 18.7	Expressed in all		
CC2D2A	JBTS9, KIAA1345, MKS6	ENSG00000048342	Coiled-coil and C2 domain containing 2A	4	15469865-15601557	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044124	Approved				Renal cancer:3.42e-9 (favourable), Stomach cancer:4.43e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 53.9	kidney: 20.8	Mixed		
CC2D2B	bA248J23.4, C10orf130	ENSG00000188649	Coiled-coil and C2 domain containing 2B	10	95907603-96032684	Predicted intracellular proteins	Evidence at protein level	HPA044091, HPA072122	Enhanced		Approved	Nucleoli		Not detected	Tissue enhanced		testis: 21.3	thyroid gland: 7.3	Mixed		
CCAR1	CARP-1, CARP1, FLJ10590	ENSG00000060339	Cell division cycle and apoptosis regulator 1	10	68721012-68792377	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA007856, HPA048513	Supported		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:1.41e-5 (unfavourable), Ovarian cancer:4.05e-5 (favourable), Renal cancer:1.37e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 34.8	Expressed in all		
CCAR2	DBC-1, DBC1, KIAA1967, NET35	ENSG00000158941	Cell cycle and apoptosis regulator 2	8	22604632-22621514	Predicted intracellular proteins	Evidence at protein level	HPA019907, HPA019943, CAB072827, CAB072828	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.60e-4 (favourable)	Expressed in all	Expressed in all			testis: 135.8	Expressed in all		
CCDC102A	MGC10992	ENSG00000135736	Coiled-coil domain containing 102A	16	57512178-57536599	Predicted intracellular proteins	Evidence at protein level	HPA040598, HPA040958	Supported		Approved	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			prostate: 5.5	Mixed		
CCDC102B	ACY1L, AN, C18orf14, FLJ23594, HsT1731	ENSG00000150636	Coiled-coil domain containing 102B	18	68715209-69055189	Predicted intracellular proteins	Evidence at protein level	HPA040623, HPA048194	Approved		Approved	Mitochondria<br>Cytosol	Renal cancer:2.90e-6 (unfavourable)	Mixed	Tissue enhanced		placenta: 41.0	gallbladder: 21.6	Cell line enhanced		ASC TERT1: 10.0;BJ hTERT+: 23.3;fHDF/TERT166: 20.3;HSkMC: 11.2
CCDC103	CILD17, FLJ13094, FLJ34211, PR46b	ENSG00000167131	Coiled-coil domain containing 103	17	44899142-44905390	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043131			Approved	Cytosol		Not detected	Group enriched	7	fallopian tube: 24.5;testis: 27.0	thyroid gland: 3.6	Cell line enhanced		A549: 10.3;U-87 MG: 9.5
CCDC105	FLJ40365	ENSG00000160994	Coiled-coil domain containing 105	19	15010744-15023269	Predicted intracellular proteins	Evidence at protein level	HPA058585	Approved					Not detected	Tissue enriched	104	testis: 11.7	skin: 0.1	Not detected		
CCDC106	HSU79303	ENSG00000173581	Coiled-coil domain containing 106	19	55641062-55653161	Predicted intracellular proteins	Evidence at protein level	HPA041925, HPA043219	Uncertain		Supported	Nucleus<br>Cytosol	Renal cancer:7.54e-11 (favourable), Pancreatic cancer:2.23e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.8	Cell line enhanced		HEK93: 77.4
CCDC110	CT52, KM-HN-1, MGC33607	ENSG00000168491	Coiled-coil domain containing 110	4	185445182-185471759	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.08e-5 (favourable)	Mixed	Tissue enriched	14	testis: 188.3	thyroid gland: 13.2	Cell line enhanced		SCLC-21H: 10.4;U-266/70: 5.6;U-266/84: 6.4
CCDC113	DKFZp434N1418, HSPC065	ENSG00000103021	Coiled-coil domain containing 113	16	58231157-58283836	Predicted intracellular proteins	Evidence at protein level	HPA040759, HPA040869	Uncertain		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:7.01e-4 (favourable), Colorectal cancer:8.65e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 50.1;testis: 32.8	parathyroid gland: 16.3	Cell line enhanced		SiHa: 30.0
CCDC114	CILD20, FLJ32926	ENSG00000105479	Coiled-coil domain containing 114	19	48296457-48321894	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042524	Approved					Tissue enhanced	Group enriched	5	fallopian tube: 6.3;testis: 5.7	lung: 1.1	Cell line enhanced		U-266/70: 1.0
CCDC115	ccp1, FLJ30131, MGC12981	ENSG00000136710	Coiled-coil domain containing 115	2	130338241-130342349	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034598	Approved		Supported	Vesicles<br>Plasma membrane	Breast cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			ovary: 55.5	Expressed in all		
CCDC116	FLJ36046	ENSG00000161180	Coiled-coil domain containing 116	22	21632716-21637327	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	29	testis: 23.1	placenta: 0.7	Cell line enhanced		HMC-1: 2.7
CCDC117	FLJ33814	ENSG00000159873	Coiled-coil domain containing 117	22	28772674-28789301	Predicted intracellular proteins	Evidence at protein level	HPA000826	Uncertain		Approved	Nucleus<br>Microtubules<br>Cytosol		Mixed	Expressed in all			testis: 67.8	Expressed in all		
CCDC12	MGC23918	ENSG00000160799	Coiled-coil domain containing 12	3	46921726-46982010	Predicted intracellular proteins	Evidence at protein level	HPA056814, HPA060530	Approved		Supported	Nucleoplasm	Renal cancer:1.15e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 58.1	Expressed in all		
CCDC120	JM11	ENSG00000147144	Coiled-coil domain containing 120	X	49053572-49069857	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA000561			Uncertain	Mitochondria		Expressed in all	Mixed			skin: 17.9	Cell line enhanced		BEWO: 28.0
CCDC121	FLJ13646, FLJ43364	ENSG00000176714	Coiled-coil domain containing 121	2	27625639-27629012	Predicted intracellular proteins	Evidence at protein level	HPA051791	Uncertain		Approved	Actin filaments<br>Cytosol	Renal cancer:1.87e-5 (favourable), Lung cancer:4.12e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 46.7	ovary: 12.2	Mixed		
CCDC122	FLJ31846	ENSG00000151773	Coiled-coil domain containing 122	13	43823909-43879727	Predicted intracellular proteins	Evidence at protein level	CAB034233, HPA054995, HPA061456	Approved		Approved	Nucleus<br>Vesicles		Mixed	Mixed			prostate,thyroid gland: 7.9	Mixed		
CCDC124		ENSG00000007080	Coiled-coil domain containing 124	19	17933016-17943991	Predicted intracellular proteins	Evidence at protein level	HPA041708, HPA046765	Supported		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:1.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 72.4	Expressed in all		
CCDC125	KENAE	ENSG00000183323	Coiled-coil domain containing 125	5	69280175-69332809	Predicted intracellular proteins	Evidence at protein level	HPA041878	Approved		Uncertain	Nucleoplasm<br>Nuclear membrane<br>Intermediate filaments	Urothelial cancer:2.51e-4 (favourable), Endometrial cancer:4.40e-4 (favourable), Breast cancer:8.06e-4 (unfavourable)	Expressed in all	Mixed			prostate: 11.5	Cell line enhanced		T-47d: 25.4
CCDC126	FLJ23031	ENSG00000169193	Coiled-coil domain containing 126	7	23597379-23644708	Predicted intracellular proteins	Evidence at protein level	HPA026883	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 62.2	Expressed in all		
CCDC127	FLJ25701	ENSG00000164366	Coiled-coil domain containing 127	5	196871-218215	Predicted intracellular proteins	Evidence at protein level	HPA045052	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:4.04e-6 (unfavourable), Renal cancer:5.95e-5 (unfavourable), Breast cancer:7.01e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 23.0	Expressed in all		
CCDC13	FLJ25467	ENSG00000244607	Coiled-coil domain containing 13	3	42692663-42773253	Predicted intracellular proteins	Evidence at protein level	HPA047429	Approved		Supported	Centrosome		Mixed	Tissue enhanced		fallopian tube: 7.6;testis: 6.8	cerebral cortex: 1.5	Not detected		
CCDC130	MGC10471	ENSG00000104957	Coiled-coil domain containing 130	19	13731760-13763296	Predicted intracellular proteins	Evidence at protein level	HPA056977	Approved		Approved	Vesicles	Head and neck cancer:7.83e-5 (favourable), Urothelial cancer:1.82e-4 (favourable), Renal cancer:1.97e-4 (unfavourable), Pancreatic cancer:2.34e-4 (favourable)	Expressed in all	Expressed in all			spleen: 24.7	Expressed in all		
CCDC137	MGC16597	ENSG00000185298	Coiled-coil domain containing 137	17	81666364-81673904	Predicted intracellular proteins	Evidence at protein level	HPA052637, HPA053914	Uncertain		Enhanced	Nucleoli	Renal cancer:1.16e-7 (unfavourable), Liver cancer:1.35e-7 (unfavourable), Lung cancer:8.32e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 19.7	Expressed in all		
CCDC138	FLJ32745	ENSG00000163006	Coiled-coil domain containing 138	2	108786757-108885477	Predicted intracellular proteins	Evidence at protein level	HPA049899, HPA054223	Enhanced		Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		testis: 19.6	fallopian tube: 6.9	Expressed in all		
CCDC14	DKFZp434L1050, FLJ12892	ENSG00000175455	Coiled-coil domain containing 14	3	123897305-123961408	Predicted intracellular proteins	Evidence at protein level	HPA035278, HPA035279	Uncertain		Enhanced	Centrosome	Renal cancer:3.50e-8 (unfavourable), Urothelial cancer:2.72e-5 (favourable), Prostate cancer:4.76e-4 (unfavourable), Liver cancer:4.82e-4 (unfavourable), Head and neck cancer:5.27e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.5	Expressed in all		
CCDC140	FLJ32447	ENSG00000163081	Coiled-coil domain containing 140	2	222298147-222305217	Predicted intracellular proteins	Evidence at transcript level	HPA042500, HPA048166	Uncertain					Tissue enriched	Not detected			skin: 0.3	Not detected		
CCDC141	CAMDI, FLJ39502	ENSG00000163492	Coiled-coil domain containing 141	2	178830269-179050086	Predicted intracellular proteins	Evidence at protein level	HPA012718			Approved	Nucleoplasm		Not detected	Tissue enriched	13	heart muscle: 50.2	lung: 3.9	Cell line enhanced		CACO-2: 4.0;HEL: 6.8;RH-30: 3.7;U-266/70: 3.7;U-698: 4.4
CCDC142	FLJ14397	ENSG00000135637	Coiled-coil domain containing 142	2	74471986-74483408	Predicted intracellular proteins	Evidence at transcript level	HPA056946	Approved				Renal cancer:3.71e-7 (unfavourable), Endometrial cancer:1.87e-4 (unfavourable), Liver cancer:4.46e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 5.8	Mixed		
CCDC144NL	MGC87631	ENSG00000205212	Coiled-coil domain containing 144 family, N-terminal like	17	20836447-20896140	Predicted intracellular proteins	Evidence at transcript level	HPA023457	Uncertain		Approved	Nucleus<br>Plasma membrane		Not detected	Tissue enriched	7	testis: 4.3	endometrium,prostate,seminal vesicle: 0.5	Cell line enriched	6	U-2 OS: 32.3
CCDC146	KIAA1505	ENSG00000135205	Coiled-coil domain containing 146	7	77122434-77329533	Predicted intracellular proteins	Evidence at protein level	HPA020082, HPA020105	Uncertain		Approved	Golgi apparatus<br>Vesicles	Head and neck cancer:7.37e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 57.6;testis: 39.3	thyroid gland: 13.8	Mixed		
CCDC148	MGC125588	ENSG00000153237	Coiled-coil domain containing 148	2	158171081-158456753	Predicted intracellular proteins	Evidence at protein level	HPA042626	Uncertain		Approved	Nucleus<br>Nucleoli	Thyroid cancer:2.54e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 4.2;testis: 5.8	fallopian tube: 2.4	Cell line enhanced		CAPAN-2: 2.2;HBF TERT88: 1.7;SCLC-21H: 2.0
CCDC15	FLJ13215	ENSG00000149548	Coiled-coil domain containing 15	11	124954121-125041489	Predicted intracellular proteins	Evidence at transcript level	HPA040450, HPA041738	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enriched	5	testis: 18.9	breast: 3.5	Mixed		
CCDC150	FLJ39660	ENSG00000144395	Coiled-coil domain containing 150	2	196639554-196763490	Predicted intracellular proteins	Evidence at protein level	HPA043968, HPA048104	Uncertain		Approved	Nucleoplasm		Mixed	Group enriched	9	kidney: 2.6;testis: 8.8	liver: 0.6	Cell line enhanced		SCLC-21H: 5.2
CCDC151	MGC20983	ENSG00000198003	Coiled-coil domain containing 151	19	11420604-11435782	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044184, HPA054626	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		fallopian tube: 13.4;parathyroid gland: 6.8;testis: 7.5	cerebral cortex: 2.0	Cell line enhanced		SCLC-21H: 2.4;T-47d: 4.5
CCDC152	LOC100129792	ENSG00000198865	Coiled-coil domain containing 152	5	42756801-42802360	Predicted intracellular proteins	Evidence at protein level	HPA036240	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			small intestine: 11.3	Cell line enhanced		HeLa: 8.9;U-2 OS: 24.5;U-266/84: 11.8
CCDC153	LOC283152	ENSG00000248712	Coiled-coil domain containing 153	11	119189638-119196769	Predicted intracellular proteins	Evidence at protein level	HPA041497	Uncertain		Uncertain	Cytosol		Mixed	Tissue enhanced		fallopian tube: 17.9	parathyroid gland: 3.8	Cell line enhanced		T-47d: 9.5
CCDC154	C16orf29, LOC645811	ENSG00000197599	Coiled-coil domain containing 154	16	1434383-1444556	Predicted intracellular proteins	Evidence at protein level	HPA041158, HPA043535, HPA048237	Uncertain		Approved	Golgi apparatus<br>Plasma membrane		Mixed	Tissue enhanced		testis: 6.5	spleen: 2.5	Group enriched	5	A-431: 8.2;SCLC-21H: 37.5
CCDC157		ENSG00000187860	Coiled-coil domain containing 157	22	30356635-30378658	Predicted intracellular proteins	Evidence at protein level	HPA042943	Uncertain					Mixed	Group enriched	5	fallopian tube: 12.0;testis: 28.4	thyroid gland: 3.9	Mixed		
CCDC158	FLJ25770	ENSG00000163749	Coiled-coil domain containing 158	4	76312997-76421868	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	27	testis: 60.4	thyroid gland: 2.2	Not detected		
CCDC159		ENSG00000183401	Coiled-coil domain containing 159	19	11344684-11354944	Predicted intracellular proteins	Evidence at protein level	HPA047126, HPA054655	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Endometrial cancer:1.87e-7 (favourable), Pancreatic cancer:1.42e-4 (favourable), Urothelial cancer:8.62e-4 (favourable), Ovarian cancer:9.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 65.5	Mixed		
CCDC160		ENSG00000203952	Coiled-coil domain containing 160	X	134237047-134246207	Predicted intracellular proteins	Evidence at transcript level	HPA044684	Uncertain				Ovarian cancer:7.62e-6 (favourable), Renal cancer:2.21e-4 (favourable), Endometrial cancer:2.31e-4 (favourable)	Mixed	Mixed			parathyroid gland: 8.4	Cell line enhanced		AF22: 29.3;NTERA-2: 4.1;RPTEC TERT1: 6.2
CCDC166		ENSG00000255181	Coiled-coil domain containing 166	8	143706694-143708109	Predicted intracellular proteins	No evidence	HPA025058	Uncertain					Not detected	Not detected			testis: 0.5	Not detected		
CCDC169	C13orf38, LOC728591, RP11-251J8.1	ENSG00000242715	Coiled-coil domain containing 169	13	36222008-36297840	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	16	testis: 78.5	parathyroid gland: 4.9	Cell line enhanced		HL-60: 14.2
CCDC169-SOHLH2	C13orf38-SOHLH2	ENSG00000250709	CCDC169-SOHLH2 readthrough	13	36168794-36297842	Predicted intracellular proteins	Evidence at transcript level	HPA029182			Uncertain	Vesicles		Not detected	Tissue enriched	28	testis: 19.5	seminal vesicle: 0.7	Cell line enhanced		BEWO: 1.3;HL-60: 2.2;U-937: 1.7
CCDC17	FLJ33084	ENSG00000159588	Coiled-coil domain containing 17	1	45620044-45624057	Predicted intracellular proteins	Evidence at protein level	HPA028338	Enhanced					Tissue enhanced	Tissue enriched	17	fallopian tube: 54.5	lung: 3.2	Not detected		
CCDC170	bA282P11.1, C6orf97, FLJ23305	ENSG00000120262	Coiled-coil domain containing 170	6	151494030-151621193	Predicted intracellular proteins	Evidence at protein level	HPA027114, HPA027185	Enhanced		Approved	Golgi apparatus<br>Cell Junctions	Endometrial cancer:3.64e-4 (favourable)	Mixed	Tissue enriched	6	fallopian tube: 53.5	thyroid gland: 9.4	Group enriched	6	MCF7: 7.9;T-47d: 5.5
CCDC171	bA536D16.1, bA778P13.1, C9orf93, Em:AL513423.1, FLJ39267, FLJ46740	ENSG00000164989	Coiled-coil domain containing 171	9	15553086-16061663	Predicted intracellular proteins	Evidence at protein level	HPA019803, HPA019806, HPA024133	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		testis: 20.7	endometrium: 9.7	Cell line enhanced		HEL: 10.5
CCDC172	C10orf96, MGC35062	ENSG00000182645	Coiled-coil domain containing 172	10	116324428-116380029	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	14	testis: 22.0	prostate: 1.5	Cell line enriched	177	NTERA-2: 30.9
CCDC173	C2orf77, LOC129881	ENSG00000154479	Coiled-coil domain containing 173	2	169645425-169694433	Predicted intracellular proteins	Evidence at protein level	HPA042995, HPA048454	Uncertain					Mixed	Tissue enriched	6	testis: 143.7	fallopian tube: 23.4	Cell line enhanced		HEL: 9.8;SCLC-21H: 3.1
CCDC174	C3orf19, FLJ33839	ENSG00000154781	Coiled-coil domain containing 174	3	14651746-14672659	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043468, HPA060129	Approved		Enhanced	Nucleoplasm	Urothelial cancer:3.81e-5 (favourable), Prostate cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 18.0	Expressed in all		
CCDC175	C14orf38	ENSG00000151838	Coiled-coil domain containing 175	14	59504539-59576831	Predicted intracellular proteins	Evidence at protein level	HPA004200	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Not detected	Tissue enriched	8	testis: 4.0	fallopian tube,rectum: 0.4	Not detected		
CCDC177	C14orf162, PLPL	ENSG00000267909	Coiled-coil domain containing 177	14	69569816-69574837	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 2.2	epididymis: 0.6	Cell line enhanced		SCLC-21H: 1.9
CCDC178	C18orf34, FLJ44050	ENSG00000166960	Coiled-coil domain containing 178	18	32937402-33441101	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 27.7	spleen: 10.6	Group enriched	15	HUVEC TERT2: 4.2;U-87 MG: 4.3
CCDC179		ENSG00000255359	Coiled-coil domain containing 179	11	22846931-22860426	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	412	testis: 46.2	urinary bladder: 0.1	Not detected		
CCDC18	NY-SAR-41	ENSG00000122483	Coiled-coil domain containing 18	1	93179919-93278730	Predicted intracellular proteins	Evidence at protein level	HPA028035	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 17.2	lymph node: 10.7	Mixed		
CCDC180	BDAG1, C9orf174, DKFZp434I2420, KIAA1529	ENSG00000197816	Coiled-coil domain containing 180	9	97307304-97378524	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	6	fallopian tube: 15.8;testis: 37.9	lung: 4.8	Cell line enhanced		HDLM-2: 3.9;U-266/70: 4.4
CCDC181	C1orf114, FLJ25846	ENSG00000117477	Coiled-coil domain containing 181	1	169394870-169460669	Predicted intracellular proteins	Evidence at protein level	HPA027189, HPA027275, HPA027281, HPA027312	Enhanced		Approved	Nuclear speckles		Mixed	Tissue enhanced		parathyroid gland: 22.9;testis: 49.6	fallopian tube: 19.6	Cell line enhanced		NTERA-2: 13.8;SCLC-21H: 9.9;SH-SY5Y: 10.5
CCDC182		ENSG00000166329	Coiled-coil domain containing 182	17	57744481-57745312	Predicted intracellular proteins	Evidence at transcript level	HPA023446	Uncertain					Not detected	Tissue enriched	211	testis: 21.0	all non-specific tissues: 0.0	Not detected		
CCDC183	bA216L13.7, KIAA1984, MGC15438	ENSG00000213213	Coiled-coil domain containing 183	9	136796350-136807741	Predicted intracellular proteins	Evidence at transcript level	HPA043812	Uncertain					Mixed	Tissue enriched	51	testis: 11.8	prostate: 0.2	Not detected		
CCDC184	C12orf68, LOC387856	ENSG00000177875	Coiled-coil domain containing 184	12	48183584-48185926	Predicted intracellular proteins	Evidence at protein level	HPA039947, HPA041715	Uncertain		Approved	Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 15.3	adrenal gland: 6.7	Cell line enhanced		AF22: 6.1;SH-SY5Y: 4.4;U-2 OS: 2.5;U-87 MG: 3.0
CCDC185	C1orf65, FLJ35728	ENSG00000178395	Coiled-coil domain containing 185	1	223393417-223395470	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	198	testis: 25.1	cerebral cortex: 0.1	Not detected		
CCDC186	C10orf118, FLJ10188, FLJ35301	ENSG00000165813	Coiled-coil domain containing 186	10	114120862-114174220	Predicted intracellular proteins	Evidence at protein level	HPA014569, HPA018019	Approved		Approved	Golgi apparatus	Renal cancer:7.65e-8 (favourable)	Expressed in all	Expressed in all			testis: 32.3	Mixed		
CCDC187	MGC50722	ENSG00000260220	Coiled-coil domain containing 187	9	136249971-136306901	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		fallopian tube: 12.2;testis: 14.7	epididymis: 3.4	Group enriched	6	RPMI-8226: 7.1;SCLC-21H: 3.6
CCDC189	C16orf93, MGC104706	ENSG00000196118	Coiled-coil domain containing 189	16	30757423-30762710	Predicted intracellular proteins	Evidence at protein level	HPA041806, HPA046289	Approved		Supported	Cytosol		Mixed	Tissue enhanced		fallopian tube: 14.6	testis: 8.6	Mixed		
CCDC190	C1orf110, MGC48998	ENSG00000185860	Coiled-coil domain containing 190	1	162824458-162868815	Predicted intracellular proteins	Evidence at transcript level	HPA028579, HPA028584, HPA028592	Uncertain		Approved	Vesicles		Mixed	Tissue enhanced		esophagus: 3.7;lung: 2.8	fallopian tube: 0.8	Cell line enhanced		hTEC/SVTERT24-B: 3.9;HUVEC TERT2: 4.0;LHCN-M2: 6.0;TIME: 13.6;U-2197: 8.2
CCDC191	KIAA1407	ENSG00000163617	Coiled-coil domain containing 191	3	113964137-114056613	Predicted intracellular proteins	Evidence at protein level	HPA047833	Approved		Approved	Mitochondria	Urothelial cancer:3.45e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 18.8	Mixed		
CCDC192	LINC01183	ENSG00000230561	Coiled-coil domain containing 192	5	127703389-127941634	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	21	testis: 20.7	skeletal muscle: 0.9	Cell line enhanced		AF22: 2.3
CCDC22	CXorf37, JM1	ENSG00000101997	Coiled-coil domain containing 22	X	49235467-49250526	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000229, HPA000888	Uncertain	Approved	Approved	Nucleoplasm<br>Cytosol	Liver cancer:2.17e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 18.4	Expressed in all		
CCDC24	MGC45441	ENSG00000159214	Coiled-coil domain containing 24	1	43991359-43996528	Predicted intracellular proteins	Evidence at protein level	HPA035424, HPA061710	Uncertain		Enhanced	Plasma membrane<br>Cytosol	Breast cancer:3.06e-5 (favourable), Liver cancer:1.70e-4 (unfavourable), Head and neck cancer:3.18e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 18.3	testis: 15.2	Cell line enhanced		CAPAN-2: 11.7
CCDC25	FLJ10853	ENSG00000147419	Coiled-coil domain containing 25	8	27733311-27772653	Predicted intracellular proteins	Evidence at protein level	HPA023256	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.11e-7 (favourable)	Expressed in all	Expressed in all			duodenum: 35.6	Expressed in all		
CCDC27	FLJ32825	ENSG00000162592	Coiled-coil domain containing 27	1	3746460-3771645	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	92	testis: 14.8	endometrium,prostate: 0.1	Cell line enriched	6	THP-1: 1.1
CCDC28A	C6orf80, CCRL1AP, DKFZp586D0623	ENSG00000024862	Coiled-coil domain containing 28A	6	138773509-138793319	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055125	Approved		Approved	Cytosol	Renal cancer:1.11e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 90.7	Expressed in all		
CCDC28B	MGC1203, RP4-622L5.5	ENSG00000160050	Coiled-coil domain containing 28B	1	32200386-32205387	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028589	Uncertain				Pancreatic cancer:1.10e-5 (favourable), Breast cancer:2.92e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 40.8	testis: 22.7	Mixed		
CCDC30	FLJ20972, LOC728621, PFD6L	ENSG00000186409	Coiled-coil domain containing 30	1	42463330-42654664	Predicted intracellular proteins	Evidence at protein level	HPA036344, HPA036345	Approved					Mixed	Tissue enhanced		testis: 6.9	fallopian tube: 5.0	Cell line enriched	19	HMC-1: 23.7
CCDC33	CT61, FLJ32855	ENSG00000140481	Coiled-coil domain containing 33	15	74202705-74336472	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	17	fallopian tube: 75.4;testis: 22.5	lung: 2.8	Group enriched	5	CAPAN-2: 7.8;SCLC-21H: 5.8;SH-SY5Y: 6.3
CCDC34	L15, NY-REN-41, RAMA3	ENSG00000109881	Coiled-coil domain containing 34	11	27330827-27363868	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037574	Uncertain		Approved	Nuclear membrane<br>Nucleoli fibrillar center	Liver cancer:1.32e-7 (unfavourable), Renal cancer:1.82e-4 (unfavourable), Ovarian cancer:8.52e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 54.8	fallopian tube: 13.4	Expressed in all		
CCDC36	CT74, FLJ25320	ENSG00000173421	Coiled-coil domain containing 36	3	49198428-49258104	Predicted intracellular proteins	Evidence at protein level	HPA045690, HPA069534	Approved		Approved	Nucleoplasm		Not detected	Tissue enriched	14	testis: 48.6	adipose tissue: 3.5	Cell line enhanced		hTEC/SVTERT24-B: 9.9;LHCN-M2: 3.5;U-2197: 5.0
CCDC38	FLJ40089	ENSG00000165972	Coiled-coil domain containing 38	12	95867048-95942974	Predicted intracellular proteins	Evidence at protein level	HPA039726			Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	18	testis: 26.3	liver: 1.4	Not detected		
CCDC39	CILD14, DKFZp434A128, FAP59	ENSG00000145075	Coiled-coil domain containing 39	3	180602858-180871005	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035363, HPA035364	Enhanced					Mixed	Mixed			lymph node: 23.7	Mixed		
CCDC40	CILD15, FAP172, FLJ20753, FLJ32021, KIAA1640	ENSG00000141519	Coiled-coil domain containing 40	17	80036632-80100613	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022974	Enhanced		Approved	Microtubules	Renal cancer:2.45e-4 (unfavourable), Endometrial cancer:2.95e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 23.7	testis: 12.8	Cell line enhanced		SCLC-21H: 14.2
CCDC42	CCDC42A, FLJ32734	ENSG00000161973	Coiled-coil domain containing 42	17	8729934-8745219	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	364	testis: 128.6	lung,spleen: 0.3	Not detected		
CCDC43	FLJ31795	ENSG00000180329	Coiled-coil domain containing 43	17	44673069-44689779	Predicted intracellular proteins	Evidence at protein level	HPA023391	Approved		Enhanced	Cytosol	Head and neck cancer:3.42e-5 (unfavourable), Liver cancer:1.33e-4 (unfavourable), Pancreatic cancer:3.19e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 26.1	Expressed in all		
CCDC50	C3orf6, DFNA44, Ymer	ENSG00000152492	Coiled-coil domain containing 50	3	191329077-191398670	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001336	Approved		Supported	Cytosol	Liver cancer:2.48e-5 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 49.2	Mixed		
CCDC54	FLJ25362, NYD-SP17, SP17	ENSG00000138483	Coiled-coil domain containing 54	3	107377194-107378637	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	137	testis: 165.4	placenta: 1.2	Not detected		
CCDC57	FLJ00130, FLJ23754	ENSG00000176155	Coiled-coil domain containing 57	17	82101460-82212830	Predicted intracellular proteins	Evidence at protein level	HPA023315, HPA023326, HPA023342, HPA023344	Approved		Approved	Microtubules<br>Microtubule organizing center<br>Cytosol	Renal cancer:2.28e-6 (unfavourable), Pancreatic cancer:5.55e-5 (favourable)	Expressed in all	Expressed in all			testis: 16.1	Mixed		
CCDC58	FLJ33273	ENSG00000160124	Coiled-coil domain containing 58	3	122359591-122383231	Predicted intracellular proteins	Evidence at protein level	HPA047777, HPA051965	Approved		Approved	Nucleoli<br>Mitochondria	Liver cancer:2.94e-5 (unfavourable), Endometrial cancer:1.53e-4 (unfavourable), Urothelial cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			kidney: 47.4	Expressed in all		
CCDC59	BR22, HSPC128, TAP26	ENSG00000133773	Coiled-coil domain containing 59	12	82223681-82358805	Predicted intracellular proteins	Evidence at protein level	HPA038555	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:1.39e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 27.4	Expressed in all		
CCDC6	D10S170, H4, PTC, TPC, TST1	ENSG00000108091	Coiled-coil domain containing 6	10	59788763-59906656	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019049, HPA019051	Enhanced		Supported	Cytosol	Liver cancer:1.11e-4 (unfavourable), Pancreatic cancer:3.95e-4 (unfavourable), Head and neck cancer:5.48e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 44.4	Expressed in all		
CCDC60	MGC39827	ENSG00000183273	Coiled-coil domain containing 60	12	119334712-119541047	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		fallopian tube: 28.0;testis: 19.7	cervix, uterine: 8.2	Not detected		
CCDC61		ENSG00000104983	Coiled-coil domain containing 61	19	45995461-46021318	Predicted intracellular proteins	Evidence at protein level	HPA040325, HPA061548	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			testis: 31.1	Expressed in all		
CCDC62	CT109, ERAP75, FLJ40344, TSP-NY	ENSG00000130783	Coiled-coil domain containing 62	12	122774327-122827528	Predicted intracellular proteins	Evidence at protein level	HPA039021, HPA058741	Approved		Approved	Nucleoplasm<br>Plasma membrane		Not detected	Tissue enriched	146	testis: 116.0	spleen: 0.7	Cell line enhanced		U-2 OS: 3.0
CCDC63	FLJ35843, ODA5	ENSG00000173093	Coiled-coil domain containing 63	12	110846769-110907535	Predicted intracellular proteins	Evidence at protein level	HPA061568			Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Tissue enriched	Tissue enriched	28	testis: 29.6	heart muscle: 1.0	Cell line enriched	14	MCF7: 3.3
CCDC65	CFAP250, CILD27, DRC2, FAP250, FLJ35732, NYD-SP28	ENSG00000139537	Coiled-coil domain containing 65	12	48904110-48931840	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038520, HPA057573	Uncertain		Approved	Vesicles<br>Microtubule organizing center		Mixed	Group enriched	12	fallopian tube: 42.8;testis: 67.9	lung: 4.4	Mixed		
CCDC66	DKFZp686C0433	ENSG00000180376	Coiled-coil domain containing 66	3	56557161-56621818	Predicted intracellular proteins	Evidence at protein level	HPA044185	Uncertain		Approved	Cell Junctions<br>Midbody ring<br>Microtubule organizing center		Expressed in all	Mixed			fallopian tube: 9.6	Expressed in all		
CCDC68	SE57-1	ENSG00000166510	Coiled-coil domain containing 68	18	54901509-54959508	Predicted intracellular proteins	Evidence at protein level	HPA040865, HPA048197	Supported		Approved	Golgi apparatus<br>Cytosol	Cervical cancer:4.50e-4 (unfavourable), Renal cancer:5.28e-4 (favourable)	Mixed	Tissue enhanced		placenta: 46.2	small intestine: 27.3	Cell line enhanced		HHSteC: 11.3;HSkMC: 10.8;TIME: 22.8
CCDC69	DKFZP434C171, FLJ13705	ENSG00000198624	Coiled-coil domain containing 69	5	151181052-151224145	Predicted intracellular proteins	Evidence at protein level	HPA043648, HPA052896	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Actin filaments	Breast cancer:3.21e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 112.8	Cell line enhanced		ASC diff: 80.3;Daudi: 136.8;U-266/70: 89.8;U-698: 84.7
CCDC7	BIOT2, C10orf68, FLJ13031, FLJ32762	ENSG00000216937	Coiled-coil domain containing 7	10	32446140-32882874	Predicted intracellular proteins	Evidence at transcript level	HPA075536			Approved	Nucleoli<br>Mitotic spindle<br>Cytosol		Not detected	Tissue enriched	43	testis: 139.0	thyroid gland: 3.2	Mixed		
CCDC70	DKFZP434K1172, FLJ25853	ENSG00000123171	Coiled-coil domain containing 70	13	51861981-51866232	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	1157	testis: 115.6	all non-specific tissues: 0.0	Not detected		
CCDC71	FLJ12800	ENSG00000177352	Coiled-coil domain containing 71	3	49162535-49166321	Predicted intracellular proteins	Evidence at protein level	HPA047547	Uncertain		Approved	Nuclear membrane	Renal cancer:9.65e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 27.2	Expressed in all		
CCDC71L	C7orf74, FLJ36031	ENSG00000253276	Coiled-coil domain containing 71-like	7	106656765-106660996	Predicted intracellular proteins	Evidence at protein level	HPA067925	Approved		Approved	Golgi apparatus<br>Actin filaments<br>Cytosol	Renal cancer:2.53e-6 (unfavourable), Cervical cancer:9.08e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 31.1	Mixed		
CCDC73	NY-SAR-79	ENSG00000186714	Coiled-coil domain containing 73	11	32602246-32794658	Predicted intracellular proteins	Evidence at protein level	HPA038668, HPA038669	Uncertain					Not detected	Tissue enriched	8	testis: 6.7	ovary: 0.8	Cell line enhanced		MOLT-4: 1.4
CCDC74A	FLJ40345	ENSG00000163040	Coiled-coil domain containing 74A	2	131527675-131533666	Predicted intracellular proteins	Evidence at transcript level	HPA060727			Uncertain	Vesicles	Renal cancer:1.70e-7 (unfavourable), Glioma:1.82e-4 (unfavourable), Testis cancer:4.92e-4 (favourable), Breast cancer:5.11e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 55.2;testis: 79.2	parathyroid gland: 27.2	Cell line enhanced		NTERA-2: 28.4;SCLC-21H: 27.2
CCDC74B	DKFZp434E2321	ENSG00000152076	Coiled-coil domain containing 74B	2	130139287-130145134	Predicted intracellular proteins	Evidence at transcript level	HPA060727			Uncertain	Vesicles	Renal cancer:1.55e-4 (unfavourable), Breast cancer:4.46e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 23.1;testis: 52.0	cervix, uterine: 13.9	Cell line enhanced		SCLC-21H: 12.3;SH-SY5Y: 15.8
CCDC77	MGC13183	ENSG00000120647	Coiled-coil domain containing 77	12	389273-442645	Predicted intracellular proteins	Evidence at protein level	HPA038854	Approved		Approved	Nuclear membrane	Liver cancer:8.11e-7 (unfavourable)	Expressed in all	Mixed			testis: 22.9	Expressed in all		
CCDC78	C16orf25, FLJ34512	ENSG00000162004	Coiled-coil domain containing 78	16	722582-726954	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	11	fallopian tube: 97.7	lung: 8.5	Cell line enhanced		SCLC-21H: 13.2
CCDC8	3M3, DKFZp564K0322, PPP1R20	ENSG00000169515	Coiled-coil domain containing 8	19	46410372-46413584	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041993	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:1.72e-5 (favourable)	Mixed	Tissue enhanced		ovary: 45.3	fallopian tube: 37.6	Cell line enhanced		AN3-CA: 20.7;RH-30: 24.3
CCDC81	FLJ16339, FLJ23514	ENSG00000149201	Coiled-coil domain containing 81	11	86374736-86423109	Predicted intracellular proteins	Evidence at protein level	HPA040745, HPA040827	Uncertain		Uncertain	Plasma membrane		Tissue enhanced	Group enriched	10	fallopian tube: 46.1;testis: 11.0	endometrium: 2.7	Cell line enhanced		BJ: 2.9;HBF TERT88: 1.8
CCDC82	FLJ23518	ENSG00000149231	Coiled-coil domain containing 82	11	96352769-96389923	Predicted intracellular proteins	Evidence at protein level	HPA038704	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 55.5	Mixed		
CCDC83	CT148, FLJ42119, MGC34732	ENSG00000150676	Coiled-coil domain containing 83	11	85855101-85920021	Predicted intracellular proteins	Evidence at transcript level	HPA039707, HPA039882			Uncertain	Nucleus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	148	testis: 63.5	cerebral cortex,endometrium: 0.4	Cell line enriched	8	MCF7: 2.1
CCDC84	DLNB14	ENSG00000186166	Coiled-coil domain containing 84	11	118998142-119015791	Predicted intracellular proteins	Evidence at protein level	HPA039906, HPA071715	Uncertain		Approved	Nucleus	Renal cancer:2.93e-5 (unfavourable)	Expressed in all	Mixed			skin: 4.6	Mixed		
CCDC85B	DIPA	ENSG00000175602	Coiled-coil domain containing 85B	11	65890112-65891635	Predicted intracellular proteins	Evidence at protein level	HPA054415	Uncertain				Renal cancer:3.78e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 27.6	adipose tissue: 21.1	Cell line enhanced		WM-115: 340.7
CCDC85C		ENSG00000205476	Coiled-coil domain containing 85C	14	99500180-99604026	Predicted intracellular proteins	Evidence at protein level	HPA058346	Uncertain		Approved	Nuclear speckles<br>Cell Junctions	Renal cancer:2.60e-5 (favourable), Endometrial cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 31.1	Mixed		
CCDC86	MGC2574	ENSG00000110104	Coiled-coil domain containing 86	11	60842071-60851081	Predicted intracellular proteins	Evidence at protein level	HPA041117, HPA041540	Enhanced		Enhanced	Nucleus<br>Nucleoli	Head and neck cancer:7.36e-5 (unfavourable), Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Tissue enriched	11	parathyroid gland: 618.3	testis: 58.1	Expressed in all		
CCDC87	FLJ10786	ENSG00000182791	Coiled-coil domain containing 87	11	66590176-66593083	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	7	testis: 18.3	parathyroid gland: 2.5	Cell line enhanced		SCLC-21H: 2.7
CCDC88A	APE, FLJ10392, GIV, GRDN, HkRP1, KIAA1212	ENSG00000115355	Coiled-coil domain containing 88A	2	55287842-55419921	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038101, HPA038102	Enhanced				Renal cancer:5.98e-8 (unfavourable), Endometrial cancer:2.06e-4 (unfavourable), Liver cancer:4.86e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 117.5	Mixed		
CCDC88C	DAPLE, HkRP2, KIAA1509, SCA40	ENSG00000015133	Coiled-coil domain containing 88C	14	91271323-91417844	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005832	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:2.80e-4 (unfavourable), Lung cancer:2.90e-4 (favourable), Head and neck cancer:3.47e-4 (favourable)	Expressed in all	Mixed			lymph node: 22.2	Cell line enhanced		SCLC-21H: 60.6;U-266/84: 47.6
CCDC89	FLJ38159	ENSG00000179071	Coiled-coil domain containing 89	11	85684866-85686277	Predicted intracellular proteins	Evidence at protein level	HPA040628	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		fallopian tube: 19.3;testis: 53.4	ovary: 8.1	Cell line enhanced		SCLC-21H: 6.3;U-2197: 5.7
CCDC9	DKFZP586M1019	ENSG00000105321	Coiled-coil domain containing 9	19	47255980-47271953	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045624, HPA072007	Approved		Approved	Cytosol		Expressed in all	Expressed in all			testis: 30.3	Expressed in all		
CCDC91	DKFZp779L1558, FLJ11088, p56	ENSG00000123106	Coiled-coil domain containing 91	12	28133249-28581511	Predicted intracellular proteins	Evidence at protein level	HPA038169	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:1.05e-4 (unfavourable), Renal cancer:7.69e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 41.5	Mixed		
CCDC92	FLJ22471	ENSG00000119242	Coiled-coil domain containing 92	12	123918660-123972831	Predicted intracellular proteins	Evidence at protein level	HPA038560, HPA057580	Approved		Supported	Nucleoplasm<br>Centrosome	Pancreatic cancer:4.59e-5 (favourable), Endometrial cancer:7.15e-4 (favourable)	Expressed in all	Mixed			testis: 18.1	Mixed		
CCDC93	FLJ10996	ENSG00000125633	Coiled-coil domain containing 93	2	117915478-118014133	Predicted intracellular proteins	Evidence at protein level	HPA054183	Approved		Supported	Vesicles<br>Plasma membrane	Liver cancer:2.97e-6 (unfavourable), Thyroid cancer:9.66e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.9	Expressed in all		
CCDC94	FLJ10374	ENSG00000105248	Coiled-coil domain containing 94	19	4247079-4269090	Predicted intracellular proteins	Evidence at protein level	HPA043606, HPA055675	Approved		Supported	Nucleoplasm	Renal cancer:6.32e-4 (favourable), Stomach cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 28.0	Expressed in all		
CCDC96	FLJ90575	ENSG00000173013	Coiled-coil domain containing 96	4	7040849-7042939	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047546	Enhanced				Renal cancer:3.80e-5 (favourable), Endometrial cancer:4.05e-4 (favourable), Pancreatic cancer:4.87e-4 (favourable)	Expressed in all	Group enriched	14	fallopian tube: 17.7;testis: 61.7	cerebral cortex,lung: 2.7	Mixed		
CCDC97	FLJ40267, MGC20255	ENSG00000142039	Coiled-coil domain containing 97	19	41310189-41324883	Predicted intracellular proteins	Evidence at protein level	HPA043320, HPA043572	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.09e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.0	Expressed in all		
CCER1	C12orf12, MGC26598	ENSG00000197651	Coiled-coil glutamate rich protein 1	12	90905622-90955176	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	341	testis: 34.0	all non-specific tissues: 0.0	Not detected		
CCHCR1	C6orf18, HCR	ENSG00000204536	Coiled-coil alpha-helical rod protein 1	6	31142439-31158238	Predicted intracellular proteins	Evidence at protein level	HPA054167			Supported	Cytosol		Expressed in all	Tissue enriched	6	testis: 86.6	fallopian tube: 13.8	Mixed		
CCIN	BTBD20, KBTBD14	ENSG00000185972	Calicin	9	36169394-36171334	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	41	testis: 112.2	smooth muscle: 2.7	Cell line enhanced		BJ: 3.3;fHDF/TERT166: 3.7;hTEC/SVTERT24-B: 5.8;TIME: 6.5
CCM2	C7orf22, MGC4607, OSM	ENSG00000136280	CCM2 scaffolding protein	7	44999475-45076469	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020273, HPA021669, HPA065815	Enhanced		Enhanced	Mitochondria	Renal cancer:5.06e-7 (unfavourable), Pancreatic cancer:1.16e-4 (favourable), Colorectal cancer:1.79e-4 (unfavourable), Glioma:3.77e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 49.1	Expressed in all		
CCM2L	C20orf160, dJ310O13.5	ENSG00000101331	CCM2 like scaffolding protein	20	32010450-32032180	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008434, HPA071063	Uncertain		Approved	Nucleoplasm		Expressed in all	Tissue enriched	8	spleen: 122.6	placenta: 15.0	Cell line enhanced		EFO-21: 9.4;HUVEC TERT2: 10.0;NTERA-2: 6.4;SCLC-21H: 12.8
CCNA1	CT146	ENSG00000133101	Cyclin A1	13	36431520-36442882	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA060646			Approved	Nucleoplasm<br>Nuclear bodies	Head and neck cancer:1.70e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 59.6;testis: 144.6	fallopian tube: 27.9	Cell line enhanced		HMC-1: 300.4;THP-1: 46.6;U-937: 68.5
CCNA2	CCN1, CCNA	ENSG00000145386	Cyclin A2	4	121816444-121823933	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000114, HPA020626	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:4.43e-6 (unfavourable), Liver cancer:9.17e-5 (unfavourable), Lung cancer:4.27e-4 (unfavourable), Endometrial cancer:8.78e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 29.3	Expressed in all		
CCNB1	CCNB	ENSG00000134057	Cyclin B1	5	69167010-69178245	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000115, CAB003804, HPA030741, HPA061448	Enhanced		Enhanced	Cytosol	Renal cancer:1.11e-16 (unfavourable), Liver cancer:1.54e-7 (unfavourable), Lung cancer:3.38e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 65.5	Expressed in all		
CCNB2	HsT17299	ENSG00000157456	Cyclin B2	15	59105078-59125045	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA008873, CAB009575	Enhanced		Enhanced	Golgi apparatus<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.74e-5 (unfavourable), Melanoma:3.21e-5 (unfavourable), Liver cancer:2.83e-4 (unfavourable), Lung cancer:4.63e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 122.6	bone marrow: 44.7	Expressed in all		
CCNB3		ENSG00000147082	Cyclin B3	X	50202713-50351910	Predicted intracellular proteins	Evidence at protein level	HPA000496	Enhanced		Supported	Nuclear speckles		Not detected	Group enriched	9	epididymis: 5.8;testis: 7.9	cerebral cortex: 0.7	Cell line enhanced		CAPAN-2: 1.5
CCNC	CycC	ENSG00000112237	Cyclin C	6	99542380-99568973	Predicted intracellular proteins	Evidence at protein level	CAB010499, HPA069322	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.12e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 99.2	Expressed in all		
CCND1	BCL1, D11S287E, PRAD1, U21B31	ENSG00000110092	Cyclin D1	11	69641087-69654474	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000024, HPA027802	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:1.96e-4 (unfavourable), Head and neck cancer:5.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 340.4	skin: 140.5	Cell line enhanced		WM-115: 1198.2
CCND2		ENSG00000118971	Cyclin D2	12	4273772-4305350	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049138, HPA054196	Approved		Supported	Nucleoplasm	Thyroid cancer:9.76e-5 (favourable), Pancreatic cancer:2.52e-4 (favourable)	Expressed in all	Mixed			epididymis: 55.9	Cell line enhanced		AF22: 155.7;HDLM-2: 235.1;Karpas-707: 252.4;RH-30: 221.5
CCND3		ENSG00000112576	Cyclin D3	6	41934933-42050357	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000116	Approved				Thyroid cancer:8.08e-6 (favourable)	Expressed in all	Expressed in all			lymph node: 159.2	Expressed in all		
CCNDBP1	DIP1, GCIP, HHM	ENSG00000166946	Cyclin D1 binding protein 1	15	43185118-43197176	Predicted intracellular proteins	Evidence at protein level	CAB020664, HPA041065	Supported		Enhanced	Nucleoplasm	Renal cancer:2.06e-4 (favourable)	Expressed in all	Mixed			bone marrow: 7.6	Cell line enhanced		HEL: 4.6
CCNE1	CCNE	ENSG00000105173	Cyclin E1	19	29811898-29824308	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000308, CAB016682, HPA018169	Approved		Enhanced	Nucleoplasm	Endometrial cancer:6.35e-6 (unfavourable), Liver cancer:3.89e-5 (unfavourable), Ovarian cancer:2.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 44.6	testis: 22.5	Expressed in all		
CCNE2	CYCE2	ENSG00000175305	Cyclin E2	8	94879770-94896678	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB007825, CAB019374	Enhanced				Head and neck cancer:5.87e-4 (favourable), Lung cancer:8.77e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 25.6	bone marrow: 22.4	Mixed		
CCNF	FBX1, FBXO1	ENSG00000162063	Cyclin F	16	2429394-2458854	Predicted intracellular proteins	Evidence at protein level	HPA060596, HPA070495, HPA071600	Enhanced		Supported	Centrosome	Liver cancer:7.46e-7 (unfavourable)	Expressed in all	Mixed			lymph node,tonsil: 8.6	Expressed in all		
CCNG1	CCNG	ENSG00000113328	Cyclin G1	5	163437569-163446151	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000350	Supported		Supported	Nucleoplasm	Colorectal cancer:7.00e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 137.7	Mixed		
CCNG2		ENSG00000138764	Cyclin G2	4	77157151-77433388	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA034684	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.47e-5 (favourable), Pancreatic cancer:8.57e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 150.2	Expressed in all		
CCNH	CycH, p34, p37	ENSG00000134480	Cyclin H	5	87391494-87413019	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB019416, HPA044138	Approved		Supported	Nucleoplasm	Renal cancer:3.92e-5 (unfavourable), Ovarian cancer:4.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 88.4	Expressed in all		
CCNI	CCNI1	ENSG00000118816	Cyclin I	4	77047158-77076005	Predicted intracellular proteins	Evidence at protein level	CAB010206, HPA039853, HPA061470	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus	Renal cancer:2.10e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 453.5	Expressed in all		
CCNI2	FLJ16793	ENSG00000205089	Cyclin I family member 2	5	132747445-132754403	Predicted intracellular proteins	Evidence at transcript level	HPA056288	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Colorectal cancer:8.21e-4 (favourable)	Tissue enhanced	Mixed			duodenum: 3.8	Cell line enriched	6	MOLT-4: 21.8
CCNJ	bA690P14.1, FLJ10895	ENSG00000107443	Cyclin J	10	96043394-96060870	Predicted intracellular proteins	Evidence at transcript level	HPA036531, HPA058151	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 9.9	Mixed		
CCNJL	FLJ14166	ENSG00000135083	Cyclin J like	5	160251652-160345396	Predicted intracellular proteins	Evidence at protein level	HPA049970	Approved		Approved	Nuclear speckles	Thyroid cancer:7.10e-4 (favourable), Colorectal cancer:7.31e-4 (favourable), Urothelial cancer:8.02e-4 (favourable)	Mixed	Tissue enhanced		testis: 19.4	lung: 10.3	Cell line enhanced		HBEC3-KT: 46.5;WM-115: 45.6
CCNK	CPR4	ENSG00000090061	Cyclin K	14	99481169-99535044	Predicted intracellular proteins	Evidence at protein level	HPA000645, HPA077073	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 84.2	Expressed in all		
CCNO	CCNU, FLJ22422, UDG2, UNG2	ENSG00000152669	Cyclin O	5	55231152-55233680	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050090	Uncertain				Stomach cancer:5.10e-4 (favourable), Endometrial cancer:6.78e-4 (favourable), Lung cancer:7.60e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 6.9	fallopian tube,seminal vesicle: 1.6	Cell line enhanced		BEWO: 4.2;T-47d: 5.6
CCNT1	CCNT, CYCT1, HIVE1	ENSG00000129315	Cyclin T1	12	48688458-48716998	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004892, CAB009016	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 20.1	Expressed in all		
CCNT2		ENSG00000082258	Cyclin T2	2	134918235-134959342	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005559	Supported		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.25e-5 (unfavourable), Prostate cancer:2.44e-4 (unfavourable), Urothelial cancer:3.28e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
CCNY	C10orf9, CBCP1, CFP1	ENSG00000108100	Cyclin Y	10	35247025-35572669	Predicted intracellular proteins	Evidence at protein level	HPA036290	Approved				Liver cancer:6.75e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 149.9	Expressed in all		
CCNYL1	FLJ40432	ENSG00000163249	Cyclin Y like 1	2	207711540-207761839	Predicted intracellular proteins	Evidence at protein level	HPA046825	Approved		Approved	Plasma membrane		Expressed in all	Expressed in all			testis: 30.4	Expressed in all		
CCP110	CP110, KIAA0419	ENSG00000103540	Centriolar coiled-coil protein 110	16	19523811-19553408	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039402	Approved		Supported	Centrosome		Expressed in all	Tissue enhanced		testis: 65.2	cerebral cortex: 29.7	Expressed in all		
CCS		ENSG00000173992	Copper chaperone for superoxide dismutase	11	66592821-66606019	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008672, HPA040026, HPA044090	Approved					Expressed in all	Expressed in all			parathyroid gland: 21.7	Expressed in all		
CCSAP	C1orf96, CSAP, FLJ41471	ENSG00000154429	Centriole, cilia and spindle associated protein	1	229321005-229343294	Predicted intracellular proteins	Evidence at protein level	HPA028402, HPA043443	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Microtubule ends	Renal cancer:4.50e-13 (unfavourable), Liver cancer:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 54.0	placenta: 18.6	Expressed in all		
CCSER1	FAM190A, KIAA1680	ENSG00000184305	Coiled-coil serine rich protein 1	4	90127535-91601913	Predicted intracellular proteins	Evidence at transcript level	HPA041880, HPA054709	Uncertain					Mixed	Tissue enhanced		testis: 4.6	adrenal gland: 1.7	Cell line enhanced		HDLM-2: 1.4;RT4: 1.0;SCLC-21H: 1.5
CCSER2	FAM190B, KIAA1128	ENSG00000107771	Coiled-coil serine rich protein 2	10	84328586-84518521	Predicted intracellular proteins	Evidence at protein level	HPA037481, HPA037482	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 39.5	Expressed in all		
CCT2	Cctb	ENSG00000166226	Chaperonin containing TCP1 subunit 2	12	69585334-69601570	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003197, HPA003198	Enhanced		Supported	Cytosol	Liver cancer:3.61e-9 (unfavourable), Prostate cancer:3.67e-4 (unfavourable), Head and neck cancer:8.38e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 367.6	Expressed in all		
CCT3	Cctg, TRIC5	ENSG00000163468	Chaperonin containing TCP1 subunit 3	1	156308968-156367873	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006543	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:3.87e-7 (unfavourable), Renal cancer:6.34e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 206.2	Expressed in all		
CCT4	Cctd	ENSG00000115484	Chaperonin containing TCP1 subunit 4	2	61868089-61888804	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029349	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.37e-12 (unfavourable), Breast cancer:2.03e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 133.6	Expressed in all		
CCT5	KIAA0098	ENSG00000150753	Chaperonin containing TCP1 subunit 5	5	10249921-10266412	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002238, HPA005958, CAB006271	Enhanced		Supported	Nucleoli<br>Cytosol	Liver cancer:6.57e-11 (unfavourable), Renal cancer:8.23e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 190.8	Expressed in all		
CCT6A	CCT6, Cctz, HTR3, TCP20, TCPZ, TTCP20	ENSG00000146731	Chaperonin containing TCP1 subunit 6A	7	56051630-56063989	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042996, HPA045576, HPA049949	Supported		Approved	Cytosol	Liver cancer:9.00e-10 (unfavourable), Renal cancer:2.19e-4 (unfavourable), Breast cancer:4.04e-4 (unfavourable), Head and neck cancer:8.45e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 120.3	Expressed in all		
CCT6B	Cctz2, TSA303	ENSG00000132141	Chaperonin containing TCP1 subunit 6B	17	34927859-34981078	Predicted intracellular proteins	Evidence at protein level	HPA042996, HPA045576, HPA049949	Uncertain		Approved	Cytosol		Mixed	Tissue enriched	33	testis: 225.1	breast: 6.9	Cell line enhanced		RPMI-8226: 8.3
CCT7	Ccth, Nip7-1	ENSG00000135624	Chaperonin containing TCP1 subunit 7	2	73233420-73253021	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008425	Approved		Approved	Cytosol	Liver cancer:1.84e-5 (unfavourable), Endometrial cancer:2.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 286.8	Expressed in all		
CCT8	C21orf112, Cctq, PRED71	ENSG00000156261	Chaperonin containing TCP1 subunit 8	21	29055805-29073797	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018520, HPA021051, HPA029426	Enhanced		Approved	Nucleus<br>Intermediate filaments<br>Cytosol	Liver cancer:1.56e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 135.9	Expressed in all		
CCT8L2	CESK1	ENSG00000198445	Chaperonin containing TCP1 subunit 8 like 2	22	16590751-16592810	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	172	testis: 17.1	all non-specific tissues: 0.0	Not detected		
CCZ1	C7orf28A, CCZ1A, CGI-43	ENSG00000122674	CCZ1 homolog, vacuolar protein trafficking and biogenesis associated	7	5898725-5926550	Predicted intracellular proteins	Evidence at protein level	HPA045114, HPA050006	Uncertain		Enhanced	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 77.0	Expressed in all		
CCZ1B	C7orf28B, DKFZP586I1023, H_NH0577018.2, MGC19819	ENSG00000146574	CCZ1 homolog B, vacuolar protein trafficking and biogenesis associated	7	6794134-6826770	Predicted intracellular proteins	Evidence at protein level	HPA045114, HPA050006	Uncertain		Enhanced	Vesicles		Mixed	Expressed in all			parathyroid gland: 48.7	Expressed in all		
CD2AP	CMS	ENSG00000198087	CD2 associated protein	6	47477789-47627263	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003267, HPA003326, CAB004352	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Pancreatic cancer:5.53e-5 (unfavourable), Urothelial cancer:7.57e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 65.8	Expressed in all		
CD2BP2	LIN1, PPP1R59, Snu40	ENSG00000169217	CD2 cytoplasmic tail binding protein 2	16	30350766-30355361	Predicted intracellular proteins	Evidence at protein level	HPA041508, HPA061309	Enhanced		Enhanced	Nuclear speckles<br>Cytosol	Liver cancer:1.84e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 80.8	Expressed in all		
CD38		ENSG00000004468	CD38 molecule	4	15778275-15853230	Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002493, HPA022132, CAB025255, HPA052381	Enhanced		Supported	Plasma membrane	Endometrial cancer:9.68e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 27.6	Cell line enhanced		Daudi: 91.6;Karpas-707: 24.9;MOLT-4: 26.4;REH: 23.7;U-266/70: 20.4
CD3EAP	ASE-1, CAST, PAF49	ENSG00000117877	CD3e molecule associated protein	19	45406209-45410766	Predicted intracellular proteins	Evidence at protein level	HPA041664, HPA041734	Supported		Enhanced	Nucleus<br>Nucleoli fibrillar center<br>Mitochondria	Liver cancer:4.79e-9 (unfavourable)	Expressed in all	Mixed			appendix,cerebral cortex: 5.4	Expressed in all		
CDA	CDD	ENSG00000158825	Cytidine deaminase	1	20588948-20618908	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064202	Enhanced		Approved	Nucleoplasm	Pancreatic cancer:8.56e-5 (unfavourable), Cervical cancer:5.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 104.6;esophagus: 56.7	liver: 33.3	Cell line enhanced		A-431: 142.3;CAPAN-2: 92.8;HeLa: 100.6;SiHa: 200.2
CDADC1	NYD-SP15	ENSG00000102543	Cytidine and dCMP deaminase domain containing 1	13	49247925-49293485	Predicted intracellular proteins	Evidence at transcript level	HPA047615, HPA058314	Uncertain		Approved	Nucleoplasm	Renal cancer:1.19e-5 (favourable), Lung cancer:6.03e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 15.7	Mixed		
CDC123	C10orf7, D123	ENSG00000151465	Cell division cycle 123	10	12195965-12250589	Predicted intracellular proteins	Evidence at protein level	HPA037830, HPA057540	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:3.16e-7 (unfavourable), Renal cancer:2.42e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 65.3	Expressed in all		
CDC14A	cdc14, Cdc14A1, Cdc14A2, DFNB105	ENSG00000079335	Cell division cycle 14A	1	100345025-100520277	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023783	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Tissue enhanced		testis: 56.3	fallopian tube: 19.8	Cell line enhanced		K-562: 25.8
CDC16	ANAPC6, APC6, CUT9	ENSG00000130177	Cell division cycle 16	13	114234887-114272723	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042826	Approved					Expressed in all	Expressed in all			testis: 83.8	Expressed in all		
CDC20	CDC20A, p55CDC	ENSG00000117399	Cell division cycle 20	1	43358955-43363203	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004525, HPA045842, HPA055288	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.00e-8 (unfavourable), Pancreatic cancer:1.32e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 64.0	tonsil: 45.2	Expressed in all		
CDC20B	FLJ37927	ENSG00000164287	Cell division cycle 20B	5	55112995-55173175	Predicted intracellular proteins	Evidence at protein level	HPA053900	Uncertain					Tissue enhanced	Group enriched	6	endometrium: 1.2;fallopian tube: 3.4;kidney: 1.2;testis: 4.9	lung: 0.4	Not detected		
CDC25A		ENSG00000164045	Cell division cycle 25A	3	48157146-48188402	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005855			Approved	Nucleus<br>Golgi apparatus<br>Vesicles		Tissue enhanced	Tissue enhanced		testis: 24.4	bone marrow: 9.3	Expressed in all		
CDC25B		ENSG00000101224	Cell division cycle 25B	20	3786772-3806121	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038892, HPA038893, HPA075215	Enhanced		Supported	Vesicles<br>Mitotic spindle	Renal cancer:2.94e-13 (unfavourable), Liver cancer:1.19e-4 (unfavourable), Endometrial cancer:4.76e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 56.6	Expressed in all		
CDC25C	CDC25, PPP1R60	ENSG00000158402	Cell division cycle 25C	5	138285265-138338355	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB003800, HPA066991	Approved		Supported	Nuclear speckles	Liver cancer:3.03e-6 (unfavourable), Colorectal cancer:2.49e-4 (favourable), Lung cancer:4.38e-4 (unfavourable)	Mixed	Tissue enriched	7	testis: 31.8	rectum: 4.4	Mixed		
CDC26	ANAPC12, APC12, C9orf17	ENSG00000176386	Cell division cycle 26	9	113255835-113275589	Predicted intracellular proteins	Evidence at protein level	HPA044130	Approved		Enhanced	Nucleoplasm	Liver cancer:1.72e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.5	Expressed in all		
CDC27	ANAPC3, APC3, D0S1430E, D17S978E, NUC2	ENSG00000004897	Cell division cycle 27	17	47117703-47189422	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016315, HPA028129, HPA052399	Supported		Enhanced	Nucleoplasm	Renal cancer:6.39e-5 (unfavourable), Colorectal cancer:1.77e-4 (favourable), Liver cancer:4.38e-4 (unfavourable), Lung cancer:8.15e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 71.5	Expressed in all		
CDC34	E2-CDC34, UBC3, UBE2R1	ENSG00000099804	Cell division cycle 34	19	531712-542092	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002382, CAB005109, CAB047311	Approved		Supported	Nuclear speckles<br>Cytosol	Liver cancer:7.57e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.5	Expressed in all		
CDC37	P50CDC37	ENSG00000105401	Cell division cycle 37	19	10391134-10420121	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA003928, CAB004214	Supported		Enhanced	Cytosol	Stomach cancer:2.33e-4 (favourable)	Expressed in all	Expressed in all			appendix: 110.5	Expressed in all		
CDC37L1	CDC37B, FLJ20639, HARC	ENSG00000106993	Cell division cycle 37 like 1	9	4679559-4708398	Predicted intracellular proteins	Evidence at protein level	HPA021175	Approved		Supported	Cytosol	Renal cancer:2.66e-7 (favourable)	Expressed in all	Expressed in all			liver: 28.5	Expressed in all		
CDC42	CDC42Hs, G25K	ENSG00000070831	Cell division cycle 42	1	22052627-22092946	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004360, HPA069590	Approved		Enhanced	Microtubules<br>Cytokinetic bridge	Liver cancer:5.28e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 252.6	Expressed in all		
CDC42BPA	FLJ23347, KIAA0451, MRCK, MRCKA, PK428	ENSG00000143776	CDC42 binding protein kinase alpha	1	226989865-227318474	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB070414, HPA071252	Approved		Approved	Intermediate filaments		Expressed in all	Expressed in all			testis: 45.2	Mixed		
CDC42BPB	KIAA1124, MRCKB	ENSG00000198752	CDC42 binding protein kinase beta	14	102932379-103057462	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022821	Approved				Renal cancer:8.67e-10 (favourable), Lung cancer:2.38e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 75.1	Mixed		
CDC42BPG	DMPK2, HSMDPKIN, kappa-200, MRCKgamma	ENSG00000171219	CDC42 binding protein kinase gamma	11	64823387-64844569	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027382, HPA061836	Enhanced		Supported	Cytosol	Renal cancer:5.99e-13 (favourable)	Mixed	Tissue enhanced		skin: 35.6	parathyroid gland: 14.5	Cell line enhanced		BEWO: 30.1;HaCaT: 21.0;MCF7: 25.1;SCLC-21H: 19.6
CDC42EP1	Borg5, CEP1, MSE55	ENSG00000128283	CDC42 effector protein 1	22	37560447-37569405	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006379	Approved		Supported	Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			stomach: 106.6	Mixed		
CDC42EP2	BORG1, CEP2	ENSG00000149798	CDC42 effector protein 2	11	65314818-65322429	Predicted intracellular proteins	Evidence at protein level	HPA038562	Approved		Supported	Microtubules<br>Cytosol	Liver cancer:2.89e-5 (unfavourable), Lung cancer:6.66e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 46.1	Cell line enhanced		U-2197: 69.2
CDC42EP3	BORG2, CEP3, UB1	ENSG00000163171	CDC42 effector protein 3	2	37641882-37738468	Predicted intracellular proteins	Evidence at protein level	HPA034986, HPA061792	Approved		Supported	Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			prostate: 153.3	Cell line enhanced		LHCN-M2: 504.9
CDC42EP4	BORG4, CEP4, KAIA1777, MGC17125, MGC3740	ENSG00000179604	CDC42 effector protein 4	17	73283624-73312175	Predicted intracellular proteins	Evidence at protein level	HPA023335, HPA024797	Approved	Supported	Enhanced	Plasma membrane<br>Actin filaments<br>Microtubules		Expressed in all	Expressed in all			cerebral cortex: 101.8	Mixed		
CDC42EP5	Borg3, CEP5	ENSG00000167617	CDC42 effector protein 5	19	54465026-54473264	Predicted intracellular proteins	Evidence at protein level	HPA043449	Approved				Renal cancer:2.79e-5 (unfavourable), Urothelial cancer:1.36e-4 (favourable)	Expressed in all	Tissue enhanced		colon: 3.1;prostate: 2.4	adipose tissue: 0.9	Not detected		
CDC42SE1	SCIP1, SPEC1	ENSG00000197622	CDC42 small effector 1	1	151050971-151070325	Predicted intracellular proteins	Evidence at protein level	HPA027634	Approved		Supported	Plasma membrane	Renal cancer:2.19e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 119.4	Expressed in all		
CDC42SE2	FLJ21967, SPEC2	ENSG00000158985	CDC42 small effector 2	5	131245493-131398447	Predicted intracellular proteins	Evidence at protein level	HPA038624	Enhanced				Colorectal cancer:4.50e-5 (favourable), Urothelial cancer:7.50e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 92.9	Expressed in all		
CDC5L	CDC5, CEF1, hCDC5, PCDC5RP	ENSG00000096401	Cell division cycle 5 like	6	44387525-44450426	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006302, HPA011361, CAB012275	Supported		Supported	Nucleoplasm	Melanoma:7.02e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.0	Expressed in all		
CDC6	CDC18L	ENSG00000094804	Cell division cycle 6	17	40287633-40304657	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050114, HPA065070	Approved		Supported	Nucleus<br>Cytokinetic bridge<br>Mitotic spindle<br>Cytosol	Liver cancer:5.96e-8 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable)	Expressed in all	Mixed			appendix: 15.4	Expressed in all		
CDC7	CDC7L1, HsCdc7, Hsk1, huCdc7	ENSG00000097046	Cell division cycle 7	1	91500893-91525764	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002669, HPA035831	Enhanced		Supported	Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle	Renal cancer:1.89e-15 (unfavourable), Liver cancer:3.15e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 32.0	spleen: 17.2	Expressed in all		
CDC73	C1orf28, FIHP, HRPT1, HRPT2, parafibromin	ENSG00000134371	Cell division cycle 73	1	193122017-193253901	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016359, HPA030772	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 32.2	Expressed in all		
CDCA2	PPP1R81, Repo-Man	ENSG00000184661	Cell division cycle associated 2	8	25458997-25507920	Predicted intracellular proteins	Evidence at protein level	HPA026293, HPA030049	Approved		Enhanced	Nucleoplasm	Renal cancer:2.30e-14 (unfavourable), Colorectal cancer:9.62e-4 (favourable)	Mixed	Tissue enriched	6	testis: 31.4	lymph node: 5.4	Mixed		
CDCA3	GRCC8, TOME-1	ENSG00000111665	Cell division cycle associated 3	12	6844793-6852066	Predicted intracellular proteins	Evidence at protein level	HPA026587			Approved	Cytosol	Liver cancer:6.51e-5 (unfavourable), Lung cancer:9.77e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 30.7	small intestine: 19.3	Mixed		
CDCA4	FLJ20764, Hepp	ENSG00000170779	Cell division cycle associated 4	14	105009573-105021148	Predicted intracellular proteins	Evidence at protein level	HPA059416, HPA064971	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.47e-6 (unfavourable), Liver cancer:4.19e-4 (unfavourable), Pancreatic cancer:6.67e-4 (unfavourable), Lung cancer:7.94e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 32.9	testis: 13.8	Expressed in all		
CDCA5		ENSG00000146670	Cell division cycle associated 5	11	65066300-65084164	Predicted intracellular proteins	Evidence at protein level	HPA023691	Approved		Supported	Nucleoplasm	Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.21e-6 (unfavourable), Pancreatic cancer:8.72e-6 (unfavourable), Endometrial cancer:2.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 31.0;testis: 46.5	lymph node: 18.9	Mixed		
CDCA7	FLJ14736, JPO1	ENSG00000144354	Cell division cycle associated 7	2	173354820-173368997	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005565	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.20e-4 (unfavourable), Melanoma:5.50e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 44.7	Mixed		
CDCA7L	JPO2, R1, RAM2	ENSG00000164649	Cell division cycle associated 7 like	7	21900900-21946084	Predicted intracellular proteins	Evidence at protein level	HPA027169	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:4.36e-6 (unfavourable), Renal cancer:1.98e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 45.7	Mixed		
CDCA8	BOR, DasraB, FLJ12042, MESRGP	ENSG00000134690	Cell division cycle associated 8	1	37692418-37709719	Predicted intracellular proteins	Evidence at protein level	HPA028120, HPA028258, HPA028783, CAB040294	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytokinetic bridge	Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.93e-10 (unfavourable), Melanoma:6.04e-4 (unfavourable), Pancreatic cancer:8.32e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 36.5	lymph node: 23.0	Mixed		
CDK1	CDC2, CDC28A	ENSG00000170312	Cyclin dependent kinase 1	10	60778331-60794852	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA003387, CAB003799	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.10e-6 (unfavourable), Pancreatic cancer:4.15e-6 (unfavourable), Lung cancer:7.88e-4 (unfavourable), Cervical cancer:8.81e-4 (favourable)	Expressed in all	Mixed			lymph node: 47.5	Expressed in all		
CDK10	PISSLRE	ENSG00000185324	Cyclin dependent kinase 10	16	89680737-89696364	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007451, HPA059634, HPA067060	Uncertain		Supported	Nucleoplasm<br>Midbody<br>Midbody ring	Pancreatic cancer:2.69e-4 (favourable), Urothelial cancer:3.63e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.4	Expressed in all		
CDK11A	CDC2L2, CDC2L3, CDK11-p110, CDK11-p46, CDK11-p58, p58GTA, PITSLRE	ENSG00000008128	Cyclin dependent kinase 11A	1	1702730-1724324	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB010467, HPA025061, HPA073626	Enhanced		Supported	Nuclear speckles<br>Cytosol	Renal cancer:1.15e-6 (unfavourable), Melanoma:5.06e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 35.1	Expressed in all		
CDK11B	CDC2L1, CDK11-p110, CDK11-p46, CDK11-p58	ENSG00000248333	Cyclin dependent kinase 11B	1	1635227-1659012	Predicted intracellular proteins	Evidence at protein level	HPA025061, HPA073626	Approved		Approved	Nuclear speckles	Head and neck cancer:1.14e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.7	Expressed in all		
CDK12	CRK7, CRKR, CRKRS, KIAA0904	ENSG00000167258	Cyclin dependent kinase 12	17	39461511-39564907	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008038	Supported		Supported	Nucleus		Expressed in all	Expressed in all			testis: 33.8	Expressed in all		
CDK13	CDC2L, CDC2L5, CHED, KIAA1791	ENSG00000065883	Cyclin dependent kinase 13	7	39950037-40097134	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059241	Uncertain		Supported	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 33.5	Expressed in all		
CDK14	PFTAIRE1, PFTK1	ENSG00000058091	Cyclin dependent kinase 14	7	90466424-91210590	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015267	Approved		Supported	Nucleus<br>Cytosol	Breast cancer:5.86e-4 (favourable), Stomach cancer:7.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 56.7	Mixed		
CDK15	ALS2CR7, PFTAIRE2, PFTK2	ENSG00000138395	Cyclin dependent kinase 15	2	201790461-201895550	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015786	Uncertain		Approved	Nucleus<br>Golgi apparatus		Not detected	Tissue enhanced		epididymis: 21.2;ovary: 8.4	testis: 4.0	Cell line enhanced		BJ hTERT+: 23.4;BJ hTERT+ SV40 Large T+ RasG12V: 22.4;HBF TERT88: 33.8;HMC-1: 58.6;LHCN-M2: 16.8
CDK16	FLJ16665, PCTAIRE, PCTAIRE1, PCTGAIRE, PCTK1	ENSG00000102225	Cyclin dependent kinase 16	X	47217860-47229997	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000974, HPA001366, CAB016535	Approved		Uncertain	Plasma membrane<br>Microtubules<br>Cytosol	Liver cancer:2.02e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 96.9	Expressed in all		
CDK17	PCTAIRE2, PCTK2	ENSG00000059758	Cyclin dependent kinase 17	12	96278261-96400560	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015325	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.09e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 71.8	Expressed in all		
CDK18	PCTAIRE3, PCTK3	ENSG00000117266	Cyclin dependent kinase 18	1	205504595-205532793	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045429	Approved		Approved	Actin filaments	Renal cancer:5.07e-6 (unfavourable), Urothelial cancer:2.81e-5 (favourable)	Expressed in all	Mixed			heart muscle: 62.0	Cell line enhanced		HBEC3-KT: 25.4
CDK19	bA346C16.3, CDC2L6, CDK11, KIAA1028	ENSG00000155111	Cyclin dependent kinase 19	6	110609978-110815958	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007053	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:4.72e-5 (unfavourable), Liver cancer:3.56e-4 (unfavourable)	Expressed in all	Mixed			prostate: 42.4	Expressed in all		
CDK2		ENSG00000123374	Cyclin dependent kinase 2	12	55966769-55972784	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013115, HPA066915	Enhanced		Enhanced	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:1.46e-10 (unfavourable), Liver cancer:8.61e-5 (unfavourable), Head and neck cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 65.5	Expressed in all		
CDK20	CCRK, p42	ENSG00000156345	Cyclin dependent kinase 20	9	87966441-87974753	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007666, HPA027379, HPA027401	Enhanced		Supported	Nucleoplasm	Renal cancer:2.12e-5 (favourable), Endometrial cancer:2.59e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 20.7	Cell line enhanced		SCLC-21H: 21.7;THP-1: 19.4
CDK2AP1	doc-1, DOC1, DORC1, p12DOC-1, ST19	ENSG00000111328	Cyclin dependent kinase 2 associated protein 1	12	123260971-123272334	Predicted intracellular proteins	Evidence at protein level	CAB019377, HPA057648, HPA068833	Approved		Supported	Nucleoplasm	Renal cancer:5.27e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 294.1	Mixed		
CDK2AP2	DOC-1R, p14	ENSG00000167797	Cyclin dependent kinase 2 associated protein 2	11	67506497-67508649	Predicted intracellular proteins	Evidence at protein level	HPA047599	Uncertain		Approved	Nucleoplasm	Renal cancer:5.20e-4 (unfavourable), Endometrial cancer:8.80e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 50.5	Expressed in all		
CDK3		ENSG00000250506	Cyclin dependent kinase 3	17	76000906-76005999	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007420	Uncertain		Approved	Cytosol		Mixed	Mixed			skin: 29.2	Expressed in all		
CDK4	PSK-J3	ENSG00000135446	Cyclin dependent kinase 4	12	57747727-57756013	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006024, CAB013116, CAB069405	Enhanced		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Cytosol	Liver cancer:2.09e-7 (unfavourable), Renal cancer:3.15e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 121.7	Group enriched	9	HBEC3-KT: 1874.1;LHCN-M2: 2370.6;RH-30: 8554.0
CDK5	PSSALRE	ENSG00000164885	Cyclin dependent kinase 5	7	151053812-151058530	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB008909, HPA064535	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 49.9	Expressed in all		
CDK5R1	Nck5a, p35, p35nck5a	ENSG00000176749	Cyclin dependent kinase 5 regulatory subunit 1	17	32486619-32491256	Predicted intracellular proteins	Evidence at protein level	HPA000252			Supported	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	7	cerebral cortex: 98.4	lymph node: 14.7	Cell line enhanced		SCLC-21H: 62.8;SK-MEL-30: 30.8
CDK5R2	NCK5AI, P39, p39nck5ai	ENSG00000171450	Cyclin dependent kinase 5 regulatory subunit 2	2	218959655-218962162	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	10	cerebral cortex: 52.1	adrenal gland: 5.1	Group enriched	10	SCLC-21H: 21.4;SH-SY5Y: 14.0
CDK5RAP1	C20orf34, C42, CGI-05, HSPC167	ENSG00000101391	CDK5 regulatory subunit associated protein 1	20	33358839-33401561	Predicted intracellular proteins	Evidence at protein level	HPA066301			Approved	Nuclear speckles<br>Mitochondria	Prostate cancer:8.07e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 19.4	Expressed in all		
CDK5RAP2	C48, CEP215, FLJ10867, MCPH3	ENSG00000136861	CDK5 regulatory subunit associated protein 2	9	120388869-120580170	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035820, HPA046529	Approved		Enhanced	Cell Junctions<br>Centrosome		Expressed in all	Expressed in all			testis: 37.4	Expressed in all		
CDK5RAP3	C53, FLJ13660, HSF-27, IC53, LZAP, MST016, OK/SW-cl.114	ENSG00000108465	CDK5 regulatory subunit associated protein 3	17	47967810-47981774	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022141, HPA022882, HPA027883	Supported		Supported	Cytosol	Renal cancer:3.61e-5 (unfavourable), Urothelial cancer:7.31e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 110.2	Expressed in all		
CDK6	PLSTIRE	ENSG00000105810	Cyclin dependent kinase 6	7	92604921-92836594	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002637, CAB004363	Enhanced		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.86e-6 (unfavourable), Urothelial cancer:2.33e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 34.2	Cell line enhanced		MOLT-4: 366.7;REH: 201.1
CDK7	CAK, CAK1, CDKN7, MO15, STK1	ENSG00000134058	Cyclin dependent kinase 7	5	69234795-69277430	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004364, HPA007932	Enhanced				Renal cancer:9.42e-7 (unfavourable), Pancreatic cancer:3.09e-4 (unfavourable)	Expressed in all	Mixed			testis: 23.7	Mixed		
CDK8	K35	ENSG00000132964	Cyclin dependent kinase 8	13	26254104-26405238	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044721			Approved	Nucleus	Stomach cancer:9.23e-4 (favourable)	Expressed in all	Expressed in all			testis: 17.7	Mixed		
CDK9	C-2k, CDC2L4, PITALRE, TAK	ENSG00000136807	Cyclin dependent kinase 9	9	127785679-127790787	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004216, HPA006738	Supported		Approved	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:8.92e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 60.5	Expressed in all		
CDKL1	KKIALRE	ENSG00000100490	Cyclin dependent kinase like 1	14	50329404-50416461	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059605, HPA065919	Uncertain		Enhanced	Nucleoplasm<br>Vesicles		Mixed	Mixed			fallopian tube: 34.5	Mixed		
CDKL2	KKIAMRE, P56	ENSG00000138769	Cyclin dependent kinase like 2	4	75578005-75630716	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040672			Approved	Nucleus<br>Centrosome	Renal cancer:6.88e-15 (favourable)	Mixed	Tissue enhanced		testis: 33.1	cerebral cortex: 9.8	Cell line enhanced		A-431: 2.7;RPTEC TERT1: 3.3
CDKL3	NKIAMRE	ENSG00000006837	Cyclin dependent kinase like 3	5	134286350-134371047	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027751			Uncertain	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	9	testis: 28.9	cerebral cortex: 3.2	Mixed		
CDKL4		ENSG00000205111	Cyclin dependent kinase like 4	2	39175646-39229588	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA067895	Uncertain					Not detected	Tissue enriched	8	testis: 5.3	fallopian tube,placenta: 0.6	Cell line enhanced		HL-60: 1.6;RT4: 1.1;SH-SY5Y: 2.8
CDKL5	CFAP247, EIEE2, STK9	ENSG00000008086	Cyclin dependent kinase like 5	X	18425583-18653629	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002847, CAB011577	Supported		Enhanced	Nucleoplasm	Renal cancer:5.54e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 31.0	testis: 14.4	Mixed		
CDKN1A	CAP20, CDKN1, CIP1, P21, p21CIP1, p21Cip1/Waf1, SDI1, WAF1	ENSG00000124762	Cyclin dependent kinase inhibitor 1A	6	36676460-36687339	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000064, HPA005946, CAB069401	Supported		Supported	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:3.14e-5 (favourable), Renal cancer:4.95e-5 (favourable), Lung cancer:7.05e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 204.8	Cell line enhanced		HHSteC: 654.9
CDKN1B	KIP1, P27KIP1	ENSG00000111276	Cyclin dependent kinase inhibitor 1B	12	12715058-12722371	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB003691, CAB021888, HPA059086	Approved		Supported	Nucleus<br>Vesicles	Liver cancer:3.25e-4 (unfavourable), Colorectal cancer:5.15e-4 (favourable), Renal cancer:8.39e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 73.1	Mixed		
CDKN1C	BWCR, BWS, KIP2, P57	ENSG00000129757	Cyclin dependent kinase inhibitor 1C	11	2883213-2885881	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002924	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Tissue enhanced		placenta: 202.5	adipose tissue: 62.5	Cell line enhanced		HeLa: 21.7;SH-SY5Y: 31.6;SiHa: 21.0
CDKN2AIP	CARF, FLJ20036	ENSG00000168564	CDKN2A interacting protein	4	183444591-183448198	Predicted intracellular proteins	Evidence at protein level	HPA041397, HPA062142	Approved		Enhanced	Nucleoplasm	Renal cancer:3.00e-5 (favourable)	Expressed in all	Expressed in all			testis: 37.6	Expressed in all		
CDKN2AIPNL	MGC13017	ENSG00000237190	CDKN2A interacting protein N-terminal like	5	134402087-134411898	Predicted intracellular proteins	Evidence at protein level	HPA043966	Approved					Expressed in all	Expressed in all			thyroid gland: 35.4	Expressed in all		
CDKN2B	CDK4I, INK4B, MTS2, P15, p15INK4b, TP15	ENSG00000147883	Cyclin dependent kinase inhibitor 2B	9	22002903-22009363	Predicted intracellular proteins	Evidence at protein level	CAB000349, HPA052838, HPA063327	Uncertain		Approved	Nucleoplasm	Endometrial cancer:4.47e-6 (unfavourable), Renal cancer:1.03e-4 (unfavourable), Liver cancer:1.49e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 32.6	Cell line enhanced		HaCaT: 30.4;SiHa: 46.3
CDKN2C	INK4C, p18	ENSG00000123080	Cyclin dependent kinase inhibitor 2C	1	50960745-50974633	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005303, CAB018398, HPA019057, HPA019764	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.70e-10 (unfavourable), Liver cancer:1.58e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 80.3	Mixed		
CDKN2D	INK4D, p19	ENSG00000129355	Cyclin dependent kinase inhibitor 2D	19	10566462-10569059	Predicted intracellular proteins	Evidence at protein level	CAB011201, HPA043546	Enhanced		Supported	Nucleoplasm<br>Cytosol	Cervical cancer:1.02e-4 (favourable), Liver cancer:4.82e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 181.1	cerebral cortex: 61.3	Expressed in all		
CDKN3	CDI1, KAP	ENSG00000100526	Cyclin dependent kinase inhibitor 3	14	54396849-54420218	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005285, HPA039311, HPA058874			Enhanced	Cytosol	Renal cancer:0.00e+0 (unfavourable), Lung cancer:4.52e-4 (unfavourable), Pancreatic cancer:7.46e-4 (unfavourable)	Expressed in all	Tissue enriched	11	testis: 342.6	lymph node: 31.7	Expressed in all		
CDO1		ENSG00000129596	Cysteine dioxygenase type 1	5	115804733-115816954	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036573, HPA057503	Enhanced		Uncertain	Nucleoplasm	Liver cancer:1.91e-5 (favourable)	Group enriched	Tissue enhanced		epididymis: 137.5;liver: 209.9	adipose tissue: 104.0	Cell line enhanced		AF22: 38.7;ASC diff: 32.4;HAP1: 14.4;NTERA-2: 14.5
CDPF1	C22orf40, LOC150383	ENSG00000205643	Cysteine rich DPF motif domain containing 1	22	46244011-46250679	Predicted intracellular proteins	Evidence at protein level	HPA018823	Uncertain		Approved	Nucleus<br>Cytosol	Endometrial cancer:3.13e-5 (favourable)	Expressed in all	Mixed			fallopian tube: 7.0	Mixed		
CDR1	CDR, CDR34, CDR62A	ENSG00000184258	Cerebellar degeneration related protein 1	X	140782405-140784871	Predicted intracellular proteins	Evidence at protein level	HPA073147			Approved	Nucleoplasm<br>Golgi apparatus<br>Centrosome		Not detected	Group enriched	7	cerebral cortex: 48.4;skin: 12.1	adipose tissue: 4.0	Cell line enhanced		BJ: 6.3;U-87 MG: 26.1
CDR2	CDR62, Yo	ENSG00000140743	Cerebellar degeneration related protein 2	16	22345936-22437165	Predicted intracellular proteins	Evidence at protein level	HPA018151, HPA023870	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 108.5	Expressed in all		
CDR2L	HUMPPA	ENSG00000109089	Cerebellar degeneration related protein 2 like	17	74987632-75005800	Predicted intracellular proteins	Evidence at protein level	HPA022015	Enhanced		Approved	Cytosol		Expressed in all	Mixed			duodenum: 22.5	Mixed		
CDRT1	FBXW10B, FBXW10P1, HREP, SM25H2	ENSG00000241322	CMT1A duplicated region transcript 1	17	15565483-15619512	Predicted intracellular proteins	Evidence at transcript level	HPA013332, HPA047457			Approved	Nucleus<br>Nucleoli		Not detected	Tissue enhanced		testis: 20.3	esophagus: 5.1	Cell line enhanced		CAPAN-2: 20.4;HaCaT: 37.7
CDRT15		ENSG00000223510	CMT1A duplicated region transcript 15	17	14235673-14236862	Predicted intracellular proteins	Evidence at protein level	HPA055952	Uncertain					Not detected	Tissue enhanced		testis: 11.5	skin: 4.0	Mixed		
CDRT4	FLJ36674	ENSG00000239704	CMT1A duplicated region transcript 4	17	15436015-15503608	Predicted intracellular proteins	Evidence at transcript level	HPA021590	Uncertain		Approved	Mitochondria		Not detected	Tissue enhanced		epididymis: 30.3	skin: 26.3	Cell line enhanced		Hep G2: 7.6
CDT1	DUP, RIS2	ENSG00000167513	Chromatin licensing and DNA replication factor 1	16	88803213-88809258	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA017224	Approved		Supported	Nucleus<br>Nuclear bodies	Liver cancer:2.12e-6 (unfavourable), Renal cancer:2.69e-6 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 20.4	lymph node: 4.7	Mixed		
CDV3	H41	ENSG00000091527	CDV3 homolog	3	133573730-133590261	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029761, HPA029762, HPA029763	Enhanced		Enhanced	Nucleoli<br>Plasma membrane<br>Cytosol	Liver cancer:5.21e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 185.6	Expressed in all		
CDX1		ENSG00000113722	Caudal type homeobox 1	5	150166795-150184558	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055196	Enhanced					Tissue enhanced	Group enriched	9	colon: 129.9;duodenum: 64.5;rectum: 134.7;small intestine: 104.9	appendix: 12.1	Cell line enhanced		BJ hTERT+: 5.4;SH-SY5Y: 1.3
CDX2	CDX3	ENSG00000165556	Caudal type homeobox 2	13	27962137-27971139	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002221, HPA045669, HPA049580	Enhanced		Supported	Nucleoplasm		Tissue enriched	Group enriched	6	colon: 30.8;duodenum: 22.3;rectum: 24.9;small intestine: 30.2	appendix: 4.7	Cell line enhanced		CACO-2: 9.4;CAPAN-2: 3.3;HEK93: 5.6
CDX4		ENSG00000131264	Caudal type homeobox 4	X	73447254-73455245	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056528	Uncertain					Tissue enriched	Tissue enriched	8	skin: 1.3	seminal vesicle,testis: 0.1	Not detected		
CDY1	CDY1A	ENSG00000172288	Chromodomain Y-linked 1	Y	25622162-25624902	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	11	testis: 1.0	all non-specific tissues: 0.0	Not detected		
CDY1B		ENSG00000172352	Chromodomain Y-linked 1B	Y	24045229-24048019	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	40	testis: 4.0	all non-specific tissues: 0.0	Not detected		
CDY2A	CDY2	ENSG00000182415	Chromodomain Y-linked 2A	Y	18025787-18028597	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	24	epididymis: 1.3;testis: 3.5	all non-specific tissues: 0.0	Not detected		
CDY2B	CDY	ENSG00000129873	Chromodomain Y-linked 2B	Y	17877410-17880220	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.2	Not detected		
CDYL	CDYL1, DKFZP586C1622	ENSG00000153046	Chromodomain Y-like	6	4706159-4955551	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB012249, HPA035578	Enhanced		Supported	Nuclear speckles	Glioma:2.10e-4 (favourable), Liver cancer:2.20e-4 (unfavourable), Melanoma:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 27.7	Expressed in all		
CDYL2	FLJ38866	ENSG00000166446	Chromodomain Y-like 2	16	80597906-80804329	Predicted intracellular proteins	Evidence at protein level	HPA041016	Approved				Endometrial cancer:6.13e-4 (favourable)	Expressed in all	Mixed			testis: 21.3	Cell line enhanced		HDLM-2: 14.7;HUVEC TERT2: 19.5;MCF7: 15.7;TIME: 28.5
CEBPA	C/EBP-alpha, CEBP	ENSG00000245848	CCAAT/enhancer binding protein alpha	19	33299934-33302564	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052734, HPA065037, HPA067937	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			adipose tissue: 108.0	Cell line enhanced		BEWO: 187.4;THP-1: 270.7;U-937: 100.7
CEBPB	C/EBP-beta, CRP2, IL6DBP, LAP, NFIL6, TCF5	ENSG00000172216	CCAAT/enhancer binding protein beta	20	50190734-50192689	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004213, HPA061355, HPA062267	Supported		Enhanced	Nucleoplasm	Renal cancer:2.44e-12 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 112.4	Expressed in all		
CEBPD	C/EBP-delta, CELF, CRP3, NF-IL6-beta	ENSG00000221869	CCAAT/enhancer binding protein delta	8	47736909-47739086	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067581			Supported	Nucleoplasm	Renal cancer:2.87e-7 (unfavourable), Breast cancer:2.28e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 71.1	Cell line enhanced		HHSteC: 29.5;NB-4: 50.0;SiHa: 33.7
CEBPE	CRP1	ENSG00000092067	CCAAT/enhancer binding protein epsilon	14	23117304-23119616	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002928, CAB005113	Enhanced		Enhanced	Nucleoplasm		Not detected	Tissue enriched	9	bone marrow: 26.0	small intestine: 2.7	Cell line enhanced		HL-60: 143.2;HMC-1: 26.7;NB-4: 58.7
CEBPG	GPE1BP, IG/EBP-1	ENSG00000153879	CCAAT/enhancer binding protein gamma	19	33373330-33382686	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA012024	Enhanced		Supported	Nucleoplasm	Endometrial cancer:7.97e-5 (unfavourable), Renal cancer:7.23e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 41.3	Expressed in all		
CEBPZ	CBF2, CTF2	ENSG00000115816	CCAAT/enhancer binding protein zeta	2	37201612-37231713	Predicted intracellular proteins	Evidence at protein level	HPA052065	Uncertain		Approved	Nucleus<br>Vesicles	Liver cancer:2.94e-5 (unfavourable), Endometrial cancer:5.07e-4 (unfavourable), Pancreatic cancer:8.13e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 67.3	Expressed in all		
CECR2	KIAA1740	ENSG00000099954	CECR2, histone acetyl-lysine reader	22	17359949-17558149	Predicted intracellular proteins	Evidence at protein level	HPA002943	Approved		Approved	Nucleus<br>Vesicles		Tissue enriched	Tissue enhanced		cerebral cortex: 7.8	skeletal muscle: 7.5	Cell line enhanced		AF22: 15.3;HAP1: 14.9;NTERA-2: 22.8;SCLC-21H: 11.9
CELA1	ELA1	ENSG00000139610	Chymotrypsin like elastase family member 1	12	51328443-51346679	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		adrenal gland: 2.5;pancreas: 1.3	lymph node: 0.9	Cell line enriched	6	BEWO: 5.2
CELF1	BRUNOL2, CUG-BP, CUGBP, CUGBP1, EDEN-BP, hNab50, NAB50, NAPOR	ENSG00000149187	CUGBP Elav-like family member 1	11	47465944-47565569	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016114, HPA044597, CAB069989	Supported		Enhanced	Nucleoplasm	Liver cancer:7.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 133.1	Expressed in all		
CELF2	BRUNOL3, CUGBP2, Etr-3, NAPOR-2	ENSG00000048740	CUGBP Elav-like family member 2	10	10798397-11336675	Predicted intracellular proteins	Evidence at protein level	CAB016395, HPA035813, HPA065098	Enhanced		Uncertain	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge	Head and neck cancer:7.61e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 77.8	Cell line enhanced		HEL: 179.2;HMC-1: 163.9
CELF3	BRUNOL1, CAGH4, ERDA4, MGC57297, TNRC4	ENSG00000159409	CUGBP Elav-like family member 3	1	151702404-151716814	Predicted intracellular proteins	Evidence at protein level	HPA006292	Uncertain		Approved	Nucleoplasm		Group enriched	Group enriched	6	adrenal gland: 15.2;cerebral cortex: 51.7	stomach: 5.5	Group enriched	10	SCLC-21H: 50.0;SH-SY5Y: 31.5
CELF4	BRUNOL4	ENSG00000101489	CUGBP Elav-like family member 4	18	37243047-37566037	Predicted intracellular proteins	Evidence at protein level	HPA037986	Approved					Mixed	Tissue enriched	9	cerebral cortex: 126.9	adrenal gland: 14.7	Group enriched	15	SCLC-21H: 51.8;SH-SY5Y: 11.4
CELF5	BRUNOL5	ENSG00000161082	CUGBP Elav-like family member 5	19	3224703-3297076	Predicted intracellular proteins	Evidence at protein level	HPA042012, HPA060336	Enhanced					Tissue enhanced	Tissue enriched	7	cerebral cortex: 38.1	ovary: 5.1	Cell line enhanced		NTERA-2: 3.5;REH: 4.0;SCLC-21H: 5.2;SH-SY5Y: 2.8
CELF6	BRUNOL6	ENSG00000140488	CUGBP Elav-like family member 6	15	72284727-72320129	Predicted intracellular proteins	Evidence at protein level	HPA046985, HPA053526	Uncertain		Approved	Cytosol		Not detected	Mixed			cerebral cortex: 11.1	Cell line enhanced		U-266/70: 2.7
CEMP1	CP-23	ENSG00000205923	Cementum protein 1	16	2530035-2531417	Predicted intracellular proteins	Evidence at transcript level	HPA057658	Approved					Not detected	Mixed			skin: 5.7	Cell line enhanced		REH: 6.9
CENPA	CenH3, CENP-A	ENSG00000115163	Centromere protein A	2	26764289-26801067	Predicted intracellular proteins	Evidence at protein level	CAB008371, HPA073086	Enhanced		Supported	Nucleoplasm	Liver cancer:2.88e-8 (unfavourable), Pancreatic cancer:1.30e-4 (unfavourable), Endometrial cancer:2.38e-4 (unfavourable), Lung cancer:3.70e-4 (unfavourable)	Mixed	Tissue enhanced		lymph node: 7.4	tonsil: 6.5	Mixed		
CENPB		ENSG00000125817	Centromere protein B	20	3783851-3786690	Predicted intracellular proteins	Evidence at protein level	CAB011626, HPA053507, HPA054405	Approved		Enhanced	Nuclear bodies	Liver cancer:6.09e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 43.4	Expressed in all		
CENPBD1	MGC16385	ENSG00000177946	CENPB DNA-binding domain containing 1	16	89969791-89972534	Predicted intracellular proteins	Evidence at transcript level	HPA052759, HPA060522	Uncertain		Approved	Nucleoli<br>Vesicles	Renal cancer:5.27e-11 (favourable)	Expressed in all	Mixed			parathyroid gland: 11.1	Expressed in all		
CENPC	CENP-C, CENPC1, hcp-4, MIF2	ENSG00000145241	Centromere protein C	4	67468748-67545606	Predicted intracellular proteins	Evidence at protein level	HPA049740, HPA058252			Enhanced	Nuclear bodies	Renal cancer:5.63e-4 (favourable), Lung cancer:9.67e-4 (favourable)	Expressed in all	Mixed			ovary: 6.2	Mixed		
CENPE	KIF10, PPP1R61	ENSG00000138778	Centromere protein E	4	103105806-103198409	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042294	Approved		Approved	Nucleoplasm<br>Microtubules<br>Cytosol		Mixed	Mixed			testis: 7.7	Mixed		
CENPF	hcp-1	ENSG00000117724	Centromere protein F	1	214603195-214664588	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052382, HPA064308, CAB070134	Enhanced		Supported	Nucleoplasm	Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.29e-5 (unfavourable), Pancreatic cancer:1.39e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 17.7;testis: 18.8	lymph node: 10.1	Mixed		
CENPH		ENSG00000153044	Centromere protein H	5	69189548-69210357	Predicted intracellular proteins	Evidence at protein level	HPA036494	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:5.11e-15 (unfavourable), Liver cancer:5.22e-5 (unfavourable), Ovarian cancer:2.50e-4 (favourable), Cervical cancer:6.86e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 53.9	lymph node: 20.6	Expressed in all		
CENPI	CENP-I, FSHPRH1, LRPR1, Mis6	ENSG00000102384	Centromere protein I	X	101098218-101163681	Predicted intracellular proteins	Evidence at protein level	HPA061297			Supported	Nuclear bodies<br>Cytosol		Mixed	Mixed			lymph node: 6.6	Mixed		
CENPJ	BM032, CPAP, LAP, LIP1, MCPH6, Sas-4, SASS4, SCKL4	ENSG00000151849	Centromere protein J	13	24882284-24922889	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA060426			Approved	Nucleoplasm<br>Plasma membrane<br>Centrosome	Renal cancer:1.75e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 42.8	thyroid gland: 20.5	Expressed in all		
CENPK	CENP-K, FKSG14, SOLT	ENSG00000123219	Centromere protein K	5	65517766-65563171	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			testis: 24.7	Expressed in all		
CENPL	C1orf155, dJ383J4.3, FLJ31044	ENSG00000120334	Centromere protein L	1	173799550-173824720	Predicted intracellular proteins	Evidence at protein level	HPA044520	Uncertain				Melanoma:2.51e-4 (unfavourable), Ovarian cancer:3.60e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 18.2	lymph node: 7.8	Expressed in all		
CENPM	C22orf18, CENP-M, MGC861, Pane1	ENSG00000100162	Centromere protein M	22	41938721-41947164	Predicted intracellular proteins	Evidence at protein level	HPA042404, HPA056500	Enhanced		Enhanced	Cytosol	Renal cancer:5.99e-7 (unfavourable), Cervical cancer:3.40e-5 (favourable), Liver cancer:5.50e-5 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 28.6	bone marrow: 17.6	Expressed in all		
CENPN	BM039, C16orf60, FLJ13607, FLJ22660	ENSG00000166451	Centromere protein N	16	81006498-81033114	Predicted intracellular proteins	Evidence at protein level	HPA052870			Supported	Nucleus	Pancreatic cancer:1.46e-5 (unfavourable), Renal cancer:4.86e-4 (unfavourable), Lung cancer:6.49e-4 (unfavourable)	Expressed in all	Mixed			prostate: 24.5	Expressed in all		
CENPO	CENP-O, MGC11266	ENSG00000138092	Centromere protein O	2	24793136-24822376	Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.71e-13 (unfavourable), Liver cancer:1.73e-6 (unfavourable), Endometrial cancer:3.54e-4 (unfavourable)	Expressed in all	Mixed			testis: 13.0	Expressed in all		
CENPP	CENP-P, RP11-19J3.3	ENSG00000188312	Centromere protein P	9	92325484-92620533	Predicted intracellular proteins	Evidence at protein level	HPA021787, HPA058945	Uncertain		Supported	Nucleus<br>Nucleoli	Head and neck cancer:3.65e-4 (favourable), Cervical cancer:3.91e-4 (favourable)	Mixed	Tissue enhanced		skin: 25.2	parathyroid gland: 8.0	Expressed in all		
CENPQ	C6orf139, CENP-Q, FLJ10545	ENSG00000031691	Centromere protein Q	6	49463378-49493107	Predicted intracellular proteins	Evidence at protein level	HPA029043, HPA046634, HPA054965	Approved		Enhanced	Nucleoplasm	Liver cancer:2.21e-5 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable), Ovarian cancer:6.26e-4 (favourable)	Expressed in all	Mixed			testis: 11.0	Expressed in all		
CENPS	APITD1, CENP-S, FAAP16, MHF1	ENSG00000175279	Centromere protein S	1	10430443-10442809	Predicted intracellular proteins	Evidence at protein level						Cervical cancer:1.24e-4 (favourable)	Expressed in all	Expressed in all			testis: 84.5	Expressed in all		
CENPT	C16orf56, CENP-T, FLJ13111	ENSG00000102901	Centromere protein T	16	67828157-67847811	Predicted intracellular proteins	Evidence at protein level	HPA041220, HPA058036	Approved		Enhanced	Nuclear bodies	Renal cancer:1.57e-7 (unfavourable), Pancreatic cancer:2.96e-4 (favourable)	Expressed in all	Expressed in all			skin: 15.9	Mixed		
CENPU	CENP-50, CENP-U, KLIP1, MLF1IP, PBIP1	ENSG00000151725	Centromere protein U	4	184694618-184734133	Predicted intracellular proteins	Evidence at protein level	HPA022048	Approved		Supported	Nucleus<br>Microtubule organizing center	Renal cancer:1.11e-9 (unfavourable), Pancreatic cancer:2.09e-4 (unfavourable), Lung cancer:7.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 45.6;testis: 67.6	lymph node: 25.3	Mixed		
CENPV	CENP-V, p30, PRR6	ENSG00000166582	Centromere protein V	17	16342534-16353656	Predicted intracellular proteins	Evidence at protein level	HPA042529, HPA042616	Enhanced					Expressed in all	Mixed			testis: 13.6	Cell line enhanced		AF22: 98.5;NTERA-2: 98.2
CENPVL1	CENPVP1, PRR6L1	ENSG00000223591	Centromere protein V like 1	X	51710512-51712131	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 3.0	cerebral cortex: 0.8	Cell line enhanced		NTERA-2: 2.1;PC-3: 4.2;U-2 OS: 3.6
CENPVL2	CENPVP2	ENSG00000283093	Centromere protein V like 2	X	51681212-51682831	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		testis: 3.0	cerebral cortex: 0.8	Cell line enhanced		NTERA-2: 2.1;PC-3: 4.2;U-2 OS: 3.6
CENPVL3	CENPVP3	ENSG00000224109	Centromere protein V like 3	X	51618055-51618918	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex: 0.7	Cell line enhanced		NTERA-2: 2.2;PC-3: 12.7;U-2 OS: 6.4
CENPW	C6orf173, CUG2	ENSG00000203760	Centromere protein W	6	126340174-126348875	Predicted intracellular proteins	Evidence at protein level	HPA067285			Supported	Nucleoplasm	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.21e-5 (unfavourable)	Expressed in all	Mixed			testis: 51.9	Expressed in all		
CENPX	CENP-X, FAAP10, MGC14480, MHF2, STRA13	ENSG00000169689	Centromere protein X	17	82018702-82024107	Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 70.2	Expressed in all		
CEP104	CFAP256, GlyBP, JBTS25, KIAA0562, ROC22, RP1-286D6.4	ENSG00000116198	Centrosomal protein 104	1	3812081-3857214	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA010126	Approved				Renal cancer:1.70e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.2	Expressed in all		
CEP112	CCDC46, MGC33887	ENSG00000154240	Centrosomal protein 112	17	65635538-66192084	Predicted intracellular proteins	Evidence at protein level	HPA024481			Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Tissue enriched	6	testis: 86.4	endometrium: 14.2	Cell line enhanced		LHCN-M2: 27.2;RH-30: 73.5
CEP120	CCDC100, FLJ36090	ENSG00000168944	Centrosomal protein 120	5	123344885-123423592	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028823, HPA051556	Uncertain		Approved	Microtubules<br>Cytosol		Expressed in all	Expressed in all			testis: 29.7	Expressed in all		
CEP126	KIAA1377	ENSG00000110318	Centrosomal protein 126	11	101915015-102001058	Predicted intracellular proteins	Evidence at protein level	HPA038381, HPA038399			Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:5.00e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 17.6	fallopian tube: 12.9	Cell line enhanced		EFO-21: 5.9
CEP128	C14orf145, C14orf61	ENSG00000100629	Centrosomal protein 128	14	80476983-80959517	Predicted intracellular proteins	Evidence at protein level	HPA000602, HPA001116, HPA018498	Uncertain		Supported	Microtubule organizing center<br>Cytosol		Mixed	Mixed			testis: 9.5	Cell line enhanced		U-266/70: 83.9
CEP131	AZ1, AZI1, KIAA1118	ENSG00000141577	Centrosomal protein 131	17	81189593-81222999	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024019	Approved		Supported	Microtubules<br>Cytokinetic bridge<br>Microtubule organizing center	Liver cancer:9.68e-5 (unfavourable)	Expressed in all	Mixed			testis: 17.3	Expressed in all		
CEP135	CEP4, FLJ13621, KIAA0635	ENSG00000174799	Centrosomal protein 135	4	55948871-56033363	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA073950			Uncertain	Focal adhesion sites	Urothelial cancer:6.11e-5 (favourable)	Mixed	Mixed			endometrium: 13.0	Expressed in all		
CEP152	KIAA0912, MCPH9, SCKL5	ENSG00000103995	Centrosomal protein 152	15	48712928-48811146	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039408	Approved		Supported	Centrosome		Mixed	Tissue enhanced		testis: 18.1	bone marrow: 10.2	Expressed in all		
CEP162	C6orf84, KIAA1009, QN1	ENSG00000135315	Centrosomal protein 162	6	84124241-84227635	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030170, HPA030171, HPA030172, HPA030173	Supported		Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Mixed			testis: 15.7	Mixed		
CEP164	KIAA1052, NPHP15	ENSG00000110274	Centrosomal protein 164	11	117314557-117413268	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037605, HPA037606, HPA061504	Uncertain		Enhanced	Nucleoplasm<br>Centrosome	Liver cancer:2.40e-5 (unfavourable), Renal cancer:2.89e-5 (unfavourable), Pancreatic cancer:5.93e-4 (favourable)	Expressed in all	Mixed			testis: 44.6	Expressed in all		
CEP170B	Cep170R, FAM68C, KIAA0284	ENSG00000099814	Centrosomal protein 170B	14	104865280-104896770	Predicted intracellular proteins	Evidence at protein level	HPA000871, HPA059017	Enhanced		Approved	Centrosome<br>Cytosol	Renal cancer:3.26e-4 (favourable), Prostate cancer:4.41e-4 (unfavourable), Liver cancer:6.12e-4 (unfavourable)	Expressed in all	Mixed			skin: 30.5	Mixed		
CEP19	C3orf34, MGC14126	ENSG00000174007	Centrosomal protein 19	3	196706277-196712293	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047614, HPA071138	Enhanced		Supported	Centrosome		Expressed in all	Tissue enhanced		testis: 18.0	fallopian tube: 6.6	Mixed		
CEP192	FLJ10352, KIAA1569, PPP1R62	ENSG00000101639	Centrosomal protein 192	18	12991362-13125052	Predicted intracellular proteins	Evidence at protein level	HPA039392, HPA040503	Uncertain		Approved	Centrosome<br>Cytosol		Expressed in all	Mixed			testis: 17.3	Expressed in all		
CEP250	C-NAP1, CEP2	ENSG00000126001	Centrosomal protein 250	20	35455164-35519280	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064875			Supported	Centrosome	Liver cancer:1.77e-7 (unfavourable), Renal cancer:1.97e-6 (unfavourable), Pancreatic cancer:9.27e-6 (favourable)	Expressed in all	Expressed in all			testis: 35.1	Expressed in all		
CEP290	3H11Ag, BBS14, CT87, FLJ13615, JBTS5, KIAA0373, LCA10, MKS4, NPHP6, POC3, rd16, SLSN6	ENSG00000198707	Centrosomal protein 290	12	88049014-88142216	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB029995, HPA043918, HPA064397	Approved		Supported	Centrosome	Renal cancer:3.21e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 21.9	Expressed in all		
CEP295	KIAA1731	ENSG00000166004	Centrosomal protein 295	11	93661639-93730358	Predicted intracellular proteins	Evidence at protein level	HPA038595, HPA038596, HPA038597	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 22.2	Expressed in all		
CEP295NL	DDC8, KIAA1731NL	ENSG00000178404	CEP295 N-terminal like	17	78870910-78903217	Predicted intracellular proteins	Evidence at transcript level	HPA023609, HPA024619, HPA025717	Uncertain		Approved	Vesicles		Not detected	Tissue enriched	46	testis: 40.5	bone marrow: 0.8	Cell line enhanced		BEWO: 1.4;U-2 OS: 2.0
CEP350	CAP350, KIAA0480	ENSG00000135837	Centrosomal protein 350	1	179954738-180114880	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028355, HPA028357, HPA030845	Enhanced		Supported	Centrosome	Renal cancer:1.02e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 44.7	Expressed in all		
CEP41	DKFZp762H1311, FLJ22445, JBTS15, TSGA14	ENSG00000106477	Centrosomal protein 41	7	130393771-130442433	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024090	Uncertain				Colorectal cancer:4.54e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 80.5	salivary gland: 18.1	Mixed		
CEP44	KIAA1712	ENSG00000164118	Centrosomal protein 44	4	174283677-174333380	Predicted intracellular proteins	Evidence at protein level	HPA041515, HPA041835	Approved					Expressed in all	Mixed			testis: 23.6	Expressed in all		
CEP55	C10orf3, CT111, FLJ10540	ENSG00000138180	Centrosomal protein 55	10	93496632-93529092	Predicted intracellular proteins	Evidence at protein level	HPA023430	Approved		Supported	Plasma membrane<br>Midbody<br>Microtubule organizing center	Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.20e-9 (unfavourable), Pancreatic cancer:2.66e-5 (unfavourable), Lung cancer:1.45e-4 (unfavourable), Stomach cancer:3.15e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 39.4	lymph node: 17.6	Mixed		
CEP57L1	bA487F23.2, C6orf182, MGC21731	ENSG00000183137	Centrosomal protein 57 like 1	6	109095110-109163932	Predicted intracellular proteins	Evidence at protein level	HPA040378	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 47.6	Expressed in all		
CEP63	FLJ13386	ENSG00000182923	Centrosomal protein 63	3	134485743-134575017	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA058154, HPA058313	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 83.9	Expressed in all		
CEP68	KIAA0582	ENSG00000011523	Centrosomal protein 68	2	65056366-65087004	Predicted intracellular proteins	Evidence at protein level	HPA040493, HPA040620	Enhanced		Supported	Nucleus<br>Microtubule organizing center	Renal cancer:3.93e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 28.4	Expressed in all		
CEP70	BITE, FLJ13036	ENSG00000114107	Centrosomal protein 70	3	138494344-138594538	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036941, HPA036942	Enhanced		Uncertain	Nucleoplasm<br>Cytosol	Prostate cancer:9.60e-5 (unfavourable), Cervical cancer:2.93e-4 (favourable)	Expressed in all	Expressed in all			testis: 123.8	Expressed in all		
CEP72	FLJ10565, KIAA1519	ENSG00000112877	Centrosomal protein 72	5	612272-667168	Predicted intracellular proteins	Evidence at protein level	HPA058235, HPA074879	Approved		Supported	Centrosome	Endometrial cancer:2.90e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 10.4	ovary: 3.3	Cell line enhanced		HDLM-2: 41.0
CEP76	C18orf9, FLJ12542, HsT1705	ENSG00000101624	Centrosomal protein 76	18	12661833-12702777	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039395	Approved					Expressed in all	Mixed			testis: 14.7	Expressed in all		
CEP78	C9orf81, FLJ12643	ENSG00000148019	Centrosomal protein 78	9	78236062-78279690	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048846	Approved					Expressed in all	Tissue enhanced		testis: 30.7	endometrium,parathyroid gland: 9.9	Expressed in all		
CEP83	CCDC41, NPHP18, NY-REN-58	ENSG00000173588	Centrosomal protein 83	12	94306449-94459988	Predicted intracellular proteins	Evidence at protein level	HPA038161	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:5.00e-10 (unfavourable), Prostate cancer:4.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 31.4	Expressed in all		
CEP85	CCDC21, DKFZP434L0117	ENSG00000130695	Centrosomal protein 85	1	26234153-26279038	Predicted intracellular proteins	Evidence at protein level	HPA028252	Approved		Supported	Nucleoli<br>Golgi apparatus<br>Microtubule organizing center<br>Cytosol	Liver cancer:4.39e-6 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 48.1;testis: 52.4	heart muscle: 17.5	Expressed in all		
CEP85L	bA57K17.2, C6orf204, NY-BR-15	ENSG00000111860	Centrosomal protein 85 like	6	118460772-118710075	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029137, HPA029138, HPA029139	Uncertain					Mixed	Tissue enhanced		testis: 53.7	lymph node: 15.6	Cell line enhanced		BEWO: 24.8
CEP97	FLJ23047, LRRIQ2	ENSG00000182504	Centrosomal protein 97	3	101723925-101770562	Predicted intracellular proteins	Evidence at protein level	HPA002980	Enhanced		Supported	Microtubule organizing center<br>Cytosol		Expressed in all	Mixed			testis: 13.4	Expressed in all		
CERK	dA59H18.2, dA59H18.3, DKFZp434E0211, FLJ21430, FLJ23239, hCERK, KIAA1646, LK4	ENSG00000100422	Ceramide kinase	22	46684411-46738261	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA064699			Approved	Vesicles	Urothelial cancer:1.58e-4 (unfavourable), Pancreatic cancer:2.35e-4 (favourable), Endometrial cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 34.3	Mixed		
CERKL	RP26	ENSG00000188452	Ceramide kinase like	2	181536676-181680665	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035443, HPA035444, HPA043203	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.10e-4 (unfavourable), Pancreatic cancer:5.25e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 24.1	spleen: 22.4	Cell line enhanced		HEL: 66.6;MOLT-4: 81.2;NB-4: 55.7;SCLC-21H: 75.7
CETN1	CEN1, CETN	ENSG00000177143	Centrin 1	18	580357-582114	Predicted intracellular proteins	Evidence at protein level	HPA028956, CAB037244	Approved					Tissue enriched	Tissue enriched	1424	testis: 142.4	all non-specific tissues: 0.0	Not detected		
CETN2	CALT, CEN2	ENSG00000147400	Centrin 2	X	152826973-152830777	Predicted intracellular proteins	Evidence at protein level	HPA028956	Uncertain				Cervical cancer:7.54e-6 (favourable), Ovarian cancer:9.97e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 374.6	Expressed in all		
CETN3	CEN3	ENSG00000153140	Centrin 3	5	90392261-90409786	Predicted intracellular proteins	Evidence at protein level	HPA035608, HPA063704	Approved		Supported	Centrosome	Liver cancer:2.22e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 225.8	ovary: 36.5	Expressed in all		
CFAP100	CCDC37, FLJ40083, MIA1	ENSG00000163885	Cilia and flagella associated protein 100	3	126394939-126436556	Predicted intracellular proteins	Evidence at protein level	HPA046354	Enhanced					Tissue enhanced	Group enriched	5	fallopian tube: 43.4;testis: 34.5	lung: 7.4	Not detected		
CFAP126	C1orf192, Flattop, Fltp	ENSG00000188931	Cilia and flagella associated protein 126	1	161364731-161367874	Predicted intracellular proteins	Evidence at protein level	HPA045904	Enhanced					Not detected	Tissue enriched	9	fallopian tube: 228.1	testis: 25.0	Cell line enhanced		CAPAN-2: 2.3;SCLC-21H: 1.0
CFAP157	C9orf117	ENSG00000160401	Cilia and flagella associated protein 157	9	127706989-127716002	Predicted intracellular proteins	Evidence at protein level	HPA021474, HPA021786	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Endometrial cancer:1.45e-4 (favourable)	Mixed	Tissue enriched	8	fallopian tube: 94.5	lung: 12.0	Cell line enhanced		A549: 5.9;SCLC-21H: 5.2
CFAP161	C15orf26, FLJ38615	ENSG00000156206	Cilia and flagella associated protein 161	15	81007033-81149175	Predicted intracellular proteins	Evidence at protein level	HPA041807	Uncertain				Endometrial cancer:3.05e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 24.8;testis: 11.5	lung: 4.1	Group enriched	5	HEL: 75.9;K-562: 25.9
CFAP20	C16orf80, fSAP23, GTL3	ENSG00000070761	Cilia and flagella associated protein 20	16	58113588-58129450	Predicted intracellular proteins	Evidence at protein level	HPA018195	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			fallopian tube: 54.4	Expressed in all		
CFAP206	C6orf165, dJ382I10.1, FLJ25974	ENSG00000272514	Cilia and flagella associated protein 206	6	87407983-87464465	Predicted intracellular proteins	Evidence at protein level	HPA044891, HPA072261	Approved		Approved	Nucleoplasm<br>Cell Junctions		Not detected	Group enriched	30	fallopian tube: 35.9;testis: 106.8	lung,thyroid gland: 2.3	Cell line enhanced		MCF7: 1.7;RPTEC TERT1: 2.0;T-47d: 4.2
CFAP221	FAP221, PCDP1	ENSG00000163075	Cilia and flagella associated protein 221	2	119544432-119662251	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		fallopian tube: 41.9;testis: 44.7	lung: 11.5	Cell line enhanced		RPTEC TERT1: 4.1
CFAP36	BARTL1, CCDC104, MGC15407	ENSG00000163001	Cilia and flagella associated protein 36	2	55519604-55545879	Predicted intracellular proteins	Evidence at protein level	HPA008994, HPA017061	Approved					Expressed in all	Expressed in all			testis: 239.2	Expressed in all		
CFAP43	bA373N18.2, C10orf79, FLJ22944, FLJ36006, WDR96	ENSG00000197748	Cilia and flagella associated protein 43	10	104129888-104232362	Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	7	fallopian tube: 78.0;testis: 103.2	lung: 12.5	Cell line enhanced		CAPAN-2: 3.7;U-266/70: 2.5
CFAP44	FLJ11142, WDR52	ENSG00000206530	Cilia and flagella associated protein 44	3	113286947-113441610	Predicted intracellular proteins	Evidence at protein level	HPA067258	Uncertain				Urothelial cancer:7.09e-6 (favourable)	Mixed	Tissue enhanced		testis: 14.4	fallopian tube: 13.7	Mixed		
CFAP45	CCDC19, NESG1	ENSG00000213085	Cilia and flagella associated protein 45	1	159872364-159900163	Predicted intracellular proteins	Evidence at protein level	HPA042204, HPA043618	Enhanced		Enhanced	Nucleoplasm		Tissue enhanced	Group enriched	7	fallopian tube: 71.3;testis: 38.9	lung: 7.7	Cell line enhanced		BEWO: 8.7;HEL: 11.0
CFAP52	FLJ37528, WDR16, WDRPUH	ENSG00000166596	Cilia and flagella associated protein 52	17	9576627-9643459	Predicted intracellular proteins	Evidence at protein level	HPA023247	Enhanced					Mixed	Group enriched	9	fallopian tube: 91.8;testis: 22.0	lung: 6.6	Cell line enhanced		CAPAN-2: 1.5;MCF7: 1.6;REH: 1.3;T-47d: 1.1
CFAP53	CCDC11, FLJ32743	ENSG00000172361	Cilia and flagella associated protein 53	18	50227193-50266522	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040595, HPA041069, HPA066142	Enhanced		Approved	Midbody	Renal cancer:5.85e-4 (favourable)	Mixed	Group enriched	12	fallopian tube: 44.6;testis: 127.0	epididymis: 6.9	Cell line enhanced		hTERT-HME1: 3.5
CFAP58	bA554P13.1, C10orf80, CCDC147, FLJ35908	ENSG00000120051	Cilia and flagella associated protein 58	10	104353764-104455090	Predicted intracellular proteins	Evidence at protein level	HPA036555, HPA036556	Uncertain		Approved	Nucleus		Mixed	Group enriched	5	fallopian tube: 13.3;testis: 23.5	cervix, uterine: 3.3	Cell line enhanced		U-2 OS: 6.5
CFAP69	C7orf63, FAP69, FLJ21062	ENSG00000105792	Cilia and flagella associated protein 69	7	90245174-90311063	Predicted intracellular proteins	Evidence at protein level	HPA062883	Uncertain					Tissue enhanced	Tissue enhanced		prostate: 25.2	fallopian tube: 17.9	Mixed		
CFAP70	FLJ25765, TTC18	ENSG00000156042	Cilia and flagella associated protein 70	10	73253759-73358859	Predicted intracellular proteins	Evidence at protein level	HPA037582, HPA070304	Enhanced					Mixed	Tissue enhanced		fallopian tube: 23.4;testis: 37.6	epididymis: 13.8	Mixed		
CFAP73	CCDC42B, MIA2	ENSG00000186710	Cilia and flagella associated protein 73	12	113149858-113159276	Predicted intracellular proteins	Evidence at protein level	HPA048539	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Vesicles	Cervical cancer:1.29e-4 (favourable), Endometrial cancer:5.52e-4 (favourable)	Tissue enhanced	Tissue enriched	9	fallopian tube: 60.1	lung: 6.9	Cell line enhanced		Daudi: 3.1;T-47d: 2.4;U-698: 6.0
CFAP74	C1orf222, FLJ45476, KIAA1751	ENSG00000142609	Cilia and flagella associated protein 74	1	1921951-2003837	Predicted intracellular proteins	Evidence at protein level	HPA028521, HPA029274, HPA030240	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 9.6;testis: 8.5	skin: 4.0	Mixed		
CFAP77	C9orf171, FLJ46082	ENSG00000188523	Cilia and flagella associated protein 77	9	132410043-132573317	Predicted intracellular proteins	Evidence at protein level	HPA021329, HPA024647, HPA061069	Enhanced		Approved	Cytosol	Endometrial cancer:7.31e-4 (favourable)	Tissue enhanced	Group enriched	10	fallopian tube: 48.8;testis: 22.9	lung: 3.4	Cell line enhanced		SH-SY5Y: 2.1
CFAP97	DKFZp434F1728, hmw, KIAA1430	ENSG00000164323	Cilia and flagella associated protein 97	4	185159665-185209504	Predicted intracellular proteins	Evidence at protein level	HPA049446, HPA053335	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 67.7	Expressed in all		
CFAP99		ENSG00000206113	Cilia and flagella associated protein 99	4	2418974-2462942	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	8	fallopian tube: 7.0;testis: 11.3	adrenal gland: 1.0	Not detected		
CFL1	CFL	ENSG00000172757	Cofilin 1	11	65823022-65862026	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033687, CAB037077, HPA053761	Approved				Liver cancer:1.73e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 1225.4	Expressed in all		
CFL2	NEM7	ENSG00000165410	Cofilin 2	14	34706769-34714823	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037078, HPA045599	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:2.16e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 242.7	Expressed in all		
CFLAR	c-FLIP, CASH, CASP8AP1, Casper, CLARP, FLAME, FLIP, I-FLICE, MRIT	ENSG00000003402	CASP8 and FADD like apoptosis regulator	2	201116104-201176687	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019044, CAB022157, CAB025216	Uncertain		Supported	Nucleus<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Head and neck cancer:2.79e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 159.9	Expressed in all		
CGGBP1	CGGBP, p20-CGGBP	ENSG00000163320	CGG triplet repeat binding protein 1	3	88051944-88149885	Predicted intracellular proteins	Evidence at protein level	HPA035568, HPA037017	Supported		Enhanced	Nucleus	Urothelial cancer:7.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 93.6	Expressed in all		
CGN	KIAA1319	ENSG00000143375	Cingulin	1	151510510-151538692	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017193, HPA027586, HPA027587, HPA027657	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:5.84e-10 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 73.4	small intestine: 61.9	Cell line enhanced		CACO-2: 75.4;CAPAN-2: 52.0
CGNL1	FLJ14957, JACOP, KIAA1749, PCING	ENSG00000128849	Cingulin like 1	15	57375967-57550727	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB013500, HPA056911, HPA069214	Enhanced		Approved	Cell Junctions	Renal cancer:1.37e-6 (favourable), Endometrial cancer:3.55e-4 (favourable), Liver cancer:5.58e-4 (favourable)	Expressed in all	Mixed			kidney: 73.1	Cell line enhanced		AF22: 12.9;HUVEC TERT2: 43.8;TIME: 26.5
CH17-140K24.5		ENSG00000279068		5	141182409-141188582	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			endometrium: 1.6	Cell line enhanced		AN3-CA: 5.5;RH-30: 3.5;U-138 MG: 7.2;U-2197: 4.5
CH17-140K24.8		ENSG00000279983		5	141223372-141245861	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		epididymis: 1.5	endometrium: 0.8	Not detected		
CH17-270A2.2		ENSG00000280778		1	145927258-145977811	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
CH17-385C13.3		ENSG00000270339		1	146344131-146344790	Predicted intracellular proteins	No evidence	HPA058345	Uncertain					Not detected	Not detected			spleen: 0.2	Not detected		
CH507-152C13.3		ENSG00000276076		21	6560714-6564489	Predicted intracellular proteins	Evidence at transcript level	HPA037737, HPA038430	Approved		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	13	kidney: 57.2	liver: 4.5	Cell line enriched	178	Hep G2: 25.5
CH507-396I9.7		ENSG00000277277		21	7768884-7770591	Predicted intracellular proteins	Evidence at transcript level	HPA045123	Uncertain					Not detected	Mixed			cerebral cortex: 3.0	Mixed		
CH507-42P11.1		ENSG00000274559		21	5972924-5973383	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Uncertain		Supported	Nucleoplasm<br>Cytosol		Not detected	Mixed			prostate: 8.2	Cell line enhanced		K-562: 40.6;U-2 OS: 43.9;U-266/84: 32.4
CH507-9B2.2		ENSG00000279493		21	5011799-5017145	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		kidney: 1.8;liver: 2.7	lymph node: 0.5	Cell line enhanced		BEWO: 1.3;CACO-2: 2.4;MCF7: 1.6;SiHa: 3.5
CH507-9B2.4		ENSG00000276612		21	5116343-5133805	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland: 0.9	Cell line enhanced		RH-30: 3.3
CH507-9B2.5		ENSG00000275464		21	5130871-5154734	Predicted intracellular proteins	Evidence at protein level	HPA024573	Uncertain		Approved	Nucleoli<br>Cytosol		Mixed	Expressed in all			cerebral cortex: 16.0	Mixed		
CH507-9B2.9		ENSG00000280433		21	5155499-5165472	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			lymph node: 13.6	Mixed		
CHAC1	MGC4504	ENSG00000128965	ChaC glutathione specific gamma-glutamylcyclotransferase 1	15	40952962-40956519	Predicted intracellular proteins	Evidence at protein level	HPA042708, HPA043505	Approved				Renal cancer:2.23e-7 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 25.5	pancreas: 14.5	Cell line enhanced		BJ hTERT+: 88.7;HHSteC: 67.5;hTCEpi: 94.1;SK-MEL-30: 73.8
CHAC2		ENSG00000143942	ChaC cation transport regulator homolog 2	2	53767792-53775196	Predicted intracellular proteins	Evidence at protein level	HPA049235	Approved		Approved	Cytosol	Liver cancer:3.80e-7 (unfavourable)	Expressed in all	Mixed			testis: 9.8	Expressed in all		
CHAF1A	CAF-1, CAF1, CAF1B, CAF1P150, MGC71229, P150	ENSG00000167670	Chromatin assembly factor 1 subunit A	19	4402662-4445018	Predicted intracellular proteins	Evidence at protein level	CAB015186	Enhanced		Supported	Nucleus<br>Cytosol	Stomach cancer:4.15e-6 (favourable), Cervical cancer:8.22e-5 (favourable)	Expressed in all	Mixed			testis: 21.9	Expressed in all		
CHAF1B	CAF-1, CAF1, CAF1A, CAF1P60, MPHOSPH7, MPP7	ENSG00000159259	Chromatin assembly factor 1 subunit B	21	36385378-36419015	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021679, CAB033604	Enhanced		Supported	Nucleoplasm	Liver cancer:6.14e-6 (unfavourable), Cervical cancer:5.44e-5 (favourable), Colorectal cancer:7.92e-4 (favourable)	Expressed in all	Mixed			testis: 5.4	Expressed in all		
CHAMP1	C13orf8, CAMP, CHAMP, ZNF828	ENSG00000198824	Chromosome alignment maintaining phosphoprotein 1	13	114314513-114327328	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA006623, HPA008900	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 19.3	Expressed in all		
CHAT		ENSG00000070748	Choline O-acetyltransferase	10	49609095-49665104	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002313, HPA048547	Supported					Not detected	Tissue enriched	8	placenta: 7.2	duodenum: 0.8	Cell line enriched	9	NB-4: 7.2
CHCHD1	C10orf34, FLJ25854	ENSG00000172586	Coiled-coil-helix-coiled-coil-helix domain containing 1	10	73782047-73783652	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA039046	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Mitochondria	Urothelial cancer:5.42e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 62.7	Expressed in all		
CHCHD10	C22orf16, N27C7-4	ENSG00000250479	Coiled-coil-helix-coiled-coil-helix domain containing 10	22	23765834-23768443	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003440	Enhanced		Supported	Mitochondria	Renal cancer:2.15e-7 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 220.6	Mixed		
CHCHD2	C7orf17	ENSG00000106153	Coiled-coil-helix-coiled-coil-helix domain containing 2	7	56101569-56106576	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027407, HPA052510	Uncertain		Enhanced	Mitochondria	Head and neck cancer:1.90e-5 (unfavourable), Liver cancer:9.41e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 585.7	Expressed in all		
CHCHD3	FLJ20420, Mic19, MINOS3, PPP1R22	ENSG00000106554	Coiled-coil-helix-coiled-coil-helix domain containing 3	7	132784868-133082088	Predicted intracellular proteins	Evidence at protein level	HPA042935	Enhanced		Supported	Mitochondria	Renal cancer:1.15e-4 (favourable), Liver cancer:3.25e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 121.2	Expressed in all		
CHCHD4	FLJ31709, MIA40, TIMM40	ENSG00000163528	Coiled-coil-helix-coiled-coil-helix domain containing 4	3	14112077-14124870	Predicted intracellular proteins	Evidence at protein level	HPA034688, HPA063727	Uncertain		Supported	Mitochondria	Renal cancer:8.63e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 31.2	Expressed in all		
CHCHD5	C2orf9, MGC11104, MIC14	ENSG00000125611	Coiled-coil-helix-coiled-coil-helix domain containing 5	2	112584240-112589275	Predicted intracellular proteins	Evidence at protein level	HPA038263	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 33.6	Mixed		
CHCHD6	CHCM1, MGC13016, Mic25, PPP1R23	ENSG00000159685	Coiled-coil-helix-coiled-coil-helix domain containing 6	3	126704220-126960406	Predicted intracellular proteins	Evidence at protein level	HPA047673, HPA051975	Approved		Supported	Mitochondria	Renal cancer:6.76e-4 (favourable), Cervical cancer:7.46e-4 (favourable)	Expressed in all	Expressed in all			testis: 48.8	Expressed in all		
CHCHD7	COX23, MGC2217	ENSG00000170791	Coiled-coil-helix-coiled-coil-helix domain containing 7	8	56211686-56218798	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050783	Approved		Approved	Cell Junctions<br>Aggresome	Endometrial cancer:1.39e-6 (unfavourable), Renal cancer:9.47e-5 (favourable)	Expressed in all	Expressed in all			ovary: 61.6	Expressed in all		
CHD1		ENSG00000153922	Chromodomain helicase DNA binding protein 1	5	98853985-98928957	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022236	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:7.25e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 44.3	Expressed in all		
CHD1L	ALC1	ENSG00000131778	Chromodomain helicase DNA binding protein 1 like	1	147242641-147295766	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027789, HPA028670	Enhanced		Supported	Nucleoplasm	Renal cancer:1.31e-9 (unfavourable), Liver cancer:3.07e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 48.4	Expressed in all		
CHD2	DKFZp547I1315, DKFZp686E01200, DKFZp781D1727, FLJ38614	ENSG00000173575	Chromodomain helicase DNA binding protein 2	15	92900189-93028005	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060744, HPA060960	Enhanced		Enhanced	Nucleus		Expressed in all	Expressed in all			bone marrow: 48.3	Mixed		
CHD3	Mi-2a, Mi2-ALPHA, ZFH	ENSG00000170004	Chromodomain helicase DNA binding protein 3	17	7884806-7912760	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043368, HPA076524	Supported		Approved	Nucleus<br>Nucleoli<br>Microtubule organizing center	Endometrial cancer:7.68e-5 (favourable), Colorectal cancer:2.43e-4 (unfavourable), Pancreatic cancer:8.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 85.1	Expressed in all		
CHD4	Mi-2b, Mi2-BETA	ENSG00000111642	Chromodomain helicase DNA binding protein 4	12	6570083-6607476	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA012008	Supported		Enhanced	Nucleus	Liver cancer:6.03e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 119.0	Expressed in all		
CHD5		ENSG00000116254	Chromodomain helicase DNA binding protein 5	1	6101793-6180123	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015809, HPA055477	Supported		Supported	Nucleoplasm<br>Nuclear speckles<br>Cytosol		Mixed	Tissue enriched	7	cerebral cortex: 42.1	testis: 6.2	Cell line enhanced		SCLC-21H: 16.0;U-2 OS: 6.3
CHD6	CHD5, dJ620E11.1, FLJ22369, KIAA1335, RIGB	ENSG00000124177	Chromodomain helicase DNA binding protein 6	20	41402101-41618494	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015543			Approved	Nucleus	Lung cancer:3.42e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 31.5	Expressed in all		
CHD7	CRG, FLJ20357, FLJ20361, KIAA1416	ENSG00000171316	Chromodomain helicase DNA binding protein 7	8	60678778-60868028	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA053075			Supported	Nucleoplasm<br>Nucleoli	Endometrial cancer:5.34e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 14.6	Cell line enhanced		AF22: 50.9;SCLC-21H: 55.1
CHD8	DUPLIN, HELSNF1, KIAA1564	ENSG00000100888	Chromodomain helicase DNA binding protein 8	14	21385194-21456126	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA052186			Supported	Nucleoplasm	Liver cancer:4.94e-4 (unfavourable), Ovarian cancer:8.35e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.1	Expressed in all		
CHD9	BC022889, FLJ12178, KIAA0308	ENSG00000177200	Chromodomain helicase DNA binding protein 9	16	53055033-53329150	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042053, HPA049420	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.84e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 28.2	Expressed in all		
CHDH		ENSG00000016391	Choline dehydrogenase	3	53812335-53846390	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036633, HPA058130	Enhanced				Renal cancer:1.88e-8 (favourable)	Mixed	Tissue enhanced		kidney: 40.1	small intestine: 16.4	Cell line enhanced		CACO-2: 9.5;Hep G2: 24.3;T-47d: 10.6
CHEK1	CHK1	ENSG00000149554	Checkpoint kinase 1	11	125625136-125676255	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044364			Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.04e-8 (unfavourable), Pancreatic cancer:3.10e-6 (unfavourable), Liver cancer:3.70e-6 (unfavourable), Colorectal cancer:3.62e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 62.5;seminal vesicle: 52.6	testis: 22.1	Expressed in all		
CHERP	DAN16, ERPROT213-21	ENSG00000085872	Calcium homeostasis endoplasmic reticulum protein	19	16517889-16542530	Predicted intracellular proteins	Evidence at protein level	HPA050647	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 22.2	Expressed in all		
CHFR	FLJ10796, RNF196	ENSG00000072609	Checkpoint with forkhead and ring finger domains	12	132822187-132956304	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045768, HPA073826	Approved		Uncertain	Nuclear bodies<br>Microtubules	Renal cancer:4.21e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 22.8	Mixed		
CHKA	CHK, CKI	ENSG00000110721	Choline kinase alpha	11	68052859-68121444	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024153, CAB072803	Approved		Approved	Endoplasmic reticulum	Liver cancer:7.75e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 136.1	Expressed in all		
CHKB	CHETK, CHKL	ENSG00000100288	Choline kinase beta	22	50578949-50601455	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018797	Approved		Approved	Cytosol	Renal cancer:1.56e-5 (unfavourable), Cervical cancer:4.66e-4 (favourable)	Expressed in all	Mixed			testis: 15.1	Mixed		
CHM	DXS540, REP-1, TCD	ENSG00000188419	CHM, Rab escort protein 1	X	85861180-86047562	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003231, CAB016171	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 21.9	Expressed in all		
CHMP1A	CHMP1, KIAA0047, PCOLN3, PRSM1, Vps46A	ENSG00000131165	Charged multivesicular body protein 1A	16	89644431-89657845	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 53.1	Expressed in all		
CHMP1B	C18orf2, CHMP1.5, Vps46B	ENSG00000255112	Charged multivesicular body protein 1B	18	11851396-11854449	Predicted intracellular proteins	Evidence at protein level	HPA061997, HPA062896	Enhanced		Supported	Nucleus<br>Midbody	Renal cancer:7.37e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 87.0	Expressed in all		
CHMP2A	BC-2, CHMP2, VPS2, VPS2A	ENSG00000130724	Charged multivesicular body protein 2A	19	58551566-58555124	Predicted intracellular proteins	Evidence at protein level	HPA041153, HPA042031	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 191.7	Expressed in all		
CHMP2B	CHMP2.5, DKFZP564O123, VPS2B	ENSG00000083937	Charged multivesicular body protein 2B	3	87227271-87255548	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035069, HPA052754	Uncertain		Supported	Cytosol	Renal cancer:1.74e-6 (favourable), Pancreatic cancer:2.11e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 78.5	Expressed in all		
CHMP3	CGI-149, NEDF, VPS24	ENSG00000115561	Charged multivesicular body protein 3	2	86503431-86563479	Predicted intracellular proteins	Evidence at protein level	HPA015673, HPA073383	Supported				Liver cancer:3.92e-5 (unfavourable), Renal cancer:5.32e-4 (favourable), Pancreatic cancer:7.39e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 114.0	Expressed in all		
CHMP4A	C14orf123, HSPC134, VPS32A	ENSG00000254505	Charged multivesicular body protein 4A	14	24209583-24213869	Predicted intracellular proteins	Evidence at protein level	HPA068473	Approved				Renal cancer:3.91e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 130.5	Expressed in all		
CHMP4B	C20orf178, dJ553F4.4, Shax1, SNF7-2, VPS32B	ENSG00000101421	Charged multivesicular body protein 4B	20	33811304-33854366	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041401, HPA051751	Enhanced				Liver cancer:5.10e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 140.4	Expressed in all		
CHMP4C	MGC22825, Shax3, VPS32C	ENSG00000164695	Charged multivesicular body protein 4C	8	81732434-81759515	Predicted intracellular proteins	Evidence at protein level	HPA023799	Enhanced				Renal cancer:1.96e-6 (favourable), Pancreatic cancer:6.99e-5 (unfavourable), Lung cancer:9.33e-5 (unfavourable), Urothelial cancer:6.45e-4 (favourable)	Mixed	Mixed			duodenum: 41.8	Cell line enhanced		CAPAN-2: 36.2;hTCEpi: 36.8
CHMP5	C9orf83, CGI-34, HSPC177, SNF7DC2, Vps60	ENSG00000086065	Charged multivesicular body protein 5	9	33264879-33282069	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033874, HPA042883, HPA056437	Enhanced		Supported	Microtubules<br>Midbody<br>Cytosol	Renal cancer:2.87e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 127.5	Expressed in all		
CHMP6	FLJ11749, VPS20	ENSG00000176108	Charged multivesicular body protein 6	17	80991598-81009517	Predicted intracellular proteins	Evidence at protein level	HPA023001, HPA024460	Approved				Pancreatic cancer:9.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
CHMP7	MGC29816	ENSG00000147457	Charged multivesicular body protein 7	8	23243637-23262000	Predicted intracellular proteins	Evidence at protein level	HPA036119	Uncertain		Supported	Nucleus<br>Cytosol		Expressed in all	Tissue enhanced		lymph node: 38.5	tonsil: 25.3	Expressed in all		
CHN2	ARHGAP3, RhoGAP3	ENSG00000106069	Chimerin 2	7	29122274-29514328	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018989	Approved		Approved	Nucleus		Mixed	Tissue enhanced		duodenum: 74.8;small intestine: 68.4	cerebral cortex: 31.7	Cell line enhanced		HEL: 34.5;HMC-1: 60.7
CHORDC1	CHP-1, CHP1	ENSG00000110172	Cysteine and histidine rich domain containing 1	11	90201160-90223364	Predicted intracellular proteins	Evidence at protein level	HPA041040	Approved		Supported	Cytosol	Liver cancer:4.93e-7 (unfavourable), Renal cancer:1.88e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 31.4	Expressed in all		
CHP1	CHP, p22, p24, Sid470p, SLC9A1BP	ENSG00000187446	Calcineurin like EF-hand protein 1	15	41230839-41281890	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006616	Approved		Approved	Vesicles	Renal cancer:2.79e-6 (favourable), Liver cancer:4.07e-6 (favourable), Endometrial cancer:9.63e-4 (favourable)	Expressed in all	Expressed in all			colon: 110.9	Expressed in all		
CHP2		ENSG00000166869	Calcineurin like EF-hand protein 2	16	23754627-23758951	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB072806	Approved					Tissue enhanced	Group enriched	10	colon: 119.1;duodenum: 252.0;rectum: 127.6;skin: 143.8;small intestine: 227.3	cervix, uterine: 17.1	Cell line enhanced		hTERT-HME1: 4.5;NB-4: 4.6
CHRAC1	CHRAC15, YCL1	ENSG00000104472	Chromatin accessibility complex 1	8	140511298-140517137	Predicted intracellular proteins	Evidence at protein level	HPA059008			Approved	Nucleus	Liver cancer:4.88e-5 (unfavourable), Endometrial cancer:2.28e-4 (unfavourable), Pancreatic cancer:5.43e-4 (unfavourable), Ovarian cancer:9.72e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 35.0	Expressed in all		
CHTF18	C16orf41, C321D2.4, CHL12, Ctf18	ENSG00000127586	Chromosome transmission fidelity factor 18	16	788046-800737	Predicted intracellular proteins	Evidence at protein level	HPA040976, HPA056209			Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.43e-8 (unfavourable), Urothelial cancer:2.78e-4 (favourable)	Expressed in all	Mixed			testis: 4.7	Cell line enhanced		BEWO: 46.5
CHTOP	C1orf77, DKFZP547E1010, FOP, SRAG	ENSG00000160679	Chromatin target of PRMT1	1	153633982-153646306	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028647, HPA030540	Approved		Enhanced	Nuclear speckles	Renal cancer:2.02e-4 (unfavourable), Urothelial cancer:2.69e-4 (favourable), Melanoma:4.08e-4 (unfavourable), Liver cancer:4.85e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.2	Expressed in all		
CHUK	IkBKA, IKK-alpha, IKK1, IKKA, NFKBIKA, TCF16	ENSG00000213341	Conserved helix-loop-helix ubiquitous kinase	10	100188298-100229619	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001402, CAB004240, CAB018564	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
CHURC1	C14orf52, FLJ33064, My015	ENSG00000258289	Churchill domain containing 1	14	64914361-64944591	Predicted intracellular proteins	Evidence at protein level	HPA040072	Approved		Approved	Cytosol		Expressed in all	Expressed in all			smooth muscle: 70.4	Expressed in all		
CHURC1-FNTB		ENSG00000125954	CHURC1-FNTB readthrough	14	64914485-65061803	Predicted intracellular proteins	Evidence at protein level	CAB009260	Uncertain					Not detected	Mixed			adipose tissue: 1.5	Mixed		
CIAO1	CIA1, WDR39	ENSG00000144021	Cytosolic iron-sulfur assembly component 1	2	96266132-96273349	Predicted intracellular proteins	Evidence at protein level	HPA017882	Uncertain		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:4.13e-5 (unfavourable), Liver cancer:1.14e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 40.4	Expressed in all		
CIAPIN1	Anamorsin	ENSG00000005194	Cytokine induced apoptosis inhibitor 1	16	57428169-57447528	Predicted intracellular proteins	Evidence at protein level	HPA041350, HPA042182	Enhanced		Supported	Mitochondria	Head and neck cancer:4.35e-4 (unfavourable), Renal cancer:4.42e-4 (favourable)	Expressed in all	Expressed in all			testis: 129.0	Expressed in all		
CIART	BC017397, C1orf51	ENSG00000159208	Circadian associated repressor of transcription	1	150282543-150287093	Predicted intracellular proteins	Evidence at protein level	HPA027515, HPA054349	Enhanced		Supported	Nucleoplasm		Expressed in all	Mixed			seminal vesicle: 33.9	Cell line enhanced		Karpas-707: 28.2
CIB1	CIB, KIP, SIP2-28	ENSG00000185043	Calcium and integrin binding 1	15	90229975-90234047	Predicted intracellular proteins	Evidence at protein level	CAB012991, HPA042413, HPA048825	Approved		Supported	Nucleoplasm<br>Plasma membrane	Endometrial cancer:2.26e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 207.5	Expressed in all		
CIB2	DFNB48, KIP2, USH1J	ENSG00000136425	Calcium and integrin binding family member 2	15	78104606-78131544	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036697	Approved	Supported			Renal cancer:6.16e-4 (favourable), Endometrial cancer:7.05e-4 (unfavourable)	Expressed in all	Mixed			testis: 31.4	Cell line enhanced		AN3-CA: 39.7;HAP1: 43.8;SCLC-21H: 46.7;SH-SY5Y: 48.9
CIB3	KIP3	ENSG00000141977	Calcium and integrin binding family member 3	19	16161368-16173525	Predicted intracellular proteins	Evidence at protein level	HPA043553	Uncertain					Tissue enriched	Not detected			bone marrow: 0.8	Cell line enhanced		HMC-1: 3.9;MCF7: 1.7;U-937: 1.6
CIB4		ENSG00000157884	Calcium and integrin binding family member 4	2	26581202-26641368	Predicted intracellular proteins	Evidence at protein level	HPA036130, HPA036131	Uncertain					Tissue enhanced	Group enriched	10	testis: 20.1;thyroid gland: 4.2	placenta: 1.1	Not detected		
CIC	KIAA0306	ENSG00000079432	Capicua transcriptional repressor	19	42268537-42295797	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026388, HPA044341, HPA064725	Approved		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 54.9	Expressed in all		
CIDEA	CIDE-A	ENSG00000176194	Cell death-inducing DFFA-like effector a	18	12254319-12277595	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	13	adipose tissue: 221.8	breast: 17.2	Cell line enriched	8	hTEC/SVTERT24-B: 1.4
CIDEB		ENSG00000136305	Cell death-inducing DFFA-like effector b	14	24305096-24311430	Predicted intracellular proteins	Evidence at protein level	HPA001272	Uncertain					Mixed	Expressed in all			liver: 184.0	Cell line enhanced		HDLM-2: 39.8;Hep G2: 32.5;HL-60: 24.6;U-937: 28.0
CIDEC	CIDE-3, FLJ20871, Fsp27	ENSG00000187288	Cell death inducing DFFA like effector c	3	9866711-9880254	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018837, HPA020553	Approved					Mixed	Tissue enriched	8	adipose tissue: 761.8	small intestine: 99.2	Cell line enhanced		ASC diff: 1149.6;ASC TERT1: 262.9;HSkMC: 164.2
CIITA	C2TA, MHC2TA, NLRA	ENSG00000179583	Class II major histocompatibility complex transactivator	16	10866222-10932281	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016084	Enhanced		Approved	Nucleoplasm		Expressed in all	Mixed			lymph node,spleen: 59.2	Cell line enhanced		HDLM-2: 44.9;REH: 81.4
CINP	MGC849	ENSG00000100865	Cyclin dependent kinase 2 interacting protein	14	102341102-102362916	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			testis: 48.3	Expressed in all		
CIPC	KIAA1737	ENSG00000198894	CLOCK interacting pacemaker	14	77098097-77117287	Predicted intracellular proteins	Evidence at protein level	HPA000644			Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.77e-10 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 54.3	Expressed in all		
CIR1	CIR	ENSG00000138433	Corepressor interacting with RBPJ, 1	2	174348022-174395715	Predicted intracellular proteins	Evidence at protein level	HPA015784, HPA061442	Approved		Supported	Nuclear speckles	Renal cancer:1.04e-7 (unfavourable), Urothelial cancer:2.04e-5 (favourable), Liver cancer:2.52e-4 (unfavourable), Endometrial cancer:9.56e-4 (unfavourable), Ovarian cancer:9.80e-4 (favourable)	Expressed in all	Expressed in all			testis: 57.1	Expressed in all		
CIRBP	CIRP	ENSG00000099622	Cold inducible RNA binding protein	19	1259384-1274880	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA060537			Supported	Nucleus<br>Nucleoli	Renal cancer:3.65e-7 (favourable), Endometrial cancer:1.36e-4 (favourable), Lung cancer:2.50e-4 (favourable), Pancreatic cancer:2.69e-4 (favourable), Cervical cancer:3.63e-4 (favourable)	Expressed in all	Expressed in all			ovary: 1042.3	Expressed in all		
CISD3	Miner2	ENSG00000277972	CDGSH iron sulfur domain 3	17	38730235-38735044	Predicted intracellular proteins	Evidence at protein level	HPA053436, HPA054400	Approved					Expressed in all	Mixed			thyroid gland: 8.5	Mixed		
CISH	CIS, CIS-1, G18, SOCS	ENSG00000114737	Cytokine inducible SH2 containing protein	3	50606490-50611831	Predicted intracellular proteins	Evidence at protein level	CAB034039, HPA040812	Approved		Approved	Microtubules<br>Cytokinetic bridge	Renal cancer:3.53e-12 (favourable), Endometrial cancer:1.13e-5 (favourable), Liver cancer:6.98e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 42.9	Group enriched	6	HDLM-2: 287.3;K-562: 65.9
CIT	CITK, CRIK, KIAA0949, STK21	ENSG00000122966	Citron rho-interacting serine/threonine kinase	12	119685790-119877291	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019082, HPA048812, HPA075506	Uncertain		Approved	Cytosol		Mixed	Mixed			cerebral cortex: 10.4	Mixed		
CITED1	MSG1	ENSG00000125931	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 1	X	72301638-72307187	Predicted intracellular proteins	Evidence at protein level	HPA049051	Enhanced		Supported	Nucleoplasm<br>Cytosol	Thyroid cancer:3.95e-4 (favourable), Testis cancer:6.10e-4 (favourable)	Tissue enriched	Tissue enriched	7	epididymis: 1798.6	testis: 258.7	Cell line enhanced		AN3-CA: 52.8;SCLC-21H: 30.2;SK-MEL-30: 179.8
CITED2	MRG1	ENSG00000164442	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2	6	139371807-139374620	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016157, CAB069879	Supported		Supported	Nucleoplasm	Stomach cancer:3.33e-4 (unfavourable), Renal cancer:3.40e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 379.3	Cell line enhanced		fHDF/TERT166: 828.8
CITED4		ENSG00000179862	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 4	1	40861051-40862366	Predicted intracellular proteins	Evidence at protein level	HPA056434	Approved		Approved	Vesicles	Endometrial cancer:4.38e-5 (favourable)	Expressed in all	Mixed			breast: 20.5	Cell line enhanced		RPTEC TERT1: 67.0;THP-1: 176.9
CIZ1	LSFR1, ZNF356	ENSG00000148337	CDKN1A interacting zinc finger protein 1	9	128166064-128204383	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020380, HPA020387	Uncertain		Enhanced	Nucleoplasm	Liver cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 87.1	Expressed in all		
CKAP2	FLJ10749, LB1, se20-10, TMAP	ENSG00000136108	Cytoskeleton associated protein 2	13	52455429-52476628	Predicted intracellular proteins	Evidence at protein level	HPA008410, HPA027821	Enhanced		Enhanced	Microtubules<br>Cytosol	Renal cancer:1.90e-5 (unfavourable), Liver cancer:3.26e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 58.5	bone marrow: 42.4	Expressed in all		
CKAP2L	FLJ40629, radmis	ENSG00000169607	Cytoskeleton associated protein 2 like	2	112736607-112764677	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039407, HPA040057, HPA070737	Uncertain		Enhanced	Mitotic spindle<br>Cytosol	Lung cancer:7.63e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 8.7;testis: 9.6	lymph node: 6.3	Mixed		
CKAP5	ch-TOG, KIAA0097, TOG, TOGp	ENSG00000175216	Cytoskeleton associated protein 5	11	46743048-46846308	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039377, HPA040375	Enhanced		Supported	Nucleoli<br>Plasma membrane<br>Centrosome	Liver cancer:1.03e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 66.2	Expressed in all		
CKB	CKBB	ENSG00000166165	Creatine kinase B	14	103519659-103523111	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001254, CAB047313	Enhanced		Supported	Cytosol	Renal cancer:4.02e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 475.1	Cell line enhanced		CACO-2: 340.9;HEK93: 940.9;SCLC-21H: 678.1
CKM	CKMM	ENSG00000104879	Creatine kinase, M-type	19	45306414-45322977	Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047859	Enhanced					Group enriched	Tissue enriched	17	skeletal muscle: 23798.9	heart muscle: 1418.8	Cell line enriched	6	SCLC-21H: 75.4
CKMT2	SMTCK	ENSG00000131730	Creatine kinase, mitochondrial 2	5	81233285-81266397	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051880	Enhanced					Mixed	Group enriched	22	heart muscle: 710.7;skeletal muscle: 505.3	adrenal gland: 27.9	Cell line enhanced		BEWO: 3.3;T-47d: 5.1
CKS1B	CKS1, ckshs1	ENSG00000173207	CDC28 protein kinase regulatory subunit 1B	1	154974653-154979249	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA003424, HPA030762	Approved	Supported	Approved	Nucleus<br>Vesicles<br>Mitochondria<br>Cytosol	Renal cancer:6.03e-7 (unfavourable), Liver cancer:2.94e-5 (unfavourable), Melanoma:3.12e-5 (unfavourable), Thyroid cancer:4.87e-4 (favourable), Pancreatic cancer:6.13e-4 (unfavourable), Endometrial cancer:7.89e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 84.9	Expressed in all		
CKS2		ENSG00000123975	CDC28 protein kinase regulatory subunit 2	9	89311198-89316703	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA003424, HPA030762	Approved	Supported	Approved	Nucleus<br>Vesicles<br>Mitochondria<br>Cytosol	Liver cancer:2.51e-6 (unfavourable), Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 341.7	lymph node: 122.6	Expressed in all		
CLASP1	KIAA0622, MAST1	ENSG00000074054	Cytoplasmic linker associated protein 1	2	121337776-121649587	Predicted intracellular proteins	Evidence at protein level	HPA065219	Uncertain				Renal cancer:6.50e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.4	Expressed in all		
CLASP2	KIAA0627	ENSG00000163539	Cytoplasmic linker associated protein 2	3	33496245-33718356	Predicted intracellular proteins	Evidence at protein level	HPA067071			Supported	Golgi apparatus<br>Cytosol	Renal cancer:1.48e-6 (favourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 193.2	endometrium: 34.2	Expressed in all		
CLASRP	CLASP, SFRS16, SWAP2	ENSG00000104859	CLK4 associating serine/arginine rich protein	19	45039040-45070956	Predicted intracellular proteins	Evidence at protein level	HPA060469, HPA062455	Approved		Enhanced	Nucleus	Renal cancer:1.69e-8 (unfavourable), Urothelial cancer:1.02e-5 (favourable), Colorectal cancer:9.77e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 11.9	Expressed in all		
CLC	Gal-10, LGALS10, MGC149659	ENSG00000105205	Charcot-Leyden crystal galectin	19	39731250-39738028	Predicted intracellular proteins	Evidence at protein level	HPA041751	Enhanced					Tissue enhanced	Tissue enriched	5	bone marrow: 285.9	urinary bladder: 55.3	Cell line enriched	14	HMC-1: 6580.2
CLEC4D	CD368, CLECSF8, Mpcl	ENSG00000166527	C-type lectin domain family 4 member D	12	8509475-8522366	Predicted intracellular proteins	Evidence at protein level	HPA004906	Approved					Tissue enriched	Group enriched	6	appendix: 10.5;bone marrow: 42.8	cervix, uterine: 4.8	Cell line enhanced		NB-4: 1.5;NTERA-2: 9.1;U-937: 4.2
CLHC1	C2orf63, FLJ31438	ENSG00000162994	Clathrin heavy chain linker domain containing 1	2	55174791-55232563	Predicted intracellular proteins	Evidence at protein level	HPA045418, HPA053557	Uncertain		Approved	Nucleoli fibrillar center<br>Centrosome	Urothelial cancer:2.15e-4 (favourable)	Mixed	Tissue enhanced		testis: 23.1	endometrium: 6.8	Mixed		
CLIC1	G6, NCC27, p64CLCP	ENSG00000213719	Chloride intracellular channel 1	6	31730581-31739763	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB020825, CAB040557	Enhanced		Supported	Cytosol	Liver cancer:8.90e-7 (unfavourable), Renal cancer:8.11e-5 (unfavourable)	Expressed in all	Expressed in all			rectum: 70.2	Expressed in all		
CLIC2	XAP121	ENSG00000155962	Chloride intracellular channel 2	X	155276211-155334657	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA047381, HPA060101	Uncertain		Approved	Plasma membrane	Renal cancer:1.74e-5 (unfavourable)	Expressed in all	Mixed			spleen: 62.8	Cell line enhanced		HDLM-2: 85.0;K-562: 44.8;Karpas-707: 31.6;RPMI-8226: 54.1
CLIC3		ENSG00000169583	Chloride intracellular channel 3	9	136994635-136996803	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA005963	Enhanced		Supported	Nuclear bodies	Renal cancer:1.12e-4 (unfavourable), Urothelial cancer:7.74e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 86.8;thyroid gland: 85.7	skin: 43.5	Cell line enhanced		BEWO: 234.7;MCF7: 88.6;T-47d: 100.2;TIME: 70.2
CLIC4	CLIC4L, DKFZP566G223, H1, huH1, P64H1	ENSG00000169504	Chloride intracellular channel 4	1	24745357-24844324	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA008019, HPA060804	Enhanced		Supported	Cytosol	Renal cancer:1.48e-5 (favourable), Cervical cancer:8.31e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 398.9	Expressed in all		
CLIC5	DFNB102	ENSG00000112782	Chloride intracellular channel 5	6	45898451-46080395	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA074371			Supported	Nuclear speckles<br>Plasma membrane		Tissue enhanced	Tissue enhanced		lung: 116.1;skeletal muscle: 119.2	heart muscle: 76.0	Group enriched	7	CAPAN-2: 13.3;EFO-21: 10.0;HDLM-2: 5.7;REH: 13.6;U-266/70: 10.5
CLIC6	CLIC1L, CLIC5	ENSG00000159212	Chloride intracellular channel 6	21	34669389-34718227	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA055123, HPA065285	Enhanced				Lung cancer:3.15e-5 (favourable), Breast cancer:6.11e-5 (favourable)	Mixed	Tissue enhanced		stomach: 79.1	cervix, uterine: 24.4	Cell line enhanced		HMC-1: 2.4;NTERA-2: 3.8;T-47d: 7.2;THP-1: 2.3
CLINT1	CLINT, ENTH, EPNR, KIAA0171	ENSG00000113282	Clathrin interactor 1	5	157785743-157859175	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043280, HPA056947	Supported		Supported	Nucleoplasm<br>Vesicles	Renal cancer:8.88e-5 (favourable), Colorectal cancer:2.95e-4 (favourable), Thyroid cancer:6.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 171.0	Expressed in all		
CLIP1	CLIP, CLIP-170, CLIP170, CYLN1, RSN	ENSG00000130779	CAP-Gly domain containing linker protein 1	12	122271432-122422632	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004399, HPA026678	Approved		Supported	Microtubule ends<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 158.6	Expressed in all		
CLIP2	CLIP, CLIP-115, CYLN2, KIAA0291, WBSCR3, WBSCR4, WSCR3, WSCR4	ENSG00000106665	CAP-Gly domain containing linker protein 2	7	74289475-74405943	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020430, CAB020767	Enhanced				Endometrial cancer:5.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 75.8	ovary: 21.0	Mixed		
CLIP3	CLIPR-59, RSNL1	ENSG00000105270	CAP-Gly domain containing linker protein 3	19	36014660-36033343	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.56e-10 (unfavourable), Pancreatic cancer:2.80e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 247.6	smooth muscle: 56.2	Cell line enhanced		ASC TERT1: 58.0;HSkMC: 67.3
CLIP4	FLJ21069, RSNL2	ENSG00000115295	CAP-Gly domain containing linker protein family member 4	2	29097705-29189643	Predicted intracellular proteins	Evidence at protein level	HPA043366, HPA056246	Uncertain		Enhanced	Vesicles	Renal cancer:1.83e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 55.8	Mixed		
CLK2	clk2	ENSG00000176444	CDC like kinase 2	1	155262868-155278491	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055366, HPA059507	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.95e-9 (unfavourable), Liver cancer:2.82e-4 (unfavourable), Colorectal cancer:3.77e-4 (unfavourable), Urothelial cancer:5.43e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.8	Expressed in all		
CLK3	clk3	ENSG00000179335	CDC like kinase 3	15	74598500-74645414	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046817	Approved		Supported	Nucleoplasm<br>Intermediate filaments	Colorectal cancer:2.05e-6 (unfavourable), Prostate cancer:5.92e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 71.7	Expressed in all		
CLLU1		ENSG00000257127	Chronic lymphocytic leukemia up-regulated 1	12	92421531-92431002	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CLLU1OS		ENSG00000205057	Chronic lymphocytic leukemia up-regulated 1 opposite strand	12	92420094-92428148	Predicted intracellular proteins	Evidence at transcript level							Mixed	Not detected			lymph node,spleen,tonsil: 0.9	Cell line enriched	7	U-698: 4.3
CLNK	MIST	ENSG00000109684	Cytokine dependent hematopoietic cell linker	4	10486395-10684865	Predicted intracellular proteins	Evidence at protein level	HPA035671, HPA035672	Uncertain		Uncertain	Vesicles		Tissue enriched	Tissue enhanced		kidney: 5.8	lymph node: 3.4	Group enriched	6	HDLM-2: 3.9;U-937: 1.6
CLNS1A	CLCI, ICln	ENSG00000074201	Chloride nucleotide-sensitive channel 1A	11	77514936-77637805	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB017840, HPA031707, HPA031708, HPA032045	Approved		Supported	Nucleus<br>Microtubules<br>Cytosol	Renal cancer:5.07e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 132.0	Expressed in all		
CLOCK	bHLHe8, KAT13D, KIAA0334	ENSG00000134852	Clock circadian regulator	4	55427903-55547138	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001867, HPA027565	Supported		Enhanced	Nucleoplasm		Expressed in all	Mixed			testis: 26.4	Expressed in all		
CLP1	hClp1, HEAB	ENSG00000172409	Cleavage and polyadenylation factor I subunit 1	11	57648992-57661868	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057770	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 17.0	Expressed in all		
CLPB	ANKCLB, FLJ13152, HSP78, SKD3	ENSG00000162129	ClpB homolog, mitochondrial AAA ATPase chaperonin	11	72292425-72434680	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039005, HPA039006, HPA064571	Enhanced				Renal cancer:8.36e-8 (favourable)	Expressed in all	Tissue enriched	10	testis: 176.6	parathyroid gland: 18.5	Expressed in all		
CLPP		ENSG00000125656	Caseinolytic mitochondrial matrix peptidase proteolytic subunit	19	6361452-6368908	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA010649	Supported		Enhanced	Mitochondria	Pancreatic cancer:6.50e-4 (favourable)	Expressed in all	Expressed in all			appendix: 48.3	Expressed in all		
CLSPN		ENSG00000092853	Claspin	1	35720218-35769967	Predicted intracellular proteins	Evidence at protein level	HPA026305, HPA026312			Enhanced	Nucleoplasm<br>Golgi apparatus	Stomach cancer:4.92e-4 (favourable)	Mixed	Tissue enhanced		testis: 10.6	bone marrow: 7.0	Mixed		
CLTA	Lca	ENSG00000122705	Clathrin light chain A	9	36190856-36304781	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002665, HPA050918, HPA054667	Enhanced		Enhanced	Vesicles<br>Endosomes<br>Lysosomes	Liver cancer:9.46e-5 (unfavourable), Thyroid cancer:1.01e-4 (favourable), Breast cancer:5.64e-4 (favourable)	Expressed in all	Expressed in all			placenta: 178.0	Expressed in all		
CLTB	Lcb	ENSG00000175416	Clathrin light chain B	5	176392455-176416569	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003692, HPA036458	Approved		Supported	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:7.89e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 242.7	Expressed in all		
CLTC	CLTCL2, Hc	ENSG00000141367	Clathrin heavy chain	17	59619689-59696956	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010389, CAB011571, CAB017155, HPA059143	Approved		Enhanced	Vesicles<br>Mitotic spindle<br>Cytosol	Urothelial cancer:2.02e-4 (unfavourable), Liver cancer:5.54e-4 (unfavourable), Cervical cancer:7.35e-4 (unfavourable), Colorectal cancer:7.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 365.5	Expressed in all		
CLTCL1	CHC22, CLH22, CLTCL, CLTD	ENSG00000070371	Clathrin heavy chain like 1	22	19179473-19291716	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA075795			Approved	Vesicles		Mixed	Tissue enhanced		skeletal muscle: 24.1;testis: 49.4	bone marrow: 10.4	Cell line enhanced		HMC-1: 56.9
CLUAP1	CFAP22, FAP22, FLJ13297, IFT38, KIAA0643	ENSG00000103351	Clusterin associated protein 1	16	3500924-3539048	Predicted intracellular proteins	Evidence at protein level	HPA036976, HPA044191	Uncertain		Supported	Nucleoplasm<br>Vesicles	Endometrial cancer:3.01e-4 (favourable)	Expressed in all	Expressed in all			testis: 71.9	Mixed		
CLUH	CLU1, KIAA0664	ENSG00000132361	Clustered mitochondria homolog	17	2689386-2712663	Predicted intracellular proteins	Evidence at protein level	HPA031505, HPA044346	Uncertain		Supported	Nuclear bodies<br>Vesicles	Renal cancer:1.92e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 50.7	Expressed in all		
CLVS1	C6orf212L, CRALBPL, MGC34646, RLBP1L1	ENSG00000177182	Clavesin 1	8	61057158-61501645	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 10.3	testis: 3.7	Cell line enhanced		SCLC-21H: 4.4;SH-SY5Y: 1.7
CLVS2	bA160A10.4, C6orf212, C6orf213, RLBP1L2	ENSG00000146352	Clavesin 2	6	122995971-123072927	Predicted intracellular proteins	Evidence at protein level	HPA043764	Uncertain					Tissue enhanced	Group enriched	6	cerebral cortex: 15.4;prostate: 5.0	endometrium: 1.7	Group enriched	8	HEL: 10.9;SCLC-21H: 10.7
CMAS		ENSG00000111726	Cytidine monophosphate N-acetylneuraminic acid synthetase	12	22046174-22065674	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039905	Supported		Uncertain	Nucleoli<br>Cytosol	Renal cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 127.9	Expressed in all		
CMBL	FLJ23617	ENSG00000164237	Carboxymethylenebutenolidase homolog	5	10275875-10308026	Predicted intracellular proteins	Evidence at protein level	HPA036571	Uncertain				Ovarian cancer:1.99e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 315.7	duodenum: 177.0	Mixed		
CMC1	C3orf68, MGC61571	ENSG00000187118	C-X9-C motif containing 1	3	28241584-28325142	Predicted intracellular proteins	Evidence at protein level	HPA043333	Approved				Urothelial cancer:5.52e-4 (favourable), Renal cancer:6.81e-4 (favourable)	Expressed in all	Expressed in all			kidney: 33.5	Expressed in all		
CMC2	C16orf61, DC13, MGC45036	ENSG00000103121	C-X9-C motif containing 2	16	80966448-81020270	Predicted intracellular proteins	Evidence at protein level	HPA006871, CAB026396	Approved		Supported	Mitochondria	Renal cancer:2.64e-5 (favourable)	Expressed in all	Expressed in all			testis: 81.9	Expressed in all		
CMC4	MTCP1, MTCP1NB, p8, P8MTCP1	ENSG00000182712	C-X9-C motif containing 4	X	155061622-155071362	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045866	Approved		Supported	Mitochondria		Not detected	Expressed in all			heart muscle: 21.4	Expressed in all		
CMIP		ENSG00000153815	C-Maf inducing protein	16	81445170-81711762	Predicted intracellular proteins	Evidence at protein level	HPA054424, HPA066710	Approved		Supported	Nucleoplasm<br>Cytosol	Lung cancer:9.47e-7 (unfavourable), Thyroid cancer:1.05e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 87.4	Expressed in all		
CMPK2	NDK, TYKi, UMP-CMPK2	ENSG00000134326	Cytidine/uridine monophosphate kinase 2	2	6840570-6866635	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041430	Approved		Approved	Mitochondria	Endometrial cancer:4.71e-4 (unfavourable)	Expressed in all	Mixed			spleen: 5.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 16.8;BJ hTERT+ SV40 Large T+ RasG12V: 15.8;HEL: 23.9;MOLT-4: 11.9
CMSS1	C3orf26, MGC4308	ENSG00000184220	Cms1 ribosomal small subunit homolog (yeast)	3	99817834-100181732	Predicted intracellular proteins	Evidence at protein level	HPA042820	Uncertain		Approved	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Mitochondria	Liver cancer:5.92e-10 (unfavourable), Endometrial cancer:3.15e-6 (unfavourable), Prostate cancer:3.10e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 53.1	Expressed in all		
CMTR1	FTSJD2, ISG95, KIAA0082, MTr1	ENSG00000137200	Cap methyltransferase 1	6	37433219-37482827	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029954, HPA029979, HPA029980	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:1.73e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 85.5	Expressed in all		
CMYA5	C5orf10, DKFZp451G223, myospryn, SPRYD2, TRIM76	ENSG00000164309	Cardiomyopathy associated 5	5	79689877-79800240	Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	8	heart muscle: 102.2;skeletal muscle: 172.4	ovary: 18.2	Cell line enhanced		RT4: 1.2;THP-1: 3.6
CNBD2	C20orf152, CNMPD1, dJ954P9.1	ENSG00000149646	Cyclic nucleotide binding domain containing 2	20	35954564-36030700	Predicted intracellular proteins	Evidence at protein level	HPA043182	Uncertain					Not detected	Tissue enhanced		testis: 38.0	epididymis: 15.3	Mixed		
CNBP	CNBP1, DM2, RNF163, ZCCHC22, ZNF9	ENSG00000169714	CCHC-type zinc finger nucleic acid binding protein	3	129169484-129183922	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063097			Supported	Nucleus<br>Cytosol	Pancreatic cancer:3.51e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 474.6	Expressed in all		
CNDP2	CN2, CPGL, FLJ10830, HsT2298, PEPA	ENSG00000133313	CNDP dipeptidase 2 (metallopeptidase M20 family)	18	74495816-74523454	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB026196, HPA036898, HPA036899	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.50e-6 (favourable)	Expressed in all	Expressed in all			kidney: 342.2	Expressed in all		
CNFN	PLAC8L2	ENSG00000105427	Cornifelin	19	42387019-42390287	Predicted intracellular proteins	Evidence at protein level	HPA049073, HPA053997	Enhanced		Approved	Microtubules<br>Cytokinetic bridge	Thyroid cancer:4.02e-5 (favourable)	Expressed in all	Group enriched	32	esophagus: 1158.0;skin: 272.5;tonsil: 260.7	breast: 17.6	Cell line enhanced		A549: 17.1;HEK93: 24.4
CNKSR1	CNK, CNK1, KSR	ENSG00000142675	Connector enhancer of kinase suppressor of Ras 1	1	26177403-26189886	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA030847	Uncertain		Approved	Cytosol	Urothelial cancer:5.91e-4 (favourable)	Mixed	Mixed			parathyroid gland: 20.6	Cell line enhanced		A-431: 15.5;CAPAN-2: 23.4;HaCaT: 17.4
CNKSR2	CNK2, KIAA0902, KSR2	ENSG00000149970	Connector enhancer of kinase suppressor of Ras 2	X	21374418-21654695	Predicted intracellular proteins	Evidence at protein level	HPA001502			Approved	Golgi apparatus<br>Plasma membrane		Tissue enhanced	Tissue enriched	9	cerebral cortex: 53.9	adrenal gland: 5.8	Cell line enhanced		A549: 6.4;NTERA-2: 10.9;RH-30: 9.6
CNKSR3	FLJ31349, MAGI1	ENSG00000153721	CNKSR family member 3	6	154387504-154510659	Predicted intracellular proteins	Evidence at protein level	CAB037133, HPA049651	Approved		Approved	Mitochondria<br>Cytosol	Renal cancer:6.00e-4 (favourable)	Mixed	Mixed			esophagus: 15.6	Mixed		
CNN1	Sm-Calp, SMCC	ENSG00000130176	Calponin 1	19	11538717-11550323	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000007, HPA014263	Enhanced		Approved	Actin filaments	Renal cancer:5.43e-6 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 2110.1;smooth muscle: 3106.1	endometrium: 1736.7	Cell line enhanced		BJ: 76.7;BJ hTERT+ SV40 Large T+: 43.2;BJ hTERT+ SV40 Large T+ RasG12V: 62.2;HBF TERT88: 68.9
CNN2		ENSG00000064666	Calponin 2	19	1026581-1039068	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049095	Approved		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:4.70e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 208.5	Mixed		
CNN3		ENSG00000117519	Calponin 3	1	94896949-94927278	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009849, HPA051237	Enhanced		Enhanced	Actin filaments<br>Cytosol	Urothelial cancer:1.99e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 345.6	Mixed		
CNOT10	FLJ12890, FLJ13165	ENSG00000182973	CCR4-NOT transcription complex subunit 10	3	32685145-32773875	Predicted intracellular proteins	Evidence at protein level	HPA035614, HPA041450	Approved		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Liver cancer:1.03e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 72.1	Expressed in all		
CNOT11	C2orf29, C40	ENSG00000158435	CCR4-NOT transcription complex subunit 11	2	101252802-101270316	Predicted intracellular proteins	Evidence at protein level	HPA069823			Supported	Nucleoplasm	Renal cancer:8.33e-6 (unfavourable), Liver cancer:1.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.0	Expressed in all		
CNOT2	CDC36, NOT2, NOT2H	ENSG00000111596	CCR4-NOT transcription complex subunit 2	12	70242994-70354993	Predicted intracellular proteins	Evidence at protein level	HPA067711	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:8.63e-5 (unfavourable), Liver cancer:2.21e-4 (unfavourable), Melanoma:6.86e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 53.9	Expressed in all		
CNOT3	KIAA0691, LENG2, NOT3, NOT3H	ENSG00000088038	CCR4-NOT transcription complex subunit 3	19	54137728-54155681	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA006408	Approved		Approved	Cytosol	Liver cancer:2.22e-4 (unfavourable), Renal cancer:2.77e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.1	Expressed in all		
CNOT4	CLONE243, NOT4, NOT4H	ENSG00000080802	CCR4-NOT transcription complex subunit 4	7	135361795-135510127	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005737	Approved				Renal cancer:7.67e-6 (favourable), Liver cancer:1.19e-4 (unfavourable), Ovarian cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.3	Expressed in all		
CNOT6	CCR4, Ccr4a, KIAA1194	ENSG00000113300	CCR4-NOT transcription complex subunit 6	5	180494412-180578405	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044568	Approved		Approved	Cytosol	Liver cancer:3.61e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 25.1	Expressed in all		
CNOT6L	Ccr4b, DKFZp434K098	ENSG00000138767	CCR4-NOT transcription complex subunit 6 like	4	77713387-77819615	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042688	Uncertain		Supported	Cytosol	Renal cancer:1.69e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 43.7	Expressed in all		
CNOT7	CAF1	ENSG00000198791	CCR4-NOT transcription complex subunit 7	8	17224964-17246878	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069543			Supported	Nuclear bodies	Colorectal cancer:4.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 112.7	Expressed in all		
CNOT8	CAF1, CALIF, hCAF1, POP2	ENSG00000155508	CCR4-NOT transcription complex subunit 8	5	154857553-154876793	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051398	Approved				Liver cancer:5.33e-4 (unfavourable), Urothelial cancer:6.41e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 74.6	Expressed in all		
CNP		ENSG00000173786	2',3'-cyclic nucleotide 3' phosphodiesterase	17	41966741-41977731	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002672, HPA023266, HPA023278, HPA023280, HPA023338	Enhanced	Supported	Enhanced	Nucleus<br>Cytosol		Expressed in all	Tissue enriched	11	cerebral cortex: 614.8	prostate: 54.9	Expressed in all		
CNPY1		ENSG00000146910	Canopy FGF signaling regulator 1	7	155474206-155555450	Predicted intracellular proteins	Evidence at transcript level	HPA047400	Uncertain					Tissue enriched	Tissue enhanced		testis: 1.8	pancreas: 0.7	Cell line enriched	11	AF22: 30.3
CNRIP1	C2orf32, CRIP1, CRIP1a, CRIP1b, DKFZP566K1924	ENSG00000119865	Cannabinoid receptor interacting protein 1	2	68284171-68320051	Predicted intracellular proteins	Evidence at protein level	HPA035337			Approved	Cytosol	Renal cancer:1.21e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 53.8	adipose tissue: 24.9	Cell line enhanced		HEL: 139.6
CNTD2	CCNP, FLJ13265	ENSG00000105219	Cyclin N-terminal domain containing 2	19	40222208-40226690	Predicted intracellular proteins	Evidence at transcript level	HPA045615	Uncertain					Mixed	Not detected			adipose tissue: 0.9	Cell line enhanced		SCLC-21H: 2.5
CNTF	HCNTF	ENSG00000242689	Ciliary neurotrophic factor	11	58622673-58625733	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019654	Uncertain		Approved	Vesicles		Mixed	Tissue enhanced		fallopian tube: 7.7	bone marrow: 4.3	Mixed		
CNTLN	bA340N12.1, C9orf101, C9orf39, FLJ20276	ENSG00000044459	Centlein	9	17134982-17503923	Predicted intracellular proteins	Evidence at protein level	HPA007201, HPA036728, HPA036729	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Mixed	Mixed			endometrium: 11.8	Cell line enhanced		HEL: 31.6
CNTRL	CEP1, CEP110	ENSG00000119397	Centriolin	9	121074863-121177610	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020468, HPA020480, HPA051583	Approved		Supported	Centrosome<br>Cytosol	Head and neck cancer:9.21e-5 (favourable)	Expressed in all	Tissue enhanced		testis: 65.8	lymph node: 29.0	Expressed in all		
CNTROB	LIP8, PP1221	ENSG00000170037	Centrobin, centriole duplication and spindle assembly protein	17	7932101-7949918	Predicted intracellular proteins	Evidence at protein level	HPA023319, HPA023320, HPA023321, HPA023325	Approved		Supported	Centrosome<br>Cytosol	Liver cancer:9.88e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 91.4	Expressed in all		
COA4	CHCHD8, CMC3, E2IG2	ENSG00000181924	Cytochrome c oxidase assembly factor 4 homolog	11	73872667-73876988	Predicted intracellular proteins	Evidence at protein level	HPA040126	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Mitochondria	Renal cancer:2.14e-4 (unfavourable), Ovarian cancer:3.87e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 81.4	Expressed in all		
COA5	C2orf64, FLJ27524, MGC52110, Pet191	ENSG00000183513	Cytochrome c oxidase assembly factor 5	2	98599310-98608515	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA057768	Uncertain		Supported	Mitochondria	Urothelial cancer:1.00e-5 (favourable), Lung cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 42.3	Expressed in all		
COA6	C1orf31	ENSG00000168275	Cytochrome c oxidase assembly factor 6	1	234373456-234384049	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028588	Approved		Supported	Mitochondria	Renal cancer:1.12e-5 (unfavourable), Urothelial cancer:7.12e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 45.4	Expressed in all		
COA7	C1orf163, FLJ12439, RESA1, SELRC1	ENSG00000162377	Cytochrome c oxidase assembly factor 7 (putative)	1	52684451-52698366	Predicted intracellular proteins	Evidence at protein level	HPA028154, HPA029926	Approved		Approved	Nucleus<br>Mitochondria	Liver cancer:7.01e-5 (unfavourable), Stomach cancer:4.35e-4 (favourable), Endometrial cancer:8.55e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 14.7	Expressed in all		
COBL	KIAA0633	ENSG00000106078	Cordon-bleu WH2 repeat protein	7	51016212-51316818	Predicted intracellular proteins	Evidence at protein level	HPA019033, HPA019167	Enhanced		Approved	Plasma membrane<br>Cell Junctions	Renal cancer:5.21e-12 (favourable)	Mixed	Mixed			parathyroid gland: 61.9	Cell line enhanced		BEWO: 31.3;HeLa: 39.5;RPMI-8226: 32.2
COBLL1	KIAA0977	ENSG00000082438	Cordon-bleu WH2 repeat protein like 1	2	164653624-164843679	Predicted intracellular proteins	Evidence at protein level	HPA044933, HPA053344	Enhanced		Approved	Cell Junctions	Renal cancer:5.27e-13 (favourable)	Expressed in all	Mixed			placenta: 77.1	Mixed		
COG1	KIAA1381, LDLB	ENSG00000166685	Component of oligomeric golgi complex 1	17	73192632-73208507	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029224	Supported				Liver cancer:2.91e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 50.8	Expressed in all		
COG2	LDLC	ENSG00000135775	Component of oligomeric golgi complex 2	1	230642489-230693982	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA076994			Approved	Golgi apparatus	Colorectal cancer:9.76e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 77.2	Expressed in all		
COG4	COD1, DKFZP586E1519	ENSG00000103051	Component of oligomeric golgi complex 4	16	70480568-70523565	Predicted intracellular proteins	Evidence at protein level	HPA040924, HPA042539	Approved		Approved	Golgi apparatus<br>Vesicles	Liver cancer:1.64e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.1	Expressed in all		
COG5	GOLTC1, GTC90	ENSG00000164597	Component of oligomeric golgi complex 5	7	107201555-107564514	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020300, HPA041583	Uncertain		Enhanced	Nucleoplasm<br>Golgi apparatus	Thyroid cancer:1.48e-4 (unfavourable), Liver cancer:3.77e-4 (unfavourable), Endometrial cancer:9.72e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 36.8	Mixed		
COG6	COD2, KIAA1134	ENSG00000133103	Component of oligomeric golgi complex 6	13	39655627-39791665	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040410, HPA040441	Uncertain		Approved	Nuclear speckles<br>Golgi apparatus	Stomach cancer:2.81e-4 (favourable)	Expressed in all	Expressed in all			testis: 31.6	Expressed in all		
COG7		ENSG00000168434	Component of oligomeric golgi complex 7	16	23388493-23453180	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040758, HPA064645	Uncertain		Enhanced	Golgi apparatus	Renal cancer:3.14e-4 (favourable), Endometrial cancer:6.95e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.8	Expressed in all		
COG8	DOR1, FLJ22315	ENSG00000213380	Component of oligomeric golgi complex 8	16	69320140-69339583	Predicted intracellular proteins	Evidence at protein level	HPA041406	Approved				Renal cancer:2.47e-7 (favourable), Pancreatic cancer:3.12e-5 (favourable)	Expressed in all	Expressed in all			testis: 29.9	Expressed in all		
COG8	DOR1, FLJ22315	ENSG00000272617	Component of oligomeric golgi complex 8	16	69326913-69339667	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041406, HPA049429	Approved		Supported	Golgi apparatus		Not detected	Expressed in all			testis: 40.0	Expressed in all		
COIL	CLN80, p80-coilin	ENSG00000121058	Coilin	17	56938187-56961054	Predicted intracellular proteins	Evidence at protein level	CAB017524, HPA027885, HPA068537, CAB069400	Enhanced		Enhanced	Nucleus<br>Nucleoli fibrillar center<br>Nuclear bodies	Liver cancer:1.28e-4 (unfavourable), Colorectal cancer:1.77e-4 (favourable)	Expressed in all	Tissue enriched	9	testis: 175.4	thyroid gland: 20.2	Expressed in all		
COL23A1	DKFZp434K0621	ENSG00000050767	Collagen type XXIII alpha 1 chain	5	178237618-178590555	Predicted intracellular proteins	Evidence at protein level	HPA067824	Uncertain				Endometrial cancer:6.46e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 57.8	seminal vesicle: 16.2	Group enriched	8	AF22: 5.7;K-562: 10.8;NB-4: 20.8;THP-1: 22.5
COL4A3BP	CERT, GPBP, STARD11	ENSG00000113163	Collagen type IV alpha 3 binding protein	5	75368486-75512138	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035645, HPA042608	Uncertain		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.24e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 70.6	Expressed in all		
COLCA2	C11orf93, CASC13	ENSG00000214290	Colorectal cancer associated 2	11	111298555-111308735	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:8.97e-6 (favourable)	Mixed	Mixed			epididymis: 33.1	Cell line enhanced		HaCaT: 4.7;Hep G2: 7.8;RT4: 8.4;T-47d: 5.3
COMMD1	C2orf5, MGC27155, MURR1	ENSG00000173163	Copper metabolism domain containing 1	2	61888724-62147247	Predicted intracellular proteins	Evidence at protein level	HPA034633, HPA049223	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 47.8	Expressed in all		
COMMD10	PTD002	ENSG00000145781	COMM domain containing 10	5	116084991-116412762	Predicted intracellular proteins	Evidence at protein level	HPA045441, HPA075641	Approved		Uncertain	Plasma membrane<br>Cytosol	Stomach cancer:2.99e-4 (unfavourable), Thyroid cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 46.8	Expressed in all		
COMMD2	HSPC042	ENSG00000114744	COMM domain containing 2	3	149738470-149752499	Predicted intracellular proteins	Evidence at protein level	HPA044190	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:3.69e-6 (unfavourable), Liver cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 23.5	Expressed in all		
COMMD3	BUP, C10orf8	ENSG00000148444	COMM domain containing 3	10	22315974-22320308	Predicted intracellular proteins	Evidence at protein level	HPA036584	Approved				Liver cancer:5.46e-7 (unfavourable)	Expressed in all	Expressed in all			breast: 53.1	Expressed in all		
COMMD3-BMI1		ENSG00000269897	COMMD3-BMI1 readthrough	10	22316388-22329542	Predicted intracellular proteins	Evidence at protein level	HPA030471, HPA030472, HPA036584	Uncertain		Approved	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol		Not detected	Tissue enhanced		testis: 10.2	seminal vesicle: 4.0	Mixed		
COMMD4	FLJ20452	ENSG00000140365	COMM domain containing 4	15	75335891-75343224	Predicted intracellular proteins	Evidence at protein level	HPA066957	Uncertain		Supported	Nucleus<br>Plasma membrane		Expressed in all	Expressed in all			testis: 76.2	Expressed in all		
COMMD5	FLJ13008, HCaRG, HT002	ENSG00000170619	COMM domain containing 5	8	144841042-144853736	Predicted intracellular proteins	Evidence at protein level	HPA046905			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			lymph node: 18.2	Expressed in all		
COMMD6	Acrg	ENSG00000188243	COMM domain containing 6	13	75525219-75549439	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			ovary: 288.2	Expressed in all		
COMMD7	C20orf92, dJ1085F17.3	ENSG00000149600	COMM domain containing 7	20	32702691-32743997	Predicted intracellular proteins	Evidence at protein level	HPA054119			Supported	Vesicles	Liver cancer:1.46e-4 (unfavourable), Urothelial cancer:3.53e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 80.3	Expressed in all		
COMMD8	FLJ20502	ENSG00000169019	COMM domain containing 8	4	47450796-47463719	Predicted intracellular proteins	Evidence at protein level	HPA035887	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.71e-5 (favourable), Liver cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 46.4	Expressed in all		
COMMD9	FLJ31106, HSPC166	ENSG00000110442	COMM domain containing 9	11	36269284-36289449	Predicted intracellular proteins	Evidence at protein level	HPA009142	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Ovarian cancer:8.54e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 48.3	Expressed in all		
COMTD1	FLJ23841	ENSG00000165644	Catechol-O-methyltransferase domain containing 1	10	75233969-75236030	Predicted intracellular proteins	Evidence at protein level	HPA042165	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.88e-4 (favourable)	Expressed in all	Mixed			duodenum: 13.6	Cell line enhanced		HEK93: 43.6;PC-3: 61.2
COPA	HEP-COP	ENSG00000122218	Coatomer protein complex subunit alpha	1	160289273-160343400	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028024	Supported		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:1.08e-4 (unfavourable), Cervical cancer:6.54e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.9	Expressed in all		
COPB1	COPB	ENSG00000129083	Coatomer protein complex subunit beta 1	11	14443440-14500027	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012338, HPA043954, HPA064403	Supported		Enhanced	Golgi apparatus<br>Vesicles<br>Cytosol	Liver cancer:5.63e-7 (unfavourable), Head and neck cancer:6.91e-4 (unfavourable), Pancreatic cancer:8.04e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 132.5	Expressed in all		
COPB2	beta'-COP, betaprime-COP	ENSG00000184432	Coatomer protein complex subunit beta 2	3	139355600-139389732	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036867, HPA058180	Approved		Approved	Cytosol	Liver cancer:2.41e-7 (unfavourable), Pancreatic cancer:1.45e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 173.0	Expressed in all		
COPE	epsilon-COP	ENSG00000105669	Coatomer protein complex subunit epsilon	19	18899514-18919397	Predicted intracellular proteins	Evidence at protein level	CAB034345, HPA041605, HPA043576	Supported		Enhanced	Golgi apparatus	Cervical cancer:2.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 122.6	Expressed in all		
COPG1	COPG	ENSG00000181789	Coatomer protein complex subunit gamma 1	3	129249606-129277773	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037866, HPA037867, HPA045712	Supported		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:1.22e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 191.9	Expressed in all		
COPG2	2-COP	ENSG00000158623	Coatomer protein complex subunit gamma 2	7	130506238-130668748	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045712	Approved					Expressed in all	Expressed in all			ovary: 48.2	Expressed in all		
COPRS	C17orf79, COPR5, HSA272196, TTP1	ENSG00000172301	Coordinator of PRMT5 and differentiation stimulator	17	31851864-31859337	Predicted intracellular proteins	Evidence at protein level	HPA052552	Approved		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Liver cancer:3.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 268.0	Expressed in all		
COPS2	ALIEN, CSN2, TRIP15	ENSG00000166200	COP9 signalosome subunit 2	15	49106068-49155661	Predicted intracellular proteins	Evidence at protein level	HPA016867, HPA018271, HPA061071	Approved		Enhanced	Vesicles<br>Cytokinetic bridge		Expressed in all	Expressed in all			thyroid gland: 103.5	Expressed in all		
COPS3	CSN3, SGN3	ENSG00000141030	COP9 signalosome subunit 3	17	17246820-17281293	Predicted intracellular proteins	Evidence at protein level	HPA021997, HPA050557	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:8.65e-5 (unfavourable), Prostate cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 162.6	Expressed in all		
COPS4	CSN4	ENSG00000138663	COP9 signalosome subunit 4	4	83034447-83075818	Predicted intracellular proteins	Evidence at protein level	HPA036894, HPA042828	Uncertain		Supported	Nuclear speckles	Renal cancer:5.21e-6 (favourable), Colorectal cancer:4.14e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.0	Expressed in all		
COPS5	CSN5, JAB1, MOV-34, SGN5	ENSG00000121022	COP9 signalosome subunit 5	8	67043079-67083783	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004242, HPA004845, HPA051531	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 92.4	Expressed in all		
COPS7A	CSN7A	ENSG00000111652	COP9 signalosome subunit 7A	12	6723741-6731875	Predicted intracellular proteins	Evidence at protein level	HPA026915	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 92.3	Expressed in all		
COPS7B	CSN7B	ENSG00000144524	COP9 signalosome subunit 7B	2	231781671-231809254	Predicted intracellular proteins	Evidence at protein level	HPA034675, HPA034676	Uncertain		Supported	Nucleoplasm	Renal cancer:1.50e-6 (unfavourable), Liver cancer:8.37e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 38.1	Expressed in all		
COPS8	COP9, CSN8, MGC1297, SGN8	ENSG00000198612	COP9 signalosome subunit 8	2	237085312-237100466	Predicted intracellular proteins	Evidence at protein level	HPA036485	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.70e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 116.1	Expressed in all		
COPS9	CSNAP, MYEOV2	ENSG00000172428	COP9 signalosome subunit 9	2	240126563-240136807	Predicted intracellular proteins	Evidence at protein level	HPA044845	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 192.2	Expressed in all		
COPZ1	CGI-120, COPZ	ENSG00000111481	Coatomer protein complex subunit zeta 1	12	54301202-54351849	Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.40e-5 (unfavourable), Renal cancer:7.45e-5 (unfavourable), Breast cancer:7.84e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 192.5	Expressed in all		
COPZ2	MGC23008	ENSG00000005243	Coatomer protein complex subunit zeta 2	17	48026167-48038030	Predicted intracellular proteins	Evidence at protein level	HPA055999	Uncertain				Renal cancer:3.45e-9 (unfavourable), Thyroid cancer:2.89e-6 (unfavourable), Urothelial cancer:4.66e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 73.1	Cell line enhanced		ASC TERT1: 132.1;fHDF/TERT166: 213.5
COQ10A	FLJ32452	ENSG00000135469	Coenzyme Q10A	12	56266858-56270966	Predicted intracellular proteins	Evidence at protein level	HPA068931			Approved	Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol	Pancreatic cancer:2.06e-4 (favourable), Renal cancer:3.44e-4 (favourable), Colorectal cancer:5.46e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 97.2	Expressed in all		
COQ10B	FLJ13448	ENSG00000115520	Coenzyme Q10B	2	197453423-197475308	Predicted intracellular proteins	Evidence at protein level	HPA046057	Approved		Approved	Cytosol		Expressed in all	Expressed in all			adrenal gland: 49.7	Expressed in all		
COQ3	bA9819.1	ENSG00000132423	Coenzyme Q3, methyltransferase	6	99369400-99394204	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031273, HPA031274	Enhanced		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:6.86e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 20.8	Expressed in all		
COQ4	CGI-92	ENSG00000167113	Coenzyme Q4	9	128322536-128334072	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021406, HPA042945	Supported		Supported	Mitochondria	Endometrial cancer:4.93e-6 (favourable), Renal cancer:5.76e-6 (favourable), Cervical cancer:2.97e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 64.9	Expressed in all		
COQ5	MGC4767	ENSG00000110871	Coenzyme Q5, methyltransferase	12	120503274-120534434	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049487	Approved		Approved	Nucleoli<br>Mitochondria		Expressed in all	Expressed in all			thyroid gland: 42.1	Expressed in all		
COQ8A	ADCK3, CABC1, COQ8, SCAR9	ENSG00000163050	Coenzyme Q8A	1	226897536-226987545	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA061662			Supported	Mitochondria		Expressed in all	Tissue enriched	6	skeletal muscle: 401.8	adrenal gland: 68.1	Cell line enhanced		HEK93: 75.6
COQ8B	ADCK4, COQ8, FLJ12229	ENSG00000123815	Coenzyme Q8B	19	40691529-40718207	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027229, HPA027277, HPA027279, HPA028303	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			fallopian tube: 41.1	Expressed in all		
COQ9	C16orf49, DKFZP434K046	ENSG00000088682	Coenzyme Q9	16	57447425-57461275	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040918	Supported		Approved	Cytosol	Renal cancer:9.03e-11 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 90.6	Expressed in all		
CORO1A	coronin-1, HCORO1, p57	ENSG00000102879	Coronin 1A	16	30182827-30189076	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB046473, HPA051132	Enhanced		Approved	Cytosol	Renal cancer:5.74e-7 (unfavourable), Head and neck cancer:4.42e-4 (favourable), Endometrial cancer:6.91e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 593.1	Cell line enhanced		Daudi: 596.0;HMC-1: 850.4;RPMI-8226: 612.4;U-937: 575.5
CORO1B	coronin-2	ENSG00000172725	Coronin 1B	11	67435510-67443821	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017616, HPA040113, HPA070456	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Endometrial cancer:1.65e-4 (favourable)	Expressed in all	Expressed in all			prostate: 85.9	Mixed		
CORO1C	coronin-3, HCRNN4	ENSG00000110880	Coronin 1C	12	108645109-108731596	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041737	Approved				Liver cancer:5.59e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 208.8	Expressed in all		
CORO2A	IR10, WDR2	ENSG00000106789	Coronin 2A	9	98120975-98192640	Predicted intracellular proteins	Evidence at protein level	HPA041161, HPA041302	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:6.56e-4 (unfavourable)	Mixed	Mixed			small intestine: 38.5	Cell line enhanced		BEWO: 64.3;SK-BR-3: 33.9
CORO2B	ClipinC, KIAA0925	ENSG00000103647	Coronin 2B	15	68578969-68727806	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017960	Enhanced		Approved	Plasma membrane<br>Focal adhesion sites		Group enriched	Tissue enhanced		cerebral cortex: 73.3;fallopian tube: 36.7	ovary: 17.9	Cell line enhanced		ASC TERT1: 40.2;HSkMC: 30.2;hTEC/SVTERT24-B: 34.6;U-87 MG: 57.2
CORO6	FLJ14871	ENSG00000167549	Coronin 6	17	29614756-29622907	Predicted intracellular proteins	Evidence at protein level	HPA021556			Supported	Golgi apparatus	Renal cancer:9.61e-7 (unfavourable)	Tissue enhanced	Tissue enhanced		skeletal muscle: 127.5	heart muscle: 46.5	Cell line enhanced		REH: 15.0;RH-30: 17.3;SH-SY5Y: 23.2
CORO7	FLJ22021	ENSG00000262246	Coronin 7	16	4354542-4425705	Predicted intracellular proteins	Evidence at protein level	HPA041657, HPA053586	Uncertain				Endometrial cancer:4.25e-4 (favourable), Cervical cancer:8.68e-4 (favourable)	Expressed in all	Mixed			bone marrow: 24.5	Cell line enhanced		RPMI-8226: 52.3
CORO7-PAM16		ENSG00000103426	CORO7-PAM16 readthrough	16	4340251-4420494	Predicted intracellular proteins	Evidence at protein level	HPA041657, HPA053586, HPA062721	Uncertain		Approved	Nucleoplasm<br>Microtubules<br>Mitochondria		Not detected	Not detected			testis: 0.2	Not detected		
COTL1	CLP	ENSG00000103187	Coactosin like F-actin binding protein 1	16	84565594-84618077	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008918, CAB062328	Enhanced				Renal cancer:5.51e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 421.9	Expressed in all		
COX16	C14orf112, HSPC203	ENSG00000133983	COX16, cytochrome c oxidase assembly homolog	14	70325081-70359731	Predicted intracellular proteins	Evidence at protein level	HPA062659	Uncertain		Supported	Mitochondria	Renal cancer:1.03e-12 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.6	Expressed in all		
COX17		ENSG00000138495	COX17, cytochrome c oxidase copper chaperone	3	119654513-119677454	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042226, HPA048158	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			adrenal gland: 114.8	Expressed in all		
COX19	MGC104475	ENSG00000240230	COX19, cytochrome c oxidase assembly factor	7	898778-975599	Predicted intracellular proteins	Evidence at protein level	HPA021226	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			fallopian tube: 10.0	Mixed		
COX5A		ENSG00000178741	Cytochrome c oxidase subunit 5A	15	74919791-74938168	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA027526	Supported				Renal cancer:6.06e-7 (favourable), Cervical cancer:2.15e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 548.4	Expressed in all		
COX5B		ENSG00000135940	Cytochrome c oxidase subunit 5B	2	97646040-97648383	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034517	Supported		Enhanced	Mitochondria	Urothelial cancer:2.73e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 447.7	Expressed in all		
COX6A2		ENSG00000156885	Cytochrome c oxidase subunit 6A2	16	31427731-31428428	Predicted intracellular proteins, Transporters	Evidence at protein level							Group enriched	Group enriched	23	heart muscle: 687.3;skeletal muscle: 1846.8	esophagus: 54.9	Cell line enhanced		HSkMC: 1.6;SiHa: 1.0;U-266/84: 7.0
COX6B1	COX6B, COXG	ENSG00000126267	Cytochrome c oxidase subunit 6B1	19	35648223-35658861	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004192	Enhanced		Supported	Mitochondria	Renal cancer:5.42e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 462.5	Expressed in all		
COX6B2	COXVIB2, CT59, FLJ32865	ENSG00000160471	Cytochrome c oxidase subunit 6B2	19	55349306-55354814	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035014			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:9.70e-5 (unfavourable)	Mixed	Tissue enriched	14	testis: 74.5	rectum: 5.2	Group enriched	6	CAPAN-2: 21.1;SCLC-21H: 11.9
CPA5		ENSG00000158525	Carboxypeptidase A5	7	130344816-130368730	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020322			Approved	Nucleus		Not detected	Tissue enriched	18	testis: 47.4	spleen: 2.6	Cell line enhanced		RH-30: 7.1;RT4: 2.7;U-266/84: 4.1
CPEB1	CPEB, FLJ13203	ENSG00000214575	Cytoplasmic polyadenylation element binding protein 1	15	82543201-82648861	Predicted intracellular proteins	Evidence at protein level	HPA040396			Supported	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enhanced		testis: 61.1	cerebral cortex: 22.3	Cell line enhanced		SK-MEL-30: 29.5;U-2197: 103.8;U-87 MG: 39.3
CPEB2		ENSG00000137449	Cytoplasmic polyadenylation element binding protein 2	4	15002674-15070153	Predicted intracellular proteins	Evidence at protein level	HPA072513			Approved	Cytosol		Expressed in all	Tissue enhanced		testis: 41.7	parathyroid gland: 20.5	Cell line enhanced		RPTEC TERT1: 26.5
CPEB3	KIAA0940	ENSG00000107864	Cytoplasmic polyadenylation element binding protein 3	10	92046692-92291087	Predicted intracellular proteins	Evidence at protein level	HPA059056			Approved	Nucleoplasm<br>Nuclear bodies<br>Intermediate filaments	Renal cancer:3.84e-9 (favourable), Liver cancer:5.06e-5 (favourable)	Mixed	Mixed			testis: 16.2	Cell line enhanced		Karpas-707: 8.9
CPEB4	KIAA1673	ENSG00000113742	Cytoplasmic polyadenylation element binding protein 4	5	173888280-173961976	Predicted intracellular proteins	Evidence at protein level	HPA038394			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:4.99e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 119.8	Cell line enhanced		U-266/70: 86.1;U-266/84: 121.7
CPED1	C7orf58, FLJ21986	ENSG00000106034	Cadherin like and PC-esterase domain containing 1	7	120988677-121297444	Predicted intracellular proteins	Evidence at transcript level	HPA012058	Uncertain		Approved	Nucleus	Lung cancer:3.00e-4 (favourable), Renal cancer:4.87e-4 (unfavourable)	Mixed	Mixed			ovary: 96.6	Cell line enhanced		BJ hTERT+: 70.8;K-562: 158.4
CPHXL		ENSG00000283755	Cytoplasmic polyadenylated homeobox like	16	75714224-75726442	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	10	testis: 1.0	all non-specific tissues: 0.0	Not detected		
CPLX1	CPX-I	ENSG00000168993	Complexin 1	4	784957-826198	Predicted intracellular proteins	Evidence at protein level	HPA071191			Uncertain	Vesicles	Cervical cancer:4.20e-4 (unfavourable), Pancreatic cancer:5.05e-4 (favourable)	Expressed in all	Tissue enriched	11	cerebral cortex: 60.2	adipose tissue: 5.3	Cell line enriched	7	SCLC-21H: 95.0
CPLX2	CPX-2, DKFZp547D155	ENSG00000145920	Complexin 2	5	175796310-175884020	Predicted intracellular proteins	Evidence at protein level	HPA071191			Uncertain	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 236.4;epididymis: 145.5	adrenal gland: 44.3	Group enriched	19	A549: 549.3;Hep G2: 253.5;SCLC-21H: 296.3
CPLX3	CPX-III	ENSG00000213578	Complexin 3	15	74826547-74831802	Predicted intracellular proteins	Evidence at protein level	CAB079003		Supported				Not detected	Group enriched	8	prostate: 143.7;spleen: 74.6	cerebral cortex: 12.8	Cell line enhanced		Daudi: 1.6;Karpas-707: 1.4;SCLC-21H: 1.0
CPLX4	CPX-IV	ENSG00000166569	Complexin 4	18	59275156-59318649	Predicted intracellular proteins	Evidence at protein level	HPA047627	Supported					Not detected	Not detected			skin,testis: 0.4	Not detected		
CPNE1	CPN1	ENSG00000214078	Copine 1	20	35626031-35664956	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047259, HPA072634	Approved		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:2.74e-10 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 104.0	Expressed in all		
CPNE2	CPN2	ENSG00000140848	Copine 2	16	57092537-57148367	Predicted intracellular proteins	Evidence at protein level	HPA041132	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			lung: 55.6	Mixed		
CPNE3		ENSG00000085719	Copine 3	8	86514427-86561498	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029552	Uncertain		Supported	Nucleus<br>Nucleoli<br>Mitochondria<br>Cytosol	Renal cancer:5.07e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 103.4	Expressed in all		
CPNE4	COPN4, CPN4	ENSG00000196353	Copine 4	3	131533555-132285410	Predicted intracellular proteins	Evidence at protein level	HPA032036, HPA078300	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 12.1;prostate: 40.8	seminal vesicle: 5.8	Cell line enhanced		A549: 5.6;AF22: 5.6
CPNE5	COPN5, CPN5, KIAA1599	ENSG00000124772	Copine 5	6	36740775-36840002	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031369	Uncertain		Approved	Cytosol	Head and neck cancer:2.87e-5 (favourable), Renal cancer:6.00e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 119.0	testis: 34.4	Cell line enhanced		Daudi: 42.5;HUVEC TERT2: 19.9;U-266/70: 15.0;U-266/84: 11.9;U-698: 19.2
CPNE6		ENSG00000100884	Copine 6	14	24070837-24078100	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031636	Approved					Tissue enhanced	Group enriched	6	cerebral cortex: 88.0;seminal vesicle: 35.2	kidney: 9.7	Cell line enhanced		U-266/84: 1.3
CPNE7		ENSG00000178773	Copine 7	16	89575768-89597246	Predicted intracellular proteins	Evidence at protein level	HPA043359	Uncertain				Renal cancer:9.52e-6 (unfavourable), Urothelial cancer:7.22e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 23.6	cerebral cortex: 9.8	Cell line enhanced		HHSteC: 87.2
CPNE8		ENSG00000139117	Copine 8	12	38646822-38907430	Predicted intracellular proteins	Evidence at protein level	HPA038600	Approved				Stomach cancer:2.11e-4 (unfavourable)	Expressed in all	Mixed			placenta: 17.2	Cell line enhanced		RPTEC TERT1: 49.5
CPNE9	KIAA4217	ENSG00000144550	Copine family member 9	3	9703807-9729908	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	5	cerebral cortex: 12.6	testis: 2.3	Cell line enhanced		Daudi: 1.6;U-937: 1.6
CPPED1	CSTP1, FLJ11151	ENSG00000103381	Calcineurin like phosphoesterase domain containing 1	16	12659799-12804017	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040938, HPA041970	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.62e-9 (favourable), Breast cancer:9.72e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 41.0	Cell line enhanced		Hep G2: 97.8;HMC-1: 114.2
CPS1		ENSG00000021826	Carbamoyl-phosphate synthase 1	2	210477682-210679107	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003781, HPA021400	Enhanced		Approved	Nucleoli	Liver cancer:6.93e-5 (favourable)	Tissue enriched	Group enriched	23	duodenum: 234.5;liver: 697.8;small intestine: 144.1	testis: 15.3	Cell line enhanced		HeLa: 249.1;SK-BR-3: 84.1
CPSF1		ENSG00000071894	Cleavage and polyadenylation specific factor 1	8	144393229-144409349	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065167, HPA068906			Enhanced	Nucleoplasm	Renal cancer:6.54e-5 (unfavourable), Liver cancer:8.64e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.5	Expressed in all		
CPSF2	KIAA1367	ENSG00000165934	Cleavage and polyadenylation specific factor 2	14	92121937-92172145	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024238	Supported		Approved	Nucleoplasm<br>Vesicles	Liver cancer:4.35e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 47.7	Expressed in all		
CPSF3	CPSF-73, CPSF73, YSH1	ENSG00000119203	Cleavage and polyadenylation specific factor 3	2	9423568-9473101	Predicted intracellular proteins	Evidence at protein level	HPA034657	Uncertain				Liver cancer:3.64e-5 (unfavourable), Renal cancer:3.93e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 87.5	Expressed in all		
CPSF4	CPSF30, NAR	ENSG00000160917	Cleavage and polyadenylation specific factor 4	7	99438922-99457371	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049094, HPA066470	Uncertain		Supported	Nucleoplasm	Renal cancer:1.68e-4 (unfavourable), Liver cancer:5.87e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.8	Expressed in all		
CPSF4L		ENSG00000187959	Cleavage and polyadenylation specific factor 4 like	17	73248449-73262352	Predicted intracellular proteins	Evidence at transcript level	HPA044047	Uncertain					Not detected	Not detected			testis: 0.9	Cell line enriched	7	Hep G2: 2.0
CPSF6	CFIM, CFIM68, HPBRII-4, HPBRII-7	ENSG00000111605	Cleavage and polyadenylation specific factor 6	12	69239537-69274358	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039973	Supported		Enhanced	Nucleoplasm<br>Nuclear speckles	Liver cancer:1.91e-6 (unfavourable), Renal cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 55.2	Expressed in all		
CPSF7	FLJ12529	ENSG00000149532	Cleavage and polyadenylation specific factor 7	11	61402641-61430031	Predicted intracellular proteins	Evidence at protein level	HPA041094	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.83e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 76.2	Expressed in all		
CPT2	CPT1, CPTASE	ENSG00000157184	Carnitine palmitoyltransferase 2	1	53196429-53214197	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028201, HPA028202, HPA028214	Enhanced		Supported	Nucleoplasm<br>Nucleoli<br>Mitochondria	Renal cancer:1.46e-12 (favourable), Colorectal cancer:5.27e-4 (favourable)	Expressed in all	Expressed in all			liver: 25.9	Expressed in all		
CPTP	GLTPD1, MGC10334	ENSG00000224051	Ceramide-1-phosphate transfer protein	1	1324756-1328897	Predicted intracellular proteins	Evidence at protein level	HPA056832	Approved		Approved	Cytosol	Renal cancer:1.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 47.0	Expressed in all		
CPXCR1	CT77	ENSG00000147183	CPX chromosome region, candidate 1	X	88747225-88754785	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	57	testis: 11.5	fallopian tube: 0.2	Not detected		
CRABP1	CRABP, CRABP-I, CRABPI, RBP5	ENSG00000166426	Cellular retinoic acid binding protein 1	15	78340324-78348230	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017203	Approved	Supported			Endometrial cancer:4.72e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 269.2	seminal vesicle: 64.5	Group enriched	7	AF22: 952.0;NTERA-2: 289.5
CRABP2	CRABP-II	ENSG00000143320	Cellular retinoic acid binding protein 2	1	156699606-156705816	Predicted intracellular proteins	Evidence at protein level	HPA004135	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.19e-13 (unfavourable), Endometrial cancer:2.11e-5 (unfavourable)	Expressed in all	Tissue enriched	5	esophagus: 1042.5	skin: 193.5	Cell line enhanced		BJ hTERT+: 1263.6;MCF7: 468.2;T-47d: 1127.9
CRACR2A	EFCAB4B, MGC4266	ENSG00000130038	Calcium release activated channel regulator 2A	12	3606633-3764819	Predicted intracellular proteins	Evidence at protein level	HPA038686	Enhanced				Prostate cancer:2.85e-6 (favourable)	Mixed	Mixed			salivary gland: 15.1	Mixed		
CRACR2B	EFCAB4A, MGC45840	ENSG00000177685	Calcium release activated channel regulator 2B	11	826144-831991	Predicted intracellular proteins	Evidence at protein level	HPA046217	Approved				Colorectal cancer:1.81e-5 (unfavourable)	Expressed in all	Tissue enhanced		salivary gland: 120.0	stomach: 56.6	Cell line enhanced		HDLM-2: 30.7;SK-BR-3: 92.6
CRADD	RAIDD	ENSG00000169372	CASP2 and RIPK1 domain containing adaptor with death domain	12	93677375-93894840	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB005337	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:4.04e-9 (favourable), Cervical cancer:9.06e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.8	Expressed in all		
CRAMP1	CRAMP1L, KIAA1426	ENSG00000007545	Cramped chromatin regulator homolog 1	16	1612325-1677908	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041752	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Stomach cancer:4.93e-4 (favourable)	Expressed in all	Mixed			testis: 31.8	Expressed in all		
CRAT	CAT1	ENSG00000095321	Carnitine O-acetyltransferase	9	129094810-129111189	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA019230, HPA020260, HPA022815	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:0.00e+0 (favourable), Endometrial cancer:2.36e-4 (favourable)	Expressed in all	Expressed in all			testis: 116.0	Mixed		
CRBN	MRT2, MRT2A	ENSG00000113851	Cereblon	3	3144628-3179727	Disease related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045910	Approved		Approved	Nucleoli		Expressed in all	Expressed in all			testis: 87.7	Expressed in all		
CRCP	CGRP-RCP, RCP, RCP9	ENSG00000241258	CGRP receptor component	7	66114604-66154568	Predicted intracellular proteins	Evidence at protein level	HPA007216	Approved		Approved	Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 32.1	Expressed in all		
CRCT1	C1orf42, NICE-1	ENSG00000169509	Cysteine rich C-terminal 1	1	152514502-152516010	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:7.03e-4 (unfavourable)	Tissue enhanced	Group enriched	11	esophagus: 84.0;skin: 82.8;tonsil: 17.6	breast: 5.6	Cell line enriched	14	CAPAN-2: 4.5
CREB1		ENSG00000118260	CAMP responsive element binding protein 1	2	207529737-207603431	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003803, HPA019150	Supported		Enhanced	Nucleoplasm	Liver cancer:2.77e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 59.1	Expressed in all		
CREB5	CRE-BPA, H_GS165L15.1	ENSG00000146592	CAMP responsive element binding protein 5	7	28299321-28825894	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050020, HPA061622			Approved	Nucleus<br>Vesicles<br>Plasma membrane		Mixed	Mixed			gallbladder: 18.6	Cell line enhanced		HL-60: 49.5
CREBBP	CBP, KAT3A, RSTS, RTS	ENSG00000005339	CREB binding protein	16	3725054-3880726	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004212, HPA055861	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.24e-5 (favourable)	Expressed in all	Expressed in all			testis: 61.7	Expressed in all		
CREBL2		ENSG00000111269	CAMP responsive element binding protein like 2	12	12611827-12645108	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043738	Uncertain		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:2.26e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 173.3	Expressed in all		
CREBRF	C5orf41, LRF	ENSG00000164463	CREB3 regulatory factor	5	173056352-173139284	Predicted intracellular proteins	Evidence at protein level	HPA015329			Supported	Nucleus	Renal cancer:3.20e-7 (favourable), Urothelial cancer:9.30e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 43.6	Mixed		
CREBZF	ZF	ENSG00000137504	CREB/ATF bZIP transcription factor	11	85659708-85682908	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021526, HPA063652	Uncertain		Approved	Nucleus<br>Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 31.7	Expressed in all		
CREM	hCREM-2	ENSG00000095794	CAMP responsive element modulator	10	35126791-35212958	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001818, CAB018352	Enhanced		Supported	Nucleus<br>Vesicles	Renal cancer:1.23e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 339.8	Expressed in all		
CRIP1	CRIP	ENSG00000213145	Cysteine rich protein 1	14	105486317-105488947	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042462	Approved		Uncertain	Nuclear speckles<br>Centrosome<br>Cytosol		Mixed	Expressed in all			small intestine: 546.1	Cell line enhanced		A549: 1118.8;CAPAN-2: 599.1;HaCaT: 653.1;HDLM-2: 498.2;T-47d: 892.4
CRIP2	CRP2, ESP1	ENSG00000182809	Cysteine rich protein 2	14	105472962-105480170	Predicted intracellular proteins	Evidence at protein level	HPA042664	Approved		Approved	Nucleus<br>Nucleoli<br>Plasma membrane		Expressed in all	Tissue enhanced		heart muscle: 315.6	fallopian tube: 115.7	Cell line enhanced		MCF7: 206.8
CRIP3	bA480N24.2, TLP, TLP-A	ENSG00000146215	Cysteine rich protein 3	6	43299710-43308797	Predicted intracellular proteins	Evidence at protein level	HPA036198	Uncertain		Approved	Nuclear speckles		Tissue enhanced	Tissue enhanced		heart muscle: 15.9;testis: 15.5	seminal vesicle: 11.8	Cell line enhanced		HAP1: 2.9;HEK93: 3.1;HeLa: 2.4;Hep G2: 4.5;NTERA-2: 5.8;RPMI-8226: 3.4
CRIPAK	FLJ34443	ENSG00000179979	Cysteine rich PAK1 inhibitor	4	1391552-1395989	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:1.55e-4 (favourable), Head and neck cancer:4.37e-4 (favourable)	Expressed in all	Mixed			skin: 15.0	Mixed		
CRIPT	HSPC139	ENSG00000119878	CXXC repeat containing interactor of PDZ3 domain	2	46616416-46625742	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046080, HPA056765	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:1.19e-4 (unfavourable), Renal cancer:5.54e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.5	Expressed in all		
CRISPLD1	Cocoacrisp, DKFZp762F133, LCRISP1	ENSG00000121005	Cysteine rich secretory protein LCCL domain containing 1	8	74984515-75034558	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024725	Uncertain					Tissue enhanced	Tissue enhanced		prostate: 39.6	breast: 35.0	Group enriched	5	AF22: 132.6;SH-SY5Y: 76.5
CRK		ENSG00000167193	CRK proto-oncogene, adaptor protein	17	1420689-1463162	Predicted intracellular proteins	Evidence at protein level	CAB010485, HPA068087	Approved		Approved	Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 61.0	Expressed in all		
CRKL		ENSG00000099942	CRK like proto-oncogene, adaptor protein	22	20917426-20953749	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000532, HPA001100	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:8.82e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 53.4	Expressed in all		
CRLF3	CREME9, CYTOR4	ENSG00000176390	Cytokine receptor like factor 3	17	30769388-30824776	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007596	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.31e-7 (unfavourable)	Expressed in all	Mixed			lymph node: 39.3	Expressed in all		
CRMP1	DPYSL1, DRP-1	ENSG00000072832	Collapsin response mediator protein 1	4	5748084-5893058	Predicted intracellular proteins	Evidence at protein level	HPA035640, CAB037313	Approved		Supported	Centrosome<br>Cytosol	Pancreatic cancer:4.54e-4 (favourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 133.7	endometrium: 24.5	Cell line enhanced		HAP1: 120.7;REH: 208.7;RH-30: 125.4;SCLC-21H: 196.8;SH-SY5Y: 112.2
CRNKL1	CLF, Clf1, CRN, SYF3	ENSG00000101343	Crooked neck pre-mRNA splicing factor 1	20	20034368-20056046	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:8.06e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.1	Expressed in all		
CRNN	C1orf10, SEP53	ENSG00000143536	Cornulin	1	152409243-152414263	Predicted intracellular proteins	Evidence at protein level	HPA024343, CAB026182	Enhanced					Group enriched	Tissue enriched	20	esophagus: 4518.8	tonsil: 225.3	Not detected		
CROCC	ROLT, rootletin	ENSG00000058453	Ciliary rootlet coiled-coil, rootletin	1	16740273-16972979	Predicted intracellular proteins	Evidence at protein level	HPA021191, HPA021762	Enhanced		Supported	Plasma membrane<br>Centrosome	Endometrial cancer:8.34e-5 (favourable), Lung cancer:7.92e-4 (favourable), Renal cancer:7.97e-4 (unfavourable)	Expressed in all	Mixed			skin: 11.6	Mixed		
CROCC2		ENSG00000226321	Ciliary rootlet coiled-coil, rootletin family member 2	2	240906330-240993311	Predicted intracellular proteins	Evidence at protein level	HPA048678	Enhanced					Tissue enhanced	Group enriched	5	fallopian tube: 8.6;spleen: 3.1	lung: 1.1	Cell line enhanced		RPMI-8226: 1.9
CROT	COT	ENSG00000005469	Carnitine O-octanoyltransferase	7	87345681-87399795	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA019052, HPA019364, HPA019365	Enhanced		Supported	Vesicles	Renal cancer:2.55e-6 (favourable), Urothelial cancer:4.02e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 68.4	Cell line enhanced		RT4: 57.9
CRTC1	FLJ14027, KIAA0616, MECT1, TORC1	ENSG00000105662	CREB regulated transcription coactivator 1	19	18683677-18782333	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022035	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.80e-5 (favourable), Renal cancer:3.83e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 23.7	Expressed in all		
CRTC2	TORC2	ENSG00000160741	CREB regulated transcription coactivator 2	1	153947669-153958625	Predicted intracellular proteins	Evidence at protein level	HPA028454, HPA028465	Supported		Enhanced	Nucleoplasm	Renal cancer:1.35e-7 (unfavourable), Urothelial cancer:6.12e-5 (favourable), Colorectal cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 36.0	Expressed in all		
CRTC3	FLJ21868	ENSG00000140577	CREB regulated transcription coactivator 3	15	90529925-90645345	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA043735, HPA063691	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			ovary: 50.7	Mixed		
CRX	CORD2, CRD, LCA7, OTX3	ENSG00000105392	Cone-rod homeobox	19	47819779-47843330	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036762, HPA036763	Enhanced					Not detected	Not detected			testis: 0.3	Not detected		
CRY1	PHLL1	ENSG00000008405	Cryptochrome circadian clock 1	12	106991364-107093829	Predicted intracellular proteins	Evidence at protein level	CAB018762	Approved		Supported	Nucleus<br>Nuclear membrane<br>Microtubules		Expressed in all	Expressed in all			testis: 62.1	Mixed		
CRYAA	CRYA1, HSPB4	ENSG00000160202	Crystallin alpha A	21	43169008-43172805	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037737, HPA038430	Supported		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	8	kidney: 12.3	liver: 1.5	Cell line enriched	95	Hep G2: 25.4
CRYBA1	CRYB1	ENSG00000108255	Crystallin beta A1	17	29246863-29254494	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022016	Supported					Not detected	Not detected			appendix: 0.2	Group enriched	8	AF22: 3.2;BEWO: 4.1
CRYBA2		ENSG00000163499	Crystallin beta A2	2	218990189-218993421	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA062293	Supported				Pancreatic cancer:7.62e-4 (favourable)	Tissue enriched	Tissue enhanced		adrenal gland: 4.6;stomach: 4.6	small intestine: 3.0	Cell line enriched	6	BEWO: 69.8
CRYBA4		ENSG00000196431	Crystallin beta A4	22	26621964-26630672	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA071178	Supported					Tissue enhanced	Tissue enhanced		epididymis: 1.8	testis: 0.7	Group enriched	7	HEL: 6.5;HMC-1: 1.4
CRYBB1		ENSG00000100122	Crystallin beta B1	22	26599278-26618088	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003448, CAB010058	Supported					Mixed	Tissue enhanced		epididymis: 10.9	placenta: 4.5	Cell line enhanced		HMC-1: 9.9;Karpas-707: 29.5;RPMI-8226: 53.1
CRYBB2	CCA2, CRYB2, CRYB2A	ENSG00000244752	Crystallin beta B2	22	25219522-25231869	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043749	Supported		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 1.5	breast,epididymis,lung,thyroid gland: 0.4	Not detected		
CRYBB3	CRYB3	ENSG00000100053	Crystallin beta B3	22	25199850-25207363	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055840	Supported					Mixed	Mixed			thyroid gland: 2.1	Cell line enhanced		HaCaT: 1.2;HEK93: 1.3
CRYBG3	DKFZp667G2110	ENSG00000080200	Crystallin beta-gamma domain containing 3	3	97822040-97944963	Predicted intracellular proteins	Evidence at protein level	HPA044122			Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.07e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 45.8	testis: 25.6	Cell line enhanced		SCLC-21H: 47.0
CRYGA	CRY-g-A, CRYG1, CRYG5	ENSG00000168582	Crystallin gamma A	2	208160740-208163576	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			cerebral cortex,testis: 0.1	Not detected		
CRYGB	CRYG2	ENSG00000182187	Crystallin gamma B	2	208142573-208146168	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Group enriched	Not detected			testis: 0.5	Not detected		
CRYGC	CRYG3	ENSG00000163254	Crystallin gamma C	2	208128137-208129830	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	testis: 2.6	epididymis: 0.3	Not detected		
CRYGD	CRYG4	ENSG00000118231	Crystallin gamma D	2	208121607-208124501	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041269			Approved	Plasma membrane<br>Intermediate filaments<br>Cytokinetic bridge		Tissue enhanced	Tissue enriched	13	ovary: 21.6	bone marrow: 1.6	Cell line enriched	17	HEL: 19.0
CRYGN		ENSG00000127377	Crystallin gamma N	7	151428835-151440813	Predicted intracellular proteins	Evidence at transcript level	HPA050788	Uncertain					Tissue enriched	Group enriched	6	seminal vesicle: 10.2;thyroid gland: 32.3	parathyroid gland: 3.4	Cell line enhanced		CACO-2: 1.1;HHSteC: 1.4;SCLC-21H: 2.0
CRYGS	CRYG8	ENSG00000213139	Crystallin gamma S	3	186538441-186546702	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035103	Uncertain		Uncertain	Cytosol	Renal cancer:3.72e-9 (unfavourable), Urothelial cancer:2.73e-4 (favourable)	Expressed in all	Mixed			lymph node,spleen: 4.1	Mixed		
CRYL1	GDH, lambda-CRY, MGC149525, MGC149526	ENSG00000165475	Crystallin lambda 1	13	20403667-20525857	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040403	Enhanced		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Plasma membrane	Renal cancer:2.30e-9 (favourable), Endometrial cancer:1.76e-5 (favourable)	Expressed in all	Expressed in all			kidney: 338.1	Mixed		
CRYM	DFNA40	ENSG00000103316	Crystallin mu	16	21238874-21303083	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019086, HPA030619	Enhanced		Supported	Cytosol		Tissue enhanced	Group enriched	6	cerebral cortex: 51.1;heart muscle: 47.8;kidney: 28.4;prostate: 24.7;urinary bladder: 14.8	lung: 5.7	Cell line enhanced		HEL: 9.4;RPTEC TERT1: 32.9;U-87 MG: 8.7
CRYZ		ENSG00000116791	Crystallin zeta	1	74705482-74733408	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021921, HPA023290	Approved		Supported	Cytosol		Expressed in all	Expressed in all			kidney: 345.5	Expressed in all		
CRYZL1	4P11, QOH-1	ENSG00000205758	Crystallin zeta like 1	21	33589341-33643926	Predicted intracellular proteins	Evidence at protein level	HPA019120, HPA029399, CAB034129	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 62.0	Expressed in all		
CSAG1	CSAGE, CT24.1	ENSG00000198930	Chondrosarcoma associated gene 1	X	152727484-152733735	Predicted intracellular proteins	Evidence at transcript level	HPA078264			Approved	Vesicles		Mixed	Tissue enhanced		testis: 2.4	lymph node: 0.8	Cell line enhanced		HMC-1: 57.5;K-562: 39.8;PC-3: 55.8;SH-SY5Y: 39.1;U-266/70: 79.2
CSAG2	CSAG3B, CT24.2, TRAG3	ENSG00000268902	CSAG family member 2	X	152708261-152714549	Predicted intracellular proteins	Evidence at transcript level	HPA078264			Approved	Vesicles		Mixed	Not detected			lymph node,testis: 0.9	Cell line enhanced		HMC-1: 13.5;SK-BR-3: 4.8;U-266/70: 3.9;U-266/84: 4.7
CSAG3	CSAG3A	ENSG00000268916	CSAG family member 3	X	152753921-152760222	Predicted intracellular proteins	Evidence at transcript level	HPA078264			Approved	Vesicles		Mixed	Group enriched	10	lymph node: 1.7;skin: 1.2;spleen: 1.9;testis: 4.2	adipose tissue,lung,placenta: 0.2	Cell line enhanced		HDLM-2: 23.7;HMC-1: 22.9;SH-SY5Y: 35.8;SK-BR-3: 23.6;U-2 OS: 25.4;U-266/70: 61.5;U-266/84: 30.6
CSDC2	PIPPin	ENSG00000172346	Cold shock domain containing C2	22	41560763-41577741	Predicted intracellular proteins	Evidence at protein level	HPA003073, HPA076549	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.42e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 62.5;ovary: 72.0	heart muscle: 45.3	Cell line enriched	6	U-2 OS: 40.5
CSDE1	D1S155E, UNR	ENSG00000009307	Cold shock domain containing E1	1	114716913-114758676	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018846, HPA052221	Enhanced		Enhanced	Cytosol		Expressed in all	Expressed in all			skeletal muscle: 490.3	Expressed in all		
CSE1L	CAS, CSE1, XPO2	ENSG00000124207	Chromosome segregation 1 like	20	49046246-49096960	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB002140, HPA038059, HPA038060	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.42e-8 (unfavourable), Endometrial cancer:2.91e-5 (unfavourable), Renal cancer:1.89e-4 (unfavourable), Urothelial cancer:6.91e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 159.7	Expressed in all		
CSGALNACT2	GALNACT-2, GALNACT2, MGC40204, PRO0082	ENSG00000169826	Chondroitin sulfate N-acetylgalactosaminyltransferase 2	10	43138486-43185308	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031540	Approved		Approved	Endoplasmic reticulum	Renal cancer:3.53e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 87.2	Expressed in all		
CSK		ENSG00000103653	C-src tyrosine kinase	15	74782057-74803198	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011203, HPA026488, HPA028425	Approved	Approved	Approved	Vesicles<br>Cytosol	Cervical cancer:5.14e-5 (favourable), Stomach cancer:1.07e-4 (favourable), Renal cancer:1.74e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 195.2	Expressed in all		
CSNK1A1	CK1, CK1a, CK1alpha, CKIa, CKIalpha	ENSG00000113712	Casein kinase 1 alpha 1	5	149492197-149551552	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016680, HPA051334	Uncertain		Approved	Cytosol	Colorectal cancer:1.15e-4 (favourable), Pancreatic cancer:5.79e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 219.6	Expressed in all		
CSNK1A1L	MGC33182	ENSG00000180138	Casein kinase 1 alpha 1 like	13	37103259-37105664	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA051334			Approved	Cytosol		Not detected	Tissue enriched	16	testis: 6.4	bone marrow: 0.3	Not detected		
CSNK1D	CKID, CKIdelta, HCKID	ENSG00000141551	Casein kinase 1 delta	17	82239023-82273731	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015410	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:2.38e-6 (unfavourable), Pancreatic cancer:9.62e-5 (favourable), Endometrial cancer:7.04e-4 (unfavourable), Renal cancer:8.34e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 66.9	Expressed in all		
CSNK1E	CKIE, CKIepsilon, HCKIE	ENSG00000213923	Casein kinase 1 epsilon	22	38290691-38318084	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009626, HPA026288	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:4.67e-6 (unfavourable), Liver cancer:8.20e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 171.1	Expressed in all		
CSNK1G2	CK1g2	ENSG00000133275	Casein kinase 1 gamma 2	19	1941149-1981338	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034868, HPA056572	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			testis: 76.8	Expressed in all		
CSNK1G3		ENSG00000151292	Casein kinase 1 gamma 3	5	123512099-123617045	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027010	Approved				Colorectal cancer:9.90e-5 (favourable)	Expressed in all	Expressed in all			testis: 28.4	Mixed		
CSNK2A1		ENSG00000101266	Casein kinase 2 alpha 1	20	473591-543821	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB020680, HPA059206, HPA061698, CAB069395	Enhanced		Supported	Nucleoplasm	Liver cancer:4.11e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 129.5	Expressed in all		
CSNK2A2	CK2alpha', CSNK2A1	ENSG00000070770	Casein kinase 2 alpha 2	16	58157907-58197920	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA077719			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Head and neck cancer:1.40e-5 (unfavourable), Liver cancer:1.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 237.6	Expressed in all		
CSNK2A3	CSNK2A1P	ENSG00000254598	Casein kinase 2 alpha 3	11	11351942-11353357	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059206, HPA061698	Uncertain		Approved	Nucleoplasm		Mixed	Not detected			testis: 0.5	Cell line enhanced		A-431: 2.1
CSNK2B		ENSG00000204435	Casein kinase 2 beta	6	31665236-31670343	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004349, HPA005944, CAB013087, CAB016059	Approved				Renal cancer:1.06e-5 (unfavourable)	Expressed in all	Mixed			epididymis: 55.3	Mixed		
CSPP1	CSPP, FLJ22490, JBTS21	ENSG00000104218	Centrosome and spindle pole associated protein 1	8	67062426-67196263	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056174			Supported	Microtubule organizing center	Thyroid cancer:2.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.9	Expressed in all		
CSRNP1	AXUD1, DKFZp566F164, FAM130B, TAIP-3, URAX1	ENSG00000144655	Cysteine and serine rich nuclear protein 1	3	39141855-39154562	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045207, HPA058463			Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:1.07e-4 (favourable), Stomach cancer:6.47e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 123.5	Cell line enhanced		SK-BR-3: 48.5
CSRNP2	C12ORF2, C12orf22, FAM130A1, PPP1R72, TAIP-12	ENSG00000110925	Cysteine and serine rich nuclear protein 2	12	51061205-51083664	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018503, HPA019914	Approved		Approved	Nuclear speckles	Liver cancer:1.08e-4 (unfavourable), Urothelial cancer:2.78e-4 (favourable), Renal cancer:6.51e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.2	Expressed in all		
CSRNP3	FAM130A2, FLJ32093, PPP1R73, TAIP-2	ENSG00000178662	Cysteine and serine rich nuclear protein 3	2	165469647-165689407	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017905	Supported		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		cerebral cortex: 16.1	endometrium: 4.6	Group enriched	5	AF22: 9.7;PC-3: 2.2;SCLC-21H: 8.4;SH-SY5Y: 6.2
CSRP1	CSRP, CYRP, D1S181E	ENSG00000159176	Cysteine and glycine rich protein 1	1	201483530-201509456	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045617	Uncertain				Renal cancer:2.11e-4 (unfavourable), Head and neck cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 3310.4	Mixed		
CSRP2	CRP2, LMO5, SmLIM	ENSG00000175183	Cysteine and glycine rich protein 2	12	76858715-76879060	Predicted intracellular proteins	Evidence at protein level	HPA045617	Uncertain				Renal cancer:4.48e-5 (unfavourable), Prostate cancer:8.52e-4 (favourable)	Expressed in all	Mixed			placenta: 114.6	Cell line enhanced		AF22: 320.2
CSRP3	CLP, CMD1M, MLP	ENSG00000129170	Cysteine and glycine rich protein 3	11	19182030-19210573	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042581	Enhanced					Tissue enriched	Group enriched	25	heart muscle: 1501.4;skeletal muscle: 467.9	prostate: 40.1	Not detected		
CSTA	STF1, STFA	ENSG00000121552	Cystatin A	3	122325244-122341972	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000469, HPA001031, CAB047315	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:2.60e-6 (unfavourable), Head and neck cancer:5.86e-4 (favourable)	Expressed in all	Group enriched	5	esophagus: 3876.3;tonsil: 833.8	skin: 429.8	Cell line enhanced		hTCEpi: 870.0;THP-1: 525.5;U-698: 341.3
CSTB	CST6, EPM1, PME, STFB	ENSG00000160213	Cystatin B	21	43772511-43776445	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA017380, CAB047320, HPA058557	Enhanced		Supported	Nucleoli<br>Cytosol	Liver cancer:6.66e-5 (unfavourable), Renal cancer:2.10e-4 (unfavourable)	Expressed in all	Tissue enriched	8	esophagus: 1822.8	tonsil: 228.0	Expressed in all		
CSTF1		ENSG00000101138	Cleavage stimulation factor subunit 1	20	56392371-56406369	Predicted intracellular proteins	Evidence at protein level	CAB019270, HPA047275, HPA065000	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
CSTF2	CstF-64	ENSG00000101811	Cleavage stimulation factor subunit 2	X	100820359-100840932	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000427, CAB004680	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:8.23e-6 (unfavourable), Renal cancer:1.12e-4 (favourable)	Expressed in all	Mixed			testis: 25.7	Expressed in all		
CSTF2T	CstF-64T, DKFZp434C1013, KIAA0689, tauCstF-64	ENSG00000177613	Cleavage stimulation factor subunit 2 tau variant	10	51695487-51699591	Predicted intracellular proteins	Evidence at protein level	HPA039216, HPA062021	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 37.6	Expressed in all		
CSTF3	CstF-77	ENSG00000176102	Cleavage stimulation factor subunit 3	11	33077188-33162371	Predicted intracellular proteins	Evidence at protein level	HPA039743, HPA040168	Enhanced		Enhanced	Nucleoplasm	Liver cancer:8.20e-6 (unfavourable), Renal cancer:1.61e-5 (unfavourable), Colorectal cancer:1.63e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 76.3	Expressed in all		
CT45A1	CT45-1, CT45.1	ENSG00000268940	Cancer/testis antigen family 45 member A1	X	135713453-135723539	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enriched	42	testis: 12.5	cerebral cortex,lung: 0.2	Group enriched	6	HMC-1: 202.8;Karpas-707: 77.5
CT45A10		ENSG00000269586	Cancer/testis antigen family 45 member A10	X	135881063-135889086	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enriched	23	testis: 16.5	cerebral cortex: 0.7	Cell line enhanced		AN3-CA: 78.6;K-562: 23.7;Karpas-707: 67.5;U-266/84: 58.7
CT45A2	CT45-2, CT45.2	ENSG00000271449	Cancer/testis antigen family 45 member A2	X	135811668-135820012	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	14	testis: 1.4	all non-specific tissues: 0.0	Group enriched	5	AN3-CA: 10.0;HMC-1: 43.4
CT45A3	CT45-3, CT45-4, CT45.3, CT45.4, CT45A4	ENSG00000269096	Cancer/testis antigen family 45 member A3	X	135759846-135768191	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	15	testis: 20.5	lung: 1.3	Group enriched	6	HMC-1: 108.1;T-47d: 68.5;U-266/84: 279.7
CT45A5	CT45-5, CT45.5	ENSG00000228836	Cancer/testis antigen family 45 member A5	X	135777130-135785298	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	62	testis: 8.6	cerebral cortex: 0.1	Cell line enhanced		HMC-1: 47.9;Karpas-707: 27.5;U-266/84: 147.8
CT45A6	CT45-6, CT45.6	ENSG00000278289	Cancer/testis antigen family 45 member A6	X	135794706-135802656	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Not detected			testis: 0.7	Cell line enriched	7	U-266/84: 72.2
CT45A7		ENSG00000273696	Cancer/testis antigen family 45 member A7	X	135829247-135837268	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	6	testis: 1.5	cerebral cortex,lung: 0.2	Not detected		
CT45A8		ENSG00000278085	Cancer/testis antigen family 45 member A8	X	135846499-135854538	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	12	testis: 1.2	all non-specific tissues: 0.0	Group enriched	6	AN3-CA: 18.9;HMC-1: 39.4
CT45A9		ENSG00000270946	Cancer/testis antigen family 45 member A9	X	135863776-135871812	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	13	testis: 1.2	all non-specific tissues: 0.0	Cell line enriched	8	HMC-1: 113.9
CT47A1	CT47.1	ENSG00000236371	Cancer/testis antigen family 47, member A1	X	120982476-120985788	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	15	testis: 1.4	all non-specific tissues: 0.0	Cell line enriched	8	U-266/70: 1.7
CT47A10	CT47.10	ENSG00000224089	Cancer/testis antigen family 47, member A10	X	120938701-120942023	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
CT47A11	CT47.11	ENSG00000226929	Cancer/testis antigen family 47, member A11	X	120933840-120937158	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	37	testis: 3.7	all non-specific tissues: 0.0	Not detected		
CT47A12	CT47.12	ENSG00000226685	Cancer/testis antigen family 47, member A12	X	120930250-120932301	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	23	testis: 2.3	all non-specific tissues: 0.0	Not detected		
CT47A2	CT47.2	ENSG00000242362	Cancer/testis antigen family 47, member A2	X	120977606-120980928	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
CT47A3	CT47.3	ENSG00000236126	Cancer/testis antigen family 47, member A3	X	120972746-120976068	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
CT47A4	CT47.4	ENSG00000230594	Cancer/testis antigen family 47, member A4	X	120967886-120971208	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
CT47A5	CT47.5	ENSG00000237957	Cancer/testis antigen family 47, member A5	X	120963026-120966348	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
CT47A6	CT47.6	ENSG00000226023	Cancer/testis antigen family 47, member A6	X	120958165-120961487	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Not detected			testis: 0.5	Not detected		
CT47A7	CT47.7	ENSG00000228517	Cancer/testis antigen family 47, member A7	X	120953288-120956600	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Not detected			testis: 0.1	Not detected		
CT47A8	CT47.8	ENSG00000230347	Cancer/testis antigen family 47, member A8	X	120948422-120951744	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
CT47A9	CT47.9	ENSG00000226600	Cancer/testis antigen family 47, member A9	X	120943561-120946883	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
CT47B1	CT47.13	ENSG00000236446	Cancer/testis antigen family 47, member B1	X	120872603-120875929	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	45	testis: 4.4	all non-specific tissues: 0.0	Not detected		
CT62		ENSG00000225362	Cancer/testis antigen 62	15	71110244-71115494	Predicted intracellular proteins	Evidence at transcript level	HPA045306	Uncertain					Group enriched	Tissue enriched	86	testis: 50.1	prostate: 0.5	Cell line enhanced		HaCaT: 1.4;T-47d: 3.2;U-2197: 2.5
CT83	CXorf61, FLJ20611, FLJ22913, KK-LC-1	ENSG00000204019	Cancer/testis antigen 83	X	116461682-116463003	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	60	testis: 85.3	salivary gland: 1.4	Cell line enhanced		HeLa: 49.1;U-266/70: 77.2;U-266/84: 38.3
CTA-150C2.22		ENSG00000284554	DNA dC->dU-editing enzyme APOBEC-3D 	22	39014363-39033276	Predicted intracellular proteins	Evidence at protein level	HPA055116	Approved						Mixed			fallopian tube: 3.8	Cell line enhanced		fHDF/TERT166: 2.7;HHSteC: 3.4;HSkMC: 2.1;hTEC/SVTERT24-B: 2.0;Karpas-707: 3.5
CTAG1A	ESO1, LAGE2A	ENSG00000268651	Cancer/testis antigen 1A	X	154585143-154586821	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB013061	Enhanced					Not detected	Tissue enriched	37	testis: 4.6	spleen: 0.1	Group enriched	942	U-266/70: 511.5;U-266/84: 120.6
CTAG1B	CT6.1, CTAG, CTAG1, ESO1, LAGE2A, LAGE2B, NY-ESO-1	ENSG00000184033	Cancer/testis antigen 1B	X	154617609-154619282	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB015453	Enhanced					Not detected	Tissue enriched	55	testis: 5.4	all non-specific tissues: 0.0	Group enriched	1072	U-266/70: 579.6;U-266/84: 139.5
CTAG2	CAMEL, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE-1a, LAGE-1b, LAGE1, MGC138724, MGC3803	ENSG00000126890	Cancer/testis antigen 2	X	154651972-154653579	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA071467	Enhanced				Liver cancer:2.35e-4 (unfavourable)	Mixed	Group enriched	8	fallopian tube: 2.6;heart muscle: 3.2;placenta: 3.6;skeletal muscle: 1.2;testis: 6.0	pancreas: 0.4	Group enriched	29	K-562: 126.4;RPMI-8226: 215.0;SK-BR-3: 146.5;U-266/84: 251.9
CTB-102L5.4		ENSG00000267748		19	38289151-38304910	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		salivary gland: 5.5	thyroid gland: 2.9	Cell line enhanced		A-431: 2.2;SK-BR-3: 3.5;U-266/84: 1.9
CTB-25J19.1		ENSG00000196589		19	7018969-7021450	Predicted intracellular proteins	No evidence	HPA051259	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
CTB-50L17.10		ENSG00000167674	Hepatoma-derived growth factor-related protein 2 	19	4472287-4502211	Predicted intracellular proteins	Evidence at protein level	HPA042559, HPA044208	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:6.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 62.2	Expressed in all		
CTB-54O9.9		ENSG00000267157		19	5784005-5785619	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			testis: 1.0	Mixed		
CTB-60B18.10		ENSG00000268655		19	49017496-49020523	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		pancreas: 1.7;testis: 1.3	stomach: 0.3	Cell line enhanced		HEK93: 1.1
CTB-96E2.2		ENSG00000273171		17	28364288-28368012	Predicted intracellular proteins	No evidence							Not detected	Not detected			liver: 0.6	Not detected		
CTBP1	BARS	ENSG00000159692	C-terminal binding protein 1	4	1211448-1249953	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004217, HPA018987, HPA044971	Approved		Enhanced	Nucleoplasm	Endometrial cancer:4.03e-4 (favourable), Urothelial cancer:8.94e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 141.8	Expressed in all		
CTBP2	ribeye	ENSG00000175029	C-terminal binding protein 2	10	124984317-125161170	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023559, HPA023564, CAB031916, HPA044971, CAB079018	Approved	Supported	Approved	Cytosol	Renal cancer:1.70e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 90.2	Mixed		
CTC-273B12.7		ENSG00000268465		19	48465837-48472431	Predicted intracellular proteins	Evidence at transcript level	HPA060662						Not detected	Tissue enhanced		colon: 1.1;endometrium: 1.3;testis: 2.8	small intestine: 0.6	Cell line enhanced		AN3-CA: 1.0;LHCN-M2: 1.1;U-698: 1.2
CTC-281F24.5		ENSG00000282936		17	6636780-6640316	Predicted intracellular proteins	Evidence at transcript level								Mixed			cerebral cortex: 1.9	Mixed		
CTC-360G5.8		ENSG00000269547		19	38915404-38949855	Predicted intracellular proteins	Evidence at protein level	HPA052730, HPA056957	Uncertain					Not detected	Mixed			ovary: 1.1	Cell line enhanced		A-431: 1.5;A549: 2.1;T-47d: 1.9;U-251 MG: 2.4
CTC-429P9.4		ENSG00000268790		19	16577642-16660115	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			endometrium: 1.3	Cell line enhanced		T-47d: 3.0
CTC-432M15.3		ENSG00000273217		5	131425891-131796983	Predicted intracellular proteins	Evidence at transcript level	HPA037982, HPA037983	Uncertain		Approved	Centrosome<br>Cytosol		Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		A549: 2.2
CTC-435M10.3		ENSG00000255730		19	41350853-41425001	Predicted intracellular proteins	Evidence at protein level	HPA036640	Approved					Not detected	Mixed			cerebral cortex: 9.1	Cell line enhanced		THP-1: 9.6
CTC-441N14.4		ENSG00000250803	Uncharacterized protein LOC100505841 	5	122129622-122183949	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	19	testis: 53.8	fallopian tube: 2.8	Not detected		
CTC-454I21.3		ENSG00000267360		19	37093019-37210512	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex,thyroid gland: 0.8	Not detected		
CTC-479C5.6		ENSG00000263201		16	68013436-68015911	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	8	placenta: 1.2;testis: 3.1	bone marrow: 0.2	Not detected		
CTC-512J12.6		ENSG00000267173		19	44329695-44401608	Predicted intracellular proteins	No evidence							Not detected	Not detected			cervix, uterine: 0.5	Not detected		
CTC-534A2.2		ENSG00000253251		5	65624765-65630891	Predicted intracellular proteins	Evidence at protein level	HPA066071, HPA068764	Approved		Supported	Nucleoplasm<br>Nucleoli	Urothelial cancer:1.17e-4 (favourable)	Expressed in all	Mixed			bone marrow: 10.0	Expressed in all		
CTC1	AAF132, C17orf68, FLJ22170	ENSG00000178971	CST telomere replication complex component 1	17	8224821-8248044	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:6.49e-5 (favourable)	Expressed in all	Expressed in all			spleen: 30.9	Expressed in all		
CTCF		ENSG00000102974	CCCTC-binding factor	16	67562407-67639183	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004122, CAB062550, CAB068181, CAB068182	Supported		Supported	Nucleoplasm	Renal cancer:4.06e-4 (favourable), Liver cancer:4.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 58.6	Expressed in all		
CTD-2006C1.13		ENSG00000267179		19	11925075-11979290	Predicted intracellular proteins	No evidence	HPA047845	Uncertain		Uncertain	Nucleus		Not detected	Not detected			testis: 0.5	Not detected		
CTD-2116N17.1		ENSG00000259316		15	64181180-64381510	Predicted intracellular proteins	Evidence at transcript level	HPA047929			Uncertain	Centrosome		Not detected	Tissue enhanced		lymph node: 31.6;tonsil: 21.4	bone marrow: 14.1	Cell line enhanced		HAP1: 299.5
CTD-2132N18.3		ENSG00000267261		17	42119674-42154916	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			appendix: 0.8	Cell line enhanced		MOLT-4: 2.9;REH: 2.3;U-87 MG: 2.2
CTD-2135J3.4		ENSG00000258724		8	10725399-10839847	Predicted intracellular proteins	Evidence at protein level	HPA009065	Uncertain		Approved	Nuclear speckles<br>Golgi apparatus		Not detected	Not detected			adipose tissue,lung: 0.5	Cell line enhanced		HaCaT: 1.3
CTD-2140B24.4		ENSG00000256825		12	133130984-133202369	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.4	Not detected		
CTD-2192J16.17		ENSG00000196826		19	12461559-12551474	Predicted intracellular proteins	No evidence							Not detected	Not detected			endometrium: 0.7	Not detected		
CTD-2192J16.24		ENSG00000269590		19	12664828-12669397	Predicted intracellular proteins	Evidence at protein level	HPA065685	Uncertain		Approved	Nuclear membrane<br>Endoplasmic reticulum		Not detected	Tissue enhanced		lymph node: 1.9	cerebral cortex,duodenum: 1.3	Cell line enhanced		MCF7: 8.8;RT4: 4.7
CTD-2200P10.1		ENSG00000266826		17	58660424-58692018	Predicted intracellular proteins	Evidence at protein level	HPA000634, HPA001004	Uncertain		Approved	Microtubules		Not detected	Tissue enriched	33	testis: 13.5	placenta: 0.4	Not detected		
CTD-2207O23.12		ENSG00000267952		19	7507052-7519622	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 5.6;skeletal muscle: 4.6	kidney: 2.9	Cell line enhanced		AF22: 10.9;ASC diff: 8.4;fHDF/TERT166: 10.6;HBF TERT88: 6.7
CTD-2207O23.3		ENSG00000268861		19	7382834-7472477	Predicted intracellular proteins	Evidence at protein level	HPA042689, HPA071867	Supported		Uncertain	Cytosol		Not detected	Tissue enhanced		lymph node: 17.2	spleen: 11.9	Cell line enhanced		Daudi: 18.2;MOLT-4: 13.4;REH: 12.3;THP-1: 12.9
CTD-2331H12.8		ENSG00000283088		19	52880663-52962768	Predicted intracellular proteins	Evidence at transcript level	HPA062474			Uncertain	Nucleoplasm<br>Cytoplasmic bodies			Mixed			parathyroid gland: 7.1	Cell line enhanced		RT4: 18.8
CTD-2410N18.5		ENSG00000272772		5	134167170-134226071	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.3	endometrium,heart muscle,small intestine: 0.6	Mixed		
CTD-2510F5.6		ENSG00000265303		17	59197566-59215226	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			endometrium,lymph node: 0.6	Cell line enhanced		NB-4: 7.0;THP-1: 4.0
CTD-2537I9.19		ENSG00000283567		19	55463002-55464707	Predicted intracellular proteins	Evidence at transcript level								Not detected			lung,seminal vesicle,testis: 0.2	Cell line enriched	104	NTERA-2: 10.3
CTD-2545M3.6		ENSG00000142539		19	50415799-50428409	Predicted intracellular proteins	Evidence at transcript level	HPA018523	Uncertain					Not detected	Tissue enhanced		appendix: 1.3;spleen: 1.8	duodenum,lymph node: 0.6	Cell line enhanced		REH: 2.7;U-2 OS: 1.1;U-266/70: 1.2;U-698: 1.3
CTD-2575K13.6		ENSG00000268041		19	41907705-41928516	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		lymph node: 3.4	appendix: 1.7	Group enriched	5	Daudi: 4.5;HMC-1: 3.9;REH: 1.2;U-2 OS: 2.8;U-266/70: 1.8;U-698: 2.6;U-937: 2.1
CTD-2583A14.10		ENSG00000268750		19	57819719-57858941	Predicted intracellular proteins	Evidence at transcript level	HPA056213	Uncertain					Not detected	Mixed			duodenum: 4.9	Cell line enhanced		HEK93: 25.5
CTD-2659N19.11		ENSG00000283980		19	12687998-12688422	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		skin: 1.2;testis: 1.6	thyroid gland: 0.8	Cell line enhanced		HEK93: 2.0;MCF7: 1.6
CTD-3074O7.11		ENSG00000256349		11	66509079-66533613	Predicted intracellular proteins	Evidence at protein level	HPA058283	Uncertain		Uncertain	Midbody		Not detected	Not detected			lymph node: 0.3	Cell line enriched	6	NTERA-2: 11.7
CTD-3088G3.8		ENSG00000188897		16	11359845-11523588	Predicted intracellular proteins	Evidence at transcript level	HPA042154	Uncertain					Not detected	Tissue enhanced		appendix: 5.3;skin: 4.3	testis: 2.8	Cell line enhanced		Daudi: 2.2;HDLM-2: 3.2
CTD-3105H18.16		ENSG00000268870		19	12391949-12441082	Predicted intracellular proteins	Evidence at protein level	HPA003150, HPA018683	Uncertain		Uncertain	Nucleoplasm<br>Microtubule organizing center		Not detected	Not detected			breast,placenta: 0.6	Cell line enhanced		RH-30: 4.0
CTD-3214H19.16		ENSG00000269711		19	7678501-7682854	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		bone marrow: 14.1;lung: 11.8	duodenum: 7.7	Cell line enhanced		EFO-21: 12.1;HMC-1: 18.1;NB-4: 7.8;THP-1: 22.2;U-937: 19.1
CTDP1	FCP1	ENSG00000060069	CTD phosphatase subunit 1	18	79679801-79756623	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB032641, HPA040394, HPA070389	Supported		Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.51e-5 (favourable), Endometrial cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			testis: 19.6	Expressed in all		
CTDSP1	NLIIF, SCP1	ENSG00000144579	CTD small phosphatase 1	2	218398256-218405941	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062654			Supported	Nucleoplasm		Expressed in all	Expressed in all			placenta: 106.8	Expressed in all		
CTDSP2	OS4, PSR2, SCP2	ENSG00000175215	CTD small phosphatase 2	12	57819927-57846739	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA052607	Uncertain		Uncertain	Nucleoplasm		Expressed in all	Expressed in all			lung: 170.1	Cell line enriched	7	RH-30: 1169.3
CTDSPL	C3orf8, HYA22, PSR1, RBSP3, SCP3	ENSG00000144677	CTD small phosphatase like	3	37861960-37984469	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048325	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:6.22e-14 (favourable)	Expressed in all	Expressed in all			skin: 65.7	Mixed		
CTDSPL2	FLJ10523, HSPC129	ENSG00000137770	CTD small phosphatase like 2	15	44427234-44529038	Predicted intracellular proteins	Evidence at protein level	HPA040763, HPA062198	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 37.8	Expressed in all		
CTF1	CT-1, CT1	ENSG00000150281	Cardiotrophin 1	16	30896607-30903560	Predicted intracellular proteins	Evidence at protein level	CAB025853	Uncertain				Glioma:5.72e-5 (unfavourable), Lung cancer:9.87e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 28.7	Mixed		
CTH		ENSG00000116761	Cystathionine gamma-lyase	1	70411218-70439851	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021591, HPA023300	Enhanced				Liver cancer:8.69e-4 (favourable)	Group enriched	Expressed in all			liver: 73.2	Cell line enhanced		Karpas-707: 52.3;SK-MEL-30: 75.8
CTIF	KIAA0427	ENSG00000134030	Cap binding complex dependent translation initiation factor	18	48539046-48863217	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA016865, HPA024801	Uncertain		Supported	Cytosol	Renal cancer:3.18e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 24.9	Mixed		
CTNNA1	CAP102	ENSG00000044115	Catenin alpha 1	5	138610967-138935034	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB021089, HPA046119, HPA063535	Approved		Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:7.34e-7 (favourable), Pancreatic cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 217.1	Mixed		
CTNNA2	CAP-R, CT114	ENSG00000066032	Catenin alpha 2	2	79185231-80648861	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037175	Enhanced					Group enriched	Group enriched	12	cerebral cortex: 111.6;epididymis: 81.5;testis: 32.2	adrenal gland: 6.3	Cell line enhanced		AF22: 7.0;Karpas-707: 5.9;NTERA-2: 6.7;SCLC-21H: 4.5;SH-SY5Y: 11.4
CTNNA3	MGC26194, VR22	ENSG00000183230	Catenin alpha 3	10	65912518-67696169	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061818	Enhanced					Tissue enhanced	Tissue enhanced		cerebral cortex: 8.5;heart muscle: 12.4	liver: 4.4	Cell line enhanced		Daudi: 1.7;NTERA-2: 1.7;RPMI-8226: 1.6;SCLC-21H: 1.8;U-266/70: 5.0
CTNNAL1	alpha-CATU, CLLP	ENSG00000119326	Catenin alpha like 1	9	108942569-109013529	Predicted intracellular proteins	Evidence at protein level						Stomach cancer:3.77e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 263.0	Expressed in all		
CTNNB1	armadillo, beta-catenin, CTNNB	ENSG00000168036	Catenin beta 1	3	41194837-41260096	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000108, CAB001950, HPA029159, HPA029160	Enhanced		Enhanced	Plasma membrane	Colorectal cancer:7.54e-4 (favourable)	Expressed in all	Expressed in all			placenta: 285.6	Expressed in all		
CTNNBIP1	ICAT, MGC15093	ENSG00000178585	Catenin beta interacting protein 1	1	9848276-9910336	Predicted intracellular proteins	Evidence at protein level	HPA042617			Approved	Plasma membrane<br>Cell Junctions<br>Mitochondria	Endometrial cancer:5.68e-6 (favourable)	Expressed in all	Expressed in all			skin: 289.6	Expressed in all		
CTNNBL1	C20orf33, FLJ21108, NAP, NYD-SP19, P14, P14L	ENSG00000132792	Catenin beta like 1	20	37693955-37872129	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA004742, HPA027907	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 75.3	Expressed in all		
CTNND1	CTNND, KIAA0384, p120, p120cas, p120ctn	ENSG00000198561	Catenin delta 1	11	57753243-57819546	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003837, HPA015954, HPA015955	Enhanced		Enhanced	Plasma membrane	Pancreatic cancer:3.02e-4 (unfavourable), Renal cancer:3.54e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 196.2	Expressed in all		
CTNND2	GT24, NPRAP	ENSG00000169862	Catenin delta 2	5	10971840-11904043	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015077, CAB037339	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cell Junctions		Tissue enriched	Tissue enriched	18	cerebral cortex: 103.2	spleen: 5.6	Cell line enhanced		AF22: 19.5;MCF7: 7.1;SK-BR-3: 4.4;U-266/84: 12.6
CTPS1	CTPS	ENSG00000171793	CTP synthase 1	1	40979335-41012565	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017111, HPA051322	Enhanced		Supported	Actin filaments<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 80.2	Expressed in all		
CTPS2		ENSG00000047230	CTP synthase 2	X	16588003-16712936	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017437	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:2.37e-5 (unfavourable), Urothelial cancer:4.56e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.4	Mixed		
CTR9	KIAA0155, p150TSP, SH2BP1, TSBP	ENSG00000198730	CTR9 homolog, Paf1/RNA polymerase II complex component	11	10750987-10779743	Predicted intracellular proteins	Evidence at protein level	HPA061027, HPA068122	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.65e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 59.9	Expressed in all		
CTTN	EMS1	ENSG00000085733	Cortactin	11	70398404-70436584	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011235, HPA057242	Supported		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane<br>Cytosol	Head and neck cancer:2.19e-6 (unfavourable), Liver cancer:4.45e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 108.9	Cell line enhanced		A-431: 778.5
CTTNBP2	C7orf8, CORTBP2, KIAA1758, Orf4	ENSG00000077063	Cortactin binding protein 2	7	117710651-117874139	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009151, HPA044654	Enhanced		Approved	Midbody ring<br>Cytosol	Renal cancer:3.71e-5 (favourable)	Mixed	Mixed			parathyroid gland: 19.1	Group enriched	6	HEL: 50.6;HMC-1: 63.2
CTTNBP2NL	DKFZp547A023	ENSG00000143079	CTTNBP2 N-terminal like	1	112396181-112463456	Predicted intracellular proteins	Evidence at protein level	HPA007301	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Colorectal cancer:1.14e-4 (favourable), Renal cancer:8.08e-4 (favourable)	Expressed in all	Mixed			placenta: 29.0	Mixed		
CTU1	ATPBD3, MGC17332, NCS6	ENSG00000142544	Cytosolic thiouridylase subunit 1	19	51097606-51108370	Predicted intracellular proteins	Evidence at protein level	HPA053797	Uncertain				Urothelial cancer:5.73e-5 (favourable)	Expressed in all	Mixed			spleen: 2.8	Cell line enhanced		HEK93: 40.6
CTU2	C16orf84, NCS2	ENSG00000174177	Cytosolic thiouridylase subunit 2	16	88706463-88715386	Predicted intracellular proteins	Evidence at protein level	HPA041135, HPA041894	Uncertain		Supported	Mitochondria	Liver cancer:5.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 10.3	Expressed in all		
CUEDC1		ENSG00000180891	CUE domain containing 1	17	57861243-57955323	Predicted intracellular proteins	Evidence at protein level	HPA023050, HPA024836	Approved		Uncertain	Centrosome<br>Mitochondria<br>Cytosol	Liver cancer:2.65e-5 (unfavourable), Renal cancer:8.46e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 52.4	Mixed		
CUEDC2	C10orf66, MGC2491	ENSG00000107874	CUE domain containing 2	10	102423245-102432661	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036544, HPA041829	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.75e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 89.9	Expressed in all		
CUL1		ENSG00000055130	Cullin 1	7	148697914-148801036	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002676, HPA064584	Supported		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 184.5	Expressed in all		
CUL2		ENSG00000108094	Cullin 2	10	35008551-35090642	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002677, HPA024578	Approved		Enhanced	Nucleoplasm	Liver cancer:8.24e-6 (unfavourable), Renal cancer:9.32e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 65.1	Expressed in all		
CUL3		ENSG00000036257	Cullin 3	2	224470150-224585397	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB002678	Supported					Expressed in all	Expressed in all			testis: 403.1	Expressed in all		
CUL4A		ENSG00000139842	Cullin 4A	13	113208193-113267108	Predicted intracellular proteins	Evidence at protein level	HPA058979			Approved	Nucleoplasm	Stomach cancer:2.84e-4 (favourable)	Expressed in all	Expressed in all			testis: 90.1	Expressed in all		
CUL4B		ENSG00000158290	Cullin 4B	X	120524609-120575794	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003046, HPA011880, CAB017786, HPA058979	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 68.3	Expressed in all		
CUL5	VACM-1	ENSG00000166266	Cullin 5	11	108008733-108107776	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002185, CAB017787	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.06e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 25.9	Expressed in all		
CUL7	dJ20C7.5, KIAA0076	ENSG00000044090	Cullin 7	6	43037617-43053945	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015449, HPA030095, HPA030096	Approved				Renal cancer:2.19e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 26.3	Expressed in all		
CUL9	H7AP1, KIAA0708, PARC	ENSG00000112659	Cullin 9	6	43182175-43224587	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016434, HPA052004	Approved		Approved	Cytosol	Head and neck cancer:2.37e-5 (favourable), Colorectal cancer:2.48e-4 (unfavourable), Urothelial cancer:4.87e-4 (favourable), Breast cancer:5.28e-4 (favourable), Pancreatic cancer:8.07e-4 (favourable)	Expressed in all	Mixed			testis: 10.0	Mixed		
CUTC	CGI-32	ENSG00000119929	CutC copper transporter	10	99702558-99756134	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA038619	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.81e-7 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 131.6	Expressed in all		
CWC15	AD002, C11orf5, Cwf15, HSPC148	ENSG00000150316	CWC15 spliceosome associated protein homolog	11	94962622-94973612	Predicted intracellular proteins	Evidence at protein level	HPA039878	Supported		Approved	Nuclear speckles<br>Mitochondria	Renal cancer:1.91e-5 (unfavourable), Thyroid cancer:7.17e-4 (favourable), Ovarian cancer:9.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.2	Expressed in all		
CWC22	EIF4GL, fSAPb, KIAA1604, NCM	ENSG00000163510	CWC22 spliceosome associated protein homolog	2	179944876-180007113	Predicted intracellular proteins	Evidence at protein level	HPA036748	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:7.76e-5 (unfavourable), Liver cancer:7.42e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 28.9	Expressed in all		
CWC25	CCDC49, FLJ20291	ENSG00000273559	CWC25 spliceosome associated protein homolog	17	38800434-38825481	Predicted intracellular proteins	Evidence at protein level	CAB014874, HPA062997	Enhanced		Enhanced	Nuclear speckles		Expressed in all	Mixed			bone marrow: 18.8	Expressed in all		
CWC27	NY-CO-10, SDCCAG-10, SDCCAG10	ENSG00000153015	CWC27 spliceosome associated protein homolog	5	64768930-65018763	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020344, HPA024149, HPA065809	Approved		Enhanced	Nucleoplasm	Liver cancer:5.27e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 31.1	Expressed in all		
CWF19L1	FLJ10998, hDrn1	ENSG00000095485	CWF19-like 1, cell cycle control (S. pombe)	10	100232298-100267680	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036889, HPA036890	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus	Liver cancer:6.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.9	Expressed in all		
CWF19L2	FLJ32343	ENSG00000152404	CWF19-like 2, cell cycle control (S. pombe)	11	107326345-107457844	Predicted intracellular proteins	Evidence at protein level	HPA038166	Uncertain		Approved	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			endometrium: 18.0	Expressed in all		
CXorf21	FLJ11577	ENSG00000120280	Chromosome X open reading frame 21	X	30558824-30577844	Predicted intracellular proteins	Evidence at protein level	HPA001185	Uncertain		Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			appendix: 14.4	Cell line enriched	6	THP-1: 107.8
CXorf23		ENSG00000173681	Chromosome X open reading frame 23	X	19912860-19970298	Predicted intracellular proteins	Evidence at protein level	HPA027215	Approved		Approved	Nucleoplasm	Lung cancer:5.42e-4 (favourable), Urothelial cancer:5.56e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 11.8	Expressed in all		
CXorf38	MGC39350	ENSG00000185753	Chromosome X open reading frame 38	X	40626921-40647554	Predicted intracellular proteins	Evidence at protein level	HPA050120	Approved		Supported	Cytosol	Urothelial cancer:1.44e-8 (favourable), Pancreatic cancer:7.30e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
CXorf40A	CXorf40, EOLA1	ENSG00000197620	Chromosome X open reading frame 40A	X	149540355-149550510	Predicted intracellular proteins	Evidence at protein level	HPA060897	Approved					Expressed in all	Expressed in all			adrenal gland: 69.6	Expressed in all		
CXorf40B		ENSG00000197021	Chromosome X open reading frame 40B	X	149929527-149938811	Predicted intracellular proteins	Evidence at transcript level	HPA060897	Approved				Thyroid cancer:1.02e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 78.6	Expressed in all		
CXorf49		ENSG00000215115	Chromosome X open reading frame 49	X	71714371-71718151	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	27	testis: 2.6	all non-specific tissues: 0.0	Cell line enriched	7	A-431: 8.0
CXorf49B		ENSG00000215113	Chromosome X open reading frame 49B	X	71763424-71767204	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	27	testis: 2.6	all non-specific tissues: 0.0	Cell line enriched	7	A-431: 8.0
CXorf51A	CXorf51	ENSG00000224440	Chromosome X open reading frame 51A	X	146814106-146814726	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CXorf51B		ENSG00000235699	Chromosome X open reading frame 51B	X	146809784-146810409	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	1092	testis: 109.1	all non-specific tissues: 0.0	Cell line enhanced		U-138 MG: 1.0
CXorf56	FLJ22965	ENSG00000018610	Chromosome X open reading frame 56	X	119538149-119565408	Predicted intracellular proteins	Evidence at protein level	HPA038245, HPA038617, HPA064831	Uncertain		Approved	Nucleus<br>Centrosome	Breast cancer:3.45e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 24.1	Expressed in all		
CXorf57	FLJ10178, FLJ14191	ENSG00000147231	Chromosome X open reading frame 57	X	106611930-106679442	Predicted intracellular proteins	Evidence at protein level	HPA000896, HPA001374	Uncertain		Approved	Intermediate filaments		Mixed	Mixed			adrenal gland: 9.4	Cell line enhanced		HEK93: 34.2;RT4: 31.7
CXorf58	FLJ25444	ENSG00000165182	Chromosome X open reading frame 58	X	23907801-23939507	Predicted intracellular proteins	Evidence at protein level	HPA031542, HPA031543, HPA031544	Uncertain					Not detected	Tissue enriched	9	testis: 6.2	fallopian tube: 0.6	Not detected		
CXorf65		ENSG00000204165	Chromosome X open reading frame 65	X	71103889-71106788	Predicted intracellular proteins	Evidence at protein level	HPA047396	Uncertain					Mixed	Tissue enriched	10	testis: 19.6	lymph node: 2.0	Cell line enhanced		HEL: 1.2;Karpas-707: 2.4;MOLT-4: 1.2;NB-4: 1.3
CXorf67		ENSG00000187690	Chromosome X open reading frame 67	X	51406915-51408843	Predicted intracellular proteins	Evidence at protein level	HPA004003, HPA006128	Enhanced		Enhanced	Nucleoplasm		Tissue enriched	Group enriched	21	placenta: 1.3;testis: 4.7	cerebral cortex,epididymis,ovary,prostate,spleen: 0.1	Cell line enriched	63	U-2 OS: 34.0
CXXC1	CFP1, CGBP, hCGBP, HsT2645, PCCX1, PHF18, SPP1, ZCGPC1	ENSG00000154832	CXXC finger protein 1	18	50282343-50288304	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044511	Supported		Enhanced	Nucleus	Liver cancer:4.18e-6 (unfavourable), Pancreatic cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 28.8	Expressed in all		
CXXC4	IDAX	ENSG00000168772	CXXC finger protein 4	4	104468312-104494901	Predicted intracellular proteins	Evidence at protein level	HPA036600, HPA036925	Uncertain		Uncertain	Nucleus<br>Golgi apparatus	Pancreatic cancer:2.19e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 8.9	thyroid gland: 4.1	Cell line enhanced		AF22: 6.9;AN3-CA: 9.0;Karpas-707: 6.4;SCLC-21H: 14.1;U-266/70: 7.4
CXXC5	HSPC195, RINF, WID	ENSG00000171604	CXXC finger protein 5	5	139647299-139683882	Predicted intracellular proteins	Evidence at protein level	HPA036508, HPA058148	Approved		Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:4.10e-7 (unfavourable), Colorectal cancer:2.40e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 99.3	Expressed in all		
CYB5D1	FLJ32499	ENSG00000182224	Cytochrome b5 domain containing 1	17	7857746-7862282	Predicted intracellular proteins	Evidence at protein level	HPA021632	Uncertain		Approved	Nucleoli<br>Golgi apparatus		Mixed	Expressed in all			fallopian tube: 41.9	Expressed in all		
CYB5R1	humb5R2, NQO3A2	ENSG00000159348	Cytochrome b5 reductase 1	1	202961869-202967280	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010641, HPA014147	Enhanced		Uncertain	Nucleoli<br>Mitochondria<br>Cytosol	Endometrial cancer:1.14e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 183.8	Expressed in all		
CYB5R4	b5+b5R, dJ676J13.1, NCB5OR	ENSG00000065615	Cytochrome b5 reductase 4	6	83859643-83967424	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018992	Approved					Expressed in all	Expressed in all			testis: 22.4	Expressed in all		
CYB5RL	LOC606495	ENSG00000215883	Cytochrome b5 reductase like	1	54169651-54200036	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042671, HPA060463	Approved		Enhanced	Nucleoplasm		Mixed	Mixed			ovary: 5.3	Expressed in all		
CYCS	CYC, HCS	ENSG00000172115	Cytochrome c, somatic	7	25120091-25125361	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004222, CAB005126, CAB018597	Enhanced		Supported	Mitochondria	Renal cancer:1.30e-5 (favourable), Head and neck cancer:2.81e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 309.2	Expressed in all		
CYFIP1	KIAA0068, P140SRA-1, SHYC	ENSG00000273749	Cytoplasmic FMR1 interacting protein 1	15	22867052-22981063	Predicted intracellular proteins	Evidence at protein level	HPA068106	Approved				Renal cancer:4.47e-5 (favourable), Lung cancer:7.39e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 111.9	Mixed		
CYFIP2	PIR121	ENSG00000055163	Cytoplasmic FMR1 interacting protein 2	5	157266079-157395595	Predicted intracellular proteins	Evidence at protein level	CAB055519, HPA068106, HPA071459	Uncertain		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:3.21e-12 (favourable), Endometrial cancer:2.42e-6 (unfavourable), Pancreatic cancer:1.18e-4 (favourable)	Expressed in all	Expressed in all			kidney: 166.2	Cell line enhanced		Daudi: 156.3;MOLT-4: 169.6
CYGB	HGB, STAP	ENSG00000161544	Cytoglobin	17	76527356-76551175	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA017757, HPA061642	Approved	Approved	Enhanced	Nuclear speckles	Endometrial cancer:2.55e-5 (favourable), Glioma:1.63e-4 (unfavourable), Renal cancer:2.13e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 46.4	Cell line enhanced		ASC diff: 50.4;Hep G2: 40.6;HHSteC: 93.4;HSkMC: 66.1;SH-SY5Y: 131.4
CYLC1		ENSG00000183035	Cylicin 1	X	83861126-83886699	Predicted intracellular proteins	Evidence at protein level	HPA070355	Enhanced					Not detected	Tissue enriched	429	testis: 42.9	all non-specific tissues: 0.0	Not detected		
CYLC2		ENSG00000155833	Cylicin 2	9	102995311-103018488	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	532	testis: 80.1	urinary bladder: 0.1	Not detected		
CYLD	CYLD1, KIAA0849, USPL2	ENSG00000083799	CYLD lysine 63 deubiquitinase	16	50742050-50801935	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011713, HPA050095	Approved		Supported	Nucleoplasm<br>Microtubule organizing center		Expressed in all	Expressed in all			testis: 70.2	Expressed in all		
CYP11A1	CYP11A, P450SCC	ENSG00000140459	Cytochrome P450 family 11 subfamily A member 1	15	74337759-74367740	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016436	Enhanced					Mixed	Tissue enriched	11	adrenal gland: 748.5	testis: 68.5	Group enriched	25	BEWO: 102.7;HEL: 79.0;SiHa: 23.2
CYP11B1	CPN1, CYP11B, FHI, P450C11	ENSG00000160882	Cytochrome P450 family 11 subfamily B member 1	8	142872356-142879846	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049171, HPA056348, HPA057752	Supported					Not detected	Tissue enriched	916	adrenal gland: 1871.2	testis: 2.0	Not detected		
CYP11B2	ALDOS, CPN2, CYP11B, CYP11BL, P-450C18, P450aldo	ENSG00000179142	Cytochrome P450 family 11 subfamily B member 2	8	142910559-142917843	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049171, HPA056348, HPA057752	Supported					Not detected	Tissue enriched	1057	adrenal gland: 126.3	testis: 0.1	Not detected		
CYP24A1	CP24, CYP24, P450-CC24	ENSG00000019186	Cytochrome P450 family 24 subfamily A member 1	20	54153449-54173973	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022261, HPA063771	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Mitochondria		Mixed	Tissue enhanced		endometrium: 24.8;urinary bladder: 50.8	placenta: 14.1	Group enriched	13	A549: 372.2;Hep G2: 83.4
CYP26A1	CP26, CYP26, P450RAI, P450RAI1	ENSG00000095596	Cytochrome P450 family 26 subfamily A member 1	10	93073475-93077890	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	liver: 9.7	cerebral cortex: 1.0	Cell line enriched	8	AF22: 60.5
CYP27A1	CP27, CTX, CYP27	ENSG00000135929	Cytochrome P450 family 27 subfamily A member 1	2	218781749-218815293	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059155	Enhanced		Enhanced	Mitochondria	Liver cancer:8.62e-6 (favourable), Breast cancer:1.05e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 279.5	lung: 98.4	Cell line enhanced		Hep G2: 187.0;RPTEC TERT1: 50.8;SK-MEL-30: 86.7;WM-115: 42.3
CYP27B1	CYP1, P450c1, PDDR, VDD1	ENSG00000111012	Cytochrome P450 family 27 subfamily B member 1	12	57762334-57768986	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Thyroid cancer:6.79e-4 (unfavourable)	Mixed	Tissue enhanced		kidney: 4.3;thyroid gland: 3.9	appendix: 1.2	Cell line enriched	8	RH-30: 47.8
CYP27C1	FLJ16008	ENSG00000186684	Cytochrome P450 family 27 subfamily C member 1	2	127184120-127220078	Predicted intracellular proteins	Evidence at protein level	HPA062460, HPA068731			Supported	Vesicles		Mixed	Tissue enhanced		skin: 6.8	cervix, uterine: 2.4	Cell line enhanced		HDLM-2: 13.5;TIME: 11.6;U-138 MG: 13.8
CYP4F3	CYP4F, LTB4H	ENSG00000186529	Cytochrome P450 family 4 subfamily F member 3	19	15640897-15662825	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA058960	Approved					Tissue enhanced	Tissue enhanced		bone marrow: 53.1;liver: 98.0	kidney: 29.4	Group enriched	7	A549: 6.6;CAPAN-2: 28.8;HaCaT: 13.3;Hep G2: 12.4
CYP7A1	CYP7	ENSG00000167910	Cytochrome P450 family 7 subfamily A member 1	8	58490178-58500236	Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:3.19e-4 (favourable)	Tissue enriched	Tissue enriched	61	liver: 26.0	duodenum: 0.4	Not detected		
CYS1		ENSG00000205795	Cystin 1	2	10056780-10080944	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.27e-5 (favourable)	Tissue enhanced	Tissue enriched	6	kidney: 101.2	ovary: 15.7	Cell line enriched	14	RPTEC TERT1: 83.8
CYSRT1	C9orf169, MGC59937	ENSG00000197191	Cysteine rich tail 1	9	137224635-137226311	Predicted intracellular proteins	Evidence at protein level	HPA021883, HPA021886	Approved		Approved	Nuclear speckles<br>Vesicles<br>Midbody		Expressed in all	Tissue enhanced		esophagus: 45.6;skin: 12.2	tonsil: 6.3	Cell line enhanced		A-431: 11.7;CAPAN-2: 14.5;HaCaT: 16.3;MCF7: 20.0
CYSTM1	C5orf32, ORF1-FL49	ENSG00000120306	Cysteine rich transmembrane module containing 1	5	140174642-140282052	Predicted intracellular proteins	Evidence at protein level	HPA050930	Enhanced				Renal cancer:9.69e-5 (favourable), Endometrial cancer:1.31e-4 (favourable), Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 484.3	Expressed in all		
CYTH1	B2-1, cytohesin-1, D17S811E, PSCD1	ENSG00000108669	Cytohesin 1	17	78674048-78782297	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047498			Uncertain	Nucleus<br>Nucleoli	Head and neck cancer:6.48e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 92.5	Expressed in all		
CYTH2	ARNO, CTS18.1, cytohesin-2, PSCD2, PSCD2L, Sec7p-L, Sec7p-like	ENSG00000105443	Cytohesin 2	19	48469032-48482314	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB014872, HPA060662	Uncertain		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Liver cancer:1.19e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)	Expressed in all	Mixed			testis: 31.2	Expressed in all		
CYTH3	ARNO3, cytohesin-3, GRP1, PSCD3	ENSG00000008256	Cytohesin 3	7	6161776-6272644	Predicted intracellular proteins	Evidence at protein level	HPA013979	Uncertain		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:2.63e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 45.5	Mixed		
CYTH4	CYT4, cytohesin-4, PSCD4	ENSG00000100055	Cytohesin 4	22	37282027-37315345	Predicted intracellular proteins	Evidence at protein level	HPA071573	Approved				Renal cancer:2.41e-8 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 89.2	spleen: 69.8	Cell line enhanced		HL-60: 27.2;HMC-1: 119.3;THP-1: 62.2
CYTIP	B3-1, CASP, CYBR, CYTHIP, HE, PSCDBP	ENSG00000115165	Cytohesin 1 interacting protein	2	157414619-157488961	Predicted intracellular proteins	Evidence at protein level	HPA007191	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:9.12e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 101.8;tonsil: 102.0	appendix: 92.4	Cell line enhanced		HDLM-2: 41.0;Karpas-707: 103.6;U-266/70: 185.5;U-266/84: 68.5
DAAM1	KIAA0666	ENSG00000100592	Dishevelled associated activator of morphogenesis 1	14	59188646-59371405	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026605, HPA064789	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.1	Expressed in all		
DAAM2	KIAA0381	ENSG00000146122	Dishevelled associated activator of morphogenesis 2	6	39792298-39904877	Predicted intracellular proteins	Evidence at protein level	HPA051300, HPA054630	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 110.8	Cell line enhanced		HSkMC: 39.9;LHCN-M2: 46.3;SK-MEL-30: 54.3;WM-115: 26.5
DAB1		ENSG00000173406	DAB1, reelin adaptor protein	1	56994778-58546734	Predicted intracellular proteins	Evidence at protein level	CAB032329, HPA052033, HPA067495	Enhanced		Supported	Vesicles		Mixed	Tissue enhanced		duodenum: 15.9;seminal vesicle: 13.8;small intestine: 24.8	prostate: 6.4	Cell line enhanced		fHDF/TERT166: 41.8;HeLa: 12.9;NTERA-2: 23.4;RT4: 25.5;WM-115: 26.3
DAB2	DOC-2	ENSG00000153071	DAB2, clathrin adaptor protein	5	39371675-39462300	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009314, HPA028888	Enhanced		Enhanced	Nucleoli fibrillar center<br>Vesicles<br>Plasma membrane	Liver cancer:7.38e-6 (unfavourable), Stomach cancer:9.67e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 321.8	Cell line enhanced		fHDF/TERT166: 273.0;U-138 MG: 234.0
DAB2IP	AF9Q34, AIP1, DIP1/2, KIAA1743	ENSG00000136848	DAB2 interacting protein	9	121567057-121785530	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.00e-15 (favourable)	Expressed in all	Mixed			testis: 33.8	Cell line enhanced		HaCaT: 72.1
DACH1	DACH	ENSG00000276644	Dachshund family transcription factor 1	13	71437966-71867192	Predicted intracellular proteins	Evidence at protein level	HPA012672	Approved		Supported	Nucleoplasm<br>Vesicles		Mixed	Mixed			cervix, uterine: 15.0	Cell line enhanced		HAP1: 23.2;HL-60: 30.0;SCLC-21H: 43.5;SH-SY5Y: 31.4;THP-1: 18.1
DACH2		ENSG00000126733	Dachshund family transcription factor 2	X	86148458-86832604	Predicted intracellular proteins	Evidence at transcript level	HPA000258	Approved					Not detected	Group enriched	8	cerebral cortex: 11.9;epididymis: 4.4;fallopian tube: 5.0	kidney: 0.8	Cell line enriched	8	HAP1: 6.1
DACT1	DAPPER, DAPPER1, FRODO, HDPR1, THYEX3	ENSG00000165617	Dishevelled binding antagonist of beta catenin 1	14	58633967-58648321	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003016	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			gallbladder: 40.2	Cell line enhanced		U-138 MG: 31.7
DACT2	bA503C24.7, C6orf116, DAPPER2	ENSG00000164488	Dishevelled binding antagonist of beta catenin 2	6	168292830-168319754	Predicted intracellular proteins	Evidence at transcript level	HPA030251, HPA030252	Approved				Endometrial cancer:1.07e-5 (favourable), Renal cancer:5.76e-5 (favourable)	Tissue enhanced	Tissue enhanced		placenta: 18.8	prostate: 7.3	Group enriched	6	A549: 3.0;CACO-2: 2.2;EFO-21: 1.4;Hep G2: 1.0;hTCEpi: 1.3;NTERA-2: 2.3;SCLC-21H: 3.0
DACT3	DAPPER3, MGC15476, RRR1	ENSG00000197380	Dishevelled binding antagonist of beta catenin 3	19	46647612-46661138	Predicted intracellular proteins	Evidence at protein level	HPA043053	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:7.97e-8 (unfavourable), Urothelial cancer:6.66e-4 (unfavourable)	Mixed	Mixed			smooth muscle: 46.6	Cell line enhanced		SH-SY5Y: 26.8
DALRD3	FLJ10496	ENSG00000178149	DALR anticodon binding domain containing 3	3	49015488-49022293	Predicted intracellular proteins	Evidence at protein level	HPA036862	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:2.79e-5 (favourable), Endometrial cancer:9.03e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 59.2	Expressed in all		
DAOA	G72	ENSG00000182346	D-amino acid oxidase activator	13	105465867-105491034	Predicted intracellular proteins	Evidence at protein level	HPA053114	Approved					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
DAP		ENSG00000112977	Death associated protein	5	10679230-10761272	Predicted intracellular proteins	Evidence at protein level	HPA029456	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Mitochondria	Liver cancer:2.15e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 156.6	Expressed in all		
DAP3	bMRP-10, DAP-3, DKFZp686G12159, MGC126058, MGC126059, MRP-S29, MRPS29	ENSG00000132676	Death associated protein 3	1	155687960-155739010	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA023687	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:4.14e-6 (unfavourable), Liver cancer:1.20e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 82.0	Expressed in all		
DAPP1	BAM32	ENSG00000070190	Dual adaptor of phosphotyrosine and 3-phosphoinositides 1	4	99816833-99870154	Predicted intracellular proteins	Evidence at protein level	CAB033822, HPA046074	Approved					Mixed	Mixed			lymph node: 51.1	Cell line enhanced		HDLM-2: 80.2;RPMI-8226: 64.7;U-698: 45.0
DARS		ENSG00000115866	Aspartyl-tRNA synthetase	2	135906677-135986100	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020451, HPA029804, HPA029805	Enhanced		Enhanced	Cytosol	Liver cancer:2.39e-6 (unfavourable), Renal cancer:1.24e-5 (unfavourable), Pancreatic cancer:6.54e-4 (unfavourable), Melanoma:7.57e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 91.0	Expressed in all		
DARS2	FLJ10514	ENSG00000117593	Aspartyl-tRNA synthetase 2, mitochondrial	1	173824503-173858546	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026506, HPA026528	Enhanced		Supported	Nucleus<br>Mitochondria	Renal cancer:1.74e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 24.9	Expressed in all		
DAW1	FLJ25955, ODA16, WDR69	ENSG00000123977	Dynein assembly factor with WD repeats 1	2	227871054-227924344	Predicted intracellular proteins	Evidence at protein level	HPA046118	Approved		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Group enriched	14	fallopian tube: 51.4;testis: 92.1	lung: 4.9	Cell line enhanced		HUVEC TERT2: 18.4;U-2197: 40.4
DAXX	DAP6	ENSG00000204209	Death domain associated protein	6	33318558-33329286	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002224, HPA008736, HPA008797, CAB025546, HPA065779	Enhanced		Enhanced	Nucleus<br>Nuclear bodies	Renal cancer:6.32e-7 (unfavourable), Breast cancer:6.05e-4 (favourable)	Expressed in all	Mixed			epididymis: 19.3	Mixed		
DAZ1	DAZ, SPGY	ENSG00000188120	Deleted in azoospermia 1	Y	23129355-23199094	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047113	Supported					Not detected	Tissue enhanced		testis: 1.7	stomach: 0.8	Group enriched	15	U-266/70: 11.7;U-266/84: 17.1
DAZ2	MGC126442, pDP1678	ENSG00000205944	Deleted in azoospermia 2	Y	23219434-23291356	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047113	Approved					Not detected	Group enriched	27	stomach: 15.5;testis: 7.2	skin: 0.4	Cell line enriched	9	SK-MEL-30: 1.4
DAZ3		ENSG00000187191	Deleted in azoospermia 3	Y	24763069-24813492	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047113	Approved					Not detected	Tissue enriched	11	testis: 1.0	all non-specific tissues: 0.0	Not detected		
DAZ4		ENSG00000205916	Deleted in azoospermia 4	Y	24833843-24907040	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047113	Approved					Not detected	Group enriched	40	stomach: 22.3;testis: 21.5	skin: 0.5	Group enriched	123	U-266/70: 117.1;U-266/84: 107.2
DAZAP1	MGC19907	ENSG00000071626	DAZ associated protein 1	19	1407569-1435687	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004201, HPA004631	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:5.86e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 102.8	Expressed in all		
DAZL	DAZH, DAZL1, DAZLA, MGC26406, SPGYLA	ENSG00000092345	Deleted in azoospermia like	3	16586792-16670306	Predicted intracellular proteins	Evidence at protein level	HPA019593, HPA019777, HPA047113	Enhanced					Tissue enriched	Tissue enriched	153	testis: 141.6	tonsil: 0.9	Cell line enriched	9	HAP1: 20.2
DBF4	ASK, chif, DBF4A, ZDBF1	ENSG00000006634	DBF4 zinc finger	7	87876216-87909541	Predicted intracellular proteins	Evidence at protein level	HPA042923			Approved	Nucleus<br>Nuclear bodies	Renal cancer:6.42e-7 (unfavourable), Liver cancer:4.45e-6 (unfavourable), Melanoma:6.86e-4 (unfavourable)	Expressed in all	Tissue enriched	41	testis: 21.4	gallbladder: 0.5	Mixed		
DBF4B	ASKL1, chifb, DRF1, FLJ13087, ZDBF1B	ENSG00000161692	DBF4 zinc finger B	17	44708608-44752264	Predicted intracellular proteins	Evidence at protein level	HPA048465	Uncertain		Supported	Nucleus		Expressed in all	Mixed			testis: 5.6	Mixed		
DBI	ACBD1, ACBP	ENSG00000155368	Diazepam binding inhibitor, acyl-CoA binding protein	2	119366921-119372560	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051428	Approved				Renal cancer:3.73e-5 (unfavourable), Cervical cancer:5.77e-5 (favourable)	Expressed in all	Expressed in all			breast: 907.6	Expressed in all		
DBN1	D0S117E	ENSG00000113758	Drebrin 1	5	177456608-177474401	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051452, HPA056940	Enhanced		Supported	Plasma membrane<br>Actin filaments	Renal cancer:8.28e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 82.9	Mixed		
DBNDD1	FLJ12582, MGC3101	ENSG00000003249	Dysbindin domain containing 1	16	90004865-90020128	Predicted intracellular proteins	Evidence at protein level	HPA043018	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:2.75e-7 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 24.0	skeletal muscle: 15.6	Cell line enhanced		MCF7: 109.1
DBNDD2	C20orf35, HSMNP1	ENSG00000244274	Dysbindin domain containing 2	20	45406057-45410610	Predicted intracellular proteins	Evidence at protein level	HPA043991	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Expressed in all			cerebral cortex: 460.2	Mixed		
DBP	DABP	ENSG00000105516	D-box binding PAR bZIP transcription factor	19	48630030-48637438	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Lung cancer:1.16e-5 (favourable), Renal cancer:2.41e-5 (favourable), Head and neck cancer:5.49e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 41.4	Cell line enhanced		NB-4: 148.5
DBR1		ENSG00000138231	Debranching RNA lariats 1	3	138161012-138174949	Predicted intracellular proteins	Evidence at protein level	HPA035365	Supported		Supported	Nucleoplasm	Liver cancer:1.36e-4 (unfavourable), Renal cancer:1.36e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 13.7	Expressed in all		
DBT		ENSG00000137992	Dihydrolipoamide branched chain transacylase E2	1	100186919-100249834	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026481, HPA026485, HPA026533	Enhanced		Supported	Mitochondria	Renal cancer:8.79e-12 (favourable)	Expressed in all	Expressed in all			kidney: 19.7	Expressed in all		
DBX1		ENSG00000109851	Developing brain homeobox 1	11	20156155-20160613	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA039802	Uncertain					Not detected	Not detected			testis: 0.2	Cell line enriched	9	NTERA-2: 1.0
DBX2	FLJ16139	ENSG00000185610	Developing brain homeobox 2	12	45014672-45051099	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA066053	Uncertain					Tissue enriched	Group enriched	5	cerebral cortex: 4.1;testis: 1.2	skin: 0.5	Not detected		
DCAF1	KIAA0800, MGC102804, VPRBP	ENSG00000145041	DDB1 and CUL4 associated factor 1	3	51395867-51500002	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036142, HPA052445, HPA053203	Approved		Enhanced	Nucleus<br>Nucleoli fibrillar center	Renal cancer:7.45e-5 (favourable)	Expressed in all	Expressed in all			testis: 96.8	Expressed in all		
DCAF10	FLJ23201, MGC10765, WDR32	ENSG00000122741	DDB1 and CUL4 associated factor 10	9	37800502-37867666	Predicted intracellular proteins	Evidence at protein level	HPA024160	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:1.02e-6 (favourable)	Expressed in all	Expressed in all			testis: 36.0	Expressed in all		
DCAF11	GL014, PRO2389, WDR23	ENSG00000100897	DDB1 and CUL4 associated factor 11	14	24114195-24125242	Predicted intracellular proteins	Evidence at protein level	HPA003583, HPA031157	Approved		Enhanced	Nucleoplasm	Renal cancer:3.50e-13 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 74.3	Expressed in all		
DCAF12	CT102, DKFZP434O125, KIAA1892, MGC1058, TCC52, WDR40A	ENSG00000198876	DDB1 and CUL4 associated factor 12	9	34086387-34127399	Predicted intracellular proteins	Evidence at protein level	HPA062279	Uncertain				Ovarian cancer:2.81e-5 (favourable)	Expressed in all	Expressed in all			testis: 113.2	Expressed in all		
DCAF12L1	KIAA1892L, WDR40B	ENSG00000198889	DDB1 and CUL4 associated factor 12 like 1	X	126549383-126552851	Predicted intracellular proteins	Evidence at protein level	HPA044737, HPA048981, HPA053138	Approved					Mixed	Tissue enhanced		epididymis: 5.9;testis: 11.4	fallopian tube: 4.0	Group enriched	21	EFO-21: 14.1;U-2 OS: 8.6
DCAF12L2	WDR40C	ENSG00000198354	DDB1 and CUL4 associated factor 12 like 2	X	126163499-126166097	Predicted intracellular proteins	Evidence at transcript level	HPA044737, HPA048981, HPA053138	Approved					Mixed	Tissue enhanced		epididymis: 28.3;testis: 9.8	seminal vesicle: 6.6	Group enriched	7	HAP1: 2.9;NTERA-2: 2.3;U-2 OS: 3.9
DCAF13	DKFZP564O0463, Gm83, HSPC064, WDSOF1	ENSG00000164934	DDB1 and CUL4 associated factor 13	8	103414714-103443453	Predicted intracellular proteins	Evidence at protein level	HPA044504	Uncertain		Supported	Nucleus<br>Nucleoli<br>Cell Junctions<br>Centrosome<br>Cytosol	Liver cancer:8.05e-6 (unfavourable), Renal cancer:2.85e-4 (unfavourable), Breast cancer:4.06e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 58.8	Expressed in all		
DCAF15	C19orf72, MGC99481	ENSG00000132017	DDB1 and CUL4 associated factor 15	19	13952492-13961449	Predicted intracellular proteins	Evidence at protein level	HPA068351			Approved	Vesicles<br>Mitochondria	Renal cancer:1.34e-5 (unfavourable), Pancreatic cancer:7.97e-4 (favourable)	Expressed in all	Expressed in all			testis: 59.9	Expressed in all		
DCAF16	C4orf30, FLJ20280	ENSG00000163257	DDB1 and CUL4 associated factor 16	4	17800655-17810758	Predicted intracellular proteins	Evidence at protein level	HPA042487	Uncertain		Approved	Plasma membrane<br>Cytosol	Lung cancer:5.78e-4 (favourable), Liver cancer:6.40e-4 (unfavourable), Urothelial cancer:7.67e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 23.0	Expressed in all		
DCAF4	DKFZp434K114, WDR21, WDR21A	ENSG00000119599	DDB1 and CUL4 associated factor 4	14	72926332-72959703	Predicted intracellular proteins	Evidence at protein level	HPA047276	Approved		Approved	Nucleoplasm	Renal cancer:4.90e-4 (favourable), Liver cancer:6.77e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 18.8	Expressed in all		
DCAF4L1	WDR21B	ENSG00000182308	DDB1 and CUL4 associated factor 4 like 1	4	41981696-41986467	Predicted intracellular proteins	Evidence at protein level	CAB073535	Enhanced					Tissue enriched	Tissue enriched	122	testis: 45.7	appendix,skin: 0.3	Mixed		
DCAF4L2	WDR21C	ENSG00000176566	DDB1 and CUL4 associated factor 4 like 2	8	87870743-87874068	Predicted intracellular proteins	Evidence at protein level	HPA067584	Uncertain					Tissue enriched	Tissue enriched	389	testis: 38.9	all non-specific tissues: 0.0	Cell line enriched	20	U-266/84: 5.1
DCAF5	BCRG2, BCRP2, D14S1461E, KIAA1824, WDR22	ENSG00000139990	DDB1 and CUL4 associated factor 5	14	69050881-69153150	Predicted intracellular proteins	Evidence at protein level	HPA041575, HPA048098	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			testis: 111.5	Expressed in all		
DCAF6	IQWD1, PC326	ENSG00000143164	DDB1 and CUL4 associated factor 6	1	167935783-168075843	Predicted intracellular proteins	Evidence at protein level	HPA054305			Supported	Nucleus<br>Focal adhesion sites		Expressed in all	Expressed in all			skeletal muscle: 223.5	Expressed in all		
DCAF7	HAN11, SWAN-1, WDR68	ENSG00000136485	DDB1 and CUL4 associated factor 7	17	63550461-63594266	Predicted intracellular proteins	Evidence at protein level	HPA022948, HPA022962	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.42e-4 (unfavourable), Renal cancer:3.49e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 61.4	Expressed in all		
DCAF8	FLJ35857, H326, WDR42A	ENSG00000132716	DDB1 and CUL4 associated factor 8	1	160215715-160262531	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027218, HPA027381	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.74e-5 (unfavourable), Pancreatic cancer:4.71e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 155.7	Expressed in all		
DCAF8L1	WDR42B	ENSG00000226372	DDB1 and CUL4 associated factor 8 like 1	X	27977993-27981449	Predicted intracellular proteins	Evidence at protein level	HPA043787	Enhanced					Not detected	Tissue enriched	56	testis: 5.5	all non-specific tissues: 0.0	Cell line enriched	16	Karpas-707: 13.4
DCAF8L2	WDR42C	ENSG00000189186	DDB1 and CUL4 associated factor 8 like 2	X	27590382-27748821	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	52	testis: 40.5	ovary: 0.7	Cell line enriched	7	U-2 OS: 9.9
DCANP1	C5orf20, DCNP1	ENSG00000251380	Dendritic cell associated nuclear protein	5	135444214-135447348	Predicted intracellular proteins	Evidence at protein level	HPA048308	Uncertain					Not detected	Not detected			lymph node: 0.7	Cell line enhanced		THP-1: 1.3
DCDC1		ENSG00000170959	Doublecortin domain containing 1	11	30830369-31369810	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		fallopian tube: 6.6;testis: 4.2	gallbladder: 2.8	Cell line enhanced		U-266/70: 1.1
DCDC2	DCDC2A, DFNB66, KIAA1154, NPHP19, RU2	ENSG00000146038	Doublecortin domain containing 2	6	24171756-24358052	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031582, HPA031583, HPA031584	Enhanced		Enhanced	Microtubules<br>Mitotic spindle<br>Microtubule organizing center<br>Cytosol		Mixed	Tissue enhanced		kidney: 23.2	parathyroid gland: 15.3	Group enriched	8	CACO-2: 59.2;EFO-21: 45.6;Hep G2: 55.9;RPTEC TERT1: 193.3
DCDC2B		ENSG00000222046	Doublecortin domain containing 2B	1	32209094-32216196	Predicted intracellular proteins	Evidence at protein level	HPA045832	Uncertain					Mixed	Tissue enriched	17	fallopian tube: 44.3	lung: 2.6	Not detected		
DCDC2C		ENSG00000214866	Doublecortin domain containing 2C	2	3703592-3847411	Predicted intracellular proteins	Evidence at transcript level	HPA045848	Uncertain					Not detected	Tissue enriched	40	testis: 5.9	fallopian tube,prostate: 0.1	Not detected		
DCK		ENSG00000156136	Deoxycytidine kinase	4	70992538-71030914	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059609, HPA062773	Approved		Supported	Nucleus	Liver cancer:6.90e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 93.9	Expressed in all		
DCLK2	DCAMKL2, DCDC3, DCDC3B, DCK2, MGC45428	ENSG00000170390	Doublecortin like kinase 2	4	150078274-150257457	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015770	Enhanced				Pancreatic cancer:2.48e-4 (favourable), Ovarian cancer:3.25e-4 (favourable)	Tissue enriched	Tissue enriched	10	cerebral cortex: 82.6	heart muscle: 7.9	Cell line enhanced		AF22: 23.3;BJ hTERT+: 20.2
DCLRE1A	hSNM1, KIAA0086, PSO2, SNM1	ENSG00000198924	DNA cross-link repair 1A	10	113834725-113854383	Predicted intracellular proteins	Evidence at protein level	HPA036907	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Liver cancer:5.74e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.4	Expressed in all		
DCLRE1B	FLJ12810, FLJ13998, SNM1B	ENSG00000118655	DNA cross-link repair 1B	1	113905141-113914086	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064934			Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.03e-7 (unfavourable), Liver cancer:4.50e-5 (unfavourable), Pancreatic cancer:6.70e-4 (unfavourable)	Expressed in all	Mixed			spleen: 5.4	Expressed in all		
DCLRE1C	A-SCID, ARTEMIS, FLJ11360, SCIDA, SNM1C	ENSG00000152457	DNA cross-link repair 1C	10	14897359-14954432	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA069295			Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:9.03e-8 (unfavourable), Head and neck cancer:1.30e-4 (favourable), Ovarian cancer:7.98e-4 (favourable)	Expressed in all	Mixed			lymph node: 16.4	Expressed in all		
DCP1A	HSA275986, SMAD4IP1, SMIF	ENSG00000272886	Decapping mRNA 1A	3	53283428-53347610	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA013202	Approved		Supported	Cytoplasmic bodies	Liver cancer:3.25e-5 (unfavourable), Colorectal cancer:9.01e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 19.1	Expressed in all		
DCP2	NUDT20	ENSG00000172795	Decapping mRNA 2	5	112976702-113020970	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB011677, HPA057676	Approved		Approved	Nucleoplasm<br>Cell Junctions<br>Cytoplasmic bodies	Renal cancer:2.66e-5 (unfavourable), Liver cancer:4.84e-4 (unfavourable)	Expressed in all	Mixed			placenta: 18.9	Expressed in all		
DCPS	HINT-5, HSL1, HSPC015	ENSG00000110063	Decapping enzyme, scavenger	11	126303752-126345749	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039632, HPA058597	Supported		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			lymph node: 24.5	Expressed in all		
DCTD		ENSG00000129187	DCMP deaminase	4	182890060-182917936	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035894	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.81e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 167.0	Expressed in all		
DCTN1		ENSG00000204843	Dynactin subunit 1	2	74361154-74392087	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009108, HPA034635	Approved		Supported	Intermediate filaments<br>Centrosome<br>Cytosol	Renal cancer:2.34e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 209.3	Expressed in all		
DCTN2	DCTN-50, RBP50	ENSG00000175203	Dynactin subunit 2	12	57530102-57547331	Predicted intracellular proteins	Evidence at protein level	HPA039715, HPA040040	Enhanced		Enhanced	Centrosome	Liver cancer:1.38e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 163.0	Expressed in all		
DCTN3	DCTN-22	ENSG00000137100	Dynactin subunit 3	9	34613545-34620523	Predicted intracellular proteins	Evidence at protein level	HPA044905	Approved		Supported	Nucleoli<br>Cytosol	Renal cancer:5.76e-11 (favourable), Ovarian cancer:2.10e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 129.7	Expressed in all		
DCTN4		ENSG00000132912	Dynactin subunit 4	5	150708440-150759109	Predicted intracellular proteins	Evidence at protein level	CAB017532, HPA038026	Uncertain		Approved	Nucleus<br>Centrosome		Expressed in all	Expressed in all			cerebral cortex: 67.3	Expressed in all		
DCTN5	MGC3248, p25	ENSG00000166847	Dynactin subunit 5	16	23641392-23677455	Predicted intracellular proteins	Evidence at protein level	HPA042003, HPA063710	Approved		Approved	Nucleoplasm<br>Nuclear membrane	Liver cancer:4.02e-4 (unfavourable), Renal cancer:4.48e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex,testis: 38.1	Expressed in all		
DCTN6	WS-3	ENSG00000104671	Dynactin subunit 6	8	30156297-30183640	Predicted intracellular proteins	Evidence at protein level	HPA024049, HPA024558	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:5.42e-4 (favourable), Liver cancer:5.51e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 93.9	Expressed in all		
DCTPP1	CDA03, MGC5627, RS21C6, XTP3TPA	ENSG00000179958	DCTP pyrophosphatase 1	16	30423619-30430075	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002832	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.71e-9 (favourable), Breast cancer:1.64e-5 (unfavourable), Liver cancer:6.28e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 64.1	Expressed in all		
DCUN1D1	DCUN1L1, RP42, SCCRO, SCRO, Tes3	ENSG00000043093	Defective in cullin neddylation 1 domain containing 1	3	182938074-182985953	Predicted intracellular proteins	Evidence at protein level	HPA035911	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Tissue enriched	13	testis: 391.8	thyroid gland: 29.4	Expressed in all		
DCUN1D2	C13orf17, FLJ10704, FLJ20092	ENSG00000150401	Defective in cullin neddylation 1 domain containing 2	13	113455819-113490952	Predicted intracellular proteins	Evidence at protein level	HPA039349	Uncertain		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:5.65e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 66.6	Expressed in all		
DCUN1D3	DKFZp686O0290, FLJ41725, MGC48972, SCCRO3	ENSG00000188215	Defective in cullin neddylation 1 domain containing 3	16	20854925-20900384	Predicted intracellular proteins	Evidence at protein level	HPA041983, HPA043511	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.41e-6 (unfavourable)	Expressed in all	Mixed			adipose tissue: 24.0	Expressed in all		
DCUN1D4	KIAA0276	ENSG00000109184	Defective in cullin neddylation 1 domain containing 4	4	51843000-51916837	Predicted intracellular proteins	Evidence at protein level	HPA036483, HPA036484	Uncertain		Supported	Nucleus<br>Vesicles		Expressed in all	Expressed in all			testis: 28.9	Expressed in all		
DCUN1D5	FLJ32431, MGC2714	ENSG00000137692	Defective in cullin neddylation 1 domain containing 5	11	103062076-103092215	Predicted intracellular proteins	Evidence at protein level	HPA050863	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:2.01e-7 (unfavourable), Ovarian cancer:9.52e-5 (favourable), Prostate cancer:4.12e-4 (unfavourable), Head and neck cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.6	Mixed		
DCX	DBCN, DC, LISX, SCLH, XLIS	ENSG00000077279	Doublecortin	X	111293779-111412429	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036121		Supported	Approved	Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 10.6	endometrium: 2.4	Group enriched	9	SCLC-21H: 65.0;SH-SY5Y: 24.0
DCXR	DCR, KIDCR, SDR20C1	ENSG00000169738	Dicarbonyl and L-xylulose reductase	17	82035136-82037732	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023371, HPA023863	Enhanced		Uncertain	Nucleoli<br>Microtubules	Renal cancer:2.13e-4 (favourable), Pancreatic cancer:4.70e-4 (favourable)	Expressed in all	Group enriched	6	epididymis: 297.5;kidney: 217.3;liver: 640.9;prostate: 137.5	adipose tissue: 56.7	Expressed in all		
DDA1	C19orf58, MGC2594, PCIA1	ENSG00000130311	DET1 and DDB1 associated 1	19	17309518-17323301	Predicted intracellular proteins	Evidence at protein level	HPA042134, HPA055272	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			placenta: 11.6	Expressed in all		
DDAH1	DDAH	ENSG00000153904	Dimethylarginine dimethylaminohydrolase 1	1	85318481-85578363	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006308	Enhanced		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:5.21e-6 (favourable), Colorectal cancer:5.99e-4 (favourable)	Expressed in all	Mixed			kidney: 121.4	Cell line enhanced		SH-SY5Y: 122.6
DDAH2	G6A	ENSG00000213722	Dimethylarginine dimethylaminohydrolase 2	6	31727038-31730617	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012509	Uncertain		Uncertain	Microtubule organizing center<br>Cytosol		Expressed in all	Mixed			thyroid gland: 22.3	Cell line enhanced		EFO-21: 23.0;U-2 OS: 18.9
DDB1		ENSG00000167986	Damage specific DNA binding protein 1	11	61299451-61342596	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032821, HPA045174, HPA068456	Approved		Enhanced	Nucleoplasm	Renal cancer:1.51e-8 (favourable), Colorectal cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 490.0	Expressed in all		
DDB2	DDBB, FLJ34321, UV-DDB2, XPE	ENSG00000134574	Damage specific DNA binding protein 2	11	47214465-47239240	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB025912, HPA058406	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Endometrial cancer:1.20e-4 (favourable), Cervical cancer:1.58e-4 (favourable), Breast cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			skin: 53.7	Expressed in all		
DDC	AADC	ENSG00000132437	Dopa decarboxylase	7	50458436-50565457	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017742	Enhanced		Approved	Actin filaments		Mixed	Tissue enhanced		duodenum: 155.2;kidney: 320.9;small intestine: 180.5	adrenal gland: 63.8	Group enriched	9	CACO-2: 44.3;Hep G2: 32.3;SCLC-21H: 154.0;SH-SY5Y: 144.1
DDHD1	KIAA1705, PA-PLA1, SPG28	ENSG00000100523	DDHD domain containing 1	14	53036745-53153282	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049870	Enhanced					Mixed	Tissue enhanced		testis: 34.2	cerebral cortex: 10.6	Expressed in all		
DDHD2	KIAA0725, SAMWD1, SPG54	ENSG00000085788	DDHD domain containing 2	8	38225218-38275558	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015202, HPA023143, HPA023147	Supported		Supported	Microtubule organizing center<br>Cytosol	Head and neck cancer:7.72e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 69.9	Expressed in all		
DDI1	FLJ36017	ENSG00000170967	DNA damage inducible 1 homolog 1	11	104036580-104039188	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	283	testis: 28.2	all non-specific tissues: 0.0	Not detected		
DDI2	MGC14844	ENSG00000197312	DNA damage inducible 1 homolog 2	1	15617500-15669044	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043119, HPA043225	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 19.7	Expressed in all		
DDIT3	CHOP, CHOP10, GADD153	ENSG00000175197	DNA damage inducible transcript 3	12	57516588-57520517	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058416, HPA068416	Approved		Supported	Nucleoplasm	Liver cancer:6.55e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 263.6	Expressed in all		
DDIT4	Dig2, FLJ20500, REDD-1, REDD1, RTP801	ENSG00000168209	DNA damage inducible transcript 4	10	72273920-72276036	Predicted intracellular proteins	Evidence at protein level	HPA034507, HPA034508	Approved		Supported	Cytosol	Renal cancer:2.54e-6 (unfavourable), Pancreatic cancer:2.78e-4 (unfavourable), Head and neck cancer:5.42e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 220.9	Expressed in all		
DDIT4L	REDD2, Rtp801L	ENSG00000145358	DNA damage inducible transcript 4 like	4	100185870-100190782	Predicted intracellular proteins	Evidence at protein level	HPA050903			Uncertain	Nucleoplasm<br>Plasma membrane<br>Actin filaments	Endometrial cancer:5.77e-4 (favourable)	Tissue enhanced	Tissue enhanced		skeletal muscle: 113.3	cervix, uterine: 33.2	Cell line enhanced		ASC TERT1: 13.5;BJ: 25.0;fHDF/TERT166: 12.5;HSkMC: 10.7;RPTEC TERT1: 15.6
DDN	KIAA0749	ENSG00000181418	Dendrin	12	48995149-48999309	Predicted intracellular proteins	Evidence at protein level	HPA060952	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	10	cerebral cortex: 96.0;skeletal muscle: 46.6	kidney: 6.9	Cell line enhanced		HAP1: 12.6;RPMI-8226: 16.5;SCLC-21H: 14.1
DDRGK1	C20orf116, dJ1187M17.3, UFBP1	ENSG00000198171	DDRGK domain containing 1	20	3190350-3204685	Predicted intracellular proteins	Evidence at protein level	HPA013373, HPA013705	Approved		Supported	Nucleoli<br>Endoplasmic reticulum	Renal cancer:2.01e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 72.4	Expressed in all		
DDTL		ENSG00000099974	D-dopachrome tautomerase-like	22	23966901-23972532	Predicted intracellular proteins	Evidence at transcript level						Liver cancer:5.98e-4 (favourable)	Expressed in all	Mixed			small intestine: 3.5	Mixed		
DDX1	DBP-RB	ENSG00000079785	DEAD-box helicase 1	2	15591178-15631111	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012280, HPA034502, HPA034503	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:9.09e-9 (unfavourable), Renal cancer:9.69e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 145.1	Expressed in all		
DDX10	HRH-J8	ENSG00000178105	DEAD-box helicase 10	11	108665025-108940930	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004691	Approved		Approved	Nucleoli	Renal cancer:2.14e-5 (favourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 29.2	Expressed in all		
DDX11	CHL1, CHLR1, KRG2, WABS	ENSG00000013573	DEAD/H-box helicase 11	12	31073845-31104791	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA065197	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Centrosome	Renal cancer:5.23e-8 (unfavourable), Liver cancer:2.40e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 19.3	Expressed in all		
DDX18	MrDb	ENSG00000088205	DEAD-box helicase 18	2	117814650-117832379	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035400, HPA041056	Approved		Enhanced	Nucleoli	Endometrial cancer:2.64e-4 (unfavourable), Liver cancer:3.07e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 49.6	Expressed in all		
DDX19A	DDX19L, FLJ11126	ENSG00000168872	DEAD-box helicase 19A	16	70346829-70373383	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045252, HPA066668	Approved		Uncertain	Nucleoplasm	Liver cancer:8.05e-5 (unfavourable), Head and neck cancer:2.38e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 51.3	Expressed in all		
DDX19B	DBP5, DDX19	ENSG00000157349	DEAD-box helicase 19B	16	70289663-70335283	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB037229, CAB037284, HPA046380, HPA066668	Approved		Uncertain	Nucleoplasm		Expressed in all	Expressed in all			testis: 82.8	Mixed		
DDX21	GURDB, RH-II/GU	ENSG00000165732	DExD-box helicase 21	10	68956128-68985073	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036592, HPA036593	Enhanced		Enhanced	Nucleus<br>Nucleoli	Pancreatic cancer:3.12e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 71.2	Expressed in all		
DDX23	prp28, PRPF28, SNRNP100, U5-100K	ENSG00000174243	DEAD-box helicase 23	12	48829764-48852842	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038680, HPA039037	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:3.03e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 58.2	Expressed in all		
DDX24		ENSG00000089737	DEAD-box helicase 24	14	94048291-94081245	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002554	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:3.06e-9 (favourable), Stomach cancer:2.89e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 45.3	testis: 26.5	Mixed		
DDX27	dJ686N3.1, DRS1	ENSG00000124228	DEAD-box helicase 27	20	49219295-49244077	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047087	Uncertain		Approved	Nucleoli	Liver cancer:6.70e-7 (unfavourable), Endometrial cancer:1.44e-5 (unfavourable), Renal cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
DDX31	FLJ13633, FLJ14578, FLJ23349, PPP1R25	ENSG00000125485	DEAD-box helicase 31	9	132592997-132670401	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020891			Supported	Nucleoli<br>Golgi apparatus<br>Vesicles	Liver cancer:1.68e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 23.0	Expressed in all		
DDX39A	BAT1L, DDX39, DDXL, URH49	ENSG00000123136	DExD-box helicase 39A	19	14408819-14419383	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055334	Approved		Approved	Nuclear speckles	Renal cancer:1.50e-10 (unfavourable), Cervical cancer:6.86e-4 (favourable)	Expressed in all	Expressed in all			testis: 209.7	Expressed in all		
DDX39B	BAT1, D6S81E, UAP56	ENSG00000198563	DExD-box helicase 39B	6	31530219-31542448	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB034012, HPA055334, HPA058450	Enhanced		Enhanced	Nuclear speckles	Renal cancer:1.11e-6 (unfavourable), Urothelial cancer:1.43e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 45.0	Expressed in all		
DDX3X	DBX, DDX14, DDX3, HLP2	ENSG00000215301	DEAD-box helicase 3, X-linked	X	41333348-41364472	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001648, HPA005631, HPA059585	Supported	Approved	Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 274.6	Expressed in all		
DDX3Y	DBY	ENSG00000067048	DEAD-box helicase 3, Y-linked	Y	12904108-12920478	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001648, HPA005631	Uncertain	Approved	Supported	Nucleus<br>Cytosol	Head and neck cancer:4.70e-5 (favourable)	Mixed	Tissue enhanced		testis: 128.6	prostate: 54.0	Cell line enhanced		HEL: 139.0
DDX4	VASA	ENSG00000152670	DEAD-box helicase 4	5	55738017-55817157	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB026170, HPA037763, HPA037764	Enhanced					Tissue enriched	Tissue enriched	526	testis: 270.5	tonsil: 0.5	Cell line enhanced		BEWO: 1.8
DDX41	ABS, MGC8828	ENSG00000183258	DEAD-box helicase 41	5	177511577-177517469	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017911, HPA048803	Enhanced		Supported	Nucleus	Renal cancer:2.21e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 52.6	Expressed in all		
DDX42	RHELP, RNAHP, SF3b125, SF3B8	ENSG00000198231	DEAD-box helicase 42	17	63773603-63819317	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023447, HPA023571, HPA025941	Enhanced		Enhanced	Nuclear speckles	Liver cancer:2.84e-4 (unfavourable), Renal cancer:9.26e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 75.1	Expressed in all		
DDX43	CT13, DKFZp434H2114, HAGE	ENSG00000080007	DEAD-box helicase 43	6	73394748-73417569	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031381	Enhanced					Tissue enriched	Tissue enriched	5	testis: 34.6	placenta: 6.8	Cell line enhanced		BEWO: 7.5;CAPAN-2: 11.7;HHSteC: 3.0;U-2 OS: 8.7
DDX46	FLJ25329, KIAA0801, Prp5, PRPF5	ENSG00000145833	DEAD-box helicase 46	5	134758771-134855133	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036554, HPA057501	Supported		Enhanced	Nuclear speckles	Colorectal cancer:9.01e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.4	Expressed in all		
DDX47	DKFZp564O176, FLJ30012, HQ0256, RRP3	ENSG00000213782	DEAD-box helicase 47	12	12813316-12829981	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014855	Approved		Enhanced	Nucleoli		Mixed	Expressed in all			thyroid gland: 55.8	Expressed in all		
DDX49	FLJ10432	ENSG00000105671	DEAD-box helicase 49	19	18919675-18928633	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041870, HPA048093	Enhanced		Approved	Nucleoli<br>Mitochondria	Cervical cancer:2.01e-6 (favourable), Renal cancer:7.44e-5 (unfavourable), Liver cancer:7.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.3	Expressed in all		
DDX5	G17P1, HLR1, p68	ENSG00000108654	DEAD-box helicase 5	17	64499616-64508199	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005868, HPA020043	Supported		Enhanced	Nucleoplasm	Colorectal cancer:2.12e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 599.5	Expressed in all		
DDX50	GU2, GUB, MGC3199, RH-II/GuB	ENSG00000107625	DExD-box helicase 50	10	68901278-68946847	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037388, HPA037389, HPA058196	Approved		Enhanced	Nucleoli		Expressed in all	Expressed in all			testis: 47.0	Expressed in all		
DDX51		ENSG00000185163	DEAD-box helicase 51	12	132136594-132144335	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039503	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:4.73e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 11.4	Expressed in all		
DDX52	ROK1	ENSG00000278053	DExD-box helicase 52	17	37609739-37643464	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056173	Uncertain		Supported	Nucleus<br>Nucleoli	Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:9.41e-4 (favourable)	Expressed in all	Mixed			epididymis: 4.6	Mixed		
DDX53	CAGE, CT26	ENSG00000184735	DEAD-box helicase 53	X	22999961-23003589	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	100	testis: 10.0	all non-specific tissues: 0.0	Cell line enhanced		K-562: 4.1;RPMI-8226: 1.6;U-2197: 1.3;U-266/84: 7.3
DDX54	APR-5, DP97, MGC2835	ENSG00000123064	DEAD-box helicase 54	12	113157174-113185479	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028244, HPA070786	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Liver cancer:1.39e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 38.8	Expressed in all		
DDX55	KIAA1595	ENSG00000111364	DEAD-box helicase 55	12	123602077-123620941	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039962, HPA044101	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:8.97e-12 (unfavourable), Liver cancer:2.11e-9 (unfavourable)	Expressed in all	Expressed in all			skin: 16.4	Expressed in all		
DDX56	NOH61	ENSG00000136271	DEAD-box helicase 56	7	44565417-44575051	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019749, CAB037320	Uncertain				Renal cancer:8.41e-7 (unfavourable), Liver cancer:1.38e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland,skin: 5.6	Expressed in all		
DDX58	DKFZp434J1111, FLJ13599, RIG-I	ENSG00000107201	DExD/H-box helicase 58	9	32455705-32526324	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB012643, HPA047193	Uncertain		Supported	Cytosol	Renal cancer:4.66e-4 (unfavourable), Endometrial cancer:5.46e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 19.8	Group enriched	6	BJ hTERT+ SV40 Large T+: 118.2;BJ hTERT+ SV40 Large T+ RasG12V: 128.1
DDX59	DKFZP564B1023, ZNHIT5	ENSG00000118197	DEAD-box helicase 59	1	200623896-200669969	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047166	Approved		Approved	Nucleus<br>Actin filaments	Renal cancer:9.02e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 33.4	Expressed in all		
DDX6	HLR2, RCK	ENSG00000110367	DEAD-box helicase 6	11	118747766-118791149	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004668, HPA024201, HPA026644	Approved		Supported	Cytosol<br>Cytoplasmic bodies	Liver cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.6	Expressed in all		
DDX60	FLJ20035	ENSG00000137628	DExD/H-box helicase 60	4	168216293-168318807	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046952	Approved		Supported	Intermediate filaments<br>Cytosol	Pancreatic cancer:3.35e-4 (unfavourable)	Expressed in all	Mixed			stomach: 45.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 35.0;BJ hTERT+ SV40 Large T+ RasG12V: 35.2
DDX60L	FLJ31033	ENSG00000181381	DEAD-box helicase 60-like	4	168356735-168537786	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043211, HPA055501	Approved		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:3.04e-5 (unfavourable), Renal cancer:2.94e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 33.7	Mixed		
DEC1	CTS9	ENSG00000173077	Deleted in esophageal cancer 1	9	115141818-115402644	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.5	Not detected		
DECR1	DECR, SDR18C1	ENSG00000104325	2,4-dienoyl-CoA reductase 1	8	90001405-90052092	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023160, HPA023162, HPA023238	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:1.79e-7 (favourable), Breast cancer:1.49e-4 (unfavourable), Urothelial cancer:6.06e-4 (favourable)	Expressed in all	Expressed in all			liver: 262.9	Expressed in all		
DECR2	PDCR, SDR17C1	ENSG00000242612	2,4-dienoyl-CoA reductase 2	16	401826-412487	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047631			Approved	Peroxisomes		Expressed in all	Mixed			duodenum: 10.5	Mixed		
DEDD	CASP8IP1, DEDD1, DEFT, FLDED1, KE05	ENSG00000158796	Death effector domain containing	1	161120974-161132688	Predicted intracellular proteins	Evidence at protein level	HPA030681, HPA073628	Approved		Approved	Nucleoplasm	Renal cancer:4.98e-7 (unfavourable), Liver cancer:8.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 47.2	Expressed in all		
DEDD2	FLAME-3	ENSG00000160570	Death effector domain containing 2	19	42198598-42220140	Predicted intracellular proteins	Evidence at protein level	HPA043419			Approved	Nucleoplasm	Urothelial cancer:3.26e-6 (favourable)	Expressed in all	Mixed			spleen: 11.8	Mixed		
DEF6	IBP, SLAT, SWAP70L	ENSG00000023892	DEF6, guanine nucleotide exchange factor	6	35297852-35321771	Predicted intracellular proteins	Evidence at protein level	HPA038975, HPA038976	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.02e-8 (unfavourable), Breast cancer:3.02e-6 (favourable), Cervical cancer:1.08e-4 (favourable), Colorectal cancer:1.71e-4 (unfavourable), Endometrial cancer:2.37e-4 (favourable)	Expressed in all	Mixed			lymph node: 56.1	Cell line enhanced		U-937: 93.5
DEFB112	DEFB-12	ENSG00000180872	Defensin beta 112	6	50043575-50048651	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	53	epididymis: 172.5	seminal vesicle: 3.2	Not detected		
DEK	D6S231E	ENSG00000124795	DEK proto-oncogene	6	18223868-18264823	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015226, HPA054505, HPA057799	Enhanced		Enhanced	Nucleus	Renal cancer:3.45e-4 (unfavourable), Liver cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 158.8	Mixed		
DENND1C	FAM31C, FLJ22757	ENSG00000205744	DENN domain containing 1C	19	6467207-6482557	Predicted intracellular proteins	Evidence at protein level	HPA042758, HPA042839	Enhanced				Renal cancer:7.51e-14 (favourable), Lung cancer:1.23e-4 (favourable), Urothelial cancer:5.62e-4 (favourable), Prostate cancer:8.95e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 28.2;lymph node: 37.1;spleen: 31.7	bone marrow: 14.0	Cell line enhanced		Daudi: 16.1;HEL: 13.5;HMC-1: 39.4;U-937: 24.3
DENND2A	FAM31D, KIAA1277	ENSG00000146966	DENN domain containing 2A	7	140518420-140673993	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.05e-6 (unfavourable), Glioma:4.97e-4 (unfavourable), Colorectal cancer:9.35e-4 (favourable)	Tissue enriched	Mixed			endometrium: 31.6	Cell line enhanced		AF22: 53.5;BJ hTERT+: 42.3;RPTEC TERT1: 51.1;U-2197: 29.5
DENND2C	dJ1156J9.1, DKFZp686G0351, DKFZp779P1149, FLJ37099, RP5-1156J9.1	ENSG00000175984	DENN domain containing 2C	1	114582848-114670422	Predicted intracellular proteins	Evidence at protein level	HPA054955	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		esophagus: 19.5;skeletal muscle: 14.3;skin: 14.8	testis: 10.0	Cell line enhanced		U-2197: 10.9;U-266/70: 19.3
DENND2D	FLJ22457, RP5-1180E21.2	ENSG00000162777	DENN domain containing 2D	1	111187174-111204535	Predicted intracellular proteins	Evidence at protein level	HPA043630, HPA048642	Approved		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:8.66e-5 (favourable), Cervical cancer:1.67e-4 (favourable), Head and neck cancer:2.70e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 110.8	tonsil: 77.1	Cell line enhanced		HDLM-2: 60.3;MOLT-4: 132.4;SK-BR-3: 76.3
DENND4A	IRLB, MYCPBP	ENSG00000174485	DENN domain containing 4A	15	65658046-65792293	Predicted intracellular proteins	Evidence at protein level	HPA065343	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 23.8	Expressed in all		
DENND6A	AFI1A, FAM116A, FLJ34969	ENSG00000174839	DENN domain containing 6A	3	57625457-57693089	Predicted intracellular proteins	Evidence at protein level	HPA062618, HPA069725, HPA071711	Approved		Supported	Vesicles	Renal cancer:7.77e-6 (favourable), Liver cancer:6.36e-4 (unfavourable), Colorectal cancer:9.21e-4 (favourable)	Expressed in all	Expressed in all			ovary: 25.6	Expressed in all		
DENND6B	AFI1B, FAM116B, MGC33692	ENSG00000205593	DENN domain containing 6B	22	50309030-50327060	Predicted intracellular proteins	Evidence at protein level	HPA018934, HPA021653, HPA029570	Uncertain		Uncertain	Plasma membrane	Endometrial cancer:5.93e-5 (favourable), Colorectal cancer:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 21.5	cerebral cortex: 12.0	Mixed		
DENR	DRP, DRP1, SMAP-3	ENSG00000139726	Density regulated re-initiation and release factor	12	122752774-122771064	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021783	Approved		Approved	Cytosol	Liver cancer:1.58e-7 (unfavourable), Renal cancer:8.57e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 108.3	Expressed in all		
DEPDC1	DEP.8, DEPDC1A, FLJ20354, SDP35	ENSG00000024526	DEP domain containing 1	1	68474152-68497221	Predicted intracellular proteins	Evidence at protein level	CAB017845	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Colorectal cancer:8.70e-5 (favourable)	Mixed	Tissue enhanced		testis: 14.5	lymph node: 5.8	Mixed		
DEPDC1B	BRCC3, XTP1	ENSG00000035499	DEP domain containing 1B	5	60596912-60700190	Predicted intracellular proteins	Evidence at protein level	HPA038255, HPA072558	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Lung cancer:6.93e-5 (unfavourable), Colorectal cancer:2.42e-4 (favourable), Liver cancer:3.08e-4 (unfavourable), Endometrial cancer:8.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 33.0;testis: 22.6	lymph node: 10.8	Mixed		
DEPDC4	DEP.4, FLJ33505	ENSG00000166153	DEP domain containing 4	12	100203669-100267079	Predicted intracellular proteins	Evidence at protein level	HPA039323	Uncertain		Approved	Microtubules		Mixed	Tissue enhanced		testis: 7.2	kidney: 1.8	Mixed		
DEPDC5	DEP.5, KIAA0645	ENSG00000100150	DEP domain containing 5	22	31753951-31907034	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA054969, HPA055619	Uncertain		Approved	Golgi apparatus	Renal cancer:2.46e-5 (favourable), Urothelial cancer:4.86e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 13.5	Expressed in all		
DEPDC7		ENSG00000121690	DEP domain containing 7	11	33015864-33033582	Predicted intracellular proteins	Evidence at protein level	HPA015800			Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:7.26e-4 (favourable)	Mixed	Tissue enhanced		liver: 37.6;testis: 50.7	small intestine: 31.2	Cell line enhanced		LHCN-M2: 44.3;RH-30: 38.6;SiHa: 39.2
DEPTOR	DEP.6, DEPDC6, FLJ12428	ENSG00000155792	DEP domain containing MTOR interacting protein	8	119873717-120050913	Predicted intracellular proteins	Evidence at protein level	CAB020841, HPA023938, HPA023945, HPA024011	Enhanced		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			thyroid gland: 163.8	Cell line enhanced		Daudi: 74.2;RPMI-8226: 128.8;RPTEC TERT1: 111.5
DERA	CGI-26, DEOC	ENSG00000023697	Deoxyribose-phosphate aldolase	12	15911172-16037282	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055897			Supported	Nucleus	Thyroid cancer:3.64e-5 (favourable), Pancreatic cancer:1.32e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 74.7	Expressed in all		
DES	CMD1I, CSM1, CSM2	ENSG00000175084	Desmin	2	219418377-219426739	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000034, HPA018803	Enhanced		Supported	Intermediate filaments	Renal cancer:5.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		heart muscle: 4151.2;skeletal muscle: 5462.0;smooth muscle: 3601.2	seminal vesicle: 3128.9	Cell line enhanced		HSkMC: 50.9;LHCN-M2: 120.4;RH-30: 321.1
DESI1	D15Wsu75e, FAM152B, PPPDE2	ENSG00000100418	Desumoylating isopeptidase 1	22	41598028-41621096	Predicted intracellular proteins	Evidence at protein level	HPA053415	Approved		Approved	Cytokinetic bridge<br>Cytosol	Endometrial cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.5	Expressed in all		
DESI2	C1orf121, CGI-146, FAM152A, FLJ21998, PNAS-4, PPPDE1	ENSG00000121644	Desumoylating isopeptidase 2	1	244652935-244709033	Predicted intracellular proteins	Evidence at protein level	HPA049950			Approved	Vesicles	Renal cancer:4.25e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 95.0	Expressed in all		
DET1	FLJ10103	ENSG00000140543	De-etiolated homolog 1 (Arabidopsis)	15	88494440-88546675	Predicted intracellular proteins	Evidence at protein level	HPA048873	Uncertain		Approved	Nucleoplasm<br>Microtubules		Expressed in all	Mixed			ovary: 14.1	Mixed		
DFFA	DFF-45, DFF1, DFF45, ICAD	ENSG00000160049	DNA fragmentation factor subunit alpha	1	10456522-10472526	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002679, HPA018859, HPA019938, HPA025230	Supported		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.57e-9 (favourable), Liver cancer:9.46e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 28.8	Expressed in all		
DFFB	CAD, CPAN, DFF-40, DFF40	ENSG00000169598	DNA fragmentation factor subunit beta	1	3857267-3885429	Predicted intracellular proteins	Evidence at protein level	CAB004328, HPA052904	Approved		Approved	Nucleus<br>Nucleoli	Urothelial cancer:6.29e-5 (favourable)	Expressed in all	Mixed			duodenum: 2.9	Mixed		
DFNB59	pejvakin	ENSG00000204311	Deafness, autosomal recessive 59	2	178451436-178461390	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA042621			Supported	Mitochondria	Renal cancer:8.92e-4 (unfavourable)	Mixed	Tissue enriched	6	testis: 32.4	ovary: 5.4	Mixed		
DGCR14	DGCR13, DGS-H, DGSI, ES2, Es2el	ENSG00000100056	DiGeorge syndrome critical region gene 14	22	19130279-19144684	Predicted intracellular proteins	Evidence at protein level	HPA001221, HPA001222	Enhanced		Approved	Nucleoplasm		Expressed in all	Mixed			testis: 1.9	Mixed		
DGCR6		ENSG00000183628	DiGeorge syndrome critical region gene 6	22	18906028-18914238	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 11.7	thyroid gland: 4.9	Mixed		
DGCR6L	FLJ10666	ENSG00000128185	DiGeorge syndrome critical region gene 6-like	22	20314276-20320080	Predicted intracellular proteins	Evidence at protein level						Cervical cancer:3.82e-5 (favourable), Lung cancer:5.37e-4 (favourable)	Expressed in all	Expressed in all			testis: 97.0	Expressed in all		
DGCR8	C22orf12, DGCRK6, Gy1, pasha	ENSG00000128191	DGCR8, microprocessor complex subunit	22	20080232-20111877	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.08e-4 (unfavourable), Renal cancer:5.67e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.1	Expressed in all		
DGKA	DAGK, DAGK1, DGK-alpha	ENSG00000065357	Diacylglycerol kinase alpha	12	55927319-55954027	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041645, HPA045462	Approved		Approved	Nucleoplasm<br>Vesicles<br>Mitochondria	Renal cancer:1.66e-5 (unfavourable)	Expressed in all	Mixed			skin: 97.4	Cell line enhanced		HBEC3-KT: 93.1;hTERT-HME1: 102.8
DGKB	DAGK2, DGK, DGK-BETA, KIAA0718	ENSG00000136267	Diacylglycerol kinase beta	7	14145049-14974777	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020321		Supported				Tissue enriched	Tissue enriched	6	cerebral cortex: 34.2	endometrium: 5.6	Cell line enhanced		AF22: 1.2;fHDF/TERT166: 2.0;SCLC-21H: 1.5;U-266/70: 2.5
DGKD	DGKdelta, KIAA0145	ENSG00000077044	Diacylglycerol kinase delta	2	233354507-233472104	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027530, HPA049101	Approved		Supported	Cytosol	Renal cancer:4.07e-8 (unfavourable), Liver cancer:1.69e-5 (unfavourable)	Expressed in all	Mixed			testis: 20.8	Expressed in all		
DGKG	DAGK3	ENSG00000058866	Diacylglycerol kinase gamma	3	186105668-186362237	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036577	Approved		Approved	Vesicles<br>Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 21.4	placenta: 11.3	Cell line enhanced		HDLM-2: 22.1;U-87 MG: 13.9
DGKH	DGKeta	ENSG00000102780	Diacylglycerol kinase eta	13	42040036-42256578	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039533, HPA040355	Uncertain					Mixed	Mixed			epididymis: 8.4	Mixed		
DGKI	DGK-IOTA	ENSG00000157680	Diacylglycerol kinase iota	7	137381037-137847092	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021924			Approved	Nucleoplasm		Mixed	Group enriched	11	cerebral cortex: 9.3;thyroid gland: 33.0	heart muscle,smooth muscle: 1.8	Cell line enhanced		SCLC-21H: 7.5;U-2197: 16.4;U-87 MG: 6.3
DGKK		ENSG00000274588	Diacylglycerol kinase kappa	X	50365409-50470738	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	adrenal gland: 4.5	cerebral cortex: 0.6	Cell line enriched	14	Hep G2: 23.8
DGKQ	DAGK, DAGK4, DAGK7	ENSG00000145214	Diacylglycerol kinase theta	4	958887-986895	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026797, CAB033835	Uncertain					Expressed in all	Expressed in all			small intestine: 26.0	Mixed		
DGKZ	DAGK5, DAGK6, DGK-ZETA, hDGKzeta	ENSG00000149091	Diacylglycerol kinase zeta	11	46332905-46380554	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051336	Supported		Supported	Nuclear speckles	Renal cancer:4.74e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 132.6	Expressed in all		
DGUOK	dGK	ENSG00000114956	Deoxyguanosine kinase	2	73926826-73958961	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034766, HPA057246	Approved				Renal cancer:8.69e-7 (unfavourable), Urothelial cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			testis: 56.6	Expressed in all		
DHDDS	DS, FLJ13102, HDS, RP59	ENSG00000117682	Dehydrodolichyl diphosphate synthase subunit	1	26432282-26471294	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026721, HPA026727	Uncertain		Uncertain	Plasma membrane	Renal cancer:4.08e-7 (favourable)	Expressed in all	Expressed in all			adipose tissue: 54.5	Expressed in all		
DHDH	HUM2DD	ENSG00000104808	Dihydrodiol dehydrogenase	19	48933682-48944969	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044131	Approved		Approved	Nucleoplasm<br>Actin filaments	Renal cancer:3.15e-4 (favourable), Endometrial cancer:9.91e-4 (unfavourable)	Expressed in all	Group enriched	5	duodenum: 10.2;kidney: 17.8;prostate: 5.1;small intestine: 18.6	testis: 2.5	Cell line enhanced		SCLC-21H: 2.5
DHFR		ENSG00000228716	Dihydrofolate reductase	5	80626228-80654983	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037129, HPA051465	Uncertain		Supported	Mitochondria		Expressed in all	Mixed			lymph node: 49.6	Expressed in all		
DHFR2	DHFRL1, DHFRP4, FLJ16119	ENSG00000178700	Dihydrofolate reductase 2	3	94047836-94063389	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051465	Uncertain		Supported	Mitochondria	Renal cancer:2.30e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 16.2	Mixed		
DHPS	MIG13	ENSG00000095059	Deoxyhypusine synthase	19	12675717-12681902	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014461, HPA029413	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 64.5	Expressed in all		
DHRS1	FLJ25430, MGC20204, SDR19C1	ENSG00000157379	Dehydrogenase/reductase 1	14	24290598-24299833	Predicted intracellular proteins	Evidence at protein level	HPA000599	Approved		Approved	Nucleus<br>Centrosome<br>Cytosol	Liver cancer:1.18e-5 (favourable), Lung cancer:6.83e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 78.3	Expressed in all		
DHRS11	MGC4172, SDR24C1	ENSG00000278535	Dehydrogenase/reductase 11	17	36591798-36600806	Predicted intracellular proteins	Evidence at protein level	HPA041226, HPA048236, HPA053623	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:3.24e-4 (favourable)	Expressed in all	Group enriched	8	colon: 44.6;duodenum: 149.5;rectum: 47.1;small intestine: 133.6	testis: 11.8	Mixed		
DHRS12	FLJ13639, SDR40C1	ENSG00000102796	Dehydrogenase/reductase 12	13	51767993-51804157	Predicted intracellular proteins	Evidence at protein level	CAB034238, HPA057028, HPA058315	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:2.22e-16 (favourable), Breast cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 22.0	Mixed		
DHRS13	MGC23280, SDR7C5	ENSG00000167536	Dehydrogenase/reductase 13	17	28897781-28903071	Predicted intracellular proteins	Evidence at protein level	HPA022991	Uncertain		Approved	Vesicles	Liver cancer:3.39e-6 (unfavourable)	Expressed in all	Mixed			bone marrow: 25.2	Mixed		
DHRS2	HEP27, SDR25C1	ENSG00000100867	Dehydrogenase/reductase 2	14	23630115-23645639	Predicted intracellular proteins	Evidence at protein level	HPA053915, HPA069551	Enhanced		Enhanced	Nucleus<br>Mitochondria	Renal cancer:3.75e-5 (unfavourable), Endometrial cancer:3.23e-4 (unfavourable), Urothelial cancer:6.45e-4 (favourable)	Tissue enriched	Group enriched	9	breast: 436.3;urinary bladder: 339.0	salivary gland: 40.8	Cell line enhanced		Hep G2: 476.9;RT4: 659.6;SK-BR-3: 2967.1;U-2 OS: 1332.4
DHRS4	FLJ11008, humNRDR, SCAD-SRL, SDR-SRL, SDR25C2	ENSG00000157326	Dehydrogenase/reductase 4	14	23953586-23969279	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023972	Uncertain		Approved	Nuclear membrane<br>Vesicles	Renal cancer:4.55e-6 (favourable)	Expressed in all	Expressed in all			kidney: 149.0	Mixed		
DHRS4L2	SDR25C3	ENSG00000187630	Dehydrogenase/reductase 4 like 2	14	23969874-24006408	Predicted intracellular proteins	Evidence at protein level	HPA023972	Uncertain		Uncertain	Nuclear membrane<br>Vesicles	Ovarian cancer:3.21e-4 (favourable)	Expressed in all	Expressed in all			kidney: 123.6	Mixed		
DHTKD1	CMT2Q, DKFZP762M115, KIAA1630, MGC3090	ENSG00000181192	Dehydrogenase E1 and transketolase domain containing 1	10	12068972-12123225	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037949, HPA037950, HPA066098	Approved		Supported	Mitochondria	Renal cancer:3.43e-4 (favourable)	Expressed in all	Expressed in all			liver: 66.5	Expressed in all		
DHX15	DBP1, DDX15, HRH2, PRP43, PRPF43, PrPp43p	ENSG00000109606	DEAH-box helicase 15	4	24517441-24584550	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047047	Approved		Enhanced	Nuclear speckles	Colorectal cancer:5.74e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 102.7	Expressed in all		
DHX16	DBP2, DDX16, Prp2, PRPF2	ENSG00000204560	DEAH-box helicase 16	6	30653119-30673037	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051455	Enhanced		Supported	Nucleoplasm		Expressed in all	Mixed			testis: 11.5	Expressed in all		
DHX32	DDX32, DHLP1, FLJ10694, FLJ10889	ENSG00000089876	DEAH-box helicase 32 (putative)	10	125836337-125896436	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048872	Approved				Pancreatic cancer:9.49e-5 (unfavourable), Prostate cancer:6.34e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.8	Mixed		
DHX33	DDX33, DKFZp762F2011, FLJ21972	ENSG00000005100	DEAH-box helicase 33	17	5440912-5469060	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA073875			Supported	Nucleoli	Prostate cancer:6.10e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 13.6	Expressed in all		
DHX34	DDX34, KIAA0134	ENSG00000134815	DExH-box helicase 34	19	47349281-47382704	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042159, HPA043558	Uncertain		Uncertain	Nucleus<br>Intermediate filaments	Renal cancer:3.16e-6 (unfavourable), Liver cancer:8.63e-6 (unfavourable)	Expressed in all	Mixed			testis: 20.8	Expressed in all		
DHX35	C20orf15, DDX35, FLJ22759, KAIA0875	ENSG00000101452	DEAH-box helicase 35	20	38962299-39039723	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054451, HPA062700	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Centrosome	Liver cancer:5.63e-6 (unfavourable), Endometrial cancer:4.25e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 14.9	Expressed in all		
DHX37	DDX37, KIAA1517, MGC2695, MGC4322	ENSG00000150990	DEAH-box helicase 37	12	124946825-124989122	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047607	Enhanced		Approved	Nuclear membrane	Liver cancer:9.54e-10 (unfavourable)	Expressed in all	Mixed			bone marrow: 10.0	Expressed in all		
DHX38	DDX38, hPrp16, KIAA0224, PRP16, PRPF16	ENSG00000140829	DEAH-box helicase 38	16	72093562-72112912	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041347, HPA041604	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 50.0	Expressed in all		
DHX40	ARG147, DDX40, FLJ22060, PAD	ENSG00000108406	DEAH-box helicase 40	17	59565525-59608345	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044350	Uncertain		Supported	Nucleus	Colorectal cancer:4.05e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 89.6	Expressed in all		
DHX57	DDX57	ENSG00000163214	DExH-box helicase 57	2	38797729-38875934	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036160	Uncertain		Approved	Nucleoli<br>Intermediate filaments<br>Microtubules<br>Cytosol	Liver cancer:3.32e-6 (unfavourable)	Expressed in all	Mixed			testis: 30.8	Expressed in all		
DHX58	D11LGP2, LGP2	ENSG00000108771	DExH-box helicase 58	17	42101404-42112733	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018670, HPA019570	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:3.45e-4 (favourable)	Expressed in all	Expressed in all			spleen: 24.9	Cell line enhanced		BJ hTERT+ SV40 Large T+: 42.1;BJ hTERT+ SV40 Large T+ RasG12V: 51.2
DHX9	DDX9, LKP, RHA	ENSG00000135829	DExH-box helicase 9	1	182839369-182887751	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011819, HPA028050, HPA055684	Supported		Enhanced	Nucleus	Liver cancer:3.17e-4 (unfavourable), Melanoma:6.04e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 137.9	Expressed in all		
DIAPH1	DFNA1, hDIA1, LFHL1	ENSG00000131504	Diaphanous related formin 1	5	141515016-141619055	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004916, HPA076913	Approved		Approved	Plasma membrane	Renal cancer:1.29e-5 (favourable), Pancreatic cancer:7.81e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 73.6	Expressed in all		
DIAPH2	DIA, DIA2, POF, POF2	ENSG00000147202	Diaphanous related formin 2	X	96684663-97604997	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005647, CAB015461, CAB068183, CAB068184	Enhanced		Supported	Nucleoli<br>Endoplasmic reticulum<br>Vesicles	Endometrial cancer:2.16e-5 (unfavourable), Pancreatic cancer:2.12e-4 (unfavourable), Renal cancer:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 17.8	Mixed		
DIAPH3	AN, AUNA1, DRF3, FLJ34705, NSDAN	ENSG00000139734	Diaphanous related formin 3	13	59665583-60163987	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032151			Supported	Plasma membrane<br>Microtubules	Lung cancer:3.72e-4 (unfavourable), Endometrial cancer:4.18e-4 (unfavourable), Colorectal cancer:9.04e-4 (favourable)	Mixed	Tissue enriched	7	testis: 34.0	placenta: 5.0	Mixed		
DICER1	Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1	ENSG00000100697	Dicer 1, ribonuclease III	14	95086228-95158010	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000694, CAB068185	Approved		Supported	Cytosol		Expressed in all	Expressed in all			placenta: 32.6	Expressed in all		
DIDO1	BYE1, C20orf158, DATF1, DIO-1, DIO1, dJ885L7.8, FLJ11265, KIAA0333	ENSG00000101191	Death inducer-obliterator 1	20	62877738-62937952	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004374, HPA049904	Supported		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Pancreatic cancer:3.88e-4 (favourable), Head and neck cancer:5.13e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 48.2	Expressed in all		
DIEXF	C1orf107, DEF, MGC29875, UTP25	ENSG00000117597	Digestive organ expansion factor homolog (zebrafish)	1	209828007-209857565	Predicted intracellular proteins	Evidence at protein level	HPA026640, HPA061682	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			ovary: 8.8	Expressed in all		
DIMT1	DIMT1L, HSA9761	ENSG00000086189	DIM1 dimethyladenosine transferase 1 homolog	5	62387254-62403939	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042944	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:8.90e-12 (unfavourable), Liver cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 33.7	Expressed in all		
DIP2B	FLJ34278, KIAA1463	ENSG00000066084	Disco interacting protein 2 homolog B	12	50504985-50748667	Predicted intracellular proteins	Evidence at protein level	HPA038472, HPA046133, HPA056045	Enhanced		Approved	Endoplasmic reticulum	Breast cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 31.0	Expressed in all		
DIRAS1	Di-Ras1, GBTS1, RIG	ENSG00000176490	DIRAS family GTPase 1	19	2714567-2721418	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:4.78e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 70.9;heart muscle: 42.5	parathyroid gland: 23.9	Cell line enhanced		HMC-1: 37.7;REH: 44.4
DIRAS2	Di-Ras2, DKFZp761C07121	ENSG00000165023	DIRAS family GTPase 2	9	90609832-90643105	Predicted intracellular proteins	Evidence at protein level	HPA043758	Uncertain					Tissue enhanced	Tissue enriched	9	cerebral cortex: 128.3	cervix, uterine: 13.9	Cell line enhanced		AF22: 7.0;EFO-21: 1.9;SCLC-21H: 1.5
DIRAS3	ARHI, NOEY2	ENSG00000162595	DIRAS family GTPase 3	1	68045962-68051631	Predicted intracellular proteins	Evidence at protein level	HPA028483, HPA028557, HPA029384	Approved		Approved	Nuclear membrane<br>Cytosol	Breast cancer:9.21e-4 (favourable), Renal cancer:9.21e-4 (favourable)	Mixed	Tissue enhanced		ovary: 57.2	parathyroid gland: 20.5	Cell line enhanced		HSkMC: 9.3;TIME: 7.1;U-251 MG: 5.6;U-87 MG: 12.2
DIRC1		ENSG00000174325	Disrupted in renal carcinoma 1	2	188734155-188790104	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA068508			Approved	Nucleoplasm		Not detected	Not detected			gallbladder: 0.4	Cell line enhanced		ASC diff: 2.6;ASC TERT1: 18.9;HSkMC: 7.2
DIRC3	FLJ14199	ENSG00000231672	Disrupted in renal carcinoma 3	2	217284019-217756593	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		parathyroid gland: 1.3	testis: 0.7	Not detected		
DIS3	dis3p, EXOSC11, KIAA1008, RRP44	ENSG00000083520	DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease	13	72752169-72782096	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039281, HPA058762	Approved		Enhanced	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 38.7	Expressed in all		
DIS3L	DIS3L1, FLJ38088, KIAA1955, MGC4562	ENSG00000166938	DIS3 like exosome 3'-5' exoribonuclease	15	66293217-66333898	Predicted intracellular proteins	Evidence at protein level	HPA041805	Approved		Approved	Plasma membrane<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 25.6	Expressed in all		
DIS3L2	FAM6A, FLJ36974, MGC42174	ENSG00000144535	DIS3 like 3'-5' exoribonuclease 2	2	231961245-232344350	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035796, HPA035797	Approved				Liver cancer:3.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.4	Expressed in all		
DISC1		ENSG00000162946	Disrupted in schizophrenia 1	1	231626815-232041272	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048911			Approved	Intermediate filaments		Mixed	Mixed			placenta: 10.5	Mixed		
DKC1	Cbf5, DKC, dyskerin, NAP57, NOLA4, XAP101	ENSG00000130826	Dyskerin pseudouridine synthase 1	X	154762742-154777689	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000166, HPA000447, HPA001022, CAB033086	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.46e-9 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Endometrial cancer:2.66e-5 (unfavourable), Head and neck cancer:2.94e-4 (unfavourable), Melanoma:9.13e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 45.5	Expressed in all		
DLAT	DLTA, PDC-E2	ENSG00000150768	Dihydrolipoamide S-acetyltransferase	11	112024814-112064390	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003782, HPA040786, HPA062766	Enhanced		Enhanced	Mitochondria	Renal cancer:1.95e-14 (favourable), Colorectal cancer:6.19e-6 (favourable), Liver cancer:7.49e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.0	Expressed in all		
DLC1	ARHGAP7, DLC-1, HP, p122-RhoGAP, STARD12	ENSG00000164741	DLC1 Rho GTPase activating protein	8	13083361-13604610	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017753	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Endometrial cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			lung: 78.7	Cell line enhanced		U-2197: 120.6
DLD	DLDH, GCSL, LAD	ENSG00000091140	Dihydrolipoamide dehydrogenase	7	107890970-107931730	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044849	Enhanced		Supported	Mitochondria	Renal cancer:7.58e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 174.7	Expressed in all		
DLEC1	CFAP81, DLC1	ENSG00000008226	Deleted in lung and esophageal cancer 1	3	38039205-38124025	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019077	Enhanced		Supported	Cytosol		Mixed	Tissue enhanced		fallopian tube: 29.7;testis: 17.3	lung: 5.9	Not detected		
DLEU1	BCMS, BCMS1, DLB1, LEU1, LINC00021, NCRNA00021, XTP6	ENSG00000176124	Deleted in lymphocytic leukemia 1	13	50082171-50723236	Predicted intracellular proteins	Evidence at protein level	CAB017848, HPA039465	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			testis: 9.3	Expressed in all		
DLEU7	FLJ44882	ENSG00000186047	Deleted in lymphocytic leukemia, 7	13	50711008-50843939	Predicted intracellular proteins	Evidence at transcript level	HPA053750	Uncertain					Mixed	Tissue enriched	7	cerebral cortex: 6.3	epididymis: 0.9	Group enriched	7	NTERA-2: 11.0;U-698: 3.4
DLG1	dJ1061C18.1.1, DLGH1, hdlg, SAP-97, SAP97	ENSG00000075711	Discs large MAGUK scaffold protein 1	3	197042560-197299300	Predicted intracellular proteins	Evidence at protein level	CAB016307, HPA069593	Supported		Uncertain	Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 94.9	Expressed in all		
DLG2	chapsyn-110, PPP1R58, PSD-93, PSD93	ENSG00000150672	Discs large MAGUK scaffold protein 2	11	83455012-85627922	Predicted intracellular proteins	Evidence at protein level	HPA021307, HPA023896, CAB072341	Enhanced		Approved	Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 72.8	thyroid gland: 25.8	Cell line enhanced		BEWO: 7.6;NTERA-2: 5.5;SCLC-21H: 6.4;SH-SY5Y: 8.7;T-47d: 19.2
DLG3	KIAA1232, MRX90, NE-Dlg, NEDLG, PPP1R82, SAP-102, SAP102	ENSG00000082458	Discs large MAGUK scaffold protein 3	X	70444861-70505490	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001733, HPA078130	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:1.72e-10 (favourable), Breast cancer:1.69e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 36.6	Mixed		
DLG5	KIAA0583, P-dlg	ENSG00000151208	Discs large MAGUK scaffold protein 5	10	77790791-77926526	Predicted intracellular proteins	Evidence at protein level	HPA001746			Supported	Cell Junctions	Liver cancer:5.38e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 33.8	Mixed		
DLGAP1	DAP-1, GKAP, SAPAP1	ENSG00000170579	DLG associated protein 1	18	3496032-4455335	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	6	cerebral cortex: 91.2	seminal vesicle: 14.6	Cell line enhanced		Daudi: 7.6;HAP1: 3.8;U-2197: 3.0
DLGAP2	DAP-2	ENSG00000198010	DLG associated protein 2	8	737596-1708474	Nuclear receptors, Predicted intracellular proteins	Evidence at protein level	HPA030320	Uncertain					Not detected	Group enriched	10	cerebral cortex: 2.0;testis: 6.1	thyroid gland: 0.4	Not detected		
DLGAP3	DAP3, SAPAP3	ENSG00000116544	DLG associated protein 3	1	34865436-34929585	Predicted intracellular proteins	Evidence at protein level	HPA026445	Enhanced					Group enriched	Group enriched	12	cerebral cortex: 21.9;testis: 5.7	spleen: 1.1	Cell line enhanced		Daudi: 5.7;NTERA-2: 4.2;SCLC-21H: 14.7
DLGAP4	DAP4, KIAA0964, SAPAP4	ENSG00000080845	DLG associated protein 4	20	36306336-36528637	Predicted intracellular proteins	Evidence at protein level	HPA054105, HPA056378	Approved		Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol	Liver cancer:3.73e-6 (unfavourable), Endometrial cancer:2.24e-5 (unfavourable), Melanoma:9.88e-5 (favourable), Renal cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 61.6	Expressed in all		
DLGAP5	DLG1, DLG7, HURP, KIAA0008	ENSG00000126787	DLG associated protein 5	14	55148112-55191678	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005546	Enhanced		Supported	Microtubule organizing center<br>Cytosol	Liver cancer:1.52e-6 (unfavourable), Pancreatic cancer:9.94e-6 (unfavourable), Endometrial cancer:4.59e-4 (unfavourable), Lung cancer:7.85e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 29.8	lymph node: 20.4	Mixed		
DLST	DLTS	ENSG00000119689	Dihydrolipoamide S-succinyltransferase	14	74881891-74903745	Citric acid cycle related proteins, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003010	Supported				Renal cancer:1.13e-12 (favourable)	Expressed in all	Expressed in all			kidney: 106.7	Expressed in all		
DLX1		ENSG00000144355	Distal-less homeobox 1	2	172084740-172089677	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035666, HPA045884	Approved		Approved	Nucleus<br>Vesicles<br>Cell Junctions		Tissue enhanced	Tissue enhanced		adrenal gland: 1.6;cerebral cortex: 5.0	prostate: 0.8	Cell line enhanced		AN3-CA: 103.9
DLX2	TES-1	ENSG00000115844	Distal-less homeobox 2	2	172099439-172102900	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056965			Approved	Nuclear speckles		Mixed	Not detected			cerebral cortex: 0.8	Group enriched	11	AN3-CA: 73.7;HEK93: 46.5
DLX3		ENSG00000064195	Distal-less homeobox 3	17	49990005-49995224	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Endometrial cancer:4.61e-4 (unfavourable)	Mixed	Group enriched	5	placenta: 10.7;skin: 21.9	thyroid gland: 3.1	Cell line enhanced		BEWO: 131.0;SK-BR-3: 33.0
DLX4	BP1, DLX7, DLX8, DLX9	ENSG00000108813	Distal-less homeobox 4	17	49968970-49974959	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059933	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		placenta: 5.4	skin: 1.2	Cell line enhanced		BEWO: 22.0;CACO-2: 13.7;HAP1: 11.5;K-562: 12.0
DLX5		ENSG00000105880	Distal-less homeobox 5	7	97020392-97025097	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005670	Approved		Approved	Nucleus		Tissue enriched	Tissue enhanced		endometrium: 20.2;placenta: 13.5;skin: 17.1	cervix, uterine: 9.6	Group enriched	5	BEWO: 41.0;HAP1: 24.0
DLX6		ENSG00000006377	Distal-less homeobox 6	7	97005548-97011039	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030608, HPA061460	Uncertain		Approved	Nuclear bodies		Tissue enriched	Tissue enhanced		endometrium: 4.4;placenta: 4.3;testis: 5.4	cervix, uterine: 3.0	Cell line enhanced		AN3-CA: 9.4;BEWO: 32.1;HAP1: 15.7;SCLC-21H: 8.6;SH-SY5Y: 11.6
DMAP1	DNMAP1, DNMTAP1, EAF2, FLJ11543, KIAA1425, MEAF2, SWC4	ENSG00000178028	DNA methyltransferase 1 associated protein 1	1	44213455-44220681	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028419, CAB033018	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 40.4	Expressed in all		
DMBX1	OTX3, PAXB	ENSG00000197587	Diencephalon/mesencephalon homeobox 1	1	46506996-46514226	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026811	Uncertain				Endometrial cancer:7.13e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 1.2	adrenal gland,thyroid gland: 0.4	Cell line enhanced		AN3-CA: 11.9;CAPAN-2: 3.6;K-562: 3.9;SiHa: 4.4
DMC1	LIM15	ENSG00000100206	DNA meiotic recombinase 1	22	38518949-38570286	Predicted intracellular proteins	Evidence at protein level	HPA001232, CAB015397	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enriched	5	testis: 22.0	endometrium: 4.0	Cell line enhanced		HDLM-2: 23.2
DMD	BMD, DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272, MRX85	ENSG00000198947	Dystrophin	X	31097677-33339441	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000119, HPA002725, HPA023885	Enhanced					Mixed	Mixed			seminal vesicle: 54.6	Cell line enhanced		AF22: 25.1;RH-30: 31.0
DMGDH		ENSG00000132837	Dimethylglycine dehydrogenase	5	78997606-79236038	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036441, HPA036442, HPA077849	Enhanced		Supported	Mitochondria	Renal cancer:1.17e-5 (favourable), Liver cancer:5.32e-5 (favourable)	Group enriched	Group enriched	11	kidney: 179.1;liver: 146.2	epididymis: 14.9	Cell line enhanced		BJ hTERT+: 2.9;Hep G2: 5.2
DMRT1	CT154, DMT1	ENSG00000137090	Doublesex and mab-3 related transcription factor 1	9	841690-969090	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027850	Enhanced					Tissue enriched	Tissue enriched	107	testis: 50.7	thyroid gland: 0.4	Cell line enriched	8	SCLC-21H: 3.8
DMRT3	DMRTA3	ENSG00000064218	Doublesex and mab-3 related transcription factor 3	9	976964-991731	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077685	Approved					Tissue enhanced	Tissue enriched	6	parathyroid gland: 65.3	thyroid gland: 10.4	Cell line enhanced		HAP1: 1.3;HEK93: 1.5;SCLC-21H: 1.1;THP-1: 1.8
DMRTA1		ENSG00000176399	DMRT like family A1	9	22446841-22455740	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044764, HPA062253	Uncertain		Approved	Vesicles	Renal cancer:1.14e-6 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 6.5	liver: 4.3	Cell line enhanced		BJ hTERT+: 5.1
DMRTB1		ENSG00000143006	DMRT like family B with proline rich C-terminal 1	1	53459399-53467488	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036490, HPA058553	Enhanced					Tissue enhanced	Tissue enriched	67	testis: 69.6	epididymis: 1.0	Not detected		
DMRTC1		ENSG00000269502	DMRT like family C1	X	72872025-72943814	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA046874, HPA046992	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 2.3	fallopian tube,thyroid gland: 1.3	Not detected		
DMRTC1B		ENSG00000184911	DMRT like family C1B	X	72777009-72848802	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA046874, HPA046992	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 16.6	ovary: 10.3	Not detected		
DMRTC2		ENSG00000142025	DMRT like family C2	19	41844743-41852333	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045016	Uncertain					Not detected	Tissue enriched	128	testis: 48.6	lymph node,parathyroid gland,thyroid gland: 0.3	Not detected		
DMTF1	DMP1, DMTF, hDMP1, MRUL	ENSG00000135164	Cyclin D binding myb like transcription factor 1	7	87152361-87196337	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023846	Supported		Supported	Nucleoplasm	Renal cancer:4.39e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 84.1	Expressed in all		
DMTN	DMT, EPB49	ENSG00000158856	Dematin actin binding protein	8	22048995-22082527	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024290	Uncertain				Renal cancer:3.85e-9 (favourable), Glioma:4.61e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 221.5	Cell line enhanced		HEL: 202.5
DMWD	D19S593E, DMR-N9, gene59	ENSG00000185800	Dystrophia myotonica, WD repeat containing	19	45782947-45792802	Predicted intracellular proteins	Evidence at protein level	HPA068172, HPA069843	Approved		Approved	Plasma membrane<br>Actin filaments	Liver cancer:1.47e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.7	Expressed in all		
DMXL1		ENSG00000172869	Dmx like 1	5	119037772-119249138	Predicted intracellular proteins	Evidence at protein level	HPA036431, HPA036432	Approved		Supported	Nucleoli<br>Cytosol	Renal cancer:5.16e-5 (favourable)	Expressed in all	Mixed			prostate: 43.4	Expressed in all		
DNA2	DNA2L, KIAA0083	ENSG00000138346	DNA replication helicase/nuclease 2	10	68414064-68472121	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037487, HPA057526	Approved		Supported	Mitochondria		Mixed	Mixed			lymph node: 6.3	Mixed		
DNAAF1	CILD13, FLJ25330, LRRC50, ODA7, swt	ENSG00000154099	Dynein axonemal assembly factor 1	16	84145287-84178767	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041166, HPA074239	Enhanced		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Endometrial cancer:2.14e-4 (favourable)	Tissue enhanced	Group enriched	19	fallopian tube: 36.3;testis: 82.6	lung: 3.0	Cell line enhanced		Hep G2: 1.4;Karpas-707: 3.6;PC-3: 1.4;U-266/70: 3.1;U-266/84: 2.0
DNAAF2	C14orf104, CILD10, FLJ10563, KTU, PF13	ENSG00000165506	Dynein axonemal assembly factor 2	14	49625174-49635230	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002894, HPA004113	Enhanced		Supported	Cytosol	Renal cancer:6.74e-7 (favourable)	Expressed in all	Expressed in all			fallopian tube: 13.9	Expressed in all		
DNAAF3	C19orf51, CILD2, FLJ36139, FLJ40069, PCD, PF22	ENSG00000167646	Dynein axonemal assembly factor 3	19	55158661-55166722	Predicted intracellular proteins	Evidence at protein level	HPA056220			Approved	Nuclear bodies<br>Mitochondria	Renal cancer:1.83e-5 (unfavourable)	Mixed	Group enriched	12	fallopian tube: 69.1;testis: 67.9	lung: 5.9	Cell line enhanced		HEK93: 24.3;HEL: 28.5;K-562: 22.5
DNAAF5	CILD18, FLJ20397, FLJ25564, FLJ31671, FLJ39381, HEATR2	ENSG00000164818	Dynein axonemal assembly factor 5	7	726701-786475	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020243	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.83e-4 (unfavourable), Head and neck cancer:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 22.8	Expressed in all		
DNAH1	DNAHC1, HDHC7, HL-11, HL11, XLHSRF-1	ENSG00000114841	Dynein axonemal heavy chain 1	3	52316319-52400491	Predicted intracellular proteins	Evidence at protein level	HPA036805, HPA036806	Uncertain					Mixed	Mixed			testis: 7.8	Mixed		
DNAH10	FLJ43808	ENSG00000197653	Dynein axonemal heavy chain 10	12	123762188-123936206	Predicted intracellular proteins	Evidence at protein level	HPA039066	Enhanced					Tissue enhanced	Group enriched	6	fallopian tube: 5.6;testis: 5.6	lung: 0.9	Not detected		
DNAH10OS	FLJ45278	ENSG00000250091	Dynein axonemal heavy chain 10 opposite strand	12	123926424-123934984	Predicted intracellular proteins	Evidence at transcript level	HPA039786	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 4.0	kidney: 1.6	Mixed		
DNAH11	CILD7, DNAHBL, Dnahc11, DNHBL, DPL11	ENSG00000105877	Dynein axonemal heavy chain 11	7	21543215-21901839	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045880, HPA056474	Approved				Renal cancer:1.49e-7 (unfavourable)	Mixed	Tissue enriched	17	parathyroid gland: 145.0	fallopian tube: 8.5	Cell line enhanced		U-2 OS: 1.1;U-2197: 1.2
DNAH12	DHC3, DLP12, DNAH12L, DNAH7L, Dnahc3, DNHD2, FLJ40427, FLJ44290, hdhc3, HL-19	ENSG00000174844	Dynein axonemal heavy chain 12	3	57293699-57544344	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA037493, HPA058203, HPA061365	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 16.3;testis: 11.1	lung: 2.7	Not detected		
DNAH17	DNAHL1, DNEL2, FLJ40457	ENSG00000187775	Dynein axonemal heavy chain 17	17	78423697-78577394	Predicted intracellular proteins	Evidence at protein level	HPA024354, HPA076261	Enhanced		Approved	Nucleoplasm<br>Plasma membrane		Tissue enhanced	Tissue enriched	21	testis: 10.3	skin: 0.4	Group enriched	5	HeLa: 3.2;MOLT-4: 1.9
DNAH3	DKFZp434N074, DLP3, Dnahc3b, Hsadhc3	ENSG00000158486	Dynein axonemal heavy chain 3	16	20933111-21159441	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062493			Approved	Nuclear membrane<br>Intermediate filaments		Mixed	Group enriched	5	fallopian tube: 8.1;testis: 6.0	lung: 1.3	Not detected		
DNAH5	CILD3, Dnahc5, HL1, KTGNR, PCD	ENSG00000039139	Dynein axonemal heavy chain 5	5	13690331-13944543	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037469, HPA037470	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 6.2;lung: 2.6	breast: 2.0	Cell line enhanced		BJ hTERT+: 1.3;PC-3: 2.5;RPTEC TERT1: 1.1
DNAH6	Dnahc6, DNHL1, FLJ37357, HL-2	ENSG00000115423	Dynein axonemal heavy chain 6	2	84516455-84819589	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036391	Enhanced					Mixed	Tissue enhanced		fallopian tube: 8.7;testis: 4.9	parathyroid gland: 3.2	Not detected		
DNAH7	KIAA0944	ENSG00000118997	Dynein axonemal heavy chain 7	2	195737703-196068812	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034724, HPA044070	Approved		Supported	Cytosol		Not detected	Tissue enhanced		fallopian tube: 15.6;testis: 18.1	thyroid gland: 4.6	Cell line enhanced		PC-3: 5.5
DNAH8	hdhc9	ENSG00000124721	Dynein axonemal heavy chain 8	6	38715341-39030529	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028447	Uncertain					Tissue enriched	Tissue enhanced		testis: 14.3	prostate: 3.4	Cell line enriched	8	HMC-1: 41.4
DNAH9	DNAH17L, Dnahc9, DNAL1, DYH9, HL-20, HL20, KIAA0357	ENSG00000007174	Dynein axonemal heavy chain 9	17	11598431-11969748	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052641	Enhanced				Endometrial cancer:6.79e-5 (favourable)	Tissue enhanced	Tissue enriched	5	fallopian tube: 56.4	testis: 11.1	Cell line enhanced		HDLM-2: 2.8;WM-115: 1.7
DNAI1	CILD1, DIC1, PCD	ENSG00000122735	Dynein axonemal intermediate chain 1	9	34457414-34520989	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021649, HPA021843	Enhanced					Tissue enhanced	Group enriched	10	fallopian tube: 54.3;testis: 61.2	lung: 5.6	Cell line enhanced		BEWO: 1.9;HDLM-2: 1.3
DNAI2	CILD9, DIC2	ENSG00000171595	Dynein axonemal intermediate chain 2	17	74274247-74314884	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB006245, HPA050565	Enhanced					Tissue enhanced	Group enriched	8	fallopian tube: 48.0;testis: 27.7	lung: 4.6	Cell line enhanced		HMC-1: 1.6
DNAJA1	dj-2, hdj-2, HSJ2, HSPF4, NEDD7	ENSG00000086061	DnaJ heat shock protein family (Hsp40) member A1	9	33025211-33039907	Predicted intracellular proteins	Evidence at protein level	HPA001306	Approved		Supported	Microtubules<br>Cytosol	Renal cancer:3.40e-4 (favourable), Ovarian cancer:5.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 241.0	Expressed in all		
DNAJA2	CPR3, DNAJ, DNJ3, HIRIP4	ENSG00000069345	DnaJ heat shock protein family (Hsp40) member A2	16	46955362-46973788	Predicted intracellular proteins	Evidence at protein level	HPA049789, HPA060538	Approved		Approved	Nucleoli<br>Intermediate filaments<br>Cytosol	Renal cancer:1.19e-9 (favourable), Head and neck cancer:2.81e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 42.0	Expressed in all		
DNAJA3	hTid-1, TID1	ENSG00000103423	DnaJ heat shock protein family (Hsp40) member A3	16	4425805-4456775	Predicted intracellular proteins	Evidence at protein level	CAB016095, HPA040875, HPA044229	Approved		Supported	Mitochondria	Renal cancer:1.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 25.4	Expressed in all		
DNAJA4	PRO1472	ENSG00000140403	DnaJ heat shock protein family (Hsp40) member A4	15	78264086-78282196	Predicted intracellular proteins	Evidence at protein level	CAB004646, HPA041790	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.08e-7 (favourable), Glioma:8.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 95.4	Cell line enhanced		CAPAN-2: 38.0;RT4: 67.8;SCLC-21H: 62.7;SiHa: 45.2
DNAJB1	Hsp40, HSPF1, RSPH16B, Sis1	ENSG00000132002	DnaJ heat shock protein family (Hsp40) member B1	19	14514770-14529770	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB017450, HPA063247	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:5.96e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 348.8	Expressed in all		
DNAJB13	RSPH16A, TSARG6	ENSG00000187726	DnaJ heat shock protein family (Hsp40) member B13	11	73950319-73970366	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052465, HPA061330	Enhanced		Approved	Plasma membrane	Renal cancer:2.10e-6 (unfavourable)	Tissue enhanced	Group enriched	7	fallopian tube: 76.0;testis: 19.1	cervix, uterine,epididymis: 6.4	Cell line enhanced		RPTEC TERT1: 3.3
DNAJB2	CMT2T, HSJ1, HSPF3	ENSG00000135924	DnaJ heat shock protein family (Hsp40) member B2	2	219279267-219286900	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036268	Approved		Enhanced	Nuclear membrane	Colorectal cancer:1.01e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 161.8	Expressed in all		
DNAJB4	HLJ1	ENSG00000162616	DnaJ heat shock protein family (Hsp40) member B4	1	77979175-78017964	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004995, HPA028383, HPA028385	Approved		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.28e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.4	Cell line enhanced		HUVEC TERT2: 150.2;LHCN-M2: 254.4
DNAJB5	Hsc40	ENSG00000137094	DnaJ heat shock protein family (Hsp40) member B5	9	34989641-34998900	Predicted intracellular proteins	Evidence at protein level	HPA023818, HPA050794	Approved		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			smooth muscle: 92.2	Mixed		
DNAJB6	LGMD1D, MRJ	ENSG00000105993	DnaJ heat shock protein family (Hsp40) member B6	7	157335381-157417439	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004670, HPA024258, HPA058593	Enhanced		Supported	Nucleoplasm	Liver cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 220.1	Expressed in all		
DNAJB7	HSC3	ENSG00000172404	DnaJ heat shock protein family (Hsp40) member B7	22	40859549-40862126	Predicted intracellular proteins	Evidence at transcript level	HPA000534	Approved					Not detected	Tissue enriched	19	testis: 10.9	duodenum,small intestine: 0.5	Not detected		
DNAJB8	CT156, MGC33884	ENSG00000179407	DnaJ heat shock protein family (Hsp40) member B8	3	128462439-128467248	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	306	testis: 30.5	all non-specific tissues: 0.0	Not detected		
DNAJC12	JDP1	ENSG00000108176	DnaJ heat shock protein family (Hsp40) member C12	10	67796665-67838166	Predicted intracellular proteins	Evidence at protein level	HPA036289	Enhanced				Renal cancer:1.97e-10 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 57.7	breast: 39.4	Cell line enhanced		Daudi: 66.4;SCLC-21H: 86.3
DNAJC17	FLJ10634	ENSG00000104129	DnaJ heat shock protein family (Hsp40) member C17	15	40765155-40807478	Predicted intracellular proteins	Evidence at protein level	HPA040914, HPA041187	Approved		Approved	Nucleoplasm	Colorectal cancer:5.89e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 24.4	Expressed in all		
DNAJC19	Pam18, Tim14, TIMM14	ENSG00000205981	DnaJ heat shock protein family (Hsp40) member C19	3	180983709-180989774	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037782	Approved				Ovarian cancer:8.53e-5 (favourable)	Expressed in all	Expressed in all			kidney: 52.9	Expressed in all		
DNAJC2	MPHOSPH11, MPP11, ZRF1, ZUO1, zuotin	ENSG00000105821	DnaJ heat shock protein family (Hsp40) member C2	7	103312474-103344873	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020454	Approved		Supported	Cytosol	Renal cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 61.7	Expressed in all		
DNAJC21	DNAJA5, GS3, JJJ1	ENSG00000168724	DnaJ heat shock protein family (Hsp40) member C21	5	34929593-34958964	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040789, HPA049208	Approved		Approved	Vesicles	Liver cancer:2.36e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 101.6	Expressed in all		
DNAJC24	DPH4, JJJ3, ZCSL3	ENSG00000170946	DnaJ heat shock protein family (Hsp40) member C24	11	31369840-31431849	Predicted intracellular proteins	Evidence at protein level	HPA020025, HPA025237	Approved		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex,thyroid gland: 11.3	Expressed in all		
DNAJC27	RabJS, RBJ	ENSG00000115137	DnaJ heat shock protein family (Hsp40) member C27	2	24943636-24972094	Predicted intracellular proteins	Evidence at protein level	HPA036815, HPA036816	Uncertain		Supported	Cytosol	Renal cancer:8.48e-5 (favourable)	Mixed	Tissue enhanced		testis: 39.5	cerebral cortex: 8.7	Mixed		
DNAJC28	C21orf55, C21orf78	ENSG00000177692	DnaJ heat shock protein family (Hsp40) member C28	21	33485530-33491720	Predicted intracellular proteins	Evidence at protein level	HPA018003, HPA030076	Approved					Mixed	Tissue enhanced		testis: 8.2	thyroid gland: 4.1	Mixed		
DNAJC6	KIAA0473, PARK19	ENSG00000116675	DnaJ heat shock protein family (Hsp40) member C6	1	65248219-65415869	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031182, HPA054917	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.81e-4 (favourable)	Tissue enhanced	Tissue enriched	10	cerebral cortex: 162.8	adrenal gland: 15.6	Cell line enhanced		HDLM-2: 58.7;HEL: 150.3;K-562: 59.3
DNAJC7	TPR2, TTC2	ENSG00000168259	DnaJ heat shock protein family (Hsp40) member C7	17	41976433-42021376	Predicted intracellular proteins	Evidence at protein level	HPA023015, HPA052395	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:3.35e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.9	Expressed in all		
DNAJC8	SPF31	ENSG00000126698	DnaJ heat shock protein family (Hsp40) member C8	1	28199456-28233025	Predicted intracellular proteins	Evidence at protein level	HPA026275, HPA026283	Approved		Enhanced	Nucleoplasm	Endometrial cancer:6.95e-5 (favourable), Thyroid cancer:2.39e-4 (favourable), Liver cancer:4.71e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 93.5	Expressed in all		
DNAJC9	JDD1, SB73	ENSG00000213551	DnaJ heat shock protein family (Hsp40) member C9	10	73183362-73248862	Predicted intracellular proteins	Evidence at protein level	HPA035215, HPA035216	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Prostate cancer:7.07e-5 (unfavourable), Lung cancer:3.26e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 37.4	Expressed in all		
DNAL1	1700010H15RiK, C14orf168, CILD16, MGC12435	ENSG00000119661	Dynein axonemal light chain 1	14	73644875-73703732	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053129	Uncertain		Approved	Nucleus<br>Microtubule organizing center	Renal cancer:5.17e-8 (favourable)	Expressed in all	Expressed in all			testis: 99.4	Expressed in all		
DNAL4	dJ327J16, PIG27	ENSG00000100246	Dynein axonemal light chain 4	22	38778508-38794198	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003647	Approved		Approved	Nucleus<br>Nucleoli<br>Centrosome<br>Cytosol	Renal cancer:1.20e-6 (favourable)	Expressed in all	Expressed in all			testis: 59.7	Mixed		
DNALI1	dJ423B22.5, hp28, P28	ENSG00000163879	Dynein axonemal light intermediate chain 1	1	37556919-37566857	Predicted intracellular proteins	Evidence at protein level	HPA028305	Approved				Lung cancer:6.02e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 86.2	testis: 38.3	Cell line enhanced		AF22: 13.9;RPTEC TERT1: 12.6;SH-SY5Y: 12.3;T-47d: 28.1
DND1	MGC34750, RBMS4	ENSG00000256453	DND microRNA-mediated repression inhibitor 1	5	140670794-140673586	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	14	testis: 9.8	parathyroid gland: 0.7	Mixed		
DNHD1	C11orf47, CCDC35, DHCD1, DKFZp686J0796, DNHD1L, FLJ32752, FLJ35709, FLJ46184	ENSG00000179532	Dynein heavy chain domain 1	11	6497260-6593758	Predicted intracellular proteins	Evidence at protein level	HPA039698, HPA040267, HPA057639	Uncertain		Approved	Nucleoplasm<br>Cytokinetic bridge		Mixed	Tissue enriched	6	testis: 19.5	bone marrow: 3.5	Mixed		
DNLZ	bA413M3.2, C9orf151, HEP, RP11-413M3.2, TIMM15, ZIM17	ENSG00000213221	DNL-type zinc finger	9	136359480-136363789	Predicted intracellular proteins	Evidence at protein level	HPA062738			Enhanced	Nucleoplasm<br>Mitochondria		Not detected	Expressed in all			cerebral cortex: 13.6	Expressed in all		
DNM1	DNM	ENSG00000106976	Dynamin 1	9	128191655-128255248	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005920, HPA049910, HPA061801	Enhanced		Supported	Nucleoplasm		Mixed	Tissue enriched	14	cerebral cortex: 364.2	cervix, uterine: 25.6	Cell line enhanced		A549: 114.8
DNM1L	DRP1, DVLP, DYMPLE, HDYNIV, VPS1	ENSG00000087470	Dynamin 1 like	12	32679200-32745650	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009952, HPA039324	Enhanced		Enhanced	Vesicles<br>Cytosol	Liver cancer:6.27e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 88.1	Expressed in all		
DNM2	CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII	ENSG00000079805	Dynamin 2	19	10718079-10833488	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA054246	Enhanced		Approved	Golgi apparatus<br>Cytosol	Liver cancer:3.63e-4 (unfavourable), Head and neck cancer:8.91e-4 (favourable)	Expressed in all	Expressed in all			colon: 103.9	Expressed in all		
DNM3	KIAA0820	ENSG00000197959	Dynamin 3	1	171841498-172418466	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064121			Approved	Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 41.1	adrenal gland: 15.6	Cell line enhanced		HEL: 20.5;RPTEC TERT1: 14.4;U-251 MG: 11.7
DNMBP	ARHGEF36, KIAA1010, Tuba	ENSG00000107554	Dynamin binding protein	10	99875577-100009919	Predicted intracellular proteins	Evidence at protein level	HPA037878, HPA058216	Uncertain		Approved	Nucleoli<br>Nuclear bodies<br>Golgi apparatus<br>Cytosol	Endometrial cancer:4.95e-6 (favourable), Urothelial cancer:6.15e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.6	Mixed		
DNMT1	CXXC9, DNMT, MCMT	ENSG00000130816	DNA methyltransferase 1	19	10133345-10231286	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002694, CAB005876	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.46e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 51.2	Expressed in all		
DNMT3A		ENSG00000119772	DNA methyltransferase 3 alpha	2	25227855-25342590	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009469, HPA026588	Approved		Supported	Nucleoplasm	Pancreatic cancer:1.18e-4 (favourable), Endometrial cancer:1.55e-4 (unfavourable), Liver cancer:1.58e-4 (unfavourable), Renal cancer:2.49e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 22.8	Cell line enhanced		NTERA-2: 59.7;SH-SY5Y: 76.5
DNMT3B		ENSG00000088305	DNA methyltransferase 3 beta	20	32762385-32809356	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001595, CAB069896	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.87e-7 (unfavourable), Endometrial cancer:5.04e-4 (unfavourable)	Tissue enriched	Tissue enhanced		testis: 9.2	skin: 4.5	Cell line enhanced		BEWO: 236.9;NTERA-2: 333.3
DNMT3L	MGC1090	ENSG00000142182	DNA methyltransferase 3 like	21	44246339-44262216	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055234, HPA066780	Uncertain		Approved	Nuclear speckles		Tissue enriched	Group enriched	6	kidney: 7.2;liver: 10.4;lymph node: 2.3	spleen: 1.1	Cell line enriched	7	BEWO: 40.9
DNPH1	C6orf108, dJ330M21.3, rcl	ENSG00000112667	2'-deoxynucleoside 5'-phosphate N-hydrolase 1	6	43225629-43229484	Predicted intracellular proteins	Evidence at protein level	HPA029675, HPA029676	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			duodenum: 104.2	Expressed in all		
DNTT	TDT	ENSG00000107447	DNA nucleotidylexotransferase	10	96304396-96338564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044194			Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	8	bone marrow: 18.3	tonsil: 2.1	Group enriched	518	MOLT-4: 325.2;REH: 1262.7
DNTTIP1	C20orf167, dJ447F3.4, Tdif1	ENSG00000101457	Deoxynucleotidyltransferase terminal interacting protein 1	20	45791937-45811427	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042479, HPA045496			Enhanced	Nucleus	Renal cancer:1.90e-6 (unfavourable), Liver cancer:1.79e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 44.6	Expressed in all		
DNTTIP2	ERBP, HSU15552, TdIF2	ENSG00000067334	Deoxynucleotidyltransferase terminal interacting protein 2	1	93866283-93879918	Predicted intracellular proteins	Evidence at protein level	HPA044502, HPA053707	Enhanced		Enhanced	Nucleoli	Liver cancer:1.90e-6 (unfavourable), Renal cancer:7.80e-5 (unfavourable)	Expressed in all	Mixed			bone marrow: 10.5	Expressed in all		
DOC2A		ENSG00000149927	Double C2 domain alpha	16	30005509-30023270	Predicted intracellular proteins	Evidence at protein level	HPA065676			Uncertain	Nucleus<br>Nucleoli<br>Cell Junctions		Tissue enhanced	Group enriched	9	cerebral cortex: 69.7;testis: 21.0	ovary: 5.2	Cell line enhanced		BEWO: 12.9;SCLC-21H: 42.7;U-937: 14.1
DOC2B	DOC2BL	ENSG00000272636	Double C2 domain beta	17	142789-181636	Predicted intracellular proteins	Evidence at protein level	HPA043168	Uncertain				Breast cancer:3.45e-4 (favourable), Head and neck cancer:8.68e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 14.4	Group enriched	8	HAP1: 9.4;SH-SY5Y: 39.6
DOCK1	ced5, DOCK180	ENSG00000150760	Dedicator of cytokinesis 1	10	126905409-127452517	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004378, HPA048692, HPA053277	Approved		Enhanced	Nucleus		Expressed in all	Mixed			parathyroid gland: 65.9	Mixed		
DOCK10	KIAA0694, ZIZ3	ENSG00000135905	Dedicator of cytokinesis 10	2	224765090-225042445	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058106	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			spleen: 46.6	Cell line enhanced		HDLM-2: 50.8
DOCK11	ACG, FLJ32122, FLJ43653, ZIZ2	ENSG00000147251	Dedicator of cytokinesis 11	X	118495898-118686163	Predicted intracellular proteins	Evidence at protein level	HPA059695	Uncertain		Approved	Nuclear membrane<br>Nucleoli	Head and neck cancer:4.87e-4 (favourable)	Expressed in all	Mixed			adipose tissue: 34.0	Cell line enhanced		HMC-1: 81.5
DOCK2	KIAA0209	ENSG00000134516	Dedicator of cytokinesis 2	5	169637247-170083382	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036469	Enhanced					Expressed in all	Mixed			lymph node: 52.1	Cell line enhanced		Daudi: 87.0;HDLM-2: 143.2;HL-60: 97.8;HMC-1: 119.0
DOCK3	KIAA0299, MOCA, PBP	ENSG00000088538	Dedicator of cytokinesis 3	3	50675241-51384198	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037543, HPA037544	Approved		Enhanced	Cytosol		Tissue enhanced	Group enriched	6	cerebral cortex: 33.7;parathyroid gland: 12.6;testis: 8.5;thyroid gland: 15.1	adrenal gland: 3.0	Cell line enhanced		AN3-CA: 5.9;U-87 MG: 8.0
DOCK4	FLJ34238, KIAA0716	ENSG00000128512	Dedicator of cytokinesis 4	7	111726110-112206411	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA071516			Approved	Nucleoli<br>Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 31.9	lung: 27.7	Cell line enhanced		hTEC/SVTERT24-B: 42.1;HUVEC TERT2: 67.4;TIME: 57.4
DOCK5	FLJ21034	ENSG00000147459	Dedicator of cytokinesis 5	8	25184723-25418082	Predicted intracellular proteins	Evidence at protein level	HPA017719, HPA056837	Approved		Enhanced	Cytosol	Renal cancer:1.18e-6 (unfavourable), Endometrial cancer:1.91e-4 (favourable)	Expressed in all	Mixed			spleen: 18.6	Mixed		
DOCK6	KIAA1395, ZIR1	ENSG00000130158	Dedicator of cytokinesis 6	19	11199295-11262481	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049423, HPA049424	Approved		Supported	Cytosol	Head and neck cancer:9.09e-4 (favourable)	Expressed in all	Mixed			skin: 29.4	Cell line enhanced		HUVEC TERT2: 57.1;TIME: 56.1
DOCK7	KIAA1771, ZIR2	ENSG00000116641	Dedicator of cytokinesis 7	1	62454298-62688368	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 30.4	Mixed		
DOCK8	FLJ00026, FLJ00152, FLJ00346, ZIR8	ENSG00000107099	Dedicator of cytokinesis 8	9	214854-465259	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003218	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Mitochondria<br>Cytosol	Urothelial cancer:6.89e-6 (favourable), Renal cancer:9.21e-6 (favourable)	Expressed in all	Mixed			spleen: 62.1	Cell line enhanced		HL-60: 42.1;NB-4: 52.6;REH: 56.3;RT4: 42.9;THP-1: 105.5
DOCK9	KIAA1058, ZIZ1	ENSG00000088387	Dedicator of cytokinesis 9	13	98793429-99086625	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034061, CAB034065, HPA043940	Uncertain					Expressed in all	Expressed in all			placenta: 141.8	Cell line enhanced		BEWO: 190.5;hTERT-HME1: 334.6
DOHH	HLRC1, MGC4293	ENSG00000129932	Deoxyhypusine hydroxylase	19	3490821-3500940	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041953	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:2.24e-4 (favourable), Pancreatic cancer:3.58e-4 (favourable)	Expressed in all	Mixed			duodenum: 17.8	Expressed in all		
DOK1	p62dok	ENSG00000115325	Docking protein 1	2	74549026-74557554	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004224, HPA048561	Approved		Supported	Cytosol	Renal cancer:3.16e-6 (unfavourable), Lung cancer:4.64e-4 (favourable), Endometrial cancer:8.42e-4 (favourable)	Expressed in all	Mixed			appendix,spleen: 8.7	Cell line enhanced		HDLM-2: 54.7
DOK2	Dok-2, p56dok-2	ENSG00000147443	Docking protein 2	8	21908873-21913860	Predicted intracellular proteins	Evidence at protein level	CAB004379, HPA066571	Enhanced				Renal cancer:2.20e-4 (unfavourable), Melanoma:4.31e-4 (favourable)	Expressed in all	Mixed			spleen: 35.0	Group enriched	9	HDLM-2: 23.7;HEL: 48.6;HMC-1: 98.0;THP-1: 28.2;U-937: 31.6
DOK3	FLJ22570	ENSG00000146094	Docking protein 3	5	177501907-177511274	Predicted intracellular proteins	Evidence at protein level	HPA077312	Enhanced				Renal cancer:3.82e-11 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 92.0	spleen: 63.6	Cell line enhanced		Daudi: 120.7;HMC-1: 116.5;REH: 193.3;U-698: 118.3
DOK4	FLJ10488	ENSG00000125170	Docking protein 4	16	57471922-57487327	Predicted intracellular proteins	Evidence at protein level	HPA055849	Supported		Approved	Vesicles<br>Microtubules<br>Cytokinetic bridge		Expressed in all	Expressed in all			small intestine: 54.7	Cell line enhanced		SH-SY5Y: 254.2
DOK5	C20orf180, dJ805C22.1	ENSG00000101134	Docking protein 5	20	54475597-54651171	Predicted intracellular proteins	Evidence at protein level	HPA054460, HPA065235	Uncertain		Approved	Focal adhesion sites	Endometrial cancer:8.99e-7 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 22.0;fallopian tube: 20.0	skeletal muscle: 15.7	Cell line enhanced		AF22: 32.4;hTEC/SVTERT24-B: 13.7;U-138 MG: 50.6
DOK6	DOK5L, HsT3226, MGC20785	ENSG00000206052	Docking protein 6	18	69401055-69849087	Predicted intracellular proteins	Evidence at protein level	HPA041099, HPA063534	Approved		Approved	Focal adhesion sites<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 21.0	placenta: 8.5	Cell line enhanced		fHDF/TERT166: 8.1;Hep G2: 7.6;RPMI-8226: 7.5;SCLC-21H: 5.6;SH-SY5Y: 11.3
DOPEY2	C21orf5, KIAA0933	ENSG00000142197	Dopey family member 2	21	36156782-36294274	Predicted intracellular proteins	Evidence at protein level	CAB034922, HPA072065	Approved		Approved	Nucleoplasm<br>Mitochondria	Breast cancer:7.08e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 85.6	Mixed		
DOT1L	DOT1, KIAA1814, KMT4	ENSG00000104885	DOT1 like histone lysine methyltransferase	19	2164149-2232578	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA011875, HPA071217			Enhanced	Nucleoplasm	Endometrial cancer:1.69e-4 (favourable), Head and neck cancer:6.00e-4 (favourable)	Expressed in all	Tissue enriched	7	testis: 92.3	appendix,bone marrow: 14.0	Expressed in all		
DPCD	DKFZP566F084, RP11-529I10.4	ENSG00000166171	Deleted in primary ciliary dyskinesia homolog (mouse)	10	101570560-101609668	Predicted intracellular proteins	Evidence at protein level	HPA036603, HPA036604	Enhanced		Approved	Nuclear speckles	Endometrial cancer:6.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 153.2	Mixed		
DPF1	BAF45b, NEUD4, neuro-d4	ENSG00000011332	Double PHD fingers 1	19	38211006-38229714	Predicted intracellular proteins	Evidence at protein level	HPA049148	Enhanced		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enriched	15	cerebral cortex: 27.4	testis: 1.8	Cell line enhanced		SCLC-21H: 26.9
DPF2	BAF45d, REQ, ubi-d4	ENSG00000133884	Double PHD fingers 2	11	65333754-65353249	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020880, HPA056786	Approved		Supported	Nucleoplasm	Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 52.1	Expressed in all		
DPH1	DPH2L, DPH2L1, OVCA1	ENSG00000108963	Diphthamide biosynthesis 1	17	2030110-2043430	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA069750			Approved	Nucleoplasm<br>Cell Junctions	Pancreatic cancer:1.78e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 31.5	Expressed in all		
DPH2	DPH2L2	ENSG00000132768	DPH2 homolog	1	43970000-43973369	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045796	Uncertain		Approved	Nucleus	Liver cancer:1.17e-8 (unfavourable), Stomach cancer:1.37e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 14.3	Expressed in all		
DPH3	DELGIP, DELGIP1, DESR1, DPH3A, KTI11, MGC20197, ZCSL2	ENSG00000154813	Diphthamide biosynthesis 3	3	16257978-16264972	Predicted intracellular proteins	Evidence at protein level	HPA035287	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.24e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 23.2	Expressed in all		
DPH5	CGI-30	ENSG00000117543	Diphthamide biosynthesis 5	1	100989623-101026088	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046439, HPA076234	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			ovary: 52.1	Expressed in all		
DPH6	ATPBD4, MGC14798	ENSG00000134146	Diphthamine biosynthesis 6	15	35217345-35546193	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042976, HPA055496	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			thyroid gland: 18.1	Expressed in all		
DPH7	C9orf112, FLJ90634, RRT2, WDR85	ENSG00000148399	Diphthamide biosynthesis 7	9	137554904-137578935	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022911	Uncertain		Approved	Nuclear bodies	Renal cancer:1.52e-5 (unfavourable), Urothelial cancer:3.23e-4 (favourable), Pancreatic cancer:6.52e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 18.1	Expressed in all		
DPM1	CDGIE, MPDS	ENSG00000000419	Dolichyl-phosphate mannosyltransferase subunit 1, catalytic	20	50934867-50958555	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051818	Approved				Liver cancer:1.94e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 80.5	Expressed in all		
DPP3		ENSG00000254986	Dipeptidyl peptidase 3	11	66480013-66509657	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035780, HPA035781	Approved		Enhanced	Nuclear speckles<br>Plasma membrane<br>Cytosol	Stomach cancer:1.34e-4 (favourable)	Expressed in all	Expressed in all			colon: 29.7	Expressed in all		
DPP8	DP8, DPRP1, FLJ14920, FLJ20283, MGC26191, MSTP141	ENSG00000074603	Dipeptidyl peptidase 8	15	65442463-65517704	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008706	Approved		Supported	Cytosol		Expressed in all	Expressed in all			testis: 48.0	Expressed in all		
DPP9		ENSG00000142002	Dipeptidyl peptidase 9	19	4675224-4724673	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036059	Approved		Supported	Cytosol	Renal cancer:3.38e-8 (unfavourable), Endometrial cancer:6.21e-5 (favourable), Stomach cancer:7.72e-5 (favourable), Breast cancer:4.96e-4 (favourable)	Expressed in all	Expressed in all			appendix: 33.1	Expressed in all		
DPPA2	CT100, PESCRG1	ENSG00000163530	Developmental pluripotency associated 2	3	109293788-109316517	Predicted intracellular proteins	Evidence at protein level	HPA036134	Uncertain		Approved	Nucleus		Tissue enriched	Tissue enriched	11	testis: 6.5	placenta: 0.5	Cell line enhanced		BEWO: 5.8;EFO-21: 10.7
DPPA3	Stella	ENSG00000187569	Developmental pluripotency associated 3	12	7711454-7717559	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		testis: 1.3	lung: 0.6	Group enriched	248	BEWO: 334.2;NTERA-2: 146.4
DPPA4	FLJ10713	ENSG00000121570	Developmental pluripotency associated 4	3	109326141-109337572	Predicted intracellular proteins	Evidence at protein level	CAB020678, HPA035249, HPA035250	Enhanced		Supported	Nucleus<br>Nucleoli		Tissue enriched	Group enriched	8	bone marrow: 2.8;placenta: 3.0;testis: 7.7	lung,lymph node: 0.5	Cell line enhanced		AF22: 42.6;HAP1: 92.5;NTERA-2: 327.0
DPPA5	Esg1	ENSG00000203909	Developmental pluripotency associated 5	6	73353062-73354295	Predicted intracellular proteins	Evidence at transcript level	HPA064505	Uncertain					Tissue enriched	Tissue enhanced		testis: 3.9	lung: 0.9	Not detected		
DPRX		ENSG00000204595	Divergent-paired related homeobox	19	53632056-53637009	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043682	Uncertain					Tissue enriched	Tissue enhanced		placenta: 1.8	epididymis,testis: 0.5	Not detected		
DPY30	Cps25, HDPY-30, Saf19	ENSG00000162961	Dpy-30, histone methyltransferase complex regulatory subunit	2	31867809-32039812	Predicted intracellular proteins	Evidence at protein level	HPA043761	Supported		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:4.26e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 138.5	Expressed in all		
DPYD	DPD	ENSG00000188641	Dihydropyrimidine dehydrogenase	1	97077743-97921049	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033241, HPA045210	Uncertain				Pancreatic cancer:6.27e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 44.1	Mixed		
DPYS	DHPase	ENSG00000147647	Dihydropyrimidinase	8	104330324-104467053	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024785	Enhanced					Group enriched	Group enriched	22	kidney: 200.4;liver: 246.2	gallbladder: 10.1	Not detected		
DPYSL2	CRMP2, DHPRP2, DRP-2, DRP2	ENSG00000092964	Dihydropyrimidinase like 2	8	26514022-26658178	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002381, CAB018719	Supported		Supported	Plasma membrane<br>Cytosol	Urothelial cancer:5.41e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 379.1	Mixed		
DPYSL3	CRMP4, DRP-3, ULIP	ENSG00000113657	Dihydropyrimidinase like 3	5	147390811-147510056	Predicted intracellular proteins	Evidence at protein level	HPA010948	Approved		Supported	Cytosol	Renal cancer:3.87e-9 (unfavourable), Urothelial cancer:8.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 310.0	seminal vesicle: 223.4	Cell line enhanced		SH-SY5Y: 728.5
DPYSL4	DRP-4, ULIP4	ENSG00000151640	Dihydropyrimidinase like 4	10	132186900-132205776	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049066	Approved		Approved	Vesicles<br>Mitochondria	Urothelial cancer:3.11e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 30.0	heart muscle: 7.5	Cell line enhanced		AF22: 51.3;AN3-CA: 63.4;SH-SY5Y: 74.6
DPYSL5	CRAM, CRMP-5, CRMP5, Ulip6	ENSG00000157851	Dihydropyrimidinase like 5	2	26847747-26950351	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034544, HPA072387	Enhanced		Approved	Nucleoplasm<br>Cytosol		Group enriched	Group enriched	8	cerebral cortex: 31.3;testis: 10.0	adrenal gland: 2.5	Cell line enhanced		AF22: 139.1;HAP1: 122.4;SCLC-21H: 196.8;SH-SY5Y: 105.0
DQX1	FLJ23757	ENSG00000144045	DEAQ-box RNA dependent ATPase 1	2	74518131-74526336	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039158	Enhanced		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		duodenum: 14.4;small intestine: 13.5	colon: 5.5	Cell line enhanced		HBEC3-KT: 4.2;Hep G2: 11.5;hTCEpi: 4.3
DR1	NC2-BETA, NC2B	ENSG00000117505	Down-regulator of transcription 1	1	93345888-93369498	Predicted intracellular proteins	Evidence at protein level	HPA050785, HPA055308	Enhanced		Supported	Nucleus	Liver cancer:9.95e-7 (unfavourable), Colorectal cancer:4.79e-4 (favourable), Renal cancer:7.23e-4 (unfavourable), Pancreatic cancer:9.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 102.1	Expressed in all		
DRAP1	NC2-alpha	ENSG00000175550	DR1 associated protein 1	11	65919257-65921561	Predicted intracellular proteins	Evidence at protein level	HPA006790	Uncertain		Approved	Cytosol	Renal cancer:3.73e-5 (unfavourable), Thyroid cancer:4.96e-5 (favourable)	Expressed in all	Expressed in all			testis: 140.8	Expressed in all		
DRC1	C2orf39, CCDC164, CILD21, FLJ32660, MGC16372	ENSG00000157856	Dynein regulatory complex subunit 1	2	26401916-26456711	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	10	fallopian tube: 62.4;testis: 36.8	lung: 4.7	Not detected		
DRC3	CFAP134, DKFZP586M1120, LRRC48	ENSG00000171962	Dynein regulatory complex subunit 3	17	17972813-18016889	Predicted intracellular proteins	Evidence at transcript level	HPA036040, HPA036041	Approved				Endometrial cancer:4.05e-5 (favourable), Breast cancer:1.51e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 99.2	testis: 21.8	Mixed		
DRC7	C16orf50, CCDC135, CFAP50, DKFZp434I099, FAP50	ENSG00000159625	Dynein regulatory complex subunit 7	16	57694793-57731805	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.61e-4 (favourable)	Tissue enhanced	Group enriched	18	fallopian tube: 32.4;testis: 81.2	parathyroid gland: 3.2	Cell line enhanced		Hep G2: 2.0
DRG1	NEDD3	ENSG00000185721	Developmentally regulated GTP binding protein 1	22	31399523-31530634	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001218	Approved		Supported	Nuclear bodies<br>Cytosol	Liver cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 265.1	Expressed in all		
DRG2		ENSG00000108591	Developmentally regulated GTP binding protein 2	17	18087886-18107971	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007716	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Endometrial cancer:1.56e-4 (favourable), Prostate cancer:7.34e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 29.4	Expressed in all		
DRGX	DRG11, PRRXL1	ENSG00000165606	Dorsal root ganglia homeobox	10	49364181-49396016	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043978	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Tissue enriched	11	adrenal gland: 8.9	skin: 0.8	Group enriched	16	RH-30: 13.8;SH-SY5Y: 68.3;U-2197: 21.7
DRICH1	C22orf43	ENSG00000189269	Aspartate rich 1	22	23608452-23632321	Predicted intracellular proteins	Evidence at protein level	HPA020446			Approved	Nucleus<br>Nucleoli		Mixed	Group enriched	8	epididymis: 20.8;parathyroid gland: 23.9;testis: 81.2	endometrium: 5.4	Cell line enhanced		CACO-2: 9.2
DROSHA	Etohi2, HSA242976, RN3, RNASE3L, RNASEN	ENSG00000113360	Drosha ribonuclease III	5	31400497-31532196	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.39e-4 (unfavourable), Endometrial cancer:6.79e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.5	Expressed in all		
DRP2		ENSG00000102385	Dystrophin related protein 2	X	101219769-101264497	Predicted intracellular proteins	Evidence at protein level	HPA002949			Approved	Nuclear speckles<br>Plasma membrane		Tissue enhanced	Tissue enriched	6	cerebral cortex: 12.3	prostate: 2.2	Cell line enhanced		RH-30: 10.4;TIME: 15.0;U-87 MG: 4.3
DSCC1	DCC1, hDCC1, MGC5528	ENSG00000136982	DNA replication and sister chromatid cohesion 1	8	119833976-119856010	Predicted intracellular proteins	Evidence at protein level	HPA023780, HPA024401	Uncertain		Approved	Nucleoplasm	Liver cancer:3.92e-6 (unfavourable), Lung cancer:3.93e-4 (unfavourable), Melanoma:5.73e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 7.9	Expressed in all		
DSCR3	DCRA	ENSG00000157538	DSCR3 arrestin fold containing	21	37223420-37267919	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023288	Uncertain		Approved	Mitochondria	Renal cancer:8.54e-4 (favourable)	Expressed in all	Expressed in all			kidney: 32.2	Expressed in all		
DSCR4	DCRB	ENSG00000184029	Down syndrome critical region 4	21	37951425-38121360	Predicted intracellular proteins	Evidence at transcript level	HPA018460	Uncertain					Tissue enriched	Group enriched	18	placenta: 2.0;testis: 1.4	all non-specific tissues: 0.0	Cell line enhanced		BEWO: 5.8;K-562: 9.1;RPMI-8226: 3.0;U-266/70: 5.5;U-266/84: 3.9
DSCR8	C21orf65, CT25.1a, CT25.1b, MMA-1a, MMA-1b, MTAG2	ENSG00000198054	Down syndrome critical region 8	21	38121451-38188016	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	7	testis: 33.8	placenta: 4.8	Cell line enhanced		BEWO: 6.6;K-562: 6.1;U-266/70: 6.9;U-266/84: 3.5
DSN1	C20orf172, dJ469A13.2, hKNL-3, KNL3, MIS13	ENSG00000149636	DSN1 homolog, MIS12 kinetochore complex component	20	36751791-36773818	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002813, HPA030627	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center<br>Nuclear bodies<br>Cytosol	Renal cancer:1.54e-5 (unfavourable), Liver cancer:4.16e-5 (unfavourable), Cervical cancer:4.49e-4 (favourable)	Expressed in all	Mixed			testis: 40.2	Expressed in all		
DSP	DPI, DPII, KPPS2, PPKS2	ENSG00000096696	Desmoplakin	6	7541575-7586717	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037324, HPA045840, HPA054950	Enhanced		Enhanced	Cell Junctions	Renal cancer:1.53e-9 (favourable), Urothelial cancer:1.82e-4 (unfavourable)	Tissue enhanced	Group enriched	8	esophagus: 345.7;skin: 1016.4	placenta: 89.1	Cell line enhanced		BEWO: 263.2;HaCaT: 265.1;hTCEpi: 482.9
DST	BP240, BPA, BPAG1, CATX-15, FLJ13425, FLJ21489, FLJ30627, FLJ32235, KIAA0728, MACF2	ENSG00000151914	Dystonin	6	56457987-56954628	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030200	Uncertain		Approved	Nucleus<br>Microtubules<br>Cytosol		Expressed in all	Expressed in all			skin: 192.1	Cell line enhanced		hTCEpi: 351.4;hTERT-HME1: 274.7
DSTN	ACTDP, ADF	ENSG00000125868	Destrin, actin depolymerizing factor	20	17569863-17609919	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037094	Approved					Expressed in all	Expressed in all			seminal vesicle: 1055.1	Expressed in all		
DSTYK	DustyPK, KIAA0472, RIP5, RIPK5	ENSG00000133059	Dual serine/threonine and tyrosine protein kinase	1	205142505-205211566	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044140	Uncertain		Uncertain	Nuclear speckles<br>Intermediate filaments	Urothelial cancer:8.73e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 28.8	Expressed in all		
DTD1	bA379J5.3, bA555E18.1, C20orf88, DUEB, HARS2, MGC119131, MGC41905, pqn-68	ENSG00000125821	D-tyrosyl-tRNA deacylase 1	20	18567453-18763917	Predicted intracellular proteins	Evidence at protein level	HPA040981, HPA042653	Uncertain		Uncertain	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 55.8	Mixed		
DTD2	C14orf126, MGC9912	ENSG00000129480	D-tyrosyl-tRNA deacylase 2 (putative)	14	31446036-31457510	Predicted intracellular proteins	Evidence at protein level	HPA001117	Approved		Approved	Vesicles	Urothelial cancer:5.74e-6 (unfavourable), Head and neck cancer:9.33e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 10.8	Expressed in all		
DTHD1	FLJ16686	ENSG00000197057	Death domain containing 1	4	36281622-36345756	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		fallopian tube: 20.9	lung: 4.9	Not detected		
DTL	CDT2, DCAF2, L2DTL, RAMP	ENSG00000143476	Denticleless E3 ubiquitin protein ligase homolog	1	212035553-212107400	Predicted intracellular proteins	Evidence at protein level	HPA028016, HPA032023, HPA032031	Uncertain		Enhanced	Nucleus<br>Cytosol	Renal cancer:1.71e-9 (unfavourable), Liver cancer:4.41e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 23.8	bone marrow: 8.2	Mixed		
DTNB		ENSG00000138101	Dystrobrevin beta	2	25377198-25673647	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061357	Uncertain		Approved	Mitochondria	Liver cancer:2.54e-4 (unfavourable), Renal cancer:3.47e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 23.8	Mixed		
DTNBP1	BLOC1S8, DBND, Dysbindin, HPS7, My031	ENSG00000047579	Dystrobrevin binding protein 1	6	15522801-15663058	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028053, HPA029615, HPA029616	Enhanced		Supported	Microtubules<br>Midbody	Lung cancer:6.34e-5 (favourable), Cervical cancer:2.82e-4 (favourable), Liver cancer:8.72e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 32.7	Expressed in all		
DTWD1	MDS009, MGC111207	ENSG00000104047	DTW domain containing 1	15	49620980-49656232	Predicted intracellular proteins	Evidence at protein level	HPA042214	Uncertain		Approved	Nucleus<br>Nucleoli<br>Vesicles		Expressed in all	Expressed in all			cervix, uterine: 39.5	Expressed in all		
DTWD2	FLJ33977	ENSG00000169570	DTW domain containing 2	5	118837322-118988545	Predicted intracellular proteins	Evidence at protein level	HPA053173, HPA054864	Approved		Supported	Nuclear bodies	Renal cancer:6.09e-5 (favourable), Colorectal cancer:3.16e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 18.7	Mixed		
DTX1	hDx-1	ENSG00000135144	Deltex E3 ubiquitin ligase 1	12	113056709-113098028	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051249, HPA055275	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:3.02e-5 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 13.4	spleen: 11.4	Group enriched	9	Daudi: 77.9;REH: 41.0;U-698: 75.9
DTX2	KIAA1528, RNF58	ENSG00000091073	Deltex E3 ubiquitin ligase 2	7	76461676-76505995	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042931	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Renal cancer:1.13e-8 (unfavourable), Glioma:7.25e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 37.2	Expressed in all		
DTX3	FLJ34766, RNF154	ENSG00000178498	Deltex E3 ubiquitin ligase 3	12	57604622-57609804	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059654	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Pancreatic cancer:1.44e-4 (favourable), Lung cancer:9.87e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 102.8	Mixed		
DTX3L	BBAP	ENSG00000163840	Deltex E3 ubiquitin ligase 3L	3	122564238-122575203	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010570	Uncertain		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:8.99e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 36.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 83.9;BJ hTERT+ SV40 Large T+ RasG12V: 107.7
DTX4	KIAA0937, RNF155	ENSG00000110042	Deltex E3 ubiquitin ligase 4	11	59171430-59208587	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056760, HPA059294	Uncertain	Approved	Approved	Vesicles	Thyroid cancer:5.81e-4 (favourable), Renal cancer:8.94e-4 (unfavourable)	Expressed in all	Mixed			lung: 27.3	Cell line enhanced		BEWO: 63.2;RT4: 80.7
DTYMK	CDC8, TMPK, TYMK	ENSG00000168393	Deoxythymidylate kinase	2	241675742-241686991	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042593, HPA042719	Approved		Approved	Mitochondria	Liver cancer:1.73e-5 (unfavourable), Renal cancer:1.22e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 24.0	Expressed in all		
DUPD1	DUSP27	ENSG00000188716	Dual specificity phosphatase and pro isomerase domain containing 1	10	75037836-75058514	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042964	Uncertain					Not detected	Tissue enriched	30	skeletal muscle: 24.4	prostate: 0.8	Not detected		
DUS1L	DUS1, PP3111	ENSG00000169718	Dihydrouridine synthase 1 like	17	82057506-82065887	Predicted intracellular proteins	Evidence at protein level	HPA023384	Uncertain		Approved	Plasma membrane	Renal cancer:5.89e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 99.0	Expressed in all		
DUS2	DUS2L, FLJ20399, SMM1	ENSG00000167264	Dihydrouridine synthase 2	16	67987746-68079320	Predicted intracellular proteins	Evidence at protein level	HPA042560, HPA043528	Enhanced		Enhanced	Cytosol	Renal cancer:3.50e-5 (favourable)	Expressed in all	Mixed			testis: 39.2	Expressed in all		
DUS3L	DUS3, FLJ13896	ENSG00000141994	Dihydrouridine synthase 3 like	19	5784832-5791238	Predicted intracellular proteins	Evidence at protein level	HPA041854, HPA041944, HPA062846	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 26.7	Mixed		
DUS4L	DUS4, PP35	ENSG00000105865	Dihydrouridine synthase 4 like	7	107563484-107578464	Predicted intracellular proteins	Evidence at protein level	HPA044301	Approved		Approved	Cytosol		Expressed in all	Mixed			thyroid gland: 2.4	Mixed		
DUSP1	CL100, HVH1, MKP-1, PTPN10	ENSG00000120129	Dual specificity phosphatase 1	5	172768090-172771195	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018554, HPA069577	Approved		Approved	Nucleoli<br>Cytosol	Stomach cancer:3.11e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 1027.0	Expressed in all		
DUSP10	MKP-5, MKP5	ENSG00000143507	Dual specificity phosphatase 10	1	221701424-221742176	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016758	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.69e-4 (unfavourable), Liver cancer:5.42e-4 (favourable)	Expressed in all	Mixed			liver: 16.7	Cell line enhanced		HaCaT: 86.1
DUSP11	PIR1	ENSG00000144048	Dual specificity phosphatase 11	2	73762184-73780157	Predicted intracellular proteins	Evidence at protein level	HPA021052			Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytokinetic bridge	Liver cancer:2.10e-7 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 62.4	Expressed in all		
DUSP12	DUSP1, YVH1	ENSG00000081721	Dual specificity phosphatase 12	1	161749758-161757238	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008840	Uncertain		Supported	Nucleus	Renal cancer:1.55e-7 (unfavourable), Liver cancer:1.99e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 20.3	Expressed in all		
DUSP14	MKP-L, MKP6	ENSG00000276023	Dual specificity phosphatase 14	17	37489831-37513501	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019911	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.97e-9 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 5.1	skin: 2.7	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 15.2;HBF TERT88: 21.7;WM-115: 13.0
DUSP15	bA243J16.5, bA243J16.6, C20orf57, FLJ20645, VHY	ENSG00000149599	Dual specificity phosphatase 15	20	31847637-31870747	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA076649	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:5.40e-7 (favourable)	Mixed	Tissue enhanced		testis: 77.1	parathyroid gland: 16.1	Cell line enhanced		REH: 14.6;SH-SY5Y: 4.6
DUSP16	KIAA1700, MKP-7, MKP7	ENSG00000111266	Dual specificity phosphatase 16	12	12474210-12562383	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020326	Approved		Supported	Nucleoplasm	Head and neck cancer:1.01e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 33.2	Cell line enhanced		NTERA-2: 39.3
DUSP18	DUSP20	ENSG00000167065	Dual specificity phosphatase 18	22	30652051-30667890	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB034070, HPA051349	Approved		Supported	Nucleoplasm		Mixed	Mixed			testis: 22.3	Expressed in all		
DUSP19	DUSP17, SKRP1	ENSG00000162999	Dual specificity phosphatase 19	2	183078559-183100005	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021501	Approved		Approved	Nucleoplasm		Mixed	Mixed			testis: 5.5	Mixed		
DUSP2	PAC-1	ENSG00000158050	Dual specificity phosphatase 2	2	96143166-96145440	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA071920			Supported	Nucleus<br>Nuclear membrane	Renal cancer:4.97e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 78.9;seminal vesicle: 86.2	lymph node: 50.7	Cell line enhanced		RT4: 27.2;SCLC-21H: 34.8;U-698: 28.6
DUSP21		ENSG00000189037	Dual specificity phosphatase 21	X	44844004-44844888	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	41	testis: 9.9	small intestine: 0.2	Not detected		
DUSP22	JKAP, JSP1, MKPX, VHX	ENSG00000112679	Dual specificity phosphatase 22	6	291630-351355	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031394	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 85.1	Expressed in all		
DUSP23	DUSP25, FLJ20442	ENSG00000158716	Dual specificity phosphatase 23	1	159780932-159782543	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028211, HPA045792	Approved		Supported	Nucleoplasm	Renal cancer:2.59e-5 (unfavourable), Liver cancer:3.06e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 40.4	Mixed		
DUSP26	DUSP24, MGC1136	ENSG00000133878	Dual specificity phosphatase 26	8	33591332-33600106	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018221	Approved		Supported	Nucleus		Tissue enhanced	Tissue enhanced		cerebral cortex: 47.1;skeletal muscle: 138.7	ovary: 39.6	Group enriched	29	SCLC-21H: 110.0;SH-SY5Y: 23.6
DUSP27		ENSG00000198842	Dual specificity phosphatase 27 (putative)	1	167094045-167129165	Predicted intracellular proteins	Evidence at protein level	HPA012608, HPA012912	Uncertain		Approved	Nucleoplasm		Group enriched	Group enriched	15	heart muscle: 41.9;skeletal muscle: 39.7	placenta,prostate: 2.6	Cell line enriched	11	RH-30: 13.7
DUSP28	DUSP26, VHP	ENSG00000188542	Dual specificity phosphatase 28	2	240560054-240564014	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047456, CAB069448	Uncertain		Uncertain	Nuclear speckles<br>Cytosol	Pancreatic cancer:1.84e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 3.9	Mixed		
DUSP3	VHR	ENSG00000108861	Dual specificity phosphatase 3	17	43766121-43778988	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063616			Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.49e-5 (favourable), Head and neck cancer:3.00e-4 (unfavourable), Glioma:9.23e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 100.8	Mixed		
DUSP4	HVH2, MKP-2, TYP	ENSG00000120875	Dual specificity phosphatase 4	8	29333064-29350668	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061967			Supported	Nucleoplasm	Renal cancer:4.19e-4 (unfavourable)	Expressed in all	Tissue enhanced		breast: 29.6	stomach: 28.2	Cell line enhanced		A549: 90.3;SK-MEL-30: 120.4;WM-115: 120.9
DUSP5	HVH3	ENSG00000138166	Dual specificity phosphatase 5	10	110497838-110511544	Enzymes, Predicted intracellular proteins	Evidence at protein level						Lung cancer:8.30e-6 (unfavourable)	Expressed in all	Mixed			esophagus: 100.1	Cell line enhanced		hTERT-HME1: 303.0;U-266/70: 167.5
DUSP6	MKP-3, PYST1	ENSG00000139318	Dual specificity phosphatase 6	12	89347232-89353271	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017566, HPA053188	Approved		Uncertain	Nucleoplasm<br>Cytosol	Endometrial cancer:7.21e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 141.2	Cell line enhanced		AN3-CA: 428.0
DUSP7	MKP-X, PYST2	ENSG00000164086	Dual specificity phosphatase 7	3	52048919-52056550	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.84e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 45.1	Expressed in all		
DUSP8	C11orf81, FLJ42958, HB5, HVH-5	ENSG00000184545	Dual specificity phosphatase 8	11	1554044-1571920	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020071	Approved		Approved	Cytosol	Renal cancer:2.75e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 5.1	smooth muscle: 2.3	Cell line enhanced		MCF7: 1.9;SH-SY5Y: 2.2
DUSP9	MKP-4, MKP4	ENSG00000130829	Dual specificity phosphatase 9	X	153642492-153651326	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003336	Enhanced		Approved	Endoplasmic reticulum	Endometrial cancer:1.60e-4 (unfavourable)	Mixed	Group enriched	35	kidney: 29.0;placenta: 103.3	testis: 1.8	Cell line enriched	6	Hep G2: 251.7
DUT	dUTPase	ENSG00000128951	Deoxyuridine triphosphatase	15	48331011-48343373	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054422, HPA060360	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 114.3	Expressed in all		
DUX4		ENSG00000260596	Double homeobox 4	4	190173774-190185942	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	HPA058451			Supported	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol		Not detected	Tissue enhanced		testis: 1.4	prostate: 0.4	Cell line enhanced		A549: 1.3;U-2 OS: 2.2;U-266/70: 3.6;U-266/84: 4.6
DUXA		ENSG00000258873	Double homeobox A	19	57154021-57167443	Predicted intracellular proteins, Transcription factors	No evidence	HPA059358	Uncertain					Not detected	Not detected			appendix,testis: 0.3	Not detected		
DUXB		ENSG00000282757	Double homeobox B	16	75693929-75701459	Predicted intracellular proteins	No evidence								Not detected			testis,thyroid gland: 0.3	Not detected		
DVL1		ENSG00000107404	Dishevelled segment polarity protein 1	1	1335276-1349350	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011538	Approved				Testis cancer:3.33e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 79.4	Expressed in all		
DVL2		ENSG00000004975	Dishevelled segment polarity protein 2	17	7225341-7234545	Predicted intracellular proteins	Evidence at protein level	CAB009312, HPA021611, HPA022914, HPA064732	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:4.34e-6 (unfavourable), Pancreatic cancer:3.85e-4 (favourable)	Expressed in all	Expressed in all			ovary: 36.1	Expressed in all		
DVL3	KIAA0208	ENSG00000161202	Dishevelled segment polarity protein 3	3	184155388-184173610	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB046486, HPA058265	Approved		Approved	Intermediate filaments<br>Midbody ring<br>Centrosome	Renal cancer:1.53e-8 (unfavourable), Prostate cancer:4.77e-5 (unfavourable), Colorectal cancer:1.90e-4 (unfavourable), Liver cancer:8.41e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 55.3	Expressed in all		
DXO	DOM3Z	ENSG00000204348	Decapping exoribonuclease	6	31969810-31972292	Predicted intracellular proteins	Evidence at protein level	HPA046708	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:4.77e-6 (unfavourable), Pancreatic cancer:5.87e-4 (favourable)	Expressed in all	Mixed			testis: 5.7	Cell line enhanced		AN3-CA: 10.2
DYDC1	bA36D19.5, DPY30D1	ENSG00000170788	DPY30 domain containing 1	10	80336105-80356755	Predicted intracellular proteins	Evidence at protein level	HPA037790, HPA037791	Uncertain					Tissue enhanced	Tissue enriched	21	testis: 200.6	fallopian tube: 9.5	Not detected		
DYDC2	bA36D19.6, MGC16186	ENSG00000133665	DPY30 domain containing 2	10	80344745-80368073	Predicted intracellular proteins	Evidence at protein level	HPA038006, HPA038007	Enhanced				Ovarian cancer:3.54e-4 (favourable)	Tissue enhanced	Tissue enriched	10	fallopian tube: 153.3	testis: 15.0	Cell line enhanced		AF22: 2.1;NTERA-2: 3.4;SCLC-21H: 3.4;SH-SY5Y: 2.1;U-2197: 2.0
DYNC1H1	CMT2O, DHC1, DNCH1, Dnchc1, DNCL, DNECL, HL-3, p22	ENSG00000197102	Dynein cytoplasmic 1 heavy chain 1	14	101964528-102050792	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003742, CAB010443	Enhanced		Supported	Centrosome<br>Cytosol	Liver cancer:3.03e-7 (unfavourable), Renal cancer:1.09e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 80.6	Expressed in all		
DYNC1I1	DNCI1, DNCIC1	ENSG00000158560	Dynein cytoplasmic 1 intermediate chain 1	7	95772506-96110322	Predicted intracellular proteins	Evidence at protein level	HPA061689	Enhanced				Endometrial cancer:3.79e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 83.9	adrenal gland: 16.8	Cell line enhanced		EFO-21: 13.2;SH-SY5Y: 11.0;WM-115: 9.0
DYNC1I2	DIC74, DNCI2	ENSG00000077380	Dynein cytoplasmic 1 intermediate chain 2	2	171687409-171748420	Predicted intracellular proteins	Evidence at protein level	CAB033836, HPA040619, HPA053987	Enhanced		Supported	Nucleoli<br>Endoplasmic reticulum<br>Microtubules<br>Cytosol	Renal cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 146.6	Expressed in all		
DYNC1LI1	DNCLI1	ENSG00000144635	Dynein cytoplasmic 1 light intermediate chain 1	3	32525971-32570874	Predicted intracellular proteins	Evidence at protein level	HPA035013	Approved		Supported	Centrosome<br>Cytosol	Liver cancer:9.19e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 74.3	Expressed in all		
DYNC1LI2	DNCLI2	ENSG00000135720	Dynein cytoplasmic 1 light intermediate chain 2	16	66720893-66751798	Predicted intracellular proteins	Evidence at protein level	HPA057201			Approved	Centrosome<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 141.9	Expressed in all		
DYNC2H1	DHC1b, DHC2, DNCH2, DYH1B, hdhc11	ENSG00000187240	Dynein cytoplasmic 2 heavy chain 1	11	103109431-103479863	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039015, HPA039016	Approved		Supported	Mitochondria	Renal cancer:8.49e-5 (favourable)	Mixed	Mixed			parathyroid gland: 17.4	Mixed		
DYNC2LI1	CGI-60, D2LIC, DKFZP564A033, LIC3	ENSG00000138036	Dynein cytoplasmic 2 light intermediate chain 1	2	43774039-43810010	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA062905	Approved		Approved	Cytosol	Renal cancer:2.73e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 86.1	Expressed in all		
DYNLL1	DLC1, DLC8, DNCL1, hdlc1, LC8, PIN	ENSG00000088986	Dynein light chain LC8-type 1	12	120469850-120498493	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039954			Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:7.97e-7 (unfavourable), Liver cancer:7.33e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 772.7	Expressed in all		
DYNLL2	Dlc2, DNCL1B, MGC17810, RSPH22	ENSG00000264364	Dynein light chain LC8-type 2	17	58083415-58095536	Predicted intracellular proteins	Evidence at protein level	HPA039954			Uncertain	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.12e-12 (favourable), Pancreatic cancer:5.26e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 95.0	Expressed in all		
DYNLRB1	DNCL2A, DNLC2A, ROBLD1	ENSG00000125971	Dynein light chain roadblock-type 1	20	34516409-34540958	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009845	Approved				Liver cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 341.0	Expressed in all		
DYNLRB2	DNCL2B, DNLC2B, ROBLD2	ENSG00000168589	Dynein light chain roadblock-type 2	16	80540734-80550760	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.91e-5 (favourable)	Mixed	Group enriched	8	fallopian tube: 134.8;testis: 325.7	epididymis: 27.5	Cell line enhanced		MCF7: 4.4;RPTEC TERT1: 2.8;SCLC-21H: 2.2
DYNLT1	TCTEL1	ENSG00000146425	Dynein light chain Tctex-type 1	6	158636474-158644739	Predicted intracellular proteins	Evidence at protein level	HPA046559			Supported	Nucleoplasm	Liver cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 273.3	Expressed in all		
DYRK1A	DYRK, DYRK1, MNBH	ENSG00000157540	Dual specificity tyrosine phosphorylation regulated kinase 1A	21	37365790-37517450	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015323, HPA015810	Approved		Approved	Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
DYRK1B	MIRK	ENSG00000105204	Dual specificity tyrosine phosphorylation regulated kinase 1B	19	39825350-39834201	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028522, HPA028786	Uncertain		Approved	Nucleus	Renal cancer:8.83e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 37.4	testis: 33.6	Cell line enhanced		SCLC-21H: 15.0;SH-SY5Y: 15.3
DYRK3	hYAK3-2, RED, REDK	ENSG00000143479	Dual specificity tyrosine phosphorylation regulated kinase 3	1	206635536-206684419	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA075041			Supported	Nucleoplasm<br>Cytosol	Renal cancer:9.41e-7 (unfavourable)	Expressed in all	Tissue enhanced		testis: 86.7	gallbladder: 23.2	Cell line enhanced		hTERT-HME1: 56.1
DYRK4		ENSG00000010219	Dual specificity tyrosine phosphorylation regulated kinase 4	12	4562204-4615302	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028065, HPA056073	Enhanced		Enhanced	Vesicles	Renal cancer:6.52e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 66.2	epididymis: 20.7	Mixed		
DYTN		ENSG00000232125	Dystrotelin	2	206651621-206718396	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			bone marrow,testis: 0.1	Not detected		
DYX1C1	CILD25, DNAAF4, EKN1, FLJ37882	ENSG00000256061	Dyslexia susceptibility 1 candidate 1	15	55410525-55508234	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051048	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		testis: 20.5	fallopian tube: 17.6	Mixed		
DZANK1	ANKRD64, bA189K21.8, C20orf12, C20orf84, dJ568F9.2, FLJ10600, FLJ30892	ENSG00000089091	Double zinc ribbon and ankyrin repeat domains 1	20	18383367-18467281	Predicted intracellular proteins	Evidence at protein level	HPA059478, HPA064255	Uncertain		Approved	Nucleoli fibrillar center		Mixed	Mixed			fallopian tube: 5.2	Cell line enhanced		THP-1: 17.4;U-266/84: 19.5
DZIP1	DZIP, KIAA0996	ENSG00000134874	DAZ interacting zinc finger protein 1	13	95578202-95644703	Predicted intracellular proteins	Evidence at protein level	HPA054891, HPA057272, HPA070194	Uncertain		Supported	Nucleoplasm<br>Microtubule organizing center<br>Cytosol		Mixed	Tissue enhanced		testis: 57.5	ovary: 30.4	Mixed		
DZIP1L	DZIP2, FLJ32844	ENSG00000158163	DAZ interacting zinc finger protein 1 like	3	138061990-138115818	Predicted intracellular proteins	Evidence at protein level	HPA030404	Approved		Approved	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge		Mixed	Mixed			fallopian tube: 16.6	Mixed		
E2F1	RBBP3, RBP3	ENSG00000101412	E2F transcription factor 1	20	33675683-33686404	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000329, HPA008003, CAB019308, HPA029735	Enhanced		Enhanced	Nucleoplasm<br>Centrosome	Cervical cancer:9.22e-6 (favourable), Liver cancer:3.83e-5 (unfavourable), Endometrial cancer:4.33e-5 (unfavourable), Renal cancer:8.99e-5 (unfavourable), Thyroid cancer:1.62e-4 (favourable), Pancreatic cancer:4.18e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 22.9	testis: 12.7	Mixed		
E2F2	E2F-2	ENSG00000007968	E2F transcription factor 2	1	23506430-23531220	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016313	Uncertain					Mixed	Tissue enhanced		bone marrow: 15.3	lymph node: 3.8	Cell line enhanced		Daudi: 33.3
E2F3		ENSG00000112242	E2F transcription factor 3	6	20401906-20493715	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029779, HPA065012			Supported	Nucleoplasm<br>Nuclear speckles<br>Cytosol	Renal cancer:1.63e-8 (unfavourable), Ovarian cancer:1.69e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 14.4	Expressed in all		
E2F4	E2F-4	ENSG00000205250	E2F transcription factor 4	16	67192169-67198918	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054128			Supported	Nucleoplasm		Expressed in all	Expressed in all			placenta: 64.2	Expressed in all		
E2F6	E2F-6	ENSG00000169016	E2F transcription factor 6	2	11444375-11466177	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075185			Supported	Nucleoplasm	Liver cancer:1.20e-5 (unfavourable), Endometrial cancer:7.13e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 7.2	Expressed in all		
E2F7		ENSG00000165891	E2F transcription factor 7	12	77021247-77065580	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064866			Supported	Nuclear speckles		Mixed	Tissue enhanced		testis: 5.1	bone marrow: 3.0	Mixed		
E2F8	FLJ23311	ENSG00000129173	E2F transcription factor 8	11	19224063-19241620	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064882			Supported	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Mixed			bone marrow: 9.2	Mixed		
E4F1	E4F	ENSG00000167967	E4F transcription factor 1	16	2223566-2235742	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052042, HPA071325			Enhanced	Nucleoplasm	Head and neck cancer:1.10e-4 (favourable), Renal cancer:5.50e-4 (unfavourable), Cervical cancer:9.13e-4 (favourable)	Expressed in all	Expressed in all			skin: 12.8	Expressed in all		
EAF1		ENSG00000144597	ELL associated factor 1	3	15427355-15450635	Predicted intracellular proteins	Evidence at protein level	HPA059516, HPA060569, HPA069538	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles<br>Cytokinetic bridge	Lung cancer:6.87e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 33.7	Expressed in all		
EAF2	BM040, TRAITS, U19	ENSG00000145088	ELL associated factor 2	3	121835183-121886526	Predicted intracellular proteins	Evidence at protein level	HPA008411	Enhanced				Cervical cancer:2.25e-9 (favourable), Endometrial cancer:2.66e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 63.7	bone marrow: 47.8	Cell line enhanced		Daudi: 52.5;HL-60: 90.7;U-698: 63.7;U-937: 50.3
EAPP	BM036, C14orf11, FLJ20578	ENSG00000129518	E2F associated phosphoprotein	14	34515929-34539711	Predicted intracellular proteins	Evidence at protein level	HPA002916	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:2.23e-6 (favourable), Thyroid cancer:2.96e-4 (favourable), Lung cancer:9.34e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 75.0	Expressed in all		
EARS2	KIAA1970, MSE1	ENSG00000103356	Glutamyl-tRNA synthetase 2, mitochondrial	16	23522014-23557731	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043289, HPA043633	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.16e-6 (favourable), Pancreatic cancer:7.20e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 32.9	Expressed in all		
EBF1	EBF, OLF1	ENSG00000164330	Early B-cell factor 1	5	158695916-159099761	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061169			Approved	Nucleoplasm<br>Vesicles	Renal cancer:9.62e-7 (unfavourable), Stomach cancer:7.80e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 41.6	placenta: 16.2	Cell line enhanced		ASC diff: 27.3;HSkMC: 22.6;REH: 81.2
EBF2	COE2, FLJ11500	ENSG00000221818	Early B-cell factor 2	8	25841730-26045397	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:2.51e-6 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 20.8	heart muscle: 6.6	Group enriched	16	ASC diff: 15.6;ASC TERT1: 32.1;HSkMC: 34.2;hTEC/SVTERT24-B: 26.8;U-138 MG: 17.0;U-2197: 21.1;U-87 MG: 18.8
EBF3	COE3, DKFZp667B0210	ENSG00000108001	Early B-cell factor 3	10	129835283-129963841	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061169			Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		adipose tissue: 20.1	lymph node: 12.7	Cell line enhanced		HAP1: 23.0;LHCN-M2: 29.6;NB-4: 29.2;RH-30: 18.6;SCLC-21H: 53.2
EBF4	COE4, KIAA1442, O/E-4, RP5-860F19.3	ENSG00000088881	Early B-cell factor 4	20	2692878-2760108	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Pancreatic cancer:2.47e-5 (favourable), Colorectal cancer:6.59e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 23.7	Cell line enhanced		SH-SY5Y: 15.8
EBLN2		ENSG00000255423	Endogenous Bornavirus-like nucleoprotein 2	3	73061659-73063337	Predicted intracellular proteins	Evidence at protein level	HPA062510, HPA068795	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			bone marrow: 10.2	Mixed		
EBNA1BP2	EBP2, NOBP, P40	ENSG00000117395	EBNA1 binding protein 2	1	43164175-43270936	Predicted intracellular proteins	Evidence at protein level	HPA026512, HPA028277	Approved		Enhanced	Nucleoli	Liver cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 71.8	Expressed in all		
ECD	GCR2, hSGT1	ENSG00000122882	Ecdysoneless cell cycle regulator	10	73130155-73169055	Predicted intracellular proteins	Evidence at protein level	HPA006465	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.87e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 38.3	Expressed in all		
ECH1	HPXEL	ENSG00000104823	Enoyl-CoA hydratase 1	19	38815422-38832005	Predicted intracellular proteins	Evidence at protein level	HPA002907, HPA005835	Supported	Approved	Supported	Mitochondria	Stomach cancer:2.23e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 188.1	Expressed in all		
ECHDC2	FLJ10948	ENSG00000121310	Enoyl-CoA hydratase domain containing 2	1	52895910-52927212	Predicted intracellular proteins	Evidence at protein level	HPA026731, HPA026768	Enhanced		Approved	Mitochondria	Urothelial cancer:2.70e-4 (favourable), Head and neck cancer:6.65e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 47.8	kidney: 26.3	Cell line enhanced		BEWO: 15.6;HHSteC: 9.5
ECHDC3	FLJ20909	ENSG00000134463	Enoyl-CoA hydratase domain containing 3	10	11742366-11764070	Predicted intracellular proteins	Evidence at protein level	HPA038306	Enhanced		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Renal cancer:3.43e-4 (favourable), Urothelial cancer:3.91e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 76.6	Cell line enhanced		A-431: 46.0;BEWO: 27.7
ECHS1	SCEH	ENSG00000127884	Enoyl-CoA hydratase, short chain 1	10	133362480-133373689	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003783, HPA021995, HPA022476	Enhanced		Enhanced	Mitochondria	Renal cancer:8.57e-5 (favourable)	Expressed in all	Expressed in all			liver: 438.0	Expressed in all		
ECI1	DCI	ENSG00000167969	Enoyl-CoA delta isomerase 1	16	2239395-2252300	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041746, HPA043227	Enhanced				Renal cancer:8.99e-8 (favourable), Cervical cancer:3.04e-5 (favourable), Liver cancer:1.07e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 69.3	Expressed in all		
ECI2	ACBD2, DRS1, HCA88, PECI	ENSG00000198721	Enoyl-CoA delta isomerase 2	6	4115689-4135597	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022130, HPA031626	Enhanced		Enhanced	Peroxisomes	Renal cancer:2.04e-6 (favourable), Head and neck cancer:2.85e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 238.6	Expressed in all		
ECT2	ARHGEF31	ENSG00000114346	Epithelial cell transforming 2	3	172750682-172821474	Predicted intracellular proteins	Evidence at protein level	HPA036363, HPA053261			Enhanced	Nucleus<br>Cytosol	Liver cancer:6.82e-6 (unfavourable), Renal cancer:1.19e-5 (unfavourable), Pancreatic cancer:2.24e-5 (unfavourable), Lung cancer:1.13e-4 (unfavourable)	Expressed in all	Mixed			testis: 29.1	Expressed in all		
ECT2L	ARHGEF32, C6orf91, FBXO49, LFDH	ENSG00000203734	Epithelial cell transforming 2 like	6	138795926-138904070	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA035488	Uncertain					Not detected	Tissue enriched	7	fallopian tube: 18.3	lung: 2.7	Not detected		
EDARADD		ENSG00000186197	EDAR associated death domain	1	236348257-236484914	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018836	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		urinary bladder: 18.9	seminal vesicle: 11.4	Cell line enhanced		HMC-1: 69.7;RT4: 52.5
EDC3	FLJ21128, hYjeF_N2-15q23, LSM16, YJDC, YJEFN2	ENSG00000179151	Enhancer of mRNA decapping 3	15	74630558-74696292	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040650, HPA044206, HPA066137	Uncertain		Supported	Cytoplasmic bodies	Liver cancer:7.80e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 65.4	Expressed in all		
EDC4	Ge-1, HEDLS, RCD-8	ENSG00000038358	Enhancer of mRNA decapping 4	16	67873023-67884503	Predicted intracellular proteins	Evidence at protein level	HPA041164, HPA043038	Supported		Enhanced	Nucleoplasm<br>Cytoplasmic bodies	Liver cancer:7.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
EDEM1	EDEM, KIAA0212	ENSG00000134109	ER degradation enhancing alpha-mannosidase like protein 1	3	5187646-5219957	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029565	Uncertain		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			lymph node: 47.7	Expressed in all		
EDF1	CFAP280, EDF-1	ENSG00000107223	Endothelial differentiation related factor 1	9	136862119-136866286	Predicted intracellular proteins	Evidence at protein level	HPA035642	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			small intestine: 557.4	Expressed in all		
EEA1	ZFYVE2	ENSG00000102189	Early endosome antigen 1	12	92770637-92929331	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005861, CAB018782, HPA038158, HPA038159	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 16.8	Expressed in all		
EED	HEED, WAIT-1	ENSG00000074266	Embryonic ectoderm development	11	86244544-86278813	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012211, HPA060089, HPA061140	Supported		Supported	Nucleoplasm	Renal cancer:1.36e-7 (unfavourable), Liver cancer:1.80e-5 (unfavourable), Urothelial cancer:2.27e-5 (favourable)	Expressed in all	Expressed in all			lymph node: 30.3	Expressed in all		
EEF1A1	EE1A1, EEF1A, EF1A, LENG7	ENSG00000156508	Eukaryotic translation elongation factor 1 alpha 1	6	73515750-73523797	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051759, HPA053862, HPA056990	Supported		Supported	Cytosol	Liver cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 14741.4	Expressed in all		
EEF1A2	EEF1AL, HS1, STN, STNL	ENSG00000101210	Eukaryotic translation elongation factor 1 alpha 2	20	63488013-63499315	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034019, HPA051759, HPA053862, HPA056990	Approved		Enhanced	Nucleoli<br>Cytosol	Endometrial cancer:2.90e-5 (unfavourable), Head and neck cancer:9.11e-4 (unfavourable)	Expressed in all	Group enriched	6	cerebral cortex: 409.3;heart muscle: 425.6;skeletal muscle: 1372.7	adrenal gland: 127.7	Cell line enhanced		MCF7: 899.8;SCLC-21H: 694.7;T-47d: 410.5;U-2 OS: 431.5
EEF1AKMT1	N6AMT2	ENSG00000150456	Eukaryotic translation elongation factor 1 alpha lysine methyltransferase 1	13	20728731-20773958	Predicted intracellular proteins	Evidence at protein level	HPA040417, HPA042543	Uncertain		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:1.82e-4 (favourable)	Expressed in all	Expressed in all			endometrium,fallopian tube: 18.1	Mixed		
EEF1B2		ENSG00000114942	Eukaryotic translation elongation factor 1 beta 2	2	206159585-206162928	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012477, HPA035029	Supported		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:3.62e-6 (unfavourable), Breast cancer:2.60e-4 (favourable), Melanoma:9.95e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 515.5	Expressed in all		
EEF1D	EF-1D, FLJ20897	ENSG00000104529	Eukaryotic translation elongation factor 1 delta	8	143579697-143599541	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045101, HPA051002	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:2.58e-5 (unfavourable), Liver cancer:3.82e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 606.8	Expressed in all		
EEF1G	EF1G	ENSG00000254772	Eukaryotic translation elongation factor 1 gamma	11	62559601-62574086	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040688, HPA055316	Enhanced		Approved	Mitochondria		Mixed	Expressed in all			ovary: 2996.8	Expressed in all		
EEF2	EEF-2, EF2	ENSG00000167658	Eukaryotic translation elongation factor 2	19	3976056-3985469	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007795, HPA040534, HPA057351	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Endometrial cancer:1.81e-6 (favourable), Renal cancer:1.25e-5 (favourable)	Expressed in all	Expressed in all			ovary: 1621.6	Expressed in all		
EEF2K	eEF-2K	ENSG00000103319	Eukaryotic elongation factor 2 kinase	16	22206282-22288732	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB007818, HPA056061	Approved		Approved	Nucleoplasm	Renal cancer:2.38e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 54.3	Expressed in all		
EEF2KMT	EFM3, FAM86A, MGC19636, SB153	ENSG00000118894	Eukaryotic elongation factor 2 lysine methyltransferase	16	5084304-5097808	Predicted intracellular proteins	Evidence at protein level	HPA041610	Approved		Uncertain	Vesicles	Urothelial cancer:2.35e-4 (unfavourable), Liver cancer:8.85e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.3	Expressed in all		
EEFSEC	eEFSec, EFSEC, SELB	ENSG00000132394	Eukaryotic elongation factor, selenocysteine-tRNA specific	3	128153454-128408646	Predicted intracellular proteins	Evidence at protein level	HPA035795	Approved		Approved	Nucleus<br>Nuclear bodies<br>Cytosol	Cervical cancer:2.98e-5 (favourable)	Expressed in all	Expressed in all			testis: 18.8	Expressed in all		
EEPD1	KIAA1706	ENSG00000122547	Endonuclease/exonuclease/phosphatase family domain containing 1	7	36153149-36301543	Predicted intracellular proteins	Evidence at protein level	HPA053668			Approved	Nuclear speckles<br>Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			cerebral cortex: 27.1	Cell line enhanced		HDLM-2: 16.9;PC-3: 20.8
EFCAB1	FLJ11767	ENSG00000034239	EF-hand calcium binding domain 1	8	48710789-48735311	Predicted intracellular proteins	Evidence at protein level	HPA023527, HPA069955	Enhanced		Approved	Nucleoplasm<br>Plasma membrane		Tissue enhanced	Tissue enhanced		fallopian tube: 149.8;testis: 47.1	ovary: 23.9	Cell line enhanced		A-431: 5.8;ASC TERT1: 4.4;CAPAN-2: 2.8;SCLC-21H: 5.8
EFCAB10		ENSG00000185055	EF-hand calcium binding domain 10	7	105565120-105600875	Predicted intracellular proteins	Evidence at transcript level	HPA019751	Uncertain					Mixed	Group enriched	10	fallopian tube: 44.0;testis: 39.9	lung: 4.3	Mixed		
EFCAB11	C14orf143	ENSG00000140025	EF-hand calcium binding domain 11	14	89794669-89954777	Predicted intracellular proteins	Evidence at transcript level	HPA051209			Approved	Cell Junctions<br>Cytosol		Expressed in all	Tissue enhanced		testis: 60.1	fallopian tube: 17.2	Expressed in all		
EFCAB12	C3orf25	ENSG00000172771	EF-hand calcium binding domain 12	3	129401321-129428651	Predicted intracellular proteins	Evidence at protein level	HPA037694	Uncertain	Supported				Mixed	Group enriched	5	fallopian tube: 31.3;testis: 6.7	prostate: 3.7	Cell line enhanced		Hep G2: 1.0;SCLC-21H: 1.0
EFCAB13	C17orf57, FLJ40342	ENSG00000178852	EF-hand calcium binding domain 13	17	47323290-47441312	Predicted intracellular proteins	Evidence at protein level	CAB002501, HPA021633, HPA023249, HPA026561	Uncertain		Supported	Nucleus<br>Nuclear speckles<br>Cytosol		Mixed	Tissue enhanced		testis: 37.3	thyroid gland: 23.6	Mixed		
EFCAB2	CFAP200, DRC8, MGC12458	ENSG00000203666	EF-hand calcium binding domain 2	1	244969705-245127164	Predicted intracellular proteins	Evidence at protein level	HPA031206, HPA031207	Approved		Approved	Plasma membrane<br>Cytosol	Thyroid cancer:6.51e-4 (unfavourable)	Mixed	Expressed in all			fallopian tube: 57.7	Expressed in all		
EFCAB3	FLJ25818	ENSG00000172421	EF-hand calcium binding domain 3	17	62343941-62416479	Predicted intracellular proteins	Evidence at protein level	HPA046862	Uncertain					Not detected	Tissue enriched	24	testis: 10.5	adipose tissue: 0.4	Not detected		
EFCAB5	FLJ46247	ENSG00000176927	EF-hand calcium binding domain 5	17	29929200-30108452	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	12	testis: 15.2	rectum: 1.2	Cell line enhanced		RPTEC TERT1: 2.2
EFCAB6	dJ185D5.1, DJBP, FLJ23588, HSCBCIP1, KIAA1672	ENSG00000186976	EF-hand calcium binding domain 6	22	43528744-43812337	Predicted intracellular proteins	Evidence at protein level	HPA003098			Uncertain	Nucleoplasm		Mixed	Group enriched	5	fallopian tube: 12.3;testis: 44.2	thyroid gland: 5.1	Mixed		
EFCAB7	KIAA1799, RP4-534K7.1	ENSG00000203965	EF-hand calcium binding domain 7	1	63523372-63572693	Predicted intracellular proteins	Evidence at protein level	HPA029611, HPA029612, HPA029613	Enhanced		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Glioma:4.84e-4 (favourable)	Mixed	Mixed			testis: 24.7	Expressed in all		
EFCAB8		ENSG00000215529	EF-hand calcium binding domain 8	20	32858923-32961609	Predicted intracellular proteins	Evidence at transcript level	CAB034246, HPA042751	Uncertain					Not detected	Tissue enriched	6	testis: 2.8	appendix,small intestine,thyroid gland: 0.4	Not detected		
EFCAB9		ENSG00000214360	EF-hand calcium binding domain 9	5	172194172-172203452	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	97	testis: 15.7	appendix,gallbladder: 0.1	Cell line enhanced		WM-115: 1.5
EFCC1	C3orf73, CCDC48, FLJ12057	ENSG00000114654	EF-hand and coiled-coil domain containing 1	3	129001629-129040742	Predicted intracellular proteins	Evidence at transcript level	HPA042798, HPA050888	Uncertain				Pancreatic cancer:9.70e-4 (favourable)	Mixed	Tissue enhanced		lung: 4.9	spleen: 3.6	Cell line enhanced		AF22: 1.3;HL-60: 3.0
EFHB	CFAP21, FLJ25200	ENSG00000163576	EF-hand domain family member B	3	19879472-19947025	Predicted intracellular proteins	Evidence at protein level	HPA078067			Approved	Nucleoli		Mixed	Group enriched	6	fallopian tube: 25.5;testis: 25.8	cerebral cortex: 4.3	Cell line enriched	30	RPTEC TERT1: 14.9
EFHC1	EJM, EJM1, FLJ10466	ENSG00000096093	EF-hand domain containing 1	6	52362123-52529886	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035307	Approved		Uncertain	Plasma membrane<br>Cytosol	Pancreatic cancer:2.33e-4 (favourable), Renal cancer:3.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 55.6	testis: 31.3	Cell line enhanced		SCLC-21H: 22.6
EFHC2	FLJ22843, MRX74	ENSG00000183690	EF-hand domain containing 2	X	44147882-44343672	Predicted intracellular proteins	Evidence at protein level	HPA034492	Uncertain	Supported				Mixed	Tissue enhanced		fallopian tube: 25.8;testis: 15.4	endometrium: 6.8	Group enriched	5	CAPAN-2: 3.8;HEL: 4.2;HMC-1: 13.1
EFHD1	FLJ13612	ENSG00000115468	EF-hand domain family member D1	2	232606057-232682781	Predicted intracellular proteins	Evidence at protein level	HPA049331, HPA056959	Enhanced		Supported	Nucleoli fibrillar center<br>Golgi apparatus	Renal cancer:2.93e-7 (favourable)	Expressed in all	Tissue enhanced		breast: 227.6	kidney: 177.3	Group enriched	7	BEWO: 121.1;RPTEC TERT1: 51.3;SK-BR-3: 225.6;T-47d: 222.0
EFHD2	MGC4342	ENSG00000142634	EF-hand domain family member D2	1	15409895-15430343	Predicted intracellular proteins	Evidence at protein level	HPA048961	Enhanced		Approved	Cytosol	Renal cancer:6.31e-9 (unfavourable), Urothelial cancer:3.60e-5 (favourable), Thyroid cancer:2.70e-4 (favourable), Lung cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 111.1	Expressed in all		
EFL1	EFTUD1, FAM42A, FLJ13119, HsT19294, RIA1	ENSG00000140598	Elongation factor like GTPase 1	15	82130230-82262763	Predicted intracellular proteins	Evidence at protein level	HPA039654, HPA047110, HPA052345	Uncertain		Approved	Cytosol	Renal cancer:1.50e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.4	Expressed in all		
EFR3A	KIAA0143	ENSG00000132294	EFR3 homolog A	8	131904088-132013642	Predicted intracellular proteins	Evidence at protein level	HPA022859, HPA023092, HPA023402	Enhanced		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 70.4	Expressed in all		
EFR3B	FLJ37871, KIAA0953	ENSG00000084710	EFR3 homolog B	2	25042130-25159137	Predicted intracellular proteins	Evidence at protein level	HPA038089	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 33.2	skeletal muscle: 6.8	Cell line enhanced		BEWO: 11.6;SH-SY5Y: 11.3;SK-BR-3: 13.6
EFS	CASS3, EFS1, EFS2, HEFS, SIN	ENSG00000100842	Embryonal Fyn-associated substrate	14	23356402-23365752	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001581, HPA001790	Approved		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:4.09e-5 (unfavourable)	Mixed	Mixed			skin: 59.4	Cell line enhanced		AF22: 61.4;BEWO: 50.1;SH-SY5Y: 62.8
EFTUD2	SNRNP116, Snrp116, Snu114, U5-116KD	ENSG00000108883	Elongation factor Tu GTP binding domain containing 2	17	44849943-44899662	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022021	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.71e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 47.7	Expressed in all		
EGLN1	C1orf12, HIFPH2, PHD2, SM-20, ZMYND6	ENSG00000135766	Egl-9 family hypoxia inducible factor 1	1	231363751-231425044	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022129	Approved		Approved	Cytosol	Cervical cancer:2.99e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.9	Expressed in all		
EGLN2	HIFPH1, PHD1	ENSG00000269858	Egl-9 family hypoxia inducible factor 2	19	40798996-40808433	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056649			Supported	Nucleoplasm	Cervical cancer:2.88e-4 (favourable), Pancreatic cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			testis: 205.1	Expressed in all		
EGLN3	HIFPH3, PHD3	ENSG00000129521	Egl-9 family hypoxia inducible factor 3	14	33924231-34462774	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA064895			Approved	Cytosol	Liver cancer:2.14e-5 (unfavourable), Renal cancer:2.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 98.0	heart muscle: 62.0	Cell line enhanced		RH-30: 43.2;RT4: 97.7
EGR1	AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268, ZNF225	ENSG00000120738	Early growth response 1	5	138465490-138469315	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019427, HPA029937, HPA029938	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 1188.8	Cell line enhanced		hTCEpi: 208.0;U-266/84: 325.4
EGR2	KROX20	ENSG00000122877	Early growth response 2	10	62811996-62919900	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031165			Supported	Nucleoplasm	Breast cancer:7.30e-5 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 234.3	epididymis: 73.8	Cell line enriched	7	U-87 MG: 22.2
EGR3	PILOT	ENSG00000179388	Early growth response 3	8	22687659-22693302	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA006206, CAB009373	Uncertain		Uncertain	Nucleus<br>Vesicles	Breast cancer:1.83e-4 (favourable), Melanoma:4.78e-4 (favourable)	Mixed	Mixed			gallbladder: 49.6	Cell line enhanced		HMC-1: 8.5;MCF7: 25.2;SK-MEL-30: 17.0
EGR4	NGFI-C, PAT133	ENSG00000135625	Early growth response 4	2	73290929-73293705	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028983	Enhanced					Mixed	Group enriched	29	cerebral cortex: 9.7;testis: 3.2	adipose tissue,appendix: 0.2	Cell line enriched	6	HMC-1: 1.4
EHBP1L1	DKFZp762C186, TANGERIN	ENSG00000173442	EH domain binding protein 1 like 1	11	65576038-65592650	Predicted intracellular proteins	Evidence at protein level	HPA039479	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:1.45e-4 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 88.6	Mixed		
EHD1	FLJ42622, FLJ44618, H-PAST, HPAST1, PAST1	ENSG00000110047	EH domain containing 1	11	64851642-64888296	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049890, HPA049986, HPA066751, HPA067747	Approved		Supported	Plasma membrane	Liver cancer:2.81e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 152.8	Expressed in all		
EHD2	PAST2	ENSG00000024422	EH domain containing 2	19	47713343-47743134	Predicted intracellular proteins	Evidence at protein level	HPA047394, HPA049890, HPA049986, HPA066751	Approved		Supported	Plasma membrane	Renal cancer:3.98e-4 (unfavourable), Ovarian cancer:8.75e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 208.8	smooth muscle: 111.7	Mixed		
EHD3	PAST3	ENSG00000013016	EH domain containing 3	2	31234337-31269447	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049890, HPA049986, HPA066751	Approved		Approved	Plasma membrane	Renal cancer:1.02e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 64.2	esophagus: 28.8	Cell line enhanced		BJ: 68.8;BJ hTERT+: 162.4;HEL: 71.6
EHD4	PAST4	ENSG00000103966	EH domain containing 4	15	41895939-41972578	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049890, HPA049986, HPA052729, HPA066751	Approved		Approved	Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 24.8	Cell line enhanced		TIME: 140.3
EHHADH	ECHD	ENSG00000113790	Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase	3	185190624-185281990	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036401, HPA042021	Enhanced				Renal cancer:1.28e-5 (favourable)	Group enriched	Group enriched	7	kidney: 148.6;liver: 173.1	duodenum: 21.4	Mixed		
EID1	C15orf3, CRI1, EID-1	ENSG00000255302	EP300 interacting inhibitor of differentiation 1	15	48877886-48880183	Predicted intracellular proteins	Evidence at protein level	HPA051122, HPA051123	Approved		Supported	Nucleoplasm	Stomach cancer:2.91e-4 (unfavourable), Head and neck cancer:9.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 315.2	Mixed		
EID2	CRI2, EID-2, MGC20452	ENSG00000176396	EP300 interacting inhibitor of differentiation 2	19	39538705-39540333	Predicted intracellular proteins	Evidence at protein level	HPA045477	Uncertain		Supported	Nucleoplasm	Prostate cancer:8.74e-4 (unfavourable), Colorectal cancer:9.73e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 26.3	Expressed in all		
EID2B	EID-3, FLJ38944	ENSG00000176401	EP300 interacting inhibitor of differentiation 2B	19	39530990-39532854	Predicted intracellular proteins	Evidence at protein level	HPA064185	Approved				Pancreatic cancer:2.57e-4 (favourable)	Mixed	Mixed			cerebral cortex: 12.4	Mixed		
EID3	FLJ25832, NSE4B, NSMCE4B	ENSG00000255150	EP300 interacting inhibitor of differentiation 3	12	104303739-104305205	Predicted intracellular proteins	Evidence at protein level	HPA059367	Uncertain		Supported	Nucleus<br>Nucleoli	Renal cancer:5.96e-5 (unfavourable), Glioma:9.70e-5 (unfavourable)	Mixed	Tissue enriched	14	testis: 111.8	seminal vesicle: 7.7	Cell line enhanced		A549: 8.2;BJ: 7.2
EIF1	A121, EIF-1, EIF1A, ISO1, SUI1	ENSG00000173812	Eukaryotic translation initiation factor 1	17	41688885-41692668	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:9.45e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 481.3	Expressed in all		
EIF1AD	haponin, MGC11102	ENSG00000175376	Eukaryotic translation initiation factor 1A domain containing	11	65996545-66002176	Predicted intracellular proteins	Evidence at protein level	HPA054991, HPA058735	Uncertain		Supported	Nucleoplasm<br>Vesicles	Endometrial cancer:3.59e-5 (unfavourable), Liver cancer:8.63e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.9	Expressed in all		
EIF1AX	eIF-1A, eIF-4C, EIF1A, EIF4C	ENSG00000173674	Eukaryotic translation initiation factor 1A, X-linked	X	20124518-20141844	Predicted intracellular proteins	Evidence at protein level	HPA002561	Uncertain	Approved	Approved	Cytosol		Expressed in all	Expressed in all			endometrium: 96.3	Expressed in all		
EIF1AY		ENSG00000198692	Eukaryotic translation initiation factor 1A, Y-linked	Y	20575725-20593154	Predicted intracellular proteins	Evidence at protein level	HPA002561	Uncertain	Approved	Approved	Cytosol		Mixed	Mixed			prostate: 42.2	Cell line enhanced		HEL: 197.1;U-698: 240.9
EIF1B	GC20	ENSG00000114784	Eukaryotic translation initiation factor 1B	3	40309684-40312424	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.08e-5 (favourable), Liver cancer:1.94e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 231.3	Expressed in all		
EIF2A	EIF-2A	ENSG00000144895	Eukaryotic translation initiation factor 2A	3	150546678-150584242	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036256	Approved		Approved	Mitochondria<br>Cytosol	Pancreatic cancer:6.57e-6 (unfavourable), Liver cancer:2.36e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 139.1	Expressed in all		
EIF2AK2	EIF2AK1, PKR, PPP1R83, PRKR	ENSG00000055332	Eukaryotic translation initiation factor 2 alpha kinase 2	2	37099210-37157065	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB003845, HPA019795, HPA063893	Approved		Enhanced	Cytosol	Pancreatic cancer:2.08e-4 (unfavourable), Endometrial cancer:3.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 25.4	Mixed		
EIF2AK4	GCN2, KIAA1338	ENSG00000128829	Eukaryotic translation initiation factor 2 alpha kinase 4	15	39934146-40035591	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA011811	Approved		Approved	Cytosol		Expressed in all	Expressed in all			endometrium: 54.3	Expressed in all		
EIF2B1	EIF-2B, EIF-2Balpha, EIF2B, EIF2BA	ENSG00000111361	Eukaryotic translation initiation factor 2B subunit alpha	12	123620406-123633766	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB034258, HPA049509	Approved		Supported	Cytosol	Renal cancer:1.78e-9 (unfavourable), Liver cancer:6.75e-7 (unfavourable)	Expressed in all	Expressed in all			skin: 59.3	Expressed in all		
EIF2B2	EIF-2Bbeta, EIF2B	ENSG00000119718	Eukaryotic translation initiation factor 2B subunit beta	14	75002911-75012366	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005841, CAB037105, HPA048028	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites	Liver cancer:2.26e-6 (unfavourable), Renal cancer:2.95e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 19.2	Expressed in all		
EIF2B3	EIF-2B, EIF2Bgamma	ENSG00000070785	Eukaryotic translation initiation factor 2B subunit gamma	1	44850522-44986722	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024213, HPA024218, HPA024219	Supported		Supported	Vesicles<br>Cytosol	Liver cancer:1.73e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.4	Expressed in all		
EIF2B4	DKFZP586J0119, EIF-2B, EIF2B, EIF2Bdelta	ENSG00000115211	Eukaryotic translation initiation factor 2B subunit delta	2	27364352-27370486	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB032234, HPA039993	Uncertain		Approved	Nuclear membrane<br>Actin filaments	Renal cancer:5.46e-8 (unfavourable), Liver cancer:1.83e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.0	Expressed in all		
EIF2B5	EIF-2B, EIF2Bepsilon	ENSG00000145191	Eukaryotic translation initiation factor 2B subunit epsilon	3	184135038-184145311	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015412, HPA064370, HPA069303	Uncertain		Enhanced	Cytosol	Liver cancer:3.38e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 39.0	Expressed in all		
EIF2D	LGTN	ENSG00000143486	Eukaryotic translation initiation factor 2D	1	206571292-206612463	Predicted intracellular proteins	Evidence at protein level	HPA028220	Approved		Approved	Nuclear bodies<br>Cytosol	Renal cancer:1.74e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 74.1	Expressed in all		
EIF2S1	EIF-2alpha, EIF2, EIF2A	ENSG00000134001	Eukaryotic translation initiation factor 2 subunit alpha	14	67359997-67386516	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011663, HPA064885	Supported		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:4.73e-7 (unfavourable), Pancreatic cancer:4.97e-4 (unfavourable), Urothelial cancer:7.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 61.1	Expressed in all		
EIF2S2	EIF2, EIF2beta, PPP1R67	ENSG00000125977	Eukaryotic translation initiation factor 2 subunit beta	20	34088298-34112332	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034415, HPA041262, HPA041332	Approved		Supported	Nucleoli<br>Endoplasmic reticulum	Renal cancer:9.64e-10 (unfavourable), Liver cancer:3.23e-5 (unfavourable), Endometrial cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 74.3	Expressed in all		
EIF2S3	EIF2, EIF2G, EIF2gamma	ENSG00000130741	Eukaryotic translation initiation factor 2 subunit gamma	X	24054716-24077971	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012471	Approved				Renal cancer:5.44e-6 (unfavourable), Liver cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 179.5	Expressed in all		
EIF2S3L		ENSG00000180574	Putative eukaryotic translation initiation factor 2 subunit 3-like protein 	12	10505602-10523135	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 4.4	duodenum: 1.0	Cell line enhanced		HaCaT: 2.3;HL-60: 3.9;MOLT-4: 3.4;RH-30: 2.9
EIF3A	EIF3, eIF3-p170, eIF3-theta, eIF3a, EIF3S10, KIAA0139, TIF32	ENSG00000107581	Eukaryotic translation initiation factor 3 subunit A	10	119033670-119080823	Predicted intracellular proteins	Evidence at protein level	HPA038315, HPA038316	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 135.7	Expressed in all		
EIF3B	eIF3b, EIF3S9, PRT1	ENSG00000106263	Eukaryotic translation initiation factor 3 subunit B	7	2354086-2380745	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017562, HPA048983	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:4.41e-9 (unfavourable), Renal cancer:9.66e-6 (unfavourable), Head and neck cancer:2.20e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 103.1	Expressed in all		
EIF3C	eIF3-p110, eIF3c, EIF3S8	ENSG00000184110	Eukaryotic translation initiation factor 3 subunit C	16	28688558-28735730	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034045, HPA047097, HPA049495, HPA050112	Supported		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 571.3	Expressed in all		
EIF3CL		ENSG00000205609	Eukaryotic translation initiation factor 3 subunit C-like	16	28379579-28403879	Predicted intracellular proteins	Evidence at protein level	HPA047097, HPA049495, HPA050112	Supported		Approved	Cytosol		Group enriched	Mixed			skin: 24.2	Expressed in all		
EIF3D	eIF3-p66, eIF3-zeta, eIF3d, EIF3S7	ENSG00000100353	Eukaryotic translation initiation factor 3 subunit D	22	36510850-36529436	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045882, HPA063330, HPA066216	Approved		Supported	Cytosol	Liver cancer:8.10e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 256.0	Expressed in all		
EIF3E	eIF3-p48, eIF3e, EIF3S6, INT6	ENSG00000104408	Eukaryotic translation initiation factor 3 subunit E	8	108201216-108435333	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA023973	Approved		Enhanced	Nuclear bodies<br>Cytosol	Renal cancer:3.06e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 731.0	Expressed in all		
EIF3F	eIF3-epsilon, eIF3-p47, eIF3f, EIF3S5	ENSG00000175390	Eukaryotic translation initiation factor 3 subunit F	11	7970251-8001862	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049250	Approved		Uncertain	Nucleoli<br>Cytosol	Liver cancer:6.86e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 178.4	Expressed in all		
EIF3G	eIF3-delta, eIF3-p44, eIF3g, EIF3S4	ENSG00000130811	Eukaryotic translation initiation factor 3 subunit G	19	10115017-10119918	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041997	Approved		Enhanced	Cytosol	Ovarian cancer:3.94e-4 (favourable)	Expressed in all	Expressed in all			ovary: 217.8	Expressed in all		
EIF3H	eIF3-gamma, eIF3-p40, eIF3h, EIF3S3	ENSG00000147677	Eukaryotic translation initiation factor 3 subunit H	8	116642130-116766925	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA023117, HPA023553	Approved		Approved	Cytosol	Breast cancer:5.26e-4 (unfavourable), Cervical cancer:8.07e-4 (unfavourable), Liver cancer:8.34e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 480.9	Expressed in all		
EIF3I	eIF3-beta, eIF3-p36, eIF3i, EIF3S2, TRIP-1	ENSG00000084623	Eukaryotic translation initiation factor 3 subunit I	1	32221928-32231604	Predicted intracellular proteins	Evidence at protein level	HPA029939, HPA029940	Enhanced		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:4.81e-6 (unfavourable), Endometrial cancer:2.14e-4 (favourable), Liver cancer:4.21e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 198.1	Expressed in all		
EIF3J	eIF3-alpha, eIF3-p35, eIF3j, EIF3S1	ENSG00000104131	Eukaryotic translation initiation factor 3 subunit J	15	44537057-44563029	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050977	Approved		Enhanced	Cytosol	Urothelial cancer:4.96e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 69.3	Expressed in all		
EIF3K	ARG134, eIF3k, EIF3S12, HSPC029, M9, PLAC-24, PRO1474, PTD001	ENSG00000178982	Eukaryotic translation initiation factor 3 subunit K	19	38619082-38636955	Predicted intracellular proteins	Evidence at protein level	HPA045446, HPA054590	Uncertain		Supported	Cytosol	Cervical cancer:1.31e-4 (favourable), Renal cancer:5.43e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 164.9	Expressed in all		
EIF3M	eIF3m, FLJ29030, GA17, hfl-B5, PCID1, TANGO7	ENSG00000149100	Eukaryotic translation initiation factor 3 subunit M	11	32583798-32606262	Predicted intracellular proteins	Evidence at protein level	HPA031063	Approved		Supported	Cytosol	Liver cancer:1.28e-9 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 235.1	Expressed in all		
EIF4A1	DDX2A, EIF-4A, EIF4A	ENSG00000161960	Eukaryotic translation initiation factor 4A1	17	7572706-7579005	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011689, HPA068286	Uncertain		Approved	Cytosol	Renal cancer:1.76e-8 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 458.2	Expressed in all		
EIF4A2	BM-010, DDX2B, EIF4A, EIF4F	ENSG00000156976	Eukaryotic translation initiation factor 4A2	3	186783205-186789900	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011690, HPA068286	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			ovary: 726.0	Expressed in all		
EIF4A3	DDX48, EIF4AIII, KIAA0111	ENSG00000141543	Eukaryotic translation initiation factor 4A3	17	80135214-80147183	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA021878	Enhanced		Supported	Nucleoplasm	Liver cancer:1.68e-5 (unfavourable), Colorectal cancer:3.57e-5 (favourable), Lung cancer:1.87e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 112.1	Expressed in all		
EIF4B		ENSG00000063046	Eukaryotic translation initiation factor 4B	12	53006158-53042209	Predicted intracellular proteins	Evidence at protein level	HPA039072, HPA046164	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			ovary: 757.9	Expressed in all		
EIF4E	EIF4E1, EIF4EL1, EIF4F	ENSG00000151247	Eukaryotic translation initiation factor 4E	4	98871684-98930637	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004077, CAB016316, HPA051311	Supported		Enhanced	Cytosol<br>Cytoplasmic bodies		Expressed in all	Expressed in all			testis: 103.5	Expressed in all		
EIF4E1B	FLJ36951	ENSG00000175766	Eukaryotic translation initiation factor 4E family member 1B	5	176630682-176646641	Predicted intracellular proteins	Evidence at transcript level	HPA045045	Approved					Not detected	Tissue enhanced		cerebral cortex: 1.6;epididymis: 1.2	testis: 0.3	Cell line enriched	6	T-47d: 3.0
EIF4E2	4EHP, EIF4EL3, IF4e	ENSG00000135930	Eukaryotic translation initiation factor 4E family member 2	2	232550052-232583644	Predicted intracellular proteins	Evidence at protein level	HPA019253			Approved	Mitochondria<br>Cytosol	Liver cancer:2.38e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 75.2	Expressed in all		
EIF4E3	MGC39820	ENSG00000163412	Eukaryotic translation initiation factor 4E family member 3	3	71675416-71754773	Predicted intracellular proteins	Evidence at protein level	HPA058649			Approved	Nucleoli fibrillar center	Ovarian cancer:4.64e-5 (favourable), Renal cancer:6.99e-5 (favourable), Lung cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 54.7	Cell line enhanced		U-937: 39.6
EIF4EBP1	4E-BP1, PHAS-I	ENSG00000187840	Eukaryotic translation initiation factor 4E binding protein 1	8	38030341-38060365	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB005032, CAB005039, HPA023501	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:8.86e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 30.5	Expressed in all		
EIF4EBP2		ENSG00000148730	Eukaryotic translation initiation factor 4E binding protein 2	10	70404379-70428618	Predicted intracellular proteins	Evidence at protein level	CAB019415, HPA037410, HPA061665	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:6.69e-6 (favourable)	Expressed in all	Expressed in all			adipose tissue: 74.3	Expressed in all		
EIF4EBP3	4E-BP3	ENSG00000243056	Eukaryotic translation initiation factor 4E binding protein 3	5	140547666-140549578	Predicted intracellular proteins	Evidence at protein level	HPA045537	Uncertain				Renal cancer:3.10e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 59.8	Mixed		
EIF4ENIF1	2610509L04Rik, 4E-T, Clast4, FLJ21601	ENSG00000184708	Eukaryotic translation initiation factor 4E nuclear import factor 1	22	31436977-31496108	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001619, HPA002078	Enhanced		Enhanced	Vesicles	Renal cancer:1.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 65.0	Expressed in all		
EIF4G1	EIF4F, EIF4G, p220, PARK18	ENSG00000114867	Eukaryotic translation initiation factor 4 gamma 1	3	184314495-184335358	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB014774, HPA028487, HPA043866	Approved		Enhanced	Cytosol	Liver cancer:7.99e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 210.0	Expressed in all		
EIF4G2	DAP5, NAT1, p97	ENSG00000110321	Eukaryotic translation initiation factor 4 gamma 2	11	10797050-10809110	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005163, HPA006773, HPA016965	Approved		Enhanced	Cytosol	Liver cancer:6.18e-5 (unfavourable), Renal cancer:1.67e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 686.8	Expressed in all		
EIF4G3	eIF4GII	ENSG00000075151	Eukaryotic translation initiation factor 4 gamma 3	1	20806292-21176888	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025031, HPA025039, HPA025041	Enhanced		Approved	Cytosol	Liver cancer:9.60e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 170.1	Mixed		
EIF4H	KIAA0038, WBSCR1, WSCR1	ENSG00000106682	Eukaryotic translation initiation factor 4H	7	74174245-74197101	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030542	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Head and neck cancer:2.15e-4 (unfavourable), Glioma:5.65e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 254.3	Expressed in all		
EIF5		ENSG00000100664	Eukaryotic translation initiation factor 5	14	103333544-103345025	Predicted intracellular proteins	Evidence at protein level	HPA000867, CAB004226	Supported		Supported	Plasma membrane<br>Cytosol	Renal cancer:5.67e-7 (favourable)	Expressed in all	Expressed in all			testis: 174.0	Expressed in all		
EIF5A	EIF-5A, EIF5A1, MGC104255, MGC99547	ENSG00000132507	Eukaryotic translation initiation factor 5A	17	7306999-7312463	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB005042, HPA061298	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.63e-5 (unfavourable), Lung cancer:9.04e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 435.8	Expressed in all		
EIF5A2		ENSG00000163577	Eukaryotic translation initiation factor 5A2	3	170888415-170908693	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA029090	Approved		Supported	Vesicles	Head and neck cancer:7.42e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 36.7	smooth muscle: 10.4	Mixed		
EIF5AL1	bA342M3.3, EIF5AP1	ENSG00000253626	Eukaryotic translation initiation factor 5A-like 1	10	79512601-79516440	Predicted intracellular proteins, Transporters	Evidence at transcript level						Cervical cancer:4.23e-4 (favourable)	Expressed in all	Tissue enriched	13	testis: 19.8	parathyroid gland: 1.5	Mixed		
EIF5B	DKFZp434I036, FLJ10524, IF2, KIAA0741	ENSG00000158417	Eukaryotic translation initiation factor 5B	2	99337353-99401326	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034648, HPA040095	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:7.15e-10 (unfavourable), Renal cancer:1.42e-6 (unfavourable), Ovarian cancer:8.99e-4 (favourable)	Expressed in all	Expressed in all			testis: 67.5	Expressed in all		
EIF6	b(2)gcn, EIF3A, ITGB4BP, p27BBP	ENSG00000242372	Eukaryotic translation initiation factor 6	20	35278907-35284985	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040873	Enhanced		Supported	Nucleoplasm	Liver cancer:7.25e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 173.2	Expressed in all		
ELAC1	D29	ENSG00000141642	ElaC ribonuclease Z 1	18	50967991-50988121	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040867, HPA066483	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:8.43e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.8	Expressed in all		
ELAC2	FLJ10530, HPC2	ENSG00000006744	ElaC ribonuclease Z 2	17	12992391-13018187	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019535	Approved		Enhanced	Nucleoplasm	Endometrial cancer:3.24e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 55.1	Expressed in all		
ELAVL1	Hua, HUR, MelG	ENSG00000066044	ELAV like RNA binding protein 1	19	7958579-8005659	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005256, HPA046298	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Ovarian cancer:4.93e-4 (favourable)	Expressed in all	Expressed in all			testis: 81.9	Expressed in all		
ELAVL2	HEL-N1, HuB	ENSG00000107105	ELAV like RNA binding protein 2	9	23690104-23826337	Predicted intracellular proteins	Evidence at protein level	CAB022222, HPA063001	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Group enriched	32	cerebral cortex: 37.9;testis: 80.3	adrenal gland: 1.8	Cell line enhanced		AF22: 36.8;SCLC-21H: 145.6
ELAVL3	DKFZp547J036, HUC, HUCL, MGC20653, PLE21	ENSG00000196361	ELAV like RNA binding protein 3	19	11451326-11481046	Predicted intracellular proteins	Evidence at protein level	CAB013066	Enhanced					Tissue enriched	Tissue enriched	45	cerebral cortex: 72.8	adrenal gland: 1.6	Group enriched	10	SCLC-21H: 95.2;SH-SY5Y: 49.4
ELAVL4	HUD, PNEM	ENSG00000162374	ELAV like RNA binding protein 4	1	50048014-50203786	Predicted intracellular proteins	Evidence at protein level	CAB004442, HPA043047	Enhanced		Approved	Nucleoplasm<br>Vesicles		Group enriched	Group enriched	9	adrenal gland: 10.7;cerebral cortex: 53.3;testis: 10.9	appendix: 2.9	Cell line enriched	21	SH-SY5Y: 131.1
ELF1		ENSG00000120690	E74 like ETS transcription factor 1	13	40932028-41061440	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001755, CAB005172	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 129.2	Expressed in all		
ELF2	EU32, NERF, NERF-1A, NERF-1B, NERF-2	ENSG00000109381	E74 like ETS transcription factor 2	4	139028112-139177218	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006057, HPA071166	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			testis: 69.4	Expressed in all		
ELF3	EPR-1, ERT, ESE-1, ESX	ENSG00000163435	E74 like ETS transcription factor 3	1	202007945-202017188	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003316, HPA003479	Enhanced		Enhanced	Nucleoplasm		Mixed	Mixed			small intestine: 161.7	Cell line enhanced		A549: 188.9;CAPAN-2: 259.7;RT4: 171.2;SK-BR-3: 304.2
ELF4	ELFR, MEF	ENSG00000102034	E74 like ETS transcription factor 4	X	130064874-130110716	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058595, HPA060277	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.49e-6 (unfavourable), Urothelial cancer:1.42e-4 (favourable)	Expressed in all	Mixed			placenta: 34.9	Mixed		
ELF5		ENSG00000135374	E74 like ETS transcription factor 5	11	34478793-34513805	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062706			Supported	Nucleoplasm	Lung cancer:3.64e-4 (favourable)	Tissue enhanced	Tissue enhanced		breast: 172.6;salivary gland: 64.2	seminal vesicle: 42.2	Group enriched	10	RT4: 24.0;T-47d: 53.3
ELK1		ENSG00000126767	ELK1, ETS transcription factor	X	47635521-47650604	Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB003808, HPA036084, HPA064381	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.25e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 50.9	Expressed in all		
ELK3	ERP, NET, SAP2	ENSG00000111145	ELK3, ETS transcription factor	12	96194382-96269835	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001600	Approved		Supported	Nucleoplasm<br>Mitochondria	Ovarian cancer:4.93e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 58.4	Expressed in all		
ELK4	SAP1	ENSG00000158711	ELK4, ETS transcription factor	1	205597556-205631962	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028863	Uncertain		Supported	Nucleoplasm	Renal cancer:2.94e-6 (unfavourable), Head and neck cancer:4.65e-4 (favourable)	Expressed in all	Expressed in all			prostate: 42.8	Expressed in all		
ELL	C19orf17, ELL1, Men, PPP1R68	ENSG00000105656	Elongation factor for RNA polymerase II	19	18442663-18522127	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046076	Uncertain					Expressed in all	Expressed in all			testis: 25.2	Expressed in all		
ELL2		ENSG00000118985	Elongation factor for RNA polymerase II 2	5	95885098-95962071	Predicted intracellular proteins	Evidence at protein level	HPA013569			Supported	Nucleoplasm	Renal cancer:1.31e-4 (unfavourable), Stomach cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 69.0	Cell line enhanced		BJ: 267.9;HDLM-2: 265.3
ELL3	FLJ22637	ENSG00000128886	Elongation factor for RNA polymerase II 3	15	43772600-43777543	Predicted intracellular proteins	Evidence at protein level	HPA028938	Approved		Supported	Nucleoplasm<br>Nucleoli		Mixed	Tissue enhanced		testis: 9.9	lymph node: 4.3	Cell line enhanced		Daudi: 5.3;SCLC-21H: 3.8;U-698: 12.4
ELMO1	CED-12, CED12, ELMO-1, KIAA0281	ENSG00000155849	Engulfment and cell motility 1	7	36854361-37449249	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.27e-5 (unfavourable), Pancreatic cancer:4.62e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 136.9	Cell line enhanced		U-698: 82.2
ELMO2	CED-12, CED12, ELMO-2, FLJ11656, KIAA1834	ENSG00000062598	Engulfment and cell motility 2	20	46366049-46432985	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018811	Approved		Supported	Cytosol	Liver cancer:4.08e-5 (unfavourable), Pancreatic cancer:6.10e-4 (favourable), Endometrial cancer:6.54e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 58.2	Expressed in all		
ELMO3	CED-12, CED12, ELMO-3, FLJ13824	ENSG00000102890	Engulfment and cell motility 3	16	67199111-67204029	Predicted intracellular proteins	Evidence at protein level	HPA021484	Approved		Approved	Plasma membrane<br>Cell Junctions	Renal cancer:2.77e-5 (favourable)	Expressed in all	Mixed			skin: 39.3	Cell line enhanced		BEWO: 31.7;CAPAN-2: 43.1;HaCaT: 41.1;T-47d: 42.8
ELMOD2	MGC10084	ENSG00000179387	ELMO domain containing 2	4	140524158-140553770	Predicted intracellular proteins	Evidence at protein level	HPA047600	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.17e-8 (favourable), Thyroid cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.2	Expressed in all		
ELMOD3	DFNB88, FLJ21977, RBED1, RBM29	ENSG00000115459	ELMO domain containing 3	2	85354394-85391752	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA012126	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.09e-6 (unfavourable), Pancreatic cancer:6.16e-6 (favourable), Urothelial cancer:2.85e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 11.4	Expressed in all		
ELMSAN1	C14orf117, C14orf43, LSR68	ENSG00000156030	ELM2 and Myb/SANT domain containing 1	14	73715122-73790285	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003111	Approved		Enhanced	Nucleoplasm	Ovarian cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.2	Expressed in all		
ELOA	SIII, TCEB3, TCEB3A	ENSG00000011007	Elongin A	1	23743155-23762059	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005910	Approved		Approved	Nuclear speckles<br>Cytosol	Liver cancer:1.44e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 38.5	Expressed in all		
ELOA2	HsT832, TCEB3B, TCEB3L	ENSG00000206181	Elongin A2	18	47032572-47035621	Predicted intracellular proteins	Evidence at protein level	HPA041009, HPA043501, HPA048971, HPA049178, HPA050086	Approved					Not detected	Tissue enriched	44	testis: 4.3	all non-specific tissues: 0.0	Not detected		
ELOA3	ELOA3A, HsT829, TCEB3C, TCEB3L2	ENSG00000183791	Elongin A3	18	47028202-47030078	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048971, HPA049178, HPA050086	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ELOA3B	HsT828, TCEB3CL	ENSG00000278674	Elongin A3 family member B	18	47022287-47023927	Predicted intracellular proteins	No evidence	HPA048971, HPA049178, HPA050086	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ELOA3C		ENSG00000275553	Elongin A3 family member C	18	46968695-46969912	Predicted intracellular proteins	No evidence	HPA049178, HPA050086	Uncertain					Not detected	Not detected			epididymis: 0.1	Not detected		
ELOA3D	TCEB3CL2	ENSG00000274744	Elongin A3 family member D	18	46962768-46964408	Predicted intracellular proteins	No evidence	HPA048971, HPA049178, HPA050086	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ELOB	SIII, TCEB2	ENSG00000103363	Elongin B	16	2771414-2777297	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			fallopian tube: 355.1	Expressed in all		
ELOC	SIII, TCEB1	ENSG00000154582	Elongin C	8	73939169-73972287	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA078113			Approved	Cell Junctions	Breast cancer:6.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 162.4	Expressed in all		
ELOF1	ELF1, MGC4549	ENSG00000130165	Elongation factor 1 homolog	19	11551147-11559236	Predicted intracellular proteins	Evidence at protein level	HPA045606	Uncertain		Approved	Cytosol	Cervical cancer:1.83e-4 (favourable)	Expressed in all	Expressed in all			testis: 163.7	Expressed in all		
ELP3	FLJ10422, KAT9	ENSG00000134014	Elongator acetyltransferase complex subunit 3	8	28089673-28191156	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA025812	Uncertain				Renal cancer:1.31e-5 (favourable), Colorectal cancer:9.25e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 37.6	Expressed in all		
ELP4	C11orf19, PAXNEB	ENSG00000109911	Elongator acetyltransferase complex subunit 4	11	31509700-31790328	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038572, HPA038573	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 15.4	Expressed in all		
ELP5	C17orf81, DERP6	ENSG00000170291	Elongator acetyltransferase complex subunit 5	17	7251416-7259940	Predicted intracellular proteins	Evidence at protein level	HPA023279	Uncertain		Supported	Cytosol	Pancreatic cancer:2.62e-4 (favourable)	Expressed in all	Expressed in all			testis: 173.3	Expressed in all		
EMC2	KIAA0103, TTC35	ENSG00000104412	ER membrane protein complex subunit 2	8	108443601-108486918	Predicted intracellular proteins	Evidence at protein level	HPA022838	Approved				Breast cancer:2.64e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 110.0	Expressed in all		
EMC8	C16orf2, C16orf4, COX4NB, FAM158B, NOC4	ENSG00000131148	ER membrane protein complex subunit 8	16	85771758-85799608	Predicted intracellular proteins	Evidence at protein level	HPA049476	Approved		Supported	Cytosol	Renal cancer:6.39e-4 (favourable), Liver cancer:8.49e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 17.4	Expressed in all		
EME1	FLJ31364, MMS4L, SLX2A	ENSG00000154920	Essential meiotic structure-specific endonuclease 1	17	50373220-50381483	Predicted intracellular proteins	Evidence at protein level	CAB016127, HPA052188	Supported		Approved	Nuclear bodies<br>Cytosol		Mixed	Tissue enhanced		epididymis: 7.7;testis: 9.8	bone marrow,lymph node: 2.8	Mixed		
EME2	FLJ00151, SLX2B	ENSG00000197774	Essential meiotic structure-specific endonuclease subunit 2	16	1773207-1781708	Predicted intracellular proteins	Evidence at protein level	HPA045770	Uncertain				Renal cancer:6.76e-7 (unfavourable), Urothelial cancer:6.32e-5 (favourable), Head and neck cancer:2.86e-4 (favourable)	Expressed in all	Mixed			prostate: 1.0	Cell line enhanced		HEK93: 8.1;SCLC-21H: 4.3
EMG1	C2F, Grcc2f, NEP1	ENSG00000126749	EMG1, N1-specific pseudouridine methyltransferase	12	6970893-6979941	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039304, HPA039666	Supported		Enhanced	Nucleus<br>Nucleoli	Renal cancer:2.83e-6 (unfavourable), Liver cancer:3.69e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 21.0	Expressed in all		
EML1	ELP79, EMAP, EMAPL, HuEMAP	ENSG00000066629	Echinoderm microtubule associated protein like 1	14	99737693-99942060	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB033137, HPA049105	Uncertain					Expressed in all	Mixed			parathyroid gland: 51.3	Cell line enhanced		HDLM-2: 84.2;U-2197: 100.9
EML2	ELP70, EMAP-2, EMAP2	ENSG00000125746	Echinoderm microtubule associated protein like 2	19	45606994-45645629	Predicted intracellular proteins	Evidence at protein level	HPA012757	Approved		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 100.7	Mixed		
EML3	ELP95, FLJ35827	ENSG00000149499	Echinoderm microtubule associated protein like 3	11	62602218-62612765	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.13e-8 (unfavourable)	Expressed in all	Expressed in all			appendix: 37.6	Expressed in all		
EML4	C2orf2, ELP120, ROPP120	ENSG00000143924	Echinoderm microtubule associated protein like 4	2	42169350-42332548	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA036687, HPA036688, HPA065337	Enhanced		Supported	Intermediate filaments<br>Microtubules<br>Cytosol		Expressed in all	Mixed			placenta: 50.5	Expressed in all		
EML5	EMAP-2, HuEMAP-2	ENSG00000165521	Echinoderm microtubule associated protein like 5	14	88612431-88792752	Predicted intracellular proteins	Evidence at protein level	HPA054019, HPA055379	Uncertain					Not detected	Tissue enhanced		ovary: 23.7	prostate: 8.7	Cell line enhanced		SH-SY5Y: 26.6
EML6	FLJ42562	ENSG00000214595	Echinoderm microtubule associated protein like 6	2	54723499-54972025	Predicted intracellular proteins	Evidence at protein level	HPA062808, HPA068759	Uncertain		Approved	Vesicles<br>Mitochondria		Mixed	Tissue enhanced		lymph node: 7.5;tonsil: 8.3	appendix: 4.4	Cell line enhanced		SCLC-21H: 32.4;U-698: 22.3
EMSY	C11orf30	ENSG00000158636	EMSY, BRCA2 interacting transcriptional repressor	11	76444923-76553025	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012234, HPA050777	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 20.4	Expressed in all		
EMX1		ENSG00000135638	Empty spiracles homeobox 1	2	72916260-72936071	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006230, HPA006421	Approved		Approved	Nucleoli	Renal cancer:1.54e-6 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 8.3;kidney: 15.5;parathyroid gland: 5.0	testis: 2.6	Cell line enhanced		BEWO: 2.2;CACO-2: 3.1;HEK93: 7.5
EMX2		ENSG00000170370	Empty spiracles homeobox 2	10	117542444-117549546	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003497, HPA065294	Enhanced	Supported	Approved	Nucleus	Renal cancer:2.28e-13 (favourable), Cervical cancer:2.80e-4 (favourable)	Group enriched	Group enriched	5	cervix, uterine: 59.5;endometrium: 114.9;epididymis: 115.2;fallopian tube: 73.0;kidney: 38.4;seminal vesicle: 65.3;smooth muscle: 59.8	cerebral cortex: 14.0	Cell line enhanced		EFO-21: 22.1;fHDF/TERT166: 20.9;RPTEC TERT1: 19.9
EN1		ENSG00000163064	Engrailed homeobox 1	2	118842171-118847678	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB014884, HPA073141	Approved		Supported	Nucleus<br>Nucleoli		Tissue enhanced	Group enriched	13	adipose tissue: 1.3;breast: 1.0;lymph node: 1.9;skeletal muscle: 4.7;skin: 2.2	testis: 0.1	Cell line enhanced		ASC diff: 10.8;fHDF/TERT166: 10.2;HSkMC: 9.7;PC-3: 7.1;U-138 MG: 9.6;U-2197: 10.2
EN2		ENSG00000164778	Engrailed homeobox 2	7	155458129-155464831	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045646, HPA069809			Supported	Nucleus<br>Nucleoli fibrillar center	Glioma:2.82e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 2.0;testis: 1.1	endometrium: 0.6	Cell line enhanced		AF22: 40.5;AN3-CA: 14.1;HEK93: 23.0
ENAH	FLJ10773, MENA, NDPP1	ENSG00000154380	Enabled homolog (Drosophila)	1	225486835-225653142	Predicted intracellular proteins	Evidence at protein level	HPA028448, HPA028696	Enhanced		Enhanced	Plasma membrane<br>Focal adhesion sites<br>Cytosol		Expressed in all	Mixed			smooth muscle: 81.3	Mixed		
ENC1	ENC-1, KLHL37, NRPB, PIG10, TP53I10	ENSG00000171617	Ectodermal-neural cortex 1	5	74627406-74641424	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA078061			Uncertain	Plasma membrane	Renal cancer:2.95e-5 (unfavourable), Breast cancer:3.88e-4 (unfavourable)	Expressed in all	Tissue enriched	15	cerebral cortex: 461.4	gallbladder: 30.8	Mixed		
ENDOV	FLJ35220	ENSG00000173818	Endonuclease V	17	80415165-80438086	Predicted intracellular proteins	Evidence at protein level						Breast cancer:4.24e-5 (favourable), Colorectal cancer:4.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.2	Mixed		
ENGASE	FLJ21865	ENSG00000167280	Endo-beta-N-acetylglucosaminidase	17	79074939-79088599	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021551	Approved		Approved	Centrosome<br>Cytosol	Renal cancer:8.97e-6 (unfavourable), Urothelial cancer:8.73e-5 (favourable), Pancreatic cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			spleen: 28.1	Mixed		
ENKD1	C16orf48, DKFZP434A1319	ENSG00000124074	Enkurin domain containing 1	16	67662945-67667265	Predicted intracellular proteins	Evidence at protein level	HPA041163, HPA041478	Approved		Supported	Plasma membrane<br>Centrosome<br>Cytosol	Endometrial cancer:1.68e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.7	Mixed		
ENKUR	C10orf63, CFAP106, enkurin, MGC26778	ENSG00000151023	Enkurin, TRPC channel interacting protein	10	24981979-25062279	Predicted intracellular proteins	Evidence at protein level	HPA037593, HPA037594, HPA061503	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 69.4	cerebral cortex: 15.2	Cell line enhanced		AN3-CA: 1.4;CAPAN-2: 2.3
ENO1	ENO1L1, MBP-1, MPB1, PPH	ENSG00000074800	Enolase 1	1	8861002-8879249	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018614, HPA068284, HPA068721, CAB069394	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:1.30e-8 (unfavourable), Glioma:2.12e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 768.2	Expressed in all		
ENO2		ENSG00000111674	Enolase 2	12	6913745-6923698	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000063, HPA068284, HPA068721, CAB073539, CAB079023	Enhanced	Supported	Supported	Plasma membrane<br>Cytosol	Renal cancer:7.89e-11 (unfavourable), Liver cancer:5.15e-4 (unfavourable), Colorectal cancer:6.96e-4 (unfavourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 431.0	parathyroid gland: 64.8	Cell line enhanced		U-87 MG: 368.8
ENO3		ENSG00000108515	Enolase 3	17	4948092-4957131	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000793, HPA068284, HPA068721	Enhanced		Supported	Plasma membrane<br>Cytosol	Colorectal cancer:7.33e-4 (unfavourable)	Expressed in all	Tissue enriched	17	skeletal muscle: 5974.6	heart muscle: 350.1	Expressed in all		
ENOPH1	E1, MASA, mtnC	ENSG00000145293	Enolase-phosphatase 1	4	82430562-82461091	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004985, HPA044607	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:1.74e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 98.3	Expressed in all		
ENOSF1	HSRTSBETA, rTS, TYMSAS	ENSG00000132199	Enolase superfamily member 1	18	670324-712676	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047829	Enhanced				Breast cancer:2.27e-4 (favourable)	Expressed in all	Mixed			kidney: 38.9	Expressed in all		
ENOX1	cCNOX, CNOX, FLJ10094, PIG38	ENSG00000120658	Ecto-NOX disulfide-thiol exchanger 1	13	43213518-43786908	Predicted intracellular proteins	Evidence at protein level	HPA038355	Supported		Supported	Plasma membrane		Mixed	Tissue enhanced		testis: 16.3	cerebral cortex: 10.5	Cell line enhanced		hTEC/SVTERT24-B: 17.3;RH-30: 23.3
ENOX2	APK1, COVA1, tNOX	ENSG00000165675	Ecto-NOX disulfide-thiol exchanger 2	X	130623369-130903317	Predicted intracellular proteins	Evidence at protein level	HPA000514	Uncertain		Approved	Nucleus<br>Actin filaments	Renal cancer:1.09e-5 (favourable)	Expressed in all	Expressed in all			endometrium: 20.0	Expressed in all		
ENPP3	B10, CD203c, gp130RB13-6, PD-IBETA, PDNP3	ENSG00000154269	Ectonucleotide pyrophosphatase/phosphodiesterase 3	6	131628442-131747418	CD markers, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043772	Enhanced				Renal cancer:1.96e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cervix, uterine: 45.4;small intestine: 49.9	seminal vesicle: 22.0	Group enriched	15	HEL: 3.9;Hep G2: 9.9;HMC-1: 5.4
ENSA	ARPP-19e, MGC4319, MGC78563, MGC8394	ENSG00000143420	Endosulfine alpha	1	150600851-150629612	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051294	Uncertain		Approved	Nucleus<br>Nucleoli<br>Microtubules<br>Cytosol	Cervical cancer:8.24e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 267.3	Cell line enriched	12	U-698: 5502.7
ENTHD1	FLJ25421	ENSG00000176177	ENTH domain containing 1	22	39743044-39893864	Predicted intracellular proteins	Evidence at protein level	HPA019800	Uncertain					Tissue enriched	Tissue enriched	25	testis: 19.7	lymph node: 0.7	Cell line enhanced		SK-MEL-30: 1.7
ENY2	DC6, FLJ20480, Sus1	ENSG00000120533	ENY2, transcription and export complex 2 subunit	8	109334324-109345953	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA024648	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:7.17e-6 (unfavourable)	Expressed in all	Expressed in all			kidney: 77.5	Expressed in all		
EOMES	TBR2	ENSG00000163508	Eomesodermin	3	27715949-27722711	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028896	Uncertain				Renal cancer:9.45e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		lymph node: 18.2;spleen: 19.4	tonsil: 5.3	Cell line enhanced		HDLM-2: 7.3;SCLC-21H: 4.9
EP300	KAT3B, p300	ENSG00000100393	E1A binding protein p300	22	41091786-41180079	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000146, HPA003128, HPA004112	Supported		Enhanced	Nucleoplasm	Renal cancer:7.45e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.2	Expressed in all		
EP400	CAGH32, DKFZP434I225, KIAA1498, KIAA1818, P400, TNRC12	ENSG00000183495	E1A binding protein p400	12	131949920-132081102	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016704, HPA049013	Supported		Supported	Nucleus	Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
EP400NL	FLJ33915	ENSG00000185684	EP400 N-terminal like	12	132084283-132131639	Predicted intracellular proteins	Evidence at protein level	HPA068417	Enhanced					Expressed in all	Tissue enriched	9	testis: 28.7	spleen: 3.1	Mixed		
EPAS1	bHLHe73, HIF2A, HLF, MOP2, PASD2	ENSG00000116016	Endothelial PAS domain protein 1	2	46293667-46386703	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031200, HPA069697			Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.63e-4 (favourable)	Expressed in all	Expressed in all			placenta: 642.0	Cell line enhanced		U-138 MG: 279.3
EPB41L1	4.1N, KIAA0338	ENSG00000088367	Erythrocyte membrane protein band 4.1 like 1	20	36091504-36232799	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA054104, HPA056817	Enhanced		Supported	Plasma membrane	Renal cancer:4.39e-10 (favourable), Endometrial cancer:6.46e-5 (unfavourable), Pancreatic cancer:9.30e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 162.4	Cell line enhanced		HaCaT: 212.9
EPB41L2	4.1-G	ENSG00000079819	Erythrocyte membrane protein band 4.1 like 2	6	130839347-131063322	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005730, HPA006642	Supported		Enhanced	Nucleus<br>Plasma membrane<br>Cell Junctions	Liver cancer:2.41e-5 (unfavourable), Ovarian cancer:2.16e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 137.3	Mixed		
EPB41L4A	NBL4	ENSG00000129595	Erythrocyte membrane protein band 4.1 like 4A	5	112142441-112419316	Predicted intracellular proteins	Evidence at protein level	HPA036580	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:3.65e-5 (favourable)	Mixed	Expressed in all			parathyroid gland: 25.6	Cell line enhanced		EFO-21: 28.6;HeLa: 23.8
EPB41L4B	EHM2	ENSG00000095203	Erythrocyte membrane protein band 4.1 like 4B	9	109171975-109320964	Predicted intracellular proteins	Evidence at protein level	HPA042862	Approved		Approved	Plasma membrane<br>Cytosol	Breast cancer:1.02e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 74.8	Cell line enhanced		BEWO: 30.5;hTCEpi: 36.0
EPB41L5	BE37, FLJ12957, KIAA1548, YMO1, YRT	ENSG00000115109	Erythrocyte membrane protein band 4.1 like 5	2	120013005-120179119	Predicted intracellular proteins	Evidence at protein level	HPA037563, HPA037564	Uncertain		Supported	Plasma membrane	Renal cancer:2.28e-6 (favourable)	Expressed in all	Mixed			testis: 56.5	Cell line enhanced		MCF7: 63.7
EPB42	MGC116735, MGC116737, PA	ENSG00000166947	Erythrocyte membrane protein band 4.2	15	43106225-43221283	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040261	Supported					Not detected	Tissue enriched	13	bone marrow: 57.6	placenta: 4.5	Cell line enriched	96	HEL: 74.7
EPC1	Epl1	ENSG00000120616	Enhancer of polycomb homolog 1	10	32267751-32378798	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:6.02e-4 (favourable), Head and neck cancer:6.40e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 32.9	Expressed in all		
EPC2	DKFZP566F2124	ENSG00000135999	Enhancer of polycomb homolog 2	2	148644440-148787568	Predicted intracellular proteins	Evidence at protein level	HPA036759	Uncertain		Approved	Nuclear speckles		Expressed in all	Expressed in all			endometrium: 44.3	Expressed in all		
EPG5	hEPG5, KIAA1632	ENSG00000152223	Ectopic P-granules autophagy protein 5 homolog	18	45847609-45967274	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031689	Uncertain		Approved	Nuclear speckles	Renal cancer:4.04e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.3	Expressed in all		
EPHX1	EPHX	ENSG00000143819	Epoxide hydrolase 1	1	225810092-225845563	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020593, HPA048847	Enhanced				Lung cancer:7.02e-5 (favourable), Prostate cancer:1.32e-4 (favourable)	Tissue enriched	Expressed in all			adrenal gland: 1085.6	Cell line enhanced		ASC diff: 821.1;SiHa: 629.7
EPHX2		ENSG00000120915	Epoxide hydrolase 2	8	27490779-27545564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023094, HPA023660	Approved		Enhanced	Cytosol	Renal cancer:1.98e-10 (favourable), Cervical cancer:2.45e-4 (favourable)	Expressed in all	Expressed in all			kidney: 171.7	Cell line enhanced		K-562: 46.0
EPHX4	ABHD7, EPHXRP, FLJ90341	ENSG00000172031	Epoxide hydrolase 4	1	92029982-92063536	Predicted intracellular proteins	Evidence at protein level	HPA035067	Uncertain		Approved	Vesicles	Pancreatic cancer:2.00e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 14.6	thyroid gland: 3.0	Cell line enhanced		A-431: 13.4;CAPAN-2: 11.4;EFO-21: 24.3;RPTEC TERT1: 27.3
EPM2A	LD, LDE	ENSG00000112425	EPM2A, laforin glucan phosphatase	6	145382535-145736023	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA053643, HPA055468			Enhanced	Nucleoplasm	Renal cancer:4.08e-7 (favourable)	Expressed in all	Mixed			skeletal muscle: 26.8	Mixed		
EPM2AIP1	FLJ11207, KIAA0766	ENSG00000178567	EPM2A interacting protein 1	3	36985043-36993168	Predicted intracellular proteins	Evidence at protein level						Cervical cancer:2.70e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 35.7	Mixed		
EPN1		ENSG00000063245	Epsin 1	19	55675226-55709858	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009729, HPA061136	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			duodenum: 89.4	Expressed in all		
EPN2	EHB21, KIAA1065	ENSG00000072134	Epsin 2	17	19215615-19336715	Predicted intracellular proteins	Evidence at protein level	HPA049809, HPA053360	Approved		Supported	Vesicles	Urothelial cancer:8.15e-5 (unfavourable), Renal cancer:9.13e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 95.0	Mixed		
EPN3	FLJ20778, MGC129899	ENSG00000049283	Epsin 3	17	50532543-50543750	Predicted intracellular proteins	Evidence at protein level	HPA055546, HPA063224	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:1.53e-5 (favourable)	Mixed	Mixed			stomach: 27.5	Cell line enhanced		HaCaT: 24.3;HBEC3-KT: 27.4;MCF7: 48.0;RT4: 38.6;T-47d: 51.4
EPOP	C17orf96, LOC100170841, PRR28	ENSG00000273604	Elongin BC and polycomb repressive complex 2 associated protein	17	38671703-38675421	Predicted intracellular proteins	Evidence at protein level	HPA055190, HPA056555	Enhanced		Supported	Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies		Expressed in all	Tissue enhanced		cerebral cortex: 5.5;testis: 5.0	parathyroid gland: 2.1	Cell line enhanced		AN3-CA: 19.3
EPPK1	EPIPL1	ENSG00000261150	Epiplakin 1	8	143857324-143878464	Predicted intracellular proteins	Evidence at protein level	HPA066808, HPA067357, HPA069333	Approved		Enhanced	Intermediate filaments	Endometrial cancer:5.52e-5 (unfavourable), Pancreatic cancer:3.94e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 11.2	small intestine: 2.9	Cell line enhanced		BEWO: 13.8;EFO-21: 12.5;HaCaT: 12.0;HeLa: 15.1;MCF7: 15.3
EPRS	EARS, GLUPRORS, PARS, QARS, QPRS	ENSG00000136628	Glutamyl-prolyl-tRNA synthetase	1	219968601-220046658	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026490, HPA030052	Enhanced		Enhanced	Cytosol	Urothelial cancer:2.62e-4 (unfavourable), Breast cancer:7.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 120.4	Expressed in all		
EPS15L1	eps15R	ENSG00000127527	Epidermal growth factor receptor pathway substrate 15 like 1	19	16355239-16472085	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019237, HPA055309	Uncertain		Approved	Vesicles	Renal cancer:8.10e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.0	Expressed in all		
EPS8		ENSG00000151491	Epidermal growth factor receptor pathway substrate 8	12	15620158-15882329	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003897	Approved		Approved	Golgi apparatus	Renal cancer:1.45e-7 (favourable), Pancreatic cancer:3.33e-7 (unfavourable), Thyroid cancer:5.11e-4 (favourable)	Expressed in all	Mixed			gallbladder: 88.1	Mixed		
EPS8L2	FLJ21935, FLJ22171, MGC3088	ENSG00000177106	EPS8 like 2	11	694438-727727	Predicted intracellular proteins	Evidence at protein level	HPA041143	Approved		Supported	Plasma membrane<br>Cytosol	Glioma:1.80e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 110.4	Cell line enhanced		A-431: 186.2;BEWO: 194.1;CAPAN-2: 171.1;SK-BR-3: 177.2
EPS8L3	FLJ21522, MGC16817	ENSG00000198758	EPS8 like 3	1	109750080-109764027	Predicted intracellular proteins	Evidence at protein level	HPA030998	Approved		Approved	Vesicles	Renal cancer:2.52e-5 (unfavourable), Liver cancer:4.13e-5 (unfavourable), Urothelial cancer:1.82e-4 (favourable)	Group enriched	Group enriched	7	colon: 75.0;duodenum: 152.1;gallbladder: 59.8;rectum: 86.1;small intestine: 167.1;stomach: 53.4	appendix: 15.1	Group enriched	12	CACO-2: 13.3;CAPAN-2: 13.3;EFO-21: 5.8;Hep G2: 25.0
ERAL1	HERA-B	ENSG00000132591	Era like 12S mitochondrial rRNA chaperone 1	17	28854938-28861067	Predicted intracellular proteins	Evidence at protein level	HPA021425, HPA024423	Supported		Enhanced	Mitochondria<br>Cytosol	Liver cancer:3.59e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 51.2	Expressed in all		
ERAS	HRAS2, HRASP	ENSG00000187682	ES cell expressed Ras	X	48826513-48830138	Predicted intracellular proteins	Evidence at transcript level							Mixed	Not detected			cerebral cortex: 0.6	Not detected		
ERBIN	ERBB2IP, LAP2	ENSG00000112851	Erbb2 interacting protein	5	65926475-66082549	Predicted intracellular proteins	Evidence at protein level	HPA048606, HPA059863	Approved		Supported	Nuclear speckles<br>Plasma membrane		Expressed in all	Expressed in all			testis: 50.1	Expressed in all		
ERC1	CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2	ENSG00000082805	ELKS/RAB6-interacting/CAST family member 1	12	990509-1495933	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019513, HPA019523, HPA024130	Approved		Supported	Vesicles<br>Plasma membrane<br>Cytosol	Urothelial cancer:7.01e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 17.1	Expressed in all		
ERC2	CAST, CAST1, ELKSL, KIAA0378, SPBC110, Spc110	ENSG00000187672	ELKS/RAB6-interacting/CAST family member 2	3	55508308-56468363	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA073739	Enhanced					Mixed	Tissue enriched	16	cerebral cortex: 24.6	seminal vesicle: 1.5	Cell line enhanced		HAP1: 2.7;Karpas-707: 6.2;SH-SY5Y: 2.2;U-266/70: 4.6
ERCC1	RAD10	ENSG00000012061	ERCC excision repair 1, endonuclease non-catalytic subunit	19	45407333-45478828	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004390, HPA029773, HPA050182, CAB072859, CAB072860	Enhanced		Enhanced	Nucleoplasm	Renal cancer:9.00e-5 (unfavourable), Liver cancer:9.69e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 71.3	Expressed in all		
ERCC2	EM9, MAG, MGC102762, MGC126218, MGC126219, TFIIH, XPD	ENSG00000104884	ERCC excision repair 2, TFIIH core complex helicase subunit	19	45349837-45370918	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005375, HPA038057, HPA069266	Approved		Supported	Nucleoplasm	Pancreatic cancer:3.26e-4 (favourable)	Expressed in all	Expressed in all			testis: 16.1	Expressed in all		
ERCC3	BTF2, GTF2H, RAD25, TFIIH, XPB	ENSG00000163161	ERCC excision repair 3, TFIIH core complex helicase subunit	2	127257290-127294176	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037153, HPA046077	Approved		Enhanced	Nucleoplasm	Liver cancer:1.62e-7 (unfavourable), Renal cancer:4.30e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 55.1	Expressed in all		
ERCC4	FANCQ, RAD1, XPF	ENSG00000175595	ERCC excision repair 4, endonuclease catalytic subunit	16	13920157-13952345	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000156, HPA045828	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			testis: 10.4	Expressed in all		
ERCC5	ERCM2, XPGC	ENSG00000134899	ERCC excision repair 5, endonuclease	13	102844844-102876001	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045845, HPA050374	Supported		Supported	Nucleoplasm	Renal cancer:2.96e-6 (unfavourable), Urothelial cancer:6.82e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 16.4	Expressed in all		
ERCC6	ARMD5, CKN2, CSB, RAD26	ENSG00000225830	ERCC excision repair 6, chromatin remodeling factor	10	49455368-49539538	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA071297			Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			parathyroid gland: 14.9	Expressed in all		
ERCC6L	FLJ20105, PICH, RAD26L	ENSG00000186871	ERCC excision repair 6 like, spindle assembly checkpoint helicase	X	72204657-72239047	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050492	Approved		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Breast cancer:1.80e-4 (unfavourable)	Tissue enhanced	Mixed			lymph node: 2.8	Mixed		
ERCC6L2	C9orf102, FLJ37706, RAD26L	ENSG00000182150	ERCC excision repair 6 like 2	9	95875701-96014571	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021260	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:8.70e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.0	Expressed in all		
ERCC8	CKN1, CSA	ENSG00000049167	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	5	60873831-60945073	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029328			Approved	Nuclear speckles		Expressed in all	Mixed			testis: 12.9	Expressed in all		
ERF	PE-2, PE2	ENSG00000105722	ETS2 repressor factor	19	42247572-42255157	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058532, HPA067952	Approved		Enhanced	Nucleoplasm	Breast cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 78.9	Expressed in all		
ERG	erg-3, p55	ENSG00000157554	ERG, ETS transcription factor	21	38380027-38661780	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB018377, HPA046598	Approved		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:6.18e-6 (unfavourable), Renal cancer:3.94e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 36.8	Cell line enhanced		HUVEC TERT2: 115.5;MOLT-4: 38.1;REH: 138.0;TIME: 92.4
ERH	DROER	ENSG00000100632	Enhancer of rudimentary homolog (Drosophila)	14	69380123-69398627	Predicted intracellular proteins	Evidence at protein level	HPA002567	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:7.89e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 112.0	Expressed in all		
ERI1	3'HEXO, THEX1	ENSG00000104626	Exoribonuclease 1	8	9002147-9116746	Predicted intracellular proteins	Evidence at protein level	CAB033838, HPA055548, HPA056074	Uncertain		Approved	Vesicles<br>Microtubules	Colorectal cancer:8.05e-5 (favourable), Renal cancer:1.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.8	Expressed in all		
ERI2	EXOD1, KIAA1504, MGC16943, ZGRF5	ENSG00000196678	ERI1 exoribonuclease family member 2	16	20780193-20900349	Predicted intracellular proteins	Evidence at protein level	HPA035384, HPA035385	Uncertain		Supported	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 23.0	Expressed in all		
ERI3	FLJ22943, PINT1, PRNPIP	ENSG00000117419	ERI1 exoribonuclease family member 3	1	44221070-44355260	Predicted intracellular proteins	Evidence at protein level	HPA027147, HPA029895	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:2.04e-6 (unfavourable), Endometrial cancer:1.18e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 81.0	Expressed in all		
ERICH1		ENSG00000104714	Glutamate rich 1	8	614746-738106	Predicted intracellular proteins	Evidence at protein level	HPA003725	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			lymph node: 24.2	Mixed		
ERICH2		ENSG00000204334	Glutamate rich 2	2	170783786-170798971	Predicted intracellular proteins	Evidence at protein level	HPA061010			Approved	Nucleoli fibrillar center<br>Vesicles	Renal cancer:8.98e-7 (unfavourable), Endometrial cancer:9.49e-4 (favourable)	Expressed in all	Tissue enriched	8	testis: 233.8	thyroid gland: 30.5	Cell line enhanced		hTCEpi: 44.3
ERICH3	C1orf173, DKFZp547I048, RP11-653A5.1	ENSG00000178965	Glutamate rich 3	1	74568111-74673738	Predicted intracellular proteins	Evidence at protein level	HPA028655	Approved				Endometrial cancer:1.56e-5 (favourable)	Tissue enhanced	Group enriched	6	cerebral cortex: 18.9;cervix, uterine: 8.6;fallopian tube: 27.7;testis: 43.1	lung: 4.2	Not detected		
ERICH4	C19orf69, LOC100170765	ENSG00000204978	Glutamate rich 4	19	41443158-41444765	Predicted intracellular proteins	Evidence at transcript level	HPA042632, HPA048484	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	27	duodenum: 42.8;kidney: 16.3;small intestine: 42.9	lung: 1.2	Group enriched	13	CACO-2: 2.1;Hep G2: 4.2;THP-1: 1.1
ERICH5	C8orf47, FLJ39553	ENSG00000177459	Glutamate rich 5	8	98064311-98093610	Predicted intracellular proteins	Evidence at protein level	HPA025070, HPA025293, HPA027233	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.76e-4 (favourable), Urothelial cancer:9.38e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 13.8;gallbladder: 13.7	stomach: 9.2	Cell line enhanced		A549: 6.1;HAP1: 6.4;HEK93: 8.2;RT4: 12.7
ERICH6	C3orf44, ERICH6A, FAM194A, MGC39662	ENSG00000163645	Glutamate rich 6	3	150659885-150703971	Predicted intracellular proteins	Evidence at protein level	HPA048373	Enhanced					Not detected	Tissue enriched	24	testis: 51.6	epididymis: 2.1	Cell line enhanced		SH-SY5Y: 1.7;U-266/84: 1.9
ERICH6B	FAM194B, FLJ32682	ENSG00000165837	Glutamate rich 6B	13	45534522-45615739	Predicted intracellular proteins	Evidence at transcript level	HPA043559	Uncertain					Not detected	Tissue enriched	35	testis: 3.4	all non-specific tissues: 0.0	Not detected		
ERMN	ERMIN, JN, KIAA1189	ENSG00000136541	Ermin	2	157318625-157327713	Predicted intracellular proteins	Evidence at protein level	HPA038295, HPA038296	Enhanced				Endometrial cancer:6.93e-6 (favourable)	Group enriched	Tissue enriched	27	cerebral cortex: 227.8	bone marrow: 8.3	Cell line enriched	8	HAP1: 20.7
ERRFI1	GENE-33, MIG-6, RALT	ENSG00000116285	ERBB receptor feedback inhibitor 1	1	8004404-8026308	Predicted intracellular proteins	Evidence at protein level	HPA027206			Supported	Cytosol		Expressed in all	Expressed in all			liver: 369.4	Cell line enhanced		HHSteC: 468.0;LHCN-M2: 368.0
ERVK3-1	HERV-K(HML6-1)	ENSG00000142396	Endogenous retrovirus group K3 member 1	19	58305319-58315663	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:7.38e-4 (unfavourable), Liver cancer:9.45e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 46.6	Expressed in all		
ESCO1	EFO1, ESO1, KIAA1911	ENSG00000141446	Establishment of sister chromatid cohesion N-acetyltransferase 1	18	21529281-21600884	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042497	Approved					Expressed in all	Expressed in all			testis: 36.6	Expressed in all		
ESCO2	EFO2, RBS	ENSG00000171320	Establishment of sister chromatid cohesion N-acetyltransferase 2	8	27771949-27812640	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027243, HPA053679			Supported	Nucleus<br>Golgi apparatus	Colorectal cancer:1.04e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 11.2	testis: 10.4	Mixed		
ESD		ENSG00000139684	Esterase D	13	46771256-46797232	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039700	Approved		Approved	Golgi apparatus<br>Cytosol	Head and neck cancer:2.16e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 245.7	Expressed in all		
ESF1	bA526K24.1, C20orf6	ENSG00000089048	ESF1 nucleolar pre-rRNA processing protein homolog	20	13714322-13784886	Predicted intracellular proteins	Evidence at protein level	HPA047083, HPA050396	Supported		Approved	Nucleus<br>Nucleoli	Liver cancer:7.81e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 25.9	Expressed in all		
ESPN	DFNB36	ENSG00000187017	Espin	1	6424788-6461370	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028674, HPA060220	Enhanced		Approved	Vesicles		Mixed	Tissue enhanced		skin: 96.5;testis: 118.3	small intestine: 77.3	Cell line enhanced		BEWO: 42.8;SK-BR-3: 110.9;T-47d: 47.8
ESPNL	FLJ42568	ENSG00000144488	Espin-like	2	238100157-238133287	Predicted intracellular proteins	Evidence at protein level	HPA055103	Uncertain					Mixed	Mixed			seminal vesicle: 1.2	Cell line enhanced		Daudi: 1.8;HHSteC: 2.1;U-87 MG: 2.0
ESR1	Era, ESR, NR3A1	ENSG00000091831	Estrogen receptor 1	6	151656691-152129619	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000037, HPA000449, HPA000450, CAB055099, CAB072858	Enhanced		Approved	Nucleus<br>Vesicles	Endometrial cancer:5.47e-7 (favourable)	Group enriched	Group enriched	8	breast: 37.6;cervix, uterine: 127.8;endometrium: 180.8;fallopian tube: 106.4;smooth muscle: 76.5	seminal vesicle: 13.5	Group enriched	11	MCF7: 34.7;T-47d: 53.2
ESR2	Erb, NR3A2	ENSG00000140009	Estrogen receptor 2	14	64084232-64338112	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB065126	Enhanced					Not detected	Tissue enhanced		testis: 10.4	adrenal gland: 6.3	Cell line enhanced		U-266/70: 7.3;U-698: 11.3
ESRP2	FLJ21918, RBM35B	ENSG00000103067	Epithelial splicing regulatory protein 2	16	68229111-68238102	Predicted intracellular proteins	Evidence at protein level	HPA040751, HPA048597, HPA048618	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.30e-6 (favourable)	Mixed	Mixed			skin: 37.1	Cell line enhanced		BEWO: 45.7;MCF7: 74.1;RT4: 40.9;T-47d: 73.0
ESRRA	ERR1, ERRa, ERRalpha, ESRL1, NR3B1	ENSG00000173153	Estrogen related receptor alpha	11	64305572-64316743	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053785			Supported	Nucleus<br>Nucleoli fibrillar center<br>Microtubules<br>Cytokinetic bridge	Renal cancer:1.34e-7 (favourable)	Expressed in all	Expressed in all			duodenum: 86.6	Expressed in all		
ESRRB	DFNB35, ERR2, ERRb, ERRbeta, ESRL2, NR3B2	ENSG00000119715	Estrogen related receptor beta	14	76310614-76501841	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Group enriched	7	heart muscle: 2.3;kidney: 5.2;skeletal muscle: 1.7;stomach: 1.5;testis: 1.4	breast: 0.3	Cell line enhanced		HMC-1: 1.0;K-562: 3.3;U-266/70: 1.2
ESRRG	NR3B3	ENSG00000196482	Estrogen related receptor gamma	1	216503246-217137755	FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044678	Uncertain		Approved	Nucleus	Renal cancer:1.13e-11 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 77.5	kidney: 31.3	Group enriched	7	RPMI-8226: 16.0;SCLC-21H: 9.4;SH-SY5Y: 44.7
ESX1	ESX1L, ESXR1	ENSG00000123576	ESX homeobox 1	X	104250038-104254933	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051992	Enhanced		Supported	Nuclear speckles		Tissue enriched	Tissue enriched	63	testis: 12.0	placenta: 0.1	Cell line enriched	9	TIME: 20.3
ETAA1	ETAA16	ENSG00000143971	Ewing tumor associated antigen 1	2	67397319-67410545	Predicted intracellular proteins	Evidence at protein level	HPA035048, HPA035049	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland,thyroid gland: 15.7	Expressed in all		
ETF1	ERF, ERF1, RF1, SUP45L1, TB3-1	ENSG00000120705	Eukaryotic translation termination factor 1	5	138506095-138543300	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011686, HPA037511	Approved				Colorectal cancer:9.33e-5 (favourable), Thyroid cancer:1.22e-4 (unfavourable), Liver cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 108.6	Expressed in all		
ETFA	EMA, GA2, MADD	ENSG00000140374	Electron transfer flavoprotein alpha subunit	15	76215355-76311472	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018990, HPA018993, HPA018996, HPA024089	Enhanced		Enhanced	Mitochondria	Renal cancer:5.04e-8 (favourable)	Expressed in all	Expressed in all			liver: 197.8	Expressed in all		
ETFB		ENSG00000105379	Electron transfer flavoprotein beta subunit	19	51345169-51366418	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018910, HPA018921, HPA018923	Supported		Enhanced	Mitochondria	Renal cancer:6.45e-5 (favourable), Cervical cancer:6.45e-4 (favourable)	Expressed in all	Expressed in all			liver: 172.1	Expressed in all		
ETFBKMT	C12orf72, DKFZp451L235, METTL20, MGC50559	ENSG00000139160	Electron transfer flavoprotein beta subunit lysine methyltransferase	12	31647160-31673114	Predicted intracellular proteins	Evidence at protein level	HPA039024	Uncertain					Mixed	Mixed			parathyroid gland: 8.8	Mixed		
ETFRF1	LYRM5	ENSG00000205707	Electron transfer flavoprotein regulatory factor 1	12	25195216-25209645	Predicted intracellular proteins	Evidence at protein level	HPA044255	Approved		Approved	Microtubule organizing center	Renal cancer:9.23e-5 (favourable), Breast cancer:9.63e-4 (favourable)	Expressed in all	Expressed in all			testis: 112.5	Expressed in all		
ETHE1	HSCO, YF13H12	ENSG00000105755	ETHE1, persulfide dioxygenase	19	43506719-43527244	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028360, HPA029028, HPA029029	Enhanced		Enhanced	Mitochondria	Lung cancer:9.58e-4 (unfavourable)	Expressed in all	Expressed in all			colon: 240.2	Mixed		
ETNK2	EKI2, FLJ10761	ENSG00000143845	Ethanolamine kinase 2	1	204131062-204152003	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA057167	Enhanced				Glioma:3.43e-4 (unfavourable), Renal cancer:6.50e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 110.6;liver: 120.7;testis: 143.1	ovary: 43.4	Mixed		
ETNPPL	AGXT2L1	ENSG00000164089	Ethanolamine-phosphate phospho-lyase	4	108742040-108763054	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044546, HPA072938	Approved		Approved	Nucleus	Glioma:1.31e-4 (favourable)	Group enriched	Group enriched	8	cerebral cortex: 141.2;liver: 98.6	stomach: 15.2	Cell line enhanced		HeLa: 3.8;Hep G2: 1.5;NTERA-2: 1.1
ETS1	ETS-1, EWSR2, FLJ10768	ENSG00000134954	ETS proto-oncogene 1, transcription factor	11	128458761-128587558	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB002575, HPA063230	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.30e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 320.7	Cell line enhanced		U-698: 322.0
ETS2		ENSG00000157557	ETS proto-oncogene 2, transcription factor	21	38805307-38824955	Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	HPA003176			Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			spleen: 252.7	Cell line enhanced		HEL: 249.9
ETV1	ER81	ENSG00000006468	ETS variant 1	7	13891228-13991425	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077249			Approved	Nucleoplasm		Expressed in all	Tissue enhanced		cerebral cortex: 106.3	lung: 43.1	Cell line enhanced		SCLC-21H: 93.4;U-87 MG: 152.1;WM-115: 77.6
ETV2	ER71	ENSG00000105672	ETS variant 2	19	35641745-35644871	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		testis: 8.7	duodenum: 2.1	Mixed		
ETV3	PE-1	ENSG00000117036	ETS variant 3	1	157121191-157138474	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004794	Supported		Approved	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 45.4	Expressed in all		
ETV3L	FLJ16478	ENSG00000253831	ETS variant 3 like	1	157092044-157099808	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Not detected			breast: 0.9	Cell line enriched	16	HDLM-2: 32.0
ETV4	E1A-F, E1AF, PEA3	ENSG00000175832	ETS variant 4	17	43527844-43579620	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005768	Approved		Supported	Nucleoli	Liver cancer:2.48e-4 (unfavourable), Thyroid cancer:7.60e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 30.3	cerebral cortex: 13.6	Cell line enhanced		AN3-CA: 164.6;SK-MEL-30: 152.6
ETV5	ERM	ENSG00000244405	ETS variant 5	3	186046308-186110318	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009590, HPA063065	Approved		Supported	Nucleoplasm	Liver cancer:7.85e-9 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 114.5	cerebral cortex: 74.7	Cell line enhanced		SK-MEL-30: 141.2
ETV6	TEL	ENSG00000139083	ETS variant 6	12	11649854-11895402	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000264	Enhanced		Enhanced	Nucleoli<br>Cytosol	Renal cancer:4.66e-8 (unfavourable), Urothelial cancer:1.54e-5 (favourable), Pancreatic cancer:9.38e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 26.4	Cell line enhanced		HDLM-2: 80.8
ETV7	TEL-2, TEL2	ENSG00000010030	ETS variant 7	6	36354091-36387800	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029033, HPA049689	Uncertain		Enhanced	Nucleoplasm	Urothelial cancer:2.95e-6 (favourable), Cervical cancer:5.16e-4 (favourable), Ovarian cancer:5.32e-4 (favourable)	Expressed in all	Mixed			skin: 19.9	Cell line enhanced		BEWO: 26.5;BJ hTERT+ SV40 Large T+ RasG12V: 26.4;HDLM-2: 55.2
EVA1B	C1orf78, FAM176B, FLJ10647	ENSG00000142694	Eva-1 homolog B	1	36322031-36324154	Predicted intracellular proteins	Evidence at protein level	HPA041928, HPA043537	Approved		Approved	Cytosol	Renal cancer:4.79e-5 (unfavourable), Breast cancer:4.58e-4 (favourable), Liver cancer:4.82e-4 (unfavourable)	Expressed in all	Mixed			placenta: 14.6	Cell line enhanced		BJ: 28.4
EVL	RNB6	ENSG00000196405	Enah/Vasp-like	14	99971449-100144236	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018849, HPA019536, CAB033987	Enhanced		Approved	Vesicles<br>Cytosol	Pancreatic cancer:4.07e-6 (favourable), Renal cancer:4.14e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 208.1	Cell line enhanced		MOLT-4: 229.2
EVPL	EVPK	ENSG00000167880	Envoplakin	17	76004502-76027452	Predicted intracellular proteins	Evidence at protein level	CAB002220, HPA053969	Enhanced		Supported	Intermediate filaments<br>Cytosol		Mixed	Group enriched	9	esophagus: 77.5;skin: 111.0	duodenum: 10.7	Cell line enhanced		HaCaT: 51.8;RT4: 68.1;T-47d: 50.1
EVPLL		ENSG00000214860	Envoplakin like	17	18377662-18389647	Predicted intracellular proteins	Evidence at transcript level	HPA045728	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Not detected	Tissue enhanced		esophagus: 1.7;skin: 3.0;testis: 1.5	lung: 0.8	Cell line enhanced		HeLa: 1.2;hTCEpi: 4.7;RT4: 1.8;SiHa: 1.3;T-47d: 1.9
EVX1		ENSG00000106038	Even-skipped homeobox 1	7	27242700-27250493	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055132			Approved	Nucleoplasm		Mixed	Tissue enhanced		adrenal gland: 3.7;prostate: 4.5;seminal vesicle: 4.0	testis: 1.3	Cell line enriched	10	RT4: 11.7
EVX2		ENSG00000174279	Even-skipped homeobox 2	2	176077472-176083913	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA041576	Uncertain					Not detected	Tissue enhanced		prostate: 2.0;seminal vesicle: 2.2;testis: 2.7	cervix, uterine: 1.1	Not detected		
EWSR1	EWS	ENSG00000182944	EWS RNA binding protein 1	22	29268009-29300525	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004230, HPA051771, HPA062953	Enhanced		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.27e-6 (unfavourable), Renal cancer:1.21e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 213.6	Expressed in all		
EXD1	EXDL1, MGC33637	ENSG00000178997	Exonuclease 3'-5' domain containing 1	15	41182725-41230743	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	72	testis: 29.5	epididymis: 0.4	Not detected		
EXD3	FLJ20433, LOC54932, mut-7	ENSG00000187609	Exonuclease 3'-5' domain containing 3	9	137306896-137423262	Predicted intracellular proteins	Evidence at protein level	HPA047395	Approved		Approved	Actin filaments<br>Focal adhesion sites	Endometrial cancer:4.30e-4 (favourable)	Expressed in all	Mixed			small intestine,spleen: 10.0	Mixed		
EXO1	HEX1, hExoI	ENSG00000174371	Exonuclease 1	1	241847967-241895148	Predicted intracellular proteins	Evidence at protein level	HPA053079, HPA069738			Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:6.94e-7 (unfavourable), Melanoma:2.04e-4 (unfavourable), Endometrial cancer:8.21e-4 (unfavourable)	Mixed	Mixed			bone marrow: 10.7	Mixed		
EXO5	C1orf176, DEM1, FLJ21144	ENSG00000164002	Exonuclease 5	1	40508741-40516556	Predicted intracellular proteins	Evidence at protein level	HPA028429			Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.16e-6 (unfavourable), Prostate cancer:2.93e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 11.3	Cell line enhanced		THP-1: 101.0
EXOC1	BM-102, FLJ10893, SEC3, SEC3L1, Sec3p	ENSG00000090989	Exocyst complex component 1	4	55853616-55905034	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA037706, HPA044873	Uncertain		Approved	Plasma membrane<br>Microtubules<br>Cytosol	Urothelial cancer:5.50e-5 (favourable), Liver cancer:2.63e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 39.7	Expressed in all		
EXOC2	FLJ11026, SEC5L1, Sec5p	ENSG00000112685	Exocyst complex component 2	6	485133-693111	Predicted intracellular proteins, RAS pathway related proteins, Transporters	Evidence at protein level	HPA032093			Supported	Vesicles		Expressed in all	Expressed in all			testis: 30.4	Expressed in all		
EXOC3	SEC6L1, Sec6p	ENSG00000180104	Exocyst complex component 3	5	443158-471937	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA037880			Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:1.54e-4 (favourable)	Expressed in all	Expressed in all			testis: 58.5	Expressed in all		
EXOC3L1	EXOC3L, FLJ35539, FLJ35587	ENSG00000179044	Exocyst complex component 3 like 1	16	67184366-67190204	Predicted intracellular proteins	Evidence at transcript level	HPA029574	Uncertain		Approved	Vesicles<br>Plasma membrane		Expressed in all	Tissue enhanced		spleen: 30.0	placenta: 8.4	Cell line enhanced		HUVEC TERT2: 2.8;SCLC-21H: 7.6
EXOC3L2	FLJ36147, XTP7	ENSG00000283632	Exocyst complex component 3 like 2	19	45212621-45245431	Predicted intracellular proteins	Evidence at protein level								Mixed			spleen: 11.0	Group enriched	7	HEL: 17.8;K-562: 16.7
EXOC3L4	C14orf73	ENSG00000205436	Exocyst complex component 3 like 4	14	103100144-103110559	Predicted intracellular proteins	Evidence at protein level	HPA043661	Approved				Colorectal cancer:1.43e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 19.2	small intestine: 10.7	Cell line enhanced		HDLM-2: 3.5;HEL: 3.4;Hep G2: 1.8;RPMI-8226: 1.8
EXOC4	KIAA1699, MGC27170, SEC8, SEC8L1, Sec8p	ENSG00000131558	Exocyst complex component 4	7	133253073-134066589	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA031443, HPA031444	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:6.85e-5 (favourable), Pancreatic cancer:6.19e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.9	Expressed in all		
EXOC5	SEC10, SEC10L1, SEC10P	ENSG00000070367	Exocyst complex component 5	14	57200507-57269008	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA060837	Approved					Expressed in all	Mixed			testis: 20.7	Expressed in all		
EXOC6	DKFZp761I2124, EXOC6A, FLJ1125, MGC33397, SEC15L, SEC15L1, Sec15p	ENSG00000138190	Exocyst complex component 6	10	92834713-93059493	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA036285, HPA059111	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:4.66e-4 (favourable)	Expressed in all	Expressed in all			placenta: 49.7	Cell line enhanced		HUVEC TERT2: 87.5
EXOC6B	KIAA0919, SEC15B, SEC15L2	ENSG00000144036	Exocyst complex component 6B	2	72175984-72826041	Predicted intracellular proteins	Evidence at protein level	HPA034546, HPA063991	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 33.6	Mixed		
EXOC7	EXO70, Exo70p, KIAA1067, YJL085W	ENSG00000182473	Exocyst complex component 7	17	76081017-76121576	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA022840, HPA022842	Supported		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 102.7	Expressed in all		
EXOC8	EXO84, Exo84p, SEC84	ENSG00000116903	Exocyst complex component 8	1	231332753-231337852	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA027438	Approved		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 17.4	Expressed in all		
EXOSC1	CGI-108, CSL4, Csl4p, hCsl4p, p13, SKI4, Ski4p	ENSG00000171311	Exosome component 1	10	97436142-97446017	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038370	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.88e-9 (unfavourable)	Expressed in all	Expressed in all			epididymis: 54.6	Expressed in all		
EXOSC10	p2, p3, p4, PM-Scl, PM/Scl-100, PMSCL2, RRP6, Rrp6p	ENSG00000171824	Exosome component 10	1	11066618-11099881	Predicted intracellular proteins	Evidence at protein level	HPA028470, HPA028484, CAB037141	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:2.49e-6 (unfavourable), Thyroid cancer:5.27e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 46.8	Expressed in all		
EXOSC2	hRrp4p, p7, RRP4, Rrp4p	ENSG00000130713	Exosome component 2	9	130693721-130704894	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021756, HPA021790	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:1.39e-5 (unfavourable), Endometrial cancer:4.36e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 21.4	Expressed in all		
EXOSC3	CGI-102, hRrp-40, hRrp40p, p10, RRP40, Rrp40p	ENSG00000107371	Exosome component 3	9	37766978-37801437	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020485	Enhanced		Supported	Nucleoplasm	Liver cancer:7.01e-5 (unfavourable), Melanoma:7.39e-4 (unfavourable)	Expressed in all	Mixed			testis: 28.2	Expressed in all		
EXOSC4	FLJ20591, hRrp41p, p12A, RRP41, RRP41A, Rrp41p, SKI6, Ski6p	ENSG00000178896	Exosome component 4	8	144078626-144080647	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024792	Approved		Supported	Intermediate filaments<br>Cytosol	Ovarian cancer:2.23e-4 (favourable)	Expressed in all	Expressed in all			testis: 56.1	Expressed in all		
EXOSC5	hRrp46p, MGC12901, p12B, RRP41B, RRP46, Rrp46p	ENSG00000077348	Exosome component 5	19	41386374-41397479	Predicted intracellular proteins	Evidence at protein level	HPA053150, HPA055677	Approved		Enhanced	Nucleus<br>Nucleoli	Renal cancer:3.45e-7 (unfavourable)	Expressed in all	Expressed in all			skin: 22.1	Expressed in all		
EXOSC6	EAP4, hMtr3p, MTR3, Mtr3p, p11	ENSG00000223496	Exosome component 6	16	70246778-70251930	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			cerebral cortex: 22.9	Expressed in all		
EXOSC7	EAP1, hRrp42p, KIAA0116, p8, RRP42, Rrp42p	ENSG00000075914	Exosome component 7	3	44975241-45036066	Predicted intracellular proteins	Evidence at protein level	HPA036182, HPA057980	Approved		Supported	Nuclear speckles	Renal cancer:2.69e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 44.9	Expressed in all		
EXOSC8	bA421P11.3, CIP3, EAP2, OIP2, p9, RRP43, Rrp43p	ENSG00000120699	Exosome component 8	13	36998816-37009613	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB034240, HPA039702, HPA043942	Uncertain		Approved	Mitochondria	Renal cancer:8.39e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 48.7	Expressed in all		
EXOSC9	p5, p6, PM/Scl-75, PMSCL1, RRP45, Rrp45p	ENSG00000123737	Exosome component 9	4	121801317-121817021	Predicted intracellular proteins	Evidence at protein level	HPA041838, HPA048257, CAB070171	Approved		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.04e-4 (unfavourable), Renal cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 90.4	Expressed in all		
EXPH5	SLAC2-B	ENSG00000110723	Exophilin 5	11	108505431-108593738	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.42e-6 (favourable), Head and neck cancer:1.46e-4 (favourable), Renal cancer:2.43e-4 (favourable), Lung cancer:5.12e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 16.1;skin: 31.3	esophagus: 8.2	Cell line enhanced		hTERT-HME1: 8.7;RT4: 16.3
EYA1	BOR	ENSG00000104313	EYA transcriptional coactivator and phosphatase 1	8	71197433-71362232	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028917			Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		parathyroid gland: 81.7;prostate: 21.2	cerebral cortex: 10.7	Cell line enhanced		AN3-CA: 28.1;RH-30: 23.1;SH-SY5Y: 57.2
EYA2	EAB1	ENSG00000064655	EYA transcriptional coactivator and phosphatase 2	20	46894624-47188844	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027024, HPA059291	Uncertain		Supported	Cytosol	Endometrial cancer:4.30e-5 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 76.3	fallopian tube: 50.0	Cell line enhanced		HBEC3-KT: 28.0;SCLC-21H: 68.4;U-266/70: 82.5;U-266/84: 98.8
EYA3	DKFZp686C132	ENSG00000158161	EYA transcriptional coactivator and phosphatase 3	1	27970344-28088696	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA052432, HPA062889	Uncertain		Enhanced	Nucleoplasm	Renal cancer:3.15e-6 (favourable), Head and neck cancer:5.11e-4 (favourable)	Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
EYA4	CMD1J, DFNA10	ENSG00000112319	EYA transcriptional coactivator and phosphatase 4	6	133240598-133532120	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004805, HPA038771, HPA038772	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		seminal vesicle: 16.0	fallopian tube: 11.5	Cell line enhanced		A549: 22.1;HeLa: 45.5;RH-30: 22.5;U-87 MG: 23.4
EYS	bA166P24.2, bA307F22.3, bA74E24.1, C6orf178, C6orf179, C6orf180, dJ1018A4.2, dJ303F19.1, EGFL10, EGFL11, RP25, SPAM	ENSG00000188107	Eyes shut homolog (Drosophila)	6	63719980-65707225	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027103	Uncertain					Not detected	Tissue enhanced		testis: 1.4	adipose tissue: 0.8	Cell line enhanced		Karpas-707: 1.1;SCLC-21H: 1.3
EZH1	KIAA0388, KMT6B	ENSG00000108799	Enhancer of zeste 1 polycomb repressive complex 2 subunit	17	42700275-42745049	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005478, HPA077684	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			ovary: 58.7	Expressed in all		
EZH2	ENX-1, EZH1, KMT6, KMT6A	ENSG00000106462	Enhancer of zeste 2 polycomb repressive complex 2 subunit	7	148807383-148884321	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009589	Enhanced		Supported	Nucleoplasm	Renal cancer:8.18e-12 (unfavourable), Liver cancer:2.11e-6 (unfavourable), Melanoma:1.96e-4 (unfavourable), Stomach cancer:6.97e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 50.5	bone marrow: 30.0	Expressed in all		
EZR	VIL2	ENSG00000092820	Ezrin	6	158765741-158819412	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004035, HPA021616, CAB047324, CAB075739	Enhanced		Enhanced	Plasma membrane	Renal cancer:9.56e-8 (favourable), Pancreatic cancer:1.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 537.0	Expressed in all		
F13A1	F13A	ENSG00000124491	Coagulation factor XIII A chain	6	6144085-6321013	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001804, CAB002155	Enhanced				Renal cancer:6.61e-6 (unfavourable)	Expressed in all	Expressed in all			placenta: 670.5	Cell line enhanced		AF22: 22.5;LHCN-M2: 7.1;RH-30: 41.4
F8A1	DXS522E, F8A	ENSG00000277203	Coagulation factor VIII-associated 1	X	154886349-154888061	Predicted intracellular proteins	Evidence at protein level	HPA046960	Uncertain				Cervical cancer:1.67e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 30.2	Mixed		
F8A2		ENSG00000274791	Coagulation factor VIII-associated 2	X	155382115-155383230	Predicted intracellular proteins	Evidence at protein level	HPA046960	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
F8A3		ENSG00000277150	Coagulation factor VIII-associated 3	X	155456914-155458672	Predicted intracellular proteins	Evidence at protein level	HPA046960	Uncertain					Not detected	Tissue enhanced		parathyroid gland: 32.9	cerebral cortex: 10.5	Cell line enhanced		U-266/70: 31.3;U-266/84: 28.7
FAAH2	AMDD, FAAH-2, FLJ31204, RP11-479E16.1	ENSG00000165591	Fatty acid amide hydrolase 2	X	57286706-57489196	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.47e-13 (favourable), Urothelial cancer:6.83e-5 (favourable), Thyroid cancer:2.66e-4 (favourable), Ovarian cancer:5.99e-4 (favourable)	Mixed	Mixed			parathyroid gland: 20.2	Cell line enhanced		CAPAN-2: 12.2;HDLM-2: 12.0;RPMI-8226: 18.0;U-266/70: 15.9
FAAP100	C17orf70, FLJ22175	ENSG00000185504	Fanconi anemia core complex associated protein 100	17	81539885-81553961	Predicted intracellular proteins	Evidence at protein level	HPA023954, HPA024626, HPA026532	Uncertain		Enhanced	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Renal cancer:1.00e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 22.3	Expressed in all		
FAAP20	C1orf86, FLJ31031	ENSG00000162585	Fanconi anemia core complex associated protein 20	1	2184461-2212720	Predicted intracellular proteins	Evidence at protein level	HPA038829	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Cell Junctions	Pancreatic cancer:2.88e-4 (favourable), Liver cancer:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 13.0	Expressed in all		
FAAP24	C19orf40, FLJ46828, MGC32020	ENSG00000131944	Fanconi anemia core complex associated protein 24	19	32972209-32978222	Predicted intracellular proteins	Evidence at protein level	HPA041168	Uncertain		Supported	Nucleoplasm<br>Vesicles	Renal cancer:4.00e-7 (unfavourable), Endometrial cancer:4.38e-4 (unfavourable)	Expressed in all	Mixed			testis: 11.9	Expressed in all		
FABP1	L-FABP	ENSG00000163586	Fatty acid binding protein 1	2	88122982-88128116	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002305, HPA028275	Enhanced		Approved	Nucleoplasm<br>Cytosol		Group enriched	Group enriched	7	colon: 4552.0;duodenum: 4123.5;liver: 5672.8;rectum: 3081.5;small intestine: 4506.9	kidney: 602.3	Group enriched	6	CACO-2: 84.1;Hep G2: 221.3
FABP12		ENSG00000197416	Fatty acid binding protein 12	8	81524981-81531378	Predicted intracellular proteins	Evidence at protein level	HPA044041	Approved					Tissue enhanced	Group enriched	13	esophagus: 4.3;testis: 15.4	lung: 0.7	Not detected		
FABP2	I-FABP	ENSG00000145384	Fatty acid binding protein 2	4	119317250-119322390	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034607, CAB047325, CAB047326	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Group enriched	Group enriched	12	duodenum: 261.4;small intestine: 554.5	rectum: 33.8	Not detected		
FABP3	FABP11, H-FABP, MDGI, O-FABP	ENSG00000121769	Fatty acid binding protein 3	1	31365625-31376850	Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017830, HPA055754	Enhanced		Approved	Golgi apparatus	Renal cancer:1.54e-7 (favourable)	Expressed in all	Tissue enriched	6	heart muscle: 2930.0	skeletal muscle: 471.2	Cell line enriched	5	ASC TERT1: 434.0
FABP4	A-FABP, aP2	ENSG00000170323	Fatty acid binding protein 4	8	81478419-81483263	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002188, CAB024961	Enhanced					Group enriched	Tissue enriched	7	adipose tissue: 3652.0	breast: 559.1	Group enriched	277	ASC diff: 2538.9;RT4: 1531.5
FABP5	E-FABP, KFABP, PA-FABP	ENSG00000164687	Fatty acid binding protein 5	8	81280363-81284777	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB017831, CAB040577, HPA051895	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.69e-10 (unfavourable)	Expressed in all	Expressed in all			esophagus: 1664.2	Mixed		
FABP7	B-FABP, BLBP	ENSG00000164434	Fatty acid binding protein 7	6	122779475-122784074	Predicted intracellular proteins	Evidence at protein level	CAB025488, HPA028825, CAB058697	Enhanced				Renal cancer:1.65e-6 (unfavourable), Breast cancer:2.49e-4 (favourable)	Group enriched	Group enriched	13	breast: 33.1;cerebral cortex: 102.3	skin: 5.2	Group enriched	8	AF22: 75.1;U-251 MG: 17.6;WM-115: 45.7
FABP9	PERF, PERF15, T-FABP	ENSG00000205186	Fatty acid binding protein 9	8	81458341-81461579	Predicted intracellular proteins	Evidence at protein level	HPA073619	Approved					Not detected	Tissue enhanced		breast: 1.6	adipose tissue: 0.7	Not detected		
FADD	GIG3, MORT1	ENSG00000168040	Fas associated via death domain	11	70203163-70207390	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001464, CAB010209	Supported		Supported	Nucleoplasm<br>Cytosol	Lung cancer:2.21e-5 (unfavourable), Head and neck cancer:8.22e-5 (unfavourable), Thyroid cancer:3.45e-4 (favourable), Cervical cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 20.3	Expressed in all		
FAF1	CGI-03, hFAF1, HFAF1s, UBXD12, UBXN3A	ENSG00000185104	Fas associated factor 1	1	50437028-50960263	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018253, CAB072814	Approved		Enhanced	Nucleus	Liver cancer:1.87e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 59.5	Mixed		
FAH		ENSG00000103876	Fumarylacetoacetate hydrolase	15	80152490-80186946	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041370, HPA044093	Enhanced		Approved	Cytosol	Head and neck cancer:8.51e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 151.9	Cell line enhanced		HHSteC: 261.9
FAHD1	C16orf36, DKFZP566J2046	ENSG00000180185	Fumarylacetoacetate hydrolase domain containing 1	16	1826941-1840207	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB025530, HPA043226, HPA043534	Enhanced		Enhanced	Nucleus<br>Mitochondria	Renal cancer:2.80e-14 (favourable), Colorectal cancer:8.27e-4 (favourable)	Expressed in all	Expressed in all			kidney: 66.1	Expressed in all		
FAHD2A	CGI-105	ENSG00000115042	Fumarylacetoacetate hydrolase domain containing 2A	2	95402721-95416616	Predicted intracellular proteins	Evidence at protein level	HPA042145, HPA044987, CAB045971, CAB045972	Enhanced					Expressed in all	Expressed in all			liver: 52.8	Expressed in all		
FAHD2B	DKFZp434N062	ENSG00000144199	Fumarylacetoacetate hydrolase domain containing 2B	2	97083583-97094882	Predicted intracellular proteins	Evidence at protein level	HPA042145, HPA044987	Approved				Glioma:2.81e-4 (unfavourable)	Mixed	Expressed in all			epididymis: 48.4	Mixed		
FAIM	FAIM1, FLJ10582	ENSG00000158234	Fas apoptotic inhibitory molecule	3	138608606-138633376	Predicted intracellular proteins	Evidence at protein level	HPA042440, HPA052209	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:3.96e-5 (unfavourable), Renal cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 61.0	Mixed		
FAM102A	bA203J24.7, C9orf132, Eeig1, SYM-3A	ENSG00000167106	Family with sequence similarity 102 member A	9	127940579-127980513	Predicted intracellular proteins	Evidence at protein level	HPA036030			Approved	Cytosol		Expressed in all	Mixed			stomach: 100.1	Expressed in all		
FAM102B	DKFZp779B126, SYM-3B	ENSG00000162636	Family with sequence similarity 102 member B	1	108560089-108644900	Predicted intracellular proteins	Evidence at protein level	HPA028451	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:3.47e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 27.9	Mixed		
FAM103A1	C15orf18, HsT19360, MGC2560, RAM	ENSG00000169612	Family with sequence similarity 103 member A1	15	82986207-82991057	Predicted intracellular proteins	Evidence at protein level	HPA041923, HPA041948	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			placenta: 37.0	Expressed in all		
FAM104A	FLJ14775	ENSG00000133193	Family with sequence similarity 104 member A	17	73207353-73236753	Predicted intracellular proteins	Evidence at protein level	HPA021459			Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.26e-10 (unfavourable), Liver cancer:2.12e-7 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 163.8	bone marrow: 27.0	Expressed in all		
FAM104B	CXorf44, FLJ20434	ENSG00000182518	Family with sequence similarity 104 member B	X	55143102-55161310	Predicted intracellular proteins	Evidence at transcript level	HPA049082	Approved				Lung cancer:1.22e-4 (favourable), Liver cancer:2.23e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 74.5	Expressed in all		
FAM106A	FLJ11800	ENSG00000213077	Family with sequence similarity 106 member A	17	18524566-18526846	Predicted intracellular proteins	Evidence at transcript level	HPA056425	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Not detected	Tissue enhanced		testis: 7.3	bone marrow,placenta: 1.6	Mixed		
FAM107A	DRR1, TU3A	ENSG00000168309	Family with sequence similarity 107 member A	3	58564117-58627610	Predicted intracellular proteins	Evidence at protein level	HPA055888	Enhanced		Supported	Nuclear speckles	Liver cancer:3.38e-4 (favourable), Endometrial cancer:3.56e-4 (unfavourable)	Tissue enriched	Group enriched	5	cerebral cortex: 485.7;fallopian tube: 125.1	epididymis: 57.5	Group enriched	6	ASC diff: 12.6;HUVEC TERT2: 48.1
FAM109A	FLJ32356, IPIP27A, SES1	ENSG00000198324	Family with sequence similarity 109 member A	12	111360651-111369121	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.15e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 30.8	Mixed		
FAM109B	DKFZp686J07229, IPIP27B, SES2	ENSG00000177096	Family with sequence similarity 109 member B	22	42074251-42079441	Predicted intracellular proteins	Evidence at protein level	HPA000647	Uncertain					Expressed in all	Mixed			placenta: 22.5	Mixed		
FAM110A	bA371L19.3, C20orf55	ENSG00000125898	Family with sequence similarity 110 member A	20	833715-857463	Predicted intracellular proteins	Evidence at protein level	CAB034110, HPA069240	Uncertain		Supported	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:4.42e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 31.3	spleen: 21.3	Cell line enhanced		SK-BR-3: 62.8
FAM110B	C8orf72, MGC39325	ENSG00000169122	Family with sequence similarity 110 member B	8	57994509-58204279	Predicted intracellular proteins	Evidence at protein level	HPA008318, HPA011781	Uncertain		Supported	Mitochondria<br>Cytosol	Endometrial cancer:3.88e-8 (unfavourable), Renal cancer:4.31e-8 (favourable), Pancreatic cancer:1.44e-4 (favourable)	Mixed	Tissue enhanced		spleen: 28.2	cerebral cortex: 17.7	Cell line enhanced		RPTEC TERT1: 9.6
FAM110C		ENSG00000184731	Family with sequence similarity 110 member C	2	38814-46870	Predicted intracellular proteins	Evidence at protein level	HPA036144, HPA036145	Uncertain				Glioma:6.77e-4 (unfavourable)	Mixed	Mixed			seminal vesicle: 29.0	Cell line enhanced		HaCaT: 11.8;RPTEC TERT1: 13.6;RT4: 20.1
FAM110D	FLJ14050, GRRP1	ENSG00000197245	Family with sequence similarity 110 member D	1	26159020-26163962	Predicted intracellular proteins	Evidence at transcript level	HPA013664	Approved					Expressed in all	Mixed			adipose tissue: 4.9	Cell line enhanced		U-2 OS: 1.6
FAM111A	FLJ22794, KIAA1895	ENSG00000166801	Family with sequence similarity 111 member A	11	59142748-59155039	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039529, HPA040176	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.15e-5 (unfavourable), Urothelial cancer:4.39e-4 (favourable)	Expressed in all	Expressed in all			prostate,spleen: 45.6	Mixed		
FAM111B	CANP	ENSG00000189057	Family with sequence similarity 111 member B	11	59107185-59127410	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038637	Uncertain		Approved	Nucleus<br>Cytosol	Pancreatic cancer:1.17e-5 (unfavourable), Liver cancer:1.76e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 14.9	Mixed		
FAM114A1	Noxp20	ENSG00000197712	Family with sequence similarity 114 member A1	4	38867677-38945739	Predicted intracellular proteins	Evidence at protein level	HPA067948, HPA069104, HPA069701	Uncertain		Enhanced	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:3.63e-6 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 88.5	Cell line enhanced		fHDF/TERT166: 212.1
FAM114A2	133K02, C5orf3	ENSG00000055147	Family with sequence similarity 114 member A2	5	153990128-154038936	Predicted intracellular proteins	Evidence at protein level	HPA035869, HPA035870	Approved		Approved	Vesicles		Expressed in all	Expressed in all			testis: 68.7	Expressed in all		
FAM117A		ENSG00000121104	Family with sequence similarity 117 member A	17	49710332-49789180	Predicted intracellular proteins	Evidence at protein level	HPA022531	Approved		Approved	Nucleoplasm	Lung cancer:8.25e-7 (favourable), Breast cancer:5.30e-5 (favourable), Pancreatic cancer:1.81e-4 (favourable)	Expressed in all	Expressed in all			spleen: 46.6	Cell line enhanced		U-266/70: 61.5
FAM117B	ALS2CR13, FLJ38771	ENSG00000138439	Family with sequence similarity 117 member B	2	202635188-202769757	Predicted intracellular proteins	Evidence at protein level	HPA003229, HPA028746	Uncertain		Approved	Nucleus<br>Centrosome		Expressed in all	Mixed			parathyroid gland: 24.4	Mixed		
FAM118A	bK268H5.C22.4, C22orf8, FLJ20635	ENSG00000100376	Family with sequence similarity 118 member A	22	45308968-45341955	Predicted intracellular proteins	Evidence at protein level	HPA003902	Uncertain		Approved	Intermediate filaments<br>Cytosol	Renal cancer:1.87e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 76.1	Expressed in all		
FAM118B	FLJ21103	ENSG00000197798	Family with sequence similarity 118 member B	11	126211414-126262986	Predicted intracellular proteins	Evidence at protein level	HPA041644, HPA042100	Approved		Approved	Intermediate filaments<br>Cytosol	Liver cancer:6.67e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 37.8	Expressed in all		
FAM120A	C9orf10, KIAA0183, OSSA	ENSG00000048828	Family with sequence similarity 120A	9	93451722-93566107	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019734, HPA055800	Approved		Enhanced	Cytosol	Renal cancer:1.08e-7 (favourable), Endometrial cancer:5.03e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 167.1	Expressed in all		
FAM120AOS	C9orf10OS	ENSG00000188938	Family with sequence similarity 120A opposite strand	9	93446494-93453592	Predicted intracellular proteins	Evidence at transcript level	HPA021475	Approved				Liver cancer:2.95e-5 (unfavourable), Renal cancer:6.04e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 50.3	Expressed in all		
FAM120B	CCPG, KIAA1838, PGCC1	ENSG00000112584	Family with sequence similarity 120B	6	170290703-170407065	Predicted intracellular proteins	Evidence at protein level	HPA037518, HPA037519	Uncertain		Approved	Nucleoplasm<br>Cytosol	Ovarian cancer:1.60e-4 (unfavourable), Pancreatic cancer:2.70e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 16.5	Expressed in all		
FAM120C	CXorf17, FLJ20506, ORF34	ENSG00000184083	Family with sequence similarity 120C	X	54068324-54183281	Predicted intracellular proteins	Evidence at protein level	HPA047677	Uncertain		Approved	Nuclear speckles	Head and neck cancer:4.48e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 9.6	Expressed in all		
FAM122A	C9orf42, MGC17347	ENSG00000187866	Family with sequence similarity 122A	9	68780034-68784608	Predicted intracellular proteins	Evidence at protein level	HPA056646	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.34e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.3	Expressed in all		
FAM122B	DKFZp686L20116, RP11-308B5.5	ENSG00000156504	Family with sequence similarity 122B	X	134769566-134797232	Predicted intracellular proteins	Evidence at protein level	HPA000266	Enhanced		Approved	Nucleoplasm	Endometrial cancer:7.19e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 66.6	Expressed in all		
FAM124A	FLJ30707	ENSG00000150510	Family with sequence similarity 124 member A	13	51222334-51284241	Predicted intracellular proteins	Evidence at protein level	HPA048182	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Mixed			cerebral cortex: 13.9	Group enriched	5	HAP1: 18.4;HUVEC TERT2: 8.8;NTERA-2: 34.8;SH-SY5Y: 14.1
FAM124B	FLJ22746	ENSG00000124019	Family with sequence similarity 124 member B	2	224378698-224402085	Predicted intracellular proteins	Evidence at protein level	HPA070240	Approved		Approved	Nucleoplasm<br>Mitochondria		Tissue enriched	Tissue enhanced		parathyroid gland: 9.8;placenta: 12.5	lung,smooth muscle: 3.6	Cell line enriched	7	HUVEC TERT2: 88.9
FAM126A	DRCTNNB1A, HCC, HYCC1, hyccin	ENSG00000122591	Family with sequence similarity 126 member A	7	22889371-23014130	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042873	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:6.04e-7 (unfavourable), Stomach cancer:5.99e-4 (unfavourable), Urothelial cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.4	Mixed		
FAM126B	HYCC2, MGC39518	ENSG00000155744	Family with sequence similarity 126 member B	2	200973718-201071671	Predicted intracellular proteins	Evidence at protein level	HPA036166, HPA036167, HPA067307	Uncertain		Supported	Nucleus<br>Cell Junctions		Expressed in all	Mixed			cerebral cortex: 14.7	Expressed in all		
FAM127A	CXX1, Mar8, MAR8C, Mart8	ENSG00000134590	Family with sequence similarity 127 member A	X	135032366-135033546	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:1.97e-4 (favourable), Endometrial cancer:2.69e-4 (unfavourable), Liver cancer:5.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 240.4	Mixed		
FAM127B	CXX1b, DKFZP564B147, MAR8A	ENSG00000203950	Family with sequence similarity 127 member B	X	135050932-135052196	Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.10e-5 (unfavourable), Ovarian cancer:2.71e-4 (favourable), Endometrial cancer:2.83e-4 (unfavourable), Cervical cancer:5.35e-4 (favourable)	Expressed in all	Expressed in all			ovary: 24.6	Mixed		
FAM127C	CXX1c, MAR8B	ENSG00000212747	Family with sequence similarity 127 member C	X	135020504-135022529	Predicted intracellular proteins	Evidence at protein level						Breast cancer:2.41e-5 (unfavourable), Stomach cancer:3.72e-4 (unfavourable)	Expressed in all	Mixed			prostate: 17.7	Cell line enhanced		U-2197: 63.0
FAM129A	C1orf24, GIG39, NIBAN	ENSG00000135842	Family with sequence similarity 129 member A	1	184790724-184974550	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA028172, HPA028231, HPA028657	Approved		Supported	Plasma membrane<br>Cytosol	Urothelial cancer:4.52e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 104.1	Mixed		
FAM129B	bA356B19.6, C9orf88, DKFZP434H0820, FLJ13518, FLJ22151, FLJ22298, MINERVA	ENSG00000136830	Family with sequence similarity 129 member B	9	127505339-127578989	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021284, HPA021417, HPA023261, HPA024312	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			esophagus: 362.3	Mixed		
FAM129C	BCNP1, FLJ39802	ENSG00000167483	Family with sequence similarity 129 member C	19	17523301-17553839	Predicted intracellular proteins	Evidence at protein level	HPA043277	Approved					Mixed	Group enriched	15	appendix: 13.9;bone marrow: 11.3;lymph node: 28.2;spleen: 36.9;tonsil: 9.4	gallbladder: 1.3	Group enriched	20	Daudi: 35.8;REH: 23.1;U-698: 21.5
FAM131B	KIAA0773	ENSG00000159784	Family with sequence similarity 131 member B	7	143353400-143362770	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA021371, HPA029992			Enhanced	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	8	cerebral cortex: 63.8	parathyroid gland: 7.5	Cell line enhanced		CACO-2: 11.5;NTERA-2: 22.2;PC-3: 19.9;SCLC-21H: 25.4
FAM131C	C1orf117, FLJ36766	ENSG00000185519	Family with sequence similarity 131 member C	1	16057769-16073632	Predicted intracellular proteins	Evidence at protein level	HPA031046	Uncertain		Approved	Nucleoli<br>Intermediate filaments<br>Cytosol	Renal cancer:9.33e-6 (favourable)	Mixed	Tissue enhanced		adrenal gland: 3.3;cerebral cortex: 4.8;kidney: 3.7	heart muscle,skin: 1.1	Cell line enhanced		A549: 7.2;HEK93: 4.6;PC-3: 5.4
FAM133A	CT115, FLJ37659, RP1-32F7.2	ENSG00000179083	Family with sequence similarity 133 member A	X	93674013-93712274	Predicted intracellular proteins	Evidence at protein level	HPA066175, HPA069513			Approved	Nucleus<br>Nucleoli		Mixed	Group enriched	6	cerebral cortex: 5.3;testis: 14.1	adrenal gland: 1.5	Cell line enhanced		Karpas-707: 33.0;U-2197: 22.2;U-266/70: 27.2;U-266/84: 58.1
FAM133B	MGC40405	ENSG00000234545	Family with sequence similarity 133 member B	7	92560793-92590394	Predicted intracellular proteins	Evidence at protein level	HPA066175, HPA069513			Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			epididymis: 34.6	Expressed in all		
FAM135A	FLJ20176, KIAA1411	ENSG00000082269	Family with sequence similarity 135 member A	6	70412941-70561174	Predicted intracellular proteins	Evidence at protein level	HPA031743, HPA031744	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.46e-4 (favourable), Colorectal cancer:8.00e-4 (favourable)	Expressed in all	Mixed			esophagus: 33.3	Cell line enhanced		RH-30: 29.8
FAM135B	C8ORFK32	ENSG00000147724	Family with sequence similarity 135 member B	8	138130023-138496822	Predicted intracellular proteins	Evidence at transcript level	HPA023911, HPA023950, HPA024815	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Tissue enhanced	Group enriched	8	adrenal gland: 3.6;cerebral cortex: 8.3;testis: 7.3	colon: 0.8	Cell line enriched	11	RH-30: 8.5
FAM136A	FLJ14668	ENSG00000035141	Family with sequence similarity 136 member A	2	70295975-70302090	Predicted intracellular proteins	Evidence at protein level	HPA030103, HPA030104	Enhanced		Approved	Mitochondria	Renal cancer:1.33e-6 (unfavourable), Liver cancer:2.66e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 34.5	Expressed in all		
FAM13A	ARHGAP48, FAM13A1, KIAA0914	ENSG00000138640	Family with sequence similarity 13 member A	4	88725955-89111398	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038108, HPA038109	Uncertain		Approved	Nucleoli<br>Cell Junctions<br>Cytosol	Urothelial cancer:4.28e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 114.4	Cell line enhanced		ASC diff: 38.0
FAM13B	ARHGAP49, C5orf5, FAM13B1, KHCHP, N61	ENSG00000031003	Family with sequence similarity 13 member B	5	137937960-138051961	Predicted intracellular proteins	Evidence at protein level	HPA036525, HPA041819, HPA071936	Uncertain		Approved	Nucleoplasm	Renal cancer:3.55e-5 (favourable)	Expressed in all	Expressed in all			testis: 63.4	Expressed in all		
FAM13C	FAM13C1	ENSG00000148541	Family with sequence similarity 13 member C	10	59246129-59363181	Predicted intracellular proteins	Evidence at protein level	HPA037888	Approved		Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 39.4	Cell line enhanced		NTERA-2: 4.3;SCLC-21H: 10.0;SH-SY5Y: 5.3
FAM149A	DKFZP564J102, MST119, MSTP119	ENSG00000109794	Family with sequence similarity 149 member A	4	186104419-186172667	Predicted intracellular proteins	Evidence at protein level	HPA044019, HPA055004	Uncertain		Approved	Golgi apparatus	Endometrial cancer:2.67e-6 (favourable)	Mixed	Mixed			kidney: 37.1	Cell line enhanced		ASC diff: 7.6;RT4: 7.7;SCLC-21H: 16.7
FAM149B1	KIAA0974	ENSG00000138286	Family with sequence similarity 149 member B1	10	73168166-73244504	Predicted intracellular proteins	Evidence at transcript level	HPA039189, HPA039859	Uncertain		Approved	Nucleoplasm	Pancreatic cancer:7.81e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 39.4	Expressed in all		
FAM151A	C1orf179, MGC27169	ENSG00000162391	Family with sequence similarity 151 member A	1	54609182-54623556	Predicted intracellular proteins	Evidence at protein level	HPA016840	Approved		Uncertain	Nucleoplasm	Renal cancer:4.09e-5 (favourable)	Group enriched	Group enriched	14	kidney: 175.3;small intestine: 66.8	liver: 8.5	Cell line enriched	41	CACO-2: 63.5
FAM151B	UNQ9217	ENSG00000152380	Family with sequence similarity 151 member B	5	80487969-80542563	Predicted intracellular proteins	Evidence at protein level	HPA043805	Uncertain		Approved	Cytosol		Mixed	Mixed			bone marrow: 2.8	Mixed		
FAM153A	NY-REN-7	ENSG00000170074	Family with sequence similarity 153 member A	5	177707981-177783398	Predicted intracellular proteins	Evidence at transcript level	HPA042585, HPA044022, HPA046691, HPA052337, HPA055498	Uncertain					Not detected	Tissue enhanced		testis: 13.8	ovary: 2.8	Not detected		
FAM153B		ENSG00000182230	Family with sequence similarity 153 member B	5	176060689-176132258	Predicted intracellular proteins	Evidence at transcript level	HPA042585, HPA044022, HPA046691, HPA052337, HPA055498	Uncertain					Not detected	Tissue enhanced		ovary: 8.4;testis: 15.4	cerebral cortex: 4.1	Cell line enriched	6	U-2 OS: 1.1
FAM153C	NY-REN-7-like	ENSG00000204677	Family with sequence similarity 153 member C	5	178006405-178055559	Predicted intracellular proteins	Evidence at protein level	HPA042585, HPA046691, HPA052337	Uncertain					Tissue enhanced	Tissue enriched	5	testis: 42.0	cerebral cortex: 8.1	Cell line enhanced		U-2 OS: 1.2
FAM156A	PRO0659, TMEM29	ENSG00000268350	Family with sequence similarity 156 member A	X	52926402-52995472	Predicted intracellular proteins	Evidence at protein level	HPA056640, HPA056643	Approved					Not detected	Expressed in all			skin: 63.1	Expressed in all		
FAM156B	TMEM29B	ENSG00000179304	Family with sequence similarity 156 member B	X	52891306-52908560	Predicted intracellular proteins	Evidence at protein level	HPA056640, HPA056643	Uncertain					Not detected	Tissue enhanced		placenta: 46.8	skin: 24.9	Expressed in all		
FAM160A1	FLJ43373	ENSG00000164142	Family with sequence similarity 160 member A1	4	151409216-151663632	Predicted intracellular proteins	Evidence at protein level	HPA046348	Enhanced		Approved	Cytosol		Mixed	Mixed			parathyroid gland: 16.7	Cell line enhanced		SiHa: 9.2
FAM160B1	bA106M7.3, KIAA1600	ENSG00000151553	Family with sequence similarity 160 member B1	10	114821744-114899832	Predicted intracellular proteins	Evidence at protein level	HPA043624	Uncertain		Approved	Nuclear speckles<br>Cytosol	Renal cancer:4.02e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 34.4	Expressed in all		
FAM160B2	FLJ21801, RAI16	ENSG00000158863	Family with sequence similarity 160 member B2	8	22089159-22104898	Predicted intracellular proteins	Evidence at protein level	HPA025040	Approved		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:4.56e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 17.7	Mixed		
FAM161A	FLJ13305, RP28	ENSG00000170264	Family with sequence similarity 161 member A	2	61824854-61854143	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032119	Enhanced				Endometrial cancer:9.02e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 10.0	fallopian tube: 6.4	Mixed		
FAM161B	C14orf44, FLJ31697	ENSG00000156050	Family with sequence similarity 161 member B	14	73931501-73950414	Predicted intracellular proteins	Evidence at protein level	HPA019125	Approved				Renal cancer:6.78e-4 (favourable)	Expressed in all	Mixed			testis: 18.8	Mixed		
FAM166A		ENSG00000188163	Family with sequence similarity 166 member A	9	137243584-137247770	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA023307	Enhanced					Not detected	Tissue enriched	44	testis: 58.6	epididymis: 1.3	Not detected		
FAM166B		ENSG00000215187	Family with sequence similarity 166 member B	9	35561831-35563899	Predicted intracellular proteins	Evidence at protein level	HPA045540	Enhanced				Ovarian cancer:6.20e-6 (favourable), Endometrial cancer:2.61e-5 (favourable)	Group enriched	Group enriched	13	adrenal gland: 369.8;fallopian tube: 159.2;skeletal muscle: 82.6	epididymis: 16.2	Cell line enhanced		Hep G2: 1.1
FAM167A	C8orf13	ENSG00000154319	Family with sequence similarity 167 member A	8	11421463-11474715	Predicted intracellular proteins	Evidence at protein level	HPA023915, HPA030426	Approved		Approved	Mitochondria	Endometrial cancer:5.96e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 32.4;thyroid gland: 88.0	lung: 15.8	Cell line enhanced		Daudi: 41.5;RPMI-8226: 43.0;SH-SY5Y: 48.2
FAM167B	C1orf90, MGC10820	ENSG00000183615	Family with sequence similarity 167 member B	1	32247233-32248856	Predicted intracellular proteins	Evidence at protein level	HPA029398, HPA062074	Approved		Approved	Actin filaments	Colorectal cancer:1.11e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 9.4	Cell line enhanced		EFO-21: 11.4;SK-MEL-30: 23.7;U-2197: 28.2
FAM168A	KIAA0280, TCRP1	ENSG00000054965	Family with sequence similarity 168 member A	11	73400487-73598189	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037580	Approved		Approved	Nucleoplasm	Renal cancer:6.41e-5 (favourable), Endometrial cancer:5.51e-4 (unfavourable), Urothelial cancer:9.70e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 104.4	Expressed in all		
FAM168B	KIAA0280L, MANI	ENSG00000152102	Family with sequence similarity 168 member B	2	131047876-131093460	Predicted intracellular proteins	Evidence at protein level	HPA043778, HPA061659	Enhanced				Renal cancer:5.30e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 112.6	Expressed in all		
FAM169A	KIAA0888, SLAP75	ENSG00000198780	Family with sequence similarity 169 member A	5	74777574-74866951	Predicted intracellular proteins	Evidence at protein level	HPA041574	Enhanced		Supported	Nuclear membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 29.2;testis: 25.4	epididymis: 23.2	Cell line enhanced		BEWO: 35.3
FAM169B	FLJ39743, KIAA0888L	ENSG00000283597	Family with sequence similarity 169 member B	15	98437162-98547728	Predicted intracellular proteins	Evidence at transcript level								Not detected			testis: 0.1	Not detected		
FAM170A	ZNFD	ENSG00000164334	Family with sequence similarity 170 member A	5	119629559-119635822	Predicted intracellular proteins	Evidence at protein level	HPA037900, HPA037902	Enhanced					Not detected	Tissue enriched	104	testis: 21.0	skin: 0.2	Not detected		
FAM170B	C10orf73, Em:AC084727.4	ENSG00000172538	Family with sequence similarity 170 member B	10	49131154-49134008	Predicted intracellular proteins	Evidence at protein level	HPA043899, HPA050610	Uncertain					Not detected	Tissue enriched	75	testis: 7.4	all non-specific tissues: 0.0	Not detected		
FAM175B	ABRO1, Em:AC068896.4, KIAA0157	ENSG00000165660	Family with sequence similarity 175 member B	10	124801785-124836670	Predicted intracellular proteins	Evidence at protein level	HPA037591, HPA037592, HPA074089	Approved		Supported	Cytosol		Expressed in all	Expressed in all			thyroid gland: 21.0	Expressed in all		
FAM177B	FLJ43505, RP11-452F19.2	ENSG00000197520	Family with sequence similarity 177 member B	1	222737207-222750805	Predicted intracellular proteins	Evidence at transcript level	HPA063059	Uncertain					Mixed	Tissue enhanced		stomach: 47.3	gallbladder: 15.8	Not detected		
FAM178B	LOC51252	ENSG00000168754	Family with sequence similarity 178 member B	2	96875882-96986592	Predicted intracellular proteins	Evidence at transcript level	HPA042516, HPA062110	Uncertain		Uncertain	Nuclear speckles<br>Golgi apparatus		Tissue enriched	Group enriched	5	bone marrow: 11.4;epididymis: 6.7;spleen: 16.7;testis: 7.4	fallopian tube: 2.0	Cell line enhanced		K-562: 23.0;RPMI-8226: 19.2;WM-115: 26.6
FAM180B	LOC399888	ENSG00000196666	Family with sequence similarity 180 member B	11	47586693-47589194	Predicted intracellular proteins	Evidence at transcript level	HPA029408	Uncertain					Tissue enhanced	Tissue enhanced		breast: 6.9;skin: 4.4	adipose tissue: 4.1	Cell line enhanced		SK-MEL-30: 1.8;U-937: 1.3
FAM181A	C14orf152	ENSG00000140067	Family with sequence similarity 181 member A	14	93918894-93929608	Predicted intracellular proteins	Evidence at protein level	HPA001603	Enhanced					Group enriched	Tissue enhanced		cerebral cortex: 3.4;testis: 13.7	fallopian tube: 2.9	Cell line enriched	10	AF22: 4.2
FAM181B	LOC220382, MGC33846	ENSG00000182103	Family with sequence similarity 181 member B	11	82729941-82733864	Predicted intracellular proteins	Evidence at transcript level	HPA066861	Approved		Approved	Nuclear membrane<br>Mitochondria	Endometrial cancer:8.07e-4 (favourable)	Tissue enriched	Tissue enriched	20	cerebral cortex: 17.5	adrenal gland,fallopian tube: 0.8	Cell line enhanced		RT4: 1.9;SH-SY5Y: 1.3;U-2 OS: 1.3
FAM182B		ENSG00000175170	Family with sequence similarity 182 member B	20	25763466-25868225	Predicted intracellular proteins	Evidence at transcript level	HPA050100	Uncertain		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		testis: 11.8	fallopian tube: 6.7	Cell line enriched	5	SCLC-21H: 15.8
FAM183A	hCG23177, LOC440585	ENSG00000186973	Family with sequence similarity 183 member A	1	43145153-43156396	Predicted intracellular proteins	Evidence at transcript level	HPA043382, HPA049120	Approved					Tissue enhanced	Tissue enriched	14	fallopian tube: 154.3	skin: 11.3	Cell line enhanced		CAPAN-2: 3.1;hTCEpi: 1.8;NTERA-2: 3.1;SCLC-21H: 3.1
FAM184A	C6orf60, FLJ13942	ENSG00000111879	Family with sequence similarity 184 member A	6	118959763-119149387	Predicted intracellular proteins	Evidence at protein level	HPA034571, HPA034572, HPA041955	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Mixed	Tissue enhanced		placenta: 46.0;testis: 45.3	cerebral cortex: 25.1	Cell line enhanced		AF22: 19.5;HEK93: 10.7;K-562: 15.2;SCLC-21H: 15.0
FAM184B	KIAA1276	ENSG00000047662	Family with sequence similarity 184 member B	4	17629306-17781512	Predicted intracellular proteins	Evidence at protein level	HPA044119, HPA048458	Enhanced					Mixed	Group enriched	6	cerebral cortex: 2.6;skeletal muscle: 1.4	kidney,parathyroid gland,skin: 0.3	Cell line enhanced		SCLC-21H: 2.5
FAM185A	MGC35361	ENSG00000222011	Family with sequence similarity 185 member A	7	102748971-102809225	Predicted intracellular proteins	Evidence at protein level	HPA020470, HPA029883	Uncertain		Enhanced	Cytosol	Renal cancer:9.36e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 4.5	Mixed		
FAM186A	LOC121006	ENSG00000185958	Family with sequence similarity 186 member A	12	50326230-50396622	Predicted intracellular proteins	Evidence at protein level	HPA047128	Uncertain					Not detected	Tissue enriched	19	testis: 10.9	skin: 0.5	Not detected		
FAM186B	C12orf25, DKFZP434J0113	ENSG00000135436	Family with sequence similarity 186 member B	12	49582885-49605639	Predicted intracellular proteins	Evidence at protein level	HPA039736, HPA040028	Uncertain					Not detected	Tissue enriched	32	testis: 76.1	parathyroid gland: 2.3	Mixed		
FAM192A	C16orf94, NIP30	ENSG00000172775	Family with sequence similarity 192 member A	16	57152466-57186116	Predicted intracellular proteins	Evidence at protein level	HPA054382, HPA059652	Uncertain		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 175.9	Expressed in all		
FAM193A	C4orf8, RES4-22	ENSG00000125386	Family with sequence similarity 193 member A	4	2536631-2732565	Predicted intracellular proteins	Evidence at protein level	HPA043116	Approved		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:4.80e-4 (favourable)	Expressed in all	Expressed in all			testis: 30.2	Expressed in all		
FAM193B	FLJ10404, IRIZIO, KIAA1931	ENSG00000146067	Family with sequence similarity 193 member B	5	177519788-177554541	Predicted intracellular proteins	Evidence at protein level	HPA035848, HPA058112	Approved		Enhanced	Nucleus<br>Nucleoli	Renal cancer:3.71e-8 (unfavourable), Urothelial cancer:1.30e-5 (favourable)	Expressed in all	Expressed in all			skin: 60.2	Expressed in all		
FAM196A	C10orf141, FLJ45557, INSYN2	ENSG00000188916	Family with sequence similarity 196 member A	10	127135426-127196158	Predicted intracellular proteins	Evidence at protein level	HPA035898, HPA035899	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 3.2	prostate: 1.3	Group enriched	7	SCLC-21H: 3.2;U-87 MG: 5.2
FAM196B	C5orf57	ENSG00000204767	Family with sequence similarity 196 member B	5	169864264-169980740	Predicted intracellular proteins	Evidence at transcript level	HPA047227	Uncertain					Mixed	Tissue enhanced		breast: 7.6;cerebral cortex: 7.0	ovary: 2.1	Cell line enhanced		fHDF/TERT166: 30.1;HUVEC TERT2: 20.4;U-138 MG: 61.2
FAM199X	CXorf39	ENSG00000123575	Family with sequence similarity 199, X-linked	X	104166620-104195902	Predicted intracellular proteins	Evidence at protein level	HPA003093	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			epididymis: 43.4	Expressed in all		
FAM200A	C7orf38, DKFZp727G131, FLJ36794	ENSG00000221909	Family with sequence similarity 200 member A	7	99546308-99558536	Predicted intracellular proteins	Evidence at protein level	HPA017855	Uncertain				Renal cancer:2.17e-7 (favourable), Liver cancer:9.24e-4 (unfavourable)	Expressed in all	Mixed			testis: 15.1	Expressed in all		
FAM200B	C4orf53	ENSG00000237765	Family with sequence similarity 200 member B	4	15681662-15705565	Predicted intracellular proteins	Evidence at protein level	HPA017855	Uncertain				Urothelial cancer:3.35e-5 (favourable), Renal cancer:3.87e-4 (favourable), Pancreatic cancer:4.39e-4 (favourable), Lung cancer:9.89e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 15.0	Mixed		
FAM204A	bA319I23.1, C10orf84, FLJ13188	ENSG00000165669	Family with sequence similarity 204 member A	10	118297930-118342328	Predicted intracellular proteins	Evidence at protein level	HPA038182, HPA062025	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:8.59e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 89.3	Expressed in all		
FAM206A	C9orf6, CG-8, FLJ20457, Simiate	ENSG00000119328	Family with sequence similarity 206 member A	9	108934181-108950744	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035917, HPA035918	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 36.8	Expressed in all		
FAM207A	C21orf70, PRED56	ENSG00000160256	Family with sequence similarity 207 member A	21	44940010-44976989	Predicted intracellular proteins	Evidence at protein level	CAB034178, HPA036354	Approved		Approved	Golgi apparatus<br>Vesicles	Liver cancer:7.04e-4 (unfavourable), Renal cancer:7.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
FAM208A	C3orf63, KIAA1105, RAP140, se89-1, TASOR	ENSG00000163946	Family with sequence similarity 208 member A	3	56620133-56683237	Predicted intracellular proteins	Evidence at protein level	HPA006735, HPA017142	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Mixed			testis: 53.5	Expressed in all		
FAM208B	bA318E3.2, C10orf18, FLJ20360, KIAA2006	ENSG00000108021	Family with sequence similarity 208 member B	10	5684838-5763740	Predicted intracellular proteins	Evidence at protein level	HPA038042, HPA038043, HPA061547	Uncertain		Supported	Nucleus<br>Cytosol	Liver cancer:2.91e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 44.0	Expressed in all		
FAM20B	GXK1, KIAA0475	ENSG00000116199	FAM20B, glycosaminoglycan xylosylkinase	1	179025804-179076562	Predicted intracellular proteins	Evidence at protein level	HPA007409	Approved		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 37.8	Expressed in all		
FAM212A	C3orf54, INKA1	ENSG00000185614	Family with sequence similarity 212 member A	3	49803254-49805030	Predicted intracellular proteins	Evidence at protein level	HPA041879	Uncertain		Approved	Nucleoplasm<br>Vesicles	Head and neck cancer:1.96e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 24.4	lung: 7.0	Cell line enhanced		HEL: 60.9;HMC-1: 39.3;THP-1: 28.1;U-937: 27.1
FAM212B	C1orf183, FLJ31105, INKA2	ENSG00000197852	Family with sequence similarity 212 member B	1	111680630-111755824	Predicted intracellular proteins	Evidence at protein level	HPA027809, HPA027811	Approved		Approved	Nucleus	Head and neck cancer:4.51e-5 (favourable)	Tissue enhanced	Mixed			cerebral cortex: 16.7	Cell line enhanced		hTEC/SVTERT24-B: 37.7;U-87 MG: 71.6
FAM213B	C1orf93, MGC26818	ENSG00000157870	Family with sequence similarity 213 member B	1	2586491-2591469	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006403	Approved	Approved	Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.28e-4 (favourable), Liver cancer:1.62e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 14.6	Mixed		
FAM214A	FLJ10980, KIAA1370	ENSG00000047346	Family with sequence similarity 214 member A	15	52581317-52709817	Predicted intracellular proteins	Evidence at protein level	HPA039369, HPA040180	Approved		Approved	Nucleoplasm	Endometrial cancer:7.27e-6 (favourable), Lung cancer:8.68e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 57.9	Expressed in all		
FAM214B	bA182N22.6, FLJ11560, KIAA1539	ENSG00000005238	Family with sequence similarity 214 member B	9	35104112-35116341	Predicted intracellular proteins	Evidence at protein level	HPA048831, HPA055751	Approved		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			bone marrow: 24.5	Mixed		
FAM216A	C12orf24, HSU79274	ENSG00000204856	Family with sequence similarity 216 member A	12	110468364-110490385	Predicted intracellular proteins	Evidence at protein level	HPA038286	Enhanced		Approved	Actin filaments	Renal cancer:4.18e-10 (unfavourable), Liver cancer:4.49e-5 (unfavourable)	Expressed in all	Group enriched	7	cerebral cortex: 16.2;testis: 61.1	appendix: 5.5	Mixed		
FAM216B	C13orf30, FLJ40919	ENSG00000179813	Family with sequence similarity 216 member B	13	42781550-42791549	Predicted intracellular proteins	Evidence at transcript level	HPA040118	Uncertain				Endometrial cancer:9.77e-4 (favourable)	Group enriched	Tissue enriched	8	fallopian tube: 122.8	lung: 15.1	Cell line enriched	13	U-87 MG: 1.7
FAM217A	C6orf146, MGC43581	ENSG00000145975	Family with sequence similarity 217 member A	6	4049434-4087344	Predicted intracellular proteins	Evidence at transcript level	HPA035455	Uncertain					Not detected	Tissue enriched	33	testis: 22.8	epididymis: 0.6	Not detected		
FAM217B	C20orf177, dJ551D2.5	ENSG00000196227	Family with sequence similarity 217 member B	20	59933764-59948680	Predicted intracellular proteins	Evidence at protein level	HPA041021, HPA056698	Approved		Supported	Nucleoplasm		Expressed in all	Mixed			cerebral cortex: 34.9	Expressed in all		
FAM218A	C4orf39, FLJ31659	ENSG00000250486	Family with sequence similarity 218 member A	4	164956948-164959122	Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			testis: 5.6	Cell line enhanced		LHCN-M2: 1.8;SCLC-21H: 5.0
FAM219A	bA573M23.5, C9orf25, FLJ39031	ENSG00000164970	Family with sequence similarity 219 member A	9	34398184-34458570	Predicted intracellular proteins	Evidence at protein level	HPA019338, HPA052909	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Liver cancer:1.98e-5 (unfavourable), Renal cancer:5.54e-5 (unfavourable), Pancreatic cancer:2.46e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 76.1	Expressed in all		
FAM219B	C15orf17, FLJ00005	ENSG00000178761	Family with sequence similarity 219 member B	15	74899987-74907121	Predicted intracellular proteins	Evidence at protein level	HPA048929, HPA058064	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.29e-4 (favourable), Colorectal cancer:1.75e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 20.8	Mixed		
FAM221A	C7orf46, DKFZp686F0810, FLJ45875, MGC72075	ENSG00000188732	Family with sequence similarity 221 member A	7	23680130-23703249	Predicted intracellular proteins	Evidence at protein level	HPA019719, HPA026748, HPA026752	Enhanced		Approved	Cytosol		Mixed	Tissue enhanced		testis: 34.7	fallopian tube: 14.6	Cell line enhanced		MOLT-4: 20.7;SCLC-21H: 26.9;SH-SY5Y: 41.2
FAM221B	C9orf128	ENSG00000204930	Family with sequence similarity 221 member B	9	35816391-35828747	Predicted intracellular proteins	Evidence at transcript level	HPA023011, HPA026577	Uncertain					Not detected	Group enriched	6	bone marrow: 2.4;testis: 10.3	prostate: 1.1	Not detected		
FAM222A	C12orf34, FLJ14721	ENSG00000139438	Family with sequence similarity 222 member A	12	109714228-109770507	Predicted intracellular proteins	Evidence at protein level	HPA040181	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites<br>Mitochondria	Cervical cancer:1.82e-5 (favourable), Pancreatic cancer:4.81e-4 (favourable), Stomach cancer:8.59e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 20.0;testis: 16.5	adrenal gland: 9.8	Cell line enriched	5	SH-SY5Y: 122.9
FAM222B	C17orf63, FLJ10700	ENSG00000173065	Family with sequence similarity 222 member B	17	28755978-28855232	Predicted intracellular proteins	Evidence at protein level	HPA051840, HPA062239	Approved		Enhanced	Nucleoplasm	Liver cancer:3.45e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.9	Expressed in all		
FAM227A		ENSG00000184949	Family with sequence similarity 227 member A	22	38578120-38656629	Predicted intracellular proteins	Evidence at protein level	HPA003077	Uncertain		Uncertain	Nucleoplasm		Mixed	Tissue enhanced		fallopian tube: 3.7	testis: 3.5	Group enriched	6	HDLM-2: 11.1;Karpas-707: 14.1
FAM227B	C15orf33, FLJ32800	ENSG00000166262	Family with sequence similarity 227 member B	15	49326962-49620931	Predicted intracellular proteins	Evidence at protein level	HPA049774, HPA061695	Uncertain		Approved	Nuclear speckles		Mixed	Expressed in all			testis: 21.4	Mixed		
FAM228A	C2orf84, FLJ30851	ENSG00000186453	Family with sequence similarity 228 member A	2	24175069-24200849	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	19	testis: 42.4	cerebral cortex: 2.2	Cell line enhanced		HHSteC: 2.0;TIME: 3.2
FAM228B		ENSG00000219626	Family with sequence similarity 228 member B	2	24076526-24169640	Predicted intracellular proteins	Evidence at protein level	HPA052598, HPA063357	Uncertain		Approved	Golgi apparatus		Mixed	Mixed			testis: 36.5	Mixed		
FAM229A		ENSG00000225828	Family with sequence similarity 229 member A	1	32361270-32364278	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:1.73e-5 (unfavourable), Urothelial cancer:2.33e-4 (favourable)	Mixed	Tissue enriched	7	testis: 15.6	spleen: 2.1	Cell line enhanced		HEK93: 7.7
FAM229B	C6orf225, DKFZp586F0922, LOC619208	ENSG00000203778	Family with sequence similarity 229 member B	6	112087599-112102790	Predicted intracellular proteins	Evidence at transcript level	HPA036068			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Renal cancer:8.76e-4 (favourable)	Expressed in all	Tissue enriched	6	testis: 542.3	fallopian tube: 85.3	Mixed		
FAM230A	DGCR15	ENSG00000277870	Family with sequence similarity 230 member A	22	18422244-18500594	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	26	testis: 24.1	stomach: 0.9	Cell line enhanced		A549: 16.6;U-266/84: 10.9
FAM231A		ENSG00000237847	Family with sequence similarity 231 member A	1	16673003-16673512	Predicted intracellular proteins	No evidence	HPA043267, HPA043292	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
FAM231B		ENSG00000268991	Family with sequence similarity 231 member B	1	16539066-16539575	Predicted intracellular proteins	No evidence	HPA043267, HPA043292	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
FAM231C		ENSG00000279132	Family with sequence similarity 231 member C	1	16733952-16734461	Predicted intracellular proteins	No evidence	HPA043267, HPA043292	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
FAM231D		ENSG00000268674	Family with sequence similarity 231 member D	Unmapped	35407-35916	Predicted intracellular proteins	No evidence	HPA043267, HPA043292	Uncertain						Not detected			all non-specific tissues: 0.0	Not detected		
FAM236A	DMRTC1-AS1, LINC00684	ENSG00000275520	Family with sequence similarity 235 member A	X	72938163-72938958	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	46	testis: 79.7	lymph node: 1.7	Not detected		
FAM236B		ENSG00000268994	Family with sequence similarity 236 member B	X	72781865-72782660	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	50	testis: 115.3	thyroid gland: 2.3	Not detected		
FAM236C		ENSG00000283594	Family with sequence similarity 236 member C	X	72912615-72913401	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	62	testis: 6.2	all non-specific tissues: 0.0	Not detected		
FAM236D		ENSG00000225396	Family with sequence similarity 236 member D	X	72807425-72808210	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	23	testis: 3.5	prostate: 0.1	Not detected		
FAM24A	AC073585.4	ENSG00000203795	Family with sequence similarity 24 member A	10	122910701-122913111	Predicted intracellular proteins	Evidence at protein level	HPA052490	Supported					Not detected	Tissue enriched	332	testis: 33.1	all non-specific tissues: 0.0	Not detected		
FAM24B	AC073585.2, MGC45962	ENSG00000213185	Family with sequence similarity 24 member B	10	122849078-122879641	Predicted intracellular proteins	Evidence at protein level	HPA052490	Supported					Expressed in all	Tissue enhanced		kidney: 13.8	testis: 11.4	Group enriched	5	hTERT-HME1: 99.8;LHCN-M2: 139.2;TIME: 44.7
FAM25A	bA96C23.5	ENSG00000188100	Family with sequence similarity 25 member A	10	87020306-87024730	Predicted intracellular proteins	Evidence at transcript level	HPA044808	Uncertain					Tissue enhanced	Tissue enhanced		esophagus: 315.5;skin: 125.9	tonsil: 54.6	Group enriched	6	A-431: 22.6;SK-BR-3: 55.0
FAM25C	bA164N7.4	ENSG00000276430	Family with sequence similarity 25 member C	10	47995355-47999791	Predicted intracellular proteins	Evidence at transcript level	HPA044808	Uncertain					Tissue enhanced	Group enriched	14	breast: 5.3;esophagus: 4.0;skin: 9.0;small intestine: 4.3;tonsil: 2.1	skeletal muscle,testis: 0.3	Cell line enriched	5	SK-BR-3: 12.1
FAM25G	bA301J7.4	ENSG00000189090	Family with sequence similarity 25 member G	10	47487219-47491693	Predicted intracellular proteins	Evidence at transcript level	HPA044808	Uncertain					Not detected	Tissue enriched	15	skin: 87.4	breast: 5.8	Cell line enriched	25	SK-BR-3: 16.5
FAM32A	DKFZP586O0120, OTAG-12	ENSG00000105058	Family with sequence similarity 32 member A	19	16185380-16192046	Predicted intracellular proteins	Evidence at protein level	HPA051712	Approved		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			placenta: 89.0	Expressed in all		
FAM3C	GS3876, ILEI	ENSG00000196937	Family with sequence similarity 3 member C	7	121348851-121396364	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043376, HPA050548	Enhanced		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 181.1	Expressed in all		
FAM43A	FLJ90022	ENSG00000185112	Family with sequence similarity 43 member A	3	194686544-194689037	Predicted intracellular proteins	Evidence at protein level	HPA048345	Uncertain		Approved	Vesicles	Urothelial cancer:9.96e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 34.0	placenta: 18.2	Cell line enhanced		HUVEC TERT2: 113.2;NB-4: 52.7;PC-3: 59.3;TIME: 55.9
FAM43B	FLJ44952	ENSG00000183114	Family with sequence similarity 43 member B	1	20552439-20555010	Predicted intracellular proteins	Evidence at protein level	HPA050813	Approved		Approved	Cytosol		Tissue enhanced	Tissue enhanced		adrenal gland: 10.3	epididymis: 3.5	Cell line enhanced		AN3-CA: 2.9;fHDF/TERT166: 3.6;SCLC-21H: 4.8;SiHa: 8.3
FAM45A		ENSG00000119979	Family with sequence similarity 45 member A	10	119104086-119137984	Predicted intracellular proteins	Evidence at protein level	HPA041159			Approved	Plasma membrane<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 21.0	Expressed in all		
FAM46A	C6orf37, FLJ20037	ENSG00000112773	Family with sequence similarity 46 member A	6	81491439-81752774	Predicted intracellular proteins	Evidence at protein level	HPA051067, HPA067140	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.07e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 143.7	gallbladder: 51.5	Cell line enhanced		HL-60: 75.4;THP-1: 108.4
FAM46C	FLJ20202	ENSG00000183508	Family with sequence similarity 46 member C	1	117605934-117628372	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA054049	Uncertain		Approved	Nucleoplasm	Renal cancer:2.77e-5 (favourable), Endometrial cancer:3.75e-5 (favourable)	Expressed in all	Mixed			testis: 58.7	Cell line enhanced		Karpas-707: 208.6;RPMI-8226: 124.6;U-266/70: 61.2
FAM46D	CT1.26, CT112, MGC26999	ENSG00000174016	Family with sequence similarity 46 member D	X	80335504-80445311	Predicted intracellular proteins	Evidence at protein level	HPA059362	Uncertain					Not detected	Tissue enriched	52	testis: 6.2	prostate,thyroid gland: 0.1	Cell line enhanced		AN3-CA: 1.0
FAM47A	MGC27003	ENSG00000185448	Family with sequence similarity 47 member A	X	34129756-34132314	Predicted intracellular proteins	Evidence at protein level	HPA000610	Uncertain					Not detected	Tissue enriched	56	testis: 5.5	all non-specific tissues: 0.0	Not detected		
FAM47B	FLJ35782	ENSG00000189132	Family with sequence similarity 47 member B	X	34942796-34944915	Predicted intracellular proteins	Evidence at protein level	HPA046829, HPA050996	Uncertain					Not detected	Tissue enriched	133	testis: 13.3	all non-specific tissues: 0.0	Not detected		
FAM47C		ENSG00000198173	Family with sequence similarity 47 member C	X	37008397-37011666	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	27	testis: 4.8	parathyroid gland: 0.1	Not detected		
FAM47E	FLJ42946, LOC100129583	ENSG00000189157	Family with sequence similarity 47 member E	4	76214040-76283780	Predicted intracellular proteins	Evidence at transcript level	HPA053331	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		fallopian tube: 28.1	thyroid gland: 16.3	Mixed		
FAM47E-STBD1		ENSG00000272414	FAM47E-STBD1 readthrough	4	76251721-76311129	Predicted intracellular proteins	Evidence at transcript level	HPA053331	Approved		Uncertain	Plasma membrane<br>Cytosol		Not detected	Mixed			adipose tissue: 33.2	Cell line enhanced		Karpas-707: 24.7
FAM49A	DKFZP566A1524, FLJ11080	ENSG00000197872	Family with sequence similarity 49 member A	2	16549459-16666331	Predicted intracellular proteins	Evidence at protein level	CAB017847, HPA060398	Approved		Approved	Nucleoplasm	Renal cancer:1.83e-6 (unfavourable), Urothelial cancer:4.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 81.4	thyroid gland: 68.3	Cell line enhanced		HMC-1: 46.7;HUVEC TERT2: 36.0;RH-30: 92.5
FAM49B	BM-009	ENSG00000153310	Family with sequence similarity 49 member B	8	129839593-130017129	Predicted intracellular proteins	Evidence at protein level	HPA009076	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:3.09e-10 (unfavourable), Liver cancer:3.02e-6 (unfavourable), Endometrial cancer:1.24e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 137.4	Expressed in all		
FAM50A	9F, DXS9928E, HXC-26, XAP5	ENSG00000071859	Family with sequence similarity 50 member A	X	154444126-154450654	Predicted intracellular proteins	Evidence at protein level	HPA003585	Supported		Enhanced	Nucleoplasm	Liver cancer:3.15e-5 (unfavourable), Colorectal cancer:9.52e-5 (unfavourable), Cervical cancer:2.05e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 67.0	Expressed in all		
FAM50B	D6S2654E, X5L	ENSG00000145945	Family with sequence similarity 50 member B	6	3849386-3851317	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064111, HPA067817	Approved		Enhanced	Nucleoplasm<br>Cytokinetic bridge	Renal cancer:4.01e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 16.0	Cell line enhanced		HDLM-2: 81.7
FAM53A	DNTNP	ENSG00000174137	Family with sequence similarity 53 member A	4	1617915-1684302	Predicted intracellular proteins	Evidence at protein level	HPA036452, HPA058138	Enhanced		Uncertain	Nucleoplasm		Mixed	Tissue enhanced		testis: 17.5	thyroid gland: 7.8	Cell line enhanced		SCLC-21H: 9.1
FAM53B	bA12J10.2, KIAA0140, smp	ENSG00000189319	Family with sequence similarity 53 member B	10	124619292-124744269	Predicted intracellular proteins	Evidence at protein level	HPA037751, HPA037752	Approved		Approved	Cytosol	Renal cancer:4.81e-7 (favourable), Pancreatic cancer:7.00e-6 (favourable), Head and neck cancer:1.97e-4 (favourable), Stomach cancer:3.26e-4 (favourable), Cervical cancer:4.96e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.9	Expressed in all		
FAM53C	C5orf6	ENSG00000120709	Family with sequence similarity 53 member C	5	138331935-138349729	Predicted intracellular proteins	Evidence at protein level	HPA042796	Approved				Endometrial cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 73.2	Expressed in all		
FAM58A	FLJ21610, MGC29729	ENSG00000262919	Family with sequence similarity 58 member A	X	153587919-153600045	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050137, HPA059843	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			epididymis: 15.4	Expressed in all		
FAM60A	C12orf14, TERA	ENSG00000139146	Family with sequence similarity 60 member A	12	31280584-31327058	Predicted intracellular proteins	Evidence at protein level	HPA038167, HPA057585	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.57e-4 (unfavourable), Liver cancer:5.78e-4 (unfavourable), Renal cancer:7.89e-4 (favourable)	Expressed in all	Mixed			endometrium: 44.5	Expressed in all		
FAM64A	CATS, FLJ10156, FLJ10491, RCS1	ENSG00000129195	Family with sequence similarity 64 member A	17	6444415-6451469	Predicted intracellular proteins	Evidence at protein level	HPA043783, HPA049934	Uncertain		Enhanced	Nucleus		Mixed	Mixed			spleen: 6.2	Cell line enhanced		AF22: 158.0
FAM65A	FLJ13725	ENSG00000039523	Family with sequence similarity 65 member A	16	67518418-67546788	Predicted intracellular proteins	Evidence at protein level	HPA005923	Uncertain		Approved	Golgi apparatus<br>Cytosol	Renal cancer:5.82e-8 (favourable), Lung cancer:5.00e-5 (unfavourable), Head and neck cancer:6.53e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 59.5	Expressed in all		
FAM65B	C6orf32, DIFF48, KIAA0386, MYONAP	ENSG00000111913	Family with sequence similarity 65 member B	6	24804282-25042018	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 92.5	spleen: 73.1	Cell line enhanced		AF22: 30.2;Daudi: 47.4;fHDF/TERT166: 47.6
FAM65C	C20orf175, C20orf176, dJ530I15.2, dJ530I15.3	ENSG00000042062	Family with sequence similarity 65 member C	20	50586108-50691528	Predicted intracellular proteins	Evidence at protein level	HPA051823, HPA054759	Uncertain		Approved	Nucleoplasm	Head and neck cancer:1.66e-5 (favourable)	Mixed	Mixed			endometrium: 18.2	Cell line enhanced		ASC diff: 24.7;HEL: 50.2;HSkMC: 24.1;K-562: 29.7
FAM69C	C18orf51	ENSG00000187773	Family with sequence similarity 69 member C	18	74434099-74457944	Predicted intracellular proteins	Evidence at protein level	HPA048928	Enhanced					Group enriched	Tissue enhanced		cerebral cortex: 28.8;testis: 8.4	skin: 4.9	Cell line enriched	7	SK-MEL-30: 4.2
FAM71A	FLJ32796	ENSG00000162771	Family with sequence similarity 71 member A	1	212624474-212626778	Predicted intracellular proteins	Evidence at protein level	HPA028462	Enhanced					Not detected	Tissue enriched	95	testis: 78.3	fallopian tube: 0.8	Not detected		
FAM71B	MGC26988	ENSG00000170613	Family with sequence similarity 71 member B	5	157161846-157166264	Predicted intracellular proteins	Evidence at protein level	HPA039478, HPA040771	Enhanced					Not detected	Tissue enriched	372	testis: 37.2	all non-specific tissues: 0.0	Not detected		
FAM71C	MGC39520	ENSG00000180219	Family with sequence similarity 71 member C	12	99647753-99650046	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	312	testis: 31.2	all non-specific tissues: 0.0	Not detected		
FAM71D	C14orf54	ENSG00000172717	Family with sequence similarity 71 member D	14	67189393-67228550	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	34	testis: 24.1	skin: 0.7	Cell line enhanced		U-2 OS: 1.1
FAM71E1		ENSG00000142530	Family with sequence similarity 71 member E1	19	50466785-50476753	Predicted intracellular proteins	Evidence at transcript level	HPA048111			Approved	Nucleoli fibrillar center	Renal cancer:5.35e-7 (favourable)	Expressed in all	Tissue enriched	11	testis: 38.4	cerebral cortex: 3.3	Cell line enhanced		HEK93: 13.1
FAM71E2	C19orf16, DKFZp434G1729	ENSG00000180043	Family with sequence similarity 71 member E2	19	55354908-55363260	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	236	testis: 23.6	all non-specific tissues: 0.0	Cell line enriched	10	SCLC-21H: 1.0
FAM71F1	FAM137A, NYD-SP18	ENSG00000135248	Family with sequence similarity 71 member F1	7	128709061-128731743	Predicted intracellular proteins	Evidence at transcript level	HPA020636			Uncertain	Cytosol		Tissue enriched	Tissue enriched	145	testis: 82.6	epididymis: 0.5	Cell line enriched	16	NTERA-2: 16.3
FAM71F2	FAM137B	ENSG00000205085	Family with sequence similarity 71 member F2	7	128672266-128683319	Predicted intracellular proteins	Evidence at protein level	HPA020513, HPA024248	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enriched	22	testis: 42.9	adipose tissue,cerebral cortex: 1.9	Mixed		
FAM72A	LMPIP, MGC57827, RP11-312O7.1, UGENE	ENSG00000196550	Family with sequence similarity 72 member A	1	206186179-206204414	Predicted intracellular proteins	Evidence at protein level	HPA043271, HPA067321	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			lymph node: 12.6	Expressed in all		
FAM72B	RP11-439A17.6	ENSG00000188610	Family with sequence similarity 72 member B	1	121167646-121185539	Predicted intracellular proteins	Evidence at transcript level	HPA043271, HPA067321	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		lymph node: 9.7	tonsil: 6.2	Mixed		
FAM72C	RP5-998N21.9	ENSG00000263513	Family with sequence similarity 72 member C	1	143955364-143971965	Predicted intracellular proteins	Evidence at transcript level	HPA043271, HPA067321	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		lymph node: 5.5;tonsil: 4.3	testis: 3.0	Mixed		
FAM72D		ENSG00000215784	Family with sequence similarity 72 member D	1	145096000-145112696	Predicted intracellular proteins	Evidence at transcript level	HPA043271, HPA067321	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		lymph node: 5.6	tonsil: 4.1	Mixed		
FAM76A	MGC34648	ENSG00000009780	Family with sequence similarity 76 member A	1	27725979-27763122	Predicted intracellular proteins	Evidence at protein level	HPA044762, HPA077897	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.4	Expressed in all		
FAM78B		ENSG00000188859	Family with sequence similarity 78 member B	1	166057426-166166969	Predicted intracellular proteins	Evidence at transcript level	HPA052789, HPA073246	Uncertain		Approved	Golgi apparatus<br>Vesicles		Mixed	Not detected			adipose tissue,cerebral cortex,duodenum,stomach,testis: 0.2	Group enriched	7	HDLM-2: 8.8;SK-MEL-30: 6.5;U-2 OS: 2.3;WM-115: 2.2
FAM81A	MGC26690	ENSG00000157470	Family with sequence similarity 81 member A	15	59372693-59523549	Predicted intracellular proteins	Evidence at protein level	HPA001847, HPA065797	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 33.3	fallopian tube: 9.9	Cell line enhanced		Daudi: 47.3
FAM81B	FLJ25333	ENSG00000153347	Family with sequence similarity 81 member B	5	95391344-95450454	Predicted intracellular proteins	Evidence at protein level	HPA072554	Approved					Mixed	Group enriched	13	fallopian tube: 78.9;testis: 121.2	parathyroid gland: 7.5	Cell line enhanced		CAPAN-2: 1.1
FAM83A	BJ-TSA-9, MGC14128	ENSG00000147689	Family with sequence similarity 83 member A	8	123178960-123210079	Predicted intracellular proteins	Evidence at protein level	HPA052615			Approved	Nucleoplasm	Lung cancer:2.98e-9 (unfavourable), Pancreatic cancer:4.99e-6 (unfavourable), Endometrial cancer:3.85e-4 (unfavourable)	Tissue enhanced	Tissue enriched	8	esophagus: 77.9	seminal vesicle: 9.3	Cell line enhanced		A-431: 72.5;HBEC3-KT: 90.5;hTCEpi: 47.9;K-562: 183.8
FAM83B	C6orf143, FLJ30642	ENSG00000168143	Family with sequence similarity 83 member B	6	54846771-54942022	Predicted intracellular proteins	Evidence at protein level	HPA031464, HPA031465	Enhanced				Urothelial cancer:1.86e-5 (unfavourable), Lung cancer:1.48e-4 (unfavourable), Pancreatic cancer:7.60e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		skin: 27.3	esophagus: 17.7	Cell line enhanced		A-431: 17.1;HaCaT: 18.9;hTCEpi: 15.2;hTERT-HME1: 21.2;RT4: 19.6
FAM83C	C20orf128, dJ614O4.7	ENSG00000125998	Family with sequence similarity 83 member C	20	35285731-35292401	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034227, HPA049978	Uncertain					Tissue enhanced	Group enriched	17	esophagus: 19.8;skin: 43.0	tonsil: 1.8	Not detected		
FAM83D	C20orf129, CHICA, dJ616B8.3	ENSG00000101447	Family with sequence similarity 83 member D	20	38926312-38953106	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.81e-14 (unfavourable), Liver cancer:5.44e-6 (unfavourable), Pancreatic cancer:4.73e-5 (unfavourable), Endometrial cancer:1.49e-4 (unfavourable), Lung cancer:9.69e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 76.1;smooth muscle: 131.9	prostate: 21.8	Expressed in all		
FAM83E	FLJ20200	ENSG00000105523	Family with sequence similarity 83 member E	19	48600810-48614854	Predicted intracellular proteins	Evidence at protein level	HPA049305	Uncertain					Mixed	Tissue enhanced		duodenum: 30.8;small intestine: 35.3;stomach: 40.7	colon: 22.5	Cell line enhanced		CAPAN-2: 2.9
FAM83F		ENSG00000133477	Family with sequence similarity 83 member F	22	39994949-40043529	Predicted intracellular proteins	Evidence at protein level	HPA051207, HPA064657	Enhanced		Approved	Nucleus<br>Mitochondria	Colorectal cancer:1.73e-4 (favourable), Pancreatic cancer:9.40e-4 (favourable)	Mixed	Tissue enhanced		testis: 21.6	skin: 16.5	Cell line enhanced		hTCEpi: 27.3;RT4: 14.8;SCLC-21H: 46.9
FAM83G	FLJ41564, PAWS1	ENSG00000188522	Family with sequence similarity 83 member G	17	18968789-19004804	Predicted intracellular proteins	Evidence at protein level	HPA023369, HPA023940	Enhanced		Supported	Cytosol	Stomach cancer:7.58e-6 (favourable), Liver cancer:8.29e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 64.4	esophagus: 24.2	Mixed		
FAM83H	FLJ46072	ENSG00000180921	Family with sequence similarity 83 member H	8	143723933-143733801	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024505, HPA024604	Enhanced		Approved	Cytosol	Lung cancer:3.77e-4 (unfavourable), Stomach cancer:4.42e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 17.2	esophagus: 10.3	Cell line enhanced		HaCaT: 37.2;MCF7: 45.2
FAM83H-AS1	onco-lncRNA-3	ENSG00000203499	FAM83H antisense RNA 1 (head to head)	8	143734140-143790644	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		epididymis: 26.2;skin: 34.3	esophagus: 13.0	Cell line enhanced		HaCaT: 26.1;hTCEpi: 25.7;MCF7: 55.1;T-47d: 60.5
FAM84A	FLJ35392, NSE1	ENSG00000162981	Family with sequence similarity 84 member A	2	14632686-14650814	Predicted intracellular proteins	Evidence at protein level	HPA047703	Uncertain		Approved	Nucleus		Mixed	Mixed			colon: 40.3	Cell line enhanced		hTCEpi: 13.1;RT4: 39.2
FAM84B	BCMP101, NSE2	ENSG00000168672	Family with sequence similarity 84 member B	8	126552442-126558393	Predicted intracellular proteins	Evidence at protein level	HPA050782, HPA062115	Approved		Approved	Nucleoplasm	Renal cancer:1.96e-8 (favourable), Urothelial cancer:1.75e-5 (favourable), Endometrial cancer:9.71e-4 (unfavourable)	Expressed in all	Mixed			kidney: 29.6	Cell line enhanced		A-431: 65.0;AN3-CA: 96.5;MCF7: 83.0;PC-3: 66.5
FAM86B1	MGC16279	ENSG00000186523	Family with sequence similarity 86 member B1	8	12182096-12194133	Predicted intracellular proteins	Evidence at transcript level	HPA041610, HPA055718	Uncertain		Uncertain	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 4.5	endometrium: 2.6	Mixed		
FAM86B2		ENSG00000145002	Family with sequence similarity 86 member B2	8	12425614-12436343	Predicted intracellular proteins	Evidence at protein level	HPA041610, HPA055718	Uncertain		Uncertain	Vesicles		Not detected	Tissue enhanced		fallopian tube: 4.3	thyroid gland: 2.3	Cell line enhanced		hTERT-HME1: 5.2;RPMI-8226: 11.6;SCLC-21H: 5.5
FAM86C1	FAM86C, FLJ10661, FLJ27199	ENSG00000158483	Family with sequence similarity 86 member C1	11	71787510-71801236	Predicted intracellular proteins	Evidence at protein level						Liver cancer:5.79e-5 (unfavourable)	Expressed in all	Mixed			thyroid gland: 9.8	Expressed in all		
FAM89A	C1orf153, MGC15887	ENSG00000182118	Family with sequence similarity 89 member A	1	231018958-231040246	Predicted intracellular proteins	Evidence at protein level	HPA059052, HPA059578	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:1.75e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 98.7	Cell line enhanced		BEWO: 141.2
FAM89B	LRAP25, MTVR1	ENSG00000176973	Family with sequence similarity 89 member B	11	65572349-65574198	Predicted intracellular proteins	Evidence at protein level	HPA046895	Approved				Renal cancer:9.48e-5 (unfavourable), Liver cancer:2.98e-4 (unfavourable), Ovarian cancer:6.00e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 38.5	Expressed in all		
FAM90A1	FLJ10408	ENSG00000171847	Family with sequence similarity 90 member A1	12	8221260-8227618	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.92e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 11.6	ovary: 5.3	Cell line enhanced		BEWO: 4.7;HDLM-2: 7.1;NTERA-2: 17.6
FAM90A26	FAM90A26P	ENSG00000229924	Family with sequence similarity 90 member A26	4	9170409-9176730	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex: 0.2	Not detected		
FAM91A1	FLJ23790	ENSG00000176853	Family with sequence similarity 91 member A1	8	123768456-123815452	Predicted intracellular proteins	Evidence at protein level	HPA027978	Approved		Approved	Nucleoplasm<br>Microtubules		Expressed in all	Expressed in all			parathyroid gland: 36.7	Expressed in all		
FAM92A	FAM92A1, FLJ38979	ENSG00000188343	Family with sequence similarity 92 member A	8	93698561-93731527	Predicted intracellular proteins	Evidence at protein level	HPA034760, HPA058942	Enhanced		Approved	Mitochondria		Expressed in all	Tissue enriched	6	testis: 198.8	parathyroid gland: 32.4	Mixed		
FAM92B	FLJ44299	ENSG00000153789	Family with sequence similarity 92 member B	16	85098358-85112508	Predicted intracellular proteins	Evidence at protein level	HPA041022	Enhanced					Group enriched	Tissue enriched	10	fallopian tube: 136.1	lung: 14.1	Cell line enhanced		SCLC-21H: 3.0
FAM96B	CGI-128, CIA2B, MIP18	ENSG00000166595	Family with sequence similarity 96 member B	16	66932055-66934423	Predicted intracellular proteins	Evidence at protein level	HPA041501, HPA041736	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 120.8	Expressed in all		
FAM98A	DKFZP564F0522	ENSG00000119812	Family with sequence similarity 98 member A	2	33583658-33599382	Predicted intracellular proteins	Evidence at protein level	HPA036250, HPA036251	Uncertain		Supported	Vesicles	Liver cancer:4.86e-7 (unfavourable), Thyroid cancer:8.18e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 127.4	Expressed in all		
FAM98C	FLJ44669	ENSG00000130244	Family with sequence similarity 98 member C	19	38403135-38409088	Predicted intracellular proteins	Evidence at protein level	HPA040930, HPA041730	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Ovarian cancer:8.51e-5 (unfavourable), Urothelial cancer:5.53e-4 (favourable)	Expressed in all	Mixed			small intestine: 15.2	Expressed in all		
FAM9A	TEX39A	ENSG00000183304	Family with sequence similarity 9 member A	X	8790795-8801383	Predicted intracellular proteins	Evidence at protein level	HPA056076	Uncertain					Not detected	Tissue enriched	25	testis: 7.2	adrenal gland,cerebral cortex: 0.2	Cell line enriched	16	U-266/84: 6.2
FAN1	KIAA1018, MTMR15	ENSG00000198690	FANCD2 and FANCI associated nuclease 1	15	30903852-30943108	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048198			Supported	Nucleoplasm<br>Cytokinetic bridge<br>Cytosol	Renal cancer:1.42e-6 (favourable)	Expressed in all	Expressed in all			epididymis: 11.4	Expressed in all		
FANCB	FAAP95, FAB, FLJ34064	ENSG00000181544	Fanconi anemia complementation group B	X	14843407-14873069	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003124	Uncertain					Mixed	Mixed			bone marrow: 2.4	Mixed		
FANCC	FA3, FAC, FACC	ENSG00000158169	Fanconi anemia complementation group C	9	95099054-95426796	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017793, HPA030771	Approved		Supported	Nucleoplasm	Renal cancer:6.03e-6 (favourable)	Expressed in all	Mixed			testis: 17.6	Expressed in all		
FANCD2	FA-D2, FACD, FAD, FANCD	ENSG00000144554	Fanconi anemia complementation group D2	3	10026414-10101930	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016117, HPA063742	Approved		Supported	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol	Ovarian cancer:5.00e-5 (unfavourable)	Expressed in all	Mixed			testis: 21.7	Mixed		
FANCD2OS	C3orf24, MGC40179	ENSG00000163705	FANCD2 opposite strand	3	10081317-10108231	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	96	testis: 54.7	bone marrow: 0.5	Cell line enhanced		CACO-2: 1.1
FANCE	FACE, FAE	ENSG00000112039	Fanconi anemia complementation group E	6	35452361-35467103	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB014893	Enhanced		Supported	Nucleoplasm	Liver cancer:2.08e-9 (unfavourable), Endometrial cancer:6.25e-4 (unfavourable)	Expressed in all	Mixed			skin: 16.1	Expressed in all		
FANCF	FAF	ENSG00000183161	Fanconi anemia complementation group F	11	22622519-22626787	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:2.27e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 10.8	Cell line enhanced		SCLC-21H: 29.4
FANCG	FAG, XRCC9	ENSG00000221829	Fanconi anemia complementation group G	9	35073835-35080016	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB008105, HPA045335	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:2.38e-7 (unfavourable), Liver cancer:2.02e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 8.7	Expressed in all		
FANCI	FLJ10719, KIAA1794	ENSG00000140525	Fanconi anemia complementation group I	15	89243949-89317261	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039972, HPA040379	Approved		Enhanced	Nucleoplasm	Renal cancer:2.71e-13 (unfavourable), Liver cancer:1.11e-4 (unfavourable), Pancreatic cancer:3.59e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 60.4	lymph node: 28.6	Expressed in all		
FANCL	FAAP43, FLJ10335, PHF9, Pog	ENSG00000115392	Fanconi anemia complementation group L	2	58159243-58241372	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033842, HPA036685, HPA036686	Supported		Approved	Nuclear bodies<br>Vesicles	Renal cancer:1.12e-7 (unfavourable), Liver cancer:2.81e-7 (unfavourable), Urothelial cancer:7.80e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 44.6	Expressed in all		
FANCM	FAAP250, KIAA1596	ENSG00000187790	Fanconi anemia complementation group M	14	45135940-45200890	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055144			Supported	Nucleoplasm		Mixed	Tissue enhanced		testis: 14.0	endometrium: 4.3	Mixed		
FANK1		ENSG00000203780	Fibronectin type III and ankyrin repeat domains 1	10	125896539-126009592	Predicted intracellular proteins	Evidence at protein level	HPA038413			Supported	Nucleoplasm	Endometrial cancer:3.83e-4 (favourable)	Mixed	Group enriched	5	fallopian tube: 55.3;testis: 92.6	epididymis: 14.3	Cell line enhanced		CAPAN-2: 16.8;RPTEC TERT1: 10.1
FARP1	CDEP, MGC87400, PLEKHC2, PPP1R75	ENSG00000152767	FERM, ARH/RhoGEF and pleckstrin domain protein 1	13	98142562-98455176	Predicted intracellular proteins	Evidence at protein level	HPA000760			Supported	Cytosol	Renal cancer:1.39e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 58.8	Mixed		
FARP2	FIR, FRG, KIAA0793, PLEKHC3	ENSG00000006607	FERM, ARH/RhoGEF and pleckstrin domain protein 2	2	241356243-241494841	Predicted intracellular proteins	Evidence at protein level	HPA031226, HPA055592	Approved		Approved	Cytosol		Expressed in all	Expressed in all			testis: 37.9	Expressed in all		
FARS2	dJ236A3.1, FARS1	ENSG00000145982	Phenylalanyl-tRNA synthetase 2, mitochondrial	6	5261044-5771580	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018148, HPA028836	Approved		Approved	Plasma membrane	Renal cancer:1.24e-6 (favourable), Colorectal cancer:5.14e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 24.5	Expressed in all		
FARSA	CML33, FARSL, FARSLA	ENSG00000179115	Phenylalanyl-tRNA synthetase alpha subunit	19	12922479-12934037	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001911	Approved		Supported	Cytosol	Cervical cancer:8.23e-4 (favourable), Stomach cancer:8.32e-4 (favourable), Endometrial cancer:9.22e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 67.2	Expressed in all		
FARSB	FARSLB, FRSB, PheHB	ENSG00000116120	Phenylalanyl-tRNA synthetase beta subunit	2	222570536-222656337	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036677, HPA036678, HPA061398	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:6.45e-10 (unfavourable), Renal cancer:3.21e-5 (unfavourable), Urothelial cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.4	Expressed in all		
FASN	FAS, SDR27X1	ENSG00000169710	Fatty acid synthase	17	82078333-82098332	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005192, HPA006461, CAB015417, HPA056108	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 290.7	Expressed in all		
FASTK	FAST	ENSG00000164896	Fas activated serine/threonine kinase	7	151076593-151080866	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031621, CAB032539	Approved		Approved	Nuclear speckles<br>Mitochondria	Pancreatic cancer:3.99e-4 (favourable), Colorectal cancer:4.73e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 41.7	Expressed in all		
FASTKD1	FLJ21901	ENSG00000138399	FAST kinase domains 1	2	169529749-169573875	Predicted intracellular proteins	Evidence at protein level	HPA043719	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			rectum: 26.5	Expressed in all		
FASTKD2	KIAA0971	ENSG00000118246	FAST kinase domains 2	2	206765357-206792509	Predicted intracellular proteins	Evidence at protein level	HPA067191			Supported	Mitochondria	Liver cancer:8.29e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 30.2	Expressed in all		
FASTKD3	FLJ23274, MGC5297	ENSG00000124279	FAST kinase domains 3	5	7859159-7869037	Predicted intracellular proteins	Evidence at protein level	HPA068525, HPA074462	Approved		Supported	Nucleus<br>Mitochondria	Liver cancer:1.87e-5 (unfavourable), Urothelial cancer:8.53e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 10.4	Expressed in all		
FASTKD5	FLJ13149	ENSG00000215251	FAST kinase domains 5	20	3146519-3159897	Predicted intracellular proteins	Evidence at protein level	HPA043833	Approved				Renal cancer:8.19e-8 (favourable), Liver cancer:4.05e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 22.9	Expressed in all		
FAU	asr1, FLJ22986, Fub1, Fubi, MNSFbeta, RPS30, S30	ENSG00000149806	FAU, ubiquitin like and ribosomal protein S30 fusion	11	65120628-65122473	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA059015	Supported		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 1268.8	Expressed in all		
FAXC	C6orf168, dJ273F20, MGC2817	ENSG00000146267	Failed axon connections homolog	6	99271169-99350062	Predicted intracellular proteins	Evidence at protein level	HPA039106	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		cerebral cortex: 23.5	seminal vesicle: 14.9	Cell line enhanced		HAP1: 24.5;SCLC-21H: 40.3;SH-SY5Y: 25.2
FBF1	ALB, FBF-1, FLJ00103, KIAA1863	ENSG00000188878	Fas binding factor 1	17	75909574-75941140	Predicted intracellular proteins	Evidence at protein level	HPA023677			Supported	Centrosome		Mixed	Tissue enhanced		testis: 32.9	skin: 15.4	Mixed		
FBL	FIB, FLRN, RNU3IP1	ENSG00000105202	Fibrillarin	19	39834458-39846414	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001514, HPA049546	Supported		Enhanced	Nucleoli fibrillar center	Renal cancer:4.52e-6 (unfavourable), Liver cancer:1.32e-4 (unfavourable), Breast cancer:1.65e-4 (favourable)	Expressed in all	Expressed in all			ovary: 212.6	Expressed in all		
FBLIM1	CAL, FBLP-1, migfilin	ENSG00000162458	Filamin binding LIM protein 1	1	15756607-15786594	Predicted intracellular proteins	Evidence at protein level	HPA025287, HPA072750	Approved		Enhanced	Nucleoli fibrillar center<br>Cell Junctions<br>Focal adhesion sites	Cervical cancer:4.07e-4 (unfavourable), Melanoma:6.15e-4 (unfavourable), Renal cancer:8.64e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 101.8	Cell line enhanced		HUVEC TERT2: 210.1;TIME: 323.6
FBLL1	LOC345630	ENSG00000188573	Fibrillarin-like 1	5	168529116-168530634	Predicted intracellular proteins	Evidence at transcript level	HPA049546			Approved	Nucleus<br>Nucleoli fibrillar center		Mixed	Tissue enhanced		cerebral cortex: 19.0	testis: 4.3	Group enriched	6	SCLC-21H: 24.5;SH-SY5Y: 18.4
FBP1	FBP	ENSG00000165140	Fructose-bisphosphatase 1	9	94603133-94640249	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005857, HPA012513, CAB033869	Enhanced		Uncertain	Mitochondria	Renal cancer:6.86e-7 (favourable), Urothelial cancer:1.64e-5 (favourable), Liver cancer:1.79e-4 (favourable), Endometrial cancer:5.16e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 443.9	duodenum: 329.6	Cell line enhanced		HaCaT: 66.7;MCF7: 184.8;RT4: 124.5;U-698: 78.4
FBP2		ENSG00000130957	Fructose-bisphosphatase 2	9	94558720-94593793	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012513, HPA055286	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	8	skeletal muscle: 266.1	stomach: 32.7	Cell line enhanced		BEWO: 3.9;MCF7: 2.4;SiHa: 3.0
FBRS	FBS, FBS1, FLJ11618	ENSG00000156860	Fibrosin	16	30658431-30670814	Predicted intracellular proteins	Evidence at protein level	HPA044117	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 78.0	Expressed in all		
FBRSL1	KIAA1545	ENSG00000112787	Fibrosin like 1	12	132489551-132585188	Predicted intracellular proteins	Evidence at protein level	HPA049880	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:1.17e-4 (favourable), Urothelial cancer:7.21e-4 (favourable), Prostate cancer:9.82e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.9	Expressed in all		
FBXL12	Fbl12, FLJ20188	ENSG00000127452	F-box and leucine rich repeat protein 12	19	9810267-9827816	Predicted intracellular proteins	Evidence at protein level	HPA002843			Approved	Mitochondria	Liver cancer:1.41e-4 (unfavourable), Head and neck cancer:3.21e-4 (favourable), Melanoma:4.96e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 21.7	Expressed in all		
FBXL13	DRC6, Fbl13, MGC21636	ENSG00000161040	F-box and leucine rich repeat protein 13	7	102813230-103074843	Predicted intracellular proteins	Evidence at protein level	HPA057232	Uncertain					Mixed	Group enriched	5	fallopian tube: 7.9;testis: 37.4	stomach: 4.5	Cell line enhanced		HUVEC TERT2: 11.6;U-266/84: 12.5;U-87 MG: 9.3;U-937: 9.5
FBXL14	Fbl14, MGC40195	ENSG00000171823	F-box and leucine rich repeat protein 14	12	1565993-1594165	Predicted intracellular proteins	Evidence at protein level	HPA053889	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:9.04e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 15.2	Mixed		
FBXL15	Fbl15, FBXO37, MGC11279	ENSG00000107872	F-box and leucine rich repeat protein 15	10	102419189-102423136	Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.82e-4 (favourable), Urothelial cancer:7.92e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 13.4	Mixed		
FBXL16	C16orf22, Fbl16, MGC33974	ENSG00000127585	F-box and leucine rich repeat protein 16	16	692498-705829	Predicted intracellular proteins	Evidence at protein level	HPA039504, HPA056354	Enhanced				Endometrial cancer:6.24e-5 (unfavourable), Pancreatic cancer:7.34e-5 (favourable), Renal cancer:1.87e-4 (favourable)	Expressed in all	Tissue enriched	23	cerebral cortex: 186.4	testis: 8.0	Cell line enhanced		AN3-CA: 16.9;SCLC-21H: 35.4;SH-SY5Y: 23.8
FBXL18	Fbl18, FLJ11467	ENSG00000155034	F-box and leucine rich repeat protein 18	7	5431335-5513798	Predicted intracellular proteins	Evidence at protein level	HPA036049			Approved	Nucleoplasm<br>Cytosol	Cervical cancer:7.88e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 9.5	Expressed in all		
FBXL19	CXXC11, DKFZp434K0410, Fbl19, JHDM1C	ENSG00000099364	F-box and leucine rich repeat protein 19	16	30923055-30948783	Predicted intracellular proteins	Evidence at protein level	HPA035317			Approved	Intermediate filaments	Cervical cancer:3.27e-4 (unfavourable), Liver cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.5	Expressed in all		
FBXL2	FBL2, FBL3	ENSG00000153558	F-box and leucine rich repeat protein 2	3	33277025-33403662	Predicted intracellular proteins	Evidence at protein level	HPA061783			Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Renal cancer:3.35e-4 (favourable)	Mixed	Mixed			cerebral cortex: 5.8	Cell line enhanced		CAPAN-2: 6.7
FBXL20	Fbl2, Fbl20, MGC15482	ENSG00000108306	F-box and leucine rich repeat protein 20	17	39252644-39402523	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044748, HPA050397	Uncertain		Supported	Microtubules	Ovarian cancer:9.54e-4 (unfavourable)	Expressed in all	Mixed			testis: 23.0	Expressed in all		
FBXL22	Fbl22, FLJ39626	ENSG00000197361	F-box and leucine rich repeat protein 22	15	63597353-63602428	Predicted intracellular proteins	Evidence at protein level	HPA047624, HPA054627	Uncertain		Uncertain	Nucleoli<br>Cytosol		Mixed	Tissue enhanced		endometrium: 50.4;seminal vesicle: 44.0;smooth muscle: 46.1	prostate: 23.3	Cell line enhanced		MCF7: 3.7;SCLC-21H: 6.3
FBXL3	FBL3, FBL3A, FBXL3A	ENSG00000005812	F-box and leucine rich repeat protein 3	13	76992598-77027195	Predicted intracellular proteins	Evidence at protein level	HPA053283, HPA065626			Enhanced	Nuclear bodies		Expressed in all	Expressed in all			thyroid gland: 80.8	Expressed in all		
FBXL4	FBL4, FBL5	ENSG00000112234	F-box and leucine rich repeat protein 4	6	98868538-98948006	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029140, CAB033362	Approved		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 25.3	Expressed in all		
FBXL5	FBL4, FBL5, FLR1	ENSG00000118564	F-box and leucine rich repeat protein 5	4	15604539-15681679	Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.18e-5 (favourable)	Expressed in all	Expressed in all			kidney: 135.1	Expressed in all		
FBXL6	FBL6	ENSG00000182325	F-box and leucine rich repeat protein 6	8	144355431-144359376	Predicted intracellular proteins	Evidence at protein level	HPA008867			Approved	Nucleus	Renal cancer:4.49e-10 (unfavourable)	Expressed in all	Mixed			duodenum: 9.0	Mixed		
FBXL7	FBL6, FBL7, KIAA0840	ENSG00000183580	F-box and leucine rich repeat protein 7	5	15500196-15939795	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055464	Uncertain				Liver cancer:1.29e-4 (unfavourable), Thyroid cancer:6.69e-4 (unfavourable)	Expressed in all	Mixed			endometrium,smooth muscle: 36.6	Mixed		
FBXL8	Fbl8	ENSG00000135722	F-box and leucine rich repeat protein 8	16	67159931-67164570	Predicted intracellular proteins	Evidence at protein level	HPA035587, HPA035588	Uncertain		Approved	Golgi apparatus	Endometrial cancer:5.39e-4 (favourable)	Expressed in all	Expressed in all			prostate: 29.2	Mixed		
FBXO10	FBX10	ENSG00000147912	F-box protein 10	9	37510892-37576349	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002863, HPA072721	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 16.4	Cell line enhanced		HHSteC: 29.5
FBXO11	FBX11, UBR6	ENSG00000138081	F-box protein 11	2	47789316-47905793	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002690			Supported	Nucleus		Expressed in all	Expressed in all			testis: 75.4	Expressed in all		
FBXO15	FBX15, MGC39671	ENSG00000141665	F-box protein 15	18	74073353-74147865	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 4.9;testis: 6.6	cerebral cortex,epididymis: 2.0	Cell line enhanced		SCLC-21H: 2.6
FBXO16	FBX16	ENSG00000214050	F-box protein 16	8	28348287-28490318	Predicted intracellular proteins	Evidence at transcript level	HPA053955, HPA058676	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol	Ovarian cancer:6.70e-5 (favourable)	Mixed	Tissue enhanced		epididymis: 22.4	thyroid gland: 12.1	Cell line enhanced		AF22: 19.5
FBXO17	FBG4, Fbx17, FBXO26, FLJ11798, FLJ25205, MGC9379	ENSG00000269190	F-box protein 17	19	38941401-38975910	Predicted intracellular proteins	Evidence at protein level						Glioma:2.10e-4 (unfavourable), Endometrial cancer:5.67e-4 (unfavourable), Stomach cancer:5.91e-4 (unfavourable)	Mixed	Mixed			kidney: 14.4	Mixed		
FBXO2	Fbg1, Fbs1, FBX2, Nfb42, OCP1	ENSG00000116661	F-box protein 2	1	11648367-11655785	Predicted intracellular proteins	Evidence at protein level	HPA005472			Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.45e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 80.5	adrenal gland: 27.7	Cell line enhanced		CACO-2: 75.6;Hep G2: 131.1;SiHa: 376.0
FBXO21	FBX21, KIAA0875	ENSG00000135108	F-box protein 21	12	117141988-117190531	Predicted intracellular proteins	Evidence at protein level	HPA062411, HPA071452	Approved		Approved	Mitochondria	Renal cancer:2.05e-8 (favourable)	Expressed in all	Expressed in all			fallopian tube: 204.6	Expressed in all		
FBXO22	FBX22, FISTC1	ENSG00000167196	F-box protein 22	15	75903859-75942510	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			testis: 15.1	Expressed in all		
FBXO24	FBX24	ENSG00000106336	F-box protein 24	7	100583982-100601117	Predicted intracellular proteins	Evidence at protein level	HPA050951	Enhanced					Mixed	Tissue enriched	36	testis: 71.4	ovary: 1.9	Cell line enhanced		U-2 OS: 2.7
FBXO25	FBX25	ENSG00000147364	F-box protein 25	8	406428-477967	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Cervical cancer:5.38e-5 (favourable), Renal cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 151.3	Mixed		
FBXO27	Fbg5, Fbx27	ENSG00000161243	F-box protein 27	19	38990714-39032785	Predicted intracellular proteins	Evidence at protein level	HPA046800, HPA062242	Approved		Approved	Nucleoplasm	Endometrial cancer:3.53e-5 (unfavourable), Breast cancer:2.15e-4 (favourable), Glioma:7.83e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 22.7	esophagus: 8.4	Cell line enhanced		RT4: 14.1
FBXO28	CENP-30, Fbx28, FLJ10766, KIAA0483	ENSG00000143756	F-box protein 28	1	224114087-224162047	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003289			Supported	Nucleus<br>Focal adhesion sites		Expressed in all	Expressed in all			parathyroid gland,skin: 25.0	Expressed in all		
FBXO3	FBA, FBX3	ENSG00000110429	F-box protein 3	11	33740939-33774543	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002467			Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.46e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 89.6	Expressed in all		
FBXO30	Fbx30, MGC21674	ENSG00000118496	F-box protein 30	6	145793502-145814753	Predicted intracellular proteins	Evidence at protein level	HPA012583			Approved	Microtubules		Expressed in all	Mixed			thyroid gland: 13.5	Expressed in all		
FBXO32	ATROGIN1, Fbx32, MAFbx	ENSG00000156804	F-box protein 32	8	123497889-123541206	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065209			Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 146.8	skeletal muscle: 88.6	Group enriched	6	HDLM-2: 163.0;U-251 MG: 43.0
FBXO33	Fbx33	ENSG00000165355	F-box protein 33	14	39397669-39432500	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046657	Approved		Approved	Nucleoplasm	Renal cancer:4.58e-4 (favourable), Lung cancer:4.94e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 33.3	Expressed in all		
FBXO34	Fbx34, FLJ20725	ENSG00000178974	F-box protein 34	14	55271303-55361918	Predicted intracellular proteins	Evidence at protein level	HPA052592	Uncertain		Approved	Nuclear speckles	Renal cancer:1.20e-13 (favourable)	Expressed in all	Expressed in all			testis: 47.1	Expressed in all		
FBXO36	Fbx36, FLJ37592	ENSG00000153832	F-box protein 36	2	229922302-230013109	Predicted intracellular proteins	Evidence at transcript level	HPA053865			Approved	Nucleus<br>Nucleoli	Endometrial cancer:2.28e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 17.6	thyroid gland: 12.5	Mixed		
FBXO38	Fbx38, FLJ13962, MOKA, SP329	ENSG00000145868	F-box protein 38	5	148383935-148442836	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034821, HPA041444	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytokinetic bridge<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 30.8	Expressed in all		
FBXO39	CT144, Fbx39, MGC35179	ENSG00000177294	F-box protein 39	17	6776223-6797101	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	62	testis: 53.5	ovary: 0.8	Not detected		
FBXO4	FBX4	ENSG00000151876	F-box protein 4	5	41925254-41941743	Predicted intracellular proteins	Evidence at protein level	HPA003362			Approved	Nucleus	Renal cancer:1.28e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 21.0	Mixed		
FBXO40	Fbx40, KIAA1195	ENSG00000163833	F-box protein 40	3	121593119-121630295	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	36	heart muscle: 56.2;skeletal muscle: 54.0	prostate: 1.5	Not detected		
FBXO41	Fbx41, KIAA1940	ENSG00000163013	F-box protein 41	2	73254682-73284431	Predicted intracellular proteins	Evidence at protein level	HPA055246, HPA058386			Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:5.76e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 38.3	parathyroid gland: 11.1	Cell line enhanced		Daudi: 33.9
FBXO42	Fbx42, KIAA1332	ENSG00000037637	F-box protein 42	1	16246839-16352454	Predicted intracellular proteins	Evidence at protein level	HPA025071	Approved		Approved	Nucleoplasm	Liver cancer:3.72e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 29.9	Expressed in all		
FBXO43	Fbx43	ENSG00000156509	F-box protein 43	8	100133360-100145800	Predicted intracellular proteins	Evidence at protein level	HPA024292, HPA024295, HPA024824	Uncertain					Mixed	Tissue enriched	18	testis: 9.8	tonsil: 0.5	Mixed		
FBXO44	FBG3, FBX30, Fbx44, Fbxo6a, MGC14140	ENSG00000132879	F-box protein 44	1	11654375-11663327	Predicted intracellular proteins	Evidence at protein level	HPA003363	Approved		Approved	Nucleoplasm	Renal cancer:6.29e-5 (favourable), Pancreatic cancer:2.63e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 98.1	Mixed		
FBXO45	Fbx45	ENSG00000174013	F-box protein 45	3	196568611-196589059	Predicted intracellular proteins	Evidence at protein level	HPA040730	Uncertain		Approved	Cytosol	Prostate cancer:1.16e-5 (unfavourable), Renal cancer:4.93e-5 (unfavourable), Liver cancer:7.61e-5 (unfavourable), Lung cancer:3.77e-4 (unfavourable)	Expressed in all	Mixed			testis: 22.3	Expressed in all		
FBXO46	20D7-FC4, Fbx46, FBXO34L	ENSG00000177051	F-box protein 46	19	45710629-45730904	Predicted intracellular proteins	Evidence at protein level	HPA049390	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol	Urothelial cancer:5.09e-6 (favourable), Endometrial cancer:2.13e-5 (unfavourable), Liver cancer:1.11e-4 (unfavourable), Renal cancer:5.33e-4 (unfavourable), Head and neck cancer:5.44e-4 (favourable), Pancreatic cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 17.7	Expressed in all		
FBXO47		ENSG00000204952	F-box protein 47	17	38936432-38967402	Predicted intracellular proteins	Evidence at transcript level	HPA057438	Uncertain					Not detected	Tissue enriched	72	testis: 7.2	all non-specific tissues: 0.0	Not detected		
FBXO48		ENSG00000204923	F-box protein 48	2	68459419-68467258	Predicted intracellular proteins	Evidence at protein level	HPA049775, HPA054782	Uncertain		Approved	Nuclear bodies		Expressed in all	Mixed			skin: 3.0	Mixed		
FBXO5	EMI1, FBX5, Fbxo31	ENSG00000112029	F-box protein 5	6	152970519-152983579	Predicted intracellular proteins	Evidence at protein level	CAB008106, HPA029048	Approved		Supported	Nucleoplasm	Stomach cancer:8.65e-4 (favourable)	Expressed in all	Mixed			bone marrow: 27.1	Expressed in all		
FBXO6	FBG2, FBS2, FBX6, Fbx6b	ENSG00000116663	F-box protein 6	1	11664124-11674354	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA051175	Approved				Renal cancer:7.83e-6 (unfavourable), Urothelial cancer:5.90e-4 (favourable), Ovarian cancer:7.12e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 21.4	Mixed		
FBXO7	Fbx, FBX7, PARK15	ENSG00000100225	F-box protein 7	22	32474676-32498829	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032113, HPA032114, CAB034296	Uncertain		Supported	Nucleus<br>Cytosol	Renal cancer:2.66e-10 (favourable), Colorectal cancer:1.08e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 225.1	Expressed in all		
FBXO8	FBS, FBX8	ENSG00000164117	F-box protein 8	4	174236658-174284264	Predicted intracellular proteins	Evidence at transcript level	HPA002885	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.29e-7 (favourable)	Expressed in all	Expressed in all			placenta: 45.0	Expressed in all		
FBXO9	FBX9, NY-REN-57	ENSG00000112146	F-box protein 9	6	53051991-53100873	Predicted intracellular proteins	Evidence at protein level	HPA064246			Approved	Centrosome	Ovarian cancer:1.51e-4 (favourable), Pancreatic cancer:1.82e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 107.5	Expressed in all		
FBXW10	C17orf1, C17orf1A, Fbw10, HREP, SM2SH2	ENSG00000171931	F-box and WD repeat domain containing 10	17	18744024-18779349	Predicted intracellular proteins	Evidence at transcript level	HPA047457			Approved	Nucleoplasm		Not detected	Tissue enriched	20	testis: 18.3	epididymis: 0.9	Cell line enhanced		A549: 2.0;CAPAN-2: 1.0;HaCaT: 1.4
FBXW11	BTRC2, BTRCP2, Fbw11, Fbw1b, FBXW1B, Hos, KIAA0696	ENSG00000072803	F-box and WD repeat domain containing 11	5	171861549-172006873	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062578, HPA072204	Approved		Approved	Nucleoli<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 72.6	Expressed in all		
FBXW2	FBW2, Fwd2, Md6	ENSG00000119402	F-box and WD repeat domain containing 2	9	120751978-120793412	Predicted intracellular proteins	Evidence at protein level	HPA067878	Approved		Approved	Nucleoplasm	Renal cancer:1.38e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.6	Expressed in all		
FBXW4	dactylin, Fbw4, SHFM3	ENSG00000107829	F-box and WD repeat domain containing 4	10	101610664-101695295	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043496	Approved		Approved	Golgi apparatus	Renal cancer:3.41e-5 (favourable), Pancreatic cancer:4.67e-4 (favourable), Endometrial cancer:4.91e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 80.8	Expressed in all		
FBXW5	DKFZP434B205, Fbw5, MGC20962	ENSG00000159069	F-box and WD repeat domain containing 5	9	136940435-136944696	Predicted intracellular proteins	Evidence at protein level	HPA046615	Approved		Approved	Mitochondria	Endometrial cancer:1.02e-4 (favourable), Renal cancer:4.74e-4 (favourable)	Expressed in all	Expressed in all			testis: 163.1	Expressed in all		
FBXW8	FBW6, FBW8, FBX29, FBXO29	ENSG00000174989	F-box and WD repeat domain containing 8	12	116910956-117031148	Predicted intracellular proteins	Evidence at protein level	HPA038850, HPA038851	Enhanced		Supported	Cytosol		Expressed in all	Expressed in all			thyroid gland: 16.2	Expressed in all		
FBXW9	Fbw9, MGC10870	ENSG00000132004	F-box and WD repeat domain containing 9	19	12688053-12696643	Predicted intracellular proteins	Evidence at protein level	HPA042087	Approved		Approved	Cytosol		Expressed in all	Mixed			fallopian tube: 21.0	Expressed in all		
FCF1	Bka, C14orf111, CGI-35, UTP24	ENSG00000119616	FCF1 rRNA-processing protein	14	74713144-74738620	Predicted intracellular proteins	Evidence at protein level	HPA046681	Approved		Approved	Nucleoplasm	Liver cancer:5.54e-6 (unfavourable), Renal cancer:2.26e-4 (favourable), Pancreatic cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 72.6	Expressed in all		
FCHO1	KIAA0290	ENSG00000130475	FCH domain only 1	19	17747718-17788568	Predicted intracellular proteins	Evidence at protein level	HPA041653, HPA062981	Approved		Enhanced	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		lymph node: 28.8	spleen: 19.9	Cell line enhanced		Daudi: 44.6
FCHO2		ENSG00000157107	FCH domain only 2	5	72955981-73090522	Predicted intracellular proteins	Evidence at protein level	HPA037685, HPA037686, HPA077850	Enhanced		Approved	Vesicles<br>Centrosome<br>Cytosol	Renal cancer:7.00e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.6	Mixed		
FCHSD1	FLJ00007	ENSG00000197948	FCH and double SH3 domains 1	5	141639302-141651419	Predicted intracellular proteins	Evidence at protein level	HPA043795	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.19e-6 (unfavourable), Urothelial cancer:1.21e-4 (favourable), Testis cancer:4.77e-4 (unfavourable), Breast cancer:8.62e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 41.1	Mixed		
FCHSD2	KIAA0769, SH3MD3	ENSG00000137478	FCH and double SH3 domains 2	11	72836745-73142261	Predicted intracellular proteins	Evidence at protein level	HPA038545, HPA038546	Uncertain		Approved	Nuclear speckles<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Colorectal cancer:1.71e-4 (favourable)	Expressed in all	Expressed in all			spleen: 64.1	Expressed in all		
FDPS		ENSG00000160752	Farnesyl diphosphate synthase	1	155308748-155320666	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028200	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:7.35e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 186.4	Expressed in all		
FDX1	ADX, FDX	ENSG00000137714	Ferredoxin 1	11	110429883-110464881	Predicted intracellular proteins	Evidence at protein level	HPA041630, HPA062087	Enhanced		Enhanced	Mitochondria	Renal cancer:3.58e-7 (favourable), Stomach cancer:2.53e-4 (favourable)	Expressed in all	Tissue enriched	11	adrenal gland: 387.5	seminal vesicle: 36.5	Expressed in all		
FDX2	FDX1L, MGC19604	ENSG00000267673	Ferredoxin 2	19	10310045-10316015	Predicted intracellular proteins	Evidence at protein level	HPA043986	Approved					Expressed in all	Expressed in all			cerebral cortex: 47.4	Expressed in all		
FDXACB1	hCG_2033039, LOC91893	ENSG00000255561	Ferredoxin-fold anticodon binding domain containing 1	11	111874056-111881243	Predicted intracellular proteins	Evidence at protein level	HPA039012, HPA061375	Uncertain		Uncertain	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 6.8	Mixed		
FDXR	ADXR	ENSG00000161513	Ferredoxin reductase	17	74862497-74873031	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB008597, CAB009818, HPA044393, HPA053673	Enhanced		Enhanced	Mitochondria	Endometrial cancer:2.38e-4 (favourable)	Expressed in all	Tissue enriched	6	adrenal gland: 232.0	testis: 39.1	Expressed in all		
FECH		ENSG00000066926	Ferrochelatase	18	57548283-57586772	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044100, HPA048177	Approved				Renal cancer:2.38e-10 (favourable)	Expressed in all	Expressed in all			bone marrow: 93.3	Expressed in all		
FEM1A		ENSG00000141965	Fem-1 homolog A	19	4791681-4801273	Predicted intracellular proteins	Evidence at protein level	HPA016565, HPA063622			Supported	Nucleus<br>Golgi apparatus<br>Cytosol		Mixed	Tissue enriched	7	skeletal muscle: 94.0	parathyroid gland: 13.6	Expressed in all		
FEM1B		ENSG00000169018	Fem-1 homolog B	15	68277803-68295865	Predicted intracellular proteins	Evidence at protein level	HPA041920, HPA042192	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 105.4	Expressed in all		
FEM1C	EUROIMAGE686608, EUROIMAGE783647, FEM1A, KIAA1785	ENSG00000145780	Fem-1 homolog C	5	115520908-115544894	Predicted intracellular proteins	Evidence at protein level	HPA059919, HPA060977	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.55e-4 (unfavourable), Colorectal cancer:1.83e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 40.2	Expressed in all		
FEN1	FEN-1, MF1, RAD2	ENSG00000168496	Flap structure-specific endonuclease 1	11	61792637-61797244	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002262, HPA006748	Enhanced		Enhanced	Nucleoplasm<br>Nucleoli	Liver cancer:3.39e-6 (unfavourable), Renal cancer:5.73e-6 (unfavourable), Ovarian cancer:7.85e-4 (favourable), Stomach cancer:9.46e-4 (favourable)	Expressed in all	Mixed			lymph node: 34.8	Expressed in all		
FER	PPP1R74, TYK3	ENSG00000151422	FER tyrosine kinase	5	108747822-109196841	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007641, CAB022464	Approved		Supported	Cytosol	Renal cancer:5.55e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 19.4	Cell line enhanced		RPMI-8226: 62.9
FERD3L	bHLHa31, N-TWIST, NATO3	ENSG00000146618	Fer3 like bHLH transcription factor	7	19144782-19145421	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043494	Uncertain					Not detected	Not detected			cerebral cortex: 0.5	Cell line enriched	129	SCLC-21H: 12.8
FERMT1	C20orf42, FLJ20116, KIND1, UNC112A, URP1	ENSG00000101311	Fermitin family member 1	20	6074845-6123544	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039778, HPA041966	Approved				Pancreatic cancer:6.60e-4 (unfavourable)	Expressed in all	Mixed			rectum: 30.8	Cell line enhanced		CAPAN-2: 58.4;HaCaT: 68.4;HBEC3-KT: 56.3
FERMT2	KIND2, mig-2, PLEKHC1, UNC112B	ENSG00000073712	Fermitin family member 2	14	52857268-52952435	Predicted intracellular proteins	Evidence at protein level	HPA040505	Uncertain		Supported	Nucleoplasm<br>Focal adhesion sites		Expressed in all	Mixed			smooth muscle: 222.9	Mixed		
FERMT3	KIND3, MGC10966, MIG-2, MIG2B, UNC112C, URP2	ENSG00000149781	Fermitin family member 3	11	64206678-64223886	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065231			Approved	Vesicles	Renal cancer:2.12e-5 (unfavourable), Endometrial cancer:9.89e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 114.2	lymph node: 101.2	Cell line enhanced		HEL: 276.6;HMC-1: 277.8
FES	FPS	ENSG00000182511	FES proto-oncogene, tyrosine kinase	15	90883695-90895776	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001376	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol	Colorectal cancer:5.78e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 96.5	Cell line enhanced		HEL: 56.3;HL-60: 45.0;HMC-1: 100.9;NB-4: 46.6;THP-1: 73.8
FEV	Pet-1	ENSG00000163497	FEV, ETS transcription factor	2	218981087-218985657	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067679		Supported	Supported	Nuclear speckles	Pancreatic cancer:4.85e-4 (favourable)	Group enriched	Tissue enhanced		adrenal gland: 2.1;duodenum: 2.9;prostate: 1.9;stomach: 2.4	small intestine: 1.6	Group enriched	6	HMC-1: 22.4;SH-SY5Y: 34.6
FEZ1	UNC-76	ENSG00000149557	Fasciculation and elongation protein zeta 1	11	125445745-125496317	Predicted intracellular proteins	Evidence at protein level	HPA038490			Supported	Microtubules<br>Cytosol	Renal cancer:2.16e-6 (unfavourable), Cervical cancer:9.06e-5 (unfavourable)	Tissue enriched	Tissue enriched	10	cerebral cortex: 410.9	urinary bladder: 41.3	Cell line enhanced		AF22: 156.1;NTERA-2: 145.3;SCLC-21H: 181.1
FEZ2		ENSG00000171055	Fasciculation and elongation protein zeta 2	2	36531805-36646087	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035978	Uncertain		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol	Liver cancer:7.79e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 78.6	Expressed in all		
FEZF1	ZNF312B	ENSG00000128610	FEZ family zinc finger 1	7	122301394-122310691	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064639, HPA073693	Approved		Supported	Nucleus<br>Cytosol		Mixed	Tissue enriched	44	testis: 7.0	adipose tissue,cerebral cortex: 0.1	Group enriched	10	NTERA-2: 161.5;SCLC-21H: 82.6
FEZF2	FEZL, FKSG36, FLJ10142, TOF, Zfp312, ZNF312	ENSG00000153266	FEZ family zinc finger 2	3	62369681-62374324	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enriched	30	cerebral cortex: 11.7	colon: 0.3	Cell line enhanced		AF22: 1.4;NTERA-2: 1.0
FGD1	FGDY, ZFYVE3	ENSG00000102302	FYVE, RhoGEF and PH domain containing 1	X	54445454-54496166	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000911	Uncertain		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:2.10e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 9.5	Mixed		
FGD2	ZFYVE4	ENSG00000146192	FYVE, RhoGEF and PH domain containing 2	6	37005646-37029070	Predicted intracellular proteins	Evidence at protein level	HPA029145, HPA049692	Approved					Mixed	Tissue enhanced		spleen: 42.4	lymph node: 25.0	Group enriched	6	CAPAN-2: 2.4;Daudi: 8.2;HDLM-2: 10.5;U-698: 6.3
FGD3	FLJ00004, ZFYVE5	ENSG00000127084	FYVE, RhoGEF and PH domain containing 3	9	92947451-93036236	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020963, HPA021018	Approved		Approved	Nucleus<br>Cytosol	Head and neck cancer:2.23e-7 (favourable), Cervical cancer:5.51e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 31.4	spleen: 29.0	Cell line enhanced		HMC-1: 35.3;Karpas-707: 40.4;RT4: 25.9
FGD4	CMT4H, frabin, FRABP, ZFYVE6	ENSG00000139132	FYVE, RhoGEF and PH domain containing 4	12	32399529-32646050	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039235	Approved		Supported	Actin filaments	Renal cancer:7.16e-5 (favourable)	Expressed in all	Expressed in all			ovary: 30.2	Mixed		
FGD5	FLJ00274, FLJ39957, ZFYVE23	ENSG00000154783	FYVE, RhoGEF and PH domain containing 5	3	14810853-14934565	Predicted intracellular proteins	Evidence at protein level	HPA014536, HPA019191	Uncertain				Urothelial cancer:7.50e-4 (favourable)	Expressed in all	Mixed			spleen: 35.0	Group enriched	8	HUVEC TERT2: 80.3;TIME: 64.8;U-2197: 19.8
FGD6	FLJ11183, ZFYVE24	ENSG00000180263	FYVE, RhoGEF and PH domain containing 6	12	95076749-95217482	Predicted intracellular proteins	Evidence at protein level	HPA007974	Approved		Approved	Vesicles	Renal cancer:5.46e-6 (unfavourable), Pancreatic cancer:4.62e-5 (unfavourable), Prostate cancer:9.83e-4 (unfavourable)	Expressed in all	Mixed			skin: 9.4	Mixed		
FGF1	AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1	ENSG00000113578	Fibroblast growth factor 1	5	142592178-142698070	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003265, CAB017519	Enhanced				Renal cancer:2.59e-5 (favourable), Thyroid cancer:3.45e-5 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 129.9;kidney: 59.4	heart muscle: 32.8	Cell line enhanced		BJ: 37.6;BJ hTERT+ SV40 Large T+: 33.4;BJ hTERT+ SV40 Large T+ RasG12V: 43.9;HBF TERT88: 62.3;hTEC/SVTERT24-B: 45.5;U-2 OS: 33.6
FGF11	FHF3, FLJ16061, MGC102953, MGC45269	ENSG00000161958	Fibroblast growth factor 11	17	7438273-7444937	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA066605, HPA075188	Enhanced		Approved	Centrosome		Mixed	Tissue enhanced		adrenal gland: 17.3;skin: 13.7	cerebral cortex: 10.3	Cell line enhanced		HaCaT: 16.3
FGF12	FGF12B, FHF1	ENSG00000114279	Fibroblast growth factor 12	3	192139395-192767764	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA071557			Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		adrenal gland: 46.7;cerebral cortex: 52.4;heart muscle: 89.9	spleen: 16.2	Cell line enhanced		AF22: 14.9;NTERA-2: 10.3;SCLC-21H: 28.2;U-251 MG: 12.2;WM-115: 17.4
FGF13	FGF2, FHF2	ENSG00000129682	Fibroblast growth factor 13	X	138614731-139222777	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA002809			Supported	Cytosol		Mixed	Tissue enhanced		parathyroid gland: 108.4	cerebral cortex: 47.9	Cell line enhanced		AF22: 42.4;HAP1: 40.9;U-2197: 64.4;WM-115: 37.0
FGF14	FHF4, SCA27	ENSG00000102466	Fibroblast growth factor 14	13	101710804-102402457	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA049828			Approved	Nucleoli fibrillar center		Tissue enhanced	Tissue enhanced		cerebral cortex: 14.8;cervix, uterine: 22.9;fallopian tube: 17.2	testis: 4.3	Group enriched	7	SCLC-21H: 5.4;SH-SY5Y: 20.7;U-87 MG: 4.1
FGF16	MF4	ENSG00000196468	Fibroblast growth factor 16	X	77447405-77457278	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Not detected	Not detected			adipose tissue: 0.4	Cell line enriched	5	U-2197: 21.1
FGF2	FGFB	ENSG00000138685	Fibroblast growth factor 2	4	122826708-122898236	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB000125	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:9.85e-4 (unfavourable)	Mixed	Mixed			adipose tissue: 26.1	Cell line enhanced		BJ: 206.0;fHDF/TERT166: 215.4
FGF20		ENSG00000078579	Fibroblast growth factor 20	8	16992169-17002181	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Tissue enhanced	Mixed			cervix, uterine: 1.5	Cell line enhanced		BJ hTERT+: 1.3;CAPAN-2: 4.6
FGF6		ENSG00000111241	Fibroblast growth factor 6	12	4428155-4445614	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Not detected	Tissue enriched	8	skeletal muscle: 5.6	esophagus: 0.7	Group enriched	5	NTERA-2: 2.4;REH: 2.4
FGF9		ENSG00000102678	Fibroblast growth factor 9	13	21671383-21704498	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA067007	Enhanced				Renal cancer:1.70e-6 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 12.1	adrenal gland: 4.7	Cell line enhanced		RPTEC TERT1: 2.5;SCLC-21H: 8.0
FGFR1OP	FOP	ENSG00000213066	FGFR1 oncogene partner	6	166999182-167052713	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA071876			Supported	Centrosome	Renal cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 105.4	Expressed in all		
FGFR1OP2	DKFZp564O1863	ENSG00000111790	FGFR1 oncogene partner 2	12	26938383-26966650	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038308, HPA038696	Supported		Approved	Mitochondria		Expressed in all	Expressed in all			ovary: 73.7	Expressed in all		
FGGY	FLJ10986	ENSG00000172456	FGGY carbohydrate kinase domain containing	1	59296638-59810647	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA054971			Approved	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			epididymis: 44.3	Cell line enhanced		HDLM-2: 39.7
FGR	c-fgr, p55c-fgr, SRC2	ENSG00000000938	FGR proto-oncogene, Src family tyrosine kinase	1	27612064-27635277	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002024	Enhanced		Approved	Plasma membrane<br>Aggresome		Expressed in all	Tissue enhanced		appendix: 85.6;bone marrow: 137.0;spleen: 90.6	lung: 56.3	Cell line enhanced		Daudi: 61.4;HMC-1: 25.8;U-266/70: 116.7
FH	fumarase	ENSG00000091483	Fumarate hydratase	1	241497603-241519761	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017785, HPA025770, HPA025948, HPA027341	Enhanced	Approved	Enhanced	Mitochondria	Renal cancer:2.76e-7 (favourable)	Expressed in all	Expressed in all			liver: 142.2	Expressed in all		
FHAD1	KIAA1937	ENSG00000142621	Forkhead associated phosphopeptide binding domain 1	1	15247272-15400283	Predicted intracellular proteins	Evidence at protein level	HPA054284	Enhanced					Mixed	Group enriched	6	fallopian tube: 24.1;lung: 5.2;testis: 24.7	cervix, uterine: 3.1	Group enriched	5	HDLM-2: 27.2;HMC-1: 70.7;K-562: 16.4;U-87 MG: 42.0
FHDC1	KIAA1727	ENSG00000137460	FH2 domain containing 1	4	152936352-152979696	Predicted intracellular proteins	Evidence at protein level	HPA008527	Uncertain				Renal cancer:1.33e-5 (favourable)	Mixed	Tissue enhanced		thyroid gland: 26.8	lung: 12.9	Cell line enhanced		BEWO: 29.6;SK-BR-3: 10.8;WM-115: 10.5
FHIT	AP3Aase, FRA3B	ENSG00000189283	Fragile histidine triad	3	59749310-61251459	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002684, HPA018840, HPA018909	Enhanced		Approved	Nucleoli fibrillar center<br>Plasma membrane	Renal cancer:1.36e-4 (favourable)	Mixed	Expressed in all			kidney: 26.8	Cell line enhanced		U-266/70: 27.6
FHL2	DRAL, SLIM3	ENSG00000115641	Four and a half LIM domains 2	2	105357712-105438513	Predicted intracellular proteins	Evidence at protein level	HPA005922, HPA006028, CAB008368	Enhanced		Enhanced	Actin filaments<br>Focal adhesion sites	Renal cancer:6.42e-5 (unfavourable), Head and neck cancer:2.01e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 659.3	Mixed		
FHL3	SLIM2	ENSG00000183386	Four and a half LIM domains 3	1	37996770-38005606	Predicted intracellular proteins	Evidence at protein level	HPA045723			Approved	Nucleus	Renal cancer:4.20e-11 (unfavourable), Liver cancer:8.59e-5 (unfavourable), Breast cancer:5.62e-4 (favourable)	Expressed in all	Tissue enriched	13	skeletal muscle: 569.1	smooth muscle: 43.5	Mixed		
FHL5	ACT, dJ393D12.2, FLJ33049	ENSG00000112214	Four and a half LIM domains 5	6	96562548-96616636	Predicted intracellular proteins	Evidence at protein level						Glioma:3.18e-4 (favourable)	Mixed	Tissue enhanced		testis: 106.4	cervix, uterine: 43.3	Cell line enriched	9	ASC diff: 3.4
FHOD1	FHOS	ENSG00000135723	Formin homology 2 domain containing 1	16	67229387-67247658	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024468	Approved		Supported	Cytosol	Renal cancer:1.90e-8 (unfavourable), Cervical cancer:9.57e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 62.3	skeletal muscle: 40.4	Expressed in all		
FIBCD1	FLJ14810	ENSG00000130720	Fibrinogen C domain containing 1	9	130902438-130939286	Predicted intracellular proteins	Evidence at protein level	HPA053898, HPA055353	Uncertain		Supported	Cell Junctions		Mixed	Tissue enhanced		adrenal gland: 4.7;parathyroid gland: 8.6;testis: 5.3	cerebral cortex: 2.5	Cell line enhanced		MCF7: 25.2;RPTEC TERT1: 18.5;U-2 OS: 17.4;U-251 MG: 11.7
FIBP	FGFIBP	ENSG00000172500	FGF1 intracellular binding protein	11	65883741-65888539	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011729	Approved		Supported	Nuclear speckles	Liver cancer:1.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 78.9	Expressed in all		
FIGLA	bHLHc8	ENSG00000183733	Folliculogenesis specific bHLH transcription factor	2	70777310-70790643	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	6	testis: 1.2	cervix, uterine: 0.2	Not detected		
FIGN		ENSG00000182263	Fidgetin, microtubule severing factor	2	163593396-163736012	Predicted intracellular proteins	Evidence at protein level	HPA034987, HPA057919	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol		Mixed	Mixed			ovary: 5.1	Cell line enhanced		AF22: 18.3
FIGNL1		ENSG00000132436	Fidgetin like 1	7	50444128-50542535	Predicted intracellular proteins	Evidence at protein level	HPA055542	Approved				Renal cancer:9.54e-7 (unfavourable), Liver cancer:1.01e-4 (unfavourable), Melanoma:4.82e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 14.7	Mixed		
FIGNL2		ENSG00000261308	Fidgetin like 2	12	51817840-51848766	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		kidney: 2.3;parathyroid gland: 2.4	placenta: 1.1	Cell line enhanced		AF22: 17.1;BEWO: 10.8;NTERA-2: 6.9
FILIP1	FILIP, KIAA1275	ENSG00000118407	Filamin A interacting protein 1	6	75291859-75493738	Predicted intracellular proteins	Evidence at protein level	HPA053564	Enhanced		Uncertain	Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		heart muscle: 35.3	smooth muscle: 19.5	Cell line enhanced		EFO-21: 6.6;U-266/70: 5.3
FILIP1L	DOC-1, GIP130	ENSG00000168386	Filamin A interacting protein 1 like	3	99830141-100114513	Predicted intracellular proteins	Evidence at protein level	HPA043133	Approved		Approved	Plasma membrane	Renal cancer:9.40e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 217.1	Cell line enhanced		HDLM-2: 74.0;TIME: 118.7
FIP1L1	DKFZp586K0717, FIP1	ENSG00000145216	Factor interacting with PAPOLA and CPSF1	4	53377643-53460861	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037475, HPA058202	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.51e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 69.8	Expressed in all		
FIZ1	FLJ14768, ZNF798	ENSG00000179943	FLT3 interacting zinc finger 1	19	55591371-55601970	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA074026			Approved	Nucleus	Urothelial cancer:2.02e-4 (favourable), Pancreatic cancer:8.42e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 19.6	Expressed in all		
FKBP15	FKBP133, KIAA0674, PPP1R76, WAFL	ENSG00000119321	FK506 binding protein 15	9	113161006-113221361	Predicted intracellular proteins	Evidence at protein level	HPA007979	Approved		Approved	Nucleoli<br>Cytosol	Testis cancer:4.92e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.0	Expressed in all		
FKBP1B	FKBP12.6, FKBP1L, FKBP9, OTK4, PPIase	ENSG00000119782	FK506 binding protein 1B	2	24049701-24063681	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045572, HPA051798	Uncertain		Approved	Vesicles		Expressed in all	Tissue enhanced		cerebral cortex: 24.4	duodenum: 18.6	Cell line enhanced		Hep G2: 30.2;NTERA-2: 41.7;SH-SY5Y: 31.9;TIME: 30.3
FKBP1C	bA184C23.2	ENSG00000198225	FK506 binding protein 1C	6	63211446-63213024	Predicted intracellular proteins	No evidence	HPA051798	Uncertain					Mixed	Not detected			appendix: 0.4	Not detected		
FKBP3	FKBP-25, PPIase	ENSG00000100442	FK506 binding protein 3	14	45115600-45135319	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000864, CAB012232, CAB012520	Supported		Supported	Cytosol		Expressed in all	Expressed in all			skeletal muscle: 143.3	Expressed in all		
FKBP4	FKBP52, FKBP59	ENSG00000004478	FK506 binding protein 4	12	2794953-2805423	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006148, CAB017441, HPA062857	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:6.12e-5 (unfavourable), Lung cancer:1.44e-4 (unfavourable), Endometrial cancer:7.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 107.4	Expressed in all		
FKBP5	FKBP51, FKBP54, P54, PPIase, Ptg-10	ENSG00000096060	FK506 binding protein 5	6	35573585-35728583	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009315, HPA031092, HPA031093, HPA031095	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			adipose tissue: 415.3	Cell line enhanced		ASC diff: 517.9;HHSteC: 495.2;HSkMC: 518.9
FKBP6	FKBP36, PPIase	ENSG00000077800	FK506 binding protein 6	7	73328164-73358637	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061109	Enhanced					Tissue enriched	Tissue enriched	273	testis: 83.0	parathyroid gland: 0.3	Not detected		
FKBPL	DIR1, NG7, WISp39	ENSG00000204315	FK506 binding protein like	6	32128707-32130291	Predicted intracellular proteins	Evidence at protein level	HPA043478, HPA060158	Enhanced		Approved	Nucleoplasm	Ovarian cancer:8.46e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 5.0	Mixed		
FKTN	FCMD, LGMD2M	ENSG00000106692	Fukutin	9	105558130-105641118	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA012820	Approved				Urothelial cancer:3.02e-4 (unfavourable), Liver cancer:9.42e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 17.3	Expressed in all		
FLAD1	FAD1, PP591	ENSG00000160688	Flavin adenine dinucleotide synthetase 1	1	154983338-154993111	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028476, HPA028486, HPA028563	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.55e-6 (unfavourable), Liver cancer:3.04e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 28.5	Expressed in all		
FLCN	BHD, MGC17998, MGC23445	ENSG00000154803	Folliculin	17	17212212-17237188	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015158, HPA028760	Supported		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:4.49e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 30.8	Expressed in all		
FLG		ENSG00000143631	Filaggrin	1	152302175-152325203	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002210, HPA027505, HPA030188, HPA030189	Enhanced		Supported	Vesicles		Tissue enriched	Tissue enriched	26	skin: 548.3	breast: 21.1	Cell line enhanced		HaCaT: 8.9;NTERA-2: 3.1;U-2 OS: 2.5;U-2197: 2.4
FLG2	IFPS	ENSG00000143520	Filaggrin family member 2	1	152348735-152360006	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028699	Approved					Tissue enriched	Tissue enriched	14	skin: 578.9	breast: 42.8	Not detected		
FLI1	EWSR2, SIC-1	ENSG00000151702	Fli-1 proto-oncogene, ETS transcription factor	11	128686535-128813267	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073099			Supported	Nucleus<br>Nuclear bodies	Renal cancer:4.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 46.1	placenta: 15.6	Cell line enhanced		HEL: 93.0;HUVEC TERT2: 46.8;REH: 44.4;TIME: 47.8
FLII	FLI, Fli1, FLIL, MGC39265	ENSG00000177731	FLII, actin remodeling protein	17	18244836-18258916	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007084, HPA008903, CAB016132	Approved		Supported	Nucleoplasm<br>Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 41.2	Expressed in all		
FLNA	ABP-280, FLN, FLN1, OPD1, OPD2	ENSG00000196924	Filamin A	X	154348524-154374638	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000356, HPA000368, HPA001016, HPA001115, HPA002925	Enhanced	Approved	Enhanced	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:1.54e-6 (unfavourable), Urothelial cancer:3.88e-4 (unfavourable), Colorectal cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1051.0	Expressed in all		
FLNB	ABP-278, FH1, FLN1L, LRS1, TABP, TAP	ENSG00000136068	Filamin B	3	58008400-58172251	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA004747, HPA004886, CAB019322	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:3.45e-6 (favourable), Pancreatic cancer:8.45e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 148.3	Expressed in all		
FLNC	ABP-280, ABPL, FLN2	ENSG00000128591	Filamin C	7	128830377-128859274	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA006135	Enhanced		Supported	Plasma membrane<br>Cytosol	Lung cancer:2.17e-5 (unfavourable), Urothelial cancer:3.73e-5 (unfavourable), Glioma:2.14e-4 (unfavourable), Renal cancer:5.69e-4 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 384.7	smooth muscle: 160.7	Cell line enhanced		BJ: 331.0;hTEC/SVTERT24-B: 190.2;U-2 OS: 169.5
FLOT1		ENSG00000137312	Flotillin 1	6	30727709-30742733	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001393, CAB007766	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane	Renal cancer:1.49e-4 (unfavourable), Ovarian cancer:3.06e-4 (favourable), Colorectal cancer:5.78e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 18.9	Expressed in all		
FLOT2	ECS-1, ECS1, ESA, ESA1, M17S1	ENSG00000132589	Flotillin 2	17	28879335-28897679	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001396, CAB004395	Enhanced					Expressed in all	Expressed in all			spleen: 93.7	Expressed in all		
FLYWCH1	DKFZp761A132	ENSG00000059122	FLYWCH-type zinc finger 1	16	2911937-2951208	Predicted intracellular proteins	Evidence at protein level	HPA040753, HPA041001	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 30.3	Expressed in all		
FLYWCH2		ENSG00000162076	FLYWCH family member 2	16	2883186-2899382	Predicted intracellular proteins	Evidence at protein level	HPA041354	Uncertain		Approved	Nucleus	Pancreatic cancer:1.87e-5 (favourable), Cervical cancer:9.38e-4 (favourable)	Expressed in all	Expressed in all			spleen: 35.1	Expressed in all		
FMC1	C7orf55, HSPC268	ENSG00000164898	Formation of mitochondrial complex V assembly factor 1 homolog	7	139339457-139346319	Predicted intracellular proteins	Evidence at protein level	HPA045663, HPA050553	Approved		Approved	Mitochondria	Ovarian cancer:5.63e-6 (favourable), Renal cancer:2.05e-5 (favourable), Lung cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			prostate: 12.8	Expressed in all		
FMN1	DKFZP686C2281, FLJ45135, FMN, LD, MGC125288, MGC125289	ENSG00000248905	Formin 1	15	32765545-33194733	Predicted intracellular proteins	Evidence at protein level	HPA005465, HPA046786	Approved		Supported	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enhanced		testis: 8.2	cervix, uterine: 4.1	Cell line enhanced		RH-30: 13.0;SK-MEL-30: 11.2;T-47d: 11.5
FMN2		ENSG00000155816	Formin 2	1	240014348-240475189	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050649			Approved	Plasma membrane<br>Actin filaments		Group enriched	Group enriched	6	cerebral cortex: 53.8;parathyroid gland: 33.5	adrenal gland: 7.0	Cell line enhanced		BJ: 60.2;fHDF/TERT166: 54.7;LHCN-M2: 63.8;U-138 MG: 48.9;WM-115: 77.8
FMNL2	FHOD2, KIAA1902	ENSG00000157827	Formin like 2	2	152335237-152649834	Predicted intracellular proteins	Evidence at protein level	HPA005464	Enhanced		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Liver cancer:9.04e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 137.8	placenta: 82.9	Cell line enhanced		BEWO: 184.8
FMNL3	DKFZp762B245, MGC45819, WBP3	ENSG00000161791	Formin like 3	12	49636499-49708165	Predicted intracellular proteins	Evidence at protein level	HPA002552, HPA023201	Uncertain		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:3.58e-5 (unfavourable)	Expressed in all	Mixed			lymph node: 28.0	Mixed		
FMR1	FMRP, FRAXA, MGC87458, POF, POF1	ENSG00000102081	Fragile X mental retardation 1	X	147911951-147951125	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012444, HPA050118, HPA056084	Approved		Enhanced	Cytosol	Endometrial cancer:1.32e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 55.4	Expressed in all		
FN3K		ENSG00000167363	Fructosamine 3 kinase	17	82735575-82751197	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059151, HPA061358	Enhanced		Approved	Mitochondria	Renal cancer:1.39e-6 (favourable), Endometrial cancer:1.10e-4 (favourable), Pancreatic cancer:2.40e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 56.8	Cell line enhanced		HAP1: 34.0;Hep G2: 42.8
FN3KRP	FLJ12171, FN3KL	ENSG00000141560	Fructosamine 3 kinase related protein	17	82716683-82730328	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056172, HPA065831	Approved		Approved	Nucleoplasm	Glioma:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 48.8	Expressed in all		
FNBP1	FBP17, KIAA0554	ENSG00000187239	Formin binding protein 1	9	129887187-130043194	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019635, HPA019691, HPA022119	Enhanced				Renal cancer:8.45e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 90.7	Mixed		
FNBP1L	C1orf39, FLJ20275, TOCA1	ENSG00000137942	Formin binding protein 1 like	1	93448131-93554661	Predicted intracellular proteins	Evidence at protein level	HPA065273	Approved		Supported	Cytosol	Renal cancer:4.72e-7 (favourable), Liver cancer:8.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 53.8	Mixed		
FNBP4	KIAA1014	ENSG00000109920	Formin binding protein 4	11	47716517-47767443	Predicted intracellular proteins	Evidence at protein level	HPA039485, HPA040029	Supported		Enhanced	Nuclear speckles	Renal cancer:1.91e-8 (unfavourable), Urothelial cancer:7.23e-5 (favourable), Liver cancer:7.33e-5 (unfavourable), Melanoma:2.50e-4 (unfavourable), Prostate cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 48.1	Expressed in all		
FNDC11	C20orf195, MGC5356	ENSG00000125531	Fibronectin type III domain containing 11	20	63547891-63556708	Predicted intracellular proteins	Evidence at protein level	HPA041341			Approved	Nucleoplasm<br>Vesicles<br>Aggresome		Mixed	Tissue enriched	19	testis: 53.0	epididymis: 2.8	Cell line enhanced		CAPAN-2: 4.5;EFO-21: 2.5;SH-SY5Y: 3.4
FNDC8	DKFZp434H2215	ENSG00000073598	Fibronectin type III domain containing 8	17	35121579-35130732	Predicted intracellular proteins	Evidence at protein level	HPA026521	Supported					Not detected	Tissue enriched	461	testis: 108.6	ovary: 0.2	Cell line enhanced		HEK93: 1.2
FNIP1	KIAA1961	ENSG00000217128	Folliculin interacting protein 1	5	131641714-131797063	Predicted intracellular proteins	Evidence at protein level	HPA068099, HPA071213	Approved					Expressed in all	Expressed in all			testis: 28.5	Expressed in all		
FNIP2	FNIPL, KIAA1450, MAPO1	ENSG00000052795	Folliculin interacting protein 2	4	158769138-158908049	Predicted intracellular proteins	Evidence at protein level	HPA042779, HPA072420	Approved				Renal cancer:3.96e-11 (favourable)	Expressed in all	Expressed in all			kidney: 51.2	Cell line enhanced		HDLM-2: 167.0
FNTA	FPTA, PGGT1A, PTAR2	ENSG00000168522	Farnesyltransferase, CAAX box, alpha	8	43034194-43085788	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB010149, HPA018830	Approved		Approved	Cytosol	Renal cancer:2.94e-12 (unfavourable)	Expressed in all	Expressed in all			placenta: 63.4	Expressed in all		
FNTB	FPTB	ENSG00000257365	Farnesyltransferase, CAAX box, beta	14	64986720-65062652	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062743	Approved		Approved	Centrosome	Liver cancer:6.03e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 17.7	Expressed in all		
FOPNL	C16orf63, DKFZp686N1651, FLJ31153, FOR20, PHSECRG2	ENSG00000133393	FGFR1OP N-terminal like	16	15865720-15888625	Predicted intracellular proteins	Evidence at protein level	HPA040599	Supported		Supported	Centrosome		Expressed in all	Expressed in all			thyroid gland: 53.9	Expressed in all		
FOS	AP-1, c-fos	ENSG00000170345	Fos proto-oncogene, AP-1 transcription factor subunit	14	75278774-75282230	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018531	Approved		Supported	Nucleoplasm	Prostate cancer:7.81e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 1853.4	Cell line enriched	5	hTCEpi: 324.8
FOSB	AP-1, DKFZp686C0818, G0S3, GOS3, GOSB, MGC42291	ENSG00000125740	FosB proto-oncogene, AP-1 transcription factor subunit	19	45467995-45475179	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB010267, HPA054663	Approved		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			gallbladder: 558.7	Cell line enhanced		HMC-1: 11.7;SK-BR-3: 7.4
FOSL1	fra-1	ENSG00000175592	FOS like 1, AP-1 transcription factor subunit	11	65892049-65900573	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004396, HPA066901	Uncertain		Enhanced	Nucleoplasm	Renal cancer:6.40e-6 (unfavourable), Pancreatic cancer:9.26e-5 (unfavourable), Lung cancer:1.95e-4 (unfavourable), Head and neck cancer:2.05e-4 (unfavourable), Glioma:2.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 35.6;gallbladder: 51.7	urinary bladder: 26.8	Cell line enhanced		PC-3: 759.0;WM-115: 1227.8
FOSL2	FLJ23306, FRA2	ENSG00000075426	FOS like 2, AP-1 transcription factor subunit	2	28392448-28417312	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004817, CAB013460, HPA061417	Supported		Enhanced	Nucleus		Expressed in all	Expressed in all			adrenal gland: 224.8	Mixed		
FOXA1	HNF3A	ENSG00000129514	Forkhead box A1	14	37589984-37596059	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011595, HPA050505	Enhanced		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Urothelial cancer:1.00e-4 (favourable)	Tissue enhanced	Tissue enhanced		prostate: 146.0	breast: 36.3	Cell line enhanced		MCF7: 98.8;PC-3: 81.2;RT4: 94.9;SK-BR-3: 88.5;T-47d: 157.4
FOXA2	HNF3B	ENSG00000125798	Forkhead box A2	20	22581005-22585455	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB001388, HPA066846	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Endometrial cancer:7.57e-6 (favourable), Pancreatic cancer:2.34e-4 (favourable), Ovarian cancer:6.28e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 21.4;lung: 20.5;stomach: 31.0	liver: 11.5	Cell line enhanced		A549: 16.1;HBEC3-KT: 14.5;Hep G2: 19.5;PC-3: 24.0;SCLC-21H: 52.3
FOXA3	HNF3G	ENSG00000170608	Forkhead box A3	19	45863989-45873797	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB015154, HPA054034	Uncertain		Approved	Nucleoplasm		Mixed	Group enriched	5	colon: 16.7;duodenum: 10.3;liver: 32.5;pancreas: 9.8;rectum: 17.9;small intestine: 13.9;stomach: 33.8	gallbladder: 3.6	Cell line enhanced		CACO-2: 8.4;HDLM-2: 11.2;Hep G2: 18.9;K-562: 20.1;NTERA-2: 10.8
FOXB1	FKH5, HFKH-5	ENSG00000171956	Forkhead box B1	15	60004222-60061730	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073369			Approved	Nucleoplasm<br>Mitochondria		Tissue enhanced	Not detected			testis: 0.7	Cell line enhanced		AF22: 6.3;HDLM-2: 13.5;HEK93: 9.8
FOXB2	bA159H20.4	ENSG00000204612	Forkhead box B2	9	77019655-77020953	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA067947	Uncertain					Tissue enhanced	Not detected			all non-specific tissues: 0.0	Cell line enriched	10	NTERA-2: 1.3
FOXC1	ARA, FKHL7, FREAC3, IGDA, IHG1, IRID1	ENSG00000054598	Forkhead box C1	6	1609972-1613897	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040670	Enhanced		Supported	Nucleoplasm<br>Cytosol	Colorectal cancer:3.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		salivary gland: 66.2	kidney: 21.8	Cell line enhanced		AN3-CA: 86.7;HEK93: 85.3
FOXC2	FKHL14, MFH-1	ENSG00000176692	Forkhead box C2	16	86567251-86569728	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056302			Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.57e-7 (unfavourable)	Mixed	Mixed			kidney: 2.8	Cell line enhanced		hTEC/SVTERT24-B: 29.9;LHCN-M2: 30.9;TIME: 34.0;U-2197: 34.2;U-87 MG: 27.6
FOXD1	FKHL8, FREAC4	ENSG00000251493	Forkhead box D1	5	73444827-73448527	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Head and neck cancer:2.73e-4 (unfavourable), Urothelial cancer:9.65e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 4.5	adrenal gland: 2.6	Cell line enhanced		hTEC/SVTERT24-B: 60.8;U-138 MG: 79.5
FOXD2	FKHL17, FREAC9	ENSG00000186564	Forkhead box D2	1	47436017-47440691	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Tissue enhanced		colon: 3.4;rectum: 2.7	prostate: 1.1	Cell line enhanced		AN3-CA: 11.3;WM-115: 17.4
FOXD3	Genesis, HFH2	ENSG00000187140	Forkhead box D3	1	63323041-63325126	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB022455	Uncertain					Group enriched	Mixed			testis: 1.0	Cell line enhanced		NTERA-2: 14.7;SK-MEL-30: 9.4;WM-115: 18.2
FOXD4	FKHL9, FOXD4a, FREAC5	ENSG00000170122	Forkhead box D4	9	116231-118204	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA012836	Uncertain		Approved	Nucleus		Mixed	Not detected			testis: 0.8	Cell line enhanced		THP-1: 2.9
FOXD4L1	FOXD5	ENSG00000184492	Forkhead box D4-like 1	2	113498665-113501155	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA012836	Uncertain		Approved	Nucleus		Not detected	Not detected			testis: 0.6	Cell line enhanced		RH-30: 1.6
FOXD4L3	FOXD6	ENSG00000187559	Forkhead box D4-like 3	9	68302867-68304905	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA012836	Uncertain		Approved	Nucleus		Not detected	Not detected			spleen: 0.3	Not detected		
FOXD4L4	bA460E7.2, FOXD4L2	ENSG00000184659	Forkhead box D4-like 4	9	65736555-65738784	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA012836	Uncertain		Approved	Nucleus		Not detected	Not detected			cerebral cortex: 0.1	Not detected		
FOXD4L5	bA15J10.2	ENSG00000204779	Forkhead box D4-like 5	9	65282101-65285209	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA012836	Uncertain		Approved	Nucleus		Not detected	Not detected			cerebral cortex: 0.6	Mixed		
FOXD4L6		ENSG00000273514	Forkhead box D4-like 6	9	41126430-41128463	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA012836	Uncertain		Approved	Nucleus		Not detected	Not detected			cerebral cortex: 0.3	Not detected		
FOXE1	FKHL15, FOXE2, HFKH4, TITF2, TTF-2	ENSG00000178919	Forkhead box E1	9	97853254-97856715	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enriched	15	thyroid gland: 327.9	tonsil: 22.1	Cell line enhanced		A-431: 12.2;HeLa: 13.5;RPTEC TERT1: 14.9;SiHa: 15.7
FOXE3	FKHL12, FREAC8	ENSG00000186790	Forkhead box E3	1	47416072-47418052	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Not detected			testis: 0.5	Not detected		
FOXF1	FKHL5, FREAC1	ENSG00000103241	Forkhead box F1	16	86510527-86515418	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028886			Approved	Nucleoplasm		Mixed	Mixed			placenta: 33.0	Cell line enhanced		BJ: 10.8;BJ hTERT+: 22.8;HHSteC: 22.2;U-2197: 11.1
FOXF2	FKHL6, FREAC2	ENSG00000137273	Forkhead box F2	6	1389834-1395597	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Mixed			lung: 18.4	Cell line enhanced		BJ hTERT+: 64.9;HEK93: 24.6;U-2197: 30.0
FOXG1	BF1, FKH2, FKHL1, FKHL2, FKHL3, FKHL4, FOXG1A, FOXG1B, FOXG1C, HBF-3, HFK1, HFK2, HFK3, QIN	ENSG00000176165	Forkhead box G1	14	28760330-28770277	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	6	cerebral cortex: 29.6	testis: 5.2	Cell line enhanced		HEK93: 10.3;SCLC-21H: 34.2;U-138 MG: 17.5;U-251 MG: 15.3
FOXH1	FAST1	ENSG00000160973	Forkhead box H1	8	144473412-144476335	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Not detected			small intestine: 0.9	Cell line enriched	21	NTERA-2: 20.6
FOXI1	FKHL10, FREAC6	ENSG00000168269	Forkhead box I1	5	170105897-170109725	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071469	Enhanced		Uncertain	Nucleoli<br>Vesicles		Group enriched	Tissue enhanced		breast: 10.4;kidney: 20.0	salivary gland: 6.2	Cell line enhanced		MCF7: 1.2
FOXI2	FLJ46831	ENSG00000186766	Forkhead box I2	10	127737235-127741186	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:4.23e-7 (favourable)	Tissue enriched	Tissue enhanced		cervix, uterine: 2.6	kidney: 1.6	Not detected		
FOXI3		ENSG00000214336	Forkhead box I3	2	88446787-88452656	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enriched	9	placenta: 7.4	testis: 0.8	Cell line enhanced		BEWO: 42.3;HAP1: 6.2;NTERA-2: 11.0
FOXJ1	FKHL13, HFH-4, HFH4	ENSG00000129654	Forkhead box J1	17	76136333-76141299	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005714	Enhanced				Renal cancer:2.03e-5 (unfavourable), Breast cancer:9.39e-4 (favourable)	Tissue enhanced	Tissue enriched	8	fallopian tube: 83.6	lung: 10.3	Group enriched	10	BEWO: 28.2;CAPAN-2: 21.8
FOXJ2	FHX	ENSG00000065970	Forkhead box J2	12	8032703-8055503	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008723	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:4.63e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Mixed		
FOXJ3	KIAA1041	ENSG00000198815	Forkhead box J3	1	42176539-42335877	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067284			Approved	Nucleoplasm<br>Nuclear speckles<br>Vesicles	Renal cancer:4.51e-7 (unfavourable), Liver cancer:5.17e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 40.1	Expressed in all		
FOXK1	IMAGE:5164497	ENSG00000164916	Forkhead box K1	7	4682309-4771443	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017998, HPA018864	Enhanced		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Liver cancer:2.54e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 12.4	Expressed in all		
FOXK2	ILF, ILF1	ENSG00000141568	Forkhead box K2	17	82519713-82644662	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027523	Approved		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.24e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 53.2	Expressed in all		
FOXL1	FKH6, FKHL11, FREAC7	ENSG00000176678	Forkhead box L1	16	86576368-86582160	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enhanced		gallbladder: 8.3	duodenum: 3.1	Cell line enhanced		CAPAN-2: 33.6;PC-3: 45.9;U-87 MG: 104.7
FOXL2	BPES, BPES1	ENSG00000183770	Forkhead box L2	3	138944224-138947140	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069613	Enhanced		Supported	Nucleus<br>Cytokinetic bridge		Mixed	Tissue enhanced		endometrium: 12.1;ovary: 29.6;parathyroid gland: 24.4	fallopian tube: 7.7	Cell line enhanced		A-431: 4.3;fHDF/TERT166: 4.3;HEL: 7.2;hTCEpi: 5.1;K-562: 7.5;SiHa: 5.9
FOXL2NB	C3orf72, FLJ43329	ENSG00000206262	FOXL2 neighbor	3	138947234-138953451	Predicted intracellular proteins	Evidence at protein level	HPA061017, HPA071790			Supported	Nucleoli fibrillar center		Mixed	Tissue enhanced		endometrium: 29.1;ovary: 50.7;parathyroid gland: 63.8	fallopian tube: 19.5	Cell line enhanced		AN3-CA: 4.1;fHDF/TERT166: 6.7;HEL: 7.8;SiHa: 7.1
FOXM1	FKHL16, HFH-11, HNF-3, INS-1, MPHOSPH2, MPP2, TGT3, trident	ENSG00000111206	Forkhead box M1	12	2857681-2877155	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017832	Uncertain		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.95e-6 (unfavourable), Pancreatic cancer:3.03e-5 (unfavourable), Lung cancer:2.92e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 39.6	bone marrow: 15.9	Expressed in all		
FOXN1	FKHL20, RONU, WHN	ENSG00000109101	Forkhead box N1	17	28506243-28538896	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Head and neck cancer:5.00e-4 (favourable), Cervical cancer:6.43e-4 (favourable)	Tissue enhanced	Tissue enhanced		esophagus: 7.2;skin: 35.2	tonsil: 5.1	Cell line enriched	8	HaCaT: 10.3
FOXN2	HTLF	ENSG00000170802	Forkhead box N2	2	48314637-48379294	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003485	Supported		Supported	Nucleus<br>Vesicles	Renal cancer:2.81e-5 (unfavourable), Glioma:5.14e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 36.4	Expressed in all		
FOXN3	C14orf116, CHES1	ENSG00000053254	Forkhead box N3	14	89124871-89619149	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059209	Approved		Approved	Nucleus<br>Plasma membrane	Renal cancer:9.58e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 111.0	Mixed		
FOXN4		ENSG00000139445	Forkhead box N4	12	109277979-109309220	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050018	Uncertain		Approved	Nucleus<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enriched	13	testis: 10.7	cervix, uterine: 0.8	Cell line enhanced		SCLC-21H: 4.2;SH-SY5Y: 3.9;U-266/70: 3.9
FOXO1	FKH1, FKHR, FOXO1A	ENSG00000150907	Forkhead box O1	13	40469953-40666597	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001252, CAB022326	Approved	Approved	Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.33e-5 (favourable), Liver cancer:3.74e-4 (favourable)	Expressed in all	Expressed in all			ovary: 80.7	Cell line enhanced		HSkMC: 39.2;U-698: 40.3
FOXO3	AF6q21, FKHRL1, FOXO2, FOXO3A	ENSG00000118689	Forkhead box O3	6	108559835-108684774	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004074, HPA063104	Supported		Enhanced	Nucleus		Expressed in all	Expressed in all			ovary: 55.1	Expressed in all		
FOXO4	AFX1, MLLT7	ENSG00000184481	Forkhead box O4	X	71096197-71103535	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	HPA039560, HPA040232	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:3.46e-4 (favourable), Head and neck cancer:4.61e-4 (favourable)	Expressed in all	Expressed in all			placenta: 172.7	Cell line enriched	8	BEWO: 154.9
FOXO6		ENSG00000204060	Forkhead box O6	1	41361922-41383590	Predicted intracellular proteins	Evidence at transcript level						Endometrial cancer:7.65e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 4.9	Cell line enhanced		BEWO: 19.9;SCLC-21H: 31.9;U-2 OS: 11.0
FOXP1	12CC4, hFKH1B, HSPC215, QRF1	ENSG00000114861	Forkhead box P1	3	70954693-71583989	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003876, CAB011501	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 39.7	Expressed in all		
FOXP2	CAGH44, SPCH1, TNRC10	ENSG00000128573	Forkhead box P2	7	114086327-114693772	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000382, HPA000383, HPA001679	Enhanced		Enhanced	Nucleoplasm		Mixed	Mixed			endometrium: 13.7	Cell line enhanced		AF22: 20.9;RH-30: 37.7
FOXP3	AIID, DIETER, IPEX, JM2, PIDX, SCURFIN, XPID	ENSG00000049768	Forkhead box P3	X	49250436-49264826	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026301, HPA045943	Enhanced		Supported	Nucleoplasm	Cervical cancer:1.91e-4 (favourable), Head and neck cancer:4.90e-4 (favourable), Endometrial cancer:7.02e-4 (favourable)	Mixed	Tissue enhanced		appendix: 8.7	lymph node: 6.0	Cell line enhanced		MCF7: 2.8;SiHa: 2.3
FOXP4	FLJ40908	ENSG00000137166	Forkhead box P4	6	41546426-41602384	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007176	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.17e-6 (unfavourable), Liver cancer:9.72e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 36.9	Expressed in all		
FOXQ1	HFH1	ENSG00000164379	Forkhead box Q1	6	1312440-1314748	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059700			Supported	Nucleus	Prostate cancer:6.68e-4 (favourable)	Expressed in all	Tissue enhanced		stomach: 105.8;urinary bladder: 43.8	skin: 33.1	Cell line enhanced		CACO-2: 32.2;HaCaT: 39.8;Hep G2: 65.9;RT4: 32.0
FOXR1	DLNB13, FOXN5	ENSG00000176302	Forkhead box R1	11	118971707-118981291	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	14	testis: 3.1	thyroid gland: 0.2	Not detected		
FOXR2	FOXN6, MGC21658	ENSG00000189299	Forkhead box R2	X	55623400-55625325	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034487, HPA057358	Uncertain		Supported	Nucleoplasm		Tissue enhanced	Tissue enriched	15	testis: 2.8	epididymis: 0.1	Group enriched	107	NTERA-2: 12.2;SH-SY5Y: 11.3;U-266/70: 5.4;U-266/84: 13.9
FOXRED1	H17	ENSG00000110074	FAD dependent oxidoreductase domain containing 1	11	126269055-126278131	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039620, HPA046192	Uncertain		Supported	Mitochondria	Renal cancer:2.01e-6 (favourable), Breast cancer:7.36e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 19.1	Expressed in all		
FOXS1	FKHL18, FREAC10	ENSG00000179772	Forkhead box S1	20	31844301-31845619	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042475	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.10e-8 (unfavourable)	Expressed in all	Mixed			placenta: 7.0	Cell line enhanced		EFO-21: 3.0;RH-30: 10.5;U-2 OS: 15.0;U-251 MG: 3.6
FPGT	GFPP	ENSG00000254685	Fucose-1-phosphate guanylyltransferase	1	74198212-74234086	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA072331			Uncertain	Vesicles	Liver cancer:2.30e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 32.8	Expressed in all		
FPGT-TNNI3K		ENSG00000259030	FPGT-TNNI3K readthrough	1	74198235-74543982	Predicted intracellular proteins	Evidence at protein level	HPA072331			Approved	Vesicles		Not detected	Mixed			heart muscle: 5.7	Cell line enhanced		SiHa: 3.3
FRA10AC1	C10orf4	ENSG00000148690	FRA10A associated CGG repeat 1	10	93667883-93702572	Predicted intracellular proteins	Evidence at protein level	HPA039204	Approved					Expressed in all	Expressed in all			cerebral cortex: 21.3	Expressed in all		
FRAT1		ENSG00000165879	FRAT1, WNT signaling pathway regulator	10	97319267-97321915	Predicted intracellular proteins	Evidence at protein level	CAB046472, HPA055258	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:6.36e-5 (favourable), Head and neck cancer:2.75e-4 (favourable), Cervical cancer:5.92e-4 (favourable)	Expressed in all	Mixed			spleen: 9.2	Mixed		
FRAT2		ENSG00000181274	FRAT2, WNT signaling pathway regulator	10	97332497-97334709	Predicted intracellular proteins	Evidence at transcript level	HPA049763	Uncertain		Approved	Nucleus<br>Mitochondria	Renal cancer:2.55e-4 (favourable), Liver cancer:3.02e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 25.5	Mixed		
FRG1	FRG1A, FSG1	ENSG00000109536	FSHD region gene 1	4	189940788-189963204	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Stomach cancer:9.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 12.5	Expressed in all		
FRG2	FRG2A	ENSG00000205097	FSHD region gene 2	4	190024351-190027257	Predicted intracellular proteins	Evidence at transcript level	HPA039264, HPA047769	Uncertain					Not detected	Not detected			skin: 0.7	Not detected		
FRG2B		ENSG00000225899	FSHD region gene 2 family member B	10	133623895-133626795	Predicted intracellular proteins	Evidence at transcript level	HPA039264, HPA047769	Uncertain					Not detected	Not detected			kidney: 0.2	Cell line enriched	20	HDLM-2: 7.4
FRG2C		ENSG00000172969	FSHD region gene 2 family member C	3	75664330-75667220	Predicted intracellular proteins	Evidence at transcript level	HPA039264, HPA047769	Uncertain					Not detected	Tissue enhanced		testis: 1.0	kidney: 0.6	Cell line enriched	17	HDLM-2: 11.8
FRK	GTK, PTK5, RAK	ENSG00000111816	Fyn related Src family tyrosine kinase	6	115931149-116060758	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025217, HPA030479	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:9.66e-7 (favourable)	Mixed	Mixed			kidney: 10.0	Mixed		
FRMD1	bA164L23.1, DKFZp434O0117, FLJ00181, FLJ22615, FLJ40260	ENSG00000153303	FERM domain containing 1	6	168055745-168081557	Predicted intracellular proteins	Evidence at protein level	HPA030347	Supported		Approved	Actin filaments		Tissue enriched	Tissue enhanced		colon: 5.8;stomach: 6.4;testis: 5.9	rectum: 4.6	Cell line enhanced		K-562: 2.8
FRMD4A	bA295P9.4, FLJ10210, FRMD4, KIAA1294	ENSG00000151474	FERM domain containing 4A	10	13643706-14462142	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038449	Uncertain		Approved	Nucleus<br>Golgi apparatus	Head and neck cancer:2.63e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 38.0	Cell line enhanced		hTEC/SVTERT24-B: 89.3;TIME: 90.6;WM-115: 154.1
FRMD4B	GRSP1, KIAA1013	ENSG00000114541	FERM domain containing 4B	3	69169990-69542583	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA009705	Uncertain	Supported			Renal cancer:5.01e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 44.4	Cell line enhanced		HUVEC TERT2: 42.3
FRMD6	C14orf31, EX1, MGC17921, willin	ENSG00000139926	FERM domain containing 6	14	51489100-51730727	Predicted intracellular proteins	Evidence at protein level	HPA001297	Uncertain	Approved	Approved	Mitochondria	Renal cancer:1.28e-4 (unfavourable), Pancreatic cancer:2.66e-4 (unfavourable), Stomach cancer:3.50e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 126.3	Cell line enhanced		fHDF/TERT166: 644.4
FRMD7	FLJ43346, NYS, NYS1	ENSG00000165694	FERM domain containing 7	X	132076993-132128020	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000886	Uncertain					Not detected	Tissue enhanced		endometrium: 2.8;kidney: 3.0;smooth muscle: 3.5	seminal vesicle: 0.7	Cell line enhanced		U-87 MG: 1.5
FRMD8	FKSG44, FLJ90369	ENSG00000126391	FERM domain containing 8	11	65386599-65413525	Predicted intracellular proteins	Evidence at protein level	HPA002861, HPA005506	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:9.94e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 24.9	Expressed in all		
FRMPD1	FRMD2, KIAA0967	ENSG00000070601	FERM and PDZ domain containing 1	9	37651000-37746904	Predicted intracellular proteins	Evidence at protein level	HPA042934	Uncertain					Mixed	Tissue enhanced		testis: 14.3	skin: 8.2	Cell line enhanced		SCLC-21H: 3.1
FRMPD3	KIAA1817, RP5-1070B1.1	ENSG00000147234	FERM and PDZ domain containing 3	X	107522450-107605251	Predicted intracellular proteins	Evidence at transcript level	HPA003164	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 5.9;ovary: 6.7;thyroid gland: 5.5	seminal vesicle: 1.9	Cell line enhanced		Daudi: 4.2;SCLC-21H: 2.1;WM-115: 2.1
FRMPD4	KIAA0316, PDZD10, PDZK10	ENSG00000169933	FERM and PDZ domain containing 4	X	12138466-12724523	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	31	cerebral cortex: 17.7;parathyroid gland: 30.1	heart muscle: 0.7	Cell line enhanced		LHCN-M2: 3.5;U-2197: 6.0;U-266/70: 4.5
FRS2	FRS2A, FRS2alpha, SNT-1, SNT1	ENSG00000166225	Fibroblast growth factor receptor substrate 2	12	69470349-69579789	Predicted intracellular proteins	Evidence at protein level	HPA038323			Approved	Cell Junctions		Expressed in all	Expressed in all			parathyroid gland: 27.6	Expressed in all		
FRS3	FRS2B, FRS2beta, SNT-2	ENSG00000137218	Fibroblast growth factor receptor substrate 3	6	41770176-41786542	Predicted intracellular proteins	Evidence at protein level	HPA030162, HPA030174	Enhanced		Uncertain	Nucleoplasm	Pancreatic cancer:3.87e-4 (favourable)	Expressed in all	Mixed			testis: 22.0	Expressed in all		
FRY	13CDNA73, bA37E23.1, C13orf14, CG003	ENSG00000073910	FRY microtubule binding protein	13	32031300-32299122	Predicted intracellular proteins	Evidence at protein level	HPA041635	Approved				Renal cancer:9.60e-4 (favourable)	Mixed	Expressed in all			heart muscle: 33.5	Cell line enhanced		HUVEC TERT2: 22.7;RT4: 25.4
FRYL	AF4p12, DKFZp686E205, KIAA0826, MOR2	ENSG00000075539	FRY like transcription coactivator	4	48497361-48780322	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031106, HPA031107	Supported		Approved	Microtubules<br>Cytokinetic bridge<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 51.2	Expressed in all		
FSBP		ENSG00000265817	Fibrinogen silencer binding protein	8	94372170-94436952	Predicted intracellular proteins	Evidence at protein level	HPA025059, HPA026509	Approved		Supported	Nucleus		Not detected	Mixed			fallopian tube: 10.7	Mixed		
FSCB	C14orf155, DKFZP434F1017	ENSG00000189139	Fibrous sheath CABYR binding protein	14	44504342-44507279	Predicted intracellular proteins	Evidence at protein level	HPA003546	Supported					Not detected	Tissue enriched	520	testis: 51.9	all non-specific tissues: 0.0	Not detected		
FSCN1	FLJ38511, p55, SNL	ENSG00000075618	Fascin actin-bundling protein 1	7	5592823-5606655	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000121, HPA005723, CAB035991, HPA050654	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:8.15e-7 (unfavourable), Lung cancer:2.28e-4 (unfavourable), Head and neck cancer:5.76e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 85.5	spleen: 54.6	Cell line enhanced		BEWO: 579.4
FSCN2	RFSN, RP30	ENSG00000186765	Fascin actin-bundling protein 2, retinal	17	81528396-81537130	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		parathyroid gland: 4.3;thyroid gland: 2.9	fallopian tube,stomach: 0.8	Cell line enhanced		EFO-21: 1.8;T-47d: 1.9
FSCN3		ENSG00000106328	Fascin actin-bundling protein 3	7	127591409-127602144	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	245	testis: 105.7	skin: 0.4	Not detected		
FSD1	MGC3213, MIR1	ENSG00000105255	Fibronectin type III and SPRY domain containing 1	19	4304600-4323843	Predicted intracellular proteins	Evidence at protein level	HPA043141	Supported				Endometrial cancer:1.61e-4 (unfavourable)	Group enriched	Group enriched	12	cerebral cortex: 25.4;testis: 9.1	lymph node: 1.4	Cell line enhanced		SCLC-21H: 65.0;SH-SY5Y: 60.9
FSD2	RP11-127F21, SPRYD1	ENSG00000186628	Fibronectin type III and SPRY domain containing 2	15	82755362-82806070	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	21	heart muscle: 34.5;skeletal muscle: 53.5	esophagus: 2.1	Mixed		
FSIP1	FLJ35989	ENSG00000150667	Fibrous sheath interacting protein 1	15	39600031-39782830	Predicted intracellular proteins	Evidence at protein level	HPA041002	Uncertain		Uncertain	Nucleoplasm		Tissue enriched	Group enriched	7	colon: 11.2;rectum: 18.4;testis: 13.6	breast: 2.2	Mixed		
FSIP2	FLJ34780	ENSG00000188738	Fibrous sheath interacting protein 2	2	185738895-185833290	Predicted intracellular proteins	Evidence at protein level	HPA036139			Approved	Microtubules<br>Mitochondria		Not detected	Tissue enriched	9	testis: 21.3	stomach: 2.4	Cell line enhanced		RT4: 1.1
FTCD		ENSG00000160282	Formimidoyltransferase cyclodeaminase	21	46136262-46155567	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020073, HPA030928, HPA030929, HPA036114	Enhanced		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable)	Tissue enriched	Group enriched	18	kidney: 100.2;liver: 184.7	testis: 7.7	Cell line enriched	24	Hep G2: 62.7
FTH1	FHC, FTH, FTHL6, PIG15, PLIF	ENSG00000167996	Ferritin heavy chain 1	11	61959718-61967660	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008623	Approved		Approved	Microtubules	Renal cancer:5.20e-5 (unfavourable), Head and neck cancer:7.56e-5 (unfavourable), Liver cancer:6.18e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 4962.3	Expressed in all		
FTHL17	CT38	ENSG00000132446	Ferritin heavy chain like 17	X	31071241-31072053	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	14	testis: 3.4	skin: 0.2	Not detected		
FTL	MGC71996, NBIA3	ENSG00000087086	Ferritin light chain	19	48965301-48966878	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB020769, HPA041602	Enhanced		Approved	Cytosol	Renal cancer:4.40e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 8050.1	Expressed in all		
FTMT	MtF	ENSG00000181867	Ferritin mitochondrial	5	121851955-121852833	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	471	testis: 47.1	all non-specific tissues: 0.0	Not detected		
FTO	ALKBH9, KIAA1752, MGC5149	ENSG00000140718	FTO, alpha-ketoglutarate dependent dioxygenase	16	53701692-54158512	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB017123, HPA041086, HPA068695	Enhanced		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 87.0	Expressed in all		
FTSJ1	CDLIV, JM23, MRX44, MRX9, SPB1, TRM7, TRMT7	ENSG00000068438	FtsJ RNA methyltransferase homolog 1 (E. coli)	X	48476021-48486364	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002718	Approved		Approved	Cytosol	Renal cancer:5.24e-10 (unfavourable), Liver cancer:1.74e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 24.7	Expressed in all		
FTSJ3	SPB1	ENSG00000108592	FtsJ homolog 3	17	63819433-63830012	Predicted intracellular proteins	Evidence at protein level	HPA055544, HPA062628	Supported		Enhanced	Nucleoli	Liver cancer:1.44e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.0	Expressed in all		
FUBP1	FBP, FUBP	ENSG00000162613	Far upstream element binding protein 1	1	77944055-77979110	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006149	Enhanced		Enhanced	Nucleoplasm	Liver cancer:9.83e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.5	Expressed in all		
FUBP3	FBP3	ENSG00000107164	Far upstream element binding protein 3	9	130578965-130638352	Predicted intracellular proteins	Evidence at protein level	HPA047658, HPA058392	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.39e-5 (favourable), Lung cancer:2.38e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 71.7	Expressed in all		
FUK	FLJ39408	ENSG00000157353	Fucokinase	16	70454421-70480274	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041971	Approved		Approved	Vesicles	Urothelial cancer:8.38e-4 (favourable), Renal cancer:8.91e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 13.9	Mixed		
FUNDC1	MGC51029	ENSG00000069509	FUN14 domain containing 1	X	44523639-44543001	Predicted intracellular proteins	Evidence at protein level	HPA038773	Uncertain				Urothelial cancer:2.58e-4 (favourable), Testis cancer:8.35e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 30.6	Mixed		
FUNDC2	DC44, HCBP6	ENSG00000165775	FUN14 domain containing 2	X	155025980-155060303	Predicted intracellular proteins	Evidence at protein level	HPA059129	Approved				Liver cancer:3.78e-5 (unfavourable), Endometrial cancer:7.26e-4 (unfavourable), Cervical cancer:9.20e-4 (favourable)	Expressed in all	Expressed in all			ovary: 7.8	Expressed in all		
FUOM	C10orf125, FLJ26016, FucM, FucU	ENSG00000148803	Fucose mutarotase	10	133355154-133358035	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039207	Uncertain					Expressed in all	Tissue enhanced		liver: 74.9	duodenum: 50.9	Mixed		
FUS	ALS6, FUS1, hnRNP-P2, HNRNPP2, TLS	ENSG00000089280	FUS RNA binding protein	16	31180110-31194871	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008784, CAB033036, CAB058691	Enhanced		Enhanced	Nucleoplasm	Liver cancer:4.38e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 145.8	Expressed in all		
FUT7		ENSG00000180549	Fucosyltransferase 7	9	137030174-137033010	Predicted intracellular proteins	Evidence at protein level	HPA042780			Approved	Golgi apparatus		Mixed	Tissue enhanced		lymph node: 3.7;spleen: 2.6	bone marrow,tonsil: 2.0	Group enriched	7	NB-4: 10.4;THP-1: 14.0;U-937: 9.1
FXR2	FMR1L2	ENSG00000129245	FMR1 autosomal homolog 2	17	7591230-7614871	Predicted intracellular proteins	Evidence at protein level	CAB011205, HPA022997	Supported		Supported	Cytosol	Pancreatic cancer:3.49e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.4	Mixed		
FYB	FYB-120/130, SLAP-130	ENSG00000082074	FYN binding protein	5	39105236-39274528	Predicted intracellular proteins	Evidence at protein level	CAB025336, HPA026796	Enhanced				Renal cancer:2.24e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 127.4;lymph node: 109.8;spleen: 114.9	tonsil: 64.3	Cell line enhanced		HEL: 61.3;MOLT-4: 171.5;REH: 58.5;U-937: 68.8
FYCO1	FLJ13335, ZFYVE7	ENSG00000163820	FYVE and coiled-coil domain containing 1	3	45917899-45995824	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035526, HPA057966	Uncertain		Enhanced	Vesicles	Renal cancer:3.33e-11 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 91.9	Expressed in all		
FYN	MGC45350, SLK, SYN	ENSG00000010810	FYN proto-oncogene, Src family tyrosine kinase	6	111660332-111873452	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005034, CAB018387, HPA023887, HPA063770	Approved		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:1.43e-4 (unfavourable), Liver cancer:1.84e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 166.1	Cell line enhanced		U-2197: 500.5
FYTTD1	DKFZp761B1514, UIF	ENSG00000122068	Forty-two-three domain containing 1	3	197737179-197787596	Predicted intracellular proteins	Evidence at protein level	HPA054474			Supported	Nuclear speckles	Endometrial cancer:3.08e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 76.4	Expressed in all		
FZR1	CDC20C, CDH1, FZR, FZR2, HCDH, HCDH1, KIAA1242	ENSG00000105325	Fizzy and cell division cycle 20 related 1	19	3506273-3538330	Predicted intracellular proteins	Evidence at protein level	HPA043536	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Cervical cancer:1.75e-4 (favourable), Endometrial cancer:2.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.1	Expressed in all		
G0S2		ENSG00000123689	G0/G1 switch 2	1	209675420-209676388	Predicted intracellular proteins	Evidence at protein level						Glioma:2.22e-4 (unfavourable), Renal cancer:3.14e-4 (unfavourable), Colorectal cancer:7.72e-4 (unfavourable)	Expressed in all	Group enriched	5	adipose tissue: 956.0;bone marrow: 937.9;skeletal muscle: 240.5	appendix: 138.1	Cell line enhanced		ASC diff: 321.2;HBEC3-KT: 528.5;PC-3: 170.1;RPMI-8226: 166.8
G2E3	FLJ20333, KIAA1333, PHF7B	ENSG00000092140	G2/M-phase specific E3 ubiquitin protein ligase	14	30559123-30620063	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001601	Approved		Supported	Vesicles<br>Cytosol		Expressed in all	Tissue enriched	6	testis: 80.4	thyroid gland: 12.9	Mixed		
G3BP1	G3BP, HDH-VIII	ENSG00000145907	G3BP stress granule assembly factor 1	5	151771045-151812785	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004052, CAB037068	Supported		Enhanced	Cytosol	Renal cancer:3.33e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 91.0	Expressed in all		
G3BP2	KIAA0660	ENSG00000138757	G3BP stress granule assembly factor 2	4	75642782-75724525	Predicted intracellular proteins	Evidence at protein level	HPA018304, HPA018425	Enhanced		Enhanced	Cytosol	Renal cancer:6.65e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 178.5	Expressed in all		
G6PD	G6PD1	ENSG00000160211	Glucose-6-phosphate dehydrogenase	X	154531391-154547572	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000247, HPA000834	Enhanced		Approved	Vesicles<br>Microtubule organizing center<br>Cytosol	Liver cancer:9.45e-13 (unfavourable)	Expressed in all	Expressed in all			testis: 107.0	Expressed in all		
GAA		ENSG00000171298	Glucosidase alpha, acid	17	80101556-80119879	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026970, HPA029126	Enhanced				Colorectal cancer:7.66e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 69.7	Mixed		
GAB1		ENSG00000109458	GRB2 associated binding protein 1	4	143336762-143474568	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB034333, HPA049599	Enhanced		Approved	Vesicles	Renal cancer:3.91e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 32.2	Cell line enhanced		REH: 67.9
GAB2	KIAA0571	ENSG00000033327	GRB2 associated binding protein 2	11	78215297-78418348	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA000271, HPA001368, CAB022159	Enhanced		Supported	Plasma membrane	Renal cancer:9.32e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 35.5	Cell line enhanced		SH-SY5Y: 66.1
GAB3		ENSG00000160219	GRB2 associated binding protein 3	X	154675249-154751583	Predicted intracellular proteins	Evidence at protein level	HPA010090	Approved				Renal cancer:5.07e-4 (unfavourable)	Mixed	Mixed			spleen: 17.6	Cell line enhanced		HEL: 21.1;HMC-1: 22.6
GAB4		ENSG00000215568	GRB2 associated binding protein family member 4	22	16961936-17008222	Predicted intracellular proteins	Evidence at transcript level	HPA044621	Uncertain					Not detected	Tissue enriched	38	testis: 3.7	all non-specific tissues: 0.0	Not detected		
GABARAP	ATG8A, MM46	ENSG00000170296	GABA type A receptor-associated protein	17	7240014-7242770	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA065883			Approved	Vesicles	Pancreatic cancer:9.52e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 763.1	Expressed in all		
GABARAPL1	APG8L, ATG8B, ATG8L, gec1	ENSG00000139112	GABA type A receptor associated protein like 1	12	10212458-10223130	Predicted intracellular proteins	Evidence at protein level	HPA051386, HPA065883	Approved		Approved	Vesicles	Renal cancer:8.19e-8 (favourable), Liver cancer:2.36e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 432.0	Cell line enhanced		HHSteC: 208.2;SiHa: 253.0
GABARAPL2	ATG8, ATG8C, GATE-16, GATE16, GEF2	ENSG00000034713	GABA type A receptor associated protein like 2	16	75566351-75577881	Predicted intracellular proteins	Evidence at protein level	HPA036726	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.95e-8 (favourable), Head and neck cancer:7.63e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 319.3	Expressed in all		
GABPA	E4TF1-60, E4TF1A, NFT2, NRF2, NRF2A	ENSG00000154727	GA binding protein transcription factor alpha subunit	21	25734570-25772460	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003258, CAB004411, HPA028791	Supported		Enhanced	Nucleoplasm	Renal cancer:3.97e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 38.1	Expressed in all		
GABPB1	E4TF1-47, GABPB, GABPB2	ENSG00000104064	GA binding protein transcription factor beta subunit 1	15	50275392-50355408	Predicted intracellular proteins	Evidence at protein level	HPA019653, HPA067444	Supported		Supported	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.7	Expressed in all		
GABPB2	MGC29891	ENSG00000143458	GA binding protein transcription factor beta subunit 2	1	151070578-151125542	Predicted intracellular proteins	Evidence at protein level	HPA028471, HPA058483	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 20.1	Mixed		
GAD1	GAD	ENSG00000128683	Glutamate decarboxylase 1	2	170813213-170861151	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004415, HPA031949, HPA058412, CAB078176	Enhanced	Supported	Approved	Vesicles	Cervical cancer:7.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)	Tissue enhanced	Tissue enriched	6	cerebral cortex: 75.3	parathyroid gland: 11.8	Cell line enhanced		HEL: 55.7
GAD2	GAD65	ENSG00000136750	Glutamate decarboxylase 2	10	26216307-26304558	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044637, CAB078177	Enhanced					Group enriched	Tissue enriched	17	cerebral cortex: 22.9	pancreas: 1.3	Group enriched	13	MOLT-4: 2.4;SCLC-21H: 7.4
GADD45A	DDIT1, GADD45	ENSG00000116717	Growth arrest and DNA damage inducible alpha	1	67685061-67688338	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA053420			Supported	Nuclear speckles	Renal cancer:8.06e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 91.1	Expressed in all		
GADD45B	DKFZP566B133, GADD45BETA, MYD118	ENSG00000099860	Growth arrest and DNA damage inducible beta	19	2476122-2478259	Predicted intracellular proteins	Evidence at protein level	HPA029816	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 218.1	Mixed		
GADD45G	CR6, DDIT2, GADD45gamma, GRP17	ENSG00000130222	Growth arrest and DNA damage inducible gamma	9	89605013-89606555	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023606	Approved		Approved	Nucleus	Pancreatic cancer:3.80e-5 (favourable), Endometrial cancer:7.06e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 47.2	Cell line enhanced		HDLM-2: 108.4;SCLC-21H: 69.0
GADD45GIP1	CKBBP2, CKbetaBP2, CRIF1, MGC4667, MGC4758, PLINP-1, Plinp1, PRG6	ENSG00000179271	GADD45G interacting protein 1	19	12953119-12957236	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055205, HPA065048	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 29.7	Expressed in all		
GADL1		ENSG00000144644	Glutamate decarboxylase like 1	3	30726200-30894765	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039160, HPA040229	Uncertain		Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		skeletal muscle: 9.0	thyroid gland: 2.5	Cell line enhanced		HAP1: 5.0
GAGE1	CT4.1	ENSG00000205777	G antigen 1	X	49589496-49608536	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	748	testis: 110.5	duodenum: 0.1	Group enriched	7	AN3-CA: 2552.7;K-562: 597.3
GAGE10		ENSG00000215274	G antigen 10	X	49303669-49319844	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		ovary: 1.1;testis: 1.4	fallopian tube: 0.7	Cell line enhanced		AN3-CA: 2.3;WM-115: 1.0
GAGE12B		ENSG00000236737	G antigen 12B	X	49529869-49529985	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		duodenum: 1.2	spleen: 0.4	Group enriched	20	PC-3: 2.6;U-2197: 1.4
GAGE12C		ENSG00000237671	G antigen 12C	X	49532211-49539538	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	461	testis: 46.0	all non-specific tissues: 0.0	Group enriched	10	U-2 OS: 9.9;U-266/84: 25.6
GAGE12D		ENSG00000227488	G antigen 12D	X	49541767-49549094	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	461	testis: 46.0	all non-specific tissues: 0.0	Group enriched	10	U-2 OS: 9.9;U-266/84: 25.6
GAGE12E		ENSG00000216649	G antigen 12E	X	49551333-49558649	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	19	testis: 1.9	all non-specific tissues: 0.0	Cell line enhanced		AN3-CA: 2.9;HeLa: 1.1;U-266/84: 1.4
GAGE12F		ENSG00000236362	G antigen 12F	X	49551278-49568218	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Cytosol		Not detected	Tissue enriched	23	testis: 300.5	stomach: 12.8	Group enriched	6	AN3-CA: 1052.1;K-562: 1042.6;T-47d: 255.7
GAGE12G		ENSG00000215269	G antigen 12G	X	49570434-49577754	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	78	stomach: 7.8	all non-specific tissues: 0.0	Cell line enriched	7	AN3-CA: 898.2
GAGE12H		ENSG00000224902	G antigen 12H	X	49579983-49587301	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	392	testis: 39.2	all non-specific tissues: 0.0	Group enriched	44	A-431: 47.0;U-266/84: 113.6
GAGE12J	GAGE11	ENSG00000224659	G antigen 12J	X	49322057-49329384	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	34	testis: 32.7	epididymis: 0.9	Group enriched	6	AN3-CA: 132.7;K-562: 134.5
GAGE13	GAGE12A	ENSG00000274274	G antigen 13	X	49331616-49338952	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	553	testis: 59.6	stomach: 0.1	Cell line enriched	6	AN3-CA: 685.8
GAGE2A	CT4.2, GAGE2	ENSG00000189064	G antigen 2A	X	49589529-49596827	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	560	testis: 176.3	cerebral cortex: 0.3	Cell line enhanced		Karpas-707: 62.0;T-47d: 279.0;WM-115: 324.4
GAGE2E	GAGE8	ENSG00000275113	G antigen 2E	X	49341192-49345922	Predicted intracellular proteins	Evidence at transcript level	HPA043232	Approved		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Group enriched	60	stomach: 15.4;testis: 8.6	small intestine: 0.2	Group enriched	5	AN3-CA: 943.7;K-562: 455.5;T-47d: 231.8
GAK	DNAJC26	ENSG00000178950	Cyclin G associated kinase	4	849276-932373	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027405, HPA027459, HPA027463	Approved		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:1.70e-6 (favourable), Urothelial cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 51.5	Expressed in all		
GALE	SDR1E1	ENSG00000117308	UDP-galactose-4-epimerase	1	23795599-23800804	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007340	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Thyroid cancer:2.68e-4 (favourable)	Expressed in all	Expressed in all			stomach: 112.8	Expressed in all		
GALK1	GALK	ENSG00000108479	Galactokinase 1	17	75751594-75765711	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007094, HPA016960	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.55e-6 (unfavourable), Urothelial cancer:1.62e-5 (unfavourable)	Expressed in all	Expressed in all			liver: 23.4	Expressed in all		
GALK2	GK2	ENSG00000156958	Galactokinase 2	15	49155656-49367869	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043564, HPA048267	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.88e-5 (favourable), Endometrial cancer:7.31e-4 (favourable)	Expressed in all	Expressed in all			kidney: 31.8	Expressed in all		
GALM		ENSG00000143891	Galactose mutarotase	2	38665910-38741237	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035472, HPA035473, HPA064835	Enhanced		Approved	Nucleoplasm	Renal cancer:9.06e-5 (favourable), Urothelial cancer:1.32e-4 (favourable)	Expressed in all	Expressed in all			kidney: 118.1	Mixed		
GALNT13	GalNAc-T13, KIAA1918	ENSG00000144278	Polypeptide N-acetylgalactosaminyltransferase 13	2	153871913-154453849	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060775	Approved					Tissue enriched	Group enriched	6	adrenal gland: 6.6;cerebral cortex: 32.7	prostate: 3.5	Cell line enhanced		SH-SY5Y: 46.7;WM-115: 33.1
GALNT16	GalNAc-T16, GALNTL1, KIAA1130	ENSG00000100626	Polypeptide N-acetylgalactosaminyltransferase 16	14	69259277-69357033	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059136	Approved		Approved	Nucleus	Renal cancer:5.23e-6 (favourable)	Mixed	Mixed			cerebral cortex: 28.5	Cell line enhanced		AF22: 9.0;hTEC/SVTERT24-B: 17.0;SCLC-21H: 10.5;U-2 OS: 21.2
GALNT4	GalNAc-T4	ENSG00000257594	Polypeptide N-acetylgalactosaminyltransferase 4	12	89519408-89524806	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA076116			Supported	Golgi apparatus<br>Vesicles		Mixed	Mixed			stomach: 31.0	Cell line enhanced		PC-3: 20.4
GALNT5	GalNAc-T5	ENSG00000136542	Polypeptide N-acetylgalactosaminyltransferase 5	2	157257598-157314211	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008963, HPA009035	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		lung: 18.4;rectum: 19.7;stomach: 16.8	colon: 13.9	Cell line enhanced		A-431: 60.2;BJ hTERT+: 63.9;fHDF/TERT166: 72.0;HaCaT: 69.5;LHCN-M2: 65.2
GALNT7	GALNAC-T7	ENSG00000109586	Polypeptide N-acetylgalactosaminyltransferase 7	4	173168753-173323967	Predicted intracellular proteins	Evidence at protein level	HPA064243, HPA065317	Enhanced		Enhanced	Nucleus<br>Golgi apparatus	Colorectal cancer:4.53e-4 (favourable), Pancreatic cancer:7.65e-4 (unfavourable)	Expressed in all	Mixed			stomach: 62.9	Mixed		
GALT		ENSG00000213930	Galactose-1-phosphate uridylyltransferase	9	34638133-34651035	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004868, HPA005729	Enhanced		Approved	Cytosol	Renal cancer:6.25e-6 (favourable), Pancreatic cancer:3.11e-5 (favourable)	Expressed in all	Expressed in all			liver: 25.7	Mixed		
GAMT	PIG2, TP53I2	ENSG00000130005	Guanidinoacetate N-methyltransferase	19	1397026-1401570	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051806	Approved				Stomach cancer:6.57e-4 (unfavourable)	Tissue enriched	Group enriched	5	epididymis: 173.0;liver: 158.9;skeletal muscle: 425.6	pancreas: 48.1	Mixed		
GAN	GAN1, KLHL16	ENSG00000261609	Gigaxonin	16	81314952-81390884	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011825, HPA049473	Approved		Supported	Microtubules		Mixed	Tissue enriched	6	skin: 29.5	cerebral cortex: 5.0	Mixed		
GANC		ENSG00000214013	Glucosidase alpha, neutral C	15	42273233-42356935	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016949	Approved		Approved	Nucleoplasm<br>Actin filaments	Lung cancer:9.76e-4 (favourable)	Expressed in all	Expressed in all			lung: 29.8	Expressed in all		
GAP43	B-50, PP46	ENSG00000172020	Growth associated protein 43	3	115623324-115721490	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004417, HPA013392, HPA015600	Enhanced		Enhanced	Plasma membrane		Tissue enriched	Tissue enriched	38	cerebral cortex: 345.9	appendix: 9.1	Group enriched	6	AF22: 34.3;NTERA-2: 74.0;SCLC-21H: 55.5;SH-SY5Y: 37.6;U-87 MG: 16.1
GAPDH	GAPD	ENSG00000111640	Glyceraldehyde-3-phosphate dehydrogenase	12	6533927-6538374	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005197, CAB016392, HPA040067, HPA061280	Supported		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:6.25e-10 (unfavourable), Liver cancer:1.79e-6 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 9869.6	Expressed in all		
GAPDHS	GAPD2, GAPDH-2, GAPDS	ENSG00000105679	Glyceraldehyde-3-phosphate dehydrogenase, spermatogenic	19	35533412-35545316	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042666	Enhanced		Approved	Nucleoplasm<br>Centrosome		Tissue enriched	Tissue enriched	13	testis: 242.8	thyroid gland: 19.0	Mixed		
GAPT	C5orf29, FLJ33641	ENSG00000175857	GRB2 binding adaptor protein, transmembrane	5	58491435-58497090	Predicted intracellular proteins	Evidence at protein level	HPA011070	Uncertain					Mixed	Tissue enhanced		appendix: 38.8;tonsil: 38.8	lymph node: 30.1	Cell line enhanced		HEL: 64.1;HL-60: 33.1;NB-4: 27.3;THP-1: 22.7;U-937: 92.5
GAPVD1	DKFZP434C212, KIAA1521	ENSG00000165219	GTPase activating protein and VPS9 domains 1	9	125261794-125367207	Predicted intracellular proteins	Evidence at protein level	HPA029386, HPA029387	Uncertain		Supported	Cytosol		Expressed in all	Expressed in all			testis: 49.2	Expressed in all		
GAR1	NOLA1	ENSG00000109534	GAR1 ribonucleoprotein	4	109815510-109824740	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059098	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:2.64e-5 (unfavourable)	Expressed in all	Expressed in all			breast: 23.0	Expressed in all		
GAREM1	C18orf11, FAM59A, FLJ21610, GAREM	ENSG00000141441	GRB2 associated regulator of MAPK1 subtype 1	18	32124877-32470484	Predicted intracellular proteins	Evidence at protein level	HPA040709, HPA042046	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.49e-6 (favourable), Pancreatic cancer:6.73e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 13.7	Cell line enhanced		hTERT-HME1: 23.0;RT4: 21.0;SH-SY5Y: 22.6
GAREM2	FAM59B, FLJ00375, GAREML, KIAA2038	ENSG00000157833	GRB2 associated regulator of MAPK1 subtype 2	2	26173091-26189663	Predicted intracellular proteins	Evidence at protein level	HPA071575			Approved	Cytosol		Mixed	Group enriched	6	cerebral cortex: 23.0;parathyroid gland: 17.8	smooth muscle: 3.4	Cell line enhanced		HAP1: 17.3;U-2 OS: 14.6
GARNL3	bA356B19.1, DKFZp761J1523	ENSG00000136895	GTPase activating Rap/RanGAP domain like 3	9	127224265-127393660	Predicted intracellular proteins	Evidence at protein level	HPA022433, HPA028757, HPA074886	Uncertain		Approved	Vesicles		Mixed	Mixed			parathyroid gland: 15.5	Cell line enhanced		SH-SY5Y: 3.7
GART	PGFT, PRGS	ENSG00000159131	Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	21	33503931-33543491	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002119, HPA005779	Approved		Uncertain	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:3.95e-6 (unfavourable), Head and neck cancer:5.05e-5 (unfavourable), Liver cancer:9.82e-5 (unfavourable), Pancreatic cancer:2.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 55.1	Expressed in all		
GAS2		ENSG00000148935	Growth arrest specific 2	11	22625642-22813055	Predicted intracellular proteins	Evidence at protein level	HPA058904	Enhanced		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:6.13e-4 (favourable)	Tissue enhanced	Tissue enhanced		liver: 20.4	kidney: 5.5	Group enriched	11	Hep G2: 29.5;Karpas-707: 61.6;SCLC-21H: 29.3;U-266/84: 21.3
GAS2L1	GAR22	ENSG00000185340	Growth arrest specific 2 like 1	22	29306582-29312785	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019858	Approved		Approved	Plasma membrane<br>Cell Junctions	Renal cancer:8.44e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.1	Cell line enhanced		U-138 MG: 75.8
GAS2L2	GAR17	ENSG00000270765	Growth arrest specific 2 like 2	17	35744511-35752878	Predicted intracellular proteins	Evidence at protein level	HPA044370	Enhanced				Endometrial cancer:7.00e-4 (favourable)	Tissue enhanced	Tissue enriched	11	fallopian tube: 28.2	epididymis,lung: 2.6	Cell line enhanced		HaCaT: 1.4
GAS2L3		ENSG00000139354	Growth arrest specific 2 like 3	12	100573683-100628286	Predicted intracellular proteins	Evidence at protein level	HPA048593	Approved				Renal cancer:3.58e-7 (unfavourable)	Mixed	Mixed			gallbladder: 7.0	Mixed		
GAS7	KIAA0394, MGC1348	ENSG00000007237	Growth arrest specific 7	17	9910609-10198551	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004838, HPA064678	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Urothelial cancer:6.89e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 154.7	cervix, uterine: 47.6	Cell line enriched	11	WM-115: 526.3
GAS8	DRC4, GAS11	ENSG00000141013	Growth arrest specific 8	16	90019629-90044975	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041311, HPA048238	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.09e-7 (favourable), Endometrial cancer:3.01e-4 (favourable), Pancreatic cancer:7.67e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 30.0	Mixed		
GATA1	ERYF1, GATA-1, GF1, NF-E1, NFE1	ENSG00000102145	GATA binding protein 1	X	48786554-48794311	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000232, HPA000233, CAB009195	Enhanced					Not detected	Tissue enriched	19	bone marrow: 33.2	testis: 1.7	Group enriched	12	HEL: 182.0;HMC-1: 176.5;K-562: 196.6
GATA2	NFE1B	ENSG00000179348	GATA binding protein 2	3	128479427-128493185	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005633, CAB024847	Approved		Supported	Nucleoplasm	Urothelial cancer:5.22e-5 (favourable), Renal cancer:2.04e-4 (favourable)	Expressed in all	Tissue enhanced		prostate: 62.7;seminal vesicle: 74.7	endometrium: 40.5	Cell line enhanced		BEWO: 272.0;HEL: 324.7;HMC-1: 165.0;SH-SY5Y: 347.2
GATA3	HDR	ENSG00000107485	GATA binding protein 3	10	8053604-8075198	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016217, HPA029730	Enhanced		Supported	Nucleoplasm	Renal cancer:3.13e-4 (unfavourable)	Group enriched	Tissue enhanced		parathyroid gland: 235.0;skin: 148.9	placenta: 44.3	Cell line enhanced		BEWO: 172.2;MCF7: 354.3;RT4: 149.5;SH-SY5Y: 145.4;T-47d: 506.9
GATA4		ENSG00000136574	GATA binding protein 4	8	11676959-11760002	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB013125, HPA073899	Uncertain		Supported	Nuclear bodies		Tissue enhanced	Tissue enhanced		duodenum: 72.5;heart muscle: 59.0;ovary: 111.8	testis: 51.5	Cell line enhanced		HEK93: 11.9;Hep G2: 21.2;HHSteC: 31.6;SH-SY5Y: 45.2
GATA5	bB379O24.1, GATAS	ENSG00000130700	GATA binding protein 5	20	62463497-62475970	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067583			Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		duodenum: 11.4;small intestine: 11.0;testis: 8.7	stomach: 7.5	Cell line enhanced		HEL: 2.6;K-562: 4.2;SiHa: 2.1;T-47d: 4.4
GATA6		ENSG00000141448	GATA binding protein 6	18	22169443-22202528	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011581, HPA066629	Uncertain		Supported	Nucleus	Renal cancer:1.92e-9 (unfavourable)	Tissue enhanced	Mixed			adrenal gland: 50.8	Cell line enhanced		BEWO: 51.6;CACO-2: 55.5
GATAD1	FLJ22489, ODAG, RG083M05.2	ENSG00000157259	GATA zinc finger domain containing 1	7	92447453-92458836	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006105, HPA072785			Supported	Nucleus		Expressed in all	Expressed in all			thyroid gland: 42.3	Expressed in all		
GATAD2A	p66alpha	ENSG00000167491	GATA zinc finger domain containing 2A	19	19385826-19508931	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006759, HPA024373	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 64.1	Expressed in all		
GATAD2B	P66beta	ENSG00000143614	GATA zinc finger domain containing 2B	1	153789030-153923360	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017015	Approved		Enhanced	Nucleoplasm	Colorectal cancer:1.30e-4 (unfavourable), Renal cancer:3.08e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 19.7	Expressed in all		
GATB	PET112, PET112L	ENSG00000059691	Glutamyl-tRNA amidotransferase subunit B	4	151670504-151761023	Predicted intracellular proteins	Evidence at protein level	HPA042610	Uncertain		Supported	Mitochondria	Renal cancer:1.20e-10 (favourable)	Expressed in all	Mixed			kidney: 22.4	Expressed in all		
GATC	15E1.2, FLJ37000, gatC	ENSG00000257218	Glutamyl-tRNA amidotransferase subunit C	12	120446438-120463749	Predicted intracellular proteins	Evidence at protein level						Liver cancer:4.21e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.1	Expressed in all		
GATM	AGAT	ENSG00000171766	Glycine amidinotransferase	15	45361124-45402327	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026077	Enhanced		Supported	Mitochondria	Renal cancer:1.38e-4 (favourable)	Expressed in all	Group enriched	6	kidney: 1904.2;liver: 1291.1;pancreas: 573.9	ovary: 195.7	Cell line enhanced		RH-30: 190.4;U-266/70: 92.4;U-266/84: 115.1
GATS	DKFZp686B07267, STAG3OS	ENSG00000239521	GATS, stromal antigen 3 opposite strand	7	100200653-100272218	Predicted intracellular proteins	Evidence at transcript level	HPA043176	Uncertain				Cervical cancer:7.56e-7 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 3.3;skeletal muscle: 2.2	bone marrow: 0.7	Cell line enhanced		A549: 1.4
GATSL2	GATSL1	ENSG00000274070	GATS protein like 2	7	74964818-75024798	Predicted intracellular proteins	Evidence at protein level	HPA057229	Uncertain					Expressed in all	Tissue enhanced		cerebral cortex: 14.9	skeletal muscle: 13.8	Cell line enhanced		A549: 24.5
GATSL3		ENSG00000239282	GATS protein like 3	22	30285117-30289627	Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			esophagus: 22.8	Mixed		
GBA2	AD035, DKFZp762K054, KIAA1605, SPG46	ENSG00000070610	Glucosylceramidase beta 2	9	35736866-35749228	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024026	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.24e-11 (favourable), Pancreatic cancer:6.00e-4 (favourable), Urothelial cancer:6.60e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 64.2	Expressed in all		
GBAS	NIPSNAP2	ENSG00000146729	Glioblastoma amplified sequence	7	55951793-56000181	Predicted intracellular proteins	Evidence at protein level	HPA063084	Enhanced		Supported	Mitochondria	Renal cancer:3.02e-8 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 224.4	Expressed in all		
GBE1		ENSG00000114480	1,4-alpha-glucan branching enzyme 1	3	81489699-81762161	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038073, HPA038074, HPA038075	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 79.6	Expressed in all		
GBF1	ARF1GEF, KIAA0248	ENSG00000107862	Golgi brefeldin A resistant guanine nucleotide exchange factor 1	10	102245532-102382899	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037759, HPA037760	Uncertain		Supported	Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 59.2	Expressed in all		
GBP1		ENSG00000117228	Guanylate binding protein 1	1	89052319-89065360	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015450	Approved				Renal cancer:5.12e-9 (unfavourable), Ovarian cancer:5.04e-4 (favourable), Colorectal cancer:8.32e-4 (favourable)	Expressed in all	Expressed in all			appendix: 118.8	Cell line enhanced		BJ hTERT+ SV40 Large T+: 109.8;BJ hTERT+ SV40 Large T+ RasG12V: 155.2
GBP2		ENSG00000162645	Guanylate binding protein 2	1	89106132-89150456	Predicted intracellular proteins	Evidence at protein level	HPA042682, CAB045975	Supported		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:2.14e-10 (unfavourable), Urothelial cancer:1.10e-5 (favourable), Pancreatic cancer:5.73e-5 (unfavourable), Breast cancer:7.57e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 195.5	Cell line enhanced		EFO-21: 57.2;HDLM-2: 65.6;RT4: 69.0
GBP3	FLJ10961	ENSG00000117226	Guanylate binding protein 3	1	89006666-89022894	Predicted intracellular proteins	Evidence at protein level	HPA045657	Approved					Expressed in all	Mixed			duodenum: 77.0	Cell line enhanced		BJ hTERT+: 64.5;LHCN-M2: 58.7
GBP4	Mpa2	ENSG00000162654	Guanylate binding protein 4	1	89181148-89198932	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030101, HPA062039	Enhanced		Approved	Plasma membrane	Renal cancer:1.30e-5 (unfavourable), Ovarian cancer:9.29e-5 (favourable)	Expressed in all	Mixed			lung: 46.9	Cell line enhanced		CAPAN-2: 10.6;HEL: 11.8;REH: 10.2;RT4: 14.7;U-266/70: 12.3
GBP5		ENSG00000154451	Guanylate binding protein 5	1	89258950-89272804	Predicted intracellular proteins	Evidence at protein level	HPA028656	Approved		Approved	Endoplasmic reticulum	Renal cancer:5.53e-8 (unfavourable), Endometrial cancer:3.73e-6 (favourable), Ovarian cancer:1.24e-4 (favourable), Colorectal cancer:9.54e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 100.5	lymph node: 60.4	Cell line enhanced		NB-4: 6.3;U-266/70: 15.8;U-937: 24.8
GBP6	DKFZp686G0786	ENSG00000183347	Guanylate binding protein family member 6	1	89364058-89386461	Predicted intracellular proteins	Evidence at protein level	HPA027744	Enhanced					Group enriched	Tissue enriched	7	esophagus: 448.5	tonsil: 65.9	Group enriched	10	A-431: 6.0;HaCaT: 13.1
GBP7	FLJ38822, GBP4L	ENSG00000213512	Guanylate binding protein 7	1	89131751-89176040	Predicted intracellular proteins	Evidence at protein level	HPA051245	Uncertain					Tissue enriched	Tissue enriched	89	liver: 48.3	adrenal gland: 0.5	Not detected		
GBX1		ENSG00000164900	Gastrulation brain homeobox 1	7	151148589-151174745	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055783	Uncertain					Tissue enhanced	Group enriched	57	skeletal muscle: 4.4;testis: 6.9	all non-specific tissues: 0.0	Cell line enhanced		HMC-1: 1.4
GBX2		ENSG00000168505	Gastrulation brain homeobox 2	2	236165236-236168369	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067809			Approved	Nucleoplasm		Group enriched	Not detected			cerebral cortex: 0.6	Cell line enhanced		AF22: 47.4;PC-3: 13.2
GCA	GCL	ENSG00000115271	Grancalcin	2	162318840-162371595	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035033, HPA035034	Enhanced		Supported	Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		bone marrow: 214.5	appendix: 88.0	Mixed		
GCAT	KBL	ENSG00000100116	Glycine C-acetyltransferase	22	37807905-37817176	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020460	Uncertain		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			prostate: 30.0	Expressed in all		
GCC1	FLJ22035, GCC1P, GCC88, MGC20706	ENSG00000179562	GRIP and coiled-coil domain containing 1	7	127580618-127593611	Predicted intracellular proteins	Evidence at protein level	HPA019369, HPA021323	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 18.7	Expressed in all		
GCC2	GCC185, KIAA0336	ENSG00000135968	GRIP and coiled-coil domain containing 2	2	108448561-108509415	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035849, HPA035850	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus	Liver cancer:4.24e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 34.0	Expressed in all		
GCDH	ACAD5	ENSG00000105607	Glutaryl-CoA dehydrogenase	19	12891026-12914207	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043252, HPA048492	Enhanced		Supported	Mitochondria	Renal cancer:6.79e-8 (favourable), Liver cancer:7.28e-5 (favourable), Lung cancer:3.35e-4 (favourable)	Expressed in all	Expressed in all			liver: 42.9	Expressed in all		
GCFC2	C2orf3, DNABF, GCF, TCF9	ENSG00000005436	GC-rich sequence DNA-binding factor 2	2	75652000-75710989	Predicted intracellular proteins	Evidence at protein level	HPA077882			Supported	Nucleoplasm	Thyroid cancer:3.09e-4 (unfavourable), Endometrial cancer:9.59e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 17.0	Expressed in all		
GCH1	DYT14, DYT5, DYT5a, GCH, GTPCH1	ENSG00000131979	GTP cyclohydrolase 1	14	54842008-54902852	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028612	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Pancreatic cancer:1.41e-4 (favourable), Urothelial cancer:6.67e-4 (favourable), Ovarian cancer:8.69e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 22.6	liver: 18.8	Cell line enhanced		SH-SY5Y: 48.2
GCHFR	GFRP, HsT16933	ENSG00000137880	GTP cyclohydrolase I feedback regulator	15	40764020-40767710	Predicted intracellular proteins	Evidence at protein level	HPA046258	Approved		Supported	Nucleoplasm	Lung cancer:5.62e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 62.4	Cell line enhanced		RPTEC TERT1: 101.8;SCLC-21H: 141.5
GCK	HK4, MODY2	ENSG00000106633	Glucokinase	7	44144271-44198170	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007034, HPA007093	Approved		Approved	Golgi apparatus<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 2.5	Cell line enriched	6	SCLC-21H: 7.7
GCKR		ENSG00000084734	Glucokinase regulator	2	27496842-27523684	Predicted intracellular proteins	Evidence at protein level	CAB034098, HPA064305	Enhanced		Approved	Intermediate filaments		Tissue enriched	Tissue enriched	7	liver: 44.3	stomach: 6.1	Group enriched	7	HEL: 12.0;Hep G2: 14.0;HUVEC TERT2: 5.3;TIME: 3.2
GCLM	GLCLR	ENSG00000023909	Glutamate-cysteine ligase modifier subunit	1	93885205-93909456	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB009568, HPA023696, CAB040554	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:9.83e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.2	Expressed in all		
GCM1	GCMA, hGCMa	ENSG00000137270	Glial cells missing homolog 1	6	53126964-53148829	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA011343	Enhanced		Approved	Vesicles		Not detected	Tissue enriched	21	placenta: 29.1	kidney: 1.3	Cell line enriched	25	BEWO: 38.0
GCM2	GCMB, hGCMb	ENSG00000124827	Glial cells missing homolog 2	6	10873223-10881941	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	997	parathyroid gland: 774.1	testis: 0.7	Not detected		
GCN1	GCN1L, GCN1L1, KIAA0219	ENSG00000089154	GCN1, eIF2 alpha kinase activator homolog	12	120127203-120194710	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018799, HPA019648, HPA024367	Enhanced		Enhanced	Cytosol	Liver cancer:1.87e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 37.5	Expressed in all		
GCNA	ACRC, NAAR1	ENSG00000147174	Germ cell nuclear acidic peptidase	X	71578411-71613583	Predicted intracellular proteins	Evidence at protein level	HPA023476	Enhanced		Approved	Vesicles		Mixed	Group enriched	5	adrenal gland: 5.9;testis: 20.6	spleen: 2.4	Mixed		
GCNT1	C2GNT, NACGT2, NAGCT2	ENSG00000187210	Glucosaminyl (N-acetyl) transferase 1, core 2	9	76419850-76507416	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003522, HPA003523, HPA031151	Uncertain		Supported	Nuclear speckles	Urothelial cancer:4.96e-4 (unfavourable), Endometrial cancer:8.44e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 186.4	duodenum: 50.1	Cell line enhanced		HHSteC: 38.9
GCNT4	C2GNT3	ENSG00000176928	Glucosaminyl (N-acetyl) transferase 4, core 2	5	75025346-75030899	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037431	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.93e-7 (favourable)	Mixed	Mixed			duodenum: 21.4	Cell line enriched	5	RT4: 25.9
GCOM1	FLJ30973, GRINL1A, MYZAP-POLR2M	ENSG00000137878	GRINL1A complex locus 1	15	57591908-57714745	Predicted intracellular proteins	Evidence at protein level	HPA039827, HPA068141	Approved		Approved	Nucleoplasm		Not detected	Mixed			heart muscle: 6.2	Cell line enhanced		HEL: 29.8;RH-30: 8.7;TIME: 11.5
GCSAM	GCET2, HGAL, MGC40441	ENSG00000174500	Germinal center associated signaling and motility	3	112120841-112133305	Predicted intracellular proteins	Evidence at protein level	HPA002473	Approved					Mixed	Tissue enhanced		lymph node: 52.0;tonsil: 53.1	skin: 26.2	Group enriched	5	Daudi: 187.5;U-698: 102.8
GCSAML	C1orf150, FLJ44728	ENSG00000169224	Germinal center associated signaling and motility like	1	247507058-247577690	Predicted intracellular proteins	Evidence at protein level	HPA027507, HPA027510	Uncertain		Approved	Cytosol		Tissue enriched	Tissue enhanced		prostate: 9.1;testis: 7.3	lung: 3.3	Group enriched	98	HEL: 133.3;HMC-1: 495.5
GDA		ENSG00000119125	Guanine deaminase	9	72114595-72257193	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019352, HPA024099, HPA030387	Enhanced		Approved	Nucleus	Renal cancer:2.66e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 102.2;duodenum: 95.2;small intestine: 104.1	kidney: 43.6	Cell line enhanced		A-431: 31.0;EFO-21: 125.3;HeLa: 32.0;hTCEpi: 45.2
GDAP2	dJ776P7.1, FLJ20142, MACROD3	ENSG00000196505	Ganglioside induced differentiation associated protein 2	1	117863485-117929630	Predicted intracellular proteins	Evidence at protein level	HPA046185	Approved		Approved	Endoplasmic reticulum		Expressed in all	Mixed			parathyroid gland: 9.5	Expressed in all		
GDF5OS		ENSG00000204183	Growth differentiation factor 5 opposite strand	20	35433029-35435450	Predicted intracellular proteins	Evidence at transcript level	HPA062720	Uncertain					Not detected	Not detected			adipose tissue: 0.3	Not detected		
GDI1	FLJ41411, GDIL, MRX41, MRX48, OPHN2, RABGDIA, XAP-4	ENSG00000203879	GDP dissociation inhibitor 1	X	154436913-154443467	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012979, HPA049290, HPA057668	Enhanced		Approved	Vesicles	Colorectal cancer:3.83e-5 (unfavourable), Breast cancer:6.84e-4 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 532.0	smooth muscle: 101.3	Expressed in all		
GDI2	RABGDIB	ENSG00000057608	GDP dissociation inhibitor 2	10	5765223-5842132	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049290, HPA057668	Supported				Liver cancer:7.56e-7 (unfavourable), Glioma:7.00e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 241.2	Expressed in all		
GDPGP1	C15orf58	ENSG00000183208	GDP-D-glucose phosphorylase 1	15	90233808-90245811	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048189, HPA059841	Approved		Approved	Cytosol	Breast cancer:6.32e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.6	Mixed		
GEM	KIR	ENSG00000164949	GTP binding protein overexpressed in skeletal muscle	8	94249253-94262350	Predicted intracellular proteins	Evidence at protein level	HPA024798	Approved				Renal cancer:1.56e-5 (unfavourable), Thyroid cancer:4.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 364.8	endometrium: 157.2	Cell line enhanced		BJ hTERT+: 67.0;U-266/70: 106.3;U-87 MG: 102.0
GEMIN2	SIP1	ENSG00000092208	Gem nuclear organelle associated protein 2	14	39114223-39136973	Predicted intracellular proteins	Evidence at protein level	CAB015426, HPA046570, HPA057114	Enhanced		Supported	Nucleus<br>Nucleoli<br>Nuclear bodies	Liver cancer:3.88e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 17.1	Expressed in all		
GEMIN4	DKFZP434B131, DKFZP434D174, HC56, HCAP1, HHRF-1, p97	ENSG00000179409	Gem nuclear organelle associated protein 4	17	744414-753999	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065699, HPA067891	Uncertain		Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 78.2	Expressed in all		
GEMIN5		ENSG00000082516	Gem nuclear organelle associated protein 5	5	154887416-154938209	Predicted intracellular proteins	Evidence at protein level	HPA037392, HPA037393	Uncertain		Enhanced	Nuclear bodies<br>Cytosol	Endometrial cancer:6.23e-5 (unfavourable), Liver cancer:1.78e-4 (unfavourable), Renal cancer:2.05e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.6	Expressed in all		
GEMIN6	FLJ23459	ENSG00000152147	Gem nuclear organelle associated protein 6	2	38751534-38785000	Predicted intracellular proteins	Evidence at protein level	HPA035726, HPA035727	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.94e-4 (unfavourable)	Expressed in all	Mixed			testis: 28.9	Expressed in all		
GEMIN7	FLJ13956	ENSG00000142252	Gem nuclear organelle associated protein 7	19	45079195-45091524	Predicted intracellular proteins	Evidence at protein level	HPA052075			Supported	Nucleus<br>Cytosol	Renal cancer:9.64e-11 (unfavourable), Liver cancer:5.86e-5 (unfavourable), Urothelial cancer:8.00e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 30.3	Expressed in all		
GEMIN8	FAM51A1, FLJ20514	ENSG00000046647	Gem nuclear organelle associated protein 8	X	14008279-14029893	Predicted intracellular proteins	Evidence at protein level	HPA028613	Uncertain		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:7.73e-5 (favourable), Liver cancer:7.78e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 31.7	Expressed in all		
GEN1	FLJ40869, Gen	ENSG00000178295	GEN1, Holliday junction 5' flap endonuclease	2	17753858-17788941	Predicted intracellular proteins	Evidence at protein level	HPA020078, HPA021141	Uncertain		Approved	Nucleoplasm	Endometrial cancer:1.68e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 15.5	Expressed in all		
GET4	C7orf20, CEE, CGI-20, H_NH1244M04.5, TRC35	ENSG00000239857	Golgi to ER traffic protein 4	7	876552-896436	Predicted intracellular proteins	Evidence at protein level	HPA019765	Uncertain		Supported	Nucleoplasm<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			testis: 49.7	Expressed in all		
GFAP	FLJ45472	ENSG00000131095	Glial fibrillary acidic protein	17	44903161-44916937	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000039, HPA056030, HPA063513	Enhanced	Supported	Supported	Intermediate filaments		Tissue enriched	Tissue enriched	398	cerebral cortex: 3768.4	bone marrow: 9.4	Mixed		
GFER	ALR, ERV1, HERV1, HPO1, HPO2, HSS	ENSG00000127554	Growth factor, augmenter of liver regeneration	16	1984207-1987749	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041227, HPA063553	Approved		Enhanced	Mitochondria<br>Cytosol	Renal cancer:4.06e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 50.0	Expressed in all		
GFI1	GFI-1, GFI1A, ZNF163	ENSG00000162676	Growth factor independent 1 transcriptional repressor	1	92474762-92486876	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011197	Uncertain				Colorectal cancer:5.68e-5 (favourable)	Mixed	Tissue enhanced		bone marrow: 34.8	lymph node: 8.1	Cell line enhanced		HL-60: 49.8;HMC-1: 42.0;THP-1: 86.5;U-937: 207.4
GFI1B	ZNF163B	ENSG00000165702	Growth factor independent 1B transcriptional repressor	9	132944000-132991687	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004420	Enhanced					Not detected	Tissue enriched	15	bone marrow: 23.8	testis: 1.5	Group enriched	6	HEL: 151.4;HMC-1: 92.4;K-562: 47.5
GFM1	EFGM, EGF1, GFM	ENSG00000168827	G elongation factor mitochondrial 1	3	158644278-158692575	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034764, HPA034765, HPA061405	Enhanced		Approved	Nucleus<br>Mitochondria	Renal cancer:1.16e-7 (favourable), Pancreatic cancer:9.20e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.5	Expressed in all		
GFM2	EFG2, FLJ21661	ENSG00000164347	G elongation factor mitochondrial 2	5	74721204-74767371	Predicted intracellular proteins	Evidence at protein level	HPA036863	Uncertain				Renal cancer:1.33e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 36.6	Expressed in all		
GFOD1	ADG-90, C6orf114, FLJ20330	ENSG00000145990	Glucose-fructose oxidoreductase domain containing 1	6	13357830-13487662	Predicted intracellular proteins	Evidence at protein level	HPA029096	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:2.29e-5 (unfavourable), Renal cancer:6.72e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 22.3	Cell line enhanced		HEL: 28.5;HMC-1: 41.5
GGA1		ENSG00000100083	Golgi associated, gamma adaptin ear containing, ARF binding protein 1	22	37608475-37633564	Predicted intracellular proteins	Evidence at protein level	HPA048280, HPA051016	Supported		Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:4.86e-4 (favourable), Liver cancer:6.29e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 199.2	Expressed in all		
GGA3	KIAA0154	ENSG00000125447	Golgi associated, gamma adaptin ear containing, ARF binding protein 3	17	75236599-75262363	Predicted intracellular proteins	Evidence at protein level	HPA022945, HPA024645	Approved		Supported	Golgi apparatus	Liver cancer:2.77e-6 (unfavourable), Renal cancer:3.41e-4 (unfavourable), Endometrial cancer:8.26e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.7	Expressed in all		
GGACT	A2LD1	ENSG00000134864	Gamma-glutamylamine cyclotransferase	13	100530164-100589528	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA065320	Enhanced					Expressed in all	Tissue enriched	6	kidney: 75.9	testis: 11.8	Cell line enriched	8	SCLC-21H: 157.1
GGCT	C7orf24, CRF21, GCTG, Ggc, MGC3077	ENSG00000006625	Gamma-glutamylcyclotransferase	7	30496621-30504844	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020735, HPA029914	Approved				Liver cancer:7.23e-4 (unfavourable), Breast cancer:7.68e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 125.5	Expressed in all		
GGN	FLJ35713, MGC33369	ENSG00000179168	Gametogenetin	19	38384265-38388082	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	11	testis: 34.9	small intestine: 3.1	Cell line enhanced		BEWO: 2.5
GGNBP2	DIF-3, DIF3, FLJ21230, FLJ22561, LZK1, ZFP403, ZNF403	ENSG00000278311	Gametogenetin binding protein 2	17	36544888-36589848	Predicted intracellular proteins	Evidence at protein level	HPA018914, HPA073392	Approved		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			testis: 55.7	Expressed in all		
GGPS1	GGPPS1	ENSG00000152904	Geranylgeranyl diphosphate synthase 1	1	235327350-235344532	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029472	Enhanced				Liver cancer:6.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 90.1	Expressed in all		
GGTLC1	dJ831C21.1, dJ831C21.2, GGTLA3, GGTLA4	ENSG00000149435	Gamma-glutamyltransferase light chain 1	20	23985050-23988779	Predicted intracellular proteins	Evidence at protein level	HPA045635, HPA047534	Uncertain					Tissue enriched	Group enriched	14	lung: 38.7;testis: 15.8	thyroid gland: 1.9	Not detected		
GGTLC2	GGTL4	ENSG00000100121	Gamma-glutamyltransferase light chain 2	22	22644475-22647903	Predicted intracellular proteins	Evidence at protein level	HPA045635, HPA047534	Uncertain					Not detected	Tissue enriched	9	testis: 7.0	small intestine: 0.7	Not detected		
GGTLC3		ENSG00000274252	Gamma-glutamyltransferase light chain 3	22	18516344-18518161	Predicted intracellular proteins	Evidence at protein level	HPA045635, HPA047534	Uncertain					Not detected	Tissue enhanced		lung: 1.9;testis: 1.0	small intestine: 0.5	Cell line enhanced		U-2197: 1.0
GID4	C17orf39, VID24	ENSG00000141034	GID complex subunit 4 homolog	17	18039292-18068404	Predicted intracellular proteins	Evidence at protein level	HPA044348	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			testis: 62.9	Expressed in all		
GID8	bA305P22.1, C20orf11, FLJ20602, TWA1	ENSG00000101193	GID complex subunit 8 homolog	20	62938119-62948475	Predicted intracellular proteins	Evidence at protein level	HPA049929, HPA055047	Approved		Supported	Nucleoplasm<br>Cell Junctions	Renal cancer:3.22e-4 (favourable), Endometrial cancer:4.78e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 32.5	Expressed in all		
GIGYF1	GYF1, PERQ1	ENSG00000146830	GRB10 interacting GYF protein 1	7	100679507-100689448	Predicted intracellular proteins	Evidence at protein level	HPA020999, HPA023995	Enhanced		Approved	Vesicles<br>Microtubules	Pancreatic cancer:1.35e-5 (favourable), Liver cancer:2.30e-4 (unfavourable), Head and neck cancer:7.42e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 35.8	Expressed in all		
GIGYF2	GYF2, KIAA0642, PARK11, PERQ2, PERQ3, TNRC15	ENSG00000204120	GRB10 interacting GYF protein 2	2	232697299-232860575	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050899, HPA054612, HPA059918, HPA065064	Approved		Enhanced	Cytosol	Renal cancer:6.97e-5 (favourable)	Expressed in all	Expressed in all			testis: 85.1	Expressed in all		
GIMAP4	FLJ11110, HIMAP4, IAN1, IMAP4	ENSG00000133574	GTPase, IMAP family member 4	7	150567277-150573955	Predicted intracellular proteins	Evidence at protein level	HPA019135, HPA019137, HPA027198	Enhanced				Renal cancer:1.13e-4 (unfavourable), Endometrial cancer:7.63e-4 (favourable)	Expressed in all	Expressed in all			spleen: 147.7	Cell line enriched	23	HUVEC TERT2: 253.7
GIMAP6	FLJ22690, IAN6	ENSG00000133561	GTPase, IMAP family member 6	7	150625375-150632648	Predicted intracellular proteins	Evidence at protein level	HPA026715, HPA050740	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Liver cancer:1.56e-4 (favourable), Head and neck cancer:2.91e-4 (favourable), Endometrial cancer:3.12e-4 (favourable), Renal cancer:5.27e-4 (unfavourable)	Expressed in all	Mixed			spleen: 88.1	Cell line enhanced		HUVEC TERT2: 104.1;MOLT-4: 34.5;TIME: 29.3
GIMAP7	IAN7, MGC27027	ENSG00000179144	GTPase, IMAP family member 7	7	150514830-150521073	Predicted intracellular proteins	Evidence at protein level	HPA020266, HPA020268	Enhanced		Approved	Vesicles<br>Cytosol	Liver cancer:8.98e-5 (favourable), Head and neck cancer:7.43e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 181.4	Group enriched	12	HUVEC TERT2: 74.2;MOLT-4: 60.4
GIMAP8	DKFZp667I133, hIAN6, IAN9	ENSG00000171115	GTPase, IMAP family member 8	7	150450630-150479392	Predicted intracellular proteins	Evidence at protein level	HPA014474, HPA017765	Supported				Testis cancer:8.47e-4 (unfavourable)	Expressed in all	Mixed			spleen: 55.9	Cell line enriched	8	HUVEC TERT2: 49.3
GIMD1		ENSG00000250298	GIMAP family P-loop NTPase domain containing 1	4	106357485-106368825	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		duodenum: 28.6;small intestine: 18.0	gallbladder: 4.9	Not detected		
GIN1	FLJ20125, GIN-1, TGIN1, ZH2C2	ENSG00000145723	Gypsy retrotransposon integrase 1	5	103086000-103120151	Predicted intracellular proteins	Evidence at protein level	HPA037402, HPA061362	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:1.63e-4 (favourable)	Expressed in all	Mixed			testis: 8.3	Expressed in all		
GINS1	KIAA0186, PSF1	ENSG00000101003	GINS complex subunit 1	20	25407727-25452628	Predicted intracellular proteins	Evidence at protein level	HPA051185	Uncertain		Approved	Nucleoplasm	Renal cancer:5.42e-11 (unfavourable), Liver cancer:4.61e-7 (unfavourable), Pancreatic cancer:5.62e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 14.7	lymph node: 6.5	Mixed		
GINS2	Pfs2, PSF2	ENSG00000131153	GINS complex subunit 2	16	85676198-85690073	Predicted intracellular proteins	Evidence at protein level	HPA057285	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			testis: 12.2	Cell line enhanced		U-698: 182.9
GINS3	FLJ13912, PSF3	ENSG00000181938	GINS complex subunit 3	16	58295080-58406144	Predicted intracellular proteins	Evidence at protein level	HPA041216, HPA048209	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Mixed			testis: 10.5	Expressed in all		
GINS4	MGC14799, SLD5	ENSG00000147536	GINS complex subunit 4	8	41529206-41545046	Predicted intracellular proteins	Evidence at protein level	HPA024663, HPA026580	Uncertain		Supported	Nucleoplasm<br>Centrosome	Endometrial cancer:2.30e-5 (unfavourable)	Mixed	Mixed			lymph node: 6.2	Mixed		
GIPC1	C19orf3, GIPC, GLUT1CBP, Hs.6454, NIP, RGS19IP1, SEMCAP, SYNECTIN, TIP-2	ENSG00000123159	GIPC PDZ domain containing family member 1	19	14477760-14496149	Predicted intracellular proteins	Evidence at protein level	HPA043958, HPA061786	Approved		Approved	Nucleus<br>Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			esophagus: 103.9	Expressed in all		
GIPC2	FLJ20075, SEMCAP-2	ENSG00000137960	GIPC PDZ domain containing family member 2	1	77979542-78138449	Predicted intracellular proteins	Evidence at protein level	HPA051212, HPA062684	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:2.11e-6 (favourable), Colorectal cancer:5.49e-4 (favourable)	Mixed	Mixed			kidney: 41.6	Cell line enhanced		Hep G2: 15.3;HUVEC TERT2: 19.2
GIPC3	C19orf64, DFNB15, DFNB72, DFNB95	ENSG00000179855	GIPC PDZ domain containing family member 3	19	3585553-3593541	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061258, HPA067765	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus		Mixed	Mixed			smooth muscle: 11.5	Cell line enhanced		HeLa: 12.6;HMC-1: 10.5;THP-1: 15.5;WM-115: 44.4
GIT1		ENSG00000108262	GIT ArfGAP 1	17	29573469-29594054	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004059, HPA004186	Approved		Enhanced	Focal adhesion sites<br>Cytosol	Liver cancer:2.54e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 127.3	Expressed in all		
GIT2	KIAA0148, PKL	ENSG00000139436	GIT ArfGAP 2	12	109929792-109996389	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004681	Approved		Approved	Microtubules	Renal cancer:2.93e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 47.9	Expressed in all		
GK5	MGC40579	ENSG00000175066	Glycerol kinase 5 (putative)	3	142157527-142225607	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042606, HPA057998	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			prostate: 13.6	Expressed in all		
GKAP1	FKSG21, GKAP42	ENSG00000165113	G kinase anchoring protein 1	9	83739421-83829516	Predicted intracellular proteins	Evidence at protein level	HPA035117, HPA035118, HPA066173	Enhanced	Approved	Approved	Microtubule organizing center<br>Cytosol	Renal cancer:1.05e-6 (favourable), Pancreatic cancer:6.96e-5 (favourable)	Mixed	Tissue enriched	21	testis: 363.1	skeletal muscle: 17.6	Mixed		
GLB1L3	FLJ90231	ENSG00000166105	Galactosidase beta 1 like 3	11	134274245-134319564	Predicted intracellular proteins	Evidence at protein level	HPA039916	Uncertain				Lung cancer:1.97e-4 (favourable)	Tissue enhanced	Tissue enhanced		prostate: 14.5;seminal vesicle: 7.0	cerebral cortex: 4.0	Cell line enhanced		HEK93: 5.2;NTERA-2: 3.5;PC-3: 4.3;SCLC-21H: 8.6
GLDC	GCSP, NKH	ENSG00000178445	Glycine decarboxylase	9	6532464-6645783	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002318, HPA052887	Enhanced		Supported	Nucleus<br>Mitochondria	Endometrial cancer:5.24e-5 (unfavourable), Renal cancer:3.50e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 30.3;liver: 19.9;placenta: 20.1	cerebral cortex: 10.6	Cell line enhanced		BEWO: 206.9;RPTEC TERT1: 67.4
GLDN	CLOM, COLM, colmedin, CRG-L2, UNC-112	ENSG00000186417	Gliomedin	15	51341629-51408013	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059441	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 23.9	adipose tissue: 12.9	Cell line enhanced		HHSteC: 2.3;U-266/70: 2.5;U-266/84: 2.0
GLE1	GLE1L, hGLE1, LCCS1	ENSG00000119392	GLE1, RNA export mediator	9	128504700-128542288	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA041689, HPA043538, HPA061560	Supported		Supported	Nuclear membrane<br>Nucleoli	Stomach cancer:7.04e-4 (favourable), Endometrial cancer:7.49e-4 (favourable)	Expressed in all	Expressed in all			testis: 58.8	Expressed in all		
GLI1	GLI	ENSG00000111087	GLI family zinc finger 1	12	57460135-57472262	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009460, HPA065172, HPA068903	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		cervix, uterine: 15.1;endometrium: 15.1	gallbladder: 8.5	Cell line enhanced		AN3-CA: 19.3;RH-30: 59.1
GLI2	HPE9, THP1, THP2	ENSG00000074047	GLI family zinc finger 2	2	120735623-120992653	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB008558, HPA074275	Approved		Supported	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		ovary: 11.6	gallbladder: 6.0	Cell line enhanced		AF22: 30.8;U-2 OS: 33.2;WM-115: 27.2
GLI3	ACLS, GCPS, PAP-A, PAPA, PAPA1, PAPB, PHS, PPDIV	ENSG00000106571	GLI family zinc finger 3	7	41960950-42237870	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005534	Approved					Mixed	Mixed			endometrium: 15.9	Cell line enhanced		AF22: 44.3;WM-115: 32.9
GLI4	HKR4, ZNF928	ENSG00000250571	GLI family zinc finger 4	8	143267433-143276931	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023131	Uncertain		Approved	Nucleus<br>Cytokinetic bridge		Expressed in all	Expressed in all			spleen: 8.8	Expressed in all		
GLIPR2	C9orf19, GAPR-1	ENSG00000122694	GLI pathogenesis related 2	9	36136536-36163913	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029478	Approved		Uncertain	Vesicles<br>Microtubules	Renal cancer:6.54e-7 (unfavourable)	Expressed in all	Expressed in all			lung: 93.6	Cell line enhanced		TIME: 103.7
GLIS1	FLJ36155	ENSG00000174332	GLIS family zinc finger 1	1	53506237-53738106	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA001409	Uncertain					Tissue enhanced	Tissue enhanced		seminal vesicle: 11.0	prostate: 3.6	Cell line enhanced		BJ hTERT+: 3.7;PC-3: 6.7;U-138 MG: 5.0
GLIS2	NPHP7	ENSG00000126603	GLIS family zinc finger 2	16	4314761-4339597	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056976			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.06e-6 (favourable), Endometrial cancer:1.59e-5 (unfavourable)	Expressed in all	Mixed			gallbladder: 9.7	Cell line enhanced		U-2197: 35.6
GLMN	FAP48, FKBPAP, GLML, GVM, VMGLOM	ENSG00000174842	Glomulin, FKBP associated protein	1	92246402-92298987	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031446, HPA031448	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.89e-8 (unfavourable), Liver cancer:2.42e-5 (unfavourable), Colorectal cancer:1.71e-4 (favourable)	Expressed in all	Mixed			testis: 15.0	Expressed in all		
GLO1	GLOD1	ENSG00000124767	Glyoxalase I	6	38675925-38703141	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB040541, CAB040542, HPA059791	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:5.21e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 274.2	Cell line enriched	5	HMC-1: 2266.7
GLOD4	C17orf25, CGI-150, HC71	ENSG00000167699	Glyoxalase domain containing 4	17	757097-783390	Predicted intracellular proteins	Evidence at protein level	HPA021623, HPA023246, HPA023248	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:2.18e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 82.7	Expressed in all		
GLOD5		ENSG00000171433	Glyoxalase domain containing 5	X	48761750-48773648	Predicted intracellular proteins	Evidence at protein level	HPA010667	Uncertain		Uncertain	Mitochondria		Mixed	Tissue enhanced		duodenum: 10.8;kidney: 11.0;small intestine: 10.7	epididymis: 6.8	Cell line enhanced		MCF7: 1.6
GLRX	GRX, GRX1	ENSG00000173221	Glutaredoxin	5	95751319-95823005	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008634, HPA046431, CAB069419	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			kidney: 218.9	Expressed in all		
GLRX2	bA101E13.1, GRX2	ENSG00000023572	Glutaredoxin 2	1	193096468-193106114	Predicted intracellular proteins	Evidence at protein level	HPA023087, HPA057224	Supported		Enhanced	Nucleoplasm	Renal cancer:3.30e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
GLRX3	bA500G10.4, GLRX4, GRX3, GRX4, PICOT, TXNL2	ENSG00000108010	Glutaredoxin 3	10	130136399-130184521	Predicted intracellular proteins	Evidence at protein level	HPA028941	Approved				Liver cancer:9.03e-6 (unfavourable), Renal cancer:9.24e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 119.3	Expressed in all		
GLRX5	C14orf87, GRX5, PR01238	ENSG00000182512	Glutaredoxin 5	14	95533503-95544724	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042465, HPA063716	Approved		Supported	Mitochondria	Renal cancer:7.83e-10 (favourable), Ovarian cancer:1.08e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 56.6	Expressed in all		
GLS2	GA, GLS, hLGA, LGA	ENSG00000135423	Glutaminase 2	12	56470944-56488414	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038608	Uncertain					Tissue enhanced	Tissue enriched	11	liver: 80.4	cerebral cortex: 7.2	Cell line enhanced		Daudi: 22.6;SCLC-21H: 10.1
GLT1D1	FLJ31978	ENSG00000151948	Glycosyltransferase 1 domain containing 1	12	128853427-128984968	Predicted intracellular proteins	Evidence at protein level	HPA039051, HPA039052			Enhanced	Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 22.4;testis: 28.2	bone marrow: 18.6	Group enriched	7	MOLT-4: 10.5;NTERA-2: 18.0;SCLC-21H: 9.9
GLT8D2	FLJ31494	ENSG00000120820	Glycosyltransferase 8 domain containing 2	12	103988984-104064183	Predicted intracellular proteins	Evidence at protein level	HPA026904	Approved		Approved	Cytosol	Renal cancer:1.58e-6 (unfavourable), Cervical cancer:7.37e-4 (unfavourable), Stomach cancer:7.92e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 57.1	Cell line enhanced		ASC TERT1: 48.9;BJ hTERT+: 73.1;HSkMC: 47.3
GLTP		ENSG00000139433	Glycolipid transfer protein	12	109850943-109880488	Predicted intracellular proteins	Evidence at protein level	HPA056461	Approved		Supported	Cytosol	Thyroid cancer:4.17e-6 (favourable), Cervical cancer:2.01e-5 (favourable), Liver cancer:7.68e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 293.8	Expressed in all		
GLTSCR1		ENSG00000063169	Glioma tumor suppressor candidate region gene 1	19	47608196-47703277	Predicted intracellular proteins	Evidence at protein level	HPA056211	Approved		Approved	Nucleoplasm	Head and neck cancer:1.34e-4 (favourable), Renal cancer:1.82e-4 (unfavourable), Urothelial cancer:9.34e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.4	Expressed in all		
GLTSCR1L	KIAA0240	ENSG00000112624	GLTSCR1 like	6	42746958-42868560	Predicted intracellular proteins	Evidence at protein level	HPA029390, HPA029391	Approved		Supported	Nucleoplasm	Head and neck cancer:5.47e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.9	Expressed in all		
GLTSCR2	PICT-1	ENSG00000105373	Glioma tumor suppressor candidate region gene 2	19	47745522-47757058	Predicted intracellular proteins	Evidence at protein level	HPA018999, HPA049600	Approved		Enhanced	Nucleoli	Endometrial cancer:2.35e-4 (favourable)	Expressed in all	Expressed in all			ovary: 534.2	Expressed in all		
GLUD2	GLUDP1	ENSG00000182890	Glutamate dehydrogenase 2	X	121047588-121050080	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042492, HPA044839, HPA061369	Uncertain		Supported	Mitochondria	Renal cancer:1.98e-4 (favourable)	Mixed	Tissue enriched	11	testis: 46.5	epididymis: 4.1	Cell line enhanced		HAP1: 7.6;K-562: 7.6;SK-MEL-30: 8.3;WM-115: 11.7
GLUL	GLNS	ENSG00000135821	Glutamate-ammonia ligase	1	182381704-182392206	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007316, HPA007571, CAB008636	Approved		Supported	Mitochondria<br>Cytosol	Breast cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 851.0	Cell line enhanced		ASC diff: 791.8;ASC TERT1: 567.1;HSkMC: 512.4
GLYAT	ACGNAT, GAT	ENSG00000149124	Glycine-N-acyltransferase	11	58640426-58731974	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040251, HPA044094	Enhanced				Renal cancer:1.31e-6 (favourable)	Group enriched	Group enriched	10	kidney: 584.9;liver: 355.3	adipose tissue: 47.4	Mixed		
GLYATL1	FLJ34646, MGC15397	ENSG00000166840	Glycine-N-acyltransferase like 1	11	58905398-59043527	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039501	Supported		Uncertain	Golgi apparatus<br>Cytosol	Renal cancer:3.03e-5 (favourable), Liver cancer:3.69e-4 (favourable)	Group enriched	Group enriched	13	kidney: 145.2;liver: 298.1	prostate: 17.4	Cell line enhanced		CACO-2: 1.6;Daudi: 3.5;RPTEC TERT1: 1.2;U-2197: 1.1
GLYATL1P3		ENSG00000255151	Glycine-N-acyltransferase like 1 pseudogene 3	11	59086307-59094786	Predicted intracellular proteins	Evidence at protein level	HPA039501	Uncertain		Uncertain	Golgi apparatus<br>Cytosol		Tissue enhanced	Group enriched	6	breast: 9.7;lymph node: 3.4	appendix,prostate: 1.1	Cell line enhanced		Daudi: 1.3;T-47d: 1.1;U-266/70: 1.4
GLYATL2	BXMAS2-10, MGC24009	ENSG00000156689	Glycine-N-acyltransferase like 2	11	58834065-58904215	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060292, HPA065454	Uncertain		Approved	Mitochondria	Endometrial cancer:9.05e-7 (favourable)	Tissue enhanced	Group enriched	6	breast: 14.3;cervix, uterine: 27.5;gallbladder: 11.0	salivary gland: 3.0	Cell line enhanced		BJ hTERT+: 4.1;HAP1: 5.9;SK-BR-3: 10.2;U-2197: 6.0
GLYATL3	bA28H17.2, C6orf140	ENSG00000203972	Glycine-N-acyltransferase like 3	6	49499958-49527047	Predicted intracellular proteins	Evidence at transcript level	HPA044044	Uncertain					Tissue enhanced	Not detected			liver: 0.7	Cell line enriched	74	T-47d: 13.7
GLYCTK	HBEBP2, HBEBP4	ENSG00000168237	Glycerate kinase	3	52287089-52293476	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006913	Approved		Approved	Golgi apparatus<br>Cytosol<br>Rods & Rings	Head and neck cancer:1.64e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 38.3;liver: 60.6	small intestine: 31.8	Expressed in all		
GLYR1	BM045, HIBDL, N-PAC, NP60	ENSG00000140632	Glyoxylate reductase 1 homolog	16	4803203-4847342	Predicted intracellular proteins	Evidence at protein level	CAB017022, HPA048226, HPA050136	Enhanced		Enhanced	Nucleoplasm<br>Nuclear speckles	Renal cancer:8.74e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 111.5	Expressed in all		
GMCL1	BTBD13, FLJ13057, GCL1, SPATA29	ENSG00000087338	Germ cell-less, spermatogenesis associated 1	2	69829642-69881396	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039579	Approved					Expressed in all	Expressed in all			testis: 39.4	Expressed in all		
GMDS	GMD, SDR3E1	ENSG00000112699	GDP-mannose 4,6-dehydratase	6	1623806-2245692	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031528	Enhanced				Endometrial cancer:5.89e-4 (favourable), Renal cancer:5.93e-4 (favourable)	Expressed in all	Mixed			duodenum: 106.3	Expressed in all		
GMEB1	P96PIF, PIF96	ENSG00000162419	Glucocorticoid modulatory element binding protein 1	1	28668732-28719353	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044811, HPA052975	Supported		Enhanced	Nucleoplasm	Liver cancer:8.91e-7 (unfavourable), Endometrial cancer:1.94e-4 (favourable)	Expressed in all	Mixed			bone marrow: 8.5	Expressed in all		
GMEB2	KIAA1269, P79PIF, PIF79	ENSG00000101216	Glucocorticoid modulatory element binding protein 2	20	63587602-63627041	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009706, HPA067455	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 12.8	Expressed in all		
GMFB	GMF	ENSG00000197045	Glia maturation factor beta	14	54474484-54489196	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002954	Approved	Approved	Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:9.48e-5 (favourable), Liver cancer:2.21e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 108.7	Expressed in all		
GMFG		ENSG00000130755	Glia maturation factor gamma	19	39328353-39342372	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002954	Uncertain	Approved	Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:9.11e-6 (unfavourable), Cervical cancer:7.35e-4 (favourable)	Expressed in all	Expressed in all			spleen: 308.1	Cell line enhanced		HMC-1: 476.8;Karpas-707: 305.6;REH: 329.6;THP-1: 378.5;U-937: 301.7
GMIP	ARHGAP46	ENSG00000089639	GEM interacting protein	19	19629476-19643667	Predicted intracellular proteins	Evidence at protein level	HPA042484, HPA045481	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:3.97e-5 (unfavourable), Stomach cancer:3.03e-4 (favourable), Urothelial cancer:5.15e-4 (favourable)	Expressed in all	Mixed			spleen: 46.7	Expressed in all		
GMNC	GEMC1	ENSG00000205835	Geminin coiled-coil domain containing	3	190852877-190892429	Predicted intracellular proteins	Evidence at protein level	HPA043663	Uncertain					Tissue enhanced	Tissue enriched	5	fallopian tube: 9.5	testis: 1.8	Cell line enriched	10	SCLC-21H: 1.1
GMNN	Gem	ENSG00000112312	Geminin, DNA replication inhibitor	6	24774931-24786099	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB011458, CAB047327, CAB047328, HPA049977, HPA054597	Enhanced		Enhanced	Nucleoplasm	Renal cancer:7.82e-5 (unfavourable), Ovarian cancer:4.13e-4 (favourable), Pancreatic cancer:9.77e-4 (unfavourable)	Expressed in all	Expressed in all			prostate,testis: 67.7	Expressed in all		
GMPPA		ENSG00000144591	GDP-mannose pyrophosphorylase A	2	219498867-219506989	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035512, HPA035513	Approved		Approved	Nucleoplasm	Renal cancer:1.90e-10 (unfavourable), Liver cancer:1.62e-4 (unfavourable), Stomach cancer:5.24e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 84.1	Expressed in all		
GMPPB	KIAA1851	ENSG00000173540	GDP-mannose pyrophosphorylase B	3	49716844-49723951	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA014657	Uncertain		Supported	Nucleus	Endometrial cancer:6.19e-6 (favourable), Renal cancer:3.17e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 42.0	Expressed in all		
GMPR		ENSG00000137198	Guanosine monophosphate reductase	6	16238580-16295549	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000904, HPA021476	Uncertain				Renal cancer:2.94e-5 (favourable), Ovarian cancer:2.06e-4 (favourable), Lung cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 105.7	Cell line enhanced		HEL: 171.8;HMC-1: 275.3
GMPR2		ENSG00000100938	Guanosine monophosphate reductase 2	14	24232422-24239242	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000904, HPA067884, HPA068782	Uncertain		Approved	Nucleoplasm<br>Nucleoli	Renal cancer:2.21e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 144.2	Expressed in all		
GMPS		ENSG00000163655	Guanine monophosphate synthase	3	155870536-155944026	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046630			Approved	Cytosol	Liver cancer:8.73e-7 (unfavourable), Endometrial cancer:5.54e-5 (unfavourable), Pancreatic cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 181.7	Expressed in all		
GNA11	FBH, FBH2, FHH2, HHC2	ENSG00000088256	G protein subunit alpha 11	19	3094410-3124004	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048886	Approved				Renal cancer:1.48e-11 (favourable), Liver cancer:4.86e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 155.9	Expressed in all		
GNA12	gep	ENSG00000146535	G protein subunit alpha 12	7	2728112-2844324	Predicted intracellular proteins	Evidence at protein level	CAB010046	Approved		Supported	Cytosol	Liver cancer:1.20e-6 (unfavourable), Renal cancer:4.71e-5 (unfavourable), Urothelial cancer:2.27e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 34.5	Expressed in all		
GNA13	G13, MGC46138	ENSG00000120063	G protein subunit alpha 13	17	65010715-65056839	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA010087	Approved		Supported	Cytosol		Expressed in all	Expressed in all			bone marrow: 99.1	Expressed in all		
GNA14		ENSG00000156049	G protein subunit alpha 14	9	77423079-77648307	Predicted intracellular proteins	Evidence at protein level	HPA048886	Approved					Mixed	Mixed			thyroid gland: 29.8	Cell line enhanced		BJ hTERT+: 1.9;PC-3: 3.0;U-2197: 2.0
GNA15	GNA16	ENSG00000060558	G protein subunit alpha 15	19	3136193-3163769	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043113	Approved				Renal cancer:4.26e-6 (unfavourable), Breast cancer:7.57e-5 (favourable), Endometrial cancer:2.01e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 48.7;esophagus: 61.3	skin: 25.9	Cell line enhanced		HMC-1: 142.1;MOLT-4: 137.5;REH: 115.4
GNAI1		ENSG00000127955	G protein subunit alpha i1	7	80133955-80219402	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022449, HPA042141	Approved		Supported	Nucleus<br>Nucleoli<br>Centrosome	Melanoma:5.09e-4 (unfavourable), Stomach cancer:6.47e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 94.5	Mixed		
GNAI2	GIP, GNAI2B	ENSG00000114353	G protein subunit alpha i2	3	50226292-50259355	Predicted intracellular proteins	Evidence at protein level	HPA007704	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Breast cancer:1.03e-4 (favourable)	Expressed in all	Expressed in all			placenta: 330.6	Expressed in all		
GNAI3	87U6	ENSG00000065135	G protein subunit alpha i3	1	109548611-109618321	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022099, HPA042141	Approved		Supported	Nucleus<br>Nucleoli<br>Centrosome	Liver cancer:5.30e-6 (unfavourable), Colorectal cancer:1.62e-4 (favourable), Renal cancer:4.34e-4 (unfavourable), Ovarian cancer:4.59e-4 (favourable)	Expressed in all	Mixed			esophagus: 7.9	Expressed in all		
GNAL		ENSG00000141404	G protein subunit alpha L	18	11688956-11885685	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015464, HPA051160	Supported		Approved	Nucleus<br>Cytosol		Mixed	Mixed			cerebral cortex: 28.8	Cell line enhanced		Daudi: 18.9;HeLa: 17.7
GNAO1	G-ALPHA-o	ENSG00000087258	G protein subunit alpha o1	16	56191347-56357457	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB008387, HPA040878	Enhanced				Pancreatic cancer:5.93e-4 (favourable)	Tissue enriched	Tissue enriched	7	cerebral cortex: 166.9	seminal vesicle: 22.6	Cell line enhanced		BJ hTERT+: 24.8;BJ hTERT+ SV40 Large T+: 18.7;SCLC-21H: 72.2
GNAQ	G-ALPHA-q, GAQ	ENSG00000156052	G protein subunit alpha q	9	77716087-78031458	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB010036, HPA048886	Uncertain		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Renal cancer:1.11e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 84.9	Mixed		
GNAT1	CSNBAD3	ENSG00000114349	G protein subunit alpha transducin 1	3	50191612-50196516	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045393	Supported					Not detected	Tissue enhanced		testis: 1.4	cerebral cortex: 0.3	Not detected		
GNAT2	ACHM4	ENSG00000134183	G protein subunit alpha transducin 2	1	109603267-109619929	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	6	testis: 3.9	placenta: 0.6	Cell line enhanced		HAP1: 2.0
GNAT3	GDCA, gustducin	ENSG00000214415	G protein subunit alpha transducin 3	7	80458671-80512020	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		duodenum: 1.9;small intestine: 1.4	testis: 0.5	Cell line enriched	8	SCLC-21H: 3.9
GNAZ		ENSG00000128266	G protein subunit alpha z	22	23070361-23125037	Predicted intracellular proteins	Evidence at protein level	HPA003011	Enhanced		Approved	Vesicles	Endometrial cancer:4.85e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 49.7	seminal vesicle: 23.0	Cell line enhanced		SCLC-21H: 44.4;SH-SY5Y: 24.7
GNB1		ENSG00000078369	G protein subunit beta 1	1	1785285-1891117	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA040736	Supported		Approved	Golgi apparatus<br>Plasma membrane	Liver cancer:3.61e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 447.4	Expressed in all		
GNB1L	GY2, WDR14	ENSG00000185838	G protein subunit beta 1 like	22	19783224-19854939	Predicted intracellular proteins	Evidence at protein level	HPA034627, HPA034628	Approved		Approved	Cytosol		Expressed in all	Mixed			duodenum: 4.2	Cell line enhanced		K-562: 59.4
GNB2		ENSG00000172354	G protein subunit beta 2	7	100673531-100679174	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010032, HPA040736	Approved		Enhanced	Plasma membrane		Expressed in all	Expressed in all			esophagus: 235.4	Expressed in all		
GNB3		ENSG00000111664	G protein subunit beta 3	12	6839954-6847393	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA040736	Approved		Approved	Golgi apparatus<br>Plasma membrane		Tissue enhanced	Mixed			smooth muscle: 3.8	Cell line enhanced		NTERA-2: 12.8;U-698: 22.7
GNB4		ENSG00000114450	G protein subunit beta 4	3	179396089-179451590	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB018383, CAB018737, HPA040736	Enhanced		Enhanced	Plasma membrane	Renal cancer:1.39e-6 (unfavourable)	Expressed in all	Mixed			skin: 37.6	Mixed		
GNB5	GB5	ENSG00000069966	G protein subunit beta 5	15	52115105-52191369	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB032353, HPA041942, HPA044198	Uncertain		Approved	Nuclear speckles<br>Centrosome<br>Rods & Rings	Renal cancer:3.32e-11 (favourable), Endometrial cancer:1.47e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 74.6	Expressed in all		
GNG10		ENSG00000242616	G protein subunit gamma 10	9	111661335-111670246	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level						Head and neck cancer:3.21e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 90.3	Expressed in all		
GNG11	GNGT11	ENSG00000127920	G protein subunit gamma 11	7	93921699-93928610	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA045255	Uncertain					Expressed in all	Expressed in all			placenta: 123.2	Cell line enhanced		EFO-21: 204.6;HUVEC TERT2: 287.9;U-87 MG: 180.8
GNG12		ENSG00000172380	G protein subunit gamma 12	1	67701466-67833467	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA057790, HPA062208	Enhanced		Approved	Mitochondria		Expressed in all	Mixed			duodenum: 122.4	Mixed		
GNG13	G(gamma)13, h2-35	ENSG00000127588	G protein subunit gamma 13	16	798041-800733	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA046272	Approved					Mixed	Tissue enhanced		cerebral cortex: 2.5;duodenum: 1.4;small intestine: 1.4	colon: 0.7	Cell line enhanced		CACO-2: 8.6;HEK93: 8.3;MCF7: 10.0
GNG2		ENSG00000186469	G protein subunit gamma 2	14	51826195-51979342	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003534, CAB018380	Uncertain	Supported	Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.90e-6 (unfavourable), Pancreatic cancer:1.64e-4 (favourable)	Expressed in all	Expressed in all			testis: 185.4	Cell line enhanced		fHDF/TERT166: 108.6;MOLT-4: 89.8;SH-SY5Y: 94.7;WM-115: 245.1
GNG3		ENSG00000162188	G protein subunit gamma 3	11	62707658-62709201	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Tissue enriched	Tissue enriched	17	cerebral cortex: 315.2	adrenal gland: 19.0	Group enriched	7	Karpas-707: 104.6;SCLC-21H: 335.7
GNG4		ENSG00000168243	G protein subunit gamma 4	1	235547687-235650754	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 25.3;ovary: 18.4;prostate: 17.5	endometrium: 8.4	Cell line enhanced		NTERA-2: 75.6;SCLC-21H: 93.5;SH-SY5Y: 118.5
GNG5		ENSG00000174021	G protein subunit gamma 5	1	84498325-84506565	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB032623, HPA043651	Approved				Liver cancer:3.23e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 133.5	Expressed in all		
GNG7	FLJ00058	ENSG00000176533	G protein subunit gamma 7	19	2511219-2702709	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA057790	Supported				Renal cancer:0.00e+0 (favourable), Lung cancer:1.35e-5 (favourable), Liver cancer:3.05e-4 (favourable), Pancreatic cancer:3.71e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 49.7	Cell line enhanced		REH: 60.2;SK-MEL-30: 23.5;U-266/70: 46.3;U-266/84: 21.0
GNG8		ENSG00000167414	G protein subunit gamma 8	19	46634076-46634685	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level						Head and neck cancer:2.14e-5 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 29.3	cerebral cortex: 10.2	Group enriched	10	SCLC-21H: 310.9;SH-SY5Y: 1226.5
GNGT1	GNG1	ENSG00000127928	G protein subunit gamma transducin 1	7	93591573-93911265	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA042721	Supported					Mixed	Tissue enriched	6	placenta: 3.9	urinary bladder: 0.6	Cell line enhanced		EFO-21: 8.7;SCLC-21H: 3.1;T-47d: 4.8
GNGT2	GNG9	ENSG00000167083	G protein subunit gamma transducin 2	17	49202791-49210574	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA043381	Supported				Renal cancer:3.11e-4 (unfavourable)	Mixed	Mixed			spleen: 26.3	Cell line enhanced		Daudi: 59.2;HDLM-2: 66.4;RH-30: 24.6
GNL1	HSR1	ENSG00000204590	G protein nucleolar 1 (putative)	6	30541377-30557174	Predicted intracellular proteins	Evidence at protein level	CAB033575, HPA043338, HPA050455	Uncertain		Supported	Vesicles		Expressed in all	Mixed			parathyroid gland: 18.8	Mixed		
GNL2	HUMAUANTIG, Ngp-1, Nog2, Nug2	ENSG00000134697	G protein nucleolar 2	1	37566816-37595935	Predicted intracellular proteins	Evidence at protein level	HPA027163, HPA060026	Approved		Enhanced	Nucleoli	Renal cancer:2.90e-11 (unfavourable), Liver cancer:5.86e-9 (unfavourable), Ovarian cancer:7.89e-4 (favourable)	Expressed in all	Expressed in all			testis: 55.6	Expressed in all		
GNL3	C77032, E2IG3, MGC800, NS	ENSG00000163938	G protein nucleolar 3	3	52681156-52694492	Predicted intracellular proteins	Evidence at protein level	CAB020770, HPA036742, HPA036743	Enhanced		Enhanced	Nucleoli<br>Nuclear bodies	Renal cancer:5.69e-5 (unfavourable), Liver cancer:2.93e-4 (unfavourable), Prostate cancer:6.11e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 78.5	Expressed in all		
GNL3L	FLJ10613, GNL3B	ENSG00000130119	G protein nucleolar 3 like	X	54530211-54561071	Predicted intracellular proteins	Evidence at protein level	HPA036314, HPA036315	Supported		Supported	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 16.4	Expressed in all		
GNMT		ENSG00000124713	Glycine N-methyltransferase	6	42960758-42963880	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027501	Enhanced		Approved	Cytosol	Liver cancer:1.86e-4 (favourable)	Group enriched	Group enriched	9	liver: 155.0;pancreas: 55.8;prostate: 32.7	breast: 9.4	Cell line enhanced		Hep G2: 5.7;SCLC-21H: 11.3;T-47d: 5.8
GNPAT	DAP-AT, DAPAT, DHAPAT	ENSG00000116906	Glyceronephosphate O-acyltransferase	1	231241207-231277973	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.29e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 59.7	Expressed in all		
GNPDA1	GNPDA, GNPI, GPI, HLN, KIAA0060	ENSG00000113552	Glucosamine-6-phosphate deaminase 1	5	141991749-142013041	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000499, HPA046891	Uncertain		Approved	Golgi apparatus<br>Vesicles	Liver cancer:2.60e-6 (unfavourable)	Expressed in all	Expressed in all			kidney: 77.6	Mixed		
GNPDA2	SB52	ENSG00000163281	Glucosamine-6-phosphate deaminase 2	4	44682200-44726595	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000499, HPA046891	Uncertain		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			thyroid gland: 32.4	Mixed		
GNPNAT1	FLJ10607, Gpnat1	ENSG00000100522	Glucosamine-phosphate N-acetyltransferase 1	14	52775194-52791668	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044647	Approved				Pancreatic cancer:8.52e-5 (unfavourable)	Expressed in all	Expressed in all			liver: 39.4	Expressed in all		
GOLGA1	golgin-97, MGC33154	ENSG00000136935	Golgin A1	9	124878357-124948492	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013065, HPA044329, HPA050555	Enhanced		Enhanced	Golgi apparatus	Endometrial cancer:2.21e-4 (favourable)	Expressed in all	Expressed in all			testis: 28.8	Expressed in all		
GOLGA2	GM130, golgin-95	ENSG00000167110	Golgin A2	9	128255829-128275995	Predicted intracellular proteins	Evidence at protein level	CAB015421, HPA021178, HPA021230, HPA021799	Enhanced		Enhanced	Golgi apparatus	Renal cancer:9.77e-5 (favourable), Colorectal cancer:1.64e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 161.0	Expressed in all		
GOLGA3	GCP170, golgin-160, MEA-2	ENSG00000090615	Golgin A3	12	132768909-132828858	Predicted intracellular proteins	Evidence at protein level	HPA039809, HPA040044	Enhanced		Supported	Nucleus<br>Golgi apparatus	Renal cancer:6.47e-5 (unfavourable), Liver cancer:2.73e-4 (unfavourable), Pancreatic cancer:3.87e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 18.5	Expressed in all		
GOLGA4	GCP2, GOLG, golgin-240, p230	ENSG00000144674	Golgin A4	3	37243177-37366751	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035102	Supported		Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Renal cancer:3.62e-6 (favourable)	Expressed in all	Expressed in all			testis: 81.0	Expressed in all		
GOLGA6A	GLP, GOLGA6	ENSG00000159289	Golgin A6 family member A	15	74069857-74082550	Predicted intracellular proteins	Evidence at protein level	HPA044978, HPA050087	Supported					Not detected	Tissue enriched	9	testis: 19.6	liver: 2.1	Cell line enhanced		U-266/70: 1.0
GOLGA6B		ENSG00000215186	Golgin A6 family member B	15	72654738-72666394	Predicted intracellular proteins	Evidence at protein level	HPA044978, HPA050087	Supported					Not detected	Group enriched	14	liver: 1.9;testis: 5.3	cerebral cortex: 0.2	Not detected		
GOLGA6C		ENSG00000167195	Golgin A6 family member C	15	75258599-75270199	Predicted intracellular proteins	Evidence at protein level	HPA044978, HPA050087	Supported					Not detected	Tissue enriched	55	testis: 10.5	epididymis,liver,skeletal muscle: 0.1	Not detected		
GOLGA6D		ENSG00000140478	Golgin A6 family member D	15	75282835-75295807	Predicted intracellular proteins	Evidence at protein level	HPA044978, HPA050087	Supported					Not detected	Tissue enriched	16	testis: 17.8	liver: 1.1	Not detected		
GOLGA6L1		ENSG00000273976	Golgin A6 family-like 1	15	23128268-23136822	Predicted intracellular proteins	Evidence at transcript level	HPA047733	Uncertain					Not detected	Tissue enriched	11	testis: 4.5	bone marrow: 0.4	Not detected		
GOLGA6L10	GOLGA6L18	ENSG00000278662	Golgin A6 family-like 10	15	82339998-82349475	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	7	testis: 8.7	ovary,skin: 1.2	Cell line enhanced		HEK93: 3.0;SK-MEL-30: 1.3
GOLGA6L2	CT105, FLJ36144	ENSG00000174450	Golgin A6 family-like 2	15	23439498-23447234	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	110	testis: 39.3	cerebral cortex: 0.3	Cell line enriched	6	U-266/70: 11.4
GOLGA6L22		ENSG00000277865	Golgin A6 family-like 22	15	22458903-22469230	Predicted intracellular proteins	Evidence at transcript level	HPA047733	Uncertain					Not detected	Tissue enriched	19	testis: 5.2	cerebral cortex,skin: 0.2	Not detected		
GOLGA6L4		ENSG00000184206	Golgin A6 family-like 4	15	84235773-84245368	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			ovary: 7.5	Mixed		
GOLGA6L6	FLJ36131	ENSG00000277322	Golgin A6 family-like 6	15	20531856-20541800	Predicted intracellular proteins	Evidence at transcript level	HPA047733	Uncertain					Not detected	Tissue enriched	41	testis: 4.1	all non-specific tissues: 0.0	Not detected		
GOLGA6L7P	GOLGA6L7	ENSG00000261649	Golgin A6 family-like 7, pseudogene	15	28841833-28848675	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	53	testis: 25.5	cerebral cortex: 0.4	Not detected		
GOLGA6L9	GOLGA6L20	ENSG00000197978	Golgin A6 family-like 9	15	82430018-82439153	Predicted intracellular proteins	Evidence at transcript level							Mixed	Not detected			stomach,testis: 0.9	Cell line enhanced		AN3-CA: 3.7;HDLM-2: 3.3
GOLGA7	GCP16, GOLGA3AP1, GOLGA7A, HSPC041	ENSG00000147533	Golgin A7	8	41490396-41510980	Predicted intracellular proteins	Evidence at protein level	HPA046878	Uncertain				Endometrial cancer:1.36e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 96.4	Expressed in all		
GOLGA7B	bA451M19.3, bA459F3.4, C10orf132, C10orf133	ENSG00000155265	Golgin A7 family member B	10	97850239-97871580	Predicted intracellular proteins	Evidence at protein level	HPA046878	Uncertain					Mixed	Group enriched	7	cerebral cortex: 18.3;epididymis: 28.5;skin: 17.4	adrenal gland: 3.1	Cell line enhanced		A-431: 4.7;HDLM-2: 5.4;SK-MEL-30: 17.6
GOLGA8A	GM88, GOLGIN-67	ENSG00000175265	Golgin A8 family member A	15	34379068-34437466	Predicted intracellular proteins	Evidence at transcript level	HPA051808	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:2.16e-6 (unfavourable), Urothelial cancer:5.68e-6 (favourable), Lung cancer:7.58e-4 (favourable)	Expressed in all	Mixed			skin: 41.0	Mixed		
GOLGA8B		ENSG00000215252	Golgin A8 family member B	15	34525207-34588503	Predicted intracellular proteins	Evidence at transcript level	HPA051808	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:9.38e-6 (unfavourable), Urothelial cancer:5.79e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 47.9	testis: 23.1	Cell line enhanced		NB-4: 15.7
GOLGA8F	DKFZp434P162	ENSG00000153684	Golgin A8 family member F	15	28378621-28392018	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	51	testis: 5.1	all non-specific tissues: 0.0	Cell line enriched	14	NB-4: 1.3
GOLGA8G	DKFZp434K052	ENSG00000183629	Golgin A8 family member G	15	28519611-28533014	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	35	testis: 3.5	all non-specific tissues: 0.0	Not detected		
GOLGA8H	GOLGA6L11	ENSG00000261794	Golgin A8 family member H	15	30604126-30614561	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 8.5	fallopian tube,thyroid gland: 1.8	Cell line enhanced		HMC-1: 2.5;RH-30: 3.9;SH-SY5Y: 2.4
GOLGA8J		ENSG00000179938	Golgin A8 family member J	15	30083053-30093499	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GOLGA8K		ENSG00000249931	Golgin A8 family member K	15	32392782-32403292	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	11	testis: 6.4	thyroid gland: 0.5	Cell line enhanced		U-937: 1.1
GOLGA8M		ENSG00000188626	Golgin A8 family member M	15	28701954-28738384	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 3.7;thyroid gland: 11.0	placenta: 2.4	Group enriched	10	HEL: 1.1;U-937: 3.5
GOLGA8N		ENSG00000232653	Golgin A8 family member N	15	32593456-32607310	Predicted intracellular proteins	Evidence at transcript level							Mixed	Expressed in all			thyroid gland: 26.0	Group enriched	6	HEL: 71.9;THP-1: 35.0;U-937: 53.1
GOLGA8O		ENSG00000206127	Golgin A8 family member O	15	32445106-32455634	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 8.7	thyroid gland: 2.2	Group enriched	14	HEL: 18.7;U-937: 23.4
GOLGA8Q		ENSG00000178115	Golgin A8 family member Q	15	30552078-30562501	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	7	thyroid gland: 20.9	parathyroid gland: 2.8	Group enriched	6	THP-1: 4.4;U-937: 7.0
GOLGA8R		ENSG00000186399	Golgin A8 family member R	15	30403740-30414162	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		thyroid gland: 10.5	testis: 5.2	Group enriched	10	HEL: 21.6;THP-1: 5.5;U-937: 7.5
GOLGA8S		ENSG00000261739	Golgin A8 family member S	15	23354748-23367231	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.7	Not detected		
GOLGA8T		ENSG00000261247	Golgin A8 family member T	15	30135149-30145567	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GOLPH3	GOPP1, GPP34, MIDAS, Vps74	ENSG00000113384	Golgi phosphoprotein 3	5	32124704-32174350	Predicted intracellular proteins	Evidence at protein level	HPA044564, HPA055841	Approved		Supported	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			gallbladder: 120.5	Expressed in all		
GOLPH3L	GPP34R	ENSG00000143457	Golgi phosphoprotein 3 like	1	150646225-150697144	Predicted intracellular proteins	Evidence at protein level	HPA028558			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 51.4	Cell line enriched	6	U-698: 294.2
GON4L	FLJ20203, GON-4, GON4, YARP	ENSG00000116580	Gon-4 like	1	155749662-155859400	Predicted intracellular proteins	Evidence at protein level	HPA006986, HPA057305, HPA074504	Uncertain		Enhanced	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:4.19e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.8	Expressed in all		
GON7	C14orf142	ENSG00000170270	GON7, KEOPS complex subunit homolog	14	93202894-93207094	Predicted intracellular proteins	Evidence at protein level	HPA051832	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:1.53e-5 (unfavourable), Renal cancer:3.08e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 31.2	Expressed in all		
GOPC	CAL, dJ94G16.2, FIG, GOPC1, PIST	ENSG00000047932	Golgi associated PDZ and coiled-coil motif containing	6	117560269-117602542	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019477, HPA024018	Approved		Enhanced	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 47.9	Expressed in all		
GORASP1	FLJ23443, GOLPH5, GRASP65, P65	ENSG00000114745	Golgi reassembly stacking protein 1	3	39096659-39108363	Predicted intracellular proteins	Evidence at protein level	HPA056283	Enhanced		Supported	Golgi apparatus	Renal cancer:1.91e-6 (favourable), Endometrial cancer:6.92e-6 (favourable), Liver cancer:5.13e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 36.8	Expressed in all		
GORASP2	GOLPH6, GRASP55, GRS2	ENSG00000115806	Golgi reassembly stacking protein 2	2	170928464-170967129	Predicted intracellular proteins	Evidence at protein level	HPA035274, HPA035275, CAB075758	Enhanced		Enhanced	Golgi apparatus	Renal cancer:1.38e-8 (unfavourable), Head and neck cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 42.2	Expressed in all		
GOT1	AST1	ENSG00000120053	Glutamic-oxaloacetic transaminase 1	10	99396870-99430624	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064532, HPA072629	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.72e-13 (favourable), Cervical cancer:6.23e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 321.5	Expressed in all		
GOT1L1	MGC33309	ENSG00000169154	Glutamic-oxaloacetic transaminase 1-like 1	8	37934281-37940129	Predicted intracellular proteins	Evidence at transcript level	HPA028778	Uncertain					Not detected	Tissue enriched	26	testis: 21.5	ovary: 0.8	Not detected		
GPALPP1	AD029, bA245H20.2, KIAA1704, LSR7	ENSG00000133114	GPALPP motifs containing 1	13	44989529-45037669	Predicted intracellular proteins	Evidence at protein level	HPA038966, HPA058739	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			thyroid gland: 15.4	Expressed in all		
GPANK1	ANKRD59, BAT4, D6S54E, G5, GPATCH10	ENSG00000204438	G-patch domain and ankyrin repeats 1	6	31661229-31666283	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006301	Approved		Approved	Endoplasmic reticulum	Pancreatic cancer:5.89e-4 (favourable)	Expressed in all	Mixed			testis: 9.7	Mixed		
GPATCH1	ECGP, FLJ10206, FLJ38686, GPATC1	ENSG00000076650	G-patch domain containing 1	19	33080880-33130542	Predicted intracellular proteins	Evidence at protein level	HPA043430, HPA043604	Approved		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:8.20e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 8.8	Expressed in all		
GPATCH11	CCDC75, CENP-Y, CENPY, FLJ38348	ENSG00000152133	G-patch domain containing 11	2	37084451-37099244	Predicted intracellular proteins	Evidence at protein level	HPA038231, HPA038232	Enhanced		Supported	Nucleus		Expressed in all	Mixed			adipose tissue: 23.8	Expressed in all		
GPATCH2	CT110, FLJ10252, GPATC2, PPP1R30	ENSG00000092978	G-patch domain containing 2	1	217426992-217631082	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027181, HPA027322	Uncertain		Supported	Nuclear speckles	Renal cancer:9.99e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.8	Mixed		
GPATCH2L	C14orf118, FLJ10033, FLJ20689	ENSG00000089916	G-patch domain containing 2 like	14	76151916-76254342	Predicted intracellular proteins	Evidence at protein level	HPA018856	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 25.4	Expressed in all		
GPATCH3	FLJ12455, GPATC3	ENSG00000198746	G-patch domain containing 3	1	26890488-26900466	Predicted intracellular proteins	Evidence at protein level	HPA032078, HPA054973	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.23e-7 (unfavourable), Pancreatic cancer:6.42e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 15.3	Expressed in all		
GPATCH4	DKFZP434F1735, FLJ20249, GPATC4	ENSG00000160818	G-patch domain containing 4	1	156594487-156601496	Predicted intracellular proteins	Evidence at protein level	HPA028323, HPA054319	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:3.17e-5 (unfavourable), Renal cancer:3.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.5	Expressed in all		
GPATCH8	GPATC8, KIAA0553	ENSG00000186566	G-patch domain containing 8	17	44395284-44503430	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044380	Approved		Approved	Nuclear speckles<br>Mitochondria		Expressed in all	Mixed			parathyroid gland: 11.7	Mixed		
GPBP1	DKFZp761C169, vasculin	ENSG00000062194	GC-rich promoter binding protein 1	5	57173948-57264679	Predicted intracellular proteins	Evidence at protein level	HPA037773	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Urothelial cancer:4.15e-5 (favourable)	Expressed in all	Expressed in all			testis: 138.7	Expressed in all		
GPBP1L1	SP192	ENSG00000159592	GC-rich promoter binding protein 1 like 1	1	45627304-45688113	Predicted intracellular proteins	Evidence at protein level	HPA028593	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites		Expressed in all	Expressed in all			testis: 107.1	Expressed in all		
GPCPD1	GDE5, GDPD6, KIAA1434	ENSG00000125772	Glycerophosphocholine phosphodiesterase 1	20	5544404-5611026	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039556, HPA042987	Uncertain		Approved	Nucleoplasm	Endometrial cancer:1.30e-4 (favourable), Renal cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 46.5	Mixed		
GPD1		ENSG00000167588	Glycerol-3-phosphate dehydrogenase 1	12	50103819-50111319	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044620	Enhanced					Mixed	Tissue enhanced		adipose tissue: 636.1;skeletal muscle: 195.7	kidney: 148.1	Cell line enhanced		ASC diff: 86.3;CACO-2: 22.1;Hep G2: 17.0;RPMI-8226: 20.7
GPD1L	KIAA0089	ENSG00000152642	Glycerol-3-phosphate dehydrogenase 1-like	3	32105689-32168713	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.33e-15 (favourable), Liver cancer:1.35e-5 (unfavourable), Lung cancer:5.71e-5 (favourable), Colorectal cancer:7.05e-4 (favourable)	Expressed in all	Expressed in all			prostate: 92.5	Expressed in all		
GPHN	KIAA1385	ENSG00000171723	Gephyrin	14	66507407-67181803	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003116, CAB004419, HPA024694	Enhanced		Uncertain	Cytoplasmic bodies	Renal cancer:5.25e-12 (favourable), Urothelial cancer:4.61e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.5	Mixed		
GPKOW	GPATC5, GPATCH5, Spp2, T54	ENSG00000068394	G-patch domain and KOW motifs	X	49113389-49123801	Predicted intracellular proteins	Evidence at protein level	HPA000287, HPA001894	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 30.8	Expressed in all		
GPN1	ATPBD1A, MBDIN, NTPBP, RPAP4, XAB1	ENSG00000198522	GPN-loop GTPase 1	2	27628247-27651508	Predicted intracellular proteins	Evidence at protein level	HPA036793, HPA036794, CAB037303	Uncertain		Supported	Nucleoplasm<br>Mitochondria<br>Cytosol	Liver cancer:1.71e-5 (unfavourable), Endometrial cancer:2.88e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 47.1	Expressed in all		
GPN2	ATPBD1B, FLJ10349	ENSG00000142751	GPN-loop GTPase 2	1	26876133-26890297	Predicted intracellular proteins	Evidence at protein level	HPA028059	Uncertain				Liver cancer:3.56e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.3	Expressed in all		
GPN3	ATPBD1C, MGC14560	ENSG00000111231	GPN-loop GTPase 3	12	110452484-110469268	Predicted intracellular proteins	Evidence at protein level	HPA039764, HPA047793	Uncertain		Approved	Nuclear speckles<br>Cytosol	Renal cancer:2.65e-6 (favourable), Liver cancer:3.98e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 74.2	Expressed in all		
GPR75-ASB3		ENSG00000270898	GPR75-ASB3 readthrough	2	53670293-53860160	Predicted intracellular proteins	Evidence at transcript level	HPA003940	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.0	spleen: 0.3	Cell line enhanced		K-562: 1.3
GPRASP1	GASP, GASP1	ENSG00000198932	G protein-coupled receptor associated sorting protein 1	X	102651366-102659083	Predicted intracellular proteins	Evidence at protein level	HPA000161, HPA031061	Uncertain		Supported	Cytosol	Pancreatic cancer:1.77e-5 (favourable), Thyroid cancer:7.38e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 64.8	Cell line enhanced		REH: 5.1
GPRASP2	FLJ37327, GASP2	ENSG00000158301	G protein-coupled receptor associated sorting protein 2	X	102712176-102717733	Predicted intracellular proteins	Evidence at protein level	HPA017438	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.60e-6 (favourable), Urothelial cancer:6.63e-5 (unfavourable), Pancreatic cancer:5.71e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 41.6	Mixed		
GPRIN1	GRIN1, KIAA1893	ENSG00000169258	G protein regulated inducer of neurite outgrowth 1	5	176595802-176610133	Predicted intracellular proteins	Evidence at protein level	HPA036478, HPA070892	Enhanced		Supported	Vesicles<br>Plasma membrane	Renal cancer:2.79e-7 (unfavourable), Lung cancer:6.83e-6 (unfavourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 27.8	duodenum: 3.8	Cell line enhanced		HDLM-2: 52.6;SCLC-21H: 70.4
GPRIN2	KIAA0514, MGC15171	ENSG00000204175	G protein regulated inducer of neurite outgrowth 2	10	46549044-46555530	Predicted intracellular proteins	Evidence at protein level	HPA038129	Approved		Approved	Nucleoplasm	Endometrial cancer:8.60e-8 (unfavourable), Head and neck cancer:3.47e-4 (favourable)	Mixed	Tissue enhanced		lung: 18.0;skin: 18.8	small intestine: 11.7	Group enriched	5	A-431: 12.9;A549: 38.1;SiHa: 8.3;SK-BR-3: 17.1
GPRIN3	FLJ42625, GRIN3	ENSG00000185477	GPRIN family member 3	4	89236386-89308010	Predicted intracellular proteins	Evidence at protein level	HPA043148, HPA057666, HPA059092	Uncertain		Approved	Nucleus<br>Nucleoli	Colorectal cancer:7.22e-5 (favourable), Renal cancer:8.33e-4 (favourable)	Mixed	Mixed			appendix: 12.0	Cell line enhanced		Karpas-707: 73.5;RPMI-8226: 18.9;SCLC-21H: 31.9
GPS1	COPS1, CSN1	ENSG00000169727	G protein pathway suppressor 1	17	82050691-82057470	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Ovarian cancer:3.06e-4 (favourable)	Expressed in all	Expressed in all			testis: 77.0	Expressed in all		
GPS2		ENSG00000132522	G protein pathway suppressor 2	17	7311324-7315564	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA067540	Approved		Supported	Nucleoplasm	Renal cancer:3.42e-5 (unfavourable), Pancreatic cancer:7.50e-5 (favourable)	Expressed in all	Expressed in all			testis: 97.4	Expressed in all		
GPSM1	AGS3, DKFZP727I051	ENSG00000160360	G-protein signaling modulator 1	9	136327476-136359605	Predicted intracellular proteins	Evidence at protein level	HPA042199	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.30e-4 (unfavourable), Colorectal cancer:6.07e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 28.4	Cell line enhanced		REH: 73.8
GPSM3	AGS4, C6orf9, G18, G18.1a, G18.1b, G18.2, NG1	ENSG00000213654	G-protein signaling modulator 3	6	32190766-32195523	Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.92e-9 (unfavourable), Endometrial cancer:5.98e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 27.5;spleen: 29.3	appendix: 24.9	Cell line enhanced		HMC-1: 35.2;NB-4: 14.7;THP-1: 16.2
GPT	ALT1, GPT1	ENSG00000167701	Glutamic--pyruvic transaminase	8	144502973-144507174	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031059, HPA031060, CAB032997, CAB032999	Enhanced				Liver cancer:1.47e-5 (favourable), Renal cancer:2.19e-4 (favourable)	Tissue enriched	Mixed			liver: 25.0	Mixed		
GPT2	ALT2	ENSG00000166123	Glutamic--pyruvic transaminase 2	16	46884378-46931297	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051514	Approved		Approved	Mitochondria	Ovarian cancer:3.17e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 85.0	Mixed		
GPX1		ENSG00000233276	Glutathione peroxidase 1	3	49357176-49358600	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011582, HPA044758	Approved		Supported	Cytosol	Endometrial cancer:7.78e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 276.3	Mixed		
GPX2	GSHPX-GI	ENSG00000176153	Glutathione peroxidase 2	14	64939152-64942905	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003545	Enhanced		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:5.10e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 696.1;rectum: 461.1	stomach: 334.9	Group enriched	20	A549: 930.0;HaCaT: 249.8;Hep G2: 659.7;RT4: 543.6;SCLC-21H: 352.2
GPX8	EPLA847, UNQ847	ENSG00000164294	Glutathione peroxidase 8 (putative)	5	55160118-55167071	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036720	Enhanced		Supported	Actin filaments<br>Cytosol	Renal cancer:5.13e-9 (unfavourable), Stomach cancer:7.96e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 48.0	Mixed		
GRAP		ENSG00000154016	GRB2-related adaptor protein	17	19020673-19047637	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046595, HPA066654	Uncertain		Approved	Centrosome		Mixed	Tissue enhanced		lymph node: 30.9;spleen: 25.4	tonsil: 20.7	Group enriched	5	Daudi: 52.5;HUVEC TERT2: 24.8;MOLT-4: 12.3;REH: 35.4;TIME: 47.9;U-698: 35.4
GRAP2	GADS, GRBLG, GrbX, Grf40, Mona	ENSG00000100351	GRB2-related adaptor protein 2	22	39901082-39973721	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005788, CAB022073	Enhanced					Mixed	Tissue enhanced		lymph node: 18.0	spleen: 12.8	Group enriched	8	HDLM-2: 22.1;HEL: 40.9;K-562: 39.9;MOLT-4: 98.1
GRAPL		ENSG00000189152	GRB2 related adaptor protein like	17	19127469-19159176	Predicted intracellular proteins	Evidence at transcript level	HPA051796, HPA066654	Uncertain		Approved	Centrosome		Not detected	Tissue enhanced		lymph node: 26.7;spleen: 32.0	tonsil: 21.5	Group enriched	6	Daudi: 27.6;HUVEC TERT2: 13.0;TIME: 34.3;U-698: 24.5
GRASP	Tamalin	ENSG00000161835	General receptor for phosphoinositides 1 associated scaffold protein	12	52006940-52015889	Predicted intracellular proteins	Evidence at protein level	HPA040664, HPA062028	Approved		Approved	Nuclear bodies<br>Vesicles		Expressed in all	Mixed			adipose tissue: 21.6	Cell line enhanced		HUVEC TERT2: 27.8;TIME: 19.7;WM-115: 43.6
GRB10		ENSG00000106070	Growth factor receptor bound protein 10	7	50590063-50793462	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB019423, HPA027502, HPA031818	Approved		Supported	Vesicles		Expressed in all	Expressed in all			thyroid gland: 44.9	Mixed		
GRB14		ENSG00000115290	Growth factor receptor bound protein 14	2	164492812-164621848	Predicted intracellular proteins	Evidence at protein level	CAB022294, HPA035052, HPA035053	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		epididymis: 6.1;kidney: 6.2;liver: 6.6	testis: 4.3	Cell line enhanced		HUVEC TERT2: 7.9;RPTEC TERT1: 5.9;TIME: 9.9
GRB2	NCKAP2	ENSG00000177885	Growth factor receptor bound protein 2	17	75318076-75405709	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002589, HPA030749, HPA030750	Approved		Supported	Nucleus	Liver cancer:6.04e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 136.5	Expressed in all		
GRB7		ENSG00000141738	Growth factor receptor bound protein 7	17	39737927-39747291	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB005226, HPA057084, CAB073538	Approved		Supported	Plasma membrane	Endometrial cancer:6.60e-7 (unfavourable), Renal cancer:8.23e-5 (favourable), Ovarian cancer:3.10e-4 (unfavourable), Pancreatic cancer:6.90e-4 (unfavourable)	Mixed	Mixed			fallopian tube: 35.1	Cell line enriched	8	SK-BR-3: 272.9
GREB1L	C18orf6, FLJ13687, KIAA1772	ENSG00000141449	Growth regulation by estrogen in breast cancer 1 like	18	21242242-21525417	Predicted intracellular proteins	Evidence at protein level	HPA041647, HPA044218	Uncertain		Approved	Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		testis: 11.5	thyroid gland: 5.8	Cell line enhanced		AF22: 50.3;BEWO: 99.4;CACO-2: 39.5
GRHL1	LBP-32, MGR, TFCP2L2	ENSG00000134317	Grainyhead like transcription factor 1	2	9951693-10002277	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005798, HPA006420	Enhanced		Enhanced	Nucleus<br>Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		esophagus: 111.4;skin: 106.8	parathyroid gland: 50.3	Cell line enhanced		BEWO: 205.8;SK-BR-3: 84.4
GRHL2	BOM, DFNA28, FLJ13782, TFCP2L3	ENSG00000083307	Grainyhead like transcription factor 2	8	101492432-101669726	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004820, HPA062839	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:6.27e-4 (unfavourable), Breast cancer:6.43e-4 (unfavourable)	Mixed	Mixed			prostate: 37.3	Cell line enhanced		A-431: 34.0;HaCaT: 40.9;RT4: 54.7;T-47d: 74.7
GRHPR	GLXR, PH2	ENSG00000137106	Glyoxylate and hydroxypyruvate reductase	9	37422666-37436990	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022971	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.39e-9 (favourable), Breast cancer:7.00e-5 (favourable)	Expressed in all	Expressed in all			liver: 323.3	Expressed in all		
GRID2IP		ENSG00000215045	Grid2 interacting protein	7	6497462-6551436	Predicted intracellular proteins	Evidence at protein level	HPA045381	Uncertain					Mixed	Mixed			parathyroid gland: 1.3	Cell line enhanced		REH: 3.3
GRIFIN		ENSG00000275572	Galectin-related inter-fiber protein	7	2474844-2476894	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			skin: 0.7	Not detected		
GRIP1		ENSG00000155974	Glutamate receptor interacting protein 1	12	66347431-66804186	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038856	Uncertain					Mixed	Mixed			seminal vesicle: 11.6	Cell line enhanced		BEWO: 22.7;HaCaT: 17.8;RT4: 17.2
GRIP2	KIAA1719	ENSG00000144596	Glutamate receptor interacting protein 2	3	14489111-14556075	Predicted intracellular proteins	Evidence at transcript level	HPA035673			Approved	Cytosol		Mixed	Tissue enhanced		skeletal muscle: 12.4	heart muscle: 8.6	Cell line enhanced		BJ hTERT+: 2.5;NTERA-2: 2.1;PC-3: 5.7;SCLC-21H: 4.0;U-2 OS: 2.4
GRIPAP1	DKFZp434P0630, GRASP-1, GRASP1, KIAA1167, MPMGp800B12492Q3	ENSG00000068400	GRIP1 associated protein 1	X	48973720-49002264	Predicted intracellular proteins	Evidence at protein level	HPA000282, HPA000615	Enhanced		Approved	Vesicles<br>Cytosol	Renal cancer:3.92e-7 (unfavourable), Urothelial cancer:4.63e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 68.5	Expressed in all		
GRK1	GPRK1, RHOK, RK	ENSG00000185974	G protein-coupled receptor kinase 1	13	113667155-113737735	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035200, HPA059376	Enhanced					Tissue enhanced	Not detected			thyroid gland: 0.8	Not detected		
GRK2	ADRBK1, BARK1	ENSG00000173020	G protein-coupled receptor kinase 2	11	67266410-67286556	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005021, CAB037248, HPA048330	Approved		Approved	Vesicles	Renal cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 127.3	Expressed in all		
GRK3	ADRBK2, BARK2	ENSG00000100077	G protein-coupled receptor kinase 3	22	25564849-25729294	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000804	Uncertain		Approved	Nucleus<br>Plasma membrane	Urothelial cancer:1.29e-4 (favourable)	Expressed in all	Mixed			adipose tissue: 32.7	Cell line enhanced		HDLM-2: 40.3;SH-SY5Y: 39.9
GRK4	GPRK2L, GPRK4	ENSG00000125388	G protein-coupled receptor kinase 4	4	2963608-3040747	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028737, HPA057023	Approved		Supported	Vesicles		Expressed in all	Tissue enriched	9	testis: 74.7	cerebral cortex: 8.1	Cell line enhanced		SCLC-21H: 18.6
GRK5	GPRK5	ENSG00000198873	G protein-coupled receptor kinase 5	10	119207589-119459742	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB025579, HPA046838	Approved		Supported	Nuclear membrane<br>Nuclear speckles<br>Plasma membrane	Renal cancer:2.38e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 78.5	Cell line enhanced		BJ hTERT+: 68.5;HUVEC TERT2: 55.7
GRK6	GPRK6	ENSG00000198055	G protein-coupled receptor kinase 6	5	177403204-177442901	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015327, HPA018903	Approved		Approved	Mitochondria	Liver cancer:5.66e-6 (unfavourable), Pancreatic cancer:1.22e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 87.5	Expressed in all		
GRK7	GPRK7	ENSG00000114124	G protein-coupled receptor kinase 7	3	141778148-141818490	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			skin,testis: 0.2	Not detected		
GRPEL1	FLJ25609, GrpE, hMGE	ENSG00000109519	GrpE like 1, mitochondrial	4	7058906-7068197	Predicted intracellular proteins	Evidence at protein level	HPA036647	Supported		Supported	Mitochondria	Renal cancer:2.00e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 43.9	Expressed in all		
GRPEL2	DKFZp451C205, FLJ23713, Mt-GrpE#2	ENSG00000164284	GrpE like 2, mitochondrial	5	149345430-149354583	Predicted intracellular proteins	Evidence at protein level	HPA018173, HPA023211	Uncertain		Enhanced	Mitochondria	Liver cancer:6.16e-8 (unfavourable), Colorectal cancer:3.87e-5 (favourable), Endometrial cancer:2.21e-4 (unfavourable), Renal cancer:4.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 30.4	thyroid gland: 9.7	Expressed in all		
GRSF1		ENSG00000132463	G-rich RNA sequence binding factor 1	4	70815782-70839945	Predicted intracellular proteins	Evidence at protein level	HPA036984, HPA036985	Enhanced		Enhanced	Mitochondria	Renal cancer:2.72e-9 (favourable), Colorectal cancer:1.47e-5 (favourable), Liver cancer:8.29e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 95.7	Expressed in all		
GRTP1	FLJ22474, TBC1D6	ENSG00000139835	Growth hormone regulated TBC protein 1	13	113324164-113364148	Predicted intracellular proteins	Evidence at protein level	HPA046201	Approved				Renal cancer:1.50e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 47.1	Cell line enhanced		T-47d: 52.1
GRWD1	GRWD, RRB1, WDR28	ENSG00000105447	Glutamate rich WD repeat containing 1	19	48445773-48457022	Predicted intracellular proteins	Evidence at protein level	HPA042643, HPA055680	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:2.16e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.2	Expressed in all		
GRXCR1	DFNB25, PPP1R88	ENSG00000215203	Glutaredoxin and cysteine rich domain containing 1	4	42893267-43030658	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040824	Uncertain					Not detected	Tissue enriched	8	seminal vesicle: 6.3	testis: 0.7	Not detected		
GRXCR2	DFNB101	ENSG00000204928	Glutaredoxin and cysteine rich domain containing 2	5	145858521-145937126	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA059421	Uncertain					Not detected	Tissue enhanced		testis: 1.6	skin: 0.6	Not detected		
GSAP	LOC54103, PION	ENSG00000186088	Gamma-secretase activating protein	7	77310751-77416400	Predicted intracellular proteins	Evidence at protein level	HPA023994			Supported	Vesicles	Urothelial cancer:4.15e-5 (favourable), Breast cancer:3.36e-4 (favourable), Renal cancer:3.51e-4 (unfavourable)	Expressed in all	Mixed			lung: 26.8	Cell line enhanced		U-937: 13.1
GSC		ENSG00000133937	Goosecoid homeobox	14	94768216-94770230	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075650			Approved	Nucleus<br>Nuclear bodies		Mixed	Tissue enhanced		adipose tissue: 2.1	breast: 1.1	Cell line enhanced		HEK93: 1.7;MCF7: 2.1;REH: 2.6;SH-SY5Y: 3.3;T-47d: 2.1;U-251 MG: 1.8
GSC2	GSCL	ENSG00000063515	Goosecoid homeobox 2	22	19148576-19150283	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043011	Uncertain					Not detected	Tissue enriched	31	testis: 3.0	all non-specific tissues: 0.0	Not detected		
GSDMA	FLJ39120, GSDM, GSDM1	ENSG00000167914	Gasdermin A	17	39953263-39977766	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023313, HPA064826	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	7	skin: 58.4	epididymis: 7.9	Cell line enhanced		HBEC3-KT: 2.9;hTCEpi: 2.0;hTERT-HME1: 4.1
GSDMB	GSDML, PRO2521	ENSG00000073605	Gasdermin B	17	39904595-39919854	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB013681, HPA023925, HPA052407	Enhanced				Renal cancer:5.13e-11 (unfavourable), Urothelial cancer:5.91e-9 (favourable), Cervical cancer:3.41e-5 (favourable)	Expressed in all	Tissue enhanced		duodenum: 67.0;small intestine: 85.1	rectum: 62.6	Cell line enriched	7	SK-BR-3: 342.4
GSDMC	MLZE	ENSG00000147697	Gasdermin C	8	129748196-129786888	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023670, HPA024767, HPA026317	Supported		Enhanced	Mitochondria		Group enriched	Tissue enhanced		esophagus: 20.0;skin: 44.3;spleen: 21.6	tonsil: 6.5	Cell line enhanced		A-431: 13.0;HaCaT: 3.1;hTCEpi: 4.5;HUVEC TERT2: 5.2;TIME: 4.3
GSDMD	DF5L, FLJ12150, GSDMDC1	ENSG00000104518	Gasdermin D	8	143553207-143563062	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004656, HPA044487	Uncertain		Supported	Nucleoplasm	Renal cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 46.5	Mixed		
GSE1	KIAA0182	ENSG00000131149	Gse1 coiled-coil protein	16	85169525-85676204	Predicted intracellular proteins	Evidence at protein level	HPA036365	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:5.20e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 83.4	Expressed in all		
GSG2	haspin	ENSG00000177602	Germ cell associated 2, haspin	17	3723903-3726699	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027422, HPA030698	Approved		Supported	Nucleus		Mixed	Tissue enhanced		testis: 13.2	lymph node: 5.0	Mixed		
GSK3A		ENSG00000105723	Glycogen synthase kinase 3 alpha	19	42230186-42242625	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004422, HPA028423	Approved		Approved	Cytosol	Liver cancer:1.13e-4 (unfavourable), Endometrial cancer:4.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.5	Expressed in all		
GSK3B		ENSG00000082701	Glycogen synthase kinase 3 beta	3	119821323-120094417	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB016263, HPA028017	Approved		Enhanced	Nucleus	Liver cancer:8.20e-5 (unfavourable), Renal cancer:1.52e-4 (favourable)	Expressed in all	Expressed in all			testis: 47.4	Expressed in all		
GSKIP	C14orf129	ENSG00000100744	GSK3B interacting protein	14	96363452-96387288	Predicted intracellular proteins	Evidence at protein level	HPA043054, HPA046782	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			small intestine: 62.0	Expressed in all		
GSPT1	eRF3a, ETF3A, GST1	ENSG00000103342	G1 to S phase transition 1	16	11868128-11916082	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052488	Approved		Approved	Vesicles<br>Cytosol	Colorectal cancer:2.10e-5 (favourable), Renal cancer:3.06e-5 (favourable), Liver cancer:7.94e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 131.6	Expressed in all		
GSPT2	eRF3b, FLJ10441	ENSG00000189369	G1 to S phase transition 2	X	51743431-51746232	Predicted intracellular proteins	Evidence at protein level	HPA044769	Approved		Supported	Cytosol		Expressed in all	Expressed in all			testis: 24.5	Cell line enhanced		NTERA-2: 47.4;PC-3: 49.6
GSR		ENSG00000104687	Glutathione-disulfide reductase	8	30678061-30727926	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001538, CAB008632	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 79.3	Expressed in all		
GSS		ENSG00000100983	Glutathione synthetase	20	34928430-34955817	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054508, HPA059315	Enhanced		Supported	Nucleus	Renal cancer:7.31e-6 (favourable), Liver cancer:7.21e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 105.8	Expressed in all		
GSTA1		ENSG00000243955	Glutathione S-transferase alpha 1	6	52791664-52803910	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004342, HPA048934, HPA053817	Supported		Supported	Cytosol	Renal cancer:3.71e-4 (unfavourable), Lung cancer:8.66e-4 (favourable)	Group enriched	Tissue enhanced		adrenal gland: 1136.4;kidney: 1310.9;liver: 1757.6	small intestine: 1002.9	Cell line enriched	11	Hep G2: 245.8
GSTA2	GST2	ENSG00000244067	Glutathione S-transferase alpha 2	6	52750089-52763569	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004342, HPA048934, HPA053817	Supported		Supported	Cytosol	Renal cancer:1.17e-4 (unfavourable)	Group enriched	Group enriched	5	kidney: 651.7;liver: 986.1	gallbladder: 155.6	Group enriched	17	CACO-2: 19.6;Hep G2: 12.5
GSTA3		ENSG00000174156	Glutathione S-transferase alpha 3	6	52896639-52909685	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004342, HPA048934, HPA053817	Approved		Supported	Cytosol		Mixed	Tissue enhanced		adrenal gland: 56.1;fallopian tube: 102.0	placenta: 32.1	Not detected		
GSTA4		ENSG00000170899	Glutathione S-transferase alpha 4	6	52977948-52995378	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048934	Approved					Expressed in all	Expressed in all			adrenal gland: 390.0	Cell line enhanced		AF22: 92.3
GSTA5		ENSG00000182793	Glutathione S-transferase alpha 5	6	52831655-52846095	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004342, HPA048934, HPA053817	Uncertain		Approved	Cytosol		Not detected	Not detected			testis: 0.1	Not detected		
GSTK1	GST13	ENSG00000197448	Glutathione S-transferase kappa 1	7	143244093-143270854	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006311, HPA022904	Enhanced		Supported	Peroxisomes	Renal cancer:2.10e-6 (favourable), Breast cancer:4.41e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 377.4	Expressed in all		
GSTM1	GST1, H-B, MU	ENSG00000134184	Glutathione S-transferase mu 1	1	109687814-109709039	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022669, CAB047357, HPA048652, HPA055972, HPA055973	Approved		Approved	Cytosol		Expressed in all	Tissue enhanced		liver: 317.1	parathyroid gland: 233.1	Cell line enhanced		HEL: 78.7;HeLa: 68.9;HHSteC: 66.1;hTEC/SVTERT24-B: 72.9;MOLT-4: 92.2
GSTM2	GST4	ENSG00000213366	Glutathione S-transferase mu 2	1	109668022-109709551	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB040547, HPA055972, HPA055973	Approved		Enhanced	Cytosol	Lung cancer:9.70e-5 (favourable)	Mixed	Expressed in all			ovary: 201.1	Cell line enhanced		ASC TERT1: 82.2;HSkMC: 85.0
GSTM3	GST5	ENSG00000134202	Glutathione S-transferase mu 3	1	109733932-109741038	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB017130, HPA035190, CAB040583, HPA055972	Enhanced		Supported	Cytosol	Melanoma:1.89e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 722.1	Cell line enhanced		T-47d: 462.4
GSTM4		ENSG00000168765	Glutathione S-transferase mu 4	1	109656081-109674836	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048652, HPA055972, HPA055973	Approved		Approved	Cytokinetic bridge<br>Cytosol	Breast cancer:9.96e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 149.7	Mixed		
GSTM5		ENSG00000134201	Glutathione S-transferase mu 5	1	109712255-109775428	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048652, HPA055972, HPA055973	Approved		Approved	Cytokinetic bridge<br>Cytosol		Mixed	Group enriched	6	breast: 845.2;ovary: 221.0	fallopian tube: 84.6	Group enriched	8	fHDF/TERT166: 12.9;HHSteC: 5.7;HSkMC: 5.3
GSTO1	GSTTLp28, P28	ENSG00000148834	Glutathione S-transferase omega 1	10	104235356-104267459	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037603, HPA037604	Enhanced				Renal cancer:2.11e-4 (unfavourable), Breast cancer:6.95e-4 (favourable), Head and neck cancer:8.83e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 266.3	Expressed in all		
GSTO2		ENSG00000065621	Glutathione S-transferase omega 2	10	104268873-104304945	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048141	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:7.10e-7 (favourable)	Mixed	Mixed			testis: 36.1	Cell line enhanced		CAPAN-2: 45.6;hTCEpi: 32.1;hTERT-HME1: 36.7;T-47d: 36.0
GSTP1	FAEES3, GST3, GSTP	ENSG00000084207	Glutathione S-transferase pi 1	11	67583595-67586660	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019779, HPA019869	Enhanced		Supported	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			esophagus: 1059.9	Expressed in all		
GSTT2B	GSTT2P	ENSG00000133433	Glutathione S-transferase theta 2B (gene/pseudogene)	22	23957414-23961186	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000750	Uncertain		Supported	Nucleoplasm<br>Cytosol	Breast cancer:5.06e-4 (favourable)	Expressed in all	Tissue enriched	7	breast: 411.1	adrenal gland: 60.8	Cell line enhanced		AN3-CA: 53.0;HHSteC: 68.3;T-47d: 60.4
GSTTP1	HS322B1A	ENSG00000276950	Glutathione S-transferase theta pseudogene 1	22	23998401-24005453	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.4	Not detected		
GSTZ1	GSTZ1-1, MAAI, MAI	ENSG00000100577	Glutathione S-transferase zeta 1	14	77320884-77331597	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004701	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.12e-7 (favourable), Ovarian cancer:3.73e-4 (favourable), Breast cancer:4.93e-4 (favourable)	Expressed in all	Expressed in all			liver: 134.5	Expressed in all		
GSX1	Gsh-1, GSH1	ENSG00000169840	GS homeobox 1	13	27792643-27794768	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Not detected			cerebral cortex: 0.7	Not detected		
GSX2	Gsh2	ENSG00000180613	GS homeobox 2	4	54099523-54102505	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Not detected			testis: 0.4	Not detected		
GTF2A1	TFIIA	ENSG00000165417	General transcription factor IIA subunit 1	14	81175452-81221377	Predicted intracellular proteins	Evidence at protein level	HPA000869	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 38.9	Expressed in all		
GTF2A1L	ALF	ENSG00000242441	General transcription factor IIA subunit 1 like	2	48617798-48733148	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	66	testis: 105.4	endometrium,gallbladder: 1.5	Cell line enhanced		ASC diff: 1.0
GTF2A2	HsT18745, TFIIA	ENSG00000140307	General transcription factor IIA subunit 2	15	59638062-59657541	Predicted intracellular proteins	Evidence at protein level	HPA056239			Supported	Nucleoplasm		Expressed in all	Tissue enriched	5	testis: 369.2	adrenal gland: 73.5	Expressed in all		
GTF2B	TFIIB	ENSG00000137947	General transcription factor IIB	1	88852932-88891944	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061626	Enhanced		Supported	Nucleus<br>Nuclear bodies	Breast cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 47.6	Expressed in all		
GTF2E1	FE, TFIIE-A	ENSG00000153767	General transcription factor IIE subunit 1	3	120742637-120783069	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009884, HPA056359, HPA066881	Enhanced		Enhanced	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 18.4	Expressed in all		
GTF2E2	FE, TF2E2, TFIIE-B	ENSG00000197265	General transcription factor IIE subunit 2	8	30578318-30658251	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004816, CAB009603, HPA025065	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:5.82e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 52.7	Expressed in all		
GTF2F1	BTF4, RAP74, TF2F1, TFIIF	ENSG00000125651	General transcription factor IIF subunit 1	19	6379569-6393981	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022793, HPA028707, HPA070752	Supported		Enhanced	Nucleus<br>Cell Junctions	Endometrial cancer:8.39e-4 (favourable), Renal cancer:9.80e-4 (favourable)	Expressed in all	Expressed in all			ovary: 93.3	Expressed in all		
GTF2F2	BTF4, RAP30, TFIIF	ENSG00000188342	General transcription factor IIF subunit 2	13	45120515-45284909	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006912	Supported		Supported	Nucleus<br>Microtubules	Head and neck cancer:1.65e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 26.3	Expressed in all		
GTF2H1	BTF2, P62, TFIIH	ENSG00000110768	General transcription factor IIH subunit 1	11	18322295-18367044	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004637, HPA046660	Enhanced		Enhanced	Nucleoplasm	Liver cancer:5.98e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 60.0	Expressed in all		
GTF2H2	BTF2, BTF2P44, p44, T-BTF2P44, TFIIH	ENSG00000145736	General transcription factor IIH subunit 2	5	71032670-71067689	Predicted intracellular proteins	Evidence at protein level	HPA047001			Supported	Nuclear speckles		Mixed	Mixed			smooth muscle: 7.6	Mixed		
GTF2H2C		ENSG00000183474	GTF2H2 family member C	5	69560208-69594723	Predicted intracellular proteins	Evidence at protein level	HPA047001			Approved	Nuclear speckles		Mixed	Mixed			thyroid gland: 8.3	Mixed		
GTF2H3	BTF2, P34, TFIIH	ENSG00000111358	General transcription factor IIH subunit 3	12	123633739-123662606	Predicted intracellular proteins	Evidence at protein level	HPA004844, HPA053562	Uncertain		Supported	Nucleoplasm	Liver cancer:6.72e-8 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 26.6	Expressed in all		
GTF2H4	P52, TFB2, TFIIH	ENSG00000213780	General transcription factor IIH subunit 4	6	30908184-30914106	Predicted intracellular proteins	Evidence at protein level	HPA074336			Supported	Nuclear speckles	Renal cancer:4.08e-4 (unfavourable)	Expressed in all	Mixed			appendix: 3.6	Mixed		
GTF2H5	bA120J8.2, C6orf175, FLJ30544, TFB5, TFIIH, TTD, TTD-A, TTDA	ENSG00000272047	General transcription factor IIH subunit 5	6	158168352-158199344	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.11e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 11.1	Expressed in all		
GTF2I	BAP-135, BTKAP1, DIWS, IB291, SPIN, TFII-I, WBSCR6	ENSG00000263001	General transcription factor IIi	7	74657667-74760692	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004595, HPA026638	Supported		Enhanced	Nucleoplasm	Renal cancer:6.35e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 232.3	Expressed in all		
GTF2IRD1	BEN, Cream1, GTF3, MusTRD1, RBAP2, WBSCR11, WBSCR12	ENSG00000006704	GTF2I repeat domain containing 1	7	74453790-74602604	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044254	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:9.71e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 34.9	Mixed		
GTF2IRD2	FLJ37938, GTF2IRD2A	ENSG00000196275	GTF2I repeat domain containing 2	7	74796144-74851551	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056679, HPA056680			Approved	Nucleoplasm		Mixed	Expressed in all			ovary: 16.2	Cell line enhanced		SK-BR-3: 44.5
GTF2IRD2B		ENSG00000174428	GTF2I repeat domain containing 2B	7	75092573-75149817	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056679, HPA056680			Approved	Nucleoplasm	Breast cancer:3.27e-4 (favourable)	Mixed	Expressed in all			ovary: 40.5	Expressed in all		
GTF3A	AP2, TFIIIA	ENSG00000122034	General transcription factor IIIA	13	27424544-27435823	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007990	Supported		Supported	Nucleus	Renal cancer:3.43e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 122.3	Expressed in all		
GTF3C2	KIAA0011, TFIIIC110	ENSG00000115207	General transcription factor IIIC subunit 2	2	27325849-27357034	Predicted intracellular proteins	Evidence at protein level	HPA035836	Uncertain				Liver cancer:1.21e-8 (unfavourable), Endometrial cancer:8.25e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 56.0	Expressed in all		
GTF3C4	KAT12, TFIIIC90	ENSG00000125484	General transcription factor IIIC subunit 4	9	132670035-132694955	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069369			Supported	Nucleus	Renal cancer:2.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.0	Expressed in all		
GTF3C5	TFiiiC2-63, TFIIIC63, TFIIICepsilon	ENSG00000148308	General transcription factor IIIC subunit 5	9	133030675-133058503	Predicted intracellular proteins	Evidence at protein level	HPA067063, HPA069805	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 48.2	Expressed in all		
GTF3C6	bA397G5.3, C6orf51, TFIIIC35	ENSG00000155115	General transcription factor IIIC subunit 6	6	110958560-110967890	Predicted intracellular proteins	Evidence at protein level	HPA056179, HPA061345	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Liver cancer:7.27e-6 (unfavourable)	Expressed in all	Expressed in all			prostate: 101.0	Expressed in all		
GTPBP1	GP-1, HSPC018	ENSG00000100226	GTP binding protein 1	22	38705723-38738299	Predicted intracellular proteins	Evidence at protein level	HPA003166, HPA064702	Approved		Approved	Nuclear bodies<br>Golgi apparatus<br>Cytosol	Liver cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 65.0	Expressed in all		
GTPBP2		ENSG00000172432	GTP binding protein 2	6	43605316-43629162	Predicted intracellular proteins	Evidence at protein level	HPA031418, HPA031419	Approved		Enhanced	Vesicles	Renal cancer:1.44e-15 (unfavourable), Liver cancer:1.08e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 47.4	Expressed in all		
GTPBP3	FLJ14700, GTPBG3, MSS1, MTGP1, THDF1	ENSG00000130299	GTP binding protein 3 (mitochondrial)	19	17334920-17342735	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042158	Approved		Supported	Mitochondria	Renal cancer:1.64e-4 (unfavourable), Liver cancer:1.86e-4 (unfavourable), Prostate cancer:2.81e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 12.3	Expressed in all		
GTPBP4	CRFG, FLJ10686, FLJ10690, NGB, NOG1	ENSG00000107937	GTP binding protein 4	10	988019-1019936	Predicted intracellular proteins	Evidence at protein level	HPA039618, HPA056468	Uncertain		Enhanced	Nuclear membrane<br>Nucleoli	Liver cancer:8.85e-12 (unfavourable), Renal cancer:2.38e-5 (unfavourable), Endometrial cancer:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.3	Expressed in all		
GTPBP6	FLJ20977, PGPL	ENSG00000178605	GTP binding protein 6 (putative)	X	304529-318819	Predicted intracellular proteins	Evidence at protein level	CAB034924, HPA035467, HPA055418	Approved		Uncertain	Mitochondria	Pancreatic cancer:1.71e-4 (favourable), Liver cancer:8.87e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 26.1	Expressed in all		
GTPBP8	HSPC135	ENSG00000163607	GTP binding protein 8 (putative)	3	112990918-113015060	Predicted intracellular proteins	Evidence at protein level	HPA034831, HPA058631	Approved		Enhanced	Mitochondria	Renal cancer:3.07e-5 (favourable)	Expressed in all	Expressed in all			testis: 33.0	Expressed in all		
GTSE1	B99, GTSE-1	ENSG00000075218	G2 and S-phase expressed 1	22	46296741-46330810	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029457, HPA060544	Uncertain		Approved	Plasma membrane<br>Centrosome	Liver cancer:1.90e-10 (unfavourable), Pancreatic cancer:1.29e-4 (unfavourable), Lung cancer:4.66e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 12.5	lymph node: 10.6	Mixed		
GTSF1	FAM112B, FLJ32942	ENSG00000170627	Gametocyte specific factor 1	12	54455950-54473602	Predicted intracellular proteins	Evidence at protein level	HPA038876, HPA038877	Approved		Approved	Nucleoplasm		Tissue enriched	Tissue enriched	16	testis: 333.8	placenta: 20.9	Cell line enhanced		HL-60: 233.8;K-562: 259.6;NB-4: 280.4;THP-1: 272.7;U-266/84: 235.1
GTSF1L	C20orf65, dJ1028D15.4, FAM112A	ENSG00000124196	Gametocyte specific factor 1 like	20	43726164-43726998	Predicted intracellular proteins	Evidence at protein level	HPA054694	Enhanced		Uncertain	Nucleoli		Tissue enriched	Tissue enriched	160	testis: 269.9	lymph node: 1.6	Cell line enhanced		REH: 1.0
GUCA1A	C6orf131, COD3, CORD14, dJ139D8.6, GCAP, GCAP1, GUCA, GUCA1	ENSG00000048545	Guanylate cyclase activator 1A	6	42155406-42180056	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005561	Supported	Approved	Uncertain	Plasma membrane		Tissue enriched	Tissue enriched	19	testis: 30.0	cerebral cortex: 1.5	Group enriched	8	NTERA-2: 3.6;SH-SY5Y: 4.7
GUCA1B	GCAP2, RP48	ENSG00000112599	Guanylate cyclase activator 1B	6	42184401-42194916	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055479	Supported					Mixed	Mixed			skin: 4.2	Mixed		
GUCA1C	GCAP3	ENSG00000138472	Guanylate cyclase activator 1C	3	108907792-108953895	Predicted intracellular proteins	Evidence at protein level	HPA041597	Approved		Approved	Focal adhesion sites		Tissue enriched	Tissue enhanced		heart muscle: 8.9;pancreas: 8.4;stomach: 5.3	testis: 1.7	Cell line enriched	83	RPTEC TERT1: 10.6
GUCD1	C22orf13, LLN4, MGC1842	ENSG00000138867	Guanylyl cyclase domain containing 1	22	24540423-24555935	Predicted intracellular proteins	Evidence at protein level	HPA022786			Approved	Nucleoplasm	Cervical cancer:6.84e-4 (favourable), Ovarian cancer:7.26e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 63.0	Expressed in all		
GUCY1A2	GC-SA2, GUC1A2	ENSG00000152402	Guanylate cyclase 1 soluble subunit alpha 2	11	106674012-107018524	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009534	Uncertain				Renal cancer:3.02e-5 (unfavourable)	Mixed	Tissue enhanced		placenta: 25.6	endometrium: 21.1	Cell line enhanced		BJ hTERT+: 9.5;BJ hTERT+ SV40 Large T+ RasG12V: 13.1;HBF TERT88: 6.9
GUCY1A3	GC-SA3, GUC1A3	ENSG00000164116	Guanylate cyclase 1 soluble subunit alpha	4	155666711-155732349	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010887, HPA056004, HPA058617	Uncertain		Supported	Nucleus	Lung cancer:2.38e-4 (favourable), Testis cancer:3.59e-4 (unfavourable), Renal cancer:7.59e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 136.7	smooth muscle: 43.8	Cell line enhanced		HAP1: 7.2;Karpas-707: 7.1;MOLT-4: 15.2;RPTEC TERT1: 9.3;RT4: 11.7;SH-SY5Y: 9.5
GUCY1B3	GC-S-beta-1, GC-SB3, GUC1B3	ENSG00000061918	Guanylate cyclase 1 soluble subunit beta	4	155758992-155807591	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010890, HPA020870	Approved		Approved	Cytosol	Renal cancer:2.42e-4 (unfavourable), Testis cancer:3.23e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 177.3	Cell line enhanced		HEL: 42.7;MOLT-4: 24.5;RPTEC TERT1: 35.1
GUF1	FLJ13220	ENSG00000151806	GUF1 homolog, GTPase	4	44678427-44700926	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003934, HPA024222	Approved		Approved	Nucleus<br>Mitochondria	Renal cancer:2.66e-6 (favourable), Thyroid cancer:1.65e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 13.4	Expressed in all		
GUK1		ENSG00000143774	Guanylate kinase 1	1	228139962-228148984	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028118, HPA048587	Approved		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:8.85e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 264.8	Expressed in all		
GVQW2		ENSG00000279968	GVQW motif containing 2	6	138725211-138773652	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 2.3	epididymis,thyroid gland: 0.5	Cell line enhanced		HEL: 1.9
GYG1	GYG	ENSG00000163754	Glycogenin 1	3	148991341-149027668	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030497	Approved		Supported	Vesicles	Liver cancer:6.15e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 210.0	Mixed		
GYG2	GN-2	ENSG00000056998	Glycogenin 2	X	2828788-2882820	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005495, HPA064686	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cytosol	Pancreatic cancer:3.01e-5 (favourable)	Expressed in all	Tissue enriched	13	adipose tissue: 173.1	breast: 13.2	Cell line enhanced		AF22: 39.5;NTERA-2: 39.5;SK-MEL-30: 68.1
GYS1	GSY, GYS	ENSG00000104812	Glycogen synthase 1	19	48968125-48993310	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB007793, HPA041598	Enhanced		Approved	Microtubules<br>Cytosol	Renal cancer:3.46e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 109.7	Expressed in all		
GYS2		ENSG00000111713	Glycogen synthase 2	12	21536189-21604847	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039482	Approved				Liver cancer:7.62e-5 (favourable)	Tissue enriched	Tissue enriched	23	liver: 91.8	adipose tissue: 3.9	Cell line enhanced		CACO-2: 1.0
GZF1	dJ322G13.2, ZBTB23, ZNF336	ENSG00000125812	GDNF inducible zinc finger protein 1	20	23362182-23373063	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024520	Uncertain		Supported	Nucleus<br>Nucleoli	Liver cancer:9.81e-7 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 25.3	Expressed in all		
H1F0	H10, H1FV	ENSG00000189060	H1 histone family member 0	22	37805093-37807436	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000843	Enhanced		Supported	Nucleus<br>Nuclear bodies<br>Golgi apparatus<br>Actin filaments	Renal cancer:7.68e-7 (favourable)	Expressed in all	Expressed in all			bone marrow: 420.2	Cell line enhanced		U-2 OS: 855.8
H1FNT	H1T2, HANP1	ENSG00000187166	H1 histone family member N, testis specific	12	48328980-48330279	Predicted intracellular proteins	Evidence at protein level	HPA046204	Approved					Not detected	Tissue enriched	350	testis: 77.1	cerebral cortex: 0.2	Not detected		
H1FOO		ENSG00000178804	H1 histone family member O, oocyte specific	3	129543214-129551467	Predicted intracellular proteins	Evidence at protein level	HPA037992	Enhanced					Not detected	Tissue enriched	59	testis: 5.8	all non-specific tissues: 0.0	Not detected		
H1FX	H1X, MGC15959, MGC8350	ENSG00000184897	H1 histone family member X	3	129314771-129316277	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012235, HPA040099	Supported		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Tissue enriched	7	bone marrow: 670.4	spleen: 95.9	Expressed in all		
H2AFB1		ENSG00000274183	H2A histone family member B1	X	154884972-154885558	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	9	testis: 4.3	bone marrow,skin: 0.4	Cell line enriched	26	HDLM-2: 12.2
H2AFB2		ENSG00000277858	H2A histone family member B2	X	155380787-155381134	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			duodenum: 0.6	Not detected		
H2AFB3	H2AFB	ENSG00000277745	H2A histone family member B3	X	155459415-155460005	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	56	testis: 18.5	spleen: 0.3	Cell line enriched	7	HDLM-2: 8.3
H2AFJ	FLJ10903, MGC921	ENSG00000246705	H2A histone family member J	12	14774383-14778002	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Expressed in all	Expressed in all			testis: 334.6	Cell line enhanced		A549: 232.9;MCF7: 259.0
H2AFV	H2AV, MGC10170, MGC10831, MGC1947	ENSG00000105968	H2A histone family member V	7	44826791-44848083	Predicted intracellular proteins	Evidence at protein level	HPA057236	Supported				Cervical cancer:4.66e-4 (favourable), Renal cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 218.5	Expressed in all		
H2AFX	H2AX	ENSG00000188486	H2A histone family member X	11	119093854-119095467	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012264, HPA041189, HPA051647	Supported		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:5.47e-9 (unfavourable), Liver cancer:1.51e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 18.7	Expressed in all		
H2AFY	macroH2A1.2	ENSG00000113648	H2A histone family member Y	5	135333900-135399914	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041189, HPA050962	Supported		Supported	Nucleus	Liver cancer:2.89e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 155.6	Expressed in all		
H2AFY2	macroH2A2	ENSG00000099284	H2A histone family member Y2	10	70052796-70112280	Predicted intracellular proteins	Evidence at protein level	HPA035865, HPA041189	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 31.3	Cell line enhanced		AF22: 166.7;SCLC-21H: 146.5;SH-SY5Y: 128.2
H2AFZ	H2A.Z, H2AZ	ENSG00000164032	H2A histone family member Z	4	99948086-99950388	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022549, HPA057236	Supported		Supported	Nucleoplasm	Renal cancer:2.16e-6 (unfavourable), Liver cancer:1.02e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 349.5	Expressed in all		
H2BFM		ENSG00000101812	H2B histone family member M	X	104039949-104042454	Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			testis: 2.4	Mixed		
H2BFS		ENSG00000234289	H2B histone family member S	21	43565189-43565648	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Not detected	Mixed			prostate: 8.2	Cell line enhanced		K-562: 40.6;U-2 OS: 43.9;U-266/84: 32.4
H2BFWT		ENSG00000123569	H2B histone family member W, testis specific	X	104011147-104013687	Predicted intracellular proteins	Evidence at protein level	HPA056289	Uncertain					Not detected	Not detected			testis: 0.6	Not detected		
H3F3A	H3.3A, H3F3	ENSG00000163041	H3 histone family member 3A	1	226061851-226072001	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB011481, CAB037178, HPA042570	Supported		Supported	Nucleoplasm	Renal cancer:1.21e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 1215.4	Expressed in all		
H3F3B	H3.3B	ENSG00000132475	H3 histone family member 3B	17	75776434-75785893	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB037166, CAB037187, CAB037221, HPA042570	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 2832.4	Expressed in all		
H3F3C	H3.5	ENSG00000188375	H3 histone family member 3C	12	31791185-31792241	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enriched	15	testis: 33.7	bone marrow: 2.2	Cell line enhanced		SH-SY5Y: 2.6
HAAO		ENSG00000162882	3-hydroxyanthranilate 3,4-dioxygenase	2	42767089-42792593	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036394, HPA042024	Enhanced				Liver cancer:5.77e-4 (favourable)	Group enriched	Tissue enhanced		liver: 152.2	small intestine: 45.5	Cell line enhanced		CACO-2: 11.2;Hep G2: 32.9;REH: 9.2
HABP4	IHABP4, SERBP1L	ENSG00000130956	Hyaluronan binding protein 4	9	96450201-96491336	Predicted intracellular proteins	Evidence at protein level	HPA055969	Approved				Renal cancer:1.10e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 73.8	Mixed		
HACE1	KIAA1320	ENSG00000085382	HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1	6	104728093-104859919	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046071			Supported	Nuclear bodies<br>Endoplasmic reticulum	Renal cancer:1.17e-5 (unfavourable), Thyroid cancer:7.50e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 44.1	testis: 19.1	Mixed		
HACL1	2-HPCL, HPCL, PHYH2	ENSG00000131373	2-hydroxyacyl-CoA lyase 1	3	15560704-15601852	Predicted intracellular proteins	Evidence at protein level	HPA035496, HPA035497	Approved				Renal cancer:2.63e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 50.9	Expressed in all		
HADH	HADH1, HADHSC, SCHAD	ENSG00000138796	Hydroxyacyl-CoA dehydrogenase	4	107989714-108035175	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039588, HPA043888	Supported		Supported	Mitochondria	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			adipose tissue: 154.5	Expressed in all		
HADHA	GBP, LCEH, LCHAD, MTPA	ENSG00000084754	Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit	2	26190635-26244726	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015536, HPA056070	Approved		Enhanced	Mitochondria	Renal cancer:3.68e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 235.3	Expressed in all		
HAGH	GLO2, GLXII, HAGH1	ENSG00000063854	Hydroxyacylglutathione hydrolase	16	1795620-1827194	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043041, HPA061143	Approved				Renal cancer:1.81e-6 (favourable), Liver cancer:5.33e-6 (favourable), Cervical cancer:5.82e-5 (favourable), Urothelial cancer:5.19e-4 (favourable)	Expressed in all	Expressed in all			liver: 124.4	Expressed in all		
HAGHL	MGC2605	ENSG00000103253	Hydroxyacylglutathione hydrolase-like	16	726936-735525	Predicted intracellular proteins	Evidence at transcript level	HPA074402	Approved				Renal cancer:1.18e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 9.1	spleen: 4.4	Cell line enhanced		RPMI-8226: 44.3;U-266/70: 49.9
HAL	HIS	ENSG00000084110	Histidine ammonia-lyase	12	95972662-95996365	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038547, HPA038548	Enhanced		Uncertain	Cytosol		Tissue enriched	Group enriched	8	liver: 51.2;skin: 72.5	bone marrow: 7.4	Cell line enhanced		BEWO: 2.1;THP-1: 7.4
HAND1	bHLHa27, eHand, Hxt, Thing1	ENSG00000113196	Heart and neural crest derivatives expressed 1	5	154474972-154478264	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA040925	Approved		Uncertain	Nucleus<br>Nuclear membrane		Group enriched	Tissue enhanced		smooth muscle: 16.8	adrenal gland: 6.2	Cell line enriched	8	SH-SY5Y: 123.7
HAND2	bHLHa26, dHand, Hed, Thing2	ENSG00000164107	Heart and neural crest derivatives expressed 2	4	173524969-173530229	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019591, CAB025576	Approved		Supported	Nucleoplasm<br>Vesicles		Tissue enhanced	Tissue enhanced		endometrium: 83.9	smooth muscle: 77.9	Cell line enriched	21	SH-SY5Y: 660.2
HAO1	GOX, GOX1	ENSG00000101323	Hydroxyacid oxidase 1	20	7882981-7940474	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049552	Enhanced					Tissue enriched	Tissue enriched	305	liver: 308.6	kidney: 1.0	Not detected		
HAO2	GIG16, HAOX2	ENSG00000116882	Hydroxyacid oxidase 2	1	119368779-119394130	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.92e-4 (favourable)	Group enriched	Group enriched	300	kidney: 317.5;liver: 219.8	adrenal gland,breast: 0.8	Not detected		
HAP1	HAP2, hHLP1, HIP5, HLP	ENSG00000173805	Huntingtin associated protein 1	17	41717742-41734644	Predicted intracellular proteins	Evidence at protein level	HPA023394	Uncertain				Pancreatic cancer:4.26e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 11.5;stomach: 12.8	thyroid gland: 6.4	Cell line enriched	8	REH: 87.3
HARBI1	C11orf77, FLJ32675	ENSG00000180423	Harbinger transposase derived 1	11	46602861-46617909	Predicted intracellular proteins	Evidence at protein level	HPA038671, HPA045457	Uncertain		Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		testis: 21.7	parathyroid gland: 5.4	Expressed in all		
HARS		ENSG00000170445	Histidyl-tRNA synthetase	5	140673173-140692024	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036539	Approved		Enhanced	Cytosol	Liver cancer:1.96e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 71.1	Expressed in all		
HAT1	KAT1	ENSG00000128708	Histone acetyltransferase 1	2	171922448-171983682	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036788, CAB037191	Enhanced		Enhanced	Nucleoplasm	Liver cancer:5.72e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 56.3	Expressed in all		
HAUS1	CCDC5, FLJ40084, HEI-C, HsT1461	ENSG00000152240	HAUS augmin like complex subunit 1	18	46104332-46128333	Predicted intracellular proteins	Evidence at protein level	HPA040601, HPA040652	Supported		Supported	Centrosome<br>Cytosol	Ovarian cancer:1.55e-4 (favourable), Liver cancer:2.45e-4 (unfavourable), Prostate cancer:6.76e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 41.4	Expressed in all		
HAUS2	C15orf25, CEP27, FLJ10460, HsT17025	ENSG00000137814	HAUS augmin like complex subunit 2	15	42548810-42569994	Predicted intracellular proteins	Evidence at protein level	HPA039965	Approved		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 22.5	Expressed in all		
HAUS3	C4orf15, dgt3, IT1, MGC4701	ENSG00000214367	HAUS augmin like complex subunit 3	4	2227464-2242164	Predicted intracellular proteins	Evidence at protein level	HPA040649, HPA048190	Approved		Approved	Microtubules<br>Cytokinetic bridge<br>Mitotic spindle<br>Mitochondria	Urothelial cancer:4.78e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 31.8	Expressed in all		
HAUS4	C14orf94, FLJ20424	ENSG00000092036	HAUS augmin like complex subunit 4	14	22946228-22957161	Predicted intracellular proteins	Evidence at protein level	HPA029803, HPA071195	Approved		Supported	Plasma membrane<br>Focal adhesion sites	Urothelial cancer:2.24e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 61.9	Expressed in all		
HAUS5	dgt5, KIAA0841	ENSG00000249115	HAUS augmin like complex subunit 5	19	35612744-35625349	Predicted intracellular proteins	Evidence at protein level	HPA067250	Approved				Renal cancer:4.15e-8 (unfavourable), Liver cancer:2.77e-6 (unfavourable), Endometrial cancer:2.01e-4 (unfavourable), Cervical cancer:7.68e-4 (favourable)	Expressed in all	Mixed			lymph node: 7.1	Expressed in all		
HAUS6	dgt6, FAM29A, FLJ20060, KIAA1574	ENSG00000147874	HAUS augmin like complex subunit 6	9	19053143-19103119	Predicted intracellular proteins	Evidence at protein level	HPA020960, HPA020965	Approved		Supported	Nuclear speckles<br>Microtubule organizing center<br>Cytosol	Renal cancer:3.13e-5 (unfavourable), Liver cancer:3.84e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 43.2	lymph node: 13.3	Expressed in all		
HAUS7	UCHL5IP, UIP1	ENSG00000213397	HAUS augmin like complex subunit 7	X	153447666-153495516	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003614			Approved	Nucleoli<br>Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:3.94e-4 (unfavourable), Cervical cancer:6.12e-4 (favourable)	Expressed in all	Mixed			skin: 64.1	Expressed in all		
HAUS8	HICE1, MGC20533, NY-SAR-48	ENSG00000131351	HAUS augmin like complex subunit 8	19	17049729-17075625	Predicted intracellular proteins	Evidence at protein level	HPA039406	Uncertain				Cervical cancer:9.54e-4 (favourable)	Expressed in all	Mixed			testis: 16.7	Mixed		
HAX1	HCLSBP1, HS1BP1	ENSG00000143575	HCLS1 associated protein X-1	1	154272511-154275875	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055141, HPA075289	Approved		Supported	Mitochondria	Renal cancer:1.34e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 114.9	Expressed in all		
HBA1	HBA-T3	ENSG00000206172	Hemoglobin subunit alpha 1	16	176680-177522	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB032534, HPA043780	Enhanced					Tissue enhanced	Group enriched	34	bone marrow: 17119.3;placenta: 3433.6	spleen: 303.5	Group enriched	51	HEL: 3255.0;K-562: 2173.8
HBA2	HBA-T2	ENSG00000188536	Hemoglobin subunit alpha 2	16	172847-173710	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB038417, HPA043780	Enhanced					Expressed in all	Group enriched	27	bone marrow: 18369.0;placenta: 4302.7	spleen: 427.2	Group enriched	18	HEL: 802.0;K-562: 265.1
HBB	beta-globin, CD113t-C, HBD	ENSG00000244734	Hemoglobin subunit beta	11	5225464-5229395	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009526, HPA043234	Enhanced		Approved	Vesicles		Expressed in all	Tissue enriched	9	bone marrow: 78046.6	placenta: 9082.6	Cell line enhanced		HEL: 5.3;SCLC-21H: 5.9;SH-SY5Y: 6.7;U-266/70: 17.4
HBE1	HBE	ENSG00000213931	Hemoglobin subunit epsilon 1	11	5268345-5505617	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043234	Approved		Approved	Vesicles		Mixed	Tissue enhanced		testis: 1.0	placenta: 0.9	Cell line enriched	15	K-562: 5976.4
HBG1	HBG-T2	ENSG00000213934	Hemoglobin subunit gamma 1	11	5248083-5249892	Predicted intracellular proteins	Evidence at protein level	HPA043234	Approved		Approved	Vesicles		Not detected	Tissue enriched	66	placenta: 1087.7	bone marrow: 16.4	Group enriched	298	HEL: 988.4;K-562: 1948.2
HBG2	HBG-T1	ENSG00000196565	Hemoglobin subunit gamma 2	11	5253190-5645789	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016143, HPA043234	Approved		Approved	Vesicles		Not detected	Tissue enriched	147	placenta: 18253.8	bone marrow: 124.0	Group enriched	301	HEL: 12101.5;K-562: 8442.3
HBM	HBAP2, HBK	ENSG00000206177	Hemoglobin subunit mu	16	153892-166768	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	29	bone marrow: 269.1	placenta: 9.2	Not detected		
HBP1		ENSG00000105856	HMG-box transcription factor 1	7	107168961-107202529	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020225, CAB032824	Approved		Enhanced	Nuclear speckles	Renal cancer:7.70e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 54.2	Expressed in all		
HBQ1	HBQ	ENSG00000086506	Hemoglobin subunit theta 1	16	180453-181181	Predicted intracellular proteins	Evidence at protein level	HPA062473	Enhanced		Approved	Lipid droplets		Mixed	Group enriched	8	bone marrow: 14.7;cerebral cortex: 3.0	placenta: 1.1	Group enriched	7	HEL: 19.6;Hep G2: 10.4;K-562: 49.1
HBZ	HBZ-T1, HBZ1	ENSG00000130656	Hemoglobin subunit zeta	16	152687-154503	Predicted intracellular proteins	Evidence at protein level	HPA071726	Approved					Not detected	Group enriched	12	bone marrow: 2.3;placenta: 1.0;testis: 3.9	skin: 0.2	Cell line enriched	80	K-562: 2107.5
HCFC1	CFF, HCF-1, HCF1, HFC1, MGC70925, MRX3, PPP1R89, VCAF	ENSG00000172534	Host cell factor C1	X	153947553-153971807	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018312			Supported	Nucleoplasm<br>Mitochondria	Liver cancer:4.31e-6 (unfavourable), Pancreatic cancer:9.62e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 24.6	Expressed in all		
HCFC1R1	FLJ20568, HPIP	ENSG00000103145	Host cell factor C1 regulator 1	16	3022620-3024286	Predicted intracellular proteins	Evidence at protein level	HPA059647	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			skeletal muscle: 184.4	Expressed in all		
HCFC2	HCF-2	ENSG00000111727	Host cell factor C2	12	104064457-104106524	Predicted intracellular proteins	Evidence at protein level	HPA006227	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 17.1	Mixed		
HCK	JTK9	ENSG00000101336	HCK proto-oncogene, Src family tyrosine kinase	20	32052188-32101856	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005195, HPA063768	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:1.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 149.6;spleen: 113.2	lung: 74.1	Group enriched	8	THP-1: 48.4;U-937: 161.1
HCLS1	CTTNL, HS1	ENSG00000180353	Hematopoietic cell-specific Lyn substrate 1	3	121631399-121660927	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019143	Supported		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			spleen: 271.3	Cell line enhanced		HMC-1: 319.6;U-266/70: 275.0;U-698: 256.8
HDAC1	GON-10, HD1, RPD3L1	ENSG00000116478	Histone deacetylase 1	1	32292086-32333635	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005017, HPA029693, CAB068191	Enhanced		Enhanced	Nucleoplasm	Liver cancer:5.76e-7 (unfavourable), Renal cancer:1.04e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 139.0	Expressed in all		
HDAC11		ENSG00000163517	Histone deacetylase 11	3	13479724-13506424	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.88e-10 (favourable), Liver cancer:1.20e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 66.7	Cell line enhanced		T-47d: 39.9
HDAC2	RPD3, YAF1	ENSG00000196591	Histone deacetylase 2	6	113933028-114011308	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005054, HPA011727	Supported		Enhanced	Nucleus	Liver cancer:5.39e-10 (unfavourable), Breast cancer:7.07e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 141.1	Expressed in all		
HDAC3	HD3, RPD3, RPD3-2	ENSG00000171720	Histone deacetylase 3	5	141620876-141636870	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005583, HPA052052	Supported		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:2.65e-6 (unfavourable), Colorectal cancer:3.39e-4 (favourable), Pancreatic cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.1	Expressed in all		
HDAC4	BDMR, HA6116, HD4, HDAC-4, HDAC-A, HDACA, KIAA0288	ENSG00000068024	Histone deacetylase 4	2	239048168-239401654	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004431, HPA048723	Approved		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.13e-4 (favourable), Ovarian cancer:6.33e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 19.3	Cell line enhanced		MOLT-4: 40.5
HDAC5	FLJ90614, KIAA0600, NY-CO-9	ENSG00000108840	Histone deacetylase 5	17	44076746-44123702	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB019400, HPA030991	Approved		Supported	Nuclear speckles<br>Golgi apparatus<br>Cytosol	Liver cancer:3.12e-5 (unfavourable), Renal cancer:3.30e-5 (favourable), Cervical cancer:6.14e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 60.0	Mixed		
HDAC6	FLJ16239, HD6, JM21, KIAA0901, PPP1R90	ENSG00000094631	Histone deacetylase 6	X	48801377-48824982	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003714, CAB004236, HPA026321	Approved		Supported	Nucleoplasm	Urothelial cancer:3.34e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 51.4	Expressed in all		
HDAC7	DKFZP586J0917, HDAC7A	ENSG00000061273	Histone deacetylase 7	12	47782722-47833132	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004775			Supported	Cytosol	Urothelial cancer:4.65e-4 (favourable), Melanoma:5.16e-4 (unfavourable), Renal cancer:8.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 43.9	Expressed in all		
HDAC8	HDACL1, MRXS6, RPD3, WTS	ENSG00000147099	Histone deacetylase 8	X	72329516-72573103	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048560	Supported		Supported	Nucleus<br>Plasma membrane		Expressed in all	Expressed in all			epididymis: 27.1	Expressed in all		
HDAC9	HD7, HDAC, HDAC7B, KIAA0744, MITR	ENSG00000048052	Histone deacetylase 9	7	18086949-19002416	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028926	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			spleen: 24.6	Cell line enhanced		HAP1: 176.1;SH-SY5Y: 71.2
HDC		ENSG00000140287	Histidine decarboxylase	15	50241947-50266026	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038891	Approved					Mixed	Tissue enhanced		epididymis: 53.2	gallbladder: 17.3	Group enriched	6	HEL: 392.3;HMC-1: 885.1
HDDC2	C6orf74, CGI-130, dJ167O5.2	ENSG00000111906	HD domain containing 2	6	125219962-125302078	Predicted intracellular proteins	Evidence at protein level	HPA035677	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 117.1	Expressed in all		
HDDC3	MGC45386	ENSG00000184508	HD domain containing 3	15	90929964-90932569	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040895	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			adrenal gland: 16.2	Expressed in all		
HDGF	HMG1L2	ENSG00000143321	Hepatoma derived growth factor	1	156742107-156766925	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB026035, HPA048728, HPA053422	Enhanced		Enhanced	Nucleoplasm	Liver cancer:2.43e-8 (unfavourable), Endometrial cancer:6.02e-4 (unfavourable), Ovarian cancer:9.84e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 190.4	Expressed in all		
HDGFL1	dJ309H15.1, PWWP1	ENSG00000112273	Hepatoma derived growth factor-like 1	6	22569493-22571666	Predicted intracellular proteins	Evidence at protein level	HPA045679, HPA063707	Enhanced					Tissue enriched	Tissue enriched	1395	testis: 139.4	all non-specific tissues: 0.0	Cell line enriched	8	K-562: 1.0
HDHD2	DKFZP564D1378	ENSG00000167220	Haloacid dehalogenase like hydrolase domain containing 2	18	47107403-47150520	Predicted intracellular proteins	Evidence at protein level	HPA040697, CAB045978, HPA059818	Approved		Approved	Vesicles	Renal cancer:3.52e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 47.9	Expressed in all		
HDHD3	C9orf158, MGC12904	ENSG00000119431	Haloacid dehalogenase like hydrolase domain containing 3	9	113373419-113376999	Predicted intracellular proteins	Evidence at protein level	HPA020427, HPA024158, HPA024585	Enhanced		Supported	Nucleoli	Renal cancer:3.54e-7 (favourable), Cervical cancer:2.72e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 86.8	Mixed		
HDLBP	HBP, VGL	ENSG00000115677	High density lipoprotein binding protein	2	241227264-241317061	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004189, CAB026457	Supported		Supported	Cytosol	Liver cancer:2.58e-5 (unfavourable), Thyroid cancer:6.39e-5 (unfavourable), Urothelial cancer:4.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 364.6	Expressed in all		
HDX	CXorf43, FLJ30678	ENSG00000165259	Highly divergent homeobox	X	84317874-84502479	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047189	Uncertain		Approved	Cytosol		Mixed	Mixed			cerebral cortex,endometrium: 3.8	Mixed		
HEATR1	BAP28, FLJ10359, UTP10	ENSG00000119285	HEAT repeat containing 1	1	236549005-236604504	Predicted intracellular proteins	Evidence at protein level	HPA046917, HPA062200	Approved		Enhanced	Nucleoli fibrillar center<br>Mitochondria	Liver cancer:2.05e-4 (unfavourable), Renal cancer:4.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 27.0	Expressed in all		
HEATR3	FLJ20718	ENSG00000155393	HEAT repeat containing 3	16	50065941-50106387	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041990, HPA058579	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:5.16e-6 (unfavourable), Liver cancer:4.11e-5 (unfavourable)	Expressed in all	Mixed			appendix: 15.6	Expressed in all		
HEATR4	MGC48595	ENSG00000187105	HEAT repeat containing 4	14	73478484-73558947	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	7	skin: 4.4;testis: 21.6	duodenum,lymph node: 1.9	Cell line enhanced		SCLC-21H: 2.9
HEATR5B	DKFZp686P15184, KIAA1414	ENSG00000008869	HEAT repeat containing 5B	2	36968383-37084342	Predicted intracellular proteins	Evidence at protein level	HPA042025, HPA055639	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 37.9	Expressed in all		
HEATR6	ABC1, FLJ22087	ENSG00000068097	HEAT repeat containing 6	17	60043194-60078931	Predicted intracellular proteins	Evidence at protein level	HPA030789, HPA062157	Uncertain		Approved	Mitochondria	Liver cancer:5.02e-6 (unfavourable), Endometrial cancer:2.03e-4 (unfavourable), Renal cancer:6.73e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.3	Cell line enhanced		MCF7: 80.3
HEATR9	C17orf66, FLJ32830	ENSG00000270379	HEAT repeat containing 9	17	35854946-35868891	Predicted intracellular proteins	Evidence at transcript level	HPA023129	Uncertain					Not detected	Tissue enriched	34	testis: 10.0	spleen: 0.2	Not detected		
HEBP1	HBP, HEBP	ENSG00000013583	Heme binding protein 1	12	12974864-13000273	Predicted intracellular proteins	Evidence at protein level	HPA056417, HPA075277	Approved		Approved	Nucleus<br>Vesicles		Expressed in all	Expressed in all			duodenum: 234.7	Expressed in all		
HEBP2	C6orf34, SOUL	ENSG00000051620	Heme binding protein 2	6	138403531-138422197	Predicted intracellular proteins	Evidence at protein level	HPA016928	Approved				Renal cancer:2.47e-5 (unfavourable), Urothelial cancer:3.07e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 114.1	Cell line enhanced		THP-1: 147.3
HECA	dJ225E12.1, HDC, HDCL, hHDC	ENSG00000112406	Hdc homolog, cell cycle regulator	6	139135112-139180802	Predicted intracellular proteins	Evidence at protein level	HPA042313	Uncertain				Renal cancer:8.09e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 38.1	Mixed		
HECTD1	KIAA1131	ENSG00000092148	HECT domain E3 ubiquitin protein ligase 1	14	31100112-31207804	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002929, HPA054461	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.20e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 109.5	Expressed in all		
HECTD2	FLJ37306	ENSG00000165338	HECT domain E3 ubiquitin protein ligase 2	10	91409280-91514829	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037767	Approved		Approved	Nucleoplasm	Renal cancer:1.67e-5 (unfavourable)	Mixed	Mixed			prostate: 28.1	Mixed		
HECTD3	FLJ21156	ENSG00000126107	HECT domain E3 ubiquitin protein ligase 3	1	45002540-45011329	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027467	Approved				Thyroid cancer:1.85e-6 (favourable), Liver cancer:2.14e-5 (unfavourable)	Expressed in all	Expressed in all			duodenum,parathyroid gland: 47.3	Expressed in all		
HECW1	KIAA0322, NEDL1	ENSG00000002746	HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1	7	43112599-43566001	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007203, HPA007593, HPA007609	Approved		Supported	Cytosol		Not detected	Tissue enhanced		cerebral cortex: 10.9;kidney: 8.2	testis: 3.4	Cell line enhanced		A549: 3.9;U-266/70: 9.1
HECW2	KIAA1301, NEDL2	ENSG00000138411	HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2	2	196194370-196593692	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034609	Uncertain		Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum	Renal cancer:5.18e-5 (unfavourable)	Mixed	Mixed			placenta: 15.8	Cell line enhanced		HDLM-2: 59.6;HUVEC TERT2: 24.5;SCLC-21H: 45.1;TIME: 32.0
HELB		ENSG00000127311	DNA helicase B	12	66302545-66347645	Enzymes, Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			lymph node: 3.5	Mixed		
HELLS	LSH, Nbla10143, PASG, SMARCA6	ENSG00000119969	Helicase, lymphoid-specific	10	94501434-94613905	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004491, HPA063242	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Cervical cancer:1.36e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 23.9	lymph node: 14.9	Expressed in all		
HELQ	Hel308	ENSG00000163312	Helicase, POLQ-like	4	83407343-83455856	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036852, HPA036853	Approved		Approved	Nucleoplasm<br>Nuclear speckles	Renal cancer:2.76e-4 (favourable), Pancreatic cancer:9.07e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 11.9	Expressed in all		
HELT	bHLHb44, HCM1228, HESL, MEGANE, Mgn	ENSG00000187821	Helt bHLH transcription factor	4	185018841-185020804	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA036188, HPA036189	Uncertain					Not detected	Not detected			lung: 0.5	Cell line enhanced		HAP1: 1.4
HELZ2	KIAA1769, PDIP1, PRIC285	ENSG00000130589	Helicase with zinc finger 2	20	63558086-63574239	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051267	Uncertain				Testis cancer:4.92e-4 (unfavourable)	Expressed in all	Mixed			spleen: 15.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 55.4
HEMGN	CT155, EDAG, NDR	ENSG00000136929	Hemogen	9	97926791-97944856	Predicted intracellular proteins	Evidence at protein level	HPA019572, HPA019604, HPA019606	Enhanced					Not detected	Group enriched	14	bone marrow: 141.7;testis: 88.2	placenta: 8.1	Group enriched	7	HEL: 54.8;K-562: 247.2
HEMK1	MTQ1	ENSG00000114735	HemK methyltransferase family member 1	3	50569152-50596168	Predicted intracellular proteins	Evidence at protein level	HPA034701, HPA034702	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 32.3	Expressed in all		
HENMT1	C1orf59, FLJ30525, HEN1	ENSG00000162639	HEN1 methyltransferase homolog 1	1	108648290-108661526	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028464, HPA028497	Uncertain		Approved	Plasma membrane<br>Focal adhesion sites	Renal cancer:2.48e-5 (unfavourable), Cervical cancer:2.56e-4 (favourable), Colorectal cancer:9.95e-4 (favourable)	Expressed in all	Tissue enriched	9	testis: 128.3	lymph node: 14.8	Cell line enhanced		U-937: 75.4
HEPN1		ENSG00000221932	Hepatocellular carcinoma, down-regulated 1	11	124919244-124920677	Predicted intracellular proteins	Evidence at transcript level	HPA043768, HPA063054	Uncertain		Approved	Golgi apparatus		Not detected	Tissue enriched	7	cerebral cortex: 79.5	adipose tissue: 11.1	Cell line enriched	358	Hep G2: 35.7
HERC1	p532, p619	ENSG00000103657	HECT and RLD domain containing E3 ubiquitin protein ligase family member 1	15	63608618-63833942	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049749	Uncertain				Renal cancer:1.36e-6 (favourable), Head and neck cancer:4.87e-5 (favourable), Pancreatic cancer:3.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.6	Expressed in all		
HERC3	KIAA0032	ENSG00000138641	HECT and RLD domain containing E3 ubiquitin protein ligase 3	4	88521048-88708542	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039170	Approved		Approved	Cytosol	Renal cancer:5.65e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 61.0	Mixed		
HES1	bHLHb39, FLJ20408, HES-1, Hes1, HRY	ENSG00000114315	Hes family bHLH transcription factor 1	3	194136145-194138732	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066929			Supported	Nucleus	Urothelial cancer:2.04e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 97.8	Mixed		
HES2	bHLHb40	ENSG00000069812	Hes family bHLH transcription factor 2	1	6412418-6424670	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA039462	Uncertain					Mixed	Tissue enhanced		skin: 17.0	placenta: 9.8	Cell line enhanced		BEWO: 19.0;HaCaT: 33.0;HBEC3-KT: 23.1;TIME: 44.9
HES3	bHLHb43	ENSG00000173673	Hes family bHLH transcription factor 3	1	6244192-6245578	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA047927, HPA072697	Uncertain		Uncertain	Nucleus		Tissue enriched	Not detected			testis: 0.1	Cell line enriched	7	NTERA-2: 11.3
HES4	bHLHb42	ENSG00000188290	Hes family bHLH transcription factor 4	1	998962-1000172	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062465			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:2.99e-4 (unfavourable), Endometrial cancer:3.85e-4 (favourable), Renal cancer:6.27e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 7.5	Cell line enriched	8	HEK93: 180.2
HES5	bHLHb38	ENSG00000197921	Hes family bHLH transcription factor 5	1	2528745-2530245	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065458, HPA076164	Enhanced		Approved	Nucleoplasm<br>Nuclear speckles<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 1.8	skin: 0.9	Cell line enhanced		HaCaT: 1.1
HES6	bHLHb41	ENSG00000144485	Hes family bHLH transcription factor 6	2	238238267-238240662	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA061763			Approved	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol	Lung cancer:9.18e-5 (favourable), Liver cancer:2.79e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 76.8	fallopian tube: 22.3	Cell line enhanced		NB-4: 122.5;SCLC-21H: 144.1;SK-MEL-30: 141.7
HES7	bHLHb37	ENSG00000179111	Hes family bHLH transcription factor 7	17	8120590-8124092	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA072105	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enhanced		placenta: 1.1	testis: 0.9	Cell line enhanced		HAP1: 8.4;HDLM-2: 6.2;HeLa: 8.1
HESX1	ANF, RPX	ENSG00000163666	HESX homeobox 1	3	57197843-57226521	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024187	Approved		Approved	Nucleus		Tissue enhanced	Tissue enhanced		testis: 12.4	skin: 5.4	Cell line enhanced		NTERA-2: 73.5;U-266/84: 17.0
HEXDC	FLJ23825	ENSG00000169660	Hexosaminidase D	17	82418318-82442645	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022834, HPA023379, HPA027844	Uncertain		Approved	Nucleoli fibrillar center<br>Mitochondria	Urothelial cancer:2.52e-5 (favourable), Head and neck cancer:2.71e-4 (favourable), Pancreatic cancer:5.57e-4 (favourable), Cervical cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			spleen: 24.4	Expressed in all		
HEXIM1	CLP-1, EDG1, HIS1, MAQ1	ENSG00000186834	Hexamethylene bisacetamide inducible 1	17	45148502-45152101	Predicted intracellular proteins	Evidence at protein level	HPA008926, CAB011625	Supported		Enhanced	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			placenta: 36.2	Expressed in all		
HEXIM2	FLJ32384	ENSG00000168517	Hexamethylene bisacetamide inducible 2	17	45160700-45170040	Predicted intracellular proteins	Evidence at protein level	HPA023323, HPA028455	Enhanced		Supported	Nucleoplasm<br>Nuclear speckles	Endometrial cancer:2.53e-4 (favourable), Ovarian cancer:9.85e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.8	Expressed in all		
HEY1	bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1	ENSG00000164683	Hes related family bHLH transcription factor with YRPW motif 1	8	79764010-79767863	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055599, HPA063472	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 96.4	placenta: 28.8	Cell line enhanced		HEK93: 120.1;SK-MEL-30: 70.9
HEY2	bHLHb32, HERP1, HESR2	ENSG00000135547	Hes related family bHLH transcription factor with YRPW motif 2	6	125747664-125761269	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030205, HPA074851	Approved		Approved	Nuclear bodies<br>Aggresome		Expressed in all	Mixed			fallopian tube: 21.6	Cell line enhanced		HEK93: 6.3;SK-MEL-30: 5.0;TIME: 11.9;U-266/70: 13.2
HEYL	bHLHb33, HESR3, HEY3	ENSG00000163909	Hes related family bHLH transcription factor with YRPW motif-like	1	39624153-39639945	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001438, HPA076960	Approved		Approved	Mitochondria<br>Cytosol	Renal cancer:2.26e-6 (unfavourable), Urothelial cancer:2.63e-5 (unfavourable), Stomach cancer:3.57e-4 (unfavourable)	Expressed in all	Mixed			placenta: 44.4	Cell line enhanced		LHCN-M2: 18.5;RH-30: 26.3
HFM1	FLJ36760, FLJ39011, MER3, SEC63D1	ENSG00000162669	HFM1, ATP dependent DNA helicase homolog	1	91260766-91404869	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035036, HPA035557			Supported	Golgi apparatus<br>Vesicles		Tissue enhanced	Tissue enriched	5	testis: 25.0	ovary: 4.7	Cell line enhanced		AF22: 5.1;AN3-CA: 2.6;K-562: 2.6;SCLC-21H: 2.1;SH-SY5Y: 2.3
HGD	AKU, HGO	ENSG00000113924	Homogentisate 1,2-dioxygenase	3	120628173-120682571	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047374, HPA052359	Enhanced		Supported	Golgi apparatus	Endometrial cancer:1.78e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 175.8;liver: 324.3	gallbladder: 87.1	Group enriched	10	CACO-2: 38.8;EFO-21: 75.8;Hep G2: 110.3;RPTEC TERT1: 153.1
HGH1	Brp16, C8orf30A, C8orf30B, FAM203A, FAM203B, FLJ40907, LOC51236	ENSG00000235173	HGH1 homolog	8	144137769-144140843	Predicted intracellular proteins	Evidence at protein level	HPA042470	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:3.72e-5 (unfavourable), Cervical cancer:3.12e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue,stomach: 2.6	Cell line enhanced		PC-3: 43.5
HGS	Hrs, Vps27, ZFYVE8	ENSG00000185359	Hepatocyte growth factor-regulated tyrosine kinase substrate	17	81683326-81703138	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004872, HPA007728	Uncertain		Enhanced	Endosomes<br>Lysosomes<br>Cytosol	Renal cancer:4.31e-7 (unfavourable), Liver cancer:5.61e-5 (unfavourable), Cervical cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 85.2	Expressed in all		
HHEX	HEX, HOX11L-PEN, PRHX	ENSG00000152804	Hematopoietically expressed homeobox	10	92689951-92695646	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051894, HPA055460	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:3.25e-5 (unfavourable), Cervical cancer:3.91e-5 (favourable), Liver cancer:6.23e-4 (unfavourable), Breast cancer:8.83e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 164.8	Cell line enhanced		HEL: 89.2;HMC-1: 92.9;HUVEC TERT2: 88.4;K-562: 137.7
HHLA3		ENSG00000197568	HERV-H LTR-associating 3	1	70354805-70385339	Predicted intracellular proteins	Evidence at protein level	HPA031323	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:2.03e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 21.7	Expressed in all		
HIBCH		ENSG00000198130	3-hydroxyisobutyryl-CoA hydrolase	2	190189735-190344193	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036540, HPA036541	Enhanced		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.04e-10 (favourable), Ovarian cancer:1.22e-4 (favourable)	Expressed in all	Expressed in all			kidney: 180.6	Expressed in all		
HIC1	ZBTB29, ZNF901	ENSG00000177374	HIC ZBTB transcriptional repressor 1	17	2054154-2063241	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043372	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:9.36e-6 (unfavourable)	Expressed in all	Mixed			endometrium: 16.3	Cell line enhanced		BJ: 10.1;TIME: 10.1
HIC2	HRG22, KIAA1020, ZBTB30, ZNF907	ENSG00000169635	HIC ZBTB transcriptional repressor 2	22	21417404-21451463	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031884, HPA059399	Uncertain		Supported	Nucleus	Endometrial cancer:7.42e-5 (unfavourable)	Tissue enriched	Mixed			placenta: 8.4	Cell line enhanced		BEWO: 66.9;K-562: 113.3
HID1	C17orf28, DMC1, HID-1	ENSG00000167861	HID1 domain containing	17	74950743-74973166	Predicted intracellular proteins	Evidence at protein level	HPA023095, HPA031406	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:3.13e-5 (favourable), Urothelial cancer:1.34e-4 (favourable)	Expressed in all	Expressed in all			prostate: 54.2	Cell line enhanced		MCF7: 89.3;SH-SY5Y: 61.4;SK-BR-3: 129.5;T-47d: 96.0
HIF1A	bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8	ENSG00000100644	Hypoxia inducible factor 1 alpha subunit	14	61695513-61748259	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000907, HPA001275, CAB017442	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane		Expressed in all	Expressed in all			bone marrow: 292.4	Mixed		
HIF1AN	DKFZp762F1811, FIH1, FLJ20615, FLJ22027	ENSG00000166135	Hypoxia inducible factor 1 alpha subunit inhibitor	10	100529072-100559998	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048742, HPA065302, CAB069903	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 25.7	Expressed in all		
HIF3A	bHLHe17, IPAS, MOP7, PASD7	ENSG00000124440	Hypoxia inducible factor 3 alpha subunit	19	46297046-46343433	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041141	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:6.90e-9 (unfavourable)	Mixed	Tissue enhanced		placenta: 39.8	spleen: 19.9	Cell line enhanced		ASC TERT1: 6.5;HHSteC: 16.0;HSkMC: 12.2;TIME: 13.1
HIKESHI	C11orf73, HSPC138, HSPC179, OPI10	ENSG00000149196	Hikeshi, heat shock protein nuclear import factor	11	86302211-86345931	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035063, HPA035064	Approved				Renal cancer:4.01e-12 (unfavourable), Liver cancer:8.81e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 46.6	Expressed in all		
HINFP	DKFZP434F162, HiNF-P, MIZF, ZNF743	ENSG00000172273	Histone H4 transcription factor	11	119121587-119136044	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061008	Uncertain				Liver cancer:4.44e-8 (unfavourable), Thyroid cancer:5.26e-4 (favourable)	Expressed in all	Expressed in all			testis: 11.9	Expressed in all		
HINT1	HINT, PKCI-1, PRKCNH1	ENSG00000169567	Histidine triad nucleotide binding protein 1	5	131159027-131171735	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044577	Approved		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 173.9	Expressed in all		
HINT3	FLJ33126	ENSG00000111911	Histidine triad nucleotide binding protein 3	6	125956781-125980244	Predicted intracellular proteins	Evidence at protein level	HPA027914	Approved		Supported	Nucleoli<br>Mitochondria<br>Cytosol	Renal cancer:1.05e-6 (favourable), Breast cancer:4.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 49.7	Expressed in all		
HIP1	ILWEQ	ENSG00000127946	Huntingtin interacting protein 1	7	75533300-75738962	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA013606, CAB015334, CAB016402, HPA017964	Enhanced		Enhanced	Vesicles		Expressed in all	Mixed			testis: 35.2	Mixed		
HIP1R	FLJ14000, HIP12, HIP3, ILWEQ, KIAA0655	ENSG00000130787	Huntingtin interacting protein 1 related	12	122834453-122862960	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB017187, HPA038135, HPA038136	Enhanced		Enhanced	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:6.50e-7 (favourable), Urothelial cancer:7.26e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 53.1	Mixed		
HIPK4	FLJ32818	ENSG00000160396	Homeodomain interacting protein kinase 4	19	40379271-40390187	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027733	Uncertain					Not detected	Group enriched	29	cerebral cortex: 4.7;testis: 14.6	endometrium: 0.3	Not detected		
HIRA	DGCR1, TUP1, TUPLE1	ENSG00000100084	Histone cell cycle regulator	22	19330698-19447450	Predicted intracellular proteins	Evidence at protein level	CAB039243, CAB039244, HPA050714, HPA052902	Enhanced		Enhanced	Nucleoplasm	Renal cancer:5.18e-6 (favourable), Pancreatic cancer:3.97e-4 (favourable), Ovarian cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 93.8	Expressed in all		
HIRIP3		ENSG00000149929	HIRA interacting protein 3	16	29992321-29996436	Predicted intracellular proteins	Evidence at protein level	HPA051897, HPA063205	Approved		Enhanced	Nucleus	Cervical cancer:2.74e-5 (favourable)	Expressed in all	Expressed in all			testis: 38.5	Expressed in all		
HIST1H1A	H1.1, H1a, H1F1	ENSG00000124610	Histone cluster 1 H1 family member a	6	26017085-26017732	Predicted intracellular proteins	Evidence at protein level	HPA043753	Supported					Not detected	Not detected			testis,thyroid gland: 0.2	Cell line enhanced		REH: 1.1;U-2 OS: 1.1
HIST1H1B	H1.5, H1b, H1F5, H1s-3	ENSG00000184357	Histone cluster 1 H1 family member b	6	27866849-27867529	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012241, HPA055907	Approved		Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		bone marrow: 6.2;lymph node: 2.6	urinary bladder: 0.9	Cell line enhanced		MOLT-4: 8.9
HIST1H1C	H1.2, H1c, H1F2, H1s-1	ENSG00000187837	Histone cluster 1 H1 family member c	6	26055787-26056428	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011507, HPA055907	Supported		Supported	Nucleus<br>Nucleoli	Urothelial cancer:8.06e-5 (favourable), Pancreatic cancer:1.12e-4 (unfavourable), Renal cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 185.2	Cell line enhanced		SiHa: 391.5;U-2 OS: 735.9;U-266/70: 600.9;U-266/84: 562.5
HIST1H1D	H1.3, H1d, H1F3, H1s-2	ENSG00000124575	Histone cluster 1 H1 family member d	6	26234268-26234933	Predicted intracellular proteins	Evidence at protein level	HPA055907	Approved					Mixed	Tissue enriched	6	bone marrow: 17.5	lymph node: 2.9	Cell line enhanced		BEWO: 6.8;MOLT-4: 9.5;SiHa: 5.0
HIST1H1E	H1.4, H1e, H1F4, H1s-4	ENSG00000168298	Histone cluster 1 H1 family member e	6	26156354-26157107	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB011506, HPA055907	Supported		Supported	Nuclear speckles		Mixed	Tissue enriched	11	bone marrow: 36.2	lymph node: 3.3	Cell line enhanced		U-266/84: 11.0;U-87 MG: 13.1
HIST1H1T	H1FT, H1t	ENSG00000187475	Histone cluster 1 H1 family member t	6	26107419-26108136	Predicted intracellular proteins	Evidence at protein level	HPA065718, HPA068266	Enhanced					Not detected	Tissue enriched	8	testis: 1.4	appendix,breast,prostate: 0.1	Not detected		
HIST1H2AA	bA317E16.2, H2AFR	ENSG00000164508	Histone cluster 1 H2A family member a	6	25726132-25726527	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Not detected	Tissue enriched	90	testis: 17.1	kidney,pancreas: 0.1	Not detected		
HIST1H2AB	H2A/m, H2AFM	ENSG00000278463	Histone cluster 1 H2A family member b	6	26033176-26033568	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Tissue enhanced		bone marrow: 1.6	lymph node,testis: 0.6	Cell line enhanced		Hep G2: 3.4
HIST1H2AC	H2AFL	ENSG00000180573	Histone cluster 1 H2A family member c	6	26124145-26139116	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Expressed in all	Expressed in all			prostate: 50.4	Cell line enhanced		SiHa: 77.5;U-2 OS: 74.5
HIST1H2AD	H2A.3, H2A/g, H2AFG	ENSG00000196866	Histone cluster 1 H2A family member d	6	26198851-26199243	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Tissue enhanced		bone marrow: 2.2;prostate: 1.9	esophagus: 1.2	Cell line enhanced		U-266/70: 15.6;U-266/84: 5.0
HIST1H2AE	H2A.1, H2A/a, H2AFA	ENSG00000277075	Histone cluster 1 H2A family member e	6	26216975-26217483	Predicted intracellular proteins	Evidence at protein level	CAB012242, HPA041189	Supported		Supported	Nucleoplasm		Expressed in all	Tissue enhanced		breast: 54.1	prostate: 21.5	Cell line enhanced		U-266/70: 28.2
HIST1H2AG	H2A.1b, H2A/p, H2AFP, pH2A/f	ENSG00000196787	Histone cluster 1 H2A family member g	6	27133042-27135291	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Expressed in all	Tissue enhanced		testis: 5.5	breast: 3.7	Cell line enhanced		SiHa: 18.4;U-266/84: 34.4
HIST1H2AH	dJ86C11.1, H2A/S, H2AFALii	ENSG00000274997	Histone cluster 1 H2A family member h	6	27147129-27147515	Predicted intracellular proteins	Evidence at protein level	CAB004030, HPA041189	Supported					Mixed	Tissue enhanced		bone marrow: 7.4	testis: 2.5	Mixed		
HIST1H2AI	H2A/c, H2AFC	ENSG00000196747	Histone cluster 1 H2A family member i	6	27808199-27808701	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Mixed			bone marrow: 3.1	Cell line enhanced		K-562: 37.5;U-266/84: 81.3
HIST1H2AJ	H2A/E, H2AFE	ENSG00000276368	Histone cluster 1 H2A family member j	6	27814354-27814740	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Tissue enhanced		bone marrow: 6.4	lymph node: 1.4	Cell line enhanced		MCF7: 14.3
HIST1H2AK	H2A/d, H2AFD	ENSG00000275221	Histone cluster 1 H2A family member k	6	27837947-27838339	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Not detected	Mixed			testis: 2.3	Cell line enhanced		A549: 2.0;AN3-CA: 2.2;SCLC-21H: 2.8;U-266/84: 2.7
HIST1H2AL	dJ193B12.9, H2A/i, H2AFI	ENSG00000276903	Histone cluster 1 H2A family member l	6	27865355-27865747	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Tissue enriched	6	bone marrow: 5.2	parathyroid gland: 0.8	Cell line enhanced		MOLT-4: 5.3
HIST1H2AM	H2A.1, H2A/n, H2AFN	ENSG00000278677	Histone cluster 1 H2A family member m	6	27892757-27893149	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Mixed			bone marrow,lymph node: 2.6	Cell line enhanced		U-266/84: 26.9
HIST1H2BA	bA317E16.3, H2BFU, STBP, TSH2B	ENSG00000146047	Histone cluster 1 H2B family member a	6	25726777-25727292	Predicted intracellular proteins	Evidence at protein level	CAB011603, HPA042205, HPA043013	Enhanced					Tissue enriched	Tissue enriched	112	testis: 11.1	all non-specific tissues: 0.0	Not detected		
HIST1H2BB	H2B/f, H2BFF	ENSG00000276410	Histone cluster 1 H2B family member b	6	26043277-26043657	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	5	bone marrow: 1.1;testis: 3.1	esophagus,lymph node: 0.3	Cell line enhanced		MOLT-4: 1.9;THP-1: 1.9;U-266/84: 2.2
HIST1H2BC	H2B.1, H2B/l, H2BFL	ENSG00000180596	Histone cluster 1 H2B family member c	6	26114873-26123926	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.75e-5 (unfavourable), Pancreatic cancer:9.01e-4 (unfavourable)	Expressed in all	Tissue enhanced		prostate: 35.5	bone marrow: 16.6	Cell line enhanced		SiHa: 80.4;U-2 OS: 53.7
HIST1H2BD	H2B/b, H2BFB	ENSG00000158373	Histone cluster 1 H2B family member d	6	26158146-26171349	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671, CAB062336	Supported		Approved	Nucleoplasm<br>Cytosol	Colorectal cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 90.2	Expressed in all		
HIST1H2BE	H2B.h, H2B/h, H2BFH	ENSG00000274290	Histone cluster 1 H2B family member e	6	26172059-26184655	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			prostate: 2.9	Mixed		
HIST1H2BF	H2B/g, H2BFG	ENSG00000277224	Histone cluster 1 H2B family member f	6	26199520-26200715	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		esophagus: 3.5;prostate: 2.6	breast: 2.2	Cell line enhanced		U-266/70: 18.9;U-266/84: 13.1
HIST1H2BG	H2B.1A, H2B/a, H2BFA	ENSG00000273802	Histone cluster 1 H2B family member g	6	26215159-26216692	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.70e-8 (unfavourable)	Expressed in all	Tissue enhanced		breast: 17.5;prostate: 11.3	bone marrow: 4.6	Cell line enhanced		SiHa: 11.2;T-47d: 19.9;U-266/70: 15.0
HIST1H2BH	H2B/j, H2BFJ	ENSG00000275713	Histone cluster 1 H2B family member h	6	26251651-26253710	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:7.52e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 3.0	small intestine: 1.2	Cell line enhanced		U-266/70: 12.9
HIST1H2BI	H2B/k, H2BFK	ENSG00000278588	Histone cluster 1 H2B family member i	6	26272976-26273356	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		bone marrow: 1.9;lymph node: 1.7	testis,urinary bladder: 0.7	Cell line enhanced		MOLT-4: 10.0
HIST1H2BJ	H2B/r, H2BFR	ENSG00000124635	Histone cluster 1 H2B family member j	6	27125897-27132750	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:1.51e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 48.9	prostate: 9.9	Cell line enhanced		K-562: 148.0;SiHa: 152.3;U-2 OS: 161.1;U-266/70: 101.2;U-266/84: 122.2
HIST1H2BK	H2BFAiii, H2BFT	ENSG00000197903	Histone cluster 1 H2B family member k	6	27146418-27146798	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.77e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 106.2	Expressed in all		
HIST1H2BL	dJ97D16.4, H2B/c, H2BFC	ENSG00000185130	Histone cluster 1 H2B family member l	6	27807444-27807931	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	6	bone marrow: 3.7	lymph node,thyroid gland: 0.6	Cell line enhanced		MOLT-4: 9.8;U-266/84: 8.5
HIST1H2BM	dJ160A22.3, H2B/e, H2BFE	ENSG00000273703	Histone cluster 1 H2B family member m	6	27815044-27815424	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		bone marrow: 3.3;lymph node: 2.6	tonsil: 1.5	Cell line enhanced		Karpas-707: 14.4;NB-4: 8.4;REH: 7.8;U-266/70: 11.7
HIST1H2BN	H2B/d, H2BFD	ENSG00000233822	Histone cluster 1 H2B family member n	6	27837760-27865798	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			testis: 3.3	Cell line enhanced		SCLC-21H: 8.5
HIST1H2BO	H2B.2, H2B/n, H2BFN	ENSG00000274641	Histone cluster 1 H2B family member o	6	27893463-27893843	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:4.89e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 2.1	lymph node,placenta: 1.3	Cell line enhanced		U-266/84: 32.7
HIST1H3A	H3/A, H3FA	ENSG00000275714	Histone cluster 1 H3 family member a	6	26020490-26020900	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Group enriched	5	bone marrow: 6.7;epididymis: 1.8;testis: 3.7	lung: 0.7	Cell line enhanced		U-2 OS: 5.3
HIST1H3B	H3/l, H3FL	ENSG00000274267	Histone cluster 1 H3 family member b	6	26031650-26032060	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enriched	6	bone marrow: 6.1	lymph node: 0.9	Mixed		
HIST1H3C	H3.1, H3/c, H3FC	ENSG00000278272	Histone cluster 1 H3 family member c	6	26045411-26045821	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enhanced		bone marrow: 3.3	testis: 1.3	Cell line enhanced		U-937: 6.7
HIST1H3D	H3/b, H3FB	ENSG00000197409	Histone cluster 1 H3 family member d	6	26196840-26197250	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported				Renal cancer:1.78e-6 (unfavourable)	Expressed in all	Tissue enriched	8	bone marrow: 6.5	adrenal gland: 0.8	Cell line enhanced		Karpas-707: 4.0;U-266/70: 6.0
HIST1H3D	H3/b, H3FB	ENSG00000282988	Histone cluster 1 H3 family member d	6	26195595-26199293	Predicted intracellular proteins	Evidence at transcript level	HPA041189	Uncertain						Tissue enhanced		bone marrow: 2.1	prostate,testis: 0.7	Cell line enhanced		K-562: 5.4;SiHa: 5.8;U-266/70: 5.2
HIST1H3E	H3.1, H3/d, H3FD	ENSG00000274750	Histone cluster 1 H3 family member e	6	26224199-26227473	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Expressed in all	Mixed			epididymis: 6.0	Cell line enhanced		EFO-21: 10.0;SCLC-21H: 14.1
HIST1H3F	H3/i, H3FI	ENSG00000277775	Histone cluster 1 H3 family member f	6	26250195-26250605	Predicted intracellular proteins	Evidence at protein level	HPA042570, CAB070190	Supported					Mixed	Tissue enhanced		bone marrow: 1.4	lymph node: 0.7	Cell line enhanced		U-266/84: 4.6
HIST1H3G	H3/h, H3FH	ENSG00000273983	Histone cluster 1 H3 family member g	6	26269405-26271815	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported				Cervical cancer:8.75e-4 (favourable)	Mixed	Not detected			epididymis,small intestine: 0.5	Cell line enhanced		SiHa: 7.2;U-266/70: 4.8
HIST1H3H	H3/k, H3F1K, H3FK	ENSG00000278828	Histone cluster 1 H3 family member h	6	27810064-27811300	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported				Pancreatic cancer:9.25e-6 (unfavourable), Renal cancer:5.73e-5 (unfavourable), Cervical cancer:4.35e-4 (favourable)	Expressed in all	Mixed			rectum: 2.9	Cell line enhanced		K-562: 30.1;SiHa: 30.0;U-266/84: 42.9
HIST1H3I	H3.f, H3/f, H3FF	ENSG00000275379	Histone cluster 1 H3 family member i	6	27871905-27872315	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Tissue enhanced	Tissue enhanced		bone marrow: 1.1	appendix: 0.6	Cell line enhanced		HEL: 2.6;MOLT-4: 4.4;NB-4: 2.3;REH: 5.1
HIST1H3J	H3/j, H3FJ	ENSG00000197153	Histone cluster 1 H3 family member j	6	27890382-27893106	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enhanced		lymph node: 1.5	testis: 0.9	Cell line enhanced		U-266/84: 8.5
HIST1H4A	H4FA	ENSG00000278637	Histone cluster 1 H4 family member a	6	26021679-26021990	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB021887, HPA042201	Supported					Mixed	Mixed			appendix: 1.9	Cell line enhanced		MOLT-4: 11.9;REH: 12.2
HIST1H4B	H4/I, H4FI	ENSG00000278705	Histone cluster 1 H4 family member b	6	26026815-26027252	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Mixed	Tissue enhanced		bone marrow: 1.3	lymph node: 0.8	Mixed		
HIST1H4C	dJ221C16.1, H4/g, H4FG	ENSG00000197061	Histone cluster 1 H4 family member c	6	26103876-26104310	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported				Renal cancer:5.74e-6 (unfavourable)	Tissue enhanced	Mixed			bone marrow: 2.9	Group enriched	5	HEK93: 31.7;MOLT-4: 6.3;PC-3: 17.3
HIST1H4D	H4/b, H4FB	ENSG00000277157	Histone cluster 1 H4 family member d	6	26188765-26189076	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Mixed	Mixed			fallopian tube: 1.7	Cell line enhanced		HEK93: 8.2;RT4: 11.7
HIST1H4E	H4/j, H4FJ	ENSG00000276966	Histone cluster 1 H4 family member e	6	26204552-26206038	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported				Renal cancer:2.00e-6 (unfavourable)	Expressed in all	Mixed			prostate: 2.3	Cell line enhanced		U-266/70: 8.6
HIST1H4F	H4, H4/c, H4FC	ENSG00000274618	Histone cluster 1 H4 family member f	6	26240426-26240737	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Tissue enhanced	Not detected			bone marrow: 0.7	Cell line enhanced		MCF7: 1.2;MOLT-4: 5.2;REH: 2.6
HIST1H4G	H4/l, H4FL	ENSG00000275663	Histone cluster 1 H4 family member g	6	26246681-26246977	Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Not detected	Not detected			small intestine: 0.2	Not detected		
HIST1H4H	H4/h, H4FH	ENSG00000158406	Histone cluster 1 H4 family member h	6	26277609-26285638	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported				Renal cancer:6.18e-6 (unfavourable), Liver cancer:6.84e-4 (unfavourable)	Expressed in all	Tissue enhanced		breast: 9.9	prostate: 6.3	Cell line enhanced		U-266/84: 49.1
HIST1H4I	H4/m, H4FM	ENSG00000276180	Histone cluster 1 H4 family member i	6	27138588-27139881	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported				Renal cancer:1.32e-5 (unfavourable), Cervical cancer:9.70e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 6.1	Cell line enhanced		K-562: 67.9;SiHa: 46.7;U-2 OS: 76.3;U-266/84: 55.8
HIST1H4J	H4/e, H4F2iv, H4FE	ENSG00000197238	Histone cluster 1 H4 family member j	6	27824108-27824480	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Mixed	Mixed			bone marrow: 15.2	Mixed		
HIST1H4K	dJ160A22.1, H4/d, H4F2iii, H4FD	ENSG00000273542	Histone cluster 1 H4 family member k	6	27831216-27831527	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Mixed	Not detected			appendix: 0.8	Not detected		
HIST1H4L	H4.k, H4/k, H4FK	ENSG00000275126	Histone cluster 1 H4 family member l	6	27873199-27873510	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Tissue enhanced	Not detected			bone marrow: 0.3	Cell line enhanced		MOLT-4: 4.5;NB-4: 1.8;REH: 1.3
HIST2H2AA3	H2A.2, H2A/q, H2AFO, HIST2H2AA	ENSG00000203812	Histone cluster 2 H2A family member a3	1	149842188-149842736	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Tissue enhanced	Tissue enhanced		bone marrow: 112.2;prostate: 125.6	spleen: 42.0	Cell line enhanced		U-266/70: 350.1;U-266/84: 191.4
HIST2H2AA4	H2A/r	ENSG00000272196	Histone cluster 2 H2A family member a4	1	149851061-149851624	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Tissue enhanced	Tissue enhanced		testis: 88.9	prostate: 32.5	Cell line enhanced		SiHa: 124.1;U-266/70: 217.3;U-266/84: 190.5
HIST2H2AB		ENSG00000184270	Histone cluster 2 H2A family member b	1	149887524-149887916	Predicted intracellular proteins	Evidence at protein level	CAB011483, HPA041189	Supported		Approved	Nucleus		Mixed	Tissue enriched	8	bone marrow: 4.0	prostate: 0.5	Cell line enhanced		MOLT-4: 3.4
HIST2H2AC	H2A, H2A/q, H2AFQ	ENSG00000184260	Histone cluster 2 H2A family member c	1	149886975-149887364	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported				Renal cancer:1.20e-10 (unfavourable), Urothelial cancer:7.86e-5 (favourable)	Expressed in all	Tissue enriched	10	bone marrow: 23.8	adrenal gland: 2.4	Cell line enhanced		MCF7: 73.2
HIST2H2BE	H2B, H2B.1, H2B/q, H2BFQ	ENSG00000184678	Histone cluster 2 H2B family member e	1	149884459-149886652	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Colorectal cancer:2.90e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 113.5	Cell line enhanced		Karpas-707: 40.8;U-266/70: 71.4
HIST2H2BF		ENSG00000203814	Histone cluster 2 H2B family member f	1	149782689-149812373	Predicted intracellular proteins	Evidence at protein level	CAB007814, HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			ovary: 24.3	Cell line enhanced		U-266/70: 38.0
HIST2H3A	H3/n, H3/o	ENSG00000203852	Histone cluster 2 H3 family member a	1	149852619-149854274	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Not detected	Not detected			cerebral cortex: 0.9	Cell line enhanced		SiHa: 5.9
HIST2H3C	H3, H3.2, H3/m, H3F2, H3FM, MGC9629	ENSG00000203811	Histone cluster 2 H3 family member c	1	149839538-149841193	Predicted intracellular proteins	Evidence at protein level	HPA042570, CAB069990	Supported					Not detected	Not detected			cerebral cortex: 0.9	Cell line enhanced		SiHa: 5.9
HIST2H3D		ENSG00000183598	Histone cluster 2 H3 family member d	1	149813271-149813681	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enhanced		bone marrow: 2.5	gallbladder: 1.8	Cell line enhanced		U-266/70: 16.7
HIST2H3PS2	p06	ENSG00000203818	Histone cluster 2 H3 pseudogene 2	1	143905556-143905966	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Not detected	Tissue enhanced		adrenal gland: 8.5;spleen: 7.7	ovary: 5.8	Cell line enhanced		BJ: 6.7;NB-4: 5.8;SH-SY5Y: 10.0;THP-1: 6.3;U-2197: 6.2
HIST2H4A	H4/n, H4F2, H4FN, HIST2H4	ENSG00000270882	Histone cluster 2 H4 family member a	1	149832659-149839767	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Not detected	Mixed			prostate: 13.8	Cell line enhanced		SiHa: 65.9;U-2 OS: 56.3
HIST2H4B	H4/o	ENSG00000270276	Histone cluster 2 H4 family member b	1	149854045-149861210	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Not detected	Mixed			fallopian tube: 4.6	Cell line enhanced		SCLC-21H: 5.7;SiHa: 7.9;U-266/70: 6.6;U-266/84: 5.4
HIST3H2A	MGC3165	ENSG00000181218	Histone cluster 3 H2A	1	228456979-228457873	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported				Glioma:5.44e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 22.7	cerebral cortex: 10.6	Cell line enhanced		SCLC-21H: 58.3
HIST3H2BB		ENSG00000196890	Histone cluster 3 H2B family member b	1	228458107-228460470	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		fallopian tube: 2.2	adrenal gland,skin: 1.3	Cell line enhanced		T-47d: 5.9;U-266/70: 23.3;U-266/84: 5.4
HIST3H3	H3.4, H3/g, H3FT, H3t	ENSG00000168148	Histone cluster 3 H3	1	228424845-228425325	Predicted intracellular proteins	Evidence at protein level	CAB001386, CAB003812, HPA042570	Supported		Supported	Nucleoplasm		Not detected	Tissue enriched	11	testis: 2.1	adrenal gland,fallopian tube,gallbladder,skin: 0.1	Not detected		
HIST4H4	MGC24116	ENSG00000197837	Histone cluster 4 H4	12	14767999-14771131	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB011503, CAB037279, HPA042201	Supported		Supported	Nucleoplasm		Mixed	Mixed			prostate: 7.2	Cell line enhanced		CAPAN-2: 4.1
HIVEP1	CIRIP, CRYBP1, MBP-1, PRDII-BF1, Schnurri-1, ZAS1, ZNF40, ZNF40A	ENSG00000095951	Human immunodeficiency virus type I enhancer binding protein 1	6	12008762-12164999	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050724	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Mitochondria		Expressed in all	Mixed			parathyroid gland: 25.7	Expressed in all		
HIVEP2	HIV-EP2, MBP-2, MIBP1, Schnurri-2, ZAS2, ZNF40B	ENSG00000010818	Human immunodeficiency virus type I enhancer binding protein 2	6	142751467-142956698	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055954			Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 31.1	Mixed		
HIVEP3	FLJ16752, KBP-1, KBP1, KIAA1555, KRC, Schnurri-3, SHN3, ZAS3, ZNF40C	ENSG00000127124	Human immunodeficiency virus type I enhancer binding protein 3	1	41506365-42035925	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005728	Approved		Supported	Nucleoplasm		Mixed	Mixed			skin: 5.6	Cell line enhanced		HDLM-2: 17.9
HJURP	DKFZp762E1312, FAKTS, hFLEG1, URLC9	ENSG00000123485	Holliday junction recognition protein	2	233833416-233854566	Predicted intracellular proteins	Evidence at protein level	HPA008436, HPA027261	Uncertain		Enhanced	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:3.37e-5 (unfavourable), Pancreatic cancer:7.72e-5 (unfavourable), Lung cancer:2.46e-4 (unfavourable), Melanoma:6.49e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 28.7;testis: 20.0	lymph node: 15.1	Mixed		
HK1		ENSG00000156515	Hexokinase 1	10	69269984-69401882	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007043, HPA007044, CAB010052, HPA011956	Supported		Enhanced	Mitochondria	Head and neck cancer:3.39e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 153.6	Cell line enhanced		K-562: 491.8
HK2		ENSG00000159399	Hexokinase 2	2	74833981-74893359	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028587	Enhanced				Renal cancer:1.37e-4 (unfavourable), Liver cancer:3.65e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 80.4	Cell line enhanced		U-87 MG: 168.5
HK3		ENSG00000160883	Hexokinase 3	5	176880869-176899332	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056743	Enhanced				Renal cancer:3.84e-8 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 87.9	spleen: 27.9	Cell line enhanced		SCLC-21H: 5.3;THP-1: 2.5;U-937: 16.3
HKDC1	FLJ22761, FLJ37767	ENSG00000156510	Hexokinase domain containing 1	10	69220303-69267559	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011956, HPA064198, HPA064230	Approved		Enhanced	Mitochondria		Mixed	Tissue enhanced		duodenum: 53.1;small intestine: 52.3	thyroid gland: 15.2	Group enriched	6	A549: 35.7;CACO-2: 46.7;CAPAN-2: 96.8;EFO-21: 31.5;Hep G2: 22.5;RPTEC TERT1: 61.4
HKR1	ZNF875	ENSG00000181666	HKR1, GLI-Kruppel zinc finger family member	19	37312837-37369365	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036126, HPA044855	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Mitochondria	Prostate cancer:5.18e-5 (unfavourable), Pancreatic cancer:4.41e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 54.6	Expressed in all		
HLCS	HCS	ENSG00000159267	Holocarboxylase synthetase	21	36750888-36990236	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017379	Approved		Supported	Cytosol	Breast cancer:7.72e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.7	Expressed in all		
HLF	MGC33822	ENSG00000108924	HLF, PAR bZIP transcription factor	17	55265012-55325065	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA068156, HPA071210			Enhanced	Nucleus	Lung cancer:2.71e-7 (favourable), Renal cancer:3.55e-6 (favourable), Head and neck cancer:1.88e-4 (favourable)	Tissue enhanced	Mixed			cerebral cortex: 65.4	Group enriched	5	HDLM-2: 25.3;Hep G2: 110.7
HLTF	HIP116A, HLTF1, RNF80, SMARCA3, SNF2L3	ENSG00000071794	Helicase like transcription factor	3	149030127-149086554	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015284, HPA049001	Uncertain		Enhanced	Nucleus	Liver cancer:7.27e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 83.4	Expressed in all		
HLX	HB24, HLX1	ENSG00000136630	H2.0 like homeobox	1	220879400-220885059	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005968	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.28e-6 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 60.3	lung: 27.1	Cell line enhanced		THP-1: 72.2
HMBOX1	FLJ21616, HNF1LA, HOT1, PBHNF	ENSG00000147421	Homeobox containing 1	8	28890394-29064764	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055855, HPA058586, CAB070418	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			testis: 13.9	Expressed in all		
HMBS	PBGD, PORC, UPS	ENSG00000256269	Hydroxymethylbilane synthase	11	119084866-119093549	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006114, HPA050659	Enhanced		Approved	Lipid droplets		Expressed in all	Tissue enriched	5	bone marrow: 52.8	parathyroid gland: 9.8	Expressed in all		
HMCES	C3orf37, DC12, SRAPD1	ENSG00000183624	5-hydroxymethylcytosine binding, ES cell specific	3	129278828-129306186	Predicted intracellular proteins	Evidence at protein level	HPA044968	Approved		Approved	Nucleus	Liver cancer:4.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 205.0	Expressed in all		
HMG20A	FLJ10739, HMGX1, HMGXB1	ENSG00000140382	High mobility group 20A	15	77420412-77485607	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008126	Supported		Approved	Nucleus		Expressed in all	Expressed in all			spleen: 49.0	Expressed in all		
HMG20B	BRAF25, BRAF35, HMGX2, HMGXB2, SMARCE1r, SOXL	ENSG00000064961	High mobility group 20B	19	3572777-3579088	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050220, HPA053157, HPA069832	Approved		Enhanced	Nucleoplasm	Endometrial cancer:1.72e-7 (favourable), Urothelial cancer:2.89e-5 (favourable)	Expressed in all	Expressed in all			prostate: 70.1	Expressed in all		
HMGA1	HMGIY	ENSG00000137309	High mobility group AT-hook 1	6	34236873-34246231	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB032200	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:1.29e-6 (unfavourable), Lung cancer:3.36e-4 (unfavourable), Endometrial cancer:7.13e-4 (unfavourable), Pancreatic cancer:8.71e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 163.8	Expressed in all		
HMGA2	BABL, HMGIC, LIPO	ENSG00000149948	High mobility group AT-hook 2	12	65824131-65966295	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017809, HPA039076	Approved		Supported	Nucleus<br>Nucleoli	Urothelial cancer:2.86e-4 (unfavourable), Head and neck cancer:4.79e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 3.7	bone marrow: 2.9	Cell line enhanced		AF22: 292.5
HMGB1	DKFZp686A04236, HMG1, HMG3, SBP-1	ENSG00000189403	High mobility group box 1	13	30456704-30617597	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003506, CAB005873	Supported		Supported	Nucleus		Expressed in all	Expressed in all			lymph node: 781.8	Expressed in all		
HMGB2	HMG2	ENSG00000164104	High mobility group box 2	4	173331695-173335125	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003506, CAB037206, HPA053314	Enhanced		Supported	Nucleus<br>Nucleoli	Renal cancer:7.60e-12 (unfavourable), Liver cancer:3.76e-5 (unfavourable), Melanoma:3.13e-4 (unfavourable), Pancreatic cancer:7.04e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 1464.0	Expressed in all		
HMGB3	HMG2A, HMG4, MGC90319	ENSG00000029993	High mobility group box 3	X	150980509-150990775	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062583	Enhanced		Approved	Nucleus<br>Nucleoli	Ovarian cancer:9.85e-5 (favourable), Renal cancer:6.15e-4 (favourable)	Expressed in all	Expressed in all			placenta: 196.4	Expressed in all		
HMGB4	FLJ40388	ENSG00000176256	High mobility group box 4	1	33860475-33864791	Predicted intracellular proteins	Evidence at protein level	HPA035699	Enhanced					Not detected	Tissue enriched	936	testis: 93.5	all non-specific tissues: 0.0	Not detected		
HMGCLL1	bA418P12.1, DKFZP434G1411	ENSG00000146151	3-hydroxymethyl-3-methylglutaryl-CoA lyase like 1	6	55434369-55579214	Enzymes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 14.5;placenta: 9.0	prostate: 5.2	Cell line enriched	11	SCLC-21H: 7.1
HMGCS1	HMGCS	ENSG00000112972	3-hydroxy-3-methylglutaryl-CoA synthase 1	5	43289395-43313512	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032907, HPA036913, HPA036914	Approved		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:3.87e-6 (favourable)	Expressed in all	Expressed in all			liver: 208.7	Expressed in all		
HMGCS2		ENSG00000134240	3-hydroxy-3-methylglutaryl-CoA synthase 2	1	119747996-119768905	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027423, HPA027442, CAB032906	Enhanced		Supported	Mitochondria	Liver cancer:2.43e-7 (favourable), Renal cancer:3.43e-5 (favourable), Ovarian cancer:2.17e-4 (favourable)	Tissue enhanced	Tissue enhanced		liver: 1270.5	colon: 363.4	Cell line enriched	15	RT4: 161.6
HMGN1	FLJ27265, FLJ31471, HMG14, MGC104230, MGC117425	ENSG00000205581	High mobility group nucleosome binding domain 1	21	39342315-39349647	Predicted intracellular proteins	Evidence at protein level	CAB012260, HPA048694	Supported		Supported	Nucleus	Renal cancer:8.74e-7 (unfavourable)	Expressed in all	Expressed in all			tonsil: 218.1	Expressed in all		
HMGN2	HMG17	ENSG00000198830	High mobility group nucleosomal binding domain 2	1	26472450-26475972	Predicted intracellular proteins	Evidence at protein level	CAB018371, HPA077364	Supported		Supported	Nucleus	Liver cancer:1.34e-4 (unfavourable), Renal cancer:3.92e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 782.8	Expressed in all		
HMGN3	TRIP7	ENSG00000118418	High mobility group nucleosomal binding domain 3	6	79201245-79234738	Predicted intracellular proteins	Evidence at protein level	CAB018370, HPA027971, HPA063572	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:1.02e-7 (unfavourable), Lung cancer:2.76e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 335.7	Mixed		
HMGN4	HMG17L3, NHC	ENSG00000182952	High mobility group nucleosomal binding domain 4	6	26538405-26546254	Predicted intracellular proteins	Evidence at protein level	HPA077364			Uncertain	Nucleus		Expressed in all	Expressed in all			thyroid gland: 131.8	Expressed in all		
HMGN5	NSBP1	ENSG00000198157	High mobility group nucleosome binding domain 5	X	81113701-81201942	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000511	Approved		Supported	Nucleus	Ovarian cancer:6.60e-4 (favourable)	Expressed in all	Expressed in all			testis: 201.5	Cell line enhanced		Karpas-707: 216.2
HMGXB3	HMGX3, KIAA0194, SMF	ENSG00000113716	HMG-box containing 3	5	150000046-150053142	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005967			Approved	Nucleoli	Liver cancer:3.37e-5 (unfavourable)	Expressed in all	Tissue enriched	10	parathyroid gland: 283.3	prostate: 27.4	Expressed in all		
HMGXB4	HMG2L1, THC211630	ENSG00000100281	HMG-box containing 4	22	35257452-35295807	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000725	Approved				Colorectal cancer:3.24e-5 (favourable), Pancreatic cancer:1.16e-4 (unfavourable), Liver cancer:4.79e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 18.8	Expressed in all		
HMHB1	HB-1, HB-1Y	ENSG00000158497	Histocompatibility minor HB-1	5	143812161-143820719	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		lymph node: 1.3;testis: 2.4	bone marrow: 0.6	Cell line enhanced		Karpas-707: 2.3;REH: 4.1
HMMR	CD168, RHAMM	ENSG00000072571	Hyaluronan mediated motility receptor	5	163460203-163491945	CD markers, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002433, HPA040025, HPA043926, HPA061524	Enhanced		Enhanced	Microtubules<br>Centrosome<br>Cytosol	Liver cancer:1.93e-7 (unfavourable), Pancreatic cancer:3.71e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Head and neck cancer:5.52e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 49.7	lymph node: 21.7	Expressed in all		
HMX1	H6, NKX5-3	ENSG00000215612	H6 family homeobox 1	4	8846076-8871817	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cerebral cortex: 1.1	testis: 0.9	Cell line enhanced		AN3-CA: 9.5;EFO-21: 5.6;HEK93: 10.2;SH-SY5Y: 4.4
HMX2	NKX5-2	ENSG00000188816	H6 family homeobox 2	10	123148122-123150672	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043379	Uncertain					Tissue enhanced	Tissue enriched	6	kidney: 1.2	duodenum,prostate,small intestine: 0.1	Cell line enriched	12	REH: 34.4
HMX3	NKX5-1	ENSG00000188620	H6 family homeobox 3	10	123135962-123137741	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069659			Approved	Nucleus<br>Microtubule organizing center		Mixed	Not detected			adipose tissue: 0.3	Cell line enhanced		HEL: 4.7;K-562: 15.8;NB-4: 3.8;SiHa: 5.0
HN1	ARM2, HN1A	ENSG00000189159	Hematological and neurological expressed 1	17	75135248-75168281	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059729	Approved		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli	Liver cancer:1.58e-7 (unfavourable), Renal cancer:1.77e-7 (unfavourable), Ovarian cancer:4.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 422.3	Expressed in all		
HN1L	C16orf34, FLJ13092, KIAA1426, L11	ENSG00000206053	Hematological and neurological expressed 1 like	16	1678256-1702280	Predicted intracellular proteins	Evidence at protein level	HPA041888, HPA041908	Approved		Enhanced	Plasma membrane<br>Cytosol	Endometrial cancer:7.85e-4 (favourable), Liver cancer:9.14e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 101.8	Expressed in all		
HNF1A	HNF1, LFB1, MODY3, TCF1	ENSG00000135100	HNF1 homeobox A	12	120978543-121002512	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010430, HPA035231	Enhanced		Supported	Nucleoplasm		Mixed	Tissue enhanced		duodenum: 15.5;kidney: 10.6;small intestine: 15.7	liver: 6.3	Group enriched	7	A549: 8.0;CACO-2: 24.3;Hep G2: 22.1
HNF1B	HNF1beta, LFB3, MODY5, TCF2, VHNF1	ENSG00000275410	HNF1 homeobox B	17	37686432-37745247	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002083, CAB068192	Enhanced		Supported	Nucleoplasm	Urothelial cancer:2.51e-6 (favourable), Renal cancer:6.00e-4 (favourable)	Tissue enhanced	Tissue enhanced		gallbladder: 21.5;kidney: 25.3	lung: 9.6	Cell line enhanced		A549: 16.8;CACO-2: 17.9;EFO-21: 26.2;RPTEC TERT1: 95.5
HNF4A	HNF4, MODY, MODY1, NR2A1, TCF14	ENSG00000101076	Hepatocyte nuclear factor 4 alpha	20	44355700-44434596	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004712, CAB019417	Enhanced		Supported	Nucleoplasm		Tissue enhanced	Group enriched	6	colon: 58.0;duodenum: 103.0;kidney: 44.7;liver: 51.0;rectum: 47.8;small intestine: 90.9;stomach: 21.9	gallbladder: 9.2	Group enriched	8	CACO-2: 126.0;Hep G2: 77.0
HNF4G	NR2A2	ENSG00000164749	Hepatocyte nuclear factor 4 gamma	8	75407914-75566843	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005438	Enhanced					Mixed	Group enriched	5	duodenum: 100.2;small intestine: 125.6	rectum: 21.0	Cell line enhanced		A549: 3.8;CAPAN-2: 13.9;PC-3: 4.4
HNMT		ENSG00000150540	Histamine N-methyltransferase	2	137964020-138016364	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035480, HPA035481	Approved				Pancreatic cancer:3.41e-4 (unfavourable), Urothelial cancer:4.68e-4 (favourable)	Expressed in all	Expressed in all			liver: 124.0	Cell line enhanced		Hep G2: 152.7;RT4: 91.6
HNRNPA0	hnRNPA0, HNRPA0	ENSG00000177733	Heterogeneous nuclear ribonucleoprotein A0	5	137745651-137754376	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036569, HPA059404	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.99e-4 (favourable), Pancreatic cancer:3.74e-4 (favourable)	Expressed in all	Expressed in all			ovary: 32.8	Expressed in all		
HNRNPA1	ALS20, hnRNP-A1, hnRNPA1, HNRPA1	ENSG00000135486	Heterogeneous nuclear ribonucleoprotein A1	12	54280193-54287088	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001609, HPA001666, HPA005812, HPA007185, CAB010894	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 1919.7	Expressed in all		
HNRNPA1L2	LOC144983	ENSG00000139675	Heterogeneous nuclear ribonucleoprotein A1-like 2	13	52640786-52643796	Predicted intracellular proteins	Evidence at protein level						Breast cancer:2.58e-4 (favourable), Pancreatic cancer:4.26e-4 (favourable)	Expressed in all	Mixed			ovary: 6.0	Expressed in all		
HNRNPA2B1	HNRPA2B1	ENSG00000122566	Heterogeneous nuclear ribonucleoprotein A2/B1	7	26189927-26201529	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001666, HPA005812, CAB012403, HPA065537	Supported		Enhanced	Nucleoplasm	Liver cancer:1.03e-6 (unfavourable), Renal cancer:8.01e-5 (unfavourable), Prostate cancer:5.12e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 753.7	Expressed in all		
HNRNPA3	HNRPA3	ENSG00000170144	Heterogeneous nuclear ribonucleoprotein A3	2	177212563-177223958	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001666, HPA005812, HPA066381	Supported		Enhanced	Nucleoplasm	Renal cancer:9.57e-7 (unfavourable), Liver cancer:2.95e-5 (unfavourable), Cervical cancer:4.87e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 309.7	Expressed in all		
HNRNPAB	ABBP1, FLJ40338, HNRPAB	ENSG00000197451	Heterogeneous nuclear ribonucleoprotein A/B	5	178204507-178211163	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046688	Approved		Enhanced	Nucleoplasm	Renal cancer:1.35e-7 (unfavourable), Ovarian cancer:9.79e-4 (favourable)	Expressed in all	Expressed in all			colon: 141.3	Expressed in all		
HNRNPC	hnRNPC, HNRPC	ENSG00000092199	Heterogeneous nuclear ribonucleoprotein C (C1/C2)	14	21209136-21269494	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005223, HPA051075, CAB075755, CAB075756	Supported		Enhanced	Nucleoplasm	Renal cancer:7.29e-5 (unfavourable), Liver cancer:7.72e-5 (unfavourable), Ovarian cancer:1.19e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 568.9	Expressed in all		
HNRNPCL1	HNRPCL1	ENSG00000179172	Heterogeneous nuclear ribonucleoprotein C-like 1	1	12847408-12848725	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
HNRNPCL2	HNRNPCP5	ENSG00000275774	Heterogeneous nuclear ribonucleoprotein C-like 2	1	13115496-13116854	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HNRNPCL3		ENSG00000277058	Heterogeneous nuclear ribonucleoprotein C-like 3	1	13060869-13062229	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HNRNPCL4		ENSG00000179412	Heterogeneous nuclear ribonucleoprotein C-like 4	1	13164586-13165467	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HNRNPD	AUF1, HNRPD	ENSG00000138668	Heterogeneous nuclear ribonucleoprotein D	4	82352498-82374503	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004911	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 341.0	Expressed in all		
HNRNPDL	HNRPDL, JKTBP, laAUF1	ENSG00000152795	Heterogeneous nuclear ribonucleoprotein D like	4	82422564-82430408	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056820, HPA063147	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 422.5	Expressed in all		
HNRNPF	HNRPF	ENSG00000169813	Heterogeneous nuclear ribonucleoprotein F	10	43385617-43409166	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016884, HPA069667	Supported		Enhanced	Nucleoplasm	Liver cancer:5.85e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 209.6	Expressed in all		
HNRNPH1	hnRNPH, HNRPH1	ENSG00000169045	Heterogeneous nuclear ribonucleoprotein H1	5	179614178-179634784	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000914, HPA001359, HPA016884, CAB032820	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:3.29e-7 (unfavourable), Renal cancer:3.46e-4 (unfavourable), Head and neck cancer:7.85e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 203.6	Expressed in all		
HNRNPH2	FTP3, hnRNPH', HNRPH', HNRPH2	ENSG00000126945	Heterogeneous nuclear ribonucleoprotein H2	X	101408295-101414133	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000914, HPA001359, CAB004436, HPA016884	Supported		Enhanced	Nucleoplasm	Renal cancer:7.37e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 216.1	Expressed in all		
HNRNPH3	2H9, HNRPH3	ENSG00000096746	Heterogeneous nuclear ribonucleoprotein H3	10	68331174-68343191	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038264			Supported	Nucleoplasm	Liver cancer:2.30e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 154.2	Expressed in all		
HNRNPK	CSBP, HNRPK, TUNP	ENSG00000165119	Heterogeneous nuclear ribonucleoprotein K	9	83968083-83980616	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004435, HPA007644, CAB016225, HPA044105	Supported		Enhanced	Nucleoplasm	Liver cancer:6.68e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 528.1	Expressed in all		
HNRNPL	HNRPL	ENSG00000104824	Heterogeneous nuclear ribonucleoprotein L	19	38836388-38852347	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016326, HPA051748, HPA052661	Supported		Enhanced	Nucleoplasm	Renal cancer:1.96e-11 (unfavourable), Liver cancer:3.25e-6 (unfavourable), Pancreatic cancer:9.69e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 110.4	Expressed in all		
HNRNPLL	HNRPLL	ENSG00000143889	Heterogeneous nuclear ribonucleoprotein L like	2	38561978-38603586	Predicted intracellular proteins	Evidence at protein level	HPA046084	Approved		Approved	Nucleus<br>Mitochondria<br>Cytosol	Liver cancer:1.22e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.5	Mixed		
HNRNPM	CEAR, HNRNPM4, HNRPM, HNRPM4, HTGR1, NAGR1	ENSG00000099783	Heterogeneous nuclear ribonucleoprotein M	19	8444767-8489114	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016113, HPA024344	Supported		Enhanced	Nucleoplasm	Liver cancer:1.80e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 203.0	Expressed in all		
HNRNPR	hnRNP-R, HNRPR	ENSG00000125944	Heterogeneous nuclear ribonucleoprotein R	1	23303771-23344336	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011687, HPA026092	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.32e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 66.5	Expressed in all		
HNRNPU	C1orf199, FLJ30202, FLJ37978, hnRNPU, HNRNPU-AS1, HNRPU, NCRNA00201, SAF-A	ENSG00000153187	Heterogeneous nuclear ribonucleoprotein U	1	244840638-244864560	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011532, HPA041057, HPA058707	Supported		Supported	Nucleoplasm	Liver cancer:8.88e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 225.2	Expressed in all		
HNRNPUL1	E1B-AP5, E1BAP5, FLJ12944, HNRPUL1	ENSG00000105323	Heterogeneous nuclear ribonucleoprotein U like 1	19	41262496-41307598	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046290, CAB046477, HPA049475	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.84e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 150.1	Expressed in all		
HNRNPUL2	DKFZp762N1910, HNRPUL2	ENSG00000214753	Heterogeneous nuclear ribonucleoprotein U like 2	11	62712630-62727349	Predicted intracellular proteins	Evidence at protein level	HPA041632, HPA056696, HPA067699	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 59.2	Expressed in all		
HOGA1	C10orf65, DHDPS2, DHDPSL, FLJ37472, NPL2	ENSG00000241935	4-hydroxy-2-oxoglutarate aldolase 1	10	97584323-97612802	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039466	Approved				Renal cancer:9.08e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 53.4;liver: 20.7	heart muscle: 8.5	Cell line enhanced		EFO-21: 9.0;Hep G2: 17.6;RPTEC TERT1: 23.2
HOMER1	HOMER-1B, SYN47, Ves-1	ENSG00000152413	Homer scaffolding protein 1	5	79372636-79514217	Predicted intracellular proteins	Evidence at protein level	CAB004437, HPA036521, HPA036522	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 48.9	thyroid gland: 25.2	Mixed		
HOMER2	CPD, Cupidin, HOMER-2, HOMER-2A, HOMER-2B, Vesl-2	ENSG00000103942	Homer scaffolding protein 2	15	82836946-82986153	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040134, CAB079014	Uncertain	Supported				Mixed	Expressed in all			prostate: 92.9	Cell line enhanced		Karpas-707: 66.5;SCLC-21H: 59.9
HOMER3	HOMER-3	ENSG00000051128	Homer scaffolding protein 3	19	18929201-18941261	Predicted intracellular proteins	Evidence at protein level	CAB032656, HPA040999, CAB079015	Enhanced	Supported	Supported	Plasma membrane<br>Cytosol<br>Cytoplasmic bodies	Colorectal cancer:4.24e-5 (unfavourable), Liver cancer:4.93e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 150.5	Mixed		
HOMEZ	KIAA1443	ENSG00000215271	Homeobox and leucine zipper encoding	14	23272422-23299447	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036316, HPA036317	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.17e-11 (favourable), Ovarian cancer:2.41e-5 (favourable), Thyroid cancer:1.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 41.7	Expressed in all		
HOOK1	HK1	ENSG00000134709	Hook microtubule tethering protein 1	1	59814786-59876378	Predicted intracellular proteins	Evidence at protein level	HPA018537, HPA018820	Enhanced				Colorectal cancer:4.53e-6 (favourable), Head and neck cancer:4.42e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 55.2	testis: 30.1	Cell line enhanced		EFO-21: 32.6;RPTEC TERT1: 24.3
HOOK2	HK2	ENSG00000095066	Hook microtubule tethering protein 2	19	12763003-12872740	Predicted intracellular proteins	Evidence at protein level	HPA043519, HPA050351	Approved		Supported	Vesicles<br>Cytosol	Prostate cancer:7.59e-5 (unfavourable), Renal cancer:3.28e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 96.0	Expressed in all		
HOOK3	HK3	ENSG00000168172	Hook microtubule tethering protein 3	8	42896932-43030539	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA024756	Approved		Supported	Golgi apparatus<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.32e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 36.6	Expressed in all		
HOPX	HOP, LAGY, NECC1, OB1, SMAP31	ENSG00000171476	HOP homeobox	4	56647988-56681899	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB018632, HPA030180	Enhanced					Mixed	Tissue enhanced		epididymis: 658.1;skin: 839.4	esophagus: 525.5	Cell line enhanced		HDLM-2: 28.9;HUVEC TERT2: 55.7;RT4: 40.2;TIME: 62.0
HORMAD1	CT46, DKFZP434A1315	ENSG00000143452	HORMA domain containing 1	1	150698060-150720888	Predicted intracellular proteins	Evidence at protein level	HPA028346, HPA037850	Enhanced		Approved	Nucleoplasm<br>Nucleoli		Tissue enhanced	Tissue enriched	26	testis: 224.9	skin: 8.8	Cell line enhanced		A549: 5.6;hTCEpi: 14.9;SiHa: 6.8;THP-1: 8.3;U-2 OS: 4.1
HORMAD2	CT46.2, MGC26710	ENSG00000176635	HORMA domain containing 2	22	30080174-30177075	Predicted intracellular proteins	Evidence at protein level	HPA003074	Enhanced					Not detected	Tissue enriched	23	testis: 35.2	liver: 1.5	Not detected		
HOXA1	HOX1, HOX1F	ENSG00000105991	Homeobox A1	7	27092993-27095996	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Head and neck cancer:6.73e-5 (unfavourable)	Mixed	Tissue enhanced		urinary bladder: 8.4	parathyroid gland,skin: 2.7	Mixed		
HOXA10	HOX1, HOX1H	ENSG00000253293	Homeobox A10	7	27170591-27180261	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019384	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		endometrium: 116.6;smooth muscle: 67.6	prostate: 42.2	Cell line enhanced		HEK93: 164.0;U-937: 78.1
HOXA10-HOXA9		ENSG00000257184		7	27163535-27180013	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		endometrium: 1.0	prostate: 0.4	Cell line enhanced		BJ: 1.1
HOXA11	HOX1, HOX1I	ENSG00000005073	Homeobox A11	7	27181510-27185223	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006770, HPA035623	Enhanced		Supported	Nucleoplasm	Renal cancer:2.57e-5 (unfavourable)	Mixed	Tissue enhanced		endometrium: 96.3;smooth muscle: 68.5	cervix, uterine: 17.9	Cell line enhanced		HEK93: 46.1;U-937: 37.5
HOXA13	HOX1, HOX1J	ENSG00000106031	Homeobox A13	7	27193503-27200106	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enhanced		cervix, uterine: 34.0;placenta: 24.5;prostate: 36.2;seminal vesicle: 32.5	rectum: 13.0	Cell line enhanced		HAP1: 27.6;HEK93: 34.0;RT4: 33.4
HOXA2	HOX1K	ENSG00000105996	Homeobox A2	7	27100354-27102811	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA078220			Approved	Nucleus<br>Vesicles		Mixed	Tissue enhanced		parathyroid gland: 8.1	epididymis: 6.2	Cell line enhanced		AN3-CA: 13.4;HaCaT: 5.3
HOXA3	HOX1, HOX1E	ENSG00000105997	Homeobox A3	7	27106184-27152581	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029157	Uncertain		Supported	Nucleoplasm	Renal cancer:2.52e-6 (unfavourable)	Mixed	Mixed			fallopian tube: 16.2	Cell line enhanced		AN3-CA: 35.4;CAPAN-2: 58.4;HEK93: 27.2;WM-115: 35.0
HOXA4	HOX1, HOX1D	ENSG00000197576	Homeobox A4	7	27128507-27130799	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060088	Approved		Enhanced	Nuclear bodies	Endometrial cancer:6.37e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 37.3;parathyroid gland: 35.3	esophagus: 16.4	Cell line enhanced		AN3-CA: 26.9;WM-115: 28.7
HOXA5	HOX1, HOX1C	ENSG00000106004	Homeobox A5	7	27141052-27143668	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Endometrial cancer:2.28e-4 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 109.7;epididymis: 60.1	fallopian tube: 44.1	Cell line enhanced		AN3-CA: 86.9;HEK93: 146.8
HOXA6	HOX1, HOX1B	ENSG00000106006	Homeobox A6	7	27145396-27150603	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA004203	Approved				Endometrial cancer:1.40e-4 (unfavourable), Renal cancer:2.03e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 9.9	endometrium: 9.0	Group enriched	9	AN3-CA: 57.3;HEK93: 77.5
HOXA7	HOX1, HOX1A	ENSG00000122592	Homeobox A7	7	27153716-27157936	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA074048			Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:1.15e-5 (favourable), Endometrial cancer:7.87e-5 (unfavourable)	Mixed	Mixed			epididymis: 21.6	Cell line enhanced		HAP1: 38.0;RPTEC TERT1: 34.0;SCLC-21H: 42.6
HOXA9	HOX1, HOX1G	ENSG00000078399	Homeobox A9	7	27162435-27175180	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061982	Uncertain		Supported	Nucleus		Mixed	Mixed			kidney: 12.6	Cell line enhanced		HEK93: 113.8;SCLC-21H: 133.7
HOXB1	HOX2, HOX2I	ENSG00000120094	Homeobox B1	17	48528526-48530997	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044576	Uncertain					Tissue enriched	Not detected			testis: 0.3	Not detected		
HOXB13		ENSG00000159184	Homeobox B13	17	48724763-48729178	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004438, HPA062852, HPA065019	Enhanced		Enhanced	Nucleoplasm		Tissue enriched	Tissue enhanced		prostate: 115.1;rectum: 39.0	colon: 21.4	Cell line enriched	13	PC-3: 139.6
HOXB2	HOX2, HOX2H	ENSG00000173917	Homeobox B2	17	48540894-48544989	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047857			Supported	Nucleus	Glioma:3.01e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 56.6	cervix, uterine: 24.4	Cell line enhanced		AF22: 58.1;HEK93: 59.6;HMC-1: 112.4;WM-115: 56.1
HOXB3	HOX2, HOX2G	ENSG00000120093	Homeobox B3	17	48548870-48604912	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009860	Approved				Urothelial cancer:8.45e-6 (favourable)	Mixed	Tissue enhanced		epididymis: 79.4	fallopian tube: 38.7	Cell line enhanced		CAPAN-2: 35.1;HEK93: 38.6
HOXB4	HOX2, HOX2F	ENSG00000182742	Homeobox B4	17	48575513-48580111	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057432	Uncertain		Supported	Nucleus<br>Centrosome	Ovarian cancer:2.23e-4 (unfavourable)	Mixed	Tissue enhanced		epididymis: 16.1	fallopian tube: 12.5	Cell line enhanced		EFO-21: 30.9;HMC-1: 17.8
HOXB5	HOX2, HOX2A	ENSG00000120075	Homeobox B5	17	48591257-48593961	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043851, HPA074454			Enhanced	Nucleus	Urothelial cancer:8.59e-5 (favourable), Lung cancer:4.61e-4 (unfavourable), Endometrial cancer:6.28e-4 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 20.2	fallopian tube: 10.7	Cell line enhanced		HEK93: 24.1;RPTEC TERT1: 14.7
HOXB6	HOX2, HOX2B	ENSG00000108511	Homeobox B6	17	48595751-48604992	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042063			Approved	Nucleus<br>Golgi apparatus	Endometrial cancer:2.46e-4 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 48.7;seminal vesicle: 30.1	cervix, uterine: 26.4	Cell line enhanced		HEK93: 71.9;RPTEC TERT1: 39.9
HOXB7	HOX2, HOX2C	ENSG00000260027	Homeobox B7	17	48607227-48633572	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049940	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Urothelial cancer:2.39e-4 (favourable)	Mixed	Tissue enriched	5	epididymis: 162.9	cervix, uterine: 32.1	Cell line enhanced		EFO-21: 76.4;SK-MEL-30: 62.0
HOXB8	HOX2, HOX2D	ENSG00000120068	Homeobox B8	17	48611377-48614939	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075905			Supported	Nucleoplasm	Renal cancer:1.30e-7 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 68.0;seminal vesicle: 32.7	cervix, uterine: 16.9	Cell line enhanced		EFO-21: 33.5;HDLM-2: 15.7;HEK93: 34.4;LHCN-M2: 15.9;RPTEC TERT1: 29.7
HOXB9	HOX2, HOX2E	ENSG00000170689	Homeobox B9	17	48621159-48626356	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031463			Approved	Nucleoplasm<br>Mitochondria	Head and neck cancer:6.64e-5 (unfavourable), Endometrial cancer:4.47e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 107.2	colon: 26.1	Cell line enhanced		HDLM-2: 315.3;HEK93: 116.2;HMC-1: 112.5;K-562: 130.4
HOXC10	HOX3I	ENSG00000180818	Homeobox C10	12	53985065-53990279	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053919	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Group enriched	9	kidney: 18.9;skeletal muscle: 40.3;skin: 8.4	breast: 2.5	Cell line enhanced		AN3-CA: 275.9;T-47d: 95.2
HOXC12	HOC3F, HOX3, HOX3F	ENSG00000123407	Homeobox C12	12	53954834-53958956	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055632	Uncertain					Mixed	Not detected			skin: 0.7	Group enriched	6	HaCaT: 20.3;K-562: 5.9;SiHa: 5.3
HOXC13	HOX3, HOX3G	ENSG00000123364	Homeobox C13	12	53938765-53946544	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051634	Supported					Mixed	Tissue enriched	8	skin: 4.6	breast,testis: 0.5	Cell line enhanced		AN3-CA: 28.1;HaCaT: 56.8;SK-BR-3: 26.3;T-47d: 25.6
HOXC4	HOX3, HOX3E	ENSG00000198353	Homeobox C4	12	54016931-54056030	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053910			Supported	Nucleus		Mixed	Tissue enhanced		fallopian tube: 33.9	kidney: 9.4	Cell line enhanced		HDLM-2: 29.1;HEK93: 30.5;SH-SY5Y: 29.6
HOXC5	HOX3, HOX3D	ENSG00000172789	Homeobox C5	12	54032853-54035358	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026794	Uncertain		Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		fallopian tube: 6.0	ovary: 3.1	Cell line enhanced		AN3-CA: 5.6;SH-SY5Y: 7.0
HOXC6	HOX3, HOX3C	ENSG00000197757	Homeobox C6	12	53990624-54030823	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054981			Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.55e-6 (unfavourable)	Mixed	Mixed			epididymis: 22.3	Cell line enhanced		AN3-CA: 85.1;HDLM-2: 73.7
HOXC8	HOX3, HOX3A	ENSG00000037965	Homeobox C8	12	54009106-54012362	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028911, CAB037020	Uncertain		Approved	Nucleoplasm<br>Microtubules	Renal cancer:1.47e-5 (unfavourable)	Mixed	Tissue enhanced		epididymis: 21.1;smooth muscle: 12.6	adrenal gland: 7.7	Cell line enhanced		ASC diff: 33.3;fHDF/TERT166: 46.1;HSkMC: 28.1;LHCN-M2: 36.5
HOXC9	HOX3, HOX3B	ENSG00000180806	Homeobox C9	12	53994895-54003337	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063965, HPA072160			Enhanced	Nucleoplasm		Mixed	Tissue enhanced		skeletal muscle: 6.2	adipose tissue: 3.3	Cell line enhanced		AN3-CA: 19.7;HDLM-2: 26.0;HEK93: 30.3
HOXD1	HOX4, HOX4G	ENSG00000128645	Homeobox D1	2	176188579-176190907	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040062, HPA056900			Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		epididymis: 8.7;fallopian tube: 7.3	lung: 4.5	Cell line enhanced		EFO-21: 5.9;RPTEC TERT1: 15.3;RT4: 12.7;SCLC-21H: 6.3
HOXD10	HOX4, HOX4D	ENSG00000128710	Homeobox D10	2	176108790-176119942	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065871			Approved	Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies	Renal cancer:1.92e-6 (unfavourable)	Mixed	Tissue enhanced		endometrium: 48.3;smooth muscle: 25.2	kidney: 12.7	Cell line enhanced		HEK93: 36.4;RPTEC TERT1: 21.3;SCLC-21H: 12.9;SiHa: 17.8;U-251 MG: 11.0
HOXD11	HOX4, HOX4F	ENSG00000128713	Homeobox D11	2	176104216-176109754	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055155			Approved	Nucleoplasm		Mixed	Tissue enhanced		endometrium: 4.2	seminal vesicle: 1.3	Cell line enhanced		HEK93: 18.4;SCLC-21H: 7.0;U-251 MG: 3.8
HOXD12	HOX4H	ENSG00000170178	Homeobox D12	2	176099730-176101193	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059444	Uncertain					Not detected	Tissue enhanced		colon: 1.0;rectum: 1.1;seminal vesicle: 1.8	prostate: 0.8	Cell line enhanced		REH: 2.3
HOXD13	HOX4I, SPD	ENSG00000128714	Homeobox D13	2	176092891-176095938	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064064			Supported	Nucleus	Colorectal cancer:6.95e-5 (unfavourable)	Mixed	Group enriched	8	cervix, uterine: 7.9;colon: 4.9;prostate: 16.9;rectum: 9.5;seminal vesicle: 24.5	urinary bladder: 1.5	Cell line enhanced		HAP1: 20.6;HEK93: 52.3;HL-60: 52.4;NB-4: 24.7;SCLC-21H: 19.3
HOXD3	HOX1D, HOX4, HOX4A	ENSG00000128652	Homeobox D3	2	176136612-176173102	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051831, HPA063671			Enhanced	Nucleoplasm<br>Nuclear bodies		Tissue enhanced	Tissue enriched	6	epididymis: 46.7	fallopian tube: 8.0	Cell line enhanced		EFO-21: 7.4;HSkMC: 6.6;RPTEC TERT1: 7.3;SCLC-21H: 16.3;SH-SY5Y: 9.8
HOXD4	HOX4, HOX4B	ENSG00000170166	Homeobox D4	2	176151222-176153226	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054383, HPA070349	Approved		Enhanced	Nucleus<br>Cell Junctions		Tissue enhanced	Tissue enhanced		endometrium: 23.6;epididymis: 22.9	fallopian tube: 15.5	Cell line enhanced		EFO-21: 11.0;HEK93: 25.9;RPTEC TERT1: 15.6
HOXD8	HOX4, HOX4E	ENSG00000175879	Homeobox D8	2	176129694-176132695	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Lung cancer:3.78e-4 (unfavourable)	Mixed	Tissue enhanced		epididymis: 122.0;kidney: 83.6	ovary: 43.1	Cell line enhanced		RPTEC TERT1: 56.9
HOXD9	HOX4, HOX4C	ENSG00000128709	Homeobox D9	2	176122720-176124937	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA068683			Supported	Nucleus<br>Nucleoli	Liver cancer:1.08e-5 (unfavourable), Colorectal cancer:8.25e-4 (unfavourable), Head and neck cancer:9.58e-4 (favourable)	Expressed in all	Tissue enhanced		endometrium: 45.4	smooth muscle: 23.7	Cell line enhanced		HEK93: 14.8;RPTEC TERT1: 14.2;SH-SY5Y: 23.1;TIME: 13.8
HP1BP3	HP1-BP74	ENSG00000127483	Heterochromatin protein 1 binding protein 3	1	20742661-20787323	Predicted intracellular proteins	Evidence at protein level	HPA028215, HPA054295	Supported		Supported	Nuclear speckles	Liver cancer:2.76e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 192.4	Expressed in all		
HPCA		ENSG00000121905	Hippocalcin	1	32885994-32898441	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012340, HPA043245	Supported					Tissue enriched	Tissue enriched	47	cerebral cortex: 153.0	testis: 3.2	Cell line enriched	8	SCLC-21H: 5.3
HPCAL1	BDR1, HLP2, VILIP-3	ENSG00000115756	Hippocalcin like 1	2	10302889-10427617	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043245	Approved				Renal cancer:4.39e-6 (unfavourable), Glioma:5.68e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 80.5	Expressed in all		
HPCAL4	DKFZp761G122, HLP4	ENSG00000116983	Hippocalcin like 4	1	39678648-39691689	Predicted intracellular proteins	Evidence at protein level	HPA053808			Approved	Cytosol		Group enriched	Tissue enriched	11	cerebral cortex: 145.7	adrenal gland: 13.3	Cell line enhanced		SH-SY5Y: 9.4;SK-MEL-30: 2.2;U-266/84: 2.1
HPD	4-HPPD, 4HPPD, GLOD3, PPD	ENSG00000158104	4-hydroxyphenylpyruvate dioxygenase	12	121839527-121863596	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038321, HPA038322	Enhanced		Uncertain	Nuclear speckles		Tissue enriched	Group enriched	86	kidney: 529.9;liver: 1293.2	seminal vesicle: 10.5	Cell line enriched	24	Hep G2: 349.1
HPDL	4-HPPD-L, GLOXD1, MGC15668	ENSG00000186603	4-hydroxyphenylpyruvate dioxygenase like	1	45326905-45328533	Predicted intracellular proteins	Evidence at protein level	HPA031997, HPA057346	Approved		Supported	Mitochondria	Endometrial cancer:1.60e-5 (unfavourable), Ovarian cancer:1.03e-4 (favourable), Breast cancer:1.81e-4 (favourable)	Mixed	Mixed			colon: 3.8	Cell line enhanced		BEWO: 118.1;SK-BR-3: 58.4
HPF1	C4orf27, FLJ20534	ENSG00000056050	Histone PARylation factor 1	4	169729465-169757953	Predicted intracellular proteins	Evidence at protein level	HPA043467	Uncertain	Approved	Approved	Microtubules<br>Cytokinetic bridge<br>Cytosol	Melanoma:5.63e-4 (unfavourable), Ovarian cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 38.5	Expressed in all		
HPGD	SDR36C1	ENSG00000164120	Hydroxyprostaglandin dehydrogenase 15-(NAD)	4	174490177-174523154	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004919, HPA005679	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.20e-4 (favourable)	Tissue enhanced	Tissue enhanced		urinary bladder: 375.7	stomach: 181.5	Cell line enhanced		A549: 128.2;HEL: 282.4;RT4: 385.2
HPGDS	GSTS, GSTS1, GSTS1-1, H-PGDS, PGD2, PGDS	ENSG00000163106	Hematopoietic prostaglandin D synthase	4	94298535-94342876	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024035	Enhanced					Mixed	Tissue enhanced		placenta: 28.1	lung: 14.5	Group enriched	9	HEL: 43.7;HMC-1: 12.2
HPRT1	HGPRT, HPRT	ENSG00000165704	Hypoxanthine phosphoribosyltransferase 1	X	134460153-134520513	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006360, CAB012200	Enhanced		Supported	Cytosol	Head and neck cancer:1.35e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 139.1	Mixed		
HPS1	BLOC3S1, HPS	ENSG00000107521	HPS1, biogenesis of lysosomal organelles complex 3 subunit 1	10	98416198-98446947	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061260	Approved				Endometrial cancer:2.93e-5 (favourable), Cervical cancer:3.37e-5 (favourable), Lung cancer:1.26e-4 (favourable), Glioma:5.53e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 24.2	Mixed		
HPS4	BLOC3S2, KIAA1667, LE	ENSG00000100099	HPS4, biogenesis of lysosomal organelles complex 3 subunit 2	22	26443423-26483837	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB033106, HPA050189	Approved		Approved	Centrosome		Expressed in all	Expressed in all			testis: 24.2	Expressed in all		
HPS5	AIBP63, BLOC2S2, RU2	ENSG00000110756	HPS5, biogenesis of lysosomal organelles complex 2 subunit 2	11	18278668-18322198	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 39.9	Expressed in all		
HPS6	BLOC2S3, FLJ22501	ENSG00000166189	HPS6, biogenesis of lysosomal organelles complex 2 subunit 3	10	102065390-102068038	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040687	Approved					Expressed in all	Expressed in all			fallopian tube: 12.0	Expressed in all		
HR	ALUNC, AU	ENSG00000168453	HR, lysine demethylase and nuclear receptor corepressor	8	22114415-22133384	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA054888			Supported	Nucleoplasm		Mixed	Tissue enhanced		skin: 58.9	cerebral cortex: 11.9	Cell line enhanced		HaCaT: 70.7;SiHa: 29.4;T-47d: 27.6
HRAS	HRAS1	ENSG00000174775	HRas proto-oncogene, GTPase	11	532242-537287	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002015, HPA049830	Approved				Liver cancer:2.32e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.0	Expressed in all		
HRASLS5	HRLP5	ENSG00000168004	HRAS like suppressor family member 5	11	63461404-63491194	Predicted intracellular proteins	Evidence at protein level						Glioma:9.80e-5 (unfavourable)	Mixed	Tissue enriched	5	testis: 96.2	adipose tissue: 17.8	Group enriched	6	HAP1: 11.7;NB-4: 2.4
HRCT1	LGLL338, PRO537, UNQ338	ENSG00000196196	Histidine rich carboxyl terminus 1	9	35906192-35907141	Predicted intracellular proteins	Evidence at transcript level	HPA067038			Approved	Nucleoplasm	Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 17.9	colon: 13.2	Cell line enhanced		EFO-21: 16.8;HeLa: 10.0;U-2197: 24.6;U-251 MG: 10.6
HRNR	FLG3, S100A16, S100a18	ENSG00000197915	Hornerin	1	152212082-152224193	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031469	Uncertain		Approved	Mitochondria		Tissue enhanced	Not detected			skin: 0.7	Cell line enhanced		NTERA-2: 1.9
HS1BP3	FLJ14249, HS1-BP3	ENSG00000118960	HCLS1 binding protein 3	2	20560448-20651089	Predicted intracellular proteins	Evidence at protein level	HPA035050	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:2.97e-5 (unfavourable), Renal cancer:2.30e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 33.3	Expressed in all		
HS3ST2	3OST2	ENSG00000122254	Heparan sulfate-glucosamine 3-sulfotransferase 2	16	22814177-22916338	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017736	Approved				Renal cancer:1.35e-4 (favourable), Glioma:2.22e-4 (unfavourable)	Mixed	Tissue enriched	30	cerebral cortex: 35.7	lung: 1.1	Group enriched	7	HaCaT: 8.5;SH-SY5Y: 17.7
HS3ST3A1	30ST3A1, 3OST3A1	ENSG00000153976	Heparan sulfate-glucosamine 3-sulfotransferase 3A1	17	13495689-13601927	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062518, HPA071530	Uncertain		Approved	Microtubules		Mixed	Tissue enhanced		spleen: 9.1	seminal vesicle: 6.8	Cell line enhanced		PC-3: 40.6;U-251 MG: 103.1;U-87 MG: 72.4
HS3ST3B1	30ST3B1, 3OST3B1	ENSG00000125430	Heparan sulfate-glucosamine 3-sulfotransferase 3B1	17	14301083-14349404	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA064126			Approved	Vesicles		Mixed	Tissue enhanced		liver: 14.7	lymph node: 7.1	Cell line enhanced		AF22: 20.5;BEWO: 14.3;HSkMC: 14.6;U-251 MG: 16.3
HS3ST5	3-OST-5	ENSG00000249853	Heparan sulfate-glucosamine 3-sulfotransferase 5	6	114055586-114343045	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021823, HPA064677	Approved					Not detected	Group enriched	5	cerebral cortex: 6.2;seminal vesicle: 2.2;skeletal muscle: 1.3	adrenal gland: 0.6	Cell line enhanced		PC-3: 4.2;RT4: 6.8;SCLC-21H: 19.0
HS3ST6	HS3ST5	ENSG00000162040	Heparan sulfate-glucosamine 3-sulfotransferase 6	16	1911463-1918440	Enzymes, Predicted intracellular proteins	Evidence at protein level						Cervical cancer:3.73e-4 (favourable)	Tissue enhanced	Tissue enriched	10	skin: 9.5	fallopian tube: 0.9	Not detected		
HSBP1		ENSG00000230989	Heat shock factor binding protein 1	16	83807843-83819737	Predicted intracellular proteins	Evidence at protein level						Ovarian cancer:2.96e-4 (favourable), Endometrial cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 58.8	Expressed in all		
HSBP1L1	FLJ10967, MGC189743	ENSG00000226742	Heat shock factor binding protein 1 like 1	18	79964561-79970822	Predicted intracellular proteins	Evidence at transcript level	HPA048273	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			colon: 12.2	Cell line enhanced		HHSteC: 113.0;SK-MEL-30: 62.5
HSCB	DNAJC20, HSC20, Jac1	ENSG00000100209	HscB mitochondrial iron-sulfur cluster cochaperone	22	28742031-28757515	Predicted intracellular proteins	Evidence at protein level	HPA018447, HPA031518	Uncertain		Supported	Nucleus<br>Mitochondria<br>Cytosol	Endometrial cancer:3.78e-4 (favourable), Urothelial cancer:8.38e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 13.2	Expressed in all		
HSD11B1	HSD11, HSD11B, SDR26C1	ENSG00000117594	Hydroxysteroid 11-beta dehydrogenase 1	1	209686178-209734950	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047729	Enhanced				Renal cancer:1.97e-10 (unfavourable)	Tissue enriched	Group enriched	9	liver: 492.5;placenta: 105.1	ovary: 31.6	Group enriched	6	ASC diff: 678.2;HHSteC: 173.0
HSD17B1	EDH17B2, EDHB17, HSD17, MGC138140, SDR28C1	ENSG00000108786	Hydroxysteroid 17-beta dehydrogenase 1	17	42549214-42555213	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021032, HPA065296	Enhanced		Supported	Cytosol		Mixed	Tissue enriched	14	placenta: 98.3	cerebral cortex: 7.1	Cell line enriched	8	BEWO: 331.8
HSD17B10	17b-HSD10, ABAD, CAMR, ERAB, HADH2, MHBD, MRPP2, MRXS10, SDR5C1	ENSG00000072506	Hydroxysteroid 17-beta dehydrogenase 10	X	53431258-53434373	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001432	Approved				Cervical cancer:2.80e-4 (favourable)	Expressed in all	Expressed in all			liver: 126.6	Expressed in all		
HSD17B13	SCDR9, SDR16C3	ENSG00000170509	Hydroxysteroid 17-beta dehydrogenase 13	4	87303789-87322906	Predicted intracellular proteins	Evidence at protein level	HPA029125	Uncertain		Approved	Golgi apparatus<br>Vesicles	Liver cancer:2.94e-4 (favourable), Lung cancer:7.80e-4 (favourable)	Tissue enriched	Tissue enriched	29	liver: 294.1	adipose tissue: 10.2	Not detected		
HSD17B14	DHRS10, retSDR3, SDR47C1	ENSG00000087076	Hydroxysteroid 17-beta dehydrogenase 14	19	48813017-48836678	Predicted intracellular proteins	Evidence at protein level	HPA021467	Approved				Pancreatic cancer:2.87e-5 (favourable), Colorectal cancer:4.39e-5 (unfavourable)	Expressed in all	Mixed			kidney: 53.3	Cell line enhanced		HHSteC: 35.4;Karpas-707: 35.4;RT4: 28.6
HSD17B4	DBP, MFE-2, SDR8C1	ENSG00000133835	Hydroxysteroid 17-beta dehydrogenase 4	5	119452443-119637199	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021302, HPA021311, HPA021479	Enhanced		Enhanced	Peroxisomes	Renal cancer:6.31e-6 (favourable), Colorectal cancer:1.33e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 229.7	Expressed in all		
HSD17B6	HSE, RODH, SDR9C6	ENSG00000025423	Hydroxysteroid 17-beta dehydrogenase 6	12	56752161-56787790	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059141	Enhanced		Approved	Nucleus<br>Vesicles	Liver cancer:6.32e-4 (favourable)	Tissue enriched	Tissue enriched	10	liver: 930.6	seminal vesicle: 96.0	Cell line enhanced		SCLC-21H: 12.9
HSD17B8	D6S2245E, FABGL, H2-KE6, HKE6, KE6, RING2, SDR30C1	ENSG00000204228	Hydroxysteroid 17-beta dehydrogenase 8	6	33204642-33206831	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042132	Enhanced				Renal cancer:2.18e-12 (favourable), Liver cancer:1.90e-5 (favourable), Breast cancer:9.99e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.9	Cell line enhanced		RPMI-8226: 11.7;T-47d: 9.9;U-266/70: 12.1
HSDL2	C9orf99, SDR13C1	ENSG00000119471	Hydroxysteroid dehydrogenase like 2	9	112379937-112472410	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042890, HPA050453	Enhanced		Supported	Mitochondria	Renal cancer:9.29e-7 (favourable), Endometrial cancer:9.23e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 79.2	Expressed in all		
HSF1	HSTF1	ENSG00000185122	Heat shock transcription factor 1	8	144291591-144314722	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004239, HPA008888	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.95e-4 (unfavourable), Endometrial cancer:8.93e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 127.1	Expressed in all		
HSF2		ENSG00000025156	Heat shock transcription factor 2	6	122399546-122433119	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016067, HPA031455	Approved		Supported	Nucleoplasm	Liver cancer:1.51e-6 (unfavourable), Renal cancer:7.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 71.4	Expressed in all		
HSF2BP		ENSG00000160207	Heat shock transcription factor 2 binding protein	21	43529192-43659493	Predicted intracellular proteins	Evidence at protein level	HPA031724			Approved	Nucleus<br>Cytosol		Mixed	Tissue enriched	9	testis: 40.8	cerebral cortex: 4.4	Cell line enhanced		HBEC3-KT: 9.1
HSF4	CTM	ENSG00000102878	Heat shock transcription factor 4	16	67164681-67169945	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048584			Supported	Nuclear speckles	Renal cancer:2.19e-6 (unfavourable), Colorectal cancer:8.24e-5 (unfavourable)	Expressed in all	Mixed			adrenal gland: 14.8	Cell line enhanced		T-47d: 12.3;U-266/70: 18.1
HSF5	FLJ40311	ENSG00000176160	Heat shock transcription factor 5	17	58420167-58488384	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063613	Enhanced					Not detected	Tissue enriched	64	testis: 88.4	lymph node: 1.3	Not detected		
HSFX1	LW-1	ENSG00000171116	Heat shock transcription factor family, X-linked 1	X	149774068-149776867	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063040	Approved					Not detected	Mixed			ovary: 4.6	Mixed		
HSFX2		ENSG00000268738	Heat shock transcription factor family, X-linked 2	X	149592515-149594716	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063040	Supported					Not detected	Tissue enriched	8	testis: 9.3	seminal vesicle: 1.1	Not detected		
HSFY1	HSF2L, HSFY	ENSG00000172468	Heat shock transcription factor, Y-linked 1	Y	18546671-18588963	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	93	testis: 24.8	epididymis,kidney,skin: 0.2	Not detected		
HSFY2	FLJ25453	ENSG00000169953	Heat shock transcription factor, Y-linked 2	Y	18731440-18828662	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	200	testis: 24.7	kidney: 0.1	Not detected		
HSH2D	ALX, FLJ14886, HSH2	ENSG00000196684	Hematopoietic SH2 domain containing	19	16134028-16158575	Predicted intracellular proteins	Evidence at protein level	HPA036616			Approved	Plasma membrane<br>Focal adhesion sites<br>Cytosol	Renal cancer:6.49e-6 (unfavourable), Colorectal cancer:9.46e-6 (unfavourable), Urothelial cancer:3.47e-5 (favourable)	Mixed	Mixed			tonsil: 32.7	Cell line enhanced		HMC-1: 49.9;NB-4: 88.6;RPMI-8226: 43.5;U-937: 106.3
HSP90AA1	FLJ31884, Hsp89, Hsp90, HSP90N, HSPC1, HSPCA	ENSG00000080824	Heat shock protein 90 alpha family class A member 1	14	102080738-102139699	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002058	Approved		Supported	Cytosol	Renal cancer:1.18e-5 (favourable), Liver cancer:3.09e-5 (unfavourable), Breast cancer:5.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1021.5	Expressed in all		
HSP90AB1	HSPC2, HSPCB	ENSG00000096384	Heat shock protein 90 alpha family class B member 1	6	44246166-44253888	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005230, HPA055729, HPA072606, HPA074351	Enhanced		Supported	Cytosol	Ovarian cancer:4.03e-4 (favourable), Renal cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 1461.8	Expressed in all		
HSPA12A	FLJ13874, KIAA0417	ENSG00000165868	Heat shock protein family A (Hsp70) member 12A	10	116671192-116849741	Predicted intracellular proteins	Evidence at protein level	HPA011273, HPA073244	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:3.61e-7 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 65.0	adrenal gland: 26.7	Cell line enhanced		RPTEC TERT1: 46.5
HSPA12B	C20orf60, dJ1009E24.2	ENSG00000132622	Heat shock protein family A (Hsp70) member 12B	20	3732667-3753111	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013659, HPA015639	Uncertain					Expressed in all	Mixed			spleen: 25.4	Cell line enhanced		CACO-2: 4.0;EFO-21: 4.6;HUVEC TERT2: 7.9;TIME: 4.3
HSPA14	HSP70-4, HSP70L1	ENSG00000187522	Heat shock protein family A (Hsp70) member 14	10	14838164-14871741	Predicted intracellular proteins	Evidence at protein level	HPA046180	Approved				Liver cancer:3.70e-8 (unfavourable), Renal cancer:1.09e-5 (unfavourable), Head and neck cancer:5.73e-4 (favourable), Ovarian cancer:9.16e-4 (favourable)	Expressed in all	Expressed in all			testis: 57.5	Expressed in all		
HSPA1A	HSP70-1, HSPA1	ENSG00000204389	Heat shock protein family A (Hsp70) member 1A	6	31815464-31817946	Predicted intracellular proteins	Evidence at protein level	CAB017451, CAB032815, HPA052504	Supported		Approved	Nucleoplasm<br>Vesicles	Colorectal cancer:1.54e-5 (unfavourable)	Expressed in all	Mixed			adrenal gland: 49.9	Cell line enriched	10	HEK93: 3834.6
HSPA1B	HSP70-2	ENSG00000204388	Heat shock protein family A (Hsp70) member 1B	6	31827735-31830255	Predicted intracellular proteins	Evidence at protein level	CAB008640, HPA052504	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Tissue enhanced		adrenal gland: 34.3	parathyroid gland: 14.6	Cell line enhanced		A549: 74.8;Karpas-707: 175.2;U-266/70: 30.2
HSPA1L	HSP70-HOM, hum70t	ENSG00000204390	Heat shock protein family A (Hsp70) member 1 like	6	31809619-31815065	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043285, HPA052504	Enhanced		Approved	Nucleoplasm<br>Vesicles	Ovarian cancer:1.02e-4 (favourable), Renal cancer:4.63e-4 (favourable)	Expressed in all	Tissue enriched	8	testis: 9.8	epididymis: 1.2	Cell line enhanced		HEK93: 2.3
HSPA2		ENSG00000126803	Heat shock protein family A (Hsp70) member 2	14	64535905-64546173	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000798, HPA052504	Enhanced	Approved	Approved	Nucleoplasm<br>Vesicles	Breast cancer:1.78e-4 (favourable), Lung cancer:9.11e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 188.6	cerebral cortex: 96.4	Cell line enhanced		A549: 67.9;BEWO: 110.2;BJ hTERT+: 80.5;SCLC-21H: 119.3
HSPA4	HS24/P52, HSPH2	ENSG00000170606	Heat shock protein family A (Hsp70) member 4	5	133051962-133106449	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA010023, CAB025529	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.13e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 116.7	Expressed in all		
HSPA4L	APG-1, HSPH3, Osp94	ENSG00000164070	Heat shock protein family A (Hsp70) member 4 like	4	127781821-127840733	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034450, HPA039149, HPA061446	Enhanced		Approved	Centrosome<br>Cytosol	Renal cancer:3.80e-9 (favourable), Urothelial cancer:6.78e-4 (unfavourable)	Mixed	Tissue enriched	8	testis: 193.3	parathyroid gland: 24.0	Cell line enhanced		HAP1: 84.6
HSPA6	HSP70B'	ENSG00000173110	Heat shock protein family A (Hsp70) member 6	1	161524540-161526910	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017452, HPA028549, HPA052504	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.98e-5 (unfavourable), Liver cancer:7.26e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 27.8	spleen: 15.1	Cell line enriched	7	Karpas-707: 36.1
HSPA8	HSC70, HSC71, HSP73, HSPA10	ENSG00000109971	Heat shock protein family A (Hsp70) member 8	11	123057489-123063230	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002056, HPA052504	Uncertain		Approved	Nucleoplasm<br>Vesicles	Colorectal cancer:6.14e-6 (favourable), Liver cancer:1.93e-4 (unfavourable), Renal cancer:3.81e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1119.0	Expressed in all		
HSPA9	GRP75, HSPA9B, mot-2, mthsp75, PBP74	ENSG00000113013	Heat shock protein family A (Hsp70) member 9	5	138554882-138575444	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000898, CAB005219	Enhanced		Enhanced	Mitochondria	Breast cancer:2.93e-4 (unfavourable), Colorectal cancer:4.53e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 263.5	Expressed in all		
HSPB1	CMT2F, Hs.76067, Hsp25, HSP27, HSP28	ENSG00000106211	Heat shock protein family B (small) member 1	7	76302544-76304295	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000497, CAB004439, CAB047330, CAB047331, CAB047332	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Colorectal cancer:9.94e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 1615.3	Expressed in all		
HSPB11	C1orf41, HSPCO34, IFT25, PP25	ENSG00000081870	Heat shock protein family B (small) member 11	1	53916574-53945929	Predicted intracellular proteins	Evidence at protein level	HPA030140	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.58e-7 (unfavourable), Renal cancer:1.03e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 116.6	Expressed in all		
HSPB2	Hs.78846, MKBP	ENSG00000170276	Heat shock protein family B (small) member 2	11	111912242-111914093	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		heart muscle: 36.6	skeletal muscle: 25.0	Cell line enhanced		ASC diff: 13.8;fHDF/TERT166: 21.7;HSkMC: 6.9;LHCN-M2: 13.3;U-138 MG: 11.8
HSPB3	HSPL27	ENSG00000169271	Heat shock protein family B (small) member 3	5	54455601-54456384	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Group enriched	10	heart muscle: 212.2;skeletal muscle: 64.3	esophagus: 14.0	Cell line enhanced		BJ hTERT+: 56.3;fHDF/TERT166: 24.5;HSkMC: 9.6
HSPB6	FLJ32389, Hsp20, PPP1R91	ENSG00000004776	Heat shock protein family B (small) member 6	19	35754569-35758079	Predicted intracellular proteins	Evidence at protein level	CAB001974, HPA044153, HPA054811	Enhanced				Urothelial cancer:1.43e-6 (unfavourable), Renal cancer:1.93e-5 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 843.0	adipose tissue: 666.5	Cell line enhanced		ASC diff: 1220.3;ASC TERT1: 521.5;HHSteC: 505.3;HSkMC: 510.5
HSPB7	cvHSP	ENSG00000173641	Heat shock protein family B (small) member 7	1	16014028-16019594	Predicted intracellular proteins	Evidence at protein level	HPA027639	Approved		Approved	Nucleoplasm	Urothelial cancer:1.26e-4 (unfavourable), Head and neck cancer:5.29e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 1571.0;skeletal muscle: 639.6	adipose tissue: 342.4	Cell line enriched	5	fHDF/TERT166: 246.0
HSPB8	CMT2L, E2IG1, H11, HSP22, HspB8	ENSG00000152137	Heat shock protein family B (small) member 8	12	119178642-119221131	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015876	Approved		Supported	Cytosol	Liver cancer:2.98e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 426.6	Cell line enhanced		EFO-21: 74.9;MCF7: 83.7
HSPB9	CT51	ENSG00000260325	Heat shock protein family B (small) member 9	17	42121431-42123352	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	14	testis: 6.7	appendix,liver,ovary: 0.4	Mixed		
HSPBAP1	FLJ22623, PASS1	ENSG00000169087	HSPB1 associated protein 1	3	122740003-122793824	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044930	Approved		Approved	Mitochondria		Expressed in all	Mixed			testis: 19.3	Expressed in all		
HSPBP1	FES1, HspBP1	ENSG00000133265	HSPA (Hsp70) binding protein 1	19	55262231-55280381	Predicted intracellular proteins	Evidence at protein level	CAB005865, HPA071444	Enhanced		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 40.1	Expressed in all		
HSPD1	GroEL, HSP60, SPG13	ENSG00000144381	Heat shock protein family D (Hsp60) member 1	2	197486581-197516737	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001523, CAB002775, HPA050025, CAB072816	Supported		Enhanced	Mitochondria	Endometrial cancer:1.61e-4 (unfavourable), Liver cancer:2.25e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 834.1	Expressed in all		
HSPE1	CPN10, EPF, GroES, HSP10	ENSG00000115541	Heat shock protein family E (Hsp10) member 1	2	197499994-197503457	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017366, HPA038755, HPA048272	Supported					Expressed in all	Expressed in all			adrenal gland: 650.8	Expressed in all		
HSPE1-MOB4		ENSG00000270757	HSPE1-MOB4 readthrough	2	197500413-197550726	Predicted intracellular proteins	Evidence at protein level	HPA038755, HPA044125, HPA048272	Approved					Not detected	Mixed			adrenal gland: 32.7	Expressed in all		
HSPH1	HSP105A, HSP105B, KIAA0201, NY-CO-25	ENSG00000120694	Heat shock protein family H (Hsp110) member 1	13	31134974-31162388	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002060, HPA028675, HPA031569	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.41e-5 (unfavourable), Head and neck cancer:4.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 123.7	Expressed in all		
HTATSF1	TAT-SF1	ENSG00000102241	HIV-1 Tat specific factor 1	X	136497079-136512346	Predicted intracellular proteins	Evidence at protein level	HPA000504	Supported		Enhanced	Nucleoplasm	Renal cancer:8.13e-8 (favourable), Cervical cancer:3.78e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 125.8	Expressed in all		
HUNK		ENSG00000142149	Hormonally up-regulated Neu-associated kinase	21	31873315-32044633	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027295, HPA027372	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:7.48e-5 (favourable)	Mixed	Mixed			placenta: 6.8	Cell line enhanced		AF22: 13.3;BEWO: 15.9;RH-30: 17.7;SCLC-21H: 17.5;SiHa: 14.1
HUS1		ENSG00000136273	HUS1 checkpoint clamp component	7	47695730-47979581	Predicted intracellular proteins	Evidence at protein level	HPA026787	Approved				Cervical cancer:4.25e-5 (unfavourable), Liver cancer:9.54e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 12.3	Expressed in all		
HUS1B		ENSG00000188996	HUS1 checkpoint clamp component B	6	655939-656963	Predicted intracellular proteins	Evidence at protein level	HPA034511, HPA063449			Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 1.2	bone marrow: 0.4	Cell line enhanced		HEK93: 1.6;U-266/84: 1.5;WM-115: 2.2
HYDIN	CILD5, DKFZp434D0513, KIAA1864, PPP1R31	ENSG00000157423	HYDIN, axonemal central pair apparatus protein	16	70807378-71230722	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA067155, HPA074129	Enhanced		Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		fallopian tube: 9.1;parathyroid gland: 5.4;testis: 6.4	epididymis: 2.6	Cell line enhanced		RPTEC TERT1: 2.1;SiHa: 6.4
HYI	HT036	ENSG00000178922	Hydroxypyruvate isomerase (putative)	1	43451003-43453989	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040092	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Urothelial cancer:2.72e-5 (favourable), Renal cancer:2.75e-5 (unfavourable), Colorectal cancer:4.96e-4 (unfavourable), Liver cancer:5.55e-4 (unfavourable), Breast cancer:9.18e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 81.4	Mixed		
HYKK	AGPHD1, LOC123688	ENSG00000188266	Hydroxylysine kinase	15	78507564-78537372	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040706	Approved		Approved	Vesicles<br>Aggresome		Mixed	Mixed			kidney: 12.5	Cell line enhanced		HEK93: 20.5
HYLS1	FLJ32915	ENSG00000198331	HYLS1, centriolar and ciliogenesis associated	11	125883614-125900648	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041210	Uncertain		Supported	Plasma membrane<br>Cytosol	Liver cancer:1.92e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 37.5	smooth muscle: 6.6	Mixed		
HYPK	C15orf63, FLJ20431, HSPC136	ENSG00000242028	Huntingtin interacting protein K	15	43796142-43803043	Predicted intracellular proteins	Evidence at protein level	HPA055252	Uncertain		Supported	Nucleoplasm<br>Microtubules		Mixed	Mixed			testis: 6.3	Mixed		
HYPM	CXorf27, HIP17	ENSG00000187516	Huntingtin interacting protein M	X	37990817-37991317	Predicted intracellular proteins	Evidence at protein level	HPA003356	Supported					Not detected	Tissue enriched	153	testis: 50.1	skin: 0.3	Not detected		
IAH1		ENSG00000134330	Isoamyl acetate-hydrolyzing esterase 1 homolog	2	9473658-9496543	Predicted intracellular proteins	Evidence at protein level	HPA040523			Supported	Nucleoplasm	Renal cancer:3.64e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 121.2	Mixed		
IARS	IARS1, ILRS	ENSG00000196305	Isoleucyl-tRNA synthetase	9	92210207-92293756	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029806	Approved		Supported	Cytosol	Liver cancer:4.98e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 141.8	Expressed in all		
IARS2	FLJ10326	ENSG00000067704	Isoleucyl-tRNA synthetase 2, mitochondrial	1	220094102-220148041	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024212, HPA024594, HPA024596	Enhanced		Enhanced	Mitochondria	Pancreatic cancer:9.24e-5 (unfavourable), Cervical cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 144.3	Expressed in all		
IBA57	C1orf69, FLJ12734	ENSG00000181873	IBA57 homolog, iron-sulfur cluster assembly	1	228165815-228182257	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030555, HPA030556, HPA030557	Approved		Supported	Mitochondria	Renal cancer:1.71e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 4.1	Mixed		
IBTK	BTBD26, BTKI, DKFZP564B116	ENSG00000005700	Inhibitor of Bruton tyrosine kinase	6	82169983-82247754	Predicted intracellular proteins	Evidence at protein level	HPA023826, HPA048438	Uncertain		Supported	Nucleoplasm	Cervical cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 21.4	Expressed in all		
ICA1L	ALS2CR14, ALS2CR15	ENSG00000163596	Islet cell autoantigen 1 like	2	202773150-202871985	Predicted intracellular proteins	Evidence at protein level	HPA042507	Approved		Supported	Mitochondria		Mixed	Mixed			cerebral cortex: 22.4	Cell line enhanced		BEWO: 21.1
ICE1	KIAA0947	ENSG00000164151	Interactor of little elongation complex ELL subunit 1	5	5420664-5490234	Predicted intracellular proteins	Evidence at protein level	HPA054452, HPA061934	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Liver cancer:1.66e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.2	Expressed in all		
ICE2	BRCC1, FLJ11896, NARG2	ENSG00000128915	Interactor of little elongation complex ELL subunit 2	15	60419609-60479160	Predicted intracellular proteins	Evidence at protein level	HPA040058			Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 54.0	Expressed in all		
ICK	KIAA0936, LCK2, MGC46090, MRK	ENSG00000112144	Intestinal cell kinase	6	53001279-53061802	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000791, HPA001113	Approved		Approved	Nucleoli fibrillar center		Expressed in all	Mixed			adrenal gland: 23.1	Expressed in all		
ID2	bHLHb26, GIG8	ENSG00000115738	Inhibitor of DNA binding 2, HLH protein	2	8678845-8684453	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027612			Approved	Nucleoplasm<br>Nuclear bodies<br>Centrosome	Head and neck cancer:9.95e-4 (favourable)	Expressed in all	Tissue enriched	6	parathyroid gland: 1985.4	thyroid gland: 359.5	Cell line enhanced		HDLM-2: 675.4;HEK93: 418.6
ID3	bHLHb25, HEIR-1	ENSG00000117318	Inhibitor of DNA binding 3, HLH protein	1	23557918-23559794	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB021353, HPA024677	Approved		Supported	Nucleoplasm	Endometrial cancer:1.27e-5 (favourable)	Expressed in all	Mixed			seminal vesicle: 91.4	Cell line enhanced		U-698: 261.7
ID4	bHLHb27	ENSG00000172201	Inhibitor of DNA binding 4, HLH protein	6	19837386-19840684	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060800			Supported	Nucleus	Pancreatic cancer:2.49e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 626.0	fallopian tube: 128.5	Cell line enhanced		AF22: 57.9;AN3-CA: 71.8;EFO-21: 163.7;HEK93: 91.1;SCLC-21H: 185.5
IDH1		ENSG00000138413	Isocitrate dehydrogenase (NADP(+)) 1, cytosolic	2	208236227-208266074	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033218, HPA035248, HPA057936, CAB062556	Enhanced		Approved	Nuclear bodies<br>Cytosol	Renal cancer:2.45e-5 (unfavourable), Liver cancer:6.93e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 338.1	Expressed in all		
IDH2		ENSG00000182054	Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial	15	90083045-90102504	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007831	Enhanced		Supported	Mitochondria	Cervical cancer:5.15e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 450.0	Expressed in all		
IDH3A		ENSG00000166411	Isocitrate dehydrogenase 3 (NAD(+)) alpha	15	78131498-78171949	Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041465, HPA062971	Supported		Enhanced	Mitochondria	Renal cancer:6.49e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 44.1	Expressed in all		
IDH3B	RP46	ENSG00000101365	Isocitrate dehydrogenase 3 (NAD(+)) beta	20	2658395-2664219	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049387, HPA054180	Enhanced		Enhanced	Mitochondria	Renal cancer:6.78e-8 (favourable), Liver cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 100.5	Expressed in all		
IDH3G		ENSG00000067829	Isocitrate dehydrogenase 3 (NAD(+)) gamma	X	153785766-153794523	Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000425, HPA002017	Enhanced		Enhanced	Mitochondria	Renal cancer:5.73e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 64.9	Expressed in all		
IDI1		ENSG00000067064	Isopentenyl-diphosphate delta isomerase 1	10	1039908-1049170	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039169	Approved				Renal cancer:1.46e-4 (favourable)	Expressed in all	Expressed in all			breast: 244.8	Expressed in all		
IDI2	IPPI2	ENSG00000148377	Isopentenyl-diphosphate delta isomerase 2	10	1018907-1025859	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	41	skeletal muscle: 76.3	heart muscle: 1.8	Not detected		
IDO1	IDO, INDO	ENSG00000131203	Indoleamine 2,3-dioxygenase 1	8	39902275-39928444	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023072, HPA023149, HPA027772, CAB072820	Enhanced				Renal cancer:1.12e-7 (unfavourable), Ovarian cancer:3.32e-4 (favourable), Melanoma:5.27e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 149.4	lymph node: 57.3	Cell line enriched	7	EFO-21: 54.8
IDO2	INDOL1	ENSG00000188676	Indoleamine 2,3-dioxygenase 2	8	39934614-40016391	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	8	liver: 2.7;placenta: 5.9	appendix,lymph node,testis: 0.5	Not detected		
IER2	ETR101	ENSG00000160888	Immediate early response 2	19	13150415-13154908	Predicted intracellular proteins	Evidence at protein level	HPA055387, HPA060574			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			fallopian tube: 161.2	Expressed in all		
IER5		ENSG00000162783	Immediate early response 5	1	181088712-181092899	Predicted intracellular proteins	Evidence at protein level	HPA029894	Uncertain	Approved	Supported	Nucleus<br>Nucleoli	Endometrial cancer:2.42e-7 (favourable), Lung cancer:1.18e-4 (unfavourable), Renal cancer:2.36e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 31.1	Expressed in all		
IER5L	bA247A12.2	ENSG00000188483	Immediate early response 5 like	9	129175552-129178262	Predicted intracellular proteins	Evidence at transcript level	HPA021327			Approved	Nucleus	Lung cancer:1.48e-6 (unfavourable)	Expressed in all	Mixed			endometrium: 5.9	Cell line enhanced		SiHa: 36.8
IFFO1	HOM-TES-103, IFFO	ENSG00000010295	Intermediate filament family orphan 1	12	6538375-6556083	Predicted intracellular proteins	Evidence at protein level	HPA069344	Approved				Renal cancer:7.47e-7 (unfavourable), Pancreatic cancer:6.53e-5 (favourable)	Expressed in all	Mixed			spleen: 12.0	Mixed		
IFFO2		ENSG00000169991	Intermediate filament family orphan 2	1	18904281-18956686	Predicted intracellular proteins	Evidence at transcript level	HPA015987, HPA064603	Approved		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			skin: 72.4	Cell line enhanced		HDLM-2: 129.1
IFI16	IFNGIP1, PYHIN2	ENSG00000163565	Interferon gamma inducible protein 16	1	158999968-159055155	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002134, CAB016293	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.11e-16 (unfavourable)	Expressed in all	Expressed in all			lymph node: 163.5	Mixed		
IFI27L1	FAM14B	ENSG00000165948	Interferon alpha inducible protein 27 like 1	14	94081282-94103846	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Tissue enhanced		testis: 71.9	ovary: 27.5	Expressed in all		
IFI35	IFP35	ENSG00000068079	Interferon induced protein 35	17	43006725-43014456	Predicted intracellular proteins	Evidence at protein level	HPA045946			Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.03e-5 (unfavourable), Breast cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			spleen: 44.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 190.3;BJ hTERT+ SV40 Large T+ RasG12V: 291.3
IFI44	MTAP44, p44, TLDC5	ENSG00000137965	Interferon induced protein 44	1	78649796-78664078	Predicted intracellular proteins	Evidence at protein level	HPA027148, HPA043858	Approved		Approved	Nucleoplasm	Renal cancer:1.37e-8 (unfavourable)	Expressed in all	Expressed in all			spleen: 88.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 163.8;BJ hTERT+ SV40 Large T+ RasG12V: 210.0
IFI44L	C1orf29, GS3686	ENSG00000137959	Interferon induced protein 44 like	1	78619922-78646145	Predicted intracellular proteins	Evidence at protein level	HPA053247, HPA060372	Enhanced		Approved	Nucleoplasm	Renal cancer:1.06e-4 (unfavourable), Endometrial cancer:2.95e-4 (unfavourable), Glioma:5.08e-4 (favourable)	Expressed in all	Mixed			spleen: 32.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 43.7;BJ hTERT+ SV40 Large T+ RasG12V: 49.2;HSkMC: 19.4;SK-MEL-30: 17.2
IFIH1	Hlcd, IDDM19, MDA-5, MDA5	ENSG00000115267	Interferon induced with helicase C domain 1	2	162267079-162318703	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002656	Approved					Expressed in all	Mixed			spleen: 31.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 72.5;BJ hTERT+ SV40 Large T+ RasG12V: 93.7
IFIT1	G10P1, GARG-16, IFI56, IFNAI1	ENSG00000185745	Interferon induced protein with tetratricopeptide repeats 1	10	89392546-89406486	Predicted intracellular proteins	Evidence at protein level	CAB045980, HPA055380	Approved		Supported	Cytosol		Expressed in all	Expressed in all			spleen: 60.6	Group enriched	5	BJ hTERT+ SV40 Large T+: 746.9;BJ hTERT+ SV40 Large T+ RasG12V: 764.4
IFIT1B	bA149I23.6, IFIT1L	ENSG00000204010	Interferon induced protein with tetratricopeptide repeats 1B	10	89378056-89385205	Predicted intracellular proteins	Evidence at protein level	HPA062924	Approved					Not detected	Group enriched	97	bone marrow: 15.3;placenta: 4.1	all non-specific tissues: 0.0	Not detected		
IFIT2	cig42, G10P2, GARG-39, IFI-54, IFI54, ISG-54K	ENSG00000119922	Interferon induced protein with tetratricopeptide repeats 2	10	89283694-89309276	Predicted intracellular proteins	Evidence at protein level	HPA003408	Approved		Approved	Vesicles	Renal cancer:6.99e-4 (unfavourable)	Expressed in all	Mixed			spleen: 39.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 132.1;BJ hTERT+ SV40 Large T+ RasG12V: 108.9
IFIT3	CIG-49, GARG-49, IFI60, IFIT4, IRG2, ISG60, RIG-G	ENSG00000119917	Interferon induced protein with tetratricopeptide repeats 3	10	89327894-89340971	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059914	Approved		Supported	Mitochondria<br>Cytosol	Renal cancer:3.17e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 63.4	Group enriched	5	BJ hTERT+: 159.3;BJ hTERT+ SV40 Large T+: 419.8;BJ hTERT+ SV40 Large T+ RasG12V: 506.2
IFIT5	RI58	ENSG00000152778	Interferon induced protein with tetratricopeptide repeats 5	10	89414586-89421001	Predicted intracellular proteins	Evidence at protein level	HPA037957, HPA062180	Uncertain		Supported	Vesicles<br>Plasma membrane		Expressed in all	Mixed			parathyroid gland: 36.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 66.6;BJ hTERT+ SV40 Large T+ RasG12V: 82.7
IFNK		ENSG00000147896	Interferon kappa	9	27524314-27526498	Predicted intracellular proteins	Evidence at protein level							Group enriched	Not detected			skin: 0.1	Not detected		
IFT122	SPG, WDR10, WDR10p, WDR140	ENSG00000163913	Intraflagellar transport 122	3	129440036-129520507	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041815	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 147.4	Expressed in all		
IFT140	gs114, KIAA0590, WDTC2	ENSG00000187535	Intraflagellar transport 140	16	1510427-1612110	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042197	Approved					Expressed in all	Mixed			fallopian tube: 23.9	Mixed		
IFT172	BBS20, NPHP17, osm-1, SLB, wim	ENSG00000138002	Intraflagellar transport 172	2	27444371-27489789	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044893	Uncertain		Approved	Vesicles	Liver cancer:6.05e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 33.5	Mixed		
IFT20		ENSG00000109083	Intraflagellar transport 20	17	28328325-28335489	Predicted intracellular proteins	Evidence at protein level	HPA021376	Approved		Approved	Microtubules	Renal cancer:5.09e-7 (unfavourable), Liver cancer:1.96e-4 (unfavourable), Endometrial cancer:8.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 79.8	Expressed in all		
IFT22	DKFZp761N0823, FLJ13225, FLJ14117, RABL5	ENSG00000128581	Intraflagellar transport 22	7	101313367-101321823	Predicted intracellular proteins	Evidence at protein level	HPA042930	Approved		Approved	Microtubules<br>Cytosol		Expressed in all	Expressed in all			testis: 139.6	Expressed in all		
IFT27	BBS19, RABL4, RAYL	ENSG00000100360	Intraflagellar transport 27	22	36758202-36776256	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018418	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Endometrial cancer:1.91e-4 (favourable), Urothelial cancer:5.55e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 57.4	Cell line enhanced		U-138 MG: 156.6
IFT43	C14orf179, FLJ32173, MGC16028	ENSG00000119650	Intraflagellar transport 43	14	75902136-76084585	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003438	Approved		Supported	Microtubules<br>Microtubule organizing center		Expressed in all	Expressed in all			fallopian tube: 99.1	Mixed		
IFT46	C11orf2, C11orf60, CFAP32, FLJ21827	ENSG00000118096	Intraflagellar transport 46	11	118544528-118572970	Predicted intracellular proteins	Evidence at protein level	HPA037909, HPA057550	Approved		Approved	Actin filaments		Expressed in all	Expressed in all			fallopian tube: 97.3	Expressed in all		
IFT52	C20orf9, CGI-53, dJ1028D15.1, NGD2, NGD5	ENSG00000101052	Intraflagellar transport 52	20	43590931-43647296	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA063367, HPA067423	Enhanced		Approved	Cytosol	Liver cancer:3.30e-6 (unfavourable), Testis cancer:3.33e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 61.3	Expressed in all		
IFT57	ESRRBL1, FLJ10147, HIPPI, MHS4R2	ENSG00000114446	Intraflagellar transport 57	3	108160812-108222570	Predicted intracellular proteins	Evidence at protein level	HPA035514, HPA035515	Supported		Approved	Nuclear speckles<br>Mitochondria<br>Cytosol	Colorectal cancer:6.96e-5 (favourable), Ovarian cancer:7.63e-4 (favourable)	Expressed in all	Mixed			testis: 67.1	Expressed in all		
IFT74	CCDC2, CMG-1, CMG1, FLJ22621	ENSG00000096872	Intraflagellar transport 74	9	26947039-27062930	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020247, HPA026684	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			testis: 84.2	Mixed		
IFT80	KIAA1374, WDR56	ENSG00000068885	Intraflagellar transport 80	3	160256986-160399880	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035868	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 46.5	Expressed in all		
IFT81	CDV-1R, CDV1, MGC4027	ENSG00000122970	Intraflagellar transport 81	12	110124335-110218797	Predicted intracellular proteins	Evidence at protein level	HPA019087, HPA020051	Enhanced		Approved	Centrosome<br>Cytosol		Expressed in all	Mixed			testis: 58.0	Expressed in all		
IFT88	D13S1056E, hTg737, MGC26259, Tg737, TTC10	ENSG00000032742	Intraflagellar transport 88	13	20567069-20691437	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.33e-4 (favourable), Pancreatic cancer:5.17e-4 (favourable)	Expressed in all	Expressed in all			testis: 126.6	Expressed in all		
IGBP1	IBP1	ENSG00000089289	Immunoglobulin binding protein 1	X	70133449-70166324	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000634, HPA001004, CAB034139	Approved		Approved	Microtubules		Expressed in all	Expressed in all			ovary: 147.3	Expressed in all		
IGF2BP1	IMP-1	ENSG00000159217	Insulin like growth factor 2 mRNA binding protein 1	17	48997412-49055650	Predicted intracellular proteins	Evidence at protein level	HPA021367, HPA062273	Enhanced		Supported	Cytosol		Tissue enriched	Group enriched	6	placenta: 8.0;testis: 9.1	kidney: 1.4	Cell line enhanced		AF22: 145.0;CACO-2: 196.9;REH: 127.4
IGF2BP2	IMP-2	ENSG00000073792	Insulin like growth factor 2 mRNA binding protein 2	3	185643739-185825056	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017126, HPA035145	Enhanced		Enhanced	Cytosol	Head and neck cancer:5.12e-5 (unfavourable), Pancreatic cancer:7.37e-5 (unfavourable), Endometrial cancer:1.22e-4 (unfavourable)	Mixed	Mixed			placenta: 21.1	Mixed		
IGF2BP3	CT98, IMP-3, IMP3	ENSG00000136231	Insulin like growth factor 2 mRNA binding protein 3	7	23310209-23470467	Predicted intracellular proteins	Evidence at protein level	HPA002037	Approved		Enhanced	Cytosol		Mixed	Tissue enhanced		placenta: 41.6	testis: 9.3	Mixed		
IGFL4		ENSG00000204869	IGF like family member 4	19	46039748-46077118	Predicted intracellular proteins	Evidence at transcript level	HPA047655	Approved		Approved	Cytosol		Mixed	Tissue enhanced		skin: 8.2	cerebral cortex: 2.6	Cell line enhanced		A549: 3.5;HaCaT: 3.0
IGFN1	DKFZp434B1231, EEF1A2BP1	ENSG00000163395	Immunoglobulin-like and fibronectin type III domain containing 1	1	201190825-201228952	Predicted intracellular proteins	Evidence at protein level	HPA050415	Enhanced		Approved	Midbody ring	Renal cancer:1.27e-8 (unfavourable)	Group enriched	Group enriched	6	endometrium: 17.1;epididymis: 18.4;skeletal muscle: 60.1	cerebral cortex: 5.6	Cell line enriched	6	HeLa: 41.8
IGHMBP2	CATF1, CMT2S, HCSA, HMN6, SMARD1, SMUBP2, ZFAND7	ENSG00000132740	Immunoglobulin mu binding protein 2	11	68903842-68940602	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060994			Approved	Nucleus	Renal cancer:1.29e-8 (unfavourable), Pancreatic cancer:5.89e-4 (favourable)	Expressed in all	Expressed in all			testis: 27.9	Expressed in all		
IGLL1	14.1, CD179B, IGL5, IGLL, IGVPB	ENSG00000128322	Immunoglobulin lambda like polypeptide 1	22	23573125-23580308	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051134, HPA071406	Enhanced		Approved	Endoplasmic reticulum		Tissue enhanced	Group enriched	18	bone marrow: 44.2;testis: 15.8	tonsil: 1.6	Cell line enriched	39	REH: 687.9
IGLL5		ENSG00000254709	Immunoglobulin lambda like polypeptide 5	22	22887780-22896107	Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.94e-8 (unfavourable), Head and neck cancer:3.41e-5 (favourable), Breast cancer:6.10e-4 (favourable)	Expressed in all	Tissue enhanced		tonsil: 836.2	urinary bladder: 638.6	Group enriched	7	Daudi: 472.9;U-266/70: 346.8;U-698: 308.3
IGSF22	FLJ37794, IGFN2	ENSG00000179057	Immunoglobulin superfamily member 22	11	18704305-18726230	Predicted intracellular proteins	Evidence at protein level	CAB026459	Uncertain					Mixed	Tissue enhanced		skin: 1.2;testis: 1.0	cerebral cortex: 0.8	Not detected		
IK	RED, RER	ENSG00000113141	IK cytokine, down-regulator of HLA II	5	140647058-140662479	Predicted intracellular proteins	Evidence at protein level	HPA048798	Supported		Enhanced	Nuclear speckles	Liver cancer:2.32e-7 (unfavourable), Cervical cancer:1.29e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 230.6	Expressed in all		
IKBKAP	DYS, ELP1, IKAP, IKI3, TOT1	ENSG00000070061	Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein	9	108867517-108934116	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB021340, HPA049677, HPA050686	Approved		Supported	Nucleoplasm<br>Cytosol	Breast cancer:1.57e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 76.5	Expressed in all		
IKBKB	IKK-beta, IKK2, IKKB, NFKBIKB	ENSG00000104365	Inhibitor of nuclear factor kappa B kinase subunit beta	8	42271302-42332653	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001249, CAB004447	Enhanced		Approved	Cytosol	Urothelial cancer:1.46e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 18.7	Expressed in all		
IKBKE	IKK-i, IKKE, KIAA0151	ENSG00000263528	Inhibitor of nuclear factor kappa B kinase subunit epsilon	1	206470476-206496889	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015788, CAB025983	Approved		Supported	Cytosol	Renal cancer:5.34e-7 (unfavourable)	Expressed in all	Mixed			lymph node: 27.4	Mixed		
IKBKG	FIP-3, FIP3, Fip3p, IKK-gamma, IP1, IP2, NEMO, ZC2HC9	ENSG00000269335	Inhibitor of nuclear factor kappa B kinase subunit gamma	X	154541199-154565046	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA000426, CAB010373	Uncertain		Enhanced	Cytosol		Expressed in all	Expressed in all			spleen: 37.2	Expressed in all		
IKZF2	Helios, ZNFN1A2	ENSG00000030419	IKAROS family zinc finger 2	2	212999691-213152427	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059142	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Mixed	Mixed			esophagus: 21.4	Cell line enhanced		MOLT-4: 24.8;RT4: 22.8
IKZF3	Aiolos, ZNFN1A3	ENSG00000161405	IKAROS family zinc finger 3	17	39757715-39864188	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017105, HPA024377	Enhanced		Uncertain	Plasma membrane<br>Cytosol	Cervical cancer:6.85e-6 (favourable), Head and neck cancer:4.16e-4 (favourable), Melanoma:5.42e-4 (favourable), Renal cancer:7.38e-4 (unfavourable)	Mixed	Tissue enhanced		lymph node: 44.7;spleen: 31.7;tonsil: 39.2	appendix: 25.5	Cell line enhanced		Daudi: 50.3;Karpas-707: 25.9;U-266/70: 32.8;U-266/84: 35.9;U-698: 78.2
IKZF4	Eos, ZNFN1A4	ENSG00000123411	IKAROS family zinc finger 4	12	56007659-56038435	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046270, HPA049016	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Lung cancer:3.46e-4 (favourable), Pancreatic cancer:4.37e-4 (favourable)	Mixed	Mixed			parathyroid gland: 17.0	Cell line enhanced		HDLM-2: 33.6
IKZF5	FLJ22973, Pegasus, ZNFN1A5	ENSG00000095574	IKAROS family zinc finger 5	10	122990806-123008817	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015297, HPA051574			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 21.3	Expressed in all		
IL15	IL-15, MGC9721	ENSG00000164136	Interleukin 15	4	141636599-141733987	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004457, HPA037738	Approved		Supported	Nucleoplasm<br>Nuclear speckles		Mixed	Mixed			spleen: 18.8	Mixed		
IL16	FLJ16806, FLJ42735, HsT19289, IL-16, LCF, prIL-16	ENSG00000172349	Interleukin 16	15	81159575-81314058	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005247, HPA018467	Enhanced		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		lymph node: 154.4;tonsil: 124.0	spleen: 118.2	Cell line enhanced		HEL: 26.3;HMC-1: 44.5;RPMI-8226: 34.9;U-266/70: 45.9;U-937: 27.4
IL17REL	FLJ41993	ENSG00000188263	Interleukin 17 receptor E like	22	49994513-50012659	Predicted intracellular proteins	Evidence at protein level	HPA045546	Supported					Mixed	Tissue enhanced		appendix: 3.1;lymph node: 2.4;tonsil: 4.0	stomach: 2.1	Not detected		
IL18	IGIF, IL-18, IL-1g, IL1F4	ENSG00000150782	Interleukin 18	11	112143251-112164117	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003980, CAB007772	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Colorectal cancer:2.78e-4 (favourable)	Expressed in all	Tissue enhanced		esophagus: 133.0;skin: 171.5	lymph node: 71.9	Cell line enhanced		CAPAN-2: 155.6;HaCaT: 143.7;hTCEpi: 132.7;U-2 OS: 214.0
IL1A	IL-1A, IL1, IL1-ALPHA, IL1F1	ENSG00000115008	Interleukin 1 alpha	2	112773915-112784590	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level						Lung cancer:1.54e-4 (unfavourable), Stomach cancer:4.03e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 12.8;testis: 18.6	tonsil: 7.4	Cell line enhanced		HBEC3-KT: 302.4;hTCEpi: 147.6;hTERT-HME1: 205.8
IL1B	IL-1B, IL1-BETA, IL1F2	ENSG00000125538	Interleukin 1 beta	2	112829751-112836903	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.49e-5 (unfavourable), Cervical cancer:1.31e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 68.0;bone marrow: 106.4	adipose tissue: 53.4	Cell line enhanced		BJ hTERT+: 478.0;HBEC3-KT: 193.4;HMC-1: 189.1;hTEC/SVTERT24-B: 291.2;U-87 MG: 514.6
IL1F10	FKSG75, IL-1F10, IL-1HY2, IL1-theta, MGC11983, MGC119832, MGC119833	ENSG00000136697	Interleukin 1 family member 10 (theta)	2	113067970-113075850	Predicted intracellular proteins	Evidence at protein level	HPA059813	Approved					Tissue enhanced	Group enriched	5	skin: 4.8;tonsil: 2.5	breast: 0.7	Not detected		
IL33	C9orf26, DKFZp586H0523, DVS27, IL1F11, NF-HEV	ENSG00000137033	Interleukin 33	9	6215786-6257983	Predicted intracellular proteins	Evidence at protein level	CAB007057, HPA024426	Supported				Breast cancer:4.42e-4 (favourable)	Expressed in all	Mixed			placenta: 87.7	Cell line enriched	10	U-2197: 151.4
IL36A	FIL1, FIL1E, IL-1F6, IL1(EPSILON), IL1F6, MGC129552, MGC129553	ENSG00000136694	Interleukin 36, alpha	2	113005461-113008044	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	1237	esophagus: 459.4;tonsil: 105.4	endometrium: 0.2	Cell line enhanced		MOLT-4: 1.0
IL36B	FIL1, FILI-(ETA), IL-1F8, IL-1H2, IL1-ETA, IL1F8, IL1H2, MGC126880, MGC126882	ENSG00000136696	Interleukin 36, beta	2	113022091-113052867	Predicted intracellular proteins	Evidence at transcript level	HPA035664	Uncertain					Tissue enhanced	Tissue enhanced		esophagus: 2.2;skin: 7.3;tonsil: 3.4	breast: 1.2	Cell line enriched	21	U-87 MG: 71.9
IL36G	IL-1F9, IL-1H1, IL-1RP2, IL1E, IL1F9, IL1H1	ENSG00000136688	Interleukin 36, gamma	2	112973203-112985665	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	10	skin: 15.8;tonsil: 39.2	esophagus: 2.7	Not detected		
IL36RN	FIL1, FIL1(DELTA), FIL1D, IL-1F5, IL1F5, IL1HY1, IL1L1, IL1RP3, IL36RA, MGC29840	ENSG00000136695	Interleukin 36 receptor antagonist	2	113058638-113065382	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034542	Uncertain					Tissue enriched	Group enriched	7	esophagus: 17.2;skin: 40.7;tonsil: 38.1	placenta: 4.7	Group enriched	18	BEWO: 25.1;U-87 MG: 19.4
IL37	FIL1, FIL1(ZETA), FIL1Z, IL-1F7, IL-1H4, IL-1RP1, IL1F7	ENSG00000125571	Interleukin 37	2	112912971-112918882	Predicted intracellular proteins	Evidence at protein level	HPA054371, HPA057950	Approved		Supported	Nucleoplasm<br>Vesicles		Tissue enriched	Tissue enriched	7	skin: 162.7	breast: 22.3	Cell line enhanced		BJ hTERT+: 2.2;PC-3: 5.5;RT4: 2.5
ILF2	NF45	ENSG00000143621	Interleukin enhancer binding factor 2	1	153661788-153671048	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007484	Supported		Enhanced	Nucleus<br>Nucleoli	Liver cancer:5.71e-8 (unfavourable), Renal cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 211.7	Expressed in all		
ILF3	DRBP76, MPHOSPH4, MPP4, NF90, NFAR-1	ENSG00000129351	Interleukin enhancer binding factor 3	19	10654261-10692417	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001897	Supported		Supported	Nucleoplasm<br>Nucleoli<br>Mitochondria	Melanoma:1.57e-4 (unfavourable), Renal cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 149.4	Expressed in all		
ILK		ENSG00000166333	Integrin linked kinase	11	6603708-6610874	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004041, HPA048437	Enhanced		Enhanced	Cell Junctions<br>Focal adhesion sites	Renal cancer:2.44e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 558.8	Expressed in all		
ILKAP	DKFZP434J2031, FLJ10181, PPM1O	ENSG00000132323	ILK associated serine/threonine phosphatase	2	238170401-238203729	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004752, HPA056099	Uncertain		Approved	Nucleoplasm	Renal cancer:9.89e-6 (unfavourable), Liver cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.0	Expressed in all		
IMMP1L	FLJ25059, IMMP1	ENSG00000148950	Inner mitochondrial membrane peptidase subunit 1	11	31432401-31509645	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA058308	Approved				Pancreatic cancer:6.72e-4 (favourable), Liver cancer:7.97e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 39.2	Expressed in all		
IMMT	HMP, Mic60, MINOS2, P87, P89	ENSG00000132305	Inner membrane mitochondrial protein	2	86143932-86195770	Predicted intracellular proteins	Evidence at protein level	CAB022439, HPA036164, HPA036165	Enhanced		Enhanced	Mitochondria	Renal cancer:3.51e-6 (favourable), Endometrial cancer:1.06e-4 (unfavourable), Liver cancer:2.03e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 107.3	Expressed in all		
IMP3	BRMS2, C15orf12, FLJ10968, MRPS4	ENSG00000177971	IMP3, U3 small nucleolar ribonucleoprotein	15	75639085-75648706	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA060955, HPA061177			Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			spleen: 47.6	Expressed in all		
IMPA1	IMPA	ENSG00000133731	Inositol monophosphatase 1	8	81657961-81686693	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037489	Approved		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			testis: 72.0	Expressed in all		
IMPA2		ENSG00000141401	Inositol monophosphatase 2	18	11981025-12030883	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029561	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			skin: 129.8	Cell line enhanced		BEWO: 240.8;SiHa: 163.4
IMPACT	RWDD5	ENSG00000154059	Impact RWD domain protein	18	24426616-24453535	Predicted intracellular proteins	Evidence at protein level	HPA041045, HPA041968	Approved		Approved	Nucleoplasm	Renal cancer:7.90e-4 (favourable)	Expressed in all	Expressed in all			testis: 65.0	Mixed		
IMPDH1	LCA11, RP10, sWSS2608	ENSG00000106348	Inosine monophosphate dehydrogenase 1	7	128392277-128410252	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001400	Approved		Supported	Cytosol<br>Rods & Rings	Renal cancer:1.78e-12 (unfavourable), Liver cancer:1.12e-7 (unfavourable), Urothelial cancer:3.72e-5 (unfavourable), Glioma:1.17e-4 (unfavourable), Cervical cancer:3.87e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 47.2	Expressed in all		
IMPDH2		ENSG00000178035	Inosine monophosphate dehydrogenase 2	3	49024325-49029408	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001400, CAB020717	Approved		Enhanced	Cytosol<br>Rods & Rings	Liver cancer:3.22e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 422.5	Expressed in all		
INA	NEF5, NF-66	ENSG00000148798	Internexin neuronal intermediate filament protein alpha	10	103277163-103290351	Predicted intracellular proteins	Evidence at protein level	CAB002059, HPA008057	Enhanced	Supported	Supported	Nucleoplasm<br>Nuclear membrane<br>Intermediate filaments		Tissue enhanced	Tissue enriched	6	cerebral cortex: 89.0	adrenal gland: 16.0	Cell line enhanced		NTERA-2: 53.4;SCLC-21H: 122.4;SH-SY5Y: 62.7;SiHa: 76.3
INAFM1	PRR24	ENSG00000257704	InaF motif containing 1	19	47274453-47275707	Predicted intracellular proteins	Evidence at transcript level	HPA064015	Uncertain				Colorectal cancer:3.20e-5 (unfavourable), Renal cancer:3.04e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 23.3	Expressed in all		
INCA1		ENSG00000196388	Inhibitor of CDK, cyclin A1 interacting protein 1	17	4988130-4997610	Predicted intracellular proteins	Evidence at protein level	HPA044359, HPA052401	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:3.61e-5 (favourable)	Expressed in all	Tissue enhanced		testis: 54.0	thyroid gland: 13.4	Mixed		
INCENP	FLJ31633	ENSG00000149503	Inner centromere protein	11	62123973-62153163	Predicted intracellular proteins	Evidence at protein level	CAB013292, HPA051339, HPA070550	Enhanced		Supported	Nucleus<br>Nuclear bodies<br>Midbody	Pancreatic cancer:5.76e-5 (unfavourable), Liver cancer:1.25e-4 (unfavourable), Lung cancer:8.58e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 12.7	Expressed in all		
INF2	C14orf151, C14orf173, MGC13251	ENSG00000203485	Inverted formin, FH2 and WH2 domain containing	14	104689606-104722535	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000724	Approved		Approved	Nuclear bodies<br>Endoplasmic reticulum	Liver cancer:8.18e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 55.6	Expressed in all		
ING1	p24ING1c, p33, p33ING1, p33ING1b, p47, p47ING1a	ENSG00000153487	Inhibitor of growth family member 1	13	110712736-110723339	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016136, CAB017773, HPA052591	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:5.81e-4 (favourable)	Expressed in all	Expressed in all			ovary: 20.9	Expressed in all		
ING2	ING1L, p33ING2	ENSG00000168556	Inhibitor of growth family member 2	4	183504994-183511096	Predicted intracellular proteins	Evidence at protein level	HPA019486, HPA021517	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:5.43e-4 (favourable), Liver cancer:8.87e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 63.3	Expressed in all		
ING3	Eaf4, FLJ20089, MEAF4, p47ING3	ENSG00000071243	Inhibitor of growth family member 3	7	120950749-120977216	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA067388, HPA067575	Approved		Supported	Nucleus		Expressed in all	Expressed in all			bone marrow: 50.3	Expressed in all		
ING4	my036, p29ING4	ENSG00000111653	Inhibitor of growth family member 4	12	6650280-6663148	Predicted intracellular proteins	Evidence at protein level	HPA031817, HPA057338	Approved		Supported	Nucleus	Lung cancer:5.16e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 43.7	Expressed in all		
ING5	FLJ23842, p28ING5	ENSG00000168395	Inhibitor of growth family member 5	2	241687085-241729478	Predicted intracellular proteins	Evidence at protein level	HPA042685	Approved				Liver cancer:2.86e-5 (unfavourable), Pancreatic cancer:1.60e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.7	Expressed in all		
INIP	C9orf80, HSPC043, hSSBIP1, MISE, SOSS-C	ENSG00000148153	INTS3 and NABP interacting protein	9	112683926-112718236	Predicted intracellular proteins	Evidence at protein level	HPA020382	Approved		Supported	Nucleoplasm	Renal cancer:2.00e-8 (favourable), Stomach cancer:2.53e-4 (favourable), Breast cancer:7.08e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 17.5	Expressed in all		
INMT		ENSG00000241644	Indolethylamine N-methyltransferase	7	30697985-30757602	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA061343			Approved	Golgi apparatus<br>Vesicles	Liver cancer:5.72e-4 (favourable)	Tissue enhanced	Tissue enhanced		lung: 144.8	seminal vesicle: 66.2	Group enriched	6	CACO-2: 13.8;HHSteC: 5.7
INO80	hINO80, Ino80, INO80A, INOC1, KIAA1259	ENSG00000128908	INO80 complex subunit	15	40978880-41116354	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041417, HPA041484			Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.30e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 18.2	Expressed in all		
INO80B	hIes2, HMGA1L4, HMGIYL4, IES2, PAP-1BP, PAPA-1, ZNHIT4	ENSG00000115274	INO80 complex subunit B	2	74455023-74457960	Predicted intracellular proteins	Evidence at protein level	HPA070644			Supported	Nucleus<br>Nucleoli	Renal cancer:1.56e-5 (unfavourable), Breast cancer:2.89e-4 (favourable), Stomach cancer:8.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.2	Expressed in all		
INO80D	FLJ20309	ENSG00000114933	INO80 complex subunit D	2	205993721-206086303	Predicted intracellular proteins	Evidence at protein level	HPA043976	Approved				Head and neck cancer:5.53e-4 (favourable)	Expressed in all	Mixed			bone marrow: 11.3	Mixed		
INO80E	CCDC95, FLJ90652	ENSG00000169592	INO80 complex subunit E	16	29995294-30005793	Predicted intracellular proteins	Evidence at protein level	HPA043146	Approved		Supported	Nucleoplasm<br>Nucleoli		Expressed in all	Expressed in all			fallopian tube: 64.2	Expressed in all		
INPP1		ENSG00000151689	Inositol polyphosphate-1-phosphatase	2	190343470-190371665	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036698, HPA036699	Supported		Approved	Vesicles	Thyroid cancer:1.12e-5 (favourable), Urothelial cancer:5.70e-4 (favourable)	Expressed in all	Expressed in all			testis: 73.6	Mixed		
INPP5B		ENSG00000204084	Inositol polyphosphate-5-phosphatase B	1	37860697-37947057	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028803	Approved		Approved	Cytosol	Renal cancer:6.11e-5 (unfavourable), Head and neck cancer:1.11e-4 (favourable), Pancreatic cancer:5.33e-4 (favourable)	Expressed in all	Expressed in all			ovary: 26.3	Expressed in all		
INPP5D	hp51CN, SHIP, SHIP1	ENSG00000168918	Inositol polyphosphate-5-phosphatase D	2	233059967-233207903	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016300, HPA070455	Uncertain		Approved	Cytosol	Head and neck cancer:2.03e-5 (favourable)	Expressed in all	Mixed			lymph node: 39.3	Cell line enhanced		HEL: 84.8;HMC-1: 83.7;hTCEpi: 63.0;NB-4: 56.4
INPP5E	CORS1, JBTS1, pharbin, PPI5PIV	ENSG00000148384	Inositol polyphosphate-5-phosphatase E	9	136428619-136439823	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA065758	Approved				Pancreatic cancer:1.82e-4 (favourable)	Expressed in all	Expressed in all			testis: 15.9	Expressed in all		
INPP5K	SKIP	ENSG00000132376	Inositol polyphosphate-5-phosphatase K	17	1494571-1516888	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031044	Uncertain				Pancreatic cancer:1.47e-6 (favourable), Endometrial cancer:2.33e-5 (favourable), Cervical cancer:3.91e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 32.2	Expressed in all		
INPPL1	SHIP2	ENSG00000165458	Inositol polyphosphate phosphatase like 1	11	72223701-72239105	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037601	Approved		Supported	Golgi apparatus<br>Cytosol	Liver cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 64.3	Expressed in all		
INSC		ENSG00000188487	Inscuteable homolog (Drosophila)	11	15112424-15247208	Predicted intracellular proteins	Evidence at protein level	HPA039769	Enhanced					Tissue enhanced	Mixed			small intestine: 2.7	Cell line enhanced		ASC TERT1: 8.1;hTERT-HME1: 4.6;TIME: 10.5
INSM1	IA-1, IA1	ENSG00000173404	INSM transcriptional repressor 1	20	20368121-20370949	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 9.3;stomach: 5.6	duodenum: 3.0	Cell line enriched	32	SCLC-21H: 438.4
INSM2	IA-6, Mlt1	ENSG00000168348	INSM transcriptional repressor 2	14	35534042-35537054	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044885, HPA051925	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enhanced		cerebral cortex: 1.3	testis: 0.7	Cell line enriched	121	SH-SY5Y: 115.7
INTS10	C8orf35, FLJ10569, INT10	ENSG00000104613	Integrator complex subunit 10	8	19817140-19852083	Predicted intracellular proteins	Evidence at protein level	HPA039129, HPA050570	Uncertain		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.22e-4 (favourable), Colorectal cancer:4.00e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 64.9	Expressed in all		
INTS11	CPSF3L, CPSF73L, FLJ20542, INT11, RC-68	ENSG00000127054	Integrator complex subunit 11	1	1311585-1324691	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028379, HPA029025	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:7.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 77.0	Expressed in all		
INTS12	INT12, PHF22, SBBI22	ENSG00000138785	Integrator complex subunit 12	4	105682627-105895986	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA035772, HPA041814	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Liver cancer:2.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 33.5	Expressed in all		
INTS13	ASUN, C12orf11, FLJ10637, Mat89Bb, NET48, SPATA30	ENSG00000064102	Integrator complex subunit 13	12	26905181-26938326	Predicted intracellular proteins	Evidence at protein level	HPA039543	Uncertain				Liver cancer:1.17e-10 (unfavourable), Renal cancer:3.16e-6 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 23.1	Expressed in all		
INTS4	INT4, MGC16733, MST093	ENSG00000149262	Integrator complex subunit 4	11	77878720-77994678	Predicted intracellular proteins	Evidence at protein level	HPA042378	Uncertain		Approved	Nucleoli	Liver cancer:9.44e-6 (unfavourable), Thyroid cancer:9.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.8	Expressed in all		
INTS5	INT5, KIAA1698	ENSG00000185085	Integrator complex subunit 5	11	62646848-62653302	Predicted intracellular proteins	Evidence at protein level	HPA056915	Uncertain		Supported	Nucleus	Renal cancer:8.44e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 21.0	Expressed in all		
INTS6	DBI-1, DDX26, DDX26A, DICE1, HDB, INT6, Notchl2	ENSG00000102786	Integrator complex subunit 6	13	51354077-51454264	Predicted intracellular proteins	Evidence at protein level	HPA001552, HPA001846	Supported		Enhanced	Nucleoplasm<br>Actin filaments		Expressed in all	Expressed in all			testis: 103.4	Expressed in all		
INTS6L	DDX26B, FLJ41215	ENSG00000165359	Integrator complex subunit 6 like	X	135520643-135582510	Predicted intracellular proteins	Evidence at protein level	HPA001552, HPA013200, HPA013335, HPA030747	Uncertain		Supported	Centrosome<br>Mitochondria	Renal cancer:4.28e-8 (unfavourable), Urothelial cancer:2.94e-4 (favourable), Cervical cancer:5.39e-4 (favourable), Pancreatic cancer:5.54e-4 (favourable)	Mixed	Mixed			lymph node: 14.6	Mixed		
INTS7	C1orf73, DKFZP434B168, INT7	ENSG00000143493	Integrator complex subunit 7	1	211940399-212035542	Predicted intracellular proteins	Evidence at protein level	HPA072611			Supported	Nuclear bodies	Renal cancer:1.42e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 38.8	thyroid gland: 11.2	Expressed in all		
INTS8	C8orf52, FLJ20530, INT8, MGC131633	ENSG00000164941	Integrator complex subunit 8	8	94813311-94881746	Predicted intracellular proteins	Evidence at protein level	HPA057299	Approved		Approved	Nucleoplasm	Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.54e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 57.3	Expressed in all		
INTS9	CPSF2L, FLJ10871, RC-74	ENSG00000104299	Integrator complex subunit 9	8	28767661-28890242	Predicted intracellular proteins	Evidence at protein level	HPA051615, HPA066822			Enhanced	Nucleoplasm	Renal cancer:1.91e-5 (favourable), Lung cancer:7.71e-4 (favourable), Endometrial cancer:9.45e-4 (favourable)	Expressed in all	Expressed in all			testis: 19.8	Expressed in all		
INTU	KIAA1284, PDZD6, PDZK6	ENSG00000164066	Inturned planar cell polarity protein	4	127623271-127726737	Predicted intracellular proteins	Evidence at protein level	HPA036714, HPA036715	Enhanced		Approved	Vesicles		Mixed	Mixed			epididymis: 6.4	Mixed		
INVS	NPHP2	ENSG00000119509	Inversin	9	100099256-100301000	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049994			Approved	Cytosol	Head and neck cancer:6.35e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 17.7	Expressed in all		
IP6K1	IHPK1, KIAA0263	ENSG00000176095	Inositol hexakisphosphate kinase 1	3	49724294-49786542	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040825	Approved		Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Renal cancer:5.77e-5 (favourable), Head and neck cancer:2.08e-4 (favourable), Pancreatic cancer:6.85e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 47.5	Expressed in all		
IP6K2	IHPK2	ENSG00000068745	Inositol hexakisphosphate kinase 2	3	48688003-48740353	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007532, HPA070811	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions	Breast cancer:1.25e-4 (favourable), Urothelial cancer:1.83e-4 (favourable), Lung cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 131.1	Expressed in all		
IP6K3	IHPK3, INSP6K3	ENSG00000161896	Inositol hexakisphosphate kinase 3	6	33721670-33746905	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053644	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.09e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 32.4;thyroid gland: 21.9	heart muscle: 9.1	Cell line enhanced		HHSteC: 18.4;LHCN-M2: 30.1;RH-30: 15.3
IPCEF1	KIAA0403, PIP3-E	ENSG00000074706	Interaction protein for cytohesin exchange factors 1	6	154154496-154356792	Predicted intracellular proteins	Evidence at protein level	HPA028708, HPA028710	Approved		Approved	Nucleoli<br>Nuclear speckles<br>Plasma membrane<br>Cytoplasmic bodies		Mixed	Tissue enhanced		thyroid gland: 66.3	cerebral cortex: 24.9	Cell line enhanced		HMC-1: 17.9;THP-1: 7.2;U-937: 8.8
IPMK		ENSG00000151151	Inositol polyphosphate multikinase	10	58191517-58267934	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037837, HPA057542	Uncertain		Enhanced	Nucleus	Renal cancer:9.96e-7 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 28.3	Mixed		
IPO13	IMP13, KIAA0724, RANBP13	ENSG00000117408	Importin 13	1	43946939-43968022	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB070425	Uncertain				Liver cancer:8.26e-7 (unfavourable), Pancreatic cancer:2.21e-4 (favourable)	Expressed in all	Expressed in all			testis: 66.6	Expressed in all		
IPO4	FLJ23338, Imp4	ENSG00000196497	Importin 4	14	24180219-24188964	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA039043, HPA064572	Uncertain		Approved	Cytosol	Liver cancer:8.08e-6 (unfavourable), Renal cancer:3.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 17.4	skin: 5.3	Mixed		
IPO5	IMB3, KPNB3, MGC2068, Pse1, RANBP5	ENSG00000065150	Importin 5	13	97953658-98024297	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009110, HPA040983, HPA056548	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 384.5	Expressed in all		
IPO7	Imp7, RANBP7	ENSG00000205339	Importin 7	11	9384622-9448126	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA019002, HPA056590	Approved	Approved	Enhanced	Nucleoplasm<br>Cytosol	Pancreatic cancer:8.38e-6 (unfavourable), Cervical cancer:4.98e-4 (unfavourable), Liver cancer:6.57e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 89.8	Expressed in all		
IPO8	IMP8, RANBP8	ENSG00000133704	Importin 8	12	30628988-30695986	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018439, HPA023765	Uncertain		Supported	Nucleus	Renal cancer:8.62e-5 (favourable), Liver cancer:1.35e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 120.8	Expressed in all		
IPP	KLHL27	ENSG00000197429	Intracisternal A particle-promoted polypeptide	1	45694324-45750650	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.11e-4 (favourable), Liver cancer:2.27e-4 (unfavourable), Colorectal cancer:9.11e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 19.8	Mixed		
IPPK	C9orf12, FLJ13163, INSP5K2, IP5K, IPK1	ENSG00000127080	Inositol-pentakisphosphate 2-kinase	9	92613184-92670265	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020603	Uncertain		Approved	Cytosol	Urothelial cancer:1.28e-4 (unfavourable)	Mixed	Mixed			skin: 34.2	Expressed in all		
IQCA1	DRC11, FLJ22527, IQCA	ENSG00000132321	IQ motif containing with AAA domain 1	2	236324147-236507542	Predicted intracellular proteins	Evidence at transcript level	HPA057320			Uncertain	Nucleus	Renal cancer:2.54e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 17.9;thyroid gland: 32.3	cerebral cortex: 11.4	Cell line enhanced		EFO-21: 3.1;HBEC3-KT: 2.2;HeLa: 2.5;U-2 OS: 12.9
IQCA1L	IQCA1P1, TCAG_9762	ENSG00000278685	IQ motif containing with AAA domain 1 like	7	151190873-151205496	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	41	testis: 4.0	all non-specific tissues: 0.0	Not detected		
IQCB1	KIAA0036, NPHP5, SLSN5	ENSG00000173226	IQ motif containing B1	3	121769763-121835079	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042028	Approved		Supported	Microtubules<br>Cytokinetic bridge<br>Mitotic spindle	Liver cancer:3.08e-5 (unfavourable), Cervical cancer:1.77e-4 (favourable), Lung cancer:3.67e-4 (favourable)	Expressed in all	Expressed in all			testis: 52.5	Expressed in all		
IQCC	FLJ10547	ENSG00000160051	IQ motif containing C	1	32205661-32208687	Predicted intracellular proteins	Evidence at protein level	HPA028602, HPA028686	Approved		Supported	Vesicles	Pancreatic cancer:8.23e-5 (favourable), Testis cancer:3.79e-4 (favourable), Lung cancer:5.65e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 11.6	thyroid gland: 6.0	Mixed		
IQCD	CFAP84, DRC10	ENSG00000166578	IQ motif containing D	12	113195441-113221094	Predicted intracellular proteins	Evidence at protein level	HPA046810, HPA048782	Supported		Approved	Nucleus	Pancreatic cancer:3.90e-4 (favourable)	Mixed	Group enriched	6	fallopian tube: 34.8;testis: 65.4	parathyroid gland: 7.7	Cell line enhanced		BJ hTERT+: 22.7
IQCE	KIAA1023	ENSG00000106012	IQ motif containing E	7	2558972-2614734	Predicted intracellular proteins	Evidence at protein level	HPA019515	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:5.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 51.5	Mixed		
IQCF2		ENSG00000184345	IQ motif containing F2	3	51861629-51863424	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	96	testis: 9.6	all non-specific tissues: 0.0	Not detected		
IQCG	CFAP122, DKFZp434B227, DRC9	ENSG00000114473	IQ motif containing G	3	197889075-197960142	Predicted intracellular proteins	Evidence at protein level	HPA042787, HPA051981	Enhanced		Approved	Actin filaments<br>Cytosol		Expressed in all	Group enriched	6	fallopian tube: 83.6;testis: 78.8	thyroid gland: 13.9	Expressed in all		
IQCH	FLJ12476	ENSG00000103599	IQ motif containing H	15	67254800-67502260	Predicted intracellular proteins	Evidence at protein level	HPA040845	Uncertain		Approved	Cytosol		Mixed	Tissue enhanced		fallopian tube: 10.8;testis: 21.1	parathyroid gland,thyroid gland: 6.8	Mixed		
IQCJ		ENSG00000214216	IQ motif containing J	3	158962928-159266307	Predicted intracellular proteins	Evidence at transcript level	HPA052835	Uncertain					Not detected	Not detected			testis: 0.9	Cell line enriched	17	Daudi: 3.7
IQCJ-SCHIP1		ENSG00000283154	IQCJ-SCHIP1 readthrough	3	158962235-159897366	Predicted intracellular proteins	Evidence at protein level	HPA003243, HPA003445	Approved		Approved	Cytosol			Tissue enhanced		cerebral cortex: 99.0	smooth muscle: 36.8	Mixed		
IQCK	FLJ36575, MGC35048	ENSG00000174628	IQ motif containing K	16	19716456-19858467	Predicted intracellular proteins	Evidence at transcript level	HPA026792, HPA048786	Approved		Approved	Nuclear speckles<br>Cytosol		Mixed	Mixed			testis: 33.1	Mixed		
IQGAP1	HUMORFA01, KIAA0051, p195, SAR1	ENSG00000140575	IQ motif containing GTPase activating protein 1	15	90388218-90502243	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013302, HPA014055	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Pancreatic cancer:5.67e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 120.4	Expressed in all		
IQGAP2		ENSG00000145703	IQ motif containing GTPase activating protein 2	5	76403249-76708132	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004241, HPA037403, HPA037404	Uncertain		Approved	Vesicles<br>Plasma membrane	Renal cancer:9.44e-12 (favourable), Liver cancer:5.65e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 126.8	testis: 92.1	Cell line enhanced		CACO-2: 61.1;HMC-1: 186.1;RPMI-8226: 56.3
IQGAP3		ENSG00000183856	IQ motif containing GTPase activating protein 3	1	156525405-156572604	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030142, HPA030143	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.94e-6 (unfavourable)	Expressed in all	Mixed			bone marrow: 9.9	Mixed		
IQSEC1	ARF-GEP100, BRAG2, GEP100, KIAA0763	ENSG00000144711	IQ motif and Sec7 domain 1	3	12897220-13073117	Predicted intracellular proteins	Evidence at protein level	HPA038143, HPA038144	Uncertain		Approved	Nucleoli<br>Vesicles	Renal cancer:3.58e-6 (favourable), Breast cancer:3.03e-5 (unfavourable), Pancreatic cancer:9.07e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 83.3	Cell line enhanced		BEWO: 75.1
IQSEC2	KIAA0522, MRX1, MRX18, MRX78	ENSG00000124313	IQ motif and Sec7 domain 2	X	53225828-53321328	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003973			Approved	Vesicles	Renal cancer:2.00e-4 (unfavourable), Urothelial cancer:2.38e-4 (favourable)	Mixed	Mixed			cerebral cortex: 38.5	Cell line enhanced		A549: 43.0
IQSEC3	KIAA1110, MGC30156	ENSG00000120645	IQ motif and Sec7 domain 3	12	66765-178460	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 16.1	fallopian tube: 5.4	Cell line enhanced		HEL: 6.3;U-266/70: 6.9;U-266/84: 1.6
IQUB	FLJ35834	ENSG00000164675	IQ motif and ubiquitin domain containing	7	123452400-123535077	Predicted intracellular proteins	Evidence at protein level	HPA049626			Approved	Nuclear speckles<br>Intermediate filaments<br>Cytosol		Mixed	Tissue enriched	8	testis: 66.3	fallopian tube: 8.2	Cell line enhanced		RPTEC TERT1: 1.8
IRAK1	IRAK, pelle	ENSG00000184216	Interleukin 1 receptor associated kinase 1	X	154010500-154019980	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004461, HPA054476	Supported		Supported	Nucleus<br>Cytosol	Renal cancer:2.06e-4 (unfavourable), Liver cancer:3.03e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 51.0	Expressed in all		
IRAK1BP1	AIP70, SIMPL	ENSG00000146243	Interleukin 1 receptor associated kinase 1 binding protein 1	6	78867472-78946440	Predicted intracellular proteins	Evidence at protein level	HPA035742, HPA035743	Uncertain		Approved	Vesicles		Mixed	Tissue enriched	8	bone marrow: 59.8	testis,thyroid gland: 7.0	Mixed		
IRAK2		ENSG00000134070	Interleukin 1 receptor associated kinase 2	3	10164865-10243743	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB013483, HPA050520	Uncertain		Approved	Vesicles	Urothelial cancer:6.60e-5 (favourable), Pancreatic cancer:2.26e-4 (unfavourable), Liver cancer:8.35e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 14.6	Cell line enhanced		BEWO: 31.5;BJ hTERT+: 28.0;CAPAN-2: 30.8;RT4: 38.6
IRAK4	NY-REN-64	ENSG00000198001	Interleukin 1 receptor associated kinase 4	12	43758944-43789543	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016685, CAB022077	Uncertain		Approved	Nucleoli<br>Microtubules<br>Cytosol	Endometrial cancer:3.46e-5 (favourable), Urothelial cancer:4.42e-5 (favourable)	Expressed in all	Mixed			lymph node: 20.3	Expressed in all		
IREB2	IRP2	ENSG00000136381	Iron responsive element binding protein 2	15	78437431-78501456	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032885, HPA040371, HPA068982	Uncertain		Approved	Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 48.0	Expressed in all		
IRF1	MAR	ENSG00000125347	Interferon regulatory factor 1	5	132481609-132490798	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011662, HPA063131	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.09e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 135.0	Expressed in all		
IRF2		ENSG00000168310	Interferon regulatory factor 2	4	184387713-184474580	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030813, CAB032306, HPA057327	Supported		Enhanced	Nucleoplasm<br>Cytosol	Breast cancer:6.95e-5 (favourable), Thyroid cancer:8.34e-5 (favourable)	Expressed in all	Expressed in all			spleen: 74.2	Expressed in all		
IRF2BP1	DKFZP434M154, IRF-2BP1	ENSG00000170604	Interferon regulatory factor 2 binding protein 1	19	45883607-45886170	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042164, HPA049480	Approved		Supported	Nucleoplasm	Renal cancer:3.85e-5 (favourable), Pancreatic cancer:2.32e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 13.2	Expressed in all		
IRF2BP2	IRF-2BP2	ENSG00000168264	Interferon regulatory factor 2 binding protein 2	1	234604269-234609525	Predicted intracellular proteins	Evidence at protein level	HPA027815, HPA062269	Approved		Enhanced	Nucleoplasm	Renal cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 98.7	Cell line enhanced		THP-1: 189.9
IRF2BPL	C14orf4, EAP1, KIAA1865	ENSG00000119669	Interferon regulatory factor 2 binding protein like	14	77024543-77028699	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050862, HPA061333	Approved		Enhanced	Nucleoplasm	Endometrial cancer:5.52e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.5	Expressed in all		
IRF3		ENSG00000126456	Interferon regulatory factor 3	19	49659569-49665875	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004895, CAB013018	Approved		Supported	Cytosol	Renal cancer:1.56e-7 (unfavourable), Urothelial cancer:3.61e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 47.2	Expressed in all		
IRF4	LSIRF, MUM1	ENSG00000137265	Interferon regulatory factor 4	6	391739-411447	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002038, HPA002698, CAB013508	Enhanced		Supported	Nucleoplasm	Head and neck cancer:1.64e-6 (favourable), Breast cancer:6.44e-4 (favourable)	Tissue enriched	Tissue enhanced		lymph node: 27.1	tonsil: 24.1	Group enriched	5	HDLM-2: 204.2;Karpas-707: 141.1;RPMI-8226: 136.6;U-266/70: 134.4;U-266/84: 98.3;U-698: 40.9;WM-115: 106.9
IRF5		ENSG00000128604	Interferon regulatory factor 5	7	128937612-128950035	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046700	Enhanced					Expressed in all	Mixed			spleen: 23.9	Cell line enhanced		HDLM-2: 121.5;RPMI-8226: 65.7;U-937: 50.3
IRF6	LPS, OFC6, VWS, VWS1	ENSG00000117595	Interferon regulatory factor 6	1	209785623-209806175	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063121, HPA076162	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:0.00e+0 (favourable)	Mixed	Mixed			skin: 84.0	Cell line enhanced		HaCaT: 216.2;HBEC3-KT: 62.1;hTCEpi: 129.2;hTERT-HME1: 67.4;RT4: 69.8
IRF7		ENSG00000185507	Interferon regulatory factor 7	11	612553-615999	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017694, HPA052757	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.71e-10 (unfavourable)	Expressed in all	Mixed			bone marrow: 1.8	Cell line enhanced		EFO-21: 3.4;Karpas-707: 4.6;SCLC-21H: 3.7
IRF8	ICSBP, ICSBP1, IRF-8	ENSG00000140968	Interferon regulatory factor 8	16	85898803-85922609	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002267, HPA002531, CAB013480	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Tissue enhanced		lymph node: 297.7;spleen: 205.7;tonsil: 232.5	appendix: 118.0	Cell line enhanced		Daudi: 177.0;THP-1: 280.9;U-698: 672.1;U-937: 108.3
IRF9	ISGF3G	ENSG00000213928	Interferon regulatory factor 9	14	24161053-24166565	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001862	Approved		Supported	Cytosol	Renal cancer:7.58e-8 (unfavourable), Urothelial cancer:9.92e-4 (favourable)	Expressed in all	Expressed in all			spleen: 94.1	Expressed in all		
IRGC	CINEMA, Iigp5, IRGC1	ENSG00000124449	Immunity related GTPase cinema	19	43716010-43720021	Predicted intracellular proteins	Evidence at protein level	HPA046769, HPA060064	Enhanced					Not detected	Tissue enriched	627	testis: 62.6	all non-specific tissues: 0.0	Not detected		
IRGM	IFI1, IRGM1, LRG-47, LRG47	ENSG00000237693	Immunity related GTPase M	5	150846523-150900736	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 1.6	appendix,spleen: 0.5	Cell line enhanced		NB-4: 1.6;U-937: 2.4
IRGQ	FKSG27, IRGQ1	ENSG00000167378	Immunity related GTPase Q	19	43584369-43596135	Predicted intracellular proteins	Evidence at protein level	HPA043254, HPA050338	Enhanced		Supported	Vesicles	Pancreatic cancer:3.57e-5 (favourable), Renal cancer:3.92e-4 (favourable), Cervical cancer:5.17e-4 (favourable), Liver cancer:9.60e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 7.2	Mixed		
IRS1	HIRS-1	ENSG00000169047	Insulin receptor substrate 1	2	226731317-226799759	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005261, HPA046433	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			thyroid gland: 33.9	Mixed		
IRS2		ENSG00000185950	Insulin receptor substrate 2	13	109752698-109786568	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016944, HPA054664	Approved		Supported	Aggresome<br>Cytosol		Expressed in all	Mixed			bone marrow: 32.9	Cell line enhanced		SH-SY5Y: 42.7;THP-1: 42.3
IRX1	IRX-5	ENSG00000170549	Iroquois homeobox 1	5	3596054-3601403	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043160	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Group enriched	Tissue enhanced		breast: 7.7;kidney: 5.3;salivary gland: 5.7	lung: 3.6	Cell line enhanced		AF22: 9.8;REH: 38.0;U-251 MG: 13.8
IRX2		ENSG00000170561	Iroquois homeobox 2	5	2745845-2751662	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050895, HPA054669	Approved		Approved	Nucleus<br>Nucleoli	Pancreatic cancer:8.84e-4 (favourable)	Mixed	Tissue enhanced		breast: 29.6;lung: 28.0	skin: 19.5	Cell line enhanced		AF22: 100.0;BEWO: 58.5;hTCEpi: 47.9
IRX3	IRX-1	ENSG00000177508	Iroquois homeobox 3	16	54283304-54286763	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062522			Approved	Vesicles		Expressed in all	Tissue enhanced		breast: 96.6	skin: 70.5	Cell line enhanced		NB-4: 129.5;RPTEC TERT1: 178.7;T-47d: 115.6;THP-1: 136.2
IRX4		ENSG00000113430	Iroquois homeobox 4	5	1877413-1887236	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064094			Uncertain	Nucleus<br>Vesicles		Mixed	Tissue enhanced		prostate: 5.8;skin: 6.9	esophagus: 1.4	Cell line enhanced		BEWO: 43.3;HaCaT: 15.1;HBEC3-KT: 6.7
IRX5	IRX-2a	ENSG00000176842	Iroquois homeobox 5	16	54930862-54934485	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047130			Approved	Nuclear speckles<br>Microtubules<br>Cytosol	Lung cancer:4.59e-4 (favourable)	Tissue enhanced	Tissue enhanced		breast: 17.9;lung: 9.6;skin: 10.1	salivary gland: 4.6	Cell line enhanced		RPTEC TERT1: 20.1;T-47d: 34.4
IRX6	IRX-3, IRX7	ENSG00000159387	Iroquois homeobox 6	16	55323760-55330760	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA018332	Uncertain		Approved	Nucleus<br>Mitochondria	Lung cancer:3.34e-4 (favourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 8.6;heart muscle: 4.9	skin: 3.3	Cell line enhanced		AF22: 1.3;HEK93: 1.5;RPTEC TERT1: 4.5;SK-MEL-30: 3.0
ISCA1	HBLD2, hIscA, ISA1, MGC4276	ENSG00000135070	Iron-sulfur cluster assembly 1	9	86264546-86283102	Predicted intracellular proteins	Evidence at protein level	HPA042789	Uncertain				Renal cancer:3.83e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 74.4	Expressed in all		
ISCA2	HBLD1, ISA2	ENSG00000165898	Iron-sulfur cluster assembly 2	14	74493720-74497106	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030492	Approved				Renal cancer:1.68e-7 (favourable), Thyroid cancer:8.98e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 56.6	Expressed in all		
ISCU	hnifU, IscU, ISU2, NIFUN	ENSG00000136003	Iron-sulfur cluster assembly enzyme	12	108562582-108569384	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB006329, HPA038602, HPA057592	Approved		Supported	Cytosol	Renal cancer:2.73e-7 (favourable), Cervical cancer:4.90e-7 (favourable), Urothelial cancer:6.12e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 399.3	Expressed in all		
ISG15	G1P2, IFI15, UCRP	ENSG00000187608	ISG15 ubiquitin-like modifier	1	1001138-1014541	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004627	Approved				Renal cancer:5.11e-10 (unfavourable)	Expressed in all	Expressed in all			salivary gland: 112.8	Expressed in all		
ISG20	CD25, HEM45	ENSG00000172183	Interferon stimulated exonuclease gene 20	15	88636153-88656483	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.86e-8 (unfavourable), Ovarian cancer:1.85e-5 (favourable), Glioma:3.12e-5 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 221.4	spleen: 136.2	Cell line enhanced		Daudi: 151.0;SK-MEL-30: 543.4
ISG20L2	FLJ12671	ENSG00000143319	Interferon stimulated exonuclease gene 20 like 2	1	156721891-156728799	Predicted intracellular proteins	Evidence at protein level	HPA028005, HPA054285	Approved		Supported	Nucleoplasm	Renal cancer:4.80e-5 (unfavourable), Liver cancer:6.15e-5 (unfavourable), Endometrial cancer:4.63e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 86.1	Expressed in all		
ISL1	Isl-1, ISLET1	ENSG00000016082	ISL LIM homeobox 1	5	51383391-51394738	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057416	Approved		Enhanced	Nucleoplasm		Tissue enhanced	Group enriched	5	placenta: 10.7;prostate: 15.5;seminal vesicle: 25.9;stomach: 9.8	testis: 2.9	Cell line enriched	14	SH-SY5Y: 307.2
ISL2	FLJ10160	ENSG00000159556	ISL LIM homeobox 2	15	76336724-76342476	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075192			Approved	Rods & Rings		Mixed	Not detected			prostate: 0.9	Cell line enhanced		HEK93: 13.3
ISOC1	CGI-111	ENSG00000066583	Isochorismatase domain containing 1	5	129094751-129114028	Predicted intracellular proteins	Evidence at protein level	HPA070307			Approved	Endoplasmic reticulum<br>Vesicles		Expressed in all	Expressed in all			endometrium: 175.5	Expressed in all		
ISOC2	FLJ23469	ENSG00000063241	Isochorismatase domain containing 2	19	55452985-55462343	Predicted intracellular proteins	Evidence at protein level	HPA043142	Enhanced		Approved	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			kidney: 63.1	Mixed		
ISPD	hCG_1745121, IspD, Nip	ENSG00000214960	Isoprenoid synthase domain containing	7	16087527-16421322	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043810, HPA053554	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.38e-11 (favourable)	Mixed	Mixed			cerebral cortex: 3.5	Cell line enhanced		HEL: 6.9
IST1	KIAA0174	ENSG00000182149	IST1, ESCRT-III associated factor	16	71845996-71931199	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041802, HPA054532	Approved		Supported	Vesicles	Renal cancer:4.55e-4 (favourable), Urothelial cancer:8.88e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 180.4	Expressed in all		
ISX	RAXLX	ENSG00000175329	Intestine specific homeobox	22	35066136-35087387	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060328	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Tissue enhanced	Group enriched	36	colon: 27.4;duodenum: 37.5;rectum: 28.2;small intestine: 29.7	smooth muscle: 0.8	Group enriched	12	CACO-2: 1.3;Hep G2: 3.1
ISY1	fSAP33, KIAA1160	ENSG00000240682	ISY1 splicing factor homolog	3	129127415-129161293	Predicted intracellular proteins	Evidence at protein level	HPA006312, HPA016995	Supported		Enhanced	Nuclear speckles	Cervical cancer:2.46e-5 (favourable), Liver cancer:7.25e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 36.5	Expressed in all		
ISY1-RAB43		ENSG00000261796	ISY1-RAB43 readthrough	3	129087575-129161036	Predicted intracellular proteins	Evidence at protein level	HPA006312, HPA016995	Approved		Enhanced	Nuclear speckles		Not detected	Expressed in all			parathyroid gland: 14.1	Mixed		
ISYNA1	Ino1, INOS, IPS	ENSG00000105655	Inositol-3-phosphate synthase 1	19	18434388-18438301	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007931, HPA008232, CAB020720	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:9.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 117.3	placenta: 63.8	Cell line enhanced		BEWO: 475.1
ITCH	AIP4	ENSG00000078747	Itchy E3 ubiquitin protein ligase	20	34363235-34511393	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021126, HPA049032	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 73.2	Expressed in all		
ITFG2	MDS028	ENSG00000111203	Integrin alpha FG-GAP repeat containing 2	12	2812622-2859791	Predicted intracellular proteins	Evidence at protein level	HPA038664, HPA038665	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Cytokinetic bridge		Expressed in all	Expressed in all			thyroid gland: 46.0	Expressed in all		
ITGB1BP1	ICAP-1A, ICAP-1alpha, ICAP-1B, ICAP1, ICAP1A, ICAP1B	ENSG00000119185	Integrin subunit beta 1 binding protein 1	2	9403475-9423547	Predicted intracellular proteins	Evidence at protein level	HPA067348, HPA071538			Supported	Nucleoplasm<br>Nuclear bodies<br>Microtubule organizing center<br>Cytosol	Endometrial cancer:1.03e-5 (unfavourable), Liver cancer:4.67e-5 (unfavourable), Renal cancer:7.10e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 125.4	Expressed in all		
ITGB1BP2	CHORDC3	ENSG00000147166	Integrin subunit beta 1 binding protein 2	X	71301734-71305371	Predicted intracellular proteins	Evidence at protein level	HPA040721			Approved	Cytosol		Mixed	Tissue enhanced		heart muscle: 52.9;smooth muscle: 23.1	skeletal muscle: 16.0	Cell line enhanced		HMC-1: 8.1
ITGB3BP	CENPR, HSU37139, NRIF3, TAP20	ENSG00000142856	Integrin subunit beta 3 binding protein	1	63440770-63593721	Predicted intracellular proteins	Evidence at protein level	HPA028463	Approved		Supported	Nucleoplasm	Renal cancer:8.45e-6 (unfavourable), Liver cancer:7.24e-5 (unfavourable), Head and neck cancer:4.32e-4 (favourable)	Expressed in all	Mixed			testis: 36.4	Expressed in all		
ITK	EMT, LYK, PSCTK2	ENSG00000113263	IL2 inducible T-cell kinase	5	157142933-157255191	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 20.2;lymph node: 33.2;tonsil: 22.3	spleen: 14.0	Cell line enhanced		HDLM-2: 3.2;HEL: 3.4;HMC-1: 3.8;MOLT-4: 18.7
ITPA	C20orf37, dJ794I6.3, HLC14-06-P	ENSG00000125877	Inosine triphosphatase	20	3208868-3223870	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022824	Approved		Supported	Cytosol	Liver cancer:2.54e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 40.3	Expressed in all		
ITPK1		ENSG00000100605	Inositol-tetrakisphosphate 1-kinase	14	92936914-93116320	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055230	Approved		Approved	Mitochondria	Endometrial cancer:8.56e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 93.1	Expressed in all		
ITPKA	IP3-3KA, IP3KA	ENSG00000137825	Inositol-trisphosphate 3-kinase A	15	41493393-41503551	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040454	Enhanced	Approved	Approved	Vesicles	Renal cancer:3.76e-9 (unfavourable), Glioma:5.08e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 25.7;duodenum: 17.7;small intestine: 19.8	stomach: 8.9	Cell line enhanced		Hep G2: 22.6
ITPKB	IP3-3KB, IP3KB	ENSG00000143772	Inositol-trisphosphate 3-kinase B	1	226631690-226739323	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030273, HPA072923	Uncertain		Approved	Nucleus	Head and neck cancer:1.72e-5 (favourable), Lung cancer:6.65e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 61.6	Cell line enhanced		SK-MEL-30: 36.3
ITPKC	IP3-3KC, IP3KC	ENSG00000086544	Inositol-trisphosphate 3-kinase C	19	40717103-40740860	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050760, HPA053003	Approved		Supported	Nuclear speckles	Lung cancer:4.91e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 69.3	Mixed		
ITSN2	KIAA1256, PRO2015, SH3D1B, SH3P18, SWA, SWAP	ENSG00000198399	Intersectin 2	2	24202864-24360714	Predicted intracellular proteins	Evidence at protein level	HPA036475	Approved		Approved	Vesicles<br>Plasma membrane	Head and neck cancer:2.98e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 84.8	Expressed in all		
IVD	ACAD2	ENSG00000128928	Isovaleryl-CoA dehydrogenase	15	40405795-40435947	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041391, HPA044250	Enhanced		Enhanced	Nucleoplasm<br>Mitochondria	Renal cancer:2.91e-9 (favourable), Liver cancer:1.95e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 151.7	Mixed		
IVL		ENSG00000163207	Involucrin	1	152908545-152911886	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002243, HPA055211	Enhanced		Supported	Nuclear bodies<br>Centrosome<br>Cytosol		Group enriched	Group enriched	7	esophagus: 308.3;skin: 131.2	tonsil: 32.9	Group enriched	24	HaCaT: 256.2;RT4: 61.2;SK-BR-3: 64.8
IVNS1ABP	HSPC068, KIAA0850, KLHL39, ND1, NS-1, NS1-BP	ENSG00000116679	Influenza virus NS1A binding protein	1	185296388-185317329	Predicted intracellular proteins	Evidence at protein level	HPA003405	Approved		Supported	Cytosol		Expressed in all	Expressed in all			bone marrow: 299.5	Expressed in all		
IWS1	DKFZp761G0123, FLJ10006, FLJ14655, FLJ32319	ENSG00000163166	IWS1, SUPT6H interacting protein	2	127436207-127526886	Predicted intracellular proteins	Evidence at protein level	HPA035719, HPA061866	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 44.2	Expressed in all		
JADE1	JADE-1, PHF17	ENSG00000077684	Jade family PHD finger 1	4	128809623-128875224	Predicted intracellular proteins	Evidence at protein level	HPA020016	Approved		Approved	Mitochondria	Renal cancer:8.22e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.9	Expressed in all		
JADE2	JADE-2, KIAA0239, PHF15	ENSG00000043143	Jade family PHD finger 2	5	134524312-134583230	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA025959, HPA055789	Uncertain		Enhanced	Nucleoplasm	Renal cancer:5.36e-6 (favourable), Ovarian cancer:4.42e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 48.6	Mixed		
JADE3	JADE-3, KIAA0215, PHF16	ENSG00000102221	Jade family PHD finger 3	X	46912276-47061242	Predicted intracellular proteins	Evidence at protein level	HPA006007, HPA064697	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 22.6	Cell line enhanced		BEWO: 63.4
JAK1	JAK1A, JAK1B, JTK3	ENSG00000162434	Janus kinase 1	1	64833229-64966504	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013088	Approved				Renal cancer:2.67e-4 (favourable), Colorectal cancer:2.81e-4 (favourable), Breast cancer:9.63e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 115.6	Expressed in all		
JAK2	JTK10	ENSG00000096968	Janus kinase 2	9	4984390-5128183	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013089, HPA040820, HPA043870	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites		Expressed in all	Mixed			appendix: 28.1	Group enriched	6	ASC diff: 34.8;HDLM-2: 71.3;HEL: 140.3
JAK3	JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK	ENSG00000105639	Janus kinase 3	19	17824780-17848071	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA070314	Enhanced				Renal cancer:2.89e-14 (unfavourable), Cervical cancer:6.42e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 48.4;lymph node: 46.6	tonsil: 27.2	Cell line enhanced		HDLM-2: 33.0;Karpas-707: 28.7;U-266/84: 17.1;U-937: 18.8
JARID2	JMJ	ENSG00000008083	Jumonji and AT-rich interaction domain containing 2	6	15246296-15522040	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063889, CAB069890	Uncertain		Supported	Nucleus<br>Mitochondria		Expressed in all	Mixed			bone marrow: 36.5	Expressed in all		
JAZF1	DKFZp761K2222, TIP27, ZNF802	ENSG00000153814	JAZF zinc finger 1	7	27830573-28180743	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB019271, HPA066967	Approved		Supported	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			adrenal gland: 112.8	Mixed		
JDP2	JUNDM2	ENSG00000140044	Jun dimerization protein 2	14	75427716-75474111	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059511	Supported		Approved	Nucleoplasm<br>Nuclear speckles	Colorectal cancer:8.58e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 85.7	Cell line enhanced		HHSteC: 140.4
JMJD1C	DKFZp761F0118, FLJ14374, KDM3C, KIAA1380, TRIP8	ENSG00000171988	Jumonji domain containing 1C	10	63167221-63521850	Predicted intracellular proteins	Evidence at protein level	HPA056175, HPA066195	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 55.9	Expressed in all		
JMJD4	FLJ12517	ENSG00000081692	Jumonji domain containing 4	1	227730425-227735411	Predicted intracellular proteins	Evidence at protein level	HPA027260, HPA052861	Uncertain		Approved	Vesicles<br>Plasma membrane	Renal cancer:3.16e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 12.9	Expressed in all		
JMJD6	KIAA0585, PTDSR, PTDSR1	ENSG00000070495	Arginine demethylase and lysine hydroxylase	17	76712832-76726799	Predicted intracellular proteins	Evidence at protein level	CAB004548, HPA059156	Supported		Supported	Nucleoplasm	Renal cancer:7.59e-7 (unfavourable), Liver cancer:5.75e-6 (unfavourable), Pancreatic cancer:5.71e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 81.0	Expressed in all		
JMJD7		ENSG00000243789	Jumonji domain containing 7	15	41828085-41837581	Predicted intracellular proteins	Evidence at protein level	HPA005726	Uncertain		Approved	Cytosol		Not detected	Expressed in all			skin: 28.0	Cell line enhanced		RT4: 34.4
JMJD7-PLA2G4B		ENSG00000168970	JMJD7-PLA2G4B readthrough	15	41828095-41848155	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA005726	Uncertain		Approved	Cytosol		Mixed	Mixed			lung: 1.6	Mixed		
JMY	FLJ37870, WHAMM2	ENSG00000152409	Junction mediating and regulatory protein, p53 cofactor	5	79236189-79327215	Predicted intracellular proteins	Evidence at protein level	HPA037508, HPA043308	Uncertain		Uncertain	Nucleoplasm	Renal cancer:3.03e-5 (favourable), Ovarian cancer:1.12e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.6	Cell line enhanced		Karpas-707: 31.6
JOSD1	KIAA0063	ENSG00000100221	Josephin domain containing 1	22	38685543-38701556	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001168	Uncertain				Liver cancer:4.50e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 56.4	Expressed in all		
JOSD2	SBBI54	ENSG00000161677	Josephin domain containing 2	19	50505998-50511353	Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.04e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 16.8	Mixed		
JRK	jerky, JH8	ENSG00000234616	Jrk helix-turn-helix protein	8	142657460-142681968	Predicted intracellular proteins	Evidence at transcript level	HPA052675			Approved	Nucleus<br>Nucleoli<br>Nuclear bodies		Expressed in all	Mixed			testis: 10.9	Expressed in all		
JRKL	HHMJG	ENSG00000183340	JRK-like	11	96389989-96507574	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046184, HPA060341	Uncertain		Approved	Nucleus<br>Cytokinetic bridge		Expressed in all	Expressed in all			parathyroid gland: 19.2	Expressed in all		
JSRP1	FLJ32416, JP-45	ENSG00000167476	Junctional sarcoplasmic reticulum protein 1	19	2252252-2269759	Predicted intracellular proteins	Evidence at protein level	HPA044741	Enhanced		Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enriched	39	skeletal muscle: 116.2	duodenum: 2.9	Cell line enhanced		Karpas-707: 117.9;RPMI-8226: 73.9;U-266/70: 338.6
JUN	AP-1, c-Jun	ENSG00000177606	Jun proto-oncogene, AP-1 transcription factor subunit	1	58780788-58784327	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003801, CAB007780, HPA059474	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 314.6	Cell line enhanced		RH-30: 282.2
JUNB		ENSG00000171223	JunB proto-oncogene, AP-1 transcription factor subunit	19	12791496-12793315	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004464, HPA019149	Approved		Enhanced	Nucleoplasm	Renal cancer:1.05e-4 (unfavourable), Ovarian cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 320.7	Expressed in all		
JUND	AP-1	ENSG00000130522	JunD proto-oncogene, AP-1 transcription factor subunit	19	18279760-18281622	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005268, HPA063029	Supported		Supported	Nucleus	Breast cancer:6.15e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 277.7	Expressed in all		
JUP	CTNNG, DP3, DPIII, PDGB, PKGB	ENSG00000173801	Junction plakoglobin	17	41754604-41786931	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002139, HPA032047	Supported		Enhanced	Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:2.06e-10 (favourable)	Expressed in all	Group enriched	6	esophagus: 491.8;skin: 785.5	fallopian tube: 113.8	Cell line enhanced		HaCaT: 960.4;RT4: 536.8
KAAG1	RU2, RU2AS	ENSG00000146049	Kidney associated antigen 1	6	24356903-24358284	Predicted intracellular proteins	Evidence at transcript level	HPA036021	Approved					Mixed	Not detected			thyroid gland: 0.5	Group enriched	6	CACO-2: 4.4;EFO-21: 3.9;HEK93: 1.0;Hep G2: 3.6
KANK1	ANKRD15, KANK, KIAA0172	ENSG00000107104	KN motif and ankyrin repeat domains 1	9	470291-746106	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005539, HPA056090	Approved		Supported	Plasma membrane		Expressed in all	Mixed			smooth muscle: 55.8	Mixed		
KANK2	ANKRD25, KIAA1518, MXRA3	ENSG00000197256	KN motif and ankyrin repeat domains 2	19	11164267-11197791	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015643	Approved				Renal cancer:8.73e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 439.0	Expressed in all		
KANK3	ANKRD47, FLJ46061	ENSG00000186994	KN motif and ankyrin repeat domains 3	19	8322584-8343262	Predicted intracellular proteins	Evidence at protein level	HPA051153	Approved		Approved	Plasma membrane	Renal cancer:1.69e-5 (favourable)	Expressed in all	Tissue enhanced		spleen: 24.9	adipose tissue: 22.2	Cell line enhanced		HUVEC TERT2: 6.8;TIME: 12.1;U-266/70: 4.5
KANK4	ANKRD38, KIAA0172	ENSG00000132854	KN motif and ankyrin repeat domains 4	1	62236979-62319414	Predicted intracellular proteins	Evidence at protein level	HPA014030	Uncertain		Uncertain	Microtubules<br>Cytosol		Mixed	Tissue enhanced		parathyroid gland: 29.5;placenta: 16.4	adipose tissue: 11.8	Cell line enhanced		BEWO: 32.2;Hep G2: 9.9;SCLC-21H: 7.5
KANSL1	CENP-36, DKFZP727C091, KIAA1267, MSL1v1, NSL1	ENSG00000120071	KAT8 regulatory NSL complex subunit 1	17	46029916-46225389	Predicted intracellular proteins	Evidence at protein level	HPA006874, HPA007208	Approved		Supported	Nucleoplasm	Liver cancer:3.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.4	Mixed		
KANSL3	FLJ10081, KIAA1310, NSL3, Rcd1	ENSG00000114982	KAT8 regulatory NSL complex subunit 3	2	96593170-96642787	Predicted intracellular proteins	Evidence at protein level	HPA035017, HPA035018, HPA041280	Approved		Enhanced	Nucleus	Liver cancer:5.34e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.3	Expressed in all		
KARS	DFNB89, KARS1, KARS2	ENSG00000065427	Lysyl-tRNA synthetase	16	75627474-75648643	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041345, HPA041550	Enhanced		Supported	Cytosol	Head and neck cancer:8.84e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 178.6	Expressed in all		
KAT14	ATAC2, CRP2BP, CSRP2BP, dJ717M23.1, PRO1194	ENSG00000149474	Lysine acetyltransferase 14	20	18138118-18188387	Predicted intracellular proteins	Evidence at protein level	CAB034224, HPA068443	Uncertain		Approved	Vesicles	Renal cancer:4.64e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.4	Expressed in all		
KAT2A	GCN5, GCN5L2, PCAF-b	ENSG00000108773	Lysine acetyltransferase 2A	17	42113108-42121358	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048958	Uncertain				Renal cancer:1.41e-8 (unfavourable), Pancreatic cancer:3.57e-4 (favourable)	Expressed in all	Expressed in all			skin: 10.9	Mixed		
KAT2B	GCN5, GCN5L, P/CAF, PCAF	ENSG00000114166	Lysine acetyltransferase 2B	3	20040023-20154404	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004526, HPA055839	Supported		Approved	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 85.2	Mixed		
KAT5	cPLA2, ESA1, HTATIP, HTATIP1, PLIP, TIP60, ZC2HC5	ENSG00000172977	Lysine acetyltransferase 5	11	65711996-65719604	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016953	Approved		Supported	Nucleoplasm	Renal cancer:1.10e-13 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.4	Expressed in all		
KAT6A	MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220	ENSG00000083168	Lysine acetyltransferase 6A	8	41929479-42051990	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017023, HPA063266, HPA065052	Supported		Approved	Nucleoli<br>Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 34.5	Expressed in all		
KAT6B	Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B	ENSG00000156650	Lysine acetyltransferase 6B	10	74825582-75032622	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006104	Supported		Approved	Nucleus<br>Nuclear bodies	Renal cancer:4.82e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.3	Expressed in all		
KAT7	HBO1, HBOA, MYST2, ZC2HC7	ENSG00000136504	Lysine acetyltransferase 7	17	49788555-49835030	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044470	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 107.0	Expressed in all		
KAT8	FLJ14040, hMOF, MOF, MYST1, ZC2HC8	ENSG00000103510	Lysine acetyltransferase 8	16	31115754-31131393	Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066324			Supported	Nucleoplasm	Lung cancer:6.34e-4 (favourable)	Expressed in all	Expressed in all			ovary: 61.6	Expressed in all		
KATNA1		ENSG00000186625	Katanin catalytic subunit A1	6	149594873-149648972	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036207	Approved		Supported	Nucleus<br>Microtubule organizing center	Liver cancer:3.57e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 80.2	Expressed in all		
KATNAL1	MGC2599	ENSG00000102781	Katanin catalytic subunit A1 like 1	13	30202630-30307484	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046205			Uncertain	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		testis: 37.7	smooth muscle: 21.9	Mixed		
KATNAL2	DKFZP667C165, MGC33211	ENSG00000167216	Katanin catalytic subunit A1 like 2	18	46917492-47102243	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040712, HPA042029	Approved		Approved	Nucleoplasm<br>Intermediate filaments	Renal cancer:1.24e-7 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 45.1;testis: 32.6	thyroid gland: 24.4	Mixed		
KATNB1		ENSG00000140854	Katanin regulatory subunit B1	16	57735730-57757250	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041165, HPA041839	Enhanced		Supported	Plasma membrane<br>Microtubules<br>Cytosol	Liver cancer:3.93e-4 (unfavourable), Pancreatic cancer:8.44e-4 (favourable), Endometrial cancer:9.24e-4 (favourable)	Expressed in all	Expressed in all			testis: 45.3	Expressed in all		
KATNBL1	C15orf29, FLJ22557	ENSG00000134152	Katanin regulatory subunit B1 like 1	15	34140674-34210096	Predicted intracellular proteins	Evidence at protein level	HPA062573	Approved		Approved	Nucleus<br>Midbody<br>Mitotic spindle	Renal cancer:4.60e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 46.7	Expressed in all		
KAZN	FLJ43806, KAZRIN, KIAA1026	ENSG00000189337	Kazrin, periplakin interacting protein	1	13892792-15118043	Predicted intracellular proteins	Evidence at protein level	HPA032095, HPA032096	Approved		Supported	Nucleoplasm<br>Nuclear speckles<br>Cytosol	Renal cancer:1.20e-6 (favourable)	Mixed	Tissue enhanced		spleen: 118.3	parathyroid gland: 42.3	Cell line enhanced		AN3-CA: 79.3
KBTBD11	KIAA0711, KLHDC7C	ENSG00000176595	Kelch repeat and BTB domain containing 11	8	1973878-2006936	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051159	Uncertain		Approved	Intermediate filaments		Tissue enhanced	Tissue enhanced		cerebral cortex: 21.7	kidney: 8.8	Cell line enhanced		HDLM-2: 12.9;SCLC-21H: 13.6;THP-1: 13.0;U-937: 21.4
KBTBD12	FLJ46299, KLHDC6	ENSG00000187715	Kelch repeat and BTB domain containing 12	3	127915232-127987671	Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	9	heart muscle: 9.2;skeletal muscle: 20.3	stomach: 1.5	Not detected		
KBTBD13	hCG_1645727, NEM6	ENSG00000234438	Kelch repeat and BTB domain containing 13	15	65076816-65078192	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA062737	Uncertain					Not detected	Tissue enriched	12	skeletal muscle: 5.2	heart muscle: 0.4	Not detected		
KBTBD2	BKLHD1, DKFZP566C134	ENSG00000170852	Kelch repeat and BTB domain containing 2	7	32868172-32894131	Predicted intracellular proteins	Evidence at protein level	HPA021133	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center	Cervical cancer:1.89e-4 (unfavourable), Liver cancer:5.69e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 38.6	Expressed in all		
KBTBD3	BKLHD3	ENSG00000182359	Kelch repeat and BTB domain containing 3	11	106051098-106077765	Predicted intracellular proteins	Evidence at protein level	HPA047385	Uncertain				Renal cancer:3.42e-7 (favourable)	Mixed	Mixed			thyroid gland: 7.7	Mixed		
KBTBD4	BKLHD4, FLJ10450, HSPC252	ENSG00000123444	Kelch repeat and BTB domain containing 4	11	47572197-47579015	Predicted intracellular proteins	Evidence at protein level	HPA037792, HPA037793	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:2.70e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 48.6	Expressed in all		
KBTBD6	DKFZp547E1912	ENSG00000165572	Kelch repeat and BTB domain containing 6	13	41127569-41132746	Predicted intracellular proteins	Evidence at protein level	HPA046861, HPA048914	Uncertain					Expressed in all	Mixed			cerebral cortex: 23.6	Expressed in all		
KBTBD7	DKFZP434E2318	ENSG00000120696	Kelch repeat and BTB domain containing 7	13	41189833-41194566	Predicted intracellular proteins	Evidence at protein level	HPA043709, HPA046861, HPA048914	Uncertain				Lung cancer:5.29e-4 (favourable), Pancreatic cancer:6.62e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.0	Mixed		
KBTBD8	KIAA1842, TA-KRP	ENSG00000163376	Kelch repeat and BTB domain containing 8	3	66998307-67011210	Predicted intracellular proteins	Evidence at protein level	HPA041285, HPA069190	Approved					Mixed	Tissue enhanced		lymph node: 24.3;tonsil: 18.9	testis: 14.5	Cell line enhanced		Daudi: 44.8;U-698: 29.8
KCMF1	DEBT91, DKFZP434L1021, PCMF, ZZZ1	ENSG00000176407	Potassium channel modulatory factor 1	2	84971093-85059472	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030383, HPA030384	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.33e-7 (unfavourable), Renal cancer:4.18e-6 (unfavourable), Pancreatic cancer:6.10e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 124.6	Expressed in all		
KCNAB1	AKR6A3, hKvb3, hKvBeta3, KCNA1B, Kvb1.3	ENSG00000169282	Potassium voltage-gated channel subfamily A member regulatory beta subunit 1	3	156037701-156539138	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044550	Approved					Tissue enhanced	Tissue enhanced		prostate: 37.4;thyroid gland: 48.4	seminal vesicle: 26.6	Cell line enhanced		hTEC/SVTERT24-B: 5.2
KCNAB2	AKR6A5, HKvbeta2.1, HKvbeta2.2, KCNA2B	ENSG00000069424	Potassium voltage-gated channel subfamily A regulatory beta subunit 2	1	5991466-6101193	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001975	Enhanced				Renal cancer:3.50e-5 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 145.9	bone marrow: 74.8	Cell line enhanced		HL-60: 277.8;U-937: 287.1
KCNAB3	AKR6A9, KCNA3B	ENSG00000170049	Potassium voltage-gated channel subfamily A regulatory beta subunit 3	17	7921859-7929803	Predicted intracellular proteins	Evidence at protein level	HPA077993			Approved	Mitochondria		Mixed	Tissue enhanced		endometrium: 14.6;smooth muscle: 8.6	cerebral cortex: 4.7	Cell line enhanced		REH: 11.9
KCNIP1	KCHIP1	ENSG00000182132	Potassium voltage-gated channel interacting protein 1	5	170353487-170736632	Predicted intracellular proteins	Evidence at protein level	HPA022864	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 40.4;epididymis: 26.3	seminal vesicle: 7.9	Cell line enriched	17	RPTEC TERT1: 43.9
KCNIP2	KCHIP2	ENSG00000120049	Potassium voltage-gated channel interacting protein 2	10	101825974-101843920	Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	9	adipose tissue: 238.6;cerebral cortex: 81.4;heart muscle: 108.2	breast: 16.6	Cell line enhanced		HEL: 13.8;HMC-1: 9.2
KCNRG		ENSG00000198553	Potassium channel regulator	13	50015254-50020922	Predicted intracellular proteins	Evidence at protein level	HPA001027			Uncertain	Vesicles	Endometrial cancer:2.61e-5 (favourable)	Mixed	Tissue enriched	12	fallopian tube: 52.2	lung: 4.5	Mixed		
KCTD1	C18orf5	ENSG00000134504	Potassium channel tetramerization domain containing 1	18	26454910-26657401	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.60e-8 (favourable), Endometrial cancer:2.22e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 72.7	Cell line enhanced		AF22: 101.7;HaCaT: 97.2
KCTD10	BTBD28, MSTP028	ENSG00000110906	Potassium channel tetramerization domain containing 10	12	109448656-109477544	Predicted intracellular proteins	Evidence at protein level	HPA014273	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:5.32e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 79.7	Expressed in all		
KCTD11	C17orf36, KCASH1, REN	ENSG00000213859	Potassium channel tetramerization domain containing 11	17	7351889-7354944	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA052035	Approved		Approved	Nucleoplasm	Ovarian cancer:5.02e-4 (unfavourable), Endometrial cancer:9.55e-4 (favourable)	Expressed in all	Mixed			esophagus: 39.8	Cell line enhanced		HBEC3-KT: 38.4
KCTD12	C13orf2, KIAA1778, PFET1	ENSG00000178695	Potassium channel tetramerization domain containing 12	13	76880166-76886390	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056987, HPA077376		Supported	Approved	Mitochondria	Renal cancer:1.14e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 122.8	Cell line enhanced		HUVEC TERT2: 191.1;TIME: 151.4
KCTD13	FKSG86, PDIP1, POLDIP1	ENSG00000174943	Potassium channel tetramerization domain containing 13	16	29905012-29927035	Predicted intracellular proteins	Evidence at protein level	HPA043524	Enhanced		Supported	Nucleus<br>Nuclear bodies	Renal cancer:8.17e-4 (unfavourable), Colorectal cancer:8.54e-4 (unfavourable), Pancreatic cancer:9.05e-4 (favourable)	Expressed in all	Mixed			testis: 12.5	Mixed		
KCTD14	MGC2376	ENSG00000151364	Potassium channel tetramerization domain containing 14	11	78015715-78046191	Predicted intracellular proteins	Evidence at protein level	HPA041118, HPA042181	Enhanced				Melanoma:3.96e-5 (unfavourable), Renal cancer:6.92e-5 (favourable), Pancreatic cancer:1.05e-4 (unfavourable), Thyroid cancer:5.93e-4 (favourable), Ovarian cancer:8.01e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 27.0	Cell line enhanced		HBEC3-KT: 18.6;Hep G2: 19.7;RPTEC TERT1: 34.1;U-2 OS: 21.2
KCTD15	MGC25497	ENSG00000153885	Potassium channel tetramerization domain containing 15	19	33795933-33815763	Predicted intracellular proteins	Evidence at protein level	HPA050822	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.65e-8 (unfavourable)	Expressed in all	Expressed in all			skin: 86.3	Mixed		
KCTD16	KIAA1317	ENSG00000183775	Potassium channel tetramerization domain containing 16	5	144170832-144485686	Predicted intracellular proteins	Evidence at protein level	HPA044590, HPA050154	Approved		Approved	Nuclear speckles		Tissue enhanced	Group enriched	7	cerebral cortex: 12.3;testis: 3.0	lung: 1.1	Cell line enhanced		SCLC-21H: 5.4;TIME: 7.3
KCTD17	FLJ12242	ENSG00000100379	Potassium channel tetramerization domain containing 17	22	37051736-37063390	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018459	Uncertain				Renal cancer:5.13e-12 (unfavourable), Liver cancer:3.59e-5 (unfavourable), Pancreatic cancer:4.22e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 55.9	testis: 35.3	Mixed		
KCTD18	6530404F10Rik, FLJ31322, FLJ37818	ENSG00000155729	Potassium channel tetramerization domain containing 18	2	200488952-200519784	Predicted intracellular proteins	Evidence at protein level	HPA045498, HPA058028	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 23.2	Expressed in all		
KCTD19	FLJ40162	ENSG00000168676	Potassium channel tetramerization domain containing 19	16	67289428-67326763	Predicted intracellular proteins	Evidence at protein level	HPA049310, HPA053321	Uncertain					Not detected	Tissue enriched	15	testis: 39.2	bone marrow: 2.6	Cell line enhanced		HBF TERT88: 2.0;U-266/70: 4.4
KCTD2	KIAA0176	ENSG00000180901	Potassium channel tetramerization domain containing 2	17	75032575-75065889	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:1.25e-5 (favourable), Liver cancer:1.83e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 3.4;cerebral cortex: 7.3	kidney: 2.0	Cell line enhanced		HEK93: 10.4
KCTD20	C6orf69, dJ108K11.3, MGC14254	ENSG00000112078	Potassium channel tetramerization domain containing 20	6	36442767-36491143	Predicted intracellular proteins	Evidence at protein level	HPA030092	Approved		Approved	Nuclear speckles<br>Endoplasmic reticulum	Glioma:7.39e-4 (favourable), Renal cancer:8.02e-4 (unfavourable), Liver cancer:8.32e-4 (unfavourable), Thyroid cancer:9.31e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 47.0	Expressed in all		
KCTD21	KCASH2	ENSG00000188997	Potassium channel tetramerization domain containing 21	11	78171249-78188822	Predicted intracellular proteins	Evidence at protein level	HPA041964	Uncertain		Approved	Cytosol	Thyroid cancer:9.57e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 18.8	Expressed in all		
KCTD3	NY-REN-45	ENSG00000136636	Potassium channel tetramerization domain containing 3	1	215567392-215621807	Predicted intracellular proteins	Evidence at protein level	HPA015142	Approved		Approved	Cytosol	Renal cancer:8.94e-6 (unfavourable), Pancreatic cancer:4.71e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 103.7	Expressed in all		
KCTD4	bA321C24.3	ENSG00000180332	Potassium channel tetramerization domain containing 4	13	45192853-45194717	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040734	Uncertain		Approved	Microtubule organizing center		Group enriched	Group enriched	10	cerebral cortex: 17.7;skin: 3.7	gallbladder: 1.1	Cell line enhanced		RPTEC TERT1: 8.8;U-138 MG: 13.7;U-87 MG: 27.1
KCTD5	FLJ20040	ENSG00000167977	Potassium channel tetramerization domain containing 5	16	2682475-2709030	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			lymph node: 23.1	Expressed in all		
KCTD6	KCASH3, MGC27385	ENSG00000168301	Potassium channel tetramerization domain containing 6	3	58492114-58502360	Predicted intracellular proteins	Evidence at protein level	HPA036100, HPA036101	Uncertain		Approved	Nucleoli<br>Mitochondria	Liver cancer:4.57e-4 (unfavourable), Renal cancer:8.63e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 40.2	Expressed in all		
KCTD9	BTBD27, FLJ20038	ENSG00000104756	Potassium channel tetramerization domain containing 9	8	25427847-25458476	Predicted intracellular proteins	Evidence at protein level	HPA042468, HPA047902			Supported	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Colorectal cancer:7.88e-4 (favourable)	Expressed in all	Expressed in all			prostate: 28.1	Expressed in all		
KDF1	C1orf172, FLJ34633, RP11-344H11.3	ENSG00000175707	Keratinocyte differentiation factor 1	1	26949562-26960406	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028639, HPA068312	Uncertain		Supported	Nucleoplasm<br>Cell Junctions<br>Mitotic spindle	Renal cancer:3.04e-13 (favourable), Urothelial cancer:4.40e-4 (favourable)	Mixed	Mixed			epididymis: 24.1	Cell line enhanced		A-431: 22.4;BEWO: 20.8;CAPAN-2: 20.7;HaCaT: 19.6;HBEC3-KT: 21.9;hTCEpi: 28.4;SK-BR-3: 19.3
KDM1B	AOF1, bA204B7.3, C6orf193, dJ298J15.2, FLJ33898, FLJ34109, FLJ43328, LSD2	ENSG00000165097	Lysine demethylase 1B	6	18155329-18223853	Predicted intracellular proteins	Evidence at protein level	HPA031269	Uncertain		Approved	Nucleus	Colorectal cancer:6.94e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 65.1	Expressed in all		
KDM2A	CXXC8, DKFZP434M1735, FBL11, FBL7, FBXL11, FLJ00115, JHDM1A, KIAA1004, LILINA	ENSG00000173120	Lysine demethylase 2A	11	67119269-67258087	Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB012272, HPA044251	Supported		Approved	Nucleus		Expressed in all	Expressed in all			testis: 60.0	Expressed in all		
KDM2B	CXXC2, Fbl10, FBXL10, JHDM1B, PCCX2	ENSG00000089094	Lysine demethylase 2B	12	121429097-121581015	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA071257			Uncertain	Nucleoplasm	Head and neck cancer:6.74e-6 (favourable), Pancreatic cancer:8.64e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 35.8	Expressed in all		
KDM3A	JHMD2A, JMJD1, JMJD1A, KIAA0742, TSGA	ENSG00000115548	Lysine demethylase 3A	2	86440647-86492716	Predicted intracellular proteins	Evidence at protein level	HPA055543, HPA065162			Enhanced	Nucleoplasm	Liver cancer:2.15e-6 (unfavourable), Renal cancer:5.25e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 93.0	Expressed in all		
KDM4A	JHDM3A, JMJD2, JMJD2A, KIAA0677, TDRD14A	ENSG00000066135	Lysine demethylase 4A	1	43650158-43705515	Predicted intracellular proteins	Evidence at protein level	HPA007610	Uncertain		Supported	Nucleoli fibrillar center	Liver cancer:1.39e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.2	Expressed in all		
KDM4B	JMJD2B, KIAA0876, TDRD14B	ENSG00000127663	Lysine demethylase 4B	19	4969113-5153595	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062872			Supported	Nucleus<br>Cytosol	Endometrial cancer:4.25e-7 (favourable), Melanoma:2.13e-4 (unfavourable), Colorectal cancer:2.74e-4 (unfavourable), Breast cancer:7.39e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 19.9	Expressed in all		
KDM4C	GASC1, JMJD2C, KIAA0780, TDRD14C	ENSG00000107077	Lysine demethylase 4C	9	6720863-7175648	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA069357			Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 36.0	Expressed in all		
KDM4D	FLJ10251, JMJD2D	ENSG00000186280	Lysine demethylase 4D	11	94973681-94999518	Predicted intracellular proteins	Evidence at protein level	HPA055854, HPA064037	Approved		Approved	Nucleoplasm		Mixed	Tissue enriched	29	testis: 60.7	parathyroid gland: 2.0	Mixed		
KDM4E	JMJD2E, KDM4DL, KDM5E	ENSG00000235268	Lysine demethylase 4E	11	95025258-95027596	Predicted intracellular proteins	Evidence at protein level	HPA051740, HPA054225	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
KDM4F	JMJD2F	ENSG00000255855	Lysine demethylase 4F	11	95049422-95051338	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KDM5A	JARID1A, RBBP2	ENSG00000073614	Lysine demethylase 5A	12	280129-389454	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006201			Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 39.0	Expressed in all		
KDM5B	CT31, JARID1B, PLU-1, PPP1R98, RBBP2H1A	ENSG00000117139	Lysine demethylase 5B	1	202724491-202809470	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027179, HPA053723, CAB068193	Enhanced		Supported	Nucleus		Expressed in all	Tissue enriched	7	testis: 228.1	skin: 30.6	Mixed		
KDM5C	DXS1272E, JARID1C, MRX13, SMCX, XE169	ENSG00000126012	Lysine demethylase 5C	X	53191321-53225422	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038244, HPA046147			Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 66.7	Expressed in all		
KDM5D	HY, HYA, JARID1D, KIAA0234, SMCY	ENSG00000012817	Lysine demethylase 5D	Y	19703865-19744939	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049086			Approved	Nucleoli fibrillar center	Head and neck cancer:3.58e-5 (favourable)	Mixed	Mixed			small intestine: 36.5	Cell line enhanced		HEL: 49.4;U-698: 32.8
KDM6B	JMJD3, KIAA0346	ENSG00000132510	Lysine demethylase 6B	17	7839904-7854796	Predicted intracellular proteins	Evidence at protein level	HPA037988	Enhanced		Approved	Nuclear speckles	Thyroid cancer:3.37e-4 (unfavourable), Renal cancer:6.07e-4 (favourable)	Expressed in all	Expressed in all			appendix: 28.8	Mixed		
KDM8	FLJ13798, JMJD5	ENSG00000155666	Lysine demethylase 8	16	27203495-27221768	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026545	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.75e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 24.2	small intestine: 13.8	Mixed		
KEAP1	INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454	ENSG00000079999	Kelch like ECH associated protein 1	19	10486120-10503741	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005558, CAB025337	Approved		Supported	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Cervical cancer:3.28e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 49.4	Expressed in all		
KHDC1L	RP11-257K9.7	ENSG00000256980	KH domain containing 1 like	6	73223544-73225770	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		testis: 4.6	lung: 1.0	Group enriched	8	A-431: 10.2;BEWO: 48.1
KHDC3L	C6orf221, ECAT1	ENSG00000203908	KH domain containing 3 like, subcortical maternal complex member	6	73362677-73364171	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043699	Uncertain					Tissue enriched	Tissue enhanced		lung: 1.0;testis: 2.2	epididymis: 0.4	Not detected		
KHDRBS1	FLJ34027, p62, Sam68	ENSG00000121774	KH RNA binding domain containing, signal transduction associated 1	1	32013829-32060850	Predicted intracellular proteins	Evidence at protein level	CAB005355, HPA051280, HPA056813	Enhanced		Enhanced	Nucleoplasm	Liver cancer:3.68e-5 (unfavourable), Renal cancer:9.32e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 134.1	Expressed in all		
KHDRBS2	MGC26664, SLM-1, SLM1	ENSG00000112232	KH RNA binding domain containing, signal transduction associated 2	6	61679960-62286227	Predicted intracellular proteins	Evidence at protein level	HPA000500, HPA029392	Supported					Tissue enhanced	Tissue enhanced		cerebral cortex: 6.6;lung: 5.6;thyroid gland: 11.0	spleen: 1.8	Cell line enhanced		AF22: 7.2;NTERA-2: 1.9;THP-1: 1.0
KHDRBS3	Etle, etoile, SALP, SLM-2, SLM2, T-STAR	ENSG00000131773	KH RNA binding domain containing, signal transduction associated 3	8	135457457-135656722	Predicted intracellular proteins	Evidence at protein level	HPA000275, HPA000500, HPA000981	Enhanced		Supported	Nucleoplasm	Renal cancer:7.16e-6 (favourable)	Expressed in all	Group enriched	7	cerebral cortex: 89.1;testis: 285.9	epididymis: 27.8	Cell line enhanced		WM-115: 83.8
KHK		ENSG00000138030	Ketohexokinase	2	27086747-27100772	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007040	Enhanced		Approved	Cytosol	Endometrial cancer:7.62e-8 (unfavourable)	Group enriched	Group enriched	11	duodenum: 113.1;kidney: 111.2;liver: 97.3;small intestine: 133.2	cerebral cortex: 10.1	Cell line enhanced		Hep G2: 32.5
KHNYN	KIAA0323	ENSG00000100441	KH and NYN domain containing	14	24429286-24441834	Predicted intracellular proteins	Evidence at protein level	HPA003402	Uncertain		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:4.38e-4 (unfavourable), Glioma:9.44e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 47.8	Mixed		
KHSRP	FBP2, FUBP2, KSRP	ENSG00000088247	KH-type splicing regulatory protein	19	6413348-6424794	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034739, HPA056518	Enhanced		Enhanced	Nucleoplasm	Renal cancer:2.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 179.1	Expressed in all		
KIAA0040		ENSG00000235750	KIAA0040	1	175156987-175192999	Predicted intracellular proteins	Evidence at protein level	HPA016895, HPA068812	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			placenta: 143.7	Cell line enhanced		Daudi: 65.1;U-698: 80.2
KIAA0141	DELE	ENSG00000081791	KIAA0141	5	141923808-141942047	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036548, HPA061490	Uncertain		Uncertain	Nucleoplasm<br>Golgi apparatus	Ovarian cancer:6.89e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 62.3	Expressed in all		
KIAA0232		ENSG00000170871	KIAA0232	4	6781375-6884170	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036891, HPA036892, HPA061498	Approved		Approved	Cytosol	Renal cancer:3.91e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.8	Expressed in all		
KIAA0355		ENSG00000166398	KIAA0355	19	34254537-34355586	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014570	Uncertain		Approved	Nucleoplasm	Melanoma:2.82e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.2	Mixed		
KIAA0368	ECM29, FLJ22036	ENSG00000136813	KIAA0368	9	111360692-111484745	Predicted intracellular proteins	Evidence at protein level	HPA021646, HPA059795	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 80.8	Mixed		
KIAA0391	MRPP3, PRORP	ENSG00000100890	KIAA0391	14	35121846-35277614	Predicted intracellular proteins	Evidence at protein level	HPA020459	Approved		Supported	Nucleus<br>Mitochondria		Mixed	Expressed in all			parathyroid gland: 42.6	Expressed in all		
KIAA0408		ENSG00000189367	KIAA0408	6	127440343-127459391	Predicted intracellular proteins	Evidence at protein level	HPA044035, HPA053341	Uncertain		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enhanced		cerebral cortex: 43.8	lung: 30.8	Cell line enhanced		AF22: 21.1;SCLC-21H: 62.8;SH-SY5Y: 28.1
KIAA0430	LKAP, Marf1, PPP1R34	ENSG00000166783	KIAA0430	16	15594386-15643166	Predicted intracellular proteins	Evidence at protein level	HPA017992	Approved		Supported	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 20.6	Expressed in all		
KIAA0513		ENSG00000135709	KIAA0513	16	85027751-85094230	Predicted intracellular proteins	Evidence at protein level	HPA012866, HPA014431	Enhanced		Uncertain	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.72e-5 (favourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 102.6	adrenal gland: 14.9	Mixed		
KIAA0556	JBTS26	ENSG00000047578	KIAA0556	16	27550133-27780369	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035089, HPA035090	Enhanced		Approved	Nuclear speckles<br>Plasma membrane	Head and neck cancer:3.00e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 47.6	thyroid gland: 26.7	Expressed in all		
KIAA0586	JBTS23, Talpid3	ENSG00000100578	KIAA0586	14	58427385-58551289	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000846, HPA050249	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.20e-4 (favourable)	Expressed in all	Mixed			testis: 29.3	Expressed in all		
KIAA0753	MNR, OFIP	ENSG00000198920	KIAA0753	17	6578148-6640927	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023057, HPA023494	Enhanced		Enhanced	Centrosome<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 33.2	Mixed		
KIAA0825	C5orf36, DKFZp686F0372, MGC34713	ENSG00000185261	KIAA0825	5	94152966-94618597	Predicted intracellular proteins	Evidence at protein level	HPA038030, HPA038031	Uncertain					Not detected	Mixed			testis: 5.4	Cell line enhanced		HeLa: 6.1
KIAA0895		ENSG00000164542	KIAA0895	7	36324221-36390125	Predicted intracellular proteins	Evidence at transcript level	HPA021036, HPA061066	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cell Junctions<br>Cytosol		Expressed in all	Tissue enhanced		testis: 44.5	parathyroid gland: 23.9	Cell line enhanced		SCLC-21H: 51.4
KIAA0895L	LOC653319	ENSG00000196123	KIAA0895 like	16	67175602-67184040	Predicted intracellular proteins	Evidence at transcript level	HPA065996	Approved		Approved	Nucleoplasm<br>Vesicles	Pancreatic cancer:3.16e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 25.4	Expressed in all		
KIAA0907	BLOM7, SNORA80EHG	ENSG00000132680	KIAA0907	1	155913043-155934400	Predicted intracellular proteins	Evidence at protein level	HPA008796	Approved		Approved	Nucleoplasm	Renal cancer:2.78e-10 (unfavourable), Liver cancer:1.01e-6 (unfavourable), Urothelial cancer:4.36e-5 (favourable), Prostate cancer:3.87e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 55.3	Expressed in all		
KIAA0930	bK268H5.C22.1, C22orf9	ENSG00000100364	KIAA0930	22	45190338-45240769	Predicted intracellular proteins	Evidence at protein level	HPA038091	Uncertain		Approved	Nuclear membrane<br>Mitochondria	Liver cancer:6.90e-8 (unfavourable), Renal cancer:8.95e-7 (unfavourable), Endometrial cancer:9.22e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 76.2	Cell line enhanced		THP-1: 220.8
KIAA1107		ENSG00000069712	KIAA1107	1	92166985-92184723	Predicted intracellular proteins	Evidence at protein level	HPA024216	Supported					Mixed	Group enriched	9	cerebral cortex: 45.9;testis: 10.7	adrenal gland,epididymis: 3.2	Mixed		
KIAA1143		ENSG00000163807	KIAA1143	3	44737661-44761662	Predicted intracellular proteins	Evidence at protein level	HPA045018, HPA061799	Approved		Approved	Nucleus<br>Cytokinetic bridge	Renal cancer:3.26e-6 (favourable), Colorectal cancer:3.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 15.0	Expressed in all		
KIAA1147	LCHN	ENSG00000257093	KIAA1147	7	141656728-141702153	Predicted intracellular proteins	Evidence at protein level	HPA029467, HPA061437	Approved		Approved	Golgi apparatus	Head and neck cancer:6.24e-4 (favourable), Renal cancer:8.01e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 21.1	Mixed		
KIAA1191	FLJ21022, p33MONOX	ENSG00000122203	KIAA1191	5	176346061-176361968	Predicted intracellular proteins	Evidence at protein level	HPA044701, HPA048145	Uncertain		Approved	Nucleoplasm	Renal cancer:9.94e-5 (favourable)	Expressed in all	Expressed in all			kidney: 198.3	Expressed in all		
KIAA1210		ENSG00000250423	KIAA1210	X	119078635-119150579	Predicted intracellular proteins	Evidence at protein level	HPA000551, HPA048322	Enhanced					Tissue enhanced	Group enriched	5	epididymis: 47.9;seminal vesicle: 27.4;testis: 58.3	fallopian tube: 8.6	Not detected		
KIAA1211		ENSG00000109265	KIAA1211	4	56049073-56328625	Predicted intracellular proteins	Evidence at protein level	HPA043249, HPA048148	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enhanced		testis: 39.9	small intestine: 23.1	Cell line enhanced		SCLC-21H: 37.8;SH-SY5Y: 72.8
KIAA1211L	C2orf55, MGC42367	ENSG00000196872	KIAA1211 like	2	98793846-98936259	Predicted intracellular proteins	Evidence at protein level	HPA051082, HPA061678	Uncertain		Approved	Microtubules<br>Cytokinetic bridge<br>Centrosome	Renal cancer:1.13e-5 (favourable), Thyroid cancer:1.33e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 36.7;epididymis: 38.2	fallopian tube: 36.1	Cell line enhanced		BEWO: 39.4;HDLM-2: 56.9
KIAA1217	DKFZP761L0424, SKT	ENSG00000120549	KIAA1217	10	23694746-24547848	Predicted intracellular proteins	Evidence at protein level	HPA004941	Approved		Approved	Nucleus<br>Cytosol	Pancreatic cancer:7.63e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 87.7	Cell line enhanced		BEWO: 79.6
KIAA1257		ENSG00000114656	KIAA1257	3	128909866-129002690	Predicted intracellular proteins	Evidence at transcript level	HPA042811, HPA048445	Uncertain		Approved	Cell Junctions<br>Cytosol		Mixed	Tissue enriched	7	testis: 34.5	placenta: 5.1	Cell line enhanced		AF22: 6.0;BEWO: 11.3;HL-60: 9.2;THP-1: 5.6
KIAA1328		ENSG00000150477	KIAA1328	18	36829106-37232172	Predicted intracellular proteins	Evidence at protein level	HPA040946	Approved		Approved	Nuclear speckles<br>Vesicles<br>Lipid droplets		Mixed	Expressed in all			testis: 35.8	Expressed in all		
KIAA1429	DKFZP434I116, fSAP121	ENSG00000164944	KIAA1429	8	94487693-94553529	Predicted intracellular proteins	Evidence at protein level	HPA031530	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 30.2	Expressed in all		
KIAA1456	C8orf79, FLJ36980	ENSG00000250305	KIAA1456	8	12945642-13031503	Predicted intracellular proteins	Evidence at transcript level	HPA024673	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:2.77e-7 (favourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 31.4	cerebral cortex: 6.6	Cell line enhanced		AF22: 6.3;BJ: 7.8;fHDF/TERT166: 9.6;SCLC-21H: 5.2
KIAA1462	JCAD	ENSG00000165757	KIAA1462	10	30012800-30115494	Predicted intracellular proteins	Evidence at protein level	HPA017956	Enhanced		Supported	Vesicles<br>Cell Junctions	Stomach cancer:2.01e-4 (unfavourable), Renal cancer:2.54e-4 (unfavourable)	Expressed in all	Mixed			placenta: 48.7	Cell line enhanced		HUVEC TERT2: 25.1;TIME: 55.5
KIAA1522		ENSG00000162522	KIAA1522	1	32741885-32774970	Predicted intracellular proteins	Evidence at protein level	HPA032050, HPA032051, HPA064839	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Liver cancer:6.29e-7 (unfavourable), Renal cancer:1.29e-5 (favourable), Pancreatic cancer:8.25e-5 (unfavourable)	Expressed in all	Mixed			skin: 72.8	Cell line enhanced		CAPAN-2: 110.4
KIAA1551	C12orf35, FLJ10652, FLJ20696, UTA2-1	ENSG00000174718	KIAA1551	12	31959370-31993107	Predicted intracellular proteins	Evidence at protein level	HPA013816, HPA015622	Approved		Supported	Nucleoli<br>Intermediate filaments<br>Cytosol	Renal cancer:5.04e-9 (unfavourable)	Expressed in all	Expressed in all			ovary: 90.9	Expressed in all		
KIAA1586		ENSG00000168116	KIAA1586	6	57046532-57055239	Predicted intracellular proteins	Evidence at protein level	HPA036370	Enhanced		Approved	Nucleus<br>Nuclear membrane		Expressed in all	Mixed			testis: 14.0	Expressed in all		
KIAA1614		ENSG00000135835	KIAA1614	1	180913154-180951614	Predicted intracellular proteins	Evidence at protein level	HPA028227, HPA061684	Approved		Approved	Nuclear membrane<br>Vesicles		Mixed	Mixed			thyroid gland: 9.2	Cell line enhanced		RH-30: 17.2;SH-SY5Y: 47.3
KIAA1671		ENSG00000197077	KIAA1671	22	24952730-25197448	Predicted intracellular proteins	Evidence at protein level	HPA018135	Approved		Approved	Microtubules	Renal cancer:3.19e-6 (favourable)	Expressed in all	Mixed			thyroid gland: 44.6	Mixed		
KIAA1683		ENSG00000130518	KIAA1683	19	18257097-18274509	Predicted intracellular proteins	Evidence at protein level	HPA042409	Enhanced					Mixed	Tissue enriched	6	testis: 34.3	endometrium: 5.3	Cell line enhanced		A549: 2.3
KIAA1755	RP5-1054A22.3	ENSG00000149633	KIAA1755	20	38210488-38260772	Predicted intracellular proteins	Evidence at protein level	HPA051064	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Vesicles		Tissue enhanced	Mixed			cerebral cortex: 33.6	Cell line enhanced		AF22: 74.8;ASC TERT1: 11.9;WM-115: 19.1
KIAA1841		ENSG00000162929	KIAA1841	2	61065871-61138034	Predicted intracellular proteins	Evidence at transcript level	HPA051240	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			prostate: 6.9	Mixed		
KIAA1958	FLJ39294	ENSG00000165185	KIAA1958	9	112486847-112669397	Predicted intracellular proteins	Evidence at protein level	HPA020625	Enhanced		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			ovary: 12.2	Mixed		
KIAA2012		ENSG00000182329	KIAA2012	2	202073289-202205203	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	9	fallopian tube: 14.7	testis: 1.5	Not detected		
KIAA2022	KIDLIA, MRX98, XPN	ENSG00000050030	KIAA2022	X	74732849-74925485	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA000407	Uncertain		Uncertain	Nucleoplasm<br>Midbody		Mixed	Tissue enhanced		cerebral cortex: 5.4;parathyroid gland: 5.3	prostate: 1.9	Group enriched	6	HAP1: 5.0;Karpas-707: 5.9;SiHa: 6.2
KIAA2026	FLJ20375	ENSG00000183354	KIAA2026	9	5881596-6007901	Predicted intracellular proteins	Evidence at protein level	HPA002109	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:8.34e-4 (favourable)	Expressed in all	Expressed in all			testis: 23.0	Expressed in all		
KIF11	Eg5, HKSP, KNSL1, TRIP5	ENSG00000138160	Kinesin family member 11	10	92593286-92655395	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006916, HPA010093, HPA010568, CAB017617	Enhanced		Supported	Mitotic spindle<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.19e-7 (unfavourable), Pancreatic cancer:2.30e-4 (unfavourable), Lung cancer:3.27e-4 (unfavourable)	Expressed in all	Mixed			testis: 21.8	Expressed in all		
KIF12		ENSG00000136883	Kinesin family member 12	9	114086126-114099291	Predicted intracellular proteins	Evidence at protein level	HPA020192, HPA024127	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		gallbladder: 36.6;kidney: 46.9	thyroid gland: 33.0	Cell line enhanced		CACO-2: 6.3;RPTEC TERT1: 31.9;SCLC-21H: 7.6
KIF13A	bA500C11.2	ENSG00000137177	Kinesin family member 13A	6	17759183-17987623	Predicted intracellular proteins	Evidence at protein level	HPA029253, HPA029254	Uncertain				Liver cancer:5.06e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.3	Mixed		
KIF13B	GAKIN, KIAA0639	ENSG00000197892	Kinesin family member 13B	8	29067279-29263124	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025023, HPA049655	Enhanced				Renal cancer:0.00e+0 (favourable), Pancreatic cancer:4.77e-4 (unfavourable), Head and neck cancer:6.26e-4 (favourable), Colorectal cancer:8.92e-4 (favourable)	Expressed in all	Tissue enriched	10	parathyroid gland: 208.8	kidney: 20.2	Mixed		
KIF14	KIAA0042	ENSG00000118193	Kinesin family member 14	1	200551497-200620734	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038061, HPA058220	Uncertain		Supported	Midbody ring<br>Cytosol	Lung cancer:8.64e-4 (unfavourable)	Mixed	Mixed			testis: 4.6	Mixed		
KIF15	HKLP2, KNSL7, NY-BR-62	ENSG00000163808	Kinesin family member 15	3	44761717-44873376	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035516, HPA035517	Approved				Colorectal cancer:3.12e-4 (favourable)	Mixed	Tissue enhanced		testis: 14.2	bone marrow: 3.1	Mixed		
KIF16B	C20orf23, dJ971B4.1, FLJ20135, SNX23	ENSG00000089177	Kinesin family member 16B	20	16272104-16573434	Predicted intracellular proteins	Evidence at protein level	HPA051198	Approved		Uncertain	Mitochondria	Renal cancer:7.61e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.9	Mixed		
KIF17	KIAA1405, KIF17B, KIF3X, KLP-2, OSM-3	ENSG00000117245	Kinesin family member 17	1	20664014-20718017	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032085	Enhanced		Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	6	testis: 23.7	cerebral cortex: 3.8	Cell line enhanced		hTERT-HME1: 3.0;U-2 OS: 2.4
KIF18A	DKFZP434G2226, PPP1R99	ENSG00000121621	Kinesin family member 18A	11	28020620-28108308	Predicted intracellular proteins	Evidence at protein level	HPA039312, HPA039484	Approved		Supported	Microtubules<br>Cytokinetic bridge		Mixed	Tissue enhanced		testis: 23.4	lymph node: 5.3	Mixed		
KIF18B		ENSG00000186185	Kinesin family member 18B	17	44924709-44947711	Predicted intracellular proteins	Evidence at protein level	HPA024205	Enhanced		Supported	Nucleus<br>Microtubule ends<br>Cytosol	Liver cancer:2.44e-6 (unfavourable), Pancreatic cancer:2.16e-4 (unfavourable), Melanoma:6.90e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 8.4	lymph node: 7.3	Mixed		
KIF19	FLJ37300, KIF19A	ENSG00000196169	Kinesin family member 19	17	74326210-74355820	Predicted intracellular proteins	Evidence at protein level	HPA043638, HPA073303	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Centrosome		Mixed	Tissue enhanced		fallopian tube: 19.0;spleen: 6.6	duodenum: 2.9	Cell line enriched	13	SCLC-21H: 5.1
KIF1A	ATSV, C2orf20, SPG30, UNC104	ENSG00000130294	Kinesin family member 1A	2	240713764-240820308	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005442			Approved	Microtubule organizing center<br>Cytosol	Endometrial cancer:4.97e-4 (unfavourable)	Tissue enhanced	Tissue enriched	13	cerebral cortex: 308.3	adrenal gland: 23.0	Cell line enhanced		AN3-CA: 79.8;HAP1: 157.5;K-562: 125.1;SCLC-21H: 477.1
KIF1B	CMT2, CMT2A, HMSNII, KIAA0591, KLP	ENSG00000054523	Kinesin family member 1B	1	10210805-10381603	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015177	Approved		Uncertain	Nucleoli fibrillar center<br>Cytosol	Renal cancer:2.91e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 105.4	Expressed in all		
KIF1BP	DKFZP586B0923, KBP, KIAA1279, TTC20	ENSG00000198954	KIF1 binding protein	10	68988721-69043544	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035538, HPA035539	Uncertain				Renal cancer:2.60e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 34.8	Mixed		
KIF1C	SAX2, SPAX2, SPG58	ENSG00000129250	Kinesin family member 1C	17	4997948-5028401	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024602, HPA045020	Approved				Renal cancer:2.26e-9 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 193.6	Expressed in all		
KIF20A	RAB6KIFL	ENSG00000112984	Kinesin family member 20A	5	138178719-138187715	Predicted intracellular proteins	Evidence at protein level	HPA036909, HPA036910	Approved		Supported	Nucleoplasm<br>Cytokinetic bridge<br>Cleavage furrow	Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.14e-12 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable), Lung cancer:6.79e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 20.2	tonsil: 11.5	Mixed		
KIF20B	CT90, KRMP1, MPHOSPH1, MPP1	ENSG00000138182	Kinesin family member 20B	10	89701610-89774939	Predicted intracellular proteins	Evidence at protein level	HPA031263	Uncertain				Renal cancer:3.06e-6 (unfavourable), Pancreatic cancer:1.21e-4 (unfavourable)	Expressed in all	Mixed			testis: 12.8	Expressed in all		
KIF21A	FEOM1, FLJ20052	ENSG00000139116	Kinesin family member 21A	12	39293228-39443390	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB022079, HPA058432	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:8.07e-8 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 75.0	fallopian tube: 54.6	Cell line enhanced		SH-SY5Y: 199.8
KIF21B	DKFZP434J212, KIAA0449	ENSG00000116852	Kinesin family member 21B	1	200969390-201023700	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027249, HPA027274	Approved					Mixed	Tissue enhanced		cerebral cortex: 28.8	bone marrow: 22.9	Cell line enhanced		HMC-1: 37.2;Karpas-707: 36.3;U-266/70: 69.6;U-266/84: 31.7
KIF22	Kid, KNSL4, OBP-1, OBP-2	ENSG00000079616	Kinesin family member 22	16	29790719-29805385	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041076, HPA048213	Approved		Approved	Nuclear speckles	Cervical cancer:3.87e-8 (favourable)	Expressed in all	Expressed in all			bone marrow: 53.9	Expressed in all		
KIF23	KNSL5, MKLP-1, MKLP1	ENSG00000137807	Kinesin family member 23	15	69414246-69448427	Predicted intracellular proteins	Evidence at protein level	CAB010414, HPA045208, HPA068831	Approved		Enhanced	Nucleoplasm	Liver cancer:3.18e-5 (unfavourable), Pancreatic cancer:3.69e-5 (unfavourable), Endometrial cancer:8.62e-4 (unfavourable)	Mixed	Mixed			testis: 19.7	Expressed in all		
KIF24	bA571F15.4, C9orf48, FLJ10933, FLJ43884	ENSG00000186638	Kinesin family member 24	9	34252381-34311371	Predicted intracellular proteins	Evidence at protein level	HPA020643	Uncertain				Cervical cancer:1.33e-4 (favourable)	Mixed	Tissue enhanced		testis: 20.2	fallopian tube: 5.2	Mixed		
KIF25	KNSL3	ENSG00000125337	Kinesin family member 25	6	167996241-168045089	Predicted intracellular proteins	Evidence at protein level	HPA046153	Uncertain					Tissue enhanced	Tissue enriched	5	adipose tissue: 8.7	placenta: 1.6	Cell line enhanced		HDLM-2: 1.1;U-937: 1.3;WM-115: 1.0
KIF26A	DKFZP434N178, KIAA1236	ENSG00000066735	Kinesin family member 26A	14	104138723-104180894	Predicted intracellular proteins	Evidence at protein level	HPA046882, HPA060346	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:7.78e-4 (unfavourable)	Group enriched	Mixed			adipose tissue: 5.0	Cell line enhanced		HeLa: 18.9;MCF7: 18.8;NTERA-2: 20.8;REH: 17.1;SCLC-21H: 22.6;SH-SY5Y: 41.6
KIF26B	FLJ10157	ENSG00000162849	Kinesin family member 26B	1	245154985-245709431	Predicted intracellular proteins	Evidence at protein level	HPA027709, HPA028478, HPA028561, HPA028562	Enhanced		Approved	Plasma membrane<br>Microtubules	Ovarian cancer:1.24e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 2.3	Cell line enhanced		HSkMC: 8.1;REH: 19.4;SH-SY5Y: 11.8;U-937: 8.1
KIF27	DKFZp434D0917	ENSG00000165115	Kinesin family member 27	9	83836698-83921465	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		testis: 46.6	thyroid gland: 14.0	Mixed		
KIF2A	HK2, KIF2	ENSG00000068796	Kinesin family member 2A	5	62306162-62537249	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004715, HPA004716	Approved		Enhanced	Nucleus<br>Nucleoli<br>Centrosome	Liver cancer:3.17e-6 (unfavourable), Renal cancer:3.81e-5 (unfavourable), Colorectal cancer:1.70e-4 (favourable), Head and neck cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			testis: 91.8	Expressed in all		
KIF2B		ENSG00000141200	Kinesin family member 2B	17	53822901-53825213	Predicted intracellular proteins	Evidence at protein level	HPA023081, HPA023103, HPA024795	Uncertain		Uncertain	Nucleoli<br>Microtubules<br>Cytokinetic bridge<br>Mitotic spindle		Not detected	Tissue enriched	1329	testis: 132.9	all non-specific tissues: 0.0	Not detected		
KIF2C	CT139, KNSL6, MCAK	ENSG00000142945	Kinesin family member 2C	1	44739818-44767767	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006219			Supported	Nucleoplasm<br>Midbody<br>Centrosome	Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.07e-7 (unfavourable), Pancreatic cancer:6.86e-4 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 135.0	bone marrow: 20.4	Mixed		
KIF3A	FLA10, KLP-20	ENSG00000131437	Kinesin family member 3A	5	132692628-132737638	Predicted intracellular proteins	Evidence at protein level	CAB037085	Approved		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 82.8	testis: 43.9	Expressed in all		
KIF3B	FLA8, KIAA0359, KLP-11	ENSG00000101350	Kinesin family member 3B	20	32277664-32335011	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007119	Approved		Uncertain	Nucleoplasm<br>Nucleoli<br>Golgi apparatus	Renal cancer:1.44e-12 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 80.8	Expressed in all		
KIF3C		ENSG00000084731	Kinesin family member 3C	2	25926596-25982749	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035755			Approved	Nuclear membrane<br>Nuclear bodies<br>Intermediate filaments	Endometrial cancer:1.32e-5 (unfavourable), Melanoma:1.22e-4 (favourable), Renal cancer:7.57e-4 (unfavourable)	Expressed in all	Tissue enriched	14	cerebral cortex: 129.6	adrenal gland: 9.1	Cell line enhanced		SH-SY5Y: 57.6
KIF4A	FLJ12530, FLJ12655, FLJ14204, FLJ20631, HSA271784, KIF4, KIF4-G1, MRX100	ENSG00000090889	Kinesin family member 4A	X	70290090-70420832	Predicted intracellular proteins	Evidence at protein level	HPA034745, HPA034746, HPA061583	Approved		Enhanced	Nucleoplasm<br>Cytokinetic bridge	Liver cancer:7.37e-6 (unfavourable), Pancreatic cancer:9.44e-6 (unfavourable)	Mixed	Mixed			bone marrow: 7.0	Mixed		
KIF4B		ENSG00000226650	Kinesin family member 4B	5	155013755-155018132	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034745, HPA034746, HPA061583	Uncertain		Enhanced	Nucleoplasm		Not detected	Tissue enriched	63	testis: 6.3	all non-specific tissues: 0.0	Not detected		
KIF5A	D12S1889, MY050, NKHC, SPG10	ENSG00000155980	Kinesin family member 5A	12	57549998-57586632	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004469, HPA073448	Enhanced	Approved	Approved	Nucleoplasm<br>Mitotic spindle<br>Cytosol	Pancreatic cancer:5.23e-4 (favourable)	Tissue enriched	Tissue enriched	28	cerebral cortex: 325.7	adrenal gland: 11.4	Cell line enhanced		HDLM-2: 28.1;NTERA-2: 15.0;SCLC-21H: 36.2
KIF5B	KNS, KNS1	ENSG00000170759	Kinesin family member 5B	10	32009010-32056431	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009846, HPA037589, HPA037590	Approved		Enhanced	Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 187.6	Expressed in all		
KIF5C		ENSG00000168280	Kinesin family member 5C	2	148875250-149026759	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035210, HPA062272	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 205.3	prostate: 44.3	Cell line enhanced		AF22: 38.5;NTERA-2: 39.3;SCLC-21H: 236.2;SH-SY5Y: 49.2
KIF6	C6orf102, dJ1043E3.1, dJ137F1.4, dJ188D3.1, DKFZp451I2418, MGC33317	ENSG00000164627	Kinesin family member 6	6	39329990-39725405	Predicted intracellular proteins	Evidence at protein level	HPA038811, HPA058624	Enhanced		Approved	Centrosome		Mixed	Group enriched	6	cerebral cortex: 7.0;fallopian tube: 6.0;testis: 9.6	lung: 1.2	Cell line enhanced		RPMI-8226: 6.3;SCLC-21H: 14.3;SK-MEL-30: 4.0
KIF7	JBTS12	ENSG00000166813	Kinesin family member 7	15	89608789-89655451	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043145	Approved				Endometrial cancer:3.80e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 5.3	Cell line enhanced		U-2197: 36.1
KIF9	MGC104186	ENSG00000088727	Kinesin family member 9	3	47228026-47283451	Predicted intracellular proteins	Evidence at protein level	HPA022031, HPA022033, HPA030429	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:5.95e-6 (favourable), Colorectal cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			testis: 87.6	Expressed in all		
KIFAP3	FLA3, KAP-1, KAP3, SMAP	ENSG00000075945	Kinesin associated protein 3	1	169921326-170085208	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023738, HPA023742	Supported					Expressed in all	Expressed in all			cerebral cortex: 106.0	Expressed in all		
KIFC1	HSET, KNSL2	ENSG00000237649	Kinesin family member C1	6	33391536-33409924	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055997, HPA062674	Supported		Approved	Centrosome	Renal cancer:0.00e+0 (unfavourable), Liver cancer:7.07e-8 (unfavourable), Pancreatic cancer:4.21e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 3.2	bone marrow: 2.8	Mixed		
KIFC3		ENSG00000140859	Kinesin family member C3	16	57758217-57863053	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA021240	Uncertain					Expressed in all	Expressed in all			skin: 98.4	Expressed in all		
KIN	KIN17, Rts2	ENSG00000151657	Kin17 DNA and RNA binding protein	10	7750962-7787981	Predicted intracellular proteins	Evidence at protein level	CAB016339, HPA038700			Enhanced	Nucleus	Renal cancer:1.44e-7 (unfavourable), Urothelial cancer:3.23e-5 (favourable)	Expressed in all	Mixed			endometrium: 5.6	Expressed in all		
KIZ	C20orf19, HT013, NCRNA00153, PLK1S1	ENSG00000088970	Kizuna centrosomal protein	20	21125983-21246622	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.11e-8 (unfavourable), Endometrial cancer:4.45e-4 (favourable)	Expressed in all	Expressed in all			testis: 82.2	Expressed in all		
KLC1	hKLC1B, hKLC1G, hKLC1J, hKLC1N, hKLC1P, hKLC1R, hKLC1S, KLC, KNS2, KNS2A	ENSG00000126214	Kinesin light chain 1	14	103561896-103714249	Predicted intracellular proteins	Evidence at protein level	CAB009798, HPA044617, HPA052450	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:6.75e-4 (favourable), Renal cancer:7.17e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 467.9	Expressed in all		
KLC2	FLJ12387	ENSG00000174996	Kinesin light chain 2	11	66257294-66267860	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040416, HPA040434	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Head and neck cancer:3.16e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 63.8	Expressed in all		
KLC3	KLC2L, KLCt, KNS2B	ENSG00000104892	Kinesin light chain 3	19	45333434-45351520	Predicted intracellular proteins	Evidence at protein level	HPA052797, HPA056508	Approved		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Endometrial cancer:1.46e-4 (unfavourable)	Mixed	Tissue enriched	6	skin: 63.9	esophagus: 10.0	Cell line enhanced		A-431: 31.4;HaCaT: 14.3
KLC4	bA387M24.3, KNSL8	ENSG00000137171	Kinesin light chain 4	6	43040777-43075099	Predicted intracellular proteins	Evidence at protein level	HPA030168, HPA030169	Enhanced		Approved	Mitochondria<br>Cytosol	Renal cancer:6.99e-6 (favourable)	Expressed in all	Expressed in all			duodenum: 70.0	Expressed in all		
KLF1	EKLF	ENSG00000105610	Kruppel like factor 1	19	12884423-12887181	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051850	Enhanced		Supported	Nucleoplasm		Not detected	Tissue enriched	24	bone marrow: 25.7	placenta: 1.0	Group enriched	33	HEL: 56.0;K-562: 136.3
KLF10	EGRA, TIEG, TIEG1	ENSG00000155090	Kruppel like factor 10	8	102648779-102655902	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Lung cancer:2.61e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 100.0	Expressed in all		
KLF11	MODY7, TIEG2, Tieg3	ENSG00000172059	Kruppel like factor 11	2	10042849-10054836	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058276			Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			testis: 56.4	Mixed		
KLF12	AP-2rep, AP2REP, HSPC122	ENSG00000118922	Kruppel like factor 12	13	73686089-73995056	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064146			Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:5.03e-6 (unfavourable)	Expressed in all	Mixed			epididymis: 13.7	Mixed		
KLF13	BTEB3, FKLF-2, NSLP1, RFLAT-1	ENSG00000169926	Kruppel like factor 13	15	31326855-31435665	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:2.37e-9 (favourable)	Expressed in all	Expressed in all			bone marrow: 37.8	Mixed		
KLF14	BTEB5	ENSG00000266265	Kruppel like factor 14	7	130731235-130734061	Predicted intracellular proteins	Evidence at transcript level	HPA044729	Uncertain					Tissue enriched	Tissue enhanced		placenta: 1.2	adipose tissue: 0.7	Cell line enhanced		RH-30: 1.2
KLF15	KKLF	ENSG00000163884	Kruppel like factor 15	3	126342635-126357442	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028866	Uncertain				Renal cancer:3.27e-7 (favourable)	Tissue enhanced	Tissue enhanced		ovary: 42.8	adipose tissue: 37.0	Cell line enhanced		ASC diff: 38.8;HHSteC: 28.8
KLF16	BTEB4, DRRF, NSLP2	ENSG00000129911	Kruppel like factor 16	19	1852399-1863568	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052481	Approved		Supported	Nucleus	Renal cancer:2.93e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 17.5	Expressed in all		
KLF17	FLJ40160, Zfp393, ZNF393	ENSG00000171872	Kruppel like factor 17	1	44118850-44135140	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024629	Enhanced					Tissue enriched	Tissue enhanced		testis: 8.1	smooth muscle: 1.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1.4;BJ hTERT+ SV40 Large T+ RasG12V: 1.2;HBF TERT88: 1.5;U-138 MG: 2.6
KLF18		ENSG00000283039	Kruppel like factor 18	1	44137821-44141631	Predicted intracellular proteins	No evidence								Not detected			testis: 0.2	Not detected		
KLF2	LKLF	ENSG00000127528	Kruppel like factor 2	19	16324817-16327874	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055964	Approved		Approved	Nucleoplasm	Liver cancer:8.55e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 115.9	Cell line enhanced		TIME: 57.5;U-266/70: 36.1;U-266/84: 34.1
KLF3	BKLF	ENSG00000109787	Kruppel like factor 3	4	38664196-38701042	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049512, HPA065054	Supported		Enhanced	Nucleoplasm	Renal cancer:4.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.1	Mixed		
KLF4	EZF, GKLF	ENSG00000136826	Kruppel like factor 4	9	107484852-107490482	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002926	Enhanced		Supported	Nucleoplasm	Renal cancer:3.93e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 128.5	Cell line enhanced		hTCEpi: 66.2;U-2197: 130.0
KLF5	BTEB2, CKLF, IKLF	ENSG00000102554	Kruppel like factor 5	13	73054976-73077542	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040398	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Pancreatic cancer:2.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 279.6	esophagus: 216.2	Cell line enhanced		HaCaT: 113.4;hTCEpi: 113.2;RT4: 108.4;SiHa: 121.1
KLF6	BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9	ENSG00000067082	Kruppel like factor 6	10	3775996-3785281	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB013529, HPA069585	Supported		Approved	Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol	Renal cancer:2.28e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 323.6	Expressed in all		
KLF7	UKLF	ENSG00000118263	Kruppel like factor 7	2	207074137-207167267	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030490	Approved		Approved	Golgi apparatus	Renal cancer:4.26e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 30.5	Mixed		
KLF8	BKLF3, DXS741, ZNF741	ENSG00000102349	Kruppel like factor 8	X	56232421-56287889	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071740			Supported	Nucleoplasm	Head and neck cancer:3.32e-4 (favourable)	Mixed	Tissue enhanced		skin: 33.8	esophagus: 16.9	Cell line enhanced		hTCEpi: 9.9;RT4: 9.7;SK-BR-3: 7.9;T-47d: 18.2
KLF9	BTEB1	ENSG00000119138	Kruppel like factor 9	9	70384597-70414624	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029308			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:6.59e-6 (favourable)	Expressed in all	Expressed in all			smooth muscle: 88.4	Cell line enhanced		ASC TERT1: 58.2;HHSteC: 90.2
KLHDC1	MST025	ENSG00000197776	Kelch domain containing 1	14	49693105-49753152	Predicted intracellular proteins	Evidence at protein level	HPA020461	Approved		Supported	Cytosol	Pancreatic cancer:1.94e-4 (favourable)	Mixed	Mixed			endometrium: 9.7	Cell line enhanced		ASC diff: 3.8;ASC TERT1: 3.7
KLHDC10	KIAA0265, slim	ENSG00000128607	Kelch domain containing 10	7	130070510-130135720	Predicted intracellular proteins	Evidence at protein level	HPA020119	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 69.5	Expressed in all		
KLHDC2	HCLP-1, LCP	ENSG00000165516	Kelch domain containing 2	14	49767608-49786385	Predicted intracellular proteins	Evidence at protein level	HPA000628	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Nuclear bodies	Renal cancer:2.75e-10 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.1	Expressed in all		
KLHDC3	dJ20C7.3, hPeas, PEAS	ENSG00000124702	Kelch domain containing 3	6	43014103-43021298	Predicted intracellular proteins	Evidence at protein level	HPA030131, HPA030132, HPA030133, HPA030134	Uncertain		Supported	Nucleoplasm	Endometrial cancer:4.52e-4 (unfavourable), Pancreatic cancer:9.08e-4 (favourable), Cervical cancer:9.15e-4 (favourable)	Expressed in all	Expressed in all			testis: 251.9	Expressed in all		
KLHDC4	DKFZp434G0522	ENSG00000104731	Kelch domain containing 4	16	87696485-87765992	Predicted intracellular proteins	Evidence at protein level	HPA041665	Approved		Supported	Nucleoli	Pancreatic cancer:1.14e-4 (favourable), Urothelial cancer:1.69e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 19.0	Expressed in all		
KLHDC7A	FLJ38753	ENSG00000179023	Kelch domain containing 7A	1	18480982-18486126	Predicted intracellular proteins	Evidence at protein level	HPA056616	Uncertain		Approved	Nuclear speckles	Renal cancer:7.81e-9 (favourable), Urothelial cancer:1.88e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 20.8	urinary bladder: 6.4	Cell line enhanced		A549: 4.7;CAPAN-2: 8.9;EFO-21: 4.8;NTERA-2: 5.6;RPTEC TERT1: 8.6;RT4: 7.4;T-47d: 9.5
KLHDC7B	MGC16635	ENSG00000130487	Kelch domain containing 7B	22	50548033-50551023	Predicted intracellular proteins	Evidence at protein level	HPA000518	Uncertain				Breast cancer:1.30e-4 (favourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 12.7	thyroid gland: 3.4	Group enriched	6	HHSteC: 18.6;HMC-1: 87.0
KLHDC8A	FLJ10748	ENSG00000162873	Kelch domain containing 8A	1	205336065-205357090	Predicted intracellular proteins	Evidence at transcript level						Thyroid cancer:8.01e-4 (favourable)	Tissue enhanced	Tissue enriched	11	ovary: 288.4	adrenal gland: 26.0	Group enriched	7	AF22: 4.1;HAP1: 8.9;NTERA-2: 2.1;SCLC-21H: 10.2
KLHDC8B	MGC35097	ENSG00000185909	Kelch domain containing 8B	3	49171611-49176486	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008463, HPA014467	Supported		Enhanced	Cytosol	Lung cancer:1.47e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 70.0	Mixed		
KLHDC9	KARCA1	ENSG00000162755	Kelch domain containing 9	1	161098361-161100346	Predicted intracellular proteins	Evidence at protein level	HPA032058, HPA043197	Uncertain		Uncertain	Nucleoplasm	Ovarian cancer:4.20e-6 (favourable)	Expressed in all	Tissue enhanced		testis: 9.5	fallopian tube: 2.3	Cell line enhanced		EFO-21: 2.0
KLHL1	FLJ30047, KIAA1490, MRP2	ENSG00000150361	Kelch like family member 1	13	69700594-70108493	Predicted intracellular proteins	Evidence at transcript level	HPA021196	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 1.9	prostate: 0.5	Cell line enriched	8	HeLa: 1.6
KLHL10	FLJ32662	ENSG00000161594	Kelch like family member 10	17	41835685-41848384	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA067538	Enhanced					Not detected	Tissue enriched	48	testis: 90.0	epididymis: 1.8	Not detected		
KLHL12	C3IP1	ENSG00000117153	Kelch like family member 12	1	202891100-202928636	Predicted intracellular proteins	Evidence at protein level	HPA071324			Supported	Vesicles<br>Microtubule organizing center		Expressed in all	Expressed in all			testis: 81.9	Expressed in all		
KLHL13	BKLHD2, FLJ10262, KIAA1309	ENSG00000003096	Kelch like family member 13	X	117897813-118117340	Predicted intracellular proteins	Evidence at protein level	HPA046039, HPA059901	Approved		Approved	Cytosol		Mixed	Tissue enhanced		endometrium: 52.6	smooth muscle: 43.9	Cell line enhanced		HeLa: 40.3;RPTEC TERT1: 80.3;SH-SY5Y: 100.1
KLHL14	KIAA1384	ENSG00000197705	Kelch like family member 14	18	32672671-32773062	Predicted intracellular proteins	Evidence at protein level	HPA024777	Uncertain		Supported	Actin filaments<br>Cytosol		Group enriched	Tissue enhanced		parathyroid gland: 19.3;seminal vesicle: 17.9;thyroid gland: 23.0	spleen: 11.7	Cell line enhanced		Hep G2: 10.5;REH: 3.8;RPTEC TERT1: 6.3;SCLC-21H: 3.7
KLHL15	KIAA1677	ENSG00000174010	Kelch like family member 15	X	23983720-24027186	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065730	Uncertain		Approved	Aggresome<br>Cytosol		Expressed in all	Mixed			bone marrow: 34.7	Expressed in all		
KLHL17		ENSG00000187961	Kelch like family member 17	1	960587-965715	Predicted intracellular proteins	Evidence at protein level	HPA031251	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:1.89e-6 (unfavourable), Renal cancer:2.70e-6 (unfavourable), Cervical cancer:4.22e-4 (unfavourable)	Expressed in all	Mixed			skin: 9.7	Expressed in all		
KLHL18	FLJ13703, KIAA0795	ENSG00000114648	Kelch like family member 18	3	47282917-47346816	Predicted intracellular proteins	Evidence at protein level	HPA035027, HPA035028	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 14.2	Expressed in all		
KLHL2	MAV	ENSG00000109466	Kelch like family member 2	4	165207618-165323156	Predicted intracellular proteins	Evidence at protein level	HPA051637			Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:3.77e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 77.5	thyroid gland: 22.0	Mixed		
KLHL20	KHLHX, KLEIP	ENSG00000076321	Kelch like family member 20	1	173714941-173786702	Predicted intracellular proteins	Evidence at protein level	HPA025034, HPA053704	Approved		Supported	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			testis: 29.3	Expressed in all		
KLHL21	KIAA0469	ENSG00000162413	Kelch like family member 21	1	6590724-6614607	Predicted intracellular proteins	Evidence at protein level	HPA051364, HPA059307	Uncertain		Supported	Centrosome	Renal cancer:1.71e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 39.8	Mixed		
KLHL23	FLJ37812, MGC22679, MGC2610	ENSG00000213160	Kelch like family member 23	2	169694488-169776989	Predicted intracellular proteins	Evidence at protein level	HPA047593			Approved	Nucleoplasm<br>Actin filaments	Renal cancer:2.43e-5 (unfavourable), Liver cancer:2.09e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 42.8	Cell line enhanced		SCLC-21H: 98.2
KLHL24	DRE1, FLJ20059	ENSG00000114796	Kelch like family member 24	3	183635568-183684477	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056337	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 73.9	Expressed in all		
KLHL25	ENC-2, ENC2, FLJ12587	ENSG00000183655	Kelch like family member 25	15	85759323-85795030	Predicted intracellular proteins	Evidence at protein level	HPA023450	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 15.8	testis: 9.9	Mixed		
KLHL26		ENSG00000167487	Kelch like family member 26	19	18636965-18671714	Predicted intracellular proteins	Evidence at protein level	HPA023074	Uncertain				Renal cancer:1.25e-6 (favourable), Breast cancer:5.01e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.2	Mixed		
KLHL28	BTBD5, FLJ20081	ENSG00000179454	Kelch like family member 28	14	44924319-45042322	Predicted intracellular proteins	Evidence at transcript level	HPA000988			Approved	Cytosol		Expressed in all	Mixed			bone marrow: 17.2	Expressed in all		
KLHL29	KBTBD9, KIAA1921	ENSG00000119771	Kelch like family member 29	2	23385217-23708611	Predicted intracellular proteins	Evidence at protein level	HPA049057, HPA057379	Approved		Approved	Mitochondria<br>Cytosol	Pancreatic cancer:2.19e-4 (favourable), Renal cancer:6.29e-4 (unfavourable)	Mixed	Mixed			adrenal gland: 12.0	Cell line enhanced		RH-30: 18.8
KLHL3	KIAA1129	ENSG00000146021	Kelch like family member 3	5	137617500-137736090	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051291	Approved					Mixed	Mixed			thyroid gland: 13.7	Cell line enhanced		TIME: 10.9;U-266/70: 6.0
KLHL30	FLJ43374	ENSG00000168427	Kelch like family member 30	2	238138722-238152947	Predicted intracellular proteins	Evidence at transcript level	HPA062095			Approved	Microtubule organizing center		Mixed	Tissue enhanced		skeletal muscle: 22.1	heart muscle: 5.6	Cell line enhanced		BEWO: 3.1;RH-30: 4.4;THP-1: 1.5
KLHL31	bA345L23.2, BKLHD6, KBTBD1	ENSG00000124743	Kelch like family member 31	6	53647901-53665708	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		heart muscle: 29.4;skeletal muscle: 51.2	adipose tissue: 9.0	Cell line enhanced		SCLC-21H: 1.2
KLHL32	BKLHD5, KIAA1900	ENSG00000186231	Kelch like family member 32	6	96924620-97140754	Predicted intracellular proteins	Evidence at protein level	HPA039150	Enhanced					Mixed	Group enriched	6	cerebral cortex: 25.3;fallopian tube: 10.3	testis: 3.1	Cell line enhanced		Daudi: 2.3;HDLM-2: 4.1;SCLC-21H: 2.1;U-266/70: 1.7
KLHL33		ENSG00000185271	Kelch like family member 33	14	20425870-20435811	Predicted intracellular proteins	Evidence at transcript level	HPA056560	Uncertain					Not detected	Tissue enriched	10	skeletal muscle: 30.9	endometrium: 3.1	Cell line enriched	9	REH: 4.3
KLHL34	FLJ34960, RP11-450P7.3	ENSG00000185915	Kelch like family member 34	X	21654690-21658330	Predicted intracellular proteins	Evidence at protein level	HPA060287	Uncertain					Not detected	Tissue enriched	8	skeletal muscle: 8.8	duodenum,heart muscle: 1.1	Not detected		
KLHL35	FLJ33790	ENSG00000149243	Kelch like family member 35	11	75422394-75430629	Predicted intracellular proteins	Evidence at protein level	HPA039232, HPA039864	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Centrosome	Cervical cancer:4.63e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 3.6;testis: 6.2	cervix, uterine: 1.1	Cell line enhanced		CACO-2: 13.0;HMC-1: 8.9;PC-3: 8.3;SiHa: 19.5
KLHL36	C16orf44, FLJ12543	ENSG00000135686	Kelch like family member 36	16	84648525-84667686	Predicted intracellular proteins	Evidence at protein level	HPA023423	Approved		Approved	Cytosol	Renal cancer:5.52e-10 (favourable), Pancreatic cancer:9.81e-5 (favourable)	Expressed in all	Expressed in all			testis: 20.1	Mixed		
KLHL38	C8ORFK36	ENSG00000175946	Kelch like family member 38	8	123645527-123652950	Predicted intracellular proteins	Evidence at protein level	HPA024770, HPA027115	Uncertain		Uncertain	Nucleoplasm<br>Vesicles		Tissue enhanced	Group enriched	15	heart muscle: 35.8;skeletal muscle: 91.2	smooth muscle: 4.3	Cell line enhanced		BJ hTERT+: 1.4;SK-BR-3: 2.1;U-2197: 4.6
KLHL4	DKELCHL, KHL4, KIAA1687	ENSG00000102271	Kelch like family member 4	X	87517749-87670050	Predicted intracellular proteins	Evidence at protein level	HPA029192	Approved		Supported	Microtubules<br>Microtubule organizing center	Renal cancer:8.08e-5 (unfavourable)	Tissue enriched	Tissue enhanced		adrenal gland: 37.2	testis: 15.6	Cell line enhanced		AF22: 15.8;HUVEC TERT2: 28.7;NTERA-2: 25.8;TIME: 31.0
KLHL40	KBTBD5, NEM8, SRYP	ENSG00000157119	Kelch like family member 40	3	42685519-42692544	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024463, HPA052201	Enhanced					Tissue enhanced	Tissue enriched	14	skeletal muscle: 61.0	prostate: 4.3	Not detected		
KLHL41	KBTBD10, Krp1, SARCOSIN	ENSG00000239474	Kelch like family member 41	2	169509702-169526262	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021165, HPA021753, HPA021760	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Group enriched	Tissue enriched	22	skeletal muscle: 1750.6	esophagus: 79.6	Group enriched	8	HSkMC: 15.5;LHCN-M2: 29.3;RH-30: 53.9
KLHL42	Ctb9, KIAA1340, KLHDC5	ENSG00000087448	Kelch like family member 42	12	27780020-27803040	Predicted intracellular proteins	Evidence at protein level	HPA020979	Uncertain				Renal cancer:2.98e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 32.9	Expressed in all		
KLHL6	FLJ00029	ENSG00000172578	Kelch like family member 6	3	183487531-183555689	Predicted intracellular proteins	Evidence at protein level	HPA024512	Uncertain				Renal cancer:3.53e-4 (unfavourable)	Mixed	Tissue enhanced		lymph node: 35.1;tonsil: 28.7	appendix: 16.0	Cell line enhanced		Daudi: 29.8;U-266/70: 62.9;U-266/84: 32.1;U-698: 86.1
KLHL7	KLHL6, RP42, SBBI26	ENSG00000122550	Kelch like family member 7	7	23105758-23177914	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029491, HPA029492	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.98e-5 (favourable), Liver cancer:7.96e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 76.1	Expressed in all		
KLHL8	KIAA1378	ENSG00000145332	Kelch like family member 8	4	87160103-87240314	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013856, HPA017762	Approved		Enhanced	Nucleoplasm	Renal cancer:1.53e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 73.6	Expressed in all		
KLHL9	FLJ13568, KIAA1354	ENSG00000198642	Kelch like family member 9	9	21329671-21335380	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046039, HPA059901	Approved		Approved	Cytosol	Renal cancer:9.43e-10 (favourable)	Expressed in all	Expressed in all			thyroid gland: 27.0	Mixed		
KLLN	killin	ENSG00000227268	Killin, p53-regulated DNA replication inhibitor	10	87859161-87863437	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA074502			Supported	Nucleus		Mixed	Mixed			fallopian tube: 2.4	Mixed		
KMT2A	ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1	ENSG00000118058	Lysine methyltransferase 2A	11	118436490-118526832	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017794, CAB024270, HPA044910	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 31.0	Expressed in all		
KMT2B	CXXC10, HRX2, KIAA0304, MLL1B, MLL2, MLL4, TRX2, WBP7	ENSG00000272333	Lysine methyltransferase 2B	19	35718019-35738878	Cancer-related genes, Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006487			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 28.8	Expressed in all		
KMT2C	HALR, KIAA1506, MLL3	ENSG00000055609	Lysine methyltransferase 2C	7	152134922-152436005	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA074736			Supported	Nucleoplasm	Renal cancer:8.01e-6 (favourable)	Expressed in all	Expressed in all			skin: 25.0	Expressed in all		
KMT2D	ALR, CAGL114, MLL2, MLL4, TNRC21	ENSG00000167548	Lysine methyltransferase 2D	12	49018975-49059774	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035977	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 46.6	Expressed in all		
KMT5B	CGI-85, SUV420H1	ENSG00000110066	Lysine methyltransferase 5B	11	68154863-68213828	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063648			Supported	Nucleus	Urothelial cancer:9.30e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.2	Expressed in all		
KMT5C	MGC2705, SUV420H2	ENSG00000133247	Lysine methyltransferase 5C	19	55339853-55348120	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA052294	Uncertain		Approved	Nucleoplasm	Renal cancer:1.05e-8 (unfavourable)	Expressed in all	Mixed			skin: 4.8	Cell line enhanced		SCLC-21H: 21.9
KNL1	AF15Q14, CASC5, CT29, D40, hKNL-1, hSpc105, KIAA1570, MCPH4, PPP1R55, Spc7	ENSG00000137812	Kinetochore scaffold 1	15	40594020-40664342	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026624, HPA049647	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies	Lung cancer:2.11e-4 (unfavourable)	Mixed	Tissue enriched	7	testis: 31.7	lymph node: 4.4	Mixed		
KNOP1	101F10.1, C16orf88, FAM191A, TSG118	ENSG00000103550	Lysine rich nucleolar protein 1	16	19701934-19718235	Predicted intracellular proteins	Evidence at protein level	HPA041079, HPA066169	Uncertain		Supported	Nucleoli<br>Cytosol	Liver cancer:3.75e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.3	Expressed in all		
KNSTRN	C15orf23, FLJ14502, kinastrin, SKAP, TRAF4AF1	ENSG00000128944	Kinetochore localized astrin/SPAG5 binding protein	15	40382721-40394246	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042027	Enhanced		Supported	Microtubules<br>Mitotic spindle<br>Cytosol	Renal cancer:7.88e-9 (unfavourable), Pancreatic cancer:3.43e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 113.9	thyroid gland: 64.1	Expressed in all		
KNTC1	KIAA0166, ROD	ENSG00000184445	Kinetochore associated 1	12	122527246-122626396	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025241	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.89e-8 (unfavourable), Liver cancer:4.79e-6 (unfavourable), Head and neck cancer:8.69e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 43.4	bone marrow: 27.1	Expressed in all		
KPNA1	IPOA5, NPI-1, RCH2, SRP1	ENSG00000114030	Karyopherin subunit alpha 1	3	122421949-122514945	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA053627, HPA063426	Enhanced		Enhanced	Nucleus<br>Cytosol	Endometrial cancer:5.81e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.3	Expressed in all		
KPNA2	IPOA1, QIP2, RCH1, SRP1alpha	ENSG00000182481	Karyopherin subunit alpha 2	17	68035519-68046842	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB015460, HPA041270	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.26e-13 (unfavourable), Liver cancer:2.12e-10 (unfavourable), Urothelial cancer:2.19e-4 (unfavourable), Colorectal cancer:3.83e-4 (favourable), Lung cancer:5.77e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 349.5	Expressed in all		
KPNA3	hSRP1, IPOA4, SRP1gamma, SRP4	ENSG00000102753	Karyopherin subunit alpha 3	13	49699307-49792921	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA046852	Approved		Approved	Nucleoplasm<br>Cytosol	Glioma:1.48e-4 (favourable), Cervical cancer:2.80e-4 (unfavourable), Renal cancer:3.81e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.8	Expressed in all		
KPNA4	IPOA3, MGC12217, MGC26703, QIP1, SRP3	ENSG00000186432	Karyopherin subunit alpha 4	3	160494995-160565588	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB034336, HPA043154, HPA045500	Enhanced		Enhanced	Nucleus	Liver cancer:6.24e-7 (unfavourable), Pancreatic cancer:1.03e-6 (unfavourable), Endometrial cancer:8.59e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 36.6	Expressed in all		
KPNA5	IPOA6, SRP6	ENSG00000196911	Karyopherin subunit alpha 5	6	116681187-116741866	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB026464, HPA054037	Enhanced		Supported	Cytosol		Expressed in all	Tissue enhanced		testis: 78.5	ovary: 22.1	Expressed in all		
KPNA6	FLJ11249, IPOA7, KPNA7, MGC17918	ENSG00000025800	Karyopherin subunit alpha 6	1	32108038-32176568	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018863	Supported		Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.28e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.4	Expressed in all		
KPNA7	IPOA8	ENSG00000185467	Karyopherin subunit alpha 7	7	99173574-99207506	Predicted intracellular proteins	Evidence at protein level	HPA031395	Uncertain					Mixed	Tissue enhanced		stomach: 3.1	fallopian tube: 0.9	Cell line enhanced		A-431: 1.7;CAPAN-2: 1.2;SK-BR-3: 1.8
KPNB1	IMB1, Impnb, IPO1, IPOB, MGC2155, MGC2156, MGC2157, NTF97	ENSG00000108424	Karyopherin subunit beta 1	17	47649476-47685505	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA029878, CAB034449, HPA050302	Enhanced		Supported	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Liver cancer:2.55e-7 (unfavourable), Renal cancer:8.43e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 219.3	Expressed in all		
KPRP	C1orf45	ENSG00000203786	Keratinocyte proline rich protein	1	152759561-152762052	Predicted intracellular proteins	Evidence at protein level	HPA031988, HPA031990	Enhanced					Group enriched	Tissue enriched	19	skin: 267.5	breast: 13.8	Cell line enhanced		hTEC/SVTERT24-B: 1.9;U-2197: 1.1
KPTN	2E4	ENSG00000118162	Kaptin, actin binding protein	19	47475144-47484268	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041710, HPA041796	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:7.91e-6 (unfavourable), Renal cancer:7.82e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 7.9	Expressed in all		
KRAS	KRAS1, KRAS2	ENSG00000133703	KRAS proto-oncogene, GTPase	12	25204789-25250936	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA049830	Approved				Renal cancer:2.75e-5 (favourable), Pancreatic cancer:3.59e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 32.6	Expressed in all		
KRBA1	KIAA1862	ENSG00000133619	KRAB-A domain containing 1	7	149714781-149734575	Predicted intracellular proteins	Evidence at protein level	HPA021237, HPA050448	Approved		Approved	Nucleus<br>Cytosol	Pancreatic cancer:2.77e-4 (favourable)	Mixed	Mixed			heart muscle: 12.1	Mixed		
KRBOX1		ENSG00000240747	KRAB box domain containing 1	3	42809483-42942792	Predicted intracellular proteins	Evidence at transcript level	HPA046901			Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enriched	31	testis: 289.2	epididymis: 9.3	Cell line enhanced		CAPAN-2: 42.0;EFO-21: 21.7;hTEC/SVTERT24-B: 33.3;U-2197: 61.0
KRBOX4	FLJ20344, ZNF673	ENSG00000147121	KRAB box domain containing 4	X	46446857-46497422	Predicted intracellular proteins	Evidence at protein level	HPA065295			Approved	Nucleoplasm	Renal cancer:1.98e-7 (unfavourable), Liver cancer:2.87e-6 (unfavourable), Lung cancer:4.67e-5 (favourable), Urothelial cancer:2.17e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 29.3	Mixed		
KRCC1	FLJ22333	ENSG00000172086	Lysine rich coiled-coil 1	2	88027205-88055729	Predicted intracellular proteins	Evidence at protein level	HPA045618, HPA052666	Approved		Approved	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 59.4	Expressed in all		
KRI1	FLJ12949	ENSG00000129347	KRI1 homolog	19	10553078-10566037	Predicted intracellular proteins	Evidence at protein level	HPA043110, HPA043574	Approved		Enhanced	Nucleoli	Renal cancer:4.89e-10 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Colorectal cancer:9.37e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 26.6	Expressed in all		
KRIT1	CAM, CCM1	ENSG00000001631	KRIT1, ankyrin repeat containing	7	92198969-92246166	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049606	Supported		Uncertain	Vesicles		Expressed in all	Expressed in all			testis: 48.7	Expressed in all		
KRR1	HRB2, RIP-1	ENSG00000111615	KRR1, small subunit processome component homolog	12	75490861-75511636	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043433, HPA051690	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			bone marrow: 27.7	Expressed in all		
KRT1	EHK1, KRT1A	ENSG00000167768	Keratin 1	12	52674736-52680407	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002153, HPA017917, HPA062908	Enhanced					Group enriched	Tissue enriched	25	skin: 15454.7	breast: 622.4	Group enriched	36	HaCaT: 84.1;hTCEpi: 28.5
KRT10	CK10, K10, KPP	ENSG00000186395	Keratin 10	17	40818117-40822595	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000132, HPA012014	Enhanced				Renal cancer:9.32e-5 (unfavourable)	Expressed in all	Tissue enriched	31	skin: 18886.8	breast: 612.8	Expressed in all		
KRT12	K12	ENSG00000187242	Keratin 12	17	40861303-40867210	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055217, HPA055835	Enhanced					Mixed	Not detected			small intestine: 0.7	Not detected		
KRT13	CK13, K13, MGC161462, MGC3781	ENSG00000171401	Keratin 13	17	41500981-41505705	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000133, HPA030877, HPA069771	Enhanced		Enhanced	Intermediate filaments	Renal cancer:1.45e-6 (unfavourable), Pancreatic cancer:1.02e-4 (unfavourable)	Group enriched	Tissue enriched	20	esophagus: 35138.5	tonsil: 1728.2	Group enriched	134	A-431: 2202.2;HaCaT: 1446.9
KRT14	EBS3, EBS4	ENSG00000186847	Keratin 14	17	41582279-41586921	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000134, HPA000452, HPA000539, HPA023040	Enhanced		Enhanced	Intermediate filaments	Breast cancer:2.66e-4 (favourable)	Group enriched	Tissue enriched	19	skin: 7943.3	breast: 421.8	Cell line enhanced		HaCaT: 3480.4;HBEC3-KT: 1395.9;hTCEpi: 1722.3;U-2197: 628.5
KRT15	CK15, K15, K1CO	ENSG00000171346	Keratin 15	17	41513743-41522529	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023910, HPA024554	Enhanced		Supported	Nucleoplasm<br>Intermediate filaments	Breast cancer:4.50e-4 (favourable)	Tissue enhanced	Group enriched	7	breast: 321.5;esophagus: 784.4;skin: 1010.3	prostate: 94.7	Group enriched	12	HaCaT: 732.6;hTCEpi: 454.1
KRT16	NEPPK	ENSG00000186832	Keratin 16	17	41609778-41615899	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000136, HPA000539	Approved		Approved	Intermediate filaments	Pancreatic cancer:1.09e-5 (unfavourable)	Group enriched	Group enriched	6	esophagus: 477.8;tonsil: 102.4	seminal vesicle: 52.5	Cell line enriched	9	hTCEpi: 593.7
KRT17	PCHC1	ENSG00000128422	Keratin 17	17	41619437-41624842	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000029, HPA000452, HPA000453, HPA000539, HPA045062	Enhanced		Enhanced	Intermediate filaments	Breast cancer:4.44e-4 (favourable), Renal cancer:5.74e-4 (unfavourable)	Expressed in all	Tissue enhanced		breast: 222.3;seminal vesicle: 226.0;urinary bladder: 322.8	prostate: 115.6	Group enriched	6	hTCEpi: 14378.7;SiHa: 8960.6
KRT18		ENSG00000111057	Keratin 18	12	52948871-52952901	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB000008, CAB000030, HPA001605	Enhanced		Enhanced	Cytosol	Pancreatic cancer:1.78e-4 (unfavourable), Lung cancer:5.06e-4 (unfavourable)	Expressed in all	Mixed			placenta: 658.9	Cell line enhanced		A549: 5013.4;CACO-2: 5077.2;CAPAN-2: 3861.0;MCF7: 6322.5
KRT19	CK19, K19, K1CS, MGC15366	ENSG00000171345	Keratin 19	17	41523617-41528308	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000031, HPA002465	Enhanced		Supported	Intermediate filaments	Renal cancer:2.98e-5 (unfavourable), Pancreatic cancer:6.82e-5 (unfavourable)	Mixed	Mixed			urinary bladder: 678.5	Cell line enhanced		HBEC3-KT: 2110.1;RT4: 2508.0;SK-BR-3: 4076.0;T-47d: 3451.5
KRT2	KRT2A, KRTE	ENSG00000172867	Keratin 2	12	52644558-52652164	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006299, CAB037321	Enhanced		Approved	Golgi apparatus<br>Intermediate filaments<br>Cytosol		Group enriched	Tissue enriched	23	skin: 2600.1	breast: 112.2	Cell line enhanced		HEL: 1.9
KRT20	CK20, K20, MGC35423	ENSG00000171431	Keratin 20	17	40875941-40885227	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000032, HPA024309, HPA024684, HPA027236	Enhanced		Supported	Cytosol	Renal cancer:1.32e-4 (unfavourable), Liver cancer:7.05e-4 (unfavourable)	Group enriched	Tissue enhanced		colon: 356.1;duodenum: 252.4;rectum: 295.3;small intestine: 499.6	stomach: 82.3	Cell line enhanced		BEWO: 1.0;RT4: 2.3
KRT222	KA21, KRT222P, MGC45562	ENSG00000213424	Keratin 222	17	40654665-40665181	Predicted intracellular proteins	Evidence at protein level	HPA043708, HPA054586, HPA069774	Uncertain		Approved	Vesicles<br>Lipid droplets		Mixed	Tissue enhanced		cerebral cortex: 10.0;epididymis: 6.0	gallbladder: 2.7	Cell line enriched	6	RPTEC TERT1: 8.8
KRT23	CK23, DKFZP434G032, HAIK1, K23, MGC26158	ENSG00000108244	Keratin 23	17	40922696-40937634	Predicted intracellular proteins	Evidence at protein level	HPA012050, HPA016959, CAB017091	Approved		Approved	Intermediate filaments<br>Cytosol	Urothelial cancer:8.26e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 68.6;skin: 70.9	salivary gland: 41.2	Group enriched	8	HBEC3-KT: 28.8;Hep G2: 17.3;T-47d: 63.7
KRT24	FLJ20261, MGC138169, MGC138173	ENSG00000167916	Keratin 24	17	40697991-40703750	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022978	Uncertain		Approved	Intermediate filaments<br>Cytosol		Tissue enhanced	Tissue enhanced		epididymis: 20.3;esophagus: 28.4;tonsil: 67.0	placenta: 10.6	Cell line enriched	11	SK-BR-3: 5.3
KRT25	KRT25A	ENSG00000204897	Keratin 25	17	40748021-40755332	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053977, HPA058943	Enhanced		Approved	Vesicles		Not detected	Group enriched	15	breast: 3.6;testis: 1.6	smooth muscle: 0.1	Cell line enriched	5	RPTEC TERT1: 1.0
KRT26	KRT25B	ENSG00000186393	Keratin 26	17	40766238-40772162	Predicted intracellular proteins	Evidence at protein level	HPA026890	Supported					Not detected	Tissue enhanced		testis: 1.0	bone marrow: 0.9	Not detected		
KRT27	KRT25C	ENSG00000171446	Keratin 27	17	40776808-40782534	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055114	Supported					Tissue enhanced	Tissue enhanced		breast: 1.3	skin,testis: 0.4	Cell line enhanced		EFO-21: 1.3
KRT28	KRT25D	ENSG00000173908	Keratin 28	17	40792203-40799959	Predicted intracellular proteins	Evidence at protein level	HPA066890	Supported					Tissue enhanced	Tissue enhanced		breast: 1.0	testis: 0.4	Not detected		
KRT3	CK3, K3	ENSG00000186442	Keratin 3	12	52789685-52796117	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	6	esophagus: 1.3;skin: 1.8	tonsil: 0.2	Group enriched	8	HaCaT: 8.3;HMC-1: 4.9
KRT31	Ha-1, KRTHA1	ENSG00000094796	Keratin 31	17	41393724-41397592	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049550, HPA055194	Supported					Group enriched	Group enriched	6	esophagus: 4.6;skin: 14.4	skeletal muscle: 1.5	Not detected		
KRT32	Ha-2, KRTHA2	ENSG00000108759	Keratin 32	17	41459811-41467429	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	14	esophagus: 7.4;skin: 2.4	breast: 0.3	Not detected		
KRT33A	Ha-3I, Krt1-3, KRTHA3A	ENSG00000006059	Keratin 33A	17	41346092-41350812	Predicted intracellular proteins	Evidence at protein level	HPA055194	Supported					Tissue enhanced	Group enriched	15	esophagus: 1.4;testis: 1.6	all non-specific tissues: 0.0	Cell line enhanced		RT4: 1.1
KRT33B	Ha-3II, KRTHA3B	ENSG00000131738	Keratin 33B	17	41363494-41369800	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055194	Supported					Tissue enhanced	Not detected			testis: 0.1	Cell line enhanced		BJ: 3.4;hTEC/SVTERT24-B: 1.5;U-2197: 1.0
KRT34	Ha-4, KRTHA4	ENSG00000131737	Keratin 34	17	41377650-41382403	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055194, HPA072208	Supported		Approved	Nucleus<br>Vesicles		Tissue enhanced	Tissue enriched	8	cervix, uterine: 4.2	testis: 0.5	Cell line enhanced		BJ: 170.4;BJ hTERT+ SV40 Large T+ RasG12V: 45.2;HBF TERT88: 41.4
KRT35	Ha-5, KRTHA5	ENSG00000197079	Keratin 35	17	41476689-41481140	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	8	skin: 2.2	salivary gland,spleen: 0.2	Not detected		
KRT36	KRTHA6	ENSG00000126337	Keratin 36	17	41486136-41492546	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		skin: 2.1;tonsil: 1.5	cervix, uterine,spleen: 0.5	Cell line enriched	11	Karpas-707: 2.2
KRT37	KRTHA7	ENSG00000108417	Keratin 37	17	41420753-41424523	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		skin: 1.2	cervix, uterine: 0.3	Not detected		
KRT38	KRTHA8	ENSG00000171360	Keratin 38	17	41436446-41440921	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Group enriched	Not detected			tonsil: 0.3	Not detected		
KRT39	KA35	ENSG00000196859	Keratin 39	17	40958417-40966892	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRT4	CK4, CYK4, K4	ENSG00000170477	Keratin 4	12	52806549-52814551	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002154, HPA034881	Supported		Enhanced	Intermediate filaments	Ovarian cancer:3.26e-4 (unfavourable), Urothelial cancer:6.26e-4 (unfavourable)	Group enriched	Tissue enriched	25	esophagus: 14861.9	tonsil: 599.4	Group enriched	28	HaCaT: 385.2;SK-BR-3: 130.9
KRT40	FLJ36600, KA36	ENSG00000204889	Keratin 40	17	40977716-40987135	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Not detected			lung: 0.2	Not detected		
KRT5	EBS2, KRT5A	ENSG00000186081	Keratin 5	12	52514575-52520687	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000027, CAB000129, HPA059479	Enhanced		Supported	Intermediate filaments	Breast cancer:1.27e-4 (favourable)	Tissue enhanced	Group enriched	9	esophagus: 3256.1;skin: 5996.8	tonsil: 516.9	Group enriched	6	HaCaT: 2557.9;HBEC3-KT: 3723.5;hTCEpi: 8392.0
KRT6A	CK6C, CK6D, K6C, K6D, KRT6C, KRT6D	ENSG00000205420	Keratin 6A	12	52487174-52493257	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045697, HPA061168	Supported		Approved	Intermediate filaments	Lung cancer:1.45e-4 (unfavourable)	Tissue enhanced	Tissue enriched	10	esophagus: 5703.6	tonsil: 564.5	Cell line enhanced		HaCaT: 1007.5;HBEC3-KT: 1727.3;hTCEpi: 7036.9
KRT6B	KRTL1	ENSG00000185479	Keratin 6B	12	52446651-52452126	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000130, HPA045697, HPA061168	Supported		Approved	Intermediate filaments	Breast cancer:9.44e-4 (favourable), Urothelial cancer:9.52e-4 (unfavourable)	Tissue enhanced	Tissue enriched	10	esophagus: 670.7	tonsil: 67.0	Cell line enhanced		HBEC3-KT: 19.9;hTCEpi: 21.8;RPMI-8226: 9.3
KRT6C	KRT6E	ENSG00000170465	Keratin 6C	12	52468516-52473785	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045697, HPA061168	Supported		Supported	Intermediate filaments	Lung cancer:1.23e-5 (unfavourable)	Tissue enhanced	Tissue enriched	50	esophagus: 525.3	cervix, uterine: 10.6	Cell line enriched	6	RPMI-8226: 66.4
KRT7	CK7, K2C7, K7, SCL	ENSG00000135480	Keratin 7	12	52232520-52252186	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000028, HPA007272	Enhanced				Renal cancer:2.77e-9 (favourable), Pancreatic cancer:7.78e-5 (unfavourable), Ovarian cancer:9.42e-5 (unfavourable), Endometrial cancer:1.99e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 984.0	urinary bladder: 454.0	Cell line enhanced		HBEC3-KT: 4461.4;RT4: 5973.0;SiHa: 6200.7
KRT71	K6IRS1, KRT6IRS, KRT6IRS1	ENSG00000139648	Keratin 71	12	52543909-52553147	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049404	Supported					Tissue enhanced	Group enriched	34	breast: 1.4;epididymis: 5.3	all non-specific tissues: 0.0	Cell line enriched	11	CACO-2: 5.1
KRT72	K6irs, K6IRS2, KRT6, KRT6IRS2	ENSG00000170486	Keratin 72	12	52585589-52601538	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065523	Supported					Not detected	Tissue enriched	5	testis: 26.8	skin: 5.2	Not detected		
KRT73	K6IRS3, KRT6IRS3	ENSG00000186049	Keratin 73	12	52607570-52618559	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044031	Enhanced					Not detected	Group enriched	7	lymph node: 2.5;skin: 12.1	appendix: 1.0	Not detected		
KRT74	K6IRS4, KRT5C, KRT6IRS4	ENSG00000170484	Keratin 74	12	52565782-52573825	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048596	Supported					Not detected	Tissue enriched	6	epididymis: 6.9	breast: 1.1	Not detected		
KRT75	K6HF	ENSG00000170454	Keratin 75	12	52424070-52434525	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019367, HPA076201	Supported		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Not detected			breast: 0.9	Group enriched	8	PC-3: 33.1;U-2 OS: 48.9
KRT76	HUMCYT2A, KRT2B, KRT2P	ENSG00000185069	Keratin 76	12	52768155-52777345	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019656, HPA019696	Approved					Tissue enriched	Tissue enriched	22	tonsil: 2.1	all non-specific tissues: 0.0	Not detected		
KRT77	KRT1B	ENSG00000189182	Keratin 77	12	52689626-52703463	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045934	Enhanced		Approved	Nuclear membrane<br>Plasma membrane		Mixed	Tissue enriched	12	skin: 308.7	breast: 26.2	Cell line enriched	33	HaCaT: 3.2
KRT78	K5B	ENSG00000170423	Keratin 78	12	52837804-52849092	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039724	Enhanced					Tissue enhanced	Tissue enriched	8	esophagus: 1055.1	tonsil: 127.1	Group enriched	7	EFO-21: 5.3;RT4: 1.3;SK-BR-3: 3.0;U-87 MG: 3.0
KRT79	K6L, KRT6L	ENSG00000185640	Keratin 79	12	52821410-52834295	Predicted intracellular proteins	Evidence at protein level	HPA059347	Enhanced					Group enriched	Group enriched	9	breast: 4.0;skin: 17.1	esophagus: 1.1	Cell line enriched	18	HMC-1: 375.1
KRT8	CARD2, CK8, CYK8, K2C8, K8, KO	ENSG00000170421	Keratin 8	12	52897187-52949954	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000131, CAB001696, HPA049866	Enhanced		Supported	Intermediate filaments	Pancreatic cancer:1.51e-4 (unfavourable)	Mixed	Tissue enhanced		small intestine: 1475.5	duodenum: 1118.4	Cell line enhanced		A549: 5518.3;BEWO: 3855.6;CACO-2: 6334.4;CAPAN-2: 4191.3;MCF7: 7987.2;SK-BR-3: 3839.1;T-47d: 4059.8
KRT80	KB20	ENSG00000167767	Keratin 80	12	52168996-52192000	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA077836, HPA077918			Enhanced	Intermediate filaments	Breast cancer:1.05e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 125.0	tonsil: 37.7	Cell line enhanced		A-431: 176.4;MCF7: 219.4;U-2 OS: 184.3
KRT81	Hb-1, KRTHB1	ENSG00000205426	Keratin 81	12	52285913-52291534	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049778	Supported					Tissue enhanced	Tissue enhanced		breast: 3.8	placenta: 1.5	Cell line enhanced		A-431: 2684.9;A549: 2072.1;PC-3: 1009.2;U-251 MG: 1766.1
KRT82	Hb-2, KRTHB2	ENSG00000161850	Keratin 82	12	52393931-52406355	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058715, HPA067230	Enhanced					Not detected	Not detected			placenta,testis: 0.1	Not detected		
KRT83	Hb-3, KRTHB3	ENSG00000170523	Keratin 83	12	52314301-52321398	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049778	Supported					Tissue enhanced	Tissue enhanced		thyroid gland: 1.7	breast,testis: 0.3	Cell line enhanced		A549: 2.9;MCF7: 2.0;RPMI-8226: 9.3
KRT84	Hb-4, KRTHB4	ENSG00000161849	Keratin 84	12	52377812-52385652	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039714	Supported					Tissue enhanced	Not detected			tonsil: 0.5	Not detected		
KRT85	Hb-5, KRTHB5	ENSG00000135443	Keratin 85	12	52360006-52367481	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049778	Supported					Not detected	Not detected			testis: 0.8	Cell line enhanced		A549: 2.0
KRT86	Hb6, KRTHB6, MNX	ENSG00000170442	Keratin 86	12	52249300-52309163	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039798, HPA049778	Supported		Approved	Cytosol		Mixed	Tissue enhanced		thyroid gland: 6.9	testis: 2.4	Cell line enhanced		A-431: 21.8;A549: 23.3;MCF7: 39.4;RPMI-8226: 22.5
KRT9	CK-9, EPPK, K9	ENSG00000171403	Keratin 9	17	41565841-41572058	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007261, CAB037322	Supported					Tissue enriched	Tissue enhanced		skin: 2.9	adrenal gland: 0.7	Cell line enhanced		BEWO: 6.7;HaCaT: 14.8;U-937: 4.1
KRTAP1-1	HB2A, KAP1.1, KAP1.1A, KAP1.1B	ENSG00000188581	Keratin associated protein 1-1	17	41040559-41041461	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			pancreas: 0.1	Not detected		
KRTAP1-3	KAP1.3	ENSG00000221880	Keratin associated protein 1-3	17	41033884-41034855	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP1-4	KAP1.4	ENSG00000204887	Keratin associated protein 1-4	17	41029697-41030104	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			skin: 0.1	Not detected		
KRTAP1-5	KAP1.5	ENSG00000221852	Keratin associated protein 1-5	17	41026026-41027202	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	14	cervix, uterine: 2.1	urinary bladder: 0.1	Cell line enhanced		BJ: 23.6;BJ hTERT+: 9.7;fHDF/TERT166: 28.2;LHCN-M2: 14.9
KRTAP10-1	KAP10.1, KAP18.1, KRTAP18-1	ENSG00000215455	Keratin associated protein 10-1	21	44538981-44540195	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-10	KAP10.10, KAP18.10, KRTAP18-10	ENSG00000221859	Keratin associated protein 10-10	21	44637356-44638455	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-11	KAP10.11, KAP18.11, KRTAP18-11, KRTAP18.11	ENSG00000243489	Keratin associated protein 10-11	21	44646414-44647650	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-12	KAP10.12, KRTAP18-12, KRTAP18.12	ENSG00000189169	Keratin associated protein 10-12	21	44697172-44698044	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-2	KAP10.2, KAP18.2, KRTAP18-2	ENSG00000205445	Keratin associated protein 10-2	21	44550357-44551505	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-3	KAP10.3, KAP18.3, KRTAP18-3	ENSG00000212935	Keratin associated protein 10-3	21	44557790-44558760	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-4	KAP10.4, KRTAP18-4, KRTAP18.4	ENSG00000215454	Keratin associated protein 10-4	21	44573724-44638284	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			fallopian tube: 0.1	Not detected		
KRTAP10-5	KAP10.5, KAP18.5, KRTAP18-5	ENSG00000241123	Keratin associated protein 10-5	21	44579455-44580604	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-6	KAP10.6, KAP18.6, KRTAP18-6, KRTAP18.6	ENSG00000188155	Keratin associated protein 10-6	21	44591268-44592505	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-7	KAP10.7, KAP18.7, KRTAP18-7	ENSG00000272804	Keratin associated protein 10-7	21	44600597-44602174	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-8	KAP10.8, KRTAP18-8, KRTAP18.8	ENSG00000187766	Keratin associated protein 10-8	21	44612079-44612954	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-9	KAP10.9, KAP18.9, KRTAP18-9	ENSG00000221837	Keratin associated protein 10-9	21	44627123-44628293	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP11-1	KAP11.1	ENSG00000182591	Keratin associated protein 11-1	21	30880644-30881555	Predicted intracellular proteins	Evidence at protein level	HPA054008	Supported					Group enriched	Not detected			skin: 0.1	Not detected		
KRTAP12-1	KAP12.1, KRTAP12.1	ENSG00000187175	Keratin associated protein 12-1	21	44681576-44682163	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			parathyroid gland,skin: 0.1	Not detected		
KRTAP12-2	KAP12.2, KRTAP12.2	ENSG00000221864	Keratin associated protein 12-2	21	44666189-44666927	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			epididymis: 0.1	Not detected		
KRTAP12-3	KRTAP12.3	ENSG00000205439	Keratin associated protein 12-3	21	44657932-44658341	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			skin: 0.1	Not detected		
KRTAP12-4	KRTAP12.4	ENSG00000212933	Keratin associated protein 12-4	21	44654213-44654659	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
KRTAP13-1	KAP13.1	ENSG00000198390	Keratin associated protein 13-1	21	30396074-30396822	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.3	Not detected		
KRTAP13-2	KAP13-2	ENSG00000182816	Keratin associated protein 13-2	21	30371391-30372257	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	20	colon: 1.9;rectum: 2.0	all non-specific tissues: 0.0	Not detected		
KRTAP13-3	KAP13.3	ENSG00000240432	Keratin associated protein 13-3	21	30425265-30425968	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP13-4	KAP13.4	ENSG00000186971	Keratin associated protein 13-4	21	30430230-30431026	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			adrenal gland,parathyroid gland: 0.2	Not detected		
KRTAP15-1	KAP15.1	ENSG00000186970	Keratin associated protein 15-1	21	30440275-30440945	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP16-1	KAP16.1	ENSG00000212657	Keratin associated protein 16-1	17	41307700-41309253	Predicted intracellular proteins	Evidence at protein level	HPA070954	Supported					Not detected	Not detected			bone marrow: 0.3	Not detected		
KRTAP17-1	KAP17.1	ENSG00000186860	Keratin associated protein 17-1	17	41314917-41315695	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			endometrium: 0.1	Group enriched	53	HDLM-2: 8.2;SCLC-21H: 6.3
KRTAP19-1	KAP19.1	ENSG00000184351	Keratin associated protein 19-1	21	30479699-30480344	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			all non-specific tissues: 0.0	Cell line enriched	13	HEK93: 19.8
KRTAP19-2	KAP19.2	ENSG00000186965	Keratin associated protein 19-2	21	30487057-30487436	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP19-3	KAP19.3	ENSG00000244025	Keratin associated protein 19-3	21	30491464-30491985	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP19-4	KAP19.4	ENSG00000186967	Keratin associated protein 19-4	21	30496824-30497133	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP19-5	KAP19.5	ENSG00000186977	Keratin associated protein 19-5	21	30501657-30502117	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	5	HEK93: 4.3
KRTAP19-6	KAP19.6	ENSG00000186925	Keratin associated protein 19-6	21	30541535-30541864	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP19-7	KAP19.7	ENSG00000244362	Keratin associated protein 19-7	21	30560875-30561314	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP19-8		ENSG00000206102	Keratin associated protein 19-8	21	31038159-31038476	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.7	Not detected		
KRTAP2-1	KAP2.1A	ENSG00000212725	Keratin associated protein 2-1	17	41046541-41047316	Predicted intracellular proteins	Evidence at protein level	HPA059203	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP2-2	KAP2.2	ENSG00000214518	Keratin associated protein 2-2	17	41054498-41055230	Predicted intracellular proteins	Evidence at protein level	HPA059203	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP2-3	KAP2.3	ENSG00000212724	Keratin associated protein 2-3	17	41059240-41060114	Predicted intracellular proteins	Evidence at protein level	HPA059203	Supported					Mixed	Not detected			all non-specific tissues: 0.0	Cell line enhanced		BJ: 31.1;fHDF/TERT166: 17.2;HBF TERT88: 30.9;LHCN-M2: 34.2;U-2 OS: 16.1
KRTAP2-4	KAP2.4	ENSG00000213417	Keratin associated protein 2-4	17	41065116-41065879	Predicted intracellular proteins	Evidence at protein level	HPA059203	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP20-1	KAP20.1	ENSG00000244624	Keratin associated protein 20-1	21	30616425-30616699	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
KRTAP20-2	KAP20.2	ENSG00000184032	Keratin associated protein 20-2	21	30635236-30635619	Predicted intracellular proteins	No evidence							Not detected	Not detected			skin: 0.6	Not detected		
KRTAP20-3	KAP19D, KAP20.3, KRTAP19P4	ENSG00000206104	Keratin associated protein 20-3	21	30642864-30643136	Predicted intracellular proteins	No evidence	HPA053598	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP20-4	KAP20.4	ENSG00000206105	Keratin associated protein 20-4	21	30620627-30620850	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	36	testis: 3.6	all non-specific tissues: 0.0	Cell line enriched	10	U-2 OS: 5.5
KRTAP21-1	KAP21.1	ENSG00000187005	Keratin associated protein 21-1	21	30754830-30755428	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	7	breast: 13.5;testis: 6.0	seminal vesicle: 1.3	Cell line enhanced		SK-MEL-30: 1.2
KRTAP21-2	KAP21.2	ENSG00000187026	Keratin associated protein 21-2	21	30746794-30747233	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	20	skin: 1.1;testis: 2.9	all non-specific tissues: 0.0	Cell line enriched	12	HEK93: 1.7
KRTAP21-3		ENSG00000231068	Keratin associated protein 21-3	21	30718525-30718777	Predicted intracellular proteins	No evidence	HPA046554	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP22-1	KAP22.1	ENSG00000186924	Keratin associated protein 22-1	21	30601087-30601382	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP22-2	KAP22.2	ENSG00000206106	Keratin associated protein 22-2	21	30590105-30590397	Predicted intracellular proteins	No evidence							Not detected	Not detected			skin: 0.2	Not detected		
KRTAP23-1	KAP23.1	ENSG00000186980	Keratin associated protein 23-1	21	30348399-30348609	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP24-1	KAP24.1	ENSG00000188694	Keratin associated protein 24-1	21	30281309-30282958	Predicted intracellular proteins	Evidence at protein level	HPA017604	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP25-1	KAP25.1	ENSG00000232263	Keratin associated protein 25-1	21	30289145-30289514	Predicted intracellular proteins	No evidence	HPA031438	Uncertain		Approved	Nuclear membrane<br>Plasma membrane<br>Cytosol		Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP26-1		ENSG00000197683	Keratin associated protein 26-1	21	30319124-30320316	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	19	placenta: 1.9	testis: 0.1	Not detected		
KRTAP27-1		ENSG00000206107	Keratin associated protein 27-1	21	30337013-30337694	Predicted intracellular proteins	Evidence at transcript level	HPA021522, HPA048826	Approved					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP29-1	KAP29.2	ENSG00000212658	Keratin associated protein 29-1	17	41301826-41302851	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	21	HDLM-2: 2.0
KRTAP3-1	KAP3.1	ENSG00000212901	Keratin associated protein 3-1	17	41008521-41019324	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Not detected			all non-specific tissues: 0.0	Cell line enhanced		BJ: 2.1;CACO-2: 5.5;HaCaT: 1.6;Hep G2: 2.3;T-47d: 1.8
KRTAP3-2	KAP3.2	ENSG00000212900	Keratin associated protein 3-2	17	40999193-40999894	Predicted intracellular proteins	Evidence at protein level	HPA042992	Approved					Not detected	Tissue enriched	7	esophagus: 3.3	skin: 0.5	Not detected		
KRTAP3-3	KAP3.3	ENSG00000212899	Keratin associated protein 3-3	17	40993430-40994133	Predicted intracellular proteins	Evidence at protein level	HPA042992	Approved					Tissue enhanced	Not detected			breast,skin: 0.1	Not detected		
KRTAP4-1	KAP4.1, KAP4.10, KRTAP4-10	ENSG00000198443	Keratin associated protein 4-1	17	41184102-41185342	Predicted intracellular proteins	Evidence at transcript level							Mixed	Not detected			colon,small intestine: 0.3	Cell line enhanced		A549: 1.5;CAPAN-2: 1.1;HDLM-2: 4.6;SCLC-21H: 1.4
KRTAP4-11	KAP4.11, KAP4.14, KRTAP4-14	ENSG00000212721	Keratin associated protein 4-11	17	41117181-41118360	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-12	KAP4.12	ENSG00000213416	Keratin associated protein 4-12	17	41123091-41124167	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-16	KAP4A, KRTAP4-16P, KRTAP4P1	ENSG00000241241	Keratin associated protein 4-16	17	41101502-41102209	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-2	KAP4.2	ENSG00000244537	Keratin associated protein 4-2	17	41177446-41178208	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-3	KAP4.3	ENSG00000196156	Keratin associated protein 4-3	17	41167231-41168194	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	11	HDLM-2: 1.1
KRTAP4-4	KAP4.13, KAP4.4, KRTAP4-13	ENSG00000171396	Keratin associated protein 4-4	17	41159651-41160731	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-5	KAP4.5	ENSG00000198271	Keratin associated protein 4-5	17	41148924-41149802	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-6	KAP4.15, KAP4.6, KRTAP4-15	ENSG00000198090	Keratin associated protein 4-6	17	41139433-41140487	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-7	KAP4.7	ENSG00000240871	Keratin associated protein 4-7	17	41084150-41085141	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-8	KAP4.8	ENSG00000204880	Keratin associated protein 4-8	17	41096981-41098141	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-9	KAP4.9	ENSG00000212722	Keratin associated protein 4-9	17	41105332-41106488	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP5-1	KRN1L, KRTAP5.1	ENSG00000205869	Keratin associated protein 5-1	11	1584342-1585283	Predicted intracellular proteins	Evidence at transcript level						Colorectal cancer:2.37e-4 (unfavourable)	Mixed	Not detected			adrenal gland,cerebral cortex,pancreas,salivary gland,small intestine,spleen,stomach: 0.1	Cell line enhanced		SCLC-21H: 1.6
KRTAP5-10	KRTAP5.10	ENSG00000204572	Keratin associated protein 5-10	11	71565563-71566738	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		epididymis: 1.7	fallopian tube,seminal vesicle,testis: 0.4	Cell line enriched	9	RT4: 2.8
KRTAP5-11	KRTAP5-6, KRTAP5.11	ENSG00000204571	Keratin associated protein 5-11	11	71579714-71603353	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			duodenum: 0.1	Not detected		
KRTAP5-2	KRTAP5-8, KRTAP5.2	ENSG00000205867	Keratin associated protein 5-2	11	1597177-1598294	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 3.6	gallbladder: 0.9	Cell line enhanced		MCF7: 1.9;SCLC-21H: 3.3;SH-SY5Y: 1.3
KRTAP5-3	KRTAP5-9, KRTAP5.3	ENSG00000196224	Keratin associated protein 5-3	11	1607565-1608463	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP5-4	KRTAP5.4	ENSG00000241598	Keratin associated protein 5-4	11	1620958-1622138	Predicted intracellular proteins	No evidence							Not detected	Not detected			skeletal muscle: 0.1	Not detected		
KRTAP5-5	KRTAP5-11, KRTAP5.5	ENSG00000185940	Keratin associated protein 5-5	11	1629775-1630707	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.1	Not detected		
KRTAP5-6	KRTAP5.6	ENSG00000205864	Keratin associated protein 5-6	11	1697195-1697755	Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.04e-5 (favourable)	Tissue enriched	Not detected			placenta: 0.6	Not detected		
KRTAP5-7	KRTAP5-3, KRTAP5.7	ENSG00000244411	Keratin associated protein 5-7	11	71527267-71528674	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.8	epididymis: 0.5	Cell line enriched	10	RT4: 1.3
KRTAP5-8	KRTAP5-2, KRTAP5.8, UHSKerB	ENSG00000241233	Keratin associated protein 5-8	11	71538025-71539207	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 1.1	epididymis,kidney: 0.8	Not detected		
KRTAP5-9	KRN1, KRTAP5-1, KRTAP5.9	ENSG00000254997	Keratin associated protein 5-9	11	71548418-71549553	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:9.25e-4 (favourable)	Tissue enhanced	Tissue enhanced		testis: 2.6	epididymis: 1.8	Cell line enriched	22	RT4: 7.2
KRTAP6-1	C21orf103, KAP6.1	ENSG00000184724	Keratin associated protein 6-1	21	30613431-30613930	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP6-2	KAP6.2	ENSG00000186930	Keratin associated protein 6-2	21	30598590-30598902	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP6-3	KAP6.3	ENSG00000212938	Keratin associated protein 6-3	21	30592440-30593075	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP7-1	KAP7.1	ENSG00000274749	Keratin associated protein 7-1 (gene/pseudogene)	21	30829039-30829759	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			skin: 0.1	Not detected		
KRTAP8-1	KAP8.1	ENSG00000183640	Keratin associated protein 8-1	21	30812697-30813252	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Not detected			testis: 0.3	Not detected		
KRTAP9-1	KAP9.1, KRTAP9L3	ENSG00000240542	Keratin associated protein 9-1	17	41189887-41190639	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	42	HDLM-2: 4.2
KRTAP9-2	KAP9.2	ENSG00000239886	Keratin associated protein 9-2	17	41226648-41227652	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
KRTAP9-3	KAP9.3	ENSG00000204873	Keratin associated protein 9-3	17	41232463-41233454	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP9-4	KAP9.4	ENSG00000241595	Keratin associated protein 9-4	17	41249687-41250653	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP9-6	KAP9.6, KRTAP9L2	ENSG00000212659	Keratin associated protein 9-6	17	41265339-41266641	Predicted intracellular proteins	No evidence							Not detected	Not detected			skin: 0.1	Not detected		
KRTAP9-7	KAP9.7, KRTAP9L1	ENSG00000180386	Keratin associated protein 9-7	17	41275659-41276697	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP9-8	KAP9.8	ENSG00000187272	Keratin associated protein 9-8	17	41238045-41239004	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	15	HDLM-2: 1.5
KRTAP9-9	KAP9.5, KAP9.9, KRTAP9-5	ENSG00000198083	Keratin associated protein 9-9	17	41255384-41256364	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KSR1	KSR, RSU2	ENSG00000141068	Kinase suppressor of ras 1	17	27456714-27626438	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB009623, HPA011215	Uncertain				Renal cancer:6.54e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 75.6	Cell line enhanced		HDLM-2: 562.3;HEL: 176.9
KSR2	FLJ25965	ENSG00000171435	Kinase suppressor of ras 2	12	117453012-117968983	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA035536	Approved					Not detected	Tissue enhanced		cerebral cortex: 4.1	adrenal gland: 1.2	Group enriched	6	HUVEC TERT2: 3.8;SCLC-21H: 3.8;TIME: 5.6
KTI12	MGC20419, SBBI81, TOT4	ENSG00000198841	KTI12 chromatin associated homolog	1	52032103-52033816	Predicted intracellular proteins	Evidence at protein level	HPA031203, HPA031204, HPA031205	Approved		Approved	Nuclear speckles<br>Cytoplasmic bodies	Liver cancer:1.02e-4 (unfavourable)	Expressed in all	Mixed			ovary: 11.5	Expressed in all		
KXD1	BORCS4, C19orf50, FLJ25480, KXDL, MGC2749	ENSG00000105700	KxDL motif containing 1	19	18557762-18569387	Predicted intracellular proteins	Evidence at protein level	HPA041507, HPA041599	Approved		Approved	Nucleoli fibrillar center<br>Centrosome<br>Cytosol	Renal cancer:7.71e-10 (unfavourable), Liver cancer:8.46e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 91.9	Expressed in all		
KY	FLJ33207	ENSG00000174611	Kyphoscoliosis peptidase	3	134603138-134651636	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036492, HPA036668	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		skin: 11.0	parathyroid gland: 9.3	Cell line enhanced		Karpas-707: 1.6;U-2197: 2.7;U-87 MG: 8.6
KYAT1	CCBL1, GTK, KATI	ENSG00000171097	Kynurenine aminotransferase 1	9	128832942-128882494	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021176, HPA021177, HPA027736	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 17.0	Expressed in all		
KYAT3	CCBL2, KAT3, KATIII, RBM1, RP11-82K18.3	ENSG00000137944	Kynurenine aminotransferase 3	1	88935773-88992953	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026538, HPA027168	Enhanced		Approved	Nucleoli<br>Cytosol	Renal cancer:5.02e-6 (favourable), Breast cancer:3.19e-5 (favourable), Head and neck cancer:1.86e-4 (favourable), Ovarian cancer:2.80e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.8	Expressed in all		
KYNU		ENSG00000115919	Kynureninase	2	142877498-143055832	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031686	Enhanced		Supported	Nucleoplasm<br>Cytosol		Mixed	Mixed			liver: 45.9	Cell line enhanced		A549: 168.9;HeLa: 138.9;hTEC/SVTERT24-B: 106.9;SiHa: 109.4;U-87 MG: 309.1
L1TD1	ECAT11, FLJ10884	ENSG00000240563	LINE1 type transposase domain containing 1	1	62194831-62212328	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		placenta: 16.6;testis: 11.0	appendix: 6.1	Cell line enriched	26	NTERA-2: 254.5
L2HGDH	C14orf160, FLJ12618	ENSG00000087299	L-2-hydroxyglutarate dehydrogenase	14	50237563-50312548	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA065409, HPA069708	Approved		Enhanced	Mitochondria	Renal cancer:9.75e-10 (favourable)	Expressed in all	Mixed			kidney: 20.8	Expressed in all		
L34079.2		ENSG00000268361		19	43554692-43593036	Predicted intracellular proteins	No evidence							Not detected	Not detected			parathyroid gland: 0.5	Not detected		
L3HYPDH	C14orf149, FLJ25436	ENSG00000126790	Trans-L-3-hydroxyproline dehydratase	14	59460363-59484430	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056694	Approved		Uncertain	Vesicles	Renal cancer:1.72e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 32.0	Expressed in all		
L3MBTL1	dJ138B7.3, DKFZp586P1522, KIAA0681, L3MBTL, ZC2HC3	ENSG00000185513	L(3)mbt-like 1 (Drosophila)	20	43507680-43550950	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA068051			Supported	Nucleus		Mixed	Mixed			testis: 10.1	Cell line enhanced		BEWO: 7.9
L3MBTL3	KIAA1798	ENSG00000198945	L(3)mbt-like 3 (Drosophila)	6	130013699-130141451	Predicted intracellular proteins	Evidence at protein level	HPA044382, HPA053035	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Mixed			endometrium: 18.5	Cell line enhanced		HMC-1: 55.3;HUVEC TERT2: 52.0
L3MBTL4	FLJ35936, HsT1031	ENSG00000154655	L(3)mbt-like 4 (Drosophila)	18	5954706-6415237	Predicted intracellular proteins	Evidence at protein level	HPA064194, HPA069042	Approved		Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			testis: 23.4	Cell line enhanced		RPMI-8226: 8.0;SCLC-21H: 6.3;SH-SY5Y: 6.2
LA16c-306E5.2		ENSG00000262621		16	3365099-3479550	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			appendix,endometrium: 1.0	Mixed		
LA16c-312E8.5		ENSG00000284395		16	1431035-1433397	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		prostate: 2.6;stomach: 1.4	duodenum: 0.7	Cell line enriched	54	SCLC-21H: 38.7
LACC1	C13orf31, FAMIN, FLJ38725	ENSG00000179630	Laccase domain containing 1	13	43879284-43893932	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB034228, HPA040150, HPA044211	Uncertain					Expressed in all	Mixed			testis: 17.1	Cell line enhanced		TIME: 93.5
LACTB2	CGI-83	ENSG00000147592	Lactamase beta 2	8	70635318-70669174	Predicted intracellular proteins	Evidence at protein level	HPA044391, HPA053040	Approved		Supported	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:5.60e-4 (favourable)	Expressed in all	Expressed in all			testis: 119.4	Cell line enhanced		SK-BR-3: 329.9
LACTBL1		ENSG00000215906	Lactamase beta like 1	1	22953043-22965338	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Not detected		
LAD1		ENSG00000159166	Ladinin 1	1	201373244-201399915	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007256, HPA028732	Enhanced		Enhanced	Actin filaments	Lung cancer:6.73e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 291.7;skin: 236.6	small intestine: 93.9	Cell line enhanced		A-431: 173.4;CAPAN-2: 150.1;HaCaT: 219.8;MCF7: 165.3;RT4: 146.2;SK-BR-3: 220.4
LAGE3	CVG5, DXS9879E, DXS9951E, ESO3, ITBA2, Pcc1	ENSG00000196976	L antigen family member 3	X	154477769-154479257	Predicted intracellular proteins	Evidence at protein level	HPA036122, HPA036123	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Cervical cancer:5.29e-6 (favourable), Renal cancer:5.42e-5 (unfavourable), Liver cancer:8.63e-5 (unfavourable), Endometrial cancer:7.60e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 26.9	Expressed in all		
LAMTOR1	C11orf59, FLJ20625, p18, p27RF-Rho, Pdro, Ragulator1	ENSG00000149357	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 1	11	72085895-72103387	Predicted intracellular proteins	Evidence at protein level	HPA002997	Approved		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane	Liver cancer:3.63e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 143.2	Expressed in all		
LAMTOR2	ENDAP, MAPBPIP, MAPKSP1AP, p14, Ragulator2, ROBLD3	ENSG00000116586	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 2	1	156054752-156058510	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004126	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.10e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 84.7	Expressed in all		
LAMTOR3	MAP2K1IP1, MAPBP, MAPKSP1, MP1, Ragulator3	ENSG00000109270	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 3	4	99878336-99894490	Predicted intracellular proteins	Evidence at protein level	HPA026858	Supported				Renal cancer:1.75e-9 (favourable), Liver cancer:2.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 57.3	Expressed in all		
LAMTOR4	C7orf59	ENSG00000188186	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 4	7	100148907-100155944	Predicted intracellular proteins	Evidence at protein level	HPA020998	Enhanced		Enhanced	Vesicles	Breast cancer:2.48e-4 (favourable), Cervical cancer:6.08e-4 (favourable)	Expressed in all	Expressed in all			skin: 314.5	Expressed in all		
LAMTOR5	HBXIP, MGC71071, XIP	ENSG00000134248	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	1	110401249-110407942	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006812	Approved		Supported	Cytosol	Liver cancer:2.60e-4 (unfavourable), Thyroid cancer:5.52e-4 (favourable), Ovarian cancer:7.23e-4 (favourable)	Expressed in all	Expressed in all			kidney: 431.6	Expressed in all		
LANCL1	GPR69A, p40	ENSG00000115365	LanC like 1	2	210431249-210477652	Predicted intracellular proteins	Evidence at protein level	HPA034994	Approved		Approved	Microtubules		Expressed in all	Expressed in all			cerebral cortex: 153.3	Expressed in all		
LANCL2	GPR69B, TASP	ENSG00000132434	LanC like 2	7	55365448-55433742	Predicted intracellular proteins	Evidence at protein level	HPA019711, HPA029535	Uncertain		Supported	Nucleus<br>Cytosol	Renal cancer:1.03e-6 (favourable), Ovarian cancer:1.89e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 41.2	parathyroid gland: 16.5	Cell line enriched	6	A-431: 130.0
LANCL3	FLJ42925	ENSG00000147036	LanC like 3	X	37571569-37684463	Predicted intracellular proteins	Evidence at protein level	HPA005470, HPA076575	Approved		Approved	Mitochondria		Not detected	Mixed			esophagus: 1.3	Cell line enhanced		HEL: 12.8;HMC-1: 3.9;K-562: 3.0
LAP3	LAP, LAPEP, PEPS	ENSG00000002549	Leucine aminopeptidase 3	4	17577192-17607972	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029606, HPA029607	Enhanced		Supported	Nucleoplasm<br>Midbody<br>Cytosol		Expressed in all	Expressed in all			appendix: 176.5	Mixed		
LARGE1	KIAA0609, LARGE	ENSG00000133424	LARGE xylosyl- and glucuronyltransferase 1	22	33162226-33922841	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Mixed			cerebral cortex: 43.2	Mixed		
LARP1	KIAA0731, LARP, MGC19556	ENSG00000155506	La ribonucleoprotein domain family member 1	5	154712902-154817607	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015222, HPA051397, HPA054819	Supported		Supported	Nucleus<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 152.1	Expressed in all		
LARP1B	DKFZp434K245, DKFZp686E0316, FLJ10378, LARP2	ENSG00000138709	La ribonucleoprotein domain family member 1B	4	128061268-128222931	Predicted intracellular proteins	Evidence at protein level	HPA036280	Approved		Approved	Cytosol	Renal cancer:5.13e-5 (favourable)	Expressed in all	Expressed in all			testis: 103.0	Expressed in all		
LARP4	PP13296	ENSG00000161813	La ribonucleoprotein domain family member 4	12	50392383-50480004	Predicted intracellular proteins	Evidence at protein level	HPA039306, HPA039673	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			adrenal gland: 36.6	Expressed in all		
LARP6	acheron, FLJ11196	ENSG00000166173	La ribonucleoprotein domain family member 6	15	70829130-70854159	Predicted intracellular proteins	Evidence at protein level	HPA020338, HPA049029	Approved		Approved	Microtubules<br>Cytokinetic bridge	Renal cancer:9.90e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 84.7	thyroid gland: 40.7	Cell line enhanced		U-2197: 216.0
LARP7	DKFZP564K112, HDCMA18P, PIP7S	ENSG00000174720	La ribonucleoprotein domain family member 7	4	112636964-112657592	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026842, HPA027930	Approved		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:4.33e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 58.5	Expressed in all		
LARS	FLJ10595, FLJ21788, HSPC192, LARS1, LEUS, RNTLS	ENSG00000133706	Leucyl-tRNA synthetase	5	146113038-146182660	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036424, HPA040881	Supported		Supported	Nuclear bodies<br>Cytosol	Liver cancer:3.78e-5 (unfavourable), Thyroid cancer:2.98e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 70.8	Expressed in all		
LARS2	KIAA0028, LEURS, MGC26121, mtLeuRS	ENSG00000011376	Leucyl-tRNA synthetase 2, mitochondrial	3	45388506-45549421	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035951, HPA045450, HPA066085	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:1.32e-11 (favourable), Colorectal cancer:1.71e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 19.2	Expressed in all		
LAS1L	FLJ12525	ENSG00000001497	LAS1 like, ribosome biogenesis factor	X	65512582-65534775	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044431, HPA061463	Supported		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 40.6	Expressed in all		
LASP1	Lasp-1, MLN50	ENSG00000002834	LIM and SH3 protein 1	17	38869859-38921770	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012072, CAB022049	Enhanced		Supported	Plasma membrane<br>Focal adhesion sites<br>Cytosol	Liver cancer:2.41e-4 (unfavourable), Endometrial cancer:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 181.3	Expressed in all		
LATS1	WARTS	ENSG00000131023	Large tumor suppressor kinase 1	6	149658153-149718256	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031804	Approved		Uncertain	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 23.6	Expressed in all		
LATS2		ENSG00000150457	Large tumor suppressor kinase 2	13	20973032-21061547	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039191, HPA049037	Approved		Supported	Microtubule organizing center<br>Cytosol	Cervical cancer:3.26e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.8	Mixed		
LBH		ENSG00000213626	Limb bud and heart development	2	30231531-30323730	Predicted intracellular proteins	Evidence at protein level	HPA034669	Approved		Approved	Vesicles	Stomach cancer:8.24e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 197.1	Cell line enhanced		fHDF/TERT166: 234.8;U-2 OS: 102.9
LBHD1	C11orf48, MGC2477	ENSG00000162194	LBH domain containing 1	11	62662817-62672255	Predicted intracellular proteins	Evidence at protein level	HPA012127, HPA023592	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 9.3	Mixed		
LBX1	HPX6, LBX1H	ENSG00000138136	Ladybird homeobox 1	10	101226195-101229794	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA002016, HPA002086	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Not detected	Tissue enriched	67	skeletal muscle: 9.1	lung: 0.1	Group enriched	8	HEK93: 3.1;RH-30: 4.1;SCLC-21H: 10.7
LBX2		ENSG00000179528	Ladybird homeobox 2	2	74497517-74503316	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA044257	Uncertain		Approved	Nucleus<br>Midbody		Mixed	Tissue enhanced		duodenum: 5.3;small intestine: 5.3	stomach: 3.0	Cell line enhanced		Hep G2: 14.9
LCA5	C6orf152	ENSG00000135338	LCA5, lebercilin	6	79484991-79537458	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029053, HPA029055	Supported				Renal cancer:4.69e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 48.1	fallopian tube: 15.6	Cell line enhanced		HEL: 13.2
LCA5L	C21orf13, MGC33295	ENSG00000157578	LCA5L, lebercilin like	21	39405844-39445805	Predicted intracellular proteins	Evidence at protein level	HPA019790, HPA032010	Enhanced		Uncertain	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	17	testis: 201.6	fallopian tube: 12.2	Mixed		
LCE1A	LEP1	ENSG00000186844	Late cornified envelope 1A	1	152827473-152827894	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	10	skin: 507.5	breast: 50.5	Not detected		
LCE1B	LEP2, SPRL2A	ENSG00000196734	Late cornified envelope 1B	1	152811971-152813109	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	9	skin: 186.0	breast: 20.1	Cell line enhanced		hTCEpi: 1.4
LCE1C	LEP3	ENSG00000197084	Late cornified envelope 1C	1	152804835-152806628	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	11	skin: 514.5	breast: 45.5	Cell line enhanced		HBEC3-KT: 1.5;hTEC/SVTERT24-B: 1.1;hTERT-HME1: 2.2
LCE1D	LEP4	ENSG00000172155	Late cornified envelope 1D	1	152796751-152798181	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	306	skin: 101.7	skeletal muscle: 0.3	Not detected		
LCE1E	LEP5	ENSG00000186226	Late cornified envelope 1E	1	152786214-152788426	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	120	skin: 74.0	breast: 0.6	Cell line enhanced		Daudi: 1.3;HaCaT: 8.8;RT4: 1.8
LCE1F	LEP6	ENSG00000240386	Late cornified envelope 1F	1	152776372-152776728	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	21	skin: 246.9	breast: 11.9	Cell line enhanced		BJ hTERT+: 5.4;hTEC/SVTERT24-B: 1.1;hTERT-HME1: 2.3
LCE2A	LEP9	ENSG00000187173	Late cornified envelope 2A	1	152698364-152699442	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	13	skin: 146.6	breast: 11.5	Cell line enhanced		BJ hTERT+: 4.7;SK-MEL-30: 1.6;U-138 MG: 1.0;U-2197: 1.3
LCE2B	LEP10, SPRL1B, XP5	ENSG00000159455	Late cornified envelope 2B	1	152686123-152687401	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	10	skin: 564.7	breast: 56.0	Not detected		
LCE2C	LEP11	ENSG00000187180	Late cornified envelope 2C	1	152675295-152676574	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	10	skin: 283.4	breast: 29.7	Not detected		
LCE2D	LEP12, SPRL1A	ENSG00000187223	Late cornified envelope 2D	1	152663396-152664659	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	14	skin: 136.2	breast: 9.9	Not detected		
LCE3A	LEP13	ENSG00000185962	Late cornified envelope 3A	1	152622834-152623103	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	22	tonsil: 99.1	esophagus: 4.5	Cell line enhanced		BJ hTERT+: 2.8;LHCN-M2: 1.2;U-138 MG: 1.7
LCE3B	LEP14	ENSG00000187238	Late cornified envelope 3B	1	152613811-152614098	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	29	tonsil: 2.8	all non-specific tissues: 0.0	Not detected		
LCE3C	LEP15, SPRL3A	ENSG00000244057	Late cornified envelope 3C	1	152600662-152601086	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	10	tonsil: 22.5	skin: 2.1	Not detected		
LCE3D	LEP16, SPRL6A, SPRL6B	ENSG00000163202	Late cornified envelope 3D	1	152579381-152580504	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		skin: 26.5;tonsil: 79.8	esophagus: 11.6	Group enriched	5	hTCEpi: 3.2;hTERT-HME1: 3.1
LCE3E	LEP17	ENSG00000185966	Late cornified envelope 3E	1	152565654-152566772	Predicted intracellular proteins	Evidence at protein level							Group enriched	Group enriched	35	esophagus: 9.6;skin: 9.0;tonsil: 18.1	breast: 0.3	Not detected		
LCE4A	LEP8, SPRL4A	ENSG00000187170	Late cornified envelope 4A	1	152708160-152709491	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	6	skin: 5.1	breast: 0.8	Not detected		
LCE5A	LEP18, SPRL5A	ENSG00000186207	Late cornified envelope 5A	1	152510844-152512177	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	skin: 94.0	breast: 16.8	Not detected		
LCE6A	C1orf44	ENSG00000235942	Late cornified envelope 6A	1	152842868-152843983	Predicted intracellular proteins	Evidence at protein level	HPA046376	Enhanced					Tissue enriched	Tissue enriched	11	skin: 303.8	breast: 26.8	Not detected		
LCK		ENSG00000182866	LCK proto-oncogene, Src family tyrosine kinase	1	32251239-32286165	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003494, CAB003816	Enhanced		Approved	Golgi apparatus	Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 125.9;tonsil: 72.4	appendix: 66.3	Group enriched	7	MOLT-4: 429.5;U-698: 207.6
LCMT1	CGI-68, PPMT1	ENSG00000205629	Leucine carboxyl methyltransferase 1	16	25111729-25178231	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041559, HPA043530	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.53e-6 (favourable), Cervical cancer:2.78e-4 (favourable), Liver cancer:5.85e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.8	Expressed in all		
LCMT2	KIAA0547, MGC9534, PPM2, TYW4	ENSG00000168806	Leucine carboxyl methyltransferase 2	15	43323649-43330605	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039401, HPA048176	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.69e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 13.2	Mixed		
LCNL1	FLJ45224	ENSG00000214402	Lipocalin like 1	9	136981904-136986410	Predicted intracellular proteins	Evidence at transcript level							Mixed	Not detected			seminal vesicle: 0.7	Not detected		
LCOR	C10orf12, DKFZP564P1916, FLJ13022, FLJ38026, KIAA1795, MLR2	ENSG00000196233	Ligand dependent nuclear receptor corepressor	10	96832260-96995959	Predicted intracellular proteins	Evidence at protein level	HPA031428, HPA031429, HPA038954, HPA057621, HPA077000	Uncertain		Enhanced	Nucleoplasm	Urothelial cancer:2.16e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 19.2	Expressed in all		
LCP1	CP64, L-PLASTIN, LC64P, PLS2	ENSG00000136167	Lymphocyte cytosolic protein 1	13	46125920-46211871	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019493, CAB020673	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			lymph node: 614.4	Cell line enhanced		HDLM-2: 728.6;HL-60: 666.2;HMC-1: 741.0;U-698: 751.3
LCP2	SLP-76, SLP76	ENSG00000043462	Lymphocyte cytosolic protein 2	5	170246237-170298227	Predicted intracellular proteins	Evidence at protein level	CAB004574, HPA036396, HPA036397	Enhanced				Renal cancer:6.22e-5 (unfavourable), Endometrial cancer:5.08e-4 (favourable)	Expressed in all	Expressed in all			spleen: 125.5	Cell line enhanced		HEL: 149.4;HL-60: 137.8;HMC-1: 372.4;MOLT-4: 84.0;U-937: 87.8
LDB1	CLIM2, NLI	ENSG00000198728	LIM domain binding 1	10	102107560-102120453	Predicted intracellular proteins	Evidence at protein level	HPA034488	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			skin: 158.2	Expressed in all		
LDB2	CLIM1, LDB1	ENSG00000169744	LIM domain binding 2	4	16501541-16898809	Predicted intracellular proteins	Evidence at protein level	CAB017544, HPA068634	Supported		Supported	Nucleus<br>Nucleoli<br>Plasma membrane		Expressed in all	Mixed			endometrium: 108.3	Cell line enhanced		HAP1: 35.5;HUVEC TERT2: 54.3;U-138 MG: 25.3
LDB3	CMD1C, KIAA0613, PDLIM6, ZASP	ENSG00000122367	LIM domain binding 3	10	86668449-86736068	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048955	Enhanced		Supported	Nucleoplasm<br>Focal adhesion sites<br>Cytosol		Mixed	Group enriched	13	heart muscle: 568.8;skeletal muscle: 1039.8	prostate: 60.3	Cell line enhanced		HSkMC: 2.3;SCLC-21H: 6.3;SK-MEL-30: 2.1
LDHA		ENSG00000134333	Lactate dehydrogenase A	11	18394388-18408425	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015336, CAB069404	Uncertain		Supported	Vesicles<br>Cytosol	Renal cancer:9.69e-9 (unfavourable), Liver cancer:3.26e-8 (unfavourable), Lung cancer:2.27e-6 (unfavourable), Pancreatic cancer:8.09e-6 (unfavourable), Cervical cancer:2.78e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 503.4	Expressed in all		
LDHAL6A	LDH6A, MGC23940	ENSG00000166800	Lactate dehydrogenase A like 6A	11	18455824-18479600	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	13	testis: 17.5	skin: 1.3	Cell line enriched	6	HL-60: 8.8
LDHAL6B	LDH6B, LDHAL6, LDHL	ENSG00000171989	Lactate dehydrogenase A like 6B	15	59206823-59208515	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053962	Enhanced					Not detected	Tissue enriched	166	testis: 76.5	gallbladder: 0.4	Not detected		
LDHB		ENSG00000111716	Lactate dehydrogenase B	12	21635342-21757857	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004641, HPA019007	Enhanced		Enhanced	Cytosol	Renal cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			kidney: 1790.8	Expressed in all		
LDHC	CT32	ENSG00000166796	Lactate dehydrogenase C	11	18412307-18452058	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045442	Enhanced					Mixed	Tissue enriched	402	testis: 472.9	thyroid gland: 1.1	Cell line enhanced		U-2197: 4.8;U-266/70: 3.5;U-266/84: 3.0
LDHD		ENSG00000166816	Lactate dehydrogenase D	16	75111860-75116771	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041766, HPA048639, HPA066148	Enhanced		Approved	Cytosol	Renal cancer:2.95e-14 (favourable), Liver cancer:5.61e-4 (favourable)	Expressed in all	Mixed			kidney: 34.0	Cell line enhanced		HMC-1: 13.2;T-47d: 27.8;U-266/70: 8.9
LDLRAP1	ARH, ARH2, DKFZp586D0624, FHCB1, FHCB2, MGC34705	ENSG00000157978	Low density lipoprotein receptor adaptor protein 1	1	25543580-25568886	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB003705, HPA050358	Approved		Approved	Microtubules		Expressed in all	Expressed in all			spleen: 50.9	Mixed		
LDOC1	BCUR1, Mar7, Mart7	ENSG00000182195	LDOC1, regulator of NFKB signaling	X	141175745-141177125	Predicted intracellular proteins	Evidence at protein level	HPA051768, HPA061842	Approved		Supported	Nucleus<br>Nucleoli		Expressed in all	Mixed			cerebral cortex: 73.0	Cell line enhanced		MCF7: 106.5;PC-3: 156.8
LDOC1L	dJ1033E15.2, DKFZp761O17121, Mar6, Mart6	ENSG00000188636	LDOC1 like	22	44492572-44498298	Predicted intracellular proteins	Evidence at protein level	HPA005697	Approved		Approved	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 42.4	Mixed		
LEF1	TCF10, TCF1ALPHA, TCF7L3	ENSG00000138795	Lymphoid enhancer binding factor 1	4	108047545-108168956	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002087, CAB019405	Enhanced		Approved	Nucleoplasm	Renal cancer:2.47e-6 (unfavourable), Endometrial cancer:1.37e-5 (favourable)	Expressed in all	Tissue enhanced		lymph node: 41.7	tonsil: 28.3	Group enriched	6	MOLT-4: 512.4;REH: 443.8
LEKR1	FLJ16641	ENSG00000197980	Leucine, glutamate and lysine rich 1	3	156825481-157046129	Predicted intracellular proteins	Evidence at protein level	HPA044039	Uncertain					Not detected	Tissue enhanced		testis: 27.3	fallopian tube: 6.7	Mixed		
LELP1		ENSG00000203784	Late cornified envelope like proline rich 1	1	153203443-153205120	Predicted intracellular proteins	Evidence at protein level	HPA070231	Enhanced					Tissue enriched	Tissue enriched	2787	testis: 784.3	seminal vesicle,small intestine: 0.2	Not detected		
LENEP	LEP503	ENSG00000163352	Lens epithelial protein	1	154993586-154994315	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			thyroid gland: 0.2	Not detected		
LENG1		ENSG00000105617	Leukocyte receptor cluster member 1	19	54155161-54159882	Predicted intracellular proteins	Evidence at protein level	HPA043541	Uncertain		Approved	Nucleus<br>Plasma membrane	Renal cancer:3.72e-4 (favourable), Pancreatic cancer:8.12e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 1.8	endometrium: 1.0	Cell line enhanced		AF22: 3.2;HaCaT: 4.1;HDLM-2: 2.8;LHCN-M2: 2.3;U-87 MG: 3.1
LENG9		ENSG00000275183	Leukocyte receptor cluster member 9	19	54461796-54463711	Predicted intracellular proteins	Evidence at protein level	HPA051671, HPA053556	Enhanced		Approved	Nucleoli fibrillar center	Endometrial cancer:9.99e-5 (favourable)	Expressed in all	Mixed			duodenum: 5.2	Cell line enhanced		HaCaT: 5.6
LEO1		ENSG00000166477	LEO1 homolog, Paf1/RNA polymerase II complex component	15	51938025-51971806	Predicted intracellular proteins	Evidence at protein level	HPA040741, HPA040941	Enhanced		Enhanced	Nucleoplasm<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			parathyroid gland: 35.6	Expressed in all		
LEUTX		ENSG00000213921	Leucine twenty homeobox	19	39776595-39786167	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA041498	Uncertain		Approved	Nucleus<br>Nucleoli		Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
LEXM	C1orf177, FLJ40201, LEM	ENSG00000162398	Lymphocyte expansion molecule	1	54806063-54842252	Predicted intracellular proteins	Evidence at protein level	HPA035889, HPA035890	Uncertain					Mixed	Group enriched	5	esophagus: 10.5;testis: 7.0	duodenum: 1.6	Not detected		
LGALS1	GBP	ENSG00000100097	Galectin 1	22	37675608-37679806	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000646, HPA000687, HPA001130, CAB002157	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.18e-10 (unfavourable), Endometrial cancer:2.36e-5 (favourable), Liver cancer:3.06e-4 (unfavourable), Urothelial cancer:5.10e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1727.9	Expressed in all		
LGALS12	GRIP1	ENSG00000133317	Galectin 12	11	63506084-63516774	Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.60e-7 (unfavourable)	Mixed	Tissue enriched	7	adipose tissue: 89.9	bone marrow: 12.5	Group enriched	15	ASC diff: 21.2;HL-60: 45.6;NB-4: 70.9;U-937: 93.2
LGALS13	PLAC8, PP13	ENSG00000105198	Galectin 13	19	39602501-39607476	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	34	placenta: 16.6	testis: 0.4	Not detected		
LGALS14	CLC2, PPL13	ENSG00000006659	Galectin 14	19	39704306-39709444	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	57	placenta: 69.0	skin: 1.2	Cell line enhanced		EFO-21: 3.0;U-266/70: 5.8
LGALS16		ENSG00000249861	Galectin 16	19	39655894-39660647	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	54	placenta: 7.7	testis: 0.1	Cell line enriched	39	BEWO: 3.9
LGALS2	HL14	ENSG00000100079	Galectin 2	22	37570246-37582616	Predicted intracellular proteins	Evidence at protein level	HPA003536, CAB025198	Enhanced		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Tissue enhanced		gallbladder: 537.1;small intestine: 225.0	kidney: 155.6	Group enriched	13	CACO-2: 92.0;Hep G2: 42.9
LGALS3	GALIG, LGALS2, MAC-2	ENSG00000131981	Galectin 3	14	55124110-55145413	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003162, CAB005191	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			colon: 871.1	Cell line enhanced		SK-MEL-30: 1368.8
LGALS4	GAL4	ENSG00000171747	Galectin 4	19	38801671-38813364	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025653, HPA031184, HPA031185, HPA031186	Enhanced		Uncertain	Plasma membrane	Renal cancer:2.28e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)	Group enriched	Tissue enhanced		colon: 736.0;duodenum: 526.9;rectum: 640.3;small intestine: 493.5	gallbladder: 138.8	Cell line enhanced		CACO-2: 1.0;RT4: 2.2;SH-SY5Y: 1.0
LGALS7	GAL7, LGALS7A, PIG1, TP53I1	ENSG00000205076	Galectin 7	19	38770971-38773492	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001549, CAB032606	Enhanced					Group enriched	Group enriched	6	breast: 18.1;esophagus: 24.3;skin: 27.7	skeletal muscle: 3.6	Cell line enhanced		HaCaT: 6.2;SCLC-21H: 1.2
LGALS7B	GAL7	ENSG00000178934	Galectin 7B	19	38789211-38791749	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001549, CAB025100	Supported				Endometrial cancer:1.59e-4 (unfavourable)	Group enriched	Tissue enhanced		breast: 10.4;esophagus: 19.3	skeletal muscle: 3.8	Cell line enriched	21	HaCaT: 3.7
LGALS8	PCTA-1	ENSG00000116977	Galectin 8	1	236518000-236552981	Predicted intracellular proteins	Evidence at protein level	HPA012734, HPA030491	Approved		Approved	Plasma membrane	Renal cancer:4.93e-7 (unfavourable), Lung cancer:9.40e-4 (favourable)	Expressed in all	Expressed in all			testis: 101.6	Mixed		
LGALS9	LGALS9A	ENSG00000168961	Galectin 9	17	27629798-27649560	Predicted intracellular proteins	Evidence at protein level	HPA046876, HPA047218	Approved		Approved	Cytosol	Renal cancer:1.52e-5 (unfavourable), Cervical cancer:2.35e-5 (favourable)	Expressed in all	Mixed			rectum: 42.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 23.0;HMC-1: 54.5;MOLT-4: 26.1;THP-1: 38.7;U-937: 38.5
LGALS9B		ENSG00000170298	Galectin 9B	17	20449395-20467539	Predicted intracellular proteins	Evidence at protein level	HPA046876, HPA047218	Approved		Uncertain	Cytosol		Mixed	Tissue enhanced		gallbladder: 11.7;rectum: 11.8;stomach: 28.8	colon: 7.5	Group enriched	7	CAPAN-2: 7.5;U-937: 2.2
LGALS9C		ENSG00000171916	Galectin 9C	17	18476737-18494945	Predicted intracellular proteins	Evidence at protein level	HPA046876, HPA047218	Approved		Approved	Cytosol		Mixed	Tissue enhanced		gallbladder: 4.9;rectum: 5.0;stomach: 10.0	colon: 2.7	Not detected		
LGALSL	GRP, HSPC159	ENSG00000119862	Galectin like	2	64453969-64461381	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046079	Approved		Approved	Nucleoplasm	Liver cancer:2.16e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 110.9	Cell line enhanced		AN3-CA: 46.2;HAP1: 75.2
LGSN	GLULD1, LGS	ENSG00000146166	Lengsin, lens protein with glutamine synthetase domain	6	63275951-63319977	Predicted intracellular proteins	Evidence at protein level	HPA030957, HPA039983	Enhanced		Approved	Nucleoplasm<br>Vesicles		Tissue enhanced	Tissue enhanced		kidney: 2.8;liver: 2.4;placenta: 1.8	testis: 0.7	Cell line enhanced		A549: 5.5;BEWO: 3.0;CACO-2: 1.6;HeLa: 1.5
LHPP	HDHD2B	ENSG00000107902	Phospholysine phosphohistidine inorganic pyrophosphate phosphatase	10	124461834-124617888	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA009163, HPA009269	Enhanced		Supported	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 70.6	Mixed		
LHX1	LIM-1, LIM1	ENSG00000273706	LIM homeobox 1	17	36936785-36944612	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073521	Enhanced				Endometrial cancer:3.63e-5 (unfavourable)	Tissue enhanced	Tissue enriched	6	kidney: 1.3	fallopian tube: 0.2	Cell line enhanced		HAP1: 3.9;WM-115: 6.9
LHX2	hLhx2, LH-2	ENSG00000106689	LIM homeobox 2	9	124001670-124033301	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA000838		Supported	Approved	Nucleoplasm	Cervical cancer:9.52e-4 (favourable)	Group enriched	Tissue enriched	11	cerebral cortex: 56.3	placenta: 5.1	Cell line enhanced		AN3-CA: 22.0;HAP1: 24.5;NTERA-2: 29.4
LHX3		ENSG00000107187	LIM homeobox 3	9	136196250-136205109	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Not detected			cerebral cortex: 0.4	Cell line enhanced		U-266/70: 1.0
LHX4	Gsh4	ENSG00000121454	LIM homeobox 4	1	180230286-180278982	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055705			Approved	Nuclear speckles		Not detected	Mixed			testis: 2.2	Cell line enhanced		BEWO: 10.3
LHX5		ENSG00000089116	LIM homeobox 5	12	113462034-113472280	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA053908	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 1.4	stomach: 0.3	Cell line enhanced		HMC-1: 1.0
LHX6	LHX6.1	ENSG00000106852	LIM homeobox 6	9	122202577-122229626	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047854, HPA058319	Approved		Uncertain	Nucleoli fibrillar center<br>Plasma membrane		Mixed	Mixed			cerebral cortex: 8.1	Cell line enhanced		CACO-2: 10.9;NB-4: 11.6;PC-3: 11.4;U-87 MG: 9.4
LHX8	Lhx7	ENSG00000162624	LIM homeobox 8	1	75128434-75161533	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071806			Approved	Nucleus<br>Nucleoli<br>Cytosol		Not detected	Tissue enhanced		placenta: 1.8;testis: 1.3;tonsil: 1.5	gallbladder,urinary bladder: 1.0	Group enriched	6	SCLC-21H: 30.2;U-266/70: 6.6
LHX9		ENSG00000143355	LIM homeobox 9	1	197911902-197935478	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009695	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		ovary: 11.5;testis: 4.5	lung: 2.2	Cell line enriched	9	fHDF/TERT166: 213.5
LIAS	LAS	ENSG00000121897	Lipoic acid synthetase	4	39458587-39485109	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018842, HPA019076	Approved	Approved	Approved	Nucleoplasm<br>Mitochondria	Renal cancer:4.11e-7 (favourable)	Expressed in all	Mixed			testis: 15.1	Expressed in all		
LIG1		ENSG00000105486	DNA ligase 1	19	48115445-48170603	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037015, HPA041431, HPA048071	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:5.75e-5 (unfavourable)	Expressed in all	Mixed			bone marrow: 20.9	Mixed		
LIG3	LIG2	ENSG00000005156	DNA ligase 3	17	34980494-35009743	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006723	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 38.7	Expressed in all		
LIG4		ENSG00000174405	DNA ligase 4	13	108207439-108218368	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001334, HPA057325	Supported		Supported	Nucleoplasm<br>Cytoplasmic bodies		Expressed in all	Mixed			parathyroid gland: 20.2	Expressed in all		
LIMA1	EPLIN	ENSG00000050405	LIM domain and actin binding 1	12	50175788-50283546	Predicted intracellular proteins	Evidence at protein level	HPA023871, HPA052645	Enhanced		Enhanced	Plasma membrane<br>Actin filaments<br>Focal adhesion sites<br>Cytosol	Head and neck cancer:1.76e-6 (unfavourable), Renal cancer:2.79e-4 (favourable)	Expressed in all	Expressed in all			rectum: 143.8	Expressed in all		
LIMCH1	DKFZP686A01247, LIMCH1A, LMO7B	ENSG00000064042	LIM and calponin homology domains 1	4	41359607-41700044	Predicted intracellular proteins	Evidence at protein level	HPA004184, HPA063840	Uncertain		Approved	Actin filaments	Renal cancer:3.82e-7 (favourable), Breast cancer:5.55e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 190.9	Cell line enhanced		HeLa: 126.0;RT4: 144.1;SiHa: 108.5;WM-115: 142.5
LIMD1		ENSG00000144791	LIM domains containing 1	3	45555394-45686338	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064220			Supported	Nucleus<br>Focal adhesion sites	Renal cancer:6.73e-5 (favourable)	Expressed in all	Expressed in all			lung: 26.6	Expressed in all		
LIMD2	MGC10986	ENSG00000136490	LIM domain containing 2	17	63695902-63701172	Predicted intracellular proteins	Evidence at protein level	HPA062867			Approved	Vesicles	Renal cancer:5.36e-11 (unfavourable)	Expressed in all	Group enriched	5	appendix: 140.1;bone marrow: 71.2;lymph node: 255.5;spleen: 191.0;tonsil: 138.2	urinary bladder: 30.2	Cell line enhanced		Daudi: 173.9;SH-SY5Y: 172.7;U-698: 174.0
LIMK1	LIMK	ENSG00000106683	LIM domain kinase 1	7	74082933-74122525	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028064, HPA028516	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:6.63e-8 (unfavourable), Liver cancer:7.79e-6 (unfavourable), Colorectal cancer:4.95e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.5	Expressed in all		
LIMK2		ENSG00000182541	LIM domain kinase 2	22	31212239-31280080	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008183, CAB019313, HPA053882	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.57e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 70.8	Expressed in all		
LIMS1	PINCH, PINCH1	ENSG00000169756	LIM zinc finger domain containing 1	2	108534355-108687246	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058455, HPA061230	Approved		Supported	Focal adhesion sites<br>Cytosol	Renal cancer:7.88e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 61.1	Expressed in all		
LIMS2	PINCH-2, PINCH2	ENSG00000072163	LIM zinc finger domain containing 2	2	127638381-127681786	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA058340	Enhanced		Supported	Focal adhesion sites	Liver cancer:6.53e-7 (favourable)	Expressed in all	Mixed			seminal vesicle: 137.8	Cell line enhanced		HHSteC: 27.3;MOLT-4: 32.1;TIME: 66.1
LIMS3		ENSG00000256977	LIM zinc finger domain containing 3	2	109898428-109924868	Predicted intracellular proteins	Evidence at transcript level	HPA058455	Uncertain		Approved	Focal adhesion sites<br>Cytosol		Not detected	Tissue enhanced		endometrium: 10.8;fallopian tube: 10.5	appendix: 3.5	Cell line enhanced		HEL: 12.7;HMC-1: 36.2
LIMS4	LIMS3L	ENSG00000256671	LIM zinc finger domain containing 4	2	110446640-110473075	Predicted intracellular proteins	Evidence at protein level	HPA058455	Uncertain					Not detected	Not detected			kidney,liver: 0.1	Cell line enhanced		hTEC/SVTERT24-B: 1.8;U-138 MG: 1.9
LIN28A	CSDD1, FLJ12457, LIN-28, LIN28, ZCCHC1	ENSG00000131914	Lin-28 homolog A	1	26410778-26429722	Predicted intracellular proteins	Evidence at protein level	CAB020785	Enhanced		Uncertain	Nucleoplasm		Tissue enriched	Tissue enriched	12	testis: 4.3	skin: 0.3	Cell line enriched	10	NTERA-2: 860.9
LIN28B	CSDD2, FLJ16517	ENSG00000187772	Lin-28 homolog B	6	104936616-105083332	Predicted intracellular proteins	Evidence at protein level	HPA036630, HPA061745	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol		Tissue enriched	Tissue enriched	12	placenta: 93.5	testis: 7.7	Cell line enhanced		BEWO: 241.5;K-562: 76.8
LIN37	F25965, lin-37, ZK418.4	ENSG00000267796	Lin-37 DREAM MuvB core complex component	19	35748361-35754519	Predicted intracellular proteins	Evidence at protein level	HPA043253, HPA047809	Uncertain		Supported	Nucleoplasm	Renal cancer:1.62e-6 (unfavourable), Pancreatic cancer:1.67e-4 (favourable)	Expressed in all	Expressed in all			ovary: 12.5	Expressed in all		
LIN52	C14orf46	ENSG00000205659	Lin-52 DREAM MuvB core complex component	14	74084796-74201235	Predicted intracellular proteins	Evidence at protein level	HPA000900, HPA001777	Uncertain		Approved	Nuclear speckles	Liver cancer:6.08e-5 (unfavourable), Head and neck cancer:6.60e-4 (favourable)	Expressed in all	Mixed			kidney: 17.3	Expressed in all		
LIN54	CXCDC1, DKFZp686L1814, JC8.6, MIP120, TCX1	ENSG00000189308	Lin-54 DREAM MuvB core complex component	4	82909973-83012926	Predicted intracellular proteins	Evidence at protein level	HPA056606	Approved		Approved	Cytosol	Renal cancer:1.06e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 17.2	Expressed in all		
LIN7A	LIN-7A, MALS-1, TIP-33, VELI1	ENSG00000111052	Lin-7 homolog A, crumbs cell polarity complex component	12	80792520-80937925	Predicted intracellular proteins	Evidence at protein level	HPA071562	Approved				Renal cancer:1.63e-11 (favourable)	Tissue enhanced	Mixed			bone marrow: 17.8	Cell line enhanced		ASC TERT1: 22.0;HAP1: 25.9;HDLM-2: 27.5;HL-60: 23.1
LIN7B	LIN-7B, MALS-2, VELI2	ENSG00000104863	Lin-7 homolog B, crumbs cell polarity complex component	19	49114324-49118460	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:7.00e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 18.2	Mixed		
LIN7C	FLJ11215, LIN-7-C, LIN-7C, Lin7c, MALS-3, VELI3	ENSG00000148943	Lin-7 homolog C, crumbs cell polarity complex component	11	27494576-27506773	Predicted intracellular proteins	Evidence at protein level	HPA051118	Approved				Renal cancer:1.09e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 24.3	Expressed in all		
LIN9	TGS	ENSG00000183814	Lin-9 DREAM MuvB core complex component	1	226231149-226309869	Predicted intracellular proteins	Evidence at protein level	HPA030241	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			testis: 16.9	Expressed in all		
LINC00094	bA374P20.3, FLJ35348, NCRNA00094	ENSG00000235106	Long intergenic non-protein coding RNA 94	9	134025439-134034666	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:4.24e-5 (favourable), Urothelial cancer:2.31e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 36.6	Expressed in all		
LINC00238	C14orf53, NCRNA00238	ENSG00000196553	Long intergenic non-protein coding RNA 238	14	66486354-66498553	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	85	testis: 8.5	all non-specific tissues: 0.0	Not detected		
LINC00371		ENSG00000226792	Long intergenic non-protein coding RNA 371	13	51082119-51200252	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			testis: 0.9	Group enriched	99	HAP1: 8.9;NTERA-2: 10.8
LINC00521	C14orf48	ENSG00000175699	Long intergenic non-protein coding RNA 521	14	93987225-94008863	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	26	testis: 11.9	heart muscle: 0.4	Cell line enhanced		U-266/70: 1.0
LINC00633		ENSG00000224107	Long intergenic non-protein coding RNA 633	X	135118955-135120526	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	63	testis: 15.1	bone marrow: 0.2	Not detected		
LINC00694		ENSG00000225873	Long intergenic non-protein coding RNA 694	3	44421127-44439946	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	8	testis: 28.4	spleen: 3.7	Cell line enhanced		HMC-1: 24.5;K-562: 4.3;NB-4: 8.8
LINC00854	TMEM106A-AS1	ENSG00000236383	Long intergenic non-protein coding RNA 854	17	43216941-43305397	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	11	testis: 45.4	spleen: 4.0	Mixed		
LINC00935		ENSG00000257987	Long intergenic non-protein coding RNA 935	12	48727435-48765786	Predicted intracellular proteins	Evidence at transcript level							Group enriched	Tissue enriched	23	testis: 22.3	stomach: 0.9	Not detected		
LINC00959		ENSG00000237489	Long intergenic non-protein coding RNA 959	10	130063900-130110817	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			thyroid gland: 10.9	Cell line enhanced		NB-4: 8.8
LINS1	LINS, WINS1	ENSG00000140471	Lines homolog 1	15	100559369-100603230	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038578, HPA038579	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 14.0	Expressed in all		
LIPE	HSL	ENSG00000079435	Lipase E, hormone sensitive type	19	42401507-42427426	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006567, CAB017700	Enhanced		Supported	Cytosol	Pancreatic cancer:1.15e-4 (favourable)	Expressed in all	Tissue enriched	20	adipose tissue: 870.5	testis: 44.0	Cell line enriched	6	ASC diff: 94.1
LIPI	CT17, LPDL, mPA-PLA1beta, PLA1C, PRED5	ENSG00000188992	Lipase I	21	14108813-14210891	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	120	epididymis: 577.5	thyroid gland: 4.8	Not detected		
LIPJ	bA425M17.2, LIPL1	ENSG00000204022	Lipase family member J	10	88586753-88606976	Predicted intracellular proteins	Evidence at transcript level	HPA048594	Uncertain					Not detected	Tissue enriched	11	testis: 12.3	epididymis,fallopian tube: 1.1	Not detected		
LIPT1	MGC12290, MGC13378	ENSG00000144182	Lipoyltransferase 1	2	99154955-99163157	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034802	Approved				Urothelial cancer:9.60e-8 (favourable), Lung cancer:5.70e-4 (favourable)	Expressed in all	Expressed in all			testis: 24.3	Expressed in all		
LIPT2		ENSG00000175536	Lipoyl(octanoyl) transferase 2 (putative)	11	74491712-74493733	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040249	Approved		Approved	Vesicles<br>Centrosome	Ovarian cancer:1.63e-4 (favourable)	Expressed in all	Mixed			testis: 14.5	Mixed		
LIX1	C5orf11, Lft	ENSG00000145721	Limb and CNS expressed 1	5	97091867-97142872	Predicted intracellular proteins	Evidence at transcript level	HPA058426	Uncertain		Approved	Vesicles<br>Cytokinetic bridge<br>Cytosol	Endometrial cancer:2.48e-4 (unfavourable)	Tissue enhanced	Tissue enriched	6	cerebral cortex: 32.8	seminal vesicle: 5.7	Cell line enriched	9	RPTEC TERT1: 24.5
LIX1L	MGC46719	ENSG00000271601	Limb and CNS expressed 1 like	1	145933423-145958001	Predicted intracellular proteins	Evidence at protein level	HPA063598			Approved	Cytosol	Renal cancer:3.19e-5 (unfavourable), Liver cancer:1.61e-4 (unfavourable), Urothelial cancer:5.27e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 45.8	Mixed		
LKAAEAR1	C20orf201	ENSG00000171695	LKAAEAR motif containing 1	20	64083380-64084359	Predicted intracellular proteins	Evidence at transcript level	HPA056463	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		testis: 2.7	cerebral cortex: 0.8	Cell line enhanced		REH: 5.1;SCLC-21H: 6.5
LL0XNC01-16G2.1		ENSG00000225110		X	153317681-153321822	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 4.0	adrenal gland: 0.9	Not detected		
LLGL1	DLG4, HUGL, HUGL-1, Lgl1, LLGL, Mgl1	ENSG00000131899	LLGL1, scribble cell polarity complex component	17	18225587-18244875	Predicted intracellular proteins	Evidence at protein level	HPA022924, HPA023569	Enhanced				Liver cancer:2.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 21.1	endometrium: 7.0	Expressed in all		
LLGL2	HGL, Hugl-2	ENSG00000073350	LLGL2, scribble cell polarity complex component	17	75525080-75575208	Predicted intracellular proteins	Evidence at protein level	HPA022913	Uncertain		Supported	Vesicles<br>Cytosol	Renal cancer:6.14e-9 (favourable), Pancreatic cancer:6.00e-5 (favourable), Head and neck cancer:9.25e-4 (favourable)	Expressed in all	Mixed			stomach: 62.8	Cell line enhanced		CAPAN-2: 118.0;MCF7: 101.3;SK-BR-3: 95.4;T-47d: 90.7
LLNLF-187D8.1		ENSG00000277531		19	46424697-46428951	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	9	cerebral cortex: 23.3	epididymis: 2.5	Group enriched	5	AF22: 1.1;HMC-1: 2.2;SH-SY5Y: 4.0
LLPH	C12orf31, hLLP, MGC14817	ENSG00000139233	LLP homolog, long-term synaptic facilitation	12	66116555-66130768	Predicted intracellular proteins	Evidence at protein level	HPA048920, HPA058786			Enhanced	Nucleoli	Liver cancer:6.44e-7 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 42.5	Expressed in all		
LMCD1		ENSG00000071282	LIM and cysteine rich domains 1	3	8501707-8574673	Predicted intracellular proteins	Evidence at protein level	HPA024059	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:8.66e-5 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 201.9	Cell line enhanced		HSkMC: 90.7;hTEC/SVTERT24-B: 93.9
LMNA	CMD1A, HGPS, LGMD1B, LMN1, LMNL1, MADA, PRO1	ENSG00000160789	Lamin A/C	1	156082573-156140089	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004022, HPA006660	Supported					Expressed in all	Expressed in all			gallbladder: 343.4	Expressed in all		
LMNB1		ENSG00000113368	Lamin B1	5	126776623-126837020	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005269, HPA050524, HPA053579	Supported		Enhanced	Nuclear membrane	Renal cancer:3.33e-16 (unfavourable), Liver cancer:3.08e-6 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 41.4	appendix: 36.2	Mixed		
LMNB2	LMN2	ENSG00000176619	Lamin B2	19	2427638-2456996	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022593, HPA047863, HPA062477	Enhanced		Supported	Nuclear membrane	Renal cancer:9.34e-5 (unfavourable), Prostate cancer:9.53e-5 (unfavourable), Liver cancer:1.32e-4 (unfavourable), Stomach cancer:3.98e-4 (favourable), Melanoma:5.88e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 21.0	Expressed in all		
LMNTD2	C11orf35, MGC35138	ENSG00000185522	Lamin tail domain containing 2	11	554855-560779	Predicted intracellular proteins	Evidence at protein level	HPA058474, HPA073912	Uncertain		Approved	Cytoplasmic bodies	Colorectal cancer:3.75e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 9.4	Cell line enhanced		AN3-CA: 4.1;T-47d: 4.6
LMO1	RBTN1, RHOM1, TTG1	ENSG00000166407	LIM domain only 1	11	8224304-8268716	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		skeletal muscle: 10.1;skin: 5.9	epididymis: 2.0	Group enriched	6	HeLa: 22.0;SCLC-21H: 14.8;SH-SY5Y: 41.0;SiHa: 8.4
LMO2	RBTN2, RBTNL1, RHOM2, TTG2	ENSG00000135363	LIM domain only 2	11	33858576-33892289	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016258, HPA029285	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.12e-4 (favourable)	Expressed in all	Mixed			spleen: 25.7	Cell line enhanced		HEL: 48.0;HL-60: 42.9;K-562: 49.4;THP-1: 47.5
LMO3	DAT1, RBTNL2, Rhom-3	ENSG00000048540	LIM domain only 3	12	16548373-16610594	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:1.10e-7 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 190.9	thyroid gland: 67.7	Group enriched	6	ASC diff: 157.0;LHCN-M2: 88.8
LMO4		ENSG00000143013	LIM domain only 4	1	87328468-87348923	Predicted intracellular proteins	Evidence at protein level	CAB022345, HPA045877, HPA061638	Approved		Supported	Nucleoplasm<br>Midbody ring	Thyroid cancer:1.42e-4 (favourable), Ovarian cancer:1.47e-4 (favourable), Liver cancer:5.25e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 217.4	Expressed in all		
LMO7DN	C13orf45	ENSG00000178734	LMO7 downstream neighbor	13	75871038-75883811	Predicted intracellular proteins	Evidence at transcript level	HPA052013	Uncertain					Not detected	Tissue enhanced		gallbladder: 1.3	esophagus,lung,testis: 0.7	Cell line enhanced		LHCN-M2: 1.1
LMOD1	1D, 64kD, D1	ENSG00000163431	Leiomodin 1	1	201896452-201946588	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028325, HPA028435, HPA030097	Enhanced		Approved	Cytosol	Liver cancer:2.52e-5 (favourable), Renal cancer:1.05e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 331.2	Group enriched	10	ASC diff: 10.7;BJ: 17.8;BJ hTERT+: 27.6;fHDF/TERT166: 13.3;HSkMC: 10.4
LMOD2		ENSG00000170807	Leiomodin 2	7	123655807-123664290	Predicted intracellular proteins	Evidence at protein level	HPA051039	Enhanced					Group enriched	Group enriched	19	heart muscle: 506.5;skeletal muscle: 316.7	esophagus: 21.9	Cell line enriched	8	HSkMC: 1.0
LMOD3		ENSG00000163380	Leiomodin 3	3	69106872-69123032	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036034	Uncertain					Tissue enriched	Group enriched	17	heart muscle: 73.7;skeletal muscle: 162.2	esophagus: 6.9	Cell line enhanced		HSkMC: 2.1
LMX1A	LMX1, LMX1.1	ENSG00000162761	LIM homeobox transcription factor 1 alpha	1	165201867-165356715	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028051, HPA030088			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Not detected	Tissue enhanced		duodenum: 1.0;testis: 2.2	adipose tissue,rectum,small intestine: 0.6	Cell line enriched	11	SCLC-21H: 1.0
LMX1B	NPS1	ENSG00000136944	LIM homeobox transcription factor 1 beta	9	126614443-126701032	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073716			Approved	Nucleus		Tissue enriched	Tissue enhanced		breast: 5.8;salivary gland: 11.2	testis: 2.2	Cell line enhanced		MCF7: 13.7;T-47d: 10.1
LNP1	NP3	ENSG00000206535	Leukemia NUP98 fusion partner 1	3	100401193-100456319	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047926			Approved	Nuclear speckles<br>Vesicles<br>Cytosol		Expressed in all	Tissue enriched	6	testis: 47.9	cerebral cortex: 7.6	Mixed		
LNX2	MGC46315, PDZRN1	ENSG00000139517	Ligand of numb-protein X 2	13	27545911-27620404	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040698	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:7.09e-13 (favourable)	Expressed in all	Expressed in all			testis: 23.3	Expressed in all		
LONP1	hLON, LonHS, PIM1, PRSS15	ENSG00000196365	Lon peptidase 1, mitochondrial	19	5691834-5720572	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002034, HPA002192	Supported		Enhanced	Nucleus<br>Mitochondria		Expressed in all	Expressed in all			adrenal gland: 140.4	Expressed in all		
LONP2	LONP, LONPL, MGC4840	ENSG00000102910	Lon peptidase 2, peroxisomal	16	48244296-48363122	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008862	Uncertain				Renal cancer:6.71e-7 (favourable), Cervical cancer:4.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 81.8	Expressed in all		
LONRF1	FLJ23749, RNF191	ENSG00000154359	LON peptidase N-terminal domain and ring finger 1	8	12721894-12756073	Predicted intracellular proteins	Evidence at protein level	HPA023584, HPA024814	Uncertain		Approved	Plasma membrane<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			skin: 30.8	Cell line enhanced		Karpas-707: 47.8;SCLC-21H: 45.0
LONRF2	FLJ45273, RNF192	ENSG00000170500	LON peptidase N-terminal domain and ring finger 2	2	100273291-100322733	Predicted intracellular proteins	Evidence at protein level	HPA057366	Approved		Supported	Nucleus	Pancreatic cancer:6.42e-5 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 55.6	endometrium: 45.2	Cell line enhanced		HAP1: 6.0;HEK93: 5.7;SCLC-21H: 14.7
LONRF3	FLJ22612, RNF127	ENSG00000175556	LON peptidase N-terminal domain and ring finger 3	X	118974614-119018355	Predicted intracellular proteins	Evidence at protein level	HPA050422, HPA061162	Uncertain		Approved	Nucleus<br>Plasma membrane	Pancreatic cancer:4.32e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 12.6	Cell line enhanced		K-562: 11.8;PC-3: 13.4;SiHa: 14.0
LOR		ENSG00000203782	Loricrin	1	153259700-153262122	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA076123, HPA077266	Enhanced				Head and neck cancer:8.53e-4 (favourable)	Tissue enriched	Tissue enriched	16	skin: 532.0	breast: 32.9	Cell line enriched	83	HDLM-2: 33.1
LOXHD1	DFNB77, FLJ32670, LH2D1	ENSG00000167210	Lipoxygenase homology domains 1	18	46476972-46657033	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	9	epididymis: 8.3;testis: 41.3	fallopian tube: 2.6	Not detected		
LPIN1	KIAA0188	ENSG00000134324	Lipin 1	2	11677595-11827409	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038021	Approved		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			testis: 102.1	Expressed in all		
LPIN2	KIAA0249	ENSG00000101577	Lipin 2	18	2916994-3013315	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015223, HPA017857, HPA030550	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Head and neck cancer:8.01e-4 (favourable)	Expressed in all	Mixed			liver: 87.3	Mixed		
LPIN3	LIPN3L, SMP2	ENSG00000132793	Lipin 3	20	41340920-41360582	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051466, HPA052667, HPA070640	Approved		Supported	Cytosol	Renal cancer:1.14e-5 (unfavourable), Ovarian cancer:1.74e-4 (unfavourable), Endometrial cancer:9.74e-4 (unfavourable)	Expressed in all	Mixed			skin: 48.5	Mixed		
LPP		ENSG00000145012	LIM domain containing preferred translocation partner in lipoma	3	188153284-188890671	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA011133, HPA017342	Enhanced		Enhanced	Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 117.9	Cell line enhanced		EFO-21: 109.0;U-698: 138.0
LPXN	LDPL	ENSG00000110031	Leupaxin	11	58526871-58578220	Predicted intracellular proteins	Evidence at protein level	HPA043741, CAB046478, HPA061441	Supported		Enhanced	Nuclear speckles<br>Focal adhesion sites<br>Cytosol	Endometrial cancer:8.81e-4 (favourable)	Expressed in all	Expressed in all			tonsil: 107.2	Cell line enhanced		HMC-1: 289.6;Karpas-707: 204.9
LRCH2	KIAA1495	ENSG00000130224	Leucine rich repeats and calponin homology domain containing 2	X	115110616-115234072	Predicted intracellular proteins	Evidence at protein level	HPA003233	Approved		Approved	Nucleoli<br>Plasma membrane		Mixed	Mixed			prostate: 13.8	Cell line enhanced		HAP1: 22.2
LRGUK	CFAP246, FLJ32786	ENSG00000155530	Leucine rich repeats and guanylate kinase domain containing	7	134127299-134264591	Predicted intracellular proteins	Evidence at protein level	HPA029505, HPA029506	Uncertain					Mixed	Group enriched	8	epididymis: 1.7;fallopian tube: 5.4;testis: 8.4	lung,thyroid gland: 0.6	Cell line enhanced		NTERA-2: 1.4;SH-SY5Y: 1.3;SK-MEL-30: 1.4
LRIF1	C1orf103, FLJ11269, RIF1	ENSG00000121931	Ligand dependent nuclear receptor interacting factor 1	1	110947185-110964079	Predicted intracellular proteins	Evidence at protein level	HPA044515	Uncertain		Supported	Nucleus<br>Microtubule organizing center	Ovarian cancer:1.73e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.8	Mixed		
LRP2BP	DKFZp761O0113	ENSG00000109771	LRP2 binding protein	4	185363879-185395899	Predicted intracellular proteins	Evidence at protein level	HPA036664, HPA036665	Approved					Mixed	Tissue enhanced		fallopian tube: 12.3;testis: 20.3	cerebral cortex: 6.3	Cell line enhanced		U-266/70: 4.7
LRP5L	DKFZp434O0213	ENSG00000100068	LDL receptor related protein 5 like	22	25351418-25405377	Predicted intracellular proteins	Evidence at transcript level	HPA028717	Uncertain		Approved	Nucleoplasm	Urothelial cancer:6.93e-6 (favourable)	Expressed in all	Mixed			thyroid gland: 9.7	Mixed		
LRPPRC	GP130, LRP130, LSFC	ENSG00000138095	Leucine rich pentatricopeptide repeat containing	2	43886508-43996005	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB033786, HPA036408, HPA036409	Enhanced		Enhanced	Mitochondria	Liver cancer:2.31e-7 (unfavourable), Renal cancer:6.65e-6 (favourable), Endometrial cancer:1.72e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 80.1	Expressed in all		
LRR1	LRR-1, MGC20689, PPIL5	ENSG00000165501	Leucine rich repeat protein 1	14	49598697-49614672	Predicted intracellular proteins	Evidence at protein level	HPA065703, HPA069364	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Renal cancer:4.90e-7 (unfavourable), Liver cancer:2.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 33.6	lymph node: 12.1	Expressed in all		
LRRC1	dJ523E19.1, FLJ10775, FLJ11834, LANO	ENSG00000137269	Leucine rich repeat containing 1	6	53794497-53924121	Predicted intracellular proteins	Evidence at protein level	HPA031603, HPA031604	Enhanced		Supported	Cytosol	Renal cancer:2.21e-7 (favourable), Pancreatic cancer:1.18e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 41.9	Mixed		
LRRC10	HRLRRP, LRRC10A	ENSG00000198812	Leucine rich repeat containing 10	12	69608564-69611162	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	28	heart muscle: 22.6	lymph node: 0.7	Not detected		
LRRC10B		ENSG00000204950	Leucine rich repeat containing 10B	11	61508800-61511018	Predicted intracellular proteins	Evidence at protein level	HPA047619	Uncertain		Approved	Nucleoplasm<br>Nucleoli		Mixed	Tissue enriched	12	fallopian tube: 47.3	lung: 3.9	Group enriched	7	AF22: 9.8;RH-30: 10.4;SCLC-21H: 6.5
LRRC14	KIAA0014, LRRC14A	ENSG00000160959	Leucine rich repeat containing 14	8	144517992-144525178	Predicted intracellular proteins	Evidence at protein level	HPA021047	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.78e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.6	Expressed in all		
LRRC14B		ENSG00000185028	Leucine rich repeat containing 14B	5	191511-195353	Predicted intracellular proteins	Evidence at protein level	HPA038046, HPA038047	Uncertain					Tissue enhanced	Group enriched	26	heart muscle: 13.6;skeletal muscle: 30.1	prostate: 0.8	Cell line enhanced		REH: 6.8;U-266/70: 7.1;U-266/84: 28.6
LRRC18	MGC34773, UNQ933, UNQ9338, VKGE9338	ENSG00000165383	Leucine rich repeat containing 18	10	48909483-48914232	Predicted intracellular proteins	Evidence at protein level	HPA039256	Enhanced					Tissue enhanced	Group enriched	8	fallopian tube: 12.1;testis: 25.3	lung: 2.3	Not detected		
LRRC2		ENSG00000163827	Leucine rich repeat containing 2	3	46515423-46580099	Predicted intracellular proteins	Evidence at protein level	HPA039138, HPA040096	Approved					Tissue enhanced	Group enriched	5	heart muscle: 30.0;skeletal muscle: 55.9;thyroid gland: 37.0	endometrium: 7.8	Cell line enhanced		fHDF/TERT166: 5.6;HEL: 3.8;LHCN-M2: 3.4
LRRC20	FLJ10751, FLJ10844	ENSG00000172731	Leucine rich repeat containing 20	10	70298970-70382650	Predicted intracellular proteins	Evidence at protein level	HPA039630			Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.41e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 120.5	heart muscle: 28.5	Cell line enhanced		U-2 OS: 83.3
LRRC23	B7, LRPB7	ENSG00000010626	Leucine rich repeat containing 23	12	6873569-6914243	Predicted intracellular proteins	Evidence at protein level	HPA037766, HPA057533	Enhanced		Supported	Nucleoli	Breast cancer:6.02e-4 (favourable)	Expressed in all	Group enriched	7	fallopian tube: 165.3;testis: 43.3	epididymis: 15.2	Mixed		
LRRC27	KIAA1674	ENSG00000148814	Leucine rich repeat containing 27	10	132332154-132379918	Predicted intracellular proteins	Evidence at protein level	HPA037595, HPA067395	Enhanced		Approved	Nucleus<br>Golgi apparatus		Mixed	Tissue enhanced		testis: 100.8	fallopian tube: 21.1	Mixed		
LRRC28	FLJ34269, FLJ45242, MGC24976	ENSG00000168904	Leucine rich repeat containing 28	15	99251362-99390729	Predicted intracellular proteins	Evidence at transcript level	HPA039378, HPA040784, HPA066130	Approved		Approved	Nucleus<br>Golgi apparatus<br>Mitochondria	Ovarian cancer:9.97e-5 (favourable), Cervical cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 50.3	Expressed in all		
LRRC29	FBL9, FBXL9	ENSG00000125122	Leucine rich repeat containing 29	16	67207139-67227048	Predicted intracellular proteins	Evidence at protein level	HPA034998	Uncertain		Uncertain	Nucleoplasm	Endometrial cancer:4.33e-4 (favourable), Pancreatic cancer:5.20e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 1.8	Mixed		
LRRC30		ENSG00000206422	Leucine rich repeat containing 30	18	7231125-7232047	Predicted intracellular proteins	Evidence at transcript level	HPA041039	Uncertain					Not detected	Tissue enriched	10	skeletal muscle: 5.6	esophagus: 0.5	Not detected		
LRRC31	FLJ23259	ENSG00000114248	Leucine rich repeat containing 31	3	169839179-169869930	Predicted intracellular proteins	Evidence at protein level	HPA037548	Uncertain					Mixed	Group enriched	5	colon: 18.2;duodenum: 8.8;rectum: 24.3;small intestine: 11.0;stomach: 9.8	liver: 2.8	Cell line enhanced		EFO-21: 1.8;HAP1: 1.4;RPTEC TERT1: 1.6
LRRC34	MGC27085	ENSG00000171757	Leucine rich repeat containing 34	3	169793428-169812986	Predicted intracellular proteins	Evidence at protein level	HPA035747	Approved		Approved	Cell Junctions<br>Microtubules<br>Cytokinetic bridge		Mixed	Group enriched	8	fallopian tube: 12.2;testis: 26.8	cerebral cortex: 2.2	Cell line enhanced		HEL: 7.6;HL-60: 7.2;NTERA-2: 8.7
LRRC36	FLJ11004	ENSG00000159708	Leucine rich repeat containing 36	16	67326798-67385203	Predicted intracellular proteins	Evidence at protein level	HPA055237, HPA058479	Enhanced					Mixed	Tissue enriched	7	testis: 62.5	placenta: 8.8	Cell line enhanced		hTEC/SVTERT24-B: 1.4
LRRC39	MGC14816	ENSG00000122477	Leucine rich repeat containing 39	1	100148449-100178273	Predicted intracellular proteins	Evidence at protein level	HPA077159	Enhanced					Mixed	Group enriched	10	heart muscle: 81.3;skeletal muscle: 175.6	testis: 12.3	Cell line enhanced		SK-MEL-30: 5.8
LRRC40	FLJ20331	ENSG00000066557	Leucine rich repeat containing 40	1	70144805-70205620	Predicted intracellular proteins	Evidence at protein level	HPA026564	Approved		Approved	Nucleoli	Colorectal cancer:4.54e-4 (favourable)	Expressed in all	Expressed in all			testis: 21.7	Expressed in all		
LRRC41	MUF1	ENSG00000132128	Leucine rich repeat containing 41	1	46261196-46303608	Predicted intracellular proteins	Evidence at protein level	HPA051941	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:1.66e-9 (unfavourable), Cervical cancer:5.50e-4 (unfavourable), Renal cancer:6.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.8	Expressed in all		
LRRC42	MGC8974	ENSG00000116212	Leucine rich repeat containing 42	1	53946077-53968168	Predicted intracellular proteins	Evidence at protein level	HPA047458, HPA050537, HPA064581	Uncertain		Enhanced	Nucleoplasm	Liver cancer:3.88e-5 (unfavourable), Lung cancer:6.02e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 39.1	Expressed in all		
LRRC43	MGC35140	ENSG00000158113	Leucine rich repeat containing 43	12	122167738-122203471	Predicted intracellular proteins	Evidence at transcript level	HPA039425, HPA047606	Uncertain		Approved	Golgi apparatus<br>Vesicles		Mixed	Group enriched	5	fallopian tube: 30.3;testis: 8.5	parathyroid gland: 3.6	Cell line enhanced		HUVEC TERT2: 2.2;SCLC-21H: 2.5
LRRC45	MGC20806	ENSG00000169683	Leucine rich repeat containing 45	17	82023302-82031151	Predicted intracellular proteins	Evidence at protein level	HPA023372, HPA023382, HPA024768	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:1.54e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 8.3	Mixed		
LRRC46	MGC16309	ENSG00000141294	Leucine rich repeat containing 46	17	47831627-47837713	Predicted intracellular proteins	Evidence at protein level	HPA021882, HPA074893	Enhanced		Approved	Cytosol	Endometrial cancer:2.11e-4 (favourable)	Tissue enhanced	Group enriched	13	fallopian tube: 120.7;testis: 55.6	lung: 6.5	Mixed		
LRRC47	KIAA1185, RP1-286D6.3	ENSG00000130764	Leucine rich repeat containing 47	1	3778558-3796504	Predicted intracellular proteins	Evidence at protein level	HPA008512, HPA012018	Enhanced		Supported	Nucleoli fibrillar center	Renal cancer:2.75e-4 (favourable), Liver cancer:3.25e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 19.7	Expressed in all		
LRRC49	FLJ20156	ENSG00000137821	Leucine rich repeat containing 49	15	70853239-71053657	Predicted intracellular proteins	Evidence at protein level	HPA015596	Uncertain					Mixed	Mixed			heart muscle: 36.4	Cell line enhanced		HHSteC: 28.0
LRRC56	DKFZp761L1518, FLJ00101	ENSG00000161328	Leucine rich repeat containing 56	11	537527-554916	Predicted intracellular proteins	Evidence at transcript level	HPA038728	Uncertain				Lung cancer:6.19e-4 (favourable), Pancreatic cancer:6.32e-4 (favourable), Endometrial cancer:7.39e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 3.9	epididymis,fallopian tube: 1.5	Cell line enhanced		AN3-CA: 1.7;Karpas-707: 1.8;T-47d: 1.8
LRRC57	FLJ36812	ENSG00000180979	Leucine rich repeat containing 57	15	42537820-42548802	Predicted intracellular proteins	Evidence at protein level	HPA040894	Approved		Approved	Mitochondria<br>Cytosol	Renal cancer:2.15e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 14.9	Expressed in all		
LRRC58		ENSG00000163428	Leucine rich repeat containing 58	3	120324509-120349339	Predicted intracellular proteins	Evidence at protein level	HPA057574	Uncertain		Approved	Nucleus<br>Cytosol	Liver cancer:4.98e-4 (unfavourable), Thyroid cancer:6.18e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 30.1	Expressed in all		
LRRC6	CILD19, LRTP, TSLRP	ENSG00000129295	Leucine rich repeat containing 6	8	132571953-132675617	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028058	Approved				Thyroid cancer:5.98e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 31.3;testis: 46.9	kidney: 12.6	Cell line enhanced		RPTEC TERT1: 12.0
LRRC61	FLJ31392, HSPC295, MGC3036	ENSG00000127399	Leucine rich repeat containing 61	7	150322639-150338150	Predicted intracellular proteins	Evidence at transcript level	HPA019355	Approved		Approved	Nucleoplasm	Glioma:2.15e-5 (unfavourable), Stomach cancer:2.85e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 22.6	Cell line enhanced		HDLM-2: 71.3;NTERA-2: 64.8
LRRC63	RP11-139H14.4	ENSG00000173988	Leucine rich repeat containing 63	13	46211943-46277366	Predicted intracellular proteins	Evidence at transcript level	HPA039318, HPA039763	Uncertain		Approved	Golgi apparatus		Not detected	Group enriched	6	cerebral cortex: 1.1;epididymis: 1.7;testis: 2.4	fallopian tube: 0.3	Cell line enhanced		HDLM-2: 1.1
LRRC69		ENSG00000214954	Leucine rich repeat containing 69	8	91101832-91219236	Predicted intracellular proteins	Evidence at transcript level	HPA046337	Uncertain		Approved	Plasma membrane		Mixed	Tissue enhanced		testis: 5.2	skin: 2.0	Cell line enhanced		HEK93: 5.7;U-266/70: 12.2;U-266/84: 6.6
LRRC7	densin-180, KIAA1365	ENSG00000033122	Leucine rich repeat containing 7	1	69568398-70151945	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 14.4	testis,thyroid gland: 4.2	Cell line enhanced		HaCaT: 13.5;HEL: 41.5;SCLC-21H: 6.0
LRRC71	C1orf92, FLJ32884	ENSG00000160838	Leucine rich repeat containing 71	1	156920650-156933094	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Group enriched	9	fallopian tube: 20.1;testis: 22.2	lung: 2.3	Cell line enhanced		HBEC3-KT: 2.6;PC-3: 1.5;TIME: 1.2
LRRC72		ENSG00000205858	Leucine rich repeat containing 72	7	16526880-16581568	Predicted intracellular proteins	Evidence at transcript level	HPA020554	Uncertain					Not detected	Tissue enriched	44	testis: 4.3	all non-specific tissues: 0.0	Not detected		
LRRC73	C6orf154, dJ337H4.2	ENSG00000204052	Leucine rich repeat containing 73	6	43506969-43510686	Predicted intracellular proteins	Evidence at protein level	HPA046698	Enhanced		Approved	Cytosol		Mixed	Tissue enhanced		fallopian tube: 8.3;testis: 24.7	cerebral cortex: 6.5	Cell line enhanced		AN3-CA: 2.9;MCF7: 2.4;T-47d: 3.0
LRRC74A	C14orf166B, LRRC74	ENSG00000100565	Leucine rich repeat containing 74A	14	76826372-76870302	Predicted intracellular proteins	Evidence at transcript level	HPA035094	Uncertain					Not detected	Tissue enriched	19	testis: 7.1	salivary gland,spleen,stomach: 0.3	Not detected		
LRRC74B		ENSG00000187905	Leucine rich repeat containing 74B	22	21045960-21064168	Predicted intracellular proteins	Evidence at transcript level	HPA049947	Uncertain					Not detected	Tissue enhanced		fallopian tube: 6.0;testis: 1.9	lung: 0.8	Not detected		
LRRC75A	C17orf76, FAM211A, FLJ35696	ENSG00000181350	Leucine rich repeat containing 75A	17	16441577-16492153	Predicted intracellular proteins	Evidence at protein level	HPA028528	Uncertain				Pancreatic cancer:7.46e-5 (favourable)	Mixed	Tissue enhanced		duodenum: 11.0	small intestine: 11.0	Cell line enhanced		HEL: 6.2
LRRC75B	C22orf36, FAM211B, MGC131773	ENSG00000178026	Leucine rich repeat containing 75B	22	24585620-24593208	Predicted intracellular proteins	Evidence at transcript level	HPA002540	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Tissue enhanced		testis: 2.2	cerebral cortex: 1.3	Cell line enhanced		SH-SY5Y: 4.4
LRRC9	FLJ46156	ENSG00000131951	Leucine rich repeat containing 9	14	59919713-60063559	Predicted intracellular proteins	Evidence at transcript level	HPA040965, HPA041381	Uncertain					Not detected	Tissue enhanced		parathyroid gland: 3.5;testis: 10.8	fallopian tube: 1.9	Cell line enhanced		NTERA-2: 1.0
LRRCC1	CLERC, KIAA1764, VFL1	ENSG00000133739	Leucine rich repeat and coiled-coil centrosomal protein 1	8	85107147-85146076	Predicted intracellular proteins	Evidence at protein level	HPA012893	Uncertain					Expressed in all	Tissue enhanced		testis: 57.8	thyroid gland: 14.2	Cell line enhanced		HDLM-2: 38.0
LRRD1	IMAGE:4798971	ENSG00000240720	Leucine rich repeats and death domain containing 1	7	92112159-92179531	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	53	testis: 30.0	epididymis,skin: 0.5	Not detected		
LRRFIP1	FLAP-1, FLIIAP1, GCF-2, HUFI-1, TRIP	ENSG00000124831	LRR binding FLII interacting protein 1	2	237627576-237813682	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006979	Approved		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 125.3	Expressed in all		
LRRFIP2	HUFI-2	ENSG00000093167	LRR binding FLII interacting protein 2	3	37052656-37183689	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035956, HPA042023	Uncertain		Approved	Plasma membrane<br>Actin filaments	Cervical cancer:6.31e-4 (favourable)	Expressed in all	Expressed in all			testis: 130.8	Expressed in all		
LRRIQ1	FLJ12303, KIAA1801	ENSG00000133640	Leucine rich repeats and IQ motif containing 1	12	85036314-85263224	Predicted intracellular proteins	Evidence at protein level	HPA046162	Uncertain					Mixed	Group enriched	7	fallopian tube: 13.7;testis: 25.7	parathyroid gland: 2.9	Cell line enhanced		RPTEC TERT1: 2.2;SH-SY5Y: 2.1
LRRIQ3	LRRC44, MGC22773	ENSG00000162620	Leucine rich repeats and IQ motif containing 3	1	74026015-74198187	Predicted intracellular proteins	Evidence at protein level	HPA030799	Approved		Supported	Plasma membrane		Not detected	Tissue enriched	11	testis: 37.1	fallopian tube: 3.5	Mixed		
LRRIQ4	LRRC64	ENSG00000188306	Leucine rich repeats and IQ motif containing 4	3	169821922-169837775	Predicted intracellular proteins	Evidence at protein level	HPA036706	Uncertain					Mixed	Tissue enriched	9	testis: 4.3	small intestine: 0.5	Cell line enhanced		RT4: 1.3;T-47d: 1.3
LRRK1	FLJ23119, KIAA1790, RIPK6, Roco1	ENSG00000154237	Leucine rich repeat kinase 1	15	100919215-101078254	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010537	Uncertain		Supported	Mitochondria<br>Cytosol	Renal cancer:5.71e-5 (unfavourable)	Mixed	Mixed			lymph node: 12.6	Cell line enhanced		Daudi: 27.9
LRRK2	DKFZp434H2111, FLJ45829, PARK8, RIPK7, ROCO2	ENSG00000188906	Leucine rich repeat kinase 2	12	40196744-40369285	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA014293, CAB037160	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:3.02e-6 (favourable)	Group enriched	Expressed in all			lung: 95.4	Cell line enhanced		A549: 7.4;ASC TERT1: 5.6;RPTEC TERT1: 6.7
LRSAM1	CMT2P, FLJ31641	ENSG00000148356	Leucine rich repeat and sterile alpha motif containing 1	9	127451486-127503501	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021403, HPA021844, CAB037304	Supported		Approved	Cytosol	Pancreatic cancer:6.78e-6 (favourable), Renal cancer:5.72e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 20.8	Expressed in all		
LRWD1	CENP-33, DKFZp434K1815, ORCA	ENSG00000161036	Leucine rich repeats and WD repeat domain containing 1	7	102464929-102473168	Predicted intracellular proteins	Evidence at protein level	HPA021320	Enhanced		Supported	Nucleus<br>Nucleoli<br>Vesicles	Pancreatic cancer:8.71e-5 (favourable), Renal cancer:1.25e-4 (unfavourable)	Expressed in all	Tissue enriched	11	testis: 209.0	fallopian tube: 18.8	Expressed in all		
LSG1	FLJ11301	ENSG00000041802	Large 60S subunit nuclear export GTPase 1	3	194640788-194672477	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037704, HPA037705	Approved		Supported	Nucleus<br>Nuclear bodies<br>Cytosol	Liver cancer:3.21e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 24.8	Expressed in all		
LSM1	CASM, YJL124C	ENSG00000175324	LSM1 homolog, mRNA degradation associated	8	38163321-38176730	Predicted intracellular proteins	Evidence at protein level	HPA024601			Supported	Vesicles<br>Cytosol		Expressed in all	Expressed in all			placenta: 35.7	Expressed in all		
LSM10	MGC15749	ENSG00000181817	LSM10, U7 small nuclear RNA associated	1	36391238-36397892	Predicted intracellular proteins	Evidence at protein level	HPA048469			Supported	Nucleus<br>Nuclear bodies	Renal cancer:6.40e-6 (unfavourable), Liver cancer:1.83e-4 (unfavourable), Pancreatic cancer:4.89e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 60.3	Expressed in all		
LSM11	FLJ38273	ENSG00000155858	LSM11, U7 small nuclear RNA associated	5	157743695-157760709	Predicted intracellular proteins	Evidence at protein level	HPA039587	Uncertain		Supported	Nucleus<br>Nuclear bodies		Expressed in all	Mixed			cerebral cortex: 8.5	Mixed		
LSM12	FLJ30656	ENSG00000161654	LSM12 homolog	17	44034635-44067619	Predicted intracellular proteins	Evidence at protein level	HPA051934	Approved		Approved	Cytosol	Renal cancer:1.18e-7 (unfavourable), Pancreatic cancer:7.49e-5 (unfavourable), Liver cancer:1.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.1	Expressed in all		
LSM14A	C19orf13, DKFZP434D1335, FAM61A, RAP55, RAP55A	ENSG00000257103	LSM14A, mRNA processing body assembly factor	19	34172504-34229515	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA017961	Approved		Supported	Cytosol<br>Cytoplasmic bodies		Expressed in all	Mixed			thyroid gland: 37.5	Cell line enhanced		THP-1: 32.4
LSM14B	bA11M20.3, C20orf40, FAM61B, FLJ25473, FT005, LSM13, RAP55B	ENSG00000149657	LSM family member 14B	20	62122461-62135378	Predicted intracellular proteins	Evidence at protein level	HPA041274, HPA061189	Approved		Supported	Nucleoli fibrillar center<br>Vesicles	Liver cancer:3.61e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 78.8	Expressed in all		
LSM2	C6orf28, G7b, YBL026W	ENSG00000204392	LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated	6	31797396-31806984	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA066718	Supported		Supported	Nucleus	Renal cancer:5.59e-9 (unfavourable)	Expressed in all	Mixed			fallopian tube: 7.1	Expressed in all		
LSM3	SMX4, USS2, YLR438C	ENSG00000170860	LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated	3	14178358-14201119	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044966	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			kidney: 21.1	Expressed in all		
LSM4	YER112W	ENSG00000130520	LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated	19	18306230-18323274	Predicted intracellular proteins	Evidence at protein level	HPA040932	Uncertain		Approved	Vesicles	Ovarian cancer:1.34e-4 (favourable), Renal cancer:2.22e-4 (favourable)	Expressed in all	Expressed in all			testis: 102.4	Expressed in all		
LSM5	YER146W	ENSG00000106355	LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated	7	32485332-32495283	Predicted intracellular proteins	Evidence at protein level	HPA019054	Uncertain				Liver cancer:7.53e-5 (unfavourable), Renal cancer:1.84e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 77.7	Expressed in all		
LSM6	YDR378C	ENSG00000164167	LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated	4	146175685-146200000	Predicted intracellular proteins	Evidence at protein level	HPA045079	Approved		Approved	Actin filaments	Melanoma:3.88e-4 (unfavourable), Renal cancer:6.65e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 11.1	Expressed in all		
LSM7	YNL147W	ENSG00000130332	LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated	19	2321517-2328620	Predicted intracellular proteins	Evidence at protein level	HPA041850	Uncertain		Approved	Nucleoli fibrillar center	Endometrial cancer:4.19e-5 (favourable), Cervical cancer:3.28e-4 (favourable), Urothelial cancer:6.96e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 70.9	Expressed in all		
LSM8	YJR022W	ENSG00000128534	LSM8 homolog, U6 small nuclear RNA associated	7	118184032-118192824	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020116	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:7.46e-6 (unfavourable), Endometrial cancer:9.85e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 52.4	Expressed in all		
LSP1	WP34	ENSG00000130592	Lymphocyte-specific protein 1	11	1852970-1892267	Predicted intracellular proteins	Evidence at protein level	CAB017781, HPA019693, HPA071843	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.54e-4 (favourable), Cervical cancer:3.56e-4 (favourable), Glioma:9.00e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 279.2	Cell line enhanced		Daudi: 229.4;HDLM-2: 1037.0;RPMI-8226: 322.1
LSS	OSC	ENSG00000160285	Lanosterol synthase	21	46188141-46228824	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA032060, HPA032062, CAB034116	Supported		Approved	Cytosol	Urothelial cancer:3.07e-4 (unfavourable), Stomach cancer:6.80e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 38.7	Expressed in all		
LTA4H		ENSG00000111144	Leukotriene A4 hydrolase	12	96000828-96043520	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008399, CAB015221, HPA017017	Supported		Supported	Nucleoplasm<br>Cytosol	Lung cancer:8.96e-4 (favourable), Breast cancer:9.79e-4 (favourable)	Expressed in all	Expressed in all			lung: 283.5	Expressed in all		
LTB	p33, TNFC, TNFSF3	ENSG00000227507	Lymphotoxin beta	6	31580525-31582522	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048884	Approved		Approved	Centrosome	Renal cancer:3.31e-7 (unfavourable), Endometrial cancer:2.36e-6 (favourable), Head and neck cancer:1.74e-4 (favourable)	Expressed in all	Group enriched	7	appendix: 18.6;lymph node: 22.1;spleen: 25.8;tonsil: 10.1	bone marrow: 2.6	Cell line enhanced		Daudi: 20.4;HDLM-2: 15.0;NB-4: 11.8;REH: 16.1;U-698: 14.4
LTV1	C6orf93, dJ468K18.4, FLJ14909	ENSG00000135521	LTV1 ribosome biogenesis factor	6	143843344-143863812	Predicted intracellular proteins	Evidence at protein level	HPA030159, HPA030160, HPA030161	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:6.01e-13 (unfavourable), Liver cancer:4.95e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 38.4	Expressed in all		
LUC7L	hLuc7B1, Luc7, LUC7B1	ENSG00000007392	LUC7 like	16	188969-229463	Predicted intracellular proteins	Evidence at protein level	HPA056424, HPA069321	Supported		Approved	Nucleus<br>Mitochondria	Pancreatic cancer:1.30e-4 (favourable), Renal cancer:2.59e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.4	Expressed in all		
LUC7L2	CGI-59, CGI-74, FLJ10657, H_NH0792N18.3, hLuc7B2, LUC7B2	ENSG00000146963	LUC7 like 2, pre-mRNA splicing factor	7	139340359-139423457	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051631	Approved		Approved	Nucleus	Renal cancer:4.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 100.7	Expressed in all		
LUC7L3	CRA, CREAP-1, CROP, FLJ11063, hLuc7A, LUC7A, OA48-18	ENSG00000108848	LUC7 like 3 pre-mRNA splicing factor	17	50719544-50756213	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018475, HPA018484, HPA020017	Enhanced		Enhanced	Nuclear speckles	Renal cancer:8.41e-7 (unfavourable), Liver cancer:1.05e-5 (unfavourable), Urothelial cancer:5.35e-5 (favourable), Pancreatic cancer:6.07e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 236.1	Expressed in all		
LURAP1	C1orf190, FLJ25163, LRAP35a	ENSG00000171357	Leucine rich adaptor protein 1	1	46203334-46221261	Predicted intracellular proteins	Evidence at protein level	HPA030060, HPA030061	Uncertain		Approved	Vesicles	Renal cancer:8.81e-8 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 18.1;thyroid gland: 17.6	testis: 9.2	Mixed		
LURAP1L	bA3L8.2, C9orf150, FLJ38505, MGC46502	ENSG00000153714	Leucine rich adaptor protein 1 like	9	12775021-12822131	Predicted intracellular proteins	Evidence at protein level	HPA024407	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			placenta: 43.0	Cell line enhanced		HHSteC: 122.7;hTERT-HME1: 91.2;T-47d: 162.8
LUZP1	LUZP	ENSG00000169641	Leucine zipper protein 1	1	23084023-23177808	Predicted intracellular proteins	Evidence at protein level	HPA028506, HPA028542	Enhanced		Uncertain	Vesicles<br>Actin filaments<br>Cytosol	Renal cancer:1.46e-7 (favourable), Cervical cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 47.1	Mixed		
LUZP4	CT-8, CT28, HOM-TES-85	ENSG00000102021	Leucine zipper protein 4	X	115289727-115307556	Predicted intracellular proteins	Evidence at protein level	HPA046436, HPA051999	Enhanced					Tissue enriched	Tissue enriched	157	testis: 15.7	all non-specific tissues: 0.0	Not detected		
LUZP6	MPD6, MTPNUT	ENSG00000267697	Leucine zipper protein 6	7	135927274-135927450	Predicted intracellular proteins	Evidence at transcript level	HPA077907			Approved	Lipid droplets		Not detected	Not detected			skeletal muscle: 0.1	Cell line enhanced		MOLT-4: 8.4;SK-MEL-30: 15.0;U-2 OS: 2.4
LXN		ENSG00000079257	Latexin	3	158645822-158672693	Predicted intracellular proteins	Evidence at protein level	HPA014179, CAB025128	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.86e-5 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 60.9	Cell line enhanced		HUVEC TERT2: 234.3;MCF7: 120.4
LYAR	ZC2HC2, ZLYAR	ENSG00000145220	Ly1 antibody reactive	4	4267701-4290169	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035881	Enhanced		Supported	Nucleus<br>Nucleoli	Renal cancer:4.36e-10 (unfavourable), Liver cancer:3.20e-5 (unfavourable), Ovarian cancer:8.82e-4 (favourable)	Expressed in all	Tissue enriched	7	testis: 185.7	lymph node: 27.6	Expressed in all		
LYL1	bHLHa18	ENSG00000104903	LYL1, basic helix-loop-helix family member	19	13099033-13103161	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075004			Approved	Golgi apparatus	Renal cancer:3.89e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 22.9;spleen: 20.7	appendix: 14.3	Cell line enhanced		HEL: 113.5;HMC-1: 179.8;K-562: 90.4;NB-4: 82.5;REH: 87.2
LYN	JTK8	ENSG00000254087	LYN proto-oncogene, Src family tyrosine kinase	8	55879813-56014168	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001231, CAB004492	Enhanced		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane	Renal cancer:3.43e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 161.1	appendix: 130.6	Cell line enhanced		HEL: 215.0;HMC-1: 205.1
LYPLA2	APT-2	ENSG00000011009	Lysophospholipase II	1	23790970-23795539	Predicted intracellular proteins	Evidence at protein level	HPA063151			Uncertain	Nucleoplasm<br>Cytosol	Liver cancer:5.84e-5 (unfavourable), Renal cancer:4.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 109.2	Expressed in all		
LYPLAL1	Q96AV0	ENSG00000143353	Lysophospholipase like 1	1	219173844-219212865	Predicted intracellular proteins	Evidence at protein level	HPA045806	Approved		Supported	Cytosol	Renal cancer:1.31e-4 (favourable)	Expressed in all	Mixed			kidney: 43.0	Mixed		
LYRM1	A211C6.1	ENSG00000102897	LYR motif containing 1	16	20899868-20925006	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059840			Supported	Nucleoplasm<br>Midbody	Endometrial cancer:7.48e-7 (favourable), Renal cancer:4.80e-4 (unfavourable), Urothelial cancer:9.50e-4 (favourable)	Expressed in all	Expressed in all			testis: 70.4	Expressed in all		
LYRM2	DJ122O8.2	ENSG00000083099	LYR motif containing 2	6	89568144-89638753	Predicted intracellular proteins	Evidence at protein level	HPA063932	Uncertain		Approved	Cytosol	Liver cancer:2.58e-8 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 42.3	Expressed in all		
LYRM4	C6orf149, CGI-203, ISD11	ENSG00000214113	LYR motif containing 4	6	5102593-5260939	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030362	Approved		Supported	Nuclear bodies		Expressed in all	Expressed in all			ovary: 29.5	Expressed in all		
LYRM7	C5orf31, FLJ20796, MZM1L	ENSG00000186687	LYR motif containing 7	5	131170810-131205426	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050053	Approved				Renal cancer:9.84e-6 (favourable)	Expressed in all	Mixed			testis: 29.9	Expressed in all		
LYRM9	C17orf108, HSD24	ENSG00000232859	LYR motif containing 9	17	27878314-27894752	Predicted intracellular proteins	Evidence at protein level	HPA023051	Uncertain				Renal cancer:5.41e-4 (favourable), Pancreatic cancer:9.46e-4 (favourable)	Mixed	Expressed in all			thyroid gland: 71.9	Cell line enhanced		T-47d: 25.0
LYSMD1	MGC35223, RP11-68I18.5, SB145	ENSG00000163155	LysM domain containing 1	1	151159748-151165948	Predicted intracellular proteins	Evidence at protein level	HPA028055, HPA064537	Uncertain		Enhanced	Nucleus		Expressed in all	Mixed			ovary: 13.3	Expressed in all		
LYSMD2	MGC35274	ENSG00000140280	LysM domain containing 2	15	51723011-51751585	Predicted intracellular proteins	Evidence at protein level	HPA040460	Approved		Approved	Nuclear bodies<br>Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 38.2	Mixed		
LYST	CHS, CHS1	ENSG00000143669	Lysosomal trafficking regulator	1	235661041-235883640	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053366, HPA055725			Approved	Nucleoplasm<br>Plasma membrane<br>Microtubule organizing center	Renal cancer:5.27e-5 (unfavourable)	Expressed in all	Mixed			bone marrow: 20.9	Cell line enhanced		HDLM-2: 28.5;THP-1: 66.9;U-937: 29.8
LZIC	MGC15436	ENSG00000162441	Leucine zipper and CTNNBIP1 domain containing	1	9922113-9943407	Predicted intracellular proteins	Evidence at protein level	HPA028184, HPA058614	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:2.47e-5 (unfavourable), Renal cancer:3.56e-5 (favourable)	Expressed in all	Expressed in all			testis: 120.1	Expressed in all		
LZTFL1	BBS17	ENSG00000163818	Leucine zipper transcription factor like 1	3	45823316-45916042	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043466, HPA048447	Enhanced		Supported	Cytosol		Expressed in all	Mixed			testis: 35.9	Mixed		
LZTR1	BTBD29, LZTR-1	ENSG00000099949	Leucine zipper like transcription regulator 1	22	20979462-20999038	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA068772, HPA071248	Approved				Liver cancer:5.15e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 25.9	Expressed in all		
LZTS1	FEZ1	ENSG00000061337	Leucine zipper tumor suppressor 1	8	20246165-20303963	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006294, HPA022046	Approved		Approved	Nucleoli<br>Plasma membrane	Renal cancer:9.28e-6 (unfavourable), Endometrial cancer:3.03e-4 (unfavourable)	Expressed in all	Tissue enriched	10	parathyroid gland: 125.4	testis: 12.4	Cell line enhanced		SK-MEL-30: 59.3;WM-115: 50.1
LZTS2	KIAA1813, LAPSER1	ENSG00000107816	Leucine zipper tumor suppressor 2	10	100996618-101007836	Predicted intracellular proteins	Evidence at protein level	HPA044956	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.39e-4 (unfavourable), Colorectal cancer:8.23e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium,seminal vesicle: 57.9	Expressed in all		
LZTS3	KIAA0552, ProSAPiP1	ENSG00000088899	Leucine zipper tumor suppressor family member 3	20	3162617-3173592	Predicted intracellular proteins	Evidence at protein level	HPA031008, HPA031009	Approved		Approved	Vesicles	Renal cancer:5.92e-8 (favourable), Endometrial cancer:7.26e-4 (unfavourable), Lung cancer:7.98e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 58.6	parathyroid gland: 20.3	Cell line enhanced		SCLC-21H: 21.3
M1AP	C2orf65, D6Mm5e, SPATA37	ENSG00000159374	Meiosis 1 associated protein	2	74557883-74648338	Predicted intracellular proteins	Evidence at protein level	HPA045420, HPA059302	Uncertain		Approved	Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		testis: 14.8	fallopian tube: 4.2	Group enriched	10	NTERA-2: 2.1;RT4: 1.6
MAATS1	AAT1, AAT1alpha, C3orf15, CaM-IP2, SPATA26	ENSG00000183833	MYCBP associated and testis expressed 1	3	119703022-119767102	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		fallopian tube: 22.7;testis: 15.8	thyroid gland: 7.8	Cell line enhanced		AF22: 1.7;RPTEC TERT1: 1.8;SCLC-21H: 4.2;SH-SY5Y: 2.7;T-47d: 1.7;U-87 MG: 1.8
MAB21L1	CAGR1	ENSG00000180660	Mab-21 like 1	13	35474182-35477209	Predicted intracellular proteins	Evidence at protein level	HPA049324, HPA059864			Enhanced	Nucleus<br>Cytosol		Mixed	Tissue enhanced		adrenal gland: 5.5;breast: 5.2	adipose tissue: 2.4	Cell line enhanced		BJ: 29.7;BJ hTERT+ SV40 Large T+: 36.9;HBF TERT88: 41.4;SH-SY5Y: 135.2
MAB21L2		ENSG00000181541	Mab-21 like 2	4	150581922-150584693	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049324, HPA059864			Enhanced	Nucleus<br>Cytosol		Tissue enhanced	Tissue enhanced		colon: 18.3;smooth muscle: 26.2	small intestine: 12.4	Group enriched	20	HHSteC: 4.9;SH-SY5Y: 16.0
MAB21L3	C1orf161, FLJ38716	ENSG00000173212	Mab-21 like 3	1	116111755-116135240	Predicted intracellular proteins	Evidence at protein level	HPA039551, HPA046187	Uncertain		Approved	Nucleoplasm		Mixed	Group enriched	5	esophagus: 7.5;skin: 7.2	colon,kidney,rectum: 1.3	Cell line enhanced		BEWO: 3.7;EFO-21: 8.0;RT4: 10.4
MACC1	7A5, SH3BP4L	ENSG00000183742	MACC1, MET transcriptional regulator	7	20134655-20217404	Predicted intracellular proteins	Evidence at protein level	HPA020081, HPA020103, HPA029476, CAB068194	Supported		Approved	Mitochondria	Renal cancer:5.71e-9 (favourable), Endometrial cancer:1.56e-5 (unfavourable)	Mixed	Mixed			small intestine: 13.0	Cell line enhanced		A-431: 85.3;HaCaT: 59.0
MACROD1	LRP16	ENSG00000133315	MACRO domain containing 1	11	63998558-64166106	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041031, HPA071075	Uncertain		Supported	Nucleoplasm	Renal cancer:4.68e-6 (favourable), Pancreatic cancer:2.90e-4 (unfavourable)	Expressed in all	Tissue enriched	6	skeletal muscle: 106.6	kidney: 17.4	Cell line enhanced		RPMI-8226: 99.7
MACROD2	C20orf133, dJ631M13.5	ENSG00000172264	MACRO domain containing 2	20	13995369-16053197	Predicted intracellular proteins	Evidence at protein level	HPA049076	Enhanced		Supported	Nucleus<br>Nucleoli<br>Centrosome		Mixed	Mixed			lung: 16.2	Cell line enhanced		EFO-21: 14.4;Karpas-707: 13.4;SCLC-21H: 12.6
MAD2L1	HSMAD2, MAD2	ENSG00000164109	MAD2 mitotic arrest deficient-like 1 (yeast)	4	120055608-120067074	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003348	Uncertain		Approved	Nucleoplasm	Renal cancer:3.07e-11 (unfavourable), Liver cancer:5.15e-5 (unfavourable), Lung cancer:2.17e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 4.6	Mixed		
MAD2L1BP	CMT2, dJ261G23.1, KIAA0110	ENSG00000124688	MAD2L1 binding protein	6	43629540-43640952	Predicted intracellular proteins	Evidence at protein level	HPA028729			Supported	Nucleus<br>Nuclear membrane<br>Nucleoli		Expressed in all	Expressed in all			bone marrow: 32.6	Expressed in all		
MAD2L2	MAD2B, POLZ2, REV7	ENSG00000116670	MAD2 mitotic arrest deficient-like 2 (yeast)	1	11674480-11691650	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB008110, HPA024176	Approved		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			testis: 73.6	Expressed in all		
MAEA	EMP, GID9	ENSG00000090316	Macrophage erythroblast attacher	4	1289851-1340147	Predicted intracellular proteins	Evidence at protein level	HPA036886, HPA058185	Approved		Enhanced	Nucleoplasm	Renal cancer:1.90e-4 (favourable), Head and neck cancer:5.34e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 38.1	Expressed in all		
MAEL	CT128, FLJ14904, SPATA35	ENSG00000143194	Maelstrom spermatogenic transposon silencer	1	166975582-167022214	Predicted intracellular proteins	Evidence at protein level	HPA078602	Approved					Tissue enhanced	Tissue enriched	30	testis: 282.8	placenta: 9.3	Cell line enriched	11	NTERA-2: 3.3
MAF	c-MAF	ENSG00000178573	MAF bZIP transcription factor	16	79585843-79600714	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB010296, HPA028289	Approved				Renal cancer:3.74e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 149.6	small intestine: 91.3	Group enriched	9	Karpas-707: 148.6;RPMI-8226: 242.2
MAF1	DKFZp586G1123	ENSG00000179632	MAF1 homolog, negative regulator of RNA polymerase III	8	144104499-144107611	Predicted intracellular proteins	Evidence at protein level	HPA024821, HPA058548	Uncertain		Supported	Nucleus<br>Nucleoli<br>Vesicles	Liver cancer:7.09e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 142.6	Expressed in all		
MAFA	hMafA, RIPE3b1	ENSG00000182759	MAF bZIP transcription factor A	8	143419182-143430406	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Group enriched	11	skeletal muscle: 8.6;testis: 2.5	placenta: 0.5	Cell line enhanced		MCF7: 1.7;SCLC-21H: 3.7;T-47d: 2.8;U-2 OS: 2.1
MAFB	KRML	ENSG00000204103	MAF bZIP transcription factor B	20	40685848-40689240	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005653	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol	Endometrial cancer:5.64e-4 (unfavourable)	Expressed in all	Tissue enriched	7	parathyroid gland: 689.3	spleen: 102.0	Cell line enhanced		HSkMC: 20.7;hTCEpi: 44.3;SCLC-21H: 19.6;SiHa: 16.5;U-138 MG: 16.2;U-2197: 22.6;U-87 MG: 15.7
MAFF	hMafF	ENSG00000185022	MAF bZIP transcription factor F	22	38200767-38216511	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025341, HPA055371	Approved		Approved	Nucleus<br>Mitochondria	Breast cancer:4.32e-4 (favourable)	Expressed in all	Mixed			gallbladder: 66.3	Cell line enhanced		hTEC/SVTERT24-B: 79.2;SK-MEL-30: 75.4
MAFG	MGC13090, MGC20149	ENSG00000197063	MAF bZIP transcription factor G	17	81918270-81927714	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025573	Approved				Liver cancer:1.90e-6 (unfavourable), Endometrial cancer:5.82e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.6	Expressed in all		
MAFK	NFE2U, P18	ENSG00000198517	MAF bZIP transcription factor K	7	1530714-1543043	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026820, HPA060841	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			placenta: 36.8	Expressed in all		
MAGEA1	CT1.1, MAGE1, MGC9326	ENSG00000198681	MAGE family member A1	X	153179285-153183880	Predicted intracellular proteins	Evidence at protein level	CAB002620	Enhanced		Supported	Cytosol		Mixed	Tissue enriched	73	testis: 7.3	all non-specific tissues: 0.0	Group enriched	13	HEL: 66.7;HMC-1: 109.1;RPMI-8226: 44.6;U-2 OS: 123.1;U-266/70: 135.4;U-266/84: 212.3
MAGEA10	CT1.10, MAGE10, MGC10599	ENSG00000124260	MAGE family member A10	X	152133310-152138578	Predicted intracellular proteins	Evidence at protein level	HPA003333, HPA070780	Approved		Supported	Nucleoplasm<br>Cytosol		Mixed	Group enriched	13	placenta: 13.5;testis: 4.8	skin: 0.7	Group enriched	9	PC-3: 7.4;SH-SY5Y: 5.3;U-266/84: 4.0;WM-115: 12.8
MAGEA11	CT1.11, MAGE-11, MAGE11, MAGEA-11, MGC10511	ENSG00000185247	MAGE family member A11	X	149688228-149717266	Predicted intracellular proteins	Evidence at protein level	HPA052687			Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Mixed	Group enriched	15	epididymis: 25.8;testis: 6.9	placenta: 1.0	Cell line enhanced		PC-3: 5.2;U-2 OS: 25.0;U-2197: 3.2
MAGEA12	CT1.12, MAGE12	ENSG00000213401	MAGE family member A12	X	152733779-152737669	Predicted intracellular proteins	Evidence at protein level						Liver cancer:3.22e-4 (unfavourable)	Tissue enhanced	Tissue enriched	16	testis: 4.9	cerebral cortex: 0.3	Cell line enhanced		HMC-1: 50.9;K-562: 80.1;PC-3: 38.7;SH-SY5Y: 51.2;U-2 OS: 91.2;U-266/70: 52.9
MAGEA2	CT1.2, MAGE2, MAGEA2A	ENSG00000268606	MAGE family member A2	X	152749863-152753884	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	54	testis: 6.9	cerebral cortex: 0.1	Cell line enhanced		HMC-1: 40.2;K-562: 58.6;SH-SY5Y: 52.5;SK-BR-3: 36.4;U-266/70: 92.1;U-266/84: 61.1
MAGEA2B	MAGE2, MAGEA2, MAGEA2b, MGC16973	ENSG00000183305	MAGE family member A2B	X	152714586-152718607	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	9	testis: 1.9	placenta: 0.2	Cell line enhanced		BEWO: 36.8;HMC-1: 34.9;K-562: 31.7;SH-SY5Y: 56.8;U-266/70: 21.5;U-266/84: 32.0
MAGEA3	CT1.3, HIP8, HYPD, MAGE3, MGC14613	ENSG00000221867	MAGE family member A3	X	152698752-152702347	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:3.58e-4 (unfavourable)	Mixed	Tissue enriched	28	testis: 12.8	placenta: 0.4	Cell line enhanced		K-562: 157.8;PC-3: 145.8;SH-SY5Y: 163.2;SK-BR-3: 132.6;U-266/70: 187.5;U-266/84: 205.2
MAGEA6	CT1.6, MAGE6	ENSG00000197172	MAGE family member A6	X	152766136-152769747	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.93e-4 (unfavourable)	Mixed	Tissue enriched	22	testis: 10.9	endometrium: 0.4	Cell line enhanced		HMC-1: 137.9;K-562: 121.3;PC-3: 136.2;SK-BR-3: 103.8;U-2 OS: 104.5;U-266/70: 133.8
MAGEA8	CT1.8, MAGE8, MGC2182	ENSG00000156009	MAGE family member A8	X	149881141-149885835	Predicted intracellular proteins	Evidence at protein level	HPA003998	Enhanced					Mixed	Tissue enriched	9	placenta: 19.0	testis: 2.0	Group enriched	27	U-2 OS: 35.5;U-266/70: 48.5
MAGEA9	CT1.9, MAGE9, MGC8421	ENSG00000123584	MAGE family member A9	X	149781930-149787737	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.6	Group enriched	7	U-266/70: 34.5;U-266/84: 23.0
MAGEA9B		ENSG00000267978	MAGE family member A9B	X	149581653-149587453	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	36	testis: 17.3	placenta: 0.4	Group enriched	15	RT4: 104.5;U-266/70: 42.1;U-266/84: 51.2
MAGEB1	CT3.1, DAM10, MAGE-Xp, MAGEL1, MGC9322	ENSG00000214107	MAGE family member B1	X	30243730-30252038	Predicted intracellular proteins	Evidence at protein level	HPA001193, HPA002820	Enhanced					Tissue enriched	Tissue enriched	45	testis: 29.2	epididymis: 0.6	Group enriched	58	K-562: 22.4;U-266/70: 41.0;U-266/84: 28.1
MAGEB10	FLJ32965	ENSG00000177689	MAGE family member B10	X	27807990-27823014	Predicted intracellular proteins	Evidence at protein level	HPA000611	Uncertain					Not detected	Tissue enriched	10	testis: 4.6	skin: 0.4	Not detected		
MAGEB16		ENSG00000189023	MAGE family member B16	X	35798342-35803735	Predicted intracellular proteins	Evidence at protein level	HPA055743	Uncertain					Tissue enhanced	Tissue enriched	63	testis: 6.2	all non-specific tissues: 0.0	Group enriched	207	K-562: 12.2;U-266/70: 45.6
MAGEB17		ENSG00000182798	MAGE family member B17	X	16167481-16171464	Predicted intracellular proteins	Evidence at transcript level	HPA003756	Uncertain					Mixed	Tissue enriched	6	testis: 2.9	epididymis: 0.4	Cell line enhanced		U-138 MG: 2.7;U-2 OS: 6.2;U-266/70: 11.3
MAGEB18	MGC33889	ENSG00000176774	MAGE family member B18	X	26138343-26140735	Predicted intracellular proteins	Evidence at protein level	HPA046141	Enhanced					Not detected	Tissue enriched	14	testis: 1.3	all non-specific tissues: 0.0	Cell line enriched	29	Karpas-707: 3.1
MAGEB2	CT3.2, DAM6, MAGE-XP-2, MGC26438	ENSG00000099399	MAGE family member B2	X	30215560-30220089	Predicted intracellular proteins	Evidence at protein level	HPA065224, HPA074544, HPA075519	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol		Tissue enriched	Tissue enriched	74	testis: 54.2	placenta: 0.7	Group enriched	9	HL-60: 72.9;K-562: 59.4;Karpas-707: 55.2;U-2 OS: 93.7;U-266/70: 113.8;U-266/84: 116.9
MAGEB3	CT3.5	ENSG00000198798	MAGE family member B3	X	30230436-30237492	Predicted intracellular proteins	Evidence at protein level	HPA072203	Approved					Not detected	Group enriched	156	epididymis: 21.5;testis: 9.5	all non-specific tissues: 0.0	Cell line enriched	10	U-266/70: 1.6
MAGEB4	CT3.6, MGC33144	ENSG00000120289	MAGE family member B4	X	30242052-30244193	Predicted intracellular proteins	Evidence at protein level	HPA030456	Enhanced					Not detected	Group enriched	117	epididymis: 34.1;testis: 17.0	breast: 0.2	Not detected		
MAGEB5	CT3.3, MAGE-B5	ENSG00000188408	MAGE family member B5	X	26216169-26218270	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA052627	Uncertain					Not detected	Not detected			testis: 0.8	Not detected		
MAGEB6	CT3.4, FLJ40242, MAGE-B6, MAGEB6A	ENSG00000176746	MAGE family member B6	X	26192440-26195646	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA041853	Approved					Tissue enhanced	Tissue enriched	58	testis: 5.7	all non-specific tissues: 0.0	Cell line enriched	13	K-562: 4.1
MAGEB6P1	MAGEB6B	ENSG00000232030	MAGE family member B6 pseudogene 1	X	26160601-26161824	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.8	Not detected		
MAGEC1	CT7, CT7.1, MAGE-C1, MGC39366	ENSG00000155495	MAGE family member C1	X	141903894-141909388	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004622, CAB015452	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enriched	134	testis: 13.3	all non-specific tissues: 0.0	Group enriched	8	K-562: 48.3;Karpas-707: 36.9;U-2 OS: 35.6;U-2197: 60.6;U-266/70: 35.4;U-266/84: 30.8
MAGEC2	CT10, HCA587, MAGE-C2, MAGEE1	ENSG00000046774	MAGE family member C2	X	142202345-142205290	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA062230	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol		Tissue enhanced	Tissue enriched	369	testis: 36.8	all non-specific tissues: 0.0	Group enriched	7	K-562: 78.0;U-266/84: 69.6
MAGEC3	CT7.2, HCA2, MAGE-C3	ENSG00000165509	MAGE family member C3	X	141838316-141897832	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA052067	Approved					Tissue enriched	Tissue enhanced		testis: 1.0	cerebral cortex: 0.6	Cell line enhanced		U-266/84: 1.5
MAGED1	DLXIN-1, NRAGE	ENSG00000179222	MAGE family member D1	X	51803007-51902357	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA043645			Approved	Cytosol	Thyroid cancer:3.25e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 193.9	Mixed		
MAGED2	11B6, BCG1, HCA10, JCL-1, MAGE-D2, MAGED, MGC8386	ENSG00000102316	MAGE family member D2	X	54807599-54816012	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031572, HPA031573	Supported		Enhanced	Nucleus<br>Nucleoli<br>Cytosol	Pancreatic cancer:2.82e-4 (favourable), Ovarian cancer:2.88e-4 (favourable), Stomach cancer:9.43e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 325.8	Expressed in all		
MAGEE1	DAMAGE, KIAA1587	ENSG00000198934	MAGE family member E1	X	76427724-76431353	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003047	Approved		Approved	Cytokinetic bridge<br>Cytosol	Renal cancer:6.86e-6 (favourable), Pancreatic cancer:3.95e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 29.8	parathyroid gland: 14.3	Mixed		
MAGEE2	HCA3	ENSG00000186675	MAGE family member E2	X	75782988-75785236	Predicted intracellular proteins	Evidence at transcript level	HPA030625	Uncertain					Tissue enriched	Group enriched	6	adrenal gland: 1.0;cerebral cortex: 3.3	endometrium,ovary,prostate,rectum,smooth muscle: 0.3	Not detected		
MAGEF1		ENSG00000177383	MAGE family member F1	3	184710367-184712002	Predicted intracellular proteins	Evidence at protein level	HPA046899, HPA054190	Uncertain		Approved	Actin filaments	Renal cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 60.1	Expressed in all		
MAGEL2	NDNL1, nM15	ENSG00000254585	MAGE family member L2	15	23643544-23647841	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 3.3	cervix, uterine: 2.9	Group enriched	6	AF22: 3.2;NTERA-2: 1.9;U-2 OS: 1.0
MAGI1	AIP3, BAIAP1, BAP1, MAGI-1, TNRC19, WWP3	ENSG00000151276	Membrane associated guanylate kinase, WW and PDZ domain containing 1	3	65353525-66038834	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031851, HPA031852, HPA031853	Enhanced		Enhanced	Nucleoplasm<br>Cell Junctions	Renal cancer:4.55e-8 (favourable)	Expressed in all	Mixed			thyroid gland: 18.9	Cell line enhanced		HEL: 32.4
MAGI2	ACVRIP1, AIP1, ARIP1, KIAA0705, MAGI-2	ENSG00000187391	Membrane associated guanylate kinase, WW and PDZ domain containing 2	7	78017057-79453574	Predicted intracellular proteins	Evidence at protein level	HPA013650	Approved				Renal cancer:1.08e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 46.2;parathyroid gland: 38.6	prostate: 14.0	Group enriched	5	AF22: 19.3;Karpas-707: 58.7
MAGI3	MAGI-3	ENSG00000081026	Membrane associated guanylate kinase, WW and PDZ domain containing 3	1	113390749-113685923	Predicted intracellular proteins	Evidence at protein level	HPA007923, HPA008444	Approved		Supported	Cell Junctions	Renal cancer:2.60e-8 (favourable), Ovarian cancer:4.29e-4 (favourable)	Expressed in all	Mixed			lung: 20.9	Mixed		
MAGIX	FLJ21687, JM10, PDZX	ENSG00000269313	MAGI family member, X-linked	X	49162564-49168483	Predicted intracellular proteins	Evidence at transcript level	HPA035302	Uncertain				Renal cancer:6.91e-9 (favourable), Urothelial cancer:2.10e-4 (favourable)	Mixed	Mixed			parathyroid gland: 5.7	Cell line enhanced		RT4: 10.2
MAGOH	MAGOH1, MAGOHA	ENSG00000162385	Mago homolog, exon junction complex core component	1	53226892-53238610	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB015425, HPA043036, HPA047754	Approved		Supported	Nucleus	Renal cancer:1.45e-5 (unfavourable), Breast cancer:1.85e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 82.2	Expressed in all		
MAGOHB	FLJ10292, MGN2	ENSG00000111196	Mago homolog B, exon junction complex core component	12	10604190-10613623	Predicted intracellular proteins	Evidence at protein level	HPA043036, HPA047754	Uncertain				Renal cancer:5.04e-8 (unfavourable), Ovarian cancer:5.56e-6 (favourable), Stomach cancer:6.50e-4 (favourable)	Expressed in all	Mixed			epididymis: 14.3	Expressed in all		
MAIP1	C2orf47, DKFZp666A212, FLJ22555	ENSG00000162972	Matrix AAA peptidase interacting protein 1	2	199955317-200008540	Predicted intracellular proteins	Evidence at protein level	HPA064013, HPA072231	Approved		Approved	Mitochondria	Melanoma:1.87e-4 (unfavourable), Endometrial cancer:2.14e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 31.9	Expressed in all		
MAJIN	C11orf85	ENSG00000168070	Membrane anchored junction protein	11	64937517-64972085	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	9	testis: 41.6	gallbladder: 4.5	Group enriched	9	CAPAN-2: 6.4;SiHa: 3.3
MAK	dJ417M14.2, RP62	ENSG00000111837	Male germ cell associated kinase	6	10762723-10838555	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	9	fallopian tube: 9.7;parathyroid gland: 10.2;testis: 20.4	lung: 1.4	Cell line enhanced		HDLM-2: 1.4
MAK16	MAK16L, RBM13	ENSG00000198042	MAK16 homolog	8	33484750-33501260	Predicted intracellular proteins	Evidence at protein level	HPA044417, HPA050574	Uncertain		Supported	Nucleoli<br>Vesicles	Liver cancer:1.00e-4 (unfavourable), Renal cancer:3.66e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 12.6	Expressed in all		
MALT1	MLT, PCASP1	ENSG00000172175	MALT1 paracaspase	18	58671386-58754477	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004494, HPA048432	Enhanced		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 34.0	Expressed in all		
MAML1	KIAA0200, Mam-1	ENSG00000161021	Mastermind like transcriptional coactivator 1	5	179732850-179796511	Predicted intracellular proteins	Evidence at protein level	HPA037687, HPA057531	Approved		Enhanced	Nucleoplasm	Renal cancer:1.84e-5 (unfavourable), Melanoma:9.70e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 15.3	small intestine: 8.5	Cell line enhanced		SK-MEL-30: 15.6
MAML2	KIAA1819, MAM3	ENSG00000184384	Mastermind like transcriptional coactivator 2	11	95976598-96343180	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035223	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.90e-4 (favourable), Pancreatic cancer:3.89e-4 (unfavourable)	Expressed in all	Mixed			placenta: 17.5	Cell line enhanced		HDLM-2: 48.9
MAML3	CAGH3, GDN, KIAA1816, MAM2, TNRC3	ENSG00000196782	Mastermind like transcriptional coactivator 3	4	139716753-140154184	Predicted intracellular proteins	Evidence at protein level	HPA037717	Approved		Supported	Nuclear speckles	Renal cancer:7.60e-5 (favourable)	Expressed in all	Mixed			endometrium: 10.8	Cell line enhanced		SCLC-21H: 18.5;SH-SY5Y: 25.4;WM-115: 20.0
MAMLD1	CG1, CXorf6, F18	ENSG00000013619	Mastermind like domain containing 1	X	150361422-150514178	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003923	Uncertain		Supported	Nucleoplasm		Expressed in all	Tissue enhanced		testis: 18.7	ovary: 16.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 22.8;U-2197: 34.4
MAMSTR	FLJ36070, MASTR	ENSG00000176909	MEF2 activating motif and SAP domain containing transcriptional regulator	19	48712742-48719721	Predicted intracellular proteins	Evidence at transcript level	HPA049765			Approved	Nuclear speckles		Expressed in all	Tissue enhanced		adrenal gland: 21.4;skeletal muscle: 31.4	fallopian tube: 10.4	Cell line enhanced		RH-30: 16.1
MAN2C1	MANA, MANA1	ENSG00000140400	Mannosidase alpha class 2C member 1	15	75355207-75368630	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040627, HPA067407	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 46.7	Expressed in all		
MAP10	KIAA1383, MTR120	ENSG00000212916	Microtubule associated protein 10	1	232804892-232808407	Predicted intracellular proteins	Evidence at protein level	HPA052496, HPA073262	Approved		Approved	Nuclear bodies<br>Cleavage furrow		Mixed	Mixed			testis: 5.8	Cell line enhanced		THP-1: 6.8
MAP1A	MAP1L	ENSG00000166963	Microtubule associated protein 1A	15	43510958-43531620	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039063, HPA039064, HPA066488	Enhanced		Approved	Cytosol	Thyroid cancer:1.09e-5 (unfavourable), Urothelial cancer:1.66e-5 (unfavourable), Renal cancer:6.59e-5 (unfavourable)	Tissue enhanced	Tissue enriched	9	cerebral cortex: 165.6	smooth muscle: 18.9	Cell line enhanced		fHDF/TERT166: 72.9;U-87 MG: 119.0
MAP1B	MAP5, PPP1R102	ENSG00000131711	Microtubule associated protein 1B	5	72107234-72209570	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009792, HPA022275	Enhanced		Enhanced	Cytosol	Urothelial cancer:8.22e-5 (unfavourable)	Tissue enriched	Tissue enriched	5	cerebral cortex: 187.6	smooth muscle: 36.8	Cell line enhanced		TIME: 228.1
MAP1LC3A	ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3	ENSG00000101460	Microtubule associated protein 1 light chain 3 alpha	20	34546854-34560345	Predicted intracellular proteins	Evidence at protein level	HPA007649, CAB037174, HPA052474, HPA052484	Enhanced				Pancreatic cancer:5.31e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 119.1	Cell line enhanced		HSkMC: 49.9;SCLC-21H: 52.4;SK-BR-3: 46.8
MAP1LC3B	ATG8F	ENSG00000140941	Microtubule associated protein 1 light chain 3 beta	16	87383995-87404779	Predicted intracellular proteins	Evidence at protein level	CAB037216, HPA052474, HPA052484, HPA053767	Uncertain				Renal cancer:2.77e-7 (favourable), Stomach cancer:8.97e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 122.4	Expressed in all		
MAP1LC3B2	ATG8G	ENSG00000258102	Microtubule associated protein 1 light chain 3 beta 2	12	116548105-116576448	Predicted intracellular proteins	Evidence at transcript level	HPA052474, HPA052484, HPA053767	Uncertain					Mixed	Mixed			adrenal gland: 2.7	Cell line enhanced		SK-MEL-30: 5.6
MAP1LC3C	ATG8J	ENSG00000197769	Microtubule associated protein 1 light chain 3 gamma	1	241995490-241999073	Predicted intracellular proteins	Evidence at protein level	HPA072670			Supported	Cytoplasmic bodies	Endometrial cancer:1.34e-7 (unfavourable)	Mixed	Tissue enhanced		breast: 12.7;placenta: 16.1	lung: 8.1	Cell line enhanced		AF22: 6.0;ASC TERT1: 3.9;BEWO: 3.7;EFO-21: 3.2
MAP1S	BPY2IP1, C19orf5, FLJ10669, MAP8, VCY2IP1	ENSG00000130479	Microtubule associated protein 1S	19	17719242-17734516	Predicted intracellular proteins	Evidence at protein level	HPA050934, HPA054637	Approved		Enhanced	Cytosol	Pancreatic cancer:2.65e-4 (favourable), Liver cancer:5.29e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 29.5	Expressed in all		
MAP2	MAP2A, MAP2B, MAP2C	ENSG00000078018	Microtubule associated protein 2	2	209424058-209734118	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001984, HPA008273, HPA012828	Enhanced	Supported	Supported	Nucleoli<br>Cytosol	Endometrial cancer:1.98e-6 (unfavourable)	Tissue enhanced	Tissue enriched	11	cerebral cortex: 296.5	thyroid gland: 27.9	Cell line enhanced		AF22: 293.3;NTERA-2: 106.5;SCLC-21H: 174.9;SH-SY5Y: 88.2
MAP2K1	MAPKK1, MEK1, PRKMK1	ENSG00000169032	Mitogen-activated protein kinase kinase 1	15	66386817-66492312	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003834, HPA026430	Approved		Enhanced	Plasma membrane<br>Cytosol	Glioma:2.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 144.4	Expressed in all		
MAP2K2	MEK2, PRKMK2	ENSG00000126934	Mitogen-activated protein kinase kinase 2	19	4090321-4124129	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003835, HPA051993	Supported		Supported	Cytosol	Stomach cancer:5.43e-5 (favourable), Cervical cancer:3.72e-4 (favourable), Head and neck cancer:7.98e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 135.0	Expressed in all		
MAP2K3	MAPKK3, MEK3, MKK3, PRKMK3	ENSG00000034152	Mitogen-activated protein kinase kinase 3	17	21284672-21315240	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB018548	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 129.9	Expressed in all		
MAP2K4	JNKK1, MEK4, MKK4, PRKMK4, SERK1	ENSG00000065559	Mitogen-activated protein kinase kinase 4	17	12020824-12143830	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007751, HPA060074	Enhanced		Approved	Nucleoplasm<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 64.0	Expressed in all		
MAP2K5	HsT17454, MAPKK5, MEK5, PRKMK5	ENSG00000137764	Mitogen-activated protein kinase kinase 5	15	67542709-67807123	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB022094, HPA027347, HPA027755	Supported		Approved	Nucleoli<br>Microtubules	Renal cancer:8.03e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.7	Expressed in all		
MAP2K6	MAPKK6, MEK6, MKK6, PRKMK6, SAPKK3	ENSG00000108984	Mitogen-activated protein kinase kinase 6	17	69414698-69543331	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB007744, HPA031134	Enhanced		Supported	Nucleus<br>Cytosol	Breast cancer:2.27e-6 (favourable), Pancreatic cancer:7.52e-4 (favourable)	Mixed	Mixed			cervix, uterine: 39.1	Cell line enhanced		A549: 36.5
MAP2K7	Jnkk2, MKK7, PRKMK7	ENSG00000076984	Mitogen-activated protein kinase kinase 7	19	7903843-7914478	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001633, CAB004262, HPA064711	Supported		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Head and neck cancer:8.54e-5 (favourable), Urothelial cancer:1.56e-4 (favourable)	Expressed in all	Expressed in all			spleen: 19.1	Expressed in all		
MAP3K10	MEKK10, MLK2, MST	ENSG00000130758	Mitogen-activated protein kinase kinase kinase 10	19	40191744-40215575	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007039	Approved		Approved	Nucleus<br>Actin filaments<br>Cytosol	Urothelial cancer:2.13e-4 (favourable), Head and neck cancer:8.69e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 31.1	testis: 7.1	Mixed		
MAP3K11	MEKK11, MLK3, PTK1, SPRK	ENSG00000173327	Mitogen-activated protein kinase kinase kinase 11	11	65597755-65615382	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB010165	Approved		Supported	Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			spleen: 54.7	Expressed in all		
MAP3K12	DLK, MEKK12, MUK, ZPK, ZPKP1	ENSG00000139625	Mitogen-activated protein kinase kinase kinase 12	12	53479669-53500063	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039936, HPA071996	Approved		Approved	Nucleus<br>Cell Junctions	Renal cancer:5.43e-10 (unfavourable), Pancreatic cancer:1.51e-4 (favourable)	Mixed	Mixed			gallbladder: 23.9	Cell line enhanced		HHSteC: 46.6
MAP3K13	LZK, MEKK13	ENSG00000073803	Mitogen-activated protein kinase kinase kinase 13	3	185282941-185489097	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016497, HPA036691, HPA036692	Uncertain		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Endometrial cancer:1.28e-5 (unfavourable), Pancreatic cancer:7.27e-5 (unfavourable), Ovarian cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 69.3	Mixed		
MAP3K14	FTDCR1B, HS, HSNIK, NIK	ENSG00000006062	Mitogen-activated protein kinase kinase kinase 14	17	45263121-45317040	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027269, HPA027270	Approved		Supported	Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol	Cervical cancer:5.27e-5 (favourable), Renal cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 22.8	Mixed		
MAP3K15	ASK3, bA723P2.3, FLJ16518	ENSG00000180815	Mitogen-activated protein kinase kinase kinase 15	X	19360056-19515261	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004006			Approved	Vesicles		Mixed	Tissue enriched	6	adrenal gland: 14.3	spleen: 2.2	Cell line enhanced		A549: 1.8;HAP1: 5.1;HEK93: 3.8;REH: 2.4
MAP3K19	FLJ23074, RCK, YSK4	ENSG00000176601	Mitogen-activated protein kinase kinase kinase 19	2	134964491-135047468	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA011388			Uncertain	Cytosol		Tissue enhanced	Group enriched	8	fallopian tube: 28.5;testis: 7.8	lung: 2.2	Not detected		
MAP3K2	MEKK2, MEKK2B	ENSG00000169967	Mitogen-activated protein kinase kinase kinase 2	2	127298730-127388465	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021540	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 29.8	Expressed in all		
MAP3K20	MLK7, MLTK, MLTKalpha, MLTKbeta, MRK, ZAK	ENSG00000091436	Mitogen-activated protein kinase kinase kinase 20	2	173075435-173268010	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017205	Approved		Supported	Cytosol	Renal cancer:3.41e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 133.3	Mixed		
MAP3K21	KIAA1804, MLK4	ENSG00000143674	Mitogen-activated protein kinase kinase kinase 21	1	233327768-233385148	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007636	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			testis: 17.8	Cell line enhanced		HEK93: 25.2
MAP3K3	MAPKKK3, MEKK3	ENSG00000198909	Mitogen-activated protein kinase kinase kinase 3	17	63622415-63696303	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007764, HPA035410, HPA035411	Uncertain		Approved	Nucleoplasm	Endometrial cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 41.5	Expressed in all		
MAP3K4	KIAA0213, MAPKKK4, MEKK4, MTK1	ENSG00000085511	Mitogen-activated protein kinase kinase kinase 4	6	160991727-161117385	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007625	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			endometrium: 15.4	Expressed in all		
MAP3K5	ASK1, MAPKKK5, MEKK5	ENSG00000197442	Mitogen-activated protein kinase kinase kinase 5	6	136557047-136792518	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007824, HPA063245, HPA064423	Approved		Supported	Cytosol	Pancreatic cancer:5.91e-4 (unfavourable), Head and neck cancer:6.08e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 115.7	Mixed		
MAP3K6	ASK2, MAPKKK6, MEKK6	ENSG00000142733	Mitogen-activated protein kinase kinase kinase 6	1	27355184-27366892	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051192	Approved		Approved	Nucleus<br>Plasma membrane<br>Actin filaments<br>Cytosol	Glioma:1.73e-4 (unfavourable), Head and neck cancer:7.26e-4 (favourable), Liver cancer:8.76e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 114.9	esophagus: 41.2	Mixed		
MAP3K7	MEKK7, TAK1	ENSG00000135341	Mitogen-activated protein kinase kinase kinase 7	6	90513573-90587045	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007633	Approved		Approved	Nuclear speckles<br>Cytosol	Liver cancer:3.51e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.0	Expressed in all		
MAP3K7CL	C21orf7, TAK1L, TAKL, TAKL-1, TAKL-2, TAKL-4	ENSG00000156265	MAP3K7 C-terminal like	21	29077471-29175889	Predicted intracellular proteins	Evidence at protein level	HPA030079, HPA042439	Uncertain		Approved	Nucleoplasm	Renal cancer:8.31e-6 (unfavourable)	Expressed in all	Mixed			heart muscle: 17.9	Cell line enhanced		HBF TERT88: 56.2;RH-30: 242.2
MAP3K8	c-COT, COT, EST, ESTF, MEKK8, Tpl-2	ENSG00000107968	Mitogen-activated protein kinase kinase kinase 8	10	30433937-30461833	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005120, HPA017962	Supported		Supported	Cytosol	Renal cancer:8.76e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 209.6	Mixed		
MAP4		ENSG00000047849	Microtubule associated protein 4	3	47850690-48089272	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038149, HPA038150	Enhanced		Supported	Plasma membrane<br>Microtubules<br>Cytosol	Liver cancer:1.82e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 241.9	Expressed in all		
MAP4K1	HPK1	ENSG00000104814	Mitogen-activated protein kinase kinase kinase kinase 1	19	38587641-38618882	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007419, CAB007754	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane	Renal cancer:7.99e-10 (unfavourable), Cervical cancer:6.17e-5 (favourable), Head and neck cancer:3.26e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 37.3;spleen: 23.8;tonsil: 27.2	appendix: 19.2	Cell line enhanced		Daudi: 34.0;HDLM-2: 44.1;Karpas-707: 34.0;U-266/70: 28.3;U-266/84: 27.3;U-698: 41.0
MAP4K2	BL44, GCK, RAB8IP	ENSG00000168067	Mitogen-activated protein kinase kinase kinase kinase 2	11	64784914-64803241	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007330	Enhanced		Approved	Vesicles	Liver cancer:3.10e-5 (unfavourable)	Expressed in all	Mixed			spleen: 22.9	Mixed		
MAP4K3	GLK, MAPKKKK3, RAB8IPL1	ENSG00000011566	Mitogen-activated protein kinase kinase kinase kinase 3	2	39249266-39437312	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030380	Approved		Approved	Centrosome		Expressed in all	Expressed in all			thyroid gland: 40.9	Expressed in all		
MAP4K4	FLH21957, HGK, NIK	ENSG00000071054	Mitogen-activated protein kinase kinase kinase kinase 4	2	101696850-101894689	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008476	Uncertain				Renal cancer:3.62e-6 (unfavourable), Lung cancer:1.57e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 154.6	Mixed		
MAP4K5	GCKR, KHS, KHS1	ENSG00000012983	Mitogen-activated protein kinase kinase kinase kinase 5	14	50418501-50561126	Predicted intracellular proteins	Evidence at protein level	HPA036696	Uncertain		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			endometrium: 55.2	Expressed in all		
MAP6	FLJ41346, KIAA1878, MAP6-N, STOP	ENSG00000171533	Microtubule associated protein 6	11	75586918-75669120	Predicted intracellular proteins	Evidence at protein level	CAB015442, CAB022600, HPA039061, HPA039062	Enhanced		Uncertain	Plasma membrane	Pancreatic cancer:3.41e-4 (favourable), Prostate cancer:9.15e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 68.1;fallopian tube: 65.5	parathyroid gland: 52.6	Group enriched	6	AF22: 37.3;CACO-2: 31.4;HDLM-2: 19.9;SCLC-21H: 73.4;SH-SY5Y: 33.6
MAP6D1	FLJ12748, SL21	ENSG00000180834	MAP6 domain containing 1	3	183815876-183825594	Predicted intracellular proteins	Evidence at protein level	HPA037991	Supported		Approved	Cytosol	Prostate cancer:3.37e-4 (unfavourable)	Mixed	Group enriched	7	cerebral cortex: 39.7;skeletal muscle: 10.3	skin: 3.6	Cell line enhanced		T-47d: 66.1
MAP7	E-MAP-115	ENSG00000135525	Microtubule associated protein 7	6	136342281-136550819	Predicted intracellular proteins	Evidence at protein level	HPA029712, HPA029713	Enhanced		Supported	Microtubules<br>Cytosol	Renal cancer:5.07e-7 (favourable), Cervical cancer:9.70e-5 (unfavourable), Liver cancer:9.22e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 52.9	Cell line enhanced		MCF7: 67.4
MAP7D1	FLJ10350, FLJ39022, PARCC1, RPRC1	ENSG00000116871	MAP7 domain containing 1	1	36155579-36180849	Predicted intracellular proteins	Evidence at protein level	HPA028075	Approved		Approved	Microtubules<br>Cytosol	Liver cancer:1.49e-6 (unfavourable), Renal cancer:8.56e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 116.6	Expressed in all		
MAP7D2	FLJ14503	ENSG00000184368	MAP7 domain containing 2	X	20006713-20116917	Predicted intracellular proteins	Evidence at protein level	HPA051508, HPA059537	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.27e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 49.2;epididymis: 45.6	testis: 18.3	Cell line enhanced		A549: 12.0;CACO-2: 16.0;HEK93: 23.8;HeLa: 15.1;SCLC-21H: 34.5;SiHa: 13.5
MAP7D3	FLJ12649	ENSG00000129680	MAP7 domain containing 3	X	136213220-136256482	Predicted intracellular proteins	Evidence at protein level	HPA035598, HPA058101	Approved		Enhanced	Centrosome	Urothelial cancer:5.38e-5 (unfavourable), Endometrial cancer:9.00e-5 (unfavourable), Stomach cancer:7.91e-4 (unfavourable)	Expressed in all	Mixed			testis: 30.0	Mixed		
MAP9	ASAP, FLJ21159	ENSG00000164114	Microtubule associated protein 9	4	155342658-155376970	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		parathyroid gland: 79.9	cerebral cortex: 27.1	Cell line enhanced		SH-SY5Y: 44.7
MAPK1	ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2	ENSG00000100030	Mitogen-activated protein kinase 1	22	21754500-21867680	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003995, CAB004229, HPA005700, HPA030069	Approved				Liver cancer:4.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 132.4	Expressed in all		
MAPK10	JNK3, p493F12, p54bSAPK, PRKM10	ENSG00000109339	Mitogen-activated protein kinase 10	4	86010395-86594131	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB022625	Approved				Renal cancer:3.11e-4 (favourable), Urothelial cancer:5.57e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 113.0	seminal vesicle: 38.6	Cell line enriched	16	AF22: 181.7
MAPK11	p38-2, p38Beta, PRKM11, SAPK2	ENSG00000185386	Mitogen-activated protein kinase 11	22	50263713-50270767	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB012961, HPA045069	Approved		Approved	Mitochondria	Renal cancer:6.02e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 27.7	Mixed		
MAPK12	ERK6, p38gamma, PRKM12, SAPK-3, SAPK3	ENSG00000188130	Mitogen-activated protein kinase 12	22	50245450-50261825	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB025483, HPA054562	Enhanced		Approved	Nuclear speckles<br>Cytosol	Renal cancer:5.00e-6 (unfavourable)	Mixed	Tissue enriched	6	skeletal muscle: 91.5	cerebral cortex: 15.7	Mixed		
MAPK13	p38delta, PRKM13, SAPK4	ENSG00000156711	Mitogen-activated protein kinase 13	6	36127809-36144524	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007667, CAB025854	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:9.00e-4 (favourable)	Expressed in all	Mixed			skin: 93.7	Cell line enhanced		HBEC3-KT: 107.0
MAPK14	CSBP1, CSBP2, CSPB1, Mxi2, p38, PRKM14, PRKM15	ENSG00000112062	Mitogen-activated protein kinase 14	6	36027677-36111236	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB010285, CAB040578, HPA051825	Approved		Supported	Nuclear speckles		Expressed in all	Expressed in all			placenta: 63.2	Expressed in all		
MAPK15	ERK7, ERK8	ENSG00000181085	Mitogen-activated protein kinase 15	8	143716259-143722458	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002704			Approved	Nucleoplasm<br>Cell Junctions<br>Cytosol		Mixed	Tissue enhanced		fallopian tube: 43.7	parathyroid gland: 13.2	Cell line enhanced		CAPAN-2: 6.9;HeLa: 10.4;MCF7: 11.8;T-47d: 12.5
MAPK1IP1L	C14orf32	ENSG00000168175	Mitogen-activated protein kinase 1 interacting protein 1 like	14	55051631-55070192	Predicted intracellular proteins	Evidence at protein level	HPA034506	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.82e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 53.2	Expressed in all		
MAPK3	ERK1, p44erk1, p44mapk, PRKM3	ENSG00000102882	Mitogen-activated protein kinase 3	16	30114105-30123506	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002683, HPA003995, HPA005700, HPA030069	Approved		Approved	Nucleoplasm	Liver cancer:1.11e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 133.7	Expressed in all		
MAPK4	Erk3-related, Erk4, PRKM4	ENSG00000141639	Mitogen-activated protein kinase 4	18	50560078-50731824	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		adrenal gland: 29.7;cerebral cortex: 33.4;parathyroid gland: 60.1	seminal vesicle: 13.9	Cell line enhanced		SCLC-21H: 13.6;SH-SY5Y: 3.0
MAPK6	ERK3, HsT17250, p97MAPK, PRKM6	ENSG00000069956	Mitogen-activated protein kinase 6	15	51952106-52067372	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB005184, HPA030262	Approved	Approved	Enhanced	Cytosol		Expressed in all	Expressed in all			testis: 53.0	Expressed in all		
MAPK7	BMK1, ERK5, PRKM7	ENSG00000166484	Mitogen-activated protein kinase 7	17	19377721-19383544	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018561, HPA031031	Uncertain		Enhanced	Nucleus<br>Cytosol	Liver cancer:1.86e-4 (unfavourable)	Expressed in all	Mixed			testis: 10.6	Mixed		
MAPK8	JNK, JNK1, PRKM8, SAPK1	ENSG00000107643	Mitogen-activated protein kinase 8	10	48306639-48439360	Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004463, CAB069396	Approved				Liver cancer:8.66e-4 (unfavourable), Renal cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 35.1	Expressed in all		
MAPK8IP1	IB1, JIP-1, JIP1, PRKM8IP	ENSG00000121653	Mitogen-activated protein kinase 8 interacting protein 1	11	45885651-45906465	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058921, HPA070332			Enhanced	Plasma membrane	Renal cancer:1.23e-11 (favourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 177.1	parathyroid gland: 33.1	Cell line enhanced		SCLC-21H: 89.8
MAPK8IP2	IB2, JIP2, PRKM8IPL	ENSG00000008735	Mitogen-activated protein kinase 8 interacting protein 2	22	50600685-50613981	Predicted intracellular proteins	Evidence at protein level	HPA034780	Uncertain					Mixed	Tissue enriched	8	cerebral cortex: 78.2	adrenal gland: 10.0	Cell line enhanced		SCLC-21H: 24.1;SH-SY5Y: 19.6
MAPK8IP3	JIP3, JSAP1, KIAA1066, syd	ENSG00000138834	Mitogen-activated protein kinase 8 interacting protein 3	16	1706183-1770317	Predicted intracellular proteins	Evidence at protein level	CAB005580, HPA041785, HPA069311	Approved		Approved	Vesicles	Renal cancer:5.25e-5 (unfavourable), Urothelial cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 83.9	Expressed in all		
MAPK9	JNK2, p54a, PRKM9, SAPK	ENSG00000050748	Mitogen-activated protein kinase 9	5	180233143-180292099	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB008910	Approved				Colorectal cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 83.9	Expressed in all		
MAPKAP1	MGC2745, MIP1, SIN1	ENSG00000119487	Mitogen-activated protein kinase associated protein 1	9	125437393-125707234	Predicted intracellular proteins	Evidence at protein level	HPA029091, HPA029092	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:7.23e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 79.7	Expressed in all		
MAPKBP1	KIAA0596	ENSG00000137802	Mitogen-activated protein kinase binding protein 1	15	41774434-41827855	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030832, HPA030833	Enhanced		Approved	Nucleoli	Endometrial cancer:1.47e-4 (favourable), Ovarian cancer:6.80e-4 (unfavourable)	Expressed in all	Mixed			testis: 34.0	Mixed		
MAPRE1	EB1	ENSG00000101367	Microtubule associated protein RP/EB family member 1	20	32819893-32850405	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003600, CAB009337, CAB019391	Enhanced		Enhanced	Microtubule organizing center<br>Cytosol	Liver cancer:6.33e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 128.4	Expressed in all		
MAPRE2	EB1, EB2, RP1	ENSG00000166974	Microtubule associated protein RP/EB family member 2	18	34976928-35143470	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016738, HPA016739	Enhanced		Uncertain	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 174.6	Mixed		
MAPRE3	EB3, RP3	ENSG00000084764	Microtubule associated protein RP/EB family member 3	2	26970612-27027196	Predicted intracellular proteins	Evidence at protein level	HPA009263	Uncertain		Supported	Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 177.3	testis: 70.2	Mixed		
MAPT	DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau	ENSG00000186868	Microtubule associated protein tau	17	45894382-46028334	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000151, HPA048895, HPA069524, HPA069570, CAB072344	Enhanced		Supported	Nuclear speckles<br>Plasma membrane		Group enriched	Tissue enriched	8	cerebral cortex: 116.2	skeletal muscle: 13.7	Cell line enhanced		HDLM-2: 37.4;SCLC-21H: 16.3;T-47d: 16.5
MARC1	FLJ22390, MOSC1	ENSG00000186205	Mitochondrial amidoxime reducing component 1	1	220786759-220819657	Predicted intracellular proteins	Evidence at protein level	HPA028702	Approved		Supported	Mitochondria	Renal cancer:4.51e-4 (unfavourable)	Mixed	Expressed in all			adipose tissue: 225.9	Cell line enhanced		BEWO: 149.0;NTERA-2: 65.7
MARCH10	FLJ35757, MARCH-X, RNF190	ENSG00000173838	Membrane associated ring-CH-type finger 10	17	62701314-62808344	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023322	Enhanced		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enriched	7	testis: 144.4	fallopian tube: 20.5	Cell line enhanced		BEWO: 2.5;EFO-21: 4.5;SCLC-21H: 9.7
MARCH7	AXOT, MARCH-VII, RNF177	ENSG00000136536	Membrane associated ring-CH-type finger 7	2	159712457-159771027	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA014275, HPA022152	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.84e-4 (unfavourable), Liver cancer:2.41e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 113.1	Expressed in all		
MARCKS	80K-L, MACS, PKCSL	ENSG00000277443	Myristoylated alanine rich protein kinase C substrate	6	113857362-113863471	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022062, HPA054820, HPA067595, HPA069443	Enhanced		Approved	Nucleus<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Liver cancer:2.78e-8 (unfavourable), Renal cancer:4.85e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 218.8	Cell line enhanced		AF22: 402.5
MARCKSL1	F52, MacMARCKS, MLP, MLP1	ENSG00000175130	MARCKS like 1	1	32333832-32336379	Predicted intracellular proteins	Evidence at protein level	CAB020787, HPA030528	Approved		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Liver cancer:1.78e-6 (unfavourable), Renal cancer:1.20e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 315.1	Cell line enhanced		AF22: 902.3;NTERA-2: 883.9
MARK1	MARK, PAR-1C	ENSG00000116141	Microtubule affinity regulating kinase 1	1	220528183-220664461	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007421, HPA008061	Uncertain				Pancreatic cancer:2.23e-5 (favourable), Melanoma:2.63e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 21.1	Cell line enhanced		RT4: 50.7
MARK2	EMK1, PAR-1, PAR-1B, Par1b	ENSG00000072518	Microtubule affinity regulating kinase 2	11	63838928-63911019	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038790, HPA074905	Approved		Supported	Nucleoplasm<br>Plasma membrane	Liver cancer:1.30e-4 (unfavourable), Endometrial cancer:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 46.1	Expressed in all		
MARS2	mtMetRS, SPAX3	ENSG00000247626	Methionyl-tRNA synthetase 2, mitochondrial	2	197705369-197708387	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035589, HPA035590	Uncertain		Approved	Intermediate filaments<br>Cytosol	Renal cancer:6.14e-5 (favourable), Glioma:1.49e-4 (favourable), Endometrial cancer:3.50e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 7.5	Expressed in all		
MAST3	KIAA0561	ENSG00000099308	Microtubule associated serine/threonine kinase 3	19	18097793-18151692	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035061, HPA035062	Uncertain		Approved	Nuclear speckles	Head and neck cancer:2.97e-4 (favourable), Pancreatic cancer:7.01e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 51.5	Mixed		
MAST4	KIAA0303	ENSG00000069020	Microtubule associated serine/threonine kinase family member 4	5	66596361-67169595	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000544	Approved		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:5.18e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 47.7	Cell line enhanced		HDLM-2: 40.1
MASTL	FLJ14813, Gwl, THC2	ENSG00000120539	Microtubule associated serine/threonine kinase like	10	27154824-27186924	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027175, HPA054273	Approved		Enhanced	Nucleoplasm	Renal cancer:1.71e-6 (unfavourable), Liver cancer:2.52e-6 (unfavourable), Pancreatic cancer:4.81e-5 (unfavourable)	Expressed in all	Mixed			testis: 12.6	Expressed in all		
MAT1A	MAT, MATA1, SAMS, SAMS1	ENSG00000151224	Methionine adenosyltransferase 1A	10	80271820-80289684	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048627	Supported					Tissue enriched	Tissue enriched	10	liver: 689.6	epididymis: 68.4	Cell line enriched	11	Hep G2: 64.0
MAT2A	MATA2, MATII, SAMS2	ENSG00000168906	Methionine adenosyltransferase 2A	2	85539165-85545280	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009968, HPA043028	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:5.29e-5 (unfavourable), Melanoma:5.94e-5 (unfavourable), Liver cancer:4.87e-4 (unfavourable), Lung cancer:8.94e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 644.9	Expressed in all		
MAT2B	MATIIbeta, SDR23E1	ENSG00000038274	Methionine adenosyltransferase 2B	5	163503114-163519336	Predicted intracellular proteins	Evidence at protein level	HPA037721, HPA037722	Uncertain				Renal cancer:4.51e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 133.5	Expressed in all		
MATK	CHK, CTK, DKFZp434N1212, HHYLTK, HYL, HYLTK, Lsk, MGC1708, MGC2101	ENSG00000007264	Megakaryocyte-associated tyrosine kinase	19	3777970-3802129	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004847	Approved				Breast cancer:5.27e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 22.0	spleen: 19.8	Cell line enhanced		HL-60: 85.8;K-562: 43.3;NB-4: 47.4;SCLC-21H: 36.7
MAX	bHLHd4, bHLHd5, bHLHd6, bHLHd7, bHLHd8	ENSG00000125952	MYC associated factor X	14	65006174-65102695	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000328, HPA003474	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Thyroid cancer:2.12e-4 (favourable), Renal cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 78.8	Expressed in all		
MB	PVALB	ENSG00000198125	Myoglobin	22	35606764-35637951	Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000060, HPA003123	Enhanced					Group enriched	Group enriched	12	heart muscle: 6603.8;skeletal muscle: 12284.0	esophagus: 762.7	Cell line enhanced		SiHa: 20.1;SK-BR-3: 131.2;T-47d: 36.7
MB21D1	C6orf150, cGAS	ENSG00000164430	Mab-21 domain containing 1	6	73413515-73452276	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031700, HPA031702	Enhanced		Approved	Microtubule organizing center<br>Cytosol	Renal cancer:2.27e-7 (unfavourable)	Expressed in all	Mixed			bone marrow: 8.7	Cell line enhanced		RH-30: 40.2
MB21D2	C3orf59	ENSG00000180611	Mab-21 domain containing 2	3	192796815-192918161	Predicted intracellular proteins	Evidence at protein level	HPA044026	Uncertain		Approved	Cytosol	Endometrial cancer:3.74e-5 (unfavourable), Head and neck cancer:9.94e-4 (unfavourable)	Mixed	Mixed			placenta: 17.1	Cell line enhanced		HDLM-2: 97.0
MBD1	CXXC3, PCM1	ENSG00000141644	Methyl-CpG binding domain protein 1	18	50266882-50281774	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009017, CAB036003, HPA068850	Approved		Enhanced	Nucleoplasm<br>Vesicles	Prostate cancer:1.70e-6 (unfavourable), Liver cancer:5.08e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 109.0	Expressed in all		
MBD2		ENSG00000134046	Methyl-CpG binding domain protein 2	18	54151601-54224788	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB037282, HPA067582, HPA067615	Approved		Enhanced	Nucleoplasm	Colorectal cancer:6.49e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 50.6	Expressed in all		
MBD3		ENSG00000071655	Methyl-CpG binding domain protein 3	19	1573596-1592801	Predicted intracellular proteins	Evidence at protein level	CAB013265	Supported		Supported	Nucleoplasm	Pancreatic cancer:1.76e-5 (favourable), Liver cancer:2.99e-4 (unfavourable), Endometrial cancer:5.08e-4 (favourable)	Expressed in all	Expressed in all			placenta: 45.8	Expressed in all		
MBD3L1	MBD3L	ENSG00000170948	Methyl-CpG binding domain protein 3 like 1	19	8832398-8843340	Predicted intracellular proteins	Evidence at protein level	HPA043121, HPA046753	Supported					Not detected	Tissue enriched	5	testis: 34.5	fallopian tube: 6.4	Not detected		
MBD3L2		ENSG00000230522	Methyl-CpG binding domain protein 3 like 2	19	7049321-7051735	Predicted intracellular proteins	Evidence at transcript level	HPA051259	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MBD3L3		ENSG00000182315	Methyl-CpG binding domain protein 3 like 3	19	7056209-7058640	Predicted intracellular proteins	No evidence	HPA051259	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
MBD3L4		ENSG00000205718	Methyl-CpG binding domain protein 3 like 4	19	7037748-7040179	Predicted intracellular proteins	No evidence	HPA051259	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
MBD3L5		ENSG00000237247	Methyl-CpG binding domain protein 3 like 5	19	7030578-7033011	Predicted intracellular proteins	No evidence	HPA051259	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MBD4	MED1	ENSG00000129071	Methyl-CpG binding domain 4, DNA glycosylase	3	129430944-129440179	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002031	Supported		Supported	Nuclear speckles	Renal cancer:2.73e-6 (unfavourable), Pancreatic cancer:2.18e-4 (unfavourable), Prostate cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 76.6	Expressed in all		
MBD5	FLJ11113, KIAA1461	ENSG00000204406	Methyl-CpG binding domain protein 5	2	148021011-148516971	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035964			Supported	Nucleus<br>Midbody	Endometrial cancer:3.72e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.3	Mixed		
MBIP		ENSG00000151332	MAP3K12 binding inhibitory protein 1	14	36298558-36320676	Predicted intracellular proteins	Evidence at protein level	HPA003388	Supported		Supported	Nucleus<br>Nucleoli<br>Cytosol	Ovarian cancer:1.14e-4 (favourable), Renal cancer:1.25e-4 (favourable), Lung cancer:1.52e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 136.4	Expressed in all		
MBLAC1	MGC49416	ENSG00000214309	Metallo-beta-lactamase domain containing 1	7	100126694-100128498	Predicted intracellular proteins	Evidence at protein level	HPA071574	Uncertain				Renal cancer:7.90e-5 (favourable), Pancreatic cancer:1.18e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 3.9	Mixed		
MBLAC2	DKFZp686P15118, MGC46734	ENSG00000176055	Metallo-beta-lactamase domain containing 2	5	90458203-90474768	Predicted intracellular proteins	Evidence at protein level	HPA037757, HPA060264	Uncertain		Approved	Nucleus<br>Nuclear bodies		Expressed in all	Mixed			parathyroid gland: 18.7	Expressed in all		
MBNL2	MBLL, MBLL39	ENSG00000139793	Muscleblind like splicing regulator 2	13	97221434-97394120	Predicted intracellular proteins	Evidence at protein level	HPA062685			Supported	Nucleoplasm	Pancreatic cancer:1.99e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 84.1	Mixed		
MBNL3	CHCR, FLJ11316, MBLX39, MBXL	ENSG00000076770	Muscleblind like splicing regulator 3	X	132369317-132489968	Predicted intracellular proteins	Evidence at protein level	HPA001584	Enhanced		Approved	Golgi apparatus<br>Vesicles	Endometrial cancer:1.57e-4 (unfavourable)	Expressed in all	Group enriched	5	placenta: 242.1;testis: 81.4	liver: 30.6	Cell line enhanced		CACO-2: 102.2;Hep G2: 116.6
MBP		ENSG00000197971	Myelin basic protein	18	76978827-77133683	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002300, HPA049222, HPA064368	Enhanced	Supported	Approved	Plasma membrane	Renal cancer:4.48e-12 (favourable)	Group enriched	Tissue enriched	29	cerebral cortex: 2930.7	parathyroid gland: 99.8	Cell line enhanced		HL-60: 79.4;SK-MEL-30: 158.4
MBTD1	FLJ20055, SA49P01	ENSG00000011258	Mbt domain containing 1	17	51177425-51260163	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021876	Approved		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 46.1	Expressed in all		
MCAT	fabD, FASN2C, MCT, MCT1, MT, NET62	ENSG00000100294	Malonyl-CoA-acyl carrier protein transacylase	22	43132206-43143394	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003122, HPA035471	Approved		Supported	Mitochondria	Renal cancer:2.18e-4 (favourable), Stomach cancer:3.89e-4 (favourable), Endometrial cancer:5.53e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 23.0	Expressed in all		
MCC		ENSG00000171444	Mutated in colorectal cancers	5	113022099-113488830	Predicted intracellular proteins	Evidence at protein level	HPA037390, HPA037391	Approved	Approved	Supported	Nucleoplasm	Renal cancer:6.19e-4 (favourable)	Expressed in all	Tissue enhanced		ovary: 87.5;parathyroid gland: 66.9	skin: 25.1	Cell line enhanced		HBEC3-KT: 39.0
MCCC2	MCCB	ENSG00000131844	Methylcrotonoyl-CoA carboxylase 2	5	71587288-71658704	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038300, HPA038301, HPA061546	Enhanced		Enhanced	Mitochondria	Renal cancer:6.43e-8 (favourable), Liver cancer:1.70e-4 (favourable), Colorectal cancer:3.62e-4 (favourable)	Expressed in all	Expressed in all			prostate: 77.2	Mixed		
MCF2	ARHGEF21, DBL	ENSG00000101977	MCF.2 cell line derived transforming sequence	X	139581770-139708227	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	11	adrenal gland: 38.3;cerebral cortex: 8.7;epididymis: 15.0;ovary: 12.9;seminal vesicle: 24.0;testis: 34.6	prostate: 2.0	Cell line enriched	12	U-251 MG: 30.6
MCF2L2	ARHGEF22, KIAA0861	ENSG00000053524	MCF.2 cell line derived transforming sequence-like 2	3	183178043-183428778	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA038946, HPA038947	Uncertain		Approved	Plasma membrane<br>Cytosol		Not detected	Group enriched	8	adrenal gland: 10.2;cerebral cortex: 17.2;parathyroid gland: 7.7;spleen: 3.5;testis: 4.7	prostate: 1.0	Cell line enhanced		HDLM-2: 5.5;Karpas-707: 3.6;REH: 3.1
MCIDAS	IDAS, MCI, MCIN	ENSG00000234602	Multiciliate differentiation and DNA synthesis associated cell cycle protein	5	55219614-55227315	Predicted intracellular proteins	Evidence at protein level	HPA049981, HPA058073	Uncertain		Supported	Nuclear bodies		Mixed	Not detected			fallopian tube,gallbladder,parathyroid gland,stomach,testis,thyroid gland: 0.1	Cell line enhanced		BEWO: 2.2;CACO-2: 2.3;HEK93: 2.0
MCM10	CNA43, DNA43, PRO2249	ENSG00000065328	Minichromosome maintenance 10 replication initiation factor	10	13161554-13211104	Predicted intracellular proteins	Evidence at protein level	HPA045899, HPA071952	Approved		Supported	Nucleus<br>Nucleoli		Mixed	Mixed			bone marrow: 5.9	Mixed		
MCM2	BM28, CCNL1, cdc19, CDCL1, D3S3194, KIAA0030	ENSG00000073111	Minichromosome maintenance complex component 2	3	127598223-127622436	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000303, HPA031495, HPA031496	Enhanced		Supported	Nucleoplasm	Liver cancer:1.51e-7 (unfavourable), Cervical cancer:4.66e-4 (favourable)	Expressed in all	Mixed			bone marrow: 38.5	Expressed in all		
MCM3		ENSG00000112118	Minichromosome maintenance complex component 3	6	52264009-52284881	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002162, HPA004789, HPA004790	Supported		Enhanced	Nucleoplasm	Thyroid cancer:3.13e-5 (favourable), Melanoma:4.40e-5 (unfavourable), Liver cancer:1.40e-4 (unfavourable), Cervical cancer:1.89e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 80.8	Expressed in all		
MCM3AP	GANP, KIAA0572, Map80, SAC3	ENSG00000160294	Minichromosome maintenance complex component 3 associated protein	21	46235126-46286297	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA021527, HPA032103	Approved		Supported	Nucleus<br>Nuclear membrane<br>Cytosol	Pancreatic cancer:2.05e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.8	Expressed in all		
MCM4	CDC21, CDC54, hCdc21, MGC33310, P1-Cdc21	ENSG00000104738	Minichromosome maintenance complex component 4	8	47960185-47978160	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004497, HPA004873, HPA031052	Supported		Enhanced	Nucleoplasm	Endometrial cancer:2.84e-5 (unfavourable), Melanoma:1.15e-4 (unfavourable), Liver cancer:1.23e-4 (unfavourable), Colorectal cancer:2.19e-4 (favourable), Pancreatic cancer:2.38e-4 (unfavourable), Renal cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 78.6	Expressed in all		
MCM5	CDC46	ENSG00000100297	Minichromosome maintenance complex component 5	22	35400063-35425430	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000101, HPA000845, HPA052880	Enhanced		Enhanced	Nucleoplasm	Cervical cancer:2.81e-6 (favourable), Renal cancer:3.58e-5 (unfavourable), Liver cancer:1.78e-4 (unfavourable), Lung cancer:3.95e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 88.5	Expressed in all		
MCM6	Mis5	ENSG00000076003	Minichromosome maintenance complex component 6	2	135839626-135876426	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004818, CAB009577	Enhanced		Enhanced	Nucleoplasm	Renal cancer:8.29e-12 (unfavourable), Liver cancer:5.70e-7 (unfavourable), Melanoma:1.09e-5 (unfavourable)	Expressed in all	Mixed			lymph node: 40.7	Expressed in all		
MCM7	CDC47, MCM2, PPP1R104	ENSG00000166508	Minichromosome maintenance complex component 7	7	100092728-100101940	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002163, HPA003898, CAB016312	Enhanced		Enhanced	Nucleoplasm	Cervical cancer:1.28e-4 (favourable), Liver cancer:2.18e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.9	Expressed in all		
MCM8	C20orf154, dJ967N21.5, MGC119522, MGC119523, MGC12866, MGC4816, REC	ENSG00000125885	Minichromosome maintenance 8 homologous recombination repair factor	20	5950652-5998977	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045141			Supported	Nucleoplasm	Liver cancer:9.30e-8 (unfavourable), Pancreatic cancer:7.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 27.6	lymph node: 10.2	Expressed in all		
MCM9	C6orf61, dJ329L24.3, FLJ20170, MCMDC1, MGC35304	ENSG00000111877	Minichromosome maintenance 9 homologous recombination repair factor	6	118813442-118935162	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031137	Approved		Approved	Nucleoplasm		Expressed in all	Mixed			epididymis: 15.5	Expressed in all		
MCMBP	C10orf119, FLJ13081, MCM-BP	ENSG00000197771	Minichromosome maintenance complex binding protein	10	119829404-119892556	Predicted intracellular proteins	Evidence at protein level	CAB013792, HPA038481	Uncertain		Enhanced	Nucleoplasm	Pancreatic cancer:2.20e-4 (unfavourable), Renal cancer:6.18e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 63.6	Expressed in all		
MCMDC2	C8orf45, FLJ25692	ENSG00000178460	Minichromosome maintenance domain containing 2	8	66870749-66922048	Predicted intracellular proteins	Evidence at protein level	HPA026522			Approved	Actin filaments		Not detected	Tissue enriched	6	testis: 21.6	ovary: 3.7	Mixed		
MCPH1	BRIT1, FLJ12847	ENSG00000147316	Microcephalin 1	8	6406592-6648504	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008238, CAB012177	Supported		Uncertain	Nucleoplasm<br>Nuclear bodies	Colorectal cancer:8.52e-4 (favourable)	Expressed in all	Expressed in all			testis: 19.5	Expressed in all		
MCRIP1	FAM195B, GRAN2, MCRIP	ENSG00000225663	MAPK regulated corepressor interacting protein 1	17	81822361-81833302	Predicted intracellular proteins	Evidence at protein level	HPA045542	Approved		Approved	Cytosol	Pancreatic cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 107.1	Expressed in all		
MCRIP2	C16orf14, FAM195A, MGC15416	ENSG00000172366	MAPK regulated corepressor interacting protein 2	16	636817-648474	Predicted intracellular proteins	Evidence at protein level	HPA060363	Uncertain				Renal cancer:1.45e-5 (favourable), Urothelial cancer:7.23e-4 (favourable)	Expressed in all	Mixed			colon: 10.8	Mixed		
MCRS1	ICP22BP, INO80Q, MCRS2, MSP58, P78	ENSG00000187778	Microspherule protein 1	12	49556544-49568153	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039057	Supported		Supported	Nucleoplasm	Liver cancer:2.30e-4 (unfavourable), Renal cancer:2.70e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 55.0	Expressed in all		
MCTS1	MCT-1	ENSG00000232119	MCTS1, re-initiation and release factor	X	120594010-120621074	Predicted intracellular proteins	Evidence at protein level	HPA001045			Supported	Plasma membrane<br>Cytosol	Head and neck cancer:3.27e-5 (unfavourable), Renal cancer:4.35e-5 (unfavourable), Breast cancer:1.38e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.7	Expressed in all		
MDC1	Em:AB023051.5, KIAA0170, NFBD1	ENSG00000137337	Mediator of DNA damage checkpoint 1	6	30699807-30717889	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA006915	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Tissue enhanced		testis: 9.6	skin: 3.3	Cell line enhanced		A-431: 21.4;HEK93: 41.5
MDFI	I-mfa	ENSG00000112559	MyoD family inhibitor	6	41636882-41654246	Predicted intracellular proteins	Evidence at protein level	HPA049973	Approved		Approved	Nucleoplasm	Renal cancer:2.85e-6 (unfavourable), Lung cancer:1.32e-5 (unfavourable), Melanoma:9.11e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 35.9	gallbladder: 19.7	Cell line enhanced		BEWO: 88.8;HBEC3-KT: 83.8;REH: 287.1
MDH1		ENSG00000014641	Malate dehydrogenase 1	2	63588609-63607197	Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027296, CAB047333, HPA054276	Uncertain		Supported	Centrosome<br>Cytosol	Endometrial cancer:7.13e-4 (unfavourable), Renal cancer:9.95e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 715.9	Expressed in all		
MDH1B	FLJ25341, RP11-95H11	ENSG00000138400	Malate dehydrogenase 1B	2	206737763-206765547	Predicted intracellular proteins	Evidence at transcript level	HPA073761	Approved					Mixed	Group enriched	5	fallopian tube: 35.3;testis: 43.8	parathyroid gland: 7.5	Cell line enhanced		SCLC-21H: 4.0
MDH2		ENSG00000146701	Malate dehydrogenase 2	7	76048051-76067508	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019714, HPA019716, HPA019848, HPA026720	Enhanced		Enhanced	Mitochondria	Renal cancer:1.49e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 233.2	Expressed in all		
MDM2	HDM2, MGC5370	ENSG00000135679	MDM2 proto-oncogene	12	68808176-68850686	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000086, CAB016303	Supported		Supported	Nucleus	Endometrial cancer:4.51e-7 (favourable), Cervical cancer:3.23e-4 (favourable)	Expressed in all	Expressed in all			rectum: 33.9	Expressed in all		
MDM4	HDMX, MDMX	ENSG00000198625	MDM4, p53 regulator	1	204516379-204558120	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA018919, HPA048821	Approved		Supported	Nucleus	Renal cancer:7.06e-6 (unfavourable), Urothelial cancer:2.49e-4 (favourable), Prostate cancer:9.87e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 37.5	Expressed in all		
MDN1	KIAA0301, Rea1	ENSG00000112159	Midasin AAA ATPase 1	6	89642499-89819723	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029666, HPA029667, HPA029668, HPA029669	Uncertain		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 13.4	Expressed in all		
MDP1	FN6Pase, MGC5987	ENSG00000213920	Magnesium dependent phosphatase 1	14	24213937-24216070	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003064, HPA070338	Uncertain		Approved	Nucleoplasm	Renal cancer:5.96e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 20.3	Mixed		
MDS2		ENSG00000197880	Myelodysplastic syndrome 2 translocation associated	1	23581495-23640568	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA052999	Uncertain					Tissue enhanced	Tissue enhanced		lymph node: 7.7;tonsil: 4.0	spleen: 2.9	Cell line enhanced		Daudi: 1.0;U-266/70: 1.0;U-698: 3.4
ME1		ENSG00000065833	Malic enzyme 1	6	83210389-83431071	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006493	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.81e-7 (unfavourable), Liver cancer:4.57e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 54.1	Cell line enhanced		CACO-2: 113.5
ME2		ENSG00000082212	Malic enzyme 2	18	50878734-50954257	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008247, HPA008880	Enhanced		Enhanced	Mitochondria	Liver cancer:8.29e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 39.2	Expressed in all		
ME3		ENSG00000151376	Malic enzyme 3	11	86441108-86672636	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038473	Approved				Urothelial cancer:3.86e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.7	Cell line enhanced		CAPAN-2: 44.6;TIME: 30.7
MEA1	MEA	ENSG00000124733	Male-enhanced antigen 1	6	43012094-43013968	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017921	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.29e-6 (unfavourable), Ovarian cancer:3.37e-4 (favourable)	Expressed in all	Expressed in all			testis: 246.1	Expressed in all		
MEAF6	C1orf149, CENP-28, Eaf6, FLJ11730, NY-SAR-91	ENSG00000163875	MYST/Esa1 associated factor 6	1	37492575-37514774	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			prostate: 139.9	Expressed in all		
MECOM	EVI1, KMT8E, MDS1, MDS1-EVI1, PRDM3	ENSG00000085276	MDS1 and EVI1 complex locus	3	169083499-169663618	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046537	Supported		Supported	Nuclear speckles	Pancreatic cancer:2.59e-4 (unfavourable)	Mixed	Mixed			stomach: 67.3	Cell line enhanced		HUVEC TERT2: 48.0;RPTEC TERT1: 55.1;RT4: 94.4;TIME: 45.0
MECP2	MRX16, MRX79, RTT	ENSG00000169057	Methyl-CpG binding protein 2	X	154021573-154137103	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000593, HPA001341, CAB037264	Enhanced		Supported	Nucleus	Renal cancer:7.32e-9 (favourable), Endometrial cancer:8.35e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.7	Expressed in all		
MECR	CGI-63, ETR1, FASN2B, NRBF1	ENSG00000116353	Mitochondrial trans-2-enoyl-CoA reductase	1	29192873-29230942	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022018, HPA022030, HPA028740	Enhanced		Supported	Mitochondria	Renal cancer:5.81e-6 (favourable), Urothelial cancer:5.29e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 18.4	Expressed in all		
MED1	CRSP1, CRSP200, DRIP230, PBP, PPARBP, PPARGBP, RB18A, TRAP220, TRIP2	ENSG00000125686	Mediator complex subunit 1	17	39404285-39451286	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017696, HPA052818	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 56.7	Expressed in all		
MED10	L6, MGC5309, NUT2, TRG20	ENSG00000133398	Mediator complex subunit 10	5	6371881-6378594	Predicted intracellular proteins	Evidence at protein level	HPA042795, HPA054188			Supported	Nucleoplasm	Liver cancer:1.62e-6 (unfavourable), Renal cancer:2.19e-5 (unfavourable), Glioma:4.81e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 44.7	Expressed in all		
MED11	HSPC296, MGC88387	ENSG00000161920	Mediator complex subunit 11	17	4731428-4733610	Predicted intracellular proteins	Evidence at protein level	HPA056669	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:1.86e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.9	Expressed in all		
MED12	CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230	ENSG00000184634	Mediator complex subunit 12	X	71118556-71142454	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003184, HPA003185	Enhanced		Approved	Nucleoplasm		Expressed in all	Expressed in all			ovary: 26.8	Expressed in all		
MED12L	KIAA1635, TNRC11L, TRALP, TRALPUSH	ENSG00000144893	Mediator complex subunit 12 like	3	151085697-151437072	Predicted intracellular proteins	Evidence at protein level	HPA036807	Uncertain		Approved	Nucleoli		Mixed	Tissue enhanced		cerebral cortex: 26.6	testis: 8.5	Cell line enhanced		BEWO: 17.8;HEL: 18.7
MED13	KIAA0593, THRAP1, TRAP240	ENSG00000108510	Mediator complex subunit 13	17	61942605-62065282	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA067939			Supported	Nucleus	Colorectal cancer:1.43e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland,testis: 35.7	Expressed in all		
MED13L	KIAA1025, THRAP2, TRAP240L	ENSG00000123066	Mediator complex subunit 13 like	12	115953872-116277338	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039445	Uncertain		Approved	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			bone marrow: 35.9	Expressed in all		
MED14	CRSP150, CRSP2, CSRP, CXorf4, EXLM1, RGR1, TRAP170	ENSG00000180182	Mediator complex subunit 14	X	40648306-40735858	Predicted intracellular proteins	Evidence at protein level	HPA064182			Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 32.3	Expressed in all		
MED15	Arc105, CAG7A, PCQAP, TIG-1, TNRC7	ENSG00000099917	Mediator complex subunit 15	22	20495913-20587632	Predicted intracellular proteins	Evidence at protein level	HPA003179	Approved		Supported	Nucleus	Endometrial cancer:7.30e-5 (favourable), Renal cancer:1.61e-4 (unfavourable), Liver cancer:3.71e-4 (unfavourable), Pancreatic cancer:9.09e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 43.5	Expressed in all		
MED16	DRIP92, THRAP5, TRAP95	ENSG00000175221	Mediator complex subunit 16	19	867630-893218	Predicted intracellular proteins	Evidence at protein level	HPA030685, HPA046495	Uncertain		Approved	Nucleoli	Renal cancer:1.11e-5 (favourable), Endometrial cancer:5.46e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 28.9	Expressed in all		
MED18	FLJ20045, p28b	ENSG00000130772	Mediator complex subunit 18	1	28329002-28335967	Predicted intracellular proteins	Evidence at protein level	HPA027429	Uncertain		Approved	Nucleoplasm	Renal cancer:8.38e-5 (favourable), Liver cancer:1.52e-4 (unfavourable), Endometrial cancer:3.93e-4 (favourable), Stomach cancer:6.72e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 13.2	Expressed in all		
MED19	LCMR1	ENSG00000156603	Mediator complex subunit 19	11	57703714-57712323	Predicted intracellular proteins	Evidence at protein level	HPA039912, HPA040860	Uncertain		Supported	Nucleus<br>Nuclear bodies	Liver cancer:1.34e-6 (unfavourable), Ovarian cancer:1.76e-6 (favourable)	Expressed in all	Expressed in all			testis: 28.6	Expressed in all		
MED21	SRB7, SURB7	ENSG00000152944	Mediator complex subunit 21	12	27022546-27066343	Predicted intracellular proteins	Evidence at protein level	HPA017177	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.74e-8 (favourable)	Expressed in all	Expressed in all			testis: 69.4	Expressed in all		
MED22	Med24, SURF5	ENSG00000148297	Mediator complex subunit 22	9	133338323-133348131	Predicted intracellular proteins	Evidence at protein level	HPA020391, HPA063694	Uncertain		Approved	Nucleoplasm	Renal cancer:3.76e-11 (favourable), Liver cancer:5.16e-6 (unfavourable), Pancreatic cancer:6.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 10.9	Expressed in all		
MED25	ACID1, ARC92, DKFZp434K0512, TCBAP0758	ENSG00000104973	Mediator complex subunit 25	19	49818279-49838816	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA068802			Supported	Nucleoplasm	Head and neck cancer:9.85e-4 (favourable)	Expressed in all	Expressed in all			testis: 111.2	Expressed in all		
MED26	CRSP7, CRSP70	ENSG00000105085	Mediator complex subunit 26	19	16574907-16629062	Predicted intracellular proteins	Evidence at protein level	HPA057997, HPA071835	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:5.50e-5 (unfavourable), Cervical cancer:2.46e-4 (favourable)	Expressed in all	Tissue enriched	6	testis: 42.0	bone marrow: 6.8	Expressed in all		
MED27	CRSP34, CRSP8, MED3, TRAP37	ENSG00000160563	Mediator complex subunit 27	9	131860107-132079908	Predicted intracellular proteins	Evidence at protein level	HPA007002	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Cervical cancer:1.59e-4 (favourable)	Expressed in all	Expressed in all			testis: 29.2	Expressed in all		
MED28	DKFZP434N185, EG1, magicin	ENSG00000118579	Mediator complex subunit 28	4	17614631-17634105	Predicted intracellular proteins	Evidence at protein level	HPA035900, HPA035901	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			endometrium: 19.0	Expressed in all		
MED29	DKFZp434H247, IXL, MED2	ENSG00000063322	Mediator complex subunit 29	19	39391303-39400637	Predicted intracellular proteins	Evidence at protein level	HPA055956			Supported	Nucleoplasm	Renal cancer:5.15e-5 (favourable), Endometrial cancer:7.27e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 64.5	Expressed in all		
MED30	THRAP6, TRAP25	ENSG00000164758	Mediator complex subunit 30	8	117520713-117540262	Predicted intracellular proteins	Evidence at protein level	HPA045767			Approved	Nucleoplasm	Renal cancer:1.70e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 27.8	Expressed in all		
MED31	CGI-125, Soh1	ENSG00000108590	Mediator complex subunit 31	17	6643315-6651634	Predicted intracellular proteins	Evidence at protein level	HPA035947	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			epididymis: 32.2	Expressed in all		
MED4	DRIP36, HSPC126, TRAP36, VDRIP	ENSG00000136146	Mediator complex subunit 4	13	48053323-48095131	Predicted intracellular proteins	Evidence at protein level	HPA006232	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 103.5	Expressed in all		
MED6	NY-REN-28	ENSG00000133997	Mediator complex subunit 6	14	70581257-70600690	Predicted intracellular proteins	Evidence at protein level	HPA030764, HPA069039	Approved		Enhanced	Nucleoplasm	Liver cancer:1.04e-4 (unfavourable), Melanoma:2.75e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 28.6	Expressed in all		
MED7	CRSP33, CRSP9	ENSG00000155868	Mediator complex subunit 7	5	157137412-157159019	Predicted intracellular proteins	Evidence at protein level	HPA067181			Supported	Nuclear bodies	Liver cancer:2.37e-5 (unfavourable), Renal cancer:8.69e-5 (favourable)	Expressed in all	Expressed in all			testis: 46.7	Expressed in all		
MED8	ARC32, MGC17544, MGC19641	ENSG00000159479	Mediator complex subunit 8	1	43383917-43389808	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028377, HPA028438	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.11e-7 (unfavourable), Liver cancer:2.04e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 41.6	Expressed in all		
MED9	FLJ10193, MED25	ENSG00000141026	Mediator complex subunit 9	17	17476986-17493226	Predicted intracellular proteins	Evidence at protein level	HPA056415	Uncertain		Approved	Nucleoplasm<br>Midbody	Renal cancer:2.83e-9 (favourable), Pancreatic cancer:4.18e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
MEDAG	AWMS3, C13orf33, FLJ14834, MEDA-4	ENSG00000102802	Mesenteric estrogen dependent adipogenesis	13	30906191-30925572	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:3.29e-5 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 153.5	smooth muscle: 32.2	Cell line enhanced		ASC diff: 206.4;ASC TERT1: 58.9;U-2197: 157.4
MEF2A	RSRFC4, RSRFC9	ENSG00000068305	Myocyte enhancer factor 2A	15	99565417-99716466	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004499, HPA046597	Approved		Supported	Nucleoplasm	Renal cancer:6.93e-4 (favourable), Stomach cancer:7.96e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 68.5	Expressed in all		
MEF2B	RSRFR2	ENSG00000213999	Myocyte enhancer factor 2B	19	19145568-19170289	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004734	Supported					Not detected	Group enriched	9	appendix: 17.6;lymph node: 45.7;tonsil: 27.2	spleen: 3.2	Group enriched	12	Daudi: 157.3;U-266/70: 161.9;U-698: 199.1
MEF2C		ENSG00000081189	Myocyte enhancer factor 2C	5	88717117-88904257	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005533, CAB068196, CAB068197	Enhanced		Supported	Nucleoplasm<br>Vesicles	Renal cancer:1.01e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 197.9	Cell line enhanced		HEL: 205.2;REH: 238.4;WM-115: 143.4
MEF2D		ENSG00000116604	Myocyte enhancer factor 2D	1	156463727-156500828	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004807, HPA007114	Enhanced		Enhanced	Nucleoplasm	Renal cancer:7.53e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 55.5	Expressed in all		
MEFV	FMF, MEF, TRIM20	ENSG00000103313	MEFV, pyrin innate immunity regulator	16	3242028-3256627	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 8.1;spleen: 7.0	bone marrow: 4.2	Cell line enhanced		THP-1: 4.4
MEIG1	bA2K17.3, SPATA39	ENSG00000197889	Meiosis/spermiogenesis associated 1	10	14959439-14988050	Predicted intracellular proteins	Evidence at transcript level	HPA044594	Uncertain					Mixed	Group enriched	12	fallopian tube: 6.7;testis: 13.0	cerebral cortex: 0.8	Cell line enhanced		HDLM-2: 5.1
MEIKIN		ENSG00000239642	Meiotic kinetochore factor	5	131806993-131945698	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	19	testis: 13.4	parathyroid gland: 0.7	Cell line enriched	8	U-2 OS: 1.6
MEIOB	C16orf73, MGC35212	ENSG00000162039	Meiosis specific with OB domains	16	1833983-1884294	Predicted intracellular proteins	Evidence at protein level	HPA042547			Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	61	testis: 71.4	kidney: 1.1	Group enriched	5	HMC-1: 24.7;K-562: 85.3;THP-1: 55.0
MEIOC	C17orf104, FLJ35848	ENSG00000180336	Meiosis specific with coiled-coil domain	17	44656404-44690308	Predicted intracellular proteins	Evidence at protein level	HPA027266	Enhanced		Uncertain	Cell Junctions		Not detected	Tissue enriched	52	testis: 86.2	cerebral cortex: 1.6	Cell line enhanced		HAP1: 17.4;HMC-1: 22.4;SiHa: 10.1
MEIS2	HsT18361, MRG1	ENSG00000134138	Meis homeobox 2	15	36889204-37101299	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003256, CAB004999	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.64e-7 (unfavourable)	Mixed	Mixed			endometrium: 63.5	Cell line enhanced		fHDF/TERT166: 89.3;SH-SY5Y: 111.8
MEN1		ENSG00000133895	Menin 1	11	64803510-64811294	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030342	Uncertain		Supported	Nucleoplasm<br>Cytosol	Stomach cancer:6.31e-5 (favourable), Liver cancer:1.08e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 22.3	Expressed in all		
MEOX1	MOX1	ENSG00000005102	Mesenchyme homeobox 1	17	43640388-43661954	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045214	Uncertain		Uncertain	Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		adipose tissue: 25.3	spleen: 16.4	Cell line enriched	10	HeLa: 16.8
MEOX2	GAX, MOX2	ENSG00000106511	Mesenchyme homeobox 2	7	15611212-15686812	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053793	Enhanced					Tissue enriched	Tissue enhanced		adipose tissue: 28.5;placenta: 57.7	lung: 10.8	Cell line enhanced		AN3-CA: 217.5;SCLC-21H: 37.0;U-138 MG: 58.7
MEPCE	BCDIN3, FLJ20257, MePCE	ENSG00000146834	Methylphosphate capping enzyme	7	100428790-100434126	Predicted intracellular proteins	Evidence at protein level	CAB026384, HPA051587	Supported		Approved	Nucleoplasm<br>Cell Junctions	Renal cancer:1.01e-10 (favourable), Endometrial cancer:6.01e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 87.8	Expressed in all		
MESDC1	MGC99595	ENSG00000140406	Mesoderm development candidate 1	15	81000944-81005788	Predicted intracellular proteins	Evidence at protein level	HPA071716			Approved	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:1.87e-7 (unfavourable), Lung cancer:1.47e-5 (unfavourable)	Expressed in all	Mixed			spleen: 14.3	Expressed in all		
MESP1	bHLHc5, MGC10676	ENSG00000166823	Mesoderm posterior bHLH transcription factor 1	15	89748661-89751310	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069981			Supported	Nucleus<br>Nucleoli		Group enriched	Tissue enhanced		adipose tissue: 4.8;prostate: 4.8	cerebral cortex: 1.4	Cell line enhanced		A-431: 3.1;HDLM-2: 2.9;HEK93: 2.7;PC-3: 5.2;SCLC-21H: 3.0
MESP2	bHLHc6, SCDO2	ENSG00000188095	Mesoderm posterior bHLH transcription factor 2	15	89760591-89778754	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Mixed			cervix, uterine: 1.2	Cell line enhanced		U-2197: 4.2
METAP1	KIAA0094, MAP1A, MetAP1A	ENSG00000164024	Methionyl aminopeptidase 1	4	98995620-99062813	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025485, HPA037997, HPA037998	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.28e-5 (unfavourable), Liver cancer:3.08e-5 (unfavourable), Renal cancer:1.72e-4 (favourable), Colorectal cancer:7.22e-4 (favourable), Urothelial cancer:9.31e-4 (favourable)	Expressed in all	Expressed in all			testis: 77.3	Expressed in all		
METAP1D	MAP1D, Metap1l	ENSG00000172878	Methionyl aminopeptidase type 1D, mitochondrial	2	171999583-172082430	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030298, HPA030299	Uncertain		Supported	Vesicles		Expressed in all	Mixed			ovary: 9.3	Expressed in all		
METAP2	MAP2, MNPEP, p67	ENSG00000111142	Methionyl aminopeptidase 2	12	95473520-95515839	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013025, HPA019095	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:4.51e-6 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 142.4	Expressed in all		
METTL1	C12orf1, TRM8, TRMT8	ENSG00000037897	Methyltransferase like 1	12	57768471-57772793	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020914, HPA050450	Uncertain		Enhanced	Nucleus	Renal cancer:3.55e-6 (unfavourable), Liver cancer:4.25e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 22.8	Cell line enriched	6	RH-30: 242.6
METTL10	C10orf138, Em:AC068896.3	ENSG00000203791	Methyltransferase like 10	10	124748149-124791870	Predicted intracellular proteins	Evidence at protein level	HPA050138	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Thyroid cancer:2.53e-4 (unfavourable), Prostate cancer:4.82e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 15.1	Expressed in all		
METTL11B	C1orf184, HOMT1B	ENSG00000203740	Methyltransferase like 11B	1	170146001-170167790	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028049	Uncertain					Not detected	Tissue enhanced		heart muscle: 1.5	skeletal muscle,testis: 0.4	Cell line enriched	13	NTERA-2: 1.7
METTL12	U99HG	ENSG00000214756	Methyltransferase like 12	11	62665309-62668496	Predicted intracellular proteins	Evidence at transcript level	HPA038115, HPA038533	Uncertain				Breast cancer:8.73e-4 (favourable)	Expressed in all	Not detected			fallopian tube: 0.8	Mixed		
METTL13	CGI-01, KIAA0859	ENSG00000010165	Methyltransferase like 13	1	171781664-171814023	Predicted intracellular proteins	Evidence at protein level	HPA044498, HPA053705	Approved		Approved	Cytosol	Liver cancer:5.68e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.7	Expressed in all		
METTL14	KIAA1627	ENSG00000145388	Methyltransferase like 14	4	118685368-118715433	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038002	Supported		Supported	Nucleoplasm	Renal cancer:1.46e-5 (favourable)	Expressed in all	Expressed in all			testis: 23.5	Expressed in all		
METTL15	FLJ33979, METT5D1	ENSG00000169519	Methyltransferase like 15	11	28108248-28527041	Predicted intracellular proteins	Evidence at protein level	HPA039885			Approved	Golgi apparatus<br>Plasma membrane<br>Actin filaments	Renal cancer:7.95e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 14.7	Expressed in all		
METTL16	METT10D, MGC3329	ENSG00000127804	Methyltransferase like 16	17	2405562-2511891	Predicted intracellular proteins	Evidence at protein level	HPA020352, HPA059798	Uncertain		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.06e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.4	Expressed in all		
METTL18	AsTP2, C1orf156, HPM1, MGC9084	ENSG00000171806	Methyltransferase like 18	1	169792529-169794966	Predicted intracellular proteins	Evidence at protein level	HPA035314	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.01e-4 (unfavourable), Urothelial cancer:3.28e-4 (favourable), Renal cancer:4.06e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 44.5	lymph node: 15.3	Expressed in all		
METTL21B	DKFZP586D0919, FAM119B	ENSG00000123427	Methyltransferase like 21B	12	57771492-57782541	Predicted intracellular proteins	Evidence at protein level	HPA043020	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 16.8	Cell line enriched	9	RH-30: 142.0
METTL21C	C13orf39, LOC196541	ENSG00000139780	Methyltransferase like 21C	13	102685744-102694504	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	13	epididymis: 42.2	seminal vesicle: 3.1	Not detected		
METTL22	C16orf68, FLJ12433, MGC2654	ENSG00000067365	Methyltransferase like 22	16	8621683-8649654	Predicted intracellular proteins	Evidence at protein level	HPA040803, HPA059882, HPA074173	Uncertain		Supported	Nucleus<br>Nucleoli	Renal cancer:2.79e-8 (unfavourable)	Expressed in all	Mixed			testis: 15.9	Expressed in all		
METTL23	C17orf95, LOC124512	ENSG00000181038	Methyltransferase like 23	17	76726830-76733936	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.93e-7 (unfavourable), Liver cancer:4.18e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 86.1	Expressed in all		
METTL25	C12orf26, FLJ22789	ENSG00000127720	Methyltransferase like 25	12	82358497-82479236	Predicted intracellular proteins	Evidence at protein level	HPA039534, HPA041207	Uncertain		Uncertain	Plasma membrane<br>Mitochondria<br>Cytosol		Expressed in all	Mixed			testis: 10.9	Mixed		
METTL26	C16orf13, MGC13114	ENSG00000130731	Methyltransferase like 26	16	634427-636366	Predicted intracellular proteins	Evidence at protein level	HPA044004	Uncertain				Renal cancer:1.73e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 43.0	Expressed in all		
METTL2A	FLJ12760, METTL2	ENSG00000087995	Methyltransferase like 2A	17	62423867-62450822	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:2.31e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 9.0	Expressed in all		
METTL3	M6A, MT-A70, Spo8	ENSG00000165819	Methyltransferase like 3	14	21498133-21511375	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:2.19e-5 (unfavourable), Pancreatic cancer:2.72e-4 (favourable), Ovarian cancer:2.78e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.5	Expressed in all		
METTL4	FLJ23017, HsT661	ENSG00000101574	Methyltransferase like 4	18	2537525-2571509	Predicted intracellular proteins	Evidence at protein level	HPA040061, HPA046734	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 17.3	Expressed in all		
METTL5	HSPC133	ENSG00000138382	Methyltransferase like 5	2	169810081-169824931	Predicted intracellular proteins	Evidence at protein level	HPA038223	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:3.06e-8 (unfavourable), Liver cancer:6.64e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 76.8	Expressed in all		
METTL6	MGC24132	ENSG00000206562	Methyltransferase like 6	3	15381275-15440566	Predicted intracellular proteins	Evidence at protein level	HPA035166	Uncertain		Approved	Vesicles	Liver cancer:2.66e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 33.8	Expressed in all		
METTL8	FLJ13984, TIP	ENSG00000123600	Methyltransferase like 8	2	171317405-171434802	Predicted intracellular proteins	Evidence at protein level	HPA035421	Uncertain		Approved	Cytosol	Endometrial cancer:2.00e-4 (unfavourable), Renal cancer:6.75e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 14.7	Expressed in all		
MEX3A	RKHD4	ENSG00000254726	Mex-3 RNA binding family member A	1	156072013-156081998	Predicted intracellular proteins	Evidence at protein level	HPA062703			Supported	Cytosol	Liver cancer:9.23e-8 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 5.9;ovary: 5.9	cerebral cortex: 4.1	Cell line enhanced		AF22: 63.9;NTERA-2: 58.9;SCLC-21H: 71.7;SH-SY5Y: 117.8
MEX3B	DKFZp434J0617, RKHD3, RNF195	ENSG00000183496	Mex-3 RNA binding family member B	15	82041778-82046141	Predicted intracellular proteins	Evidence at protein level	HPA041093	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 41.6	endometrium: 10.1	Cell line enhanced		AN3-CA: 58.8;HEL: 43.1
MEX3D	KIAA2031, OK/SW-cl.4, RKHD1, RNF193, Tino	ENSG00000181588	Mex-3 RNA binding family member D	19	1554669-1568058	Predicted intracellular proteins	Evidence at protein level	HPA065385	Approved					Expressed in all	Mixed			testis: 17.7	Expressed in all		
MFAP1		ENSG00000140259	Microfibrillar associated protein 1	15	43804492-43824802	Predicted intracellular proteins	Evidence at protein level	HPA042370	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.04e-9 (favourable), Liver cancer:2.50e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.2	Expressed in all		
MFHAS1	LRRC65, MASL1	ENSG00000147324	Malignant fibrous histiocytoma amplified sequence 1	8	8783354-8893645	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051213, HPA054471	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			spleen: 16.6	Cell line enhanced		MOLT-4: 111.7
MGEA5	MEA5, NCOAT, OGA	ENSG00000198408	Meningioma expressed antigen 5 (hyaluronidase)	10	101784443-101818465	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036141, HPA076501	Approved		Supported	Cytosol	Colorectal cancer:8.69e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 129.4	Expressed in all		
MGLL	HU-K5, MGL	ENSG00000074416	Monoglyceride lipase	3	127689062-127823250	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011348, HPA011993, HPA011994	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:6.41e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 188.3	Cell line enhanced		BJ hTERT+: 193.8
MGME1	bA504H3.4, C20orf72, DDK1	ENSG00000125871	Mitochondrial genome maintenance exonuclease 1	20	17968913-17991122	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040913	Approved		Supported	Mitochondria	Liver cancer:6.98e-8 (unfavourable), Renal cancer:1.13e-7 (unfavourable)	Expressed in all	Expressed in all			skin: 39.7	Expressed in all		
MGMT		ENSG00000170430	O-6-methylguanine-DNA methyltransferase	10	129467184-129768007	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002786, HPA032135, HPA032136, HPA069497, CAB069881	Supported		Enhanced	Nucleoplasm	Liver cancer:1.54e-4 (favourable), Cervical cancer:9.42e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 26.1	Mixed		
MGRN1	KIAA0544, RNF156	ENSG00000102858	Mahogunin ring finger 1	16	4616493-4690974	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007653	Approved					Expressed in all	Expressed in all			cerebral cortex: 56.4	Expressed in all		
MIB1	DIP-1, KIAA1323, MIB, ZZANK2, ZZZ6	ENSG00000101752	Mindbomb E3 ubiquitin protein ligase 1	18	21704957-21870957	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019100, CAB037044	Approved		Approved	Nuclear membrane<br>Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 24.2	Expressed in all		
MIB2	FLJ39787, skeletrophin, ZZANK1, ZZZ5	ENSG00000197530	Mindbomb E3 ubiquitin protein ligase 2	1	1615415-1630610	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA068322	Enhanced					Expressed in all	Tissue enhanced		skeletal muscle: 12.4	cerebral cortex: 4.4	Cell line enhanced		SCLC-21H: 18.4
MICAL1	DKFZp434B1517, FLJ11937, FLJ21739, MICAL, NICAL	ENSG00000135596	Microtubule associated monooxygenase, calponin and LIM domain containing 1	6	109444062-109465968	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030175, HPA030176, HPA030178	Approved				Pancreatic cancer:2.63e-7 (favourable), Renal cancer:6.71e-7 (unfavourable)	Expressed in all	Mixed			bone marrow: 39.5	Cell line enhanced		THP-1: 95.6
MICALCL	FLJ14966	ENSG00000133808	MICAL C-terminal like	11	12276080-12359144	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039895, HPA040438	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		skin: 17.3;testis: 13.4	lung: 10.3	Cell line enhanced		HBEC3-KT: 18.3;RT4: 12.1;U-2 OS: 9.9
MICALL1	KIAA1668, MICAL-L1, MIRAB13	ENSG00000100139	MICAL like 1	22	37905657-37942822	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043480, HPA051956	Uncertain		Supported	Cell Junctions<br>Microtubule organizing center<br>Cytosol	Liver cancer:3.08e-6 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 51.2	Expressed in all		
MICALL2	FLJ23471, JRAB, MGC46023, MICAL-L2	ENSG00000164877	MICAL like 2	7	1428465-1459502	Predicted intracellular proteins	Evidence at protein level	HPA025695	Enhanced				Renal cancer:6.53e-9 (unfavourable)	Expressed in all	Mixed			small intestine: 17.5	Cell line enhanced		HMC-1: 23.3
MICU2	EFHA1	ENSG00000165487	Mitochondrial calcium uptake 2	13	21492691-21604214	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045511, HPA058790	Approved		Approved	Nucleus<br>Mitochondria	Renal cancer:1.40e-7 (favourable)	Expressed in all	Expressed in all			kidney: 78.5	Expressed in all		
MID1IP1	FLJ10386, G12-like, MIG12, STRAIT11499, THRSPL	ENSG00000165175	MID1 interacting protein 1	X	38801432-38806537	Predicted intracellular proteins	Evidence at protein level	HPA038816	Uncertain				Renal cancer:1.15e-4 (favourable), Liver cancer:2.20e-4 (unfavourable), Urothelial cancer:8.06e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 66.2	Expressed in all		
MID2	FXY2, MRX101, RNF60, TRIM1	ENSG00000080561	Midline 2	X	107825755-107927193	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Stomach cancer:3.73e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 23.4	Cell line enhanced		HUVEC TERT2: 34.7;Karpas-707: 25.8
MIDN		ENSG00000167470	Midnolin	19	1248553-1259140	Predicted intracellular proteins	Evidence at protein level	HPA042018, HPA049432	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 51.5	Expressed in all		
MIEN1	C17orf37, C35, MGC14832, ORB3, Rdx12, XTP4	ENSG00000141741	Migration and invasion enhancer 1	17	39728496-39730787	Predicted intracellular proteins	Evidence at protein level	HPA061344	Approved					Expressed in all	Expressed in all			prostate: 41.0	Cell line enriched	5	SK-BR-3: 451.5
MIER2	KIAA1193	ENSG00000105556	MIER family member 2	19	301444-344815	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041439	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.22e-6 (unfavourable), Endometrial cancer:1.72e-5 (favourable), Colorectal cancer:2.89e-4 (unfavourable)	Expressed in all	Mixed			testis: 12.8	Mixed		
MIER3	DKFZp686L09111, DKFZp781I1119, FLJ35954	ENSG00000155545	MIER family member 3	5	56919602-56971675	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058349, HPA065946	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			colon: 30.2	Expressed in all		
MIF	GIF, GLIF	ENSG00000240972	Macrophage migration inhibitory factor (glycosylation-inhibiting factor)	22	23894004-23895227	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003868, CAB005284	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			prostate: 41.3	Expressed in all		
MIF4GD	AD023, MGC45027, MIFD, SLIP1	ENSG00000125457	MIF4G domain containing	17	75266228-75271227	Predicted intracellular proteins	Evidence at protein level	HPA051222	Approved		Supported	Nucleoli<br>Cytosol	Pancreatic cancer:2.70e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 45.8	Expressed in all		
MIIP	FLJ12438, IIp45	ENSG00000116691	Migration and invasion inhibitory protein	1	12019466-12032045	Predicted intracellular proteins	Evidence at protein level	HPA044948	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:8.26e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 27.4	Cell line enriched	8	HDLM-2: 334.7
MINDY1	FAM63A, FLJ11280, MINDY-1	ENSG00000143409	MINDY lysine 48 deubiquitinase 1	1	150996086-151008375	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028351, HPA028358, HPA061086	Approved		Supported	Nucleoplasm	Renal cancer:3.43e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 79.1	Cell line enhanced		T-47d: 46.6
MINDY2	FAM63B, KIAA1164	ENSG00000128923	MINDY lysine 48 deubiquitinase 2	15	58771192-58861900	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051103, HPA063669	Approved		Enhanced	Nucleoplasm	Renal cancer:3.00e-8 (favourable)	Expressed in all	Mixed			thyroid gland: 16.3	Expressed in all		
MINDY3	C10orf97, CARP, DERP5, FAM188A, FLJ13397, my042	ENSG00000148481	MINDY lysine 48 deubiquitinase 3	10	15778170-15860520	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038400, HPA038406	Uncertain		Supported	Nucleoplasm<br>Nuclear membrane		Expressed in all	Expressed in all			testis: 39.2	Expressed in all		
MINDY4	C7orf67, FAM188B, FLJ22374	ENSG00000106125	MINDY lysine 48 deubiquitinase 4	7	30771417-30892387	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019475, HPA030129, HPA030130	Approved		Supported	Vesicles<br>Cytosol		Mixed	Mixed			fallopian tube: 18.6	Cell line enhanced		K-562: 17.1
MINDY4B	C3orf76, FAM188B2	ENSG00000214237	MINDY family member 4B	3	150871045-150905439	Predicted intracellular proteins	No evidence							Not detected	Not detected			endometrium: 0.6	Not detected		
MINK1	B55, MAP4K6, MINK, YSK2, ZC3	ENSG00000141503	Misshapen like kinase 1	17	4833388-4898061	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056296	Approved				Pancreatic cancer:2.77e-4 (favourable), Liver cancer:3.00e-4 (unfavourable), Prostate cancer:9.27e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.5	Expressed in all		
MIOS	FLJ20323, MIO, Sea4	ENSG00000164654	Meiosis regulator for oocyte development	7	7566872-7608929	Predicted intracellular proteins	Evidence at protein level	HPA042928, HPA052223	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.28e-6 (favourable), Endometrial cancer:6.51e-4 (favourable), Liver cancer:9.14e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 54.8	Expressed in all		
MIOX	ALDRL6	ENSG00000100253	Myo-inositol oxygenase	22	50486784-50490648	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039451, HPA039562	Enhanced				Renal cancer:2.60e-6 (favourable)	Tissue enriched	Tissue enriched	30	kidney: 821.5	thyroid gland: 26.9	Cell line enhanced		HDLM-2: 23.3;Karpas-707: 9.3;U-266/70: 5.9
MIPEP	MIP	ENSG00000027001	Mitochondrial intermediate peptidase	13	23730189-23889419	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030676, HPA031669, HPA031670	Approved		Enhanced	Mitochondria	Renal cancer:7.66e-12 (favourable)	Expressed in all	Expressed in all			fallopian tube: 27.4	Expressed in all		
MIPOL1	CCDC193	ENSG00000151338	Mirror-image polydactyly 1	14	37197913-37552361	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002893, HPA050179	Enhanced		Approved	Cytosol		Mixed	Mixed			testis: 13.9	Cell line enhanced		HUVEC TERT2: 20.9
MIS12	hMIS12, KNTC2AP, MGC2488, MTW1	ENSG00000167842	MIS12, kinetochore complex component	17	5486285-5490814	Predicted intracellular proteins	Evidence at protein level	HPA044482	Approved				Pancreatic cancer:8.00e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 38.6	Expressed in all		
MIS18A	B28, C21orf45, C21orf46, FASP1, hMis18alpha	ENSG00000159055	MIS18 kinetochore protein A	21	32268219-32279069	Predicted intracellular proteins	Evidence at protein level	HPA018286, HPA020585	Enhanced		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 38.8	Expressed in all		
MIS18BP1	C14orf106, FLJ11186, KIAA1903, KNL2, M18BP1	ENSG00000129534	MIS18 binding protein 1	14	45203190-45253540	Predicted intracellular proteins	Evidence at protein level	HPA006504	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:3.83e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 25.9	Expressed in all		
MISP	C19orf21, Caprice, DKFZp686H18209, MISP1	ENSG00000099812	Mitotic spindle positioning	19	751126-764318	Predicted intracellular proteins	Evidence at protein level	HPA049511, HPA062232	Enhanced		Enhanced	Plasma membrane<br>Focal adhesion sites		Tissue enhanced	Group enriched	6	colon: 94.7;duodenum: 173.3;rectum: 52.6;small intestine: 217.1	stomach: 21.6	Cell line enhanced		A549: 110.0;HaCaT: 79.4;hTCEpi: 59.7;SK-BR-3: 101.1
MISP3		ENSG00000141854	MISP family member 3	19	14072536-14075062	Predicted intracellular proteins	Evidence at protein level	HPA042225	Uncertain				Stomach cancer:3.11e-5 (favourable), Renal cancer:9.52e-4 (favourable)	Expressed in all	Mixed			small intestine: 8.5	Cell line enhanced		Karpas-707: 7.7;RPMI-8226: 8.7
MITD1	LOC129531	ENSG00000158411	Microtubule interacting and trafficking domain containing 1	2	99161427-99181058	Predicted intracellular proteins	Evidence at protein level	HPA036162, HPA036163	Approved		Enhanced	Vesicles	Renal cancer:1.32e-11 (unfavourable), Urothelial cancer:5.46e-8 (favourable), Liver cancer:1.47e-6 (unfavourable), Breast cancer:5.96e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 42.2	Expressed in all		
MITF	bHLHe32, MI, WS2, WS2A	ENSG00000187098	Melanogenesis associated transcription factor	3	69739435-69968337	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002578, HPA003259	Enhanced				Renal cancer:8.35e-10 (favourable)	Group enriched	Tissue enhanced		cervix, uterine: 80.9;endometrium: 79.3	smooth muscle: 69.5	Cell line enhanced		HMC-1: 78.7;SK-MEL-30: 205.7
MIXL1	MILD1, MIXL	ENSG00000185155	Mix paired-like homeobox	1	226223618-226227054	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005662			Approved	Nucleus		Tissue enriched	Tissue enhanced		tonsil: 3.0	lymph node: 2.8	Cell line enhanced		HAP1: 1.7;Hep G2: 5.7;U-698: 1.5
MKI67	MIB-, PPP1R105	ENSG00000148773	Marker of proliferation Ki-67	10	128096659-128126385	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000058, HPA000451, HPA001164, CAB068198	Enhanced		Enhanced	Nucleus<br>Nucleoli<br>Nuclear bodies	Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.61e-6 (unfavourable), Pancreatic cancer:9.47e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 28.8	lymph node: 17.9	Mixed		
MKL1	BSAC, KIAA1438, MAL, MRTF-A	ENSG00000196588	Megakaryoblastic leukemia (translocation) 1	22	40410281-40636702	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030782	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.58e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 51.3	Expressed in all		
MKL2	FLJ31823, MRTF-B	ENSG00000186260	MKL1/myocardin like 2	16	14071321-14266773	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011286	Supported		Supported	Nuclear speckles	Renal cancer:6.20e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 50.1	Expressed in all		
MKLN1	TWA2	ENSG00000128585	Muskelin 1	7	131110096-131496636	Predicted intracellular proteins	Evidence at protein level	HPA022817, HPA041810	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			prostate: 26.0	Expressed in all		
MKNK2	GPRK7, MNK2	ENSG00000099875	MAP kinase interacting serine/threonine kinase 2	19	2037465-2051244	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021875, CAB037253, HPA070499	Enhanced		Supported	Nuclear bodies	Endometrial cancer:4.86e-5 (favourable), Stomach cancer:4.01e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 174.3	Expressed in all		
MKRN1	RNF61	ENSG00000133606	Makorin ring finger protein 1	7	140453040-140479569	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000567			Approved	Nucleus<br>Nuclear membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 224.7	Expressed in all		
MKRN2	HSPC070, RNF62	ENSG00000075975	Makorin ring finger protein 2	3	12557014-12583713	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037559, HPA037560	Enhanced		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.58e-4 (unfavourable), Renal cancer:6.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 100.1	Expressed in all		
MKRN2OS	C3orf83, MKRN2-AS1	ENSG00000225526	MKRN2 opposite strand	3	12514934-12561059	Predicted intracellular proteins	Evidence at transcript level	HPA065586, HPA065753	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		epididymis: 11.1	small intestine: 8.4	Cell line enhanced		CAPAN-2: 12.4;RT4: 4.7;T-47d: 3.1
MKRN3	D15S9, MGC88288, RNF63, ZFP127, ZNF127	ENSG00000179455	Makorin ring finger protein 3	15	23565678-23630075	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029494	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Glioma:9.23e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 5.9;placenta: 4.1;testis: 3.6	epididymis: 1.1	Cell line enhanced		K-562: 22.8
MKS1	BBS13, FLJ20345, MKS, POC12	ENSG00000011143	Meckel syndrome, type 1	17	58205437-58219605	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021372, HPA021812	Enhanced				Pancreatic cancer:1.25e-4 (favourable), Renal cancer:1.33e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 32.0	Expressed in all		
MKX	C10orf48, IRXL1, MGC39616	ENSG00000150051	Mohawk homeobox	10	27672875-27746060	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA006927	Uncertain		Approved	Nucleoplasm<br>Nuclear speckles		Mixed	Tissue enhanced		ovary: 13.6;prostate: 26.0	fallopian tube: 8.2	Cell line enhanced		BJ: 43.3;BJ hTERT+: 23.7;BJ hTERT+ SV40 Large T+: 30.7;fHDF/TERT166: 114.3
MLF1		ENSG00000178053	Myeloid leukemia factor 1	3	158571163-158607252	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:2.15e-5 (unfavourable), Stomach cancer:5.54e-4 (unfavourable)	Mixed	Tissue enriched	7	testis: 671.8	fallopian tube: 97.0	Cell line enhanced		A-431: 71.8
MLF2	NTN4	ENSG00000089693	Myeloid leukemia factor 2	12	6747996-6767475	Predicted intracellular proteins	Evidence at protein level	HPA010811, HPA010859	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 272.5	Expressed in all		
MLH1	COCA2, FCC2, HNPCC, HNPCC2	ENSG00000076242	MutL homolog 1	3	36993332-37050918	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013294, HPA052707, HPA060714, CAB070868	Supported		Enhanced	Nucleoplasm	Liver cancer:8.24e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 60.0	Mixed		
MLH3		ENSG00000119684	MutL homolog 3	14	75013764-75051532	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA060570			Approved	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 24.4	Mixed		
MLIP	C6orf142, CIP, MGC18257	ENSG00000146147	Muscular LMNA interacting protein	6	53929982-54266280	Predicted intracellular proteins	Evidence at protein level	HPA029252, HPA046654	Approved		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		heart muscle: 112.5;liver: 67.0;skeletal muscle: 45.7	skin: 20.6	Group enriched	7	HUVEC TERT2: 16.4;SK-MEL-30: 14.9
MLKL	FLJ34389	ENSG00000168404	Mixed lineage kinase domain like pseudokinase	16	74671855-74700960	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level						Endometrial cancer:2.16e-4 (favourable)	Expressed in all	Mixed			spleen: 28.9	Mixed		
MLLT1	ENL, LTG19, YEATS1	ENSG00000130382	MLLT1, super elongation complex subunit	19	6210379-6279948	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031166	Approved		Supported	Nucleoplasm	Head and neck cancer:6.03e-5 (favourable)	Expressed in all	Expressed in all			placenta: 61.5	Expressed in all		
MLLT11	AF1Q	ENSG00000213190	Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11	1	151057758-151068497	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000540	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.25e-12 (unfavourable), Endometrial cancer:4.26e-5 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 122.5	parathyroid gland: 24.0	Cell line enhanced		AF22: 129.2;SH-SY5Y: 151.4
MLLT3	AF-9, AF9, YEATS3	ENSG00000171843	MLLT3, super elongation complex subunit	9	20341665-20622543	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001824	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.84e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 40.6	Cell line enhanced		HEL: 229.3
MLLT6	AF17, FLJ23480	ENSG00000275023	MLLT6, PHD finger domain containing	17	38705542-38729803	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA004021	Approved		Approved	Nucleus	Head and neck cancer:3.98e-4 (favourable), Breast cancer:4.18e-4 (favourable), Pancreatic cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.4	Expressed in all		
MLPH	exophilin-3, l(1)-3Rk, l1Rk3, ln, Slac-2a	ENSG00000115648	Melanophilin	2	237485428-237555318	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014685	Uncertain				Endometrial cancer:5.14e-6 (favourable), Renal cancer:1.50e-4 (unfavourable)	Mixed	Mixed			prostate: 97.9	Cell line enhanced		MCF7: 192.8;SK-BR-3: 174.6;SK-MEL-30: 137.5;U-87 MG: 230.5
MLST8	GbetaL, GBL, Lst8, Pop3	ENSG00000167965	MTOR associated protein, LST8 homolog	16	2204248-2209416	Predicted intracellular proteins	Evidence at protein level	CAB019935, HPA041841	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cell Junctions	Renal cancer:7.60e-4 (favourable)	Expressed in all	Expressed in all			testis: 28.6	Expressed in all		
MLX	bHLHd13, MAD7, MXD7, TCFL4	ENSG00000108788	MLX, MAX dimerization protein	17	42567068-42573239	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025329, HPA052766, HPA064438	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Expressed in all	Expressed in all			duodenum: 46.3	Expressed in all		
MLYCD	hMCD, MCD	ENSG00000103150	Malonyl-CoA decarboxylase	16	83899126-83927026	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031625	Enhanced				Renal cancer:2.61e-7 (favourable)	Expressed in all	Mixed			heart muscle: 3.2	Mixed		
MMAA	cblA	ENSG00000151611	Methylmalonic aciduria (cobalamin deficiency) cblA type	4	145618263-145660035	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037361	Approved		Approved	Cytosol	Renal cancer:2.23e-5 (favourable), Urothelial cancer:3.21e-4 (favourable), Colorectal cancer:3.38e-4 (favourable)	Expressed in all	Mixed			liver: 12.3	Mixed		
MMAB	cblB, CFAP23	ENSG00000139428	Methylmalonic aciduria (cobalamin deficiency) cblB type	12	109553737-109573874	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039017	Approved		Approved	Mitochondria	Renal cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 32.5	Expressed in all		
MMACHC	cblC, DKFZP564I122	ENSG00000132763	Methylmalonic aciduria (cobalamin deficiency) cblC type, with homocystinuria	1	45500053-45513382	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027394, HPA027399, HPA027402	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			liver: 8.9	Expressed in all		
MMADHC	C2orf25, cblD, CL25022	ENSG00000168288	Methylmalonic aciduria and homocystinuria, cblD type	2	149569634-149587816	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037531, HPA037532	Supported				Pancreatic cancer:2.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 123.1	Expressed in all		
MMEL1	MMEL2, NEPII, NL1, NL2, SEP	ENSG00000142606	Membrane metalloendopeptidase like 1	1	2590639-2632990	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007876, HPA008205, CAB020786	Uncertain					Mixed	Tissue enhanced		testis: 5.4	stomach: 2.5	Cell line enhanced		CAPAN-2: 2.1;EFO-21: 2.4;MCF7: 1.9;SK-BR-3: 10.6
MMP23B	MIFR, MIFR-1, MMP22	ENSG00000189409	Matrix metallopeptidase 23B	1	1632095-1635263	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Mixed			gallbladder,placenta: 4.1	Cell line enhanced		HHSteC: 3.5;NTERA-2: 1.8;U-266/70: 2.5
MMP24-AS1		ENSG00000126005	MMP24 antisense RNA 1	20	35201745-35278131	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Expressed in all			adipose tissue: 46.9	Expressed in all		
MMS19	hMMS19, MET18, MMS19L	ENSG00000155229	MMS19 homolog, cytosolic iron-sulfur assembly component	10	97458324-97498794	Predicted intracellular proteins	Evidence at protein level	HPA051936, HPA056299	Approved		Enhanced	Nucleoplasm	Urothelial cancer:3.39e-4 (unfavourable), Liver cancer:6.88e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.6	Expressed in all		
MMS22L	C6orf167, dJ39B17.2	ENSG00000146263	MMS22 like, DNA repair protein	6	97142161-97283217	Predicted intracellular proteins	Evidence at protein level	HPA067042			Supported	Nucleoplasm		Mixed	Tissue enhanced		testis: 12.4	bone marrow: 4.5	Expressed in all		
MN1	MGCR, MGCR1, MGCR1-PEN	ENSG00000169184	MN1 proto-oncogene, transcriptional regulator	22	27748277-27801498	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003072	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		skeletal muscle: 22.0	cerebral cortex: 6.4	Cell line enhanced		AF22: 31.4;RH-30: 12.4;TIME: 16.8;U-2 OS: 17.9;U-2197: 17.1
MNAT1	MAT1, RNF66	ENSG00000020426	MNAT1, CDK activating kinase assembly factor	14	60734742-60969953	Predicted intracellular proteins	Evidence at protein level	HPA000701, HPA001154, CAB004495	Approved		Enhanced	Nucleoplasm	Head and neck cancer:2.45e-4 (unfavourable), Renal cancer:3.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 88.9	Expressed in all		
MND1	GAJ	ENSG00000121211	Meiotic nuclear divisions 1	4	153344649-153415118	Predicted intracellular proteins	Evidence at protein level	HPA043499	Enhanced				Liver cancer:2.72e-4 (unfavourable), Melanoma:3.40e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 28.8	lymph node: 14.3	Mixed		
MNDA	PYHIN3	ENSG00000163563	Myeloid cell nuclear differentiation antigen	1	158831317-158849506	Predicted intracellular proteins	Evidence at protein level	HPA034532, HPA073215	Enhanced		Supported	Nucleoplasm<br>Nucleoli		Expressed in all	Tissue enhanced		bone marrow: 194.8;spleen: 144.9	appendix: 111.3	Group enriched	13	NB-4: 93.3;THP-1: 185.6;U-937: 141.2
MNS1	FLJ11222, SPATA40	ENSG00000138587	Meiosis specific nuclear structural 1	15	56421544-56465137	Predicted intracellular proteins	Evidence at protein level	HPA039975, HPA040382	Uncertain		Approved	Nucleoplasm<br>Nuclear speckles		Expressed in all	Group enriched	6	fallopian tube: 33.7;testis: 86.9	kidney: 9.7	Mixed		
MNT	bHLHd3, MAD6, MXD6, ROX	ENSG00000070444	MAX network transcriptional repressor	17	2384060-2401118	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059532, HPA067578			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 15.2	Expressed in all		
MNX1	HB9, HLXB9, HOXHB9, SCRA1	ENSG00000130675	Motor neuron and pancreas homeobox 1	7	156994051-157010651	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071717			Approved	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Tissue enhanced		duodenum: 7.3;small intestine: 6.7	colon: 3.7	Cell line enhanced		AN3-CA: 16.0;EFO-21: 15.3;RPMI-8226: 25.9;SCLC-21H: 22.6
MOAP1	MAP-1, PNMA4	ENSG00000165943	Modulator of apoptosis 1	14	93182196-93184928	Predicted intracellular proteins	Evidence at protein level	HPA000939	Uncertain		Approved	Nucleus<br>Cell Junctions	Lung cancer:7.37e-9 (favourable), Renal cancer:3.15e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 86.1	Expressed in all		
MOB1A	C2orf6, FLJ10788, FLJ11595, Mats1, MOB1, Mob4B, MOBK1B, MOBKL1B	ENSG00000114978	MOB kinase activator 1A	2	74152528-74178898	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047088, HPA071690	Supported		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:3.34e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 107.8	Expressed in all		
MOB1B	MOB4A, MOBKL1A	ENSG00000173542	MOB kinase activator 1B	4	70902326-71022449	Predicted intracellular proteins	Evidence at protein level	HPA047088, HPA071690	Supported		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:4.92e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 24.2	Expressed in all		
MOB2	HCCA2	ENSG00000182208	MOB kinase activator 2	11	1469457-1501247	Predicted intracellular proteins	Evidence at protein level	HPA046313	Uncertain		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:2.02e-4 (favourable), Glioma:7.86e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 70.7	Expressed in all		
MOB3A	MOB-LAK, MOB1C, MOBKL2A, moblak	ENSG00000172081	MOB kinase activator 3A	19	2071038-2096673	Predicted intracellular proteins	Evidence at protein level	HPA057744			Uncertain	Intermediate filaments<br>Cytosol	Endometrial cancer:1.33e-6 (favourable), Renal cancer:1.93e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 85.3	Expressed in all		
MOB3B	C9orf35, FLJ13204, MOB1D, MOBKL2B	ENSG00000120162	MOB kinase activator 3B	9	27325209-27529781	Predicted intracellular proteins	Evidence at protein level	HPA057744			Uncertain	Intermediate filaments<br>Cytosol	Renal cancer:2.33e-10 (favourable), Thyroid cancer:1.02e-4 (unfavourable)	Expressed in all	Mixed			ovary: 32.0	Cell line enhanced		HAP1: 17.3;K-562: 44.7
MOB3C	MOB1E, MOBKL2C	ENSG00000142961	MOB kinase activator 3C	1	46607715-46616891	Predicted intracellular proteins	Evidence at protein level	HPA057744			Uncertain	Intermediate filaments<br>Cytosol	Cervical cancer:3.16e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 20.7	Mixed		
MOB4	2C4D, CGI-95, DKFZP564M112, MOB3, MOBKL3, PHOCN, PREI3	ENSG00000115540	MOB family member 4, phocein	2	197515571-197553699	Predicted intracellular proteins	Evidence at protein level	CAB034082, HPA044125	Approved				Renal cancer:4.68e-4 (unfavourable), Liver cancer:8.29e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 79.6	Expressed in all		
MOBP		ENSG00000168314	Myelin-associated oligodendrocyte basic protein	3	39467198-39529479	Predicted intracellular proteins	Evidence at protein level	HPA035152	Supported					Tissue enriched	Tissue enriched	23	cerebral cortex: 175.9	parathyroid gland: 7.5	Cell line enriched	56	HAP1: 19.1
MOCOS	FLJ20733, HMCS, MOS	ENSG00000075643	Molybdenum cofactor sulfurase	18	36187519-36272157	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039412, HPA047958	Uncertain		Supported	Mitochondria<br>Cytosol	Renal cancer:3.03e-12 (unfavourable), Pancreatic cancer:1.29e-4 (unfavourable), Lung cancer:3.55e-4 (unfavourable)	Mixed	Mixed			adrenal gland: 11.4	Cell line enhanced		hTERT-HME1: 38.4;SiHa: 58.4;SK-MEL-30: 30.1
MOCS1	MOCOD	ENSG00000124615	Molybdenum cofactor synthesis 1	6	39899578-39934551	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045783, HPA058177, HPA075505	Uncertain		Approved	Plasma membrane<br>Cytosol	Cervical cancer:1.07e-5 (unfavourable), Pancreatic cancer:6.07e-5 (favourable)	Expressed in all	Mixed			placenta: 60.3	Cell line enhanced		CACO-2: 38.2
MOCS2	MOCO1	ENSG00000164172	Molybdenum cofactor synthesis 2	5	53095679-53110063	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037679, HPA037680	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:3.68e-6 (favourable)	Expressed in all	Expressed in all			kidney: 106.4	Expressed in all		
MOCS3	dJ914P20.3, UBA4	ENSG00000124217	Molybdenum cofactor synthesis 3	20	50958826-50963931	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027556	Uncertain				Liver cancer:1.39e-4 (unfavourable), Endometrial cancer:5.82e-4 (unfavourable), Renal cancer:7.55e-4 (favourable)	Expressed in all	Mixed			testis: 5.2	Expressed in all		
MOK	RAGE, RAGE1, STK30	ENSG00000080823	MOK protein kinase	14	102224500-102305200	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027292			Supported	Endoplasmic reticulum		Mixed	Tissue enhanced		testis: 71.8	fallopian tube: 34.3	Cell line enhanced		HBF TERT88: 143.8;hTEC/SVTERT24-B: 382.7;NB-4: 315.3;U-138 MG: 197.5
MON1A	MGC13272, SAND1	ENSG00000164077	MON1 homolog A, secretory trafficking associated	3	49908862-49930173	Predicted intracellular proteins	Evidence at protein level	HPA053752, HPA058032	Uncertain		Approved	Cytosol	Pancreatic cancer:3.30e-4 (favourable)	Expressed in all	Mixed			duodenum: 14.5	Expressed in all		
MON1B	HSRG1, KIAA0872, SAND2	ENSG00000103111	MON1 homolog B, secretory trafficking associated	16	77190835-77202405	Predicted intracellular proteins	Evidence at protein level	HPA046285	Approved		Approved	Cytosol	Renal cancer:9.42e-5 (favourable), Endometrial cancer:6.90e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.2	Expressed in all		
MON2	KIAA1040	ENSG00000061987	MON2 homolog, regulator of endosome-to-Golgi trafficking	12	62466817-62600479	Predicted intracellular proteins	Evidence at protein level	HPA038697, HPA057607	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center	Head and neck cancer:2.03e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.8	Expressed in all		
MORC1	CT33, MORC, ZCW6	ENSG00000114487	MORC family CW-type zinc finger 1	3	108958239-109118142	Predicted intracellular proteins	Evidence at protein level	HPA036413	Supported					Not detected	Tissue enriched	68	testis: 29.7	epididymis: 0.4	Group enriched	7	Karpas-707: 1.8;RPMI-8226: 5.3
MORC2	AC004542.C22.1, KIAA0852, ZCW3, ZCWCC1	ENSG00000133422	MORC family CW-type zinc finger 2	22	30925130-30968298	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000436	Enhanced		Supported	Nucleus<br>Cytosol	Renal cancer:6.54e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 55.5	Expressed in all		
MORC3	KIAA0136, NXP2, ZCW5, ZCWCC3	ENSG00000159256	MORC family CW-type zinc finger 3	21	36320189-36386148	Predicted intracellular proteins	Evidence at protein level	HPA018406, HPA034848	Approved		Enhanced	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			endometrium: 30.9	Expressed in all		
MORC4	FLJ11565, ZCW4, ZCWCC2	ENSG00000133131	MORC family CW-type zinc finger 4	X	106813871-107000244	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA000395, HPA015547, HPA050250	Enhanced		Enhanced	Nucleoplasm	Breast cancer:3.56e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 114.4	Expressed in all		
MORF4L1	Eaf3, HsT17725, MEAF3, MORFRG15, MRG15	ENSG00000185787	Mortality factor 4 like 1	15	78810487-78898133	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042360, HPA062010	Approved		Supported	Nuclear speckles		Expressed in all	Expressed in all			testis: 1065.7	Expressed in all		
MORF4L2	KIAA0026, MRGX	ENSG00000123562	Mortality factor 4 like 2	X	103675496-103688158	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031872, HPA054102	Supported		Enhanced	Nucleus	Renal cancer:7.86e-7 (unfavourable), Head and neck cancer:4.29e-5 (unfavourable), Breast cancer:9.83e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 493.3	Expressed in all		
MORN1	FLJ13941	ENSG00000116151	MORN repeat containing 1	1	2321253-2391707	Predicted intracellular proteins	Evidence at transcript level	HPA005858, HPA070703	Uncertain		Approved	Nucleus<br>Mitochondria		Mixed	Tissue enhanced		fallopian tube: 17.7	testis: 12.1	Mixed		
MORN2	MOPT	ENSG00000188010	MORN repeat containing 2	2	38875962-38929072	Predicted intracellular proteins	Evidence at protein level	HPA057815	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 265.7	Expressed in all		
MORN3		ENSG00000139714	MORN repeat containing 3	12	121648742-121672631	Predicted intracellular proteins	Evidence at protein level	HPA038709, HPA038710	Uncertain		Approved	Nucleoplasm	Breast cancer:1.16e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 6.7	testis: 5.1	Group enriched	7	BEWO: 14.7;CACO-2: 7.0
MORN4	bA548K23.4, C10orf83, FLJ25925, rtp	ENSG00000171160	MORN repeat containing 4	10	97614553-97633500	Predicted intracellular proteins	Evidence at protein level	HPA052718	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 32.1	Mixed		
MORN5	C9orf113, C9orf18, FLJ46909	ENSG00000185681	MORN repeat containing 5	9	122159908-122200088	Predicted intracellular proteins	Evidence at transcript level						Endometrial cancer:4.86e-4 (favourable)	Tissue enhanced	Group enriched	6	fallopian tube: 175.5;testis: 106.4	smooth muscle: 24.7	Cell line enhanced		NB-4: 1.0;U-87 MG: 1.1
MOS		ENSG00000172680	MOS proto-oncogene, serine/threonine kinase	8	56112942-56113982	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040424	Uncertain					Not detected	Not detected			testis: 0.8	Not detected		
MOV10	fSAP113, gb110, MGC2948	ENSG00000155363	Mov10 RISC complex RNA helicase	1	112673141-112700746	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031627			Approved	Cytosol	Renal cancer:1.48e-11 (unfavourable), Liver cancer:3.44e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.9	Mixed		
MOV10L1	CHAMP, DJ402G11.8, DKFZp434B0717	ENSG00000073146	Mov10 RISC complex RNA helicase like 1	22	50089879-50161690	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA019034	Approved					Mixed	Tissue enriched	9	testis: 39.9	endometrium: 4.2	Group enriched	6	HHSteC: 2.1;HUVEC TERT2: 10.4;TIME: 4.7
MPDZ	MUPP1	ENSG00000107186	Multiple PDZ domain crumbs cell polarity complex component	9	13105704-13279590	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013512, HPA020255, HPA026686	Uncertain				Pancreatic cancer:7.40e-4 (favourable), Liver cancer:8.68e-4 (favourable)	Expressed in all	Mixed			liver: 44.3	Cell line enhanced		AF22: 57.0
MPG	MDG	ENSG00000103152	N-methylpurine DNA glycosylase	16	77007-85853	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006531	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.82e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 49.0	Expressed in all		
MPHOSPH6	MPP6	ENSG00000135698	M-phase phosphoprotein 6	16	82147798-82170226	Predicted intracellular proteins	Evidence at protein level	CAB003674, HPA026948	Approved		Supported	Nucleus<br>Nucleoli	Ovarian cancer:3.41e-5 (favourable), Liver cancer:4.36e-5 (unfavourable), Prostate cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 91.8	Expressed in all		
MPHOSPH8	HSMPP8, mpp8	ENSG00000196199	M-phase phosphoprotein 8	13	19633681-19673459	Predicted intracellular proteins	Evidence at protein level	HPA039701, HPA040035	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			ovary: 63.5	Expressed in all		
MPHOSPH9	MPP9	ENSG00000051825	M-phase phosphoprotein 9	12	123152320-123244014	Predicted intracellular proteins	Evidence at protein level	HPA037485	Approved		Uncertain	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			testis: 22.7	Expressed in all		
MPI		ENSG00000178802	Mannose phosphate isomerase	15	74890005-74902219	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007200	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:2.39e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.3	Expressed in all		
MPLKIP	C7orf11, ORF20, TTDN1	ENSG00000168303	M-phase specific PLK1 interacting protein	7	40126023-40134659	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA058457, HPA065463	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Expressed in all	Mixed			liver: 4.3	Expressed in all		
MPND	FLJ14981	ENSG00000008382	MPN domain containing	19	4343527-4360086	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043274, HPA045475	Approved		Approved	Nucleus<br>Nucleoli	Lung cancer:1.55e-4 (favourable), Cervical cancer:2.99e-4 (favourable), Endometrial cancer:6.12e-4 (favourable), Renal cancer:7.04e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 30.9	Expressed in all		
MPP1	DXS552E, PEMP	ENSG00000130830	Membrane palmitoylated protein 1	X	154778684-154821007	Predicted intracellular proteins	Evidence at protein level	HPA000167			Approved	Nucleoli<br>Nuclear speckles<br>Cytosol	Renal cancer:4.60e-6 (favourable)	Expressed in all	Expressed in all			placenta: 119.5	Cell line enhanced		HEL: 191.8
MPP2	DKFZp761D0712, DLG2	ENSG00000108852	Membrane palmitoylated protein 2	17	43875357-43909711	Predicted intracellular proteins	Evidence at protein level	HPA026486	Approved		Approved	Mitochondria<br>Cytosol	Endometrial cancer:1.87e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 37.9;epididymis: 33.0;parathyroid gland: 43.8	testis: 24.0	Mixed		
MPP3	DLG3	ENSG00000161647	Membrane palmitoylated protein 3	17	43800799-43833170	Predicted intracellular proteins	Evidence at protein level	HPA021818, HPA024742	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 2.9	Cell line enhanced		SCLC-21H: 11.2
MPP4	DLG6	ENSG00000082126	Membrane palmitoylated protein 4	2	201644870-201698694	Predicted intracellular proteins	Evidence at protein level	HPA057393, CAB079019		Supported	Supported	Actin filaments<br>Cytosol		Not detected	Tissue enhanced		skin: 1.0	testis: 0.9	Cell line enhanced		HBF TERT88: 21.5;hTEC/SVTERT24-B: 21.1;LHCN-M2: 71.6;U-87 MG: 21.4
MPP5	FLJ12615, PALS1	ENSG00000072415	Membrane palmitoylated protein 5	14	67241109-67335819	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000993, HPA063890	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.71e-12 (favourable), Liver cancer:5.62e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 43.9	Expressed in all		
MPP6	p55T, PALS2, VAM-1	ENSG00000105926	Membrane palmitoylated protein 6	7	24573268-24694193	Predicted intracellular proteins	Evidence at protein level	HPA019085, HPA020456	Enhanced				Renal cancer:3.05e-5 (favourable), Head and neck cancer:8.85e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Thyroid cancer:5.28e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 29.9;testis: 45.3	cerebral cortex: 14.9	Expressed in all		
MPP7	FLJ32798	ENSG00000150054	Membrane palmitoylated protein 7	10	28050993-28334486	Predicted intracellular proteins	Evidence at protein level	HPA037597, HPA037598	Enhanced		Supported	Cell Junctions	Renal cancer:2.79e-14 (favourable), Lung cancer:5.88e-4 (favourable)	Mixed	Expressed in all			esophagus: 41.2	Cell line enhanced		CACO-2: 37.3;T-47d: 83.8
MPPED2	239FB, C11orf8, D11S302E, dJ1024C24.1, dJ873F21.1, FAM1B, Hs.46638	ENSG00000066382	Metallophosphoesterase domain containing 2	11	30384493-30586872	Predicted intracellular proteins	Evidence at protein level	HPA062575			Approved	Nucleoli<br>Vesicles<br>Mitochondria		Mixed	Tissue enhanced		cervix, uterine: 38.7;thyroid gland: 43.7	prostate: 20.9	Cell line enhanced		HaCaT: 19.2;HAP1: 13.2;RT4: 7.3;SH-SY5Y: 7.2
MPRIP	M-RIP, p116Rip, RHOIP3	ENSG00000133030	Myosin phosphatase Rho interacting protein	17	17042545-17217679	Predicted intracellular proteins	Evidence at protein level	HPA022034, HPA022901	Enhanced		Supported	Actin filaments<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 197.8	Expressed in all		
MPST	MST, TST2, TUM1	ENSG00000128309	Mercaptopyruvate sulfurtransferase	22	37019635-37029822	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001240	Enhanced		Approved	Mitochondria<br>Cytosol	Urothelial cancer:5.89e-4 (favourable)	Expressed in all	Mixed			duodenum: 108.8	Expressed in all		
MRAS	M-RAs, R-RAS3, RRAS3	ENSG00000158186	Muscle RAS oncogene homolog	3	138347648-138405534	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA042728	Approved				Endometrial cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 114.0	Cell line enhanced		EFO-21: 110.3
MRE11	ATLD, MRE11A	ENSG00000020922	MRE11 homolog, double strand break repair nuclease	11	94415578-94493908	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002691, CAB004081	Supported		Enhanced	Nucleoplasm	Liver cancer:7.14e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 18.7	Expressed in all		
MREG	DSU, FLJ10116, WDT2	ENSG00000118242	Melanoregulin	2	215942805-216034096	Predicted intracellular proteins	Evidence at protein level	HPA068583			Approved	Vesicles	Thyroid cancer:4.20e-4 (favourable)	Expressed in all	Mixed			esophagus: 29.4	Cell line enhanced		MCF7: 74.2
MRFAP1	PAM14, PGR1	ENSG00000179010	Morf4 family associated protein 1	4	6640091-6642745	Predicted intracellular proteins	Evidence at protein level	CAB042447, HPA056367	Approved		Approved	Nucleus	Renal cancer:2.90e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 505.0	Expressed in all		
MRFAP1L1	MGC9651	ENSG00000178988	Morf4 family associated protein 1 like 1	4	6707701-6709880	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.80e-5 (favourable), Urothelial cancer:5.26e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 91.2	Expressed in all		
MRGBP	C20orf20, Eaf7, FLJ10914, MRG15BP	ENSG00000101189	MRG domain binding protein	20	62796453-62801738	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017012	Enhanced		Supported	Nucleus	Renal cancer:2.48e-6 (unfavourable), Liver cancer:3.80e-6 (unfavourable), Endometrial cancer:2.33e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 64.3	ovary: 10.6	Expressed in all		
MRI1	MGC3207, MRDI, mtnA, Ypr118w	ENSG00000037757	Methylthioribose-1-phosphate isomerase 1	19	13764532-13774282	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042744, CAB045988	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			placenta: 23.1	Mixed		
MRM1	FLJ22578	ENSG00000278619	Mitochondrial rRNA methyltransferase 1	17	36601572-36608971	Predicted intracellular proteins	Evidence at protein level	HPA021598	Supported		Enhanced	Mitochondria		Expressed in all	Mixed			adrenal gland: 5.0	Mixed		
MRM2	FJH1, FTSJ2, RRMJ2	ENSG00000122687	Mitochondrial rRNA methyltransferase 2	7	2234231-2242198	Predicted intracellular proteins	Evidence at protein level	HPA019826, HPA049622	Uncertain				Liver cancer:5.21e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 19.6	Expressed in all		
MRM3	FLJ10581, HC90, RMTL1, RNMTL1	ENSG00000171861	Mitochondrial rRNA methyltransferase 3	17	782273-792509	Predicted intracellular proteins	Evidence at protein level	HPA022534, HPA023031, HPA023292	Enhanced		Supported	Mitochondria	Endometrial cancer:2.81e-4 (favourable), Renal cancer:3.00e-4 (favourable)	Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
MRNIP	C5orf45, DKFZp686L2452, LOC51149, MGC65027, MGC78537	ENSG00000161010	MRN complex interacting protein	5	179835133-179862173	Predicted intracellular proteins	Evidence at protein level	HPA043975	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.64e-5 (unfavourable)	Expressed in all	Mixed			fallopian tube: 13.8	Mixed		
MRO	B29, C18orf3, FLJ30140	ENSG00000134042	Maestro	18	50795120-50825402	Predicted intracellular proteins	Evidence at transcript level	HPA022011	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 27.5;kidney: 25.5;testis: 54.7	thyroid gland: 10.4	Cell line enhanced		ASC diff: 1.9;ASC TERT1: 6.0
MROH1	HEATR7A, KIAA1833	ENSG00000179832	Maestro heat like repeat family member 1	8	144148016-144261940	Predicted intracellular proteins	Evidence at protein level	HPA044465	Approved	Supported			Renal cancer:3.65e-6 (favourable), Endometrial cancer:6.74e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 14.9	Mixed		
MROH2A	HEATR7B1	ENSG00000185038	Maestro heat like repeat family member 2A	2	233775679-233833423	Predicted intracellular proteins	Evidence at transcript level	HPA052107	Uncertain		Uncertain	Cytosol		Tissue enhanced	Group enriched	8	testis: 3.2;thyroid gland: 2.7	liver,stomach: 0.3	Cell line enriched	8	RT4: 4.8
MROH2B	DKFZp781F0822, FLJ40243, HEATR7B2	ENSG00000171495	Maestro heat like repeat family member 2B	5	40998017-41071342	Predicted intracellular proteins	Evidence at protein level	HPA059457	Supported					Tissue enriched	Tissue enriched	418	testis: 41.8	all non-specific tissues: 0.0	Not detected		
MROH6	C8orf73	ENSG00000204839	Maestro heat like repeat family member 6	8	143566187-143572971	Predicted intracellular proteins	Evidence at protein level	HPA068049	Uncertain		Approved	Nucleus		Expressed in all	Mixed			bone marrow: 4.0	Cell line enhanced		A-431: 14.0;HaCaT: 11.7;SK-BR-3: 20.9;U-937: 12.8
MROH7	C1orf175, FLJ46354, HEATR8	ENSG00000184313	Maestro heat like repeat family member 7	1	54641754-54710266	Predicted intracellular proteins	Evidence at protein level	HPA071840	Enhanced					Not detected	Tissue enriched	30	testis: 49.5	ovary: 1.6	Not detected		
MROH8	C20orf131, C20orf132, dJ621N11.3, dJ621N11.4	ENSG00000101353	Maestro heat like repeat family member 8	20	37101226-37179588	Predicted intracellular proteins	Evidence at transcript level	HPA060298	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		testis: 41.1	epididymis: 8.8	Mixed		
MROH9	ARMC11, C1orf129, FLJ23550	ENSG00000117501	Maestro heat like repeat family member 9	1	170935471-171064765	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	7	fallopian tube: 3.9;lung: 1.2;testis: 2.7	endometrium: 0.3	Not detected		
MRPL1	BM022	ENSG00000169288	Mitochondrial ribosomal protein L1	4	77862520-77952790	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043656	Supported		Supported	Mitochondria	Renal cancer:3.35e-5 (favourable)	Expressed in all	Expressed in all			kidney: 29.5	Expressed in all		
MRPL10	L10MT, MGC17973, MRP-L10, MRP-L8, MRPL8, RPML8	ENSG00000159111	Mitochondrial ribosomal protein L10	17	47823272-47831534	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA021234, HPA029885	Enhanced		Enhanced	Mitochondria	Liver cancer:6.67e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 61.1	Expressed in all		
MRPL11		ENSG00000174547	Mitochondrial ribosomal protein L11	11	66435075-66466738	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA057685	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			fallopian tube: 26.7	Expressed in all		
MRPL12	MRPL7, MRPL7/L12, RPML12	ENSG00000262814	Mitochondrial ribosomal protein L12	17	81703357-81707526	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA022853, HPA023043	Supported		Supported	Mitochondria	Lung cancer:2.35e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 57.4	Expressed in all		
MRPL13	L13, L13A, L13mt, RPL13, RPML13	ENSG00000172172	Mitochondrial ribosomal protein L13	8	120380761-120445402	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA060899	Approved				Breast cancer:1.37e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 49.4	Expressed in all		
MRPL14	MRP-L32, RPML32	ENSG00000180992	Mitochondrial ribosomal protein L14	6	44113454-44127457	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA038769, HPA076790	Uncertain		Supported	Mitochondria	Renal cancer:7.46e-5 (unfavourable), Thyroid cancer:1.08e-4 (favourable), Ovarian cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			lung: 85.6	Expressed in all		
MRPL15	HSPC145, L15mt, MRP-L15, MRP-L7, RPML7	ENSG00000137547	Mitochondrial ribosomal protein L15	8	54135210-54147901	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA044425	Enhanced				Endometrial cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 84.8	Expressed in all		
MRPL16	FLJ20484, PNAS-111	ENSG00000166902	Mitochondrial ribosomal protein L16	11	59806135-59810872	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA054133	Supported				Breast cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 71.6	Expressed in all		
MRPL17	MRP-L26, RPML26	ENSG00000158042	Mitochondrial ribosomal protein L17	11	6680782-6683401	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043666, HPA050552	Uncertain		Uncertain	Nucleoli<br>Golgi apparatus<br>Vesicles	Renal cancer:3.15e-7 (unfavourable), Liver cancer:2.59e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 37.0	Expressed in all		
MRPL18	HSPC071	ENSG00000112110	Mitochondrial ribosomal protein L18	6	159789812-159798436	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA028774, HPA028775	Enhanced				Renal cancer:9.02e-5 (unfavourable), Liver cancer:3.61e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 85.9	Expressed in all		
MRPL19	KIAA0104, MRP-L15, RLX1, RPML15	ENSG00000115364	Mitochondrial ribosomal protein L19	2	75646783-75690851	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046805, HPA056622	Approved		Supported	Mitochondria	Pancreatic cancer:1.97e-5 (unfavourable), Colorectal cancer:7.39e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 66.4	Expressed in all		
MRPL20	FLJ10024	ENSG00000242485	Mitochondrial ribosomal protein L20	1	1401908-1407313	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047074	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			epididymis: 156.4	Expressed in all		
MRPL23	L23MRP, RPL23L	ENSG00000214026	Mitochondrial ribosomal protein L23	11	1947278-1984522	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050406	Approved		Supported	Nucleoli fibrillar center<br>Mitochondria	Endometrial cancer:3.97e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 89.5	Cell line enhanced		HEK93: 573.2
MRPL28	MAAT1, p15	ENSG00000086504	Mitochondrial ribosomal protein L28	16	367384-370527	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA030594, CAB033542, HPA055589	Enhanced		Supported	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 71.5	Expressed in all		
MRPL3	MRL3, RPML3	ENSG00000114686	Mitochondrial ribosomal protein L3	3	131462212-131502983	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043665, HPA060132	Approved				Liver cancer:4.33e-7 (unfavourable), Pancreatic cancer:3.51e-6 (unfavourable), Ovarian cancer:1.36e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 107.7	Expressed in all		
MRPL30	MRP-L28, RPML28	ENSG00000185414	Mitochondrial ribosomal protein L30	2	99181079-99197626	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047255	Approved					Expressed in all	Expressed in all			thyroid gland: 20.3	Expressed in all		
MRPL33	C2orf1, RPL33L	ENSG00000243147	Mitochondrial ribosomal protein L33	2	27771717-27988087	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA066872	Approved				Liver cancer:1.66e-4 (unfavourable), Head and neck cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 586.9	Expressed in all		
MRPL36	BRIP1, L36mt, MRP-L36, PRPL36, RPMJ	ENSG00000171421	Mitochondrial ribosomal protein L36	5	1798386-1801366	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047238	Approved		Supported	Nuclear bodies<br>Mitochondria	Renal cancer:2.21e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 95.6	Expressed in all		
MRPL37	MRP-L2, RPML2	ENSG00000116221	Mitochondrial ribosomal protein L37	1	54184041-54225464	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA025767, HPA025826, HPA025951	Enhanced		Supported	Mitochondria	Liver cancer:6.45e-5 (unfavourable), Colorectal cancer:6.99e-4 (favourable), Stomach cancer:9.25e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 61.8	Expressed in all		
MRPL38	HSPC262, MGC4810, MRP-L3, RPML3	ENSG00000204316	Mitochondrial ribosomal protein L38	17	75898643-75905413	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA023054, HPA023135	Approved		Supported	Mitochondria	Urothelial cancer:9.21e-5 (favourable), Pancreatic cancer:4.23e-4 (favourable), Renal cancer:5.58e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 30.7	Expressed in all		
MRPL39	C21orf92, FLJ20451, L39mt, MGC104174, MGC3400, MRP-L5, MSTP003, PRED22, PRED66, RPML5	ENSG00000154719	Mitochondrial ribosomal protein L39	21	25585656-25607517	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA018331	Approved				Pancreatic cancer:5.84e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 94.7	Expressed in all		
MRPL4	CGI-28	ENSG00000105364	Mitochondrial ribosomal protein L4	19	10251901-10260045	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA051261	Approved		Supported	Nucleus<br>Nucleoli<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 38.9	Expressed in all		
MRPL40	MRP-L22, NLVCF	ENSG00000185608	Mitochondrial ribosomal protein L40	22	19431902-19436075	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA006181	Uncertain		Enhanced	Nucleoli<br>Mitochondria	Cervical cancer:7.57e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.8	Expressed in all		
MRPL41	BMRP, MRP-L27, MRPL27, PIG3, RPML27	ENSG00000182154	Mitochondrial ribosomal protein L41	9	137551199-137552555	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA024550, HPA027160	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 59.8	Expressed in all		
MRPL42	HSPC204, MRP-L31, MRPL31, MRPS32, PTD007, RPML31	ENSG00000198015	Mitochondrial ribosomal protein L42	12	93467488-93516213	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA039398	Approved		Supported	Plasma membrane<br>Mitochondria	Liver cancer:7.49e-4 (unfavourable), Urothelial cancer:8.12e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 57.2	Expressed in all		
MRPL43	bMRP36a	ENSG00000055950	Mitochondrial ribosomal protein L43	10	100969458-100987515	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA073022			Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			thyroid gland: 57.8	Expressed in all		
MRPL44	FLJ12701, FLJ13990	ENSG00000135900	Mitochondrial ribosomal protein L44	2	223957404-223967714	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA038147, HPA038148	Approved		Approved	Nucleus<br>Plasma membrane<br>Mitochondria	Liver cancer:1.29e-4 (unfavourable), Renal cancer:2.02e-4 (favourable)	Expressed in all	Expressed in all			kidney: 37.5	Expressed in all		
MRPL45	MGC11321	ENSG00000278845	Mitochondrial ribosomal protein L45	17	38297023-38323218	Predicted intracellular proteins	Evidence at protein level	HPA023373, HPA023385	Enhanced		Enhanced	Mitochondria		Expressed in all	Mixed			endometrium: 10.2	Cell line enhanced		AF22: 27.5;Daudi: 49.3;K-562: 38.3;REH: 31.0;U-266/84: 28.8;U-698: 34.9
MRPL46	C15orf4, LIECG2, P2ECSL	ENSG00000259494	Mitochondrial ribosomal protein L46	15	88459476-88467419	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050166	Uncertain		Supported	Nucleoplasm<br>Cell Junctions<br>Mitochondria	Renal cancer:2.09e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 50.3	Expressed in all		
MRPL47	CGI-204, NCM1	ENSG00000136522	Mitochondrial ribosomal protein L47	3	179588285-179604654	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA037553, HPA047779	Approved		Enhanced	Mitochondria	Endometrial cancer:3.15e-4 (unfavourable), Cervical cancer:6.44e-4 (favourable)	Expressed in all	Expressed in all			testis: 85.1	Expressed in all		
MRPL48	CGI-118	ENSG00000175581	Mitochondrial ribosomal protein L48	11	73787316-73865133	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA040241, HPA040864	Approved				Liver cancer:3.30e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.1	Expressed in all		
MRPL49	C11orf4, L49mt, NOF, NOF1	ENSG00000149792	Mitochondrial ribosomal protein L49	11	65122183-65127371	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046778	Approved				Renal cancer:4.22e-15 (favourable), Breast cancer:3.79e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 83.4	Expressed in all		
MRPL50	FLJ20493, MRP-L50	ENSG00000136897	Mitochondrial ribosomal protein L50	9	101387633-101398614	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA022925, HPA056854	Approved		Supported	Vesicles<br>Cytosol	Renal cancer:1.21e-10 (favourable)	Expressed in all	Expressed in all			adrenal gland: 20.8	Expressed in all		
MRPL51	bMRP64, CDA09, HSPC241, MRP64	ENSG00000111639	Mitochondrial ribosomal protein L51	12	6491886-6493841	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA039923	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			testis: 234.8	Expressed in all		
MRPL53		ENSG00000204822	Mitochondrial ribosomal protein L53	2	74471958-74473322	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA056185	Uncertain		Approved	Nucleoli	Renal cancer:1.16e-8 (unfavourable), Liver cancer:7.36e-5 (unfavourable), Pancreatic cancer:1.37e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 24.6	Expressed in all		
MRPL54		ENSG00000183617	Mitochondrial ribosomal protein L54	19	3762664-3768575	Predicted intracellular proteins	Evidence at protein level	HPA042117, HPA046767	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 90.1	Expressed in all		
MRPL57	MRP63	ENSG00000173141	Mitochondrial ribosomal protein L57	13	21176645-21179084	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA039779, HPA059370	Enhanced		Supported	Mitochondria	Pancreatic cancer:8.35e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 21.8	Expressed in all		
MRPL58	DS-1, ICT1	ENSG00000167862	Mitochondrial ribosomal protein L58	17	75012670-75021261	Enzymes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003634	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.09e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 36.1	Expressed in all		
MRPL9		ENSG00000143436	Mitochondrial ribosomal protein L9	1	151759643-151763564	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA008579	Approved		Supported	Mitochondria	Liver cancer:1.04e-7 (unfavourable), Renal cancer:1.44e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 60.5	Expressed in all		
MRPS10	FLJ10567	ENSG00000048544	Mitochondrial ribosomal protein S10	6	42206801-42217865	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA029133, HPA029134	Enhanced		Approved	Actin filaments<br>Mitochondria		Expressed in all	Expressed in all			esophagus: 41.8	Expressed in all		
MRPS11	FLJ22512, FLJ23406, HCC-2	ENSG00000181991	Mitochondrial ribosomal protein S11	15	88467453-88480773	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043752, HPA050345	Enhanced		Supported	Mitochondria	Cervical cancer:3.60e-4 (favourable), Ovarian cancer:4.75e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 13.6	Expressed in all		
MRPS12	RPMS12, RPS12, RPSM12	ENSG00000128626	Mitochondrial ribosomal protein S12	19	38930548-38933162	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046775, HPA050633	Uncertain					Expressed in all	Expressed in all			duodenum: 12.0	Expressed in all		
MRPS15	FLJ11564	ENSG00000116898	Mitochondrial ribosomal protein S15	1	36455718-36464437	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA028100, HPA028134, HPA067137	Enhanced		Supported	Mitochondria	Renal cancer:3.55e-4 (unfavourable), Liver cancer:3.59e-4 (unfavourable), Ovarian cancer:7.83e-4 (favourable)	Expressed in all	Expressed in all			testis: 242.5	Expressed in all		
MRPS16	CGI-132	ENSG00000182180	Mitochondrial ribosomal protein S16	10	73248843-73252693	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050081, HPA054538	Supported		Supported	Mitochondria<br>Cytosol	Liver cancer:4.57e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.4	Expressed in all		
MRPS17	HSPC011, MRP-S17, RPMS17	ENSG00000239789	Mitochondrial ribosomal protein S17	7	55951819-55956501	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047159	Approved					Expressed in all	Expressed in all			fallopian tube: 16.0	Expressed in all		
MRPS18A	FLJ10548, MRPS18-3	ENSG00000096080	Mitochondrial ribosomal protein S18A	6	43671303-43687791	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA035450, HPA035451	Approved				Thyroid cancer:4.03e-5 (favourable)	Expressed in all	Expressed in all			prostate: 58.1	Expressed in all		
MRPS18B	C6orf14, HSPC183, MRPS18-2, PTD017	ENSG00000204568	Mitochondrial ribosomal protein S18B	6	30617709-30626395	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043485, HPA050334	Supported		Supported	Cell Junctions<br>Mitochondria	Renal cancer:3.99e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 13.3	Expressed in all		
MRPS18C	CGI-134, FLJ11146, FLJ22967, MRPS18-1	ENSG00000163319	Mitochondrial ribosomal protein S18C	4	83455932-83469735	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050404	Approved				Renal cancer:2.90e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 39.7	Expressed in all		
MRPS2	CGI-91	ENSG00000122140	Mitochondrial ribosomal protein S2	9	135499984-135504673	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA029487, HPA057261	Approved		Supported	Mitochondria	Renal cancer:6.96e-9 (favourable)	Expressed in all	Expressed in all			fallopian tube: 55.1	Expressed in all		
MRPS21		ENSG00000266472	Mitochondrial ribosomal protein S21	1	150293720-150308979	Predicted intracellular proteins	Evidence at protein level	HPA078289			Supported	Mitochondria	Liver cancer:2.62e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 73.9	Expressed in all		
MRPS23	CGI-138, HSPC329, MRP-S23	ENSG00000181610	Mitochondrial ribosomal protein S23	17	57834781-57850056	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA023453	Supported		Supported	Nuclear membrane<br>Mitochondria	Liver cancer:9.52e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 61.5	Expressed in all		
MRPS24	HSPC335, MRP-S24	ENSG00000062582	Mitochondrial ribosomal protein S24	7	43866558-43869893	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA020983			Approved	Nucleoplasm<br>Vesicles	Lung cancer:1.91e-4 (unfavourable), Renal cancer:9.89e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 147.5	Expressed in all		
MRPS25	DKFZp313H0817, FLJ00023, MRP-S25, RPMS25	ENSG00000131368	Mitochondrial ribosomal protein S25	3	15042460-15065335	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043490	Approved		Enhanced	Mitochondria	Renal cancer:3.60e-7 (favourable)	Expressed in all	Expressed in all			testis: 32.9	Expressed in all		
MRPS26	C20orf193, dJ534B8.3, MRP-S13, MRP-S26, RPMS13	ENSG00000125901	Mitochondrial ribosomal protein S26	20	3045945-3048254	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA045472, HPA054610	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			prostate: 50.0	Expressed in all		
MRPS27	KIAA0264	ENSG00000113048	Mitochondrial ribosomal protein S27	5	72219409-72320646	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA071751	Approved					Expressed in all	Expressed in all			thyroid gland: 59.5	Expressed in all		
MRPS30	PAP, PDCD9	ENSG00000112996	Mitochondrial ribosomal protein S30	5	44808925-44820428	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA018686, HPA021149	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.87e-9 (favourable), Liver cancer:5.91e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 19.5	Expressed in all		
MRPS31	IMOGN38	ENSG00000102738	Mitochondrial ribosomal protein S31	13	40729135-40771173	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA039083, HPA046344	Uncertain		Supported	Nucleoli<br>Mitochondria		Expressed in all	Expressed in all			testis,thyroid gland: 33.6	Expressed in all		
MRPS33	CGI-139	ENSG00000090263	Mitochondrial ribosomal protein S33	7	141002610-141015228	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA030425	Uncertain					Expressed in all	Expressed in all			epididymis: 96.2	Expressed in all		
MRPS34	MGC2616, MRP-S12	ENSG00000074071	Mitochondrial ribosomal protein S34	16	1771890-1773155	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA042112	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 22.2	Expressed in all		
MRPS35	MDS023, MRPS28	ENSG00000061794	Mitochondrial ribosomal protein S35	12	27710773-27756295	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA038513	Enhanced		Approved	Mitochondria<br>Cytosol	Renal cancer:1.51e-5 (favourable), Liver cancer:1.64e-4 (unfavourable), Colorectal cancer:5.01e-4 (favourable), Breast cancer:9.41e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 78.7	Expressed in all		
MRPS36	DC47, MRP-S36	ENSG00000134056	Mitochondrial ribosomal protein S36	5	69217760-69230129	Predicted intracellular proteins	Evidence at protein level	HPA035802, HPA056795	Supported		Enhanced	Mitochondria	Renal cancer:5.02e-6 (favourable)	Expressed in all	Expressed in all			kidney: 52.2	Expressed in all		
MRPS5	MRP-S5, S5mt	ENSG00000144029	Mitochondrial ribosomal protein S5	2	95087207-95149434	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055765	Approved		Supported	Mitochondria	Endometrial cancer:7.98e-7 (unfavourable), Liver cancer:7.73e-5 (unfavourable), Thyroid cancer:6.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.9	Expressed in all		
MRPS6	C21orf101, MRP-S6, RPMS6	ENSG00000243927	Mitochondrial ribosomal protein S6	21	34073224-34143034	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA007861, HPA049676	Supported				Urothelial cancer:1.06e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 121.0	Expressed in all		
MRPS7	MRP-S, RP-S7, RPMS7	ENSG00000125445	Mitochondrial ribosomal protein S7	17	75261674-75266373	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA022522, HPA023007	Supported		Approved	Mitochondria	Colorectal cancer:1.12e-4 (favourable), Liver cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 60.8	Expressed in all		
MRPS9	MRP-S9, RPMS9, S9mt	ENSG00000135972	Mitochondrial ribosomal protein S9	2	105037983-105099960	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043476, HPA048479	Enhanced		Enhanced	Nucleoli<br>Mitochondria	Liver cancer:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.4	Expressed in all		
MRRF	RRF	ENSG00000148187	Mitochondrial ribosome recycling factor	9	122264603-122331343	Predicted intracellular proteins	Evidence at protein level	HPA047177, HPA049987	Enhanced		Approved	Microtubules<br>Cytokinetic bridge	Renal cancer:2.14e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.6	Expressed in all		
MRTO4	C1orf33, dJ657E11.4, MRT4	ENSG00000053372	MRT4 homolog, ribosome maturation factor	1	19251539-19260128	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA026446	Approved		Approved	Nucleus<br>Nuclear membrane<br>Nucleoli	Liver cancer:1.56e-8 (unfavourable), Renal cancer:4.11e-8 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 25.7	Expressed in all		
MSANTD1	C4orf44, LOC345222	ENSG00000188981	Myb/SANT DNA binding domain containing 1	4	3244369-3271738	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	7	cerebral cortex: 1.9;testis: 2.4	epididymis,lung,spleen: 0.3	Not detected		
MSANTD2	C11orf61, FLJ23342	ENSG00000120458	Myb/SANT DNA binding domain containing 2	11	124766498-124800673	Predicted intracellular proteins	Evidence at protein level	HPA038694, HPA038695	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.50e-4 (unfavourable), Urothelial cancer:2.65e-4 (favourable)	Expressed in all	Mixed			endometrium: 14.5	Expressed in all		
MSANTD3	C9orf30, MGC17337	ENSG00000066697	Myb/SANT DNA binding domain containing 3	9	100427156-100451711	Predicted intracellular proteins	Evidence at protein level	HPA062662			Approved	Nucleoplasm	Renal cancer:3.22e-7 (unfavourable), Liver cancer:3.23e-6 (unfavourable), Head and neck cancer:6.66e-5 (unfavourable), Lung cancer:3.56e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 23.4	Expressed in all		
MSANTD4	KIAA1826	ENSG00000170903	Myb/SANT DNA binding domain containing 4 with coiled-coils	11	105995623-106022403	Predicted intracellular proteins	Evidence at protein level	HPA014411	Approved		Approved	Nucleus	Renal cancer:1.26e-5 (favourable), Breast cancer:4.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 27.4	Mixed		
MSC	ABF-1, bHLHa22	ENSG00000178860	Musculin	8	71841549-71844468	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062878			Supported	Nucleoplasm	Renal cancer:1.07e-13 (unfavourable), Liver cancer:4.83e-5 (unfavourable), Glioma:7.15e-4 (unfavourable)	Expressed in all	Mixed			placenta: 22.4	Cell line enriched	14	HDLM-2: 729.2
MSGN1	pMesogenin1	ENSG00000151379	Mesogenin 1	2	17816496-17817101	Predicted intracellular proteins, Transcription factors	No evidence							Not detected	Not detected			esophagus: 0.4	Not detected		
MSH2	COCA1, HNPCC, HNPCC1	ENSG00000095002	MutS homolog 2	2	47402969-47562311	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009572, HPA066845, CAB070867	Supported		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.72e-9 (unfavourable), Endometrial cancer:4.44e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.2	Expressed in all		
MSH4		ENSG00000057468	MutS homolog 4	1	75796882-75913238	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	7	epididymis: 2.3;testis: 7.7	spleen: 0.7	Cell line enhanced		AN3-CA: 1.6
MSH6	GTBP	ENSG00000116062	MutS homolog 6	2	47695530-47810101	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009091, HPA028376, HPA028446, CAB070870	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:1.06e-7 (unfavourable), Endometrial cancer:1.34e-4 (unfavourable), Liver cancer:7.86e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 74.5	Expressed in all		
MSI1		ENSG00000135097	Musashi RNA binding protein 1	12	120341330-120369180	Predicted intracellular proteins	Evidence at protein level	HPA064401			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Pancreatic cancer:5.99e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 17.5;testis: 14.6	skeletal muscle: 7.2	Cell line enhanced		AF22: 118.2;HAP1: 57.0;NTERA-2: 62.4;SCLC-21H: 104.1;SH-SY5Y: 45.6
MSI2		ENSG00000153944	Musashi RNA binding protein 2	17	57255851-57684685	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB022300	Approved		Supported	Cytosol	Renal cancer:9.22e-8 (favourable), Stomach cancer:2.00e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 119.2	Expressed in all		
MSL1	DKFZp686P24239, hMSL1, MSL-1	ENSG00000188895	Male specific lethal 1 homolog	17	40122298-40136916	Predicted intracellular proteins	Evidence at protein level	HPA022800, HPA023567	Uncertain		Enhanced	Nucleoplasm	Renal cancer:3.06e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 107.0	Expressed in all		
MSL2	FLJ10546, KIAA1585, msl-2, MSL2L1, RNF184	ENSG00000174579	Male-specific lethal 2 homolog (Drosophila)	3	136148922-136197241	Predicted intracellular proteins	Evidence at protein level	HPA003413, HPA048482	Uncertain		Approved	Cytosol	Cervical cancer:4.80e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.9	Expressed in all		
MSL3	MSL3L1	ENSG00000005302	Male-specific lethal 3 homolog (Drosophila)	X	11758159-11775753	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034535, HPA034536	Uncertain		Approved	Nucleoplasm	Renal cancer:3.14e-9 (unfavourable), Urothelial cancer:2.17e-4 (favourable), Head and neck cancer:3.28e-4 (favourable), Liver cancer:4.93e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 59.8	Expressed in all		
MSMP	PC-3, PSMP	ENSG00000215183	Microseminoprotein, prostate associated	9	35752990-35756613	Predicted intracellular proteins	Evidence at protein level	HPA055174	Uncertain		Supported	Vesicles<br>Cytosol		Not detected	Tissue enriched	5	placenta: 1.8	appendix: 0.3	Group enriched	8	HUVEC TERT2: 72.1;PC-3: 101.9
MSN		ENSG00000147065	Moesin	X	65588377-65741931	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047338	Enhanced		Enhanced	Plasma membrane	Renal cancer:1.60e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 420.9	Mixed		
MSRB1	SelR, SelX, SepR, SEPX1	ENSG00000198736	Methionine sulfoxide reductase B1	16	1938210-1943326	Predicted intracellular proteins	Evidence at protein level	CAB008650, HPA043463, HPA069557	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			liver: 61.7	Expressed in all		
MSS51	FLJ39565, ZMYND17	ENSG00000166343	MSS51 mitochondrial translational activator	10	73423579-73433561	Predicted intracellular proteins	Evidence at protein level	HPA038564			Uncertain	Vesicles<br>Cytosol		Mixed	Group enriched	15	parathyroid gland: 162.6;skeletal muscle: 81.4	heart muscle: 8.3	Mixed		
MSTO1	FLJ10504, LST005, misato, MST	ENSG00000125459	Misato 1, mitochondrial distribution and morphology regulator	1	155610205-155614967	Predicted intracellular proteins	Evidence at protein level	HPA005899, HPA005914	Approved		Approved	Nuclear membrane<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.90e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 24.9	Expressed in all		
MSX1	HOX7, HYD1, OFC5	ENSG00000163132	Msh homeobox 1	4	4859666-4863936	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026198, HPA063895, HPA073604	Enhanced		Supported	Nucleoplasm	Endometrial cancer:1.64e-7 (favourable), Renal cancer:1.18e-5 (unfavourable)	Tissue enriched	Group enriched	6	cervix, uterine: 61.1;endometrium: 23.7	adipose tissue: 6.6	Cell line enhanced		CACO-2: 39.5
MSX2	CRS2, FPP, HOX8, MSH, PFM, PFM1	ENSG00000120149	Msh homeobox 2	5	174724533-174730893	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005652	Uncertain		Supported	Nuclear speckles	Endometrial cancer:8.43e-5 (favourable), Lung cancer:6.93e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 47.8	parathyroid gland: 16.4	Cell line enriched	7	BEWO: 311.1
MT1A	MT1, MT1S	ENSG00000205362	Metallothionein 1A	16	56638666-56640087	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002161, CAB013056	Approved					Expressed in all	Tissue enhanced		adipose tissue: 258.9	liver: 59.5	Cell line enhanced		HMC-1: 26.0;hTEC/SVTERT24-B: 80.4;NTERA-2: 40.1
MT1B	MT1, MT1Q	ENSG00000169688	Metallothionein 1B	16	56651899-56653204	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		duodenum: 1.3;liver: 3.2	appendix: 0.5	Not detected		
MT1E	MT1, MTD	ENSG00000169715	Metallothionein 1E	16	56625475-56627112	Predicted intracellular proteins	Evidence at protein level	HPA041152	Approved		Approved	Nucleoplasm	Renal cancer:5.06e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 419.6	Cell line enhanced		HBEC3-KT: 785.4;LHCN-M2: 689.5;RPTEC TERT1: 700.7;U-2 OS: 539.7
MT1F	MT1	ENSG00000198417	Metallothionein 1F	16	56657694-56660698	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.02e-7 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 285.2;thyroid gland: 817.7	small intestine: 138.4	Cell line enhanced		HDLM-2: 71.6;NB-4: 79.2;NTERA-2: 77.1;RPTEC TERT1: 250.9
MT1H	MT1	ENSG00000205358	Metallothionein 1H	16	56669814-56671129	Predicted intracellular proteins	Evidence at protein level						Glioma:4.29e-7 (unfavourable), Renal cancer:5.44e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		kidney: 501.3;small intestine: 335.4;thyroid gland: 541.2	liver: 136.0	Cell line enhanced		BEWO: 1.1;EFO-21: 3.4;SCLC-21H: 1.0
MT1HL1	MT1P2	ENSG00000244020	Metallothionein 1H like 1	1	237004103-237004418	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	8	heart muscle: 2.8	urinary bladder: 0.3	Not detected		
MT1M	MT1, MT1K	ENSG00000205364	Metallothionein 1M	16	56632233-56633986	Predicted intracellular proteins	Evidence at protein level						Melanoma:2.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 110.2	small intestine: 47.6	Cell line enhanced		ASC diff: 7.8;HAP1: 9.5;RPTEC TERT1: 38.2
MT1X	MT-1l, MT1	ENSG00000187193	Metallothionein 1X	16	56682424-56684196	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.82e-10 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 1347.9	Expressed in all		
MT2A	MT2	ENSG00000125148	Metallothionein 2A	16	56608199-56609497	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.92e-9 (unfavourable), Lung cancer:5.74e-5 (unfavourable), Pancreatic cancer:9.52e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 1202.2	Cell line enhanced		HBEC3-KT: 6860.6;LHCN-M2: 3182.4;U-87 MG: 3004.5
MT3	GIF	ENSG00000087250	Metallothionein 3	16	56589074-56591088	Predicted intracellular proteins	Evidence at protein level	HPA004011, CAB017779	Enhanced					Tissue enriched	Tissue enriched	17	cerebral cortex: 738.6	adrenal gland: 42.9	Group enriched	7	RPMI-8226: 3.1;SCLC-21H: 8.7;U-87 MG: 12.1
MT4	MTIV	ENSG00000102891	Metallothionein 4	16	56565049-56568957	Predicted intracellular proteins	Evidence at transcript level							Group enriched	Tissue enriched	5	skin: 13.7	testis: 2.6	Not detected		
MTA1		ENSG00000182979	Metastasis associated 1	14	105419820-105470729	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004508, HPA005544	Supported		Enhanced	Nucleoplasm<br>Cytosol	Pancreatic cancer:9.48e-5 (favourable), Liver cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.8	Expressed in all		
MTA2	MTA1-L1, MTA1L1	ENSG00000149480	Metastasis associated 1 family member 2	11	62593214-62601840	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005315, HPA006214, CAB017522	Enhanced		Enhanced	Nucleoplasm	Liver cancer:4.82e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 88.3	Expressed in all		
MTA3	KIAA1266	ENSG00000057935	Metastasis associated 1 family member 3	2	42494569-42756947	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039433	Approved		Supported	Nucleus<br>Vesicles	Endometrial cancer:2.30e-4 (unfavourable), Liver cancer:4.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.4	Mixed		
MTAP	c86fus, MSAP	ENSG00000099810	Methylthioadenosine phosphorylase	9	21802543-21937651	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046915			Supported	Cytosol	Liver cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 15.7	Mixed		
MTBP		ENSG00000172167	MDM2 binding protein	8	120445400-120542133	Predicted intracellular proteins	Evidence at protein level	HPA025694, HPA050594	Uncertain		Approved	Nucleus		Mixed	Mixed			testis: 9.1	Mixed		
MTCL1	CCDC165, KIAA0802, SOGA2	ENSG00000168502	Microtubule crosslinking factor 1	18	8705661-8832778	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046245	Uncertain				Renal cancer:5.19e-4 (unfavourable), Cervical cancer:6.45e-4 (unfavourable)	Mixed	Mixed			gallbladder: 12.8	Mixed		
MTCP1	P13MTCP1, p8MTCP1	ENSG00000214827	Mature T-cell proliferation 1	X	155061622-155147937	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032040			Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:4.52e-8 (unfavourable)	Mixed	Mixed			testis: 8.7	Mixed		
MTERF1	MTERF	ENSG00000127989	Mitochondrial transcription termination factor 1	7	91692008-91880720	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044894, HPA069560	Uncertain		Supported	Mitochondria		Expressed in all	Expressed in all			lymph node: 16.4	Expressed in all		
MTERF2	FLJ14062, MTERFD3	ENSG00000120832	Mitochondrial transcription termination factor 2	12	106977291-106987166	Predicted intracellular proteins	Evidence at protein level	HPA003526	Approved				Cervical cancer:8.50e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 29.1	Mixed		
MTERF3	CGI-12, FLJ10939, MTERFD1	ENSG00000156469	Mitochondrial transcription termination factor 3	8	96239398-96261610	Predicted intracellular proteins	Evidence at protein level	HPA002966			Supported	Nucleoplasm<br>Mitochondria	Renal cancer:5.88e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.4	Expressed in all		
MTERF4	MGC61716, MTERFD2	ENSG00000122085	Mitochondrial transcription termination factor 4	2	241072169-241102332	Predicted intracellular proteins	Evidence at protein level	HPA027097	Uncertain		Supported	Mitochondria<br>Cytosol	Pancreatic cancer:3.48e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 58.3	Expressed in all		
MTF1		ENSG00000188786	Metal regulatory transcription factor 1	1	37809567-37859620	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028604, HPA028689	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Mixed			bone marrow: 13.1	Expressed in all		
MTF2	M96, PCL2, TDRD19A	ENSG00000143033	Metal response element binding transcription factor 2	1	93079235-93139081	Predicted intracellular proteins	Evidence at protein level	HPA069047, HPA069066			Enhanced	Nucleoplasm	Renal cancer:2.47e-7 (unfavourable), Liver cancer:8.90e-7 (unfavourable), Prostate cancer:1.05e-4 (unfavourable)	Expressed in all	Mixed			testis: 30.7	Expressed in all		
MTFMT	FMT1	ENSG00000103707	Mitochondrial methionyl-tRNA formyltransferase	15	65001512-65029639	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040710	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.31e-8 (favourable)	Expressed in all	Mixed			smooth muscle: 2.7	Mixed		
MTFR1	CHPPR, FAM54A2, KIAA0009	ENSG00000066855	Mitochondrial fission regulator 1	8	65644734-65771261	Predicted intracellular proteins	Evidence at protein level	HPA023152, HPA056120	Uncertain		Supported	Mitochondria<br>Cytosol	Breast cancer:4.06e-4 (unfavourable), Thyroid cancer:5.21e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.2	Expressed in all		
MTFR1L	FAM54B	ENSG00000117640	Mitochondrial fission regulator 1 like	1	25818640-25832942	Predicted intracellular proteins	Evidence at protein level	HPA027124, HPA027130	Approved		Approved	Cell Junctions<br>Mitochondria	Renal cancer:5.89e-12 (favourable), Endometrial cancer:6.81e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 150.7	Expressed in all		
MTG1	GTPBP7	ENSG00000148824	Mitochondrial ribosome associated GTPase 1	10	133394094-133421307	Predicted intracellular proteins	Evidence at protein level	HPA037826, HPA037827	Approved		Supported	Mitochondria	Renal cancer:6.79e-7 (unfavourable), Urothelial cancer:1.03e-5 (favourable), Pancreatic cancer:5.08e-4 (favourable)	Expressed in all	Expressed in all			testis: 29.5	Expressed in all		
MTG2	dJ1005F21.2, FLJ10741, GTPBP5, ObgH1	ENSG00000101181	Mitochondrial ribosome associated GTPase 2	20	62183029-62203568	Predicted intracellular proteins	Evidence at protein level	HPA047379	Approved				Pancreatic cancer:6.31e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 15.8	Expressed in all		
MTHFD2L	MGC72244	ENSG00000163738	Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like	4	74114174-74303099	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035434	Uncertain					Mixed	Mixed			adrenal gland: 4.8	Mixed		
MTHFR		ENSG00000177000	Methylenetetrahydrofolate reductase	1	11785723-11806920	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA063389			Approved	Cell Junctions	Head and neck cancer:3.97e-5 (favourable), Pancreatic cancer:4.81e-5 (favourable), Liver cancer:1.19e-4 (unfavourable), Renal cancer:2.12e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 64.9	Expressed in all		
MTHFS	HsT19268	ENSG00000136371	Methenyltetrahydrofolate synthetase	15	79833585-79897379	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008067, HPA054177	Approved		Supported	Cytosol	Liver cancer:1.29e-6 (favourable), Renal cancer:2.04e-4 (favourable), Glioma:6.94e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 116.1	Expressed in all		
MTHFSD	FLJ12998	ENSG00000103248	Methenyltetrahydrofolate synthetase domain containing	16	86530176-86555235	Predicted intracellular proteins	Evidence at protein level	HPA041333	Uncertain		Approved	Nucleus<br>Vesicles	Colorectal cancer:9.88e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 33.0	Mixed		
MTIF2	IF-2mt	ENSG00000085760	Mitochondrial translational initiation factor 2	2	55236595-55269347	Predicted intracellular proteins	Evidence at protein level	HPA006021, HPA061422	Uncertain		Enhanced	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 40.0	Expressed in all		
MTIF3	IF-3mt, IF3(mt)	ENSG00000122033	Mitochondrial translational initiation factor 3	13	27435643-27450591	Predicted intracellular proteins	Evidence at protein level	HPA039791	Approved		Supported	Nucleoplasm<br>Mitochondria	Urothelial cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 101.3	Expressed in all		
MTM1		ENSG00000171100	Myotubularin 1	X	150568619-150673322	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA010008, HPA010665	Approved		Supported	Plasma membrane	Renal cancer:7.40e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 27.3	Expressed in all		
MTMR1		ENSG00000063601	Myotubularin related protein 1	X	150692971-150765103	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002977, HPA018502	Approved		Approved	Microtubule organizing center		Expressed in all	Expressed in all			parathyroid gland: 26.6	Mixed		
MTMR10	FLJ20313	ENSG00000166912	Myotubularin related protein 10	15	30938941-30991607	Predicted intracellular proteins	Evidence at protein level	HPA006081	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:7.77e-12 (favourable)	Expressed in all	Expressed in all			placenta: 36.9	Expressed in all		
MTMR11	CRA	ENSG00000014914	Myotubularin related protein 11	1	149928651-149936869	Predicted intracellular proteins	Evidence at protein level	HPA030351	Approved		Approved	Centrosome		Expressed in all	Mixed			rectum: 27.6	Mixed		
MTMR12	3-PAP, 3PAP, FLJ20476, KIAA1682, PIP3AP	ENSG00000150712	Myotubularin related protein 12	5	32226994-32313009	Predicted intracellular proteins	Evidence at protein level	HPA051333	Supported				Renal cancer:1.29e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.6	Expressed in all		
MTMR2	CMT4B, KIAA1073	ENSG00000087053	Myotubularin related protein 2	11	95832882-95925315	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049831	Approved		Supported	Vesicles	Liver cancer:1.61e-8 (unfavourable), Pancreatic cancer:3.60e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.8	Expressed in all		
MTMR3	FYVE-DSP1, KIAA0371, ZFYVE10	ENSG00000100330	Myotubularin related protein 3	22	29883155-30030866	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034515, HPA034516, HPA061399	Uncertain		Supported	Nucleoplasm<br>Cytosol		Mixed	Expressed in all			bone marrow: 52.3	Expressed in all		
MTMR4	KIAA0647, ZFYVE11	ENSG00000108389	Myotubularin related protein 4	17	58489529-58517905	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.53e-5 (unfavourable), Pancreatic cancer:5.09e-4 (favourable)	Expressed in all	Expressed in all			testis: 35.2	Expressed in all		
MTMR6		ENSG00000139505	Myotubularin related protein 6	13	25246201-25288009	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			testis: 30.6	Expressed in all		
MTMR7		ENSG00000003987	Myotubularin related protein 7	8	17298030-17413528	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 22.9;parathyroid gland: 15.2	thyroid gland: 5.5	Cell line enhanced		SCLC-21H: 12.4;SH-SY5Y: 6.5
MTMR8	FLJ20126	ENSG00000102043	Myotubularin related protein 8	X	64268081-64395431	Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			fallopian tube: 3.7	Cell line enhanced		NTERA-2: 4.3
MTMR9	C8orf9, DKFZp434K171, LIP-STYX, MTMR8	ENSG00000104643	Myotubularin related protein 9	8	11284416-11328146	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA070944			Approved	Actin filaments<br>Centrosome		Expressed in all	Mixed			cerebral cortex: 22.4	Expressed in all		
MTO1		ENSG00000135297	Mitochondrial tRNA translation optimization 1	6	73461578-73509236	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030230, HPA030232	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 24.9	Expressed in all		
MTOR	FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1	ENSG00000198793	Mechanistic target of rapamycin	1	11106535-11262507	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB069425, HPA071227	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.49e-5 (favourable)	Expressed in all	Expressed in all			testis: 62.2	Expressed in all		
MTPAP	FLJ10486, mtPAP, PAPD1, SPAX4	ENSG00000107951	Mitochondrial poly(A) polymerase	10	30309801-30374448	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038620, HPA058232	Approved		Supported	Mitochondria	Liver cancer:4.20e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 22.7	Expressed in all		
MTPN	GCDP, MYOTROPHIN, V-1	ENSG00000105887	Myotrophin	7	135926761-135977353	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019735	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.19e-4 (unfavourable), Pancreatic cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 193.6	Expressed in all		
MTR	cblG	ENSG00000116984	5-methyltetrahydrofolate-homocysteine methyltransferase	1	236795281-236903981	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044474, HPA054915	Approved		Supported	Cytosol	Thyroid cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
MTRF1	MGC47721, MTTRF1, RF1	ENSG00000120662	Mitochondrial translation release factor 1	13	41216369-41263577	Predicted intracellular proteins	Evidence at protein level	HPA043316	Uncertain					Expressed in all	Expressed in all			testis: 25.6	Expressed in all		
MTRF1L	HMRF1L, mtRF1a	ENSG00000112031	Mitochondrial translational release factor 1 like	6	152987362-153002685	Predicted intracellular proteins	Evidence at protein level	HPA036367	Uncertain				Breast cancer:4.82e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 13.0	Expressed in all		
MTRNR2L1		ENSG00000256618	MT-RNR2-like 1	17	22523111-22524663	Predicted intracellular proteins	Evidence at transcript level						Liver cancer:8.99e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 1105.5	Expressed in all		
MTRNR2L10		ENSG00000256045	MT-RNR2-like 10	X	55181391-55182920	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			kidney: 69.1	Cell line enhanced		A549: 99.9;HeLa: 270.2;Hep G2: 240.3
MTRNR2L12		ENSG00000269028	MT-RNR2-like 12	3	96617188-96618236	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Expressed in all			heart muscle: 15284.0	Expressed in all		
MTRNR2L13		ENSG00000270394	MT-RNR2-like 13	4	116298876-116300320	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland: 0.8	Cell line enhanced		HeLa: 2.2;Hep G2: 1.2
MTRNR2L3		ENSG00000256222	MT-RNR2-like 3	20	57358442-57359980	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			bone marrow,skeletal muscle,testis: 0.2	Not detected		
MTRNR2L4		ENSG00000232196	MT-RNR2-like 4	16	3370979-3372740	Predicted intracellular proteins	Evidence at transcript level							Not detected	Expressed in all			skeletal muscle: 98.2	Cell line enhanced		AN3-CA: 43.4;HaCaT: 43.7;HeLa: 44.1
MTRNR2L5		ENSG00000249860	MT-RNR2-like 5	10	55599303-55600041	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			skeletal muscle: 0.3	Not detected		
MTRNR2L6		ENSG00000270672	MT-RNR2-like 6	7	142666272-142667718	Predicted intracellular proteins	Evidence at transcript level							Mixed	Expressed in all			skeletal muscle: 131.7	Cell line enhanced		HeLa: 101.5;Hep G2: 93.3
MTRNR2L7		ENSG00000256892	MT-RNR2-like 7	10	37601440-37602974	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland,cerebral cortex,heart muscle,kidney,rectum,skeletal muscle: 0.1	Not detected		
MTRNR2L8		ENSG00000255823	MT-RNR2-like 8	11	10507887-10509189	Predicted intracellular proteins	Evidence at transcript level							Mixed	Expressed in all			heart muscle: 2071.6	Expressed in all		
MTSS1	KIAA0429, MIM, MIMA, MIMB	ENSG00000170873	MTSS1, I-BAR domain containing	8	124550790-124728429	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA075540	Approved				Renal cancer:2.11e-7 (favourable)	Expressed in all	Expressed in all			placenta: 51.6	Cell line enhanced		HDLM-2: 92.3;HEL: 304.1
MTSS1L	ABBA, ABBA-1, LOC92154	ENSG00000132613	MTSS1L, I-BAR domain containing	16	70661204-70686066	Predicted intracellular proteins	Evidence at protein level	HPA048531, HPA066469	Approved		Supported	Focal adhesion sites	Breast cancer:2.85e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 320.2	Mixed		
MTURN	C7orf41, Ells1, FLJ25903	ENSG00000180354	Maturin, neural progenitor differentiation regulator homolog	7	30134810-30162762	Predicted intracellular proteins	Evidence at protein level	HPA029507	Approved		Approved	Cytosol	Renal cancer:7.64e-13 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 351.3	Cell line enhanced		HEL: 86.3;SCLC-21H: 80.0
MTUS2	CAZIP, ICIS, KIAA0774, TIP150	ENSG00000132938	Microtubule associated tumor suppressor candidate 2	13	28820348-29505947	Predicted intracellular proteins	Evidence at protein level	HPA031473, HPA031474, HPA031475	Enhanced		Supported	Microtubules<br>Cytokinetic bridge		Mixed	Group enriched	5	heart muscle: 33.4;ovary: 9.5	cerebral cortex: 4.2	Cell line enhanced		HaCaT: 11.7;HeLa: 3.7
MTX3		ENSG00000177034	Metaxin 3	5	79976731-79991262	Predicted intracellular proteins	Evidence at protein level	HPA047858, HPA062061	Approved		Approved	Mitochondria	Liver cancer:5.08e-5 (unfavourable), Ovarian cancer:2.54e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.6	Mixed		
MUM1	EXPAND1, MUM-1	ENSG00000160953	Melanoma associated antigen (mutated) 1	19	1354711-1378431	Predicted intracellular proteins	Evidence at protein level	HPA048063	Uncertain		Approved	Nucleus<br>Cytosol	Pancreatic cancer:2.25e-6 (favourable), Endometrial cancer:4.82e-4 (favourable)	Expressed in all	Expressed in all			testis: 51.0	Expressed in all		
MUM1L1	FLJ33516	ENSG00000157502	MUM1 like 1	X	106168305-106208956	Predicted intracellular proteins	Evidence at protein level	HPA000168, HPA020464	Enhanced				Thyroid cancer:5.95e-4 (unfavourable)	Mixed	Tissue enriched	7	ovary: 226.8	testis: 33.9	Cell line enhanced		AF22: 2.9;HSkMC: 2.1;LHCN-M2: 4.6;NTERA-2: 2.1;T-47d: 1.7
MURC	cavin-4, CAVIN4	ENSG00000170681	Muscle related coiled-coil protein	9	100578079-100587906	Predicted intracellular proteins	Evidence at protein level	HPA020973, HPA020987, HPA021021	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane		Tissue enhanced	Group enriched	9	heart muscle: 34.8;skeletal muscle: 103.8	prostate: 7.4	Cell line enhanced		NTERA-2: 9.6;SCLC-21H: 17.1
MUS81	FLJ44872, SLX3	ENSG00000172732	MUS81 structure-specific endonuclease subunit	11	65857126-65867653	Predicted intracellular proteins	Evidence at protein level	HPA059530	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:6.05e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 25.0	Expressed in all		
MUSTN1	Mustang	ENSG00000272573	Musculoskeletal, embryonic nuclear protein 1	3	52833114-52835219	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	6	skeletal muscle: 414.1	cervix, uterine: 71.5	Cell line enhanced		Hep G2: 4.1;RH-30: 5.0
MUT		ENSG00000146085	Methylmalonyl-CoA mutase	6	49430360-49463191	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035971, HPA035972	Enhanced		Approved	Mitochondria<br>Cytosol	Renal cancer:8.71e-13 (favourable)	Expressed in all	Expressed in all			liver: 104.1	Expressed in all		
MUTYH	MYH	ENSG00000132781	MutY DNA glycosylase	1	45329163-45340470	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008732	Uncertain		Supported	Nucleus	Liver cancer:4.76e-8 (unfavourable), Renal cancer:7.25e-5 (unfavourable)	Expressed in all	Mixed			thyroid gland: 10.7	Expressed in all		
MVB12A	FAM125A, FLJ32495	ENSG00000141971	Multivesicular body subunit 12A	19	17405722-17433724	Predicted intracellular proteins	Evidence at protein level	HPA041885, HPA042231	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Cervical cancer:3.26e-4 (favourable)	Expressed in all	Expressed in all			ovary: 38.1	Expressed in all		
MVB12B	C9orf28, FAM125B, FLJ00001	ENSG00000196814	Multivesicular body subunit 12B	9	126326849-126507041	Predicted intracellular proteins	Evidence at protein level	HPA043683, HPA049383	Uncertain		Approved	Golgi apparatus<br>Vesicles	Pancreatic cancer:7.89e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 36.5	Cell line enhanced		AF22: 34.2
MVK	LRBP, MK	ENSG00000110921	Mevalonate kinase	12	109573255-109598117	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016961	Approved					Expressed in all	Expressed in all			testis: 31.6	Expressed in all		
MVP	LRP, VAULT1	ENSG00000013364	Major vault protein	16	29820394-29848039	Cancer-related genes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA002321, CAB002752, CAB022717, HPA064740	Enhanced		Enhanced	Cytosol	Renal cancer:5.49e-5 (favourable), Breast cancer:4.51e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 165.7	Expressed in all		
MX1	IFI-78K, MxA	ENSG00000157601	MX dynamin like GTPase 1	21	41420304-41459214	Predicted intracellular proteins	Evidence at protein level	HPA030917, HPA030918, HPA049724	Approved	Approved	Supported	Nuclear membrane<br>Cytosol	Renal cancer:1.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 114.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 786.8;BJ hTERT+ SV40 Large T+ RasG12V: 735.0;SK-MEL-30: 205.0
MX2	MXB	ENSG00000183486	MX dynamin like GTPase 2	21	41361943-41409390	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA030235	Uncertain				Endometrial cancer:3.71e-5 (unfavourable)	Expressed in all	Mixed			spleen: 45.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 156.9;BJ hTERT+ SV40 Large T+ RasG12V: 158.8;MOLT-4: 89.4;U-266/84: 131.4;U-937: 146.7
MXD1	bHLHc58, MAD, MAD1	ENSG00000059728	MAX dimerization protein 1	2	69897688-69942945	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001599	Enhanced		Uncertain	Nucleoplasm<br>Mitochondria<br>Cytosol	Endometrial cancer:8.14e-6 (unfavourable), Pancreatic cancer:8.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 113.8;esophagus: 101.9	appendix: 56.3	Mixed		
MXD3	bHLHc13, MAD3	ENSG00000213347	MAX dimerization protein 3	5	177301461-177312757	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA070111			Approved	Nucleus<br>Nucleoli	Liver cancer:3.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 24.2	skin: 12.6	Cell line enhanced		HDLM-2: 162.8
MXD4	bHLHc12, MAD4, MST149, MSTP149	ENSG00000123933	MAX dimerization protein 4	4	2247432-2262294	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053363			Supported	Cytosol	Pancreatic cancer:1.39e-5 (favourable), Head and neck cancer:2.21e-5 (favourable)	Expressed in all	Expressed in all			spleen: 41.3	Expressed in all		
MXI1	bHLHc11, MAD2, MXD2, MXI	ENSG00000119950	MAX interactor 1, dimerization protein	10	110207605-110287365	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035319, HPA056762	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.02e-5 (unfavourable), Prostate cancer:9.17e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 88.1	Expressed in all		
MYB	c-myb	ENSG00000118513	MYB proto-oncogene, transcription factor	6	135181315-135219173	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017704	Approved		Approved	Nucleus<br>Plasma membrane	Prostate cancer:9.65e-4 (favourable), Stomach cancer:9.87e-4 (favourable)	Tissue enhanced	Tissue enhanced		breast: 26.3;rectum: 29.1	colon: 25.2	Cell line enhanced		HL-60: 173.9;MOLT-4: 321.7;REH: 222.8;THP-1: 230.7;U-937: 145.8
MYBBP1A	FLJ37886, P160, PAP2	ENSG00000132382	MYB binding protein 1a	17	4538897-4555631	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005466	Supported		Supported	Nucleoli<br>Vesicles	Pancreatic cancer:1.61e-4 (favourable), Renal cancer:5.95e-4 (unfavourable), Thyroid cancer:8.12e-4 (unfavourable), Melanoma:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 21.6	Expressed in all		
MYBL1	A-myb, AMYB	ENSG00000185697	MYB proto-oncogene like 1	8	66562175-66614247	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008791	Uncertain				Renal cancer:2.03e-8 (unfavourable)	Mixed	Tissue enhanced		lymph node: 24.2;testis: 21.4	tonsil: 14.9	Cell line enhanced		BJ hTERT+ SV40 Large T+: 76.9;HBF TERT88: 109.4
MYBL2	B-MYB, BMYB	ENSG00000101057	MYB proto-oncogene like 2	20	43667019-43716496	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017114, HPA030530, HPA055416	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.11e-7 (unfavourable), Endometrial cancer:9.73e-4 (unfavourable)	Tissue enriched	Tissue enhanced		bone marrow: 57.0;lymph node: 67.3;tonsil: 49.9	appendix: 32.7	Mixed		
MYBPC1		ENSG00000196091	Myosin binding protein C, slow type	12	101568353-101686018	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021004, HPA027614	Enhanced				Breast cancer:4.76e-5 (favourable)	Tissue enhanced	Tissue enriched	31	skeletal muscle: 3918.4	prostate: 125.8	Not detected		
MYBPC2	MGC163408, MYBPC, MYBPCF	ENSG00000086967	Myosin binding protein C, fast type	19	50432903-50466321	Predicted intracellular proteins	Evidence at protein level	HPA042991, HPA046745	Enhanced					Tissue enriched	Group enriched	124	parathyroid gland: 934.4;skeletal muscle: 1495.9	prostate: 9.7	Group enriched	19	HDLM-2: 54.5;Karpas-707: 102.8
MYBPC3	CMH4, FHC, MYBP-C	ENSG00000134571	Myosin binding protein C, cardiac	11	47331397-47352702	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040147, HPA043898	Enhanced					Not detected	Tissue enriched	496	heart muscle: 711.2	testis: 1.4	Cell line enriched	15	U-937: 4.9
MYBPH		ENSG00000133055	Myosin binding protein H	1	203167811-203175813	Predicted intracellular proteins	Evidence at protein level	HPA061383	Enhanced		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Group enriched	Group enriched	5	prostate: 5.1;skeletal muscle: 7.9	esophagus: 1.2	Cell line enhanced		CACO-2: 25.5;HSkMC: 41.6;THP-1: 10.2
MYBPHL		ENSG00000221986	Myosin binding protein H like	1	109292365-109307041	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	14	heart muscle: 53.2	fallopian tube: 3.7	Cell line enhanced		Hep G2: 1.7;RH-30: 1.3
MYC	bHLHe39, c-Myc, MYCC	ENSG00000136997	V-myc avian myelocytomatosis viral oncogene homolog	8	127735434-127741434	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000084, CAB010307, HPA055893, HPA066556	Supported		Enhanced	Nucleoplasm	Renal cancer:5.49e-8 (unfavourable), Urothelial cancer:4.96e-5 (unfavourable), Ovarian cancer:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 151.6	Expressed in all		
MYCBP	AMY-1	ENSG00000214114	MYC binding protein	1	38862964-38874105	Predicted intracellular proteins	Evidence at protein level	HPA041188	Supported				Liver cancer:6.03e-6 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 38.8	Expressed in all		
MYCBP2	FLJ10106, KIAA0916, PAM	ENSG00000005810	MYC binding protein 2, E3 ubiquitin protein ligase	13	77044655-77327050	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA058807			Supported	Nucleus<br>Vesicles	Renal cancer:5.01e-5 (favourable)	Expressed in all	Expressed in all			skin: 82.7	Expressed in all		
MYCBPAP	AMAP-1, DKFZp434N1415	ENSG00000136449	MYCBP associated protein	17	50508384-50531501	Predicted intracellular proteins	Evidence at protein level	HPA023257, HPA024405	Enhanced		Approved	Vesicles		Mixed	Tissue enriched	12	testis: 91.5	fallopian tube: 7.5	Cell line enhanced		HDLM-2: 3.7
MYCL	bHLHe38, LMYC, MYCL1	ENSG00000116990	V-myc avian myelocytomatosis viral oncogene lung carcinoma derived homolog	1	39895426-39902256	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063132			Supported	Nucleus	Lung cancer:4.49e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 41.6	urinary bladder: 23.7	Group enriched	7	U-266/70: 372.1;U-266/84: 268.8
MYCN	bHLHe37, MYCNOT, N-myc, NMYC	ENSG00000134323	V-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog	2	15940564-15947007	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057420			Approved	Nucleus<br>Nucleoli		Tissue enhanced	Tissue enhanced		placenta: 13.7	cerebral cortex: 7.2	Cell line enhanced		AF22: 43.5;BEWO: 230.1;HMC-1: 50.4;NTERA-2: 91.1;RH-30: 61.3
MYCNOS	MYCN-AS1, N-CYM, NCYM	ENSG00000233718	MYCN opposite strand	2	15939898-15941723	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 3.9	cerebral cortex: 1.2	Cell line enhanced		BEWO: 17.5;HMC-1: 5.0;NTERA-2: 4.2
MYD88		ENSG00000172936	Myeloid differentiation primary response 88	3	38138478-38143022	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009104	Approved		Supported	Vesicles<br>Mitochondria<br>Cytosol	Breast cancer:8.45e-4 (favourable)	Expressed in all	Mixed			lung: 57.1	Expressed in all		
MYEF2	FLJ11213, HsT18564, KIAA1341, MEF-2	ENSG00000104177	Myelin expression factor 2	15	48134631-48178517	Predicted intracellular proteins	Evidence at protein level	HPA004883	Supported		Supported	Nucleoplasm		Mixed	Tissue enhanced		testis: 51.3	cerebral cortex: 47.2	Cell line enhanced		AF22: 100.6;SCLC-21H: 106.7
MYF5	bHLHc2	ENSG00000111049	Myogenic factor 5	12	80716912-80719673	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041691			Supported	Nucleoplasm		Not detected	Tissue enhanced		skeletal muscle: 1.9	prostate: 0.4	Cell line enriched	19	LHCN-M2: 398.0
MYF6	bHLHc4, MRF4	ENSG00000111046	Myogenic factor 6	12	80707498-80709474	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Head and neck cancer:2.05e-4 (unfavourable)	Group enriched	Tissue enriched	15	skeletal muscle: 99.2	prostate: 6.4	Cell line enriched	20	LHCN-M2: 19.4
MYH1	MGC133384, MYHa, MyHC-2X/D, MYHSA1	ENSG00000109061	Myosin heavy chain 1	17	10492307-10518543	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001349, CAB010759	Enhanced					Tissue enriched	Tissue enriched	738	skeletal muscle: 2753.9	esophagus: 3.7	Not detected		
MYH10	NMMHCB	ENSG00000133026	Myosin heavy chain 10	17	8474205-8630761	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017180, HPA047541, HPA057198	Enhanced		Enhanced	Actin filaments<br>Mitochondria<br>Cytosol	Renal cancer:1.38e-4 (favourable), Urothelial cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 81.0	Cell line enhanced		AF22: 213.4
MYH11	SMHC, SMMHC	ENSG00000133392	Myosin heavy chain 11	16	15703172-15857033	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002302, HPA014539, HPA015310	Enhanced		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.10e-5 (favourable)	Tissue enhanced	Tissue enhanced		seminal vesicle: 1381.0;smooth muscle: 1022.0	prostate: 899.8	Cell line enhanced		BEWO: 1.7;NB-4: 1.2;U-698: 3.4
MYH13	MyHC-eo	ENSG00000006788	Myosin heavy chain 13	17	10300865-10373130	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			placenta: 0.7	Cell line enhanced		U-2 OS: 3.1
MYH14	DFNA4, FLJ13881, KIAA2034, MHC16, MYH17	ENSG00000105357	Myosin heavy chain 14	19	50188186-50310545	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062391, HPA067889, HPA070260	Enhanced		Approved	Nucleoplasm	Renal cancer:3.97e-8 (favourable), Stomach cancer:7.83e-4 (favourable)	Expressed in all	Mixed			small intestine: 83.5	Cell line enhanced		CAPAN-2: 50.4;HaCaT: 91.2;MCF7: 44.9;RT4: 116.8
MYH15	KIAA1000	ENSG00000144821	Myosin heavy chain 15	3	108380369-108529322	Predicted intracellular proteins	Evidence at protein level	HPA034871	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Mitochondria		Not detected	Tissue enhanced		cerebral cortex: 1.9	testis: 0.8	Cell line enhanced		Karpas-707: 1.7;PC-3: 4.7;SH-SY5Y: 1.9;U-87 MG: 1.9
MYH2	IBM3, MYH2A, MYHas8, MyHC-2A, MyHC-IIa, MYHSA2	ENSG00000125414	Myosin heavy chain 2	17	10521148-10549957	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001349, CAB010760	Enhanced					Tissue enriched	Tissue enriched	100	skeletal muscle: 4306.1	esophagus: 43.2	Cell line enhanced		fHDF/TERT166: 3.1;HSkMC: 1.3;NTERA-2: 8.3
MYH3	HEMHC, MYHC-EMB, MYHSE1, SMHCE	ENSG00000109063	Myosin heavy chain 3	17	10628526-10657309	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021808	Enhanced					Mixed	Group enriched	7	esophagus: 9.7;prostate: 46.3;seminal vesicle: 24.5	testis,urinary bladder: 4.0	Cell line enriched	30	HSkMC: 43.3
MYH4	MYH2B, MyHC-2B, MyHC-IIb	ENSG00000264424	Myosin heavy chain 4	17	10443290-10469559	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001349	Supported					Tissue enriched	Tissue enriched	22	skeletal muscle: 3.6	testis: 0.1	Not detected		
MYH6		ENSG00000197616	Myosin heavy chain 6	14	23381990-23408277	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001239, HPA001349, CAB075723, CAB075724, CAB075725	Enhanced					Tissue enriched	Tissue enriched	96	heart muscle: 1838.3	skeletal muscle: 19.1	Cell line enriched	33	NTERA-2: 4.6
MYH7	CMD1S, CMH1, MPD1	ENSG00000092054	Myosin heavy chain 7	14	23412738-23435718	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001239, HPA001349, CAB015384	Enhanced					Group enriched	Group enriched	27	heart muscle: 2309.1;skeletal muscle: 5111.1	esophagus: 135.7	Cell line enriched	23	HSkMC: 8.2
MYH7B	dJ756N5.1, KIAA1512, MHC14, MYH14	ENSG00000078814	Myosin heavy chain 7B	20	34975403-35002437	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:8.44e-5 (favourable)	Mixed	Group enriched	11	heart muscle: 46.9;skeletal muscle: 55.9;testis: 11.7	cerebral cortex,prostate: 3.3	Cell line enhanced		U-138 MG: 1.5
MYH8	MyHC-peri, MyHC-pn	ENSG00000133020	Myosin heavy chain 8	17	10390322-10421950	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001349, CAB016527	Enhanced					Tissue enhanced	Group enriched	5	esophagus: 16.9;skeletal muscle: 5.5	prostate: 2.2	Cell line enriched	10	HSkMC: 5.2
MYH9	DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA	ENSG00000100345	Myosin heavy chain 9	22	36281281-36388018	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001644, CAB015386, HPA064783	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			spleen: 308.5	Expressed in all		
MYL10	MGC3479, MYLC2PL, PLRLC	ENSG00000106436	Myosin light chain 10	7	101613325-101629296	Predicted intracellular proteins	Evidence at protein level	HPA019763	Uncertain		Uncertain	Microtubules		Tissue enhanced	Not detected			cervix, uterine,placenta: 0.7	Cell line enhanced		PC-3: 1.7;RH-30: 2.3
MYL12A	MLCB, MRCL3, MRLC3, MYL2B	ENSG00000101608	Myosin light chain 12A	18	3247481-3256236	Predicted intracellular proteins	Evidence at protein level	CAB004503, HPA039262, HPA045244, HPA059197	Supported		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			heart muscle: 2635.3	Expressed in all		
MYL12B	MRLC2	ENSG00000118680	Myosin light chain 12B	18	3261909-3278284	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039262, HPA045244, HPA059197	Supported		Approved	Nucleus<br>Nucleoli fibrillar center	Thyroid cancer:6.62e-6 (favourable), Renal cancer:8.17e-5 (favourable), Pancreatic cancer:9.69e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 586.9	Expressed in all		
MYL2	CMH10	ENSG00000111245	Myosin light chain 2	12	110910819-110920722	Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019763, HPA039262	Supported		Uncertain	Microtubules	Head and neck cancer:2.60e-4 (unfavourable)	Group enriched	Group enriched	36	heart muscle: 16309.5;skeletal muscle: 9731.7	esophagus: 357.2	Group enriched	6	EFO-21: 3.7;HSkMC: 6.1;U-2 OS: 17.9
MYL3	CMH8, MLC1SB, MLC1V, VLC1	ENSG00000160808	Myosin light chain 3	3	46857872-46882169	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016564, CAB018662, HPA046859, HPA063034	Enhanced		Approved	Nucleoli<br>Mitochondria	Renal cancer:1.22e-8 (favourable)	Tissue enhanced	Group enriched	11	heart muscle: 1578.0;skeletal muscle: 1730.1	esophagus: 157.4	Cell line enhanced		CACO-2: 6.4;HSkMC: 5.6;RPTEC TERT1: 27.5
MYL4	ALC1, AMLC, GT1, PRO1957	ENSG00000198336	Myosin light chain 4	17	47200446-47223679	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046859, HPA051884, HPA063034	Enhanced		Approved	Plasma membrane		Group enriched	Tissue enriched	21	heart muscle: 1686.3	bone marrow: 79.9	Group enriched	20	HEL: 495.8;K-562: 118.9
MYL5		ENSG00000215375	Myosin light chain 5	4	673580-682033	Predicted intracellular proteins	Evidence at protein level	HPA037381, HPA039262	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 22.9	Expressed in all		
MYL6	ESMLC, MLC1SM, MLC3NM	ENSG00000092841	Myosin light chain 6	12	56158161-56163496	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046859, HPA063034	Approved					Expressed in all	Expressed in all			smooth muscle: 5966.7	Expressed in all		
MYL6B	MLC1SA	ENSG00000196465	Myosin light chain 6B	12	56152256-56159647	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038887, HPA046859, HPA063034	Enhanced		Approved	Vesicles	Liver cancer:2.87e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 149.6	Expressed in all		
MYL7	MYL2A, MYLC2A	ENSG00000106631	Myosin light chain 7	7	44138864-44141332	Predicted intracellular proteins	Evidence at protein level	HPA013331, CAB033884, HPA039262	Enhanced					Tissue enriched	Tissue enriched	1272	heart muscle: 8172.3	breast: 6.4	Group enriched	26	BEWO: 34.4;CACO-2: 103.4
MYL9	LC20, MLC2, MRLC1, MYRL2	ENSG00000101335	Myosin light chain 9	20	36541484-36551447	Predicted intracellular proteins	Evidence at protein level	HPA039262, HPA045244, HPA059197	Supported		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:7.92e-7 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 3139.3	Cell line enhanced		BJ: 876.7;fHDF/TERT166: 644.0
MYLIP	IDOL, MIR	ENSG00000007944	Myosin regulatory light chain interacting protein	6	16129125-16148248	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Lung cancer:6.44e-6 (favourable), Urothelial cancer:4.11e-5 (favourable), Renal cancer:3.67e-4 (favourable)	Expressed in all	Expressed in all			placenta: 119.3	Mixed		
MYLK2	KMLC, MLCK2, skMLCK	ENSG00000101306	Myosin light chain kinase 2	20	31819308-31834689	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059704, HPA059890	Enhanced		Supported	Endoplasmic reticulum	Glioma:5.74e-4 (favourable)	Tissue enhanced	Tissue enriched	49	skeletal muscle: 253.1	esophagus: 5.1	Cell line enhanced		RH-30: 10.2;RPMI-8226: 6.2
MYLPF	HUMMLC2B, MRLC2, MYL11	ENSG00000180209	Myosin light chain, phosphorylatable, fast skeletal muscle	16	30370934-30377991	Predicted intracellular proteins	Evidence at protein level	HPA039262, HPA055059	Enhanced					Tissue enhanced	Tissue enriched	95	skeletal muscle: 6541.1	esophagus: 69.1	Group enriched	18	BEWO: 68.9;HSkMC: 114.2
MYNN	SBBIZ1, ZBTB31, ZNF902	ENSG00000085274	Myoneurin	3	169772831-169789716	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045149	Approved		Supported	Nucleus		Expressed in all	Expressed in all			testis: 18.2	Expressed in all		
MYO10	KIAA0799	ENSG00000145555	Myosin X	5	16661914-16936276	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015224, HPA024223	Enhanced		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:2.75e-4 (favourable), Cervical cancer:4.35e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 68.3	Mixed		
MYO15A	DFNB3, MYO15	ENSG00000091536	Myosin XVA	17	18108706-18179802	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA078501	Supported					Not detected	Tissue enhanced		testis: 10.4	ovary: 2.5	Not detected		
MYO15B	MYO15BP	ENSG00000266714	Myosin XVB	17	75588058-75626501	Predicted intracellular proteins	Evidence at transcript level	HPA022857, HPA023105			Approved	Cytosol	Urothelial cancer:6.90e-5 (favourable), Breast cancer:9.34e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 148.3	Cell line enhanced		A549: 36.9;HMC-1: 21.7;THP-1: 24.6
MYO16	KIAA0865, Myo16b, MYR8, NYAP3, PPP1R107	ENSG00000041515	Myosin XVI	13	108596152-109208007	Predicted intracellular proteins	Evidence at protein level	HPA040110, HPA058769, HPA071948	Uncertain		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 2.1	testis: 1.0	Cell line enhanced		SH-SY5Y: 2.4;U-2197: 1.2
MYO18A	KIAA0216, MysPDZ	ENSG00000196535	Myosin XVIIIA	17	29071124-29180412	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019646, HPA021121	Enhanced				Renal cancer:3.18e-4 (favourable), Ovarian cancer:3.28e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 133.5	Expressed in all		
MYO18B	BK125H2.1	ENSG00000133454	Myosin XVIIIB	22	25742144-26031041	Predicted intracellular proteins	Evidence at protein level	HPA000953	Uncertain		Supported	Nucleoplasm<br>Centrosome		Mixed	Group enriched	8	heart muscle: 47.3;skeletal muscle: 52.5	testis: 5.8	Cell line enhanced		HDLM-2: 9.7;REH: 13.6;RH-30: 29.4;U-2 OS: 13.9;U-266/70: 7.2
MYO19	FLJ22865, MYOHD1	ENSG00000278259	Myosin XIX	17	36495633-36543435	Predicted intracellular proteins	Evidence at protein level	HPA021415, HPA059715	Approved		Enhanced	Cytosol	Liver cancer:8.33e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 14.5	Expressed in all		
MYO1A	DFNA48, MYHL	ENSG00000166866	Myosin IA	12	57028517-57051198	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053490	Enhanced					Group enriched	Group enriched	13	colon: 67.8;duodenum: 333.2;rectum: 71.8;small intestine: 338.4	stomach: 16.1	Cell line enhanced		BEWO: 1.9;CACO-2: 6.6;Hep G2: 3.7
MYO1B	myr1	ENSG00000128641	Myosin IB	2	191245185-191425389	Predicted intracellular proteins	Evidence at protein level	HPA013607, HPA060144	Approved		Enhanced	Plasma membrane	Renal cancer:2.36e-5 (unfavourable)	Expressed in all	Mixed			liver: 130.2	Cell line enhanced		hTERT-HME1: 276.9
MYO1C	myr2	ENSG00000197879	Myosin IC	17	1464098-1492812	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001768, HPA005924, CAB037023	Enhanced		Enhanced	Nuclear bodies<br>Plasma membrane	Lung cancer:5.22e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 192.4	Mixed		
MYO1D	KIAA0727, myr4, PPP1R108	ENSG00000176658	Myosin ID	17	32492522-32877177	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054744	Uncertain		Approved	Cytosol	Urothelial cancer:4.53e-6 (unfavourable), Renal cancer:5.01e-6 (favourable)	Expressed in all	Mixed			colon: 109.1	Cell line enhanced		CACO-2: 120.9
MYO1E	HuncM-IC, MGC104638, MYO1C	ENSG00000157483	Myosin IE	15	59132434-59372900	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023886	Approved				Lung cancer:1.57e-6 (unfavourable), Endometrial cancer:4.19e-4 (favourable), Pancreatic cancer:7.99e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 67.0	Mixed		
MYO1F		ENSG00000142347	Myosin IF	19	8520790-8577577	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055242	Enhanced				Renal cancer:3.27e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 50.4;bone marrow: 59.7;spleen: 63.3	lung: 23.4	Cell line enhanced		HDLM-2: 45.8;HMC-1: 73.1;NB-4: 127.9;THP-1: 99.8;U-937: 61.8
MYO1G	HA-2	ENSG00000136286	Myosin IG	7	44962662-44979098	Predicted intracellular proteins	Evidence at protein level	HPA021252	Enhanced				Renal cancer:8.71e-8 (unfavourable), Cervical cancer:8.26e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 27.7;lymph node: 27.7;spleen: 24.6	appendix: 21.9	Cell line enhanced		HDLM-2: 53.6;HEL: 62.4;HL-60: 31.8;MOLT-4: 71.7;THP-1: 52.2;U-937: 44.7
MYO1H	FLJ37587	ENSG00000174527	Myosin IH	12	109347903-109455523	Predicted intracellular proteins	Evidence at protein level	HPA039516	Uncertain					Not detected	Tissue enriched	6	testis: 1.7	thyroid gland: 0.3	Not detected		
MYO3A	DFNB30	ENSG00000095777	Myosin IIIA	10	25934267-26212527	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048951, HPA051893	Approved		Supported	Plasma membrane<br>Actin filaments<br>Cytoplasmic bodies		Mixed	Tissue enriched	9	testis: 6.8	skin: 0.8	Cell line enhanced		CAPAN-2: 2.0;HEK93: 2.2;SCLC-21H: 2.3;U-2 OS: 3.7;U-698: 8.6
MYO3B		ENSG00000071909	Myosin IIIB	2	170178145-170655171	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045483	Approved					Mixed	Group enriched	5	epididymis: 11.8;kidney: 4.8;parathyroid gland: 15.3;urinary bladder: 4.2	thyroid gland: 1.6	Group enriched	11	HDLM-2: 8.9;HEL: 7.8;RT4: 7.8
MYO5A	GS1, MYH12, MYO5, MYR12	ENSG00000197535	Myosin VA	15	52307283-52529050	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001356	Approved		Approved	Focal adhesion sites<br>Microtubule organizing center	Urothelial cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 96.4	Cell line enhanced		Karpas-707: 145.4
MYO5B	KIAA1119	ENSG00000167306	Myosin VB	18	49822813-50195093	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040593, HPA040902, HPA069773	Enhanced		Approved	Plasma membrane	Renal cancer:1.45e-11 (favourable), Pancreatic cancer:2.26e-5 (unfavourable)	Expressed in all	Mixed			small intestine: 67.6	Cell line enhanced		HaCaT: 88.6;RH-30: 147.5
MYO5C	MGC74969	ENSG00000128833	Myosin VC	15	52192322-52295798	Predicted intracellular proteins	Evidence at protein level	CAB020790, HPA032115, HPA032116	Enhanced		Supported	Nucleus<br>Cytosol	Renal cancer:2.47e-5 (favourable), Endometrial cancer:5.18e-5 (favourable), Stomach cancer:5.82e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 38.6	Cell line enhanced		MCF7: 35.3;SK-BR-3: 25.4;T-47d: 38.5
MYO6	DFNA22, DFNB37, KIAA0389	ENSG00000196586	Myosin VI	6	75749192-75919537	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010762, HPA035483	Enhanced				Renal cancer:1.27e-12 (favourable)	Expressed in all	Mixed			parathyroid gland: 85.5	Mixed		
MYO7A	DFNA11, DFNB2, NSRD2, USH1B	ENSG00000137474	Myosin VIIA	11	77128264-77215239	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028918, CAB034059	Uncertain		Approved	Cytosol	Renal cancer:3.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 26.8;placenta: 20.8	testis: 17.2	Cell line enhanced		BEWO: 11.1;RH-30: 20.1;RPMI-8226: 9.7;SK-BR-3: 8.1;U-937: 11.1
MYO7B		ENSG00000169994	Myosin VIIB	2	127535802-127637729	Predicted intracellular proteins	Evidence at protein level	HPA039131	Enhanced				Renal cancer:1.25e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 113.9;small intestine: 92.1	colon: 35.2	Cell line enriched	17	MOLT-4: 228.8
MYO9A	FLJ11061, FLJ13244, MGC71859	ENSG00000066933	Myosin IXA	15	71822289-72118577	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039812, HPA040071	Approved		Approved	Plasma membrane	Renal cancer:2.14e-4 (favourable)	Mixed	Tissue enhanced		testis: 51.5	thyroid gland: 22.1	Expressed in all		
MYO9B	CELIAC4	ENSG00000099331	Myosin IXB	19	17075781-17214537	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB037190, HPA042043	Approved		Supported	Cytosol	Renal cancer:5.66e-6 (unfavourable), Ovarian cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 98.8	Expressed in all		
MYOCD	MYCD	ENSG00000141052	Myocardin	17	12665890-12768949	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB046485	Approved					Mixed	Tissue enhanced		seminal vesicle: 28.9	smooth muscle: 22.9	Cell line enhanced		BJ: 5.5;BJ hTERT+: 5.2;HBF TERT88: 10.1;hTEC/SVTERT24-B: 11.7;REH: 7.6
MYOD1	bHLHc1, MYF3, MYOD, PUM	ENSG00000129152	Myogenic differentiation 1	11	17719568-17722131	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051362			Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Tissue enhanced	Tissue enriched	10	skeletal muscle: 9.0	prostate: 0.9	Cell line enriched	17	RH-30: 447.0
MYOG	bHLHc3, MYF4	ENSG00000122180	Myogenin	1	203083132-203086036	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028336, HPA038093	Approved		Supported	Nucleoplasm		Group enriched	Tissue enriched	9	skeletal muscle: 31.7	prostate: 3.3	Group enriched	197	HSkMC: 21.2;RH-30: 55.2
MYOM1		ENSG00000101605	Myomesin 1	18	3066807-3220108	Predicted intracellular proteins	Evidence at protein level	HPA014305, HPA049193	Enhanced					Tissue enhanced	Group enriched	13	heart muscle: 278.1;skeletal muscle: 299.1	gallbladder: 22.9	Group enriched	12	HAP1: 13.8;HMC-1: 3.1;HSkMC: 4.5
MYOM2		ENSG00000036448	Myomesin 2	8	2045040-2165552	Predicted intracellular proteins	Evidence at protein level	HPA001765, HPA005953	Enhanced		Approved	Mitochondria		Mixed	Group enriched	19	heart muscle: 197.4;skeletal muscle: 110.2	breast: 8.1	Group enriched	8	HEK93: 4.8;SCLC-21H: 2.6;U-266/84: 2.0
MYOM3	FLJ35961	ENSG00000142661	Myomesin 3	1	24056035-24112175	Predicted intracellular proteins	Evidence at protein level	HPA028132, HPA029752	Uncertain		Approved	Vesicles	Renal cancer:4.28e-6 (favourable)	Tissue enhanced	Group enriched	5	heart muscle: 69.9;kidney: 31.8;skeletal muscle: 86.5	testis: 12.1	Cell line enhanced		A549: 4.2;Hep G2: 12.2
MYOT	LGMD1, LGMD1A, TTID	ENSG00000120729	Myotilin	5	137867791-137887851	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037733, HPA037734	Enhanced				Head and neck cancer:8.85e-4 (unfavourable)	Tissue enhanced	Tissue enriched	21	skeletal muscle: 766.9	esophagus: 36.1	Not detected		
MYOZ1	CS-2, FATZ, MYOZ	ENSG00000177791	Myozenin 1	10	73631654-73641757	Predicted intracellular proteins	Evidence at protein level	HPA037848, HPA038437	Enhanced					Tissue enhanced	Tissue enriched	38	skeletal muscle: 2058.9	esophagus: 54.7	Cell line enriched	25	BEWO: 38.7
MYOZ2	C4orf5, CS-1	ENSG00000172399	Myozenin 2	4	119135784-119187789	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035763, HPA035764	Enhanced		Approved	Nucleus<br>Cytosol		Tissue enhanced	Tissue enriched	8	heart muscle: 500.2	skeletal muscle: 63.4	Cell line enhanced		HSkMC: 1.6;SK-MEL-30: 4.7;U-87 MG: 6.0
MYOZ3	CS-3, CS3, FRP3	ENSG00000164591	Myozenin 3	5	150660874-150679365	Predicted intracellular proteins	Evidence at protein level	HPA039166	Enhanced					Mixed	Tissue enriched	11	skeletal muscle: 87.7	testis: 7.8	Cell line enhanced		HAP1: 5.3;NTERA-2: 9.1;REH: 13.2
MYPN	MYOP	ENSG00000138347	Myopalladin	10	68106117-68212017	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036299, HPA061494	Enhanced		Approved	Nucleus<br>Vesicles<br>Cytosol		Tissue enriched	Group enriched	27	heart muscle: 41.6;skeletal muscle: 99.9	prostate: 2.6	Cell line enhanced		BJ: 33.6;fHDF/TERT166: 87.0;HBF TERT88: 24.6;LHCN-M2: 39.6
MYPOP	P42pop	ENSG00000176182	Myb related transcription factor, partner of profilin	19	45890020-45902604	Predicted intracellular proteins	Evidence at protein level	HPA065307			Approved	Nucleoplasm	Ovarian cancer:8.67e-5 (unfavourable), Liver cancer:1.21e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 10.2	Expressed in all		
MYRIP	DKFZp586F1018, exophilin-8, MyRIP, SLAC2-C, SLAC2C	ENSG00000170011	Myosin VIIA and Rab interacting protein	3	39808914-40260321	Predicted intracellular proteins	Evidence at protein level	HPA006433			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Renal cancer:3.96e-8 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 20.6	spleen: 9.9	Cell line enhanced		HAP1: 4.2;HUVEC TERT2: 13.0;SCLC-21H: 3.8;SH-SY5Y: 10.0
MYSM1	KIAA1915	ENSG00000162601	Myb like, SWIRM and MPN domains 1	1	58654739-58700092	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054291, HPA067133	Approved		Supported	Nucleoplasm<br>Plasma membrane	Head and neck cancer:5.09e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 11.2	Mixed		
MYT1	MTF1, MYTI, NZF2, PLPB1, ZC2H2C1, ZC2HC4A	ENSG00000196132	Myelin transcription factor 1	20	64151791-64242253	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006303	Uncertain		Supported	Nucleoplasm<br>Cytosol		Tissue enhanced	Group enriched	7	adrenal gland: 2.5;cerebral cortex: 5.7	testis: 0.6	Cell line enhanced		REH: 3.3;SCLC-21H: 16.5;SH-SY5Y: 3.0
MYT1L	KIAA1106, NZF1, ZC2H2C2, ZC2HC4B	ENSG00000186487	Myelin transcription factor 1 like	2	1789113-2331260	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060245			Approved	Vesicles		Not detected	Tissue enriched	11	cerebral cortex: 60.0	testis: 5.3	Group enriched	12	SCLC-21H: 7.8;SH-SY5Y: 5.2
MYZAP	GCOM1, Gup, Gup1, MYOZAP	ENSG00000263155	Myocardial zonula adherens protein	15	57591941-57685364	Predicted intracellular proteins	Evidence at protein level	HPA039827	Approved					Mixed	Tissue enhanced		heart muscle: 388.5	placenta: 84.1	Cell line enhanced		HEL: 121.1;HUVEC TERT2: 24.2;TIME: 25.5
MZF1	MZF-1, MZF1B, Zfp98, ZNF42, ZSCAN6	ENSG00000099326	Myeloid zinc finger 1	19	58561931-58573575	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001757	Approved		Supported	Nucleus	Renal cancer:2.83e-8 (unfavourable), Urothelial cancer:4.09e-5 (favourable), Pancreatic cancer:7.97e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 14.6	Cell line enhanced		HEK93: 39.4
MZT1	C13orf37, FLJ21869, LOC440145, MGC150539, MOZART1, RP11-11C5.2	ENSG00000204899	Mitotic spindle organizing protein 1	13	72708357-72727687	Predicted intracellular proteins	Evidence at protein level	HPA063299, HPA066715	Approved				Renal cancer:1.01e-5 (unfavourable), Liver cancer:3.22e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.1	Expressed in all		
MZT2A	FAM128A, MOZART2A	ENSG00000173272	Mitotic spindle organizing protein 2A	2	131464900-131492743	Predicted intracellular proteins	Evidence at protein level	HPA051758, HPA052623	Approved		Supported	Centrosome<br>Cytosol	Renal cancer:3.04e-11 (unfavourable), Breast cancer:3.04e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 40.5	Mixed		
MZT2B	FAM128B, FLJ14346, MOZART2B	ENSG00000152082	Mitotic spindle organizing protein 2B	2	130181737-130190729	Predicted intracellular proteins	Evidence at protein level	HPA051758, HPA052623	Approved		Supported	Centrosome<br>Cytosol	Renal cancer:9.37e-8 (unfavourable), Liver cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 81.3	Expressed in all		
N4BP1		ENSG00000102921	NEDD4 binding protein 1	16	48538726-48620148	Predicted intracellular proteins	Evidence at protein level	HPA040849, HPA041080	Approved		Approved	Nucleoli fibrillar center	Renal cancer:9.03e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 22.1	Expressed in all		
N4BP2	B3BP	ENSG00000078177	NEDD4 binding protein 2	4	40056826-40158252	Predicted intracellular proteins	Evidence at protein level	HPA036770, HPA042607	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Centrosome		Expressed in all	Mixed			endometrium: 5.6	Cell line enhanced		MOLT-4: 20.8
N4BP2L1	CG018	ENSG00000139597	NEDD4 binding protein 2 like 1	13	32400723-32428311	Predicted intracellular proteins	Evidence at protein level	HPA038971	Approved		Uncertain	Nucleoplasm<br>Cytosol	Liver cancer:3.11e-4 (favourable)	Expressed in all	Expressed in all			ovary: 47.8	Cell line enhanced		HEL: 21.3;NB-4: 38.0
N4BP3	LZTS4	ENSG00000145911	NEDD4 binding protein 3	5	178113443-178126087	Predicted intracellular proteins	Evidence at protein level	HPA030972, HPA030973, HPA061387	Approved		Supported	Nucleoplasm<br>Centrosome	Renal cancer:2.38e-4 (favourable)	Mixed	Tissue enhanced		placenta: 11.8	parathyroid gland: 10.2	Cell line enhanced		MCF7: 15.8;RH-30: 19.3;SK-BR-3: 53.2
N6AMT1	C21orf127, HEMK2, MTQ2, N6AMT, PRED28	ENSG00000156239	N-6 adenine-specific DNA methyltransferase 1 (putative)	21	28872191-28885371	Predicted intracellular proteins	Evidence at protein level	CAB034133, CAB034135, HPA059242	Approved		Approved	Nucleoplasm<br>Centrosome		Expressed in all	Mixed			parathyroid gland: 10.8	Expressed in all		
NAA10	ARD1, ARD1A, DXS707, TE2	ENSG00000102030	N(alpha)-acetyltransferase 10, NatA catalytic subunit	X	153929242-153935223	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB006269, HPA030711	Supported		Enhanced	Nucleoli<br>Cytosol	Renal cancer:3.29e-8 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 25.7	Expressed in all		
NAA11	ARD1B, ARD2, hARD2	ENSG00000156269	N(alpha)-acetyltransferase 11, NatA catalytic subunit	4	79225694-79326050	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035922	Approved					Tissue enhanced	Group enriched	37	placenta: 6.1;testis: 11.4	cerebral cortex,endometrium,parathyroid gland,smooth muscle,thyroid gland: 0.2	Cell line enhanced		K-562: 11.1;U-266/70: 25.3;U-266/84: 8.0
NAA15	FLJ13340, NARG1, NATH, TBDN100	ENSG00000164134	N(alpha)-acetyltransferase 15, NatA auxiliary subunit	4	139301455-139420033	Predicted intracellular proteins	Evidence at protein level	HPA023589, HPA050661	Approved		Enhanced	Cytosol	Liver cancer:2.03e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.1	Expressed in all		
NAA16	FLJ22054, MGC40612, NARG1L, PRO2435	ENSG00000172766	N(alpha)-acetyltransferase 16, NatA auxiliary subunit	13	41311205-41377030	Predicted intracellular proteins	Evidence at protein level	HPA039761, HPA040157	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			bone marrow: 14.4	Expressed in all		
NAA20	dJ1002M8.1, NAT3, NAT5	ENSG00000173418	N(alpha)-acetyltransferase 20, NatB catalytic subunit	20	20017116-20033655	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA063344			Supported	Cytosol	Head and neck cancer:1.96e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 82.5	Expressed in all		
NAA30	C14orf35, FLJ35355, MAK3, Mak3p, NAT12	ENSG00000139977	N(alpha)-acetyltransferase 30, NatC catalytic subunit	14	57390544-57415917	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA057824	Uncertain		Supported	Cytosol	Renal cancer:1.25e-8 (favourable)	Expressed in all	Expressed in all			testis: 34.2	Expressed in all		
NAA35	bA379P1.1, FLJ21613, FLJ22643, MAK10	ENSG00000135040	N(alpha)-acetyltransferase 35, NatC auxiliary subunit	9	85941146-86022298	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021547, HPA051586	Approved		Supported	Vesicles	Liver cancer:1.16e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 37.9	Expressed in all		
NAA40	FLJ13848, NAT11	ENSG00000110583	N(alpha)-acetyltransferase 40, NatD catalytic subunit	11	63938959-63957328	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037816	Uncertain		Approved	Nuclear bodies	Liver cancer:1.43e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 27.1	Expressed in all		
NAA50	FLJ13194, MAK3, NAT13, NAT5, San	ENSG00000121579	N(alpha)-acetyltransferase 50, NatE catalytic subunit	3	113716460-113746300	Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.51e-5 (unfavourable), Pancreatic cancer:7.92e-5 (unfavourable), Endometrial cancer:2.32e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 111.8	Expressed in all		
NAA60	FLJ14154, NAT15	ENSG00000122390	N(alpha)-acetyltransferase 60, NatF catalytic subunit	16	3443611-3486963	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040916	Approved		Uncertain	Actin filaments<br>Cytosol	Endometrial cancer:3.14e-4 (favourable), Pancreatic cancer:4.30e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 86.3	Expressed in all		
NAALADL1		ENSG00000168060	N-acetylated alpha-linked acidic dipeptidase like 1	11	65044818-65058549	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047123	Enhanced		Uncertain	Cytosol		Expressed in all	Tissue enriched	5	small intestine: 104.2	duodenum: 20.1	Cell line enhanced		fHDF/TERT166: 6.0;HHSteC: 17.2;HSkMC: 9.8;SCLC-21H: 12.7
NAB1		ENSG00000138386	NGFI-A binding protein 1	2	190646746-190692766	Predicted intracellular proteins	Evidence at protein level	HPA002738	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane	Pancreatic cancer:1.01e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 80.6	Expressed in all		
NAB2	MADER	ENSG00000166886	NGFI-A binding protein 2	12	57088894-57095476	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004510, HPA027464	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:9.38e-6 (unfavourable), Breast cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			ovary: 39.3	Expressed in all		
NABP1	DKFZp667M1322, FLJ13624, FLJ22833, hSSB2, MGC111163, OBFC2A, SOSS-B2, SSB2	ENSG00000173559	Nucleic acid binding protein 1	2	191678068-191696659	Predicted intracellular proteins	Evidence at protein level	HPA054978, HPA067802			Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.20e-7 (unfavourable)	Expressed in all	Mixed			appendix: 49.2	Mixed		
NABP2	hSSB1, MGC2731, OBFC2B, SOSS-B1, SSB1	ENSG00000139579	Nucleic acid binding protein 2	12	56222015-56229854	Predicted intracellular proteins	Evidence at protein level	HPA044615, HPA057213	Supported		Enhanced	Nucleoplasm	Liver cancer:7.44e-6 (unfavourable), Cervical cancer:8.35e-6 (favourable), Renal cancer:2.69e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 42.0	Expressed in all		
NACA	NACA1	ENSG00000196531	Nascent polypeptide-associated complex alpha subunit	12	56712428-56731628	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA073152, HPA073648			Approved	Cytosol	Renal cancer:4.58e-11 (unfavourable)	Expressed in all	Expressed in all			ovary: 2552.0	Expressed in all		
NACA2	MGC71999, NACAL	ENSG00000253506	Nascent polypeptide associated complex alpha subunit 2	17	61590426-61591202	Predicted intracellular proteins	Evidence at protein level	HPA073152, HPA073648			Approved	Cytosol		Mixed	Tissue enriched	129	testis: 104.2	appendix,ovary: 0.8	Cell line enhanced		NB-4: 2.1
NACAD	KIAA0363	ENSG00000136274	NAC alpha domain containing	7	45080438-45088914	Predicted intracellular proteins	Evidence at protein level	HPA020981	Enhanced		Approved	Nucleus<br>Cytosol	Glioma:2.23e-4 (unfavourable)	Group enriched	Tissue enriched	6	cerebral cortex: 48.7	ovary: 7.6	Cell line enhanced		SCLC-21H: 30.5;SH-SY5Y: 19.0
NACC1	BEND8, BTBD14B, BTBD30, NAC-1, NAC1	ENSG00000160877	Nucleus accumbens associated 1	19	13118103-13141141	Predicted intracellular proteins	Evidence at protein level	HPA021238, HPA062245, CAB069927	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 37.1	Expressed in all		
NACC2	BEND9, BTBD14A, BTBD31, MGC23427	ENSG00000148411	NACC family member 2	9	136006537-136095285	Predicted intracellular proteins	Evidence at protein level	HPA047924, HPA052962	Approved		Approved	Nucleoli<br>Mitochondria	Renal cancer:8.28e-5 (favourable), Stomach cancer:8.63e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 46.8	Mixed		
NADK	FLJ13052	ENSG00000008130	NAD kinase	1	1751232-1780457	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048909, HPA053368	Uncertain		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			spleen: 77.4	Expressed in all		
NADK2	C5orf33, FLJ30596, MNADK, NADKD1	ENSG00000152620	NAD kinase 2, mitochondrial	5	36192592-36242279	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038366, HPA038367, HPA061492	Enhanced					Expressed in all	Expressed in all			liver: 173.0	Expressed in all		
NADSYN1	FLJ10631	ENSG00000172890	NAD synthetase 1	11	71453109-71524107	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB017798, HPA038523, HPA038524	Approved		Enhanced	Cytosol	Liver cancer:5.17e-6 (unfavourable), Renal cancer:8.72e-5 (unfavourable), Urothelial cancer:5.10e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 41.7	Expressed in all		
NAE1	APP-BP1, APPBP1, ula-1	ENSG00000159593	NEDD8 activating enzyme E1 subunit 1	16	66802875-66873256	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041178, HPA042041	Enhanced		Approved	Nucleus<br>Microtubules<br>Centrosome	Liver cancer:3.92e-8 (unfavourable), Thyroid cancer:9.44e-5 (favourable)	Expressed in all	Expressed in all			testis: 86.4	Expressed in all		
NAF1		ENSG00000145414	Nuclear assembly factor 1 ribonucleoprotein	4	163110073-163166921	Predicted intracellular proteins	Evidence at protein level	HPA036241, HPA036242, HPA066090	Approved		Enhanced	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 24.4	Expressed in all		
NAGK	GNK	ENSG00000124357	N-acetylglucosamine kinase	2	71064344-71079805	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035206, HPA035207	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:4.35e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable), Endometrial cancer:6.88e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 148.0	Expressed in all		
NAIF1	bA379C10.2, C9orf90, DKFZp762G199	ENSG00000171169	Nuclear apoptosis inducing factor 1	9	128061233-128068206	Predicted intracellular proteins	Evidence at protein level	HPA054898, HPA064931			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.02e-5 (favourable), Renal cancer:8.30e-5 (favourable), Liver cancer:1.61e-4 (unfavourable)	Expressed in all	Mixed			testis: 4.6	Expressed in all		
NAIP	BIRC1, NLRB1	ENSG00000249437	NLR family apoptosis inhibitory protein	5	70968483-71025114	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042438	Approved					Not detected	Mixed			appendix,spleen: 3.9	Cell line enhanced		MOLT-4: 3.0;SiHa: 2.2;T-47d: 2.1
NAMPT	PBEF, PBEF1	ENSG00000105835	Nicotinamide phosphoribosyltransferase	7	106248285-106286326	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034349, HPA047776, HPA057722	Approved		Approved	Nuclear speckles<br>Cell Junctions	Renal cancer:2.49e-6 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable), Cervical cancer:4.78e-4 (unfavourable), Head and neck cancer:8.81e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 778.1	Expressed in all		
NANOG	FLJ12581, FLJ40451	ENSG00000111704	Nanog homeobox	12	7787794-7799141	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019380	Supported					Tissue enriched	Tissue enhanced		testis: 1.9	lung: 0.7	Cell line enriched	438	NTERA-2: 118.9
NANOGNB		ENSG00000205857	NANOG neighbor homeobox	12	7765216-7774121	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA060371	Uncertain					Tissue enriched	Not detected			testis: 0.5	Not detected		
NANOGP8		ENSG00000255192	Nanog homeobox pseudogene 8	15	35084193-35085110	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			testis: 0.8	Cell line enriched	125	NTERA-2: 50.8
NANOS1	NOS1, ZC2HC12A	ENSG00000188613	Nanos C2HC-type zinc finger 1	10	119029716-119033732	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012219	Approved		Supported	Nucleoplasm<br>Cytosol	Breast cancer:1.52e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 13.2	thyroid gland: 11.9	Cell line enhanced		SH-SY5Y: 85.4;SK-BR-3: 34.9;SK-MEL-30: 28.2
NANOS2	NOS2, ZC2HC12B	ENSG00000188425	Nanos C2HC-type zinc finger 2	19	45913214-45914870	Predicted intracellular proteins	Evidence at protein level	HPA014190	Approved					Not detected	Tissue enriched	37	testis: 3.6	all non-specific tissues: 0.0	Not detected		
NANOS3	NANOS1L, NOS3, ZC2HC12C	ENSG00000187556	Nanos C2HC-type zinc finger 3	19	13862063-13880757	Predicted intracellular proteins	Evidence at protein level	HPA062989	Enhanced					Tissue enriched	Tissue enriched	6	testis: 7.0	cerebral cortex: 1.1	Not detected		
NANP	C20orf147, dJ694B14.3, HDHD4, MGC26833	ENSG00000170191	N-acetylneuraminic acid phosphatase	20	25612935-25624175	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050342	Uncertain		Approved	Nuclear membrane	Liver cancer:9.01e-6 (unfavourable)	Expressed in all	Mixed			testis: 4.9	Expressed in all		
NANS	SAS	ENSG00000095380	N-acetylneuraminate synthase	9	98056739-98083075	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019223	Approved		Approved	Nucleoplasm	Endometrial cancer:1.71e-4 (favourable), Liver cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 148.2	Expressed in all		
NAP1L1	MGC23410, MGC8688, NAP1, NAP1L, NRP	ENSG00000187109	Nucleosome assembly protein 1 like 1	12	76036587-76085033	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028861	Approved		Uncertain	Microtubules	Renal cancer:6.14e-13 (unfavourable), Liver cancer:3.29e-9 (unfavourable)	Expressed in all	Expressed in all			ovary: 742.4	Expressed in all		
NAP1L2	BPX, MGC26243	ENSG00000186462	Nucleosome assembly protein 1 like 2	X	73212299-73214848	Predicted intracellular proteins	Evidence at protein level	HPA054050, HPA057065			Enhanced	Vesicles<br>Plasma membrane<br>Cytosol	Pancreatic cancer:5.41e-4 (favourable)	Mixed	Tissue enriched	5	cerebral cortex: 90.1	parathyroid gland,prostate: 17.8	Cell line enhanced		EFO-21: 15.7;NTERA-2: 18.1;U-2197: 13.6;U-266/84: 21.9
NAP1L3	MB20, MGC26312, NPL3	ENSG00000186310	Nucleosome assembly protein 1 like 3	X	93670930-93673568	Predicted intracellular proteins	Evidence at protein level	HPA026075			Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 131.3	testis: 31.1	Cell line enhanced		AF22: 13.4;HAP1: 13.7;NTERA-2: 24.0;U-2197: 15.0
NAP1L4	NAP2	ENSG00000205531	Nucleosome assembly protein 1 like 4	11	2944431-2992377	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011567	Approved		Supported	Nucleoplasm	Liver cancer:1.68e-7 (unfavourable), Thyroid cancer:1.55e-4 (favourable), Cervical cancer:9.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 148.6	Expressed in all		
NAP1L5	DRLM	ENSG00000177432	Nucleosome assembly protein 1 like 5	4	88695915-88698235	Predicted intracellular proteins	Evidence at protein level	HPA058227	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 91.1	adrenal gland: 29.5	Cell line enhanced		SH-SY5Y: 42.7
NAP1L6	FLJ33596	ENSG00000204118	Nucleosome assembly protein 1 like 6	X	73126037-73128080	Predicted intracellular proteins	Evidence at transcript level	HPA044957	Uncertain					Mixed	Mixed			thyroid gland: 1.2	Group enriched	6	U-2 OS: 3.4;U-266/84: 2.1
NAPA		ENSG00000105402	NSF attachment protein alpha	19	47487637-47515240	Predicted intracellular proteins	Evidence at protein level	CAB010100, HPA046149, HPA050196	Approved		Uncertain	Cytosol	Renal cancer:4.26e-9 (favourable)	Expressed in all	Expressed in all			prostate: 157.4	Expressed in all		
NAPB	SNAP-BETA, SNAPB	ENSG00000125814	NSF attachment protein beta	20	23374519-23421519	Predicted intracellular proteins	Evidence at protein level	CAB037225, CAB037227, HPA046149, HPA050196	Approved		Uncertain	Cytosol	Renal cancer:1.14e-4 (unfavourable)	Expressed in all	Tissue enriched	9	cerebral cortex: 303.2	adrenal gland: 32.1	Expressed in all		
NAPEPLD	C7orf18, FMP30, NAPE-PLD	ENSG00000161048	N-acyl phosphatidylethanolamine phospholipase D	7	103099776-103149560	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019832, HPA024338	Approved		Enhanced	Cytosol	Renal cancer:7.32e-6 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.2	Mixed		
NAPG		ENSG00000134265	NSF attachment protein gamma	18	10525905-10552761	Predicted intracellular proteins	Evidence at protein level	HPA008208, HPA011389	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:8.14e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 50.5	Expressed in all		
NAPRT	NAPRT1, PP3856	ENSG00000147813	Nicotinate phosphoribosyltransferase	8	143574785-143578649	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023739, HPA024017, CAB068206, CAB068207	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:6.28e-4 (favourable)	Expressed in all	Tissue enhanced		duodenum: 21.4;small intestine: 20.7	bone marrow: 9.6	Cell line enhanced		CAPAN-2: 33.3;SK-BR-3: 30.1
NARF	DKFZp434G0420, FLJ10067, IOP2	ENSG00000141562	Nuclear prelamin A recognition factor	17	82458180-82490537	Predicted intracellular proteins	Evidence at protein level	HPA053006			Supported	Nucleus<br>Nucleoli	Renal cancer:1.48e-10 (unfavourable), Cervical cancer:1.15e-4 (favourable)	Expressed in all	Expressed in all			testis: 47.3	Expressed in all		
NARFL	FLJ21988, HPRN, IOP1, NAR1, PRN	ENSG00000103245	Nuclear prelamin A recognition factor like	16	729753-741329	Predicted intracellular proteins	Evidence at protein level	HPA040851	Approved		Approved	Plasma membrane<br>Cytosol	Cervical cancer:1.32e-5 (favourable), Renal cancer:9.83e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.3	Expressed in all		
NARS	NARS1	ENSG00000134440	Asparaginyl-tRNA synthetase	18	57600656-57622213	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034257, HPA040017	Enhanced		Approved	Cytosol	Liver cancer:1.23e-7 (unfavourable), Renal cancer:1.73e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 154.1	Expressed in all		
NARS2	DFNB94, FLJ23441, SLM5	ENSG00000137513	Asparaginyl-tRNA synthetase 2, mitochondrial (putative)	11	78435961-78574874	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026793	Supported		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:1.22e-6 (favourable), Ovarian cancer:1.39e-5 (favourable)	Expressed in all	Expressed in all			kidney: 19.8	Expressed in all		
NASP	DKFZp547F162, FLB7527, FLJ31599, FLJ35510, MGC19722, MGC20372, MGC2297, PRO1999	ENSG00000132780	Nuclear autoantigenic sperm protein	1	45583846-45618904	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028136, HPA030518, HPA030520	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.91e-8 (unfavourable), Liver cancer:4.96e-6 (unfavourable), Melanoma:3.67e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 149.6	Expressed in all		
NAT1	AAC1	ENSG00000171428	N-acetyltransferase 1	8	18170477-18223689	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB017782, HPA043704	Approved				Colorectal cancer:5.07e-4 (favourable)	Tissue enriched	Mixed			epididymis: 18.4	Mixed		
NAT10	FLJ10774, FLJ12179, hALP, KIAA1709, NET43	ENSG00000135372	N-acetyltransferase 10	11	34105602-34147670	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB035546, HPA057576, HPA071628	Enhanced		Enhanced	Nucleoli<br>Midbody	Liver cancer:9.61e-8 (unfavourable), Renal cancer:8.83e-5 (unfavourable), Head and neck cancer:1.07e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.7	Expressed in all		
NAT16	C7orf52, FLJ39237	ENSG00000167011	N-acetyltransferase 16 (putative)	7	101170493-101180276	Predicted intracellular proteins	Evidence at transcript level	HPA021918	Uncertain		Approved	Nucleus		Tissue enhanced	Group enriched	8	cerebral cortex: 5.1;thyroid gland: 3.0	pancreas: 0.5	Cell line enhanced		RPMI-8226: 1.6;SH-SY5Y: 3.6;SK-MEL-30: 2.0;U-2 OS: 3.1;U-87 MG: 1.6
NAT2	AAC2	ENSG00000156006	N-acetyltransferase 2	8	18391245-18401218	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043704	Uncertain				Colorectal cancer:4.61e-5 (favourable)	Tissue enhanced	Group enriched	13	colon: 14.4;duodenum: 32.7;liver: 62.4;rectum: 14.0;small intestine: 27.1	smooth muscle: 2.3	Cell line enhanced		RT4: 1.2;SCLC-21H: 2.5;SK-BR-3: 1.0
NAT6	FUS2	ENSG00000243477	N-acetyltransferase 6	3	50296402-50299421	Predicted intracellular proteins	Evidence at protein level	HPA039576	Approved				Renal cancer:1.71e-4 (favourable), Breast cancer:3.62e-4 (favourable)	Expressed in all	Expressed in all			testis: 45.8	Expressed in all		
NAT9	DKFZP564C103	ENSG00000109065	N-acetyltransferase 9 (putative)	17	74770547-74776367	Predicted intracellular proteins	Evidence at protein level	HPA021820, HPA057149	Approved		Approved	Nucleoplasm	Renal cancer:6.26e-6 (unfavourable), Pancreatic cancer:3.21e-5 (favourable), Liver cancer:3.25e-5 (unfavourable), Stomach cancer:7.80e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 39.1	Expressed in all		
NATD1	C17orf103, Gtlf3b, MGC33894	ENSG00000274180	N-acetyltransferase domain containing 1	17	21238870-21253410	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.55e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.0	Cell line enhanced		BEWO: 22.1
NAV1	DKFZp781D0314, FLJ12560, FLJ14203, KIAA1151, MGC14961, POMFIL3, steerin-1	ENSG00000134369	Neuron navigator 1	1	201622885-201826969	Predicted intracellular proteins	Evidence at protein level	CAB012302, HPA018127, HPA027887	Enhanced		Approved	Microtubules	Renal cancer:3.10e-6 (unfavourable)	Mixed	Mixed			cerebral cortex: 31.8	Cell line enhanced		TIME: 153.0
NAV2	FLJ10633, FLJ11030, FLJ23707, HELAD1, KIAA1419, POMFIL2, RAINB1	ENSG00000166833	Neuron navigator 2	11	19350724-20121598	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011755, HPA011891	Approved		Supported	Nucleoplasm		Expressed in all	Mixed			heart muscle: 39.2	Cell line enhanced		hTERT-HME1: 69.3;SH-SY5Y: 87.7
NAXD	CARKD, FLJ10769, LP3298	ENSG00000213995	NAD(P)HX dehydratase	13	110615460-110639993	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010551	Uncertain				Renal cancer:4.63e-5 (favourable), Endometrial cancer:3.15e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 26.9	Mixed		
NBDY	LINC01420, NoBody	ENSG00000204272	Negative regulator of P-body association	X	56729241-56818380	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.14e-5 (unfavourable), Head and neck cancer:3.11e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 71.9	Mixed		
NBEAL1	ALS2CR16, ALS2CR17, MGC164581	ENSG00000144426	Neurobeachin like 1	2	203014879-203226378	Predicted intracellular proteins	Evidence at protein level	HPA049189, HPA049447	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			thyroid gland: 7.7	Mixed		
NBEAL2	KIAA0540	ENSG00000160796	Neurobeachin like 2	3	46979683-47009703	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051969	Approved				Head and neck cancer:4.60e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 76.6	Cell line enhanced		HEL: 69.8
NBN	AT-V1, AT-V2, ATV, NBS, NBS1	ENSG00000104320	Nibrin	8	89933336-90003228	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001429, CAB003836	Supported		Approved	Nucleoplasm<br>Golgi apparatus	Lung cancer:5.46e-5 (unfavourable), Pancreatic cancer:4.20e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 37.4	Expressed in all		
NBPF1	FLJ20719, KIAA1693	ENSG00000219481	Neuroblastoma breakpoint family member 1	1	16562319-16613562	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Approved		Approved	Vesicles	Renal cancer:1.06e-4 (favourable)	Expressed in all	Mixed			testis: 21.9	Mixed		
NBPF10	AG1	ENSG00000271425	Neuroblastoma breakpoint family member 10	1	146064699-146144804	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Approved		Approved	Vesicles		Not detected	Mixed			skin: 8.1	Mixed		
NBPF11	NBPF24	ENSG00000263956	Neuroblastoma breakpoint family member 11	1	148102046-148152322	Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA038752, HPA042595, HPA043105, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles	Urothelial cancer:3.20e-5 (favourable), Lung cancer:6.87e-4 (favourable)	Mixed	Expressed in all			epididymis: 20.8	Mixed		
NBPF12	COAS1, KIAA1245	ENSG00000268043	Neuroblastoma breakpoint family member 12	1	146938744-146996202	Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Approved		Approved	Vesicles	Pancreatic cancer:9.01e-7 (favourable), Urothelial cancer:2.47e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 19.8	Expressed in all		
NBPF14	DJ328E19.C1.1	ENSG00000270629	Neuroblastoma breakpoint family member 14	1	148531385-148679751	Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles		Mixed	Expressed in all			skin: 66.5	Mixed		
NBPF15	MGC8902, NBPF16	ENSG00000266338	Neuroblastoma breakpoint family member 15	1	144421386-144461674	Predicted intracellular proteins	Evidence at protein level	HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Approved		Approved	Vesicles	Renal cancer:4.11e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 25.4	Mixed		
NBPF19		ENSG00000271383	Neuroblastoma breakpoint family member 19	1	149390623-149556361	Predicted intracellular proteins	Evidence at protein level	HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles		Mixed	Expressed in all			skin: 79.4	Expressed in all		
NBPF20		ENSG00000162825	Neuroblastoma breakpoint family member 20	1	145289900-145405778	Predicted intracellular proteins	Evidence at protein level	HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles		Not detected	Mixed			parathyroid gland: 17.1	Mixed		
NBPF3	AE2	ENSG00000142794	Neuroblastoma breakpoint family member 3	1	21440128-21485005	Predicted intracellular proteins	Evidence at protein level	HPA042595, HPA043692, HPA044023, HPA046971, HPA058050	Supported					Mixed	Tissue enriched	6	testis: 20.4	breast,placenta: 3.4	Cell line enhanced		BJ hTERT+: 12.6
NBPF4	FLJ32833	ENSG00000196427	Neuroblastoma breakpoint family member 4	1	108223341-108244081	Predicted intracellular proteins	Evidence at transcript level	HPA045044, HPA046411, HPA047447, HPA058050	Uncertain					Tissue enriched	Tissue enhanced		testis: 7.1	small intestine: 1.5	Cell line enhanced		BEWO: 6.8;K-562: 9.7;MCF7: 9.6
NBPF6		ENSG00000186086	Neuroblastoma breakpoint family member 6	1	108450282-108471002	Predicted intracellular proteins	Evidence at transcript level	HPA045044, HPA046411, HPA047447, HPA058050	Uncertain					Tissue enriched	Tissue enriched	6	testis: 4.6	placenta,small intestine: 0.7	Cell line enhanced		BEWO: 6.2;K-562: 9.6
NBPF9	AE01	ENSG00000269713	Neuroblastoma breakpoint family member 9	1	149054027-149103561	Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Approved		Approved	Vesicles		Mixed	Expressed in all			thyroid gland: 23.1	Expressed in all		
NBR1	1A1-3B, CA125, KIAA0049, M17S2	ENSG00000188554	NBR1, autophagy cargo receptor	17	43170481-43211689	Predicted intracellular proteins	Evidence at protein level	HPA022944, HPA022999, HPA023999	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Renal cancer:2.00e-5 (favourable)	Expressed in all	Expressed in all			testis: 259.6	Expressed in all		
NCALD		ENSG00000104490	Neurocalcin delta	8	101686543-102124907	Predicted intracellular proteins	Evidence at protein level	HPA043245	Approved				Pancreatic cancer:5.30e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 125.0	Group enriched	5	AF22: 133.9;HDLM-2: 161.9
NCAPD2	CAP-D2, CNAP1, hCAP-D2, KIAA0159	ENSG00000010292	Non-SMC condensin I complex subunit D2	12	6493356-6531955	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012423, HPA036947, HPA037363	Supported		Supported	Nucleus<br>Cytosol	Liver cancer:1.79e-8 (unfavourable), Renal cancer:1.13e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 28.7	Expressed in all		
NCAPD3	CAP-D3, FLJ42888, hCAP-D3, hcp-6, hHCP-6, KIAA0056	ENSG00000151503	Non-SMC condensin II complex subunit D3	11	134150119-134225454	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040286			Supported	Nucleoplasm		Tissue enriched	Tissue enriched	11	prostate: 194.2	testis: 17.2	Expressed in all		
NCAPG	CAP-G, FLJ12450, hCAP-G, YCG1	ENSG00000109805	Non-SMC condensin I complex subunit G	4	17810902-17844862	Predicted intracellular proteins	Evidence at protein level	HPA039613	Uncertain				Liver cancer:3.13e-6 (unfavourable), Pancreatic cancer:7.65e-5 (unfavourable), Endometrial cancer:8.28e-4 (unfavourable)	Mixed	Mixed			lymph node,testis: 9.9	Mixed		
NCAPG2	CAP-G2, FLJ20311, hCAP-G2, LUZP5, MTB	ENSG00000146918	Non-SMC condensin II complex subunit G2	7	158631311-158704829	Predicted intracellular proteins	Evidence at protein level	HPA026631	Approved		Supported	Nuclear speckles	Liver cancer:3.00e-5 (unfavourable), Renal cancer:4.06e-5 (unfavourable), Head and neck cancer:1.91e-4 (favourable), Melanoma:3.21e-4 (unfavourable), Endometrial cancer:7.94e-4 (unfavourable), Pancreatic cancer:8.50e-4 (unfavourable)	Expressed in all	Mixed			testis: 27.7	Expressed in all		
NCAPH	BRRN1, CAP-H, hCAP-H	ENSG00000121152	Non-SMC condensin I complex subunit H	2	96335787-96373845	Predicted intracellular proteins	Evidence at protein level	HPA002647, HPA003008	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:9.53e-6 (unfavourable), Pancreatic cancer:1.02e-4 (unfavourable), Lung cancer:6.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 55.4	lymph node: 21.3	Mixed		
NCAPH2	384D8-2, CAP-H2, hCAP-H2	ENSG00000025770	Non-SMC condensin II complex subunit H2	22	50508216-50523472	Predicted intracellular proteins	Evidence at protein level	HPA067932, HPA069056	Enhanced		Enhanced	Nucleoplasm<br>Cytokinetic bridge	Cervical cancer:2.24e-8 (favourable), Liver cancer:8.25e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 49.4	Expressed in all		
NCBP1	CBP80, NCBP, Sto1	ENSG00000136937	Nuclear cap binding protein subunit 1	9	97633626-97673748	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA042411, HPA049031	Enhanced		Supported	Nucleoplasm<br>Cytosol	Prostate cancer:4.17e-4 (unfavourable), Colorectal cancer:5.28e-4 (favourable)	Expressed in all	Expressed in all			testis: 31.5	Expressed in all		
NCBP2	Cbc2, CBP20, NIP1	ENSG00000114503	Nuclear cap binding protein subunit 2	3	196935402-196942597	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044850, HPA062483	Supported		Enhanced	Nucleoplasm	Liver cancer:2.37e-7 (unfavourable), Prostate cancer:2.27e-4 (unfavourable), Pancreatic cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 79.3	Expressed in all		
NCBP2L		ENSG00000170935	Nuclear cap binding protein subunit 2-like	X	107774899-107795829	Predicted intracellular proteins	Evidence at transcript level	HPA010664	Uncertain					Not detected	Tissue enhanced		adrenal gland: 1.4;testis: 3.9	fallopian tube: 1.2	Not detected		
NCBP3	C17orf85, ELG, HSA277841	ENSG00000074356	Nuclear cap binding subunit 3	17	3802165-3846251	Predicted intracellular proteins	Evidence at protein level	HPA008959, HPA013195	Supported		Approved	Nuclear speckles	Melanoma:4.68e-4 (unfavourable), Prostate cancer:4.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 16.3	Expressed in all		
NCCRP1	FBXO50, LOC342897, NCCRP-1	ENSG00000188505	Non-specific cytotoxic cell receptor protein 1 homolog (zebrafish)	19	39196961-39201884	Predicted intracellular proteins	Evidence at protein level	HPA052812	Uncertain		Approved	Mitochondria	Endometrial cancer:1.01e-4 (unfavourable)	Mixed	Group enriched	22	esophagus: 263.4;skin: 175.5;tonsil: 113.3	breast: 8.2	Cell line enriched	7	SK-BR-3: 23.1
NCDN	NCDN-1, NCDN-2	ENSG00000020129	Neurochondrin	1	35557473-35567274	Predicted intracellular proteins	Evidence at protein level	HPA023676	Enhanced	Supported	Supported	Cytosol	Liver cancer:1.91e-5 (unfavourable), Pancreatic cancer:3.73e-4 (favourable)	Expressed in all	Tissue enriched	13	cerebral cortex: 284.4	adrenal gland: 22.7	Expressed in all		
NCF1	NCF1A, NOXO2, p47phox, SH3PXD1A	ENSG00000158517	Neutrophil cytosolic factor 1	7	74773962-74789315	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004524, HPA047836, HPA052095	Enhanced					Mixed	Tissue enhanced		lymph node: 71.2;spleen: 74.1	bone marrow: 60.9	Group enriched	6	Daudi: 72.6;HMC-1: 122.5
NCF2	NOXA2, p67phox	ENSG00000116701	Neutrophil cytosolic factor 2	1	183555563-183590876	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002327, HPA006040, CAB022160	Enhanced		Enhanced	Nucleoli<br>Cytosol	Liver cancer:7.91e-6 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 127.5	lung: 111.6	Cell line enhanced		A-431: 22.9;hTERT-HME1: 39.8;U-2 OS: 52.5
NCF4	p40phox, SH3PXD4	ENSG00000100365	Neutrophil cytosolic factor 4	22	36860988-36878015	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010146, HPA036156, HPA057975	Enhanced		Supported	Cytosol	Renal cancer:7.06e-8 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 119.9	appendix: 59.4	Cell line enhanced		HEL: 78.2;HMC-1: 349.8;NB-4: 93.8;RPMI-8226: 102.1;THP-1: 92.9
NCK1	NCK, NCKalpha	ENSG00000158092	NCK adaptor protein 1	3	136862208-136949823	Predicted intracellular proteins	Evidence at protein level	CAB005063, HPA030766	Supported		Enhanced	Plasma membrane<br>Cytosol	Pancreatic cancer:9.14e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 48.8	Expressed in all		
NCK2	NCKbeta	ENSG00000071051	NCK adaptor protein 2	2	105744897-105894274	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016116, HPA031004	Approved					Expressed in all	Expressed in all			small intestine: 58.3	Cell line enhanced		SK-MEL-30: 139.0
NCKAP5	ERIH1, ERIH2, NAP5	ENSG00000176771	NCK associated protein 5	2	132671799-133568463	Predicted intracellular proteins	Evidence at protein level	HPA034639, HPA044859	Uncertain		Approved	Nucleoli<br>Golgi apparatus<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		lung: 17.3	cerebral cortex,kidney: 4.4	Cell line enriched	7	AF22: 45.7
NCKAP5L	KIAA1602	ENSG00000167566	NCK associated protein 5 like	12	49791146-49828750	Predicted intracellular proteins	Evidence at protein level	HPA041034	Approved		Approved	Golgi apparatus	Renal cancer:1.16e-5 (unfavourable), Liver cancer:2.07e-4 (unfavourable), Pancreatic cancer:4.87e-4 (favourable)	Expressed in all	Expressed in all			placenta: 12.9	Mixed		
NCL	C23	ENSG00000115053	Nucleolin	2	231453531-231483641	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004210, HPA023981	Supported		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.41e-6 (unfavourable), Endometrial cancer:2.28e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 449.8	Expressed in all		
NCOA1	bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1	ENSG00000084676	Nuclear receptor coactivator 1	2	24491914-24770702	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019402, HPA070213, HPA070520	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 59.0	Expressed in all		
NCOA2	bHLHe75, GRIP1, KAT13C, NCoA-2, TIF2	ENSG00000140396	Nuclear receptor coactivator 2	8	70109762-70403805	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060243			Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.08e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 36.0	Expressed in all		
NCOA3	ACTR, AIB1, bHLHe42, CAGH16, KAT13B, p/CIP, RAC3, SRC-3, SRC3, TNRC16, TRAM-1	ENSG00000124151	Nuclear receptor coactivator 3	20	47501902-47656877	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009800, HPA024210	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:8.09e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 44.8	Expressed in all		
NCOA4	ARA70, DKFZp762E1112, ELE1, PTC3, RFG	ENSG00000266412	Nuclear receptor coactivator 4	10	46005088-46030714	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051260, HPA065208	Uncertain		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol	Renal cancer:8.04e-6 (favourable), Glioma:2.88e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 247.1	Expressed in all		
NCOA5	bA465L10.6, CIA	ENSG00000124160	Nuclear receptor coactivator 5	20	46060985-46089952	Predicted intracellular proteins	Evidence at protein level	HPA050231	Uncertain		Supported	Nucleus<br>Actin filaments	Liver cancer:1.41e-5 (unfavourable), Pancreatic cancer:1.09e-4 (favourable), Lung cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 48.0	Expressed in all		
NCOA6	AIB3, ASC2, KIAA0181, NRC, PRIP, RAP250, TRBP	ENSG00000198646	Nuclear receptor coactivator 6	20	34689097-34825649	Predicted intracellular proteins	Evidence at protein level	HPA004198, HPA050211	Supported		Supported	Nucleoplasm	Renal cancer:8.78e-5 (favourable), Liver cancer:4.65e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.6	Expressed in all		
NCOA7	dJ187J11.3, ERAP140, TLDC4	ENSG00000111912	Nuclear receptor coactivator 7	6	125781161-125932030	Predicted intracellular proteins	Evidence at protein level	HPA030289, HPA030290, HPA030291, HPA030292	Approved		Approved	Nuclear bodies<br>Golgi apparatus	Renal cancer:1.78e-6 (favourable)	Expressed in all	Expressed in all			urinary bladder: 88.4	Expressed in all		
NCOR1	hCIT529I10, hN-CoR, KIAA1047, MGC104216, N-CoR, PPP1R109, TRAC1	ENSG00000141027	Nuclear receptor corepressor 1	17	16029157-16218185	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043246, HPA050288, HPA051168, CAB072830	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:7.92e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.7	Expressed in all		
NCOR2	CTG26, SMRT, SMRTE, TNRC14, TRAC-1	ENSG00000196498	Nuclear receptor corepressor 2	12	124324415-124567589	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001928	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 81.2	Expressed in all		
NCS1	FREQ, NCS-1	ENSG00000107130	Neuronal calcium sensor 1	9	130172578-130237304	Predicted intracellular proteins	Evidence at protein level	CAB018587, HPA019713	Enhanced	Supported	Enhanced	Plasma membrane	Liver cancer:1.11e-4 (unfavourable), Breast cancer:5.40e-4 (unfavourable), Thyroid cancer:8.25e-4 (unfavourable), Endometrial cancer:8.69e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 178.1	seminal vesicle: 92.3	Mixed		
NDC80	HEC, HEC1, hsNDC80, KNTC2, TID3	ENSG00000080986	NDC80, kinetochore complex component	18	2571511-2616635	Predicted intracellular proteins	Evidence at protein level	HPA066330			Supported	Nucleoplasm<br>Centrosome	Liver cancer:2.53e-8 (unfavourable)	Expressed in all	Mixed			testis: 27.3	Expressed in all		
NDE1	FLJ20101, NDE, nudE	ENSG00000072864	NudE neurodevelopment protein 1	16	15643267-15726353	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024075	Approved				Renal cancer:8.19e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 14.8	Expressed in all		
NDEL1	MITAP1, NDE1L1, NDE2, NUDEL	ENSG00000166579	NudE neurodevelopment protein 1 like 1	17	8413131-8490411	Predicted intracellular proteins	Evidence at protein level	HPA017916	Approved					Expressed in all	Expressed in all			adrenal gland: 81.4	Expressed in all		
NDOR1	bA350O14.9, NR1	ENSG00000188566	NADPH dependent diflavin oxidoreductase 1	9	137205685-137217009	Predicted intracellular proteins	Evidence at protein level	HPA024504	Approved		Approved	Nucleus<br>Intermediate filaments<br>Cytosol		Expressed in all	Mixed			spleen: 14.1	Expressed in all		
NDRG1	CAP43, DRG1, NDR1, RTP, TDD5	ENSG00000104419	N-myc downstream regulated 1	8	133237171-133302022	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006881	Approved		Supported	Microtubules<br>Cytosol	Liver cancer:1.47e-4 (unfavourable), Renal cancer:4.13e-4 (unfavourable), Glioma:7.24e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 535.2	Cell line enhanced		hTCEpi: 403.8;hTERT-HME1: 857.9;U-87 MG: 734.9
NDRG3		ENSG00000101079	NDRG family member 3	20	36651766-36746078	Predicted intracellular proteins	Evidence at protein level	HPA017851, HPA018256	Approved				Liver cancer:4.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 125.3	Expressed in all		
NDST3	HSST3	ENSG00000164100	N-deacetylase and N-sulfotransferase 3	4	118033618-118258648	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056189	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 3.0;spleen: 2.8	cervix, uterine: 0.7	Cell line enriched	16	MOLT-4: 13.3
NDST4		ENSG00000138653	N-deacetylase and N-sulfotransferase 4	4	114827763-115113876	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011129	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.4;ovary: 1.8	spleen: 1.0	Cell line enhanced		AF22: 2.8;CACO-2: 2.4;RH-30: 14.2;T-47d: 3.1
NDUFA12	B17.2, DAP13	ENSG00000184752	NADH:ubiquinone oxidoreductase subunit A12	12	94897055-95003770	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039903	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 189.2	Expressed in all		
NDUFA2	B8	ENSG00000131495	NADH:ubiquinone oxidoreductase subunit A2	5	140638740-140647785	Predicted intracellular proteins	Evidence at protein level	HPA035933	Uncertain				Cervical cancer:6.53e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 117.4	Expressed in all		
NDUFA5	B13, CI-13kB, CI-13KD-B, NUFM, UQOR13	ENSG00000128609	NADH:ubiquinone oxidoreductase subunit A5	7	123536997-123558255	Predicted intracellular proteins	Evidence at protein level	HPA043175	Supported				Renal cancer:3.99e-9 (favourable), Breast cancer:8.47e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 250.6	Expressed in all		
NDUFA6	B14, CI-B14, LYRM6, NADHB14	ENSG00000184983	NADH:ubiquinone oxidoreductase subunit A6	22	42085525-42090955	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.05e-6 (favourable), Cervical cancer:3.87e-4 (favourable), Endometrial cancer:4.96e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.6	Mixed		
NDUFA7	B14.5a	ENSG00000267855	NADH:ubiquinone oxidoreductase subunit A7	19	8308768-8321396	Predicted intracellular proteins	Evidence at protein level	HPA059251, HPA071866	Enhanced		Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 67.3	Expressed in all		
NDUFA8	MGC793, PGIV	ENSG00000119421	NADH:ubiquinone oxidoreductase subunit A8	9	122144058-122159819	Predicted intracellular proteins	Evidence at protein level	HPA041510, HPA041600	Enhanced		Enhanced	Mitochondria	Renal cancer:4.17e-6 (favourable)	Expressed in all	Expressed in all			heart muscle: 226.5	Expressed in all		
NDUFAB1	ACP, ACP1, FASN2A, SDAP	ENSG00000004779	NADH:ubiquinone oxidoreductase subunit AB1	16	23581002-23596356	Predicted intracellular proteins	Evidence at protein level	HPA054364	Uncertain		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:1.94e-7 (favourable)	Expressed in all	Expressed in all			heart muscle: 179.6	Expressed in all		
NDUFAF1	CGI-65, CIA30	ENSG00000137806	NADH:ubiquinone oxidoreductase complex assembly factor 1	15	41387349-41402519	Predicted intracellular proteins	Evidence at protein level	HPA039933, HPA040064	Supported		Enhanced	Cytosol	Renal cancer:3.34e-6 (favourable), Liver cancer:2.88e-5 (favourable)	Expressed in all	Expressed in all			testis: 45.5	Expressed in all		
NDUFAF2	B17.2L, mimitin, MMTN, NDUFA12L	ENSG00000164182	NADH:ubiquinone oxidoreductase complex assembly factor 2	5	60945129-61153037	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048082, HPA054776	Supported		Enhanced	Mitochondria	Renal cancer:2.49e-4 (unfavourable), Liver cancer:2.56e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 48.0	Expressed in all		
NDUFAF3	2P1, C3orf60, DKFZP564J0123, E3-3, MGC10527	ENSG00000178057	NADH:ubiquinone oxidoreductase complex assembly factor 3	3	49020459-49023495	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035376, HPA035377	Enhanced				Renal cancer:1.86e-5 (favourable)	Expressed in all	Expressed in all			testis: 287.5	Expressed in all		
NDUFAF4	bA22L21.1, C6orf66, HRPAP20, HSPC125, My013	ENSG00000123545	NADH:ubiquinone oxidoreductase complex assembly factor 4	6	96889313-96897881	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046560	Uncertain		Supported	Mitochondria	Breast cancer:1.31e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 29.0	Expressed in all		
NDUFAF5	C20orf7, dJ842G6.1	ENSG00000101247	NADH:ubiquinone oxidoreductase complex assembly factor 5	20	13784950-13821582	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051184	Uncertain				Renal cancer:2.27e-6 (favourable)	Expressed in all	Mixed			skeletal muscle: 6.9	Expressed in all		
NDUFAF6	C8orf38, MGC40214	ENSG00000156170	NADH:ubiquinone oxidoreductase complex assembly factor 6	8	94895767-95116455	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047148, HPA050545	Approved					Expressed in all	Mixed			thyroid gland: 10.5	Expressed in all		
NDUFAF7	C2orf56, MidA, PRO1853	ENSG00000003509	NADH:ubiquinone oxidoreductase complex assembly factor 7	2	37231631-37253403	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045217	Uncertain				Liver cancer:1.48e-4 (unfavourable), Lung cancer:3.08e-4 (favourable)	Expressed in all	Tissue enriched	5	testis: 69.1	adrenal gland: 12.9	Expressed in all		
NDUFAF8	C17orf89	ENSG00000224877	NADH:ubiquinone oxidoreductase complex assembly factor 8	17	81239239-81241281	Predicted intracellular proteins	Evidence at protein level	HPA057732	Uncertain		Approved	Mitochondria	Renal cancer:1.70e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 63.7	Expressed in all		
NDUFB10	PDSW	ENSG00000140990	NADH:ubiquinone oxidoreductase subunit B10	16	1959508-1961975	Predicted intracellular proteins	Evidence at protein level	HPA073189	Enhanced				Renal cancer:9.43e-6 (favourable), Cervical cancer:7.38e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 449.6	Expressed in all		
NDUFB2	AGGG, CI-AGGG	ENSG00000090266	NADH:ubiquinone oxidoreductase subunit B2	7	140690777-140722790	Predicted intracellular proteins	Evidence at protein level	HPA051377	Approved				Renal cancer:7.60e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 497.1	Expressed in all		
NDUFB7	B18, CI-B18, MGC2480	ENSG00000099795	NADH:ubiquinone oxidoreductase subunit B7	19	14566078-14572062	Predicted intracellular proteins	Evidence at protein level	HPA002817	Approved				Renal cancer:2.41e-4 (favourable), Cervical cancer:3.54e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 248.7	Expressed in all		
NDUFB9	B22, LYRM3, UQOR22	ENSG00000147684	NADH:ubiquinone oxidoreductase subunit B9	8	124539103-124568510	Predicted intracellular proteins	Evidence at protein level	HPA042768	Approved		Supported	Mitochondria	Renal cancer:3.42e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 443.1	Expressed in all		
NDUFS1	CI-75k	ENSG00000023228	NADH:ubiquinone oxidoreductase core subunit S1	2	206114817-206159603	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA064605, CAB070844	Approved		Supported	Mitochondria	Renal cancer:1.47e-12 (favourable), Breast cancer:3.85e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 71.1	Expressed in all		
NDUFS2	CI-49	ENSG00000158864	NADH:ubiquinone oxidoreductase core subunit S2	1	161197104-161214395	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA055140, HPA061953	Enhanced		Enhanced	Nucleoplasm<br>Mitochondria	Renal cancer:2.32e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 124.0	Expressed in all		
NDUFS3	CI-30	ENSG00000213619	NADH:ubiquinone oxidoreductase core subunit S3	11	47565336-47584562	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004484	Approved		Supported	Nuclear bodies<br>Mitochondria	Renal cancer:2.61e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 127.2	Expressed in all		
NDUFS4	AQDQ, CI-18	ENSG00000164258	NADH:ubiquinone oxidoreductase subunit S4	5	53560633-53683340	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003884	Supported		Supported	Mitochondria	Renal cancer:3.85e-6 (favourable)	Expressed in all	Expressed in all			kidney: 139.9	Expressed in all		
NDUFS5	CI-15k	ENSG00000168653	NADH:ubiquinone oxidoreductase subunit S5	1	39026318-39034636	Predicted intracellular proteins	Evidence at protein level	HPA042582	Supported				Ovarian cancer:3.54e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 642.7	Expressed in all		
NDUFS6	CI-13kA	ENSG00000145494	NADH:ubiquinone oxidoreductase subunit S6	5	1801400-1816605	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064221	Supported					Expressed in all	Expressed in all			skeletal muscle: 112.0	Expressed in all		
NDUFS7	CI-20, FLJ45860, FLJ46880, PSST	ENSG00000115286	NADH:ubiquinone oxidoreductase core subunit S7	19	1383527-1395589	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.90e-7 (favourable), Cervical cancer:2.03e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 96.7	duodenum: 40.7	Mixed		
NDUFV2	CI-24k	ENSG00000178127	NADH:ubiquinone oxidoreductase core subunit V2	18	9102630-9134345	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003404, HPA077896	Supported	Approved	Supported	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 190.8	Expressed in all		
NDUFV3	CI-10k	ENSG00000160194	NADH:ubiquinone oxidoreductase subunit V3	21	42879644-42913304	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019791, HPA020463, HPA030427, CAB034142	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 29.0	Expressed in all		
NEB	NEB177D, NEM2	ENSG00000183091	Nebulin	2	151485336-151734487	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016601	Enhanced					Tissue enhanced	Tissue enriched	97	skeletal muscle: 3273.5	prostate: 33.7	Cell line enhanced		RH-30: 33.2;U-266/70: 9.8
NEBL	LASP2, LNEBL	ENSG00000078114	Nebulette	10	20779973-21174187	Predicted intracellular proteins	Evidence at protein level	HPA013994, HPA013995	Approved				Renal cancer:2.77e-8 (favourable), Urothelial cancer:5.56e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 200.0;thyroid gland: 125.4	cerebral cortex: 61.3	Cell line enhanced		SCLC-21H: 69.4;SH-SY5Y: 37.8;SK-BR-3: 42.1
NECAB1	EFCBP1	ENSG00000123119	N-terminal EF-hand calcium binding protein 1	8	90791550-90959408	Predicted intracellular proteins	Evidence at protein level	HPA023252, HPA023629, HPA025963, HPA031262, CAB068208, CAB068209, CAB068210	Enhanced	Supported	Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	10	cerebral cortex: 79.7	lung: 8.1	Mixed		
NECAB2	EFCBP2	ENSG00000103154	N-terminal EF-hand calcium binding protein 2	16	83968632-84002776	Predicted intracellular proteins	Evidence at protein level	HPA013998, HPA014144, CAB068211	Enhanced	Supported	Approved	Vesicles	Renal cancer:1.58e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 46.8	kidney: 10.6	Cell line enhanced		AF22: 10.4;SCLC-21H: 47.1;U-87 MG: 13.8
NECAP1	DKFZP566B183	ENSG00000089818	NECAP endocytosis associated 1	12	8076939-8097859	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053980, HPA063300	Uncertain		Approved	Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 117.8	parathyroid gland: 34.8	Expressed in all		
NECAP2	FLJ10420	ENSG00000157191	NECAP endocytosis associated 2	1	16440672-16460078	Predicted intracellular proteins	Evidence at protein level	HPA028077	Approved		Approved	Endoplasmic reticulum	Liver cancer:6.13e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 86.0	Expressed in all		
NEDD1	GCP-WD, TUBGCP7	ENSG00000139350	Neural precursor cell expressed, developmentally down-regulated 1	12	96907223-96953777	Predicted intracellular proteins	Evidence at protein level	HPA038591	Approved				Liver cancer:1.94e-4 (unfavourable), Lung cancer:3.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 42.9	Expressed in all		
NEDD4	KIAA0093, MGC176705, NEDD4-1, RPF1	ENSG00000069869	Neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase	15	55826922-55993746	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB001991, HPA039883, CAB072833	Approved		Approved	Cytosol	Renal cancer:3.74e-6 (unfavourable), Lung cancer:5.14e-4 (unfavourable)	Expressed in all	Mixed			placenta: 22.4	Mixed		
NEDD4L	KIAA0439, NEDD4-2, RSP5	ENSG00000049759	Neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase	18	58044367-58401540	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024618, HPA064730	Approved		Approved	Focal adhesion sites	Renal cancer:6.55e-15 (favourable)	Expressed in all	Expressed in all			prostate: 71.5	Mixed		
NEDD8	Nedd-8	ENSG00000129559	Neural precursor cell expressed, developmentally down-regulated 8	14	24216852-24232454	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004082, HPA027583, HPA060254	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 559.0	Expressed in all		
NEDD8-MDP1		ENSG00000255526	NEDD8-MDP1 readthrough	14	24213955-24232352	Predicted intracellular proteins	Evidence at protein level	HPA003064, HPA060254	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enhanced		parathyroid gland: 2.7	testis: 1.8	Cell line enhanced		MOLT-4: 6.6
NEDD9	CAS-L, CASS2, HEF1	ENSG00000111859	Neural precursor cell expressed, developmentally down-regulated 9	6	11183298-11382348	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009720, HPA038768, HPA039270	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			lung: 103.4	Cell line enhanced		EFO-21: 129.1
NEFH		ENSG00000100285	Neurofilament heavy	22	29480230-29491390	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB007786, HPA061615	Enhanced		Approved	Nucleoli<br>Cytosol	Breast cancer:2.33e-6 (favourable)	Group enriched	Tissue enriched	11	prostate: 405.8	cerebral cortex: 37.3	Cell line enriched	6	SiHa: 193.4
NEFL	CMT1F, CMT2E, NF68, NFL, PPP1R110	ENSG00000277586	Neurofilament light	8	24950955-24957110	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA014850, HPA015021	Enhanced	Supported	Approved	Nuclear speckles<br>Intermediate filaments	Renal cancer:4.91e-4 (unfavourable)	Tissue enhanced	Tissue enriched	10	cerebral cortex: 289.3	adrenal gland: 29.0	Cell line enhanced		HEK93: 544.8;PC-3: 147.7
NEFM	NEF3, NF-M, NFM	ENSG00000104722	Neurofilament medium	8	24913012-24919098	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010900, CAB012976, HPA022845, HPA023138	Enhanced		Enhanced	Intermediate filaments		Mixed	Tissue enhanced		cerebral cortex: 171.7;seminal vesicle: 42.2	adrenal gland: 28.2	Cell line enriched	22	HEK93: 3411.6
NEIL1	FLJ22402, FPG1, hFPG1, NEI1	ENSG00000140398	Nei like DNA glycosylase 1	15	75346955-75357114	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054084	Approved		Supported	Nucleoplasm	Pancreatic cancer:2.09e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 10.6	Mixed		
NEIL2	FLJ31644, MGC2832, MGC4505, NEH2	ENSG00000154328	Nei like DNA glycosylase 2	8	11769639-11787346	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA073029, HPA073916			Enhanced	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 45.4	Mixed		
NEIL3	FLJ10858, FPG2, hFPG2, hNEI3, ZGRF3	ENSG00000109674	Nei like DNA glycosylase 3	4	177309836-177362943	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065761			Enhanced	Nucleoplasm	Lung cancer:1.16e-4 (unfavourable), Endometrial cancer:5.45e-4 (unfavourable)	Mixed	Mixed			bone marrow: 4.3	Mixed		
NEK1	KIAA1901, NY-REN-55	ENSG00000137601	NIMA related kinase 1	4	169392857-169612629	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020873, HPA040413	Approved		Approved	Nuclear membrane<br>Nucleoli	Renal cancer:1.42e-4 (favourable)	Expressed in all	Mixed			testis: 21.8	Expressed in all		
NEK10	FLJ32685	ENSG00000163491	NIMA related kinase 10	3	27110085-27369460	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038941	Uncertain		Approved	Nucleoplasm<br>Vesicles	Breast cancer:4.20e-4 (favourable)	Tissue enriched	Tissue enhanced		testis: 65.9	breast: 18.6	Cell line enhanced		LHCN-M2: 6.8;U-2 OS: 7.1
NEK11	FLJ23495	ENSG00000114670	NIMA related kinase 11	3	131026850-131350465	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016908	Approved		Supported	Nucleoplasm	Renal cancer:5.92e-6 (favourable), Cervical cancer:7.10e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 34.6	testis: 28.0	Mixed		
NEK2	NEK2A, NLK1, PPP1R111, RP67	ENSG00000117650	NIMA related kinase 2	1	211658657-211675630	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017530, HPA064967	Enhanced		Supported	Nucleus<br>Centrosome	Liver cancer:9.47e-6 (unfavourable), Lung cancer:9.11e-4 (unfavourable)	Mixed	Tissue enriched	11	testis: 121.2	bone marrow: 11.2	Mixed		
NEK3	HSPK36, MGC29949	ENSG00000136098	NIMA related kinase 3	13	52132639-52159861	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019062, HPA043230	Enhanced		Approved	Microtubules		Expressed in all	Expressed in all			testis: 29.6	Mixed		
NEK4	NRK2, pp12301, STK2	ENSG00000114904	NIMA related kinase 4	3	52708449-52770949	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015750, HPA058543	Approved		Supported	Cytosol	Colorectal cancer:2.69e-5 (favourable)	Expressed in all	Expressed in all			testis: 84.3	Expressed in all		
NEK5		ENSG00000197168	NIMA related kinase 5	13	52033611-52129078	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035565, HPA041399	Enhanced					Mixed	Group enriched	8	fallopian tube: 12.2;testis: 18.7	lung: 1.9	Cell line enhanced		T-47d: 1.0
NEK6	SID6-1512	ENSG00000119408	NIMA related kinase 6	9	124257606-124353307	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB045993, HPA056828	Approved		Supported	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Testis cancer:7.66e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 44.3	Cell line enhanced		HMC-1: 219.5
NEK7		ENSG00000151414	NIMA related kinase 7	1	198156963-198322420	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA015520, HPA018193	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			heart muscle: 93.3	Expressed in all		
NEK8	NPHP9	ENSG00000160602	NIMA related kinase 8	17	28725897-28743455	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040661, HPA040679	Approved				Lung cancer:4.52e-4 (favourable), Colorectal cancer:6.98e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 9.7	Mixed		
NEK9	DKFZp434D0935, MGC16714, Nek8, NERCC	ENSG00000119638	NIMA related kinase 9	14	75079353-75127344	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001405	Approved		Approved	Mitochondria	Pancreatic cancer:5.63e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 29.9	Mixed		
NELFA	NELF-A, WHSC2	ENSG00000185049	Negative elongation factor complex member A	4	1982714-2041903	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009960, HPA039858, HPA043931	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:4.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 31.7	Expressed in all		
NELFB	COBRA1, KIAA1182, NELF-B	ENSG00000188986	Negative elongation factor complex member B	9	137255173-137273546	Predicted intracellular proteins	Evidence at protein level	HPA020259	Enhanced		Enhanced	Nucleoplasm	Renal cancer:4.31e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 47.4	Expressed in all		
NELFCD	HSPC130, NELF-C, NELF-D, TH1, TH1L	ENSG00000101158	Negative elongation factor complex member C/D	20	58981208-58995133	Predicted intracellular proteins	Evidence at protein level	HPA050641, HPA066262			Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles<br>Cytosol	Endometrial cancer:4.98e-5 (unfavourable), Liver cancer:1.90e-4 (unfavourable), Prostate cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.6	Expressed in all		
NELFE	D6S45, NELF-E, RD, RDBP, RDP	ENSG00000204356	Negative elongation factor complex member E	6	31952087-31959110	Predicted intracellular proteins	Evidence at protein level	HPA007187, HPA007594, HPA046502	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.4	Expressed in all		
NEMF	FLJ10051, NY-CO-1, SDCCAG1	ENSG00000165525	Nuclear export mediator factor	14	49782083-49853203	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004160	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:2.85e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.3	Expressed in all		
NES	FLJ21841	ENSG00000132688	Nestin	1	156668763-156677397	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005889, HPA006286, HPA007007, HPA026111, CAB058692	Enhanced		Enhanced	Intermediate filaments	Renal cancer:8.02e-7 (unfavourable)	Group enriched	Mixed			heart muscle: 103.1	Cell line enhanced		AF22: 620.1;HUVEC TERT2: 268.3;LHCN-M2: 427.4;RH-30: 502.3
NET1	ARHGEF8, NET1A	ENSG00000173848	Neuroepithelial cell transforming 1	10	5412551-5458463	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020068	Uncertain		Approved	Nucleus<br>Vesicles	Liver cancer:3.87e-5 (unfavourable), Pancreatic cancer:8.27e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 96.4	Expressed in all		
NEU1	NEU	ENSG00000204386	Neuraminidase 1	6	31857659-31862906	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015634, HPA021506	Approved		Supported	Vesicles<br>Cell Junctions		Expressed in all	Mixed			thyroid gland: 14.3	Expressed in all		
NEU2	SIAL2	ENSG00000115488	Neuraminidase 2	2	233032672-233035057	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB022336	Uncertain					Not detected	Tissue enriched	13	skin: 1.4	breast: 0.1	Not detected		
NEU3		ENSG00000162139	Neuraminidase 3	11	74988134-75018893	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038729, HPA038730, HPA070381	Uncertain		Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:5.98e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 25.4	Expressed in all		
NEU4		ENSG00000204099	Neuraminidase 4	2	241808825-241817413	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037394, HPA037395	Uncertain					Group enriched	Group enriched	6	bone marrow: 2.4;cerebral cortex: 6.3;colon: 8.3;duodenum: 5.6;liver: 4.1;rectum: 3.7;small intestine: 5.3	fallopian tube,gallbladder: 0.7	Group enriched	20	Hep G2: 26.3;HMC-1: 45.5
NEURL1	h-neu, neu-1, NEURL, RNF67	ENSG00000107954	Neuralized E3 ubiquitin protein ligase 1	10	103493979-103592552	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA044204	Uncertain					Mixed	Tissue enhanced		skeletal muscle: 50.9	cerebral cortex: 30.1	Cell line enhanced		BEWO: 13.2;SCLC-21H: 20.2;SiHa: 9.4
NEURL1B	DKFZP761M1511, Neur2	ENSG00000214357	Neuralized E3 ubiquitin protein ligase 1B	5	172641266-172691540	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037612	Approved		Supported	Vesicles	Renal cancer:3.00e-6 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 45.0	Cell line enhanced		REH: 39.9
NEURL2	C20orf163, dJ337O18.6, FLJ30259, Ozz, Ozz-E3	ENSG00000124257	Neuralized E3 ubiquitin protein ligase 2	20	45888625-45891287	Predicted intracellular proteins	Evidence at transcript level	HPA043402, HPA059842	Approved		Approved	Vesicles		Mixed	Mixed			ovary: 8.4	Mixed		
NEURL3	Lincr, LOC93082	ENSG00000163121	Neuralized E3 ubiquitin protein ligase 3	2	96497643-96508109	Enzymes, Predicted intracellular proteins	Evidence at transcript level						Liver cancer:6.46e-4 (unfavourable)	Mixed	Tissue enhanced		salivary gland: 13.9	pancreas: 4.2	Cell line enhanced		BEWO: 3.6;CAPAN-2: 13.6;RPMI-8226: 6.9;RT4: 3.7
NEURL4	KIAA1787	ENSG00000215041	Neuralized E3 ubiquitin protein ligase 4	17	7315628-7329393	Predicted intracellular proteins	Evidence at protein level	HPA043678, HPA055314	Uncertain				Pancreatic cancer:2.34e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 18.9	Expressed in all		
NEUROD1	BETA2, BHF-1, bHLHa3, MODY6, NEUROD	ENSG00000162992	Neuronal differentiation 1	2	181673088-181680876	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003278, CAB022450	Approved				Glioma:6.83e-5 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 5.9;duodenum: 6.0;small intestine: 4.4;stomach: 4.9	pancreas: 1.8	Cell line enriched	79	SCLC-21H: 331.4
NEUROD2	bHLHa1, NDRF	ENSG00000171532	Neuronal differentiation 2	17	39603536-39609777	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enriched	142	cerebral cortex: 14.9	stomach: 0.1	Cell line enriched	302	SCLC-21H: 30.2
NEUROD4	ATH-3, Atoh3, bHLHa4, MATH-3	ENSG00000123307	Neuronal differentiation 4	12	55019945-55030014	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015545	Supported					Not detected	Tissue enhanced		adrenal gland: 2.3	testis: 0.5	Group enriched	8	AF22: 1.3;SCLC-21H: 3.3
NEUROD6	Atoh2, bHLHa2, Math-2, Nex1, NEX1M	ENSG00000164600	Neuronal differentiation 6	7	31337461-31340894	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027046, HPA074530	Enhanced	Approved				Not detected	Tissue enriched	180	cerebral cortex: 18.0	all non-specific tissues: 0.0	Cell line enriched	71	SCLC-21H: 7.0
NEUROG1	AKA, bHLHa6, Math4C, NEUROD3, ngn1	ENSG00000181965	Neurogenin 1	5	135534282-135535949	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
NEUROG2	Atoh4, bHLHa8, Math4A, ngn-2, NGN2	ENSG00000178403	Neurogenin 2	4	112513516-112516172	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	CAB012342	Uncertain					Tissue enhanced	Tissue enhanced		testis: 1.5	cerebral cortex: 0.4	Cell line enriched	8	SH-SY5Y: 216.2
NEUROG3	Atoh5, bHLHa7, Math4B, ngn3	ENSG00000122859	Neurogenin 3	10	69571698-69573238	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039785	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 2.8;small intestine: 1.3	colon,rectum: 0.4	Group enriched	19	HMC-1: 1.7;THP-1: 7.1
NEXN	NELIN, nexilin	ENSG00000162614	Nexilin F-actin binding protein	1	77888513-77943895	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011185	Approved				Colorectal cancer:5.60e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 298.6;skeletal muscle: 248.9	prostate: 109.6	Cell line enhanced		BJ: 129.6;LHCN-M2: 116.4;RH-30: 106.0
NF2	ACN, BANF, merlin, SCH	ENSG00000186575	Neurofibromin 2	22	29603556-29698598	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003097, CAB005385	Supported		Enhanced	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:2.89e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.7	Expressed in all		
NFAT5	KIAA0827, NF-AT5, NFATL1, NFATZ, OREBP, TONEBP	ENSG00000102908	Nuclear factor of activated T-cells 5	16	69565094-69704666	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057304, HPA069711	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.4	Expressed in all		
NFATC1	NF-ATC, NFAT2, NFATc	ENSG00000131196	Nuclear factor of activated T-cells 1	18	79395856-79529325	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004513, HPA071732	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			lymph node: 24.7	Cell line enhanced		U-698: 42.3
NFATC2	NF-ATP, NFAT1, NFATp	ENSG00000101096	Nuclear factor of activated T-cells 2	20	51386957-51562831	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008789, CAB018567, HPA024369	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.57e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 26.8	Cell line enhanced		HDLM-2: 22.7;HMC-1: 23.5;WM-115: 40.4
NFATC2IP	ESC2, FLJ14639, NIP45, RAD60	ENSG00000176953	Nuclear factor of activated T-cells 2 interacting protein	16	28950807-28967097	Predicted intracellular proteins	Evidence at protein level	HPA053587			Approved	Nucleus	Renal cancer:1.03e-5 (unfavourable), Prostate cancer:5.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.1	Expressed in all		
NFATC3	NFAT4, NFATX	ENSG00000072736	Nuclear factor of activated T-cells 3	16	68084751-68229259	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050665			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 50.0	Expressed in all		
NFATC4	NFAT3	ENSG00000100968	Nuclear factor of activated T-cells 4	14	24365673-24379604	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031641, CAB032859, HPA076526	Uncertain		Supported	Nuclear speckles<br>Cytosol	Renal cancer:1.81e-6 (unfavourable), Colorectal cancer:5.84e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 75.9	Cell line enhanced		BJ hTERT+: 80.5
NFE2	NF-E2	ENSG00000123405	Nuclear factor, erythroid 2	12	54292111-54301121	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001914	Enhanced		Approved	Nucleoplasm<br>Actin filaments		Mixed	Tissue enriched	6	bone marrow: 68.6	spleen: 11.9	Cell line enhanced		HEL: 328.8;K-562: 144.5;NB-4: 71.3
NFE2L2	NRF2	ENSG00000116044	Nuclear factor, erythroid 2 like 2	2	177227595-177392697	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002990, CAB020317, HPA043438	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 267.1	Expressed in all		
NFE4	NF-E4	ENSG00000230257	Nuclear factor, erythroid 4	7	102973437-102988856	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	7	placenta: 25.4	testis: 3.7	Cell line enhanced		BEWO: 36.5;HUVEC TERT2: 39.4
NFIA	KIAA1439, NFI-L	ENSG00000162599	Nuclear factor I A	1	60865259-61462793	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006111, HPA008884	Enhanced		Enhanced	Nucleoplasm	Urothelial cancer:2.03e-4 (unfavourable), Renal cancer:7.01e-4 (favourable), Head and neck cancer:7.30e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.8	Cell line enhanced		AN3-CA: 77.5
NFIB	NFI-RED, NFIB2, NFIB3	ENSG00000147862	Nuclear factor I B	9	14081843-14398983	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003956	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:3.53e-4 (favourable)	Expressed in all	Mixed			breast: 44.5	Cell line enhanced		AN3-CA: 151.3
NFIC	CTF, CTF5, NF-I, NFI	ENSG00000141905	Nuclear factor I C	19	3359563-3469217	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004300, CAB004674, HPA052625	Supported		Enhanced	Nucleus<br>Nucleoli fibrillar center	Endometrial cancer:1.52e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 68.9	Cell line enhanced		SiHa: 191.4
NFIL3	E4BP4, IL3BP1, NF-IL3A, NFIL3A	ENSG00000165030	Nuclear factor, interleukin 3 regulated	9	91409045-91423862	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003261	Approved		Approved	Nuclear bodies	Renal cancer:3.23e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 137.2	Expressed in all		
NFIX	NF1A	ENSG00000008441	Nuclear factor I X	19	12995608-13098796	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007533	Supported		Supported	Nucleoplasm	Lung cancer:2.35e-4 (favourable), Liver cancer:4.66e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 191.5	Cell line enhanced		U-138 MG: 192.9;U-2197: 175.5
NFKB1	KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50	ENSG00000109320	Nuclear factor kappa B subunit 1	4	102501329-102617302	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB004031, HPA027305	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 56.9	Expressed in all		
NFKB2	LYT-10, NF-kB2, p105, p49/p100, p52	ENSG00000077150	Nuclear factor kappa B subunit 2	10	102394110-102402529	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008422, CAB022098, HPA023900	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.69e-12 (unfavourable), Melanoma:8.45e-5 (favourable), Colorectal cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 70.7	Expressed in all		
NFKBIA	IkappaBalpha, IKBA, MAD-3, NFKBI	ENSG00000100906	NFKB inhibitor alpha	14	35401511-35404749	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003815, HPA029207	Approved		Enhanced	Cytosol	Breast cancer:1.33e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 711.6	Expressed in all		
NFKBIB	IKBB, TRIP9	ENSG00000104825	NFKB inhibitor beta	19	38899700-38908893	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063734			Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Tissue enhanced		testis: 16.6	appendix: 7.1	Expressed in all		
NFKBID	IkappaBNS, TA-NFKBH	ENSG00000167604	NFKB inhibitor delta	19	35887653-35902303	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043573			Approved	Mitochondria	Urothelial cancer:8.34e-6 (favourable), Head and neck cancer:5.43e-4 (favourable), Breast cancer:6.01e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 9.8	appendix: 5.9	Mixed		
NFKBIE	IKBE	ENSG00000146232	NFKB inhibitor epsilon	6	44258166-44265788	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002692, HPA005941, CAB010272	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Renal cancer:1.37e-6 (unfavourable), Breast cancer:1.72e-5 (favourable), Liver cancer:3.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Mixed			spleen: 26.1	Expressed in all		
NFKBIL1	IKBL, NFKBIL	ENSG00000204498	NFKB inhibitor like 1	6	31546870-31558829	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Endometrial cancer:3.38e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 4.2	Cell line enhanced		HEK93: 22.4;U-266/70: 8.2;U-266/84: 6.7
NFKBIZ	FLJ34463, INAP, MAIL	ENSG00000144802	NFKB inhibitor zeta	3	101827991-101861022	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA010547, HPA075363	Enhanced		Supported	Nuclear speckles<br>Cytoplasmic bodies	Renal cancer:4.30e-8 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 268.5	Cell line enhanced		BJ hTERT+: 58.3
NFRKB	DKFZp547B2013, INO80G	ENSG00000170322	Nuclear factor related to kappaB binding protein	11	129863636-129895590	Predicted intracellular proteins	Evidence at protein level	HPA007082, HPA007128	Approved		Enhanced	Nucleus	Liver cancer:5.78e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 38.1	Expressed in all		
NFS1	IscS, NifS	ENSG00000244005	NFS1, cysteine desulfurase	20	35668055-35699359	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB034314, HPA051801, HPA054755	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.72e-6 (favourable)	Expressed in all	Expressed in all			kidney: 43.7	Expressed in all		
NFU1	CGI-33, HIRIP5, NifU, NIFUC	ENSG00000169599	NFU1 iron-sulfur cluster scaffold	2	69395750-69437628	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035826	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 71.2	Expressed in all		
NFX1	MGC20369, NFX2, TEG-42, Tex42	ENSG00000086102	Nuclear transcription factor, X-box binding 1	9	33290511-33371157	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056310, HPA061382, HPA073519	Approved		Enhanced	Nucleus<br>Cytosol	Ovarian cancer:3.75e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 38.8	Expressed in all		
NFYA	CBF-B, HAP2, NF-YA	ENSG00000001167	Nuclear transcription factor Y subunit alpha	6	41072945-41099976	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009250, HPA050779	Enhanced		Enhanced	Nucleoplasm	Liver cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 70.9	Expressed in all		
NFYB	CBF-A, HAP3, NF-YB	ENSG00000120837	Nuclear transcription factor Y subunit beta	12	104117077-104138289	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004211	Supported		Supported	Nucleoplasm	Renal cancer:9.28e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 123.9	Expressed in all		
NFYC	CBF-C, NF-YC	ENSG00000066136	Nuclear transcription factor Y subunit gamma	1	40691648-40771603	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055011			Supported	Nucleoplasm	Renal cancer:1.24e-4 (favourable), Liver cancer:7.24e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 58.6	Expressed in all		
NGB		ENSG00000165553	Neuroglobin	14	77265483-77271312	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA042615, HPA058596	Enhanced					Tissue enhanced	Group enriched	5	adrenal gland: 10.1;cerebral cortex: 4.8;fallopian tube: 2.2	pancreas: 1.0	Group enriched	30	RPMI-8226: 4.3;SCLC-21H: 14.4
NGDN	C14orf120, CANu1, DKFZP564O092, LCP5, lpd-2, NGD	ENSG00000129460	Neuroguidin	14	23469688-23509862	Predicted intracellular proteins	Evidence at protein level	HPA000944	Approved		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Expressed in all			endometrium: 55.2	Expressed in all		
NHEJ1	Cernunnos, FLJ12610, XLF	ENSG00000187736	Non-homologous end joining factor 1	2	219075317-219160865	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012334, HPA043869	Approved		Supported	Nucleus<br>Nucleoli fibrillar center		Mixed	Expressed in all			testis: 44.0	Expressed in all		
NHLH1	bHLHa35, HEN1, NSCL, NSCL1	ENSG00000171786	Nescient helix-loop-helix 1	1	160367067-160372848	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA017943, CAB033854	Uncertain		Approved	Golgi apparatus		Group enriched	Not detected			skin: 0.8	Cell line enriched	12	SCLC-21H: 30.9
NHLH2	bHLHa34, HEN2, NSCL2	ENSG00000177551	Nescient helix-loop-helix 2	1	115836377-115843917	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055238	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Not detected	Tissue enhanced		skin: 3.9	cerebral cortex,testis: 0.8	Cell line enriched	11	SCLC-21H: 68.8
NHLRC1	bA204B7.2, EPM2B, malin	ENSG00000187566	NHL repeat containing E3 ubiquitin protein ligase 1	6	18120440-18122687	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA066030			Uncertain	Vesicles	Urothelial cancer:5.30e-4 (favourable), Endometrial cancer:9.01e-4 (unfavourable)	Expressed in all	Mixed			skin: 4.5	Cell line enhanced		EFO-21: 6.4;SCLC-21H: 7.2
NHLRC2	DKFZp779F115, FLJ20147, FLJ25621, FLJ33312, MGC45492	ENSG00000196865	NHL repeat containing 2	10	113854661-113917194	Predicted intracellular proteins	Evidence at protein level	HPA038493, HPA057564	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 18.6	Expressed in all		
NHLRC4		ENSG00000257108	NHL repeat containing 4	16	566996-569495	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		fallopian tube: 18.9	parathyroid gland: 6.3	Cell line enhanced		HEL: 3.0;HMC-1: 8.4;RPMI-8226: 2.9
NHP2	FLJ20479, NOLA2	ENSG00000145912	NHP2 ribonucleoprotein	5	178149460-178153967	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA044171, HPA050400	Enhanced		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:4.97e-4 (unfavourable), Liver cancer:5.24e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 114.9	Expressed in all		
NHS		ENSG00000188158	NHS actin remodeling regulator	X	17375420-17735994	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031497, HPA076257	Uncertain		Supported	Cell Junctions	Endometrial cancer:1.68e-4 (favourable)	Mixed	Mixed			endometrium: 7.9	Cell line enhanced		EFO-21: 12.0;RPTEC TERT1: 14.5
NHSL1	bA43P8.1, C6orf63, KIAA1357	ENSG00000135540	NHS like 1	6	138422043-138692571	Predicted intracellular proteins	Evidence at protein level	HPA029966, HPA029967, HPA029968	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Expressed in all	Mixed			small intestine: 25.8	Cell line enhanced		TIME: 52.4
NHSL2		ENSG00000204131	NHS like 2	X	71910818-72161750	Predicted intracellular proteins	Evidence at protein level	HPA049771, HPA054858	Uncertain					Mixed	Mixed			smooth muscle: 10.0	Cell line enhanced		AF22: 24.9;EFO-21: 27.8;HUVEC TERT2: 23.1;TIME: 13.2;U-937: 16.2
NICN1	MGC12936	ENSG00000145029	Nicolin 1	3	49422946-49429326	Predicted intracellular proteins	Evidence at protein level	HPA058014			Supported	Nucleoplasm	Renal cancer:8.81e-7 (favourable), Pancreatic cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.5	Mixed		
NIFK	hNIFK, MKI67IP, Nopp34	ENSG00000155438	Nucleolar protein interacting with the FHA domain of MKI67	2	121726945-121736923	Predicted intracellular proteins	Evidence at protein level	CAB015382, HPA035735, HPA035736, CAB075728, CAB075729	Supported		Enhanced	Nucleoli	Renal cancer:5.01e-11 (unfavourable), Liver cancer:2.92e-6 (unfavourable), Endometrial cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 49.6	Expressed in all		
NIN		ENSG00000100503	Ninein	14	50719763-50831121	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005939, HPA070691	Enhanced		Enhanced	Nucleus<br>Nucleoli<br>Centrosome		Expressed in all	Mixed			lymph node: 47.5	Expressed in all		
NINL	KIAA0980, NLP	ENSG00000101004	Ninein like	20	25452705-25585517	Predicted intracellular proteins	Evidence at protein level	HPA000686	Uncertain		Approved	Cytokinetic bridge<br>Cytosol	Renal cancer:1.03e-5 (favourable), Pancreatic cancer:1.47e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 17.9	Cell line enhanced		Hep G2: 25.6;SCLC-21H: 26.8
NIP7	CGI-37, FLJ10296, HSPC031, KD93	ENSG00000132603	NIP7, nucleolar pre-rRNA processing protein	16	69339430-69343111	Predicted intracellular proteins	Evidence at protein level	HPA040856, HPA059850	Enhanced		Supported	Nucleus<br>Nucleoli	Pancreatic cancer:6.69e-5 (unfavourable), Head and neck cancer:1.52e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 23.0	Expressed in all		
NIPBL	DKFZp434L1319, FLJ11203, FLJ12597, FLJ13354, FLJ13648, IDN3, Scc2	ENSG00000164190	NIPBL, cohesin loading factor	5	36876759-37066413	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040834, HPA058239	Approved		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 43.0	Expressed in all		
NIPSNAP1		ENSG00000184117	Nipsnap homolog 1	22	29554808-29581337	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059227	Uncertain				Renal cancer:8.82e-6 (favourable)	Expressed in all	Expressed in all			liver: 134.2	Expressed in all		
NIPSNAP3A	DKFZp564D177, FLJ13953, HSPC299, MGC14553	ENSG00000136783	Nipsnap homolog 3A	9	104747688-104760122	Predicted intracellular proteins	Evidence at protein level	HPA042491	Approved					Expressed in all	Expressed in all			adrenal gland: 50.9	Expressed in all		
NIPSNAP3B	FLJ11275	ENSG00000165028	Nipsnap homolog 3B	9	104764157-104777457	Predicted intracellular proteins	Evidence at protein level	HPA042491	Uncertain					Mixed	Mixed			adipose tissue: 15.6	Cell line enhanced		REH: 3.9
NISCH	I-1, IRAS, KIAA0975	ENSG00000010322	Nischarin	3	52455118-52493071	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023189	Approved				Pancreatic cancer:1.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 96.0	Expressed in all		
NIT1		ENSG00000158793	Nitrilase 1	1	161118086-161125445	Predicted intracellular proteins	Evidence at protein level	HPA006657	Approved				Renal cancer:4.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.9	Expressed in all		
NIT2		ENSG00000114021	Nitrilase family member 2	3	100334701-100361635	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036999	Approved		Supported	Centrosome<br>Cytosol	Endometrial cancer:4.62e-4 (unfavourable)	Expressed in all	Mixed			kidney: 19.0	Expressed in all		
NKAP	FLJ22626	ENSG00000101882	NFKB activating protein	X	119920672-119943772	Predicted intracellular proteins	Evidence at protein level	HPA000916	Supported		Supported	Nucleoplasm<br>Cytosol	Breast cancer:4.20e-4 (unfavourable)	Expressed in all	Mixed			ovary: 6.5	Expressed in all		
NKAPL	bA424I5.1, C6orf194	ENSG00000189134	NFKB activating protein like	6	28259320-28260958	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	15	testis: 53.4	seminal vesicle: 3.6	Cell line enhanced		ASC diff: 2.2;BJ: 1.2;fHDF/TERT166: 1.7;HHSteC: 3.9;HSkMC: 2.2
NKD1		ENSG00000140807	Naked cuticle homolog 1	16	50548330-50649249	Predicted intracellular proteins	Evidence at protein level	HPA041352, HPA049413	Uncertain		Approved	Nucleoli fibrillar center		Tissue enhanced	Mixed			smooth muscle: 8.1	Group enriched	6	AF22: 6.2;CACO-2: 11.1;Hep G2: 24.6
NKD2	Naked2	ENSG00000145506	Naked cuticle homolog 2	5	1008829-1038943	Predicted intracellular proteins	Evidence at protein level	HPA049463	Uncertain				Renal cancer:2.66e-5 (unfavourable), Melanoma:9.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 5.5;skin: 3.8	spleen: 2.9	Cell line enhanced		BEWO: 17.2;NB-4: 11.0;RPMI-8226: 29.0
NKIRAS1	kappaB-Ras1, KBRAS1	ENSG00000197885	NFKB inhibitor interacting Ras like 1	3	23891660-23946591	Predicted intracellular proteins	Evidence at protein level	HPA062521			Approved	Microtubules	Renal cancer:7.71e-13 (favourable), Lung cancer:3.69e-4 (favourable), Endometrial cancer:8.31e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 50.4	Expressed in all		
NKIRAS2	DKFZP434N1526, kappaB-Ras2, KBRAS2	ENSG00000168256	NFKB inhibitor interacting Ras like 2	17	42011382-42025644	Predicted intracellular proteins	Evidence at protein level	HPA062861			Approved	Nucleus<br>Nucleoli	Renal cancer:1.23e-4 (unfavourable), Liver cancer:5.56e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 49.2	Expressed in all		
NKRF	ITBA4, NRF	ENSG00000186416	NFKB repressing factor	X	119588337-119605895	Predicted intracellular proteins	Evidence at protein level	HPA001476			Supported	Nucleus<br>Nucleoli	Liver cancer:4.92e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 20.3	Expressed in all		
NKTR	p104	ENSG00000114857	Natural killer cell triggering receptor	3	42600614-42648741	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022120, HPA051576	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:1.05e-5 (favourable), Head and neck cancer:1.26e-4 (favourable), Renal cancer:5.02e-4 (unfavourable), Prostate cancer:6.01e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.3	Expressed in all		
NKX1-1	HSPX153, SAX2	ENSG00000235608	NK1 homeobox 1	4	1402932-1406331	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA029367	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
NKX1-2	bB238F13.2, C10orf121	ENSG00000229544	NK1 homeobox 2	10	124445239-124450184	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA029367	Uncertain					Tissue enhanced	Not detected			cerebral cortex: 0.7	Cell line enhanced		HaCaT: 4.8;hTCEpi: 3.7;NTERA-2: 10.3;SCLC-21H: 5.3
NKX2-1	BCH, NKX2A, TITF1, TTF-1, TTF1	ENSG00000136352	NK2 homeobox 1	14	36516392-36521149	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000078, CAB053633, HPA074316	Enhanced		Uncertain	Golgi apparatus<br>Vesicles		Group enriched	Group enriched	177	lung: 101.3;thyroid gland: 103.5	stomach: 0.5	Cell line enriched	36	SCLC-21H: 119.8
NKX2-2	NKX2.2, NKX2B	ENSG00000125820	NK2 homeobox 2	20	21511010-21514026	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003468	Approved					Group enriched	Tissue enhanced		cerebral cortex: 9.9;stomach: 2.6	duodenum: 2.4	Cell line enhanced		HAP1: 4.3;T-47d: 4.6;U-138 MG: 17.1;U-2 OS: 3.7;WM-115: 7.0
NKX2-3	CSX3, NKX2.3, NKX2C, NKX4-3	ENSG00000119919	NK2 homeobox 3	10	99532933-99536524	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047561	Uncertain		Uncertain	Nucleoli<br>Cytosol		Tissue enhanced	Tissue enhanced		small intestine: 12.7;spleen: 29.6	duodenum: 11.5	Cell line enhanced		NB-4: 1.1;REH: 2.0
NKX2-4	NKX2.4, NKX2D	ENSG00000125816	NK2 homeobox 4	20	21395367-21398028	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA074996			Approved	Nuclear bodies		Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Cell line enhanced		HAP1: 1.9;HEK93: 3.6;SCLC-21H: 3.0;SK-MEL-30: 2.3
NKX2-5	CSX, CSX1, NKX2.5, NKX2E, NKX4-1	ENSG00000183072	NK2 homeobox 5	5	173232109-173235357	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065034			Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	126	heart muscle: 32.7;spleen: 14.5	breast,placenta,urinary bladder: 0.1	Cell line enhanced		HEK93: 27.1;NTERA-2: 10.7;U-2 OS: 24.8;U-251 MG: 15.4
NKX2-6	CSX2, NKX4-2	ENSG00000180053	NK2 homeobox 6	8	23702451-23706598	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		hTEC/SVTERT24-B: 3.6
NKX2-8	Nkx2-9, NKX2.8, NKX2H	ENSG00000136327	NK2 homeobox 8	14	36580579-36582607	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062879	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		testis: 3.1	lung: 0.6	Cell line enhanced		HaCaT: 4.6;PC-3: 2.8;SiHa: 1.3
NKX3-1	BAPX2, NKX3.1, NKX3A	ENSG00000167034	NK3 homeobox 1	8	23678693-23682927	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA078571	Enhanced					Tissue enriched	Tissue enriched	11	prostate: 485.5	testis: 45.0	Cell line enhanced		SiHa: 27.8;U-138 MG: 25.5
NKX3-2	BAPX1, NKX3.2, NKX3B	ENSG00000109705	NK3 homeobox 2	4	13540830-13545050	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA027564	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		spleen: 2.7	smooth muscle: 1.6	Cell line enhanced		HAP1: 3.6;NB-4: 6.2;NTERA-2: 5.3;THP-1: 3.9
NKX6-1	Nkx6.1, NKX6A	ENSG00000163623	NK6 homeobox 1	4	84491987-84498450	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036774, CAB070169	Supported		Supported	Nucleoplasm		Mixed	Tissue enhanced		esophagus: 6.9;thyroid gland: 2.9	testis: 1.4	Cell line enhanced		AF22: 4.0;HAP1: 6.0;HEK93: 4.7;HMC-1: 3.4;U-2197: 5.9
NKX6-2	GTX, NKX6.1, NKX6B	ENSG00000148826	NK6 homeobox 2	10	132783179-132786052	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Group enriched	25	cerebral cortex: 15.7;stomach: 16.7	testis: 0.6	Not detected		
NKX6-3	FLJ25169	ENSG00000165066	NK6 homeobox 3	8	41645178-41650669	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA042790	Uncertain					Group enriched	Tissue enhanced		duodenum: 17.3;stomach: 50.6	parathyroid gland: 7.3	Group enriched	7	Daudi: 4.2;THP-1: 1.8
NLE1	FLJ10458	ENSG00000073536	Notchless homolog 1	17	35128753-35142315	Predicted intracellular proteins	Evidence at protein level	HPA018807	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:8.64e-8 (unfavourable), Urothelial cancer:6.39e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 15.9	Expressed in all		
NLK		ENSG00000087095	Nemo like kinase	17	28041737-28196381	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018192, HPA056511	Approved		Supported	Nucleus<br>Nucleoli<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 52.4	Expressed in all		
NLN	AGTBP, KIAA1226	ENSG00000123213	Neurolysin	5	65722196-65871725	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031862	Approved		Approved	Mitochondria	Renal cancer:5.58e-7 (favourable), Pancreatic cancer:7.51e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 8.2	Expressed in all		
NLRC3	CLR16.2, FLJ00348, NOD3	ENSG00000167984	NLR family CARD domain containing 3	16	3539033-3577400	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048062			Supported	Microtubule organizing center<br>Cytosol		Mixed	Tissue enhanced		lymph node: 15.7	spleen: 11.1	Cell line enhanced		HEL: 7.8;HL-60: 14.5;HMC-1: 7.7;NB-4: 12.3;U-698: 19.1;U-937: 10.6
NLRC4	CARD12, CLAN, CLAN1, CLANA, CLANB, CLANC, CLAND, CLR2.1, ipaf	ENSG00000091106	NLR family CARD domain containing 4	2	32224453-32265854	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006592	Uncertain					Mixed	Tissue enhanced		appendix: 12.4	lung: 9.3	Cell line enhanced		HL-60: 2.4
NLRC5	CLR16.1, FLJ21709, NOD27	ENSG00000140853	NLR family CARD domain containing 5	16	56989485-57083531	Predicted intracellular proteins	Evidence at protein level	HPA059120, HPA060405			Supported	Centrosome	Ovarian cancer:2.30e-4 (favourable), Renal cancer:2.44e-4 (unfavourable), Cervical cancer:9.69e-4 (favourable)	Expressed in all	Mixed			spleen: 45.1	Cell line enhanced		HEL: 84.3
NLRP1	CARD7, CLR17.1, DEFCAP, DKFZp586O1822, KIAA0926, NAC, NALP1, SLEV1, VAMAS1	ENSG00000091592	NLR family pyrin domain containing 1	17	5499427-5619424	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009189, HPA064431	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.60e-5 (unfavourable), Pancreatic cancer:7.57e-4 (favourable)	Expressed in all	Mixed			skin: 62.6	Cell line enhanced		HDLM-2: 53.6;Karpas-707: 70.7;U-266/70: 37.1
NLRP10	CLR11.1, NALP10, NOD8, PAN5, Pynod	ENSG00000182261	NLR family pyrin domain containing 10	11	7959424-7965426	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039498, HPA040101	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Tissue enhanced	Tissue enriched	12	skin: 3.2	breast: 0.2	Cell line enhanced		A-431: 14.7;BJ: 4.2;HBF TERT88: 6.6
NLRP11	CLR19.6, NALP11, NOD17, PAN10, PYPAF6	ENSG00000179873	NLR family pyrin domain containing 11	19	55785397-55836800	Predicted intracellular proteins	Evidence at protein level	HPA046402, HPA078027	Uncertain		Supported	Cytosol		Not detected	Tissue enhanced		epididymis: 1.4;testis: 1.3	tonsil: 0.6	Group enriched	18	Daudi: 82.3;Karpas-707: 17.0;RPMI-8226: 44.9;U-266/70: 83.8;U-266/84: 35.2;U-698: 57.1
NLRP12	CLR19.3, Monarch1, NALP12, PAN6, PYPAF7, RNO2	ENSG00000142405	NLR family pyrin domain containing 12	19	53793603-53824394	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042981	Approved					Tissue enriched	Tissue enhanced		appendix: 3.1;bone marrow: 4.1	spleen: 2.2	Cell line enhanced		HMC-1: 3.9;THP-1: 2.7;U-87 MG: 4.2;U-937: 2.9
NLRP13	CLR19.7, NALP13, NOD14, PAN13	ENSG00000173572	NLR family pyrin domain containing 13	19	55891699-55932336	Predicted intracellular proteins	Evidence at protein level	HPA060459	Uncertain					Not detected	Not detected			breast: 0.7	Not detected		
NLRP14	CLR11.2, GC-LRR, Nalp-iota, NALP14, NOD5, PAN8	ENSG00000158077	NLR family pyrin domain containing 14	11	7020446-7071308	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039477	Uncertain		Uncertain	Cytosol		Not detected	Tissue enhanced		testis: 1.6	parathyroid gland: 0.6	Not detected		
NLRP2	CLR19.9, FLJ20510, NALP2, NBS1, PAN1, PYPAF2	ENSG00000022556	NLR family pyrin domain containing 2	19	54953130-55001142	Predicted intracellular proteins	Evidence at protein level	HPA020765, HPA021183	Uncertain		Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Pancreatic cancer:2.91e-4 (unfavourable)	Tissue enriched	Mixed			testis: 5.6	Cell line enhanced		BEWO: 33.1;K-562: 11.5;U-266/84: 11.6
NLRP2B	CLRX.1, NALP2P, NLRP2P, NOD24, POP4	ENSG00000215174	NLR family pyrin domain containing 2B	X	57677067-57680260	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
NLRP3	AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1, FCAS, FCU, MWS, NALP3, PYPAF1	ENSG00000162711	NLR family pyrin domain containing 3	1	247416156-247449108	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA012878	Uncertain					Mixed	Tissue enhanced		bone marrow: 34.4	appendix: 14.5	Cell line enhanced		NB-4: 9.6;THP-1: 54.1;U-937: 15.5
NLRP4	CLR19.5, CT58, FLJ32126, NALP4, PAN2, PYPAF4, RNH2	ENSG00000160505	NLR family pyrin domain containing 4	19	55836578-55881854	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		testis: 12.8;tonsil: 4.6	lymph node: 1.9	Cell line enriched	6	Daudi: 58.8
NLRP6	CLR11.4, NALP6, PAN3, PYPAF5	ENSG00000174885	NLR family pyrin domain containing 6	11	278365-285359	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043681, HPA048500	Supported				Liver cancer:4.23e-5 (favourable)	Mixed	Group enriched	13	duodenum: 39.4;small intestine: 40.2	appendix: 3.0	Cell line enhanced		REH: 1.8;U-266/70: 2.8
NLRP7	CLR19.4, NALP7, NOD12, PAN7, PYPAF3	ENSG00000167634	NLR family pyrin domain containing 7	19	54923509-54966312	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051382	Uncertain		Uncertain	Golgi apparatus		Tissue enriched	Tissue enriched	14	testis: 2.8	duodenum: 0.2	Cell line enhanced		BEWO: 1.8;U-266/84: 3.4
NLRP8	CLR19.2, NALP8, NOD16, PAN4	ENSG00000179709	NLR family pyrin domain containing 8	19	55947832-55988629	Predicted intracellular proteins	Evidence at transcript level	HPA056989	Uncertain					Not detected	Not detected			breast,testis: 0.3	Not detected		
NLRP9	CLR19.1, NALP9, NOD6, PAN12	ENSG00000185792	NLR family pyrin domain containing 9	19	55708432-55738402	Predicted intracellular proteins	Evidence at transcript level	HPA042623	Uncertain					Tissue enriched	Tissue enhanced		prostate: 1.4	testis: 0.6	Not detected		
NLRX1	CLR11.3, NOD9	ENSG00000160703	NLR family member X1	11	119166568-119184016	Predicted intracellular proteins	Evidence at protein level	HPA061516	Supported		Supported	Plasma membrane<br>Cell Junctions<br>Mitochondria	Renal cancer:2.59e-6 (favourable), Endometrial cancer:2.47e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 37.8	Mixed		
NMD3	CGI-07	ENSG00000169251	NMD3 ribosome export adaptor	3	161104696-161253532	Predicted intracellular proteins	Evidence at protein level	HPA035019			Supported	Nucleus<br>Nucleoli	Pancreatic cancer:2.03e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 44.8	Expressed in all		
NME2	NDPKB, NM23-H2	ENSG00000243678	NME/NM23 nucleoside diphosphate kinase 2	17	51165435-51171747	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041113	Approved				Renal cancer:1.55e-6 (unfavourable), Cervical cancer:4.74e-4 (unfavourable), Liver cancer:7.09e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 512.0	Expressed in all		
NME4	NDPKD, nm23-H4, NM23H4	ENSG00000103202	NME/NM23 nucleoside diphosphate kinase 4	16	396725-410367	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB045997, HPA072588	Approved		Supported	Mitochondria	Renal cancer:1.61e-7 (unfavourable), Cervical cancer:6.53e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 167.2	Mixed		
NME5	nm23-H5, RSPH23	ENSG00000112981	NME/NM23 family member 5	5	138115172-138139443	Predicted intracellular proteins	Evidence at protein level	HPA035648, HPA044555	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:7.24e-5 (favourable), Renal cancer:1.76e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 59.4;testis: 95.0	epididymis: 28.2	Cell line enhanced		RPTEC TERT1: 22.4;SCLC-21H: 8.0;U-87 MG: 5.4
NME6	IPIA-ALPHA, NM23-H6	ENSG00000172113	NME/NM23 nucleoside diphosphate kinase 6	3	48293264-48301685	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017909	Approved		Approved	Vesicles	Liver cancer:2.17e-7 (unfavourable), Renal cancer:3.18e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 27.7	Expressed in all		
NME7	CFAP67, FLJ37194, NM23-H7	ENSG00000143156	NME/NM23 family member 7	1	169132531-169367967	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038014, HPA054289	Uncertain		Approved	Mitochondria	Liver cancer:3.24e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 39.0	Expressed in all		
NME8	CILD6, NM23-H8, SPTRX2, TXNDC3	ENSG00000086288	NME/NM23 family member 8	7	37848597-37900401	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016416, HPA019259	Supported					Mixed	Group enriched	14	bone marrow: 8.2;testis: 18.4	appendix,spleen: 0.9	Cell line enhanced		HMC-1: 1.1;NB-4: 1.2;NTERA-2: 1.7;THP-1: 1.1;U-937: 4.1
NME9	NM23-H9, TXL-2, TXNDC6	ENSG00000181322	NME/NM23 family member 9	3	138261437-138329886	Predicted intracellular proteins	Evidence at protein level	HPA040000, HPA043881	Enhanced					Mixed	Tissue enhanced		fallopian tube: 30.0	testis: 6.7	Mixed		
NMI		ENSG00000123609	N-myc and STAT interactor	2	151270465-151290057	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008588	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.57e-7 (unfavourable), Liver cancer:1.15e-4 (unfavourable), Pancreatic cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 46.9	Mixed		
NMNAT1	LCA9, NMNAT, PNAT1	ENSG00000173614	Nicotinamide nucleotide adenylyltransferase 1	1	9943428-9985501	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059447	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.85e-14 (favourable)	Expressed in all	Mixed			thyroid gland: 12.5	Mixed		
NMNAT2	C1orf15, KIAA0479, PNAT2	ENSG00000157064	Nicotinamide nucleotide adenylyltransferase 2	1	183248237-183418602	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA061714	Enhanced					Mixed	Tissue enriched	6	cerebral cortex: 73.5	testis: 13.3	Cell line enhanced		SCLC-21H: 91.4;U-2197: 42.4;U-87 MG: 34.4
NMNAT3	PNAT3	ENSG00000163864	Nicotinamide nucleotide adenylyltransferase 3	3	139560180-139678017	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039077, HPA057402	Approved		Supported	Mitochondria	Renal cancer:1.95e-5 (favourable), Pancreatic cancer:7.29e-5 (favourable), Cervical cancer:9.67e-4 (favourable)	Mixed	Mixed			ovary: 20.5	Cell line enhanced		HEL: 22.9;THP-1: 8.5;U-266/70: 11.9
NMRAL1	FLJ25918, HSCARG, SDR48A1	ENSG00000153406	NmrA like redox sensor 1	16	4461680-4495763	Predicted intracellular proteins	Evidence at protein level	HPA041353, HPA062287	Uncertain		Enhanced	Nucleus	Cervical cancer:3.33e-7 (favourable)	Expressed in all	Mixed			fallopian tube: 21.5	Mixed		
NMRK1	bA235O14.2, C9orf95, FLJ20559, NRK1	ENSG00000106733	Nicotinamide riboside kinase 1	9	75060573-75088217	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049795	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:3.70e-6 (favourable), Renal cancer:5.60e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 120.8	Cell line enhanced		HDLM-2: 70.8
NMRK2	ITGB1BP3, MIBP, NRK2	ENSG00000077009	Nicotinamide riboside kinase 2	19	3933103-3942416	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049909, HPA054792, HPA072450	Approved		Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:1.19e-4 (favourable)	Tissue enhanced	Group enriched	49	heart muscle: 374.4;skeletal muscle: 218.4	esophagus: 6.1	Group enriched	9	BEWO: 28.1;NTERA-2: 24.3
NMT1	NMT	ENSG00000136448	N-myristoyltransferase 1	17	45051610-45109016	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022949, HPA022963	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:4.94e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 58.6	Expressed in all		
NMT2		ENSG00000152465	N-myristoyltransferase 2	10	15102584-15168693	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001303	Approved		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 39.4	Cell line enhanced		TIME: 123.2
NNMT		ENSG00000166741	Nicotinamide N-methyltransferase	11	114257787-114313285	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059180	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.02e-6 (unfavourable), Stomach cancer:1.75e-4 (unfavourable), Head and neck cancer:2.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 197.2	adipose tissue: 107.8	Cell line enhanced		HSkMC: 300.0;RPTEC TERT1: 491.7
NOB1	ART-4, MST158, NOB1P, PSMD8BP1	ENSG00000141101	NIN1/PSMD8 binding protein 1 homolog	16	69741867-69754940	Predicted intracellular proteins	Evidence at protein level	HPA041522, HPA049430, HPA067411	Approved		Approved	Focal adhesion sites<br>Cytosol	Head and neck cancer:4.21e-5 (unfavourable), Liver cancer:8.16e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 69.4	Expressed in all		
NOBOX	OG2, Og2x	ENSG00000106410	NOBOX oogenesis homeobox	7	144397240-144410227	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Not detected			testis: 0.7	Not detected		
NOC2L	DKFZP564C186, NET15, NET7, NIR, PPP1R112	ENSG00000188976	NOC2 like nucleolar associated transcriptional repressor	1	944204-959309	Predicted intracellular proteins	Evidence at protein level	HPA044258, HPA062195	Approved		Enhanced	Nucleoli		Expressed in all	Expressed in all			skin: 42.0	Expressed in all		
NOC3L	AD24, C10orf117, FAD24, FLJ12820	ENSG00000173145	NOC3 like DNA replication regulator	10	94333226-94362959	Predicted intracellular proteins	Evidence at protein level	HPA063958, HPA067638, HPA070981			Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 19.2	Expressed in all		
NOC4L	MGC3162, NET49, UTP19	ENSG00000184967	Nucleolar complex associated 4 homolog	12	132144448-132152473	Predicted intracellular proteins	Evidence at protein level	HPA053424			Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 24.7	Expressed in all		
NOCT	Ccr4c, CCR4L, CCRN4L, NOC	ENSG00000151014	Nocturnin	4	139015789-139045939	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012287, HPA053714	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.05e-5 (unfavourable), Lung cancer:5.28e-5 (unfavourable), Urothelial cancer:6.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 21.2	gallbladder: 8.4	Expressed in all		
NOD1	CARD4, CLR7.1, NLRC1	ENSG00000106100	Nucleotide binding oligomerization domain containing 1	7	30424527-30478784	Predicted intracellular proteins	Evidence at protein level	HPA074367			Approved	Mitochondria	Thyroid cancer:1.95e-4 (favourable), Renal cancer:6.68e-4 (unfavourable)	Expressed in all	Mixed			lung: 17.9	Mixed		
NOD2	BLAU, CARD15, CD, CLR16.3, IBD1, NLRC2, PSORAS1	ENSG00000167207	Nucleotide binding oligomerization domain containing 2	16	50693603-50733077	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041985, HPA054494	Enhanced		Approved	Golgi apparatus<br>Cytosol		Mixed	Mixed			skin: 11.2	Cell line enhanced		HMC-1: 10.3;T-47d: 5.3;THP-1: 4.8;U-266/70: 12.4;U-266/84: 5.1
NOL10	FLJ14075, PQBP5	ENSG00000115761	Nucleolar protein 10	2	10570766-10689987	Predicted intracellular proteins	Evidence at protein level	HPA035286, HPA043075	Approved		Supported	Nucleoli	Liver cancer:1.43e-7 (unfavourable), Endometrial cancer:2.92e-5 (unfavourable), Renal cancer:7.51e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 27.6	Expressed in all		
NOL11	DKFZP586L0724	ENSG00000130935	Nucleolar protein 11	17	67717833-67744531	Predicted intracellular proteins	Evidence at protein level	HPA022010	Supported		Enhanced	Nucleoli	Colorectal cancer:1.00e-6 (favourable), Liver cancer:2.59e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 25.5	Expressed in all		
NOL12	MGC3731, Nop25, RRP17	ENSG00000273899	Nucleolar protein 12	22	37681673-37693478	Predicted intracellular proteins	Evidence at protein level	HPA003547	Uncertain		Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:2.56e-6 (unfavourable), Cervical cancer:6.80e-5 (favourable), Urothelial cancer:3.24e-4 (favourable), Lung cancer:9.41e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 25.1	Expressed in all		
NOL3	ARC, CARD2, MYP, NOP30	ENSG00000140939	Nucleolar protein 3	16	67170154-67175735	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009208	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:6.43e-5 (unfavourable), Renal cancer:2.41e-4 (unfavourable)	Expressed in all	Mixed			skin: 69.2	Mixed		
NOL4	CT125, HRIHFB2255, NOLP	ENSG00000101746	Nucleolar protein 4	18	33851100-34224952	Predicted intracellular proteins	Evidence at protein level	HPA046740			Supported	Nucleus		Tissue enhanced	Group enriched	7	cerebral cortex: 15.9;testis: 22.8	thyroid gland: 2.9	Cell line enhanced		SCLC-21H: 44.1;SH-SY5Y: 10.6;U-698: 5.7
NOL4L	C20orf112, C20orf113, dJ1184F4.2, dJ1184F4.4, DKFZP566G1424	ENSG00000197183	Nucleolar protein 4 like	20	32443059-32585074	Predicted intracellular proteins	Evidence at protein level	HPA041768, HPA043600	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.01e-4 (unfavourable), Urothelial cancer:2.63e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 60.2	small intestine: 21.8	Cell line enhanced		CACO-2: 60.7
NOL7	C6orf90, dJ223E5.2, NOP27, PQBP3, RARG-1	ENSG00000225921	Nucleolar protein 7	6	13615327-13632739	Predicted intracellular proteins	Evidence at protein level	HPA029185, HPA049693	Supported		Enhanced	Nucleus<br>Nucleoli<br>Mitochondria	Ovarian cancer:3.64e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 92.8	Expressed in all		
NOL8	C9orf34, FLJ20736, Nop132	ENSG00000198000	Nucleolar protein 8	9	92297358-92325636	Predicted intracellular proteins	Evidence at protein level	HPA044440, HPA062922	Uncertain		Supported	Nucleoli	Renal cancer:1.02e-5 (unfavourable), Liver cancer:1.50e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.4	Expressed in all		
NOL9	FLJ23323, Grc3, NET6	ENSG00000162408	Nucleolar protein 9	1	6521347-6554535	Predicted intracellular proteins	Evidence at protein level	HPA036347			Supported	Nucleoli<br>Intermediate filaments	Liver cancer:3.69e-5 (unfavourable)	Expressed in all	Mixed			spleen: 8.4	Expressed in all		
NOLC1	KIAA0035, NOPP130, NOPP140, P130	ENSG00000166197	Nucleolar and coiled-body phosphoprotein 1	10	102152176-102163871	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032654, HPA037366, HPA050388	Supported		Enhanced	Nucleoli	Thyroid cancer:8.25e-5 (unfavourable), Renal cancer:9.19e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.2	Expressed in all		
NOM1	C7orf3, PPP1R113, SGD1	ENSG00000146909	Nucleolar protein with MIF4G domain 1	7	156949723-156973182	Predicted intracellular proteins	Evidence at protein level	HPA019866, HPA051624	Approved		Enhanced	Nucleoli		Expressed in all	Mixed			testis: 7.5	Expressed in all		
NONO	NMT55, NRB54, P54, P54NRB, PPP1R114	ENSG00000147140	Non-POU domain containing, octamer-binding	X	71283192-71301168	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB022069, HPA054094, HPA054559	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:9.29e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 245.9	Expressed in all		
NOP10	MGC70651, NOLA3, NOP10P	ENSG00000182117	NOP10 ribonucleoprotein	15	34341713-34343177	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059198	Supported		Supported	Nuclear bodies	Endometrial cancer:1.48e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 289.4	Expressed in all		
NOP14	C4orf9, NOL14, RES4-25, UTP2	ENSG00000087269	NOP14 nucleolar protein	4	2937933-2963385	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039596, HPA055652	Approved		Enhanced	Nucleus<br>Nucleoli	Colorectal cancer:3.93e-5 (favourable), Liver cancer:9.10e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 27.3	Expressed in all		
NOP16	HSPC111, HSPC185, LOC51491	ENSG00000048162	NOP16 nucleolar protein	5	176383938-176388975	Predicted intracellular proteins	Evidence at protein level	HPA036506, HPA058147	Approved		Enhanced	Nucleoli	Renal cancer:5.75e-6 (unfavourable), Liver cancer:5.14e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 26.1	Expressed in all		
NOP2	NOL1, NOP120, NSUN1, p120	ENSG00000111641	NOP2 nucleolar protein	12	6556863-6568691	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040119	Supported		Supported	Nucleoli	Renal cancer:2.35e-10 (unfavourable), Liver cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 35.6	Expressed in all		
NOP56	NOL5A, SCA36	ENSG00000101361	NOP56 ribonucleoprotein	20	2652145-2658393	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049918, CAB075757	Enhanced		Enhanced	Nucleoli fibrillar center	Renal cancer:2.22e-16 (unfavourable), Liver cancer:1.59e-7 (unfavourable), Endometrial cancer:1.24e-4 (unfavourable), Melanoma:6.77e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 60.3	Expressed in all		
NOP58	HSPC120, NOP5	ENSG00000055044	NOP58 ribonucleoprotein	2	202265716-202303666	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018472, HPA021062	Supported		Enhanced	Nucleus<br>Nucleoli fibrillar center	Renal cancer:3.38e-9 (unfavourable), Liver cancer:1.97e-6 (unfavourable), Ovarian cancer:9.86e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 69.3	Expressed in all		
NOP9	C14orf21	ENSG00000196943	NOP9 nucleolar protein	14	24299862-24309124	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000850			Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:9.39e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.9	Expressed in all		
NOS1	nNOS, NOS	ENSG00000089250	Nitric oxide synthase 1	12	117208142-117452170	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002167, HPA058312	Uncertain		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		skeletal muscle: 12.9	cerebral cortex: 3.0	Cell line enhanced		HaCaT: 4.0;RH-30: 9.0;RPTEC TERT1: 4.4
NOS1AP	CAPON, KIAA0464	ENSG00000198929	Nitric oxide synthase 1 adaptor protein	1	162069774-162370475	Predicted intracellular proteins	Evidence at protein level	CAB018582, HPA030066, HPA055561	Approved		Approved	Nucleus<br>Vesicles		Mixed	Tissue enriched	6	cerebral cortex: 23.4	adrenal gland: 3.8	Cell line enhanced		A-431: 3.6;HEL: 4.5
NOS2	HEP-NOS, iNOS, NOS, NOS2A	ENSG00000007171	Nitric oxide synthase 2	17	27756766-27800499	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002014	Approved					Tissue enhanced	Group enriched	5	appendix: 18.9;colon: 7.0;duodenum: 12.3;rectum: 9.8;small intestine: 24.1;urinary bladder: 6.5	smooth muscle: 2.5	Group enriched	8	CACO-2: 13.0;SCLC-21H: 14.7
NOS3	ECNOS, eNOS	ENSG00000164867	Nitric oxide synthase 3	7	150990995-151014588	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002168	Enhanced				Renal cancer:3.63e-4 (unfavourable)	Expressed in all	Tissue enriched	7	spleen: 71.8	adipose tissue: 10.6	Cell line enhanced		BEWO: 22.3;HUVEC TERT2: 37.6;TIME: 67.7
NOSIP	CGI-25	ENSG00000142546	Nitric oxide synthase interacting protein	19	49555711-49590262	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043464, HPA062132	Approved		Enhanced	Nucleus		Expressed in all	Expressed in all			testis: 97.6	Expressed in all		
NOSTRIN	MGC20702	ENSG00000163072	Nitric oxide synthase trafficking	2	168786539-168865514	Predicted intracellular proteins	Evidence at protein level	HPA044384	Approved		Supported	Nuclear speckles		Mixed	Mixed			placenta: 36.4	Cell line enhanced		BEWO: 9.8;HEL: 35.7;K-562: 27.4
NOTCH2NL	N2N	ENSG00000264343	Notch 2 N-terminal like	1	146146203-146229026	Predicted intracellular proteins	Evidence at protein level	CAB004669	Approved					Not detected	Expressed in all			testis: 41.4	Expressed in all		
NOTO		ENSG00000214513	Notochord homeobox	2	73202258-73212513	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA034660	Uncertain					Not detected	Not detected			skin: 0.4	Not detected		
NOVA1		ENSG00000139910	NOVA alternative splicing regulator 1	14	26443093-26597754	Predicted intracellular proteins	Evidence at protein level	HPA004155	Uncertain		Supported	Nucleus<br>Nucleoli		Tissue enriched	Tissue enhanced		cerebral cortex: 62.2	breast: 31.8	Cell line enhanced		AF22: 40.2;HAP1: 20.8
NOVA2	ANOVA, NOVA3	ENSG00000104967	NOVA alternative splicing regulator 2	19	45933734-45973546	Predicted intracellular proteins	Evidence at protein level	HPA045607	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus	Renal cancer:3.04e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 24.3	adipose tissue: 6.0	Cell line enhanced		AF22: 10.0;HDLM-2: 10.4;HUVEC TERT2: 14.6;TIME: 21.5
NOXA1	FLJ25475, NY-CO-31, SDCCAG31	ENSG00000188747	NADPH oxidase activator 1	9	137423350-137434406	Predicted intracellular proteins	Evidence at protein level	HPA044781	Uncertain		Approved	Vesicles	Renal cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			skin: 21.5	Cell line enhanced		CAPAN-2: 11.1;EFO-21: 10.7;MCF7: 15.1;T-47d: 17.6
NOXO1	P41NOXA, P41NOXB, P41NOXC, SH3PXD5, SNX28	ENSG00000196408	NADPH oxidase organizer 1	16	1978917-1984192	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071540	Enhanced					Not detected	Tissue enhanced		appendix: 6.3;colon: 7.4;rectum: 6.5	duodenum: 3.3	Cell line enhanced		CAPAN-2: 2.4;HaCaT: 1.4;SCLC-21H: 1.6
NOXRED1	C14orf148, FLJ32809	ENSG00000165555	NADP dependent oxidoreductase domain containing 1	14	77394021-77423517	Predicted intracellular proteins	Evidence at transcript level	HPA055658	Approved					Mixed	Tissue enriched	7	testis: 11.7	thyroid gland: 1.6	Not detected		
NPAP1	C15orf2	ENSG00000185823	Nuclear pore associated protein 1	15	24675868-24683393	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018828, HPA019562	Uncertain					Not detected	Tissue enriched	11	testis: 5.2	skin: 0.4	Not detected		
NPAS1	bHLHe11, MOP5, PASD5	ENSG00000130751	Neuronal PAS domain protein 1	19	47019820-47045775	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043364, HPA072259		Approved	Approved	Nucleoplasm		Tissue enhanced	Group enriched	5	cerebral cortex: 3.9;skin: 4.4;spleen: 1.8;stomach: 2.6	lymph node: 0.6	Cell line enhanced		HEK93: 10.1;NB-4: 11.4
NPAS2	bHLHe9, MOP4, PASD4	ENSG00000170485	Neuronal PAS domain protein 2	2	100820152-100996829	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019674	Uncertain	Supported	Approved	Nucleoplasm	Renal cancer:3.55e-7 (unfavourable), Liver cancer:2.07e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 27.5	Cell line enhanced		PC-3: 102.3
NPAS3	bHLHe12, MOP6, PASD6	ENSG00000151322	Neuronal PAS domain protein 3	14	32934933-33804176	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002892	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 24.9	cervix, uterine: 10.1	Group enriched	8	AF22: 9.3;U-266/70: 17.8;U-266/84: 5.0
NPAS4	bHLHe79, Le-PAS, NXF, PASD10	ENSG00000174576	Neuronal PAS domain protein 4	11	66421004-66426707	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039255	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 4.1;endometrium: 1.9	smooth muscle: 1.6	Not detected		
NPAT	E14, p220	ENSG00000149308	Nuclear protein, coactivator of histone transcription	11	108157215-108222642	Predicted intracellular proteins	Evidence at protein level	HPA045908, HPA066370			Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			lymph node: 17.5	Expressed in all		
NPEPL1	bA261P9.2, FLJ11583	ENSG00000215440	Aminopeptidase-like 1	20	58689131-58719238	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004986, CAB017025, HPA036356	Approved		Approved	Nucleoplasm	Renal cancer:1.87e-9 (unfavourable), Urothelial cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			spleen: 24.7	Cell line enhanced		MCF7: 78.7
NPEPPS	MP100, PSA	ENSG00000141279	Aminopeptidase puromycin sensitive	17	47522942-47623276	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021453, HPA045649	Uncertain		Supported	Cytosol	Colorectal cancer:3.39e-5 (favourable), Liver cancer:3.67e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 106.9	Expressed in all		
NPHP1	JBTS4, NPH1, SLSN1	ENSG00000144061	Nephrocystin 1	2	110122311-110205066	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046093, HPA074071	Uncertain		Uncertain	Vesicles		Mixed	Tissue enhanced		testis: 46.0	fallopian tube: 28.4	Mixed		
NPHP3	CFAP31, FLJ30691, FLJ36696, KIAA2000, MKS7, NPH3, SLSN3	ENSG00000113971	Nephrocystin 3	3	132680609-132722442	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA009150	Uncertain				Renal cancer:8.28e-9 (unfavourable)	Mixed	Mixed			endometrium: 16.5	Mixed		
NPHP3-ACAD11		ENSG00000274810	NPHP3-ACAD11 readthrough (NMD candidate)	3	132558142-132722459	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		ovary: 4.8	endometrium: 3.2	Cell line enhanced		ASC TERT1: 4.4
NPL	C1orf13, DHDPS1, NPL1	ENSG00000135838	N-acetylneuraminate pyruvate lyase	1	182789293-182830384	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028345			Approved	Vesicles<br>Plasma membrane	Renal cancer:6.63e-4 (unfavourable), Liver cancer:8.05e-4 (unfavourable)	Expressed in all	Mixed			placenta: 63.8	Mixed		
NPLOC4	FLJ20657, KIAA1499, NPL4	ENSG00000182446	NPL4 homolog, ubiquitin recognition factor	17	81556887-81648465	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA021560, HPA023295	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.95e-7 (unfavourable), Liver cancer:1.16e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 67.6	Expressed in all		
NPM1	B23, NPM	ENSG00000181163	Nucleophosmin	5	171387116-171411137	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011384, CAB012983	Supported		Enhanced	Nucleus<br>Nucleoli	Renal cancer:2.89e-6 (unfavourable), Liver cancer:4.82e-6 (unfavourable), Head and neck cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 1800.2	Expressed in all		
NPM2		ENSG00000158806	Nucleophosmin/nucleoplasmin 2	8	22024125-22036897	Predicted intracellular proteins	Evidence at protein level	HPA041070	Enhanced		Approved	Nucleus<br>Nucleoli	Renal cancer:3.18e-6 (favourable), Pancreatic cancer:9.02e-4 (favourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 69.7;thyroid gland: 42.7	cerebral cortex: 31.8	Cell line enhanced		HaCaT: 15.6;HEL: 13.0;Hep G2: 21.9
NPM3		ENSG00000107833	Nucleophosmin/nucleoplasmin 3	10	101781325-101783413	Predicted intracellular proteins	Evidence at protein level	HPA036295, HPA036296	Approved		Approved	Nucleoli<br>Actin filaments<br>Cytosol	Head and neck cancer:1.42e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 28.8	Expressed in all		
NPRL2	NPR2, NPR2L, TUSC4	ENSG00000114388	NPR2-like, GATOR1 complex subunit	3	50347330-50351091	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038196, HPA038197	Approved		Supported	Cytosol	Lung cancer:1.59e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 13.8	Expressed in all		
NPRL3	C16orf35, CGTHBA, HS-40, MARE, NPR3, RMD11	ENSG00000103148	NPR3 like, GATOR1 complex subunit	16	84271-138860	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA011741	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 27.1	Mixed		
NQO1	DHQU, DIA4, DTD, NMOR1, QR1	ENSG00000181019	NAD(P)H quinone dehydrogenase 1	16	69706996-69726951	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007308, CAB012421	Enhanced		Enhanced	Cytosol	Head and neck cancer:1.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		breast: 379.3;stomach: 556.0	gallbladder: 320.2	Expressed in all		
NR0B1	AHC, AHCH, DAX1, DSS	ENSG00000169297	Nuclear receptor subfamily 0 group B member 1	X	30304206-30309598	Cancer-related genes, Disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061948, HPA067207			Supported	Nuclear speckles<br>Vesicles<br>Microtubule organizing center		Tissue enhanced	Group enriched	8	adrenal gland: 27.8;testis: 35.0	ovary: 4.1	Cell line enhanced		A549: 51.8;RT4: 14.5;U-87 MG: 7.9
NR0B2	SHP	ENSG00000131910	Nuclear receptor subfamily 0 group B member 2	1	26911489-26913966	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Group enriched	Tissue enhanced		duodenum: 78.6;liver: 48.8	small intestine: 28.9	Cell line enriched	19	Hep G2: 53.5
NR1D1	ear-1, hRev, Rev-ErbAalpha, THRA1, THRAL	ENSG00000126368	Nuclear receptor subfamily 1 group D member 1	17	40092787-40100725	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007935	Uncertain		Supported	Nuclear bodies	Melanoma:1.36e-4 (favourable), Colorectal cancer:1.94e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 37.4	Expressed in all		
NR1D2	BD73, EAR-1r, Hs.37288, HZF2, RVR	ENSG00000174738	Nuclear receptor subfamily 1 group D member 2	3	23945260-23980618	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053868, HPA054798	Approved		Approved	Nucleoplasm	Renal cancer:4.47e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 90.4	Expressed in all		
NR1H2	LXR-b, NER, NER-I, RIP15, UNR	ENSG00000131408	Nuclear receptor subfamily 1 group H member 2	19	50329653-50382982	Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056838, HPA070212	Uncertain		Approved	Nucleoplasm	Colorectal cancer:9.86e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 87.6	Expressed in all		
NR1H3	LXR-a, RLD-1	ENSG00000025434	Nuclear receptor subfamily 1 group H member 3	11	47248300-47269032	Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036443, CAB037109	Approved				Renal cancer:1.40e-5 (unfavourable), Urothelial cancer:3.40e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Liver cancer:5.60e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 55.2	Mixed		
NR1H4	FXR, HRR-1, HRR1, RIP14	ENSG00000012504	Nuclear receptor subfamily 1 group H member 4	12	100473708-100564413	Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	HPA047699			Approved	Nucleoplasm		Group enriched	Tissue enhanced		liver: 66.6;small intestine: 44.4	kidney: 29.9	Group enriched	26	Hep G2: 20.2;HHSteC: 14.1;RPTEC TERT1: 34.8
NR1I2	BXR, ONR1, PAR2, PXR, SXR	ENSG00000144852	Nuclear receptor subfamily 1 group I member 2	3	119780484-119818485	FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029309, HPA055121, HPA073926			Enhanced	Nucleoplasm		Group enriched	Group enriched	10	colon: 10.3;duodenum: 27.2;gallbladder: 6.4;liver: 20.0;rectum: 10.7;small intestine: 30.0	stomach: 1.7	Group enriched	7	Hep G2: 9.8;RH-30: 3.3
NR1I3	CAR, CAR1, MB67	ENSG00000143257	Nuclear receptor subfamily 1 group I member 3	1	161229666-161238302	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051365			Approved	Nucleoplasm		Tissue enriched	Tissue enriched	9	liver: 82.5	kidney: 9.4	Cell line enhanced		CACO-2: 3.7
NR2C1	TR2, TR2-11	ENSG00000120798	Nuclear receptor subfamily 2 group C member 1	12	95020229-95073703	Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035040, HPA035041, HPA067767	Enhanced		Supported	Nucleus<br>Cell Junctions<br>Cytosol	Renal cancer:1.03e-6 (unfavourable), Liver cancer:5.18e-5 (unfavourable), Urothelial cancer:5.62e-5 (favourable)	Expressed in all	Mixed			testis: 21.9	Expressed in all		
NR2C2	hTAK1, TAK1, TR2R1, TR4	ENSG00000177463	Nuclear receptor subfamily 2 group C member 2	3	14947584-15053600	Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006313	Approved		Enhanced	Nucleoplasm	Head and neck cancer:1.51e-5 (favourable)	Expressed in all	Expressed in all			testis: 38.6	Expressed in all		
NR2C2AP	TRA16	ENSG00000184162	Nuclear receptor 2C2 associated protein	19	19201416-19203424	Predicted intracellular proteins	Evidence at protein level	HPA042054, HPA055653	Approved		Enhanced	Nucleoplasm	Liver cancer:5.63e-5 (unfavourable), Thyroid cancer:1.65e-4 (favourable), Colorectal cancer:8.53e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 24.0	Expressed in all		
NR2E1	TLL, TLX, XTLL	ENSG00000112333	Nuclear receptor subfamily 2 group E member 1	6	108166058-108188809	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036954, HPA055642	Enhanced		Approved	Nuclear bodies		Tissue enriched	Tissue enriched	46	cerebral cortex: 11.4	adrenal gland: 0.2	Cell line enhanced		BEWO: 2.9;U-251 MG: 3.3
NR2E3	PNR, rd7, RP37	ENSG00000278570	Nuclear receptor subfamily 2 group E member 3	15	71792638-71818259	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Not detected			prostate: 0.7	Not detected		
NR2F1	COUP-TFI, EAR-3, ERBAL3, SVP44, TCFCOUP1, TFCOUP1	ENSG00000175745	Nuclear receptor subfamily 2 group F member 1	5	93583337-93594615	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019281, HPA058974			Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.47e-4 (unfavourable), Renal cancer:3.47e-4 (unfavourable)	Expressed in all	Mixed			placenta: 75.6	Cell line enhanced		AF22: 228.5;HHSteC: 146.5;PC-3: 180.1
NR2F2	ARP1, COUP-TFII, COUPTFB, NF-E3, SVP40, TFCOUP2	ENSG00000185551	Nuclear receptor subfamily 2 group F member 2	15	96325938-96340263	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058974			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		ovary: 360.7	endometrium: 187.1	Mixed		
NR2F6	EAR-2, ERBAL2	ENSG00000160113	Nuclear receptor subfamily 2 group F member 6	19	17231883-17245940	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Endometrial cancer:4.36e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 30.9	Expressed in all		
NR3C1	GR, GRL	ENSG00000113580	Nuclear receptor subfamily 3 group C member 1	5	143277931-143435512	Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004248, CAB010435	Supported		Enhanced	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:1.72e-6 (unfavourable), Endometrial cancer:3.64e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 67.0	Mixed		
NR3C2	MLR, MR	ENSG00000151623	Nuclear receptor subfamily 3 group C member 2	4	148078762-148444698	Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009155, HPA074979	Enhanced		Supported	Nucleoplasm	Renal cancer:3.10e-11 (favourable)	Mixed	Mixed			thyroid gland: 32.3	Cell line enhanced		HUVEC TERT2: 4.9;Karpas-707: 4.5;PC-3: 5.4;RPTEC TERT1: 5.9;TIME: 6.4
NR4A1	GFRP1, HMR, N10, NAK-1, NGFIB, NUR77, TR3	ENSG00000123358	Nuclear receptor subfamily 4 group A member 1	12	52022832-52059507	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059742, HPA070142	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:6.99e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 748.8	Cell line enhanced		MCF7: 67.2;SK-BR-3: 60.1;SK-MEL-30: 111.2
NR4A2	HZF-3, NOT, NURR1, RNR1, TINUR	ENSG00000153234	Nuclear receptor subfamily 4 group A member 2	2	156324432-156342348	Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000543, CAB010481	Uncertain		Supported	Nuclear speckles		Expressed in all	Tissue enhanced		adrenal gland: 174.3	ovary: 95.8	Cell line enhanced		HeLa: 10.1;HMC-1: 9.6;U-266/70: 11.3
NR4A3	CHN, CSMF, MINOR, NOR1	ENSG00000119508	Nuclear receptor subfamily 4 group A member 3	9	99821855-99866891	Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043360	Uncertain				Breast cancer:5.97e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 88.9	urinary bladder: 42.2	Cell line enhanced		BJ hTERT+: 21.0;SK-MEL-30: 14.0;U-266/70: 7.9
NR5A1	AD4BP, ELP, FTZ1, FTZF1, hSF-1, SF-1	ENSG00000136931	Nuclear receptor subfamily 5 group A member 1	9	124481236-124507430	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Group enriched	Group enriched	6	adrenal gland: 137.7;ovary: 36.3;spleen: 151.6	testis: 19.6	Group enriched	31	HEL: 73.5;Hep G2: 36.2;K-562: 17.7
NR5A2	B1F2, FTF, FTZ-F1, FTZ-F1beta, hB1F, hB1F-2, LRH-1	ENSG00000116833	Nuclear receptor subfamily 5 group A member 2	1	200027602-200177424	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005455, HPA017067	Supported		Uncertain	Nuclear speckles		Tissue enhanced	Mixed			liver: 19.5	Cell line enhanced		A549: 22.3;HAP1: 15.3;HUVEC TERT2: 17.0
NR6A1	CT150, GCNF, GCNF1, RTR	ENSG00000148200	Nuclear receptor subfamily 6 group A member 1	9	124517275-124771310	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031461, HPA045145			Supported	Nucleus		Tissue enriched	Tissue enriched	8	testis: 42.7	thyroid gland: 5.1	Cell line enhanced		BEWO: 107.1;K-562: 31.0;NTERA-2: 39.7
NRAP		ENSG00000197893	Nebulin related anchoring protein	10	113588716-113664127	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037953, HPA037954	Approved					Group enriched	Group enriched	17	heart muscle: 210.6;skeletal muscle: 814.0	prostate: 30.3	Not detected		
NRARP	MGC61598	ENSG00000198435	NOTCH-regulated ankyrin repeat protein	9	137300482-137302251	Predicted intracellular proteins	Evidence at transcript level	HPA025729	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.73e-6 (unfavourable)	Expressed in all	Tissue enhanced		colon: 38.4	rectum: 22.0	Cell line enhanced		HaCaT: 34.8;NTERA-2: 28.5;TIME: 23.6
NRAS	N-ras	ENSG00000213281	Neuroblastoma RAS viral oncogene homolog	1	114704469-114716894	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010157, HPA049830	Uncertain				Liver cancer:3.03e-7 (unfavourable), Pancreatic cancer:1.36e-4 (unfavourable), Renal cancer:7.87e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 39.4	Expressed in all		
NRBF2	COPR1, COPR2, DKFZp564C1664, FLJ30395	ENSG00000148572	Nuclear receptor binding factor 2	10	63133247-63155031	Predicted intracellular proteins	Evidence at protein level	HPA021670, HPA059477	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.36e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 30.7	Expressed in all		
NRBP1	BCON3, MADM, MUDPNP, NRBP	ENSG00000115216	Nuclear receptor binding protein 1	2	27427790-27442259	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029527, CAB033078	Supported		Supported	Cytosol	Liver cancer:2.22e-5 (unfavourable), Renal cancer:5.84e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 125.8	Expressed in all		
NRBP2	DKFZp434P086	ENSG00000185189	Nuclear receptor binding protein 2	8	143833594-143840974	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB020944, HPA029051, HPA029052	Approved		Approved	Cytosol	Renal cancer:2.01e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 55.2	Mixed		
NRDC	hNRD1, hNRD2, NRD1	ENSG00000078618	Nardilysin convertase	1	51789191-51878937	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053661			Approved	Nucleoplasm	Renal cancer:2.12e-9 (unfavourable), Liver cancer:5.49e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 167.5	Expressed in all		
NREP	C5orf13, D4S114, P311, PRO1873, PTZ17, SEZ17	ENSG00000134986	Neuronal regeneration related protein	5	111662621-111997464	Predicted intracellular proteins	Evidence at protein level	HPA000545	Approved		Approved	Vesicles	Stomach cancer:3.09e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 175.0	Cell line enhanced		AF22: 411.4;SH-SY5Y: 475.7
NRF1	ALPHA-PAL, EWG	ENSG00000106459	Nuclear respiratory factor 1	7	129611714-129757082	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029329	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.02e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 20.9	Expressed in all		
NRGN	RC3	ENSG00000154146	Neurogranin	11	124739846-124747210	Predicted intracellular proteins	Evidence at protein level	CAB006908, HPA038171	Enhanced				Renal cancer:1.52e-5 (unfavourable)	Expressed in all	Tissue enriched	17	cerebral cortex: 961.5	lung: 56.2	Cell line enhanced		HEL: 133.6;PC-3: 108.8
NRIP1	RIP140	ENSG00000180530	Nuclear receptor interacting protein 1	21	14961235-15065936	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046571, HPA060036	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			cervix, uterine: 38.9	Cell line enhanced		REH: 87.8
NRIP2	DKFZP761G1913	ENSG00000053702	Nuclear receptor interacting protein 2	12	2825348-2835544	Predicted intracellular proteins	Evidence at protein level	HPA039197, HPA039860	Enhanced		Approved	Nucleus<br>Nuclear bodies<br>Cytosol	Pancreatic cancer:8.69e-5 (favourable), Colorectal cancer:8.05e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 12.4	Mixed		
NRIP3	C11orf14	ENSG00000175352	Nuclear receptor interacting protein 3	11	8980576-9004049	Predicted intracellular proteins	Evidence at protein level	HPA040573, HPA058827	Uncertain		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 36.5;testis: 55.5	adrenal gland: 13.3	Cell line enhanced		HMC-1: 44.7;SiHa: 35.9;U-87 MG: 46.3
NRL	D14S46E, NRL-MAF, RP27	ENSG00000129535	Neural retina leucine zipper	14	24080107-24115014	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026066, HPA064599	Supported		Supported	Nucleoplasm<br>Cytosol		Mixed	Mixed			parathyroid gland: 4.6	Mixed		
NSA2	FLJ94393, HCLG1, HUSSY-29, TINP1	ENSG00000164346	NSA2, ribosome biogenesis homolog	5	74766991-74780113	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043487	Approved		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			ovary: 73.8	Expressed in all		
NSD1	ARA267, FLJ22263, KMT3B, STO	ENSG00000165671	Nuclear receptor binding SET domain protein 1	5	177133025-177300215	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048431, HPA070333, HPA073705	Supported		Supported	Nucleus<br>Plasma membrane		Expressed in all	Expressed in all			testis: 43.2	Mixed		
NSD2	KMT3G, MMSET, WHSC1	ENSG00000109685	Nuclear receptor binding SET domain protein 2	4	1871424-1982207	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015801, CAB068246, CAB068247	Enhanced		Supported	Nucleus	Liver cancer:2.61e-4 (unfavourable), Renal cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 66.6	Expressed in all		
NSD3	FLJ20353, KMT3F, WHISTLE, WHSC1L1	ENSG00000147548	Nuclear receptor binding SET domain protein 3	8	38269697-38382272	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005659, CAB013721, HPA018893	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 47.8	Expressed in all		
NSF	SKD2	ENSG00000073969	N-ethylmaleimide sensitive factor, vesicle fusing ATPase	17	46590669-46757464	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA003154, CAB009324, CAB013645, HPA071089	Enhanced		Supported	Cytosol		Expressed in all	Tissue enriched	5	cerebral cortex: 134.3	parathyroid gland: 25.6	Mixed		
NSFL1C	dJ776F14.1, p47, UBX1, UBXD10, UBXN2C	ENSG00000088833	NSFL1 cofactor	20	1442162-1473842	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047108, HPA050628	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.29e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 35.4	Expressed in all		
NSL1	C1orf48, DC8, DKFZP566O1646, MIS14	ENSG00000117697	NSL1, MIS12 kinetochore complex component	1	212726153-212791782	Predicted intracellular proteins	Evidence at protein level	HPA045761, HPA053721	Enhanced		Supported	Nucleoplasm<br>Nuclear speckles		Expressed in all	Expressed in all			cerebral cortex: 35.6	Expressed in all		
NSMAF	FAN, GRAMD5	ENSG00000035681	Neutral sphingomyelinase activation associated factor	8	58583504-58659844	Predicted intracellular proteins	Evidence at protein level	HPA023067, HPA023148, HPA023151	Uncertain		Approved	Nucleoli	Renal cancer:4.61e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.6	Expressed in all		
NSMCE1	NSE1	ENSG00000169189	NSE1 homolog, SMC5-SMC6 complex component	16	27224991-27268794	Predicted intracellular proteins	Evidence at protein level	HPA041567, HPA043091	Enhanced		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 122.9	Expressed in all		
NSMCE2	C8orf36, FLJ32440, MMS21, NSE2, ZMIZ7	ENSG00000156831	NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO ligase	8	125091679-125367120	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051614, HPA065734	Supported		Supported	Nucleus<br>Nuclear bodies	Liver cancer:7.54e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 30.0	Expressed in all		
NSMCE3	HCA4, MAGEG1, MAGEL3, NDNL2, NSE3	ENSG00000185115	NSE3 homolog, SMC5-SMC6 complex component	15	29264992-29269829	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Head and neck cancer:1.94e-4 (unfavourable)	Expressed in all	Not detected			cerebral cortex: 0.8	Not detected		
NSMCE4A	bA500G22.3, C10orf86, FLJ20003, NSE4A	ENSG00000107672	NSE4 homolog A, SMC5-SMC6 complex component	10	121957088-121975217	Predicted intracellular proteins	Evidence at protein level	HPA037459, HPA038412, HPA044872	Approved		Enhanced	Nucleoplasm	Lung cancer:2.72e-5 (favourable), Renal cancer:2.45e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 34.5	Expressed in all		
NSMF	NELF	ENSG00000165802	NMDA receptor synaptonuclear signaling and neuronal migration factor	9	137447570-137459334	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044316	Enhanced		Supported	Nucleoplasm	Renal cancer:1.85e-6 (favourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 189.6	duodenum: 36.2	Mixed		
NSRP1	CCDC55, DKFZP434K1421, NSrp70	ENSG00000126653	Nuclear speckle splicing regulatory protein 1	17	30115521-30186475	Predicted intracellular proteins	Evidence at protein level	HPA015593, HPA015603	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 44.6	Expressed in all		
NSUN2	FLJ20303, Misu, MRT5, TRM4	ENSG00000037474	NOP2/Sun RNA methyltransferase family member 2	5	6599239-6633291	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037896	Enhanced		Supported	Nucleus	Renal cancer:5.69e-5 (unfavourable)	Expressed in all	Expressed in all			breast: 44.2	Expressed in all		
NSUN3	FLJ22609	ENSG00000178694	NOP2/Sun RNA methyltransferase family member 3	3	94062916-94128545	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036181, HPA057979	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Expressed in all	Mixed			testis: 8.0	Expressed in all		
NSUN4	MGC22960, SHTAP	ENSG00000117481	NOP2/Sun RNA methyltransferase family member 4	1	46340177-46365152	Predicted intracellular proteins	Evidence at protein level	HPA028489	Approved				Liver cancer:1.97e-5 (unfavourable)	Expressed in all	Tissue enriched	14	testis: 98.9	adrenal gland: 7.2	Expressed in all		
NSUN5	FLJ10267, NOL1R, NSUN5A, p120(NOL1), WBSCR20, WBSCR20A, Ynl022cL	ENSG00000130305	NOP2/Sun RNA methyltransferase family member 5	7	73302517-73308867	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020536, HPA045590, HPA046867	Approved		Enhanced	Nucleus<br>Nucleoli	Glioma:2.11e-4 (unfavourable), Liver cancer:3.96e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 26.0	Mixed		
NSUN6	ARL5B-AS1, FLJ23743, NOPD1	ENSG00000241058	NOP2/Sun RNA methyltransferase family member 6	10	18545561-18659285	Predicted intracellular proteins	Evidence at protein level	HPA045902	Approved		Approved	Golgi apparatus	Renal cancer:5.55e-5 (unfavourable), Lung cancer:8.42e-4 (favourable)	Expressed in all	Expressed in all			liver: 30.7	Expressed in all		
NSUN7	FLJ14001	ENSG00000179299	NOP2/Sun RNA methyltransferase family member 7	4	40749897-40809985	Predicted intracellular proteins	Evidence at protein level	HPA020653	Uncertain		Supported	Vesicles	Renal cancer:2.76e-8 (favourable)	Mixed	Tissue enhanced		testis: 31.5	fallopian tube: 11.4	Cell line enhanced		CAPAN-2: 5.0;Karpas-707: 2.9;T-47d: 3.9
NT5C	cdN, DNT-1, DNT1, PN-I, UMPH2	ENSG00000125458	5', 3'-nucleotidase, cytosolic	17	75130225-75131795	Predicted intracellular proteins	Evidence at protein level	HPA021581, HPA023632	Approved		Supported	Cytosol	Liver cancer:3.05e-4 (unfavourable), Urothelial cancer:7.66e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 31.3	Expressed in all		
NT5C1A	CN-I, CN-IA, CN1, CN1A, MGC119199, MGC119201	ENSG00000116981	5'-nucleotidase, cytosolic IA	1	39659121-39672038	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050283, HPA054158	Supported					Not detected	Tissue enhanced		heart muscle: 7.5;skeletal muscle: 24.9	cerebral cortex: 4.8	Cell line enriched	20	SH-SY5Y: 18.9
NT5C1B	AIRP, CN-IB	ENSG00000185013	5'-nucleotidase, cytosolic IB	2	18562872-18589572	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at transcript level	HPA056683	Uncertain					Not detected	Tissue enriched	43	testis: 57.5	skin: 1.3	Mixed		
NT5C1B-RDH14		ENSG00000250741	NT5C1B-RDH14 readthrough	2	18555545-18589564	Predicted intracellular proteins	Evidence at transcript level	HPA056683	Uncertain					Not detected	Tissue enriched	174	testis: 23.1	duodenum: 0.1	Not detected		
NT5C2	cN-II, GMP, NT5B, PNT5, SPG65	ENSG00000076685	5'-nucleotidase, cytosolic II	10	103088017-103193306	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003751	Approved					Expressed in all	Expressed in all			thyroid gland: 119.6	Expressed in all		
NT5C3B	cN-IIIB, MGC20781, NT5C3L	ENSG00000141698	5'-nucleotidase, cytosolic IIIB	17	41825181-41836263	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030786, HPA057095	Approved				Liver cancer:8.11e-5 (unfavourable), Pancreatic cancer:2.67e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 79.2	Mixed		
NT5DC1	dJ486I3.1, MGC24302, NT5C2L1	ENSG00000178425	5'-nucleotidase domain containing 1	6	116100849-116249497	Predicted intracellular proteins	Evidence at protein level	HPA030352	Uncertain				Renal cancer:7.49e-7 (favourable), Colorectal cancer:2.61e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.2	Expressed in all		
NT5DC2	FLJ12442	ENSG00000168268	5'-nucleotidase domain containing 2	3	52524385-52535054	Predicted intracellular proteins	Evidence at protein level	HPA050683	Approved				Liver cancer:2.16e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 96.1	Mixed		
NT5DC4		ENSG00000144130	5'-nucleotidase domain containing 4	2	112721486-112742879	Predicted intracellular proteins	Evidence at transcript level	HPA046856	Uncertain					Tissue enhanced	Tissue enriched	7	testis: 3.4	lymph node: 0.5	Cell line enriched	10	K-562: 14.2
NT5M	dNT-2, dNT2, mdN	ENSG00000205309	5',3'-nucleotidase, mitochondrial	17	17303335-17347663	Predicted intracellular proteins	Evidence at protein level	HPA043777	Uncertain				Ovarian cancer:8.42e-5 (favourable)	Expressed in all	Mixed			testis: 4.8	Cell line enhanced		U-266/70: 6.6
NTAN1		ENSG00000157045	N-terminal asparagine amidase	16	15037853-15056079	Predicted intracellular proteins	Evidence at protein level	HPA051418			Approved	Nucleoplasm<br>Golgi apparatus	Glioma:8.85e-4 (unfavourable), Stomach cancer:9.07e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 20.4	Expressed in all		
NTHL1	NTH1, OCTS3	ENSG00000065057	Nth like DNA glycosylase 1	16	2039815-2047866	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB025152	Supported					Expressed in all	Expressed in all			fallopian tube: 21.3	Expressed in all		
NTMT1	AD-003, C9orf32, HOMT1A, METTL11A, NRMT, NRMT1	ENSG00000148335	N-terminal Xaa-Pro-Lys N-methyltransferase 1	9	129608884-129636131	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020092, HPA058420	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 90.5	Expressed in all		
NTPCR	C1orf57, HCR-NTPase, MGC13186	ENSG00000135778	Nucleoside-triphosphatase, cancer-related	1	232950605-232983882	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028125, HPA054304	Uncertain		Approved	Cytosol		Expressed in all	Mixed			parathyroid gland: 11.4	Mixed		
NUAK1	ARK5, KIAA0537, NuaK1	ENSG00000074590	NUAK family kinase 1	12	106063340-106140033	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA057143			Supported	Nucleus<br>Nucleoli fibrillar center<br>Microtubules	Stomach cancer:4.27e-4 (unfavourable), Endometrial cancer:9.83e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 47.0;parathyroid gland: 42.5	skin: 21.0	Cell line enhanced		AF22: 50.0;EFO-21: 47.3;RH-30: 70.1
NUB1	BS4, NUB1L, NYREN18	ENSG00000013374	Negative regulator of ubiquitin like proteins 1	7	151341699-151378449	Predicted intracellular proteins	Evidence at protein level	HPA021220, HPA050722, HPA053648	Approved		Enhanced	Nucleus<br>Nucleoli	Liver cancer:8.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 97.9	Expressed in all		
NUBP1	NBP1, NBP35	ENSG00000103274	Nucleotide binding protein 1	16	10743786-10769351	Predicted intracellular proteins	Evidence at protein level	HPA041656, HPA041799	Enhanced		Supported	Cytosol	Renal cancer:7.61e-8 (favourable), Cervical cancer:2.81e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 55.1	Expressed in all		
NUBP2	CFD1	ENSG00000095906	Nucleotide binding protein 2	16	1782901-1789191	Predicted intracellular proteins	Evidence at protein level	HPA041704	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:9.63e-5 (favourable)	Expressed in all	Expressed in all			spleen: 17.4	Expressed in all		
NUCKS1	NUCKS	ENSG00000069275	Nuclear casein kinase and cyclin dependent kinase substrate 1	1	205712819-205750276	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062351, HPA063843	Supported		Supported	Nucleus<br>Nucleoli	Endometrial cancer:1.41e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 179.2	Expressed in all		
NUDCD1	CML66, FLJ14991	ENSG00000120526	NudC domain containing 1	8	109240919-109334385	Predicted intracellular proteins	Evidence at protein level	HPA023183	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.71e-6 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Lung cancer:4.37e-5 (unfavourable), Pancreatic cancer:6.94e-4 (unfavourable)	Expressed in all	Mixed			testis: 24.2	Expressed in all		
NUDCD2	DKFZp686E10109, NudCL2	ENSG00000170584	NudC domain containing 2	5	163446526-163460140	Predicted intracellular proteins	Evidence at protein level	HPA037384, HPA037385	Uncertain				Colorectal cancer:2.80e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 24.6	Expressed in all		
NUDCD3	KIAA1068, NudCL	ENSG00000015676	NudC domain containing 3	7	44379121-44490880	Predicted intracellular proteins	Evidence at protein level	HPA019136, HPA019528, HPA019529	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:9.16e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 12.4	Expressed in all		
NUDT1	MTH1	ENSG00000106268	Nudix hydrolase 1	7	2242222-2251146	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012636	Approved		Approved	Cytosol	Renal cancer:1.30e-7 (unfavourable), Liver cancer:4.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.4	Expressed in all		
NUDT10	DIPP3a, hDIPP3alpha	ENSG00000122824	Nudix hydrolase 10	X	51332231-51337525	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047027, HPA057684	Approved		Approved	Cytosol		Group enriched	Tissue enhanced		testis: 49.7	prostate: 24.8	Group enriched	8	AF22: 7.4;HAP1: 14.7;HEK93: 9.7;NTERA-2: 25.9;SH-SY5Y: 6.0;U-2 OS: 13.4
NUDT11	DIPP3b, FLJ10628, hDIPP3beta	ENSG00000196368	Nudix hydrolase 11	X	51490011-51496596	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047027, HPA057684	Approved		Approved	Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 40.1;testis: 67.7	prostate,seminal vesicle: 14.7	Cell line enhanced		HAP1: 71.2;NTERA-2: 42.7
NUDT12	DKFZP761I172	ENSG00000112874	Nudix hydrolase 12	5	103548855-103562793	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045449	Supported				Renal cancer:2.86e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 45.1	Mixed		
NUDT13	DKFZp586P2219	ENSG00000166321	Nudix hydrolase 13	10	73110375-73131828	Predicted intracellular proteins	Evidence at transcript level	HPA040636	Approved		Approved	Nucleus		Mixed	Mixed			epididymis,parathyroid gland: 4.7	Mixed		
NUDT14	UGPP	ENSG00000183828	Nudix hydrolase 14	14	105172938-105181323	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046755, HPA058759	Approved		Approved	Nucleoli<br>Microtubules	Renal cancer:1.18e-5 (favourable), Ovarian cancer:1.66e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 24.7	Mixed		
NUDT15	FLJ10956, MTH2	ENSG00000136159	Nudix hydrolase 15	13	48037567-48047222	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038968, HPA038969	Approved		Supported	Nucleoplasm	Melanoma:1.25e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 22.8	Expressed in all		
NUDT16	FLJ31265	ENSG00000198585	Nudix hydrolase 16	3	131381671-131388830	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060452, HPA062492	Uncertain		Supported	Nucleus<br>Nucleoli	Renal cancer:1.05e-7 (favourable), Cervical cancer:9.39e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 54.8	Mixed		
NUDT16L1	SDOS	ENSG00000168101	Nudix hydrolase 16 like 1	16	4693694-4695859	Predicted intracellular proteins	Evidence at protein level	HPA044186, HPA063605	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.02e-6 (favourable), Lung cancer:2.79e-4 (favourable)	Expressed in all	Expressed in all			prostate: 30.1	Expressed in all		
NUDT17	FLJ34433	ENSG00000186364	Nudix hydrolase 17	1	145845629-145848953	Predicted intracellular proteins	Evidence at protein level	HPA030145	Enhanced		Approved	Centrosome<br>Cytosol	Renal cancer:1.81e-7 (unfavourable), Liver cancer:8.73e-4 (unfavourable)	Expressed in all	Mixed			testis: 5.2	Cell line enhanced		T-47d: 11.4
NUDT18	FLJ22494, MTH3	ENSG00000275074	Nudix hydrolase 18	8	22106872-22109419	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028581, HPA030125	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:2.49e-6 (favourable), Cervical cancer:1.43e-4 (favourable), Pancreatic cancer:2.47e-4 (favourable), Renal cancer:8.30e-4 (favourable)	Expressed in all	Mixed			epididymis: 16.2	Mixed		
NUDT2	APAH1	ENSG00000164978	Nudix hydrolase 2	9	34329506-34343713	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004684, HPA044903, HPA058623, HPA067639	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			epididymis: 43.6	Expressed in all		
NUDT21	CFIM25, CPSF5	ENSG00000167005	Nudix hydrolase 21	16	56429133-56452199	Predicted intracellular proteins	Evidence at protein level	HPA019863, HPA074228	Uncertain		Supported	Nuclear bodies<br>Microtubule organizing center		Expressed in all	Expressed in all			testis: 128.9	Expressed in all		
NUDT22	MGC13045	ENSG00000149761	Nudix hydrolase 22	11	64225941-64230686	Predicted intracellular proteins	Evidence at protein level	HPA039334, HPA053464	Approved		Enhanced	Nucleoplasm	Renal cancer:2.18e-6 (favourable)	Expressed in all	Expressed in all			duodenum: 31.1	Expressed in all		
NUDT3	DIPP	ENSG00000272325	Nudix hydrolase 3	6	34279679-34392674	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047027, HPA055953	Uncertain		Approved	Cytosol	Cervical cancer:5.29e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 77.5	Expressed in all		
NUDT4	DIPP2, DIPP2alpha, DIPP2beta, HDCMB47P, KIAA0487	ENSG00000173598	Nudix hydrolase 4	12	93377883-93408146	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017593, HPA047027, HPA057684	Approved		Approved	Cytosol	Renal cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			ovary: 184.7	Expressed in all		
NUDT4P1		ENSG00000177144	Nudix hydrolase 4 pseudogene 1	1	148748894-148750099	Predicted intracellular proteins	Evidence at protein level	HPA017593, HPA047027, HPA057684	Approved		Approved	Cytosol		Not detected	Mixed			gallbladder: 25.4	Cell line enhanced		CACO-2: 28.7;RT4: 24.9
NUDT5	hYSAH1, YSA1H	ENSG00000165609	Nudix hydrolase 5	10	12165325-12196144	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019827	Approved		Approved	Nucleus<br>Vesicles<br>Centrosome	Renal cancer:7.14e-12 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 45.6	Expressed in all		
NUDT6	FGF-AS, FGF2AS, gfg, gfg-1	ENSG00000170917	Nudix hydrolase 6	4	122888697-122922968	Predicted intracellular proteins	Evidence at protein level	HPA039202, HPA066115	Uncertain		Approved	Microtubules		Mixed	Mixed			kidney: 20.0	Expressed in all		
NUDT7		ENSG00000140876	Nudix hydrolase 7	16	77722492-77742260	Predicted intracellular proteins	Evidence at protein level	HPA042042	Supported		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:5.36e-11 (favourable), Head and neck cancer:1.84e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 35.7	Cell line enhanced		THP-1: 33.4
NUDT8	FLJ41567	ENSG00000167799	Nudix hydrolase 8	11	67627938-67629930	Predicted intracellular proteins	Evidence at protein level	HPA041252, HPA041466	Enhanced		Approved	Nucleoli<br>Cytosol	Renal cancer:3.70e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 20.8	Cell line enhanced		RPMI-8226: 155.8
NUF2	CDCA1, CT106, NUF2R	ENSG00000143228	NUF2, NDC80 kinetochore complex component	1	163266576-163355764	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059692			Supported	Nucleus	Liver cancer:1.04e-5 (unfavourable), Melanoma:4.83e-4 (unfavourable), Lung cancer:9.16e-4 (unfavourable), Pancreatic cancer:9.75e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 95.1	lymph node: 21.8	Mixed		
NUFIP1	NUFIP	ENSG00000083635	NUFIP1, FMR1 interacting protein 1	13	44939249-44989483	Predicted intracellular proteins	Evidence at protein level	HPA029958, HPA029959	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 10.2	Expressed in all		
NUFIP2	182-FIP, 82-FIP, FIP-82, KIAA1321, MGC117262, PIG1	ENSG00000108256	NUFIP2, FMR1 interacting protein 2	17	29255836-29294118	Predicted intracellular proteins	Evidence at protein level	HPA067443			Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 53.3	Expressed in all		
NUGGC	C8orf80, HMFN0672, SLIP-GC	ENSG00000189233	Nuclear GTPase, germinal center associated	8	28021964-28083871	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		lymph node: 22.9;tonsil: 21.4	liver: 11.0	Cell line enhanced		Daudi: 84.7;Karpas-707: 28.5;U-698: 59.8
NUMA1		ENSG00000137497	Nuclear mitotic apparatus protein 1	11	72002864-72080693	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019841, HPA019859, HPA029912	Enhanced		Enhanced	Nucleoplasm	Renal cancer:7.92e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 247.9	Expressed in all		
NUMB	C14orf41	ENSG00000133961	NUMB, endocytic adaptor protein	14	73275107-73463642	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002874, CAB011478	Approved		Enhanced	Cell Junctions<br>Cytosol	Renal cancer:2.32e-6 (favourable)	Expressed in all	Expressed in all			lung: 78.0	Expressed in all		
NUMBL	CAG3A, CTG3a, NUMB-R, NUMBLIKE, NUMBR, TNRC23	ENSG00000105245	NUMB like, endocytic adaptor protein	19	40665905-40690972	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058251, HPA058380	Approved				Renal cancer:7.55e-15 (unfavourable), Ovarian cancer:1.52e-4 (unfavourable), Colorectal cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 41.7	Expressed in all		
NUP133	FLJ10814	ENSG00000069248	Nucleoporin 133	1	229440260-229508341	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA059767	Approved		Supported	Nuclear membrane		Expressed in all	Expressed in all			parathyroid gland: 33.1	Expressed in all		
NUP153	HNUP153	ENSG00000124789	Nucleoporin 153	6	17615035-17706834	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA027896, HPA027897, HPA027898	Enhanced		Enhanced	Nuclear membrane		Expressed in all	Expressed in all			testis: 53.6	Expressed in all		
NUP160	FLJ22583, KIAA0197	ENSG00000030066	Nucleoporin 160	11	47778087-47848555	Predicted intracellular proteins, Transporters	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 39.6	Expressed in all		
NUP35	MP44	ENSG00000163002	Nucleoporin 35	2	183117513-183161680	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018401, HPA018410, HPA018441	Enhanced		Supported	Nucleoplasm<br>Nuclear membrane<br>Plasma membrane	Ovarian cancer:3.45e-4 (favourable), Liver cancer:5.02e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 44.4	Expressed in all		
NUP37	FLJ22618, MGC5585	ENSG00000075188	Nucleoporin 37	12	102073103-102120124	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA056300, HPA073708	Enhanced		Supported	Nucleoplasm	Liver cancer:7.70e-6 (unfavourable), Head and neck cancer:6.72e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 32.2	Expressed in all		
NUP43	bA350J20.1, FLJ13287	ENSG00000120253	Nucleoporin 43	6	149724315-149749665	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA027126, HPA027291, HPA028500	Enhanced				Liver cancer:7.13e-7 (unfavourable), Breast cancer:2.08e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 18.6	Expressed in all		
NUP50	NPAP60L	ENSG00000093000	Nucleoporin 50	22	45163841-45188015	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA047162, HPA048328	Enhanced		Enhanced	Nucleoplasm<br>Nuclear membrane	Stomach cancer:4.06e-4 (favourable)	Expressed in all	Expressed in all			testis: 54.6	Expressed in all		
NUP54		ENSG00000138750	Nucleoporin 54	4	76114659-76148515	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035929, HPA058122	Approved		Approved	Nucleoplasm	Liver cancer:4.64e-4 (unfavourable), Colorectal cancer:8.80e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.1	Expressed in all		
NUP58	KIAA0410, NUP45, NUPL1	ENSG00000139496	Nucleoporin 58	13	25301524-25349800	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA039360	Approved		Approved	Plasma membrane<br>Mitochondria<br>Cytosol	Cervical cancer:2.57e-4 (unfavourable), Liver cancer:3.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 87.0	Expressed in all		
NUP62	DKFZp547L134, FLJ20822, FLJ43869, IBSN, MGC841, p62, SNDI	ENSG00000213024	Nucleoporin 62	19	49906825-49929763	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA005435, CAB020724	Enhanced		Supported	Nucleus<br>Nuclear membrane	Renal cancer:5.71e-12 (unfavourable), Liver cancer:2.50e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 76.9	Expressed in all		
NUP62CL	FLJ20130	ENSG00000198088	Nucleoporin 62 C-terminal like	X	107123427-107206433	Predicted intracellular proteins	Evidence at protein level	HPA001884	Approved				Cervical cancer:5.66e-5 (favourable), Lung cancer:2.11e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 27.5	testis: 22.1	Cell line enhanced		A549: 19.9;CAPAN-2: 20.6;HeLa: 21.0;K-562: 20.5
NUP88	MGC8530	ENSG00000108559	Nucleoporin 88	17	5360963-5420160	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB002209, HPA021816	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 94.6	Expressed in all		
NUP98	NUP96	ENSG00000110713	Nucleoporin 98	11	3671083-3797792	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA074810			Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 150.7	Expressed in all		
NUPL2	CG1, H_RG271G13.9, hCG1, NLP_1	ENSG00000136243	Nucleoporin like 2	7	23181827-23201011	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA049036, HPA057251			Enhanced	Nucleus		Expressed in all	Expressed in all			testis: 32.2	Expressed in all		
NUPR1	COM1, p8	ENSG00000176046	Nuclear protein 1, transcriptional regulator	16	28532708-28539174	Predicted intracellular proteins	Evidence at protein level	HPA053895			Approved	Nucleus<br>Cytosol		Expressed in all	Tissue enhanced		thyroid gland: 512.5	pancreas: 235.5	Cell line enhanced		HHSteC: 221.9;hTCEpi: 321.9;SK-MEL-30: 256.2;T-47d: 179.8
NUPR2	NUPR1L	ENSG00000185290	Nuclear protein 2, transcriptional regulator	7	56114681-56116400	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:9.53e-5 (favourable)	Mixed	Tissue enriched	13	testis: 112.4	thyroid gland: 8.7	Mixed		
NUSAP1	ANKT, BM037, FLJ13421, LNP, NuSAP1, PRO0310p1, Q0310, SAPL	ENSG00000137804	Nucleolar and spindle associated protein 1	15	41332694-41381050	Predicted intracellular proteins	Evidence at protein level	HPA042904, HPA074847	Enhanced		Enhanced	Nucleus<br>Nucleoli fibrillar center	Renal cancer:6.82e-14 (unfavourable), Pancreatic cancer:6.27e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 75.3	lymph node: 57.2	Expressed in all		
NUTF2	NTF2, PP15	ENSG00000102898	Nuclear transport factor 2	16	67846732-67872567	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040915, HPA040956	Enhanced		Approved	Microtubules	Head and neck cancer:1.15e-4 (unfavourable), Renal cancer:2.58e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 83.7	Expressed in all		
NUTM1	C15orf55, DKFZp434O192, FAM22H, NUT	ENSG00000184507	NUT midline carcinoma family member 1	15	34343315-34357737	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040421	Enhanced					Not detected	Tissue enriched	78	testis: 22.5	duodenum,skin: 0.2	Not detected		
NUTM2A	FAM22A	ENSG00000184923	NUT family member 2A	10	87225448-87236908	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			skin: 1.9	Cell line enhanced		HMC-1: 8.3
NUTM2B	bA119F19.1, FAM22B	ENSG00000188199	NUT family member 2B	10	79703227-79714681	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			testis: 2.2	Mixed		
NUTM2D	FAM22D	ENSG00000214562	NUT family member 2D	10	87357668-87370695	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 7.1	Mixed		
NUTM2E	FAM22E	ENSG00000228570	NUT family member 2E	10	79841358-79850878	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.1	epididymis: 0.6	Cell line enhanced		HMC-1: 1.7;NB-4: 1.0
NUTM2F	DKFZp434I1117, FAM22F	ENSG00000130950	NUT family member 2F	9	94318196-94328644	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	12	testis: 1.2	all non-specific tissues: 0.0	Cell line enriched	13	NTERA-2: 1.3
NUTM2G	FAM22G	ENSG00000188152	NUT family member 2G	9	96928310-96940253	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 2.0	skin: 1.0	Mixed		
NVL	NVL2	ENSG00000143748	Nuclear VCP-like	1	224227334-224330387	Predicted intracellular proteins	Evidence at protein level	HPA028207, HPA028219, HPA028224, HPA028654	Enhanced		Enhanced	Nucleoli	Renal cancer:4.10e-11 (unfavourable), Liver cancer:5.77e-5 (unfavourable), Lung cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			skin: 18.7	Expressed in all		
NWD1		ENSG00000188039	NACHT and WD repeat domain containing 1	19	16719976-16817963	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:2.55e-4 (favourable)	Tissue enriched	Group enriched	7	cerebral cortex: 1.9;fallopian tube: 7.7;prostate: 5.8;seminal vesicle: 1.6	lung: 0.6	Group enriched	7	MCF7: 1.0;U-937: 2.3
NWD2	KIAA1239	ENSG00000174145	NACHT and WD repeat domain containing 2	4	37244220-37449465	Predicted intracellular proteins	Evidence at protein level	HPA046911	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 6.2;thyroid gland: 1.4	adipose tissue: 0.8	Not detected		
NXF1	DKFZp667O0311, Mex67, TAP	ENSG00000162231	Nuclear RNA export factor 1	11	62792123-62806302	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB016327, HPA061593	Supported		Supported	Nucleoplasm	Pancreatic cancer:4.08e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 147.7	Expressed in all		
NXF2	CT39, TAPL-2	ENSG00000269405	Nuclear RNA export factor 2	X	102247161-102326719	Predicted intracellular proteins	Evidence at protein level	HPA002079	Uncertain					Not detected	Group enriched	21	epididymis: 18.6;testis: 23.3	fallopian tube: 0.9	Cell line enriched	38	U-266/84: 24.8
NXF2B	bA353J17.1	ENSG00000269437	Nuclear RNA export factor 2B	X	102360395-102463274	Predicted intracellular proteins	Evidence at protein level	HPA002079	Uncertain					Not detected	Group enriched	6	epididymis: 19.1;testis: 4.9	fallopian tube: 2.1	Cell line enriched	30	U-266/84: 25.0
NXF3		ENSG00000147206	Nuclear RNA export factor 3	X	103075810-103093125	Predicted intracellular proteins	Evidence at protein level	HPA003132, HPA046757	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		fallopian tube: 39.8;testis: 71.8	epididymis: 13.5	Cell line enhanced		HEL: 44.1;HL-60: 37.4;U-2197: 127.8;U-937: 80.9
NXF5		ENSG00000126952	Nuclear RNA export factor 5	X	101832112-101857577	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA002079	Uncertain					Not detected	Not detected			cerebral cortex,epididymis,spleen: 0.1	Not detected		
NXN	FLJ12614, NRX	ENSG00000167693	Nucleoredoxin	17	799313-979770	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023566	Approved		Supported	Golgi apparatus<br>Cytosol		Expressed in all	Mixed			endometrium: 42.7	Mixed		
NXNL1	RDCVF, TXNL6	ENSG00000171773	Nucleoredoxin-like 1	19	17455425-17460954	Predicted intracellular proteins	Evidence at protein level	HPA042010	Approved					Not detected	Tissue enhanced		adipose tissue: 2.0	skin: 1.0	Not detected		
NXNL2	C9orf121	ENSG00000130045	Nucleoredoxin-like 2	9	88535101-88584274	Predicted intracellular proteins	Evidence at transcript level	HPA045526	Uncertain		Approved	Cytosol	Endometrial cancer:3.83e-8 (favourable), Breast cancer:6.53e-4 (favourable), Renal cancer:9.60e-4 (favourable)	Group enriched	Mixed			adipose tissue: 7.7	Cell line enhanced		RPTEC TERT1: 7.9
NXPE2	FAM55B, FLJ25224	ENSG00000204361	Neurexophilin and PC-esterase domain family member 2	11	114678386-114706933	Predicted intracellular proteins	Evidence at protein level	HPA039744, HPA039876	Enhanced				Colorectal cancer:9.29e-5 (favourable)	Tissue enhanced	Tissue enhanced		colon: 9.5;epididymis: 30.3;rectum: 9.7	salivary gland: 8.2	Not detected		
NXT1	MTR2, P15	ENSG00000132661	Nuclear transport factor 2 like export factor 1	20	23350736-23354777	Predicted intracellular proteins	Evidence at protein level	HPA047471			Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.15e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 26.6	Expressed in all		
NXT2	P15-2	ENSG00000101888	Nuclear transport factor 2 like export factor 2	X	109535781-109544690	Predicted intracellular proteins	Evidence at protein level	HPA024199, HPA072010	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 52.0	Expressed in all		
NYAP1	C7orf51, FLJ37538, KIAA1486L	ENSG00000166924	Neuronal tyrosine phosphorylated phosphoinositide-3-kinase adaptor 1	7	100483927-100494799	Predicted intracellular proteins	Evidence at protein level	HPA022251	Uncertain		Supported	Golgi apparatus<br>Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 25.1;testis: 7.7	adrenal gland: 3.3	Cell line enhanced		HUVEC TERT2: 3.2;SH-SY5Y: 9.9
NYAP2	KIAA1486	ENSG00000144460	Neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 2	2	225399710-225654018	Predicted intracellular proteins	Evidence at protein level	HPA045531	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments		Not detected	Tissue enriched	6	cerebral cortex: 1.8	lung: 0.3	Cell line enhanced		SiHa: 2.0
NYNRIN	CGIN1, FLJ11811, KIAA1305	ENSG00000205978	NYN domain and retroviral integrase containing	14	24398786-24419288	Predicted intracellular proteins	Evidence at protein level	HPA018945	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Expressed in all	Mixed			ovary: 42.7	Cell line enhanced		HUVEC TERT2: 28.9;RT4: 23.0
OARD1	C6orf130, dJ34B21.3, MGC19570, TARG1	ENSG00000124596	O-acyl-ADP-ribose deacylase 1	6	41033627-41097787	Predicted intracellular proteins	Evidence at protein level	HPA029036	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:1.13e-4 (favourable)	Expressed in all	Expressed in all			testis: 106.4	Expressed in all		
OAS1	IFI-4, OIAS, OIASI	ENSG00000089127	2'-5'-oligoadenylate synthetase 1	12	112906777-112933222	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003657, CAB021104	Uncertain		Approved	Cytosol	Urothelial cancer:6.12e-6 (favourable), Pancreatic cancer:3.02e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 90.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 266.2;BJ hTERT+ SV40 Large T+ RasG12V: 396.9;U-266/70: 307.4;U-266/84: 229.8
OAS2		ENSG00000111335	2'-5'-oligoadenylate synthetase 2	12	112978395-113011723	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB024984, HPA045947	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.31e-6 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)	Expressed in all	Mixed			spleen: 59.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 292.1;BJ hTERT+ SV40 Large T+ RasG12V: 247.3;SK-MEL-30: 98.7
OAS3		ENSG00000111331	2'-5'-oligoadenylate synthetase 3	12	112938352-112973249	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041253, HPA041372	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.23e-5 (unfavourable)	Expressed in all	Mixed			spleen: 33.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 251.3;BJ hTERT+ SV40 Large T+ RasG12V: 285.0
OASL	p59OASL, TRIP14	ENSG00000135114	2'-5'-oligoadenylate synthetase like	12	121019111-121039242	Predicted intracellular proteins	Evidence at protein level	HPA001474	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.70e-9 (unfavourable), Pancreatic cancer:9.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 35.4;stomach: 22.1	lung: 19.9	Cell line enhanced		BJ hTERT+ SV40 Large T+: 131.5;BJ hTERT+ SV40 Large T+ RasG12V: 70.4;hTEC/SVTERT24-B: 56.8
OAT	HOGA	ENSG00000065154	Ornithine aminotransferase	10	124397303-124418976	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033576, HPA040098, HPA064742	Enhanced		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			small intestine: 859.8	Mixed		
OAZ1	AZI, MGC138338, OAZ	ENSG00000104904	Ornithine decarboxylase antizyme 1	19	2269509-2273490	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA009291	Uncertain		Approved	Vesicles<br>Microtubule organizing center	Pancreatic cancer:4.10e-5 (favourable), Liver cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 268.1	Expressed in all		
OAZ2		ENSG00000180304	Ornithine decarboxylase antizyme 2	15	64687573-64703281	Predicted intracellular proteins	Evidence at protein level	HPA047694	Uncertain		Approved	Golgi apparatus	Colorectal cancer:9.05e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.1	Expressed in all		
OAZ3		ENSG00000143450	Ornithine decarboxylase antizyme 3	1	151762899-151771334	Predicted intracellular proteins	Evidence at protein level	HPA030136			Supported	Nucleoplasm		Mixed	Tissue enriched	13	testis: 197.6	prostate: 14.7	Mixed		
OBSCN	ARHGEF30, KIAA1556, KIAA1639, UNC89	ENSG00000154358	Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF	1	228208130-228378874	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021186	Enhanced		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:1.64e-4 (unfavourable)	Mixed	Tissue enriched	7	skeletal muscle: 301.1	heart muscle: 45.7	Mixed		
OBSL1	KIAA0657	ENSG00000124006	Obscurin like 1	2	219550729-219571859	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036404, HPA036405	Approved		Approved	Centrosome	Glioma:8.52e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 220.5	Cell line enhanced		BEWO: 148.8
OCEL1	FLJ22709	ENSG00000099330	Occludin/ELL domain containing 1	19	17226204-17229219	Predicted intracellular proteins	Evidence at protein level	HPA042070, HPA043223	Uncertain		Approved	Golgi apparatus		Expressed in all	Expressed in all			epididymis: 22.2	Expressed in all		
OCIAD2	MGC45416	ENSG00000145247	OCIA domain containing 2	4	48885019-48906937	Predicted intracellular proteins	Evidence at protein level	HPA040979, HPA041090	Enhanced		Enhanced	Mitochondria	Renal cancer:2.67e-5 (favourable), Urothelial cancer:2.34e-4 (favourable), Ovarian cancer:6.56e-4 (favourable), Pancreatic cancer:6.89e-4 (unfavourable), Endometrial cancer:7.37e-4 (favourable)	Expressed in all	Expressed in all			kidney: 151.5	Cell line enhanced		U-251 MG: 320.9
OCM	OCM1	ENSG00000122543	Oncomodulin	7	5879827-5886362	Predicted intracellular proteins	Evidence at protein level	HPA046422	Uncertain					Not detected	Tissue enhanced		lymph node: 2.4	testis: 1.5	Not detected		
OCM2		ENSG00000135175	Oncomodulin 2	7	97984684-97991169	Predicted intracellular proteins	No evidence	HPA046422	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
OCRL	OCRL1	ENSG00000122126	OCRL, inositol polyphosphate-5-phosphatase	X	129539849-129592561	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA012495	Approved		Approved	Microtubules<br>Cytosol	Breast cancer:2.93e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.3	Mixed		
ODC1	ODC	ENSG00000115758	Ornithine decarboxylase 1	2	10439968-10448504	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001536, CAB035996	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:3.07e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 242.0	Expressed in all		
ODF1	CT133, HSPB10, ODF27, ODFPG, RT7	ENSG00000155087	Outer dense fiber of sperm tails 1	8	102551572-102561017	Predicted intracellular proteins	Evidence at protein level	HPA064295	Approved					Not detected	Tissue enriched	1426	testis: 418.3	cerebral cortex: 0.2	Not detected		
ODF2	CT134, ODF84	ENSG00000136811	Outer dense fiber of sperm tails 2	9	128455186-128501292	Predicted intracellular proteins	Evidence at protein level	HPA001874, HPA048841	Enhanced		Supported	Centrosome	Liver cancer:1.58e-4 (unfavourable), Prostate cancer:1.72e-4 (unfavourable)	Expressed in all	Tissue enriched	15	testis: 535.2	fallopian tube: 36.6	Expressed in all		
ODF2L	KIAA1229	ENSG00000122417	Outer dense fiber of sperm tails 2 like	1	86346824-86396342	Predicted intracellular proteins	Evidence at protein level	HPA028020, HPA028095, HPA028333	Uncertain		Approved	Mitochondria	Renal cancer:4.69e-7 (unfavourable)	Mixed	Expressed in all			fallopian tube: 34.3	Mixed		
ODF3	CT135, hSHIPPO, SHIPPO1	ENSG00000177947	Outer dense fiber of sperm tails 3	11	196738-200261	Predicted intracellular proteins	Evidence at protein level	HPA038919, HPA039241	Enhanced					Not detected	Tissue enriched	94	testis: 9.4	all non-specific tissues: 0.0	Not detected		
ODF3B		ENSG00000177989	Outer dense fiber of sperm tails 3B	22	50529710-50532580	Predicted intracellular proteins	Evidence at protein level	HPA062837	Enhanced				Renal cancer:2.65e-5 (unfavourable), Endometrial cancer:2.84e-4 (favourable), Head and neck cancer:4.89e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 75.0	appendix: 36.7	Cell line enhanced		Karpas-707: 29.6;U-266/70: 44.1
ODF3L1	MGC48986	ENSG00000182950	Outer dense fiber of sperm tails 3 like 1	15	75723977-75727688	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	6	testis: 24.0	gallbladder: 3.9	Cell line enhanced		U-87 MG: 1.2
ODF3L2	C19orf19, FLJ40059	ENSG00000181781	Outer dense fiber of sperm tails 3 like 2	19	463346-474983	Predicted intracellular proteins	Evidence at protein level	HPA067973	Uncertain					Not detected	Group enriched	10	skeletal muscle: 2.7;testis: 7.6	spleen: 0.5	Not detected		
OFD1	71-7A, CXorf5, JBTS10, RP23	ENSG00000046651	OFD1, centriole and centriolar satellite protein	X	13734745-13769353	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031102, HPA031103, HPA031104	Approved		Supported	Microtubules	Urothelial cancer:2.76e-7 (favourable), Renal cancer:1.63e-4 (unfavourable), Cervical cancer:9.62e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.7	Expressed in all		
OGDH	E1k	ENSG00000105953	Oxoglutarate dehydrogenase	7	44606572-44709066	Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019514, HPA020347	Supported		Enhanced	Mitochondria	Renal cancer:2.22e-14 (favourable)	Expressed in all	Expressed in all			heart muscle: 147.8	Expressed in all		
OGDHL	FLJ10851	ENSG00000197444	Oxoglutarate dehydrogenase-like	10	49734643-49762379	Citric acid cycle related proteins, Predicted intracellular proteins	Evidence at protein level	HPA052497	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Renal cancer:1.21e-14 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 128.4;parathyroid gland: 56.3	liver: 41.6	Cell line enhanced		AN3-CA: 19.8;RPTEC TERT1: 32.9;SH-SY5Y: 17.3
OGFOD1	FLJ10826, KIAA1612, TPA1	ENSG00000087263	2-oxoglutarate and iron dependent oxygenase domain containing 1	16	56451490-56479100	Predicted intracellular proteins	Evidence at protein level	HPA003215	Approved	Approved	Supported	Nucleus<br>Cytosol	Head and neck cancer:6.65e-4 (unfavourable), Liver cancer:7.02e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 22.1	Expressed in all		
OGFOD2	FLJ13491, FLJ37501	ENSG00000111325	2-oxoglutarate and iron dependent oxygenase domain containing 2	12	122974580-122980043	Predicted intracellular proteins	Evidence at protein level	HPA039448, HPA040306	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Expressed in all			testis: 23.1	Expressed in all		
OGFR	7-60	ENSG00000060491	Opioid growth factor receptor	20	62804835-62814000	Predicted intracellular proteins	Evidence at protein level	HPA017899	Enhanced		Approved	Nucleoplasm	Urothelial cancer:5.19e-4 (favourable)	Expressed in all	Expressed in all			spleen: 52.6	Expressed in all		
OGFRL1	dJ331H24.1	ENSG00000119900	Opioid growth factor receptor like 1	6	71288803-71308950	Predicted intracellular proteins	Evidence at protein level	HPA027122			Approved	Nucleoplasm<br>Golgi apparatus	Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 70.3	Mixed		
OGT	FLJ23071, HRNT1, MGC22921, O-GLCNAC	ENSG00000147162	O-linked N-acetylglucosamine (GlcNAc) transferase	X	71533083-71575897	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030751, HPA030752, HPA030753, HPA030754, CAB034099	Approved		Supported	Nucleoplasm<br>Plasma membrane	Urothelial cancer:6.85e-7 (favourable), Renal cancer:2.36e-6 (unfavourable), Head and neck cancer:1.97e-4 (favourable), Endometrial cancer:8.33e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 83.2	Expressed in all		
OIP5	CT86, hMIS18beta, MIS18B	ENSG00000104147	Opa interacting protein 5	15	41309268-41332621	Predicted intracellular proteins	Evidence at protein level	HPA052271, HPA059602	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:9.34e-5 (unfavourable), Liver cancer:1.79e-4 (unfavourable), Lung cancer:2.26e-4 (unfavourable)	Mixed	Tissue enriched	6	testis: 37.2	lymph node: 6.7	Mixed		
OLA1	GTPBP9, PTD004	ENSG00000138430	Obg like ATPase 1	2	174072447-174248698	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035790, HPA041443	Approved		Enhanced	Cytosol	Liver cancer:9.73e-8 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 99.7	Expressed in all		
OLAH	FLJ11106, SAST, THEDC1	ENSG00000152463	Oleoyl-ACP hydrolase	10	15032227-15073852	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037947, HPA037948	Enhanced					Group enriched	Tissue enriched	7	testis: 46.0	breast: 6.2	Cell line enhanced		hTCEpi: 3.3;LHCN-M2: 3.0;SK-BR-3: 4.2
OLIG1	BHLHB6, bHLHe21	ENSG00000184221	Oligodendrocyte transcription factor 1	21	33070144-33072420	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	104	cerebral cortex: 142.6	kidney: 1.3	Cell line enhanced		NB-4: 24.7;RPMI-8226: 14.1;THP-1: 17.1;U-937: 22.7
OLIG2	BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17	ENSG00000205927	Oligodendrocyte transcription factor 2	21	33025845-33029196	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003254, CAB019381	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane		Tissue enriched	Tissue enriched	245	cerebral cortex: 91.0	duodenum: 0.3	Cell line enhanced		HMC-1: 46.5;NB-4: 25.3;THP-1: 23.2;WM-115: 10.9
OLIG3	Bhlhb7, bHLHe20	ENSG00000177468	Oligodendrocyte transcription factor 3	6	137492202-137494250	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018303, CAB024865	Uncertain					Not detected	Not detected			esophagus: 0.1	Cell line enhanced		NTERA-2: 1.2
OMP		ENSG00000254550	Olfactory marker protein	11	77102840-77103331	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		duodenum: 2.7;small intestine: 2.8	rectum: 2.0	Not detected		
ONECUT1	HNF-6, HNF6, HNF6A	ENSG00000169856	One cut homeobox 1	15	52756989-52791078	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003457	Enhanced					Group enriched	Group enriched	6	gallbladder: 8.4;liver: 5.9;pancreas: 2.3;testis: 1.8	bone marrow: 0.7	Cell line enhanced		MCF7: 1.7;WM-115: 1.5
ONECUT2	OC-2	ENSG00000119547	One cut homeobox 2	18	57435685-57491297	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057058	Enhanced		Supported	Nucleoplasm<br>Actin filaments		Group enriched	Tissue enhanced		duodenum: 10.4;gallbladder: 16.3	liver: 4.5	Cell line enhanced		HDLM-2: 19.1;HeLa: 8.5;SCLC-21H: 12.1
ONECUT3		ENSG00000205922	One cut homeobox 3	19	1752373-1780988	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059936			Supported	Nucleoplasm		Group enriched	Tissue enhanced		stomach: 4.0	gallbladder: 1.0	Group enriched	9	HaCaT: 6.2;PC-3: 14.4
OOEP	C6orf156, Em:AC019205.2, KHDC2	ENSG00000203907	Oocyte expressed protein	6	73368555-73395133	Predicted intracellular proteins	Evidence at protein level	HPA055165	Approved					Tissue enriched	Tissue enriched	11	testis: 23.1	placenta: 2.0	Cell line enhanced		BEWO: 2.5;CAPAN-2: 7.2;MCF7: 2.1;U-2 OS: 1.8
OPA1	FLJ12460, KIAA0567, MGM1, NPG, NTG	ENSG00000198836	OPA1, mitochondrial dynamin like GTPase	3	193593144-193697823	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA036926, HPA036927	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Pancreatic cancer:8.44e-5 (unfavourable), Renal cancer:1.84e-4 (favourable), Endometrial cancer:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 56.2	Expressed in all		
OPHN1	ARHGAP41, MRX60, OPN1	ENSG00000079482	Oligophrenin 1	X	68042344-68433913	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002919	Approved		Approved	Nucleus<br>Plasma membrane		Mixed	Mixed			cerebral cortex: 20.1	Mixed		
OPLAH	5-Opase, OPLA	ENSG00000178814	5-oxoprolinase (ATP-hydrolysing)	8	144051266-144063965	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026562, HPA028260, HPA052429	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:1.53e-6 (favourable)	Expressed in all	Tissue enhanced		testis: 58.2	duodenum: 13.8	Cell line enhanced		AN3-CA: 31.2;BEWO: 20.2;PC-3: 24.2
OPTN	FIP-2, FIP2, GLC1E, HIP7, HYPL, NRP, TFIIIA-INTP	ENSG00000123240	Optineurin	10	13099449-13138308	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003279, HPA003360, CAB019303	Supported		Enhanced	Cytosol	Renal cancer:5.81e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 300.1	Mixed		
ORAOV1	TAOS1	ENSG00000149716	Oral cancer overexpressed 1	11	69653076-69675416	Predicted intracellular proteins	Evidence at protein level	HPA062696			Approved	Nucleoplasm	Renal cancer:1.51e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 21.9	Expressed in all		
ORC1	HSORC1, ORC1L, PARC1	ENSG00000085840	Origin recognition complex subunit 1	1	52372829-52404459	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027450	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Colorectal cancer:1.74e-5 (favourable), Liver cancer:3.22e-5 (unfavourable), Melanoma:3.69e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 17.9	lymph node: 7.9	Mixed		
ORC2	ORC2L	ENSG00000115942	Origin recognition complex subunit 2	2	200908973-200963680	Predicted intracellular proteins	Evidence at protein level	CAB003693, HPA073881	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.97e-4 (unfavourable), Melanoma:8.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 38.1	Expressed in all		
ORC4	HsORC4, ORC4L, Orc4p	ENSG00000115947	Origin recognition complex subunit 4	2	147930397-148021604	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015124, HPA064562	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:4.98e-8 (unfavourable), Renal cancer:4.10e-6 (favourable), Endometrial cancer:7.27e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.5	Expressed in all		
ORC5	ORC5L, Orc5p, ORC5T, PPP1R117	ENSG00000164815	Origin recognition complex subunit 5	7	104126341-104208047	Predicted intracellular proteins	Evidence at protein level	HPA019730	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 34.4	Expressed in all		
ORC6	ORC6L	ENSG00000091651	Origin recognition complex subunit 6	16	46689643-46698394	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016330, HPA072587	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center	Ovarian cancer:1.48e-4 (favourable), Melanoma:3.53e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 12.3	lymph node: 8.8	Expressed in all		
OSBP	OSBP1	ENSG00000110048	Oxysterol binding protein	11	59574398-59616144	Predicted intracellular proteins	Evidence at protein level	HPA039227, HPA043625	Enhanced		Enhanced	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:3.08e-7 (favourable), Colorectal cancer:2.08e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 73.9	Expressed in all		
OSBP2	KIAA1664, ORP-4, ORP4, OSBPL1	ENSG00000184792	Oxysterol binding protein 2	22	30693782-30907824	Predicted intracellular proteins	Evidence at protein level	HPA021514	Uncertain		Approved	Cytosol	Renal cancer:3.79e-6 (favourable)	Expressed in all	Tissue enhanced		testis: 34.5	bone marrow: 31.8	Cell line enhanced		HeLa: 98.3;SiHa: 41.6
OSBPL10		ENSG00000144645	Oxysterol binding protein like 10	3	31657890-32077580	Predicted intracellular proteins	Evidence at protein level	HPA003636			Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.51e-4 (favourable), Pancreatic cancer:3.14e-4 (unfavourable), Urothelial cancer:4.85e-4 (unfavourable)	Mixed	Mixed			testis: 32.1	Cell line enhanced		hTERT-HME1: 61.7;RPTEC TERT1: 64.6
OSBPL11	FLJ13012, FLJ13164, ORP-11, ORP11	ENSG00000144909	Oxysterol binding protein like 11	3	125528858-125595090	Predicted intracellular proteins	Evidence at protein level	HPA039144			Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			spleen: 22.9	Expressed in all		
OSBPL1A	ORP-1, ORP1, OSBPL1B	ENSG00000141447	Oxysterol binding protein like 1A	18	24162044-24397880	Predicted intracellular proteins	Evidence at protein level	HPA040959, HPA043401	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.98e-13 (favourable), Stomach cancer:1.86e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 131.1	Mixed		
OSBPL2	DFNA67, KIAA0772, ORP-2	ENSG00000130703	Oxysterol binding protein like 2	20	62231922-62296213	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041127, HPA042659	Uncertain		Approved	Cytosol	Renal cancer:4.20e-5 (favourable)	Expressed in all	Expressed in all			skin: 49.7	Expressed in all		
OSBPL3	KIAA0704, ORP-3, ORP3, OSBP3	ENSG00000070882	Oxysterol binding protein like 3	7	24796539-24981634	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000691, HPA048401	Enhanced		Supported	Nucleoli<br>Cytosol	Pancreatic cancer:7.88e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 33.4	Mixed		
OSBPL6	ORP6	ENSG00000079156	Oxysterol binding protein like 6	2	178194481-178402891	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032131	Enhanced		Approved	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 15.5	skin: 9.2	Cell line enhanced		HEL: 43.7
OSBPL7	MGC71150, ORP7	ENSG00000006025	Oxysterol binding protein like 7	17	47807372-47821834	Predicted intracellular proteins	Evidence at protein level	HPA036076, HPA053083	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.19e-5 (favourable), Renal cancer:8.30e-4 (unfavourable)	Expressed in all	Mixed			stomach: 33.1	Cell line enhanced		HaCaT: 38.6
OSBPL9		ENSG00000117859	Oxysterol binding protein like 9	1	51577179-51798427	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027378, HPA027397	Supported	Approved	Supported	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 96.6	Expressed in all		
OSCP1	C1orf102, NOR1	ENSG00000116885	Organic solute carrier partner 1	1	36415827-36450451	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA028436, HPA052655	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Renal cancer:2.18e-6 (favourable), Endometrial cancer:6.88e-4 (favourable)	Expressed in all	Expressed in all			testis: 126.7	Mixed		
OSER1	C20orf111, dJ1183I21.1, HSPC207, Osr1, Perit1	ENSG00000132823	Oxidative stress responsive serine rich 1	20	44196496-44210791	Predicted intracellular proteins	Evidence at protein level	HPA045125	Approved		Approved	Nucleoli<br>Nuclear speckles	Endometrial cancer:2.58e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 184.6	Expressed in all		
OSGEP	GCPL1, KAE1, OSGEP1, PRSMG1	ENSG00000092094	O-sialoglycoprotein endopeptidase	14	20446411-20455105	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039751	Uncertain		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:4.64e-6 (unfavourable), Breast cancer:1.48e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 12.7	Expressed in all		
OSGEPL1	OSGEPL, Qri7	ENSG00000128694	O-sialoglycoprotein endopeptidase like 1	2	189746660-189763227	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030693	Uncertain		Enhanced	Mitochondria	Ovarian cancer:3.19e-4 (favourable), Liver cancer:3.71e-4 (unfavourable)	Expressed in all	Mixed			testis: 12.2	Expressed in all		
OSGIN1	BDGI, OKL38	ENSG00000140961	Oxidative stress induced growth inhibitor 1	16	83948282-83966332	Predicted intracellular proteins	Evidence at protein level	HPA019239			Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:4.89e-5 (favourable)	Tissue enriched	Tissue enhanced		liver: 57.3	duodenum: 31.3	Cell line enhanced		A549: 60.9;Hep G2: 69.5;T-47d: 69.3;WM-115: 61.3
OSGIN2	C8orf1, hT41	ENSG00000164823	Oxidative stress induced growth inhibitor family member 2	8	89901859-89927888	Predicted intracellular proteins	Evidence at transcript level	HPA028515, HPA050595	Approved		Approved	Nucleoli	Liver cancer:3.91e-6 (unfavourable), Lung cancer:2.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 88.9	Expressed in all		
OSR1	ODD	ENSG00000143867	Odd-skipped related transciption factor 1	2	19351485-19358653	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA015525	Uncertain					Mixed	Mixed			adipose tissue: 22.1	Cell line enriched	14	U-2197: 92.8
OSR2	FLJ90037	ENSG00000164920	Odd-skipped related transciption factor 2	8	98944403-98952104	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052425, HPA063486	Uncertain		Approved	Nucleus<br>Plasma membrane	Head and neck cancer:2.44e-5 (favourable)	Mixed	Tissue enhanced		endometrium: 205.3;fallopian tube: 144.6	ovary: 102.9	Cell line enriched	13	ASC diff: 372.1
OSTF1	bA235O14.1, OSF, SH3P2	ENSG00000134996	Osteoclast stimulating factor 1	9	75088543-75147265	Predicted intracellular proteins	Evidence at protein level	HPA020514	Approved		Supported	Cytosol	Endometrial cancer:3.67e-5 (favourable)	Expressed in all	Expressed in all			spleen: 122.7	Cell line enhanced		HDLM-2: 286.9
OTC		ENSG00000036473	Ornithine carbamoyltransferase	X	38352545-38421450	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000243, HPA000570	Enhanced		Supported	Mitochondria		Tissue enriched	Group enriched	26	duodenum: 114.4;liver: 195.4;small intestine: 96.9	colon: 5.3	Not detected		
OTP		ENSG00000171540	Orthopedia homeobox	5	77628712-77639688	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059342	Supported					Tissue enriched	Not detected			lung,testis: 0.1	Not detected		
OTUB1	FLJ20113, FLJ40710	ENSG00000167770	OTU deubiquitinase, ubiquitin aldehyde binding 1	11	63985853-64001811	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039176, CAB072836	Approved	Supported	Approved	Nucleus<br>Cytosol	Head and neck cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 116.0	Expressed in all		
OTUB2	C14orf137, FLJ21916, MGC3102	ENSG00000089723	OTU deubiquitinase, ubiquitin aldehyde binding 2	14	94026329-94048930	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002329	Enhanced					Mixed	Tissue enhanced		testis: 9.7	skin: 4.7	Cell line enhanced		Karpas-707: 12.8;RPTEC TERT1: 8.5
OTUD1	DUBA7, OTDC1	ENSG00000165312	OTU deubiquitinase 1	10	23439458-23442390	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038503, HPA038504	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus	Renal cancer:6.61e-7 (favourable), Endometrial cancer:4.59e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 43.3	Cell line enhanced		CAPAN-2: 37.8;HaCaT: 36.0;SiHa: 28.0
OTUD3	DUBA4, KIAA0459	ENSG00000169914	OTU deubiquitinase 3	1	19882513-19912945	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028543, HPA028544	Approved		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol		Expressed in all	Mixed			testis: 19.4	Expressed in all		
OTUD4	DUBA6, HSHIN1, KIAA1046	ENSG00000164164	OTU deubiquitinase 4	4	145110838-145180161	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036623	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			testis: 72.7	Expressed in all		
OTUD5	DKFZp761A052, DUBA	ENSG00000068308	OTU deubiquitinase 5	X	48922028-48958386	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017375	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Lung cancer:1.48e-4 (favourable), Pancreatic cancer:8.20e-4 (favourable), Cervical cancer:9.57e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 69.9	Group enriched	8	U-266/70: 1128.2;U-266/84: 277.1
OTUD6A	DUBA2, FLJ25831, HSHIN6	ENSG00000189401	OTU deubiquitinase 6A	X	70062491-70064179	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053304	Enhanced					Tissue enriched	Tissue enriched	14	testis: 9.5	thyroid gland: 0.7	Not detected		
OTUD6B	CGI-77, DUBA5	ENSG00000155100	OTU domain containing 6B	8	91070196-91087095	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024046, HPA024503, HPA024772	Enhanced	Approved	Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:7.50e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 17.2	Expressed in all		
OTUD7A	C15orf16, CEZANNE2, OTUD7	ENSG00000169918	OTU deubiquitinase 7A	15	31475398-31870789	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044554	Uncertain		Approved	Nucleoli<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 13.5	testis: 5.1	Cell line enhanced		SCLC-21H: 6.3;SH-SY5Y: 2.7
OTUD7B	CEZANNE, ZA20D1	ENSG00000264522	OTU deubiquitinase 7B	1	149937812-150010676	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027045	Supported		Approved	Nucleoplasm<br>Microtubules	Melanoma:5.09e-5 (favourable), Endometrial cancer:7.47e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 23.7	Mixed		
OTULIN	FAM105B, FLJ34884	ENSG00000154124	OTU deubiquitinase with linear linkage specificity	5	14664664-14699711	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051074	Uncertain		Approved	Plasma membrane<br>Mitochondria	Renal cancer:2.59e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 17.1	Expressed in all		
OTX1		ENSG00000115507	Orthodenticle homeobox 1	2	63050057-63057836	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB012341, HPA052122	Approved		Uncertain	Nuclear speckles<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 1.7;skin: 6.1	prostate: 1.0	Cell line enriched	6	THP-1: 35.9
OTX2		ENSG00000165588	Orthodenticle homeobox 2	14	56799905-56810479	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000633	Approved					Tissue enriched	Not detected			testis: 0.5	Group enriched	735	HAP1: 239.3;NTERA-2: 192.9
OVCA2		ENSG00000262664	Ovarian tumor suppressor candidate 2	17	2041936-2043430	Predicted intracellular proteins	Evidence at protein level	HPA059002			Supported	Nucleoplasm<br>Cytosol		Not detected	Expressed in all			gallbladder: 34.2	Expressed in all		
OVOL1	HOVO1	ENSG00000172818	Ovo like transcriptional repressor 1	11	65787022-65797219	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003984	Uncertain		Approved	Nucleus	Renal cancer:1.00e-13 (favourable), Endometrial cancer:1.87e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 37.3;skin: 33.4;testis: 35.3	urinary bladder: 15.5	Cell line enhanced		A-431: 16.3;BEWO: 49.5;HaCaT: 27.3;RT4: 24.5;SK-BR-3: 17.8
OVOL2	bA504H3.3, CHED, CHED1, HOVO2, ZNF339	ENSG00000125850	Ovo like zinc finger 2	20	17956979-18059188	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038531	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		stomach: 8.0	colon: 3.5	Cell line enhanced		A-431: 5.2;CAPAN-2: 6.7;HaCaT: 5.0;SCLC-21H: 10.2;SK-BR-3: 4.4
OVOL3	HOVO3	ENSG00000105261	Ovo like zinc finger 3	19	36111151-36113711	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Group enriched	5	skin: 1.0;testis: 2.8	appendix: 0.3	Cell line enhanced		U-266/84: 2.1
OVOS2		ENSG00000177359		12	31111652-31206154	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	8	testis: 2.8	stomach: 0.3	Cell line enhanced		U-266/70: 1.0
OXLD1	C17orf90, MGC104712	ENSG00000204237	Oxidoreductase like domain containing 1	17	81665036-81666635	Predicted intracellular proteins	Evidence at protein level	HPA056878, HPA057019	Uncertain		Approved	Vesicles<br>Cytosol	Cervical cancer:2.91e-4 (favourable)	Expressed in all	Mixed			testis: 10.7	Cell line enhanced		A549: 54.5
OXR1	TLDC3	ENSG00000164830	Oxidation resistance 1	8	106359476-106752694	Predicted intracellular proteins	Evidence at protein level	HPA027375, HPA027380, HPA027395	Enhanced		Supported	Vesicles	Renal cancer:5.82e-5 (favourable), Pancreatic cancer:3.85e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 110.7	Expressed in all		
OXSM	CEM1, FASN2D, FLJ20604, KS	ENSG00000151093	3-oxoacyl-ACP synthase, mitochondrial	3	25782917-25794534	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021293, HPA021300, HPA021337	Enhanced		Approved	Mitochondria<br>Cytosol	Renal cancer:4.18e-9 (favourable), Colorectal cancer:1.35e-4 (favourable), Endometrial cancer:5.51e-4 (favourable)	Expressed in all	Expressed in all			testis: 17.4	Mixed		
OXSR1	KIAA1101, OSR1	ENSG00000172939	Oxidative stress responsive 1	3	38165089-38255488	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008237, CAB017181	Enhanced		Enhanced	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 43.0	Expressed in all		
PA2G4		ENSG00000170515	Proliferation-associated 2G4	12	56104319-56113907	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011711, CAB012428, HPA016484	Supported		Approved	Cytosol	Renal cancer:4.59e-7 (unfavourable), Liver cancer:6.31e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 138.1	Expressed in all		
PABPC1	PAB1, PABP1, PABPC2, PABPL1	ENSG00000070756	Poly(A) binding protein cytoplasmic 1	8	100685816-100722809	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011536, HPA045423, HPA067156	Enhanced		Supported	Cytosol	Renal cancer:5.70e-12 (unfavourable), Glioma:1.35e-4 (favourable), Liver cancer:5.80e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 1151.0	Expressed in all		
PABPC1L	C20orf119, dJ1069P2.3, ePAB, PABPC1L1	ENSG00000101104	Poly(A) binding protein cytoplasmic 1 like	20	44910062-44959035	Predicted intracellular proteins	Evidence at protein level	HPA066650			Approved	Nuclear bodies<br>Cytosol	Renal cancer:4.00e-15 (unfavourable), Colorectal cancer:3.80e-4 (unfavourable), Urothelial cancer:8.84e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 54.1	Expressed in all		
PABPC1L2A	RBM32A	ENSG00000186288	Poly(A) binding protein cytoplasmic 1 like 2A	X	73077276-73079512	Predicted intracellular proteins	Evidence at transcript level	HPA041573	Approved					Tissue enriched	Group enriched	5	adrenal gland: 2.0;cerebral cortex: 6.7;prostate: 3.6;testis: 2.8	epididymis: 0.7	Cell line enhanced		HeLa: 2.6;NTERA-2: 1.4
PABPC1L2B	RBM32B	ENSG00000184388	Poly(A) binding protein cytoplasmic 1 like 2B	X	73003517-73005713	Predicted intracellular proteins	Evidence at transcript level	HPA041573	Approved					Tissue enriched	Group enriched	5	cerebral cortex: 8.7;prostate: 4.6	testis: 1.2	Cell line enhanced		NTERA-2: 1.6
PABPC3	PABP3, PABPL3, tPABP	ENSG00000151846	Poly(A) binding protein cytoplasmic 3	13	25095868-25099254	Predicted intracellular proteins	Evidence at protein level	HPA045423, HPA067156	Approved		Approved	Cytosol	Ovarian cancer:8.00e-4 (unfavourable)	Mixed	Tissue enriched	151	testis: 60.6	cerebral cortex: 0.4	Cell line enriched	9	U-266/84: 4.3
PABPC4	APP-1, iPABP	ENSG00000090621	Poly(A) binding protein cytoplasmic 4	1	39560816-39576790	Predicted intracellular proteins	Evidence at protein level	HPA027301, HPA056496	Approved		Enhanced	Cytosol	Renal cancer:3.00e-10 (unfavourable), Liver cancer:1.14e-7 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 206.3	Expressed in all		
PABPC4L		ENSG00000254535	Poly(A) binding protein cytoplasmic 4 like	4	134196333-134201748	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.11e-5 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 12.8;placenta: 14.7	endometrium: 6.4	Cell line enhanced		HAP1: 11.9;HeLa: 10.3;REH: 7.4;RH-30: 8.3;U-2 OS: 9.1
PABPC5	PABP5	ENSG00000174740	Poly(A) binding protein cytoplasmic 5	X	91434595-91438584	Predicted intracellular proteins	Evidence at transcript level	HPA000164, HPA000165	Approved					Mixed	Tissue enhanced		ovary: 13.4	adrenal gland: 9.6	Cell line enhanced		AF22: 6.8;RH-30: 8.1
PABPN1	OPMD, PAB2, PABP2	ENSG00000100836	Poly(A) binding protein nuclear 1	14	23321289-23326185	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000637	Supported	Approved			Renal cancer:2.41e-7 (unfavourable), Liver cancer:3.55e-4 (unfavourable), Pancreatic cancer:9.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 205.2	Expressed in all		
PABPN1L	ePABP2	ENSG00000205022	Poly(A) binding protein nuclear 1 like, cytoplasmic	16	88863333-88866660	Predicted intracellular proteins	Evidence at transcript level	HPA043415	Uncertain					Not detected	Tissue enhanced		adrenal gland: 1.0	bone marrow: 0.5	Cell line enhanced		MCF7: 2.0;NB-4: 1.1;SCLC-21H: 5.5;T-47d: 1.3
PACRGL	C4orf28, MGC29898	ENSG00000163138	PARK2 coregulated like	4	20696282-20752907	Predicted intracellular proteins	Evidence at protein level	HPA054666			Approved	Nucleoplasm<br>Vesicles	Urothelial cancer:4.85e-4 (favourable)	Expressed in all	Expressed in all			testis: 60.3	Expressed in all		
PACS1	FLJ10209, KIAA1175	ENSG00000175115	Phosphofurin acidic cluster sorting protein 1	11	66070363-66244747	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038914	Approved		Approved	Microtubules<br>Cytosol		Expressed in all	Expressed in all			testis: 74.1	Expressed in all		
PACS2	KIAA0602, PACS1L	ENSG00000179364	Phosphofurin acidic cluster sorting protein 2	14	105300563-105398147	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001423, HPA077892	Approved		Approved	Mitochondria	Liver cancer:3.11e-5 (unfavourable), Renal cancer:1.56e-4 (favourable), Pancreatic cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 63.3	Expressed in all		
PACSIN1	SDPI	ENSG00000124507	Protein kinase C and casein kinase substrate in neurons 1	6	34466061-34535231	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009929, HPA028852, HPA055491	Enhanced		Approved	Nucleus<br>Vesicles		Mixed	Tissue enriched	32	cerebral cortex: 133.6	lymph node: 4.1	Cell line enhanced		MCF7: 9.2;RPMI-8226: 9.7;T-47d: 20.2;U-266/84: 11.7
PACSIN2	SDPII	ENSG00000100266	Protein kinase C and casein kinase substrate in neurons 2	22	42835412-43015145	Predicted intracellular proteins	Evidence at protein level	HPA049854, HPA056520	Enhanced		Supported	Nuclear speckles<br>Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:1.09e-13 (favourable), Liver cancer:7.33e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 95.3	Expressed in all		
PACSIN3	SDPIII	ENSG00000165912	Protein kinase C and casein kinase substrate in neurons 3	11	47177525-47186443	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039480, HPA043904	Approved	Approved	Supported	Plasma membrane<br>Cytosol	Ovarian cancer:2.09e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 164.2	heart muscle: 93.6	Mixed		
PADI1	HPAD10, PAD1, PDI, PDI1	ENSG00000142623	Peptidyl arginine deiminase 1	1	17205126-17246005	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062294	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:8.34e-11 (unfavourable)	Tissue enhanced	Tissue enriched	7	esophagus: 37.1	skin: 5.4	Cell line enhanced		CAPAN-2: 4.5;EFO-21: 2.3;HaCaT: 1.3;LHCN-M2: 1.6;RPTEC TERT1: 1.9
PADI2	KIAA0994, PDI2	ENSG00000117115	Peptidyl arginine deiminase 2	1	17066761-17119435	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047735	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 85.0;colon: 89.8;rectum: 99.9;skeletal muscle: 108.6	breast: 48.8	Group enriched	5	A549: 10.4;RPTEC TERT1: 25.1;SK-BR-3: 38.1;T-47d: 13.1
PADI3	PDI3	ENSG00000142619	Peptidyl arginine deiminase 3	1	17249098-17284233	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043739	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.55e-11 (unfavourable), Endometrial cancer:3.22e-4 (unfavourable)	Tissue enhanced	Group enriched	10	esophagus: 3.7;seminal vesicle: 4.9;urinary bladder: 10.2	epididymis: 0.6	Cell line enhanced		EFO-21: 13.2;RT4: 13.9;T-47d: 12.0
PADI4	PAD, PADI5, PDI4, PDI5	ENSG00000159339	Peptidyl arginine deiminase 4	1	17308195-17364004	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017007, HPA042825	Enhanced					Not detected	Tissue enriched	12	bone marrow: 71.8	spleen: 5.9	Cell line enhanced		HEL: 1.1;RPMI-8226: 1.0
PADI6		ENSG00000276747	Peptidyl arginine deiminase 6	1	17372196-17401699	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PAF1	F23149_1, FLJ11123, PD2	ENSG00000006712	PAF1 homolog, Paf1/RNA polymerase II complex component	19	39385852-39391195	Predicted intracellular proteins	Evidence at protein level	HPA041875, HPA043637	Approved		Supported	Nucleoplasm	Pancreatic cancer:8.66e-4 (favourable), Liver cancer:8.68e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 87.1	Expressed in all		
PAFAH1B1	LIS1, MDCR, MDS, NudF, PAFAH	ENSG00000007168	Platelet activating factor acetylhydrolase 1b regulatory subunit 1	17	2593210-2685615	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004489, HPA020036	Approved		Enhanced	Centrosome	Renal cancer:3.16e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 178.7	Expressed in all		
PAFAH1B2		ENSG00000168092	Platelet activating factor acetylhydrolase 1b catalytic subunit 2	11	117144267-117176894	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051836	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Pancreatic cancer:7.79e-5 (unfavourable), Lung cancer:3.07e-4 (unfavourable), Ovarian cancer:4.25e-4 (favourable), Liver cancer:9.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 68.2	Expressed in all		
PAFAH1B3		ENSG00000079462	Platelet activating factor acetylhydrolase 1b catalytic subunit 3	19	42297033-42303546	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035639	Uncertain		Approved	Intermediate filaments	Renal cancer:2.07e-4 (unfavourable), Liver cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 36.7	Mixed		
PAFAH2	HSD-PLA2	ENSG00000158006	Platelet activating factor acetylhydrolase 2	1	25959767-25998157	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018157	Approved				Renal cancer:0.00e+0 (favourable), Endometrial cancer:3.28e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 29.1	Expressed in all		
PAG1	CBP, PAG	ENSG00000076641	Phosphoprotein membrane anchor with glycosphingolipid microdomains 1	8	80967810-81112068	Predicted intracellular proteins	Evidence at protein level	HPA001632, HPA066527	Uncertain		Supported	Vesicles<br>Plasma membrane	Renal cancer:1.24e-6 (unfavourable), Testis cancer:6.82e-4 (unfavourable)	Expressed in all	Mixed			placenta: 23.0	Cell line enhanced		Daudi: 25.3;HMC-1: 40.0;SK-MEL-30: 28.4
PAGE1	CT16.3, GAGE-9, GAGEB1, PAGE-1	ENSG00000068985	PAGE family member 1	X	49687450-49695993	Predicted intracellular proteins	Evidence at protein level	HPA003473	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Mitochondria		Tissue enhanced	Tissue enriched	168	testis: 25.1	epididymis,placenta: 0.1	Group enriched	7	A-431: 161.4;Karpas-707: 98.5;U-266/84: 157.3
PAGE2	CT16.4, GAGEC2, MGC62094, PAGE-2	ENSG00000234068	PAGE family member 2	X	55089008-55092842	Predicted intracellular proteins	Evidence at protein level	HPA052619	Supported					Mixed	Tissue enriched	42	testis: 43.8	placenta: 1.0	Group enriched	444	U-2 OS: 260.7;U-266/70: 782.4;U-266/84: 993.0
PAGE2B	CT16.5	ENSG00000238269	PAGE family member 2B	X	55075063-55078909	Predicted intracellular proteins	Evidence at protein level	HPA052619	Supported				Endometrial cancer:3.02e-4 (unfavourable)	Mixed	Tissue enriched	29	testis: 84.8	bone marrow: 2.8	Group enriched	6	U-266/70: 1167.1;U-266/84: 1756.5
PAGE3	CT16.6, GAGED1, PAGE-3	ENSG00000204279	PAGE family member 3	X	55258412-55264846	Predicted intracellular proteins	Evidence at protein level	HPA062248	Uncertain					Not detected	Tissue enriched	86	testis: 8.5	all non-specific tissues: 0.0	Not detected		
PAGE4	CT16.7, GAGEC1, PAGE-4	ENSG00000101951	PAGE family member 4	X	49829260-49833973	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA023880	Enhanced		Approved	Golgi apparatus<br>Vesicles		Group enriched	Group enriched	6	epididymis: 1456.6;placenta: 2041.1	prostate: 269.4	Group enriched	9	CACO-2: 8.5;U-266/70: 9.3;U-266/84: 33.4
PAGE5	CT16.1, CT16.2, PAGE-5	ENSG00000158639	PAGE family member 5	X	55220355-55224108	Predicted intracellular proteins	Evidence at protein level	HPA052619, HPA055869	Supported		Uncertain	Mitochondria		Group enriched	Tissue enriched	74	testis: 41.0	fallopian tube,liver: 0.5	Group enriched	160	Karpas-707: 324.6;U-266/84: 709.6
PAGR1	C16orf53, GAS, MGC4606, PA1	ENSG00000280789	PAXIP1 associated glutamate rich protein 1	16	29815952-29820117	Predicted intracellular proteins	Evidence at protein level	HPA041440, HPA043608	Uncertain					Expressed in all	Expressed in all			ovary: 60.4	Expressed in all		
PAH	PH	ENSG00000171759	Phenylalanine hydroxylase	12	102836885-102958410	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028407, HPA031642	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Liver cancer:4.30e-4 (favourable)	Tissue enriched	Tissue enhanced		kidney: 504.6;liver: 722.4	gallbladder: 125.9	Cell line enriched	26	Hep G2: 161.3
PAICS	ADE2H1, AIRC, PAIS	ENSG00000128050	Phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase	4	56435741-56464579	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035895, HPA041538	Uncertain		Approved	Cytosol	Renal cancer:5.85e-5 (unfavourable), Liver cancer:1.50e-4 (unfavourable), Thyroid cancer:2.41e-4 (unfavourable), Ovarian cancer:8.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 74.0	Expressed in all		
PAIP1		ENSG00000172239	Poly(A) binding protein interacting protein 1	5	43526267-43557758	Predicted intracellular proteins	Evidence at protein level	HPA073653, HPA076187	Approved		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:4.79e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 153.0	Expressed in all		
PAIP2	PAIP2A	ENSG00000120727	Poly(A) binding protein interacting protein 2	5	139341587-139369720	Predicted intracellular proteins	Evidence at protein level	HPA035945, CAB037212, HPA056766	Approved		Supported	Vesicles		Expressed in all	Expressed in all			testis: 306.7	Expressed in all		
PAIP2B	KIAA1155	ENSG00000124374	Poly(A) binding protein interacting protein 2B	2	71182739-71227083	Predicted intracellular proteins	Evidence at protein level	HPA046784, HPA072371	Approved		Approved	Cytosol	Renal cancer:6.96e-12 (favourable), Endometrial cancer:8.17e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 24.6	Cell line enhanced		SCLC-21H: 27.5
PAK1		ENSG00000149269	P21 (RAC1) activated kinase 1	11	77321707-77474635	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003565, CAB005312	Enhanced	Supported	Enhanced	Plasma membrane<br>Cytosol	Glioma:9.48e-5 (unfavourable), Colorectal cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 184.2	Mixed		
PAK1IP1	bA421M1.5, FLJ20624, hPIP1, MAK11, PIP1, WDR84	ENSG00000111845	PAK1 interacting protein 1	6	10694695-10709782	Predicted intracellular proteins	Evidence at protein level	HPA030111, HPA030112	Supported		Supported	Nucleoplasm<br>Nucleoli	Renal cancer:7.02e-8 (unfavourable), Liver cancer:1.35e-6 (unfavourable)	Expressed in all	Expressed in all			prostate: 104.5	Expressed in all		
PAK2	PAK65, PAKgamma	ENSG00000180370	P21 (RAC1) activated kinase 2	3	196739857-196832647	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB007794	Approved		Enhanced	Nucleus<br>Vesicles	Pancreatic cancer:3.36e-4 (unfavourable), Prostate cancer:9.58e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 60.1	Expressed in all		
PAK3	bPAK, hPAK3, MRX30, MRX47	ENSG00000077264	P21 (RAC1) activated kinase 3	X	110944285-111227361	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA044791, HPA060219	Approved		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 34.3	thyroid gland: 10.4	Cell line enhanced		EFO-21: 10.2;HAP1: 10.2;HDLM-2: 11.9;NTERA-2: 9.6;SCLC-21H: 14.7;U-251 MG: 11.1
PAK4		ENSG00000130669	P21 (RAC1) activated kinase 4	19	39125770-39182816	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB025747, CAB044670, HPA070175, HPA072220	Uncertain		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:5.29e-5 (favourable), Prostate cancer:9.85e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 47.8	Expressed in all		
PAK5	KIAA1264, PAK7	ENSG00000101349	P21 (RAC1) activated kinase 5	20	9537389-9839041	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA020444	Approved		Approved	Nucleoplasm		Mixed	Tissue enriched	5	cerebral cortex: 13.4	adrenal gland: 2.6	Group enriched	10	SCLC-21H: 5.6;SH-SY5Y: 1.8
PAK6	PAK5	ENSG00000137843	P21 (RAC1) activated kinase 6	15	40238759-40277487	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA031124	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions		Not detected	Mixed			cerebral cortex: 28.6	Cell line enhanced		CACO-2: 17.4;HaCaT: 28.5;hTCEpi: 13.9
PALB2	FANCN, FLJ21816	ENSG00000083093	Partner and localizer of BRCA2	16	23603160-23641310	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB014895, HPA057000	Approved		Supported	Nucleoplasm	Pancreatic cancer:2.35e-5 (unfavourable), Colorectal cancer:2.83e-5 (favourable)	Expressed in all	Mixed			testis: 14.5	Expressed in all		
PALLD	CGI-151, KIAA0992, SIH002	ENSG00000129116	Palladin, cytoskeletal associated protein	4	168497066-168928457	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035905, CAB070159	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Urothelial cancer:3.28e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 444.9	Cell line enhanced		LHCN-M2: 240.0
PALM	KIAA0270	ENSG00000099864	Paralemmin	19	708939-748329	Predicted intracellular proteins	Evidence at protein level	HPA041713, HPA049578	Approved		Enhanced	Nucleus<br>Plasma membrane	Renal cancer:5.44e-4 (favourable), Pancreatic cancer:9.81e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 84.8	adipose tissue: 53.1	Cell line enhanced		AN3-CA: 28.0;EFO-21: 25.9;REH: 46.8;SH-SY5Y: 33.4
PALM2		ENSG00000243444	Paralemmin 2	9	109640788-109946703	Predicted intracellular proteins	Evidence at protein level	HPA074153			Approved	Plasma membrane		Not detected	Tissue enhanced		cerebral cortex: 9.8	liver: 3.6	Cell line enhanced		RH-30: 19.4
PALM2-AKAP2		ENSG00000157654	PALM2-AKAP2 readthrough	9	109780309-110172512	Predicted intracellular proteins	Evidence at protein level	HPA058905, HPA074153	Uncertain					Not detected	Tissue enhanced		adipose tissue: 23.4	heart muscle: 19.7	Cell line enhanced		hTEC/SVTERT24-B: 27.6;RH-30: 52.6;WM-115: 31.6
PALM3		ENSG00000187867	Paralemmin 3	19	14053365-14059159	Predicted intracellular proteins	Evidence at protein level	HPA052794, HPA056119	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane	Endometrial cancer:7.87e-4 (unfavourable)	Mixed	Mixed			kidney: 15.7	Cell line enhanced		AN3-CA: 35.4;CACO-2: 34.5;HAP1: 35.4;NTERA-2: 24.5
PALMD	C1orf11, FLJ20271, PALML	ENSG00000099260	Palmdelphin	1	99645943-99694541	Predicted intracellular proteins	Evidence at protein level	HPA017959, HPA030549	Supported		Supported	Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Head and neck cancer:5.90e-5 (favourable), Endometrial cancer:9.42e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 141.1	placenta: 60.5	Cell line enhanced		HUVEC TERT2: 126.3;TIME: 174.6;U-87 MG: 88.7
PAM16	Magmas, Tim16, TIMM16	ENSG00000217930	Presequence translocase associated motor 16 homolog	16	4331549-4355607	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA062721			Approved	Nucleoplasm<br>Microtubules<br>Mitochondria	Renal cancer:5.73e-5 (unfavourable), Urothelial cancer:1.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 15.1	Expressed in all		
PAN2	hPAN2, KIAA0710, USP52	ENSG00000135473	PAN2 poly(A) specific ribonuclease subunit	12	56316223-56334053	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.0	Expressed in all		
PAN3		ENSG00000152520	PAN3 poly(A) specific ribonuclease subunit	13	28138506-28295335	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028817	Approved					Expressed in all	Expressed in all			spleen: 28.7	Expressed in all		
PANK1	MGC24596, PANK, PANK1a, PANK1b	ENSG00000152782	Pantothenate kinase 1	10	89579497-89645572	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.55e-10 (favourable), Liver cancer:1.50e-4 (favourable)	Mixed	Tissue enhanced		kidney: 46.6;liver: 55.1	duodenum: 20.6	Mixed		
PANK2	C20orf48, FLJ11729, HARP, HSS, NBIA1, PKAN	ENSG00000125779	Pantothenate kinase 2	20	3888839-3929882	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008440	Approved		Supported	Cytosol	Liver cancer:1.20e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 51.9	Expressed in all		
PANK3	FLJ12899	ENSG00000120137	Pantothenate kinase 3	5	168548495-168579600	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062358			Approved	Nucleoplasm<br>Golgi apparatus	Colorectal cancer:3.94e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 40.8	Expressed in all		
PANK4	FLJ10782	ENSG00000157881	Pantothenate kinase 4	1	2508533-2526628	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011723, HPA012036, HPA027961	Uncertain		Approved	Cytosol	Renal cancer:1.57e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 3.2	skin: 2.9	Mixed		
PANO1	PANO	ENSG00000274897	Proapoptotic nucleolar protein 1	11	797511-799190	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			cerebral cortex,skin: 1.4	Cell line enhanced		BEWO: 5.3;SCLC-21H: 5.1
PAOX	PAO	ENSG00000148832	Polyamine oxidase	10	133379234-133391694	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047782			Uncertain	Nucleoplasm<br>Centrosome	Head and neck cancer:1.38e-5 (favourable), Cervical cancer:6.07e-5 (favourable), Renal cancer:9.49e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 7.6	cerebral cortex: 3.2	Cell line enhanced		A-431: 5.2;U-266/70: 12.5
PAPD4	FLJ38499, GLD2, TUT2	ENSG00000164329	Poly(A) RNA polymerase D4, non-canonical	5	79612120-79686648	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054468			Approved	Cytosol		Expressed in all	Expressed in all			spleen: 38.4	Expressed in all		
PAPD5	TRF4-2	ENSG00000121274	Poly(A) RNA polymerase D5, non-canonical	16	50152918-50235310	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042968, HPA048225	Uncertain				Renal cancer:1.85e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.5	Expressed in all		
PAPOLB	PAPT	ENSG00000218823	Poly(A) polymerase beta	7	4857733-4861994	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	539	testis: 53.9	all non-specific tissues: 0.0	Not detected		
PAPSS1	ATPSK1, PAPSS	ENSG00000138801	3'-phosphoadenosine 5'-phosphosulfate synthase 1	4	107590276-107720452	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049781	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:2.70e-5 (unfavourable), Endometrial cancer:8.58e-4 (favourable), Colorectal cancer:9.14e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 73.7	Expressed in all		
PAPSS2	ATPSK2	ENSG00000198682	3'-phosphoadenosine 5'-phosphosulfate synthase 2	10	87659613-87747705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071224			Approved	Mitochondria	Melanoma:1.33e-6 (unfavourable), Thyroid cancer:3.21e-5 (unfavourable), Pancreatic cancer:6.58e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 157.6	Cell line enhanced		fHDF/TERT166: 365.8
PARD3	ASIP, Baz, Bazooka, PAR3, PARD3A, PPP1R118	ENSG00000148498	Par-3 family cell polarity regulator	10	34109560-34815325	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030443	Approved		Enhanced	Cell Junctions	Liver cancer:1.73e-5 (unfavourable), Urothelial cancer:4.41e-4 (unfavourable)	Expressed in all	Mixed			skin: 68.7	Mixed		
PARD3B	ALS2CR19, PAR3beta, Par3L	ENSG00000116117	Par-3 family cell polarity regulator beta	2	204545793-205620162	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035283	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cell Junctions	Renal cancer:2.67e-10 (favourable)	Expressed in all	Mixed			parathyroid gland: 13.4	Cell line enhanced		ASC diff: 12.1
PARD6A	PAR-6, PAR-6A, PAR6alpha, TAX40, TIP-40	ENSG00000102981	Par-6 family cell polarity regulator alpha	16	67660946-67662778	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009733, HPA041551	Approved		Supported	Cell Junctions<br>Actin filaments<br>Cytosol	Renal cancer:3.08e-7 (favourable), Breast cancer:5.40e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 20.2	cerebral cortex: 12.1	Cell line enhanced		REH: 24.9;SCLC-21H: 25.2
PARD6B	PAR-6B	ENSG00000124171	Par-6 family cell polarity regulator beta	20	50731544-50756795	Predicted intracellular proteins	Evidence at protein level	HPA013376	Uncertain		Supported	Cytosol	Liver cancer:1.02e-5 (unfavourable), Renal cancer:6.38e-5 (favourable), Pancreatic cancer:8.38e-4 (unfavourable)	Expressed in all	Mixed			kidney: 16.7	Cell line enhanced		CACO-2: 23.7;MCF7: 39.2;T-47d: 45.5
PARD6G	PAR-6G, PAR6gamma	ENSG00000178184	Par-6 family cell polarity regulator gamma	18	80157232-80247546	Predicted intracellular proteins	Evidence at protein level	HPA047017	Uncertain		Approved	Plasma membrane	Liver cancer:3.19e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 44.9	thyroid gland: 30.0	Cell line enhanced		HMC-1: 31.8;U-2 OS: 30.2
PARG		ENSG00000227345	Poly(ADP-ribose) glycohydrolase	10	49818279-49970203	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021819, HPA053007	Enhanced		Enhanced	Nucleus<br>Vesicles	Liver cancer:5.57e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 16.9	Expressed in all		
PARK2	AR-JP, parkin, PDJ	ENSG00000185345	Parkin RBR E3 ubiquitin protein ligase	6	161347420-162727771	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016257, HPA036012	Enhanced		Supported	Nuclear speckles<br>Cytosol	Renal cancer:6.75e-12 (favourable)	Mixed	Mixed			cerebral cortex: 13.8	Cell line enhanced		HEL: 4.7;Karpas-707: 2.3;RPMI-8226: 2.3
PARK7	DJ-1, DJ1	ENSG00000116288	Parkinsonism associated deglycase	1	7954291-7985505	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004190, CAB005870	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 515.7	Expressed in all		
PARN	DAN	ENSG00000140694	Poly(A)-specific ribonuclease	16	14435701-14632728	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006314, CAB011673, HPA012010	Enhanced		Approved	Nucleoli<br>Nuclear speckles	Head and neck cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.0	Expressed in all		
PARP1	ADPRT, PARP, PPOL	ENSG00000143799	Poly(ADP-ribose) polymerase 1	1	226360691-226408079	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727	Supported	Supported	Enhanced	Nucleus	Renal cancer:1.35e-5 (unfavourable), Liver cancer:3.40e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 198.4	Expressed in all		
PARP10	FLJ14464	ENSG00000178685	Poly(ADP-ribose) polymerase family member 10	8	143977153-144012772	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028122, HPA052427	Approved		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			spleen: 56.4	Mixed		
PARP11	C12orf6	ENSG00000111224	Poly(ADP-ribose) polymerase family member 11	12	3791047-3873448	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026895	Uncertain					Expressed in all	Mixed			testis: 17.6	Mixed		
PARP12	FLJ22693, PARP-12, ZC3H1, ZC3HDC1	ENSG00000059378	Poly(ADP-ribose) polymerase family member 12	7	140023744-140063721	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003584, HPA063872	Approved		Approved	Nucleus	Renal cancer:4.12e-7 (unfavourable), Liver cancer:1.63e-4 (unfavourable)	Expressed in all	Mixed			skin: 13.8	Mixed		
PARP14	KIAA1268, pART8	ENSG00000173193	Poly(ADP-ribose) polymerase family member 14	3	122680618-122730840	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008846, HPA012063	Supported		Enhanced	Cytosol	Renal cancer:1.79e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 51.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 67.0;BJ hTERT+ SV40 Large T+ RasG12V: 107.2
PARP2	ADPRTL2	ENSG00000129484	Poly(ADP-ribose) polymerase 2	14	20343582-20357905	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA052003	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:6.48e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 46.3	Expressed in all		
PARP3	ADPRT3, ADPRTL3, hPARP-3, IRT1, pADPRT-3	ENSG00000041880	Poly(ADP-ribose) polymerase family member 3	3	51942345-51948867	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA067657	Supported				Renal cancer:1.25e-8 (favourable), Breast cancer:6.39e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 53.0	Expressed in all		
PARP4	ADPRTL1, p193, VAULT3, VPARP, VWA5C	ENSG00000102699	Poly(ADP-ribose) polymerase family member 4	13	24420926-24512810	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011739	Approved		Supported	Cytosol	Renal cancer:1.21e-5 (favourable)	Expressed in all	Expressed in all			gallbladder: 46.0	Expressed in all		
PARP6	pART17	ENSG00000137817	Poly(ADP-ribose) polymerase family member 6	15	72241181-72272999	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026991	Approved		Approved	Plasma membrane	Renal cancer:8.02e-8 (unfavourable), Cervical cancer:3.17e-5 (favourable), Colorectal cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 46.9	Mixed		
PARP8	FLJ21308, pART16	ENSG00000151883	Poly(ADP-ribose) polymerase family member 8	5	50665899-50846522	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049183	Approved		Approved	Nucleoplasm<br>Cell Junctions<br>Midbody ring<br>Cytosol	Urothelial cancer:1.12e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 72.9	Cell line enhanced		THP-1: 65.6
PARP9	BAL, BAL1	ENSG00000138496	Poly(ADP-ribose) polymerase family member 9	3	122527924-122564577	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA066708			Supported	Nucleoplasm<br>Mitochondria<br>Cytosol	Ovarian cancer:6.65e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.9	Cell line enhanced		BJ hTERT+ SV40 Large T+: 89.2;BJ hTERT+ SV40 Large T+ RasG12V: 110.6
PARPBP	C12orf48, FLJ20641, PARI	ENSG00000185480	PARP1 binding protein	12	102120185-102197520	Predicted intracellular proteins	Evidence at protein level	HPA039677	Approved		Supported	Nucleoplasm	Melanoma:3.17e-4 (unfavourable)	Mixed	Mixed			testis: 7.2	Mixed		
PARS2	DKFZp727A071	ENSG00000162396	Prolyl-tRNA synthetase 2, mitochondrial (putative)	1	54756898-54764514	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028308, HPA028314, HPA028518	Uncertain		Approved	Nucleoli fibrillar center<br>Mitochondria	Renal cancer:1.24e-6 (favourable), Colorectal cancer:1.26e-5 (favourable), Liver cancer:2.34e-4 (unfavourable)	Expressed in all	Mixed			testis: 8.0	Mixed		
PASD1	CT63	ENSG00000166049	PAS domain containing repressor 1	X	151563622-151676739	Predicted intracellular proteins	Evidence at protein level	HPA011122, HPA011152	Enhanced		Supported	Nuclear speckles		Mixed	Tissue enriched	298	testis: 29.8	all non-specific tissues: 0.0	Group enriched	7	BEWO: 33.0;HMC-1: 47.7;U-266/84: 19.0
PASK	KIAA0135, PASKIN, STK37	ENSG00000115687	PAS domain containing serine/threonine kinase	2	241106099-241150264	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016450, HPA021079	Uncertain		Supported	Cytosol		Expressed in all	Tissue enhanced		testis: 25.5	prostate: 16.3	Mixed		
PATJ	Cipp, INADL	ENSG00000132849	PATJ, crumbs cell polarity complex component	1	61742477-62178675	Predicted intracellular proteins	Evidence at protein level	HPA066352, HPA066960, HPA069079	Approved		Supported	Cell Junctions<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.47e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.6	Cell line enhanced		A-431: 31.4
PATL1	FLJ36874, Pat1b	ENSG00000166889	PAT1 homolog 1, processing body mRNA decay factor	11	59636716-59668980	Predicted intracellular proteins	Evidence at protein level	HPA039030	Uncertain		Supported	Cytoplasmic bodies	Pancreatic cancer:2.04e-4 (unfavourable), Colorectal cancer:4.56e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 37.0	Expressed in all		
PATZ1	dJ400N23, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, ZSG	ENSG00000100105	POZ/BTB and AT hook containing zinc finger 1	22	31325804-31346232	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047893, HPA048315	Approved		Supported	Nucleoplasm	Renal cancer:8.54e-8 (favourable), Urothelial cancer:7.79e-6 (favourable), Glioma:6.53e-5 (favourable), Lung cancer:8.71e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 40.4	Expressed in all		
PAWR	par-4, PAR4	ENSG00000177425	Pro-apoptotic WT1 regulator	12	79574979-79691097	Predicted intracellular proteins	Evidence at protein level	HPA012640, CAB020779	Approved		Enhanced	Plasma membrane<br>Actin filaments		Expressed in all	Mixed			endometrium: 45.4	Mixed		
PAX1		ENSG00000125813	Paired box 1	20	21705659-21718486	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	11	parathyroid gland: 185.2	tonsil: 17.5	Cell line enriched	6	SCLC-21H: 1.6
PAX3	HUP2, WS1	ENSG00000135903	Paired box 3	2	222199888-222298996	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063659, HPA069000	Approved		Supported	Nucleoplasm		Tissue enriched	Group enriched	8	breast: 1.2;skeletal muscle: 1.1;skin: 3.2;testis: 2.4	prostate: 0.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 9.6;BJ hTERT+ SV40 Large T+ RasG12V: 11.6;RH-30: 16.2;SK-MEL-30: 24.6
PAX5	BSAP	ENSG00000196092	Paired box 5	9	36833275-37034185	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026269, CAB026869, HPA056394, HPA068498	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		lymph node: 48.5;spleen: 26.2;tonsil: 33.2	appendix: 19.5	Group enriched	6	Daudi: 48.5;REH: 181.0;U-698: 61.2
PAX7	Hup1	ENSG00000009709	Paired box 7	1	18631006-18748866	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Group enriched	Group enriched	7	cerebral cortex: 1.3;skeletal muscle: 2.2	esophagus,testis: 0.2	Group enriched	7	A549: 1.3;CAPAN-2: 1.4;U-2 OS: 3.5
PAX8		ENSG00000125618	Paired box 8	2	113215997-113278950	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030062, CAB055097, CAB061888, HPA064554	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.75e-5 (unfavourable)	Group enriched	Tissue enriched	10	thyroid gland: 644.0	kidney: 65.2	Group enriched	8	EFO-21: 76.3;RPTEC TERT1: 144.9
PAX9		ENSG00000198807	Paired box 9	14	36657568-36679715	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038462	Enhanced		Approved	Nucleoplasm<br>Mitochondria	Cervical cancer:5.38e-4 (favourable)	Mixed	Group enriched	8	esophagus: 56.1;parathyroid gland: 102.3;salivary gland: 21.7	tonsil: 7.5	Cell line enhanced		HDLM-2: 44.7;PC-3: 18.6
PAXBP1	C21orf66, fSAP105, GCFC, GCFC1	ENSG00000159086	PAX3 and PAX7 binding protein 1	21	32733899-32771858	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003757	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.50e-5 (unfavourable), Prostate cancer:9.43e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 18.7	Expressed in all		
PAXIP1	CAGF28, CAGF29, PAXIP1L, PTIP, TNRC2	ENSG00000157212	PAX interacting protein 1	7	154943687-155003084	Predicted intracellular proteins	Evidence at protein level	HPA006694, HPA016950	Enhanced		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			testis: 16.2	Expressed in all		
PBDC1	CXorf26, MGC874	ENSG00000102390	Polysaccharide biosynthesis domain containing 1	X	76172936-76178204	Predicted intracellular proteins	Evidence at protein level	HPA003155	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Thyroid cancer:8.57e-4 (favourable)	Expressed in all	Expressed in all			prostate: 39.7	Mixed		
PBK	CT84, FLJ14385, Nori-3, SPK, TOPK	ENSG00000168078	PDZ binding kinase	8	27809620-27838095	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005753, HPA050656	Enhanced	Supported	Approved	Cytosol	Renal cancer:1.18e-12 (unfavourable), Liver cancer:8.29e-5 (unfavourable), Pancreatic cancer:6.56e-4 (unfavourable)	Expressed in all	Tissue enriched	8	testis: 108.8	lymph node: 13.3	Mixed		
PBLD	FLJ14767, MAWBP, MAWDBP	ENSG00000108187	Phenazine biosynthesis like protein domain containing	10	68282660-68333049	Predicted intracellular proteins	Evidence at protein level	HPA038035, HPA038036	Enhanced		Approved	Vesicles	Liver cancer:1.44e-4 (favourable)	Expressed in all	Expressed in all			kidney: 278.7	Expressed in all		
PBOV1	UC28, UROC28	ENSG00000254440	Prostate and breast cancer overexpressed 1	6	138215986-138218491	Predicted intracellular proteins	Evidence at transcript level	HPA063021	Uncertain					Not detected	Not detected			bone marrow,kidney,parathyroid gland,skin: 0.1	Not detected		
PBRM1	BAF180, PB1	ENSG00000163939	Polybromo 1	3	52545352-52685917	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015629, HPA059373	Uncertain		Supported	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 44.7	Expressed in all		
PBX1		ENSG00000185630	PBX homeobox 1	1	164555584-164899296	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003505, HPA003881, CAB018768	Supported		Enhanced	Nucleoplasm		Mixed	Expressed in all			endometrium: 248.2	Cell line enhanced		SK-BR-3: 173.0
PBX2	G17, HOX12, PBX2MHC	ENSG00000204304	PBX homeobox 2	6	32184741-32190186	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061478	Enhanced		Approved	Nucleoplasm	Endometrial cancer:8.90e-5 (unfavourable), Ovarian cancer:6.84e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 36.1	Mixed		
PBX3		ENSG00000167081	PBX homeobox 3	9	125747345-125967377	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003881	Supported		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 340.6	Mixed		
PBX4		ENSG00000105717	PBX homeobox 4	19	19561707-19618916	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049859, HPA056469	Enhanced		Enhanced	Vesicles	Urothelial cancer:5.94e-7 (favourable), Cervical cancer:8.69e-6 (favourable)	Mixed	Tissue enhanced		testis: 2.6;thyroid gland: 2.2	lymph node: 0.8	Cell line enhanced		PC-3: 1.5;RT4: 1.6
PC	PCB	ENSG00000173599	Pyruvate carboxylase	11	66848233-66958376	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033742, HPA043922, HPA058765	Uncertain		Enhanced	Mitochondria	Ovarian cancer:7.86e-5 (unfavourable), Renal cancer:8.22e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 63.8	Mixed		
PCBD1	DCOH, PCBD, PCD	ENSG00000166228	Pterin-4 alpha-carbinolamine dehydratase 1	10	70882280-70888784	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037575, HPA061723	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			liver: 157.7	Mixed		
PCBD2	DCOH2, DCOHM	ENSG00000132570	Pterin-4 alpha-carbinolamine dehydratase 2	5	134904906-135007959	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036428	Uncertain		Approved	Plasma membrane		Expressed in all	Expressed in all			parathyroid gland: 16.1	Expressed in all		
PCBP1	hnRNP-E1, hnRNP-X, HNRPE1, HNRPX	ENSG00000169564	Poly(rC) binding protein 1	2	70087454-70089203	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037113, HPA043803, HPA068497	Supported		Enhanced	Nuclear speckles<br>Cytoplasmic bodies	Renal cancer:1.71e-5 (favourable)	Expressed in all	Expressed in all			spleen: 284.0	Expressed in all		
PCBP2	hnRNP-E2, HNRNPE2, HNRPE2	ENSG00000197111	Poly(rC) binding protein 2	12	53452102-53481162	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038356	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.82e-5 (unfavourable), Ovarian cancer:8.23e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 745.7	Expressed in all		
PCBP3	FLJ44028, PCBP3-OT1, PCBP3OT	ENSG00000183570	Poly(rC) binding protein 3	21	45643694-45942454	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030247	Approved					Mixed	Tissue enhanced		testis: 21.6	cerebral cortex: 12.7	Cell line enhanced		HDLM-2: 53.3;HSkMC: 30.0;SH-SY5Y: 50.2;U-87 MG: 24.6;U-937: 24.7
PCBP4	LIP4, MCG10	ENSG00000090097	Poly(rC) binding protein 4	3	51957454-51974016	Predicted intracellular proteins	Evidence at protein level	HPA057754			Supported	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 113.5	Cell line enhanced		SH-SY5Y: 170.4
PCCA		ENSG00000175198	Propionyl-CoA carboxylase alpha subunit	13	100089015-100530437	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041716, HPA047792	Enhanced				Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			epididymis: 266.0	Cell line enhanced		RPTEC TERT1: 124.8;SCLC-21H: 107.6;U-937: 103.1
PCED1A	bA12M19.1, C20orf81, FAM113A, FLJ22376	ENSG00000132635	PC-esterase domain containing 1A	20	2835314-2841190	Predicted intracellular proteins	Evidence at protein level	HPA050816	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.96e-5 (favourable), Liver cancer:7.31e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 81.5	Expressed in all		
PCED1B	FAM113B, MGC16044	ENSG00000179715	PC-esterase domain containing 1B	12	47079603-47236662	Predicted intracellular proteins	Evidence at protein level	HPA043901	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:4.55e-6 (unfavourable), Urothelial cancer:5.36e-5 (favourable)	Expressed in all	Mixed			lymph node: 42.3	Cell line enhanced		A549: 57.4;K-562: 43.7
PCGF1	MGC10882, NSPC1, RNF68	ENSG00000115289	Polycomb group ring finger 1	2	74505043-74508580	Predicted intracellular proteins	Evidence at protein level	HPA011356, HPA069156	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.69e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 5.2	Expressed in all		
PCGF2	MEL-18, RNF110, ZNF144	ENSG00000277258	Polycomb group ring finger 2	17	38733897-38749817	Predicted intracellular proteins	Evidence at protein level	HPA047732, HPA063531	Uncertain		Supported	Nucleus	Colorectal cancer:4.55e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 20.1	Mixed		
PCGF3	DONG1, FLJ36550, MGC40413, RNF3, RNF3A	ENSG00000185619	Polycomb group ring finger 3	4	705748-770640	Predicted intracellular proteins	Evidence at protein level	HPA061879			Supported	Nucleoplasm	Pancreatic cancer:1.44e-4 (favourable), Head and neck cancer:3.73e-4 (favourable), Urothelial cancer:5.25e-4 (favourable)	Expressed in all	Expressed in all			skin: 62.8	Expressed in all		
PCGF5	MGC16202, RNF159	ENSG00000180628	Polycomb group ring finger 5	10	91163012-91284331	Predicted intracellular proteins	Evidence at protein level	HPA038349	Approved		Supported	Nucleoli	Renal cancer:4.98e-4 (favourable), Urothelial cancer:6.90e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 40.5	Expressed in all		
PCGF6	MBLR, RNF134	ENSG00000156374	Polycomb group ring finger 6	10	103302796-103351134	Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.54e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 16.2	Expressed in all		
PCID2	FLJ11305	ENSG00000126226	PCI domain containing 2	13	113177539-113208715	Predicted intracellular proteins	Evidence at protein level	HPA069107, HPA073074	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:4.24e-6 (unfavourable), Head and neck cancer:7.80e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 81.9	Expressed in all		
PCIF1	bA465L10.1, C20orf67, PPP1R121	ENSG00000100982	PDX1 C-terminal inhibiting factor 1	20	45934628-45948023	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049517	Enhanced		Supported	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge	Renal cancer:1.50e-6 (favourable), Endometrial cancer:8.86e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 49.1	Expressed in all		
PCK1	PEPCK-C	ENSG00000124253	Phosphoenolpyruvate carboxykinase 1	20	57561080-57568112	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006277, HPA006507, CAB017027	Approved				Renal cancer:1.47e-5 (favourable)	Tissue enriched	Tissue enhanced		kidney: 425.9;liver: 319.7	small intestine: 157.6	Cell line enriched	9	ASC diff: 14.0
PCK2	PEPCK, PEPCK2	ENSG00000100889	Phosphoenolpyruvate carboxykinase 2, mitochondrial	14	24094053-24110598	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB018734, HPA051162, HPA053502	Enhanced		Enhanced	Mitochondria	Liver cancer:2.81e-4 (favourable)	Expressed in all	Group enriched	6	duodenum: 367.6;kidney: 192.2;liver: 258.6;small intestine: 276.5	colon: 47.0	Expressed in all		
PCLAF	KIAA0101, NS5ATP9, OEATC-1, p15(PAF), PAF15	ENSG00000166803	PCNA clamp associated factor	15	64364311-64387687	Predicted intracellular proteins	Evidence at protein level	HPA047929			Supported	Centrosome	Renal cancer:9.77e-15 (unfavourable), Liver cancer:3.26e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 76.2;lymph node: 50.8	tonsil: 36.9	Mixed		
PCM1	PTC4	ENSG00000078674	Pericentriolar material 1	8	17922840-18029944	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023370, HPA023374, CAB058695	Enhanced		Enhanced	Nuclear membrane<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			testis: 277.4	Expressed in all		
PCMTD1	FLJ10883	ENSG00000168300	Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1	8	51817575-51899186	Predicted intracellular proteins	Evidence at protein level	HPA025696, HPA061444	Approved		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			parathyroid gland: 186.8	Expressed in all		
PCMTD2	C20orf36, FLJ10883	ENSG00000203880	Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2	20	64255695-64287821	Predicted intracellular proteins	Evidence at protein level	HPA057849	Approved		Approved	Nucleoplasm<br>Mitochondria	Lung cancer:2.13e-4 (favourable), Renal cancer:3.82e-4 (favourable)	Expressed in all	Expressed in all			skin: 78.7	Expressed in all		
PCNA		ENSG00000132646	Proliferating cell nuclear antigen	20	5114953-5126626	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000148, HPA030521, HPA030522, HPA030523	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.03e-6 (unfavourable), Cervical cancer:1.86e-5 (favourable), Liver cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 223.2	Expressed in all		
PCNP		ENSG00000081154	PEST proteolytic signal containing nuclear protein	3	101574095-101594437	Predicted intracellular proteins	Evidence at protein level	HPA035011	Supported		Supported	Nucleus	Liver cancer:6.00e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 80.6	Expressed in all		
PCNT	KEN, KIAA0402, PCN, PCNT2, PCNTB, SCKL4	ENSG00000160299	Pericentrin	21	46324122-46445769	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016820, HPA019887, HPA032101	Enhanced		Enhanced	Centrosome		Expressed in all	Mixed			skeletal muscle: 24.3	Expressed in all		
PCOTH	C1QTNF9B-AS1	ENSG00000205861	Pro-X-Gly collagen triple helix like repeat containing	13	23888889-23897263	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		prostate: 24.5;skin: 25.5;testis: 38.3	epididymis: 6.1	Cell line enhanced		hTEC/SVTERT24-B: 11.5;LHCN-M2: 10.9
PCP2	GPSM4, MGC41903	ENSG00000174788	Purkinje cell protein 2	19	7631611-7633748	Predicted intracellular proteins	Evidence at protein level	HPA057428			Approved	Nuclear speckles<br>Vesicles	Urothelial cancer:2.76e-5 (favourable), Breast cancer:7.93e-4 (favourable)	Mixed	Tissue enriched	9	testis: 72.6	skin: 8.1	Cell line enhanced		HMC-1: 7.2;NB-4: 11.1
PCP4	PEP-19	ENSG00000183036	Purkinje cell protein 4	21	39867317-39929397	Predicted intracellular proteins	Evidence at protein level	HPA005792	Enhanced	Supported	Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.85e-7 (favourable), Cervical cancer:9.76e-4 (favourable)	Mixed	Tissue enhanced		seminal vesicle: 1209.1	prostate: 369.5	Cell line enhanced		RPMI-8226: 108.9;SK-BR-3: 19.1;T-47d: 44.5
PCP4L1	IQM1	ENSG00000248485	Purkinje cell protein 4 like 1	1	161258727-161285450	Predicted intracellular proteins	Evidence at protein level	HPA052833	Enhanced	Supported	Approved	Nucleoplasm<br>Mitochondria	Lung cancer:8.10e-5 (favourable)	Group enriched	Tissue enhanced		cerebral cortex: 45.2;urinary bladder: 39.5	seminal vesicle: 22.7	Cell line enhanced		RT4: 10.8;T-47d: 8.2
PCSK6	PACE4, SPC4	ENSG00000140479	Proprotein convertase subtilisin/kexin type 6	15	101297142-101525202	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004774	Uncertain				Renal cancer:7.06e-7 (unfavourable), Breast cancer:9.99e-4 (favourable)	Mixed	Tissue enhanced		liver: 90.3;spleen: 124.6	placenta: 53.9	Cell line enhanced		BEWO: 57.8;HEK93: 58.5;Hep G2: 39.9
PCTP	STARD2	ENSG00000141179	Phosphatidylcholine transfer protein	17	55750979-55842830	Predicted intracellular proteins	Evidence at protein level	HPA022979	Approved		Approved	Nucleus<br>Nucleoli	Head and neck cancer:3.43e-6 (unfavourable)	Expressed in all	Expressed in all			liver: 49.3	Expressed in all		
PCYT1A	CT, CTPCT, PCYT1	ENSG00000161217	Phosphate cytidylyltransferase 1, choline, alpha	3	196214222-196287957	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035428	Approved		Approved	Nucleus	Liver cancer:8.65e-5 (unfavourable)	Expressed in all	Expressed in all			duodenum: 66.9	Expressed in all		
PCYT1B	CCT-beta, CTB	ENSG00000102230	Phosphate cytidylyltransferase 1, choline, beta	X	24558087-24672677	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006367	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 21.9;testis: 17.4	fallopian tube,smooth muscle: 4.7	Cell line enhanced		AF22: 11.6;CACO-2: 21.4;HEL: 28.7;NTERA-2: 13.3;SCLC-21H: 10.7
PCYT2	ET	ENSG00000185813	Phosphate cytidylyltransferase 2, ethanolamine	17	81900965-81911464	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023033, HPA023034	Enhanced		Supported	Intermediate filaments<br>Centrosome	Renal cancer:4.29e-6 (favourable)	Expressed in all	Expressed in all			testis: 241.6	Expressed in all		
PDAP1	HASPP28, PAP, PAP1	ENSG00000106244	PDGFA associated protein 1	7	99392048-99408829	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB021103, HPA050294, HPA060836	Approved		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:6.67e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 37.3	Expressed in all		
PDC	MEKA	ENSG00000116703	Phosducin	1	186443566-186461122	Predicted intracellular proteins	Evidence at protein level	HPA062235	Supported					Not detected	Not detected			cerebral cortex,testis: 0.3	Not detected		
PDCD10	CCM3, TFAR15	ENSG00000114209	Programmed cell death 10	3	167683298-167734939	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027095	Approved				Pancreatic cancer:5.22e-5 (unfavourable), Liver cancer:2.30e-4 (unfavourable), Head and neck cancer:3.89e-4 (unfavourable), Renal cancer:5.88e-4 (favourable), Endometrial cancer:9.34e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 80.8	Expressed in all		
PDCD11	ALG-4, KIAA0185, RRP5	ENSG00000148843	Programmed cell death 11	10	103396648-103446292	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017924, CAB026472	Approved		Supported	Nucleoli<br>Vesicles	Liver cancer:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 27.9	Expressed in all		
PDCD2	RP8, ZMYND7	ENSG00000071994	Programmed cell death 2	6	170575295-170584692	Predicted intracellular proteins	Evidence at protein level	HPA026713, HPA075534	Uncertain		Approved	Nucleoplasm<br>Cytokinetic bridge	Liver cancer:1.42e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 57.9	Expressed in all		
PDCD2L	MGC13096	ENSG00000126249	Programmed cell death 2 like	19	34404384-34426168	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA052181	Approved		Uncertain	Mitochondria	Renal cancer:1.23e-5 (unfavourable), Liver cancer:5.81e-4 (unfavourable)	Expressed in all	Mixed			testis: 17.5	Mixed		
PDCD4	H731	ENSG00000150593	Programmed cell death 4	10	110871795-110900006	Predicted intracellular proteins	Evidence at protein level	HPA001032, HPA027214, CAB037024	Supported		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 461.7	Expressed in all		
PDCD5	MGC9294, TFAR19	ENSG00000105185	Programmed cell death 5	19	32581068-32587452	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018471	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 175.1	Expressed in all		
PDCD6	ALG-2, PEF1B	ENSG00000249915	Programmed cell death 6	5	271621-353856	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA047221			Approved	Cytosol	Renal cancer:5.16e-6 (unfavourable), Liver cancer:5.47e-5 (unfavourable), Urothelial cancer:2.19e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 120.9	Expressed in all		
PDCD6IP	AIP1, Alix, Hp95	ENSG00000170248	Programmed cell death 6 interacting protein	3	33798352-33869707	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA011905, CAB016212	Approved		Enhanced	Cytosol	Renal cancer:3.90e-9 (favourable), Colorectal cancer:1.16e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 64.1	Expressed in all		
PDCD7	ES18, HES18	ENSG00000090470	Programmed cell death 7	15	65117379-65133836	Predicted intracellular proteins	Evidence at protein level	HPA049388	Approved		Approved	Nucleoli<br>Plasma membrane	Renal cancer:1.00e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 30.7	Expressed in all		
PDCL	DKFZp564M1863, PhLP	ENSG00000136940	Phosducin like	9	122798389-122828631	Predicted intracellular proteins	Evidence at protein level	HPA021571, HPA021647, CAB026473	Uncertain		Supported	Cytosol	Renal cancer:7.00e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 23.9	Mixed		
PDCL2	GCPHLP	ENSG00000163440	Phosducin like 2	4	55556525-55592212	Predicted intracellular proteins	Evidence at protein level	HPA048260	Enhanced					Group enriched	Tissue enriched	306	testis: 110.4	skin: 0.3	Cell line enhanced		HaCaT: 1.7
PDCL3	VIAF1	ENSG00000115539	Phosducin like 3	2	100562690-100576735	Predicted intracellular proteins	Evidence at protein level	HPA018469, HPA027094	Approved		Enhanced	Nucleus<br>Cytosol	Renal cancer:2.55e-5 (unfavourable), Liver cancer:6.07e-5 (unfavourable), Urothelial cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 40.3	Expressed in all		
PDE10A		ENSG00000112541	Phosphodiesterase 10A	6	165327287-165986603	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB045998, HPA047200	Supported				Renal cancer:4.44e-7 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 14.5	testis: 12.2	Cell line enhanced		LHCN-M2: 14.4;SH-SY5Y: 11.1;TIME: 14.8
PDE12	2'-PDE, DKFZp667B1218	ENSG00000174840	Phosphodiesterase 12	3	57556276-57566844	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043171	Approved				Renal cancer:3.63e-8 (favourable), Colorectal cancer:2.85e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 15.9	Expressed in all		
PDE1A		ENSG00000115252	Phosphodiesterase 1A	2	182140036-182523192	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022151	Approved		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		thyroid gland: 76.5	testis: 63.0	Cell line enhanced		ASC diff: 25.5;HHSteC: 18.5;HSkMC: 34.2
PDE1B	PDES1B	ENSG00000123360	Phosphodiesterase 1B	12	54549350-54579239	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018492	Approved				Renal cancer:4.77e-6 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 18.4	parathyroid gland: 11.9	Cell line enhanced		HDLM-2: 10.6;HL-60: 5.1;HMC-1: 10.2;NB-4: 5.1;THP-1: 5.1;U-937: 5.0
PDE1C	Hcam3	ENSG00000154678	Phosphodiesterase 1C	7	31751179-32299329	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021751, HPA052375	Uncertain		Approved	Nucleus		Tissue enhanced	Tissue enhanced		heart muscle: 37.2	cerebral cortex: 20.8	Cell line enhanced		fHDF/TERT166: 114.5;U-251 MG: 66.4;WM-115: 102.6
PDE4A	DPDE2	ENSG00000065989	Phosphodiesterase 4A	19	10416773-10469631	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017632, HPA043310, HPA076091	Uncertain		Supported	Plasma membrane		Expressed in all	Mixed			parathyroid gland: 34.0	Cell line enhanced		HMC-1: 32.2
PDE4B	DPDE4	ENSG00000184588	Phosphodiesterase 4B	1	65792514-66374579	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003005	Uncertain		Approved	Golgi apparatus<br>Cytosol	Renal cancer:5.04e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 67.0	Cell line enhanced		AN3-CA: 57.3;HUVEC TERT2: 77.6;NTERA-2: 56.0
PDE4C	DPDE1	ENSG00000105650	Phosphodiesterase 4C	19	18207961-18255419	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048975	Enhanced					Mixed	Mixed			endometrium: 7.4	Cell line enhanced		BEWO: 3.8;U-87 MG: 5.5
PDE4D	DPDE3	ENSG00000113448	Phosphodiesterase 4D	5	58969038-60522120	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045895	Approved		Approved	Nuclear membrane<br>Plasma membrane<br>Cytosol	Renal cancer:4.00e-5 (favourable)	Mixed	Mixed			bone marrow: 47.7	Cell line enhanced		A549: 56.1;AN3-CA: 65.2;HeLa: 68.4
PDE4DIP	CMYA2, KIAA0454, KIAA0477, MMGL	ENSG00000178104	Phosphodiesterase 4D interacting protein	1	148808181-149048286	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008162, HPA012678	Uncertain		Supported	Golgi apparatus		Expressed in all	Expressed in all			skeletal muscle: 766.6	Expressed in all		
PDE5A		ENSG00000138735	Phosphodiesterase 5A	4	119494395-119628991	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004729, HPA012873	Approved		Approved	Cytosol	Urothelial cancer:1.17e-4 (unfavourable), Cervical cancer:5.20e-4 (favourable)	Expressed in all	Mixed			prostate: 97.7	Cell line enhanced		BJ hTERT+: 38.5;HHSteC: 55.3
PDE6A	PDEA, RP43	ENSG00000132915	Phosphodiesterase 6A	5	149857955-149944793	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016970, HPA074677	Enhanced					Not detected	Tissue enriched	8	epididymis: 20.2	testis: 2.4	Cell line enhanced		CACO-2: 2.1
PDE6B	CSNB3, CSNBAD2, PDEB, rd1, RP40	ENSG00000133256	Phosphodiesterase 6B	4	625584-670782	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA054148, HPA059929	Supported		Approved	Cytosol	Lung cancer:5.34e-4 (favourable)	Mixed	Mixed			cerebral cortex: 22.3	Cell line enhanced		MOLT-4: 25.1;REH: 15.3;SCLC-21H: 23.8;SH-SY5Y: 12.6;U-266/84: 16.5
PDE6C	ACHM5, COD4, PDEA2	ENSG00000095464	Phosphodiesterase 6C	10	93612588-93666010	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			skin: 0.6	Not detected		
PDE6D	JBTS22	ENSG00000156973	Phosphodiesterase 6D	2	231732425-231786272	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037433, HPA037434	Uncertain				Renal cancer:4.02e-5 (unfavourable), Urothelial cancer:4.97e-4 (favourable)	Expressed in all	Expressed in all			testis: 48.3	Expressed in all		
PDE6G	PDEG, RP57	ENSG00000185527	Phosphodiesterase 6G	17	81650459-81663112	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045118	Supported					Tissue enhanced	Tissue enhanced		lymph node: 26.1;spleen: 33.3	placenta: 18.9	Cell line enhanced		NTERA-2: 10.5;REH: 11.5
PDE6H		ENSG00000139053	Phosphodiesterase 6H	12	14973022-14981865	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045118	Supported					Not detected	Tissue enhanced		bone marrow: 2.4;placenta: 1.3	adrenal gland: 0.5	Not detected		
PDE7B		ENSG00000171408	Phosphodiesterase 7B	6	135851696-136195574	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023967	Uncertain		Approved	Nucleoplasm	Renal cancer:1.59e-4 (favourable)	Mixed	Mixed			ovary: 16.2	Cell line enhanced		EFO-21: 15.3;HSkMC: 16.3;U-2197: 10.6
PDE8A	HsT19550	ENSG00000073417	Phosphodiesterase 8A	15	84980440-85139145	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007722	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 30.2	Expressed in all		
PDE8B		ENSG00000113231	Phosphodiesterase 8B	5	77210449-77429807	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036911, HPA036912	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	6	thyroid gland: 293.7	cerebral cortex: 53.0	Cell line enhanced		BJ hTERT+: 14.6;HeLa: 32.2;SK-BR-3: 10.4
PDE9A		ENSG00000160191	Phosphodiesterase 9A	21	42653636-42775509	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011380	Enhanced		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Tissue enhanced		prostate: 56.8	spleen: 25.5	Cell line enhanced		AF22: 29.5;EFO-21: 28.2;NTERA-2: 41.2;SCLC-21H: 26.8
PDHA2	PDHAL	ENSG00000163114	Pyruvate dehydrogenase (lipoamide) alpha 2	4	95840019-95841474	Citric acid cycle related proteins, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047487, HPA047864, HPA063053	Approved		Supported	Mitochondria		Not detected	Tissue enriched	1010	testis: 101.0	all non-specific tissues: 0.0	Not detected		
PDHB		ENSG00000168291	Pyruvate dehydrogenase (lipoamide) beta	3	58427630-58433857	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033794, HPA036744, HPA036745	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.79e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 112.0	Expressed in all		
PDHX	DLDBP, E3BP, OPDX, PDX1, proX	ENSG00000110435	Pyruvate dehydrogenase complex component X	11	34915829-35020591	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038484, HPA038485	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Mitochondria	Renal cancer:1.83e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 53.3	Expressed in all		
PDK1		ENSG00000152256	Pyruvate dehydrogenase kinase 1	2	172555373-172608669	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017554, HPA027376, HPA059083	Approved		Approved	Nucleoli<br>Mitochondria	Renal cancer:1.10e-8 (unfavourable), Cervical cancer:7.30e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 22.2	Expressed in all		
PDK2	PDHK2	ENSG00000005882	Pyruvate dehydrogenase kinase 2	17	50094737-50112152	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008287	Supported		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:9.59e-5 (favourable), Cervical cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 151.5	Mixed		
PDK3		ENSG00000067992	Pyruvate dehydrogenase kinase 3	X	24465221-24539837	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046583, HPA072492	Approved		Supported	Nucleoli<br>Mitochondria	Liver cancer:2.76e-4 (unfavourable)	Expressed in all	Mixed			testis: 24.9	Mixed		
PDK4		ENSG00000004799	Pyruvate dehydrogenase kinase 4	7	95583499-95596491	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056731	Approved				Stomach cancer:1.80e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 763.0	Cell line enriched	7	ASC diff: 333.3
PDLIM1	CLIM1, CLP-36, CLP36, hCLIM1	ENSG00000107438	PDZ and LIM domain 1	10	95237572-95291024	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017010, CAB072838, CAB072840	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Actin filaments	Endometrial cancer:1.14e-5 (favourable)	Expressed in all	Expressed in all			small intestine: 273.0	Cell line enhanced		HaCaT: 680.7
PDLIM2		ENSG00000120913	PDZ and LIM domain 2	8	22578279-22598025	Predicted intracellular proteins	Evidence at protein level	HPA003880	Approved		Approved	Actin filaments<br>Focal adhesion sites	Renal cancer:1.37e-7 (unfavourable), Glioma:7.23e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 267.3	Mixed		
PDLIM3	ALP	ENSG00000154553	PDZ and LIM domain 3	4	185500660-185535612	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004749	Enhanced				Renal cancer:4.97e-7 (unfavourable), Thyroid cancer:2.13e-6 (unfavourable), Liver cancer:7.22e-4 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 1097.6	seminal vesicle: 292.1	Cell line enhanced		LHCN-M2: 125.9;RH-30: 35.3;U-266/70: 91.6
PDLIM4	RIL	ENSG00000131435	PDZ and LIM domain 4	5	132257671-132273454	Predicted intracellular proteins	Evidence at protein level	HPA011912	Uncertain		Approved	Actin filaments<br>Cytosol		Mixed	Mixed			smooth muscle: 61.9	Cell line enhanced		hTEC/SVTERT24-B: 117.7
PDLIM7	ENIGMA	ENSG00000196923	PDZ and LIM domain 7	5	177483394-177497606	Predicted intracellular proteins	Evidence at protein level	HPA018794, HPA048815	Approved		Enhanced	Actin filaments<br>Focal adhesion sites	Renal cancer:6.19e-10 (unfavourable), Lung cancer:4.07e-4 (unfavourable), Endometrial cancer:5.45e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 288.9	Expressed in all		
PDP1	PDH, PDP, PPM2A, PPM2C	ENSG00000164951	Pyruvate dehyrogenase phosphatase catalytic subunit 1	8	93857807-93926066	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018483, HPA019081, HPA021152	Uncertain		Supported	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:8.42e-9 (favourable), Breast cancer:8.61e-5 (unfavourable), Ovarian cancer:5.60e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 82.3	Expressed in all		
PDP2	KIAA1348, PPM2B, PPM2C2	ENSG00000172840	Pyruvate dehyrogenase phosphatase catalytic subunit 2	16	66878589-66895754	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019950, HPA062059	Approved		Supported	Mitochondria	Renal cancer:9.75e-7 (favourable)	Expressed in all	Mixed			thyroid gland: 15.5	Expressed in all		
PDPK1	PDK1	ENSG00000140992	3-phosphoinositide dependent protein kinase 1	16	2537964-2603188	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004272, HPA035199, HPA068961	Supported		Approved	Vesicles	Renal cancer:1.29e-14 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.0	Expressed in all		
PDPR	PDP3	ENSG00000090857	Pyruvate dehydrogenase phosphatase regulatory subunit	16	70113626-70162537	Predicted intracellular proteins	Evidence at protein level	HPA048092, HPA070386	Uncertain		Approved	Mitochondria	Renal cancer:8.36e-4 (favourable)	Expressed in all	Expressed in all			testis: 29.0	Expressed in all		
PDRG1	C20orf126, dJ310O13.3	ENSG00000088356	P53 and DNA damage regulated 1	20	31944342-31952092	Predicted intracellular proteins	Evidence at protein level	HPA047084, HPA063542	Approved		Approved	Actin filaments	Liver cancer:2.62e-5 (unfavourable), Endometrial cancer:1.69e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 64.5	Expressed in all		
PDS5A	KIAA0648, PIG54, SCC-112	ENSG00000121892	PDS5 cohesin associated factor A	4	39822863-39977956	Predicted intracellular proteins	Evidence at protein level	HPA036661, HPA036662	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 57.4	Expressed in all		
PDS5B	APRIN, AS3, CG008, FLJ23236, KIAA0979	ENSG00000083642	PDS5 cohesin associated factor B	13	32586427-32778019	Predicted intracellular proteins	Evidence at protein level	HPA039513, HPA040015	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 31.3	Expressed in all		
PDSS1	COQ1, TPRT, TPT	ENSG00000148459	Decaprenyl diphosphate synthase subunit 1	10	26697659-26746798	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038032, HPA042741	Uncertain		Approved	Cytosol	Liver cancer:1.25e-5 (unfavourable), Endometrial cancer:1.66e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 18.4	Expressed in all		
PDSS2	bA59I9.3, C6orf210	ENSG00000164494	Decaprenyl diphosphate synthase subunit 2	6	107152557-107459564	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029685, HPA029686	Approved		Enhanced	Cytosol	Renal cancer:3.75e-7 (favourable), Breast cancer:1.34e-5 (unfavourable), Colorectal cancer:5.74e-5 (favourable)	Expressed in all	Expressed in all			prostate: 23.4	Expressed in all		
PDX1	IDX-1, IPF1, MODY4, PDX-1, STF-1	ENSG00000139515	Pancreatic and duodenal homeobox 1	13	27920020-27926231	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025873, HPA059146	Enhanced		Supported	Nucleoplasm		Group enriched	Tissue enriched	7	duodenum: 43.6	stomach: 6.2	Group enriched	6	AN3-CA: 1.2;CACO-2: 1.0;CAPAN-2: 1.2;HDLM-2: 3.9;HEK93: 2.2;HeLa: 4.1
PDXDC1	KIAA0251	ENSG00000179889	Pyridoxal dependent decarboxylase domain containing 1	16	14974591-15139339	Predicted intracellular proteins	Evidence at protein level	HPA047369, HPA049121, HPA051484	Approved		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:3.13e-4 (favourable)	Expressed in all	Expressed in all			testis: 105.7	Expressed in all		
PDXK	C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79	ENSG00000160209	Pyridoxal kinase	21	43719094-43762307	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030196, HPA030197, HPA030198, CAB033918	Approved		Enhanced	Nucleus		Expressed in all	Expressed in all			cerebral cortex: 47.5	Expressed in all		
PDXP	CIN, dJ37E16.5, FLJ32703	ENSG00000241360	Pyridoxal phosphatase	22	37658727-37666934	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000531	Approved					Mixed	Tissue enhanced		cerebral cortex: 135.9	testis: 30.5	Mixed		
PDZD11	PDZK11	ENSG00000120509	PDZ domain containing 11	X	70286595-70290514	Predicted intracellular proteins	Evidence at protein level	HPA003972	Approved					Expressed in all	Expressed in all			cerebral cortex,thyroid gland: 59.9	Expressed in all		
PDZD2	KIAA0300, PDZK3	ENSG00000133401	PDZ domain containing 2	5	31639410-32110931	Predicted intracellular proteins	Evidence at protein level	CAB020784, HPA036503, HPA036504, HPA064387	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			ovary: 18.3	Cell line enhanced		BEWO: 8.1;SiHa: 12.6;SK-BR-3: 8.1
PDZD3	FLJ22756, IKEPP, PDZK2	ENSG00000172367	PDZ domain containing 3	11	119185457-119190223	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		duodenum: 17.3;kidney: 10.8;small intestine: 21.2	rectum: 6.7	Not detected		
PDZD4	FLJ34125, KIAA1444, LNX5, LU1, PDZK4, PDZRN4L	ENSG00000067840	PDZ domain containing 4	X	153802166-153830565	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA003878	Enhanced				Pancreatic cancer:2.96e-5 (favourable)	Tissue enhanced	Tissue enriched	9	cerebral cortex: 123.5	seminal vesicle: 13.7	Cell line enhanced		AF22: 24.1;RH-30: 16.8;SCLC-21H: 34.7;SH-SY5Y: 30.4;U-2 OS: 14.9
PDZD7	bA108L7.8, DFNB57, FLJ23209, PDZK7	ENSG00000186862	PDZ domain containing 7	10	101007683-101031157	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		small intestine: 13.2	cerebral cortex: 8.9	Cell line enhanced		SCLC-21H: 16.1;THP-1: 10.8
PDZD9	C16orf65, MGC50721	ENSG00000155714	PDZ domain containing 9	16	21983865-22001110	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	39	testis: 10.3	cerebral cortex: 0.2	Not detected		
PDZK1	NHERF3, PDZD1	ENSG00000174827	PDZ domain containing 1	1	145670852-145708148	Predicted intracellular proteins	Evidence at protein level	HPA005755, HPA006155, CAB008971	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.54e-7 (favourable)	Group enriched	Tissue enhanced		kidney: 561.5;small intestine: 127.1	duodenum: 69.0	Cell line enhanced		CACO-2: 83.6;RPTEC TERT1: 168.6;T-47d: 547.9
PDZRN3	KIAA1095, LNX3, SEMACAP3	ENSG00000121440	PDZ domain containing ring finger 3	3	73382433-73624940	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038822, HPA061420	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:3.65e-7 (favourable), Endometrial cancer:3.35e-5 (favourable), Pancreatic cancer:4.93e-4 (favourable)	Mixed	Mixed			ovary: 85.7	Cell line enhanced		AF22: 31.7;ASC diff: 39.1;BJ hTERT+: 34.1;HSkMC: 30.3
PEA15	HMAT1, HUMMAT1H, MAT1, MAT1H, PEA-15, PED	ENSG00000162734	Phosphoprotein enriched in astrocytes 15	1	160205337-160215376	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028356, HPA070820	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:6.53e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1087.0	Expressed in all		
PEAK1	KIAA2002, sgk269	ENSG00000173517	Pseudopodium enriched atypical kinase 1	15	77100656-77420144	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026313, HPA026517	Approved					Expressed in all	Mixed			spleen: 40.6	Expressed in all		
PEBP1	HCNP, PBP, PEBP, RKIP	ENSG00000089220	Phosphatidylethanolamine binding protein 1	12	118135858-118145584	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008819, CAB013493, HPA063904	Enhanced		Supported	Plasma membrane	Renal cancer:2.15e-13 (favourable), Pancreatic cancer:1.52e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 1642.0	Expressed in all		
PECR	HSA250303, SDR29C1, TERP	ENSG00000115425	Peroxisomal trans-2-enoyl-CoA reductase	2	215996329-216082955	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021593, HPA022539	Enhanced		Supported	Peroxisomes	Renal cancer:1.36e-5 (favourable)	Expressed in all	Expressed in all			liver: 82.8	Mixed		
PEF1	PEF1A	ENSG00000162517	Penta-EF-hand domain containing 1	1	31629862-31644896	Predicted intracellular proteins	Evidence at protein level	HPA061608			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:2.88e-4 (unfavourable), Cervical cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 183.0	Expressed in all		
PEG10	HB-1, KIAA1051, Mar2, Mart2, MEF3L, RGAG3	ENSG00000242265	Paternally expressed 10	7	94656325-94669695	Predicted intracellular proteins	Evidence at protein level	HPA021324, HPA029915, HPA051038	Enhanced		Supported	Nucleus<br>Cytosol	Endometrial cancer:8.15e-4 (unfavourable)	Expressed in all	Group enriched	5	adrenal gland: 224.2;placenta: 663.3	ovary: 80.7	Cell line enhanced		AF22: 763.0;HAP1: 1045.3;Hep G2: 547.0;SCLC-21H: 574.7
PEG3	KIAA0287, ZKSCAN22, ZNF904, ZSCAN24	ENSG00000198300	Paternally expressed 3	19	56810083-56840728	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026070	Approved		Supported	Nucleoplasm	Thyroid cancer:1.56e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		ovary: 340.4;placenta: 197.8	adrenal gland: 102.0	Cell line enhanced		BEWO: 100.6;Hep G2: 150.6;RH-30: 70.4
PELI1		ENSG00000197329	Pellino E3 ubiquitin protein ligase 1	2	64092652-64144454	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053182	Uncertain		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments	Renal cancer:5.67e-6 (unfavourable), Endometrial cancer:5.33e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 143.9	Cell line enhanced		U-698: 99.2
PELI2		ENSG00000139946	Pellino E3 ubiquitin protein ligase family member 2	14	56117814-56301526	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053182	Uncertain		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments	Renal cancer:1.53e-6 (favourable)	Mixed	Mixed			testis: 18.8	Cell line enhanced		HMC-1: 29.1;MOLT-4: 31.6;SCLC-21H: 20.6
PELI3	MGC35521	ENSG00000174516	Pellino E3 ubiquitin protein ligase family member 3	11	66466327-66477337	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033750, HPA038875, HPA062281	Uncertain		Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:8.19e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 23.7	Mixed		
PELO		ENSG00000152684	Pelota homolog (Drosophila)	5	52787940-52804046	Predicted intracellular proteins	Evidence at protein level	HPA031458	Approved		Approved	Nucleoli fibrillar center	Breast cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 20.0	Expressed in all		
PELP1	MNAR	ENSG00000141456	Proline, glutamate and leucine rich protein 1	17	4669774-4704337	Predicted intracellular proteins	Evidence at protein level	HPA053966, HPA056028, HPA060760	Supported		Enhanced	Nucleus<br>Nucleoli	Pancreatic cancer:4.07e-5 (favourable), Liver cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.2	Expressed in all		
PEPD		ENSG00000124299	Peptidase D	19	33386950-33521794	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015599, HPA072045	Approved		Supported	Nucleoplasm	Renal cancer:6.50e-9 (favourable)	Expressed in all	Expressed in all			kidney: 342.6	Expressed in all		
PER1	PER, RIGUI	ENSG00000179094	Period circadian clock 1	17	8140472-8156506	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA047947, HPA067064			Supported	Nucleoplasm<br>Cytosol	Stomach cancer:1.94e-4 (unfavourable), Liver cancer:2.56e-4 (favourable), Cervical cancer:3.89e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 70.3	Expressed in all		
PER2	KIAA0347	ENSG00000132326	Period circadian clock 2	2	238244038-238290102	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA060510	Enhanced				Head and neck cancer:2.29e-4 (favourable)	Expressed in all	Expressed in all			testis: 22.2	Mixed		
PER3		ENSG00000049246	Period circadian clock 3	1	7784320-7845177	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019530	Approved		Uncertain	Cytosol	Renal cancer:2.20e-5 (favourable), Head and neck cancer:1.34e-4 (favourable), Cervical cancer:7.14e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 39.2	Mixed		
PERM1	C1orf170, MGC13275, Perm1, RP11-54O7.8	ENSG00000187642	PPARGC1 and ESRR induced regulator, muscle 1	1	975204-982093	Predicted intracellular proteins	Evidence at protein level	HPA031711, HPA031712	Enhanced				Renal cancer:1.95e-4 (unfavourable)	Mixed	Group enriched	15	heart muscle: 20.7;skeletal muscle: 68.1	esophagus: 3.0	Cell line enhanced		HaCaT: 1.3;SK-BR-3: 1.2
PES1	PES	ENSG00000100029	Pescadillo ribosomal biogenesis factor 1	22	30576625-30607083	Predicted intracellular proteins	Evidence at protein level	HPA040210, HPA062439, HPA066670	Supported		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.84e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.0	Expressed in all		
PET100	C19orf79	ENSG00000229833	PET100 homolog	19	7629737-7631956	Predicted intracellular proteins	Evidence at protein level	HPA067288			Approved	Nucleoplasm<br>Mitochondria	Urothelial cancer:2.44e-4 (favourable), Cervical cancer:6.81e-4 (favourable), Lung cancer:7.97e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 54.6	Expressed in all		
PEX1	ZWS, ZWS1	ENSG00000127980	Peroxisomal biogenesis factor 1	7	92487020-92528531	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA020235	Approved		Supported	Peroxisomes		Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
PEX19	D1S2223E, HK33, PMP1, PMPI, PXF, PXMP1	ENSG00000162735	Peroxisomal biogenesis factor 19	1	160276812-160286348	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044837, HPA051966	Supported		Enhanced	Peroxisomes	Renal cancer:2.92e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 86.2	Expressed in all		
PEX5	PTS1R, PXR1	ENSG00000139197	Peroxisomal biogenesis factor 5	12	7188685-7218574	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039259, HPA039260	Enhanced		Supported	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			testis: 81.3	Expressed in all		
PEX5L	PEX5R, PXR2, TRIP8b	ENSG00000114757	Peroxisomal biogenesis factor 5 like	3	179794958-180037053	Predicted intracellular proteins	Evidence at protein level	HPA058026	Enhanced					Tissue enhanced	Group enriched	9	cerebral cortex: 67.5;parathyroid gland: 94.8	testis: 8.6	Group enriched	5	HDLM-2: 7.2;MOLT-4: 22.2;RPMI-8226: 15.1;SCLC-21H: 15.0;U-266/70: 12.8
PEX6	PAF-2, PXAAA1	ENSG00000124587	Peroxisomal biogenesis factor 6	6	42963870-42979220	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA025924, HPA074179	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Expressed in all	Expressed in all			fallopian tube: 36.5	Expressed in all		
PEX7	PTS2R, RD	ENSG00000112357	Peroxisomal biogenesis factor 7	6	136822564-136913937	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA049202	Uncertain		Supported	Nucleoplasm<br>Vesicles	Renal cancer:1.85e-10 (favourable), Colorectal cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 25.3	Mixed		
PFAS	FGARAT, KIAA0361, PURL	ENSG00000178921	Phosphoribosylformylglycinamidine synthase	17	8247618-8270491	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022140, HPA022886	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Liver cancer:9.19e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 11.6	Expressed in all		
PFDN2		ENSG00000143256	Prefoldin subunit 2	1	161100556-161118111	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028700, HPA058304	Approved		Enhanced	Cytosol	Renal cancer:4.39e-8 (unfavourable), Head and neck cancer:9.10e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 109.6	Expressed in all		
PFDN4	C-1, C1, PFD4	ENSG00000101132	Prefoldin subunit 4	20	54207847-54228052	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024055	Approved				Renal cancer:1.47e-10 (unfavourable), Liver cancer:7.66e-5 (unfavourable), Head and neck cancer:9.40e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 11.3	Expressed in all		
PFDN5	MM-1, PFD5	ENSG00000123349	Prefoldin subunit 5	12	53295291-53299450	Predicted intracellular proteins	Evidence at protein level	HPA008587	Approved				Renal cancer:1.54e-6 (unfavourable), Pancreatic cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 1080.1	Expressed in all		
PFDN6	H2-KE2, HKE2, KE-2, PFD6	ENSG00000204220	Prefoldin subunit 6	6	33289302-33298401	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043032, HPA048123	Enhanced		Approved	Nucleus<br>Golgi apparatus	Ovarian cancer:1.01e-4 (favourable), Renal cancer:8.97e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 20.9	Expressed in all		
PFKFB1	PFRX	ENSG00000158571	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1	X	54932961-54998534	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Group enriched	8	adipose tissue: 30.1;liver: 18.7;skeletal muscle: 39.3	breast: 3.8	Cell line enhanced		ASC diff: 5.9;Hep G2: 2.4
PFKFB2		ENSG00000123836	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2	1	207034366-207081024	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049975, HPA063575	Uncertain		Enhanced	Nucleus	Renal cancer:3.23e-7 (favourable), Thyroid cancer:8.63e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 86.2	Mixed		
PFKFB3		ENSG00000170525	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	10	6144934-6254644	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008266, CAB020795, HPA043889	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.87e-7 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 345.8	Expressed in all		
PFKFB4		ENSG00000114268	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	3	48517684-48562015	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047719, HPA066058	Uncertain		Approved	Nucleoli	Renal cancer:3.91e-8 (unfavourable), Cervical cancer:3.04e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 31.7	small intestine: 22.7	Cell line enhanced		U-87 MG: 80.8;WM-115: 72.6
PFKL		ENSG00000141959	Phosphofructokinase, liver type	21	44300051-44327376	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030047	Approved		Approved	Nucleoli<br>Mitochondria	Ovarian cancer:4.41e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 101.7	Expressed in all		
PFKM	PFK-1, PFKX, PPP1R122	ENSG00000152556	Phosphofructokinase, muscle	12	48105139-48146404	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002117	Approved		Approved	Endoplasmic reticulum	Renal cancer:2.28e-7 (favourable), Endometrial cancer:5.85e-6 (unfavourable), Head and neck cancer:7.91e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 549.3	Expressed in all		
PFN3		ENSG00000196570	Profilin 3	5	177400107-177400636	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	21	kidney: 1.0;testis: 3.2	all non-specific tissues: 0.0	Not detected		
PFN4		ENSG00000176732	Profilin family member 4	2	24115371-24123477	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	39	testis: 139.8	thyroid gland: 3.5	Mixed		
PGAM1	PGAM-B, PGAMA	ENSG00000171314	Phosphoglycerate mutase 1	10	97426160-97433441	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042528, HPA060483	Approved		Approved	Nucleoplasm	Breast cancer:2.04e-4 (unfavourable), Cervical cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 421.2	Expressed in all		
PGAM2	PGAM-M	ENSG00000164708	Phosphoglycerate mutase 2	7	44062727-44065587	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050314, HPA060173	Enhanced		Approved	Nucleoplasm<br>Cytosol		Not detected	Group enriched	8	heart muscle: 521.3;skeletal muscle: 1459.5	testis: 126.6	Cell line enriched	10	SCLC-21H: 77.0
PGAM4	dJ1000K24.1, PGAM-B, PGAM1, PGAM3	ENSG00000226784	Phosphoglycerate mutase family member 4	X	77968874-77969638	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042528, HPA060483	Uncertain		Approved	Nucleoplasm		Mixed	Not detected			appendix: 0.5	Cell line enhanced		A-431: 1.9
PGBD1	dJ874C20.4, HUCEP-4, SCAND4	ENSG00000137338	PiggyBac transposable element derived 1	6	28281572-28302549	Predicted intracellular proteins	Evidence at protein level	HPA007267	Uncertain		Approved	Nucleoplasm<br>Cytosol	Melanoma:1.71e-4 (unfavourable), Liver cancer:3.77e-4 (unfavourable), Renal cancer:4.97e-4 (unfavourable), Pancreatic cancer:6.79e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 7.9	Mixed		
PGBD2		ENSG00000185220	PiggyBac transposable element derived 2	1	248906196-248919946	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029888, HPA029889, HPA029890	Uncertain		Supported	Vesicles	Urothelial cancer:2.05e-4 (favourable), Head and neck cancer:6.08e-4 (favourable), Renal cancer:7.86e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 13.4	Expressed in all		
PGBD4	FLJ32638, FLJ37497	ENSG00000182405	PiggyBac transposable element derived 4	15	34102073-34108684	Predicted intracellular proteins	Evidence at protein level	HPA040896, HPA059823	Uncertain		Approved	Nucleoplasm<br>Centrosome		Mixed	Mixed			testis: 3.5	Mixed		
PGBD5	DKFZp761A0620, FLJ11413	ENSG00000177614	PiggyBac transposable element derived 5	1	230314482-230426371	Predicted intracellular proteins	Evidence at protein level	HPA065010			Approved	Nucleoplasm	Glioma:1.20e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 40.1;cervix, uterine: 29.1	adrenal gland: 12.6	Cell line enhanced		Daudi: 21.9;NTERA-2: 30.2;RH-30: 15.9;SCLC-21H: 48.7
PGD		ENSG00000142657	Phosphogluconate dehydrogenase	1	10398592-10420144	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031314, HPA031315	Enhanced	Supported	Approved	Intermediate filaments<br>Cytosol	Liver cancer:3.98e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 486.8	Expressed in all		
PGGHG	ATHL1, FLJ22635	ENSG00000142102	Protein-glucosylgalactosylhydroxylysine glucosidase	11	289135-296107	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039383, HPA058829	Uncertain		Enhanced	Cytosol	Urothelial cancer:5.12e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 73.6	Mixed		
PGGT1B	BGGI, GGTI	ENSG00000164219	Protein geranylgeranyltransferase type I subunit beta	5	115204012-115262872	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030646	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 19.0	Expressed in all		
PGK1		ENSG00000102144	Phosphoglycerate kinase 1	X	78065188-78129296	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010065, HPA045385, HPA073644, HPA073656	Approved				Breast cancer:7.05e-8 (unfavourable), Head and neck cancer:2.65e-6 (unfavourable), Cervical cancer:2.69e-5 (unfavourable), Liver cancer:2.74e-4 (unfavourable), Pancreatic cancer:8.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.2	Expressed in all		
PGK2	PGK-2, PGKPS	ENSG00000170950	Phosphoglycerate kinase 2	6	49785651-49787307	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045385, HPA073644, HPA073656	Supported					Not detected	Tissue enriched	774	testis: 346.1	epididymis: 0.4	Not detected		
PGLS	6PGL	ENSG00000130313	6-phosphogluconolactonase	19	17511629-17521288	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040744, HPA042032	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 46.7	Expressed in all		
PGM1		ENSG00000079739	Phosphoglucomutase 1	1	63593276-63660245	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004666, HPA024190, HPA024637, HPA046329	Approved		Enhanced	Actin filaments	Pancreatic cancer:8.74e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 512.9	Mixed		
PGM2	FLJ10983	ENSG00000169299	Phosphoglucomutase 2	4	37826633-37862937	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040676	Uncertain		Approved	Intermediate filaments	Colorectal cancer:2.14e-5 (favourable)	Expressed in all	Mixed			esophagus: 36.5	Expressed in all		
PGM2L1	BM32A, FLJ32029	ENSG00000165434	Phosphoglucomutase 2 like 1	11	74330318-74398473	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056995, HPA060948	Enhanced		Approved	Mitochondria		Mixed	Tissue enriched	9	cerebral cortex: 64.1	endometrium: 7.3	Cell line enhanced		RH-30: 18.2
PGM3	AGM1, DKFZP434B187, PAGM	ENSG00000013375	Phosphoglucomutase 3	6	83161150-83193936	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004998, HPA029759, HPA029760	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.39e-7 (unfavourable), Cervical cancer:5.67e-4 (unfavourable), Breast cancer:8.78e-4 (unfavourable), Ovarian cancer:9.96e-4 (favourable)	Expressed in all	Expressed in all			prostate: 82.2	Expressed in all		
PGM5	PGMRP	ENSG00000154330	Phosphoglucomutase 5	9	68328308-68531061	Predicted intracellular proteins	Evidence at protein level	CAB034397, HPA046329, HPA067102	Enhanced				Renal cancer:1.83e-5 (favourable)	Tissue enhanced	Tissue enhanced		prostate: 283.6;seminal vesicle: 327.6	smooth muscle: 217.9	Cell line enhanced		PC-3: 55.9;RH-30: 40.1;SK-BR-3: 38.8
PGP		ENSG00000184207	Phosphoglycolate phosphatase	16	2211997-2214807	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043096, HPA046739	Approved		Approved	Nuclear bodies	Urothelial cancer:6.42e-4 (favourable), Renal cancer:7.05e-4 (favourable)	Expressed in all	Expressed in all			testis: 28.1	Expressed in all		
PGPEP1	Pcp, PGP, PGP-I, PGPI	ENSG00000130517	Pyroglutamyl-peptidase I	19	18340587-18369950	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035368, HPA055277	Approved		Approved	Golgi apparatus	Renal cancer:3.71e-8 (favourable), Pancreatic cancer:1.71e-4 (favourable), Melanoma:6.80e-4 (favourable)	Expressed in all	Expressed in all			kidney: 29.3	Cell line enhanced		HMC-1: 51.6
PGPEP1L		ENSG00000183571	Pyroglutamyl-peptidase I-like	15	98968230-99007795	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA041781	Uncertain					Not detected	Group enriched	6	heart muscle: 2.4;skeletal muscle: 10.5;testis: 3.8	breast,esophagus: 0.9	Cell line enhanced		U-2 OS: 1.1
PGR	NR3C3, PR	ENSG00000082175	Progesterone receptor	11	101029624-101130524	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000068, HPA004751, HPA008428, HPA017176, CAB055100	Enhanced				Endometrial cancer:5.76e-8 (favourable)	Group enriched	Group enriched	6	cervix, uterine: 96.2;endometrium: 172.3;fallopian tube: 53.3;smooth muscle: 114.9	ovary: 19.5	Cell line enriched	349	T-47d: 157.7
PGS1	DKFZP762M186	ENSG00000087157	Phosphatidylglycerophosphate synthase 1	17	78378640-78425114	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022526	Approved		Approved	Vesicles<br>Cell Junctions<br>Intermediate filaments	Renal cancer:1.16e-5 (unfavourable), Pancreatic cancer:7.33e-5 (favourable), Liver cancer:1.37e-4 (unfavourable), Prostate cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 26.7	Expressed in all		
PHACTR2	C6orf56, KIAA0680	ENSG00000112419	Phosphatase and actin regulator 2	6	143536845-143831185	Predicted intracellular proteins	Evidence at protein level	HPA031719, HPA031720, HPA031725	Approved				Renal cancer:1.99e-4 (favourable)	Expressed in all	Expressed in all			placenta: 120.1	Cell line enhanced		TIME: 66.9
PHACTR3	C20orf101, PPP1R123	ENSG00000087495	Phosphatase and actin regulator 3	20	59577509-59847711	Predicted intracellular proteins	Evidence at protein level	HPA051834, HPA054847			Enhanced	Nucleoplasm		Group enriched	Tissue enriched	9	cerebral cortex: 64.8	spleen: 7.4	Cell line enhanced		RPTEC TERT1: 18.7;THP-1: 88.0;U-937: 25.4
PHACTR4	FLJ13171, PPP1R124	ENSG00000204138	Phosphatase and actin regulator 4	1	28369582-28500369	Predicted intracellular proteins	Evidence at protein level	HPA028985	Approved		Approved	Plasma membrane<br>Intermediate filaments<br>Cytosol	Head and neck cancer:1.05e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 35.7	Expressed in all		
PHAX	FLJ13193, RNUXA	ENSG00000164902	Phosphorylated adaptor for RNA export	5	126600268-126627252	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA059630, HPA070326	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 17.8	Expressed in all		
PHB2	Bap37, BCAP37, p22, REA	ENSG00000215021	Prohibitin 2	12	6965327-6970825	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB014889, CAB026335, HPA039874	Supported		Enhanced	Mitochondria	Endometrial cancer:3.80e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 269.3	Expressed in all		
PHC1	EDR1, HPH1, RAE28	ENSG00000111752	Polyhomeotic homolog 1	12	8913896-8941467	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA006973	Approved		Supported	Nucleus		Tissue enriched	Expressed in all			testis: 80.4	Group enriched	6	BEWO: 158.3;NTERA-2: 593.1
PHC2	EDR2, HPH2	ENSG00000134686	Polyhomeotic homolog 2	1	33323623-33431052	Predicted intracellular proteins	Evidence at protein level	HPA047403	Supported		Supported	Nucleoplasm	Liver cancer:2.28e-6 (unfavourable), Renal cancer:2.35e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 88.1	Expressed in all		
PHC3	EDR3, FLJ12729, FLJ12967, HPH3	ENSG00000173889	Polyhomeotic homolog 3	3	170086732-170181749	Predicted intracellular proteins	Evidence at protein level	HPA039162, HPA062031	Approved		Supported	Nucleus		Expressed in all	Expressed in all			bone marrow: 33.5	Expressed in all		
PHF1	MTF2L2, PCL1, TDRD19C	ENSG00000112511	PHD finger protein 1	6	33410399-33416453	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031038	Approved		Approved	Nucleoplasm	Colorectal cancer:9.64e-5 (unfavourable), Urothelial cancer:1.72e-4 (favourable)	Expressed in all	Mixed			testis: 16.0	Mixed		
PHF10	BAF45a, FLJ10975, XAP135	ENSG00000130024	PHD finger protein 10	6	169703905-169725566	Predicted intracellular proteins	Evidence at protein level	HPA055649	Supported		Supported	Nucleus	Pancreatic cancer:1.12e-5 (favourable), Renal cancer:1.56e-5 (unfavourable), Liver cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 103.6	Expressed in all		
PHF11	BCAP, IGER, NY-REN-34	ENSG00000136147	PHD finger protein 11	13	49495610-49528987	Predicted intracellular proteins	Evidence at protein level	HPA016566, HPA016708	Uncertain		Supported	Nucleoplasm<br>Nuclear membrane	Renal cancer:4.46e-7 (unfavourable), Endometrial cancer:7.98e-6 (favourable), Urothelial cancer:3.46e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 57.6	Mixed		
PHF12	KIAA1523, PF1	ENSG00000109118	PHD finger protein 12	17	28905250-28951771	Predicted intracellular proteins	Evidence at protein level	HPA021410, HPA021452	Approved		Enhanced	Nucleoplasm	Renal cancer:1.24e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 28.8	Expressed in all		
PHF13	MGC43399	ENSG00000116273	PHD finger protein 13	1	6613685-6624033	Predicted intracellular proteins	Evidence at protein level	HPA026830	Uncertain				Liver cancer:6.86e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 58.9	Expressed in all		
PHF14	KIAA0783	ENSG00000106443	PHD finger protein 14	7	10973872-11169630	Predicted intracellular proteins	Evidence at protein level	HPA000538, HPA017376	Supported		Approved	Nucleus<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 20.8	Expressed in all		
PHF19	DKFZP727G051, MTF2L1, PCL3, TDRD19B	ENSG00000119403	PHD finger protein 19	9	120855652-120894896	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.16e-7 (unfavourable), Liver cancer:5.16e-5 (unfavourable), Endometrial cancer:7.60e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 49.5	Expressed in all		
PHF2	CENP-35, JHDM1E, KDM7C, KIAA0662	ENSG00000197724	PHD finger protein 2	9	93576407-93679587	Predicted intracellular proteins	Evidence at protein level	HPA010831	Approved				Renal cancer:1.12e-5 (favourable), Colorectal cancer:9.34e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 30.7	Expressed in all		
PHF20	C20orf104, dJ1121G12.1, TDRD20A	ENSG00000025293	PHD finger protein 20	20	35771974-35950381	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029619, HPA029620, HPA029621	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Liver cancer:2.49e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 22.4	Expressed in all		
PHF20L1	CGI-72, FLJ13649, FLJ21615, MGC64923, TDRD20B	ENSG00000129292	PHD finger protein 20-like 1	8	132775358-132848807	Predicted intracellular proteins	Evidence at protein level	HPA025060, HPA028417	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 38.1	Expressed in all		
PHF21A	BHC80, BM-006, KIAA1696	ENSG00000135365	PHD finger protein 21A	11	45929323-46121178	Predicted intracellular proteins	Evidence at protein level	HPA023580	Uncertain				Renal cancer:2.59e-8 (unfavourable), Liver cancer:1.66e-6 (unfavourable), Colorectal cancer:6.15e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.7	Expressed in all		
PHF21B	BHC80L, FLJ34161, PHF4	ENSG00000056487	PHD finger protein 21B	22	44881162-45009999	Predicted intracellular proteins	Evidence at protein level	HPA053834	Uncertain		Uncertain	Nucleus<br>Nucleoli fibrillar center		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.7;cervix, uterine: 5.5;testis: 6.4	endometrium: 5.4	Cell line enhanced		AF22: 11.1;AN3-CA: 9.4;SCLC-21H: 10.3;SH-SY5Y: 41.0;U-2 OS: 9.1
PHF23	FLJ16355, MGC2941	ENSG00000040633	PHD finger protein 23	17	7235028-7239722	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052410	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 41.7	Expressed in all		
PHF24	KIAA1045	ENSG00000122733	PHD finger protein 24	9	34957608-34982544	Predicted intracellular proteins	Evidence at protein level	HPA020974	Approved					Tissue enhanced	Group enriched	36	cerebral cortex: 58.6;testis: 25.9	skin: 1.1	Cell line enhanced		WM-115: 1.1
PHF3		ENSG00000118482	PHD finger protein 3	6	63635820-63779336	Predicted intracellular proteins	Evidence at protein level	HPA024676, HPA025763	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 48.5	Expressed in all		
PHF5A	bK223H9.2, INI, MGC1346, Rds3, SAP14b, SF3b14b, SF3B7	ENSG00000100410	PHD finger protein 5A	22	41459717-41468725	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028885	Supported		Enhanced	Nucleoplasm	Liver cancer:3.02e-8 (unfavourable)	Expressed in all	Expressed in all			lymph node: 39.8	Expressed in all		
PHF6	BFLS, BORJ, CENP-31, KIAA1823, MGC14797	ENSG00000156531	PHD finger protein 6	X	134373253-134428791	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001023	Enhanced		Enhanced	Nucleus<br>Nucleoli	Liver cancer:3.38e-4 (unfavourable), Pancreatic cancer:9.96e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 41.7	Expressed in all		
PHF7	HSPC226, NYD-SP6	ENSG00000010318	PHD finger protein 7	3	52410657-52423641	Predicted intracellular proteins	Evidence at protein level	HPA036283, HPA070305	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.05e-6 (favourable), Breast cancer:7.38e-5 (favourable), Endometrial cancer:9.44e-5 (favourable)	Expressed in all	Tissue enriched	432	testis: 2183.4	rectum: 5.0	Cell line enhanced		U-266/70: 13.2
PHF8	JHDM1F, KDM7B, KIAA1111, ZNF422	ENSG00000172943	PHD finger protein 8	X	53936676-54048958	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038779, HPA062015	Approved		Supported	Nucleus	Urothelial cancer:3.74e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 85.8	Expressed in all		
PHGDH	PDG, PGDH, SERA	ENSG00000092621	Phosphoglycerate dehydrogenase	1	119659798-119744215	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003681, HPA021241, HPA024031, CAB068216	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:1.48e-4 (unfavourable), Glioma:2.26e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 216.7	skin: 115.9	Mixed		
PHGR1		ENSG00000233041	Proline, histidine and glycine rich 1	15	40351033-40356434	Predicted intracellular proteins	Evidence at protein level	HPA068787	Enhanced		Approved	Vesicles	Breast cancer:2.05e-4 (favourable)	Group enriched	Group enriched	7	colon: 1448.4;duodenum: 892.1;rectum: 399.5;small intestine: 1777.5	stomach: 166.8	Cell line enhanced		BEWO: 12.3;HaCaT: 16.0;SCLC-21H: 72.5
PHIP	BRWD2, DCAF14, FLJ20705, ndrp, WDR11	ENSG00000146247	Pleckstrin homology domain interacting protein	6	78935867-79078236	Predicted intracellular proteins	Evidence at protein level	HPA019140, HPA019838	Approved		Supported	Nucleoplasm	Renal cancer:1.71e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.2	Expressed in all		
PHKA1	PHKA	ENSG00000067177	Phosphorylase kinase regulatory subunit alpha 1	X	72578814-72714319	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001081	Enhanced		Approved	Vesicles	Endometrial cancer:6.84e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 40.1;skeletal muscle: 35.5	adrenal gland: 15.6	Mixed		
PHKA2	PHK, PYK	ENSG00000044446	Phosphorylase kinase regulatory subunit alpha 2	X	18892300-18984598	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002912	Approved		Approved	Nucleoplasm	Liver cancer:1.25e-5 (unfavourable), Renal cancer:1.55e-5 (unfavourable), Urothelial cancer:2.96e-5 (favourable), Pancreatic cancer:7.68e-4 (favourable)	Expressed in all	Expressed in all			ovary: 18.5	Expressed in all		
PHKB		ENSG00000102893	Phosphorylase kinase regulatory subunit beta	16	47461123-47701523	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA073380			Approved	Golgi apparatus	Renal cancer:3.89e-9 (favourable), Thyroid cancer:3.24e-4 (unfavourable), Colorectal cancer:3.69e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 99.3	Expressed in all		
PHLDA1	DT1P1B11, PHRIP, TDAG51	ENSG00000139289	Pleckstrin homology like domain family A member 1	12	76025447-76033932	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB016160, HPA019000, HPA063520	Approved		Supported	Nucleoli		Expressed in all	Mixed			salivary gland: 68.6	Mixed		
PHLDA2	BWR1C, HLDA2, IPL, TSSC3	ENSG00000181649	Pleckstrin homology like domain family A member 2	11	2928273-2929455	Predicted intracellular proteins	Evidence at protein level	HPA003994			Uncertain	Nucleoli	Renal cancer:2.63e-6 (unfavourable), Liver cancer:4.22e-5 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 54.3	stomach: 6.6	Cell line enhanced		HDLM-2: 185.5;PC-3: 149.3;SK-MEL-30: 101.3;WM-115: 170.7
PHLDA3	TIH1	ENSG00000174307	Pleckstrin homology like domain family A member 3	1	201464383-201469237	Predicted intracellular proteins	Evidence at protein level	HPA027601	Approved				Endometrial cancer:1.77e-4 (favourable), Renal cancer:3.67e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 61.5	Cell line enhanced		BEWO: 275.2;WM-115: 162.5
PHLDB1	FLJ00141, KIAA0638, LL5a	ENSG00000019144	Pleckstrin homology like domain family B member 1	11	118606440-118658038	Predicted intracellular proteins	Evidence at protein level	HPA037959, HPA038448, HPA061506	Approved		Approved	Nucleoplasm	Renal cancer:6.36e-6 (unfavourable)	Expressed in all	Mixed			adipose tissue: 56.5	Cell line enhanced		ASC TERT1: 74.2
PHLDB3	FLJ40193	ENSG00000176531	Pleckstrin homology like domain family B member 3	19	43474954-43504935	Predicted intracellular proteins	Evidence at protein level	HPA043425	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Pancreatic cancer:6.36e-6 (favourable), Renal cancer:4.11e-5 (unfavourable), Stomach cancer:5.77e-4 (unfavourable)	Expressed in all	Mixed			testis: 24.6	Mixed		
PHLPP1	KIAA0606, PHLPP, PLEKHE1, PPM3A, SCOP	ENSG00000081913	PH domain and leucine rich repeat protein phosphatase 1	18	62715450-62980433	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020200	Uncertain				Renal cancer:5.35e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 40.9	Mixed		
PHLPP2	KIAA0931, PHLPPL, PPM3B	ENSG00000040199	PH domain and leucine rich repeat protein phosphatase 2	16	71637835-71724701	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048598	Approved		Approved	Vesicles		Expressed in all	Mixed			small intestine: 24.2	Expressed in all		
PHOSPHO1		ENSG00000173868	Phosphoethanolamine/phosphocholine phosphatase	17	49223362-49230766	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053016, HPA065025	Uncertain		Approved	Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		spleen: 20.4;testis: 41.1	bone marrow: 12.4	Cell line enhanced		Daudi: 4.3;EFO-21: 3.6;HDLM-2: 4.0
PHOSPHO2	MGC22679	ENSG00000144362	Phosphatase, orphan 2	2	169694454-169701708	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034726, HPA034727	Uncertain		Approved	Vesicles	Liver cancer:3.82e-6 (unfavourable), Renal cancer:9.53e-4 (favourable)	Expressed in all	Expressed in all			testis: 23.0	Expressed in all		
PHOX2A	ARIX, CFEOM2, FEOM2, PMX2A	ENSG00000165462	Paired like homeobox 2a	11	72239077-72245664	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065621, HPA078004	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Vesicles		Tissue enriched	Tissue enriched	14	adrenal gland: 26.4	appendix: 1.8	Cell line enriched	240	SH-SY5Y: 603.9
PHOX2B	NBPhox, Phox2b, PMX2B	ENSG00000109132	Paired like homeobox 2b	4	41744082-41748970	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA074325, HPA074941			Enhanced	Nucleoplasm		Not detected	Tissue enriched	8	adrenal gland: 10.3	small intestine: 1.2	Cell line enriched	92	SH-SY5Y: 130.2
PHPT1	bA216L13.10, CGI-202, DKFZp564M173, HSPC141, PHP14	ENSG00000054148	Phosphohistidine phosphatase 1	9	136848724-136851027	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB013584, HPA020952	Approved		Approved	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			heart muscle: 73.8	Expressed in all		
PHRF1	KIAA1542, PPP1R125, RNF221	ENSG00000070047	PHD and ring finger domains 1	11	576486-612222	Predicted intracellular proteins	Evidence at protein level	HPA019867, HPA062933	Uncertain				Liver cancer:6.00e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 4.5	Cell line enhanced		EFO-21: 13.5;Hep G2: 16.4;MOLT-4: 31.6;SCLC-21H: 13.1;U-138 MG: 20.9
PHYH	PAHX, PHYH1, RD	ENSG00000107537	Phytanoyl-CoA 2-hydroxylase	10	13277796-13302412	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007598, HPA011796	Enhanced				Renal cancer:7.28e-12 (favourable)	Expressed in all	Expressed in all			liver: 334.1	Mixed		
PHYHD1	MGC16638	ENSG00000175287	Phytanoyl-CoA dioxygenase domain containing 1	9	128920895-128942041	Predicted intracellular proteins	Evidence at protein level	HPA012115			Approved	Nuclear speckles	Renal cancer:6.38e-10 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 59.9	Cell line enhanced		ASC diff: 31.7;BEWO: 49.9;RPTEC TERT1: 59.0
PHYHIP	DYRK1AP3, KIAA0273, PAHX-AP	ENSG00000168490	Phytanoyl-CoA 2-hydroxylase interacting protein	8	22219704-22232341	Predicted intracellular proteins	Evidence at protein level	HPA068030, HPA069318	Approved		Enhanced	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 182.7;skin: 58.2	adrenal gland: 28.8	Cell line enhanced		RPMI-8226: 6.4;SH-SY5Y: 3.6
PHYHIPL	Em:AC025038.1, KIAA1796	ENSG00000165443	Phytanoyl-CoA 2-hydroxylase interacting protein like	10	59176590-59247774	Predicted intracellular proteins	Evidence at protein level	HPA038746	Uncertain		Approved	Cytosol	Renal cancer:1.60e-7 (favourable)	Group enriched	Tissue enhanced		cerebral cortex: 89.4	adrenal gland: 22.4	Cell line enhanced		Hep G2: 22.4;SCLC-21H: 6.7;SH-SY5Y: 20.0;SK-BR-3: 6.0
PHYKPL	AGXT2L2, MGC15875	ENSG00000175309	5-phosphohydroxy-L-lysine phospho-lyase	5	178208497-178232791	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036461, HPA063608	Approved		Approved	Mitochondria	Renal cancer:3.82e-5 (unfavourable)	Expressed in all	Expressed in all			rectum: 34.5	Expressed in all		
PI4K2A	DKFZP761G1923, PI4KII, PIK42A	ENSG00000155252	Phosphatidylinositol 4-kinase type 2 alpha	10	97640686-97676434	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB030649	Approved				Colorectal cancer:4.21e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.3	Expressed in all		
PI4K2B	FLJ11105, PI4KIIB, PIK42B	ENSG00000038210	Phosphatidylinositol 4-kinase type 2 beta	4	25233975-25279092	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004099	Approved		Supported	Cytosol	Colorectal cancer:9.64e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 33.9	Expressed in all		
PI4KB	PI4K-BETA, pi4K92, PIK4CB	ENSG00000143393	Phosphatidylinositol 4-kinase beta	1	151291797-151327715	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006280, HPA006281, CAB022071	Approved		Supported	Golgi apparatus	Pancreatic cancer:1.25e-5 (favourable), Liver cancer:2.97e-4 (unfavourable), Renal cancer:3.23e-4 (unfavourable), Thyroid cancer:6.78e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 102.7	Expressed in all		
PIAS1	DDXBP1, GBP, GU/RH-II, ZMIZ3	ENSG00000033800	Protein inhibitor of activated STAT 1	15	68054179-68198603	Predicted intracellular proteins	Evidence at protein level	HPA005743, CAB012304	Supported		Approved	Microtubules		Expressed in all	Expressed in all			testis: 37.7	Expressed in all		
PIAS3	FLJ14651, ZMIZ5	ENSG00000131788	Protein inhibitor of activated STAT 3	1	145848522-145859836	Predicted intracellular proteins	Evidence at protein level	HPA006389, HPA067383	Approved		Supported	Nucleoplasm	Renal cancer:1.21e-7 (unfavourable), Liver cancer:6.12e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 60.1	Expressed in all		
PIAS4	FLJ12419, Piasg, PIASY, ZMIZ6	ENSG00000105229	Protein inhibitor of activated STAT 4	19	4007646-4039386	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010598	Approved		Approved	Nucleoplasm	Endometrial cancer:1.18e-5 (favourable), Pancreatic cancer:7.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 29.3	Expressed in all		
PIBF1	C13orf24, CEP90	ENSG00000083535	Progesterone immunomodulatory binding factor 1	13	72782059-73016461	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052269, HPA066120	Approved		Supported	Microtubule organizing center		Expressed in all	Expressed in all			testis: 25.9	Expressed in all		
PICALM	CALM, CLTH	ENSG00000073921	Phosphatidylinositol binding clathrin assembly protein	11	85957684-86069882	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019053, HPA019061	Enhanced		Supported	Vesicles	Renal cancer:2.02e-6 (favourable), Pancreatic cancer:6.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 297.2	Expressed in all		
PICK1	dJ1039K5, MGC15204, PRKCABP	ENSG00000100151	Protein interacting with PRKCA 1	22	38056311-38075701	Predicted intracellular proteins	Evidence at protein level	HPA067384, HPA072674	Approved		Approved	Mitochondria<br>Cytosol	Stomach cancer:5.26e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 53.2	Mixed		
PID1	FLJ20701, NYGGF4	ENSG00000153823	Phosphotyrosine interaction domain containing 1	2	228850526-229271285	Predicted intracellular proteins	Evidence at protein level	HPA036103	Approved		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			cerebral cortex: 67.2	Cell line enhanced		hTEC/SVTERT24-B: 86.1;LHCN-M2: 48.1;REH: 56.9;RH-30: 88.5
PIDD1	DKFZp434D229, LRDD, MGC16925, PIDD	ENSG00000177595	P53-induced death domain protein 1	11	799179-809753	Predicted intracellular proteins	Evidence at protein level	CAB012647, HPA055473	Supported		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:3.32e-5 (favourable), Cervical cancer:8.19e-5 (favourable), Renal cancer:1.52e-4 (unfavourable), Head and neck cancer:3.91e-4 (favourable)	Expressed in all	Mixed			bone marrow: 4.6	Cell line enhanced		BEWO: 25.3
PIF1	C15orf20, FLJ22692	ENSG00000140451	PIF1 5'-to-3' DNA helicase	15	64815632-64825668	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018701	Supported		Supported	Nucleoplasm	Melanoma:5.22e-4 (unfavourable)	Tissue enhanced	Mixed			lymph node: 5.3	Mixed		
PIFO	C1orf88, FLJ23853, pitchfork	ENSG00000173947	Primary cilia formation	1	111346288-111353013	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.44e-4 (favourable), Pancreatic cancer:2.48e-4 (favourable)	Mixed	Tissue enriched	6	fallopian tube: 272.5	testis: 43.1	Cell line enhanced		RPTEC TERT1: 3.4;RT4: 4.3;T-47d: 3.5;U-87 MG: 3.4
PIGBOS1		ENSG00000225973	PIGB opposite strand 1	15	55317184-55319161	Predicted intracellular proteins	Evidence at transcript level						Breast cancer:4.19e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.2	Expressed in all		
PIH1D1	FLJ20643, NOP17	ENSG00000104872	PIH1 domain containing 1	19	49446298-49453497	Predicted intracellular proteins	Evidence at protein level	HPA047258	Approved		Approved	Cytosol		Expressed in all	Expressed in all			fallopian tube: 64.8	Expressed in all		
PIH1D2		ENSG00000150773	PIH1 domain containing 2	11	112064010-112074274	Predicted intracellular proteins	Evidence at protein level	HPA039496			Uncertain	Nucleoplasm<br>Cytosol		Mixed	Group enriched	7	fallopian tube: 35.4;testis: 126.7	thyroid gland: 11.6	Mixed		
PIH1D3	CXorf41, MGC35261, NYSAR97	ENSG00000080572	PIH1 domain containing 3	X	107206632-107244243	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA072496	Enhanced					Tissue enhanced	Group enriched	8	fallopian tube: 17.4;testis: 13.8	lung: 1.9	Not detected		
PIK3C2A	PI3K-C2alpha	ENSG00000011405	Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	11	17077730-17207983	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037641, HPA037642	Uncertain		Supported	Nucleus	Renal cancer:1.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 94.6	Expressed in all		
PIK3C2B	C2-PI3K, PI3K-C2beta	ENSG00000133056	Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta	1	204422628-204494724	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030515, HPA050360	Approved		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.16e-4 (favourable), Liver cancer:5.42e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 28.2	Cell line enhanced		BEWO: 67.8;RT4: 60.2
PIK3C2G		ENSG00000139144	Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma	12	18247614-18648416	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:3.50e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 20.4;stomach: 20.0	parathyroid gland: 17.3	Group enriched	6	BEWO: 1.2;HaCaT: 1.8;hTERT-HME1: 2.9
PIK3C3	Vps34	ENSG00000078142	Phosphatidylinositol 3-kinase catalytic subunit type 3	18	41955206-42087830	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040718	Approved				Renal cancer:4.97e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.9	Expressed in all		
PIK3CA	PI3K	ENSG00000121879	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	179148114-179240093	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA009985, CAB017804	Approved		Approved	Cytosol		Expressed in all	Mixed			parathyroid gland: 23.8	Expressed in all		
PIK3CB	PIK3C1	ENSG00000051382	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	3	138652699-138834938	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB031938, HPA064207	Approved		Approved	Nucleoplasm<br>Nucleoli<br>Midbody	Pancreatic cancer:3.99e-5 (unfavourable), Liver cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 88.9	Expressed in all		
PIK3CD	p110D	ENSG00000171608	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	9651732-9729114	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB015420, HPA044953	Enhanced		Approved	Vesicles<br>Cytokinetic bridge		Expressed in all	Tissue enhanced		lymph node: 56.4	spleen: 51.2	Cell line enhanced		HDLM-2: 146.7;REH: 64.7;U-937: 63.7
PIK3CG		ENSG00000105851	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	7	106865278-106907145	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069976			Supported	Plasma membrane		Mixed	Tissue enhanced		bone marrow: 28.1	lymph node: 22.0	Cell line enhanced		HMC-1: 30.6;MOLT-4: 44.8;U-266/70: 53.9;U-937: 40.5
PIK3R1	GRB1, p85, p85-ALPHA	ENSG00000145675	Phosphoinositide-3-kinase regulatory subunit 1	5	68215720-68301821	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001216, CAB004268	Approved		Approved	Cytosol	Liver cancer:8.09e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 132.9	Expressed in all		
PIK3R2	p85, P85B	ENSG00000105647	Phosphoinositide-3-kinase regulatory subunit 2	19	18153118-18170540	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA069291	Approved		Approved	Golgi apparatus		Mixed	Expressed in all			cerebral cortex: 47.3	Expressed in all		
PIK3R3	p55	ENSG00000117461	Phosphoinositide-3-kinase regulatory subunit 3	1	46040140-46133036	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA005751, HPA071988	Approved		Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:1.93e-4 (favourable), Head and neck cancer:3.62e-4 (favourable)	Expressed in all	Mixed			testis: 46.2	Expressed in all		
PIK3R4	p150, VPS15	ENSG00000196455	Phosphoinositide-3-kinase regulatory subunit 4	3	130678935-130746829	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036032, HPA036033	Approved		Approved	Vesicles<br>Microtubules	Renal cancer:4.40e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.6	Expressed in all		
PIK3R5	p101, P101-PI3K	ENSG00000141506	Phosphoinositide-3-kinase regulatory subunit 5	17	8878911-8965712	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044505, HPA052247, HPA052412	Uncertain		Supported	Microtubule organizing center<br>Cytosol		Expressed in all	Tissue enhanced		bone marrow: 55.2	spleen: 27.9	Cell line enhanced		HDLM-2: 36.3;U-937: 8.8
PIK3R6	C17orf38, FLJ34500, HsT41028, p87PIKAP	ENSG00000276231	Phosphoinositide-3-kinase regulatory subunit 6	17	8802723-8867677	Predicted intracellular proteins	Evidence at protein level	HPA023077	Approved				Renal cancer:1.50e-6 (unfavourable)	Mixed	Mixed			spleen: 4.1	Cell line enriched	7	HMC-1: 131.5
PIKFYVE	FAB1, KIAA0981, MGC40423, p235, PIKfyve, PIP5K, PIP5K3, ZFYVE29	ENSG00000115020	Phosphoinositide kinase, FYVE-type zinc finger containing	2	208266267-208358751	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042604	Uncertain		Uncertain	Nuclear speckles	Head and neck cancer:6.81e-4 (favourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
PIM1	PIM	ENSG00000137193	Pim-1 proto-oncogene, serine/threonine kinase	6	37170203-37175426	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003941, CAB017040	Uncertain		Supported	Nucleoli<br>Cytosol	Endometrial cancer:9.73e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 133.9	Expressed in all		
PIM3		ENSG00000198355	Pim-3 proto-oncogene, serine/threonine kinase	22	49960513-49964080	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA068758			Supported	Cytosol	Renal cancer:8.09e-4 (favourable), Ovarian cancer:9.68e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 61.2	Expressed in all		
PIN1	dod	ENSG00000127445	Peptidylprolyl cis/trans isomerase, NIMA-interacting 1	19	9835257-9849682	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004528, CAB009326, HPA068650	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:7.80e-5 (favourable), Pancreatic cancer:3.25e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 136.9	Expressed in all		
PIN4	EPVH, PAR14, PAR17	ENSG00000102309	Peptidylprolyl cis/trans isomerase, NIMA-interacting 4	X	72181353-72302926	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054483, HPA064504	Approved		Supported	Nucleus<br>Nucleoli	Testis cancer:2.58e-4 (favourable), Urothelial cancer:2.66e-4 (favourable), Lung cancer:6.37e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 24.3	Expressed in all		
PINK1	PARK6	ENSG00000158828	PTEN induced putative kinase 1	1	20633455-20651511	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001931, CAB026191	Uncertain				Renal cancer:1.11e-16 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 145.5	Expressed in all		
PINX1	FLJ20565, LPTL, LPTS, MGC8850, PinX1	ENSG00000254093	PIN2/TERF1 interacting, telomerase inhibitor 1	8	10764963-10839884	Predicted intracellular proteins	Evidence at protein level	HPA023139	Uncertain				Cervical cancer:2.45e-5 (favourable)	Expressed in all	Expressed in all			testis: 16.1	Expressed in all		
PIP4K2A	PIP5K2A, PIP5KIIA, PIP5KIIalpha	ENSG00000150867	Phosphatidylinositol-5-phosphate 4-kinase type 2 alpha	10	22534849-22714555	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065440, HPA068771	Supported		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.46e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 144.3	Expressed in all		
PIP4K2B	PIP5K2B, PIP5KIIB, PIP5KIIbeta	ENSG00000276293	Phosphatidylinositol-5-phosphate 4-kinase type 2 beta	17	38765689-38800126	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047875, HPA062220	Approved		Supported	Nucleoplasm	Thyroid cancer:1.36e-4 (favourable), Liver cancer:4.54e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 51.6	Expressed in all		
PIP4K2C	FLJ22055, PIP5K2C	ENSG00000166908	Phosphatidylinositol-5-phosphate 4-kinase type 2 gamma	12	57591174-57603418	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028658, HPA058551	Approved		Approved	Vesicles	Renal cancer:2.06e-6 (favourable), Liver cancer:7.98e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 109.1	Mixed		
PIP5K1A		ENSG00000143398	Phosphatidylinositol-4-phosphate 5-kinase type 1 alpha	1	151197949-151249536	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029366	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:4.16e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 67.8	Expressed in all		
PIP5K1B	MSS4, STM7	ENSG00000107242	Phosphatidylinositol-4-phosphate 5-kinase type 1 beta	9	68705414-69009176	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA009687	Uncertain		Approved	Nucleus<br>Vesicles	Renal cancer:1.03e-9 (favourable)	Mixed	Mixed			testis: 50.3	Cell line enhanced		AF22: 47.6;HEL: 16.8;U-266/70: 14.2
PIP5K1C	KIAA0589, LCCS3, PIP5Kgamma	ENSG00000186111	Phosphatidylinositol-4-phosphate 5-kinase type 1 gamma	19	3630183-3700479	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017168	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:7.28e-5 (favourable), Cervical cancer:1.79e-4 (favourable), Pancreatic cancer:2.32e-4 (favourable), Renal cancer:3.00e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 52.9	Expressed in all		
PIP5KL1	bA203J24.5, MGC46424	ENSG00000167103	Phosphatidylinositol-4-phosphate 5-kinase like 1	9	127920879-127930797	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056240	Uncertain		Supported	Cytosol		Mixed	Tissue enhanced		parathyroid gland: 3.8	skin: 2.2	Cell line enhanced		Karpas-707: 32.1;RPMI-8226: 21.0
PIPOX	LPIPOX	ENSG00000179761	Pipecolic acid and sarcosine oxidase	17	28950513-29057220	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:1.49e-4 (favourable)	Group enriched	Group enriched	7	kidney: 137.9;liver: 235.9	epididymis: 26.0	Group enriched	5	AF22: 30.7;Hep G2: 65.9;NTERA-2: 61.7;RH-30: 85.6
PIR		ENSG00000087842	Pirin	X	15384799-15493564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000697	Enhanced		Supported	Cytosol	Renal cancer:6.11e-7 (unfavourable), Cervical cancer:2.78e-4 (favourable), Ovarian cancer:4.94e-4 (favourable)	Expressed in all	Mixed			urinary bladder: 22.6	Cell line enhanced		HUVEC TERT2: 565.7;SK-MEL-30: 201.8
PITHD1	C1orf128, HT014, TXNL1CL	ENSG00000057757	PITH domain containing 1	1	23778405-23788232	Predicted intracellular proteins	Evidence at protein level	HPA016936	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 208.8	Expressed in all		
PITPNA	PITPN, VIB1A	ENSG00000174238	Phosphatidylinositol transfer protein alpha	17	1517718-1562816	Predicted intracellular proteins	Evidence at protein level	HPA000528	Uncertain		Approved	Vesicles<br>Cytosol	Pancreatic cancer:1.80e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Renal cancer:9.35e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 117.9	Expressed in all		
PITPNB	VIB1B	ENSG00000180957	Phosphatidylinositol transfer protein beta	22	27851669-27920134	Predicted intracellular proteins	Evidence at protein level	HPA000528	Uncertain		Approved	Vesicles<br>Cytosol	Head and neck cancer:5.28e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 70.3	Expressed in all		
PITPNC1	RDGB-BETA, RDGBB, RDGBB1	ENSG00000154217	Phosphatidylinositol transfer protein, cytoplasmic 1	17	67377281-67697261	Predicted intracellular proteins	Evidence at protein level	HPA026563, HPA031250	Uncertain		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:4.85e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 46.6	Mixed		
PITPNM1	DRES9, NIR2, PITPNM, Rd9, RDGB, RDGB1, RDGBA1	ENSG00000110697	Phosphatidylinositol transfer protein membrane associated 1	11	67491768-67506263	Predicted intracellular proteins	Evidence at protein level	HPA060227, HPA062757	Approved		Enhanced	Microtubule organizing center<br>Cytosol<br>Cytoplasmic bodies		Expressed in all	Expressed in all			fallopian tube: 37.0	Expressed in all		
PITPNM2	NIR3, RDGB2, RDGBA2	ENSG00000090975	Phosphatidylinositol transfer protein membrane associated 2	12	122983480-123150015	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003414, HPA003978	Approved		Supported	Vesicles		Expressed in all	Mixed			ovary: 19.1	Cell line enhanced		HEL: 26.5;MOLT-4: 44.3
PITPNM3	ACKR6, CORD5, NIR1, RDGBA3	ENSG00000091622	PITPNM family member 3	17	6451264-6556494	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022432, HPA059005	Enhanced		Approved	Plasma membrane	Head and neck cancer:3.67e-6 (favourable)	Mixed	Tissue enhanced		spleen: 76.8	ovary: 33.7	Cell line enhanced		HaCaT: 15.7;hTCEpi: 36.7
PITRM1	hMP1, KIAA1104, MP1, PreP	ENSG00000107959	Pitrilysin metallopeptidase 1	10	3137728-3172841	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006753, HPA006754	Enhanced		Supported	Mitochondria		Expressed in all	Expressed in all			testis: 86.6	Expressed in all		
PITX1	BFT, POTX, PTX1	ENSG00000069011	Paired like homeodomain 1	5	135027735-135034813	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008743	Approved		Supported	Nucleoli		Tissue enhanced	Tissue enriched	5	esophagus: 211.7	salivary gland: 38.5	Cell line enhanced		CACO-2: 116.7;K-562: 103.4;T-47d: 154.3
PITX2	ARP1, Brx1, IGDS, IHG2, IRID2, Otlx2, RGS, RIEG, RIEG1, RS	ENSG00000164093	Paired like homeodomain 2	4	110617423-110642123	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050074, HPA062728			Enhanced	Nucleus		Mixed	Tissue enhanced		placenta: 72.2	skeletal muscle: 18.3	Cell line enhanced		CACO-2: 23.3;LHCN-M2: 25.4;RH-30: 24.6
PITX3	ASMD	ENSG00000107859	Paired like homeodomain 3	10	102230186-102241474	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Group enriched	11	adipose tissue: 1.2;skeletal muscle: 5.6	testis: 0.3	Cell line enriched	17	RH-30: 28.7
PIWIL1	CT80.1, HIWI, PIWI	ENSG00000125207	Piwi like RNA-mediated gene silencing 1	12	130337887-130372637	Predicted intracellular proteins	Evidence at protein level	CAB012217, HPA018798	Enhanced					Tissue enhanced	Tissue enriched	34	testis: 5.2	cervix, uterine,duodenum,spleen: 0.1	Cell line enhanced		CAPAN-2: 2.3
PIWIL2	CT80, FLJ10351, HILI, Mili	ENSG00000197181	Piwi like RNA-mediated gene silencing 2	8	22275297-22357563	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	9	testis: 53.4	duodenum: 6.1	Cell line enriched	21	NTERA-2: 38.0
PIWIL3	HIWI3	ENSG00000184571	Piwi like RNA-mediated gene silencing 3	22	24719034-24774720	Predicted intracellular proteins	Evidence at protein level	HPA061955	Uncertain					Not detected	Tissue enriched	13	testis: 1.7	skin: 0.1	Not detected		
PJA1	FLJ11830, RNF70	ENSG00000181191	Praja ring finger ubiquitin ligase 1	X	69160851-69165793	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000595	Enhanced		Approved	Nucleus<br>Nucleoli	Renal cancer:7.44e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 181.5	Cell line enhanced		HAP1: 88.6
PJA2	KIAA0438, Neurodap1, RNF131	ENSG00000198961	Praja ring finger ubiquitin ligase 2	5	109334709-109409994	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040347, HPA057636	Enhanced		Supported	Intermediate filaments	Ovarian cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 254.4	Expressed in all		
PKIA	PRKACN1	ENSG00000171033	CAMP-dependent protein kinase inhibitor alpha	8	78516139-78605267	Predicted intracellular proteins	Evidence at protein level	HPA042791	Uncertain				Stomach cancer:5.41e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 407.4	heart muscle,parathyroid gland: 123.6	Cell line enhanced		HUVEC TERT2: 86.5;RT4: 79.9
PKIB	PRKACN2	ENSG00000135549	CAMP-dependent protein kinase inhibitor beta	6	122471917-122726373	Predicted intracellular proteins	Evidence at protein level	HPA030156	Approved				Renal cancer:2.47e-7 (favourable), Liver cancer:4.72e-7 (unfavourable)	Expressed in all	Tissue enhanced		colon: 89.1;placenta: 85.4	parathyroid gland: 78.0	Cell line enhanced		AF22: 71.0;PC-3: 106.9;RPTEC TERT1: 141.0;SCLC-21H: 186.3
PKIG		ENSG00000168734	CAMP-dependent protein kinase inhibitor gamma	20	44531785-44624247	Predicted intracellular proteins	Evidence at protein level	HPA042703, HPA063690	Uncertain		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:4.90e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 177.2	Cell line enhanced		BJ hTERT+: 425.9
PKLR		ENSG00000143627	Pyruvate kinase, liver and RBC	1	155289839-155301434	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006653, CAB034376, CAB034378	Enhanced		Approved	Endoplasmic reticulum<br>Golgi apparatus		Tissue enriched	Tissue enhanced		kidney: 14.0;liver: 26.4	bone marrow: 7.8	Cell line enriched	16	K-562: 72.0
PKM	OIP3, PK3, PKM2, THBP1	ENSG00000067225	Pyruvate kinase, muscle	15	72199029-72231822	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB019421, HPA029501	Uncertain		Enhanced	Cytosol	Liver cancer:2.74e-6 (unfavourable), Pancreatic cancer:5.17e-5 (unfavourable), Head and neck cancer:1.30e-4 (unfavourable), Lung cancer:2.85e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 1492.3	Expressed in all		
PKN1	DBK, MGC46204, PAK1, PKN, PRK1, PRKCL1	ENSG00000123143	Protein kinase N1	19	14433053-14471867	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003982, CAB010278	Approved		Supported	Nucleus<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			spleen: 85.9	Expressed in all		
PKN3	PKNbeta, UTDP4-1	ENSG00000160447	Protein kinase N3	9	128702523-128720918	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045390, HPA058305	Uncertain		Approved	Vesicles		Expressed in all	Mixed			adipose tissue: 7.6	Cell line enhanced		HeLa: 45.8
PKNOX1	PREP1	ENSG00000160199	PBX/knotted 1 homeobox 1	21	42974510-43033931	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004285, HPA057215, HPA065017	Approved		Enhanced	Nucleoplasm	Liver cancer:4.54e-8 (unfavourable), Pancreatic cancer:6.71e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 16.8	Expressed in all		
PKNOX2		ENSG00000165495	PBX/knotted 1 homeobox 2	11	125164687-125433389	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028867, CAB034342, HPA055368, HPA066962	Supported		Enhanced	Nucleus<br>Cytokinetic bridge		Tissue enhanced	Mixed			thyroid gland: 20.1	Cell line enhanced		AF22: 38.2;AN3-CA: 9.0;LHCN-M2: 9.6;WM-115: 21.0
PKP1	B6P	ENSG00000081277	Plakophilin 1	1	201283452-201332993	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027221, HPA027589, CAB033130	Enhanced		Enhanced	Nucleoplasm		Tissue enhanced	Group enriched	11	esophagus: 281.6;skin: 821.6	prostate: 51.7	Cell line enhanced		HaCaT: 205.1;HBEC3-KT: 102.1;hTCEpi: 358.4;hTERT-HME1: 100.7;PC-3: 176.6
PKP2		ENSG00000057294	Plakophilin 2	12	32790745-32896840	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014314, CAB037336, HPA056908	Enhanced		Enhanced	Nucleoplasm<br>Cell Junctions	Lung cancer:6.79e-4 (unfavourable), Colorectal cancer:8.55e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 114.2;heart muscle: 123.3	parathyroid gland: 50.6	Cell line enhanced		CACO-2: 161.1
PKP3		ENSG00000184363	Plakophilin 3	11	392614-404908	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012993, HPA062937	Enhanced		Enhanced	Nucleoplasm<br>Cell Junctions<br>Cytosol	Lung cancer:2.89e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable), Pancreatic cancer:3.93e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 98.2;skin: 148.2	duodenum: 31.4	Cell line enhanced		A-431: 131.6;HaCaT: 174.9;SK-BR-3: 111.1
PKP4	p0071	ENSG00000144283	Plakophilin 4	2	158456964-158682879	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037334, HPA066647, HPA070648	Approved		Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:3.29e-7 (favourable), Endometrial cancer:5.80e-4 (favourable)	Expressed in all	Expressed in all			kidney: 65.6	Expressed in all		
PLA2G4A	cPLA2-alpha, PLA2G4	ENSG00000116711	Phospholipase A2 group IVA	1	186828953-186988981	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010050, HPA050062, HPA054206	Approved		Supported	Cytosol	Endometrial cancer:2.85e-4 (favourable), Breast cancer:9.07e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 200.5	seminal vesicle: 68.3	Cell line enhanced		RPMI-8226: 50.7;U-2197: 61.7
PLA2G4B	cPLA2-beta, HsT16992	ENSG00000243708	Phospholipase A2 group IVB	15	41837775-41848147	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Not detected	Tissue enhanced		skin: 36.3	esophagus: 14.1	Cell line enhanced		RT4: 5.9
PLA2G4C	cPLA2-gamma	ENSG00000105499	Phospholipase A2 group IVC	19	48047843-48110817	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA043083	Approved		Approved	Cytosol		Mixed	Mixed			parathyroid gland: 29.7	Cell line enhanced		HHSteC: 12.1;TIME: 17.1
PLA2G4D	cPLA2delta	ENSG00000159337	Phospholipase A2 group IVD	15	42067009-42094554	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Mixed	Group enriched	29	prostate: 34.2;skin: 16.5	esophagus: 0.8	Cell line enriched	30	RPMI-8226: 12.2
PLA2G4E	FLJ45651	ENSG00000188089	Phospholipase A2 group IVE	15	41981582-42051190	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA041105	Enhanced					Tissue enhanced	Tissue enriched	10	skin: 20.4	esophagus,tonsil: 2.0	Not detected		
PLA2G4F	PLA2G4F/Z	ENSG00000168907	Phospholipase A2 group IVF	15	42139034-42156636	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA042713, HPA056752	Enhanced		Approved	Nucleus<br>Vesicles	Endometrial cancer:2.00e-4 (unfavourable)	Mixed	Tissue enriched	5	skin: 92.5	lung: 18.4	Cell line enhanced		hTCEpi: 1.4;RT4: 6.6
PLAA	DOA1, FLJ11281, FLJ12699, PLA2P, PLAP	ENSG00000137055	Phospholipase A2 activating protein	9	26904083-26947463	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005035, HPA020994, HPA020996	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Ovarian cancer:7.87e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.9	Mixed		
PLAC8	C15, onzin	ENSG00000145287	Placenta specific 8	4	83090048-83137075	Predicted intracellular proteins	Evidence at protein level	HPA040465, HPA077912	Supported		Approved	Cytosol	Cervical cancer:3.03e-4 (favourable)	Mixed	Mixed			bone marrow: 235.8	Cell line enhanced		A-431: 158.5;CAPAN-2: 447.2;HL-60: 259.1;RPMI-8226: 161.8
PLAC8L1		ENSG00000173261	PLAC8 like 1	5	146084386-146104369	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	10	testis: 31.1	skin: 3.0	Cell line enhanced		AN3-CA: 5.5
PLAG1	ZNF912	ENSG00000181690	PLAG1 zinc finger	8	56160904-56211324	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA072290			Supported	Nuclear speckles		Mixed	Mixed			ovary: 5.9	Mixed		
PLAGL1	LOT1, ZAC	ENSG00000118495	PLAG1 like zinc finger 1	6	143940300-144064599	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055706			Supported	Nuclear bodies<br>Golgi apparatus<br>Vesicles	Renal cancer:4.94e-6 (unfavourable), Stomach cancer:6.61e-4 (unfavourable)	Mixed	Tissue enriched	5	placenta: 365.4	skin: 72.8	Cell line enhanced		AF22: 105.6;RH-30: 105.2
PLAGL2	ZNF900	ENSG00000126003	PLAG1 like zinc finger 2	20	32192503-32207791	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005900	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
PLCB1	KIAA0581, PLC-I, PLC154	ENSG00000182621	Phospholipase C beta 1	20	8077251-8968360	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004275, CAB005334, HPA034743, HPA057910	Enhanced		Approved	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 68.3;parathyroid gland: 121.3	placenta: 28.2	Cell line enhanced		Hep G2: 46.8
PLCB2	FLJ38135	ENSG00000137841	Phospholipase C beta 2	15	40278176-40307935	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009443, HPA041298	Approved		Approved	Cytosol	Renal cancer:7.20e-5 (unfavourable), Head and neck cancer:3.00e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 55.9	appendix: 38.2	Cell line enhanced		HEL: 70.2;HMC-1: 82.2;U-937: 41.8
PLCB3		ENSG00000149782	Phospholipase C beta 3	11	64251523-64269150	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009257, HPA039279, HPA043907	Enhanced		Enhanced	Nucleoplasm	Renal cancer:4.31e-5 (unfavourable), Liver cancer:1.39e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 114.9	Expressed in all		
PLCB4		ENSG00000101333	Phospholipase C beta 4	20	9068763-9481242	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007951	Supported		Approved	Nucleoplasm<br>Microtubules	Endometrial cancer:2.11e-4 (favourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 58.5	epididymis: 30.5	Cell line enhanced		fHDF/TERT166: 87.3;LHCN-M2: 74.5;RPTEC TERT1: 85.5
PLCD1		ENSG00000187091	Phospholipase C delta 1	3	38007496-38029762	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009913, HPA020107, HPA021677	Approved		Approved	Microtubules	Renal cancer:9.25e-11 (favourable)	Expressed in all	Mixed			testis: 38.3	Mixed		
PLCD3		ENSG00000161714	Phospholipase C delta 3	17	45108967-45133354	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025711, HPA053665	Approved		Approved	Plasma membrane	Lung cancer:2.89e-6 (unfavourable), Thyroid cancer:4.28e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 29.7	Mixed		
PLCD4		ENSG00000115556	Phospholipase C delta 4	2	218607765-218637184	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009914, HPA038139, HPA038140	Enhanced		Approved	Nuclear membrane<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		skeletal muscle: 38.4	testis: 9.7	Cell line enhanced		SH-SY5Y: 21.8
PLCE1	KIAA1516, NPHS3, PLCE	ENSG00000138193	Phospholipase C epsilon 1	10	94030812-94332823	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA015597, HPA015598	Enhanced		Supported	Cytosol		Expressed in all	Mixed			endometrium: 21.6	Cell line enhanced		RT4: 17.8;U-2 OS: 13.5
PLCG1	NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1	ENSG00000124181	Phospholipase C gamma 1	20	41136960-41196801	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004277, HPA036681, HPA036682	Approved		Supported	Cytosol	Pancreatic cancer:4.72e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 47.6	Expressed in all		
PLCG2		ENSG00000197943	Phospholipase C gamma 2	16	81739097-81962693	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004280, HPA020099, HPA020100	Enhanced		Approved	Vesicles	Renal cancer:4.88e-4 (favourable), Head and neck cancer:6.71e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 78.9	tonsil: 65.8	Cell line enhanced		Daudi: 130.7;HMC-1: 74.1;U-698: 278.1
PLCH1	DKFZp434C1372, KIAA1069, MGC117152, PLCeta1, PLCL3	ENSG00000114805	Phospholipase C eta 1	3	155375580-155745067	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036176, HPA057978	Uncertain		Enhanced	Vesicles	Renal cancer:3.03e-5 (favourable)	Mixed	Tissue enhanced		testis: 20.6	fallopian tube: 13.0	Cell line enhanced		AF22: 38.5;NTERA-2: 20.8
PLCH2	KIAA0450, PLC-eta2, PLCeta2, PLCL4, RP3-395M20.1	ENSG00000149527	Phospholipase C eta 2	1	2425980-2505530	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA072705	Approved					Mixed	Tissue enhanced		skin: 58.5	esophagus: 14.0	Cell line enhanced		HBEC3-KT: 91.6;hTCEpi: 42.6;hTERT-HME1: 26.9
PLCL1	PLC-L, PLCE, PLCL, PPP1R127, PRIP	ENSG00000115896	Phospholipase C like 1	2	197804702-198572581	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031849	Enhanced				Renal cancer:3.91e-7 (favourable)	Mixed	Mixed			kidney: 34.3	Cell line enhanced		HUVEC TERT2: 7.3;K-562: 13.7;Karpas-707: 7.9;MOLT-4: 8.6
PLCL2	KIAA1092, PLCE2	ENSG00000154822	Phospholipase C like 2	3	16802651-17090594	Predicted intracellular proteins	Evidence at protein level	HPA047616	Uncertain				Renal cancer:2.98e-10 (favourable)	Expressed in all	Mixed			ovary: 15.2	Cell line enhanced		Daudi: 17.6;HAP1: 25.5
PLCXD1	FLJ11323	ENSG00000182378	Phosphatidylinositol specific phospholipase C X domain containing 1	X	276322-303356	Predicted intracellular proteins	Evidence at protein level	HPA007721	Approved		Approved	Cytosol	Renal cancer:7.82e-14 (unfavourable), Head and neck cancer:2.50e-4 (favourable), Endometrial cancer:8.10e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 25.8	Expressed in all		
PLCXD2	FLJ31579	ENSG00000240891	Phosphatidylinositol specific phospholipase C X domain containing 2	3	111674676-111846447	Predicted intracellular proteins	Evidence at protein level	HPA055947	Uncertain		Approved	Nucleoplasm	Renal cancer:1.23e-7 (favourable), Urothelial cancer:2.99e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 6.4	lymph node: 3.3	Mixed		
PLCXD3		ENSG00000182836	Phosphatidylinositol specific phospholipase C X domain containing 3	5	41306954-41510628	Predicted intracellular proteins	Evidence at protein level	HPA046849	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		adrenal gland: 16.7;heart muscle: 22.0;ovary: 28.4	cerebral cortex: 8.3	Cell line enhanced		BJ hTERT+: 6.9;PC-3: 6.9;SH-SY5Y: 36.5;TIME: 15.0
PLCZ1	NYD-SP27, PLCzeta	ENSG00000139151	Phospholipase C zeta 1	12	18683169-18738057	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	23	testis: 48.5	skin: 2.1	Not detected		
PLD1		ENSG00000075651	Phospholipase D1	3	171600405-171810950	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004527, HPA042396	Enhanced		Approved	Plasma membrane	Urothelial cancer:4.76e-6 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 138.3	small intestine: 49.2	Cell line enhanced		HUVEC TERT2: 49.2;TIME: 42.2
PLD2		ENSG00000129219	Phospholipase D2	17	4807096-4823434	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA013397	Approved					Expressed in all	Expressed in all			esophagus: 42.5	Mixed		
PLEC	EBS1, PCN, PLEC1, PLTN	ENSG00000178209	Plectin	8	143915147-143976734	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003847, HPA025967, HPA029906	Enhanced		Enhanced	Intermediate filaments<br>Focal adhesion sites<br>Cytosol	Renal cancer:7.98e-6 (unfavourable), Colorectal cancer:4.29e-4 (unfavourable), Lung cancer:5.33e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 94.8	Expressed in all		
PLEK	P47	ENSG00000115956	Pleckstrin	2	68365173-68397453	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031838, HPA057341	Enhanced		Approved	Nucleoli	Renal cancer:1.95e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 371.1	lymph node: 142.4	Cell line enhanced		HEL: 475.7;HMC-1: 170.8;THP-1: 139.2;U-937: 256.0
PLEK2		ENSG00000100558	Pleckstrin 2	14	67386983-67412200	Predicted intracellular proteins	Evidence at protein level	HPA001208	Enhanced		Uncertain	Vesicles<br>Cytosol	Pancreatic cancer:8.26e-5 (unfavourable), Lung cancer:1.58e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 43.1	Cell line enhanced		A-431: 77.9;CAPAN-2: 81.3;HBEC3-KT: 124.1
PLEKHA1	TAPP1	ENSG00000107679	Pleckstrin homology domain containing A1	10	122374696-122442602	Predicted intracellular proteins	Evidence at protein level	HPA002043, HPA064795	Approved		Enhanced	Nucleus<br>Cytosol		Expressed in all	Expressed in all			skin: 79.2	Cell line enhanced		RPTEC TERT1: 153.9
PLEKHA2	TAPP2	ENSG00000169499	Pleckstrin homology domain containing A2	8	38901235-38973909	Predicted intracellular proteins	Evidence at protein level	HPA004706	Approved		Uncertain	Nucleus<br>Nuclear bodies<br>Cytosol	Renal cancer:1.95e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 91.8	Cell line enhanced		Daudi: 113.1
PLEKHA3	FAPP1	ENSG00000116095	Pleckstrin homology domain containing A3	2	178480468-178516462	Predicted intracellular proteins	Evidence at protein level	HPA034496, HPA034497	Approved		Enhanced	Golgi apparatus		Expressed in all	Mixed			testis: 15.1	Mixed		
PLEKHA4	PEPP1	ENSG00000105559	Pleckstrin homology domain containing A4	19	48837097-48868632	Predicted intracellular proteins	Evidence at protein level	HPA042978, HPA048473	Uncertain		Approved	Plasma membrane<br>Cytokinetic bridge<br>Centrosome<br>Cytosol	Breast cancer:1.97e-4 (favourable), Liver cancer:8.68e-4 (unfavourable)	Expressed in all	Mixed			ovary: 22.3	Cell line enhanced		AN3-CA: 58.6;BJ hTERT+ SV40 Large T+ RasG12V: 48.0;SK-MEL-30: 57.7
PLEKHA5	FLJ10667, KIAA1686, PEPP2	ENSG00000052126	Pleckstrin homology domain containing A5	12	19129752-19376400	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035923, HPA035924, HPA041455	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.41e-5 (unfavourable), Renal cancer:7.42e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 55.1	Cell line enhanced		HDLM-2: 61.6;NTERA-2: 64.9
PLEKHA6	KIAA0969, PEPP3	ENSG00000143850	Pleckstrin homology domain containing A6	1	204218851-204377665	Predicted intracellular proteins	Evidence at protein level	HPA028152, HPA054311	Approved		Supported	Vesicles<br>Cell Junctions<br>Microtubule organizing center	Urothelial cancer:3.57e-4 (favourable)	Expressed in all	Mixed			stomach: 40.6	Cell line enhanced		BEWO: 88.4;CAPAN-2: 75.9;PC-3: 64.5;RT4: 62.5
PLEKHA7	DKFZp686M22243	ENSG00000166689	Pleckstrin homology domain containing A7	11	16777317-17014443	Predicted intracellular proteins	Evidence at protein level	HPA038610, HPA066103	Approved		Supported	Nucleus<br>Cell Junctions<br>Cytosol	Renal cancer:1.89e-15 (favourable)	Mixed	Mixed			parathyroid gland: 50.8	Cell line enhanced		CAPAN-2: 113.7;HaCaT: 75.7;RT4: 94.4
PLEKHA8	FAPP2, MGC3358	ENSG00000106086	Pleckstrin homology domain containing A8	7	30027404-30130483	Predicted intracellular proteins	Evidence at protein level	HPA072314			Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			placenta: 11.6	Mixed		
PLEKHB1	KPL1, PHR1, PHRET1	ENSG00000021300	Pleckstrin homology domain containing B1	11	73646178-73662819	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.99e-6 (favourable), Pancreatic cancer:6.02e-4 (favourable)	Expressed in all	Group enriched	7	cerebral cortex: 494.8;parathyroid gland: 148.4	thyroid gland: 48.4	Cell line enhanced		EFO-21: 18.8;Hep G2: 52.2;U-266/84: 21.1
PLEKHB2	EVT2, FLJ20783	ENSG00000115762	Pleckstrin homology domain containing B2	2	131104847-131353709	Predicted intracellular proteins	Evidence at protein level	HPA075014	Approved				Renal cancer:1.72e-8 (favourable), Liver cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 125.3	Expressed in all		
PLEKHD1	UPF0639	ENSG00000175985	Pleckstrin homology and coiled-coil domain containing D1	14	69484692-69531551	Predicted intracellular proteins	Evidence at protein level	HPA051875	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 2.8;thyroid gland: 2.7	epididymis: 2.0	Cell line enhanced		SK-BR-3: 1.8;T-47d: 2.1
PLEKHF1	APPD, MGC4090, PHAFIN1, ZFYVE15	ENSG00000166289	Pleckstrin homology and FYVE domain containing 1	19	29665056-29675457	Predicted intracellular proteins	Evidence at protein level	HPA025925	Uncertain				Renal cancer:1.54e-5 (unfavourable), Urothelial cancer:4.54e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 18.6	Cell line enhanced		BEWO: 33.0
PLEKHF2	FLJ13187, PHAFIN2, ZFYVE18	ENSG00000175895	Pleckstrin homology and FYVE domain containing 2	8	95133804-95156684	Predicted intracellular proteins	Evidence at protein level	HPA024829	Uncertain				Renal cancer:1.49e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 62.6	Expressed in all		
PLEKHG1	ARHGEF41, KIAA1209	ENSG00000120278	Pleckstrin homology and RhoGEF domain containing G1	6	150599883-150843665	Predicted intracellular proteins	Evidence at protein level	HPA027128, HPA027319, HPA028270	Approved		Enhanced	Nucleoplasm		Expressed in all	Tissue enhanced		spleen: 48.4	lymph node: 23.1	Cell line enhanced		AF22: 18.8;HAP1: 29.5;Karpas-707: 16.8
PLEKHG2	ARHGEF42, CLG, FLJ00018	ENSG00000090924	Pleckstrin homology and RhoGEF domain containing G2	19	39412585-39428415	Predicted intracellular proteins	Evidence at protein level	HPA017973, HPA048054	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.79e-8 (unfavourable), Colorectal cancer:3.53e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.2	Expressed in all		
PLEKHG3	ARHGEF43, KIAA0599	ENSG00000126822	Pleckstrin homology and RhoGEF domain containing G3	14	64704102-64750247	Predicted intracellular proteins	Evidence at protein level	HPA063455, HPA065323, HPA073702, HPA074734	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytokinetic bridge<br>Centrosome<br>Cytosol	Renal cancer:7.39e-8 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 53.5	Mixed		
PLEKHG4	ARHGEF44, DKFZP434I216, SCA4	ENSG00000196155	Pleckstrin homology and RhoGEF domain containing G4	16	67277510-67289499	Predicted intracellular proteins	Evidence at protein level	HPA055696			Approved	Cell Junctions	Renal cancer:6.72e-9 (unfavourable)	Expressed in all	Tissue enhanced		testis: 41.5	ovary: 18.8	Mixed		
PLEKHG4B	KIAA1909	ENSG00000153404	Pleckstrin homology and RhoGEF domain containing G4B	5	92151-189972	Predicted intracellular proteins	Evidence at protein level	HPA036274, HPA058157	Uncertain		Approved	Nucleoplasm	Lung cancer:3.47e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 5.2	testis: 3.2	Cell line enhanced		REH: 30.0;SCLC-21H: 16.5;T-47d: 17.9
PLEKHG5	GEF720, KIAA0720, Syx, Tech	ENSG00000171680	Pleckstrin homology and RhoGEF domain containing G5	1	6466092-6520061	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049570	Uncertain		Approved	Nucleus	Glioma:8.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 110.9	spleen: 34.6	Mixed		
PLEKHG6	FLJ10665, MYOGEF	ENSG00000008323	Pleckstrin homology and RhoGEF domain containing G6	12	6310436-6328506	Predicted intracellular proteins	Evidence at protein level	HPA041459, HPA058230	Uncertain		Supported	Cell Junctions<br>Centrosome		Mixed	Tissue enhanced		small intestine: 47.7	duodenum: 36.5	Cell line enhanced		BEWO: 147.7;CACO-2: 41.4;RT4: 42.4
PLEKHG7	FLJ46688	ENSG00000187510	Pleckstrin homology and RhoGEF domain containing G7	12	92721462-92772455	Predicted intracellular proteins	Evidence at transcript level	HPA060632	Uncertain					Mixed	Tissue enhanced		epididymis: 3.6;fallopian tube: 4.3	cervix, uterine: 2.6	Cell line enhanced		RPMI-8226: 1.1
PLEKHH1	KIAA1200	ENSG00000054690	Pleckstrin homology, MyTH4 and FERM domain containing H1	14	67533301-67589612	Predicted intracellular proteins	Evidence at protein level	HPA047707, HPA051964	Uncertain		Approved	Centrosome	Renal cancer:4.03e-7 (favourable), Endometrial cancer:8.03e-5 (favourable), Urothelial cancer:2.26e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 43.3;thyroid gland: 51.2	prostate: 16.7	Cell line enhanced		AN3-CA: 9.4;BEWO: 9.4;SK-MEL-30: 9.8;T-47d: 9.1
PLEKHH2	KIAA2028, PLEKHH1L	ENSG00000152527	Pleckstrin homology, MyTH4 and FERM domain containing H2	2	43637273-43767987	Predicted intracellular proteins	Evidence at protein level	HPA077225			Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol		Tissue enhanced	Mixed			endometrium: 32.1	Mixed		
PLEKHH3	FLJ21019	ENSG00000068137	Pleckstrin homology, MyTH4 and FERM domain containing H3	17	42667914-42676994	Predicted intracellular proteins	Evidence at protein level	HPA046234	Uncertain		Approved	Golgi apparatus	Renal cancer:9.62e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 11.6	Cell line enhanced		T-47d: 46.9
PLEKHJ1	FLJ10297	ENSG00000104886	Pleckstrin homology domain containing J1	19	2230084-2237704	Predicted intracellular proteins	Evidence at protein level	HPA048989	Approved		Approved	Mitochondria	Renal cancer:1.10e-5 (favourable), Stomach cancer:6.99e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 107.8	Expressed in all		
PLEKHM1	KIAA0356	ENSG00000225190	Pleckstrin homology and RUN domain containing M1	17	45435900-45490749	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA025018, HPA039473	Approved		Supported	Nucleoli<br>Vesicles	Endometrial cancer:1.28e-6 (favourable), Liver cancer:3.25e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 11.8	Mixed		
PLEKHM2	KIAA0842	ENSG00000116786	Pleckstrin homology and RUN domain containing M2	1	15684332-15734769	Predicted intracellular proteins	Evidence at protein level	HPA032304	Approved				Liver cancer:1.36e-8 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 50.0	Expressed in all		
PLEKHM3	DAPR, PLEKHM1L	ENSG00000178385	Pleckstrin homology domain containing M3	2	207821288-208025560	Predicted intracellular proteins	Evidence at protein level	HPA035046	Uncertain		Approved	Vesicles<br>Cytosol		Mixed	Mixed			parathyroid gland: 18.9	Mixed		
PLEKHN1	DKFZP434H2010	ENSG00000187583	Pleckstrin homology domain containing N1	1	966497-975865	Predicted intracellular proteins	Evidence at protein level	HPA031742	Uncertain		Approved	Nuclear speckles	Renal cancer:4.97e-5 (unfavourable)	Mixed	Group enriched	11	esophagus: 16.9;skin: 44.0	urinary bladder: 2.7	Cell line enhanced		HaCaT: 22.0
PLEKHO1	CKIP-1, OC120	ENSG00000023902	Pleckstrin homology domain containing O1	1	150149183-150164720	Predicted intracellular proteins	Evidence at protein level	HPA061018			Supported	Mitochondria	Renal cancer:6.47e-11 (unfavourable)	Expressed in all	Mixed			appendix: 78.1	Mixed		
PLEKHO2	DKFZp761K2312, PLEKHQ1, PP1628, pp9099	ENSG00000241839	Pleckstrin homology domain containing O2	15	64841883-64868007	Predicted intracellular proteins	Evidence at protein level	HPA040055	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			spleen: 119.5	Mixed		
PLEKHS1	bA211N11.2, C10orf81, FLJ23537	ENSG00000148735	Pleckstrin homology domain containing S1	10	113751454-113783429	Predicted intracellular proteins	Evidence at protein level	HPA037583			Supported	Centrosome	Urothelial cancer:1.03e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 88.6	duodenum: 41.1	Cell line enhanced		CAPAN-2: 7.3;RH-30: 3.8;RT4: 12.5;T-47d: 4.9
PLGRKT	AD025, C9orf46, FLJ14688, MDS030, Plg-RKT	ENSG00000107020	Plasminogen receptor with a C-terminal lysine	9	5357973-5437878	Predicted intracellular proteins	Evidence at protein level	HPA008214, HPA011144	Enhanced		Uncertain	Mitochondria	Renal cancer:5.09e-5 (favourable), Breast cancer:5.56e-4 (favourable)	Expressed in all	Expressed in all			rectum: 55.2	Cell line enhanced		HDLM-2: 245.6
PLIN2	ADFP, ADRP	ENSG00000147872	Perilipin 2	9	19108375-19149290	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016607, CAB037331	Supported		Supported	Lipid droplets	Thyroid cancer:2.16e-4 (favourable), Renal cancer:3.32e-4 (unfavourable)	Group enriched	Expressed in all			liver: 450.7	Cell line enhanced		ASC diff: 1543.1;HHSteC: 1631.5
PLIN3	M6PRBP1, PP17, TIP47	ENSG00000105355	Perilipin 3	19	4838341-4867768	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006427, HPA066538	Uncertain		Enhanced	Lipid droplets<br>Cytosol	Renal cancer:9.15e-7 (unfavourable), Lung cancer:7.67e-6 (unfavourable), Liver cancer:3.27e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 115.7	Expressed in all		
PLIN4	KIAA1881, S3-12	ENSG00000167676	Perilipin 4	19	4502180-4518465	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044682, HPA054657	Enhanced		Supported	Vesicles<br>Lipid droplets<br>Plasma membrane<br>Cytosol	Endometrial cancer:2.31e-4 (unfavourable), Colorectal cancer:8.31e-4 (unfavourable)	Mixed	Tissue enriched	14	adipose tissue: 812.2	skeletal muscle: 59.1	Cell line enriched	7	ASC diff: 171.0
PLIN5	LSDA5, LSDP5, MLDP, OXPAT	ENSG00000214456	Perilipin 5	19	4522531-4535224	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.97e-4 (favourable), Urothelial cancer:2.16e-4 (favourable), Liver cancer:2.81e-4 (favourable), Breast cancer:7.68e-4 (favourable), Endometrial cancer:8.56e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 34.5;ovary: 42.4	salivary gland: 25.8	Cell line enhanced		BEWO: 3.2;SH-SY5Y: 3.0;T-47d: 5.9
PLK1	PLK	ENSG00000166851	Polo like kinase 1	16	23677656-23690367	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051638, HPA053229	Approved				Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.70e-7 (unfavourable), Lung cancer:2.28e-5 (unfavourable), Pancreatic cancer:4.12e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 44.2	lymph node: 32.8	Expressed in all		
PLK2	SNK	ENSG00000145632	Polo like kinase 2	5	58453982-58460260	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009624, HPA069329	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:2.08e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 96.0	Cell line enhanced		T-47d: 343.8
PLK3	CNK, FNK, PRK	ENSG00000173846	Polo like kinase 3	1	44800225-44805990	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060318	Enhanced				Renal cancer:1.75e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 24.3	Mixed		
PLK4	Sak, STK18	ENSG00000142731	Polo like kinase 4	4	127880861-127899195	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017327, HPA035026, HPA043198	Approved		Supported	Centrosome<br>Cytosol	Colorectal cancer:7.46e-5 (favourable), Lung cancer:5.13e-4 (unfavourable), Pancreatic cancer:5.14e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 40.9	bone marrow: 13.9	Mixed		
PLK5	PLK5P, SgK384ps	ENSG00000185988	Polo like kinase 5	19	1524074-1535456	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035024	Enhanced					Mixed	Tissue enhanced		cervix, uterine: 4.5;endometrium: 4.7;testis: 6.9	epididymis: 3.3	Not detected		
PLRG1	Cwc1, PRL1, Prp46, PRPF46, TANGO4	ENSG00000171566	Pleiotropic regulator 1	4	154535006-154550435	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035931, HPA035932, HPA061486	Supported		Enhanced	Nuclear membrane<br>Nuclear speckles	Renal cancer:8.20e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 67.1	Expressed in all		
PLS1	I-plastin, Plastin-1	ENSG00000120756	Plastin 1	3	142596387-142713664	Predicted intracellular proteins	Evidence at protein level	HPA055744	Enhanced				Renal cancer:8.76e-6 (favourable), Pancreatic cancer:4.84e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 192.4;small intestine: 348.5	rectum: 152.0	Cell line enhanced		BEWO: 108.3;RPTEC TERT1: 108.5
PLS3	T-plastin	ENSG00000102024	Plastin 3	X	115561174-115650861	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020433, HPA076083	Enhanced		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:6.07e-5 (unfavourable), Renal cancer:1.01e-4 (unfavourable), Thyroid cancer:3.72e-4 (favourable), Pancreatic cancer:4.59e-4 (unfavourable), Urothelial cancer:7.04e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 293.0	Mixed		
PLSCR1	MMTRA1B	ENSG00000188313	Phospholipid scramblase 1	3	146515180-146544864	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA068923, CAB070421	Approved		Supported	Nucleus<br>Golgi apparatus<br>Plasma membrane	Endometrial cancer:1.35e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 114.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 292.9;BJ hTERT+ SV40 Large T+ RasG12V: 404.0;SK-MEL-30: 418.1
PLSCR2		ENSG00000163746	Phospholipid scramblase 2	3	146391421-146495991	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	10	testis: 23.5	epididymis: 2.2	Not detected		
PM20D2	ACY1L2, bA63L7.3	ENSG00000146281	Peptidase M20 domain containing 2	6	89146050-89165565	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030325, HPA030326, HPA030327	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			prostate: 41.1	Mixed		
PMAIP1	APR, NOXA	ENSG00000141682	Phorbol-12-myristate-13-acetate-induced protein 1	18	59899948-59904306	Predicted intracellular proteins	Evidence at protein level	HPA051063	Uncertain		Approved	Vesicles	Renal cancer:3.15e-6 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 55.8	placenta: 18.4	Cell line enhanced		U-138 MG: 194.4
PMF1		ENSG00000160783	Polyamine modulated factor 1	1	156212993-156240042	Predicted intracellular proteins	Evidence at protein level	HPA034583, HPA071854			Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			thyroid gland: 68.6	Expressed in all		
PMF1-BGLAP		ENSG00000260238	PMF1-BGLAP readthrough	1	156212982-156243332	Predicted intracellular proteins	Evidence at protein level	HPA034583, HPA071854			Approved	Nucleoplasm<br>Vesicles	Liver cancer:1.50e-4 (unfavourable), Renal cancer:3.22e-4 (unfavourable)	Mixed	Mixed			fallopian tube: 8.2	Expressed in all		
PMFBP1		ENSG00000118557	Polyamine modulated factor 1 binding protein 1	16	72112157-72176878	Predicted intracellular proteins	Evidence at protein level	HPA056716			Approved	Endoplasmic reticulum		Mixed	Tissue enhanced		epididymis: 16.0;testis: 32.3	skin: 5.3	Cell line enhanced		SCLC-21H: 25.3;SH-SY5Y: 11.4
PML	MYL, RNF71, TRIM19	ENSG00000140464	Promyelocytic leukemia	15	73994673-74047812	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008312, CAB010194, CAB016304	Supported		Enhanced	Nuclear bodies	Renal cancer:6.27e-8 (unfavourable), Breast cancer:3.24e-4 (favourable), Pancreatic cancer:3.29e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 45.1	Expressed in all		
PMM1	Sec53	ENSG00000100417	Phosphomannomutase 1	22	41576894-41589890	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030712	Uncertain				Endometrial cancer:6.09e-6 (favourable), Pancreatic cancer:2.05e-4 (favourable), Cervical cancer:5.92e-4 (favourable)	Expressed in all	Expressed in all			ovary: 54.9	Expressed in all		
PMM2	CDG1, CDG1a, CDGS, PMI, PMI1	ENSG00000140650	Phosphomannomutase 2	16	8788823-8849331	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040852, HPA063649	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:8.97e-6 (unfavourable), Colorectal cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			rectum: 28.3	Expressed in all		
PMP2	FABP8, M-FABP, MP2	ENSG00000147588	Peripheral myelin protein 2	8	81440326-81447523	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	55	cerebral cortex: 288.6	seminal vesicle: 5.2	Cell line enhanced		WM-115: 1.3
PMPCA	Alpha-MPP, INPP5E, KIAA0123	ENSG00000165688	Peptidase, mitochondrial processing alpha subunit	9	136410570-136423761	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021648, HPA063735	Enhanced		Enhanced	Mitochondria	Renal cancer:2.14e-6 (favourable), Pancreatic cancer:8.00e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 38.6	Expressed in all		
PMPCB	MPPB, MPPP52	ENSG00000105819	Peptidase, mitochondrial processing beta subunit	7	103297422-103329511	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040674, HPA074168	Approved		Supported	Mitochondria	Renal cancer:2.95e-8 (favourable), Breast cancer:2.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 70.0	Expressed in all		
PMS1	MLH2, PMSL1	ENSG00000064933	PMS1 homolog 1, mismatch repair system component	2	189784085-189877629	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010233, HPA031013	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.86e-6 (unfavourable), Liver cancer:2.38e-6 (unfavourable), Urothelial cancer:3.73e-4 (favourable)	Expressed in all	Expressed in all			testis: 85.0	Expressed in all		
PMS2	H_DJ0042M02.9, HNPCC4, MLH4, PMSL2	ENSG00000122512	PMS1 homolog 2, mismatch repair system component	7	5973239-6009125	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB010235, HPA044400, HPA066490, HPA070310	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.23e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 20.2	Expressed in all		
PMVK	HUMPMKI, PMK, PMKA	ENSG00000163344	Phosphomevalonate kinase	1	154924734-154936991	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029900	Approved				Renal cancer:4.96e-4 (favourable), Ovarian cancer:9.70e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.5	Expressed in all		
PNCK	CaMK1b, MGC45419	ENSG00000130822	Pregnancy up-regulated nonubiquitous CaM kinase	X	153669730-153689010	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007458	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.04e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 40.5;seminal vesicle: 52.3	smooth muscle: 22.4	Cell line enriched	7	AN3-CA: 29.8
PNISR	bA98I9.2, C6orf111, DKFZp564B0769, FLJ14752, SFRS18, SRrp130	ENSG00000132424	PNN interacting serine and arginine rich protein	6	99398051-99425331	Predicted intracellular proteins	Evidence at protein level	HPA038796	Uncertain		Supported	Nuclear speckles<br>Cytosol	Urothelial cancer:1.09e-4 (favourable), Renal cancer:1.41e-4 (unfavourable), Pancreatic cancer:5.27e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 127.1	Expressed in all		
PNKP	PNK	ENSG00000039650	Polynucleotide kinase 3'-phosphatase	19	49859882-49878351	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006782	Supported		Supported	Nucleus<br>Nucleoli	Breast cancer:9.18e-4 (favourable)	Expressed in all	Expressed in all			spleen: 38.1	Expressed in all		
PNMA1	MA1	ENSG00000176903	Paraneoplastic Ma antigen 1	14	73711783-73714372	Predicted intracellular proteins	Evidence at protein level	HPA003817, HPA015007	Enhanced		Supported	Focal adhesion sites<br>Cytosol	Liver cancer:3.00e-5 (unfavourable), Urothelial cancer:4.51e-5 (unfavourable), Head and neck cancer:7.49e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 193.5	Mixed		
PNMA2	MA2, RGAG2	ENSG00000240694	Paraneoplastic Ma antigen 2	8	26504686-26514092	Predicted intracellular proteins	Evidence at protein level	HPA001936	Enhanced				Lung cancer:1.81e-4 (favourable), Stomach cancer:6.23e-4 (unfavourable)	Tissue enhanced	Tissue enriched	12	cerebral cortex: 163.4	adrenal gland: 13.5	Cell line enhanced		AF22: 59.2;HAP1: 38.7;SH-SY5Y: 45.6
PNMA3	MA3, MA5, MGC132756, MGC132758	ENSG00000183837	Paraneoplastic Ma antigen 3	X	153056409-153060467	Predicted intracellular proteins	Evidence at transcript level	HPA047920	Approved				Endometrial cancer:4.14e-5 (unfavourable)	Mixed	Group enriched	13	cerebral cortex: 15.4;epididymis: 45.4;testis: 12.3	fallopian tube: 1.8	Cell line enhanced		NTERA-2: 3.2;SCLC-21H: 1.2
PNMA5	KIAA1934	ENSG00000198883	Paraneoplastic Ma antigen family member 5	X	152988824-152994127	Predicted intracellular proteins	Evidence at protein level	HPA044690	Enhanced				Colorectal cancer:2.25e-4 (unfavourable), Lung cancer:3.16e-4 (favourable)	Mixed	Group enriched	20	cerebral cortex: 8.1;testis: 16.3	skin,spleen: 0.5	Group enriched	495	HMC-1: 311.7;U-266/70: 426.0;U-266/84: 249.2
PNMA6A	MGC15827, PNMA6C	ENSG00000235961	Paraneoplastic Ma antigen family member 6A	X	153072482-153075018	Predicted intracellular proteins	Evidence at protein level	HPA045007, HPA052115	Uncertain		Uncertain	Nucleoli<br>Mitochondria	Renal cancer:1.93e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 22.9	epididymis: 7.3	Cell line enhanced		HHSteC: 6.4;U-2 OS: 15.5
PNMAL1	FLJ10781, KIAA1183L	ENSG00000182013	Paraneoplastic Ma antigen family like 1	19	46466491-46471563	Predicted intracellular proteins	Evidence at protein level	HPA012956	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 133.9	testis: 42.5	Cell line enhanced		HAP1: 33.8;K-562: 32.4;LHCN-M2: 29.9;SH-SY5Y: 33.2
PNMAL2	KIAA1183	ENSG00000204851	Paraneoplastic Ma antigen family like 2	19	46486906-46496498	Predicted intracellular proteins	Evidence at protein level	HPA054810	Enhanced					Mixed	Group enriched	5	adrenal gland: 12.1;cerebral cortex: 32.9	ovary: 4.3	Cell line enhanced		AF22: 1.2;AN3-CA: 1.4;SH-SY5Y: 1.3
PNMT	PENT	ENSG00000141744	Phenylethanolamine N-methyltransferase	17	39667981-39670475	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017029, HPA043412, HPA051005	Enhanced				Endometrial cancer:3.95e-5 (unfavourable)	Tissue enhanced	Tissue enriched	8	adrenal gland: 226.6	seminal vesicle: 29.2	Cell line enhanced		HEL: 4.8;K-562: 10.4;NB-4: 14.5;SCLC-21H: 7.0;SH-SY5Y: 5.8
PNN	memA	ENSG00000100941	Pinin, desmosome associated protein	14	39175183-39183218	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001378	Supported		Enhanced	Nuclear speckles	Prostate cancer:2.44e-4 (unfavourable), Liver cancer:5.79e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 143.3	Expressed in all		
PNO1	KHRBP1, RRP20	ENSG00000115946	Partner of NOB1 homolog	2	68157844-68176238	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056928			Supported	Nucleus<br>Nucleoli	Liver cancer:3.04e-8 (unfavourable), Endometrial cancer:1.12e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 20.8	Expressed in all		
PNPLA1	dJ50J22.1, FLJ38755	ENSG00000180316	Patatin like phospholipase domain containing 1	6	36243203-36312229	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037853			Uncertain	Intermediate filaments		Mixed	Tissue enriched	6	skin: 35.0	kidney: 5.6	Cell line enriched	5	U-937: 15.5
PNPLA2	ATGL, desnutrin, FP17548, iPLA2zeta, TTS-2.2	ENSG00000177666	Patatin like phospholipase domain containing 2	11	818902-825573	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA055173, HPA062602			Enhanced	Nucleoplasm<br>Lipid droplets		Expressed in all	Tissue enriched	13	adipose tissue: 420.0	skeletal muscle: 33.4	Expressed in all		
PNPLA3	adiponutrin, ADPN, C22orf20, dJ796I17.1, FLJ22012, iPLA2epsilon	ENSG00000100344	Patatin like phospholipase domain containing 3	22	43923739-43964488	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA058058	Approved		Approved	Nucleoli<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		liver: 16.2	kidney: 4.7	Mixed		
PNPLA5	dJ388M5.4, GS2L	ENSG00000100341	Patatin like phospholipase domain containing 5	22	43879678-43892013	Predicted intracellular proteins	Evidence at transcript level	HPA050409, HPA054211	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 1.1;epididymis: 2.1	skin: 0.7	Cell line enhanced		NTERA-2: 1.4;RPMI-8226: 1.9;SCLC-21H: 1.0
PNPO	PDXPO	ENSG00000108439	Pyridoxamine 5'-phosphate oxidase	17	47941506-47948288	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023204, HPA027776	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			liver: 51.3	Mixed		
PNPT1	DFNB70, old-35, OLD35, PNPase	ENSG00000138035	Polyribonucleotide nucleotidyltransferase 1	2	55634265-55693910	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033424, HPA034602, HPA034603	Supported		Enhanced	Mitochondria	Liver cancer:1.95e-7 (unfavourable), Pancreatic cancer:5.44e-5 (unfavourable), Endometrial cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 9.9	Expressed in all		
PNRC1	B4-2, PROL2, PRR2	ENSG00000146278	Proline rich nuclear receptor coactivator 1	6	89080751-89085160	Predicted intracellular proteins	Evidence at protein level	HPA029839, HPA066513	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:6.88e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 272.4	Expressed in all		
PNRC2		ENSG00000189266	Proline rich nuclear receptor coactivator 2	1	23959109-23963462	Predicted intracellular proteins	Evidence at protein level	HPA027820, HPA045837	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:7.97e-5 (unfavourable), Melanoma:1.41e-4 (unfavourable), Urothelial cancer:4.05e-4 (favourable), Breast cancer:6.02e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 203.4	Expressed in all		
POC1A	DKFZP434C245, WDR51A	ENSG00000164087	POC1 centriolar protein A	3	52075253-52154690	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040600	Approved				Renal cancer:9.43e-7 (unfavourable), Pancreatic cancer:1.76e-4 (unfavourable), Colorectal cancer:1.78e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 23.1	bone marrow: 7.0	Expressed in all		
POC1B	FLJ14923, TUWD12, WDR51B	ENSG00000139323	POC1 centriolar protein B	12	89419718-89526024	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.45e-6 (favourable), Endometrial cancer:9.59e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 19.8	Expressed in all		
POC1B-GALNT4		ENSG00000259075	POC1B-GALNT4 readthrough	12	89519408-89526262	Predicted intracellular proteins	Evidence at transcript level	HPA076116						Not detected	Mixed			appendix,gallbladder: 2.2	Cell line enhanced		AN3-CA: 10.0
POC5	C5orf37, FLJ35779, hPOC5, MGC120442, MGC120443, MGC120444	ENSG00000152359	POC5 centriolar protein	5	75674124-75717481	Predicted intracellular proteins	Evidence at protein level	HPA037509, HPA037510, HPA061521	Approved		Approved	Nucleus	Liver cancer:1.60e-7 (unfavourable), Renal cancer:6.74e-5 (unfavourable), Urothelial cancer:1.09e-4 (favourable)	Expressed in all	Mixed			testis: 36.2	Expressed in all		
PODN	MGC24995, PCAN, PODOCAN, SLRR5A	ENSG00000174348	Podocan	1	53062052-53085502	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.02e-5 (unfavourable), Endometrial cancer:1.54e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 161.0	ovary: 107.6	Cell line enhanced		BJ: 33.5;fHDF/TERT166: 18.5;HHSteC: 78.9;U-2197: 43.8
POF1B	FLJ22792, POF	ENSG00000124429	Premature ovarian failure, 1B	X	85277396-85379743	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002033, HPA050027	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:2.03e-4 (unfavourable), Endometrial cancer:3.08e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		skin: 144.4	rectum: 52.8	Cell line enhanced		A549: 19.6;CAPAN-2: 19.5;HaCaT: 19.9;RT4: 60.9
POGK	BASS2, KIAA15131, KRBOX2, LST003	ENSG00000143157	Pogo transposable element with KRAB domain	1	166839447-166856344	Predicted intracellular proteins	Evidence at protein level	HPA007838, HPA031630	Approved		Supported	Nucleoplasm<br>Vesicles	Liver cancer:5.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.2	Expressed in all		
POGZ	KIAA0461, ZNF280E, ZNF635m	ENSG00000143442	Pogo transposable element with ZNF domain	1	151402724-151459465	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006800, HPA008781	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.92e-5 (unfavourable), Urothelial cancer:4.40e-4 (favourable), Endometrial cancer:8.67e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 76.7	Expressed in all		
POLA1	NSX, p180, POLA	ENSG00000101868	DNA polymerase alpha 1, catalytic subunit	X	24693919-24996986	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002947, CAB012274	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.80e-5 (unfavourable)	Expressed in all	Mixed			lymph node: 8.7	Expressed in all		
POLA2	FLJ21662	ENSG00000014138	DNA polymerase alpha 2, accessory subunit	11	65261762-65305589	Predicted intracellular proteins	Evidence at protein level	HPA037570	Enhanced		Supported	Nucleoplasm	Renal cancer:4.09e-8 (unfavourable), Liver cancer:2.11e-6 (unfavourable), Cervical cancer:4.61e-4 (favourable)	Expressed in all	Mixed			lymph node,tonsil: 12.5	Expressed in all		
POLB		ENSG00000070501	DNA polymerase beta	8	42338454-42371808	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011616, HPA049104	Enhanced		Approved	Vesicles	Renal cancer:2.15e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Urothelial cancer:5.65e-4 (favourable)	Expressed in all	Expressed in all			testis: 92.7	Expressed in all		
POLD1	CDC2, POLD	ENSG00000062822	DNA polymerase delta 1, catalytic subunit	19	50384204-50418018	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004375, HPA046524	Enhanced		Supported	Nucleoplasm	Liver cancer:2.87e-6 (unfavourable)	Expressed in all	Mixed			bone marrow: 21.4	Expressed in all		
POLD2		ENSG00000106628	DNA polymerase delta 2, accessory subunit	7	44114681-44124358	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026745	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			fallopian tube: 122.1	Expressed in all		
POLD3	KIAA0039, P66, P68, PPP1R128	ENSG00000077514	DNA polymerase delta 3, accessory subunit	11	74493851-74669117	Predicted intracellular proteins	Evidence at protein level	HPA058846	Enhanced		Supported	Nucleus	Renal cancer:7.90e-6 (unfavourable), Melanoma:5.48e-4 (unfavourable), Liver cancer:9.17e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 45.6	Expressed in all		
POLD4	p12, POLDS	ENSG00000175482	DNA polymerase delta 4, accessory subunit	11	67350777-67356972	Predicted intracellular proteins	Evidence at protein level	HPA071529			Uncertain	Nucleus<br>Nucleoli<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			small intestine: 120.1	Mixed		
POLDIP2	DKFZP586F1524, PDIP38	ENSG00000004142	DNA polymerase delta interacting protein 2	17	28347177-28357522	Predicted intracellular proteins	Evidence at protein level	HPA007700			Approved	Mitochondria		Expressed in all	Expressed in all			kidney: 109.1	Expressed in all		
POLDIP3	KIAA1649, PDIP46	ENSG00000100227	DNA polymerase delta interacting protein 3	22	42583721-42614962	Predicted intracellular proteins	Evidence at protein level	HPA018419, HPA048790	Approved		Enhanced	Nuclear speckles<br>Cytoplasmic bodies	Renal cancer:3.36e-4 (favourable), Glioma:6.67e-4 (favourable)	Expressed in all	Expressed in all			ovary: 109.8	Expressed in all		
POLE	POLE1	ENSG00000177084	DNA polymerase epsilon, catalytic subunit	12	132623753-132687365	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058210, HPA067385			Enhanced	Nucleus<br>Plasma membrane	Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.1	Expressed in all		
POLE2	DPE2	ENSG00000100479	DNA polymerase epsilon 2, accessory subunit	14	49643555-49688422	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027555	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Expressed in all	Mixed			bone marrow: 10.7	Mixed		
POLE3	CHARAC17, CHRAC17, p17, Ybl1	ENSG00000148229	DNA polymerase epsilon 3, accessory subunit	9	113407235-113410672	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047945	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:8.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 76.4	Expressed in all		
POLE4	p12	ENSG00000115350	DNA polymerase epsilon 4, accessory subunit	2	74958492-74970128	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA054979, HPA071815	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 12.8	Mixed		
POLG	POLG1, POLGA	ENSG00000140521	DNA polymerase gamma, catalytic subunit	15	89305198-89334861	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA056821	Approved				Prostate cancer:5.73e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 19.7	Expressed in all		
POLG2	HP55, MTPOLB	ENSG00000256525	DNA polymerase gamma 2, accessory subunit	17	64477785-64497036	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017030, HPA023202	Approved		Approved	Nuclear bodies<br>Mitochondria	Liver cancer:1.39e-6 (unfavourable), Renal cancer:1.17e-5 (unfavourable), Prostate cancer:6.59e-4 (unfavourable)	Expressed in all	Mixed			testis: 20.2	Expressed in all		
POLH	RAD30A, XP-V	ENSG00000170734	DNA polymerase eta	6	43576150-43615660	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006721, HPA026762	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
POLI	RAD30B, RAD3OB	ENSG00000101751	DNA polymerase iota	18	54269404-54321266	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012000, HPA064696	Enhanced		Supported	Nuclear speckles<br>Cytoplasmic bodies		Expressed in all	Expressed in all			testis: 69.7	Expressed in all		
POLK	DINB1, DINP, POLQ	ENSG00000122008	DNA polymerase kappa	5	75511756-75601144	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012035, HPA057303, HPA068117, HPA069375			Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			thyroid gland: 12.8	Mixed		
POLM	Tdt-N	ENSG00000122678	DNA polymerase mu	7	44072247-44082540	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA058900, HPA066007			Supported	Nucleus		Expressed in all	Expressed in all			spleen: 10.9	Cell line enhanced		HBEC3-KT: 47.1
POLN		ENSG00000130997	DNA polymerase nu	4	2071918-2242121	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035939, HPA035940			Enhanced	Nucleoplasm		Mixed	Tissue enhanced		adipose tissue: 3.0;testis: 4.4	epididymis,prostate: 1.0	Mixed		
POLQ	POLH	ENSG00000051341	DNA polymerase theta	3	121431427-121546641	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048931, HPA053359			Uncertain	Nucleus<br>Golgi apparatus<br>Cytosol	Endometrial cancer:5.46e-5 (unfavourable), Stomach cancer:1.04e-4 (favourable)	Mixed	Mixed			testis: 4.0	Mixed		
POLR1A	DKFZP586M0122, FLJ21915, RPA1, RPO1-4	ENSG00000068654	RNA polymerase I subunit A	2	86020216-86106155	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010145, HPA031513, HPA049700	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:3.70e-9 (unfavourable), Ovarian cancer:3.37e-4 (unfavourable), Thyroid cancer:8.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.3	Expressed in all		
POLR1B	FLJ10816, FLJ21921, RPA2, Rpo1-2	ENSG00000125630	RNA polymerase I subunit B	2	112541915-112577150	Enzymes, Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA037528			Supported	Nucleoli<br>Cytosol	Endometrial cancer:2.71e-5 (unfavourable), Pancreatic cancer:5.52e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.0	Expressed in all		
POLR1C	RPA39, RPA40, RPA5, RPAC1	ENSG00000171453	RNA polymerase I subunit C	6	43509702-43529585	Disease related genes, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA031010			Supported	Nucleus	Renal cancer:4.17e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.5	Expressed in all		
POLR1D	MGC9850, RPA16, RPA9, RPAC2, RPO1-3	ENSG00000186184	RNA polymerase I subunit D	13	27620742-27744237	Disease related genes, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA039337	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 108.1	Expressed in all		
POLR2A	POLR2, POLRA, RPB1	ENSG00000181222	RNA polymerase II subunit A	17	7484366-7514616	Enzymes, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	CAB012226, CAB016388, HPA021563, CAB022311, HPA053012	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 117.6	Expressed in all		
POLR2B	RPB2	ENSG00000047315	RNA polymerase II subunit B	4	56977722-57031168	Enzymes, Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA037506	Supported		Supported	Nucleoplasm	Renal cancer:7.17e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 86.2	Expressed in all		
POLR2C	RPB3	ENSG00000102978	RNA polymerase II subunit C	16	57462387-57472010	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA040919, HPA041826	Enhanced		Supported	Nucleoplasm<br>Microtubules<br>Cytosol	Renal cancer:3.03e-6 (favourable), Head and neck cancer:1.48e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 68.2	Expressed in all		
POLR2D	RBP4	ENSG00000144231	RNA polymerase II subunit D	2	127843551-127858157	Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA034694, HPA046092	Approved		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:2.79e-4 (unfavourable), Liver cancer:8.91e-4 (unfavourable)	Expressed in all	Tissue enriched	5	testis: 134.0	tonsil: 24.4	Expressed in all		
POLR2E	hRPB25, hsRPB5, RPABC1, RPB5, XAP4	ENSG00000099817	RNA polymerase II subunit E	19	1086579-1095380	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA063030, HPA068992	Supported		Supported	Nucleoplasm	Renal cancer:3.21e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.5	Expressed in all		
POLR2F	HRBP14.4, RPB6	ENSG00000100142	RNA polymerase II subunit F	22	37952607-38041915	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA000827, CAB009882	Supported		Enhanced	Nucleus<br>Nucleoli fibrillar center		Tissue enhanced	Expressed in all			cerebral cortex: 120.8	Expressed in all		
POLR2G	hRPB19, hsRPB7, RPB7	ENSG00000168002	RNA polymerase II subunit G	11	62761544-62766710	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA053000	Approved		Supported	Nucleoplasm	Liver cancer:6.02e-5 (unfavourable), Renal cancer:1.11e-4 (unfavourable), Endometrial cancer:8.23e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 100.0	Expressed in all		
POLR2H	RPB8	ENSG00000163882	RNA polymerase II subunit H	3	184361718-184368596	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA037745, HPA055813	Enhanced		Supported	Nucleus	Renal cancer:1.65e-10 (unfavourable), Liver cancer:2.01e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 71.8	Expressed in all		
POLR2I	hRPB14.5, RPB9	ENSG00000105258	RNA polymerase II subunit I	19	36113710-36115346	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA035632, HPA045156	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 18.4	Expressed in all		
POLR2J	hRPB14, POLR2J1, RPB11, RPB11A, RPB11m	ENSG00000005075	RNA polymerase II subunit J	7	102473118-102478907	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA042997, HPA044010, HPA046970	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			adrenal gland: 72.4	Expressed in all		
POLR2J2	RPB11b1	ENSG00000228049	RNA polymerase II subunit J2	7	102665368-102671629	Predicted intracellular proteins	Evidence at protein level	HPA042997, HPA044010, HPA046970	Uncertain		Approved	Nucleoplasm		Not detected	Mixed			appendix: 6.6	Cell line enhanced		MOLT-4: 17.9;U-2 OS: 14.2
POLR2J3		ENSG00000168255	RNA polymerase II subunit J3	7	102537918-102572656	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at transcript level	HPA011403, HPA042997, HPA044010, HPA046970	Approved		Approved	Nucleoplasm		Mixed	Expressed in all			cerebral cortex: 56.5	Expressed in all		
POLR2K	RPB10alpha	ENSG00000147669	RNA polymerase II subunit K	8	100150584-100154002	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA063185			Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 98.4	Expressed in all		
POLR2L	hRPB7.6, hsRPB10b, RBP10, RPABC5, RPB10beta, RPB7.6	ENSG00000177700	RNA polymerase II subunit L	11	837356-842545	Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level						Liver cancer:2.37e-4 (unfavourable), Renal cancer:5.56e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 68.0	Expressed in all		
POLR2M	GCOM1, Gdown, Gdown1, GRINL1A	ENSG00000255529	RNA polymerase II subunit M	15	57706629-57782762	Predicted intracellular proteins	Evidence at protein level	HPA068141			Approved	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 59.9	Expressed in all		
POLR3A	hRPC155, RPC1, RPC155	ENSG00000148606	RNA polymerase III subunit A	10	77969251-78029545	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA037926	Uncertain		Supported	Nucleoplasm	Liver cancer:3.64e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 17.9	Expressed in all		
POLR3B	FLJ10388, RPC2	ENSG00000013503	RNA polymerase III subunit B	12	106357658-106510198	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA036466	Supported		Approved	Nuclear speckles	Renal cancer:1.21e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 24.1	Expressed in all		
POLR3C	RPC3, RPC62	ENSG00000186141	RNA polymerase III subunit C	1	145824088-145842505	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA027508, HPA027516	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.85e-5 (unfavourable), Melanoma:1.50e-4 (unfavourable), Endometrial cancer:1.56e-4 (unfavourable), Liver cancer:5.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 53.2	Expressed in all		
POLR3D	BN51T, RPC4, TSBN51	ENSG00000168495	RNA polymerase III subunit D	8	22245104-22254600	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA061331, HPA067875, HPA068461, HPA069089	Enhanced		Enhanced	Nucleoplasm	Renal cancer:9.15e-6 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Urothelial cancer:2.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.6	Expressed in all		
POLR3E	FLJ10509, RPC5, SIN	ENSG00000058600	RNA polymerase III subunit E	16	22297375-22335103	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA041419, HPA041477	Approved		Enhanced	Nucleoplasm	Prostate cancer:1.74e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 8.9	Expressed in all		
POLR3F	RPC39, RPC6	ENSG00000132664	RNA polymerase III subunit F	20	18467127-18484643	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA049441, HPA050173, HPA072298	Uncertain		Approved	Nucleus	Liver cancer:8.87e-9 (unfavourable), Pancreatic cancer:6.48e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 11.6	Expressed in all		
POLR3G	RPC32, RPC7	ENSG00000113356	RNA polymerase III subunit G	5	90471748-90514553	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	CAB010109, HPA052658	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			parathyroid gland: 10.7	Expressed in all		
POLR3GL	flj32422, MGC3200	ENSG00000121851	RNA polymerase III subunit G like	1	145964702-145978848	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA027288	Uncertain				Endometrial cancer:6.52e-5 (favourable), Breast cancer:2.96e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 59.5	Expressed in all		
POLR3H	KIAA1665, RPC8	ENSG00000100413	RNA polymerase III subunit H	22	41525804-41544606	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA046787	Approved		Supported	Nucleoplasm<br>Vesicles<br>Centrosome	Liver cancer:2.04e-4 (unfavourable), Pancreatic cancer:5.41e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 35.5	Expressed in all		
POLR3K	RPC11	ENSG00000161980	RNA polymerase III subunit K	16	46407-53628	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA005891	Approved		Uncertain	Nucleus<br>Cytosol		Expressed in all	Expressed in all			lymph node: 20.5	Expressed in all		
POLRMT	APOLMT, h-mtRPOL, MTRNAP, MTRPOL	ENSG00000099821	RNA polymerase mitochondrial	19	617224-633604	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006366	Uncertain		Supported	Mitochondria	Endometrial cancer:4.50e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.8	Expressed in all		
POM121	DKFZP586G1822, DKFZP586P2220, KIAA0618, POM121A	ENSG00000196313	POM121 transmembrane nucleoporin	7	72879365-72951440	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB003710, HPA043809, HPA049817	Approved		Enhanced	Nucleoplasm<br>Nuclear membrane		Expressed in all	Expressed in all			cerebral cortex: 30.2	Expressed in all		
POM121C		ENSG00000272391	POM121 transmembrane nucleoporin C	7	75416787-75486271	Predicted intracellular proteins	Evidence at transcript level	HPA043809, HPA049817	Approved		Approved	Nucleoplasm<br>Nuclear membrane		Expressed in all	Expressed in all			parathyroid gland: 28.1	Expressed in all		
POM121L12	DKFZp564N2472	ENSG00000221900	POM121 transmembrane nucleoporin like 12	7	53035642-53036924	Predicted intracellular proteins	Evidence at protein level	HPA027836	Enhanced					Not detected	Tissue enriched	88	testis: 8.7	all non-specific tissues: 0.0	Not detected		
POM121L2	POM121-L	ENSG00000158553	POM121 transmembrane nucleoporin like 2	6	27285903-27312170	Predicted intracellular proteins	Evidence at transcript level	HPA046150	Uncertain					Not detected	Tissue enriched	152	testis: 15.1	all non-specific tissues: 0.0	Not detected		
POMP	C13orf12, HSPC014, UMP1	ENSG00000132963	Proteasome maturation protein	13	28659104-28678925	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026995	Approved		Supported	Nuclear speckles	Head and neck cancer:2.05e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 146.5	Expressed in all		
POMZP3	POM-ZP3, POM121	ENSG00000146707	POM121 and ZP3 fusion	7	76609986-76627261	Predicted intracellular proteins	Evidence at transcript level	HPA049817	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane	Liver cancer:3.78e-4 (unfavourable), Cervical cancer:4.34e-4 (favourable), Ovarian cancer:9.31e-4 (favourable)	Expressed in all	Mixed			testis: 13.7	Expressed in all		
POP1		ENSG00000104356	POP1 homolog, ribonuclease P/MRP subunit	8	98117297-98159834	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA066194			Supported	Nucleoli	Liver cancer:1.26e-6 (unfavourable), Breast cancer:2.54e-4 (unfavourable), Renal cancer:5.97e-4 (unfavourable), Lung cancer:9.88e-4 (unfavourable)	Expressed in all	Mixed			testis: 6.0	Expressed in all		
POP4	RPP29	ENSG00000105171	POP4 homolog, ribonuclease P/MRP subunit	19	29604017-29617237	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042748	Approved				Liver cancer:3.31e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 15.2	Expressed in all		
POP5		ENSG00000167272	POP5 homolog, ribonuclease P/MRP subunit	12	120578764-120581398	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047598, HPA069204	Approved		Approved	Nucleus<br>Nucleoli	Cervical cancer:2.68e-5 (favourable), Renal cancer:4.85e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 51.8	Expressed in all		
POP7	RPP2, RPP20	ENSG00000172336	POP7 homolog, ribonuclease P/MRP subunit	7	100706053-100707495	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021007	Uncertain		Supported	Nucleoli<br>Vesicles	Liver cancer:4.99e-5 (unfavourable), Renal cancer:6.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 41.1	Expressed in all		
POT1	DKFZp586D211, hPot1	ENSG00000128513	Protection of telomeres 1	7	124822386-124929983	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA068538			Supported	Nucleus		Expressed in all	Mixed			thyroid gland: 21.6	Expressed in all		
POTEB	A26B1, CT104.5, POTE-15, POTE15	ENSG00000233917	POTE ankyrin domain family member B	15	21846329-21877703	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Not detected	Tissue enriched	10	testis: 1.0	all non-specific tissues: 0.0	Not detected		
POTEB2		ENSG00000230031	POTE ankyrin domain family member B2	15	20835372-20866314	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Not detected	Tissue enriched	40	testis: 3.9	all non-specific tissues: 0.0	Not detected		
POTEB3		ENSG00000278522	POTE ankyrin domain family member B3	15	21408243-21440451	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Not detected	Tissue enriched	22	testis: 2.2	all non-specific tissues: 0.0	Not detected		
POTEC	A26B2, CT104.6, DKFZp686J0529, POTE-18, POTE18	ENSG00000183206	POTE ankyrin domain family member C	18	14507339-14543585	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Not detected	Tissue enriched	14	testis: 1.4	prostate: 0.1	Not detected		
POTED	A26B3, ANKRD21, CT104.1, POTE, POTE-21, POTE21	ENSG00000166351	POTE ankyrin domain family member D	21	13609858-13641585	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Not detected	Tissue enriched	14	testis: 1.3	all non-specific tissues: 0.0	Not detected		
POTEE	A26C1, A26C1A, CT104.2, POTE-2, POTE2, POTE2gamma	ENSG00000188219	POTE ankyrin domain family member E	2	131218067-131265278	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271, HPA042822, HPA043260	Uncertain					Not detected	Tissue enhanced		testis: 2.1	prostate: 0.7	Cell line enhanced		AN3-CA: 1.0;BEWO: 1.3;K-562: 1.3;U-2 OS: 2.8
POTEF	A26C1B, POTE2alpha, POTEACTIN	ENSG00000196604	POTE ankyrin domain family member F	2	130074030-130129222	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271, HPA042822, HPA043260	Uncertain					Not detected	Tissue enriched	9	testis: 2.7	breast,placenta,prostate: 0.2	Cell line enhanced		AN3-CA: 2.3;BEWO: 1.9;CACO-2: 1.9;U-2 OS: 5.6;U-266/70: 2.0
POTEG	A26C2, CT104.4, POTE-14, POTE14, POTE14alpha	ENSG00000187537	POTE ankyrin domain family member G	14	19402486-19434341	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Tissue enhanced	Tissue enhanced		prostate: 3.5	testis: 0.7	Not detected		
POTEH	A26C3, ACTBL1, CT104.7, POTE22	ENSG00000198062	POTE ankyrin domain family member H	22	15690026-15721631	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Tissue enriched	Group enriched	36	prostate: 5.7;testis: 1.4	all non-specific tissues: 0.0	Cell line enhanced		U-2 OS: 1.1
POTEI	POTE2beta	ENSG00000196834	POTE ankyrin domain family member I	2	130459455-130509666	Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271, HPA042822, HPA043260	Uncertain					Not detected	Group enriched	16	prostate: 17.4;testis: 10.3	breast: 0.8	Cell line enhanced		AN3-CA: 2.5;BEWO: 3.2;K-562: 3.0;U-2 OS: 7.5
POTEJ	POTE2beta	ENSG00000222038	POTE ankyrin domain family member J	2	130611481-130658091	Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271, HPA042822, HPA043260	Uncertain					Not detected	Tissue enhanced		testis: 1.1	prostate: 0.6	Not detected		
POTEM	ACT, P704P, POTE14beta	ENSG00000222036	POTE ankyrin domain family member M	14	18967434-18999012	Predicted intracellular proteins	No evidence	HPA042822	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
POU1F1	GHF-1, PIT1, POU1F1a	ENSG00000064835	POU class 1 homeobox 1	3	87259404-87276587	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041646, HPA050624	Enhanced					Not detected	Not detected			adrenal gland,cerebral cortex,gallbladder,skeletal muscle,spleen,thyroid gland: 0.1	Not detected		
POU2AF1	BOB1, OBF1	ENSG00000110777	POU class 2 associating factor 1	11	111352252-111455630	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011193	Enhanced				Cervical cancer:1.63e-4 (favourable), Breast cancer:1.68e-4 (favourable), Head and neck cancer:3.59e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 101.7;tonsil: 93.7	appendix: 55.5	Cell line enhanced		Daudi: 190.2;Karpas-707: 212.1;U-266/70: 217.7;U-698: 374.3
POU2F1	OCT1, OTF1	ENSG00000143190	POU class 2 homeobox 1	1	167220829-167427345	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002608, HPA058559, HPA064323	Supported		Supported	Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles	Renal cancer:2.98e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 8.0	Mixed		
POU2F2	OCT2, OTF2	ENSG00000028277	POU class 2 homeobox 2	19	42086110-42196585	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002513, HPA049056, HPA062096, HPA064404	Enhanced		Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:7.57e-11 (unfavourable)	Mixed	Tissue enhanced		lymph node: 62.3;tonsil: 44.4	appendix,spleen: 37.6	Cell line enhanced		BJ hTERT+: 42.5;Daudi: 81.0;hTEC/SVTERT24-B: 42.8;U-266/70: 57.7;U-266/84: 54.8;U-698: 61.5
POU2F3	Epoc-1, OCT11, PLA-1, Skn-1a	ENSG00000137709	POU class 2 homeobox 3	11	120236640-120319944	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019652	Enhanced				Thyroid cancer:8.14e-4 (favourable)	Mixed	Group enriched	11	parathyroid gland: 15.5;skin: 72.3	seminal vesicle: 3.8	Cell line enhanced		CAPAN-2: 3.7;SK-BR-3: 2.2;T-47d: 5.2
POU3F1	OCT6, OTF6, SCIP	ENSG00000185668	POU class 3 homeobox 1	1	38044611-38046794	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055980, HPA073824			Enhanced	Nucleoplasm		Mixed	Tissue enriched	14	skin: 23.6	cerebral cortex: 1.6	Group enriched	9	AF22: 12.9;HDLM-2: 22.0;NTERA-2: 6.3;SCLC-21H: 5.3;SK-MEL-30: 15.0
POU3F2	BRN2, OCT7, OTF7, POUF3	ENSG00000184486	POU class 3 homeobox 2	6	98834592-98839470	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047081, HPA056261		Approved	Supported	Nucleus		Tissue enriched	Tissue enriched	70	cerebral cortex: 20.4	testis: 0.2	Cell line enhanced		AF22: 123.9;U-251 MG: 32.8;WM-115: 33.3
POU3F3	BRN1, OTF8	ENSG00000198914	POU class 3 homeobox 3	2	104855511-104858574	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052792, HPA056039, HPA067151	Approved		Enhanced	Nucleus	Endometrial cancer:4.26e-5 (unfavourable)	Group enriched	Group enriched	45	cerebral cortex: 43.9;epididymis: 46.3;kidney: 36.6;seminal vesicle: 23.2	skin: 0.8	Group enriched	5	AF22: 58.4;AN3-CA: 52.7;HEK93: 20.3;RPTEC TERT1: 50.7;SH-SY5Y: 19.7
POU3F4	BRN4, DFN3, DFNX2, OTF9	ENSG00000196767	POU class 3 homeobox 4	X	83508250-83512127	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031984, HPA062295	Uncertain		Supported	Nucleus		Tissue enriched	Tissue enriched	11	cerebral cortex: 7.9	kidney: 0.7	Cell line enriched	96	AF22: 9.6
POU4F1	BRN3A, RDC-1	ENSG00000152192	POU class 4 homeobox 1	13	78598362-78603560	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA068024	Enhanced					Mixed	Tissue enhanced		testis: 1.8	tonsil: 0.7	Cell line enhanced		HEK93: 12.9;HEL: 13.8;RH-30: 17.3;SCLC-21H: 20.1;U-266/70: 12.2
POU4F2	Brn-3b, BRN3B	ENSG00000151615	POU class 4 homeobox 2	4	146638893-146642474	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	18	testis: 1.8	all non-specific tissues: 0.0	Cell line enhanced		SCLC-21H: 2.1
POU4F3	BRN3C, DFNA15, DFNA42, DFNA52	ENSG00000091010	POU class 4 homeobox 3	5	146339024-146340520	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038215	Uncertain		Supported	Nucleoplasm		Tissue enhanced	Not detected			all non-specific tissues: 0.0	Not detected		
POU5F1	MGC22487, OCT3, Oct4, OTF3	ENSG00000204531	POU class 5 homeobox 1	6	31164337-31180731	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025600, CAB026380, HPA058267	Approved		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:2.04e-5 (favourable)	Tissue enriched	Mixed			fallopian tube: 6.4	Group enriched	12	HAP1: 366.6;NTERA-2: 938.2
POU5F1B	OTF3C, OTF3P1, POU5F1P1	ENSG00000212993	POU class 5 homeobox 1B	8	127414290-127420069	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058267			Supported	Nucleoplasm		Tissue enhanced	Not detected			parathyroid gland: 0.7	Cell line enhanced		hTERT-HME1: 1.1
POU5F2	FLJ25680, SPRM-1	ENSG00000248483	POU domain class 5, transcription factor 2	5	93733220-93741637	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Tissue enhanced		testis: 2.7	skin: 0.6	Cell line enriched	7	U-2 OS: 3.1
POU6F1	BRN5, MPOU, TCFB1	ENSG00000184271	POU class 6 homeobox 1	12	51186936-51217708	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047021, HPA050411	Enhanced		Supported	Nuclear bodies<br>Actin filaments	Pancreatic cancer:6.61e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 10.9	Mixed		
POU6F2	RPF-1	ENSG00000106536	POU class 6 homeobox 2	7	38977998-39493095	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 3.1;placenta: 1.8	gallbladder,testis: 1.2	Cell line enhanced		EFO-21: 3.0;NTERA-2: 3.1;T-47d: 5.3;U-266/70: 4.7;U-266/84: 5.5
PP2D1	C3orf48, FLJ25449	ENSG00000183977	Protein phosphatase 2C like domain containing 1	3	19979961-20012330	Predicted intracellular proteins	Evidence at protein level	HPA036870, HPA066083	Supported		Uncertain	Nucleoplasm<br>Intermediate filaments		Not detected	Tissue enriched	11	testis: 12.8	bone marrow: 1.1	Not detected		
PPA1	IOPPP, PP, PP1, Ppase, SID6-8061	ENSG00000180817	Pyrophosphatase (inorganic) 1	10	70202830-70233911	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019878, HPA020096	Supported		Supported	Vesicles		Expressed in all	Expressed in all			breast: 226.6	Expressed in all		
PPA2	FLJ20459	ENSG00000138777	Pyrophosphatase (inorganic) 2	4	105369077-105474081	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030888, HPA031671, HPA031672	Supported		Approved	Nucleus<br>Mitochondria	Renal cancer:1.27e-11 (favourable), Breast cancer:2.98e-4 (unfavourable), Colorectal cancer:6.60e-4 (favourable)	Expressed in all	Expressed in all			prostate: 21.3	Expressed in all		
PPAN	BXDC3, SSF, SSF1, SSF2	ENSG00000130810	Peter pan homolog (Drosophila)	19	10106289-10111634	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043265	Approved					Expressed in all	Expressed in all			lymph node: 20.2	Expressed in all		
PPARA	hPPAR, NR1C1, PPAR	ENSG00000186951	Peroxisome proliferator activated receptor alpha	22	46150521-46243756	FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058901, HPA067049, CAB075701	Supported		Enhanced	Nucleus	Renal cancer:4.39e-9 (favourable)	Expressed in all	Expressed in all			kidney: 24.2	Mixed		
PPARD	FAAR, NR1C2, NUC1, NUCII	ENSG00000112033	Peroxisome proliferator activated receptor delta	6	35342558-35428191	FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017635	Approved				Liver cancer:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 40.2	Expressed in all		
PPARG	NR1C3, PPARG1, PPARG2, PPARgamma	ENSG00000132170	Peroxisome proliferator activated receptor gamma	3	12287368-12434356	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004282, HPA051239, HPA063663	Approved		Enhanced	Nucleus<br>Vesicles	Renal cancer:1.59e-8 (favourable), Liver cancer:3.41e-5 (unfavourable), Urothelial cancer:5.52e-5 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 173.3	placenta: 59.2	Cell line enhanced		ASC diff: 131.6;BEWO: 223.4;RT4: 116.1
PPARGC1A	PGC-1alpha, PGC1, PGC1A, PPARGC1	ENSG00000109819	PPARG coactivator 1 alpha	4	23755041-23904089	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA063136			Supported	Nucleoplasm	Renal cancer:1.49e-14 (favourable), Liver cancer:3.35e-6 (favourable), Thyroid cancer:5.80e-4 (unfavourable)	Tissue enhanced	Mixed			kidney,parathyroid gland: 29.2	Cell line enriched	8	A-431: 76.6
PPARGC1B	PERC, PGC1B	ENSG00000155846	PPARG coactivator 1 beta	5	149730298-149855022	Predicted intracellular proteins	Evidence at protein level	HPA050543			Supported	Nucleus		Mixed	Mixed			parathyroid gland: 14.6	Mixed		
PPAT	GPAT, PRAT	ENSG00000128059	Phosphoribosyl pyrophosphate amidotransferase	4	56393362-56435615	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036091, HPA036092	Approved		Approved	Midbody ring	Liver cancer:1.14e-8 (unfavourable), Endometrial cancer:5.15e-5 (unfavourable), Thyroid cancer:1.95e-4 (unfavourable), Renal cancer:8.34e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.1	Expressed in all		
PPCDC	FLJ14585, MDS018	ENSG00000138621	Phosphopantothenoylcysteine decarboxylase	15	75023555-75117462	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045667	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 22.4	Expressed in all		
PPCS	FLJ11838	ENSG00000127125	Phosphopantothenoylcysteine synthetase	1	42456117-42473385	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031361, HPA031363	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Mitochondria	Liver cancer:5.96e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 110.6	Expressed in all		
PPDPF	C20orf149, dJ697K14.9, exdpf	ENSG00000125534	Pancreatic progenitor cell differentiation and proliferation factor	20	63520724-63522206	Predicted intracellular proteins	Evidence at protein level	HPA040929			Approved	Nucleoplasm<br>Nucleoli<br>Microtubules	Renal cancer:3.91e-4 (favourable)	Expressed in all	Expressed in all			stomach: 210.2	Mixed		
PPEF1	PPEF, PPP7CA	ENSG00000086717	Protein phosphatase with EF-hand domain 1	X	18675909-18827921	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034577	Uncertain		Uncertain	Plasma membrane<br>Cytokinetic bridge		Mixed	Tissue enriched	7	testis: 26.4	cerebral cortex: 3.6	Cell line enhanced		A549: 1.0;HeLa: 1.1
PPEF2	PPP7CB	ENSG00000156194	Protein phosphatase with EF-hand domain 2	4	75859864-75902571	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.4	Not detected		
PPFIA2		ENSG00000139220	PTPRF interacting protein alpha 2	12	81257975-81759553	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	5	cerebral cortex: 61.0	testis: 11.4	Group enriched	9	HAP1: 30.3;SCLC-21H: 11.7
PPFIA3	KIAA0654, LPNA3, MGC126567, MGC126569	ENSG00000177380	PTPRF interacting protein alpha 3	19	49119389-49151026	Predicted intracellular proteins	Evidence at protein level	HPA043567, HPA050340	Enhanced		Uncertain	Nucleoli fibrillar center<br>Vesicles	Head and neck cancer:6.46e-7 (favourable), Liver cancer:2.24e-5 (unfavourable), Breast cancer:3.09e-4 (unfavourable), Endometrial cancer:8.65e-4 (favourable)	Expressed in all	Group enriched	6	cerebral cortex: 21.5;skin: 20.2	parathyroid gland: 3.6	Cell line enhanced		PC-3: 33.5
PPFIA4		ENSG00000143847	PTPRF interacting protein alpha 4	1	203026498-203078740	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053419, HPA054132	Enhanced				Renal cancer:1.73e-8 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 24.8;heart muscle: 14.5	skeletal muscle: 6.5	Cell line enhanced		RH-30: 13.1;U-87 MG: 12.1
PPFIBP1	hSGT2, hSgt2p, L2, SGT2	ENSG00000110841	PPFIA binding protein 1	12	27523431-27695564	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001924	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:5.11e-7 (favourable), Pancreatic cancer:2.56e-4 (unfavourable), Lung cancer:5.11e-4 (unfavourable), Endometrial cancer:6.29e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 106.4	Mixed		
PPFIBP2	Cclp1	ENSG00000166387	PPFIA binding protein 2	11	7513298-7657127	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001935, HPA003911	Approved		Approved	Mitochondria	Renal cancer:5.39e-8 (favourable), Urothelial cancer:1.34e-5 (favourable), Lung cancer:2.26e-5 (favourable), Head and neck cancer:2.32e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 184.8	Cell line enhanced		BEWO: 77.4;RT4: 91.3
PPHLN1		ENSG00000134283	Periphilin 1	12	42238447-42459715	Predicted intracellular proteins	Evidence at protein level	HPA038902, HPA038903	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus	Liver cancer:1.28e-7 (unfavourable), Renal cancer:5.06e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 102.1	Expressed in all		
PPIA	CYPA	ENSG00000196262	Peptidylprolyl isomerase A	7	44796680-44824564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004655, HPA058345	Uncertain				Liver cancer:2.27e-6 (unfavourable)	Expressed in all	Expressed in all			breast: 1679.8	Expressed in all		
PPIAL4A	COAS2, PPIAL4, PPIAL4B	ENSG00000263353	Peptidylprolyl isomerase A like 4A	1	120889746-120890405	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA058345	Uncertain					Not detected	Not detected			cerebral cortex: 0.4	Mixed		
PPIAL4C		ENSG00000263464	Peptidylprolyl isomerase A like 4C	1	149583865-149584464	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA058345	Uncertain					Not detected	Mixed			duodenum: 3.9	Mixed		
PPIAL4D		ENSG00000256374	Peptidylprolyl isomerase A like 4D	1	145241630-145242124	Enzymes, Predicted intracellular proteins	No evidence	HPA058345	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PPIAL4E		ENSG00000271567	Peptidylprolyl isomerase A like 4E	1	144372875-144373659	Enzymes, Predicted intracellular proteins	No evidence	HPA058345	Uncertain					Not detected	Not detected			bone marrow: 0.3	Not detected		
PPIAL4F		ENSG00000279782	Peptidylprolyl isomerase A like 4F	1	144592868-144593527	Enzymes, Predicted intracellular proteins	No evidence	HPA058345	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PPIAL4G		ENSG00000236334	Peptidylprolyl isomerase A like 4G	1	148479824-148483679	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA058345	Uncertain					Not detected	Not detected			skeletal muscle: 0.9	Not detected		
PPID	CYP-40	ENSG00000171497	Peptidylprolyl isomerase D	4	158709134-158723396	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019520, HPA019692	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			duodenum: 50.9	Expressed in all		
PPIE	CyP-33, MGC111222, MGC3736	ENSG00000084072	Peptidylprolyl isomerase E	1	39692182-39763914	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019357, HPA020131	Approved		Supported	Nuclear speckles	Renal cancer:5.05e-5 (unfavourable), Liver cancer:1.76e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 67.3	Expressed in all		
PPIF	Cyp-D, hCyP3	ENSG00000108179	Peptidylprolyl isomerase F	10	79347469-79355337	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA077416			Supported	Mitochondria		Expressed in all	Expressed in all			adrenal gland: 188.4	Expressed in all		
PPIG	CARS-Cyp, SCAF10, SRCyp	ENSG00000138398	Peptidylprolyl isomerase G	2	169584340-169641406	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021788, HPA057469	Supported		Supported	Nuclear speckles<br>Cytosol	Renal cancer:4.56e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 84.6	Expressed in all		
PPIH	CYP-20, CYPH, MGC5016, SnuCyp-20, USA-CYP	ENSG00000171960	Peptidylprolyl isomerase H	1	42658425-42676758	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059019	Approved				Renal cancer:1.78e-9 (unfavourable), Liver cancer:1.55e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 60.1	Expressed in all		
PPIL1	CYPL1	ENSG00000137168	Peptidylprolyl isomerase like 1	6	36854827-36875024	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062916			Approved	Nucleoli	Liver cancer:1.28e-5 (unfavourable), Ovarian cancer:4.90e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 42.0	Expressed in all		
PPIL2	CYC4, Cyp-60, UBOX7	ENSG00000100023	Peptidylprolyl isomerase like 2	22	21666009-21700015	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035344, HPA055637	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 31.5	Expressed in all		
PPIL4		ENSG00000131013	Peptidylprolyl isomerase like 4	6	149504733-149546038	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031599, HPA031600	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 48.0	Expressed in all		
PPIL6	bA425D10.6, dJ919F19.1, MGC41939, RSPH12	ENSG00000185250	Peptidylprolyl isomerase like 6	6	109390215-109441171	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA036717	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cytosol		Mixed	Tissue enhanced		fallopian tube: 53.2;testis: 32.6	thyroid gland: 17.7	Cell line enhanced		AN3-CA: 5.4;ASC diff: 6.2;ASC TERT1: 7.8
PPIP5K1	HISPPD2A, IPS1, KIAA0377, VIP1	ENSG00000168781	Diphosphoinositol pentakisphosphate kinase 1	15	43533462-43590253	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039380	Approved		Supported	Cytosol	Renal cancer:7.14e-8 (favourable), Ovarian cancer:8.57e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 53.1	Expressed in all		
PPIP5K2	CFAP160, HISPPD1, KIAA0433, VIP2	ENSG00000145725	Diphosphoinositol pentakisphosphate kinase 2	5	103120149-103212799	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037895, HPA038442	Approved		Approved	Vesicles	Thyroid cancer:1.12e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.3	Expressed in all		
PPL		ENSG00000118898	Periplakin	16	4882507-4960741	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042550, HPA059859	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Ovarian cancer:2.76e-4 (unfavourable)	Expressed in all	Group enriched	7	esophagus: 558.8;skin: 149.5	tonsil: 52.0	Cell line enhanced		HaCaT: 168.9;SiHa: 108.6
PPM1A	MGC9201, PP2CA, PP2Calpha	ENSG00000100614	Protein phosphatase, Mg2+/Mn2+ dependent 1A	14	60245752-60299087	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029209	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.57e-9 (favourable)	Expressed in all	Expressed in all			testis: 100.1	Expressed in all		
PPM1B	PP2CB, PP2CBETA, PPC2BETAX	ENSG00000138032	Protein phosphatase, Mg2+/Mn2+ dependent 1B	2	44167969-44244384	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016745	Approved		Approved	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 82.3	Expressed in all		
PPM1D	PP2C-DELTA, Wip1	ENSG00000170836	Protein phosphatase, Mg2+/Mn2+ dependent 1D	17	60600183-60666280	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022277	Uncertain		Approved	Endoplasmic reticulum	Colorectal cancer:3.52e-4 (favourable), Liver cancer:4.27e-4 (unfavourable)	Expressed in all	Mixed			testis: 9.6	Expressed in all		
PPM1E	CaMKP-N, KIAA1072, POPX1, PP2CH	ENSG00000175175	Protein phosphatase, Mg2+/Mn2+ dependent 1E	17	58755869-58985176	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018462, HPA019263	Approved		Approved	Nucleus<br>Nucleoli		Tissue enhanced	Group enriched	5	adrenal gland: 7.3;cerebral cortex: 20.5;testis: 12.1	fallopian tube: 2.4	Cell line enhanced		AF22: 12.1;HAP1: 20.6;SCLC-21H: 10.7;SH-SY5Y: 19.9
PPM1F	CAMKP, CaMKPase, FEM-2, KIAA0015, POPX2	ENSG00000100034	Protein phosphatase, Mg2+/Mn2+ dependent 1F	22	21919420-21952837	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030989, HPA030990	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:6.03e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 38.9	Expressed in all		
PPM1G	PP2CG, PP2Cgamma	ENSG00000115241	Protein phosphatase, Mg2+/Mn2+ dependent 1G	2	27381194-27409687	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035530, HPA035531	Enhanced		Enhanced	Nucleoplasm	Liver cancer:3.14e-7 (unfavourable), Ovarian cancer:6.08e-5 (favourable)	Expressed in all	Tissue enriched	5	testis: 337.3	lymph node: 65.2	Expressed in all		
PPM1H	ARHCL1, FLJ13253, KIAA1157, NERPP-2C	ENSG00000111110	Protein phosphatase, Mg2+/Mn2+ dependent 1H	12	62643982-62935037	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB020694, HPA044244, HPA058777	Approved		Supported	Nucleoplasm	Renal cancer:2.72e-5 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 54.2	cerebral cortex: 23.0	Cell line enhanced		CACO-2: 67.4;HMC-1: 56.0
PPM1J	DKFZp434P1514, FLJ35951, MGC19531, PP2Czeta, PPP2CZ	ENSG00000155367	Protein phosphatase, Mg2+/Mn2+ dependent 1J	1	112709994-112715477	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046045	Uncertain		Approved	Vesicles		Mixed	Group enriched	6	epididymis: 22.8;skeletal muscle: 24.1;skin: 21.4;testis: 46.5	heart muscle: 4.7	Cell line enhanced		T-47d: 18.2
PPM1K	BDP, DKFZp761G058, hPTMP, PP2Ckappa, PP2Cm	ENSG00000163644	Protein phosphatase, Mg2+/Mn2+ dependent 1K	4	88257620-88284769	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020066, HPA020862, HPA023891	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 61.4	Mixed		
PPM1M	FLJ32332, PP2Ceta	ENSG00000164088	Protein phosphatase, Mg2+/Mn2+ dependent 1M	3	52245793-52250597	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036905, HPA062291	Uncertain		Approved	Nuclear bodies	Renal cancer:1.61e-5 (unfavourable), Lung cancer:6.69e-4 (favourable), Cervical cancer:7.73e-4 (favourable)	Expressed in all	Expressed in all			lung: 35.0	Mixed		
PPM1N	FLJ40125	ENSG00000213889	Protein phosphatase, Mg2+/Mn2+ dependent 1N (putative)	19	45488777-45502510	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043577			Supported	Vesicles		Tissue enhanced	Tissue enriched	5	skeletal muscle: 69.9	spleen: 12.9	Cell line enhanced		RT4: 24.0
PPME1	PME-1	ENSG00000214517	Protein phosphatase methylesterase 1	11	74171099-74254703	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004541, HPA043900, HPA064396	Uncertain		Supported	Nucleus<br>Nuclear bodies	Liver cancer:4.45e-6 (unfavourable), Renal cancer:2.76e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 156.1	Expressed in all		
PPP1CB	PP-1B, PP1B, PP1beta	ENSG00000213639	Protein phosphatase 1 catalytic subunit beta	2	28751640-28802940	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB022558, HPA065425, CAB069426	Supported		Enhanced	Nucleus<br>Plasma membrane	Liver cancer:6.52e-6 (unfavourable)	Expressed in all	Expressed in all			esophagus: 273.8	Expressed in all		
PPP1CC	PP1C, PP1gamma	ENSG00000186298	Protein phosphatase 1 catalytic subunit gamma	12	110719680-110742939	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022645	Uncertain				Liver cancer:2.75e-6 (unfavourable), Cervical cancer:7.44e-4 (favourable)	Expressed in all	Expressed in all			testis: 257.5	Expressed in all		
PPP1R10	CAT53, FB19, p99, PNUTS	ENSG00000204569	Protein phosphatase 1 regulatory subunit 10	6	30600400-30618612	Predicted intracellular proteins	Evidence at protein level	CAB025501, HPA047248, HPA056756	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:9.74e-5 (favourable), Cervical cancer:4.84e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 10.5	Expressed in all		
PPP1R11	CFAP255, HCG-V, HCGV, TCTE5, Tctex5	ENSG00000204619	Protein phosphatase 1 regulatory inhibitor subunit 11	6	30066709-30070333	Predicted intracellular proteins	Evidence at protein level	HPA043266, HPA060174	Approved		Approved	Vesicles		Expressed in all	Tissue enhanced		epididymis: 38.2	fallopian tube: 17.0	Cell line enhanced		A-431: 42.0;AN3-CA: 57.2;HEL: 34.3;RPTEC TERT1: 32.3;U-266/84: 30.5
PPP1R12A	M130, MBS, MYPT1	ENSG00000058272	Protein phosphatase 1 regulatory subunit 12A	12	79773563-79935460	Predicted intracellular proteins	Evidence at protein level	HPA041296, HPA071956	Approved		Enhanced	Actin filaments<br>Cytosol	Liver cancer:1.72e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 120.9	Expressed in all		
PPP1R12B	MGC131980, MGC87886, MYPT2, PP1bp55	ENSG00000077157	Protein phosphatase 1 regulatory subunit 12B	1	202348699-202592706	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024171, HPA024640	Enhanced		Supported	Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			endometrium: 366.8	Mixed		
PPP1R12C	DKFZP434D0412, LENG3, MBS85, p84, p85	ENSG00000125503	Protein phosphatase 1 regulatory subunit 12C	19	55090913-55117559	Predicted intracellular proteins	Evidence at protein level	HPA043532	Approved				Pancreatic cancer:4.10e-5 (favourable)	Expressed in all	Expressed in all			endometrium: 112.5	Expressed in all		
PPP1R13B	ASPP1, KIAA0771, p53BP2-like, p85	ENSG00000088808	Protein phosphatase 1 regulatory subunit 13B	14	103733752-103847590	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006394, CAB015454	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.28e-11 (favourable), Lung cancer:1.41e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 43.9	Mixed		
PPP1R13L	IASPP, RAI	ENSG00000104881	Protein phosphatase 1 regulatory subunit 13 like	19	45379634-45406349	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005016, HPA041231, HPA059883	Approved		Enhanced	Cytosol	Lung cancer:3.39e-5 (unfavourable), Ovarian cancer:5.40e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 191.4	esophagus: 53.8	Cell line enhanced		hTCEpi: 138.6
PPP1R14A	CPI-17, PPP1INL	ENSG00000167641	Protein phosphatase 1 regulatory inhibitor subunit 14A	19	38251237-38256591	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005044, CAB009803, HPA042097, HPA054534	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.25e-5 (unfavourable), Stomach cancer:7.12e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 110.8	Cell line enhanced		A549: 89.9;EFO-21: 78.3;K-562: 38.3
PPP1R14B	PHI-1, PLCB3N, PNG, SOM172	ENSG00000173457	Protein phosphatase 1 regulatory inhibitor subunit 14B	11	64244480-64246941	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053882	Approved				Liver cancer:1.75e-6 (unfavourable), Pancreatic cancer:6.77e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 87.3	Expressed in all		
PPP1R14C	CPI17-like, KEPI, NY-BR-81	ENSG00000198729	Protein phosphatase 1 regulatory inhibitor subunit 14C	6	150143076-150250357	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 76.2;thyroid gland: 101.5	heart muscle: 52.5	Cell line enhanced		HBEC3-KT: 63.9;hTCEpi: 77.1
PPP1R14D	CPI17-like, FLJ20251, GBPI-1, MGC119014, MGC119016	ENSG00000166143	Protein phosphatase 1 regulatory inhibitor subunit 14D	15	40815445-40828709	Predicted intracellular proteins	Evidence at protein level	HPA041846	Uncertain				Renal cancer:3.07e-4 (unfavourable)	Tissue enhanced	Group enriched	7	colon: 105.5;duodenum: 111.1;gallbladder: 24.2;rectum: 100.0;small intestine: 89.8	appendix: 12.4	Cell line enhanced		RPMI-8226: 2.1;RT4: 1.5;U-266/84: 1.4
PPP1R15A	GADD34	ENSG00000087074	Protein phosphatase 1 regulatory subunit 15A	19	48872392-48876057	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB018395, HPA020240	Approved		Uncertain	Vesicles	Liver cancer:1.95e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 358.1	Expressed in all		
PPP1R15B	FLJ14744	ENSG00000158615	Protein phosphatase 1 regulatory subunit 15B	1	204403387-204411791	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061088			Approved	Golgi apparatus	Renal cancer:8.74e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 81.6	Expressed in all		
PPP1R16A	MGC14333, MYPT3	ENSG00000160972	Protein phosphatase 1 regulatory subunit 16A	8	144477969-144502121	Predicted intracellular proteins	Evidence at protein level	HPA023755	Uncertain		Approved	Plasma membrane		Expressed in all	Mixed			duodenum: 27.2	Mixed		
PPP1R16B	ANKRD4, KIAA0823, TIMAP	ENSG00000101445	Protein phosphatase 1 regulatory subunit 16B	20	38805705-38923024	Predicted intracellular proteins	Evidence at protein level	HPA049571			Supported	Nuclear speckles<br>Plasma membrane	Head and neck cancer:7.87e-5 (favourable), Cervical cancer:2.11e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 50.9	lymph node: 44.2	Cell line enhanced		Daudi: 40.9;HMC-1: 52.2;HUVEC TERT2: 29.7;U-266/70: 73.8;U-266/84: 29.1
PPP1R17	C7orf16, GSBS	ENSG00000106341	Protein phosphatase 1 regulatory subunit 17	7	31686715-31708455	Predicted intracellular proteins	Evidence at protein level	HPA047819, HPA073123	Supported		Supported	Nucleoplasm		Tissue enhanced	Group enriched	5	adrenal gland: 4.8;cerebral cortex: 2.6;testis: 1.1	lung: 0.5	Group enriched	225	NTERA-2: 33.8;SCLC-21H: 120.1
PPP1R18	KIAA1949, phostensin	ENSG00000146112	Protein phosphatase 1 regulatory subunit 18	6	30676389-30687895	Predicted intracellular proteins	Evidence at protein level	HPA044745, HPA051000	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:1.11e-16 (unfavourable), Colorectal cancer:4.71e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 53.3	spleen: 35.1	Mixed		
PPP1R1A		ENSG00000135447	Protein phosphatase 1 regulatory inhibitor subunit 1A	12	54575387-54588659	Predicted intracellular proteins	Evidence at protein level	CAB007811, HPA041542	Approved				Endometrial cancer:2.36e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 252.9;skeletal muscle: 291.2	kidney: 74.4	Cell line enhanced		ASC diff: 6.1;NTERA-2: 29.5;RPTEC TERT1: 24.5
PPP1R1B	DARPP-32, FLJ20940	ENSG00000131771	Protein phosphatase 1 regulatory inhibitor subunit 1B	17	39626740-39636626	Predicted intracellular proteins	Evidence at protein level	CAB004026, HPA048630, HPA061142	Approved	Approved				Mixed	Tissue enhanced		rectum: 219.9	colon: 209.5	Cell line enhanced		CAPAN-2: 11.0;HSkMC: 23.1;SCLC-21H: 31.9
PPP1R1C	Inhibitor-1-like	ENSG00000150722	Protein phosphatase 1 regulatory inhibitor subunit 1C	2	181954241-182131398	Predicted intracellular proteins	Evidence at protein level	HPA055043			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Mixed	Tissue enriched	9	heart muscle: 14.1	prostate: 1.6	Not detected		
PPP1R2	IPP2	ENSG00000184203	Protein phosphatase 1 regulatory inhibitor subunit 2	3	195514425-195543386	Predicted intracellular proteins	Evidence at protein level	HPA043729, HPA059420			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 52.4	Expressed in all		
PPP1R21	CCDC128, FLJ16566, KLRAQ1	ENSG00000162869	Protein phosphatase 1 regulatory subunit 21	2	48440598-48515391	Predicted intracellular proteins	Evidence at protein level	HPA036791, HPA036792	Approved		Approved	Vesicles	Renal cancer:4.59e-6 (favourable), Endometrial cancer:6.83e-4 (unfavourable), Pancreatic cancer:8.05e-4 (favourable), Thyroid cancer:9.87e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 62.3	Expressed in all		
PPP1R26	KIAA0649	ENSG00000196422	Protein phosphatase 1 regulatory subunit 26	9	135479079-135488893	Predicted intracellular proteins	Evidence at protein level	HPA044686, HPA063817	Uncertain		Enhanced	Nucleoplasm	Renal cancer:6.20e-13 (favourable), Colorectal cancer:3.98e-4 (unfavourable), Pancreatic cancer:6.93e-4 (favourable), Endometrial cancer:9.91e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 27.6	Mixed		
PPP1R27	DYSFIP1, toonin	ENSG00000182676	Protein phosphatase 1 regulatory subunit 27	17	81833492-81835050	Predicted intracellular proteins	Evidence at protein level	HPA048632	Uncertain					Tissue enriched	Tissue enriched	38	skeletal muscle: 170.9	prostate: 4.5	Group enriched	26	HL-60: 317.1;THP-1: 513.1
PPP1R2P3	MGC87149	ENSG00000231989	Protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 3	5	156850538-156852528	Predicted intracellular proteins	Evidence at transcript level	HPA043729, HPA059420			Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	435	testis: 43.5	all non-specific tissues: 0.0	Not detected		
PPP1R2P9	I-4	ENSG00000102055	Protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 9	X	42777368-42778247	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	584	testis: 60.2	lymph node,tonsil: 0.1	Not detected		
PPP1R32	C11orf66, FLJ32771, IIIG9	ENSG00000162148	Protein phosphatase 1 regulatory subunit 32	11	61481120-61490931	Predicted intracellular proteins	Evidence at protein level	HPA039068	Enhanced				Endometrial cancer:4.13e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 64.8;testis: 87.5	epididymis: 15.5	Mixed		
PPP1R35	C7orf47, MGC22793	ENSG00000160813	Protein phosphatase 1 regulatory subunit 35	7	100435282-100436565	Predicted intracellular proteins	Evidence at protein level	HPA021604, HPA051607	Enhanced		Approved	Nucleoplasm	Urothelial cancer:4.97e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 34.2	spleen: 17.9	Expressed in all		
PPP1R36	C14orf50	ENSG00000165807	Protein phosphatase 1 regulatory subunit 36	14	64549902-64589380	Predicted intracellular proteins	Evidence at protein level	HPA077492	Enhanced					Mixed	Group enriched	6	fallopian tube: 17.4;testis: 58.9	duodenum: 6.6	Group enriched	6	CAPAN-2: 12.6;SCLC-21H: 3.4
PPP1R37	LRRC68	ENSG00000104866	Protein phosphatase 1 regulatory subunit 37	19	45091396-45148077	Predicted intracellular proteins	Evidence at protein level	HPA041500	Approved		Approved	Cytosol	Urothelial cancer:2.04e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 22.3	Expressed in all		
PPP1R3B	FLJ14005, GL, PPP1R4	ENSG00000173281	Protein phosphatase 1 regulatory subunit 3B	8	9136255-9151574	Predicted intracellular proteins	Evidence at protein level	HPA028731	Approved		Approved	Cytosol	Renal cancer:4.08e-7 (unfavourable), Stomach cancer:6.03e-5 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 151.3	Cell line enhanced		HUVEC TERT2: 39.3;RPTEC TERT1: 46.9
PPP1R3C	PPP1R5, PTG	ENSG00000119938	Protein phosphatase 1 regulatory subunit 3C	10	91628442-91633054	Predicted intracellular proteins	Evidence at protein level	HPA027041	Uncertain					Expressed in all	Tissue enhanced		skeletal muscle: 322.7	heart muscle: 111.2	Cell line enhanced		HHSteC: 43.7;LHCN-M2: 86.1
PPP1R3D	PPP1R6	ENSG00000132825	Protein phosphatase 1 regulatory subunit 3D	20	59936668-59940297	Predicted intracellular proteins	Evidence at protein level	HPA041146	Approved		Approved	Nucleoli<br>Vesicles<br>Mitochondria	Stomach cancer:9.14e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 11.1	Mixed		
PPP1R3E	FLJ00089	ENSG00000235194	Protein phosphatase 1 regulatory subunit 3E	14	23295643-23302848	Predicted intracellular proteins	Evidence at protein level	HPA061600	Approved		Approved	Microtubules<br>Mitotic spindle<br>Mitochondria	Colorectal cancer:6.89e-5 (unfavourable), Lung cancer:3.10e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 14.5	Cell line enhanced		U-266/70: 31.3
PPP1R3G		ENSG00000219607	Protein phosphatase 1 regulatory subunit 3G	6	5084581-5089487	Predicted intracellular proteins	Evidence at protein level	HPA056393	Uncertain					Tissue enhanced	Mixed			spleen: 3.6	Cell line enhanced		EFO-21: 3.4;PC-3: 3.3;THP-1: 8.6
PPP1R42	dtr, LRRC67, TLLR	ENSG00000178125	Protein phosphatase 1 regulatory subunit 42	8	66964099-67056604	Predicted intracellular proteins	Evidence at transcript level	HPA024313, HPA027983, HPA028628	Uncertain					Mixed	Group enriched	20	fallopian tube: 7.9;testis: 15.6	lung: 0.6	Not detected		
PPP1R7	sds22	ENSG00000115685	Protein phosphatase 1 regulatory subunit 7	2	241149576-241183652	Predicted intracellular proteins	Evidence at protein level	HPA034500, HPA034501	Supported		Approved	Nucleoli		Expressed in all	Expressed in all			testis: 287.5	Expressed in all		
PPP1R8	ard-1, ARD1, NIPP-1, NIPP1, PRO2047	ENSG00000117751	Protein phosphatase 1 regulatory subunit 8	1	27830778-27851676	Predicted intracellular proteins	Evidence at protein level	HPA027406, HPA027417, HPA027452	Enhanced		Enhanced	Nucleoplasm<br>Nuclear speckles	Liver cancer:2.19e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 46.5	Expressed in all		
PPP1R9A	FLJ20068, KIAA1222, Neurabin-I	ENSG00000158528	Protein phosphatase 1 regulatory subunit 9A	7	94907202-95296415	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027726, HPA075591	Uncertain		Approved	Plasma membrane	Renal cancer:8.63e-6 (favourable), Ovarian cancer:7.17e-4 (favourable)	Mixed	Mixed			cerebral cortex: 20.6	Mixed		
PPP1R9B	PPP1R6, PPP1R9, SPINO, Spn	ENSG00000108819	Protein phosphatase 1 regulatory subunit 9B	17	50133735-50150630	Predicted intracellular proteins	Evidence at protein level	CAB022461	Approved				Pancreatic cancer:3.11e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 76.2	Expressed in all		
PPP2CA	PP2AC, PP2Calpha	ENSG00000113575	Protein phosphatase 2 catalytic subunit alpha	5	134194334-134226142	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB003848, HPA043236	Approved				Liver cancer:7.33e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 126.6	Expressed in all		
PPP2CB	PP2Abeta	ENSG00000104695	Protein phosphatase 2 catalytic subunit beta	8	30774457-30814314	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018600, HPA043236	Approved		Supported	Nucleoplasm	Renal cancer:5.82e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 207.5	Expressed in all		
PPP2R1A	PP2A-Aalpha, PP2AA, PR65A	ENSG00000105568	Protein phosphatase 2 scaffold subunit Aalpha	19	52190039-52229533	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018599			Approved	Cytosol	Renal cancer:1.20e-4 (favourable), Liver cancer:1.76e-4 (unfavourable), Lung cancer:2.50e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 207.6	Expressed in all		
PPP2R1B	PP2A-Abeta, PR65B	ENSG00000137713	Protein phosphatase 2 scaffold subunit Abeta	11	111726908-111766427	Predicted intracellular proteins	Evidence at protein level	CAB004034, HPA018908	Approved		Approved	Nucleus<br>Plasma membrane<br>Centrosome<br>Cytosol	Liver cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			testis: 98.6	Expressed in all		
PPP2R2A	B55A, PR52A, PR55A	ENSG00000221914	Protein phosphatase 2 regulatory subunit Balpha	8	26291491-26372680	Predicted intracellular proteins	Evidence at protein level	HPA042122, HPA042770, CAB079289	Approved		Approved	Cytosol		Expressed in all	Expressed in all			placenta: 72.2	Expressed in all		
PPP2R2B	PR52B, PR55-BETA, SCA12	ENSG00000156475	Protein phosphatase 2 regulatory subunit Bbeta	5	146581146-147084784	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038118, HPA042122, HPA042770	Approved		Approved	Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 135.2	testis: 33.9	Cell line enhanced		HaCaT: 19.5;HDLM-2: 97.5;RT4: 19.0
PPP2R2C	IMYPNO, MGC33570, PR52, PR55G	ENSG00000074211	Protein phosphatase 2 regulatory subunit Bgamma	4	6320578-6563600	Predicted intracellular proteins	Evidence at protein level	HPA042122, HPA042770	Approved				Lung cancer:4.94e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 164.4	endometrium: 53.2	Cell line enhanced		A-431: 30.5;A549: 45.5;MCF7: 32.3;PC-3: 43.7;SCLC-21H: 53.0
PPP2R2D	MDS026	ENSG00000175470	Protein phosphatase 2 regulatory subunit Bdelta	10	131900644-131959834	Predicted intracellular proteins	Evidence at protein level	HPA042122, HPA042770	Approved		Approved	Cytosol	Colorectal cancer:3.14e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 6.7	Mixed		
PPP2R3A	PPP2R3	ENSG00000073711	Protein phosphatase 2 regulatory subunit B''alpha	3	135965673-136147891	Predicted intracellular proteins	Evidence at protein level	HPA035829, HPA035830, HPA065338	Uncertain		Approved	Golgi apparatus	Pancreatic cancer:1.14e-5 (unfavourable), Renal cancer:1.15e-5 (favourable), Urothelial cancer:3.91e-4 (unfavourable), Endometrial cancer:4.38e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 63.3	heart muscle: 34.3	Mixed		
PPP2R3B	PPP2R3L, PPP2R3LY, PR48	ENSG00000167393	Protein phosphatase 2 regulatory subunit B''beta	X	333963-386955	Predicted intracellular proteins	Evidence at protein level	HPA074545			Uncertain	Endoplasmic reticulum	Urothelial cancer:1.90e-5 (favourable), Pancreatic cancer:2.92e-5 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 14.7	heart muscle: 4.6	Cell line enhanced		PC-3: 20.0;U-698: 23.8
PPP2R3C	C14orf10, FLJ20644, G4-1, G5PR	ENSG00000092020	Protein phosphatase 2 regulatory subunit B''gamma	14	35085467-35122517	Predicted intracellular proteins	Evidence at protein level	HPA040835, HPA058834	Approved		Approved	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 98.1	Expressed in all		
PPP2R5A	B56A, PR61A	ENSG00000066027	Protein phosphatase 2 regulatory subunit B'alpha	1	212285537-212361863	Predicted intracellular proteins	Evidence at protein level	HPA059288			Supported	Cytosol		Expressed in all	Expressed in all			lung: 86.5	Expressed in all		
PPP2R5B	B56B, FLJ35411, PR61B	ENSG00000068971	Protein phosphatase 2 regulatory subunit B'beta	11	64917553-64934473	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036607	Approved				Liver cancer:3.24e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 59.7	Expressed in all		
PPP2R5C	B56G, PR61G	ENSG00000078304	Protein phosphatase 2 regulatory subunit B'gamma	14	101761798-101927989	Predicted intracellular proteins	Evidence at protein level	HPA027553	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			lymph node: 157.9	Expressed in all		
PPP2R5D	B56D	ENSG00000112640	Protein phosphatase 2 regulatory subunit B'delta	6	42984499-43012342	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029045, HPA029046	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.89e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.3	Expressed in all		
PPP2R5E		ENSG00000154001	Protein phosphatase 2 regulatory subunit B'epsilon	14	63371357-63543374	Predicted intracellular proteins	Evidence at protein level	HPA006034, CAB072342	Approved		Supported	Cytosol	Liver cancer:1.95e-4 (unfavourable), Renal cancer:4.16e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 33.9	Expressed in all		
PPP3CA	CALN, CALNA, CNA1, PPP2B	ENSG00000138814	Protein phosphatase 3 catalytic subunit alpha	4	101023409-101348278	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012778, CAB018581	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.82e-4 (unfavourable)	Tissue enriched	Expressed in all			cerebral cortex: 164.3	Expressed in all		
PPP3CB	CALNA2, CALNB, CNA2, PP2Bbeta	ENSG00000107758	Protein phosphatase 3 catalytic subunit beta	10	73436428-73496024	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008233, HPA008823	Uncertain		Approved	Mitochondria	Pancreatic cancer:6.96e-5 (favourable), Liver cancer:9.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 153.2	Expressed in all		
PPP3CC	CALNA3, PP2Bgamma	ENSG00000120910	Protein phosphatase 3 catalytic subunit gamma	8	22440819-22541142	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023396, CAB024950	Approved		Approved	Vesicles	Lung cancer:6.80e-5 (favourable)	Expressed in all	Expressed in all			testis: 101.2	Expressed in all		
PPP3R1	CALNB1, CNB, CNB1	ENSG00000221823	Protein phosphatase 3 regulatory subunit B, alpha	2	68178857-68256237	Predicted intracellular proteins	Evidence at protein level	CAB005610, HPA047157	Approved		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:9.08e-6 (unfavourable), Renal cancer:1.70e-5 (unfavourable), Liver cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 197.5	Expressed in all		
PPP3R2	PPP3RL	ENSG00000188386	Protein phosphatase 3 regulatory subunit B, beta	9	101591615-101595021	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047157	Uncertain		Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enriched	1372	testis: 137.1	all non-specific tissues: 0.0	Not detected		
PPP4C	PP4, PPX	ENSG00000149923	Protein phosphatase 4 catalytic subunit	16	30075978-30085377	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043837	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 78.0	Expressed in all		
PPP4R1	PP4R1	ENSG00000154845	Protein phosphatase 4 regulatory subunit 1	18	9546791-9615240	Predicted intracellular proteins	Evidence at protein level	HPA040905, HPA041089	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			esophagus: 78.2	Expressed in all		
PPP4R2		ENSG00000163605	Protein phosphatase 4 regulatory subunit 2	3	72996785-73069199	Predicted intracellular proteins	Evidence at protein level	HPA034695, HPA039837, HPA073758	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 66.7	Expressed in all		
PPP4R3A	FLFL1, FLJ20707, KIAA2010, MSTP033, PP4R3, SMEK1, smk-1, smk1	ENSG00000100796	Protein phosphatase 4 regulatory subunit 3A	14	91457611-91510554	Predicted intracellular proteins	Evidence at protein level	HPA002568, HPA063917	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 61.2	Expressed in all		
PPP4R3B	FLFL2, FLJ31474, KIAA1387, PSY2, SMEK2	ENSG00000275052	Protein phosphatase 4 regulatory subunit 3B	2	55547292-55618880	Predicted intracellular proteins	Evidence at protein level	HPA001233, CAB017185	Approved		Supported	Nucleoplasm<br>Nuclear speckles<br>Centrosome	Renal cancer:6.03e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 58.0	Expressed in all		
PPP4R3CP	FLFL3P, FLJ32867, SMEK3P, smk1	ENSG00000224960	Protein phosphatase 4 regulatory subunit 3C, pseudogene	X	27460211-27463341	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	11	testis: 3.6	placenta: 0.3	Cell line enriched	146	U-2197: 19.0
PPP4R4	CFAP14, KIAA1622, PP4R4	ENSG00000119698	Protein phosphatase 4 regulatory subunit 4	14	94146128-94279735	Predicted intracellular proteins	Evidence at protein level	HPA041866, HPA050321	Approved		Supported	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 14.0;testis: 11.1	ovary: 5.4	Cell line enhanced		RH-30: 17.0;T-47d: 17.6
PPP5C	PP5, PPP5	ENSG00000011485	Protein phosphatase 5 catalytic subunit	19	46346994-46392981	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB022641, HPA029065, HPA056933	Approved		Supported	Vesicles<br>Cytosol	Liver cancer:3.45e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 44.3	Expressed in all		
PPP5D1		ENSG00000230510	PPP5 tetratricopeptide repeat domain containing 1	19	46480796-46601200	Predicted intracellular proteins	Evidence at transcript level	HPA073186	Uncertain		Uncertain	Cytosol		Not detected	Mixed			cerebral cortex: 4.8	Mixed		
PPP6C	PP6	ENSG00000119414	Protein phosphatase 6 catalytic subunit	9	125146573-125189939	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050940	Uncertain				Renal cancer:4.50e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.7	Expressed in all		
PPP6R1	KIAA1115, SAP190, SAPS1	ENSG00000105063	Protein phosphatase 6 regulatory subunit 1	19	55229780-55258995	Predicted intracellular proteins	Evidence at protein level	HPA043989, HPA063681	Approved		Enhanced	Cytosol	Liver cancer:3.82e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 117.3	Expressed in all		
PPP6R2	dJ579N16.1, KIAA0685, SAP190, SAPS2	ENSG00000100239	Protein phosphatase 6 regulatory subunit 2	22	50343304-50445090	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030656, CAB034919	Uncertain		Supported	Vesicles<br>Cytosol	Endometrial cancer:1.70e-5 (favourable), Pancreatic cancer:7.51e-4 (favourable)	Expressed in all	Expressed in all			testis: 65.3	Expressed in all		
PPP6R3	C11orf23, DKFZp781E17107, DKFZp781E2374, DKFZp781O2362, FLJ11058, FLJ43065, KIAA1558, MGC125711, MGC125712, PP6R3, SAP190, SAPL, SAPLa, SAPS3	ENSG00000110075	Protein phosphatase 6 regulatory subunit 3	11	68460731-68615334	Predicted intracellular proteins	Evidence at protein level	CAB017183, HPA038467, HPA038468	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Testis cancer:8.23e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 93.8	Expressed in all		
PPRC1	KIAA0595, MGC74642, PRC	ENSG00000148840	Peroxisome proliferator-activated receptor gamma, coactivator-related 1	10	102132994-102150331	Predicted intracellular proteins	Evidence at protein level	HPA038511, HPA057571	Approved		Enhanced	Nucleoplasm	Renal cancer:6.71e-7 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 20.8	Expressed in all		
PPTC7	TA-PP2C	ENSG00000196850	PTC7 protein phosphatase homolog	12	110533245-110583320	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039335, HPA040614	Approved		Approved	Plasma membrane<br>Cytosol	Ovarian cancer:1.43e-5 (unfavourable), Renal cancer:4.48e-5 (favourable), Pancreatic cancer:6.76e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.4	Expressed in all		
PPWD1	KIAA0073	ENSG00000113593	Peptidylprolyl isomerase domain and WD repeat containing 1	5	65563236-65587549	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019353, HPA019360	Enhanced		Supported	Nuclear bodies	Liver cancer:2.19e-4 (unfavourable), Renal cancer:6.72e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 31.6	Expressed in all		
PQBP1	MRX2, MRX55, MRXS3, MRXS8, RENS1, SHS	ENSG00000102103	Polyglutamine binding protein 1	X	48897912-48903143	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001880	Supported		Enhanced	Nuclear speckles	Renal cancer:2.68e-7 (unfavourable), Cervical cancer:1.48e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube,ovary: 49.9	Expressed in all		
PRAC1	C17orf92, PRAC	ENSG00000159182	Prostate cancer susceptibility candidate 1	17	48721719-48722522	Predicted intracellular proteins	Evidence at transcript level	HPA047871	Approved					Tissue enriched	Group enriched	38	colon: 102.9;prostate: 171.7;rectum: 220.8	urinary bladder: 4.3	Cell line enriched	32	PC-3: 343.9
PRAG1	DKFZp761P0423, NACK, PEAK2, PRAGMIN, SgK223	ENSG00000275342	PEAK1 related kinase activating pseudokinase 1	8	8317736-8386498	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012066	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:4.81e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 28.3	small intestine: 12.2	Cell line enhanced		A549: 45.2
PRAM1	PML-RAR	ENSG00000133246	PML-RARA regulated adaptor molecule 1	19	8490056-8503112	Predicted intracellular proteins	Evidence at protein level	HPA045236, HPA050161	Approved		Approved	Golgi apparatus	Renal cancer:8.08e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 65.1	appendix: 15.2	Cell line enhanced		HL-60: 18.4;THP-1: 26.7;U-937: 99.1
PRAME	CT130, MAPE	ENSG00000185686	Preferentially expressed antigen in melanoma	22	22547701-22559361	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045153	Enhanced				Renal cancer:7.48e-9 (unfavourable), Head and neck cancer:3.41e-4 (unfavourable)	Group enriched	Group enriched	8	epididymis: 17.1;testis: 80.5	endometrium: 6.3	Cell line enhanced		HMC-1: 154.1;K-562: 872.4;SH-SY5Y: 199.7;U-2 OS: 171.5
PRAMEF1		ENSG00000116721	PRAME family member 1	1	12791397-12796628	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
PRAMEF10		ENSG00000187545	PRAME family member 10	1	12892896-12898270	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	12	liver: 1.1	all non-specific tissues: 0.0	Not detected		
PRAMEF11		ENSG00000239810	PRAME family member 11	1	12824605-12831410	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
PRAMEF12		ENSG00000116726	PRAME family member 12	1	12774841-12777906	Plasma proteins, Predicted intracellular proteins	No evidence	HPA045286, HPA051704	Uncertain		Uncertain	Nucleoplasm		Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF13		ENSG00000279169	PRAME family member 13	1	13196330-13201409	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
PRAMEF14		ENSG00000204481	PRAME family member 14	1	13342034-13347134	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF15		ENSG00000204501	PRAME family member 15	1	13315581-13322598	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF17		ENSG00000204479	PRAME family member 17	1	13389632-13392629	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF18		ENSG00000279804	PRAME family member 18	1	13222705-13226106	Predicted intracellular proteins	No evidence	HPA057423	Uncertain					Not detected	Not detected			bone marrow: 0.1	Not detected		
PRAMEF19		ENSG00000204480	PRAME family member 19	1	13369067-13371693	Predicted intracellular proteins	No evidence	HPA057423	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF2	FLJ43580	ENSG00000120952	PRAME family member 2	1	12857086-12861909	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
PRAMEF20	OTTHUMT00000008157, PRAMEF21	ENSG00000204478	PRAME family member 20	1	13410450-13421328	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
PRAMEF25		ENSG00000229571	PRAME family member 25	1	13068677-13077884	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF26		ENSG00000280267	PRAME family member 26	1	13148905-13155961	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF27		ENSG00000274764	PRAME family member 27	1	13049476-13056491	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF33	PRAMEF33P	ENSG00000237700	PRAME family member 33	1	13303539-13308907	Predicted intracellular proteins	No evidence							Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF4	RP5-845O24.6	ENSG00000243073	PRAME family member 4	1	12879224-12886201	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF5	PRAMEF23, PRAMEF5L	ENSG00000270601	PRAME family member 5	1	13254212-13263314	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF6		ENSG00000232423	PRAME family member 6	1	12938472-12947580	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF7		ENSG00000204510	PRAME family member 7	1	12916610-12920482	Predicted intracellular proteins	Evidence at transcript level	HPA049887, HPA051704	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF8		ENSG00000182330	PRAME family member 8	1	13281035-13285174	Predicted intracellular proteins	Evidence at transcript level	HPA049887, HPA051704	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF9		ENSG00000204505	PRAME family member 9	1	13172455-13179464	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRC1	ASE1	ENSG00000198901	Protein regulator of cytokinesis 1	15	90966038-90995629	Predicted intracellular proteins	Evidence at protein level	HPA034521	Enhanced				Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:2.76e-5 (unfavourable), Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 85.8	Expressed in all		
PRCC	RCCP1	ENSG00000143294	Papillary renal cell carcinoma (translocation-associated)	1	156750610-156800817	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017151, HPA019463, HPA019481	Supported		Enhanced	Nuclear speckles	Renal cancer:8.99e-15 (unfavourable), Thyroid cancer:3.72e-4 (unfavourable), Endometrial cancer:5.55e-4 (unfavourable), Liver cancer:8.63e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 54.5	Expressed in all		
PRDM1	BLIMP1, PRDI-BF1	ENSG00000057657	PR/SET domain 1	6	106086320-106109939	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030033	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:9.81e-5 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 61.0	endometrium: 30.1	Cell line enhanced		Karpas-707: 158.5;U-266/70: 62.6;U-266/84: 39.9
PRDM10	KIAA1231, MGC131802, PFM7	ENSG00000170325	PR/SET domain 10	11	129899706-130002835	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026997	Approved		Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Vesicles		Expressed in all	Mixed			parathyroid gland: 7.6	Expressed in all		
PRDM11	PFM8	ENSG00000019485	PR/SET domain 11	11	45095806-45235110	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA057072	Approved					Mixed	Mixed			thyroid gland: 13.9	Mixed		
PRDM13		ENSG00000112238	PR/SET domain 13	6	99606730-99615578	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA070592	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRDM14		ENSG00000147596	PR/SET domain 14	8	70051651-70071693	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019094, HPA057070	Uncertain		Uncertain	Nucleoplasm		Tissue enriched	Tissue enhanced		testis: 1.7	skin: 0.5	Cell line enriched	101	NTERA-2: 50.3
PRDM15	C21orf83, ZNF298	ENSG00000141956	PR/SET domain 15	21	41798225-41879482	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024268, HPA029255, HPA029256	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			lymph node: 8.8	Cell line enhanced		Daudi: 21.6;U-698: 37.6
PRDM16	KIAA1675, KMT8F, MEL1, MGC166915, PFM13	ENSG00000142611	PR/SET domain 16	1	3069168-3438621	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050343, HPA060467			Enhanced	Nucleoplasm	Thyroid cancer:4.70e-5 (unfavourable)	Mixed	Mixed			thyroid gland: 7.6	Cell line enhanced		AN3-CA: 1.4;CACO-2: 1.2;HAP1: 1.4;HEK93: 1.6;HHSteC: 1.7;MCF7: 1.2
PRDM2	HUMHOXY1, KMT8, KMT8A, MTB-ZF, RIZ, RIZ1, RIZ2	ENSG00000116731	PR/SET domain 2	1	13700198-13825079	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005809	Approved		Approved	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			bone marrow: 51.2	Expressed in all		
PRDM4	PFM1	ENSG00000110851	PR/SET domain 4	12	107732866-107761272	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024322, HPA067437	Approved		Supported	Nucleoplasm	Renal cancer:3.15e-7 (favourable), Liver cancer:1.86e-4 (unfavourable), Melanoma:7.66e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 90.0	Expressed in all		
PRDM5	PFM2	ENSG00000138738	PR/SET domain 5	4	120684919-120922870	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051406	Enhanced		Supported	Nucleus<br>Nucleoli<br>Nuclear bodies		Mixed	Mixed			parathyroid gland: 20.7	Mixed		
PRDM6	KMT8C, PRISM	ENSG00000061455	PR/SET domain 6	5	123089121-123194266	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030322, HPA030324	Uncertain		Uncertain	Nucleoplasm		Mixed	Tissue enhanced		gallbladder: 5.2;placenta: 5.9	lung: 4.0	Cell line enhanced		BEWO: 3.5;HEK93: 4.7
PRDM7	ZNF910	ENSG00000126856	PR/SET domain 7	16	90056566-90092072	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059944	Approved		Uncertain	Nuclear speckles		Tissue enriched	Tissue enriched	11	testis: 1.1	all non-specific tissues: 0.0	Group enriched	30	REH: 3.8;SK-MEL-30: 2.1
PRDM8	KMT8D	ENSG00000152784	PR/SET domain 8	4	80183879-80204329	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057253			Approved	Nuclear bodies		Tissue enhanced	Tissue enhanced		prostate: 40.8;seminal vesicle: 37.7	cerebral cortex: 23.2	Cell line enhanced		LHCN-M2: 34.7;NB-4: 30.5;SCLC-21H: 116.7
PRDM9	KMT8B, MSBP3, PFM6, ZNF899	ENSG00000164256	PR/SET domain 9	5	23443586-23528597	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059555	Uncertain					Not detected	Group enriched	7	epididymis: 1.7;testis: 7.1	bone marrow: 0.6	Cell line enriched	7	U-266/70: 5.0
PRDX1	NKEFA, PAGA	ENSG00000117450	Peroxiredoxin 1	1	45511036-45523047	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004682, HPA007730	Approved		Supported	Mitochondria	Liver cancer:1.17e-5 (unfavourable), Urothelial cancer:2.89e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 1209.9	Expressed in all		
PRDX2	MGC4104, NKEFB, PRP, PRX2, PRXII, TDPX1, TSA	ENSG00000167815	Peroxiredoxin 2	19	12796820-12801859	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008713	Approved				Renal cancer:5.66e-11 (favourable)	Expressed in all	Expressed in all			adrenal gland: 468.9	Mixed		
PRDX3	AOP-1, AOP1, MER5, SP-22	ENSG00000165672	Peroxiredoxin 3	10	119167703-119178833	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008656, HPA041488	Enhanced					Expressed in all	Expressed in all			adrenal gland: 429.1	Expressed in all		
PRDX5	ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10	ENSG00000126432	Peroxiredoxin 5	11	64318088-64321811	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008661, HPA037915, HPA037916	Enhanced		Enhanced	Mitochondria<br>Cytosol	Renal cancer:1.24e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 606.1	Expressed in all		
PRDX6	1-Cys, aiPLA2, AOP2, KIAA0106, MGC46173, NSGPx, p29, PRX	ENSG00000117592	Peroxiredoxin 6	1	173477266-173488807	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006983, CAB008663	Supported		Supported	Plasma membrane<br>Cytosol	Head and neck cancer:1.23e-5 (unfavourable), Renal cancer:9.51e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 370.1	Expressed in all		
PRELID1	CGI-106, PRELI, PX19	ENSG00000169230	PRELI domain containing 1	5	177303774-177306959	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005701	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.89e-7 (unfavourable), Liver cancer:5.46e-5 (unfavourable)	Expressed in all	Expressed in all			small intestine: 130.3	Expressed in all		
PRELID2	FLJ38376, MGC21644	ENSG00000186314	PRELI domain containing 2	5	145471799-145835369	Predicted intracellular proteins	Evidence at transcript level	HPA042486	Uncertain		Approved	Nucleoplasm	Renal cancer:9.65e-6 (unfavourable), Pancreatic cancer:3.78e-4 (unfavourable)	Mixed	Tissue enhanced		small intestine: 28.7	rectum: 19.2	Mixed		
PRELID3A	C18orf43, FLJ31484, HFL-EDDG1, SLMO1	ENSG00000141391	PRELI domain containing 3A	18	12407896-12432238	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:5.89e-7 (unfavourable)	Mixed	Mixed			seminal vesicle: 16.6	Mixed		
PRELID3B	C20orf45, dJ543J19.5, SLMO2	ENSG00000101166	PRELI domain containing 3B	20	59033145-59042909	Predicted intracellular proteins	Evidence at protein level	HPA047721	Uncertain		Approved	Nucleus	Liver cancer:6.96e-5 (unfavourable), Endometrial cancer:5.04e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 88.0	Expressed in all		
PREP		ENSG00000085377	Prolyl endopeptidase	6	105277565-105403084	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025414, HPA031388, HPA031389, HPA031390	Enhanced		Enhanced	Cytosol	Head and neck cancer:3.33e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 53.9	Expressed in all		
PREPL	KIAA0436	ENSG00000138078	Prolyl endopeptidase-like	2	44316281-44361862	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA063238	Approved					Expressed in all	Expressed in all			cerebral cortex: 257.4	Expressed in all		
PREX1	KIAA1415, P-REX1	ENSG00000124126	Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1	20	48624252-48827883	Predicted intracellular proteins	Evidence at protein level	HPA001927	Supported		Supported	Vesicles<br>Cytosol	Head and neck cancer:8.56e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.8	Cell line enhanced		MCF7: 124.7;SK-BR-3: 123.7;T-47d: 138.8
PREX2	DEP.2, DEPDC2, FLJ12987, P-REX2, PPP1R129	ENSG00000046889	Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2	8	67952118-68237030	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015234, HPA075956	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.61e-7 (unfavourable)	Mixed	Mixed			cerebral cortex: 11.9	Cell line enhanced		AF22: 13.9;HUVEC TERT2: 16.1;NTERA-2: 12.2;RH-30: 5.3
PRICKLE1	EPM1B, FLJ31937, RILP	ENSG00000139174	Prickle planar cell polarity protein 1	12	42456757-42590355	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001379, HPA050037	Enhanced		Approved	Nucleoplasm	Glioma:5.56e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 21.2	Cell line enriched	13	HBEC3-KT: 727.1
PRICKLE2	DKFZp686D143	ENSG00000163637	Prickle planar cell polarity protein 2	3	64092242-64445476	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035493			Approved	Golgi apparatus<br>Vesicles		Mixed	Mixed			endometrium: 29.7	Cell line enhanced		ASC diff: 16.5;HSkMC: 16.1;U-87 MG: 15.2
PRICKLE3	LMO6	ENSG00000012211	Prickle planar cell polarity protein 3	X	49175264-49186528	Predicted intracellular proteins	Evidence at protein level	HPA000998, HPA001442	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Centrosome	Renal cancer:5.73e-6 (unfavourable), Urothelial cancer:4.84e-5 (favourable)	Expressed in all	Mixed			skin: 11.7	Mixed		
PRICKLE4	C6orf49, DKFZp761H221, OEBT	ENSG00000278224	Prickle planar cell polarity protein 4	6	41780762-41787372	Predicted intracellular proteins	Evidence at transcript level	HPA031240			Uncertain	Mitotic spindle<br>Microtubule organizing center		Not detected	Mixed			fallopian tube: 3.9	Cell line enhanced		BEWO: 3.9
PRIM1		ENSG00000198056	Primase (DNA) subunit 1	12	56731596-56752373	Predicted intracellular proteins	Evidence at protein level	HPA040010	Uncertain		Supported	Vesicles	Liver cancer:2.40e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 21.8	Expressed in all		
PRIM2	PRIM2A	ENSG00000146143	Primase (DNA) subunit 2	6	57314805-57646849	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046566			Supported	Nucleoplasm	Renal cancer:7.34e-6 (unfavourable), Ovarian cancer:3.00e-5 (favourable), Liver cancer:3.44e-5 (unfavourable), Pancreatic cancer:5.25e-4 (unfavourable), Endometrial cancer:6.98e-4 (unfavourable)	Expressed in all	Tissue enhanced		prostate: 51.6	testis: 11.5	Expressed in all		
PRIMPOL	CCDC111, FLJ33167	ENSG00000164306	Primase and DNA directed polymerase	4	184649613-184694963	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA054372	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			endometrium: 17.2	Expressed in all		
PRKAA1	AMPKa1	ENSG00000132356	Protein kinase AMP-activated catalytic subunit alpha 1	5	40759379-40798374	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005050, HPA035409, HPA064946	Supported		Supported	Nuclear speckles		Expressed in all	Expressed in all			testis: 74.4	Expressed in all		
PRKAB1		ENSG00000111725	Protein kinase AMP-activated non-catalytic subunit beta 1	12	119667753-119681630	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004247, CAB005058	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.40e-9 (favourable), Endometrial cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			kidney: 53.5	Expressed in all		
PRKAB2		ENSG00000131791	Protein kinase AMP-activated non-catalytic subunit beta 2	1	147155106-147172550	Predicted intracellular proteins	Evidence at protein level	HPA044342	Approved		Approved	Nucleoplasm	Thyroid cancer:6.78e-7 (unfavourable), Breast cancer:4.55e-4 (unfavourable), Head and neck cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 45.5	Expressed in all		
PRKACA	PKACa	ENSG00000072062	Protein kinase cAMP-activated catalytic subunit alpha	19	14091688-14118084	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010361, HPA071185	Approved		Approved	Cytosol	Cervical cancer:6.28e-6 (favourable), Endometrial cancer:6.26e-5 (unfavourable), Pancreatic cancer:6.47e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 200.4	Expressed in all		
PRKACB	PKACb	ENSG00000142875	Protein kinase cAMP-activated catalytic subunit beta	1	84078062-84238498	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010363, HPA029754, HPA071185	Approved		Approved	Cytosol	Renal cancer:1.89e-6 (favourable), Liver cancer:9.49e-4 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 316.3	adrenal gland: 63.1	Mixed		
PRKACG	PKACg	ENSG00000165059	Protein kinase cAMP-activated catalytic subunit gamma	9	69012529-69014113	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004530, HPA071185	Supported		Approved	Cytosol		Not detected	Tissue enriched	302	testis: 30.1	all non-specific tissues: 0.0	Not detected		
PRKAG2	AAKG, AAKG2, CMH6, H91620p, WPWS	ENSG00000106617	Protein kinase AMP-activated non-catalytic subunit gamma 2	7	151556111-151877125	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004246, CAB018641	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			heart muscle: 81.8	Mixed		
PRKAG3		ENSG00000115592	Protein kinase AMP-activated non-catalytic subunit gamma 3	2	218822383-218832086	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	18	skeletal muscle: 23.9	esophagus: 1.3	Not detected		
PRKAR1A	CNC1, PRKAR1, TSE1	ENSG00000108946	Protein kinase cAMP-dependent type I regulatory subunit alpha	17	68511780-68551319	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB019378, HPA049979	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 564.4	Expressed in all		
PRKAR1B		ENSG00000188191	Protein kinase cAMP-dependent type I regulatory subunit beta	7	549197-727650	Predicted intracellular proteins	Evidence at protein level	HPA026719	Approved					Expressed in all	Tissue enriched	9	cerebral cortex: 239.1	ovary: 26.3	Expressed in all		
PRKAR2A	PRKAR2	ENSG00000114302	Protein kinase cAMP-dependent type II regulatory subunit alpha	3	48744597-48847846	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005023, HPA038268	Uncertain		Supported	Golgi apparatus<br>Vesicles<br>Microtubule organizing center	Colorectal cancer:4.27e-5 (favourable), Liver cancer:1.97e-4 (unfavourable), Renal cancer:2.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 124.3	Mixed		
PRKAR2B	PRKAR2	ENSG00000005249	Protein kinase cAMP-dependent type II regulatory subunit beta	7	107044649-107161811	Predicted intracellular proteins	Evidence at protein level	HPA008421	Enhanced		Approved	Golgi apparatus<br>Centrosome<br>Mitochondria<br>Cytosol	Pancreatic cancer:4.03e-4 (favourable), Colorectal cancer:6.38e-4 (favourable), Thyroid cancer:8.74e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 139.4	adrenal gland: 39.1	Cell line enhanced		AN3-CA: 64.4;Daudi: 70.1;U-698: 172.6
PRKCA	PKCA	ENSG00000154229	Protein kinase C alpha	17	66302636-66810743	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003844, HPA006563, HPA006564, CAB016290	Enhanced	Approved	Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 45.0	Cell line enhanced		U-87 MG: 157.3
PRKCB	PKCB, PRKCB1, PRKCB2	ENSG00000166501	Protein kinase C beta	16	23836001-24220611	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003843, HPA048321, HPA054203	Approved		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 125.4	spleen: 64.5	Cell line enhanced		HEL: 145.7;HMC-1: 137.9;K-562: 211.8
PRKCD		ENSG00000163932	Protein kinase C delta	3	53156009-53192717	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001863, HPA001890, CAB010469, CAB013225	Enhanced		Enhanced	Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol	Liver cancer:2.24e-4 (unfavourable), Lung cancer:9.01e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 70.4	Expressed in all		
PRKCDBP	cavin-3, CAVIN3, HSRBC, MGC20400, SRBC	ENSG00000170955	Protein kinase C delta binding protein	11	6318946-6320647	Predicted intracellular proteins	Evidence at protein level	HPA055136, HPA073327	Approved		Approved	Plasma membrane	Renal cancer:5.21e-6 (unfavourable), Cervical cancer:3.75e-5 (unfavourable)	Expressed in all	Mixed			adipose tissue: 30.4	Cell line enhanced		A-431: 88.2;BJ: 80.0;TIME: 91.9;U-87 MG: 101.1;WM-115: 110.6
PRKCE		ENSG00000171132	Protein kinase C epsilon	2	45651345-46187990	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB001948, HPA044496, HPA054252	Enhanced		Approved	Vesicles	Renal cancer:2.63e-7 (favourable), Endometrial cancer:2.42e-4 (unfavourable), Lung cancer:9.62e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 48.3	parathyroid gland: 20.5	Mixed		
PRKCG	MGC57564, PKCC, PKCG, SCA14	ENSG00000126583	Protein kinase C gamma	19	53879190-53907652	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB013051, HPA047870, HPA054560	Supported					Mixed	Tissue enriched	9	cerebral cortex: 40.9	testis: 4.7	Cell line enhanced		A549: 2.0;SH-SY5Y: 1.5
PRKCH	PKC-L, PKCL, PRKCL	ENSG00000027075	Protein kinase C eta	14	61187559-61550976	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026294, HPA053709	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:8.55e-6 (favourable)	Expressed in all	Expressed in all			lymph node: 61.7	Cell line enhanced		BEWO: 78.7;HUVEC TERT2: 90.5;MOLT-4: 60.3;TIME: 58.5
PRKCI	DXS1179E, PKCI	ENSG00000163558	Protein kinase C iota	3	170222365-170305981	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026574, HPA038635	Approved		Enhanced	Microtubules<br>Cytokinetic bridge<br>Cytosol	Endometrial cancer:3.93e-6 (unfavourable), Pancreatic cancer:1.22e-4 (unfavourable), Liver cancer:3.02e-4 (unfavourable), Renal cancer:3.10e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Expressed in all		
PRKCQ		ENSG00000065675	Protein kinase C theta	10	6427143-6580301	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065279, HPA073098			Enhanced	Microtubule organizing center	Thyroid cancer:5.27e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 43.0	thyroid gland: 25.0	Cell line enhanced		HEL: 50.9;MOLT-4: 34.7
PRKCZ	PKC2	ENSG00000067606	Protein kinase C zeta	1	2050470-2185395	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021851	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.64e-9 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 99.7	placenta: 62.3	Cell line enhanced		BEWO: 45.1
PRKD2	DKFZP586E0820, HSPC187, PKD2	ENSG00000105287	Protein kinase D2	19	46674275-46717127	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021490, HPA056727	Enhanced		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:9.15e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.3	Expressed in all		
PRKD3	EPK2, PRKCN	ENSG00000115825	Protein kinase D3	2	37250502-37324808	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029529	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:3.47e-4 (unfavourable), Colorectal cancer:4.84e-4 (favourable)	Expressed in all	Expressed in all			testis: 44.4	Expressed in all		
PRKDC	DNA-PKcs, DNAPK, DNPK1, HYRC, HYRC1, p350, XRCC7	ENSG00000253729	Protein kinase, DNA-activated, catalytic polypeptide	8	47773108-47960183	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005167, HPA035174	Supported		Enhanced	Nucleoplasm	Endometrial cancer:1.03e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.6	Expressed in all		
PRKG1	PGK, PKG, PRKG1B, PRKGR1B	ENSG00000185532	Protein kinase, cGMP-dependent, type I	10	50991358-52298350	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007699, CAB009629	Enhanced		Approved	Vesicles<br>Cytosol		Mixed	Mixed			smooth muscle: 25.1	Cell line enhanced		AN3-CA: 19.3;BJ hTERT+: 17.6;fHDF/TERT166: 13.4
PRKG2	cGKII, PRKGR2	ENSG00000138669	Protein kinase, cGMP-dependent, type II	4	81087370-81215117	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007386, CAB018739	Approved					Tissue enhanced	Tissue enhanced		prostate: 15.3;small intestine: 14.4	duodenum: 9.7	Cell line enhanced		HEL: 18.8;SCLC-21H: 7.3
PRKRA	DYT16, HSD14, PACT, RAX	ENSG00000180228	Protein activator of interferon induced protein kinase EIF2AK2	2	178431414-178451512	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004648, HPA034996, HPA034997	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:8.33e-5 (unfavourable), Testis cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			testis: 56.2	Expressed in all		
PRKRIP1	C114, FLJ13902, KRBOX3	ENSG00000128563	PRKR interacting protein 1 (IL11 inducible)	7	102363872-102426676	Predicted intracellular proteins	Evidence at protein level	HPA051146	Uncertain		Supported	Actin filaments<br>Cytosol	Urothelial cancer:1.94e-4 (favourable), Colorectal cancer:3.65e-4 (unfavourable), Renal cancer:4.39e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.7	Expressed in all		
PRKX	PKX1	ENSG00000183943	Protein kinase, X-linked	X	3604370-3713608	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015324	Supported		Supported	Nucleus		Expressed in all	Tissue enhanced		thyroid gland: 58.0	fallopian tube: 31.8	Cell line enhanced		HMC-1: 67.0
PRM1	CT94.1	ENSG00000175646	Protamine 1	16	11280836-11281350	Predicted intracellular proteins	Evidence at protein level	HPA055150	Enhanced					Tissue enriched	Tissue enriched	5169	testis: 9195.1	small intestine: 1.7	Cell line enhanced		NB-4: 1.3;U-2197: 1.4
PRM2	CT94.2	ENSG00000122304	Protamine 2	16	11275639-11276480	Predicted intracellular proteins	Evidence at protein level	CAB032738, HPA056386	Enhanced					Tissue enriched	Tissue enriched	5145	testis: 7760.7	small intestine: 1.5	Cell line enhanced		BEWO: 1.1;U-2197: 1.7
PRM3		ENSG00000178257	Protamine 3	16	11273218-11273641	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	23	testis: 42.3	bone marrow: 1.8	Cell line enhanced		TIME: 3.0
PRMT1	ANM1, HCP1, HRMT1L2	ENSG00000126457	Protein arginine methyltransferase 1	19	49675786-49689029	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022550, HPA069769, HPA072136	Enhanced		Supported	Nucleoplasm	Liver cancer:8.04e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 181.1	Expressed in all		
PRMT2	HRMT1L1, MGC111373	ENSG00000160310	Protein arginine methyltransferase 2	21	46635167-46665124	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018976, HPA029591	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			ovary: 98.6	Expressed in all		
PRMT3	HRMT1L3	ENSG00000185238	Protein arginine methyltransferase 3	11	20387530-20509294	Predicted intracellular proteins	Evidence at protein level	HPA007832, CAB022083	Uncertain				Liver cancer:2.81e-5 (unfavourable), Pancreatic cancer:3.17e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 27.4	Expressed in all		
PRMT5	HRMT1L5, SKB1, SKB1Hs	ENSG00000100462	Protein arginine methyltransferase 5	14	22920511-22929585	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005525, CAB012459, HPA064708	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:4.77e-5 (unfavourable), Urothelial cancer:1.04e-4 (unfavourable), Head and neck cancer:1.82e-4 (unfavourable), Pancreatic cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 72.8	Expressed in all		
PRMT6	FLJ10559, HRMT1L6	ENSG00000198890	Protein arginine methyltransferase 6	1	107056679-107059294	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059424	Approved		Supported	Nucleus<br>Nucleoli	Endometrial cancer:3.05e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 17.2	Cell line enhanced		MCF7: 235.5
PRMT7	FLJ10640, KIAA1933	ENSG00000132600	Protein arginine methyltransferase 7	16	68310974-68358563	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044241	Supported		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Endometrial cancer:2.31e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 25.0	Expressed in all		
PRMT8	HRMT1L3, HRMT1L4	ENSG00000111218	Protein arginine methyltransferase 8	12	3381349-3593973	Predicted intracellular proteins	Evidence at protein level	HPA039747, HPA069769	Enhanced					Tissue enhanced	Tissue enriched	8	cerebral cortex: 19.9	testis: 2.4	Cell line enriched	11	hTERT-HME1: 37.3
PRMT9	FLJ46629, PRMT10	ENSG00000164169	Protein arginine methyltransferase 9	4	147637785-147684230	Predicted intracellular proteins	Evidence at protein level	HPA036844, HPA042537	Uncertain		Approved	Nucleoplasm<br>Microtubules<br>Cytosol	Renal cancer:3.58e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 14.2	Expressed in all		
PROB1	C5orf65	ENSG00000228672	Proline rich basic protein 1	5	139390592-139395713	Predicted intracellular proteins	Evidence at protein level	HPA060103	Enhanced		Approved	Nucleoplasm	Cervical cancer:9.26e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 24.8	heart muscle: 6.0	Cell line enriched	6	HDLM-2: 97.1
PROCA1	MGC39650	ENSG00000167525	Protein interacting with cyclin A1	17	28703197-28711854	Predicted intracellular proteins	Evidence at transcript level	HPA023648	Approved					Mixed	Tissue enriched	20	testis: 139.5	spleen: 6.9	Cell line enhanced		REH: 11.1
PRODH	HSPOX2, PIG6, PRODH1, PRODH2, TP53I6	ENSG00000100033	Proline dehydrogenase 1	22	18912777-18936553	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020361	Uncertain				Cervical cancer:1.54e-4 (favourable)	Tissue enhanced	Tissue enhanced		small intestine: 25.2	duodenum: 5.7	Cell line enriched	6	RPTEC TERT1: 28.5
PRODH2	HSPOX1	ENSG00000250799	Proline dehydrogenase 2	19	35799988-35813299	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051287	Approved		Supported	Nucleoplasm<br>Cytosol		Group enriched	Group enriched	96	kidney: 132.8;liver: 45.1	testis: 0.9	Cell line enriched	14	Hep G2: 21.4
PROP1		ENSG00000175325	PROP paired-like homeobox 1	5	177992235-177996242	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049839	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRORY	CYorf17	ENSG00000183146	Proline rich, Y-linked	Y	21382954-21386360	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		small intestine: 1.8	colon,rectum: 0.6	Cell line enhanced		U-266/84: 2.4
PROSC		ENSG00000147471	Proline synthetase cotranscribed homolog (bacterial)	8	37762593-37779767	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB017033, HPA023646, HPA023733	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 59.4	Expressed in all		
PROSER1	bA50D16.2, C13orf23, FLJ12661	ENSG00000120685	Proline and serine rich 1	13	39009866-39038076	Predicted intracellular proteins	Evidence at protein level	CAB034225, HPA055687	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			placenta: 30.3	Expressed in all		
PROSER2	C10orf47, MGC35403	ENSG00000148426	Proline and serine rich 2	10	11823339-11872277	Predicted intracellular proteins	Evidence at protein level	HPA041337	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Mixed	Mixed			placenta: 10.3	Cell line enhanced		A-431: 74.3;CAPAN-2: 87.1
PROSER3	C19orf55, FLJ30657	ENSG00000167595	Proline and serine rich 3	19	35758143-35771028	Predicted intracellular proteins	Evidence at protein level	HPA058492	Approved		Approved	Golgi apparatus	Renal cancer:3.74e-7 (unfavourable)	Expressed in all	Mixed			testis: 14.1	Mixed		
PROX1		ENSG00000117707	Prospero homeobox 1	1	213983181-214041502	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000842, HPA001030			Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		liver: 45.3	adrenal gland: 13.3	Cell line enhanced		Hep G2: 21.7;RH-30: 15.7;SH-SY5Y: 83.1
PROX2	FLJ36749	ENSG00000119608	Prospero homeobox 2	14	74852871-74871940	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045057	Uncertain					Not detected	Mixed			skin: 2.4	Cell line enhanced		AF22: 1.8
PRPF18	hPrp18	ENSG00000165630	Pre-mRNA processing factor 18	10	13586927-13630868	Predicted intracellular proteins	Evidence at protein level	HPA037599, HPA047950	Supported		Approved	Nuclear speckles<br>Cytosol	Liver cancer:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 38.5	Expressed in all		
PRPF19	hPSO4, NMP200, PRP19, PSO4, SNEV, UBOX4	ENSG00000110107	Pre-mRNA processing factor 19	11	60890730-60906588	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012448, HPA038051, HPA059070	Supported		Enhanced	Nuclear speckles	Liver cancer:4.11e-8 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 128.9	Expressed in all		
PRPF3	hPrp3, Prp3, RP18, SNRNP90	ENSG00000117360	Pre-mRNA processing factor 3	1	150321476-150353195	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027226, HPA067116	Approved		Enhanced	Nucleoplasm	Renal cancer:3.19e-5 (unfavourable), Liver cancer:6.59e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 40.6	Expressed in all		
PRPF31	hPrp31, NY-BR-99, PRP31, RP11, SNRNP61	ENSG00000105618	Pre-mRNA processing factor 31	19	54115410-54131719	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041939, HPA061873	Supported		Supported	Nucleus	Liver cancer:7.33e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 26.7	Expressed in all		
PRPF38A	FLJ14936, Prp38	ENSG00000134748	Pre-mRNA processing factor 38A	1	52404564-52420839	Predicted intracellular proteins	Evidence at protein level	HPA053099, HPA058407	Uncertain		Enhanced	Nucleus	Liver cancer:3.83e-5 (unfavourable), Renal cancer:7.41e-5 (unfavourable), Colorectal cancer:7.16e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 23.0	Expressed in all		
PRPF38B	FLJ10330, NET1	ENSG00000134186	Pre-mRNA processing factor 38B	1	108692323-108701803	Predicted intracellular proteins	Evidence at protein level	HPA053255	Approved				Renal cancer:2.03e-4 (unfavourable), Liver cancer:2.26e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 51.7	Expressed in all		
PRPF39	FLJ11128, FLJ20666	ENSG00000185246	Pre-mRNA processing factor 39	14	45084099-45116282	Predicted intracellular proteins	Evidence at protein level	HPA001176	Approved		Approved	Nucleoplasm	Liver cancer:3.84e-5 (unfavourable), Urothelial cancer:2.99e-4 (favourable), Prostate cancer:4.04e-4 (unfavourable), Melanoma:6.51e-4 (unfavourable), Ovarian cancer:8.48e-4 (favourable)	Expressed in all	Mixed			prostate: 9.8	Expressed in all		
PRPF4	HPRP4, HPRP4P, PRP4, Prp4p, SNRNP60	ENSG00000136875	Pre-mRNA processing factor 4	9	113275343-113292905	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021794, HPA022248	Enhanced		Enhanced	Nuclear speckles	Liver cancer:9.35e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 24.3	Expressed in all		
PRPF40A	FBP-11, FBP11, FLAF1, FLJ20585, FNBP3, HIP10, HYPA, NY-REN-6, Prp40	ENSG00000196504	Pre-mRNA processing factor 40 homolog A	2	152651593-152717997	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038272, HPA038273	Approved		Enhanced	Nuclear speckles	Pancreatic cancer:1.58e-5 (unfavourable), Liver cancer:1.68e-4 (unfavourable), Renal cancer:5.89e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.1	Expressed in all		
PRPF40B	HYPC	ENSG00000110844	Pre-mRNA processing factor 40 homolog B	12	49568218-49644666	Predicted intracellular proteins	Evidence at protein level	HPA038426, HPA038599	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Aggresome<br>Cytosol		Mixed	Mixed			testis: 39.2	Expressed in all		
PRPF4B	KIAA0536, PR4H, Prp4	ENSG00000112739	Pre-mRNA processing factor 4B	6	4021267-4064983	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020638	Approved		Supported	Nuclear speckles	Urothelial cancer:6.82e-5 (favourable), Liver cancer:2.27e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 37.7	Expressed in all		
PRPF6	ANT-1, bB152O15.1, C20orf14, hPrp6, Prp6, RP60, SNRNP102, TOM, U5-102K	ENSG00000101161	Pre-mRNA processing factor 6	20	63981135-64033100	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047106	Enhanced		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			fallopian tube: 80.3	Expressed in all		
PRPF8	hPrp8, Prp8, PRPC8, RP13, SNRNP220	ENSG00000174231	Pre-mRNA processing factor 8	17	1650629-1684882	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009941, CAB015457	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 94.4	Expressed in all		
PRPH	NEF4, PRPH1	ENSG00000135406	Peripherin	12	49293252-49298686	Predicted intracellular proteins	Evidence at protein level	CAB002437, HPA039277, HPA063887	Enhanced					Mixed	Tissue enhanced		adrenal gland: 20.5	testis: 11.6	Group enriched	93	AN3-CA: 342.0;SCLC-21H: 92.7
PRPS1	CMTX5, DFN2, DFNX1	ENSG00000147224	Phosphoribosyl pyrophosphate synthetase 1	X	107628424-107651026	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043760	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			thyroid gland: 73.9	Expressed in all		
PRPS1L1	PRPS3, PRPSL	ENSG00000229937	Phosphoribosyl pyrophosphate synthetase 1-like 1	7	18026774-18027863	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	575	testis: 57.5	all non-specific tissues: 0.0	Not detected		
PRPS2		ENSG00000101911	Phosphoribosyl pyrophosphate synthetase 2	X	12791355-12824222	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA067599, CAB070417	Enhanced		Approved	Vesicles	Cervical cancer:1.90e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 242.3	seminal vesicle: 117.1	Expressed in all		
PRPSAP1	PAP39	ENSG00000161542	Phosphoribosyl pyrophosphate synthetase associated protein 1	17	76309486-76384521	Predicted intracellular proteins	Evidence at protein level	HPA062396			Approved	Cytosol	Colorectal cancer:1.39e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 82.4	Expressed in all		
PRPSAP2	PAP41	ENSG00000141127	Phosphoribosyl pyrophosphate synthetase associated protein 2	17	18840085-18931287	Predicted intracellular proteins	Evidence at protein level	HPA021881	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.71e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 61.1	Expressed in all		
PRR11	FLJ11029	ENSG00000068489	Proline rich 11	17	59155499-59204705	Predicted intracellular proteins	Evidence at protein level	HPA023923, HPA052376	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.35e-7 (unfavourable), Lung cancer:1.79e-4 (unfavourable), Endometrial cancer:1.90e-4 (unfavourable), Pancreatic cancer:6.18e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 11.2	Mixed		
PRR12	KIAA1205	ENSG00000126464	Proline rich 12	19	49591643-49626439	Predicted intracellular proteins	Evidence at protein level	HPA011959	Approved		Approved	Cytosol		Expressed in all	Mixed			skin: 15.3	Expressed in all		
PRR13	DKFZP564J157, FLJ23818	ENSG00000205352	Proline rich 13	12	53441605-53446645	Predicted intracellular proteins	Evidence at protein level	HPA039396, HPA046219	Uncertain		Enhanced	Nucleoplasm	Urothelial cancer:7.55e-4 (favourable), Cervical cancer:9.08e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 515.4	Expressed in all		
PRR14	MGC3121	ENSG00000156858	Proline rich 14	16	30650717-30656440	Predicted intracellular proteins	Evidence at protein level	HPA052022, HPA060265	Uncertain		Approved	Nucleoplasm	Cervical cancer:8.19e-5 (favourable)	Expressed in all	Expressed in all			spleen: 20.0	Expressed in all		
PRR14L	C22orf30, MGC50372	ENSG00000183530	Proline rich 14 like	22	31676256-31750140	Predicted intracellular proteins	Evidence at protein level	HPA062645	Uncertain		Approved	Nucleoplasm	Renal cancer:3.00e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.2	Expressed in all		
PRR15		ENSG00000176532	Proline rich 15	7	29563811-29567295	Predicted intracellular proteins	Evidence at protein level	HPA040996, HPA048121	Enhanced		Uncertain	Vesicles<br>Cell Junctions	Renal cancer:1.83e-6 (favourable), Endometrial cancer:6.37e-4 (favourable), Lung cancer:7.23e-4 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 91.4	colon: 79.1	Cell line enhanced		CAPAN-2: 33.6;HaCaT: 39.3;SK-BR-3: 55.3
PRR15L	ATAD4, MGC11242	ENSG00000167183	Proline rich 15 like	17	47951967-47957878	Predicted intracellular proteins	Evidence at protein level	HPA022918	Approved		Approved	Cytosol	Renal cancer:6.29e-13 (favourable), Stomach cancer:1.69e-5 (favourable)	Mixed	Tissue enhanced		duodenum: 180.5	small intestine: 141.6	Cell line enhanced		HaCaT: 18.3;MCF7: 15.0;SCLC-21H: 13.8;SK-BR-3: 26.8;T-47d: 22.7
PRR16	DSC54	ENSG00000184838	Proline rich 16	5	120464278-120687332	Predicted intracellular proteins	Evidence at protein level	HPA049254	Approved		Approved	Nucleus<br>Midbody<br>Cytosol		Tissue enriched	Mixed			cervix, uterine: 21.7	Cell line enhanced		BJ hTERT+: 67.6;fHDF/TERT166: 78.9;LHCN-M2: 80.9;U-138 MG: 115.3
PRR18	MGC35308	ENSG00000176381	Proline rich 18	6	166305300-166308448	Predicted intracellular proteins	Evidence at protein level	HPA077250	Enhanced					Tissue enhanced	Tissue enriched	9	cerebral cortex: 32.6	fallopian tube: 3.4	Group enriched	11	SCLC-21H: 5.0;SH-SY5Y: 2.7
PRR19	MGC70924	ENSG00000188368	Proline rich 19	19	42302098-42310821	Predicted intracellular proteins	Evidence at protein level	HPA070350			Approved	Nucleus<br>Nucleoli<br>Nuclear bodies		Mixed	Tissue enriched	10	testis: 22.5	cerebral cortex: 2.1	Mixed		
PRR20A	FLJ40296, PRR20	ENSG00000204919	Proline rich 20A	13	57140918-57143939	Predicted intracellular proteins	Evidence at transcript level	HPA059485	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
PRR20B		ENSG00000204918	Proline rich 20B	13	57147488-57150509	Predicted intracellular proteins	No evidence	HPA059485	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
PRR20C		ENSG00000229665	Proline rich 20C	13	57140918-57157082	Predicted intracellular proteins	Evidence at protein level	HPA059485	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
PRR20D		ENSG00000227151	Proline rich 20D	13	57160632-57163653	Predicted intracellular proteins	Evidence at protein level	HPA059485	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
PRR20E		ENSG00000234278	Proline rich 20E	13	57167197-57170218	Predicted intracellular proteins	Evidence at protein level	HPA059485	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
PRR21		ENSG00000221961	Proline rich 21	2	240041813-240042982	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRR22	MGC24975	ENSG00000212123	Proline rich 22	19	5782960-5784765	Predicted intracellular proteins	Evidence at protein level	HPA044157	Enhanced		Approved	Nucleus<br>Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		testis: 21.9	skin: 4.9	Cell line enhanced		HMC-1: 15.2
PRR23A		ENSG00000206260	Proline rich 23A	3	139005468-139006268	Predicted intracellular proteins	Evidence at transcript level	HPA047473	Uncertain					Tissue enriched	Tissue enriched	10	testis: 1.9	ovary: 0.1	Not detected		
PRR23B	FLJ46116	ENSG00000184814	Proline rich 23B	3	139019031-139020926	Predicted intracellular proteins	Evidence at transcript level	HPA047473	Uncertain					Not detected	Tissue enriched	16	testis: 1.5	all non-specific tissues: 0.0	Not detected		
PRR23C	FLJ46210	ENSG00000233701	Proline rich 23C	3	139042102-139044892	Predicted intracellular proteins	Evidence at transcript level	HPA047473	Uncertain					Not detected	Tissue enriched	12	testis: 1.7	cerebral cortex,skin,spleen: 0.1	Not detected		
PRR23D1		ENSG00000255251	Proline rich 23 domain containing 1	8	7539628-7542450	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	54	epididymis: 75.6	testis: 1.3	Not detected		
PRR23D2		ENSG00000255378	Proline rich 23 domain containing 2	8	7778591-7781413	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	54	epididymis: 75.6	testis: 1.3	Not detected		
PRR25	gs64	ENSG00000167945	Proline rich 25	16	805443-813861	Predicted intracellular proteins	No evidence	HPA042974	Uncertain					Not detected	Not detected			adipose tissue,appendix,cerebral cortex: 0.1	Not detected		
PRR26	C10orf108, FLJ38681	ENSG00000180525	Proline rich 26	10	649948-669581	Predicted intracellular proteins	Evidence at transcript level	HPA066037	Uncertain					Mixed	Mixed			gallbladder: 7.9	Cell line enhanced		CACO-2: 1.4;CAPAN-2: 1.2;EFO-21: 1.4;RPTEC TERT1: 1.9
PRR29	C17orf72, DKFZp761M2312, FLJ11724	ENSG00000224383	Proline rich 29	17	63998351-64004304	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	12	fallopian tube: 92.9	testis: 7.9	Cell line enhanced		CAPAN-2: 3.0;REH: 3.3;TIME: 2.3
PRR3	CAT56, Em:AB014077.1, Em:AB023052.2	ENSG00000204576	Proline rich 3	6	30556886-30563723	Predicted intracellular proteins	Evidence at protein level	HPA064061			Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.84e-7 (unfavourable), Ovarian cancer:6.49e-6 (favourable), Pancreatic cancer:5.61e-5 (favourable)	Expressed in all	Mixed			epididymis: 1.6	Cell line enhanced		AN3-CA: 9.7;HAP1: 13.6
PRR30	C2orf53, MGC44505	ENSG00000186143	Proline rich 30	2	27136848-27139410	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	1041	testis: 104.0	all non-specific tissues: 0.0	Not detected		
PRR32	CXorf64	ENSG00000183631	Proline rich 32	X	126819764-126821786	Predicted intracellular proteins	No evidence	HPA048386	Uncertain					Tissue enriched	Not detected			fallopian tube: 0.9	Not detected		
PRR33	C11orf89, LOC728008	ENSG00000283787	Proline rich 33	11	1888577-1891895	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		skin: 12.2	skeletal muscle,spleen: 11.5	Cell line enhanced		Daudi: 2.2;HDLM-2: 8.1;Karpas-707: 4.1;U-937: 3.4
PRR34	C22orf26, FLJ10945	ENSG00000182257	Proline rich 34	22	46049478-46054144	Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			skeletal muscle: 1.7	Cell line enhanced		HeLa: 3.9
PRR35	C16orf11	ENSG00000161992	Proline rich 35	16	560422-565528	Predicted intracellular proteins	Evidence at transcript level	HPA069297	Uncertain					Not detected	Tissue enhanced		kidney: 2.9	testis: 0.8	Not detected		
PRR36		ENSG00000183248	Proline rich 36	19	7868719-7874379	Predicted intracellular proteins	Evidence at protein level	HPA062741	Uncertain		Approved	Nucleus<br>Golgi apparatus	Testis cancer:7.74e-4 (favourable)	Mixed	Tissue enriched	9	cerebral cortex: 18.0	prostate: 1.9	Cell line enhanced		REH: 26.2;SCLC-21H: 9.4;SH-SY5Y: 19.0
PRR5	FLJ20185k, PP610, Protor-1	ENSG00000186654	Proline rich 5	22	44668547-44737681	Predicted intracellular proteins	Evidence at protein level	HPA054072	Approved				Endometrial cancer:2.47e-5 (favourable)	Expressed in all	Mixed			spleen: 17.5	Cell line enhanced		U-266/70: 75.3
PRR5-ARHGAP8		ENSG00000248405	PRR5-ARHGAP8 readthrough	22	44702233-44862706	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			parathyroid gland,spleen,thyroid gland: 1.2	Cell line enhanced		BEWO: 2.9;HEK93: 3.0;U-266/70: 4.8
PRR5L	FLJ14213, PROTOR-2	ENSG00000135362	Proline rich 5 like	11	36296288-36465204	Predicted intracellular proteins	Evidence at protein level	HPA070174			Approved	Cytokinetic bridge<br>Cytosol	Renal cancer:7.71e-8 (unfavourable), Endometrial cancer:7.30e-5 (favourable), Stomach cancer:4.86e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 51.1	colon: 35.0	Cell line enhanced		HMC-1: 51.8;hTERT-HME1: 46.7;SiHa: 43.9
PRR7	MGC10772	ENSG00000131188	Proline rich 7, synaptic	5	177446445-177456286	Predicted intracellular proteins	Evidence at transcript level	HPA046636	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.50e-4 (unfavourable), Renal cancer:1.98e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 8.1	bone marrow: 3.7	Mixed		
PRR9		ENSG00000203783	Proline rich 9	1	153217584-153219317	Predicted intracellular proteins	Evidence at transcript level	HPA027714	Approved					Group enriched	Tissue enriched	5	testis: 2.8	breast,placenta: 0.5	Cell line enhanced		HaCaT: 1.9;U-87 MG: 1.6
PRRC2A	BAT2, D6S51E, G2	ENSG00000204469	Proline rich coiled-coil 2A	6	31620720-31637771	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB026383, HPA046791, HPA066501	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			testis: 20.7	Cell line enhanced		HBEC3-KT: 58.8;HEK93: 135.9;U-266/70: 57.4;U-266/84: 59.9;U-698: 54.2
PRRC2B	BAT2L, BAT2L1, KIAA0515, LQFBS-1, MGC10526	ENSG00000130723	Proline rich coiled-coil 2B	9	131394093-131500197	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021022, HPA064301	Uncertain		Approved	Nuclear bodies<br>Cytosol	Renal cancer:5.42e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 153.7	Expressed in all		
PRRC2C	BAT2D1, BAT2L2, KIAA1096, XTP2	ENSG00000117523	Proline rich coiled-coil 2C	1	171485551-171593511	Predicted intracellular proteins	Evidence at protein level	HPA025766, HPA028659	Approved		Enhanced	Cytosol	Renal cancer:7.76e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.3	Expressed in all		
PRRX1	PHOX1, PMX1	ENSG00000116132	Paired related homeobox 1	1	170662728-170739419	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051084, HPA063566	Uncertain		Supported	Nucleoplasm	Renal cancer:6.60e-10 (unfavourable)	Mixed	Mixed			cervix, uterine: 135.8	Cell line enhanced		ASC diff: 240.8;ASC TERT1: 194.6;BJ hTERT+: 165.0;U-138 MG: 137.1;U-2197: 125.0
PRRX2	PMX2, PRX2	ENSG00000167157	Paired related homeobox 2	9	129665641-129722674	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA006607, HPA026808	Approved		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		cervix, uterine: 9.9;skin: 10.7	testis: 6.3	Cell line enhanced		BJ: 24.1;BJ hTERT+: 16.5;fHDF/TERT166: 32.1;U-2197: 31.5
PRSS45	TESSP5	ENSG00000188086	Protease, serine 45	3	46742092-46744755	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA060284	Uncertain					Mixed	Tissue enhanced		epididymis: 9.8;parathyroid gland: 8.6	skeletal muscle: 3.7	Not detected		
PRSS46	TESSP6	ENSG00000261603	Protease, serine 46	3	46719583-46736429	Enzymes, Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		epididymis: 4.5;testis: 8.4	parathyroid gland: 2.7	Not detected		
PRTFDC1	HHGP	ENSG00000099256	Phosphoribosyl transferase domain containing 1	10	24848607-24952604	Predicted intracellular proteins	Evidence at protein level	HPA021458	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:9.27e-5 (unfavourable), Endometrial cancer:2.66e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 47.5	Cell line enhanced		CACO-2: 62.8;CAPAN-2: 82.9
PRUNE1	DRES-17, H-PRUNE, HTCD37, PRUNE	ENSG00000143363	Prune exopolyphosphatase	1	151008420-151035713	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028411	Uncertain		Supported	Cytosol	Renal cancer:3.48e-4 (unfavourable), Endometrial cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 53.9	Expressed in all		
PRX	KIAA1620	ENSG00000105227	Periaxin	19	40393768-40413366	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001868	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane		Expressed in all	Tissue enhanced		lung: 28.8	parathyroid gland: 9.4	Mixed		
PRY	PRY1, PTPN13LY	ENSG00000169789	PTPN13-like, Y-linked	Y	22490397-22514637	Predicted intracellular proteins	Evidence at protein level	HPA046366	Uncertain					Not detected	Not detected			epididymis,testis: 0.2	Not detected		
PRY2	PTPN13LY2	ENSG00000169807	PTPN13-like, Y-linked 2	Y	22071756-22096007	Predicted intracellular proteins	Evidence at protein level	HPA046366	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
PSAT1	PSA	ENSG00000135069	Phosphoserine aminotransferase 1	9	78297143-78330093	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB014882, CAB040567, HPA042924	Enhanced		Enhanced	Cytosol	Renal cancer:6.00e-7 (unfavourable), Endometrial cancer:5.62e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 186.0	liver: 138.7	Cell line enhanced		hTCEpi: 853.3
PSD	EFA6, EFA6A, KIAA2011, PSD1, TYL	ENSG00000059915	Pleckstrin and Sec7 domain containing	10	102402617-102421539	Predicted intracellular proteins	Evidence at protein level	HPA059237	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 112.7	endometrium: 40.4	Cell line enhanced		HSkMC: 5.6;SCLC-21H: 8.7;SH-SY5Y: 6.8
PSD2	DKFZp761B0514, EFA6C	ENSG00000146005	Pleckstrin and Sec7 domain containing 2	5	139795821-139844466	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	29	cerebral cortex: 58.5	epididymis: 2.0	Cell line enhanced		SH-SY5Y: 1.0
PSD3	DKFZp761K1423, EFA6D, EFA6R, HCA67, KIAA0942	ENSG00000156011	Pleckstrin and Sec7 domain containing 3	8	18527301-19084730	Predicted intracellular proteins	Evidence at protein level	HPA002455	Enhanced		Approved	Nucleus<br>Vesicles	Endometrial cancer:5.76e-5 (unfavourable), Colorectal cancer:7.55e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 83.3	testis: 29.6	Cell line enhanced		U-87 MG: 48.5
PSD4	EFA6B, TIC	ENSG00000125637	Pleckstrin and Sec7 domain containing 4	2	113157325-113209396	Predicted intracellular proteins	Evidence at protein level	HPA034722, HPA034723	Enhanced				Liver cancer:9.91e-5 (favourable), Stomach cancer:4.00e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 34.0	Cell line enhanced		HMC-1: 50.4
PSIP1	LEDGF, p52, p75, PSIP2	ENSG00000164985	PC4 and SFRS1 interacting protein 1	9	15464066-15511019	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013718, HPA019697	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 161.3	Expressed in all		
PSMA1	HC2, MGC14542, MGC14575, MGC14751, MGC1667, MGC21459, MGC22853, MGC23915, NU, PROS30	ENSG00000129084	Proteasome subunit alpha 1	11	14504874-14643635	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB033765, HPA037646, HPA043891	Supported		Enhanced	Nucleoplasm	Renal cancer:4.03e-11 (unfavourable), Liver cancer:3.79e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 120.9	Expressed in all		
PSMA2	HC3, MU, PMSA2	ENSG00000106588	Proteasome subunit alpha 2	7	42916857-42932223	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008188	Uncertain				Ovarian cancer:6.73e-5 (favourable), Liver cancer:1.29e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 165.2	Expressed in all		
PSMA3	HC8	ENSG00000100567	Proteasome subunit alpha 3	14	58244831-58272012	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000905	Approved		Approved	Microtubules<br>Cytokinetic bridge	Thyroid cancer:2.91e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 150.8	Expressed in all		
PSMA4	HC9, HsT17706	ENSG00000041357	Proteasome subunit alpha 4	15	78540405-78552419	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004973, HPA055466, HPA060613	Supported		Enhanced	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:6.74e-10 (unfavourable)	Expressed in all	Expressed in all			testis: 174.1	Expressed in all		
PSMA5	ZETA	ENSG00000143106	Proteasome subunit alpha 5	1	109399031-109426427	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028392, HPA028398, HPA028441	Approved		Approved	Cytosol	Colorectal cancer:1.45e-5 (favourable), Liver cancer:2.28e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 14.9	Cell line enhanced		MOLT-4: 36.7
PSMA6	IOTA, MGC22756, MGC2333, MGC23846, p27K, PROS27	ENSG00000100902	Proteasome subunit alpha 6	14	35278633-35317493	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003049	Approved		Supported	Nucleoplasm	Ovarian cancer:3.27e-4 (favourable)	Expressed in all	Expressed in all			testis: 390.4	Expressed in all		
PSMA7	C6, HSPC, RC6-1, XAPC7	ENSG00000101182	Proteasome subunit alpha 7	20	62136735-62143440	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB046007, CAB046008, HPA047266	Enhanced				Liver cancer:2.54e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 208.4	Expressed in all		
PSMA8	MGC26605, PSMA7L	ENSG00000154611	Proteasome subunit alpha 8	18	26133852-26193355	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	20	testis: 39.0	lymph node,tonsil: 1.9	Group enriched	73	Daudi: 24.2;U-266/70: 15.3;U-266/84: 15.8
PSMB1	HC5, PMSB1	ENSG00000008018	Proteasome subunit beta 1	6	170535117-170553341	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029635, HPA029637, CAB033911	Enhanced		Supported	Nucleus	Renal cancer:3.76e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 320.2	Expressed in all		
PSMB10	beta2i, LMP10, MECL1, MGC1665	ENSG00000205220	Proteasome subunit beta 10	16	67934502-67937087	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030224, HPA030225, CAB034384	Enhanced		Enhanced	Cytosol	Urothelial cancer:5.44e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 91.2	Mixed		
PSMB11	beta5t	ENSG00000222028	Proteasome subunit beta 11	14	23042167-23044276	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028967, HPA056970	Enhanced					Not detected	Not detected			testis: 0.2	Not detected		
PSMB2	HC7-I	ENSG00000126067	Proteasome subunit beta 2	1	35599544-35641844	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026322, HPA026324	Approved		Enhanced	Nucleoplasm	Liver cancer:3.49e-7 (unfavourable), Renal cancer:2.80e-6 (unfavourable)	Expressed in all	Expressed in all			placenta: 43.3	Expressed in all		
PSMB3	HC10-II, MGC4147	ENSG00000277791	Proteasome subunit beta 3	17	38752736-38764231	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042775, HPA048147	Approved		Enhanced	Mitochondria	Renal cancer:1.71e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 83.6	Expressed in all		
PSMB4	HN3, PROS26	ENSG00000159377	Proteasome subunit beta 4	1	151399534-151401944	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006700	Approved		Approved	Intermediate filaments<br>Centrosome<br>Cytosol	Renal cancer:2.90e-10 (unfavourable), Liver cancer:7.45e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 275.5	Expressed in all		
PSMB5	MB1, X	ENSG00000100804	Proteasome subunit beta 5	14	23016543-23035230	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049518, HPA061796	Approved		Supported	Nucleus<br>Centrosome	Liver cancer:2.90e-5 (unfavourable), Ovarian cancer:1.08e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable), Urothelial cancer:4.73e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 141.7	Expressed in all		
PSMB6	DELTA, Y	ENSG00000142507	Proteasome subunit beta 6	17	4796144-4798503	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023312, HPA063656	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 200.1	Expressed in all		
PSMB7		ENSG00000136930	Proteasome subunit beta 7	9	124353466-124415444	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052408, HPA054902	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 236.9	Expressed in all		
PSMB8	beta5i, D6S216E, LMP7, PSMB5i, RING10	ENSG00000204264	Proteasome subunit beta 8	6	32840717-32844703	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046995, HPA050327	Enhanced		Approved	Vesicles<br>Cytokinetic bridge	Breast cancer:5.08e-4 (favourable), Endometrial cancer:7.16e-4 (favourable)	Expressed in all	Mixed			lymph node: 23.0	Mixed		
PSMB9	beta1i, LMP2, PSMB6i, RING12	ENSG00000240065	Proteasome subunit beta 9	6	32844136-32859585	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015180, HPA042818, HPA053280	Enhanced		Supported	Cytosol	Renal cancer:1.33e-4 (unfavourable)	Expressed in all	Mixed			spleen: 39.1	Cell line enhanced		Daudi: 46.2;REH: 43.8
PSMC1	p56, S4	ENSG00000100764	Proteasome 26S subunit, ATPase 1	14	90256495-90275429	Predicted intracellular proteins	Evidence at protein level	HPA000872	Approved		Enhanced	Nucleoplasm<br>Cytosol	Head and neck cancer:1.78e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 140.2	Expressed in all		
PSMC2	MSS1, Nbla10058, S7	ENSG00000161057	Proteasome 26S subunit, ATPase 2	7	103344254-103369395	Predicted intracellular proteins	Evidence at protein level	HPA019238, HPA049621	Supported		Supported	Cytosol<br>Cytoplasmic bodies		Expressed in all	Expressed in all			testis: 105.0	Expressed in all		
PSMC3	TBP-1, TBP1	ENSG00000165916	Proteasome 26S subunit, ATPase 3	11	47418769-47426473	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006065	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 119.6	Expressed in all		
PSMC3IP	GT198, Hop2, HUMGT198A, TBPIP	ENSG00000131470	PSMC3 interacting protein	17	42572315-42577831	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044439	Enhanced		Supported	Nucleoplasm	Renal cancer:9.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 32.2	fallopian tube: 9.6	Expressed in all		
PSMC4	MGC13687, MGC23214, MGC8570, MIP224, S6, TBP-7, TBP7	ENSG00000013275	Proteasome 26S subunit, ATPase 4	19	39971005-39981441	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002044, HPA005471	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 43.2	Expressed in all		
PSMC5	p45, p45/SUG, S8, SUG-1, SUG1, TBP10, TRIP1	ENSG00000087191	Proteasome 26S subunit, ATPase 5	17	63827152-63832026	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017871, HPA064293	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:3.13e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 251.4	Expressed in all		
PSMC6	p42	ENSG00000100519	Proteasome 26S subunit, ATPase 6	14	52707172-52728587	Predicted intracellular proteins	Evidence at protein level	HPA042823	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 91.8	Expressed in all		
PSMD10	p28	ENSG00000101843	Proteasome 26S subunit, non-ATPase 10	X	108084207-108091618	Predicted intracellular proteins	Evidence at protein level	HPA002920, CAB010434	Approved		Supported	Intermediate filaments<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 70.0	Expressed in all		
PSMD11	MGC3844, p44.5, Rpn6, S9	ENSG00000108671	Proteasome 26S subunit, non-ATPase 11	17	32444261-32483318	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042275, HPA067433	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:5.73e-6 (unfavourable), Liver cancer:6.33e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.7	Expressed in all		
PSMD12	p55, Rpn5	ENSG00000197170	Proteasome 26S subunit, non-ATPase 12	17	67337916-67366627	Predicted intracellular proteins	Evidence at protein level	HPA023119	Enhanced		Approved	Nucleus<br>Microtubules<br>Cytosol	Renal cancer:4.73e-6 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Colorectal cancer:4.39e-4 (favourable), Ovarian cancer:6.32e-4 (favourable)	Expressed in all	Expressed in all			testis: 26.2	Expressed in all		
PSMD13	p40.5, Rpn9	ENSG00000185627	Proteasome 26S subunit, non-ATPase 13	11	236546-252984	Predicted intracellular proteins	Evidence at protein level	HPA038691, HPA038692	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:1.52e-13 (unfavourable), Liver cancer:4.76e-5 (unfavourable), Endometrial cancer:5.74e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 41.7	Expressed in all		
PSMD14	pad1, POH1, Rpn11	ENSG00000115233	Proteasome 26S subunit, non-ATPase 14	2	161308038-161411717	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002114, HPA003828	Approved		Supported	Nucleoplasm	Liver cancer:2.66e-8 (unfavourable), Renal cancer:3.10e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 56.1	Expressed in all		
PSMD3	P58, Rpn3, S3, TSTA2	ENSG00000108344	Proteasome 26S subunit, non-ATPase 3	17	39980797-39997960	Predicted intracellular proteins	Evidence at protein level	CAB017038, HPA048972	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.47e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 83.6	Expressed in all		
PSMD4	AF, AF-1, Rpn10, S5A	ENSG00000159352	Proteasome 26S subunit, non-ATPase 4	1	151254703-151267479	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA038807, HPA039252, CAB047300	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:6.66e-10 (unfavourable)	Expressed in all	Expressed in all			testis: 174.0	Expressed in all		
PSMD5	KIAA0072, S5B	ENSG00000095261	Proteasome 26S subunit, non-ATPase 5	9	120815496-120842984	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003216	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			prostate: 28.7	Mixed		
PSMD6	KIAA0107, p44S10, Rpn7, S10	ENSG00000163636	Proteasome 26S subunit, non-ATPase 6	3	64010549-64024010	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036921, HPA036922	Uncertain		Supported	Golgi apparatus<br>Vesicles	Liver cancer:1.68e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 216.4	Cell line enriched	5	MCF7: 1051.2
PSMD7	MOV34, P40, Rpn8, S12	ENSG00000103035	Proteasome 26S subunit, non-ATPase 7	16	74296775-74306288	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB019379, HPA049824, HPA056069	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.71e-6 (unfavourable), Head and neck cancer:6.64e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 107.1	Expressed in all		
PSMD8	HIP6, HYPF, Nin1p, p31, Rpn12, S14	ENSG00000099341	Proteasome 26S subunit, non-ATPase 8	19	38374536-38383824	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006702, CAB021101	Enhanced		Approved	Nuclear speckles<br>Cytosol	Endometrial cancer:3.84e-4 (unfavourable), Renal cancer:4.66e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 195.0	Expressed in all		
PSMD9	p27, Rpn4	ENSG00000110801	Proteasome 26S subunit, non-ATPase 9	12	121888731-121918297	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040512, HPA044220	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:1.32e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 17.8	Expressed in all		
PSME1	IFI5111, PA28alpha	ENSG00000092010	Proteasome activator subunit 1	14	24136158-24138967	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006632	Approved				Breast cancer:8.87e-5 (favourable), Thyroid cancer:4.60e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 329.6	Expressed in all		
PSME2	PA28beta	ENSG00000100911	Proteasome activator subunit 2	14	24143362-24147570	Predicted intracellular proteins	Evidence at protein level	HPA062661			Approved	Nucleus	Renal cancer:3.47e-5 (unfavourable), Breast cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 287.9	Expressed in all		
PSME3	Ki, PA28-gamma, PA28G, REG-GAMMA	ENSG00000131467	Proteasome activator subunit 3	17	42824385-42843758	Predicted intracellular proteins	Evidence at protein level	CAB008388, HPA012510	Supported		Enhanced	Nucleoplasm	Liver cancer:5.41e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 106.3	Expressed in all		
PSME4	KIAA0077, PA200	ENSG00000068878	Proteasome activator subunit 4	2	53864067-53970840	Predicted intracellular proteins	Evidence at protein level	HPA060922	Approved		Supported	Nucleoplasm	Liver cancer:4.84e-4 (unfavourable), Endometrial cancer:8.99e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 78.1	Expressed in all		
PSMF1	PI31	ENSG00000125818	Proteasome inhibitor subunit 1	20	1113263-1189415	Predicted intracellular proteins	Evidence at protein level	HPA041122, HPA041300	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			testis: 136.0	Expressed in all		
PSMG1	c21-LRP, DSCR2, LRPC21, PAC1	ENSG00000183527	Proteasome assembly chaperone 1	21	39174769-39183851	Predicted intracellular proteins	Evidence at protein level	HPA057193, HPA070225	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.58e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 68.5	Expressed in all		
PSMG2	CLAST3, HCCA3, HsT1707, MDS003, MGC15092, PAC2, TNFSF5IP1	ENSG00000128789	Proteasome assembly chaperone 2	18	12658043-12725740	Predicted intracellular proteins	Evidence at protein level	HPA041517, HPA046741	Uncertain		Approved	Nucleus<br>Nuclear bodies	Ovarian cancer:3.09e-4 (favourable)	Expressed in all	Expressed in all			testis: 172.4	Expressed in all		
PSMG3	C7orf48, MGC10911, PAC3	ENSG00000157778	Proteasome assembly chaperone 3	7	1567330-1571005	Predicted intracellular proteins	Evidence at protein level	HPA023876	Approved				Liver cancer:2.40e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 46.6	Expressed in all		
PSMG4	C6orf86, PAC4	ENSG00000180822	Proteasome assembly chaperone 4	6	3231403-3303373	Predicted intracellular proteins	Evidence at protein level	HPA067652			Approved	Nucleus<br>Mitochondria	Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 22.2	Expressed in all		
PSORS1C1	C6orf16, SEEK1	ENSG00000204540	Psoriasis susceptibility 1 candidate 1	6	31114750-31140092	Predicted intracellular proteins	Evidence at transcript level	HPA045049			Uncertain	Nucleus		Mixed	Tissue enriched	9	testis: 27.3	epididymis: 3.0	Cell line enhanced		hTCEpi: 1.1
PSPC1	FLJ10955, PSP1	ENSG00000121390	Paraspeckle component 1	13	19674752-19783019	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038904	Supported		Approved	Nucleoplasm<br>Nucleoli fibrillar center	Thyroid cancer:1.46e-4 (favourable), Liver cancer:2.21e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 45.5	Expressed in all		
PSPH	PSP	ENSG00000146733	Phosphoserine phosphatase	7	56011051-56051604	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020376, HPA029515	Approved		Approved	Cytosol	Liver cancer:2.75e-5 (unfavourable), Breast cancer:2.30e-4 (unfavourable), Pancreatic cancer:3.77e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 25.3	Expressed in all		
PSRC1	DDA3	ENSG00000134222	Proline and serine rich coiled-coil 1	1	109279556-109283186	Predicted intracellular proteins	Evidence at protein level	HPA049315, HPA056561	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.36e-9 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 36.6	testis: 14.0	Expressed in all		
PSTK	C10orf89, MGC35392	ENSG00000179988	Phosphoseryl-tRNA kinase	10	122954381-122997513	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037780, HPA037781	Approved		Approved	Nucleoli<br>Nuclear bodies<br>Actin filaments		Mixed	Mixed			testis: 5.9	Mixed		
PSTPIP1	CD2BP1, CD2BP1L, CD2BP1S, H-PIP, PAPAS, PSTPIP	ENSG00000140368	Proline-serine-threonine phosphatase interacting protein 1	15	76993359-77037332	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA010600	Enhanced				Renal cancer:7.36e-9 (unfavourable), Endometrial cancer:4.74e-5 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 37.6	appendix: 16.2	Cell line enhanced		HDLM-2: 55.7;NB-4: 15.1;U-937: 50.2
PSTPIP2		ENSG00000152229	Proline-serine-threonine phosphatase interacting protein 2	18	45983536-46072272	Predicted intracellular proteins	Evidence at protein level	HPA040923, HPA040944	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Mitochondria	Renal cancer:2.39e-7 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 47.2;spleen: 69.7	placenta: 17.3	Cell line enhanced		HEL: 91.3;HMC-1: 95.2
PTAR1		ENSG00000188647	Protein prenyltransferase alpha subunit repeat containing 1	9	69709522-69759959	Predicted intracellular proteins	Evidence at protein level	HPA021248	Uncertain		Approved	Microtubule organizing center<br>Rods & Rings	Renal cancer:4.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.5	Expressed in all		
PTBP1	HNRNP-I, HNRPI, pPTB, PTB, PTB-1, PTB2, PTB3, PTB4	ENSG00000011304	Polypyrimidine tract binding protein 1	19	797075-812327	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013507	Supported		Supported	Nucleoplasm	Liver cancer:2.71e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 173.4	Expressed in all		
PTBP2	brPTB, nPTB, PTB, PTBLP	ENSG00000117569	Polypyrimidine tract binding protein 2	1	96721665-96823738	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047420	Uncertain		Approved	Nucleoplasm	Endometrial cancer:7.80e-4 (unfavourable)	Expressed in all	Mixed			testis: 47.6	Expressed in all		
PTBP3	DKFZp781I1117, ROD1	ENSG00000119314	Polypyrimidine tract binding protein 3	9	112217716-112333667	Predicted intracellular proteins	Evidence at protein level	HPA048374			Approved	Nucleus	Pancreatic cancer:1.22e-4 (unfavourable), Lung cancer:2.10e-4 (unfavourable), Renal cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			testis: 44.1	Expressed in all		
PTCD1	KIAA0632	ENSG00000106246	Pentatricopeptide repeat domain 1	7	99416739-99466163	Predicted intracellular proteins	Evidence at protein level	HPA020106, HPA047679	Uncertain		Approved	Mitochondria	Renal cancer:1.13e-4 (unfavourable), Liver cancer:2.34e-4 (unfavourable)	Expressed in all	Mixed			skin: 5.0	Expressed in all		
PTCD2	FLJ12598	ENSG00000049883	Pentatricopeptide repeat domain 2	5	72320367-72368395	Predicted intracellular proteins	Evidence at protein level	HPA043686	Approved					Expressed in all	Mixed			parathyroid gland: 6.9	Expressed in all		
PTCD3	DKFZp666K071, FLJ20758	ENSG00000132300	Pentatricopeptide repeat domain 3	2	86106182-86142157	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA041154, HPA041382	Supported		Enhanced	Mitochondria	Stomach cancer:6.77e-4 (favourable), Urothelial cancer:6.86e-4 (favourable)	Expressed in all	Expressed in all			testis: 31.2	Expressed in all		
PTEN	BZS, MHAM, MMAC1, PTEN1, TEP1	ENSG00000171862	Phosphatase and tensin homolog	10	87863113-87971930	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004076, HPA031335	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:7.35e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 83.6	Expressed in all		
PTER		ENSG00000165983	Phosphotriesterase related	10	16436943-16513745	Predicted intracellular proteins	Evidence at protein level	HPA038044, HPA038045	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.52e-6 (favourable), Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 42.7	Mixed		
PTF1A	bHLHa29, PTF1-p48	ENSG00000168267	Pancreas specific transcription factor, 1a	10	23192327-23194252	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB022612			Approved	Nucleoplasm		Tissue enhanced	Tissue enriched	6	pancreas: 18.2	testis: 3.1	Cell line enriched	10	U-2 OS: 2.6
PTGES2	C9orf15, FLJ14038	ENSG00000148334	Prostaglandin E synthase 2	9	128120693-128128462	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020631, HPA020733	Approved		Approved	Mitochondria	Renal cancer:5.83e-7 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 35.1	Expressed in all		
PTGES3	cPGES, p23, TEBP	ENSG00000110958	Prostaglandin E synthase 3	12	56663341-56688408	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034319, HPA038672, HPA038673	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.44e-6 (unfavourable), Breast cancer:2.15e-5 (unfavourable), Ovarian cancer:4.36e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 347.2	Expressed in all		
PTGES3L		ENSG00000267060	Prostaglandin E synthase 3 like	17	42968088-42980433	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		heart muscle: 30.2;skeletal muscle: 58.7	smooth muscle: 16.3	Cell line enhanced		THP-1: 17.1
PTGES3L-AARSD1		ENSG00000108825	PTGES3L-AARSD1 readthrough	17	42950526-42980528	Predicted intracellular proteins	Evidence at protein level	HPA021408, HPA022869, HPA023714	Approved		Approved	Nuclear membrane<br>Cytosol		Not detected	Tissue enhanced		smooth muscle: 7.5	testis: 4.0	Cell line enhanced		THP-1: 6.4
PTGR1	LTB4DH, ZADH3	ENSG00000106853	Prostaglandin reductase 1	9	111549722-111599855	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036724	Enhanced				Renal cancer:5.53e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 315.8	Mixed		
PTGR2	FLJ39091, ZADH1	ENSG00000140043	Prostaglandin reductase 2	14	73851844-73886827	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001125	Approved		Approved	Vesicles	Renal cancer:4.55e-12 (favourable)	Expressed in all	Mixed			thyroid gland: 21.2	Cell line enhanced		T-47d: 39.4
PTK2	FADK, FAK, FAK1, PPP1R71	ENSG00000169398	Protein tyrosine kinase 2	8	140657900-141002216	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001842, CAB004036, HPA029671	Approved		Supported	Vesicles<br>Focal adhesion sites<br>Cytosol	Breast cancer:3.21e-4 (unfavourable), Endometrial cancer:9.11e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 107.1	Mixed		
PTK2B	CADTK, CAKB, FAK2, PTK, PYK2, RAFTK	ENSG00000120899	Protein tyrosine kinase 2 beta	8	27311482-27459391	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003850, HPA026091, HPA026276	Approved		Enhanced	Plasma membrane<br>Cytosol	Cervical cancer:3.32e-4 (favourable), Thyroid cancer:5.11e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 91.1	Cell line enhanced		REH: 128.1
PTK6	BRK	ENSG00000101213	Protein tyrosine kinase 6	20	63528001-63537370	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB032952, HPA036070, HPA036071	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Renal cancer:1.26e-9 (unfavourable), Pancreatic cancer:1.96e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 61.0;skin: 60.4	duodenum: 29.2	Cell line enhanced		A-431: 19.4;CAPAN-2: 36.5;HaCaT: 30.0;hTCEpi: 32.5;RT4: 21.3;T-47d: 23.7
PTMA	TMSA	ENSG00000187514	Prothymosin, alpha	2	231706895-231713541	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047183, HPA052651	Approved		Enhanced	Nucleus<br>Cytosol	Renal cancer:1.99e-7 (unfavourable), Liver cancer:3.61e-4 (unfavourable), Cervical cancer:6.56e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 1620.2	Expressed in all		
PTMS	ParaT	ENSG00000159335	Parathymosin	12	6765516-6770952	Predicted intracellular proteins	Evidence at protein level	HPA038186	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:6.18e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 136.1	Expressed in all		
PTOV1		ENSG00000104960	Prostate tumor overexpressed 1	19	49850735-49860744	Predicted intracellular proteins	Evidence at protein level	HPA051812, HPA075125	Approved		Supported	Nucleus	Colorectal cancer:6.64e-4 (unfavourable), Pancreatic cancer:9.20e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 59.4	Expressed in all		
PTP4A1	PRL-1, PTPCAAX1	ENSG00000112245	Protein tyrosine phosphatase type IVA, member 1	6	63521748-63583587	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003281	Approved				Cervical cancer:5.53e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 354.5	Expressed in all		
PTP4A2	HU-PP-1, OV-1, PRL-2, ptp-IV1a, PTP4A, PTPCAAX2	ENSG00000184007	Protein tyrosine phosphatase type IVA, member 2	1	31906421-31944856	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003281, CAB011204	Uncertain				Renal cancer:5.10e-11 (unfavourable), Liver cancer:2.62e-5 (unfavourable), Urothelial cancer:2.72e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 283.0	Expressed in all		
PTP4A3	PRL-3, PRL-R, PRL3	ENSG00000184489	Protein tyrosine phosphatase type IVA, member 3	8	141391993-141432454	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003281	Uncertain				Renal cancer:1.81e-5 (unfavourable)	Expressed in all	Group enriched	6	heart muscle: 69.6;skeletal muscle: 153.1	prostate: 19.1	Cell line enhanced		HDLM-2: 232.0;Karpas-707: 52.7;RPMI-8226: 54.1;U-266/84: 59.5
PTPA	PPP2R4, PR53	ENSG00000119383	Protein phosphatase 2 phosphatase activator	9	129110950-129148946	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005695, CAB022068, CAB035999	Approved		Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:6.50e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 225.9	Expressed in all		
PTPDC1	FLJ37312, PTP9Q22	ENSG00000158079	Protein tyrosine phosphatase domain containing 1	9	94030794-94109856	Predicted intracellular proteins	Evidence at protein level	HPA016747, HPA026832	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			testis: 14.2	Mixed		
PTPN11	BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2	ENSG00000179295	Protein tyrosine phosphatase, non-receptor type 11	12	112418351-112509913	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB005377	Approved		Supported	Nucleus<br>Nucleoli<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 126.0	Expressed in all		
PTPN12	PTP-PEST, PTPG1	ENSG00000127947	Protein tyrosine phosphatase, non-receptor type 12	7	77537275-77640071	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007097	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:7.27e-6 (unfavourable), Cervical cancer:1.15e-4 (unfavourable), Pancreatic cancer:2.01e-4 (unfavourable), Liver cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 107.2	Expressed in all		
PTPN13	PTP-BAS, PTP-BL, PTP1E, PTPL1	ENSG00000163629	Protein tyrosine phosphatase, non-receptor type 13	4	86594315-86815171	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002213, HPA048888, HPA065290	Approved		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			skin: 65.9	Cell line enhanced		AF22: 114.7
PTPN14	PEZ	ENSG00000152104	Protein tyrosine phosphatase, non-receptor type 14	1	214348696-214552449	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011469, HPA053864, CAB069441	Uncertain		Enhanced	Nucleoplasm	Pancreatic cancer:2.29e-4 (unfavourable), Stomach cancer:5.16e-4 (unfavourable)	Expressed in all	Mixed			skin: 19.9	Mixed		
PTPN18	BDP1	ENSG00000072135	Protein tyrosine phosphatase, non-receptor type 18	2	130356007-130375409	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB012174, HPA053367	Uncertain		Approved	Intermediate filaments		Expressed in all	Expressed in all			lymph node: 47.5	Expressed in all		
PTPN20	bA142I17.1, bA42B19.1, CT126, DKFZP566K0524, PTPN20A, PTPN20B	ENSG00000204179	Protein tyrosine phosphatase, non-receptor type 20	10	46911396-47002488	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043337, HPA046896, HPA048310	Uncertain		Supported	Microtubule organizing center		Mixed	Tissue enhanced		testis: 25.3	adrenal gland: 12.2	Cell line enhanced		HDLM-2: 46.4;SiHa: 9.6
PTPN21	PTPD1, PTPRL10	ENSG00000070778	Protein tyrosine phosphatase, non-receptor type 21	14	88465778-88554733	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB011468, HPA073999	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol	Renal cancer:3.16e-9 (favourable)	Expressed in all	Mixed			skin: 34.5	Cell line enhanced		RH-30: 34.1
PTPN22	Lyp, Lyp1, Lyp2, PTPN8	ENSG00000134242	Protein tyrosine phosphatase, non-receptor type 22	1	113813811-113871759	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004912, CAB012209, HPA013350	Approved		Uncertain	Nucleoplasm<br>Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		bone marrow: 24.8	lymph node: 23.3	Cell line enhanced		Daudi: 49.5;U-698: 25.4
PTPN23	DKFZP564F0923, HD-PTP, KIAA1471	ENSG00000076201	Protein tyrosine phosphatase, non-receptor type 23	3	47381011-47413441	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016845	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.82e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.9	Expressed in all		
PTPN3	PTPH1	ENSG00000070159	Protein tyrosine phosphatase, non-receptor type 3	9	109375466-109498313	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038343, HPA046728	Approved				Renal cancer:1.22e-15 (favourable), Endometrial cancer:1.52e-4 (favourable), Breast cancer:6.71e-4 (unfavourable)	Mixed	Mixed			skin: 35.8	Mixed		
PTPN4	PTPMEG	ENSG00000088179	Protein tyrosine phosphatase, non-receptor type 4	2	119759631-119983818	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019351	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Lung cancer:5.16e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 24.5	Mixed		
PTPN6	HCP, HCPH, PTP-1C, SHP-1, SHP1	ENSG00000111679	Protein tyrosine phosphatase, non-receptor type 6	12	6946468-6961316	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001466, CAB004572, CAB072845	Enhanced		Supported	Nucleus<br>Nucleoli	Urothelial cancer:2.64e-8 (favourable), Cervical cancer:1.87e-4 (favourable), Colorectal cancer:5.42e-4 (unfavourable), Endometrial cancer:6.65e-4 (favourable)	Expressed in all	Mixed			lymph node: 161.5	Cell line enhanced		HEL: 143.6;HMC-1: 527.9;THP-1: 163.9
PTPN7	HEPTP, LC-PTP	ENSG00000143851	Protein tyrosine phosphatase, non-receptor type 7	1	202147013-202161588	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009530, HPA019118	Approved				Renal cancer:2.42e-8 (unfavourable), Endometrial cancer:1.52e-4 (favourable), Head and neck cancer:1.84e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 25.2;lymph node: 24.3	tonsil: 19.3	Cell line enhanced		HEL: 48.4;HL-60: 93.9;HMC-1: 132.7;U-937: 65.7
PTPN9	MEG2	ENSG00000169410	Protein tyrosine phosphatase, non-receptor type 9	15	75463251-75579289	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041922	Approved		Approved	Vesicles	Renal cancer:2.49e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 54.8	Expressed in all		
PTRF	cavin-1, CAVIN1	ENSG00000177469	Polymerase I and transcript release factor	17	42402452-42423517	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049838, HPA074213	Supported		Supported	Vesicles<br>Plasma membrane	Urothelial cancer:5.87e-4 (unfavourable), Ovarian cancer:5.92e-4 (unfavourable), Colorectal cancer:6.36e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 343.1	Cell line enhanced		BJ: 868.3;U-138 MG: 835.1
PTRH1	C9orf115, PTH1	ENSG00000187024	Peptidyl-tRNA hydrolase 1 homolog	9	127692978-127724873	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021223	Uncertain					Not detected	Expressed in all			adipose tissue: 11.1	Expressed in all		
PTRHD1	C2orf79, LOC391356	ENSG00000184924	Peptidyl-tRNA hydrolase domain containing 1	2	24789734-24793382	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019951	Approved		Approved	Nucleoplasm	Renal cancer:2.31e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 14.0	Expressed in all		
PTS	PTPS	ENSG00000150787	6-pyruvoyltetrahydropterin synthase	11	112226365-112269955	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001481	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			adrenal gland: 66.9	Expressed in all		
PTTG1	EAP1, HPTTG, PTTG, securin, TUTR1	ENSG00000164611	Pituitary tumor-transforming 1	5	160421822-160428744	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB008373, HPA008890, HPA045034	Enhanced		Supported	Nucleoli<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.62e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 286.7	thyroid gland: 121.5	Expressed in all		
PTTG2		ENSG00000250254	Pituitary tumor-transforming 2	4	37960435-37961125	Predicted intracellular proteins	Evidence at transcript level	HPA008890, HPA045034	Uncertain		Approved	Nucleoli<br>Cytosol		Not detected	Not detected			bone marrow: 0.7	Not detected		
PUDP	DXF68S1E, FAM16AX, GS1, HDHD1, HDHD1A	ENSG00000130021	Pseudouridine 5'-phosphatase	X	7048920-7148190	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA072672	Approved				Thyroid cancer:4.80e-4 (favourable), Pancreatic cancer:7.27e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 31.3	Mixed		
PUF60	FIR, RoBPI, SIAHBP1	ENSG00000179950	Poly(U) binding splicing factor 60	8	143816344-143829859	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045733, HPA052096, HPA059714	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 26.1	Expressed in all		
PUM1	KIAA0099, PUMH1	ENSG00000134644	Pumilio RNA binding family member 1	1	30931506-31065991	Predicted intracellular proteins	Evidence at protein level	HPA027424, HPA027449	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:7.62e-8 (favourable), Liver cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 73.0	Expressed in all		
PUM2	KIAA0235, PUMH2	ENSG00000055917	Pumilio RNA binding family member 2	2	20248691-20352234	Predicted intracellular proteins	Evidence at protein level	HPA030316, HPA049670	Approved		Enhanced	Cytosol	Liver cancer:5.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 98.1	Expressed in all		
PUM3	HA-8, hPUF-A, KIAA0020, PEN, PUF6, XTP5	ENSG00000080608	Pumilio RNA binding family member 3	9	2720469-2844241	Predicted intracellular proteins	Evidence at protein level	HPA002353	Approved		Supported	Nucleoli	Liver cancer:4.89e-5 (unfavourable), Prostate cancer:1.74e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 28.4	Expressed in all		
PURA	PUR-ALPHA, PUR1, PURALPHA	ENSG00000185129	Purine rich element binding protein A	5	140107777-140125619	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:4.77e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 26.9	Expressed in all		
PURB	PURBETA	ENSG00000146676	Purine rich element binding protein B	7	44876293-44885361	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048766			Supported	Nucleus		Expressed in all	Expressed in all			cerebral cortex: 24.5	Expressed in all		
PURG	PURG-A, PURG-B	ENSG00000172733	Purine rich element binding protein G	8	30995802-31033715	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047746	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.6;testis: 4.8	endometrium: 2.6	Cell line enhanced		AF22: 6.0;NTERA-2: 4.8;SH-SY5Y: 6.0
PUS1		ENSG00000177192	Pseudouridylate synthase 1	12	131929200-131945896	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051636, HPA057593	Approved		Supported	Nucleus<br>Mitochondria	Renal cancer:3.49e-8 (unfavourable)	Expressed in all	Expressed in all			lymph node: 21.4	Expressed in all		
PUS10	CCDC139, FLJ32312	ENSG00000162927	Pseudouridylate synthase 10	2	60940222-61018259	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044736, HPA049582	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Mitochondria		Expressed in all	Mixed			thyroid gland: 10.3	Expressed in all		
PUS3	FKSG32	ENSG00000110060	Pseudouridylate synthase 3	11	125893485-125903221	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038040, HPA063802	Uncertain		Approved	Nucleus<br>Cytosol	Head and neck cancer:8.10e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 16.9	Expressed in all		
PUS7	FLJ20485	ENSG00000091127	Pseudouridylate synthase 7 (putative)	7	105439661-105522267	Predicted intracellular proteins	Evidence at protein level	HPA024116	Approved		Approved	Nucleus	Renal cancer:1.03e-8 (unfavourable), Liver cancer:4.89e-6 (unfavourable), Melanoma:7.58e-5 (unfavourable), Thyroid cancer:6.28e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.0	Expressed in all		
PUS7L	DKFZP434G1415	ENSG00000129317	Pseudouridylate synthase 7 like	12	43718993-43758817	Predicted intracellular proteins	Evidence at protein level	HPA056203, HPA058750	Uncertain		Supported	Nuclear speckles		Expressed in all	Mixed			parathyroid gland: 9.8	Expressed in all		
PUSL1	FLJ90811	ENSG00000169972	Pseudouridylate synthase-like 1	1	1308567-1311677	Predicted intracellular proteins	Evidence at protein level	HPA032057, HPA039999	Uncertain		Enhanced	Vesicles	Renal cancer:1.62e-5 (unfavourable), Liver cancer:1.33e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 9.1	Expressed in all		
PVALB	D22S749	ENSG00000100362	Parvalbumin	22	36800684-36819479	Predicted intracellular proteins	Evidence at protein level	CAB002515, HPA048536	Enhanced	Approved	Approved	Nucleoplasm<br>Nucleoli<br>Cell Junctions		Group enriched	Tissue enriched	13	parathyroid gland: 547.2	kidney: 43.5	Cell line enriched	144	RPMI-8226: 558.1
PWP1	IEF-SSP-9502	ENSG00000136045	PWP1 homolog, endonuclein	12	107685732-107713167	Predicted intracellular proteins	Evidence at protein level	HPA038708			Approved	Nucleoli<br>Golgi apparatus	Liver cancer:1.40e-5 (unfavourable), Renal cancer:2.26e-4 (unfavourable), Head and neck cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 55.0	Expressed in all		
PWP2	EHOC-17, PWP2H, UTP1	ENSG00000241945	PWP2 periodic tryptophan protein homolog (yeast)	21	44107290-44131181	Predicted intracellular proteins	Evidence at protein level	HPA024573	Uncertain		Supported	Nucleoli<br>Cytosol		Mixed	Mixed			skin: 5.4	Cell line enhanced		CACO-2: 61.4
PWWP2A	KIAA1935	ENSG00000170234	PWWP domain containing 2A	5	160061801-160119423	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA046733, HPA058233	Uncertain		Supported	Nucleoplasm<br>Focal adhesion sites	Urothelial cancer:3.51e-4 (favourable), Renal cancer:3.70e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 15.4	Expressed in all		
PWWP2B	bA432J24.1, FLJ46823, PWWP2	ENSG00000171813	PWWP domain containing 2B	10	132397168-132417863	Predicted intracellular proteins	Evidence at protein level	HPA038056, HPA038502			Enhanced	Nucleoplasm	Renal cancer:5.75e-4 (favourable)	Expressed in all	Mixed			spleen: 16.4	Cell line enhanced		BEWO: 53.5;MCF7: 33.4
PXDC1	C6orf145	ENSG00000168994	PX domain containing 1	6	3722614-3752026	Predicted intracellular proteins	Evidence at protein level	HPA019246			Approved	Plasma membrane	Endometrial cancer:1.14e-4 (unfavourable), Colorectal cancer:3.64e-4 (unfavourable)	Expressed in all	Mixed			placenta: 82.7	Mixed		
PXK	FLJ20335	ENSG00000168297	PX domain containing serine/threonine kinase like	3	58332880-58426126	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024068	Supported		Supported	Plasma membrane<br>Microtubule organizing center<br>Cytosol	Lung cancer:5.68e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 124.5	Expressed in all		
PXN		ENSG00000089159	Paxillin	12	120210439-120265771	Predicted intracellular proteins	Evidence at protein level	CAB003841, HPA051309	Enhanced		Enhanced	Focal adhesion sites<br>Centrosome<br>Cytosol	Head and neck cancer:3.72e-5 (unfavourable), Glioma:6.11e-5 (unfavourable), Liver cancer:7.12e-5 (unfavourable), Lung cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 100.4	Expressed in all		
PXT1	STEPP	ENSG00000179165	Peroxisomal, testis specific 1	6	36390551-36442889	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	7	testis: 3.5	appendix: 0.4	Cell line enhanced		HDLM-2: 2.0
PYCARD	ASC, CARD5, TMS-1	ENSG00000103490	PYD and CARD domain containing	16	31201485-31203450	Predicted intracellular proteins	Evidence at protein level	CAB006853, CAB015948, HPA049074, HPA054496	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:6.09e-7 (unfavourable)	Expressed in all	Mixed			duodenum: 51.4	Cell line enhanced		MCF7: 97.4;NB-4: 127.0;THP-1: 98.8
PYCR1	P5C	ENSG00000183010	Pyrroline-5-carboxylate reductase 1	17	81932384-81942412	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047660	Approved				Renal cancer:7.33e-12 (unfavourable), Liver cancer:2.33e-4 (unfavourable)	Expressed in all	Mixed			salivary gland: 52.3	Mixed		
PYCR2	P5CR2	ENSG00000143811	Pyrroline-5-carboxylate reductase family member 2	1	225919877-225924340	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA056873	Approved		Approved	Mitochondria	Renal cancer:1.42e-6 (unfavourable), Colorectal cancer:5.02e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 71.9	Expressed in all		
PYCRL	FLJ13852	ENSG00000104524	Pyrroline-5-carboxylate reductase-like	8	143603913-143609773	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA063416, HPA069706	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 4.1	Expressed in all		
PYDC1	ASC2, POP1	ENSG00000169900	Pyrin domain containing 1	16	31215962-31217359	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	8	skin: 4.3	cerebral cortex: 0.5	Not detected		
PYDC2	POP2	ENSG00000253548	Pyrin domain containing 2	3	191461163-191461456	Predicted intracellular proteins	Evidence at protein level	HPA055895	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	10	A549: 1.0
PYGB		ENSG00000100994	Glycogen phosphorylase B	20	25248069-25298014	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031067	Approved		Approved	Cytosol	Lung cancer:1.10e-4 (unfavourable), Urothelial cancer:1.43e-4 (unfavourable), Liver cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 149.4	Expressed in all		
PYGL		ENSG00000100504	Glycogen phosphorylase L	14	50857891-50944736	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000962, HPA004119	Enhanced		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:2.63e-4 (unfavourable), Head and neck cancer:5.97e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 116.5	Mixed		
PYGM		ENSG00000068976	Glycogen phosphorylase, muscle associated	11	64746389-64760297	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA056003	Enhanced					Mixed	Tissue enriched	32	skeletal muscle: 2831.9	esophagus: 89.0	Cell line enhanced		HSkMC: 2.6
PYGO1		ENSG00000171016	Pygopus family PHD finger 1	15	55538890-55588947	Predicted intracellular proteins	Evidence at protein level	HPA042248	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		parathyroid gland: 29.9	thyroid gland: 12.0	Cell line enhanced		U-698: 23.4
PYGO2		ENSG00000163348	Pygopus family PHD finger 2	1	154957026-154963853	Predicted intracellular proteins	Evidence at protein level	HPA023689	Supported		Approved	Nucleoplasm	Liver cancer:3.88e-6 (unfavourable), Urothelial cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 51.7	Expressed in all		
PYHIN1	IFIX, MGC23885	ENSG00000163564	Pyrin and HIN domain family member 1	1	158930796-158977054	Predicted intracellular proteins	Evidence at protein level	HPA051224	Enhanced					Mixed	Tissue enhanced		lymph node: 26.3;spleen: 19.2	tonsil: 11.3	Cell line enriched	6	U-698: 33.8
PYM1	PYM, WIBG	ENSG00000170473	PYM homolog 1, exon junction complex associated factor	12	55901413-55932618	Predicted intracellular proteins	Evidence at protein level	CAB012803, HPA039717, HPA046200	Supported		Supported	Nucleus<br>Nucleoli<br>Cell Junctions<br>Cytosol	Urothelial cancer:1.34e-4 (favourable), Liver cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 50.6	Expressed in all		
PYROXD1	DKFZp762G094, FLJ22028	ENSG00000121350	Pyridine nucleotide-disulphide oxidoreductase domain 1	12	21437615-21471252	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038319, HPA038320	Uncertain		Approved	Nuclear speckles	Urothelial cancer:1.70e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.4	Expressed in all		
PYROXD2	C10orf33, FLJ23849	ENSG00000119943	Pyridine nucleotide-disulphide oxidoreductase domain 2	10	98383565-98415184	Predicted intracellular proteins	Evidence at protein level	HPA037566, HPA037567, HPA067394	Uncertain		Approved	Mitochondria	Urothelial cancer:3.37e-4 (favourable), Glioma:8.17e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 15.4	Cell line enhanced		U-937: 24.6
PYURF	PreY	ENSG00000145337	PIGY upstream reading frame	4	88520985-88523813	Predicted intracellular proteins	Evidence at protein level	HPA036455	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			breast: 113.4	Mixed		
QDPR	DHPR, PKU2, SDR33C1	ENSG00000151552	Quinoid dihydropteridine reductase	4	17460261-17512234	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA058951, HPA065649	Enhanced		Approved	Mitochondria	Renal cancer:7.84e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 226.3	Expressed in all		
QKI	QK3	ENSG00000112531	QKI, KH domain containing RNA binding	6	163414000-163578596	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA019123, CAB022602	Enhanced	Supported	Supported	Nucleoplasm	Renal cancer:2.31e-5 (unfavourable), Liver cancer:1.27e-4 (unfavourable), Stomach cancer:3.69e-4 (unfavourable)	Tissue enriched	Expressed in all			cerebral cortex: 359.6	Expressed in all		
QPCTL	FLJ20084	ENSG00000011478	Glutaminyl-peptide cyclotransferase like	19	45692483-45703989	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040797	Approved		Supported	Golgi apparatus	Renal cancer:2.15e-8 (unfavourable)	Expressed in all	Mixed			thyroid gland: 8.6	Expressed in all		
QRICH1	FLJ20259	ENSG00000198218	Glutamine rich 1	3	49029707-49094363	Predicted intracellular proteins	Evidence at protein level	HPA037677, HPA037678	Approved		Enhanced	Nucleoplasm	Ovarian cancer:7.46e-4 (favourable)	Expressed in all	Expressed in all			testis: 78.9	Expressed in all		
QRICH2	DKFZP434P0316	ENSG00000129646	Glutamine rich 2	17	76274049-76307998	Predicted intracellular proteins	Evidence at protein level	HPA052219	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles		Expressed in all	Tissue enriched	11	testis: 22.2	thyroid gland: 1.9	Mixed		
QRSL1	DKFZP564C1278, FLJ10989, FLJ12189, FLJ13447, GatA	ENSG00000130348	Glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1	6	106629578-106668417	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029585, HPA029587	Approved		Approved	Vesicles<br>Centrosome	Liver cancer:7.97e-5 (unfavourable), Renal cancer:3.83e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 18.6	Expressed in all		
QSER1	FLJ21924	ENSG00000060749	Glutamine and serine rich 1	11	32893178-32993316	Predicted intracellular proteins	Evidence at protein level	HPA005682	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.27e-5 (unfavourable), Liver cancer:7.94e-5 (unfavourable), Renal cancer:6.87e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 17.4	Expressed in all		
QTRT1	TGT	ENSG00000213339	Queuine tRNA-ribosyltransferase catalytic subunit 1	19	10701430-10713437	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042695, HPA048651, HPA049440	Approved		Approved	Mitochondria	Renal cancer:1.13e-6 (unfavourable), Cervical cancer:7.63e-5 (favourable), Pancreatic cancer:2.13e-4 (favourable), Head and neck cancer:4.90e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 25.5	Expressed in all		
QTRT2	FLJ12960, QTRTD1	ENSG00000151576	Queuine tRNA-ribosyltransferase accessory subunit 2	3	114005833-114088422	Predicted intracellular proteins	Evidence at protein level	HPA036827, HPA036828	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments	Prostate cancer:6.95e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.3	Expressed in all		
R3HCC1	DKFZp564N123	ENSG00000104679	R3H domain and coiled-coil containing 1	8	23270120-23296279	Predicted intracellular proteins	Evidence at protein level	HPA023073, HPA023153	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.80e-5 (favourable), Colorectal cancer:4.08e-4 (favourable), Pancreatic cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 43.0	Expressed in all		
R3HCC1L	C10orf28, GIDRP86, PSORT	ENSG00000166024	R3H domain and coiled-coil containing 1 like	10	98134624-98244897	Predicted intracellular proteins	Evidence at protein level	HPA037367	Approved		Approved	Nucleoplasm<br>Nuclear speckles		Expressed in all	Expressed in all			testis: 38.9	Expressed in all		
R3HDM1	KIAA0029, R3HDM	ENSG00000048991	R3H domain containing 1	2	135531455-135725270	Predicted intracellular proteins	Evidence at protein level	HPA030936			Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.83e-7 (unfavourable), Lung cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 82.3	Expressed in all		
R3HDM2	KIAA1002	ENSG00000179912	R3H domain containing 2	12	57253762-57431005	Predicted intracellular proteins	Evidence at protein level	HPA038327, HPA038328	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 51.8	Expressed in all		
R3HDM4	C19orf22, MGC16353	ENSG00000198858	R3H domain containing 4	19	896503-913245	Predicted intracellular proteins	Evidence at protein level	HPA043025, HPA048638	Uncertain		Approved	Nucleus<br>Cytosol	Endometrial cancer:7.33e-6 (favourable)	Expressed in all	Expressed in all			appendix: 67.7	Expressed in all		
RAB10		ENSG00000084733	RAB10, member RAS oncogene family	2	26034107-26137454	Predicted intracellular proteins	Evidence at protein level	HPA045611	Approved				Liver cancer:1.99e-5 (unfavourable), Pancreatic cancer:7.37e-5 (unfavourable), Endometrial cancer:7.40e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 185.7	Expressed in all		
RAB11A	YL8	ENSG00000103769	RAB11A, member RAS oncogene family	15	65726054-65891991	Predicted intracellular proteins	Evidence at protein level	CAB013097, HPA051697, HPA060686	Approved		Enhanced	Vesicles<br>Microtubule organizing center	Renal cancer:1.46e-5 (favourable), Pancreatic cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 524.8	Expressed in all		
RAB11B	H-YPT3	ENSG00000185236	RAB11B, member RAS oncogene family	19	8389981-8404434	Predicted intracellular proteins	Evidence at protein level	HPA054396			Approved	Vesicles<br>Microtubule organizing center	Pancreatic cancer:7.58e-5 (favourable), Renal cancer:2.06e-4 (favourable), Cervical cancer:2.08e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 151.9	Expressed in all		
RAB11FIP1	FLJ22524, FLJ22622, Rab11-FIP1, RCP	ENSG00000156675	RAB11 family interacting protein 1	8	37858618-37899467	Predicted intracellular proteins	Evidence at protein level	CAB017037, HPA023904, HPA024010, HPA025960	Enhanced		Enhanced	Vesicles	Renal cancer:1.14e-6 (favourable), Head and neck cancer:6.61e-4 (favourable)	Mixed	Expressed in all			lung: 111.7	Cell line enhanced		K-562: 65.6
RAB11FIP2	KIAA0941, nRip11, Rab11-FIP2	ENSG00000107560	RAB11 family interacting protein 2	10	118004916-118046603	Predicted intracellular proteins	Evidence at protein level	HPA037726	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:9.69e-5 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 36.4	Expressed in all		
RAB11FIP3	eferin, KIAA0665, Rab11-FIP3	ENSG00000090565	RAB11 family interacting protein 3	16	425619-523011	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA028088, HPA028631, HPA030086	Approved		Supported	Vesicles<br>Cytokinetic bridge<br>Microtubule organizing center	Pancreatic cancer:3.16e-5 (favourable), Liver cancer:9.87e-5 (unfavourable), Endometrial cancer:1.22e-4 (favourable), Renal cancer:7.99e-4 (favourable)	Expressed in all	Expressed in all			kidney: 56.9	Expressed in all		
RAB11FIP4	FLJ00131, KIAA1821, MGC11316, RAB11-FIP4	ENSG00000131242	RAB11 family interacting protein 4	17	31391624-31538217	Predicted intracellular proteins	Evidence at protein level	HPA021595	Approved				Renal cancer:7.74e-8 (favourable), Stomach cancer:1.22e-4 (favourable), Colorectal cancer:2.70e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 67.9	testis: 42.4	Cell line enhanced		BEWO: 62.0;HMC-1: 36.4
RAB11FIP5	GAF1, KIAA0857, pp75, RIP11	ENSG00000135631	RAB11 family interacting protein 5	2	73073382-73156721	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036406, HPA036407	Enhanced		Enhanced	Vesicles<br>Microtubule organizing center	Renal cancer:2.26e-5 (favourable), Ovarian cancer:3.87e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 73.1	parathyroid gland: 26.9	Mixed		
RAB12		ENSG00000206418	RAB12, member RAS oncogene family	18	8609445-8639381	Predicted intracellular proteins	Evidence at protein level	HPA040727	Approved		Approved	Vesicles		Expressed in all	Expressed in all			skeletal muscle: 67.4	Expressed in all		
RAB13		ENSG00000143545	RAB13, member RAS oncogene family	1	153981617-153986358	Predicted intracellular proteins	Evidence at protein level	HPA003996	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			prostate: 150.3	Mixed		
RAB14	FBP, RAB-14	ENSG00000119396	RAB14, member RAS oncogene family	9	121178137-121223014	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026419, CAB037066	Approved		Supported	Vesicles	Renal cancer:1.79e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 83.4	Expressed in all		
RAB15		ENSG00000139998	RAB15, member RAS oncogene family	14	64945814-64972776	Predicted intracellular proteins	Evidence at protein level	HPA041177	Uncertain		Approved	Vesicles<br>Microtubule organizing center	Liver cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 62.9	Cell line enhanced		HAP1: 153.9;RH-30: 186.0;RT4: 173.7
RAB17		ENSG00000124839	RAB17, member RAS oncogene family	2	237574322-237601614	Predicted intracellular proteins	Evidence at protein level	HPA035176	Approved				Renal cancer:3.33e-13 (favourable), Urothelial cancer:2.51e-4 (favourable), Pancreatic cancer:4.14e-4 (favourable)	Mixed	Mixed			small intestine: 64.3	Cell line enhanced		BEWO: 40.2;MCF7: 36.3;SK-BR-3: 37.2;SK-MEL-30: 95.1
RAB19	RAB19B	ENSG00000146955	RAB19, member RAS oncogene family	7	140404043-140426250	Predicted intracellular proteins	Evidence at protein level	HPA051077	Uncertain				Renal cancer:2.36e-8 (favourable)	Mixed	Mixed			parathyroid gland: 6.2	Cell line enhanced		CAPAN-2: 4.4;HDLM-2: 10.4;MCF7: 3.8;RT4: 5.6;SK-BR-3: 4.1;T-47d: 5.7
RAB1A	RAB1, YPT1	ENSG00000138069	RAB1A, member RAS oncogene family	2	65070701-65130106	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005331, HPA056141	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Head and neck cancer:4.19e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 219.2	Expressed in all		
RAB1B		ENSG00000174903	RAB1B, member RAS oncogene family	11	66268533-66277492	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010225, HPA056141	Approved		Supported	Endoplasmic reticulum<br>Golgi apparatus	Renal cancer:1.09e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 185.0	Expressed in all		
RAB20	FLJ20429	ENSG00000139832	RAB20, member RAS oncogene family	13	110523066-110561733	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052111, HPA068647	Uncertain		Supported	Golgi apparatus<br>Vesicles	Urothelial cancer:4.48e-4 (favourable), Renal cancer:8.57e-4 (favourable)	Expressed in all	Mixed			spleen: 42.0	Cell line enhanced		SK-BR-3: 63.7;T-47d: 50.6
RAB21	KIAA0118	ENSG00000080371	RAB21, member RAS oncogene family	12	71754874-71800285	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016988, CAB037048	Approved				Renal cancer:5.39e-8 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.2	Expressed in all		
RAB22A		ENSG00000124209	RAB22A, member RAS oncogene family	20	58309696-58367507	Predicted intracellular proteins	Evidence at protein level	HPA058894, HPA066920	Approved		Uncertain	Centrosome	Liver cancer:7.33e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
RAB23		ENSG00000112210	RAB23, member RAS oncogene family	6	57186992-57222314	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029135, HPA029136	Enhanced		Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Mixed			smooth muscle: 110.0	Expressed in all		
RAB24		ENSG00000169228	RAB24, member RAS oncogene family	5	177301198-177303744	Predicted intracellular proteins	Evidence at protein level	HPA034945			Uncertain	Focal adhesion sites	Renal cancer:2.54e-7 (unfavourable), Liver cancer:7.56e-5 (unfavourable), Head and neck cancer:6.22e-4 (favourable)	Expressed in all	Expressed in all			spleen: 40.1	Expressed in all		
RAB25	CATX-8	ENSG00000132698	RAB25, member RAS oncogene family	1	156061160-156070514	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA010872, CAB033645	Enhanced		Uncertain	Cell Junctions<br>Cytosol	Renal cancer:1.38e-6 (favourable)	Mixed	Tissue enhanced		esophagus: 297.5	skin: 169.0	Cell line enhanced		BEWO: 114.9;CAPAN-2: 103.6;MCF7: 128.3;RT4: 119.8;SK-BR-3: 179.2;T-47d: 210.8
RAB27A	GS2, HsT18676, RAB27, RAM	ENSG00000069974	RAB27A, member RAS oncogene family	15	55202966-55319113	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001333, CAB034046	Enhanced				Renal cancer:1.67e-4 (unfavourable), Breast cancer:2.56e-4 (favourable)	Expressed in all	Mixed			stomach: 115.1	Cell line enhanced		K-562: 212.3
RAB27B		ENSG00000041353	RAB27B, member RAS oncogene family	18	54717860-54895516	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017712, HPA019849	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.13e-4 (unfavourable)	Mixed	Tissue enhanced		prostate: 31.7;stomach: 40.5	cerebral cortex: 24.3	Cell line enhanced		HEL: 54.6;U-87 MG: 154.0
RAB28		ENSG00000157869	RAB28, member RAS oncogene family	4	13361354-13484365	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044575	Approved				Urothelial cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			testis: 67.7	Expressed in all		
RAB29	RAB7L, RAB7L1	ENSG00000117280	RAB29, member RAS oncogene family	1	205767986-205775460	Predicted intracellular proteins	Evidence at protein level	CAB020822, HPA026303	Approved		Approved	Nuclear membrane<br>Nucleoli	Endometrial cancer:1.82e-5 (unfavourable), Liver cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 76.2	Expressed in all		
RAB2A	RAB2	ENSG00000104388	RAB2A, member RAS oncogene family	8	60516857-60623627	Predicted intracellular proteins	Evidence at protein level	CAB018781	Approved				Breast cancer:8.22e-4 (unfavourable), Endometrial cancer:9.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 108.0	Expressed in all		
RAB2B	FLJ14824	ENSG00000129472	RAB2B, member RAS oncogene family	14	21459020-21476973	Predicted intracellular proteins	Evidence at protein level	HPA050292	Uncertain					Expressed in all	Expressed in all			prostate: 19.1	Expressed in all		
RAB30		ENSG00000137502	RAB30, member RAS oncogene family	11	82973133-83071923	Predicted intracellular proteins	Evidence at protein level	HPA054514, HPA060565	Approved		Enhanced	Vesicles		Expressed in all	Expressed in all			cerebral cortex,tonsil: 28.4	Cell line enhanced		U-698: 116.4
RAB31	Rab22B	ENSG00000168461	RAB31, member RAS oncogene family	18	9708165-9862551	Predicted intracellular proteins	Evidence at protein level	HPA019717	Approved					Expressed in all	Expressed in all			cerebral cortex: 169.8	Mixed		
RAB32		ENSG00000118508	RAB32, member RAS oncogene family	6	146543693-146554965	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025731	Approved		Approved	Cytosol	Liver cancer:1.08e-7 (unfavourable), Colorectal cancer:1.56e-4 (favourable), Endometrial cancer:6.51e-4 (unfavourable), Renal cancer:8.62e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 91.9	Mixed		
RAB33A	RabS10	ENSG00000134594	RAB33A, member RAS oncogene family	X	130171649-130184870	Predicted intracellular proteins	Evidence at protein level	HPA059737	Uncertain		Approved	Vesicles		Group enriched	Tissue enhanced		cerebral cortex: 31.9	lymph node: 9.1	Cell line enhanced		HMC-1: 70.4;Karpas-707: 65.9;U-266/70: 50.9
RAB33B	DKFZP434G099	ENSG00000172007	RAB33B, member RAS oncogene family	4	139453232-139476609	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048367	Uncertain				Urothelial cancer:9.19e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 13.0	Expressed in all		
RAB34	NARR, RAB39, RAH	ENSG00000109113	RAB34, member RAS oncogene family	17	28714281-28718429	Predicted intracellular proteins	Evidence at protein level	HPA021366	Approved				Renal cancer:1.64e-7 (unfavourable), Thyroid cancer:1.06e-5 (favourable)	Expressed in all	Mixed			endometrium: 122.5	Mixed		
RAB35	H-ray	ENSG00000111737	RAB35, member RAS oncogene family	12	120095095-120117502	Predicted intracellular proteins	Evidence at protein level	HPA054146	Approved				Liver cancer:6.46e-6 (unfavourable), Lung cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 37.8	Expressed in all		
RAB37		ENSG00000172794	RAB37, member RAS oncogene family	17	74670578-74747335	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.80e-6 (unfavourable), Testis cancer:9.27e-4 (unfavourable)	Mixed	Mixed			spleen: 20.9	Cell line enhanced		HEL: 47.0;HMC-1: 48.4;U-266/70: 61.0;U-937: 27.5
RAB38	NY-MEL-1	ENSG00000123892	RAB38, member RAS oncogene family	11	88113242-88175467	Predicted intracellular proteins	Evidence at protein level	HPA071701			Uncertain	Nuclear bodies<br>Mitochondria	Renal cancer:8.26e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 47.4	esophagus: 36.3	Cell line enhanced		hTCEpi: 216.3;hTERT-HME1: 203.2;SK-MEL-30: 129.2
RAB39A	RAB39	ENSG00000179331	RAB39A, member RAS oncogene family	11	107928503-107963482	Predicted intracellular proteins	Evidence at protein level	HPA042505	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 7.0	spleen: 4.3	Cell line enhanced		RPMI-8226: 11.4;SCLC-21H: 33.8;SH-SY5Y: 18.8
RAB39B	MRX72	ENSG00000155961	RAB39B, member RAS oncogene family	X	155258241-155264589	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001114, HPA042505	Approved				Breast cancer:8.95e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 19.4	epididymis: 7.5	Cell line enhanced		Daudi: 19.2;Karpas-707: 24.8;SCLC-21H: 15.4;U-266/70: 26.3;U-266/84: 17.9
RAB3A		ENSG00000105649	RAB3A, member RAS oncogene family	19	18196784-18204074	Predicted intracellular proteins	Evidence at protein level	HPA003160, CAB009949, CAB078998	Enhanced	Supported	Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:6.14e-7 (favourable), Endometrial cancer:3.17e-4 (unfavourable)	Expressed in all	Tissue enriched	12	cerebral cortex: 250.5	adrenal gland: 20.6	Cell line enhanced		SCLC-21H: 43.5;U-2197: 23.9
RAB3B		ENSG00000169213	RAB3B, member RAS oncogene family	1	51907956-51990764	Predicted intracellular proteins	Evidence at protein level	HPA003159, CAB023293	Enhanced		Approved	Cell Junctions		Group enriched	Tissue enhanced		cerebral cortex: 8.2;prostate: 17.8	adrenal gland: 4.0	Cell line enhanced		BJ: 105.7;TIME: 79.3
RAB3C		ENSG00000152932	RAB3C, member RAS oncogene family	5	58582221-58859394	Predicted intracellular proteins	Evidence at protein level	HPA003160, HPA048156	Enhanced		Approved	Cytosol		Mixed	Group enriched	17	adrenal gland: 12.0;cerebral cortex: 55.3	small intestine: 2.0	Cell line enhanced		HEL: 2.2;SCLC-21H: 11.9;SH-SY5Y: 3.9
RAB3D	D2-2, GOV, RAB16, RAD3D	ENSG00000105514	RAB3D, member RAS oncogene family	19	11322046-11346270	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018067, HPA063283	Approved		Approved	Vesicles	Glioma:3.30e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 62.5	esophagus: 28.1	Cell line enhanced		SK-BR-3: 51.2
RAB3GAP1	KIAA0066, RAB3GAP, RAB3GAP130, WARBM1	ENSG00000115839	RAB3 GTPase activating protein catalytic subunit 1	2	135052265-135176394	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034494, HPA034495	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.96e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 57.5	Expressed in all		
RAB3GAP2	DKFZP434D245, KIAA0839, RAB3-GAP150, SPG69	ENSG00000118873	RAB3 GTPase activating non-catalytic protein subunit 2	1	220148293-220272454	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026273, HPA027299	Approved		Supported	Plasma membrane<br>Cytosol	Breast cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.9	Expressed in all		
RAB3IL1	GRAB	ENSG00000167994	RAB3A interacting protein like 1	11	61897301-61920269	Predicted intracellular proteins	Evidence at protein level	HPA039723	Uncertain		Approved	Cytosol	Liver cancer:1.61e-7 (unfavourable), Renal cancer:1.49e-4 (unfavourable), Thyroid cancer:3.30e-4 (unfavourable), Colorectal cancer:6.08e-4 (unfavourable)	Expressed in all	Mixed			testis: 48.7	Cell line enhanced		K-562: 39.5;U-2197: 52.9
RAB3IP	FLJ22548, RABIN3, RABIN8	ENSG00000127328	RAB3A interacting protein	12	69738681-69823204	Predicted intracellular proteins	Evidence at protein level	HPA039794	Uncertain		Approved	Intermediate filaments	Renal cancer:5.68e-13 (favourable)	Mixed	Tissue enhanced		testis: 134.1	epididymis: 53.2	Expressed in all		
RAB40A	Rar-2, RAR2A	ENSG00000172476	RAB40A, member RAS oncogene family	X	103499130-103519489	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		epididymis: 9.8;esophagus: 7.8	prostate,testis: 5.9	Cell line enhanced		AF22: 3.3;NTERA-2: 3.7
RAB40AL	RAR2, RLGP	ENSG00000102128	RAB40A, member RAS oncogene family-like	X	102937272-102938300	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			epididymis: 0.3	Not detected		
RAB40B	RAR, SEC4L	ENSG00000141542	RAB40B, member RAS oncogene family	17	82654973-82698728	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:2.95e-6 (favourable), Lung cancer:9.77e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 56.8	epididymis: 18.0	Mixed		
RAB40C	RARL, RASL8C	ENSG00000197562	RAB40C, member RAS oncogene family	16	589357-629272	Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.18e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 26.5	Expressed in all		
RAB41		ENSG00000147127	RAB41, member RAS oncogene family	X	70282093-70285002	Predicted intracellular proteins	Evidence at protein level	HPA001510	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 5.0;testis: 7.0	skin: 1.6	Cell line enhanced		U-2197: 3.5;U-87 MG: 4.5
RAB42	MGC45806	ENSG00000188060	RAB42, member RAS oncogene family	1	28592200-28595443	Predicted intracellular proteins	Evidence at transcript level	HPA050290			Approved	Endoplasmic reticulum		Mixed	Mixed			lymph node: 9.5	Cell line enhanced		Hep G2: 11.8
RAB43	ISY1, RAB11B, RAB41	ENSG00000172780	RAB43, member RAS oncogene family	3	129087569-129122801	Predicted intracellular proteins	Evidence at protein level	HPA046840, HPA060085	Enhanced		Supported	Plasma membrane		Mixed	Mixed			thyroid gland: 37.3	Mixed		
RAB44	dJ431A14.3, RASD3, RASL13	ENSG00000255587	RAB44, member RAS oncogene family	6	36697851-36733183	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	28	bone marrow: 38.8	gallbladder,lung: 1.3	Group enriched	204	HEL: 19.9;HL-60: 24.8;HMC-1: 79.3;NB-4: 50.2;THP-1: 20.3;U-937: 48.2
RAB4A	HRES-1/RAB4, RAB4	ENSG00000168118	RAB4A, member RAS oncogene family	1	229271062-229305894	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			prostate: 56.2	Mixed		
RAB4B	FLJ78649, MGC52123	ENSG00000167578	RAB4B, member RAS oncogene family	19	40778216-40796938	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:1.99e-5 (favourable), Renal cancer:1.28e-4 (unfavourable), Pancreatic cancer:2.08e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 56.1	Expressed in all		
RAB5A	RAB5	ENSG00000144566	RAB5A, member RAS oncogene family	3	19947079-19985175	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004567, HPA049354	Approved					Expressed in all	Expressed in all			parathyroid gland: 79.4	Expressed in all		
RAB5B		ENSG00000111540	RAB5B, member RAS oncogene family	12	55973913-55996683	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010224, HPA068337	Approved		Supported	Vesicles	Breast cancer:2.24e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 175.6	Expressed in all		
RAB5C	RAB5CL, RABL	ENSG00000108774	RAB5C, member RAS oncogene family	17	42124976-42155044	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003426, HPA004167	Approved		Enhanced	Endosomes	Head and neck cancer:7.08e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 180.6	Mixed		
RAB6A	RAB6	ENSG00000175582	RAB6A, member RAS oncogene family	11	73675638-73761137	Predicted intracellular proteins	Evidence at protein level	CAB009936, HPA059131	Approved		Approved	Golgi apparatus	Endometrial cancer:8.18e-5 (unfavourable), Liver cancer:1.34e-4 (unfavourable), Pancreatic cancer:2.24e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 267.9	Expressed in all		
RAB6B		ENSG00000154917	RAB6B, member RAS oncogene family	3	133824239-133895836	Predicted intracellular proteins	Evidence at protein level	CAB017713, HPA059131	Uncertain		Approved	Golgi apparatus	Pancreatic cancer:3.97e-6 (favourable), Endometrial cancer:9.01e-4 (unfavourable)	Expressed in all	Group enriched	5	cerebral cortex: 211.3;parathyroid gland: 77.1	fallopian tube: 26.2	Cell line enhanced		HEL: 207.7;K-562: 49.3;SCLC-21H: 56.7
RAB6C	WTH3	ENSG00000222014	RAB6C, member RAS oncogene family	2	129979664-129982738	Predicted intracellular proteins	Evidence at protein level	HPA059131	Uncertain		Uncertain	Golgi apparatus		Tissue enhanced	Tissue enhanced		parathyroid gland: 7.5	breast: 3.2	Group enriched	6	BEWO: 2.4;HMC-1: 1.9;REH: 4.9;T-47d: 3.0;U-266/70: 1.6
RAB7A	RAB7	ENSG00000075785	RAB7A, member RAS oncogene family	3	128726122-128814796	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006964, CAB037131	Supported		Supported	Lysosomes	Liver cancer:9.89e-6 (unfavourable), Endometrial cancer:1.52e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 270.2	Expressed in all		
RAB7B	MGC16212, MGC9726	ENSG00000276600	RAB7B, member RAS oncogene family	1	205976740-206003461	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:4.87e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 59.9	gallbladder: 22.9	Cell line enhanced		HBEC3-KT: 23.4;HMC-1: 75.9;hTCEpi: 26.8
RAB8A	MEL, RAB8	ENSG00000167461	RAB8A, member RAS oncogene family	19	16111629-16134234	Predicted intracellular proteins	Evidence at protein level	HPA041945			Supported	Nucleus<br>Plasma membrane	Renal cancer:6.56e-5 (unfavourable), Thyroid cancer:1.71e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 64.5	Expressed in all		
RAB8B		ENSG00000166128	RAB8B, member RAS oncogene family	15	63189469-63267782	Predicted intracellular proteins	Evidence at protein level	HPA074534			Supported	Nucleoplasm<br>Vesicles	Renal cancer:2.44e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 50.6	Expressed in all		
RAB9A	RAB9	ENSG00000123595	RAB9A, member RAS oncogene family	X	13689125-13710506	Predicted intracellular proteins	Evidence at protein level	HPA003094, CAB016411	Enhanced		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:3.35e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 68.1	Expressed in all		
RABEP1	neurocrescin, RAB5EP, rabaptin-5, RABPT5	ENSG00000029725	Rabaptin, RAB GTPase binding effector protein 1	17	5282265-5385812	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004549, HPA019669, HPA024235, HPA024691	Enhanced		Enhanced	Vesicles	Pancreatic cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 88.9	Expressed in all		
RABEP2	FLJ23282, FRA	ENSG00000177548	Rabaptin, RAB GTPase binding effector protein 2	16	28904421-28936526	Predicted intracellular proteins	Evidence at protein level	HPA047641	Approved		Supported	Vesicles<br>Cytosol	Renal cancer:1.24e-6 (favourable), Head and neck cancer:5.84e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 57.1	Expressed in all		
RABEPK	bA65N13.1, RAB9P40	ENSG00000136933	Rab9 effector protein with kelch motifs	9	125200542-125234158	Predicted intracellular proteins	Evidence at protein level	HPA023920, HPA067106	Enhanced		Uncertain	Plasma membrane		Expressed in all	Expressed in all			liver: 30.6	Expressed in all		
RABGEF1	rabex-5, RABEX5	ENSG00000154710	RAB guanine nucleotide exchange factor 1	7	66682164-66811464	Predicted intracellular proteins	Evidence at protein level	HPA001407			Supported	Nucleoli<br>Cytosol	Glioma:2.90e-5 (unfavourable), Renal cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 49.5	Expressed in all		
RABGEF1		ENSG00000284461	RAB guanine nucleotide exchange factor 1	7	66628958-66811459	Predicted intracellular proteins	Evidence at transcript level								Mixed			adrenal gland: 8.8	Mixed		
RABGGTA	PTAR3	ENSG00000100949	Rab geranylgeranyltransferase alpha subunit	14	24265538-24271739	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043488	Approved		Enhanced	Nucleoplasm	Thyroid cancer:1.51e-4 (favourable), Renal cancer:5.44e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 34.0	Expressed in all		
RABGGTB		ENSG00000137955	Rab geranylgeranyltransferase beta subunit	1	75786197-75795079	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026585, HPA027167, HPA030793	Approved	Approved	Supported	Vesicles	Renal cancer:1.12e-5 (unfavourable), Liver cancer:9.80e-5 (unfavourable)	Expressed in all	Expressed in all			kidney: 69.4	Expressed in all		
RABIF	mss4, RASGRF3	ENSG00000183155	RAB interacting factor	1	202878957-202889135	Predicted intracellular proteins	Evidence at protein level	HPA027715, HPA054936	Approved		Approved	Microtubules<br>Cytokinetic bridge	Renal cancer:2.61e-5 (unfavourable), Ovarian cancer:5.64e-5 (favourable), Liver cancer:1.55e-4 (unfavourable)	Expressed in all	Mixed			testis: 26.1	Expressed in all		
RABL2A		ENSG00000144134	RAB, member of RAS oncogene family-like 2A	2	113627229-113643396	Predicted intracellular proteins	Evidence at protein level	HPA042642, HPA042700, HPA044007	Approved		Approved	Vesicles<br>Centrosome	Renal cancer:1.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 31.5	cerebral cortex: 8.1	Mixed		
RABL2B		ENSG00000079974	RAB, member of RAS oncogene family-like 2B	22	50767501-50783663	Predicted intracellular proteins	Evidence at protein level	HPA042642, HPA042700, HPA044007	Approved		Approved	Vesicles<br>Centrosome	Liver cancer:4.58e-5 (unfavourable), Endometrial cancer:5.58e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 110.4	Expressed in all		
RABL3	MGC23920	ENSG00000144840	RAB, member of RAS oncogene family like 3	3	120686681-120742993	Predicted intracellular proteins	Evidence at protein level	HPA035150, HPA035151	Uncertain		Approved	Nucleoplasm	Renal cancer:2.79e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 33.1	Expressed in all		
RABL6	bA216L13.9, C9orf86, FLJ10101, FLJ13045, Parf, pp8875, RBEL1	ENSG00000196642	RAB, member RAS oncogene family-like 6	9	136807943-136841187	Predicted intracellular proteins	Evidence at protein level	HPA044037	Uncertain		Supported	Centrosome<br>Cytosol	Pancreatic cancer:1.46e-4 (favourable), Endometrial cancer:4.00e-4 (favourable), Stomach cancer:9.14e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 59.7	Expressed in all		
RAC1	p21-Rac1, Rac-1, TC-25	ENSG00000136238	Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)	7	6374523-6403977	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB035994, HPA047820	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:1.74e-5 (unfavourable), Pancreatic cancer:4.57e-5 (unfavourable), Renal cancer:2.11e-4 (unfavourable), Lung cancer:4.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 281.6	Expressed in all		
RAC2	EN-7	ENSG00000128340	Ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)	22	37225261-37244448	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB022946, HPA047820	Approved				Renal cancer:1.06e-6 (unfavourable), Breast cancer:1.03e-5 (favourable)	Expressed in all	Expressed in all			lymph node: 443.7	Cell line enhanced		HL-60: 579.7;HMC-1: 1246.3;U-87 MG: 600.7
RAC3		ENSG00000169750	Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)	17	82031624-82034204	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA047820	Uncertain				Endometrial cancer:6.21e-5 (unfavourable), Thyroid cancer:4.69e-4 (unfavourable)	Expressed in all	Mixed			testis: 22.7	Expressed in all		
RACGAP1	MgcRacGAP	ENSG00000161800	Rac GTPase activating protein 1	12	49976923-50033136	Predicted intracellular proteins	Evidence at protein level	CAB025859, HPA039427, HPA043912	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.98e-8 (unfavourable), Liver cancer:1.86e-6 (unfavourable), Pancreatic cancer:4.12e-6 (unfavourable), Breast cancer:1.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 84.3	lymph node: 28.6	Expressed in all		
RACK1	Gnb2-rs1, GNB2L1, H12.3	ENSG00000204628	Receptor for activated C kinase 1	5	181236909-181248096	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB004288, HPA021676	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.98e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 2103.5	Expressed in all		
RAD1	HRAD1, REC1	ENSG00000113456	RAD1 checkpoint DNA exonuclease	5	34905264-34918989	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006692	Approved		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.06e-5 (unfavourable), Breast cancer:6.30e-4 (unfavourable)	Expressed in all	Mixed			testis: 11.9	Expressed in all		
RAD17	CCYC, RAD17Sp, Rad24	ENSG00000152942	RAD17 checkpoint clamp loader component	5	69369293-69414801	Predicted intracellular proteins	Evidence at protein level	CAB004551, HPA005448	Approved		Enhanced	Nucleoplasm	Renal cancer:5.79e-6 (favourable)	Expressed in all	Expressed in all			testis: 39.3	Mixed		
RAD18	RNF73	ENSG00000070950	RAD18, E3 ubiquitin protein ligase	3	8775402-8963773	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006716, HPA006724, HPA008752	Supported	Approved	Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.65e-5 (unfavourable), Liver cancer:1.12e-4 (unfavourable), Prostate cancer:3.73e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 10.2	Expressed in all		
RAD21	hHR21, KIAA0078, SCC1	ENSG00000164754	RAD21 cohesin complex component	8	116845935-116874866	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020044, CAB022065	Supported		Enhanced	Nucleoplasm	Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 162.4	Expressed in all		
RAD21L1	dJ545L17.2, RAD21L	ENSG00000244588	RAD21 cohesin complex component like 1	20	1226056-1296421	Predicted intracellular proteins	Evidence at transcript level	HPA053282	Approved					Not detected	Tissue enriched	77	testis: 21.7	seminal vesicle: 0.2	Cell line enhanced		BJ hTERT+: 1.2;TIME: 1.2
RAD23A	HHR23A, MGC111083	ENSG00000179262	RAD23 homolog A, nucleotide excision repair protein	19	12945855-12953642	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA026418, HPA053901, HPA057003, HPA065599	Supported		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 334.1	Expressed in all		
RAD23B	HHR23B, HR23B, P58	ENSG00000119318	RAD23 homolog B, nucleotide excision repair protein	9	107283137-107332194	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029718, HPA029720, CAB033868	Enhanced		Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:2.58e-4 (unfavourable), Lung cancer:6.71e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 110.8	Expressed in all		
RAD50	hRad50, RAD50-2	ENSG00000113522	RAD50 double strand break repair protein	5	132556019-132646344	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022103, CAB024979, HPA052291	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.95e-4 (favourable), Cervical cancer:3.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 14.6	Expressed in all		
RAD51	BRCC5, FANCR, HsRad51, HsT16930, RAD51A, RECA	ENSG00000051180	RAD51 recombinase	15	40694774-40732339	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB010381, HPA039310	Enhanced		Enhanced	Nucleoli<br>Mitochondria<br>Cytosol	Breast cancer:7.94e-4 (unfavourable), Liver cancer:9.33e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 45.4	lymph node: 13.0	Mixed		
RAD51AP1	PIR51	ENSG00000111247	RAD51 associated protein 1	12	4538798-4560048	Predicted intracellular proteins	Evidence at protein level	HPA051499			Approved	Nucleus	Renal cancer:4.44e-15 (unfavourable), Pancreatic cancer:1.22e-5 (unfavourable), Liver cancer:3.53e-4 (unfavourable), Endometrial cancer:9.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 11.4	Mixed		
RAD51AP2	FLJ17540	ENSG00000214842	RAD51 associated protein 2	2	17510584-17518439	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	39	testis: 16.9	cerebral cortex: 0.4	Not detected		
RAD51C	FANCO, RAD51L2	ENSG00000108384	RAD51 paralog C	17	58692573-58735611	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045198			Supported	Nucleus<br>Vesicles<br>Cell Junctions<br>Mitochondria<br>Cytosol	Liver cancer:8.68e-5 (unfavourable), Pancreatic cancer:5.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.3	Expressed in all		
RAD51D	HsTRAD, R51H3, RAD51L3, Trad	ENSG00000185379	RAD51 paralog D	17	35092208-35121522	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.20e-9 (unfavourable), Pancreatic cancer:3.35e-6 (favourable), Endometrial cancer:5.37e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 9.6	Expressed in all		
RAD51L3-RFFL		ENSG00000267618		17	35011349-35121493	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 4.2	cerebral cortex: 1.6	Cell line enhanced		A549: 3.6
RAD52		ENSG00000002016	RAD52 homolog, DNA repair protein	12	912077-990053	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA028957			Approved	Nuclear speckles<br>Plasma membrane	Renal cancer:2.22e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 13.0	Expressed in all		
RAD54B	RDH54	ENSG00000197275	RAD54 homolog B (S. cerevisiae)	8	94371960-94475109	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007087	Uncertain					Mixed	Mixed			testis: 7.8	Mixed		
RAD54L	hHR54, hRAD54, RAD54A	ENSG00000085999	RAD54-like (S. cerevisiae)	1	46247688-46278473	Predicted intracellular proteins	Evidence at protein level	HPA028954, HPA051537	Approved		Enhanced	Nucleoplasm	Cervical cancer:6.67e-4 (favourable)	Mixed	Tissue enhanced		testis: 20.0	tonsil: 7.9	Mixed		
RAD54L2	ARIP4, KIAA0809, SRISNF2L	ENSG00000164080	RAD54-like 2 (S. cerevisiae)	3	51541144-51668667	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035004, HPA039992			Supported	Nucleus<br>Cytosol	Renal cancer:1.71e-5 (favourable)	Expressed in all	Expressed in all			testis: 8.8	Expressed in all		
RAD9A	RAD9	ENSG00000172613	RAD9 checkpoint clamp component A	11	67317871-67398410	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006725, HPA048155	Enhanced		Enhanced	Nucleoplasm	Urothelial cancer:7.52e-6 (favourable), Renal cancer:2.82e-5 (unfavourable), Cervical cancer:6.95e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 15.0	Mixed		
RAD9B	FLJ40346	ENSG00000151164	RAD9 checkpoint clamp component B	12	110501655-110532086	Predicted intracellular proteins	Evidence at protein level	HPA040643	Approved					Mixed	Tissue enriched	30	testis: 20.5	ovary: 0.6	Cell line enhanced		SiHa: 2.6
RADIL	FLJ10324, KIAA1849, RASIP2	ENSG00000157927	Rap associating with DIL domain	7	4797055-4883719	Predicted intracellular proteins	Evidence at protein level	HPA051776	Approved		Approved	Nucleus<br>Nuclear membrane		Mixed	Tissue enhanced		testis: 9.5	lung: 4.3	Cell line enhanced		AN3-CA: 8.1;SCLC-21H: 12.4;SH-SY5Y: 24.2
RAE1	Mnrp41	ENSG00000101146	Ribonucleic acid export 1	20	57351010-57379211	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA048795			Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:2.12e-7 (unfavourable), Endometrial cancer:2.44e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 183.9	bone marrow: 31.4	Expressed in all		
RAF1	c-Raf, CRAF, Raf-1	ENSG00000132155	Raf-1 proto-oncogene, serine/threonine kinase	3	12583601-12664226	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA002640, CAB019291	Approved		Approved	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 100.7	Expressed in all		
RAG1	MGC43321, RNF74	ENSG00000166349	Recombination activating 1	11	36510709-36593156	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043939			Supported	Nucleus		Mixed	Tissue enhanced		thyroid gland: 4.2	spleen: 3.6	Group enriched	102	MOLT-4: 227.0;REH: 243.3
RAG2		ENSG00000175097	Recombination activating 2	11	36575574-36598279	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065704			Approved	Nucleoplasm		Tissue enriched	Tissue enriched	22	thyroid gland: 40.1	testis: 1.8	Group enriched	114	MOLT-4: 37.4;REH: 167.6
RAI1	DKFZP434A139, KIAA1820, MGC12824, SMCR, SMS	ENSG00000108557	Retinoic acid induced 1	17	17681473-17811453	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023898, HPA054906	Approved		Enhanced	Nucleoplasm	Ovarian cancer:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 19.7	Expressed in all		
RAI14	DKFZp564G013, KIAA1334, NORPEG, RAI13	ENSG00000039560	Retinoic acid induced 14	5	34656237-34832627	Predicted intracellular proteins	Evidence at protein level	HPA036949, HPA036950	Supported		Supported	Nucleus<br>Actin filaments<br>Cytosol	Stomach cancer:2.05e-4 (unfavourable), Renal cancer:9.75e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 92.0	Mixed		
RAI2		ENSG00000131831	Retinoic acid induced 2	X	17800049-17861337	Predicted intracellular proteins	Evidence at protein level	HPA051054	Uncertain		Approved	Plasma membrane	Renal cancer:3.39e-14 (favourable), Pancreatic cancer:2.77e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 79.1	Cell line enriched	9	ASC diff: 71.0
RALA	RAL	ENSG00000006451	RAS like proto-oncogene A	7	39623483-39708124	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA065232	Approved				Liver cancer:5.32e-5 (unfavourable), Pancreatic cancer:6.30e-4 (unfavourable), Ovarian cancer:7.46e-4 (favourable)	Expressed in all	Expressed in all			lung: 60.3	Expressed in all		
RALB		ENSG00000144118	RAS like proto-oncogene B	2	120240064-120294713	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB026010, HPA065232	Enhanced				Pancreatic cancer:1.67e-4 (unfavourable)	Expressed in all	Tissue enriched	8	parathyroid gland: 664.6	placenta: 82.8	Expressed in all		
RALBP1	RIP, RIP1, RLIP76	ENSG00000017797	RalA binding protein 1	18	9475009-9538116	Predicted intracellular proteins, RAS pathway related proteins, Transporters	Evidence at protein level	CAB046010, HPA046651	Approved		Approved	Nuclear membrane<br>Vesicles<br>Cytosol	Renal cancer:5.39e-6 (favourable), Ovarian cancer:8.47e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 70.4	Expressed in all		
RALGAPB	DKFZp781M2411, KIAA1219, RalGAPbeta	ENSG00000170471	Ral GTPase activating protein non-catalytic beta subunit	20	38472816-38578861	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051454	Approved		Approved	Nuclear speckles	Renal cancer:7.25e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.2	Expressed in all		
RALGDS	RalGEF, RGDS, RGF	ENSG00000160271	Ral guanine nucleotide dissociation stimulator	9	133097720-133149334	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA025961, CAB032582	Approved		Approved	Nucleus	Cervical cancer:4.19e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 52.9	Expressed in all		
RALGPS1	KIAA0351, RALGEF2, RALGPS1A	ENSG00000136828	Ral GEF with PH domain and SH3 binding motif 1	9	126914774-127223166	Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.20e-11 (favourable)	Expressed in all	Expressed in all			small intestine: 32.0	Mixed		
RALGPS2	FLJ10244, FLJ25604, KIAA0351	ENSG00000116191	Ral GEF with PH domain and SH3 binding motif 2	1	178725147-178921841	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027143, HPA028328	Enhanced		Uncertain	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		testis: 138.2	lymph node: 62.7	Cell line enhanced		U-266/84: 172.2;U-698: 134.0
RALY	HNRPCL2, P542	ENSG00000125970	RALY heterogeneous nuclear ribonucleoprotein	20	33993646-34108308	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040971, HPA043614	Enhanced		Enhanced	Nucleoplasm	Liver cancer:3.60e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 140.8	Expressed in all		
RALYL	HNRPCL3	ENSG00000184672	RALY RNA binding protein-like	8	84182787-84921844	Predicted intracellular proteins	Evidence at protein level	HPA055868, HPA059112	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		adrenal gland: 26.1;cerebral cortex: 49.2;kidney: 19.7	gallbladder: 8.1	Cell line enhanced		AF22: 4.0
RAN	ARA24, Gsp1, TC4	ENSG00000132341	RAN, member RAS oncogene family	12	130871879-130877678	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA063353			Uncertain	Nucleus	Liver cancer:9.99e-8 (unfavourable), Renal cancer:1.46e-7 (unfavourable), Prostate cancer:7.86e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 559.9	Expressed in all		
RANBP1	HTF9A	ENSG00000099901	RAN binding protein 1	22	20115938-20127357	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065868, HPA065931	Enhanced		Supported	Cytosol	Renal cancer:1.16e-6 (unfavourable), Liver cancer:1.58e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 152.5	Expressed in all		
RANBP10	KIAA1464	ENSG00000141084	RAN binding protein 10	16	67723066-67806652	Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.52e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 26.7	Expressed in all		
RANBP2	ADANE, ANE1, NUP358	ENSG00000153201	RAN binding protein 2	2	108719481-108785811	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564	Supported					Expressed in all	Expressed in all			parathyroid gland: 74.9	Expressed in all		
RANBP3		ENSG00000031823	RAN binding protein 3	19	5916139-5978142	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA043375, HPA043389	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.22e-5 (favourable), Pancreatic cancer:4.14e-4 (favourable), Thyroid cancer:8.14e-4 (favourable)	Expressed in all	Expressed in all			testis: 60.1	Expressed in all		
RANBP3L	FLJ25422	ENSG00000164188	RAN binding protein 3 like	5	36248434-36302114	Predicted intracellular proteins	Evidence at protein level	HPA037471, HPA037472, HPA061526	Approved		Uncertain	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 31.0;kidney: 28.7;prostate: 23.0	breast: 10.0	Cell line enhanced		ASC diff: 8.5;HSkMC: 1.8;T-47d: 2.0
RANBP6		ENSG00000137040	RAN binding protein 6	9	6011043-6015625	Predicted intracellular proteins	Evidence at protein level	HPA043748, HPA052684	Approved		Supported	Vesicles	Renal cancer:1.34e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 26.2	Expressed in all		
RANBP9	RanBPM	ENSG00000010017	RAN binding protein 9	6	13621498-13711564	Predicted intracellular proteins	Evidence at protein level	CAB033767, HPA050007	Approved		Supported	Nucleoplasm<br>Cytosol	Ovarian cancer:2.47e-4 (favourable), Head and neck cancer:9.97e-4 (favourable)	Expressed in all	Expressed in all			testis: 211.6	Expressed in all		
RANGAP1	Fug1, KIAA1835, SD	ENSG00000100401	Ran GTPase activating protein 1	22	41245611-41286251	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004293, HPA050110, HPA062034	Enhanced		Enhanced	Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:1.08e-4 (unfavourable), Stomach cancer:5.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 206.1	Expressed in all		
RANGRF	HSPC165, HSPC236, MOG1, RANGNRF	ENSG00000108961	RAN guanine nucleotide release factor	17	8288497-8290092	Predicted intracellular proteins	Evidence at protein level	HPA057280, HPA057888	Approved		Supported	Nucleoplasm	Endometrial cancer:1.65e-4 (favourable), Pancreatic cancer:4.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 71.2	Expressed in all		
RAP1A	KREV-1, SMGP21	ENSG00000116473	RAP1A, member of RAS oncogene family	1	111542218-111716691	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 203.3	Expressed in all		
RAP1B	DKFZp586H0723, K-REV, RAL1B	ENSG00000127314	RAP1B, member of RAS oncogene family	12	68610839-68671901	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level						Renal cancer:8.08e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 243.9	Expressed in all		
RAP1GAP	KIAA0474, RAP1GA1, RAP1GAP1, RAP1GAPII	ENSG00000076864	RAP1 GTPase activating protein	1	21596215-21669363	Predicted intracellular proteins	Evidence at protein level	HPA001922, CAB003851	Enhanced	Supported	Approved	Cytosol	Renal cancer:1.12e-6 (favourable), Liver cancer:5.85e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 122.1;thyroid gland: 232.8	adrenal gland: 93.2	Cell line enhanced		A549: 41.8;K-562: 26.3;SCLC-21H: 61.3
RAP1GAP2	GARNL4, KIAA1039	ENSG00000132359	RAP1 GTPase activating protein 2	17	2755705-3037739	Predicted intracellular proteins	Evidence at protein level	HPA022148, HPA022896	Approved		Supported	Nuclear membrane<br>Cytosol	Renal cancer:1.36e-6 (favourable)	Expressed in all	Mixed			cerebral cortex: 35.2	Cell line enhanced		SH-SY5Y: 55.4
RAP1GDS1	SmgGDS	ENSG00000138698	Rap1 GTPase-GDP dissociation stimulator 1	4	98261384-98443861	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA019060	Approved		Supported	Cytosol	Renal cancer:2.00e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 93.9	Expressed in all		
RAP2A	K-REV, RAP2	ENSG00000125249	RAP2A, member of RAS oncogene family	13	97434222-97469128	Predicted intracellular proteins	Evidence at protein level	CAB018552	Uncertain				Liver cancer:1.55e-4 (unfavourable), Renal cancer:8.06e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.9	Expressed in all		
RAP2B		ENSG00000181467	RAP2B, member of RAS oncogene family	3	153162270-153170620	Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.65e-4 (unfavourable), Ovarian cancer:9.21e-4 (favourable)	Expressed in all	Mixed			placenta: 12.4	Mixed		
RAP2C	DKFZp313B211	ENSG00000123728	RAP2C, member of RAS oncogene family	X	132203024-132219480	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.81e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 102.6	Expressed in all		
RAPGEF1	C3G, GRF2	ENSG00000107263	Rap guanine nucleotide exchange factor 1	9	131576770-131740074	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006426	Approved				Renal cancer:1.18e-5 (favourable)	Expressed in all	Expressed in all			placenta: 80.8	Expressed in all		
RAPGEF2	DKFZP586O1422, KIAA0313, PDZ-GEF1, PDZGEF1, RA-GEF	ENSG00000109756	Rap guanine nucleotide exchange factor 2	4	159104178-159360169	Predicted intracellular proteins	Evidence at protein level	HPA057169			Supported	Nucleoplasm<br>Vesicles<br>Centrosome	Renal cancer:1.76e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 109.8	Mixed		
RAPGEF3	bcm910, cAMP-GEFI, EPAC	ENSG00000079337	Rap guanine nucleotide exchange factor 3	12	47734367-47771040	Predicted intracellular proteins	Evidence at protein level	CAB004386, HPA040365, HPA043518	Approved		Approved	Cytosol	Renal cancer:6.67e-7 (favourable)	Expressed in all	Mixed			thyroid gland: 43.0	Cell line enhanced		EFO-21: 26.0
RAPGEF4	cAMP-GEFII, CGEF2	ENSG00000091428	Rap guanine nucleotide exchange factor 4	2	172735274-173052893	Predicted intracellular proteins	Evidence at protein level	CAB004388, HPA028968	Approved		Approved	Focal adhesion sites	Pancreatic cancer:1.32e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 53.3;cerebral cortex: 119.2	liver: 18.3	Cell line enhanced		Karpas-707: 15.5;SCLC-21H: 9.8;U-266/70: 8.4;U-266/84: 16.0
RAPGEF6	PDZ-GEF2, PDZGEF2, RA-GEF-2	ENSG00000158987	Rap guanine nucleotide exchange factor 6	5	131423921-131635236	Predicted intracellular proteins	Evidence at protein level	HPA037982, HPA037983	Approved		Approved	Centrosome<br>Cytosol	Renal cancer:3.87e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 21.9	Expressed in all		
RAPGEFL1	Link-GEFII	ENSG00000108352	Rap guanine nucleotide exchange factor like 1	17	40177010-40195656	Predicted intracellular proteins	Evidence at protein level	HPA022895			Approved	Nucleus<br>Microtubules<br>Cytokinetic bridge	Renal cancer:0.00e+0 (unfavourable), Cervical cancer:3.28e-4 (favourable), Breast cancer:8.43e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 277.1	esophagus: 93.2	Expressed in all		
RAPH1	ALS2CR18, ALS2CR9, KIAA1681	ENSG00000173166	Ras association (RalGDS/AF-6) and pleckstrin homology domains 1	2	203394345-203535410	Predicted intracellular proteins	Evidence at protein level	HPA016744, HPA020027	Approved		Approved	Nuclear bodies<br>Plasma membrane<br>Cytosol		Mixed	Expressed in all			thyroid gland: 50.0	Mixed		
RAPSN	CMS1D, CMS1E, RNF205	ENSG00000165917	Receptor associated protein of the synapse	11	47437757-47449178	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039475	Approved		Approved	Plasma membrane<br>Centrosome<br>Cytosol		Mixed	Tissue enriched	10	skeletal muscle: 30.0	placenta: 2.9	Group enriched	40	LHCN-M2: 47.4;RH-30: 226.0
RARA	NR1B1, RAR	ENSG00000131759	Retinoic acid receptor alpha	17	40309192-40357643	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058282			Supported	Nucleus<br>Cytosol	Endometrial cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 68.6	Expressed in all		
RARB	HAP, NR1B2, RRB2	ENSG00000077092	Retinoic acid receptor beta	3	25174332-25597932	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002617, HPA004174	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.43e-5 (favourable)	Expressed in all	Mixed			placenta: 20.6	Cell line enhanced		HEK93: 14.7;HUVEC TERT2: 11.2;WM-115: 36.1
RARG	NR1B3, RARC	ENSG00000172819	Retinoic acid receptor gamma	12	53210567-53232980	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053883	Supported		Supported	Nucleoplasm	Renal cancer:3.08e-6 (unfavourable), Endometrial cancer:3.68e-6 (unfavourable)	Expressed in all	Tissue enhanced		skin: 143.4	esophagus: 77.3	Mixed		
RARS	DALRD1	ENSG00000113643	Arginyl-tRNA synthetase	5	168486445-168519299	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003979, HPA004130	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.10e-8 (unfavourable), Head and neck cancer:7.59e-5 (unfavourable)	Expressed in all	Expressed in all			duodenum: 54.4	Expressed in all		
RARS2	DALRD2, dJ382I10.6, MGC14993, MGC23778, PRO1992, RARSL	ENSG00000146282	Arginyl-tRNA synthetase 2, mitochondrial	6	87514378-87590003	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039987, HPA042645	Uncertain		Approved	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 56.9	Expressed in all		
RASA1	CM-AVM, GAP, p120, p120GAP, p120RASGAP, RASA	ENSG00000145715	RAS p21 protein activator 1	5	87267888-87391931	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB007789, HPA036393, HPA064556	Enhanced					Expressed in all	Expressed in all			placenta: 136.4	Expressed in all		
RASA3	GAP1IP4BP, GAPIII	ENSG00000185989	RAS p21 protein activator 3	13	113977783-114132611	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA046759	Uncertain				Renal cancer:1.99e-6 (unfavourable)	Expressed in all	Mixed			lymph node: 17.6	Mixed		
RASA4	CAPRI, GAPL, KIAA0538	ENSG00000105808	RAS p21 protein activator 4	7	102573807-102616757	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at transcript level	HPA043010	Uncertain		Uncertain	Vesicles		Not detected	Expressed in all			skeletal muscle: 85.0	Cell line enhanced		SH-SY5Y: 34.2;U-138 MG: 44.7
RASA4B		ENSG00000170667	RAS p21 protein activator 4B	7	102482445-102517781	Predicted intracellular proteins, RAS pathway related proteins	Evidence at transcript level	HPA043010	Uncertain		Uncertain	Vesicles<br>Cell Junctions		Not detected	Tissue enhanced		skeletal muscle: 39.7	cerebral cortex: 15.7	Cell line enhanced		SH-SY5Y: 14.3;U-138 MG: 18.0;U-2 OS: 16.6
RASAL1	RASAL	ENSG00000111344	RAS protein activator like 1	12	113098819-113136239	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA041650	Uncertain		Approved	Plasma membrane<br>Cell Junctions<br>Cytosol	Endometrial cancer:3.26e-5 (unfavourable)	Mixed	Tissue enriched	6	parathyroid gland: 118.8	cerebral cortex: 19.4	Cell line enhanced		EFO-21: 18.2;REH: 20.3;RPMI-8226: 34.6;RPTEC TERT1: 14.4;U-698: 28.8
RASAL2	nGAP	ENSG00000075391	RAS protein activator like 2	1	178094141-178484147	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA018805, HPA020453	Enhanced		Approved	Plasma membrane<br>Focal adhesion sites	Urothelial cancer:2.05e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 19.4	Mixed		
RASAL3	FLJ21438	ENSG00000105122	RAS protein activator like 3	19	15451624-15464571	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA043417	Enhanced				Renal cancer:1.16e-6 (unfavourable), Endometrial cancer:3.58e-5 (favourable), Head and neck cancer:3.07e-4 (favourable), Cervical cancer:8.75e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 37.5	spleen: 24.6	Cell line enhanced		HDLM-2: 28.2;HEL: 22.6;HMC-1: 40.9;Karpas-707: 37.6;TIME: 28.9;U-937: 26.4
RASD1	AGS1, DEXRAS1	ENSG00000108551	Ras related dexamethasone induced 1	17	17494437-17496395	Predicted intracellular proteins	Evidence at protein level	HPA047896	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			adipose tissue: 113.2	Cell line enhanced		ASC diff: 48.2;REH: 65.3
RASD2	MGC:4834, Rhes, TEM2	ENSG00000100302	RASD family member 2	22	35540868-35554001	Predicted intracellular proteins	Evidence at protein level	HPA005839	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.22e-5 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 32.2	epididymis: 18.5	Cell line enhanced		SK-BR-3: 4.2;U-2 OS: 3.3;U-87 MG: 3.9
RASEF	FLJ31614, RAB45	ENSG00000165105	RAS and EF-hand domain containing	9	82979585-83063177	Predicted intracellular proteins	Evidence at protein level	HPA021431			Approved	Microtubules		Mixed	Expressed in all			thyroid gland: 44.6	Mixed		
RASGEF1A	CG4853, FLJ37817	ENSG00000198915	RasGEF domain family member 1A	10	43194535-43266919	Predicted intracellular proteins	Evidence at protein level	HPA035593	Enhanced		Approved	Golgi apparatus	Renal cancer:4.11e-7 (unfavourable), Breast cancer:1.86e-5 (favourable), Endometrial cancer:4.28e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 22.7	parathyroid gland: 12.8	Cell line enhanced		K-562: 15.4;SCLC-21H: 18.4;T-47d: 14.7
RASGEF1C	FLJ35841	ENSG00000146090	RasGEF domain family member 1C	5	180100791-180209153	Predicted intracellular proteins	Evidence at transcript level	HPA028242	Uncertain		Approved	Mitochondria		Tissue enhanced	Group enriched	8	cerebral cortex: 16.4;testis: 6.1	seminal vesicle: 1.3	Cell line enhanced		BEWO: 2.2;MCF7: 1.9;SCLC-21H: 9.1;U-2 OS: 2.5
RASGRF1	CDC25, CDC25L, GNRP, GRF1, GRF55, H-GRF55, PP13187	ENSG00000058335	Ras protein specific guanine nucleotide releasing factor 1	15	78959947-79090773	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010413, HPA041965	Approved		Supported	Golgi apparatus	Endometrial cancer:6.14e-6 (favourable)	Mixed	Group enriched	14	cerebral cortex: 30.5;lung: 11.3	lymph node: 1.5	Cell line enhanced		A-431: 7.3;BEWO: 7.5;Karpas-707: 7.5;RPMI-8226: 9.0;U-2 OS: 15.8
RASGRF2	GRF2, Ras-GRF2	ENSG00000113319	Ras protein specific guanine nucleotide releasing factor 2	5	80960672-81230156	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA018679	Uncertain		Supported	Endoplasmic reticulum		Mixed	Tissue enhanced		cerebral cortex: 25.5	ovary: 22.8	Cell line enhanced		BEWO: 37.2;CACO-2: 19.9;Hep G2: 21.9;HHSteC: 17.6
RASGRP1	CalDAG-GEFII, RASGRP	ENSG00000172575	RAS guanyl releasing protein 1	15	38488103-38565575	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA039389			Supported	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 28.4;lymph node: 25.0	tonsil: 15.2	Cell line enhanced		HDLM-2: 50.5;MOLT-4: 41.7
RASGRP2	CALDAG-GEFI	ENSG00000068831	RAS guanyl releasing protein 2	11	64726911-64745456	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA015667	Approved				Renal cancer:1.38e-4 (unfavourable)	Mixed	Tissue enhanced		lymph node: 122.0;spleen: 107.0	bone marrow: 94.3	Cell line enhanced		HEL: 90.3;HL-60: 145.9;NB-4: 219.4;REH: 94.2;THP-1: 72.4
RASGRP3	CalDAG-GEFIII, GRP3, KIAA0846	ENSG00000152689	RAS guanyl releasing protein 3	2	33436324-33564750	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA058937			Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Mixed			lymph node: 33.8	Group enriched	5	Daudi: 64.5;HEL: 85.5;U-266/70: 109.3;U-266/84: 41.0;U-698: 27.2
RASGRP4		ENSG00000171777	RAS guanyl releasing protein 4	19	38409051-38426305	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		bone marrow: 13.1	appendix: 8.7	Group enriched	6	HEL: 21.5;HMC-1: 20.1;U-937: 4.8
RASIP1	FLJ20401, RAIN	ENSG00000105538	Ras interacting protein 1	19	48720587-48740721	Predicted intracellular proteins	Evidence at protein level	HPA077251	Approved				Head and neck cancer:7.17e-5 (favourable), Pancreatic cancer:9.46e-4 (favourable)	Expressed in all	Mixed			spleen: 17.8	Cell line enhanced		HEK93: 12.7;HUVEC TERT2: 30.5;SiHa: 20.8;TIME: 40.9
RASL10A	RRP22	ENSG00000100276	RAS like family 10 member A	22	29312933-29319679	Predicted intracellular proteins	Evidence at protein level	HPA056169	Approved					Tissue enhanced	Tissue enriched	15	cerebral cortex: 33.5	breast: 2.2	Cell line enhanced		HEK93: 1.4;NB-4: 1.5;U-2 OS: 1.1;U-266/70: 2.0
RASL10B	RRP17, VTS58635	ENSG00000270885	RAS like family 10 member B	17	35731649-35743521	Predicted intracellular proteins	Evidence at protein level	HPA046842, HPA057092	Enhanced		Approved	Vesicles	Endometrial cancer:6.38e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 16.0;seminal vesicle: 21.0	skeletal muscle: 11.1	Cell line enhanced		HAP1: 25.2;HHSteC: 22.5;NTERA-2: 41.3
RASL11A		ENSG00000122035	RAS like family 11 member A	13	27270327-27273690	Predicted intracellular proteins	Evidence at protein level	HPA004859, HPA053296	Supported		Approved	Nuclear bodies	Renal cancer:3.52e-4 (unfavourable), Lung cancer:5.43e-4 (favourable)	Expressed in all	Mixed			rectum: 25.0	Cell line enhanced		ASC diff: 56.5;PC-3: 18.3
RASL11B		ENSG00000128045	RAS like family 11 member B	4	52862290-52866835	Predicted intracellular proteins	Evidence at transcript level	HPA057803	Uncertain		Approved	Nuclear bodies		Mixed	Tissue enhanced		ovary: 26.0;parathyroid gland: 30.1	cerebral cortex: 13.5	Cell line enhanced		BEWO: 13.0;NTERA-2: 14.5;SH-SY5Y: 38.8
RASL12	RIS	ENSG00000103710	RAS like family 12	15	65053337-65076690	Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.20e-5 (unfavourable), Urothelial cancer:2.17e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 101.5	prostate: 64.1	Cell line enhanced		CACO-2: 11.7;EFO-21: 20.5;NTERA-2: 9.4
RASSF1	123F2, NORE2A, RDA32, REH3P21	ENSG00000068028	Ras association domain family member 1	3	50329782-50340980	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA040735	Approved				Renal cancer:8.58e-5 (unfavourable), Head and neck cancer:2.60e-4 (favourable), Cervical cancer:2.64e-4 (favourable), Liver cancer:9.77e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 51.8	Expressed in all		
RASSF10		ENSG00000189431	Ras association domain family member 10	11	13009577-13012106	Predicted intracellular proteins	Evidence at transcript level	HPA040406			Approved	Vesicles<br>Cytosol	Renal cancer:4.12e-5 (favourable), Head and neck cancer:2.76e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 5.4	parathyroid gland: 3.8	Cell line enhanced		A549: 8.6;CAPAN-2: 7.5;HaCaT: 11.6;HMC-1: 5.6;RPTEC TERT1: 9.8
RASSF2	CENP-34, KIAA0168	ENSG00000101265	Ras association domain family member 2	20	4780023-4823645	Predicted intracellular proteins	Evidence at protein level	HPA051200	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:7.82e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 148.5	lymph node: 68.8	Cell line enhanced		HL-60: 59.0;NB-4: 60.4;U-937: 91.0
RASSF4	AD037, MGC44914	ENSG00000107551	Ras association domain family member 4	10	44959407-44995891	Predicted intracellular proteins	Evidence at protein level	HPA038834	Approved		Approved	Nucleus<br>Nucleoli<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 71.4	Cell line enhanced		RH-30: 158.1;U-937: 67.6;WM-115: 54.3
RASSF5	Maxp1, NORE1, RAPL	ENSG00000266094	Ras association domain family member 5	1	206507530-206589448	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA070480	Approved				Renal cancer:1.22e-6 (unfavourable), Cervical cancer:1.46e-4 (favourable)	Expressed in all	Mixed			spleen: 77.2	Cell line enhanced		HMC-1: 80.2;Karpas-707: 138.2;RPMI-8226: 150.4
RASSF6		ENSG00000169435	Ras association domain family member 6	4	73571550-73620631	Predicted intracellular proteins	Evidence at protein level	HPA037712	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enhanced		stomach: 33.0	rectum: 13.8	Cell line enhanced		Daudi: 53.8;RT4: 55.3;U-698: 42.2
RASSF7	C11orf13, HRAS1, HRC1	ENSG00000099849	Ras association domain family member 7	11	560404-564021	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA078015			Supported	Microtubule organizing center	Glioma:8.86e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 44.4	Cell line enhanced		CAPAN-2: 75.6;HaCaT: 76.6
RASSF8	C12orf2, HoJ-1	ENSG00000123094	Ras association domain family member 8	12	25959029-26079892	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038163, HPA038164	Uncertain		Approved	Mitochondria<br>Cytosol		Expressed in all	Tissue enhanced		testis: 106.4	endometrium: 47.0	Cell line enhanced		U-2197: 100.3
RASSF9	P-CIP1, PAMCI	ENSG00000198774	Ras association domain family member 9	12	85800697-85836570	Predicted intracellular proteins	Evidence at transcript level	HPA039428, HPA039678	Approved					Mixed	Mixed			fallopian tube: 10.1	Cell line enhanced		HeLa: 2.6;HUVEC TERT2: 2.0;RPTEC TERT1: 2.8;U-138 MG: 2.7
RAVER1	KIAA1978	ENSG00000161847	Ribonucleoprotein, PTB binding 1	19	10316212-10333640	Predicted intracellular proteins	Evidence at protein level	HPA043575, HPA049457	Enhanced		Supported	Nucleoplasm		Expressed in all	Mixed			small intestine: 20.2	Expressed in all		
RAVER2	FLJ10770, KIAA1579	ENSG00000162437	Ribonucleoprotein, PTB binding 2	1	64745095-64833232	Predicted intracellular proteins	Evidence at protein level	HPA045785	Approved		Approved	Nucleoplasm	Renal cancer:5.14e-6 (favourable)	Expressed in all	Mixed			rectum: 29.4	Mixed		
RAX	RX	ENSG00000134438	Retina and anterior neural fold homeobox	18	59267035-59274086	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Not detected			prostate: 0.2	Cell line enhanced		HMC-1: 1.6;SH-SY5Y: 1.0
RAX2	ARMD6, CORD11, MGC15631, RAXL1	ENSG00000173976	Retina and anterior neural fold homeobox 2	19	3769089-3772221	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052533	Uncertain					Not detected	Tissue enhanced		parathyroid gland: 1.2	fallopian tube: 0.7	Not detected		
RB1CC1	ATG17, Cc1, DRAGOU14, FIP200, KIAA0203, PPP1R131	ENSG00000023287	RB1 inducible coiled-coil 1	8	52622456-52745843	Predicted intracellular proteins	Evidence at protein level	HPA024391, HPA053049	Approved		Supported	Nuclear membrane<br>Cytosol	Endometrial cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.4	Expressed in all		
RBAK	ZNF769	ENSG00000146587	RB associated KRAB zinc finger	7	5045821-5069488	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071231			Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 14.8	Expressed in all		
RBAK-RBAKDN		ENSG00000272968	RBAK-RBAKDN readthrough	7	4983718-5073221	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	155	testis: 109.8	cerebral cortex: 0.7	Mixed		
RBBP4	lin-53, NURF55, RbAp48	ENSG00000162521	RB binding protein 4, chromatin remodeling factor	1	32651142-32686211	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB006264, HPA060710, HPA060724	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.89e-6 (unfavourable), Melanoma:6.45e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 138.7	Expressed in all		
RBBP5	RBQ3, SWD1	ENSG00000117222	RB binding protein 5, histone lysine methyltransferase complex subunit	1	205086142-205122015	Predicted intracellular proteins	Evidence at protein level	HPA049042, HPA058085	Uncertain		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			thyroid gland: 16.4	Expressed in all		
RBBP6	P2P-R, PACT, SNAMA	ENSG00000122257	RB binding protein 6, ubiquitin ligase	16	24537693-24572863	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB032866, HPA041725, HPA043544	Approved		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			bone marrow: 91.5	Expressed in all		
RBBP7	RbAp46	ENSG00000102054	RB binding protein 7, chromatin remodeling factor	X	16839283-16870414	Predicted intracellular proteins	Evidence at protein level	CAB037084, HPA060710, HPA060724	Supported				Thyroid cancer:2.43e-4 (favourable), Liver cancer:5.55e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 376.0	Expressed in all		
RBBP8	COM1, CtIP, RIM, SCKL2	ENSG00000101773	RB binding protein 8, endonuclease	18	22798261-23026488	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039890, HPA052946	Approved		Supported	Nucleoplasm	Renal cancer:1.71e-5 (favourable), Melanoma:7.21e-4 (unfavourable)	Expressed in all	Mixed			testis: 52.7	Expressed in all		
RBBP8NL	C20orf151, dJ908M14.3	ENSG00000130701	RBBP8 N-terminal like	20	62410237-62427533	Predicted intracellular proteins	Evidence at protein level	HPA042627	Uncertain				Urothelial cancer:6.91e-4 (favourable)	Mixed	Tissue enhanced		small intestine: 5.2	duodenum: 4.5	Cell line enhanced		BEWO: 17.9;CACO-2: 22.7;MCF7: 8.7;SK-BR-3: 9.3
RBBP9	Bog	ENSG00000089050	RB binding protein 9, serine hydrolase	20	18486540-18497243	Predicted intracellular proteins	Evidence at protein level	HPA015830, HPA049005	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 40.8	Expressed in all		
RBCK1	C20orf18, HOIL1, RBCK2, RNF54, UBCE7IP3, XAP4, ZRANB4	ENSG00000125826	RANBP2-type and C3HC4-type zinc finger containing 1	20	407498-430966	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.41e-9 (unfavourable)	Expressed in all	Expressed in all			spleen: 51.2	Expressed in all		
RBFA	C18orf22, FLJ21172, HsT169	ENSG00000101546	Ribosome binding factor A (putative)	18	80034358-80046397	Predicted intracellular proteins	Evidence at protein level	HPA040485, HPA041479	Approved		Supported	Mitochondria	Liver cancer:2.06e-6 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 20.3	Expressed in all		
RBFOX1	A2BP1, FOX-1, HRNBP1	ENSG00000078328	RNA binding protein, fox-1 homolog 1	16	6019094-7713338	Predicted intracellular proteins	Evidence at protein level	HPA040809	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Cytosol		Tissue enhanced	Group enriched	5	cerebral cortex: 110.5;skeletal muscle: 32.9	heart muscle: 13.9	Cell line enriched	18	RH-30: 26.2
RBFOX2	FOX-2, HNRBP2, HRNBP2, RBM9	ENSG00000100320	RNA binding protein, fox-1 homolog 2	22	35738736-36028425	Predicted intracellular proteins	Evidence at protein level	HPA006240	Enhanced		Supported	Nucleoplasm		Expressed in all	Mixed			endometrium: 108.5	Expressed in all		
RBFOX3	FOX-3, HRNBP3, NeuN	ENSG00000167281	RNA binding protein, fox-1 homolog 3	17	79089345-79516148	Predicted intracellular proteins	Evidence at protein level	HPA030790, CAB078782	Enhanced	Approved	Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 62.3;seminal vesicle: 33.2	prostate: 24.1	Group enriched	7	A549: 14.1;NTERA-2: 13.9;SCLC-21H: 26.0;U-2 OS: 10.8
RBKS	DKFZp686G13268, RBSK	ENSG00000171174	Ribokinase	2	27781364-27891098	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019725, HPA028285	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		adrenal gland: 34.7	kidney: 19.5	Cell line enhanced		EFO-21: 10.8;RPTEC TERT1: 18.4
RBL2	p130, Rb2	ENSG00000103479	RB transcriptional corepressor like 2	16	53433977-53491649	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016547, HPA019703	Supported		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.57e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 149.6	Expressed in all		
RBM10	DXS8237E, GPATC9, GPATCH9, KIAA0122, ZRANB5	ENSG00000182872	RNA binding motif protein 10	X	47144869-47186813	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034972, HPA057372	Approved		Enhanced	Nuclear speckles	Pancreatic cancer:2.86e-6 (favourable), Cervical cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			ovary: 35.1	Expressed in all		
RBM11		ENSG00000185272	RNA binding motif protein 11	21	14216130-14228372	Predicted intracellular proteins	Evidence at protein level	HPA045885			Supported	Nucleoplasm		Mixed	Tissue enriched	17	epididymis: 56.5	cerebral cortex: 3.2	Cell line enhanced		HEL: 1.1
RBM12	HRIHFB2091, KIAA0765, SWAN	ENSG00000244462	RNA binding motif protein 12	20	35648925-35664956	Predicted intracellular proteins	Evidence at protein level	HPA043258, HPA043621	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.54e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 47.6	Expressed in all		
RBM12B		ENSG00000183808	RNA binding motif protein 12B	8	93729356-93741017	Predicted intracellular proteins	Evidence at protein level	HPA024398, HPA053050	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 33.0	Mixed		
RBM14	COAA, DKFZp779J0927, SIP, SYTIP1	ENSG00000239306	RNA binding motif protein 14	11	66616582-66627347	Predicted intracellular proteins	Evidence at protein level	HPA006628	Supported		Supported	Nuclear speckles	Liver cancer:2.02e-7 (unfavourable), Pancreatic cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 50.0	Expressed in all		
RBM14-RBM4		ENSG00000248643	RBM14-RBM4 readthrough	11	66616626-66646469	Predicted intracellular proteins	Evidence at protein level	HPA047849	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Not detected			epididymis: 0.9	Cell line enhanced		NB-4: 5.4
RBM15	OTT, OTT1	ENSG00000162775	RNA binding motif protein 15	1	110338506-110346681	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015201, HPA019824, HPA049642	Supported		Enhanced	Nucleoplasm	Renal cancer:1.37e-4 (unfavourable), Liver cancer:7.61e-4 (unfavourable), Stomach cancer:7.97e-4 (favourable)	Expressed in all	Mixed			bone marrow: 27.9	Expressed in all		
RBM15B	HUMAGCGB, OTT3	ENSG00000259956	RNA binding motif protein 15B	3	51391268-51397908	Predicted intracellular proteins	Evidence at protein level	HPA036645, HPA058136	Approved		Enhanced	Nucleoplasm	Renal cancer:1.84e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
RBM17	MGC14439, SPF45	ENSG00000134453	RNA binding motif protein 17	10	6088987-6117457	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037477, HPA037478	Supported		Supported	Nucleoplasm	Liver cancer:4.57e-8 (unfavourable), Renal cancer:4.31e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 104.6	Expressed in all		
RBM18	MGC2734	ENSG00000119446	RNA binding motif protein 18	9	122237624-122264839	Predicted intracellular proteins	Evidence at protein level	HPA057281	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Midbody	Renal cancer:8.00e-7 (favourable)	Expressed in all	Expressed in all			breast: 20.3	Expressed in all		
RBM19	DKFZp586F1023, KIAA0682	ENSG00000122965	RNA binding motif protein 19	12	113816738-113966371	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038860, HPA058732	Supported		Supported	Nucleoli	Liver cancer:5.87e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 19.6	Expressed in all		
RBM20		ENSG00000203867	RNA binding motif protein 20	10	110644397-110839469	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035806, HPA037703	Uncertain		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytokinetic bridge		Mixed	Tissue enhanced		heart muscle: 26.4	skeletal muscle: 5.4	Cell line enhanced		HEK93: 5.5;RH-30: 15.9;SH-SY5Y: 16.0;T-47d: 8.7
RBM22	Cwc2, FLJ10290, fSAP47, ZC3H16	ENSG00000086589	RNA binding motif protein 22	5	150690794-150701107	Predicted intracellular proteins	Evidence at protein level	HPA001634	Supported		Enhanced	Nucleus	Liver cancer:5.50e-6 (unfavourable), Renal cancer:3.58e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 40.5	Expressed in all		
RBM23	CAPERbeta, FLJ10482, RNPC4	ENSG00000100461	RNA binding motif protein 23	14	22893206-22919184	Predicted intracellular proteins	Evidence at protein level	HPA004144	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments	Renal cancer:8.06e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 144.3	Expressed in all		
RBM24	dJ259A10.1, FLJ30829, RNPC6	ENSG00000112183	RNA binding motif protein 24	6	17281346-17293875	Predicted intracellular proteins	Evidence at protein level	HPA066927, HPA067231	Enhanced		Enhanced	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		heart muscle: 90.9;skeletal muscle: 109.8	endometrium: 51.6	Cell line enhanced		LHCN-M2: 49.0;RH-30: 57.9;T-47d: 26.5
RBM25	fSAP94, NET52, RNPC7, S164, Snu71	ENSG00000119707	RNA binding motif protein 25	14	73058436-73123898	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003025, HPA070713	Supported		Enhanced	Nuclear speckles	Liver cancer:1.42e-4 (unfavourable), Renal cancer:4.26e-4 (unfavourable), Prostate cancer:8.09e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 53.4	Expressed in all		
RBM26	ARRS2, C13orf10, FLJ20957, PPP1R132, PRO1777, SE70-2, ZC3H17	ENSG00000139746	RNA binding motif protein 26	13	79311824-79406477	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040252	Approved		Approved	Nuclear speckles	Renal cancer:5.87e-6 (unfavourable), Prostate cancer:3.46e-4 (unfavourable), Urothelial cancer:8.20e-4 (favourable)	Expressed in all	Expressed in all			testis: 56.0	Expressed in all		
RBM27	ARRS1, KIAA1311, Psc1, ZC3H20	ENSG00000091009	RNA binding motif protein 27	5	146203600-146289132	Predicted intracellular proteins	Evidence at protein level	HPA035944, HPA036422	Approved		Approved	Nuclear speckles	Liver cancer:8.58e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 19.0	Expressed in all		
RBM28	FLJ10377	ENSG00000106344	RNA binding motif protein 28	7	128297685-128343908	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019058, HPA026672, HPA031519	Enhanced		Enhanced	Nucleoli	Liver cancer:2.72e-11 (unfavourable), Endometrial cancer:2.94e-4 (unfavourable), Melanoma:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.9	Expressed in all		
RBM33	DKFZp434D1319, DKFZp686F102, MGC20460, PRR8	ENSG00000184863	RNA binding motif protein 33	7	155644451-155781485	Predicted intracellular proteins	Evidence at protein level	HPA019232, HPA021497, HPA021768	Approved		Approved	Nucleoplasm	Head and neck cancer:9.63e-5 (favourable), Renal cancer:1.05e-4 (unfavourable), Urothelial cancer:4.29e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 40.8	Expressed in all		
RBM34	KIAA0117	ENSG00000188739	RNA binding motif protein 34	1	235131183-235161457	Predicted intracellular proteins	Evidence at protein level	HPA028606	Approved		Supported	Nucleus<br>Nucleoli		Mixed	Expressed in all			testis: 35.5	Expressed in all		
RBM38	dJ800J21.2, HSRNASEB, RNPC1, seb4B, SEB4D	ENSG00000132819	RNA binding motif protein 38	20	57391407-57409333	Predicted intracellular proteins	Evidence at protein level	CAB017036	Approved		Supported	Nucleoplasm<br>Cytosol	Cervical cancer:3.64e-7 (favourable), Renal cancer:1.05e-5 (unfavourable), Thyroid cancer:1.63e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 86.8	Mixed		
RBM39	CAPER, CAPERalpha, CC1.3, fSAP59, HCC1, RNPC2	ENSG00000131051	RNA binding motif protein 39	20	35701347-35742312	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001591	Supported		Supported	Nucleoplasm<br>Nuclear speckles<br>Microtubules<br>Microtubule organizing center	Renal cancer:2.78e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 123.0	Expressed in all		
RBM4	LARK, RBM4A, ZCCHC21, ZCRB3A	ENSG00000173933	RNA binding motif protein 4	11	66638617-66666682	Predicted intracellular proteins	Evidence at protein level	HPA042174, HPA047849	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 133.6	Expressed in all		
RBM41	FLJ11016	ENSG00000089682	RNA binding motif protein 41	X	107064420-107118823	Predicted intracellular proteins	Evidence at protein level	HPA042881	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:3.04e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 19.3	Expressed in all		
RBM42	MGC10433	ENSG00000126254	RNA binding motif protein 42	19	35629030-35637686	Predicted intracellular proteins	Evidence at protein level	HPA043671	Supported		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			spleen: 38.7	Expressed in all		
RBM43	C2orf38, FLJ45645	ENSG00000184898	RNA binding motif protein 43	2	151247940-151261879	Predicted intracellular proteins	Evidence at protein level	HPA038204	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			thyroid gland: 20.6	Mixed		
RBM44	FLJ40411	ENSG00000177483	RNA binding motif protein 44	2	237798389-237842808	Predicted intracellular proteins	Evidence at protein level	HPA003298	Enhanced					Not detected	Tissue enriched	61	testis: 35.7	bone marrow,lung: 0.5	Not detected		
RBM45	DRB1, FLJ44612	ENSG00000155636	RNA binding motif protein 45	2	178112424-178139011	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020448	Approved		Supported	Nucleus	Renal cancer:5.34e-9 (unfavourable), Liver cancer:5.74e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.4	Expressed in all		
RBM46	CT68, MGC27016	ENSG00000151962	RNA binding motif protein 46	4	154781213-154828813	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	59	testis: 50.2	thyroid gland: 0.8	Not detected		
RBM47	FLJ20273, NET18	ENSG00000163694	RNA binding motif protein 47	4	40423267-40630875	Predicted intracellular proteins	Evidence at protein level	HPA006347	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.33e-16 (favourable)	Expressed in all	Mixed			small intestine: 71.5	Cell line enhanced		BEWO: 135.3;CAPAN-2: 55.4
RBM48	C7orf64, DKFZp564O0523, HSPC304	ENSG00000127993	RNA binding motif protein 48	7	92528773-92538005	Predicted intracellular proteins	Evidence at protein level	HPA021777, HPA025306	Uncertain		Enhanced	Nucleoplasm	Liver cancer:3.17e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 19.8	Expressed in all		
RBM4B	MGC10871, RBM30, RBM4L, ZCCHC15, ZCCHC21B, ZCRB3B	ENSG00000173914	RNA binding motif protein 4B	11	66664998-66677921	Predicted intracellular proteins	Evidence at protein level	HPA042174, HPA047849	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.02e-4 (unfavourable), Pancreatic cancer:2.10e-4 (favourable), Liver cancer:2.94e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 36.2	Expressed in all		
RBM5	H37, LUCA15	ENSG00000003756	RNA binding motif protein 5	3	50088908-50119021	Predicted intracellular proteins	Evidence at protein level	HPA017335, HPA018011	Approved		Enhanced	Nucleoplasm	Lung cancer:6.46e-4 (favourable), Pancreatic cancer:7.58e-4 (favourable), Liver cancer:9.77e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 112.7	Expressed in all		
RBM6	3G2, DEF-3, DEF3, g16, NY-LU-12	ENSG00000004534	RNA binding motif protein 6	3	49940007-50100045	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026272, HPA027164	Enhanced		Approved	Nuclear speckles<br>Cytoplasmic bodies	Urothelial cancer:5.13e-5 (favourable), Pancreatic cancer:1.41e-4 (favourable), Renal cancer:8.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 83.7	Expressed in all		
RBM7		ENSG00000076053	RNA binding motif protein 7	11	114400030-114414203	Predicted intracellular proteins	Evidence at protein level	HPA013993, HPA048003	Supported		Enhanced	Nucleoplasm	Pancreatic cancer:1.17e-4 (unfavourable), Colorectal cancer:6.14e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 40.8	Expressed in all		
RBM8A	BOV-1A, BOV-1B, BOV-1C, RBM8, RBM8B, Y14, ZNRP	ENSG00000265241	RNA binding motif protein 8A	1	145917714-145927678	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018403	Supported		Enhanced	Nuclear speckles	Prostate cancer:1.55e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 161.4	Expressed in all		
RBMS1	C2orf12, DKFZp564H0764, HCC-4, MSSP-1, MSSP-2, MSSP-3, SCR2, YC1	ENSG00000153250	RNA binding motif single stranded interacting protein 1	2	160272151-160493794	Predicted intracellular proteins	Evidence at protein level	HPA047943, HPA061791			Supported	Cytosol	Renal cancer:1.33e-7 (unfavourable), Liver cancer:4.45e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 119.9	Mixed		
RBMS2	SCR3	ENSG00000076067	RNA binding motif single stranded interacting protein 2	12	56521929-56596196	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039225, HPA058784	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Renal cancer:3.22e-4 (favourable)	Expressed in all	Expressed in all			lung: 37.9	Mixed		
RBMS3		ENSG00000144642	RNA binding motif single stranded interacting protein 3	3	28574791-30010391	Predicted intracellular proteins	Evidence at protein level	HPA034719	Uncertain		Approved	Vesicles	Renal cancer:1.85e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 28.0	Mixed		
RBMX	hnRNP-G, HNRNPG, RNMX	ENSG00000147274	RNA binding motif protein, X-linked	X	136848004-136880764	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA057707	Supported		Approved	Nucleoplasm	Liver cancer:5.16e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 296.7	Expressed in all		
RBMX2	CGI-79, Snu17	ENSG00000134597	RNA binding motif protein, X-linked 2	X	130401969-130413343	Predicted intracellular proteins	Evidence at protein level	HPA026609	Approved		Approved	Nuclear membrane<br>Nucleoli	Renal cancer:8.44e-9 (unfavourable), Liver cancer:7.04e-4 (unfavourable), Lung cancer:9.15e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 29.4	Expressed in all		
RBMXL1	KAT3	ENSG00000213516	RNA binding motif protein, X-linked like 1	1	88979456-88992960	Predicted intracellular proteins	Evidence at protein level	HPA057707	Supported		Approved	Nucleoplasm	Pancreatic cancer:7.26e-4 (unfavourable), Breast cancer:7.60e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
RBMXL2	HNRNPG-T, HNRPGT	ENSG00000170748	RNA binding motif protein, X-linked like 2	11	7089027-7090900	Predicted intracellular proteins	Evidence at protein level	HPA038912, HPA051842	Enhanced					Tissue enriched	Tissue enriched	499	testis: 49.8	all non-specific tissues: 0.0	Not detected		
RBMXL3	CXorf55, FLJ40249	ENSG00000175718	RNA binding motif protein, X-linked like 3	X	115189427-115192868	Predicted intracellular proteins	Evidence at protein level	HPA051842	Supported					Tissue enriched	Tissue enriched	26	testis: 2.5	all non-specific tissues: 0.0	Not detected		
RBMY1A1	RBM1, RBM2, YRRM1, YRRM2	ENSG00000234414	RNA binding motif protein, Y-linked, family 1, member A1	Y	21511372-21549326	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Tissue enriched	161	testis: 17.5	kidney,placenta: 0.1	Cell line enriched	9	U-266/84: 10.5
RBMY1B		ENSG00000242875	RNA binding motif protein, Y-linked, family 1, member B	Y	21511338-21549094	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Tissue enriched	33	testis: 3.3	all non-specific tissues: 0.0	Not detected		
RBMY1D		ENSG00000244395	RNA binding motif protein, Y-linked, family 1, member D	Y	21880076-21894526	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Not detected			testis: 0.2	Not detected		
RBMY1E		ENSG00000242389	RNA binding motif protein, Y-linked, family 1, member E	Y	21903618-21918067	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Tissue enriched	22	testis: 2.2	all non-specific tissues: 0.0	Cell line enriched	8	U-266/84: 1.6
RBMY1F	MGC33094	ENSG00000169800	RNA binding motif protein, Y-linked, family 1, member F	Y	22168542-22182982	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Tissue enriched	51	testis: 5.0	all non-specific tissues: 0.0	Group enriched	244	U-266/70: 23.8;U-266/84: 24.9
RBMY1J		ENSG00000226941	RNA binding motif protein, Y-linked, family 1, member J	Y	22403461-22417881	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Tissue enriched	17	testis: 2.7	lung: 0.1	Group enriched	138	U-266/70: 18.5;U-266/84: 8.9
RBP1	CRABP-I, CRBP, CRBP1, CRBPI, RBPC	ENSG00000114115	Retinol binding protein 1	3	139517434-139539829	Predicted intracellular proteins	Evidence at protein level	HPA007338, CAB018603, CAB019276	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		fallopian tube: 634.8;ovary: 1297.7	adrenal gland: 376.4	Cell line enriched	6	SH-SY5Y: 887.3
RBP2	CRABP-II, CRBP2, CRBPII, RBPC2	ENSG00000114113	Retinol binding protein 2	3	139452884-139480747	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035866	Enhanced		Approved	Golgi apparatus		Tissue enhanced	Group enriched	204	duodenum: 2746.0;small intestine: 2037.7	lung: 11.7	Cell line enriched	6	CACO-2: 65.5
RBP5	CRBPIII	ENSG00000139194	Retinol binding protein 5	12	7123684-7128942	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038723	Enhanced		Approved	Golgi apparatus<br>Vesicles	Urothelial cancer:3.68e-4 (favourable), Lung cancer:8.37e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 455.7;liver: 204.9	spleen: 102.0	Cell line enhanced		Hep G2: 17.0;K-562: 46.6
RBP7	CRBPIV	ENSG00000162444	Retinol binding protein 7	1	9997206-10016020	Predicted intracellular proteins	Evidence at protein level	HPA034749	Enhanced		Uncertain	Nuclear speckles<br>Cytosol	Colorectal cancer:2.49e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 260.1	breast: 82.2	Cell line enhanced		EFO-21: 12.5;SK-MEL-30: 7.2;T-47d: 32.2
RBPJ	CBF1, IGKJRB, IGKJRB1, KBF2, RBP-J, RBPJK, RBPSUH, SUH	ENSG00000168214	Recombination signal binding protein for immunoglobulin kappa J region	4	26163455-26435131	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060647			Supported	Nucleoplasm	Endometrial cancer:2.98e-4 (favourable)	Expressed in all	Expressed in all			placenta: 77.2	Expressed in all		
RBPJL	RBP-L, RBPSUHL, SUH, SUHL	ENSG00000124232	Recombination signal binding protein for immunoglobulin kappa J region like	20	45306851-45317824	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB006846	Enhanced					Group enriched	Tissue enriched	151	pancreas: 205.8	stomach: 1.3	Not detected		
RBPMS	HERMES	ENSG00000157110	RNA binding protein with multiple splicing	8	30384479-30572261	Predicted intracellular proteins	Evidence at protein level	HPA056999	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			seminal vesicle: 267.6	Cell line enhanced		ASC diff: 222.6
RBPMS2		ENSG00000166831	RNA binding protein with multiple splicing 2	15	64739892-64775587	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.48e-4 (favourable)	Expressed in all	Tissue enhanced		heart muscle: 134.9	seminal vesicle: 63.9	Cell line enhanced		AF22: 38.7;AN3-CA: 51.6;HEL: 77.7;NTERA-2: 76.7
RBSN	ZFYVE20	ENSG00000131381	Rabenosyn, RAB effector	3	15070073-15099163	Predicted intracellular proteins	Evidence at protein level	HPA044878	Approved		Enhanced	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 30.7	Expressed in all		
RBX1	BA554C12.1, RNF75, ROC1	ENSG00000100387	Ring-box 1	22	40951347-40973309	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003038			Supported	Nucleoplasm	Ovarian cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 70.6	Expressed in all		
RC3H1	KIAA2025, RNF198, roquin, RP5-1198E17.5	ENSG00000135870	Ring finger and CCCH-type domains 1	1	173931214-174022297	Predicted intracellular proteins	Evidence at protein level	HPA027428, HPA027434, HPA027448	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.96e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 12.9	Mixed		
RC3H2	FLJ20301, FLJ20713, MNAB, RNF164	ENSG00000056586	Ring finger and CCCH-type domains 2	9	122844556-122905341	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042863, HPA062144	Approved		Supported	Vesicles	Renal cancer:5.50e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 25.5	Expressed in all		
RCAN1	DSCR1	ENSG00000159200	Regulator of calcineurin 1	21	34513142-34615142	Predicted intracellular proteins	Evidence at protein level	CAB037218	Uncertain		Approved	Cytosol		Expressed in all	Tissue enriched	8	parathyroid gland: 1116.7	placenta: 137.4	Cell line enhanced		SK-MEL-30: 987.4;WM-115: 803.4
RCAN3	DSCR1L2	ENSG00000117602	RCAN family member 3	1	24502351-24541040	Predicted intracellular proteins	Evidence at protein level	HPA034533, HPA064289	Enhanced		Approved	Nucleoli fibrillar center<br>Nuclear speckles		Expressed in all	Tissue enhanced		prostate: 54.8	lymph node: 22.9	Mixed		
RCBTB1	CLLD7, CLLL7, FLJ10716	ENSG00000136144	RCC1 and BTB domain containing protein 1	13	49531946-49585583	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056783			Approved	Nucleoplasm	Ovarian cancer:1.21e-5 (unfavourable), Lung cancer:5.51e-5 (favourable), Renal cancer:1.75e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 74.0	Expressed in all		
RCBTB2	CHC1L	ENSG00000136161	RCC1 and BTB domain containing protein 2	13	48488959-48533256	Predicted intracellular proteins	Evidence at protein level	HPA040242	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:2.45e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 45.0	Cell line enriched	10	MOLT-4: 221.7
RCC1	CHC1	ENSG00000180198	Regulator of chromosome condensation 1	1	28505943-28539300	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015413, HPA027573, HPA027574	Enhanced		Supported	Nucleus<br>Nuclear membrane	Renal cancer:2.43e-11 (unfavourable), Liver cancer:1.91e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 63.8	Expressed in all		
RCC1L	WBSCR16	ENSG00000274523	RCC1 like	7	75027122-75074228	Predicted intracellular proteins	Evidence at protein level	HPA052184, HPA060643	Approved		Approved	Nucleus<br>Cytosol	Glioma:6.65e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 36.4	Expressed in all		
RCC2	TD-60	ENSG00000179051	Regulator of chromosome condensation 2	1	17406760-17439724	Predicted intracellular proteins	Evidence at protein level	HPA072281	Approved				Liver cancer:3.42e-8 (unfavourable), Renal cancer:4.03e-8 (unfavourable), Melanoma:1.30e-4 (unfavourable), Cervical cancer:3.31e-4 (favourable)	Expressed in all	Mixed			skin: 35.3	Expressed in all		
RCCD1	MGC14386	ENSG00000166965	RCC1 domain containing 1	15	90954870-90963125	Predicted intracellular proteins	Evidence at protein level	HPA039683, HPA040776	Enhanced		Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 8.9	Mixed		
RCHY1	ARNIP, CHIMP, DKFZp586C1620, PIRH2, PRO1996, RNF199, ZCHY, ZNF363	ENSG00000163743	Ring finger and CHY zinc finger domain containing 1	4	75479037-75514764	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030339	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.62e-5 (favourable), Urothelial cancer:7.89e-5 (favourable), Colorectal cancer:9.09e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.7	Expressed in all		
RCL1	RNAC, RPCL1	ENSG00000120158	RNA terminal phosphate cyclase like 1	9	4792869-4885917	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA071308			Approved	Nucleoplasm	Renal cancer:2.40e-7 (favourable), Breast cancer:5.48e-4 (favourable), Liver cancer:8.02e-4 (favourable)	Expressed in all	Expressed in all			liver: 123.7	Expressed in all		
RCOR2		ENSG00000167771	REST corepressor 2	11	63911221-63916844	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021638	Uncertain		Approved	Nucleus<br>Vesicles<br>Midbody		Mixed	Tissue enhanced		cerebral cortex: 13.2	testis: 3.7	Cell line enhanced		AF22: 39.9;NTERA-2: 52.3;SCLC-21H: 95.8;SH-SY5Y: 57.5
RCOR3	FLJ10876	ENSG00000117625	REST corepressor 3	1	211258377-211316385	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007413, HPA071997	Enhanced		Approved	Nucleus<br>Nucleoli	Glioma:1.92e-5 (favourable), Lung cancer:5.75e-5 (favourable)	Expressed in all	Expressed in all			testis: 66.3	Expressed in all		
RCSD1	CapZIP, MGC21854, MK2S4	ENSG00000198771	RCSD domain containing 1	1	167630093-167706249	Predicted intracellular proteins	Evidence at protein level	HPA016597	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane	Head and neck cancer:2.97e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 107.2	spleen: 72.4	Cell line enhanced		Daudi: 144.4;REH: 185.8;RPMI-8226: 96.4;U-266/70: 99.4;U-698: 91.2
RCVRN	RCV1	ENSG00000109047	Recoverin	17	9896320-9905621	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015783, CAB022363	Supported					Not detected	Not detected			cerebral cortex: 0.3	Cell line enriched	7	WM-115: 2.3
RD3	C1orf36, LCA12	ENSG00000198570	Retinal degeneration 3	1	211476522-211492917	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029941, HPA029943	Supported					Tissue enhanced	Not detected			adrenal gland,epididymis: 0.3	Group enriched	14	HEL: 2.4;HMC-1: 6.0;SH-SY5Y: 10.6
RD3L	TDRD9-AS1, TDRD9AS1	ENSG00000227729	Retinal degeneration 3-like	14	103940426-103942308	Predicted intracellular proteins	Evidence at transcript level	HPA067971	Uncertain					Not detected	Tissue enriched	89	heart muscle: 20.8	liver: 0.2	Not detected		
RDH14	PAN2, SDR7C4	ENSG00000240857	Retinol dehydrogenase 14 (all-trans/9-cis/11-cis)	2	18554723-18560680	Predicted intracellular proteins	Evidence at protein level	HPA056686	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 31.6	Expressed in all		
RDX	DFNB24	ENSG00000137710	Radixin	11	110174880-110296722	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000263, HPA000763, CAB037312	Enhanced		Enhanced	Plasma membrane		Expressed in all	Expressed in all			adrenal gland: 198.2	Mixed		
REC114	C15orf60, CT147, FLJ27520, FLJ36860, FLJ44083, LOC283677	ENSG00000183324	REC114 meiotic recombination protein	15	73443158-73560014	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	96	testis: 63.6	heart muscle: 0.6	Not detected		
REC8	kleisin-alpha, REC8L1, Rec8p	ENSG00000100918	REC8 meiotic recombination protein	14	24171853-24180257	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031727, HPA031729	Approved		Approved	Nucleoplasm	Renal cancer:1.41e-7 (unfavourable), Breast cancer:2.19e-4 (favourable), Pancreatic cancer:5.57e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 37.4	testis: 28.9	Cell line enhanced		AF22: 20.6;MOLT-4: 18.0;SH-SY5Y: 98.0
RECQL	RecQ1, RecQL1	ENSG00000004700	RecQ like helicase	12	21468911-21501669	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009743, HPA030960, HPA064259	Enhanced		Enhanced	Nucleoplasm	Ovarian cancer:3.15e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 51.1	Expressed in all		
RECQL4	RecQ4	ENSG00000160957	RecQ like helicase 4	8	144511288-144517845	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB017800, HPA025821	Supported		Enhanced	Nucleus	Liver cancer:1.91e-4 (unfavourable)	Expressed in all	Mixed			testis: 17.3	Mixed		
RECQL5	FLJ90603, RecQ5	ENSG00000108469	RecQ like helicase 5	17	75626845-75667189	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029971			Supported	Nucleus<br>Cytosol	Endometrial cancer:1.73e-6 (unfavourable), Pancreatic cancer:4.34e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.9	Expressed in all		
REL	c-Rel, I-Rel	ENSG00000162924	REL proto-oncogene, NF-kB subunit	2	60881521-60931610	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB004404	Uncertain					Mixed	Mixed			bone marrow: 29.8	Expressed in all		
RELA	NFKB3, p65	ENSG00000173039	RELA proto-oncogene, NF-kB subunit	11	65653596-65663094	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB004264, CAB005030, HPA063461	Supported		Enhanced	Cytosol	Renal cancer:5.66e-4 (unfavourable), Liver cancer:9.18e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 62.5	Expressed in all		
RELB	REL-B	ENSG00000104856	RELB proto-oncogene, NF-kB subunit	19	45001430-45038198	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB007753, HPA040506	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.99e-6 (unfavourable), Breast cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			appendix: 25.1	Cell line enhanced		HDLM-2: 73.5
REM1	GES, REM	ENSG00000088320	RRAD and GEM like GTPase 1	20	31475293-31484905	Predicted intracellular proteins	Evidence at protein level	HPA049821	Approved				Renal cancer:1.84e-6 (unfavourable)	Mixed	Mixed			cervix, uterine: 12.3	Cell line enriched	35	WM-115: 21.8
REM2	FLJ38964	ENSG00000139890	RRAD and GEM like GTPase 2	14	22883165-22887686	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 6.0;parathyroid gland: 4.6	testis: 2.9	Cell line enhanced		AF22: 3.0
RENBP	RBP, RNBP	ENSG00000102032	Renin binding protein	X	153935263-153944691	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000428, HPA000522	Enhanced				Renal cancer:3.08e-5 (favourable), Cervical cancer:3.95e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 58.5	kidney: 37.8	Cell line enhanced		EFO-21: 31.9;HMC-1: 101.6;SK-MEL-30: 61.5;U-266/84: 49.9
REP15	RAB15EP	ENSG00000174236	RAB15 effector protein	12	27696519-27697596	Predicted intracellular proteins	Evidence at protein level	HPA040448, HPA059868	Approved				Colorectal cancer:9.43e-5 (favourable)	Mixed	Tissue enhanced		colon: 39.7;rectum: 70.4;stomach: 82.2	small intestine: 39.4	Mixed		
REPS1		ENSG00000135597	RALBP1 associated Eps domain containing 1	6	138903493-138988261	Predicted intracellular proteins	Evidence at protein level	HPA029961, HPA029962	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Liver cancer:9.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 66.1	Expressed in all		
RERE	ARG, ARP, ATN1L, DNB1, KIAA0458	ENSG00000142599	Arginine-glutamic acid dipeptide repeats	1	8352397-8817643	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024093	Uncertain					Expressed in all	Expressed in all			endometrium: 93.2	Expressed in all		
RERG	MGC15754	ENSG00000134533	RAS like estrogen regulated growth inhibitor	12	15107783-15348675	Predicted intracellular proteins	Evidence at protein level	HPA041387	Approved				Endometrial cancer:7.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 141.5	smooth muscle: 125.5	Group enriched	5	AN3-CA: 14.0;BEWO: 32.9;T-47d: 62.0;U-2 OS: 22.6
RERGL	FLJ22655	ENSG00000111404	RERG like	12	18080869-18320107	Predicted intracellular proteins	Evidence at protein level	HPA041740	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			epididymis: 47.0	Cell line enriched	734	REH: 214.1
RESP18		ENSG00000182698	Regulated endocrine specific protein 18	2	219327409-219333177	Predicted intracellular proteins	Evidence at transcript level	HPA045849	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 2.1	testis: 0.7	Not detected		
REST	NRSF, XBR	ENSG00000084093	RE1 silencing transcription factor	4	56907876-56966678	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006079, CAB068222	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.50e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.2	Mixed		
REV1	REV1L	ENSG00000135945	REV1, DNA directed polymerase	2	99400475-99490035	Predicted intracellular proteins	Evidence at protein level	HPA044534, HPA051036	Uncertain		Approved	Cytosol	Prostate cancer:2.03e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 23.2	Expressed in all		
REV3L	POLZ, REV3	ENSG00000009413	REV3 like, DNA directed polymerase zeta catalytic subunit	6	111299028-111483715	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064853, HPA069382	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			cervix, uterine: 41.2	Expressed in all		
REXO1	EloA-BP1, KIAA1138, TCEB3BP1	ENSG00000079313	RNA exonuclease 1 homolog	19	1815246-1848463	Predicted intracellular proteins	Evidence at protein level	HPA042155, HPA042552	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			testis: 35.1	Expressed in all		
REXO2	CGI-114, DKFZP566E144, SFN	ENSG00000076043	RNA exonuclease 2	11	114439386-114450279	Predicted intracellular proteins	Evidence at protein level	HPA038450, HPA038451	Enhanced		Supported	Nucleoli<br>Focal adhesion sites<br>Mitochondria	Colorectal cancer:6.51e-4 (favourable), Urothelial cancer:6.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 259.4	Expressed in all		
REXO4	hPMC2, XPMC2H	ENSG00000148300	REX4 homolog, 3'-5' exonuclease	9	133406059-133418096	Predicted intracellular proteins	Evidence at protein level	HPA047006	Uncertain		Supported	Nucleus<br>Nucleoli	Liver cancer:4.76e-6 (unfavourable), Renal cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			testis: 11.2	Expressed in all		
RFC1	A1, MHCBFB, PO-GA, RFC140	ENSG00000035928	Replication factor C subunit 1	4	39287456-39366375	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009520, HPA046116, HPA069306	Supported		Enhanced	Nucleus	Colorectal cancer:4.43e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 66.7	Expressed in all		
RFC2	A1, RFC40	ENSG00000049541	Replication factor C subunit 2	7	74231499-74254458	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029493	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:2.09e-7 (unfavourable), Liver cancer:6.35e-4 (unfavourable), Cervical cancer:9.91e-4 (favourable)	Expressed in all	Expressed in all			tonsil: 28.1	Expressed in all		
RFC3	MGC5276, RFC38	ENSG00000133119	Replication factor C subunit 3	13	33818049-33966558	Predicted intracellular proteins	Evidence at protein level	HPA030149	Approved		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			lymph node: 26.8	Expressed in all		
RFC4	A1, RFC37	ENSG00000163918	Replication factor C subunit 4	3	186789880-186807058	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004557, HPA049123, HPA058507	Enhanced		Enhanced	Nucleoplasm	Renal cancer:2.22e-16 (unfavourable), Liver cancer:6.75e-7 (unfavourable), Cervical cancer:7.41e-5 (favourable), Pancreatic cancer:7.38e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 40.7	Expressed in all		
RFC5	RFC36	ENSG00000111445	Replication factor C subunit 5	12	118013588-118033130	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041037	Supported		Approved	Nucleoplasm	Cervical cancer:8.05e-5 (favourable), Renal cancer:2.30e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 22.2	Expressed in all		
RFESD		ENSG00000175449	Rieske Fe-S domain containing	5	95646754-95684773	Predicted intracellular proteins	Evidence at protein level	CAB016546	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 22.1	bone marrow: 16.5	Group enriched	5	HEL: 37.0;K-562: 69.7
RFFL	CARP-2, CARP2, fring, rififylin, RNF189, RNF34L	ENSG00000092871	Ring finger and FYVE like domain containing E3 ubiquitin protein ligase	17	35005990-35089319	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB008096, HPA017910, HPA019492	Approved		Approved	Vesicles	Renal cancer:2.43e-5 (unfavourable), Colorectal cancer:4.92e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 54.1	Expressed in all		
RFK	FLJ11149, RIFK	ENSG00000135002	Riboflavin kinase	9	76385517-76394517	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023259, CAB033887, HPA057163	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			cerebral cortex: 37.8	Expressed in all		
RFLNA	Cfm2, FAM101A, FLJ44614, RefilinA	ENSG00000178882	Refilin A	12	123973241-124316024	Predicted intracellular proteins	Evidence at protein level	HPA058911, HPA078021	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus	Lung cancer:3.16e-5 (unfavourable)	Mixed	Tissue enriched	5	stomach: 90.8	small intestine: 16.8	Cell line enhanced		hTEC/SVTERT24-B: 13.8;HUVEC TERT2: 16.5;LHCN-M2: 28.9;RH-30: 10.8
RFLNB	Cfm1, FAM101B, MGC45871, RefilinB	ENSG00000183688	Refilin B	17	439978-445939	Predicted intracellular proteins	Evidence at protein level	HPA030879, HPA060388	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:1.54e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 49.3	placenta: 15.2	Cell line enhanced		fHDF/TERT166: 74.0;HMC-1: 195.7
RFPL1	RNF78	ENSG00000128250	Ret finger protein like 1	22	29438583-29442455	Predicted intracellular proteins	Evidence at transcript level	HPA048320, HPA072380			Approved	Nuclear speckles<br>Plasma membrane		Not detected	Tissue enriched	8	cerebral cortex: 27.8	adrenal gland: 3.6	Cell line enhanced		HDLM-2: 6.6;HMC-1: 2.3;Karpas-707: 2.0;SH-SY5Y: 3.5;THP-1: 2.2
RFPL2	RNF79	ENSG00000128253	Ret finger protein like 2	22	32190435-32203477	Predicted intracellular proteins	Evidence at transcript level	HPA048320, HPA072380			Approved	Nuclear speckles<br>Plasma membrane	Prostate cancer:4.16e-4 (favourable)	Tissue enriched	Tissue enriched	7	prostate: 5.8	cerebral cortex: 0.8	Not detected		
RFPL3		ENSG00000128276	Ret finger protein like 3	22	32354885-32361161	Predicted intracellular proteins	Evidence at protein level	HPA048320, HPA072380			Approved	Nuclear speckles<br>Plasma membrane		Not detected	Tissue enriched	13	testis: 3.6	prostate: 0.2	Not detected		
RFPL3S	NCRNA00005, RFPL3-AS, RFPL3-AS1	ENSG00000205853	RFPL3 antisense	22	32359906-32382052	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	17	testis: 99.1	cerebral cortex: 5.8	Cell line enhanced		U-266/84: 5.5
RFPL4A	RFPL4, RNF210	ENSG00000223638	Ret finger protein like 4A	19	55759014-55763175	Predicted intracellular proteins	Evidence at protein level	HPA046368	Uncertain		Approved	Centrosome<br>Cytosol		Tissue enriched	Tissue enhanced		epididymis: 2.5;testis: 2.5	liver: 1.2	Cell line enriched	19	U-2 OS: 88.7
RFPL4AL1		ENSG00000229292	Ret finger protein like 4A like 1	19	55769141-55773179	Predicted intracellular proteins	Evidence at transcript level	HPA046368	Uncertain		Approved	Centrosome<br>Cytosol		Not detected	Not detected			spleen: 0.6	Cell line enriched	26	U-2 OS: 27.1
RFPL4B	RNF211	ENSG00000251258	Ret finger protein like 4B	6	112347330-112351296	Predicted intracellular proteins	Evidence at transcript level	HPA059324, HPA066464	Uncertain					Group enriched	Tissue enriched	5	testis: 2.9	placenta: 0.5	Cell line enhanced		K-562: 1.7;RPTEC TERT1: 1.8;U-266/84: 5.6
RFTN1	FLJ23866, KIAA0084, MIG2, Raftlin	ENSG00000131378	Raftlin, lipid raft linker 1	3	16313574-16514026	Predicted intracellular proteins	Evidence at protein level	HPA048725	Approved				Renal cancer:1.29e-7 (unfavourable)	Expressed in all	Mixed			lymph node: 135.3	Cell line enhanced		HDLM-2: 165.3;SH-SY5Y: 142.4
RFTN2	C2orf11, FLJ30574, Raftlin-2	ENSG00000162944	Raftlin family member 2	2	197568224-197676045	Predicted intracellular proteins	Evidence at protein level	HPA035232	Approved					Group enriched	Tissue enhanced		cerebral cortex: 31.4	ovary: 8.7	Cell line enhanced		AF22: 17.0;ASC diff: 8.0;WM-115: 7.5
RFWD2	COP1, FLJ10416, RNF200	ENSG00000143207	Ring finger and WD repeat domain 2	1	175944831-176207493	Enzymes, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.96e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 42.2	Expressed in all		
RFWD3	FLJ10520, RNF201	ENSG00000168411	Ring finger and WD repeat domain 3	16	74621394-74666881	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048258, HPA075649			Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 46.9	Expressed in all		
RFX1	EF-C	ENSG00000132005	Regulatory factor X1	19	13961538-14007039	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048722	Approved		Supported	Nucleoplasm	Head and neck cancer:2.42e-4 (favourable), Pancreatic cancer:4.92e-4 (favourable)	Expressed in all	Expressed in all			testis: 16.8	Expressed in all		
RFX2	FLJ14226	ENSG00000087903	Regulatory factor X2	19	5993164-6199572	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048969	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Endometrial cancer:2.67e-4 (favourable), Cervical cancer:2.80e-4 (favourable), Pancreatic cancer:7.36e-4 (favourable)	Mixed	Tissue enhanced		testis: 93.1	fallopian tube: 32.8	Cell line enhanced		SCLC-21H: 27.7
RFX3		ENSG00000080298	Regulatory factor X3	9	3218297-3526004	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035689	Enhanced		Approved	Nucleoplasm<br>Vesicles	Breast cancer:1.47e-4 (favourable)	Mixed	Tissue enhanced		testis: 38.6	fallopian tube: 18.3	Cell line enhanced		AF22: 26.0;SCLC-21H: 16.6
RFX4		ENSG00000111783	Regulatory factor X4	12	106582907-106762803	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050527	Enhanced		Approved	Nucleus		Tissue enriched	Group enriched	236	cerebral cortex: 30.8;testis: 135.8	prostate: 0.3	Cell line enriched	13	AF22: 47.1
RFX5		ENSG00000143390	Regulatory factor X5	1	151340640-151347357	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018519	Supported					Expressed in all	Expressed in all			lymph node: 85.6	Expressed in all		
RFX6	dJ955L16.1, MGC33442, RFXDC1	ENSG00000185002	Regulatory factor X6	6	116877212-116932163	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA037696, HPA037697	Approved		Supported	Nucleus<br>Nucleoli	Pancreatic cancer:3.59e-4 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 5.9;stomach: 7.2	duodenum: 2.3	Cell line enhanced		HEK93: 1.2
RFX7	FLJ12994, RFXDC2	ENSG00000181827	Regulatory factor X7	15	56087280-56243266	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035462	Supported		Approved	Nucleus<br>Nuclear membrane	Renal cancer:1.12e-5 (unfavourable)	Expressed in all	Mixed			testis: 8.2	Expressed in all		
RFX8	FLJ42986	ENSG00000196460	RFX family member 8, lacking RFX DNA binding domain	2	101397361-101474703	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059745			Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		bone marrow: 2.6	testis: 1.3	Cell line enhanced		hTEC/SVTERT24-B: 13.4;LHCN-M2: 5.8;U-87 MG: 8.3
RFXANK	ANKRA1, BLS, F14150_1, MGC138628, RFX-B	ENSG00000064490	Regulatory factor X associated ankyrin containing protein	19	19192229-19201869	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049157, HPA053330	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			fallopian tube: 50.1	Expressed in all		
RFXAP		ENSG00000133111	Regulatory factor X associated protein	13	36819224-36829104	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA032035			Approved	Nuclear speckles	Lung cancer:2.26e-5 (favourable), Pancreatic cancer:4.18e-4 (favourable), Stomach cancer:4.91e-4 (favourable)	Expressed in all	Mixed			testis: 12.2	Expressed in all		
RGAG1	KIAA1318, Mar9, Mart9	ENSG00000243978	Retrotransposon gag domain containing 1	X	110358816-110456334	Predicted intracellular proteins	Evidence at protein level	HPA001242	Enhanced					Not detected	Tissue enriched	18	testis: 19.5	placenta: 1.0	Cell line enhanced		hTEC/SVTERT24-B: 2.0;U-2197: 1.4;U-87 MG: 1.1
RGAG4	KIAA2001, Mar5, Mart5	ENSG00000242732	Retrotransposon gag domain containing 4	X	72127110-72131901	Predicted intracellular proteins	Evidence at transcript level	HPA003652	Approved		Approved	Nucleoplasm	Pancreatic cancer:3.41e-4 (favourable), Lung cancer:7.30e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 4.1	Cell line enhanced		AF22: 3.7;AN3-CA: 3.9;SCLC-21H: 5.9;SH-SY5Y: 7.4
RGL1	RGL	ENSG00000143344	Ral guanine nucleotide dissociation stimulator like 1	1	183636085-183928531	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA019788	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Liver cancer:1.49e-5 (unfavourable), Lung cancer:4.32e-4 (favourable)	Expressed in all	Mixed			spleen: 62.6	Cell line enhanced		HSkMC: 39.9
RGL2	HKE1.5, KE1.5, RAB2L	ENSG00000237441	Ral guanine nucleotide dissociation stimulator like 2	6	33291654-33299324	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA047039, HPA053444	Approved		Approved	Nucleoplasm	Pancreatic cancer:6.16e-4 (favourable)	Expressed in all	Mixed			spleen: 1.5	Mixed		
RGL3	FLJ32585	ENSG00000205517	Ral guanine nucleotide dissociation stimulator like 3	19	11384341-11419342	Predicted intracellular proteins	Evidence at protein level	HPA042763, HPA043615, HPA064578	Uncertain		Uncertain	Nucleus<br>Cytosol	Renal cancer:6.61e-4 (favourable), Breast cancer:7.35e-4 (favourable)	Mixed	Group enriched	6	parathyroid gland: 128.2;thyroid gland: 36.8	seminal vesicle: 13.3	Cell line enhanced		BEWO: 17.4;RT4: 17.3;T-47d: 14.8
RGN	RC, SMP30	ENSG00000130988	Regucalcin	X	47078355-47093314	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029102, HPA029103	Enhanced		Approved	Nucleus	Renal cancer:5.10e-10 (favourable), Liver cancer:7.55e-4 (favourable)	Tissue enriched	Tissue enhanced		adrenal gland: 202.7;liver: 196.4	kidney: 57.0	Group enriched	6	CACO-2: 17.9;fHDF/TERT166: 5.3;Hep G2: 22.3
RGP1	KIAA0258	ENSG00000107185	RGP1 homolog, RAB6A GEF complex partner 1	9	35749287-35758575	Predicted intracellular proteins	Evidence at protein level	HPA020414, HPA021085	Approved		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:8.55e-13 (favourable), Liver cancer:7.09e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.9	Expressed in all		
RGPD1	RGP1	ENSG00000187627	RANBP2-like and GRIP domain containing 1	2	86907953-87013981	Predicted intracellular proteins	Evidence at transcript level	HPA049497, HPA051675, HPA067564	Uncertain		Approved	Nuclear membrane<br>Vesicles		Not detected	Group enriched	12	cervix, uterine: 11.8;placenta: 9.0;testis: 24.5	parathyroid gland: 1.2	Cell line enhanced		BEWO: 6.0;MOLT-4: 8.6;NTERA-2: 3.1
RGPD2	RANBP2L2, RGP2	ENSG00000185304	RANBP2-like and GRIP domain containing 2	2	87755955-87825952	Predicted intracellular proteins	Evidence at transcript level	HPA049497, HPA051675, HPA067564	Uncertain		Approved	Nuclear membrane<br>Vesicles		Not detected	Tissue enhanced		placenta: 14.3;testis: 33.3	bone marrow: 6.3	Cell line enhanced		BEWO: 10.9;MOLT-4: 10.5;NTERA-2: 5.4;SiHa: 4.7
RGPD3	RGP3	ENSG00000153165	RANBP2-like and GRIP domain containing 3	2	106391290-106468376	Predicted intracellular proteins	Evidence at transcript level	HPA049497, HPA051675, HPA067564	Uncertain		Approved	Nuclear membrane<br>Vesicles		Not detected	Tissue enriched	13	testis: 11.7	cerebral cortex,kidney: 0.8	Cell line enhanced		HEL: 1.4;MOLT-4: 4.1
RGPD4	DKFZp686P0288, RGP4	ENSG00000196862	RANBP2-like and GRIP domain containing 4	2	107826937-107890841	Predicted intracellular proteins	Evidence at transcript level	HPA049497, HPA051675, HPA067564	Uncertain		Uncertain	Nuclear membrane<br>Vesicles		Not detected	Tissue enriched	57	testis: 5.7	all non-specific tissues: 0.0	Not detected		
RGPD5	BS-63, DKFZp686I1842, RGP5	ENSG00000015568	RANBP2-like and GRIP domain containing 5	2	109792758-109857695	Predicted intracellular proteins	Evidence at protein level	HPA045704, HPA049497, HPA051675, HPA067564	Uncertain		Uncertain	Nuclear membrane<br>Vesicles		Not detected	Tissue enhanced		testis: 6.6	duodenum: 3.2	Mixed		
RGPD6	RGP6	ENSG00000183054	RANBP2-like and GRIP domain containing 6	2	110513812-110577185	Predicted intracellular proteins	Evidence at protein level	HPA045704, HPA049497, HPA051675, HPA067564	Uncertain		Uncertain	Nuclear membrane<br>Vesicles		Not detected	Expressed in all			testis: 83.3	Mixed		
RGPD8	RanBP2alpha, RANBP2L1	ENSG00000169629	RANBP2-like and GRIP domain containing 8	2	112370092-112434488	Predicted intracellular proteins	Evidence at protein level	HPA045704, HPA049497, HPA051675, HPA067564	Uncertain		Uncertain	Nuclear membrane<br>Vesicles		Not detected	Tissue enriched	5	testis: 31.7	cerebral cortex: 5.8	Cell line enhanced		HEL: 14.4
RGS1	1R20, BL34, IER1, IR20	ENSG00000090104	Regulator of G-protein signaling 1	1	192575727-192580031	Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.91e-5 (unfavourable), Stomach cancer:9.57e-4 (unfavourable)	Expressed in all	Mixed			appendix: 225.9	Group enriched	26	Karpas-707: 152.1;U-266/70: 700.2
RGS10		ENSG00000148908	Regulator of G-protein signaling 10	10	119499828-119542708	Predicted intracellular proteins	Evidence at protein level	CAB004559, HPA021305, HPA058485	Enhanced	Supported	Supported	Nucleus<br>Plasma membrane	Renal cancer:4.20e-10 (unfavourable), Endometrial cancer:6.32e-4 (favourable), Cervical cancer:6.81e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 137.6	Cell line enhanced		HMC-1: 456.7
RGS11		ENSG00000076344	Regulator of G-protein signaling 11	16	268301-275980	Predicted intracellular proteins	Evidence at protein level	HPA041692, HPA043039	Uncertain				Pancreatic cancer:1.24e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 20.3	adipose tissue: 8.1	Cell line enhanced		HHSteC: 2.6;SCLC-21H: 3.6;SH-SY5Y: 2.5;T-47d: 2.4
RGS12		ENSG00000159788	Regulator of G-protein signaling 12	4	3293028-3439913	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054646, HPA067421			Supported	Nucleus<br>Nucleoli	Head and neck cancer:7.03e-4 (favourable), Renal cancer:8.43e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 20.7	Mixed		
RGS13		ENSG00000127074	Regulator of G-protein signaling 13	1	192636138-192660306	Predicted intracellular proteins	Evidence at protein level	HPA044952	Uncertain					Mixed	Group enriched	6	appendix: 14.3;lymph node: 68.4;tonsil: 36.9	small intestine: 7.1	Cell line enriched	12	Daudi: 37.3
RGS14		ENSG00000169220	Regulator of G-protein signaling 14	5	177357837-177372601	Predicted intracellular proteins	Evidence at protein level	HPA046847, HPA061819	Enhanced		Enhanced	Nucleoplasm<br>Vesicles	Liver cancer:1.84e-6 (unfavourable), Glioma:9.11e-4 (unfavourable)	Expressed in all	Mixed			spleen: 21.7	Cell line enhanced		HDLM-2: 101.9;HMC-1: 82.1;RPMI-8226: 39.1
RGS16	A28-RGS14, RGS-r	ENSG00000143333	Regulator of G-protein signaling 16	1	182598623-182604408	Predicted intracellular proteins	Evidence at protein level	HPA053250, HPA055824	Uncertain		Approved	Cytosol	Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Tissue enriched	7	thyroid gland: 171.8	gallbladder: 25.1	Cell line enhanced		Daudi: 77.3;SCLC-21H: 127.9;U-266/70: 93.7;U-698: 109.4
RGS17	RGS-17, RGSZ2	ENSG00000091844	Regulator of G-protein signaling 17	6	153004459-153131249	Predicted intracellular proteins	Evidence at protein level	HPA022276, HPA056493	Approved		Approved	Vesicles		Mixed	Mixed			cerebral cortex: 5.5	Cell line enhanced		hTERT-HME1: 13.2;LHCN-M2: 14.6;U-87 MG: 14.3
RGS18	RGS13	ENSG00000150681	Regulator of G-protein signaling 18	1	192158457-192185815	Predicted intracellular proteins	Evidence at protein level	HPA028727, HPA045780	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		spleen: 35.0	appendix: 19.2	Group enriched	6	HEL: 53.8;HL-60: 36.8;NB-4: 27.4;U-937: 31.1
RGS19	GAIP, RGSGAIP	ENSG00000171700	Regulator of G-protein signaling 19	20	64073181-64079988	Predicted intracellular proteins	Evidence at protein level	HPA056384, HPA069984	Enhanced		Supported	Nucleoli fibrillar center<br>Cell Junctions	Renal cancer:2.06e-9 (unfavourable), Liver cancer:2.75e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 53.7	lymph node: 39.8	Expressed in all		
RGS2	G0S8	ENSG00000116741	Regulator of G-protein signaling 2	1	192809039-192812283	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013385			Approved	Cytosol	Renal cancer:2.90e-5 (unfavourable), Breast cancer:2.43e-4 (favourable), Stomach cancer:3.56e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 749.0	Cell line enhanced		hTCEpi: 101.7;PC-3: 208.8
RGS20	RGSZ1, ZGAP1	ENSG00000147509	Regulator of G-protein signaling 20	8	53851808-53959303	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA070193	Enhanced					Tissue enhanced	Tissue enhanced		cerebral cortex: 10.1	thyroid gland: 2.1	Cell line enhanced		SK-MEL-30: 23.4;U-87 MG: 28.2
RGS21		ENSG00000253148	Regulator of G-protein signaling 21	1	192316992-192367285	Predicted intracellular proteins	Evidence at transcript level	HPA052843	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RGS22	CT145, DKFZP434I092, PRTD-NY2	ENSG00000132554	Regulator of G-protein signaling 22	8	99960936-100131268	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	6	testis: 108.9	fallopian tube: 16.7	Not detected		
RGS3	C2PA, FLJ20370, PDZ-RGS3	ENSG00000138835	Regulator of G-protein signaling 3	9	113444731-113597743	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032507, HPA041109			Enhanced	Nucleoplasm<br>Mitochondria<br>Cytosol	Liver cancer:6.62e-4 (unfavourable), Breast cancer:9.93e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 66.4	Cell line enhanced		BJ hTERT+: 201.8;HDLM-2: 382.8
RGS4	SCZD9	ENSG00000117152	Regulator of G-protein signaling 4	1	163068775-163076802	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030802			Approved	Intermediate filaments	Stomach cancer:1.92e-4 (unfavourable), Renal cancer:3.97e-4 (unfavourable), Glioma:4.33e-4 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 289.2	adrenal gland: 54.0	Cell line enhanced		LHCN-M2: 245.4;SH-SY5Y: 612.2;TIME: 986.1
RGS5		ENSG00000143248	Regulator of G-protein signaling 5	1	163111121-163321791	Predicted intracellular proteins	Evidence at protein level	HPA001821		Approved	Supported	Cytosol	Renal cancer:9.17e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 406.2	Group enriched	45	HUVEC TERT2: 1084.9;SH-SY5Y: 4496.0
RGS6		ENSG00000182732	Regulator of G-protein signaling 6	14	71932439-72566529	Predicted intracellular proteins	Evidence at protein level	HPA003067	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 17.5;testis: 18.7	thyroid gland: 8.8	Group enriched	8	HEL: 10.1;Karpas-707: 24.7
RGS7		ENSG00000182901	Regulator of G-protein signaling 7	1	240775515-241357230	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017561	Enhanced		Enhanced	Cytosol		Tissue enhanced	Group enriched	8	adrenal gland: 10.7;cerebral cortex: 46.4;testis: 10.9	stomach: 2.9	Cell line enhanced		U-2 OS: 6.8
RGS7BP	R7BP	ENSG00000186479	Regulator of G-protein signaling 7 binding protein	5	64506257-64612312	Predicted intracellular proteins	Evidence at protein level	HPA039600	Approved					Mixed	Tissue enhanced		cerebral cortex: 38.9	fallopian tube: 13.2	Cell line enhanced		HUVEC TERT2: 9.7;NTERA-2: 2.0;SCLC-21H: 1.5
RGS8	MGC119067, MGC119068, MGC119069	ENSG00000135824	Regulator of G-protein signaling 8	1	182641816-182684576	Predicted intracellular proteins	Evidence at protein level	HPA076764	Supported					Group enriched	Group enriched	5	cerebral cortex: 5.3;testis: 4.9;thyroid gland: 11.3	adrenal gland: 1.3	Group enriched	5	AF22: 5.6;SCLC-21H: 18.7
RGS9	MGC111763, MGC26458, PERRS, RGS9L	ENSG00000108370	Regulator of G-protein signaling 9	17	65100812-65227703	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013550, HPA014137	Supported	Supported	Uncertain	Nucleoplasm	Pancreatic cancer:1.35e-4 (favourable)	Mixed	Mixed			fallopian tube: 5.5	Group enriched	9	HDLM-2: 24.5;HEL: 9.6
RHEB	RHEB2	ENSG00000106615	Ras homolog enriched in brain	7	151466012-151520120	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB019436	Uncertain				Liver cancer:9.08e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 207.2	Expressed in all		
RHEBL1	FLJ25797, MGC34869	ENSG00000167550	Ras homolog enriched in brain like 1	12	49064685-49070025	Predicted intracellular proteins	Evidence at protein level	HPA053111, HPA061001	Uncertain		Uncertain	Nucleus<br>Centrosome		Mixed	Mixed			fallopian tube,lymph node: 3.8	Cell line enhanced		HDLM-2: 26.3;U-266/84: 40.4
RHNO1	C12orf32, HKMT1188, MGC13204, RHINO	ENSG00000171792	RAD9-HUS1-RAD1 interacting nuclear orphan 1	12	2876258-2889523	Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.74e-13 (unfavourable), Liver cancer:2.20e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.4	Expressed in all		
RHOA	ARH12, ARHA, Rho12, RhoA, RHOH12	ENSG00000067560	Ras homolog family member A	3	49359145-49412998	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB005052	Approved				Renal cancer:3.21e-6 (favourable), Colorectal cancer:3.08e-4 (favourable), Liver cancer:9.15e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 592.0	Expressed in all		
RHOB	ARH6, ARHB, MST081, RhoB, RHOH6	ENSG00000143878	Ras homolog family member B	2	20447074-20449445	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 710.5	Cell line enhanced		RPTEC TERT1: 344.8;SK-BR-3: 419.9
RHOBTB1	KIAA0740	ENSG00000072422	Rho related BTB domain containing 1	10	60869438-61001440	Predicted intracellular proteins	Evidence at protein level	HPA040205, HPA040226	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			placenta: 52.5	Cell line enhanced		Hep G2: 45.7
RHOBTB2	DBC2, KIAA0717	ENSG00000008853	Rho related BTB domain containing 2	8	22987417-23020199	Predicted intracellular proteins	Evidence at protein level	HPA060938	Approved		Approved	Plasma membrane	Renal cancer:2.98e-4 (favourable)	Expressed in all	Mixed			lung: 52.7	Expressed in all		
RHOBTB3	KIAA0878	ENSG00000164292	Rho related BTB domain containing 3	5	95713522-95824383	Predicted intracellular proteins	Evidence at protein level	HPA000265			Uncertain	Vesicles		Expressed in all	Expressed in all			ovary: 99.0	Cell line enhanced		HaCaT: 281.3
RHOC	ARH9, ARHC, RhoC	ENSG00000155366	Ras homolog family member C	1	112701106-112707434	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA051461	Uncertain				Renal cancer:3.65e-5 (unfavourable), Liver cancer:2.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 699.4	Expressed in all		
RHOD	ARHD, Rho, RhoD, RhoHP1	ENSG00000173156	Ras homolog family member D	11	67056818-67072013	Predicted intracellular proteins	Evidence at protein level						Lung cancer:3.10e-4 (unfavourable), Cervical cancer:9.17e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 37.0	Cell line enhanced		A-431: 131.9;HaCaT: 116.3;HBEC3-KT: 125.2;hTCEpi: 146.2;T-47d: 136.0
RHOF	ARHF, FLJ20247, RIF	ENSG00000139725	Ras homolog family member F, filopodia associated	12	121777754-121803403	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045912, HPA076019	Enhanced		Uncertain	Nucleus<br>Golgi apparatus		Mixed	Expressed in all			lymph node: 46.0	Cell line enhanced		CAPAN-2: 112.6;HDLM-2: 171.6;PC-3: 116.5
RHOG	ARHG, MGC125835, MGC125836, RhoG	ENSG00000177105	Ras homolog family member G	11	3826978-3840983	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039871	Enhanced				Renal cancer:9.49e-8 (unfavourable), Colorectal cancer:1.81e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 170.5	Expressed in all		
RHOH	ARHH, RhoH, TTF	ENSG00000168421	Ras homolog family member H	4	40191053-40246967	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030345	Uncertain					Mixed	Tissue enhanced		lymph node: 98.3;tonsil: 77.5	appendix: 47.7	Cell line enhanced		Daudi: 89.6;HMC-1: 81.4;MOLT-4: 142.8;U-266/70: 49.6;U-698: 79.5
RHOJ	ARHJ, FLJ14445, RASL7B, TCL	ENSG00000126785	Ras homolog family member J	14	63204114-63293219	Predicted intracellular proteins	Evidence at protein level	HPA003050	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Renal cancer:1.31e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 48.3	Cell line enhanced		AF22: 64.5;HUVEC TERT2: 319.9;TIME: 83.9;WM-115: 109.1
RHOU	ARHU, CDC42L1, DJ646B12.2, fJ646B12.2, FLJ10616, hG28K, WRCH-1, WRCH1	ENSG00000116574	Ras homolog family member U	1	228735077-228746669	Predicted intracellular proteins	Evidence at protein level	HPA049592	Approved				Renal cancer:3.56e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 62.1	Cell line enhanced		BEWO: 172.7;MOLT-4: 67.1;RT4: 62.2
RHOV	ARHV, Chp, WRCH2	ENSG00000104140	Ras homolog family member V	15	40872214-40874289	Predicted intracellular proteins	Evidence at protein level	HPA053343	Enhanced				Lung cancer:2.33e-4 (unfavourable), Pancreatic cancer:4.19e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 71.5;skin: 72.6	tonsil: 20.2	Cell line enhanced		HaCaT: 66.2;SK-BR-3: 237.1
RHOXF1	OTEX, PEPP1	ENSG00000101883	Rhox homeobox family member 1	X	120109053-120115937	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056506	Approved					Mixed	Tissue enriched	9	testis: 15.5	adipose tissue: 1.6	Not detected		
RHOXF2	CT107, PEPP-2, PEPP2, THG1	ENSG00000131721	Rhox homeobox family member 2	X	120158561-120165630	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003314, CAB020794	Enhanced					Tissue enhanced	Tissue enriched	184	testis: 20.8	skin: 0.1	Cell line enhanced		K-562: 209.3;NB-4: 108.3;THP-1: 42.9;U-266/84: 73.5
RHOXF2B		ENSG00000203989	Rhox homeobox family member 2B	X	120070672-120077705	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003314	Supported					Not detected	Tissue enriched	19	testis: 2.7	ovary,skin,spleen: 0.1	Group enriched	341	HL-60: 168.7;K-562: 191.8;NB-4: 216.8
RHPN1	KIAA1929, ODF5, RHPN	ENSG00000158106	Rhophilin Rho GTPase binding protein 1	8	143368887-143384220	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024288, HPA024671	Approved		Approved	Nucleoplasm		Expressed in all	Tissue enhanced		cerebral cortex: 7.1	parathyroid gland: 4.8	Cell line enhanced		MCF7: 21.9;MOLT-4: 21.1;T-47d: 42.5
RHPN2		ENSG00000131941	Rhophilin Rho GTPase binding protein 2	19	32978593-33064888	Predicted intracellular proteins	Evidence at protein level	HPA051749	Uncertain				Renal cancer:1.22e-8 (favourable), Head and neck cancer:1.58e-4 (unfavourable)	Expressed in all	Mixed			prostate: 43.6	Mixed		
RIBC1	FLJ32783	ENSG00000158423	RIB43A domain with coiled-coils 1	X	53422690-53431120	Predicted intracellular proteins	Evidence at protein level	HPA001150, HPA021613	Uncertain		Approved	Nuclear bodies	Cervical cancer:1.90e-5 (favourable), Endometrial cancer:9.66e-4 (favourable)	Mixed	Group enriched	7	fallopian tube: 45.0;testis: 41.7	thyroid gland: 6.1	Cell line enhanced		T-47d: 7.4
RIBC2	C22orf11, DKFZp566F0546, FLJ25720	ENSG00000128408	RIB43A domain with coiled-coils 2	22	45413691-45432496	Predicted intracellular proteins	Evidence at transcript level	HPA003210	Uncertain				Cervical cancer:7.08e-8 (favourable)	Mixed	Group enriched	8	fallopian tube: 15.9;testis: 37.3	parathyroid gland: 3.1	Cell line enhanced		SiHa: 13.9
RIC8A	synembryn, synembryn-A	ENSG00000177963	RIC8 guanine nucleotide exchange factor A	11	207511-215113	Predicted intracellular proteins	Evidence at protein level	HPA041491, CAB046012	Approved		Supported	Cytosol	Liver cancer:1.11e-6 (unfavourable), Endometrial cancer:8.60e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 72.1	Expressed in all		
RIC8B	FLJ10620, hSyn, RIC8	ENSG00000111785	RIC8 guanine nucleotide exchange factor B	12	106774595-106889316	Predicted intracellular proteins	Evidence at protein level	HPA042746	Approved		Approved	Centrosome<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 21.8	Mixed		
RICTOR	AVO3, KIAA1999, MGC39830, PIA	ENSG00000164327	RPTOR independent companion of MTOR complex 2	5	38937919-39074408	Predicted intracellular proteins	Evidence at protein level	HPA037802, HPA037803	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			testis: 17.2	Expressed in all		
RIF1	FLJ10599, FLJ12870	ENSG00000080345	Replication timing regulatory factor 1	2	151409883-151508013	Predicted intracellular proteins	Evidence at protein level	HPA036887, HPA036888	Supported		Uncertain	Nucleus<br>Nuclear bodies<br>Plasma membrane		Expressed in all	Expressed in all			testis: 21.1	Expressed in all		
RIIAD1	C1orf230, FLJ36032, NCRNA00166	ENSG00000178796	Regulatory subunit of type II PKA R-subunit (RIIa) domain containing 1	1	151710433-151729805	Predicted intracellular proteins	Evidence at protein level	HPA045703	Enhanced		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:5.46e-4 (favourable)	Tissue enhanced	Group enriched	9	fallopian tube: 70.7;testis: 22.5	cerebral cortex: 5.4	Group enriched	9	CACO-2: 3.6;SCLC-21H: 2.7;SH-SY5Y: 4.8;SK-BR-3: 5.4
RILP	FLJ31193	ENSG00000167705	Rab interacting lysosomal protein	17	1646145-1650077	Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.51e-5 (favourable), Urothelial cancer:7.12e-4 (favourable), Breast cancer:7.97e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 8.7	Cell line enhanced		HEL: 16.7;HMC-1: 8.2
RILPL1	FLJ39378	ENSG00000188026	Rab interacting lysosomal protein like 1	12	123470054-123533718	Predicted intracellular proteins	Evidence at protein level	HPA041314	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			heart muscle: 34.5	Mixed		
RILPL2	FLJ30380, FLJ32372, MGC7036	ENSG00000150977	Rab interacting lysosomal protein like 2	12	123410683-123436717	Predicted intracellular proteins	Evidence at protein level	HPA028958	Uncertain		Supported	Cytosol	Endometrial cancer:5.24e-7 (favourable)	Expressed in all	Mixed			bone marrow: 21.6	Expressed in all		
RIMBP2	KIAA0318, MGC15831, PPP1R133, RBP2, RIM-BP2	ENSG00000060709	RIMS binding protein 2	12	130396137-130517917	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:4.16e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 95.0	cerebral cortex: 24.4	Group enriched	10	SCLC-21H: 26.1;SH-SY5Y: 41.8
RIMBP3	KIAA1666, RIMBP3.1, RIMBP3A	ENSG00000275793	RIMS binding protein 3	22	18605815-18611919	Predicted intracellular proteins	Evidence at protein level	HPA001183	Supported		Uncertain	Vesicles<br>Plasma membrane		Not detected	Tissue enriched	37	testis: 45.4	parathyroid gland: 1.2	Mixed		
RIMBP3B		ENSG00000274600	RIMS binding protein 3B	22	21383374-21389478	Predicted intracellular proteins	Evidence at protein level	HPA001183	Supported		Uncertain	Vesicles<br>Plasma membrane		Not detected	Tissue enriched	26	testis: 12.1	parathyroid gland: 0.4	Cell line enhanced		RH-30: 1.0;THP-1: 1.0
RIMBP3C		ENSG00000183246	RIMS binding protein 3C	22	21545357-21551461	Predicted intracellular proteins	Evidence at protein level	HPA001183	Supported		Uncertain	Vesicles<br>Plasma membrane		Not detected	Tissue enriched	32	testis: 15.7	spleen: 0.4	Not detected		
RIMKLA	FAM80A, MGC47816, NAAGS-II, RP11-157D18.1	ENSG00000177181	Ribosomal modification protein rimK like family member A	1	42380795-42422578	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027826	Uncertain		Uncertain	Nucleoli fibrillar center	Lung cancer:1.43e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 10.2	parathyroid gland,rectum: 3.8	Cell line enhanced		AN3-CA: 6.7;SCLC-21H: 12.8
RIMKLB	FAM80B, KIAA1238, NAAGS, NAAGS-I	ENSG00000166532	Ribosomal modification protein rimK like family member B	12	8681600-8783095	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059552			Approved	Nucleoplasm<br>Microtubule organizing center		Mixed	Expressed in all			endometrium: 74.7	Cell line enhanced		U-698: 113.0
RIMS2	KIAA0751, OBOE, RAB3IP3, RIM2	ENSG00000176406	Regulating synaptic membrane exocytosis 2	8	103500748-104256094	Predicted intracellular proteins	Evidence at protein level	HPA046538, HPA066498, CAB079049	Enhanced	Supported	Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		adrenal gland: 67.7;cerebral cortex: 45.0	cervix, uterine: 11.5	Cell line enhanced		Daudi: 10.2;RT4: 8.0;SCLC-21H: 28.6
RIMS3	NIM3, RIM3	ENSG00000117016	Regulating synaptic membrane exocytosis 3	1	40620679-40665657	Predicted intracellular proteins	Evidence at protein level	HPA055285			Approved	Nucleoli<br>Mitochondria		Mixed	Tissue enriched	7	cerebral cortex: 60.4	adrenal gland: 8.3	Cell line enhanced		Daudi: 55.3;SCLC-21H: 23.5;SH-SY5Y: 37.4;U-87 MG: 31.5
RIMS4	C20orf190, dJ781B1.3	ENSG00000101098	Regulating synaptic membrane exocytosis 4	20	44751808-44810338	Predicted intracellular proteins	Evidence at protein level	HPA060928	Approved		Approved	Nucleoplasm		Group enriched	Tissue enhanced		cerebral cortex: 27.3;testis: 20.3	fallopian tube: 13.3	Cell line enhanced		HAP1: 20.7;SCLC-21H: 48.2;SH-SY5Y: 22.3;SiHa: 15.5
RIN1		ENSG00000174791	Ras and Rab interactor 1	11	66330242-66336840	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA035491	Uncertain		Approved	Nucleus<br>Nuclear membrane	Renal cancer:9.34e-7 (unfavourable), Endometrial cancer:2.21e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 19.3	cerebral cortex: 5.2	Cell line enhanced		U-2197: 58.9
RIN2	RASSF4	ENSG00000132669	Ras and Rab interactor 2	20	19886521-20002457	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034641	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol	Renal cancer:8.34e-6 (favourable)	Expressed in all	Expressed in all			gallbladder: 28.9	Cell line enhanced		PC-3: 44.5
RIN3	FLJ22439	ENSG00000100599	Ras and Rab interactor 3	14	92513774-92688994	Predicted intracellular proteins	Evidence at protein level	HPA039836	Uncertain					Expressed in all	Mixed			bone marrow: 29.5	Cell line enhanced		HMC-1: 94.1
RING1	RNF1	ENSG00000204227	Ring finger protein 1	6	33208495-33212722	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008701	Supported		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			endometrium: 8.2	Mixed		
RINL	FLJ45909	ENSG00000187994	Ras and Rab interactor like	19	38867834-38878279	Predicted intracellular proteins	Evidence at protein level	HPA042083, HPA042103	Uncertain		Approved	Nucleoplasm<br>Vesicles	Cervical cancer:6.49e-5 (favourable), Head and neck cancer:1.64e-4 (favourable)	Expressed in all	Mixed			lymph node: 13.9	Cell line enhanced		HMC-1: 20.0;Karpas-707: 19.3
RINT1	FLJ11785, RINT-1	ENSG00000135249	RAD50 interactor 1	7	105532085-105567677	Predicted intracellular proteins	Evidence at protein level	HPA019875, HPA031646	Approved		Approved	Golgi apparatus	Thyroid cancer:2.39e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 19.0	Expressed in all		
RIOK1	AD034, bA288G3.1, FLJ30006, RRP10	ENSG00000124784	RIO kinase 1	6	7389496-7418037	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017866, HPA051446	Enhanced		Approved	Nucleoli<br>Nuclear speckles<br>Cytosol	Liver cancer:3.41e-5 (unfavourable), Renal cancer:5.85e-5 (unfavourable), Melanoma:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 29.6	Expressed in all		
RIOK2	FLJ11159	ENSG00000058729	RIO kinase 2	5	97160867-97183260	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005681	Uncertain		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 22.1	Expressed in all		
RIOK3	SUDD	ENSG00000101782	RIO kinase 3	18	23452823-23486603	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001620, HPA024184	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol	Pancreatic cancer:4.10e-4 (unfavourable), Prostate cancer:5.80e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 74.9	Expressed in all		
RIOX1	C14orf169, FLJ21802, JMJD9, MAPJD, NO66	ENSG00000170468	Ribosomal oxygenase 1	14	73490964-73493392	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003730			Supported	Nucleoli		Expressed in all	Expressed in all			testis: 17.7	Mixed		
RIOX2	FLJ14393, JMJD10, mdig, MINA, MINA53, NO52	ENSG00000170854	Ribosomal oxygenase 2	3	97941818-97972457	Predicted intracellular proteins	Evidence at protein level	HPA007603, HPA008080, CAB013458	Supported		Enhanced	Nucleus<br>Nucleoli	Breast cancer:4.41e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 100.7	Mixed		
RIPK1	RIP	ENSG00000137275	Receptor interacting serine/threonine kinase 1	6	3063991-3115187	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB010302, HPA015257	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Urothelial cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			skin: 26.1	Expressed in all		
RIPK2	CARD3, CARDIAK, RICK, RIP2	ENSG00000104312	Receptor interacting serine/threonine kinase 2	8	89757747-89791063	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015273, HPA016499	Approved		Enhanced	Cytosol	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:5.00e-6 (unfavourable), Lung cancer:6.33e-5 (unfavourable), Urothelial cancer:8.05e-4 (favourable)	Expressed in all	Mixed			gallbladder: 13.9	Mixed		
RIPK3	RIP3	ENSG00000129465	Receptor interacting serine/threonine kinase 3	14	24336021-24340045	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055087	Uncertain					Mixed	Mixed			small intestine: 25.1	Cell line enhanced		CAPAN-2: 11.3;HDLM-2: 6.9;SK-BR-3: 15.6
RIPK4	ANKK2, ANKRD3, DIK, PKK, RIP4	ENSG00000183421	Receptor interacting serine/threonine kinase 4	21	41739369-41767106	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030942	Enhanced				Ovarian cancer:6.22e-5 (unfavourable), Pancreatic cancer:3.48e-4 (unfavourable), Renal cancer:6.52e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 31.5	small intestine: 15.0	Cell line enhanced		CAPAN-2: 27.8;HaCaT: 41.4
RIPPLY2	C6orf159, dJ237I15.1	ENSG00000203877	Ripply transcriptional repressor 2	6	83853266-83857515	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047454	Uncertain					Tissue enhanced	Tissue enriched	8	cerebral cortex: 14.9	adrenal gland: 1.8	Cell line enhanced		SCLC-21H: 30.7;SH-SY5Y: 18.9
RIPPLY3	DSCR6	ENSG00000183145	Ripply transcriptional repressor 3	21	37006150-37019659	Predicted intracellular proteins	Evidence at transcript level	HPA055541	Uncertain					Mixed	Not detected			prostate: 0.2	Cell line enhanced		SCLC-21H: 3.2;T-47d: 1.5
RIT1	MGC125864, MGC125865, RIBB, RIT, ROC1	ENSG00000143622	Ras like without CAAX 1	1	155897808-155911404	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053249	Approved				Liver cancer:8.64e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 50.5	Expressed in all		
RIT2	RIBA, RIN	ENSG00000152214	Ras like without CAAX 2	18	42743227-43115691	Predicted intracellular proteins	Evidence at protein level	HPA072174	Supported					Tissue enriched	Tissue enriched	6	cerebral cortex: 18.3	adrenal gland: 2.8	Not detected		
RITA1	C12orf52, FLJ14827, RITA	ENSG00000139405	RBPJ interacting and tubulin associated 1	12	113185526-113192368	Predicted intracellular proteins	Evidence at protein level	HPA039094, HPA039095, HPA061531	Supported		Supported	Nucleus	Liver cancer:9.79e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 20.4	Expressed in all		
RLBP1	CRALBP	ENSG00000140522	Retinaldehyde binding protein 1	15	89209869-89221751	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042051, HPA044083	Supported	Approved	Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Group enriched	Tissue enriched	9	cerebral cortex: 6.1	testis: 0.6	Cell line enriched	53	SK-MEL-30: 16.5
RLF	Zn-15L, ZNF292L	ENSG00000117000	Rearranged L-myc fusion	1	40161373-40240921	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054653, HPA057300	Uncertain		Approved	Nucleus	Renal cancer:7.68e-6 (unfavourable), Liver cancer:1.75e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 20.8	Expressed in all		
RLIM	MGC15161, NY-REN-43, RNF12	ENSG00000131263	Ring finger protein, LIM domain interacting	X	74585217-74614617	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018895	Approved		Supported	Nucleoplasm<br>Cytosol	Thyroid cancer:6.04e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 29.0	Expressed in all		
RMI1	BLAP75, C9orf76, FLJ12888	ENSG00000178966	RecQ mediated genome instability 1	9	83980711-84004074	Predicted intracellular proteins	Evidence at protein level	HPA021661			Supported	Nucleoplasm<br>Nuclear bodies	Liver cancer:8.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 21.0	Expressed in all		
RMI2	BLAP18, C16orf75, MGC24665	ENSG00000175643	RecQ mediated genome instability 2	16	11249619-11351762	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040995	Uncertain		Supported	Nuclear speckles<br>Cytosol	Liver cancer:2.77e-5 (unfavourable), Cervical cancer:5.69e-5 (favourable)	Expressed in all	Mixed			lymph node: 36.9	Expressed in all		
RMND5A	FLJ13910, GID2, GID2A, p44CTLH, RMD5	ENSG00000153561	Required for meiotic nuclear division 5 homolog A	2	86720173-86778041	Predicted intracellular proteins	Evidence at protein level	HPA046795, HPA060843	Uncertain		Approved	Nucleoplasm	Endometrial cancer:3.03e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 39.1	Expressed in all		
RMND5B	FLJ22318, GID2, GID2B	ENSG00000145916	Required for meiotic nuclear division 5 homolog B	5	178130996-178150565	Predicted intracellular proteins	Evidence at protein level	HPA047778	Uncertain		Approved	Nucleoplasm	Renal cancer:7.22e-8 (favourable), Pancreatic cancer:7.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 94.7	Expressed in all		
RNASEH2A	AGS4, RNASEHI, RNHIA, RNHL	ENSG00000104889	Ribonuclease H2 subunit A	19	12802063-12813638	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042692			Enhanced	Nucleus<br>Cytosol	Renal cancer:6.29e-6 (unfavourable), Liver cancer:8.72e-5 (unfavourable), Cervical cancer:1.18e-4 (favourable), Ovarian cancer:1.22e-4 (favourable), Colorectal cancer:6.18e-4 (favourable)	Expressed in all	Expressed in all			testis: 26.5	Expressed in all		
RNASEH2B	AGS2, DLEU8, FLJ11712	ENSG00000136104	Ribonuclease H2 subunit B	13	50909678-50973745	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040084, HPA041469	Approved		Enhanced	Nucleus	Renal cancer:2.54e-8 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 29.9	Expressed in all		
RNASEH2C	AGS3, AYP1	ENSG00000172922	Ribonuclease H2 subunit C	11	65714896-65720947	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065375			Approved	Nucleus	Pancreatic cancer:3.68e-5 (favourable), Renal cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.1	Expressed in all		
RNASEL	PRCA1, RNS4	ENSG00000135828	Ribonuclease L	1	182573634-182589256	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002633, CAB010906	Approved		Supported	Cytosol		Expressed in all	Mixed			parathyroid gland: 17.6	Mixed		
RND1	ARHS, Rho6, RHOS	ENSG00000172602	Rho family GTPase 1	12	48857145-48865898	Predicted intracellular proteins	Evidence at protein level	HPA077800			Supported	Vesicles<br>Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		cerebral cortex: 39.8;liver: 31.1	gallbladder: 23.6	Cell line enriched	6	SK-BR-3: 51.2
RND2	ARHN, Rho7, RhoN	ENSG00000108830	Rho family GTPase 2	17	43025241-43032036	Predicted intracellular proteins	Evidence at protein level	HPA077757	Approved					Group enriched	Tissue enhanced		cerebral cortex: 37.0;testis: 30.7	thyroid gland: 11.0	Cell line enhanced		AF22: 11.9;AN3-CA: 14.4;HAP1: 12.5;NTERA-2: 17.2;SH-SY5Y: 11.0
RND3	ARHE, Rho8, RhoE	ENSG00000115963	Rho family GTPase 3	2	150468195-150539011	Predicted intracellular proteins	Evidence at protein level	HPA060504	Uncertain				Renal cancer:1.78e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 169.5	Cell line enhanced		BJ: 570.2;BJ hTERT+: 1071.0;hTERT-HME1: 496.5
RNF10	KIAA0262, RIE2	ENSG00000022840	Ring finger protein 10	12	120533480-120577594	Predicted intracellular proteins	Evidence at protein level	HPA052643	Approved		Approved	Nucleoplasm<br>Mitochondria	Liver cancer:5.30e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 179.5	Expressed in all		
RNF103-CHMP3	RNF103-VPS24	ENSG00000249884	RNF103-CHMP3 readthrough	2	86505668-86721122	Predicted intracellular proteins	Evidence at protein level	HPA015673, HPA073383	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 4.2	bone marrow,heart muscle: 2.7	Mixed		
RNF11	CGI-123, MGC51169, Sid1669p	ENSG00000123091	Ring finger protein 11	1	51236271-51273455	Predicted intracellular proteins	Evidence at protein level	HPA045781	Uncertain				Renal cancer:3.14e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 151.4	Mixed		
RNF111	ARK, Arkadia, DKFZP761D081, FLJ38008	ENSG00000157450	Ring finger protein 111	15	58865175-59097419	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038576, HPA038577	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 22.9	Expressed in all		
RNF113A	Cwc24, RNF113, ZNF183	ENSG00000125352	Ring finger protein 113A	X	119870475-119871827	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000160, HPA076658	Approved		Approved	Nucleoplasm	Urothelial cancer:6.23e-4 (favourable), Renal cancer:7.93e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 24.5	Expressed in all		
RNF113B	RNF161, ZNF183L1	ENSG00000139797	Ring finger protein 113B	13	98175785-98177265	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	588	testis: 58.8	all non-specific tissues: 0.0	Not detected		
RNF114	PSORS12, ZNF313	ENSG00000124226	Ring finger protein 114	20	49936336-49953892	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021184	Approved		Supported	Plasma membrane<br>Cytosol	Endometrial cancer:8.10e-6 (unfavourable), Thyroid cancer:3.01e-4 (favourable), Liver cancer:3.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 149.2	Expressed in all		
RNF115	CL469780, ZNF364	ENSG00000265491	Ring finger protein 115	1	145738868-145824077	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019130	Approved		Approved	Nucleoli<br>Mitochondria	Liver cancer:2.95e-4 (unfavourable)	Expressed in all	Mixed			heart muscle: 16.4	Expressed in all		
RNF123	FLJ12565, KPC1	ENSG00000164068	Ring finger protein 123	3	49689499-49721529	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA065983, HPA071879	Approved		Approved	Cytosol	Renal cancer:1.33e-8 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 53.1	Expressed in all		
RNF125	FLJ20456	ENSG00000101695	Ring finger protein 125	18	32018372-32073213	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041514	Uncertain		Uncertain	Nucleoli<br>Golgi apparatus<br>Cytosol	Renal cancer:4.06e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 11.5	Cell line enhanced		HMC-1: 42.3
RNF126	FLJ20552	ENSG00000070423	Ring finger protein 126	19	647526-663277	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043050	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 38.2	Expressed in all		
RNF135	MGC13061	ENSG00000181481	Ring finger protein 135	17	30968785-30999911	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021576, HPA052404	Approved		Approved	Vesicles	Renal cancer:7.51e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Mixed		
RNF138	NARF, STRIN	ENSG00000134758	Ring finger protein 138	18	32091855-32131561	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041101			Approved	Mitochondria		Expressed in all	Expressed in all			testis: 167.7	Expressed in all		
RNF14	ARA54, HFB30, TRIAD2	ENSG00000013561	Ring finger protein 14	5	141958328-141990291	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008716	Approved		Supported	Cytosol	Renal cancer:1.71e-4 (favourable), Thyroid cancer:2.21e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 137.2	Expressed in all		
RNF141	ZFP26, ZNF230	ENSG00000110315	Ring finger protein 141	11	10511678-10541230	Predicted intracellular proteins	Evidence at protein level	HPA018133	Approved		Approved	Nucleoplasm<br>Microtubules	Pancreatic cancer:1.14e-4 (unfavourable), Renal cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			testis: 130.2	Expressed in all		
RNF151		ENSG00000179580	Ring finger protein 151	16	1966823-1968975	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	430	testis: 73.0	appendix,skin,stomach,thyroid gland: 0.1	Not detected		
RNF157	KIAA1917	ENSG00000141576	Ring finger protein 157	17	76142453-76240373	Predicted intracellular proteins	Evidence at protein level	HPA021854, HPA021991, HPA023922	Uncertain		Approved	Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		cerebral cortex: 60.6;testis: 57.3	skeletal muscle: 24.9	Cell line enhanced		HDLM-2: 92.0;U-266/70: 38.2
RNF165	ARKL2, RNF111L2	ENSG00000141622	Ring finger protein 165	18	46326809-46463140	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041615, HPA047798	Uncertain		Approved	Nucleus<br>Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 9.3;parathyroid gland: 9.8	thyroid gland: 7.0	Cell line enhanced		AF22: 13.9;SCLC-21H: 17.1;SH-SY5Y: 17.5
RNF166	MGC14381, MGC2647	ENSG00000158717	Ring finger protein 166	16	88696495-88706421	Predicted intracellular proteins	Evidence at protein level	HPA042970			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:9.45e-6 (unfavourable), Pancreatic cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 57.1	Expressed in all		
RNF168	FLJ35794	ENSG00000163961	Ring finger protein 168	3	196468783-196503768	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046109			Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:2.29e-4 (unfavourable), Cervical cancer:8.21e-4 (favourable), Pancreatic cancer:8.31e-4 (unfavourable)	Expressed in all	Mixed			testis: 20.0	Expressed in all		
RNF169	KIAA1991	ENSG00000166439	Ring finger protein 169	11	74748868-74842413	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046138, HPA058368	Uncertain		Supported	Nuclear speckles	Pancreatic cancer:8.04e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 14.8	Expressed in all		
RNF17	FLJ11045, Mmip-2, SPATA23, TDRD4	ENSG00000132972	Ring finger protein 17	13	24764152-24879921	Predicted intracellular proteins	Evidence at protein level	HPA039699, HPA040111	Approved					Tissue enriched	Tissue enriched	19	testis: 44.0	placenta: 2.3	Not detected		
RNF181	HSPC238	ENSG00000168894	Ring finger protein 181	2	85595725-85597613	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046112, HPA062121	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.06e-6 (unfavourable), Thyroid cancer:4.59e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 171.6	Expressed in all		
RNF187		ENSG00000168159	Ring finger protein 187	1	228487061-228495766	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030098	Approved		Supported	Nucleoplasm<br>Cytosol	Colorectal cancer:2.83e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 143.2	Expressed in all		
RNF2	BAP-1, BAP1, DING, HIPI3, RING1B, RING2	ENSG00000121481	Ring finger protein 2	1	185045364-185102608	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026803	Uncertain		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.94e-7 (unfavourable), Liver cancer:1.08e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 42.2	Expressed in all		
RNF20	BRE1, BRE1A, FLJ11189, FLJ20382, hBRE1, KAIA2779	ENSG00000155827	Ring finger protein 20	9	101533851-101563344	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB012478, HPA051773	Supported		Enhanced	Nucleoplasm	Renal cancer:1.64e-6 (favourable)	Expressed in all	Expressed in all			testis: 59.3	Expressed in all		
RNF207	C1orf188, FLJ32096, FLJ46380	ENSG00000158286	Ring finger protein 207	1	6205475-6221299	Predicted intracellular proteins	Evidence at protein level	HPA028378, HPA042535	Uncertain		Approved	Cytosol	Renal cancer:1.92e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 11.1	seminal vesicle: 5.2	Cell line enhanced		CAPAN-2: 14.3
RNF208	DKFZP761H1710	ENSG00000212864	Ring finger protein 208	9	137220247-137221581	Predicted intracellular proteins	Evidence at protein level	HPA021256, HPA021429	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.12e-8 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 25.1	adrenal gland: 7.4	Cell line enhanced		MCF7: 42.5;REH: 40.9
RNF212	FLJ38841, LOC285498	ENSG00000178222	Ring finger protein 212	4	1056250-1113562	Predicted intracellular proteins	Evidence at transcript level	HPA057527	Uncertain				Cervical cancer:1.39e-4 (favourable)	Mixed	Mixed			thyroid gland: 5.8	Cell line enhanced		A-431: 11.1;HeLa: 25.6;SiHa: 24.3
RNF212B	C14orf164	ENSG00000215277	Ring finger protein 212B	14	23185316-23273477	Predicted intracellular proteins	Evidence at transcript level	HPA053574	Uncertain					Not detected	Group enriched	20	kidney: 27.7;testis: 10.4	thyroid gland: 0.9	Not detected		
RNF214	DKFZp547C195	ENSG00000167257	Ring finger protein 214	11	117232625-117286445	Predicted intracellular proteins	Evidence at protein level	HPA039332	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:6.03e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 33.4	Expressed in all		
RNF216	TRIAD3, UBCE7IP1, ZIN	ENSG00000011275	Ring finger protein 216	7	5620047-5781739	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018955, HPA021123	Supported		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:6.24e-5 (favourable), Liver cancer:2.26e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.0	Expressed in all		
RNF219	C13orf7, FLJ13449	ENSG00000152193	Ring finger protein 219	13	78614291-78659179	Predicted intracellular proteins	Evidence at protein level	HPA034785, HPA034786	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:4.99e-6 (unfavourable)	Expressed in all	Mixed			testis: 27.3	Mixed		
RNF224		ENSG00000233198	Ring finger protein 224	9	137227271-137229638	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			esophagus: 1.1	Cell line enhanced		CAPAN-2: 4.5;MCF7: 7.0
RNF25	AO7, FLJ13906	ENSG00000163481	Ring finger protein 25	2	218663864-218672411	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036420, HPA036421	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:6.58e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 14.6	Expressed in all		
RNF31	FLJ10111, FLJ23501, HOIP, ZIBRA	ENSG00000092098	Ring finger protein 31	14	24146683-24160661	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009063, HPA048745	Approved		Approved	Cytosol		Expressed in all	Expressed in all			skin: 44.4	Expressed in all		
RNF32	FKSG33, HSD15, LMBR2	ENSG00000105982	Ring finger protein 32	7	156640281-156677130	Predicted intracellular proteins	Evidence at protein level	HPA073560	Enhanced				Colorectal cancer:2.21e-4 (unfavourable)	Mixed	Tissue enriched	8	testis: 110.5	epididymis: 13.4	Cell line enhanced		HDLM-2: 12.4
RNF38		ENSG00000137075	Ring finger protein 38	9	36336396-36487548	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015853	Approved		Supported	Nucleoplasm	Renal cancer:2.90e-6 (favourable)	Expressed in all	Expressed in all			testis: 116.8	Expressed in all		
RNF39	HZFw1, LIRF	ENSG00000204618	Ring finger protein 39	6	30070266-30075887	Predicted intracellular proteins	Evidence at protein level	CAB019278, HPA047115	Uncertain		Uncertain	Vesicles<br>Plasma membrane<br>Centrosome		Mixed	Tissue enhanced		skin: 3.5	breast: 2.0	Cell line enhanced		A-431: 1.1;U-266/84: 2.5
RNF4	RES4-26, SLX5, SNURF	ENSG00000063978	Ring finger protein 4	4	2462220-2625320	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049356	Approved				Lung cancer:6.38e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.0	Expressed in all		
RNF40	BRE1B, KIAA0661, RBP95, STARING	ENSG00000103549	Ring finger protein 40	16	30761745-30776307	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041330, HPA054227	Approved		Enhanced	Nucleoplasm	Renal cancer:8.11e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 78.9	Expressed in all		
RNF41	NRDP1, SBBI03	ENSG00000181852	Ring finger protein 41	12	56202175-56221933	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016812	Approved		Approved	Nucleus<br>Nuclear bodies<br>Midbody ring	Renal cancer:2.52e-5 (favourable), Liver cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 55.3	Expressed in all		
RNF44	KIAA1100	ENSG00000146083	Ring finger protein 44	5	176526697-176538025	Predicted intracellular proteins	Evidence at protein level	HPA038981	Uncertain		Approved	Nucleoplasm	Endometrial cancer:2.57e-7 (unfavourable), Liver cancer:8.45e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 50.1	Expressed in all		
RNF6	DKFZp686P0776	ENSG00000127870	Ring finger protein 6	13	26132115-26222493	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039343, HPA040048	Approved		Supported	Nuclear membrane	Cervical cancer:3.07e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 61.0	Mixed		
RNF7	CKBBP1, ROC2, SAG	ENSG00000114125	Ring finger protein 7	3	141738204-141747560	Predicted intracellular proteins	Evidence at protein level	HPA036995	Approved		Supported	Nucleoplasm	Renal cancer:1.54e-9 (unfavourable), Liver cancer:2.21e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 86.2	Expressed in all		
RNF8	KIAA0646	ENSG00000112130	Ring finger protein 8	6	37353972-37394738	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050731, HPA064925	Approved		Supported	Nucleus<br>Cytosol	Liver cancer:3.33e-5 (unfavourable), Prostate cancer:4.99e-5 (unfavourable), Melanoma:1.91e-4 (unfavourable)	Expressed in all	Mixed			testis: 18.5	Expressed in all		
RNGTT	hCAP, HCE, HCE1	ENSG00000111880	RNA guanylyltransferase and 5'-phosphatase	6	88610272-88963721	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003750	Approved		Approved	Nucleoplasm	Liver cancer:1.37e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 21.1	Expressed in all		
RNH1	RAI, RNH	ENSG00000023191	Ribonuclease/angiogenin inhibitor 1	11	494512-507300	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039223, HPA040781	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.14e-5 (favourable)	Expressed in all	Expressed in all			skin: 73.1	Expressed in all		
RNMT	RG7MT1	ENSG00000101654	RNA guanine-7 methyltransferase	18	13726660-13764558	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039409	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 31.0	Expressed in all		
RNPC3	FLJ20008, KIAA1839, RBM40, SNRNP65	ENSG00000185946	RNA binding region (RNP1, RRM) containing 3	1	103525691-103555239	Predicted intracellular proteins	Evidence at protein level	HPA052434			Supported	Nucleoplasm	Lung cancer:1.53e-4 (favourable), Urothelial cancer:5.25e-4 (favourable), Prostate cancer:7.70e-4 (unfavourable), Pancreatic cancer:7.82e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 67.0	Expressed in all		
RNPEPL1		ENSG00000142327	Arginyl aminopeptidase like 1	2	240565804-240581372	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036772	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:5.06e-4 (unfavourable), Head and neck cancer:7.43e-4 (favourable)	Expressed in all	Expressed in all			skin: 29.2	Mixed		
RNPS1		ENSG00000205937	RNA binding protein with serine rich domain 1	16	2253116-2268412	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044014	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 143.8	Expressed in all		
ROCK1	p160ROCK	ENSG00000067900	Rho associated coiled-coil containing protein kinase 1	18	20946906-21111851	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004562, HPA007567, HPA045639	Approved				Pancreatic cancer:9.93e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 12.3	Expressed in all		
ROCK2		ENSG00000134318	Rho associated coiled-coil containing protein kinase 2	2	11179761-11348330	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007459, CAB008666, HPA044109	Approved		Supported	Cytosol	Renal cancer:1.57e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 41.0	Expressed in all		
ROGDI	FLJ22386	ENSG00000067836	Rogdi homolog	16	4796968-4802950	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041000	Uncertain				Renal cancer:2.67e-5 (favourable), Pancreatic cancer:9.71e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 39.2	Mixed		
ROMO1	bA353C18.2, C20orf52, MTGMP	ENSG00000125995	Reactive oxygen species modulator 1	20	35699272-35700984	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA012782	Uncertain					Expressed in all	Expressed in all			adrenal gland: 120.8	Expressed in all		
ROPN1	CT91, ODF6, ROPN1A, ropporin	ENSG00000065371	Rhophilin associated tail protein 1	3	123968521-123992178	Predicted intracellular proteins	Evidence at protein level	HPA052530	Supported					Group enriched	Tissue enriched	9	testis: 223.8	breast: 24.1	Cell line enriched	7	SK-MEL-30: 21.4
ROPN1B		ENSG00000114547	Rhophilin associated tail protein 1B	3	125969144-125983454	Predicted intracellular proteins	Evidence at protein level	HPA052530	Supported					Tissue enhanced	Tissue enriched	8	testis: 372.8	breast: 44.7	Group enriched	7	SK-MEL-30: 40.5;WM-115: 18.2
ROPN1L	ASP, FLJ25776, RSPH11	ENSG00000145491	Rhophilin associated tail protein 1 like	5	10441524-10472029	Predicted intracellular proteins	Evidence at protein level	HPA039193, HPA041830	Enhanced					Group enriched	Tissue enriched	7	testis: 298.1	fallopian tube: 43.4	Cell line enhanced		HMC-1: 2.3;NB-4: 8.4
RORA	NR1F1, ROR1, ROR2, ROR3, RZRA	ENSG00000069667	RAR related orphan receptor A	15	60488284-61229319	Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009861	Approved				Renal cancer:5.42e-6 (favourable)	Mixed	Expressed in all			skin: 76.3	Cell line enhanced		Karpas-707: 52.5;U-266/70: 31.7;U-266/84: 43.2
RORB	NR1F2, ROR-BETA, RZRB	ENSG00000198963	RAR related orphan receptor B	9	74497365-74693177	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008393	Uncertain		Approved	Nucleus		Group enriched	Tissue enhanced		cerebral cortex: 12.6;cervix, uterine: 14.1	prostate: 7.4	Cell line enhanced		HHSteC: 18.9;HSkMC: 9.0;MOLT-4: 5.5;SH-SY5Y: 14.3
RORC	NR1F3, RORG, RZRG, TOR	ENSG00000143365	RAR related orphan receptor C	1	151806071-151831872	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065620			Supported	Nuclear bodies	Renal cancer:2.94e-5 (favourable), Colorectal cancer:1.83e-4 (favourable)	Mixed	Mixed			thyroid gland: 50.4	Cell line enhanced		HDLM-2: 24.3;Karpas-707: 9.4;MOLT-4: 5.6;T-47d: 10.0
RP1	DCDC4A, ORP1	ENSG00000104237	RP1, axonemal microtubule associated	8	54554361-54871720	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042257	Supported					Not detected	Tissue enhanced		fallopian tube: 16.3;lung: 5.4	testis: 2.4	Cell line enhanced		HDLM-2: 4.8;RPTEC TERT1: 7.7;U-2197: 2.2
RP1-130H16.18		ENSG00000248751		22	30285238-30299482	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 1.2	Cell line enhanced		HSkMC: 1.2;REH: 1.0
RP1-139D8.6		ENSG00000214732		6	42155426-42163439	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	363	testis: 67.8	cervix, uterine,esophagus: 0.1	Not detected		
RP1-179P9.3		ENSG00000282218		6	117318211-117573571	Predicted intracellular proteins	Evidence at transcript level	HPA019477	Uncertain		Approved	Golgi apparatus<br>Cytosol			Not detected			epididymis,lung: 0.8	Cell line enriched	47	U-138 MG: 8.8
RP1-20N18.10		ENSG00000283227		1	152947154-152949258	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	8	skin: 50.7	breast: 6.5	Group enriched	9	HaCaT: 1.8;hTCEpi: 3.8
RP1-321E8.5		ENSG00000278646		X	120877496-120878924	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	8	testis: 3.3	adrenal gland: 0.4	Cell line enhanced		U-266/70: 2.9
RP1-5O6.7		ENSG00000283900	Casein kinase I isoform epsilon 	22	38291918-38398522	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026288	Uncertain						Tissue enhanced		parathyroid gland: 6.5	cerebral cortex: 2.6	Cell line enhanced		Karpas-707: 5.1
RP1-66C13.4		ENSG00000266202		17	27798806-27893365	Predicted intracellular proteins	Evidence at transcript level	HPA023051	Uncertain					Not detected	Tissue enhanced		ovary: 1.1	cerebral cortex: 0.7	Not detected		
RP11-1012A1.4		ENSG00000258466		14	67659820-67690367	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Not detected			appendix,gallbladder,urinary bladder: 0.5	Cell line enhanced		SK-BR-3: 1.0
RP11-101E3.5		ENSG00000251184		9	128941478-128957021	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			endometrium,urinary bladder: 0.6	Cell line enhanced		BJ: 1.6;HL-60: 1.4;RH-30: 1.8;U-138 MG: 1.4
RP11-1021N1.1		ENSG00000261130		16	15395754-15515348	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RP11-108K14.8		ENSG00000254536		10	133390834-133420495	Predicted intracellular proteins	Evidence at protein level	HPA037826, HPA037827	Uncertain		Approved	Mitochondria		Not detected	Tissue enhanced		testis: 2.5	duodenum: 1.3	Cell line enhanced		Karpas-707: 17.8;U-266/70: 4.0
RP11-111M22.2		ENSG00000179240		11	76381313-76414619	Predicted intracellular proteins	Evidence at transcript level	HPA057405	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Centrosome		Not detected	Mixed			testis: 8.4	Mixed		
RP11-119J18.1		ENSG00000250378		5	135812667-135826584	Predicted intracellular proteins	Evidence at transcript level							Mixed	Group enriched	12	skin: 2.1;testis: 4.6	breast,duodenum,esophagus,kidney: 0.2	Cell line enhanced		HEL: 1.4;SK-MEL-30: 1.3
RP11-134F2.8		ENSG00000283149		3	186581995-186597103	Predicted intracellular proteins	Evidence at protein level	HPA010814	Uncertain		Uncertain	Endoplasmic reticulum			Mixed			epididymis: 36.6	Mixed		
RP11-136C24.3		ENSG00000273291		3	42809446-43055871	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	13	testis: 2.1	prostate,rectum: 0.1	Not detected		
RP11-152F13.10		ENSG00000260836		15	82540032-82555932	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex,parathyroid gland: 0.2	Cell line enriched	26	U-2197: 19.4
RP11-153I24.5		ENSG00000283384		13	108335354-108448316	Predicted intracellular proteins	Evidence at transcript level								Mixed			testis: 1.2	Not detected		
RP11-159D12.5		ENSG00000266086		17	57989038-58005253	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			skin: 17.9	Expressed in all		
RP11-15H20.8		ENSG00000283201		19	23222755-23274221	Predicted intracellular proteins	Evidence at transcript level								Mixed			epididymis: 4.5	Mixed		
RP11-15K19.2		ENSG00000249773		7	55887277-55955239	Predicted intracellular proteins	Evidence at transcript level	HPA047159	Uncertain					Not detected	Tissue enhanced		testis: 3.1	endometrium: 1.3	Mixed		
RP11-162P23.2		ENSG00000257767		12	111753890-111791418	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		adipose tissue: 63.9	stomach: 16.0	Cell line enhanced		BEWO: 8.7;EFO-21: 16.7
RP11-173A6.4		ENSG00000284188		1	244730375-244730962	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	8	testis: 1.5	kidney,parathyroid gland: 0.1	Not detected		
RP11-176H8.1		ENSG00000203546		14	31334312-31457441	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		adipose tissue: 1.1	skeletal muscle: 0.4	Not detected		
RP11-178C3.1		ENSG00000267318		17	59940908-59973101	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			testis: 11.4	Cell line enhanced		U-266/84: 15.4
RP11-178L8.4		ENSG00000131152		16	87302876-87334273	Predicted intracellular proteins	Evidence at transcript level	HPA040850	Uncertain					Not detected	Not detected			duodenum,endometrium,lymph node,skeletal muscle: 0.6	Mixed		
RP11-192H23.4		ENSG00000258472		17	28455752-28614197	Predicted intracellular proteins	Evidence at protein level	HPA046590	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 2.2	lung: 1.2	Cell line enhanced		A549: 2.3;PC-3: 1.1
RP11-195F19.29		ENSG00000258728		9	34646645-34657113	Predicted intracellular proteins	No evidence							Not detected	Not detected			fallopian tube: 0.3	Not detected		
RP11-195F19.5		ENSG00000187186		9	34664163-34666112	Predicted intracellular proteins	Evidence at protein level	HPA069617	Enhanced		Approved	Nucleoli<br>Endoplasmic reticulum<br>Vesicles	Glioma:5.81e-5 (unfavourable)	Mixed	Tissue enriched	5	testis: 138.9	cerebral cortex: 25.6	Cell line enhanced		HeLa: 31.7
RP11-20I23.3		ENSG00000259784		16	2513965-2527955	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		bone marrow: 1.1;small intestine: 1.3	smooth muscle: 0.5	Cell line enhanced		REH: 1.4
RP11-211G3.2		ENSG00000223401		3	187743686-187746028	Predicted intracellular proteins	Evidence at transcript level						Breast cancer:6.93e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 8.0	bone marrow: 4.5	Cell line enhanced		Daudi: 2.1;U-698: 4.6
RP11-214K3.25		ENSG00000274874		12	123973944-124088594	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 1.3	Mixed		
RP11-231C18.3		ENSG00000282278		4	53377839-54295272	Predicted intracellular proteins	Evidence at protein level	HPA058202							Tissue enhanced		appendix: 1.2;cerebral cortex: 3.3	ovary,smooth muscle: 0.7	Cell line enhanced		BJ hTERT+: 2.8;fHDF/TERT166: 6.4;HDLM-2: 2.1;NTERA-2: 1.8;U-2197: 1.7
RP11-231I13.2		ENSG00000242120		3	70196894-70312726	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RP11-249C24.12		ENSG00000275691		16	56676132-56677763	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		thyroid gland: 1.1	rectum: 0.7	Not detected		
RP11-249L12.1		ENSG00000283434		3	88338413-88467562	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	411	testis: 41.1	all non-specific tissues: 0.0	Not detected		
RP11-27I1.4		ENSG00000214654	Putative UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase LOC100288842 	9	120793551-120799918	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Mixed			thyroid gland: 5.0	Mixed		
RP11-286H14.4		ENSG00000230626		7	129126518-129130793	Predicted intracellular proteins	Evidence at protein level	HPA051993	Uncertain		Approved	Cytosol		Mixed	Tissue enriched	51	testis: 5.0	all non-specific tissues: 0.0	Not detected		
RP11-286N22.8		ENSG00000256591		11	61429220-61485822	Predicted intracellular proteins	Evidence at transcript level	HPA039732	Uncertain					Not detected	Mixed			cervix, uterine: 9.3	Mixed		
RP11-295P9.13		ENSG00000282246		10	13610047-13655929	Predicted intracellular proteins	Evidence at protein level	HPA047950	Uncertain						Mixed			skin: 14.3	Mixed		
RP11-298A10.1		ENSG00000283528		7	143639230-143647646	Predicted intracellular proteins	Evidence at protein level	HPA038756, HPA038758	Uncertain						Not detected			placenta: 0.3	Not detected		
RP11-298I3.5		ENSG00000259132		14	22946270-22982258	Predicted intracellular proteins	Evidence at protein level	HPA029803	Approved		Approved	Plasma membrane<br>Focal adhesion sites		Not detected	Mixed			skin: 9.3	Cell line enhanced		Hep G2: 29.1
RP11-298J23.10		ENSG00000124593	Prickle-like protein 4 	6	41780349-41790141	Predicted intracellular proteins	Evidence at transcript level	HPA031240			Uncertain	Mitotic spindle<br>Microtubule organizing center	Renal cancer:2.47e-4 (unfavourable), Lung cancer:8.24e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 3.2	Cell line enhanced		AF22: 2.3;ASC TERT1: 1.1;HeLa: 1.1;HSkMC: 1.1;TIME: 1.6
RP11-302B13.5		ENSG00000272822		12	48903503-48957365	Predicted intracellular proteins	Evidence at transcript level	HPA068942			Approved	Nucleus<br>Nuclear bodies		Not detected	Mixed			cerebral cortex: 2.1	Cell line enhanced		BJ hTERT+: 3.6
RP11-309L24.4		ENSG00000272899		7	128866308-128872044	Predicted intracellular proteins	Evidence at transcript level						Endometrial cancer:8.21e-4 (unfavourable)	Mixed	Mixed			small intestine: 3.7	Cell line enhanced		CAPAN-2: 6.0;HMC-1: 4.8
RP11-315D16.2		ENSG00000260007		15	68184032-68229718	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			seminal vesicle,smooth muscle: 0.5	Cell line enhanced		BJ hTERT+: 1.3;HAP1: 1.7;HEK93: 2.7
RP11-318A15.7		ENSG00000267168		17	76732978-76738522	Predicted intracellular proteins	No evidence							Not detected	Not detected			bone marrow: 0.1	Not detected		
RP11-321E2.2		ENSG00000284439		5	17518367-17518963	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RP11-321E2.5		ENSG00000284552		5	17486231-17486829	Predicted intracellular proteins	Evidence at transcript level								Not detected			epididymis: 0.4	Cell line enriched	12	U-937: 2.5
RP11-321E2.6		ENSG00000284373	Putative TAF11-like protein ENSP00000332601 	5	17498231-17498827	Predicted intracellular proteins	No evidence								Not detected			testis: 0.2	Not detected		
RP11-321E2.7		ENSG00000284283		5	17521801-17522397	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RP11-321E2.8		ENSG00000284234		5	17525235-17525831	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	12	testis: 1.2	all non-specific tissues: 0.0	Not detected		
RP11-321E2.9		ENSG00000284042		5	17528669-17529265	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RP11-322E11.6		ENSG00000267140		18	35443871-35497940	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			fallopian tube: 5.3	Cell line enriched	58	HUVEC TERT2: 215.0
RP11-322N21.2		ENSG00000250719	Homo sapiens phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3), transcript variant 13, mRNA.	1	46175486-46176478	Predicted intracellular proteins, RAS pathway related proteins	Evidence at transcript level							Not detected	Tissue enriched	937	testis: 93.7	all non-specific tissues: 0.0	Not detected		
RP11-343C2.11		ENSG00000260914		16	69299682-69322700	Predicted intracellular proteins	Evidence at protein level	HPA060092			Uncertain	Midbody		Not detected	Expressed in all			cerebral cortex: 85.3	Expressed in all		
RP11-343C2.9		ENSG00000260371		16	69335091-69356306	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			testis: 2.1	Mixed		
RP11-345F18.1		ENSG00000250821		4	55819819-55837487	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Cell line enhanced		HEK93: 1.4
RP11-345J4.3		ENSG00000258150		16	29464967-29467833	Predicted intracellular proteins	Evidence at transcript level	HPA053608	Uncertain					Not detected	Tissue enhanced		testis: 7.0	gallbladder: 4.1	Group enriched	6	A549: 5.4;CAPAN-2: 23.5;SK-BR-3: 15.5
RP11-345J4.5		ENSG00000261740	BOLA2-SMG1P6 protein isoform a 	16	29443230-29454651	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Expressed in all			lymph node: 17.7	Expressed in all		
RP11-347C12.3		ENSG00000258130		16	30204316-30209071	Predicted intracellular proteins	Evidence at transcript level	HPA053608	Uncertain					Not detected	Tissue enhanced		testis: 9.8	salivary gland: 3.8	Group enriched	5	A549: 8.7;CAPAN-2: 31.1;SK-BR-3: 22.1
RP11-350E12.6		ENSG00000283205		9	87956214-87956883	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	40	testis: 7.3	cervix, uterine: 0.1	Not detected		
RP11-371E8.4		ENSG00000259066		14	93184973-93218586	Predicted intracellular proteins	No evidence							Not detected	Not detected			skeletal muscle: 0.2	Not detected		
RP11-382A20.3		ENSG00000166503	Hepatoma-derived growth factor-related protein 3 	15	83112738-83208018	Predicted intracellular proteins	Evidence at protein level	HPA040719	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		parathyroid gland: 33.0	cerebral cortex: 19.5	Mixed		
RP11-385D13.1		ENSG00000251537		17	15571491-15651653	Predicted intracellular proteins	Evidence at protein level	HPA023623, HPA066431	Uncertain		Approved	Plasma membrane<br>Cytosol		Not detected	Not detected			skin: 0.4	Cell line enhanced		A549: 1.2;CAPAN-2: 1.0;HaCaT: 2.2
RP11-38C17.1		ENSG00000273155		2	99154998-99195298	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			appendix: 1.7	Mixed		
RP11-397G17.1		ENSG00000226733		6	50093616-50181007	Predicted intracellular proteins	Evidence at transcript level							Group enriched	Group enriched	8	epididymis: 136.0;kidney: 50.9	liver: 12.3	Not detected		
RP11-398C13.8		ENSG00000284024		10	14838166-14844727	Predicted intracellular proteins	Evidence at transcript level								Mixed			testis: 8.8	Expressed in all		
RP11-402G3.3		ENSG00000230601		9	114666434-114682066	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	234	testis: 28.7	appendix: 0.1	Cell line enriched	8	Karpas-707: 4.7
RP11-402G3.5		ENSG00000230054		9	114656304-114662374	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	115	testis: 56.5	appendix,skin: 0.4	Cell line enhanced		Karpas-707: 1.3
RP11-402P6.15		ENSG00000283599		X	71667542-71671524	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	24	testis: 9.5	cerebral cortex: 0.3	Not detected		
RP11-404P21.8		ENSG00000258691		14	96204844-96263929	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			esophagus,gallbladder: 1.4	Cell line enhanced		BJ hTERT+: 5.0;HaCaT: 2.5;U-87 MG: 3.9
RP11-426L16.10		ENSG00000271810		1	112702614-112711433	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 8.4	parathyroid gland: 3.5	Cell line enhanced		WM-115: 5.1
RP11-432M8.12		ENSG00000283776		5	17632088-17632684	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RP11-432M8.13		ENSG00000250782		5	17634460-17635053	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	11	U-2 OS: 1.0
RP11-432M8.2		ENSG00000284465		5	17585162-17585758	Predicted intracellular proteins	No evidence								Not detected			testis: 0.2	Not detected		
RP11-432M8.22		ENSG00000283740		5	17604177-17605377	Predicted intracellular proteins	Evidence at transcript level								Not detected			testis: 0.5	Cell line enhanced		U-2 OS: 1.0
RP11-432M8.3		ENSG00000283967		5	17590364-17590960	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RP11-432M8.4		ENSG00000283988		5	17593798-17594394	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RP11-432M8.5		ENSG00000284356		5	17597232-17597828	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	12	testis: 1.2	all non-specific tissues: 0.0	Not detected		
RP11-432M8.9		ENSG00000249156		5	17610496-17611583	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Cell line enhanced		U-2 OS: 1.5
RP11-437B10.1		ENSG00000279765		15	92883413-92949230	Predicted intracellular proteins	Evidence at transcript level							Not detected	Expressed in all			bone marrow: 243.6	Mixed		
RP11-449H3.3		ENSG00000275740		5	146203550-146339251	Predicted intracellular proteins	Evidence at transcript level	HPA035944, HPA036422	Approved		Approved	Nuclear speckles		Not detected	Tissue enriched	5	testis: 12.2	thyroid gland: 2.4	Mixed		
RP11-457D20.2		ENSG00000278499	Putative UPF0607 protein ENSP00000381418 	16	60358455-60359480	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	17	testis: 4.3	skeletal muscle: 0.2	Not detected		
RP11-467J12.4		ENSG00000277639		16	53035690-53052873	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	7	fallopian tube: 124.4	cervix, uterine: 18.1	Cell line enhanced		BEWO: 11.2
RP11-475E11.9		ENSG00000274068		1	108837660-108963484	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		parathyroid gland: 1.5	adrenal gland,cerebral cortex: 0.9	Cell line enhanced		HDLM-2: 1.8
RP11-47I22.4		ENSG00000258989		14	61529128-61657964	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			epididymis: 12.7	Cell line enhanced		U-2 OS: 31.5
RP11-484M3.5		ENSG00000251012		3	119147375-119187807	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
RP11-490B18.9		ENSG00000284484		16	75660227-75677009	Predicted intracellular proteins	No evidence								Not detected			skin: 0.1	Not detected		
RP11-505K9.4		ENSG00000260300		16	83908132-83951445	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			heart muscle: 2.7	Mixed		
RP11-506B6.7		ENSG00000281613		6	112236806-112350094	Predicted intracellular proteins	Evidence at transcript level	HPA059324	Uncertain					Not detected	Tissue enriched	14	testis: 8.2	placenta: 0.6	Cell line enriched	12	RPTEC TERT1: 2.7
RP11-507K12.1		ENSG00000283321		7	17299295-17467234	Predicted intracellular proteins	Evidence at transcript level	HPA029722	Uncertain						Group enriched	5	cervix, uterine: 12.8;urinary bladder: 23.3	fallopian tube: 3.3	Cell line enriched	5	RT4: 44.0
RP11-509I21.2		ENSG00000283473	Uncharacterized protein LOC100132146 	3	46612435-46626543	Predicted intracellular proteins	No evidence								Not detected			breast: 0.4	Not detected		
RP11-510M2.4		ENSG00000260734		16	71430262-71433376	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	18	testis: 1.8	all non-specific tissues: 0.0	Not detected		
RP11-511P7.7		ENSG00000284041		7	150368790-150396915	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		parathyroid gland: 2.1	endometrium: 1.0	Cell line enhanced		RPMI-8226: 4.0;SH-SY5Y: 5.5
RP11-514O12.4		ENSG00000249141		6	166858094-166956124	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			epididymis: 2.6	Cell line enhanced		NB-4: 2.8
RP11-514P8.7		ENSG00000270249		7	102541501-102592444	Predicted intracellular proteins	Evidence at transcript level	HPA046970	Uncertain		Uncertain	Nucleoplasm		Not detected	Tissue enhanced		parathyroid gland: 3.9	duodenum,epididymis: 1.0	Not detected		
RP11-515E23.1		ENSG00000261873		17	55448433-55511444	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	17	testis: 2.5	bone marrow,cerebral cortex,spleen: 0.1	Not detected		
RP11-526A4.1		ENSG00000234828		4	149351903-149896233	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	20	testis: 8.3	rectum: 0.4	Not detected		
RP11-529K1.3		ENSG00000260537		16	70299194-70372582	Predicted intracellular proteins	Evidence at protein level	HPA046380, HPA066668	Approved		Uncertain	Nucleoplasm		Not detected	Mixed			urinary bladder: 7.1	Mixed		
RP11-543B16.5		ENSG00000283952		1	211082872-211188533	Predicted intracellular proteins	No evidence								Not detected			testis: 0.7	Not detected		
RP11-546B8.6		ENSG00000275038		5	171305981-171308755	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		SH-SY5Y: 1.9
RP11-548K23.11		ENSG00000249967		10	97584374-97673910	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		parathyroid gland: 1.6	cerebral cortex,seminal vesicle: 0.9	Cell line enhanced		AN3-CA: 1.0;EFO-21: 1.1
RP11-561N12.2		ENSG00000241149		7	63998874-64016130	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	38	testis: 3.7	all non-specific tissues: 0.0	Not detected		
RP11-565P22.6		ENSG00000254706		1	162365407-162383531	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		seminal vesicle: 4.2	gallbladder: 2.3	Cell line enhanced		HEL: 6.5
RP11-569D9.5		ENSG00000283361		13	114179238-114223084	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	16	fallopian tube: 15.8	testis: 0.9	Not detected		
RP11-571M6.15		ENSG00000257921		12	57773028-57787046	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			lymph node,prostate: 0.1	Cell line enhanced		RH-30: 1.2
RP11-574F21.3		ENSG00000258465		1	160217464-160285130	Predicted intracellular proteins	Evidence at protein level	HPA027218, HPA027381, HPA044837	Approved		Approved	Nucleoplasm<br>Cytosol		Not detected	Mixed			heart muscle: 2.5	Cell line enhanced		EFO-21: 3.9;HDLM-2: 3.7
RP11-603J24.9		ENSG00000257411		12	56101331-56109289	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cervix, uterine: 22.6	Cell line enhanced		HBF TERT88: 119.8;LHCN-M2: 60.3;U-698: 57.6
RP11-606E8.2		ENSG00000284057		11	93741664-93812378	Predicted intracellular proteins	Evidence at protein level	HPA040511, HPA064236	Approved		Approved	Nucleoplasm<br>Vesicles			Tissue enhanced		kidney: 6.9	duodenum: 3.1	Mixed		
RP11-618P17.4		ENSG00000266953		19	34396315-34409364	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		skeletal muscle: 3.0	stomach: 0.7	Mixed		
RP11-624J6.2		ENSG00000283536		12	53241889-53245134	Predicted intracellular proteins	No evidence								Not detected			skin: 0.2	Not detected		
RP11-638I8.1		ENSG00000283247		7	45860008-45873082	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		placenta: 1.2	breast: 0.8	Not detected		
RP11-644F5.10		ENSG00000258311		12	55716036-55724703	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			adipose tissue: 9.6	Cell line enhanced		U-87 MG: 11.2
RP11-666A8.13		ENSG00000284526		17	76563710-76570544	Predicted intracellular proteins	Evidence at transcript level								Mixed			skin: 20.6	Mixed		
RP11-697E2.12		ENSG00000275674		15	90266317-90314499	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		duodenum: 1.2	cerebral cortex,small intestine: 0.8	Cell line enhanced		BEWO: 1.8
RP11-717K11.2		ENSG00000281028		4	25160663-25277306	Predicted intracellular proteins	Evidence at protein level	HPA004099	Uncertain		Uncertain	Cytosol		Not detected	Mixed			testis: 11.3	Mixed		
RP11-722G7.1		ENSG00000269226		X	104063871-104076212	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			ovary: 7.6	Cell line enhanced		AF22: 10.6;AN3-CA: 9.4
RP11-723O4.6		ENSG00000187695	Uncharacterized protein FLJ43738 	3	128909874-128971330	Predicted intracellular proteins	Evidence at transcript level							Mixed	Group enriched	5	fallopian tube: 10.7;skin: 6.8;testis: 20.3	lung: 2.4	Cell line enhanced		HAP1: 4.6;HL-60: 4.8
RP11-724O16.1		ENSG00000251569		2	169479480-169525922	Predicted intracellular proteins	Evidence at transcript level	HPA046125	Uncertain					Not detected	Tissue enhanced		testis: 16.8	fallopian tube,thyroid gland: 3.8	Cell line enhanced		ASC TERT1: 3.8;HSkMC: 2.9;LHCN-M2: 4.9
RP11-727F15.14		ENSG00000283268		11	62832319-62832803	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	34	testis: 40.8	thyroid gland: 1.2	Not detected		
RP11-736N17.11		ENSG00000283071	Homo sapiens translation initiation factor IF-2-like (LOC107984640), mRNA.	14	103084210-103090027	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		testis: 1.0	cerebral cortex: 0.5	Not detected		
RP11-73M18.2		ENSG00000256500		14	103562962-103685924	Predicted intracellular proteins	Evidence at protein level	HPA044617, HPA052450	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		cerebral cortex: 21.5;testis: 21.6	skeletal muscle: 9.0	Expressed in all		
RP11-762I7.5		ENSG00000257390		12	55757275-55827546	Predicted intracellular proteins	Evidence at protein level	HPA017653, HPA030902, HPA030903	Uncertain		Enhanced	Nuclear speckles		Not detected	Tissue enriched	17	testis: 15.2	gallbladder,lymph node: 0.8	Mixed		
RP11-766F14.2		ENSG00000248713		4	99636529-99654648	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	26	skeletal muscle: 24.6	kidney: 0.9	Cell line enhanced		RH-30: 1.6
RP11-793H13.10		ENSG00000267281		12	53506688-53625979	Predicted intracellular proteins	Evidence at transcript level	HPA003384	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Not detected			lung: 0.8	Cell line enhanced		A549: 1.1
RP11-80H18.3		ENSG00000255154	Hydroxyacyl-thioester dehydratase type 2, mitochondrial 	3	58306262-58318574	Predicted intracellular proteins	Evidence at protein level	HPA066812			Supported	Nucleoli<br>Mitochondria		Not detected	Expressed in all			thyroid gland: 14.6	Expressed in all		
RP11-811O14.1		ENSG00000283428		2	224703764-224716365	Predicted intracellular proteins	Evidence at transcript level								Not detected			tonsil: 0.2	Cell line enhanced		Daudi: 1.7
RP11-81A22.5		ENSG00000262165		17	4801159-4807013	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			ovary: 3.1	Cell line enhanced		AN3-CA: 3.1;SCLC-21H: 12.1
RP11-831H9.11		ENSG00000255432		11	62649694-62665178	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex: 0.5	Not detected		
RP11-834C11.12		ENSG00000273049		12	53985845-54034888	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 1.5	skeletal muscle: 0.8	Cell line enhanced		AN3-CA: 8.1;HDLM-2: 3.0
RP11-849H4.2		ENSG00000254469	Putative short transient receptor potential channel 2-like protein 	11	71865509-71928654	Predicted intracellular proteins	Evidence at protein level	HPA051121, HPA058841	Uncertain		Supported	Nucleoli		Mixed	Mixed			epididymis: 7.0	Expressed in all		
RP11-934B9.3		ENSG00000258973		14	24332310-24337382	Predicted intracellular proteins	Evidence at protein level	HPA055087	Uncertain					Not detected	Not detected			placenta,skin: 0.5	Not detected		
RP11-949J7.8		ENSG00000283189		3	49416777-49429314	Predicted intracellular proteins	No evidence								Not detected			duodenum,lung: 0.2	Not detected		
RP11-96L14.8		ENSG00000282872		1	26164161-26168581	Predicted intracellular proteins	Evidence at transcript level								Not detected			testis: 0.6	Cell line enriched	10	SCLC-21H: 4.0
RP11-96O20.4		ENSG00000260170		15	45587351-45676314	Predicted intracellular proteins	Evidence at transcript level	HPA041589	Uncertain					Not detected	Not detected			colon: 0.7	Cell line enhanced		HBEC3-KT: 1.8;HDLM-2: 1.4
RP13-1032I1.10		ENSG00000262660		17	81703371-81720539	Predicted intracellular proteins	Evidence at protein level	HPA022853, HPA023043, HPA023048	Approved		Enhanced	Mitochondria		Not detected	Tissue enhanced		duodenum: 2.1	cerebral cortex: 1.1	Cell line enhanced		MOLT-4: 14.1
RP13-198D9.4		ENSG00000283329		9	38694263-38720428	Predicted intracellular proteins	No evidence								Not detected			testis: 0.8	Not detected		
RP13-210D15.4		ENSG00000238210		X	135252061-135253583	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	16	testis: 11.8	skin: 0.7	Not detected		
RP13-210D15.9		ENSG00000283644		X	135309480-135309659	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		seminal vesicle: 1.1;skin: 1.4	thyroid gland: 0.6	Not detected		
RP13-347D8.7		ENSG00000277535		X	119073226-119076373	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	76	testis: 7.6	all non-specific tissues: 0.0	Not detected		
RP13-512J5.1		ENSG00000255767		2	3531984-3547957	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			smooth muscle: 24.1	Mixed		
RP13-582O9.6		ENSG00000264668		8	143247110-143276403	Predicted intracellular proteins	Evidence at transcript level	HPA047232, HPA056268	Uncertain		Uncertain	Nucleus<br>Nucleoli		Not detected	Tissue enhanced		fallopian tube: 1.1	cerebral cortex: 0.7	Mixed		
RP13-672B3.2		ENSG00000256632		12	132688049-132714912	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		duodenum: 2.6	kidney,small intestine,testis: 0.6	Cell line enhanced		REH: 1.1;U-698: 1.0
RP13-794C1.1		ENSG00000282827		3	48446846-48467645	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		testis: 1.3	thyroid gland: 0.6	Cell line enhanced		AF22: 1.8;NTERA-2: 1.4;RT4: 2.2
RP1L1	DCDC4B	ENSG00000183638	RP1 like 1	8	10606349-10712187	Predicted intracellular proteins	Evidence at protein level	HPA024686, HPA024744	Enhanced					Not detected	Not detected			skin: 0.2	Not detected		
RP2	NM23-H10, NME10, TBCCD2	ENSG00000102218	Retinitis pigmentosa 2 (X-linked recessive)	X	46836940-46882358	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000234, HPA000909	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane	Liver cancer:7.97e-4 (unfavourable)	Expressed in all	Mixed			placenta: 35.0	Expressed in all		
RP3-369A17.6		ENSG00000282804		6	24797373-24809798	Predicted intracellular proteins	No evidence								Not detected			appendix: 0.5	Not detected		
RP3-370M22.8		ENSG00000225528		22	39960397-39964718	Predicted intracellular proteins	Evidence at transcript level	HPA047397			Uncertain	Nucleus<br>Nucleoli<br>Nuclear bodies		Not detected	Not detected			bone marrow,lymph node: 0.8	Cell line enhanced		HEL: 2.7;K-562: 11.1;MOLT-4: 1.7
RP3-454G6.2		ENSG00000283683		1	171600621-171638799	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		cervix, uterine: 8.0;fallopian tube: 4.6	epididymis: 4.1	Cell line enriched	6	HEL: 24.8
RP4-533D7.6		ENSG00000278139		1	46043661-46176488	Predicted intracellular proteins, RAS pathway related proteins	Evidence at transcript level	HPA005751	Uncertain					Not detected	Tissue enriched	30	testis: 41.3	gallbladder: 1.3	Cell line enhanced		HeLa: 2.1;RT4: 8.4
RP4-559A3.7		ENSG00000255835		1	225886696-225924278	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex: 0.1	Not detected		
RP4-583P15.14		ENSG00000273047		20	63738270-63740398	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		kidney: 1.1;liver: 2.4;urinary bladder: 1.3	adipose tissue: 1.0	Cell line enhanced		Hep G2: 4.0;HHSteC: 1.0;U-698: 1.5
RP4-635E18.9		ENSG00000277726		1	11012662-11030528	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			epididymis: 3.0	Cell line enhanced		Hep G2: 2.1;MCF7: 1.1;RT4: 1.6
RP4-777O23.3		ENSG00000281039		7	30497077-30550761	Predicted intracellular proteins	Evidence at protein level	HPA020735	Uncertain					Not detected	Mixed			epididymis: 30.5	Mixed		
RP4-809F18.1		ENSG00000255595		12	126191263-126361065	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex,gallbladder,pancreas,salivary gland: 0.1	Not detected		
RP4-816N1.8		ENSG00000283297	Uncharacterized protein ENSP00000372125 	12	2849039-2857083	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		skin: 4.3;testis: 7.4	appendix,lymph node,spleen: 1.3	Cell line enhanced		HeLa: 1.5;Karpas-707: 2.1
RP5-1052I5.2		ENSG00000267561		1	86993009-87169204	Predicted intracellular proteins	Evidence at protein level	HPA043069, HPA043603	Approved		Uncertain	Mitochondria		Not detected	Tissue enhanced		adipose tissue: 22.0	breast: 8.9	Cell line enhanced		ASC TERT1: 6.6;HEL: 13.2;HMC-1: 15.7;THP-1: 8.5
RP5-850E9.3		ENSG00000270299		20	646626-675800	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 2.7;testis: 1.7	endometrium: 1.5	Cell line enhanced		Hep G2: 9.9;SK-BR-3: 6.5
RP5-864K19.6		ENSG00000274944		1	38864501-38881617	Predicted intracellular proteins	Evidence at transcript level	HPA041188	Uncertain					Not detected	Tissue enhanced		testis: 11.6	lymph node: 3.6	Mixed		
RP5-874C20.8		ENSG00000276302		6	28267121-28281580	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 1.7	Cell line enhanced		HEK93: 1.9
RP5-900K19.2		ENSG00000284292		7	99325879-99394653	Predicted intracellular proteins	Evidence at protein level	HPA004334	Uncertain		Approved	Cell Junctions<br>Cytosol			Mixed			appendix: 3.3	Mixed		
RP5-937E21.8		ENSG00000283697		X	149548210-149549932	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	7	testis: 17.3	adrenal gland: 2.3	Not detected		
RP6-24A23.6		ENSG00000260548		X	108722070-108732687	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		ovary: 12.9;thyroid gland: 12.5	endometrium: 5.6	Cell line enhanced		HEK93: 15.4;NTERA-2: 2.4;RT4: 3.5;WM-115: 4.3
RP9	PAP-1	ENSG00000164610	Retinitis pigmentosa 9 (autosomal dominant)	7	33094797-33109401	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031523, HPA050778	Uncertain		Supported	Nucleus<br>Cytosol	Renal cancer:2.65e-5 (unfavourable), Liver cancer:2.58e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.9	Expressed in all		
RPA1	HSSB, REPA1, RF-A, RP-A, RPA70	ENSG00000132383	Replication protein A1	17	1829702-1900082	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004563, HPA006914, HPA046497	Supported		Enhanced	Nucleoplasm	Liver cancer:9.00e-9 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 44.7	Expressed in all		
RPA2		ENSG00000117748	Replication protein A2	1	27891524-27914746	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016538, HPA026306, HPA026309	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies	Cervical cancer:4.33e-4 (favourable), Head and neck cancer:8.12e-4 (favourable)	Expressed in all	Expressed in all			testis: 103.7	Expressed in all		
RPA3	REPA3	ENSG00000106399	Replication protein A3	7	7636518-7718607	Predicted intracellular proteins	Evidence at protein level	HPA005708	Approved				Liver cancer:5.16e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.7	Expressed in all		
RPA4	HSU24186	ENSG00000204086	Replication protein A4	X	96883908-96885467	Predicted intracellular proteins	Evidence at protein level	HPA066010	Approved					Not detected	Tissue enriched	7	testis: 2.1	placenta: 0.2	Not detected		
RPAIN	hRIP, MGC4189, RIP	ENSG00000129197	RPA interacting protein	17	5419641-5432876	Predicted intracellular proteins	Evidence at protein level	HPA023924, HPA031526	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Prostate cancer:4.41e-5 (unfavourable), Pancreatic cancer:5.20e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 26.7	Expressed in all		
RPAP3	FLJ21908, spag	ENSG00000005175	RNA polymerase II associated protein 3	12	47661249-47706061	Predicted intracellular proteins	Evidence at protein level	HPA038311, HPA038312	Enhanced		Approved	Cytosol	Liver cancer:2.01e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 34.4	Expressed in all		
RPE		ENSG00000197713	Ribulose-5-phosphate-3-epimerase	2	210002565-210022259	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036498, HPA036499	Approved				Liver cancer:1.42e-6 (unfavourable), Pancreatic cancer:7.00e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 49.6	Expressed in all		
RPE65	BCO3, LCA2, rd12, RP20	ENSG00000116745	RPE65, retinoid isomerohydrolase	1	68428822-68449959	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 2.7;prostate: 3.0;seminal vesicle: 6.2	endometrium: 1.0	Group enriched	27	A-431: 3.0;PC-3: 5.3;U-2 OS: 1.4
RPEL1		ENSG00000235376	Ribulose-5-phosphate-3-epimerase like 1	10	103245887-103248016	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA036498, HPA036499	Approved					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RPF1	BXDC5	ENSG00000117133	Ribosome production factor 1 homolog	1	84479259-84497790	Predicted intracellular proteins	Evidence at protein level	HPA024642	Supported		Enhanced	Nucleoli	Liver cancer:1.60e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 58.7	Expressed in all		
RPF2	bA397G5.4, BXDC1, FLJ21087	ENSG00000197498	Ribosome production factor 2 homolog	6	110982015-111028263	Predicted intracellular proteins	Evidence at protein level	HPA035475	Supported		Supported	Nucleus<br>Nucleoli	Renal cancer:2.07e-6 (unfavourable), Head and neck cancer:2.04e-4 (unfavourable), Liver cancer:2.25e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.2	Expressed in all		
RPGRIP1	CORD13, LCA6, RGI1, RPGRIP	ENSG00000092200	Retinitis pigmentosa GTPase regulator interacting protein 1	14	21287939-21351301	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042955, HPA060190	Enhanced					Tissue enhanced	Tissue enriched	48	testis: 105.9	spleen: 2.1	Cell line enhanced		RT4: 3.1
RPGRIP1L	CORS3, FTM, JBTS7, KIAA1005, MKS5, NPHP8, PPP1R134	ENSG00000103494	RPGRIP1 like	16	53597683-53703938	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039405, HPA040530	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:5.95e-4 (unfavourable), Breast cancer:6.93e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 27.9	parathyroid gland: 19.3	Expressed in all		
RPH3A	exophilin-1, KIAA0985, rabphilin	ENSG00000089169	Rabphilin 3A	12	112570380-112898881	Predicted intracellular proteins	Evidence at protein level	HPA002475	Enhanced					Tissue enriched	Tissue enriched	7	cerebral cortex: 95.2	bone marrow: 13.8	Cell line enhanced		SH-SY5Y: 17.7
RPH3AL	Noc2	ENSG00000181031	Rabphilin 3A-like (without C2 domains)	17	212389-386254	Predicted intracellular proteins	Evidence at protein level	HPA024311	Approved				Renal cancer:1.03e-8 (favourable)	Mixed	Mixed			spleen: 11.8	Cell line enhanced		A549: 19.6
RPIA		ENSG00000153574	Ribose 5-phosphate isomerase A	2	88691644-88750935	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042620	Approved				Renal cancer:8.53e-6 (unfavourable), Liver cancer:1.46e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 54.2	Expressed in all		
RPL10	DXS648, DXS648E, FLJ23544, L10, NOV, QM	ENSG00000147403	Ribosomal protein L10	X	154389955-154409168	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB010339, HPA011311	Enhanced		Enhanced	Endoplasmic reticulum<br>Cytosol	Renal cancer:7.67e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 9682.7	Expressed in all		
RPL10A	Csa-19, L10A, NEDD6	ENSG00000198755	Ribosomal protein L10a	6	35468408-35470785	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA053803	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:3.77e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3924.2	Expressed in all		
RPL10L		ENSG00000165496	Ribosomal protein L10 like	14	46651010-46651821	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA011311	Uncertain		Approved	Endoplasmic reticulum<br>Cytosol		Tissue enriched	Tissue enriched	45	testis: 127.0	rectum: 2.8	Cell line enriched	54	U-2 OS: 40.6
RPL11	L11	ENSG00000142676	Ribosomal protein L11	1	23691779-23696425	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA002734, HPA074839	Approved		Approved	Vesicles	Renal cancer:5.93e-6 (unfavourable), Breast cancer:2.55e-4 (favourable)	Expressed in all	Expressed in all			ovary: 4915.9	Expressed in all		
RPL12	L12	ENSG00000197958	Ribosomal protein L12	9	127447674-127451405	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003403	Approved		Approved	Golgi apparatus	Renal cancer:7.42e-7 (unfavourable), Head and neck cancer:5.66e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3674.5	Expressed in all		
RPL13	BBC1, D16S444E, L13	ENSG00000167526	Ribosomal protein L13	16	89560657-89566828	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA051702	Approved		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Endometrial cancer:6.26e-4 (favourable), Renal cancer:6.64e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3872.9	Expressed in all		
RPL13A	L13A, TSTA1	ENSG00000142541	Ribosomal protein L13a	19	49487554-49492308	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA038751	Approved		Approved	Nucleoli<br>Cytosol	Renal cancer:1.44e-5 (unfavourable), Liver cancer:9.97e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 4609.7	Expressed in all		
RPL14	CTG-B33, hRL14, L14, RL14	ENSG00000188846	Ribosomal protein L14	3	40457292-40468587	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA004136	Approved		Supported	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			breast: 312.8	Expressed in all		
RPL15	EC45, L15, RPL10, RPLY10, RPYL10	ENSG00000174748	Ribosomal protein L15	3	23916545-23923692	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level							Expressed in all	Expressed in all			ovary: 3477.9	Expressed in all		
RPL17	L17, rpL23	ENSG00000265681	Ribosomal protein L17	18	49488453-49492523	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043724, HPA046385	Supported		Supported	Endoplasmic reticulum<br>Cytosol	Liver cancer:3.60e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 4394.8	Expressed in all		
RPL17-C18orf32		ENSG00000215472	RPL17-C18orf32 readthrough	18	49481681-49492479	Predicted intracellular proteins	Evidence at protein level	HPA043724, HPA046385	Approved		Supported	Endoplasmic reticulum<br>Cytosol		Not detected	Expressed in all			cerebral cortex: 66.2	Mixed		
RPL18	L18	ENSG00000063177	Ribosomal protein L18	19	48615328-48619536	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046572	Approved		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:1.21e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2572.0	Expressed in all		
RPL18A	L18A	ENSG00000105640	Ribosomal protein L18a	19	17859876-17864153	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055259	Approved		Approved	Nucleoli<br>Cytosol	Renal cancer:1.48e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3084.5	Expressed in all		
RPL19	DKFZp779D216, FLJ27452, L19, MGC71997	ENSG00000108298	Ribosomal protein L19	17	39200283-39204727	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043014, HPA051987	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:6.87e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 4350.4	Cell line enriched	6	SK-BR-3: 28538.8
RPL21	DKFZp686C06101, FLJ27458, L21, MGC104274, MGC104275, MGC71252	ENSG00000122026	Ribosomal protein L21	13	27251309-27256691	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047252	Approved		Supported	Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol	Melanoma:6.66e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2382.8	Expressed in all		
RPL22	EAP, L22	ENSG00000116251	Ribosomal protein L22	1	6181269-6209389	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA068294			Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			ovary: 1343.4	Expressed in all		
RPL22L1		ENSG00000163584	Ribosomal protein L22 like 1	3	170864875-170870483	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA048060, HPA056207, HPA068294	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:5.13e-12 (unfavourable), Ovarian cancer:8.60e-5 (favourable)	Expressed in all	Expressed in all			appendix: 87.1	Expressed in all		
RPL23	L23, rpL17	ENSG00000125691	Ribosomal protein L23	17	38847865-38853843	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003373	Approved		Supported	Cytosol	Renal cancer:4.19e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 4496.9	Expressed in all		
RPL23A	L23A	ENSG00000198242	Ribosomal protein L23a	17	28719393-28724359	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA051754	Approved				Renal cancer:5.16e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 2755.0	Expressed in all		
RPL24	L24	ENSG00000114391	Ribosomal protein L24	3	101681091-101686782	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA051653	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.72e-5 (unfavourable), Thyroid cancer:8.25e-4 (favourable)	Expressed in all	Expressed in all			ovary: 2893.2	Expressed in all		
RPL26	L26	ENSG00000161970	Ribosomal protein L26	17	8377520-8383213	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA030449, CAB037301	Supported		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			breast: 5194.8	Expressed in all		
RPL26L1	RPL26P1	ENSG00000037241	Ribosomal protein L26 like 1	5	172958729-172969771	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA030449	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Head and neck cancer:2.49e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 124.9	Expressed in all		
RPL27	L27	ENSG00000131469	Ribosomal protein L27	17	42998273-43002959	Cancer-related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA002649	Approved				Renal cancer:7.80e-8 (unfavourable)	Expressed in all	Expressed in all			breast: 2437.8	Expressed in all		
RPL27A	L27A	ENSG00000166441	Ribosomal protein L27a	11	8682411-8714759	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA060776, HPA063379	Supported		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.83e-10 (unfavourable), Breast cancer:7.84e-5 (favourable)	Expressed in all	Expressed in all			lymph node: 2813.8	Expressed in all		
RPL28	FLJ43307, L28	ENSG00000108107	Ribosomal protein L28	19	55385345-55403250	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050459	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:6.61e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 1969.2	Expressed in all		
RPL29	HIP, HUMRPL29, L29, RPL29P10	ENSG00000162244	Ribosomal protein L29	3	51993600-51995942	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA069064	Approved		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 2738.5	Expressed in all		
RPL30	L30	ENSG00000156482	Ribosomal protein L30	8	98024851-98046469	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA002651	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.41e-9 (unfavourable)	Expressed in all	Expressed in all			ovary: 5911.7	Expressed in all		
RPL31	L31	ENSG00000071082	Ribosomal protein L31	2	101001715-101024032	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA072263	Approved				Renal cancer:8.08e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 5539.1	Expressed in all		
RPL32	L32	ENSG00000144713	Ribosomal protein L32	3	12834485-12841588	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047501, HPA051994	Enhanced		Approved	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 4513.7	Expressed in all		
RPL34	L34	ENSG00000109475	Ribosomal protein L34	4	108620566-108630412	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA035139	Uncertain		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Endometrial cancer:2.76e-5 (favourable)	Expressed in all	Expressed in all			breast: 4622.0	Expressed in all		
RPL35	L35	ENSG00000136942	Ribosomal protein L35	9	124857880-124861981	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA006047	Approved		Approved	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 2747.0	Expressed in all		
RPL35A	L35A	ENSG00000182899	Ribosomal protein L35a	3	197949987-197956610	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level						Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.43e-4 (unfavourable), Liver cancer:9.89e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2041.8	Expressed in all		
RPL36	DKFZp566B023, L36	ENSG00000130255	Ribosomal protein L36	19	5674947-5691876	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047153	Supported		Uncertain	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.32e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2363.0	Expressed in all		
RPL36A	L36A, RPL44	ENSG00000241343	Ribosomal protein L36a	X	101390824-101396154	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA063979, HPA077586	Uncertain		Supported	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:8.81e-11 (unfavourable)	Expressed in all	Expressed in all			ovary: 3453.0	Expressed in all		
RPL36A-HNRNPH2		ENSG00000257529	RPL36A-HNRNPH2 readthrough	X	101391011-101412297	Predicted intracellular proteins	Evidence at transcript level	HPA077586			Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol		Not detected	Mixed			ovary: 2.6	Cell line enhanced		BJ: 10.0
RPL36AL	RPL36A	ENSG00000165502	Ribosomal protein L36a like	14	49618519-49620685	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA077586			Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Thyroid cancer:2.83e-4 (favourable)	Expressed in all	Expressed in all			ovary: 529.4	Expressed in all		
RPL37	L37	ENSG00000145592	Ribosomal protein L37	5	40825262-40835335	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level						Renal cancer:2.67e-6 (unfavourable), Urothelial cancer:6.34e-4 (favourable)	Expressed in all	Expressed in all			breast: 925.8	Expressed in all		
RPL37A	L37A	ENSG00000197756	Ribosomal protein L37a	2	216498189-216579180	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA065327	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.14e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 4523.8	Expressed in all		
RPL38	L38	ENSG00000172809	Ribosomal protein L38	17	74203582-74210655	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA052543	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:6.17e-8 (unfavourable), Head and neck cancer:2.51e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2584.8	Expressed in all		
RPL39	L39, RPL39P42	ENSG00000198918	Ribosomal protein L39	X	119786504-119791643	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047105	Uncertain				Renal cancer:1.71e-9 (unfavourable)	Expressed in all	Expressed in all			breast: 5369.7	Expressed in all		
RPL39L	RPL39L1	ENSG00000163923	Ribosomal protein L39 like	3	187120948-187180908	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047105	Approved				Glioma:9.50e-7 (unfavourable), Ovarian cancer:1.94e-4 (favourable), Endometrial cancer:6.05e-4 (unfavourable)	Expressed in all	Tissue enriched	15	testis: 220.3	breast: 14.6	Mixed		
RPL3L		ENSG00000140986	Ribosomal protein L3 like	16	1943974-1957606	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA049136	Enhanced		Approved	Nuclear speckles		Mixed	Tissue enriched	5	skeletal muscle: 323.9	heart muscle: 61.3	Cell line enhanced		CACO-2: 3.3
RPL4	L4	ENSG00000174444	Ribosomal protein L4	15	66498015-66524532	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA034600	Uncertain		Supported	Nucleoli<br>Nuclear bodies<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:5.20e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 3692.5	Expressed in all		
RPL41	L41	ENSG00000229117	Ribosomal protein L41	12	56116586-56117943	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA053169	Approved					Expressed in all	Expressed in all			ovary: 10643.4	Expressed in all		
RPL5	L5, PPP1R135	ENSG00000122406	Ribosomal protein L5	1	92832025-92841924	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043717, HPA054444	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:6.81e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 4042.9	Expressed in all		
RPL6	L6, TAXREB107, TXREB1	ENSG00000089009	Ribosomal protein L6	12	112405190-112418838	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA060903, HPA068418	Approved		Approved	Microtubules<br>Cytokinetic bridge	Renal cancer:6.95e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3221.7	Expressed in all		
RPL7	humL7-1, L7	ENSG00000147604	Ribosomal protein L7	8	73290267-73295789	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA058373	Approved		Approved	Nucleoli<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 5525.6	Expressed in all		
RPL7A	L7A, SURF3, TRUP	ENSG00000148303	Ribosomal protein L7a	9	133348214-133351426	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046794			Approved	Nucleoli<br>Vesicles	Ovarian cancer:3.60e-5 (unfavourable), Liver cancer:8.99e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2618.0	Expressed in all		
RPL7L1	dJ475N16.4	ENSG00000146223	Ribosomal protein L7 like 1	6	42879618-42889925	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046049, HPA050478			Approved	Nucleoli<br>Mitochondria	Liver cancer:8.53e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 71.5	Expressed in all		
RPL8	L8	ENSG00000161016	Ribosomal protein L8	8	144789765-144792587	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA045095, HPA050165	Enhanced		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Liver cancer:7.22e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 954.7	Expressed in all		
RPL9	L9	ENSG00000163682	Ribosomal protein L9	4	39454124-39458948	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003372	Approved	Approved	Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:7.34e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 2710.2	Expressed in all		
RPLP0	L10E, LP0, P0, PRLP0, RPP0	ENSG00000089157	Ribosomal protein lateral stalk subunit P0	12	120196686-120201235	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003512	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:7.66e-12 (unfavourable)	Expressed in all	Expressed in all			breast: 2860.7	Expressed in all		
RPLP1	LP1	ENSG00000137818	Ribosomal protein lateral stalk subunit P1	15	69452784-69456194	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003368			Enhanced	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.30e-9 (unfavourable)	Expressed in all	Expressed in all			ovary: 1840.0	Expressed in all		
RPP14	P14	ENSG00000163684	Ribonuclease P/MRP subunit p14	3	58306247-58324695	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036194	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.07e-10 (favourable), Thyroid cancer:2.96e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 21.1	Expressed in all		
RPP21	C6orf135, Em:AB014085.3, FLJ22638	ENSG00000241370	Ribonuclease P/MRP subunit p21	6	30345131-30346884	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.04e-5 (unfavourable), Urothelial cancer:6.78e-5 (favourable)	Expressed in all	Mixed			skin: 16.1	Cell line enhanced		HEK93: 51.3;SCLC-21H: 53.7
RPP25	FLJ20374	ENSG00000178718	Ribonuclease P and MRP subunit p25	15	74954416-74957464	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046900	Approved		Supported	Nucleoplasm<br>Microtubule organizing center	Glioma:3.67e-5 (unfavourable)	Expressed in all	Mixed			ovary: 12.2	Cell line enhanced		SCLC-21H: 38.4;SK-MEL-30: 39.1
RPP25L	bA296L22.5, C9orf23, MGC29635	ENSG00000164967	Ribonuclease P/MRP subunit p25 like	9	34610486-34612104	Predicted intracellular proteins	Evidence at protein level	HPA052187, HPA059698	Uncertain		Supported	Nucleus	Renal cancer:3.01e-9 (favourable), Urothelial cancer:8.21e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 38.7	Expressed in all		
RPP30	TSG15	ENSG00000148688	Ribonuclease P/MRP subunit p30	10	90871716-90908553	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037578	Enhanced		Approved	Nucleus<br>Nucleoli<br>Microtubule ends<br>Cytosol	Renal cancer:1.01e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 50.5	Expressed in all		
RPP38		ENSG00000152464	Ribonuclease P/MRP subunit p38	10	15097180-15139818	Enzymes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA045128, HPA050398	Approved		Supported	Nucleoli	Urothelial cancer:2.89e-6 (favourable), Liver cancer:1.46e-4 (unfavourable), Renal cancer:6.25e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 76.3	Expressed in all		
RPP40	bA428J1.3, RNASEP1	ENSG00000124787	Ribonuclease P/MRP subunit p40	6	4994732-5004063	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035685, HPA035686	Uncertain		Approved	Nucleoplasm	Renal cancer:7.54e-8 (unfavourable), Endometrial cancer:6.10e-6 (unfavourable), Liver cancer:5.41e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 11.9	Expressed in all		
RPRD1A	FLJ10656, HsT3101, P15RS	ENSG00000141425	Regulation of nuclear pre-mRNA domain containing 1A	18	35984387-36067576	Predicted intracellular proteins	Evidence at protein level	HPA040602	Supported		Supported	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			epididymis: 140.2	Expressed in all		
RPRD1B	C20orf77, CREPT, dJ1057B20.2, DKFZp434P0735, FLJ44520, NET60	ENSG00000101413	Regulation of nuclear pre-mRNA domain containing 1B	20	38033546-38127780	Predicted intracellular proteins	Evidence at protein level	HPA066290	Supported		Supported	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 29.6	Expressed in all		
RPRD2	FLJ32145, HSPC099, KIAA0460	ENSG00000163125	Regulation of nuclear pre-mRNA domain containing 2	1	150363091-150476566	Predicted intracellular proteins	Evidence at protein level	HPA061693	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 38.5	Expressed in all		
RPS10	MGC88819, S10	ENSG00000124614	Ribosomal protein S10	6	34417454-34426125	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047268, HPA048084	Approved		Approved	Cytosol	Renal cancer:2.57e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 2704.4	Expressed in all		
RPS10-NUDT3		ENSG00000270800	RPS10-NUDT3 readthrough	6	34284887-34426071	Predicted intracellular proteins	Evidence at protein level	HPA047027, HPA047268, HPA048084, HPA055953	Uncertain		Approved	Cytosol		Not detected	Mixed			testis: 11.1	Expressed in all		
RPS11	S11	ENSG00000142534	Ribosomal protein S11	19	49496365-49499689	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA049719	Uncertain		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:3.50e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 6662.2	Expressed in all		
RPS12	S12	ENSG00000112306	Ribosomal protein S12	6	132814441-132817564	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA006124, HPA006365	Approved		Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Renal cancer:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3959.0	Expressed in all		
RPS13	S13	ENSG00000110700	Ribosomal protein S13	11	17074389-17077787	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA005985	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:1.54e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2365.9	Expressed in all		
RPS14	EMTB, S14	ENSG00000164587	Ribosomal protein S14	5	150443190-150449756	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA018504	Uncertain		Enhanced	Endoplasmic reticulum<br>Cytosol	Liver cancer:7.73e-4 (unfavourable), Renal cancer:8.69e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 1992.0	Expressed in all		
RPS15	MGC111130, RIG, S15	ENSG00000115268	Ribosomal protein S15	19	1438358-1440494	Cancer-related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA054510, HPA057793	Enhanced		Approved	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 1335.2	Expressed in all		
RPS16	S16	ENSG00000105193	Ribosomal protein S16	19	39433207-39435948	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA064222	Approved		Enhanced	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 3703.7	Expressed in all		
RPS17	MGC72007, RPS17L, RPS17L1, RPS17L2, S17	ENSG00000182774	Ribosomal protein S17	15	82536753-82540564	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055060	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:1.78e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 1572.3	Expressed in all		
RPS18	D6S218E, HKE3, KE-3, KE3, S18	ENSG00000231500	Ribosomal protein S18	6	33272010-33276510	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050159, HPA055007	Approved		Supported	Cytosol	Renal cancer:1.15e-10 (unfavourable), Breast cancer:9.81e-4 (favourable)	Expressed in all	Expressed in all			ovary: 1305.1	Expressed in all		
RPS19	DBA, S19	ENSG00000105372	Ribosomal protein S19	19	41859918-41872926	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA063217			Supported	Nucleoplasm	Renal cancer:2.32e-8 (unfavourable)	Expressed in all	Expressed in all			ovary: 3251.4	Expressed in all		
RPS19BP1	FLJ21770, MGC52010	ENSG00000187051	Ribosomal protein S19 binding protein 1	22	39529093-39532855	Predicted intracellular proteins	Evidence at protein level	HPA042874	Uncertain		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:3.71e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 57.2	Expressed in all		
RPS2	LLREP3, S2	ENSG00000140988	Ribosomal protein S2	16	1962052-1964860	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055133	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:3.04e-7 (unfavourable), Liver cancer:7.70e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3063.2	Expressed in all		
RPS20	S20	ENSG00000008988	Ribosomal protein S20	8	56067295-56074581	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003570	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.21e-8 (unfavourable)	Expressed in all	Expressed in all			ovary: 4364.3	Expressed in all		
RPS21	S21	ENSG00000171858	Ribosomal protein S21	20	62387116-62388520	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003371	Approved		Enhanced	Endoplasmic reticulum<br>Cytosol	Liver cancer:8.46e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2356.2	Expressed in all		
RPS23	S23	ENSG00000186468	Ribosomal protein S23	5	82273358-82278577	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA054853	Approved		Enhanced	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.17e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 4322.3	Expressed in all		
RPS24	S24	ENSG00000138326	Ribosomal protein S24	10	78033760-78056812	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003364	Approved		Approved	Nuclear bodies<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:1.10e-10 (unfavourable), Breast cancer:1.50e-4 (favourable)	Expressed in all	Expressed in all			ovary: 6825.3	Expressed in all		
RPS25	S25	ENSG00000118181	Ribosomal protein S25	11	119015712-119018691	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA031801	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:3.00e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 945.5	Expressed in all		
RPS26	S26	ENSG00000197728	Ribosomal protein S26	12	56041853-56044675	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043961, HPA055803	Uncertain		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 824.8	Expressed in all		
RPS27	MPS-1, MPS1, S27	ENSG00000177954	Ribosomal protein S27	1	153990759-153992150	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA066851			Approved	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:4.86e-7 (unfavourable), Breast cancer:9.69e-4 (favourable)	Expressed in all	Expressed in all			ovary: 12000.9	Expressed in all		
RPS27A	S27A, Uba80, UBCEP80	ENSG00000143947	Ribosomal protein S27a	2	55231903-55235853	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB033319, HPA041344, HPA049132, HPA054087	Supported		Approved	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:2.60e-6 (unfavourable), Liver cancer:2.26e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3413.3	Expressed in all		
RPS28	S28	ENSG00000233927	Ribosomal protein S28	19	8321158-8323340	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047132	Approved		Approved	Cytosol	Endometrial cancer:2.47e-4 (favourable)	Expressed in all	Expressed in all			ovary: 306.5	Expressed in all		
RPS29	S29	ENSG00000213741	Ribosomal protein S29	14	49570984-49599164	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA004107	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Breast cancer:2.66e-4 (favourable)	Expressed in all	Expressed in all			breast: 3653.3	Expressed in all		
RPS3	FLJ26283, FLJ27450, MGC87870, S3	ENSG00000149273	Ribosomal protein S3	11	75399486-75422280	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA063339	Uncertain		Enhanced	Endoplasmic reticulum<br>Cytosol	Renal cancer:6.92e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 3537.9	Expressed in all		
RPS3A	MFTL, S3A	ENSG00000145425	Ribosomal protein S3A	4	151099573-151104652	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047100, HPA053454	Approved		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Liver cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 5260.9	Expressed in all		
RPS4X	CCG2, DXS306, FLJ40595, RPS4, S4, SCAR, SCR10	ENSG00000198034	Ribosomal protein S4, X-linked	X	72255679-72277300	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA000857	Supported				Renal cancer:4.50e-6 (unfavourable), Thyroid cancer:4.22e-4 (favourable)	Expressed in all	Expressed in all			ovary: 1948.7	Expressed in all		
RPS4Y1	MGC119100, MGC5070, RPS4Y, S4	ENSG00000129824	Ribosomal protein S4, Y-linked 1	Y	2841486-2932000	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA000857	Approved					Mixed	Mixed			prostate: 403.7	Cell line enhanced		U-698: 1166.0
RPS4Y2	RPS4Y2P	ENSG00000280969	Ribosomal protein S4, Y-linked 2	Y	20756164-20781032	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA000857	Uncertain					Tissue enriched	Group enriched	13	prostate: 3.5;testis: 2.2	tonsil: 0.2	Cell line enriched	7	U-266/84: 1.3
RPS5	S5	ENSG00000083845	Ribosomal protein S5	19	58386400-58394806	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055878, HPA061979	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Liver cancer:1.12e-5 (unfavourable), Renal cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2648.9	Expressed in all		
RPS6	S6	ENSG00000137154	Ribosomal protein S6	9	19375715-19380254	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB004027, HPA031153	Supported		Enhanced	Endoplasmic reticulum<br>Cytosol	Endometrial cancer:4.12e-4 (favourable)	Expressed in all	Expressed in all			ovary: 4805.4	Expressed in all		
RPS6KA1	HU-1, p90Rsk, RSK, RSK1	ENSG00000117676	Ribosomal protein S6 kinase A1	1	26529761-26575030	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003852, HPA007981	Enhanced		Supported	Nucleus<br>Cytosol	Endometrial cancer:7.20e-7 (favourable), Renal cancer:1.84e-4 (favourable), Stomach cancer:4.58e-4 (favourable), Urothelial cancer:8.33e-4 (favourable)	Expressed in all	Mixed			small intestine: 38.9	Mixed		
RPS6KA2	HU-2, RSK, RSK3	ENSG00000071242	Ribosomal protein S6 kinase A2	6	166409364-166906451	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB026243, HPA045061, HPA054237, CAB069428	Approved		Supported	Nucleoplasm	Renal cancer:2.86e-5 (favourable), Ovarian cancer:8.63e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.4	Cell line enhanced		ASC diff: 147.2;HHSteC: 133.3;hTERT-HME1: 133.1
RPS6KA3	CLS, HU-3, MRX19, RSK, RSK2	ENSG00000177189	Ribosomal protein S6 kinase A3	X	20149911-20267100	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003221, CAB003853, CAB013520	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 92.7	Mixed		
RPS6KA4	MSK2, RSK-B	ENSG00000162302	Ribosomal protein S6 kinase A4	11	64359148-64372215	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008649, HPA023225	Approved		Supported	Nucleus<br>Cytosol	Liver cancer:8.17e-4 (unfavourable), Lung cancer:9.27e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 23.1	Expressed in all		
RPS6KA5	MSK1, RLPK	ENSG00000100784	Ribosomal protein S6 kinase A5	14	90847862-91060636	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001274, HPA001780, CAB025458	Approved		Enhanced	Nucleoplasm		Mixed	Mixed			breast: 12.1	Cell line enhanced		HMC-1: 40.2
RPS6KA6	RSK4	ENSG00000072133	Ribosomal protein S6 kinase A6	X	84058346-84187907	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002852, HPA003904	Uncertain		Supported	Nucleus<br>Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		parathyroid gland: 18.9;thyroid gland: 21.9	kidney: 8.9	Cell line enhanced		PC-3: 13.7;RH-30: 17.3;SH-SY5Y: 15.2
RPS6KB1	p70(S6K)-alpha, PS6K, S6K1, STK14A	ENSG00000108443	Ribosomal protein S6 kinase B1	17	59893046-59950564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003838, CAB018346, HPA039442	Approved		Supported	Nucleoplasm	Renal cancer:5.09e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.3	Expressed in all		
RPS6KB2	KLS, P70-BETA, p70S6Kb, STK14B	ENSG00000175634	Ribosomal protein S6 kinase B2	11	67428460-67435408	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010010, CAB019404	Approved		Supported	Cytosol	Renal cancer:2.03e-7 (unfavourable)	Expressed in all	Expressed in all			skin: 65.3	Expressed in all		
RPS6KC1	humS6PKh1	ENSG00000136643	Ribosomal protein S6 kinase C1	1	213051233-213274773	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026531, HPA031565	Approved		Enhanced	Endosomes<br>Lysosomes<br>Cytosol	Renal cancer:2.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.4	Expressed in all		
RPS6KL1	MGC11287	ENSG00000198208	Ribosomal protein S6 kinase like 1	14	74903954-74923396	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA027451, HPA027794	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		cerebral cortex: 31.4	testis: 14.7	Cell line enhanced		SCLC-21H: 41.7
RPS7	S7	ENSG00000171863	Ribosomal protein S7	2	3575205-3580919	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA056586	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.34e-8 (unfavourable), Liver cancer:5.27e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2616.2	Expressed in all		
RPS8	S8	ENSG00000142937	Ribosomal protein S8	1	44775251-44778779	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA029266			Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:9.05e-9 (unfavourable), Liver cancer:2.36e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 5543.6	Expressed in all		
RPS9	S9	ENSG00000170889	Ribosomal protein S9	19	54200742-54249003	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA048746	Approved				Renal cancer:1.63e-4 (unfavourable), Breast cancer:9.23e-4 (favourable)	Expressed in all	Expressed in all			ovary: 112.4	Expressed in all		
RPSA	37LRP, LAMR1, LRP, p40, SA	ENSG00000168028	Ribosomal protein SA	3	39406689-39412542	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB009561	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			ovary: 2084.6	Expressed in all		
RPTN	FLJ39117	ENSG00000215853	Repetin	1	152153595-152159228	Predicted intracellular proteins	Evidence at protein level	HPA030483, HPA030485	Enhanced					Tissue enhanced	Group enriched	34	skin: 35.1;tonsil: 47.4	esophagus: 1.2	Not detected		
RPUSD1	C16orf40, MGC19600, RLUCL	ENSG00000007376	RNA pseudouridylate synthase domain containing 1	16	784974-788397	Predicted intracellular proteins	Evidence at protein level	HPA041144, HPA041938	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			appendix: 13.0	Expressed in all		
RPUSD2	C15orf19, C18B11, FLJ31409	ENSG00000166133	RNA pseudouridylate synthase domain containing 2	15	40569300-40574943	Predicted intracellular proteins	Evidence at protein level	HPA042079, HPA042194	Approved		Approved	Nucleoplasm<br>Microtubules	Renal cancer:7.63e-7 (favourable)	Expressed in all	Mixed			lymph node: 7.7	Expressed in all		
RPUSD3	MGC29784	ENSG00000156990	RNA pseudouridylate synthase domain containing 3	3	9837849-9844602	Predicted intracellular proteins	Evidence at protein level	HPA037551, HPA037552	Uncertain		Approved	Nucleus	Liver cancer:1.73e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 54.0	Expressed in all		
RPUSD4	FLJ14494	ENSG00000165526	RNA pseudouridylate synthase domain containing 4	11	126202094-126211692	Predicted intracellular proteins	Evidence at protein level	HPA039689	Approved		Approved	Nucleoplasm<br>Mitochondria	Liver cancer:1.24e-4 (unfavourable), Colorectal cancer:6.14e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 44.9	Expressed in all		
RRAD	RAD, REM3	ENSG00000166592	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	16	66921679-66925644	Predicted intracellular proteins	Evidence at protein level	HPA041755	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane		Expressed in all	Tissue enhanced		heart muscle: 98.8;skeletal muscle: 67.5	esophagus: 62.8	Group enriched	8	HDLM-2: 166.9;U-87 MG: 48.4
RRAGA	FIP-1, RAGA	ENSG00000155876	Ras related GTP binding A	9	19049395-19050983	Predicted intracellular proteins	Evidence at protein level	HPA003734	Supported		Approved	Golgi apparatus<br>Vesicles	Head and neck cancer:7.43e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 128.1	Expressed in all		
RRAGB		ENSG00000083750	Ras related GTP binding B	X	55717739-55758774	Predicted intracellular proteins	Evidence at protein level	HPA003734	Approved		Approved	Golgi apparatus<br>Vesicles	Lung cancer:3.64e-6 (favourable), Glioma:5.36e-5 (favourable), Colorectal cancer:7.60e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 42.3	Expressed in all		
RRAGC	FLJ13311, GTR2	ENSG00000116954	Ras related GTP binding C	1	38838198-38859823	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018247, HPA055489	Enhanced		Supported	Nucleus<br>Vesicles	Liver cancer:9.97e-9 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 40.4	Expressed in all		
RRAGD	bA11D8.2.1, DKFZP761H171	ENSG00000025039	Ras related GTP binding D	6	89364636-89412270	Predicted intracellular proteins	Evidence at protein level	HPA068664	Approved		Approved	Nucleoplasm<br>Centrosome	Renal cancer:8.47e-8 (favourable), Liver cancer:7.80e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 46.8	Cell line enhanced		Karpas-707: 45.9;SCLC-21H: 39.1;U-266/70: 61.2
RRAS		ENSG00000126458	Related RAS viral (r-ras) oncogene homolog	19	49635292-49640201	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010160, HPA060364, CAB069439	Uncertain		Approved	Vesicles	Renal cancer:1.54e-9 (unfavourable), Glioma:6.03e-5 (unfavourable), Lung cancer:5.28e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 209.2	Mixed		
RRAS2	TC21	ENSG00000133818	Related RAS viral (r-ras) oncogene homolog 2	11	14277926-14364506	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010420, HPA050942	Approved		Approved	Nucleus<br>Cytosol	Pancreatic cancer:2.44e-4 (unfavourable), Liver cancer:3.31e-4 (unfavourable), Head and neck cancer:7.80e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.3	Mixed		
RREB1	HNT	ENSG00000124782	Ras responsive element binding protein 1	6	7107597-7251980	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001756, HPA034843	Approved		Supported	Nucleoli fibrillar center<br>Nuclear speckles	Renal cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Mixed		
RRM1		ENSG00000167325	Ribonucleotide reductase catalytic subunit M1	11	4094707-4138876	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022093, HPA057265, HPA064297	Enhanced		Enhanced	Cytosol	Liver cancer:1.53e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 60.4	Expressed in all		
RRN3	DKFZp566E104, TIF-IA	ENSG00000085721	RRN3 homolog, RNA polymerase I transcription factor	16	15060022-15094317	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049837	Supported		Enhanced	Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 22.3	Expressed in all		
RRP1	D21S2056E, NNP-1, Nop52, RRP1A	ENSG00000160214	Ribosomal RNA processing 1	21	43789513-43805293	Predicted intracellular proteins	Evidence at protein level	HPA016818, HPA018166	Approved		Enhanced	Nucleoli	Renal cancer:6.29e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 12.1	Expressed in all		
RRP15	CGI-115, KIAA0507	ENSG00000067533	Ribosomal RNA processing 15 homolog	1	218285287-218337983	Predicted intracellular proteins	Evidence at protein level	HPA024639	Approved		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Liver cancer:4.26e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 7.7	Expressed in all		
RRP1B	KIAA0179, Nnp1, PPP1R136, RRP1	ENSG00000160208	Ribosomal RNA processing 1B	21	43659548-43696079	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017893, HPA020324	Supported		Enhanced	Nucleoli	Renal cancer:2.95e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 21.7	Expressed in all		
RRP36	C6orf153, dJ20C7.4	ENSG00000124541	Ribosomal RNA processing 36	6	43021645-43034156	Predicted intracellular proteins	Evidence at protein level	HPA029904, HPA029905	Uncertain		Supported	Nucleus<br>Nucleoli	Renal cancer:2.48e-5 (unfavourable), Liver cancer:5.95e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
RRP7A	CGI-96	ENSG00000189306	Ribosomal RNA processing 7 homolog A	22	42509968-42519802	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001586, HPA046768	Approved		Approved	Nucleus<br>Nucleoli<br>Cell Junctions	Liver cancer:1.21e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 47.3	Expressed in all		
RRP8	KIAA0409, NML	ENSG00000132275	Ribosomal RNA processing 8, methyltransferase, homolog (yeast)	11	6595075-6603620	Predicted intracellular proteins	Evidence at protein level	HPA038487, HPA057562	Supported		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:3.10e-7 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 12.4	Expressed in all		
RRP9	RNU3IP2, U3-55K	ENSG00000114767	Ribosomal RNA processing 9, small subunit (SSU) processome component, homolog (yeast)	3	51933430-51941941	Predicted intracellular proteins	Evidence at protein level	HPA038798	Uncertain		Supported	Nucleus	Liver cancer:2.90e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 18.9	Expressed in all		
RRS1	KIAA0112	ENSG00000179041	Ribosome biogenesis regulator homolog	8	66429028-66430733	Predicted intracellular proteins	Evidence at protein level	HPA055549, HPA060937	Approved		Enhanced	Nucleoli		Expressed in all	Expressed in all			appendix: 16.3	Expressed in all		
RSAD1	FLJ11164	ENSG00000136444	Radical S-adenosyl methionine domain containing 1	17	50478800-50485975	Predicted intracellular proteins	Evidence at protein level	HPA022436, HPA022967	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:5.04e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.7	Expressed in all		
RSAD2	cig5, vig1, viperin	ENSG00000134321	Radical S-adenosyl methionine domain containing 2	2	6865806-6898239	Predicted intracellular proteins	Evidence at protein level	HPA041160, HPA049409	Approved		Supported	Nucleoli fibrillar center<br>Endoplasmic reticulum	Endometrial cancer:4.60e-4 (unfavourable)	Expressed in all	Mixed			spleen: 17.6	Cell line enhanced		BJ hTERT+ SV40 Large T+: 75.1;BJ hTERT+ SV40 Large T+ RasG12V: 120.3;HMC-1: 51.2
RSBN1	FLJ11220, ROSBIN	ENSG00000081019	Round spermatid basic protein 1	1	113761832-113812476	Predicted intracellular proteins	Evidence at protein level	HPA042124, HPA049484	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 22.0	Expressed in all		
RSBN1L	FLJ42526, FLJ45813, MGC71764	ENSG00000187257	Round spermatid basic protein 1 like	7	77696443-77783022	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA020406, HPA020413	Approved		Supported	Nuclear speckles<br>Plasma membrane	Lung cancer:3.74e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.7	Expressed in all		
RSC1A1	RS1	ENSG00000215695	Regulator of solute carriers 1	1	15659869-15661722	Predicted intracellular proteins	Evidence at protein level	HPA027813, HPA028676	Approved		Supported	Nucleoplasm<br>Cell Junctions		Not detected	Mixed			smooth muscle: 5.3	Mixed		
RSG1	C1orf89, MGC10731	ENSG00000132881	REM2 and RAB like small GTPase 1	1	16231700-16237162	Predicted intracellular proteins	Evidence at protein level	HPA028453, HPA041672	Approved		Enhanced	Nucleoplasm	Renal cancer:1.36e-10 (favourable)	Expressed in all	Mixed			fallopian tube: 11.0	Mixed		
RSL1D1	CSIG, DKFZP564M182, L12, PBK1, UTP30	ENSG00000171490	Ribosomal L1 domain containing 1	16	11833850-11851585	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043483	Supported		Enhanced	Nucleoli	Liver cancer:1.38e-4 (unfavourable), Head and neck cancer:2.95e-4 (unfavourable), Renal cancer:3.24e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 145.4	Expressed in all		
RSL24D1	C15orf15, HRP-L30-iso, L30, RPL24, RPL24L	ENSG00000137876	Ribosomal L24 domain containing 1	15	55180806-55197067	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA062724, HPA063392	Enhanced		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			ovary: 124.4	Expressed in all		
RSPH1	CILD24, FLJ32753, RSP44, RSPH10A, TSGA2	ENSG00000160188	Radial spoke head 1 homolog	21	42472486-42496354	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA016816, HPA017382	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Tissue enriched	6	fallopian tube: 251.8	testis: 42.3	Cell line enhanced		HEL: 4.8;MCF7: 8.1;RPTEC TERT1: 11.5
RSPH10B		ENSG00000155026	Radial spoke head 10 homolog B	7	5925550-5970683	Predicted intracellular proteins	Evidence at protein level	HPA049182	Supported					Not detected	Group enriched	8	fallopian tube: 13.4;testis: 35.8	parathyroid gland: 3.0	Not detected		
RSPH10B2		ENSG00000169402	Radial spoke head 10 homolog B2	7	6754109-6799365	Predicted intracellular proteins	Evidence at protein level	HPA049182	Supported					Not detected	Group enriched	7	fallopian tube: 16.1;testis: 35.8	parathyroid gland: 3.6	Not detected		
RSPH14	RTDR1	ENSG00000100218	Radial spoke head 14 homolog	22	23059415-23145021	Predicted intracellular proteins	Evidence at protein level	HPA018420, HPA050425	Approved		Uncertain	Nucleoli	Renal cancer:4.04e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 18.3;testis: 29.1	kidney: 7.3	Cell line enhanced		RPTEC TERT1: 3.1;SCLC-21H: 3.2;U-266/70: 3.6
RSPH3	dJ111C20.1, RSHL2, RSP3	ENSG00000130363	Radial spoke 3 homolog	6	158972871-159000187	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039109, HPA040230	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:2.19e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 26.4	Mixed		
RSPH4A	CILD11, dJ412I7.1, FLJ37974, RSHL3, RSPH6B	ENSG00000111834	Radial spoke head 4 homolog A	6	116616479-116632985	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031196, HPA031197, HPA031198	Enhanced		Supported	Nucleus		Tissue enhanced	Tissue enriched	8	fallopian tube: 59.7	lung: 7.1	Cell line enhanced		RPMI-8226: 2.3;U-266/84: 1.7
RSPH6A	RSHL1, RSP4, RSP6, RSPH4B	ENSG00000104941	Radial spoke head 6 homolog A	19	45795710-45815319	Predicted intracellular proteins	Evidence at protein level	HPA045382	Enhanced					Tissue enriched	Tissue enriched	7	testis: 30.4	thyroid gland: 4.5	Cell line enriched	11	RPMI-8226: 1.9
RSPH9	C6orf206, CILD12, FLJ30845, MRPS18AL1	ENSG00000172426	Radial spoke head 9 homolog	6	43645046-43672599	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031703	Enhanced					Mixed	Group enriched	6	fallopian tube: 13.4;testis: 12.2	lung: 2.0	Cell line enhanced		U-87 MG: 2.1
RSRC1	BM-011, MGC12197, SFRS21, SRrp53	ENSG00000174891	Arginine and serine rich coiled-coil 1	3	158105855-158545730	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044792	Enhanced		Approved	Nuclear speckles	Endometrial cancer:7.40e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.0	Expressed in all		
RSRC2	FLJ11021	ENSG00000111011	Arginine and serine rich coiled-coil 2	12	122503458-122527000	Predicted intracellular proteins	Evidence at protein level	HPA040070, HPA048183	Uncertain		Enhanced	Nucleoli fibrillar center<br>Nuclear speckles<br>Cytosol	Liver cancer:2.05e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 42.5	Expressed in all		
RSRP1	C1orf63, DJ465N24.2.1	ENSG00000117616	Arginine and serine rich protein 1	1	25242237-25338213	Predicted intracellular proteins	Evidence at protein level	HPA058992, HPA067651	Uncertain		Approved	Nucleoplasm	Urothelial cancer:2.91e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 34.2	Mixed		
RSU1	FLJ31034, RSP-1	ENSG00000148484	Ras suppressor protein 1	10	16590611-16817528	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025927	Uncertain		Approved	Vesicles	Renal cancer:9.32e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 58.8	Expressed in all		
RTCA	RPC, RTC1, RTCD1	ENSG00000137996	RNA 3'-terminal phosphate cyclase	1	100266207-100292769	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027982, HPA027990, HPA028151	Uncertain		Enhanced	Nucleus	Liver cancer:2.76e-5 (unfavourable)	Expressed in all	Expressed in all			kidney: 35.8	Expressed in all		
RTCB	C22orf28, FAAP, HSPC117	ENSG00000100220	RNA 2',3'-cyclic phosphate and 5'-OH ligase	22	32387582-32412255	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000535, HPA001103	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:4.25e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 104.2	Expressed in all		
RTEL1	bK3184A7.3, C20orf41, DKFZP434C013, KIAA1088, NHL, RTEL	ENSG00000258366	Regulator of telomere elongation helicase 1	20	63657810-63696253	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020622, HPA067329, HPA078328			Approved	Nuclear speckles<br>Nuclear bodies		Not detected	Expressed in all			testis: 13.2	Expressed in all		
RTFDC1	C20orf43, CDAO5, HSPC164	ENSG00000022277	Replication termination factor 2 domain containing 1	20	56468585-56519449	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053986	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:1.31e-4 (unfavourable), Endometrial cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 140.4	Expressed in all		
RTKN	B5	ENSG00000114993	Rhotekin	2	74425836-74442422	Predicted intracellular proteins	Evidence at protein level	HPA030259	Approved		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Mixed			cerebral cortex: 56.0	Mixed		
RTKN2	bA531F24.1, Em:AC024597.2, FLJ39352, PLEKHK1	ENSG00000182010	Rhotekin 2	10	62183035-62268707	Predicted intracellular proteins	Evidence at protein level	HPA037946, HPA038446	Enhanced		Approved	Nucleoplasm<br>Mitochondria		Mixed	Tissue enriched	8	lung: 121.3	testis: 14.7	Cell line enhanced		A-431: 40.4
RTN4IP1	NIMP	ENSG00000130347	Reticulon 4 interacting protein 1	6	106571971-106629487	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036357	Approved				Renal cancer:8.55e-6 (favourable), Breast cancer:9.18e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.4	Expressed in all		
RTTN	DKFZP434G145	ENSG00000176225	Rotatin	18	70003031-70205945	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041343, HPA041967	Uncertain					Expressed in all	Mixed			testis: 5.2	Mixed		
RUBCN	KIAA0226, rubicon, rundataxin	ENSG00000145016	RUN and cysteine rich domain containing beclin 1 interacting protein	3	197671393-197749727	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050908, HPA054497	Approved		Supported	Vesicles<br>Cytosol	Liver cancer:9.91e-5 (unfavourable), Prostate cancer:1.62e-4 (unfavourable), Colorectal cancer:6.65e-4 (unfavourable)	Expressed in all	Expressed in all			spleen,testis: 24.3	Expressed in all		
RUBCNL	C13orf18, FLJ21562, KIAA0226L	ENSG00000102445	RUN and cysteine rich domain containing beclin 1 interacting protein like	13	46342000-46438190	Predicted intracellular proteins	Evidence at protein level	HPA026614	Approved		Supported	Cytosol	Endometrial cancer:3.76e-5 (favourable)	Tissue enriched	Mixed			lymph node: 35.0	Cell line enhanced		Daudi: 99.1;REH: 36.6;U-698: 157.0
RUFY1	FLJ22251, RABIP4, ZFYVE12	ENSG00000176783	RUN and FYVE domain containing 1	5	179550558-179610026	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038804, HPA057614	Approved		Supported	Nucleus<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			spleen: 20.2	Expressed in all		
RUFY3	KIAA0871, RIPx, Singar1, ZFYVE30	ENSG00000018189	RUN and FYVE domain containing 3	4	70704204-70807315	Predicted intracellular proteins	Evidence at protein level	HPA022952, HPA022970	Enhanced		Supported	Cytosol	Pancreatic cancer:8.02e-5 (favourable), Head and neck cancer:1.28e-4 (favourable), Liver cancer:8.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 143.0	Expressed in all		
RUFY4	FLJ46536, ZFYVE31	ENSG00000188282	RUN and FYVE domain containing 4	2	218034960-218090581	Predicted intracellular proteins	Evidence at protein level	HPA037980	Uncertain					Mixed	Tissue enhanced		spleen: 2.5	lymph node: 1.3	Cell line enriched	12	Karpas-707: 7.6
RUNDC1	DKFZp761H0421	ENSG00000198863	RUN domain containing 1	17	42980565-42993690	Predicted intracellular proteins	Evidence at protein level	HPA023726	Uncertain		Approved	Nuclear speckles<br>Cytosol	Endometrial cancer:6.93e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 23.5	Expressed in all		
RUNDC3A	RAP2IP, RPIP8	ENSG00000108309	RUN domain containing 3A	17	44308413-44318671	Predicted intracellular proteins	Evidence at protein level	HPA023548, HPA070733	Enhanced	Supported	Approved	Vesicles		Tissue enhanced	Tissue enriched	10	cerebral cortex: 178.0	adrenal gland: 18.2	Group enriched	8	SCLC-21H: 72.5;SH-SY5Y: 41.7
RUNDC3B	RPIB9, RPIP9	ENSG00000105784	RUN domain containing 3B	7	87627548-87832296	Predicted intracellular proteins	Evidence at protein level	HPA056968, HPA057155	Uncertain				Renal cancer:2.62e-6 (favourable)	Mixed	Tissue enhanced		adrenal gland: 9.7	cerebral cortex: 7.2	Cell line enhanced		SCLC-21H: 3.1;SH-SY5Y: 1.3
RUNX1	AML1, AMLCR1, CBFA2, PEBP2A2	ENSG00000159216	Runt related transcription factor 1	21	34787801-36004667	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004176, HPA037912	Enhanced		Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:3.44e-15 (unfavourable)	Expressed in all	Mixed			breast: 34.0	Cell line enhanced		HEL: 225.2
RUNX1T1	AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2	ENSG00000079102	RUNX1 translocation partner 1	8	91954967-92103286	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049852, HPA070951	Approved		Supported	Nucleoplasm		Mixed	Mixed			cervix, uterine: 12.8	Cell line enhanced		Daudi: 14.0;HEL: 32.2
RUNX2	AML3, CBFA1, CCD, CCD1, PEBP2A1, PEBP2aA1	ENSG00000124813	Runt related transcription factor 2	6	45328157-45664349	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB008374, HPA022040, CAB062561, CAB068226	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.97e-9 (unfavourable), Urothelial cancer:6.66e-5 (unfavourable), Stomach cancer:2.24e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 10.6	Cell line enhanced		Karpas-707: 54.6;RH-30: 54.1;U-698: 41.3
RUNX3	AML2, CBFA3, PEBP2A3	ENSG00000020633	Runt related transcription factor 3	1	24899511-24965121	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004195, CAB025416, HPA059006	Enhanced		Supported	Nucleus<br>Cytosol	Renal cancer:5.59e-5 (unfavourable), Colorectal cancer:8.71e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 50.5	bone marrow: 45.2	Cell line enhanced		HDLM-2: 125.1;Karpas-707: 125.3;SK-MEL-30: 77.0
RUSC1	NESCA	ENSG00000160753	RUN and SH3 domain containing 1	1	155320896-155331114	Predicted intracellular proteins	Evidence at protein level	HPA028510, HPA029922, HPA029923	Approved		Supported	Cytosol	Liver cancer:7.78e-6 (unfavourable), Renal cancer:9.24e-6 (unfavourable), Prostate cancer:2.65e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 38.5	Expressed in all		
RUSC2	KIAA0375	ENSG00000198853	RUN and SH3 domain containing 2	9	35490127-35561898	Predicted intracellular proteins	Evidence at protein level	HPA021297	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 48.5	Mixed		
RUVBL1	ECP54, INO80H, NMP238, Pontin52, RVB1, TIH1, TIP49, TIP49a	ENSG00000175792	RuvB like AAA ATPase 1	3	128064778-128153914	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019947, HPA019948	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.21e-8 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 81.6	Expressed in all		
RUVBL2	ECP51, INO80J, Reptin52, RVB2, TIH2, TIP48, TIP49b	ENSG00000183207	RuvB like AAA ATPase 2	19	48993448-49015995	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012432, HPA042880, HPA067966	Enhanced		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Liver cancer:9.28e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 72.4	Expressed in all		
RWDD1	PTD013	ENSG00000111832	RWD domain containing 1	6	116571367-116597675	Predicted intracellular proteins	Evidence at protein level	HPA028712, HPA028713	Approved				Liver cancer:5.16e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 61.8	Expressed in all		
RWDD2A	dJ747H23.2, MGC13523, RWDD2	ENSG00000013392	RWD domain containing 2A	6	83193379-83198932	Predicted intracellular proteins	Evidence at protein level	HPA030105, HPA030106, HPA030107	Uncertain				Ovarian cancer:3.82e-5 (favourable), Pancreatic cancer:1.38e-4 (favourable), Glioma:7.17e-4 (favourable)	Expressed in all	Mixed			prostate: 18.7	Mixed		
RWDD2B	C21orf6, GL011	ENSG00000156253	RWD domain containing 2B	21	29004384-29019378	Predicted intracellular proteins	Evidence at protein level	HPA018316	Uncertain					Expressed in all	Mixed			testis,thyroid gland: 1.8	Mixed		
RWDD3	DKFZP566K023	ENSG00000122481	RWD domain containing 3	1	95234155-95247225	Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.46e-8 (unfavourable), Urothelial cancer:2.06e-4 (favourable)	Expressed in all	Mixed			endometrium,fallopian tube: 14.6	Expressed in all		
RWDD4	FAM28A, MGC10198, RWDD4A	ENSG00000182552	RWD domain containing 4	4	183639635-183659225	Predicted intracellular proteins	Evidence at protein level	HPA036501, HPA036502	Approved		Approved	Intermediate filaments	Renal cancer:1.01e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 68.2	Expressed in all		
RXRA	NR2B1	ENSG00000186350	Retinoid X receptor alpha	9	134317098-134440585	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004565, CAB005352	Supported		Supported	Nucleus<br>Golgi apparatus	Renal cancer:5.58e-4 (unfavourable), Pancreatic cancer:7.02e-4 (favourable)	Expressed in all	Mixed			esophagus: 25.8	Mixed		
RXRB	H-2RIIBP, NR2B2, RCoR-1	ENSG00000204231	Retinoid X receptor beta	6	33193588-33200688	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002003, HPA063653	Supported		Supported	Nucleus		Expressed in all	Mixed			epididymis: 15.7	Cell line enhanced		RH-30: 8.5;T-47d: 8.2
RXRG	NR2B3	ENSG00000143171	Retinoid X receptor gamma	1	165400917-165445355	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002615, HPA012933	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Thyroid cancer:9.40e-5 (favourable)	Group enriched	Tissue enhanced		skeletal muscle: 16.7	cervix, uterine: 4.7	Cell line enriched	6	SK-MEL-30: 29.1
RYBP	AAP1, DEDAF, YEAF1	ENSG00000163602	RING1 and YY1 binding protein	3	72371825-72446621	Predicted intracellular proteins	Evidence at protein level	HPA053357	Approved		Supported	Nucleoplasm	Renal cancer:2.50e-5 (favourable)	Expressed in all	Mixed			endometrium: 30.7	Expressed in all		
S100A1	S100-alpha, S100A	ENSG00000160678	S100 calcium binding protein A1	1	153627926-153632039	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB002599, HPA006462	Enhanced				Endometrial cancer:1.12e-4 (unfavourable), Renal cancer:3.08e-4 (unfavourable)	Group enriched	Group enriched	5	heart muscle: 1882.3;skeletal muscle: 995.9	thyroid gland: 267.2	Cell line enhanced		EFO-21: 122.7;Hep G2: 207.0;SK-MEL-30: 802.9
S100A11	S100C	ENSG00000163191	S100 calcium binding protein A11	1	152032506-152047907	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034320, HPA042745	Enhanced				Renal cancer:3.24e-6 (unfavourable), Liver cancer:3.64e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 2721.4	Expressed in all		
S100A12	CAAF1, CAGC, CGRP, ENRAGE, MRP6, p6	ENSG00000163221	S100 calcium binding protein A12	1	153373706-153375649	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002881, CAB025872	Enhanced				Renal cancer:5.03e-4 (unfavourable)	Tissue enhanced	Tissue enriched	19	bone marrow: 2045.4	spleen: 107.1	Cell line enhanced		hTCEpi: 1.6;THP-1: 1.0
S100A13		ENSG00000189171	S100 calcium binding protein A13	1	153618787-153631360	Predicted intracellular proteins	Evidence at protein level	HPA019592, CAB025494	Approved		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:1.97e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 331.5	Mixed		
S100A14	BCMP84, S100A15	ENSG00000189334	S100 calcium binding protein A14	1	153614255-153616986	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027613	Enhanced		Supported	Nuclear bodies<br>Plasma membrane<br>Cell Junctions<br>Cytosol		Mixed	Tissue enhanced		esophagus: 2205.9	skin: 591.6	Group enriched	9	A-431: 692.6;HaCaT: 944.8;HBEC3-KT: 1089.8;hTCEpi: 1601.4;SK-BR-3: 1180.8
S100A16	DT1P1A7, MGC17528, S100F	ENSG00000188643	S100 calcium binding protein A16	1	153606886-153613145	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045841	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Lung cancer:3.14e-5 (unfavourable), Renal cancer:3.91e-5 (unfavourable), Pancreatic cancer:2.04e-4 (unfavourable), Liver cancer:3.18e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 1489.4	skin: 394.6	Mixed		
S100A2	CAN19, S100L	ENSG00000196754	S100 calcium binding protein A2	1	153561108-153567890	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002600, CAB047340, HPA062451	Enhanced		Supported	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.04e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 1481.8	tonsil: 368.4	Cell line enhanced		HBEC3-KT: 15305.5;RT4: 6706.3
S100A3	S100E	ENSG00000188015	S100 calcium binding protein A3	1	153547329-153549372	Predicted intracellular proteins	Evidence at protein level	HPA042674, HPA056140	Approved		Enhanced	Nucleoli<br>Cytosol	Renal cancer:1.61e-6 (unfavourable)	Expressed in all	Tissue enhanced		lung: 19.9;skin: 17.3	esophagus: 7.5	Cell line enhanced		A549: 71.3;U-2197: 41.8
S100A4	18A2, 42A, CAPL, FSP1, MTS1, P9KA, PEL98	ENSG00000196154	S100 calcium binding protein A4	1	153543613-153550136	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002618, HPA007973, CAB027387, CAB058698, CAB068227, CAB068228	Enhanced		Enhanced	Plasma membrane	Head and neck cancer:4.03e-5 (favourable), Renal cancer:2.90e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 990.6	Cell line enhanced		BJ hTERT+: 4403.5;fHDF/TERT166: 3054.2
S100A5	S100D	ENSG00000196420	S100 calcium binding protein A5	1	153537147-153541765	Predicted intracellular proteins	Evidence at protein level	HPA064184			Approved	Nucleoplasm		Group enriched	Tissue enhanced		skin: 4.3;thyroid gland: 8.8	lymph node: 1.7	Cell line enhanced		RT4: 15.9;SCLC-21H: 20.4
S100A6	2A9, CABP, CACY, PRA	ENSG00000197956	S100 calcium binding protein A6	1	153534599-153536244	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002601, HPA007575, CAB040549, CAB047354	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Urothelial cancer:7.56e-4 (favourable)	Expressed in all	Expressed in all			lung: 1678.1	Cell line enhanced		RPTEC TERT1: 7409.7
S100A7	PSOR1, S100A7c	ENSG00000143556	S100 calcium binding protein A7	1	153457744-153460701	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001453, HPA006997, CAB033766	Enhanced					Group enriched	Group enriched	6	skin: 326.2;tonsil: 885.9	esophagus: 95.9	Cell line enhanced		HaCaT: 5.4;SK-BR-3: 10.6
S100A7A	S100A15, S100A7f, S100A7L1	ENSG00000184330	S100 calcium binding protein A7A	1	153416524-153423225	Predicted intracellular proteins	Evidence at protein level	HPA006997	Supported					Tissue enhanced	Group enriched	14	skin: 1.9;tonsil: 5.4	esophagus,testis: 0.2	Not detected		
S100A7L2	s100a7b	ENSG00000197364	S100 calcium binding protein A7 like 2	1	153437058-153439949	Predicted intracellular proteins	Evidence at protein level	HPA057828	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
S100A8	60B8AG, CAGA, CFAG, CGLA, MRP8, P8	ENSG00000143546	S100 calcium binding protein A8	1	153390032-153391188	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002791, HPA024372	Enhanced		Supported	Intermediate filaments	Renal cancer:8.94e-7 (unfavourable)	Expressed in all	Group enriched	9	bone marrow: 14915.7;esophagus: 12755.4;tonsil: 4867.3	appendix: 1232.5	Group enriched	28	hTCEpi: 103.6;SK-BR-3: 396.8;THP-1: 195.3
S100A9	60B8AG, CAGB, CFAG, CGLB, LIAG, MAC387, MIF, MRP14, NIF, P14	ENSG00000163220	S100 calcium binding protein A9	1	153357854-153361027	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004193, CAB009441	Enhanced		Supported	Nucleoplasm<br>Cell Junctions<br>Cytosol	Liver cancer:1.13e-6 (unfavourable), Renal cancer:8.10e-4 (unfavourable)	Expressed in all	Group enriched	6	bone marrow: 20959.3;esophagus: 24239.1	tonsil: 3911.6	Cell line enriched	5	SK-BR-3: 1782.7
S100B	S100beta	ENSG00000160307	S100 calcium binding protein B	21	46598962-46605208	Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000073, HPA015768, CAB078196	Enhanced		Approved	Nucleus<br>Vesicles		Group enriched	Group enriched	8	adipose tissue: 208.2;cerebral cortex: 626.3	seminal vesicle: 49.5	Group enriched	6	SK-MEL-30: 519.7;WM-115: 1274.2
S100G	CABP1, CABP9K, CALB3	ENSG00000169906	S100 calcium binding protein G	X	16650158-16654670	Predicted intracellular proteins	Evidence at protein level	CAB017688, HPA055873	Enhanced					Group enriched	Tissue enriched	11	duodenum: 240.6	small intestine: 22.6	Cell line enhanced		RPMI-8226: 1.6
S100P		ENSG00000163993	S100 calcium binding protein P	4	6693069-6697170	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019502	Enhanced		Supported	Nuclear bodies	Pancreatic cancer:2.00e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		bone marrow: 169.5;stomach: 363.3;urinary bladder: 178.9	placenta: 130.7	Cell line enhanced		BEWO: 180.4;Hep G2: 139.7;hTCEpi: 158.3;RT4: 329.6;SK-BR-3: 170.0
S100PBP	FLJ12903, S100PBPR	ENSG00000116497	S100P binding protein	1	32816767-32858879	Predicted intracellular proteins	Evidence at protein level	HPA027242, HPA027328	Approved		Supported	Nuclear speckles	Liver cancer:1.26e-6 (unfavourable), Head and neck cancer:5.22e-5 (favourable), Renal cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 61.5	Expressed in all		
S100Z	Gm625, S100-zeta	ENSG00000171643	S100 calcium binding protein Z	5	76850001-76921650	Predicted intracellular proteins	Evidence at protein level	HPA051929	Approved					Tissue enhanced	Mixed			spleen: 3.3	Cell line enriched	6	U-698: 55.6
SAAL1	FLJ41463	ENSG00000166788	Serum amyloid A like 1	11	18069935-18106091	Predicted intracellular proteins	Evidence at protein level	HPA039003, HPA039004	Approved		Supported	Nucleoplasm	Renal cancer:5.78e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 23.2	Expressed in all		
SAC3D1	HSU79266, SHD1	ENSG00000168061	SAC3 domain containing 1	11	65040901-65044828	Predicted intracellular proteins	Evidence at protein level	HPA042677	Uncertain		Approved	Cytosol	Liver cancer:9.67e-6 (unfavourable), Renal cancer:5.66e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 11.6	cerebral cortex: 2.9	Mixed		
SACS	ARSACS, DKFZp686B15167, DNAJC29, KIAA0730, PPP1R138, SPAX6	ENSG00000151835	Sacsin molecular chaperone	13	23328826-23411513	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017714	Uncertain				Renal cancer:6.21e-6 (unfavourable), Endometrial cancer:9.04e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 32.5	cerebral cortex: 16.0	Mixed		
SAE1	AOS1, FLJ3091, Sua1	ENSG00000142230	SUMO1 activating enzyme subunit 1	19	47113274-47210636	Predicted intracellular proteins	Evidence at protein level	HPA041906, HPA043552	Enhanced				Liver cancer:5.49e-8 (unfavourable), Renal cancer:8.15e-5 (unfavourable), Thyroid cancer:2.76e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 145.7	Expressed in all		
SAFB	HET, SAFB1	ENSG00000160633	Scaffold attachment factor B	19	5623035-5668478	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001969, HPA016832, HPA020076	Supported		Enhanced	Nucleoplasm	Pancreatic cancer:9.75e-5 (favourable), Urothelial cancer:1.70e-4 (favourable)	Expressed in all	Expressed in all			spleen: 53.9	Expressed in all		
SAFB2	KIAA0138	ENSG00000130254	Scaffold attachment factor B2	19	5586999-5624046	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050894	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Urothelial cancer:2.12e-4 (favourable), Pancreatic cancer:2.53e-4 (favourable), Endometrial cancer:7.10e-4 (favourable)	Expressed in all	Expressed in all			ovary: 40.0	Expressed in all		
SAG	ARRESTIN, RP47	ENSG00000130561	S-antigen visual arrestin	2	233307816-233347055	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004946	Supported					Not detected	Group enriched	8	epididymis: 1.1;testis: 1.9	endometrium: 0.1	Not detected		
SAGE1	CT14, SAGE	ENSG00000181433	Sarcoma antigen 1	X	135889205-135913061	Predicted intracellular proteins	Evidence at protein level	HPA003033, HPA003208	Enhanced		Enhanced	Nucleus		Mixed	Tissue enriched	58	testis: 8.9	cerebral cortex: 0.1	Group enriched	11	AN3-CA: 19.0;K-562: 13.8;Karpas-707: 18.3;U-2 OS: 7.4;U-266/70: 6.7;U-266/84: 16.5
SALL1	Hsal1, TBS, ZNF794	ENSG00000103449	Spalt like transcription factor 1	16	51135975-51151367	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049829	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:1.91e-7 (favourable), Endometrial cancer:1.28e-4 (favourable)	Group enriched	Tissue enhanced		thyroid gland: 40.1	cerebral cortex: 30.3	Cell line enhanced		AF22: 29.2;NTERA-2: 48.0;RPTEC TERT1: 30.7;U-87 MG: 45.3
SALL2	Hsal2, KIAA0360, ZNF795	ENSG00000165821	Spalt like transcription factor 2	14	21521081-21537216	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004162	Approved		Approved	Nucleus<br>Vesicles	Pancreatic cancer:1.23e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 67.9	cerebral cortex: 42.4	Cell line enhanced		AF22: 123.9;NTERA-2: 95.1;SCLC-21H: 50.0
SALL3	ZNF796	ENSG00000256463	Spalt like transcription factor 3	18	78980275-79002677	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016656	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 4.1;prostate: 2.0	kidney: 0.9	Group enriched	29	HAP1: 4.8;HEK93: 2.5;NTERA-2: 9.5
SALL4	dJ1112F19.1, ZNF797	ENSG00000101115	Spalt like transcription factor 4	20	51782331-51802520	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015291, HPA015791	Enhanced		Enhanced	Nucleoplasm		Tissue enriched	Group enriched	7	parathyroid gland: 6.7;prostate: 1.4;testis: 5.8;thyroid gland: 3.5	urinary bladder: 0.6	Cell line enhanced		AF22: 24.7;AN3-CA: 16.2;BEWO: 32.0;NTERA-2: 60.1;SiHa: 16.5
SAMD1		ENSG00000141858	Sterile alpha motif domain containing 1	19	14087840-14091036	Predicted intracellular proteins	Evidence at protein level	HPA041662, HPA049059	Uncertain		Approved	Mitochondria<br>Cytosol	Liver cancer:1.96e-5 (unfavourable), Renal cancer:7.98e-5 (unfavourable), Cervical cancer:7.41e-4 (favourable), Stomach cancer:8.31e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 32.2	Expressed in all		
SAMD10	C20orf136	ENSG00000130590	Sterile alpha motif domain containing 10	20	63974113-63980008	Predicted intracellular proteins	Evidence at protein level	HPA040973	Approved		Approved	Nucleoplasm	Liver cancer:4.60e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 7.6	Mixed		
SAMD12	FLJ39458	ENSG00000177570	Sterile alpha motif domain containing 12	8	118189459-118621995	Predicted intracellular proteins	Evidence at protein level	HPA024634	Uncertain		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.52e-6 (favourable), Endometrial cancer:1.11e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 14.1	Cell line enhanced		SK-BR-3: 25.4
SAMD13		ENSG00000203943	Sterile alpha motif domain containing 13	1	84298366-84389957	Predicted intracellular proteins	Evidence at protein level	HPA058929	Enhanced		Approved	Mitochondria	Glioma:2.06e-8 (favourable)	Mixed	Tissue enhanced		rectum: 25.8;testis: 28.7	colon: 20.7	Mixed		
SAMD14	FLJ36890	ENSG00000167100	Sterile alpha motif domain containing 14	17	50110040-50129882	Predicted intracellular proteins	Evidence at protein level	HPA051916	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.2	testis: 1.8	Cell line enhanced		HDLM-2: 12.8;HEL: 7.8;HMC-1: 24.7;SH-SY5Y: 14.0
SAMD15	C14orf174, FAM15A, FLJ35963	ENSG00000100583	Sterile alpha motif domain containing 15	14	77376689-77391497	Predicted intracellular proteins	Evidence at protein level	HPA030673, HPA030677	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Nucleoli		Mixed	Tissue enhanced		testis: 32.0	fallopian tube: 7.3	Mixed		
SAMD3	bA73O6.2, FLJ34032	ENSG00000164483	Sterile alpha motif domain containing 3	6	130144315-130365425	Predicted intracellular proteins	Evidence at protein level	HPA028992, HPA028993	Uncertain					Not detected	Tissue enhanced		spleen: 13.0	lymph node: 11.5	Group enriched	5	HBF TERT88: 1.7;HDLM-2: 3.1;hTEC/SVTERT24-B: 2.2;NTERA-2: 1.7;PC-3: 1.1
SAMD4A	DKFZP434H0350, hSmaug1, KIAA1053, SAMD4, Smaug, SMG, SMGA	ENSG00000020577	Sterile alpha motif domain containing 4A	14	54567097-54793315	Predicted intracellular proteins	Evidence at protein level	HPA043061, HPA065309	Approved		Approved	Cell Junctions<br>Cytosol		Expressed in all	Tissue enhanced		testis: 102.6	skeletal muscle: 32.7	Mixed		
SAMD4B	FLJ10211, hSmaug2, MGC99832, SMGB	ENSG00000179134	Sterile alpha motif domain containing 4B	19	39342396-39385710	Predicted intracellular proteins	Evidence at protein level	HPA016800, HPA059385	Approved		Enhanced	Cytosol	Endometrial cancer:2.17e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 68.4	Expressed in all		
SAMD7	DKFZp686E1583	ENSG00000187033	Sterile alpha motif domain containing 7	3	169911572-169939175	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			lymph node,testis: 0.2	Not detected		
SAMD9	C7orf5, FLJ20073, KIAA2004	ENSG00000205413	Sterile alpha motif domain containing 9	7	93099513-93118023	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021318, HPA021319	Approved		Enhanced	Vesicles<br>Cytosol	Renal cancer:8.40e-7 (unfavourable), Pancreatic cancer:8.31e-5 (unfavourable), Lung cancer:2.93e-4 (unfavourable), Endometrial cancer:3.14e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 43.2	spleen: 24.2	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 64.9
SAMD9L	C7orf6, FLJ39885, KIAA2005	ENSG00000177409	Sterile alpha motif domain containing 9 like	7	93130055-93148369	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019461, HPA019465, HPA019488	Enhanced		Approved	Cytosol	Renal cancer:6.63e-5 (unfavourable)	Expressed in all	Mixed			spleen: 52.5	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 52.6;HDLM-2: 47.0;Karpas-707: 94.3
SAMHD1	AGS5, HDDC1, Mg11, MOP-5, SBBI88	ENSG00000101347	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	20	36890229-36951843	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047072	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:5.12e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 133.3	Cell line enhanced		ASC diff: 345.7;BJ hTERT+ SV40 Large T+: 170.4;BJ hTERT+ SV40 Large T+ RasG12V: 204.5
SAMM50	CGI-51, OMP85, SAM50, TOB55, TRG-3, YNL026W	ENSG00000100347	SAMM50 sorting and assembly machinery component	22	43955421-44010531	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034537	Enhanced		Enhanced	Mitochondria	Renal cancer:4.43e-8 (favourable), Endometrial cancer:2.63e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 242.2	Expressed in all		
SAMSN1	HACS1, NASH1, SASH2, SH3D6B, SLy2	ENSG00000155307	SAM domain, SH3 domain and nuclear localization signals 1	21	14485228-14583402	Predicted intracellular proteins	Evidence at protein level	HPA010645, HPA017055	Approved		Enhanced	Plasma membrane	Renal cancer:4.52e-6 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 110.1;bone marrow: 123.6	spleen: 43.6	Cell line enhanced		HEL: 244.0;K-562: 292.8;Karpas-707: 97.1
SAP130	FLJ12761	ENSG00000136715	Sin3A associated protein 130	2	127941217-128028120	Predicted intracellular proteins	Evidence at protein level	HPA034664			Supported	Nuclear speckles	Liver cancer:7.89e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 86.9	Expressed in all		
SAP18	2HOR0202, MGC27131, SAP18p	ENSG00000150459	Sin3A associated protein 18	13	21140514-21149084	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA011352, CAB012273	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 257.2	Expressed in all		
SAP25	FLJ00248	ENSG00000205307	Sin3A associated protein 25	7	100572228-100573820	Predicted intracellular proteins	Evidence at protein level	HPA062610	Uncertain		Approved	Nuclear bodies		Mixed	Tissue enhanced		spleen: 48.2	lymph node: 32.7	Cell line enhanced		HMC-1: 26.8;NB-4: 44.5;U-937: 21.3
SAP30BP	HCNGP, HTRG, HTRP	ENSG00000161526	SAP30 binding protein	17	75667116-75708062	Predicted intracellular proteins	Evidence at protein level	HPA042382, HPA052943	Supported		Enhanced	Nucleoplasm	Liver cancer:4.71e-5 (unfavourable), Renal cancer:1.98e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.5	Expressed in all		
SAP30L	FLJ11526, NS4ATP2	ENSG00000164576	SAP30 like	5	154445957-154461054	Predicted intracellular proteins	Evidence at protein level	HPA048665			Supported	Nucleus<br>Nucleoli	Pancreatic cancer:2.06e-5 (favourable), Renal cancer:1.71e-4 (favourable), Urothelial cancer:2.69e-4 (favourable), Head and neck cancer:9.09e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 25.2	Expressed in all		
SAPCD1	C6orf26, NG23	ENSG00000228727	Suppressor APC domain containing 1	6	31762799-31764851	Predicted intracellular proteins	Evidence at transcript level	HPA071699			Approved	Vesicles<br>Cell Junctions		Mixed	Tissue enhanced		skin: 3.2	bone marrow: 1.0	Cell line enhanced		HeLa: 2.5
SAPCD2	C9orf140, p42.3	ENSG00000186193	Suppressor APC domain containing 2	9	137062124-137070588	Predicted intracellular proteins	Evidence at protein level	HPA044154	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Lung cancer:5.88e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 12.6	small intestine: 4.8	Mixed		
SAR1B	SARA2	ENSG00000152700	Secretion associated Ras related GTPase 1B	5	134601144-134649271	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006923, HPA048368	Supported		Approved	Endoplasmic reticulum	Liver cancer:6.59e-4 (favourable), Endometrial cancer:7.11e-4 (favourable)	Expressed in all	Expressed in all			testis: 118.6	Expressed in all		
SARDH	DMGDHL1, SDH	ENSG00000123453	Sarcosine dehydrogenase	9	133663560-133739955	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057267, HPA058086	Approved		Approved	Mitochondria	Glioma:3.50e-4 (unfavourable)	Tissue enriched	Tissue enhanced		epididymis: 59.3;liver: 43.0	kidney: 12.5	Group enriched	5	AN3-CA: 16.3;Hep G2: 20.7;LHCN-M2: 9.2;MOLT-4: 18.0;RH-30: 17.5;RPMI-8226: 26.5;SH-SY5Y: 15.4
SARNP	CIP29, Hcc-1, THO1	ENSG00000205323	SAP domain containing ribonucleoprotein	12	55752463-55817756	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030902, HPA030903	Supported		Supported	Nuclear speckles		Mixed	Expressed in all			testis: 92.7	Expressed in all		
SARS	SERS	ENSG00000031698	Seryl-tRNA synthetase	1	109213918-109238169	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016939, HPA064668	Uncertain		Enhanced	Cytosol	Liver cancer:6.13e-5 (unfavourable), Head and neck cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 240.7	Expressed in all		
SARS2	FLJ20450, mtSerRS, SARS, SARSM, SerRSmt, SERS, SYS	ENSG00000104835	Seryl-tRNA synthetase 2, mitochondrial	19	38915266-38930896	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA052730, HPA056957	Approved					Expressed in all	Expressed in all			thyroid gland: 8.9	Expressed in all		
SART1	Ara1, SNRNP110, Snu66	ENSG00000175467	Squamous cell carcinoma antigen recognized by T-cells 1	11	65961689-65979828	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031188, HPA031189, HPA031190	Supported		Enhanced	Nuclear speckles<br>Golgi apparatus		Expressed in all	Expressed in all			spleen: 32.3	Expressed in all		
SART3	KIAA0156, p110, RP11-13G14, TIP110	ENSG00000075856	Squamous cell carcinoma antigen recognized by T-cells 3	12	108522580-108561400	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044322	Approved				Liver cancer:6.32e-6 (unfavourable), Melanoma:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.9	Expressed in all		
SASH1	dJ323M4.1, KIAA0790, SH3D6A	ENSG00000111961	SAM and SH3 domain containing 1	6	148272304-148552050	Predicted intracellular proteins	Evidence at protein level	HPA029947, HPA029949	Uncertain		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.42e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 63.6	Cell line enhanced		ASC diff: 133.3;WM-115: 91.6
SASH3	753P9, CXorf9, HACS2, SH3D6C, SLY	ENSG00000122122	SAM and SH3 domain containing 3	X	129779979-129795201	Predicted intracellular proteins	Evidence at protein level	HPA001085	Enhanced		Approved	Plasma membrane	Renal cancer:6.51e-5 (unfavourable), Endometrial cancer:3.15e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 136.7;spleen: 99.3;tonsil: 97.4	appendix: 80.4	Cell line enhanced		Daudi: 116.3;MOLT-4: 95.0;NB-4: 56.4;REH: 79.9;U-698: 101.7;U-937: 90.0
SASS6	DKFZp761A078, FLJ22097, SAS-6, SAS6	ENSG00000156876	SAS-6 centriolar assembly protein	1	100083563-100132955	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028187	Uncertain		Supported	Microtubule organizing center<br>Cytosol		Expressed in all	Mixed			testis: 13.3	Mixed		
SAT1	SAT, SSAT	ENSG00000130066	Spermidine/spermine N1-acetyltransferase 1	X	23783173-23786226	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB047343, HPA055312, CAB069914	Supported				Endometrial cancer:2.87e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 1269.5	Expressed in all		
SAT2	SSAT2	ENSG00000141504	Spermidine/spermine N1-acetyltransferase family member 2	17	7626234-7627876	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022136, HPA057096	Enhanced				Endometrial cancer:8.76e-6 (favourable), Pancreatic cancer:6.05e-5 (favourable), Lung cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 91.0	Mixed		
SATB2	FLJ21474, KIAA1034	ENSG00000119042	SATB homeobox 2	2	199269500-199471266	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001042, CAB023669, HPA029543, CAB062562, CAB067751, CAB068229, CAB068230, CAB068231	Enhanced		Supported	Nucleoplasm	Renal cancer:5.37e-8 (favourable)	Tissue enhanced	Group enriched	5	cerebral cortex: 22.7;colon: 34.1;rectum: 43.2	small intestine: 6.3	Mixed		
SATL1		ENSG00000184788	Spermidine/spermine N1-acetyl transferase-like 1	X	85092287-85109048	Predicted intracellular proteins	Evidence at transcript level	HPA060369	Uncertain					Not detected	Tissue enhanced		testis: 1.3	cerebral cortex: 0.4	Not detected		
SAV1	salvador, WW45, WWP4	ENSG00000151748	Salvador family WW domain containing protein 1	14	50632058-50668331	Predicted intracellular proteins	Evidence at protein level	HPA001808	Approved		Supported	Cytosol	Renal cancer:3.83e-6 (favourable), Breast cancer:2.92e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 58.3	Expressed in all		
SAXO1	C9orf138, FAM154A, MGC35182	ENSG00000155875	Stabilizer of axonemal microtubules 1	9	18927658-19049354	Predicted intracellular proteins	Evidence at protein level	HPA023899	Enhanced					Not detected	Tissue enriched	112	testis: 58.4	epididymis: 0.5	Not detected		
SBDS	CGI-97, FLJ10917, SDS, SWDS	ENSG00000126524	SBDS ribosome assembly guanine nucleotide exchange factor	7	66987677-66995601	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028891	Approved		Supported	Nucleus<br>Cytosol	Breast cancer:1.49e-4 (unfavourable), Head and neck cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 243.3	Expressed in all		
SBF1	DENND7A, MTMR5	ENSG00000100241	SET binding factor 1	22	50445000-50475024	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA074004			Approved	Nuclear bodies	Head and neck cancer:3.46e-5 (favourable)	Expressed in all	Expressed in all			testis: 84.1	Expressed in all		
SBF2	CMT4B2, DENND7B, KIAA1766, MTMR13	ENSG00000133812	SET binding factor 2	11	9778667-10294207	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050933	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Renal cancer:3.66e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.1	Expressed in all		
SBNO1	FLJ10701, FLJ10833, MOP3, Sno	ENSG00000139697	Strawberry notch homolog 1	12	123289109-123364843	Predicted intracellular proteins	Evidence at protein level	HPA042388	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 126.2	Expressed in all		
SBNO2	FLJ00173, KIAA0963, Sno, Stno	ENSG00000064932	Strawberry notch homolog 2	19	1107636-1174283	Predicted intracellular proteins	Evidence at protein level	HPA041867	Approved				Renal cancer:7.98e-8 (unfavourable)	Expressed in all	Mixed			adipose tissue: 13.9	Cell line enhanced		HDLM-2: 61.0
SCAF1	FLJ00034, SR-A1	ENSG00000126461	SR-related CTD associated factor 1	19	49642125-49658642	Predicted intracellular proteins	Evidence at protein level	HPA046828, HPA054593	Approved		Approved	Nucleoplasm<br>Cytosol	Colorectal cancer:9.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 51.6	Expressed in all		
SCAF4	DKFZp434E098, KIAA1172, SFRS15, SRA4	ENSG00000156304	SR-related CTD associated factor 4	21	31671033-31732075	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018319, HPA018668, HPA021504, HPA028807	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 28.4	Expressed in all		
SCAF8	KIAA1116, RBM16	ENSG00000213079	SR-related CTD associated factor 8	6	154733325-154834244	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035601, HPA035602	Enhanced		Enhanced	Nucleoplasm	Ovarian cancer:6.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 45.1	Expressed in all		
SCAI	C9orf126, FLJ36664, NET40	ENSG00000173611	Suppressor of cancer cell invasion	9	124942608-125143506	Predicted intracellular proteins	Evidence at protein level	HPA020632	Approved		Supported	Nucleus<br>Nuclear membrane		Mixed	Mixed			cerebral cortex: 11.7	Expressed in all		
SCAND1	RAZ1, SDP1	ENSG00000171222	SCAN domain containing 1	20	35953617-35959472	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047138			Supported	Nucleus<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			duodenum: 29.4	Expressed in all		
SCAPER	Zfp291, ZNF291	ENSG00000140386	S-phase cyclin A associated protein in the ER	15	76347904-76905444	Predicted intracellular proteins	Evidence at protein level	HPA046253, HPA061180	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:2.69e-9 (favourable)	Expressed in all	Expressed in all			testis: 38.4	Expressed in all		
SCEL	FLJ21667, MGC22531	ENSG00000136155	Sciellin	13	77535674-77645263	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039737, HPA040154	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:1.73e-5 (unfavourable), Pancreatic cancer:1.24e-4 (unfavourable), Endometrial cancer:4.07e-4 (unfavourable), Renal cancer:6.87e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 476.6;skin: 397.0	lung: 98.9	Cell line enhanced		CAPAN-2: 28.9;HaCaT: 54.8;HBEC3-KT: 21.3;RPTEC TERT1: 89.6
SCFD1	C14orf163, KIAA0917, RA410, SLY1, STXBP1L2	ENSG00000092108	Sec1 family domain containing 1	14	30622112-30735812	Predicted intracellular proteins	Evidence at protein level	HPA003579	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 73.1	Expressed in all		
SCFD2	FLJ39514, STXBP1L1	ENSG00000184178	Sec1 family domain containing 2	4	52872982-53366075	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036526, HPA036527	Enhanced		Approved	Nucleus	Renal cancer:3.81e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 14.7	Expressed in all		
SCGN	CALBL, DJ501N12.8, SECRET, SEGN	ENSG00000079689	Secretagogin, EF-hand calcium binding protein	6	25652201-25701783	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004005, HPA006641, CAB044060, CAB062563, CAB068232	Enhanced	Supported				Tissue enhanced	Tissue enhanced		rectum: 21.5;stomach: 20.6	colon: 17.0	Cell line enriched	6	SCLC-21H: 29.5
SCHIP1	SCHIP-1	ENSG00000151967	Schwannomin interacting protein 1	3	159839861-159897360	Predicted intracellular proteins	Evidence at protein level	HPA003243, HPA069824	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Glioma:3.78e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 102.8;heart muscle: 53.1	skeletal muscle: 25.5	Cell line enhanced		AN3-CA: 45.4;HUVEC TERT2: 48.7;NTERA-2: 29.7;SH-SY5Y: 177.1
SCIN	KIAA1905	ENSG00000006747	Scinderin	7	12570577-12660179	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020518, HPA024264	Enhanced		Enhanced	Plasma membrane	Renal cancer:4.26e-8 (favourable)	Tissue enhanced	Tissue enhanced		placenta: 110.4	kidney: 52.0	Cell line enhanced		RPTEC TERT1: 71.2;SK-BR-3: 76.9
SCLT1	FLJ30655, hCAP-1A	ENSG00000151466	Sodium channel and clathrin linker 1	4	128864921-129093607	Predicted intracellular proteins	Evidence at protein level	HPA036560, HPA036561	Approved		Supported	Microtubules<br>Cytosol		Mixed	Mixed			spleen: 11.3	Expressed in all		
SCLY	SCL	ENSG00000132330	Selenocysteine lyase	2	238060889-238099413	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055760	Uncertain		Approved	Golgi apparatus		Not detected	Expressed in all			testis: 12.9	Expressed in all		
SCMH1	Scml3	ENSG00000010803	Sex comb on midleg homolog 1 (Drosophila)	1	41027200-41242154	Predicted intracellular proteins	Evidence at protein level	HPA048898, HPA053292			Supported	Nucleoplasm<br>Nuclear bodies	Liver cancer:3.82e-4 (unfavourable), Urothelial cancer:5.80e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.0	Mixed		
SCML1		ENSG00000047634	Sex comb on midleg-like 1 (Drosophila)	X	17737449-17754988	Predicted intracellular proteins	Evidence at protein level	HPA035270, HPA035271, HPA061397	Enhanced		Approved	Nucleus		Expressed in all	Expressed in all			testis: 54.2	Cell line enhanced		U-2197: 82.3
SCML2		ENSG00000102098	Sex comb on midleg-like 2 (Drosophila)	X	18239314-18354727	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001662, HPA064713	Enhanced		Approved	Nucleoli<br>Cytosol		Mixed	Tissue enhanced		testis: 19.2	ovary: 6.3	Cell line enhanced		NTERA-2: 35.7
SCML4	dJ47M23.1	ENSG00000146285	Sex comb on midleg-like 4 (Drosophila)	6	107704104-107824317	Predicted intracellular proteins	Evidence at protein level	HPA063326, HPA065958	Approved		Enhanced	Nucleoplasm		Mixed	Tissue enhanced		lymph node: 16.1	spleen: 11.1	Cell line enriched	6	HDLM-2: 60.8
SCNM1	MGC3180	ENSG00000163156	Sodium channel modifier 1	1	151156664-151170297	Predicted intracellular proteins	Evidence at protein level	HPA052439, HPA054324	Uncertain		Approved	Nucleus	Renal cancer:2.17e-13 (unfavourable), Ovarian cancer:1.23e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 45.2	Expressed in all		
SCOC	HRIHFB2072, SCOCO, UNC-69	ENSG00000153130	Short coiled-coil protein	4	140257286-140385726	Predicted intracellular proteins	Evidence at protein level	HPA061198, HPA070321	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:4.82e-12 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 187.9	Expressed in all		
SCP2		ENSG00000116171	Sterol carrier protein 2	1	52927229-53051703	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027101, HPA027135, HPA027317	Supported		Enhanced	Peroxisomes	Renal cancer:7.85e-8 (favourable), Colorectal cancer:7.05e-5 (favourable)	Expressed in all	Expressed in all			liver: 601.5	Expressed in all		
SCP2D1	C20orf79, dJ1068E13.2, HSD22	ENSG00000132631	SCP2 sterol binding domain containing 1	20	18813726-18814392	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	593	testis: 59.2	all non-specific tissues: 0.0	Not detected		
SCRIB	KIAA0147, SCRB1, Vartul	ENSG00000180900	Scribbled planar cell polarity protein	8	143790920-143815379	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015463, CAB022081, HPA023557, HPA064312	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cell Junctions<br>Rods & Rings		Expressed in all	Expressed in all			skin: 22.0	Expressed in all		
SCRN1	KIAA0193	ENSG00000136193	Secernin 1	7	29920103-29990289	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024517	Enhanced		Approved	Cytosol	Renal cancer:1.15e-5 (favourable), Endometrial cancer:4.00e-5 (unfavourable), Urothelial cancer:2.60e-4 (unfavourable), Ovarian cancer:7.27e-4 (unfavourable), Breast cancer:8.32e-4 (unfavourable), Cervical cancer:8.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 172.0	parathyroid gland: 129.1	Mixed		
SCRN2		ENSG00000141295	Secernin 2	17	47837692-47841333	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022934, HPA023434	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:3.86e-4 (favourable), Urothelial cancer:5.83e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 84.3	Expressed in all		
SCRN3	FLJ23142	ENSG00000144306	Secernin 3	2	174395730-174429575	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034689, HPA034690	Approved		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 48.4	Mixed		
SCRT1	DKFZp547F072, ZNF898	ENSG00000261678	Scratch family transcriptional repressor 1	8	144330565-144336281	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045265	Uncertain		Supported	Nuclear bodies		Tissue enhanced	Tissue enriched	7	cerebral cortex: 10.9	adrenal gland: 1.5	Group enriched	12	SCLC-21H: 11.4;SH-SY5Y: 2.3
SCRT2	ZNF898B	ENSG00000215397	Scratch family transcriptional repressor 2	20	661596-676179	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA067697			Approved	Nucleoplasm		Tissue enriched	Not detected			cerebral cortex: 0.6	Group enriched	5	Karpas-707: 1.4;NTERA-2: 1.8;RPMI-8226: 2.8;SCLC-21H: 2.2;SH-SY5Y: 2.1
SCX	bHLHa41, bHLHa48, SCXA, SCXB	ENSG00000260428	Scleraxis bHLH transcription factor	8	144266560-144268481	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043183	Uncertain				Glioma:2.46e-4 (unfavourable)	Group enriched	Tissue enhanced		skeletal muscle: 5.3	parathyroid gland: 2.9	Cell line enhanced		BEWO: 4.9;HaCaT: 5.0
SCYL1	GKLP, HT019, MGC78454, NKTL, NTKL, P105, TAPK, TEIF, TRAP	ENSG00000142186	SCY1 like pseudokinase 1	11	65525077-65538704	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015015	Uncertain		Supported	Cytosol		Expressed in all	Expressed in all			thyroid gland: 55.2	Expressed in all		
SCYL2	CVAK104, KIAA1360	ENSG00000136021	SCY1 like pseudokinase 2	12	100267140-100341724	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021050	Approved					Expressed in all	Expressed in all			parathyroid gland: 41.8	Expressed in all		
SCYL3	PACE-1, PACE1	ENSG00000000457	SCY1 like pseudokinase 3	1	169849631-169894267	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005624	Approved		Uncertain	Nuclear bodies<br>Microtubules	Urothelial cancer:8.85e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 24.6	Expressed in all		
SDAD1	FLJ10498	ENSG00000198301	SDA1 domain containing 1	4	75940950-75990962	Predicted intracellular proteins	Evidence at protein level	HPA035949	Uncertain		Supported	Nucleus<br>Nucleoli	Liver cancer:1.32e-4 (unfavourable), Renal cancer:2.13e-4 (favourable)	Expressed in all	Expressed in all			testis: 38.4	Expressed in all		
SDCBP	MDA-9, SYCL	ENSG00000137575	Syndecan binding protein	8	58552924-58582860	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012245, HPA023840	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Expressed in all	Expressed in all			placenta: 365.1	Mixed		
SDCBP2	SITAC18, ST-2	ENSG00000125775	Syndecan binding protein 2	20	1309909-1329239	Predicted intracellular proteins	Evidence at protein level	HPA054554, HPA064490	Enhanced		Approved	Vesicles<br>Cytosol	Lung cancer:2.42e-4 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable), Urothelial cancer:3.37e-4 (favourable)	Expressed in all	Tissue enhanced		duodenum: 135.1;small intestine: 143.9	stomach: 94.5	Cell line enhanced		CAPAN-2: 16.0
SDCCAG3	NY-CO-3	ENSG00000165689	Serologically defined colon cancer antigen 3	9	136401922-136410609	Predicted intracellular proteins	Evidence at protein level	HPA029303	Approved				Renal cancer:8.50e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 36.4	Expressed in all		
SDCCAG8	BBS16, CCCAP, NPHP10, NY-CO-8, SLSN7	ENSG00000054282	Serologically defined colon cancer antigen 8	1	243256034-243500092	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA025737, HPA044477, HPA072495	Approved		Enhanced	Centrosome		Expressed in all	Expressed in all			thyroid gland: 24.2	Cell line enhanced		WM-115: 31.8
SDE2	C1orf55, FLJ35382	ENSG00000143751	SDE2 telomere maintenance homolog	1	225982702-225999331	Predicted intracellular proteins	Evidence at protein level	HPA028467, HPA031255, HPA031256	Approved		Approved	Nuclear speckles<br>Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 21.1	Expressed in all		
SDHA	FP, SDH2, SDHF	ENSG00000073578	Succinate dehydrogenase complex flavoprotein subunit A	5	218241-256700	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB034929, HPA041981, HPA064582	Enhanced		Enhanced	Mitochondria	Renal cancer:9.53e-8 (favourable), Breast cancer:6.00e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 248.9	Expressed in all		
SDHAF1	LYRM8	ENSG00000205138	Succinate dehydrogenase complex assembly factor 1	19	35995199-35996315	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064277			Approved	Mitochondria	Renal cancer:2.11e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 13.8	Expressed in all		
SDHAF2	C11orf79, FLJ20487, PGL2, SDH5	ENSG00000167985	Succinate dehydrogenase complex assembly factor 2	11	61430042-61447529	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039464, HPA039732	Supported		Supported	Nucleoli<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 35.5	Expressed in all		
SDHAF3	ACN9, DC11, LYRM10, Sdh7	ENSG00000196636	Succinate dehydrogenase complex assembly factor 3	7	97116590-97181763	Predicted intracellular proteins	Evidence at protein level	HPA020523	Approved		Approved	Microtubules<br>Mitochondria		Expressed in all	Expressed in all			testis: 15.1	Mixed		
SDPR	cavin-2, CAVIN2, PS-p68, SDR	ENSG00000168497	Serum deprivation response	2	191834302-191847255	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039325, HPA062122	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:8.45e-5 (favourable), Stomach cancer:3.69e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 165.9	Group enriched	6	fHDF/TERT166: 118.5;HEL: 101.3;HUVEC TERT2: 284.6;LHCN-M2: 440.0;TIME: 114.4
SDR39U1	C14orf124, HCDI	ENSG00000100445	Short chain dehydrogenase/reductase family 39U member 1	14	24439766-24442905	Predicted intracellular proteins	Evidence at protein level	HPA044294	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.34e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 42.9	Expressed in all		
SDR9C7	RDHS, SDR-O	ENSG00000170426	Short chain dehydrogenase/reductase family 9C member 7	12	56923154-56934405	Predicted intracellular proteins	Evidence at protein level	HPA039059			Approved	Nucleoli<br>Cytosol		Group enriched	Tissue enhanced		esophagus: 10.7;skin: 46.1	tonsil: 6.8	Not detected		
SDS	SDH	ENSG00000135094	Serine dehydratase	12	113392445-113426301	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039230	Uncertain		Approved	Mitochondria<br>Cytosol	Cervical cancer:5.24e-4 (favourable)	Tissue enriched	Tissue enriched	18	liver: 189.8	cerebral cortex: 10.5	Cell line enhanced		HMC-1: 1.5
SEBOX	OG9, OG9X	ENSG00000274529	SEBOX homeobox	17	28364268-28365244	Predicted intracellular proteins	No evidence	HPA045689	Uncertain					Not detected	Not detected			testis: 0.4	Not detected		
SEC13	D3S1231E, npp-20, SEC13L1, SEC13R	ENSG00000157020	SEC13 homolog, nuclear pore and COPII coat complex component	3	10293131-10321178	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035292, HPA057943	Approved		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 120.0	Expressed in all		
SEC14L1	PRELID4A, SEC14L	ENSG00000129657	SEC14 like lipid binding 1	17	77086716-77217101	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021463, HPA028703	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			placenta: 119.5	Expressed in all		
SEC14L2	C22orf6, KIAA1186, KIAA1658, SPF, TAP, TAP1	ENSG00000100003	SEC14 like lipid binding 2	22	30396857-30425317	Predicted intracellular proteins	Evidence at protein level	HPA064466	Approved		Supported	Nucleus<br>Cytosol	Head and neck cancer:7.63e-6 (unfavourable), Breast cancer:3.05e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 104.9;liver: 125.6;prostate: 83.0	breast: 57.3	Cell line enhanced		HBEC3-KT: 61.6
SEC14L4	dJ130H16.5, TAP3	ENSG00000133488	SEC14 like lipid binding 4	22	30488913-30505711	Predicted intracellular proteins	Evidence at protein level	HPA069748			Approved	Centrosome		Tissue enhanced	Group enriched	8	bone marrow: 5.0;liver: 10.3;lung: 6.9;parathyroid gland: 10.5;testis: 7.1	adrenal gland: 0.9	Cell line enhanced		A549: 6.7;BEWO: 36.9;SiHa: 9.8
SEC14L5	KIAA0420, PRELID4B	ENSG00000103184	SEC14 like lipid binding 5	16	4958317-5019158	Predicted intracellular proteins	Evidence at protein level	HPA041492, HPA041825			Uncertain	Golgi apparatus<br>Cytosol		Mixed	Tissue enriched	7	cerebral cortex: 17.1	heart muscle: 2.3	Cell line enhanced		SCLC-21H: 3.2;T-47d: 1.7
SEC14L6		ENSG00000214491	SEC14 like lipid binding 6	22	30522799-30546682	Predicted intracellular proteins	Evidence at transcript level	HPA067695			Approved	Nucleoplasm		Tissue enriched	Tissue enhanced		epididymis: 25.8;parathyroid gland: 46.1	lung: 17.8	Cell line enhanced		K-562: 11.1;RPTEC TERT1: 16.7;SiHa: 7.0
SEC23A		ENSG00000100934	Sec23 homolog A, coat complex II component	14	39031919-39109646	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043806, HPA069974	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.69e-4 (unfavourable), Stomach cancer:2.94e-4 (unfavourable), Colorectal cancer:3.56e-4 (favourable), Cervical cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 140.0	Expressed in all		
SEC23B	CDA-II, CDAII, CDAN2, HEMPAS	ENSG00000101310	Sec23 homolog B, coat complex II component	20	18507493-18561415	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008216, HPA069974	Uncertain		Supported	Vesicles	Endometrial cancer:8.25e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 85.7	Expressed in all		
SEC23IP	p125	ENSG00000107651	SEC23 interacting protein	10	119892711-119944658	Predicted intracellular proteins	Evidence at protein level	HPA038403, HPA043305	Approved		Enhanced	Vesicles		Expressed in all	Expressed in all			smooth muscle: 30.5	Expressed in all		
SEC24A		ENSG00000113615	SEC24 homolog A, COPII coat complex component	5	134648789-134727823	Predicted intracellular proteins	Evidence at protein level	HPA038901, HPA056825	Approved		Approved	Nucleoli fibrillar center<br>Vesicles	Cervical cancer:3.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 25.8	Expressed in all		
SEC24B		ENSG00000138802	SEC24 homolog B, COPII coat complex component	4	109433772-109540896	Predicted intracellular proteins	Evidence at protein level	HPA038181	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:2.33e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.8	Expressed in all		
SEC24C	KIAA0079	ENSG00000176986	SEC24 homolog C, COPII coat complex component	10	73744384-73772161	Predicted intracellular proteins	Evidence at protein level	HPA040196, HPA040213	Supported		Supported	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 85.5	Expressed in all		
SEC24D	KIAA0755	ENSG00000150961	SEC24 homolog D, COPII coat complex component	4	118722823-118838683	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041626, HPA053486	Approved		Approved	Vesicles	Renal cancer:3.42e-6 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 76.6	Expressed in all		
SEC31B	DKFZP434M183, SEC31B-1, SEC31L2	ENSG00000075826	SEC31 homolog B, COPII coat complex component	10	100486642-100519864	Predicted intracellular proteins	Evidence at protein level	HPA035882, HPA040819, HPA060052	Uncertain		Approved	Nucleus<br>Nucleoli<br>Vesicles<br>Cytosol	Renal cancer:6.41e-7 (unfavourable)	Mixed	Mixed			testis: 3.2	Mixed		
SECISBP2L	KIAA0256	ENSG00000138593	SECIS binding protein 2 like	15	48988476-49046563	Predicted intracellular proteins	Evidence at protein level	HPA039875	Approved		Approved	Nucleoplasm	Renal cancer:5.65e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.6	Expressed in all		
SEH1L	SEC13L, Seh1, SEH1A, SEH1B	ENSG00000085415	SEH1 like nucleoporin	18	12947133-12987536	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA039964	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 33.9	Expressed in all		
SELENBP1	hSBP, hSP56, LPSB	ENSG00000143416	Selenium binding protein 1	1	151364302-151372733	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005741, CAB008366, HPA011731	Enhanced		Supported	Nucleoli	Head and neck cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			rectum: 488.9	Cell line enhanced		ASC diff: 97.2;HEL: 100.3;SK-BR-3: 194.4
SELENOH	C11orf31, SELH	ENSG00000211450	Selenoprotein H	11	57741250-57743554	Predicted intracellular proteins	Evidence at protein level	HPA048362	Uncertain		Approved	Nucleus<br>Nucleoli	Ovarian cancer:1.80e-4 (favourable), Liver cancer:4.30e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 69.6	Expressed in all		
SELENOV	SELV	ENSG00000186838	Selenoprotein V	19	39515113-39520686	Predicted intracellular proteins	Evidence at transcript level	HPA059274	Uncertain				Thyroid cancer:7.43e-4 (unfavourable)	Tissue enhanced	Group enriched	13	parathyroid gland: 1.8;testis: 5.5;thyroid gland: 2.1	cerebral cortex: 0.2	Not detected		
SELENOW	SELW, SEPW1	ENSG00000178980	Selenoprotein W	19	47778572-47784686	Predicted intracellular proteins	Evidence at protein level						Lung cancer:5.44e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 440.9	Mixed		
SEM1	DSS1, ECD, SHFD1, Shfdg1, SHFM1, SHSF1	ENSG00000127922	SEM1, 26S proteasome complex subunit	7	96481626-96709891	Predicted intracellular proteins	Evidence at protein level	HPA020429, HPA072648	Uncertain		Approved	Cytosol	Urothelial cancer:8.00e-5 (favourable), Ovarian cancer:2.52e-4 (favourable), Renal cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 223.1	Expressed in all		
SEMA3D	coll-2, Sema-Z2	ENSG00000153993	Semaphorin 3D	7	84995553-85186855	Predicted intracellular proteins	Evidence at protein level	HPA037522	Uncertain		Approved	Golgi apparatus<br>Plasma membrane		Mixed	Group enriched	5	spleen: 66.2;thyroid gland: 76.6	prostate: 13.4	Cell line enhanced		fHDF/TERT166: 22.0;HaCaT: 25.4;TIME: 36.0
SENP1		ENSG00000079387	SUMO1/sentrin specific peptidase 1	12	48042898-48106308	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011765, HPA046491			Enhanced	Nucleus<br>Focal adhesion sites	Liver cancer:7.72e-5 (unfavourable), Renal cancer:8.37e-4 (unfavourable)	Expressed in all	Tissue enriched	8	testis: 110.1	lymph node: 13.3	Expressed in all		
SENP2	AXAM2, DKFZp762A2316, KIAA1331, SMT3IP2	ENSG00000163904	SUMO1/sentrin/SMT3 specific peptidase 2	3	185582496-185633551	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA029247, HPA029248	Approved		Supported	Cytosol	Endometrial cancer:7.98e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 26.9	Expressed in all		
SENP3	DKFZP586K0919, DKFZp762A152, SMT3IP1, SSP3, Ulp1	ENSG00000161956	SUMO1/sentrin/SMT3 specific peptidase 3	17	7561875-7571969	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA060290	Supported		Supported	Nucleus<br>Nucleoli	Pancreatic cancer:6.22e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 57.4	Expressed in all		
SENP5	MGC27076	ENSG00000119231	SUMO1/sentrin specific peptidase 5	3	196867856-196934714	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.14e-5 (unfavourable), Endometrial cancer:4.04e-4 (unfavourable), Liver cancer:4.15e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.8	Expressed in all		
SENP6	KIAA0797, SUSP1	ENSG00000112701	SUMO1/sentrin specific peptidase 6	6	75601509-75718278	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024376	Approved		Supported	Nucleoplasm<br>Cytosol	Thyroid cancer:2.83e-5 (unfavourable), Renal cancer:6.09e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 75.2	Expressed in all		
SENP7		ENSG00000138468	SUMO1/sentrin specific peptidase 7	3	101324205-101513241	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027259	Approved		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 44.4	Expressed in all		
SENP8	DEN1, HsT17512, NEDP1, PRSC2	ENSG00000166192	SUMO/sentrin peptidase family member, NEDD8 specific	15	72114258-72143688	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036273	Approved		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		testis: 27.7	thyroid gland: 8.3	Expressed in all		
SEPHS1	SPS, SPS1	ENSG00000086475	Selenophosphate synthetase 1	10	13317424-13348298	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037645, HPA062118	Enhanced		Uncertain	Nucleoplasm	Liver cancer:2.16e-7 (unfavourable), Pancreatic cancer:3.12e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 92.9	Expressed in all		
SEPHS2	SPS2, SPS2b	ENSG00000179918	Selenophosphate synthetase 2	16	30443631-30446181	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047931	Approved		Approved	Nucleoplasm	Renal cancer:4.35e-8 (favourable)	Expressed in all	Expressed in all			liver: 180.4	Expressed in all		
SEPSECS	SLA, SLA/LP	ENSG00000109618	Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase	4	25120014-25160442	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA070409			Approved	Vesicles		Expressed in all	Expressed in all			liver: 16.7	Expressed in all		
SEPT1	DIFF6, PNUTL3	ENSG00000180096	Septin 1	16	30378133-30395991	Predicted intracellular proteins	Evidence at protein level	HPA041566, HPA060339	Enhanced		Uncertain	Actin filaments	Renal cancer:2.40e-7 (unfavourable), Endometrial cancer:3.04e-5 (favourable), Lung cancer:7.24e-5 (favourable), Cervical cancer:9.72e-5 (favourable), Pancreatic cancer:2.22e-4 (favourable), Head and neck cancer:6.63e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 16.3;spleen: 11.3	tonsil: 6.0	Cell line enhanced		Daudi: 27.2;MOLT-4: 53.0;REH: 35.4;U-266/84: 23.4
SEPT10	FLJ11619	ENSG00000186522	Septin 10	2	109542982-109614206	Predicted intracellular proteins	Evidence at protein level	HPA047860, HPA056304, HPA060310	Enhanced		Enhanced	Actin filaments		Expressed in all	Mixed			testis: 140.8	Mixed		
SEPT11	FLJ10849	ENSG00000138758	Septin 11	4	76949703-77040384	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003459, HPA005665	Approved		Approved	Cytosol	Liver cancer:1.70e-5 (unfavourable), Renal cancer:2.40e-4 (favourable)	Expressed in all	Expressed in all			placenta: 120.1	Mixed		
SEPT12	FLJ25410	ENSG00000140623	Septin 12	16	4777669-4788521	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041128			Uncertain	Microtubules		Tissue enhanced	Tissue enriched	668	testis: 107.9	bone marrow: 0.1	Not detected		
SEPT14	FLJ44060	ENSG00000154997	Septin 14	7	55793544-55862789	Predicted intracellular proteins	Evidence at protein level	HPA073255	Enhanced					Tissue enriched	Tissue enriched	15	testis: 41.7	parathyroid gland: 2.7	Cell line enhanced		BEWO: 6.0
SEPT2	DIFF6, hNedd5, KIAA0158, NEDD5, Pnutl3	ENSG00000168385	Septin 2	2	241315100-241354027	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017190, HPA018481	Supported		Supported	Nucleus<br>Actin filaments	Liver cancer:3.66e-4 (unfavourable), Glioma:4.32e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 369.5	Expressed in all		
SEPT3	SEP3	ENSG00000100167	Septin 3	22	41976272-41998221	Predicted intracellular proteins	Evidence at protein level	HPA003548, CAB017633	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments	Endometrial cancer:1.78e-4 (unfavourable)	Tissue enhanced	Tissue enriched	11	cerebral cortex: 234.8	parathyroid gland: 21.5	Cell line enhanced		AF22: 26.2;SCLC-21H: 84.0
SEPT4	ARTS, CE5B3, H5, hCDCREL-2, hucep-7, MART, PNUTL2	ENSG00000108387	Septin 4	17	58520250-58540818	Predicted intracellular proteins	Evidence at protein level	CAB006855, HPA021587, HPA022905	Enhanced		Supported	Nucleoplasm	Renal cancer:3.28e-7 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 217.2;cerebral cortex: 287.9	spleen: 56.8	Cell line enhanced		HHSteC: 11.8;SK-MEL-30: 25.2
SEPT5	H5, HCDCREL-1, PNUTL1	ENSG00000184702	Septin 5	22	19714464-19724772	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB016120, HPA029095, HPA063885	Enhanced		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:6.87e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 386.8	Cell line enhanced		K-562: 211.0
SEPT6	KIAA0128, MGC16619, MGC20339, SEP2, SEPT2	ENSG00000125354	Septin 6	X	119615724-119693370	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003459, HPA005665	Supported		Approved	Cytosol		Expressed in all	Mixed			lymph node: 140.7	Cell line enhanced		MOLT-4: 239.1;REH: 246.9;SH-SY5Y: 417.7
SEPT7	CDC10, CDC3, SEPT7A	ENSG00000122545	Septin 7	7	35800932-35907105	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023309, HPA029524	Enhanced		Enhanced	Nucleoli<br>Actin filaments<br>Midbody	Liver cancer:2.37e-4 (unfavourable), Renal cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 430.4	Expressed in all		
SEPT8	KIAA0202, SEP2	ENSG00000164402	Septin 8	5	132750817-132807241	Predicted intracellular proteins	Evidence at protein level	HPA005665, HPA036534	Approved		Approved	Actin filaments<br>Cytosol	Renal cancer:6.98e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 280.3	Mixed		
SERBP1	CGI-55, CHD3IP, DKFZP564M2423, HABP4L, PAI-RBP1, PAIRBP1	ENSG00000142864	SERPINE1 mRNA binding protein 1	1	67407810-67430415	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020559, CAB026297	Enhanced		Enhanced	Cytosol	Liver cancer:1.36e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 293.4	Expressed in all		
SERF2	4F5REL, FAM2C, H4F5rel, HsT17089	ENSG00000140264	Small EDRK-rich factor 2	15	43777087-43802589	Predicted intracellular proteins	Evidence at protein level	HPA056613			Uncertain	Nucleus<br>Nucleoli	Endometrial cancer:5.33e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 911.3	Expressed in all		
SERGEF	DelGEF, Gnefr	ENSG00000129158	Secretion regulating guanine nucleotide exchange factor	11	17788048-18013162	Predicted intracellular proteins	Evidence at protein level	HPA037811, HPA037812, HPA074086	Supported		Enhanced	Nucleoplasm<br>Vesicles<br>Cytosol	Glioma:7.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 52.9	Expressed in all		
SERHL2		ENSG00000183569	Serine hydrolase-like 2	22	42553617-42574382	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Group enriched	Tissue enriched	12	breast: 558.7	epididymis: 45.4	Cell line enriched	9	SK-BR-3: 207.3
SERPINB1	anti-elastase, EI, ELANH2, PI2	ENSG00000021355	Serpin family B member 1	6	2832332-2842006	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018871, HPA018882, HPA052642	Enhanced		Supported	Cytoplasmic bodies		Expressed in all	Expressed in all			esophagus: 464.5	Cell line enhanced		U-937: 105.0
SERPINB10	bomapin, PI10	ENSG00000242550	Serpin family B member 10	18	63897174-63936111	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015480, HPA059582	Uncertain					Not detected	Tissue enriched	32	bone marrow: 50.1	skin: 1.5	Cell line enriched	7	U-937: 82.6
SERPINB11	EPIPIN	ENSG00000206072	Serpin family B member 11 (gene/pseudogene)	18	63647579-63726432	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Group enriched	5	esophagus: 28.7;prostate: 49.9	tonsil: 7.2	Not detected		
SERPINB12	YUKOPIN	ENSG00000166634	Serpin family B member 12	18	63556160-63567011	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Head and neck cancer:1.76e-4 (favourable)	Group enriched	Tissue enriched	5	skin: 78.3	esophagus: 15.2	Not detected		
SERPINB3	HsT1196, SCC, SCCA1, T4-A	ENSG00000057149	Serpin family B member 3	18	63655197-63661963	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018772, CAB036006, CAB036007, HPA048341, HPA049988, HPA055992	Enhanced		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:3.19e-4 (unfavourable)	Tissue enhanced	Group enriched	7	cervix, uterine: 298.5;esophagus: 848.0	urinary bladder: 87.5	Cell line enhanced		HaCaT: 5.5;SiHa: 4.1;U-2197: 7.3
SERPINB4	LEUPIN, PI11, SCCA-2, SCCA1, SCCA2	ENSG00000206073	Serpin family B member 4	18	63637259-63644298	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048341, HPA049988, HPA055992	Supported				Pancreatic cancer:5.48e-4 (unfavourable)	Tissue enhanced	Tissue enriched	5	esophagus: 98.3	urinary bladder: 19.5	Cell line enhanced		HaCaT: 1.9;SiHa: 1.8;U-2197: 5.5
SERPINB5	maspin, PI5	ENSG00000206075	Serpin family B member 5	18	63476761-63505085	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009570, HPA019025, HPA019132, HPA020136	Enhanced		Supported	Vesicles	Pancreatic cancer:5.71e-6 (unfavourable), Lung cancer:1.54e-4 (unfavourable)	Tissue enhanced	Group enriched	5	esophagus: 220.2;skin: 261.8	breast: 44.2	Cell line enhanced		HaCaT: 1048.4;HBEC3-KT: 281.3;hTCEpi: 583.7
SERPINB6	CAP, DFNB91, PI6, PTI	ENSG00000124570	Serpin family B member 6	6	2948159-2972165	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA009668, HPA012736	Enhanced		Approved	Centrosome	Renal cancer:2.21e-4 (unfavourable), Ovarian cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			testis: 255.6	Mixed		
SERPINB7	MEGSIN	ENSG00000166396	Serpin family B member 7	18	63752935-63805376	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024200	Enhanced		Approved	Endoplasmic reticulum<br>Mitochondria	Pancreatic cancer:3.03e-5 (unfavourable)	Mixed	Tissue enhanced		skin: 123.7;tonsil: 34.1	breast: 17.4	Cell line enhanced		BJ: 202.3;fHDF/TERT166: 131.6;HaCaT: 363.6;HBF TERT88: 215.1;U-138 MG: 215.5
SERPINB8	CAP2, PI8	ENSG00000166401	Serpin family B member 8	18	63969925-64019779	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034300	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:3.31e-5 (unfavourable)	Expressed in all	Mixed			skin: 48.9	Mixed		
SERPINB9	CAP3, PI9	ENSG00000170542	Serpin family B member 9	6	2887266-2903280	Predicted intracellular proteins	Evidence at protein level	HPA030067	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.66e-6 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 74.8	appendix: 48.4	Cell line enhanced		BEWO: 219.1;U-698: 69.6
SERTAD1	SEI1, TRIP-Br1	ENSG00000197019	SERTA domain containing 1	19	40421592-40426025	Predicted intracellular proteins	Evidence at protein level	HPA063323			Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			gallbladder: 19.6	Mixed		
SERTAD2	KIAA0127, Sei-2, TRIP-Br2	ENSG00000179833	SERTA domain containing 2	2	64631621-64751005	Predicted intracellular proteins	Evidence at protein level	HPA019021, HPA020904	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.70e-4 (unfavourable), Endometrial cancer:4.03e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 54.0	Expressed in all		
SERTAD3	RBT1	ENSG00000167565	SERTA domain containing 3	19	40440844-40444705	Predicted intracellular proteins	Evidence at protein level	HPA068262			Supported	Nucleoli		Expressed in all	Expressed in all			prostate: 40.4	Expressed in all		
SERTAD4	DJ667H12.2	ENSG00000082497	SERTA domain containing 4	1	210232799-210246631	Predicted intracellular proteins	Evidence at protein level	HPA027344, HPA028514	Uncertain		Supported	Nucleoplasm		Mixed	Mixed			breast: 4.6	Cell line enhanced		SCLC-21H: 8.7;T-47d: 9.8;U-2 OS: 9.1
SESN1	PA26, SEST1	ENSG00000080546	Sestrin 1	6	108986437-109094819	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA073659			Supported	Nucleus<br>Nucleoli fibrillar center	Head and neck cancer:6.47e-5 (favourable), Prostate cancer:2.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 78.9	Expressed in all		
SESN2	DKFZp761M0212, HI95, SES2, SEST2	ENSG00000130766	Sestrin 2	1	28259527-28282491	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018191	Uncertain		Approved	Cytosol	Liver cancer:4.78e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 25.6	Expressed in all		
SESN3	MGC29667, SEST3	ENSG00000149212	Sestrin 3	11	95165513-95232541	Predicted intracellular proteins	Evidence at protein level	HPA037935			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		testis: 104.8	parathyroid gland: 54.5	Cell line enhanced		AF22: 27.8;ASC diff: 32.0;ASC TERT1: 35.5
SESTD1	DKFZp434O0515, Solo	ENSG00000187231	SEC14 and spectrin domain containing 1	2	179101692-179264790	Predicted intracellular proteins	Evidence at protein level	HPA058236, HPA077408			Enhanced	Intermediate filaments	Renal cancer:2.78e-11 (favourable), Liver cancer:1.88e-4 (unfavourable), Stomach cancer:2.67e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.9	Mixed		
SET	2PP2A, IPP2A2, PHAPII	ENSG00000119335	SET nuclear proto-oncogene	9	128683424-128696400	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005232, HPA063683	Supported		Supported	Nucleoplasm<br>Lipid droplets	Liver cancer:9.41e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 361.2	Expressed in all		
SETBP1	KIAA0437, SEB	ENSG00000152217	SET binding protein 1	18	44680173-45068510	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049022, HPA057259	Uncertain		Supported	Nucleus<br>Nuclear bodies<br>Cytosol	Renal cancer:6.34e-8 (favourable)	Mixed	Expressed in all			seminal vesicle: 13.8	Cell line enhanced		AF22: 15.8;Karpas-707: 45.8
SETD1A	KIAA0339, KMT2F, Set1	ENSG00000099381	SET domain containing 1A	16	30957294-30984664	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020646, HPA058376	Enhanced		Supported	Nuclear speckles	Liver cancer:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.5	Expressed in all		
SETD1B	KIAA1076, KMT2G, Set1B	ENSG00000139718	SET domain containing 1B	12	121804180-121832584	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021667, HPA059412	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 19.0	Expressed in all		
SETD2	FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A	ENSG00000181555	SET domain containing 2	3	47016429-47163967	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042451	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:7.99e-6 (favourable), Melanoma:8.19e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.8	Expressed in all		
SETD3	C14orf154, FLJ23027	ENSG00000183576	SET domain containing 3	14	99397746-99480889	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003591, HPA003639	Approved		Approved	Mitochondria	Renal cancer:1.89e-15 (favourable), Head and neck cancer:6.46e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 154.4	Expressed in all		
SETD4	C21orf18, C21orf27	ENSG00000185917	SET domain containing 4	21	36034541-36079389	Predicted intracellular proteins	Evidence at protein level	HPA024073, HPA035405	Approved		Approved	Nuclear speckles		Expressed in all	Expressed in all			testis: 41.9	Expressed in all		
SETD5	FLJ10707	ENSG00000168137	SET domain containing 5	3	9397615-9479240	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB017093, HPA035574	Approved		Enhanced	Nucleus<br>Cytosol	Renal cancer:4.27e-4 (unfavourable), Liver cancer:6.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.7	Expressed in all		
SETD6	FLJ21148	ENSG00000103037	SET domain containing 6	16	58515479-58521181	Predicted intracellular proteins	Evidence at protein level	HPA041481, HPA053546	Uncertain		Supported	Nucleus<br>Cytosol	Prostate cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 19.8	Mixed		
SETD7	KIAA1717, KMT7, SET7, SET7/9, Set9	ENSG00000145391	SET domain containing lysine methyltransferase 7	4	139495941-139606699	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058111	Approved		Supported	Nucleoli	Breast cancer:8.28e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 60.7	Mixed		
SETD9	C5orf35, MGC33648	ENSG00000155542	SET domain containing 9	5	56909260-56925532	Predicted intracellular proteins	Evidence at protein level	HPA049936			Approved	Nucleoplasm		Expressed in all	Tissue enriched	6	testis: 27.1	thyroid gland: 4.3	Mixed		
SETDB2	C13orf4, CLLD8, CLLL8, KMT1F	ENSG00000136169	SET domain bifurcated 2	13	49444374-49495003	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012190, HPA071677	Approved		Approved	Nucleoplasm	Renal cancer:1.92e-7 (favourable)	Expressed in all	Mixed			testis: 28.2	Expressed in all		
SETMAR	metnase	ENSG00000170364	SET domain and mariner transposase fusion gene	3	4303304-4317567	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA057999			Supported	Nucleoli	Renal cancer:6.61e-6 (favourable), Liver cancer:2.85e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 16.0	Mixed		
SETSIP	SETP18	ENSG00000230667	SET-like protein	1	92074533-92075441	Predicted intracellular proteins	Evidence at protein level	HPA063683	Approved		Supported	Nucleoplasm<br>Lipid droplets		Mixed	Not detected			testis: 0.4	Not detected		
SETX	ALS4, AOA2, KIAA0625, SCAR1	ENSG00000107290	Senataxin	9	132261356-132354985	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024105, HPA057269	Approved		Supported	Nucleus<br>Cytokinetic bridge		Expressed in all	Expressed in all			testis: 58.3	Expressed in all		
SF1	ZCCHC25, ZFM1, ZNF162	ENSG00000168066	Splicing factor 1	11	64764606-64778786	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018883	Supported		Enhanced	Nucleoplasm	Liver cancer:4.85e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 145.9	Expressed in all		
SF3A1	Prp21, PRPF21, SAP114, SF3a120	ENSG00000099995	Splicing factor 3a subunit 1	22	30331988-30356947	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000690, HPA030083	Enhanced		Enhanced	Nuclear speckles	Renal cancer:1.16e-4 (favourable)	Expressed in all	Expressed in all			testis: 88.7	Expressed in all		
SF3A2	Prp11, PRPF11, SAP62, SF3a66	ENSG00000104897	Splicing factor 3a subunit 2	19	2236504-2248679	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042843, HPA049439	Enhanced		Approved	Nucleoplasm	Liver cancer:3.23e-5 (unfavourable), Renal cancer:2.07e-4 (unfavourable), Cervical cancer:7.16e-4 (favourable), Colorectal cancer:8.64e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.3	Expressed in all		
SF3A3	PRP9, PRPF9, SAP61, SF3a60	ENSG00000183431	Splicing factor 3a subunit 3	1	37956975-37990921	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032054, HPA032055	Enhanced		Enhanced	Nucleoplasm	Liver cancer:2.11e-8 (unfavourable)	Expressed in all	Expressed in all			endometrium: 35.2	Expressed in all		
SF3B2	Cus1, SAP145, SF3b1, SF3b145	ENSG00000087365	Splicing factor 3b subunit 2	11	66050729-66069308	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045028	Supported		Enhanced	Nuclear speckles	Renal cancer:3.51e-5 (favourable), Liver cancer:6.43e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 192.7	Expressed in all		
SF3B3	KIAA0017, RSE1, SAP130, SF3b130	ENSG00000189091	Splicing factor 3b subunit 3	16	70523788-70577670	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041134, HPA042986	Supported		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 40.9	Expressed in all		
SF3B4	Hsh49, SAP49, SF3b49	ENSG00000143368	Splicing factor 3b subunit 4	1	149923317-149928344	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028578, HPA064660	Approved		Approved	Nuclear speckles	Renal cancer:1.74e-7 (unfavourable), Liver cancer:1.54e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 72.6	Expressed in all		
SF3B5	MGC3133, SF3b10, Ysf3	ENSG00000169976	Splicing factor 3b subunit 5	6	144094881-144095573	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054408	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			fallopian tube: 204.2	Expressed in all		
SF3B6	CGI-110, Ht006, P14, SAP14a, SF3B14a	ENSG00000115128	Splicing factor 3b subunit 6	2	24067584-24076443	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034829, HPA034830	Enhanced		Supported	Nucleoplasm	Liver cancer:5.57e-5 (unfavourable), Renal cancer:1.74e-4 (unfavourable), Pancreatic cancer:8.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 153.3	Expressed in all		
SFI1	KIAA0542, PISD, PPP1R139	ENSG00000198089	SFI1 centrin binding protein	22	31488688-31618586	Predicted intracellular proteins	Evidence at protein level						Head and neck cancer:1.10e-4 (favourable), Urothelial cancer:1.31e-4 (favourable), Pancreatic cancer:5.80e-4 (favourable)	Expressed in all	Mixed			lymph node: 13.9	Expressed in all		
SFMBT1	DKFZp434L243, RU1, SFMBT	ENSG00000163935	Scm-like with four mbt domains 1	3	52903572-53046750	Predicted intracellular proteins	Evidence at protein level	HPA036152, HPA064564			Enhanced	Nucleoplasm	Endometrial cancer:3.86e-4 (unfavourable)	Expressed in all	Group enriched	6	parathyroid gland: 32.9;testis: 83.1	thyroid gland: 9.9	Expressed in all		
SFMBT2	KIAA1617	ENSG00000198879	Scm-like with four mbt domains 2	10	7158624-7411486	Predicted intracellular proteins	Evidence at protein level	HPA035447, HPA035448	Uncertain		Supported	Nuclear speckles		Mixed	Mixed			parathyroid gland: 15.3	Cell line enhanced		Karpas-707: 19.0;REH: 22.4;SH-SY5Y: 19.1;THP-1: 19.7
SFN	YWHAS	ENSG00000175793	Stratifin	1	26863138-26864457	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB006268, HPA011105, CAB040552	Enhanced		Supported	Cytosol	Renal cancer:7.45e-6 (unfavourable), Liver cancer:5.68e-5 (unfavourable), Endometrial cancer:1.92e-4 (favourable), Pancreatic cancer:6.01e-4 (unfavourable)	Expressed in all	Group enriched	8	esophagus: 1090.0;skin: 1156.7	tonsil: 132.7	Cell line enhanced		A-431: 663.2;HaCaT: 1030.0;HBEC3-KT: 1288.5;hTCEpi: 852.9
SFPQ	PPP1R140, PSF	ENSG00000116560	Splicing factor proline and glutamine rich	1	35176378-35193148	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009886, HPA047513, HPA054689	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.91e-13 (unfavourable), Breast cancer:9.56e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 135.5	Expressed in all		
SFR1	bA373N18.1, C10orf78, FLJ41960, MEI5, MEIR5	ENSG00000156384	SWI5 dependent homologous recombination repair protein 1	10	104122058-104126385	Predicted intracellular proteins	Evidence at protein level	HPA039617	Uncertain				Liver cancer:2.59e-5 (unfavourable), Renal cancer:2.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.1	Expressed in all		
SFSWAP	SFRS8, SWAP	ENSG00000061936	Splicing factor SWAP homolog	12	131711081-131799737	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039362, HPA040063	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:3.33e-8 (unfavourable), Melanoma:1.10e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 18.1	Expressed in all		
SFTA3	NANCI, SFTPH	ENSG00000229415	Surfactant associated 3	14	36473288-36513829	Predicted intracellular proteins	Evidence at protein level						Lung cancer:8.29e-4 (favourable)	Group enriched	Group enriched	467	lung: 85.7;thyroid gland: 49.2	stomach: 0.1	Cell line enriched	234	SCLC-21H: 23.3
SFTPC	BRICD6, PSP-C, SFTP2, SMDP2, SP-C	ENSG00000168484	Surfactant protein C	8	22156913-22164479	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA010928	Enhanced					Tissue enriched	Tissue enriched	832	lung: 25269.5	adrenal gland: 30.3	Group enriched	9	BEWO: 9.2;NB-4: 8.0;SCLC-21H: 6.1;U-2197: 24.0
SGF29	CCDC101, FLJ32446, TDRD29	ENSG00000176476	SAGA complex associated factor 29	16	28553915-28591790	Predicted intracellular proteins	Evidence at protein level	HPA052590, HPA053608	Enhanced		Approved	Nucleus<br>Nucleoli	Pancreatic cancer:2.99e-4 (favourable), Lung cancer:3.37e-4 (favourable), Cervical cancer:4.77e-4 (favourable)	Expressed in all	Expressed in all			testis: 41.6	Expressed in all		
SGIP1	DKFZp761D221	ENSG00000118473	SH3 domain GRB2 like endophilin interacting protein 1	1	66533383-66748299	Predicted intracellular proteins	Evidence at protein level	HPA017963	Approved		Approved	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 36.2	endometrium: 16.9	Cell line enhanced		BJ: 24.8;BJ hTERT+: 30.5;fHDF/TERT166: 18.7;RPTEC TERT1: 20.7;SH-SY5Y: 15.7;U-138 MG: 26.6
SGK1	SGK	ENSG00000118515	Serum/glucocorticoid regulated kinase 1	6	134169246-134318112	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB022085, CAB025148, HPA051251	Approved		Enhanced	Nuclear speckles	Cervical cancer:5.26e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 793.4	Cell line enhanced		RPTEC TERT1: 354.6;TIME: 304.3
SGK2		ENSG00000101049	SGK2, serine/threonine kinase 2	20	43558968-43588237	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008859, HPA011387	Uncertain		Supported	Nucleoplasm	Urothelial cancer:5.65e-4 (favourable)	Group enriched	Mixed			kidney: 43.2	Group enriched	5	A549: 16.2;CAPAN-2: 12.2;EFO-21: 6.5;Hep G2: 12.5;RPTEC TERT1: 19.0
SGK3	SGK2, SGKL	ENSG00000104205	Serum/glucocorticoid regulated kinase family member 3	8	66712418-66862022	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006699, HPA027146	Supported		Approved	Nucleoplasm<br>Vesicles	Breast cancer:5.52e-6 (favourable), Cervical cancer:8.28e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 48.5	Mixed		
SGK494		ENSG00000167524	Uncharacterized serine/threonine-protein kinase SgK494	17	28607964-28614200	Predicted intracellular proteins	Evidence at protein level	HPA046590	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane		Mixed	Mixed			testis: 10.5	Mixed		
SGO1	NY-BR-85, SGOL1	ENSG00000129810	Shugoshin 1	3	20160593-20186292	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035501, HPA069857	Enhanced		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 13.2	lymph node: 8.1	Mixed		
SGO2	FLJ25211, SGOL2, TRIPIN	ENSG00000163535	Shugoshin 2	2	200510008-200583782	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035163, HPA040817	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enriched	6	testis: 59.6	lymph node: 9.2	Expressed in all		
SGSM1	KIAA1941, RUTBC2	ENSG00000167037	Small G protein signaling modulator 1	22	24806169-24927578	Predicted intracellular proteins	Evidence at protein level	HPA003986	Approved					Mixed	Tissue enhanced		cerebral cortex: 14.8;parathyroid gland: 19.0	fallopian tube: 7.6	Cell line enhanced		RPMI-8226: 1.5;SCLC-21H: 2.4;SH-SY5Y: 1.4
SGSM2	KIAA0397, RUTBC1	ENSG00000141258	Small G protein signaling modulator 2	17	2337498-2381058	Predicted intracellular proteins	Evidence at protein level	HPA021641, HPA024553	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:9.00e-6 (favourable), Head and neck cancer:3.11e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 78.0	Expressed in all		
SGTA	SGT	ENSG00000104969	Small glutamine rich tetratricopeptide repeat containing alpha	19	2754714-2783371	Predicted intracellular proteins	Evidence at protein level	HPA056309	Approved		Approved	Nucleoplasm	Endometrial cancer:1.04e-4 (favourable), Renal cancer:2.35e-4 (favourable), Cervical cancer:9.70e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 64.6	Mixed		
SGTB	FLJ39002, Sgt2	ENSG00000197860	Small glutamine rich tetratricopeptide repeat containing beta	5	65665928-65723035	Predicted intracellular proteins	Evidence at protein level	HPA044689, HPA063674	Enhanced		Uncertain	Nucleus		Expressed in all	Tissue enhanced		cerebral cortex: 52.0	appendix: 10.4	Expressed in all		
SH2B1	FLJ30542, SH2B	ENSG00000178188	SH2B adaptor protein 1	16	28846600-28874212	Predicted intracellular proteins	Evidence at protein level	HPA076175			Approved	Vesicles	Renal cancer:2.81e-6 (favourable), Urothelial cancer:1.60e-4 (favourable), Pancreatic cancer:4.38e-4 (favourable), Lung cancer:9.40e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 105.8	Expressed in all		
SH2B2	APS	ENSG00000160999	SH2B adaptor protein 2	7	102285091-102321711	Predicted intracellular proteins	Evidence at protein level	HPA051131	Uncertain		Enhanced	Cytosol	Renal cancer:6.99e-7 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 12.9	Cell line enhanced		Daudi: 46.0;Karpas-707: 43.6;U-266/70: 42.7;U-266/84: 73.5;U-698: 59.4
SH2B3	IDDM20, LNK	ENSG00000111252	SH2B adaptor protein 3	12	111405948-111451623	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005483	Approved		Approved	Nucleoplasm	Renal cancer:6.20e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 51.1	Cell line enhanced		hTEC/SVTERT24-B: 141.0;U-87 MG: 207.2;WM-115: 163.2
SH2D1A	DSHP, EBVS, IMD5, LYP, MTCP1, SAP, XLP, XLPD	ENSG00000183918	SH2 domain containing 1A	X	124227868-124373197	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.94e-6 (unfavourable), Breast cancer:2.03e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 36.3;spleen: 17.5	tonsil: 13.2	Group enriched	6	HDLM-2: 89.9;Karpas-707: 148.7;MOLT-4: 209.2
SH2D1B	EAT2	ENSG00000198574	SH2 domain containing 1B	1	162395266-162412138	Predicted intracellular proteins	Evidence at protein level	HPA054791	Uncertain					Not detected	Tissue enhanced		spleen: 10.3	lung: 3.3	Cell line enhanced		CAPAN-2: 1.3;EFO-21: 2.5;Karpas-707: 3.2;TIME: 1.1
SH2D2A	F2771, TSAd	ENSG00000027869	SH2 domain containing 2A	1	156806243-156816862	Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.26e-12 (unfavourable), Urothelial cancer:1.31e-4 (favourable), Breast cancer:4.96e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 15.0	lymph node: 10.5	Cell line enhanced		HDLM-2: 42.7;HMC-1: 29.0;Karpas-707: 57.7
SH2D3A	NSP1	ENSG00000125731	SH2 domain containing 3A	19	6752160-6767588	Predicted intracellular proteins	Evidence at protein level	HPA035722, HPA064382	Uncertain		Approved	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge	Renal cancer:1.42e-4 (favourable), Prostate cancer:6.21e-4 (unfavourable)	Mixed	Mixed			skin: 14.0	Cell line enhanced		A-431: 35.6;HBEC3-KT: 47.1
SH2D3C	NSP3	ENSG00000095370	SH2 domain containing 3C	9	127738317-127778741	Predicted intracellular proteins	Evidence at protein level	HPA047586	Enhanced				Head and neck cancer:1.98e-4 (favourable), Endometrial cancer:9.47e-4 (favourable)	Expressed in all	Mixed			spleen: 49.7	Cell line enhanced		HMC-1: 47.3;HUVEC TERT2: 50.2;REH: 55.2;RPMI-8226: 32.1;TIME: 40.8
SH2D4A	FLJ20967, PPP1R38, SH2A	ENSG00000104611	SH2 domain containing 4A	8	19313617-19396218	Predicted intracellular proteins	Evidence at protein level	HPA001871, HPA001919	Enhanced		Enhanced	Cytosol	Renal cancer:6.02e-8 (favourable)	Expressed in all	Mixed			ovary: 44.9	Cell line enhanced		fHDF/TERT166: 140.4;U-2197: 121.2
SH2D4B		ENSG00000178217	SH2 domain containing 4B	10	80537902-80646560	Predicted intracellular proteins	Evidence at protein level	HPA040022	Uncertain					Not detected	Not detected			epididymis: 0.5	Cell line enriched	64	REH: 17.4
SH2D5		ENSG00000189410	SH2 domain containing 5	1	20719732-20732837	Predicted intracellular proteins	Evidence at protein level	HPA030182			Supported	Cytosol		Tissue enhanced	Group enriched	7	cerebral cortex: 16.6;placenta: 5.1;testis: 9.9	thyroid gland: 1.5	Cell line enhanced		HBEC3-KT: 34.9;hTERT-HME1: 46.6
SH2D6	FLJ35993	ENSG00000152292	SH2 domain containing 6	2	85418721-85437029	Predicted intracellular proteins	Evidence at transcript level	HPA053873	Uncertain					Mixed	Tissue enhanced		duodenum: 1.5;testis: 3.1;thyroid gland: 1.4	small intestine: 1.1	Cell line enhanced		LHCN-M2: 1.7
SH2D7	LOC646892	ENSG00000183476	SH2 domain containing 7	15	78077808-78104909	Predicted intracellular proteins	Evidence at transcript level	HPA051320	Approved					Mixed	Group enriched	7	colon: 1.6;duodenum: 2.1;small intestine: 1.9;testis: 5.7	cerebral cortex: 0.4	Cell line enhanced		SH-SY5Y: 1.4
SH3BGR	21-GARP	ENSG00000185437	SH3 domain binding glutamate rich protein	21	39445855-39515506	Predicted intracellular proteins	Evidence at protein level	CAB003685, HPA030690	Enhanced		Approved	Plasma membrane<br>Cytosol		Expressed in all	Group enriched	6	heart muscle: 100.8;skeletal muscle: 435.9	prostate: 41.4	Cell line enhanced		U-87 MG: 100.6
SH3BGRL	MGC117402	ENSG00000131171	SH3 domain binding glutamate rich protein like	X	81201943-81298547	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051248	Approved		Approved	Vesicles	Stomach cancer:4.08e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 360.6	Mixed		
SH3BGRL2		ENSG00000198478	SH3 domain binding glutamate rich protein like 2	6	79631283-79703659	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047486	Approved		Supported	Nucleoplasm	Renal cancer:2.24e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 98.4	Cell line enhanced		CACO-2: 66.4;HEL: 37.0
SH3BGRL3		ENSG00000142669	SH3 domain binding glutamate rich protein like 3	1	26279176-26281522	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030848, HPA076219	Approved		Approved	Nuclear bodies	Renal cancer:2.17e-10 (unfavourable)	Expressed in all	Expressed in all			epididymis: 448.9	Expressed in all		
SH3BP1	ARHGAP43	ENSG00000100092	SH3 domain binding protein 1	22	37634654-37666932	Predicted intracellular proteins	Evidence at protein level	HPA000757	Enhanced		Approved	Cytosol	Renal cancer:3.48e-7 (unfavourable), Stomach cancer:3.39e-4 (favourable), Liver cancer:9.55e-4 (unfavourable)	Expressed in all	Mixed			spleen: 17.9	Mixed		
SH3BP2	CRBM, RES4-23	ENSG00000087266	SH3 domain binding protein 2	4	2793023-2841098	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036790	Approved		Approved	Nucleus<br>Actin filaments	Endometrial cancer:5.42e-6 (unfavourable), Head and neck cancer:1.57e-5 (favourable), Urothelial cancer:2.67e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.9	Mixed		
SH3BP4		ENSG00000130147	SH3 domain binding protein 4	2	234951973-235055714	Predicted intracellular proteins	Evidence at protein level	HPA037533, HPA037534	Uncertain				Renal cancer:2.07e-6 (favourable)	Expressed in all	Mixed			breast: 42.6	Mixed		
SH3BP5	Sab	ENSG00000131370	SH3 domain binding protein 5	3	15254853-15341368	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036445, HPA057988	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:8.17e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 221.2	Expressed in all		
SH3BP5L	KIAA1720	ENSG00000175137	SH3 binding domain protein 5 like	1	248810446-248826633	Predicted intracellular proteins	Evidence at protein level	HPA038067, HPA038068	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			cerebral cortex: 19.7	Expressed in all		
SH3D19	DKFZp434D0215, EBP, EVE1, Kryn, SH3P19	ENSG00000109686	SH3 domain containing 19	4	151102751-151325632	Predicted intracellular proteins	Evidence at protein level	HPA016424, HPA058562	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.38e-5 (favourable)	Expressed in all	Mixed			gallbladder: 99.5	Cell line enhanced		ASC diff: 130.5;ASC TERT1: 113.0
SH3D21	C1orf113, FLJ22938	ENSG00000214193	SH3 domain containing 21	1	36306387-36324886	Predicted intracellular proteins	Evidence at protein level	HPA042212, HPA042456, HPA066168	Approved		Approved	Nucleus<br>Plasma membrane	Renal cancer:1.76e-6 (unfavourable), Breast cancer:2.60e-4 (favourable)	Mixed	Tissue enhanced		small intestine: 22.2	skin: 15.5	Cell line enhanced		HaCaT: 15.2
SH3GL1	CNSA1, EEN, MGC111371, SH3D2B, SH3P8	ENSG00000141985	SH3 domain containing GRB2 like 1, endophilin A2	19	4360370-4400547	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021485	Approved		Enhanced	Cytosol	Renal cancer:9.36e-8 (unfavourable), Liver cancer:1.10e-4 (unfavourable), Cervical cancer:1.50e-4 (favourable), Endometrial cancer:1.86e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 114.5	Expressed in all		
SH3GL2	CNSA2, EEN-B1, SH3D2A, SH3P4	ENSG00000107295	SH3 domain containing GRB2 like 2, endophilin A1	9	17579082-17797129	Predicted intracellular proteins	Evidence at protein level	CAB010056, HPA026685, HPA063573	Enhanced	Supported	Approved	Microtubules<br>Cytokinetic bridge<br>Mitotic spindle	Renal cancer:6.68e-12 (favourable)	Tissue enhanced	Tissue enriched	10	cerebral cortex: 170.1	kidney: 17.5	Cell line enhanced		HeLa: 14.7;RT4: 34.0;SCLC-21H: 31.7
SH3GL3	CNSA3, EEN-B2, HsT19371, SH3D2C, SH3P13	ENSG00000140600	SH3 domain containing GRB2 like 3, endophilin A3	15	83447228-83618743	Predicted intracellular proteins	Evidence at protein level	HPA039381	Enhanced					Mixed	Group enriched	12	cerebral cortex: 29.9;testis: 38.5	lung: 2.9	Cell line enhanced		HAP1: 30.3;HEK93: 13.3;K-562: 21.4;RH-30: 8.7
SH3GLB1	Bif-1, CGI-61, KIAA0491, PPP1R70	ENSG00000097033	SH3 domain containing GRB2 like endophilin B1	1	86704570-86748184	Predicted intracellular proteins	Evidence at protein level	CAB004650, HPA015608, HPA019900	Enhanced		Enhanced	Cytosol	Liver cancer:2.90e-5 (unfavourable), Pancreatic cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 198.5	Expressed in all		
SH3GLB2	KIAA1848	ENSG00000148341	SH3 domain containing GRB2 like endophilin B2	9	129007036-129028303	Predicted intracellular proteins	Evidence at protein level	HPA021438, HPA024734	Approved		Supported	Nucleoplasm<br>Cytosol	Cervical cancer:1.56e-6 (favourable), Renal cancer:2.32e-4 (favourable), Urothelial cancer:4.28e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 92.1	Expressed in all		
SH3KBP1	CIN85	ENSG00000147010	SH3 domain containing kinase binding protein 1	X	19533975-19887601	Predicted intracellular proteins	Evidence at protein level	HPA003351, HPA003355, CAB021892	Enhanced		Supported	Cytosol	Renal cancer:2.10e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 79.5	Expressed in all		
SH3PXD2A	FISH, KIAA0418, SH3MD1	ENSG00000107957	SH3 and PX domains 2A	10	103594027-103855543	Predicted intracellular proteins	Evidence at protein level	HPA037922, HPA037923	Approved				Renal cancer:2.04e-6 (unfavourable), Ovarian cancer:3.18e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 63.3	Cell line enhanced		BJ hTERT+: 68.9
SH3PXD2B	FLJ20831, KIAA1295	ENSG00000174705	SH3 and PX domains 2B	5	172325000-172454523	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036471	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Liver cancer:7.51e-5 (unfavourable), Renal cancer:1.90e-4 (unfavourable), Urothelial cancer:8.45e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 35.7	Mixed		
SH3RF1	KIAA1494, POSH, RNF142, SH3MD2	ENSG00000154447	SH3 domain containing ring finger 1	4	169094256-169271105	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA074783			Supported	Vesicles<br>Intermediate filaments	Renal cancer:5.51e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 32.1	Mixed		
SH3RF2	FLJ23654, Hepp1, POSHER, PPP1R39, RNF158	ENSG00000156463	SH3 domain containing ring finger 2	5	145936579-146081791	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035903, HPA058119	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		skin: 67.3	heart muscle: 26.1	Cell line enhanced		CACO-2: 57.4
SH3TC2	CMT4C, KIAA1985	ENSG00000169247	SH3 domain and tetratricopeptide repeats 2	5	148923639-149063163	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037683, HPA037684	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	6	cerebral cortex: 3.0;placenta: 2.8;testis: 8.8	cervix, uterine,heart muscle: 0.7	Cell line enhanced		RT4: 6.6;SK-MEL-30: 5.9;WM-115: 8.2
SH3YL1	DKFZP586F1318, Ray	ENSG00000035115	SH3 and SYLF domain containing 1	2	217730-266398	Predicted intracellular proteins	Evidence at protein level	HPA030926, HPA030927	Approved		Approved	Nucleus	Renal cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			kidney: 150.0	Mixed		
SHANK1	SPANK-1, SSTRIP, synamon	ENSG00000161681	SH3 and multiple ankyrin repeat domains 1	19	50661827-50719450	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032129, HPA032130	Uncertain		Supported	Plasma membrane		Tissue enhanced	Tissue enriched	24	cerebral cortex: 35.8	adrenal gland: 1.5	Cell line enhanced		REH: 4.6;U-138 MG: 2.6;U-2 OS: 7.1
SHANK2	CORTBP1, CTTNBP1, ProSAP1, SHANK, SPANK-3	ENSG00000162105	SH3 and multiple ankyrin repeat domains 2	11	70467856-71252577	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008174	Approved				Renal cancer:1.94e-6 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 20.9	thyroid gland: 11.6	Cell line enhanced		Karpas-707: 16.4;RT4: 16.7;T-47d: 15.1
SHANK3	KIAA1650, prosap2, PSAP2, SPANK-2	ENSG00000251322	SH3 and multiple ankyrin repeat domains 3	22	50674415-50733298	Predicted intracellular proteins	Evidence at protein level	HPA003446, CAB079070	Enhanced	Approved			Colorectal cancer:7.40e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 2.7	Cell line enhanced		HEL: 3.8;TIME: 4.6
SHARPIN	DKFZP434N1923, SIPL1	ENSG00000179526	SHANK associated RH domain interactor	8	144098633-144108124	Predicted intracellular proteins	Evidence at protein level	HPA044453	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 66.1	Expressed in all		
SHB		ENSG00000107338	SH2 domain containing adaptor protein B	9	37919134-38069211	Predicted intracellular proteins	Evidence at protein level	CAB010161, HPA049911, HPA052108	Uncertain		Enhanced	Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies		Expressed in all	Expressed in all			parathyroid gland: 16.2	Mixed		
SHC1	p66, SHC, ShcA	ENSG00000160691	SHC adaptor protein 1	1	154962298-154974395	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001844, CAB005374, CAB016305	Supported		Enhanced	Cytosol	Renal cancer:2.22e-16 (unfavourable), Lung cancer:1.92e-4 (unfavourable), Cervical cancer:6.74e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 162.2	Expressed in all		
SHC2	SCK, SHCB, SLI	ENSG00000129946	SHC adaptor protein 2	19	416583-460996	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA006136	Approved		Approved	Cytosol	Colorectal cancer:4.58e-4 (unfavourable), Pancreatic cancer:8.53e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 18.7	Cell line enhanced		SCLC-21H: 14.8;SH-SY5Y: 12.0
SHC3	N-Shc, NSHC, SHCC	ENSG00000148082	SHC adaptor protein 3	9	89005771-89178767	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA031427, HPA046656, HPA072448	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 45.3	parathyroid gland: 12.6	Cell line enhanced		AF22: 20.5;SH-SY5Y: 8.1;U-87 MG: 11.2
SHC4	RaLP, SHCD	ENSG00000185634	SHC adaptor protein 4	15	48823735-48963444	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA074146			Approved	Cytosol		Tissue enhanced	Group enriched	7	cerebral cortex: 13.1;testis: 20.1	gallbladder: 2.3	Cell line enhanced		AN3-CA: 9.5;SK-MEL-30: 15.2;WM-115: 16.3
SHCBP1	FLJ22009, PAL	ENSG00000171241	SHC binding and spindle associated 1	16	46580554-46621626	Predicted intracellular proteins	Evidence at protein level	HPA048876	Uncertain		Approved	Nuclear bodies<br>Microtubules<br>Cytokinetic bridge	Pancreatic cancer:4.47e-5 (unfavourable)	Mixed	Tissue enhanced		lymph node: 17.4	bone marrow: 16.7	Mixed		
SHCBP1L	C1orf14	ENSG00000157060	SHC binding and spindle associated 1 like	1	182899865-182953525	Predicted intracellular proteins	Evidence at protein level	HPA036124, HPA036125, HPA064821	Enhanced					Tissue enhanced	Tissue enriched	989	testis: 98.9	all non-specific tissues: 0.0	Not detected		
SHD		ENSG00000105251	Src homology 2 domain containing transforming protein D	19	4278601-4290724	Predicted intracellular proteins	Evidence at protein level	HPA017955	Uncertain		Uncertain	Microtubule organizing center<br>Cytosol		Tissue enhanced	Tissue enriched	6	cerebral cortex: 22.1	heart muscle: 3.8	Group enriched	57	RH-30: 51.7;SH-SY5Y: 181.9
SHF		ENSG00000138606	Src homology 2 domain containing F	15	45167214-45201175	Predicted intracellular proteins	Evidence at protein level	HPA057381			Approved	Nucleus		Expressed in all	Mixed			adrenal gland: 29.9	Cell line enhanced		SCLC-21H: 142.5;SH-SY5Y: 57.3
SHMT1	CSHMT, MGC15229, MGC24556, SHMT	ENSG00000176974	Serine hydroxymethyltransferase 1	17	18327860-18363563	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023314	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:8.54e-6 (favourable), Liver cancer:2.52e-4 (favourable)	Expressed in all	Expressed in all			kidney: 271.5	Expressed in all		
SHMT2	SHMT	ENSG00000182199	Serine hydroxymethyltransferase 2	12	57229327-57234935	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020543, HPA020549	Enhanced		Enhanced	Microtubules<br>Mitochondria	Renal cancer:4.84e-8 (unfavourable), Breast cancer:8.37e-5 (unfavourable)	Expressed in all	Expressed in all			liver: 74.8	Expressed in all		
SHOC2	KIAA0862, SOC-2, SOC2, SUR-8, SUR8	ENSG00000108061	SHOC2, leucine rich repeat scaffold protein	10	110919547-111013667	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA009164			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 65.3	Expressed in all		
SHOX	GCFX, PHOG, SHOXY, SS	ENSG00000185960	Short stature homeobox	X	624344-659411	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035141, HPA060931			Enhanced	Nucleoplasm<br>Vesicles		Not detected	Mixed			spleen: 1.0	Cell line enhanced		BJ: 19.3;BJ hTERT+: 9.5
SHOX2	OG12, OG12X, SHOT	ENSG00000168779	Short stature homeobox 2	3	158095954-158106503	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		adipose tissue: 4.1;testis: 3.3	cervix, uterine: 2.8	Cell line enhanced		SH-SY5Y: 26.1;THP-1: 28.6
SHPK	CARKL, SHK	ENSG00000197417	Sedoheptulokinase	17	3608262-3636322	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024361, HPA064939	Enhanced		Approved	Nucleoplasm<br>Nuclear speckles		Expressed in all	Mixed			duodenum: 13.4	Expressed in all		
SHPRH	bA545I5.2, FLJ90837, KIAA2023	ENSG00000146414	SNF2 histone linker PHD RING helicase	6	145864245-145964423	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034854, HPA034950	Approved		Approved	Mitochondria		Mixed	Mixed			ovary: 15.1	Expressed in all		
SHQ1	FLJ10539, Shq1p	ENSG00000144736	SHQ1, H/ACA ribonucleoprotein assembly factor	3	72749277-72861914	Predicted intracellular proteins	Evidence at protein level	HPA042792	Uncertain		Supported	Nucleoplasm	Colorectal cancer:2.83e-4 (favourable), Endometrial cancer:6.49e-4 (favourable)	Expressed in all	Expressed in all			testis: 18.0	Expressed in all		
SHROOM1	APXL2, KIAA1960	ENSG00000164403	Shroom family member 1	5	132822141-132830898	Predicted intracellular proteins	Evidence at protein level	HPA037690, HPA037691	Uncertain		Approved	Vesicles	Renal cancer:5.72e-6 (unfavourable)	Expressed in all	Tissue enhanced		prostate: 54.5	seminal vesicle: 21.3	Mixed		
SHROOM2	APXL	ENSG00000146950	Shroom family member 2	X	9786456-9949443	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051646, HPA061435	Approved		Approved	Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.35e-7 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.8	Cell line enhanced		WM-115: 22.8
SHROOM3	APXL3, KIAA1481, SHRM, ShrmL	ENSG00000138771	Shroom family member 3	4	76435100-76783253	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047784	Enhanced				Renal cancer:1.64e-13 (favourable)	Expressed in all	Mixed			parathyroid gland: 27.6	Cell line enhanced		AF22: 30.8
SHROOM4	KIAA1202	ENSG00000158352	Shroom family member 4	X	50591647-50814302	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA010565	Uncertain				Renal cancer:4.66e-4 (unfavourable), Endometrial cancer:8.37e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 19.2	placenta: 13.1	Cell line enhanced		EFO-21: 6.5;HUVEC TERT2: 22.2;TIME: 8.3
SHTN1	KIAA1598, shootin-1, shootin1	ENSG00000187164	Shootin 1	10	116881482-117126586	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA037942, HPA037943	Enhanced	Approved	Approved	Nucleus<br>Plasma membrane<br>Cytosol	Urothelial cancer:5.08e-6 (unfavourable), Prostate cancer:5.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 36.1	parathyroid gland: 18.7	Mixed		
SIAH1	hSIAH1	ENSG00000196470	Siah E3 ubiquitin protein ligase 1	16	48356364-48448402	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018724	Enhanced		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			placenta: 70.4	Expressed in all		
SIAH2		ENSG00000181788	Siah E3 ubiquitin protein ligase 2	3	150741127-150763477	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061293, CAB069930	Approved		Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:8.21e-5 (unfavourable), Breast cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 95.3	Expressed in all		
SIAH3	FLJ39203	ENSG00000215475	Siah E3 ubiquitin protein ligase family member 3	13	45777243-45851736	Predicted intracellular proteins	Evidence at transcript level	HPA060576	Uncertain					Tissue enhanced	Tissue enhanced		fallopian tube: 5.0	cerebral cortex,cervix, uterine: 1.4	Cell line enriched	8	EFO-21: 1.0
SIKE1	FLJ21168, SIKE	ENSG00000052723	Suppressor of IKBKE 1	1	114769479-114780685	Predicted intracellular proteins	Evidence at protein level	HPA024177, HPA025726	Supported		Approved	Vesicles<br>Focal adhesion sites		Expressed in all	Expressed in all			thyroid gland: 19.4	Expressed in all		
SIM1	bHLHe14	ENSG00000112246	Single-minded family bHLH transcription factor 1	6	100385015-100464929	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA024385			Approved	Nuclear speckles	Renal cancer:5.32e-7 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 3.5;kidney: 11.2;seminal vesicle: 3.2	skeletal muscle: 1.2	Cell line enhanced		BJ: 13.9;BJ hTERT+: 19.3;RPTEC TERT1: 13.9
SIM2	bHLHe15, MGC119447, SIM	ENSG00000159263	Single-minded family bHLH transcription factor 2	21	36699133-36749917	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029295	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.88e-4 (favourable)	Tissue enhanced	Tissue enhanced		esophagus: 22.8;kidney: 13.0;prostate: 10.3	stomach: 5.1	Cell line enhanced		PC-3: 40.7;RPTEC TERT1: 41.3;RT4: 26.9
SIMC1	C5orf25, FLJ44216, OOMA1, PLEIAD	ENSG00000170085	SUMO interacting motifs containing 1	5	176238367-176345991	Predicted intracellular proteins	Evidence at protein level	HPA037889, HPA037890	Uncertain		Supported	Nucleus<br>Nucleoli fibrillar center	Endometrial cancer:2.32e-6 (unfavourable), Glioma:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 71.8	ovary: 58.7	Mixed		
SIN3A	DKFZP434K2235, KIAA0700	ENSG00000169375	SIN3 transcription regulator family member A	15	75369379-75455842	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004506, HPA047213, HPA062123	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 55.3	Expressed in all		
SIN3B	KIAA0700	ENSG00000127511	SIN3 transcription regulator family member B	19	16829400-16880353	Predicted intracellular proteins	Evidence at protein level	HPA050329	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Prostate cancer:3.58e-4 (unfavourable), Pancreatic cancer:4.37e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 112.3	Expressed in all		
SIPA1	SPA1	ENSG00000213445	Signal-induced proliferation-associated 1	11	65638097-65650930	Predicted intracellular proteins	Evidence at protein level	CAB020833, HPA039867	Enhanced		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Plasma membrane	Renal cancer:3.52e-6 (unfavourable), Colorectal cancer:9.42e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 99.7	lymph node: 71.0	Expressed in all		
SIPA1L1	E6TP1, KIAA0440	ENSG00000197555	Signal induced proliferation associated 1 like 1	14	71320449-71741229	Predicted intracellular proteins	Evidence at protein level	HPA002875	Approved		Approved	Plasma membrane<br>Actin filaments	Renal cancer:6.80e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.0	Mixed		
SIPA1L2	KIAA1389	ENSG00000116991	Signal induced proliferation associated 1 like 2	1	232397965-232561558	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024181, HPA027224	Approved		Approved	Nuclear membrane<br>Nuclear bodies<br>Golgi apparatus	Renal cancer:8.15e-4 (unfavourable)	Expressed in all	Mixed			placenta: 29.1	Cell line enhanced		AF22: 74.1;NTERA-2: 60.3;WM-115: 50.8
SIPA1L3	KIAA0545	ENSG00000105738	Signal induced proliferation associated 1 like 3	19	37907228-38208372	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042072, HPA045480	Uncertain		Approved	Nuclear membrane<br>Nuclear speckles		Expressed in all	Mixed			small intestine: 19.8	Expressed in all		
SIRT1	SIR2L1	ENSG00000096717	Sirtuin 1	10	67884669-67918390	Predicted intracellular proteins	Evidence at protein level	CAB003855, HPA006295, HPA052351	Approved		Enhanced	Nucleus<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			testis: 49.0	Expressed in all		
SIRT2	SIR2L	ENSG00000068903	Sirtuin 2	19	38878555-38899862	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004573, HPA011165	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Endometrial cancer:7.20e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 83.9	Expressed in all		
SIRT3	SIR2L3	ENSG00000142082	Sirtuin 3	11	215458-236931	Predicted intracellular proteins	Evidence at protein level	HPA026809, CAB037142	Approved				Renal cancer:4.85e-9 (favourable), Endometrial cancer:8.51e-5 (favourable), Pancreatic cancer:4.45e-4 (favourable), Glioma:9.21e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 50.7	Expressed in all		
SIRT4	SIR2L4	ENSG00000089163	Sirtuin 4	12	120302316-120313249	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA029691, HPA029692	Enhanced				Renal cancer:1.75e-4 (favourable)	Mixed	Mixed			testis: 9.5	Mixed		
SIRT5		ENSG00000124523	Sirtuin 5	6	13574529-13615158	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021798, HPA022002, HPA022992	Approved		Enhanced	Mitochondria	Renal cancer:8.76e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.1	Expressed in all		
SIRT6		ENSG00000077463	Sirtuin 6	19	4174109-4182604	Predicted intracellular proteins	Evidence at protein level	HPA049729, HPA071776	Supported		Supported	Nucleoplasm	Urothelial cancer:2.58e-4 (favourable), Endometrial cancer:2.85e-4 (favourable), Stomach cancer:9.13e-4 (favourable)	Expressed in all	Expressed in all			colon: 13.2	Expressed in all		
SIRT7		ENSG00000187531	Sirtuin 7	17	81911939-81921323	Predicted intracellular proteins	Evidence at protein level	CAB037261, HPA053669	Enhanced		Supported	Nucleoli fibrillar center<br>Vesicles	Renal cancer:1.69e-7 (unfavourable), Liver cancer:1.97e-5 (unfavourable)	Expressed in all	Mixed			esophagus: 21.6	Expressed in all		
SIVA1	CD27BP, SIVA, Siva-1, Siva-2	ENSG00000184990	SIVA1 apoptosis inducing factor	14	104753100-104768494	Predicted intracellular proteins	Evidence at protein level	HPA065398, HPA066693			Supported	Nucleoplasm	Cervical cancer:5.95e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 62.0	Expressed in all		
SIX1	DFNA23	ENSG00000126778	SIX homeobox 1	14	60643415-60658259	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001893, CAB058690	Enhanced		Supported	Nucleus<br>Nucleoli	Endometrial cancer:8.92e-6 (unfavourable), Lung cancer:3.94e-4 (favourable)	Mixed	Group enriched	6	cervix, uterine: 21.9;parathyroid gland: 53.5;prostate: 21.2;salivary gland: 21.6;skeletal muscle: 41.5	adipose tissue: 5.6	Cell line enhanced		LHCN-M2: 118.6;RH-30: 69.5
SIX2		ENSG00000170577	SIX homeobox 2	2	45005161-45009430	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056958			Supported	Nucleoplasm<br>Nuclear membrane		Mixed	Group enriched	5	cervix, uterine: 18.7;parathyroid gland: 8.6;prostate: 6.3;salivary gland: 9.4;skeletal muscle: 6.7	adipose tissue: 1.9	Cell line enhanced		ASC TERT1: 34.1;LHCN-M2: 39.0;RH-30: 30.9;SCLC-21H: 63.8;U-2197: 32.8;U-698: 29.5
SIX3	HPE2	ENSG00000138083	SIX homeobox 3	2	44941898-44946077	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067988			Approved	Nucleoplasm		Mixed	Tissue enriched	31	parathyroid gland: 39.3	cervix, uterine: 1.2	Cell line enhanced		HAP1: 12.7;SCLC-21H: 77.1;SH-SY5Y: 27.8
SIX4	AREC3	ENSG00000100625	SIX homeobox 4	14	60709528-60724348	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031794	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enriched	5	parathyroid gland: 23.9	skeletal muscle: 4.7	Cell line enhanced		A-431: 29.3;RH-30: 31.5
SIX5	DMAHP	ENSG00000177045	SIX homeobox 5	19	45764785-45769226	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042068	Approved					Expressed in all	Mixed			ovary: 33.7	Mixed		
SIX6	OPTX2, Six9	ENSG00000184302	SIX homeobox 6	14	60508951-60512850	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001403	Approved		Approved	Nucleoplasm		Tissue enriched	Not detected			testis: 0.1	Cell line enriched	14	MOLT-4: 33.0
SKA1	C18orf24, MGC10200	ENSG00000154839	Spindle and kinetochore associated complex subunit 1	18	50374995-50394173	Predicted intracellular proteins	Evidence at protein level	HPA045495	Approved		Supported	Microtubules	Liver cancer:9.60e-8 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 5.5;testis: 5.9	lymph node: 4.1	Mixed		
SKA2	FAM33A, FLJ12758	ENSG00000182628	Spindle and kinetochore associated complex subunit 2	17	59109951-59155269	Predicted intracellular proteins	Evidence at protein level	HPA059235	Uncertain				Renal cancer:2.90e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 43.1	Expressed in all		
SKA3	C13orf3, MGC4832, RAMA1	ENSG00000165480	Spindle and kinetochore associated complex subunit 3	13	21153595-21176602	Predicted intracellular proteins	Evidence at protein level	HPA039272	Approved		Uncertain	Plasma membrane<br>Cytosol	Liver cancer:9.73e-6 (unfavourable), Pancreatic cancer:3.77e-4 (unfavourable), Melanoma:8.71e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 10.1	lymph node: 5.0	Mixed		
SKAP1	SCAP1, SKAP55	ENSG00000141293	Src kinase associated phosphoprotein 1	17	48133440-48430275	Predicted intracellular proteins	Evidence at protein level	HPA002969, CAB025882, CAB055513	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Urothelial cancer:3.14e-4 (favourable), Breast cancer:5.07e-4 (favourable)	Mixed	Mixed			lymph node: 33.6	Cell line enhanced		CAPAN-2: 26.1;HDLM-2: 14.7;HMC-1: 11.3;Karpas-707: 11.5;RPMI-8226: 13.6;RPTEC TERT1: 17.6;U-266/70: 11.0
SKAP2	RA70, SAPS, SCAP2, SKAP-HOM, SKAP55R	ENSG00000005020	Src kinase associated phosphoprotein 2	7	26667062-26995239	Predicted intracellular proteins	Evidence at protein level	HPA005560, HPA024045	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 54.6	Cell line enhanced		CAPAN-2: 125.0
SKI		ENSG00000157933	SKI proto-oncogene	1	2228695-2310119	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010449, HPA066567	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			endometrium: 36.2	Expressed in all		
SKIDA1	C10orf140, FLJ45187	ENSG00000180592	SKI/DACH domain containing 1	10	21513478-21526368	Predicted intracellular proteins	Evidence at protein level	HPA039208, HPA040439	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 3.9	testis: 3.1	Cell line enhanced		AF22: 25.8;BEWO: 11.6
SKIL	SNO, SnoA, SnoN	ENSG00000136603	SKI like proto-oncogene	3	170357678-170396835	Predicted intracellular proteins	Evidence at protein level	HPA008472	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.19e-7 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 36.9	Expressed in all		
SKIV2L	170A, DDX13, HLP, SKI2W, SKIV2, SKIV2L1	ENSG00000204351	Ski2 like RNA helicase	6	31959080-31969755	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051959, HPA054419	Uncertain		Approved	Nucleoplasm	Renal cancer:3.02e-7 (unfavourable), Liver cancer:6.58e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 10.5	Mixed		
SKIV2L2	Dob1, fSAP118, KIAA0052, Mtr4	ENSG00000039123	Ski2 like RNA helicase 2	5	55307760-55425581	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037379	Supported		Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 37.1	Expressed in all		
SKOR1	CORL1, FUSSEL15, LBXCOR1	ENSG00000188779	SKI family transcriptional corepressor 1	15	67819704-67834561	Predicted intracellular proteins	Evidence at protein level	HPA040673	Approved					Not detected	Not detected			testis: 0.8	Cell line enhanced		U-266/70: 1.8;U-266/84: 1.3;U-698: 1.4
SKOR2	CORL2, Fussel-18, FUSSEL18	ENSG00000215474	SKI family transcriptional corepressor 2	18	47206322-47251603	Predicted intracellular proteins	Evidence at protein level	HPA046206	Uncertain					Not detected	Not detected			testis: 0.7	Cell line enhanced		NTERA-2: 3.9
SKP1	EMC19, MGC34403, OCP-II, OCP2, p19A, SKP1A, TCEB1L	ENSG00000113558	S-phase kinase associated protein 1	5	134148935-134177038	Predicted intracellular proteins	Evidence at protein level	CAB012982, HPA053745, HPA058134	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:5.20e-4 (favourable), Liver cancer:5.72e-4 (unfavourable), Breast cancer:7.53e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 934.2	Expressed in all		
SKP2	FBL1, FBXL1, p45	ENSG00000145604	S-phase kinase associated protein 2	5	36151989-36184319	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB013491, CAB013533, HPA051196, HPA054633	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:4.77e-15 (unfavourable), Melanoma:3.72e-7 (unfavourable), Ovarian cancer:8.57e-4 (favourable)	Expressed in all	Tissue enriched	6	placenta: 84.6	lymph node: 13.7	Expressed in all		
SLA	hSLAP, SLA1, SLAP, SLAP-1	ENSG00000155926	Src like adaptor	8	133036724-133103054	Predicted intracellular proteins	Evidence at protein level	HPA012296, HPA074192	Approved		Approved	Nuclear membrane		Expressed in all	Tissue enhanced		appendix: 104.2	lymph node: 79.7	Cell line enhanced		HMC-1: 39.6;Karpas-707: 88.0;MOLT-4: 27.3;U-266/84: 51.3;U-937: 38.7
SLA2	C20orf156, FLJ21992, SLAP-2	ENSG00000101082	Src like adaptor 2	20	36612318-36646216	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053746, HPA058217			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:6.77e-8 (unfavourable), Cervical cancer:7.36e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 11.8	spleen: 8.9	Cell line enriched	9	HEL: 81.2
SLAIN1	C13orf32, FLJ30046	ENSG00000139737	SLAIN motif family member 1	13	77697854-77764242	Predicted intracellular proteins	Evidence at protein level	HPA040798			Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Ovarian cancer:9.07e-4 (favourable)	Tissue enhanced	Expressed in all			cerebral cortex: 217.1	Cell line enhanced		HL-60: 61.7;MOLT-4: 72.0;SCLC-21H: 69.0
SLAIN2	FLJ21611, KIAA1458	ENSG00000109171	SLAIN motif family member 2	4	48341322-48426212	Predicted intracellular proteins	Evidence at protein level	HPA035824, HPA063599	Approved		Enhanced	Centrosome<br>Cytosol	Renal cancer:1.50e-4 (favourable), Colorectal cancer:5.77e-4 (favourable), Pancreatic cancer:6.71e-4 (unfavourable), Endometrial cancer:7.98e-4 (favourable)	Expressed in all	Expressed in all			testis: 72.9	Expressed in all		
SLBP	HBP	ENSG00000163950	Stem-loop binding protein	4	1692800-1712555	Predicted intracellular proteins	Evidence at protein level	HPA019254, HPA061670	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:2.29e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 130.6	Expressed in all		
SLC22A18AS	BWR1B, BWSCR1B, ORCTL2S, p27-BWR1B, SLC22A1LS	ENSG00000254827	Solute carrier family 22 member 18 antisense	11	2887780-2903740	Predicted intracellular proteins	Evidence at protein level	HPA068288	Enhanced		Supported	Nucleoplasm		Mixed	Tissue enhanced		colon: 14.4;duodenum: 13.5	small intestine: 11.0	Cell line enhanced		A549: 8.7;CAPAN-2: 8.3;MCF7: 14.0;SK-MEL-30: 26.1;WM-115: 14.7
SLC25A1	CTP, SLC20A3	ENSG00000100075	Solute carrier family 25 member 1	22	19175575-19178830	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level							Expressed in all	Expressed in all			duodenum: 112.7	Expressed in all		
SLC25A12	Aralar	ENSG00000115840	Solute carrier family 25 member 12	2	171784370-171999859	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035333, HPA035334	Enhanced		Uncertain	Nuclear speckles<br>Cytosol	Renal cancer:2.91e-8 (favourable), Endometrial cancer:7.86e-4 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 55.3	Mixed		
SLC25A13	ARALAR2, CITRIN, CTLN2	ENSG00000004864	Solute carrier family 25 member 13	7	96120220-96322147	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018997	Approved		Supported	Mitochondria	Renal cancer:9.14e-4 (favourable)	Expressed in all	Expressed in all			liver: 77.3	Mixed		
SLC25A21	ODC, ODC1	ENSG00000183032	Solute carrier family 25 member 21	14	36678431-37172866	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA000662	Uncertain					Not detected	Tissue enhanced		testis: 7.6	bone marrow: 3.8	Group enriched	6	HEK93: 8.7;K-562: 23.4;Karpas-707: 39.1
SLC25A24	APC1, DKFZp586G0123	ENSG00000085491	Solute carrier family 25 member 24	1	108134036-108200849	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA028519, HPA063636	Enhanced		Enhanced	Mitochondria	Colorectal cancer:1.01e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 22.1	Mixed		
SLC25A27	FLJ33552, UCP4	ENSG00000153291	Solute carrier family 25 member 27	6	46652915-46678193	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA069732			Supported	Mitochondria	Pancreatic cancer:6.16e-4 (favourable)	Expressed in all	Mixed			epididymis: 85.3	Cell line enhanced		HeLa: 29.3
SLC25A28	MRS3/4, MRS4L	ENSG00000155287	Solute carrier family 25 member 28	10	99610522-99620609	Predicted intracellular proteins, Transporters	Evidence at protein level						Cervical cancer:2.18e-6 (favourable), Renal cancer:7.28e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 93.6	Expressed in all		
SLC25A29	C14orf69, FLJ38975	ENSG00000197119	Solute carrier family 25 member 29	14	100291111-100306547	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA030781	Uncertain				Pancreatic cancer:2.90e-4 (favourable), Urothelial cancer:5.26e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 159.1	Mixed		
SLC25A30		ENSG00000174032	Solute carrier family 25 member 30	13	45393316-45418455	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045260			Approved	Nucleoplasm	Renal cancer:9.91e-8 (favourable), Ovarian cancer:3.32e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 46.1	Mixed		
SLC25A32	MFTC	ENSG00000164933	Solute carrier family 25 member 32	8	103398635-103415189	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA024763, HPA047402	Uncertain		Supported	Mitochondria	Renal cancer:1.53e-6 (unfavourable), Lung cancer:2.09e-4 (unfavourable), Endometrial cancer:7.23e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder,lymph node: 21.0	Expressed in all		
SLC25A37	HT015, MFRN, MFRN1, MSCP	ENSG00000147454	Solute carrier family 25 member 37	8	23528805-23575463	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045680	Uncertain				Renal cancer:4.37e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 80.1	Expressed in all		
SLC25A41	APC4, FLJ40442, MGC34725	ENSG00000181240	Solute carrier family 25 member 41	19	6426037-6433779	Predicted intracellular proteins, Transporters	Evidence at transcript level	HPA043591	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.0;testis: 1.9	esophagus: 0.4	Cell line enhanced		HMC-1: 2.4;U-937: 1.3
SLC2A4RG	GEF, HDBP1, Si-1-2, Si-1-2-19	ENSG00000125520	SLC2A4 regulator	20	63739861-63743505	Predicted intracellular proteins	Evidence at protein level	HPA063050			Approved	Nuclear speckles		Expressed in all	Expressed in all			adipose tissue: 53.7	Expressed in all		
SLC4A1AP	HLC3, kanadaptin	ENSG00000163798	Solute carrier family 4 member 1 adaptor protein	2	27663471-27694976	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA036679	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Liver cancer:3.76e-7 (unfavourable), Endometrial cancer:1.49e-4 (unfavourable), Urothelial cancer:1.79e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 62.0	Expressed in all		
SLC7A6OS	FLJ13291	ENSG00000103061	Solute carrier family 7 member 6 opposite strand	16	68284503-68310946	Predicted intracellular proteins	Evidence at protein level	HPA041533	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.35e-4 (favourable)	Mixed	Expressed in all			lymph node: 18.9	Expressed in all		
SLC9A3R1	EBP50, NHERF	ENSG00000109062	SLC9A3 regulator 1	17	74748652-74769353	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB001962, HPA009672, HPA027247	Enhanced		Approved	Vesicles<br>Plasma membrane<br>Microtubule organizing center	Liver cancer:9.83e-5 (unfavourable)	Expressed in all	Expressed in all			small intestine: 302.4	Expressed in all		
SLC9A3R2	E3KARP, NHERF-2, SIP-1, TKA-1	ENSG00000065054	SLC9A3 regulator 2	16	2025356-2039026	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001672, HPA066520	Enhanced		Supported	Plasma membrane	Endometrial cancer:1.03e-4 (favourable)	Expressed in all	Mixed			lung: 160.8	Cell line enhanced		MCF7: 234.6;PC-3: 259.8
SLFN11	FLJ34922	ENSG00000172716	Schlafen family member 11	17	35350305-35373701	Predicted intracellular proteins	Evidence at protein level	HPA023030, HPA062062	Uncertain		Enhanced	Nucleoplasm	Renal cancer:9.93e-10 (unfavourable)	Expressed in all	Expressed in all			lung: 56.0	Mixed		
SLFN12	FLJ10260	ENSG00000172123	Schlafen family member 12	17	35411060-35433283	Predicted intracellular proteins	Evidence at protein level	HPA022523	Uncertain				Renal cancer:4.14e-5 (unfavourable)	Mixed	Mixed			spleen: 13.2	Mixed		
SLFN13	FLJ31952	ENSG00000154760	Schlafen family member 13	17	35435096-35448837	Predicted intracellular proteins	Evidence at protein level	HPA022532, HPA023064	Uncertain		Approved	Cytokinetic bridge	Cervical cancer:3.82e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 41.2	fallopian tube: 26.9	Cell line enhanced		HL-60: 104.7;REH: 68.4;U-266/70: 48.2
SLFN14		ENSG00000236320	Schlafen family member 14	17	35548125-35558098	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022994, HPA023065	Uncertain					Not detected	Tissue enhanced		bone marrow: 2.5	lymph node: 0.6	Cell line enriched	7	HEL: 19.4
SLFN5	MGC19764	ENSG00000166750	Schlafen family member 5	17	35243036-35273655	Predicted intracellular proteins	Evidence at protein level	HPA017760	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			lymph node: 37.4	Cell line enhanced		hTERT-HME1: 113.0
SLFNL1	FLJ23878	ENSG00000171790	Schlafen like 1	1	41015597-41023237	Predicted intracellular proteins	Evidence at protein level	HPA054956			Approved	Cytosol		Not detected	Tissue enriched	16	testis: 47.8	lung: 3.0	Cell line enhanced		CACO-2: 4.4
SLIRP	C14orf156, DC50	ENSG00000119705	SRA stem-loop interacting RNA binding protein	14	77708071-77761104	Predicted intracellular proteins	Evidence at protein level	HPA020291	Approved		Supported	Mitochondria	Head and neck cancer:4.88e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 205.7	Expressed in all		
SLK	KIAA0204, se20-9, STK2	ENSG00000065613	STE20 like kinase	10	103967201-104029233	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015757	Approved		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:2.77e-5 (unfavourable), Renal cancer:3.95e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 61.0	Expressed in all		
SLU7	9G8	ENSG00000164609	SLU7 homolog, splicing factor	5	160401641-160421711	Predicted intracellular proteins	Evidence at protein level	HPA035907, HPA058120	Uncertain		Enhanced	Nucleoplasm<br>Nuclear speckles	Renal cancer:1.98e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 50.1	Expressed in all		
SLX1A	GIYD1	ENSG00000132207	SLX1 homolog A, structure-specific endonuclease subunit	16	30193887-30197561	Predicted intracellular proteins	Evidence at protein level	HPA047038	Uncertain		Approved	Nucleoplasm		Not detected	Expressed in all			duodenum: 50.3	Mixed		
SLX1B	GIYD2, MGC5178	ENSG00000181625	SLX1 homolog B, structure-specific endonuclease subunit	16	29454501-29458219	Predicted intracellular proteins	Evidence at protein level	HPA047038	Uncertain		Approved	Nucleoplasm		Not detected	Mixed			small intestine: 29.4	Expressed in all		
SLX4	BTBD12, FANCP, KIAA1784, KIAA1987	ENSG00000188827	SLX4 structure-specific endonuclease subunit	16	3581181-3611598	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049421, HPA066238	Approved		Supported	Nucleoplasm<br>Cell Junctions<br>Cytosol		Expressed in all	Tissue enhanced		testis: 12.7	lymph node: 4.9	Expressed in all		
SLX4IP	C20orf94, dJ1099D15.3	ENSG00000149346	SLX4 interacting protein	20	10435303-10636829	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046372	Approved		Approved	Cytosol	Renal cancer:9.51e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 8.1	Mixed		
SMAD1	JV4-1, MADH1, MADR1	ENSG00000170365	SMAD family member 1	4	145481194-145558079	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005389	Approved		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 67.4	Cell line enhanced		HUVEC TERT2: 94.6
SMAD3	HsT17436, JV15-2, MADH3	ENSG00000166949	SMAD family member 3	15	67063763-67195195	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB008094, HPA046386, HPA067203, CAB069409	Approved		Enhanced	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 54.2	Expressed in all		
SMAD4	DPC4, MADH4	ENSG00000141646	SMAD family member 4	18	51028394-51085045	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019154	Approved		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:1.92e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.3	Expressed in all		
SMAD5	Dwfc, JV5-1, MADH5	ENSG00000113658	SMAD family member 5	5	136132845-136188747	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058931	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			endometrium: 43.1	Expressed in all		
SMAD6	HsT17432, MADH6, MADH7	ENSG00000137834	SMAD family member 6	15	66702228-66782848	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061917			Supported	Nucleus<br>Nuclear bodies<br>Golgi apparatus	Urothelial cancer:5.45e-5 (favourable)	Expressed in all	Tissue enhanced		lung: 16.8	placenta: 10.7	Cell line enhanced		EFO-21: 28.0
SMAD7	MADH7, MADH8	ENSG00000101665	SMAD family member 7	18	48919853-48950711	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026212, HPA028897	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:5.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.0	Mixed		
SMAD9	MADH6, MADH9, SMAD8, SMAD8/9	ENSG00000120693	SMAD family member 9	13	36844831-36920765	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009119, HPA031162	Approved		Supported	Nucleoplasm<br>Cytosol	Glioma:4.39e-4 (favourable), Thyroid cancer:4.92e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 62.8	prostate: 22.2	Cell line enhanced		SH-SY5Y: 41.4
SMAP1	FLJ13159, SMAP-1	ENSG00000112305	Small ArfGAP 1	6	70667776-70862015	Predicted intracellular proteins	Evidence at protein level	HPA030574	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 51.5	Expressed in all		
SMAP2	SMAP1L	ENSG00000084070	Small ArfGAP2	1	40344850-40423326	Predicted intracellular proteins	Evidence at protein level	HPA021466, HPA024424	Approved				Head and neck cancer:5.34e-5 (favourable), Liver cancer:2.53e-4 (unfavourable), Cervical cancer:6.55e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 232.8	Expressed in all		
SMARCA1	hSNF2L, ISWI, NURF140, SNF2L, SNF2L1, SNF2LB, SWI	ENSG00000102038	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1	X	129446501-129523500	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003335, HPA064712	Uncertain		Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:3.03e-4 (favourable), Renal cancer:5.09e-4 (favourable)	Expressed in all	Mixed			testis: 113.1	Mixed		
SMARCA4	BAF190, BRG1, FLJ39786, hSNF2b, SNF2, SNF2-BETA, SNF2L4, SNF2LB, SWI2	ENSG00000127616	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	19	10961001-11065395	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004208	Supported		Supported	Nucleoplasm	Liver cancer:1.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 39.5	Expressed in all		
SMARCA5	hISWI, hSNF2H, ISWI	ENSG00000153147	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5	4	143513463-143557486	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005227, HPA008751	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.1	Expressed in all		
SMARCAD1	DKFZP762K2015, ETL1, KIAA1122	ENSG00000163104	SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1	4	94207611-94291292	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016737	Approved		Enhanced	Nucleoplasm	Liver cancer:3.22e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.6	Expressed in all		
SMARCAL1	HARP, HHARP	ENSG00000138375	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a like 1	2	216412414-216483053	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020337	Uncertain		Supported	Nucleoplasm	Liver cancer:5.22e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 19.8	Expressed in all		
SMARCB1	BAF47, hSNFS, Ini1, PPP1R144, RDT, Sfh1p, SNF5L1, Snr1	ENSG00000099956	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1	22	23786963-23834516	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009196, HPA018248, HPA019127	Supported		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Renal cancer:1.14e-6 (favourable), Liver cancer:6.52e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.2	Expressed in all		
SMARCC1	BAF155, CRACC1, Rsc8, SRG3	ENSG00000173473	SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 1	3	47585272-47782106	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011576, CAB016336, HPA024352, HPA026853	Enhanced		Enhanced	Nucleoplasm	Colorectal cancer:3.34e-4 (favourable), Liver cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 36.1	Expressed in all		
SMARCC2	BAF170, CRACC2, Rsc8	ENSG00000139613	SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 2	12	56162983-56189567	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004321, HPA021213, HPA061788	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 76.8	Expressed in all		
SMARCD1	BAF60A, CRACD1, Rsc6p	ENSG00000066117	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1	12	50084972-50100712	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA004101	Supported		Approved	Nucleoplasm<br>Vesicles	Liver cancer:2.53e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 86.5	Expressed in all		
SMARCD2	BAF60B, CRACD2, PRO2451, Rsc6p	ENSG00000108604	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2	17	63832081-63843065	Predicted intracellular proteins	Evidence at protein level	HPA059934, HPA061348			Enhanced	Nucleoplasm	Melanoma:3.51e-4 (unfavourable), Renal cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 104.6	Expressed in all		
SMARCD3	BAF60C, CRACD3, Rsc6p	ENSG00000082014	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3	7	151238764-151277896	Predicted intracellular proteins	Evidence at protein level	HPA063955, HPA065517	Uncertain		Enhanced	Nucleoplasm	Colorectal cancer:5.50e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 82.7	Cell line enhanced		AN3-CA: 63.9
SMARCE1	BAF57	ENSG00000073584	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1	17	40624962-40648508	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003916, CAB037318	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 74.3	Expressed in all		
SMC1A	DXS423E, KIAA0178, SB1.8, SMC1L1, Smcb	ENSG00000072501	Structural maintenance of chromosomes 1A	X	53374149-53422728	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005499, CAB025404	Supported		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 52.8	Expressed in all		
SMC1B	bK268H5, SMC1L2	ENSG00000077935	Structural maintenance of chromosomes 1B	22	45344063-45413619	Predicted intracellular proteins	Evidence at protein level	HPA001500	Enhanced		Supported	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	152	testis: 57.3	lymph node,parathyroid gland: 0.3	Cell line enhanced		A-431: 7.8;EFO-21: 3.8;SiHa: 19.3
SMC2	CAP-E, hCAP-E, SMC2L1	ENSG00000136824	Structural maintenance of chromosomes 2	9	104094260-104141417	Predicted intracellular proteins	Evidence at protein level	HPA071309	Approved		Supported	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 22.2	Expressed in all		
SMC3	BAM, bamacan, CSPG6, HCAP, SMC3L1	ENSG00000108055	Structural maintenance of chromosomes 3	10	110567691-110604636	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037411, HPA043206	Uncertain		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 94.9	Expressed in all		
SMC4	CAP-C, hCAP-C, SMC4L1	ENSG00000113810	Structural maintenance of chromosomes 4	3	160399274-160434962	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029449, CAB055509	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:8.05e-7 (unfavourable), Pancreatic cancer:4.20e-5 (unfavourable), Liver cancer:2.94e-4 (unfavourable), Endometrial cancer:7.63e-4 (unfavourable), Prostate cancer:9.00e-4 (unfavourable)	Expressed in all	Mixed			testis: 54.9	Expressed in all		
SMC5	KIAA0594, SMC5L1	ENSG00000198887	Structural maintenance of chromosomes 5	9	70258962-70354888	Predicted intracellular proteins	Evidence at protein level	HPA054900	Enhanced		Supported	Nuclear speckles		Expressed in all	Expressed in all			ovary: 30.8	Expressed in all		
SMC6	FLJ22116, SMC6L1	ENSG00000163029	Structural maintenance of chromosomes 6	2	17663812-17800242	Predicted intracellular proteins	Evidence at protein level	HPA035057, CAB037186, HPA042733	Uncertain		Supported	Nucleoplasm	Renal cancer:3.15e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 64.7	Expressed in all		
SMCHD1	FSHD2, KIAA0650	ENSG00000101596	Structural maintenance of chromosomes flexible hinge domain containing 1	18	2655738-2805017	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039441	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.40e-4 (unfavourable), Liver cancer:5.39e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 40.5	Expressed in all		
SMCO1	C3orf43, DKFZp313B0440, FLJ41923	ENSG00000214097	Single-pass membrane protein with coiled-coil domains 1	3	196506877-196515366	Predicted intracellular proteins	Evidence at transcript level	HPA061937	Uncertain					Not detected	Group enriched	15	heart muscle: 24.2;skeletal muscle: 51.1	esophagus: 2.5	Not detected		
SMCP	MCSP	ENSG00000163206	Sperm mitochondria associated cysteine rich protein	1	152878317-152885047	Predicted intracellular proteins	Evidence at protein level	HPA035105	Supported					Tissue enhanced	Tissue enriched	480	testis: 797.7	cerebral cortex: 1.6	Not detected		
SMCR8	FLJ34716	ENSG00000176994	Smith-Magenis syndrome chromosome region, candidate 8	17	18315310-18328055	Predicted intracellular proteins	Evidence at protein level	HPA021557, HPA024646	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.35e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.0	Expressed in all		
SMG1	ATX, KIAA0421, LIP	ENSG00000157106	SMG1, nonsense mediated mRNA decay associated PI3K related kinase	16	18804853-18926454	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006870, HPA031623, HPA073972	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			skin: 50.1	Expressed in all		
SMG7	C1orf16, EST1C, KIAA0250, SGA56M, SMG-7	ENSG00000116698	SMG7, nonsense mediated mRNA decay factor	1	183472216-183598246	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029350	Supported		Supported	Intermediate filaments<br>Cytosol		Expressed in all	Expressed in all			testis: 123.1	Expressed in all		
SMIM10L1		ENSG00000256537	Small integral membrane protein 10 like 1	12	11171222-11176016	Predicted intracellular proteins	Evidence at transcript level						Ovarian cancer:2.71e-4 (favourable), Renal cancer:3.56e-4 (unfavourable), Urothelial cancer:9.70e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 15.6	Expressed in all		
SMIM15	C5orf43, DKFZP686E2158	ENSG00000188725	Small integral membrane protein 15	5	61157709-61162474	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:9.23e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 59.6	Mixed		
SMIM23	C5orf50, LOC644994	ENSG00000185662	Small integral membrane protein 23	5	171782432-171796126	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	140	testis: 24.9	spleen: 0.1	Not detected		
SMKR1		ENSG00000240204	Small lysine rich protein 1	7	129502479-129512932	Predicted intracellular proteins	Evidence at transcript level	HPA078358			Approved	Nucleoli		Mixed	Tissue enriched	13	testis: 119.8	fallopian tube: 9.4	Cell line enhanced		SCLC-21H: 34.4
SMN1	BCD541, GEMIN1, SMA, SMA@, SMA1, SMA2, SMA3, SMNT, TDRD16A	ENSG00000172062	Survival of motor neuron 1, telomeric	5	70925030-70953942	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045271, CAB069888	Enhanced				Renal cancer:6.62e-13 (unfavourable)	Expressed in all	Mixed			lymph node: 17.0	Cell line enhanced		MOLT-4: 95.9;T-47d: 82.9;WM-115: 116.4
SMN2	BCD541, GEMIN1, SMNC, TDRD16B	ENSG00000205571	Survival of motor neuron 2, centromeric	5	70049612-70078522	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009344, HPA045271	Supported					Expressed in all	Mixed			epididymis: 27.1	Cell line enhanced		BEWO: 126.1
SMNDC1	SMNR, SPF30, TDRD16C	ENSG00000119953	Survival motor neuron domain containing 1	10	110290730-110304951	Predicted intracellular proteins	Evidence at protein level	HPA061214			Supported	Nucleus<br>Nuclear bodies	Liver cancer:8.08e-6 (unfavourable), Pancreatic cancer:7.20e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 26.3	Expressed in all		
SMOX	C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO	ENSG00000088826	Spermine oxidase	20	4120980-4187747	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047117, HPA060198	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Liver cancer:3.33e-6 (unfavourable), Renal cancer:1.06e-4 (unfavourable), Lung cancer:1.36e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 49.7	gallbladder: 23.5	Cell line enhanced		A549: 104.6;Karpas-707: 139.7
SMPD1	ASM	ENSG00000166311	Sphingomyelin phosphodiesterase 1	11	6390431-6394998	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.57e-6 (favourable), Glioma:1.09e-4 (unfavourable), Pancreatic cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.5	Mixed		
SMPX	DFN6, DFNX4	ENSG00000091482	Small muscle protein, X-linked	X	21705972-21758163	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA077360			Approved	Plasma membrane	Head and neck cancer:3.04e-5 (unfavourable)	Tissue enhanced	Group enriched	22	heart muscle: 456.2;skeletal muscle: 383.1	esophagus: 19.4	Cell line enhanced		CACO-2: 1.2;Hep G2: 2.7;HSkMC: 3.0;Karpas-707: 2.2;U-266/70: 3.3;U-266/84: 1.2
SMS	MRSR, SPMSY, SpS, SRS	ENSG00000102172	Spermine synthase	X	21940573-21994835	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029849, HPA029852	Approved		Approved	Nuclear bodies<br>Cytosol	Liver cancer:7.79e-8 (unfavourable), Renal cancer:7.85e-5 (unfavourable), Head and neck cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 202.4	Expressed in all		
SMTN		ENSG00000183963	Smoothelin	22	31064105-31104757	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001721, HPA051778, HPA058590	Enhanced		Enhanced	Nucleoplasm<br>Actin filaments	Renal cancer:2.73e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 251.4	Expressed in all		
SMTNL1	CHASM	ENSG00000214872	Smoothelin like 1	11	57542641-57550274	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	26	skeletal muscle: 240.9	esophagus: 9.3	Cell line enhanced		U-266/70: 1.2
SMTNL2	FLJ42461	ENSG00000188176	Smoothelin like 2	17	4583999-4608319	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.28e-4 (favourable)	Tissue enhanced	Group enriched	9	kidney: 26.8;skeletal muscle: 133.8	fallopian tube: 9.0	Group enriched	7	CACO-2: 40.8;SCLC-21H: 13.5
SMU1	BWD, FLJ10805, fSAP57, SMU-1	ENSG00000122692	DNA replication regulator and spliceosomal factor	9	33041764-33076659	Predicted intracellular proteins	Evidence at protein level	HPA019228, HPA019708	Supported		Approved	Vesicles	Renal cancer:1.67e-5 (favourable), Ovarian cancer:1.25e-4 (favourable), Cervical cancer:2.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.4	Expressed in all		
SMUG1	FDG, HMUDG, UNG3	ENSG00000123415	Single-strand-selective monofunctional uracil-DNA glycosylase 1	12	54121277-54189008	Predicted intracellular proteins	Evidence at protein level	HPA051149, HPA071486			Approved	Vesicles<br>Centrosome	Ovarian cancer:1.31e-4 (favourable), Liver cancer:6.96e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 48.8	Expressed in all		
SMURF1	KIAA1625	ENSG00000198742	SMAD specific E3 ubiquitin protein ligase 1	7	99027438-99144100	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055245	Approved					Expressed in all	Expressed in all			testis: 22.9	Expressed in all		
SMURF2		ENSG00000108854	SMAD specific E3 ubiquitin protein ligase 2	17	64542295-64662068	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA071508	Enhanced		Supported	Nuclear speckles		Expressed in all	Mixed			testis: 32.9	Expressed in all		
SMYD1	BOP, KMT3D, ZMYND22	ENSG00000115593	SET and MYND domain containing 1	2	88067780-88113387	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062282	Enhanced					Tissue enhanced	Group enriched	9	heart muscle: 107.0;skeletal muscle: 170.8;smooth muscle: 38.5	parathyroid gland: 11.6	Not detected		
SMYD2	HSKM-B, KMT3C, ZMYND14	ENSG00000143499	SET and MYND domain containing 2	1	214281102-214337131	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029023	Uncertain		Approved	Intermediate filaments<br>Mitochondria<br>Cytosol	Cervical cancer:1.53e-5 (unfavourable), Renal cancer:8.68e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 153.5	Expressed in all		
SMYD3	KMT3E, ZMYND1, ZNFN3A1	ENSG00000185420	SET and MYND domain containing 3	1	245749342-246507312	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB012229, HPA045821, HPA054352	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			epididymis,thyroid gland: 27.0	Expressed in all		
SMYD5	NN8-4AG, RAI15, RRG1, ZMYND23	ENSG00000135632	SMYD family member 5	2	73214222-73227237	Predicted intracellular proteins	Evidence at protein level	HPA015514, HPA049002	Uncertain		Approved	Mitochondria	Liver cancer:6.58e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 34.2	Expressed in all		
SNAI1	SLUGH2, SNA, SNAH, SNAIL, SNAIL1	ENSG00000124216	Snail family transcriptional repressor 1	20	49982999-49988886	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005883, HPA056831, HPA069985, CAB078687	Supported		Supported	Nucleus<br>Cytosol	Renal cancer:2.63e-7 (unfavourable), Thyroid cancer:8.82e-7 (unfavourable), Lung cancer:1.61e-5 (unfavourable), Colorectal cancer:4.76e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 26.2	thyroid gland: 13.4	Cell line enhanced		SiHa: 30.1;TIME: 32.4;WM-115: 25.0
SNAI2	SLUG, SLUGH, SLUGH1, SNAIL2	ENSG00000019549	Snail family transcriptional repressor 2	8	48917768-48921740	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011671	Supported		Approved	Nucleus	Renal cancer:4.69e-8 (unfavourable), Urothelial cancer:7.16e-4 (unfavourable), Pancreatic cancer:7.83e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 71.0	Cell line enhanced		ASC diff: 194.2;ASC TERT1: 202.4;LHCN-M2: 229.9;U-138 MG: 243.9
SNAI3	SMUC, Zfp293, ZNF293	ENSG00000185669	Snail family transcriptional repressor 3	16	88677682-88686493	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA071127			Approved	Nucleoplasm	Cervical cancer:1.39e-4 (favourable), Pancreatic cancer:3.58e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 10.9	lymph node: 4.3	Cell line enhanced		NB-4: 11.5;RPMI-8226: 19.9
SNAP25	bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25	ENSG00000132639	Synaptosome associated protein 25	20	10218830-10307418	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000360, HPA001830	Enhanced	Supported				Group enriched	Tissue enriched	31	cerebral cortex: 1759.0	adrenal gland: 57.2	Cell line enhanced		SCLC-21H: 92.0;SH-SY5Y: 49.5;U-87 MG: 54.7
SNAP29	CEDNIK, SNAP-29	ENSG00000099940	Synaptosome associated protein 29	22	20858983-20891218	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031823, CAB037092, HPA056492	Supported		Supported	Nucleoplasm<br>Cytosol	Cervical cancer:6.99e-4 (favourable)	Expressed in all	Expressed in all			testis: 74.6	Expressed in all		
SNAP47	C1orf142, SNAP-47, SVAP1	ENSG00000143740	Synaptosome associated protein 47	1	227728539-227781231	Predicted intracellular proteins	Evidence at protein level	HPA028167	Enhanced		Approved	Cytosol		Expressed in all	Expressed in all			testis: 56.6	Expressed in all		
SNAP91	AP180, CALM, KIAA0656	ENSG00000065609	Synaptosome associated protein 91	6	83552880-83709691	Predicted intracellular proteins	Evidence at protein level	CAB009745, HPA029632, HPA029633	Enhanced		Uncertain	Centrosome<br>Cytosol		Tissue enhanced	Tissue enriched	7	cerebral cortex: 152.1	testis: 22.5	Group enriched	16	SCLC-21H: 27.9;SH-SY5Y: 15.7
SNAPC1	PTFgamma, SNAP43	ENSG00000023608	Small nuclear RNA activating complex polypeptide 1	14	61762357-61796428	Predicted intracellular proteins	Evidence at protein level	HPA067076, HPA072276			Supported	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 35.6	Expressed in all		
SNAPC2	PTFdelta, SNAP45	ENSG00000104976	Small nuclear RNA activating complex polypeptide 2	19	7920316-7923250	Predicted intracellular proteins	Evidence at protein level	HPA049843, HPA077597	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:4.89e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 30.1	Expressed in all		
SNAPC3	MGC132011, MGC33124, PTFbeta, SNAP50	ENSG00000164975	Small nuclear RNA activating complex polypeptide 3	9	15422704-15465953	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053145, HPA066031			Supported	Nucleus<br>Nucleoli<br>Nuclear bodies		Expressed in all	Mixed			cerebral cortex: 11.9	Expressed in all		
SNAPC4	FLJ13451, PTFalpha, SNAP190	ENSG00000165684	Small nuclear RNA activating complex polypeptide 4	9	136375577-136400168	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046627, HPA073243	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane	Pancreatic cancer:4.52e-5 (favourable)	Expressed in all	Expressed in all			testis: 20.6	Expressed in all		
SNAPC5	SNAP19	ENSG00000174446	Small nuclear RNA activating complex polypeptide 5	15	66490135-66497813	Predicted intracellular proteins	Evidence at protein level	HPA024379	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			testis: 63.7	Expressed in all		
SNAPIN	BLOC1S7, BORCS3, SNAPAP	ENSG00000143553	SNAP associated protein	1	153658654-153661830	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA046974	Approved		Approved	Nucleoli<br>Golgi apparatus	Renal cancer:5.42e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 42.3	Expressed in all		
SNCA	alpha-synuclein, NACP, PARK1, PARK4, PD1	ENSG00000145335	Synuclein alpha	4	89724099-89838315	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA005459, CAB010877	Enhanced					Tissue enriched	Group enriched	5	bone marrow: 160.8;cerebral cortex: 459.2	endometrium: 57.1	Cell line enhanced		HEL: 198.4;HUVEC TERT2: 218.9;SK-MEL-30: 203.3;TIME: 246.6
SNCAIP	SYPH1	ENSG00000064692	Synuclein alpha interacting protein	5	122311354-122464219	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064687	Uncertain		Supported	Nucleoplasm<br>Cytoplasmic bodies		Mixed	Tissue enhanced		endometrium: 29.8;ovary: 43.3	cervix, uterine: 25.8	Cell line enhanced		AF22: 4.9;BJ hTERT+: 3.9;RPMI-8226: 3.7
SNCB		ENSG00000074317	Synuclein beta	5	176620084-176630556	Predicted intracellular proteins	Evidence at protein level	CAB002681, HPA035876	Enhanced	Supported				Tissue enriched	Tissue enriched	71	cerebral cortex: 329.2	adrenal gland: 4.6	Cell line enriched	15	SCLC-21H: 68.9
SNCG	BCSG1, persyn, SR	ENSG00000173267	Synuclein gamma	10	86958618-86963260	Predicted intracellular proteins	Evidence at protein level	CAB001452, HPA014404, CAB040581	Enhanced	Approved			Renal cancer:2.29e-8 (unfavourable), Stomach cancer:7.15e-4 (unfavourable)	Group enriched	Tissue enhanced		adipose tissue: 174.6;adrenal gland: 198.1;urinary bladder: 183.2	seminal vesicle: 114.9	Cell line enhanced		CAPAN-2: 463.6;RT4: 350.3;T-47d: 106.9
SND1	p100, TDRD11	ENSG00000197157	Staphylococcal nuclease and tudor domain containing 1	7	127652180-128092609	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002529, HPA002632, CAB019323	Enhanced		Enhanced	Cytosol	Endometrial cancer:1.95e-4 (favourable)	Expressed in all	Expressed in all			placenta: 122.3	Expressed in all		
SNF8	Dot3, EAP30, VPS22	ENSG00000159210	SNF8, ESCRT-II complex subunit	17	48929316-48945117	Predicted intracellular proteins	Evidence at protein level	HPA059320	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.81e-7 (unfavourable), Liver cancer:7.64e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 41.0	Expressed in all		
SNIP1		ENSG00000163877	Smad nuclear interacting protein 1	1	37534449-37554344	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036896	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 7.6	Expressed in all		
SNRK	FLJ20224, HSNFRK, KIAA0096	ENSG00000163788	SNF related kinase	3	43286512-43424764	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042163	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.41e-5 (favourable), Breast cancer:9.28e-4 (favourable)	Expressed in all	Expressed in all			placenta: 47.8	Expressed in all		
SNRNP200	ASCC3L1, BRR2, HELIC2, KIAA0788, RP33, U5-200KD	ENSG00000144028	Small nuclear ribonucleoprotein U5 subunit 200	2	96274336-96305515	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029321	Approved		Supported	Nucleoplasm	Endometrial cancer:3.89e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 116.4	Expressed in all		
SNRNP25	C16orf33, U11/U12-25K	ENSG00000161981	Small nuclear ribonucleoprotein U11/U12 subunit 25	16	53010-57669	Predicted intracellular proteins	Evidence at protein level	HPA041183, HPA044248	Uncertain		Supported	Nucleoplasm<br>Cytokinetic bridge<br>Cytosol	Renal cancer:1.16e-5 (favourable), Cervical cancer:1.95e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 55.4	Expressed in all		
SNRNP27	RY1, U4/U6.U5-27K	ENSG00000124380	Small nuclear ribonucleoprotein U4/U6.U5 subunit 27	2	69893560-69905575	Predicted intracellular proteins	Evidence at protein level	HPA034541	Approved		Approved	Nucleoplasm	Endometrial cancer:2.33e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 43.3	Expressed in all		
SNRNP35	U1SNRNPBP	ENSG00000184209	Small nuclear ribonucleoprotein U11/U12 subunit 35	12	123457641-123473154	Predicted intracellular proteins	Evidence at protein level	HPA059145, HPA067031	Supported		Supported	Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 34.2	Expressed in all		
SNRNP48	C6orf151, dJ336K20B.1, dJ512B11.2, FLJ32234	ENSG00000168566	Small nuclear ribonucleoprotein U11/U12 subunit 48	6	7590199-7611967	Predicted intracellular proteins	Evidence at protein level	HPA029234	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.16e-4 (unfavourable), Breast cancer:8.30e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 10.7	Expressed in all		
SNRNP70	RNPU1Z, RPU1, Snp1, SNRP70, U1-70K	ENSG00000104852	Small nuclear ribonucleoprotein U1 subunit 70	19	49085419-49108605	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001718, HPA042050, HPA043516	Supported		Enhanced	Nucleoplasm	Pancreatic cancer:4.59e-5 (favourable), Urothelial cancer:5.35e-5 (favourable), Renal cancer:6.12e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 59.8	Expressed in all		
SNRPA	Mud1, U1-A, U1A	ENSG00000077312	Small nuclear ribonucleoprotein polypeptide A	19	40750637-40765389	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004652, HPA046440, HPA054834	Enhanced		Enhanced	Nucleoplasm	Renal cancer:2.96e-9 (unfavourable), Liver cancer:1.34e-5 (unfavourable), Cervical cancer:2.50e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 60.7	Expressed in all		
SNRPA1	Lea1	ENSG00000131876	Small nuclear ribonucleoprotein polypeptide A'	15	101281510-101295282	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045622, HPA048499	Supported		Supported	Nucleoplasm<br>Nuclear speckles<br>Nuclear bodies	Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.56e-5 (unfavourable), Ovarian cancer:8.83e-5 (favourable)	Expressed in all	Expressed in all			testis: 68.6	Expressed in all		
SNRPB	COD, Sm-B/B', SmB/SmB', snRNP-B, SNRPB1	ENSG00000125835	Small nuclear ribonucleoprotein polypeptides B and B1	20	2461634-2470853	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003482, CAB009610, HPA067842	Approved		Supported	Nucleoplasm	Liver cancer:1.07e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 202.0	Expressed in all		
SNRPB2	Msl1, U2B''	ENSG00000125870	Small nuclear ribonucleoprotein polypeptide B2	20	16729961-16742563	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050814, HPA076104	Supported		Supported	Nuclear speckles	Liver cancer:6.03e-7 (unfavourable), Renal cancer:2.79e-4 (unfavourable), Endometrial cancer:7.57e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 49.8	Expressed in all		
SNRPC	U1-C, Yhc1	ENSG00000124562	Small nuclear ribonucleoprotein polypeptide C	6	34757406-34773794	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034338, HPA042419, HPA055490	Supported		Enhanced	Nucleoplasm	Renal cancer:8.20e-5 (unfavourable), Liver cancer:5.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 151.1	Expressed in all		
SNRPD1	HsT2456, Sm-D1, SNRPD	ENSG00000167088	Small nuclear ribonucleoprotein D1 polypeptide	18	21612267-21633524	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040516	Supported				Ovarian cancer:7.90e-6 (favourable), Liver cancer:1.82e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 81.2	Expressed in all		
SNRPD2	Sm-D2, SNRPD1	ENSG00000125743	Small nuclear ribonucleoprotein D2 polypeptide	19	45687454-45692569	Predicted intracellular proteins	Evidence at protein level	HPA041437	Supported		Uncertain	Cytosol	Renal cancer:8.58e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 334.8	Expressed in all		
SNRPD3	Sm-D3, SMD3	ENSG00000100028	Small nuclear ribonucleoprotein D3 polypeptide	22	24555503-24609980	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001170	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 78.0	Expressed in all		
SNRPE	Sm-E	ENSG00000182004	Small nuclear ribonucleoprotein polypeptide E	1	203861603-203870550	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.38e-5 (unfavourable), Ovarian cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			breast: 97.4	Expressed in all		
SNRPG	Sm-G	ENSG00000143977	Small nuclear ribonucleoprotein polypeptide G	2	70281362-70293771	Predicted intracellular proteins	Evidence at protein level	HPA064152, HPA067814	Enhanced		Approved	Nucleoplasm	Renal cancer:1.08e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 114.2	Expressed in all		
SNRPN	HCERN3, PWCR, RT-LI, SM-D, SMN, SNRNP-N, SNURF-SNRPN	ENSG00000128739	Small nuclear ribonucleoprotein polypeptide N	15	24823637-24978723	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003482, HPA067842	Approved		Supported	Nucleoplasm	Renal cancer:8.93e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 515.1	Cell line enhanced		NTERA-2: 762.8
SNTA1	LQT12, SNT1, TACIP1	ENSG00000101400	Syntrophin alpha 1	20	33407955-33443892	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB037059	Approved				Endometrial cancer:9.60e-6 (unfavourable), Pancreatic cancer:3.72e-4 (favourable), Melanoma:7.08e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 102.0	Mixed		
SNTG1	G1SYN, SYN4	ENSG00000147481	Syntrophin gamma 1	8	49909789-50794118	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA072282	Supported					Tissue enhanced	Tissue enhanced		cerebral cortex: 8.6;spleen: 3.8	testis: 1.2	Not detected		
SNTG2	G2SYN, SYN5	ENSG00000172554	Syntrophin gamma 2	2	950868-1367613	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		spleen: 2.5;testis: 2.4	adipose tissue,endometrium: 2.0	Cell line enhanced		Daudi: 1.1;HAP1: 1.8;NTERA-2: 2.1;SCLC-21H: 2.3
SNTN	FLJ44379, S100AL	ENSG00000188817	Sentan, cilia apical structure protein	3	63652668-63679020	Predicted intracellular proteins	Evidence at protein level	HPA043322, HPA058399	Enhanced					Group enriched	Tissue enriched	12	fallopian tube: 349.6	thyroid gland: 29.2	Not detected		
SNU13	15.5K, FA-1, NHP2L1, SNRNP15-5, SPAG12, SSFA1	ENSG00000100138	SNU13 homolog, small nuclear ribonucleoprotein (U4/U6.U5)	22	41673930-41690504	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA029199	Uncertain					Expressed in all	Expressed in all			testis: 168.8	Expressed in all		
SNUPN	RNUT1, SNURPORTIN-1, Snurportin1	ENSG00000169371	Snurportin 1	15	75598083-75626469	Predicted intracellular proteins	Evidence at protein level	CAB005004	Approved		Supported	Nuclear membrane		Expressed in all	Expressed in all			testis: 54.1	Expressed in all		
SNURF		ENSG00000273173	SNRPN upstream reading frame	15	24954986-24977850	Predicted intracellular proteins	Evidence at protein level	HPA065733			Supported	Nuclear speckles		Mixed	Expressed in all			cerebral cortex: 197.0	Cell line enhanced		NTERA-2: 224.6
SNW1	Bx42, NCoA-62, Prp45, PRPF45, SKIIP, SKIP	ENSG00000100603	SNW domain containing 1	14	77717599-77761207	Predicted intracellular proteins	Evidence at protein level	HPA002457, CAB009931, HPA017370	Supported		Enhanced	Nucleoplasm	Liver cancer:1.96e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 85.0	Expressed in all		
SNX1	HsT17379, MGC8664, SNX1A, Vps5	ENSG00000028528	Sorting nexin 1	15	64094123-64146090	Predicted intracellular proteins	Evidence at protein level	HPA047373, HPA052761	Approved		Enhanced	Endosomes<br>Lysosomes	Renal cancer:9.88e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 163.5	Expressed in all		
SNX10		ENSG00000086300	Sorting nexin 10	7	26291895-26374329	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015605, HPA064782	Approved		Approved	Nucleus<br>Nucleoli<br>Microtubules	Renal cancer:8.06e-5 (unfavourable), Glioma:9.81e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 94.3	lung: 60.1	Cell line enhanced		WM-115: 291.7
SNX11		ENSG00000002919	Sorting nexin 11	17	48103357-48123074	Predicted intracellular proteins	Evidence at protein level	HPA044787, HPA054660	Approved		Approved	Cytosol		Expressed in all	Expressed in all			thyroid gland: 32.1	Expressed in all		
SNX12		ENSG00000147164	Sorting nexin 12	X	71056332-71073426	Predicted intracellular proteins	Evidence at protein level	CAB070423	Approved				Renal cancer:1.51e-7 (favourable), Endometrial cancer:1.17e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.0	Expressed in all		
SNX15		ENSG00000110025	Sorting nexin 15	11	65027408-65040572	Predicted intracellular proteins	Evidence at protein level	HPA038955	Approved		Supported	Nucleoli<br>Cytosol		Not detected	Expressed in all			cerebral cortex: 24.7	Expressed in all		
SNX16		ENSG00000104497	Sorting nexin 16	8	81799581-81842866	Predicted intracellular proteins	Evidence at protein level	HPA024730, HPA024731, HPA024817	Approved		Supported	Vesicles		Expressed in all	Mixed			testis: 27.7	Expressed in all		
SNX17	KIAA0064	ENSG00000115234	Sorting nexin 17	2	27370496-27377533	Predicted intracellular proteins	Evidence at protein level	HPA043867	Supported		Supported	Vesicles		Expressed in all	Expressed in all			fallopian tube: 97.8	Expressed in all		
SNX18	SH3PX2, SH3PXD3B, SNAG1	ENSG00000178996	Sorting nexin 18	5	54517759-54546585	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037800	Approved		Approved	Cytosol	Renal cancer:1.58e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 43.8	Mixed		
SNX2		ENSG00000205302	Sorting nexin 2	5	122774996-122830108	Predicted intracellular proteins	Evidence at protein level	HPA037400	Approved		Enhanced	Endosomes<br>Lysosomes	Renal cancer:8.76e-7 (favourable), Liver cancer:7.90e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 124.4	Expressed in all		
SNX20	SLIC-1, SLIC1	ENSG00000167208	Sorting nexin 20	16	50666300-50681353	Predicted intracellular proteins	Evidence at protein level	HPA043649	Uncertain		Uncertain	Nucleoplasm	Renal cancer:6.00e-6 (unfavourable), Head and neck cancer:6.56e-4 (favourable), Cervical cancer:9.07e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 31.5	appendix: 26.4	Cell line enhanced		HDLM-2: 27.0;HMC-1: 67.9;NB-4: 29.9;U-266/70: 19.2;U-937: 21.8
SNX21	C20orf161, dJ337O18.4, SNX-L	ENSG00000124104	Sorting nexin family member 21	20	45833810-45843275	Predicted intracellular proteins	Evidence at protein level	HPA046359	Approved		Approved	Vesicles<br>Microtubule organizing center		Expressed in all	Mixed			skin: 25.5	Cell line enhanced		PC-3: 28.8;U-87 MG: 27.0
SNX22	FLJ13952	ENSG00000157734	Sorting nexin 22	15	64151715-64157481	Predicted intracellular proteins	Evidence at protein level	HPA038470	Approved		Approved	Nucleoplasm<br>Vesicles	Breast cancer:2.89e-5 (favourable), Thyroid cancer:2.19e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 16.2;thyroid gland: 14.4	lymph node: 9.0	Cell line enhanced		Daudi: 13.5;SCLC-21H: 4.9
SNX24	SBBI31	ENSG00000064652	Sorting nexin 24	5	122843439-123029354	Predicted intracellular proteins	Evidence at protein level	HPA044566, HPA073934	Approved		Approved	Vesicles	Endometrial cancer:7.93e-6 (unfavourable), Renal cancer:1.28e-4 (favourable), Liver cancer:8.88e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 39.4	Mixed		
SNX25	SBBI31	ENSG00000109762	Sorting nexin 25	4	185204237-185370185	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA036928			Supported	Vesicles		Expressed in all	Expressed in all			lung: 42.7	Expressed in all		
SNX27	KIAA0488, MGC20471, MY014	ENSG00000143376	Sorting nexin family member 27	1	151612065-151699091	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045816			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 19.1	Expressed in all		
SNX29	FLJ12363, RUNDC2A	ENSG00000048471	Sorting nexin 29	16	11976737-12574289	Predicted intracellular proteins	Evidence at protein level	HPA008889	Approved				Renal cancer:1.38e-7 (favourable), Urothelial cancer:1.03e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 39.7	Mixed		
SNX3	Grd19	ENSG00000112335	Sorting nexin 3	6	108211222-108261260	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Breast cancer:4.37e-5 (unfavourable), Renal cancer:2.30e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 288.7	Expressed in all		
SNX30	ATG24A	ENSG00000148158	Sorting nexin family member 30	9	112750838-112881671	Predicted intracellular proteins	Evidence at protein level	HPA019346	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.01e-7 (favourable)	Expressed in all	Mixed			lung: 32.2	Expressed in all		
SNX31	MGC39715	ENSG00000174226	Sorting nexin 31	8	100572882-100663415	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA024284, HPA053466	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Testis cancer:1.47e-4 (favourable)	Tissue enriched	Tissue enhanced		urinary bladder: 32.4	esophagus: 7.3	Cell line enriched	51	RT4: 64.7
SNX32	FLJ30934, SNX6B	ENSG00000172803	Sorting nexin 32	11	65833641-65856896	Predicted intracellular proteins	Evidence at protein level	HPA041775	Uncertain		Uncertain	Cell Junctions<br>Focal adhesion sites		Mixed	Tissue enhanced		cerebral cortex: 7.7	testis: 1.8	Cell line enhanced		HHSteC: 3.0;HSkMC: 3.4;SH-SY5Y: 1.9;U-266/70: 4.3
SNX33	MGC32065, SH3PX3, SH3PXD3C, SNX30	ENSG00000173548	Sorting nexin 33	15	75647906-75662301	Predicted intracellular proteins	Evidence at protein level	HPA040988	Approved				Ovarian cancer:5.24e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 26.6	Mixed		
SNX4	ATG24B	ENSG00000114520	Sorting nexin 4	3	125446644-125520197	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005709	Uncertain				Renal cancer:5.01e-5 (favourable), Endometrial cancer:6.10e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 75.4	Expressed in all		
SNX5		ENSG00000089006	Sorting nexin 5	20	17941597-17968980	Predicted intracellular proteins	Evidence at protein level	CAB020679, HPA051187	Approved				Liver cancer:2.30e-10 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 132.4	Expressed in all		
SNX6		ENSG00000129515	Sorting nexin 6	14	34561094-34630183	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049374	Approved		Supported	Endosomes<br>Lysosomes	Liver cancer:1.25e-4 (unfavourable), Pancreatic cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 220.7	Expressed in all		
SNX7		ENSG00000162627	Sorting nexin 7	1	98661701-98760500	Predicted intracellular proteins	Evidence at protein level	HPA037419, HPA054338	Enhanced		Approved	Nucleoli fibrillar center<br>Cytosol	Liver cancer:9.59e-7 (unfavourable), Colorectal cancer:5.10e-5 (favourable)	Expressed in all	Mixed			smooth muscle: 37.7	Mixed		
SNX8	Mvp1	ENSG00000106266	Sorting nexin 8	7	2251770-2354318	Predicted intracellular proteins	Evidence at protein level	HPA057296, HPA060194	Approved		Supported	Vesicles	Liver cancer:8.47e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 38.0	Expressed in all		
SNX9	SDP1, SH3PX1, SH3PXD3A	ENSG00000130340	Sorting nexin 9	6	157700387-157945077	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031410, HPA057203	Approved		Enhanced	Plasma membrane<br>Cytosol	Lung cancer:3.77e-4 (unfavourable), Cervical cancer:5.95e-4 (unfavourable), Renal cancer:9.95e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 68.2	Mixed		
SOBP	FLJ10159	ENSG00000112320	Sine oculis binding protein homolog	6	107489958-107660167	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029242	Uncertain		Approved	Nucleoplasm<br>Vesicles	Pancreatic cancer:1.55e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 26.4	ovary: 13.7	Cell line enhanced		AF22: 12.5;AN3-CA: 15.3
SOCS1	Cish1, JAB, SOCS-1, SSI-1, TIP3	ENSG00000185338	Suppressor of cytokine signaling 1	16	11254405-11256179	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010355, HPA074108	Approved		Supported	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:1.08e-6 (unfavourable), Head and neck cancer:1.10e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 19.3	lymph node: 15.7	Cell line enriched	6	HDLM-2: 102.4
SOCS2	CIS2, Cish2, SOCS-2, SSI-2, SSI2, STATI2	ENSG00000120833	Suppressor of cytokine signaling 2	12	93569814-93583487	Predicted intracellular proteins	Evidence at protein level	CAB010356	Approved		Approved	Endoplasmic reticulum	Pancreatic cancer:8.17e-7 (favourable), Liver cancer:1.09e-6 (favourable)	Expressed in all	Expressed in all			smooth muscle: 130.2	Cell line enhanced		CACO-2: 137.8;K-562: 124.1;REH: 295.4
SOCS3	CIS3, Cish3, SOCS-3, SSI-3	ENSG00000184557	Suppressor of cytokine signaling 3	17	78356778-78360077	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012220, HPA068569	Approved		Approved	Cytosol	Renal cancer:9.34e-9 (unfavourable), Breast cancer:4.80e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 321.5	gallbladder: 297.9	Cell line enhanced		HDLM-2: 142.9
SOCS4	SOCS7	ENSG00000180008	Suppressor of cytokine signaling 4	14	55027230-55049488	Predicted intracellular proteins	Evidence at protein level	CAB013478, HPA057961	Approved		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			thyroid gland: 12.5	Expressed in all		
SOCS5	CIS6, Cish5, CISH6, KIAA0671, SOCS-5	ENSG00000171150	Suppressor of cytokine signaling 5	2	46698952-46763129	Predicted intracellular proteins	Evidence at protein level	HPA020884, CAB025510	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:7.28e-4 (unfavourable), Ovarian cancer:7.53e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 31.1	Expressed in all		
SOCS6	CIS4, Cish4, HSPC060, SOCS4, SSI4, STAI4, STATI4	ENSG00000170677	Suppressor of cytokine signaling 6	18	70288901-70330200	Predicted intracellular proteins	Evidence at protein level	CAB010189	Uncertain		Approved	Nuclear speckles<br>Cytosol	Renal cancer:1.02e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.0	Mixed		
SOCS7	NAP4, NCKAP4	ENSG00000274211	Suppressor of cytokine signaling 7	17	38352228-38405593	Predicted intracellular proteins	Evidence at protein level	HPA004475	Approved		Approved	Cytosol	Breast cancer:7.49e-4 (unfavourable), Endometrial cancer:7.87e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 54.4	thyroid gland: 13.1	Expressed in all		
SOD1	ALS, ALS1, IPOA	ENSG00000142168	Superoxide dismutase 1	21	31659622-31668931	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001401, CAB008670	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			liver: 768.9	Expressed in all		
SOD2		ENSG00000112096	Superoxide dismutase 2	6	159669057-159762529	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001814, CAB002013	Supported				Renal cancer:1.72e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 734.4	Expressed in all		
SOGA1	C20orf117, dJ132F21.1, FLJ44670, KIAA0889, SOGA	ENSG00000149639	Suppressor of glucose, autophagy associated 1	20	36777442-36863686	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043992	Approved		Approved	Nucleoli<br>Cytosol	Ovarian cancer:8.28e-5 (unfavourable), Renal cancer:4.49e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 20.2	Mixed		
SOHLH1	bA100C15.3, bHLHe80, C9orf157, NOHLH, SPATA27, TEB2	ENSG00000165643	Spermatogenesis and oogenesis specific basic helix-loop-helix 1	9	135693407-135699528	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059439			Approved	Nuclear speckles		Mixed	Group enriched	27	cerebral cortex: 6.3;testis: 13.4	skin: 0.3	Group enriched	36	CACO-2: 14.6;U-266/84: 19.8
SOHLH2	bHLHe81, FLJ20449, SPATA28, TEB1	ENSG00000120669	Spermatogenesis and oogenesis specific basic helix-loop-helix 2	13	36168208-36214615	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA029182						Mixed	Tissue enriched	15	testis: 46.2	prostate: 3.0	Cell line enhanced		A-431: 7.0;HL-60: 8.5;Karpas-707: 8.3;NB-4: 9.8;U-266/84: 11.1
SON	BASS1, C21orf50, DBP-5, FLJ21099, FLJ33914, KIAA1019, NREBP	ENSG00000159140	SON DNA binding protein	21	33542618-33577481	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023535, HPA031755, HPA031756	Supported		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 223.1	Expressed in all		
SORBS1	CAP, FLJ12406, KIAA1296, ponsin, SH3D5, sh3p12	ENSG00000095637	Sorbin and SH3 domain containing 1	10	95311771-95561414	Predicted intracellular proteins	Evidence at protein level	HPA027559, HPA043084	Enhanced		Supported	Plasma membrane<br>Focal adhesion sites<br>Centrosome	Breast cancer:2.84e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 320.1	Cell line enhanced		CACO-2: 21.9;HMC-1: 39.4;SK-MEL-30: 30.9
SORBS2	ARGBP2, KIAA0777	ENSG00000154556	Sorbin and SH3 domain containing 2	4	185585444-185956652	Predicted intracellular proteins	Evidence at protein level	HPA036754, HPA036755	Supported		Supported	Nucleoplasm	Renal cancer:3.10e-6 (favourable), Liver cancer:1.47e-5 (favourable), Endometrial cancer:6.07e-5 (favourable)	Expressed in all	Tissue enhanced		heart muscle: 378.9;thyroid gland: 462.8	parathyroid gland: 282.5	Cell line enhanced		AF22: 235.7;TIME: 107.2;WM-115: 71.3
SORBS3	SCAM-1, SH3D4, vinexin	ENSG00000120896	Sorbin and SH3 domain containing 3	8	22544986-22575788	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015849, HPA048034	Approved		Approved	Nucleoplasm<br>Focal adhesion sites	Urothelial cancer:1.53e-5 (unfavourable), Pancreatic cancer:4.88e-4 (favourable)	Expressed in all	Expressed in all			placenta: 95.6	Mixed		
SORD		ENSG00000140263	Sorbitol dehydrogenase	15	45023104-45077185	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040260, HPA040621	Enhanced		Approved	Cytosol	Liver cancer:6.14e-5 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 404.7	Mixed		
SOS1	GF1, GINGF, HGF	ENSG00000115904	SOS Ras/Rac guanine nucleotide exchange factor 1	2	38981396-39124345	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB005396, HPA012613	Uncertain		Uncertain	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 41.0	Expressed in all		
SOS2		ENSG00000100485	SOS Ras/Rho guanine nucleotide exchange factor 2	14	50117120-50231558	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004577, HPA047368, HPA052689	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:8.48e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 80.7	Expressed in all		
SOWAHB	ANKRD56	ENSG00000186212	Sosondowah ankyrin repeat domain family member B	4	76894928-76898147	Predicted intracellular proteins	Evidence at protein level	HPA036809, HPA036810	Approved		Approved	Nucleoli fibrillar center	Renal cancer:1.22e-15 (favourable)	Mixed	Mixed			parathyroid gland: 9.1	Cell line enhanced		BEWO: 8.3;RT4: 15.1;T-47d: 5.0
SOWAHC	ANKRD57, C2orf26, FLJ21870	ENSG00000198142	Sosondowah ankyrin repeat domain family member C	2	109614334-109618990	Predicted intracellular proteins	Evidence at protein level	HPA056131	Enhanced		Approved	Cytosol	Renal cancer:3.56e-5 (favourable), Endometrial cancer:1.29e-4 (unfavourable), Pancreatic cancer:1.66e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 36.4	Cell line enhanced		HDLM-2: 147.6
SOWAHD	ANKRD58	ENSG00000187808	Sosondowah ankyrin repeat domain family member D	X	119758613-119760164	Predicted intracellular proteins	Evidence at protein level	HPA065955	Uncertain					Tissue enriched	Tissue enhanced		spleen: 5.0	testis: 3.6	Cell line enhanced		BEWO: 4.3;THP-1: 5.8;U-937: 6.0
SOX1		ENSG00000182968	SRY-box 1	13	112067647-112070488	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Group enriched	Group enriched	8	cerebral cortex: 3.6;testis: 1.5	skin: 0.3	Group enriched	6	AF22: 44.0;SCLC-21H: 10.1
SOX10	DOM, WS2E, WS4	ENSG00000100146	SRY-box 10	22	37970686-37987422	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003171, HPA068898	Enhanced		Supported	Nucleoplasm		Not detected	Tissue enhanced		cerebral cortex: 56.6;salivary gland: 50.5	breast: 24.0	Group enriched	686	SK-MEL-30: 236.8;WM-115: 425.1
SOX11		ENSG00000176887	SRY-box 11	2	5692667-5701385	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000536, CAB056152, CAB056153	Approved					Group enriched	Tissue enriched	15	cerebral cortex: 5.4	smooth muscle: 0.3	Group enriched	7	AF22: 48.1;NTERA-2: 23.8;REH: 16.5;RH-30: 18.0;SCLC-21H: 35.0;SH-SY5Y: 47.7;WM-115: 11.2
SOX12	SOX22	ENSG00000177732	SRY-box 12	20	325595-330224	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055052, HPA061627			Supported	Nucleoplasm	Liver cancer:6.64e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 10.7	Mixed		
SOX13	ICA12, MGC117216, Sox-13	ENSG00000143842	SRY-box 13	1	204073115-204127743	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051790, HPA054843			Enhanced	Nucleoplasm	Colorectal cancer:6.49e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 53.8	Cell line enhanced		SK-BR-3: 103.3
SOX14	SOX28	ENSG00000168875	SRY-box 14	3	137764284-137766338	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Group enriched	19	placenta: 2.4;prostate: 1.2	all non-specific tissues: 0.0	Not detected		
SOX15	SOX20, SOX26, SOX27	ENSG00000129194	SRY-box 15	17	7588178-7590170	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067196, HPA074049	Enhanced		Supported	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Vesicles		Tissue enhanced	Tissue enhanced		skin: 40.5	esophagus: 17.5	Group enriched	8	A-431: 108.6;HaCaT: 120.2;HBEC3-KT: 39.0;hTCEpi: 38.2
SOX17		ENSG00000164736	SRY-box 17	8	54457935-54460888	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025594, HPA068399	Enhanced		Approved	Nucleoplasm	Endometrial cancer:2.76e-4 (favourable)	Group enriched	Tissue enhanced		cervix, uterine: 30.2;endometrium: 32.2;fallopian tube: 30.1	adipose tissue: 14.7	Cell line enriched	8	EFO-21: 102.6
SOX18		ENSG00000203883	SRY-box 18	20	64047582-64049641	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073703			Approved	Nucleus		Expressed in all	Tissue enhanced		adipose tissue: 32.9	lung: 12.0	Cell line enhanced		HUVEC TERT2: 17.4;NB-4: 22.5;REH: 7.7;TIME: 7.8
SOX2		ENSG00000181449	SRY-box 2	3	181711924-181714436	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB010648, HPA045725, HPA071379	Approved	Supported	Supported	Nucleoplasm		Tissue enhanced	Tissue enriched	8	cerebral cortex: 117.9	esophagus: 14.8	Cell line enhanced		AF22: 273.3;HAP1: 122.7;NTERA-2: 226.0
SOX21	SOX25	ENSG00000125285	SRY-box 21	13	94709622-94712399	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA048337, HPA064084	Approved		Approved	Nucleus	Glioma:1.34e-4 (favourable), Cervical cancer:7.60e-4 (favourable)	Tissue enhanced	Group enriched	6	cerebral cortex: 17.9;esophagus: 6.9;skin: 19.4;stomach: 33.4	tonsil: 3.1	Cell line enhanced		AF22: 80.6;HAP1: 12.8;NTERA-2: 22.0;PC-3: 11.6
SOX3	PHP	ENSG00000134595	SRY-box 3	X	140502985-140505116	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054720, HPA075003			Enhanced	Nucleoplasm		Tissue enhanced	Tissue enriched	7	fallopian tube: 14.2	testis: 2.0	Group enriched	11	AF22: 7.2;HEK93: 7.2;NTERA-2: 17.4
SOX30		ENSG00000039600	SRY-box 30	5	157625679-157671480	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006159, CAB009382	Enhanced					Mixed	Tissue enriched	94	testis: 144.4	fallopian tube: 1.5	Cell line enhanced		A-431: 1.7;CACO-2: 1.0;HDLM-2: 3.8
SOX4		ENSG00000124766	SRY-box 4	6	21592768-21598619	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029901	Approved		Supported	Nucleoplasm<br>Mitochondria	Liver cancer:2.57e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 80.5	Cell line enhanced		AN3-CA: 194.4;MOLT-4: 151.8;SH-SY5Y: 123.8
SOX5	L-SOX5, MGC35153	ENSG00000134532	SRY-box 5	12	23529500-23951032	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060499			Supported	Nucleoplasm		Mixed	Tissue enhanced		testis: 58.4	cerebral cortex: 11.7	Cell line enhanced		AF22: 14.4;HDLM-2: 25.3;K-562: 15.1;WM-115: 13.9
SOX6		ENSG00000110693	SRY-box 6	11	15966449-16739591	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001923, HPA003908	Enhanced		Approved	Nucleoplasm	Renal cancer:6.47e-12 (favourable)	Mixed	Tissue enhanced		testis: 25.9	bone marrow: 16.5	Cell line enhanced		WM-115: 20.4
SOX7		ENSG00000171056	SRY-box 7	8	10723768-10730512	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009065	Approved		Approved	Nuclear speckles<br>Golgi apparatus		Expressed in all	Tissue enhanced		placenta: 49.6	lung: 18.7	Cell line enhanced		HaCaT: 21.1;HUVEC TERT2: 46.6;TIME: 36.3
SOX8		ENSG00000005513	SRY-box 8	16	981808-986979	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041640, HPA058665	Enhanced		Supported	Nucleus		Tissue enriched	Tissue enriched	29	cerebral cortex: 109.9	salivary gland: 3.8	Cell line enriched	5	RH-30: 112.8
SOX9	CMD1, CMPD1, SRA1	ENSG00000125398	SRY-box 9	17	72121020-72126420	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001758, CAB022456, CAB068240	Enhanced		Enhanced	Nucleoplasm	Lung cancer:2.07e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 61.3	Cell line enhanced		AN3-CA: 72.2;Hep G2: 65.5;U-251 MG: 54.6
SP1		ENSG00000185591	Sp1 transcription factor	12	53380176-53416446	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000330, HPA001853, HPA012292	Supported		Enhanced	Nucleoplasm	Pancreatic cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 54.3	Expressed in all		
SP100		ENSG00000067066	SP100 nuclear antigen	2	230415942-230544090	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016707, HPA017384	Enhanced		Supported	Nucleus<br>Nuclear bodies	Renal cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 139.6	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 274.7
SP110	IFI41, IFI75	ENSG00000135899	SP110 nuclear body protein	2	230167293-230225729	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047036, HPA058554	Approved		Supported	Nucleus	Renal cancer:1.17e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 66.3	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 94.0
SP140	LYSP100-A, LYSP100-B	ENSG00000079263	SP140 nuclear body protein	2	230203110-230313215	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006162, HPA067493	Enhanced		Approved	Nucleoli fibrillar center<br>Mitochondria		Mixed	Group enriched	6	appendix: 32.8;lymph node: 64.4;spleen: 38.3;tonsil: 50.7	urinary bladder: 7.6	Cell line enhanced		Daudi: 22.1;HDLM-2: 48.5;Karpas-707: 18.0;RPMI-8226: 11.2
SP140L		ENSG00000185404	SP140 nuclear body protein like	2	230327184-230403732	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055864	Uncertain		Approved	Nucleoplasm	Renal cancer:5.09e-10 (unfavourable)	Expressed in all	Mixed			spleen: 28.7	Mixed		
SP2	KIAA0048	ENSG00000167182	Sp2 transcription factor	17	47896150-47928957	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003357, CAB010245	Supported		Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:1.82e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 40.3	Expressed in all		
SP3	SPR-2	ENSG00000172845	Sp3 transcription factor	2	173906459-173965702	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004580, HPA032145, HPA032146	Supported	Supported			Renal cancer:2.46e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 91.7	Expressed in all		
SP4	HF1B, MGC130008, MGC130009, SPR-1	ENSG00000105866	Sp4 transcription factor	7	21428034-21514822	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB010246, HPA040395	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 14.9	Cell line enhanced		REH: 24.6
SP5		ENSG00000204335	Sp5 transcription factor	2	170715351-170718078	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA074123			Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		endometrium: 3.9	stomach: 2.3	Group enriched	12	CACO-2: 23.0;Hep G2: 83.0
SP6	Epfn, KLF14	ENSG00000189120	Sp6 transcription factor	17	47844908-47855874	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024516, HPA044469			Supported	Nucleoplasm<br>Mitotic spindle<br>Centrosome	Lung cancer:2.11e-6 (unfavourable), Urothelial cancer:5.72e-4 (favourable), Stomach cancer:6.39e-4 (favourable)	Mixed	Tissue enhanced		placenta: 32.5;seminal vesicle: 14.7	skin: 7.2	Cell line enriched	5	BEWO: 88.4
SP7	osterix, OSX	ENSG00000170374	Sp7 transcription factor	12	53326575-53345315	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029964, HPA063202	Enhanced	Approved				Not detected	Tissue enhanced		testis: 1.3	parathyroid gland,thyroid gland: 0.4	Not detected		
SP8		ENSG00000164651	Sp8 transcription factor	7	20782283-20786886	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054006	Uncertain		Approved	Nucleus		Tissue enhanced	Tissue enriched	12	prostate: 10.5	skin: 0.8	Cell line enhanced		HUVEC TERT2: 5.3;NTERA-2: 13.0;PC-3: 20.5
SP9	ZNF990	ENSG00000217236	Sp9 transcription factor	2	174334946-174338492	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA062616	Uncertain		Approved	Mitochondria		Mixed	Tissue enhanced		fallopian tube: 1.4	skin: 0.9	Cell line enhanced		A549: 6.5;fHDF/TERT166: 4.2;THP-1: 7.8
SPA17	CT22, SP17	ENSG00000064199	Sperm autoantigenic protein 17	11	124673798-124697518	Predicted intracellular proteins	Evidence at protein level	HPA037568	Enhanced		Approved	Vesicles	Endometrial cancer:1.03e-4 (favourable)	Expressed in all	Group enriched	7	fallopian tube: 124.1;testis: 430.2	epididymis: 38.3	Mixed		
SPAAR	LINC00961, SPAR	ENSG00000235387	Small regulatory polypeptide of amino acid response	9	35909483-35937153	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		adipose tissue: 8.1;testis: 10.9	placenta: 6.8	Group enriched	12	HUVEC TERT2: 28.2;TIME: 32.4
SPACA9	C9orf9, Mast	ENSG00000165698	Sperm acrosome associated 9	9	132878027-132890201	Predicted intracellular proteins	Evidence at protein level	HPA022243, HPA051600	Enhanced		Approved	Mitochondria	Renal cancer:8.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)	Expressed in all	Group enriched	5	epididymis: 90.3;fallopian tube: 63.1;testis: 130.1	thyroid gland: 18.0	Mixed		
SPAG1	CILD28, CT140, FLJ32920, HSD-3.8, SP75, TPIS	ENSG00000104450	Sperm associated antigen 1	8	100157906-100259278	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023748, HPA053682	Enhanced		Supported	Cytosol	Urothelial cancer:2.62e-4 (favourable), Renal cancer:3.87e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 34.1	rectum: 20.0	Mixed		
SPAG16	DKFZp666P1710, FLJ22724, PF20, WDR29	ENSG00000144451	Sperm associated antigen 16	2	213284379-214410501	Predicted intracellular proteins	Evidence at protein level	HPA037542	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.82e-4 (favourable), Prostate cancer:4.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 84.3	Mixed		
SPAG17	CT143, FLJ34497, PF6, RP4-776P7.2	ENSG00000155761	Sperm associated antigen 17	1	117953861-118185223	Predicted intracellular proteins	Evidence at protein level	HPA028597, HPA028666	Enhanced					Mixed	Tissue enhanced		fallopian tube: 13.6;testis: 27.9	esophagus: 6.8	Not detected		
SPAG5	DEEPEST, hMAP126, MAP126	ENSG00000076382	Sperm associated antigen 5	17	28577565-28599279	Predicted intracellular proteins	Evidence at protein level	HPA022008, HPA022479	Approved				Renal cancer:5.43e-13 (unfavourable), Liver cancer:5.43e-5 (unfavourable), Pancreatic cancer:3.02e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 120.0	kidney: 25.1	Mixed		
SPAG6	CT141, pf16, Repro-SA-1	ENSG00000077327	Sperm associated antigen 6	10	22345445-22454224	Predicted intracellular proteins	Evidence at protein level	HPA038440	Enhanced					Mixed	Group enriched	12	fallopian tube: 77.7;testis: 172.6	lung: 10.7	Cell line enriched	22	U-937: 82.7
SPAG7	ACRP, FSA-1, MGC20134	ENSG00000091640	Sperm associated antigen 7	17	4959226-4967872	Predicted intracellular proteins	Evidence at protein level	HPA024032, HPA052394	Uncertain		Supported	Nucleus	Renal cancer:5.79e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 102.8	Expressed in all		
SPAG8	BS-84, CT142, HSD-1, hSMP-1, SPAG3	ENSG00000137098	Sperm associated antigen 8	9	35808045-35812272	Predicted intracellular proteins	Evidence at protein level	HPA068012	Enhanced				Endometrial cancer:2.15e-4 (favourable)	Mixed	Group enriched	10	fallopian tube: 28.6;testis: 16.3	thyroid gland: 2.2	Not detected		
SPANXA1	CT11.1, NAP-X, SPAN-Xa, SPAN-Xb, SPANX	ENSG00000198021	Sperm protein associated with the nucleus, X-linked, family member A1	X	141583674-141585011	Predicted intracellular proteins	Evidence at protein level	HPA046423, HPA073647	Supported		Supported	Nucleoplasm<br>Vesicles		Not detected	Tissue enriched	93	testis: 9.2	all non-specific tissues: 0.0	Cell line enhanced		U-2 OS: 1.6
SPANXA2	SPANX	ENSG00000203926	SPANX family member A2	X	141589435-141590772	Predicted intracellular proteins	Evidence at protein level	HPA046423, HPA073647	Supported		Supported	Nucleoplasm<br>Vesicles		Not detected	Tissue enriched	93	testis: 9.2	all non-specific tissues: 0.0	Cell line enhanced		U-2 OS: 1.6
SPANXB1	CT11.2, SPANXB2, SPANXF1, SPANXF2	ENSG00000227234	SPANX family member B1	X	141002591-141003706	Predicted intracellular proteins	Evidence at protein level	HPA046423, HPA073647	Supported		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	370	testis: 42.5	kidney: 0.1	Group enriched	26	A-431: 70.8;U-2 OS: 28.0
SPANXC	CT11.3, CTp11	ENSG00000198573	SPANX family member C	X	141241463-141242496	Predicted intracellular proteins	Evidence at protein level	HPA046423, HPA073647	Supported		Supported	Nucleoplasm<br>Vesicles		Tissue enhanced	Tissue enriched	187	testis: 18.7	all non-specific tissues: 0.0	Cell line enhanced		A-431: 7.8;U-2 OS: 4.3
SPANXD	CT11.4, SPANXE	ENSG00000196406	SPANX family member D	X	141697411-141698739	Predicted intracellular proteins	Evidence at protein level	HPA046423, HPA073647	Supported		Approved	Nucleoplasm<br>Vesicles		Not detected	Tissue enriched	193	testis: 19.3	all non-specific tissues: 0.0	Group enriched	10	A-431: 2.2;U-2 OS: 4.8
SPANXN1	CT11.6, SPANX-N1	ENSG00000203923	SPANX family member N1	X	145246828-145256112	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	14	testis: 1.3	all non-specific tissues: 0.0	Not detected		
SPANXN2	CT11.7, SPANX-N2	ENSG00000268988	SPANX family member N2	X	143711955-143721423	Predicted intracellular proteins	Evidence at protein level	HPA045652			Approved	Nucleus<br>Nucleoli fibrillar center		Not detected	Tissue enriched	26	testis: 2.5	all non-specific tissues: 0.0	Not detected		
SPANXN3	CT11.8, SPANX-N3	ENSG00000189252	SPANX family member N3	X	143508735-143517475	Predicted intracellular proteins	Evidence at transcript level	HPA045652			Approved	Nucleus<br>Nucleoli fibrillar center		Not detected	Tissue enriched	58	testis: 52.1	duodenum: 0.8	Cell line enriched	6	U-2 OS: 1.9
SPANXN4	CT11.9, SPANX-N4	ENSG00000189326	SPANX family member N4	X	143025918-143034702	Predicted intracellular proteins	Evidence at transcript level	HPA045730	Uncertain					Not detected	Tissue enriched	227	testis: 22.7	all non-specific tissues: 0.0	Not detected		
SPANXN5	CT11.10, SPANX-N5	ENSG00000204363	SPANX family member N5	X	52796144-52798101	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	106	testis: 11.5	placenta: 0.1	Not detected		
SPATA1	SP-2	ENSG00000122432	Spermatogenesis associated 1	1	84506300-84566194	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	8	testis: 4.5	skin: 0.5	Not detected		
SPATA12		ENSG00000186451	Spermatogenesis associated 12	3	57060441-57075432	Predicted intracellular proteins	Evidence at transcript level	HPA043323			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	54	testis: 23.0	fallopian tube,lung: 0.4	Not detected		
SPATA13	ARHGEF29, FLJ31208	ENSG00000182957	Spermatogenesis associated 13	13	23979805-24307074	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040185, HPA041208	Approved		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:1.16e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 90.2	lymph node: 27.2	Cell line enhanced		HDLM-2: 43.0
SPATA16	NYD-SP12	ENSG00000144962	Spermatogenesis associated 16	3	172889358-173141268	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037884	Enhanced					Not detected	Tissue enriched	606	testis: 105.7	kidney: 0.1	Not detected		
SPATA17	IQCH	ENSG00000162814	Spermatogenesis associated 17	1	217631324-217871696	Predicted intracellular proteins	Evidence at protein level	HPA030099	Enhanced		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		fallopian tube: 6.5;testis: 18.2	epididymis: 4.1	Cell line enhanced		SCLC-21H: 1.5
SPATA18	FLJ32906	ENSG00000163071	Spermatogenesis associated 18	4	52051331-52097292	Predicted intracellular proteins	Evidence at protein level	HPA036854, HPA036855	Enhanced				Renal cancer:3.73e-9 (favourable), Endometrial cancer:1.32e-5 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 109.4;testis: 42.6	cervix, uterine: 16.2	Cell line enhanced		ASC TERT1: 22.1;BEWO: 23.6;HSkMC: 21.4;hTCEpi: 20.9
SPATA19	CT132, FLJ25851, SPAS1, spergen1	ENSG00000166118	Spermatogenesis associated 19	11	133840631-133845538	Predicted intracellular proteins	Evidence at protein level	HPA040082	Enhanced					Not detected	Tissue enriched	509	testis: 142.8	esophagus: 0.2	Not detected		
SPATA2	KIAA0757, PD1, PPP1R145, tamo	ENSG00000158480	Spermatogenesis associated 2	20	49903391-49915508	Predicted intracellular proteins	Evidence at protein level	HPA048581, HPA052224	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center	Endometrial cancer:1.87e-4 (unfavourable), Thyroid cancer:4.53e-4 (unfavourable), Melanoma:9.08e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 22.4	Expressed in all		
SPATA21	spergen-2, spergen2	ENSG00000187144	Spermatogenesis associated 21	1	16387117-16437424	Predicted intracellular proteins	Evidence at transcript level	HPA032080			Approved	Vesicles<br>Cytosol		Not detected	Tissue enriched	13	testis: 8.0	skin: 0.6	Cell line enriched	7	Hep G2: 3.7
SPATA22	NYD-SP20	ENSG00000141255	Spermatogenesis associated 22	17	3440019-3513852	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	80	testis: 415.6	placenta: 5.1	Group enriched	8	K-562: 6.9;TIME: 8.9
SPATA24	CCDC161, T6441	ENSG00000170469	Spermatogenesis associated 24	5	139396563-139404088	Predicted intracellular proteins	Evidence at protein level	HPA044000	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:2.75e-4 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 177.4	epididymis: 25.6	Expressed in all		
SPATA25	C20orf165, dJ337O18.8, TSG23	ENSG00000149634	Spermatogenesis associated 25	20	45886489-45887635	Predicted intracellular proteins	Evidence at protein level	HPA041386			Approved	Golgi apparatus		Mixed	Mixed			testis: 15.4	Mixed		
SPATA2L	C16orf76, MGC26885, tamo	ENSG00000158792	Spermatogenesis associated 2 like	16	89696343-89701705	Predicted intracellular proteins	Evidence at protein level	HPA041182, HPA042453	Uncertain		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 9.1	Cell line enhanced		MCF7: 25.9
SPATA32	AEP2, C17orf46, FLJ25414, TEX34, VAD1.2	ENSG00000184361	Spermatogenesis associated 32	17	45254393-45262112	Predicted intracellular proteins	Evidence at protein level	HPA024549	Approved					Not detected	Tissue enriched	86	testis: 40.7	duodenum: 0.4	Cell line enhanced		A549: 1.1
SPATA33	C16orf55, FLJ31606	ENSG00000167523	Spermatogenesis associated 33	16	89657802-89671272	Predicted intracellular proteins	Evidence at protein level	HPA045648, HPA073096	Enhanced		Approved	Nucleoplasm<br>Vesicles	Cervical cancer:1.06e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 77.2	fallopian tube: 25.6	Expressed in all		
SPATA4	SPEF1B, TSARG2	ENSG00000150628	Spermatogenesis associated 4	4	176184638-176195671	Predicted intracellular proteins	Evidence at protein level	HPA019220	Enhanced					Not detected	Tissue enriched	18	testis: 243.1	fallopian tube: 13.5	Cell line enhanced		U-87 MG: 2.4
SPATA45	C1orf227, LOC149643	ENSG00000185523	Spermatogenesis associated 45	1	212830141-212847649	Predicted intracellular proteins	Evidence at transcript level	HPA049921	Uncertain					Not detected	Tissue enriched	11	testis: 13.2	fallopian tube: 1.2	Mixed		
SPATA46	C1orf111	ENSG00000171722	Spermatogenesis associated 46	1	162373203-162376870	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	testis: 28.9	adrenal gland: 4.2	Cell line enhanced		SCLC-21H: 1.1
SPATA5	AFG2, SPAF	ENSG00000145375	Spermatogenesis associated 5	4	122923074-123319450	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036450, HPA036451	Approved		Approved	Cytosol		Expressed in all	Mixed			testis: 4.2	Mixed		
SPATA5L1	FLJ12286, MGC5347	ENSG00000171763	Spermatogenesis associated 5 like 1	15	45402331-45421419	Predicted intracellular proteins	Evidence at protein level	HPA043679	Uncertain		Approved	Nucleus<br>Nucleoli	Prostate cancer:7.88e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 8.9	Expressed in all		
SPATA6	FLJ10007, SRF-1, SRF1	ENSG00000132122	Spermatogenesis associated 6	1	48295372-48472208	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA028234			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		testis: 89.0	fallopian tube: 24.6	Cell line enhanced		ASC TERT1: 14.7
SPATA6L	C9orf68, FLJ10058	ENSG00000106686	Spermatogenesis associated 6 like	9	4553386-4666674	Predicted intracellular proteins	Evidence at protein level	HPA039585	Enhanced					Mixed	Tissue enhanced		fallopian tube: 5.8;testis: 6.4	gallbladder,lung: 2.3	Cell line enhanced		BEWO: 1.3;CAPAN-2: 2.1;HDLM-2: 1.3;RPTEC TERT1: 1.3;SCLC-21H: 1.8
SPATA7	HSD3, LCA3	ENSG00000042317	Spermatogenesis associated 7	14	88384924-88470350	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038082, HPA038083	Enhanced		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:2.50e-5 (favourable), Pancreatic cancer:4.16e-5 (favourable)	Expressed in all	Tissue enriched	5	testis: 102.9	thyroid gland: 20.1	Mixed		
SPATA8	MGC44294	ENSG00000185594	Spermatogenesis associated 8	15	96783389-96785615	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	1454	testis: 404.5	adrenal gland,gallbladder,placenta: 0.2	Not detected		
SPATC1	MGC61633, SPATA15, SPERIOLIN	ENSG00000186583	Spermatogenesis and centriole associated 1	8	144012414-144047085	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	5	bone marrow: 6.2;testis: 21.7	appendix: 2.5	Cell line enriched	8	U-937: 6.3
SPATC1L	C21orf56	ENSG00000160284	Spermatogenesis and centriole associated 1 like	21	46161148-46184476	Predicted intracellular proteins	Evidence at protein level	HPA018979, HPA019165, HPA029394	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.16e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 11.7	prostate: 7.4	Cell line enhanced		K-562: 33.7
SPATS1	FLJ25442, SPATA8, SRSP1	ENSG00000249481	Spermatogenesis associated serine rich 1	6	44342660-44377167	Predicted intracellular proteins	Evidence at transcript level	HPA030897, HPA049722	Approved		Approved	Nucleoplasm		Not detected	Group enriched	5	fallopian tube: 14.2;testis: 45.3	epididymis: 5.6	Cell line enriched	60	SK-MEL-30: 5.9
SPATS2	FLJ13117, SCR59, SPATA10	ENSG00000123352	Spermatogenesis associated serine rich 2	12	49366584-49527424	Predicted intracellular proteins	Evidence at protein level	HPA038642, HPA038643, HPA066105	Uncertain		Enhanced	Cytosol	Liver cancer:9.57e-8 (unfavourable), Ovarian cancer:1.44e-4 (favourable), Renal cancer:5.20e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.6	Expressed in all		
SPATS2L	DNAPTP6, SGNP	ENSG00000196141	Spermatogenesis associated serine rich 2 like	2	200305881-200482263	Predicted intracellular proteins	Evidence at protein level	HPA055427, HPA066310	Uncertain		Enhanced	Nucleoli<br>Cytosol	Pancreatic cancer:7.43e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 167.5	Mixed		
SPC24	FLJ90806, SPBC24	ENSG00000161888	SPC24, NDC80 kinetochore complex component	19	11131520-11155808	Predicted intracellular proteins	Evidence at protein level	HPA051234	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.22e-4 (unfavourable), Liver cancer:1.46e-4 (unfavourable), Cervical cancer:3.59e-4 (favourable)	Expressed in all	Mixed			bone marrow: 16.6	Mixed		
SPC25	AD024, MGC22228, SPBC25	ENSG00000152253	SPC25, NDC80 kinetochore complex component	2	168834132-168913371	Predicted intracellular proteins	Evidence at protein level	HPA047144, HPA050544	Approved		Enhanced	Cytosol	Liver cancer:4.74e-6 (unfavourable), Endometrial cancer:8.61e-5 (unfavourable), Lung cancer:9.44e-5 (unfavourable)	Mixed	Mixed			lymph node: 4.9	Mixed		
SPCS3	FLJ22649, PRO3567, SPC22/23, SPC3, YLR066W	ENSG00000129128	Signal peptidase complex subunit 3	4	176319964-176332245	Predicted intracellular proteins	Evidence at protein level	HPA053180	Approved				Endometrial cancer:8.89e-6 (favourable), Pancreatic cancer:1.87e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 104.1	Expressed in all		
SPDEF	bA375E1.3, PDEF	ENSG00000124664	SAM pointed domain containing ETS transcription factor	6	34537802-34556333	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055707			Supported	Nucleus<br>Nucleoli	Endometrial cancer:9.26e-9 (favourable)	Group enriched	Tissue enhanced		prostate: 172.4	breast: 42.6	Cell line enhanced		MCF7: 221.8;SK-BR-3: 144.8;T-47d: 145.8
SPDL1	CCDC99, FLJ20364, hSpindly	ENSG00000040275	Spindle apparatus coiled-coil protein 1	5	169583634-169604778	Predicted intracellular proteins	Evidence at protein level	HPA044700, HPA048146	Enhanced		Approved	Cytosol	Liver cancer:1.48e-6 (unfavourable), Renal cancer:2.13e-6 (unfavourable), Pancreatic cancer:1.19e-5 (unfavourable), Endometrial cancer:1.18e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 60.9	lymph node: 16.4	Expressed in all		
SPDYA	Ringo3, SPDY1, SPY1	ENSG00000163806	Speedy/RINGO cell cycle regulator family member A	2	28782517-28850611	Predicted intracellular proteins	Evidence at protein level	HPA035162, HPA066214	Enhanced		Supported	Nucleoplasm		Not detected	Tissue enriched	30	testis: 58.6	skin: 1.9	Mixed		
SPDYC	Ringo2	ENSG00000204710	Speedy/RINGO cell cycle regulator family member C	11	65170154-65173244	Predicted intracellular proteins	Evidence at protein level	HPA039891	Uncertain				Breast cancer:1.20e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		liver: 1.4;testis: 1.5	epididymis: 0.4	Cell line enhanced		BEWO: 6.0;HEL: 6.3;K-562: 15.4
SPDYE1	Ringo1, SPDYE, WBSCR19	ENSG00000136206	Speedy/RINGO cell cycle regulator family member E1	7	44000889-44010122	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051750	Supported					Mixed	Tissue enriched	6	testis: 8.2	skin: 1.3	Mixed		
SPDYE16		ENSG00000185040	Speedy/RINGO cell cycle regulator family member E16	7	76531319-76541459	Predicted intracellular proteins	Evidence at protein level	HPA051750	Supported					Not detected	Not detected			testis: 0.6	Cell line enhanced		HeLa: 1.9
SPDYE2	MGC119295	ENSG00000205238	Speedy/RINGO cell cycle regulator family member E2	7	102551232-102562308	Predicted intracellular proteins	Evidence at protein level	HPA051750	Approved					Mixed	Tissue enhanced		testis: 15.0	skin: 4.1	Mixed		
SPDYE2B		ENSG00000173678	Speedy/RINGO cell cycle regulator family member E2B	7	102650325-102661398	Predicted intracellular proteins	Evidence at protein level	HPA051750	Supported					Not detected	Tissue enhanced		testis: 3.9	spleen: 2.0	Cell line enhanced		Karpas-707: 4.2
SPDYE3		ENSG00000214300	Speedy/RINGO cell cycle regulator family member E3	7	100307702-100322196	Predicted intracellular proteins	Evidence at protein level	HPA051750	Supported				Endometrial cancer:2.00e-6 (unfavourable), Breast cancer:8.73e-4 (favourable)	Expressed in all	Tissue enriched	11	testis: 2.3	skin: 0.2	Not detected		
SPDYE4		ENSG00000183318	Speedy/RINGO cell cycle regulator family member E4	17	8753106-8758559	Predicted intracellular proteins	Evidence at protein level	HPA025704, HPA051750	Enhanced					Not detected	Tissue enriched	20	testis: 10.5	bone marrow: 0.5	Cell line enhanced		A549: 1.4;HeLa: 1.1
SPDYE5		ENSG00000170092	Speedy/RINGO cell cycle regulator family member E5	7	75493625-75504304	Predicted intracellular proteins	Evidence at protein level	HPA051750	Approved					Mixed	Tissue enhanced		testis: 4.8	skin: 2.3	Mixed		
SPDYE6		ENSG00000260097	Speedy/RINGO cell cycle regulator family member E6	7	102347206-102356444	Predicted intracellular proteins	Evidence at protein level	HPA051750	Approved					Mixed	Tissue enhanced		testis: 6.6	skin: 3.9	Mixed		
SPECC1	CYTSB, FLJ36955, HCMOGT-1, NSP	ENSG00000128487	Sperm antigen with calponin homology and coiled-coil domains 1	17	20009344-20319026	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021421, HPA021430	Enhanced				Lung cancer:1.06e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 67.2	Cell line enhanced		SiHa: 107.9
SPECC1L	CYTSA, KIAA0376	ENSG00000100014	Sperm antigen with calponin homology and coiled-coil domains 1 like	22	24270817-24417740	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA070614	Uncertain		Supported	Actin filaments	Pancreatic cancer:7.92e-4 (favourable)	Expressed in all	Expressed in all			testis: 58.2	Expressed in all		
SPEF1	C20orf28, CLAMP, DKFZP434I114, SPEF1A	ENSG00000101222	Sperm flagellar 1	20	3777504-3781448	Predicted intracellular proteins	Evidence at protein level	HPA050786	Enhanced				Thyroid cancer:9.87e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 15.9;testis: 6.5	cerebral cortex: 2.9	Cell line enhanced		A549: 1.9;MCF7: 1.2
SPEF2	CT122, FLJ23577, KPL2	ENSG00000152582	Sperm flagellar 2	5	35617844-35814611	Predicted intracellular proteins	Evidence at protein level	HPA039606, HPA040343	Enhanced					Mixed	Mixed			fallopian tube: 25.5	Cell line enhanced		HDLM-2: 12.3
SPEG	APEG1, BPEG, KIAA1297, MGC12676, SPEGalpha, SPEGbeta	ENSG00000072195	SPEG complex locus	2	219434846-219498287	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018904	Enhanced		Approved	Vesicles		Mixed	Mixed			skeletal muscle: 43.2	Cell line enhanced		U-2 OS: 22.8;U-87 MG: 23.6
SPEN	KIAA0929, MINT, RBM15C, SHARP	ENSG00000065526	Spen family transcriptional repressor	1	15847864-15940460	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015825, HPA050257	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 39.0	Expressed in all		
SPERT	CBY2, NURIT	ENSG00000174015	Spermatid associated	13	45702311-45714559	Predicted intracellular proteins	Evidence at protein level	HPA039359, HPA040046	Enhanced		Approved	Plasma membrane<br>Cell Junctions		Mixed	Tissue enriched	178	testis: 49.0	fallopian tube,urinary bladder: 0.2	Not detected		
SPG20	KIAA0610, TAHCCP1	ENSG00000133104	Spastic paraplegia 20 (Troyer syndrome)	13	36301638-36370180	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039053, HPA039054	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			epididymis: 81.4	Mixed		
SPG21	ACP33, BM-019, GL010, MAST	ENSG00000090487	SPG21, maspardin	15	64963021-64990310	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040407, HPA040436	Approved		Supported	Vesicles<br>Cytosol		Expressed in all	Expressed in all			epididymis: 182.9	Expressed in all		
SPHAR		ENSG00000213029	S-phase response (cyclin related)	1	229304857-229305504	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SPHK1	SPHK	ENSG00000176170	Sphingosine kinase 1	17	76376584-76387860	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022829, HPA028761	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:5.14e-6 (unfavourable)	Expressed in all	Mixed			gallbladder: 19.0	Mixed		
SPHK2		ENSG00000063176	Sphingosine kinase 2	19	48619291-48630717	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA065508			Supported	Vesicles	Renal cancer:2.59e-5 (favourable), Endometrial cancer:5.19e-4 (unfavourable), Pancreatic cancer:9.30e-4 (favourable)	Expressed in all	Mixed			duodenum: 22.1	Expressed in all		
SPHKAP	SKIP	ENSG00000153820	SPHK1 interactor, AKAP domain containing	2	227979950-228181645	Predicted intracellular proteins	Evidence at protein level	HPA042499, HPA048168	Enhanced					Not detected	Group enriched	7	cerebral cortex: 19.4;heart muscle: 19.0	ovary: 2.7	Cell line enriched	17	BJ hTERT+: 37.3
SPIB	SPI-B	ENSG00000269404	Spi-B transcription factor	19	50418938-50431313	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018523	Uncertain				Head and neck cancer:2.14e-5 (favourable), Breast cancer:4.76e-5 (favourable)	Mixed	Tissue enhanced		appendix: 53.9;lymph node: 103.3;tonsil: 91.1	spleen: 39.2	Group enriched	10	Daudi: 119.1;HDLM-2: 99.4;Karpas-707: 37.4;U-698: 159.1
SPIC	MGC40611, SPI-C	ENSG00000166211	Spi-C transcription factor	12	101475421-101486997	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enriched	12	spleen: 46.7	lymph node: 3.9	Not detected		
SPICE1	CCDC52, SPICE	ENSG00000163611	Spindle and centriole associated protein 1	3	113442718-113515187	Predicted intracellular proteins	Evidence at protein level	HPA064843	Approved		Supported	Centrosome		Expressed in all	Mixed			endometrium: 17.7	Expressed in all		
SPIDR	KIAA0146	ENSG00000164808	Scaffolding protein involved in DNA repair	8	47260575-47736306	Predicted intracellular proteins	Evidence at protein level	HPA027201, HPA041582	Approved		Supported	Nucleoplasm	Renal cancer:2.04e-6 (unfavourable), Ovarian cancer:8.91e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 30.7	Expressed in all		
SPIN1	SPIN, TDRD24	ENSG00000106723	Spindlin 1	9	88388419-88478694	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000162, HPA068784	Uncertain		Supported	Nucleoplasm	Renal cancer:8.69e-6 (favourable)	Expressed in all	Expressed in all			endometrium: 101.8	Mixed		
SPIN2A	DXF34, SPIN2, TDRD25	ENSG00000147059	Spindlin family member 2A	X	57134530-57137625	Predicted intracellular proteins	Evidence at protein level	HPA000162, HPA069835	Uncertain		Approved	Nucleoplasm		Not detected	Mixed			cerebral cortex: 1.6	Mixed		
SPIN2B	SPIN-2, TDRD26	ENSG00000186787	Spindlin family member 2B	X	57118551-57121546	Predicted intracellular proteins	Evidence at transcript level	HPA000162, HPA069835	Uncertain		Approved	Nucleoplasm	Renal cancer:1.78e-5 (favourable), Pancreatic cancer:3.39e-4 (favourable), Ovarian cancer:3.43e-4 (favourable)	Expressed in all	Expressed in all			prostate: 18.0	Expressed in all		
SPIN4	FLJ44984, TDRD28	ENSG00000186767	Spindlin family member 4	X	63347228-63351344	Predicted intracellular proteins	Evidence at protein level	HPA044559	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:3.56e-6 (unfavourable)	Expressed in all	Mixed			placenta: 6.3	Mixed		
SPIRE1	KIAA1135, spir-1	ENSG00000134278	Spire type actin nucleation factor 1	18	12446512-12658134	Predicted intracellular proteins	Evidence at protein level	HPA040737, HPA040942	Uncertain		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.07e-4 (unfavourable), Stomach cancer:7.92e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 61.3	cerebral cortex: 50.4	Mixed		
SPIRE2	KIAA1832, spir-2	ENSG00000204991	Spire type actin nucleation factor 2	16	89818179-89871319	Predicted intracellular proteins	Evidence at protein level	HPA041413, HPA049415	Uncertain		Approved	Nucleus<br>Vesicles<br>Intermediate filaments	Liver cancer:9.77e-5 (unfavourable)	Expressed in all	Mixed			stomach: 14.0	Mixed		
SPO11	CT35, SPATA43, TOPVIA	ENSG00000054796	SPO11, initiator of meiotic double stranded breaks	20	57329759-57343994	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	154	testis: 15.3	all non-specific tissues: 0.0	Not detected		
SPOCD1	FLJ25348, PPP1R146	ENSG00000134668	SPOC domain containing 1	1	31790422-31816051	Predicted intracellular proteins	Evidence at protein level	HPA031713, HPA031714, HPA031715	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cytosol	Urothelial cancer:4.05e-5 (favourable)	Group enriched	Tissue enhanced		testis: 14.1;urinary bladder: 10.0	appendix: 4.4	Cell line enhanced		hTEC/SVTERT24-B: 51.5;RT4: 71.0;U-87 MG: 82.7
SPOP	BTBD32, TEF2	ENSG00000121067	Speckle type BTB/POZ protein	17	49598884-49678234	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.88e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 121.2	Expressed in all		
SPOPL	BTBD33	ENSG00000144228	Speckle type BTB/POZ protein like	2	138501801-138573547	Predicted intracellular proteins	Evidence at protein level	HPA034687	Uncertain		Approved	Vesicles	Renal cancer:3.63e-4 (favourable)	Expressed in all	Expressed in all			breast: 16.2	Mixed		
SPOUT1	C9orf114, CENP-32, HSPC109	ENSG00000198917	SPOUT domain containing methyltransferase 1	9	128819651-128829821	Predicted intracellular proteins	Evidence at protein level	HPA022990			Approved	Nucleus<br>Nucleoli	Pancreatic cancer:4.09e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 22.0	Expressed in all		
SPR	SDR38C1	ENSG00000116096	Sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase)	2	72887360-72892158	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039505	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 49.9	Mixed		
SPRR1A		ENSG00000169474	Small proline rich protein 1A	1	152985231-152985500	Predicted intracellular proteins	Evidence at protein level	CAB011237	Enhanced				Pancreatic cancer:1.03e-4 (unfavourable)	Tissue enhanced	Tissue enriched	12	esophagus: 9968.1	tonsil: 835.5	Group enriched	6	HaCaT: 21.3;hTCEpi: 49.9;RT4: 21.6
SPRR1B	GADD33, SPRR1	ENSG00000169469	Small proline rich protein 1B	1	153031202-153032900	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:7.64e-5 (unfavourable), Lung cancer:7.66e-5 (unfavourable), Urothelial cancer:7.28e-4 (unfavourable)	Group enriched	Tissue enriched	6	esophagus: 2454.9	tonsil: 406.1	Cell line enriched	8	hTCEpi: 263.1
SPRR2A		ENSG00000241794	Small proline rich protein 2A	1	153056113-153057537	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:1.37e-5 (unfavourable)	Tissue enhanced	Tissue enriched	8	esophagus: 5298.0	tonsil: 643.7	Group enriched	8	HaCaT: 5.3;hTCEpi: 5.2;hTERT-HME1: 7.3;Karpas-707: 8.4;U-266/70: 1.8
SPRR2B		ENSG00000196805	Small proline rich protein 2B	1	153070224-153070840	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Group enriched	18	esophagus: 30.3;skin: 17.1;testis: 8.2;tonsil: 14.1	ovary: 0.9	Not detected		
SPRR2D		ENSG00000163216	Small proline rich protein 2D	1	153039725-153041931	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:1.62e-4 (unfavourable)	Group enriched	Tissue enriched	7	esophagus: 2272.9	tonsil: 348.0	Group enriched	10	hTCEpi: 29.4;hTERT-HME1: 27.2;SK-MEL-30: 14.0;U-87 MG: 6.4
SPRR2E		ENSG00000203785	Small proline rich protein 2E	1	153093135-153106184	Predicted intracellular proteins	Evidence at transcript level						Urothelial cancer:9.47e-4 (unfavourable)	Tissue enhanced	Group enriched	18	esophagus: 2005.4;skin: 804.8;tonsil: 459.7	breast: 61.4	Cell line enriched	9	hTCEpi: 12.1
SPRR2F		ENSG00000244094	Small proline rich protein 2F	1	153112114-153113515	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	9	esophagus: 167.0;ovary: 83.7;tonsil: 63.0	testis: 11.8	Cell line enriched	9	K-562: 2.4
SPRR2G		ENSG00000159516	Small proline rich protein 2G	1	153149582-153150869	Predicted intracellular proteins	Evidence at transcript level							Group enriched	Tissue enriched	10	skin: 271.7	tonsil: 27.2	Cell line enriched	12	hTCEpi: 2.5
SPRR3		ENSG00000163209	Small proline rich protein 3	1	153001747-153003856	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA044467	Enhanced				Pancreatic cancer:6.27e-5 (unfavourable)	Tissue enhanced	Tissue enriched	10	esophagus: 22075.5	tonsil: 2218.1	Cell line enhanced		CAPAN-2: 5.2;hTCEpi: 6.9;RT4: 10.0
SPRR4		ENSG00000184148	Small proline rich protein 4	1	152970666-152972574	Predicted intracellular proteins	Evidence at protein level	HPA055963	Enhanced					Tissue enhanced	Tissue enriched	6	skin: 48.3	breast: 7.8	Not detected		
SPRTN	C1orf124, DKFZP547N043, DVC1, Spartan	ENSG00000010072	SprT-like N-terminal domain	1	231337104-231355023	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA025073	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			testis: 25.0	Expressed in all		
SPRYD4	DKFZp686N0877	ENSG00000176422	SPRY domain containing 4	12	56468567-56479707	Predicted intracellular proteins	Evidence at protein level	HPA053469	Approved		Approved	Nucleoplasm	Endometrial cancer:8.85e-5 (unfavourable), Lung cancer:4.52e-4 (favourable)	Expressed in all	Mixed			liver: 7.8	Mixed		
SPRYD7	C13orf1, CLLD6	ENSG00000123178	SPRY domain containing 7	13	49912706-49936490	Predicted intracellular proteins	Evidence at protein level	HPA043934	Approved		Approved	Vesicles	Cervical cancer:8.48e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 18.7	Mixed		
SPSB1	SSB-1	ENSG00000171621	SplA/ryanodine receptor domain and SOCS box containing 1	1	9292880-9369532	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.08e-6 (unfavourable)	Expressed in all	Mixed			adipose tissue: 62.2	Cell line enhanced		hTEC/SVTERT24-B: 81.5
SPSB2	GRCC9, SSB-2	ENSG00000111671	SplA/ryanodine receptor domain and SOCS box containing 2	12	6870935-6889358	Predicted intracellular proteins	Evidence at protein level	HPA055225	Approved				Liver cancer:2.62e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 12.6	Expressed in all		
SPSB3	C16orf31, SSB-3	ENSG00000162032	SplA/ryanodine receptor domain and SOCS box containing 3	16	1776712-1793700	Predicted intracellular proteins	Evidence at protein level	HPA046602	Approved		Approved	Mitochondria		Mixed	Expressed in all			adrenal gland: 29.1	Mixed		
SPSB4	SSB-4	ENSG00000175093	SplA/ryanodine receptor domain and SOCS box containing 4	3	141051402-141148611	Predicted intracellular proteins	Evidence at protein level	HPA062793			Approved	Nucleoplasm<br>Golgi apparatus	Glioma:2.57e-4 (favourable)	Group enriched	Tissue enhanced		cerebral cortex: 1.3;spleen: 1.5;testis: 2.4	pancreas: 1.2	Cell line enhanced		AF22: 12.9;NTERA-2: 3.7;RH-30: 4.3;SH-SY5Y: 3.9;U-2 OS: 3.1
SPTA1	EL2	ENSG00000163554	Spectrin alpha, erythrocytic 1	1	158610706-158686698	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016193, HPA028048, HPA028253, CAB037246	Supported					Not detected	Tissue enriched	19	bone marrow: 47.1	placenta: 2.5	Group enriched	7	HEL: 7.6;K-562: 34.1
SPTAN1		ENSG00000197694	Spectrin alpha, non-erythrocytic 1	9	128552558-128633662	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004581, HPA007927	Enhanced		Approved	Vesicles<br>Microtubules	Renal cancer:1.84e-12 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 201.9	Expressed in all		
SPTB		ENSG00000070182	Spectrin beta, erythrocytic	14	64746283-64879883	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003394, HPA003398, CAB015169, CAB016232	Enhanced		Uncertain	Golgi apparatus<br>Cytosol		Mixed	Tissue enhanced		bone marrow: 38.3;skeletal muscle: 43.1	heart muscle: 15.1	Cell line enhanced		HEL: 35.6;K-562: 43.0;U-937: 11.1
SPTBN1		ENSG00000115306	Spectrin beta, non-erythrocytic 1	2	54456285-54671445	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012685, HPA013149	Supported		Approved	Golgi apparatus	Renal cancer:2.59e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 376.6	Mixed		
SPTBN2	SCA5	ENSG00000173898	Spectrin beta, non-erythrocytic 2	11	66685248-66729226	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009844, HPA039293, HPA043529	Enhanced		Supported	Cell Junctions<br>Cytosol	Pancreatic cancer:3.14e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 73.0;skin: 59.3;testis: 48.4	parathyroid gland: 24.6	Cell line enhanced		NTERA-2: 49.7;SCLC-21H: 59.4
SPTBN4	KIAA1642, SPTBN3	ENSG00000160460	Spectrin beta, non-erythrocytic 4	19	40466241-40576464	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054481	Enhanced		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enriched	6	cerebral cortex: 18.6	adrenal gland: 2.8	Cell line enhanced		K-562: 1.6;Karpas-707: 1.8;SCLC-21H: 4.6;SH-SY5Y: 2.5
SPTBN5	BSPECV, HUBSPECV, HUSPECV	ENSG00000137877	Spectrin beta, non-erythrocytic 5	15	41848144-41894077	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			gallbladder,heart muscle,thyroid gland: 1.3	Cell line enhanced		SCLC-21H: 6.0;TIME: 11.0;WM-115: 4.2
SPTY2D1	DKFZp686I068, FLJ39441, Spt2	ENSG00000179119	SPT2 chromatin protein domain containing 1	11	18606401-18634791	Predicted intracellular proteins	Evidence at protein level	HPA039372, HPA047957	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:2.07e-4 (favourable), Pancreatic cancer:2.59e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 21.3	Expressed in all		
SPZ1	FLJ25709, NYD-TSP1, PPP1R148	ENSG00000164299	Spermatogenic leucine zipper 1	5	80319625-80321842	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	453	testis: 45.2	all non-specific tissues: 0.0	Not detected		
SQRDL	CGI-44	ENSG00000137767	Sulfide quinone reductase-like (yeast)	15	45631148-45691294	Predicted intracellular proteins	Evidence at protein level	HPA017079, HPA041589	Enhanced		Enhanced	Mitochondria	Endometrial cancer:2.57e-4 (favourable), Lung cancer:8.80e-4 (unfavourable)	Expressed in all	Expressed in all			colon: 193.5	Cell line enhanced		HBEC3-KT: 198.5
SQSTM1	A170, OSIL, p60, p62, p62B, PDB3	ENSG00000161011	Sequestosome 1	5	179806398-179838078	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004587, HPA064165, HPA068843	Supported		Enhanced	Vesicles<br>Cytosol	Liver cancer:2.31e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 371.5	Expressed in all		
SRA1	SRA, STRAA1	ENSG00000213523	Steroid receptor RNA activator 1	5	140537340-140558252	Predicted intracellular proteins	Evidence at protein level	HPA044598, HPA050153	Approved		Supported	Nucleoplasm<br>Microtubules<br>Cytosol	Endometrial cancer:8.01e-6 (favourable)	Expressed in all	Mixed			adrenal gland: 17.5	Expressed in all		
SRBD1	FLJ10379	ENSG00000068784	S1 RNA binding domain 1	2	45388680-45612165	Predicted intracellular proteins	Evidence at protein level	HPA030567, HPA030568	Approved		Approved	Mitochondria<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 31.8	Expressed in all		
SRC	ASV, c-src, SRC1	ENSG00000197122	SRC proto-oncogene, non-receptor tyrosine kinase	20	37344685-37406050	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004023, HPA030875	Approved		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 43.6	Mixed		
SRCAP	DOMO1, EAF1, KIAA0309, SWR1	ENSG00000080603	Snf2 related CREBBP activator protein	16	30698209-30741409	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028929	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 55.6	Expressed in all		
SRCIN1	KIAA1684, p140Cap, SNIP	ENSG00000277363	SRC kinase signaling inhibitor 1	17	38530016-38605930	Predicted intracellular proteins	Evidence at protein level	HPA009701, HPA063795	Enhanced		Approved	Cell Junctions	Urothelial cancer:1.76e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 22.1	skin: 4.7	Cell line enriched	5	SCLC-21H: 14.7
SREK1	DKFZp564B176, SFRS12, SRrp508, SRrp86	ENSG00000153914	Splicing regulatory glutamic acid and lysine rich protein 1	5	66139971-66183615	Predicted intracellular proteins	Evidence at protein level	HPA037673, HPA037674, HPA059332	Enhanced		Enhanced	Nucleoplasm<br>Nuclear speckles	Head and neck cancer:2.54e-4 (favourable), Renal cancer:5.77e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.0	Expressed in all		
SREK1IP1	FLJ36754, P18SRP, SFRS12IP1	ENSG00000153006	SREK1 interacting protein 1	5	64718144-64768685	Predicted intracellular proteins	Evidence at protein level	HPA045677, HPA062853	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:9.03e-4 (unfavourable), Renal cancer:9.68e-4 (unfavourable)	Expressed in all	Mixed			placenta: 12.4	Expressed in all		
SRF	MCM1	ENSG00000112658	Serum response factor	6	43171299-43181507	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001819, CAB005416	Supported		Supported	Nucleus	Renal cancer:2.01e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 70.2	Expressed in all		
SRFBP1	BUD22, FLJ25286, p49, Rlb1, STRAP	ENSG00000151304	Serum response factor binding protein 1	5	121961961-122075570	Predicted intracellular proteins	Evidence at protein level	HPA042737, HPA058150	Approved		Supported	Nucleus<br>Nucleoli fibrillar center<br>Vesicles	Pancreatic cancer:5.31e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 13.8	Expressed in all		
SRGAP1	ARHGAP13, KIAA1304	ENSG00000196935	SLIT-ROBO Rho GTPase activating protein 1	12	63844293-64162221	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052416	Uncertain		Approved	Nuclear speckles	Ovarian cancer:5.67e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 13.1	Cell line enhanced		hTERT-HME1: 36.0
SRGAP2	ARHGAP34, FNBP2, KIAA0456, SRGAP2A	ENSG00000266028	SLIT-ROBO Rho GTPase activating protein 2	1	206203345-206464443	Predicted intracellular proteins	Evidence at protein level	HPA028191, HPA028196	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.61e-7 (unfavourable), Liver cancer:9.61e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 55.9	Expressed in all		
SRGAP2B	SRGAP2P2	ENSG00000196369	SLIT-ROBO Rho GTPase activating protein 2B	1	144887265-145095528	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			skin: 21.7	Expressed in all		
SRGAP2C	SRGAP2P1	ENSG00000171943	SLIT-ROBO Rho GTPase activating protein 2C	1	121184810-121392822	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		parathyroid gland: 34.2	skin: 18.1	Cell line enhanced		WM-115: 78.0
SRGAP3	ARHGAP14, KIAA0411, MEGAP, SRGAP2, WRP	ENSG00000196220	SLIT-ROBO Rho GTPase activating protein 3	3	8980591-9363053	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036959, HPA044074	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		cerebral cortex: 26.5;fallopian tube: 17.4	cervix, uterine: 7.9	Cell line enhanced		AF22: 8.9;HBEC3-KT: 5.7;RT4: 8.6;T-47d: 9.6
SRI		ENSG00000075142	Sorcin	7	88205118-88226993	Predicted intracellular proteins	Evidence at protein level	HPA019004, HPA073666	Enhanced		Supported	Nucleoplasm<br>Cytosol	Lung cancer:3.08e-4 (favourable), Pancreatic cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			colon: 562.9	Mixed		
SRM	SPS1, SRML1	ENSG00000116649	Spermidine synthase	1	11054584-11060024	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015746	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.80e-8 (unfavourable), Liver cancer:2.25e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 73.5	Expressed in all		
SRMS	C20orf148, dJ697K14.1, PTK70, SRM	ENSG00000125508	Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	20	63540810-63547504	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB044668, CAB044669, HPA073987	Uncertain		Approved	Intermediate filaments<br>Actin filaments<br>Cytosol		Mixed	Mixed			stomach: 1.4	Cell line enhanced		CAPAN-2: 2.9;MCF7: 2.2;RT4: 4.8
SRP19		ENSG00000153037	Signal recognition particle 19	5	112861222-112869788	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA029272	Approved				Renal cancer:3.72e-10 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 64.7	Expressed in all		
SRP54		ENSG00000100883	Signal recognition particle 54	14	34981957-35029567	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA048977, HPA062044	Approved		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			testis: 89.4	Expressed in all		
SRP68		ENSG00000167881	Signal recognition particle 68	17	76038775-76072653	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023303, HPA055617	Approved		Enhanced	Focal adhesion sites<br>Cytosol	Liver cancer:4.28e-5 (unfavourable), Head and neck cancer:2.18e-4 (unfavourable), Thyroid cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 71.8	Expressed in all		
SRP72		ENSG00000174780	Signal recognition particle 72	4	56466915-56503680	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034621	Approved				Liver cancer:3.25e-6 (unfavourable), Colorectal cancer:3.83e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 89.0	Expressed in all		
SRP9		ENSG00000143742	Signal recognition particle 9	1	225777813-225790466	Predicted intracellular proteins, Transporters	Evidence at protein level							Expressed in all	Expressed in all			cerebral cortex: 340.2	Expressed in all		
SRPK1	SFRSK1	ENSG00000096063	SRSF protein kinase 1	6	35832966-35921342	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016431, HPA056486	Approved		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Liver cancer:7.90e-6 (unfavourable), Pancreatic cancer:6.53e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 81.0	Expressed in all		
SRPK2	SFRSK2	ENSG00000135250	SRSF protein kinase 2	7	105110704-105399308	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015522, HPA020876	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 197.4	Expressed in all		
SRPK3	MSSK1, STK23	ENSG00000184343	SRSF protein kinase 3	X	153776412-153785732	Enzymes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		heart muscle: 28.7;skeletal muscle: 73.6	prostate: 10.9	Cell line enhanced		RH-30: 45.4
SRPRA	SR-alpha, Sralpha, SRP-alpha, SRPR	ENSG00000182934	SRP receptor alpha subunit	11	126262919-126269144	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:8.56e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 170.3	Expressed in all		
SRR	ILV1, ISO1	ENSG00000167720	Serine racemase	17	2303383-2325260	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007529, CAB015343	Approved		Approved	Vesicles	Renal cancer:2.45e-6 (favourable), Endometrial cancer:6.20e-5 (favourable), Pancreatic cancer:8.16e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 25.5	Expressed in all		
SRRD	HC/HCC, SRR1L	ENSG00000100104	SRR1 domain containing	22	26483877-26494658	Predicted intracellular proteins	Evidence at protein level	HPA002945	Uncertain		Approved	Cytosol	Liver cancer:2.16e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 17.7	Expressed in all		
SRRM1	MGC39488, POP101, SRM160	ENSG00000133226	Serine and arginine repetitive matrix 1	1	24631716-24673267	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA049941, HPA058612	Supported		Enhanced	Nuclear speckles	Liver cancer:1.08e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 96.3	Expressed in all		
SRRM2	Cwc21, KIAA0324, SRL300, SRm300	ENSG00000167978	Serine/arginine repetitive matrix 2	16	2752329-2772538	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041411, HPA066181	Supported		Enhanced	Nuclear speckles	Renal cancer:4.82e-4 (unfavourable), Liver cancer:5.08e-4 (unfavourable), Head and neck cancer:6.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 288.8	Expressed in all		
SRRM3	FLJ37078	ENSG00000177679	Serine/arginine repetitive matrix 3	7	76201900-76287288	Predicted intracellular proteins	Evidence at protein level	HPA019337	Uncertain		Approved	Plasma membrane<br>Intermediate filaments<br>Microtubules		Mixed	Group enriched	10	adrenal gland: 2.7;cerebral cortex: 8.5;testis: 1.8	stomach: 0.4	Group enriched	12	SCLC-21H: 12.8;SH-SY5Y: 8.5
SRRM4	KIAA1853, nSR100	ENSG00000139767	Serine/arginine repetitive matrix 4	12	118981495-119163051	Predicted intracellular proteins	Evidence at protein level	HPA052783	Uncertain					Tissue enriched	Tissue enriched	9	cerebral cortex: 13.5	adrenal gland: 1.5	Group enriched	5	HeLa: 2.3;SCLC-21H: 4.6;SH-SY5Y: 3.3
SRRM5		ENSG00000226763	Serine/arginine repetitive matrix 5	19	43596617-43614497	Predicted intracellular proteins	Evidence at protein level	HPA047399	Uncertain					Mixed	Tissue enriched	31	testis: 40.1	lymph node: 1.3	Mixed		
SRRT	ARS2, Asr2, serrate	ENSG00000087087	Serrate, RNA effector molecule	7	100875111-100888664	Predicted intracellular proteins	Evidence at protein level	HPA042858, HPA058379	Supported		Enhanced	Nucleoplasm	Renal cancer:1.01e-6 (unfavourable), Liver cancer:1.90e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 203.6	Expressed in all		
SRSF1	ASF, MGC5228, SF2, SF2p33, SFRS1, SRp30a	ENSG00000136450	Serine and arginine rich splicing factor 1	17	58003360-58007346	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013073, HPA061301	Supported		Enhanced	Nucleoplasm	Liver cancer:1.64e-6 (unfavourable), Renal cancer:2.95e-5 (unfavourable), Colorectal cancer:4.56e-5 (favourable), Cervical cancer:7.00e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 156.5	Expressed in all		
SRSF10	FUSIP1, FUSIP2, PPP1R149, SFRS13, SFRS13A, SRp38, SRrp40, TASR1, TASR2	ENSG00000188529	Serine and arginine rich splicing factor 10	1	23964804-23980927	Predicted intracellular proteins	Evidence at protein level	HPA053805, HPA053831	Uncertain		Supported	Nucleoplasm	Liver cancer:1.18e-6 (unfavourable), Renal cancer:1.01e-5 (unfavourable), Prostate cancer:1.74e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 100.9	Expressed in all		
SRSF11	NET2, p54, SFRS11	ENSG00000116754	Serine and arginine rich splicing factor 11	1	70205682-70253052	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008762	Supported		Supported	Nuclear speckles	Renal cancer:6.53e-6 (unfavourable), Liver cancer:3.91e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 96.1	Expressed in all		
SRSF12	SFRS13B, SFRS19, SRrp35	ENSG00000154548	Serine and arginine rich splicing factor 12	6	89095959-89118081	Predicted intracellular proteins	Evidence at protein level	HPA049782	Approved					Mixed	Group enriched	6	cerebral cortex: 6.9;testis: 20.9	parathyroid gland,thyroid gland: 2.1	Cell line enhanced		AF22: 9.1;AN3-CA: 8.8;HAP1: 7.7;HEK93: 7.0;REH: 6.9;SCLC-21H: 9.5;SH-SY5Y: 8.4
SRSF2	PR264, SC-35, SC35, SFRS2, SFRS2A	ENSG00000161547	Serine and arginine rich splicing factor 2	17	76734115-76737374	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049905	Supported		Approved	Nucleus<br>Cytosol	Liver cancer:3.53e-8 (unfavourable), Renal cancer:1.05e-7 (unfavourable), Endometrial cancer:8.73e-4 (unfavourable), Urothelial cancer:9.87e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 127.2	Expressed in all		
SRSF3	SFRS3, SRp20	ENSG00000112081	Serine and arginine rich splicing factor 3	6	36594353-36605600	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012986, HPA056981	Supported		Supported	Nucleoplasm	Liver cancer:6.22e-5 (unfavourable), Ovarian cancer:1.37e-4 (favourable), Melanoma:1.95e-4 (unfavourable), Renal cancer:2.02e-4 (unfavourable), Colorectal cancer:2.56e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 139.5	Expressed in all		
SRSF4	SFRS4, SRP75	ENSG00000116350	Serine and arginine rich splicing factor 4	1	29147743-29181987	Predicted intracellular proteins	Evidence at protein level	HPA050975	Supported		Supported	Nuclear speckles	Melanoma:3.27e-4 (unfavourable), Prostate cancer:4.26e-4 (unfavourable), Renal cancer:4.30e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 78.8	Expressed in all		
SRSF5	HRS, SFRS5, SRP40	ENSG00000100650	Serine and arginine rich splicing factor 5	14	69726900-69772005	Predicted intracellular proteins	Evidence at protein level	HPA043484, HPA056523	Approved		Enhanced	Nucleus<br>Nucleoli	Cervical cancer:7.91e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 311.9	Expressed in all		
SRSF6	B52, SFRS6, SRP55	ENSG00000124193	Serine and arginine rich splicing factor 6	20	43457928-43464247	Predicted intracellular proteins	Evidence at protein level	HPA029005, CAB034889	Supported		Supported	Nuclear speckles	Renal cancer:2.82e-4 (unfavourable), Liver cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 83.5	Expressed in all		
SRSF7	9G8, AAG3, HSSG1, RBM37, SFRS7, ZCCHC20, ZCRB2	ENSG00000115875	Serine and arginine rich splicing factor 7	2	38743599-38751494	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043850, HPA056926	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.18e-8 (unfavourable), Liver cancer:2.90e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 99.7	Expressed in all		
SRSF8	SFRS2B, SRP46	ENSG00000263465	Serine and arginine rich splicing factor 8	11	95067197-95071224	Predicted intracellular proteins	Evidence at protein level	HPA049905	Supported		Supported	Nucleus<br>Cytosol	Renal cancer:9.99e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 41.8	Mixed		
SRSF9	SFRS9, SRp30c	ENSG00000111786	Serine and arginine rich splicing factor 9	12	120461668-120469793	Predicted intracellular proteins	Evidence at protein level	HPA049849	Enhanced		Approved	Nucleoplasm	Liver cancer:9.85e-7 (unfavourable), Melanoma:7.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 139.2	Expressed in all		
SRXN1	C20orf139, dJ850E9.2, Npn3, SRX1, YKL086W	ENSG00000271303	Sulfiredoxin 1	20	646615-653370	Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.22e-5 (unfavourable)	Mixed	Expressed in all			adrenal gland: 44.5	Mixed		
SRY	TDF	ENSG00000184895	Sex determining region Y	Y	2786855-2787699	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enhanced		skin: 1.0;testis: 2.8	esophagus: 0.7	Cell line enhanced		RT4: 1.7
SS18	SSXT, SYT	ENSG00000141380	SS18, nBAF chromatin remodeling complex subunit	18	26016253-26091217	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055741, HPA059539	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.86e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 75.7	Expressed in all		
SS18L1	CREST, KIAA0693	ENSG00000184402	SS18L1, nBAF chromatin remodeling complex subunit	20	62143795-62182484	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB011827, HPA059046	Approved		Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:8.00e-5 (favourable), Lung cancer:3.74e-4 (favourable)	Expressed in all	Expressed in all			skin: 23.7	Expressed in all		
SS18L2	KIAA-iso	ENSG00000008324	SS18 like 2	3	42581840-42595114	Predicted intracellular proteins	Evidence at protein level	HPA047377	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Lung cancer:7.03e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 61.0	Expressed in all		
SSB	La, La/SSB, LARP3	ENSG00000138385	Sjogren syndrome antigen B	2	169791933-169812064	Predicted intracellular proteins	Evidence at protein level	CAB004643, HPA017287	Supported		Approved	Nucleoplasm	Liver cancer:8.30e-8 (unfavourable), Renal cancer:6.17e-6 (unfavourable), Head and neck cancer:5.99e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 131.2	Expressed in all		
SSBP1	mtSSB, SSBP	ENSG00000106028	Single stranded DNA binding protein 1	7	141738321-141787922	Predicted intracellular proteins	Evidence at protein level	HPA002866	Enhanced		Supported	Mitochondria	Ovarian cancer:3.40e-4 (favourable), Liver cancer:4.42e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 147.7	Expressed in all		
SSBP3	CSDP, FLJ10355, SSDP, SSDP1	ENSG00000157216	Single stranded DNA binding protein 3	1	54225432-54413479	Predicted intracellular proteins	Evidence at protein level						Cervical cancer:2.48e-9 (favourable), Endometrial cancer:2.10e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 117.5	Expressed in all		
SSBP4		ENSG00000130511	Single stranded DNA binding protein 4	19	18418864-18434562	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.04e-10 (unfavourable), Pancreatic cancer:1.01e-4 (favourable)	Expressed in all	Expressed in all			spleen: 51.1	Expressed in all		
SSFA2	CS-1, KIAA1927, KRAP, SPAG13	ENSG00000138434	Sperm specific antigen 2	2	181891833-181930738	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034665, HPA039989	Uncertain		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:2.91e-5 (favourable), Urothelial cancer:5.79e-5 (unfavourable), Pancreatic cancer:8.19e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 137.2	Mixed		
SSH1	KIAA1298	ENSG00000084112	Slingshot protein phosphatase 1	12	108778192-108857590	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019845	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:5.80e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 9.5	Expressed in all		
SSH2	KIAA1725	ENSG00000141298	Slingshot protein phosphatase 2	17	29625938-29930276	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB017189, HPA057099	Uncertain					Expressed in all	Expressed in all			bone marrow: 35.7	Expressed in all		
SSH3	FLJ10928, FLJ20515	ENSG00000172830	Slingshot protein phosphatase 3	11	67303448-67312607	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019949, HPA019957	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Actin filaments<br>Cytosol	Pancreatic cancer:2.89e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 37.5	Cell line enhanced		RT4: 69.9
SSNA1	N14, NA14	ENSG00000176101	SS nuclear autoantigen 1	9	137188647-137190370	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:8.94e-4 (favourable)	Expressed in all	Expressed in all			testis: 101.1	Expressed in all		
SSRP1	FACT80	ENSG00000149136	Structure specific recognition protein 1	11	57325985-57335877	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002697	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:4.03e-7 (unfavourable), Pancreatic cancer:1.40e-4 (unfavourable), Renal cancer:5.63e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 124.9	Expressed in all		
SSSCA1	p27	ENSG00000173465	Sjogren syndrome/scleroderma autoantigen 1	11	65570430-65573942	Predicted intracellular proteins	Evidence at protein level	HPA039789, HPA064670	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 52.6	Expressed in all		
SSU72	HSPC182	ENSG00000160075	SSU72 homolog, RNA polymerase II CTD phosphatase	1	1541673-1574869	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069290, HPA070604	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 149.3	Expressed in all		
SSU72P2		ENSG00000284306	SSU72 pseudogene 2	11	4242056-4242640	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
SSU72P3		ENSG00000284546	SSU72 pseudogene 3	11	4329865-4330449	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
SSU72P4		ENSG00000283873	SSU72 pseudogene 4	11	4287499-4288083	Predicted intracellular proteins	No evidence								Not detected			rectum: 0.2	Not detected		
SSU72P5		ENSG00000284018	SSU72 pseudogene 5	11	4233288-4233872	Predicted intracellular proteins	No evidence								Not detected			rectum,smooth muscle: 0.1	Not detected		
SSU72P7		ENSG00000284438	SSU72 pseudogene 7	11	4338660-4339244	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
SSU72P8		ENSG00000230268	SSU72 pseudogene 8	7	124476371-124476955	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	26	testis: 2.5	all non-specific tissues: 0.0	Not detected		
SSUH2	C3orf32, fls485, ssu-2	ENSG00000125046	Ssu-2 homolog (C. elegans)	3	8619400-8745040	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049777	Approved					Mixed	Tissue enhanced		duodenum: 4.2;small intestine: 3.9;testis: 4.0	spleen: 1.5	Cell line enriched	13	Hep G2: 18.2
SSX1	CT5.1	ENSG00000126752	SSX family member 1	X	48255317-48267444	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045683	Supported		Approved	Nucleus<br>Nucleoli		Tissue enhanced	Tissue enriched	26	testis: 12.7	epididymis: 0.4	Group enriched	9	Daudi: 47.0;Karpas-707: 66.3;U-2197: 20.0
SSX2	CT5.2a, HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX	ENSG00000241476	SSX family member 2	X	52696896-52707189	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045683, CAB046020	Enhanced		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	113	testis: 46.1	thyroid gland: 0.4	Not detected		
SSX2B	CT5.2b	ENSG00000268447	SSX family member 2B	X	52751132-52790305	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045683	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	23	testis: 14.9	thyroid gland: 0.6	Cell line enhanced		HMC-1: 1.7;PC-3: 1.8;U-2197: 1.1
SSX2IP	hMsd1	ENSG00000117155	SSX family member 2 interacting protein	1	84643707-84690803	Predicted intracellular proteins	Evidence at protein level	HPA027306, HPA075946	Approved		Approved	Cell Junctions	Colorectal cancer:1.45e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 191.9	cerebral cortex: 45.8	Expressed in all		
SSX3	CT5.3	ENSG00000165584	SSX family member 3	X	48346428-48356707	Predicted intracellular proteins	Evidence at protein level	HPA045683	Approved		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	70	testis: 25.3	thyroid gland: 0.3	Cell line enhanced		Karpas-707: 1.5
SSX4	CT5.4	ENSG00000268009	SSX family member 4	X	48383516-48393347	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA045683	Approved		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	15	testis: 3.8	fallopian tube: 0.2	Group enriched	8	BEWO: 2.1;Karpas-707: 3.9;U-266/70: 2.4;U-266/84: 4.3
SSX4B	OTTHUMT00000056510	ENSG00000269791	SSX family member 4B	X	48402078-48411910	Predicted intracellular proteins	Evidence at transcript level	HPA045683	Approved		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	15	testis: 3.8	fallopian tube: 0.2	Group enriched	8	BEWO: 2.1;Karpas-707: 3.9;U-266/70: 2.4;U-266/84: 4.3
SSX5		ENSG00000165583	SSX family member 5	X	48186220-48196763	Predicted intracellular proteins	Evidence at protein level	HPA045683	Uncertain		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enhanced		thyroid gland: 1.0	testis: 0.9	Cell line enriched	6	BEWO: 4.8
SSX7		ENSG00000187754	SSX family member 7	X	52644090-52654900	Predicted intracellular proteins	Evidence at transcript level	HPA045683	Uncertain		Approved	Nucleus<br>Nucleoli		Not detected	Not detected			skin: 0.4	Cell line enhanced		HMC-1: 2.8;RT4: 1.4
ST13	FAM10A1, HIP, HSPABP1, P48, SNC6	ENSG00000100380	Suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein)	22	40824535-40857022	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043233, HPA046412, HPA047114, HPA047116	Enhanced		Enhanced	Cytosol	Renal cancer:3.10e-4 (favourable), Head and neck cancer:5.23e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 653.8	Expressed in all		
ST18	KIAA0535, NZF3, ZC2H2C3, ZC2HC10, ZNF387	ENSG00000147488	ST18, C2H2C-type zinc finger	8	52110839-52460959	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044919	Uncertain					Tissue enhanced	Tissue enriched	7	cerebral cortex: 11.6	stomach: 1.5	Cell line enhanced		HAP1: 2.8;SCLC-21H: 11.3;U-87 MG: 1.5
ST20	HCCS-1	ENSG00000180953	Suppressor of tumorigenicity 20	15	79898840-79923702	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:7.69e-8 (unfavourable)	Expressed in all	Mixed			spleen: 11.3	Mixed		
ST20-MTHFS		ENSG00000259332	ST20-MTHFS readthrough	15	79845150-79923754	Predicted intracellular proteins	Evidence at protein level	HPA008067	Uncertain					Not detected	Mixed			parathyroid gland: 15.1	Mixed		
ST5	DENND2B, HTS1, p126	ENSG00000166444	Suppression of tumorigenicity 5	11	8693351-8910951	Predicted intracellular proteins	Evidence at protein level	HPA046796	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 194.5	Mixed		
STAC	STAC1	ENSG00000144681	SH3 and cysteine rich domain	3	36380344-36548007	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035143	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		parathyroid gland: 23.4;prostate: 21.7	lung: 15.8	Cell line enhanced		fHDF/TERT166: 34.6;HaCaT: 28.9;SH-SY5Y: 48.5;U-87 MG: 45.7
STAC2	24b2	ENSG00000141750	SH3 and cysteine rich domain 2	17	39210536-39225872	Predicted intracellular proteins	Evidence at protein level	HPA017288			Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:4.05e-5 (unfavourable), Glioma:5.04e-4 (unfavourable), Ovarian cancer:6.66e-4 (unfavourable)	Group enriched	Group enriched	6	breast: 32.0;cerebral cortex: 30.1;epididymis: 13.8;seminal vesicle: 35.6	skin: 4.5	Cell line enhanced		HeLa: 22.2;hTEC/SVTERT24-B: 4.8;U-87 MG: 14.4
STAC3	MGC2793	ENSG00000185482	SH3 and cysteine rich domain 3	12	57243453-57251193	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039285, HPA039527			Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:7.11e-6 (unfavourable), Cervical cancer:2.01e-4 (favourable), Colorectal cancer:7.10e-4 (unfavourable)	Expressed in all	Tissue enriched	24	skeletal muscle: 802.4	prostate: 34.1	Cell line enriched	26	RH-30: 2201.5
STAG1	SA-1, SA1, SCC3A	ENSG00000118007	Stromal antigen 1	3	136336233-136752403	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035015, HPA058653	Supported		Enhanced	Nucleus<br>Nuclear bodies		Expressed in all	Expressed in all			endometrium: 31.9	Expressed in all		
STAG2	SA-2, SA2, SCC3B	ENSG00000101972	Stromal antigen 2	X	123960212-124422664	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002857	Supported					Expressed in all	Expressed in all			parathyroid gland: 112.2	Mixed		
STAG3		ENSG00000066923	Stromal antigen 3	7	100177563-100221488	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049106, HPA058330	Enhanced				Cervical cancer:8.45e-4 (favourable)	Mixed	Tissue enriched	5	testis: 130.2	fallopian tube: 23.9	Group enriched	6	BEWO: 49.1;HMC-1: 56.4;U-698: 13.2
STAM	STAM1	ENSG00000136738	Signal transducing adaptor molecule	10	17644125-17715914	Predicted intracellular proteins	Evidence at protein level	CAB034399, HPA043882	Supported		Supported	Vesicles	Liver cancer:3.44e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 41.9	Expressed in all		
STAM2	Hbp	ENSG00000115145	Signal transducing adaptor molecule 2	2	152116801-152175992	Predicted intracellular proteins	Evidence at protein level	HPA035528, HPA035529	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 22.8	Expressed in all		
STAMBP	AMSH	ENSG00000124356	STAM binding protein	2	73828916-73873659	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035800, HPA035801	Uncertain		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:4.70e-5 (unfavourable), Pancreatic cancer:5.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.1	Cell line enriched	11	LHCN-M2: 926.0
STAMBPL1	ALMalpha, AMSH-FP, AMSH-LP, bA399O19.2, FLJ31524, KIAA1373	ENSG00000138134	STAM binding protein like 1	10	88879734-88975153	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040202	Uncertain		Approved	Plasma membrane	Renal cancer:1.08e-5 (unfavourable)	Mixed	Mixed			adrenal gland,testis: 29.7	Mixed		
STAP1	BRDG1, STAP-1	ENSG00000035720	Signal transducing adaptor family member 1	4	67558728-67607337	Predicted intracellular proteins	Evidence at protein level	HPA038529	Enhanced		Uncertain	Nucleoplasm<br>Vesicles		Tissue enriched	Group enriched	6	appendix: 23.8;kidney: 13.2;lymph node: 59.6;spleen: 26.6;tonsil: 56.3	testis: 6.1	Cell line enhanced		Daudi: 141.5;U-698: 60.7;U-937: 22.3
STAP2	BKS, STAP-2	ENSG00000178078	Signal transducing adaptor family member 2	19	4324043-4342786	Predicted intracellular proteins	Evidence at protein level	HPA002375, HPA027761	Approved				Endometrial cancer:3.03e-5 (favourable), Cervical cancer:2.76e-4 (favourable), Urothelial cancer:4.13e-4 (favourable)	Expressed in all	Mixed			small intestine: 79.8	Cell line enhanced		A-431: 75.0;MCF7: 77.8;RT4: 107.6
STAR	StAR, STARD1	ENSG00000147465	Steroidogenic acute regulatory protein	8	38143649-38151265	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023644, HPA027318, CAB032598	Enhanced					Tissue enhanced	Tissue enriched	12	adrenal gland: 2879.8	ovary: 245.8	Group enriched	7	HEL: 92.1;K-562: 433.7
STARD10	CGI-52, NY-CO-28, PCTP2, SDCCAG28	ENSG00000214530	StAR related lipid transfer domain containing 10	11	72754729-72794168	Predicted intracellular proteins	Evidence at protein level	HPA026661	Uncertain				Breast cancer:6.92e-4 (favourable)	Expressed in all	Expressed in all			rectum: 205.1	Expressed in all		
STARD13	ARHGAP37, DLC2, GT650, LINC00464	ENSG00000133121	StAR related lipid transfer domain containing 13	13	33103135-33350630	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039535, HPA058867	Enhanced		Approved	Nuclear membrane<br>Nucleoli<br>Cytosol	Renal cancer:1.23e-4 (unfavourable)	Expressed in all	Mixed			placenta: 35.3	Cell line enhanced		LHCN-M2: 41.8;WM-115: 40.0
STARD4		ENSG00000164211	StAR related lipid transfer domain containing 4	5	111496033-111512590	Predicted intracellular proteins	Evidence at protein level	HPA046177, HPA048081	Approved		Approved	Plasma membrane	Liver cancer:4.80e-5 (unfavourable), Renal cancer:5.89e-5 (unfavourable), Urothelial cancer:2.84e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 41.4	Mixed		
STARD5	MGC10327	ENSG00000172345	StAR related lipid transfer domain containing 5	15	81309053-81324183	Predicted intracellular proteins	Evidence at protein level	HPA040662	Approved		Approved	Vesicles<br>Cytosol		Mixed	Mixed			skin: 9.4	Cell line enhanced		HMC-1: 5.2;U-266/70: 5.5;U-937: 5.4
STARD6		ENSG00000174448	StAR related lipid transfer domain containing 6	18	54324358-54357964	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	83	testis: 47.5	cerebral cortex,thyroid gland: 0.5	Cell line enhanced		HDLM-2: 1.9;Karpas-707: 1.9;U-266/70: 2.5
STARD8	ARHGAP38, KIAA0189	ENSG00000130052	StAR related lipid transfer domain containing 8	X	68647666-68725842	Predicted intracellular proteins	Evidence at protein level	HPA060788	Uncertain					Expressed in all	Mixed			adipose tissue: 14.9	Cell line enhanced		HEL: 14.3;K-562: 18.2
STARD9	KIAA1300, KIF16A	ENSG00000159433	StAR related lipid transfer domain containing 9	15	42575659-42720981	Predicted intracellular proteins	Evidence at protein level	HPA014562, HPA038631	Uncertain		Supported	Microtubules		Mixed	Mixed			testis: 14.4	Mixed		
STAT1	ISGF-3, STAT91	ENSG00000115415	Signal transducer and activator of transcription 1	2	190964358-191020960	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000931, HPA000982, CAB004049	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.22e-5 (unfavourable), Ovarian cancer:1.75e-4 (favourable), Pancreatic cancer:4.23e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 193.8	Expressed in all		
STAT2	STAT113	ENSG00000170581	Signal transducer and activator of transcription 2	12	56341597-56360155	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003858, HPA018888	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.78e-13 (unfavourable), Endometrial cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 47.9	Expressed in all		
STAT3	APRF	ENSG00000168610	Signal transducer and activator of transcription 3	17	42313324-42388568	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001671, CAB003859, HPA058603, CAB068241, CAB068242	Supported		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			gallbladder: 127.5	Mixed		
STAT4		ENSG00000138378	Signal transducer and activator of transcription 4	2	191029576-191151596	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001860, CAB013108	Enhanced				Renal cancer:1.07e-8 (unfavourable), Pancreatic cancer:5.88e-4 (favourable)	Mixed	Tissue enhanced		testis: 50.5	spleen: 18.5	Group enriched	7	Karpas-707: 34.1;U-266/70: 20.1;U-266/84: 6.9
STAT5A	MGF, STAT5	ENSG00000126561	Signal transducer and activator of transcription 5A	17	42287547-42311943	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003860, HPA027873, HPA042128, HPA049883, HPA051156	Approved		Enhanced	Nucleoplasm<br>Cytosol	Breast cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 90.3	Cell line enhanced		HDLM-2: 100.4;HEL: 145.8;K-562: 246.3;MOLT-4: 160.1
STAT5B		ENSG00000173757	Signal transducer and activator of transcription 5B	17	42199168-42276707	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004298, HPA042128, HPA049883, HPA051156	Approved				Renal cancer:2.39e-5 (favourable), Pancreatic cancer:1.63e-4 (favourable), Endometrial cancer:9.37e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 71.3	Cell line enhanced		HDLM-2: 112.6
STAT6	D12S1644, IL-4-STAT	ENSG00000166888	Signal transducer and activator of transcription 6	12	57095408-57132139	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001861	Approved		Enhanced	Nucleoplasm<br>Cytosol	Urothelial cancer:1.14e-4 (favourable), Endometrial cancer:1.69e-4 (favourable), Thyroid cancer:7.76e-4 (favourable)	Expressed in all	Expressed in all			skin: 163.9	Mixed		
STAU1	PPP1R150, STAU	ENSG00000124214	Staufen double-stranded RNA binding protein 1	20	49113339-49188367	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB020839, HPA049892	Approved		Supported	Cytosol	Prostate cancer:4.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 140.5	Expressed in all		
STAU2	39K2	ENSG00000040341	Staufen double-stranded RNA binding protein 2	8	73420369-73747708	Predicted intracellular proteins	Evidence at protein level	HPA019155, CAB020836	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 74.0	Expressed in all		
STBD1	FLJ41801, GENX-3414	ENSG00000118804	Starch binding domain 1	4	76306026-76311599	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA011952, HPA012849	Enhanced		Supported	Cytosol		Mixed	Tissue enhanced		adipose tissue: 46.7;skeletal muscle: 32.8	liver: 14.5	Cell line enhanced		HDLM-2: 24.3;Karpas-707: 37.9;U-266/70: 25.8
STH	MAPTIT	ENSG00000256762	Saitohin	17	45999250-45999694	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.4	placenta: 0.5	Not detected		
STIL	MCPH7, SIL	ENSG00000123473	SCL/TAL1 interrupting locus	1	47250139-47314147	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046543			Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.33e-4 (unfavourable)	Mixed	Mixed			testis: 12.9	Mixed		
STIP1	HOP, STI1	ENSG00000168439	Stress induced phosphoprotein 1	11	64185272-64204543	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017448, HPA039291, HPA044062	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:6.18e-8 (unfavourable), Head and neck cancer:1.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 220.4	Expressed in all		
STK10	LOK, PRO2729	ENSG00000072786	Serine/threonine kinase 10	5	172042073-172188386	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015083, CAB020840	Enhanced				Renal cancer:1.63e-4 (unfavourable), Colorectal cancer:2.76e-4 (favourable)	Expressed in all	Expressed in all			spleen: 61.0	Expressed in all		
STK11	LKB1, PJS	ENSG00000118046	Serine/threonine kinase 11	19	1177558-1228435	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016231, HPA017254, CAB022105, HPA067481	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:3.69e-5 (favourable), Head and neck cancer:1.96e-4 (favourable)	Expressed in all	Expressed in all			testis: 77.1	Mixed		
STK11IP	KIAA1898, LIP1, LKB1IP, STK11IP1	ENSG00000144589	Serine/threonine kinase 11 interacting protein	2	219597860-219616451	Predicted intracellular proteins	Evidence at protein level	HPA036837, HPA036838, HPA053192	Approved		Enhanced	Vesicles	Pancreatic cancer:1.63e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.7	Expressed in all		
STK16	MPSK, PKL12	ENSG00000115661	Serine/threonine kinase 16	2	219245455-219250337	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029450	Approved		Approved	Cytosol	Endometrial cancer:6.09e-4 (favourable)	Expressed in all	Expressed in all			testis,thyroid gland: 28.6	Expressed in all		
STK19	D6S60, G11, RP1	ENSG00000204344	Serine/threonine kinase 19	6	31971091-31982821	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031510, HPA031511, HPA068559	Uncertain		Supported	Nuclear speckles	Melanoma:1.18e-4 (unfavourable)	Expressed in all	Mixed			testis: 1.2	Cell line enhanced		HDLM-2: 1.9;REH: 1.7
STK24	MST-3, MST3, MST3B, STE20, STK3	ENSG00000102572	Serine/threonine kinase 24	13	98445185-98577940	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026435, HPA026502	Enhanced		Supported	Nucleoli<br>Cytosol	Lung cancer:6.23e-6 (unfavourable), Renal cancer:6.91e-5 (favourable), Pancreatic cancer:5.81e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 169.5	Expressed in all		
STK25	SOK1, YSK1	ENSG00000115694	Serine/threonine kinase 25	2	241492674-241509730	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047147	Uncertain				Liver cancer:3.91e-8 (unfavourable), Colorectal cancer:6.03e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 168.2	Expressed in all		
STK26	MASK, MST4	ENSG00000134602	Serine/threonine kinase 26	X	132023265-132075943	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059921	Approved		Approved	Nucleus<br>Golgi apparatus<br>Centrosome<br>Cytosol	Renal cancer:6.87e-5 (unfavourable), Liver cancer:6.82e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 68.5	Mixed		
STK3	KRS1, MST2	ENSG00000104375	Serine/threonine kinase 3	8	98401403-98942827	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007120, CAB025316	Uncertain		Approved	Intermediate filaments<br>Rods & Rings	Pancreatic cancer:9.21e-5 (unfavourable), Endometrial cancer:1.53e-4 (unfavourable), Lung cancer:4.25e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 41.5	Mixed		
STK31	SgK396, TDRD8	ENSG00000196335	Serine/threonine kinase 31	7	23710167-23832513	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023194	Enhanced					Mixed	Tissue enriched	197	testis: 112.9	lung: 0.5	Cell line enriched	7	CACO-2: 15.0
STK32A	MGC22688, YANK1	ENSG00000169302	Serine/threonine kinase 32A	5	147234963-147387852	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040236	Uncertain		Approved	Centrosome		Tissue enhanced	Tissue enhanced		adrenal gland: 15.6;thyroid gland: 16.1	cerebral cortex: 7.3	Group enriched	6	RT4: 12.4;SK-MEL-30: 43.0
STK32B	HSA250839, STK32, STKG6, YANK2	ENSG00000152953	Serine/threonine kinase 32B	4	5051442-5500998	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA058536			Approved	Microtubules	Renal cancer:1.63e-8 (favourable)	Mixed	Tissue enhanced		kidney: 15.8	testis: 8.6	Cell line enhanced		HUVEC TERT2: 22.9;REH: 22.7;U-2197: 40.5;WM-115: 110.5
STK32C	MGC23665, PKE, YANK3	ENSG00000165752	Serine/threonine kinase 32C	10	132207492-132331847	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017894	Uncertain				Liver cancer:1.68e-6 (unfavourable), Renal cancer:5.31e-6 (unfavourable), Endometrial cancer:1.09e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.6	Expressed in all		
STK33		ENSG00000130413	Serine/threonine kinase 33	11	8391868-8594289	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015742, HPA056855	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:4.89e-6 (favourable)	Mixed	Tissue enhanced		fallopian tube: 67.1;testis: 93.1	parathyroid gland: 43.4	Cell line enhanced		SCLC-21H: 26.8
STK35	bA550O8.2, CLIK1	ENSG00000125834	Serine/threonine kinase 35	20	2101611-2177038	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026452, HPA051673	Uncertain		Supported	Nucleus<br>Nuclear bodies	Liver cancer:9.46e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 25.2	Expressed in all		
STK38	NDR	ENSG00000112079	Serine/threonine kinase 38	6	36493892-36547470	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004673, HPA038623, HPA051324	Uncertain		Approved	Cytosol	Melanoma:9.44e-5 (unfavourable)	Expressed in all	Expressed in all			rectum: 40.3	Expressed in all		
STK38L	KIAA0965, NDR2	ENSG00000211455	Serine/threonine kinase 38 like	12	27243968-27325959	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038623, HPA051324	Approved		Approved	Cytosol	Pancreatic cancer:5.82e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.3	Expressed in all		
STK39	DCHT, SPAK	ENSG00000198648	Serine/threonine kinase 39	2	167954020-168248141	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB046022, HPA061803, HPA062802	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:5.67e-5 (unfavourable), Breast cancer:3.96e-4 (favourable)	Expressed in all	Mixed			testis: 71.4	Mixed		
STK4	KRS2, MST1, YSK3	ENSG00000101109	Serine/threonine kinase 4	20	44966474-45079959	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004038, HPA015270	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.84e-5 (unfavourable), Liver cancer:8.04e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 50.6	Expressed in all		
STMN1	C1orf215, FLJ32206, Lag, LAP18, OP18, PP17, PP19, PR22, SMN	ENSG00000117632	Stathmin 1	1	25884181-25906991	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010107	Approved		Supported	Cytosol	Liver cancer:9.90e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1039.4	Expressed in all		
STMN2	SCG10, SCGN10	ENSG00000104435	Stathmin 2	8	79610814-79666175	Predicted intracellular proteins	Evidence at protein level	HPA026922		Supported	Approved	Endoplasmic reticulum<br>Vesicles		Group enriched	Tissue enriched	6	cerebral cortex: 489.4	adrenal gland: 88.0	Cell line enriched	10	SH-SY5Y: 696.7
STMN3	SCLIP	ENSG00000197457	Stathmin 3	20	63639705-63657682	Predicted intracellular proteins	Evidence at protein level	HPA012947	Enhanced					Expressed in all	Tissue enhanced		cerebral cortex: 225.7	thyroid gland: 52.6	Cell line enhanced		SCLC-21H: 225.8;SH-SY5Y: 155.0
STMN4	RB3	ENSG00000015592	Stathmin 4	8	27235323-27258420	Predicted intracellular proteins	Evidence at protein level	HPA027765			Uncertain	Golgi apparatus<br>Vesicles		Tissue enriched	Tissue enriched	25	cerebral cortex: 338.4	adrenal gland: 13.3	Cell line enriched	29	SCLC-21H: 102.2
STN1	bA541N10.2, FLJ22559, OBFC1	ENSG00000107960	STN1, CST complex subunit	10	103882542-103918205	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037924, HPA037925			Supported	Nucleus	Renal cancer:1.12e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 49.8	Expressed in all		
STON1	SBLF, stoned-b1	ENSG00000243244	Stonin 1	2	48529383-48598513	Predicted intracellular proteins	Evidence at protein level	HPA005715	Uncertain				Renal cancer:4.69e-4 (unfavourable)	Mixed	Mixed			smooth muscle: 37.4	Cell line enhanced		ASC diff: 16.3;ASC TERT1: 20.1;HSkMC: 26.3
STON1-GTF2A1L	SALF	ENSG00000068781	STON1-GTF2A1L readthrough	2	48529925-48776517	Predicted intracellular proteins	Evidence at protein level	HPA005715	Uncertain					Not detected	Mixed			endometrium,smooth muscle: 3.6	Cell line enhanced		ASC diff: 1.5;ASC TERT1: 1.4;HSkMC: 1.0
STPG1	C1orf201, FLJ33340, MAPO2	ENSG00000001460	Sperm tail PG-rich repeat containing 1	1	24356999-24416934	Predicted intracellular proteins	Evidence at protein level	HPA024301			Approved	Nucleoplasm	Endometrial cancer:1.33e-4 (favourable), Renal cancer:2.31e-4 (favourable)	Mixed	Tissue enhanced		testis: 46.9	fallopian tube: 26.8	Mixed		
STPG2	C4orf37, MGC46496	ENSG00000163116	Sperm tail PG-rich repeat containing 2	4	97184093-98143240	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 3.9	thyroid gland: 0.9	Not detected		
STPG3	C9orf173, FLJ40246	ENSG00000197768	Sperm-tail PG-rich repeat containing 3	9	137251261-137253483	Predicted intracellular proteins	Evidence at transcript level	HPA044352			Uncertain	Vesicles		Mixed	Tissue enriched	7	testis: 27.7	duodenum: 3.9	Cell line enhanced		HDLM-2: 3.0;T-47d: 1.8
STRA8		ENSG00000146857	Stimulated by retinoic acid 8	7	135231979-135258492	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		testis: 1.6	skin: 0.6	Cell line enhanced		BEWO: 1.2;THP-1: 1.7
STRADA	LYK5, NY-BR-96, Stlk, STRAD	ENSG00000266173	STE20-related kinase adaptor alpha	17	63682336-63741986	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031637	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.08e-7 (unfavourable), Pancreatic cancer:5.34e-5 (favourable), Urothelial cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			testis: 67.7	Expressed in all		
STRADB	ALS2CR2, CALS-21, ILPIP, ILPIPA, PAPK	ENSG00000082146	STE20-related kinase adaptor beta	2	201387858-201480846	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026549, HPA028520	Approved		Supported	Aggresome<br>Cytosol	Renal cancer:1.35e-4 (unfavourable), Thyroid cancer:4.45e-4 (favourable)	Expressed in all	Expressed in all			kidney: 73.4	Cell line enhanced		LHCN-M2: 154.7
STRAP	MAWD, pt-wd, UNRIP	ENSG00000023734	Serine/threonine kinase receptor associated protein	12	15882391-15903478	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027320, HPA055557, HPA073876	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:6.83e-6 (unfavourable), Urothelial cancer:5.10e-4 (unfavourable), Thyroid cancer:9.07e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 144.2	Expressed in all		
STRBP	FLJ11307, ILF3L, SPNR	ENSG00000165209	Spermatid perinuclear RNA binding protein	9	123109500-123268576	Predicted intracellular proteins	Evidence at protein level	HPA020651	Approved				Renal cancer:1.70e-10 (favourable), Liver cancer:8.18e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 79.0	Mixed		
STRIP1	FAM40A, FAR11A, FLJ14743, KIAA1761	ENSG00000143093	Striatin interacting protein 1	1	110031577-110074641	Predicted intracellular proteins	Evidence at protein level	HPA060302, HPA060498	Approved		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 34.8	Expressed in all		
STRIP2	FAM40B, FAR11B, KIAA1170	ENSG00000128578	Striatin interacting protein 2	7	129434433-129488399	Predicted intracellular proteins	Evidence at protein level	HPA019657	Uncertain		Supported	Cytosol	Stomach cancer:5.41e-4 (favourable), Lung cancer:6.78e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 13.9;testis: 23.5	skeletal muscle: 9.7	Mixed		
STRN	PPP2R6A, STRN1	ENSG00000115808	Striatin	2	36843640-36966472	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA017286	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.27e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 23.8	Expressed in all		
STRN3	PPP2R6B, S/G2NA, SG2NA	ENSG00000196792	Striatin 3	14	30893799-31026401	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003392, HPA004636, CAB069925	Approved		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:9.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 44.5	Expressed in all		
STUB1	CHIP, HSPABP2, NY-CO-7, SDCCAG7, UBOX1	ENSG00000103266	STIP1 homology and U-box containing protein 1	16	680224-682870	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037202, CAB037209, HPA041222, HPA043531	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.49e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 137.7	Expressed in all		
STX11		ENSG00000135604	Syntaxin 11	6	144150526-144188370	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA007992, HPA076253	Approved		Supported	Nuclear bodies<br>Mitochondria		Expressed in all	Tissue enhanced		bone marrow: 100.8	adipose tissue: 32.1	Cell line enhanced		HDLM-2: 37.8;Karpas-707: 15.3;TIME: 14.2;U-266/70: 19.0
STX19	MGC21382	ENSG00000178750	Syntaxin 19	3	94014369-94028610	Predicted intracellular proteins	Evidence at protein level	HPA030604	Uncertain		Approved	Intermediate filaments<br>Cytosol		Mixed	Tissue enhanced		epididymis: 19.7	rectum: 14.5	Cell line enhanced		CAPAN-2: 5.2;HaCaT: 1.1;hTCEpi: 2.9
STXBP1	hUNC18, MUNC18-1, rbSec1, UNC18	ENSG00000136854	Syntaxin binding protein 1	9	127579370-127696027	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008209, HPA023483, CAB034434	Enhanced		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:1.47e-4 (unfavourable), Endometrial cancer:4.78e-4 (unfavourable), Liver cancer:5.73e-4 (unfavourable), Pancreatic cancer:9.81e-4 (favourable)	Expressed in all	Tissue enriched	8	cerebral cortex: 396.3	fallopian tube: 52.6	Cell line enhanced		SCLC-21H: 169.1
STXBP2	Hunc18b, UNC18B	ENSG00000076944	Syntaxin binding protein 2	19	7636881-7647873	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015564, HPA063868	Approved		Enhanced	Cytosol	Urothelial cancer:5.13e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Liver cancer:4.65e-4 (unfavourable), Thyroid cancer:7.68e-4 (favourable)	Expressed in all	Mixed			bone marrow: 125.3	Mixed		
STXBP3	UNC-18C	ENSG00000116266	Syntaxin binding protein 3	1	108746674-108809526	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027225	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 65.9	Expressed in all		
STXBP4	MGC50337, Synip	ENSG00000166263	Syntaxin binding protein 4	17	54968727-55173632	Predicted intracellular proteins	Evidence at protein level	CAB007760, HPA022138, HPA022888, HPA024227	Approved		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			parathyroid gland: 12.5	Mixed		
STXBP5	LLGL3, tomosyn	ENSG00000164506	Syntaxin binding protein 5	6	147204425-147390476	Predicted intracellular proteins	Evidence at protein level	HPA039991, HPA049727, CAB079016	Enhanced	Supported	Enhanced	Cytosol	Renal cancer:2.74e-7 (unfavourable), Breast cancer:4.48e-4 (unfavourable)	Expressed in all	Tissue enriched	7	parathyroid gland: 278.8	testis: 40.2	Cell line enhanced		HEL: 188.3;HMC-1: 193.3
STXBP5L	KIAA1006, LLGL4	ENSG00000145087	Syntaxin binding protein 5 like	3	120908072-121424761	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 15.7;ovary: 12.3;thyroid gland: 14.1	seminal vesicle: 4.8	Cell line enhanced		AF22: 6.5;MOLT-4: 5.3;SCLC-21H: 10.6;SH-SY5Y: 4.2
STXBP6	amisyn, HSPC156	ENSG00000168952	Syntaxin binding protein 6	14	24809656-25050297	Predicted intracellular proteins	Evidence at protein level	HPA003552	Approved					Mixed	Mixed			placenta: 61.2	Cell line enhanced		HBF TERT88: 62.1
STYX		ENSG00000198252	Serine/threonine/tyrosine interacting protein	14	52730180-52774998	Predicted intracellular proteins	Evidence at protein level	HPA040290	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 20.5	Expressed in all		
STYXL1	DUSP24, MK-STYX	ENSG00000127952	Serine/threonine/tyrosine interacting like 1	7	75996338-76048004	Predicted intracellular proteins	Evidence at transcript level	HPA050261	Uncertain		Approved	Nuclear speckles	Urothelial cancer:8.22e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 46.0	Expressed in all		
SUB1	p14, p15, PC4	ENSG00000113387	SUB1 homolog, transcriptional regulator	5	32531633-32604079	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001311, CAB015351	Supported		Supported	Nucleus<br>Nucleoli	Liver cancer:5.25e-6 (unfavourable), Melanoma:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 234.5	Expressed in all		
SUCLA2		ENSG00000136143	Succinate-CoA ligase ADP-forming beta subunit	13	47936491-48001354	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039435, HPA039536, HPA061528	Enhanced	Supported	Enhanced	Mitochondria	Renal cancer:7.59e-14 (favourable), Urothelial cancer:1.22e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 78.7	Expressed in all		
SUCLG2		ENSG00000172340	Succinate-CoA ligase GDP-forming beta subunit	3	67360460-67654614	Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046705, HPA051998	Enhanced		Supported	Plasma membrane<br>Mitochondria	Renal cancer:2.79e-10 (favourable), Colorectal cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			colon: 168.2	Expressed in all		
SUFU	PRO1280, SUFUH, SUFUXL	ENSG00000107882	SUFU negative regulator of hedgehog signaling	10	102503987-102633535	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008700	Enhanced		Supported	Nucleus		Expressed in all	Mixed			parathyroid gland: 16.1	Expressed in all		
SUGCT	C7orf10, DERP13, FLJ11808, ORF19	ENSG00000175600	Succinyl-CoA:glutarate-CoA transferase	7	40134977-40860763	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026698, HPA026704, HPA026705	Enhanced				Renal cancer:3.93e-7 (favourable), Urothelial cancer:2.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 45.0	liver: 14.6	Cell line enhanced		HBEC3-KT: 30.6;LHCN-M2: 21.2
SUGP1	DKFZp434E2216, F23858, RBP, SF4	ENSG00000105705	SURP and G-patch domain containing 1	19	19276018-19320844	Predicted intracellular proteins	Evidence at protein level	HPA004890	Approved		Enhanced	Nucleoplasm		Expressed in all	Mixed			testis: 17.0	Expressed in all		
SUGP2	KIAA0365, SFRS14	ENSG00000064607	SURP and G-patch domain containing 2	19	18990888-19034023	Predicted intracellular proteins	Evidence at protein level	HPA041557, HPA061111	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 161.7	Expressed in all		
SUGT1	SGT1	ENSG00000165416	SGT1 homolog, MIS12 kinetochore complex assembly cochaperone	13	52652709-52700909	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015942, HPA043949	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Head and neck cancer:8.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.4	Expressed in all		
SULT1A1	P-PST, STP, STP1	ENSG00000196502	Sulfotransferase family 1A member 1	16	28605196-28623625	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049500, HPA051051	Supported				Lung cancer:7.02e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 136.6	Cell line enhanced		EFO-21: 161.0;Hep G2: 241.3
SULT1A2	HAST4, STP2	ENSG00000197165	Sulfotransferase family 1A member 2	16	28591943-28597109	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049500, HPA051051	Supported					Tissue enhanced	Tissue enhanced		duodenum: 49.2;small intestine: 49.2	liver: 21.0	Cell line enhanced		BEWO: 9.6;EFO-21: 12.0;Hep G2: 33.5
SULT1A3	STM, TL-PST	ENSG00000261052	Sulfotransferase family 1A member 3	16	30199228-30204310	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049500, HPA051051	Supported					Not detected	Expressed in all			duodenum: 106.1	Expressed in all		
SULT1A4		ENSG00000213648	Sulfotransferase family 1A member 4	16	29459889-29464976	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049500, HPA051051	Supported					Not detected	Tissue enhanced		duodenum: 173.4;small intestine: 131.0	colon: 38.4	Cell line enhanced		CAPAN-2: 107.9;EFO-21: 93.9;HEL: 76.5;Hep G2: 188.0;Karpas-707: 114.2
SULT1B1	ST1B2	ENSG00000173597	Sulfotransferase family 1B member 1	4	69721162-69787961	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002107	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus		Group enriched	Group enriched	5	colon: 68.9;duodenum: 99.0;rectum: 67.1;small intestine: 103.7;stomach: 41.6	appendix: 13.8	Group enriched	6	HUVEC TERT2: 92.0;TIME: 29.6;U-2197: 29.2
SULT1C2	ST1C1, SULT1C1	ENSG00000198203	Sulfotransferase family 1C member 2	2	108288639-108309915	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007190	Approved					Mixed	Tissue enhanced		kidney: 69.0;stomach: 149.5	duodenum: 28.5	Cell line enhanced		RPTEC TERT1: 19.5;RT4: 6.0
SULT1C3		ENSG00000196228	Sulfotransferase family 1C member 3	2	108247195-108265351	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	142	breast: 450.3	duodenum: 3.1	Not detected		
SULT1C4	SULT1C, SULT1C2	ENSG00000198075	Sulfotransferase family 1C member 4	2	108377911-108388057	Predicted intracellular proteins	Evidence at protein level	HPA034530			Approved	Cytosol	Renal cancer:9.99e-7 (favourable)	Group enriched	Tissue enhanced		gallbladder: 41.5	ovary: 31.2	Cell line enhanced		AF22: 8.6;HUVEC TERT2: 7.8;SH-SY5Y: 42.4
SULT1E1	EST, STE	ENSG00000109193	Sulfotransferase family 1E member 1	4	69810780-69860152	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028213, HPA028728, CAB047344	Enhanced		Uncertain	Nuclear membrane<br>Cytosol	Cervical cancer:4.06e-4 (favourable)	Mixed	Group enriched	7	duodenum: 27.7;liver: 18.7;skin: 7.6;small intestine: 29.7	adrenal gland: 3.1	Group enriched	17	HHSteC: 59.4;HSkMC: 23.3;hTCEpi: 19.7;HUVEC TERT2: 16.9
SULT2A1	DHEA-ST, STD	ENSG00000105398	Sulfotransferase family 2A member 1	19	47870466-47886397	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018755, HPA041487, HPA063633	Enhanced		Supported	Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 189.9;liver: 514.2	small intestine: 91.1	Group enriched	30	Hep G2: 25.8;RT4: 20.3
SULT2B1	HSST2	ENSG00000088002	Sulfotransferase family 2B member 1	19	48552075-48599425	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB033013, HPA041724, HPA043539	Approved		Supported	Vesicles<br>Cytosol		Mixed	Tissue enhanced		esophagus: 152.2;skin: 152.4	cervix, uterine: 45.8	Cell line enhanced		CAPAN-2: 59.3;MCF7: 32.5;T-47d: 31.4
SULT4A1	hBR-STL-1, SULTX3	ENSG00000130540	Sulfotransferase family 4A member 1	22	43824509-43862503	Predicted intracellular proteins	Evidence at protein level	HPA003129	Enhanced					Tissue enhanced	Tissue enriched	35	cerebral cortex: 143.6	adrenal gland: 4.0	Not detected		
SULT6B1		ENSG00000138068	Sulfotransferase family 6B member 1	2	37167820-37196598	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	11	fallopian tube: 1.0;testis: 4.3	bone marrow: 0.2	Cell line enriched	6	WM-115: 2.2
SUMO1	GMP1, OFC10, PIC1, SMT3C, SMT3H3, SUMO-1, UBL1	ENSG00000116030	Small ubiquitin-like modifier 1	2	202206180-202238608	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004269, HPA056956	Supported		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Nuclear bodies	Ovarian cancer:7.93e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 171.0	Expressed in all		
SUMO2	SMT3B, SMT3H2	ENSG00000188612	Small ubiquitin-like modifier 2	17	75165586-75182983	Predicted intracellular proteins	Evidence at protein level	CAB037314, HPA042123, HPA048064	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.23e-6 (unfavourable), Endometrial cancer:1.88e-5 (unfavourable), Liver cancer:2.12e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 342.9	Expressed in all		
SUMO3	SMT3A, SMT3H1	ENSG00000184900	Small ubiquitin-like modifier 3	21	44805617-44818779	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012180, HPA042123, HPA048064	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:7.88e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 80.8	Expressed in all		
SUMO4	dJ281H8.4, IDDM5, SMT3H4	ENSG00000177688	Small ubiquitin-like modifier 4	6	149400227-149401292	Predicted intracellular proteins	Evidence at protein level	HPA042123, HPA048064	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Not detected	Not detected			liver: 0.6	Not detected		
SUOX		ENSG00000139531	Sulfite oxidase	12	55997180-56006641	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038208, HPA038209	Approved				Renal cancer:4.77e-7 (favourable), Urothelial cancer:8.32e-5 (favourable), Pancreatic cancer:6.28e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 108.9	Mixed		
SUPT16H	CDC68, FACT, FACTP140, FLJ10857, FLJ14010, SPT16/CDC68	ENSG00000092201	SPT16 homolog, facilitates chromatin remodeling subunit	14	21351472-21384266	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022551, HPA049787	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			parathyroid gland: 95.7	Expressed in all		
SUPT20H	bA421P11.4, C13orf19, FAM48A, P38IP, SPT20	ENSG00000102710	SPT20 homolog, SAGA complex component	13	37009312-37059713	Predicted intracellular proteins	Evidence at protein level	HPA038906, HPA038907	Uncertain		Supported	Nucleoli fibrillar center		Expressed in all	Expressed in all			testis: 100.1	Expressed in all		
SUPT3H	SPT3, SPT3L	ENSG00000196284	SPT3 homolog, SAGA and STAGA complex component	6	44809317-45377953	Predicted intracellular proteins	Evidence at protein level	HPA024371	Enhanced		Supported	Nucleoplasm	Ovarian cancer:1.72e-4 (favourable), Glioma:3.05e-4 (favourable)	Expressed in all	Mixed			testis: 14.5	Mixed		
SUPT4H1	Spt4, SPT4H, Supt4a, SUPT4H	ENSG00000213246	SPT4 homolog, DSIF elongation factor subunit	17	58345175-58353093	Predicted intracellular proteins	Evidence at protein level	HPA059748			Approved	Nucleus	Liver cancer:7.69e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 82.4	Expressed in all		
SUPT5H	FLJ34157, SPT5, SPT5H	ENSG00000196235	SPT5 homolog, DSIF elongation factor subunit	19	39436156-39476670	Predicted intracellular proteins	Evidence at protein level	HPA029273, CAB034370	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.00e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 169.6	Expressed in all		
SUPT6H	KIAA0162, SPT6H	ENSG00000109111	SPT6 homolog, histone chaperone	17	28662091-28702684	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012416, HPA036382	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:3.68e-5 (unfavourable), Renal cancer:4.36e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 62.1	Expressed in all		
SUPT7L	KIAA0764, SPT7L, STAF65, STAF65gamma	ENSG00000119760	SPT7-like STAGA complex gamma subunit	2	27650812-27663840	Predicted intracellular proteins	Evidence at protein level	HPA039565, HPA063643	Uncertain		Approved	Nucleoplasm	Liver cancer:4.46e-7 (unfavourable), Renal cancer:1.53e-4 (unfavourable), Endometrial cancer:2.28e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 45.6	Expressed in all		
SUPV3L1	SUV3	ENSG00000156502	Suv3 like RNA helicase	10	69180232-69209099	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038380, HPA038405	Enhanced		Supported	Mitochondria		Expressed in all	Expressed in all			testis: 29.0	Expressed in all		
SURF2		ENSG00000148291	Surfeit 2	9	133356552-133361169	Predicted intracellular proteins	Evidence at protein level	HPA044340, HPA052213	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 39.1	Expressed in all		
SURF6	FLJ30322, RRP14	ENSG00000148296	Surfeit 6	9	133328774-133336398	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023608, HPA074622	Approved		Enhanced	Nucleus<br>Nucleoli	Renal cancer:7.31e-5 (favourable)	Expressed in all	Mixed			ovary: 8.8	Expressed in all		
SUV39H1	KMT1A, SUV39H	ENSG00000101945	Suppressor of variegation 3-9 homolog 1	X	48695554-48709012	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.91e-7 (unfavourable), Cervical cancer:8.93e-5 (favourable)	Expressed in all	Mixed			epididymis: 14.4	Expressed in all		
SUV39H2	FLJ23414, KMT1B	ENSG00000152455	Suppressor of variegation 3-9 homolog 2	10	14878820-14904315	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045901, HPA057554	Enhanced		Approved	Mitochondria	Liver cancer:2.01e-6 (unfavourable), Renal cancer:5.71e-5 (unfavourable), Breast cancer:5.55e-4 (unfavourable)	Expressed in all	Tissue enriched	12	testis: 73.2	placenta: 6.1	Expressed in all		
SUZ12	CHET9, JJAZ1, KIAA0160	ENSG00000178691	SUZ12 polycomb repressive complex 2 subunit	17	31937018-32001045	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA057436	Approved		Approved	Nucleus<br>Nucleoli<br>Nuclear bodies		Expressed in all	Expressed in all			testis: 50.7	Expressed in all		
SVBP	CCDC23, MGC45441	ENSG00000177868	Small vasohibin binding protein	1	42807052-42817252	Predicted intracellular proteins	Evidence at protein level	HPA008507	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:1.18e-4 (unfavourable), Breast cancer:6.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.8	Expressed in all		
SVIL		ENSG00000197321	Supervillin	10	29457338-29736781	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010878, HPA020095, HPA020138	Approved		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Urothelial cancer:5.70e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 279.8	Cell line enhanced		HaCaT: 106.2
SVIP	DKFZp313A2432	ENSG00000198168	Small VCP interacting protein	11	22813799-22830299	Predicted intracellular proteins	Evidence at protein level	HPA039807	Uncertain				Renal cancer:1.77e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.1	Cell line enhanced		SCLC-21H: 58.2
SWAP70	KIAA0640, SWAP-70	ENSG00000133789	SWAP switching B-cell complex subunit 70	11	9664077-9752991	Predicted intracellular proteins	Evidence at protein level	HPA006810	Supported					Expressed in all	Expressed in all			spleen: 82.2	Mixed		
SWI5	bA395P17.9, C9orf119, SAE3	ENSG00000175854	SWI5 homologous recombination repair protein	9	128275379-128288990	Predicted intracellular proteins	Evidence at protein level	HPA052032, HPA055472	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.78e-4 (unfavourable), Renal cancer:9.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 129.1	Expressed in all		
SWT1	C1orf26, FLJ20121, HsSwt1	ENSG00000116668	SWT1, RNA endoribonuclease homolog	1	185157080-185291765	Predicted intracellular proteins	Evidence at protein level	HPA024214, HPA027334	Enhanced		Approved	Cytosol	Renal cancer:5.63e-4 (favourable)	Expressed in all	Tissue enriched	8	testis: 69.4	thyroid gland: 8.7	Mixed		
SYCE1	bA108K14.6, C10orf94, CT76	ENSG00000171772	Synaptonemal complex central element protein 1	10	133553901-133569835	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040208	Enhanced		Uncertain	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	6	testis: 81.8	placenta: 13.3	Group enriched	10	K-562: 16.5;U-2 OS: 16.2
SYCE1L	MRP2	ENSG00000205078	Synaptonemal complex central element protein 1 like	16	77199397-77213215	Predicted intracellular proteins	Evidence at protein level	HPA062464, HPA066691			Enhanced	Intermediate filaments	Renal cancer:2.11e-5 (unfavourable), Endometrial cancer:6.65e-4 (favourable)	Mixed	Tissue enriched	5	testis: 23.8	prostate: 4.6	Cell line enhanced		HEK93: 10.5
SYCE2	CESC1	ENSG00000161860	Synaptonemal complex central element protein 2	19	12898786-12919276	Predicted intracellular proteins	Evidence at protein level	HPA042080, HPA062919	Enhanced		Supported	Nucleus	Cervical cancer:3.85e-5 (favourable), Endometrial cancer:9.91e-4 (unfavourable)	Mixed	Tissue enriched	15	testis: 38.9	cerebral cortex: 2.5	Cell line enhanced		EFO-21: 11.1;SiHa: 12.6
SYCE3	C22orf41	ENSG00000217442	Synaptonemal complex central element protein 3	22	50551112-50562905	Predicted intracellular proteins	Evidence at protein level	HPA047813			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Mixed	Tissue enriched	38	testis: 116.7	thyroid gland: 3.0	Cell line enhanced		CAPAN-2: 4.5;Karpas-707: 3.1
SYCP1	CT8, HOM-TES-14, SCP1	ENSG00000198765	Synaptonemal complex protein 1	1	114854803-114995370	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021083	Enhanced					Not detected	Tissue enriched	96	testis: 72.5	breast: 0.7	Cell line enriched	65	THP-1: 11.4
SYCP2	SCP2	ENSG00000196074	Synaptonemal complex protein 2	20	59863563-59933655	Predicted intracellular proteins	Evidence at protein level	HPA062401, HPA065613			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Group enriched	Group enriched	8	breast: 17.7;testis: 76.9	prostate: 6.0	Cell line enhanced		MOLT-4: 43.5;SiHa: 97.9;T-47d: 77.3
SYCP2L	C6orf177, dJ62D2.1, NO145	ENSG00000153157	Synaptonemal complex protein 2 like	6	10886831-10979320	Predicted intracellular proteins	Evidence at protein level	HPA034679			Supported	Nucleoplasm		Tissue enhanced	Tissue enriched	20	parathyroid gland: 122.5	testis: 5.9	Cell line enhanced		HL-60: 10.7;HMC-1: 35.1;K-562: 9.5;NB-4: 9.1
SYCP3		ENSG00000139351	Synaptonemal complex protein 3	12	101728648-101739472	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB032978, HPA039635, HPA043938	Enhanced					Tissue enriched	Tissue enriched	265	testis: 172.2	lung: 0.6	Cell line enhanced		Karpas-707: 1.0
SYDE1	7h3, FLJ13511, SYD1	ENSG00000105137	Synapse defective Rho GTPase homolog 1	19	15107403-15114988	Predicted intracellular proteins	Evidence at protein level	HPA013328	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:5.63e-7 (unfavourable), Urothelial cancer:8.27e-4 (unfavourable)	Expressed in all	Mixed			placenta: 21.8	Cell line enhanced		U-138 MG: 104.0
SYDE2	FLJ13815	ENSG00000097096	Synapse defective Rho GTPase homolog 2	1	85156873-85201046	Predicted intracellular proteins	Evidence at protein level	HPA027138, HPA058378	Uncertain		Approved	Nucleoli<br>Golgi apparatus		Mixed	Mixed			parathyroid gland: 7.0	Cell line enhanced		BEWO: 13.9
SYF2	CBPIN, DKFZp564O2082, fSAP29, NTC31, p29	ENSG00000117614	SYF2 pre-mRNA splicing factor	1	25222679-25232502	Predicted intracellular proteins	Evidence at protein level	HPA018265, HPA070710	Approved		Supported	Nuclear speckles	Urothelial cancer:5.72e-4 (favourable)	Expressed in all	Expressed in all			ovary: 135.9	Expressed in all		
SYK		ENSG00000165025	Spleen associated tyrosine kinase	9	90801787-90898549	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001384, CAB007773	Enhanced		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 96.0	Cell line enhanced		Daudi: 89.3;HEL: 64.8;HL-60: 80.0;REH: 76.3
SYMPK	SPK, SYM	ENSG00000125755	Symplekin	19	45815410-45863290	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041756, HPA042449	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 74.7	Expressed in all		
SYN1		ENSG00000008056	Synapsin I	X	47571898-47619943	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000397, CAB021929	Enhanced					Tissue enhanced	Tissue enriched	26	cerebral cortex: 378.9	adrenal gland: 14.5	Cell line enhanced		NTERA-2: 17.4;SCLC-21H: 35.6;SH-SY5Y: 8.3
SYN2	SYNII, SYNIIa, SYNIIb	ENSG00000157152	Synapsin II	3	12004402-12191400	Predicted intracellular proteins	Evidence at protein level	HPA037012, CAB079005		Supported	Approved	Nucleoplasm		Tissue enhanced	Tissue enriched	29	cerebral cortex: 200.0	testis: 6.8	Cell line enhanced		HMC-1: 4.4;NTERA-2: 4.3;SCLC-21H: 4.0;SH-SY5Y: 14.4
SYN3		ENSG00000185666	Synapsin III	22	32512552-33058372	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034566	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 9.5;testis: 7.9	placenta: 4.2	Cell line enhanced		HAP1: 5.8;NTERA-2: 3.7;SCLC-21H: 8.6
SYNC	SYNC1, SYNCOILIN	ENSG00000162520	Syncoilin, intermediate filament protein	1	32680360-32703596	Predicted intracellular proteins	Evidence at protein level	HPA028311	Approved		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		smooth muscle: 74.1	skeletal muscle: 36.1	Cell line enhanced		BJ hTERT+: 65.1;fHDF/TERT166: 91.5;U-138 MG: 98.1;WM-115: 67.5
SYNCRIP	dJ3J17.2, GRY-RBP, hnRNP-Q, HNRNPQ, HNRPQ1, NSAP1	ENSG00000135316	Synaptotagmin binding cytoplasmic RNA interacting protein	6	85607785-85643792	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010895, HPA041275	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:6.28e-5 (unfavourable), Ovarian cancer:5.59e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 132.3	Expressed in all		
SYNGAP1	KIAA1938, RASA5, SYNGAP	ENSG00000197283	Synaptic Ras GTPase activating protein 1	6	33419661-33457541	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA038373	Enhanced		Approved	Nucleus	Renal cancer:1.34e-6 (unfavourable), Head and neck cancer:2.80e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 26.3	endometrium: 12.5	Cell line enhanced		AF22: 28.5
SYNJ1	INPP5G, PARK20	ENSG00000159082	Synaptojanin 1	21	32628759-32728048	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA011916	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Prostate cancer:2.58e-4 (unfavourable), Head and neck cancer:4.43e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 65.9	testis: 18.4	Expressed in all		
SYNJ2	INPP5H	ENSG00000078269	Synaptojanin 2	6	157981887-158099176	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031575	Approved		Approved	Microtubules<br>Cytosol	Renal cancer:4.02e-6 (unfavourable), Breast cancer:2.63e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 34.8	Mixed		
SYNJ2BP-COX16		ENSG00000258644	SYNJ2BP-COX16 readthrough	14	70326064-70417074	Predicted intracellular proteins	Evidence at protein level	HPA000866, HPA062659	Approved	Supported	Enhanced	Mitochondria		Not detected	Tissue enhanced		testis: 39.7	skeletal muscle: 15.1	Mixed		
SYNM	DMN, KIAA0353, SYN	ENSG00000182253	Synemin	15	99098217-99135593	Predicted intracellular proteins	Evidence at protein level	CAB017192, HPA040066, HPA044200	Enhanced					Expressed in all	Tissue enhanced		seminal vesicle: 404.4	smooth muscle: 227.4	Cell line enhanced		A549: 33.4;HeLa: 36.9;WM-115: 122.8
SYNPO	KIAA1029	ENSG00000171992	Synaptopodin	5	150601080-150659220	Predicted intracellular proteins	Evidence at protein level	CAB033265, HPA034631, CAB037325, HPA071347	Enhanced		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:1.53e-6 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 446.6	heart muscle: 226.3	Cell line enhanced		BEWO: 85.1;TIME: 144.5;U-87 MG: 148.8
SYNPO2	MYOPODIN	ENSG00000172403	Synaptopodin 2	4	118850688-119061247	Predicted intracellular proteins	Evidence at protein level	HPA030665, CAB037231, HPA049707, HPA068563	Enhanced		Supported	Vesicles<br>Actin filaments<br>Cytosol	Renal cancer:5.67e-5 (unfavourable), Urothelial cancer:3.91e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 421.3	smooth muscle: 342.7	Cell line enhanced		fHDF/TERT166: 44.3;SH-SY5Y: 89.5
SYNPO2L	FLJ12921	ENSG00000166317	Synaptopodin 2 like	10	73644881-73663803	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055192, HPA057142	Enhanced		Approved	Nuclear speckles<br>Cell Junctions<br>Cytosol		Group enriched	Group enriched	12	heart muscle: 168.4;skeletal muscle: 95.9	esophagus: 11.1	Cell line enhanced		CACO-2: 3.4;HSkMC: 2.3;RH-30: 3.0;SK-BR-3: 2.5
SYNRG	AP1GBP1, MGC104959, SYNG	ENSG00000275066	Synergin gamma	17	37514797-37609496	Predicted intracellular proteins	Evidence at protein level	HPA023554, HPA023555	Approved		Approved	Cytosol	Urothelial cancer:3.96e-4 (favourable)	Expressed in all	Expressed in all			testis: 20.4	Expressed in all		
SYT11	DKFZp781D015, KIAA0080, MGC10881, MGC17226	ENSG00000132718	Synaptotagmin 11	1	155859509-155885199	Predicted intracellular proteins	Evidence at protein level	HPA064091	Enhanced				Endometrial cancer:2.93e-5 (unfavourable)	Tissue enriched	Tissue enriched	14	cerebral cortex: 402.2	endometrium: 28.4	Cell line enhanced		Karpas-707: 130.6;SCLC-21H: 84.6;SH-SY5Y: 83.1;U-87 MG: 84.4
SYT12	SRG1	ENSG00000173227	Synaptotagmin 12	11	67006778-67050863	Predicted intracellular proteins	Evidence at protein level	HPA011006	Uncertain				Pancreatic cancer:4.13e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	parathyroid gland: 115.1	cerebral cortex: 17.2	Cell line enhanced		HeLa: 31.9;MCF7: 25.6;SiHa: 44.9;SK-BR-3: 15.2;T-47d: 19.2
SYT13	KIAA1427	ENSG00000019505	Synaptotagmin 13	11	45240301-45286319	Predicted intracellular proteins	Evidence at protein level	HPA046224, HPA056602	Uncertain		Supported	Vesicles	Endometrial cancer:7.79e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 69.9;gallbladder: 32.9	small intestine: 14.4	Group enriched	9	A549: 17.3;NTERA-2: 8.8;RPTEC TERT1: 43.3;SCLC-21H: 17.8
SYT17		ENSG00000103528	Synaptotagmin 17	16	19167971-19268334	Predicted intracellular proteins	Evidence at protein level	HPA042059			Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 39.8;parathyroid gland: 32.6	prostate: 14.9	Cell line enhanced		BEWO: 13.7;CAPAN-2: 24.6;MCF7: 16.6
SYT4	HsT1192, KIAA1342	ENSG00000132872	Synaptotagmin 4	18	43267878-43277650	Predicted intracellular proteins	Evidence at protein level	HPA010574	Approved		Supported	Vesicles<br>Plasma membrane		Tissue enhanced	Tissue enhanced		adrenal gland: 20.4;cerebral cortex: 82.5	seminal vesicle: 11.3	Cell line enriched	10	SH-SY5Y: 251.0
SYTL1	exophilin-7, FLJ14996, JFC1, SLP1	ENSG00000142765	Synaptotagmin like 1	1	27342020-27353937	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037825	Enhanced				Endometrial cancer:6.83e-7 (favourable), Renal cancer:1.12e-5 (unfavourable)	Mixed	Mixed			skin: 69.0	Cell line enhanced		BEWO: 46.5;CAPAN-2: 49.3;NB-4: 51.8
SYTL2	CHR11SYT, exophilin-4, FLJ20163, FLJ21219, KIAA1597, MGC102768, PPP1R151, SGA72M, SLP2	ENSG00000137501	Synaptotagmin like 2	11	85694224-85811159	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA039651	Approved		Approved	Nucleus<br>Golgi apparatus<br>Plasma membrane	Colorectal cancer:2.67e-4 (favourable), Urothelial cancer:9.07e-4 (favourable)	Mixed	Tissue enhanced		stomach: 120.5	rectum: 81.4	Cell line enhanced		RH-30: 170.2;RPTEC TERT1: 95.1
SYTL3	exophilin-6, SLP3	ENSG00000164674	Synaptotagmin like 3	6	158650014-158764876	Predicted intracellular proteins	Evidence at protein level	HPA030584, HPA030585, HPA030586	Approved		Approved	Nucleoli fibrillar center<br>Vesicles	Cervical cancer:8.84e-5 (favourable)	Mixed	Tissue enhanced		thyroid gland: 44.5	fallopian tube: 22.9	Cell line enhanced		HMC-1: 21.4;SCLC-21H: 19.1;U-2 OS: 20.9;U-266/70: 21.7
SYTL4		ENSG00000102362	Synaptotagmin like 4	X	100674491-100732123	Predicted intracellular proteins	Evidence at protein level	HPA001475, HPA001589	Approved		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Renal cancer:2.09e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 71.5;ovary: 83.7	smooth muscle: 49.0	Cell line enhanced		HAP1: 30.4;HMC-1: 52.7;RT4: 32.5;TIME: 28.4
SYTL5		ENSG00000147041	Synaptotagmin like 5	X	38006582-38128819	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026074	Uncertain		Approved	Nucleoplasm<br>Microtubules<br>Cytosol		Mixed	Tissue enhanced		stomach: 11.8	placenta: 10.6	Cell line enhanced		CACO-2: 5.1;MCF7: 4.4;SK-MEL-30: 11.6;U-2 OS: 5.0
SZRD1	C1orf144, DKFZp566C0424	ENSG00000055070	SUZ RNA binding domain containing 1	1	16352575-16398145	Predicted intracellular proteins	Evidence at protein level	HPA024221	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:5.98e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 91.5	Expressed in all		
SZT2	C1orf84, FLJ10387, FLJ34502, KIAA0467, RP11-506B15.1, SZT2A, SZT2B	ENSG00000198198	Seizure threshold 2 homolog (mouse)	1	43389882-43454247	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029012	Approved		Approved	Nucleoplasm<br>Vesicles<br>Actin filaments	Head and neck cancer:1.47e-7 (favourable), Liver cancer:2.53e-4 (unfavourable), Lung cancer:6.20e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.4	Expressed in all		
T		ENSG00000164458	T brachyury transcription factor	6	166157656-166168700	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003322	Uncertain		Supported	Nucleus		Tissue enriched	Tissue enriched	20	parathyroid gland: 8.7	testis: 0.4	Group enriched	6	HeLa: 10.3;SCLC-21H: 4.2
TAB1	MAP3K7IP1	ENSG00000100324	TGF-beta activated kinase 1 (MAP3K7) binding protein 1	22	39399741-39437060	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032328, HPA039988, HPA057104	Approved		Enhanced	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 23.1	Expressed in all		
TAB2	KIAA0733, MAP3K7IP2	ENSG00000055208	TGF-beta activated kinase 1/MAP3K7 binding protein 2	6	149218641-149411613	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065436, HPA070137, HPA071215	Approved		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 70.3	Expressed in all		
TAB3	MAP3K7IP3	ENSG00000157625	TGF-beta activated kinase 1 and MAP3K7 binding protein 3	X	30827442-30975084	Predicted intracellular proteins	Evidence at protein level	HPA034980, HPA034981	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:8.45e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 53.6	Expressed in all		
TACC1		ENSG00000147526	Transforming acidic coiled-coil containing protein 1	8	38728186-38853028	Predicted intracellular proteins	Evidence at protein level	CAB017041, HPA024702	Approved				Renal cancer:1.06e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 166.8	Expressed in all		
TACC2	AZU-1	ENSG00000138162	Transforming acidic coiled-coil containing protein 2	10	121989174-122254545	Predicted intracellular proteins	Evidence at protein level	HPA031020, HPA031021, HPA061394	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.50e-10 (favourable), Thyroid cancer:8.45e-4 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 112.7	Mixed		
TACC3	ERIC1	ENSG00000013810	Transforming acidic coiled-coil containing protein 3	4	1721490-1745176	Predicted intracellular proteins	Evidence at protein level	HPA005781, HPA006050, CAB010111, HPA022039	Enhanced		Enhanced	Vesicles<br>Mitotic spindle<br>Microtubule organizing center<br>Centrosome<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.30e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 74.9	lymph node: 55.8	Expressed in all		
TACO1	CCDC44	ENSG00000136463	Translational activator of cytochrome c oxidase I	17	63600872-63608365	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021626, HPA021643, HPA024294	Enhanced		Enhanced	Mitochondria	Pancreatic cancer:3.73e-4 (favourable)	Expressed in all	Expressed in all			kidney: 30.7	Expressed in all		
TADA1	ADA1, hADA1, HFI1, STAF42, TADA1L	ENSG00000152382	Transcriptional adaptor 1	1	166856510-166876327	Predicted intracellular proteins	Evidence at protein level	HPA028651	Approved		Supported	Nucleoplasm<br>Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 23.9	Expressed in all		
TADA2A	ADA2, ADA2A, hADA2, TADA2L	ENSG00000276234	Transcriptional adaptor 2A	17	37406874-37479730	Predicted intracellular proteins	Evidence at transcript level	HPA076497			Approved	Nuclear speckles	Renal cancer:2.25e-5 (unfavourable)	Expressed in all	Mixed			testis: 13.8	Mixed		
TADA2B	MGC21874	ENSG00000173011	Transcriptional adaptor 2B	4	7041899-7057952	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035770	Approved		Approved	Nuclear speckles	Renal cancer:7.17e-11 (favourable), Urothelial cancer:1.59e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 27.4	Expressed in all		
TADA3	ADA3, FLJ20221, FLJ21329, hADA3, NGG1, TADA3L	ENSG00000171148	Transcriptional adaptor 3	3	9779860-9793011	Predicted intracellular proteins	Evidence at protein level	HPA042250	Approved		Supported	Nucleoplasm	Renal cancer:5.47e-5 (favourable)	Expressed in all	Expressed in all			testis: 71.9	Expressed in all		
TAF1	BA2R, CCG1, CCGS, DYT3, DYT3/TAF1, KAT4, NSCL2, TAF2A, TAFII250	ENSG00000147133	TATA-box binding protein associated factor 1	X	71366239-71532374	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001075, CAB016283	Supported		Enhanced	Nucleoplasm	Renal cancer:6.03e-4 (unfavourable), Lung cancer:6.54e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.2	Expressed in all		
TAF10	TAF2A, TAF2H, TAFII30	ENSG00000166337	TATA-box binding protein associated factor 10	11	6606296-6612667	Predicted intracellular proteins	Evidence at protein level	HPA004148, CAB022405	Supported		Supported	Nucleoplasm	Renal cancer:1.84e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 133.2	Expressed in all		
TAF11	TAF2I, TAFII28	ENSG00000064995	TATA-box binding protein associated factor 11	6	34877778-34888089	Predicted intracellular proteins	Evidence at protein level	HPA029326, HPA049127			Supported	Nucleoplasm<br>Golgi apparatus	Ovarian cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			testis: 54.8	Expressed in all		
TAF12	TAF2J, TAFII20	ENSG00000120656	TATA-box binding protein associated factor 12	1	28589323-28643085	Predicted intracellular proteins	Evidence at protein level	HPA008519	Approved				Renal cancer:1.36e-7 (unfavourable), Liver cancer:1.16e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.1	Expressed in all		
TAF13	TAF2K, TAFII18	ENSG00000197780	TATA-box binding protein associated factor 13	1	109062486-109076002	Predicted intracellular proteins	Evidence at protein level	HPA044492	Approved		Enhanced	Nucleus<br>Nucleoli	Liver cancer:8.74e-6 (unfavourable), Ovarian cancer:2.42e-5 (favourable)	Expressed in all	Expressed in all			smooth muscle: 50.5	Expressed in all		
TAF1A	SL1, TAFI48	ENSG00000143498	TATA-box binding protein associated factor, RNA polymerase I subunit A	1	222557902-222589933	Predicted intracellular proteins	Evidence at protein level	HPA054334	Approved		Supported	Nucleoplasm	Cervical cancer:9.26e-6 (unfavourable)	Expressed in all	Mixed			testis: 12.0	Expressed in all		
TAF1C	MGC:39976, SL1, TAFI110, TAFI95	ENSG00000103168	TATA-box binding protein associated factor, RNA polymerase I subunit C	16	84177847-84187070	Predicted intracellular proteins	Evidence at protein level	HPA072229			Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:8.08e-6 (unfavourable), Pancreatic cancer:1.76e-4 (favourable), Urothelial cancer:3.22e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 15.5	Expressed in all		
TAF1L		ENSG00000122728	TATA-box binding protein associated factor 1 like	9	32629454-32635669	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056605	Uncertain					Not detected	Tissue enriched	31	testis: 3.0	all non-specific tissues: 0.0	Not detected		
TAF2	CIF150, TAF2B, TAFII150	ENSG00000064313	TATA-box binding protein associated factor 2	8	119730775-119832863	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:2.45e-4 (unfavourable), Liver cancer:9.58e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.4	Expressed in all		
TAF3	TAF140, TAFII140	ENSG00000165632	TATA-box binding protein associated factor 3	10	7818504-8016627	Predicted intracellular proteins	Evidence at protein level	HPA066184			Supported	Nucleoplasm<br>Nuclear membrane	Liver cancer:2.14e-7 (unfavourable), Renal cancer:5.01e-4 (unfavourable)	Expressed in all	Mixed			testis: 14.1	Expressed in all		
TAF4	TAF2C, TAF2C1, TAF4A, TAFII130, TAFII135	ENSG00000130699	TATA-box binding protein associated factor 4	20	61953469-62065810	Predicted intracellular proteins	Evidence at protein level	HPA008599, CAB031484	Supported		Enhanced	Nucleoplasm	Liver cancer:3.31e-4 (unfavourable)	Expressed in all	Mixed			testis: 6.6	Mixed		
TAF4B	TAF2C2, TAFII105	ENSG00000141384	TATA-box binding protein associated factor 4b	18	26225936-26391685	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028937	Uncertain		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Urothelial cancer:1.72e-4 (unfavourable), Renal cancer:3.08e-4 (unfavourable)	Mixed	Mixed			testis: 4.2	Cell line enhanced		Daudi: 24.6
TAF5	TAF2D, TAFII100	ENSG00000148835	TATA-box binding protein associated factor 5	10	103367967-103389065	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006195, HPA006474	Supported		Supported	Nucleoplasm	Renal cancer:1.36e-9 (unfavourable), Stomach cancer:7.39e-5 (favourable)	Expressed in all	Tissue enhanced		testis: 20.7	lymph node,placenta: 5.1	Expressed in all		
TAF5L	PAF65B	ENSG00000135801	TATA-box binding protein associated factor 5 like	1	229593111-229626047	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA067941			Enhanced	Nuclear speckles<br>Cytoplasmic bodies		Expressed in all	Expressed in all			placenta: 20.6	Expressed in all		
TAF6	MGC:8964, TAF2E, TAFII70, TAFII80, TAFII85	ENSG00000106290	TATA-box binding protein associated factor 6	7	100107070-100119841	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA006566	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.06e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 62.4	Expressed in all		
TAF6L	PAF65A	ENSG00000162227	TATA-box binding protein associated factor 6 like	11	62771303-62787342	Predicted intracellular proteins	Evidence at protein level	HPA067239	Approved		Supported	Nucleoplasm	Head and neck cancer:8.98e-5 (favourable)	Expressed in all	Expressed in all			skin: 11.9	Expressed in all		
TAF7	TAF2F, TAFII55	ENSG00000178913	TATA-box binding protein associated factor 7	5	141260225-141320821	Predicted intracellular proteins	Evidence at protein level	HPA006429	Approved		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 138.7	Expressed in all		
TAF7L	CT40, TAF2Q	ENSG00000102387	TATA-box binding protein associated factor 7 like	X	101268253-101293057	Predicted intracellular proteins	Evidence at protein level	HPA001879	Approved		Approved	Nucleoplasm	Cervical cancer:8.71e-4 (favourable)	Tissue enhanced	Tissue enriched	14	testis: 62.6	parathyroid gland: 4.6	Cell line enriched	23	SiHa: 60.1
TAF8	FLJ32821, TAF(II)43, TBN	ENSG00000137413	TATA-box binding protein associated factor 8	6	42050513-42087461	Predicted intracellular proteins	Evidence at protein level	HPA031730, HPA031731, HPA031734	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 24.3	Expressed in all		
TAF9	AD-004, CGI-137, MGC1603, MGC3647, MGC5067, TAF2G, TAFII31, TAFII32, TAFIID32	ENSG00000273841	TATA-box binding protein associated factor 9	5	69364743-69370013	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.48e-5 (unfavourable), Renal cancer:9.20e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 146.1	Expressed in all		
TAF9B	DN-7, DN7, TAF9L, TAFII31L, TFIID-31	ENSG00000187325	TATA-box binding protein associated factor 9b	X	78129748-78139706	Predicted intracellular proteins	Evidence at protein level	HPA045275	Approved				Cervical cancer:5.40e-5 (favourable)	Expressed in all	Expressed in all			smooth muscle: 43.8	Expressed in all		
TAGAP	ARHGAP47, FLJ32631, IDDM21	ENSG00000164691	T-cell activation RhoGTPase activating protein	6	159034468-159045152	Predicted intracellular proteins	Evidence at protein level	HPA031000	Uncertain					Expressed in all	Tissue enhanced		bone marrow: 129.8	lymph node: 55.5	Cell line enhanced		Daudi: 27.0;HMC-1: 50.5;Karpas-707: 41.7;U-698: 34.9;U-937: 30.4
TAGLN	DKFZp686P11128, SM22, SMCC, TAGLN1, WS3-10	ENSG00000149591	Transgelin	11	117199321-117204782	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001447, HPA019467	Enhanced		Approved	Microtubules<br>Mitochondria<br>Cytosol	Renal cancer:2.12e-7 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 11975.2	Expressed in all		
TAGLN3	NP22, NP25	ENSG00000144834	Transgelin 3	3	111998664-112013887	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062620	Enhanced					Tissue enhanced	Tissue enriched	8	cerebral cortex: 356.0	adrenal gland: 42.3	Group enriched	6	AF22: 98.0;RPTEC TERT1: 30.7;SCLC-21H: 63.4;SH-SY5Y: 96.4
TAL1	bHLHa17, SCL, TCL5	ENSG00000162367	TAL bHLH transcription factor 1, erythroid differentiation factor	1	47216290-47232220	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017805, HPA047866, HPA073983	Approved		Supported	Nucleus		Mixed	Tissue enhanced		bone marrow: 17.7	placenta: 10.0	Cell line enhanced		HEL: 137.6;HMC-1: 62.0;K-562: 43.6;TIME: 28.0
TAL2	bHLHa19	ENSG00000186051	TAL bHLH transcription factor 2	9	105662457-105663112	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030886	Uncertain		Approved	Cytosol	Renal cancer:2.69e-4 (favourable)	Tissue enhanced	Group enriched	5	kidney: 3.5;skeletal muscle: 4.8	epididymis: 0.8	Cell line enhanced		HAP1: 3.1;K-562: 7.5
TALDO1		ENSG00000177156	Transaldolase 1	11	747329-765024	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040373, HPA048089			Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.29e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 262.9	Expressed in all		
TAMM41	C3orf31, DKFZp434E0519, MGC16471	ENSG00000144559	TAM41 mitochondrial translocator assembly and maintenance homolog	3	11790442-11846919	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036834, HPA044861	Uncertain		Approved	Cytosol	Colorectal cancer:1.23e-4 (favourable)	Expressed in all	Mixed			epididymis: 11.8	Expressed in all		
TANC1	KIAA1728, ROLSB	ENSG00000115183	Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1	2	158968671-159232659	Predicted intracellular proteins	Evidence at protein level	HPA036750	Approved					Expressed in all	Mixed			skin: 24.7	Mixed		
TANC2	DKFZP564D166, FLJ10215, FLJ11824, KIAA1148, KIAA1636, rols, ROLSA	ENSG00000170921	Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2	17	63009556-63427699	Predicted intracellular proteins	Evidence at protein level	HPA023274	Uncertain		Approved	Cytosol		Mixed	Tissue enhanced		parathyroid gland: 78.0	testis: 34.9	Mixed		
TANGO2	C22orf25, DKFZp761P1121	ENSG00000183597	Transport and golgi organization 2 homolog	22	20017014-20065926	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003080	Approved	Approved			Pancreatic cancer:3.01e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 47.5	Expressed in all		
TANK	I-TRAF, TRAF2	ENSG00000136560	TRAF family member associated NFKB activator	2	161136908-161236221	Predicted intracellular proteins	Evidence at protein level	CAB010345, HPA037675, HPA037676	Approved		Supported	Nucleoli<br>Cytosol	Renal cancer:2.78e-6 (unfavourable), Liver cancer:2.90e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 68.2	Expressed in all		
TAOK1	FLJ14314, KIAA1361, MAP3K16, MARKK, PSK2, TAO1	ENSG00000160551	TAO kinase 1	17	29390464-29551904	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007669	Approved		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 41.5	Expressed in all		
TAOK3	DPK, JIK, MAP3K18	ENSG00000135090	TAO kinase 3	12	118149801-118372945	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017160	Approved		Uncertain	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 48.8	Expressed in all		
TARBP1	TRM3, TRP-185	ENSG00000059588	TAR (HIV-1) RNA binding protein 1	1	234391313-234479103	Predicted intracellular proteins	Evidence at protein level	CAB020810, HPA024632	Uncertain		Approved	Nuclear speckles	Renal cancer:5.14e-10 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 16.1	Expressed in all		
TARBP2	Trbp	ENSG00000139546	TARBP2, RISC loading complex RNA binding subunit	12	53500921-53506431	Predicted intracellular proteins	Evidence at protein level	HPA051181, HPA061454, CAB069406	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:4.75e-6 (unfavourable), Liver cancer:3.09e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 18.9	Expressed in all		
TARDBP	ALS10, TDP-43	ENSG00000120948	TAR DNA binding protein	1	11012344-11026420	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003703, HPA017284	Supported		Enhanced	Nucleoplasm	Liver cancer:1.20e-7 (unfavourable), Cervical cancer:1.15e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 178.4	Expressed in all		
TARS		ENSG00000113407	Threonyl-tRNA synthetase	5	33440696-33469539	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037425	Approved		Supported	Actin filaments<br>Cytosol	Liver cancer:9.88e-7 (unfavourable), Breast cancer:6.14e-5 (unfavourable), Endometrial cancer:5.17e-4 (unfavourable), Renal cancer:9.63e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 44.3	Expressed in all		
TARS2	FLJ12528, TARSL1	ENSG00000143374	Threonyl-tRNA synthetase 2, mitochondrial (putative)	1	150487364-150507609	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028626	Approved		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 29.2	Expressed in all		
TARSL2	FLJ25005	ENSG00000185418	Threonyl-tRNA synthetase like 2	15	101653598-101724604	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA066697	Approved		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 15.7	Expressed in all		
TASP1	C20orf13, dJ585I14.2, FLJ20212	ENSG00000089123	Taspase 1	20	13389392-13638940	Predicted intracellular proteins	Evidence at protein level	HPA030824, HPA030825	Uncertain		Approved	Plasma membrane	Thyroid cancer:6.78e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.7	Mixed		
TAT		ENSG00000198650	Tyrosine aminotransferase	16	71565660-71577130	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.51e-4 (favourable)	Tissue enriched	Tissue enriched	8	liver: 619.8	breast: 75.9	Cell line enhanced		Hep G2: 1.7
TATDN2	KIAA0218	ENSG00000157014	TatD DNase domain containing 2	3	10248023-10281218	Predicted intracellular proteins	Evidence at protein level	HPA036822, HPA058001	Approved		Supported	Nucleus<br>Nuclear speckles<br>Cytosol	Pancreatic cancer:4.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.3	Expressed in all		
TATDN3		ENSG00000203705	TatD DNase domain containing 3	1	212791828-212816626	Predicted intracellular proteins	Evidence at protein level	HPA032092	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Focal adhesion sites	Renal cancer:1.59e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 22.1	Expressed in all		
TAX1BP3	TIP-1	ENSG00000213977	Tax1 binding protein 3	17	3662896-3668682	Predicted intracellular proteins	Evidence at protein level	HPA046410, HPA063078	Approved		Approved	Nucleoli fibrillar center<br>Vesicles<br>Actin filaments	Glioma:1.66e-4 (unfavourable), Lung cancer:1.76e-4 (unfavourable), Renal cancer:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 228.1	Expressed in all		
TBATA	C10orf27, FLJ32820, spatial	ENSG00000166220	Thymus, brain and testes associated	10	70771239-70785401	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	27	testis: 32.0	spleen: 1.1	Cell line enriched	28	SK-BR-3: 3.0
TBC1D1	KIAA1108, TBC, TBC1	ENSG00000065882	TBC1 domain family member 1	4	37891087-38139175	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA041816, HPA058158	Approved		Uncertain	Nucleoli	Renal cancer:1.47e-8 (favourable), Lung cancer:5.22e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 251.2	Expressed in all		
TBC1D10A	AC004997.C22.2, EPI64, TBC1D10	ENSG00000099992	TBC1 domain family member 10A	22	30291990-30327046	Predicted intracellular proteins	Evidence at protein level	HPA007725, HPA008142, HPA076041	Approved		Enhanced	Plasma membrane		Expressed in all	Mixed			esophagus: 31.2	Expressed in all		
TBC1D10B	DKFZP434P1750, EPI64B, FLJ13130, Rab27A-GAPbeta	ENSG00000169221	TBC1 domain family member 10B	16	30357102-30370264	Predicted intracellular proteins	Evidence at protein level	HPA048894	Uncertain				Liver cancer:8.94e-5 (unfavourable), Colorectal cancer:1.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.1	Expressed in all		
TBC1D12	KIAA0608	ENSG00000108239	TBC1 domain family member 12	10	94402504-94535930	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA038277, HPA038645	Uncertain		Approved	Nucleoplasm<br>Nuclear speckles	Colorectal cancer:1.79e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 19.4	Mixed		
TBC1D13	FLJ10743	ENSG00000107021	TBC1 domain family member 13	9	128787204-128810432	Predicted intracellular proteins	Evidence at protein level	HPA045865	Approved		Approved	Nucleoli	Renal cancer:1.58e-7 (favourable), Pancreatic cancer:3.14e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.2	Expressed in all		
TBC1D14	KIAA1322	ENSG00000132405	TBC1 domain family member 14	4	6909242-7033118	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036930, HPA067398	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:5.28e-10 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 67.5	Expressed in all		
TBC1D15	DKFZp761D0223, FLJ12085	ENSG00000121749	TBC1 domain family member 15	12	71839707-71927248	Predicted intracellular proteins	Evidence at protein level	HPA013388, HPA015592	Supported		Supported	Mitochondria<br>Cytosol	Renal cancer:5.34e-4 (favourable), Cervical cancer:7.06e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 50.9	Expressed in all		
TBC1D16	FLJ20748, MGC25062	ENSG00000167291	TBC1 domain family member 16	17	79932343-80035848	Predicted intracellular proteins	Evidence at protein level	HPA024482, HPA065839	Approved		Approved	Intermediate filaments		Expressed in all	Mixed			adipose tissue: 40.7	Cell line enhanced		SK-MEL-30: 155.6
TBC1D17	FLJ12168	ENSG00000104946	TBC1 domain family member 17	19	49877425-49888749	Predicted intracellular proteins	Evidence at protein level	HPA068119	Uncertain				Pancreatic cancer:4.02e-4 (favourable), Head and neck cancer:7.18e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.8	Expressed in all		
TBC1D2	Armus, PARIS1, TBC1D2A	ENSG00000095383	TBC1 domain family member 2	9	98198999-98255721	Predicted intracellular proteins	Evidence at protein level	HPA030871	Uncertain		Approved	Nucleus<br>Cytosol	Head and neck cancer:2.77e-4 (unfavourable), Testis cancer:5.62e-4 (unfavourable)	Expressed in all	Mixed			lung: 33.2	Cell line enhanced		HaCaT: 86.0
TBC1D21	MGC34741, MgcRabGAP	ENSG00000167139	TBC1 domain family member 21	15	73873608-73889214	Predicted intracellular proteins	Evidence at protein level	HPA043319	Enhanced	Supported				Not detected	Tissue enriched	621	testis: 62.0	all non-specific tissues: 0.0	Not detected		
TBC1D22A	C22orf4	ENSG00000054611	TBC1 domain family member 22A	22	46762617-47175699	Predicted intracellular proteins	Evidence at protein level	HPA001173	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Liver cancer:2.42e-4 (unfavourable), Ovarian cancer:6.94e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 22.1	Expressed in all		
TBC1D22B	C6orf197, dJ744I24.2, FLJ20337	ENSG00000065491	TBC1 domain family member 22B	6	37257772-37332970	Predicted intracellular proteins	Evidence at protein level	HPA027908, HPA027909, HPA027910	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Endometrial cancer:8.15e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 18.8	Expressed in all		
TBC1D24	DFNA65, DFNB86, KIAA1171, TLDC6	ENSG00000162065	TBC1 domain family member 24	16	2475051-2509560	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044712, HPA068080	Uncertain		Supported	Plasma membrane<br>Cell Junctions	Breast cancer:3.22e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 23.0	Expressed in all		
TBC1D25	OATL1	ENSG00000068354	TBC1 domain family member 25	X	48539457-48562609	Predicted intracellular proteins	Evidence at protein level	HPA029197	Approved	Supported				Expressed in all	Expressed in all			parathyroid gland: 12.9	Expressed in all		
TBC1D26	MGC51025	ENSG00000214946	TBC1 domain family member 26	17	15732247-15749192	Predicted intracellular proteins	Evidence at transcript level	HPA050460	Uncertain					Not detected	Tissue enriched	68	testis: 16.4	breast,cerebral cortex,lung,parathyroid gland,skin: 0.2	Cell line enhanced		U-698: 1.0
TBC1D28	FLJ40244	ENSG00000189375	TBC1 domain family member 28	17	18635006-18661950	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	70	testis: 18.1	spleen,tonsil: 0.2	Not detected		
TBC1D29	DKFZP434O047	ENSG00000266733	TBC1 domain family member 29	17	30557112-30563493	Predicted intracellular proteins	Evidence at transcript level	HPA059178	Uncertain					Not detected	Tissue enriched	11	testis: 10.6	epididymis: 0.9	Not detected		
TBC1D31	Gm85, MGC21654, WDR67	ENSG00000156787	TBC1 domain family member 31	8	123041968-123152153	Predicted intracellular proteins	Evidence at protein level	HPA023710	Approved		Approved	Centrosome	Lung cancer:2.91e-4 (unfavourable)	Mixed	Mixed			testis: 8.4	Expressed in all		
TBC1D4	AS160, DKFZp779C0666, KIAA0603	ENSG00000136111	TBC1 domain family member 4	13	75284665-75482114	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA040145, HPA059885	Approved		Supported	Cytosol	Renal cancer:1.07e-11 (favourable)	Expressed in all	Expressed in all			adrenal gland: 82.8	Cell line enhanced		CACO-2: 70.0
TBC1D8B	FLJ20298, GRAMD8B, RP11-321G1.1	ENSG00000133138	TBC1 domain family member 8B	X	106802680-106876145	Predicted intracellular proteins	Evidence at protein level	HPA023883, HPA027527	Enhanced	Supported	Approved	Cytosol		Mixed	Mixed			adrenal gland: 25.7	Mixed		
TBC1D9	GRAMD9, KIAA0882, MDR1	ENSG00000109436	TBC1 domain family member 9	4	140620765-140756120	Predicted intracellular proteins	Evidence at protein level	HPA000262, HPA006317, HPA006503	Uncertain	Supported	Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.61e-6 (favourable)	Tissue enriched	Mixed			breast: 65.6	Mixed		
TBC1D9B	GRAMD9B, KIAA0676	ENSG00000197226	TBC1 domain family member 9B	5	179862066-179907859	Predicted intracellular proteins	Evidence at protein level	HPA038350	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Plasma membrane	Thyroid cancer:3.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.3	Expressed in all		
TBCA		ENSG00000171530	Tubulin folding cofactor A	5	77691166-77868780	Predicted intracellular proteins	Evidence at protein level	HPA036487	Approved		Supported	Nucleoli<br>Microtubules		Expressed in all	Expressed in all			adrenal gland: 305.8	Expressed in all		
TBCB	CG22, CKAP1, CKAPI	ENSG00000105254	Tubulin folding cofactor B	19	36114289-36125947	Predicted intracellular proteins	Evidence at protein level	HPA041428, HPA041722	Approved		Supported	Cytosol	Liver cancer:2.09e-4 (unfavourable), Pancreatic cancer:3.11e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 249.9	Expressed in all		
TBCC	CFC	ENSG00000124659	Tubulin folding cofactor C	6	42744481-42746096	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035073, HPA035074	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			lymph node: 32.8	Expressed in all		
TBCCD1	FLJ10560	ENSG00000113838	TBCC domain containing 1	3	186546073-186570543	Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.87e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.5	Expressed in all		
TBCE	HRD, KCS, KCS1, pac2	ENSG00000116957	Tubulin folding cofactor E	1	235367360-235448968	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026552, HPA026557	Uncertain				Renal cancer:7.87e-13 (unfavourable), Head and neck cancer:7.90e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 18.3	Expressed in all		
TBCEL	LRRC35, MGC10233	ENSG00000154114	Tubulin folding cofactor E like	11	121024072-121090775	Predicted intracellular proteins	Evidence at protein level	HPA038593, HPA038594	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 35.7	Mixed		
TBCK	HSPC302, MGC16169	ENSG00000145348	TBC1 domain containing kinase	4	106041599-106321495	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039951, HPA051611	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center	Renal cancer:3.20e-4 (favourable)	Expressed in all	Mixed			testis: 16.0	Expressed in all		
TBK1	NAK	ENSG00000183735	TANK binding kinase 1	12	64451880-64502108	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA045797, HPA060211	Uncertain		Supported	Nucleoplasm	Renal cancer:4.20e-6 (unfavourable), Liver cancer:3.30e-4 (unfavourable), Melanoma:3.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.3	Expressed in all		
TBKBP1	KIAA0775, ProSAPiP2	ENSG00000198933	TBK1 binding protein 1	17	47694081-47712050	Predicted intracellular proteins	Evidence at protein level	HPA062347, HPA064856	Approved		Approved	Nucleoplasm	Pancreatic cancer:8.14e-6 (favourable), Urothelial cancer:1.59e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 32.9	Cell line enhanced		CACO-2: 52.0
TBL1X	EBI, TBL1	ENSG00000101849	Transducin beta like 1X-linked	X	9463295-9719743	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005363, HPA067703	Approved		Approved	Nucleus<br>Nucleoli	Pancreatic cancer:1.32e-4 (favourable), Renal cancer:4.58e-4 (favourable), Breast cancer:8.50e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 63.9	Mixed		
TBL1XR1	C21, DC42, FLJ12894, IRA1, TBLR1	ENSG00000177565	Transducin beta like 1 X-linked receptor 1	3	177019340-177228000	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019182	Supported		Approved	Nucleoplasm	Liver cancer:1.08e-7 (unfavourable), Renal cancer:4.25e-5 (unfavourable), Glioma:7.23e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 59.4	Expressed in all		
TBL1Y	TBL1	ENSG00000092377	Transducin beta like 1, Y-linked	Y	6910686-7091683	Predicted intracellular proteins	Evidence at protein level	HPA060073	Uncertain					Tissue enriched	Tissue enhanced		prostate: 2.6;thyroid gland: 1.4	testis: 0.5	Cell line enhanced		BEWO: 1.5;NTERA-2: 1.3;RT4: 1.2;SCLC-21H: 1.1;U-698: 6.6
TBL3	SAZD, UTP13	ENSG00000183751	Transducin beta like 3	16	1972037-1982933	Predicted intracellular proteins	Evidence at protein level	HPA042562, HPA055695	Enhanced	Supported	Enhanced	Nucleoli	Renal cancer:7.33e-4 (favourable)	Expressed in all	Mixed			testis: 5.6	Expressed in all		
TBP	GTF2D1, SCA17, TFIID	ENSG00000112592	TATA-box binding protein	6	170554302-170572870	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009442, HPA049805	Approved		Supported	Nucleoplasm	Liver cancer:1.51e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 61.8	Expressed in all		
TBPL1	STUD, TLF, TLP, TRF2	ENSG00000028839	TATA-box binding protein like 1	6	133952170-133990432	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071810, HPA071813	Enhanced		Enhanced	Nucleoplasm<br>Nucleoli	Liver cancer:7.91e-5 (unfavourable), Renal cancer:4.14e-4 (unfavourable), Glioma:4.67e-4 (favourable), Pancreatic cancer:7.23e-4 (favourable)	Expressed in all	Tissue enriched	8	testis: 227.4	thyroid gland: 28.2	Expressed in all		
TBPL2	TBP2, TRF3	ENSG00000182521	TATA-box binding protein like 2	14	55413541-55456726	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA056241	Uncertain					Tissue enriched	Mixed			skin: 2.0	Cell line enhanced		HDLM-2: 5.4;U-2 OS: 3.1;U-937: 3.1
TBR1		ENSG00000136535	T-box, brain 1	2	161416094-161425870	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051256, HPA078644, HPA078657	Enhanced	Approved				Not detected	Tissue enriched	30	cerebral cortex: 30.6	testis: 1.0	Not detected		
TBRG1	FLJ14621, NIAM, TB-5	ENSG00000154144	Transforming growth factor beta regulator 1	11	124622836-124635398	Predicted intracellular proteins	Evidence at protein level	HPA055645, HPA068022			Enhanced	Nucleus		Expressed in all	Expressed in all			spleen: 16.0	Expressed in all		
TBRG4	Cpr2, FASTKD4, H_TD2522F11.8, KIAA0948	ENSG00000136270	Transforming growth factor beta regulator 4	7	45100100-45112047	Predicted intracellular proteins	Evidence at protein level	HPA020582, HPA050430	Approved		Enhanced	Mitochondria	Liver cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.8	Expressed in all		
TBX1	CATCH22, VCF	ENSG00000184058	T-box 1	22	19756703-19783593	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029330			Approved	Nuclear bodies<br>Cytoplasmic bodies	Urothelial cancer:8.90e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 23.0	testis: 10.5	Cell line enhanced		K-562: 107.3;TIME: 35.1
TBX15	TBX14	ENSG00000092607	T-box 15	1	118883046-118989556	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052245, HPA053713	Uncertain		Approved	Nucleoplasm<br>Centrosome	Renal cancer:5.57e-8 (unfavourable)	Mixed	Group enriched	7	adipose tissue: 17.0;breast: 8.9;liver: 24.1;skeletal muscle: 42.2	lymph node: 3.1	Cell line enhanced		ASC diff: 36.8;BJ hTERT+ SV40 Large T+ RasG12V: 20.9;fHDF/TERT166: 22.5;HSkMC: 28.3;RH-30: 29.4;U-2197: 26.3
TBX18		ENSG00000112837	T-box 18	6	84687351-84764519	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Mixed			adipose tissue: 6.1	Cell line enhanced		A549: 52.2
TBX19	dj747L4.1, TPIT	ENSG00000143178	T-box 19	1	168281040-168314426	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005800, HPA072686	Supported		Approved	Nuclear speckles	Renal cancer:4.55e-9 (unfavourable)	Expressed in all	Mixed			endometrium: 5.4	Cell line enhanced		HaCaT: 4.8
TBX2		ENSG00000121068	T-box 2	17	61399896-61409466	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008586, CAB013636	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		lung: 50.0	seminal vesicle: 40.0	Cell line enhanced		AN3-CA: 124.2;MCF7: 62.0;SH-SY5Y: 65.7;WM-115: 44.0
TBX20		ENSG00000164532	T-box 20	7	35202430-35254147	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enhanced		adrenal gland: 5.6;heart muscle: 22.2	placenta: 5.0	Cell line enhanced		SH-SY5Y: 7.5;WM-115: 4.2
TBX21	T-bet, TBLYM	ENSG00000073861	T-box 21	17	47733244-47746119	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009524, CAB030043	Enhanced					Mixed	Tissue enhanced		lymph node: 8.5;spleen: 11.1	bone marrow: 6.4	Cell line enriched	152	HDLM-2: 15.1
TBX22	CLPA, CPX	ENSG00000122145	T-box 22	X	80014756-80031769	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Group enriched	19	testis: 10.4;thyroid gland: 3.5	seminal vesicle: 0.3	Cell line enriched	6	HDLM-2: 1.6
TBX3	TBX3-ISO, UMS, XHL	ENSG00000135111	T-box 3	12	114670254-114684164	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005799			Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:3.28e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 200.0	prostate: 119.8	Cell line enhanced		BJ: 87.5;BJ hTERT+: 80.2;RT4: 103.3
TBX4		ENSG00000121075	T-box 4	17	61452404-61485110	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB032413, HPA044457	Uncertain		Approved	Vesicles		Mixed	Group enriched	6	lung: 43.6;placenta: 29.8;prostate: 14.9	urinary bladder: 4.8	Cell line enhanced		BJ: 2.4;THP-1: 3.9
TBX5	HOS	ENSG00000089225	T-box 5	12	114353931-114408442	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008786, HPA064683	Uncertain		Approved	Nucleoplasm		Mixed	Group enriched	6	heart muscle: 40.0;lung: 18.0;placenta: 46.8	prostate: 6.2	Cell line enhanced		BJ: 17.0;BJ hTERT+: 36.2;BJ hTERT+ SV40 Large T+: 9.5;BJ hTERT+ SV40 Large T+ RasG12V: 12.1;HAP1: 18.0
TBX6		ENSG00000149922	T-box 6	16	30085793-30091887	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062498			Approved	Nucleus		Mixed	Mixed			stomach: 4.4	Cell line enhanced		RT4: 5.5;U-266/70: 5.4
TC2N	C14orf47, C2CD1, FLJ36557, MTAC2D1, Tac2-N	ENSG00000165929	Tandem C2 domains, nuclear	14	91779751-91867536	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027549	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:4.13e-5 (favourable), Pancreatic cancer:9.86e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 40.3	Cell line enhanced		CAPAN-2: 16.8;RT4: 29.2;SK-BR-3: 32.5;T-47d: 20.0
TCAF1	FAM115A, KIAA0738	ENSG00000198420	TRPM8 channel associated factor 1	7	143851375-143902198	Predicted intracellular proteins	Evidence at protein level	HPA011732	Approved				Ovarian cancer:5.93e-4 (favourable)	Expressed in all	Expressed in all			placenta: 115.9	Mixed		
TCAF2	FAM115C, FAM139A, FLJ40722	ENSG00000170379	TRPM8 channel associated factor 2	7	143620950-143730409	Predicted intracellular proteins	Evidence at protein level	HPA038756, HPA038758	Uncertain		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:4.17e-6 (unfavourable), Glioma:6.78e-5 (unfavourable)	Mixed	Mixed			placenta: 8.1	Cell line enhanced		HDLM-2: 11.0;TIME: 15.8;U-87 MG: 14.1
TCAIM	C3orf23, DKFZp313N0621, TOAG-1	ENSG00000179152	T-cell activation inhibitor, mitochondrial	3	44338119-44409451	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:2.19e-7 (favourable), Urothelial cancer:2.81e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
TCAP	CMD1N, LGMD2G, T-cap, TELE, telethonin	ENSG00000173991	Titin-cap	17	39664187-39666555	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004591, HPA026477	Enhanced				Urothelial cancer:4.55e-4 (favourable)	Group enriched	Group enriched	18	heart muscle: 2132.6;skeletal muscle: 4963.5	esophagus: 195.0	Cell line enhanced		SK-BR-3: 5.6
TCEA1	GTF2S, SII, TCEA, TF2S, TFIIS	ENSG00000187735	Transcription elongation factor A1	8	53966552-54022529	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043786	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:3.75e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 199.9	Expressed in all		
TCEA2	TFIIS	ENSG00000171703	Transcription elongation factor A2	20	64049836-64072347	Predicted intracellular proteins	Evidence at protein level	HPA043836	Approved		Supported	Nucleoplasm<br>Centrosome		Expressed in all	Expressed in all			cerebral cortex: 73.8	Expressed in all		
TCEA3	TFIIS.H	ENSG00000204219	Transcription elongation factor A3	1	23381061-23424740	Predicted intracellular proteins	Evidence at protein level	HPA044960, HPA055811	Approved		Approved	Nucleoplasm<br>Vesicles	Head and neck cancer:2.56e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 157.4	ovary: 62.8	Cell line enhanced		Hep G2: 43.0;SiHa: 21.8;T-47d: 30.3
TCEAL1	p21, pp21, SIIR, WEX9	ENSG00000172465	Transcription elongation factor A like 1	X	103628704-103630953	Predicted intracellular proteins	Evidence at protein level	HPA057345, HPA060384			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 146.5	Mixed		
TCEAL2	my048, MY0876G05, WEX1	ENSG00000184905	Transcription elongation factor A like 2	X	102125688-102127711	Predicted intracellular proteins	Evidence at protein level	HPA076317			Approved	Nuclear speckles<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 191.7	ovary: 77.7	Cell line enhanced		HAP1: 6.0;SCLC-21H: 7.3;U-2 OS: 11.7
TCEAL3	MGC15737, WEX8	ENSG00000196507	Transcription elongation factor A like 3	X	103607451-103629690	Predicted intracellular proteins	Evidence at protein level	HPA045564, HPA058982	Uncertain				Lung cancer:4.05e-4 (favourable), Ovarian cancer:8.33e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 97.9	Mixed		
TCEAL4	FLJ21174, WEX7	ENSG00000133142	Transcription elongation factor A like 4	X	103576231-103587736	Predicted intracellular proteins	Evidence at protein level						Head and neck cancer:3.11e-5 (unfavourable), Lung cancer:2.75e-4 (favourable)	Expressed in all	Expressed in all			ovary: 555.7	Mixed		
TCEAL5	WEX4	ENSG00000204065	Transcription elongation factor A like 5	X	103273691-103276872	Predicted intracellular proteins	Evidence at protein level	HPA045564, HPA058982, HPA072199	Supported		Uncertain	Nucleoplasm<br>Cytosol	Pancreatic cancer:8.60e-4 (favourable), Endometrial cancer:9.09e-4 (unfavourable)	Tissue enhanced	Group enriched	7	cerebral cortex: 82.5;testis: 82.5	adrenal gland: 11.9	Group enriched	7	SCLC-21H: 9.3;SH-SY5Y: 25.9
TCEAL6	WEX2	ENSG00000204071	Transcription elongation factor A like 6	X	102140476-102142970	Predicted intracellular proteins	Evidence at protein level	HPA045564, HPA058982	Supported					Tissue enriched	Group enriched	6	adrenal gland: 14.3;cerebral cortex: 63.5;testis: 34.6	endometrium: 5.8	Not detected		
TCEAL7	MGC23947, WEX5	ENSG00000182916	Transcription elongation factor A like 7	X	103330196-103332326	Predicted intracellular proteins	Evidence at protein level	HPA051507, HPA065080	Enhanced		Supported	Nucleus	Stomach cancer:3.53e-4 (unfavourable), Renal cancer:4.31e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 145.6	endometrium: 76.7	Cell line enhanced		hTEC/SVTERT24-B: 81.8;SCLC-21H: 242.8
TCEAL8	MGC45400, WEX3	ENSG00000180964	Transcription elongation factor A like 8	X	103252995-103255203	Predicted intracellular proteins	Evidence at protein level	HPA059115	Uncertain		Approved	Nucleoplasm	Head and neck cancer:8.53e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 149.7	Mixed		
TCEAL9	DKFZp313K1940, WBP5, WEX6	ENSG00000185222	Transcription elongation factor A like 9	X	103356452-103358451	Predicted intracellular proteins	Evidence at protein level	HPA011790	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			placenta: 275.0	Mixed		
TCEANC	MGC17403	ENSG00000176896	Transcription elongation factor A N-terminal and central domain containing	X	13653189-13681964	Predicted intracellular proteins	Evidence at protein level	HPA001013	Uncertain					Mixed	Mixed			epididymis: 3.6	Mixed		
TCERG1	CA150, TAF2S, Urn1	ENSG00000113649	Transcription elongation regulator 1	5	146447311-146511961	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064854, HPA069752, HPA069808	Enhanced		Enhanced	Nucleoplasm	Renal cancer:4.70e-11 (unfavourable), Liver cancer:5.34e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 20.7	Expressed in all		
TCERG1L	FLJ38950	ENSG00000176769	Transcription elongation regulator 1 like	10	131092391-131311721	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	6	thyroid gland: 25.1	cerebral cortex: 4.1	Cell line enhanced		BEWO: 4.1;U-2 OS: 1.1
TCF15	bHLHa40, EC2, PARAXIS	ENSG00000125878	Transcription factor 15 (basic helix-loop-helix)	20	603797-610398	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050998, HPA060221	Uncertain		Supported	Nuclear speckles	Ovarian cancer:3.25e-4 (unfavourable)	Mixed	Group enriched	5	adipose tissue: 6.3;heart muscle: 3.4;placenta: 4.8;skeletal muscle: 4.6;testis: 1.3	lung: 0.7	Cell line enhanced		HEL: 9.5;HMC-1: 14.7
TCF19	SC1	ENSG00000137310	Transcription factor 19	6	31158542-31167159	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.54e-10 (unfavourable), Liver cancer:5.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 11.3	skin: 6.7	Cell line enhanced		A-431: 72.1;HEK93: 41.2;SCLC-21H: 57.4;U-138 MG: 47.7
TCF20	AR1, SPBP	ENSG00000100207	Transcription factor 20	22	42160013-42343616	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017849, HPA036786	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Colorectal cancer:1.88e-4 (favourable), Liver cancer:4.89e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 3.7	Mixed		
TCF21	bHLHa23, POD1	ENSG00000118526	Transcription factor 21	6	133889138-133895553	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA013189	Uncertain					Mixed	Tissue enhanced		placenta: 62.4;spleen: 46.9	ovary: 32.1	Cell line enriched	10	HHSteC: 13.5
TCF23	bHLHa24, OUT	ENSG00000163792	Transcription factor 23	2	27149004-27156974	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		endometrium: 33.8;ovary: 22.7;smooth muscle: 30.8	fallopian tube: 13.9	Cell line enriched	7	THP-1: 2.3
TCF24	bHLHa25	ENSG00000261787	Transcription factor 24	8	66946501-66962590	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		kidney: 1.2;testis: 2.8	fallopian tube: 0.7	Cell line enhanced		HAP1: 2.2;HEK93: 5.0;HMC-1: 4.1
TCF25	KIAA1049, Nulp1	ENSG00000141002	Transcription factor 25	16	89873570-89913627	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041699, HPA041786	Enhanced				Endometrial cancer:6.95e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 123.7	Expressed in all		
TCF3	bHLHb21, E2A, E47, ITF1, MGC129647, MGC129648, VDIR	ENSG00000071564	Transcription factor 3	19	1609290-1652605	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB018351, HPA049808, HPA062476	Approved		Enhanced	Nucleoplasm	Renal cancer:1.53e-4 (unfavourable), Liver cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 103.3	Expressed in all		
TCF4	bHLHb19, E2-2, ITF2, SEF2-1B	ENSG00000196628	Transcription factor 4	18	55222331-55664787	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB020722, HPA025958	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:7.24e-5 (unfavourable), Urothelial cancer:9.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex,cervix, uterine: 44.9	Cell line enhanced		HDLM-2: 128.1;SH-SY5Y: 177.9
TCF7	TCF-1	ENSG00000081059	Transcription factor 7 (T-cell specific, HMG-box)	5	134114711-134151865	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019403, HPA058863, HPA070505	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Tissue enhanced		lymph node: 110.1	appendix: 71.7	Cell line enriched	13	MOLT-4: 1060.4
TCF7L1	TCF3	ENSG00000152284	Transcription factor 7 like 1	2	85133410-85310388	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071298			Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.16e-5 (unfavourable), Endometrial cancer:1.70e-4 (unfavourable), Renal cancer:2.06e-4 (unfavourable), Stomach cancer:2.72e-4 (unfavourable), Urothelial cancer:5.38e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue,endometrium,thyroid gland: 22.5	Cell line enhanced		NTERA-2: 99.6;RH-30: 43.7;T-47d: 41.9
TCF7L2	TCF-4, TCF4	ENSG00000148737	Transcription factor 7 like 2	10	112950250-113167678	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB013535, HPA038800	Supported	Approved	Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			endometrium: 30.9	Mixed		
TCFL5	bHLHe82, CHA, E2BP-1, Figlb	ENSG00000101190	Transcription factor like 5	20	62841115-62861763	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055223	Approved		Supported	Nucleoplasm	Endometrial cancer:3.24e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 144.4	Expressed in all		
TCHH	THH	ENSG00000159450	Trichohyalin	1	152106317-152115454	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028375	Uncertain					Tissue enhanced	Tissue enhanced		placenta: 1.6;spleen: 2.1	testis: 1.2	Cell line enhanced		HaCaT: 3.2;SCLC-21H: 1.3;THP-1: 1.3
TCHHL1	S100A17, THHL1	ENSG00000182898	Trichohyalin like 1	1	152084144-152089064	Predicted intracellular proteins	Evidence at protein level	HPA042579, HPA063483	Enhanced		Approved	Nuclear membrane<br>Nucleoli		Not detected	Not detected			epididymis: 0.1	Cell line enriched	37	SK-BR-3: 3.7
TCHP	MGC10854, TpMs	ENSG00000139437	Trichoplein keratin filament binding	12	109900264-109983841	Predicted intracellular proteins	Evidence at protein level	HPA038638, HPA061543	Supported		Supported	Plasma membrane<br>Centrosome<br>Cytosol	Stomach cancer:5.52e-4 (favourable)	Expressed in all	Expressed in all			skin: 32.6	Expressed in all		
TCL1A	TCL1	ENSG00000100721	T-cell leukemia/lymphoma 1A	14	95709967-95714196	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004045, HPA016604	Enhanced					Tissue enriched	Tissue enhanced		lymph node: 324.7;tonsil: 196.7	spleen: 77.8	Group enriched	147	Daudi: 334.2;REH: 557.7;U-698: 425.7
TCL1B	TML1	ENSG00000213231	T-cell leukemia/lymphoma 1B	14	95686417-95692643	Predicted intracellular proteins	Evidence at protein level	HPA053163	Uncertain		Approved	Cytosol		Tissue enriched	Tissue enhanced		lymph node: 2.4;testis: 3.6;tonsil: 2.2	placenta: 1.2	Cell line enriched	5	U-698: 337.9
TCOF1	TCS, treacle	ENSG00000070814	Treacle ribosome biogenesis factor 1	5	150357639-150400308	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033199, HPA038237, HPA038238	Enhanced		Enhanced	Nucleoli fibrillar center	Liver cancer:2.26e-8 (unfavourable), Renal cancer:2.62e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 22.0	Expressed in all		
TCP1	CCT1, Ccta, D6S230E	ENSG00000120438	T-complex 1	6	159778498-159789749	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017460, HPA027337, HPA031082	Approved				Liver cancer:1.49e-5 (unfavourable), Breast cancer:8.88e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 325.2	Expressed in all		
TCP10		ENSG00000203690	T-complex 10	6	167357031-167384510	Predicted intracellular proteins	Evidence at transcript level	HPA044709	Approved					Not detected	Tissue enriched	14	testis: 14.1	small intestine: 0.9	Not detected		
TCP10L	PRED77	ENSG00000242220	T-complex 10-like	21	32574841-32587373	Predicted intracellular proteins	Evidence at protein level	HPA044709	Approved					Tissue enhanced	Tissue enriched	27	testis: 285.4	liver: 10.7	Cell line enriched	7	SCLC-21H: 14.6
TCP10L2	bA517H2.3	ENSG00000166984	T-complex 10-like 2	6	167146414-167196913	Predicted intracellular proteins	Evidence at transcript level	CAB034197, HPA044709	Uncertain					Not detected	Tissue enhanced		epididymis: 1.6;testis: 1.5	small intestine: 0.3	Not detected		
TCP11	D6S230E, FPPR, KIAA0229	ENSG00000124678	T-complex 11	6	35118071-35148610	Predicted intracellular proteins	Evidence at protein level	HPA048311	Supported				Cervical cancer:5.02e-4 (favourable)	Tissue enhanced	Tissue enriched	356	testis: 562.3	fallopian tube: 1.5	Cell line enhanced		hTEC/SVTERT24-B: 1.6;WM-115: 2.0
TCP11L1	FLJ11336	ENSG00000176148	T-complex 11 like 1	11	33039417-33105943	Predicted intracellular proteins	Evidence at protein level	HPA005769	Approved		Approved	Cytosol	Renal cancer:1.39e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 20.9	Expressed in all		
TCP11L2	MGC40368	ENSG00000166046	T-complex 11 like 2	12	106301929-106347015	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039483, HPA042188	Uncertain		Supported	Nuclear speckles	Head and neck cancer:9.52e-4 (favourable)	Mixed	Expressed in all			lung: 25.9	Mixed		
TCP11X2		ENSG00000215029	T-complex 11 family, X-linked 2	X	102374628-102471812	Predicted intracellular proteins	Evidence at protein level	HPA048311	Supported					Not detected	Tissue enhanced		testis: 1.5	fallopian tube: 0.9	Cell line enriched	6	SCLC-21H: 1.2
TCTE1	D6S46, DRC5, FAP155, MGC33600	ENSG00000146221	T-complex-associated-testis-expressed 1	6	44278743-44297688	Predicted intracellular proteins	Evidence at transcript level	HPA031739			Uncertain	Vesicles		Tissue enhanced	Group enriched	13	fallopian tube: 23.1;testis: 35.3	lung: 2.2	Cell line enhanced		SCLC-21H: 1.0
TCTE3	TCTEX1D3	ENSG00000184786	T-complex-associated-testis-expressed 3	6	169740114-169751587	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	173	testis: 17.2	all non-specific tissues: 0.0	Not detected		
TCTEX1D1	FLJ40873	ENSG00000152760	Tctex1 domain containing 1	1	66752459-66778787	Predicted intracellular proteins	Evidence at protein level	HPA028420	Uncertain					Tissue enriched	Tissue enhanced		fallopian tube: 16.6;placenta: 9.6	liver: 4.0	Group enriched	6	HEL: 14.3;HUVEC TERT2: 13.0;THP-1: 12.0
TCTEX1D2	MGC33212	ENSG00000213123	Tctex1 domain containing 2	3	196291219-196318299	Predicted intracellular proteins	Evidence at protein level	HPA049555			Approved	Cytosol	Renal cancer:6.23e-4 (unfavourable), Cervical cancer:7.83e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 49.2	testis: 39.1	Mixed		
TCTEX1D4		ENSG00000188396	Tctex1 domain containing 4	1	44805913-44806675	Predicted intracellular proteins	Evidence at protein level	HPA062652	Enhanced				Endometrial cancer:1.58e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 5.9	epididymis: 1.7	Not detected		
TDG		ENSG00000139372	Thymine DNA glycosylase	12	103965804-103988874	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA052263	Supported		Supported	Nucleoplasm	Renal cancer:1.90e-10 (unfavourable), Liver cancer:6.27e-5 (unfavourable), Melanoma:6.90e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 23.8	Expressed in all		
TDGF1	CR, CRIPTO, Cripto-1	ENSG00000241186	Teratocarcinoma-derived growth factor 1	3	46574534-46582463	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		spleen: 24.8	kidney: 8.1	Group enriched	30	HEL: 19.6;NTERA-2: 95.4
TDO2	TDO, TPH2	ENSG00000151790	Tryptophan 2,3-dioxygenase	4	155854738-155920406	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039611	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	18	liver: 278.3	appendix: 15.7	Group enriched	5	EFO-21: 7.3;HDLM-2: 14.7;U-87 MG: 8.6
TDP1	FLJ11090, SCAN1	ENSG00000042088	Tyrosyl-DNA phosphodiesterase 1	14	89954939-90044768	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA071317			Supported	Nucleus<br>Plasma membrane	Liver cancer:8.99e-5 (unfavourable)	Expressed in all	Mixed			testis: 40.6	Expressed in all		
TDRD1	CT41.1	ENSG00000095627	Tudor domain containing 1	10	114179270-114232304	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037729	Enhanced					Tissue enhanced	Tissue enriched	13	testis: 32.0	kidney: 2.3	Cell line enhanced		MCF7: 6.3;RH-30: 10.6;SK-BR-3: 38.6;U-266/84: 8.6
TDRD10	DKFZp434M202	ENSG00000163239	Tudor domain containing 10	1	154502219-154548147	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA054327			Approved	Vesicles	Thyroid cancer:8.04e-5 (favourable)	Tissue enhanced	Tissue enriched	12	testis: 77.3	lung: 6.3	Cell line enhanced		HUVEC TERT2: 2.5;TIME: 1.3
TDRD12	ECAT8, FLJ13072	ENSG00000173809	Tudor domain containing 12	19	32719753-32829580	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Group enriched	8	epididymis: 10.9;testis: 33.5	ovary: 2.6	Group enriched	34	HDLM-2: 23.6;NTERA-2: 93.5
TDRD15		ENSG00000218819	Tudor domain containing 15	2	21123917-21143272	Predicted intracellular proteins	Evidence at transcript level	HPA051770, HPA054675	Uncertain					Not detected	Tissue enriched	77	testis: 10.0	liver: 0.1	Cell line enhanced		U-266/70: 5.9;U-266/84: 2.1
TDRD3	FLJ21007	ENSG00000083544	Tudor domain containing 3	13	60396457-60573878	Predicted intracellular proteins	Evidence at protein level	CAB034925, HPA067153	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Endometrial cancer:2.77e-4 (favourable)	Expressed in all	Expressed in all			testis: 22.8	Expressed in all		
TDRD5	FLJ34823, TUDOR3	ENSG00000162782	Tudor domain containing 5	1	179591613-179691272	Predicted intracellular proteins	Evidence at protein level	HPA029418	Enhanced					Mixed	Tissue enriched	5	testis: 42.6	epididymis: 8.0	Cell line enhanced		SK-BR-3: 4.4;T-47d: 9.6;U-266/70: 10.9;U-266/84: 9.0
TDRD6	bA446F17.4, CT41.2, NY-CO-45, SPATA36	ENSG00000180113	Tudor domain containing 6	6	46687875-46704319	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	6	testis: 42.8;thyroid gland: 10.1	appendix,lymph node: 4.7	Not detected		
TDRD7	PCTAIRE2BP	ENSG00000196116	Tudor domain containing 7	9	97411950-97496125	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB020800, HPA022250, HPA024529	Approved		Supported	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:4.76e-5 (favourable), Liver cancer:5.91e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 64.1	Cell line enhanced		HDLM-2: 49.4
TDRD9	C14orf75, DKFZp434N0820, FLJ36164, NET54	ENSG00000156414	Tudor domain containing 9	14	103928462-104052667	Enzymes, Predicted intracellular proteins	Evidence at protein level						Thyroid cancer:5.52e-4 (unfavourable)	Mixed	Group enriched	6	parathyroid gland: 39.7;testis: 75.0	thyroid gland: 9.1	Cell line enhanced		HDLM-2: 22.6;HeLa: 13.9;HMC-1: 82.8;RPTEC TERT1: 19.5
TDRP	C8orf42, INM01, TDRP1, TDRP2	ENSG00000180190	Testis development related protein	8	489792-545781	Predicted intracellular proteins	Evidence at protein level	HPA008462	Approved		Supported	Vesicles<br>Cytosol	Endometrial cancer:1.52e-4 (unfavourable), Pancreatic cancer:9.37e-4 (favourable)	Expressed in all	Mixed			placenta: 46.8	Cell line enhanced		BEWO: 48.4
TEAD1	AA, TCF13, TEF-1	ENSG00000187079	TEA domain transcription factor 1	11	12674591-12944483	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057339, HPA062471			Enhanced	Nucleoplasm		Expressed in all	Mixed			parathyroid gland: 88.3	Mixed		
TEAD2	ETF, TEF-4, TEF4	ENSG00000074219	TEA domain transcription factor 2	19	49340595-49362457	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066292, HPA069963			Enhanced	Nucleoplasm	Liver cancer:8.66e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 58.9	Cell line enhanced		AF22: 134.1;AN3-CA: 137.1
TEAD3	ETFR-1, TEAD5, TEF-5	ENSG00000007866	TEA domain transcription factor 3	6	35473597-35497076	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028906	Uncertain				Renal cancer:1.01e-7 (unfavourable), Endometrial cancer:5.09e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 80.5	Cell line enhanced		BEWO: 114.2
TEAD4	EFTR-2, RTEF-1, TCF13L1, TEF-3, TEFR-1	ENSG00000197905	TEA domain transcription factor 4	12	2959330-3040673	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056896	Uncertain		Supported	Nucleoplasm	Renal cancer:9.78e-9 (unfavourable)	Tissue enriched	Tissue enhanced		skeletal muscle: 38.8	thyroid gland: 17.8	Cell line enhanced		HBEC3-KT: 263.0
TEC	PSCTK4	ENSG00000135605	Tec protein tyrosine kinase	4	48135783-48269864	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005733, HPA024657	Approved		Supported	Plasma membrane	Ovarian cancer:7.12e-4 (favourable)	Mixed	Mixed			epididymis: 5.0	Cell line enhanced		HEL: 11.8;HMC-1: 17.4;U-266/70: 15.1;U-266/84: 10.6
TECPR1	DKFZP434B0335, FLJ23419, FLJ90593, KIAA1358	ENSG00000205356	Tectonin beta-propeller repeat containing 1	7	98214624-98252251	Predicted intracellular proteins	Evidence at protein level	HPA021061	Approved		Supported	Vesicles	Pancreatic cancer:8.12e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.1	Expressed in all		
TECPR2	KIAA0329	ENSG00000196663	Tectonin beta-propeller repeat containing 2	14	102362963-102502481	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000658	Enhanced		Approved	Nucleus	Renal cancer:6.53e-9 (favourable), Liver cancer:5.66e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.4	Mixed		
TEF	KIAA1655	ENSG00000167074	TEF, PAR bZIP transcription factor	22	41367333-41399326	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:3.47e-11 (favourable)	Expressed in all	Mixed			parathyroid gland: 58.6	Expressed in all		
TEFM	C17orf42, FLJ22729	ENSG00000172171	Transcription elongation factor, mitochondrial	17	30897336-30906820	Predicted intracellular proteins	Evidence at protein level	HPA023788, HPA053044	Approved		Enhanced	Mitochondria	Melanoma:8.64e-4 (unfavourable), Liver cancer:9.20e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 5.6	Expressed in all		
TEKT1		ENSG00000167858	Tektin 1	17	6789133-6831761	Predicted intracellular proteins	Evidence at protein level	HPA044444, HPA062285	Approved				Endometrial cancer:6.08e-4 (favourable)	Group enriched	Group enriched	7	fallopian tube: 79.5;testis: 16.7	lung: 6.9	Not detected		
TEKT2	TEKTB1	ENSG00000092850	Tektin 2	1	36084075-36088275	Predicted intracellular proteins	Evidence at protein level	HPA027248, HPA027461	Approved		Uncertain	Microtubules	Renal cancer:1.98e-4 (favourable)	Tissue enhanced	Group enriched	9	fallopian tube: 97.8;testis: 63.3	lung: 8.8	Cell line enriched	5	NB-4: 23.2
TEKT3	FLJ32828	ENSG00000125409	Tektin 3	17	15303811-15341641	Predicted intracellular proteins	Evidence at protein level	HPA044354	Uncertain					Mixed	Tissue enriched	6	testis: 46.1	fallopian tube: 7.5	Cell line enhanced		HMC-1: 1.3
TEKT4	MGC27019	ENSG00000163060	Tektin 4	2	94871433-94876829	Predicted intracellular proteins	Evidence at protein level	HPA048600, HPA053929	Uncertain		Uncertain	Intermediate filaments	Endometrial cancer:1.29e-4 (favourable)	Tissue enriched	Group enriched	15	fallopian tube: 4.2;testis: 5.2	lung: 0.3	Not detected		
TEKT5	CT149, FLJ32871	ENSG00000153060	Tektin 5	16	10627501-10694945	Predicted intracellular proteins	Evidence at protein level	HPA043578			Supported	Actin filaments		Mixed	Tissue enriched	48	testis: 45.6	stomach: 0.9	Cell line enriched	16	BEWO: 12.0
TEN1	C17orf106, FLJ39785	ENSG00000257949	TEN1, CST complex subunit	17	75979220-76000586	Predicted intracellular proteins	Evidence at protein level							Not detected	Expressed in all			skin: 29.9	Expressed in all		
TEN1-CDK3		ENSG00000261408	TEN1-CDK3 readthrough (NMD candidate)	17	75979231-76005999	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		small intestine: 1.4	adipose tissue,spleen: 1.1	Cell line enhanced		BEWO: 2.6;SH-SY5Y: 3.9
TEP1	p240, TLP1, TP1, TROVE1, VAULT2	ENSG00000129566	Telomerase associated protein 1	14	20365667-20413429	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029206			Supported	Nucleoplasm<br>Vesicles	Endometrial cancer:9.58e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 46.9	Expressed in all		
TEPSIN	C17orf56, ENTHD2, FLJ31528	ENSG00000167302	TEPSIN, adaptor related protein complex 4 accessory protein	17	81228277-81239091	Predicted intracellular proteins	Evidence at protein level	HPA063410			Supported	Nuclear membrane<br>Nuclear speckles<br>Golgi apparatus	Renal cancer:7.31e-8 (unfavourable), Pancreatic cancer:6.95e-4 (favourable), Head and neck cancer:9.96e-4 (favourable)	Expressed in all	Expressed in all			spleen: 15.8	Expressed in all		
TERB1	CCDC79, FLJ35894	ENSG00000249961	Telomere repeat binding bouquet formation protein 1	16	66754976-66801620	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	22	testis: 25.0	bone marrow: 1.1	Not detected		
TERB2	C15orf43, MGC33951	ENSG00000167014	Telomere repeat binding bouquet formation protein 2	15	44956702-44979229	Predicted intracellular proteins	Evidence at protein level	HPA041780, HPA041941			Uncertain	Nucleus<br>Nucleoli<br>Centrosome		Not detected	Tissue enriched	25	testis: 40.1	breast: 1.6	Not detected		
TERF1	PIN2, TRBF1, TRF, TRF1	ENSG00000147601	Telomeric repeat binding factor 1	8	73008864-73048122	Predicted intracellular proteins	Evidence at protein level	HPA048379			Supported	Nucleoli fibrillar center<br>Nuclear bodies	Renal cancer:6.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 45.8	Expressed in all		
TERF2	TRBF2, TRF2	ENSG00000132604	Telomeric repeat binding factor 2	16	69355561-69408571	Predicted intracellular proteins	Evidence at protein level	HPA001907, HPA002735, CAB010451	Enhanced		Supported	Nuclear bodies		Expressed in all	Expressed in all			lymph node: 42.2	Expressed in all		
TERF2IP	RAP1	ENSG00000166848	TERF2 interacting protein	16	75647786-75761872	Predicted intracellular proteins	Evidence at protein level	HPA006719, CAB018660, CAB018749	Supported		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.15e-5 (favourable), Ovarian cancer:6.14e-5 (favourable), Pancreatic cancer:1.46e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 221.2	Expressed in all		
TES	DKFZP586B2022, TESS-2, TESTIN	ENSG00000135269	Testin LIM domain protein	7	116210493-116258783	Predicted intracellular proteins	Evidence at protein level	HPA015269, HPA018123	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Focal adhesion sites<br>Cytosol	Pancreatic cancer:1.20e-5 (unfavourable), Renal cancer:8.71e-5 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 271.7	Cell line enhanced		EFO-21: 215.5
TESC	CHP3, FLJ20607, TSC	ENSG00000088992	Tescalcin	12	117038923-117099479	Predicted intracellular proteins	Evidence at protein level	HPA053200	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Tissue enhanced		epididymis: 135.9;salivary gland: 131.3;stomach: 118.8	bone marrow: 67.0	Cell line enhanced		HMC-1: 320.8;NB-4: 389.7;U-937: 158.6
TESK1		ENSG00000107140	Testis-specific kinase 1	9	35605305-35610041	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:9.68e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
TESK2		ENSG00000070759	Testis-specific kinase 2	1	45343883-45491166	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027257, HPA063869	Uncertain		Enhanced	Nucleoplasm	Cervical cancer:2.22e-4 (favourable)	Expressed in all	Mixed			prostate: 25.0	Mixed		
TESMIN	CXCDC2, MTL5	ENSG00000132749	Testis expressed metallothionein like protein	11	68707440-68751564	Predicted intracellular proteins	Evidence at protein level	HPA018539			Supported	Nucleoplasm	Endometrial cancer:1.75e-5 (unfavourable)	Mixed	Tissue enriched	17	testis: 95.3	breast: 5.5	Cell line enhanced		T-47d: 22.3
TESPA1	KIAA0748	ENSG00000135426	Thymocyte expressed, positive selection associated 1	12	54948018-54984746	Predicted intracellular proteins	Evidence at protein level	HPA058823	Approved					Mixed	Tissue enhanced		lymph node: 46.7	cerebral cortex: 34.7	Group enriched	6	HEL: 238.5;HMC-1: 184.2
TET1	bA119F7.1, CXXC6, KIAA1676, LCX	ENSG00000138336	Tet methylcytosine dioxygenase 1	10	68560656-68694482	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019032, HPA057273			Supported	Nucleus<br>Nuclear membrane		Tissue enriched	Mixed			parathyroid gland: 2.4	Cell line enhanced		BEWO: 17.6;HAP1: 21.7;K-562: 11.0;NTERA-2: 12.2
TET2	FLJ20032, KIAA1546	ENSG00000168769	Tet methylcytosine dioxygenase 2	4	105145875-105279816	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043135	Supported		Approved	Nucleoplasm		Mixed	Mixed			bone marrow: 15.7	Mixed		
TET3	hCG_40738, MGC22014	ENSG00000187605	Tet methylcytosine dioxygenase 3	2	73986404-74108176	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050845	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:3.58e-5 (unfavourable)	Expressed in all	Mixed			skin: 17.9	Mixed		
TEX11	TGC1, TSGA3	ENSG00000120498	Testis expressed 11	X	70528940-70908731	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002950	Approved					Tissue enhanced	Group enriched	10	pancreas: 12.3;testis: 21.1	rectum: 1.7	Not detected		
TEX12		ENSG00000150783	Testis expressed 12	11	112167372-112172559	Predicted intracellular proteins	Evidence at protein level	HPA038289, HPA038290	Enhanced					Not detected	Tissue enriched	38	testis: 32.7	skin: 0.8	Cell line enhanced		U-698: 1.0
TEX13A		ENSG00000268629	Testis expressed 13A	X	105218929-105220674	Predicted intracellular proteins	Evidence at protein level	HPA072257	Enhanced					Not detected	Tissue enriched	79	testis: 7.9	all non-specific tissues: 0.0	Not detected		
TEX13B	TGC3B, TSGA5	ENSG00000170925	Testis expressed 13B	X	107980864-107982370	Predicted intracellular proteins	Evidence at protein level	HPA011283	Uncertain					Not detected	Not detected			testis: 0.8	Not detected		
TEX13C		ENSG00000282815	TEX13 family member C	X	125320120-125325214	Predicted intracellular proteins	Evidence at protein level								Tissue enriched	28	testis: 2.8	all non-specific tissues: 0.0	Not detected		
TEX13D		ENSG00000282419	TEX13 family member D	X	124246249-124336862	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	33	testis: 3.2	all non-specific tissues: 0.0	Not detected		
TEX14	CT113	ENSG00000121101	Testis expressed 14, intercellular bridge forming factor	17	58556678-58692055	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA030620, HPA077020	Enhanced		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol		Mixed	Tissue enriched	43	testis: 48.9	bone marrow: 1.1	Cell line enhanced		HDLM-2: 5.9;Karpas-707: 5.7;MCF7: 2.5
TEX15	CT42	ENSG00000133863	Testis expressed 15, meiosis and synapsis associated	8	30831544-30890606	Predicted intracellular proteins	Evidence at protein level	HPA036799, HPA036800	Enhanced		Approved	Nuclear speckles		Not detected	Group enriched	32	endometrium: 11.0;smooth muscle: 8.3;testis: 22.3	cerebral cortex,gallbladder: 0.4	Cell line enhanced		HAP1: 8.7;HEL: 17.3;K-562: 4.9;SCLC-21H: 4.9
TEX19	FLJ35767	ENSG00000182459	Testis expressed 19	17	82359247-82363776	Predicted intracellular proteins	Evidence at protein level	HPA054577	Enhanced					Not detected	Tissue enriched	266	testis: 27.2	cerebral cortex: 0.1	Cell line enhanced		Daudi: 20.1;HMC-1: 20.0;MOLT-4: 16.0;U-266/70: 22.3
TEX22		ENSG00000226174	Testis expressed 22	14	105398579-105450106	Predicted intracellular proteins	Evidence at protein level	HPA065576	Enhanced					Mixed	Tissue enhanced		testis: 2.1	cerebral cortex: 0.8	Cell line enhanced		HDLM-2: 2.6;U-266/70: 1.7
TEX26	C13orf26, MGC40178	ENSG00000175664	Testis expressed 26	13	30932703-30975502	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	30	testis: 40.7	cervix, uterine: 1.3	Not detected		
TEX30	C13orf27	ENSG00000151287	Testis expressed 30	13	102765990-102773811	Predicted intracellular proteins	Evidence at protein level	HPA053545	Enhanced				Prostate cancer:2.10e-6 (unfavourable), Cervical cancer:2.09e-5 (favourable)	Expressed in all	Group enriched	7	epididymis: 87.8;testis: 223.6	placenta: 22.3	Cell line enhanced		NB-4: 184.1
TEX33	C22orf33, EAN57, MGC35206	ENSG00000185264	Testis expressed 33	22	36991120-37007841	Predicted intracellular proteins	Evidence at protein level	HPA005998	Enhanced					Not detected	Tissue enriched	574	testis: 87.1	cerebral cortex: 0.1	Not detected		
TEX35	C1orf49, DKFZP564J047, TSC24	ENSG00000240021	Testis expressed 35	1	178513077-178548602	Predicted intracellular proteins	Evidence at protein level	HPA039190	Approved					Not detected	Tissue enriched	34	testis: 174.3	skin: 5.1	Mixed		
TEX36	bA383C5.1, C10orf122	ENSG00000175018	Testis expressed 36	10	125576522-125683144	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	64	testis: 47.4	smooth muscle: 0.7	Cell line enriched	8	U-2197: 7.9
TEX37	C2orf51, FLJ25369, TSC21	ENSG00000172073	Testis expressed 37	2	88524651-88529584	Predicted intracellular proteins	Evidence at protein level	HPA043987	Enhanced					Tissue enriched	Tissue enriched	515	testis: 82.4	placenta: 0.1	Cell line enriched	40	BEWO: 48.5
TEX40	C11orf20, DKFZP566E164	ENSG00000219435	Testis expressed 40	11	64300391-64304770	Predicted intracellular proteins	Evidence at protein level	HPA052822			Approved	Nucleoplasm		Not detected	Tissue enriched	105	testis: 519.6	cerebral cortex: 4.9	Cell line enhanced		CACO-2: 11.9;PC-3: 7.8;T-47d: 6.5
TEX43	C5orf48, FLJ27505, MGC163367, MGC163369, Tseg7	ENSG00000196900	Testis expressed 43	5	126631722-126636287	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	62	testis: 35.7	colon: 0.5	Not detected		
TEX44	C2orf57, MGC35154	ENSG00000177673	Testis expressed 44	2	231592901-231594283	Predicted intracellular proteins	Evidence at protein level	HPA049917, HPA056433	Enhanced					Not detected	Tissue enriched	1204	testis: 120.3	all non-specific tissues: 0.0	Not detected		
TEX9		ENSG00000151575	Testis expressed 9	15	56244009-56445997	Predicted intracellular proteins	Evidence at protein level	HPA039415	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			fallopian tube: 44.5	Mixed		
TFAP2A	AP-2, AP2TF, TFAP2	ENSG00000137203	Transcription factor AP-2 alpha	6	10393186-10419659	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000326, HPA028850, HPA056871	Enhanced		Enhanced	Nucleoplasm	Lung cancer:1.09e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		breast: 40.0;placenta: 42.3;skin: 76.1	epididymis: 24.9	Cell line enhanced		HDLM-2: 103.3
TFAP2B	AP2-B	ENSG00000008196	Transcription factor AP-2 beta	6	50818723-50847613	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034683, HPA062942	Supported		Approved	Nucleoplasm		Tissue enriched	Tissue enhanced		epididymis: 39.4	breast: 9.6	Group enriched	5	AF22: 94.8;SH-SY5Y: 188.6
TFAP2C	AP2-GAMMA, ERF1, hAP-2g, TFAP2G	ENSG00000087510	Transcription factor AP-2 gamma	20	56629302-56639283	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016061, CAB016079, HPA055179, HPA057076	Enhanced		Supported	Nucleoplasm	Cervical cancer:6.90e-4 (favourable)	Tissue enhanced	Tissue enhanced		skin: 63.0	breast: 31.6	Cell line enhanced		BEWO: 183.4;MCF7: 128.7;SK-BR-3: 231.1;WM-115: 112.9
TFAP2D	TFAP2BL1	ENSG00000008197	Transcription factor AP-2 delta	6	50713828-50772988	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048962	Uncertain					Tissue enriched	Not detected			cerebral cortex: 0.1	Cell line enhanced		HAP1: 1.3
TFAP2E	AP2E	ENSG00000116819	Transcription factor AP-2 epsilon	1	35573370-35595328	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		skin: 7.2	lymph node: 2.1	Cell line enhanced		NB-4: 4.5;U-937: 4.6
TFAP4	AP-4, bHLHc41	ENSG00000090447	Transcription factor AP-4	16	4257186-4273075	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001912	Supported		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:4.31e-6 (unfavourable), Liver cancer:3.32e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 12.0	Expressed in all		
TFB1M	CGI-75, mtTFB	ENSG00000029639	Transcription factor B1, mitochondrial	6	155257509-155314493	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029428	Approved					Expressed in all	Expressed in all			testis: 19.6	Expressed in all		
TFB2M	FLJ22661, FLJ23182, Hkp1	ENSG00000162851	Transcription factor B2, mitochondrial	1	246540560-246566324	Predicted intracellular proteins	Evidence at protein level	HPA028482, HPA028554, HPA030265	Approved		Enhanced	Mitochondria		Expressed in all	Expressed in all			adrenal gland: 29.5	Expressed in all		
TFCP2	CP2, LBP-1C, LSF, TFCP2C	ENSG00000135457	Transcription factor CP2	12	51093663-51173134	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA070247			Supported	Nucleoplasm<br>Cytosol	Melanoma:1.18e-4 (unfavourable), Liver cancer:1.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 44.3	Mixed		
TFCP2L1	CRTR1, LBP-9	ENSG00000115112	Transcription factor CP2 like 1	2	121216587-121285207	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029708	Uncertain		Supported	Nucleoli fibrillar center	Renal cancer:7.72e-6 (favourable)	Mixed	Tissue enhanced		kidney: 49.0	thyroid gland: 45.7	Cell line enhanced		BEWO: 17.6;HEL: 14.0;hTCEpi: 12.5;RPTEC TERT1: 32.4;RT4: 25.3;SCLC-21H: 15.6
TFDP1	DILC, Dp-1, DP1, DRTF1	ENSG00000198176	Transcription factor Dp-1	13	113584721-113641470	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB033605, HPA044754, HPA068909	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.03e-4 (unfavourable), Stomach cancer:6.17e-4 (favourable), Renal cancer:7.57e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 99.9	Expressed in all		
TFDP2	Dp-2	ENSG00000114126	Transcription factor Dp-2	3	141944428-142149544	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB018396	Supported		Supported	Nucleus<br>Vesicles	Cervical cancer:6.32e-4 (favourable), Renal cancer:9.84e-4 (favourable)	Expressed in all	Expressed in all			testis: 127.5	Expressed in all		
TFDP3	CT30, E2F-like, HCA661	ENSG00000183434	Transcription factor Dp family member 3	X	133216669-133218348	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	81	testis: 8.0	all non-specific tissues: 0.0	Not detected		
TFE3	bHLHe33, TFEA	ENSG00000068323	Transcription factor binding to IGHM enhancer 3	X	49028726-49043486	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023881	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.19e-8 (unfavourable), Liver cancer:6.03e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 24.4	Expressed in all		
TFEB	bHLHe35, TCFEB	ENSG00000112561	Transcription factor EB	6	41683978-41736259	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049532			Supported	Nucleoplasm	Renal cancer:1.06e-5 (favourable), Pancreatic cancer:4.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 54.3	Cell line enhanced		BEWO: 65.1;U-698: 44.9
TFEC	bHLHe34, TCFEC, TFECL	ENSG00000105967	Transcription factor EC	7	115935148-116159896	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB032260, HPA063577	Approved		Supported	Nucleoplasm		Tissue enhanced	Mixed			appendix: 26.3	Cell line enhanced		HEL: 14.6;HUVEC TERT2: 9.2;THP-1: 14.4;TIME: 10.2;U-937: 19.1
TFG	FLJ36137, SPG57, TF6	ENSG00000114354	TRK-fused gene	3	100709331-100748966	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019473, HPA052206	Approved		Approved	Vesicles<br>Cytosol	Pancreatic cancer:1.50e-4 (unfavourable), Liver cancer:5.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 164.5	Expressed in all		
TFIP11	DKFZP434B194, Spp382, TIP39	ENSG00000100109	Tuftelin interacting protein 11	22	26491225-26512505	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027085			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 50.0	Expressed in all		
TFPT	amida, FB1, INO80F	ENSG00000105619	TCF3 fusion partner	19	54107013-54115675	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034958, HPA058534	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Pancreatic cancer:3.13e-4 (favourable), Colorectal cancer:5.13e-4 (unfavourable), Liver cancer:5.25e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 10.6	Mixed		
TGDS	SDR2E1, TDPGD	ENSG00000088451	TDP-glucose 4,6-dehydratase	13	94574051-94596257	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039927, HPA040857	Approved		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments<br>Cleavage furrow	Prostate cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 21.7	Expressed in all		
TGFB1I1	ARA55, Hic-5, TSC-5	ENSG00000140682	Transforming growth factor beta 1 induced transcript 1	16	31471585-31477960	Predicted intracellular proteins	Evidence at protein level	CAB020844	Enhanced		Supported	Focal adhesion sites<br>Cytosol	Renal cancer:6.06e-8 (unfavourable), Urothelial cancer:7.73e-5 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 137.4;smooth muscle: 150.3	seminal vesicle: 104.2	Mixed		
TGFBRAP1	TRAP-1, TRAP1, VPS3	ENSG00000135966	Transforming growth factor beta receptor associated protein 1	2	105264391-105330034	Predicted intracellular proteins	Evidence at protein level	HPA037672, HPA038397	Approved		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 20.9	Expressed in all		
TGIF1	HPE4, TGIF	ENSG00000177426	TGFB induced factor homeobox 1	18	3411608-3459978	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062160			Supported	Nucleoplasm	Pancreatic cancer:6.47e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 162.4	Mixed		
TGIF2		ENSG00000118707	TGFB induced factor homeobox 2	20	36573488-36593950	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053786			Supported	Nucleoplasm		Expressed in all	Mixed			fallopian tube: 38.3	Mixed		
TGIF2LX		ENSG00000153779	TGFB induced factor homeobox 2 like, X-linked	X	89921882-89922883	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034543	Supported		Approved	Nucleoplasm		Tissue enhanced	Tissue enriched	134	testis: 13.3	all non-specific tissues: 0.0	Group enriched	10	SH-SY5Y: 11.2;U-2 OS: 12.7;U-266/84: 14.3
TGIF2LY		ENSG00000176679	TGFB induced factor homeobox 2 like, Y-linked	Y	3579041-3580041	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	74	testis: 7.3	all non-specific tissues: 0.0	Not detected		
TGM1	ICR2, LI, LI1, TGASE, TGK	ENSG00000092295	Transglutaminase 1	14	24249114-24264432	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015159, HPA040171	Enhanced					Tissue enhanced	Tissue enriched	12	esophagus: 831.8	tonsil: 72.2	Cell line enhanced		BEWO: 33.0;HaCaT: 42.3;MCF7: 27.0;SK-BR-3: 31.6
TGM2	TGC	ENSG00000198959	Transglutaminase 2	20	38127387-38166578	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002598, HPA021019, HPA029518	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.67e-7 (unfavourable), Pancreatic cancer:2.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 461.0	placenta: 319.8	Cell line enhanced		CAPAN-2: 1300.3;EFO-21: 458.7;HUVEC TERT2: 559.8;TIME: 720.5
TGM3	TGE	ENSG00000125780	Transglutaminase 3	20	2296001-2341078	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004728	Enhanced					Tissue enriched	Tissue enriched	12	esophagus: 1513.9	tonsil: 126.4	Cell line enriched	7	EFO-21: 5.7
TGM4	TGP	ENSG00000163810	Transglutaminase 4	3	44874608-44914990	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032072, CAB033571	Enhanced					Tissue enriched	Tissue enriched	465	prostate: 689.9	adrenal gland: 1.4	Cell line enhanced		BEWO: 4.7;NB-4: 1.7;RPMI-8226: 1.3;SH-SY5Y: 1.5
TGM5	TGX	ENSG00000104055	Transglutaminase 5	15	43232595-43266857	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	7	esophagus: 8.4;skin: 22.3	breast: 2.3	Cell line enriched	8	HEL: 16.7
TGM6	dJ734P14.3, SCA35, TGM3L, TGY	ENSG00000166948	Transglutaminase 6	20	2380908-2432753	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059196	Uncertain					Not detected	Not detected			tonsil: 0.4	Not detected		
TGM7	TGMZ	ENSG00000159495	Transglutaminase 7	15	43276280-43302255	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Group enriched	5	testis: 1.5;tonsil: 1.5	esophagus: 0.2	Cell line enriched	33	EFO-21: 3.3
TGS1	NCOA6IP, PIMT	ENSG00000137574	Trimethylguanosine synthase 1	8	55773142-55825448	Predicted intracellular proteins	Evidence at protein level	HPA025024, HPA029824	Supported		Enhanced	Nucleus<br>Cytosol	Endometrial cancer:4.63e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 15.3	Expressed in all		
TH	DYT5b	ENSG00000180176	Tyrosine hydroxylase	11	2163929-2171877	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002522, HPA013768, HPA061003, CAB072340	Enhanced	Supported				Tissue enhanced	Tissue enriched	81	adrenal gland: 259.8	adipose tissue: 3.2	Group enriched	26	PC-3: 54.8;SK-BR-3: 15.7
THADA	ARMC13, FLJ21877, GITA, KIAA1767	ENSG00000115970	THADA, armadillo repeat containing	2	43230836-43596046	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035191, HPA035192	Uncertain		Approved	Cytosol	Liver cancer:6.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 26.8	Mixed		
THAP1	4833431A01Rik, DYT6, FLJ10477	ENSG00000131931	THAP domain containing 1	8	42836674-42843325	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071310			Supported	Nucleus		Expressed in all	Mixed			testis: 17.6	Expressed in all		
THAP10		ENSG00000129028	THAP domain containing 10	15	70881342-70892785	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041416	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.05e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 10.0	Cell line enhanced		U-2197: 36.6
THAP11	CTG-B43a, CTG-B45d, HRIHFB2206	ENSG00000168286	THAP domain containing 11	16	67842082-67844195	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041434, HPA042189	Supported		Enhanced	Nucleoplasm<br>Cytokinetic bridge		Expressed in all	Expressed in all			fallopian tube: 25.4	Expressed in all		
THAP2	DKFZP564I0422	ENSG00000173451	THAP domain containing 2	12	71663009-71680639	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039790	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			adrenal gland: 35.2	Expressed in all		
THAP3		ENSG00000041988	THAP domain containing 3	1	6624866-6635586	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067114	Approved		Approved	Nucleus	Colorectal cancer:1.33e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 18.0	Expressed in all		
THAP5	DKFZp313O1132	ENSG00000177683	THAP domain containing 5	7	108554543-108569750	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043170, HPA051488	Approved		Enhanced	Nucleus	Renal cancer:8.99e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.7	Expressed in all		
THAP6	MGC30052	ENSG00000174796	THAP domain containing 6	4	75513946-75550473	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035767	Uncertain		Approved	Nucleus<br>Centrosome		Expressed in all	Expressed in all			testis: 43.6	Expressed in all		
THAP7	MGC10963	ENSG00000184436	THAP domain containing 7	22	20999104-21002196	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003083	Approved		Approved	Nucleus<br>Vesicles		Expressed in all	Expressed in all			testis: 20.4	Expressed in all		
THAP8	FLJ32891	ENSG00000161277	THAP domain containing 8	19	36034985-36054762	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064056, HPA070139			Enhanced	Nucleoplasm	Liver cancer:1.32e-4 (unfavourable), Pancreatic cancer:3.19e-4 (favourable)	Expressed in all	Mixed			testis: 9.0	Mixed		
THAP9	FLJ34093	ENSG00000168152	THAP domain containing 9	4	82900684-82919969	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA037420, HPA037421	Uncertain		Approved	Mitochondria	Renal cancer:3.50e-5 (favourable)	Expressed in all	Mixed			testis: 11.4	Mixed		
THEG	CT56, THEG1	ENSG00000105549	Theg spermatid protein	19	361747-376670	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	9	testis: 33.5	skin: 3.9	Cell line enriched	5	HDLM-2: 79.5
THEGL		ENSG00000249693	Theg spermatid protein-like	4	56530609-56603507	Predicted intracellular proteins	Evidence at protein level	HPA068093	Uncertain					Not detected	Tissue enriched	7	testis: 5.6	smooth muscle: 0.8	Not detected		
THEM4	CTMP	ENSG00000159445	Thioesterase superfamily member 4	1	151873584-151909808	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028161	Approved				Liver cancer:1.38e-4 (unfavourable), Pancreatic cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			epididymis,kidney: 11.6	Mixed		
THEM5	FLJ37964	ENSG00000196407	Thioesterase superfamily member 5	1	151847263-151853697	Enzymes, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Tissue enriched	25	skin: 204.8	cerebral cortex: 8.3	Cell line enriched	6	HDLM-2: 64.7
THEM6	C8orf55, DSCD75	ENSG00000130193	Thioesterase superfamily member 6	8	142727203-142736927	Predicted intracellular proteins	Evidence at protein level	HPA023255	Uncertain		Approved	Nuclear speckles<br>Cytosol	Renal cancer:6.66e-7 (favourable), Urothelial cancer:4.49e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 18.5	Cell line enhanced		RT4: 89.6
THEMIS	bA325O24.3, bA325O24.4, C6orf190, C6orf207, FLJ40584, TSEPA	ENSG00000172673	Thymocyte selection associated	6	127708072-127918631	Predicted intracellular proteins	Evidence at protein level	HPA031422, HPA031425	Enhanced					Mixed	Tissue enhanced		lymph node: 8.4	cerebral cortex,spleen: 4.5	Cell line enhanced		HDLM-2: 30.2;MOLT-4: 41.2;RPMI-8226: 15.0
THEMIS2	C1orf38, ICB-1	ENSG00000130775	Thymocyte selection associated family member 2	1	27872543-27886685	Predicted intracellular proteins	Evidence at protein level	HPA031096, HPA031097	Uncertain		Approved	Golgi apparatus		Expressed in all	Tissue enhanced		bone marrow: 137.5	spleen: 117.3	Cell line enhanced		Karpas-707: 98.1;U-266/70: 80.2
THG1L	FLJ11601, FLJ20546, hTHG1, ICF45, IHG-1	ENSG00000113272	TRNA-histidine guanylyltransferase 1 like	5	157731197-157741448	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035877, HPA035878	Approved				Renal cancer:3.93e-6 (unfavourable)	Expressed in all	Mixed			endometrium: 10.3	Expressed in all		
THNSL1	FLJ22002, TSH1	ENSG00000185875	Threonine synthase like 1	10	25016658-25026664	Predicted intracellular proteins	Evidence at protein level	HPA037585	Uncertain		Approved	Nuclear bodies<br>Mitochondria<br>Cytosol		Expressed in all	Mixed			thyroid gland: 14.1	Mixed		
THNSL2	FLJ10916, SOFAT, TSH2	ENSG00000144115	Threonine synthase like 2	2	88170295-88186636	Predicted intracellular proteins	Evidence at protein level	HPA035395	Approved					Expressed in all	Tissue enhanced		parathyroid gland: 74.4	thyroid gland: 38.2	Cell line enhanced		HHSteC: 19.8;T-47d: 21.4
THOC2	CXorf3, dJ506G2.1, MRX12, MRX35, THO2	ENSG00000125676	THO complex 2	X	123600561-123733056	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047921	Supported		Approved	Nucleoplasm	Liver cancer:5.77e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 46.6	Expressed in all		
THOC5	C22orf19, Fmip, fSAP79, KIAA0983, PK1.3	ENSG00000100296	THO complex 5	22	29505879-29555216	Predicted intracellular proteins	Evidence at protein level	HPA048402			Supported	Nucleoplasm	Liver cancer:3.76e-6 (unfavourable), Renal cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 43.1	Expressed in all		
THOC6	fSAP35, MGC2655, WDR58	ENSG00000131652	THO complex 6	16	3024027-3027755	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052953	Uncertain		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:4.40e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 29.2	Expressed in all		
THOC7	FLJ23445, fSAP24, NIF3L1BP1	ENSG00000163634	THO complex 7	3	63833870-63863903	Predicted intracellular proteins	Evidence at protein level	HPA044143	Approved		Supported	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			breast: 84.4	Expressed in all		
THOP1		ENSG00000172009	Thimet oligopeptidase 1	19	2785460-2815807	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025497, HPA035262	Uncertain		Supported	Cytosol	Endometrial cancer:2.35e-4 (favourable), Stomach cancer:5.90e-4 (favourable)	Expressed in all	Expressed in all			testis: 36.1	Mixed		
THRA	AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3	ENSG00000126351	Thyroid hormone receptor, alpha	17	40058290-40093867	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009654, CAB023349	Uncertain		Supported	Cytosol	Renal cancer:6.05e-8 (favourable), Lung cancer:1.84e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 238.9	Expressed in all		
THRAP3	TRAP150	ENSG00000054118	Thyroid hormone receptor associated protein 3	1	36224416-36305357	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012041, CAB017472, HPA063765	Supported		Enhanced	Nuclear speckles	Stomach cancer:5.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 99.0	Expressed in all		
THRB	ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2	ENSG00000151090	Thyroid hormone receptor beta	3	24117160-24495282	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002008, CAB002009, HPA061035	Approved		Supported	Nuclear bodies	Renal cancer:9.46e-8 (favourable)	Mixed	Mixed			cerebral cortex: 36.3	Cell line enhanced		K-562: 43.8;RT4: 28.1
THRSP	Lpgp, LPGP1, S14, SPOT14, THRP	ENSG00000151365	Thyroid hormone responsive	11	78063861-78068351	Predicted intracellular proteins	Evidence at protein level	HPA040642	Approved		Approved	Nucleoplasm	Renal cancer:1.16e-4 (unfavourable), Thyroid cancer:3.28e-4 (favourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 231.2;liver: 182.9	breast: 43.6	Cell line enriched	12	ASC diff: 52.2
THTPA	THTPASE	ENSG00000259431	Thiamine triphosphatase	14	23555988-23560271	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028876	Approved		Uncertain	Nucleus<br>Nucleoli	Renal cancer:1.70e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 33.5	Expressed in all		
THUMPD1	FLJ20274, Tan1	ENSG00000066654	THUMP domain containing 1	16	20702816-20742084	Predicted intracellular proteins	Evidence at protein level	HPA027851	Approved		Approved	Cytosol	Renal cancer:8.52e-8 (favourable), Colorectal cancer:2.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 68.5	Expressed in all		
THUMPD2	C2orf8, MGC2454	ENSG00000138050	THUMP domain containing 2	2	39736060-39779267	Predicted intracellular proteins	Evidence at protein level	HPA043042, HPA058025	Approved		Uncertain	Nucleoplasm	Renal cancer:7.27e-5 (unfavourable), Liver cancer:6.05e-4 (unfavourable)	Expressed in all	Mixed			ovary,thyroid gland: 3.8	Mixed		
THUMPD3	DKFZP434F091	ENSG00000134077	THUMP domain containing 3	3	9362842-9386791	Predicted intracellular proteins	Evidence at protein level	HPA036170, HPA036171	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:1.25e-7 (unfavourable), Renal cancer:1.03e-4 (favourable)	Expressed in all	Expressed in all			testis: 107.5	Expressed in all		
THYN1	THY28	ENSG00000151500	Thymocyte nuclear protein 1	11	134248279-134253370	Predicted intracellular proteins	Evidence at protein level	HPA038732, HPA038733	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Lung cancer:1.01e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 92.2	Expressed in all		
TIA1		ENSG00000116001	TIA1 cytotoxic granule associated RNA binding protein	2	70209444-70248660	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056961			Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.05e-7 (unfavourable), Urothelial cancer:1.02e-5 (favourable), Lung cancer:6.79e-5 (favourable)	Expressed in all	Expressed in all			endometrium: 113.1	Expressed in all		
TIAF1		ENSG00000221995	TGFB1-induced anti-apoptotic factor 1	17	29073521-29078857	Predicted intracellular proteins	Evidence at transcript level	HPA051129	Uncertain					Mixed	Mixed			skin: 4.8	Cell line enhanced		REH: 6.4
TIAL1	TIAR	ENSG00000151923	TIA1 cytotoxic granule associated RNA binding protein like 1	10	119571802-119597029	Predicted intracellular proteins	Evidence at protein level	HPA060962			Approved	Nucleus<br>Vesicles	Liver cancer:7.81e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 86.8	Expressed in all		
TIAM1		ENSG00000156299	T-cell lymphoma invasion and metastasis 1	21	31118416-31559977	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010416, HPA034853	Uncertain		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Cell Junctions<br>Cytokinetic bridge<br>Cytosol		Mixed	Mixed			skin: 28.0	Cell line enhanced		BEWO: 33.2;SCLC-21H: 38.3
TIAM2	STEF	ENSG00000146426	T-cell lymphoma invasion and metastasis 2	6	154832697-155257723	Predicted intracellular proteins	Evidence at protein level	HPA011134, HPA013903	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 18.0;testis: 24.4	thyroid gland: 10.2	Cell line enhanced		AF22: 62.0;HDLM-2: 27.3;RH-30: 39.8
TICAM1	MGC35334, PRVTIRB, TICAM-1, TRIF	ENSG00000127666	Toll like receptor adaptor molecule 1	19	4815932-4831704	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042460	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Lung cancer:3.48e-4 (unfavourable), Endometrial cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 22.0	Mixed		
TICAM2	TICAM-2, TIRP, TRAM	ENSG00000243414	Toll like receptor adaptor molecule 2	5	115578650-115602479	Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			cervix, uterine: 6.1	Cell line enhanced		HDLM-2: 32.3;U-138 MG: 20.3;U-2197: 20.8
TICRR	C15orf42, FLJ41618, MGC45866, SLD3, Treslin	ENSG00000140534	TOPBP1 interacting checkpoint and replication regulator	15	89575482-89631056	Predicted intracellular proteins	Evidence at protein level	HPA046746, HPA049454			Enhanced	Nucleoplasm	Melanoma:2.87e-6 (unfavourable), Endometrial cancer:4.44e-4 (unfavourable)	Mixed	Mixed			testis: 2.7	Mixed		
TIFA	MGC20791, T2BP, T6BP, TIFAA	ENSG00000145365	TRAF interacting protein with forkhead associated domain	4	112274542-112285903	Predicted intracellular proteins	Evidence at protein level	HPA045889	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 37.6	Expressed in all		
TIFAB		ENSG00000255833	TIFA inhibitor	5	135444218-135452399	Predicted intracellular proteins	Evidence at protein level	HPA049372	Uncertain					Tissue enhanced	Tissue enhanced		appendix: 4.9;lymph node: 6.3	tonsil: 4.5	Group enriched	14	THP-1: 6.0;U-937: 1.5
TIGAR	C12orf5	ENSG00000078237	TP53 induced glycolysis regulatory phosphatase	12	4307763-4354593	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB034010, HPA040354, HPA044111	Approved		Enhanced	Cytosol	Liver cancer:3.18e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 9.9	Cell line enhanced		BEWO: 81.8
TIGD1	EEYORE	ENSG00000221944	Tigger transposable element derived 1	2	232547968-232550592	Predicted intracellular proteins	Evidence at protein level	HPA041717	Approved		Supported	Nucleus<br>Nucleoli<br>Nuclear bodies	Renal cancer:4.41e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 16.3	Expressed in all		
TIGD2		ENSG00000180346	Tigger transposable element derived 2	4	89111500-89114899	Predicted intracellular proteins	Evidence at protein level	HPA054844, HPA071168	Uncertain		Approved	Nuclear bodies	Colorectal cancer:4.59e-4 (favourable), Urothelial cancer:7.02e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 18.0	Expressed in all		
TIGD3		ENSG00000173825	Tigger transposable element derived 3	11	65354767-65357613	Predicted intracellular proteins	Evidence at transcript level	HPA040016			Approved	Nucleoplasm<br>Nuclear membrane		Mixed	Tissue enhanced		testis: 3.9	small intestine: 2.3	Cell line enhanced		SCLC-21H: 4.6
TIGD4		ENSG00000169989	Tigger transposable element derived 4	4	152769354-152779764	Predicted intracellular proteins	Evidence at protein level	HPA035649	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 8.6	fallopian tube: 3.2	Cell line enhanced		U-266/70: 3.4;U-266/84: 6.5
TIGD5	FLJ14926	ENSG00000179886	Tigger transposable element derived 5	8	143597835-143603224	Predicted intracellular proteins	Evidence at protein level						Renal cancer:9.16e-5 (favourable), Liver cancer:7.68e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 2.2	Mixed		
TIGD6	DKFZp761E2110	ENSG00000164296	Tigger transposable element derived 6	5	149993118-150001167	Predicted intracellular proteins	Evidence at protein level	HPA044599	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Actin filaments	Colorectal cancer:5.35e-4 (favourable), Pancreatic cancer:5.88e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 21.4	testis: 6.7	Mixed		
TIGD7	Sancho	ENSG00000140993	Tigger transposable element derived 7	16	3298832-3305729	Predicted intracellular proteins	Evidence at protein level	HPA041357, HPA041474	Uncertain		Supported	Plasma membrane<br>Cytosol		Mixed	Mixed			parathyroid gland: 14.7	Mixed		
TIMELESS	hTIM, TIM, TIM1	ENSG00000111602	Timeless circadian clock	12	56416373-56449403	Predicted intracellular proteins	Evidence at protein level	HPA060655	Enhanced		Supported	Nucleus	Melanoma:1.06e-5 (unfavourable), Renal cancer:2.61e-5 (unfavourable), Liver cancer:3.61e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 18.2	Expressed in all		
TIMM10	TIM10, TIM10A, TIMM10A	ENSG00000134809	Translocase of inner mitochondrial membrane 10	11	57528463-57530803	Predicted intracellular proteins	Evidence at protein level	HPA039946	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			epididymis: 52.6	Expressed in all		
TIMM10B	FXC1, TIM10B, Tim9b	ENSG00000132286	Translocase of inner mitochondrial membrane 10B	11	6481447-6484679	Predicted intracellular proteins	Evidence at protein level	HPA052265	Approved				Renal cancer:3.19e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.8	Expressed in all		
TIMM13	Tim13, TIMM13B	ENSG00000099800	Translocase of inner mitochondrial membrane 13	19	2425624-2427894	Predicted intracellular proteins	Evidence at protein level	HPA048985	Uncertain		Supported	Nucleoli fibrillar center<br>Mitochondria	Renal cancer:3.88e-5 (favourable), Endometrial cancer:4.68e-5 (favourable), Pancreatic cancer:9.77e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 53.1	Expressed in all		
TIMM29	C19orf52	ENSG00000142444	Translocase of inner mitochondrial membrane 29	19	10928733-10933535	Predicted intracellular proteins	Evidence at protein level	HPA041858	Approved		Approved	Nucleoplasm<br>Mitochondria	Stomach cancer:7.03e-7 (favourable), Cervical cancer:9.93e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex,testis: 7.5	Expressed in all		
TIMM44	TIM44	ENSG00000104980	Translocase of inner mitochondrial membrane 44	19	7926718-7943920	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043052	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			heart muscle: 19.1	Expressed in all		
TIMM8A	DDP, DFN1, MTS	ENSG00000126953	Translocase of inner mitochondrial membrane 8A	X	101345661-101349196	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003628	Supported		Enhanced	Mitochondria	Breast cancer:7.89e-5 (unfavourable), Endometrial cancer:8.87e-5 (unfavourable), Renal cancer:1.69e-4 (favourable)	Expressed in all	Mixed			liver: 8.9	Expressed in all		
TIMM8B	DDP2, FLJ21744, MGC102866, MGC117373, TIM8B	ENSG00000150779	Translocase of inner mitochondrial membrane 8 homolog B	11	112084800-112086798	Predicted intracellular proteins	Evidence at protein level	HPA041173	Approved					Expressed in all	Expressed in all			adrenal gland: 39.3	Expressed in all		
TIMM9	TIM9A	ENSG00000100575	Translocase of inner mitochondrial membrane 9	14	58408494-58427614	Predicted intracellular proteins	Evidence at protein level	HPA002932	Approved		Enhanced	Mitochondria	Ovarian cancer:6.39e-5 (favourable), Liver cancer:9.89e-5 (unfavourable), Breast cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.7	Expressed in all		
TINAG		ENSG00000137251	Tubulointerstitial nephritis antigen	6	54307859-54390152	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035427	Approved				Liver cancer:2.05e-5 (unfavourable), Renal cancer:8.75e-5 (favourable)	Tissue enhanced	Tissue enriched	7	kidney: 113.9	small intestine: 15.7	Cell line enriched	36	RPTEC TERT1: 69.3
TINCR	FLJ90734, LINC00036, NCRNA00036, onco-lncRNA-16, PLAC2	ENSG00000223573	Tissue differentiation-inducing non-protein coding RNA	19	5558167-5568034	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	6	skin: 107.2	placenta: 19.0	Cell line enhanced		BEWO: 31.4;HaCaT: 25.8;SK-BR-3: 31.6
TIPARP	DDF1, DKFZP434J214, DKFZp686N0351, PARP-1, PARP-7, PARP7, pART14, RM1	ENSG00000163659	TCDD inducible poly(ADP-ribose) polymerase	3	156673235-156706770	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA036796	Uncertain		Approved	Microtubules	Breast cancer:2.00e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 232.4	Expressed in all		
TIPIN	FLJ20516	ENSG00000075131	TIMELESS interacting protein	15	66336206-66386746	Predicted intracellular proteins	Evidence at protein level	HPA039704, HPA058799	Enhanced		Supported	Nucleus<br>Vesicles	Liver cancer:2.47e-4 (unfavourable), Cervical cancer:4.15e-4 (favourable), Prostate cancer:9.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 36.9	parathyroid gland: 12.6	Expressed in all		
TIPRL	dJ69E11.3, MGC3794, TIP41, TIPRL1	ENSG00000143155	TOR signaling pathway regulator	1	168178933-168202114	Predicted intracellular proteins	Evidence at protein level	HPA027995, HPA054282	Approved		Supported	Vesicles<br>Cytosol	Renal cancer:1.45e-8 (unfavourable), Liver cancer:1.60e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 38.5	Expressed in all		
TIRAP	Mal, wyatt	ENSG00000150455	TIR domain containing adaptor protein	11	126283065-126298845	Predicted intracellular proteins	Evidence at protein level	HPA054431	Uncertain		Approved	Nucleoplasm<br>Cytokinetic bridge<br>Cytosol	Endometrial cancer:1.24e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 13.4	Mixed		
TISP43		ENSG00000183292	Uncharacterized LOC150527	2	130570829-130584161	Predicted intracellular proteins	Evidence at transcript level	HPA044732	Uncertain					Not detected	Tissue enriched	11	testis: 11.5	skin: 1.0	Not detected		
TJAP1	PILT, TJP4	ENSG00000137221	Tight junction associated protein 1	6	43477523-43506556	Predicted intracellular proteins	Evidence at protein level	HPA030164, HPA030165, HPA030166	Supported		Approved	Golgi apparatus	Liver cancer:9.02e-6 (unfavourable), Renal cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 33.8	Expressed in all		
TJP1	DKFZp686M05161, MGC133289, ZO-1	ENSG00000104067	Tight junction protein 1	15	29699367-29968865	Predicted intracellular proteins	Evidence at protein level	HPA001636, HPA001637, CAB010822	Enhanced		Enhanced	Cell Junctions	Renal cancer:1.72e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 49.6	Mixed		
TJP2	DFNA51, X104, ZO-2, ZO2	ENSG00000119139	Tight junction protein 2	9	69121264-69255208	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001813, CAB009228, HPA070714	Supported		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.78e-14 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 104.1	Mixed		
TJP3	ZO-3	ENSG00000105289	Tight junction protein 3	19	3708109-3750813	Predicted intracellular proteins	Evidence at protein level	CAB013244, HPA046863, HPA053337	Enhanced		Enhanced	Nucleoplasm<br>Cell Junctions	Renal cancer:9.36e-8 (favourable), Endometrial cancer:1.83e-6 (favourable), Head and neck cancer:9.52e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 41.5;small intestine: 41.3	colon: 30.6	Cell line enhanced		BEWO: 42.4;CAPAN-2: 39.5;SK-BR-3: 19.4;T-47d: 51.5
TK1		ENSG00000167900	Thymidine kinase 1	17	78174075-78187233	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004683	Enhanced				Renal cancer:6.50e-11 (unfavourable), Lung cancer:3.03e-5 (unfavourable), Liver cancer:6.87e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 45.7	Expressed in all		
TK2	SCA31	ENSG00000166548	Thymidine kinase 2, mitochondrial	16	66508003-66552544	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041162	Uncertain				Renal cancer:2.18e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 89.9	Mixed		
TKFC	DAK, DKFZP586B1621, NET45	ENSG00000149476	Triokinase and FMN cyclase	11	61333210-61353295	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039486, HPA048186	Enhanced		Approved	Nucleus<br>Cytosol	Endometrial cancer:1.32e-5 (favourable), Renal cancer:8.38e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 194.2	Expressed in all		
TKT		ENSG00000163931	Transketolase	3	53224707-53256052	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029480, HPA029481	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.21e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 431.3	Expressed in all		
TKTL1	TKR, TKT2	ENSG00000007350	Transketolase like 1	X	154295671-154330350	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000505, CAB032191	Enhanced					Tissue enriched	Tissue enriched	141	testis: 225.8	heart muscle,lung: 1.5	Cell line enriched	147	THP-1: 315.9
TKTL2	DKFZP434L1717, FLJ32975	ENSG00000151005	Transketolase like 2	4	163471093-163473746	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	495	testis: 103.8	spleen: 0.2	Not detected		
TLDC1	KIAA1609	ENSG00000140950	TBC/LysM-associated domain containing 1	16	84476421-84554033	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041020	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Lung cancer:1.03e-5 (unfavourable), Pancreatic cancer:7.05e-5 (unfavourable)	Expressed in all	Mixed			placenta: 15.5	Mixed		
TLDC2	C20orf118, dJ132F21.2	ENSG00000101342	TBC/LysM-associated domain containing 2	20	36876121-36894235	Predicted intracellular proteins	Evidence at transcript level	HPA047468	Approved				Renal cancer:9.97e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 19.0;small intestine: 20.1	rectum: 13.3	Cell line enriched	10	HMC-1: 30.5
TLE1	ESG, ESG1, GRG1	ENSG00000196781	Transducin like enhancer of split 1	9	81583683-81689305	Predicted intracellular proteins	Evidence at protein level	CAB011482, HPA071396	Supported		Supported	Nucleoplasm	Thyroid cancer:7.60e-4 (unfavourable), Renal cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 51.2	Mixed		
TLE2	ESG, ESG2, FLJ41188, GRG2	ENSG00000065717	Transducin like enhancer of split 2	19	2997638-3047635	Predicted intracellular proteins	Evidence at protein level	HPA049103	Approved		Supported	Nuclear bodies<br>Focal adhesion sites	Pancreatic cancer:2.39e-6 (favourable), Renal cancer:9.49e-6 (favourable), Endometrial cancer:2.51e-4 (favourable), Urothelial cancer:8.88e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 39.6	Cell line enhanced		AN3-CA: 39.6;RT4: 27.6
TLE3	ESG, ESG3, GRG3, HsT18976, KIAA1547	ENSG00000140332	Transducin like enhancer of split 3	15	70047790-70098176	Predicted intracellular proteins	Evidence at protein level	HPA054116	Approved		Supported	Nucleoplasm	Cervical cancer:2.09e-5 (favourable)	Expressed in all	Mixed			bone marrow: 48.7	Expressed in all		
TLE4	E(spI), ESG, GRG4	ENSG00000106829	Transducin like enhancer of split 4	9	79571773-79726882	Predicted intracellular proteins	Evidence at protein level	HPA065357			Supported	Nucleus	Renal cancer:6.94e-4 (favourable)	Expressed in all	Expressed in all			testis: 201.9	Cell line enhanced		fHDF/TERT166: 131.2
TLE6	FLJ14009, GRG6	ENSG00000104953	Transducin like enhancer of split 6	19	2977446-2995184	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		thyroid gland: 9.7	placenta: 6.5	Cell line enhanced		BEWO: 16.5;U-266/70: 11.1
TLK1	KIAA0137, PKU-BETA	ENSG00000198586	Tousled like kinase 1	2	170990823-171231314	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016043	Approved		Enhanced	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 40.9	Expressed in all		
TLK2	MGC44450, PKU-ALPHA	ENSG00000146872	Tousled like kinase 2	17	62458658-62615481	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:9.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 96.2	Expressed in all		
TLL1		ENSG00000038295	Tolloid like 1	4	165873258-166103895	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060767			Approved	Vesicles		Mixed	Tissue enhanced		placenta: 10.5	gallbladder: 4.4	Cell line enhanced		HeLa: 4.3;Karpas-707: 7.1;PC-3: 3.3
TLN1	ILWEQ, TLN	ENSG00000137076	Talin 1	9	35696948-35732395	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002006, HPA004748	Supported		Supported	Plasma membrane<br>Focal adhesion sites<br>Microtubule organizing center<br>Cytosol	Colorectal cancer:5.56e-4 (unfavourable), Renal cancer:7.21e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 204.8	Expressed in all		
TLN2	ILWEQ, KIAA0320	ENSG00000171914	Talin 2	15	62390526-62844631	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017194, HPA051828, HPA054787	Enhanced		Supported	Focal adhesion sites<br>Cytosol	Renal cancer:1.81e-6 (favourable), Breast cancer:6.53e-4 (favourable), Stomach cancer:7.74e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 41.2;kidney: 41.1	thyroid gland: 21.7	Mixed		
TLX1	HOX11, TCL3	ENSG00000107807	T-cell leukemia homeobox 1	10	101130505-101137789	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Colorectal cancer:7.32e-4 (unfavourable)	Mixed	Tissue enriched	5	spleen: 31.3	salivary gland: 6.0	Cell line enhanced		HAP1: 4.1;K-562: 10.7;SH-SY5Y: 2.9
TLX2	Enx, HOX11L1, NCX, Tlx2	ENSG00000115297	T-cell leukemia homeobox 2	2	74513463-74517147	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040969, HPA062254	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		adrenal gland: 2.7	testis: 0.8	Cell line enriched	17	SH-SY5Y: 68.4
TLX3	HOX11L2, RNX	ENSG00000164438	T-cell leukemia homeobox 3	5	171309284-171312134	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030504, HPA060957, HPA069359	Approved		Supported	Nucleoplasm		Tissue enhanced	Not detected			all non-specific tissues: 0.0	Cell line enriched	6	SH-SY5Y: 28.2
TMA16	C4orf43, FLJ11184	ENSG00000198498	Translation machinery associated 16 homolog	4	163494442-163520539	Predicted intracellular proteins	Evidence at protein level	HPA041571, HPA052688	Uncertain		Enhanced	Nucleoli	Liver cancer:2.70e-5 (unfavourable), Lung cancer:4.40e-4 (unfavourable), Renal cancer:7.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.7	Expressed in all		
TMA7	CCDC72, HSPC016	ENSG00000232112	Translation machinery associated 7 homolog	3	48440257-48444208	Predicted intracellular proteins	Evidence at protein level	HPA047397			Approved	Nucleus<br>Nucleoli<br>Nuclear bodies	Lung cancer:8.33e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 420.1	Expressed in all		
TMED8	FAM15B	ENSG00000100580	Transmembrane p24 trafficking protein family member 8	14	77335021-77377109	Predicted intracellular proteins	Evidence at protein level	HPA001205	Approved					Expressed in all	Mixed			lymph node: 20.8	Expressed in all		
TMEM102	CBAP, FLJ36878	ENSG00000181284	Transmembrane protein 102	17	7435443-7437679	Predicted intracellular proteins	Evidence at protein level	HPA024433	Uncertain		Approved	Vesicles	Renal cancer:9.90e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 3.5	Mixed		
TMEM263	C12orf23, MGC17943	ENSG00000151135	Transmembrane protein 263	12	106955719-106978778	Predicted intracellular proteins	Evidence at protein level	HPA042339	Uncertain				Thyroid cancer:1.83e-4 (unfavourable), Liver cancer:7.84e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 63.7	Expressed in all		
TMEM5	HP10481	ENSG00000118600	Transmembrane protein 5	12	63779803-63809558	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064014			Approved	Nucleoplasm<br>Golgi apparatus	Liver cancer:5.24e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
TMF1	ARA160, TMF	ENSG00000144747	TATA element modulatory factor 1	3	69019827-69052303	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008729	Approved		Supported	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 28.1	Expressed in all		
TMLHE	BBOX2, FLJ10727, TMLH, XAP130	ENSG00000185973	Trimethyllysine hydroxylase, epsilon	X	155490115-155669944	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034589, HPA040331	Approved		Supported	Mitochondria	Renal cancer:3.68e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.7	Mixed		
TMOD1	D9S57E, ETMOD, TMOD	ENSG00000136842	Tropomodulin 1	9	97501180-97601748	Predicted intracellular proteins	Evidence at protein level	HPA051202	Enhanced		Approved	Cytosol		Tissue enhanced	Mixed			heart muscle: 93.4	Group enriched	7	EFO-21: 35.5;HDLM-2: 143.0;K-562: 47.3;SH-SY5Y: 166.4
TMOD2	NTMOD	ENSG00000128872	Tropomodulin 2	15	51751561-51816368	Predicted intracellular proteins	Evidence at protein level	HPA041365	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center	Pancreatic cancer:4.53e-4 (favourable)	Tissue enhanced	Tissue enriched	9	cerebral cortex: 111.0	seminal vesicle: 11.7	Cell line enhanced		SCLC-21H: 43.4
TMOD3	UTMOD	ENSG00000138594	Tropomodulin 3	15	51829628-51947295	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001849	Approved		Approved	Actin filaments<br>Cytosol	Pancreatic cancer:3.38e-5 (unfavourable), Cervical cancer:3.25e-4 (unfavourable), Lung cancer:6.25e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 47.7	Expressed in all		
TMOD4	Sk-Tmod	ENSG00000163157	Tropomodulin 4	1	151169986-151176284	Predicted intracellular proteins	Evidence at protein level	HPA028203	Enhanced					Not detected	Tissue enriched	29	skeletal muscle: 378.9	prostate: 13.0	Mixed		
TMPRSS15	ENTK, MGC133046, PRSS7	ENSG00000154646	Transmembrane protease, serine 15	21	18269116-18485879	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015611, HPA072934	Enhanced					Group enriched	Tissue enriched	44	duodenum: 1010.9	small intestine: 22.7	Group enriched	22	U-138 MG: 50.9;U-87 MG: 140.8
TMSB10	TB10	ENSG00000034510	Thymosin beta 10	2	84905625-84906675	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.49e-7 (unfavourable), Thyroid cancer:4.97e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 3706.7	Expressed in all		
TMSB15A	TMSL8, TMSNB	ENSG00000158164	Thymosin beta 15a	X	102513676-102516784	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		prostate: 22.5	thyroid gland: 8.5	Cell line enhanced		AF22: 507.9;NTERA-2: 133.4;RH-30: 226.1;SH-SY5Y: 141.1
TMSB15B	MGC39900	ENSG00000158427	Thymosin beta 15B	X	103918896-103966712	Predicted intracellular proteins	Evidence at protein level	HPA064607	Uncertain					Not detected	Mixed			endometrium: 18.6	Cell line enhanced		AF22: 73.0;REH: 52.5
TMSB4X	TB4X, TMSB4	ENSG00000205542	Thymosin beta 4, X-linked	X	12975108-12977227	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033806	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:6.20e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 11540.2	Expressed in all		
TMSB4Y	TB4Y	ENSG00000154620	Thymosin beta 4, Y-linked	Y	13703567-13706024	Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			testis: 5.7	Cell line enhanced		BEWO: 13.6;HEL: 10.6;RPTEC TERT1: 13.5;SCLC-21H: 6.1
TNF	DIF, TNF-alpha, TNFA, TNFSF2	ENSG00000232810	Tumor necrosis factor	6	31575567-31578336	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 3.7	lymph node: 1.3	Group enriched	5	HDLM-2: 13.9;HMC-1: 12.0;NB-4: 27.3
TNFAIP1	B12, B61, BTBD34, EDP1, MGC2317	ENSG00000109079	TNF alpha induced protein 1	17	28335602-28347009	Predicted intracellular proteins	Evidence at protein level	HPA013333, HPA014641	Uncertain		Enhanced	Nucleoli	Endometrial cancer:7.48e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 69.1	Expressed in all		
TNFAIP2	B94, EXOC3L3	ENSG00000185215	TNF alpha induced protein 2	14	103123442-103137439	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004598, HPA030624	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Golgi apparatus<br>Cytosol	Stomach cancer:2.79e-5 (favourable), Urothelial cancer:7.17e-5 (favourable), Renal cancer:4.10e-4 (unfavourable)	Expressed in all	Expressed in all			urinary bladder: 203.5	Cell line enhanced		RT4: 616.3
TNFAIP3	A20, OTUD7C	ENSG00000118503	TNF alpha induced protein 3	6	137867188-137883312	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002116, HPA067479	Approved		Supported	Vesicles	Renal cancer:6.05e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 345.2	Cell line enhanced		Karpas-707: 118.8;REH: 135.9
TNFAIP8	GG2-1, MDC-3.13, SCC-S2	ENSG00000145779	TNF alpha induced protein 8	5	119268692-119399688	Predicted intracellular proteins	Evidence at protein level	HPA054434, HPA057089	Uncertain		Approved	Nucleoplasm	Breast cancer:2.45e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 134.4	Expressed in all		
TNFAIP8L1	MGC17791	ENSG00000185361	TNF alpha induced protein 8 like 1	19	4639518-4655568	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.28e-7 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 37.1	spleen: 17.5	Expressed in all		
TNFAIP8L2	FLJ23467	ENSG00000163154	TNF alpha induced protein 8 like 2	1	151156629-151159749	Predicted intracellular proteins	Evidence at protein level	HPA062742			Uncertain	Vesicles	Renal cancer:3.53e-7 (unfavourable), Melanoma:3.64e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 34.7;spleen: 39.1	appendix: 25.8	Group enriched	6	HEL: 26.1;HL-60: 13.6;HMC-1: 38.0;NB-4: 15.6;THP-1: 62.9;U-937: 28.8
TNFAIP8L3	FLJ41287	ENSG00000183578	TNF alpha induced protein 8 like 3	15	51056598-51105276	Predicted intracellular proteins	Evidence at protein level	HPA048372, HPA077484	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:3.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 137.0;smooth muscle: 122.3	fallopian tube: 38.9	Cell line enhanced		ASC TERT1: 61.0;HUVEC TERT2: 64.8;LHCN-M2: 60.7;TIME: 85.7
TNFSF13	APRIL, CD256	ENSG00000161955	Tumor necrosis factor superfamily member 13	17	7558292-7561608	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004863	Uncertain				Renal cancer:1.30e-9 (favourable), Glioma:8.28e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 149.6	Cell line enhanced		EFO-21: 41.1;RPTEC TERT1: 83.9
TNFSF4	CD252, gp34, OX-40L, TXGP1	ENSG00000117586	Tumor necrosis factor superfamily member 4	1	173183734-173207313	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059579	Approved		Approved	Nucleus<br>Vesicles		Expressed in all	Tissue enhanced		testis: 7.5	appendix: 3.1	Cell line enhanced		fHDF/TERT166: 32.7;HUVEC TERT2: 68.0;LHCN-M2: 56.4
TNFSF9	4-1BB-L	ENSG00000125657	Tumor necrosis factor superfamily member 9	19	6530999-6535928	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059857			Approved	Golgi apparatus	Renal cancer:1.04e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 3.4	Cell line enhanced		HMC-1: 73.8
TNIK	KIAA0551	ENSG00000154310	TRAF2 and NCK interacting kinase	3	171061339-171460408	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA012128, HPA012297	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 35.5	Cell line enhanced		HEL: 58.9;HMC-1: 63.1;WM-115: 53.8
TNIP1	ABIN-1, KIAA0113, NAF1, VAN	ENSG00000145901	TNFAIP3 interacting protein 1	5	151029945-151093577	Predicted intracellular proteins	Evidence at protein level	HPA037893, HPA037894, HPA071950	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:6.86e-5 (favourable), Breast cancer:5.69e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 132.2	Expressed in all		
TNIP2	ABIN-2, FLIP1, KLIP, MGC4289	ENSG00000168884	TNFAIP3 interacting protein 2	4	2741648-2756376	Predicted intracellular proteins	Evidence at protein level	CAB020818, HPA049886, HPA063197	Supported		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.94e-5 (unfavourable), Endometrial cancer:1.13e-4 (favourable), Lung cancer:5.73e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 22.1	Expressed in all		
TNIP3	ABIN-3, FLJ21162, LIND	ENSG00000050730	TNFAIP3 interacting protein 3	4	121131408-121227466	Predicted intracellular proteins	Evidence at protein level	HPA043063	Uncertain					Mixed	Tissue enhanced		appendix: 8.8	lymph node,tonsil: 2.9	Cell line enhanced		HDLM-2: 6.8;hTEC/SVTERT24-B: 8.0;U-138 MG: 30.3;U-266/70: 6.7;U-266/84: 6.5
TNK1		ENSG00000174292	Tyrosine kinase non receptor 1	17	7380534-7389774	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012065, HPA056452	Uncertain		Approved	Cell Junctions	Urothelial cancer:1.52e-4 (favourable), Endometrial cancer:4.28e-4 (favourable), Renal cancer:6.40e-4 (favourable)	Mixed	Mixed			skin: 5.1	Cell line enhanced		HaCaT: 8.0;T-47d: 6.9
TNK2	ACK, ACK1, p21cdc42Hs	ENSG00000061938	Tyrosine kinase non receptor 2	3	195863364-195911945	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041954	Approved		Approved	Cytosol	Urothelial cancer:1.00e-4 (favourable), Renal cancer:1.30e-4 (unfavourable), Endometrial cancer:8.96e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 109.5	Expressed in all		
TNKS	PARP-5a, PARP5A, pART5, TIN1, TINF1, TNKS1	ENSG00000173273	Tankyrase	8	9555914-9782346	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA025690	Approved		Approved	Nucleoplasm<br>Nuclear membrane		Expressed in all	Expressed in all			testis: 52.8	Expressed in all		
TNKS1BP1	FLJ45975, KIAA1741, TAB182	ENSG00000149115	Tankyrase 1 binding protein 1	11	57299638-57324952	Predicted intracellular proteins	Evidence at protein level	HPA037929, HPA037930	Enhanced				Renal cancer:2.11e-8 (unfavourable)	Expressed in all	Expressed in all			skin: 79.1	Expressed in all		
TNKS2	PARP-5b, PARP-5c, PARP5B, PARP5C, pART6, TANK2, TNKL	ENSG00000107854	Tankyrase 2	10	91798312-91865276	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036606			Approved	Microtubules		Expressed in all	Expressed in all			thyroid gland: 50.4	Expressed in all		
TNNC1	TNNC	ENSG00000114854	Troponin C1, slow skeletal and cardiac type	3	52451102-52454070	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002450, HPA044848, HPA056897	Enhanced		Approved	Nucleoplasm<br>Actin filaments<br>Mitochondria		Mixed	Group enriched	16	heart muscle: 4938.6;skeletal muscle: 7104.7	esophagus: 383.0	Cell line enhanced		CACO-2: 53.1;EFO-21: 58.5;HSkMC: 46.0;U-2 OS: 99.1
TNNC2		ENSG00000101470	Troponin C2, fast skeletal type	20	45823214-45833745	Predicted intracellular proteins	Evidence at protein level	HPA043174, HPA058481	Enhanced		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	78	skeletal muscle: 9898.9	esophagus: 126.3	Group enriched	6	Hep G2: 6.4;HSkMC: 10.1;SCLC-21H: 12.6
TNNI1		ENSG00000159173	Troponin I1, slow skeletal type	1	201403768-201429866	Predicted intracellular proteins	Evidence at protein level	HPA028190	Approved		Uncertain	Nucleus<br>Nucleoli	Head and neck cancer:9.27e-4 (unfavourable)	Group enriched	Tissue enriched	21	skeletal muscle: 4420.6	esophagus: 206.1	Cell line enriched	12	RH-30: 471.8
TNNI2	AMCD2B, DA2B, FSSV	ENSG00000130598	Troponin I2, fast skeletal type	11	1838989-1841680	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB018697, HPA055938	Enhanced		Approved	Plasma membrane<br>Intermediate filaments		Group enriched	Tissue enriched	38	skeletal muscle: 5537.1	esophagus: 144.6	Cell line enhanced		CAPAN-2: 62.9;hTCEpi: 145.7;T-47d: 23.3
TNNI3	CMD2A, CMH7, TNNC1	ENSG00000129991	Troponin I3, cardiac type	19	55151767-55157773	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009349, HPA046428	Enhanced		Approved	Vesicles<br>Cytosol		Mixed	Tissue enriched	174	heart muscle: 3607.1	breast: 20.7	Cell line enhanced		HEK93: 11.1;HMC-1: 17.7;K-562: 34.7
TNNI3K	CARK	ENSG00000116783	TNNI3 interacting kinase	1	74235401-74544428	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	heart muscle: 39.5	testis: 5.3	Not detected		
TNNT1	ANM, FLJ98147, MGC104241, NEM5, STNT, TNT, TNTS	ENSG00000105048	Troponin T1, slow skeletal type	19	55132794-55149354	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015168, HPA058448	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:2.53e-4 (unfavourable), Colorectal cancer:4.66e-4 (unfavourable), Endometrial cancer:4.66e-4 (unfavourable)	Expressed in all	Tissue enriched	12	skeletal muscle: 7568.7	esophagus: 632.9	Cell line enhanced		HMC-1: 728.7;RH-30: 606.8
TNNT2	CMD1D, CMH2, CMPD2	ENSG00000118194	Troponin T2, cardiac type	1	201359008-201377762	Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015371, HPA015774, HPA017888	Enhanced		Uncertain	Nucleus<br>Nucleoli<br>Focal adhesion sites		Mixed	Tissue enriched	203	heart muscle: 5120.1	skin: 25.2	Cell line enriched	30	RH-30: 1495.9
TNNT3	AMCD2B, DA2B, DKFZp779M2348, FSSV	ENSG00000130595	Troponin T3, fast skeletal type	11	1919562-1938706	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB002451, HPA037810, HPA056909	Enhanced				Cervical cancer:7.37e-4 (favourable)	Group enriched	Tissue enriched	72	skeletal muscle: 9522.9	esophagus: 132.2	Cell line enriched	15	HSkMC: 34.3
TNP1		ENSG00000118245	Transition protein 1	2	216859458-216860064	Predicted intracellular proteins	Evidence at protein level	HPA044387	Enhanced					Group enriched	Tissue enriched	2184	testis: 4403.1	thyroid gland: 2.0	Cell line enhanced		Hep G2: 1.7;U-2197: 1.0
TNP2	TP2	ENSG00000178279	Transition protein 2	16	11267748-11269533	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	387	testis: 38.6	all non-specific tissues: 0.0	Not detected		
TNPO1	IPO2, KPNB2, MIP, MIP1, TRN	ENSG00000083312	Transportin 1	5	72816312-72916733	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB016325	Approved		Supported	Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies	Liver cancer:6.55e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 110.4	Expressed in all		
TNPO2	FLJ12155, IPO3, KPNB2B, TRN2	ENSG00000105576	Transportin 2	19	12699194-12724011	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB046446, HPA071498	Approved		Approved	Nucleus<br>Nucleoli	Endometrial cancer:7.16e-5 (unfavourable), Renal cancer:8.18e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 90.9	Expressed in all		
TNPO3	IPO12, LGMD1F, MTR10A, TRN-SR, TRN-SR2	ENSG00000064419	Transportin 3	7	128954180-129055173	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039555, HPA041537	Approved		Enhanced	Vesicles	Liver cancer:3.29e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 48.4	Expressed in all		
TNRC18	CAGL79, KIAA1856, TNRC18A	ENSG00000182095	Trinucleotide repeat containing 18	7	5306790-5425414	Predicted intracellular proteins	Evidence at protein level	HPA020730, HPA024251	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 86.4	Expressed in all		
TNRC6A	CAGH26, GW182, KIAA1460, TNRC6	ENSG00000090905	Trinucleotide repeat containing 6A	16	24610209-24827632	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015305, HPA017869	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 68.2	Expressed in all		
TNRC6B	KIAA1093	ENSG00000100354	Trinucleotide repeat containing 6B	22	40044817-40335808	Predicted intracellular proteins	Evidence at protein level	HPA003180	Approved					Expressed in all	Mixed			testis: 27.6	Expressed in all		
TNRC6C	FLJ20015, KIAA1582	ENSG00000078687	Trinucleotide repeat containing 6C	17	77959240-78108835	Predicted intracellular proteins	Evidence at protein level	HPA022007, HPA062051	Uncertain		Approved	Nucleus	Pancreatic cancer:6.56e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 18.4	Cell line enhanced		MOLT-4: 27.6
TNS1	DKFZp586K0617, MXRA6, PPP1R155, TNS	ENSG00000079308	Tensin 1	2	217799789-218002995	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018774, HPA036089, HPA036090	Approved		Enhanced	Focal adhesion sites	Colorectal cancer:2.41e-4 (unfavourable), Urothelial cancer:5.19e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 319.5	Cell line enhanced		ASC diff: 102.7;fHDF/TERT166: 59.1;REH: 80.9
TNS2	C1-TEN, KIAA1075, TENC1	ENSG00000111077	Tensin 2	12	53046969-53064372	Predicted intracellular proteins	Evidence at protein level	HPA034659	Approved				Pancreatic cancer:1.72e-4 (favourable), Prostate cancer:9.32e-4 (favourable)	Expressed in all	Mixed			adipose tissue: 114.4	Cell line enhanced		ASC diff: 78.4;ASC TERT1: 54.1;HSkMC: 62.2
TNS3	FLJ13732, H_NH0549I23.2, TEM6, TENS1	ENSG00000136205	Tensin 3	7	47275154-47582558	Predicted intracellular proteins	Evidence at protein level	HPA055338, HPA056015	Approved		Enhanced	Focal adhesion sites	Renal cancer:5.21e-4 (favourable)	Expressed in all	Expressed in all			placenta: 81.5	Cell line enhanced		A549: 240.1
TNS4	CTEN	ENSG00000131746	Tensin 4	17	40475828-40501597	Predicted intracellular proteins	Evidence at protein level						Lung cancer:5.16e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 66.6	esophagus: 31.6	Cell line enhanced		HaCaT: 123.8;HBEC3-KT: 447.5;hTCEpi: 328.7;hTERT-HME1: 108.8
TOB1	APRO5, TOB, TROB, TROB1	ENSG00000141232	Transducer of ERBB2, 1	17	50862223-50867978	Predicted intracellular proteins	Evidence at protein level	HPA047839	Approved		Approved	Nucleoplasm<br>Vesicles	Pancreatic cancer:5.04e-5 (unfavourable), Prostate cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 278.7	Expressed in all		
TOB2	APRO5, bK223H9, TOB4, TOBL, TROB2	ENSG00000183864	Transducer of ERBB2, 2	22	41433492-41447023	Predicted intracellular proteins	Evidence at protein level	HPA016603, HPA054112	Approved		Approved	Cytosol	Renal cancer:1.18e-6 (favourable), Endometrial cancer:3.08e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 60.1	Expressed in all		
TOE1	hCaf1z	ENSG00000132773	Target of EGR1, member 1 (nuclear)	1	45339670-45343975	Predicted intracellular proteins	Evidence at protein level	HPA053775, HPA069119	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:6.12e-9 (unfavourable), Renal cancer:2.71e-4 (unfavourable), Head and neck cancer:9.05e-4 (favourable), Stomach cancer:9.98e-4 (favourable)	Expressed in all	Mixed			testis: 11.8	Expressed in all		
TOGARAM2	Crescerin-2, FAM179A, FLJ43249, LOC165186	ENSG00000189350	TOG array regulator of axonemal microtubules 2	2	28956611-29061373	Predicted intracellular proteins	Evidence at protein level	HPA037561, HPA037562	Uncertain					Not detected	Tissue enriched	5	fallopian tube: 13.7	lung: 2.5	Mixed		
TOLLIP	IL-1RAcPIP	ENSG00000078902	Toll interacting protein	11	1274371-1309654	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038621, HPA038622	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.11e-16 (favourable), Glioma:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 132.3	Expressed in all		
TOM1		ENSG00000100284	Target of myb1 membrane trafficking protein	22	35299275-35347994	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA000818, HPA001749	Approved		Approved	Plasma membrane<br>Microtubule organizing center<br>Cytosol	Endometrial cancer:2.20e-5 (favourable), Renal cancer:3.72e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 54.6	Expressed in all		
TOM1L2		ENSG00000175662	Target of myb1 like 2 membrane trafficking protein	17	17843511-17972422	Predicted intracellular proteins	Evidence at protein level	HPA022541, HPA023304	Enhanced		Supported	Golgi apparatus<br>Intermediate filaments	Renal cancer:6.21e-9 (favourable), Head and neck cancer:1.24e-4 (favourable), Pancreatic cancer:1.92e-4 (favourable), Ovarian cancer:2.58e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 110.6	Expressed in all		
TOMM34	HTOM34P, TOM34	ENSG00000025772	Translocase of outer mitochondrial membrane 34	20	44942130-44960486	Predicted intracellular proteins	Evidence at protein level	HPA018845, HPA056875	Enhanced		Enhanced	Cytosol	Liver cancer:8.71e-6 (unfavourable), Head and neck cancer:4.47e-5 (unfavourable), Thyroid cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			testis: 182.2	Expressed in all		
TOMM40	C19orf1, D19S1177E, PER-EC1, PEREC1, TOM40	ENSG00000130204	Translocase of outer mitochondrial membrane 40	19	44890569-44903689	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA036231, HPA036232	Supported		Enhanced	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 34.9	Expressed in all		
TOMM40L	FLJ12770, TOMM40B	ENSG00000158882	Translocase of outer mitochondrial membrane 40 like	1	161225939-161230744	Predicted intracellular proteins	Evidence at protein level	HPA051304	Approved				Liver cancer:1.36e-4 (unfavourable), Endometrial cancer:1.44e-4 (unfavourable), Renal cancer:7.80e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 20.3	Expressed in all		
TOMM5	bA613M10.3, C9orf105, Tom5	ENSG00000175768	Translocase of outer mitochondrial membrane 5	9	37582646-37592642	Predicted intracellular proteins	Evidence at protein level	HPA048712	Approved		Supported	Mitochondria	Liver cancer:2.09e-4 (unfavourable), Ovarian cancer:2.37e-4 (favourable), Melanoma:5.49e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 98.5	Expressed in all		
TOMM6	OBTP, Tom6	ENSG00000214736	Translocase of outer mitochondrial membrane 6	6	41787662-41789898	Predicted intracellular proteins	Evidence at protein level	HPA004801	Approved		Supported	Mitochondria		Not detected	Expressed in all			epididymis: 322.2	Expressed in all		
TONSL	IKBR, NFKBIL2	ENSG00000160949	Tonsoku-like, DNA repair protein	8	144428775-144444444	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024679, HPA046494	Uncertain		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.62e-7 (unfavourable), Liver cancer:2.84e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 5.4	Mixed		
TOP1		ENSG00000198900	Topoisomerase (DNA) I	20	41028818-41124487	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009058, HPA019039	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 71.7	Expressed in all		
TOP1MT		ENSG00000184428	Topoisomerase (DNA) I, mitochondrial	8	143304384-143359979	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001915, HPA021542	Approved		Supported	Mitochondria	Renal cancer:1.52e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 41.2	Expressed in all		
TOP2A	TOP2	ENSG00000131747	Topoisomerase (DNA) II alpha	17	40388516-40417950	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002448, HPA006458, HPA026773	Enhanced	Approved	Supported	Nucleus<br>Nucleoli	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.92e-6 (unfavourable), Pancreatic cancer:3.83e-5 (unfavourable), Lung cancer:4.99e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 108.5	lymph node: 47.7	Expressed in all		
TOP2B		ENSG00000077097	Topoisomerase (DNA) II beta	3	25597905-25664907	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004601, HPA024120, HPA050441	Supported		Enhanced	Nucleus	Liver cancer:1.86e-7 (unfavourable), Renal cancer:2.43e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 107.4	Expressed in all		
TOP3A	TOP3, ZGRF7	ENSG00000177302	Topoisomerase (DNA) III alpha	17	18271428-18315007	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002449	Approved				Pancreatic cancer:1.39e-4 (favourable), Prostate cancer:4.59e-4 (unfavourable)	Expressed in all	Mixed			testis: 12.4	Expressed in all		
TOP3B		ENSG00000100038	Topoisomerase (DNA) III beta	22	21957025-21982816	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA069678			Approved	Vesicles		Not detected	Mixed			spleen: 18.9	Expressed in all		
TOPAZ1	C3orf77, FLJ36157	ENSG00000173769	Testis and ovary specific PAZ domain containing 1	3	44241886-44332098	Predicted intracellular proteins	Evidence at protein level	HPA047431, HPA051034	Uncertain					Not detected	Tissue enriched	65	testis: 6.5	all non-specific tissues: 0.0	Not detected		
TOPBP1	KIAA0259, TOP2BP1	ENSG00000163781	Topoisomerase (DNA) II binding protein 1	3	133598175-133661893	Predicted intracellular proteins	Evidence at protein level	CAB022451, HPA036738, HPA036739	Approved		Enhanced	Nucleus	Liver cancer:4.66e-5 (unfavourable), Endometrial cancer:5.76e-5 (unfavourable), Pancreatic cancer:1.88e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 54.2	Expressed in all		
TOPORS	LUN, RP31, TP53BPL	ENSG00000197579	TOP1 binding arginine/serine rich protein	9	32540544-32552553	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060640, HPA065661	Enhanced		Supported	Nucleoplasm	Renal cancer:6.64e-6 (favourable), Ovarian cancer:7.07e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.6	Expressed in all		
TOR4A	C9orf167, FLJ20245	ENSG00000198113	Torsin family 4 member A	9	137277749-137282641	Predicted intracellular proteins	Evidence at protein level	HPA044913	Enhanced		Approved	Nucleoplasm	Liver cancer:3.44e-4 (unfavourable), Colorectal cancer:6.48e-4 (unfavourable)	Expressed in all	Mixed			stomach: 11.5	Mixed		
TOX	KIAA0808, TOX1	ENSG00000198846	Thymocyte selection associated high mobility group box	8	58805418-59119208	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018322, HPA073241	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.90e-7 (unfavourable), Lung cancer:5.20e-4 (favourable)	Expressed in all	Mixed			lymph node: 21.1	Cell line enhanced		MOLT-4: 117.4;SH-SY5Y: 46.0
TOX2	C20orf100, dJ1108D11.2, GCX-1	ENSG00000124191	TOX high mobility group box family member 2	20	43914864-44069616	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049900, HPA058396	Approved		Supported	Nucleoplasm	Renal cancer:7.45e-8 (unfavourable), Endometrial cancer:2.60e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 19.8	Cell line enhanced		HHSteC: 99.2;U-266/70: 59.6
TOX3	CAGF9, TNRC9	ENSG00000103460	TOX high mobility group box family member 3	16	52438005-52547802	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040376	Enhanced		Approved	Nucleoplasm	Renal cancer:3.08e-12 (favourable), Urothelial cancer:3.95e-4 (favourable)	Mixed	Mixed			stomach: 18.0	Cell line enhanced		AF22: 39.9;HAP1: 20.6;RT4: 62.7;SCLC-21H: 31.8
TOX4	C14orf92, KIAA0737, LCP1	ENSG00000092203	TOX high mobility group box family member 4	14	21476597-21499175	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017880, HPA027551	Approved		Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:8.38e-5 (favourable), Liver cancer:3.46e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.4	Expressed in all		
TP53	LFS1, p53	ENSG00000141510	Tumor protein p53	17	7661779-7687550	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	CAB002973, CAB039238, CAB039239, HPA051244, CAB072876	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.35e-4 (favourable), Prostate cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 50.3	Expressed in all		
TP53AIP1	p53AIP1	ENSG00000120471	Tumor protein p53 regulated apoptosis inducing protein 1	11	128934731-128943399	Predicted intracellular proteins	Evidence at transcript level	HPA044300, HPA048797	Approved					Tissue enhanced	Tissue enhanced		esophagus: 6.3;skin: 22.2	fallopian tube: 4.1	Not detected		
TP53BP1	53BP1, p202, TDRD30	ENSG00000067369	Tumor protein p53 binding protein 1	15	43403061-43510728	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004083, HPA008788, HPA022133	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 51.2	Expressed in all		
TP53BP2	53BP2, ASPP2, PPP1R13A	ENSG00000143514	Tumor protein p53 binding protein 2	1	223779899-223845972	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA021603, HPA050429	Supported		Enhanced	Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 34.6	Mixed		
TP53I3	PIG3	ENSG00000115129	Tumor protein p53 inducible protein 3	2	24077433-24085861	Predicted intracellular proteins	Evidence at protein level	CAB017479, HPA022012, HPA028742	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			esophagus: 97.1	Cell line enriched	7	T-47d: 553.5
TP53INP1	DKFZp434M1317, FLJ22139, P53DINP1, SIP, Teap, TP53INP1A, TP53INP1B	ENSG00000164938	Tumor protein p53 inducible nuclear protein 1	8	94925972-94949411	Predicted intracellular proteins	Evidence at protein level	HPA005856	Uncertain		Supported	Cytosol	Urothelial cancer:5.45e-5 (favourable), Head and neck cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			testis: 52.8	Cell line enhanced		Karpas-707: 57.1;U-266/70: 65.0
TP53INP2	C20orf110, dJ1181N3.1, DKFZp434B2411, DKFZp434O0827, DOR, FLJ21759, FLJ23500, PINH	ENSG00000078804	Tumor protein p53 inducible nuclear protein 2	20	34704290-34713439	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.26e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 86.9	Expressed in all		
TP53RK	BUD32, C20orf64, dJ101A2.2, Nori-2p, prpk	ENSG00000172315	TP53 regulating kinase	20	46684365-46689779	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004688, HPA015837	Approved				Liver cancer:6.27e-5 (unfavourable), Endometrial cancer:6.70e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 16.6	Expressed in all		
TP53TG3	P53TG3, TP53TG3A	ENSG00000183632	TP53 target 3	16	32673528-32676732	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex: 0.3	Not detected		
TP53TG3B		ENSG00000261509	TP53 target 3B	16	33360274-33363478	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	18	epididymis: 22.3	testis: 1.2	Not detected		
TP53TG3C		ENSG00000205457	TP53 target 3C	16	33193659-33196858	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.7	Not detected		
TP53TG3D		ENSG00000205456	TP53 target 3D	16	32252719-32255922	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		epididymis: 4.2;testis: 4.2	adrenal gland,cerebral cortex: 1.1	Cell line enhanced		AN3-CA: 1.1;HEL: 1.0;HMC-1: 1.2;RH-30: 1.0;SCLC-21H: 1.4;U-2 OS: 1.3
TP53TG3E		ENSG00000275034	TP53 target 3 family member E	16	33303739-33306935	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			placenta: 0.2	Not detected		
TP53TG3F		ENSG00000278848	TP53 target 3 family member F	16	33459045-33462249	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	14	epididymis: 7.4;testis: 4.2	placenta: 0.4	Cell line enhanced		HEL: 1.0
TP53TG5	C20orf10, CLG01, dJ453C12.5	ENSG00000124251	TP53 target 5	20	45372563-45407889	Predicted intracellular proteins	Evidence at protein level	HPA041979	Enhanced					Not detected	Tissue enriched	12	testis: 22.2	cerebral cortex: 1.8	Cell line enhanced		CACO-2: 1.6
TP63	EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L	ENSG00000073282	Tumor protein p63	3	189631416-189897279	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000083, HPA006288, HPA007010	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:1.07e-4 (favourable)	Group enriched	Tissue enhanced		esophagus: 60.9;skin: 164.1	urinary bladder: 28.8	Group enriched	5	HaCaT: 77.1;HBEC3-KT: 119.9;hTCEpi: 89.8;hTERT-HME1: 90.5;RT4: 147.6
TP73	P73	ENSG00000078900	Tumor protein p73	1	3652520-3736201	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002514, CAB003022, HPA027314, HPA044516	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:1.82e-4 (favourable), Cervical cancer:2.98e-4 (favourable), Head and neck cancer:9.50e-4 (favourable)	Mixed	Group enriched	5	fallopian tube: 10.8;skin: 7.7	prostate: 1.8	Cell line enhanced		SCLC-21H: 21.2
TPD52L1	D53, hD53	ENSG00000111907	Tumor protein D52-like 1	6	125119049-125264407	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027915, HPA027916	Enhanced		Approved	Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:3.26e-4 (favourable), Thyroid cancer:3.97e-4 (favourable), Urothelial cancer:5.34e-4 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 320.2	salivary gland: 126.1	Cell line enhanced		AN3-CA: 249.0;hTCEpi: 169.3;MCF7: 277.5;RPTEC TERT1: 204.5
TPD52L2	D54, hD54	ENSG00000101150	Tumor protein D52 like 2	20	63865228-63891545	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047489	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.74e-8 (unfavourable), Liver cancer:1.39e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 105.2	Expressed in all		
TPD52L3	NYD-SP25	ENSG00000170777	Tumor protein D52 like 3	9	6328375-6331900	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	2754	testis: 275.3	all non-specific tissues: 0.0	Cell line enriched	12	BEWO: 1.2
TPGS1	C19orf20, GTRGEO22, PGs1	ENSG00000141933	Tubulin polyglutamylase complex subunit 1	19	507497-519654	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:2.24e-4 (favourable), Pancreatic cancer:8.82e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 6.6	Cell line enhanced		HEK93: 32.8;SH-SY5Y: 38.0
TPGS2	C18orf10, DKFZP586M1523, HsT3006	ENSG00000134779	Tubulin polyglutamylase complex subunit 2	18	36777647-36829216	Predicted intracellular proteins	Evidence at protein level	HPA040596, HPA040617, HPA061753	Uncertain		Supported	Nucleoli	Liver cancer:1.24e-5 (unfavourable), Ovarian cancer:1.93e-5 (favourable), Cervical cancer:4.09e-4 (favourable), Testis cancer:7.74e-4 (favourable)	Expressed in all	Expressed in all			testis: 367.2	Expressed in all		
TPH1	TPH, TPRH	ENSG00000129167	Tryptophan hydroxylase 1	11	18017564-18042426	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010767, HPA022483	Enhanced		Uncertain	Cytosol		Mixed	Group enriched	6	colon: 8.8;duodenum: 10.2;rectum: 21.0;small intestine: 12.6;stomach: 15.5	prostate: 2.4	Mixed		
TPH2	FLJ37295, NTPH	ENSG00000139287	Tryptophan hydroxylase 2	12	71938846-72186618	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046274, CAB078198	Enhanced	Supported				Not detected	Tissue enhanced		cerebral cortex: 1.0	testis: 0.2	Not detected		
TPI1		ENSG00000111669	Triosephosphate isomerase 1	12	6867119-6870948	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050924, HPA053568	Uncertain		Enhanced	Nucleoplasm	Liver cancer:1.04e-5 (unfavourable), Renal cancer:6.54e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 942.7	Expressed in all		
TPK1	HTPK1, PP20	ENSG00000196511	Thiamin pyrophosphokinase 1	7	144451941-144836395	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021545, HPA021849	Approved		Approved	Vesicles		Mixed	Mixed			duodenum: 14.4	Cell line enhanced		AN3-CA: 65.0;EFO-21: 19.9
TPM2	AMCD1, DA1, NEM4	ENSG00000198467	Tropomyosin 2 (beta)	9	35681992-35691020	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047089, HPA053624	Approved				Renal cancer:8.51e-10 (unfavourable), Colorectal cancer:2.64e-4 (unfavourable)	Expressed in all	Tissue enriched	6	skeletal muscle: 13466.0	smooth muscle: 2282.0	Cell line enhanced		BJ: 1627.6
TPM3	NEM1, TRK	ENSG00000143549	Tropomyosin 3	1	154155304-154194648	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000261, HPA009066, HPA047089, HPA053624	Approved		Approved	Actin filaments<br>Cytosol	Liver cancer:6.73e-6 (unfavourable), Ovarian cancer:2.39e-5 (favourable), Renal cancer:3.12e-5 (unfavourable), Pancreatic cancer:3.65e-4 (unfavourable), Lung cancer:4.01e-4 (unfavourable)	Expressed in all	Tissue enriched	7	skeletal muscle: 2869.3	bone marrow: 428.4	Expressed in all		
TPM4		ENSG00000167460	Tropomyosin 4	19	16067021-16103005	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004685, HPA047089, HPA053624	Approved		Approved	Actin filaments<br>Cytosol	Renal cancer:1.26e-10 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 814.8	Expressed in all		
TPMT		ENSG00000137364	Thiopurine S-methyltransferase	6	18128311-18155074	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019851	Approved				Endometrial cancer:8.45e-5 (unfavourable), Renal cancer:1.10e-4 (favourable), Ovarian cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 129.8	Expressed in all		
TPP2	TPPII	ENSG00000134900	Tripeptidyl peptidase 2	13	102597003-102679958	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021069, HPA049630	Approved		Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 66.8	Expressed in all		
TPPP	p25, p25alpha, TPPP/p25, TPPP1	ENSG00000171368	Tubulin polymerization promoting protein	5	659862-693395	Predicted intracellular proteins	Evidence at protein level	HPA036575, HPA036576	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:5.40e-6 (favourable)	Expressed in all	Tissue enriched	10	cerebral cortex: 166.6	fallopian tube: 16.9	Cell line enhanced		A549: 6.6;AN3-CA: 5.0;SCLC-21H: 15.6
TPPP2	C14orf8, CT152, p18, p25beta	ENSG00000179636	Tubulin polymerization promoting protein family member 2	14	21024109-21036276	Predicted intracellular proteins	Evidence at protein level	HPA004120	Enhanced					Tissue enhanced	Tissue enriched	46	testis: 309.1	liver: 6.7	Not detected		
TPPP3	CGI-38, p20, p25gamma	ENSG00000159713	Tubulin polymerization promoting protein family member 3	16	67389809-67393535	Predicted intracellular proteins	Evidence at protein level	HPA047629	Approved		Approved	Nucleoli fibrillar center	Renal cancer:8.84e-4 (unfavourable)	Expressed in all	Tissue enriched	6	fallopian tube: 1311.7	lung: 213.8	Cell line enhanced		A549: 51.8;RH-30: 29.0;SCLC-21H: 54.1;SH-SY5Y: 21.0
TPR		ENSG00000047410	Translocated promoter region, nuclear basket protein	1	186311652-186375693	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA019661, HPA019663, HPA024336	Enhanced		Enhanced	Nuclear membrane	Liver cancer:1.06e-4 (unfavourable), Head and neck cancer:4.71e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.0	Expressed in all		
TPRG1	FAM79B, FLJ41238, FLJ43694	ENSG00000188001	Tumor protein p63 regulated 1	3	188947214-189325304	Predicted intracellular proteins	Evidence at protein level	HPA044751, HPA060187	Uncertain		Supported	Nucleoplasm	Breast cancer:5.43e-4 (favourable)	Tissue enhanced	Tissue enhanced		esophagus: 49.1	breast: 28.4	Cell line enhanced		HDLM-2: 8.9;Karpas-707: 3.3;T-47d: 3.9;U-266/70: 3.5
TPRG1L	FAM79A, FLJ21811, RP11-46F15.3	ENSG00000158109	Tumor protein p63 regulated 1 like	1	3625002-3630127	Predicted intracellular proteins	Evidence at protein level	HPA063163, CAB079051		Supported	Approved	Vesicles<br>Cytosol	Renal cancer:1.76e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 102.1	Expressed in all		
TPRKB	CGI-121, CGI121	ENSG00000144034	TP53RK binding protein	2	73729104-73737400	Predicted intracellular proteins	Evidence at protein level	HPA035712	Approved		Supported	Cytosol		Expressed in all	Expressed in all			testis: 79.9	Expressed in all		
TPRN	C9orf75, DFNB79, FLJ90254	ENSG00000176058	Taperin	9	137191617-137204193	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020899	Uncertain		Approved	Plasma membrane	Renal cancer:5.16e-9 (favourable), Cervical cancer:2.13e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 28.3	Mixed		
TPRX1	FLJ40321	ENSG00000178928	Tetrapeptide repeat homeobox 1	19	47801243-47819051	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA044922	Uncertain					Not detected	Tissue enriched	13	testis: 1.3	endometrium: 0.1	Not detected		
TPT1	fortilin, TCTP	ENSG00000133112	Tumor protein, translationally-controlled 1	13	45333471-45341370	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008364, HPA039437	Approved		Supported	Cytosol	Renal cancer:2.54e-5 (unfavourable), Thyroid cancer:4.31e-5 (favourable), Breast cancer:5.90e-5 (favourable), Endometrial cancer:2.35e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 8103.8	Expressed in all		
TPX2	C20orf1, C20orf2, DIL-2, p100	ENSG00000088325	TPX2, microtubule nucleation factor	20	31739271-31801805	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA005487	Enhanced		Enhanced	Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle<br>Microtubule organizing center	Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.07e-7 (unfavourable), Endometrial cancer:2.43e-6 (unfavourable), Pancreatic cancer:2.68e-5 (unfavourable), Lung cancer:6.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 55.6	lymph node: 31.4	Expressed in all		
TRA2A	AWMS1, htra-2-alpha, tra2a	ENSG00000164548	Transformer 2 alpha homolog	7	23504780-23532041	Predicted intracellular proteins	Evidence at protein level	HPA054018	Uncertain		Supported	Nucleoli<br>Vesicles	Renal cancer:1.79e-6 (unfavourable), Liver cancer:2.07e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 67.7	Expressed in all		
TRA2B	Htra2-beta, PPP1R156, SFRS10	ENSG00000136527	Transformer 2 beta homolog (Drosophila)	3	185915906-185938136	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011692, HPA063597, HPA064972	Supported		Enhanced	Nucleoplasm	Ovarian cancer:2.15e-4 (favourable), Liver cancer:8.51e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 56.6	Expressed in all		
TRADD	Hs.89862	ENSG00000102871	TNFRSF1A associated via death domain	16	67154180-67160298	Predicted intracellular proteins	Evidence at protein level	CAB004602, HPA071341	Enhanced		Approved	Cytosol	Endometrial cancer:1.40e-4 (favourable)	Expressed in all	Mixed			spleen: 17.6	Mixed		
TRAF1	EBI6	ENSG00000056558	TNF receptor associated factor 1	9	120902393-120929173	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA001852, CAB009593	Enhanced		Approved	Nucleoplasm	Pancreatic cancer:2.19e-5 (favourable), Renal cancer:4.42e-5 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 37.6	appendix: 27.3	Group enriched	7	HDLM-2: 85.6;WM-115: 111.3
TRAF2	TRAP3	ENSG00000127191	TNF receptor associated factor 2	9	136881912-136926607	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004603, HPA009972, HPA010634	Uncertain		Enhanced	Cytosol	Renal cancer:2.09e-4 (unfavourable), Liver cancer:3.06e-4 (unfavourable), Colorectal cancer:9.32e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 22.5	Expressed in all		
TRAF3	CAP-1, CD40bp, CRAF1, LAP1	ENSG00000131323	TNF receptor associated factor 3	14	102777476-102911500	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002933	Uncertain				Liver cancer:1.02e-5 (unfavourable), Pancreatic cancer:2.42e-5 (favourable)	Expressed in all	Mixed			appendix: 25.7	Expressed in all		
TRAF3IP1	DKFZP434F124, IFT54, MIP-T3, MIPT3	ENSG00000204104	TRAF3 interacting protein 1	2	238320441-238400900	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037857, HPA037858	Approved				Melanoma:2.19e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 30.9	Mixed		
TRAF3IP2	ACT1, C6orf2, C6orf4, C6orf5, C6orf6, CIKS, DKFZP586G0522	ENSG00000056972	TRAF3 interacting protein 2	6	111556454-111606278	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036352	Approved		Approved	Golgi apparatus<br>Vesicles	Endometrial cancer:4.73e-5 (favourable), Renal cancer:5.16e-5 (unfavourable), Cervical cancer:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 50.8	Cell line enhanced		U-2197: 94.7
TRAF4	CART1, MLN62, RNF83	ENSG00000076604	TNF receptor associated factor 4	17	28743984-28750958	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052377	Enhanced					Expressed in all	Mixed			duodenum: 47.2	Expressed in all		
TRAF5	RNF84	ENSG00000082512	TNF receptor associated factor 5	1	211326615-211374946	Predicted intracellular proteins	Evidence at protein level	HPA008052, CAB010277	Enhanced		Supported	Cytosol	Renal cancer:2.94e-10 (unfavourable), Urothelial cancer:7.29e-5 (favourable)	Expressed in all	Mixed			lymph node: 35.1	Cell line enhanced		HDLM-2: 33.6
TRAF6	RNF85	ENSG00000175104	TNF receptor associated factor 6	11	36487027-36510272	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004605, HPA019805, HPA020599	Approved		Supported	Nucleoli<br>Mitochondria	Renal cancer:1.36e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 16.2	Expressed in all		
TRAF7	DKFZp586I021, MGC7807, RFWD1, RNF119	ENSG00000131653	TNF receptor associated factor 7	16	2155698-2178129	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041229	Approved		Supported	Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			skin: 40.6	Expressed in all		
TRAFD1	FLN29	ENSG00000135148	TRAF-type zinc finger domain containing 1	12	112125501-112153609	Predicted intracellular proteins	Evidence at protein level	HPA039254, HPA039266	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.26e-6 (unfavourable), Urothelial cancer:3.92e-5 (favourable), Liver cancer:4.87e-4 (unfavourable), Cervical cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			testis: 53.7	Expressed in all		
TRAIP	RNF206, TRIP	ENSG00000183763	TRAF interacting protein	3	49828599-49856574	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036261, HPA036262	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:8.77e-5 (unfavourable)	Expressed in all	Mixed			testis: 11.3	Mixed		
TRAK1	KIAA1042, MILT1, OIP106	ENSG00000182606	Trafficking kinesin protein 1	3	42013802-42225889	Predicted intracellular proteins	Evidence at protein level	HPA005853, HPA011367	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum	Renal cancer:4.84e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 110.1	Expressed in all		
TRAK2	ALS2CR3, CALS-C, GRIF-1, KIAA0549, MILT2, OIP98	ENSG00000115993	Trafficking kinesin protein 2	2	201377207-201451579	Predicted intracellular proteins	Evidence at protein level	HPA015827, HPA062163	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Renal cancer:7.42e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.1	Expressed in all		
TRANK1	KIAA0342, LBA1	ENSG00000168016	Tetratricopeptide repeat and ankyrin repeat containing 1	3	36826820-36945057	Predicted intracellular proteins	Evidence at protein level	HPA035508	Approved		Approved	Nucleoplasm	Renal cancer:2.52e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 39.1	Cell line enhanced		Daudi: 68.8;HMC-1: 33.4
TRAP1	HSP75, HSP90L	ENSG00000126602	TNF receptor associated protein 1	16	3651639-3717597	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041082, HPA044227	Enhanced		Enhanced	Mitochondria	Colorectal cancer:1.80e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 95.4	Expressed in all		
TRAPPC1	BET5, MUM2	ENSG00000170043	Trafficking protein particle complex 1	17	7930345-7932123	Predicted intracellular proteins	Evidence at protein level	HPA052398	Approved					Expressed in all	Expressed in all			placenta: 165.1	Expressed in all		
TRAPPC10	EHOC-1, TMEM1, TRS130	ENSG00000160218	Trafficking protein particle complex 10	21	44012319-44106552	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050423	Supported					Expressed in all	Expressed in all			parathyroid gland: 14.4	Expressed in all		
TRAPPC11	C4orf41, FLJ12716, foigr, gry	ENSG00000168538	Trafficking protein particle complex 11	4	183659267-183713594	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045427			Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:2.66e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.2	Expressed in all		
TRAPPC12	CGI-87, TTC-15, TTC15	ENSG00000171853	Trafficking protein particle complex 12	2	3379675-3485094	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034799	Uncertain				Breast cancer:1.80e-5 (favourable), Renal cancer:2.44e-4 (unfavourable), Pancreatic cancer:9.15e-4 (favourable)	Expressed in all	Expressed in all			testis: 48.7	Expressed in all		
TRAPPC13	C5orf44, FLJ13611, FLJ26957, MGC48585	ENSG00000113597	Trafficking protein particle complex 13	5	65624716-65666233	Predicted intracellular proteins	Evidence at protein level	HPA037777	Approved		Approved	Nucleus<br>Plasma membrane	Renal cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			prostate: 29.8	Expressed in all		
TRAPPC2	hYP38334, MIP-2A, SEDL, SEDT, TRS20, ZNF547L	ENSG00000196459	Trafficking protein particle complex 2	X	13712244-13734635	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004665, HPA063308	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles	Urothelial cancer:7.89e-5 (favourable), Ovarian cancer:6.35e-4 (favourable), Cervical cancer:8.09e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 16.5	Expressed in all		
TRAPPC2B	MIP-2A, SEDLP, SEDLP1, TRAPPC2P1	ENSG00000256060	Trafficking protein particle complex 2B	19	57363511-57365353	Predicted intracellular proteins	Evidence at protein level	HPA063308			Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles	Renal cancer:1.28e-4 (favourable)	Expressed in all	Expressed in all			testis: 28.8	Mixed		
TRAPPC2L	HSPC176	ENSG00000167515	Trafficking protein particle complex 2 like	16	88856220-88862686	Predicted intracellular proteins	Evidence at protein level	HPA041714	Approved		Supported	Vesicles<br>Cytosol	Endometrial cancer:3.75e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 91.5	Expressed in all		
TRAPPC3	BET3	ENSG00000054116	Trafficking protein particle complex 3	1	36136570-36156053	Predicted intracellular proteins	Evidence at protein level	HPA028408	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:2.70e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 102.1	Expressed in all		
TRAPPC3L	bA259P20.2, BET3L, FLJ11180	ENSG00000173626	Trafficking protein particle complex 3 like	6	116494989-116545610	Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			spleen: 6.5	Cell line enhanced		Karpas-707: 4.7
TRAPPC4	PTD009, SBDN, TRS23	ENSG00000196655	Trafficking protein particle complex 4	11	119018432-119025454	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039752, HPA041371	Approved		Approved	Cytosol	Liver cancer:2.03e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 15.0	Expressed in all		
TRAPPC5	MGC52424, TRS31	ENSG00000181029	Trafficking protein particle complex 5	19	7680843-7687703	Predicted intracellular proteins	Evidence at protein level	HPA042221, HPA049064	Uncertain		Approved	Vesicles		Mixed	Expressed in all			testis: 69.8	Expressed in all		
TRAPPC6A	HSPC289, MGC2650, TRS33	ENSG00000007255	Trafficking protein particle complex 6A	19	45162928-45178237	Predicted intracellular proteins	Evidence at protein level	HPA043043	Approved				Renal cancer:2.23e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.5	Expressed in all		
TRAPPC6B		ENSG00000182400	Trafficking protein particle complex 6B	14	39147811-39170532	Predicted intracellular proteins	Evidence at protein level	HPA047928	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 45.8	Expressed in all		
TRAPPC8	GSG1, HsT2706, KIAA1012, TRS85	ENSG00000153339	Trafficking protein particle complex 8	18	31829173-31953136	Predicted intracellular proteins	Evidence at protein level	HPA041107	Approved		Approved	Microtubules<br>Cytosol	Renal cancer:1.85e-9 (favourable)	Expressed in all	Expressed in all			testis: 54.2	Expressed in all		
TRAPPC9	IKBKBBP, KIAA1882, MRT13, NIBP, T1, TRS120	ENSG00000167632	Trafficking protein particle complex 9	8	139730343-140458579	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026579			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:5.11e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 49.7	Expressed in all		
TRDMT1	DNMT2, RNMT1	ENSG00000107614	TRNA aspartic acid methyltransferase 1	10	17142254-17202054	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009468, HPA036945, HPA036946	Approved		Approved	Nucleus<br>Nucleoli<br>Centrosome		Mixed	Mixed			parathyroid gland: 8.7	Mixed		
TRERF1	BCAR2, dJ139D8.5, HSA277276, RAPA, TReP-132	ENSG00000124496	Transcriptional regulating factor 1	6	42224931-42452051	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027771, HPA051273, HPA059943	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.67e-5 (unfavourable)	Mixed	Mixed			testis: 10.9	Cell line enhanced		HDLM-2: 133.6
TREX2		ENSG00000183479	Three prime repair exonuclease 2	X	153444720-153470587	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054060	Uncertain					Mixed	Tissue enriched	8	skin: 28.8	seminal vesicle: 3.4	Cell line enhanced		U-937: 5.4
TRIAP1	HSPC132, MDM35, P53CSV, WF-1	ENSG00000170855	TP53 regulated inhibitor of apoptosis 1	12	120443961-120446412	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA053640	Approved		Approved	Nucleoplasm<br>Mitochondria	Melanoma:2.22e-4 (unfavourable), Renal cancer:8.77e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 40.3	Expressed in all		
TRIB1	C8FW, GIG2, TRB1	ENSG00000173334	Tribbles pseudokinase 1	8	125430321-125438405	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA063982			Approved	Plasma membrane		Expressed in all	Expressed in all			bone marrow: 243.6	Cell line enhanced		HEL: 173.6
TRIB3	C20orf97, dJ1103G7.3, TRB3	ENSG00000101255	Tribbles pseudokinase 3	20	362835-397559	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055442	Approved		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli	Renal cancer:2.07e-13 (unfavourable), Liver cancer:6.75e-5 (unfavourable), Head and neck cancer:1.70e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 51.4	liver: 12.5	Cell line enhanced		HHSteC: 437.1;hTERT-HME1: 292.4;SK-MEL-30: 388.6
TRIM10	HERF1, RFB30, RNF9	ENSG00000204613	Tripartite motif containing 10	6	30151945-30160934	Predicted intracellular proteins	Evidence at protein level	HPA043325	Uncertain					Mixed	Not detected			kidney: 0.4	Not detected		
TRIM11	BIA1, RNF92	ENSG00000154370	Tripartite motif containing 11	1	228393673-228406840	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028541, HPA043879	Approved		Enhanced	Nucleus<br>Cytosol	Liver cancer:7.42e-5 (unfavourable), Renal cancer:1.62e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 18.8	Expressed in all		
TRIM14	KIAA0129	ENSG00000106785	Tripartite motif containing 14	9	98069275-98119212	Predicted intracellular proteins	Evidence at protein level	HPA053217	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 37.6	Mixed		
TRIM15	RNF93, ZNF178, ZNFB7	ENSG00000204610	Tripartite motif containing 15	6	30163206-30172696	Predicted intracellular proteins	Evidence at protein level	HPA047527	Uncertain					Tissue enhanced	Tissue enhanced		colon: 2.6;duodenum: 3.6	appendix,small intestine: 1.1	Cell line enriched	24	HEL: 15.2
TRIM16	EBBP	ENSG00000221926	Tripartite motif containing 16	17	15627960-15684311	Predicted intracellular proteins	Evidence at protein level	HPA023623, HPA066431	Uncertain		Supported	Plasma membrane<br>Cytosol	Liver cancer:3.94e-4 (unfavourable), Urothelial cancer:6.71e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 117.8	Cell line enhanced		A549: 255.9;HaCaT: 197.9
TRIM16L	TRIM70	ENSG00000108448	Tripartite motif containing 16-like	17	18697998-18736118	Predicted intracellular proteins	Evidence at protein level	HPA066431			Approved	Plasma membrane<br>Cytosol	Thyroid cancer:2.29e-5 (unfavourable), Liver cancer:2.87e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 22.7	Cell line enhanced		A549: 290.9;HeLa: 215.6
TRIM17	RBCC, RNF16, terf	ENSG00000162931	Tripartite motif containing 17	1	228407940-228416861	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054908	Uncertain		Approved	Vesicles	Breast cancer:1.86e-4 (favourable)	Mixed	Tissue enhanced		testis: 27.8	cerebral cortex: 6.1	Cell line enhanced		BEWO: 8.7;SH-SY5Y: 5.0;T-47d: 10.6
TRIM2	CMT2R, KIAA0517, RNF86	ENSG00000109654	Tripartite motif containing 2	4	153152342-153339320	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035853, HPA035854	Enhanced		Approved	Centrosome	Renal cancer:6.58e-14 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 155.1	thyroid gland: 110.7	Cell line enhanced		AF22: 68.3
TRIM21	RNF81, Ro/SSA, RO52, SSA1	ENSG00000132109	Tripartite motif containing 21	11	4384897-4393696	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004566, HPA005673	Approved		Approved	Nucleoplasm	Thyroid cancer:2.26e-6 (favourable), Breast cancer:4.83e-5 (favourable), Liver cancer:1.87e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 41.2	Mixed		
TRIM22	GPSTAF50, RNF94, STAF50	ENSG00000132274	Tripartite motif containing 22	11	5689689-5737089	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003307, HPA003575	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			spleen: 174.9	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 183.3
TRIM23	ARD1, ARFD1, RNF46	ENSG00000113595	Tripartite motif containing 23	5	65589680-65625975	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039605	Approved					Expressed in all	Expressed in all			cerebral cortex: 46.9	Expressed in all		
TRIM25	EFP, RNF147, ZNF147	ENSG00000121060	Tripartite motif containing 25	17	56887909-56914038	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005909	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Pancreatic cancer:3.36e-4 (favourable), Stomach cancer:9.35e-4 (favourable), Liver cancer:9.37e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 34.8	Mixed		
TRIM26	RNF95, ZNF173	ENSG00000234127	Tripartite motif containing 26	6	30184455-30213427	Predicted intracellular proteins	Evidence at protein level	HPA044975, HPA050456	Approved		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:3.25e-5 (favourable)	Expressed in all	Mixed			fallopian tube: 10.4	Mixed		
TRIM27	RFP, RNF76	ENSG00000204713	Tripartite motif containing 27	6	28903002-28923989	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048684, HPA053408	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:3.50e-6 (unfavourable), Urothelial cancer:2.71e-4 (favourable)	Expressed in all	Mixed			appendix: 5.6	Mixed		
TRIM29	ATDC, FLJ36085	ENSG00000137699	Tripartite motif containing 29	11	120111275-120185529	Predicted intracellular proteins	Evidence at protein level	HPA020053	Enhanced		Supported	Nucleoplasm<br>Intermediate filaments	Endometrial cancer:2.88e-4 (unfavourable), Pancreatic cancer:4.46e-4 (unfavourable), Stomach cancer:4.93e-4 (favourable)	Tissue enhanced	Group enriched	6	esophagus: 400.3;skin: 455.7	tonsil: 68.3	Cell line enhanced		HaCaT: 211.2;hTCEpi: 225.5;RT4: 101.2;SiHa: 190.1
TRIM3	BERP, HAC1, RNF22, RNF97	ENSG00000110171	Tripartite motif containing 3	11	6448613-6474459	Predicted intracellular proteins	Evidence at protein level	HPA043396, HPA048233	Uncertain		Approved	Mitochondria	Renal cancer:1.07e-5 (unfavourable), Pancreatic cancer:5.49e-5 (favourable), Endometrial cancer:2.20e-4 (favourable)	Expressed in all	Mixed			duodenum: 17.8	Cell line enhanced		SK-BR-3: 40.6
TRIM31	C6orf13, HCG1, HCGI, RNF	ENSG00000204616	Tripartite motif containing 31	6	30102897-30113106	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046400	Uncertain					Group enriched	Group enriched	6	colon: 10.0;small intestine: 2.3;stomach: 2.1;urinary bladder: 2.7	duodenum: 0.7	Cell line enriched	527	RT4: 232.7
TRIM32	BBS11, HT2A, LGMD2H, TATIP	ENSG00000119401	Tripartite motif containing 32	9	116687302-116701300	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050060	Approved		Approved	Intermediate filaments	Head and neck cancer:4.53e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 21.2	Mixed		
TRIM33	FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA	ENSG00000197323	Tripartite motif containing 33	1	114392777-114511160	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004345	Supported		Approved	Nucleoplasm<br>Vesicles	Colorectal cancer:6.20e-4 (favourable), Head and neck cancer:8.93e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
TRIM34	RNF21	ENSG00000258659	Tripartite motif containing 34	11	5619764-5644398	Predicted intracellular proteins	Evidence at protein level	HPA077996			Approved	Nucleoli<br>Centrosome		Not detected	Mixed			spleen: 18.5	Mixed		
TRIM35	HLS5, KIAA1098, MAIR	ENSG00000104228	Tripartite motif containing 35	8	27284887-27311319	Predicted intracellular proteins	Evidence at protein level	HPA019647	Approved		Approved	Nucleoplasm	Renal cancer:5.59e-7 (favourable), Head and neck cancer:1.38e-4 (favourable)	Expressed in all	Expressed in all			skin: 14.6	Expressed in all		
TRIM36	HAPRIN, RBCC728, RNF98	ENSG00000152503	Tripartite motif containing 36	5	115124762-115180546	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA061321			Approved	Nucleus<br>Cytosol		Tissue enhanced	Tissue enriched	16	testis: 313.5	cerebral cortex: 19.9	Cell line enhanced		RH-30: 23.2;SCLC-21H: 31.3;SH-SY5Y: 20.6
TRIM37	KIAA0898, MUL, POB1, TEF3	ENSG00000108395	Tripartite motif containing 37	17	58982638-59106921	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021911	Uncertain				Liver cancer:4.99e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 117.5	Expressed in all		
TRIM38	RNF15, RORET	ENSG00000112343	Tripartite motif containing 38	6	25962802-25991226	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031685	Approved		Approved	Plasma membrane<br>Cell Junctions<br>Centrosome	Urothelial cancer:4.94e-9 (favourable), Thyroid cancer:8.20e-5 (favourable), Ovarian cancer:8.95e-5 (favourable)	Expressed in all	Mixed			spleen: 19.7	Mixed		
TRIM39	RNF23	ENSG00000204599	Tripartite motif containing 39	6	30326479-30343729	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051120, HPA059496	Uncertain		Supported	Cytosol	Pancreatic cancer:2.50e-4 (favourable)	Expressed in all	Mixed			testis: 4.1	Mixed		
TRIM39-RPP21		ENSG00000248167	TRIM39-RPP21 readthrough	6	30328907-30346854	Predicted intracellular proteins	Evidence at protein level	HPA051120	Uncertain		Supported	Cytosol		Not detected	Not detected			esophagus,testis: 0.2	Not detected		
TRIM4	RNF87	ENSG00000146833	Tripartite motif containing 4	7	99876958-99919600	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019356, HPA029461	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.36e-6 (favourable)	Expressed in all	Expressed in all			ovary: 50.6	Mixed		
TRIM40	RNF35	ENSG00000204614	Tripartite motif containing 40	6	30136108-30148735	Predicted intracellular proteins	Evidence at protein level	HPA043818	Uncertain					Tissue enhanced	Not detected			colon: 0.4	Cell line enriched	11	HEL: 1.0
TRIM41	MGC1127, RINCK	ENSG00000146063	Tripartite motif containing 41	5	181222499-181235809	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024204	Approved		Supported	Nucleoli<br>Nuclear bodies	Thyroid cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 21.7	Expressed in all		
TRIM42	FLJ40097, PPP1R40, T4A1	ENSG00000155890	Tripartite motif containing 42	3	140678039-140701150	Predicted intracellular proteins	Evidence at protein level	HPA003581, HPA022481			Uncertain	Nucleoplasm<br>Mitochondria		Not detected	Tissue enriched	293	testis: 29.2	all non-specific tissues: 0.0	Not detected		
TRIM43	TRIM43A	ENSG00000144015	Tripartite motif containing 43	2	95592018-95599778	Predicted intracellular proteins	Evidence at protein level	HPA042223, HPA042772	Uncertain					Not detected	Not detected			testis: 0.7	Not detected		
TRIM43B		ENSG00000144010	Tripartite motif containing 43B	2	95476967-95484731	Predicted intracellular proteins	No evidence	HPA042223, HPA042772	Uncertain					Not detected	Not detected			testis: 0.6	Not detected		
TRIM44	DIPB, MC7	ENSG00000166326	Tripartite motif containing 44	11	35662805-35818007	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049053, HPA057633	Approved		Approved	Vesicles<br>Plasma membrane	Liver cancer:5.24e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.7	Mixed		
TRIM45	FLJ13181, RNF99	ENSG00000134253	Tripartite motif containing 45	1	117111060-117122587	Predicted intracellular proteins	Evidence at protein level	HPA030266, HPA054308	Uncertain		Supported	Cytokinetic bridge<br>Cytosol	Breast cancer:1.58e-4 (favourable), Thyroid cancer:2.92e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 14.4	Cell line enhanced		RH-30: 30.6
TRIM46	FLJ23229, TRIFIC	ENSG00000163462	Tripartite motif containing 46	1	155173787-155184971	Predicted intracellular proteins	Evidence at protein level	HPA030389, HPA055583	Enhanced		Approved	Intermediate filaments<br>Cytosol	Endometrial cancer:2.61e-7 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 7.9;epididymis: 4.0	smooth muscle: 1.5	Cell line enhanced		SH-SY5Y: 11.1
TRIM47	GOA, RNF100	ENSG00000132481	Tripartite motif containing 47	17	75874161-75878575	Predicted intracellular proteins	Evidence at protein level	HPA014933	Uncertain		Supported	Cytosol	Liver cancer:5.59e-5 (unfavourable), Renal cancer:9.69e-5 (unfavourable), Breast cancer:6.54e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 23.8	Mixed		
TRIM48	RNF101	ENSG00000150244	Tripartite motif containing 48	11	55262182-55271119	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Not detected			skin: 0.3	Not detected		
TRIM49	RNF18, TRIM49A	ENSG00000168930	Tripartite motif containing 49	11	89797655-89808575	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Not detected		
TRIM49B		ENSG00000182053	Tripartite motif containing 49B	11	49027501-49038451	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
TRIM49C	TRIM49L2	ENSG00000204449	Tripartite motif containing 49C	11	90031106-90042025	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
TRIM49D1	TRIM49D, TRIM49D1P, TRIM49DP	ENSG00000223417	Tripartite motif containing 49D1	11	89911111-89921767	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
TRIM49D2	TRIM49D2P, TRIM49L, TRIM49L1	ENSG00000233802	Tripartite motif containing 49D2	11	89924064-89933063	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
TRIM5	RNF88, TRIM5alpha	ENSG00000132256	Tripartite motif containing 5	11	5663557-5938619	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB013497, HPA023420, HPA023422	Approved		Supported	Cytosol		Expressed in all	Mixed			epididymis: 26.9	Expressed in all		
TRIM50	FLJ32804, TRIM50A	ENSG00000146755	Tripartite motif containing 50	7	73312539-73328082	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019862, HPA047843	Uncertain		Approved	Cytosol	Renal cancer:9.36e-7 (favourable)	Group enriched	Tissue enhanced		stomach: 10.4;testis: 4.6	kidney: 1.7	Cell line enriched	25	Hep G2: 4.6
TRIM51	SPRYD5, TRIM51A	ENSG00000124900	Tripartite motif-containing 51	11	55883297-55891810	Predicted intracellular proteins	Evidence at transcript level	HPA044988, HPA077883	Uncertain		Approved	Nucleoli<br>Vesicles		Tissue enriched	Not detected			testis: 0.4	Group enriched	101	SK-MEL-30: 45.9;WM-115: 14.6
TRIM52	RNF102	ENSG00000183718	Tripartite motif containing 52	5	181254417-181261139	Predicted intracellular proteins	Evidence at protein level	HPA054565, HPA056819	Uncertain		Supported	Nucleoli<br>Intermediate filaments	Renal cancer:3.46e-4 (unfavourable), Urothelial cancer:4.07e-4 (favourable)	Expressed in all	Expressed in all			spleen: 16.6	Expressed in all		
TRIM54	MURF, MURF-3, RNF30	ENSG00000138100	Tripartite motif containing 54	2	27282392-27307439	Predicted intracellular proteins	Evidence at protein level	HPA019690	Uncertain				Renal cancer:6.46e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 63.9;skeletal muscle: 181.1	epididymis: 30.7	Group enriched	13	HAP1: 7.4;NTERA-2: 15.3
TRIM56	RNF109	ENSG00000169871	Tripartite motif containing 56	7	101085439-101097967	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024358	Approved		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:2.13e-4 (favourable), Liver cancer:3.87e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 29.5	Mixed		
TRIM58	BIA2	ENSG00000162722	Tripartite motif containing 58	1	247857199-247878205	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023637	Uncertain					Mixed	Group enriched	6	bone marrow: 16.1;placenta: 6.8;testis: 5.4;thyroid gland: 22.0	prostate: 2.1	Group enriched	5	HAP1: 15.0;HEL: 35.6;K-562: 19.9;PC-3: 34.5;U-2 OS: 31.0;U-937: 8.8;WM-115: 38.8
TRIM6	RNF89	ENSG00000121236	Tripartite motif containing 6	11	5596109-5612958	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060514	Uncertain					Mixed	Tissue enhanced		kidney: 22.5	testis: 17.2	Cell line enhanced		NTERA-2: 22.2;U-2 OS: 22.5
TRIM6-TRIM34		ENSG00000258588	TRIM6-TRIM34 readthrough	11	5596725-5644398	Predicted intracellular proteins	Evidence at transcript level	HPA077996			Approved	Nucleoli<br>Centrosome		Not detected	Not detected			testis: 0.6	Cell line enriched	7	A549: 4.1
TRIM60	FLJ35882, RNF129, RNF33	ENSG00000176979	Tripartite motif containing 60	4	165031953-165041744	Predicted intracellular proteins	Evidence at transcript level	HPA035809, HPA035810, HPA061496	Uncertain					Tissue enriched	Group enriched	13	placenta: 2.1;testis: 2.7	skin: 0.1	Cell line enriched	17	BEWO: 13.5
TRIM61	RNF35	ENSG00000183439	Tripartite motif containing 61	4	164954446-164977668	Predicted intracellular proteins	Evidence at transcript level	HPA049109	Uncertain		Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		testis: 10.5	thyroid gland: 4.6	Cell line enhanced		HHSteC: 6.6;U-266/70: 8.1;U-266/84: 4.0
TRIM62	DEAR1, FLJ10759	ENSG00000116525	Tripartite motif containing 62	1	33145402-33182059	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050061			Approved	Vesicles<br>Focal adhesion sites	Renal cancer:7.08e-5 (unfavourable)	Expressed in all	Mixed			skin: 11.6	Expressed in all		
TRIM63	IRF, MURF-1, RNF28, SMRZ	ENSG00000158022	Tripartite motif containing 63	1	26051304-26068436	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Group enriched	16	heart muscle: 101.2;skeletal muscle: 139.3	esophagus: 7.6	Group enriched	35	ASC diff: 11.0;SK-MEL-30: 42.2
TRIM64	C11orf28, TRIM64A	ENSG00000204450	Tripartite motif containing 64	11	89968502-89975228	Predicted intracellular proteins	Evidence at transcript level	HPA045370	Approved					Not detected	Tissue enriched	11	placenta: 1.1	all non-specific tissues: 0.0	Not detected		
TRIM64B		ENSG00000189253	Tripartite motif containing 64B	11	89869282-89876017	Predicted intracellular proteins	Evidence at transcript level	HPA045370	Approved					Not detected	Tissue enriched	18	placenta: 3.1	testis,thyroid gland: 0.1	Not detected		
TRIM64C		ENSG00000214891	Tripartite motif containing 64C	11	49053714-49059112	Predicted intracellular proteins	No evidence	HPA045370	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TRIM65		ENSG00000141569	Tripartite motif containing 65	17	75880335-75897003	Predicted intracellular proteins	Evidence at protein level	HPA021575, HPA021578, HPA064820	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:4.74e-6 (unfavourable), Renal cancer:1.82e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 20.4	Expressed in all		
TRIM66	C11orf29, KIAA0298, TIF1D	ENSG00000166436	Tripartite motif containing 66	11	8612037-8671866	Predicted intracellular proteins	Evidence at protein level	HPA027420	Approved		Supported	Nucleoplasm	Renal cancer:3.96e-4 (unfavourable), Pancreatic cancer:8.89e-4 (favourable)	Expressed in all	Mixed			testis: 14.0	Mixed		
TRIM67	TNL	ENSG00000119283	Tripartite motif containing 67	1	231162112-231221556	Predicted intracellular proteins	Evidence at transcript level	HPA034776	Uncertain					Not detected	Tissue enriched	28	cerebral cortex: 10.3	adrenal gland,testis: 0.3	Cell line enhanced		SCLC-21H: 2.8
TRIM68	FLJ10369, RNF137, SS-56	ENSG00000167333	Tripartite motif containing 68	11	4598672-4608259	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023455	Uncertain		Supported	Nucleus<br>Cytosol	Renal cancer:4.14e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 16.0	Mixed		
TRIM69	RNF36, Trif, TRIMLESS	ENSG00000185880	Tripartite motif containing 69	15	44728988-44767829	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028894	Enhanced				Renal cancer:2.26e-5 (favourable)	Expressed in all	Tissue enriched	17	testis: 57.2	cerebral cortex: 3.4	Cell line enhanced		Karpas-707: 1.8;U-266/70: 6.7
TRIM7	GNIP, RNF90	ENSG00000146054	Tripartite motif containing 7	5	181193924-181205293	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039213	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol		Mixed	Group enriched	5	skeletal muscle: 67.7;skin: 22.1	esophagus: 8.6	Cell line enhanced		HDLM-2: 34.1;PC-3: 18.2
TRIM71	LIN-41, LIN41	ENSG00000206557	Tripartite motif containing 71	3	32818018-32897826	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038141, HPA038142	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Focal adhesion sites		Tissue enriched	Tissue enriched	8	testis: 9.1	lung: 1.1	Group enriched	6	AF22: 31.1;BEWO: 91.3;CACO-2: 19.0;Hep G2: 43.4;NTERA-2: 84.2
TRIM72	MG53	ENSG00000177238	Tripartite motif containing 72	16	31214021-31231537	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023122, HPA054909	Enhanced		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enriched	19	skeletal muscle: 52.4	prostate: 2.8	Cell line enhanced		LHCN-M2: 9.1;RH-30: 27.1;U-266/70: 13.3
TRIM73	TRIM50B	ENSG00000178809	Tripartite motif containing 73	7	75395063-75410996	Predicted intracellular proteins	Evidence at transcript level	HPA047843, HPA051845	Uncertain		Approved	Cytosol		Not detected	Mixed			stomach: 8.8	Cell line enhanced		Hep G2: 7.1
TRIM74	MGC45440, TRIM50C	ENSG00000155428	Tripartite motif containing 74	7	72959485-72969466	Predicted intracellular proteins	Evidence at protein level	HPA047843			Approved	Cytosol		Not detected	Tissue enhanced		stomach: 5.3	testis: 3.9	Cell line enhanced		HEK93: 3.5
TRIM75P	TRIM75	ENSG00000250374	Tripartite motif containing 75, pseudogene	4	165059148-165060554	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			placenta,testis: 0.2	Cell line enriched	17	BEWO: 2.0
TRIM77	TRIM77P	ENSG00000214414	Tripartite motif containing 77	11	89710299-89717872	Predicted intracellular proteins	Evidence at transcript level	HPA039896	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TRIM8	GERP, RNF27	ENSG00000171206	Tripartite motif containing 8	10	102644496-102658407	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023560, HPA023561	Approved		Enhanced	Nucleoplasm<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 60.9	Expressed in all		
TRIM9	RNF91, SPRING	ENSG00000100505	Tripartite motif containing 9	14	50975262-51096061	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041489			Supported	Cytosol		Tissue enriched	Tissue enriched	11	cerebral cortex: 79.2	gallbladder: 6.9	Cell line enhanced		AN3-CA: 29.8;HAP1: 23.6;HDLM-2: 33.8;SCLC-21H: 38.5
TRIML1	FLJ36180, RNF209	ENSG00000184108	Tripartite motif family like 1	4	188139419-188147743	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	147	testis: 14.7	all non-specific tissues: 0.0	Cell line enriched	12	BEWO: 1.5
TRIML2	FLJ25801, SPRYD6	ENSG00000179046	Tripartite motif family like 2	4	188091273-188109603	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043838	Uncertain		Approved	Plasma membrane<br>Cytosol		Tissue enriched	Group enriched	26	placenta: 5.9;testis: 3.4	cerebral cortex,lung: 0.1	Cell line enhanced		A549: 30.5;BEWO: 17.7;hTCEpi: 15.4;NTERA-2: 34.0
TRIOBP	DFNB28, HRIHFB2122, KIAA1662, TAP68, Tara	ENSG00000100106	TRIO and F-actin binding protein	22	37697004-37776556	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003747, HPA019769	Enhanced				Cervical cancer:4.29e-4 (favourable)	Expressed in all	Expressed in all			spleen: 65.9	Expressed in all		
TRIP10	CIP4, HSTP, STOT, STP	ENSG00000125733	Thyroid hormone receptor interactor 10	19	6737925-6751526	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041934, HPA072625, HPA073886	Approved		Supported	Nucleoplasm<br>Vesicles	Head and neck cancer:1.76e-4 (favourable), Colorectal cancer:3.61e-4 (unfavourable), Renal cancer:4.66e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 129.0	Mixed		
TRIP11	CEV14, GMAP-210, GMAP210, Trip230	ENSG00000100815	Thyroid hormone receptor interactor 11	14	91965991-92040896	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002570, HPA070684	Supported		Enhanced	Nucleus<br>Golgi apparatus	Renal cancer:1.78e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.5	Expressed in all		
TRIP12	KIAA0045	ENSG00000153827	Thyroid hormone receptor interactor 12	2	229763838-229923239	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036835, HPA045893	Enhanced		Approved	Nuclear speckles	Liver cancer:3.60e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 270.8	Expressed in all		
TRIP13	16E1BP	ENSG00000071539	Thyroid hormone receptor interactor 13	5	892643-919357	Predicted intracellular proteins	Evidence at protein level	HPA005727, HPA053093	Enhanced		Approved	Nucleus	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.30e-6 (unfavourable), Ovarian cancer:1.39e-4 (favourable), Endometrial cancer:3.93e-4 (unfavourable)	Mixed	Tissue enriched	5	testis: 53.5	fallopian tube: 9.9	Mixed		
TRIP4	HsT17391, ZC2HC5	ENSG00000103671	Thyroid hormone receptor interactor 4	15	64387748-64455303	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA016605, HPA050666	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.34e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 42.2	Expressed in all		
TRIP6	MGC10556, MGC10558, MGC29959, MGC3837, MGC4423, OIP1, ZRP-1	ENSG00000087077	Thyroid hormone receptor interactor 6	7	100867138-100873454	Predicted intracellular proteins	Evidence at protein level	CAB046454, CAB046460, HPA052813	Approved		Supported	Plasma membrane<br>Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 84.7	Mixed		
TRIT1	FLJ20061, IPT	ENSG00000043514	TRNA isopentenyltransferase 1	1	39841022-39883511	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024174	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.08e-8 (unfavourable), Liver cancer:5.34e-6 (unfavourable), Endometrial cancer:8.80e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 25.1	Expressed in all		
TRMO	C9orf156, HSPC219	ENSG00000136932	TRNA methyltransferase O	9	97904489-97922570	Predicted intracellular proteins	Evidence at protein level	HPA021281, HPA052197	Approved		Approved	Nucleoplasm	Renal cancer:4.81e-10 (favourable)	Expressed in all	Expressed in all			thyroid gland: 29.7	Expressed in all		
TRMT1	FLJ20244, TRM1	ENSG00000104907	TRNA methyltransferase 1	19	13104902-13117567	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041130, HPA041380	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:9.87e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 26.6	Expressed in all		
TRMT10A	MGC27034, RG9MTD2, TRM10	ENSG00000145331	TRNA methyltransferase 10A	4	99546709-99564032	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047601, HPA058241	Uncertain		Approved	Nucleoplasm<br>Nucleoli<br>Actin filaments<br>Cytosol	Thyroid cancer:2.14e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 21.2	Expressed in all		
TRMT10B	bA3J10.9, FLJ31455, RG9MTD3	ENSG00000165275	TRNA methyltransferase 10B	9	37753803-37778972	Predicted intracellular proteins	Evidence at transcript level	HPA021800	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Lung cancer:3.91e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable)	Expressed in all	Mixed			skin: 12.9	Expressed in all		
TRMT10C	FLJ20432, MRPP1, RG9MTD1	ENSG00000174173	TRNA methyltransferase 10C, mitochondrial RNase P subunit	3	101561862-101566446	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036671	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.32e-5 (favourable), Liver cancer:6.56e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.8	Expressed in all		
TRMT11	C6orf75, dJ187J11.2, MDS024, TRM11, TRMT11-1	ENSG00000066651	TRNA methyltransferase 11 homolog	6	125986430-126039276	Predicted intracellular proteins	Evidence at protein level	HPA030473			Approved	Nuclear bodies		Expressed in all	Expressed in all			thyroid gland: 16.5	Mixed		
TRMT112	HSPC152, HSPC170, hTrm112, TRM112, TRMT11-2	ENSG00000173113	TRNA methyltransferase 11-2 homolog (S. cerevisiae)	11	64316460-64318084	Predicted intracellular proteins	Evidence at protein level	HPA039901, HPA040006	Uncertain		Approved	Nucleus<br>Microtubules	Head and neck cancer:1.62e-4 (unfavourable), Renal cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 306.4	Expressed in all		
TRMT12	FLJ20772, Trm12, TYW2	ENSG00000183665	TRNA methyltransferase 12 homolog	8	124450820-124462150	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023939	Approved		Approved	Nucleoplasm<br>Mitochondria	Head and neck cancer:2.99e-5 (unfavourable), Liver cancer:5.10e-4 (unfavourable), Thyroid cancer:9.25e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 14.7	Cell line enhanced		MCF7: 55.6
TRMT13	CCDC76, FLJ10287, FLJ11219	ENSG00000122435	TRNA methyltransferase 13 homolog	1	100133150-100150497	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028494	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Renal cancer:6.89e-6 (unfavourable), Liver cancer:5.81e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.5	Expressed in all		
TRMT1L	C1orf25	ENSG00000121486	TRNA methyltransferase 1 like	1	185118098-185157072	Predicted intracellular proteins	Evidence at protein level	HPA026728	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 50.4	Expressed in all		
TRMT2A	HTF9C	ENSG00000099899	TRNA methyltransferase 2 homolog A	22	20111866-20117392	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001077	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:2.99e-8 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.6	Expressed in all		
TRMT2B	CXorf34, FLJ12687	ENSG00000188917	TRNA methyltransferase 2 homolog B	X	101009346-101052116	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003745, HPA035120, HPA040814	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.30e-7 (favourable), Breast cancer:1.58e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 21.5	Expressed in all		
TRMT44	C4orf23, FLJ35725, METTL19, TRM44	ENSG00000155275	TRNA methyltransferase 44 homolog (S. cerevisiae)	4	8436140-8493531	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045461	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			endometrium: 10.0	Expressed in all		
TRMT5	KIAA1393, TRM5	ENSG00000126814	TRNA methyltransferase 5	14	60971451-60981358	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000943	Supported		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
TRMT6	CGI-09, GCD10, Gcd10p, MGC5029	ENSG00000089195	TRNA methyltransferase 6	20	5937235-5950558	Predicted intracellular proteins	Evidence at protein level	HPA047032, HPA050408	Approved		Supported	Nucleus	Liver cancer:4.70e-12 (unfavourable)	Expressed in all	Expressed in all			testis: 25.4	Expressed in all		
TRMT61A	C14orf172, FLJ40452, GCD14, Gcd14p, hTRM61	ENSG00000166166	TRNA methyltransferase 61A	14	103529184-103537073	Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.60e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 10.1	Expressed in all		
TRMT61B	FLJ20628	ENSG00000171103	TRNA methyltransferase 61B	2	28849821-28870301	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026747, HPA026751	Enhanced		Uncertain	Cytosol	Renal cancer:9.61e-5 (favourable), Liver cancer:3.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 23.5	Expressed in all		
TRMU	FLJ10140, MTO2, TRMT	ENSG00000100416	TRNA 5-methylaminomethyl-2-thiouridylate methyltransferase	22	46330875-46357340	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000824, HPA035273, HPA043300	Uncertain		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:5.63e-6 (unfavourable), Liver cancer:3.04e-5 (unfavourable), Pancreatic cancer:6.86e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.0	Expressed in all		
TRNAU1AP	FLJ20503, SECP43, TRSPAP1	ENSG00000180098	TRNA selenocysteine 1 associated protein 1	1	28553085-28578545	Predicted intracellular proteins	Evidence at protein level	HPA032068, HPA032069	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.16e-5 (unfavourable), Liver cancer:8.64e-5 (unfavourable), Endometrial cancer:2.22e-4 (favourable), Thyroid cancer:9.45e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 8.3	Expressed in all		
TRNT1	CCA1, CGI-47, MtCCA	ENSG00000072756	TRNA nucleotidyl transferase 1	3	3126916-3150879	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036938	Uncertain		Enhanced	Mitochondria		Expressed in all	Expressed in all			prostate: 24.5	Expressed in all		
TRO	KIAA1114, MAGE-D3, MAGED3	ENSG00000067445	Trophinin	X	54920462-54931431	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053358			Approved	Nucleus<br>Nucleoli fibrillar center	Endometrial cancer:4.41e-5 (unfavourable), Pancreatic cancer:1.93e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 30.0	endometrium: 22.2	Cell line enhanced		AF22: 36.8;SCLC-21H: 29.3;SH-SY5Y: 35.5
TROAP	TASTIN	ENSG00000135451	Trophinin associated protein	12	49323236-49331731	Predicted intracellular proteins	Evidence at protein level	HPA044102	Uncertain				Liver cancer:1.39e-5 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 32.0;testis: 44.1	tonsil: 13.7	Expressed in all		
TROVE2	Ro60, SSA2	ENSG00000116747	TROVE domain family member 2	1	193059422-193091777	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002835, HPA005142	Uncertain		Approved	Nucleoplasm<br>Cytosol	Thyroid cancer:3.31e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 28.1	Expressed in all		
TRPC4AP	C20orf188, dJ756N5.2, DKFZp586C1223, DKFZP727M231, PPP1R158, TRRP4AP	ENSG00000100991	Transient receptor potential cation channel subfamily C member 4 associated protein	20	35002404-35092871	Predicted intracellular proteins	Evidence at protein level	HPA051197, HPA065061	Uncertain		Approved	Cytosol	Liver cancer:6.25e-8 (unfavourable), Renal cancer:1.17e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 72.6	Expressed in all		
TRPC5OS	TRPC5-AS1	ENSG00000204025	TRPC5 opposite strand	X	111876051-111903990	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	58	testis: 45.5	epididymis: 0.7	Cell line enhanced		U-937: 1.0
TRPS1	GC79, LGCR	ENSG00000104447	Transcriptional repressor GATA binding 1	8	115408496-115809673	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060380, HPA071767	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:3.16e-4 (unfavourable), Head and neck cancer:9.42e-4 (favourable)	Tissue enriched	Tissue enhanced		breast: 75.9	testis: 22.6	Cell line enhanced		SK-BR-3: 58.4;T-47d: 230.2
TRPT1	MGC11134	ENSG00000149743	TRNA phosphotransferase 1	11	64223799-64226254	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038705, HPA038706	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			testis: 44.9	Expressed in all		
TRUB1	PUS4	ENSG00000165832	TruB pseudouridine synthase family member 1	10	114938193-114977676	Predicted intracellular proteins	Evidence at protein level	HPA037914, HPA057552	Approved		Supported	Vesicles<br>Actin filaments		Expressed in all	Expressed in all			adrenal gland: 38.5	Expressed in all		
TRUB2	CLONE24922	ENSG00000167112	TruB pseudouridine synthase family member 2	9	128305161-128322742	Predicted intracellular proteins	Evidence at protein level	HPA021211, HPA052190	Uncertain		Supported	Cytosol	Renal cancer:5.57e-10 (favourable)	Expressed in all	Mixed			cerebral cortex: 9.0	Expressed in all		
TSACC	C1orf182, SIP, SSTK-IP	ENSG00000163467	TSSK6 activating cochaperone	1	156337314-156346995	Predicted intracellular proteins	Evidence at protein level	HPA029897			Approved	Nucleus<br>Nuclear bodies		Tissue enhanced	Tissue enriched	506	testis: 1514.6	epididymis: 2.9	Mixed		
TSC22D1	MGC17597, TGFB1I4, TSC22	ENSG00000102804	TSC22 domain family member 1	13	44432143-44577147	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077414			Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:4.54e-4 (favourable), Ovarian cancer:7.97e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 269.2	Cell line enhanced		HEL: 221.4
TSC22D2	KIAA0669, TILZ4a, TILZ4b, TILZ4c	ENSG00000196428	TSC22 domain family member 2	3	150408335-150466431	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004926	Approved		Approved	Cytosol	Endometrial cancer:2.74e-4 (unfavourable), Renal cancer:5.80e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium,smooth muscle: 38.2	Expressed in all		
TSC22D3	DIP, DSIPI, GILZ, hDIP, TSC-22R	ENSG00000157514	TSC22 domain family member 3	X	107713221-107777342	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001916, CAB034364	Approved		Approved	Nuclear speckles<br>Golgi apparatus<br>Cytosol	Endometrial cancer:2.43e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 548.3	Cell line enhanced		ASC diff: 261.1;HHSteC: 527.6;hTCEpi: 413.6;Karpas-707: 261.7
TSEN15	C1orf19	ENSG00000198860	TRNA splicing endonuclease subunit 15	1	184051677-184074212	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029237	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:3.66e-10 (unfavourable), Liver cancer:2.07e-5 (unfavourable), Ovarian cancer:4.59e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.8	Expressed in all		
TSEN2	MGC2776, SEN2, SEN2L	ENSG00000154743	TRNA splicing endonuclease subunit 2	3	12484432-12539623	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027120, HPA027125, HPA027268	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.13e-5 (unfavourable), Urothelial cancer:3.49e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 14.7	Expressed in all		
TSEN34	LENG5, SEN34, SEN34L	ENSG00000170892	TRNA splicing endonuclease subunit 34	19	54189938-54194536	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041111, HPA048208	Approved		Supported	Nucleus	Liver cancer:1.44e-7 (unfavourable)	Expressed in all	Mixed			fallopian tube: 37.2	Mixed		
TSEN54	SEN54, SEN54L	ENSG00000182173	TRNA splicing endonuclease subunit 54	17	75516060-75524739	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053097	Uncertain				Liver cancer:8.06e-6 (unfavourable), Pancreatic cancer:2.62e-5 (favourable), Stomach cancer:7.78e-5 (favourable), Urothelial cancer:8.54e-4 (favourable)	Expressed in all	Expressed in all			skin: 20.4	Expressed in all		
TSFM	EF-TS, EF-Tsmt	ENSG00000123297	Ts translation elongation factor, mitochondrial	12	57782589-57808071	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA006204			Supported	Nucleus<br>Mitochondria	Renal cancer:8.82e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 63.7	Cell line enriched	7	RH-30: 980.3
TSG101	TSG10, VPS23	ENSG00000074319	Tumor susceptibility 101	11	18468336-18527232	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004283, HPA006161	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Liver cancer:3.74e-6 (unfavourable), Renal cancer:5.52e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 81.8	Expressed in all		
TSGA10	CEP4L, CT79	ENSG00000135951	Testis specific 10	2	98997261-99154964	Predicted intracellular proteins	Evidence at protein level	HPA036879			Approved	Cytosol		Mixed	Group enriched	11	fallopian tube: 19.2;testis: 92.9	thyroid gland: 4.8	Cell line enhanced		RPTEC TERT1: 3.1
TSGA10IP	FAM161C, FLJ32880	ENSG00000175513	Testis specific 10 interacting protein	11	65945445-65959963	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	26	testis: 5.9	thyroid gland: 0.2	Cell line enhanced		NTERA-2: 2.1
TSGA13		ENSG00000213265	Testis specific 13	7	130668648-130687432	Predicted intracellular proteins	Evidence at transcript level	HPA022968	Uncertain					Not detected	Tissue enriched	100	testis: 21.0	fallopian tube: 0.2	Not detected		
TSHZ1	NY-CO-33, SDCCAG33, TSH1	ENSG00000179981	Teashirt zinc finger homeobox 1	18	75210755-75289950	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006982	Approved		Approved	Nucleoplasm	Thyroid cancer:1.71e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 46.4	Cell line enhanced		HDLM-2: 45.8
TSHZ2	C20orf17, OVC10-2, TSH2, ZABC2, ZNF218	ENSG00000182463	Teashirt zinc finger homeobox 2	20	52972407-53495330	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038123	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Mixed			ovary: 21.7	Cell line enhanced		AN3-CA: 24.7;HeLa: 15.8;SiHa: 16.3;U-2197: 12.7
TSHZ3	KIAA1474, TSH3, ZNF537	ENSG00000121297	Teashirt zinc finger homeobox 3	19	31274945-31349547	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008834	Approved		Supported	Nucleoplasm	Renal cancer:2.92e-4 (unfavourable)	Mixed	Mixed			ovary: 37.5	Cell line enhanced		RH-30: 44.3;U-138 MG: 31.7
TSKS	PPP1R161, TSSKS	ENSG00000126467	Testis specific serine kinase substrate	19	49739753-49763330	Predicted intracellular proteins	Evidence at protein level	HPA045729	Enhanced					Tissue enhanced	Tissue enriched	43	testis: 72.4	skin: 1.6	Cell line enhanced		K-562: 1.7;NB-4: 7.2;THP-1: 1.6
TSNAX	TRAX	ENSG00000116918	Translin associated factor X	1	231528653-231566524	Predicted intracellular proteins	Evidence at protein level	HPA031054, HPA031055, CAB034263	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 54.4	Expressed in all		
TSNAXIP1	TXI1	ENSG00000102904	Translin associated factor X interacting protein 1	16	67806765-67832148	Predicted intracellular proteins	Evidence at protein level	HPA053516			Approved	Nucleus<br>Cytosol	Endometrial cancer:2.22e-4 (favourable)	Mixed	Group enriched	10	fallopian tube: 15.6;testis: 39.9	parathyroid gland: 2.7	Cell line enhanced		AN3-CA: 2.8
TSPOAP1	BZRAP1, KIAA0612, PRAX-1, RIM-BP1, RIMBP1	ENSG00000005379	TSPO associated protein 1	17	58301228-58328760	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024662, HPA025244	Enhanced				Pancreatic cancer:9.15e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 69.1	Cell line enhanced		HDLM-2: 164.7;HL-60: 51.5;REH: 119.1
TSPY1	CT78, TSPY	ENSG00000258992	Testis specific protein, Y-linked 1	Y	9466955-9469748	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Tissue enriched	Tissue enriched	84	testis: 8.3	all non-specific tissues: 0.0	Group enriched	298	U-266/70: 186.9;U-266/84: 172.0
TSPY10		ENSG00000236424	Testis specific protein, Y-linked 10	Y	9527880-9530682	Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Tissue enriched	Tissue enriched	17	testis: 3.1	adipose tissue: 0.1	Group enriched	208	U-266/70: 8.9;U-266/84: 43.7
TSPY2	TSPYQ1	ENSG00000168757	Testis specific protein, Y-linked 2	Y	6246223-6249019	Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Tissue enriched	Tissue enriched	132	testis: 14.1	adipose tissue: 0.1	Group enriched	484	U-266/70: 81.8;U-266/84: 82.9
TSPY3	CT78	ENSG00000228927	Testis specific protein, Y-linked 3	Y	9398421-9401223	Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Not detected	Tissue enriched	6	testis: 4.2	epididymis: 0.6	Group enriched	62	U-266/70: 113.3;U-266/84: 101.1
TSPY4		ENSG00000233803	Testis specific protein, Y-linked 4	Y	9337464-9340284	Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Not detected	Tissue enriched	205	testis: 62.6	spleen: 0.3	Group enriched	498	U-266/70: 1493.8;U-266/84: 1550.5
TSPY8		ENSG00000229549	Testis specific protein, Y-linked 8	Y	9357797-9360599	Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Not detected	Tissue enriched	13	testis: 1.3	all non-specific tissues: 0.0	Cell line enriched	228	U-266/84: 191.8
TSPYL1	TSPYL	ENSG00000189241	TSPY like 1	6	116276578-116279903	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031970, HPA031971	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.48e-13 (favourable), Pancreatic cancer:5.40e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 191.9	Expressed in all		
TSPYL2	CDA1, CINAP, CTCL, DENTT, HRIHFB2216, SE20-4, TSPX	ENSG00000184205	TSPY like 2	X	53082367-53088540	Predicted intracellular proteins	Evidence at protein level	HPA044133	Approved				Pancreatic cancer:6.74e-8 (favourable), Renal cancer:8.16e-7 (unfavourable), Colorectal cancer:3.23e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 144.3	Expressed in all		
TSPYL4	dJ486I3.2, KIAA0721	ENSG00000187189	TSPY like 4	6	116249961-116254140	Predicted intracellular proteins	Evidence at protein level	HPA044863	Approved				Renal cancer:5.13e-7 (favourable), Pancreatic cancer:8.46e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 120.8	Mixed		
TSPYL5	KIAA1750	ENSG00000180543	TSPY like 5	8	97273474-97277964	Predicted intracellular proteins	Evidence at protein level	HPA031347	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.40e-5 (favourable), Breast cancer:1.21e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 81.4	ovary: 30.4	Cell line enhanced		SCLC-21H: 70.7;SH-SY5Y: 49.4
TSPYL6		ENSG00000178021	TSPY like 6	2	54253184-54256272	Predicted intracellular proteins	Evidence at protein level	HPA034699, HPA034700	Enhanced		Approved	Nucleoli<br>Centrosome<br>Cytosol		Tissue enriched	Tissue enriched	390	testis: 39.0	all non-specific tissues: 0.0	Cell line enriched	73	K-562: 7.3
TSR1	FLJ10534	ENSG00000167721	TSR1, ribosome maturation factor	17	2322503-2337507	Predicted intracellular proteins	Evidence at protein level	HPA024434, HPA053087	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 28.8	Expressed in all		
TSR2	DT1P1A10, RP1-112K5.2, WGG1	ENSG00000158526	TSR2, ribosome maturation factor	X	54440401-54445487	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030514	Approved		Approved	Nucleus<br>Nucleoli<br>Cell Junctions<br>Cytosol	Renal cancer:1.21e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 88.4	Expressed in all		
TSR3	C16orf42, MGC24381	ENSG00000007520	TSR3, acp transferase ribosome maturation factor	16	1349240-1351911	Predicted intracellular proteins	Evidence at protein level	HPA040760, HPA046265	Uncertain		Approved	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 36.7	Expressed in all		
TSSC1		ENSG00000032389	Tumor suppressing subtransferable candidate 1	2	3188925-3377882	Predicted intracellular proteins	Evidence at protein level	HPA031231, HPA031232, HPA031233, HPA031234	Approved		Supported	Nucleus<br>Nucleoli<br>Intermediate filaments	Liver cancer:3.67e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 34.8	Expressed in all		
TSSC4		ENSG00000184281	Tumor suppressing subtransferable candidate 4	11	2400488-2403878	Predicted intracellular proteins	Evidence at protein level	HPA041801, HPA058763	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.91e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 56.5	Expressed in all		
TSSK3	SPOGA3, STK22C	ENSG00000162526	Testis specific serine kinase 3	1	32351521-32364312	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037516	Uncertain		Approved	Nucleus<br>Nucleoli<br>Nuclear bodies		Not detected	Tissue enhanced		testis: 25.5	bone marrow: 5.5	Mixed		
TSSK6	CT72, FLJ24002, SSTK	ENSG00000178093	Testis specific serine kinase 6	19	19512418-19515685	Enzymes, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Tissue enriched	24	testis: 18.6	duodenum,spleen: 0.7	Cell line enhanced		BEWO: 3.9
TST	RDS	ENSG00000128311	Thiosulfate sulfurtransferase	22	37010859-37020183	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003044, HPA003643, CAB009546	Enhanced		Supported	Mitochondria	Renal cancer:7.59e-6 (favourable), Urothelial cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			colon: 143.5	Mixed		
TSTA3	FX, P35B, SDR4E1	ENSG00000104522	Tissue specific transplantation antigen P35B	8	143612618-143618048	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023361	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.59e-4 (unfavourable), Ovarian cancer:2.41e-4 (favourable)	Expressed in all	Expressed in all			stomach: 50.3	Expressed in all		
TSTD1	KAT	ENSG00000215845	Thiosulfate sulfurtransferase like domain containing 1	1	161037631-161038990	Predicted intracellular proteins	Evidence at protein level	HPA006518, HPA006655	Approved		Approved	Cytosol<br>Cytoplasmic bodies		Expressed in all	Expressed in all			thyroid gland: 146.9	Cell line enhanced		SK-BR-3: 203.3;T-47d: 247.1;U-266/70: 231.6
TSTD2	C9orf97, PP4189	ENSG00000136925	Thiosulfate sulfurtransferase like domain containing 2	9	97600080-97633575	Predicted intracellular proteins	Evidence at protein level	HPA022537, HPA024241, HPA064304	Uncertain		Approved	Nucleoplasm	Renal cancer:5.75e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.9	Expressed in all		
TSTD3		ENSG00000228439	Thiosulfate sulfurtransferase (rhodanese)-like domain containing 3	6	99520693-99531918	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Mixed			parathyroid gland: 7.4	Mixed		
TTBK1	KIAA1855	ENSG00000146216	Tau tubulin kinase 1	6	43243680-43288259	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031735, HPA031736	Enhanced		Supported	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enriched	6	cerebral cortex: 18.9	small intestine: 3.1	Group enriched	13	SCLC-21H: 24.9;SH-SY5Y: 8.7
TTBK2	KIAA0847, SCA11	ENSG00000128881	Tau tubulin kinase 2	15	42738734-42920809	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018113, HPA049866	Approved		Uncertain	Intermediate filaments		Mixed	Tissue enhanced		testis: 61.5	cerebral cortex: 16.6	Mixed		
TTC1	TPR1	ENSG00000113312	Tetratricopeptide repeat domain 1	5	160009113-160065543	Predicted intracellular proteins	Evidence at protein level	HPA036557, HPA057502	Approved		Enhanced	Cytosol	Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 80.4	Expressed in all		
TTC12	FLJ13859, FLJ20535, TPARM	ENSG00000149292	Tetratricopeptide repeat domain 12	11	113314529-113383544	Predicted intracellular proteins	Evidence at protein level	HPA038542, HPA038543, HPA061364	Approved		Approved	Nucleoplasm	Endometrial cancer:2.48e-5 (favourable), Renal cancer:5.95e-5 (favourable), Colorectal cancer:3.14e-4 (favourable)	Expressed in all	Expressed in all			testis: 92.4	Cell line enhanced		SiHa: 27.4
TTC16	FLJ32780	ENSG00000167094	Tetratricopeptide repeat domain 16	9	127716066-127731600	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	12	fallopian tube: 10.9;testis: 18.3	lung: 1.1	Not detected		
TTC17	FLJ10890	ENSG00000052841	Tetratricopeptide repeat domain 17	11	43358932-43494933	Predicted intracellular proteins	Evidence at protein level	HPA038508	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.75e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 61.8	Expressed in all		
TTC21A	IFT139A, STI2	ENSG00000168026	Tetratricopeptide repeat domain 21A	3	39107704-39138903	Predicted intracellular proteins	Evidence at protein level	HPA035510, HPA035511	Enhanced		Supported	Nucleoplasm	Endometrial cancer:1.79e-4 (favourable)	Mixed	Tissue enriched	25	testis: 39.4	fallopian tube: 1.5	Not detected		
TTC21B	FLJ11457, IFT139B, JBTS11, NPHP12, THM1	ENSG00000123607	Tetratricopeptide repeat domain 21B	2	165857475-165953843	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035494, HPA035495	Uncertain		Supported	Mitochondria	Renal cancer:1.36e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 14.4	Mixed		
TTC22	FLJ20619	ENSG00000006555	Tetratricopeptide repeat domain 22	1	54779712-54801267	Predicted intracellular proteins	Evidence at protein level	HPA035072	Uncertain				Breast cancer:2.06e-4 (favourable), Liver cancer:7.73e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 40.6	skin: 22.7	Cell line enhanced		A-431: 7.9;CAPAN-2: 9.5;HaCaT: 11.0;hTCEpi: 5.0;RPMI-8226: 5.6
TTC23	FLJ12572, HCC-8	ENSG00000103852	Tetratricopeptide repeat domain 23	15	99136323-99251223	Predicted intracellular proteins	Evidence at protein level	HPA039806, HPA040369	Uncertain		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:1.07e-4 (favourable), Breast cancer:3.17e-4 (favourable)	Expressed in all	Mixed			testis: 24.3	Mixed		
TTC23L	FLJ25439	ENSG00000205838	Tetratricopeptide repeat domain 23 like	5	34838833-34899456	Predicted intracellular proteins	Evidence at protein level	HPA037807	Enhanced					Not detected	Tissue enriched	7	testis: 39.2	fallopian tube: 5.8	Not detected		
TTC24		ENSG00000187862	Tetratricopeptide repeat domain 24	1	156579727-156586770	Predicted intracellular proteins	Evidence at protein level	HPA029799			Approved	Nucleoplasm		Not detected	Tissue enhanced		lymph node: 6.4;spleen: 3.8;tonsil: 4.2	appendix: 2.4	Cell line enhanced		MOLT-4: 2.5;REH: 10.7;U-698: 1.5
TTC25	DKFZP434H0115	ENSG00000204815	Tetratricopeptide repeat domain 25	17	41930635-41965651	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023908	Enhanced					Mixed	Group enriched	8	fallopian tube: 47.3;testis: 70.5	parathyroid gland: 7.4	Cell line enhanced		SCLC-21H: 4.9;U-87 MG: 4.8
TTC26	dyf-13, DYF13, FLJ12571, IFT56	ENSG00000105948	Tetratricopeptide repeat domain 26	7	139133744-139191986	Predicted intracellular proteins	Evidence at protein level	HPA036338, HPA036339	Enhanced		Approved	Nuclear speckles<br>Intermediate filaments<br>Cytosol		Expressed in all	Tissue enhanced		fallopian tube: 22.6;testis: 22.1	parathyroid gland: 13.6	Expressed in all		
TTC27	FLJ20272	ENSG00000018699	Tetratricopeptide repeat domain 27	2	32628032-32821051	Predicted intracellular proteins	Evidence at protein level	HPA031246	Approved		Approved	Nucleoli<br>Mitochondria	Liver cancer:1.42e-5 (unfavourable), Renal cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 23.4	Expressed in all		
TTC28	KIAA1043	ENSG00000100154	Tetratricopeptide repeat domain 28	22	27978014-28679865	Predicted intracellular proteins	Evidence at protein level	HPA003099			Approved	Nucleoli<br>Mitochondria	Renal cancer:5.65e-5 (favourable), Thyroid cancer:1.21e-4 (unfavourable), Lung cancer:4.30e-4 (favourable)	Expressed in all	Mixed			ovary: 20.8	Mixed		
TTC29	NYD-SP14	ENSG00000137473	Tetratricopeptide repeat domain 29	4	146706638-146945882	Predicted intracellular proteins	Evidence at protein level	HPA037006, HPA061473	Uncertain					Tissue enhanced	Group enriched	27	fallopian tube: 34.2;testis: 151.1	lung: 3.4	Cell line enhanced		ASC TERT1: 3.4;hTERT-HME1: 1.2;U-266/70: 1.6;U-87 MG: 1.0
TTC30A	FLJ13946, IFT70A	ENSG00000197557	Tetratricopeptide repeat domain 30A	2	177612992-177618966	Predicted intracellular proteins	Evidence at protein level	HPA051714, HPA052100, HPA052487	Supported		Approved	Nucleus<br>Centrosome	Glioma:9.98e-4 (unfavourable)	Expressed in all	Mixed			testis: 17.3	Mixed		
TTC30B	fleer, FLJ30990, IFT70B	ENSG00000196659	Tetratricopeptide repeat domain 30B	2	177548998-177553014	Predicted intracellular proteins	Evidence at protein level	HPA051714, HPA052100, HPA052487	Supported		Approved	Nucleus<br>Centrosome		Expressed in all	Mixed			fallopian tube: 15.6	Mixed		
TTC31	FLJ12788	ENSG00000115282	Tetratricopeptide repeat domain 31	2	74483073-74494886	Predicted intracellular proteins	Evidence at protein level	HPA041783	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:2.49e-4 (favourable), Endometrial cancer:6.70e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.8	Expressed in all		
TTC32		ENSG00000183891	Tetratricopeptide repeat domain 32	2	19896643-19901986	Predicted intracellular proteins	Evidence at protein level	HPA036024	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:5.45e-6 (unfavourable), Lung cancer:9.44e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 36.4	Expressed in all		
TTC34		ENSG00000215912	Tetratricopeptide repeat domain 34	1	2635976-2801717	Predicted intracellular proteins	Evidence at transcript level	HPA066832	Uncertain					Not detected	Tissue enhanced		fallopian tube: 1.6;testis: 2.6	thyroid gland: 0.8	Not detected		
TTC36	HBP21	ENSG00000172425	Tetratricopeptide repeat domain 36	11	118527472-118531197	Predicted intracellular proteins	Evidence at protein level	HPA038731	Enhanced		Uncertain	Nucleoplasm	Liver cancer:1.81e-5 (favourable)	Group enriched	Tissue enhanced		liver: 64.4	epididymis: 15.5	Cell line enhanced		SK-BR-3: 5.3
TTC37	KIAA0372, THES	ENSG00000198677	Tetratricopeptide repeat domain 37	5	95463895-95555007	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037905	Approved		Supported	Nucleoplasm<br>Cytosol	Colorectal cancer:2.62e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 82.3	Expressed in all		
TTC38	FLJ20699	ENSG00000075234	Tetratricopeptide repeat domain 38	22	46267961-46294008	Predicted intracellular proteins	Evidence at protein level	HPA029302	Approved		Approved	Cytosol	Endometrial cancer:3.21e-6 (favourable)	Expressed in all	Expressed in all			small intestine: 88.3	Mixed		
TTC4	FLJ41930, MGC5097	ENSG00000243725	Tetratricopeptide repeat domain 4	1	54715822-54742657	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041608, HPA042459	Approved					Expressed in all	Expressed in all			cervix, uterine: 13.3	Expressed in all		
TTC5	Strap	ENSG00000136319	Tetratricopeptide repeat domain 5	14	20256558-20305994	Predicted intracellular proteins	Evidence at protein level	HPA045008, HPA054198	Approved		Supported	Nucleoplasm	Renal cancer:8.54e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 10.5	Mixed		
TTC6	C14orf25, NCRNA00291	ENSG00000139865	Tetratricopeptide repeat domain 6	14	37595847-38041442	Predicted intracellular proteins	Evidence at protein level	HPA069293			Approved	Centrosome		Group enriched	Group enriched	6	breast: 10.5;prostate: 28.3;testis: 10.4	stomach: 2.6	Cell line enhanced		Hep G2: 5.7;MCF7: 9.4;RT4: 6.7;T-47d: 21.4
TTC7A	KIAA1140, TTC7	ENSG00000068724	Tetratricopeptide repeat domain 7A	2	46916157-47076137	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036781, HPA036782	Enhanced				Ovarian cancer:1.36e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 40.9	lung: 17.7	Expressed in all		
TTC7B	TTC7L1	ENSG00000165914	Tetratricopeptide repeat domain 7B	14	90524564-90816479	Predicted intracellular proteins	Evidence at protein level	HPA058363, HPA059577	Enhanced		Supported	Plasma membrane	Renal cancer:3.20e-6 (favourable)	Mixed	Expressed in all			cerebral cortex: 72.6	Mixed		
TTC9	KIAA0227, TTC9A	ENSG00000133985	Tetratricopeptide repeat domain 9	14	70641787-70675360	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.10e-8 (favourable), Endometrial cancer:1.82e-5 (favourable)	Expressed in all	Tissue enhanced		esophagus: 44.6	fallopian tube: 15.9	Cell line enhanced		A-431: 15.5;RH-30: 20.2;SK-BR-3: 26.6
TTC9C	MGC29649	ENSG00000162222	Tetratricopeptide repeat domain 9C	11	62728069-62740293	Predicted intracellular proteins	Evidence at protein level	HPA055169	Approved		Approved	Nucleoplasm	Renal cancer:4.67e-7 (unfavourable), Stomach cancer:4.15e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.0	Expressed in all		
TTF1		ENSG00000125482	Transcription termination factor 1	9	132375548-132406851	Predicted intracellular proteins	Evidence at protein level	HPA054837	Supported		Supported	Nucleus<br>Nucleoli	Liver cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 18.2	Expressed in all		
TTF2	HuF2, ZGRF6	ENSG00000116830	Transcription termination factor 2	1	117060303-117107453	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005776, HPA070762	Approved		Supported	Cytosol		Expressed in all	Mixed			lymph node: 8.7	Expressed in all		
TTI1	KIAA0406, smg-10	ENSG00000101407	TELO2 interacting protein 1	20	37983007-38033468	Predicted intracellular proteins	Evidence at protein level	CAB034230, HPA068338	Uncertain		Approved	Nucleoplasm<br>Vesicles	Liver cancer:2.40e-7 (unfavourable), Endometrial cancer:3.30e-5 (unfavourable)	Expressed in all	Expressed in all			testis,thyroid gland: 20.3	Expressed in all		
TTK	CT96, MPH1, MPS1, MPS1L1	ENSG00000112742	TTK protein kinase	6	80003887-80042527	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010166, CAB013229	Enhanced		Approved	Nucleoli<br>Cytosol	Liver cancer:3.84e-10 (unfavourable), Endometrial cancer:1.44e-5 (unfavourable), Pancreatic cancer:2.54e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 60.8	bone marrow: 15.5	Mixed		
TTL	MGC46235	ENSG00000114999	Tubulin tyrosine ligase	2	112482154-112541739	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA066819			Approved	Nucleoplasm<br>Vesicles	Liver cancer:5.65e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 4.4	Mixed		
TTLL1	C22orf7	ENSG00000100271	Tubulin tyrosine ligase like 1	22	43039644-43089428	Predicted intracellular proteins	Evidence at transcript level	HPA048392	Approved		Approved	Nucleoli<br>Mitochondria	Liver cancer:2.34e-5 (unfavourable), Renal cancer:1.68e-4 (favourable), Endometrial cancer:1.85e-4 (favourable)	Expressed in all	Mixed			testis: 20.2	Mixed		
TTLL10	FLJ36119, TTLL5	ENSG00000162571	Tubulin tyrosine ligase like 10	1	1173884-1197935	Predicted intracellular proteins	Evidence at protein level	HPA042712	Uncertain				Endometrial cancer:1.61e-5 (favourable)	Mixed	Group enriched	8	fallopian tube: 14.2;testis: 27.9	lung: 2.7	Cell line enriched	31	SCLC-21H: 27.2
TTLL12	KIAA0153	ENSG00000100304	Tubulin tyrosine ligase like 12	22	43166622-43187133	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003054, CAB046029	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:2.84e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 74.3	Expressed in all		
TTLL13P	FLJ46079, MGC33417, TTLL13	ENSG00000213471	Tubulin tyrosine ligase like 13, pseudogene	15	90249530-90265482	Predicted intracellular proteins	Evidence at protein level	HPA041305	Enhanced					Not detected	Tissue enriched	50	testis: 5.0	all non-specific tissues: 0.0	Not detected		
TTLL2	C6orf104, dJ366N23.3, NYD-TSPG	ENSG00000120440	Tubulin tyrosine ligase like 2	6	167325086-167359503	Predicted intracellular proteins	Evidence at protein level	HPA027985			Approved	Nuclear membrane<br>Nucleoli		Not detected	Tissue enriched	189	testis: 34.1	liver,ovary: 0.1	Cell line enhanced		CACO-2: 1.5
TTLL3	DKFZP434B103, HOTTL	ENSG00000214021	Tubulin tyrosine ligase like 3	3	9808086-9855138	Predicted intracellular proteins	Evidence at protein level	HPA051413	Approved				Renal cancer:6.45e-6 (unfavourable), Urothelial cancer:9.51e-6 (favourable)	Mixed	Expressed in all			testis: 52.5	Cell line enhanced		BEWO: 59.9
TTLL4	KIAA0173	ENSG00000135912	Tubulin tyrosine ligase like 4	2	218710845-218755416	Predicted intracellular proteins	Evidence at protein level	HPA027091, HPA050252	Approved		Approved	Mitochondria	Renal cancer:6.63e-12 (unfavourable), Liver cancer:2.95e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 46.8	Expressed in all		
TTLL5	KIAA0998	ENSG00000119685	Tubulin tyrosine ligase like 5	14	75633625-75955078	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032128	Uncertain		Supported	Plasma membrane<br>Cytosol		Expressed in all	Tissue enriched	5	testis: 104.0	parathyroid gland: 20.4	Expressed in all		
TTLL6	FLJ35808	ENSG00000170703	Tubulin tyrosine ligase like 6	17	48762235-48817214	Predicted intracellular proteins	Evidence at protein level	HPA052397	Enhanced		Approved	Vesicles<br>Microtubules		Mixed	Tissue enhanced		testis: 26.0	fallopian tube: 5.8	Cell line enriched	5	HDLM-2: 4.1
TTLL7	FLJ23033	ENSG00000137941	Tubulin tyrosine ligase like 7	1	83865028-83999150	Predicted intracellular proteins	Evidence at protein level	HPA052249, HPA059321	Uncertain		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 46.8	smooth muscle: 10.8	Cell line enhanced		HDLM-2: 26.3;RH-30: 21.3;SCLC-21H: 16.4
TTLL8		ENSG00000138892	Tubulin tyrosine ligase like 8	22	50015123-50056935	Predicted intracellular proteins	Evidence at transcript level	HPA016882	Uncertain					Not detected	Tissue enriched	42	testis: 4.2	all non-specific tissues: 0.0	Not detected		
TTLL9	C20orf125, dJ310O13.1	ENSG00000131044	Tubulin tyrosine ligase like 9	20	31870702-31944963	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA041772, HPA055676	Uncertain		Uncertain	Nucleoplasm<br>Microtubules		Tissue enhanced	Tissue enhanced		fallopian tube: 7.1;testis: 6.3	epididymis: 3.2	Not detected		
TTPA	AVED	ENSG00000137561	Alpha tocopherol transfer protein	8	63048553-63086053	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	17	liver: 82.7	rectum: 4.8	Cell line enhanced		SK-BR-3: 4.7;U-2 OS: 3.3;U-2197: 3.6
TTPAL	C20orf121, dJ179M20.3	ENSG00000124120	Alpha tocopherol transfer protein like	20	44475886-44494603	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046957, HPA066532	Uncertain		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:3.47e-5 (unfavourable), Renal cancer:8.09e-5 (unfavourable), Head and neck cancer:2.94e-4 (unfavourable)	Expressed in all	Mixed			skin: 14.9	Expressed in all		
TUB	rd5	ENSG00000166402	Tubby bipartite transcription factor	11	8019244-8106112	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA017997, HPA049019	Uncertain		Approved	Nucleoli<br>Microtubule organizing center<br>Centrosome	Renal cancer:2.35e-5 (favourable), Pancreatic cancer:2.85e-4 (favourable)	Mixed	Mixed			cerebral cortex: 51.4	Cell line enhanced		HEK93: 34.0;HeLa: 33.4;SCLC-21H: 65.2;SH-SY5Y: 43.8
TUBA1A	B-ALPHA-1, FLJ25113, TUBA3	ENSG00000167552	Tubulin alpha 1a	12	49184796-49189324	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB008686, HPA039247, HPA043684, HPA063394	Enhanced		Enhanced	Microtubules	Renal cancer:2.90e-4 (unfavourable)	Tissue enriched	Expressed in all			cerebral cortex: 1373.1	Expressed in all		
TUBA1B	K-ALPHA-1	ENSG00000123416	Tubulin alpha 1b	12	49127782-49131397	Predicted intracellular proteins	Evidence at protein level	CAB011513, HPA039247, HPA043684, HPA063394	Enhanced		Supported	Microtubules	Renal cancer:2.85e-12 (unfavourable), Liver cancer:1.68e-7 (unfavourable), Breast cancer:5.49e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1433.9	Expressed in all		
TUBA1C	bcm948, MGC10851, MGC14580, TUBA6	ENSG00000167553	Tubulin alpha 1c	12	49188736-49274603	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039247, HPA043684, HPA063394	Supported		Supported	Microtubules	Liver cancer:8.48e-8 (unfavourable), Renal cancer:6.26e-7 (unfavourable), Pancreatic cancer:5.64e-6 (unfavourable), Colorectal cancer:7.37e-5 (favourable), Breast cancer:2.90e-4 (unfavourable), Lung cancer:6.85e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 311.2	Expressed in all		
TUBA3C	bA408E5.3, TUBA2	ENSG00000198033	Tubulin alpha 3c	13	19173770-19181852	Predicted intracellular proteins	Evidence at protein level	HPA039247, HPA043684, HPA063394	Uncertain		Supported	Microtubules		Mixed	Tissue enriched	2118	testis: 513.8	epididymis: 0.2	Group enriched	51	HDLM-2: 97.4;U-2 OS: 263.4;U-266/70: 63.0;U-266/84: 75.1
TUBA3D	H2-ALPHA	ENSG00000075886	Tubulin alpha 3d	2	131476093-131482934	Predicted intracellular proteins	Evidence at protein level	CAB004972, HPA039247, HPA043684, HPA063394	Uncertain		Supported	Microtubules	Renal cancer:4.75e-9 (unfavourable), Breast cancer:4.65e-4 (favourable)	Mixed	Tissue enriched	31	testis: 250.3	epididymis: 8.1	Not detected		
TUBA3E		ENSG00000152086	Tubulin alpha 3e	2	130191743-130198461	Predicted intracellular proteins	Evidence at protein level	HPA039247, HPA043684, HPA063394	Uncertain		Supported	Microtubules		Mixed	Tissue enriched	26	testis: 74.6	heart muscle: 2.9	Group enriched	11	BEWO: 4.0;U-2 OS: 2.7
TUBA4A	FLJ30169, H2-ALPHA, TUBA1	ENSG00000127824	Tubulin alpha 4a	2	219249711-219278170	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004621, CAB005887, HPA039247, HPA043684, HPA063394	Approved		Enhanced	Microtubules	Liver cancer:4.54e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 181.8	Cell line enhanced		HBEC3-KT: 297.7
TUBA4B	FLJ13940, TUBA4	ENSG00000243910	Tubulin alpha 4b	2	219253243-219272188	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	14	fallopian tube: 64.2	lung: 4.5	Not detected		
TUBAL3	FLJ21665	ENSG00000178462	Tubulin alpha like 3	10	5393098-5404830	Predicted intracellular proteins	Evidence at protein level	HPA045900, HPA063394	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 24.4;small intestine: 31.0	colon: 11.8	Group enriched	6	HEL: 11.9;K-562: 3.8
TUBB	M40, MGC16435, OK/SW-cl.56, Tubb5	ENSG00000196230	Tubulin beta class I	6	30720201-30725426	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005417, CAB012406, HPA043640, HPA046280	Enhanced		Supported	Microtubules	Renal cancer:2.62e-8 (unfavourable), Liver cancer:5.97e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 72.3	Mixed		
TUBB1	dJ543J19.4	ENSG00000101162	Tubulin beta 1 class VI	20	59019254-59026654	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004286, HPA043640, HPA046280	Approved					Not detected	Group enriched	5	bone marrow: 4.8;lung: 2.1;placenta: 1.5;spleen: 5.6;testis: 1.5	gallbladder: 0.5	Cell line enriched	20	HEL: 24.9
TUBB2A	dJ40E16.7, TUBB, TUBB2	ENSG00000137267	Tubulin beta 2A class IIa	6	3153669-3157526	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015339, HPA043640, HPA046280	Supported		Supported	Microtubules	Urothelial cancer:1.61e-4 (unfavourable), Renal cancer:4.65e-4 (favourable)	Expressed in all	Tissue enriched	9	cerebral cortex: 622.8	skin: 72.0	Expressed in all		
TUBB2B	bA506K6.1, DKFZp566F223, MGC8685	ENSG00000137285	Tubulin beta 2B class IIb	6	3224261-3231730	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043640, HPA046280	Supported				Endometrial cancer:1.94e-4 (unfavourable)	Tissue enriched	Tissue enriched	6	cerebral cortex: 308.7	epididymis: 51.8	Cell line enhanced		AF22: 504.0;CACO-2: 319.1;SCLC-21H: 896.6;SH-SY5Y: 392.2
TUBB3	beta-4, CFEOM3, CFEOM3A, FEOM3	ENSG00000258947	Tubulin beta 3 class III	16	89921392-89938761	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043640, HPA046280	Approved					Mixed	Tissue enriched	6	cerebral cortex: 195.6	adrenal gland: 34.5	Cell line enhanced		SCLC-21H: 490.8
TUBB4A	beta-5, DYT4, TUBB4	ENSG00000104833	Tubulin beta 4A class IVa	19	6494319-6502848	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010768, HPA043640, HPA046280	Approved		Supported	Microtubules	Endometrial cancer:8.42e-7 (unfavourable)	Group enriched	Tissue enhanced		adrenal gland: 137.6;cerebral cortex: 554.4	testis: 102.4	Cell line enhanced		AN3-CA: 82.5;HAP1: 52.9;HEL: 69.1
TUBB4B	Beta2, TUBB2C	ENSG00000188229	Tubulin beta 4B class IVb	9	137241213-137243707	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010880, HPA043640, HPA046280	Enhanced		Supported	Microtubules	Thyroid cancer:6.36e-6 (favourable), Endometrial cancer:4.91e-4 (favourable), Liver cancer:9.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 786.8	Expressed in all		
TUBB6	HsT1601, MGC4083	ENSG00000176014	Tubulin beta 6 class V	18	12307669-12344320	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043640, HPA046280	Approved				Renal cancer:1.22e-7 (unfavourable), Urothelial cancer:9.69e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 214.3	Mixed		
TUBB8	bA631M21.2	ENSG00000261456	Tubulin beta 8 class VIII	10	46892-74163	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043640, HPA046280	Uncertain					Tissue enriched	Tissue enhanced		testis: 1.0	parathyroid gland: 0.8	Cell line enhanced		MCF7: 1.1
TUBD1	FLJ12709, TUBD	ENSG00000108423	Tubulin delta 1	17	59859482-59892945	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004609, HPA023980, HPA027090	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.00e-5 (unfavourable), Colorectal cancer:2.04e-4 (favourable), Renal cancer:6.06e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 12.5	Expressed in all		
TUBE1	dJ142L7.2, FLJ22589, TUBE	ENSG00000074935	Tubulin epsilon 1	6	112070777-112087529	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA032073, HPA032074	Approved					Expressed in all	Expressed in all			testis: 55.3	Expressed in all		
TUBG1	TUBG, TUBGCP1	ENSG00000131462	Tubulin gamma 1	17	42609676-42615234	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004608	Enhanced				Liver cancer:1.08e-8 (unfavourable), Renal cancer:6.48e-5 (unfavourable), Endometrial cancer:8.99e-4 (favourable)	Expressed in all	Tissue enriched	6	testis: 242.8	smooth muscle: 40.2	Expressed in all		
TUBG2		ENSG00000037042	Tubulin gamma 2	17	42659305-42667006	Predicted intracellular proteins	Evidence at protein level	CAB011495	Approved		Supported	Microtubule organizing center	Liver cancer:4.68e-5 (unfavourable), Renal cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 77.4	Mixed		
TUBGCP2	GCP2, SPBC97, Spc97p	ENSG00000130640	Tubulin gamma complex associated protein 2	10	133278630-133312337	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037885	Approved		Supported	Nucleoplasm<br>Centrosome		Expressed in all	Expressed in all			fallopian tube: 34.3	Expressed in all		
TUBGCP3	GCP3, SPBC98, Spc98p	ENSG00000126216	Tubulin gamma complex associated protein 3	13	112485005-112588167	Predicted intracellular proteins	Evidence at protein level	HPA043913	Approved					Expressed in all	Expressed in all			testis: 33.2	Expressed in all		
TUBGCP4	76P, FLJ14797	ENSG00000137822	Tubulin gamma complex associated protein 4	15	43369221-43409771	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043212	Approved		Supported	Centrosome		Expressed in all	Expressed in all			parathyroid gland: 13.1	Expressed in all		
TUBGCP5	GCP5, KIAA1899	ENSG00000275835	Tubulin gamma complex associated protein 5	15	22983192-23039673	Predicted intracellular proteins	Evidence at protein level	HPA039366, HPA040366	Supported		Supported	Centrosome<br>Cytosol		Expressed in all	Expressed in all			testis: 24.5	Expressed in all		
TUBGCP6	DJ402G11.6, GCP6, KIAA1669	ENSG00000128159	Tubulin gamma complex associated protein 6	22	50217689-50244992	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043928	Approved				Urothelial cancer:3.18e-5 (favourable), Pancreatic cancer:5.75e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.2	Expressed in all		
TUFM	EF-TuMT, EFTu	ENSG00000178952	Tu translation elongation factor, mitochondrial	16	28842411-28846408	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018991, HPA024087, CAB075730, CAB075731	Enhanced		Enhanced	Mitochondria	Renal cancer:2.69e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 162.7	Expressed in all		
TUFT1		ENSG00000143367	Tuftelin 1	1	151540305-151583583	Predicted intracellular proteins	Evidence at protein level	HPA028112, HPA054301	Approved	Approved	Approved	Vesicles	Endometrial cancer:4.83e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 92.8	esophagus: 25.8	Mixed		
TULP1	LCA15, RP14, TUBL1	ENSG00000112041	Tubby like protein 1	6	35497874-35512938	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Not detected			prostate: 0.7	Cell line enhanced		BEWO: 2.6;MCF7: 1.2
TULP2	CT65, TUBL2	ENSG00000104804	Tubby like protein 2	19	48880965-48898733	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	12	testis: 41.0	bone marrow: 3.4	Cell line enhanced		BEWO: 2.5;U-266/70: 2.3;U-266/84: 2.4
TULP3	TUBL3	ENSG00000078246	Tubby like protein 3	12	2877223-2941140	Predicted intracellular proteins	Evidence at protein level	HPA015285, HPA018496	Uncertain		Supported	Nucleus<br>Nucleoli<br>Plasma membrane	Liver cancer:7.97e-5 (unfavourable), Endometrial cancer:2.99e-4 (favourable), Renal cancer:7.18e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 46.5	Expressed in all		
TULP4	KIAA1397, TUSP	ENSG00000130338	Tubby like protein 4	6	158232236-158511828	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005445	Approved					Expressed in all	Mixed			cerebral cortex: 12.6	Expressed in all		
TUSC1	TSG-9	ENSG00000198680	Tumor suppressor candidate 1	9	25676389-25678440	Predicted intracellular proteins	Evidence at protein level	HPA051426	Approved		Approved	Nucleus<br>Vesicles		Expressed in all	Expressed in all			testis: 16.5	Cell line enhanced		HEL: 34.6
TUSC2	C3orf11, FUS1, PAP, PDAP2	ENSG00000114383	Tumor suppressor candidate 2	3	50320027-50328251	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA030116			Approved	Vesicles<br>Cytosol	Renal cancer:8.70e-7 (favourable), Liver cancer:2.84e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 42.1	Expressed in all		
TUT1	FLJ21850, FLJ22267, FLJ22347, PAPD2, RBM21, TUTase	ENSG00000149016	Terminal uridylyl transferase 1, U6 snRNA-specific	11	62575045-62592177	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069055, HPA071838			Supported	Nucleus<br>Cytosol	Colorectal cancer:9.51e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 17.8	Expressed in all		
TWF1	A6, PTK9	ENSG00000151239	Twinfilin actin binding protein 1	12	43793723-43806375	Predicted intracellular proteins	Evidence at protein level	HPA018116	Approved		Enhanced	Cytosol	Liver cancer:1.53e-4 (unfavourable), Colorectal cancer:8.29e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 119.5	Expressed in all		
TWF2	A6r, A6RP, PTK9L	ENSG00000247596	Twinfilin actin binding protein 2	3	52228610-52239260	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053874	Uncertain		Supported	Plasma membrane		Expressed in all	Expressed in all			lymph node: 61.2	Expressed in all		
TWIST1	ACS3, bHLHa38, BPES2, BPES3, CRS, CRS1, H-twist, SCS, TWIST	ENSG00000122691	Twist family bHLH transcription factor 1	7	19020991-19117672	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Tissue enhanced		adipose tissue: 22.7;endometrium: 30.7	placenta: 17.3	Cell line enriched	6	SH-SY5Y: 272.1
TWIST2	bHLHa39, Dermo-1, DERMO1	ENSG00000233608	Twist family bHLH transcription factor 2	2	238848032-238910543	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062870			Supported	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		cervix, uterine: 40.1	adipose tissue: 27.3	Cell line enhanced		ASC diff: 104.1;BJ: 108.5;BJ hTERT+: 326.5;fHDF/TERT166: 143.5;U-2197: 143.4
TWISTNB		ENSG00000105849	TWIST neighbor	7	19695462-19709087	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA019071, HPA022416	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:1.85e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 19.7	Expressed in all		
TWNK	C10orf2, FLJ21832, IOSCA, PEO, PEO1, TWINKLE, TWINL	ENSG00000107815	Twinkle mtDNA helicase	10	100987367-100994401	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002532	Uncertain					Expressed in all	Expressed in all			testis: 13.6	Expressed in all		
TXK	BTKL, PSCTK5, PTK4, RLK, TKL	ENSG00000074966	TXK tyrosine kinase	4	48066393-48134256	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062482			Approved	Vesicles		Mixed	Tissue enhanced		lymph node: 17.9	epididymis: 15.1	Cell line enhanced		HMC-1: 12.2;WM-115: 31.5
TXLNA	DKFZp451J0118	ENSG00000084652	Taxilin alpha	1	32179686-32198285	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA045383, HPA072477	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:7.21e-7 (unfavourable), Liver cancer:1.57e-6 (unfavourable), Pancreatic cancer:8.69e-5 (favourable), Head and neck cancer:5.53e-4 (favourable), Breast cancer:6.24e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 48.1	Expressed in all		
TXLNB	C6orf198, dJ522B19.2, DKFZp451A175, MDP77	ENSG00000164440	Taxilin beta	6	139240061-139292139	Predicted intracellular proteins	Evidence at protein level	HPA030401, HPA030402, HPA030403	Enhanced					Mixed	Group enriched	6	heart muscle: 52.2;skeletal muscle: 102.3	ovary: 13.7	Cell line enhanced		Daudi: 3.4;RPMI-8226: 2.5;U-698: 4.7
TXLNG	CXorf15, FIAT, FLJ11209, LSR5, MGC126621, MGC126625, TXLNGX	ENSG00000086712	Taxilin gamma	X	16786427-16844519	Predicted intracellular proteins	Evidence at protein level	HPA000297, HPA000841	Enhanced		Approved	Cytosol	Liver cancer:6.33e-6 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 20.8	Expressed in all		
TXN	TRX	ENSG00000136810	Thioredoxin	9	110243811-110256640	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008678, HPA047478, HPA055752	Enhanced		Enhanced	Nucleus<br>Nucleoli<br>Cytosol	Endometrial cancer:3.40e-6 (favourable)	Expressed in all	Expressed in all			esophagus: 702.9	Expressed in all		
TXN2	MT-TRX	ENSG00000100348	Thioredoxin 2	22	36467036-36482030	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000994, CAB008681	Approved		Enhanced	Mitochondria	Renal cancer:1.17e-6 (favourable), Prostate cancer:2.04e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 145.2	Expressed in all		
TXNDC17	MGC14353, TRP14, TXNL5	ENSG00000129235	Thioredoxin domain containing 17	17	6640758-6644541	Predicted intracellular proteins	Evidence at protein level	HPA022931	Approved				Renal cancer:1.15e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 70.0	Expressed in all		
TXNDC2	SPTRX1	ENSG00000168454	Thioredoxin domain containing 2	18	9885726-9889275	Predicted intracellular proteins	Evidence at protein level	CAB016414, HPA018817	Enhanced		Enhanced	Nucleus<br>Cytosol		Not detected	Tissue enriched	473	testis: 143.7	smooth muscle: 0.3	Cell line enhanced		K-562: 1.3;U-2 OS: 1.2
TXNDC8	bA427L11.2, SPTRX-3, TRX6	ENSG00000204193	Thioredoxin domain containing 8	9	110303521-110337884	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	371	testis: 44.0	kidney,lymph node,seminal vesicle: 0.1	Cell line enhanced		THP-1: 1.1
TXNDC9	APACD	ENSG00000115514	Thioredoxin domain containing 9	2	99318982-99340702	Predicted intracellular proteins	Evidence at protein level	HPA031844, HPA031845, HPA031846	Approved		Enhanced	Cytosol	Liver cancer:9.63e-7 (unfavourable), Head and neck cancer:4.31e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 36.4	Expressed in all		
TXNIP	ARRDC6, EST01027, HHCPA78, THIF, VDUP1	ENSG00000265972	Thioredoxin interacting protein	1	145992435-145996600	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA031085, HPA053694	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 1576.7	Cell line enhanced		ASC TERT1: 662.0;HSkMC: 921.1
TXNL1	TRP32, Txl, TXNL	ENSG00000091164	Thioredoxin like 1	18	56597208-56651600	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002828, HPA002829, CAB016446	Supported	Supported	Enhanced	Cytosol	Liver cancer:9.62e-6 (unfavourable), Ovarian cancer:6.26e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 334.3	Expressed in all		
TXNL4A	DIB1, DIM1, HsT161, SNRNP15, TXNL4, U5-15kD	ENSG00000141759	Thioredoxin like 4A	18	79970811-80033949	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041324			Approved	Nucleus<br>Nuclear membrane<br>Cytosol	Liver cancer:3.38e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 82.5	Expressed in all		
TXNL4B	Dim2, DLP, FLJ20511	ENSG00000140830	Thioredoxin like 4B	16	72044289-72094431	Predicted intracellular proteins	Evidence at protein level	HPA065865			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 28.8	Expressed in all		
TXNRD1	GRIM-12, Trxr1, TXNR	ENSG00000198431	Thioredoxin reductase 1	12	104215779-104350305	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001395, CAB004607, CAB015834, HPA043871	Approved		Supported	Nucleus	Liver cancer:1.12e-5 (unfavourable), Renal cancer:1.20e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 109.1	Expressed in all		
TXNRD3	TGR, TR2, TRXR3	ENSG00000197763	Thioredoxin reductase 3	3	126607052-126655155	Predicted intracellular proteins	Evidence at protein level	CAB020802, HPA036109	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.72e-4 (favourable), Pancreatic cancer:2.86e-4 (unfavourable), Endometrial cancer:3.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 43.4	parathyroid gland: 18.4	Mixed		
TXNRD3NB	TR2IT1, TXNRD3IT1, TXNRD3NT1	ENSG00000206483	Thioredoxin reductase 3 neighbor	3	126571789-126572636	Predicted intracellular proteins	Evidence at transcript level	HPA058257	Uncertain					Not detected	Not detected			ovary,testis: 0.2	Not detected		
TXNRD3NB	TR2IT1, TXNRD3IT1, TXNRD3NT1	ENSG00000283374	Thioredoxin reductase 3 neighbor	3	126571779-126608555	Predicted intracellular proteins	Evidence at transcript level	HPA058257	Uncertain						Not detected			parathyroid gland,testis: 0.1	Not detected		
TYK2	JTK1	ENSG00000105397	Tyrosine kinase 2	19	10350529-10380676	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005157	Uncertain		Supported	Cytosol	Head and neck cancer:1.05e-5 (favourable), Pancreatic cancer:1.02e-4 (favourable), Urothelial cancer:4.16e-4 (favourable), Renal cancer:4.43e-4 (unfavourable), Endometrial cancer:9.62e-4 (favourable)	Expressed in all	Expressed in all			spleen: 68.2	Expressed in all		
TYMP	ECGF1, MNGIE	ENSG00000025708	Thymidine phosphorylase	22	50525752-50530056	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000530, HPA001072, CAB002518	Enhanced		Approved	Nuclear bodies<br>Golgi apparatus	Renal cancer:3.50e-8 (unfavourable), Endometrial cancer:4.34e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 100.6	spleen: 53.1	Cell line enhanced		CAPAN-2: 37.3;HHSteC: 84.7;Karpas-707: 72.1;U-266/70: 36.4
TYMS	HsT422, TMS, TS, Tsase	ENSG00000176890	Thymidylate synthetase	18	657604-673578	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002784	Enhanced				Liver cancer:5.10e-6 (unfavourable)	Expressed in all	Mixed			testis: 59.1	Expressed in all		
TYSND1	MGC34695, NET41	ENSG00000156521	Trypsin domain containing 1	10	70137981-70146676	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030304	Uncertain		Uncertain	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Mixed			adipose tissue: 5.8	Cell line enhanced		HaCaT: 24.4;PC-3: 39.1
TYW3	C1orf171, FLJ40918	ENSG00000162623	TRNA-yW synthesizing protein 3 homolog	1	74733152-74766678	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029641	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.49e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 32.6	Expressed in all		
TYW5	C2orf60, FLJ37953	ENSG00000162971	TRNA-yW synthesizing protein 5	2	199929975-199955736	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028294, HPA045803	Uncertain		Approved	Nuclear bodies		Expressed in all	Mixed			appendix: 1.6	Mixed		
U2AF1	RN, RNU2AF1, U2AF35, U2AFBP	ENSG00000160201	U2 small nuclear RNA auxiliary factor 1	21	43092956-43107587	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044833, HPA052083	Supported		Enhanced	Nucleoplasm		Not detected	Expressed in all			thyroid gland: 70.1	Expressed in all		
U2AF1L4	MGC33901, U2AF1L3, U2af26	ENSG00000161265	U2 small nuclear RNA auxiliary factor 1 like 4	19	35742464-35745445	Predicted intracellular proteins	Evidence at protein level	HPA052083, HPA061644	Supported		Approved	Nucleoplasm	Head and neck cancer:2.58e-5 (favourable), Pancreatic cancer:8.58e-5 (favourable), Renal cancer:9.73e-5 (unfavourable), Breast cancer:2.44e-4 (favourable), Urothelial cancer:7.05e-4 (favourable)	Expressed in all	Mixed			testis: 7.7	Mixed		
U2AF1L5		ENSG00000275895	U2 small nuclear RNA auxiliary factor 1 like 5	21	6484623-6499261	Predicted intracellular proteins	Evidence at protein level	HPA044833, HPA052083	Supported		Uncertain	Nucleoplasm		Not detected	Expressed in all			tonsil: 100.1	Expressed in all		
U2AF2	U2AF65	ENSG00000063244	U2 small nuclear RNA auxiliary factor 2	19	55654146-55674715	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010910, HPA041943, HPA043562	Supported	Supported	Enhanced	Nucleoplasm<br>Nuclear speckles	Liver cancer:1.54e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 137.2	Expressed in all		
U2SURP	fSAPa, SR140	ENSG00000163714	U2 snRNP associated SURP domain containing	3	142964497-143060546	Predicted intracellular proteins	Evidence at protein level	HPA037545, HPA037546, HPA061407	Enhanced		Supported	Nucleoplasm	Renal cancer:8.86e-7 (unfavourable), Liver cancer:3.15e-5 (unfavourable), Urothelial cancer:6.78e-4 (favourable), Endometrial cancer:8.44e-4 (unfavourable), Pancreatic cancer:8.92e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.6	Expressed in all		
U82695.5		ENSG00000214897		X	153395640-153401420	Predicted intracellular proteins	Evidence at transcript level							Mixed	Group enriched	35	epididymis: 5.8;ovary: 4.7;testis: 10.9	fallopian tube: 0.2	Not detected		
UACA	FLJ10128, KIAA1561	ENSG00000137831	Uveal autoantigen with coiled-coil domains and ankyrin repeats	15	70654554-70763593	Predicted intracellular proteins	Evidence at protein level	HPA041412, HPA043503	Uncertain		Supported	Nucleus<br>Cytosol	Pancreatic cancer:7.01e-5 (unfavourable), Urothelial cancer:1.03e-4 (unfavourable), Renal cancer:1.62e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 59.6	Cell line enhanced		BJ: 206.5
UAP1	AgX, AGX1, SPAG2	ENSG00000117143	UDP-N-acetylglucosamine pyrophosphorylase 1	1	162561506-162599842	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014659	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:5.12e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 166.1	Expressed in all		
UAP1L1		ENSG00000197355	UDP-N-acetylglucosamine pyrophosphorylase 1 like 1	9	137077501-137084539	Predicted intracellular proteins	Evidence at protein level	HPA044356	Approved		Approved	Intermediate filaments<br>Cytosol	Liver cancer:3.77e-4 (unfavourable), Pancreatic cancer:5.23e-4 (favourable)	Expressed in all	Mixed			spleen: 13.2	Mixed		
UBA3	hUba3, NAE2, UBE1C	ENSG00000144744	Ubiquitin like modifier activating enzyme 3	3	69054730-69080408	Predicted intracellular proteins	Evidence at protein level	HPA034873, HPA034874, HPA065335	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol	Liver cancer:8.57e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 66.8	Expressed in all		
UBA52	CEP52, HUBCEP52, L40, MGC126879, MGC126881, MGC57125, RPL40	ENSG00000221983	Ubiquitin A-52 residue ribosomal protein fusion product 1	19	18571730-18577550	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA041344, HPA049132, HPA056624	Supported		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			ovary: 1914.0	Expressed in all		
UBA6	FLJ10808, UBE1L2	ENSG00000033178	Ubiquitin like modifier activating enzyme 6	4	67612652-67701179	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037001	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:7.01e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 18.7	Expressed in all		
UBAC1	GBDR1, KPC2, UBADC1	ENSG00000130560	UBA domain containing 1	9	135932969-135961380	Predicted intracellular proteins	Evidence at protein level	HPA005651	Approved		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:3.58e-7 (favourable), Cervical cancer:4.34e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 88.7	Expressed in all		
UBALD2	FAM100B, MGC29814	ENSG00000185262	UBA like domain containing 2	17	76265202-76271299	Predicted intracellular proteins	Evidence at protein level	HPA023046	Uncertain					Expressed in all	Expressed in all			bone marrow: 140.7	Expressed in all		
UBAP1	UBAP	ENSG00000165006	Ubiquitin associated protein 1	9	34179005-34252523	Predicted intracellular proteins	Evidence at protein level	HPA019804, HPA041590	Approved		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:7.49e-6 (favourable)	Expressed in all	Expressed in all			testis: 88.6	Expressed in all		
UBAP1L		ENSG00000246922	Ubiquitin associated protein 1 like	15	65092770-65115197	Predicted intracellular proteins	Evidence at protein level	HPA065334			Uncertain	Nuclear bodies		Mixed	Mixed			cerebral cortex: 1.8	Cell line enhanced		SK-MEL-30: 1.9
UBAP2L	KIAA0144, NICE-4	ENSG00000143569	Ubiquitin associated protein 2 like	1	154220179-154271510	Predicted intracellular proteins	Evidence at protein level	HPA035068	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:2.89e-5 (unfavourable), Liver cancer:4.65e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 122.8	Expressed in all		
UBASH3A	CLIP4, STS-2, TULA	ENSG00000160185	Ubiquitin associated and SH3 domain containing A	21	42403447-42447681	Predicted intracellular proteins	Evidence at protein level	HPA035367			Supported	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enhanced		lymph node: 12.5	appendix: 6.7	Group enriched	6	HEL: 20.6;MOLT-4: 38.2
UBASH3B	KIAA1959, STS-1, TULA2	ENSG00000154127	Ubiquitin associated and SH3 domain containing B	11	122655675-122814473	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038605, HPA038607	Approved		Approved	Plasma membrane		Mixed	Tissue enhanced		placenta: 19.6;spleen: 21.3	lung: 6.7	Cell line enhanced		HEL: 108.5;HMC-1: 77.6
UBB	FLJ25987, MGC8385	ENSG00000170315	Ubiquitin B	17	16380798-16382745	Predicted intracellular proteins	Evidence at protein level	CAB013048, HPA041344, HPA049132	Supported				Renal cancer:1.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 2234.2	Mixed		
UBC		ENSG00000150991	Ubiquitin C	12	124911604-124917368	Predicted intracellular proteins	Evidence at protein level	CAB000362, CAB005419, HPA041344, HPA049132	Supported				Renal cancer:7.90e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 1965.2	Expressed in all		
UBD	FAT10	ENSG00000213886	Ubiquitin D	6	29555515-29559925	Predicted intracellular proteins	Evidence at protein level	HPA043710			Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:2.40e-5 (unfavourable), Ovarian cancer:7.35e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 94.9;tonsil: 92.5	appendix: 43.0	Cell line enriched	6	RT4: 24.7
UBE2A	HHR6A, RAD6A, UBC2	ENSG00000077721	Ubiquitin conjugating enzyme E2 A	X	119574467-119591083	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003875, HPA051765, HPA065898			Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:2.20e-6 (unfavourable), Cervical cancer:2.16e-4 (favourable), Head and neck cancer:9.07e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 76.5	Expressed in all		
UBE2B	HHR6B, RAD6B, UBC2	ENSG00000119048	Ubiquitin conjugating enzyme E2 B	5	134371179-134391992	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003875, HPA051765, HPA065898			Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			adrenal gland: 99.1	Expressed in all		
UBE2C	UBCH10	ENSG00000175063	Ubiquitin conjugating enzyme E2 C	20	45812576-45816957	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB011464, HPA034569, CAB035990, HPA054975	Approved		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.24e-6 (unfavourable), Pancreatic cancer:6.91e-4 (unfavourable)	Expressed in all	Mixed			tonsil: 56.9	Mixed		
UBE2D1	E2(17)KB1, SFT, UBC4/5, UBCH5, UbcH5A	ENSG00000072401	Ubiquitin conjugating enzyme E2 D1	10	58334975-58370753	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003920	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:8.04e-6 (unfavourable), Liver cancer:5.58e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 47.8	Mixed		
UBE2D2	UBC4, UbcH5B	ENSG00000131508	Ubiquitin conjugating enzyme E2 D2	5	139526431-139628433	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA003920	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:9.63e-7 (unfavourable), Renal cancer:2.09e-5 (unfavourable), Colorectal cancer:5.09e-5 (favourable), Endometrial cancer:5.90e-4 (favourable)	Expressed in all	Expressed in all			testis: 239.4	Expressed in all		
UBE2D3	UbcH5C	ENSG00000109332	Ubiquitin conjugating enzyme E2 D3	4	102794383-102868896	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003920	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.51e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 300.9	Expressed in all		
UBE2D4	HBUCE1	ENSG00000078967	Ubiquitin conjugating enzyme E2 D4 (putative)	7	43926438-43956136	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003920	Approved		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:4.86e-4 (favourable), Prostate cancer:5.77e-4 (favourable), Renal cancer:6.51e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 12.5	Expressed in all		
UBE2E1	UbcH6	ENSG00000170142	Ubiquitin conjugating enzyme E2 E1	3	23805903-23891316	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030445, CAB073413	Approved		Approved	Nucleoplasm	Liver cancer:9.97e-7 (unfavourable)	Expressed in all	Expressed in all			placenta: 119.1	Expressed in all		
UBE2E2	FLJ25157, UbcH8	ENSG00000182247	Ubiquitin conjugating enzyme E2 E2	3	23203020-23591793	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003303, HPA028872, HPA030445, CAB073417	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 40.1	Mixed		
UBE2E3	UbcH9	ENSG00000170035	Ubiquitin conjugating enzyme E2 E3	2	180967248-181076585	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003303, HPA030445	Approved				Pancreatic cancer:1.78e-5 (unfavourable), Head and neck cancer:8.08e-5 (unfavourable), Liver cancer:9.11e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 131.8	Expressed in all		
UBE2F	NCE2	ENSG00000184182	Ubiquitin conjugating enzyme E2 F (putative)	2	237966827-238042782	Predicted intracellular proteins	Evidence at protein level	HPA037444	Approved		Approved	Cytosol	Renal cancer:1.59e-7 (unfavourable), Liver cancer:2.72e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 64.0	Expressed in all		
UBE2G1	UBC7, UBE2G	ENSG00000132388	Ubiquitin conjugating enzyme E2 G1	17	4269259-4366628	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045681, HPA050551	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 73.2	Expressed in all		
UBE2G2	UBC7	ENSG00000184787	Ubiquitin conjugating enzyme E2 G2	21	44768580-44802019	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003332	Approved				Renal cancer:7.02e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 26.5	Expressed in all		
UBE2H	GID3, UBC8, UBCH	ENSG00000186591	Ubiquitin conjugating enzyme E2 H	7	129830732-129952949	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003302	Approved		Supported	Mitochondria	Pancreatic cancer:2.33e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 94.5	Expressed in all		
UBE2I	UBC9	ENSG00000103275	Ubiquitin conjugating enzyme E2 I	16	1308880-1327018	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA003909, CAB009021	Approved		Enhanced	Cytosol	Thyroid cancer:5.68e-4 (favourable), Liver cancer:7.50e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 117.1	Expressed in all		
UBE2K	HIP2, HYPG, UBC1	ENSG00000078140	Ubiquitin conjugating enzyme E2 K	4	39698044-39782792	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028869, CAB033212, CAB033515	Supported		Supported	Intermediate filaments<br>Actin filaments<br>Cytosol	Pancreatic cancer:8.60e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 64.7	Expressed in all		
UBE2L3	UBCH7	ENSG00000185651	Ubiquitin conjugating enzyme E2 L3	22	21549447-21624034	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045609, HPA062415	Approved		Approved	Nucleus<br>Cytosol	Ovarian cancer:3.82e-6 (favourable), Liver cancer:1.29e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 67.1	Expressed in all		
UBE2L5P	UBE2L5	ENSG00000236444	Ubiquitin conjugating enzyme E2 L5, pseudogene	13	30422488-30428616	Predicted intracellular proteins	Evidence at protein level	HPA045609, HPA062415	Approved		Uncertain	Nucleus<br>Cytosol		Mixed	Tissue enriched	76	testis: 86.2	endometrium: 1.1	Not detected		
UBE2L6	UBCH8	ENSG00000156587	Ubiquitin conjugating enzyme E2 L6	11	57551656-57568284	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003328, CAB073407	Enhanced		Approved	Cytosol	Pancreatic cancer:4.88e-4 (unfavourable), Breast cancer:6.75e-4 (favourable)	Expressed in all	Expressed in all			spleen: 148.0	Mixed		
UBE2M	hUbc12, UBC12	ENSG00000130725	Ubiquitin conjugating enzyme E2 M	19	58555712-58558960	Predicted intracellular proteins	Evidence at protein level	CAB004993, HPA054551, HPA057800	Approved		Supported	Nucleus<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 108.0	Expressed in all		
UBE2N	MGC8489, UBC13, UbcH-ben	ENSG00000177889	Ubiquitin conjugating enzyme E2 N	12	93405673-93442262	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044976	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:2.41e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 253.6	Expressed in all		
UBE2O	E2-230K	ENSG00000175931	Ubiquitin conjugating enzyme E2 O	17	76389451-76453206	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023605	Uncertain		Supported	Nucleus<br>Nuclear bodies	Renal cancer:4.34e-9 (unfavourable), Liver cancer:6.84e-8 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 36.0	Expressed in all		
UBE2Q1	NICE-5, PRO3094, UBE2Q	ENSG00000160714	Ubiquitin conjugating enzyme E2 Q1	1	154548577-154559028	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA063368	Approved		Approved	Nucleoplasm<br>Centrosome	Renal cancer:4.84e-7 (unfavourable), Thyroid cancer:1.86e-5 (favourable), Liver cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.0	Expressed in all		
UBE2Q2	DKFZp762C143	ENSG00000140367	Ubiquitin conjugating enzyme E2 Q2	15	75843285-75901078	Enzymes, Predicted intracellular proteins	Evidence at protein level						Ovarian cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 51.5	Expressed in all		
UBE2Q2L		ENSG00000259511	Ubiquitin conjugating enzyme E2 Q2 like	15	84172490-84182234	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		ovary: 2.2	testis: 1.2	Cell line enhanced		K-562: 2.0;Karpas-707: 1.3
UBE2QL1	FLJ25076	ENSG00000215218	Ubiquitin conjugating enzyme E2 Q family like 1	5	6448623-6494909	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057414			Supported	Nucleus<br>Plasma membrane	Renal cancer:6.81e-8 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 41.8	seminal vesicle: 10.4	Cell line enhanced		Karpas-707: 29.4;PC-3: 32.0;SCLC-21H: 37.2;U-266/70: 57.9;U-266/84: 50.5
UBE2R2	CDC34B, FLJ20419, MGC10481, UBC3B	ENSG00000107341	Ubiquitin conjugating enzyme E2 R2	9	33817567-33920404	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA061000			Approved	Nucleus<br>Nucleoli	Liver cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 68.7	Expressed in all		
UBE2S	E2-EPF	ENSG00000108106	Ubiquitin conjugating enzyme E2 S	19	55399745-55407777	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB015228, HPA057150	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:8.16e-8 (unfavourable), Liver cancer:8.00e-6 (unfavourable), Endometrial cancer:2.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 120.1	Expressed in all		
UBE2T	FANCT, HSPC150	ENSG00000077152	Ubiquitin conjugating enzyme E2 T	1	202331657-202341980	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002831			Approved	Nucleus<br>Nucleoli	Renal cancer:2.22e-16 (unfavourable), Liver cancer:4.79e-6 (unfavourable), Ovarian cancer:6.90e-6 (favourable)	Expressed in all	Mixed			testis: 36.0	Expressed in all		
UBE2U	MGC35130	ENSG00000177414	Ubiquitin conjugating enzyme E2 U (putative)	1	64203627-64267368	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	39	testis: 79.4	stomach: 2.0	Not detected		
UBE2V1	CROC-1, CROC1, UBE2V, UEV-1, UEV1A	ENSG00000244687	Ubiquitin conjugating enzyme E2 V1	20	50081124-50115959	Predicted intracellular proteins	Evidence at protein level	HPA052535, HPA053186			Enhanced	Nucleoplasm	Renal cancer:4.58e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 109.7	Expressed in all		
UBE2V2	DDVit-1, DDVIT1, EDAF-1, EDPF-1, EDPF1, MMS2, UEV-2, UEV2	ENSG00000169139	Ubiquitin conjugating enzyme E2 V2	8	48008400-48064708	Predicted intracellular proteins	Evidence at protein level	HPA052535, HPA053186			Supported	Nucleoplasm	Renal cancer:4.96e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 97.6	Expressed in all		
UBE2W	FLJ11011, UBC-16	ENSG00000104343	Ubiquitin conjugating enzyme E2 W	8	73780097-73878910	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045161, HPA073181	Uncertain		Supported	Nucleoli		Expressed in all	Expressed in all			testis: 19.6	Expressed in all		
UBE2Z	FLJ13855, USE1	ENSG00000159202	Ubiquitin conjugating enzyme E2 Z	17	48908369-48929056	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007922	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.05e-4 (unfavourable), Colorectal cancer:4.62e-4 (favourable), Liver cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 82.7	Expressed in all		
UBE3B		ENSG00000151148	Ubiquitin protein ligase E3B	12	109477402-109536705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041012	Approved		Approved	Nuclear speckles<br>Mitochondria	Renal cancer:2.49e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.1	Expressed in all		
UBE3C	KIAA0010, KIAA10	ENSG00000009335	Ubiquitin protein ligase E3C	7	157138913-157269372	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039915	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Mitochondria	Renal cancer:9.18e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 51.1	Expressed in all		
UBE3D	C6orf157, DKFZp434A1520, H10BH, UBE2CBP, YJR141W	ENSG00000118420	Ubiquitin protein ligase E3D	6	82892398-83065841	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027231	Uncertain		Approved	Rods & Rings		Mixed	Mixed			fallopian tube: 6.3	Expressed in all		
UBE4A	E4, KIAA0126, UBOX2, UFD2	ENSG00000110344	Ubiquitination factor E4A	11	118359585-118399211	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055035, HPA064010	Approved		Supported	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 43.7	Expressed in all		
UBE4B	E4, KIAA0684, UBOX3, UFD2	ENSG00000130939	Ubiquitination factor E4B	1	10032832-10181239	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019219	Approved				Liver cancer:3.69e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 43.4	Expressed in all		
UBFD1	FLJ38870, FLJ42145, UBPH	ENSG00000103353	Ubiquitin family domain containing 1	16	23557362-23574389	Predicted intracellular proteins	Evidence at protein level	HPA051746			Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 56.5	Expressed in all		
UBL3	DKFZP434K151, FLJ32018, HCG-1, PNSC1	ENSG00000122042	Ubiquitin like 3	13	29764371-29850684	Predicted intracellular proteins	Evidence at protein level	HPA053772, HPA058781	Uncertain		Approved	Centrosome	Renal cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 90.6	Expressed in all		
UBL4A	DXS254E, GDX, GET5, MDY2, TMA24, UBL4	ENSG00000102178	Ubiquitin like 4A	X	154483717-154486670	Predicted intracellular proteins	Evidence at protein level	HPA003617	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:8.64e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 31.8	Expressed in all		
UBL4B	FLJ25690	ENSG00000186150	Ubiquitin like 4B	1	110112468-110113945	Predicted intracellular proteins	Evidence at protein level	HPA031364	Enhanced		Uncertain	Intermediate filaments<br>Mitochondria		Tissue enhanced	Tissue enriched	61	testis: 69.3	fallopian tube: 1.1	Cell line enriched	5	BJ hTERT+: 16.6
UBL5		ENSG00000198258	Ubiquitin like 5	19	9827892-9830115	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			epididymis: 582.9	Expressed in all		
UBL7	BMSC-UbP, MGC14421	ENSG00000138629	Ubiquitin like 7	15	74445977-74461182	Predicted intracellular proteins	Evidence at protein level	HPA040423, HPA041897	Approved		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:6.37e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 76.4	Expressed in all		
UBLCP1	CPUB1, MGC10067	ENSG00000164332	Ubiquitin like domain containing CTD phosphatase 1	5	159263081-159286040	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039615	Approved		Enhanced	Nucleus<br>Nucleoli	Liver cancer:4.46e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 49.9	Expressed in all		
UBN1		ENSG00000118900	Ubinuclein 1	16	4846665-4882360	Predicted intracellular proteins	Evidence at protein level	HPA061029, HPA069045	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 70.4	Expressed in all		
UBN2	FLJ25778, KIAA2030	ENSG00000157741	Ubinuclein 2	7	139230356-139308236	Predicted intracellular proteins	Evidence at protein level	HPA019743, HPA020122, HPA020124	Uncertain		Supported	Nucleoplasm	Head and neck cancer:4.49e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 26.4	skin: 11.8	Expressed in all		
UBOX5	KIAA0860, RNF37, Ubce7ip5, UIP5	ENSG00000185019	U-box domain containing 5	20	3107573-3160196	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028871	Approved		Approved	Nucleoplasm	Pancreatic cancer:1.80e-5 (favourable), Head and neck cancer:4.52e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 7.1	Expressed in all		
UBP1	LBP-1a	ENSG00000153560	Upstream binding protein 1 (LBP-1a)	3	33388336-33441371	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003967			Supported	Nucleoplasm	Colorectal cancer:1.81e-4 (favourable), Liver cancer:9.45e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 54.5	Expressed in all		
UBQLN1	DA41, DSK2, PLIC-1, XDRP1	ENSG00000135018	Ubiquilin 1	9	83659963-83708203	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037256, HPA054143	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.07e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 113.8	Expressed in all		
UBQLN2	Chap1, CHAP1/DSK2, Dsk2, LIC-2, N4BP4, PLIC-2, PLIC2, RIHFB2157	ENSG00000188021	Ubiquilin 2	X	56563639-56567868	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006431, CAB013481	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:2.29e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 53.7	Expressed in all		
UBQLN3	TUP-1	ENSG00000175520	Ubiquilin 3	11	5507300-5509985	Predicted intracellular proteins	Evidence at protein level	HPA020547, HPA062018	Enhanced					Not detected	Tissue enriched	693	testis: 216.4	epididymis: 0.3	Not detected		
UBQLN4	A1U, C1orf6, UBIN	ENSG00000160803	Ubiquilin 4	1	156035301-156053794	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA061797	Approved		Supported	Nucleus		Expressed in all	Expressed in all			cerebral cortex: 41.1	Expressed in all		
UBQLNL	MGC20470, MGC26958	ENSG00000175518	Ubiquilin-like	11	5514393-5516705	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	30	testis: 40.2	epididymis: 1.3	Not detected		
UBR5	DD5, EDD, EDD1, HYD, KIAA0896	ENSG00000104517	Ubiquitin protein ligase E3 component n-recognin 5	8	102253012-102412841	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053688			Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.26e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 80.2	Expressed in all		
UBR7	C14orf130	ENSG00000012963	Ubiquitin protein ligase E3 component n-recognin 7 (putative)	14	93207056-93229215	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000861	Approved		Approved	Nucleus	Liver cancer:8.12e-5 (unfavourable), Renal cancer:9.76e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.3	Expressed in all		
UBTD1	FLJ11807	ENSG00000165886	Ubiquitin domain containing 1	10	97498868-97571209	Predicted intracellular proteins	Evidence at protein level	HPA034825	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Colorectal cancer:5.54e-4 (unfavourable)	Expressed in all	Mixed			testis: 34.0	Mixed		
UBTD2	DC-UbP, MGC30022	ENSG00000168246	Ubiquitin domain containing 2	5	172209640-172284071	Predicted intracellular proteins	Evidence at protein level	HPA035891, HPA035892	Uncertain				Liver cancer:1.44e-5 (unfavourable), Colorectal cancer:5.92e-5 (favourable)	Expressed in all	Mixed			testis: 53.4	Expressed in all		
UBTF	NOR-90, UBF, UBF1, UBF2	ENSG00000108312	Upstream binding transcription factor, RNA polymerase I	17	44205033-44221626	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004611, HPA006385	Enhanced	Supported	Enhanced	Nucleoli fibrillar center		Expressed in all	Expressed in all			parathyroid gland: 81.5	Expressed in all		
UBTFL1	C11orf27	ENSG00000255009	Upstream binding transcription factor, RNA polymerase I-like 1	11	90085950-90087131	Predicted intracellular proteins, Transcription factors	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
UBXN1	2B28, LOC51035, SAKS1, UBXD10	ENSG00000162191	UBX domain protein 1	11	62676498-62679117	Predicted intracellular proteins	Evidence at protein level	HPA012669	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			ovary: 145.9	Expressed in all		
UBXN10	FLJ25429, UBXD3	ENSG00000162543	UBX domain protein 10	1	20186085-20196048	Predicted intracellular proteins	Evidence at protein level	HPA028555, HPA028564	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Glioma:1.64e-4 (unfavourable), Endometrial cancer:2.02e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 79.1	testis: 25.5	Group enriched	6	HEL: 2.5;HMC-1: 6.3;K-562: 7.6;SCLC-21H: 6.6
UBXN11	SOC, SOCI, UBXD5	ENSG00000158062	UBX domain protein 11	1	26281328-26318363	Predicted intracellular proteins	Evidence at protein level	HPA028600, HPA031357	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:5.90e-6 (unfavourable), Cervical cancer:2.54e-5 (favourable), Endometrial cancer:1.90e-4 (favourable), Head and neck cancer:4.90e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 50.2	Expressed in all		
UBXN2A	UBXD4	ENSG00000173960	UBX domain protein 2A	2	23927285-24004909	Predicted intracellular proteins	Evidence at protein level	HPA065482, HPA069096	Supported		Approved	Centrosome	Liver cancer:1.39e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 12.5	Expressed in all		
UBXN2B	p37	ENSG00000215114	UBX domain protein 2B	8	58411264-58451501	Predicted intracellular proteins	Evidence at protein level	HPA045278	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 27.0	Expressed in all		
UBXN6	UBXD1, UBXDC2	ENSG00000167671	UBX domain protein 6	19	4444999-4457822	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040906, HPA041313, HPA061872	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:2.78e-5 (favourable), Endometrial cancer:5.68e-5 (favourable), Pancreatic cancer:6.95e-4 (favourable)	Expressed in all	Expressed in all			testis: 138.8	Expressed in all		
UBXN7	KIAA0794, UBXD7	ENSG00000163960	UBX domain protein 7	3	196347662-196432474	Predicted intracellular proteins	Evidence at protein level	HPA048441, HPA049442	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 22.2	Expressed in all		
UCHL1	PARK5, PGP9.5, Uch-L1	ENSG00000154277	Ubiquitin C-terminal hydrolase L1	4	41256413-41268455	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002580, HPA005993, CAB079024	Enhanced	Supported	Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:4.08e-5 (unfavourable), Urothelial cancer:1.93e-4 (unfavourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 785.9	adrenal gland: 107.9	Cell line enhanced		EFO-21: 912.4;SCLC-21H: 1141.2;U-87 MG: 916.2
UCHL3		ENSG00000118939	Ubiquitin C-terminal hydrolase L3	13	75549480-75606020	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019678, CAB037139, CAB037208	Approved		Supported	Nucleus<br>Cytosol	Liver cancer:6.41e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 90.7	Expressed in all		
UCHL5	CGI-70, INO80R, UCH37	ENSG00000116750	Ubiquitin C-terminal hydrolase L5	1	193012250-193060080	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005908, HPA006069, HPA075383	Approved	Approved	Approved	Nucleoplasm<br>Mitochondria	Thyroid cancer:7.10e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 43.0	Expressed in all		
UCK1	FLJ12255, URK1	ENSG00000130717	Uridine-cytidine kinase 1	9	131523801-131531268	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050969	Approved		Approved	Nucleus	Renal cancer:2.21e-7 (favourable), Cervical cancer:3.19e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.2	Expressed in all		
UCK2	UMPK	ENSG00000143179	Uridine-cytidine kinase 2	1	165827531-165911618	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA057128			Approved	Nucleus	Renal cancer:5.12e-13 (unfavourable), Liver cancer:9.22e-8 (unfavourable), Lung cancer:4.98e-4 (unfavourable), Melanoma:6.70e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 41.1	Expressed in all		
UCKL1	FLJ20517, URKL1	ENSG00000198276	Uridine-cytidine kinase 1 like 1	20	63939829-63956415	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004722, HPA004769	Approved		Approved	Endoplasmic reticulum	Pancreatic cancer:4.42e-4 (favourable)	Expressed in all	Expressed in all			spleen: 40.1	Expressed in all		
UCP2	BMIQ4, SLC25A8	ENSG00000175567	Uncoupling protein 2	11	73974667-73983307	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB025583, HPA075202	Approved		Supported	Mitochondria	Renal cancer:7.80e-6 (unfavourable), Cervical cancer:4.65e-5 (favourable)	Expressed in all	Expressed in all			lymph node: 385.7	Cell line enhanced		SK-BR-3: 390.7
UCP3	SLC25A9	ENSG00000175564	Uncoupling protein 3	11	74000281-74009435	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB010771, HPA072225	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	19	skeletal muscle: 71.2	testis: 3.8	Group enriched	5	HDLM-2: 13.8;RH-30: 3.3
UEVLD	Attp, UEV3	ENSG00000151116	UEV and lactate/malate dehyrogenase domains	11	18529609-18588747	Predicted intracellular proteins	Evidence at protein level	HPA047134	Approved		Approved	Nucleus<br>Cytosol	Colorectal cancer:7.07e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.8	Mixed		
UFC1	HSPC155	ENSG00000143222	Ubiquitin-fold modifier conjugating enzyme 1	1	161152776-161158856	Predicted intracellular proteins	Evidence at protein level	HPA027481, HPA028722	Enhanced		Approved	Nuclear speckles<br>Cytosol	Renal cancer:2.62e-6 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 253.4	Expressed in all		
UFD1L	UFD1	ENSG00000070010	Ubiquitin fusion degradation 1 like (yeast)	22	19449910-19479215	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA030287, HPA030288, HPA073425	Approved		Enhanced	Endoplasmic reticulum	Renal cancer:4.50e-8 (unfavourable), Liver cancer:2.59e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 66.0	Expressed in all		
UFL1	KIAA0776, Maxer, NLBP, RCAD	ENSG00000014123	UFM1 specific ligase 1	6	96521595-96555276	Predicted intracellular proteins	Evidence at protein level	HPA030558, HPA030559, HPA030560	Enhanced		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			thyroid gland: 47.1	Expressed in all		
UFM1	bA131P10.1, C13orf20	ENSG00000120686	Ubiquitin fold modifier 1	13	38349849-38363619	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039758	Approved				Head and neck cancer:1.08e-4 (unfavourable), Endometrial cancer:9.35e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 101.2	Expressed in all		
UFSP1	UFSP	ENSG00000176125	UFM1 specific peptidase 1 (inactive)	7	100888723-100889718	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA027099	Uncertain					Expressed in all	Mixed			adipose tissue: 2.0	Mixed		
UFSP2	C4orf20, FLJ11200	ENSG00000109775	UFM1 specific peptidase 2	4	185399540-185425985	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039985, HPA043298	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.07e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.0	Expressed in all		
UGDH		ENSG00000109814	UDP-glucose 6-dehydrogenase	4	39498755-39528311	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034444, HPA036656, HPA036657	Enhanced		Enhanced	Nucleoplasm	Renal cancer:5.51e-10 (unfavourable)	Expressed in all	Expressed in all			colon: 95.4	Expressed in all		
UGGT1	HUGT1, UGCGL1	ENSG00000136731	UDP-glucose glycoprotein glucosyltransferase 1	2	128091200-128195677	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012761, HPA015127	Enhanced		Uncertain	Cytosol	Renal cancer:6.37e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 24.3	Expressed in all		
UGP2	UGP1, UGPP1	ENSG00000169764	UDP-glucose pyrophosphorylase 2	2	63840940-63891562	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034696, HPA034697, HPA064836	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Mitochondria	Liver cancer:2.50e-5 (favourable)	Expressed in all	Expressed in all			liver: 593.9	Expressed in all		
UHMK1	KIS, Kist	ENSG00000152332	U2AF homology motif kinase 1	1	162497251-162529629	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA071190			Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 44.2	Expressed in all		
UHRF1	FLJ21925, ICBP90, Np95, RNF106, TDRD22	ENSG00000276043	Ubiquitin like with PHD and ring finger domains 1	19	4903080-4962154	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049408, HPA055446	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:4.52e-5 (unfavourable), Liver cancer:1.63e-4 (unfavourable), Melanoma:6.81e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 18.8	bone marrow: 17.5	Expressed in all		
UHRF1BP1	C6orf107, dJ349A12.1, FLJ20302, ICBP90	ENSG00000065060	UHRF1 binding protein 1	6	34792015-34883138	Predicted intracellular proteins	Evidence at protein level	HPA032099, HPA032100	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Liver cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.2	Expressed in all		
UHRF1BP1L	KIAA0701	ENSG00000111647	UHRF1 binding protein 1 like	12	100028455-100142848	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039671, HPA040399	Uncertain		Approved	Plasma membrane		Expressed in all	Mixed			cerebral cortex: 32.9	Expressed in all		
UHRF2	MGC33463, NIRF, RNF107, TDRD23, URF2	ENSG00000147854	Ubiquitin like with PHD and ring finger domains 2	9	6413151-6507054	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026633, HPA026697			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 32.8	Expressed in all		
UIMC1	RAP80	ENSG00000087206	Ubiquitin interaction motif containing 1	5	176905005-177022633	Predicted intracellular proteins	Evidence at protein level	HPA037503, HPA037504	Enhanced		Enhanced	Nuclear bodies	Liver cancer:7.67e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 109.5	Expressed in all		
ULK1	ATG1, ATG1A	ENSG00000177169	Unc-51 like autophagy activating kinase 1	12	131894651-131923167	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063990			Approved	Cytosol		Expressed in all	Expressed in all			skin: 23.7	Expressed in all		
ULK2	ATG1B, KIAA0623, Unc51.2	ENSG00000083290	Unc-51 like autophagy activating kinase 2	17	19770829-19867936	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA009027, CAB037021	Approved					Expressed in all	Expressed in all			testis: 65.9	Mixed		
ULK3	DKFZP434C131, FLJ90566	ENSG00000140474	Unc-51 like kinase 3	15	74836116-74843346	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040474	Approved				Pancreatic cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 28.4	Expressed in all		
UMAD1	RPA3-AS1, RPA3OS	ENSG00000219545	UBAP1-MVB12-associated (UMA) domain containing 1	7	7640711-7968020	Predicted intracellular proteins	Evidence at protein level	HPA044806	Approved		Approved	Nucleoplasm	Renal cancer:1.73e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 41.1	Expressed in all		
UMPS		ENSG00000114491	Uridine monophosphate synthetase	3	124730366-124749273	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036178, HPA036179	Uncertain		Supported	Cytosol	Prostate cancer:9.20e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland,spleen: 3.4	Expressed in all		
UNC119	HRG4, POC7, POC7A	ENSG00000109103	Unc-119 lipid binding chaperone	17	28546707-28552668	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041912	Supported				Pancreatic cancer:8.09e-5 (favourable), Melanoma:2.38e-4 (unfavourable), Thyroid cancer:9.82e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 45.5	Expressed in all		
UNC119B	MGC5139, POC7B	ENSG00000175970	Unc-119 lipid binding chaperone B	12	120710435-120723640	Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.69e-10 (favourable), Pancreatic cancer:1.26e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 75.8	Expressed in all		
UNC13A	KIAA1032, Munc13-1	ENSG00000130477	Unc-13 homolog A	19	17601328-17688365	Predicted intracellular proteins	Evidence at protein level	HPA041418, HPA077242	Uncertain		Uncertain	Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol		Tissue enhanced	Tissue enriched	16	cerebral cortex: 53.5	adrenal gland: 3.4	Group enriched	7	HMC-1: 14.3;NTERA-2: 23.7;SCLC-21H: 45.8;SH-SY5Y: 9.8
UNC13B	hmunc13, UNC13, Unc13h2	ENSG00000198722	Unc-13 homolog B	9	35161992-35405338	Predicted intracellular proteins	Evidence at protein level	HPA024493, HPA062300	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:4.34e-11 (favourable), Lung cancer:6.59e-5 (favourable), Head and neck cancer:8.51e-5 (favourable), Pancreatic cancer:3.71e-4 (favourable), Colorectal cancer:4.96e-4 (favourable)	Expressed in all	Mixed			lung: 58.2	Mixed		
UNC13C	DKFZp547H074, Munc13-3	ENSG00000137766	Unc-13 homolog C	15	54012904-54633414	Predicted intracellular proteins	Evidence at protein level	HPA041516	Uncertain					Not detected	Group enriched	15	cerebral cortex: 17.4;testis: 15.3	ovary,thyroid gland: 1.1	Group enriched	9	Karpas-707: 52.9;U-266/70: 74.2
UNC13D	Munc13-4	ENSG00000092929	Unc-13 homolog D	17	75827225-75844717	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA067117, HPA073525	Enhanced		Supported	Vesicles<br>Cytosol	Renal cancer:5.28e-12 (unfavourable), Endometrial cancer:3.62e-4 (unfavourable), Pancreatic cancer:6.01e-4 (unfavourable)	Expressed in all	Mixed			spleen: 38.6	Cell line enhanced		HEL: 219.6;HMC-1: 213.8;SK-BR-3: 125.9
UNC45B	CMYA4, UNC45	ENSG00000141161	Unc-45 myosin chaperone B	17	35147817-35189345	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA017861	Uncertain		Supported	Cytosol		Group enriched	Group enriched	21	heart muscle: 65.8;skeletal muscle: 68.0	prostate: 3.1	Group enriched	9	BEWO: 1.6;HSkMC: 1.8
UNC5CL	MGC34763, ZUD	ENSG00000124602	Unc-5 family C-terminal like	6	41026911-41039217	Predicted intracellular proteins	Evidence at protein level	HPA015725	Enhanced		Approved	Centrosome		Mixed	Tissue enhanced		duodenum: 37.3;small intestine: 32.4;stomach: 23.8	kidney: 15.0	Cell line enhanced		CACO-2: 5.8;RPTEC TERT1: 10.0
UNC80	C2orf21, FLJ33496, KIAA1843, UNC-80	ENSG00000144406	Unc-80 homolog, NALCN activator	2	209771993-209999300	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042472	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enhanced		adrenal gland: 5.1;cerebral cortex: 15.8;testis: 5.2	gallbladder: 1.9	Cell line enhanced		AF22: 2.4;SCLC-21H: 4.7;SH-SY5Y: 2.4
UNCX	Uncx4.1	ENSG00000164853	UNC homeobox	7	1232907-1237318	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA063294			Approved	Nucleoplasm		Not detected	Not detected			kidney: 0.4	Cell line enriched	16	NB-4: 63.3
UNG	DGU, HIGM4, UDG, UNG1, UNG2	ENSG00000076248	Uracil DNA glycosylase	12	109097574-109110992	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011605	Uncertain		Approved	Cytosol	Melanoma:3.06e-4 (unfavourable), Liver cancer:6.40e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 56.2	Expressed in all		
UNK	KIAA1753, ZC3H5, ZC3HDC5	ENSG00000132478	Unkempt family zinc finger	17	75784771-75825799	Predicted intracellular proteins	Evidence at protein level	HPA023636, HPA027962	Uncertain		Supported	Cytosol<br>Cytoplasmic bodies	Pancreatic cancer:6.58e-5 (favourable), Head and neck cancer:2.02e-4 (favourable)	Expressed in all	Expressed in all			skin: 16.4	Expressed in all		
UNKL	C16orf28, FLJ23360, ZC3H5L, ZC3HDC5L	ENSG00000059145	Unkempt family like zinc finger	16	1363205-1414751	Predicted intracellular proteins	Evidence at protein level	HPA055801, HPA073949	Approved		Supported	Cytosol		Expressed in all	Mixed			endometrium: 9.6	Mixed		
UPB1	BUP1	ENSG00000100024	Beta-ureidopropionase 1	22	24494107-24528390	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000728	Enhanced				Liver cancer:2.30e-7 (favourable)	Tissue enriched	Group enriched	23	kidney: 51.2;liver: 161.7	testis: 4.6	Cell line enhanced		CACO-2: 6.0;NB-4: 1.9;THP-1: 2.7;U-937: 3.5
UPF1	HUPF1, KIAA0221, NORF1, pNORF1, RENT1, smg-2	ENSG00000005007	UPF1, RNA helicase and ATPase	19	18831938-18868236	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019587, HPA020857	Approved		Supported	Nucleoplasm	Renal cancer:2.97e-6 (favourable), Melanoma:2.72e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 56.7	Expressed in all		
UPF2	DKFZP434D222, KIAA1408, RENT2, smg-3	ENSG00000151461	UPF2 regulator of nonsense transcripts homolog (yeast)	10	11920022-12043170	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA067008			Supported	Cytosol<br>Cytoplasmic bodies	Liver cancer:6.13e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.0	Expressed in all		
UPF3A	HUPF3A, RENT3A, UPF3	ENSG00000169062	UPF3 regulator of nonsense transcripts homolog A (yeast)	13	114281584-114305817	Predicted intracellular proteins	Evidence at protein level	HPA018325, HPA061316	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol	Pancreatic cancer:7.09e-5 (favourable), Urothelial cancer:3.71e-4 (favourable)	Expressed in all	Expressed in all			testis: 84.4	Expressed in all		
UPF3B	HUPF3B, MRX62, RENT3B, UPF3BP1, UPF3BP2, UPF3BP3, UPF3X	ENSG00000125351	UPF3 regulator of nonsense transcripts homolog B (yeast)	X	119805311-119852998	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001592, HPA001800, HPA001882	Approved		Enhanced	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.44e-7 (unfavourable), Liver cancer:1.52e-6 (unfavourable), Melanoma:5.39e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 23.9	Expressed in all		
UPP1	UDRPASE, UP, UPASE, UPP	ENSG00000183696	Uridine phosphorylase 1	7	48088628-48108733	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054040, HPA055394	Enhanced		Enhanced	Nucleoplasm	Cervical cancer:1.02e-4 (unfavourable), Lung cancer:1.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 35.1	appendix: 17.8	Cell line enhanced		hTERT-HME1: 369.7;WM-115: 110.3
UPP2	UDRPASE2, UP2, UPASE2	ENSG00000007001	Uridine phosphorylase 2	2	157876702-158136154	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035225, HPA035226			Approved	Nucleus<br>Vesicles<br>Mitochondria		Tissue enriched	Group enriched	14	kidney: 52.2;liver: 14.3	cerebral cortex: 2.4	Not detected		
UPRT	DKFZp781E1243, FUR1, MGC23937, RP11-311P8.3	ENSG00000094841	Uracil phosphoribosyltransferase homolog	X	75274085-75304600	Predicted intracellular proteins	Evidence at protein level	HPA000805	Uncertain		Approved	Vesicles	Renal cancer:4.14e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.4	Mixed		
UQCC2	bA6B20.2, C6orf125, Cbp6, M19, MGC14833, MNF1	ENSG00000137288	Ubiquinol-cytochrome c reductase complex assembly factor 2	6	33694293-33711727	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039111	Uncertain		Supported	Nuclear bodies<br>Mitochondria		Expressed in all	Expressed in all			testis: 131.3	Expressed in all		
UQCRB	QCR7, QP-C, UQBP, UQCR6	ENSG00000156467	Ubiquinol-cytochrome c reductase binding protein	8	96225920-96235634	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043060	Approved				Renal cancer:2.90e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 520.9	Expressed in all		
UQCRC1	D3S3191, QCR1, UQCR1	ENSG00000010256	Ubiquinol-cytochrome c reductase core protein I	3	48599002-48610976	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002815, HPA003525, CAB033782	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:2.35e-10 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 88.3	Expressed in all		
UQCRC2	QCR2, UQCR2	ENSG00000140740	Ubiquinol-cytochrome c reductase core protein II	16	21952660-21983660	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007998, HPA019146	Enhanced		Enhanced	Mitochondria	Renal cancer:6.58e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 151.1	Expressed in all		
UQCRFS1	RIP1, RIS1, RISP, UQCR5	ENSG00000169021	Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1	19	29205321-29213541	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041863, HPA050339	Enhanced		Enhanced	Mitochondria	Renal cancer:3.92e-9 (favourable), Colorectal cancer:3.29e-4 (favourable), Ovarian cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 70.9	Expressed in all		
UQCRH	QCR6, UQCR8	ENSG00000173660	Ubiquinol-cytochrome c reductase hinge protein	1	46303631-46316776	Predicted intracellular proteins	Evidence at protein level	HPA042574	Supported				Liver cancer:4.63e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 502.5	Expressed in all		
UQCRHL		ENSG00000233954	Ubiquinol-cytochrome c reductase hinge protein like	1	15807169-15809348	Predicted intracellular proteins	Evidence at protein level	HPA042574	Approved					Expressed in all	Mixed			skin: 1.3	Not detected		
UQCRQ	QCR8, QP-C, UQCR7	ENSG00000164405	Ubiquinol-cytochrome c reductase complex III subunit VII	5	132866560-132868031	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046693, HPA053323	Approved		Enhanced	Mitochondria	Endometrial cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 376.0	Expressed in all		
URAD	PRHOXNB	ENSG00000183463	Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase	13	27977714-27988654	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA038972	Uncertain					Tissue enriched	Group enriched	6	colon: 12.6;duodenum: 8.3;small intestine: 17.9	appendix: 2.3	Group enriched	12	BEWO: 2.6;CACO-2: 2.1
URB1	C21orf108, KIAA0539, NPA1	ENSG00000142207	URB1 ribosome biogenesis 1 homolog (S. cerevisiae)	21	32311018-32393026	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018334	Supported		Supported	Nucleoli fibrillar center	Liver cancer:4.93e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 12.0	Expressed in all		
URB2	KIAA0133, NET10, NPA2	ENSG00000135763	URB2 ribosome biogenesis 2 homolog (S. cerevisiae)	1	229626234-229660199	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008902, HPA046788	Uncertain		Enhanced	Nucleoli		Expressed in all	Mixed			testis: 10.6	Expressed in all		
URGCP-MRPS24		ENSG00000270617	URGCP-MRPS24 readthrough	7	43866558-43906589	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cervix, uterine: 1.3	Cell line enhanced		SCLC-21H: 3.9
URI1	C19orf2, FLJ10575, NNX3, PPP1R19, RMP, URI	ENSG00000105176	URI1, prefoldin like chaperone	19	29923644-30016608	Predicted intracellular proteins	Evidence at protein level	HPA071709	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:1.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 94.9	Expressed in all		
URM1	C9orf74, MGC2668	ENSG00000167118	Ubiquitin related modifier 1	9	128371319-128392016	Predicted intracellular proteins	Evidence at protein level	HPA053645, HPA065160	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:7.43e-6 (favourable), Liver cancer:6.91e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 25.1	Expressed in all		
UROC1	FLJ31300, HMFN0320	ENSG00000159650	Urocanate hydratase 1	3	126481281-126517773	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA069863	Enhanced					Tissue enriched	Tissue enriched	126	liver: 43.0	fallopian tube: 0.3	Cell line enriched	7	NB-4: 2.6
UROD		ENSG00000126088	Uroporphyrinogen decarboxylase	1	45012147-45015575	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027468, HPA028668, HPA030350	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 115.4	Expressed in all		
UROS		ENSG00000188690	Uroporphyrinogen III synthase	10	125784980-125823248	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044038	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.27e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 84.7	Expressed in all		
USB1	C16orf57, FLJ13154, HVSL1, Mpn1	ENSG00000103005	U6 snRNA biogenesis phosphodiesterase 1	16	57999546-58021618	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041791, HPA059854	Approved		Supported	Nucleus	Liver cancer:6.69e-7 (unfavourable), Renal cancer:2.02e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 37.4	Expressed in all		
USF1	bHLHb11, MLTFI, UEF	ENSG00000158773	Upstream transcription factor 1	1	161039251-161045977	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB001480, HPA036233, HPA036535	Supported		Enhanced	Nucleoplasm	Renal cancer:6.01e-12 (unfavourable), Urothelial cancer:1.95e-5 (favourable), Head and neck cancer:8.70e-4 (favourable)	Expressed in all	Expressed in all			spleen: 34.8	Expressed in all		
USF2	bHLHb12, FIP	ENSG00000105698	Upstream transcription factor 2, c-fos interacting	19	35268978-35279821	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029764, HPA046567			Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:5.12e-5 (favourable), Urothelial cancer:3.28e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 215.5	Expressed in all		
USF3	KIAA2018	ENSG00000176542	Upstream transcription factor family member 3	3	113648385-113696646	Predicted intracellular proteins	Evidence at protein level	HPA029243, HPA029245	Uncertain		Uncertain	Nucleoplasm<br>Nucleoli<br>Centrosome	Renal cancer:1.74e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 13.6	Expressed in all		
USH1C	AIE-75, DFNB18, harmonin, NY-CO-37, NY-CO-38, PDZ-73, PDZ73, PDZD7C	ENSG00000006611	USH1 protein network component harmonin	11	17493895-17544416	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB013690, HPA027398, HPA027492, HPA028033	Supported		Enhanced	Cytosol	Liver cancer:2.20e-4 (unfavourable), Renal cancer:9.41e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 99.2;small intestine: 106.9	kidney: 55.4	Cell line enhanced		CACO-2: 50.5;CAPAN-2: 7.4;HeLa: 14.4
USH1G	ANKS4A, FLJ33924, Sans	ENSG00000182040	USH1 protein network component sans	17	74916084-74923256	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024360	Uncertain					Tissue enhanced	Tissue enhanced		epididymis: 2.3;esophagus: 2.6;skin: 1.8	testis: 1.4	Cell line enhanced		HaCaT: 1.6;hTCEpi: 1.2;K-562: 1.2;MCF7: 1.5;U-2 OS: 1.0
USHBP1	AIEBP, FLJ38709, MCC2	ENSG00000130307	USH1 protein network component harmonin binding protein 1	19	17249176-17282786	Predicted intracellular proteins	Evidence at protein level	HPA052471	Uncertain					Mixed	Mixed			placenta: 8.2	Cell line enhanced		BEWO: 10.6
USO1	p115, TAP, VDP	ENSG00000138768	USO1 vesicle transport factor	4	75724593-75814286	Predicted intracellular proteins	Evidence at protein level	CAB010108, HPA038282, HPA038283	Supported		Enhanced	Nucleoli fibrillar center<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 91.1	Expressed in all		
USP1		ENSG00000162607	Ubiquitin specific peptidase 1	1	62436297-62451804	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028387, HPA028440	Approved		Supported	Nucleoplasm	Liver cancer:5.81e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 92.3	Expressed in all		
USP10	KIAA0190, UBPO	ENSG00000103194	Ubiquitin specific peptidase 10	16	84699978-84779922	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006731, HPA006749	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.00e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.1	Expressed in all		
USP12	USP12L1	ENSG00000152484	Ubiquitin specific peptidase 12	13	27066142-27171896	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007288	Uncertain					Expressed in all	Expressed in all			bone marrow: 45.6	Expressed in all		
USP13	IsoT-3	ENSG00000058056	Ubiquitin specific peptidase 13 (isopeptidase T-3)	3	179652755-179789401	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004827	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.46e-6 (unfavourable), Liver cancer:2.40e-5 (unfavourable), Urothelial cancer:3.06e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 52.2	Mixed		
USP15	KIAA0529, UNPH4	ENSG00000135655	Ubiquitin specific peptidase 15	12	62260338-62417431	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006237, HPA006428, HPA071014	Approved		Enhanced	Cytosol	Renal cancer:1.58e-5 (unfavourable), Liver cancer:8.04e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 121.6	Expressed in all		
USP16	Ubp-M	ENSG00000156256	Ubiquitin specific peptidase 16	21	29024629-29054488	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021140	Supported		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 57.2	Expressed in all		
USP17L1	USP17L1P	ENSG00000230549	Ubiquitin specific peptidase 17-like family member 1	8	7332387-7333979	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			cerebral cortex: 0.3	Not detected		
USP17L10		ENSG00000231396	Ubiquitin specific peptidase 17-like family member 10	4	9210657-9212608	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L11		ENSG00000233136	Ubiquitin specific peptidase 17-like family member 11	4	9215405-9217356	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			thyroid gland: 0.2	Not detected		
USP17L12		ENSG00000227551	Ubiquitin specific peptidase 17-like family member 12	4	9220152-9221744	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L13		ENSG00000232399	Ubiquitin specific peptidase 17-like family member 13	4	9224896-9226847	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L15		ENSG00000223569	Ubiquitin specific peptidase 17-like family member 15	4	9234385-9236334	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L17		ENSG00000249104	Ubiquitin specific peptidase 17-like family member 17	4	9243879-9245830	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L18		ENSG00000250844	Ubiquitin specific peptidase 17-like family member 18	4	9248630-9250581	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L19		ENSG00000248920	Ubiquitin specific peptidase 17-like family member 19	4	9253378-9255329	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L2	DUB3	ENSG00000223443	Ubiquitin specific peptidase 17-like family member 2	8	12137168-12139077	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L20		ENSG00000250745	Ubiquitin specific peptidase 17-like family member 20	4	9258124-9260075	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L21		ENSG00000249811	Ubiquitin specific peptidase 17-like family member 21	4	9262872-9264823	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L22		ENSG00000248933	Ubiquitin specific peptidase 17-like family member 22	4	9267619-9269570	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L23		ENSG00000250913	Ubiquitin specific peptidase 17-like family member 23	4	9272364-9272914	Enzymes, Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L24		ENSG00000232264	Ubiquitin specific peptidase 17-like family member 24	4	9325165-9327116	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L25		ENSG00000230430	Ubiquitin specific peptidase 17-like family member 25	4	9329911-9331862	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L26		ENSG00000229579	Ubiquitin specific peptidase 17-like family member 26	4	9334658-9336609	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L27		ENSG00000235780	Ubiquitin specific peptidase 17-like family member 27	4	9344148-9345740	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L28		ENSG00000231051	Ubiquitin specific peptidase 17-like family member 28	4	9348893-9350485	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L29		ENSG00000231637	Ubiquitin specific peptidase 17-like family member 29	4	9353638-9355230	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L3	USP17B, USP17F	ENSG00000225327	Ubiquitin specific peptidase 17-like family member 3	8	7976393-7977985	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L30		ENSG00000228856	Ubiquitin specific peptidase 17-like family member 30	4	9363129-9364721	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L4		ENSG00000236125	Ubiquitin specific peptidase 17-like family member 4	8	7337115-7338707	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L5		ENSG00000227140	Ubiquitin specific peptidase 17-like family member 5	4	9339403-9340995	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L7		ENSG00000226430	Ubiquitin specific peptidase 17-like family member 7	8	12132417-12134438	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L8		ENSG00000237038	Ubiquitin specific peptidase 17-like family member 8	8	7971661-7973253	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP18		ENSG00000184979	Ubiquitin specific peptidase 18	22	18149899-18177397	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044768	Uncertain		Approved	Cytosol		Expressed in all	Mixed			testis: 15.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 144.8;BJ hTERT+ SV40 Large T+ RasG12V: 163.7
USP2	UBP41	ENSG00000036672	Ubiquitin specific peptidase 2	11	119355215-119381726	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006777, HPA007222	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:3.09e-11 (favourable)	Expressed in all	Tissue enhanced		testis: 119.4	skeletal muscle: 59.3	Cell line enhanced		U-266/70: 43.2
USP20	KIAA1003	ENSG00000136878	Ubiquitin specific peptidase 20	9	129834698-129881838	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006287, HPA007008	Uncertain	Approved	Approved	Nucleus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.54e-7 (favourable), Renal cancer:5.65e-5 (favourable), Colorectal cancer:2.48e-4 (unfavourable), Endometrial cancer:4.01e-4 (favourable), Cervical cancer:8.01e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 22.1	Expressed in all		
USP21	USP16, USP23	ENSG00000143258	Ubiquitin specific peptidase 21	1	161159450-161165723	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028397	Uncertain	Supported	Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:9.50e-6 (unfavourable), Urothelial cancer:3.35e-5 (favourable), Liver cancer:1.68e-4 (unfavourable), Endometrial cancer:7.05e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 45.7	Expressed in all		
USP22	KIAA1063, USP3L	ENSG00000124422	Ubiquitin specific peptidase 22	17	20999593-21043760	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044980	Supported		Supported	Nuclear speckles	Renal cancer:1.53e-7 (favourable), Liver cancer:9.66e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 154.1	Expressed in all		
USP24	KIAA1057	ENSG00000162402	Ubiquitin specific peptidase 24	1	55066359-55215113	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026723, HPA028428, HPA067124	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.34e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 38.1	Expressed in all		
USP25	USP21	ENSG00000155313	Ubiquitin specific peptidase 25	21	15730025-15880069	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018297, HPA024142	Approved		Supported	Cytosol		Expressed in all	Expressed in all			testis: 97.6	Expressed in all		
USP26		ENSG00000134588	Ubiquitin specific peptidase 26	X	133024631-133097109	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	testis: 1.1	bone marrow,breast,endometrium,epididymis,gallbladder,lymph node,prostate,skin,spleen,thyroid gland: 0.1	Not detected		
USP27X	USP27	ENSG00000273820	Ubiquitin specific peptidase 27, X-linked	X	49879948-49882565	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA077264			Approved	Nucleoplasm<br>Vesicles	Liver cancer:6.14e-4 (unfavourable), Pancreatic cancer:9.31e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 19.7	cerebral cortex: 10.3	Mixed		
USP28	KIAA1515	ENSG00000048028	Ubiquitin specific peptidase 28	11	113797874-113875570	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006778, HPA006779	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			heart muscle: 40.2	Expressed in all		
USP29		ENSG00000131864	Ubiquitin specific peptidase 29	19	57119138-57131926	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021064	Uncertain					Not detected	Tissue enriched	5	testis: 9.0	skin: 1.7	Not detected		
USP31	KIAA1203	ENSG00000103404	Ubiquitin specific peptidase 31	16	23061406-23149270	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006937	Uncertain		Approved	Cytosol	Renal cancer:4.41e-5 (unfavourable)	Expressed in all	Mixed			testis: 22.2	Expressed in all		
USP32	NY-REN-60, USP10	ENSG00000170832	Ubiquitin specific peptidase 32	17	60179094-60422470	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044365	Approved		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:1.50e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 155.0	Expressed in all		
USP33	KIAA1097, VDU1	ENSG00000077254	Ubiquitin specific peptidase 33	1	77695987-77759852	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005719	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 55.5	Expressed in all		
USP34	KIAA0570, KIAA0729	ENSG00000115464	Ubiquitin specific peptidase 34	2	61187463-61470769	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA025815, HPA070764	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			epididymis: 66.0	Expressed in all		
USP35	KIAA1372	ENSG00000118369	Ubiquitin specific peptidase 35	11	78188812-78214711	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055213, HPA058592	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Tissue enhanced		parathyroid gland: 34.3	adrenal gland: 14.8	Expressed in all		
USP36	FLJ12851, KIAA1453	ENSG00000055483	Ubiquitin specific peptidase 36	17	78787381-78841441	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012082, HPA012395, HPA052860	Uncertain	Approved	Enhanced	Nucleoli<br>Nuclear speckles	Endometrial cancer:5.18e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 38.4	Expressed in all		
USP37	KIAA1594	ENSG00000135913	Ubiquitin specific peptidase 37	2	218450251-218568361	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045160	Approved		Approved	Nucleus<br>Nucleoli	Head and neck cancer:2.85e-4 (favourable)	Mixed	Mixed			testis: 23.2	Expressed in all		
USP38	HP43.8KD, KIAA1891	ENSG00000170185	Ubiquitin specific peptidase 38	4	143184917-143223830	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036990, HPA047948	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.20e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 14.1	Expressed in all		
USP39	CGI-21, SAD1, SNRNP65	ENSG00000168883	Ubiquitin specific peptidase 39	2	85602856-85649282	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034823		Approved	Supported	Nucleoplasm	Renal cancer:4.05e-7 (unfavourable), Liver cancer:2.84e-6 (unfavourable), Endometrial cancer:5.52e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 38.4	Expressed in all		
USP4	UNP, Unph	ENSG00000114316	Ubiquitin specific peptidase 4	3	49277831-49340712	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018499	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.29e-5 (favourable), Lung cancer:4.46e-5 (favourable)	Expressed in all	Expressed in all			testis: 56.8	Expressed in all		
USP40	FLJ10785	ENSG00000085982	Ubiquitin specific peptidase 40	2	233475520-233566782	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005821	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 31.5	Mixed		
USP41		ENSG00000161133	Ubiquitin specific peptidase 41	22	20350578-20390758	Enzymes, Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex: 0.3	Cell line enhanced		RH-30: 1.2;SCLC-21H: 1.8
USP42	FLJ12697	ENSG00000106346	Ubiquitin specific peptidase 42	7	6104884-6161564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006752, HPA064800	Uncertain		Approved	Nucleus		Expressed in all	Tissue enhanced		testis: 27.8	parathyroid gland: 8.8	Expressed in all		
USP43	FLJ30626	ENSG00000154914	Ubiquitin specific peptidase 43	17	9644698-9729691	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023389, HPA027762	Uncertain				Stomach cancer:5.39e-4 (favourable)	Mixed	Mixed			placenta: 11.9	Cell line enhanced		BEWO: 11.2;T-47d: 9.2
USP44	FLJ14528	ENSG00000136014	Ubiquitin specific peptidase 44	12	95516560-95551490	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026543			Approved	Nucleoli fibrillar center<br>Microtubules		Tissue enhanced	Tissue enriched	7	testis: 43.6	parathyroid gland: 6.0	Cell line enriched	6	NTERA-2: 137.8
USP45	MGC14793	ENSG00000123552	Ubiquitin specific peptidase 45	6	99432379-99521728	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029602, HPA029604	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			gallbladder: 9.9	Expressed in all		
USP46	FLJ12552	ENSG00000109189	Ubiquitin specific peptidase 46	4	52590972-52659335	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007288, CAB076369, CAB076370	Uncertain		Enhanced	Nucleoli		Expressed in all	Expressed in all			cerebral cortex: 44.7	Mixed		
USP47		ENSG00000170242	Ubiquitin specific peptidase 47	11	11841423-11959323	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029286, HPA029289	Supported		Approved	Intermediate filaments		Expressed in all	Expressed in all			parathyroid gland: 75.4	Expressed in all		
USP48	FLJ11328, FLJ20103, FLJ23054, FLJ23277, MGC14879, USP31	ENSG00000090686	Ubiquitin specific peptidase 48	1	21678298-21783606	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030045, HPA030046	Approved	Approved	Supported	Nucleoplasm<br>Mitochondria<br>Cytosol	Liver cancer:6.09e-8 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 54.0	Expressed in all		
USP49	MGC20741	ENSG00000164663	Ubiquitin specific peptidase 49	6	41789896-41895361	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030254, HPA030255	Uncertain					Mixed	Mixed			testis: 9.1	Cell line enhanced		REH: 42.8;U-698: 45.4
USP5	IsoT	ENSG00000111667	Ubiquitin specific peptidase 5	12	6852128-6866632	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006756	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 87.5	Expressed in all		
USP50		ENSG00000170236	Ubiquitin specific peptidase 50	15	50500562-50546708	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA039470	Uncertain					Not detected	Tissue enriched	18	testis: 1.8	all non-specific tissues: 0.0	Not detected		
USP51		ENSG00000247746	Ubiquitin specific peptidase 51	X	55484616-55489202	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001942	Uncertain		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:2.63e-5 (favourable), Ovarian cancer:5.70e-4 (favourable)	Mixed	Tissue enriched	7	epididymis: 62.9	parathyroid gland: 9.3	Mixed		
USP53	KIAA1350	ENSG00000145390	Ubiquitin specific peptidase 53	4	119212587-119295517	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035844, HPA035845	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.58e-8 (favourable), Colorectal cancer:3.15e-6 (favourable), Prostate cancer:7.54e-6 (unfavourable)	Expressed in all	Mixed			fallopian tube: 48.8	Cell line enhanced		BJ hTERT+: 265.8;SK-MEL-30: 79.9
USP54	bA137L10.3, bA137L10.4, C10orf29, FLJ37318	ENSG00000166348	Ubiquitin specific peptidase 54	10	73497538-73625953	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047663	Approved		Approved	Mitochondria	Lung cancer:7.00e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 59.6	cerebral cortex: 30.7	Cell line enhanced		PC-3: 29.7
USP6	HRP1, Tre-2, TRE17, Tre2, TRESMCR	ENSG00000129204	Ubiquitin specific peptidase 6	17	5116438-5175034	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046969			Uncertain	Vesicles		Tissue enriched	Group enriched	5	ovary: 3.5;skeletal muscle: 7.5;testis: 17.1	smooth muscle: 1.8	Mixed		
USP6NL	KIAA0019, RN-tre, RNTRE, TRE2NL, USP6NL-IT1	ENSG00000148429	USP6 N-terminal like	10	11453946-11611754	Predicted intracellular proteins	Evidence at protein level	HPA039196	Approved				Head and neck cancer:8.06e-4 (favourable)	Expressed in all	Mixed			testis: 45.0	Mixed		
USP7	HAUSP	ENSG00000187555	Ubiquitin specific peptidase 7	16	8892094-8964514	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB008108, HPA015641	Approved				Renal cancer:8.56e-5 (favourable)	Expressed in all	Expressed in all			testis: 109.1	Expressed in all		
USP8	HumORF8, KIAA0055, SPG59, UBPY	ENSG00000138592	Ubiquitin specific peptidase 8	15	50424380-50514419	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050215	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:1.29e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 77.0	Expressed in all		
USP9X	DFFRX, FAF, MRX99	ENSG00000124486	Ubiquitin specific peptidase 9, X-linked	X	41085635-41236579	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011618, HPA047417, CAB070164	Approved		Uncertain	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 90.1	Expressed in all		
USP9Y	DFFRY	ENSG00000114374	Ubiquitin specific peptidase 9, Y-linked	Y	12701231-12860839	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057687			Uncertain	Vesicles		Tissue enhanced	Tissue enhanced		prostate: 9.9	seminal vesicle: 6.9	Cell line enhanced		RPTEC TERT1: 13.3
USPL1	bA121O19.1, C13orf22, D13S106E	ENSG00000132952	Ubiquitin specific peptidase like 1	13	30617693-30660770	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039342, HPA040172	Uncertain					Expressed in all	Expressed in all			testis: 40.5	Expressed in all		
UTF1		ENSG00000171794	Undifferentiated embryonic cell transcription factor 1	10	133230274-133231558	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	11	testis: 1.4	spleen: 0.1	Group enriched	18	NTERA-2: 5.7;RPMI-8226: 1.4
UTP11	CGI-94, UTP11L	ENSG00000183520	UTP11, small subunit processome component homolog (S. cerevisiae)	1	38009258-38024824	Predicted intracellular proteins	Evidence at protein level	HPA045830	Approved		Approved	Nucleus	Renal cancer:1.42e-8 (unfavourable), Liver cancer:7.44e-8 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 37.3	Expressed in all		
UTP14A	NY-CO-16, SDCCAG16	ENSG00000156697	UTP14A small subunit processome component	X	129906121-129929761	Predicted intracellular proteins	Evidence at protein level	HPA047217, HPA054023	Uncertain		Supported	Nucleoli<br>Cytosol	Renal cancer:8.12e-8 (unfavourable), Head and neck cancer:7.67e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 18.5	Expressed in all		
UTP14C	2700066J21Rik, KIAA0266	ENSG00000253797	UTP14, small subunit processome component homolog C (S. cerevisiae)	13	52024691-52033600	Predicted intracellular proteins	Evidence at protein level	HPA047217, HPA054023	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:1.46e-5 (favourable), Ovarian cancer:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.6	Expressed in all		
UTP15	FLJ12787, FLJ23637, NET21	ENSG00000164338	UTP15, small subunit processome component	5	73565443-73583377	Predicted intracellular proteins	Evidence at protein level	HPA044697			Supported	Nucleoli<br>Endoplasmic reticulum		Expressed in all	Expressed in all			bone marrow: 23.2	Expressed in all		
UTP18	CGI-48, WDR50	ENSG00000011260	UTP18, small subunit processome component	17	51260528-51297936	Predicted intracellular proteins	Evidence at protein level	HPA052378	Approved		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli	Liver cancer:1.99e-4 (unfavourable), Colorectal cancer:3.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 106.1	Expressed in all		
UTP20	1A6/DRIM, DRIM	ENSG00000120800	UTP20, small subunit processome component	12	101280109-101386616	Predicted intracellular proteins	Evidence at protein level	HPA049341			Supported	Nucleoli<br>Plasma membrane	Liver cancer:1.15e-5 (unfavourable), Renal cancer:8.87e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.2	Expressed in all		
UTP23	C8orf53, MGC14595	ENSG00000147679	UTP23, small subunit processome component	8	116766503-116849463	Predicted intracellular proteins	Evidence at protein level	HPA044418	Uncertain		Approved	Nucleoli	Breast cancer:5.18e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 21.2	Expressed in all		
UTP3	CRLZ1, DKFZp761F222, FLJ23256, SAS10	ENSG00000132467	UTP3, small subunit processome component homolog (S. cerevisiae)	4	70688479-70690551	Predicted intracellular proteins	Evidence at protein level	HPA035655, HPA041453	Approved		Supported	Nucleoli<br>Vesicles	Renal cancer:3.16e-4 (favourable)	Expressed in all	Expressed in all			spleen: 43.2	Expressed in all		
UTP6	C17orf40, HCA66	ENSG00000108651	UTP6, small subunit processome component	17	31860899-31901765	Predicted intracellular proteins	Evidence at protein level	HPA025936, HPA055806	Enhanced		Enhanced	Nucleoli	Renal cancer:1.16e-6 (unfavourable), Liver cancer:1.86e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 15.7	Expressed in all		
UTRN	DMDL, DRP, DRP1	ENSG00000152818	Utrophin	6	144285701-144853034	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016348, HPA018894	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:7.61e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 174.0	Cell line enhanced		HAP1: 226.1
UVRAG	VPS38	ENSG00000198382	UV radiation resistance associated	11	75815167-76143195	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA016932	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 42.2	Expressed in all		
UVSSA	KIAA1530	ENSG00000163945	UV stimulated scaffold protein A	4	1347266-1388049	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050824, HPA053496	Approved		Approved	Nucleoplasm	Renal cancer:1.90e-4 (unfavourable), Urothelial cancer:6.87e-4 (favourable)	Expressed in all	Mixed			testis: 12.2	Expressed in all		
UXT	ART-27, STAP1	ENSG00000126756	Ubiquitously expressed prefoldin like chaperone	X	47651798-47659161	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050499, HPA058400	Approved		Supported	Nucleus<br>Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			ovary: 184.1	Expressed in all		
VAC14	ArPIKfyve, FLJ10305, TAX1BP2	ENSG00000103043	Vac14, PIKFYVE complex component	16	70687439-70801161	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027766	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.56e-6 (favourable), Cervical cancer:8.33e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 31.6	Expressed in all		
VARS	VARS2	ENSG00000204394	Valyl-tRNA synthetase	6	31777518-31795953	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046710	Approved		Enhanced	Cytosol	Liver cancer:1.86e-4 (unfavourable), Lung cancer:6.90e-4 (unfavourable), Cervical cancer:7.25e-4 (unfavourable)	Expressed in all	Mixed			testis: 5.5	Mixed		
VARS2	DKFZP434L1435, G7a, KIAA1885, VARS2L, VARSL	ENSG00000137411	Valyl-tRNA synthetase 2, mitochondrial	6	30908242-30926459	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA062449, HPA070267	Approved		Approved	Mitochondria		Expressed in all	Mixed			esophagus: 5.2	Mixed		
VASH2	FLJ12505	ENSG00000143494	Vasohibin 2	1	212950520-212992037	Predicted intracellular proteins	Evidence at protein level	HPA045820			Approved	Cytosol		Tissue enhanced	Tissue enhanced		testis: 11.3	appendix,esophagus,prostate: 4.5	Cell line enhanced		AN3-CA: 27.4;NTERA-2: 46.2;RH-30: 131.2
VASP		ENSG00000125753	Vasodilator-stimulated phosphoprotein	19	45506579-45526983	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004612, HPA005724	Enhanced		Supported	Plasma membrane<br>Cell Junctions<br>Focal adhesion sites	Renal cancer:5.91e-7 (unfavourable), Liver cancer:3.49e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 90.5	Expressed in all		
VAT1	FLJ20230, VATI	ENSG00000108828	Vesicle amine transport 1	17	43014605-43025123	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045170	Uncertain				Liver cancer:1.39e-4 (unfavourable), Renal cancer:5.89e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 241.6	Expressed in all		
VAT1L	KIAA1576	ENSG00000171724	Vesicle amine transport 1 like	16	77788530-77980107	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044061, CAB046032	Enhanced		Approved	Cytosol	Renal cancer:3.01e-6 (unfavourable)	Tissue enhanced	Group enriched	6	adrenal gland: 90.6;cerebral cortex: 38.8	heart muscle: 10.3	Cell line enhanced		BJ hTERT+: 55.2;fHDF/TERT166: 29.2;NTERA-2: 79.1;U-87 MG: 80.3
VAV1	VAV	ENSG00000141968	Vav guanine nucleotide exchange factor 1	19	6772714-6857366	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001864	Enhanced		Approved	Cytosol	Renal cancer:1.48e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 57.6	appendix: 53.0	Cell line enhanced		HMC-1: 96.0;Karpas-707: 90.4;MOLT-4: 100.9;U-937: 80.7
VAV2		ENSG00000160293	Vav guanine nucleotide exchange factor 2	9	133761894-133992604	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003224	Uncertain		Approved	Vesicles	Renal cancer:7.39e-7 (favourable), Thyroid cancer:4.33e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 32.2	Mixed		
VAV3		ENSG00000134215	Vav guanine nucleotide exchange factor 3	1	107571160-107965144	Predicted intracellular proteins	Evidence at protein level	CAB002012	Uncertain				Renal cancer:4.60e-8 (favourable)	Expressed in all	Tissue enhanced		kidney: 90.9	skin: 58.7	Cell line enhanced		REH: 48.1;RH-30: 60.2;RPTEC TERT1: 66.0;T-47d: 100.9
VAX1		ENSG00000148704	Ventral anterior homeobox 1	10	117128521-117138301	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028946	Uncertain		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enhanced		cerebral cortex: 1.4	testis: 0.4	Group enriched	8	A-431: 2.9;WM-115: 2.4
VAX2	DRES93	ENSG00000116035	Ventral anterior homeobox 2	2	70900590-70933446	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009708			Approved	Nuclear speckles		Mixed	Tissue enhanced		cerebral cortex: 3.2	adipose tissue,adrenal gland,breast,endometrium: 0.7	Cell line enhanced		SH-SY5Y: 7.0
VBP1	PFD3, PFDN3	ENSG00000155959	VHL binding protein 1	X	155197007-155239817	Predicted intracellular proteins	Evidence at protein level	CAB006260, HPA023230	Approved		Supported	Vesicles<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 85.3	Expressed in all		
VCL		ENSG00000035403	Vinculin	10	73995193-74121363	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002131, CAB002453, HPA063777	Enhanced		Enhanced	Focal adhesion sites	Pancreatic cancer:2.75e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 326.5	Expressed in all		
VCP	IBMPFD, p97	ENSG00000165280	Valosin containing protein	9	35056064-35073249	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB005593, HPA012728, HPA012814	Supported		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:9.63e-7 (favourable), Endometrial cancer:7.30e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 94.2	Expressed in all		
VCPIP1	DUBA3, FLJ23132, KIAA1850, VCIP135	ENSG00000175073	Valosin containing protein interacting protein 1	8	66628487-66667217	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023932	Uncertain		Approved	Plasma membrane		Expressed in all	Mixed			bone marrow: 13.1	Expressed in all		
VCPKMT	C14orf138, METTL21D, VCP-KMT	ENSG00000100483	Valosin containing protein lysine methyltransferase	14	50108632-50116600	Predicted intracellular proteins	Evidence at protein level	HPA001146, HPA076561	Uncertain		Supported	Cytosol	Lung cancer:2.40e-4 (favourable), Prostate cancer:4.75e-4 (unfavourable), Renal cancer:6.79e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 5.3	Expressed in all		
VCX	VCX-10r, VCX-B1, VCX1, VCX10R	ENSG00000182583	Variable charge, X-linked	X	7842262-7844143	Predicted intracellular proteins	Evidence at protein level	HPA044996, HPA049357	Supported					Mixed	Tissue enriched	159	testis: 39.1	duodenum: 0.2	Cell line enhanced		NB-4: 1.0;U-138 MG: 1.4;U-266/70: 2.2
VCX2	VCX-2r	ENSG00000177504	Variable charge, X-linked 2	X	8169944-8171267	Predicted intracellular proteins	Evidence at protein level	HPA044642, HPA044996, HPA049357	Enhanced					Tissue enhanced	Tissue enriched	32	testis: 3.1	all non-specific tissues: 0.0	Not detected		
VCX3A	VCX-8r, VCX-A, VCX3	ENSG00000169059	Variable charge, X-linked 3A	X	6533618-6535118	Predicted intracellular proteins	Evidence at protein level	HPA044996, HPA049357	Supported					Mixed	Tissue enriched	205	testis: 27.5	placenta: 0.1	Cell line enhanced		HMC-1: 4.3;PC-3: 2.3;U-138 MG: 7.3;U-266/70: 3.5
VCX3B	VCX-C	ENSG00000205642	Variable charge, X-linked 3B	X	8464830-8466510	Predicted intracellular proteins	Evidence at protein level	HPA044996, HPA049357	Supported					Tissue enhanced	Tissue enriched	88	testis: 32.5	breast: 0.3	Cell line enriched	20	U-138 MG: 18.3
VCY	BPY1, VCY1, VCY1A	ENSG00000129864	Variable charge, Y-linked	Y	13985772-13986513	Predicted intracellular proteins	Evidence at protein level	HPA044996, HPA049357	Supported					Not detected	Tissue enriched	85	testis: 27.1	placenta: 0.3	Cell line enriched	6	U-266/70: 1.0
VCY1B	BPY1B	ENSG00000129862	Variable charge, Y-linked 1B	Y	14056217-14056958	Predicted intracellular proteins	Evidence at protein level	HPA044996, HPA049357	Supported					Not detected	Tissue enriched	85	testis: 27.1	placenta: 0.3	Cell line enriched	6	U-266/70: 1.0
VDAC1	MGC111064, PORIN	ENSG00000213585	Voltage dependent anion channel 1	5	133971915-134005133	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005885, HPA030780, CAB072343	Supported		Approved	Cytosol	Lung cancer:2.87e-5 (unfavourable), Head and neck cancer:4.90e-4 (unfavourable), Breast cancer:5.30e-4 (unfavourable), Liver cancer:8.49e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 363.8	Expressed in all		
VDAC2		ENSG00000165637	Voltage dependent anion channel 2	10	75210154-75231448	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA043475	Enhanced		Enhanced	Mitochondria	Head and neck cancer:4.51e-4 (unfavourable), Liver cancer:4.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 269.4	Expressed in all		
VDAC3	HD-VDAC3	ENSG00000078668	Voltage dependent anion channel 3	8	42391624-42405897	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026864	Uncertain		Supported	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 327.2	Expressed in all		
VDR	NR1I1, PPP1R163	ENSG00000111424	Vitamin D (1,25- dihydroxyvitamin D3) receptor	12	47841537-47943048	Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	CAB004617, HPA047740			Enhanced	Nucleoplasm	Renal cancer:4.89e-6 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 175.9	small intestine: 57.9	Cell line enhanced		HDLM-2: 73.7;U-937: 60.2
VENTX	HPX42B, VENTX2	ENSG00000151650	VENT homeobox	10	133237404-133241929	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050955	Uncertain		Uncertain	Nucleoli fibrillar center<br>Cytosol		Tissue enriched	Mixed			appendix: 4.7	Group enriched	22	NB-4: 10.5;NTERA-2: 9.2
VEPH1	FLJ12604, KIAA1692	ENSG00000197415	Ventricular zone expressed PH domain containing 1	3	157259742-157533619	Predicted intracellular proteins	Evidence at protein level	HPA026645	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:7.75e-9 (favourable)	Mixed	Tissue enhanced		adrenal gland: 26.6;kidney: 28.8;lung: 43.9	epididymis: 21.4	Cell line enhanced		HUVEC TERT2: 204.2;TIME: 119.8
VEZF1	DB1, ZNF161	ENSG00000136451	Vascular endothelial zinc finger 1	17	57971547-57988259	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027520, HPA048315	Uncertain		Enhanced	Nucleoplasm	Colorectal cancer:6.14e-5 (favourable), Liver cancer:6.46e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 82.1	Expressed in all		
VGLL1	TDU, TONDU	ENSG00000102243	Vestigial like family member 1	X	136532152-136556807	Predicted intracellular proteins	Evidence at protein level	HPA042403, HPA064616	Supported		Supported	Nucleus	Endometrial cancer:4.54e-4 (unfavourable)	Tissue enhanced	Tissue enriched	14	placenta: 257.6	urinary bladder: 18.3	Group enriched	11	A-431: 102.6;BEWO: 166.1;CAPAN-2: 56.3;RT4: 243.2;SK-BR-3: 219.4
VGLL2		ENSG00000170162	Vestigial like family member 2	6	117265558-117273565	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	13	skeletal muscle: 45.1	heart muscle: 3.5	Group enriched	6	RH-30: 13.5;U-2 OS: 5.0
VGLL3	VGL-3	ENSG00000206538	Vestigial like family member 3	3	86876388-86991119	Predicted intracellular proteins	Evidence at protein level	HPA054983	Approved		Approved	Nucleoli<br>Cytosol		Tissue enhanced	Tissue enhanced		placenta: 57.8	adipose tissue: 24.4	Cell line enriched	5	U-2197: 482.9
VGLL4	KIAA0121	ENSG00000144560	Vestigial like family member 4	3	11556070-11771350	Predicted intracellular proteins	Evidence at protein level	HPA038225, HPA038614	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.32e-5 (favourable)	Expressed in all	Expressed in all			ovary: 111.1	Expressed in all		
VHL	VHL1	ENSG00000134086	Von Hippel-Lindau tumor suppressor	3	10141008-10152220	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB005430, HPA031631, HPA031632	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.32e-5 (unfavourable), Breast cancer:9.02e-5 (unfavourable), Stomach cancer:7.84e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 34.7	Expressed in all		
VHLL	VHLP, VLP	ENSG00000189030	Von Hippel-Lindau tumor suppressor like	1	156298624-156299299	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			esophagus,gallbladder,testis: 0.1	Not detected		
VIL1	D2S1471, VIL	ENSG00000127831	Villin 1	2	218419092-218453295	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002452, HPA006884, HPA006885	Enhanced		Enhanced	Plasma membrane		Tissue enhanced	Group enriched	7	colon: 173.7;duodenum: 398.5;rectum: 199.6;small intestine: 480.0	gallbladder: 44.7	Group enriched	91	CACO-2: 628.4;Hep G2: 245.1
VILL		ENSG00000136059	Villin like	3	37988059-38007188	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035675	Enhanced				Glioma:1.16e-4 (unfavourable), Head and neck cancer:1.75e-4 (favourable)	Tissue enhanced	Tissue enhanced		stomach: 93.8	small intestine: 67.6	Cell line enhanced		CAPAN-2: 21.9
VIM		ENSG00000026025	Vimentin	10	17228259-17237593	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000080, HPA001762, CAB058687	Enhanced		Approved	Intermediate filaments	Renal cancer:8.69e-8 (unfavourable), Endometrial cancer:9.75e-6 (favourable)	Expressed in all	Expressed in all			ovary: 4304.6	Cell line enhanced		ASC TERT1: 12818.5
VIPAS39	C14orf133, hSPE-39, SPE-39, SPE39, VIPAR, VPS16B	ENSG00000151445	VPS33B interacting protein, apical-basolateral polarity regulator, spe-39 homolog	14	77426675-77457952	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003589, HPA003593	Approved				Liver cancer:1.06e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 29.2	Expressed in all		
VMAC		ENSG00000187650	Vimentin-type intermediate filament associated coiled-coil protein	19	5904858-5910853	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:5.67e-6 (favourable), Urothelial cancer:7.24e-4 (favourable), Head and neck cancer:8.20e-4 (favourable)	Expressed in all	Mixed			prostate: 7.9	Cell line enhanced		U-266/70: 12.2
VPS11	PEP5, RNF108	ENSG00000160695	VPS11, CORVET/HOPS core subunit	11	119067692-119081978	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039020	Approved		Approved	Cytosol	Renal cancer:1.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.5	Expressed in all		
VPS13A	CHAC, KIAA0986	ENSG00000197969	Vacuolar protein sorting 13 homolog A	9	77177353-77421541	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021652, HPA021662	Enhanced					Expressed in all	Expressed in all			skin: 40.2	Expressed in all		
VPS13B	CHS1, COH1	ENSG00000132549	Vacuolar protein sorting 13 homolog B	8	99013266-99877580	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043865			Approved	Cell Junctions		Expressed in all	Mixed			parathyroid gland: 14.7	Expressed in all		
VPS13C	FLJ10381, FLJ20136, KIAA1421	ENSG00000129003	Vacuolar protein sorting 13 homolog C	15	61852389-62060473	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043507	Uncertain		Approved	Microtubules		Expressed in all	Expressed in all			parathyroid gland: 27.4	Expressed in all		
VPS13D	FLJ10619, KIAA0453	ENSG00000048707	Vacuolar protein sorting 13 homolog D	1	12230067-12512047	Predicted intracellular proteins	Evidence at protein level	HPA027332, HPA051621	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:7.42e-12 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 29.5	Expressed in all		
VPS16		ENSG00000215305	VPS16, CORVET/HOPS core subunit	20	2840703-2866732	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043229, HPA048661	Approved				Pancreatic cancer:5.89e-5 (favourable), Renal cancer:8.02e-5 (unfavourable), Liver cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.5	Expressed in all		
VPS18	KIAA1475, PEP3	ENSG00000104142	VPS18, CORVET/HOPS core subunit	15	40894430-40903975	Predicted intracellular proteins	Evidence at protein level	HPA040701	Approved				Renal cancer:1.61e-6 (favourable), Pancreatic cancer:8.69e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 15.8	Expressed in all		
VPS25	DERP9, EAP20, MGC10540	ENSG00000131475	Vacuolar protein sorting 25 homolog	17	42773436-42779599	Predicted intracellular proteins	Evidence at protein level	CAB004978, HPA052217, HPA057284	Uncertain		Approved	Centrosome	Colorectal cancer:3.18e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 93.3	Expressed in all		
VPS26A	Hbeta58, PEP8A, VPS26	ENSG00000122958	VPS26, retromer complex component A	10	69123512-69172861	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011602, HPA057498, CAB075733	Enhanced		Enhanced	Endosomes<br>Lysosomes	Liver cancer:1.70e-6 (unfavourable), Pancreatic cancer:9.18e-6 (unfavourable), Head and neck cancer:1.72e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 86.8	Expressed in all		
VPS26B	MGC10485, Pep8b	ENSG00000151502	VPS26, retromer complex component B	11	134224645-134247792	Predicted intracellular proteins	Evidence at protein level	HPA038172	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 60.4	Expressed in all		
VPS28		ENSG00000160948	VPS28, ESCRT-I subunit	8	144423601-144428563	Predicted intracellular proteins	Evidence at protein level	HPA024688, HPA024745	Enhanced				Endometrial cancer:9.93e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 237.0	Expressed in all		
VPS29	DC15, DC7, PEP11	ENSG00000111237	VPS29, retromer complex component	12	110491097-110502117	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039748	Uncertain		Supported	Vesicles<br>Cytosol	Liver cancer:2.79e-5 (unfavourable), Ovarian cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 109.0	Expressed in all		
VPS33A		ENSG00000139719	VPS33A, CORVET/HOPS core subunit	12	122229564-122266521	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038701			Approved	Nucleoplasm	Liver cancer:9.11e-5 (unfavourable), Thyroid cancer:2.41e-4 (favourable), Renal cancer:5.29e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.8	Expressed in all		
VPS33B	FLJ14848	ENSG00000184056	VPS33B, late endosome and lysosome associated	15	90998416-91022603	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040415	Approved					Expressed in all	Expressed in all			cerebral cortex: 16.1	Expressed in all		
VPS35	FLJ10752, MEM3, PARK17	ENSG00000069329	VPS35, retromer complex component	16	46656132-46689518	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040802	Enhanced		Supported	Endosomes<br>Lysosomes	Liver cancer:2.10e-6 (unfavourable), Renal cancer:9.75e-5 (favourable), Colorectal cancer:7.74e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.8	Expressed in all		
VPS36	C13orf9, CGI-145, Eap45	ENSG00000136100	Vacuolar protein sorting 36 homolog	13	52412602-52450628	Predicted intracellular proteins	Evidence at protein level	HPA039734, HPA043947	Approved		Supported	Vesicles<br>Lysosomes<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.91e-6 (favourable)	Expressed in all	Expressed in all			skin: 62.4	Expressed in all		
VPS37A	FLJ32642, HCRP1, PQBP2, SPG53	ENSG00000155975	VPS37A, ESCRT-I subunit	8	17246571-17302427	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024705, HPA024781	Enhanced		Approved	Vesicles<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			testis: 57.3	Expressed in all		
VPS37C	FLJ20847	ENSG00000167987	VPS37C, ESCRT-I subunit	11	61130256-61161617	Predicted intracellular proteins	Evidence at protein level	HPA043348	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:2.37e-7 (favourable), Liver cancer:5.85e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 25.2	Expressed in all		
VPS37D	MGC35352, WBSCR24	ENSG00000176428	VPS37D, ESCRT-I subunit	7	73667825-73672112	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040978	Uncertain		Approved	Vesicles	Renal cancer:5.80e-9 (favourable), Pancreatic cancer:2.07e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 6.3	Cell line enhanced		SH-SY5Y: 12.4
VPS39	KIAA0770, VAM6	ENSG00000166887	VPS39, HOPS complex subunit	15	42158701-42208316	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.21e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 65.7	Expressed in all		
VPS41	HVSP41	ENSG00000006715	VPS41, HOPS complex subunit	7	38722963-38932394	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020080, HPA020299	Approved				Renal cancer:3.40e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 96.8	Expressed in all		
VPS45	h-vps45, H1, VPS45A, VPS45B	ENSG00000136631	Vacuolar protein sorting 45 homolog	1	150067293-150145327	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027425, HPA027441	Uncertain		Approved	Microtubules	Liver cancer:6.57e-6 (unfavourable), Renal cancer:1.05e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 37.6	Expressed in all		
VPS4A	FLJ22197, SKD1, SKD1A, SKD2, VPS4, VPS4-1	ENSG00000132612	Vacuolar protein sorting 4 homolog A	16	69311356-69326939	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018751, CAB034411, HPA060092	Approved				Renal cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 31.9	Expressed in all		
VPS4B	SKD1, SKD1B, VPS4-2	ENSG00000119541	Vacuolar protein sorting 4 homolog B	18	63389190-63422483	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040393, CAB046445, HPA057649	Approved		Approved	Vesicles<br>Intermediate filaments	Renal cancer:1.23e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 82.7	Expressed in all		
VPS50	CCDC132, DKFZp313I2429, FLJ20097, KIAA1861, VPS54L	ENSG00000004766	VPS50, EARP/GARPII complex subunit	7	93232340-93361121	Predicted intracellular proteins	Evidence at protein level	HPA026679	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.35e-6 (favourable), Liver cancer:7.21e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.4	Expressed in all		
VPS52	ARE1, SACM2L	ENSG00000223501	VPS52, GARP complex subunit	6	33250272-33272047	Predicted intracellular proteins	Evidence at protein level	HPA042667, HPA048128	Approved					Expressed in all	Mixed			thyroid gland: 8.6	Mixed		
VPS53	FLJ10979, HCCS1	ENSG00000141252	VPS53, GARP complex subunit	17	508668-721717	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022988, HPA024446	Enhanced		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:1.08e-5 (favourable), Pancreatic cancer:1.56e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 9.3	Expressed in all		
VPS54	HCC8, PPP1R164	ENSG00000143952	VPS54, GARP complex subunit	2	63892146-64019072	Predicted intracellular proteins	Evidence at protein level	HPA055894, HPA067981, HPA070582			Enhanced	Nucleoplasm<br>Golgi apparatus	Pancreatic cancer:2.03e-4 (favourable), Liver cancer:2.47e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.8	Expressed in all		
VPS72	Swc2, TCFL1, YL-1, YL1	ENSG00000163159	Vacuolar protein sorting 72 homolog	1	151169987-151195321	Predicted intracellular proteins	Evidence at protein level	HPA065709			Supported	Nuclear speckles	Liver cancer:4.41e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 43.1	Expressed in all		
VPS8	FLJ32099, KIAA0804	ENSG00000156931	VPS8, CORVET complex subunit	3	184812143-185052614	Predicted intracellular proteins	Evidence at protein level	HPA036871	Uncertain		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 31.2	Expressed in all		
VPS9D1	ATP-BL, C16orf7	ENSG00000075399	VPS9 domain containing 1	16	89707134-89720986	Predicted intracellular proteins	Evidence at protein level	HPA007847, HPA023620	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.91e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 26.4	Mixed		
VRK3		ENSG00000105053	Vaccinia related kinase 3	19	49976467-50025946	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056489	Approved		Supported	Nucleus<br>Vesicles	Renal cancer:1.83e-4 (favourable), Urothelial cancer:5.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 168.6	Expressed in all		
VRTN	C14orf115, FLJ10811, vertnin	ENSG00000133980	Vertebrae development associated	14	74303069-74360008	Predicted intracellular proteins	Evidence at protein level	HPA001460	Uncertain		Approved	Nucleoplasm		Tissue enriched	Tissue enhanced		epididymis: 1.8;testis: 2.9	lymph node: 0.5	Cell line enriched	10	NTERA-2: 49.5
VSNL1	HLP3, HPCAL3, HUVISL1, VILIP, VILIP-1	ENSG00000163032	Visinin like 1	2	17539126-17657018	Predicted intracellular proteins	Evidence at protein level	HPA053808					Glioma:9.39e-4 (unfavourable)	Mixed	Tissue enriched	14	cerebral cortex: 624.2	esophagus: 44.0	Cell line enhanced		HaCaT: 107.2;Hep G2: 85.4
VSX1	PPCD, PPCD1, PPD	ENSG00000100987	Visual system homeobox 1	20	25070885-25082365	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enhanced		ovary: 1.7	cerebral cortex: 1.4	Cell line enriched	5	Karpas-707: 3.1
VSX2	CHX10, HOX10, RET1	ENSG00000119614	Visual system homeobox 2	14	74239472-74262738	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003436	Supported					Tissue enriched	Not detected			testis: 0.2	Not detected		
VTA1	C6orf55, HSPC228, My012	ENSG00000009844	Vesicle trafficking 1	6	142147162-142224689	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030968, HPA030969	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:6.58e-6 (unfavourable), Breast cancer:7.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 60.9	Expressed in all		
VWA3A	FLJ40941, FLJ46765	ENSG00000175267	Von Willebrand factor A domain containing 3A	16	22092538-22156966	Predicted intracellular proteins	Evidence at protein level	HPA041696, HPA042044	Uncertain				Endometrial cancer:8.15e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 10.8;testis: 3.3	lung: 2.8	Not detected		
VWA3B	DKFZp686F2227, MGC26733	ENSG00000168658	Von Willebrand factor A domain containing 3B	2	98087116-98313299	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036700, HPA036701	Approved		Approved	Nucleus		Tissue enhanced	Group enriched	9	fallopian tube: 41.2;testis: 36.2	lung: 4.3	Not detected		
VWA5A	BCSC-1, LOH11CR2A	ENSG00000110002	Von Willebrand factor A domain containing 5A	11	124115362-124147721	Predicted intracellular proteins	Evidence at protein level	HPA037813, HPA037814, HPA061500	Uncertain		Enhanced	Nucleus	Renal cancer:1.55e-5 (favourable)	Expressed in all	Expressed in all			gallbladder: 48.7	Cell line enhanced		CAPAN-2: 52.4;HEL: 39.5;HUVEC TERT2: 32.9;RPTEC TERT1: 32.4
VWA5B1	FLJ32784	ENSG00000158816	Von Willebrand factor A domain containing 5B1	1	20290919-20354894	Predicted intracellular proteins	Evidence at protein level	HPA027496, HPA028405, HPA064829	Enhanced		Approved	Plasma membrane<br>Mitochondria<br>Cytosol		Mixed	Tissue enhanced		testis: 5.0	epididymis: 1.6	Cell line enriched	10	SCLC-21H: 1.4
VWA8	KIAA0564	ENSG00000102763	Von Willebrand factor A domain containing 8	13	41566837-41961120	Predicted intracellular proteins	Evidence at protein level	HPA039075, HPA045478	Uncertain		Approved	Vesicles<br>Lipid droplets	Renal cancer:6.38e-14 (favourable), Liver cancer:8.56e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.8	Mixed		
WAPL	FOE, KIAA0261, WAPAL	ENSG00000062650	WAPL cohesin release factor	10	86435256-86521815	Predicted intracellular proteins	Evidence at protein level	HPA037874, HPA037875	Enhanced					Expressed in all	Expressed in all			testis: 64.5	Expressed in all		
WARS	IFI53, IFP53	ENSG00000140105	Tryptophanyl-tRNA synthetase	14	100333788-100376805	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005573, HPA018944			Enhanced	Cytosol	Ovarian cancer:1.94e-4 (favourable), Liver cancer:7.88e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 473.2	Expressed in all		
WARS2	TrpRS	ENSG00000116874	Tryptophanyl tRNA synthetase 2, mitochondrial	1	119031216-119140671	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069692	Enhanced		Supported	Plasma membrane<br>Mitochondria	Renal cancer:1.45e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 15.2	Expressed in all		
WAS	IMD2, THC, WASP, WASPA	ENSG00000015285	Wiskott-Aldrich syndrome	X	48676596-48691427	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002022, CAB004290	Enhanced				Renal cancer:5.58e-6 (unfavourable), Head and neck cancer:3.78e-4 (favourable), Endometrial cancer:4.95e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 69.0;lymph node: 60.8;spleen: 68.8	bone marrow: 37.5	Cell line enhanced		HMC-1: 135.1;U-937: 66.6
WASF1	KIAA0269, SCAR1, WAVE, WAVE1	ENSG00000112290	WAS protein family member 1	6	110099819-110180004	Predicted intracellular proteins	Evidence at protein level	HPA004105, CAB022161	Approved	Approved			Liver cancer:2.82e-8 (unfavourable), Renal cancer:2.79e-5 (unfavourable)	Expressed in all	Group enriched	5	cerebral cortex: 138.9;testis: 149.9	ovary: 27.8	Mixed		
WASF2	SCAR2, WAVE2	ENSG00000158195	WAS protein family member 2	1	27404226-27490158	Predicted intracellular proteins	Evidence at protein level	CAB022632, HPA045288	Enhanced		Approved	Plasma membrane<br>Cytosol	Liver cancer:5.29e-8 (unfavourable), Ovarian cancer:8.48e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 88.1	Expressed in all		
WASF3	KIAA0900, SCAR3, WAVE3	ENSG00000132970	WAS protein family member 3	13	26557703-26688948	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB037086	Approved				Pancreatic cancer:2.21e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 86.4	thyroid gland: 28.1	Cell line enhanced		ASC diff: 56.8
WASHC1	FAM39E, FLJ00038, WASH1	ENSG00000181404	WASH complex subunit 1	9	14521-29739	Predicted intracellular proteins	Evidence at protein level	HPA002689	Uncertain		Supported	Vesicles		Expressed in all	Expressed in all			epididymis: 24.5	Expressed in all		
WASHC2A	bA56A21.1, bA98I6.1, FAM21A, FAM21B, FLJ10824	ENSG00000099290	WASH complex subunit 2A	10	50067888-50133506	Predicted intracellular proteins	Evidence at protein level	HPA047844, HPA060975, HPA061022	Supported		Supported	Nucleoli<br>Vesicles<br>Cytosol	Liver cancer:6.75e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.7	Expressed in all		
WASHC2C	Em:AC012044.3, FAM21C, KIAA0592	ENSG00000172661	WASH complex subunit 2C	10	45727200-45792961	Predicted intracellular proteins	Evidence at protein level	HPA047844, HPA060975, HPA061022	Supported		Supported	Nucleoli<br>Vesicles<br>Cytosol	Liver cancer:1.35e-5 (unfavourable), Lung cancer:4.69e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 41.9	Expressed in all		
WASHC3	CCDC53, CGI-116	ENSG00000120860	WASH complex subunit 3	12	102012927-102062149	Predicted intracellular proteins	Evidence at protein level	HPA038338, HPA038339	Approved		Approved	Vesicles		Expressed in all	Expressed in all			testis: 165.7	Expressed in all		
WASHC4	KIAA1033, SWIP	ENSG00000136051	WASH complex subunit 4	12	105107324-105169134	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045666, HPA046737	Uncertain		Enhanced	Nucleoplasm	Cervical cancer:2.02e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 51.1	Expressed in all		
WASHC5	KIAA0196, SPG8	ENSG00000164961	WASH complex subunit 5	8	125024260-125091840	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034216, CAB034219, HPA064649, HPA070916	Enhanced		Supported	Nucleoplasm	Liver cancer:6.74e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 39.6	Expressed in all		
WASL	N-WASP, NWASP, WASPB	ENSG00000106299	Wiskott-Aldrich syndrome like	7	123681935-123749067	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005399, HPA005750	Supported		Approved	Nucleoli<br>Cytosol	Renal cancer:4.51e-8 (favourable), Pancreatic cancer:5.30e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 73.8	Expressed in all		
WBP11	NPWBP, PPP1R165, SIPP1	ENSG00000084463	WW domain binding protein 11	12	14784579-14803540	Predicted intracellular proteins	Evidence at protein level	HPA039710, HPA040037, HPA046403, HPA049126	Approved		Enhanced	Nucleoplasm	Liver cancer:9.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 69.0	Expressed in all		
WBP2	GRAMD6, WBP-2	ENSG00000132471	WW domain binding protein 2	17	75845699-75856507	Predicted intracellular proteins	Evidence at protein level	HPA065682, HPA068819	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 360.8	Expressed in all		
WBP2NL	FLJ26145, GRAMD7, MGC26816, PAWP	ENSG00000183066	WBP2 N-terminal like	22	41998725-42058456	Predicted intracellular proteins	Evidence at protein level	HPA048557	Enhanced					Not detected	Tissue enriched	8	testis: 11.7	epididymis: 1.5	Not detected		
WBP4	FBP21, MGC117310	ENSG00000120688	WW domain binding protein 4	13	41061274-41084006	Predicted intracellular proteins	Evidence at protein level	HPA038965, HPA058738	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Thyroid cancer:2.89e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 27.7	Expressed in all		
WBSCR17	GalNAc-T5L, GALNTL3	ENSG00000185274	Williams-Beuren syndrome chromosome region 17	7	71132169-71713600	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA013624, HPA047986	Approved		Uncertain	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Golgi apparatus	Testis cancer:3.91e-4 (favourable), Ovarian cancer:4.60e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 76.4	ovary: 29.1	Cell line enhanced		AF22: 14.1;NTERA-2: 10.8;RPMI-8226: 8.6;SK-BR-3: 34.1
WBSCR22	MERM1, MGC19709, MGC2022, MGC5140, PP3381, WBMT	ENSG00000071462	Williams-Beuren syndrome chromosome region 22	7	73683025-73705161	Predicted intracellular proteins	Evidence at protein level	HPA052185	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.46e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 207.8	Expressed in all		
WBSCR27		ENSG00000165171	Williams Beuren syndrome chromosome region 27	7	73834590-73842535	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022420	Uncertain		Supported	Focal adhesion sites	Renal cancer:1.10e-6 (favourable), Colorectal cancer:1.73e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 8.4	Cell line enhanced		RPMI-8226: 54.9;T-47d: 21.0
WDCP	C2orf44, FLJ21945	ENSG00000163026	WD repeat and coiled coil containing	2	24029340-24049575	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041054	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:5.14e-8 (unfavourable), Endometrial cancer:6.53e-4 (unfavourable)	Expressed in all	Mixed			testis: 9.3	Expressed in all		
WDFY1	FENS-1, KIAA1435, WDF1, ZFYVE17	ENSG00000085449	WD repeat and FYVE domain containing 1	2	223855716-223945387	Predicted intracellular proteins	Evidence at protein level	HPA050603	Approved					Expressed in all	Expressed in all			placenta: 38.8	Expressed in all		
WDFY2	ZFYVE22	ENSG00000139668	WD repeat and FYVE domain containing 2	13	51584455-51767707	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Mixed			skin: 21.3	Expressed in all		
WDFY3	ALFY, KIAA0993, ZFYVE25	ENSG00000163625	WD repeat and FYVE domain containing 3	4	84669610-84966391	Predicted intracellular proteins	Evidence at protein level	HPA042734, HPA048572	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:3.64e-5 (favourable), Stomach cancer:9.35e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.2	Mixed		
WDPCP	BBS15, C2orf86, fritz, hFrtz	ENSG00000143951	WD repeat containing planar cell polarity effector	2	63121383-63827843	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044144	Uncertain		Approved	Cell Junctions		Mixed	Mixed			testis: 11.4	Expressed in all		
WDR1		ENSG00000071127	WD repeat domain 1	4	10074339-10116949	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB020804, HPA036434, HPA070293	Approved		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:1.73e-5 (favourable)	Expressed in all	Expressed in all			smooth muscle: 308.6	Expressed in all		
WDR12	FLJ10881, YTM1	ENSG00000138442	WD repeat domain 12	2	202874782-203014798	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036389	Uncertain		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Liver cancer:2.57e-6 (unfavourable)	Expressed in all	Mixed			testis: 7.3	Expressed in all		
WDR13		ENSG00000101940	WD repeat domain 13	X	48590042-48608867	Predicted intracellular proteins	Evidence at protein level	HPA000913	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Microtubule organizing center		Expressed in all	Expressed in all			fallopian tube: 91.9	Expressed in all		
WDR18	Ipi3	ENSG00000065268	WD repeat domain 18	19	984271-998438	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050193, HPA050200	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 17.9	Expressed in all		
WDR19	DYF-2, FLJ23127, IFT144, KIAA1638, NPHP13, ORF26, Oseg6, Pwdmp	ENSG00000157796	WD repeat domain 19	4	39182404-39285810	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039616, HPA058847	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:2.70e-4 (favourable), Liver cancer:4.43e-4 (unfavourable), Prostate cancer:8.58e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 30.7	Mixed		
WDR20	DMR, FLJ33659, MGC33177	ENSG00000140153	WD repeat domain 20	14	102139503-102224847	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.26e-9 (favourable)	Expressed in all	Expressed in all			testis: 40.6	Expressed in all		
WDR24	C16orf21, DKFZp434F054, JFP7	ENSG00000127580	WD repeat domain 24	16	684622-690444	Predicted intracellular proteins	Evidence at protein level	HPA039506	Approved				Renal cancer:3.75e-6 (favourable)	Expressed in all	Expressed in all			testis: 11.8	Expressed in all		
WDR26	FLJ21016, GID7	ENSG00000162923	WD repeat domain 26	1	224385143-224437033	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028539, HPA061094	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.31e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 53.9	Expressed in all		
WDR27	MGC43690	ENSG00000184465	WD repeat domain 27	6	169457212-169702048	Predicted intracellular proteins	Evidence at protein level	HPA037497, HPA037498	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.78e-5 (unfavourable)	Expressed in all	Mixed			testis: 15.8	Expressed in all		
WDR3	DIP2, FLJ12796, UTP12	ENSG00000065183	WD repeat domain 3	1	117929720-117966542	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027509, HPA054354			Supported	Nucleus<br>Nuclear membrane<br>Nucleoli	Liver cancer:7.33e-5 (unfavourable), Pancreatic cancer:8.82e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.3	Expressed in all		
WDR31	FLJ35921	ENSG00000148225	WD repeat domain 31	9	113313222-113340298	Predicted intracellular proteins	Evidence at transcript level	HPA019340, HPA019347	Approved		Approved	Nuclear bodies<br>Cytosol	Renal cancer:1.90e-9 (favourable), Endometrial cancer:1.85e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 16.3	testis: 9.2	Mixed		
WDR34	bA216B9.3, DIC5, FAP133, MGC20486	ENSG00000119333	WD repeat domain 34	9	128633661-128656787	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040764, HPA041091	Approved		Approved	Cytosol	Endometrial cancer:7.01e-5 (favourable), Cervical cancer:1.63e-4 (favourable), Liver cancer:8.79e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 53.0	Expressed in all		
WDR35	IFT121, IFTA1, KIAA1336, MGC33196	ENSG00000118965	WD repeat domain 35	2	19910260-19990131	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044147	Approved					Expressed in all	Mixed			parathyroid gland: 26.2	Mixed		
WDR36	GLC1G, TA-WDRP, UTP21	ENSG00000134987	WD repeat domain 36	5	111091716-111130502	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037796, HPA037797	Supported		Supported	Nucleoli	Thyroid cancer:1.18e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 17.2	Expressed in all		
WDR37	KIAA0982	ENSG00000047056	WD repeat domain 37	10	1049538-1132297	Predicted intracellular proteins	Evidence at protein level	HPA037376, HPA037565	Enhanced		Uncertain	Intermediate filaments<br>Centrosome<br>Cytosol	Pancreatic cancer:1.46e-6 (favourable), Thyroid cancer:1.34e-5 (unfavourable), Head and neck cancer:1.75e-5 (favourable)	Expressed in all	Expressed in all			testis: 36.4	Expressed in all		
WDR38		ENSG00000136918	WD repeat domain 38	9	124853417-124857890	Predicted intracellular proteins	Evidence at transcript level	HPA056607	Uncertain				Endometrial cancer:3.97e-4 (favourable)	Tissue enhanced	Tissue enriched	17	fallopian tube: 125.2	lung: 7.3	Not detected		
WDR4	TRM82, TRMT82	ENSG00000160193	WD repeat domain 4	21	42843094-42879568	Predicted intracellular proteins	Evidence at protein level	HPA017381	Uncertain		Supported	Nucleus<br>Cytosol	Liver cancer:5.48e-7 (unfavourable)	Expressed in all	Mixed			lymph node: 10.9	Expressed in all		
WDR41	FLJ10904	ENSG00000164253	WD repeat domain 41	5	77425970-77620611	Predicted intracellular proteins	Evidence at protein level	HPA043124	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Liver cancer:4.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.6	Expressed in all		
WDR43	KIAA0007, NET12, UTP5	ENSG00000163811	WD repeat domain 43	2	28894643-28948222	Predicted intracellular proteins	Evidence at protein level	HPA044733	Uncertain				Liver cancer:3.66e-5 (unfavourable), Endometrial cancer:5.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.5	Expressed in all		
WDR44	DKFZp686L20145, RAB11BP, RPH11	ENSG00000131725	WD repeat domain 44	X	118346073-118449961	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038084, HPA046719	Approved		Supported	Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 23.2	Expressed in all		
WDR45B	WDR45L, WIPI3	ENSG00000141580	WD repeat domain 45B	17	82614562-82648553	Predicted intracellular proteins	Evidence at protein level	HPA017886			Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Liver cancer:2.98e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 82.9	Expressed in all		
WDR46	BING4, C6orf11, UTP7	ENSG00000227057	WD repeat domain 46	6	33279108-33289527	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043004	Uncertain				Renal cancer:4.75e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 16.5	tonsil: 10.0	Group enriched	29	BEWO: 30.8;HMC-1: 27.8;U-698: 49.4
WDR47	KIAA0893	ENSG00000085433	WD repeat domain 47	1	108970214-109042113	Predicted intracellular proteins	Evidence at protein level	HPA027287, HPA027289	Approved		Approved	Actin filaments	Head and neck cancer:9.86e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 73.3	Expressed in all		
WDR48	KIAA1449, P80, SPG60	ENSG00000114742	WD repeat domain 48	3	39051998-39096671	Predicted intracellular proteins	Evidence at protein level	HPA038421, HPA058015	Approved		Supported	Vesicles	Renal cancer:1.63e-7 (favourable)	Expressed in all	Expressed in all			testis: 72.5	Expressed in all		
WDR49	FLJ33620	ENSG00000174776	WD repeat domain 49	3	167478684-167653983	Predicted intracellular proteins	Evidence at protein level	HPA036225, HPA036226	Uncertain					Tissue enhanced	Tissue enhanced		fallopian tube: 18.4	small intestine: 5.0	Group enriched	17	AF22: 2.8;NTERA-2: 3.2;THP-1: 10.1;U-937: 6.2
WDR5	CFAP89, SWD3	ENSG00000196363	WD repeat domain 5	9	134135365-134159968	Predicted intracellular proteins	Evidence at protein level	HPA047182			Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 63.0	Expressed in all		
WDR53	MGC12928, MGC64882	ENSG00000185798	WD repeat domain 53	3	196554177-196568674	Predicted intracellular proteins	Evidence at protein level	HPA016420, HPA019332	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.57e-6 (unfavourable), Melanoma:3.09e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 112.5	parathyroid gland: 19.9	Expressed in all		
WDR54	FLJ12953	ENSG00000005448	WD repeat domain 54	2	74421678-74425755	Predicted intracellular proteins	Evidence at protein level	HPA043257, HPA053558	Enhanced		Approved	Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		fallopian tube: 113.2	testis: 48.2	Expressed in all		
WDR55	FLJ20195, FLJ21702	ENSG00000120314	WD repeat domain 55	5	140664676-140674124	Predicted intracellular proteins	Evidence at protein level	HPA043470, HPA048143	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:8.88e-6 (unfavourable), Breast cancer:1.51e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 12.7	Expressed in all		
WDR59	FLJ12270	ENSG00000103091	WD repeat domain 59	16	74871367-75000173	Predicted intracellular proteins	Evidence at protein level	HPA041084, HPA048218	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 44.0	Expressed in all		
WDR5B	FLJ11287	ENSG00000196981	WD repeat domain 5B	3	122412332-122416051	Predicted intracellular proteins	Evidence at transcript level	HPA042994	Approved					Expressed in all	Mixed			epididymis: 13.3	Mixed		
WDR6		ENSG00000178252	WD repeat domain 6	3	49007062-49015953	Predicted intracellular proteins	Evidence at protein level	HPA042622	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:2.97e-6 (unfavourable), Renal cancer:4.52e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 204.8	Expressed in all		
WDR60	FAP163, FLJ10300	ENSG00000126870	WD repeat domain 60	7	158856578-158956747	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020607, HPA021316	Approved		Approved	Microtubule organizing center		Expressed in all	Expressed in all			testis: 75.5	Expressed in all		
WDR61	REC14	ENSG00000140395	WD repeat domain 61	15	78277835-78299794	Predicted intracellular proteins	Evidence at protein level	HPA039932, HPA040065	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.03e-10 (favourable)	Expressed in all	Expressed in all			epididymis: 126.8	Expressed in all		
WDR62	C19orf14, DKFZP434J046, FLJ33298, MCPH2	ENSG00000075702	WD repeat domain 62	19	36054881-36105106	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043255, HPA043639, CAB046468	Enhanced		Enhanced	Microtubule organizing center<br>Cytosol		Mixed	Group enriched	8	skeletal muscle: 15.9;testis: 76.4	heart muscle: 6.0	Mixed		
WDR63	DIC3, FLJ30067, NYD-SP29	ENSG00000162643	WD repeat domain 63	1	84999147-85133138	Predicted intracellular proteins	Evidence at protein level	HPA038526	Enhanced					Tissue enhanced	Tissue enhanced		adrenal gland: 28.3;fallopian tube: 23.1;testis: 33.6	parathyroid gland: 6.2	Cell line enhanced		ASC TERT1: 5.9;HSkMC: 4.1;hTCEpi: 5.0;LHCN-M2: 5.2
WDR64	FLJ32978	ENSG00000162843	WD repeat domain 64	1	241652278-241802133	Predicted intracellular proteins	Evidence at protein level	HPA046186	Uncertain					Not detected	Tissue enriched	10	testis: 5.5	placenta: 0.5	Not detected		
WDR66	CaM-IP4, MGC33630	ENSG00000158023	WD repeat domain 66	12	121917862-122003927	Predicted intracellular proteins	Evidence at protein level	HPA039902, HPA040005	Supported		Uncertain	Plasma membrane<br>Cytosol	Endometrial cancer:3.11e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 32.6;testis: 30.7	thyroid gland: 7.4	Cell line enhanced		HBEC3-KT: 22.5;hTCEpi: 21.0;hTERT-HME1: 15.0
WDR7	KIAA0541, TRAG	ENSG00000091157	WD repeat domain 7	18	56651343-57036606	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042074, HPA051057	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.13e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 38.6	parathyroid gland: 17.0	Expressed in all		
WDR70	FLJ10233	ENSG00000082068	WD repeat domain 70	5	37379212-37753435	Predicted intracellular proteins	Evidence at protein level	HPA043064, HPA048149	Uncertain		Approved	Mitochondria<br>Cytosol	Melanoma:3.73e-4 (unfavourable), Endometrial cancer:4.34e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 18.1	Expressed in all		
WDR72	FLJ38736	ENSG00000166415	WD repeat domain 72	15	53513741-53762878	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048212, HPA057410, HPA059819	Uncertain		Approved	Vesicles	Renal cancer:3.33e-16 (favourable), Thyroid cancer:1.80e-4 (unfavourable)	Mixed	Group enriched	6	kidney: 104.7;thyroid gland: 92.1	liver: 16.9	Cell line enhanced		A549: 8.9;EFO-21: 5.9;NTERA-2: 5.9;RPMI-8226: 11.9;RPTEC TERT1: 8.1;U-266/70: 5.7
WDR73	FLJ14888, HSPC264	ENSG00000177082	WD repeat domain 73	15	84639281-84654343	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039357	Uncertain					Mixed	Mixed			endometrium: 5.7	Expressed in all		
WDR74	FLJ10439	ENSG00000133316	WD repeat domain 74	11	62832342-62841809	Predicted intracellular proteins	Evidence at protein level	HPA037795, HPA038419	Uncertain		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			bone marrow: 82.7	Expressed in all		
WDR75	FLJ12519, NET16, UTP17	ENSG00000115368	WD repeat domain 75	2	189441433-189475565	Predicted intracellular proteins	Evidence at protein level	HPA038199	Approved		Approved	Nucleoplasm	Renal cancer:3.15e-11 (unfavourable), Liver cancer:6.50e-8 (unfavourable)	Expressed in all	Expressed in all			endometrium: 39.6	Expressed in all		
WDR76	FLJ12973	ENSG00000092470	WD repeat domain 76	15	43826963-43868419	Predicted intracellular proteins	Evidence at protein level	HPA039804, HPA040626	Uncertain		Approved	Nucleoli fibrillar center<br>Nuclear bodies	Renal cancer:1.35e-8 (unfavourable), Lung cancer:8.02e-5 (unfavourable), Pancreatic cancer:5.02e-4 (unfavourable), Liver cancer:6.98e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 23.7	Expressed in all		
WDR77	MEP50, p44	ENSG00000116455	WD repeat domain 77	1	111439890-111449376	Predicted intracellular proteins	Evidence at protein level	HPA026437, HPA026448, HPA027271	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:2.06e-6 (unfavourable), Ovarian cancer:7.88e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 162.6	Expressed in all		
WDR78	DIC4, FLJ23129	ENSG00000152763	WD repeat domain 78	1	66812885-66924887	Predicted intracellular proteins	Evidence at protein level						Renal cancer:9.60e-5 (favourable)	Mixed	Group enriched	5	fallopian tube: 43.8;testis: 62.9	parathyroid gland: 10.2	Cell line enhanced		RPTEC TERT1: 8.6
WDR82	MST107, MSTP107, PRO2730, PRO34047, SWD2, TMEM113, WDR82A	ENSG00000164091	WD repeat domain 82	3	52254421-52288020	Predicted intracellular proteins	Evidence at protein level	HPA040427			Approved	Nucleoli		Expressed in all	Expressed in all			endometrium: 93.6	Expressed in all		
WDR83	MORG1	ENSG00000123154	WD repeat domain 83	19	12666800-12675832	Predicted intracellular proteins	Evidence at protein level	HPA042629, HPA042838	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Centrosome	Urothelial cancer:3.12e-4 (favourable), Pancreatic cancer:5.44e-4 (favourable)	Expressed in all	Mixed			testis: 9.4	Mixed		
WDR86		ENSG00000187260	WD repeat domain 86	7	151375909-151410727	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		parathyroid gland: 20.9;spleen: 14.3	endometrium: 7.5	Group enriched	5	HSkMC: 9.9;NTERA-2: 2.6;SCLC-21H: 6.9;SH-SY5Y: 4.4
WDR87	NYD-SP11	ENSG00000171804	WD repeat domain 87	19	37884823-37906677	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	203	testis: 30.5	thyroid gland: 0.1	Not detected		
WDR88	PQWD	ENSG00000166359	WD repeat domain 88	19	33132090-33175795	Predicted intracellular proteins	Evidence at protein level	HPA041916, HPA050336	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enriched	7	testis: 11.1	cerebral cortex,thyroid gland: 1.6	Mixed		
WDR89	C14orf150, MGC9907	ENSG00000140006	WD repeat domain 89	14	63597039-63641861	Predicted intracellular proteins	Evidence at protein level	HPA000813	Uncertain		Approved	Intermediate filaments<br>Cytosol	Liver cancer:3.26e-4 (unfavourable), Breast cancer:3.37e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 20.6	Expressed in all		
WDR91	HSPC049, SORF-1	ENSG00000105875	WD repeat domain 91	7	135183839-135211534	Predicted intracellular proteins	Evidence at protein level	HPA024260	Uncertain				Liver cancer:1.53e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 14.7	Expressed in all		
WDR92	FLJ31741, Monad	ENSG00000243667	WD repeat domain 92	2	68122936-68157560	Predicted intracellular proteins	Evidence at protein level	HPA035335, HPA035336	Approved		Approved	Nucleoplasm		Mixed	Mixed			epididymis: 19.8	Expressed in all		
WDR93		ENSG00000140527	WD repeat domain 93	15	89690797-89743638	Predicted intracellular proteins	Evidence at transcript level	HPA046196, HPA048112	Uncertain		Uncertain	Actin filaments		Mixed	Tissue enhanced		fallopian tube: 14.2;testis: 21.1	epididymis: 6.1	Mixed		
WDR97	KIAA1875	ENSG00000179698	WD repeat domain 97	8	144107726-144118315	Predicted intracellular proteins	Evidence at transcript level	HPA059409	Uncertain					Mixed	Tissue enriched	9	testis: 1.1	adrenal gland: 0.1	Not detected		
WDSUB1	FLJ36175, UBOX6, WDSAM1	ENSG00000196151	WD repeat, sterile alpha motif and U-box domain containing 1	2	159235793-159286799	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036840, HPA058172	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:2.67e-4 (unfavourable), Cervical cancer:3.35e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 27.9	Expressed in all		
WDTC1	ADP, DCAF9, KIAA1037	ENSG00000142784	WD and tetratricopeptide repeats 1	1	27234516-27308633	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028177, HPA028180, HPA028182	Uncertain		Supported	Golgi apparatus<br>Vesicles	Renal cancer:8.84e-8 (favourable), Cervical cancer:4.51e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 73.7	Expressed in all		
WDYHV1	C8orf32, FLJ10204	ENSG00000156795	WDYHV motif containing 1	8	123416725-123467230	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024823, HPA053680	Approved		Supported	Nucleoplasm<br>Vesicles	Endometrial cancer:4.93e-5 (unfavourable), Liver cancer:3.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 18.5	Expressed in all		
WEE1	WEE1A	ENSG00000166483	WEE1 G2 checkpoint kinase	11	9573681-9593457	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004619, HPA068845	Approved		Approved	Nucleoli	Renal cancer:5.19e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 90.6	Expressed in all		
WEE2	FLJ16107	ENSG00000214102	WEE1 homolog 2	7	141708353-141731271	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027418	Uncertain		Supported	Nucleoplasm<br>Cytosol		Not detected	Not detected			skin,thyroid gland: 0.8	Cell line enhanced		CACO-2: 2.6
WFDC9	dJ688G8.2, WAP9	ENSG00000180205	WAP four-disulfide core domain 9	20	45607939-45631268	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	405	epididymis: 1257.7	seminal vesicle: 3.1	Not detected		
WHAMM	KIAA1971, WHAMM1, WHDC1	ENSG00000156232	WAS protein homolog associated with actin, golgi membranes and microtubules	15	82809628-82836108	Predicted intracellular proteins	Evidence at protein level	HPA039690, HPA040231	Supported		Supported	Cytosol	Prostate cancer:2.31e-4 (unfavourable), Cervical cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 18.8	Expressed in all		
WI2-2373I1.1		ENSG00000248767		7	290170-294422	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.5	Not detected		
WIPF1	WASPIP, WIP	ENSG00000115935	WAS/WASL interacting protein family member 1	2	174559572-174682916	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003739, CAB009737, HPA070706	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.14e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 157.5	Cell line enhanced		Karpas-707: 220.1
WIPF2	WICH, WIRE	ENSG00000171475	WAS/WASL interacting protein family member 2	17	40219304-40284136	Predicted intracellular proteins	Evidence at protein level	HPA024000, HPA024001, HPA024467	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 32.4	Expressed in all		
WIPF3	CR16, FLJ36931	ENSG00000122574	WAS/WASL interacting protein family member 3	7	29806486-29917066	Predicted intracellular proteins	Evidence at protein level	HPA041145, HPA041211	Uncertain		Uncertain	Mitochondria	Breast cancer:7.93e-4 (favourable)	Mixed	Tissue enhanced		ovary: 52.8;testis: 37.3	epididymis: 25.0	Cell line enhanced		HAP1: 19.3;K-562: 6.0;NTERA-2: 5.3;RPMI-8226: 8.0
WIPI1	ATG18, ATG18A, FLJ10055, WIPI49	ENSG00000070540	WD repeat domain, phosphoinositide interacting 1	17	68420948-68457513	Predicted intracellular proteins	Evidence at protein level	HPA007493, CAB037230	Enhanced				Melanoma:3.11e-4 (favourable)	Expressed in all	Expressed in all			placenta: 90.1	Cell line enhanced		HHSteC: 180.5
WIPI2	ATG18B, ATG21, CGI-50, DKFZP434J154, DKFZp686P02188, FLJ12979, FLJ14217, FLJ42984	ENSG00000157954	WD repeat domain, phosphoinositide interacting 2	7	5190188-5233826	Predicted intracellular proteins	Evidence at protein level	HPA019852, HPA021488	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.05e-6 (favourable), Endometrial cancer:7.69e-5 (unfavourable), Pancreatic cancer:9.78e-4 (favourable)	Expressed in all	Expressed in all			testis: 92.7	Expressed in all		
WIZ	ZNF803	ENSG00000011451	Widely interspaced zinc finger motifs	19	15419980-15449951	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA022923, HPA023774	Supported		Enhanced	Nucleoplasm<br>Midbody	Endometrial cancer:5.12e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 31.1	Expressed in all		
WNK2	KIAA1760, NY-CO-43, PRKWNK2, SDCCAG43	ENSG00000165238	WNK lysine deficient protein kinase 2	9	93184916-93320572	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015555, HPA016519, CAB017813	Enhanced		Approved	Cytosol		Mixed	Mixed			heart muscle: 29.1	Cell line enhanced		Hep G2: 21.0;SCLC-21H: 44.2
WNK3	PRKWNK3	ENSG00000196632	WNK lysine deficient protein kinase 3	X	54192823-54358642	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA077678			Approved	Vesicles		Mixed	Group enriched	6	epididymis: 14.3;testis: 18.6	ovary: 2.6	Cell line enhanced		AF22: 4.4;HAP1: 5.4;NTERA-2: 9.1;SiHa: 4.8;U-2 OS: 4.1
WNK4	PRKWNK4	ENSG00000126562	WNK lysine deficient protein kinase 4	17	42780678-42796936	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016500	Approved					Mixed	Tissue enhanced		kidney: 19.0;prostate: 15.4;rectum: 12.0	colon: 8.8	Cell line enhanced		fHDF/TERT166: 26.2;K-562: 34.7;TIME: 29.5;WM-115: 23.9
WNT7A		ENSG00000154764	Wnt family member 7A	3	13816258-13880121	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015719, CAB025894	Approved				Pancreatic cancer:3.03e-6 (unfavourable), Endometrial cancer:2.96e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 6.7;gallbladder: 3.6;placenta: 3.9	lung: 3.0	Group enriched	5	BEWO: 56.9;EFO-21: 52.0;PC-3: 18.2;RPTEC TERT1: 74.6
WRAP53	FLJ10385, TCAB1, WDR79	ENSG00000141499	WD repeat containing antisense to TP53	17	7686071-7703502	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023026, HPA028130, HPA029928	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:4.70e-4 (unfavourable), Pancreatic cancer:8.26e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 21.8	Mixed		
WRAP73	WDR8	ENSG00000116213	WD repeat containing, antisense to TP73	1	3630767-3652761	Predicted intracellular proteins	Evidence at protein level	HPA026893	Uncertain		Approved	Nucleoplasm<br>Cell Junctions	Liver cancer:1.37e-4 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:3.49e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 20.4	Expressed in all		
WRN	RECQ3, RECQL2	ENSG00000165392	Werner syndrome RecQ like helicase	8	31033801-31173769	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028661	Approved		Supported	Nuclear speckles		Expressed in all	Mixed			endometrium: 14.8	Expressed in all		
WRNIP1	bA420G6.2, FLJ22526, WHIP	ENSG00000124535	Werner helicase interacting protein 1	6	2765414-2786952	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031752, HPA031753	Enhanced		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 78.7	Expressed in all		
WSB2	MGC10210, SBA2	ENSG00000176871	WD repeat and SOCS box containing 2	12	118032694-118062430	Predicted intracellular proteins	Evidence at protein level	HPA052606	Uncertain				Liver cancer:2.42e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 193.2	Expressed in all		
WT1	AWT1, GUD, NPHS4, WAGR, WIT-2	ENSG00000184937	Wilms tumor 1	11	32387775-32435630	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000327, HPA035717, HPA053848	Enhanced		Supported	Nucleoplasm		Tissue enriched	Tissue enhanced		endometrium: 112.9;fallopian tube: 126.5;smooth muscle: 80.2	testis: 55.1	Cell line enhanced		HEL: 23.8;HMC-1: 28.7;K-562: 21.7;NB-4: 40.6;THP-1: 20.5
WTAP	KIAA0105, MGC3925, Mum2	ENSG00000146457	Wilms tumor 1 associated protein	6	159725585-159756319	Predicted intracellular proteins	Evidence at protein level	HPA010549, HPA010550	Supported		Enhanced	Nucleoplasm<br>Nuclear speckles	Liver cancer:6.57e-6 (unfavourable), Renal cancer:3.01e-5 (unfavourable), Ovarian cancer:7.51e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 177.1	Expressed in all		
WTH3DI		ENSG00000233087	RAB6C-like	2	131361111-131364142	Predicted intracellular proteins	Evidence at protein level	HPA059131	Uncertain		Approved	Golgi apparatus		Tissue enhanced	Tissue enriched	6	parathyroid gland: 14.4	prostate: 2.3	Cell line enhanced		MOLT-4: 1.7
WTIP		ENSG00000142279	Wilms tumor 1 interacting protein	19	34481638-34512304	Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			ovary: 34.3	Mixed		
WWC1	KIAA0869, KIBRA, PPP1R168	ENSG00000113645	WW and C2 domain containing 1	5	168291651-168472303	Predicted intracellular proteins	Evidence at protein level	HPA038016, HPA038017	Approved		Approved	Golgi apparatus	Renal cancer:1.95e-8 (favourable)	Expressed in all	Mixed			salivary gland: 61.5	Cell line enhanced		RPTEC TERT1: 195.6
WWC2	BOMB, FLJ22029	ENSG00000151718	WW and C2 domain containing 2	4	183099293-183320777	Predicted intracellular proteins	Evidence at protein level	HPA044005	Uncertain		Approved	Microtubules	Cervical cancer:8.61e-4 (unfavourable), Renal cancer:9.29e-4 (favourable)	Expressed in all	Mixed			lung: 42.5	Mixed		
WWC3	BM042, KIAA1280	ENSG00000047644	WWC family member 3	X	10015562-10144478	Predicted intracellular proteins	Evidence at protein level	HPA039814	Uncertain		Approved	Actin filaments<br>Cytosol	Renal cancer:1.06e-5 (unfavourable), Colorectal cancer:1.31e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 39.8	Cell line enhanced		T-47d: 129.2
WWOX	FOR, SDR41C1, WOX1	ENSG00000186153	WW domain containing oxidoreductase	16	78099413-79212667	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050992	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:4.49e-5 (favourable), Breast cancer:9.07e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 33.6	Cell line enhanced		MCF7: 65.2
WWP2	AIP2	ENSG00000198373	WW domain containing E3 ubiquitin protein ligase 2	16	69762306-69941741	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.87e-11 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 50.2	Expressed in all		
WWTR1	DKFZp586I1419, TAZ	ENSG00000018408	WW domain containing transcription regulator 1	3	149517235-149736714	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA007415, CAB017483, CAB068248	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			endometrium: 71.0	Cell line enhanced		EFO-21: 230.5
XAB2	HCNP, HCRN, NTC90, SYF1	ENSG00000076924	XPA binding protein 2	19	7619525-7629565	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048751			Approved	Nucleus<br>Vesicles	Cervical cancer:4.04e-4 (favourable), Endometrial cancer:4.96e-4 (favourable), Pancreatic cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.3	Expressed in all		
XAF1	BIRC4BP, HSXIAPAF1, XIAPAF1	ENSG00000132530	XIAP associated factor 1	17	6755447-6775647	Predicted intracellular proteins	Evidence at protein level	HPA057302	Approved		Supported	Nucleus<br>Mitochondria<br>Rods & Rings	Renal cancer:2.73e-7 (unfavourable)	Expressed in all	Mixed			spleen: 81.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 69.2;BJ hTERT+ SV40 Large T+ RasG12V: 74.2
XAGE1A	CT12.1a, GAGED2, XAGE-1, XAGE1	ENSG00000204379	X antigen family member 1A	X	52495676-52500812	Predicted intracellular proteins	Evidence at protein level	HPA077164			Uncertain	Nuclear speckles		Not detected	Tissue enriched	186	testis: 65.7	adipose tissue,cervix, uterine,liver,lymph node: 0.3	Cell line enhanced		HMC-1: 491.2;NB-4: 361.0;THP-1: 391.2;U-2 OS: 422.6;U-266/84: 543.0;U-937: 364.8
XAGE1B	CT12.1b	ENSG00000204382	X antigen family member 1B	X	52512077-52520803	Predicted intracellular proteins	Evidence at protein level	HPA077164			Uncertain	Nuclear speckles		Not detected	Tissue enriched	42	testis: 70.1	lung: 1.6	Cell line enhanced		HMC-1: 528.0;NB-4: 387.4;THP-1: 397.2;U-2 OS: 451.2;U-266/84: 561.1;U-937: 379.7
XAGE2	CT12.2, GAGED3, XAGE-2, XAGE2B	ENSG00000155622	X antigen family member 2	X	52369030-52375680	Predicted intracellular proteins	Evidence at protein level	HPA052507, HPA060900	Supported					Mixed	Tissue enriched	35	placenta: 294.4	lung: 8.4	Cell line enhanced		BEWO: 95.0;SK-BR-3: 17.4;T-47d: 19.2
XAGE3	CT12.3a, CT12.3b, GAGED4, PLAC6, pp9012, XAGE-3	ENSG00000171402	X antigen family member 3	X	52862525-52868068	Predicted intracellular proteins	Evidence at protein level	HPA052507, HPA059045, HPA060900	Approved					Mixed	Tissue enriched	167	placenta: 575.4	adipose tissue: 3.4	Cell line enhanced		BEWO: 1.2;U-266/70: 1.6;U-266/84: 1.4
XAGE5	CT12.5, GAGED5, XAGE-5	ENSG00000171405	X antigen family member 5	X	52812204-52818301	Predicted intracellular proteins	Evidence at transcript level	HPA052507, HPA055941, HPA059045	Uncertain		Approved	Nucleoplasm<br>Vesicles		Tissue enhanced	Tissue enriched	10	testis: 2.1	skin: 0.2	Cell line enriched	47	U-2 OS: 22.9
XDH	XO, XOR	ENSG00000158125	Xanthine dehydrogenase	2	31334321-31414715	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062641, HPA069323	Supported		Supported	Nucleus	Urothelial cancer:8.73e-6 (favourable)	Mixed	Tissue enhanced		breast: 48.3;duodenum: 45.6;liver: 35.9;small intestine: 54.6	colon: 11.2	Cell line enhanced		HBEC3-KT: 14.4;hTERT-HME1: 23.9
XIAP	API3, BIRC4, hILP	ENSG00000101966	X-linked inhibitor of apoptosis	X	123859724-123913979	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009203, HPA042428	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Breast cancer:9.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.4	Mixed		
XIRP1	CMYA1, DKFZp451D042, Xin	ENSG00000168334	Xin actin binding repeat containing 1	3	39183210-39192596	Predicted intracellular proteins	Evidence at protein level	HPA016750, HPA018458, CAB026391	Enhanced		Approved	Nucleus<br>Actin filaments		Tissue enhanced	Group enriched	14	heart muscle: 113.0;skeletal muscle: 58.4	esophagus: 5.9	Cell line enhanced		HSkMC: 3.2;RH-30: 2.9
XIRP2	CMYA3	ENSG00000163092	Xin actin binding repeat containing 2	2	166888487-167259753	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034813, HPA074599	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Tissue enriched	Group enriched	22	heart muscle: 84.0;skeletal muscle: 301.6	prostate: 8.8	Cell line enhanced		AN3-CA: 1.4;HUVEC TERT2: 3.5;U-2197: 2.7
XPA	XP1, XPAC	ENSG00000136936	XPA, DNA damage recognition and repair factor	9	97674909-97697357	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB000155, HPA056856	Supported		Approved	Nucleus<br>Cytokinetic bridge	Renal cancer:4.28e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 38.9	Expressed in all		
XPC	RAD4, XPCC	ENSG00000154767	XPC complex subunit, DNA damage recognition and repair factor	3	14145147-14178783	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009932, HPA035707, HPA069673	Supported		Enhanced	Nucleus<br>Plasma membrane	Renal cancer:4.14e-7 (favourable), Urothelial cancer:2.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.4	Expressed in all		
XPNPEP1	XPNPEP, XPNPEPL, XPNPEPL1	ENSG00000108039	X-prolyl aminopeptidase 1	10	109864766-109923553	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB025196, HPA030419, HPA030420, HPA030422	Supported		Enhanced	Cytosol	Liver cancer:2.12e-5 (unfavourable)	Expressed in all	Expressed in all			small intestine: 66.1	Expressed in all		
XPNPEP3	APP3, ICP55, NPHPL1	ENSG00000196236	X-prolyl aminopeptidase 3	22	40857077-40932815	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000527	Enhanced				Thyroid cancer:6.10e-4 (unfavourable), Breast cancer:8.19e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 14.5	Mixed		
XPO1	CRM1, emb	ENSG00000082898	Exportin 1	2	61477849-61538626	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB010184, HPA042933	Supported		Enhanced	Nucleoplasm<br>Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:1.84e-5 (unfavourable), Renal cancer:3.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 139.1	Expressed in all		
XPO4	FLJ13046, KIAA1721	ENSG00000132953	Exportin 4	13	20777329-20903048	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA053768			Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.63e-4 (unfavourable), Endometrial cancer:8.25e-4 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 15.7	Expressed in all		
XPO5	KIAA1291	ENSG00000124571	Exportin 5	6	43522330-43576075	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB012357, HPA018402, HPA023959, HPA029909	Enhanced		Enhanced	Nucleoplasm	Liver cancer:3.98e-8 (unfavourable), Endometrial cancer:4.94e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 43.5	Expressed in all		
XPO6	FLJ22519, KIAA0370, RANBP20	ENSG00000169180	Exportin 6	16	28097979-28211920	Predicted intracellular proteins	Evidence at protein level	HPA038246	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Liver cancer:3.68e-4 (unfavourable), Urothelial cancer:8.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 93.8	Expressed in all		
XPOT	XPO3	ENSG00000184575	Exportin for tRNA	12	64404350-64451127	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA048067, HPA057602			Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.41e-12 (unfavourable), Liver cancer:1.81e-7 (unfavourable), Urothelial cancer:5.79e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 83.0	Expressed in all		
XRCC1	RCC	ENSG00000073050	X-ray repair cross complementing 1	19	43543040-43580473	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB005427, HPA006717	Supported		Enhanced	Nucleoplasm	Liver cancer:7.33e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 34.6	Expressed in all		
XRCC2	FANCU	ENSG00000196584	X-ray repair cross complementing 2	7	152644779-152676165	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065153			Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			testis: 3.7	Mixed		
XRCC3		ENSG00000126215	X-ray repair cross complementing 3	14	103697609-103715504	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA062422, HPA068953			Enhanced	Nucleus		Expressed in all	Expressed in all			skin: 46.0	Expressed in all		
XRCC4		ENSG00000152422	X-ray repair cross complementing 4	5	83077498-83353787	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA006801, HPA051538	Enhanced		Supported	Nucleus	Breast cancer:1.80e-5 (unfavourable)	Expressed in all	Mixed			testis: 16.1	Expressed in all		
XRCC5	KARP-1, KU80, Ku86, KUB2	ENSG00000079246	X-ray repair cross complementing 5	2	216107464-216206303	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004468, HPA025813, HPA064685	Supported		Enhanced	Nucleoplasm	Liver cancer:2.10e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 213.3	Expressed in all		
XRCC6	D22S671, D22S731, G22P1, KU70, ML8	ENSG00000196419	X-ray repair cross complementing 6	22	41621119-41664048	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004254, HPA047549, HPA062226	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 396.5	Expressed in all		
XRN1	SEP1	ENSG00000114127	5'-3' exoribonuclease 1	3	142306607-142448062	Predicted intracellular proteins	Evidence at protein level	HPA035005, HPA035006	Approved		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:9.43e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.2	Cell line enriched	5	RH-30: 137.9
XRN2		ENSG00000088930	5'-3' exoribonuclease 2	20	21303304-21389827	Predicted intracellular proteins	Evidence at protein level	HPA047118, HPA050485	Supported		Enhanced	Nucleus<br>Nucleoli	Liver cancer:3.54e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 75.0	Expressed in all		
XRRA1	FLJ00225	ENSG00000166435	X-ray radiation resistance associated 1	11	74807739-74949200	Predicted intracellular proteins	Evidence at protein level	HPA039263			Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Tissue enhanced		testis: 35.5	thyroid gland: 11.8	Cell line enhanced		hTERT-HME1: 27.8
XX-FW81066F1.2		ENSG00000283463		X	149929645-149931287	Predicted intracellular proteins	Evidence at transcript level								Group enriched	33	adrenal gland: 4.8;testis: 17.6	skin: 0.3	Not detected		
XXbac-BPG32J3.22		ENSG00000263020		6	31666102-31673546	Predicted intracellular proteins	Evidence at protein level	HPA005944, HPA048307	Uncertain					Not detected	Tissue enriched	20	bone marrow: 6.6	cerebral cortex: 0.3	Mixed		
XXcos-LUCA11.5		ENSG00000272104		3	50350892-50367923	Predicted intracellular proteins	Evidence at protein level	HPA042817	Uncertain					Not detected	Mixed			small intestine: 6.9	Cell line enhanced		HMC-1: 7.9;Karpas-707: 7.6
XYLB	FLJ10343, FLJ12539	ENSG00000093217	Xylulokinase	3	38346760-38421348	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037863, HPA038415	Uncertain		Approved	Nuclear speckles	Renal cancer:8.57e-4 (favourable)	Mixed	Tissue enhanced		liver: 15.2	kidney: 9.9	Mixed		
YAE1D1	C7orf36, GK003	ENSG00000241127	Yae1 domain containing 1	7	39566376-39610320	Predicted intracellular proteins	Evidence at protein level	HPA019226, HPA031249	Uncertain		Approved	Cytosol	Liver cancer:1.64e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.5	Expressed in all		
YAF2		ENSG00000015153	YY1 associated factor 2	12	42157104-42238349	Predicted intracellular proteins	Evidence at protein level	HPA026867	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 29.5	Expressed in all		
YAP1	YAP65	ENSG00000137693	Yes associated protein 1	11	102110461-102233423	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009370, HPA038885, CAB069915, HPA070359	Enhanced		Supported	Nucleus<br>Nucleoli	Pancreatic cancer:2.03e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 147.1	Mixed		
YARS	tyrRS, YRS, YTS	ENSG00000134684	Tyrosyl-tRNA synthetase	1	32775237-32818153	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017936, HPA018950, HPA018954	Enhanced		Enhanced	Cytosol	Renal cancer:1.02e-11 (unfavourable), Liver cancer:6.97e-11 (unfavourable), Urothelial cancer:6.57e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 81.5	Expressed in all		
YARS2	CGI-04, FLJ13995, mt-TyrRS	ENSG00000139131	Tyrosyl-tRNA synthetase 2	12	32727490-32755902	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038721, HPA057610, HPA074097	Uncertain		Supported	Nuclear bodies<br>Mitochondria	Liver cancer:3.19e-5 (unfavourable)	Expressed in all	Mixed			placenta: 11.1	Expressed in all		
YBEY	C21orf57	ENSG00000182362	YbeY metallopeptidase (putative)	21	46286337-46297751	Predicted intracellular proteins	Evidence at protein level	HPA016593, HPA018162	Uncertain		Enhanced	Nucleoplasm	Breast cancer:5.54e-4 (favourable)	Expressed in all	Expressed in all			testis: 92.0	Mixed		
YBX1	BP-8, CSDA2, CSDB, DBPB, MDR-NF1, NSEP-1, NSEP1, YB-1, YB1	ENSG00000065978	Y-box binding protein 1	1	42682427-42702349	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005875, HPA040304, HPA057159	Supported		Enhanced	Vesicles<br>Cytosol	Liver cancer:9.87e-10 (unfavourable), Renal cancer:3.59e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 1542.9	Expressed in all		
YBX2	Contrin, CSDA3, MSY2	ENSG00000006047	Y-box binding protein 2	17	7288252-7294615	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB012332, HPA053904, HPA056744	Enhanced		Supported	Nucleoli fibrillar center	Endometrial cancer:6.50e-5 (unfavourable)	Mixed	Tissue enriched	64	testis: 385.4	adipose tissue: 6.0	Cell line enhanced		CACO-2: 8.7;MCF7: 14.2;T-47d: 25.9
YBX3	CSDA, CSDA1, dbpA, ZONAB	ENSG00000060138	Y-box binding protein 3	12	10699089-10723312	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034838	Approved		Supported	Cytosol	Renal cancer:6.17e-13 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 1300.9	Mixed		
YDJC		ENSG00000161179	YdjC homolog (bacterial)	22	21628089-21630064	Predicted intracellular proteins	Evidence at protein level	HPA061005			Approved	Nucleoplasm	Urothelial cancer:8.98e-5 (favourable), Liver cancer:9.84e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 2.8	Cell line enhanced		K-562: 71.0
YEATS2	FLJ10201, FLJ12841, FLJ13308, KIAA1197	ENSG00000163872	YEATS domain containing 2	3	183697818-183812625	Predicted intracellular proteins	Evidence at protein level	HPA045891	Uncertain		Approved	Nucleoplasm	Renal cancer:6.90e-9 (unfavourable), Liver cancer:4.82e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 19.5	Expressed in all		
YEATS4	GAS41, NuBI-1, YAF9	ENSG00000127337	YEATS domain containing 4	12	69359703-69390796	Predicted intracellular proteins	Evidence at protein level	HPA072532			Approved	Nucleoplasm<br>Nuclear membrane	Liver cancer:3.52e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 69.3	Expressed in all		
YES1	c-yes, HsT441, Yes	ENSG00000176105	YES proto-oncogene 1, Src family tyrosine kinase	18	721588-812546	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004370, HPA026480	Approved		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 62.0	Mixed		
YJEFN3	FLJ44968, hYjeF_N3-19p13.11	ENSG00000250067	YjeF N-terminal domain containing 3	19	19528861-19537581	Predicted intracellular proteins	Evidence at protein level	HPA060789	Approved		Approved	Mitochondria	Renal cancer:1.30e-7 (unfavourable), Pancreatic cancer:7.25e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 15.6;testis: 5.6	epididymis: 3.0	Cell line enhanced		BEWO: 8.5;HEK93: 9.6
YKT6		ENSG00000106636	YKT6 v-SNARE homolog (S. cerevisiae)	7	44200968-44214294	Predicted intracellular proteins	Evidence at protein level	HPA030817, HPA030818	Approved		Approved	Mitochondria<br>Cytosol	Liver cancer:1.02e-4 (unfavourable), Head and neck cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 61.8	Expressed in all		
YLPM1	C14orf170, PPP1R169, ZAP	ENSG00000119596	YLP motif containing 1	14	74763366-74859435	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048070, HPA061123	Uncertain		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:6.08e-7 (favourable)	Expressed in all	Expressed in all			testis: 39.1	Expressed in all		
YOD1	DKFZp451J1719, DUBA8, OTUD2	ENSG00000180667	YOD1 deubiquitinase	1	207043849-207052980	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028400, HPA028439	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		bone marrow: 37.1	esophagus: 27.8	Cell line enhanced		HEL: 78.5;K-562: 55.5
YPEL1		ENSG00000100027	Yippee like 1	22	21697544-21735834	Predicted intracellular proteins	Evidence at transcript level	HPA030501, HPA045621	Uncertain				Endometrial cancer:3.09e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 36.6	cerebral cortex: 16.2	Cell line enhanced		AF22: 9.6;MOLT-4: 10.8;REH: 10.9;SCLC-21H: 13.5
YPEL2	FKSG4	ENSG00000175155	Yippee like 2	17	59331689-59401729	Predicted intracellular proteins	Evidence at protein level	HPA030501, HPA045621	Uncertain				Endometrial cancer:6.73e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 26.2	Cell line enhanced		HDLM-2: 26.2
YPEL3	MGC10500	ENSG00000090238	Yippee like 3	16	30092314-30096915	Predicted intracellular proteins	Evidence at transcript level	HPA030501, HPA045621	Uncertain				Head and neck cancer:1.09e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 117.0	Mixed		
YPEL4	FLJ30213	ENSG00000166793	Yippee like 4	11	57645087-57649944	Predicted intracellular proteins	Evidence at transcript level	HPA045621	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 19.0	ovary: 4.3	Cell line enhanced		AF22: 3.2;SK-MEL-30: 3.1
YPEL5	CGI-127	ENSG00000119801	Yippee like 5	2	30146941-30160533	Predicted intracellular proteins	Evidence at protein level	HPA042809	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 271.5	Expressed in all		
YRDC	FLJ23476, IRIP, SUA5	ENSG00000196449	YrdC N6-threonylcarbamoyltransferase domain containing	1	37802944-37808185	Predicted intracellular proteins	Evidence at protein level	HPA030147	Approved		Approved	Mitochondria	Liver cancer:1.83e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 31.7	Expressed in all		
YTHDC1	KIAA1966, YT521, YT521-B	ENSG00000083896	YTH domain containing 1	4	68310387-68350089	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036462	Supported		Approved	Nucleoplasm<br>Plasma membrane	Urothelial cancer:7.29e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 75.1	Expressed in all		
YTHDC2	DKFZp564A186, FLJ10053, FLJ2194	ENSG00000047188	YTH domain containing 2	5	113513683-113595285	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037364, HPA072678	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytoplasmic bodies	Colorectal cancer:1.82e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.0	Expressed in all		
YTHDF1	C20orf21, FLJ20391	ENSG00000149658	YTH N6-methyladenosine RNA binding protein 1	20	63195429-63216234	Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.65e-5 (unfavourable), Breast cancer:7.96e-4 (unfavourable), Thyroid cancer:9.60e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 42.4	Expressed in all		
YTHDF2	CAHL, HGRG8, NY-REN-2	ENSG00000198492	YTH N6-methyladenosine RNA binding protein 2	1	28736621-28769775	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030063, HPA054080, HPA059621	Approved		Enhanced	Cytosol<br>Cytoplasmic bodies	Liver cancer:6.14e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 58.9	Expressed in all		
YTHDF3	FLJ31657	ENSG00000185728	YTH N6-methyladenosine RNA binding protein 3	8	63168553-63212786	Predicted intracellular proteins	Evidence at protein level	HPA048703			Approved	Nuclear membrane<br>Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 59.1	Expressed in all		
YWHAB	YWHAA	ENSG00000166913	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta	20	44885676-44908532	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003759, HPA007925, HPA011212	Enhanced		Supported	Cytosol	Liver cancer:1.91e-6 (unfavourable), Renal cancer:2.52e-5 (favourable), Endometrial cancer:5.46e-4 (unfavourable), Lung cancer:6.01e-4 (unfavourable), Head and neck cancer:6.14e-4 (unfavourable), Breast cancer:9.18e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 445.0	Expressed in all		
YWHAE	FLJ45465	ENSG00000108953	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	17	1344272-1400378	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008445, CAB016200, CAB021109, CAB047350	Approved		Uncertain	Cytosol	Endometrial cancer:6.48e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 451.5	Expressed in all		
YWHAG	PPP1R170	ENSG00000170027	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma	7	76326794-76359031	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013274, CAB018389, HPA026918	Approved	Supported			Renal cancer:4.01e-4 (unfavourable), Cervical cancer:4.53e-4 (unfavourable), Lung cancer:5.34e-4 (unfavourable), Pancreatic cancer:7.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 611.5	Expressed in all		
YWHAH	YWHA1	ENSG00000128245	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta	22	31944461-31957603	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025918	Uncertain				Liver cancer:1.59e-5 (unfavourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 896.7	lung: 137.7	Expressed in all		
YWHAQ	14-3-3, HS1	ENSG00000134308	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta	2	9583972-9631014	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007925, CAB010286	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.83e-6 (unfavourable), Endometrial cancer:8.20e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 398.1	Expressed in all		
YWHAZ	14-3-3-zeta, KCIP-1, YWHAD	ENSG00000164924	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	8	100916525-100953388	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005065	Approved				Renal cancer:2.03e-6 (unfavourable), Pancreatic cancer:1.20e-5 (unfavourable), Liver cancer:2.28e-5 (unfavourable), Endometrial cancer:3.91e-4 (unfavourable), Lung cancer:3.93e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 925.0	Expressed in all		
YY1	DELTA, INO80S, NF-E1, UCRBP, YIN-YANG-1	ENSG00000100811	YY1 transcription factor	14	100238298-100282792	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001119, CAB009392	Supported		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Vesicles	Liver cancer:3.44e-4 (unfavourable), Endometrial cancer:6.13e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 65.8	Expressed in all		
YY1AP1	HCCA2, YAP, YY1AP	ENSG00000163374	YY1 associated protein 1	1	155659443-155689000	Predicted intracellular proteins	Evidence at protein level	HPA006986, HPA064249	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:2.01e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 130.2	Expressed in all		
YY2	ZNF631	ENSG00000230797	YY2 transcription factor	X	21855987-21858727	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001119, HPA030335	Enhanced		Approved	Nuclear bodies		Mixed	Tissue enhanced		testis: 10.9	endometrium: 2.8	Mixed		
ZADH2	MGC45594	ENSG00000180011	Zinc binding alcohol dehydrogenase domain containing 2	18	75195108-75209348	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021468, HPA053646	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Renal cancer:1.02e-6 (favourable), Thyroid cancer:1.94e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 52.3	Expressed in all		
ZAP70	SRK, STD, ZAP-70	ENSG00000115085	Zeta chain of T-cell receptor associated protein kinase 70	2	97713560-97739862	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002625, HPA003134	Enhanced				Renal cancer:3.02e-8 (unfavourable), Endometrial cancer:9.66e-8 (favourable), Head and neck cancer:3.93e-6 (favourable), Cervical cancer:6.89e-5 (favourable)	Mixed	Tissue enhanced		appendix: 36.2;lymph node: 64.3;spleen: 37.7	tonsil: 16.2	Cell line enriched	16	MOLT-4: 144.9
ZAR1	Z3CXXC6	ENSG00000182223	Zygote arrest 1	4	48490252-48494389	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 1.1	bone marrow: 0.2	Not detected		
ZAR1L	Z3CXXC7	ENSG00000189167	Zygote arrest 1-like	13	32303700-32315344	Predicted intracellular proteins	Evidence at transcript level	HPA041319	Uncertain					Not detected	Not detected			testis: 0.7	Not detected		
ZBBX	FLJ23049	ENSG00000169064	Zinc finger B-box domain containing	3	167240287-167381346	Predicted intracellular proteins	Evidence at protein level	HPA036327, HPA036328	Enhanced					Tissue enhanced	Group enriched	10	fallopian tube: 38.1;testis: 67.6	lung: 5.5	Not detected		
ZBED1	ALTE, DREF, hDREF, KIAA0785, TRAMP	ENSG00000214717	Zinc finger BED-type containing 1	X	2486414-2500967	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 24.6	Cell line enhanced		BEWO: 87.7
ZBED2	MGC10796	ENSG00000177494	Zinc finger BED-type containing 2	3	111592900-111595443	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029786			Approved	Nuclear bodies<br>Mitochondria<br>Cytosol	Pancreatic cancer:8.83e-4 (unfavourable)	Tissue enriched	Tissue enhanced		fallopian tube: 30.3;thyroid gland: 113.1	lung: 14.9	Cell line enhanced		CAPAN-2: 45.9;EFO-21: 33.6;HaCaT: 44.7;HBEC3-KT: 81.4;RPTEC TERT1: 56.1
ZBED3	MGC15435	ENSG00000132846	Zinc finger BED-type containing 3	5	77072072-77087323	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055995	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:1.68e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 18.8	Mixed		
ZBED4	KIAA0637	ENSG00000100426	Zinc finger BED-type containing 4	22	49853842-49890078	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045341	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 7.7	Expressed in all		
ZBED5	Buster1	ENSG00000236287	Zinc finger BED-type containing 5	11	10812074-10858796	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048472, HPA050994	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Golgi apparatus	Liver cancer:2.19e-5 (unfavourable), Urothelial cancer:3.87e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 90.6	Expressed in all		
ZBED6		ENSG00000257315	Zinc finger BED-type containing 6	1	203795714-203854999	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026439, HPA028490, HPA028526, HPA068807	Approved		Approved	Nucleoplasm<br>Microtubule organizing center		Expressed in all	Mixed			cervix, uterine: 14.3	Mixed		
ZBED6CL	C7orf29	ENSG00000188707	ZBED6 C-terminal like	7	150329789-150332721	Predicted intracellular proteins	Evidence at transcript level	HPA019724, HPA055805	Approved		Approved	Nuclear membrane<br>Vesicles	Renal cancer:1.38e-5 (unfavourable), Pancreatic cancer:2.44e-5 (favourable), Glioma:5.65e-5 (unfavourable), Breast cancer:9.48e-5 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 31.7;parathyroid gland: 30.4	lymph node: 9.8	Cell line enhanced		HDLM-2: 80.9;K-562: 33.8
ZBED8	Buster3, C5orf54	ENSG00000221886	Zinc finger BED-type containing 8	5	160393148-160400097	Predicted intracellular proteins	Evidence at protein level	HPA045445, HPA055817	Approved		Enhanced	Nucleoplasm	Pancreatic cancer:3.72e-4 (favourable)	Expressed in all	Mixed			ovary: 13.3	Mixed		
ZBED9	Buster4, FLJ31087, KIAA1925, SCAND3, ZFP38-L, ZNF305P2, ZNF452	ENSG00000232040	Zinc finger BED-type containing 9	6	28571630-28616212	Predicted intracellular proteins	Evidence at protein level	HPA007246	Uncertain		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Mixed	Tissue enhanced		testis: 18.8	epididymis: 4.6	Cell line enhanced		EFO-21: 5.6;K-562: 9.2
ZBP1	C20orf183, DAI, dJ718J7.3, DLM-1, DLM1	ENSG00000124256	Z-DNA binding protein 1	20	57603846-57620576	Predicted intracellular proteins	Evidence at protein level	HPA041256	Enhanced					Mixed	Mixed			spleen: 29.8	Cell line enhanced		Karpas-707: 24.3;U-266/70: 12.6;U-266/84: 16.2
ZBTB1	KIAA0997, ZNF909	ENSG00000126804	Zinc finger and BTB domain containing 1	14	64503712-64533690	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050516	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Head and neck cancer:4.92e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 53.5	Expressed in all		
ZBTB10	FLJ12752, RINZF	ENSG00000205189	Zinc finger and BTB domain containing 10	8	80485619-80526265	Predicted intracellular proteins	Evidence at protein level	HPA021554, HPA050569	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.52e-4 (favourable)	Expressed in all	Expressed in all			placenta: 25.2	Mixed		
ZBTB12	C6orf46, D6S59E, G10, NG35	ENSG00000204366	Zinc finger and BTB domain containing 12	6	31899607-31901992	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047161	Approved				Renal cancer:1.52e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 1.7	Mixed		
ZBTB14	ZFP161, ZNF478	ENSG00000198081	Zinc finger and BTB domain containing 14	18	5289019-5297053	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050758, HPA070819	Uncertain		Enhanced	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 28.9	Expressed in all		
ZBTB16	PLZF, ZNF145	ENSG00000109906	Zinc finger and BTB domain containing 16	11	114059593-114250676	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001499, CAB004540	Uncertain				Renal cancer:2.21e-4 (favourable)	Tissue enhanced	Mixed			ovary: 59.5	Cell line enhanced		ASC diff: 40.2;ASC TERT1: 23.6;HEL: 33.4;HHSteC: 21.2;HSkMC: 19.6;hTCEpi: 18.6;hTERT-HME1: 17.2
ZBTB17	MIZ1, pHZ-67, ZNF151, ZNF60	ENSG00000116809	Zinc finger and BTB domain containing 17	1	15941869-15976132	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005789	Approved				Liver cancer:2.38e-6 (unfavourable), Renal cancer:3.27e-5 (unfavourable), Urothelial cancer:2.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 21.9	Expressed in all		
ZBTB18	C2H2-171, RP58, TAZ-1, ZNF238	ENSG00000179456	Zinc finger and BTB domain containing 18	1	244048939-244057476	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Urothelial cancer:6.78e-6 (favourable), Endometrial cancer:1.34e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 76.3	Mixed		
ZBTB2	bA351K16.2, KIAA1483, ZNF437	ENSG00000181472	Zinc finger and BTB domain containing 2	6	151364117-151391548	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023136, HPA023137, HPA023458, HPA023487	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:9.36e-6 (unfavourable), Liver cancer:1.21e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.0	Expressed in all		
ZBTB20	DKFZp566F123, DPZF, ODA-8S, ZNF288	ENSG00000181722	Zinc finger and BTB domain containing 20	3	114314501-115147271	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015551, HPA016815	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Tissue enhanced	Mixed			testis: 17.4	Mixed		
ZBTB21	KIAA1227, ZNF295	ENSG00000173276	Zinc finger and BTB domain containing 21	21	41986831-42010387	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024655, HPA031757, HPA031758	Enhanced		Enhanced	Nucleus		Expressed in all	Mixed			adrenal gland: 47.6	Expressed in all		
ZBTB22	BING1, fru, fruitless, ZBTB22A, ZNF297, ZNF297A	ENSG00000236104	Zinc finger and BTB domain containing 22	6	33314406-33317942	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043848			Approved	Nucleoplasm		Expressed in all	Tissue enhanced		parathyroid gland: 28.9	epididymis: 11.8	Mixed		
ZBTB24	BIF1, KIAA0441, PATZ2, ZNF450	ENSG00000112365	Zinc finger and BTB domain containing 24	6	109462594-109483237	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017872, HPA049003	Uncertain		Approved	Nucleus<br>Cytokinetic bridge<br>Centrosome	Liver cancer:3.15e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.9	Expressed in all		
ZBTB25	C14orf51, KUP, ZNF46	ENSG00000089775	Zinc finger and BTB domain containing 25	14	64449106-64505213	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054699	Uncertain		Enhanced	Nucleoplasm	Renal cancer:3.56e-6 (unfavourable)	Expressed in all	Mixed			thyroid gland: 14.8	Expressed in all		
ZBTB26	ZNF481	ENSG00000171448	Zinc finger and BTB domain containing 26	9	122915566-122931500	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021444	Uncertain					Expressed in all	Mixed			testis: 18.2	Expressed in all		
ZBTB3	FLJ23392	ENSG00000185670	Zinc finger and BTB domain containing 3	11	62748319-62754188	Predicted intracellular proteins	Evidence at protein level	HPA035321, HPA035322	Enhanced		Approved	Mitochondria	Renal cancer:1.65e-5 (favourable), Stomach cancer:9.98e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 7.1	Expressed in all		
ZBTB32	FAXF, FAZF, Rog, TZFP, ZNF538	ENSG00000011590	Zinc finger and BTB domain containing 32	19	35704527-35717038	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA076730	Enhanced					Mixed	Tissue enriched	11	testis: 43.3	lymph node: 3.9	Cell line enhanced		HDLM-2: 3.9;hTEC/SVTERT24-B: 2.0
ZBTB33	kaiso, WUGSC:H_DJ525N14.1, ZNF-kaiso, ZNF348	ENSG00000177485	Zinc finger and BTB domain containing 33	X	120250752-120258398	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000755, CAB001980, HPA005732	Approved		Enhanced	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 23.4	Expressed in all		
ZBTB34	KIAA1993, MGC24652, ZNF918	ENSG00000177125	Zinc finger and BTB domain containing 34	9	126860665-126885878	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023893	Approved		Supported	Nucleoplasm		Expressed in all	Mixed			placenta: 9.6	Expressed in all		
ZBTB37	MGC2629, ZNF908	ENSG00000185278	Zinc finger and BTB domain containing 37	1	173868082-173903549	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023438	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Mixed	Tissue enhanced		testis: 17.0	spleen: 5.3	Mixed		
ZBTB38	CIBZ, FLJ35036, PPP1R171, ZNF921	ENSG00000177311	Zinc finger and BTB domain containing 38	3	141324213-141449792	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA014865, HPA059378			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 126.8	Cell line enhanced		RPMI-8226: 273.3
ZBTB39	KIAA0352, ZNF922	ENSG00000166860	Zinc finger and BTB domain containing 39	12	56998834-57006446	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016866, HPA020306	Uncertain		Approved	Vesicles		Expressed in all	Mixed			testis: 13.4	Expressed in all		
ZBTB4	KAISO-L1, KIAA1538, ZNF903	ENSG00000174282	Zinc finger and BTB domain containing 4	17	7459366-7484263	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB008980, HPA064763	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.65e-9 (favourable), Pancreatic cancer:2.53e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.8	Mixed		
ZBTB40	KIAA0478, ZNF923	ENSG00000184677	Zinc finger and BTB domain containing 40	1	22451851-22531157	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042386			Approved	Nucleus	Liver cancer:7.78e-8 (unfavourable), Pancreatic cancer:4.12e-5 (favourable), Head and neck cancer:2.01e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 20.8	Mixed		
ZBTB41	DKFZp686C06120, FLJ36199, FRBZ1, ZNF924	ENSG00000177888	Zinc finger and BTB domain containing 41	1	197153680-197200542	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034841, HPA034842	Uncertain		Approved	Nucleus<br>Nuclear membrane<br>Cytosol	Liver cancer:5.86e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 12.7	Expressed in all		
ZBTB42	ZNF925	ENSG00000179627	Zinc finger and BTB domain containing 42	14	104800596-104804712	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000703, HPA066961	Uncertain		Supported	Nucleus	Renal cancer:2.30e-9 (favourable)	Expressed in all	Mixed			prostate: 8.9	Cell line enhanced		HDLM-2: 17.6;MCF7: 24.3;T-47d: 24.0
ZBTB43	FLJ22470, KIAA0414, ZBTB22B, ZNF-X, ZNF297B	ENSG00000169155	Zinc finger and BTB domain containing 43	9	126805006-126838210	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016825	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:8.73e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 38.8	Expressed in all		
ZBTB44	BTBD15, HSPC063, ZNF851	ENSG00000196323	Zinc finger and BTB domain containing 44	11	130226677-130314686	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052589	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 75.4	Expressed in all		
ZBTB45	FLJ14486, ZNF499	ENSG00000119574	Zinc finger and BTB domain containing 45	19	58513530-58538911	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA035754	Uncertain		Approved	Cytosol	Renal cancer:5.38e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 10.5	Expressed in all		
ZBTB46	BTBD4, BZEL, FLJ13502, RINZF, ZNF340	ENSG00000130584	Zinc finger and BTB domain containing 46	20	63743666-63831244	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA013997	Uncertain		Approved	Nucleus	Pancreatic cancer:2.17e-4 (favourable)	Expressed in all	Mixed			spleen: 13.3	Mixed		
ZBTB47	DKFZp434N0615, KIAA1190, ZNF651	ENSG00000114853	Zinc finger and BTB domain containing 47	3	42653684-42665854	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA074057			Approved	Nucleoplasm	Renal cancer:7.96e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 50.0	Cell line enhanced		ASC diff: 42.2
ZBTB48	HKR3, ZNF855	ENSG00000204859	Zinc finger and BTB domain containing 48	1	6580001-6589280	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030417	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.19e-6 (favourable), Cervical cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.9	Expressed in all		
ZBTB49	FLJ38559, ZNF509	ENSG00000168826	Zinc finger and BTB domain containing 49	4	4290251-4321786	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024450	Approved		Approved	Nucleoplasm<br>Microtubules<br>Cytosol	Urothelial cancer:2.88e-5 (favourable), Pancreatic cancer:1.76e-4 (favourable), Head and neck cancer:5.24e-4 (favourable)	Expressed in all	Mixed			testis: 7.4	Expressed in all		
ZBTB5	KIAA0354	ENSG00000168795	Zinc finger and BTB domain containing 5	9	37438114-37465399	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021521	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 17.6	Expressed in all		
ZBTB6	ZID, ZNF482	ENSG00000186130	Zinc finger and BTB domain containing 6	9	122908056-122913330	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054111, HPA076894	Approved		Approved	Nucleoplasm<br>Mitochondria	Glioma:9.75e-6 (favourable), Renal cancer:5.08e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 12.6	Expressed in all		
ZBTB7A	DKFZp547O146, FBI-1, LRF, pokemon, ZBTB7, ZNF857A	ENSG00000178951	Zinc finger and BTB domain containing 7A	19	4044364-4066945	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB037214, CAB037285, HPA046387	Enhanced		Approved	Nucleoplasm	Renal cancer:1.34e-6 (favourable), Endometrial cancer:6.50e-6 (favourable), Stomach cancer:1.79e-4 (favourable), Pancreatic cancer:2.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 23.9	Expressed in all		
ZBTB7B	c-Krox, hcKrox, ZBTB15, ZFP67, ZNF857B	ENSG00000160685	Zinc finger and BTB domain containing 7B	1	155002630-155018522	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006811, HPA025820	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			skin: 89.4	Mixed		
ZBTB7C	ZBTB36, ZNF857C	ENSG00000184828	Zinc finger and BTB domain containing 7C	18	48026673-48410752	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Colorectal cancer:1.59e-4 (favourable)	Mixed	Mixed			esophagus: 31.7	Cell line enhanced		RPMI-8226: 6.7;RT4: 34.0;SCLC-21H: 6.5;SH-SY5Y: 7.3
ZBTB8A	BOZF1, FLJ90065, ZBTB8, ZNF916A	ENSG00000160062	Zinc finger and BTB domain containing 8A	1	32539427-32605939	Predicted intracellular proteins	Evidence at protein level	HPA031768, HPA031769, HPA031770	Approved		Approved	Nuclear speckles<br>Focal adhesion sites		Expressed in all	Mixed			endometrium: 10.3	Mixed		
ZBTB8B	DKFZp547H154, RP1-27O5.1, ZNF916B	ENSG00000273274	Zinc finger and BTB domain containing 8B	1	32465069-32496686	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055553	Approved					Tissue enhanced	Not detected			cerebral cortex: 0.6	Cell line enhanced		SCLC-21H: 1.1
ZBTB8OS	ARCH	ENSG00000176261	Zinc finger and BTB domain containing 8 opposite strand	1	32600172-32650903	Predicted intracellular proteins	Evidence at protein level	HPA046315	Approved		Approved	Plasma membrane	Renal cancer:7.11e-8 (unfavourable), Liver cancer:4.25e-4 (unfavourable), Melanoma:8.56e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 43.3	Expressed in all		
ZBTB9	MGC23166, ZNF919	ENSG00000213588	Zinc finger and BTB domain containing 9	6	33453970-33457548	Predicted intracellular proteins	Evidence at protein level	HPA036767	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Not detected	Mixed			tonsil: 2.6	Cell line enhanced		BEWO: 9.8;U-698: 8.1
ZC2HC1A	C8orf70, CGI-62, FAM164A	ENSG00000104427	Zinc finger C2HC-type containing 1A	8	78666047-78719765	Predicted intracellular proteins	Evidence at protein level	HPA024726	Approved		Approved	Actin filaments<br>Cytosol	Stomach cancer:5.85e-4 (unfavourable), Ovarian cancer:9.00e-4 (unfavourable)	Expressed in all	Mixed			skin: 52.9	Cell line enhanced		SK-BR-3: 58.7
ZC2HC1B	C6orf94, dJ468K18.5, FAM164B	ENSG00000118491	Zinc finger C2HC-type containing 1B	6	143864436-143938356	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	74	testis: 23.4	skin: 0.3	Not detected		
ZC2HC1C	C14orf140, FAM164C	ENSG00000119703	Zinc finger C2HC-type containing 1C	14	75064170-75079987	Predicted intracellular proteins	Evidence at protein level	HPA050928, HPA065062	Enhanced		Approved	Nuclear speckles<br>Mitochondria	Renal cancer:4.63e-13 (favourable)	Mixed	Tissue enhanced		testis: 118.3	epididymis: 34.2	Mixed		
ZC3H10	FLJ14451, ZC3HDC10	ENSG00000135482	Zinc finger CCCH-type containing 10	12	56118159-56127514	Predicted intracellular proteins	Evidence at protein level	HPA039236, HPA062265	Uncertain		Approved	Vesicles		Expressed in all	Mixed			testis: 10.3	Expressed in all		
ZC3H11A	KIAA0663, ZC3HDC11A	ENSG00000058673	Zinc finger CCCH-type containing 11A	1	203795654-203854999	Predicted intracellular proteins	Evidence at protein level	HPA026439, HPA028490, HPA028526	Approved		Approved	Nuclear speckles	Renal cancer:5.58e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.6	Expressed in all		
ZC3H11B	ZC3HDC11B	ENSG00000215817	Zinc finger CCCH-type containing 11B pseudogene	1	219608347-219613145	Predicted intracellular proteins	Evidence at protein level	HPA026439, HPA028490, HPA028526	Uncertain		Approved	Nuclear speckles		Not detected	Tissue enriched	13	testis: 8.1	skin: 0.6	Not detected		
ZC3H12A	FLJ23231, MCPIP1	ENSG00000163874	Zinc finger CCCH-type containing 12A	1	37474552-37484379	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032052, HPA032053	Uncertain		Supported	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:5.95e-5 (unfavourable), Endometrial cancer:9.67e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 84.3	gallbladder: 55.5	Cell line enhanced		RT4: 48.1
ZC3H12B	CXorf32, MCPIP2	ENSG00000102053	Zinc finger CCCH-type containing 12B	X	65366638-65507887	Predicted intracellular proteins	Evidence at transcript level	HPA000836	Uncertain		Approved	Endoplasmic reticulum<br>Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		cerebral cortex: 4.6	endometrium: 2.2	Cell line enhanced		AF22: 2.1
ZC3H12C	KIAA1726, MCPIP3	ENSG00000149289	Zinc finger CCCH-type containing 12C	11	110093361-110171841	Predicted intracellular proteins	Evidence at protein level	HPA038836, HPA038837	Approved		Approved	Nuclear membrane<br>Golgi apparatus	Renal cancer:9.90e-6 (favourable)	Expressed in all	Mixed			thyroid gland: 13.6	Mixed		
ZC3H12D	C6orf95, dJ281H8.1, MCPIP4	ENSG00000178199	Zinc finger CCCH-type containing 12D	6	149446795-149485061	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036897	Uncertain		Supported	Nucleoplasm<br>Cytoplasmic bodies		Mixed	Tissue enhanced		appendix: 9.6;lymph node: 11.5;tonsil: 11.6	spleen: 5.9	Cell line enhanced		Daudi: 5.7;HDLM-2: 31.7;REH: 6.4
ZC3H13	DKFZp434D1812, KIAA0853	ENSG00000123200	Zinc finger CCCH-type containing 13	13	45954465-46052759	Predicted intracellular proteins	Evidence at protein level	HPA039340, HPA040140, HPA047806	Uncertain		Approved	Nuclear membrane<br>Actin filaments	Renal cancer:2.69e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 33.5	Expressed in all		
ZC3H14	FLJ11806, NY-REN-37, UKp68	ENSG00000100722	Zinc finger CCCH-type containing 14	14	88562909-88627596	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049798, HPA053510	Enhanced		Enhanced	Nuclear speckles	Renal cancer:7.08e-4 (favourable)	Expressed in all	Expressed in all			testis: 327.4	Expressed in all		
ZC3H15	LEREPO4	ENSG00000065548	Zinc finger CCCH-type containing 15	2	186486156-186509363	Predicted intracellular proteins	Evidence at protein level	HPA031099, HPA031100, HPA031101	Enhanced		Enhanced	Cytosol	Liver cancer:1.48e-7 (unfavourable), Cervical cancer:6.45e-5 (unfavourable), Ovarian cancer:3.98e-4 (favourable), Pancreatic cancer:9.75e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 78.5	Expressed in all		
ZC3H18	NHN1	ENSG00000158545	Zinc finger CCCH-type containing 18	16	88570381-88631966	Predicted intracellular proteins	Evidence at protein level	HPA040847, HPA041327	Enhanced		Enhanced	Nuclear speckles	Renal cancer:3.68e-4 (favourable), Liver cancer:4.06e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 30.8	Expressed in all		
ZC3H3	KIAA0150, ZC3HDC3	ENSG00000014164	Zinc finger CCCH-type containing 3	8	143437655-143541453	Predicted intracellular proteins	Evidence at protein level	HPA023658, HPA050577	Uncertain		Uncertain	Nucleoplasm<br>Golgi apparatus	Renal cancer:4.38e-7 (unfavourable), Liver cancer:4.06e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 13.5	Expressed in all		
ZC3H4	C19orf7, KIAA1064	ENSG00000130749	Zinc finger CCCH-type containing 4	19	47064187-47113752	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040934, HPA041068	Supported		Enhanced	Nucleoplasm<br>Cytosol	Urothelial cancer:2.23e-4 (favourable)	Expressed in all	Expressed in all			spleen: 13.5	Expressed in all		
ZC3H6	FLJ41410, FLJ45877, KIAA2035, ZC3HDC6	ENSG00000188177	Zinc finger CCCH-type containing 6	2	112275594-112340063	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036019, HPA036020, HPA076065	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			ovary: 7.6	Mixed		
ZC3H7A	FLJ20318, HSPC055, ZC3H7, ZC3HDC7	ENSG00000122299	Zinc finger CCCH-type containing 7A	16	11750586-11797267	Predicted intracellular proteins	Evidence at protein level	HPA040808, HPA059849	Uncertain		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 47.0	Expressed in all		
ZC3H7B	DKFZp434K0920, FLJ13787, KIAA1031, RoXaN	ENSG00000100403	Zinc finger CCCH-type containing 7B	22	41301522-41360147	Predicted intracellular proteins	Evidence at protein level	HPA001784	Uncertain		Uncertain	Cytosol	Renal cancer:5.43e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 81.6	Expressed in all		
ZC3H8	Fliz1, ZC3HDC8	ENSG00000144161	Zinc finger CCCH-type containing 8	2	112211525-112255136	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034803, HPA034804	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:1.12e-6 (unfavourable), Renal cancer:1.89e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 16.2	Expressed in all		
ZC3HAV1	FLB6421, FLJ13288, MGC48898, PARP13, ZAP, ZC3H2, ZC3HDC2	ENSG00000105939	Zinc finger CCCH-type containing, antiviral 1	7	139043520-139109719	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047818, HPA059096	Approved		Enhanced	Golgi apparatus<br>Cytosol	Liver cancer:8.77e-7 (unfavourable), Stomach cancer:6.86e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 54.6	Expressed in all		
ZC3HAV1L	C7orf39, MGC14289	ENSG00000146858	Zinc finger CCCH-type containing, antiviral 1 like	7	139025706-139036029	Predicted intracellular proteins	Evidence at protein level	HPA020386, HPA050741	Uncertain		Enhanced	Cytosol	Cervical cancer:7.35e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 14.2	Mixed		
ZC3HC1	NIPA	ENSG00000091732	Zinc finger C3HC-type containing 1	7	130018286-130051451	Predicted intracellular proteins	Evidence at protein level	HPA019089, HPA024023	Enhanced		Supported	Nucleus<br>Nuclear membrane	Liver cancer:1.02e-6 (unfavourable), Endometrial cancer:3.36e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.5	Expressed in all		
ZC4H2	HCA127, KIAA1166, WWS	ENSG00000126970	Zinc finger C4H2-type containing	X	64915802-65034713	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049584	Approved		Approved	Vesicles<br>Microtubules	Thyroid cancer:3.51e-5 (unfavourable)	Mixed	Mixed			parathyroid gland: 17.5	Cell line enhanced		NTERA-2: 51.9;REH: 36.2
ZCCHC10	FLJ20094	ENSG00000155329	Zinc finger CCHC-type containing 10	5	132996985-133026604	Predicted intracellular proteins	Evidence at protein level	HPA038944	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 43.5	Expressed in all		
ZCCHC11	KIAA0191, PAPD3, TUT4	ENSG00000134744	Zinc finger CCHC-type containing 11	1	52408282-52553487	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027412, HPA027973	Supported		Supported	Nucleoli<br>Cytosol	Liver cancer:9.00e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.8	Mixed		
ZCCHC12	FLJ16123, PNMA7A, SIZN, SIZN1	ENSG00000174460	Zinc finger CCHC-type containing 12	X	118823790-118826968	Predicted intracellular proteins	Evidence at protein level	HPA031016, HPA034940	Uncertain		Approved	Nuclear bodies	Thyroid cancer:3.42e-5 (favourable)	Tissue enriched	Group enriched	8	endometrium: 167.0;fallopian tube: 184.1;smooth muscle: 203.5	cerebral cortex: 24.3	Cell line enhanced		HAP1: 4.0;HEK93: 9.1;NTERA-2: 3.1;SH-SY5Y: 2.6
ZCCHC13	4930513O09RIK, Cnbp2, ZNF9L	ENSG00000187969	Zinc finger CCHC-type containing 13	X	74304190-74305031	Predicted intracellular proteins	Evidence at protein level	HPA003382	Enhanced					Not detected	Tissue enriched	234	testis: 23.3	all non-specific tissues: 0.0	Not detected		
ZCCHC14	BDG29, MGC14139	ENSG00000140948	Zinc finger CCHC-type containing 14	16	87406246-87492045	Predicted intracellular proteins	Evidence at protein level	HPA014122			Uncertain	Nuclear membrane	Renal cancer:1.47e-14 (favourable)	Expressed in all	Expressed in all			testis: 61.6	Mixed		
ZCCHC16	FLJ46608, Mar4, Mart4	ENSG00000187823	Zinc finger CCHC-type containing 16	X	112454500-112457112	Predicted intracellular proteins	Evidence at transcript level	HPA003272	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Group enriched	Not detected			kidney: 0.8	Not detected		
ZCCHC17	HSPC251, pNO40, PS1D	ENSG00000121766	Zinc finger CCHC-type containing 17	1	31296982-31364953	Predicted intracellular proteins	Evidence at protein level	HPA053727	Approved		Supported	Nuclear speckles	Liver cancer:3.27e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 78.7	Expressed in all		
ZCCHC18	PNMA7B, SIZN2	ENSG00000166707	Zinc finger CCHC-type containing 18	X	104112131-104115846	Predicted intracellular proteins	Evidence at transcript level	HPA034940	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 5.6	ovary: 4.2	Cell line enhanced		Karpas-707: 3.3;SH-SY5Y: 3.2
ZCCHC2	C18orf49, FLJ20222, FLJ20281, KIAA1744	ENSG00000141664	Zinc finger CCHC-type containing 2	18	62523007-62587709	Predicted intracellular proteins	Evidence at protein level	HPA040943	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			testis: 22.4	Mixed		
ZCCHC24	C10orf56, FLJ90798, Z3CXXC8	ENSG00000165424	Zinc finger CCHC-type containing 24	10	79382325-79445627	Predicted intracellular proteins	Evidence at protein level	HPA038348	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:5.35e-6 (unfavourable), Ovarian cancer:3.76e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 70.6	Cell line enhanced		ASC diff: 92.6;ASC TERT1: 80.6;BJ hTERT+: 74.4;HSkMC: 87.6
ZCCHC3	C20orf99, dJ1103G7.7	ENSG00000247315	Zinc finger CCHC-type containing 3	20	296968-300321	Predicted intracellular proteins	Evidence at protein level	HPA042972			Approved	Vesicles	Pancreatic cancer:1.29e-4 (favourable)	Expressed in all	Expressed in all			placenta: 23.2	Expressed in all		
ZCCHC4	FLJ23024, HSPC052, ZGRF4	ENSG00000168228	Zinc finger CCHC-type containing 4	4	25312785-25370383	Predicted intracellular proteins	Evidence at protein level	HPA035575, HPA035576	Uncertain		Approved	Nuclear speckles<br>Golgi apparatus		Expressed in all	Mixed			testis: 8.2	Expressed in all		
ZCCHC5	FLJ38865, Mar3, Mart3, ZHC5	ENSG00000179300	Zinc finger CCHC-type containing 5	X	78656069-78659328	Predicted intracellular proteins	Evidence at transcript level	HPA051991, HPA053174, HPA075136	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane		Not detected	Not detected			endometrium: 0.8	Cell line enhanced		fHDF/TERT166: 1.4;HBF TERT88: 2.3;hTEC/SVTERT24-B: 1.7;RH-30: 2.0;U-251 MG: 1.3
ZCCHC6	FLJ13409, KIAA1711, PAPD6, TUT7	ENSG00000083223	Zinc finger CCHC-type containing 6	9	86287733-86354454	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020615, HPA020620	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			prostate: 36.1	Expressed in all		
ZCCHC7	AIR1, FLJ22611	ENSG00000147905	Zinc finger CCHC-type containing 7	9	37120539-37358149	Predicted intracellular proteins	Evidence at protein level	HPA020600, HPA021088, HPA029522	Uncertain		Enhanced	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 28.4	Expressed in all		
ZCCHC8	DKFZp434E2220	ENSG00000033030	Zinc finger CCHC-type containing 8	12	122471600-122501073	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA037483, HPA037484	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.36e-4 (unfavourable), Melanoma:7.40e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 33.1	Expressed in all		
ZCCHC9	DKFZp761J139, PPP1R41	ENSG00000131732	Zinc finger CCHC-type containing 9	5	81301590-81313297	Predicted intracellular proteins	Evidence at protein level	HPA038404, HPA057521	Uncertain		Approved	Intermediate filaments		Expressed in all	Expressed in all			placenta: 27.4	Expressed in all		
ZCRB1	MADP-1, MADP1, RBM36, SNRNP31, ZCCHC19	ENSG00000139168	Zinc finger CCHC-type and RNA binding motif containing 1	12	42312078-42326118	Predicted intracellular proteins	Evidence at protein level						Liver cancer:5.33e-7 (unfavourable), Renal cancer:1.37e-6 (unfavourable), Ovarian cancer:7.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 153.7	Expressed in all		
ZCWPW1	DKFZp434N0510, FLJ10057, ZCW1	ENSG00000078487	Zinc finger CW-type and PWWP domain containing 1	7	100400826-100428992	Predicted intracellular proteins	Evidence at protein level	HPA020911			Approved	Golgi apparatus	Pancreatic cancer:1.93e-4 (favourable), Cervical cancer:1.99e-4 (favourable), Lung cancer:4.84e-4 (favourable), Urothelial cancer:5.26e-4 (favourable)	Expressed in all	Tissue enriched	8	testis: 71.2	thyroid gland: 8.6	Mixed		
ZCWPW2	ZCW2	ENSG00000206559	Zinc finger CW-type and PWWP domain containing 2	3	28349146-28538122	Predicted intracellular proteins	Evidence at protein level	HPA035035, HPA039839	Uncertain		Approved	Nuclear speckles		Mixed	Tissue enhanced		testis: 18.5	thyroid gland: 5.3	Mixed		
ZDBF2	FLJ45338, KIAA1571	ENSG00000204186	Zinc finger DBF-type containing 2	2	206274663-206314428	Predicted intracellular proteins	Evidence at protein level	HPA039121, HPA050311	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Mixed	Mixed			cerebral cortex: 5.1	Mixed		
ZEB1	AREB6, BZP, FECD6, NIL-2-A, PPCD3, TCF8, ZEB, Zfhep, Zfhx1a	ENSG00000148516	Zinc finger E-box binding homeobox 1	10	31318495-31529814	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027524, CAB058686	Enhanced		Supported	Nucleoplasm	Renal cancer:7.34e-6 (unfavourable)	Expressed in all	Mixed			smooth muscle: 79.9	Cell line enhanced		ASC TERT1: 102.9
ZEB2	KIAA0569, SIP-1, SIP1, ZFHX1B	ENSG00000169554	Zinc finger E-box binding homeobox 2	2	144364364-144524583	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003456	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:6.04e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 99.9	Mixed		
ZER1	C9orf60, Hzyg, ZYG, ZYG11BL	ENSG00000160445	Zyg-11 related cell cycle regulator	9	128729786-128772414	Predicted intracellular proteins	Evidence at protein level	HPA048464			Approved	Cytosol	Renal cancer:5.15e-11 (favourable), Cervical cancer:1.18e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 71.5	Expressed in all		
ZFAND1	FLJ14007	ENSG00000104231	Zinc finger AN1-type containing 1	8	81701334-81732903	Predicted intracellular proteins	Evidence at protein level	HPA023383	Approved		Approved	Centrosome<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 92.5	Expressed in all		
ZFAND2A	AIRAP	ENSG00000178381	Zinc finger AN1-type containing 2A	7	1152071-1160759	Predicted intracellular proteins	Evidence at transcript level	HPA019469	Approved				Renal cancer:5.47e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 50.0	Expressed in all		
ZFAND2B	AIRAPL	ENSG00000158552	Zinc finger AN1-type containing 2B	2	219195237-219209651	Predicted intracellular proteins	Evidence at protein level	HPA035159, HPA035160	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Pancreatic cancer:9.38e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 68.0	Expressed in all		
ZFAND3	FLJ13222, TEX27	ENSG00000156639	Zinc finger AN1-type containing 3	6	37819499-38154624	Predicted intracellular proteins	Evidence at protein level	HPA016755	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 185.0	Expressed in all		
ZFAND4	ANUBL1, FLJ40185	ENSG00000172671	Zinc finger AN1-type containing 4	10	45615501-45672780	Predicted intracellular proteins	Evidence at transcript level	HPA037839, HPA057543	Uncertain		Approved	Golgi apparatus		Expressed in all	Tissue enriched	13	testis: 95.4	lymph node: 7.5	Cell line enhanced		Daudi: 32.0
ZFAND5	ZA20D2, ZFAND5A, ZNF216	ENSG00000107372	Zinc finger AN1-type containing 5	9	72351425-72365235	Predicted intracellular proteins	Evidence at protein level	HPA018129	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:4.43e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 310.8	Expressed in all		
ZFAND6	AWP1, ZA20D3, ZFAND5B	ENSG00000086666	Zinc finger AN1-type containing 6	15	80059568-80138393	Predicted intracellular proteins	Evidence at protein level	HPA034845	Uncertain				Urothelial cancer:8.20e-4 (favourable)	Expressed in all	Expressed in all			testis: 247.8	Expressed in all		
ZFAT	KIAA1485, ZFAT1, ZNF406	ENSG00000066827	Zinc finger and AT-hook domain containing	8	134477788-134713049	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020989, HPA063592	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies		Expressed in all	Group enriched	6	kidney: 10.5;placenta: 44.3	testis: 4.3	Mixed		
ZFC3H1	CCDC131, CSRC2, KIAA0546, MGC23401, PSRC2	ENSG00000133858	Zinc finger C3H1-type containing	12	71609472-71667725	Predicted intracellular proteins	Evidence at protein level	HPA007072, HPA007151	Enhanced		Approved	Nucleoplasm<br>Intermediate filaments	Renal cancer:1.48e-5 (unfavourable), Liver cancer:3.63e-4 (unfavourable)	Expressed in all	Mixed			testis: 19.1	Expressed in all		
ZFHX2	KIAA1056, KIAA1762, ZFH-5, ZNF409	ENSG00000136367	Zinc finger homeobox 2	14	23520855-23556192	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000720, HPA005146	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Mixed	Tissue enhanced		testis: 13.0	parathyroid gland: 4.0	Cell line enhanced		AN3-CA: 4.5
ZFHX3	ATBF1, ZNF927	ENSG00000140836	Zinc finger homeobox 3	16	72782885-73059698	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059353	Uncertain				Renal cancer:1.37e-5 (favourable), Breast cancer:1.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 28.3	thyroid gland: 12.4	Mixed		
ZFHX4	FLJ20980, ZFH4	ENSG00000091656	Zinc finger homeobox 4	8	76681219-76867285	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023837	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center		Mixed	Tissue enhanced		seminal vesicle: 8.0;testis: 12.1	cerebral cortex: 5.0	Cell line enhanced		TIME: 35.2
ZFP1	FLJ34243, ZNF475	ENSG00000184517	ZFP1 zinc finger protein	16	75148492-75172236	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044916, HPA062910	Uncertain		Approved	Nucleus	Glioma:5.81e-5 (favourable), Stomach cancer:9.80e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 25.0	Expressed in all		
ZFP14	KIAA1559, ZNF531	ENSG00000142065	ZFP14 zinc finger protein	19	36334453-36379199	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030637	Uncertain		Approved	Nuclear speckles	Urothelial cancer:2.75e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 8.4	Mixed		
ZFP2	FLJ21628, ZNF751	ENSG00000198939	ZFP2 zinc finger protein	5	178895894-178933212	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023364	Uncertain					Mixed	Mixed			testis: 7.8	Cell line enhanced		AN3-CA: 5.1;HAP1: 2.7
ZFP28	KIAA1431, mkr5	ENSG00000196867	ZFP28 zinc finger protein	19	56538948-56556810	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028879	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			ovary: 13.0	Mixed		
ZFP3	FLJ30726, ZNF752	ENSG00000180787	ZFP3 zinc finger protein	17	5078248-5096374	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053085, HPA057290	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.69e-7 (favourable), Pancreatic cancer:1.07e-4 (favourable), Lung cancer:1.38e-4 (favourable), Cervical cancer:5.68e-4 (favourable)	Mixed	Mixed			parathyroid gland: 13.1	Cell line enhanced		SH-SY5Y: 6.1
ZFP30	KIAA0961, ZNF745	ENSG00000120784	ZFP30 zinc finger protein	19	37613749-37692337	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030606	Uncertain		Approved	Cytosol	Renal cancer:3.86e-4 (favourable)	Expressed in all	Mixed			testis: 14.0	Cell line enhanced		U-2 OS: 34.4
ZFP36	G0S24, NUP475, RNF162A, TIS11, TTP	ENSG00000128016	ZFP36 ring finger protein	19	39406813-39409412	Predicted intracellular proteins	Evidence at transcript level	HPA006009	Approved		Approved	Vesicles<br>Intermediate filaments		Expressed in all	Expressed in all			gallbladder: 928.0	Expressed in all		
ZFP36L1	Berg36, BRF1, cMG1, ERF1, RNF162B, TIS11B	ENSG00000185650	ZFP36 ring finger protein like 1	14	68787660-68796253	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001301	Uncertain					Expressed in all	Expressed in all			endometrium: 583.2	Expressed in all		
ZFP36L2	BRF2, ERF2, RNF162C, TIS11D	ENSG00000152518	ZFP36 ring finger protein like 2	2	43222402-43226609	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047428	Approved					Expressed in all	Expressed in all			thyroid gland: 274.7	Expressed in all		
ZFP37	ZNF906	ENSG00000136866	ZFP37 zinc finger protein	9	113038380-113056759	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA049112	Uncertain		Approved	Nucleus<br>Vesicles	Glioma:9.22e-5 (favourable)	Mixed	Mixed			ovary: 8.8	Mixed		
ZFP41	FLJ00028, FLJ38705, ZNF753	ENSG00000181638	ZFP41 zinc finger protein	8	143246821-143262705	Predicted intracellular proteins	Evidence at transcript level	HPA047232, HPA056268	Uncertain		Uncertain	Nucleus<br>Nucleoli<br>Plasma membrane	Liver cancer:3.46e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 7.5	Mixed		
ZFP42	REX1, ZNF754	ENSG00000179059	ZFP42 zinc finger protein	4	187995771-188005050	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025557	Uncertain					Tissue enriched	Tissue enhanced		testis: 3.1	placenta: 1.0	Cell line enriched	17	BEWO: 113.6
ZFP57	bA145L22, bA145L22.2, C6orf40, ZNF698	ENSG00000204644	ZFP57 zinc finger protein	6	29672392-29681110	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047172	Uncertain				Pancreatic cancer:1.95e-4 (favourable)	Tissue enriched	Not detected			cerebral cortex,heart muscle: 0.4	Cell line enriched	25	BEWO: 6.2
ZFP62	FLJ34231, ZET, ZNF755	ENSG00000196670	ZFP62 zinc finger protein	5	180847611-180861285	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048629	Approved		Approved	Nucleoplasm<br>Actin filaments		Expressed in all	Expressed in all			thyroid gland: 39.6	Expressed in all		
ZFP64	dJ548G19.1, dJ831D17.1, FLJ10734, FLJ12628, ZNF338	ENSG00000020256	ZFP64 zinc finger protein	20	52051663-52204308	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035112, HPA058387	Uncertain		Approved	Nucleus	Liver cancer:9.86e-7 (unfavourable)	Expressed in all	Expressed in all			skin: 13.8	Expressed in all		
ZFP69	FLJ16030, ZFP69A, ZKSCAN23A, ZNF642, ZSCAN54A	ENSG00000187815	ZFP69 zinc finger protein	1	40477215-40496343	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027808, HPA054942	Uncertain		Approved	Nucleus	Renal cancer:5.00e-6 (unfavourable), Head and neck cancer:9.31e-4 (favourable)	Expressed in all	Mixed			testis: 6.7	Cell line enhanced		THP-1: 39.0
ZFP69B	FLJ34293, ZKSCAN23B, ZNF643, ZSCAN54B	ENSG00000187801	ZFP69 zinc finger protein B	1	40450102-40463718	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044289	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Mixed			cerebral cortex: 3.7	Mixed		
ZFP82	KIAA1948, MGC45380, ZNF545	ENSG00000181007	ZFP82 zinc finger protein	19	36383120-36418656	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA051669, HPA060470	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Mixed	Mixed			thyroid gland: 8.8	Mixed		
ZFP90	KIAA1954, NK10, ZNF756	ENSG00000184939	ZFP90 zinc finger protein	16	68530090-68576072	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029017	Uncertain		Supported	Vesicles<br>Plasma membrane<br>Centrosome	Renal cancer:1.78e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 31.7	Mixed		
ZFP91	PZF, ZNF757	ENSG00000186660	ZFP91 zinc finger protein	11	58579111-58621042	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024037, CAB025417, HPA065325	Approved		Supported	Nucleus<br>Nucleoli	Pancreatic cancer:3.74e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 175.7	Expressed in all		
ZFP92	ZNF897	ENSG00000189420	ZFP92 zinc finger protein	X	153418322-153426481	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003030	Uncertain					Tissue enhanced	Mixed			fallopian tube: 5.3	Cell line enhanced		HDLM-2: 3.5;HMC-1: 3.1;U-937: 4.8
ZFPM1	FOG, FOG1, ZC2HC11A, ZNF89A	ENSG00000179588	Zinc finger protein, FOG family member 1	16	88453317-88537016	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046603	Enhanced		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:4.24e-4 (favourable)	Expressed in all	Mixed			stomach: 13.7	Cell line enhanced		K-562: 26.0
ZFPM2	FOG2, hFOG-2, ZC2HC11B, ZNF89B	ENSG00000169946	Zinc finger protein, FOG family member 2	8	104590733-105804532	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004094	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		ovary: 41.0	smooth muscle: 26.3	Cell line enhanced		AF22: 6.4;BJ hTERT+: 11.5;HHSteC: 8.3;HUVEC TERT2: 9.0
ZFR	SPG71, ZFR1	ENSG00000056097	Zinc finger RNA binding protein	5	32354350-32444761	Predicted intracellular proteins	Evidence at protein level	HPA016666	Supported		Approved	Nucleoplasm	Liver cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 77.5	Expressed in all		
ZFR2	KIAA1086	ENSG00000105278	Zinc finger RNA binding protein 2	19	3804024-3869032	Predicted intracellular proteins	Evidence at protein level	HPA043275, HPA055678	Uncertain		Uncertain	Nucleoplasm		Tissue enhanced	Group enriched	9	adrenal gland: 3.8;cerebral cortex: 12.7;testis: 19.0	fallopian tube: 1.3	Group enriched	12	HMC-1: 24.1;NTERA-2: 47.6;SiHa: 15.2
ZFX	ZNF926	ENSG00000005889	Zinc finger protein, X-linked	X	24149173-24216255	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001748, HPA003877, HPA071863	Supported		Approved	Nucleoplasm<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 33.2	Expressed in all		
ZFY	ZNF911	ENSG00000067646	Zinc finger protein, Y-linked	Y	2935281-2982506	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001748, HPA071863	Uncertain		Approved	Nucleoplasm<br>Nucleoli	Head and neck cancer:3.58e-5 (favourable)	Mixed	Mixed			testis: 12.8	Mixed		
ZFYVE1	DFCP1, KIAA1589, PPP1R172, TAFF1, ZNFN2A1	ENSG00000165861	Zinc finger FYVE-type containing 1	14	72969451-73027212	Predicted intracellular proteins	Evidence at protein level	HPA002898	Approved		Supported	Endoplasmic reticulum	Renal cancer:5.07e-12 (favourable)	Expressed in all	Expressed in all			testis: 22.6	Expressed in all		
ZFYVE16	KIAA0305, PPP1R69	ENSG00000039319	Zinc finger FYVE-type containing 16	5	80408013-80479350	Predicted intracellular proteins	Evidence at protein level	HPA035935, HPA035936	Supported		Enhanced	Vesicles<br>Cytosol		Expressed in all	Mixed			cervix, uterine: 24.0	Expressed in all		
ZFYVE19	ANCHR, FLJ14840	ENSG00000166140	Zinc finger FYVE-type containing 19	15	40807086-40815084	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040283, HPA041946	Uncertain				Endometrial cancer:7.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.3	Expressed in all		
ZFYVE26	KIAA0321, SPG15	ENSG00000072121	Zinc finger FYVE-type containing 26	14	67727374-67816590	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055500	Approved				Renal cancer:1.54e-6 (favourable), Liver cancer:2.84e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 14.7	Expressed in all		
ZFYVE28	KIAA1643	ENSG00000159733	Zinc finger FYVE-type containing 28	4	2269582-2418663	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038175, HPA057587	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:1.35e-6 (favourable)	Mixed	Mixed			cerebral cortex: 9.9	Mixed		
ZFYVE9	MADHIP, PPP1R173, SARA, SMADIP	ENSG00000157077	Zinc finger FYVE-type containing 9	1	52142094-52346686	Predicted intracellular proteins	Evidence at protein level	CAB017702, HPA065852, HPA065862	Approved		Enhanced	Vesicles<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 45.2	Mixed		
ZGLP1	GATAD3, GLP-1, GLP1	ENSG00000220201	Zinc finger, GATA-like protein 1	19	10304803-10309880	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049855	Uncertain		Approved	Nucleus<br>Vesicles		Mixed	Mixed			testis: 3.1	Cell line enhanced		NB-4: 20.8
ZGPAT	dJ583P15.3, FLJ14972, GPATC6, GPATCH6, KIAA1847, MGC44880, ZC3H9, ZC3HDC9, ZIP	ENSG00000197114	Zinc finger CCCH-type and G-patch domain containing	20	63707465-63736142	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056705			Supported	Nucleus<br>Plasma membrane	Head and neck cancer:6.17e-5 (favourable)	Expressed in all	Expressed in all			liver: 27.5	Expressed in all		
ZGRF1	C4orf21, FLJ11331	ENSG00000138658	Zinc finger GRF-type containing 1	4	112539333-112636995	Predicted intracellular proteins	Evidence at protein level	HPA030704, HPA030706	Uncertain		Approved	Cytosol		Mixed	Mixed			testis: 6.7	Mixed		
ZHX1		ENSG00000165156	Zinc fingers and homeoboxes 1	8	123248451-123275541	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055357, HPA060251			Enhanced	Nucleoplasm	Endometrial cancer:6.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 62.9	Expressed in all		
ZHX1-C8orf76		ENSG00000259305	ZHX1-C8orf76 readthrough	8	123226189-123274284	Predicted intracellular proteins	Evidence at transcript level	HPA023708	Uncertain		Uncertain	Nucleoplasm<br>Cytosol		Mixed	Mixed			bone marrow: 5.3	Cell line enhanced		SK-BR-3: 19.4
ZHX2	KIAA0854	ENSG00000178764	Zinc fingers and homeoboxes 2	8	122781394-122974512	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006769, HPA006996	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 32.8	Cell line enhanced		REH: 47.1
ZHX3	KIAA0395, TIX1	ENSG00000174306	Zinc fingers and homeoboxes 3	20	41178448-41317672	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046498			Supported	Nucleoplasm	Urothelial cancer:1.84e-5 (unfavourable), Renal cancer:2.53e-5 (favourable), Endometrial cancer:1.62e-4 (unfavourable), Thyroid cancer:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.5	Expressed in all		
ZIC1	ZIC, ZNF201	ENSG00000152977	Zic family member 1	3	147393422-147510293	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004098	Supported		Supported	Nucleoplasm		Tissue enhanced	Tissue enriched	9	cerebral cortex: 23.8	skin: 2.5	Cell line enriched	5	AF22: 171.9
ZIC2	HPE5	ENSG00000043355	Zic family member 2	13	99981772-99986773	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055031			Supported	Nuclear bodies	Cervical cancer:2.64e-4 (favourable), Liver cancer:2.91e-4 (unfavourable)	Mixed	Tissue enriched	6	cerebral cortex: 7.3	testis: 1.2	Cell line enhanced		AF22: 84.4;HEK93: 60.2;NTERA-2: 79.9;SCLC-21H: 209.9
ZIC3	HTX, HTX1, ZNF203	ENSG00000156925	Zic family member 3	X	137566142-137577691	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052936, HPA069523	Approved		Supported	Nucleoplasm		Tissue enriched	Group enriched	12	cerebral cortex: 1.6;testis: 1.3	bone marrow,skin: 0.1	Group enriched	38	AF22: 39.4;NTERA-2: 44.7
ZIC5		ENSG00000139800	Zic family member 5	13	99962964-99971909	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA074045			Uncertain	Nucleoplasm<br>Vesicles		Mixed	Group enriched	45	cerebral cortex: 2.3;testis: 6.6	all non-specific tissues: 0.0	Cell line enhanced		AF22: 21.7;NTERA-2: 15.0;SCLC-21H: 100.6
ZIK1	ZNF762	ENSG00000171649	Zinc finger protein interacting with K protein 1	19	57578456-57593777	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA059975	Uncertain		Approved	Intermediate filaments		Mixed	Mixed			parathyroid gland: 12.2	Cell line enhanced		HEK93: 26.5;NTERA-2: 34.3
ZIM2	ZNF656	ENSG00000269699	Zinc finger imprinted 2	19	56774552-56840729	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071856			Approved	Nuclear speckles<br>Cytosol		Not detected	Group enriched	7	adrenal gland: 5.8;cerebral cortex: 5.1;ovary: 9.9;placenta: 6.8;testis: 7.7	endometrium: 1.0	Cell line enhanced		BEWO: 4.7;Hep G2: 4.0;NTERA-2: 1.6;RH-30: 1.6;U-2 OS: 1.2
ZIM3	ZNF657	ENSG00000141946	Zinc finger imprinted 3	19	57134096-57145202	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA034575	Uncertain					Not detected	Not detected			testis: 0.7	Not detected		
ZKSCAN1	KOX18, PHZ-37, ZNF139, ZNF36, ZSCAN33	ENSG00000106261	Zinc finger with KRAB and SCAN domains 1	7	100015572-100041689	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006672	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Mitochondria		Expressed in all	Expressed in all			skin: 38.9	Expressed in all		
ZKSCAN2	FLJ23199, ZNF694, ZSCAN34	ENSG00000155592	Zinc finger with KRAB and SCAN domains 2	16	25236001-25257931	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049141	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus	Renal cancer:1.70e-6 (favourable)	Expressed in all	Mixed			testis: 7.6	Mixed		
ZKSCAN3	ZF47, Zfp47, ZNF306, ZNF309, ZSCAN35	ENSG00000189298	Zinc finger with KRAB and SCAN domains 3	6	28349914-28369177	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009637, HPA060116	Approved		Enhanced	Nucleoplasm	Glioma:6.55e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 10.1	Mixed		
ZKSCAN4	FLJ32136, P1P373C6, p373c6.1, ZNF307, ZNF427, ZSCAN36	ENSG00000187626	Zinc finger with KRAB and SCAN domains 4	6	28244623-28252224	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009637	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.90e-6 (unfavourable), Lung cancer:5.04e-4 (favourable)	Expressed in all	Mixed			testis: 18.3	Expressed in all		
ZKSCAN5	ZFP95, ZNF914, ZSCAN37	ENSG00000196652	Zinc finger with KRAB and SCAN domains 5	7	99504651-99534700	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003201	Uncertain		Approved	Intermediate filaments	Liver cancer:7.59e-6 (unfavourable), Thyroid cancer:1.13e-4 (unfavourable)	Expressed in all	Mixed			testis: 15.1	Expressed in all		
ZKSCAN7	FLJ12738, ZNF167, ZNF448, ZNF64, ZSCAN39	ENSG00000196345	Zinc finger with KRAB and SCAN domains 7	3	44555193-44594173	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048312, HPA049906, HPA071850	Uncertain		Enhanced	Cytosol		Mixed	Mixed			ovary: 4.1	Cell line enhanced		AN3-CA: 3.9;SH-SY5Y: 5.2
ZKSCAN8	LD5-1, ZNF192, ZSCAN40	ENSG00000198315	Zinc finger with KRAB and SCAN domains 8	6	28141910-28159472	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003483	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:1.33e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 25.0	Expressed in all		
ZMAT1	KIAA1789	ENSG00000166432	Zinc finger matrin-type 1	X	101882288-101932031	Predicted intracellular proteins	Evidence at protein level	HPA012827	Enhanced		Approved	Nucleoplasm	Pancreatic cancer:1.72e-5 (favourable)	Mixed	Tissue enhanced		epididymis: 25.8	parathyroid gland: 12.2	Cell line enhanced		Karpas-707: 5.9;U-266/70: 3.1
ZMAT2	FLJ31121, hSNU23, Snu23	ENSG00000146007	Zinc finger matrin-type 2	5	140698680-140706676	Predicted intracellular proteins	Evidence at protein level	HPA036518	Approved		Approved	Nucleus<br>Mitochondria	Colorectal cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 103.3	Expressed in all		
ZMAT3	FLJ12296, MGC10613, PAG608, WIG-1, WIG1	ENSG00000172667	Zinc finger matrin-type 3	3	179017223-179072279	Predicted intracellular proteins	Evidence at protein level	HPA027569, HPA028671, HPA054356	Enhanced		Supported	Nucleoplasm		Expressed in all	Mixed			cerebral cortex: 29.0	Expressed in all		
ZMAT4	FLJ13842	ENSG00000165061	Zinc finger matrin-type 4	8	40530590-40897833	Predicted intracellular proteins	Evidence at protein level	HPA056671, HPA069813	Enhanced		Approved	Intermediate filaments	Thyroid cancer:3.51e-4 (unfavourable)	Tissue enhanced	Group enriched	8	cerebral cortex: 10.1;thyroid gland: 27.6	testis: 2.4	Group enriched	5	AF22: 22.3;U-2197: 13.1
ZMAT5	SNRNP20, ZC3H19	ENSG00000100319	Zinc finger matrin-type 5	22	29730956-29767011	Predicted intracellular proteins	Evidence at protein level	HPA004858	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			fallopian tube: 35.5	Expressed in all		
ZMIZ1	FLJ13541, hZIMP10, KIAA1224, MIZ, RAI17, RP11-519K18.1, Zimp10	ENSG00000108175	Zinc finger MIZ-type containing 1	10	79069035-79316528	Predicted intracellular proteins	Evidence at protein level	HPA045144	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:3.64e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 65.3	Mixed		
ZMIZ2	DKFZp761I2123, hZIMP7, KIAA1886, NET27, ZIMP7	ENSG00000122515	Zinc finger MIZ-type containing 2	7	44748581-44769881	Predicted intracellular proteins	Evidence at protein level	HPA040716	Supported		Supported	Nucleoplasm	Liver cancer:6.82e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 40.7	Expressed in all		
ZMYM1	FLJ23151, MYM	ENSG00000197056	Zinc finger MYM-type containing 1	1	35059786-35115859	Predicted intracellular proteins	Evidence at protein level	HPA064019			Approved	Microtubule organizing center	Liver cancer:3.21e-6 (unfavourable)	Expressed in all	Mixed			testis: 6.9	Mixed		
ZMYM2	FIM, MYM, RAMP, ZNF198	ENSG00000121741	Zinc finger MYM-type containing 2	13	19958670-20091829	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031765	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum	Urothelial cancer:6.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 88.0	Expressed in all		
ZMYM3	DXS6673E, KIAA0385, MYM, ZNF198L2, ZNF261	ENSG00000147130	Zinc finger MYM-type containing 3	X	71239624-71255146	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003211, HPA075255	Approved		Enhanced	Nucleoplasm	Liver cancer:5.18e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 44.0	Expressed in all		
ZMYM4	KIAA0425, MYM, ZNF198L3, ZNF262	ENSG00000146463	Zinc finger MYM-type containing 4	1	35268967-35422058	Predicted intracellular proteins	Evidence at protein level	HPA051301, HPA054802	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.75e-9 (unfavourable), Renal cancer:8.10e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.9	Expressed in all		
ZMYND10	BLU, CILD22	ENSG00000004838	Zinc finger MYND-type containing 10	3	50341110-50346852	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035255			Approved	Plasma membrane<br>Cytosol	Renal cancer:6.75e-5 (favourable)	Tissue enhanced	Group enriched	16	fallopian tube: 231.5;testis: 284.6	lung: 15.8	Cell line enhanced		T-47d: 6.1;U-87 MG: 4.3
ZMYND12	DKFZp434N2435	ENSG00000066185	Zinc finger MYND-type containing 12	1	42430329-42456267	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:1.11e-5 (favourable)	Mixed	Tissue enhanced		fallopian tube: 23.4;testis: 51.8	epididymis: 8.7	Cell line enhanced		HSkMC: 1.6;SK-MEL-30: 1.5;WM-115: 1.4
ZMYND15	DKFZp434N127	ENSG00000141497	Zinc finger MYND-type containing 15	17	4740015-4746119	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023286			Uncertain	Nuclear speckles<br>Cytosol		Expressed in all	Tissue enhanced		parathyroid gland: 15.7;testis: 29.5	lung: 7.5	Cell line enhanced		A-431: 1.9;CAPAN-2: 1.8
ZMYND19	MIZIP	ENSG00000165724	Zinc finger MYND-type containing 19	9	137582079-137590490	Predicted intracellular proteins	Evidence at protein level	HPA020642, HPA050761	Supported		Approved	Golgi apparatus<br>Vesicles	Liver cancer:1.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 46.1	Expressed in all		
ZMYND8	PRKCBP1, RACK7	ENSG00000101040	Zinc finger MYND-type containing 8	20	47209214-47356889	Predicted intracellular proteins	Evidence at protein level	HPA020949	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:7.06e-5 (unfavourable), Breast cancer:2.56e-4 (unfavourable), Liver cancer:2.62e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 40.5	Expressed in all		
ZNF10	KOX1	ENSG00000256223	Zinc finger protein 10	12	133130575-133159465	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003204	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			parathyroid gland: 40.9	Mixed		
ZNF100		ENSG00000197020	Zinc finger protein 100	19	21722766-21767628	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059135	Uncertain				Urothelial cancer:5.47e-4 (favourable)	Mixed	Mixed			testis: 11.6	Cell line enhanced		MOLT-4: 24.6
ZNF101	DKFZp570I0164, HZF12	ENSG00000181896	Zinc finger protein 101	19	19668796-19683509	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023449, HPA055486	Uncertain				Cervical cancer:5.76e-5 (favourable), Stomach cancer:1.11e-4 (favourable), Head and neck cancer:2.15e-4 (favourable), Ovarian cancer:2.26e-4 (favourable), Urothelial cancer:4.37e-4 (favourable), Lung cancer:6.65e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 31.4	tonsil: 22.3	Expressed in all		
ZNF106	SH3BP3, ZFP106, ZNF474	ENSG00000103994	Zinc finger protein 106	15	42412823-42491123	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054267	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 144.2	Expressed in all		
ZNF107	smap-7, ZFD25, ZNF588	ENSG00000196247	Zinc finger protein 107	7	64666083-64711582	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:2.62e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 19.4	Expressed in all		
ZNF112	ZFP112, ZNF228	ENSG00000062370	Zinc finger protein 112	19	44326555-44367217	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA023856	Approved		Approved	Centrosome	Renal cancer:1.54e-5 (favourable)	Mixed	Mixed			testis: 13.8	Cell line enhanced		U-2197: 16.1
ZNF114	MGC17986	ENSG00000178150	Zinc finger protein 114	19	48270102-48287608	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA025019, HPA029553	Uncertain		Approved	Nucleus<br>Cytosol	Head and neck cancer:3.29e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 10.3	parathyroid gland: 3.6	Cell line enhanced		BEWO: 21.9;Hep G2: 18.9
ZNF117	H-plk, HPF9	ENSG00000152926	Zinc finger protein 117	7	64971776-65006684	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031148			Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:2.17e-11 (unfavourable)	Expressed in all	Mixed			adrenal gland: 25.2	Mixed		
ZNF12	GIOT-3, KOX3, ZNF325	ENSG00000164631	Zinc finger protein 12	7	6688433-6706923	Predicted intracellular proteins	Evidence at protein level	HPA063402			Supported	Nucleoplasm<br>Centrosome		Expressed in all	Expressed in all			parathyroid gland: 31.2	Expressed in all		
ZNF121	D19S204, ZHC32, ZNF20	ENSG00000197961	Zinc finger protein 121	19	9560353-9584533	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054961	Uncertain		Uncertain	Nucleoplasm<br>Nucleoli<br>Centrosome	Urothelial cancer:5.75e-5 (favourable), Ovarian cancer:6.59e-5 (favourable), Renal cancer:1.01e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
ZNF124	HZF-16, HZF16	ENSG00000196418	Zinc finger protein 124	1	247121975-247172016	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031127	Uncertain		Approved	Nucleus<br>Nuclear membrane	Urothelial cancer:1.03e-4 (favourable)	Expressed in all	Mixed			salivary gland: 16.8	Mixed		
ZNF131	pHZ-10, ZBTB35	ENSG00000172262	Zinc finger protein 131	5	43065176-43192021	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007023, HPA027748, HPA074630	Approved		Enhanced	Nucleoplasm<br>Intermediate filaments	Liver cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.4	Expressed in all		
ZNF132	pHZ-12	ENSG00000131849	Zinc finger protein 132	19	58432814-58440222	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA008726	Uncertain		Approved	Vesicles<br>Intermediate filaments	Renal cancer:7.26e-13 (favourable), Pancreatic cancer:1.92e-4 (favourable)	Mixed	Mixed			parathyroid gland: 11.6	Mixed		
ZNF133	pHZ-13, pHZ-66, ZNF150	ENSG00000125846	Zinc finger protein 133	20	18288283-18316996	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001493	Enhanced		Approved	Nucleus<br>Vesicles	Liver cancer:4.46e-6 (unfavourable), Renal cancer:2.20e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 20.1	Mixed		
ZNF134	pHZ-15	ENSG00000213762	Zinc finger protein 134	19	57614233-57624723	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009064	Supported		Approved	Nucleoplasm	Cervical cancer:1.03e-4 (unfavourable), Renal cancer:2.61e-4 (favourable), Head and neck cancer:5.21e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 20.9	Mixed		
ZNF135	pHZ-17, ZNF61, ZNF78L1	ENSG00000176293	Zinc finger protein 135	19	58059239-58086310	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006961	Approved		Approved	Cytosol	Renal cancer:3.93e-5 (favourable)	Mixed	Mixed			parathyroid gland: 25.0	Cell line enhanced		T-47d: 6.6
ZNF136	pHZ-20	ENSG00000196646	Zinc finger protein 136	19	12163064-12189881	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054120			Approved	Nucleoli	Renal cancer:4.75e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 14.5	Mixed		
ZNF138	pHZ-32	ENSG00000197008	Zinc finger protein 138	7	64794388-64833681	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077435			Uncertain	Cytosol		Expressed in all	Mixed			cerebral cortex: 9.1	Expressed in all		
ZNF14	GIOT-4, KOX6	ENSG00000105708	Zinc finger protein 14	19	19710471-19733097	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049863	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:8.09e-6 (favourable), Lung cancer:7.96e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 13.3	Mixed		
ZNF140	pHZ-39	ENSG00000196387	Zinc finger protein 140	12	133079838-133107544	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048332	Uncertain					Expressed in all	Expressed in all			thyroid gland: 16.3	Mixed		
ZNF141	D4S90, pHZ-44	ENSG00000131127	Zinc finger protein 141	4	337814-384864	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Urothelial cancer:4.76e-4 (favourable)	Expressed in all	Mixed			adrenal gland,thyroid gland: 14.9	Mixed		
ZNF142	KIAA0236, pHZ-49	ENSG00000115568	Zinc finger protein 142	2	218637916-218659655	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049594	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center	Liver cancer:1.35e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 14.9	Expressed in all		
ZNF143	pHZ-1, SBF, STAF	ENSG00000166478	Zinc finger protein 143	11	9460319-9528524	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003263, HPA074818	Supported		Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Liver cancer:1.76e-5 (unfavourable), Renal cancer:6.78e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 31.1	Expressed in all		
ZNF146	OZF	ENSG00000167635	Zinc finger protein 146	19	36214602-36238774	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003358	Supported		Supported	Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 63.2	Expressed in all		
ZNF148	BERF-1, BFCOL1, HT-BETA, pHZ-52, ZBP-89, ZFP148	ENSG00000163848	Zinc finger protein 148	3	125225561-125375354	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001656, CAB017486	Supported		Supported	Nucleus<br>Golgi apparatus	Pancreatic cancer:2.88e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.4	Expressed in all		
ZNF154	pHZ-92	ENSG00000179909	Zinc finger protein 154	19	57697367-57709194	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			parathyroid gland: 9.5	Cell line enhanced		AF22: 5.2;MOLT-4: 3.6;NTERA-2: 2.9
ZNF155	pHZ-96	ENSG00000204920	Zinc finger protein 155	19	43967862-43998325	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003220	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			parathyroid gland: 14.5	Mixed		
ZNF157	HZF22	ENSG00000147117	Zinc finger protein 157	X	47370583-47414305	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003319	Uncertain					Tissue enhanced	Mixed			fallopian tube: 2.1	Cell line enhanced		U-266/84: 1.6
ZNF16	KOX9	ENSG00000170631	Zinc finger protein 16	8	144930358-144950888	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035782, HPA061835	Uncertain		Supported	Nucleus<br>Nucleoli	Head and neck cancer:2.39e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 16.1	Expressed in all		
ZNF160	F11, FLJ00032, HKr18, HZF5, KIAA1611, KR18	ENSG00000170949	Zinc finger protein 160	19	53066606-53103436	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA023599	Uncertain		Approved	Nuclear speckles<br>Cytosol	Urothelial cancer:2.67e-5 (favourable)	Expressed in all	Expressed in all			spleen: 37.4	Mixed		
ZNF165	CT53, ZSCAN7	ENSG00000197279	Zinc finger protein 165	6	28080975-28089563	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007247			Approved	Nuclear speckles<br>Microtubules	Renal cancer:1.19e-5 (favourable), Urothelial cancer:9.82e-5 (favourable), Ovarian cancer:2.10e-4 (favourable)	Mixed	Tissue enhanced		testis: 35.8	epididymis: 7.5	Cell line enhanced		BEWO: 23.4
ZNF169	MGC51961	ENSG00000175787	Zinc finger protein 169	9	94259311-94301454	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041769	Uncertain		Approved	Nuclear speckles<br>Cytosol		Mixed	Mixed			spleen: 7.7	Mixed		
ZNF17	FLJ40864, FLJ46058, FLJ46615, HPF3, KIAA1947, KOX10	ENSG00000186272	Zinc finger protein 17	19	57411163-57421939	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Pancreatic cancer:6.03e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.3	Expressed in all		
ZNF174	ZSCAN8	ENSG00000103343	Zinc finger protein 174	16	3401235-3409370	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009656	Approved		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 28.3	Expressed in all		
ZNF175	OTK18	ENSG00000105497	Zinc finger protein 175	19	51571298-51592508	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002717	Uncertain		Supported	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Thyroid cancer:6.64e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 19.7	Cell line enhanced		HEL: 45.3
ZNF177		ENSG00000188629	Zinc finger protein 177	19	9363020-9382617	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003141	Uncertain					Not detected	Tissue enhanced		testis: 14.3	epididymis: 8.7	Mixed		
ZNF18	HDSG1, KOX11, Zfp535, ZKSCAN6, ZNF535, ZSCAN38	ENSG00000154957	Zinc finger protein 18	17	11977439-11997510	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006144	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:3.06e-6 (unfavourable), Pancreatic cancer:5.12e-6 (favourable), Cervical cancer:6.32e-4 (favourable)	Expressed in all	Expressed in all			testis: 22.3	Expressed in all		
ZNF180	HHZ168	ENSG00000167384	Zinc finger protein 180	19	44474428-44500524	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028979, HPA028980	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			parathyroid gland: 12.3	Mixed		
ZNF181	HHZ181, MGC44316	ENSG00000197841	Zinc finger protein 181	19	34734155-34745378	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043701, HPA062305	Uncertain		Approved	Nucleus	Pancreatic cancer:1.05e-4 (favourable), Melanoma:2.60e-4 (unfavourable), Urothelial cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			ovary: 21.5	Mixed		
ZNF182	HHZ150, KOX14, Zfp182, ZNF21	ENSG00000147118	Zinc finger protein 182	X	47974851-48003978	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA059574	Uncertain		Approved	Nucleus	Urothelial cancer:1.55e-7 (favourable), Renal cancer:2.42e-5 (unfavourable), Liver cancer:3.73e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 9.2	Expressed in all		
ZNF184		ENSG00000096654	Zinc finger protein 184	6	27450743-27473118	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003226, HPA064793	Uncertain		Supported	Nucleus	Ovarian cancer:4.41e-5 (favourable)	Expressed in all	Mixed			testis: 15.2	Expressed in all		
ZNF185	SCELL	ENSG00000147394	Zinc finger protein 185 (LIM domain)	X	152914442-152973480	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000400, HPA016438	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Focal adhesion sites<br>Cytosol	Pancreatic cancer:3.30e-5 (unfavourable), Lung cancer:1.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 400.1;esophagus: 278.4;seminal vesicle: 202.3	cervix, uterine: 105.3	Cell line enhanced		A-431: 108.1;EFO-21: 131.6;TIME: 192.3
ZNF189		ENSG00000136870	Zinc finger protein 189	9	101398873-101410660	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034814	Uncertain		Approved	Intermediate filaments	Renal cancer:5.32e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 104.7	Expressed in all		
ZNF19	KOX12, MGC51021	ENSG00000157429	Zinc finger protein 19	16	71464555-71565089	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA063685	Approved		Approved	Mitochondria		Mixed	Expressed in all			testis: 29.2	Mixed		
ZNF195		ENSG00000005801	Zinc finger protein 195	11	3339261-3379222	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030605	Uncertain		Approved	Nucleus<br>Cytosol	Urothelial cancer:4.79e-7 (favourable), Liver cancer:3.53e-5 (unfavourable), Renal cancer:7.89e-5 (unfavourable), Prostate cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 21.3	Expressed in all		
ZNF197	D3S1363E, P18, ZKSCAN9, ZNF166, ZSCAN41	ENSG00000186448	Zinc finger protein 197	3	44584888-44648471	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054567	Uncertain		Approved	Nucleoplasm	Prostate cancer:6.78e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 9.2	Mixed		
ZNF2	A1-5, Zfp661, ZNF661	ENSG00000275111	Zinc finger protein 2	2	95165432-95184317	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041358	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Lung cancer:4.69e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 6.4	Expressed in all		
ZNF20	KOX13	ENSG00000132010	Zinc finger protein 20	19	12092843-12140407	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020887	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Not detected	Mixed			testis: 9.3	Mixed		
ZNF200		ENSG00000010539	Zinc finger protein 200	16	3222325-3236221	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018981, HPA059310	Uncertain		Approved	Mitochondria		Expressed in all	Tissue enhanced		testis: 31.6	placenta: 8.8	Expressed in all		
ZNF202	ZKSCAN10, ZSCAN42	ENSG00000166261	Zinc finger protein 202	11	123724177-123741675	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:9.93e-7 (unfavourable), Liver cancer:2.52e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 16.7	Expressed in all		
ZNF205	Zfp13, ZNF210	ENSG00000122386	Zinc finger protein 205	16	3112560-3120517	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001791	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 14.6	Mixed		
ZNF208	PMIDP, ZNF95	ENSG00000160321	Zinc finger protein 208	19	21932958-22010949	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Mixed			testis: 16.5	Group enriched	10	NTERA-2: 33.9;U-266/84: 7.7
ZNF211	CH2H2-25, ZNF-25	ENSG00000121417	Zinc finger protein 211	19	57630395-57642779	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA011340, HPA049967	Approved		Approved	Mitochondria<br>Rods & Rings		Expressed in all	Expressed in all			parathyroid gland: 32.7	Mixed		
ZNF212	C2H2-150	ENSG00000170260	Zinc finger protein 212	7	149239651-149255609	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049807, HPA054178	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			testis: 15.1	Expressed in all		
ZNF213	CR53, ZKSCAN21, ZSCAN53	ENSG00000085644	Zinc finger protein 213	16	3129777-3142805	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA035000, HPA056750	Uncertain		Approved	Nucleus<br>Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:6.74e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.3	Expressed in all		
ZNF214		ENSG00000149050	Zinc finger protein 214	11	6999318-7020368	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055391	Uncertain					Mixed	Mixed			fallopian tube: 6.9	Mixed		
ZNF215	ZKSCAN11, ZSCAN43	ENSG00000149054	Zinc finger protein 215	11	6926404-7001004	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047243, HPA051010	Enhanced		Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			lymph node: 4.5	Cell line enhanced		U-698: 14.5
ZNF217	ZABC1	ENSG00000171940	Zinc finger protein 217	20	53567065-53609907	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051857	Approved		Enhanced	Nuclear speckles		Expressed in all	Mixed			testis: 41.2	Expressed in all		
ZNF219		ENSG00000165804	Zinc finger protein 219	14	21090046-21104722	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030761, HPA056168	Approved		Supported	Nucleus		Expressed in all	Expressed in all			skin: 44.0	Expressed in all		
ZNF22	HKR-T1, KOX15, Zfp422, ZNF422	ENSG00000165512	Zinc finger protein 22	10	45000475-45005326	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016736, HPA054893	Approved		Enhanced	Nucleus	Renal cancer:1.11e-5 (unfavourable), Stomach cancer:8.06e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 46.7	Mixed		
ZNF221		ENSG00000159905	Zinc finger protein 221	19	43951223-43967709	Predicted intracellular proteins	Evidence at transcript level	HPA059435	Uncertain		Approved	Nuclear bodies		Mixed	Mixed			parathyroid gland: 5.1	Mixed		
ZNF222		ENSG00000159885	Zinc finger protein 222	19	44025342-44033112	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004086	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:5.56e-7 (favourable)	Expressed in all	Mixed			testis: 16.9	Mixed		
ZNF223		ENSG00000178386	Zinc finger protein 223	19	44051367-44067991	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067823			Approved	Nucleus<br>Mitochondria		Mixed	Mixed			prostate,thyroid gland: 10.6	Cell line enhanced		RT4: 18.6
ZNF224	BMZF-2, KOX22, ZNF255, ZNF27	ENSG00000267680	Zinc finger protein 224	19	44094339-44109886	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054045	Approved		Supported	Nucleus<br>Nuclear membrane	Urothelial cancer:1.53e-7 (favourable), Renal cancer:5.32e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 35.7	Expressed in all		
ZNF225		ENSG00000256294	Zinc finger protein 225	19	44112181-44134816	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073778			Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 22.8	breast: 10.6	Mixed		
ZNF226		ENSG00000167380	Zinc finger protein 226	19	44165073-44178381	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006145, CAB034353	Uncertain		Approved	Nuclear bodies	Urothelial cancer:2.37e-5 (favourable), Pancreatic cancer:8.34e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Expressed in all		
ZNF227		ENSG00000131115	Zinc finger protein 227	19	44207547-44237268	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030573	Uncertain		Approved	Plasma membrane	Urothelial cancer:2.64e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 18.7	Mixed		
ZNF229		ENSG00000278318	Zinc finger protein 229	19	44417519-44448578	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA001494	Uncertain		Approved	Vesicles<br>Plasma membrane	Renal cancer:8.43e-5 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 6.7	fallopian tube,thyroid gland: 3.1	Mixed		
ZNF23	KOX16, Zfp612, ZNF359, ZNF612	ENSG00000167377	Zinc finger protein 23	16	71447597-71463095	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023534	Uncertain		Approved	Cytosol		Not detected	Mixed			cerebral cortex: 12.0	Expressed in all		
ZNF230	FDZF2	ENSG00000159882	Zinc finger protein 230	19	44002948-44013926	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006172			Approved	Mitochondria		Mixed	Mixed			ovary: 5.2	Mixed		
ZNF232	ZSCAN11	ENSG00000167840	Zinc finger protein 232	17	5105541-5123116	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027309, HPA028611	Uncertain		Supported	Nucleus<br>Vesicles<br>Cytosol	Liver cancer:4.66e-4 (unfavourable), Pancreatic cancer:6.55e-4 (favourable)	Expressed in all	Mixed			ovary: 4.3	Mixed		
ZNF233	FLJ38032	ENSG00000159915	Zinc finger protein 233	19	44259880-44275317	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA020975	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 26.1	cerebral cortex: 5.8	Mixed		
ZNF234	HZF4, ZNF269	ENSG00000263002	Zinc finger protein 234	19	44141557-44160309	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001664	Approved		Approved	Nuclear bodies	Urothelial cancer:4.34e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.1	Mixed		
ZNF235	ANF270, HZF6, ZFP93, ZNF270	ENSG00000159917	Zinc finger protein 235	19	44228729-44305046	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045582	Uncertain		Supported	Nucleoplasm		Mixed	Mixed			parathyroid gland: 5.1	Mixed		
ZNF236		ENSG00000130856	Zinc finger protein 236	18	76822607-76970727	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008600	Uncertain					Expressed in all	Mixed			testis: 13.3	Mixed		
ZNF239	HOK-2, MOK2	ENSG00000196793	Zinc finger protein 239	10	43556344-43574618	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030843, HPA046679	Uncertain		Approved	Nucleus<br>Nuclear bodies	Renal cancer:4.70e-7 (unfavourable)	Expressed in all	Mixed			testis: 14.7	Cell line enhanced		NTERA-2: 24.4
ZNF24	KOX17, Zfp191, ZNF191, ZSCAN3	ENSG00000172466	Zinc finger protein 24	18	35332212-35345482	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024062, CAB025642	Supported		Supported	Nucleus	Renal cancer:1.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.6	Expressed in all		
ZNF248	bA162G10.3	ENSG00000198105	Zinc finger protein 248	10	37776526-37858106	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018237, HPA018287, HPA018455	Uncertain		Approved	Nucleoplasm	Lung cancer:1.04e-4 (favourable), Pancreatic cancer:1.22e-4 (favourable), Renal cancer:2.25e-4 (unfavourable), Prostate cancer:6.71e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 25.9	Expressed in all		
ZNF25	FLJ31890, KOX19, Zfp9	ENSG00000175395	Zinc finger protein 25	10	37949572-37976633	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030190	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			cerebral cortex: 26.9	Mixed		
ZNF250	MGC9718, ZFP647, ZNF647	ENSG00000196150	Zinc finger protein 250	8	144876497-144902168	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020853	Uncertain		Supported	Nuclear speckles	Renal cancer:2.43e-7 (favourable), Urothelial cancer:8.26e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 20.1	Expressed in all		
ZNF251		ENSG00000198169	Zinc finger protein 251	8	144720907-144756417	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA018290	Approved		Approved	Nucleoplasm	Renal cancer:1.42e-9 (unfavourable)	Expressed in all	Mixed			thyroid gland: 13.8	Mixed		
ZNF253	BMZF-1, FLJ90391, ZNF411	ENSG00000256771	Zinc finger protein 253	19	19865886-19894674	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:9.69e-5 (favourable), Glioma:1.11e-4 (favourable), Ovarian cancer:2.19e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 25.9	Mixed		
ZNF254	BMZF-5, HD-ZNF1, ZNF539, ZNF91L	ENSG00000213096	Zinc finger protein 254	19	24033405-24129961	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Lung cancer:8.60e-4 (favourable), Urothelial cancer:9.96e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 29.3	Mixed		
ZNF256	BMZF-3	ENSG00000152454	Zinc finger protein 256	19	57940833-57947675	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055390	Uncertain		Supported	Nucleus		Expressed in all	Mixed			testis: 7.9	Cell line enhanced		HEK93: 30.4
ZNF257	BMZF-4	ENSG00000197134	Zinc finger protein 257	19	22052452-22091480	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Ovarian cancer:2.05e-4 (favourable)	Tissue enhanced	Mixed			testis: 4.2	Cell line enhanced		NTERA-2: 11.0;RH-30: 5.6
ZNF260	ozrf1, Zfp260	ENSG00000254004	Zinc finger protein 260	19	36510695-36528660	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028806	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.44e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 20.5	Mixed		
ZNF263	FPM315, ZKSCAN12, ZSCAN44	ENSG00000006194	Zinc finger protein 263	16	3263800-3301401	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035085, HPA035086	Approved		Supported	Nucleoplasm<br>Mitotic spindle<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 58.2	Expressed in all		
ZNF264	KIAA0412	ENSG00000083844	Zinc finger protein 264	19	57191500-57222846	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057665	Uncertain					Expressed in all	Expressed in all			testis: 18.3	Mixed		
ZNF266	HZF1	ENSG00000174652	Zinc finger protein 266	19	9412598-9435578	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026836, HPA054110	Uncertain		Enhanced	Nucleus<br>Vesicles<br>Rods & Rings	Head and neck cancer:3.94e-6 (favourable), Pancreatic cancer:3.03e-5 (favourable), Urothelial cancer:9.15e-5 (favourable), Cervical cancer:1.41e-4 (favourable), Renal cancer:1.82e-4 (unfavourable), Lung cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 117.7	Mixed		
ZNF267	HZF2	ENSG00000185947	Zinc finger protein 267	16	31873758-31917357	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003866	Approved		Approved	Nucleoplasm	Renal cancer:1.58e-6 (unfavourable)	Expressed in all	Mixed			appendix: 24.9	Expressed in all		
ZNF268	HZF3	ENSG00000090612	Zinc finger protein 268	12	133181409-133214831	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001794	Approved		Approved	Actin filaments<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 23.5	Mixed		
ZNF273	HZF9	ENSG00000198039	Zinc finger protein 273	7	64870172-64930966	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077549			Approved	Nucleoplasm		Mixed	Mixed			testis: 2.9	Mixed		
ZNF274	ZKSCAN19, ZSCAN51	ENSG00000171606	Zinc finger protein 274	19	58183029-58213562	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028880	Uncertain		Supported	Nucleus<br>Centrosome	Prostate cancer:1.75e-4 (unfavourable), Glioma:4.26e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 40.2	Expressed in all		
ZNF275		ENSG00000063587	Zinc finger protein 275	X	153334155-153360110	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000566	Approved		Approved	Nucleoli		Expressed in all	Expressed in all			adrenal gland: 79.3	Cell line enhanced		U-266/70: 46.8
ZNF276	CENP-Z, CENPZ, MGC45417, ZADT, ZFP276, ZNF477	ENSG00000158805	Zinc finger protein 276	16	89720400-89740903	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021309, HPA022255	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 22.9	Expressed in all		
ZNF277	NRIF4, ZNF277P	ENSG00000198839	Zinc finger protein 277	7	112206588-112343096	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027307	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:9.47e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 33.4	Expressed in all		
ZNF28	DKFZp781D0275, KOX24	ENSG00000198538	Zinc finger protein 28	19	52797409-52857600	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Breast cancer:9.29e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 17.9	Mixed		
ZNF280A	3'OY11.1, SUHW1, ZNF280, ZNF636	ENSG00000169548	Zinc finger protein 280A	22	22513736-22520270	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA044475	Uncertain		Uncertain	Nucleoplasm		Tissue enhanced	Not detected			adrenal gland: 0.3	Cell line enhanced		BEWO: 1.8;K-562: 7.3;SK-MEL-30: 1.6
ZNF280B	5'OY11.1, SUHW2, ZNF279, ZNF632	ENSG00000275004	Zinc finger protein 280B	22	22484421-22509154	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059519	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enriched	7	testis: 12.6	cerebral cortex: 1.8	Cell line enhanced		K-562: 8.3;U-2 OS: 4.7
ZNF280C	FLJ20095, SUHW3, ZNF633	ENSG00000056277	Zinc finger protein 280C	X	130202711-130268899	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051494, HPA055788	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Tissue enhanced		testis: 17.5	epididymis: 6.3	Mixed		
ZNF280D	FLJ20086, SUHW4, ZNF634	ENSG00000137871	Zinc finger protein 280D	15	56630181-56918571	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030233	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			endometrium: 31.8	Mixed		
ZNF281	ZBP-99	ENSG00000162702	Zinc finger protein 281	1	200404940-200410056	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051228	Uncertain		Enhanced	Nucleoplasm	Renal cancer:2.60e-5 (unfavourable), Cervical cancer:1.16e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 21.5	Expressed in all		
ZNF282	HUB1	ENSG00000170265	Zinc finger protein 282	7	149195485-149226248	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024374	Supported		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.03e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine,fallopian tube: 14.9	Expressed in all		
ZNF283		ENSG00000167637	Zinc finger protein 283	19	43827292-43852017	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA072977			Approved	Nucleoplasm		Mixed	Mixed			parathyroid gland: 10.2	Cell line enhanced		U-2 OS: 25.1
ZNF284	DKFZp781F1775	ENSG00000186026	Zinc finger protein 284	19	44072144-44089613	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			skin: 3.6	Mixed		
ZNF285	ZNF285A	ENSG00000267508	Zinc finger protein 285	19	44382298-44401608	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046100, HPA049212	Uncertain					Mixed	Mixed			ovary: 7.9	Mixed		
ZNF286A	KIAA1874, ZNF286	ENSG00000187607	Zinc finger protein 286A	17	15699577-15720787	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021594			Approved	Nucleoli		Mixed	Mixed			ovary: 21.8	Mixed		
ZNF286B	ZNF286C, ZNF286L, ZNF590	ENSG00000249459	Zinc finger protein 286B	17	18658429-18682262	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA068125	Uncertain		Approved	Nuclear speckles<br>Cytosol		Mixed	Mixed			ovary: 2.6	Mixed		
ZNF287	ZKSCAN13, ZSCAN45	ENSG00000141040	Zinc finger protein 287	17	16551387-16569206	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029290	Uncertain		Approved	Golgi apparatus	Renal cancer:5.28e-5 (favourable)	Mixed	Mixed			parathyroid gland: 13.0	Mixed		
ZNF292	bA393I2.3, KIAA0530, ZFP292, Zn-15, Zn-16	ENSG00000188994	Zinc finger protein 292	6	87152833-87264196	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA032154, HPA050618	Uncertain		Approved	Nucleus<br>Nuclear membrane		Expressed in all	Expressed in all			endometrium: 17.1	Expressed in all		
ZNF296	ZNF342	ENSG00000170684	Zinc finger protein 296	19	45071500-45076588	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046940, HPA049576	Uncertain		Approved	Nucleoplasm<br>Centrosome	Head and neck cancer:5.24e-4 (favourable)	Expressed in all	Mixed			spleen: 3.7	Cell line enhanced		Daudi: 16.2;U-698: 18.2
ZNF3	A8-51, FLJ20216, HF.12, KOX25, PP838, Zfp113	ENSG00000166526	Zinc finger protein 3	7	100064033-100082548	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003719	Supported	Approved	Approved	Nucleoplasm	Melanoma:1.59e-4 (unfavourable), Urothelial cancer:2.20e-4 (favourable), Lung cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 56.8	Expressed in all		
ZNF30	DKFZp686N19164, FLJ20562, KOX28	ENSG00000168661	Zinc finger protein 30	19	34926903-34945170	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030400	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.16e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 5.0	Mixed		
ZNF300		ENSG00000145908	Zinc finger protein 300	5	150894392-150904983	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028975, HPA051777	Uncertain		Supported	Nucleoplasm<br>Nucleoli	Renal cancer:3.21e-6 (unfavourable)	Expressed in all	Mixed			ovary: 12.4	Mixed		
ZNF302	ZNF135L, ZNF140L, ZNF327	ENSG00000089335	Zinc finger protein 302	19	34677639-34686397	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059503			Approved	Vesicles<br>Cytokinetic bridge	Endometrial cancer:2.03e-5 (unfavourable), Urothelial cancer:9.85e-5 (favourable), Renal cancer:5.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.1	Mixed		
ZNF304		ENSG00000131845	Zinc finger protein 304	19	57351307-57359898	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050531	Approved		Approved	Nuclear speckles	Renal cancer:1.52e-7 (favourable), Melanoma:4.95e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.9	Mixed		
ZNF311		ENSG00000197935	Zinc finger protein 311	6	28994785-29005316	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA050541	Uncertain					Mixed	Not detected			fallopian tube: 0.4	Not detected		
ZNF316	ENST00000305834, MZF-3	ENSG00000205903	Zinc finger protein 316	7	6637322-6656432	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Pancreatic cancer:6.03e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 50.8	Expressed in all		
ZNF317		ENSG00000130803	Zinc finger protein 317	19	9140380-9163424	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042075, HPA048625	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 20.7	Expressed in all		
ZNF318	HRIHFB2436, ZFP318	ENSG00000171467	Zinc finger protein 318	6	43307134-43369478	Predicted intracellular proteins	Evidence at protein level	HPA027022, HPA027031	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 49.6	Expressed in all		
ZNF319	KIAA1388, Zfp319	ENSG00000166188	Zinc finger protein 319	16	57994668-58000453	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052584	Uncertain		Approved	Nucleus	Pancreatic cancer:5.87e-5 (favourable), Liver cancer:1.90e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.9	Expressed in all		
ZNF32	KOX30	ENSG00000169740	Zinc finger protein 32	10	43643859-43648856	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039148, HPA059640			Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:3.02e-4 (favourable), Liver cancer:7.08e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 71.8	Mixed		
ZNF320	DKFZp686G16228, ZFPL	ENSG00000182986	Zinc finger protein 320	19	52863790-52897693	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043696, HPA062474	Uncertain		Approved	Nucleoplasm<br>Cytoplasmic bodies		Expressed in all	Mixed			parathyroid gland: 22.5	Cell line enhanced		RT4: 70.3
ZNF322	bA457M11.2, bA457M11.3, HCG12, ZNF322A, ZNF388, ZNF489	ENSG00000181315	Zinc finger protein 322	6	26634383-26659752	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043161, HPA046692	Approved		Supported	Nucleus<br>Centrosome<br>Cytosol	Glioma:1.75e-4 (favourable), Lung cancer:8.57e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 29.2	Mixed		
ZNF324	ZF5128, ZNF324A	ENSG00000083812	Zinc finger protein 324	19	58467045-58475436	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039774	Uncertain		Approved	Nucleus<br>Nuclear membrane<br>Cytosol	Renal cancer:1.34e-7 (favourable), Pancreatic cancer:4.74e-5 (favourable), Thyroid cancer:6.99e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 8.6	Expressed in all		
ZNF324B	FLJ45850	ENSG00000249471	Zinc finger protein 324B	19	58451604-58457833	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023400	Uncertain		Approved	Nucleoli<br>Cytosol	Pancreatic cancer:2.83e-4 (favourable)	Expressed in all	Mixed			spleen: 4.7	Cell line enhanced		HEK93: 35.2
ZNF326	FLJ20403, ZAN75, Zfp326, ZIRD	ENSG00000162664	Zinc finger protein 326	1	89995112-90035531	Predicted intracellular proteins	Evidence at protein level	HPA028450, HPA028461, HPA028466	Supported		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Urothelial cancer:2.84e-4 (favourable), Breast cancer:9.46e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 29.5	Expressed in all		
ZNF329	FLJ12586	ENSG00000181894	Zinc finger protein 329	19	58126252-58155110	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044373	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:8.58e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 16.9	Mixed		
ZNF330	HSA6591, NOA36	ENSG00000109445	Zinc finger protein 330	4	141220887-141234697	Predicted intracellular proteins	Evidence at protein level	HPA015705, HPA056325	Uncertain		Supported	Nucleoli	Prostate cancer:3.66e-6 (unfavourable), Renal cancer:7.27e-6 (favourable)	Expressed in all	Expressed in all			heart muscle: 68.3	Expressed in all		
ZNF331	RITA, ZNF361, ZNF463	ENSG00000130844	Zinc finger protein 331	19	53520981-53580269	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063157			Approved	Nucleoplasm	Stomach cancer:4.79e-4 (unfavourable), Thyroid cancer:7.43e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 208.6	Cell line enhanced		HEK93: 73.6
ZNF334	bA179N14.1	ENSG00000198185	Zinc finger protein 334	20	46499630-46513559	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050022	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Mixed			ovary: 19.4	Cell line enhanced		AF22: 15.3;BEWO: 18.7;NTERA-2: 10.4;SCLC-21H: 15.2
ZNF335	bA465L10.2, NIF-1	ENSG00000198026	Zinc finger protein 335	20	45948653-45972172	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063999, HPA071230			Enhanced	Nucleoplasm	Renal cancer:2.77e-5 (unfavourable), Liver cancer:1.59e-4 (unfavourable), Head and neck cancer:4.48e-4 (favourable), Prostate cancer:7.04e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 24.6	Expressed in all		
ZNF337	dJ694B14.1	ENSG00000130684	Zinc finger protein 337	20	25674215-25696841	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044303, HPA064219	Approved		Approved	Nuclear speckles<br>Plasma membrane	Renal cancer:2.87e-6 (unfavourable)	Mixed	Expressed in all			parathyroid gland: 27.9	Expressed in all		
ZNF33A	FLJ23404, KIAA0065, KOX31, KOX5, ZNF11A, ZNF33, ZZAPK	ENSG00000189180	Zinc finger protein 33A	10	38010650-38065088	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056638	Approved					Expressed in all	Expressed in all			parathyroid gland: 35.1	Expressed in all		
ZNF33B	KOX2, KOX31, ZNF11B	ENSG00000196693	Zinc finger protein 33B	10	42574185-42638568	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056638	Approved					Expressed in all	Expressed in all			parathyroid gland: 32.1	Mixed		
ZNF341	dJ553F4.3	ENSG00000131061	Zinc finger protein 341	20	33731657-33792269	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023240, HPA024607, HPA067108	Uncertain		Approved	Nucleoplasm<br>Vesicles	Liver cancer:1.87e-4 (unfavourable), Head and neck cancer:3.93e-4 (favourable)	Expressed in all	Mixed			testis: 2.3	Mixed		
ZNF343	MGC10715	ENSG00000088876	Zinc finger protein 343	20	2481817-2524702	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030587, HPA052438	Approved		Approved	Nucleoplasm	Liver cancer:1.38e-6 (unfavourable), Renal cancer:4.53e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.6	Expressed in all		
ZNF345	HZF10	ENSG00000251247	Zinc finger protein 345	19	36850361-36913029	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA025816	Uncertain					Mixed	Mixed			testis: 17.7	Mixed		
ZNF346	JAZ, Zfp346	ENSG00000113761	Zinc finger protein 346	5	177022696-177081189	Predicted intracellular proteins	Evidence at protein level	HPA018485	Approved		Enhanced	Nucleus	Liver cancer:1.88e-7 (unfavourable), Endometrial cancer:9.54e-5 (unfavourable), Pancreatic cancer:1.20e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 18.0	Expressed in all		
ZNF347	ZNF1111	ENSG00000197937	Zinc finger protein 347	19	53124072-53159075	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023448	Uncertain		Approved	Microtubules		Mixed	Expressed in all			spleen: 13.3	Mixed		
ZNF35	HF.10, HF10, Zfp105	ENSG00000169981	Zinc finger protein 35	3	44648727-44660791	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051859, HPA054738	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			testis: 9.2	Mixed		
ZNF350	ZBRK1, ZFQR	ENSG00000256683	Zinc finger protein 350	19	51964343-51986856	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001521	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Urothelial cancer:2.54e-4 (favourable)	Expressed in all	Mixed			prostate: 45.0	Mixed		
ZNF354A	EZNF, HKL1, KID-1, KID1, TCF17	ENSG00000169131	Zinc finger protein 354A	5	178694605-178730702	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052043	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.45e-6 (unfavourable), Ovarian cancer:8.28e-4 (favourable)	Expressed in all	Expressed in all			testis: 15.7	Mixed		
ZNF354B	FLJ25008, KID2	ENSG00000178338	Zinc finger protein 354B	5	178859953-178888122	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA029056	Approved		Approved	Nucleoplasm	Renal cancer:1.30e-5 (unfavourable), Head and neck cancer:9.52e-4 (favourable)	Expressed in all	Expressed in all			placenta: 19.9	Mixed		
ZNF354C	KID3	ENSG00000177932	Zinc finger protein 354C	5	179060415-179083537	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030904	Uncertain		Supported	Nuclear membrane<br>Cytosol		Mixed	Mixed			ovary: 9.2	Cell line enhanced		AN3-CA: 17.5
ZNF358	FLJ10390, ZFEND	ENSG00000198816	Zinc finger protein 358	19	7515292-7521026	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030887, HPA063624	Approved		Approved	Nucleus	Pancreatic cancer:2.50e-4 (favourable)	Expressed in all	Expressed in all			ovary: 84.0	Mixed		
ZNF362	FLJ25476, lin-29, RN	ENSG00000160094	Zinc finger protein 362	1	33256545-33300719	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059239	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			spleen: 22.1	Expressed in all		
ZNF365	KIAA0844, UAN	ENSG00000138311	Zinc finger protein 365	10	62374192-62672011	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052446	Enhanced		Supported	Vesicles<br>Microtubule organizing center		Mixed	Tissue enhanced		cerebral cortex: 54.5	parathyroid gland: 10.9	Cell line enhanced		HaCaT: 18.7;PC-3: 12.7;U-251 MG: 14.7
ZNF366	FLJ39796	ENSG00000178175	Zinc finger protein 366	5	72442652-72507727	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023128, HPA023526	Uncertain					Mixed	Mixed			placenta: 10.2	Cell line enhanced		HUVEC TERT2: 1.0;TIME: 1.1
ZNF367	FLJ33970	ENSG00000165244	Zinc finger protein 367	9	96385941-96418329	Predicted intracellular proteins	Evidence at protein level	HPA015319, HPA015785	Uncertain		Supported	Nucleoplasm	Thyroid cancer:2.34e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 16.0	testis: 11.2	Mixed		
ZNF37A	KOX21, ZNF37	ENSG00000075407	Zinc finger protein 37A	10	38094334-38150293	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003172	Approved		Approved	Vesicles	Renal cancer:2.31e-4 (unfavourable), Liver cancer:2.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 18.1	Expressed in all		
ZNF382	FLJ14686, KS1	ENSG00000161298	Zinc finger protein 382	19	36604817-36634113	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049259	Approved		Approved	Nuclear speckles		Mixed	Mixed			cerebral cortex: 10.9	Mixed		
ZNF383	FLJ35863	ENSG00000188283	Zinc finger protein 383	19	37217926-37248738	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063945	Approved		Supported	Nucleus<br>Nuclear membrane	Urothelial cancer:3.71e-4 (favourable), Pancreatic cancer:9.97e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 9.2	Mixed		
ZNF384	CAGH1A, CIZ, NMP4, NP, TNRC1	ENSG00000126746	Zinc finger protein 384	12	6666477-6689572	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004051	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 66.0	Expressed in all		
ZNF385A	DKFZp586G1122, Hzf, ZFP385, ZNF385	ENSG00000161642	Zinc finger protein 385A	12	54369133-54391298	Predicted intracellular proteins	Evidence at protein level	HPA039799			Supported	Nucleus<br>Cytosol	Renal cancer:9.75e-5 (unfavourable), Colorectal cancer:5.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 170.0	cerebral cortex: 66.1	Cell line enhanced		HEL: 98.3
ZNF385B	FLJ25270, ZNF533	ENSG00000144331	Zinc finger protein 385B	2	179441982-179861505	Predicted intracellular proteins	Evidence at protein level	HPA046086			Supported	Nucleoli fibrillar center	Renal cancer:1.04e-9 (favourable), Breast cancer:4.86e-8 (favourable)	Group enriched	Tissue enhanced		lung: 27.5	prostate: 20.0	Cell line enhanced		Daudi: 12.3;HAP1: 32.8;U-698: 60.0
ZNF385C		ENSG00000187595	Zinc finger protein 385C	17	42025576-42098479	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 8.9	ovary: 2.0	Cell line enhanced		HDLM-2: 1.7;MOLT-4: 2.6;SCLC-21H: 3.0
ZNF385D	FLJ22419, ZNF659	ENSG00000151789	Zinc finger protein 385D	3	21412222-22373321	Predicted intracellular proteins	Evidence at protein level	HPA036190	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 4.8	adipose tissue: 3.1	Cell line enhanced		ASC TERT1: 2.2;RPTEC TERT1: 3.3;U-87 MG: 8.1
ZNF391	dJ153G14.3	ENSG00000124613	Zinc finger protein 391	6	27374615-27403904	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA050886	Uncertain				Ovarian cancer:1.89e-4 (favourable)	Mixed	Mixed			testis: 9.0	Mixed		
ZNF394	FLJ12298, ZKSCAN14, ZSCAN46	ENSG00000160908	Zinc finger protein 394	7	99486519-99500324	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051421, HPA054639	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.09e-4 (favourable), Lung cancer:2.11e-4 (favourable), Breast cancer:3.56e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 62.0	Expressed in all		
ZNF395	DKFZp434K1210, HDBP2, PBF, PRF-1	ENSG00000186918	Zinc finger protein 395	8	28345585-28402701	Predicted intracellular proteins	Evidence at protein level	HPA049382			Approved	Nucleus<br>Cytosol	Renal cancer:5.71e-5 (unfavourable), Liver cancer:1.66e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 67.0	Expressed in all		
ZNF396	FLJ31213, ZSCAN14	ENSG00000186496	Zinc finger protein 396	18	35366697-35377337	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006686	Uncertain					Mixed	Mixed			thyroid gland: 14.3	Mixed		
ZNF397	MGC13250, ZNF47, ZSCAN15	ENSG00000186812	Zinc finger protein 397	18	35241030-35267133	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026087	Uncertain		Approved	Nucleoli<br>Plasma membrane<br>Microtubules<br>Cytosol	Pancreatic cancer:9.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.8	Mixed		
ZNF398	KIAA1339, P51, P71, ZER6	ENSG00000197024	Zinc finger protein 398	7	149126416-149182802	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071533			Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			testis: 16.1	Expressed in all		
ZNF404		ENSG00000176222	Zinc finger protein 404	19	43872363-43901385	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA032014, HPA063607	Uncertain		Approved	Nucleoli<br>Intermediate filaments		Mixed	Mixed			epididymis: 11.7	Cell line enriched	6	U-2 OS: 45.7
ZNF407	FLJ13839, FLJ20307, KIAA1703	ENSG00000215421	Zinc finger protein 407	18	74597870-75065671	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028255, HPA041673	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:9.79e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.0	Mixed		
ZNF408	FLJ12827	ENSG00000175213	Zinc finger protein 408	11	46700818-46705912	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017892	Uncertain		Approved	Microtubule organizing center<br>Cytosol	Liver cancer:6.59e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 8.3	Expressed in all		
ZNF41	MGC8941, MRX89	ENSG00000147124	Zinc finger protein 41	X	47445879-47482946	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069102	Enhanced		Approved	Nucleoplasm	Renal cancer:6.95e-4 (favourable), Head and neck cancer:8.32e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 19.4	Expressed in all		
ZNF410	APA-1, APA1	ENSG00000119725	Zinc finger protein 410	14	73886617-73932511	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002871			Approved	Nuclear bodies		Mixed	Expressed in all			testis: 81.3	Expressed in all		
ZNF414	MGC15716, Zfp414	ENSG00000133250	Zinc finger protein 414	19	8509678-8514164	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053769	Approved		Approved	Nucleus<br>Cytosol	Head and neck cancer:1.67e-6 (favourable), Endometrial cancer:4.17e-4 (favourable), Pancreatic cancer:4.59e-4 (favourable), Urothelial cancer:8.71e-4 (favourable)	Expressed in all	Expressed in all			spleen: 12.3	Mixed		
ZNF415		ENSG00000170954	Zinc finger protein 415	19	53107879-53133077	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005553	Approved		Approved	Nucleoli fibrillar center<br>Microtubules		Mixed	Mixed			testis: 39.6	Cell line enhanced		RT4: 17.7
ZNF416	FLJ20557	ENSG00000083817	Zinc finger protein 416	19	57571566-57578927	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063318			Approved	Nuclear bodies<br>Cytosol	Renal cancer:1.20e-5 (favourable)	Expressed in all	Mixed			testis: 7.8	Mixed		
ZNF417	MGC34079	ENSG00000173480	Zinc finger protein 417	19	57900296-57916610	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042125, HPA043288, HPA056213	Uncertain		Uncertain	Nucleoplasm	Urothelial cancer:3.48e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 59.9	Mixed		
ZNF418	FLJ31551, KIAA1956	ENSG00000196724	Zinc finger protein 418	19	57921884-57935393	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043800, HPA053762, HPA072145	Approved		Uncertain	Nucleus	Prostate cancer:1.72e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 14.8	Cell line enhanced		AF22: 11.0
ZNF420	FLJ32191	ENSG00000197050	Zinc finger protein 420	19	37007857-37130314	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059675	Approved		Approved	Nucleoplasm	Glioma:4.88e-5 (favourable), Renal cancer:1.83e-4 (favourable)	Expressed in all	Mixed			testis: 18.5	Mixed		
ZNF423	Ebfaz, JBTS19, KIAA0760, NPHP14, OAZ, Roaz, Zfp104	ENSG00000102935	Zinc finger protein 423	16	49487524-49857919	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015258, HPA065820	Uncertain		Enhanced	Nucleus		Mixed	Mixed			fallopian tube: 15.4	Cell line enhanced		AF22: 53.5;NTERA-2: 27.7;REH: 22.3;SCLC-21H: 34.3;SH-SY5Y: 92.6
ZNF425		ENSG00000204947	Zinc finger protein 425	7	149102784-149126346	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020087	Uncertain		Supported	Nucleus		Mixed	Mixed			parathyroid gland: 5.5	Mixed		
ZNF426	MGC2663	ENSG00000130818	Zinc finger protein 426	19	9523224-9538645	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029342	Approved		Approved	Nucleoplasm	Renal cancer:2.57e-6 (favourable), Urothelial cancer:1.81e-4 (favourable), Head and neck cancer:3.74e-4 (favourable)	Expressed in all	Mixed			esophagus: 22.7	Mixed		
ZNF428	C19orf37, MGC51082, Zfp428	ENSG00000131116	Zinc finger protein 428	19	43607219-43619874	Predicted intracellular proteins	Evidence at protein level	HPA042596, HPA048072	Uncertain		Approved	Nucleoli<br>Mitochondria	Pancreatic cancer:3.60e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 71.5	Expressed in all		
ZNF429		ENSG00000197013	Zinc finger protein 429	19	21496682-21556270	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004139			Approved	Nucleus	Ovarian cancer:1.96e-8 (favourable), Pancreatic cancer:7.30e-4 (favourable)	Mixed	Mixed			thyroid gland: 16.3	Mixed		
ZNF43	HTF6, KOX27, ZNF39L1	ENSG00000198521	Zinc finger protein 43	19	21804949-21852125	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA050271	Uncertain				Ovarian cancer:3.16e-5 (favourable)	Mixed	Mixed			testis: 16.2	Cell line enhanced		MOLT-4: 31.1
ZNF430	FLJ13659	ENSG00000118620	Zinc finger protein 430	19	21020620-21060050	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059135	Uncertain					Mixed	Mixed			ovary: 15.8	Mixed		
ZNF431	KIAA1969	ENSG00000196705	Zinc finger protein 431	19	21142024-21196053	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059135	Uncertain					Mixed	Mixed			ovary: 26.8	Mixed		
ZNF432	KIAA0798	ENSG00000256087	Zinc finger protein 432	19	52031379-52095738	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052082, HPA060274, HPA065606	Uncertain		Supported	Nucleoplasm	Urothelial cancer:4.11e-5 (favourable), Renal cancer:6.47e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 21.1	Mixed		
ZNF436	KIAA1710, Zfp46	ENSG00000125945	Zinc finger protein 436	1	23359448-23369442	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043817	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			ovary: 12.4	Cell line enhanced		HSkMC: 26.4
ZNF439	DKFZp571K0837	ENSG00000171291	Zinc finger protein 439	19	11848726-11883750	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047845	Uncertain		Uncertain	Nucleus		Mixed	Mixed			parathyroid gland: 25.5	Cell line enhanced		U-138 MG: 15.4
ZNF44	KOX7, ZNF504, ZNF55, ZNF58	ENSG00000197857	Zinc finger protein 44	19	12224686-12294887	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003146	Supported		Approved	Nucleoplasm<br>Microtubules<br>Cytosol	Urothelial cancer:9.21e-6 (favourable), Lung cancer:7.54e-4 (favourable), Head and neck cancer:8.74e-4 (favourable)	Expressed in all	Mixed			skin: 8.6	Mixed		
ZNF440	FLJ37933	ENSG00000171295	Zinc finger protein 440	19	11814284-11835201	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047845	Uncertain		Uncertain	Nucleus	Renal cancer:1.18e-4 (favourable), Prostate cancer:3.57e-4 (unfavourable), Urothelial cancer:9.88e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 23.2	Mixed		
ZNF441	FLJ38637	ENSG00000197044	Zinc finger protein 441	19	11767000-11784078	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA063338			Approved	Nuclear speckles		Expressed in all	Mixed			thyroid gland: 12.1	Mixed		
ZNF442	FLJ14356	ENSG00000198342	Zinc finger protein 442	19	12345949-12365905	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA045738, HPA053407	Uncertain		Approved	Nuclear membrane<br>Vesicles		Mixed	Mixed			ovary: 6.0	Mixed		
ZNF443	ZK1	ENSG00000180855	Zinc finger protein 443	19	12429707-12441112	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003150, HPA018683	Supported		Uncertain	Nucleoplasm<br>Microtubule organizing center	Renal cancer:2.74e-7 (favourable), Urothelial cancer:3.91e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 7.0	Mixed		
ZNF444	EZF2, FLJ11137, ZSCAN17	ENSG00000167685	Zinc finger protein 444	19	56132599-56160893	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056895, HPA065203	Approved		Supported	Nucleus<br>Nucleoli	Urothelial cancer:1.87e-4 (favourable), Renal cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 27.8	Expressed in all		
ZNF445	ZKSCAN15, ZNF168, ZSCAN47	ENSG00000185219	Zinc finger protein 445	3	44431720-44477670	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006678	Uncertain		Approved	Nucleus<br>Mitochondria<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 7.2	Mixed		
ZNF446	FLJ20626, ZKSCAN20, ZSCAN52	ENSG00000083838	Zinc finger protein 446	19	58474017-58481230	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052786			Approved	Nuclear speckles	Pancreatic cancer:1.32e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 11.6	Expressed in all		
ZNF45	ZNF13	ENSG00000124459	Zinc finger protein 45	19	43912629-43935278	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038611, HPA075124	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			parathyroid gland: 18.3	Expressed in all		
ZNF451	COASTER, dJ417I1.1, KIAA0576, KIAA1702	ENSG00000112200	Zinc finger protein 451	6	57086844-57170307	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028838			Approved	Nucleus		Expressed in all	Expressed in all			testis: 51.2	Expressed in all		
ZNF454	FLJ37444	ENSG00000178187	Zinc finger protein 454	5	178941191-178966433	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA024556	Uncertain					Mixed	Mixed			testis: 4.0	Cell line enhanced		AF22: 1.0;EFO-21: 1.9;HHSteC: 1.3;HSkMC: 1.3;NTERA-2: 1.5;SH-SY5Y: 1.1
ZNF460	HZF8, ZNF272	ENSG00000197714	Zinc finger protein 460	19	57280051-57293569	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053004, HPA066506	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			adrenal gland: 6.3	Cell line enhanced		Karpas-707: 9.7
ZNF461	GIOT-1, MGC33911	ENSG00000197808	Zinc finger protein 461	19	36637192-36666853	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA021139	Uncertain		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Endometrial cancer:3.64e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 6.2	Mixed		
ZNF462	DKFZP762N2316, KIAA1803, Zfp462	ENSG00000148143	Zinc finger protein 462	9	106863097-107013634	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA022283	Uncertain		Approved	Nucleoplasm	Renal cancer:6.19e-4 (favourable)	Mixed	Mixed			parathyroid gland: 15.9	Mixed		
ZNF467	EZI, Zfp467	ENSG00000181444	Zinc finger protein 467	7	149764182-149773479	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042907	Uncertain		Approved	Mitochondria	Pancreatic cancer:4.56e-4 (favourable)	Expressed in all	Mixed			spleen: 14.1	Cell line enhanced		AN3-CA: 30.3;HMC-1: 16.5;T-47d: 17.2
ZNF468		ENSG00000204604	Zinc finger protein 468	19	52838008-52857649	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:3.94e-7 (favourable), Breast cancer:6.87e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 20.4	Mixed		
ZNF469	KIAA1858	ENSG00000225614	Zinc finger protein 469	16	88427471-88440757	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069784			Approved	Vesicles		Mixed	Mixed			cervix, uterine: 2.2	Cell line enhanced		SiHa: 5.3;THP-1: 4.3
ZNF470	CZF-1, FLJ26175	ENSG00000197016	Zinc finger protein 470	19	56567511-56588911	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029000	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			cerebral cortex,testis: 5.8	Cell line enhanced		HEK93: 10.0
ZNF471	KIAA1396, Z1971	ENSG00000196263	Zinc finger protein 471	19	56507843-56530221	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066695	Uncertain		Supported	Nucleus	Renal cancer:2.37e-4 (favourable)	Mixed	Mixed			ovary: 27.4	Mixed		
ZNF473	DKFZP434N043, HZFP100, KIAA1141	ENSG00000142528	Zinc finger protein 473	19	50025714-50053414	Predicted intracellular proteins	Evidence at protein level	HPA004191, HPA073309	Uncertain		Supported	Nucleoplasm	Liver cancer:3.72e-4 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 76.4	fallopian tube: 11.1	Expressed in all		
ZNF474	4933409D10Rik, FLJ32921	ENSG00000164185	Zinc finger protein 474	5	122129513-122153571	Predicted intracellular proteins	Evidence at transcript level							Mixed	Group enriched	8	fallopian tube: 26.7;testis: 13.4	lung: 2.5	Mixed		
ZNF479	KR19	ENSG00000185177	Zinc finger protein 479	7	57119614-57139864	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Tissue enriched	42	testis: 4.1	all non-specific tissues: 0.0	Not detected		
ZNF48	DKFZp762K013, FLJ31751, MGC43952, ZNF553	ENSG00000180035	Zinc finger protein 48	16	30378106-30400108	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023806	Uncertain		Supported	Mitochondria	Pancreatic cancer:1.20e-6 (favourable), Renal cancer:7.50e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 14.0	Expressed in all		
ZNF480	MGC32104	ENSG00000198464	Zinc finger protein 480	19	52297177-52325922	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042218	Uncertain		Supported	Nucleoplasm	Melanoma:1.65e-4 (unfavourable), Renal cancer:2.03e-4 (favourable)	Expressed in all	Mixed			lymph node: 14.8	Mixed		
ZNF483	KIAA1962, ZKSCAN16, ZSCAN48	ENSG00000173258	Zinc finger protein 483	9	111525159-111577844	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055041	Uncertain		Approved	Nucleoli		Tissue enhanced	Mixed			cerebral cortex: 13.0	Cell line enhanced		NTERA-2: 7.5;SCLC-21H: 5.1
ZNF484	BA526D8.4, FLJ33884	ENSG00000127081	Zinc finger protein 484	9	92845031-92878038	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028973	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Mixed	Mixed			parathyroid gland: 6.9	Mixed		
ZNF485		ENSG00000198298	Zinc finger protein 485	10	43606407-43617903	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA059356	Uncertain				Breast cancer:5.24e-4 (unfavourable)	Expressed in all	Mixed			testis: 7.2	Mixed		
ZNF486	KRBO2, MGC2396	ENSG00000256229	Zinc finger protein 486	19	20167228-20200490	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		thyroid gland: 63.5	urinary bladder: 17.2	Cell line enhanced		HBF TERT88: 23.4
ZNF487	KRBO1, ZNF487P	ENSG00000243660	Zinc finger protein 487	10	43436841-43483179	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA037820			Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Mixed	Tissue enriched	5	testis: 51.4	fallopian tube: 9.9	Mixed		
ZNF490	KIAA1198	ENSG00000188033	Zinc finger protein 490	19	12577961-12640098	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005576	Uncertain					Mixed	Mixed			thyroid gland: 2.8	Mixed		
ZNF491	FLJ34791	ENSG00000177599	Zinc finger protein 491	19	11797667-11809622	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Mixed			parathyroid gland: 3.6	Mixed		
ZNF492	KIAA1473, ZNF115	ENSG00000229676	Zinc finger protein 492	19	22634324-22667670	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Group enriched	Tissue enhanced		testis: 3.6	bone marrow: 1.6	Cell line enhanced		BEWO: 5.4;NTERA-2: 4.1;U-2197: 3.7
ZNF493	FLJ36504	ENSG00000196268	Zinc finger protein 493	19	21397119-21427573	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Expressed in all			thyroid gland: 34.6	Mixed		
ZNF496	MGC15548, ZKSCAN17, ZSCAN49	ENSG00000162714	Zinc finger protein 496	1	247297412-247331846	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055834			Uncertain	Golgi apparatus		Expressed in all	Expressed in all			fallopian tube: 24.2	Expressed in all		
ZNF497	FLJ44773	ENSG00000174586	Zinc finger protein 497	19	58354357-58362848	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047872	Uncertain		Approved	Nucleus<br>Cell Junctions		Mixed	Mixed			fallopian tube: 8.1	Cell line enhanced		HEK93: 18.3
ZNF500	KIAA0557, ZKSCAN18, ZSCAN50	ENSG00000103199	Zinc finger protein 500	16	4748239-4767624	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035498, HPA057963	Supported		Enhanced	Nucleoplasm<br>Cytosol	Stomach cancer:3.41e-4 (favourable)	Expressed in all	Mixed			spleen: 5.6	Expressed in all		
ZNF501	MGC21738, ZNF52	ENSG00000186446	Zinc finger protein 501	3	44729596-44737083	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044161	Uncertain		Approved	Endoplasmic reticulum		Mixed	Mixed			prostate,testis: 2.7	Mixed		
ZNF502	FLJ12515, FLJ14855	ENSG00000196653	Zinc finger protein 502	3	44712643-44723831	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024761, HPA029557	Uncertain				Renal cancer:4.51e-5 (favourable), Urothelial cancer:2.06e-4 (favourable)	Expressed in all	Mixed			testis: 5.0	Mixed		
ZNF503	FLJ45745, MGC2555, Nlz2	ENSG00000165655	Zinc finger protein 503	10	75397830-75401906	Predicted intracellular proteins	Evidence at protein level	HPA026848	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.97e-4 (favourable), Prostate cancer:3.50e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 25.7	Cell line enhanced		HEK93: 100.8;PC-3: 132.2
ZNF506	DKFZp761G1812	ENSG00000081665	Zinc finger protein 506	19	19785839-19821751	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Expressed in all	Expressed in all			thyroid gland: 16.2	Mixed		
ZNF507	KIAA1084	ENSG00000168813	Zinc finger protein 507	19	32345594-32387667	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030964, HPA049728	Uncertain		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			testis: 35.0	Expressed in all		
ZNF510	KIAA0972	ENSG00000081386	Zinc finger protein 510	9	96755865-96778129	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049139	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:5.94e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 12.5	Expressed in all		
ZNF512	KIAA1805	ENSG00000243943	Zinc finger protein 512	2	27582969-27623215	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031430	Approved		Enhanced	Nucleus	Lung cancer:5.08e-9 (favourable), Endometrial cancer:5.10e-4 (unfavourable), Pancreatic cancer:5.19e-4 (favourable), Breast cancer:9.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 45.7	Mixed		
ZNF512B	GM632, MGC149845, MGC149846	ENSG00000196700	Zinc finger protein 512B	20	63956702-63969865	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006688	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex,parathyroid gland: 16.9	Mixed		
ZNF513	FLJ32203, RP58	ENSG00000163795	Zinc finger protein 513	2	27377231-27380790	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051493	Uncertain				Liver cancer:6.21e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 25.9	Expressed in all		
ZNF514	FLJ14457	ENSG00000144026	Zinc finger protein 514	2	95147330-95165413	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA028974	Approved		Approved	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			epididymis: 32.8	Expressed in all		
ZNF516	HsT287, KIAA0222	ENSG00000101493	Zinc finger protein 516	18	76358190-76495190	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015792	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.21e-4 (favourable), Liver cancer:2.79e-4 (unfavourable), Breast cancer:7.09e-4 (favourable), Pancreatic cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 54.4	Mixed		
ZNF517		ENSG00000197363	Zinc finger protein 517	8	144798876-144811169	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055337			Approved	Nucleoplasm	Pancreatic cancer:1.66e-4 (favourable)	Expressed in all	Mixed			skin: 7.5	Mixed		
ZNF518A	KIAA0335, ZNF518	ENSG00000177853	Zinc finger protein 518A	10	96129715-96205288	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029049			Approved	Nucleus		Expressed in all	Mixed			testis: 30.1	Mixed		
ZNF518B	KIAA1729	ENSG00000178163	Zinc finger protein 518B	4	10439874-10457410	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031215, HPA031216	Approved		Approved	Nucleus		Mixed	Mixed			testis: 16.9	Mixed		
ZNF519	FLJ36809, HsT2362	ENSG00000175322	Zinc finger protein 519	18	14057457-14132490	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028982	Uncertain		Approved	Nucleoli		Mixed	Mixed			endometrium: 4.0	Mixed		
ZNF521	EHZF, Evi3	ENSG00000198795	Zinc finger protein 521	18	25061926-25352190	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023056, HPA023849	Enhanced		Approved	Nucleoplasm		Mixed	Mixed			spleen: 29.0	Cell line enhanced		AF22: 66.8;HUVEC TERT2: 39.1
ZNF524	MGC23143	ENSG00000171443	Zinc finger protein 524	19	55600022-55603138	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050981	Uncertain		Approved	Nucleus	Urothelial cancer:4.98e-8 (favourable)	Expressed in all	Expressed in all			spleen: 15.7	Mixed		
ZNF525	KIAA1979	ENSG00000203326	Zinc finger protein 525	19	53365693-53392217	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			parathyroid gland: 20.7	Mixed		
ZNF526	KIAA1951, MGC4267	ENSG00000167625	Zinc finger protein 526	19	42220271-42228201	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023070, HPA056609	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Vesicles		Expressed in all	Mixed			skin: 6.2	Expressed in all		
ZNF527	KIAA1829	ENSG00000189164	Zinc finger protein 527	19	37371061-37393066	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA037740, HPA037741	Uncertain		Approved	Nuclear speckles<br>Golgi apparatus		Mixed	Mixed			parathyroid gland: 4.8	Mixed		
ZNF528	KIAA1827	ENSG00000167555	Zinc finger protein 528	19	52397849-52418412	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA065435			Approved	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 31.1	Mixed		
ZNF529	KIAA1615	ENSG00000186020	Zinc finger protein 529	19	36534774-36605276	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA031311	Uncertain		Approved	Nucleoplasm	Urothelial cancer:1.39e-5 (favourable)	Expressed in all	Mixed			testis: 17.4	Mixed		
ZNF530	KIAA1508	ENSG00000183647	Zinc finger protein 530	19	57599885-57612722	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045868	Uncertain		Approved	Vesicles		Mixed	Mixed			spleen: 3.1	Cell line enhanced		HEK93: 68.7;U-266/84: 40.3
ZNF532	FLJ10697	ENSG00000074657	Zinc finger protein 532	18	58862600-58986480	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015322	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:6.46e-5 (unfavourable), Urothelial cancer:5.76e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 104.4	Cell line enhanced		AF22: 113.9
ZNF534	FLJ25344, KRBO3	ENSG00000198633	Zinc finger protein 534	19	52429187-52452315	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Tissue enhanced		testis: 2.4	cerebral cortex: 0.9	Not detected		
ZNF536	KIAA0390	ENSG00000198597	Zinc finger protein 536	19	30228290-30713538	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077341			Approved	Nucleus<br>Cell Junctions		Mixed	Tissue enhanced		cerebral cortex: 19.0	thyroid gland: 5.3	Cell line enhanced		HAP1: 11.4;SH-SY5Y: 31.3;WM-115: 12.5
ZNF540	DKFZp547B0714	ENSG00000171817	Zinc finger protein 540	19	37551406-37614097	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003444	Supported		Supported	Nucleoplasm<br>Vesicles<br>Cytosol		Mixed	Mixed			thyroid gland: 13.3	Mixed		
ZNF541	DKFZp434I1930	ENSG00000118156	Zinc finger protein 541	19	47520685-47555856	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058541, HPA076453	Enhanced		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:2.94e-4 (favourable)	Tissue enhanced	Tissue enriched	11	testis: 19.2	ovary: 1.7	Group enriched	6	HEL: 1.4;SiHa: 5.3;U-87 MG: 1.6
ZNF543	DKFZp434H055	ENSG00000178229	Zinc finger protein 543	19	57320509-57330776	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029736, HPA057665	Uncertain		Approved	Nuclear speckles<br>Cytosol	Renal cancer:2.03e-5 (favourable)	Expressed in all	Mixed			ovary: 6.0	Mixed		
ZNF544	AF020591	ENSG00000198131	Zinc finger protein 544	19	58228594-58277495	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002732	Approved		Approved	Nucleoplasm	Liver cancer:1.04e-5 (unfavourable), Melanoma:3.65e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 48.6	Cell line enhanced		HEK93: 153.3
ZNF546	MGC43537, ZNF49	ENSG00000187187	Zinc finger protein 546	19	39984134-40021041	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030838			Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		testis: 14.4	parathyroid gland,thyroid gland: 3.2	Mixed		
ZNF547	FLJ31100	ENSG00000152433	Zinc finger protein 547	19	57363477-57379565	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA056001	Uncertain					Mixed	Mixed			thyroid gland: 5.2	Mixed		
ZNF548	FLJ32932	ENSG00000188785	Zinc finger protein 548	19	57389850-57402992	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066042	Uncertain		Approved	Nucleus	Breast cancer:7.85e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 32.6	Mixed		
ZNF549	FLJ34917	ENSG00000121406	Zinc finger protein 549	19	57527325-57557542	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039511	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			parathyroid gland: 10.2	Mixed		
ZNF550	MGC41917	ENSG00000251369	Zinc finger protein 550	19	57535257-57559863	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003251	Uncertain		Approved	Vesicles<br>Microtubules	Prostate cancer:2.21e-4 (unfavourable)	Expressed in all	Mixed			ovary: 12.7	Mixed		
ZNF551	DKFZp686H1038	ENSG00000204519	Zinc finger protein 551	19	57681969-57717301	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038187			Approved	Nucleoplasm<br>Nuclear speckles	Melanoma:7.68e-5 (unfavourable), Renal cancer:1.32e-4 (favourable)	Expressed in all	Mixed			testis: 8.0	Mixed		
ZNF552	FLJ21603	ENSG00000178935	Zinc finger protein 552	19	57803841-57814913	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043800, HPA053762, HPA072145	Uncertain		Uncertain	Nucleus	Colorectal cancer:2.66e-4 (favourable), Breast cancer:4.57e-4 (favourable), Head and neck cancer:9.96e-4 (favourable)	Expressed in all	Mixed			breast: 33.9	Expressed in all		
ZNF554	FLJ34817	ENSG00000172006	Zinc finger protein 554	19	2819874-2835773	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060247, HPA063358	Uncertain		Supported	Nucleoplasm<br>Nucleoli	Renal cancer:1.99e-5 (favourable), Pancreatic cancer:4.69e-4 (favourable), Urothelial cancer:5.00e-4 (favourable), Lung cancer:9.31e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 7.5	Mixed		
ZNF555	MGC26707	ENSG00000186300	Zinc finger protein 555	19	2841435-2860484	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053956, HPA055430	Uncertain					Mixed	Mixed			testis: 10.4	Mixed		
ZNF556	FLJ11637	ENSG00000172000	Zinc finger protein 556	19	2867335-2883445	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA060593			Approved	Nucleus		Mixed	Tissue enhanced		fallopian tube: 3.3;ovary: 6.5	testis: 1.3	Cell line enhanced		Hep G2: 9.1;RH-30: 18.6
ZNF557	MGC4054	ENSG00000130544	Zinc finger protein 557	19	7069444-7087968	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003151, HPA029291	Uncertain		Approved	Nucleus<br>Intermediate filaments<br>Cytosol	Head and neck cancer:3.67e-6 (favourable), Pancreatic cancer:1.51e-4 (favourable), Lung cancer:2.62e-4 (favourable), Endometrial cancer:5.70e-4 (favourable)	Expressed in all	Mixed			testis: 5.4	Expressed in all		
ZNF558	FLJ30932	ENSG00000167785	Zinc finger protein 558	19	8806170-8832328	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003151	Uncertain				Renal cancer:1.23e-6 (unfavourable), Urothelial cancer:9.30e-5 (favourable), Head and neck cancer:1.04e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 19.0	Mixed		
ZNF559	MGC13105	ENSG00000188321	Zinc finger protein 559	19	9323772-9351162	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059632, HPA065485	Approved		Supported	Nucleoplasm<br>Cytosol	Ovarian cancer:6.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 40.8	Mixed		
ZNF559-ZNF177		ENSG00000270011	ZNF559-ZNF177 readthrough	19	9324174-9382617	Predicted intracellular proteins	Evidence at transcript level	HPA003141	Uncertain					Not detected	Mixed			testis: 10.2	Cell line enhanced		HEK93: 6.1
ZNF560	FLJ31986	ENSG00000198028	Zinc finger protein 560	19	9466507-9498607	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045439, HPA063209			Supported	Nucleoplasm<br>Plasma membrane		Tissue enriched	Tissue enriched	9	testis: 11.9	placenta: 1.2	Cell line enhanced		HEL: 19.1;NTERA-2: 20.6
ZNF561	MGC45408	ENSG00000171469	Zinc finger protein 561	19	9604680-9621399	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055332, HPA062397	Uncertain		Approved	Nucleoplasm	Renal cancer:1.16e-4 (favourable), Ovarian cancer:1.31e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 38.2	Mixed		
ZNF562	FLJ20079	ENSG00000171466	Zinc finger protein 562	19	9641808-9675086	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055332, HPA062397	Uncertain		Approved	Nucleoplasm	Head and neck cancer:4.17e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 18.7	Expressed in all		
ZNF563	FLJ34797	ENSG00000188868	Zinc finger protein 563	19	12317477-12333720	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042136	Uncertain					Expressed in all	Tissue enhanced		testis: 25.7	thyroid gland: 8.5	Mixed		
ZNF564	MGC26914	ENSG00000249709	Zinc finger protein 564	19	12525370-12551542	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043998	Uncertain		Approved	Golgi apparatus		Not detected	Mixed			thyroid gland: 10.5	Mixed		
ZNF565	FLJ36991	ENSG00000196357	Zinc finger protein 565	19	36182060-36246257	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044123	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			testis: 11.6	Mixed		
ZNF566	FLJ14779, MGC12515	ENSG00000186017	Zinc finger protein 566	19	36445119-36489902	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023456	Uncertain		Approved	Nucleus	Endometrial cancer:1.86e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 8.0	Mixed		
ZNF567	MGC45586	ENSG00000189042	Zinc finger protein 567	19	36687612-36727701	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023937	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 16.1	Mixed		
ZNF568	DKFZp686B0797	ENSG00000198453	Zinc finger protein 568	19	36916329-36998700	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052061	Uncertain					Mixed	Mixed			parathyroid gland: 14.3	Mixed		
ZNF569	FLJ32053, ZAP1	ENSG00000196437	Zinc finger protein 569	19	37411155-37469275	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052994	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Mixed	Mixed			testis: 20.5	Mixed		
ZNF57	ZNF424	ENSG00000171970	Zinc finger protein 57	19	2900898-2918476	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA061915			Approved	Nucleoli	Renal cancer:4.11e-9 (favourable), Lung cancer:6.26e-4 (favourable), Pancreatic cancer:7.72e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 47.3	skin: 11.5	Mixed		
ZNF571	HSPC059	ENSG00000180479	Zinc finger protein 571	19	37554782-37594790	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA054762			Approved	Nucleus<br>Nucleoli<br>Plasma membrane		Mixed	Tissue enriched	6	thyroid gland: 130.6	parathyroid gland: 21.6	Mixed		
ZNF572	FLJ38002	ENSG00000180938	Zinc finger protein 572	8	124973298-124979389	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066838	Enhanced		Approved	Nuclear speckles		Expressed in all	Mixed			testis: 6.7	Mixed		
ZNF573	FLJ30921	ENSG00000189144	Zinc finger protein 573	19	37735833-37817300	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA042776	Uncertain		Approved	Intermediate filaments<br>Cytosol		Mixed	Mixed			thyroid gland: 4.2	Mixed		
ZNF574	FLJ22059	ENSG00000105732	Zinc finger protein 574	19	42068477-42081549	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023196, HPA057274	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 36.5	Expressed in all		
ZNF575	FLJ32567	ENSG00000176472	Zinc finger protein 575	19	43525497-43536130	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051865	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Expressed in all	Mixed			colon: 4.3	Cell line enhanced		MOLT-4: 6.2
ZNF576	MGC2508	ENSG00000124444	Zinc finger protein 576	19	43596392-43601157	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050064	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus	Liver cancer:1.29e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 15.4	Expressed in all		
ZNF577	MGC4400	ENSG00000161551	Zinc finger protein 577	19	51804816-51890950	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041499, HPA046761	Uncertain		Supported	Nucleus<br>Nucleoli	Urothelial cancer:2.03e-4 (favourable)	Mixed	Mixed			ovary: 28.9	Mixed		
ZNF578	FLJ31384	ENSG00000258405	Zinc finger protein 578	19	52453576-52512154	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	5	testis: 14.0	thyroid gland: 2.6	Cell line enhanced		NTERA-2: 4.2;U-266/84: 6.8
ZNF579	FLJ35453	ENSG00000218891	Zinc finger protein 579	19	55576770-55580845	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062812	Approved		Approved	Nucleus	Renal cancer:1.00e-5 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 13.0	Expressed in all		
ZNF580		ENSG00000213015	Zinc finger protein 580	19	55635016-55643469	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054058	Approved		Approved	Nucleus	Renal cancer:5.79e-6 (unfavourable), Pancreatic cancer:2.36e-5 (favourable), Liver cancer:5.63e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 38.1	Expressed in all		
ZNF581	FLJ22550, HSPC189	ENSG00000171425	Zinc finger protein 581	19	55635459-55645622	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059657	Uncertain				Liver cancer:5.74e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 21.7	Expressed in all		
ZNF582	FLJ30927	ENSG00000018869	Zinc finger protein 582	19	56375846-56393545	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA028858	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			thyroid gland: 12.4	Cell line enhanced		HEK93: 26.0
ZNF583	FLJ31030	ENSG00000198440	Zinc finger protein 583	19	56397966-56436035	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023805, HPA023957	Uncertain		Approved	Nucleoli<br>Cytosol		Mixed	Mixed			testis: 13.7	Mixed		
ZNF585A	FLJ23765	ENSG00000196967	Zinc finger protein 585A	19	37106734-37172741	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Expressed in all			thyroid gland: 17.9	Mixed		
ZNF585B	FLJ14928, SZFP41	ENSG00000245680	Zinc finger protein 585B	19	37181579-37218153	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA075556			Approved	Nucleoplasm<br>Cytoplasmic bodies		Expressed in all	Mixed			parathyroid gland: 19.7	Mixed		
ZNF586	FLJ20070	ENSG00000083828	Zinc finger protein 586	19	57769655-57819939	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030306, HPA060782	Approved		Approved	Nucleoli fibrillar center<br>Vesicles	Breast cancer:9.83e-5 (favourable), Urothelial cancer:5.36e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 16.3	Mixed		
ZNF587	FLJ14710, FLJ20813, UBF-fl, ZF6	ENSG00000198466	Zinc finger protein 587	19	57849857-57865112	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042125, HPA043288, HPA056213	Uncertain		Uncertain	Nucleoplasm	Renal cancer:7.98e-4 (unfavourable)	Expressed in all	Mixed			rectum: 17.0	Expressed in all		
ZNF587B		ENSG00000269343	Zinc finger protein 587B	19	57819741-57846238	Predicted intracellular proteins	Evidence at protein level	HPA043800, HPA053762, HPA072145	Uncertain		Uncertain	Nucleus	Prostate cancer:1.33e-4 (unfavourable), Melanoma:1.37e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.2	Expressed in all		
ZNF589	SZF1	ENSG00000164048	Zinc finger protein 589	3	48241100-48299253	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003145	Uncertain		Approved	Nucleoplasm	Lung cancer:6.45e-5 (favourable), Pancreatic cancer:1.21e-4 (favourable), Head and neck cancer:1.71e-4 (favourable), Cervical cancer:2.50e-4 (favourable)	Expressed in all	Mixed			prostate: 28.0	Expressed in all		
ZNF592	CAMOS, KIAA0211, SCAR5	ENSG00000166716	Zinc finger protein 592	15	84748635-84806432	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020332, HPA021600	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 16.7	Expressed in all		
ZNF593	ZT86	ENSG00000142684	Zinc finger protein 593	1	26169871-26170873	Predicted intracellular proteins	Evidence at protein level	HPA054363, HPA059387	Supported		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			breast: 16.4	Expressed in all		
ZNF594	KIAA1871	ENSG00000180626	Zinc finger protein 594	17	5179536-5191883	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060283, HPA067178, HPA069360			Enhanced	Nucleus		Mixed	Mixed			ovary,parathyroid gland: 13.9	Mixed		
ZNF595	FLJ31740	ENSG00000272602	Zinc finger protein 595	4	53285-88211	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			placenta: 87.9	Cell line enhanced		K-562: 222.3;SH-SY5Y: 169.9
ZNF596		ENSG00000172748	Zinc finger protein 596	8	232137-264703	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055463	Uncertain		Approved	Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		testis: 27.8	parathyroid gland: 12.9	Mixed		
ZNF597	FLJ33071, HIT-4	ENSG00000167981	Zinc finger protein 597	16	3432422-3443542	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA001556	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 7.2	Mixed		
ZNF598	FLJ00086	ENSG00000167962	Zinc finger protein 598	16	1997654-2009823	Predicted intracellular proteins	Evidence at protein level	HPA041760, HPA041896	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			spleen: 11.5	Expressed in all		
ZNF599	FLJ30663	ENSG00000153896	Zinc finger protein 599	19	34758076-34773229	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA014701	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Mixed			epididymis: 14.6	Mixed		
ZNF600	DKFZp686F06123, KR-ZNF1	ENSG00000189190	Zinc finger protein 600	19	52764195-52786791	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:4.98e-7 (unfavourable), Urothelial cancer:1.11e-5 (favourable)	Expressed in all	Mixed			spleen: 7.8	Cell line enhanced		RT4: 17.0
ZNF605		ENSG00000196458	Zinc finger protein 605	12	132918308-132956306	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA061970, HPA062655	Uncertain		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			parathyroid gland: 11.3	Mixed		
ZNF606	FLJ14260, KIAA1852, ZNF328	ENSG00000166704	Zinc finger protein 606	19	57977053-58003349	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041712, HPA043584	Uncertain		Supported	Nucleoplasm	Urothelial cancer:4.75e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 18.9	Cell line enhanced		HEK93: 21.5
ZNF607	FLJ14802, MGC13071	ENSG00000198182	Zinc finger protein 607	19	37696363-37719790	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049465, HPA055018	Uncertain		Approved	Nucleoplasm	Urothelial cancer:5.23e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.6	Mixed		
ZNF608	DKFZp434M098, KIAA1281, NY-REN-36	ENSG00000168916	Zinc finger protein 608	5	124636913-124748807	Predicted intracellular proteins	Evidence at protein level	HPA005545	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.28e-5 (unfavourable), Endometrial cancer:5.47e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 18.2	Cell line enhanced		AF22: 60.2;REH: 100.7
ZNF609	KIAA0295	ENSG00000180357	Zinc finger protein 609	15	64460742-64686068	Predicted intracellular proteins	Evidence at protein level	HPA040742, HPA040832	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 40.7	Expressed in all		
ZNF610	FLJ36040	ENSG00000167554	Zinc finger protein 610	19	52336245-52367778	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055771, HPA078134	Enhanced		Approved	Nucleus	Renal cancer:1.05e-7 (favourable), Ovarian cancer:3.38e-4 (favourable)	Mixed	Tissue enhanced		testis: 22.0	ovary: 10.4	Mixed		
ZNF611	MGC5384	ENSG00000213020	Zinc finger protein 611	19	52702813-52735073	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:3.33e-4 (favourable)	Mixed	Mixed			fallopian tube: 11.1	Mixed		
ZNF613	FLJ13590	ENSG00000176024	Zinc finger protein 613	19	51927147-51948759	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA026833	Uncertain		Approved	Nucleoplasm<br>Vesicles	Urothelial cancer:1.92e-6 (favourable)	Expressed in all	Tissue enhanced		prostate: 32.4	placenta: 9.8	Mixed		
ZNF614	FLJ21941	ENSG00000142556	Zinc finger protein 614	19	52012765-52030240	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021197	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Cytosol		Expressed in all	Mixed			prostate: 14.0	Expressed in all		
ZNF615	FLJ33710	ENSG00000197619	Zinc finger protein 615	19	51991332-52008230	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA052422	Uncertain		Approved	Nucleoli<br>Mitochondria	Urothelial cancer:2.98e-4 (favourable)	Expressed in all	Mixed			prostate: 28.7	Mixed		
ZNF616	MGC45556	ENSG00000204611	Zinc finger protein 616	19	52113091-52139922	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062639, HPA071539	Approved		Approved	Centrosome		Expressed in all	Expressed in all			adrenal gland: 17.2	Mixed		
ZNF618	KIAA1952, NEDD10	ENSG00000157657	Zinc finger protein 618	9	113876282-114056591	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023116, HPA061732	Uncertain		Approved	Nucleoplasm	Renal cancer:5.22e-7 (favourable), Glioma:8.34e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 16.5	Mixed		
ZNF619	FLJ90764	ENSG00000177873	Zinc finger protein 619	3	40477113-40490236	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045094	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments		Expressed in all	Mixed			parathyroid gland: 7.7	Mixed		
ZNF620	MGC50836	ENSG00000177842	Zinc finger protein 620	3	40505992-40518736	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031452, HPA059383	Uncertain		Approved	Centrosome		Mixed	Mixed			thyroid gland: 6.0	Mixed		
ZNF621	FLJ45246	ENSG00000172888	Zinc finger protein 621	3	40524878-40574685	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065518, HPA071440			Supported	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 22.6	Expressed in all		
ZNF622	MGC17552, MGC2485, ZPR9	ENSG00000173545	Zinc finger protein 622	5	16451519-16465792	Predicted intracellular proteins	Evidence at protein level	HPA036514, HPA036515	Uncertain		Enhanced	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			heart muscle: 28.4	Expressed in all		
ZNF623	KIAA0628	ENSG00000183309	Zinc finger protein 623	8	143636013-143656418	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA044372	Uncertain		Approved	Nucleus	Endometrial cancer:2.94e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 6.2	Cell line enhanced		SiHa: 24.6
ZNF624	KIAA1349	ENSG00000197566	Zinc finger protein 624	17	16620737-16653856	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023157, HPA023244	Uncertain		Approved	Vesicles		Mixed	Mixed			testis: 9.0	Mixed		
ZNF625		ENSG00000257591	Zinc finger protein 625	19	12142090-12156729	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA074014			Approved	Nucleus<br>Mitochondria		Mixed	Mixed			thyroid gland: 4.7	Mixed		
ZNF626		ENSG00000188171	Zinc finger protein 626	19	20620061-20661596	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA045631	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles		Mixed	Expressed in all			parathyroid gland: 52.8	Mixed		
ZNF627	FLJ90365	ENSG00000198551	Zinc finger protein 627	19	11559374-11619135	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049770, HPA073463	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:6.93e-7 (favourable), Head and neck cancer:8.12e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 20.7	Expressed in all		
ZNF628	ZEC, Zfp628	ENSG00000197483	Zinc finger protein 628	19	55476332-55484487	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044451	Uncertain		Approved	Nucleoplasm		Expressed in all	Tissue enhanced		testis: 7.2	spleen: 2.7	Mixed		
ZNF629	KIAA0326, ZNF65	ENSG00000102870	Zinc finger protein 629	16	30778449-30787202	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019550, HPA056051	Uncertain		Supported	Nucleus<br>Golgi apparatus	Renal cancer:4.57e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.8	Mixed		
ZNF630	BC037316, dJ54B20.2, FLJ20573, MGC138344	ENSG00000221994	Zinc finger protein 630	X	47983356-48071658	Predicted intracellular proteins	Evidence at protein level	HPA001053, HPA068130	Supported		Approved	Nucleus<br>Cytosol		Mixed	Mixed			parathyroid gland: 7.5	Cell line enhanced		SiHa: 5.2
ZNF638	MGC26130, NP220, ZFML, Zfp638	ENSG00000075292	Zinc finger protein 638	2	71276561-71435069	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036784, HPA057395	Supported		Enhanced	Nucleoplasm<br>Vesicles	Urothelial cancer:8.73e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.9	Expressed in all		
ZNF639	ANC-2H01, ZASC1	ENSG00000121864	Zinc finger protein 639	3	179322991-179338583	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049023, HPA052163	Uncertain		Supported	Nucleoplasm	Glioma:7.36e-5 (favourable), Liver cancer:2.13e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 69.0	Expressed in all		
ZNF641	FLJ31295	ENSG00000167528	Zinc finger protein 641	12	48337180-48351414	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035189	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:8.30e-5 (favourable), Ovarian cancer:3.91e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 28.8	Expressed in all		
ZNF644	BM-005, KIAA1221, MGC60165, MGC70410	ENSG00000122482	Zinc finger protein 644	1	90915298-91022272	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057795	Uncertain		Uncertain	Vesicles	Colorectal cancer:4.27e-4 (favourable), Endometrial cancer:8.39e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 31.0	Expressed in all		
ZNF645	CT138, FLJ25735, HAKAIL	ENSG00000175809	Zinc finger protein 645	X	22272943-22274461	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	141	testis: 14.1	all non-specific tissues: 0.0	Not detected		
ZNF646	KIAA0296	ENSG00000167395	Zinc finger protein 646	16	31074422-31084196	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042364, HPA066468	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.28e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 34.3	spleen: 10.8	Expressed in all		
ZNF648	FLJ46813	ENSG00000179930	Zinc finger protein 648	1	182054570-182061712	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA053897	Uncertain					Not detected	Not detected			ovary,testis: 0.6	Cell line enriched	87	HMC-1: 31.7
ZNF649	FLJ12644	ENSG00000198093	Zinc finger protein 649	19	51889224-51905040	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026541	Uncertain				Renal cancer:4.60e-5 (favourable), Melanoma:7.44e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 33.8	Mixed		
ZNF652	KIAA0924	ENSG00000198740	Zinc finger protein 652	17	49289206-49362473	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044408	Uncertain		Approved	Nucleus	Endometrial cancer:1.35e-4 (favourable)	Expressed in all	Mixed			breast: 7.2	Mixed		
ZNF653	Zip67	ENSG00000161914	Zinc finger protein 653	19	11483427-11505923	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023631, HPA023635	Uncertain		Supported	Nucleus	Endometrial cancer:4.15e-4 (favourable), Colorectal cancer:8.37e-4 (unfavourable), Urothelial cancer:8.74e-4 (favourable)	Expressed in all	Mixed			testis: 19.0	Expressed in all		
ZNF654	FLJ10997, FLJ21142	ENSG00000175105	Zinc finger protein 654	3	88059274-88144665	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036172, HPA036173, HPA049262, HPA077939	Uncertain		Supported	Nucleoplasm<br>Microtubules	Prostate cancer:9.97e-6 (unfavourable)	Expressed in all	Mixed			testis: 11.8	Expressed in all		
ZNF655	VIK, VIK-1	ENSG00000197343	Zinc finger protein 655	7	99558406-99576453	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029534, HPA050750	Uncertain		Supported	Nucleoplasm<br>Plasma membrane	Breast cancer:7.12e-4 (favourable), Melanoma:7.24e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 21.2	Mixed		
ZNF658	DKFZp572C163, FLJ32813, MGC35232	ENSG00000274349	Zinc finger protein 658	9	66856426-66932141	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047730, HPA048668	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			skin: 9.7	Mixed		
ZNF660	FLJ36870	ENSG00000144792	Zinc finger protein 660	3	44578223-44599694	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029705	Uncertain		Uncertain	Nucleoli fibrillar center<br>Cytosol		Mixed	Mixed			ovary: 3.1	Cell line enhanced		AF22: 3.3;HEL: 3.1;NTERA-2: 5.2;RH-30: 3.3
ZNF662	FLJ45880	ENSG00000182983	Zinc finger protein 662	3	42905731-42917641	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039116, HPA040377	Uncertain					Mixed	Mixed			skin: 13.3	Cell line enhanced		SH-SY5Y: 3.6;U-2 OS: 4.9
ZNF664	DKFZp761B128, ZFOC1, ZNF176	ENSG00000179195	Zinc finger protein 664	12	123971845-124015439	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA047846			Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 236.1	Expressed in all		
ZNF665	FLJ14345	ENSG00000197497	Zinc finger protein 665	19	53159213-53193386	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA023437	Uncertain		Approved	Nuclear membrane		Mixed	Mixed			ovary: 3.7	Mixed		
ZNF667	FLJ14011	ENSG00000198046	Zinc finger protein 667	19	56439325-56478065	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030731, HPA046673	Uncertain		Approved	Nucleus		Mixed	Mixed			cerebral cortex: 18.3	Cell line enhanced		HEL: 11.0;U-138 MG: 14.5
ZNF668	FLJ13479	ENSG00000167394	Zinc finger protein 668	16	31060843-31074320	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043048	Uncertain		Approved	Nucleus<br>Nucleoli	Prostate cancer:6.24e-4 (unfavourable)	Expressed in all	Mixed			testis: 6.9	Expressed in all		
ZNF669	FLJ12606	ENSG00000188295	Zinc finger protein 669	1	247099962-247104372	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044043	Uncertain		Approved	Nucleoli	Renal cancer:4.59e-7 (favourable)	Expressed in all	Mixed			testis: 8.7	Mixed		
ZNF670	MGC12466	ENSG00000277462	Zinc finger protein 670	1	247036784-247078755	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003142	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 6.1	Expressed in all		
ZNF671	FLJ23506	ENSG00000083814	Zinc finger protein 671	19	57719751-57727624	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046099	Uncertain		Approved	Nucleoplasm	Breast cancer:2.20e-4 (favourable), Pancreatic cancer:3.57e-4 (favourable)	Mixed	Mixed			parathyroid gland: 16.6	Mixed		
ZNF672	FLJ22301	ENSG00000171161	Zinc finger protein 672	1	248838210-248849517	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055779, HPA062506	Approved		Enhanced	Nucleoplasm	Urothelial cancer:1.79e-5 (favourable), Pancreatic cancer:7.51e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 24.8	Expressed in all		
ZNF674	MRX92, ZNF673B	ENSG00000251192	Zinc finger protein 674	X	46497727-46545457	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031026, HPA065295	Uncertain					Mixed	Mixed			prostate: 3.3	Mixed		
ZNF675	TBZF, TIZ	ENSG00000197372	Zinc finger protein 675	19	23525631-23687220	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Expressed in all			testis: 25.1	Cell line enhanced		HDLM-2: 56.3
ZNF676		ENSG00000196109	Zinc finger protein 676	19	22179091-22196951	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Tissue enhanced		parathyroid gland: 4.4;testis: 4.0	thyroid gland: 3.0	Cell line enriched	9	NTERA-2: 7.0
ZNF677	MGC48625	ENSG00000197928	Zinc finger protein 677	19	53235381-53254898	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023106, HPA024796	Approved		Approved	Nucleus<br>Centrosome		Mixed	Expressed in all			testis: 71.1	Cell line enhanced		NTERA-2: 30.7
ZNF678	MGC42493	ENSG00000181450	Zinc finger protein 678	1	227563543-227677443	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA028507	Uncertain		Approved	Nucleoli<br>Mitochondria<br>Cytosol		Expressed in all	Mixed			thyroid gland: 8.9	Expressed in all		
ZNF679	MGC42415	ENSG00000197123	Zinc finger protein 679	7	64228474-64266931	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	17	testis: 1.6	all non-specific tissues: 0.0	Not detected		
ZNF680	FLJ90430	ENSG00000173041	Zinc finger protein 680	7	64519884-64563106	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003173			Approved	Nucleus		Expressed in all	Expressed in all			thyroid gland: 42.5	Mixed		
ZNF681	FLJ31526	ENSG00000196172	Zinc finger protein 681	19	23739195-23758891	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			testis: 4.6	Cell line enhanced		HDLM-2: 15.0
ZNF682	BC39498_3	ENSG00000197124	Zinc finger protein 682	19	19997058-20039506	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055998	Uncertain		Uncertain	Golgi apparatus	Urothelial cancer:3.51e-4 (favourable)	Tissue enhanced	Mixed			thyroid gland: 13.3	Cell line enhanced		AN3-CA: 20.2
ZNF683	Hobit, MGC33414	ENSG00000176083	Zinc finger protein 683	1	26361634-26374522	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023865	Uncertain				Endometrial cancer:2.90e-5 (favourable), Urothelial cancer:3.45e-5 (favourable)	Mixed	Tissue enriched	11	testis: 78.7	lung: 7.1	Cell line enhanced		NB-4: 1.4
ZNF684	MGC27466	ENSG00000117010	Zinc finger protein 684	1	40531561-40548169	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA059153	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:4.89e-10 (favourable)	Expressed in all	Mixed			kidney: 6.8	Cell line enhanced		THP-1: 23.3
ZNF687	KIAA1441	ENSG00000143373	Zinc finger protein 687	1	151281618-151292180	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021193, HPA023948	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 26.0	Expressed in all		
ZNF688		ENSG00000229809	Zinc finger protein 688	16	30569346-30572734	Predicted intracellular proteins	Evidence at transcript level	HPA048922	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:4.58e-5 (favourable), Lung cancer:3.24e-4 (favourable), Breast cancer:5.90e-4 (favourable), Pancreatic cancer:6.61e-4 (favourable), Cervical cancer:7.74e-4 (favourable)	Expressed in all	Expressed in all			testis: 23.7	Expressed in all		
ZNF689	FLJ90415	ENSG00000156853	Zinc finger protein 689	16	30602558-30624012	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054095, HPA055385	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Pancreatic cancer:9.89e-4 (favourable)	Expressed in all	Expressed in all			testis: 35.4	Expressed in all		
ZNF69	Cos5	ENSG00000198429	Zinc finger protein 69	19	11887784-11914329	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047845	Uncertain		Uncertain	Nucleus	Endometrial cancer:1.55e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 24.9	kidney: 10.3	Cell line enhanced		AF22: 13.8
ZNF692	AREBP, FLJ20531, Zfp692	ENSG00000171163	Zinc finger protein 692	1	248850006-248859144	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059337, HPA062792	Uncertain		Enhanced	Nucleus<br>Nucleoli	Renal cancer:7.72e-9 (unfavourable), Urothelial cancer:8.35e-5 (favourable), Pancreatic cancer:4.09e-4 (favourable)	Expressed in all	Expressed in all			testis: 26.8	Expressed in all		
ZNF695	SBZF3	ENSG00000197472	Zinc finger protein 695	1	246945547-247008093	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024743	Uncertain		Approved	Nuclear speckles		Mixed	Tissue enhanced		testis: 1.2	small intestine: 0.6	Mixed		
ZNF696	FLJ14129	ENSG00000185730	Zinc finger protein 696	8	143289676-143298061	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057855, HPA072473	Uncertain		Approved	Nucleus<br>Nucleoli	Endometrial cancer:3.52e-5 (unfavourable), Cervical cancer:6.63e-5 (unfavourable), Pancreatic cancer:1.41e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 9.8	Mixed		
ZNF697	MGC45731	ENSG00000143067	Zinc finger protein 697	1	119619422-119647773	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049933	Uncertain		Approved	Nucleoplasm	Renal cancer:6.20e-5 (favourable)	Expressed in all	Mixed			placenta: 10.9	Cell line enhanced		SK-MEL-30: 35.9;WM-115: 45.9
ZNF699	FLJ38144, hang	ENSG00000196110	Zinc finger protein 699	19	9294275-9309838	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058287	Uncertain					Mixed	Mixed			parathyroid gland: 4.9	Cell line enhanced		U-138 MG: 14.3
ZNF7	HF.16, KOX4	ENSG00000147789	Zinc finger protein 7	8	144827464-144847509	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030296, HPA059090	Uncertain		Approved	Mitochondria	Renal cancer:8.46e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
ZNF70	Cos17, MGC48959	ENSG00000187792	Zinc finger protein 70	22	23738678-23751092	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018821	Uncertain		Supported	Cytosol		Mixed	Mixed			ovary: 4.9	Mixed		
ZNF700	DKFZp434I1610	ENSG00000196757	Zinc finger protein 700	19	11925068-11950773	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA047845	Uncertain		Uncertain	Nucleus	Renal cancer:2.01e-5 (unfavourable), Urothelial cancer:2.53e-5 (favourable), Head and neck cancer:1.27e-4 (favourable), Prostate cancer:1.75e-4 (unfavourable), Melanoma:2.58e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 19.1	Mixed		
ZNF701	FLJ10891	ENSG00000167562	Zinc finger protein 701	19	52555457-52587174	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005532	Uncertain		Approved	Nucleoplasm<br>Microtubule organizing center	Urothelial cancer:4.89e-5 (favourable)	Mixed	Expressed in all			thyroid gland: 16.2	Mixed		
ZNF703	FLJ14299, NLZ1, ZEPPO1, ZNF503L, Zpo1	ENSG00000183779	Zinc finger protein 703	8	37695751-37700021	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023930, CAB068249	Supported				Renal cancer:2.70e-7 (unfavourable)	Expressed in all	Mixed			fallopian tube: 30.7	Cell line enhanced		HEK93: 142.2
ZNF704	FLJ16218, Gig1	ENSG00000164684	Zinc finger protein 704	8	80628451-80874781	Predicted intracellular proteins	Evidence at protein level	HPA024285, HPA024302	Uncertain		Approved	Nucleoplasm	Renal cancer:4.02e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 35.3	Cell line enhanced		HaCaT: 63.8;RH-30: 44.5;SH-SY5Y: 61.9;SK-BR-3: 54.1
ZNF705A	FLJ16353	ENSG00000196946	Zinc finger protein 705A	12	8157034-8188537	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 8.9	Cell line enhanced		AN3-CA: 5.3;BJ hTERT+: 5.5;HDLM-2: 5.4;NTERA-2: 6.4
ZNF705B		ENSG00000215356	Zinc finger protein 705B	8	7926337-7952413	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	18	testis: 1.8	all non-specific tissues: 0.0	Not detected		
ZNF705D		ENSG00000215343	Zinc finger protein 705D	8	12104389-12115516	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Tissue enriched	6	epididymis: 4.5	testis: 0.7	Not detected		
ZNF705E		ENSG00000214534	Zinc finger protein 705E	11	71814045-71821548	Predicted intracellular proteins	No evidence							Not detected	Not detected			epididymis: 0.6	Not detected		
ZNF705G		ENSG00000215372	Zinc finger protein 705G	8	7355517-7385558	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Not detected			testis: 0.9	Not detected		
ZNF706	HSPC038	ENSG00000120963	Zinc finger protein 706	8	101177878-101206193	Predicted intracellular proteins	Evidence at protein level	HPA042793			Approved	Plasma membrane	Renal cancer:5.90e-11 (unfavourable), Endometrial cancer:3.12e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 159.9	Expressed in all		
ZNF707		ENSG00000181135	Zinc finger protein 707	8	143684452-143713898	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044991	Approved		Enhanced	Nucleoplasm	Endometrial cancer:6.79e-4 (unfavourable)	Expressed in all	Mixed			skin: 4.9	Mixed		
ZNF708	KOX8, ZNF15, ZNF15L1	ENSG00000182141	Zinc finger protein 708	19	21291160-21329425	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Ovarian cancer:3.53e-4 (favourable), Glioma:6.32e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 17.7	Mixed		
ZNF709	FLJ38281	ENSG00000242852	Zinc finger protein 709	19	12461184-12513854	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA045573, HPA053153	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enhanced		testis: 14.0	thyroid gland: 4.8	Mixed		
ZNF71	Cos26, EZFIT	ENSG00000197951	Zinc finger protein 71	19	56595264-56626481	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018124	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			cerebral cortex: 5.3	Mixed		
ZNF710	DKFZp547K1113, FLJ00306, FLJ37393	ENSG00000140548	Zinc finger protein 710	15	90001392-90082206	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030226, HPA030227, HPA030228	Enhanced		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			appendix: 20.4	Expressed in all		
ZNF711	CMPX1, dJ75N13.1, MRX97, Zfp711, ZNF4, ZNF5, ZNF6	ENSG00000147180	Zinc finger protein 711	X	85244032-85273362	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030654	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 69.8	cerebral cortex: 32.7	Cell line enhanced		AF22: 34.0;HAP1: 51.8;HEK93: 42.5;RH-30: 40.6
ZNF713	FLJ39963	ENSG00000178665	Zinc finger protein 713	7	55887475-55942225	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059425, HPA062887	Uncertain		Approved	Nucleoli		Mixed	Mixed			testis: 8.4	Cell line enhanced		SH-SY5Y: 7.3
ZNF714		ENSG00000160352	Zinc finger protein 714	19	21082159-21125270	Predicted intracellular proteins	Evidence at protein level						Ovarian cancer:4.27e-5 (favourable), Endometrial cancer:5.47e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 25.9	ovary: 21.9	Mixed		
ZNF716	FLJ46189	ENSG00000182111	Zinc finger protein 716	7	57450177-57473546	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Not detected			testis: 0.9	Not detected		
ZNF717	X17, ZNF838	ENSG00000227124	Zinc finger protein 717	3	75709643-75785583	Predicted intracellular proteins	Evidence at transcript level	HPA044549	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane		Mixed	Expressed in all			epididymis: 29.3	Cell line enhanced		K-562: 73.1
ZNF718	FLJ90036	ENSG00000250312	Zinc finger protein 718	4	124480-163989	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:7.67e-6 (favourable)	Expressed in all	Mixed			thyroid gland: 8.7	Cell line enhanced		REH: 18.4
ZNF720		ENSG00000197302	Zinc finger protein 720	16	31713229-31794869	Predicted intracellular proteins	Evidence at transcript level	HPA041570	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 15.5	Expressed in all		
ZNF721	KIAA1982	ENSG00000182903	Zinc finger protein 721	4	425815-499156	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA065313			Approved	Microtubule organizing center<br>Cytosol	Urothelial cancer:2.76e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 30.8	Expressed in all		
ZNF724	ZNF724P	ENSG00000196081	Zinc finger protein 724	19	23221599-23250390	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			esophagus: 2.9	Mixed		
ZNF726		ENSG00000213967	Zinc finger protein 726	19	23914876-23945159	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			epididymis: 6.3	Mixed		
ZNF727	ZNF727P	ENSG00000214652	Zinc finger protein 727	7	64045443-64078549	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051027, HPA061215	Uncertain		Uncertain	Nucleoplasm		Tissue enhanced	Mixed			thyroid gland: 5.8	Cell line enriched	7	T-47d: 7.1
ZNF728		ENSG00000269067	Zinc finger protein 728	19	22975468-23003176	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	5	testis: 18.2	thyroid gland: 3.6	Cell line enriched	5	U-266/84: 2.1
ZNF729		ENSG00000196350	Zinc finger protein 729	19	22286408-22317176	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	22	testis: 3.8	breast,cerebral cortex,endometrium,parathyroid gland: 0.1	Cell line enhanced		NTERA-2: 2.6
ZNF730		ENSG00000183850	Zinc finger protein 730	19	23075210-23147219	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		testis: 9.3	ovary: 3.1	Cell line enhanced		NTERA-2: 23.2;REH: 19.3
ZNF732	FLJ59067	ENSG00000186777	Zinc finger protein 732	4	270675-305321	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 2.6	skin: 0.8	Cell line enhanced		NTERA-2: 7.2;SH-SY5Y: 1.7
ZNF735	ZNF735P	ENSG00000223614	Zinc finger protein 735	7	64207090-64220508	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
ZNF736		ENSG00000234444	Zinc finger protein 736	7	64307459-64354860	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051027, HPA061215	Uncertain		Uncertain	Nucleoplasm	Endometrial cancer:3.03e-4 (unfavourable), Prostate cancer:5.01e-4 (unfavourable), Urothelial cancer:8.65e-4 (favourable)	Mixed	Mixed			testis: 15.1	Mixed		
ZNF737	ZNF102	ENSG00000237440	Zinc finger protein 737	19	20535825-20565809	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			thyroid gland: 66.9	Cell line enhanced		MOLT-4: 22.1;RT4: 22.5
ZNF738		ENSG00000172687	Zinc finger protein 738	19	21358930-21379302	Predicted intracellular proteins	Evidence at protein level	HPA059135	Uncertain				Ovarian cancer:2.27e-4 (favourable)	Mixed	Mixed			ovary: 11.7	Mixed		
ZNF74	Cos52, Zfp520, ZNF520	ENSG00000185252	Zinc finger protein 74	22	20394115-20408461	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003354	Approved		Supported	Nucleoplasm<br>Actin filaments		Expressed in all	Mixed			ovary: 4.8	Cell line enhanced		K-562: 37.4
ZNF740	Zfp740	ENSG00000139651	Zinc finger protein 740	12	53180700-53195141	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035691	Approved		Approved	Nucleus	Melanoma:4.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 14.3	Expressed in all		
ZNF746	FLJ31413, PARIS	ENSG00000181220	Zinc finger protein 746	7	149472794-149497817	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020272	Approved				Renal cancer:7.47e-6 (unfavourable), Liver cancer:2.32e-5 (unfavourable), Pancreatic cancer:4.22e-4 (favourable)	Expressed in all	Expressed in all			testis: 23.0	Expressed in all		
ZNF747	MGC2474	ENSG00000169955	Zinc finger protein 747	16	30530367-30535347	Predicted intracellular proteins	Evidence at protein level	HPA003203, HPA069173	Uncertain		Approved	Centrosome<br>Cytosol	Pancreatic cancer:4.46e-4 (favourable), Cervical cancer:6.53e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.6	Mixed		
ZNF749	FLJ16360	ENSG00000186230	Zinc finger protein 749	19	57435329-57445485	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042082, HPA042091, HPA056001	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Expressed in all	Mixed			parathyroid gland: 4.2	Expressed in all		
ZNF750	FLJ13841, Zfp750	ENSG00000141579	Zinc finger protein 750	17	82829435-82840578	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021573, HPA023012	Enhanced					Mixed	Tissue enhanced		esophagus: 60.5;skin: 54.4	salivary gland: 13.0	Cell line enhanced		BEWO: 16.4;hTCEpi: 4.5;MCF7: 3.6;SK-BR-3: 9.5
ZNF75A	FLJ31529	ENSG00000162086	Zinc finger protein 75a	16	3305406-3318852	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001665	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			parathyroid gland: 46.7	Mixed		
ZNF75D	D8C6, ZKSCAN24, ZNF75, ZNF82, ZSCAN28	ENSG00000186376	Zinc finger protein 75D	X	135248920-135344087	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004705	Supported		Approved	Nucleoplasm<br>Golgi apparatus	Urothelial cancer:7.42e-5 (favourable), Renal cancer:1.31e-4 (favourable)	Expressed in all	Expressed in all			prostate: 15.8	Mixed		
ZNF76	D6S229E, Zfp523, ZNF523	ENSG00000065029	Zinc finger protein 76	6	35258909-35295985	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030090, HPA030091	Approved		Approved	Nucleoplasm<br>Cytosol	Ovarian cancer:1.18e-4 (favourable), Pancreatic cancer:5.09e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.7	Expressed in all		
ZNF761	FLJ16231, FLJ35333, KIAA2033	ENSG00000160336	Zinc finger protein 761	19	53431993-53458261	Predicted intracellular proteins	Evidence at transcript level						Liver cancer:2.04e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 91.8	Mixed		
ZNF763	ZNF440L	ENSG00000197054	Zinc finger protein 763	19	11965037-11980381	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA047845	Uncertain		Uncertain	Nucleus		Mixed	Mixed			parathyroid gland: 11.5	Cell line enhanced		BEWO: 5.9
ZNF764	MGC13138	ENSG00000169951	Zinc finger protein 764	16	30553764-30558498	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003203	Uncertain		Approved	Cytosol	Endometrial cancer:6.84e-4 (favourable)	Expressed in all	Mixed			testis: 6.0	Expressed in all		
ZNF765		ENSG00000196417	Zinc finger protein 765	19	53389793-53430413	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Breast cancer:9.11e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 13.0	Mixed		
ZNF766		ENSG00000196214	Zinc finger protein 766	19	52269571-52296046	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044882, HPA063496	Uncertain		Supported	Centrosome		Expressed in all	Expressed in all			testis: 43.6	Expressed in all		
ZNF768	FLJ23436	ENSG00000169957	Zinc finger protein 768	16	30524001-30526821	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024630, HPA066512	Supported		Approved	Nucleus<br>Vesicles	Renal cancer:9.30e-6 (favourable), Urothelial cancer:6.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 55.9	Expressed in all		
ZNF77	pT1	ENSG00000175691	Zinc finger protein 77	19	2933218-2944971	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA023397	Uncertain		Approved	Nucleus<br>Nucleoli	Lung cancer:6.79e-6 (favourable), Endometrial cancer:6.65e-5 (favourable), Cervical cancer:8.49e-4 (favourable)	Expressed in all	Mixed			breast: 5.8	Mixed		
ZNF770	FLJ20582, PRO1914	ENSG00000198146	Zinc finger protein 770	15	34978341-34988287	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024518	Approved					Expressed in all	Expressed in all			thyroid gland: 73.6	Expressed in all		
ZNF771	DSC43	ENSG00000179965	Zinc finger protein 771	16	30407297-30431108	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030730, HPA046672, HPA059398	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			cerebral cortex: 7.0	Expressed in all		
ZNF772	DKFZp686I1569	ENSG00000197128	Zinc finger protein 772	19	57466663-57477570	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031312	Uncertain		Approved	Cytosol	Renal cancer:1.02e-6 (favourable)	Mixed	Mixed			parathyroid gland: 20.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 28.4
ZNF773	MGC4728, ZNF419B	ENSG00000152439	Zinc finger protein 773	19	57499915-57518404	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003152	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Mixed	Mixed			parathyroid gland: 13.1	Mixed		
ZNF774	MGC75360	ENSG00000196391	Zinc finger protein 774	15	90352245-90369146	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030839, HPA030840	Uncertain		Supported	Intermediate filaments<br>Cytosol		Mixed	Mixed			cerebral cortex: 8.1	Mixed		
ZNF775	MGC33584	ENSG00000196456	Zinc finger protein 775	7	150379335-150398631	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Pancreatic cancer:1.35e-5 (favourable), Renal cancer:2.84e-4 (favourable), Head and neck cancer:3.48e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 7.1	Mixed		
ZNF776	FLJ38288	ENSG00000152443	Zinc finger protein 776	19	57746796-57758159	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046653, HPA068553	Uncertain		Approved	Nucleus<br>Cytosol	Cervical cancer:9.74e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 26.3	Mixed		
ZNF777	KIAA1285	ENSG00000196453	Zinc finger protein 777	7	149431363-149461123	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003252	Approved		Approved	Nucleus		Expressed in all	Expressed in all			cerebral cortex: 10.4	Mixed		
ZNF778	FLJ31875	ENSG00000170100	Zinc finger protein 778	16	89217703-89237071	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052057, HPA057151	Uncertain		Supported	Nucleus<br>Nuclear bodies		Mixed	Mixed			parathyroid gland: 15.1	Mixed		
ZNF780A	ZNF780	ENSG00000197782	Zinc finger protein 780A	19	40069152-40090938	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003311	Uncertain		Approved	Nucleus<br>Centrosome	Urothelial cancer:9.30e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 8.4	Expressed in all		
ZNF780B	ZNF779	ENSG00000128000	Zinc finger protein 780B	19	40028260-40056209	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003311	Uncertain		Approved	Nucleus<br>Centrosome		Expressed in all	Mixed			thyroid gland: 8.0	Mixed		
ZNF781	FLJ37549	ENSG00000196381	Zinc finger protein 781	19	37667751-37692322	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062512	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			smooth muscle: 3.7	Cell line enhanced		AN3-CA: 2.1;SH-SY5Y: 2.4;U-266/84: 2.0
ZNF782	FLJ16636	ENSG00000196597	Zinc finger protein 782	9	96816472-96875623	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA011013	Approved		Approved	Nucleus<br>Mitochondria		Expressed in all	Mixed			testis: 10.4	Mixed		
ZNF783	DKFZp667J212	ENSG00000204946	Zinc finger family member 783	7	149262171-149297302	Predicted intracellular proteins	Evidence at protein level	HPA020375	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.24e-7 (unfavourable), Urothelial cancer:4.11e-4 (favourable)	Expressed in all	Mixed			spleen: 9.2	Mixed		
ZNF784	MGC75238	ENSG00000179922	Zinc finger protein 784	19	55620742-55624601	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059676	Uncertain		Approved	Nucleus	Urothelial cancer:1.02e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 14.7	Expressed in all		
ZNF785	FLJ32130	ENSG00000197162	Zinc finger protein 785	16	30573740-30585771	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030510			Approved	Nucleoplasm<br>Plasma membrane	Pancreatic cancer:2.03e-5 (favourable), Lung cancer:8.99e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 11.7	Mixed		
ZNF786	DKFZp762I137	ENSG00000197362	Zinc finger protein 786	7	149069643-149090782	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021518, HPA053459	Uncertain		Approved	Nucleoplasm<br>Nuclear speckles	Liver cancer:1.09e-4 (unfavourable), Pancreatic cancer:2.01e-4 (favourable)	Expressed in all	Mixed			skin: 7.2	Expressed in all		
ZNF787		ENSG00000142409	Zinc finger protein 787	19	56087366-56121280	Predicted intracellular proteins	Evidence at protein level	HPA035140	Supported		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Expressed in all			spleen: 19.3	Expressed in all		
ZNF788	FLJ46419	ENSG00000214189	Zinc finger family member 788	19	12092263-12137235	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			testis: 5.6	Cell line enhanced		K-562: 20.7;NTERA-2: 20.5
ZNF789		ENSG00000198556	Zinc finger protein 789	7	99472841-99503650	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029500, HPA050793	Uncertain		Enhanced	Nucleoplasm	Urothelial cancer:5.31e-6 (favourable), Renal cancer:3.56e-4 (unfavourable), Pancreatic cancer:7.14e-4 (favourable)	Expressed in all	Mixed			prostate: 13.9	Expressed in all		
ZNF79	pT7	ENSG00000196152	Zinc finger protein 79	9	127424374-127445372	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028977	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:6.04e-7 (favourable), Pancreatic cancer:5.42e-5 (favourable), Endometrial cancer:6.83e-5 (favourable), Lung cancer:5.96e-4 (favourable)	Expressed in all	Mixed			testis: 11.4	Expressed in all		
ZNF790	FLJ20350, MGC62100	ENSG00000197863	Zinc finger protein 790	19	36817428-36850787	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA056134, HPA060288	Uncertain		Approved	Nucleoli	Endometrial cancer:7.66e-4 (unfavourable)	Expressed in all	Mixed			testis: 20.5	Mixed		
ZNF791	FLJ90396	ENSG00000173875	Zinc finger protein 791	19	12610918-12633840	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021537	Uncertain		Approved	Nucleus	Urothelial cancer:1.39e-5 (favourable), Lung cancer:9.07e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 25.1	Expressed in all		
ZNF792	FLJ38451	ENSG00000180884	Zinc finger protein 792	19	34956354-34964049	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035157, HPA035158	Supported		Approved	Nucleoplasm<br>Nuclear bodies	Colorectal cancer:2.72e-4 (favourable)	Expressed in all	Mixed			lung: 6.2	Cell line enhanced		HEL: 11.5;HMC-1: 14.3;SH-SY5Y: 11.1
ZNF793		ENSG00000188227	Zinc finger protein 793	19	37506939-37548762	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA034781	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Mixed			parathyroid gland: 15.7	Cell line enhanced		AN3-CA: 12.6;U-266/70: 15.1
ZNF799	HIT-40, MGC71805, ZNF842	ENSG00000196466	Zinc finger protein 799	19	12390016-12401271	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003150, HPA018683	Supported		Uncertain	Nucleoplasm<br>Microtubule organizing center	Endometrial cancer:2.39e-4 (favourable)	Mixed	Mixed			placenta: 6.9	Mixed		
ZNF8	HF.18, Zfp128	ENSG00000278129	Zinc finger protein 8	19	58278951-58302805	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034797, HPA034798	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			parathyroid gland: 4.5	Mixed		
ZNF80	pT17	ENSG00000174255	Zinc finger protein 80	3	114234631-114237578	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA065484	Uncertain					Not detected	Tissue enhanced		breast: 6.4	lymph node: 2.7	Cell line enhanced		MCF7: 1.2
ZNF800		ENSG00000048405	Zinc finger protein 800	7	127346790-127431924	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023090, HPA052194	Approved		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 47.9	Expressed in all		
ZNF804A	C2orf10	ENSG00000170396	Zinc finger protein 804A	2	184598366-184939492	Predicted intracellular proteins	Evidence at protein level	HPA029195	Uncertain		Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.4	thyroid gland: 2.7	Cell line enhanced		Daudi: 21.5;RH-30: 19.3;U-698: 15.3
ZNF804B	FLJ32110	ENSG00000182348	Zinc finger protein 804B	7	88759368-89337057	Predicted intracellular proteins	Evidence at protein level	HPA026702	Uncertain					Not detected	Tissue enriched	7	thyroid gland: 7.3	kidney: 0.9	Not detected		
ZNF805		ENSG00000204524	Zinc finger protein 805	19	57240685-57255135	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA057665, HPA058895	Uncertain					Mixed	Mixed			parathyroid gland: 5.1	Mixed		
ZNF808		ENSG00000198482	Zinc finger protein 808	19	52527652-52564464	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Urothelial cancer:3.88e-4 (favourable), Thyroid cancer:7.82e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 8.8	Mixed		
ZNF81	HFZ20, MRX45	ENSG00000197779	Zinc finger protein 81	X	47836902-48002561	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA001689	Approved					Mixed	Mixed			parathyroid gland: 9.9	Mixed		
ZNF813	FLJ16542	ENSG00000198346	Zinc finger protein 813	19	53467735-53496255	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056406	Uncertain		Approved	Vesicles		Expressed in all	Mixed			prostate: 8.1	Cell line enhanced		RT4: 14.6
ZNF814		ENSG00000204514	Zinc finger protein 814	19	57848731-57889074	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043800, HPA053762, HPA072145	Approved		Uncertain	Nucleus		Mixed	Mixed			thyroid gland: 18.2	Cell line enhanced		NTERA-2: 34.7
ZNF816-ZNF321P	ZNF816-ZNF321	ENSG00000221874	ZNF816-ZNF321P readthrough	19	52928475-52962823	Predicted intracellular proteins	Evidence at transcript level	HPA051271	Uncertain		Uncertain	Nucleoplasm		Not detected	Tissue enhanced		prostate: 2.7	rectum: 1.6	Cell line enriched	7	RT4: 7.2
ZNF821		ENSG00000102984	Zinc finger protein 821	16	71859680-71895336	Predicted intracellular proteins	Evidence at protein level	HPA036372, HPA042742	Enhanced		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:6.32e-10 (favourable), Pancreatic cancer:4.27e-5 (favourable), Glioma:1.55e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 33.2	cerebral cortex: 13.7	Cell line enhanced		SCLC-21H: 15.5
ZNF823	HSZFP36	ENSG00000197933	Zinc finger protein 823	19	11721265-11739009	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Head and neck cancer:6.76e-5 (favourable), Renal cancer:4.49e-4 (favourable), Stomach cancer:5.05e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.5	Mixed		
ZNF827		ENSG00000151612	Zinc finger protein 827	4	145757627-145938635	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021166	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			prostate: 37.4	Cell line enhanced		WM-115: 67.4
ZNF829	DKFZp779O175	ENSG00000185869	Zinc finger protein 829	19	36888124-36916291	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA073073			Approved	Nucleus<br>Nuclear bodies		Mixed	Tissue enriched	5	testis: 18.3	ovary: 3.4	Mixed		
ZNF83	FLJ11015, HPF1, ZNF816B	ENSG00000167766	Zinc finger protein 83	19	52594060-52690496	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA025970	Approved		Approved	Nucleoplasm	Urothelial cancer:6.92e-6 (favourable), Renal cancer:3.13e-5 (unfavourable), Head and neck cancer:3.83e-4 (favourable), Ovarian cancer:9.06e-4 (favourable), Melanoma:9.20e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 111.9	Mixed		
ZNF830	CCDC16, MGC20398, OMCG1	ENSG00000198783	Zinc finger protein 830	17	34961530-34963775	Predicted intracellular proteins	Evidence at protein level	HPA024754, HPA027211	Enhanced		Enhanced	Nucleoplasm	Prostate cancer:2.01e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.6	Expressed in all		
ZNF831	C20orf174, dJ492J12.1	ENSG00000124203	Zinc finger protein 831	20	59123381-59259113	Predicted intracellular proteins	Evidence at protein level	HPA016839	Uncertain					Not detected	Tissue enhanced		lymph node: 7.1	spleen: 3.6	Cell line enhanced		Daudi: 2.9
ZNF835	BC37295_3	ENSG00000127903	Zinc finger protein 835	19	56661981-56671783	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA051136	Uncertain		Approved	Microtubules		Mixed	Mixed			ovary: 5.3	Cell line enhanced		BEWO: 2.3;EFO-21: 1.9;NTERA-2: 4.7;SH-SY5Y: 2.6;U-266/84: 2.8
ZNF836	FLJ16287	ENSG00000196267	Zinc finger protein 836	19	52153864-52171643	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:3.77e-4 (favourable), Cervical cancer:5.11e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 34.6	Mixed		
ZNF837		ENSG00000152475	Zinc finger protein 837	19	58367618-58381060	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042833	Uncertain		Approved	Nucleoli	Renal cancer:1.76e-5 (favourable), Endometrial cancer:1.27e-4 (favourable)	Expressed in all	Mixed			skin,spleen: 1.4	Cell line enhanced		HEK93: 8.6
ZNF839	C14orf131	ENSG00000022976	Zinc finger protein 839	14	102317377-102342702	Predicted intracellular proteins	Evidence at protein level	HPA020434	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Pancreatic cancer:4.57e-4 (favourable), Renal cancer:5.00e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.2	Expressed in all		
ZNF84	HPF2	ENSG00000198040	Zinc finger protein 84	12	133037292-133063304	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028860	Approved		Supported	Nucleoplasm	Liver cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 33.1	Mixed		
ZNF841	LOC284371	ENSG00000197608	Zinc finger protein 841	19	52064466-52095765	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:3.56e-6 (unfavourable), Urothelial cancer:8.92e-5 (favourable), Head and neck cancer:2.93e-4 (favourable)	Expressed in all	Mixed			prostate: 23.1	Mixed		
ZNF843	MGC46336	ENSG00000176723	Zinc finger protein 843	16	31432593-31443160	Predicted intracellular proteins	Evidence at protein level	HPA030911, HPA030912	Uncertain					Mixed	Mixed			ovary: 3.8	Cell line enhanced		ASC diff: 1.6;EFO-21: 1.7
ZNF844	FLJ14959	ENSG00000223547	Zinc finger protein 844	19	12064699-12081565	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046982	Uncertain				Renal cancer:0.00e+0 (favourable)	Expressed in all	Mixed			thyroid gland: 20.3	Cell line enhanced		U-266/84: 12.3
ZNF845		ENSG00000213799	Zinc finger protein 845	19	53333749-53354869	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:3.98e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 7.6	Mixed		
ZNF846		ENSG00000196605	Zinc finger protein 846	19	9751993-9793180	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034617, HPA034618	Approved		Approved	Actin filaments	Head and neck cancer:5.25e-8 (favourable)	Expressed in all	Mixed			seminal vesicle: 26.3	Mixed		
ZNF85	HPF4, HTF1	ENSG00000105750	Zinc finger protein 85	19	20923222-20950697	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044760	Uncertain		Supported	Nucleus	Ovarian cancer:6.45e-6 (favourable), Endometrial cancer:5.20e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 28.0	thyroid gland: 12.0	Mixed		
ZNF850	ZNF850P	ENSG00000267041	Zinc finger protein 850	19	36714383-36772825	Predicted intracellular proteins	Evidence at transcript level	HPA029299	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			testis: 4.7	Cell line enhanced		HEL: 13.4
ZNF852		ENSG00000178917	Zinc finger protein 852	3	44498970-44510636	Predicted intracellular proteins	Evidence at protein level	HPA048312, HPA049885, HPA071850	Uncertain					Mixed	Mixed			parathyroid gland: 2.8	Mixed		
ZNF853	DKFZp434J1015	ENSG00000236609	Zinc finger protein 853	7	6615617-6624290	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067690	Approved		Approved	Nucleoli	Renal cancer:2.30e-6 (favourable)	Mixed	Mixed			cerebral cortex: 17.4	Cell line enhanced		AN3-CA: 18.6;SH-SY5Y: 31.3;U-2 OS: 20.5
ZNF860		ENSG00000197385	Zinc finger protein 860	3	31981771-31991628	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA063386	Uncertain		Approved	Nucleus<br>Nucleoli		Mixed	Mixed			prostate: 4.7	Cell line enriched	6	BEWO: 44.1
ZNF862		ENSG00000106479	Zinc finger protein 862	7	149838367-149867479	Predicted intracellular proteins	Evidence at protein level	HPA024154	Uncertain		Approved	Mitochondria	Urothelial cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.7	Mixed		
ZNF865		ENSG00000261221	Zinc finger protein 865	19	55605405-55617269	Predicted intracellular proteins	Evidence at protein level	HPA068079	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			skeletal muscle: 8.4	Expressed in all		
ZNF878		ENSG00000257446	Zinc finger protein 878	19	12043805-12052939	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA052735	Uncertain		Approved	Nucleus<br>Nucleoli		Tissue enriched	Mixed			placenta,testis: 1.0	Mixed		
ZNF879	DKFZp686E2433	ENSG00000234284	Zinc finger protein 879	5	179023752-179035064	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA068608	Uncertain		Approved	Nucleus		Mixed	Mixed			testis: 11.3	Mixed		
ZNF880		ENSG00000221923	Zinc finger protein 880	19	52369917-52385795	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:4.33e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.2	Mixed		
ZNF883		ENSG00000228623	Zinc finger protein 883	9	112957722-113050043	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Stomach cancer:2.89e-6 (unfavourable), Renal cancer:7.07e-4 (unfavourable)	Mixed	Not detected			cervix, uterine: 0.3	Not detected		
ZNF888		ENSG00000213793	Zinc finger protein 888	19	52904417-52923481	Predicted intracellular proteins	Evidence at transcript level						Breast cancer:5.28e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 18.3	Cell line enriched	5	RT4: 58.3
ZNF891		ENSG00000214029	Zinc finger protein 891	12	133106817-133130473	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA040301	Uncertain					Mixed	Mixed			testis: 2.1	Mixed		
ZNF90	HTF9	ENSG00000213988	Zinc finger protein 90	19	20077994-20127076	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003227	Uncertain		Approved	Nucleus<br>Golgi apparatus		Tissue enhanced	Tissue enhanced		parathyroid gland: 7.6	thyroid gland: 2.7	Cell line enhanced		AN3-CA: 9.0;NTERA-2: 16.5
ZNF91	HPF7, HTF10	ENSG00000167232	Zinc finger protein 91	19	23304991-23395560	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Urothelial cancer:3.48e-4 (favourable), Renal cancer:7.58e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 17.6	Mixed		
ZNF92	HPF12, TF12	ENSG00000146757	Zinc finger protein 92	7	65373799-65401135	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003173			Approved	Nucleus	Liver cancer:6.56e-4 (unfavourable)	Expressed in all	Mixed			breast: 13.2	Expressed in all		
ZNF93	FLJ12488, HPF34, TF34, ZNF505	ENSG00000184635	Zinc finger protein 93	19	19900913-19935575	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Ovarian cancer:9.31e-6 (favourable)	Mixed	Mixed			thyroid gland: 13.9	Cell line enhanced		NTERA-2: 41.8
ZNF99	C19orf9, MGC24986	ENSG00000213973	Zinc finger protein 99	19	22752183-22784107	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Tissue enriched	7	testis: 3.0	cerebral cortex: 0.4	Not detected		
ZNFX1	FLJ11277, KIAA1404	ENSG00000124201	Zinc finger NFX1-type containing 1	20	49237946-49278426	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046629	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 27.1	Expressed in all		
ZNHIT1	CG1I, H_DJ0747G18.14, ZNFN4A1	ENSG00000106400	Zinc finger HIT-type containing 1	7	101217668-101224190	Predicted intracellular proteins	Evidence at protein level	HPA019043	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			liver: 50.6	Expressed in all		
ZNHIT2	C11orf5, FON	ENSG00000174276	Zinc finger HIT-type containing 2	11	65116403-65117708	Predicted intracellular proteins	Evidence at protein level	HPA058066	Uncertain					Expressed in all	Tissue enhanced		testis: 18.9	adrenal gland: 7.7	Mixed		
ZNHIT3	TRIP3	ENSG00000273611	Zinc finger HIT-type containing 3	17	36486629-36499310	Predicted intracellular proteins	Evidence at protein level	HPA060019			Approved	Mitochondria		Expressed in all	Expressed in all			testis: 43.2	Expressed in all		
ZNHIT6	BCD1, C1orf181, FLJ20729, NY-BR-75	ENSG00000117174	Zinc finger HIT-type containing 6	1	85649423-85708433	Predicted intracellular proteins	Evidence at protein level	HPA018132	Uncertain		Approved	Nuclear speckles<br>Vesicles	Liver cancer:6.08e-6 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine,endometrium: 21.1	Expressed in all		
ZNRD1	HTEX-6, hZR14, RPA12, tctex-6	ENSG00000066379	Zinc ribbon domain containing 1	6	30058899-30064909	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA055074, HPA077979	Supported		Supported	Nucleoli fibrillar center	Renal cancer:2.17e-7 (unfavourable), Urothelial cancer:2.75e-5 (favourable)	Expressed in all	Mixed			lymph node: 5.9	Mixed		
ZNRF1	DKFZp434E229, FLJ14846, nin283	ENSG00000186187	Zinc and ring finger 1	16	74999030-75110994	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027470	Approved				Cervical cancer:9.90e-4 (favourable)	Expressed in all	Expressed in all			testis: 34.3	Expressed in all		
ZNRF2	RNF202	ENSG00000180233	Zinc and ring finger 2	7	30284307-30367692	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA072244	Approved				Renal cancer:2.29e-4 (favourable), Endometrial cancer:7.68e-4 (unfavourable), Thyroid cancer:8.71e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.7	Expressed in all		
ZPR1	ZNF259	ENSG00000109917	ZPR1 zinc finger	11	116773799-116788050	Predicted intracellular proteins	Evidence at protein level	CAB022596, HPA030979	Uncertain		Approved	Vesicles	Liver cancer:5.87e-6 (unfavourable), Head and neck cancer:8.01e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.9	Expressed in all		
ZRANB1	TRABID	ENSG00000019995	Zinc finger RANBP2-type containing 1	10	124942123-124988189	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029239, HPA029240, HPA029241	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 35.9	Expressed in all		
ZRANB2	ZIS, ZIS1, ZIS2, ZNF265	ENSG00000132485	Zinc finger RANBP2-type containing 2	1	71063291-71081297	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053960, HPA061949, HPA063298	Supported		Enhanced	Nucleus	Renal cancer:1.57e-8 (unfavourable), Liver cancer:7.29e-5 (unfavourable), Prostate cancer:5.70e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 116.1	Expressed in all		
ZRANB3	DKFZP434B1727	ENSG00000121988	Zinc finger RANBP2-type containing 3	2	135136916-135531236	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA035234			Supported	Nucleus		Mixed	Mixed			testis: 8.6	Expressed in all		
ZRSR1	U2AF1-RS1, U2AF1L1, U2AF1P, U2AF1RS1, U2AFBPL, ZC3H21	ENSG00000212643	Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 1	5	112891422-112893094	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			epididymis: 1.1	Mixed		
ZRSR2	U2AF1-RS2, U2AF1L2, URP, ZC3H22	ENSG00000169249	Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2	X	15790472-15823260	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.87e-5 (unfavourable), Endometrial cancer:8.50e-5 (favourable), Urothelial cancer:2.97e-4 (favourable), Breast cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			spleen: 34.1	Expressed in all		
ZSCAN1	FLJ33779, ZNF915	ENSG00000152467	Zinc finger and SCAN domain containing 1	19	58034032-58054631	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007938	Uncertain		Approved	Nucleoli	Ovarian cancer:7.36e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 7.4	cerebral cortex: 5.3	Cell line enhanced		EFO-21: 2.8;HMC-1: 1.8;NTERA-2: 2.1;T-47d: 2.9
ZSCAN10	ZNF206	ENSG00000130182	Zinc finger and SCAN domain containing 10	16	3088890-3099317	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Not detected			skin: 0.6	Cell line enriched	123	NTERA-2: 56.8
ZSCAN12	dJ29K1.2, KIAA0426, ZFP96, ZNF29K1, ZNF305, ZNF96	ENSG00000158691	Zinc finger and SCAN domain containing 12	6	28378955-28399734	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006637	Approved		Approved	Microtubules<br>Cytosol		Expressed in all	Mixed			thyroid gland: 8.7	Mixed		
ZSCAN16	dJ265C24.3, FLJ22191, ZNF392, ZNF435	ENSG00000196812	Zinc finger and SCAN domain containing 16	6	28124560-28130082	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007290	Supported		Approved	Nucleus	Ovarian cancer:1.14e-5 (favourable), Urothelial cancer:3.41e-5 (favourable), Lung cancer:3.19e-4 (favourable), Cervical cancer:5.73e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.6	Mixed		
ZSCAN18	FLJ12895, ZNF447	ENSG00000121413	Zinc finger and SCAN domain containing 18	19	58083838-58118427	Predicted intracellular proteins	Evidence at protein level	HPA024318	Supported		Approved	Nucleoplasm	Renal cancer:3.95e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 78.8	Cell line enhanced		HEK93: 121.2;SCLC-21H: 73.3
ZSCAN2	FLJ20595, ZFP29, ZNF854	ENSG00000176371	Zinc finger and SCAN domain containing 2	15	84600986-84627796	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007296, HPA024331	Supported		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:4.16e-5 (favourable), Pancreatic cancer:3.52e-4 (favourable), Renal cancer:7.46e-4 (favourable)	Expressed in all	Expressed in all			testis: 13.8	Expressed in all		
ZSCAN20	KOX29, ZNF31, ZNF360	ENSG00000121903	Zinc finger and SCAN domain containing 20	1	33472645-33496507	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA017933	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			parathyroid gland: 5.4	Mixed		
ZSCAN21	DKFZp434L134, NY-REN-21, Zipro1, ZNF38	ENSG00000166529	Zinc finger and SCAN domain containing 21	7	100049774-100065038	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016948, HPA023591	Uncertain		Approved	Endoplasmic reticulum	Thyroid cancer:4.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 20.4	Expressed in all		
ZSCAN22	HKR2, ZNF50	ENSG00000182318	Zinc finger and SCAN domain containing 22	19	58327019-58342332	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006471	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 3.3	Cell line enhanced		HEK93: 13.4
ZSCAN23	dJ29K1.3.1, ZNF390, ZNF453	ENSG00000187987	Zinc finger and SCAN domain containing 23	6	28431930-28443502	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035959, HPA035960	Uncertain					Not detected	Mixed			parathyroid gland: 2.1	Cell line enhanced		SCLC-21H: 2.1
ZSCAN25	FLJ32468, ZNF498	ENSG00000197037	Zinc finger and SCAN domain containing 25	7	99616946-99632407	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055127, HPA057173	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Mixed			parathyroid gland: 10.0	Expressed in all		
ZSCAN26	SRE-ZBP, ZNF187	ENSG00000197062	Zinc finger and SCAN domain containing 26	6	28267010-28278224	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027521			Enhanced	Nucleus<br>Nucleoli	Renal cancer:6.79e-5 (unfavourable), Liver cancer:7.81e-5 (unfavourable), Urothelial cancer:1.68e-4 (favourable)	Expressed in all	Expressed in all			ovary: 40.4	Expressed in all		
ZSCAN30	ZNF397OS, ZNF917	ENSG00000186814	Zinc finger and SCAN domain containing 30	18	35251058-35290245	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007289	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 26.4	Expressed in all		
ZSCAN31	ZNF310P, ZNF323	ENSG00000235109	Zinc finger and SCAN domain containing 31	6	28324693-28356271	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007124	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.19e-5 (favourable)	Expressed in all	Expressed in all			testis: 38.7	Cell line enhanced		EFO-21: 37.9;U-2 OS: 50.9
ZSCAN32	FLJ20417, ZNF434	ENSG00000140987	Zinc finger and SCAN domain containing 32	16	3382081-3401065	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005758	Uncertain		Approved	Nucleoplasm		Mixed	Expressed in all			parathyroid gland: 13.6	Expressed in all		
ZSCAN4	FLJ35105, ZNF494	ENSG00000180532	Zinc finger and SCAN domain containing 4	19	57668935-57679152	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA006491	Uncertain					Tissue enhanced	Tissue enhanced		stomach: 2.5	placenta: 1.2	Not detected		
ZSCAN5A	MGC4161, ZNF495, ZSCAN5	ENSG00000131848	Zinc finger and SCAN domain containing 5A	19	56219670-56368383	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041263, HPA043123, HPA046836, HPA060667	Uncertain		Uncertain	Nuclear speckles		Mixed	Tissue enhanced		testis: 34.6	fallopian tube: 11.4	Expressed in all		
ZSCAN5B	ZNF371, ZNF495B	ENSG00000197213	Zinc finger and SCAN domain containing 5B	19	56189570-56197920	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043123, HPA046836, HPA059494, HPA060667	Uncertain		Uncertain	Nuclear speckles		Not detected	Tissue enriched	22	testis: 2.7	fallopian tube: 0.1	Not detected		
ZSCAN5C	ZNF495C, ZSCAN5CP	ENSG00000204532	Zinc finger and SCAN domain containing 5C	19	56202301-56209452	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041263, HPA043123, HPA046836, HPA060667	Uncertain		Uncertain	Nuclear speckles		Not detected	Not detected			testis: 0.1	Not detected		
ZSCAN9	PRD51, ZNF193	ENSG00000137185	Zinc finger and SCAN domain containing 9	6	28224886-28233482	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054512, HPA059951	Uncertain		Approved	Nucleoplasm	Renal cancer:1.21e-6 (unfavourable), Urothelial cancer:1.16e-5 (favourable), Liver cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.8	Mixed		
ZSWIM1	C20orf162, dJ337O18.5	ENSG00000168612	Zinc finger SWIM-type containing 1	20	45881227-45885266	Predicted intracellular proteins	Evidence at protein level	HPA041147, HPA046751	Uncertain		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.77e-4 (favourable), Liver cancer:5.47e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 9.3	Expressed in all		
ZSWIM2	MGC33890, ZZZ2	ENSG00000163012	Zinc finger SWIM-type containing 2	2	186827835-186849208	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	133	testis: 18.4	cerebral cortex,placenta: 0.1	Not detected		
ZSWIM3	C20orf164, dJ337O18.7, PPP1R174	ENSG00000132801	Zinc finger SWIM-type containing 3	20	45857617-45879122	Predicted intracellular proteins	Evidence at protein level	HPA055692, HPA060508	Uncertain		Approved	Nucleoli fibrillar center<br>Vesicles<br>Cytosol	Breast cancer:9.32e-5 (unfavourable), Endometrial cancer:4.21e-4 (unfavourable)	Expressed in all	Mixed			testis: 5.2	Mixed		
ZSWIM4	FLJ12221	ENSG00000132003	Zinc finger SWIM-type containing 4	19	13795460-13832230	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level	HPA042084	Uncertain				Renal cancer:7.85e-5 (unfavourable)	Expressed in all	Mixed			appendix: 5.7	Mixed		
ZSWIM5	KIAA1511	ENSG00000162415	Zinc finger SWIM-type containing 5	1	45016399-45306209	Predicted intracellular proteins	Evidence at transcript level	HPA018211	Uncertain		Approved	Nuclear speckles		Expressed in all	Mixed			parathyroid gland: 15.8	Cell line enhanced		SCLC-21H: 8.6
ZSWIM6	KIAA1577	ENSG00000130449	Zinc finger SWIM-type containing 6	5	61332273-61546170	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035938	Uncertain		Approved	Cytosol		Expressed in all	Mixed			parathyroid gland: 17.0	Mixed		
ZSWIM7	SWS1	ENSG00000214941	Zinc finger SWIM-type containing 7	17	15976560-15999717	Predicted intracellular proteins	Evidence at protein level	HPA054681	Uncertain		Uncertain	Cytosol	Endometrial cancer:3.54e-5 (favourable), Pancreatic cancer:1.77e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.9	Expressed in all		
ZSWIM8	4832404P21Rik, KIAA0913	ENSG00000214655	Zinc finger SWIM-type containing 8	10	73785582-73801797	Predicted intracellular proteins	Evidence at protein level	HPA041244	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:5.61e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.2	Expressed in all		
ZUFSP	C6orf113, dJ412I7.3	ENSG00000153975	Zinc finger with UFM1 specific peptidase domain	6	116635618-116668794	Predicted intracellular proteins	Evidence at protein level	HPA044426	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Mixed			testis: 10.8	Expressed in all		
ZW10	KNTC1AP	ENSG00000086827	Zw10 kinetochore protein	11	113733187-113773811	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011565, HPA051253, HPA055410	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Colorectal cancer:2.70e-4 (favourable), Liver cancer:8.57e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 23.4	Expressed in all		
ZWILCH	FLJ10036, KNTC1AP	ENSG00000174442	Zwilch kinetochore protein	15	66504959-66550128	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:2.90e-5 (unfavourable), Renal cancer:2.58e-4 (unfavourable), Prostate cancer:7.34e-4 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 97.0	lymph node: 13.5	Expressed in all		
ZWINT	KNTC2AP, SIP30, Zwint1	ENSG00000122952	ZW10 interacting kinetochore protein	10	56357228-56361275	Predicted intracellular proteins	Evidence at protein level	HPA005757, HPA022264, CAB033926	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:3.72e-12 (unfavourable), Liver cancer:1.77e-8 (unfavourable)	Expressed in all	Mixed			testis: 47.7	Mixed		
ZXDA	ZNF896	ENSG00000198205	Zinc finger, X-linked, duplicated A	X	57906708-57910820	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043789	Approved		Approved	Nucleoplasm	Renal cancer:8.55e-4 (favourable)	Mixed	Mixed			ovary: 5.3	Mixed		
ZXDB	ZNF905	ENSG00000198455	Zinc finger, X-linked, duplicated B	X	57591652-57597545	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043789	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 10.0	Mixed		
ZXDC	FLJ13861, MGC11349	ENSG00000070476	ZXD family zinc finger C	3	126437601-126475919	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049593			Supported	Nucleoli<br>Vesicles	Liver cancer:2.27e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 25.4	Expressed in all		
ZYG11A	ZYG11	ENSG00000203995	Zyg-11 family member A, cell cycle regulator	1	52842511-52894998	Predicted intracellular proteins	Evidence at protein level	HPA030378, HPA030379	Uncertain		Approved	Nucleus		Tissue enriched	Tissue enhanced		testis: 7.1;thyroid gland: 4.0	kidney: 3.1	Cell line enhanced		hTEC/SVTERT24-B: 10.5;SiHa: 11.4
ZYG11B	FLJ13456, ZYG11	ENSG00000162378	Zyg-11 family member B, cell cycle regulator	1	52726467-52827342	Predicted intracellular proteins	Evidence at protein level	HPA028156	Uncertain		Approved	Golgi apparatus<br>Intermediate filaments	Renal cancer:9.80e-7 (favourable), Colorectal cancer:5.42e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.0	Expressed in all		
ZYX		ENSG00000159840	Zyxin	7	143381080-143391111	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004835, CAB009321, HPA073497, CAB075747	Approved		Supported	Focal adhesion sites	Renal cancer:7.92e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 391.0	Expressed in all		
ZZZ3	ATAC1, DKFZP564I052	ENSG00000036549	Zinc finger ZZ-type containing 3	1	77562416-77683419	Predicted intracellular proteins	Evidence at protein level	HPA053663, HPA054913, HPA066197	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:6.96e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 32.9	Expressed in all		
